FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Fagan, RL
   Cryderman, DE
   Kopelovich, L
   Wallrath, LL
   Brenner, C
AF Fagan, Rebecca L.
   Cryderman, Diane E.
   Kopelovich, Levy
   Wallrath, Lori L.
   Brenner, Charles
TI Laccaic Acid A Is a Direct, DNA-competitive Inhibitor of DNA
   Methyltransferase 1
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER CELLS; TUMOR-SUPPRESSOR GENES; TRANSCRIPTIONAL REGULATION;
   EPIGENETIC REGULATION; ENZYMATIC-PROPERTIES; PPAR-GAMMA; METHYLATION;
   DNMT1; MOUSE; EXPRESSION
AB Methylation of cytosines in CpG dinucleotides is the predominant epigenetic mark on vertebrate DNA. DNA methylation is associated with transcriptional repression. The pattern of DNA methylation changes during development and with disease. Human DNA methyltransferase 1 (Dnmt1), a 1616-amino acid multidomain enzyme, is essential for maintenance of DNA methylation in proliferating cells and is considered an important cancer drug target. Using a fluorogenic, endonuclease-coupled DNA methylation assay with an activated form of Dnmt1 engineered to lack the replication foci targeting sequence domain, we discovered that laccaic acid A (LCA), a highly substituted anthraquinone natural product, is a direct inhibitor with a 310 nM K-i. LCA is competitive with the DNA substrate in in vitro methylation assays and alters the expression of methylated genes in MCF-7 breast cancer cells synergistically with 5-aza-2'-deoxycytidine. LCA represents a novel class of Dnmt-targeted molecular probes, with biochemical properties that allow it to distinguish between non DNA-bound and DNA-bound Dnmt1.
C1 [Fagan, Rebecca L.; Cryderman, Diane E.; Wallrath, Lori L.; Brenner, Charles] Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.
   [Kopelovich, Levy] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
C3 University of Iowa; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI)
RP Brenner, C (通讯作者)，Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.
EM charles-brenner@uiowa.edu
RI ; Brenner, Charles/D-6339-2014
OI Switzer, Rebecca/0000-0003-0591-2538; Wallrath,
   Lori/0000-0002-4391-7199; Brenner, Charles/0000-0002-4955-3226
FU National Institutes of Health [R01CA075954]; National Cancer Institute
   [HHSN261200433000C]; Oberley Seed Grants from the University of Iowa
   Holden Comprehensive Cancer Center; American Cancer Society postdoctoral
   fellowship
FX This work was supported by National Institutes of Health Grant
   R01CA075954, Contract HHSN261200433000C from the National Cancer
   Institute and a generous gift from the Roy J. Carver Charitable Trust
   (to C. B.). This work was also supported by Oberley Seed Grants from the
   University of Iowa Holden Comprehensive Cancer Center (to C. B. and L.
   L. W.), and an American Cancer Society postdoctoral fellowship (to R. L.
   F.).
CR Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x
   Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Callebaut I, 1999, FEBS LETT, V446, P189, DOI 10.1016/S0014-5793(99)00132-5
   Ceccaldi A, 2011, CHEMBIOCHEM, V12, P1337, DOI 10.1002/cbic.201100130
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Daniel FI, 2011, CANCER-AM CANCER SOC, V117, P677, DOI 10.1002/cncr.25482
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200
   Eads CA, 2002, CANCER RES, V62, P1296
   Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157
   Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710
   Goyal R, 2006, NUCLEIC ACIDS RES, V34, P1182, DOI 10.1093/nar/gkl002
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Huang J., 2013, ONCOGENE IN PRESS
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Karahoca M, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-3
   Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c
   LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Liu ZY, 2004, J BIOL CHEM, V279, P14120, DOI 10.1074/jbc.M309547200
   MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327
   MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Norwood LE, 2004, GENE, V336, P37, DOI 10.1016/j.gene.2004.04.003
   Ohno M, 2012, J BIOCHEM MOL TOXIC, V26, P16, DOI 10.1002/jbt.20408
   Oleaga C, 2012, EUR J NUTR, V51, P465, DOI 10.1007/s00394-011-0231-2
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Place TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014617
   Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684
   Rao CN, 2003, INT J ONCOL, V22, P843
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596
   Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105
   Song JK, 2012, SCIENCE, V335, P709, DOI 10.1126/science.1214453
   Song JK, 2011, SCIENCE, V331, P1036, DOI 10.1126/science.1195380
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Subbaramaiah K, 2012, CANCER PREV RES, V5, P1183, DOI 10.1158/1940-6207.CAPR-12-0201
   Syeda F, 2011, J BIOL CHEM, V286, P15344, DOI 10.1074/jbc.M110.209882
   SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4
   Taberlay PC, 2011, PROG DRUG RES, V67, P1, DOI 10.1007/978-3-7643-8989-5_1
   Takeshita K, 2011, P NATL ACAD SCI USA, V108, P9055, DOI 10.1073/pnas.1019629108
   Tanaka T, 1997, FOOD ADDIT CONTAM, V14, P373, DOI 10.1080/02652039709374540
   Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611
   Teodoridis JM, 2008, CANCER LETT, V268, P177, DOI 10.1016/j.canlet.2008.03.022
   Vilkaitis G, 2005, J BIOL CHEM, V280, P64, DOI 10.1074/jbc.M411126200
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wiechec E, 2008, GENE CHROMOSOME CANC, V47, P766, DOI 10.1002/gcc.20578
   Wood RJ, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq047
   Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125
   Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
NR 59
TC 59
Z9 64
U1 1
U2 19
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 16
PY 2013
VL 288
IS 33
BP 23858
EP 23867
DI 10.1074/jbc.M113.480517
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 302NO
UT WOS:000330611400025
PM 23839987
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Diede, SJ
   Yao, ZZ
   Keyes, CC
   Tyler, AE
   Dey, J
   Hackett, CS
   Elsaesser, K
   Kemp, CJ
   Neiman, PE
   Weiss, WA
   Olson, JM
   Tapscott, SJ
AF Diede, Scott J.
   Yao, Zizhen
   Keyes, C. Chip
   Tyler, Ashlee E.
   Dey, Joyoti
   Hackett, Christopher S.
   Elsaesser, Katrina
   Kemp, Christopher J.
   Neiman, Paul E.
   Weiss, William A.
   Olson, James M.
   Tapscott, Stephen J.
TI Fundamental differences in promoter CpG island DNA hypermethylation
   between human cancer and genetically engineered mouse models of cancer
SO EPIGENETICS
LA English
DT Article
DE cancer; DNA methylation; epigenomics; genetically engineered mouse
   models; medulloblastoma
ID METABOTROPIC GLUTAMATE RECEPTORS; TRANSGENIC MOUSE; METHYLATION; GROWTH;
   GENES; PROLIFERATION; INFLAMMATION; ACTIVATION; HALLMARKS; LYMPHOMA
AB Genetic and epigenetic alterations are essential for the initiation and progression of human cancer. We previously reported that primary human medulloblastomas showed extensive cancer-specific CpG island DNA hypermethylation in critical developmental pathways. To determine whether genetically engineered mouse models (GEMMs) of medulloblastoma have comparable epigenetic changes, we assessed genome-wide DNA methylation in three mouse models of medulloblastoma. In contrast to human samples, very few loci with cancer-specific DNA hypermethylation were detected, and in almost all cases the degree of methylation was relatively modest compared with the dense hypermethylation in the human cancers. To determine if this finding was common to other GEMMs, we examined a Burkitt lymphoma and breast cancer model and did not detect promoter CpG island DNA hypermethylation, suggesting that human cancers and at least some GEMMs are fundamentally different with respect to this epigenetic modification. These findings provide an opportunity to both better understand the mechanism of aberrant DNA methylation in human cancer and construct better GEMMs to serve as preclinical platforms for therapy development.
C1 [Diede, Scott J.; Dey, Joyoti; Olson, James M.; Tapscott, Stephen J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
   [Diede, Scott J.; Olson, James M.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA.
   [Yao, Zizhen; Keyes, C. Chip; Tyler, Ashlee E.; Tapscott, Stephen J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA.
   [Hackett, Christopher S.; Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
   [Hackett, Christopher S.; Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Hackett, Christopher S.; Weiss, William A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
   [Elsaesser, Katrina; Kemp, Christopher J.; Neiman, Paul E.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA.
   [Kemp, Christopher J.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
   [Neiman, Paul E.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
   [Tapscott, Stephen J.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
C3 Fred Hutchinson Cancer Center; University of Washington; University of
   Washington Seattle; Fred Hutchinson Cancer Center; University of
   California System; University of California San Francisco; University of
   California System; University of California San Francisco; University of
   California System; University of California San Francisco; Fred
   Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of
   Washington; University of Washington Seattle; University of Washington;
   University of Washington Seattle
RP Diede, SJ (通讯作者)，Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
EM sjdiede@fhcrc.org; stapscot@fhcrc.org
RI ; Diede, Scott/G-2288-2012
OI Yao, Zizhen/0000-0002-9361-5607; Weiss, William/0000-0003-2230-9132;
   Tapscott, Stephen/0000-0002-0319-0968; Diede, Scott/0000-0001-5422-549X
FU American Brain Tumor Association/Emily Dorfman Foundation for Children
   Basic Research Fellowship; Alex's Lemonade Stand Foundation; University
   of Washington Child Health Research Center (NIH) [K12 HD43376]; NIAMS
   [AR045113]
FX We thank Parker M for the gift of primary mouse fibroblast cells. Diede
   SJ was supported as a St Baldrick's Foundation Scholar, a Hyundai Hope
   on Wheels Scholar, and by the American Brain Tumor Association/Emily
   Dorfman Foundation for Children Basic Research Fellowship in memory of
   Emily Ann Dorfman, Alex's Lemonade Stand Foundation, and University of
   Washington Child Health Research Center (NIH grant K12 HD43376). This
   study was also supported by NIAMS AR045113 (Tapscott SJ).
CR Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Canudas AM, 2004, J NEUROSCI, V24, P10343, DOI 10.1523/JNEUROSCI.3229-04.2004
   Conerly ML, 2010, GENOME RES, V20, P1383, DOI 10.1101/gr.106542.110
   Dey J, 2012, MOL CELL BIOL, V32, P4104, DOI 10.1128/MCB.00862-12
   Diede SJ, 2010, P NATL ACAD SCI USA, V107, P234, DOI 10.1073/pnas.0907606106
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957
   Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hirai H, 2005, NAT NEUROSCI, V8, P1534, DOI 10.1038/nn1576
   Iacovelli L, 2006, J NEUROSCI, V26, P8388, DOI 10.1523/JNEUROSCI.2285-06.2006
   Iriyama T, 2009, EMBO J, V28, P843, DOI 10.1038/emboj.2009.32
   JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117
   KLEIN E, 1968, CANCER RES, V28, P1300
   Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442
   Lee S, 2010, BRIT J CANCER, V103, P265, DOI 10.1038/sj.bjc.6605711
   Mahoney SE, 2012, EPIGENETICS-US, V7, P400, DOI 10.4161/epi.19463
   Martín-Subero JI, 2009, BLOOD, V113, P2488, DOI 10.1182/blood-2008-04-152900
   Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X
   Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012
   Politi K, 2011, J CLIN ONCOL, V29, P2273, DOI 10.1200/JCO.2010.30.8304
   PULVERTAFT RJV, 1964, LANCET, V1, P238
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010
   Shah MY, 2010, CANCER RES, V70, P5840, DOI 10.1158/0008-5472.CAN-10-0847
   Steine EJ, 2011, J CLIN INVEST, V121, P1748, DOI 10.1172/JCI43169
   Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510
   TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299
   Tommasi S, 2013, NUCLEIC ACIDS RES, V41, P182, DOI 10.1093/nar/gks1051
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Xi YP, 2009, BMC BIOINFORMATICS, V10, DOI [10.1186/1471-2105-10-S1-S58, 10.1186/1471-2105-10-232]
NR 39
TC 14
Z9 15
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD DEC 1
PY 2013
VL 8
IS 12
BP 1254
EP 1260
DI 10.4161/epi.26486
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 298DO
UT WOS:000330304500002
PM 24107773
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Wielscher, M
   Liou, W
   Pulverer, W
   Singer, CF
   Rappaport-Fuerhauser, C
   Kandioler, D
   Egger, G
   Weinhäusel, A
AF Wielscher, Matthias
   Liou, Willy
   Pulverer, Walter
   Singer, Christian F.
   Rappaport-Fuerhauser, Christine
   Kandioler, Daniela
   Egger, Gerda
   Weinhaeusel, Andreas
TI Cytosine 5-Hydroxymethylation of the <i>LZTS1</i> Gene Is Reduced in
   Breast Cancer
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID DNA METHYLATION; DOWN-REGULATION; 5-METHYLCYTOSINE; FEZ1/LZTS1;
   CHROMATIN; MODIFIER; TET; 8P
AB Change of DNA cytosine methylation (5mC) is an early event in the development of cancer, and the recent discovery of a 5-hydroxymethylated form (5hmC) of cytosine suggests a regulatory epigenetic role that might be different from 5-methylcytosine. Here, we aimed at elucidating the role of 5hmC in breast cancer. To interrogate the 5hmC levels of the leucine zipper, putative tumor suppressor 1 (LZTS1) gene in detail, we analyzed 75 primary breast cancer tissue samples from initial diagnosis and 12 normal breast tissue samples derived from healthy persons. Samples were subjected to 5hmC glucosyltransferase treatment followed by restriction digestion and segment-specific amplification of 11 polymerase chain reaction products. Nine of the 11 5'LZTS1 fragments showed significantly lower (fold change of 1.61-6.01, P <.05) 5hmC content in primary breast cancer tissue compared to normal breast tissue samples. No significant differences were observed for 5mC DNA methylation. Furthermore, both LZTS1 and TET1 mRNA expressions were significantly reduced in tumor samples (n = 75, P <.001, Student's t test), which correlated significantly with 5hmC levels in samples. 5hmC levels in breast cancer tissues were associated with unfavorable histopathologic parameters such as lymph node involvement (P <.05, Student's t test). A decrease of 5hmC levels of LZTS1, a classic tumor suppressor gene known to influence metastasis in breast cancer progression, is correlated to down-regulation of LZTS1 mRNA expression in breast cancer and might epigenetically enhance carcinogenesis. The study provides support for the novel hypothesis that suggests a strong influence of 5hmC on mRNA expression. Finally, one may also consider 5hmC as a new biomarker.
C1 [Wielscher, Matthias; Liou, Willy; Pulverer, Walter; Weinhaeusel, Andreas] Austrian Inst Technol, Mol Diagnost Unit, Hlth & Environm Dept, A-1190 Vienna, Austria.
   [Singer, Christian F.; Rappaport-Fuerhauser, Christine] Med Univ Vienna, Dept Obstet & Gynecol, Vienna, Austria.
   [Singer, Christian F.; Rappaport-Fuerhauser, Christine] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria.
   [Kandioler, Daniela] Univ Hosp Vienna, Dept Surg, Vienna, Austria.
   [Egger, Gerda] Med Univ Vienna, Clin Inst Pathol, Vienna, Austria.
C3 Austrian Institute of Technology (AIT); Medical University of Vienna;
   Medical University of Vienna; University Hospital Vienna; Medical
   University of Vienna
RP Weinhäusel, A (通讯作者)，Austrian Inst Technol, Dept Mol Diagnost, Muthgasse 11-2, A-1190 Vienna, Austria.
EM andreas.weinhaeusel@ait.ac.at
RI Weinhaeusel, Andreas/A-7644-2018; Egger, Gerda/B-7177-2013; Wielscher,
   Matthias/GLS-8316-2022
OI Egger, Gerda/0000-0003-2489-155X; Weinhaeusel,
   Andreas/0000-0002-9318-1204; Rappaport-Fuerhauser,
   Christine/0000-0002-6820-0020
FU project RESOLVE; European Commission [202047]; Austrian Science Fund
   (FWF) Elise Richter [V102-B12]; Oesterreichische Nationalbank
   (Anniversary Fund) [13061]; Marie Curie International Reintegration
   [230984]
FX This work was supported by the project RESOLVE funded by the European
   Commission under FP7-HEALTH-F4-2008, ContractNo. 202047
   (http://resolve.punkt-international.eu/). G.E. was supported by grants
   from the Austrian Science Fund (FWF) Elise Richter (V102-B12), the
   Oesterreichische Nationalbank (Anniversary Fund, project No. 13061), and
   the EU-FP7 (Marie Curie International Reintegration grant 230984). The
   authors declare that they have no conflicts of interest.
CR Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bocker MT, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1826
   Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Chen L, 2009, BREAST CANCER RES TR, V116, P471, DOI 10.1007/s10549-008-0147-6
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ehrlich M, 2013, ADV EXP MED BIOL, V754, P31, DOI 10.1007/978-1-4419-9967-2_2
   Ficz G, 2011, NATURE, V473, P398, DOI 10.1038/nature10008
   Inoue A, 2011, SCIENCE, V334, P194, DOI 10.1126/science.1212483
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Jin SG, 2011, NUCLEIC ACIDS RES, V39, P5015, DOI 10.1093/nar/gkr120
   Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   Li WW, 2011, J NUCLEIC ACIDS, V2011, DOI 10.4061/2011/870726
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Nestor C, 2010, BIOTECHNIQUES, V48, P317, DOI 10.2144/000113403
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Onken MD, 2008, CLIN CANCER RES, V14, P3737, DOI 10.1158/1078-0432.CCR-07-5144
   Ono K, 2003, INT J ONCOL, V23, P297
   Pulverer W, 2012, BIOCHIMIE, V94, P2345, DOI 10.1016/j.biochi.2012.06.023
   Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609
   Shen L, 2013, CELL, V153, P692, DOI 10.1016/j.cell.2013.04.002
   Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tsou JA, 2007, LUNG CANCER, V58, P220, DOI 10.1016/j.lungcan.2007.06.015
   Vecchione A, 2007, CANCER CELL, V11, P275, DOI 10.1016/j.ccr.2007.01.014
   Wang XX, 2011, HUM PATHOL, V42, P1410, DOI 10.1016/j.humpath.2010.12.007
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wielscher M, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-11
   Williams K, 2012, EMBO REP, V13, P28, DOI 10.1038/embor.2011.233
   Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Zhao YD, 2008, CANCER INFORM, V6, P9
NR 36
TC 22
Z9 27
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD DEC
PY 2013
VL 6
IS 6
BP 715
EP U348
DI 10.1593/tlo.13523
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 298RP
UT WOS:000330342400013
PM 24466374
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, H
   Wang, J
   Xiao, W
   Xia, D
   Lang, B
   Wang, T
   Guo, XL
   Hu, ZQ
   Ye, ZQ
   Xu, H
AF Li, Heng
   Wang, Ji
   Xiao, Wei
   Xia, Ding
   Lang, Bin
   Wang, Tao
   Guo, Xiaolin
   Hu, Zhiquan
   Ye, Zhangqun
   Xu, Hua
TI Epigenetic Inactivation of KLF4 is Associated with Urothelial Cancer
   Progression and Early Recurrence
SO JOURNAL OF UROLOGY
LA English
DT Article
DE urinary bladder; urothelium; carcinoma; genes, tumor suppressor;
   mortality
ID BREAST-CANCER; DOWN-REGULATION; BLADDER-CANCER; KRUPPEL; GROWTH;
   IDENTIFICATION; EXPRESSION; GENE; KRUPPEL-LIKE-FACTOR-4; CELLS
AB Purpose: KLF4 is a transcription factor with divergent functions in different malignancies. We analyzed KLF4 expression and DNA methylation, and their clinical relevance and biological function in urothelial cancer.
   Materials and Methods: Immunohistochemistry and Sequenom (TM) MassARRAY (R) were done to detect the expression and promoter methylation of KLF4 in urothelial cancer tissues. The association of the recurrence-free survival rate and decreased KLF4 or KLF4 methylation status was analyzed by the Kaplan-Meier method, Cox regression analysis and ROC assay. Lentivirus based KLF4 over expression and dsRNA mediated knockdown were used to detect KLF4 functions in urothelial cancer in vitro and in vivo.
   Results: KLF4 was down-regulated in urothelial cancer due to promoter hypermethylation. Each correlated with recurrence-free survival in patients with nonmuscle invasive bladder cancer after transurethral resection of bladder cancer, which potentiates them as valuable predictive biomarkers for early recurrence. Moreover, in and ex vivo experiments showed that KLF4 suppressed urothelial cancer cell growth, migration and invasion inhibited the epithelial-to-mesenchymal transition.
   Conclusions: KLF4 may function as a tumor suppressor gene in urothelial cancer since down-regulation of KLF4 by promoter hypermethylation would promote cancer progression. In addition, decreased expression of KLF4 or its promoter hypermethylation may have predictive value for early recurrence in patients with nonmuscle invasive bladder cancer.
C1 [Li, Heng; Xiao, Wei; Xia, Ding; Wang, Tao; Guo, Xiaolin; Hu, Zhiquan; Ye, Zhangqun; Xu, Hua] Huazhong Univ Sci & Technol, Dept Urol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Lang, Bin] Macao Polytech Inst, Sch Hlth Sci, Macao, Peoples R China.
   [Wang, Ji] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA.
   [Wang, Ji] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA.
C3 Huazhong University of Science & Technology; Macao Polytechnic
   University; University of California System; University of California
   San Francisco; University of California System; University of California
   San Francisco; UCSF Medical Center; UCSF Helen Diller Family
   Comprehensive Cancer Center
RP Xu, H (通讯作者)，Huazhong Univ Sci & Technol, Dept Urol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China.
EM xuhua@mail.hust.edu.cn
RI zhang, yachao/KEJ-4957-2024
OI Li, Heng/0000-0003-2166-4116
FU National Natural Science Foundation of China [31072238, 31172441,
   81170650, 81101944]; National Major Scientific and Technological Special
   Project for Significant New Drugs Development [2012ZX09303018]
FX Supported by National Natural Science Foundation of China (31072238,
   31172441, 81170650 and 81101944), and National Major Scientific and
   Technological Special Project for Significant New Drugs Development
   (2012ZX09303018).
CR Aleman A, 2008, CLIN CANCER RES, V14, P8236, DOI 10.1158/1078-0432.CCR-08-0778
   Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307
   Foster KW, 2000, CANCER RES, V60, P6488
   GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hu WX, 2009, CLIN CANCER RES, V15, P5688, DOI 10.1158/1078-0432.CCR-09-0310
   Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355
   Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034
   Li Q, 2012, GASTROENTEROLOGY, V143, P799, DOI 10.1053/j.gastro.2012.05.043
   Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11
   Nakahara Y, 2010, NEOPLASIA, V12, P20, DOI 10.1593/neo.91122
   Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1
   PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0
   RUBBEN H, 1988, J UROLOGY, V139, P283, DOI 10.1016/S0022-5347(17)42387-1
   Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414
   Wang L, 2010, AM J CLIN NUTR, V91, P1359, DOI 10.3945/ajcn.2009.28858
   Wei DY, 2008, CANCER RES, V68, P4631, DOI 10.1158/0008-5472.CAN-07-5953
   Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619
   Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x
   Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090
   Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422
   Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260
   Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067
NR 26
TC 41
Z9 44
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD FEB
PY 2014
VL 191
IS 2
BP 493
EP 501
DI 10.1016/j.juro.2013.08.087
PG 9
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 291MM
UT WOS:000329832800094
PM 24018236
DA 2025-01-12
ER

PT J
AU Cunningham, JM
   Cicek, MS
   Larson, NB
   Davila, J
   Wang, C
   Larson, MC
   Song, H
   Dicks, EM
   Harrington, P
   Wick, M
   Winterhoff, BJ
   Hamidi, H
   Konecny, GE
   Chien, J
   Bibikova, M
   Fan, JB
   Kalli, KR
   Lindor, NM
   Fridley, BL
   Pharoah, PPD
   Goode, EL
AF Cunningham, J. M.
   Cicek, M. S.
   Larson, N. B.
   Davila, J.
   Wang, C.
   Larson, M. C.
   Song, H.
   Dicks, E. M.
   Harrington, P.
   Wick, M.
   Winterhoff, B. J.
   Hamidi, H.
   Konecny, G. E.
   Chien, J.
   Bibikova, M.
   Fan, J. -B.
   Kalli, K. R.
   Lindor, N. M.
   Fridley, B. L.
   Pharoah, P. P. D.
   Goode, E. L.
TI Clinical Characteristics of Ovarian Cancer Classified by <i>BRCA1</i>,
   <i>BRCA2</i>, and <i>RAD51C</i> Status
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SUSCEPTIBILITY GENE; GERMLINE MUTATIONS; CONFER SUSCEPTIBILITY; BREAST;
   IDENTIFICATION; METHYLATION; HEREDITARY; CARCINOMA; SURVIVAL; BRCANESS
AB We evaluated homologous recombination deficient (HRD) phenotypes in epithelial ovarian cancer (EOC) considering BRCA1, BRCA2, and RAD51C in a large well-annotated patient set. We evaluated EOC patients for germline deleterious mutations (n=5899), somatic mutations (n=5279) and epigenetic alterations (n=5 482) in these genes using NGS and genome-wide methylation arrays. Deleterious germline mutations were identified in 32 (3.6%) patients for BRCA1, in 28 (3.1%) for BRCA2 and in 26 (2.9%) for RAD51C. Ten somatically sequenced patients had deleterious alterations, six (2.1%) in BRCA1 and four (1.4%) in BRCA2. Fifty two patients (10.8%) had methylated BRCA1 or RAD51C. HRD patients with germline or somatic alterations in any gene were more likely to be high grade serous, have an earlier diagnosis age and have ovarian and/or breast cancer family history. The HRD phenotype was most common in high grade serous EOC. Identification of EOC patients with an HRD phenotype may help tailor specific therapies.
C1 [Cunningham, J. M.] Mayo Clin, Dept Pathol & Lab Med, Div Expt Pathol, Rochester, MN USA.
   [Cicek, M. S.; Goode, E. L.] Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA.
   [Larson, N. B.; Davila, J.; Wang, C.; Larson, M. C.] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN USA.
   [Song, H.; Dicks, E. M.; Harrington, P.; Pharoah, P. P. D.] Univ Cambridge, Dept Oncol, Cambridge, England.
   [Wick, M.; Winterhoff, B. J.] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN USA.
   [Hamidi, H.; Konecny, G. E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
   [Chien, J.] Univ Kansas, Med Ctr, Dept Translat Genom, Kansas City, KS 66103 USA.
   [Bibikova, M.; Fan, J. -B.] Illumina Corp, San Diego, CA USA.
   [Kalli, K. R.] Mayo Clin, Dept Med Oncol, Rochester, MN USA.
   [Lindor, N. M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
   [Fridley, B. L.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA.
   [Pharoah, P. P. D.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Cambridge; Mayo
   Clinic; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; University of Kansas; University of
   Kansas Medical Center; Illumina; Mayo Clinic; Mayo Clinic; University of
   Kansas; University of Kansas Medical Center; University of Cambridge
RP Goode, EL (通讯作者)，Mayo Clin, Dept Hlth Sci Res, Div Epidemiol, Rochester, MN 55905 USA.
EM egoode@mayo.edu
RI Fridley, Brooke/D-8315-2015; Cunningham, Julie/KII-0320-2024; Pharoah,
   Paul/V-6658-2019; Davila, Jaime/AAI-2023-2019; Larson,
   Nicholas/AEY-9578-2022; Chien, Jeremy/AID-8939-2022; Wang,
   Chen/B-3244-2011; Hamidi, Habib/H-8030-2016
OI Wang, Chen/0000-0003-2638-3081; Davila, Jaime/0000-0002-8163-6267;
   Hamidi, Habib/0000-0003-0196-9852; Chien, Jeremy/0000-0003-4744-8374
FU National Institutes of Health [R01-CA122443, P50-CA136393, P30-CA15083];
   Fred C. and Katherine B. Andersen Foundation
FX This work was supported by National Institutes of Health grants
   R01-CA122443, P50-CA136393, P30-CA15083, and the Fred C. and Katherine
   B. Andersen Foundation. We thank Gary Kenney, M.D. for pathology review
   of tumor tissue. We thank Craig Luccarini, Caroline Baynes from
   University of Cambridge for assisting our sample sequencing.
CR Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613
   Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451
   Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545
   [Anonymous], MOL CANC RES
   Asmann YW, 2012, BIOINFORMATICS, V28, P277, DOI 10.1093/bioinformatics/btr612
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Berchuck A, 1998, CLIN CANCER RES, V4, P2433
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Bojesen SE, 2013, NAT GENET, V45, P371, DOI 10.1038/ng.2566
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   Bolton KL, 2012, JAMA-J AM MED ASSOC, V307, P382, DOI 10.1001/jama.2012.20
   Bolton KL, 2010, NAT GENET, V42, P880, DOI 10.1038/ng.666
   Cicek MS, 2013, HUM MOL GENET, V22, P3038, DOI 10.1093/hmg/ddt160
   Clague J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025632
   Coulet F, 2013, CLIN GENET, V83, P332, DOI 10.1111/j.1399-0004.2012.01917.x
   Demsky R, 2013, GYNECOL ONCOL, V130, P329, DOI 10.1016/j.ygyno.2013.05.003
   Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589
   Foster KA, 1996, CANCER RES, V56, P3622
   Goode EL, 2011, CANCER EPIDEM BIOMAR, V20, P1638, DOI 10.1158/1055-9965.EPI-11-0455
   Goode LL, 2010, NAT GENET, V42, P874, DOI 10.1038/ng.668
   Hansmann T, 2012, HUM MOL GENET, V21, P4669, DOI 10.1093/hmg/dds308
   Kobel M, 2013, CANCER EPIDEM BIOMAR, V22, P1677, DOI 10.1158/1055-9965.EPI-13-0391
   Larson DE, 2012, BIOINFORMATICS, V28, P311, DOI 10.1093/bioinformatics/btr665
   Liu J, 2012, CANCER GENET-NY, V205, P34, DOI 10.1016/j.cancergen.2012.01.008
   Loveday C, 2012, NAT GENET, V44, P475, DOI 10.1038/ng.2224
   Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   McLaughlin JR, 2013, JNCI-J NATL CANCER I, V105, P141, DOI 10.1093/jnci/djs494
   Meindl A, 2011, DTSCH ARZTEBL INT, V108, P323, DOI 10.3238/arztebl.2011.0323
   Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Permuth-Wey J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2613
   Pharoah PDP, 2013, NAT GENET, V45, P362, DOI 10.1038/ng.2564
   Pharoah PDP, 1999, CANCER RES, V59, P868
   Pharoah PDP, 2002, BEST PRACT RES CL OB, V16, P449, DOI 10.1053/beog.2002.0296
   Ramus SJ, 2009, MOL ONCOL, V3, P138, DOI 10.1016/j.molonc.2009.02.001
   Rigakos G, 2012, ONCOLOGIST, V17, P956, DOI 10.1634/theoncologist.2012-0028
   Shen H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2629
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Song HL, 2009, NAT GENET, V41, P996, DOI 10.1038/ng.424
   Tan DSP, 2008, J CLIN ONCOL, V26, P5530, DOI 10.1200/JCO.2008.16.1703
   Tinker AV, 2012, CURR PHARM DESIGN, V18, P3770
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6
   Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
NR 47
TC 114
Z9 125
U1 1
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 7
PY 2014
VL 4
AR 4026
DI 10.1038/srep04026
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AA6SB
UT WOS:000331227200002
PM 24504028
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Sike, A
   Nagy, E
   Vedelek, B
   Pusztai, D
   Szerémy, P
   Venetianer, A
   Boros, IM
AF Sike, Adam
   Nagy, Enikoe
   Vedelek, Balazs
   Pusztai, David
   Szeremy, Peter
   Venetianer, Aniko
   Boros, Imre M.
TI mRNA Levels of Related <i>Abcb</i> Genes Change Opposite to Each Other
   upon Histone Deacetylase Inhibition in Drug-Resistant Rat Hepatoma Cells
SO PLOS ONE
LA English
DT Article
ID P-GLYCOPROTEIN GENE; MULTIDRUG-RESISTANCE; TRANSCRIPTIONAL REGULATION;
   MDR1 EXPRESSION; PROMOTER REGION; BREAST-CANCER; HUMAN GENOME; LINES;
   ACETYLATION; ACTIVATION
AB The multidrug-resistant phenotype of tumor cells is acquired via an increased capability of drug efflux by ABC transporters and causes serious problems in cancer treatment. With the aim to uncover whether changes induced by epigenetic mechanisms in the expression level of drug transporter genes correlates with changes in the drug resistance phenotypes of resistant cells, we studied the expression of drug transporters in rat hepatoma cell lines. We found that of the three major rat ABC transporter genes Abcb1a, Abcb1b and Abcc1 the activity of only Abcb1b increased significantly in colchicine-selected, drug-resistant cells. Increased transporter expression in drug-resistant cells results primarily from transcriptional activation. A change in histone modification at the regulatory regions of the chromosomally adjacent Abcb1a and Abcb1b genes differentially affects the levels of corresponding mRNAs. Transcriptional up-and down-regulation accompany an increase in acetylation levels of histone H3 lysine 9 at the promoter regions of Abcb1b and Abcb1a, respectively. Drug efflux activity, however, does not follow tightly the transcriptional activity of drug transporter genes in hepatoma cells. Our results point out the need for careful analysis of cause-and-effect relationships between changes in histone modification, drug transporter expression and drug resistance phenotypes.
C1 [Sike, Adam; Nagy, Enikoe; Vedelek, Balazs; Pusztai, David; Boros, Imre M.] Univ Szeged, Dept Biochem & Mol Biol, Szeged, Hungary.
   [Boros, Imre M.] Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary.
   [Szeremy, Peter] SOLVO Biotechnol, Szeged, Hungary.
   [Venetianer, Aniko] Biol Res Ctr, Inst Genet, H-6701 Szeged, Hungary.
C3 Szeged University; Hungarian Research Network; Hungarian Academy of
   Sciences; HUN-REN Biological Research Center; Hungarian Research
   Network; Hungarian Academy of Sciences; HUN-REN Biological Research
   Center
RP Boros, IM (通讯作者)，Univ Szeged, Dept Biochem & Mol Biol, Szeged, Hungary.
EM borosi@bio.u-szeged.hu
RI Boros, Ildikó/H-6721-2012; Vedelek, Balázs/M-4274-2018
OI Boros, Imre/0000-0001-8504-9687
FU European Union; Europian Social Fund [HURO/1101/173/2.2.1,
   TAMOP-4.2.2.A-11/1/KONV-2012-0035]; European Social Fund
   [TAMOP-4.2.2.A-11/1/KONV-2012-0035];  [TAMOP 4.2.4. A/2-11-1-2012-0001]
FX This work was supported by the European Union and co-funded by the
   Europian Social Fund. Project numbers: HURO/1101/173/2.2.1;
   TAMOP-4.2.2.A-11/1/KONV-2012-0035. AS was supported by fellowships of
   TAMOP 4.2.4. A/2-11-1-2012-0001 "National Excellence Program -
   Elaborating and operating an inland student and researcher personal
   support system convergence program'' The project was subsidized by the
   European Union and co-financed by the European Social Fund and until
   31st of May, 2013 from TAMOP-4.2.2/B-10/1-2010-0012. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR COHEN D, 1991, J BIOL CHEM, V266, P2239
   CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652
   El-Khoury V, 2007, BRIT J CANCER, V97, P562, DOI 10.1038/sj.bjc.6603914
   Eyal S, 2006, BRIT J PHARMACOL, V149, P250, DOI 10.1038/sj.bjp.0706830
   FARDEL O, 1993, FEBS LETT, V327, P189, DOI 10.1016/0014-5793(93)80167-S
   Fazlina N, 2008, Malays J Pathol, V30, P87
   Gatti L, 2005, METH MOLEC MED, V111, P127
   Hevér-Szabó A, 1998, ANTICANCER RES, V18, P3045
   HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2
   HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596
   HSU SIH, 1989, J BIOL CHEM, V264, P12053
   Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377
   Katoh M, 2006, J PHARM SCI-US, V95, P2673, DOI 10.1002/jps.20686
   Kim SN, 2009, MOL CANCER RES, V7, P735, DOI 10.1158/1541-7786.MCR-08-0296
   Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207
   KOHNO K, 1994, J BIOL CHEM, V269, P20503
   KUO MT, 1992, CELL GROWTH DIFFER, V3, P531
   Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101
   Loeuillet C, 2007, PHARMACOGENET GENOM, V17, P951, DOI 10.1097/FPC.0b013e3282eff934
   Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000
   Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362
   Nishida H, 2006, CHROMOSOME RES, V14, P203, DOI 10.1007/s10577-006-1036-7
   Pirity M, 1996, CYTOTECHNOLOGY, V19, P207, DOI 10.1007/BF00744214
   Raguz S, 2008, INT J CANCER, V122, P1058, DOI 10.1002/ijc.23149
   Rajagopal A, 2002, CANCER RES, V62, P391
   Robey RW, 2006, CLIN CANCER RES, V12, P1547, DOI 10.1158/1078-0432.CCR-05-1423
   Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505
   Sarkadi B, 2006, PHYSIOL REV, V86, P1179, DOI 10.1152/physrev.00037.2005
   Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028
   SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7
   Schwab D, 2003, J MED CHEM, V46, P1716, DOI 10.1021/jm021012t
   Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950
   SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471
   SONG RD, 1995, J BIOL CHEM, V270, P25468, DOI 10.1074/jbc.270.43.25468
   STEIN U, 1994, EUR J CANCER, V30A, P1541, DOI 10.1016/0959-8049(94)00287-F
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202
   Toth M, 2012, CANC SCI
   UEDA K, 1987, J BIOL CHEM, V262, P17432
   Yagüe E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200
   YANG CPH, 1990, J BIOL CHEM, V265, P10282
   Yatouji S, 2007, INT J ONCOL, V30, P1003
   ZHAO JY, 1993, ENDOCRINOLOGY, V133, P521, DOI 10.1210/en.133.2.521
NR 45
TC 5
Z9 6
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 7
PY 2014
VL 9
IS 1
AR e84915
DI 10.1371/journal.pone.0084915
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 286JC
UT WOS:000329463500035
PM 24409311
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Weng, JR
   Lai, IL
   Yang, HC
   Lin, CN
   Bai, LY
AF Weng, Jing-Ru
   Lai, I-Lu
   Yang, Hsiao-Ching
   Lin, Chun-Nan
   Bai, Li-Yuan
TI Identification of Kazinol Q, a Natural Product from Formosan Plants, as
   an Inhibitor of DNA Methyltransferase
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE kazinol Q; DNA methyltransferase; drug discovery; screening
ID TUMOR-SUPPRESSOR GENES; CANCER EPIGENETICS; BROUSSONETIA-KAZINOKI;
   HISTONE DEACETYLASE; HUMAN BREAST; METHYLATION; PROCAINAMIDE;
   HYDRALAZINE; EXPRESSION; CONSTITUENTS
AB DNA methylation plays a pivotal role in the epigenetic regulation of the transcription of a number of cancer-related genes, thereby representing an important target for cancer prevention and treatment. In our search for DNA methyltransferase (DNMT) inhibitors from Formosan plants, by screening against a library consisting of 12 structurally distinct natural products, we identified kazinol Q {4-[6-(1,1-dimethyl-allyl)-7-hydroxy-chroman-2-yl]-3,6-bis-(3-methyl-but-2-enyl)-benzene-1,2-diol} as an inhibitor of recombinant DNMT1 with IC50 of 7M. The effect of kazinol Q on DNMT inhibition was validated by its ability to reactivate the expression of a DNA methylation-silenced gene, E-cadherin, in MDA-MB-231 breast cancer cells. Moreover, kazinol Q suppressed the proliferation of MCF-7 breast and LNCaP prostate cancer cells, in part, through apoptosis induction. The role of DNMT1 inhibition in mediating kazinol Q's antiproliferative effect was supported by the protective effect of ectopic expression of DNMT1 on kazinol Q-induced cell death. Molecular modeling analysis suggests that kazinol Q inhibited DNMT activity by competing with cytosine binding, a mechanism similar to that described for (-)-epigallocatechin-3-gallate (EGCG). Relative to EGCG, kazinol Q exhibits several desirable features for drug development, including chemical stability and increased hydrophobicity, and might have therapeutic relevance to cancer treatment. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Weng, Jing-Ru; Lin, Chun-Nan] China Med Univ, Dept Biol Sci & Technol, Taichung 40402, Taiwan.
   [Lai, I-Lu] Ohio State Univ, Div Med Chem, Coll Pharm, Columbus, OH 43210 USA.
   [Yang, Hsiao-Ching] Fu Jen Catholic Univ, Dept Chem, New Taipei 24205, Taiwan.
   [Lin, Chun-Nan] Kaohsiung Med Univ, Coll Pharm, Fac Fragrance & Cosmet, Kaohsiung 80708, Taiwan.
   [Bai, Li-Yuan] China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung 40447, Taiwan.
   [Bai, Li-Yuan] China Med Univ, Sch Med, Taichung 40402, Taiwan.
C3 China Medical University Taiwan; University System of Ohio; Ohio State
   University; Fu Jen Catholic University; Kaohsiung Medical University;
   China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan
RP Weng, JR (通讯作者)，China Med Univ, Dept Biol Sci & Technol, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM columnster@gmail.com
RI Weng, Jing-Ru/L-1743-2013; Yang, Hsiao-Ching/AGI-3553-2022
OI Yang, Hsiao-Ching/0000-0002-7970-1357
FU Taiwan Department of Health; China Medical University Hospital Cancer
   Research of Excellence [DOH102-TD-C-111-005]; China Medical University
   Hospital [DMR-102-009]; National Science Council [NSC
   101-2320-B-039-029-MY2]
FX This work was supported by grants from the Taiwan Department of Health,
   China Medical University Hospital Cancer Research of Excellence
   (DOH102-TD-C-111-005), China Medical University Hospital (DMR-102-009)
   and National Science Council (NSC 101-2320-B-039-029-MY2).
CR Bai LY, 2011, ORAL ONCOL, V47, P1127, DOI 10.1016/j.oraloncology.2011.07.031
   Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045
   Biel M, 2005, ANGEW CHEM INT EDIT, V44, P3186, DOI 10.1002/anie.200461346
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Chung MI, 1997, PHYTOCHEMISTRY, V44, P943
   CHUNG MI, 1993, J NAT PROD, V56, P929, DOI 10.1021/np50096a018
   CORNACCHIA E, 1988, J IMMUNOL, V140, P2197
   Day SH, 1999, J NAT PROD, V62, P1056, DOI 10.1021/np9900167
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Fang MZ, 2003, CANCER RES, V63, P7563
   Gan KH, 1998, J NAT PROD, V61, P485, DOI 10.1021/np9704664
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2005, SEMIN HEMATOL, V42, pS3, DOI 10.1053/j.seminhematol.2005.05.001
   Ko HH, 1997, J NAT PROD, V60, P1008, DOI 10.1021/np970186o
   Ko HH, 1999, J NAT PROD, V62, P164, DOI 10.1021/np980281c
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074/jbc.M505593200
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Moggs JG, 2004, TOXICOL APPL PHARM, V196, P422, DOI 10.1016/j.taap.2004.01.009
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Naasani I, 2003, CANCER RES, V63, P824
   Nass SJ, 2000, CANCER RES, V60, P4346
   Piña IC, 2003, J ORG CHEM, V68, P3866, DOI 10.1021/jo034248t
   Quina AS, 2006, BIOCHEM PHARMACOL, V72, P1563, DOI 10.1016/j.bcp.2006.06.016
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596
   Wei BL, 2011, MOLECULES, V16, P3212, DOI 10.3390/molecules16043212
   Weng JR, 2006, PHYTOCHEMISTRY, V67, P824, DOI 10.1016/j.phytochem.2006.01.030
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44
NR 34
TC 27
Z9 32
U1 3
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JAN
PY 2014
VL 28
IS 1
BP 49
EP 54
DI 10.1002/ptr.4955
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 287AM
UT WOS:000329510400007
PM 23447335
DA 2025-01-12
ER

PT J
AU Pradhan, MP
   Desai, A
   Palakal, MJ
AF Pradhan, Meeta P.
   Desai, Akshay
   Palakal, Mathew J.
TI Systems biology approach to stage-wise characterization of epigenetic
   genes in lung adenocarcinoma
SO BMC SYSTEMS BIOLOGY
LA English
DT Article
DE Epigenetic genes; Stages; LUAD; TFs; Subnetwork; NSCLC; SCLC
ID GENOME-WIDE ANALYSIS; CPG ISLAND HYPERMETHYLATION; DNA METHYLATION
   BIOMARKERS; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; HUMAN-DISEASE; HOX
   GENES; EXPRESSION; IDENTIFICATION; TRANSCRIPTION
AB Background: Epigenetics refers to the reversible functional modifications of the genome that do not correlate to changes in the DNA sequence. The aim of this study is to understand DNA methylation patterns across different stages of lung adenocarcinoma (LUAD).
   Results: Our study identified 72, 93 and 170 significant DNA methylated genes in Stages I, II and III respectively. A set of common 34 significant DNA methylated genes located in the promoter section of the true CpG islands were found across stages, and these were: HOX genes, FOXG1, GRIK3, HAND2, PRKCB, etc. Of the total significant DNA methylated genes, 65 correlated with transcription function. The epigenetic analysis identified the following novel genes across all stages: PTGDR, TLX3, and POU4F2. The stage-wise analysis observed the appearance of NEUROG1 gene in Stage I and its re-appearance in Stage III. The analysis showed similar epigenetic pattern across Stage I and Stage III. Pathway analysis revealed important signaling and metabolic pathways of LUAD to correlate with epigenetics. Epigenetic subnetwork analysis identified a set of seven conserved genes across all stages: UBC, KRAS, PIK3CA, PIK3R3, RAF1, BRAF, and RAP1A. A detailed literature analysis elucidated epigenetic genes like FOXG1, HLA-G, and NKX6-2 to be known as prognostic targets.
   Conclusion: Integrating epigenetic information for genes with expression data can be useful for comprehending in-depth disease mechanism and for the ultimate goal of better target identification.
C1 [Pradhan, Meeta P.; Desai, Akshay; Palakal, Mathew J.] Indiana Univ Purdue Univ, Sch Informat & Comp, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University
RP Palakal, MJ (通讯作者)，Indiana Univ Purdue Univ, Sch Informat & Comp, Indianapolis, IN 46202 USA.
EM mpalakal@iupui.edu
CR Anderson KR, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-65
   Antoon JW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00539
   Arora H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023802
   Awan A, 2007, IET SYST BIOL, V1, P292, DOI 10.1049/iet-syb:20060068
   Bailey-Wilson JE, 2004, AM J HUM GENET, V75, P460, DOI 10.1086/423857
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Brena RM, 2007, HUM MOL GENET, V16, pR96, DOI 10.1093/hmg/ddm073
   Brose MS, 2002, CANCER RES, V62, P6997
   Buckingham LE, 2007, J THORAC ONCOL, V2, P414, DOI 10.1097/01.JTO.0000268675.02744.b0
   Buness A, 2007, BIOINFORMATICS, V23, P2273, DOI 10.1093/bioinformatics/btm340
   Cao M, 2011, TISSUE ANTIGENS, V78, P120, DOI 10.1111/j.1399-0039.2011.01716.x
   Carvalho RH, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-9
   Castro IC, 2013, MOL CANCER RES, V11, P161, DOI 10.1158/1541-7786.MCR-12-0414-T
   Chao C, 2010, PLOS ONE, V6
   Charlesworth JC, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-29
   Chen PY, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-r62
   Cheng WC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017347
   Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230
   Choi K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001226
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Chung W, 2011, CANCER EPIDEM BIOMAR, V20, P1483, DOI 10.1158/1055-9965.EPI-11-0067
   Cui J, 1998, CANCER GENET CYTOGEN, V107, P51, DOI 10.1016/S0165-4608(98)00074-0
   Cui QH, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100200
   Davis E, 2008, ONCOGENE, V27, P976, DOI 10.1038/sj.onc.1210701
   Dong J, 2012, NAT GENET, V44, P895, DOI 10.1038/ng.2351
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Du X, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/598987
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Garnis C, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-9
   Geng JF, 2012, ONCOL LETT, V3, P901, DOI 10.3892/ol.2012.587
   Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104
   Gray S, 2011, J PANCREAS, V12, P216
   Guenin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042704
   Gyöngyösi E, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-36
   Han L, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-65
   Hartmann O, 2009, CLIN CANCER RES, V15, P315, DOI 10.1158/1078-0432.CCR-08-0166
   Heller G, 2013, CARCINOGENESIS, V34, P513, DOI 10.1093/carcin/bgs363
   Heyn H, 2013, CARCINOGENESIS, V34, P102, DOI 10.1093/carcin/bgs321
   Hofsli E, 2008, BRIT J CANCER, V99, P1330, DOI 10.1038/sj.bjc.6604565
   Hollander M., 2013, Nonparametric Statistical Methods
   Huang X, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-22
   Hwang SH, 2011, CLIN CHEM LAB MED, V49, P699, DOI 10.1515/CCLM.2011.108
   Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002
   JAGLA K, 1995, MECH DEVELOP, V53, P345, DOI 10.1016/0925-4773(95)00450-5
   Kalari S, 2010, ADV GENET, V70, P277, DOI [10.1016/B978-0-12-380866-0.60010-1, 10.1016/S0065-2660(10)70010-9]
   Kamnasaran D, 2002, J MED GENET, V39, P81, DOI 10.1136/jmg.39.2.81
   Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
   Kelly ZL, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-16
   Ketterer K, 2009, CANCER LETT, V277, P72, DOI 10.1016/j.canlet.2008.11.028
   Kim TH, 2009, J KOREAR MED SCI, V24, P3
   Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y
   KRUSKAL WH, 1957, J AM STAT ASSOC, V52, P356, DOI 10.2307/2280906
   Kwon YJ, 2012, J THORAC ONCOL, V7, P20, DOI 10.1097/JTO.0b013e3182307f62
   Lauss M, 2012, EPIGENETICS-US, V7, P858, DOI 10.4161/epi.20837
   Levenson VV, 2012, PHARMACEUTICALS, V5, P94, DOI 10.3390/ph5010094
   Li L, 2012, GENOME RES, V22, P1222, DOI 10.1101/gr.128819.111
   Lin NJ, 2012, MOL CANCER RES, V10, P208, DOI 10.1158/1541-7786.MCR-10-0109
   Liu H, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-158
   Lleras RA, 2011, AM J PATHOL, V178, P1965, DOI 10.1016/j.ajpath.2011.01.049
   Lokk K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039813
   López-Lago MA, 2010, CANCER RES, V70, P9682, DOI 10.1158/0008-5472.CAN-10-2279
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Makinoshima H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-537
   McCabe MT, 2009, CANCER RES, V69, P282, DOI 10.1158/0008-5472.CAN-08-3274
   Metodieva SN, 2011, TUMORI, V97, P86, DOI 10.1177/030089161109700116
   Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022
   Milenkovic T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023016
   Mise N, 2012, J BIOL CHEM, V287, P31393, DOI 10.1074/jbc.M112.357624
   Mogi A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/583929
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   Mosca E, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-76
   Mukhopadhyay NK, 2005, J CELL MOL MED, V9, P387, DOI 10.1111/j.1582-4934.2005.tb00364.x
   Newman M. E. J., 2010, NETWORKS INTRO, DOI [10.1162/artl_r_00062, 10.1093/acprof:oso/9780199206650.001.0001]
   Newman RH, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.12
   Nguewa PA, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-103
   Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Okamoto J, 2010, ONCOGENE, V29, P5969, DOI 10.1038/onc.2010.330
   Okudela K, 2007, PATHOL INT, V57, P664, DOI 10.1111/j.1440-1827.2007.02155.x
   Palacios D, 2010, MOL CELL BIOL, V30, P3805, DOI 10.1128/MCB.00050-10
   Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396
   Pinto A, 2011, CANCER IMMUNOL IMMUN, V60, P1211, DOI 10.1007/s00262-011-1057-8
   Ponger L, 2002, BIOINFORMATICS, V18, P631, DOI 10.1093/bioinformatics/18.4.631
   Pradhan MP, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-331
   Rácz A, 2000, INT J ONCOL, V17, P67
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rauch TA, 2012, TUMOR BIOL, V33, P287, DOI 10.1007/s13277-011-0282-2
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7
   Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226
   Reimand J, 2011, NUCLEIC ACIDS RES, V39, pW307, DOI 10.1093/nar/gkr378
   Rindskopf D, 1997, J EDUC BEHAV STAT, V22, P245
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Salon C, 2007, J PATHOL, V213, P303, DOI 10.1002/path.2223
   Savani M, 2012, THER ADV MED ONCOL, V4, P225, DOI 10.1177/1758834012450362
   Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557
   Shinjo K, 2012, CARCINOGENESIS, V33, P1277, DOI 10.1093/carcin/bgs154
   Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269
   Snoussi K, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-38
   Spisák S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046215
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Steen HB, 2000, CARCINOGENESIS, V21, P1773, DOI 10.1093/carcin/21.10.1773
   Steinmann Katrin, 2011, Genes Cancer, V2, P65, DOI 10.1177/1947601911405043
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346
   Sun WY, 2010, CLIN CANCER RES, V16, P857, DOI 10.1158/1078-0432.CCR-09-2604
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tseng RC, 2008, LUNG CANCER, V59, P332, DOI 10.1016/j.lungcan.2007.08.038
   Tsuji T, 1997, Gan To Kagaku Ryoho, V24 Suppl 2, P263
   van Vlodrop IJH, 2010, AM J PATHOL, V176, P575, DOI 10.2353/ajpath.2010.090442
   Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016
   Vilas-Zornoza A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017012
   Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431
   Wang YF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019085
   Watanabe T, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-2
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wrzodek C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035327
   Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631
   Xie LL, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S3-S4
   Xu L, 2013, MOL BIOL CELL, V24, P42, DOI 10.1091/mbc.E12-07-0519
   Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591
   Yang SH, 2007, INT J MOL MED, V20, P225
   Yin DT, 2012, DISCOV MED, V14, P33
   Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5
   Yu GC, 2010, BIOINFORMATICS, V26, P976, DOI 10.1093/bioinformatics/btq064
   Zhang Y, 2011, MOL MED REP, V4, P1201, DOI 10.3892/mmr.2011.540
   ZHAO YX, 2013, INT J MOL MED, V5, P1211
   Zhou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-34
NR 133
TC 44
Z9 46
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1752-0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD DEC 26
PY 2013
VL 7
AR 141
DI 10.1186/1752-0509-7-141
PG 21
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA 290UC
UT WOS:000329782800001
PM 24369052
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Martínez-Galán, J
   Torres-Torres, B
   Núñez, MI
   López-Peñalver, J
   Del Moral, R
   De Almodóvar, JMR
   Menjón, S
   Concha, A
   Chamorro, C
   Ríos, S
   Delgado, JR
AF Martinez-Galan, Joaquina
   Torres-Torres, Blanca
   Isabel Nunez, Maria
   Lopez-Penalver, Jesus
   Del Moral, Rosario
   Ruiz De Almodovar, Jose Mariano
   Menjon, Salomon
   Concha, Angel
   Chamorro, Clara
   Rios, Sandra
   Ramon Delgado, Juan
TI <i>ESR1</i> gene promoter region methylation in free circulating DNA and
   its correlation with estrogen receptor protein expression in tumor
   tissue in breast cancer patients
SO BMC CANCER
LA English
DT Article
DE Breast cancer; Methylation; Luminal phenotypes
ID POLYMERASE-CHAIN-REACTION; CPG ISLAND METHYLATION; PROSTATE-CANCER;
   SERUM; PROGESTERONE; CELLS; ER; HYPERMETHYLATION; INACTIVATION;
   METASTASIS
AB Background: Tumor expression of estrogen receptor (ER) is an important marker of prognosis, and is predictive of response to endocrine therapy in breast cancer. Several studies have observed that epigenetic events, such methylation of cytosines and deacetylation of histones, are involved in the complex mechanisms that regulate promoter transcription. However, the exact interplay of these factors in transcription activity is not well understood. In this study, we explored the relationship between ER expression status in tumor tissue samples and the methylation of the 5' CpG promoter region of the estrogen receptor gene (ESR1) isolated from free circulating DNA (fcDNA) in plasma samples from breast cancer patients.
   Methods: Patients (n = 110) with non-metastatic breast cancer had analyses performed of ER expression (luminal phenotype in tumor tissue, by immunohistochemistry method), and the ESR1-DNA methylation status (fcDNA in plasma, by quantitative methylation specific PCR technique).
   Results: Our results showed a significant association between presence of methylated ESR1 in patients with breast cancer and ER negative status in the tumor tissue (p = 0.0179). There was a trend towards a higher probability of ESR1-methylation in those phenotypes with poor prognosis i.e. 80% of triple negative patients, 60% of HER2 patients, compared to 28% and 5.9% of patients with better prognosis such as luminal A and luminal B, respectively.
   Conclusion: Silencing, by methylation, of the promoter region of the ESR1 affects the expression of the estrogen receptor protein in tumors of breast cancer patients; high methylation of ESR1-DNA is associated with estrogen receptor negative status which, in turn, may be implicated in the patient's resistance to hormonal treatment in breast cancer. As such, epigenetic markers in plasma may be of interest as new targets for anticancer therapy, especially with respect to endocrine treatment.
C1 [Martinez-Galan, Joaquina; Ramon Delgado, Juan] Univ Granada, Hosp Univ Virgen Nieves, Dept Med Oncol, Granada 18011, Spain.
   [Torres-Torres, Blanca; Lopez-Penalver, Jesus; Ruiz De Almodovar, Jose Mariano] Univ Granada, Ctr Invest Biomed, Granada 18011, Spain.
   [Isabel Nunez, Maria; Rios, Sandra] Fac Med Granada, Dept Radiol & Med Fis, Granada, Spain.
   [Del Moral, Rosario] Hosp Univ Virgen Nieves, Serv Oncolo Radioterap, Granada, Spain.
   [Menjon, Salomon] Hosp Univ Virgen Nieves, Serv Ginecol, Granada, Spain.
   [Concha, Angel; Chamorro, Clara] Hosp Univ Virgen Nieves, Serv Anat Patol, Granada, Spain.
C3 Hospital Universitario Virgen de las Nieves; University of Granada;
   University of Granada; Hospital Universitario Virgen de las Nieves;
   Hospital Universitario Virgen de las Nieves; Hospital Universitario
   Virgen de las Nieves
RP Martínez-Galán, J (通讯作者)，Univ Granada, Hosp Univ Virgen Nieves, Dept Med Oncol, Ave Fuerzas Armadas S-N, Granada 18011, Spain.
EM jmgalan22@hotmail.com
RI Galán, Joaquina/ABH-2618-2020; Núñez, María/L-9924-2014; Lopez Penalver,
   Jesus J./E-5848-2012
OI Ruiz De Almodovar Rivera, Jose Mariano/0000-0002-7053-1072; Concha
   Lopez, Angel/0009-0007-9757-1051; Lopez Penalver, Jesus
   J./0000-0002-0823-4499; Martinez-Galan, Joaquina/0000-0002-6814-2748
FU Ministerio de Educacion y Ciencia [CICYT: SAF 2004-00889]
FX The study was funded, in part, by a grant from the Ministerio de
   Educacion y Ciencia (CICYT: SAF 2004-00889). The funding body had no
   involvement in the generation of the results, or in their interpretation
   and the decision to publish.
CR Bastian PJ, 2005, CLIN CANCER RES, V11, P4037, DOI 10.1158/1078-0432.CCR-04-2446
   Chan MF, 2000, CURR TOP MICROBIOL, V249, P75
   Dumitrescu Ramona G, 2012, Methods Mol Biol, V863, P3, DOI 10.1007/978-1-61779-612-8_1
   Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469
   Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243
   FUQUA SAW, 1993, BREAST CANCER RES TR, V26, P191, DOI 10.1007/BF00689692
   HEARD E, 1994, HUM MOL GENET, V3, P1481, DOI 10.1093/hmg/3.suppl_1.1481
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2005, J CLIN ONCOL, V23, P6569, DOI 10.1200/JCO.2005.07.009
   Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407
   Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035
   Martínez-Galán J, 2008, CANCER BIOL THER, V7, P962, DOI 10.4161/cbt.7.6.5966
   Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0
   Müller HM, 2003, CANCER RES, V63, P7641
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890
   Prabhu JS, 2012, TUMOR BIOL, V33, P315, DOI 10.1007/s13277-012-0343-1
   Ramezani F, 2012, ASIAN PAC J CANCER P, V13, P451, DOI 10.7314/APJCP.2012.13.2.451
   Ray S, 2011, J ENDOCRINOL, V208, P21, DOI 10.1677/JOE-10-0137
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Sotiriou C, 2006, ANN ONCOL, V17, pX259, DOI 10.1093/annonc/mdl270
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Valenzuela MT, 2002, EUR UROL, V42, P622, DOI 10.1016/S0302-2838(02)00468-2
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217
NR 33
TC 65
Z9 69
U1 0
U2 23
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 4
PY 2014
VL 14
AR 59
DI 10.1186/1471-2407-14-59
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AA4UT
UT WOS:000331092600001
PM 24495356
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Slingerland, M
   Guchelaar, HJ
   Gelderblom, H
AF Slingerland, Marije
   Guchelaar, Henk-Jan
   Gelderblom, Hans
TI Histone deacetylase inhibitors: an overview of the clinical studies in
   solid tumors
SO ANTI-CANCER DRUGS
LA English
DT Article
DE cancer; histone deacetylase; histone deacetylase inhibitors; solid
   tumors
ID PHASE-II TRIAL; SUBEROYLANILIDE HYDROXAMIC ACID; CELL LUNG-CANCER;
   CHROMOBACTERIUM-VIOLACEUM NO-968; REFRACTORY THYROID-CARCINOMA; VALPROIC
   ACID; EPIGENETIC THERAPY; PANOBINOSTAT LBH589; BREAST-CANCER; RECURRENT
   GLIOBLASTOMA
AB The histone deacetylase inhibitors (HDACi) are a group of small molecules that target histone deacetylases (HDACs) by inhibiting their activity. HDACi have a long history of use in neurology and psychiatry as antiepileptics and mood stabilizers. More recently, they have been investigated as possible treatments for cancer. HDACi have undergone rapid clinical development in recent years, on the basis of their preclinical in-vitro and in-vivo antitumor activity in hematological malignancies and solid tumors. Many HDACi have entered phase I-III clinical trials. Among the HDACi, vorinostat and romidepsin are currently the most extensively studied. In 2006 and 2009, respectively, they received approval by the United States Food and Drug Administration for treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell lymphoma. Other HDACi, such as panobinostat and valproic acid, also demonstrated activity as therapeutic anticancer agents. In this article we give an overview of the clinical studies of HDACi in solid tumors. We start with a short description of the working mechanism of HDACi in general. (C) 2014 Wolters Kluwer Health Lippincott Williams & Wilkins.
C1 [Slingerland, Marije; Gelderblom, Hans] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands.
   [Guchelaar, Henk-Jan] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, NL-2300 RC Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC
RP Slingerland, M (通讯作者)，Leiden Univ, Med Ctr, Dept Clin Oncol, Albinusdreef 2, NL-2300 RC Leiden, Netherlands.
EM m.slingerland@lumc.nl
RI Slingerland, Marije/AAD-8159-2022; guchelaar, henk-jan/AAP-1381-2021
OI Gelderblom, Hans/0000-0001-9270-8636; Guchelaar,
   Henk-Jan/0000-0002-7085-1383
CR Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019
   Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851
   Bates SE, 2006, CLIN CANCER RES, V12, P3871, DOI 10.1158/1078-0432.CCR-06-1017
   Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Chavez-Blanco A, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-22
   Chu BF, 2013, CANCER CHEMOTH PHARM, V71, P115, DOI 10.1007/s00280-012-1986-8
   Coiffier B, 2012, J CLIN ONCOL, V30, P631, DOI 10.1200/JCO.2011.37.4223
   Coronel J, 2011, MED ONCOL, V28, pS540, DOI 10.1007/s12032-010-9700-3
   Daud AI, 2009, CLIN CANCER RES, V15, P2479, DOI 10.1158/1078-0432.CCR-08-1931
   David KA, 2010, CANCER BIOL THER, V9, P678, DOI 10.4161/cbt.9.9.11436
   de Bono JS, 2008, CLIN CANCER RES, V14, P6663, DOI 10.1158/1078-0432.CCR-08-0376
   Dizon DS, 2012, INT J GYNECOL CANCER, V22, P979, DOI 10.1097/IGC.0b013e31825736fd
   Dong M, 2012, CANCER CHEMOTH PHARM, V69, P1413, DOI 10.1007/s00280-012-1847-5
   Drappatz J, 2012, J NEURO-ONCOL, V107, P133, DOI 10.1007/s11060-011-0717-z
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fakih MG, 2012, CANCER CHEMOTH PHARM, V69, P743, DOI 10.1007/s00280-011-1762-1
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Friday BB, 2012, NEURO-ONCOLOGY, V14, P215, DOI 10.1093/neuonc/nor198
   Fukutomi A, 2012, INVEST NEW DRUG, V30, P1096, DOI 10.1007/s10637-011-9666-9
   Galanis E, 2009, J CLIN ONCOL, V27, P2052, DOI 10.1200/JCO.2008.19.0694
   Giaccone G, 2011, J CLIN ONCOL, V29, P2052, DOI 10.1200/JCO.2010.32.4467
   Gore L, 2008, CLIN CANCER RES, V14, P4517, DOI 10.1158/1078-0432.CCR-07-1461
   Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/fmc.12.3, 10.4155/FMC.12.3]
   Haigentz M, 2012, ORAL ONCOL, V48, P1281, DOI 10.1016/j.oraloncology.2012.05.024
   Hainsworth JD, 2011, CANCER INVEST, V29, P451, DOI 10.3109/07357907.2011.590568
   Hauschild A, 2008, MELANOMA RES, V18, P274, DOI 10.1097/CMR.0b013e328307c248
   Iwamoto FM, 2011, NEURO-ONCOLOGY, V13, P509, DOI 10.1093/neuonc/nor017
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones SF, 2012, CANCER CHEMOTH PHARM, V70, P471, DOI 10.1007/s00280-012-1931-x
   Jones SF, 2012, CANCER INVEST, V30, P481, DOI 10.3109/07357907.2012.675382
   Jones Suzanne F, 2011, Clin Adv Hematol Oncol, V9, P225
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kelly WK, 2003, CLIN CANCER RES, V9, P3578
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791
   Lassen U, 2010, BRIT J CANCER, V103, P12, DOI 10.1038/sj.bjc.6605726
   Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Mackay HJ, 2010, EUR J CANCER, V46, P1573, DOI 10.1016/j.ejca.2010.02.047
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009
   Mohammed TA, 2011, ONCOLOGIST, V16, P835, DOI 10.1634/theoncologist.2011-0031
   Molife LR, 2010, ANN ONCOL, V21, P109, DOI 10.1093/annonc/mdp270
   Morita S, 2012, INVEST NEW DRUG, V30, P1950, DOI 10.1007/s10637-011-9751-0
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   Otterson GA, 2010, J THORAC ONCOL, V5, P1644, DOI 10.1097/JTO.0b013e3181ec1713
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182/blood-2010-10-312603
   Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150
   Pili R, 2012, BRIT J CANCER, V106, P77, DOI 10.1038/bjc.2011.527
   Plumb JA, 2003, MOL CANCER THER, V2, P721
   Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132
   Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162
   Ramalingam SS, 2010, J CLIN ONCOL, V28, P56, DOI 10.1200/JCO.2009.24.9094
   Ramalingam SS, 2009, J THORAC ONCOL, V4, P97, DOI 10.1097/JTO.0b013e318191520c
   Rathkopf D, 2010, CANCER CHEMOTH PHARM, V66, P181, DOI 10.1007/s00280-010-1289-x
   Razak ARA, 2011, BRIT J CANCER, V104, P756, DOI 10.1038/bjc.2011.13
   Rocca A, 2009, BRIT J CANCER, V100, P28, DOI 10.1038/sj.bjc.6604817
   Rodriguez-Gonzalez A, 2008, CANCER RES, V68, P2557, DOI 10.1158/0008-5472.CAN-07-5989
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Sandor V, 2002, CLIN CANCER RES, V8, P718
   Scherpereel A, 2011, EUR RESPIR J, V37, P129, DOI 10.1183/09031936.00037310
   Schrump DS, 2008, CLIN CANCER RES, V14, P188, DOI 10.1158/1078-0432.CCR-07-0135
   Shah MH, 2006, CLIN CANCER RES, V12, P3997, DOI 10.1158/1078-0432.CCR-05-2689
   Sherman EJ, 2013, THYROID, V23, P593, DOI 10.1089/thy.2012.0393
   SHIGEMATSU N, 1994, J ANTIBIOT, V47, P311, DOI 10.7164/antibiotics.47.311
   Siu LL, 2008, J CLIN ONCOL, V26, P1940, DOI 10.1200/JCO.2007.14.5730
   Stadler WM, 2006, CLIN GENITOURIN CANC, V5, P57, DOI 10.3816/CGC.2006.n.018
   Steele NL, 2008, CLIN CANCER RES, V14, P804, DOI 10.1158/1078-0432.CCR-07-1786
   Strickler JH, 2012, CANCER CHEMOTH PHARM, V70, P251, DOI 10.1007/s00280-012-1911-1
   Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478
   UEDA H, 1994, J ANTIBIOT, V47, P301
   Vansteenkiste J, 2008, INVEST NEW DRUG, V26, P483, DOI 10.1007/s10637-008-9131-6
   Wang HB, 2012, ANTICANCER RES, V32, P1027
   Whitehead RP, 2009, INVEST NEW DRUG, V27, P469, DOI 10.1007/s10637-008-9190-8
   Whittaker SJ, 2010, J CLIN ONCOL, V28, P4485, DOI 10.1200/JCO.2010.28.9066
   Witta SE, 2012, J CLIN ONCOL, V30, P2248, DOI 10.1200/JCO.2011.38.9411
   Woyach JA, 2009, J CLIN ENDOCR METAB, V94, P164, DOI 10.1210/jc.2008-1631
   Yeo W, 2012, J CLIN ONCOL, V30, P3361, DOI 10.1200/JCO.2011.41.2395
   Yong WP, 2011, ANN ONCOL, V22, P2516, DOI 10.1093/annonc/mdq784
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 91
TC 138
Z9 157
U1 1
U2 56
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4973
EI 1473-5741
J9 ANTI-CANCER DRUG
JI Anti-Cancer Drugs
PD FEB
PY 2014
VL 25
IS 2
BP 140
EP 149
DI 10.1097/CAD.0000000000000040
PG 10
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 292BJ
UT WOS:000329876400002
PM 24185382
DA 2025-01-12
ER

PT J
AU Salz, T
   Li, GY
   Kaye, F
   Zhou, L
   Qiu, Y
   Huang, SM
AF Salz, Tal
   Li, Guangyao
   Kaye, Frederic
   Zhou, Lei
   Qiu, Yi
   Huang, Suming
TI hSETD1A Regulates Wnt Target Genes and Controls Tumor Growth of
   Colorectal Cancer Cells
SO CANCER RESEARCH
LA English
DT Article
ID MESENCHYMAL TRANSITION; STEM-CELLS; BREAST-CANCER; HUMAN GENOME;
   HISTONE; METHYLATION; EXPRESSION; DISEASE; COMPLEX; EPIGENETICS
AB hSETD1A is a member of the trithorax (TrxG) family of histone methyltransferases (HMT) that methylate H3K4 at promoters of active genes. Although misregulation of mixed lineage leukemia (MLL) family proteins has been associated with acute leukemia, the role of hSETD1A in cancer remains unknown. In this study, we report that hSETD1A and its associated H3K4me3 are upregulated in human colorectal cancer cells and patient samples. Depletion of hSETD1A inhibits colorectal cancer cell growth, colony formation, and tumor engraftment. Genome-wide expression profiling of colorectal cancer cells reveals that approximately 50% of Wnt/beta-catenin target genes are affected by the hSETD1A knockdown. We further demonstrate that hSETD1A is recruited to promoters of those Wnt signaling target genes through its interaction with beta-catenin, a master regulator of the Wnt signaling pathway. The recruitment of the hSETD1A HMT complex confers promoter-associated H3K4me3 that leads to assembly of transcription preinitiation complex and transcriptional activation. Furthermore, the expression levels of hSETD1A are positively correlated with H3K4me3 enrichment at the promoters of Wnt/beta-catenin target genes and the aberrant activation of these genes in human colorectal cancer. These results provide new biologic and mechanistic insights into the cooperative role of hSETD1A and beta-catenin in regulation of Wnt target genes as well as in colorectal cancer cell growth in vitro and in vivo. (C) 2013 AACR.
C1 [Salz, Tal; Huang, Suming] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   [Li, Guangyao; Zhou, Lei] Univ Florida, Coll Med, Dept Microbiol & Mol Genet, Gainesville, FL 32610 USA.
   [Kaye, Frederic] Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA.
   [Qiu, Yi] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
   [Kaye, Frederic; Zhou, Lei; Qiu, Yi; Huang, Suming] Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida; State University System of Florida;
   University of Florida
RP Huang, SM (通讯作者)，Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
EM sumingh@ufl.edu
RI Li, Guangyao/I-8241-2015; kaye, frederic/E-2437-2011
OI , Yi/0000-0002-3282-6072
FU NIHealth [R01HL090589, R01HL091929, R01HL091929-01A1S1, R01HL095674,
   R56AI079074 ARRA]
FX This work was supported by grants from the NIHealth (to S. Huang,
   R01HL090589, R01HL091929, and R01HL091929-01A1S1-the ARRA Administrative
   supplement; to Y. Qiu, R01HL095674; to L. Zhou, R56AI079074 ARRA).
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Arzate-Mejía RG, 2011, IUBMB LIFE, V63, P881, DOI 10.1002/iub.557
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Cadigan KM, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002881
   Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Deng CW, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003524
   Enroth S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-450
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hirata A, 2013, DEVELOPMENT, V140, P66, DOI 10.1242/dev.084103
   Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370
   Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669
   Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052
   Lemieux S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-391
   Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523
   Li XG, 2011, BLOOD, V118, P1386, DOI 10.1182/blood-2010-11-319111
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Mohan M, 2010, NAT REV CANCER, V10, P720, DOI 10.1038/nrc2915
   Morgan MA, 2013, MOL CELL BIOL, V33, P1698, DOI 10.1128/MCB.00203-13
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100
   Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806
   Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270
   Suraweera N, 2006, INT J CANCER, V119, P1837, DOI 10.1002/ijc.22046
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   van Ingen H, 2008, STRUCTURE, V16, P1245, DOI 10.1016/j.str.2008.04.015
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012
NR 34
TC 62
Z9 69
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2014
VL 74
IS 3
BP 775
EP 786
DI 10.1158/0008-5472.CAN-13-1400
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AA4NX
UT WOS:000331073900015
PM 24247718
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Cheng, GC
   Sun, XQ
   Wang, JL
   Xiao, G
   Wang, XM
   Fan, XM
   Zu, LD
   Hao, MG
   Qu, Q
   Mao, Y
   Xue, YJ
   Wang, JH
AF Cheng, Guangcun
   Sun, Xueqing
   Wang, Jinglong
   Xiao, Gang
   Wang, Xiumin
   Fan, Xuemei
   Zu, Lidong
   Hao, Mingang
   Qu, Qing
   Mao, Yan
   Xue, Yunjing
   Wang, Jianhua
TI HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression
   through Misregulation of LCN2
SO CANCER RESEARCH
LA English
DT Article
ID GELATINASE-ASSOCIATED LIPOCALIN; ACUTE MYELOID-LEUKEMIA;
   TUMOR-SUPPRESSOR GENE; DIRECT TARGET GENE; TRANSCRIPTIONAL REPRESSION;
   MESENCHYMAL TRANSITION; DNA HYPERMETHYLATION; ENDOCYTIC RECEPTOR;
   ALLELIC LOSS; METHYLATION
AB The tumor suppressor gene HIC1 is frequently deleted or epigenetically silenced in human cancer, where its restoration may improve cancer prognosis. Here, we report results illuminating how HIC1 silencing alters effect or signals in triple-negative breast cancer (TNBC), which are crucial for its pathogenesis. HIC1 expression was silenced only in TNBC compared with other molecular subtypes of breast cancer. Restoring HIC1 expression in TNBC cells reduced cell migration, invasion, and metastasis, whereas RNAi-mediated silencing of HIC1 in untransformed human breast cells increased their invasive capabilities. Mechanistic investigations identified the small-secreted protein lipocalin-2 (LCN2), as a critical downstream target of HIC1 in TNBC cells. Elevating LCN2 expression in cells expressing HIC1 partially rescued its suppression of cell invasion and metastasis. Notably, autocrine secretion of LCN2 induced by loss of HIC1 activated the AKT pathway through the neutrophil gelatinase-associated lipocalin receptor, which is associated with TNBC progression. Taken together, our findings revealed that the HIC1-LCN2 axis may serve as a subtype-specific prognostic biomarker, providing an appealing candidate target for TNBC therapy.
C1 [Cheng, Guangcun; Sun, Xueqing; Wang, Jinglong; Xiao, Gang; Wang, Xiumin; Fan, Xuemei; Zu, Lidong; Hao, Mingang; Xue, Yunjing; Wang, Jianhua] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China.
   [Qu, Qing; Mao, Yan] Rui Jin Hosp, Comprehens Breast Hlth Ctr, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wang, JH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China.
EM jianhuaw2007@gmail.com
RI Xiao, Gang/IQU-8191-2023; Hao, Mingang/AAL-7254-2020
OI Hao, Mingang/0000-0001-6456-1710; Xiao, Gang/0000-0001-7784-4963
FU National Natural Foundation of China [81071747, 81272404]; National Key
   Program (973) for Basic Research of China [2011CB510106, 2011CB504300];
   Program for Professor of Special Appointment (Eastern Scholar) at the
   Shanghai Institute of Higher Learning; Program of the Shanghai Municipal
   Health Bureau Subject Chief Scientist [XBR20110052]
FX Research in the authors' laboratory is supported by the National Natural
   Foundation of China (81071747 and 81272404), the National Key Program
   (973) for Basic Research of China (2011CB510106, 2011CB504300), the
   Program for Professor of Special Appointment (Eastern Scholar to J.
   Wang) at the Shanghai Institute of Higher Learning, and Program of the
   Shanghai Municipal Health Bureau Subject Chief Scientist (XBR20110052).
CR Bauer M, 2008, BREAST CANCER RES TR, V108, P389, DOI 10.1007/s10549-007-9619-3
   Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908
   Burstein HJ, 2013, BREAST, V22, pS147, DOI 10.1016/j.breast.2013.07.027
   Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607
   Chakraborty S, 2012, BBA-REV CANCER, V1826, P129, DOI 10.1016/j.bbcan.2012.03.008
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Cho H, 2009, J HISTOCHEM CYTOCHEM, V57, P513, DOI 10.1369/jhc.2009.953257
   Cramer EP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039646
   Dehennaut V, 2013, BIOCHEM BIOPH RES CO, V430, P49, DOI 10.1016/j.bbrc.2012.11.045
   Deneberg S, 2010, LEUKEMIA, V24, P932, DOI 10.1038/leu.2010.41
   Devarajan P, 2007, CONTRIB NEPHROL, V156, P203
   Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027
   Eguchi K, 1997, CANCER RES, V57, P4913
   Engebraaten O, 2013, AM J PATHOL, V183, P1064, DOI 10.1016/j.ajpath.2013.05.033
   Fang WK, 2007, BIOCHEM J, V403, P297, DOI 10.1042/BJ20060836
   Fernández CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hayashi M, 2001, ANTICANCER RES, V21, P535
   Hvidberg V, 2005, FEBS LETT, V579, P773, DOI 10.1016/j.febslet.2004.12.031
   KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070
   Leng XH, 2011, J CELL PHYSIOL, V226, P309, DOI 10.1002/jcp.22403
   Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934
   Linn Sabine C, 2009, Eur J Cancer, V45 Suppl 1, P11, DOI 10.1016/S0959-8049(09)70012-7
   Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401
   Melki JR, 1999, CANCER RES, V59, P3730
   Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0
   Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163
   Parrella P, 2005, CANCER LETT, V222, P75, DOI 10.1016/j.canlet.2004.08.026
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Rodvold JJ, 2012, CANCER LETT, V316, P132, DOI 10.1016/j.canlet.2011.11.002
   Rood BR, 2002, CANCER RES, V62, P3794
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Stankovic-Valentin N, 2007, MOL CELL BIOL, V27, P2661, DOI 10.1128/MCB.01098-06
   Stockmans G, 2008, CURR OPIN ONCOL, V20, P614, DOI 10.1097/CCO.0b013e328312efba
   Stoesz SP, 1998, INT J CANCER, V79, P565, DOI 10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.3.CO;2-6
   Van Rechem C, 2010, MOL CELL BIOL, V30, P4045, DOI 10.1128/MCB.00582-09
   Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350
   Wang YP, 2013, HEPATOLOGY, V58, P1349, DOI 10.1002/hep.26467
   Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4
   Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106
   Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12
   Zheng JH, 2013, CLIN CANCER RES, V19, P1400, DOI 10.1158/1078-0432.CCR-12-2888
NR 43
TC 43
Z9 47
U1 0
U2 22
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2014
VL 74
IS 3
BP 862
EP 872
DI 10.1158/0008-5472.CAN-13-2420
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AA4NX
UT WOS:000331073900023
PM 24295734
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Williams, KE
   Anderton, DL
   Lee, MP
   Pentecost, BT
   Arcaro, KF
AF Williams, Kristin E.
   Anderton, Douglas L.
   Lee, Maxwell P.
   Pentecost, Brian T.
   Arcaro, Kathleen F.
TI High-density array analysis of DNA methylation in Tamoxifen-resistant
   breast cancer cell lines
SO EPIGENETICS
LA English
DT Article
DE Tamoxifen Resistance; Breast Cancer; Estrogen Receptor;
   HumanMethylation450 BeadChip; methylation; ZNF350; MAGED1
ID GENE-EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; INDUCTION; INVASION; VARIANT
AB Roughly two-thirds of all breast cancers are ER-positive and can be treated with the antiestrogen, Tamoxifen, however resistance occurs in 33% of women who take the drug for more than 5 y. Aberrant DNA methylation, an epigenetic mechanism that alters gene expression in cancer, is thought to play a role in this resistance. To develop an understanding of Tamoxifen-resistance and identify novel pathways and targets of aberrant methylation, DNA from MCF-7 breast cancer cells and Tamoxifen-resistant derivatives, TMX2-11 and TMX2-28, were analyzed using the Illumina HumanMethylation450 BeadChip. Normalizing against MCF-7 values, ER-positive TMX2-11 had 4000 hypermethylated sites and ER-negative TMX2-28 had over 33000. Analysis of CpG sites altered in both TMX2-11 and TMX2-28 revealed that the Tamoxifen-resistant cell lines share 3000 hypermethylated and 200 hypomethylated CpGs. ZNF350 and MAGED1, two genes hypermethylated in both cell lines, were examined in greater detail. Treatment with 5-aza-2?deoxycitidine caused a significant reduction in promoter methylation of both ZNF350 and MAGED1 and a corresponding increase in expression in TMX2-28. A similar relationship between methylation and expression was not detected in TMX2-11. Our findings are indicative of the variable responses to methylation-targeted breast cancer therapy and highlight the need for biomarkers that accurately predict treatment outcome.
C1 [Williams, Kristin E.; Arcaro, Kathleen F.] Univ Massachusetts, Dept Vet & Anim Sci, Mol & Cellular Biol Grad Program, Amherst, MA 01003 USA.
   [Anderton, Douglas L.] Univ S Carolina, Dept Sociol, Columbia, SC 29208 USA.
   [Lee, Maxwell P.] NIH, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Pentecost, Brian T.] Wadsworth Ctr, Albany, NY USA.
C3 University of Massachusetts System; University of Massachusetts Amherst;
   University of South Carolina System; University of South Carolina
   Columbia; National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); Wadsworth Center
RP Arcaro, KF (通讯作者)，Univ Massachusetts, Dept Vet & Anim Sci, Mol & Cellular Biol Grad Program, Amherst, MA 01003 USA.
EM karcaro@vasci.umass.edu
FU Department of Defense CDMRP Breast Cancer Pre-doctoral grant; Avon
   Foundation for Women; Rays of Hope Foundation
FX The authors would like to thank Dr John Gierthy for his generous gift of
   TMX2-11 and TMX2-28. Williams KE was funded by the Department of Defense
   CDMRP Breast Cancer Pre-doctoral grant. This research was supported by
   grants from the Avon Foundation for Women and the Rays of Hope
   Foundation to KFA.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   [Anonymous], 2012, MINFI ANAL ILLUMINAS
   Badia E, 2000, CANCER RES, V60, P4130
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Du Q, 2009, ONCOL REP, V22, P659, DOI 10.3892/or_00000486
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fasco MJ, 2003, MOL CELL ENDOCRINOL, V206, P33, DOI 10.1016/S0303-7207(03)00256-9
   Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250
   Garcia V, 2004, J PATHOL, V202, P224, DOI 10.1002/path.1513
   Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926
   Gozgit JM, 2006, MOL CANCER RES, V4, P905, DOI 10.1158/1541-7786.MCR-06-0147
   Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Jjingo D, 2012, ONCOTARGET, V3, P462, DOI 10.18632/oncotarget.497
   Krausz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044479
   Liang G, 2002, CANCER RES, V62, P961
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Sasaki A, 2005, J RECEPT SIG TRANSD, V25, P181, DOI 10.1080/10799890500210511
   Schmelz K, 2005, LEUKEMIA, V19, P103, DOI 10.1038/sj.leu.2403552
   Stone A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040466
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zhou CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3144
   Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970
NR 27
TC 22
Z9 25
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB 1
PY 2014
VL 9
IS 2
BP 297
EP 307
DI 10.4161/epi.27111
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AB6EK
UT WOS:000331880200014
PM 24225485
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Hsieh, CJ
   Kuo, PL
   Hsu, YC
   Huang, YF
   Tsai, EM
   Hsu, YL
AF Hsieh, Chia-Jung
   Kuo, Po-Lin
   Hsu, Ying-Chan
   Huang, Ya-Fang
   Tsai, Eing-Mei
   Hsu, Ya-Ling
TI Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen
   receptor-negative breast cancer cells through the ROS/p38 MAPK pathway
   and epigenetic regulation
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Arctigenin; Phytoestrogen; Apoptosis; Oxidative stress; Epigenetic;
   Breast cancer; Free radicals
ID ACTIVATING TRANSCRIPTION FACTOR-2; OXYGEN SPECIES GENERATION; OXIDATIVE
   STRESS; NADPH OXIDASE; ARCTIUM-LAPPA; SIGNALING PATHWAY; HEPATOMA-CELLS;
   CYCLE ARREST; GROWTH; TUMOR
AB This study investigates the anticancer effect of arctigenin (ATG), a natural lignan product of Arctium lappa L, in human breast cancer MDA-MB-231 cells. Results indicate that ATG inhibits MDA-MB-231 cell growth by inducing apoptosis in vitro and in vivo. ATG triggers the mitochondria] caspase-independent pathways, as indicated by changes in Bax/Bcl-2 ratio, resulting in AIF and EndoG nuclear translocation. ATG increased cellular reactive oxygen species (ROS) production by increasing p22(phox)/NADPH oxidase 1 interaction and decreasing glutathione level. ATG clearly increases the activation of p38 MAPK, but not JNK and ERK1/2. Antioxidant EUK-8, a synthetic catalytic superoxide and hydrogen peroxide scavenger, significantly decreases ATG-mediated p38 activation and apoptosis. Blocking p38 with a specific inhibitor suppresses ATG-mediated Bcl-2 downregulation and apoptosis. Moreover, ATG activates ATF-2, a transcription factor activated by p38, and then upregulates histone H3K9 trimethylation in the Bcl-2 gene promoter region, resulting in Bcl-2 downregulation. Taken together, the results demonstrate that ATG induces apoptosis of MDA-MB-231 cells via the ROS/p38 MAPK pathway and epigenetic regulation of Bcl-2 by upregulation of histone H3K9 trimethylation. Crown Copyright (C) 2013 Published by Elsevier Inc. All rights reserved.
C1 [Hsieh, Chia-Jung; Hsu, Ya-Ling] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 807, Taiwan.
   [Kuo, Po-Lin; Huang, Ya-Fang] Kaohsiung Med Univ, Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan.
   [Tsai, Eing-Mei] Kaohsiung Med Univ, Ctr Resources Res & Dev, Kaohsiung 807, Taiwan.
   [Hsieh, Chia-Jung; Hsu, Ying-Chan] Kaohsiung Med Univ Hosp, Dept Chinese Med, Kaohsiung 807, Taiwan.
   [Kuo, Po-Lin; Huang, Ya-Fang] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung 807, Taiwan.
   [Kuo, Po-Lin] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.
   [Tsai, Eing-Mei] Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital
RP Tsai, EM (通讯作者)，Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung 807, Taiwan.
EM tsaieing@yahoo.com; hsuyl326@gmail.com
RI Hsu, Ya-Ling/D-5143-2009
OI Huang, Ya-Fang/0000-0002-7790-8071
FU National Science Council of Taiwan [NSC 102-2632-B-037-001-MY3, NSC
   99-2320-B-037-017-MY3]; Excellence for Cancer Research Center grant,
   Department of Health, Executive Yuan, Taipei, Taiwan
   [DOH102-TD-C-111-002]; Kaohsiung Medical University Research Foundation
   [KMUER008]; Kaohsiung Medical University Hospital Research Foundation
   [KMUH 98-8G03, KMUH9836, 10034]
FX This study was supported by grants from the National Science Council of
   Taiwan (NSC 102-2632-B-037-001-MY3 and NSC 99-2320-B-037-017-MY3); an
   Excellence for Cancer Research Center grant, Department of Health,
   Executive Yuan, Taipei, Taiwan (DOH102-TD-C-111-002); the Kaohsiung
   Medical University Research Foundation (KMUER008); and the Kaohsiung
   Medical University Hospital Research Foundation (KMUH 98-8G03, KMUH9836,
   and 10034). The authors thank the Center for Resources, Research, and
   Development of Kaohsiung Medical University for support with
   instrumentation.
CR Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959
   Awale S, 2006, CANCER RES, V66, P1751, DOI 10.1158/0008-5472.CAN-05-3143
   Bhoumik A, 2008, CELL CYCLE, V7, P2341, DOI 10.4161/cc.6388
   Chen SY, 2008, J DERMATOL SCI, V51, P210, DOI 10.1016/j.jdermsci.2008.04.008
   Cheng YY, 2012, ONCOL REP, V28, P1482, DOI 10.3892/or.2012.1923
   Cho MK, 2004, INT IMMUNOPHARMACOL, V4, P1419, DOI 10.1016/j.intimp.2004.06.011
   Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233
   Duffy C, 2003, J WOMENS HEALTH, V12, P617, DOI 10.1089/154099903322404276
   Duffy C, 2007, CA-CANCER J CLIN, V57, P260, DOI 10.3322/CA.57.5.260
   Filomeni G, 2005, CANCER RES, V65, P11735, DOI 10.1158/0008-5472.CAN-05-3067
   FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6
   Fujino G, 2006, SEMIN CANCER BIOL, V16, P427, DOI 10.1016/j.semcancer.2006.09.003
   Gu Y, 2012, BIOCHEM PHARMACOL, V84, P468, DOI 10.1016/j.bcp.2012.06.002
   Ham YM, 2006, J PHARMACOL EXP THER, V319, P1276, DOI 10.1124/jpet.106.109926
   Hausott B, 2003, J CANCER RES CLIN, V129, P569, DOI 10.1007/s00432-003-0461-7
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Jemal A., 2010, CA CANC J DIN, V60, P277
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jeong JB, 2011, INT IMMUNOPHARMACOL, V11, P1573, DOI 10.1016/j.intimp.2011.05.016
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim BC, 2005, BIOCHEM PHARMACOL, V70, P1398, DOI 10.1016/j.bcp.2005.07.025
   Kondo N, 2006, ANTIOXID REDOX SIGN, V8, P1881, DOI 10.1089/ars.2006.8.1881
   Kuo PL, 2007, CANCER RES, V67, P7406, DOI 10.1158/0008-5472.CAN-07-1089
   Lee SH, 2010, ONCOGENE, V29, P5182, DOI 10.1038/onc.2010.251
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Liem AA, 2003, BRIT J CANCER, V88, P1281, DOI 10.1038/sj.bjc.6600898
   Liu Y, 2009, CANCER RES, V69, P5954, DOI 10.1158/0008-5472.CAN-09-0778
   Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681
   Ma Q, 2007, J CELL BIOCHEM, V101, P477, DOI 10.1002/jcb.21198
   Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06
   Matsumoto T, 2006, PLANTA MED, V72, P276, DOI 10.1055/s-2005-916174
   Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538
   Moungjaroen J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI 10.1124/jpet.106.110965
   Ortiz C, 2008, BIOCHEM PHARMACOL, V75, P1935, DOI 10.1016/j.bcp.2008.02.015
   Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361
   Paletta-Silva R, 2013, INT J MOL SCI, V14, P3683, DOI 10.3390/ijms14023683
   Park DH, 2011, ONCOL REP, V26, P833, DOI 10.3892/or.2011.1364
   Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086
   Rochefort H, 2003, ENDOCR-RELAT CANCER, V10, P261, DOI 10.1677/erc.0.0100261
   Saleh A, 2008, GENE, V423, P43, DOI 10.1016/j.gene.2008.06.022
   Sirtori CR, 2005, ANN MED, V37, P423, DOI 10.1080/07853890510044586
   Stearns V, 2007, CANCER INVEST, V25, P659, DOI 10.1080/07357900701719234
   Susanti S, 2012, J NAT MED-TOKYO, V66, P614, DOI 10.1007/s11418-012-0628-0
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Velentzis LS, 2008, EUR J CANCER, V44, P1799, DOI 10.1016/j.ejca.2008.05.019
   Wang X, 2011, TOXICOL SCI, V123, P399, DOI 10.1093/toxsci/kfr180
   Woo IS, 2002, INT J ONCOL, V20, P527
   YIM CY, 1994, J IMMUNOL, V152, P5796
   Yoo JH, 2010, FOOD CHEM TOXICOL, V48, P2247, DOI 10.1016/j.fct.2010.05.056
   Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361
   Zhao F, 2009, J ETHNOPHARMACOL, V122, P457, DOI 10.1016/j.jep.2009.01.038
NR 53
TC 132
Z9 144
U1 0
U2 40
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB
PY 2014
VL 67
BP 159
EP 170
DI 10.1016/j.freeradbiomed.2013.10.004
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AB5UM
UT WOS:000331854200016
PM 24140706
DA 2025-01-12
ER

PT J
AU Gao, F
   Ji, GY
   Gao, ZW
   Han, X
   Ye, MZ
   Yuan, ZM
   Luo, HJ
   Huang, XJ
   Natarajan, K
   Wang, J
   Yang, HM
   Zhang, XQ
AF Gao, Fei
   Ji, Guanyu
   Gao, Zhaowei
   Han, Xu
   Ye, Mingzhi
   Yuan, Zhimei
   Luo, Huijuan
   Huang, Xiaojun
   Natarajan, Karthikraj
   Wang, Jun
   Yang, Huanming
   Zhang, Xiuqing
TI Direct ChIP-bisulfite sequencing reveals a role of H3K27me3 mediating
   aberrant hypermethylation of promoter CpG islands in cancer cells
SO GENOMICS
LA English
DT Article
DE DNA methylation; Chromatin immunoprecipitation; CpG Island; Gastric
   cancer
ID EMBRYONIC STEM-CELLS; DNA METHYLATION; BREAST-CANCER; HISTONE H3;
   GENOME; CHROMATIN; GENES; SEQ; CARCINOGENESIS; TRANSCRIPTION
AB The model describing that aberrant CpG island (CGI) methylation leads to repression of tumour suppressor genes in cancers has been influential, but it remains unclear how such aberrancy is induced. Recent studies provided clues indicating that promoter hypermethylation in cancers might be associated with PRC target genes. Here, we used ChIP-BS-seq to examine methylation of the DNA fragments precipitated by the antibodies to both H3K27me3 and H3K4me3 histone modifications. We showed that, for a set of genes highly enriched with H3K27me3 both in cancer and normal cells, CGI promoters were aberrantly hypermethylated only in cancer cells in comparison with normal cells. In contrast, such aberrant CGI hypermethylation in cancer promoters that were deficient of H3K27me3 was not notable. Furthermore, we confirmed that these genes were consistently hypermethylated in TCGA primary cancer cells. These works support the association between H3K27me3 and DNA methylation marks for specific cancer genes and will spur future work on combined histone and DNA methylation that could define cancer's epigenetic abnormalities. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Gao, Fei; Ji, Guanyu; Gao, Zhaowei; Han, Xu; Ye, Mingzhi; Yuan, Zhimei; Luo, Huijuan; Huang, Xiaojun; Natarajan, Karthikraj; Wang, Jun; Yang, Huanming; Zhang, Xiuqing] BGI Shenzhen, Sci & Technol Dept, Shenzhen 518083, Peoples R China.
   [Wang, Jun] Univ Copenhagen, Dept Biol, DK-2200 Copenhagen, Denmark.
   [Wang, Jun] King Abdulaziz Univ, Jeddah 21589, Saudi Arabia.
   [Wang, Jun] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, DK-2200 Copenhagen, Denmark.
   [Huang, Xiaojun] Wuhan Univ, Coll Life Sci, Wuhan 430072, Peoples R China.
C3 Beijing Genomics Institute (BGI); University of Copenhagen; King
   Abdulaziz University; Novo Nordisk Foundation; University of Copenhagen;
   Wuhan University
RP Gao, F (通讯作者)，BGI Shenzhen, Sci & Technol Dept, Shenzhen 518083, Peoples R China.
EM gaofei@genomics.cn
RI gao, zhaowei/KEI-1214-2024; Wang, Jun/A-7261-2013; Yang,
   Huanming/C-6513-2013; Wang, Jun/B-9503-2016; Wang, Jun/C-8434-2016
OI Ji, Guanyu/0000-0001-9818-8694; Yang, Huanming/0000-0002-0858-3410;
   Wang, Jun/0000-0002-2113-5874; Wang, Jun/0000-0002-8540-8931
FU National High Technology Research and Development Program of China (863
   Program) [2009AA022707]
FX We thank Laurie Goodman for help in editing the manuscript and thank
   Youyong Lv for kindly providing the two gastric cancer cell lines. This
   study was supported by grants from the National High Technology Research
   and Development Program of China (863 Program, No. 2009AA022707).
CR Bauerschlag DO, 2011, ONCOLOGY-BASEL, V80, P12, DOI 10.1159/000327746
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bestor TH, 2003, ANN NY ACAD SCI, V983, P22, DOI 10.1111/j.1749-6632.2003.tb05959.x
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Brune K, 2008, CANCER EPIDEM BIOMAR, V17, P3536, DOI 10.1158/1055-9965.EPI-08-0630
   Buck-Koehntop BA, 2013, EPIGENETICS-US, V8, P131, DOI 10.4161/epi.23632
   Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Gonzalez M, 2012, EPIGENETICS-US, V7, P14, DOI 10.4161/epi.7.1.18545
   Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Li GQ, 2009, NUCLEIC ACIDS RES, V37, pD1025, DOI 10.1093/nar/gkn966
   Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Moison C, 2013, FASEB J, V27, P1468, DOI 10.1096/fj.12-210971
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pedersen SF, 2013, CANCER RES, V73, P1658, DOI 10.1158/0008-5472.CAN-12-4188
   Prevarskaya N, 2013, EXPERT OPIN THER TAR, V17, P225, DOI 10.1517/14728222.2013.741594
   Severson P.L., 2013, EPIGENETICS, P8
   Simon SA, 2011, CURR OPIN PLANT BIOL, V14, P148, DOI 10.1016/j.pbi.2010.11.007
   Song QA, 2011, BIOINFORMATICS, V27, P870, DOI 10.1093/bioinformatics/btr030
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang SS, 2008, CANCER RES, V68, P2489, DOI 10.1158/0008-5472.CAN-07-3194
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
NR 42
TC 31
Z9 32
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0888-7543
EI 1089-8646
J9 GENOMICS
JI Genomics
PD FEB-MAR
PY 2014
VL 103
IS 2-3
BP 204
EP 210
DI 10.1016/j.ygeno.2013.12.006
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AF6KH
UT WOS:000334823500006
PM 24407023
OA Bronze
DA 2025-01-12
ER

PT J
AU Jeong, KW
   Andreu-Vieyra, C
   You, JS
   Jones, PA
   Stallcup, MR
AF Jeong, Kwang Won
   Andreu-Vieyra, Claudia
   You, Jueng Soo
   Jones, Peter A.
   Stallcup, Michael R.
TI Establishment of active chromatin structure at enhancer elements by
   mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID DNA METHYLTRANSFERASE; EPIGENETIC SIGNATURES; HUMAN GENOME; CXXC DOMAIN;
   RECEPTOR; METHYLATION; COMPLEX; MLL1; IDENTIFICATION; DEMETHYLATION
AB A number of genome-wide analyses have revealed that estrogen receptor alpha binding to and regulation of its target genes correlate with binding of FOXA1, a pioneer factor, to nearby DNA sites in MCF-7 breast cancer cells. The enhancer element-specific histone H3K4me1/2 mark is enriched at the specific FOXA1/ER alpha recruitment sites in chromatin, but the mechanism by which these enhancer marks are established in chromatin before hormone treatment is unclear. Here, we show that mixed-lineage leukemia 1 (MLL1) protein is a key determinant that maintains permissive chromatin structure of the TFF1 enhancer region. MLL1 occupies the TFF1 enhancer region and methylates H3K4 before hormone stimulation. In vitro, MLL1 binds directly to the CpG-rich region of the TFF1 enhancer, and its binding is dependent on hypomethylation of DNA. Furthermore, the depletion of MLL1 in MCF-7 cells results in a dramatic decrease of chromatin accessibility and recruitment of FOXA1 and ER alpha to the enhancer element. Our study defines the mechanism by which MLL1 nucleates histone H3K4 methylation marks in CpG-enriched regions to maintain permissive chromatin architecture and allow FOXA1 and estrogen receptor alpha binding to transcriptional regulatory sites in breast cancer cells.
C1 [Jeong, Kwang Won] Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, Inchon 406840, South Korea.
   [Andreu-Vieyra, Claudia; Jones, Peter A.] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90089 USA.
   [Andreu-Vieyra, Claudia; Jones, Peter A.; Stallcup, Michael R.] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.
   [You, Jueng Soo] Konkuk Univ, Sch Med, Dept Biochem, Seoul 143701, South Korea.
C3 Gachon University; University of Southern California; University of
   Southern California; Konkuk University; Konkuk University Medical Center
RP Stallcup, MR (通讯作者)，Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.
EM kwjeong@gachon.ac.kr; stallcup@usc.edu
FU National Institutes of Health (NIH) [DK043093, R37CA 082422]; National
   Cancer Institute [P30CA014089]
FX National Institutes of Health (NIH) [DK043093 to M.R.S., R37CA 082422 to
   P.A.J.]; National Cancer Institute provided the Cancer Center Support
   Grant [P30CA014089 to the University of Southern California]. Funding
   for open access charge: NIH [DK043093].
CR Ansari KI, 2008, BBA-GENE REGUL MECH, V1779, P66, DOI 10.1016/j.bbagrm.2007.11.006
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Auerbach RK, 2009, P NATL ACAD SCI USA, V106, P14926, DOI 10.1073/pnas.0905443106
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Cheung E, 2011, NAT GENET, V43, P11, DOI 10.1038/ng0111-11
   Cierpicki T, 2010, NAT STRUCT MOL BIOL, V17, P62, DOI 10.1038/nsmb.1714
   Crawford BD, 2006, ACS CHEM BIOL, V1, P495, DOI 10.1021/cb600367v
   Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256
   Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105
   Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000
   Fujita N, 1999, MOL CELL BIOL, V19, P6415
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153
   Jeong KW, 2009, J BIOL CHEM, V284, P29298, DOI 10.1074/jbc.M109.037010
   John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kim ST, 2007, P NATL ACAD SCI USA, V104, P17052, DOI 10.1073/pnas.0708293104
   Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207
   Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Milne TA, 2010, MOL CELL, V38, P853, DOI 10.1016/j.molcel.2010.05.011
   Miranda T.B., 2010, CURRENT PROTOCOLS MO
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Santangelo S, 2009, CHROMOSOME RES, V17, P485, DOI 10.1007/s10577-009-9040-3
   Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509
   Sérandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444
   Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Thomassin H, 2001, EMBO J, V20, P1974, DOI 10.1093/emboj/20.8.1974
   Voo KS, 2000, MOL CELL BIOL, V20, P2108
   Wiench M, 2011, EMBO J, V30, P3028, DOI 10.1038/emboj.2011.210
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Xi HL, 2007, PLOS GENET, V3, P1377, DOI 10.1371/journal.pgen.0030136
   Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228
   Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111
NR 50
TC 20
Z9 23
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD FEB
PY 2014
VL 42
IS 4
BP 2245
EP 2256
DI 10.1093/nar/gkt1236
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AC2YA
UT WOS:000332381000021
PM 24288367
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Liu, MX
   Siu, MK
   Liu, SS
   Yam, JW
   Ngan, HY
   Chan, DW
AF Liu, Michelle X.
   Siu, Michelle Ky
   Liu, Stephanie S.
   Yam, Judy Wp
   Ngan, Hextan Ys
   Chan, David W.
TI Epigenetic silencing of microRNA-199b-5p is associated with acquired
   chemoresistance via activation of JAG1-Notch1 signaling in ovarian
   cancer
SO ONCOTARGET
LA English
DT Article
DE MiR-199b-5p; JAG1-Notch1; acquired chemoresistance; epithelial ovarian
   cancer
ID CLEAR-CELL CARCINOMA; BREAST-CANCER; DRUG-RESISTANCE; TUMOR-SUPPRESSOR;
   DOWN-REGULATION; UP-REGULATION; CISPLATIN; PATHWAY; NOTCH; MICRORNAS
AB Epithelial ovarian cancer is a highly lethal and aggressive gynecological malignancy. The high mortality rate is due in part to the fact that many advanced cancer patients become refractory to current chemotherapeutic agents, leading to tumor recurrence and death. However, the underlying mechanisms leading to chemoresistance remain obscure. Here, we report that the loss of miR-199b-5p due to progressive epigenetic silencing leads to the activation of the JAG1-mediated Notch1 signaling cascade, thereby leading to the development of acquired chemoresistance in ovarian cancer. Using miRCURY LNA (TM) microRNA array and Q-PCR analyses of two pairs of cisplatin-sensitive and -resistant ovarian cancer cell lines, we identified miR-199b-5p as significantly down-regulated in cisplatin-resistant ovarian cancer cells and confirmed that miR-199b-5p is clinically associated with advanced and poor survival ovarian cancers. Interestingly, the loss of miR-199b-5p could be restored by 5-Aza-dC-mediated demethylation, and methylated specific PCR (MS-PCR), bisulfite-sequencing and pyrosequencing revealed that the promoter region of miR-199b-5p was hypermethylated. Computational and mechanistic analyses identified JAG1 as a primary target of miR-199b-5p. Notably, the reduced expression of miR-199b-5p was found to be inversely correlated with the increased expression of JAG1 using an ovarian cancer tissue array. Enforced expression of miR-199b-5p sensitized ovarian cancer cells to cisplatin-induced cytotoxicity both in vitro and in vivo. Conversely, re-expression of miR-199b-5p and siRNA-mediated JAG1 knockdown or treatment with Notch specific inhibitor Y-secretase (GSI) attenuated JAG1-Notch1 signaling activity, thereby enhancing cisplatin-mediated cell cytotoxicity. Taken together, our study suggests that the epigenetic silencing of miR-199b-5p during tumor progression is significantly associated with acquired chemoresistance in ovarian cancer through the activation of JAG1-Notch1 signaling.
C1 [Liu, Michelle X.; Siu, Michelle Ky; Liu, Stephanie S.; Ngan, Hextan Ys; Chan, David W.] Univ Hong Kong, Dept Obstet & Gynaecol, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Yam, Judy Wp] Univ Hong Kong, Dept Pathol, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Ngan, HY (通讯作者)，Univ Hong Kong, Dept Obstet & Gynaecol, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
EM hysngan@hku.hk; dwchan@hku.hk
RI Yam, Judy Wai Ping/C-4454-2009; Chan, David/O-9896-2018
OI Yam, Judy Wai Ping/0000-0002-5637-121X; Liu, Michelle
   Xin/0000-0002-5795-2948; Ngan, Hextan Y S/0000-0003-3945-159X; Chan,
   David/0000-0002-6951-3467
CR Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123
   Aktas S, 2010, HEPATO-GASTROENTEROL, V57, P891
   Al-Bahlani S, 2011, ONCOGENE, V30, P4219, DOI 10.1038/onc.2011.134
   [Anonymous], 2011, NATURE, V474, P609
   Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020
   Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167
   Chen L, 2012, CARCINOGENESIS
   Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001
   Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061
   Eltabbakh G H, 2001, Expert Opin Pharmacother, V2, P109, DOI 10.1517/14656566.2.1.109
   Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002
   Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112
   Geisler J P, 2004, Minerva Ginecol, V56, P539
   Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6
   Hopfer O, 2005, BRIT J CANCER, V93, P709, DOI 10.1038/sj.bjc.6602719
   Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630
   Ibrahim N, 2010, CANCER RES, V70, P7155, DOI 10.1158/0008-5472.CAN-10-0668
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Kim A, 2009, INT J CANCER, V125, P2316, DOI 10.1002/ijc.24587
   Kofler Natalie M, 2011, Genes Cancer, V2, P1106, DOI 10.1177/1947601911423030
   Lee YM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3059
   Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547
   Marchini S, 2013, EUR J CANCER, V49, P520, DOI 10.1016/j.ejca.2012.06.026
   McAuliffe SM, 2012, P NATL ACAD SCI USA, V109, pE2939, DOI 10.1073/pnas.1206400109
   Meng RD, 2009, CANCER RES, V69, P573, DOI 10.1158/0008-5472.CAN-08-2088
   Muggia F, 2009, GYNECOL ONCOL, V112, P275, DOI 10.1016/j.ygyno.2008.09.034
   Nehme A, 1997, CANCER RES, V57, P3253
   Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153
   Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092
   Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035
   Ravi D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000527
   Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106
   Santarpia L, 2010, ENDOCR-RELAT CANCER, V17, pF51, DOI 10.1677/ERC-09-0222
   Shahzad MMK, 2009, DRUG RESIST UPDATE, V12, P148, DOI 10.1016/j.drup.2009.09.001
   Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528
   Shimizu M, 2011, CANCER RES, V71, P277, DOI 10.1158/0008-5472.CAN-10-2523
   Simon DP, 2012, CLIN CANCER RES, V18, P2452, DOI 10.1158/1078-0432.CCR-11-2371
   Stany MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021121
   Steg AD, 2011, CLIN CANCER RES, V17, P5674, DOI 10.1158/1078-0432.CCR-11-0432
   Suzuki S, 2011, CANCER SCI, V102, P1622, DOI 10.1111/j.1349-7006.2011.02003.x
   van Jaarsveld MTM, 2010, INT J BIOCHEM CELL B, V42, P1282, DOI 10.1016/j.biocel.2010.01.014
   Vecchione A, 2013, P NATL ACAD SCI USA, V110, P9845, DOI 10.1073/pnas.1305472110
   Wang ZW, 2010, J CELL BIOCHEM, V109, P726, DOI 10.1002/jcb.22451
   Wang ZW, 2006, INT J CANCER, V118, P1930, DOI 10.1002/ijc.21589
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223
   Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200
   Zeller C., 2012, Oncogene
   Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105
   Zhang Zu-Ping, 2009, Ai Zheng, V28, P100
NR 62
TC 112
Z9 126
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB
PY 2014
VL 5
IS 4
BP 944
EP 958
DI 10.18632/oncotarget.1458
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AI6EA
UT WOS:000336962300009
PM 24659709
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Lepore, I
   Dell'Aversana, C
   Pilyugin, M
   Conte, M
   Nebbioso, A
   De Bellis, F
   Tambaro, FP
   Izzo, T
   Garcia-Manero, G
   Ferrara, F
   Irminger-Finger, I
   Altucci, L
AF Lepore, Ilaria
   Dell'Aversana, Carmela
   Pilyugin, Maxim
   Conte, Mariarosaria
   Nebbioso, Angela
   De Bellis, Floriana
   Tambaro, Francesco P.
   Izzo, Tiziana
   Garcia-Manero, Guillermo
   Ferrara, Felicetto
   Irminger-Finger, Irmgard
   Altucci, Lucia
TI HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid
   Leukemia Cells via Activation of miR-19a and/or b
SO PLOS ONE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; MS-275; IDENTIFICATION; VORINOSTAT;
   MICRORNAS; CANCER; TRANSLOCATION; INTERFERENCE; CARCINOMA; APOPTOSIS
AB Over the past years BARD1 (BRCA1-associated RING domain 1) has been considered as both a BRCA1 (BReast Cancer susceptibility gene 1, early onset) interactor and tumor suppressor gene mutated in breast and ovarian cancers. Despite its role as a stable heterodimer with BRCA1, increasing evidence indicates that BARD1 also has BRCA1-independent oncogenic functions. Here, we investigate BARD1 expression and function in human acute myeloid leukemias and its modulation by epigenetic mechanism(s) and microRNAs. We show that the HDACi (histone deacetylase inhibitor) Vorinostat reduces BARD1 mRNA levels by increasing miR-19a and miR-19b expression levels. Moreover, we identify a specific BARD1 isoform, which might act as tumor diagnostic and prognostic markers.
C1 [Lepore, Ilaria; Dell'Aversana, Carmela; Conte, Mariarosaria; Nebbioso, Angela; De Bellis, Floriana; Tambaro, Francesco P.; Altucci, Lucia] Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Naples, Italy.
   [Dell'Aversana, Carmela; Altucci, Lucia] Inst Genet & Biophys IGB, Naples, Italy.
   [Tambaro, Francesco P.; Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Pilyugin, Maxim; Irminger-Finger, Irmgard] HUG, Univ Hosp Geneva, Mol Gynecol & Obstet Lab, Dept Gynecol & Obstet, Geneva, Switzerland.
   [Pilyugin, Maxim; Irminger-Finger, Irmgard] HUG, Univ Hosp Geneva, Dept Genet & Lab Med, Geneva, Switzerland.
   [Izzo, Tiziana; Ferrara, Felicetto] Cardarelli Hosp, Div Hematol, Naples, Italy.
   [Izzo, Tiziana; Ferrara, Felicetto] Cardarelli Hosp, Stem Cell Transplantat Unit, Naples, Italy.
C3 Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso"
   (IGB-CNR); University of Texas System; UTMD Anderson Cancer Center;
   University of Geneva; University of Geneva; Antonio Cardarelli Hospital;
   Antonio Cardarelli Hospital
RP Altucci, L (通讯作者)，Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Naples, Italy.
EM lucia.altucci@unina2.it
RI Altucci, Lucia/S-8031-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Conte,
   Mariarosaria/K-7352-2016; NEBBIOSO, Angela/C-3566-2016; dell'aversana,
   carmela/P-7829-2018; Tambaro, Francesco Paolo/AAN-4408-2021
OI Conte, Mariarosaria/0000-0002-3622-1476; NEBBIOSO,
   Angela/0000-0001-5374-3527; dell'aversana, carmela/0000-0001-6588-698X;
   Tambaro, Francesco Paolo/0000-0002-9145-3691; altucci,
   lucia/0000-0002-7312-5387
FU EU: Blueprint [282510]; Italian IHEC (Flag Project: EPIGEN); Italian
   Association for Cancer Research (AIRC) [11812]; Italian Ministry of
   University and Research [PRIN_2009PX2T2E_004]; Swiss National Research
   Foundations [NF 3100A0-122353]; Ligue SuisseContre le Cancer [KLS
   01962-10-2006]; LigueGenevoiseContre le Cancer [(LGCC 1117]; 
   [PON0101227]
FX Grant Support. This work was supported by EU: Blueprint (contract no.
   282510); Italian IHEC (Flag Project: EPIGEN); the Italian Association
   for Cancer Research (AIRC no. 11812); Italian Ministry of University and
   Research (PRIN_2009PX2T2E_004); PON0101227; Swiss National Research
   Foundations (NF 3100A0-122353), Ligue SuisseContre le Cancer (KLS
   01962-10-2006), and LigueGenevoiseContre le Cancer (LGCC 1117) to IIF.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921
   Bosse KR, 2012, CANCER RES, V72, P2068, DOI 10.1158/0008-5472.CAN-11-3703
   Bracker TU, 2009, INT J ONCOL, V35, P909, DOI 10.3892/ijo_00000406
   Breving K, 2010, INT J BIOCHEM CELL B, V42, P1316, DOI 10.1016/j.biocel.2009.09.016
   Brueckner B, 2007, CANCER RES, V67, P1419, DOI 10.1158/0008-5472.CAN-06-4074
   Chan SP, 2007, DEV CELL, V13, P605, DOI 10.1016/j.devcel.2007.10.010
   Choudhury AD, 2005, J BIOL CHEM, V280, P24669, DOI 10.1074/jbc.M502446200
   Conte M, 2012, CLIN CANCER RES, V18, P5526, DOI 10.1158/1078-0432.CCR-12-2037
   Edwards RA, 2008, BIOCHEMISTRY-US, V47, P11446, DOI 10.1021/bi801115g
   Feki A, 2005, ONCOGENE, V24, P3726, DOI 10.1038/sj.onc.1208491
   Garcia-Manero G, 2012, J CLIN ONCOL, V30, P2204, DOI 10.1200/JCO.2011.38.3265
   Gautier F, 2000, CANCER RES, V60, P6895
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   Henderson BR, 2005, BIOESSAYS, V27, P884, DOI 10.1002/bies.20277
   Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009
   Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878
   Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3
   Irminger-Finger I, 2010, GYNECOL ONCOL, V117, P211, DOI 10.1016/j.ygyno.2009.10.079
   Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427
   Li L, 2007, CANCER RES, V67, P11876, DOI 10.1158/0008-5472.CAN-07-2370
   Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1
   Mahadevan D, 2006, AM J HEMATOL, V81, P779, DOI 10.1002/ajh.20690
   Mai A, 2005, J MED CHEM, V48, P3344, DOI 10.1021/jm049002a
   Mann BS, 2007, CLIN CANCER RES, V13, P2318, DOI 10.1158/1078-0432.CCR-06-2672
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037
   Mercurio C, 2010, PHARMACOL RES, V62, P18, DOI 10.1016/j.phrs.2010.02.010
   Nebbioso A, 2009, EMBO REP, V10, P776, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]
   O'Connor OA, 2006, J CLIN ONCOL, V24, P166, DOI 10.1200/JCO.2005.01.9679
   Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004
   Rosato RR, 2003, CANCER RES, V63, P3637
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Ryser S, 2009, CANCER RES, V69, P1125, DOI 10.1158/0008-5472.CAN-08-2134
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110
   Shan G, 2010, INT J BIOCHEM CELL B, V42, P1243, DOI 10.1016/j.biocel.2009.04.023
   Sporn JC, 2011, CLIN CANCER RES, V17, P5451, DOI 10.1158/1078-0432.CCR-11-0263
   Tembe V, 2007, J BIOL CHEM, V282, P20513, DOI 10.1074/jbc.M702627200
   Wang YM, 2011, RESULTS PROBL CELL D, V53, P459, DOI 10.1007/978-3-642-19065-0_19
   Wu JY, 2006, INT J CANCER, V118, P1215, DOI 10.1002/ijc.21428
   Xu XM, 2012, CANCER LETT, V322, P148, DOI 10.1016/j.canlet.2012.02.038
   Zhang YQ, 2012, INT J CANCER, V131, P83, DOI 10.1002/ijc.26346
NR 45
TC 32
Z9 34
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 11
PY 2013
VL 8
IS 12
AR e83018
DI 10.1371/journal.pone.0083018
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 276EG
UT WOS:000328730300122
PM 24349422
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Smith, SS
AF Smith, Steven S.
TI Maintaining the unmethylated state
SO CLINICAL EPIGENETICS
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; EUKARYOTIC CHROMOSOME
   STABILITY; SINGLE-STRAND CONFORMERS; FRAGILE-X-SYNDROME; C-HA-RAS; DNA
   METHYLATION; BREAST-CANCER; PROMOTER HYPERMETHYLATION; ABERRANT
   METHYLATION
AB Background: A remarkable correspondence exists between the cytogenetic locations of the known fragile sites and frequently reported sites of hypermethylation. The best-known features of fragile sites are sequence motifs that are prone to the spontaneous formation of a non-B DNA structure. These facts, coupled with the known enzymological specificities of DNA methyltransferase 1 (DNMT1), the ATP-dependent and actin-dependent helicases, and the ten-eleven translocation (TET) dioxygenases, suggest that these enzymes are involved in an epigenetic cycle that maintains the unmethylated state at these sites by resolving non-B structure, preventing both the sequestration of DNA methyltransferases (DNMTs) and hypermethylation in normal cells.
   Presentation of the hypothesis: The innate tendency of DNA sequences present at fragile sites to form non-B DNA structures results in de novo methylation of DNA at these sites that is held in check in normal cells by the action of ATP-dependent and actin-dependent helicases coupled with the action of TET dioxygenases. This constitutes a previously unrecognized epigenetic repair cycle in which spontaneously forming non-B DNA structures formed at fragile sites are methylated by DNMTs as they are removed by the action of ATP-dependent and actin-dependent helicases, with the resulting nascent methylation rendered non-transmissible by TET dioxygenases.
   Testing the hypothesis: A strong prediction of the hypothesis is that knockdown of ATP-dependent and actin-dependent helicases will result in enhanced bisulfite sensitivity and hypermethylation at non-B structures in multiple fragile sites coupled with global hypomethylation.
   Implications of the hypothesis: A key implication of the hypothesis is that helicases, like the lymphoid-specific helicase and alpha thalassemia/mental retardation syndrome X-linked helicase, passively promote accurate maintenance of DNA methylation by preventing the sequestration of DNMTs at sites of unrepaired non-B DNA structure. When helicase action is blocked due to mutation or downregulation of the respective genes, DNMTs stall at unrepaired non-B structures in fragile sites after methylating them and are unable to methylate other sites in the genome, resulting in hypermethylation at non-B DNA-forming sites, along with hypomethylation elsewhere.
C1 City Hope Natl Med Ctr, Duarte, CA 91010 USA.
C3 City of Hope
RP Smith, SS (通讯作者)，City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM ssmith@coh.org
CR Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103
   Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bebek G, 2012, HUM MOL GENET, V21, P1557, DOI 10.1093/hmg/ddr593
   Beggs AD, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003488
   Bennett LB, 2009, GENE CHROMOSOME CANC, V48, P828, DOI 10.1002/gcc.20687
   BESTOR T, 1987, NUCLEIC ACIDS RES, V15, P3835, DOI 10.1093/nar/15.9.3835
   Bourc'his D, 2002, BIOESSAYS, V24, P297, DOI 10.1002/bies.10078
   Cai LY, 2007, LIFE SCI, V80, P1458, DOI 10.1016/j.lfs.2007.01.015
   Cavicchioli F, 2012, CANCER RES, V72, DOI 10.1158/0008-5472.SABCS12-P4-06-10
   CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199
   Clark Jarrod, 2008, Cancer Genomics & Proteomics, V5, P241
   Corn PG, 2001, CLIN CANCER RES, V7, P2765
   Cortés-Sempere M, 2013, ONCOGENE, V32, P1274, DOI 10.1038/onc.2012.146
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dodge JE, 2005, J BIOL CHEM, V280, P17986, DOI 10.1074/jbc.M413246200
   Estécio MRH, 2011, FEBS LETT, V585, P2078, DOI 10.1016/j.febslet.2010.12.001
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2000, CANCER RES, V60, P2368
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fan L, 2008, CELL, V133, P789, DOI 10.1016/j.cell.2008.04.030
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Fernandez SV, 2012, INT J ONCOL, V41, P369, DOI 10.3892/ijo.2012.1444
   Ficz G, 2011, NATURE, V473, P398, DOI 10.1038/nature10008
   Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797
   Fukutomi S, 2007, SCAND J GASTROENTERO, V42, P1486, DOI 10.1080/00365520701491173
   GACY AM, 1995, CELL, V81, P533
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Ghoshal K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010338
   GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2
   Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191
   Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122
   Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Heyn H, 2013, EPIGENETICS-US, V8, P28, DOI 10.4161/epi.23366
   Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398
   Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437
   Inoue A, 2011, SCIENCE, V334, P194, DOI 10.1126/science.1212483
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jarrard DF, 1998, CANCER RES, V58, P5310
   Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803
   Jeong P, 2012, EJSO-EUR J SURG ONC, V38, P1095, DOI 10.1016/j.ejso.2012.07.116
   Johnson JE, 2010, NUCLEIC ACIDS RES, V38, P1114, DOI 10.1093/nar/gkp1103
   Kanda M, 2011, MOL CARCINOGEN, V50, P571, DOI 10.1002/mc.20735
   Kho MR, 1998, J MOL BIOL, V275, P67, DOI 10.1006/jmbi.1997.1430
   Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y
   Kinoshita T, 2011, HEPATO-GASTROENTEROL, V58, P1051
   KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F
   Kober P, 2011, MOL CARCINOGEN, V50, P846, DOI 10.1002/mc.20763
   Koga T, 2013, HUM PATHOL, V44, P1382, DOI 10.1016/j.humpath.2012.11.008
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Kroeger H, 2008, BLOOD, V112, P1366, DOI 10.1182/blood-2007-11-126227
   LAAYOUN A, 1995, NUCLEIC ACIDS RES, V23, P1584, DOI 10.1093/nar/23.9.1584
   Lamparska K, 2012, NUCLEIC ACIDS RES, V40, P9788, DOI 10.1093/nar/gks706
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249
   Lind GE, 2006, CELL ONCOL, V28, P259
   Lindsey JC, 2007, BRIT J CANCER, V97, P267, DOI 10.1038/sj.bjc.6603852
   Lou W, 1999, CANCER RES, V59, P2329
   Lukusa T, 2008, BBA-GENE REGUL MECH, V1779, P3, DOI 10.1016/j.bbagrm.2007.10.005
   Luo Y, 2013, ONCOGENE, V32, P2037, DOI 10.1038/onc.2012.225
   Mardin WA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-549
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843
   Myant K, 2011, GENOME RES, V21, P83, DOI 10.1101/gr.108498.110
   Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213
   Ng CW, 2013, P NATL ACAD SCI USA, V110, P2354, DOI 10.1073/pnas.1221292110
   Nordlund J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034513
   OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097
   Okuwaki M, 2004, J BIOL CHEM, V279, P2904, DOI 10.1074/jbc.M310111200
   Old RW, 2007, REPROD BIOMED ONLINE, V15, P227, DOI 10.1016/S1472-6483(10)60713-4
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Papaggeli P C, 2003, J BUON, V8, P341
   Pfister S, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm094
   Pirzio LM, 2008, J CELL BIOL, V180, P305, DOI 10.1083/jcb.200705126
   Raghavan SC, 2006, METHOD ENZYMOL, V409, P301, DOI 10.1016/S0076-6879(05)09017-8
   Ripperger T, 2007, HAEMATOLOGICA, V92, P460, DOI 10.3324/haematol.10337
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Rogstad DK, 2009, CHEM RES TOXICOL, V22, P1194, DOI 10.1021/tx900131u
   ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207
   Saito K, 2008, CANCER SCI, V99, P253, DOI 10.1111/j.1349-7006.2007.00682.x
   Sakata M, 2013, HEPATO-GASTROENTEROL, V60, P781, DOI 10.5754/hge10439
   Sarafidou T, 2004, GENOMICS, V84, P69, DOI 10.1016/j.ygeno.2003.12.017
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   Saulnier A, 2012, INT J CANCER, V130, P2484, DOI 10.1002/ijc.26299
   SCHMID M, 1984, HUM GENET, V67, P257, DOI 10.1007/BF00291352
   Smith SS, 1998, INT J MOL MED, V1, P147
   SMITH SS, 1987, NUCLEIC ACIDS RES, V15, P6899, DOI 10.1093/nar/15.17.6899
   SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A
   SMITH SS, 1994, J MOL BIOL, V243, P143, DOI 10.1006/jmbi.1994.1640
   Smith SS, 1999, MOL CARCINOGEN, V26, P1, DOI 10.1002/(SICI)1098-2744(199909)26:1<1::AID-MC1>3.0.CO;2-P
   Smith SS, 1997, BIOCHEM BIOPH RES CO, V234, P73, DOI 10.1006/bbrc.1997.6581
   SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744
   SMITH SS, 1991, MOL CARCINOGEN, V4, P91, DOI 10.1002/mc.2940040202
   SMITH SS, 1989, BIOCHEM BIOPH RES CO, V160, P1397, DOI 10.1016/S0006-291X(89)80159-7
   Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172
   Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791
   Suh I, 2010, ARCH SURG-CHICAGO, V145, P226, DOI 10.1001/archsurg.2009.292
   Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511
   Toyota M, 2000, CANCER RES, V60, P4044
   TURK PW, 1995, CARCINOGENESIS, V16, P1253, DOI 10.1093/carcin/16.5.1253
   Unoki M, 2003, FEBS LETT, V554, P67, DOI 10.1016/S0014-5793(03)01092-5
   van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278
   Vasiljevic N, 2013, PROSTATE CANCER P D, V16, P35, DOI 10.1038/pcan.2012.47
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Walter K, 2012, CLIN CANCER RES, V18, P2360, DOI 10.1158/1078-0432.CCR-11-2635-T
   Wang JX, 2011, WORLD J GASTROENTERO, V17, P4225, DOI 10.3748/wjg.v17.i37.4225
   Wang LJ, 2013, CHINESE MED J-PEKING, V126, P2062, DOI 10.3760/cma.j.issn.0366-6999.20123570
   Wendel JA, 1998, NANOTECHNOLOGY, V9, P297, DOI 10.1088/0957-4484/9/3/021
   Woodson K, 2006, EPIGENETICS-US, V1, P183, DOI 10.4161/epi.1.4.3530
   Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052
   Youssef EM, 2004, CANCER RES, V64, P2411, DOI 10.1158/0008-5472.CAN-03-0164
   Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861
   Yuan JH, 2003, CANCER RES, V63, P4174
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 126
TC 3
Z9 3
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD SEP 30
PY 2013
VL 5
AR 17
DI 10.1186/1868-7083-5-17
PG 10
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 286GR
UT WOS:000329455200001
PM 24079333
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kullmann, K
   Deryal, M
   Ong, MF
   Schmidt, W
   Mahlknecht, U
AF Kullmann, Kathrin
   Deryal, Mustafa
   Ong, Mei Fang
   Schmidt, Werner
   Mahlknecht, Ulrich
TI DNMT1 genetic polymorphisms affect breast cancer risk in the central
   European Caucasian population
SO CLINICAL EPIGENETICS
LA English
DT Article
DE DNMT; SNP; Breast cancer
ID DNA METHYLTRANSFERASE; EPIGENETIC GENES; LUNG-CANCER; EXPRESSION;
   METHYLATION; 3A; 3B; OVEREXPRESSION; CARCINOMAS; MUTATIONS
AB Introduction: DNA methylation of CpG islands within the promoter region of genes is an epigenetic modification with an important role in the development of cancer and it is typically mediated by DNA methyltransferases (DNMTs). In cancer cells, global hypomethylation of the genome as a whole and regional hypermethylation of CpG islands have been reported. Four groups of DNMTs have been identified: DNMT1, DNMT2 (TRDMT1), DNMT3A and DNMT3B. DNMT2 uses the catalytic mechanism of DNMTs, but does in fact methylate RNA. Little is known about the significance of these genes in human breast cancer. In the study presented herein, we analyzed five distinct DNMT single SNPs with regard to potential associations with breast cancer risk.
   Case description: In this study, we genotyped 221 female Caucasian breast cancer patients and 221 female Caucasian healthy controls, and we used five allele-specific real-time polymerase chain reaction (qPCR) assays. We selected one locus within the DNMT1 gene and two loci within the DNMT3A and DNMT3B genes, respectively. Statistics were calculated using the chi-squared and Fisher's exact tests, and correlated with clinical parameters such as age, diagnosis, histology, TNM stage, hormonal receptor status, human epidermal growth factor receptor 2 (HER2) status, response to treatment and survival. Statistically significant results were obtained for correlations with the DNMT1 gene.
   Discussion and Evaluation: Five genomic loci within the DNMT1, DNMT3A and DNMT3B genes were assessed. Statistical significance (P = 0.030) was identified for DNMT1 SNP (A201G, rs2228612): six women within the control group were GG homozygous (variant), while this mutation was absent in the breast cancer group.
   Conclusions: We conclude that women with the DNMT1 SNP (A201G, rs2228612) GG homozygous genotype (variant) have a lower risk of developing breast cancer compared to heterozygous or wildtype genotypes. To date, alterations within the DNMT1 gene have not been reported to be associated with cancer in the Caucasian population.
C1 [Kullmann, Kathrin; Mahlknecht, Ulrich] Univ Saarland, Med Ctr, Jose Carreras Res Ctr, Dept Internal Med,Div Immunotherapy & Gene Therap, D-66421 Homburg, Germany.
   [Deryal, Mustafa; Schmidt, Werner] Univ Saarland, Med Ctr, Dept Obstet & Gynecol, D-66421 Homburg, Germany.
   [Ong, Mei Fang] Univ Saarland, Inst Med Biometr Epidemiol & Med Informat, D-66421 Homburg, Germany.
   [Mahlknecht, Ulrich] St Lukas Clin Solingen, Dept Hematol Oncol, D-42697 Solingen, Germany.
C3 Saarland University; Saarland University; Saarland University
RP Mahlknecht, U (通讯作者)，Univ Saarland, Med Ctr, Jose Carreras Res Ctr, Dept Internal Med,Div Immunotherapy & Gene Therap, D-66421 Homburg, Germany.
EM mahlknecht@gmx.de
CR Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460
   BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Gao XA, 2010, CLIN BREAST CANCER, V10, P373, DOI 10.3816/CBC.2010.n.049
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976
   Jurkowski TP, 2008, RNA, V14, P1663, DOI 10.1261/rna.970408
   Lavoie G, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-31
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Milne RL, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2797
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Nickels S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003284
   Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Shen HB, 2002, CANCER RES, V62, P4992
   Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44
   Ye CZ, 2010, BREAST CANCER RES TR, V121, P765, DOI 10.1007/s10549-009-0569-9
   YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287
NR 36
TC 29
Z9 32
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD MAY 2
PY 2013
VL 5
AR 7
DI 10.1186/1868-7083-5-7
PG 8
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 286GC
UT WOS:000329453500001
PM 23638630
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kristiansen, S
   Jorgensen, LM
   Guldberg, P
   Sölétormos, G
AF Kristiansen, Soren
   Jorgensen, Lars M.
   Guldberg, Per
   Soletormos, Gyorgy
TI Aberrantly methylated DNA as a biomarker in breast cancer
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
LA English
DT Article
DE Breast cancer; DNA biomarker; DNA methylation; Epigenetic; Promoter
   methylation
ID GENE PROMOTER HYPERMETHYLATION; HORMONE-RECEPTOR STATUS; E-CADHERIN;
   SERUM DNA; ESTROGEN-RECEPTOR; POOR-PROGNOSIS; TUMOR-CELLS;
   CLINICAL-SIGNIFICANCE; ENDOCRINE THERAPY; PLASMA DNA
AB Aberrant DNA hypermethylation at gene promoters is a frequent event in human breast cancer. Recent genome-wide studies have identified hundreds of genes that exhibit differential methylation between breast cancer cells and normal breast tissue. Due to the tumor-specific nature of DNA hypermethylation events, their use as tumor biomarkers is usually not hampered by analytical signals from normal cells, which is a general problem for existing protein tumor markers used for clinical assessment of breast cancer. There is accumulating evidence that DNA-methylation changes in breast cancer patients occur early during tumorigenesis. This may open up for effective screening, and analysis of blood or nipple aspirate may later help in diagnosing breast cancer. As a more detailed molecular characterization of different types of breast cancer becomes available, the ability to divide patients into subgroups based on DNA biomarkers may improve prognosis. Serial monitoring of DNA-methylation markers in blood during treatment may be useful, particularly when the cancer burden is below the detection level for standard imaging techniques. Overall, aberrant DNA methylation has a great potential as a versatile biomarker tool for screening, diagnosis, prognosis and monitoring of breast cancer. Standardization of methods and biomarker panels will be required to fully exploit this clinical potential.
C1 [Kristiansen, Soren; Jorgensen, Lars M.; Soletormos, Gyorgy] Hillerod Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.
   [Guldberg, Per] Danish Canc Soc Res Ctr, Copenhagen, Denmark.
C3 University of Copenhagen; Danish Cancer Society
RP Kristiansen, S (通讯作者)，Hillerod Hosp, Dept Clin Biochem, Dyrehavevej 29,Entrance 16A,Level 2, DK-3400 Hillerod, Denmark.
EM soeren.kristiansen.01@regionh.dk
OI Kristiansen, Soren/0000-0003-1851-5363
CR Antill YC, 2010, CANCER EPIDEM BIOMAR, V19, P265, DOI 10.1158/1055-9965.EPI-09-0359
   Arai T, 2008, EJSO-EUR J SURG ONC, V34, P734, DOI 10.1016/j.ejso.2007.07.008
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68
   Dietrich D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-247
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2004, ONCOGENE, V23, P1, DOI 10.1038/sj.onc.1207316
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feng J, 2010, TUMOR BIOL, V31, P321, DOI 10.1007/s13277-010-0040-x
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Fumagalli C, 2012, BREAST CANCER RES TR, V134, P131, DOI 10.1007/s10549-011-1945-9
   Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856
   Göbel G, 2011, BREAST CANCER RES TR, V130, P109, DOI 10.1007/s10549-010-1335-8
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hartmann O, 2009, CLIN CANCER RES, V15, P315, DOI 10.1158/1078-0432.CCR-08-0166
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Hu XC, 2003, ONCOL REP, V10, P1811
   Hu XC, 2002, LIFE SCI, V71, P1397, DOI 10.1016/S0024-3205(02)01843-X
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Jerónimo C, 2003, CLIN CANCER RES, V9, P3413
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jing F, 2008, ONCOLOGY-BASEL, V75, P60, DOI 10.1159/000155145
   Jing F, 2007, ONKOLOGIE, V30, P14, DOI 10.1159/000096892
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Liggett TE, 2011, INT J CANCER, V128, P492, DOI 10.1002/ijc.25363
   Maier S, 2007, EUR J CANCER, V43, P1679, DOI 10.1016/j.ejca.2007.04.025
   Martens JWM, 2005, CANCER RES, V65, P4101, DOI 10.1158/0008-5472.CAN-05-0064
   Martínez-Galán J, 2008, CANCER BIOL THER, V7, P962, DOI 10.4161/cbt.7.6.5966
   Martins AT, 2011, BREAST CANCER RES TR, V129, P1, DOI 10.1007/s10549-010-1160-0
   Matuschek C, 2010, EUR J MED RES, V15, P277
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mirza S, 2010, CLIN BIOCHEM, V43, P380, DOI 10.1016/j.clinbiochem.2009.11.016
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nimmrich I, 2008, BREAST CANCER RES TR, V111, P429, DOI 10.1007/s10549-007-9800-8
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Petersen PH, 2008, CLIN CHEM LAB MED, V46, P157, DOI 10.1515/CCLM.2008.042
   Petersen PH, 2011, CLIN CHEM LAB MED, V49, P303, DOI 10.1515/CCLM.2011.045
   Prasad CP, 2008, LIFE SCI, V83, P318, DOI 10.1016/j.lfs.2008.06.019
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Sharma G, 2012, TUMOR BIOL, V33, P1837, DOI 10.1007/s13277-012-0443-y
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Sölétormos G, 2013, CLIN CHEM, V59, P52, DOI 10.1373/clinchem.2011.180778
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Taback B, 2006, ANN NY ACAD SCI, V1075, P211, DOI 10.1196/annals.1368.029
   Tan SH, 2007, ONCOL REP, V18, P1225
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Van de Voorde L, 2012, MUTAT RES-REV MUTAT, V751, P304, DOI 10.1016/j.mrrev.2012.06.001
   Van der Auwera I, 2009, BRIT J CANCER, V100, P1277, DOI 10.1038/sj.bjc.6605013
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Zhu WZ, 2010, INT J CANCER, V126, P474, DOI 10.1002/ijc.24728
   Zou DH, 2009, J PATHOL, V218, P265, DOI 10.1002/path.2541
   Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217
NR 77
TC 7
Z9 10
U1 0
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0393-6155
EI 1724-6008
J9 INT J BIOL MARKER
JI Int. J. Biol. Markers
PD APR-JUN
PY 2013
VL 28
IS 2
BP 141
EP 150
DI 10.5301/JBM.5000009
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA 287FD
UT WOS:000329526200003
PM 23564623
DA 2025-01-12
ER

PT J
AU Chu, CS
   Lo, PW
   Yeh, YH
   Hsu, PH
   Peng, SH
   Teng, YC
   Kang, ML
   Wong, CH
   Juan, LJ
AF Chu, Chi-Shuen
   Lo, Pei-Wen
   Yeh, Yi-Hsien
   Hsu, Pang-Hung
   Peng, Shih-Huan
   Teng, Yu-Ching
   Kang, Ming-Lun
   Wong, Chi-Huey
   Juan, Li-Jung
TI O-GlcNAcylation regulates EZH2 protein stability and function
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HISTONE METHYLTRANSFERASE ACTIVITY;
   ACETYLGLUCOSAMINE TRANSFERASE OGT; H3 LYSINE-27 METHYLATION; INVASIVE
   BREAST-CANCER; N-ACETYLGLUCOSAMINE; GLCNAC TRANSFERASE;
   SUBSTRATE-SPECIFICITY; H3K27 METHYLATION; LINKED GLCNAC
AB O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) is the only known enzyme that catalyzes the O-GlcNAcylation of proteins at the Ser or Thr side chain hydroxyl group. OGT participates in transcriptional and epigenetic regulation, and dysregulation of OGT has been implicated in diseases such as cancer. However, the underlying mechanism is largely unknown. Here we show that OGT is required for the trimethylation of histone 3 at K27 to form the product H3K27me3, a process catalyzed by the histone methyltransferase enhancer of zeste homolog 2 (EZH2) in the polycomb repressive complex 2 (PRC2). H3K27me3 is one of the most important histone modifications to mark the transcriptionally silenced chromatin. We found that the level of H3K27me3, but not other H3 methylation products, was greatly reduced upon OGT depletion. OGT knockdown specifically down-regulated the protein stability of EZH2, without altering the levels of H3K27 demethylases UTX and JMJD3, and disrupted the integrity of the PRC2 complex. Furthermore, the interaction of OGT and EZH2/PRC2 was detected by coimmunoprecipitation and cosedimentation experiments. Importantly, we identified that serine 75 is the site for EZH2 O-GlcNAcylation, and the EZH2 mutant S75A exhibited reduction in stability. Finally, microarray and ChIP analysis have characterized a specific subset of potential tumor suppressor genes subject to repression via the OGT-EZH2 axis. Together these results indicate that OGT-mediated O-GlcNAcylation at S75 stabilizes EZH2 and hence facilitates the formation of H3K27me3. The study not only uncovers a functional posttranslational modification of EZH2 but also reveals a unique epigenetic role of OGT in regulating histone methylation.
C1 [Chu, Chi-Shuen; Lo, Pei-Wen; Yeh, Yi-Hsien; Peng, Shih-Huan; Teng, Yu-Ching; Kang, Ming-Lun; Wong, Chi-Huey; Juan, Li-Jung] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Lo, Pei-Wen] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Hsu, Pang-Hung] Natl Taiwan Ocean Univ, Dept Life Sci, Keelung 202, Taiwan.
   [Hsu, Pang-Hung] Natl Taiwan Ocean Univ, Inst Biosci & Biotechnol, Keelung 202, Taiwan.
   [Peng, Shih-Huan] Natl Taiwan Univ, Inst Mol Med, Taipei 100, Taiwan.
C3 Academia Sinica - Taiwan; National Yang Ming Chiao Tung University;
   National Taiwan Ocean University; National Taiwan Ocean University;
   National Taiwan University
RP Wong, CH (通讯作者)，Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
EM chwong@gate.sinica.edu.tw; ljjuan@gate.sinica.edu.tw
RI /CAE-7269-2022; Juan, Li-Jung/H-6631-2015; Hsu, Pang-Hung/C-5587-2018
OI Juan, Li-Jung/0009-0000-5504-544X; Teng, Yu-Ching/0000-0001-9313-7804;
   Hsu, Pang-Hung/0000-0001-6873-6434; Peng, Shih-Huan/0000-0002-7540-6027
FU Academia Sinica
FX We thank Drs. W. H. Lee at University of California, Irvine, and Y.
   Zhang at Harvard Medical School for critical suggestions, and Affymetrix
   Gene Expression Service Laboratory at Academia Sinica for performing the
   microarray experiments. This study was supported by grants from Academia
   Sinica [to L.-J.J. (career development grant) and C.-H.W.].
CR Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551
   Chen Q, 2013, NATURE, V493, P561, DOI 10.1038/nature11742
   Cheng CJ, 2009, CANCER RES, V69, P3634, DOI 10.1158/0008-5472.CAN-08-3615
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Deplus R, 2013, EMBO J, V32, P645, DOI 10.1038/emboj.2012.357
   DONG DLY, 1994, J BIOL CHEM, V269, P19321
   Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3
   Fardini Y, 2013, FRONT ENDOCRINOL, V4, DOI 10.3389/fendo.2013.00099
   Fong JJ, 2012, J BIOL CHEM, V287, P12195, DOI 10.1074/jbc.M111.315804
   Fujiki R, 2011, NATURE, V480, P557, DOI 10.1038/nature10656
   Gambetta MC, 2009, SCIENCE, V325, P93, DOI 10.1126/science.1169727
   Gewinner C, 2004, J BIOL CHEM, V279, P3563, DOI 10.1074/jbc.M306449200
   HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563
   Hanover JA, 2012, NAT REV MOL CELL BIO, V13, P312, DOI 10.1038/nrm3334
   Hart GW, 2011, ANNU REV BIOCHEM, V80, P825, DOI 10.1146/annurev-biochem-060608-102511
   HOLT GD, 1986, J BIOL CHEM, V261, P8049
   Hosogane M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003698
   Hübner MR, 2010, COLD SH Q B, V75, P43, DOI 10.1101/sqb.2010.75.020
   Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200
   Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200
   Jang H, 2012, CELL STEM CELL, V11, P62, DOI 10.1016/j.stem.2012.03.001
   Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3
   Klymenko T, 2006, GENE DEV, V20, P1110, DOI 10.1101/gad.377406
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Kreppel LK, 1997, J BIOL CHEM, V272, P9308
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Laughlin ST, 2007, NAT PROTOC, V2, P2930, DOI 10.1038/nprot.2007.422
   Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636
   Love DC, 2010, P NATL ACAD SCI USA, V107, P7413, DOI 10.1073/pnas.0911857107
   Miyamoto Y, 2010, INT J ONCOL, V36, P1253, DOI 10.3892/ijo_00000609
   Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Mustafi R, 2012, CARCINOGENESIS, V33, P1930, DOI 10.1093/carcin/bgs231
   Myers SA, 2011, P NATL ACAD SCI USA, V108, P9490, DOI 10.1073/pnas.1019289108
   Nie DS, 2013, MOL BIOL REP, V40, P1905, DOI 10.1007/s11033-012-2246-z
   Ou DSC, 2011, CELL RES, V21, P642, DOI 10.1038/cr.2011.10
   Özcan S, 2010, BBA-GENE REGUL MECH, V1799, P353, DOI 10.1016/j.bbagrm.2010.02.005
   Sakabe K, 2010, P NATL ACAD SCI USA, V107, P19915, DOI 10.1073/pnas.1009023107
   Shi FT, 2013, J BIOL CHEM, V288, P20776, DOI 10.1074/jbc.M113.460386
   Simanek EE, 1998, J AM CHEM SOC, V120, P11567, DOI 10.1021/ja982312w
   Sinclair DAR, 2009, P NATL ACAD SCI USA, V106, P13427, DOI 10.1073/pnas.0904638106
   Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114
   TORRES CR, 1984, J BIOL CHEM, V259, P3308
   Vella P, 2013, MOL CELL, V49, P645, DOI 10.1016/j.molcel.2012.12.019
   Vocadlo DJ, 2012, CURR OPIN CHEM BIOL, V16, P488, DOI 10.1016/j.cbpa.2012.10.021
   Wang ZH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000526
   Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515
   Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3
   Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7
   Zhang SS, 2011, J BIOL CHEM, V286, P37483, DOI 10.1074/jbc.M111.284885
NR 57
TC 178
Z9 201
U1 0
U2 43
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 28
PY 2014
VL 111
IS 4
BP 1355
EP 1360
DI 10.1073/pnas.1323226111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 297BV
UT WOS:000330231100042
PM 24474760
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Cacan, E
   Ali, MW
   Boyd, NH
   Hooks, SB
   Greer, SF
AF Cacan, Ercan
   Ali, Mourad W.
   Boyd, Nathaniel H.
   Hooks, Shelley B.
   Greer, Susanna F.
TI Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease
   Ovarian Cancer Chemoresistance
SO PLOS ONE
LA English
DT Article
ID HISTONE-DEACETYLASE INHIBITORS; CPG-BINDING PROTEIN; HUMAN
   BREAST-CANCER; DNA METHYLATION; PREDICT PROGNOSIS; CELL-GROWTH;
   REGULATOR; TARGET; GENE; METHYLTRANSFERASE
AB RGS10 is an important regulator of cell survival and chemoresistance in ovarian cancer. We recently showed that RGS10 transcript expression is suppressed during acquired chemoresistance in ovarian cancer. The suppression of RGS10 is due to DNA hypermethylation and histone deacetylation, two important mechanisms that contribute to silencing of tumor suppressor genes during cancer progression. Here, we fully investigate the molecular mechanisms of epigenetic silencing of RGS10 expression in chemoresistant A2780-AD ovarian cancer cells. We identify two important epigenetic regulators, HDAC1 and DNMT1, that exhibit aberrant association with RGS10 promoters in chemoresistant ovarian cancer cells. Knockdown of HDAC1 or DNMT1 expression, and pharmacological inhibition of DNMT or HDAC enzymatic activity, significantly increases RGS10 expression and cisplatin-mediated cell death. Finally, DNMT1 knock down also decreases HDAC1 binding to the RGS10 promoter in chemoresistant cells, suggesting HDAC1 recruitment to RGS10 promoters requires DNMT1 activity. Our results suggest that HDAC1 and DNMT1 contribute to the suppression of RGS10 during acquired chemoresistance and support inhibition of HDAC1 and DNMT1 as an adjuvant therapeutic approach to overcome ovarian cancer chemoresistance.
C1 [Cacan, Ercan; Boyd, Nathaniel H.; Greer, Susanna F.] Georgia State Univ, Dept Biol, Div Cellular Biol & Immunol, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA.
   [Ali, Mourad W.; Hooks, Shelley B.] Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
C3 University System of Georgia; Georgia State University; University
   System of Georgia; University of Georgia
RP Greer, SF (通讯作者)，Georgia State Univ, Dept Biol, Div Cellular Biol & Immunol, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA.
EM sgreer@gsu.edu
RI Cacan, Ercan/AAC-1204-2019
OI Ali, Mourad Wagdy/0000-0003-3263-9055; Cacan, Ercan/0000-0002-3487-9493;
   Hooks, Shelley/0000-0003-4702-0490
FU American Cancer Society [RSG-09-067-01-LB]
FX Research was supported by grant # RSG-09-067-01-LB from the American
   Cancer Society. The funder had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ali MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060185
   ANDREWS PA, 1985, CANCER RES, V45, P6250
   Arts J, 2007, BRIT J CANCER, V97, P1344, DOI 10.1038/sj.bjc.6604025
   Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103
   Barneda-Zahonero B, 2012, MOL ONCOL, V6, P579, DOI 10.1016/j.molonc.2012.07.003
   Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269
   Bodle CR, 2013, FUTURE MED CHEM, V5, P995, DOI 10.4155/fmc.13.91
   Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31
   Cai Y., 2013, ONCOGENE
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cao X, 2006, ONCOGENE, V25, P3719, DOI 10.1038/sj.onc.1209408
   Carafa V, 2011, RECENT PAT ANTI-CANC, V6, P131, DOI 10.2174/157489211793980088
   Carrieri A, 2013, CURR TOP MED CHEM, V13, P1069, DOI 10.2174/15680266113139990028
   Dear RF, 2010, ASIA-PAC J CLIN ONCO, V6, P66, DOI 10.1111/j.1743-7563.2009.01263.x
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3
   Espino PS, 2005, J CELL BIOCHEM, V94, P1088, DOI 10.1002/jcb.20387
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Falchook GS, 2013, INVEST NEW DRUGS
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   García-Bernal D, 2011, J IMMUNOL, V187, P1264, DOI 10.4049/jimmunol.1002960
   Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002
   Giacinti L, 2008, CLIN TER, V159, P347
   Gold SJ, 2002, J NEUROCHEM, V82, P828, DOI 10.1046/j.1471-4159.2002.01002.x
   Gu YF, 2013, ONCOL LETT, V5, P452, DOI 10.3892/ol.2012.1057
   Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herzog TJ, 2011, GYNECOL ONCOL, V120, P454, DOI 10.1016/j.ygyno.2010.11.008
   Hooks SB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-289
   Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0
   Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028
   Hurst JH, 2009, PHARMACOLOGY, V83, P333, DOI 10.1159/000217582
   Ito K, 2000, METH MOLEC MED, V44, P309, DOI 10.1385/1-59259-072-1:309
   Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   JONES PL, 2002, METH MOL B, V181, P297
   Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200
   Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307
   Lee JK, 2012, J NEUROCHEM, V122, P333, DOI 10.1111/j.1471-4159.2012.07780.x
   Liang GQ, 2009, J BIOL CHEM, V284, P21719, DOI 10.1074/jbc.M109.028407
   Liu B, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-7
   LOUIE KG, 1985, CANCER RES, V45, P2110
   Lu JB, 2008, EUR J PHARMACOL, V601, P66, DOI 10.1016/j.ejphar.2008.10.044
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Manuyakorn A, 2010, J CLIN ONCOL, V28, P1358, DOI 10.1200/JCO.2009.24.5639
   Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5
   Meng CF, 2011, MOL MED REP, V4, P1273, DOI 10.3892/mmr.2011.557
   Meng FL, 2013, INT J ONCOL, V43, P495, DOI 10.3892/ijo.2013.1960
   MODEST EJ, 1974, CANCER CHEMOTH REP 1, V58, P35
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598
   O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521
   Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rivero G, 2013, PSYCHOPHARMACOLOGY, V226, P177, DOI 10.1007/s00213-012-2888-5
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Shi GX, 2004, J IMMUNOL, V172, P5175, DOI 10.4049/jimmunol.172.9.5175
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   Wang C, 2011, J NAT PROD, V74, P2031, DOI 10.1021/np200324x
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Xie Y, 2013, BIOCHEM PHARMACOL, V85, P1454, DOI 10.1016/j.bcp.2013.03.001
   Xie Y, 2009, CANCER RES, V69, P5743, DOI 10.1158/0008-5472.CAN-08-3564
   Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611
   Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
   Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121
NR 79
TC 78
Z9 87
U1 0
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2014
VL 9
IS 1
AR e87455
DI 10.1371/journal.pone.0087455
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 301BI
UT WOS:000330507300185
PM 24475290
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Bae, WK
   Hennighausen, L
AF Bae, Woo Kyun
   Hennighausen, Lothar
TI Canonical and non-canonical roles of the histone methyltransferase EZH2
   in mammary development and cancer
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE EZH2; Histone methyltransferase; Breast
ID GROUP PROTEIN EZH2; B-CELL LYMPHOMAS; BREAST-CANCER; DNA METHYLATION;
   EPITHELIAL-CELLS; PROSTATE-CANCER; GENE-EXPRESSION; LYSINE 27; POLYCOMB;
   TARGET
AB Although hormones and downstream transcription factors are considered main drivers directing mammary gland development and oncogenic transformation, an emerging body of evidence suggests these processes are modulated by dynamic histone methylation landscapes. The methyltransferase EZH2 catalyzes the formation of trimethyl groups on lysine 27 of histone 3 (H3K27me3) and loss- and gain-of-function studies have provided insight into its role in normal mammary development and oncogenic transformation. EZH2 controls the homeostasis of mouse mammary stem cells, and mammary epithelium devoid of EZH2 does not undergo functional development during pregnancy, possibly due to a paucity of stem cells. EZH2 levels are frequently elevated in breast cancer suggesting a link between H3K27me3 and cell proliferation. In addition to its role as epigenetic regulator, recent studies have placed EZH2 into the category of transcriptional co-activators and thus opened the possibility of non-canonical signaling pathways. In contrast to solid tumors, loss of EZH2 from hematopoietic cells has been linked to malignancies (Fig. 1). The challenge will be to understand not only cell-specific functions of EZH2, but also the extent to which it relies on its enzymatic activity versus its ability to serve as a transcriptional co-factor. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Bae, Woo Kyun; Hennighausen, Lothar] NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA.
   [Bae, Woo Kyun] Chonnam Natl Univ, Dept Hematol & Oncol, Hwasun Hosp, Hwasun Gun, Jeollanamdo, South Korea.
   [Hennighausen, Lothar] Dankook Univ, Natl Dept Nanobiomed Sci, Chungnam 330714, South Korea.
   [Hennighausen, Lothar] Dankook Univ, WCU Res Ctr Nanobiomed Sci, Chungnam 330714, South Korea.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Diabetes & Digestive & Kidney Diseases (NIDDK); Chonnam National
   University; Dankook University; Dankook University
RP Bae, WK (通讯作者)，NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 105, Bethesda, MD 20892 USA.
EM wookyun.bae@mail.nih.gov
OI Hennighausen, Lothar/0000-0001-8319-9841
FU intramural research program (IRP) of the NIDDK at the National
   Institutes of Health (NIH), USA; World Class University Program,
   Ministry of Education, Science and Technology, through the National
   Research Foundation of Korea, South Korea [R31-100069]; WCU Research
   Center, Dankook University; Research Institute of Medical Sciences,
   Chonnam National University
FX This work was supported in part by the intramural research program (IRP)
   of the NIDDK at the National Institutes of Health (NIH), USA, the World
   Class University Program, Ministry of Education, Science and Technology,
   through the National Research Foundation of Korea, South Korea
   (R31-100069); WCU Research Center, Dankook University, and Research
   Institute of Medical Sciences, Chonnam National University.
CR Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Ezhkova E, 2011, GENE DEV, V25, P485, DOI 10.1101/gad.2019811
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714
   Hidalgo I, 2012, CELL STEM CELL, V11, P649, DOI 10.1016/j.stem.2012.08.001
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219
   Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Mousavi K, 2012, MOL CELL, V45, P255, DOI 10.1016/j.molcel.2011.11.019
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yamaji D, 2013, NUCLEIC ACIDS RES, V41, P1622, DOI 10.1093/nar/gks1310
   Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
NR 38
TC 30
Z9 35
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 25
PY 2014
VL 382
IS 1
BP 593
EP 597
DI 10.1016/j.mce.2013.05.002
PG 5
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 299UQ
UT WOS:000330421600062
PM 23684884
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Swift-Scanlan, T
   Smith, CT
   Bardowell, SA
   Boettiger, CA
AF Swift-Scanlan, Theresa
   Smith, Christopher T.
   Bardowell, Sabrina A.
   Boettiger, Charlotte A.
TI Comprehensive interrogation of CpG island methylation in the gene
   encoding COMT, a key estrogen and catecholamine regulator
SO BMC MEDICAL GENOMICS
LA English
DT Article
ID O-METHYLTRANSFERASE COMT; BREAST-CANCER RISK; DNA METHYLATION;
   ENZYME-ACTIVITY; VAL158MET POLYMORPHISM; EPIGENETIC REGULATION; PROTEIN
   EXPRESSION; MESSENGER-RNA; ASSOCIATION; SCHIZOPHRENIA
AB Background: The catechol-O-methyltransferase (COMT) enzyme has been widely studied due to its multiple roles in neurological functioning, estrogen biology, and methylation metabolic pathways. Numerous studies have investigated variation in the large COMT gene, with the majority focusing on single nucleotide polymorphisms (SNPs). This body of work has linked COMT genetic variation with a vast array of conditions, including several neurobehavioral disorders, pain sensitivity, and multiple human cancers. Based on COMT's numerous biological roles and recent studies suggesting that methylation of the COMT gene impacts COMT gene expression, we comprehensively interrogated methylation in over 200 CpG dinucleotide sequences spanning the length of the COMT gene.
   Methods: Using saliva-derived DNA from a non-clinical sample of human subjects, we tested for associations between COMT CpG methylation and factors reported to interact with COMT genetic effects, including demographic factors and alcohol use. Finally, we tested associations between COMT CpG methylation state and COMT gene expression in breast cancer cell lines. We interrogated >200 CpGs in 13 amplicons spanning the 5' UTR to the last exon of the CpG dinucleotide-rich COMT gene in n = 48 subjects, n = 11 cell lines and 1 endogenous 18S rRNA control.
   Results: With the exception of the CpG island in the 5' UTR and 1st exon, all other CpG islands were strongly methylated with typical dynamic ranges between 50-90%. In the saliva samples, methylation of multiple COMT loci was associated with socioeconomic status or ethnicity. We found associations between methylation at numerous loci and genotype at the functional Val(158)Met SNP (rs4680), and most of the correlations between methylation and demographic and alcohol use factors were Val(158)Met allele-specific. Methylation at several of these loci also associated with COMT gene expression in breast cancer cell lines.
   Conclusions: We report the first comprehensive interrogation of COMT methylation. We corroborate previous findings of variation in COMT methylation with gene expression and the Val(158)Met genotype, and also report novel associations with socioeconomic status (SES) and ethnicity at several methylated loci. These results point to novel mechanisms for COMT regulation, which may have broad therapeutic implications.
C1 [Swift-Scanlan, Theresa; Bardowell, Sabrina A.] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA.
   [Swift-Scanlan, Theresa] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Smith, Christopher T.; Boettiger, Charlotte A.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA.
   [Boettiger, Charlotte A.] Univ N Carolina, Dept Psychol, Biomed Res Imaging Ctr, Chapel Hill, NC USA.
   [Boettiger, Charlotte A.] Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Swift-Scanlan, T (通讯作者)，Univ N Carolina, Sch Nursing, Carrington Hall,CB 7460, Chapel Hill, NC 27515 USA.
EM tswift@unc.edu; cab@unc.edu
RI Boettiger, Charlotte/J-9094-2012; Smith, Christopher/A-8388-2013
OI Boettiger, Charlotte/0000-0003-1853-1574; Gardner,
   Sabrina/0000-0003-2566-3743; Smith, Christopher/0000-0002-8212-7886
FU National Center for Research Resources [UL1TR000083, KL2RR025746];
   National Institute on Alcohol and Alcoholism [P60AA011605]; Susan G.
   Komen Foundation [KG090180]; NIH/NCI Breast SPORE [CA058823]; 
   [T32DA007244];  [F31AA020132]
FX This work was supported by Award Numbers UL1TR000083 (formerly
   UL1RR025747) and KL2RR025746 (TSS and CAB) from the National Center for
   Research Resources, P60AA011605 (CAB) from the National Institute on
   Alcohol and Alcoholism, KG090180 (TSS) from the Susan G. Komen
   Foundation, CA058823 (S.Earp) from the NIH/NCI Breast SPORE, and by
   T32DA007244 and F31AA020132 (CTS). The authors thank R. Bigler, A.
   Desai, E. Freeman-Daniels, C. Lang, N. Le, J. Lopez, Victoria Benson and
   E. Steel for technical assistance.
CR Abdolmaleky HM, 2006, HUM MOL GENET, V15, P3132, DOI 10.1093/hmg/ddl253
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boettiger CA, 2007, J NEUROSCI, V27, P14383, DOI 10.1523/JNEUROSCI.2551-07.2007
   Bönsch D, 2004, J NEURAL TRANSM, V111, P1611, DOI 10.1007/s00702-004-0232-x
   BOUDIKOVA B, 1990, CLIN PHARMACOL THER, V48, P381, DOI 10.1038/clpt.1990.166
   Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013
   Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Eisenberg J, 1999, AM J MED GENET, V88, P497, DOI 10.1002/(SICI)1096-8628(19991015)88:5<497::AID-AJMG12>3.0.CO;2-F
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Gallicchio L, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-173
   Harlaar N, 2013, DRUG ALCOHOL DEPEN, V133, P305, DOI 10.1016/j.drugalcdep.2013.07.026
   Harrison PJ, 2008, NEUROPSYCHOPHARMACOL, V33, P3037, DOI 10.1038/sj.npp.1301543
   Hatzimanolis A, 2013, J AFFECT DISORDERS, V148, P316, DOI 10.1016/j.jad.2012.12.018
   He XF, 2012, MOL BIOL REP, V39, P6811, DOI 10.1007/s11033-012-1506-2
   Hollingshead A. B., 1975, Four Factor Index of Social Status
   Iwasaki M, 2014, NUTR CANCER, V66, P57, DOI 10.1080/01635581.2014.847963
   KAROUM F, 1994, J NEUROCHEM, V63, P972, DOI 10.1046/j.1471-4159.1994.63030972.x
   Klauke B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039709
   Kolassa IT, 2010, BIOL PSYCHIAT, V67, P304, DOI 10.1016/j.biopsych.2009.10.009
   Kontis D, 2013, NEUROSCI LETT, V537, P17, DOI 10.1016/j.neulet.2013.01.012
   Kunugi H, 1997, PSYCHIAT GENET, V7, P97, DOI 10.1097/00041444-199723000-00001
   Laatikainen LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061839
   Labonté B, 2012, ARCH GEN PSYCHIAT, V69, P722, DOI 10.1001/archgenpsychiatry.2011.2287
   Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007
   Lavigne JA, 1997, CANCER RES, V57, P5493
   Li K, TUMOUR BIOL IN PRESS
   Lim Unhee, 2012, Methods Mol Biol, V863, P359, DOI 10.1007/978-1-61779-612-8_23
   LOTTA T, 1995, BIOCHEMISTRY-US, V34, P4202, DOI 10.1021/bi00013a008
   Männistö PT, 1999, PHARMACOL REV, V51, P593
   MANNISTO PT, 1990, PHARMACOL TOXICOL, V66, P317
   Valente NLM, 2011, J MOL NEUROSCI, V43, P516, DOI 10.1007/s12031-010-9474-2
   McLean SA, 2011, J PAIN, V12, P101, DOI 10.1016/j.jpain.2010.05.008
   Murphy BC, 2005, AM J MED GENET B, V133B, P37, DOI 10.1002/ajmg.b.30134
   Nackley AG, 2006, SCIENCE, V314, P1930, DOI 10.1126/science.1131262
   Nackley AG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005237
   Nohesara S, 2011, J PSYCHIATR RES, V45, P1432, DOI 10.1016/j.jpsychires.2011.06.013
   Norrholm SD, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00030
   Ono H, 2012, CANCER SCI, V103, P2159, DOI 10.1111/cas.12013
   Ponomarev I, 2012, J NEUROSCI, V32, P1884, DOI 10.1523/JNEUROSCI.3136-11.2012
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Radua J, SOC COGN AF IN PRESS
   Roffman JL, 2008, P NATL ACAD SCI USA, V105, P17573, DOI 10.1073/pnas.0803727105
   Roffman JL, 2008, AM J MED GENET B, V147B, P990, DOI 10.1002/ajmg.b.30684
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Sasaki M, 2003, CANCER RES, V63, P3101
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Schellekens AFA, 2013, ADDICT BIOL, V18, P344, DOI 10.1111/j.1369-1600.2012.00438.x
   Schernhammer ES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021102
   Schreiner F, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-115
   Smith CT, 2012, PSYCHOPHARMACOLOGY, V222, P609, DOI 10.1007/s00213-012-2653-9
   Thompson PA, 1998, CANCER RES, V58, P2107
   Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924
   Tian C, TUMOUR BIO IN PRESS
   Tiihonen J, 1999, MOL PSYCHIATR, V4, P286, DOI 10.1038/sj.mp.4000509
   Tunbridge EM, 2007, CEREB CORTEX, V17, P1206, DOI 10.1093/cercor/bhl032
   Tunbridge EM, 2008, AM J MED GENET B, V147B, P996, DOI 10.1002/ajmg.b.30700
   Turner RJ, 2003, J HEALTH SOC BEHAV, V44, P488, DOI 10.2307/1519795
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   Ursini G, 2011, J NEUROSCI, V31, P6692, DOI 10.1523/JNEUROSCI.6631-10.2011
   Vandenbergh DJ, 1997, AM J MED GENET, V74, P439, DOI 10.1002/(SICI)1096-8628(19970725)74:4<439::AID-AJMG16>3.3.CO;2-5
   Wagner S, 2010, ACTA PSYCHIAT SCAND, V122, P110, DOI 10.1111/j.1600-0447.2009.01501.x
   WEINSHILBOUM RM, 1977, AM J HUM GENET, V29, P125
   Witte AV, 2012, BRAIN RES BULL, V88, P418, DOI 10.1016/j.brainresbull.2011.11.012
   Yager James D, 2012, Drug Discov Today Dis Mech, V9, pe41
   Yagi E, 2001, CARCINOGENESIS, V22, P1505, DOI 10.1093/carcin/22.9.1505
   Yu CP, 2007, ANTICANCER RES, V27, P1727
   Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335
   Zhang HP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065648
   Zhang HP, 2013, ALCOHOL CLIN EXP RES, V37, pE108, DOI 10.1111/j.1530-0277.2012.01928.x
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
   Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546
NR 74
TC 24
Z9 27
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD JAN 24
PY 2014
VL 7
AR 5
DI 10.1186/1755-8794-7-5
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AB5HD
UT WOS:000331818600001
PM 24460628
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Soung, YH
   Pruitt, K
   Chung, J
AF Soung, Young Hwa
   Pruitt, Kevin
   Chung, Jun
TI Epigenetic silencing of ARRDC3 expression in basal-like breast cancer
   cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENE-EXPRESSION; SIRT2; UBIQUITINATION; DEACETYLATION; INTERACTS;
   THERAPY; DOMAIN; ROLES; LINES
AB Arrestin domain-containing 3 (ARRDC3) is a tumor suppressor whose expression is either lost or suppressed in basal-like breast cancer (BLBC). However, the mechanism by which BLBC suppresses ARRDC3 expression is not established. Here, we show that expression of ARRDC3 in BLBC cells is suppressed at the transcriptional level. Suppression of ARRDC3 expression in BLBC cells involves epigenetic silencing as inhibitors of class III histone deacetylases (HDACs) significantly restores ARRDC3 levels in BLBC cells. SIRT2, among class III HDACs, plays a major role in epigenetic silencing of ARRDC3 in MDA-MB-231 cells. Acetylation levels of the ARRDC3 promoter in BLBC cells is significantly lower than that of other sub-types of BC cells. Chromatin immunopreciptitation analysis established SIRT2 binding at ARRDC3 promoter in BLBC cells. Our studies indicate that SIRT2 dependent epigenetic silencing of ARRDC3 is one of the important events that may contribute to the aggressive nature of BLBC cells.
C1 [Soung, Young Hwa; Chung, Jun] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.
   [Soung, Young Hwa; Chung, Jun] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK 73104 USA.
   [Pruitt, Kevin] Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; Louisiana State University System; Louisiana State
   University Health Sciences Center at Shreveport
RP Chung, J (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.
EM Jun-Chung@ouhsc.edu
FU American Cancer Society [RSG-09-091-01-CSM]; NIH-NCI [R01CA163657-01A1,
   5 R01 CA155223-02]
FX This study is supported by American Cancer Society (RSG-09-091-01-CSM:
   J.C.), NIH-NCI (R01CA163657-01A1: J.C.), NIH-NCI (5 R01 CA155223-02: K.
   P.).
CR Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Barnes WG, 2005, J BIOL CHEM, V280, P8041, DOI 10.1074/jbc.M412924200
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bonezzi K, 2012, NEOPLASIA, V14, P846, DOI 10.1593/neo.12728
   Bosch A, 2010, CANCER TREAT REV, V36, P206, DOI 10.1016/j.ctrv.2009.12.002
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Carey LA, 2010, CLIN BREAST CANCER, V10, P188, DOI 10.3816/CBC.2010.n.026
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200
   Da Silva L, 2010, MODERN PATHOL, V23, pS46, DOI 10.1038/modpathol.2010.37
   Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101
   de Ruijter TC, 2011, J CANCER RES CLIN, V137, P183, DOI 10.1007/s00432-010-0957-x
   Draheim KM, 2010, ONCOGENE, V29, P5032, DOI 10.1038/onc.2010.250
   Goodison S, 2010, BIOANALYSIS, V2, P855, DOI 10.4155/BIO.10.35
   Haupt B, 2010, ARCH PATHOL LAB MED, V134, P130, DOI 10.1043/1543-2165-134.1.130
   Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617
   Ismail-Khan R, 2010, CANCER CONTROL, V17, P173, DOI 10.1177/107327481001700305
   Jin YH, 2008, BIOCHEM BIOPH RES CO, V368, P690, DOI 10.1016/j.bbrc.2008.01.114
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kovacs JJ, 2009, DEV CELL, V17, P443, DOI 10.1016/j.devcel.2009.09.011
   Lin SX, 2010, NAT REV ENDOCRINOL, V6, P485, DOI 10.1038/nrendo.2010.92
   Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116
   McClure JM, 2012, J BIOL CHEM, V287, P20957, DOI 10.1074/jbc.M112.367524
   Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312
   Nabhan JF, 2010, EMBO REP, V11, P605, DOI 10.1038/embor.2010.80
   North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8
   Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971
   Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683
   Peserico A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/371832
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Rothgiesser KM, 2010, J CELL SCI, V123, P4251, DOI 10.1242/jcs.073783
   Seal MD, 2010, CANCER J, V16, P12, DOI 10.1097/PPO.0b013e3181cf04be
   Taylor DM, 2008, CELL MOL LIFE SCI, V65, P4000, DOI 10.1007/s00018-008-8357-y
   Toft DJ, 2011, MOL ENDOCRINOL, V25, P199, DOI 10.1210/me.2010-0164
   Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Venkitaraman R, 2010, EXPERT REV ANTICANC, V10, P199, DOI 10.1586/ERA.09.189
   Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
NR 40
TC 54
Z9 61
U1 0
U2 19
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 24
PY 2014
VL 4
AR 3846
DI 10.1038/srep03846
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 295TH
UT WOS:000330137900004
PM 24457910
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Laszlo, GS
   Gudgeon, CJ
   Harrington, KH
   Dell'Aringa, J
   Newhall, KJ
   Means, GD
   Sinclair, AM
   Kischel, R
   Frankel, SR
   Walter, RB
AF Laszlo, George S.
   Gudgeon, Chelsea J.
   Harrington, Kimberly H.
   Dell'Aringa, Justine
   Newhall, Kathryn J.
   Means, Gary D.
   Sinclair, Angus M.
   Kischel, Roman
   Frankel, Stanley R.
   Walter, Roland B.
TI Cellular determinants for preclinical activity of a novel CD33/CD3
   bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; OZOGAMICIN-INDUCED
   CYTOTOXICITY; RESISTANCE PROTEIN BCRP/ABCG2; ACUTE NONLYMPHOCYTIC
   LEUKEMIA; GEMTUZUMAB-OZOGAMICIN; DRUG-RESISTANCE; TARGETED THERAPY;
   PROGENITOR CELLS; FREE SURVIVAL
AB CD33 is a valid target for acute myeloid leukemia (AML) but has proven challenging for antibody-drug conjugates. Herein, we investigated the cellular determinants for the activity of the novel CD33/CD3-directed bispecific T-cell engager antibody, AMG 330. In the presence of T cells, AMG 330 was highly active against human AML cell lines and primary AML cells in a dose-and effector to target cell ratio-dependent manner. Using cell lines engineered to express wild-type CD33 at increased levels, we found a quantitative relationship between AMG 330 cytotoxicity and CD33 expression; in contrast, AMG 330 cytotoxicity was neither affected by common CD33 single nucleotide polymorphisms nor expression of the adenosine triphosphate-binding cassette (ABC) transporter proteins, P-glycoprotein or breast cancer resistance protein. Unlike bivalent CD33 antibodies, AMG 330 did not reduce surface CD33 expression. The epigenetic modifier drugs, panobinostat and azacitidine, increased CD33 expression in some cell lines and augmented AMG 330-induced cytotoxicity. These findings demonstrate that AMG 330 has potent CD33-dependent cytolytic activity in vitro, which can be further enhanced with other clinically available therapeutics. As it neither modulates CD33 expression nor is affected by ABC transporter activity, AMG 330 is highly promising for clinical exploration as it may overcome some limitations of previous CD33-targeted agents.
C1 [Laszlo, George S.; Gudgeon, Chelsea J.; Harrington, Kimberly H.; Walter, Roland B.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
   [Dell'Aringa, Justine; Newhall, Kathryn J.; Means, Gary D.] Amgen Inc, Mol Sci Oncol Biomarker, Seattle, WA USA.
   [Sinclair, Angus M.] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA.
   [Kischel, Roman] Amgen Res GmbH, ARM BiTE Technol, Munich, Germany.
   [Frankel, Stanley R.] Amgen Inc, Med Sci Early Dev, Rockville, MD USA.
   [Walter, Roland B.] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA.
   [Walter, Roland B.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
C3 Fred Hutchinson Cancer Center; Amgen; Amgen; Amgen; Amgen Research
   Munich GmbH; Amgen; University of Washington; University of Washington
   Seattle; University of Washington; University of Washington Seattle
RP Walter, RB (通讯作者)，Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D2-190, Seattle, WA 98109 USA.
EM rwalter@fhcrc.org
RI Walter, Roland/C-1064-2008
OI Walter, Roland/0000-0002-9268-3341
FU Amgen, Inc.; National Institutes of Health, National Cancer Institute
   (Bethesda, MD) [P30-CA015704-35S6]
FX This work was supported by a research contract from Amgen, Inc. (R. B.
   W.) and by grant P30-CA015704-35S6 (R. B. W.) from the National
   Institutes of Health, National Cancer Institute (Bethesda, MD).
CR Aigner M, 2013, LEUKEMIA, V27, P1107, DOI 10.1038/leu.2012.341
   Baeuerle PA, 2009, CANCER RES, V69, P4941, DOI 10.1158/0008-5472.CAN-09-0547
   Balaian L, 2006, LEUKEMIA, V20, P2093, DOI 10.1038/sj.leu.2404437
   BERNSTEIN ID, 1987, J CLIN INVEST, V79, P1153, DOI 10.1172/JCI112932
   BERNSTEIN ID, 1992, BLOOD, V79, P1811, DOI 10.1182/blood.V79.7.1811.1811
   Burnett AK, 2012, J CLIN ONCOL, V30, P3924, DOI 10.1200/JCO.2012.42.2964
   Burnett AK, 2011, J CLIN ONCOL, V29, P369, DOI 10.1200/JCO.2010.31.4310
   Castaigne S, 2012, LANCET, V379, P1508, DOI 10.1016/S0140-6736(12)60485-1
   Choi BD, 2011, EXPERT OPIN BIOL TH, V11, P843, DOI 10.1517/14712598.2011.572874
   Cowan AJ, 2013, FRONT BIOSCI-LANDMRK, V18, P1312, DOI 10.2741/4181
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   DINNDORF PA, 1986, BLOOD, V67, P1048
   FIALKOW PJ, 1981, BLOOD, V57, P1068
   FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802
   Frankel SR, 2013, CURR OPIN CHEM BIOL, V17, P385, DOI 10.1016/j.cbpa.2013.03.029
   Garcia-Manero G, 2012, BEST PRACT RES CL HA, V25, P427, DOI 10.1016/j.beha.2012.10.005
   GRIFFIN JD, 1984, LEUKEMIA RES, V8, P521, DOI 10.1016/0145-2126(84)90001-8
   Griffiths EA, 2013, ADV EXP MED BIOL, V754, P253, DOI 10.1007/978-1-4419-9967-2_13
   Kurimoto M, 2013, LEUKEMIA, V27, P233, DOI 10.1038/leu.2012.178
   LESLEY J, 1989, EXP CELL RES, V182, P215, DOI 10.1016/0014-4827(89)90293-0
   Linenberger ML, 2001, BLOOD, V98, P988, DOI 10.1182/blood.V98.4.988
   Mahadevan D, 2004, BLOOD, V104, P1940, DOI 10.1182/blood-2003-07-2490
   MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163
   Mortland L, 2013, CLIN CANCER RES, V19, P1620, DOI 10.1158/1078-0432.CCR-12-3115
   Naito K, 2000, LEUKEMIA, V14, P1436, DOI 10.1038/sj.leu.2401851
   Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002
   Pollard JA, 2012, BLOOD, V119, P3705, DOI 10.1182/blood-2011-12-398370
   Quintás-Cardama A, 2011, LEUKEMIA, V25, P226, DOI 10.1038/leu.2010.276
   SCHEINBERG DA, 1991, J CLIN ONCOL, V9, P478, DOI 10.1200/JCO.1991.9.3.478
   Steinbach D, 2007, LEUKEMIA, V21, P1172, DOI 10.1038/sj.leu.2404692
   Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072
   ten Cate B, 2007, LEUKEMIA, V21, P248, DOI 10.1038/sj.leu.2404477
   Thomas X, 2012, EXPERT OPIN DRUG DIS, V7, P1039, DOI 10.1517/17460441.2012.722618
   Topp MS, 2012, BLOOD, V120, P5185, DOI 10.1182/blood-2012-07-441030
   Topp MS, 2011, J CLIN ONCOL, V29, P2493, DOI 10.1200/JCO.2010.32.7270
   van der Velden VHJ, 2004, LEUKEMIA, V18, P983, DOI 10.1038/sj.leu.2403350
   van der Velden VHJ, 2001, BLOOD, V97, P3197, DOI 10.1182/blood.V97.10.3197
   Walter RB, 2005, BLOOD, V105, P1295, DOI 10.1182/blood-2004-07-2784
   Walter RB, 2004, LEUKEMIA, V18, P1914, DOI 10.1038/sj.leu.2403461
   Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825
   Walter RB, 2003, BLOOD, V102, P1466, DOI 10.1182/blood-2003-02-0396
   Walter RB, 2007, BLOOD, V109, P4168, DOI 10.1182/blood-2006-09-047399
   Walter RB, 2012, BLOOD, V119, P6198, DOI 10.1182/blood-2011-11-325050
NR 43
TC 144
Z9 203
U1 0
U2 21
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JAN 23
PY 2014
VL 123
IS 4
BP 554
EP 561
DI 10.1182/blood-2013-09-527044
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA AE8MH
UT WOS:000334254200019
PM 24311721
OA Green Published
DA 2025-01-12
ER

PT J
AU Monteiro, J
   Gaspar, C
   Richer, W
   Franken, PF
   Sacchetti, A
   Joosten, R
   Idali, A
   Brandao, J
   Decraene, C
   Fodde, R
AF Monteiro, Joana
   Gaspar, Claudia
   Richer, Wilfrid
   Franken, Patrick F.
   Sacchetti, Andrea
   Joosten, Rosalie
   Idali, Anouar
   Brandao, Joana
   Decraene, Charles
   Fodde, Riccardo
TI Cancer stemness in Wnt-driven mammary tumorigenesis
SO CARCINOGENESIS
LA English
DT Article
ID WNT/BETA-CATENIN PATHWAY; BREAST-CANCER; GENE-EXPRESSION; MESENCHYMAL
   TRANSITION; HISTOLOGIC GRADE; BETA-CATENIN; CELLS; MOUSE; GLAND;
   IDENTIFICATION
AB Wnt signaling plays a central role in mammary stem cell (MaSC) homeostasis and in breast cancer. In particular, epigenetic alterations at different members of the Wnt pathway have been identified among triple-negative, basal-like breast cancers. Previously, we developed a mouse model for metaplastic breast adenocarcinoma, a subtype of triple-negative breast cancer, by targeting a hypomorphic mutations in the endogenous Apc gene (Apc(1572T/)). Here, by employing the CD24 and CD29 cell surface antigens, we have identified a subpopulation of mammary cancer stem cells (MaCSCs) from Apc(1572T/) capable of self-renewal and differentiation both in vivo and in vitro. Moreover, immunohistochemical analysis of micro- and macrolung metastases and preliminary intravenous transplantation assays suggest that the MaCSCs underlie metastasis at distant organ sites. Expression profiling of the normal and tumor cell subpopulations encompassing MaSCs and CSCs revealed that the normal stem cell compartment is more similar to tumor cells than to their own differentiated progenies. Accordingly, Wnt signaling appears to be active in both the normal and cancer stem cell compartments, although at different levels. By comparing normal with cancer mouse mammary compartments, we identified a MaCSC gene signature able to predict outcome in breast cancer in man. Overall, our data indicate that constitutive Wnt signaling activation affects self-renewal and differentiation of MaSCs leading to metaplasia and basal-like adenocarcinomas.
C1 [Monteiro, Joana; Gaspar, Claudia; Franken, Patrick F.; Sacchetti, Andrea; Joosten, Rosalie; Brandao, Joana; Fodde, Riccardo] Erasmus MC, Josephine Nefkens Inst, Dept Pathol, NL-3000 CA Rotterdam, Netherlands.
   [Richer, Wilfrid; Idali, Anouar; Decraene, Charles] Ctr Rech, Inst Curie, Dept Translat Res, F-75248 Paris, France.
   [Decraene, Charles] CNRS, UMR144, F-75248 Paris, France.
C3 Erasmus University Rotterdam; Erasmus MC; UNICANCER; Universite PSL;
   Institut Curie; Centre National de la Recherche Scientifique (CNRS);
   CNRS - National Institute for Biology (INSB); Sorbonne Universite;
   Universite PSL; UNICANCER; Institut Curie
RP Fodde, R (通讯作者)，Erasmus MC, Josephine Nefkens Inst, Dept Pathol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM r.fodde@erasmusmc.nl
RI Sacchetti, Andrea/H-8763-2019; Fodde, Riccardo/IIS-2405-2023; Gaspar,
   Claudia/I-6402-2013
OI Fodde, Riccardo/0000-0001-9839-4324; Monteiro,
   Joana/0000-0003-0249-2283; Gaspar, Claudia/0000-0003-1051-0998; Richer,
   Wilfrid/0000-0003-1802-3529
FU Dutch Cancer Society [EMCR 2001-2482]; Netherlands Organisation for
   Scientific Research [NWO/Vici 016.036.636]; BSIK (Kennisinfrastructuur)
   program of the Dutch Government [03038]; Netherlands Institute for
   Regenerative Medicine; EU [037297]; Integrated concept of tumor
   metastasis [HEALTH-F2-2008-201662]; Portuguese Foundation for Science
   and Technology (FCT)
FX Dutch Cancer Society (EMCR 2001-2482); the Netherlands Organisation for
   Scientific Research (NWO/Vici 016.036.636); BSIK (Kennisinfrastructuur)
   program of the Dutch Government (03038); the Netherlands Institute for
   Regenerative Medicine (www.nirm.nl); EU FP6 and FP7 consortia 'Migrating
   Cancer Stem Cells' (037297; www.mcscs.eu); Integrated concept of tumor
   metastasis (HEALTH-F2-2008-201662;
   http://itgmv1.fzk.de/www/tumic/tumic_main.htm); the Portuguese
   Foundation for Science and Technology (FCT;
   http://www.fct.pt/index.phtml.en).
CR Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007
   Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547
   Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041
   Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hennessy BT, 2006, ANN ONCOL, V17, P605, DOI 10.1093/annonc/mdl006
   Hennessy BT, 2005, J CLIN ONCOL, V23, P7827, DOI 10.1200/JCO.2004.00.9589
   Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Jolliffe I. T., 2002, Principal Component Analysis, DOI [DOI 10.1016/0169-7439(87)80084-9, DOI 10.1007/B98835]
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107
   Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239
   López-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741
   Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prosperi JR, 2010, CURR DRUG TARGETS, V11, P1074
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6
   Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949
   van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573
   Venet D, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002240
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
   Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353
NR 50
TC 40
Z9 48
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2014
VL 35
IS 1
BP 2
EP 13
DI 10.1093/carcin/bgt279
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 281WB
UT WOS:000329130600002
PM 23955540
DA 2025-01-12
ER

PT J
AU Chik, F
   Machnes, Z
   Szyf, M
AF Chik, Flora
   Machnes, Ziv
   Szyf, Moshe
TI Synergistic anti-breast cancer effect of a combined treatment with the
   methyl donor <i>S</i>-adenosyl methionine and the DNA methylation
   inhibitor 5-aza-2-deoxycytidine
SO CARCINOGENESIS
LA English
DT Article
ID UROKINASE UPA PROMOTER; PROSTATE-CANCER; PLASMINOGEN-ACTIVATOR; CELL
   INVASIVENESS; MYELOID-LEUKEMIA; IN-VITRO; HYPOMETHYLATION; GENE;
   5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION
AB DNA-demethylating agents activate tumor suppressor genes that are silenced by DNA methylation in cancer and are therefore emerging as a novel approach to cancer therapy. 5-azacytidine (VIDAZA), the first representative of this class of drugs was approved for treatment of myelodysplastic syndromes and is currently being tested on other cancers including solid tumors. However, 5-azacytidine or its deoxy-analog, 5-aza-2-deoxycytidine (5-azaCdR) could also induce methylated prometastatic genes by DNA demethylation and induce cancer cell invasiveness. Since 5-azacytidine is a potent cancer growth inhibitor, we tested whether combining it with a DNA-methylating agent, the methyl donor S-adenosyl methionine (SAM), would block the adverse demethylating activity of 5-azaCdR while maintaining its growth suppression effects. We show here using several invasive and non-invasive breast cancer cell lines that SAM inhibits global- and gene-specific demethylation induced by 5-azaCdR, prevents 5-azaCdR activation of prometastatic genes uPA and MMP2, resulting in inhibition of cell invasiveness while augmenting the growth inhibitory effects of 5-azaCdR and its effects on tumor suppressor genes. Combination of drugs acting on the DNA methylation machinery at different levels is proposed as a new strategy for epigenetic therapy of cancer.
C1 [Chik, Flora; Machnes, Ziv; Szyf, Moshe] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
   [Szyf, Moshe] McGill Univ, Sackler Program Epigenet & Dev Psychobiol, Montreal, PQ H3G 1Y6, Canada.
C3 McGill University; McGill University
RP Szyf, M (通讯作者)，McGill Univ, Dept Pharmacol & Therapeut, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.
EM moshe.szyf@mcgill.ca
FU Canadian Institute of Health Research [MOP-42411]
FX Canadian Institute of Health Research (MOP-42411 to M.S.).
CR Anderson OS, 2012, J NUTR BIOCHEM, V23, P853, DOI 10.1016/j.jnutbio.2012.03.003
   [Anonymous], 2010, COLD SPRING HARB PRO
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Chik F, 2011, CARCINOGENESIS, V32, P224, DOI 10.1093/carcin/bgq221
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   DANTE R, 1992, ANTICANCER RES, V12, P559
   Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200
   Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/bst0300207
   FEINBERG AP, 1988, CANCER RES, V48, P1159
   Fenaux Pierre, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS36, DOI 10.1038/ncponc0351
   Gagnon J, 2003, ANTI-CANCER DRUG, V14, P193, DOI 10.1097/00001813-200303000-00002
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Hasan MK, 2008, INT J ONCOL, V32, P663
   Itzykson R, 2012, CURR OPIN HEMATOL, V19, P65, DOI 10.1097/MOH.0b013e32834ff58a
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545
   Li HC, 2004, BREAST CANCER RES TR, V88, P75, DOI 10.1007/s10549-004-1200-8
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Pakneshan P, 2005, CURR CANCER DRUG TAR, V5, P471, DOI 10.2174/156800905774574011
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Pulukuri SMK, 2005, INT J ONCOL, V26, P863
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7
   Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797
   Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010
   Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4
   Szyf M, 2001, FRONT BIOSCI-LANDMRK, V6, pD599, DOI 10.2741/szyf
   Xiao L, 2010, MOL BIOL REP, V37, P2355, DOI 10.1007/s11033-009-9741-x
   Ying JM, 2004, BLOOD, V103, P743, DOI 10.1182/blood-2003-09-3193
   Yu YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012710
   Yuan YF, 2005, INT J CANCER, V113, P654, DOI 10.1002/ijc.20628
NR 38
TC 55
Z9 62
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2014
VL 35
IS 1
BP 138
EP 144
DI 10.1093/carcin/bgt284
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 281WB
UT WOS:000329130600017
PM 23985780
DA 2025-01-12
ER

PT J
AU Li, QY
   Jiang, Y
   Wei, W
   Ji, YN
   Gao, H
   Liu, JL
AF Li, Qiuyun
   Jiang, Yi
   Wei, Wei
   Ji, Yinan
   Gao, Hui
   Liu, Jianlun
TI Frequent epigenetic inactivation of RSK4 by promoter methylation in
   cancerous and non-cancerous tissues of breast cancer
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Breast cancer; Ribosomal s6 kinase4 RSK4; Methylation
ID X-LINKED GENES; DNA METHYLATION; 5-AZA-2'-DEOXYCYTIDINE;
   HYPERMETHYLATION; KINASE; FAMILY
AB Breast cancer is one of the most common cancers and is the second leading cause of cancer-related death in women worldwide. Ribosomal s6 kinase4 (RSK4) is a potential tumor suppressor in multiple cancers, while its role in breast cancer is largely unknown. Our study here aimed to explore the relationship between RSK4 expression with the clinicopathologic characteristics and the promoter methylation status of RSK4. Real-time PCR and bisulfite sequencing PCR were, respectively, used to detect the expression difference of RSK4 mRNA and RSK4 methylation in the 49 breast cancer and paired non-cancerous samples. The associations of RSK4 expression and methylation status with the clinicopathologic characteristics were analyzed. In the 49 breast cancer patients' specimens, RSK4 mRNA expression was found to be significantly decreased in most of breast cancer tissues compared with paired non-cancerous tissues (p = 0.002), which was largely due to the promoter hypermethylation (p = 0.005). Frequency of RSK4 promoter methylation in breast cancers was significantly higher than paired non-cancerous tissues (p = 0.009); RSK4 methylation was not associated with all clinicopathological features. The silencing of RSK4 due to promoter hypermethylation is a frequent event in breast cancer. The majority of cancers have a higher level of methylation status when compared with non-cancerous tissues. RSK4 may be a valuable biomarker for the study of breast cancer carcinogenesis and progression.
C1 [Li, Qiuyun; Jiang, Yi; Wei, Wei; Ji, Yinan; Gao, Hui; Liu, Jianlun] Guangxi Med Univ, Dept Breast Surg, Affiliated Tumor Hosp, Nanning 530021, Guangxi, Peoples R China.
   [Li, Qiuyun] 303 Hosp PLA, Nanning 530021, Guangxi, Peoples R China.
C3 Guangxi Medical University
RP Liu, JL (通讯作者)，Guangxi Med Univ, Dept Breast Surg, Affiliated Tumor Hosp, Nanning 530021, Guangxi, Peoples R China.
EM jianlunliu@hotmail.com
RI LIU, Juan/AAO-6435-2020
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509
   Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Bender CM, 1998, CANCER RES, V58, P95
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Chu D, 2011, MOL CANCER THER, V10, P47, DOI 10.1158/1535-7163.MCT-10-0614
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855
   Dümmler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   López-Vicente L, 2009, CLIN CANCER RES, V15, P4546, DOI 10.1158/1078-0432.CCR-08-3159
   Nowsheen S, 2014, CANCER LETT, V342, P213, DOI 10.1016/j.canlet.2012.05.015
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Thakur A, 2005, BREAST CANCER RES TR, V93, P135, DOI 10.1007/s10549-005-4516-0
   Thakur A, 2008, CLIN CANCER RES, V14, P4427, DOI 10.1158/1078-0432.CCR-08-0458
   Thakur A, 2007, MOL CANCER RES, V5, P171, DOI 10.1158/1541-7786.MCR-06-0071
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004
   Zhang ML, 2012, ZHONGHUA LIU XING BI, V33, P1049
NR 23
TC 20
Z9 23
U1 0
U2 7
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD JAN
PY 2014
VL 31
IS 1
AR 793
DI 10.1007/s12032-013-0793-3
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 278AB
UT WOS:000328859300029
PM 24338215
DA 2025-01-12
ER

PT J
AU Ma, WJ
   Zhou, Y
   Lu, D
   Dong, D
   Tian, XJ
   Wen, JX
   Zhang, J
AF Ma, Wei-Jie
   Zhou, Yu
   Lu, Dan
   Dong, Dong
   Tian, Xiao-Jun
   Wen, Jie-xi
   Zhang, Jun
TI Reduced expression of Slit2 in renal cell carcinoma
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Slit2; Renal cell carcinoma; Methylation; Tumor suppressor
ID TUMOR-SUPPRESSOR GENES; FREQUENT EPIGENETIC INACTIVATION; PROMOTER
   HYPERMETHYLATION; METHYLATION ANALYSIS; CERVICAL-CANCER; BREAST-CANCER;
   AXON GUIDANCE; GROWTH; ANGIOGENESIS; DROSOPHILA
AB Slit2, initially identified as an important axon guidance molecule in the nervous system, was suggested to be involved in multiple cellular processes. Recently, Slit2 was reported to function as a potential tumor suppressor in diverse tumors. In this study, we systematically analyzed the expression level of Slit2 in renal cell carcinoma. Compared to paired adjacent non-malignant tissues, both Slit2 mRNA and protein expression were significantly down-regulated in renal cell carcinoma (RCC). Methylation-specific PCR showed that Slit2 promoter was methylated in two renal carcinoma cell lines. Pharmacologic demethylation dramatically induced Slit2 expression in cancer cell lines with weak expression of Slit2. Besides, bisulfite genomic sequencing confirmed that dense methylation existed in Slit2 promoter. Furthermore, in paired RCC samples, Slit2 methylation was observed in 8 out of 38 patients (21.1 %), which was well correlated with the down-regulation of Slit2 in RCC. Therefore, Slit2 may also be a potential tumor suppressor in RCC, which is down-regulated in RCC partially due to promoter methylation.
C1 [Ma, Wei-Jie; Zhou, Yu; Lu, Dan; Dong, Dong; Wen, Jie-xi; Zhang, Jun] Peking Univ, Sch Basic Med Sci, Dept Immunol, Key Lab Med Immunol,Minist Hlth,Hlth Sci Ctr, Beijing 100191, Peoples R China.
   [Tian, Xiao-Jun] Peking Univ, Dept Urol, Hosp 3, Beijing 100191, Peoples R China.
C3 Peking University; Peking University
RP Zhang, J (通讯作者)，Peking Univ, Sch Basic Med Sci, Dept Immunol, Key Lab Med Immunol,Minist Hlth,Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM junzhang@bjmu.edu.cn
RI Ma, Weijie/AAF-1959-2021; Tian, Xiaojun/M-9242-2014; dong,
   Dong/JFJ-3808-2023
OI Ma, Weijie/0000-0002-4434-1371
FU Beijing Municipal Natural Science Foundation [7122104]; National Natural
   Science Foundation of China [81072395]
FX This work received supports from Beijing Municipal Natural Science
   Foundation (7122104) and the National Natural Science Foundation of
   China (81072395).
CR Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Baldewijns MML, 2008, BBA-REV CANCER, V1785, P133, DOI 10.1016/j.bbcan.2007.12.002
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Fitamant J, 2008, P NATL ACAD SCI USA, V105, P4850, DOI 10.1073/pnas.0709810105
   GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85
   Hoffman AM, 2011, EPIGENOMICS-UK, V3, P19, DOI 10.2217/EPI.10.64
   Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365
   Jones CA, 2009, NAT CELL BIOL, V11, P1325, DOI 10.1038/ncb1976
   Kagara I, 2008, J UROLOGY, V180, P343, DOI 10.1016/j.juro.2008.02.044
   Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9
   Kikuyama M, 2012, CANCER LETT, V322, P204, DOI 10.1016/j.canlet.2012.03.016
   Kolodkin AL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a001727
   Legg JA, 2008, ANGIOGENESIS, V11, P13, DOI 10.1007/s10456-008-9100-x
   Lu D, 2013, CLIN CANCER RES, V19, P2883, DOI 10.1158/1078-0432.CCR-12-2978
   Lv D, 2011, EUR J CANCER, V47, P2068, DOI 10.1016/j.ejca.2011.04.021
   Mertsch S, 2008, J NEURO-ONCOL, V87, P1, DOI 10.1007/s11060-007-9484-2
   Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   Onay H, 2009, UROL INT, V83, P107, DOI 10.1159/000224878
   Qiu HF, 2011, ASIAN PAC J CANCER P, V12, P791
   Singh RK, 2007, HUM GENET, V122, P71, DOI 10.1007/s00439-007-0375-6
   Sogabe Y, 2008, INT J ONCOL, V32, P1253
   Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8
NR 29
TC 9
Z9 9
U1 0
U2 14
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD JAN
PY 2014
VL 31
IS 1
AR 768
DI 10.1007/s12032-013-0768-4
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 278AB
UT WOS:000328859300005
PM 24287947
DA 2025-01-12
ER

PT J
AU Hagrass, HA
   Pasha, HF
   Shaheen, MA
   Bary, EHA
   Kassem, R
AF Hagrass, Hoda A.
   Pasha, Heba F.
   Shaheen, Mohamed A.
   Bary, Eman H. Abdel
   Kassem, Rasha
TI Methylation status and protein expression of RASSF1A in breast cancer
   patients
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE RAS association domain family protein 1A; Methylated polymerase chain
   reaction; Breast cancer; Egypt
ID TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; DNA METHYLATION; CPG
   ISLAND; ABERRANT METHYLATION; ESTROGEN-RECEPTOR; MULTIPLE GENES; PCR
   ASSAY; INACTIVATION; P16(INK4A)
AB Recently genetics and epigenetics alterations have been found to be characteristic of malignancy and hence can be used as targets for detection of neoplasia. RAS association domain family protein 1A (RASSF1A) gene hypermethylation has been a subject of interest in recent researches on cancer breast patients. The aim of the present study was to evaluate whether RASSF1A methylation status and RASSF1A protein expression are associated with the major clinico-pathological parameters. One hundred and twenty breast cancer Egyptian patients and 100-control subjects diagnosed with benign lesions of the breast were enrolled in this study. We evaluated RASSF1A methylation status in tissue and serum samples using Methyl specific PCR together with RASSF1A protein expression in tissues by immunohistochemistry. Results were studied in relation to known prognostic clinicopathological features in breast cancer. Frequency of RASSF1A methylation in tissues and serum were 70 and 63.3 % respectively and RASSF1A protein expression showed frequency of 46.7 %. There was an association between RASSF1A methylation in tissues, serum and loss of protein expression in tissues with invasive carcinoma, advanced stage breast cancer, L.N. metastasis, ER/PR and HER2 negativity. RASSF1A methylation in serum showed high degree of concordance with methylation in tissues (Kappa = 0.851, P < 0.001). RASSF1A hypermethylation in tissues and serum and its protein expression may be a valid, reliable and sensitive tool for detection and follow up of breast cancer patients.
C1 [Hagrass, Hoda A.] Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig, Egypt.
   [Pasha, Heba F.] Zagazig Univ, Dept Med Biochem, Fac Med, Zagazig, Egypt.
   [Shaheen, Mohamed A.] Zagazig Univ, Histol & Cell Biol Dept, Fac Med, Zagazig, Egypt.
   [Bary, Eman H. Abdel] Zagazig Univ, Dept Pathol, Fac Med, Zagazig, Egypt.
   [Kassem, Rasha] Zagazig Univ, Dept Surg, Fac Med, Zagazig, Egypt.
C3 Egyptian Knowledge Bank (EKB); Zagazig University; Egyptian Knowledge
   Bank (EKB); Zagazig University; Egyptian Knowledge Bank (EKB); Zagazig
   University; Egyptian Knowledge Bank (EKB); Zagazig University; Egyptian
   Knowledge Bank (EKB); Zagazig University
RP Hagrass, HA (通讯作者)，Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig, Egypt.
EM hudahagrass@gmail.com
RI Pasha, Heba/Y-6005-2019; Shaheen, Mohamed/P-3861-2018
OI , rasha/0000-0002-8561-1569; A. Shaheen, Mohamed/0000-0002-8239-9793
FU academic research in Zagazig University Projects, Zagazig University
   Postgraduate & Research Affairs
FX This work was funded by support of academic research in Zagazig
   University Projects, Zagazig University Postgraduate & Research Affairs.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Allam M F, 2012, J Prev Med Hyg, V53, P195
   Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Dammann R, 2001, CANCER RES, V61, P3105
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Göbel G, 2011, BREAST CANCER RES TR, V130, P109, DOI 10.1007/s10549-010-1335-8
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jeronimo C, 2008, BREAST CANCER RES TR, V109, P27, DOI 10.1007/s10549-007-9620-x
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Karray-Chouayekh S, 2010, J CANCER RES CLIN, V136, P203, DOI 10.1007/s00432-009-0649-6
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee MG, 2001, CANCER RES, V61, P6688
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li YM, 2008, ONCOL REP, V19, P1149
   Lo KW, 2001, CANCER RES, V61, P3877
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Müller HM, 2003, CANCER RES, V63, P7641
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Tavassoeli FA, 2003, WHO CLASSIFICATION T, P10
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Yamamoto N, 2012, BREAST CANCER RES TR, V132, P165, DOI 10.1007/s10549-011-1575-2
NR 41
TC 24
Z9 30
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JAN
PY 2014
VL 41
IS 1
BP 57
EP 65
DI 10.1007/s11033-013-2837-3
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 281KP
UT WOS:000329100500008
PM 24253900
DA 2025-01-12
ER

PT J
AU Chen, YL
   Kuo, MH
   Lin, PY
   Chuang, WL
   Hsu, CC
   Chu, PY
   Lee, CH
   Huang, THM
   Leu, YW
   Hsiao, SH
AF Chen, Yao-Li
   Kuo, Ming-Han
   Lin, Ping-Yi
   Chuang, Wan-Ling
   Hsu, Chia-Chen
   Chu, Pei-Yi
   Lee, Chia-Huei
   Huang, Tim H. -M.
   Leu, Yu-Wei
   Hsiao, Shu-Huei
TI <i>ENSA</i> expression correlates with attenuated tumor propagation in
   liver cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE DNA methylation; Epigenetic; Liver cancer; Chromatin immunoprecipitation
ID POLYCOMB GROUP PROTEINS; DNA METHYLATION; STEM-CELLS; ALPHA-ENDOSULFINE;
   GENE-EXPRESSION; SUPPRESSOR GENES; GREATWALL KINASE; HYPOMETHYLATION;
   PHOSPHATASE; REGULATOR
AB Endosulfine alpha (ENSA) is an endogenous ligand of sulfonylurea receptor that was reported to be associated with an ATP-dependent potassium channel that controls insulin release and the onset of type 2 diabetes. ENSA also interacts with microtubule-associated serine/threonine-protein kinase-like (MASTL) to regulate the cell cycle. Previously, we identified ENSA as a possible bivalent gene in mesenchymal stem cells (MSCs) and hypothesized its methylation might determine cellular differentiation and transformation. Because there was no link between aberrant ENSA expression and tumorigenesis, we aimed to determine if ENSA is abnormally regulated in liver cancer and plays a role in liver cancer propagation. The epigenetic states of the ENSA promoter were evaluated in different cancer cell lines and patient samples. ENSA was overexpressed in a liver cancer cell line, and its interaction with MASTL and possible tumor suppression capabilities were also determined in cultured cells and mice. Distinct ENSA promoter methylation was observed in liver cancer (n = 100 pairs) and breast cancer (n = 100 pairs). ENSA was predominantly hypomethylated in liver cancer but was hypermethylated in breast cancer. Overexpressed ENSA interacts with MASTL and suppresses hepatic tumor growth. We also found that ENSA is hypermethylated in CD90-expressing (CD90(+)) cells compared to CD90 non-expressing (CD90(-)) liver cancer cells. These data reveal ENSA methylation changes during hepatic tumor evolution. Overexpressed ENSA suppresses tumor growth in an established hepatic cell line whereas hypermethylated ENSA might help maintain liver cancer initiating cells. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Chen, Yao-Li; Lin, Ping-Yi; Chuang, Wan-Ling] Changhua Christian Hosp, Transplant Med & Surg Res Ctr, Changhua, Taiwan.
   [Chen, Yao-Li] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan.
   [Kuo, Ming-Han; Hsu, Chia-Chen; Leu, Yu-Wei; Hsiao, Shu-Huei] Natl Chung Cheng Univ, Inst Mol Biol, Dept Life Sci, Human Epigenom Ctr, Chiayi 621, Taiwan.
   [Kuo, Ming-Han; Hsu, Chia-Chen; Leu, Yu-Wei; Hsiao, Shu-Huei] Natl Chung Cheng Univ, Inst Biomed Sci, Chiayi 621, Taiwan.
   [Chu, Pei-Yi] St Martin De Porres Hosp, Dept Pathol, Chiayi, Taiwan.
   [Lee, Chia-Huei] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan, Miaoli, Taiwan.
   [Huang, Tim H. -M.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Mol Med, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Huang, Tim H. -M.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Inst Biotechnol, San Antonio, TX 78229 USA.
C3 Changhua Christian Hospital; Kaohsiung Medical University; National
   Chung Cheng University; National Chung Cheng University; National Health
   Research Institutes - Taiwan; Cancer Therapy & Research Center;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio
RP Leu, YW (通讯作者)，Natl Chung Cheng Univ, Inst Mol Biol, Dept Life Sci, Chiayi 621, Taiwan.
EM bioywl@ccu.edu.tw; bioshh@ccu.edu.tw
RI Lee, Chia-Huei/B-1063-2010; Chen, Yuanyuan/GXG-2130-2022
OI Lee, Chia-Huei/0000-0002-8847-3288; Chu, Pei-Yi/0000-0001-7336-2465
FU Changhua Christian Hospital, Taiwan [101-CCH-IRP-79]; NSC Taiwan
   [100-2320-B-194-001, 101-2320-B-194-001, 100-2321-B-750-001]; CCU; NSC
   [102-2320-B-194-003-MY3]; NHRI Taiwan [NHRI-EX102-10259NI]
FX YWL, SHH, PYL, and YLC are supported by Changhua Christian Hospital,
   Taiwan (101-CCH-IRP-79). YWL, SHH, and PYC are supported by NSC Taiwan
   (100-2320-B-194-001, 101-2320-B-194-001, and 100-2321-B-750-001). YWL
   and SHH are supported by CCU, NSC (102-2320-B-194-003-MY3) and NHRI
   (NHRI-EX102-10259NI) Taiwan.
CR Balch C, 2007, BIOESSAYS, V29, P842, DOI 10.1002/bies.20619
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Biederman JI, 2005, KIDNEY INT, V67, P554, DOI 10.1111/j.1523-1755.2005.67112.x
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Chen YH, 2012, AM J TRANSL RES, V4, P364
   Chen YL, 2012, BIOCHEM BIOPH RES CO, V425, P290, DOI 10.1016/j.bbrc.2012.07.084
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Guttula SV, 2010, INT J DIABETES DEV C, V30, P52, DOI 10.4103/0973-3930.60003
   Héron L, 1999, DIABETES, V48, P1873, DOI 10.2337/diabetes.48.9.1873
   Hsiao SH, 2010, BIOCHEM BIOPH RES CO, V400, P305, DOI 10.1016/j.bbrc.2010.08.048
   Hsu CC, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-12
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Justin N, 2010, CURR OPIN STRUC BIOL, V20, P730, DOI 10.1016/j.sbi.2010.09.012
   Köhler C, 2008, TRENDS CELL BIOL, V18, P236, DOI 10.1016/j.tcb.2008.02.005
   Krajewska M, 2010, CELL CYCLE, V9, P3842, DOI 10.4161/cc.9.19.13282
   Leu YW, 2013, ADV EXP MED BIOL, V754, P195, DOI 10.1007/978-1-4419-9967-2_10
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Lorca T, 2013, ONCOGENE, V32, P537, DOI 10.1038/onc.2012.79
   Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Luis NM, 2012, CELL STEM CELL, V11, P16, DOI 10.1016/j.stem.2012.06.005
   Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Schuettengruber B, 2011, NAT REV MOL CELL BIO, V12, P799, DOI 10.1038/nrm3230
   Shi HD, 2003, CANCER RES, V63, P2164
   Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008-5472.CAN-10-3418
   Thameem F, 2004, MOL GENET METAB, V81, P16, DOI 10.1016/j.ymgme.2003.09.013
   Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832
   Wang H, 2004, MOL GENET METAB, V81, P9, DOI 10.1016/j.ymgme.2003.08.003
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013
NR 35
TC 8
Z9 8
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 6
PY 2013
VL 442
IS 1-2
BP 56
EP 61
DI 10.1016/j.bbrc.2013.10.165
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 282CB
UT WOS:000329146800010
PM 24211627
DA 2025-01-12
ER

PT J
AU Kim, TW
   Kim, B
   Kim, JH
   Kang, S
   Park, SB
   Jeong, G
   Kang, HS
   Kim, SJ
AF Kim, Tae Woo
   Kim, Byungtak
   Kim, Ju Hee
   Kang, Seongeun
   Park, Sung-Bin
   Jeong, Gookjoo
   Kang, Han-Sung
   Kim, Sun Jung
TI Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an
   opposite epigenetic mode based on estrogen receptor status in breast
   cancer
SO BMC CANCER
LA English
DT Article
DE Breast cancer; Epigenetics; Estrogen receptor; MRPL41; MTO1
ID GENE-EXPRESSION; DNA METHYLATION; ALPHA; PROTEIN; 17-BETA-ESTRADIOL;
   PHOSPHATASE; BINDING; BCL-2; BETA; BMRP
AB Background: MTO1 and MRPL41 are nuclear-encoded mitochondrial genes encoding a mitochondrial tRNA-modifying enzyme and a mitochondrial ribosomal protein, respectively. Although both genes have been known to have potential roles in cancer, little is known about their molecular regulatory mechanism, particularly from an epigenetic approach. In this study, we aimed to address their epigenetic regulation through the estrogen receptor (ER) in breast cancer.
   Methods: Digital differential display (DDD) was conducted to identify mammary gland-specific gene candidates including MTO1 and MRPL41. Promoter CpG methylation and expression in breast cancer cell lines and tissues were examined by methylation-specific PCR and real time RT-PCR. Effect of estradiol (E2), tamoxifen, and trichostatin A (TSA) on gene expression was examined in ER + and ER- breast cancer cell lines. Chromatin immunoprecipitation and luciferase reporter assay were performed to identify binding and influencing of the ER to the promoters.
   Results: Examination of both cancer tissues and cell lines revealed that the two genes showed an opposite expression pattern according to ER status; higher expression of MTO1 and MRPL41 in ER- and ER+ cancer types, respectively, and their expression levels were inversely correlated with promoter methylation. Tamoxifen, E2, and TSA upregulated MTO1 expression only in ER+ cells with no significant changes in ER- cells. However, these chemicals upregulated MRPL41 expression only in ER-cells without significant changes in ER+ cells, except for tamoxifen that induced downregulation. Chromatin immunoprecipitation and luciferase reporter assay identified binding and influencing of the ER to the promoters and the binding profiles were differentially regulated in ER+ and ER- cells.
   Conclusions: These results indicate that different epigenetic status including promoter methylation and different responses through the ER are involved in the differential expression of MTO1 and MRPL41 in breast cancer.
C1 [Kim, Tae Woo; Kim, Byungtak; Kim, Ju Hee; Kang, Seongeun; Park, Sung-Bin; Jeong, Gookjoo; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Seoul 100715, South Korea.
   [Kang, Han-Sung] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi Do 411764, South Korea.
C3 Dongguk University; National Cancer Center - Korea (NCC)
RP Kang, HS (通讯作者)，Natl Canc Ctr, Res Inst & Hosp, Gyeonggi Do 411764, South Korea.
EM rorerr@ncc.re.kr; sunjungk@dongguk.edu
RI Kim, Dokyun/IYJ-2278-2023; kang, han/KIC-4795-2024; kim, sun/T-1013-2019
FU Basic Science Research Program through the National Research Foundation
   of Korea; Ministry of Education, Science, and Technology
   [NRF-2012R1A1A2040830]; National Cancer Center, Korea
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea funded by the Ministry of
   Education, Science, and Technology (NRF-2012R1A1A2040830) and by a grant
   provided by the National Cancer Center, Korea.
CR Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938
   Bonneville R, 2013, BIOINFORMATICS, V29, P22, DOI 10.1093/bioinformatics/bts639
   Boudot A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020898
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Chen YZ, 2011, CANCER LETT, V302, P63, DOI 10.1016/j.canlet.2010.12.014
   Chintharlapalli SR, 2005, J CELL BIOCHEM, V94, P611, DOI 10.1002/jcb.20292
   Cohen I, 2007, CLIN CANCER RES, V13, P4069, DOI 10.1158/1078-0432.CCR-06-2546
   Conde JA, 2012, J CELL BIOCHEM, V113, P3498, DOI 10.1002/jcb.24226
   Creighton CJ, 2009, BREAST CANCER RES TR, V114, P287, DOI 10.1007/s10549-008-0017-2
   Cui XJ, 2005, J CLIN ONCOL, V23, P7721, DOI 10.1200/JCO.2005.09.004
   Dong E, 2007, P NATL ACAD SCI USA, V104, P4676, DOI 10.1073/pnas.0700529104
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Ghezzi D, 2012, AM J HUM GENET, V90, P1079, DOI 10.1016/j.ajhg.2012.04.011
   Guido C, 2012, CELL CYCLE, V11, P2911, DOI 10.4161/cc.21336
   Hu DG, 2009, MOL PHARMACOL, V76, P425, DOI 10.1124/mol.109.057380
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Keen JC, 2004, CANCER BIOL THER, V3, P1304, DOI 10.4161/cbt.3.12.1458
   Kim SJ, 2011, CANCER LETT, V302, P47, DOI 10.1016/j.canlet.2010.12.010
   Lappano R, 2010, MOL CELL ENDOCRINOL, V320, P162, DOI 10.1016/j.mce.2010.02.006
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Mandal S, 2010, J CELL PHYSIOL, V224, P28, DOI 10.1002/jcp.22078
   Morimoto-Kamata R, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/456462
   Motrich RD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053211
   Murphy LC, 2012, SEMIN REPROD MED, V30, P5, DOI 10.1055/s-0031-1299592
   Ramaswamy B, 2009, MOL ENDOCRINOL, V23, P176, DOI 10.1210/me.2008-0211
   Saavedra K, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-13
   Shigetomi H, 2011, ONCOL LETT, V2, P591, DOI 10.3892/ol.2011.316
   Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200
   Suzuki A, 2010, J BIOL CHEM, V285, P13444, DOI 10.1074/jbc.M109.062430
   Tsunashima R, 2012, CANCER LETT, V324, P42, DOI 10.1016/j.canlet.2012.04.017
   Vasta V, 2012, PEDIATR INT, V54, P585, DOI 10.1111/j.1442-200X.2012.03644.x
   Wang XJ, 2010, J MOL BIOL, V395, P1038, DOI 10.1016/j.jmb.2009.12.002
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Xing DQ, 2009, ARTERIOSCL THROM VAS, V29, P289, DOI 10.1161/ATVBAHA.108.182279
   Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005
NR 35
TC 13
Z9 15
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 27
PY 2013
VL 13
AR 502
DI 10.1186/1471-2407-13-502
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 280JN
UT WOS:000329025200002
PM 24160266
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Teoh-Fitzgerald, ML
   Fitzgerald, MP
   Zhong, W
   Askeland, RW
   Domann, FE
AF Teoh-Fitzgerald, M. L.
   Fitzgerald, M. P.
   Zhong, W.
   Askeland, R. W.
   Domann, F. E.
TI Epigenetic reprogramming governs EcSOD expression during human mammary
   epithelial cell differentiation, tumorigenesis and metastasis
SO ONCOGENE
LA English
DT Article
DE three-dimensional culture; DNA methylation; experimental lung
   metastasis; spontaneous metastasis; acinar morphogenesis;
   laminin-enriched extracellular matrix
ID EXTRACELLULAR-SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; MATRIX COMPONENTS;
   DNA METHYLATION; BINDING-SITE; CANCER; GROWTH; INACTIVATION;
   OVEREXPRESSION; IDENTIFICATION
AB Expression of the antioxidant enzyme EcSOD in normal human mammary epithelial cells was not recognized until recently. Although expression of EcSOD was not detectable in non-malignant human mammary epithelial cells (HMEC) cultured in conventional two-dimensional (2D) culture conditions, EcSOD protein expression was observed in normal human breast tissues, suggesting that the 2D-cultured condition induces a repressive status of EcSOD gene expression in HMEC. With the use of laminin-enriched extracellular matrix (IrECM), we were able to detect expression of EcSOD when HMEC formed polarized acinar structures in a 3D-culture condition. Repression of the EcSOD-gene expression was again seen when the HMEC acini were sub-cultured as a monolayer, implying that IrECM-induced acinar morphogenesis is essential in EcSOD-gene activation. We have further shown the involvement of DNA methylation in regulating EcSOD expression in HMEC under these cell culture conditions. EcSOD mRNA expression was strongly induced in the 2D-cultured HMEC after treatment with a DNA methyltransferase inhibitor. In addition, epigenetic analyses showed a decrease in the degree of CpG methylation in the EcSOD promoter in the 3D versus 2D-cultured HMEC. More importantly, > 80% of clinical mammary adenocarcinoma samples showed significantly decreased EcSOD mRNA and protein expression levels compared with normal mammary tissues and there is an inverse correlation between the expression levels of EcSOD and the clinical stages of breast cancer. Combined bisulfite restriction analysis analysis of some of the tumors also revealed an association of DNA methylation with the loss of EcSOD expression in vivo. Furthermore, overexpression of EcSOD inhibited breast cancer metastasis in both the experimental lung metastasis model and the syngeneic mouse model. This study suggests that epigenetic silencing of EcSOD may contribute to mammary tumorigenesis and that restoring the extracellular superoxide scavenging activity could be an effective strategy for breast cancer treatment.
C1 [Teoh-Fitzgerald, M. L.; Fitzgerald, M. P.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA USA.
   [Zhong, W.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Askeland, R. W.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Wisconsin System; University of
   Wisconsin Madison; University of Iowa
RP Teoh-Fitzgerald, ML (通讯作者)，Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
EM m.teohfitzgerald@unmc.edu; frederick-domann@uiowa.edu
OI Domann, Frederick/0000-0002-0489-2179
FU NIH [R01 CA073612, R01 CA115438]; Susan G Komen for the Cure [KG080437];
   SFRBM Research Mini-Fellowship; Oberley Seed Grant; Carver Research
   Program of Excellence in Redox Biology and Medicine; Holden
   Comprehensive Cancer Center Breast Cancer Research Fund
FX The authors thank Dr James Crapo (National Jewish Medical and Research
   Center, Denver, CO, USA) for providing antibodies to EcSOD and Dr
   Michael Henry (Department of Molecular Physiology and Biophysics,
   University of Iowa, IA, USA) for providing the 4T1 luc cells. We also
   thank Justin Fishbaugh from the Flow Cytometry Core Facility for
   assisting with the DCFH assays as well as the Central Microscopy
   Research Facility. This study was supported by NIH grant R01 CA073612
   and R01 CA115438 (FE Domann), Susan G Komen for the Cure grant KG080437
   (M Teoh-Fitzgerald), SFRBM Research Mini-Fellowship (M Teoh-Fitzgerald),
   Oberley Seed Grant (M Teoh-Fitzgerald), and Carver Research Program of
   Excellence in Redox Biology and Medicine, and by the Holden
   Comprehensive Cancer Center Breast Cancer Research Fund.
CR ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F
   Behrend L, 2003, BIOCHEM SOC T, V31, P1441
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729
   BLASCHKE RJ, 1994, METHOD ENZYMOL, V245, P535
   Case AJ, 2011, FREE RADICAL BIO MED, V50, P448, DOI 10.1016/j.freeradbiomed.2010.11.025
   CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45
   Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4
   Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230
   Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519
   Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249
   Henrotin Y, 2009, ADV CLIN CHEM, V49, P31, DOI 10.1016/S0065-2423(09)49002-4
   Hewetson A, 2002, MOL ENDOCRINOL, V16, P2101, DOI 10.1210/me.2002-0064
   HICKS CL, 1979, J DAIRY SCI, V62, P529, DOI 10.3168/jds.S0022-0302(79)83285-3
   HICKS CL, 1980, J DAIRY SCI, V63, P1199, DOI 10.3168/jds.S0022-0302(80)83065-7
   Jolivet G, 2005, J CELL BIOCHEM, V95, P313, DOI 10.1002/jcb.20397
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7
   MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006
   OBERLEY LW, 1979, CANCER RES, V39, P1141
   OBERLEY LW, 1981, MED HYPOTHESES, V7, P21, DOI 10.1016/0306-9877(81)90018-9
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   Raats CJI, 1997, J BIOL CHEM, V272, P26734, DOI 10.1074/jbc.272.42.26734
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   Shan WH, 2010, FREE RADICAL BIO MED, V49, P2078, DOI 10.1016/j.freeradbiomed.2010.10.691
   Svensson RU, 2007, CANCER RES, V67, P10445, DOI 10.1158/0008-5472.CAN-07-1955
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tang XY, 2011, J BIOL CHEM, V286, P13244, DOI 10.1074/jbc.M110.206615
   Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005
   Teoh ML, 2007, CLIN CANCER RES, V13, P7441, DOI 10.1158/1078-0432.CCR-07-0851
   Teoh MLT, 2009, CANCER RES, V69, P6355, DOI 10.1158/0008-5472.CAN-09-1195
   Teoh-Fitzgerald MLT, 2012, MOL CANCER RES, V10, P40, DOI 10.1158/1541-7786.MCR-11-0501
   Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123
   VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q
   Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3
   Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934
   Xu R, 2007, J BIOL CHEM, V282, P14992, DOI 10.1074/jbc.M610316200
NR 41
TC 69
Z9 78
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 16
PY 2014
VL 33
IS 3
BP 358
EP 368
DI 10.1038/onc.2012.582
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 296VR
UT WOS:000330214000010
PM 23318435
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Xiang, Y
   Ma, N
   Wang, D
   Zhang, Y
   Zhou, J
   Wu, G
   Zhao, R
   Huang, H
   Wang, X
   Qiao, Y
   Li, F
   Han, D
   Wang, L
   Zhang, G
   Gao, X
AF Xiang, Y.
   Ma, N.
   Wang, D.
   Zhang, Y.
   Zhou, J.
   Wu, G.
   Zhao, R.
   Huang, H.
   Wang, X.
   Qiao, Y.
   Li, F.
   Han, D.
   Wang, L.
   Zhang, G.
   Gao, X.
TI MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin
   sensitivity by targeting DNMT1 directly: a novel epigenetic therapy
   independent of decitabine
SO ONCOGENE
LA English
DT Article
DE cisplatin resistance; microRNA; DNMT1; decitabine; ovarian cancer
ID DNA METHYLTRANSFERASE 1; GENE-EXPRESSION; IN-VITRO;
   HEPATOCELLULAR-CARCINOMA; ENDOMETRIAL CANCER; PLATINUM-RESISTANT;
   DRUG-RESISTANCE; BREAST-CANCER; LINES; METHYLATION
AB Epithelial ovarian cancer (EOC) is a highly lethal gynaecological malignancy. Cisplatin is the basal chemotherapeutic agent used to treat EOC, but resistance to cisplatin leads to chemotherapy failure. MicroRNAs are a novel class of regulators that function by controlling gene expression at the post-transcriptional level. Several recent reports have identified some microRNAs that are related to chemotherapy sensitivity. In this study, we found two microRNAs miR-152 and miR-185 that were significantly downregulated in the cisplatin-resistant ovarian cell lines SKOV3/DDP and A2780/DDP, compared with their sensitive parent line SKOV3 and A2780, respectively. Subsequently, the roles of miR-152 and miR-185 were evaluated in vitro and in vivo. The overexpression of miR-152 or miR-185 increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis, then we further confirmed that these miRNAs functioned through suppressing DNA methyltransferase 1 (DNMT1) directly. Concordantly, CD-1/CD-1 nude mice that were injected intraperitoneally with SKOV3/DDP cells transfected with miR-152 mimics exhibited upregulated cisplatin sensitivity in vivo. Interestingly, we found that there were no significant changes in the expression of these two microRNAs after treatment with decitabine (DAC), a traditional epigenetic therapeutic agent, suggesting these miRNAs represented two new regulators independent of DAC. Finally, the survival assay in A549 and HepG2 cells revealed that the two microRNAs involved in cisplatin sensitivity were related to cell types. Our results indicated that miR-152 and miR-185 were involved in ovarian cancer cisplatin resistance in vitro and in vivo by targeting DNMT1 directly. These molecules may serve as potential epigenetic therapeutic targets in other cancers.
C1 [Xiang, Y.; Ma, N.; Wang, D.; Zhou, J.; Wu, G.; Zhao, R.; Huang, H.; Wang, X.; Qiao, Y.; Li, F.; Han, D.; Wang, L.; Gao, X.] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150086, Peoples R China.
   [Zhang, Y.] Harbin Med Univ, Dept Lab Diag, Affiliated Hosp 1, Harbin 150086, Peoples R China.
   [Zhang, G.] Harbin Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150086, Peoples R China.
   [Gao, X.] Minist Educ, Key Lab Cardiovasc Med Res, Harbin, Peoples R China.
   [Gao, X.] Harbin Med Univ, State Prov Key Labs Biomed Pharmaceut China, Harbin 150086, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University; Harbin Medical University
RP Zhang, G (通讯作者)，Harbin Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150086, Peoples R China.
EM zhangguangmei@126.com; gaoxu_671227@yahoo.com.cn
RI gao, xu/U-4765-2019; ma, ning/E-4057-2013
OI Lam, H.K./0000-0001-7589-0747; Xiang, Ying/0000-0002-4879-2751
FU Natural Science Foundation of Heilongjiang Province for youth and for
   outstanding youth [QC2010002, JC201110]; Natural Science Foundation of
   China [81101373, 81270511, 81001033]; Science Foundation of Health
   Department of Heilongjiang Province [2012-525]; Science Foundation of
   the First Affiliated Hospital of Harbin Medical University [2009Y24]
FX This work was supported by the Natural Science Foundation of
   Heilongjiang Province for youth (QC2010002) and for outstanding youth
   (JC201110), the Natural Science Foundation of China
   (81101373/81270511/81001033), the Science Foundation of Health
   Department of Heilongjiang Province(2012-525) and the Science Foundation
   of the First Affiliated Hospital of Harbin Medical University (2009Y24).
CR Akçakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043
   Barabas K, 2008, VET COMP ONCOL, V6, P1, DOI 10.1111/j.1476-5829.2007.00142.x
   Basu A., 2010, J NUCL ACIDS, V2010
   Blum KA, 2010, BRIT J HAEMATOL, V150, P189, DOI 10.1111/j.1365-2141.2010.08213.x
   Blum W, 2012, BLOOD, V119, P6025, DOI 10.1182/blood-2012-03-413898
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Chen Huaping, 2011, Frontiers in Genetics, V2, P67, DOI 10.3389/fgene.2011.00067
   Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2
   Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246
   Fan H, 2009, WORLD J GASTROENTERO, V15, P2020, DOI 10.3748/wjg.15.2020
   Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204
   Fu X, 2012, FEBS LETT, V586, P1279, DOI 10.1016/j.febslet.2012.03.006
   Fung-Kee-Fung M, 2007, Curr Oncol, V14, P195
   Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024
   Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342
   Hendrickson DG, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000238
   Holleman A, 2011, ONCOGENE, V30, P4386, DOI 10.1038/onc.2011.148
   Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660
   Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233
   Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kantarjian HM, 2005, SEMIN HEMATOL, V42, pS17, DOI 10.1053/j.seminhematol.2005.05.006
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Kwon MJ, 2011, INT J MOL SCI, V12, P983, DOI 10.3390/ijms12020983
   LENZI R, 1994, ANTICANCER RES, V14, P247
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Liao JM, 2011, J BIOL CHEM, V286, P33901, DOI 10.1074/jbc.M111.262030
   Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850
   Luszczek W, 2010, MOL CANCER THER, V9, P2309, DOI 10.1158/1535-7163.MCT-10-0309
   Malizia AP, 2011, WIRES SYST BIOL MED, V3, P183, DOI 10.1002/wsbm.111
   Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909
   Matei DE, 2010, GYNECOL ONCOL, V116, P195, DOI 10.1016/j.ygyno.2009.09.043
   Myatt SS, 2010, CANCER RES, V70, P367, DOI 10.1158/0008-5472.CAN-09-1891
   OZOLS RF, 1991, SEMIN ONCOL, V18, P222
   Plumb JA, 2000, CANCER RES, V60, P6039
   Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038
   Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098
   Sangodkar J, 2012, J CLIN INVEST, V122, P2637, DOI 10.1172/JCI62058
   Selvakumaran M, 2003, CANCER RES, V63, P1311
   Selvakumaran M, 2001, CANCER RES, V61, P1291
   Singh RK, 2008, GYNECOL ONCOL, V109, P240, DOI 10.1016/j.ygyno.2008.01.042
   Takahashi Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006677
   Tang MQ, 2009, CURR GENOMICS, V10, P336, DOI 10.2174/138920209788920994
   Tohyama K, 2012, CURR PHARM DESIGN, V18, P3190, DOI 10.2174/1381612811209023190
   Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919
   Tsuruta T, 2011, CANCER RES, V71, P6450, DOI 10.1158/0008-5472.CAN-11-0364
   Yang DF, 2012, J IMMUNOL, V188, P4441, DOI 10.4049/jimmunol.1103035
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954
   Yi TZ, 2012, CHEMOTHERAPY, V58, P19, DOI 10.1159/000333077
   Zhang JQ, 2012, GASTROENTEROLOGY, V143, P246, DOI 10.1053/j.gastro.2012.03.045
   Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
   Zhao ZW, 2012, BIOCHEM J, V444, P291, DOI 10.1042/BJ20111855
   Zhou X, 2012, ONCOL REP, V27, P447, DOI 10.3892/or.2011.1482
NR 56
TC 183
Z9 200
U1 1
U2 47
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 16
PY 2014
VL 33
IS 3
BP 378
EP 386
DI 10.1038/onc.2012.575
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 296VR
UT WOS:000330214000012
PM 23318422
OA Bronze
DA 2025-01-12
ER

PT J
AU Hong, KJ
   Wu, DC
   Cheng, KH
   Chen, LT
   Hung, WC
AF Hong, Kun-Jing
   Wu, Deng-Chyang
   Cheng, Kuang-Hung
   Chen, Li-Tzong
   Hung, Wen-Chun
TI RECK Inhibits Stemness Gene Expression and Tumorigenicity of Gastric
   Cancer Cells by Suppressing ADAM-Mediated Notch1 Activation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BREAST-CANCER; IN-VIVO; EPIGENETIC REGULATION; TUMOR ANGIOGENESIS;
   CD133; PATHWAY; RESISTANCE; CARCINOMA; PROTEIN; GROWTH
AB The Reversion-inducing Cysteine-rich Protein with Kazal Motifs (RECK) gene encodes a membrane-anchored glycoprotein that exhibits strong inhibitory activity against various matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase 10 (ADAM10). RECK functions as a tumor suppressor by inhibiting migration, invasion, and angiogenesis. However, whether RECK can modulate the stem-like phenotypes of cancer cells is not known. In this study, we demonstrate that RECK is down-regulated in gastric cancer cells and is further reduced in CD133-positive cancer stem-like cells. Ectopic expression of RECK induces down-regulation of the expression of stemness genes including Sox2, Oct4, and Nanog and the cancer stem cell marker CD133. Treatment of DAPT (a -secretase inhibitor) or TAPI-2 (a hydroxamate-based inhibitor of MMPs, tumor necrosis factor converting enzyme and ADAM17) reduces Notch1 shedding and activation which results in attenuation of stemness genes and CD133. Our data show that ADAM10 and ADAM17 are co-pulled down by RECK suggesting a physical interaction between RECK and ADAMs on cell surface. In addition, RECK suppresses sphere formation and sphere size of CD133-positive gastric cancer cells. Overexpression of Notch intracellular domain (NICD) or ADAM17 effectively reverse the inhibitory effect of RECK in CD133-positive cells. More importantly, RECK reduces tumorigenic activity of CD133-positive cells in vivo. Conversely, knockdown of RECK in non-tumorigenic GI2 cells increases stemness and CD133 expression and sphere forming ability. Collectively, these results indicate that RECK represses stemness gene expression and stem-like properties by inhibiting ADAM-mediated Notch1 shedding and activation. J. Cell. Physiol. 229: 191-201, 2014. (c) 2013 Wiley Periodicals, Inc.
C1 [Hong, Kun-Jing; Cheng, Kuang-Hung; Hung, Wen-Chun] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.
   [Wu, Deng-Chyang] Kaohsiung Med Univ, Kaohsiung Municipal Hsiao Kang Hosp, Div Internal Med, Kaohsiung, Taiwan.
   [Wu, Deng-Chyang; Chen, Li-Tzong] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan.
   [Wu, Deng-Chyang; Chen, Li-Tzong] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan.
   [Chen, Li-Tzong; Hung, Wen-Chun] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 704, Taiwan.
C3 National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung
   Municipal Siao-Gang Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; National Health Research Institutes -
   Taiwan
RP Hung, WC (通讯作者)，Natl Hlth Res Inst, Natl Inst Canc Res, 367 Shengli Rd, Tainan 704, Taiwan.
EM hung1228@ms10.hinet.net
RI Chen, Li-Tzong/D-2071-2010; Hung, Wen-Chun/F-4846-2011
CR Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159
   Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374
   Bolós V, 2009, CLIN TRANSL ONCOL, V11, P11, DOI 10.1007/s12094-009-0305-2
   Campos B, 2011, INT J CANCER, V128, P501, DOI 10.1002/ijc.25687
   Curtin JC, 2010, ONCOTARGET, V1, P563, DOI 10.18632/oncotarget.191
   Dubrovska A, 2012, BRIT J CANCER, V107, P43, DOI 10.1038/bjc.2012.105
   Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254
   He W, 2012, WORLD J GASTROENTERO, V18, P712, DOI 10.3748/wjg.v18.i7.712
   Hong KJ, 2011, FEBS LETT, V585, P591, DOI 10.1016/j.febslet.2011.01.021
   Hsu MC, 2008, CLIN CANCER RES, V14, P4045, DOI 10.1158/1078-0432.CCR-07-5040
   Huang YS, 2012, APOPTOSIS, V17, P749, DOI 10.1007/s10495-012-0734-1
   Ishigami S, 2010, ANTICANCER RES, V30, P2453
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114
   Jiang LG, 2011, J CLIN NEUROSCI, V18, P387, DOI 10.1016/j.jocn.2010.07.131
   Kim TH, 2011, J EXP MED, V208, P677, DOI 10.1084/jem.20101737
   Kitajima S, 2011, ONCOGENE, V30, P737, DOI 10.1038/onc.2010.448
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704
   Li YC, 2012, STEM CELLS, V30, P741, DOI 10.1002/stem.1030
   Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Mak AB, 2012, CANCER RES, V72, P1929, DOI 10.1158/0008-5472.CAN-11-3589
   Meng N, 2008, HISTOL HISTOPATHOL, V23, P1003, DOI 10.14670/HH-23.1003
   Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846
   Miki T, 2010, MOL CANCER RES, V8, P665, DOI 10.1158/1541-7786.MCR-09-0351
   Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283
   Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998
   Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922
   Nagini S, 2012, WORLD J GASTRO ONCOL, V4, P156, DOI 10.4251/wjgo.v4.i7.156
   Pan MR, 2009, J BIOL CHEM, V284, P2746, DOI 10.1074/jbc.M806223200
   Paulissen G, 2006, MOL MED, V12, P171, DOI 10.2119/2006-00028.Paulissen
   Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186
   Ribatti D, 2012, CANCER LETT, V321, P13, DOI 10.1016/j.canlet.2012.02.024
   Shmelkov SV, 2005, INT J BIOCHEM CELL B, V37, P715, DOI 10.1016/j.biocel.2004.08.010
   Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881
   Corrêa TCS, 2010, J CELL BIOCHEM, V110, P52, DOI 10.1002/jcb.22472
   Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946
   Tabu K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-39
   Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221
   Wang JP, 2012, MOL BIOL REP, V39, P2497, DOI 10.1007/s11033-011-1001-1
   Wang T, 2011, BRIT J CANCER, V105, P658, DOI 10.1038/bjc.2011.287
   Wang Z, 2012, CELL STEM CELL, V10, P440, DOI 10.1016/j.stem.2012.02.016
   Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001
   Yang YC, 2007, J GASTROEN HEPATOL, V22, P1460, DOI 10.1111/j.1440-1746.2007.05031.x
   Yang YC, 2009, EUR J GASTROEN HEPAT, V21, P1016, DOI 10.1097/MEG.0b013e32831d7b9c
   Yeh TS, 2009, CANCER RES, V69, P5039, DOI 10.1158/0008-5472.CAN-08-4021
   Yi JM, 2008, CANCER RES, V68, P8094, DOI 10.1158/0008-5472.CAN-07-6208
   You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544
   Zardawi SJ, 2010, HISTOPATHOLOGY, V56, P286, DOI 10.1111/j.1365-2559.2009.03475.x
   Zhang Y, 2012, CANCER SCI, V103, P1084, DOI 10.1111/j.1349-7006.2012.02265.x
NR 51
TC 62
Z9 66
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2014
VL 229
IS 2
BP 191
EP 201
DI 10.1002/jcp.24434
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 268AS
UT WOS:000328140800009
PM 23881612
OA Bronze
DA 2025-01-12
ER

PT J
AU Vestin, A
   Mills, AA
AF Vestin, Assaf
   Mills, Alea A.
TI The tumor suppressor Chd5 is induced during neuronal differentiation in
   the developing mouse brain
SO GENE EXPRESSION PATTERNS
LA English
DT Article
DE CHD5; Cancer; Gene expression; Chromatin; Mouse brain
ID ENDOCRINE NEOPLASIA TYPE-2; HUMAN COLORECTAL-CANCER; PRIMARY
   BREAST-CANCER; CHROMOSOME ARM 1P; DE-NOVO MUTATIONS; OLIGODENDROGLIAL
   TUMORS; INACTIVATING MUTATIONS; GASTRIC-CANCER; OVARIAN-CANCER; ALLELIC
   LOSS
AB Epigenetic regulation of gene expression orchestrates dynamic cellular processes that become perturbed in human disease. An understanding of how subversion of chromatin-mediated events leads to pathologies such as cancer and neurodevelopmental syndromes may offer better treatment options for these pathological conditions. Chromodomain Helicase DNA-binding protein 5 (CHD5) is a dosage-sensitive tumor suppressor that is inactivated in human cancers, including neural-associated malignancies such as neuroblastoma and glioma. Here we report a detailed analysis of the temporal and cell type-specific expression pattern of Chd5 in the mammalian brain. By analyzing endogenous Chd5 protein expression during mouse embryogenesis, in the neonate, and in the adult, we found that Chd5 is expressed broadly in multiple brain regions, that Chd5 sub-cellular localization undergoes a switch from the cytoplasm to the nucleus during mid-gestation, and that Chd5 expression is retained at high levels in differentiated neurons of the adult. These findings may have important implications for defining the role of CHD5-mediated chromatin dynamics in the brain and for elucidating how perturbation of these epigenetic processes leads to neuronal malignancies, neurodegenerative diseases, and neurodevelopmental syndromes. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Vestin, Assaf; Mills, Alea A.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Vestin, Assaf] SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA.
C3 Cold Spring Harbor Laboratory; State University of New York (SUNY)
   System; Stony Brook University
RP Mills, AA (通讯作者)，Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.
EM mills@cshl.edu
CR Aarts M, 2006, GENE CHROMOSOME CANC, V45, P83, DOI 10.1002/gcc.20268
   Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923
   Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095
   Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052
   Barbashina V, 2005, CLIN CANCER RES, V11, P1119
   Batsukh T, 2010, HUM MOL GENET, V19, P2858, DOI 10.1093/hmg/ddq189
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   BELLO MJ, 1995, INT J CANCER, V64, P207
   BELLO MJ, 1994, CANCER GENET CYTOGEN, V73, P122, DOI 10.1016/0165-4608(94)90195-3
   Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744
   BIECHE I, 1993, CANCER RES, V53, P1990
   Bièche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2
   BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1
   Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305
   Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E
   Cheung TH, 2005, GYNECOL ONCOL, V96, P510, DOI 10.1016/j.ygyno.2004.10.035
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Dong Z, 2004, BRIT J CANCER, V91, P1105, DOI 10.1038/sj.bjc.6602093
   DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614
   Egan CM, 2013, DEV CELL, V26, P223, DOI 10.1016/j.devcel.2013.07.008
   Ezaki T, 1996, BRIT J CANCER, V73, P424, DOI 10.1038/bjc.1996.76
   Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x
   Feng WJ, 2013, CELL STEM CELL, V13, P62, DOI 10.1016/j.stem.2013.05.002
   Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176
   Garcia I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-277
   Godfried MB, 2002, EUR J CANCER, V38, P1513, DOI 10.1016/S0959-8049(02)00137-5
   Gorringe KL, 2008, NEOPLASIA, V10, P1253, DOI 10.1593/neo.08718
   HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105
   Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967
   Kleer CG, 2000, ENDOCR PATHOL, V11, P137, DOI 10.1385/EP:11:2:137
   Koyama H, 2012, CLIN CANCER RES, V18, P1588, DOI 10.1158/1078-0432.CCR-11-2644
   Lang J, 2011, BRIT J DERMATOL, V164, P1010, DOI 10.1111/j.1365-2133.2011.10223.x
   LEISTER I, 1990, CANCER RES, V50, P7232
   Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903
   Meléndez B, 2003, LEUKEMIA RES, V27, P627, DOI 10.1016/S0145-2126(02)00278-3
   Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012
   MOLEY JF, 1992, CANCER RES, V52, P770
   Mori N, 2003, BRIT J HAEMATOL, V122, P226, DOI 10.1046/j.1365-2141.2003.04434.x
   Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409
   Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610
   MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307
   Murawska M, 2011, TRANSCR-AUSTIN, V2, P244, DOI 10.4161/trns.2.6.17840
   NAGAI H, 1995, CANCER RES, V55, P1752
   O'Roak BJ, 2012, NATURE, V485, P246, DOI 10.1038/nature10989
   O'Roak BJ, 2011, NAT GENET, V43, P585, DOI 10.1038/ng.835
   Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675
   Oliver SS, 2012, BIOCHEMISTRY-US, V51, P6534, DOI 10.1021/bi3006972
   Paul S, 2013, CELL REP, V3, P92, DOI 10.1016/j.celrep.2012.12.009
   Piaskowski S, 2005, CANCER GENET CYTOGEN, V162, P63, DOI 10.1016/j.cancergencyto.2005.02.009
   Poetsch M, 2003, MELANOMA RES, V13, P29, DOI 10.1097/00008390-200302000-00006
   Potts RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024515
   PRAML C, 1995, ONCOGENE, V11, P1357
   Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211
   WADA M, 1988, CANCER RES, V48, P2988
   Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95
   White PS, 2005, ONCOGENE, V24, P2684, DOI 10.1038/sj.onc.1208306
   WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520
   Wong RRY, 2011, GYNECOL OBSTET INVES, V72, P203, DOI 10.1159/000323883
   Zhao R, 2012, LUNG CANCER, V76, P324, DOI 10.1016/j.lungcan.2011.11.019
   Zhou CZ, 2004, WORLD J GASTROENTERO, V10, P1431
NR 62
TC 13
Z9 14
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-133X
EI 1872-7298
J9 GENE EXPR PATTERNS
JI Gene Expr. Patterns
PD DEC
PY 2013
VL 13
IS 8
BP 482
EP 489
DI 10.1016/j.gep.2013.09.003
PG 8
WC Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Genetics & Heredity
GA 274GP
UT WOS:000328595100024
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Beamer, LC
   Linder, L
   Wu, BH
   Eggert, J
AF Beamer, Laura Curr
   Linder, Lauri
   Wu, Bohua
   Eggert, Julia
TI The Impact of Genomics on Oncology Nursing
SO NURSING CLINICS OF NORTH AMERICA
LA English
DT Article
DE Cancer genetics; Genomics; Oncology nursing; Genetic Information
   Nondiscrimination Act (GINA); Epigenetics
ID HEREDITARY BREAST-CANCER; RISK-FACTORS; COLORECTAL-CANCER;
   COWDEN-SYNDROME; PTEN MUTATIONS; GENE; PHARMACOGENETICS; CHILDREN;
   BRCA1; PREVENTION
AB Since 2003, genetics and genomics information has led to exciting new diagnostics, prognostics, and treatment options in oncology practice. Profiling of cancers offers providers insight into treatment and prognostic factors. Germ line testing provides an individual with information for surveillance or therapy that may help them prevent cancer in their lifetime and options for family members as yet untouched by malignancy. This offers a challenge for oncology nurses and other oncology health care providers to become comfortable with incorporating education about genetics/genomics into their clinical practice and patient education.
C1 [Beamer, Laura Curr] No Illinois Univ, Sch Nursing & Hlth Studies, Coll Hlth & Human Sci, De Kalb, IL 60115 USA.
   [Beamer, Laura Curr; Linder, Lauri] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA.
   [Linder, Lauri] Primary Childrens Med Ctr, Canc Transplant Serv Line, Salt Lake City, UT 84113 USA.
   [Wu, Bohua; Eggert, Julia] Clemson Univ, Sch Nursing, Healthcare Genet Doctoral Program, Coll Educ & Human Dev, Clemson, SC 29634 USA.
   [Eggert, Julia] Bon Secours St Francis Hosp, Screening Program, Greenville, SC 29601 USA.
C3 Northern Illinois University; Utah System of Higher Education;
   University of Utah; Clemson University
RP Eggert, J (通讯作者)，Clemson Univ, Sch Nursing, Coll Hlth Educ & Human Dev, Clemson, SC 29634 USA.
EM jaegger@clemson.edu
OI Beamer, Laura/0000-0001-6234-8094
FU American Cancer Society, Doctoral Cancer Nursing Scholarship
   [121293-DSCN-11-197-01-SCN]
FX None (L. Linder, J. Eggert); American Cancer Society, Doctoral Cancer
   Nursing Scholarship, 121293-DSCN-11-197-01-SCN (L.C. Beamer).
CR Alkner S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-114
   [Anonymous], 2013, ONCOL NURS FORUM, V40, P10, DOI 10.1188/13.ONF.10-11
   [Anonymous], 2013, Genetics Home Reference
   [Anonymous], 2013, GENETICS HOME REFERE
   [Anonymous], 2013, US NURS WORKF TRENDS
   [Anonymous], 1866, Versuche Uber Pflanzen-hybriden, DOI DOI 10.5962/BHL.TITLE.61004
   [Anonymous], 2010, RHABDOID TUMOR PREDI
   [Anonymous], 2009, Essentials of genetic and genomic nursing: Competencies, curricula guidelines and outcome indicators
   [Anonymous], 2012, US NATL LIB MED
   [Anonymous], NATL HUMAN GENOME TA
   [Anonymous], 1986, GENETICS GENOMICS TI
   [Anonymous], 2013, GENECARDS
   [Anonymous], 1927, GENETICS GENOMICS TI
   [Anonymous], 1920, GENETICS GENOMICS TI
   [Anonymous], NCCN GUID VERS 2 201
   [Anonymous], 2013, GENECARDS
   [Anonymous], NATL CANC I DICT GEN
   [Anonymous], 2013, WIKIBOOKS
   [Anonymous], NCI DICT GENETICS TE
   [Anonymous], 2008, REC PREV PED HLTH CA
   ATM, 2013, GEN HOM REF
   Beauchamp T. L., 2019, Principles of Biomedical Ethics, V8th
   Bennett Robin L, 2008, J Genet Couns, V17, P424, DOI 10.1007/s10897-008-9169-9
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bernstein JL, 2010, J NATL CANCER I, V102, P475, DOI 10.1093/jnci/djq055
   Bird TD, 2011, GENEREVIEWS
   BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0
   Boffetta P, 2010, JNCI-J NATL CANCER I, V102, P529, DOI 10.1093/jnci/djq072
   Brevik A, 2010, CANCER EPIDEM BIOMAR, V19, P3167, DOI 10.1158/1055-9965.EPI-10-0606
   BUSHBY KMD, 1992, ARCH DIS CHILD, V67, P1286, DOI 10.1136/adc.67.10.1286
   Caga-anan ECF, 2012, PEDIATRICS, V129, P163, DOI 10.1542/peds.2010-3743
   *CONS BREAST CANC, 2008, DRUG INT TAM GUID BR
   Cotterman R, 2008, CANCER RES, V68, P9654, DOI 10.1158/0008-5472.CAN-08-1961
   CRICK FHC, 1957, SCI AM, V197, P188, DOI 10.1038/scientificamerican0957-188
   D'Orazio JA, 2010, J PEDIAT HEMATOL ONC, V32, P195, DOI 10.1097/MPH.0b013e3181ced34c
   El-Din MAA, 2009, INT J RADIAT ONCOL, V73, P69, DOI 10.1016/j.ijrobp.2008.03.066
   El-Din MAA, 2008, INT J RADIAT ONCOL, V72, P1291, DOI 10.1016/j.ijrobp.2008.07.060
   Eng C., 2010, GENEREVIEWS
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Engert S, 2008, HUM MUTAT, V29, P948, DOI 10.1002/humu.20723
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Evans DG, 2013, GENEREVIEWS
   Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526
   Fallat ME, 2013, PEDIATRICS, V131, P620, DOI 10.1542/peds.2012-3680
   Feinberg AP, 2005, CANCER CELL, V8, P267, DOI 10.1016/j.ccr.2005.09.014
   Feramisco JD, 2008, PEDIATR DERMATOL, V25, P99, DOI 10.1111/j.1525-1470.2007.00594.x
   Filipovich A, 2011, GENEREVIEWS
   Franks AL, 2012, ANTICANCER RES, V32, P1119
   Frantzen C, 2012, GENEREVIEWS
   Friedenson B, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-152
   Friedman JM, 2012, GENEREVIEWS
   Garber JE, 2005, J CLIN ONCOL, V23, P276, DOI 10.1200/JCO.2005.10.042
   Garber K, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq556
   Gatti R., 2010, GENEREVIEWS
   Genetic Alliance Johns Hopkins University National Coalition for Health Professional Education in Genetics, 2010, NAT COAL HLTH PROF E
   Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504
   Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376
   Gilbert Walter, 1932, GENETICS GENOMICS TI
   Gillon R, 2003, J MED ETHICS, V29, P307, DOI 10.1136/jme.29.5.307
   Giusti F, 2012, GENEREVIEWS
   Glukhov AI, 2011, APPL BIOCHEM MICRO+, V47, P655, DOI 10.1134/S0003683811070039
   Goncalves R, 2013, J NATL COMPR CANC NE, V11, P174, DOI 10.6004/jnccn.2013.0025
   Guengerich FP, 2008, CHEM RES TOXICOL, V21, P70, DOI 10.1021/tx700079z
   Haidle JL, 2011, GENEREVIEWS
   HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302
   HANKE JH, 2004, DRUG DISCOV TODAY, V1, P411
   Hartman M, 2007, J CLIN ONCOL, V25, P4210, DOI 10.1200/JCO.2006.10.5056
   Hon LS, 2008, CURR BIOINFORM, V3, P46
   Hoskins JM, 2008, CLIN CANCER RES, V14, P1788, DOI 10.1158/1078-0432.CCR-07-1472
   Indiana University Department of Medicine Division of Clinical Pharmacology, 2009, P450 DRUG INT TABL
   Inheritance in Man OMIM®, 2012, OMIM PARTNER LOCALIZ
   Jarvis C., 2012, Physical examination health assessment, V6th
   Jasperson K W., 2011, GeneReviews
   Johnson RH, 2012, GENEREVIEWS
   Jung AC, 2010, INT J CANCER, V126, P1882, DOI 10.1002/ijc.24911
   Kaurah P, 2011, GENEREVIEWS
   Kelly P, 2003, CANCER NURS, V26, P370, DOI 10.1097/00002820-200310000-00005
   KENNEDY BJ, 2004, COMPREHENSIVE GERIAT, P3
   King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251
   Kirmani S, 2012, GENEREVIEWS
   Kohlmann W, 2012, GENEREVIEWS
   Korf B R, 2000, Oncologist, V5, P477, DOI 10.1634/theoncologist.5-6-477
   Lanfear DE, 2007, AM FAM PHYSICIAN, V76, P1179
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee W, 2005, ONCOLOGIST, V10, P104, DOI 10.1634/theoncologist.10-2-104
   Leonard M, 2011, NURSING CARE CHILD A, P236
   Lodish H.F., 2013, Molecular cell biology
   Lohmann DR, 2010, GENEREVIEWS
   Lowry KP, 2012, CANCER-AM CANCER SOC, V118, P2021, DOI 10.1002/cncr.26424
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Mattison LK, 2006, CLIN CANCER RES, V12, P549, DOI 10.1158/1078-0432.CCR-05-2020
   McGuire AL, 2008, NAT REV GENET, V9, P152, DOI 10.1038/nrg2302
   Mealing S, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-5
   Mester JL, 2011, EUR J HUM GENET, V19, P763, DOI 10.1038/ejhg.2011.20
   Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841
   Milosavljevic A, 2011, TRENDS GENET, V27, P242, DOI 10.1016/j.tig.2011.03.001
   Mize DE, 2009, CANC SYNDROM
   Moline J, 2013, GENEREVIEWS
   MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4
   Muraki K, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00135
   National Cancer Institute, 2013, CANC GEN RISK ASS CO
   National Coalition of Healthcare Provider Education in Genetics, GENETIC RED FLAGS QU
   National Comprehensive Cancer Network, 2013, NCCN GUID BREAST CAN
   National Human Genome Research Institute, 2012, EPIGENOMICS
   NCCN, 2013, NCCN GUID LYNCH SYND
   NCCN, 2013, NCCN GUID CERV CANC
   NCCN, 2013, BREAST CANC SCREEN D
   NCCN guidelines, 2013, NCCN GUID HODGK LYMP
   Palmer A., 2013, FDN CANC RES HUMAN G
   Pangilinan J. M., 2008, COMMUN ONCOL, V5, P99
   Petrucelli N, 2010, GENEREVIEWS
   Pilarski R, 2011, J MED GENET, V48, P505, DOI 10.1136/jmg.2011.088807
   Pithukpakorn M, 2010, GENEREVIEWS
   PTEN, 2013, GENECARDS
   Qiu J, 2006, NATURE, V441, P143, DOI 10.1038/441143a
   Quillin JM, 2011, J ONCOL PRACT, V7, P183, DOI 10.1200/JOP.2010.000190
   Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099
   Relling MV, 2011, CLIN PHARMACOL THER, V89, P387, DOI 10.1038/clpt.2010.320
   Rishel CJ, 2013, ONCOL NURS FORUM, V40, P114, DOI 10.1188/13.ONF.114-115
   Ritchie W, 2012, BIOINFORMATICS, V28, P1058, DOI 10.1093/bioinformatics/bts114
   Roden DM, 2006, ANN INTERN MED, V145, P749, DOI 10.7326/0003-4819-145-10-200611210-00007
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728
   Salavoura K, 2008, ANTICANCER RES, V28, P1263
   Sanger Frederick, 1918, GENETICS GENOMICS TI
   Sanz MM, 2010, GENEREVIEWS
   Saslow D, 2007, CA-CANCER J CLIN, V57, P7, DOI 10.3322/canjclin.57.1.7
   Saslow D, 2012, AM J CLIN PATHOL, V137, P516, DOI [10.1309/AJCPTGD94EVRSJCG, 10.3322/caac.21139]
   Schiller Jeannine S, 2012, Vital Health Stat 10, P1
   Schneider K, 2013, GENEREVIEWS
   Seewald L, 2012, MOL GENET METAB, V107, P25, DOI 10.1016/j.ymgme.2012.07.011
   Shenfield Gillian M, 2004, Clin Biochem Rev, V25, P203
   Shuman CBJ, 2010, GENEREVIEWS
   Siomi MC, 2011, NAT REV MOL CELL BIO, V12, P246, DOI 10.1038/nrm3089
   Slavin TP, 2009, CURR OPIN PEDIATR, V21, P717, DOI 10.1097/MOP.0b013e328332c612
   Soon WW, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.61
   Thakker RV, 2010, BEST PRACT RES CL EN, V24, P355, DOI 10.1016/j.beem.2010.07.003
   Tiede C, 2013, TRANSPLANTATION, V95, P479, DOI 10.1097/TP.0b013e3182762e07
   Toffoli G, 2003, INT J CANCER, V103, P294, DOI 10.1002/ijc.10847
   Toro JR, 2008, GENEREVIEWS
   Tuna M, 2012, CANC LETT
   Turner NC, 2012, LANCET ONCOL, V13, pE178, DOI 10.1016/S1470-2045(11)70335-7
   US Department of Energy Genome Programs, 2008, GENETICS PRIVACY LEG
   Watanabe Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023320
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   Weitzel JN, 2007, JAMA-J AM MED ASSOC, V297, P2587, DOI 10.1001/jama.297.23.2587
   Whitehead KA, 2011, ANNU REV CHEM BIOMOL, V2, P77, DOI 10.1146/annurev-chembioeng-061010-114133
   Wolin KY, 2009, BRIT J CANCER, V100, P611, DOI 10.1038/sj.bjc.6604917
   Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87
   World Cancer Research Fund/American Institute for Cancer Research, 2012, CONT UPD PROJ REP
   World Cancer Research Fund/American Institute for Cancer Research, 2010, ONT UPD PROJ REP
   World Cancer Research Fund/American Institute for Cancer Research, 2011, CONT UPD PROJ REP
   Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240
   Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456
   Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003
   Zhao JH, 2010, CAN J PUBLIC HEALTH, V101, P281, DOI 10.1007/BF03405287
NR 156
TC 7
Z9 7
U1 0
U2 18
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0029-6465
EI 1558-1357
J9 NURS CLIN N AM
JI Nurs. Clin. North Am.
PD DEC
PY 2013
VL 48
IS 4
BP 585
EP +
DI 10.1016/j.cnur.2013.09.007
PG 43
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA 278VD
UT WOS:000328917100006
PM 24295189
DA 2025-01-12
ER

PT J
AU Huangyang, PW
   Shang, YF
AF Huangyang, Peiwei
   Shang, Yongfeng
TI Epigenetic Regulation of Epithelial to Mesenchymal Transition
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE DNMT inhibitors; EMT; epigenetic regulation; epigenetic therapy; HDAC
   inhibitors; metastasis; miRNAs
ID HISTONE DEACETYLASE INHIBITORS; E-CADHERIN REPRESSION; SQUAMOUS-CELL
   CARCINOMA; NOVO DNA METHYLATION; GROUP PROTEIN EZH2; BREAST-CANCER;
   MIR-200 FAMILY; TUMOR-SUPPRESSOR; HDAC INHIBITORS; GENE-EXPRESSION
AB Epithelial-mesenchymal transition (EMT) is a vital process implemented in embryo development, organ fibrosis, and cancer metastasis. Several transcription factors and signaling pathways impinge on the transcriptional program of the cell, leading to the change of cell phenotype without alteration of genotype. Accumulating evidence suggests that epigenetic mechanisms play important roles in inducing EMT and orchestrating the heredity and reversibility of EMT. In this review, we discuss how DNA methylation, histone modifications, and microRNAs (miRNAs) act in a concerted manner to regulate EMT. 'Epigenetic therapies'-inhibitors of DNA methyltransferases and histone deacetylases as well as microRNAs are emerging as promising agents for cancer intervention.
C1 [Huangyang, Peiwei; Shang, Yongfeng] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100191, Peoples R China.
   [Shang, Yongfeng] Tianjin Med Univ, Tianjin Key Lab Med Epigenet, Dept Biochem & Mol Biol, Tianjin 300070, Peoples R China.
C3 Peking University; Tianjin Medical University
RP Shang, YF (通讯作者)，Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.
EM yshang@hsc.pku.edu.cn
RI HUANG, YANGPEIWEI/AAS-7683-2021
FU National Natural Science Foundation of China [91219201, 81130048];
   Ministry of Science and Technology of China [2011CB504204]
FX This work in our lab was supported by grants (91219201 and 81130048 to
   Y.S.) from the National Natural Science Foundation of China and grants
   (973 Program: 2011CB504204 to Y.S.) from the Ministry of Science and
   Technology of China.
CR Abell AN, 2011, CELL STEM CELL, V8, P525, DOI 10.1016/j.stem.2011.03.008
   Abell AN, 2009, MOL CELL BIOL, V29, P2748, DOI 10.1128/MCB.01391-08
   Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Barshishat M, 2000, BRIT J CANCER, V82, P195
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574
   Budhu A, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-37
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cano A, 2008, TRENDS CELL BIOL, V18, P357, DOI 10.1016/j.tcb.2008.05.005
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cha YH, 2012, CELL CYCLE, V11, P1273, DOI 10.4161/cc.19618
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Chen QM, 2004, BIOCHEM BIOPH RES CO, V315, P850, DOI 10.1016/j.bbrc.2004.01.143
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Childs G, 2012, NAT CELL BIOL, V14, P337, DOI 10.1038/ncb2477
   Cohen SM, 2009, NAT METHODS, V6, P873, DOI 10.1038/nmeth1209-873
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Coral S, 2006, J CELL PHYSIOL, V207, P58, DOI 10.1002/jcp.20540
   Coral S, 2012, BRIT J CANCER, V107, P1116, DOI 10.1038/bjc.2012.361
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   De Schutter H, 2009, ANTI-CANCER AGENT ME, V9, P99, DOI 10.2174/187152009787047707
   Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Du R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030771
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783
   Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Fonsatti E, 2007, CLIN CANCER RES, V13, P3333, DOI 10.1158/1078-0432.CCR-06-3091
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Furuno K, 2006, BIOCHEM BIOPH RES CO, V345, P1051, DOI 10.1016/j.bbrc.2006.05.014
   Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
   Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Guttilla IK, 2012, TRENDS ENDOCRIN MET, V23, P73, DOI 10.1016/j.tem.2011.12.001
   Hajra KM, 2002, CANCER RES, V62, P1613
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HAY ED, 1990, CELL DIFFER DEV, V32, P367, DOI 10.1016/0922-3371(90)90052-X
   Heemskerk B, 2013, EMBO J, V32, P194, DOI 10.1038/emboj.2012.333
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07
   Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaimori A, 2010, HEPATOLOGY, V52, P1033, DOI 10.1002/hep.23765
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209
   Kondo K, 1998, CANCER RES, V58, P2014
   Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Krause CD, 2007, PHARMACOL THERAPEUT, V113, P50, DOI 10.1016/j.pharmthera.2006.06.007
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004
   Lande-Diner L, 2007, J BIOL CHEM, V282, P12194, DOI 10.1074/jbc.M607838200
   Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111
   Law ME, 2013, ONCOGENE, V32, P1316, DOI 10.1038/onc.2012.138
   Leung DC, 2011, P NATL ACAD SCI USA, V108, P5718, DOI 10.1073/pnas.1014660108
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523
   Li XH, 2011, MOL CANCER RES, V9, P824, DOI 10.1158/1541-7786.MCR-10-0529
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lu YJ, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1053
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016/j.biocel.2008.08.020
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mani SA, 2011, MOL CELL, V43, P697, DOI 10.1016/j.molcel.2011.08.012
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Meng FY, 2012, J CELL MOL MED, V16, P160, DOI 10.1111/j.1582-4934.2011.01282.x
   López-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043
   Nam JS, 2004, CLIN EXP METASTAS, V21, P49, DOI 10.1023/B:CLIN.0000017180.19881.c1
   Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Pandiyan K, 2013, NUCLEIC ACIDS RES, V41, P3973, DOI 10.1093/nar/gkt077
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903
   Rao SP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-3
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Roussos ET, 2010, CANCER RES, V70, P7360, DOI 10.1158/0008-5472.CAN-10-1208
   Savickiene J, 2012, CELL BIOL INT, V36, P1067, DOI 10.1042/CBI20110649
   Savickiene J, 2012, CELL MOL BIOL LETT, V17, P501, DOI 10.2478/s11658-012-0024-5
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391
   Sleeman JP, 2011, CELL, V145, DOI 10.1016/j.cell.2011.03.029
   Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984
   Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040
   Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thomas M, 2012, ONCOGENE, V31, P918, DOI 10.1038/onc.2011.278
   Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184
   Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Weiler J, 2006, GENE THER, V13, P496, DOI 10.1038/sj.gt.3302654
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   Wu Y, 2008, J HUAZHONG U SCI-MED, V28, P356, DOI 10.1007/s11596-008-0330-3
   Xia H, 2012, CANCER GENE THER, V19, P723, DOI 10.1038/cgt.2012.58
   Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156
NR 173
TC 13
Z9 14
U1 0
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD NOV
PY 2013
VL 13
IS 9
BP 973
EP 985
DI 10.2174/15680096113136660103
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 273TY
UT WOS:000328560400009
PM 24168185
DA 2025-01-12
ER

PT J
AU Ratovitski, EA
AF Ratovitski, Edward A.
TI Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
SO CURRENT GENOMICS
LA English
DT Article
DE Apoptosis; Autophagy; Cell cycle arrest; Cell metabolism;
   Chemoresistance; Epigenetics; microRNA; TP63
ID LUNG-CANCER; PROMOTES APOPTOSIS; CARCINOMA-CELLS; DOWN-REGULATION;
   TRANSCRIPTIONAL REPRESSION; HEPATOCELLULAR-CARCINOMA; HISTONE
   MODIFICATIONS; INDUCE APOPTOSIS; GENE-REGULATION; REGULATES XIAP
AB Non-coding microRNAs are involved in multiple regulatory mechanisms underlying response of cancer cells to stress leading to apoptosis, cell cycle arrest and autophagy. Many molecular layers are implicated in such cellular response including epigenetic regulation of transcription, RNA processing, metabolism, signaling. The molecular interrelationship between tumor protein (TP)-p53 family members and specific microRNAs is a key functional network supporting tumor cell response to chemotherapy and potentially playing a decisive role in chemoresistance of human epithelial cancers. TP63 was shown to modulate the expression of numerous microRNAs involved in regulation of epithelial cell proliferation, differentiation, senescence, "stemness" and skin maintenance, epithelial/mesenchymal transition, and tumorigenesis in several types of epithelial cancers (e. g. squamous cell carcinoma, ovarian carcinoma, prostate carcinoma, gastric cancer, bladder cancer, and breast tumors), as well as in chemoresistance of cancer cells. TP63/microRNA network was shown to be involved in cell cycle arrest, apoptosis, autophagy, metabolism and epigenetic transcriptional regulation, thereby providing the groundwork for novel chemotherapeutic venues.
C1 Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21231 USA.
C3 Johns Hopkins University
RP Ratovitski, EA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Canc Res Bldg 2,1550 Orleans St, Baltimore, MD 21231 USA.
EM eratovi1@jhmi.edu
FU Flight Attendant Research Institutions grant [082469]
FX I thank Dr. Yiping Huang (Johns Hopkins University School of Medicine)
   for many years of collaboration and friendship, her dedication and
   support. This study was supported in part by the Flight Attendant
   Research Institutions grant (#082469).
CR Antonini D, 2010, J INVEST DERMATOL, V130, P1249, DOI 10.1038/jid.2009.438
   Bailey SG, 2010, APOPTOSIS, V15, P541, DOI 10.1007/s10495-010-0456-1
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Bergholz J, 2012, CANCER MICROENVIRON, V5, P311, DOI 10.1007/s12307-012-0116-9
   Bertero T, 2013, CELL CYCLE, V12, P2183, DOI 10.4161/cc.25330
   Biggar KK, 2011, J MOL CELL BIOL, V3, P167, DOI 10.1093/jmcb/mjq045
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Canavese M, 2012, CANCER BIOL THER, V13, P451, DOI 10.4161/cbt.19589
   Cervo PRD, 2012, P NATL ACAD SCI USA, V109, P1133, DOI 10.1073/pnas.1112257109
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Chen B, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-228
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Chikh A, 2011, EMBO J, V30, P4261, DOI 10.1038/emboj.2011.302
   Chio CC, 2013, ARCH TOXICOL, V87, P459, DOI 10.1007/s00204-012-0965-5
   Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Dávalos A, 2011, P NATL ACAD SCI USA, V108, P9232, DOI 10.1073/pnas.1102281108
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fu LL, 2012, INT J BIOCHEM CELL B, V44, P733, DOI 10.1016/j.biocel.2012.02.004
   Galasso M, 2010, GENOME MED, V2, DOI 10.1186/gm133
   Gallant-Behm CL, 2012, GENE DEV, V26, P2325, DOI 10.1101/gad.198069.112
   Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112
   Gao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065138
   Garofalo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067581
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Germain M, 2011, EMBO J, V30, P395, DOI 10.1038/emboj.2010.327
   Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018
   Gong J, 2013, ONCOGENE, V32, P3071, DOI 10.1038/onc.2012.318
   Gonzalez S, 2008, CELL CYCLE, V7, P2601, DOI 10.4161/cc.7.16.6541
   Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   He XP, 2012, FEBS J, V279, P4201, DOI 10.1111/febs.12013
   Huang Y, 2011, CELL DEATH DIFFER, V18, P1220, DOI 10.1038/cdd.2010.188
   Huang YP, 2008, CELL CYCLE, V7, P2846, DOI 10.4161/cc.7.18.6627
   Huang YP, 2013, CELL CYCLE, V12, P684, DOI 10.4161/cc.23598
   Huang YP, 2012, CELL CYCLE, V11, P3810, DOI 10.4161/cc.22022
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Iguchi Haruhisa, 2010, Curr Drug Discov Technol, V7, P95
   Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005
   Jackson SJ, 2013, DEVELOPMENT, V140, P1882, DOI 10.1242/dev.089649
   Jegga AG, 2011, AUTOPHAGY, V7, P477, DOI 10.4161/auto.7.5.14811
   Jeon TI, 2012, TRENDS ENDOCRIN MET, V23, P65, DOI 10.1016/j.tem.2011.10.004
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Kim DH, 2008, P NATL ACAD SCI USA, V105, P16230, DOI 10.1073/pnas.0808830105
   Kim HR, 2013, BIOCHEM BIOPH RES CO, V437, P225, DOI 10.1016/j.bbrc.2013.06.043
   Kim HR, 2012, BIOCHEM BIOPH RES CO, V418, P682, DOI 10.1016/j.bbrc.2012.01.077
   Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002
   Knouf EC, 2012, NUCLEIC ACIDS RES, V40, P499, DOI 10.1093/nar/gkr731
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Krutovskikh VA, 2010, BIOESSAYS, V32, P894, DOI 10.1002/bies.201000040
   Krützfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kumar S, 2007, CELL DEATH DIFFER, V14, P32, DOI 10.1038/sj.cdd.4402060
   Kwon JE, 2013, APOPTOSIS, V18, P896, DOI 10.1007/s10495-013-0841-7
   Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200
   Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070987
   Liao JM, 2012, CELL CYCLE, V11, P2624, DOI 10.4161/cc.20809
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu S, 2013, FEBS LETT, V587, P2247, DOI 10.1016/j.febslet.2013.05.054
   Lizé M, 2011, CELL CYCLE, V10, P2874, DOI 10.4161/cc.10.17.17181
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Lovat F, 2011, SEMIN ONCOL, V38, P724, DOI 10.1053/j.seminoncol.2011.08.006
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu T, 2013, CANCER GENE THER, V20, P33, DOI 10.1038/cgt.2012.81
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mangala LS, 2009, CLIN CANCER RES, V15, P3770, DOI 10.1158/1078-0432.CCR-08-2306
   Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McKenna DJ, 2010, J VIROL, V84, P10644, DOI 10.1128/JVI.00703-10
   Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451
   Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10
   Melino G, 2010, CELL DEATH DIFFER, V17, P189, DOI 10.1038/cdd.2009.122
   Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Müller J, 2009, CURR OPIN GENET DEV, V19, P150, DOI 10.1016/j.gde.2009.03.001
   Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305
   Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   Ory B, 2011, ONCOTARGET, V2, P259
   Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162
   Patron JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035345
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105
   Pratt AJ, 2009, J BIOL CHEM, V284, P17897, DOI 10.1074/jbc.R900012200
   Qiu TZ, 2013, INT J MOL MED, V32, P593, DOI 10.3892/ijmm.2013.1439
   Ramsey MR, 2011, CANCER RES, V71, P4373, DOI 10.1158/0008-5472.CAN-11-0046
   Ratovitski EA, 2013, FEBS LETT, V587, P2536, DOI 10.1016/j.febslet.2013.06.020
   Roccaro AM, 2010, BLOOD, V116, P1506, DOI 10.1182/blood-2010-01-265686
   Sachdeva M, 2011, ONCOGENE, V30, P822, DOI 10.1038/onc.2010.463
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Song T, 2013, J CANCER RES CLIN, V139, P1189, DOI 10.1007/s00432-013-1392-6
   Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886
   Suzuki K, 2009, CURR TOP MED CHEM, V9, P1079, DOI 10.2174/156802609789630875
   Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200
   Takata A, 2013, HEPATOLOGY, V57, P162, DOI 10.1002/hep.26011
   Tibiche C., 2008, Open Syst Biology J, DOI DOI 10.2174/1876392800801010001
   Tran MN, 2013, J BIOL CHEM, V288, P3275, DOI 10.1074/jbc.M112.408104
   Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24
   Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Verdoodt B, 2013, INT J ONCOL, V43, P307, DOI 10.3892/ijo.2013.1915
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Walensky LD, 2006, CELL DEATH DIFFER, V13, P1339, DOI 10.1038/sj.cdd.4401992
   Wang F, 2013, FEBS LETT, V587, P488, DOI 10.1016/j.febslet.2013.01.016
   Wang YM, 2011, RESULTS PROBL CELL D, V53, P459, DOI 10.1007/978-3-642-19065-0_19
   Wang YS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030635, 10.1371/journal.pone.0048669, 10.1371/journal.pone.0047302]
   Wiklund ED, 2010, EPIGENOMICS-UK, V2, P823, DOI 10.2217/EPI.10.51
   Wilfred BR, 2007, MOL GENET METAB, V91, P209, DOI 10.1016/j.ymgme.2007.03.011
   Wu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045761
   Xie Y, 2013, ONCOGENE, V32, P2442, DOI 10.1038/onc.2012.258
   Xu JZ, 2012, AUTOPHAGY, V8, P873, DOI 10.4161/auto.19629
   Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823
   Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Younger ST, 2011, MOL BIOSYST, V7, P2383, DOI 10.1039/c1mb05090g
   Yousefi S, 2007, CRIT REV ONCOL HEMAT, V63, P241, DOI 10.1016/j.critrevonc.2007.06.005
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zang YS, 2012, CANCER GENE THER, V19, P773, DOI 10.1038/cgt.2012.60
   Zeng XZ, 2011, CELL CYCLE, V10, P579, DOI 10.4161/cc.10.4.14722
   Zhang JG, 2011, J THORAC ONCOL, V6, P671, DOI 10.1097/JTO.0b013e318208eb35
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
   Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714
   Zhu A, 2012, MED ONCOL, V29, P2701, DOI 10.1007/s12032-011-0134-3
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
NR 144
TC 18
Z9 19
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
EI 1875-5488
J9 CURR GENOMICS
JI Curr. Genomics
PD NOV
PY 2013
VL 14
IS 7
BP 441
EP 452
DI 10.2174/13892029113146660011
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 262ZK
UT WOS:000327776200003
PM 24396276
OA Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Mungamuri, SK
   Murk, W
   Grumolato, L
   Bernstein, E
   Aaronson, SA
AF Mungamuri, Sathish Kumar
   Murk, William
   Grumolato, Luca
   Bernstein, Emily
   Aaronson, Stuart A.
TI Chromatin Modifications Sequentially Enhance ErbB2 Expression in
   ErbB2-Positive Breast Cancers
SO CELL REPORTS
LA English
DT Article
ID HISTONE H3; ADJUVANT TRASTUZUMAB; THERAPEUTIC TARGET; HER2; ONCOGENE;
   WDR5; MLL1; OVEREXPRESSION; RECOGNITION; INHIBITION
AB ErbB2 gene amplification occurs in 20%-25% of breast cancers, and its therapeutic targeting has markedly improved survival of patients with breast cancer in the adjuvant setting. However, resistance to these therapies can develop. Because epigenetic mechanisms can importantly influence oncogene expression and be druggable as well, we investigated histone modifications that influence ErbB2 overexpression, independent of gene amplification. We demonstrate here that ErbB2-overexpressing breast carcinomas acquire the H3K4me3 mark on the erbB2 promoter and that receptor-amplified tumors further acquire the H3K9ac mark, which is dependent on H3K4me3 mark acquisition. Targeting WD repeat domain 5 (Wdr5), which is absolutely required for H3K4me3 enrichment, decreased ErbB2 overexpression, associated with a decrease in the H3K4me3 mark on the erbB2 promoter. Of note, Wdr5 silencing cooperated with trastuzumab or chemotherapy in specifically inhibiting the growth of ErbB2-positive breast tumor cells. Thus, our studies illuminate epigenetic steps in the selection for ErbB2 activation.
C1 [Mungamuri, Sathish Kumar; Murk, William; Grumolato, Luca; Bernstein, Emily; Aaronson, Stuart A.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Aaronson, SA (通讯作者)，Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.
EM stuart.aaronson@mssm.edu
RI grumolato, luca/A-1697-2015
OI grumolato, luca/0000-0001-8231-3032; Mungamuri, Sathish
   Kumar/0000-0002-0012-5298
FU Breast Cancer Research Foundation; National Cancer Institute
   [P01CA080058]; Mary Kay Foundation; JJR Foundation
FX The authors would like to thank S.W. Lee, K.E. Lee, H. Wang, J. Lim, and
   A. Gaspar-Maia for the useful discussions. This research was supported
   by grants from the Breast Cancer Research Foundation (S.A.A.) and the
   National Cancer Institute (P01CA080058; S.A.A.). E.B. is supported by
   Mary Kay Foundation and JJR Foundation research awards. The content of
   this paper is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Cancer
   Institute or the US National Institutes of Health.
CR Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497
   Andrechek ER, 2003, CANCER RES, V63, P4920
   Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003
   Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744
   Bosher JM, 1996, ONCOGENE, V13, P1701
   CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285
   Couture JF, 2006, NAT STRUCT MOL BIOL, V13, P698, DOI 10.1038/nsmb1116
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917
   Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   DOUGALL WC, 1994, ONCOGENE, V9, P2109
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fisher CL, 2011, CURR OPIN GENET DEV, V21, P140, DOI 10.1016/j.gde.2011.01.015
   Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320
   Grooteclaes M, 1999, CANCER RES, V59, P2527
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Han ZF, 2006, MOL CELL, V22, P137, DOI 10.1016/j.molcel.2006.03.018
   Hemshekhar M., 2011, BASIC CLIN PHARMACOL, DOI DOI 10.1111/J.1742-7843.2011.00833
   Kancha RK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026760
   Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339
   Koutelou E, 2010, CURR OPIN CELL BIOL, V22, P374, DOI 10.1016/j.ceb.2010.03.005
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x
   Mai A, 2006, J MED CHEM, V49, P6897, DOI 10.1021/jm060601m
   MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5
   Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830
   Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271
   Nadler Y, 2010, ANN ONCOL, V21, P466, DOI 10.1093/annonc/mdp346
   Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612
   Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440
   Patel A, 2009, J BIOL CHEM, V284, P24242, DOI 10.1074/jbc.M109.014498
   Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526
   Peltomäki P, 2012, EXP CELL RES, V318, P299, DOI 10.1016/j.yexcr.2011.12.001
   Pero Stephanie C, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403006227
   Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
   Ramsey B, 2011, BREAST CANCER RES TR, V127, P659, DOI 10.1007/s10549-010-1010-0
   Robert N, 2006, J CLIN ONCOL, V24, P2786, DOI 10.1200/JCO.2005.04.1764
   Rodriguez-Navarro S, 2009, EMBO REP, V10, P843, DOI 10.1038/embor.2009.168
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Ruthenburg AJ, 2006, NAT STRUCT MOL BIOL, V13, P704, DOI 10.1038/nsmb1119
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x
   Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131
   Thompson BA, 2008, MOL CELL BIOL, V28, P3894, DOI 10.1128/MCB.00322-08
   Trievel RC, 2009, NAT STRUCT MOL BIOL, V16, P678, DOI 10.1038/nsmb0709-678
   Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z
   Wajapeyee N, 2006, J BIOL CHEM, V281, P16207, DOI 10.1074/jbc.M600539200
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Xu W, 2000, NAT GENET, V26, P229
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 59
TC 36
Z9 37
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD OCT
PY 2013
VL 5
IS 2
BP 302
EP 313
DI 10.1016/j.celrep.2013.09.009
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 269SU
UT WOS:000328263000003
PM 24120871
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Aran, D
   Sabato, S
   Hellman, A
AF Aran, Dvir
   Sabato, Sivan
   Hellman, Asaf
TI DNA methylation of distal regulatory sites characterizes dysregulation
   of cancer genes
SO GENOME BIOLOGY
LA English
DT Article
DE Cancer; DNA methylation; distal control elements; enhancers;
   epigenomics; gene-enhancer pairing; gene regulation; machine-learning
ID BODY-SPECIFIC METHYLATION; PLURIPOTENT STEM-CELLS; REPRESSED GENES;
   BREAST-CANCER; CHROMATIN; ENHANCER; HYPERMETHYLATION; SIGNATURE;
   DYNAMICS; HYPOMETHYLATION
AB Background: Abnormal epigenetic marking is well documented in gene promoters of cancer cells, but the study of distal regulatory siteshas lagged behind. We performed a systematic analysis of DNA methylation sites connected with gene expression profilesacross normal and cancerous human genomes.
   Results: Utilizing methylation and expression data in 58 cell types, we developed a model for methylation-expression relationships in gene promoters and extrapolated it to the genome. We mapped numerous sites at which DNA methylation was associated with expression of distal genes. These sites bind transcription factors in a methylation-dependent manner, and carry the chromatin marks of a particular class of transcriptional enhancers. In contrast to the traditional model of one enhancer site per cell type, we found that single enhancer sites may define gradients of expression levels across many different cell types. Strikingly, the identified sites were drastically hypermethylated sites with downregulation. Moreover, the association between enhancer methylation and gene deregulation in cancerwas significantly stronger than the association of promoter methylationwith gene deregulation.
   Conclusions: Methylation of distal regulatory sites is closely related to gene expression levels across the genome. Single enhancers may modulate ranges of cell-specific transcription levels, from constantlyopen promoters. In contrast to the remote relationships between promoter methylation and gene dysregulation in cancer, altered methylation of enhancer sites is closely related to gene expression profiles of transformed cells.
C1 [Aran, Dvir; Hellman, Asaf] Hebrew Univ Jerusalem, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, Fac Med,Hadassah Med Sch, IL-91120 Jerusalem, Israel.
   [Aran, Dvir; Sabato, Sivan] Hebrew Univ Jerusalem, Rachel & Selim Benin Sch Comp Sci & Engn, IL-91904 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem
RP Hellman, A (通讯作者)，Hebrew Univ Jerusalem, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, Fac Med,Hadassah Med Sch, Ein Kerem Campus, IL-91120 Jerusalem, Israel.
EM asafh@ekmd.huji.ac.il
RI Aran, Dvir/AAV-5625-2020; Sabato, Sivan/U-4730-2017
OI Aran, Dvir/0000-0001-6334-5039; Sabato, Sivan/0000-0002-7975-0044
FU Adams Fellowship Program of the Israel Academy of Sciences and
   Humanities; I-CORE Program of the Planning and Budgeting Committee;
   Israel Science Foundation [41/11, 887/08]
FX We are grateful to Shai Shalev-Shwartz for his helpful advice regarding
   the development of the machine-learning algorithm. Thanks are also due
   to Yehudit Bergman, Gadi Glaser, Amir Eden, Benjamin Glaser, Reuven
   Laskov and Howard Cedar for helpful discussions and comments. This work
   was supported by the Adams Fellowship Program of the Israel Academy of
   Sciences and Humanities (to SS), by the I-CORE Program of the Planning
   and Budgeting Committee and the Israel Science Foundation (Grant No.
   41/11 to AH), and by the Israel Science Foundation (Grant No. 887/08 to
   AH).
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Angrisano T, 2011, NUCLEIC ACIDS RES, V39, P1993, DOI 10.1093/nar/gkq864
   [Anonymous], 2011, PLOS BIOL, DOI DOI 10.1371/JOURNAL.PBIO.1001046
   Aran D, 2011, HUM MOL GENET, V20, P670, DOI 10.1093/hmg/ddq513
   Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019
   Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024
   Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev-biochem-052610-091920
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Feng SH, 2010, P NATL ACAD SCI USA, V107, P8689, DOI 10.1073/pnas.1002720107
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Nazor KL, 2012, CELL STEM CELL, V10, P620, DOI 10.1016/j.stem.2012.02.013
   Oehler VG, 2009, BLOOD, V114, P3299, DOI 10.1182/blood-2008-07-170282
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Raddatz G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003146
   Rödelsperger C, 2011, NUCLEIC ACIDS RES, V39, P2492, DOI 10.1093/nar/gkq1081
   Sandovici I, 2011, P NATL ACAD SCI USA, V108, P5449, DOI 10.1073/pnas.1019007108
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Steinmann Katrin, 2011, Genes Cancer, V2, P65, DOI 10.1177/1947601911405043
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Taberlay PC, 2011, CELL, V147, P1283, DOI 10.1016/j.cell.2011.10.040
   Tekpli X, 2012, INT J CANCER, V131, P1509, DOI 10.1002/ijc.27421
   Visel A, 2009, NATURE, V461, P199, DOI 10.1038/nature08451
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wiench M, 2011, EMBO J, V30, P3028, DOI 10.1038/emboj.2011.210
   Xu J, 2009, GENE DEV, V23, P2824, DOI 10.1101/gad.1861209
   Yue Y., 2007, P 30 ANN INT ACM SIG, P271
   Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366
NR 41
TC 249
Z9 316
U1 0
U2 24
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-6906
EI 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2013
VL 14
IS 3
AR R21
DI 10.1186/gb-2013-14-3-r21
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 268TP
UT WOS:000328193700001
PM 23497655
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Sung, FL
   Cui, Y
   Hui, EP
   Li, LL
   Loh, TKS
   Tao, Q
   Chan, ATC
AF Sung, Fion L.
   Cui, Yan
   Hui, Edwin P.
   Li, Lili
   Loh, Thomas K. S.
   Tao, Qian
   Chan, Anthony T. C.
TI Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by
   promoter methylation activates carbonic anhydrase IX in nasopharyngeal
   carcinoma
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Lysyl oxidase; nasopharyngeal carcinoma; epigenetics; growth inhibition;
   apoptosis; metastasis; hypoxia; carbonic anhydrase IX
ID SQUAMOUS-CELL CARCINOMA; DNA METHYLATION; BREAST-CANCER; PROPEPTIDE
   DOMAIN; POOR-PROGNOSIS; EXPRESSION; SURVIVAL; MARKER; GROWTH; LUNG
AB Lysyl oxidase (LOX) is an oxidative enzyme known to initiate the cross-linking of collagens and elastin, and suggested recently as a tumor suppressor for several tumor types including lung, pancreatic and gastric cancers. Previously we showed that LOX is strongly induced upon hypoxia in nasopharyngeal carcinoma (NPC) cell lines CNE2 and HONE1 but only slightly in HK1 and not in C666-1. Here, we further studied the regulatory mechanism and functions of LOX in NPC. LOX is widely expressed in human normal tissues with variations in expression levels. LOX was expressed in most NPC cell lines except for C666-1, while HK1 and FaDu (laryngeal cancer) only expressed low level of LOX. Methylation analysis showed that the LOX promoter was methylated in C666-1 and partially methylated in HK1. After demethylation with 5-aza-2'-deoxycytidine, LOX expression was reactivated along with increased unmethylated alleles. LOX promoter methylation was detected in 42/49 (85.7%) of NPC primary tumors but only 3/16 (18.75%) of nose swab samples from NPC patients. LOX overexpression reduced the clonogenicity and cell growth of NPC cells, and also inhibited the migration and invasion of the NPC cells. Carbonic anhydrase IX (CA9) mRNA level was obviously decreased in HK1 cells after transfection with LOX. The elevation of CA9 protein upon hypoxia was inhibited in LOX-transfected HK1 cells. The protein levels of an apoptosis marker cPARP were increased in LOX-transfected HK1 cells upon hypoxia treatment. Our data showed that silencing or down-regulation of LOX in NPC was due to its promoter methylation and LOX acts as a tumor suppressor in NPC. LOX silencing would facilitate NPC cells to escape from hypoxia-induced apoptosis and maintains a malignant and metastatic phenotype.
C1 [Sung, Fion L.; Cui, Yan; Hui, Edwin P.; Li, Lili; Tao, Qian; Chan, Anthony T. C.] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong Canc Inst, State Key Lab Oncol South China,Sir YK Pao Ctr Ca, Shatin, Hong Kong, Peoples R China.
   [Loh, Thomas K. S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore 117595, Singapore.
C3 Chinese University of Hong Kong; State Key Lab Oncology South China;
   National University of Singapore
RP Tao, Q (通讯作者)，Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China.
EM qtao@cuhk.edu.hk; anthonytcchan@cuhk.edu.hk
RI Loh, Thomas/GYU-2298-2022; Hui, Edwin/ABC-1818-2021; Tao,
   Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018; Li,
   Lili/Q-5750-2018
OI Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak
   Cheung/0000-0002-6912-8091; Li, Lili/0000-0002-0292-5889
FU Hong Kong RGC grant CUHK [4443/05M]; Hong Kong RGC grant TBRS
   [T12-401/13R]; CUHK direct grant; CUHK Group Research Scheme
FX This project was supported by Hong Kong RGC grants CUHK #4443/05M and
   TBRS#T12-401/13R, a CUHK direct grant and the CUHK Group Research
   Scheme. We thank Prof. George Tsao, (Dolly Huang), Guiyuan Li, Kaitai
   Yao for some cell lines.
CR Albinger-Hegyi A, 2010, INT J CANCER, V126, P2653, DOI 10.1002/ijc.24948
   Beasley NJP, 2001, CANCER RES, V61, P5262
   Beketic-Oreskovic L, 2011, PATHOL ONCOL RES, V17, P593, DOI 10.1007/s12253-010-9355-6
   BRODY JS, 1979, AM REV RESPIR DIS, V120, P1289
   Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547
   Chiang JW, 2006, GYNECOL ONCOL, V101, P403, DOI 10.1016/j.ygyno.2005.10.034
   Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470
   Cianchi F, 2010, J PHARMACOL EXP THER, V334, P710, DOI 10.1124/jpet.110.167270
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   Hui EP, 2002, CLIN CANCER RES, V8, P2595
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KAGAN HM, 1995, J CELL BIOCHEM, V59, P329, DOI 10.1002/jcb.240590305
   Kaneda A, 2004, CANCER RES, V64, P6410, DOI 10.1158/0008-5472.CAN-04-1543
   Kikuchi S, 2006, CANCER-AM CANCER SOC, V106, P1751, DOI 10.1002/cncr.21800
   Kon-No H, 2006, LUNG CANCER, V54, P409, DOI 10.1016/j.lungcan.2006.08.017
   Le QT, 2009, J CLIN ONCOL, V27, P4281, DOI 10.1200/JCO.2008.20.6003
   Loncaster JA, 2001, CANCER RES, V61, P6394
   Lui VWY, 2011, ONCOGENE, V30, P1518, DOI 10.1038/onc.2010.529
   Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867
   Min CY, 2009, CANCER RES, V69, P6685, DOI 10.1158/0008-5472.CAN-08-4818
   Palamakumbura AH, 2004, J BIOL CHEM, V279, P40593, DOI 10.1074/jbc.M406639200
   Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392
   Peridis S, 2011, EUR ARCH OTO-RHINO-L, V268, P661, DOI 10.1007/s00405-011-1488-z
   Poulsen SA, 2010, EXPERT OPIN THER PAT, V20, P795, DOI 10.1517/13543776.2010.484803
   Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533
   Robertson N, 2004, CANCER RES, V64, P6160, DOI 10.1158/0008-5472.CAN-03-2224
   Sakai M, 2009, ANN SURG ONCOL, V16, P2494, DOI 10.1245/s10434-009-0559-5
   Sansone P, 2009, J CELL MOL MED, V13, P3876, DOI 10.1111/j.1582-4934.2008.00580.x
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Sung FL, 2007, CANCER LETT, V253, P74, DOI 10.1016/j.canlet.2007.01.012
   Sung FL, 2005, IN VIVO, V19, P237
   Svastová E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043
   Svastova E, 2012, J BIOL CHEM, V287, P3392, DOI 10.1074/jbc.M111.286062
   Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Winum JY, 2009, ANTI-CANCER AGENT ME, V9, P693, DOI 10.2174/187152009788680028
   Woznick AR, 2005, AM J SURG, V189, P297, DOI 10.1016/j.amjsurg.2004.11.031
   Wu M, 2007, CANCER RES, V67, P6278, DOI 10.1158/0008-5472.CAN-07-0776
   Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267
NR 40
TC 21
Z9 24
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2014
VL 4
IS 6
BP 789
EP 800
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AX3QZ
UT WOS:000346855300015
PM 25520868
DA 2025-01-12
ER

PT J
AU Conway, K
   Edmiston, SN
   May, R
   Kuan, PF
   Chu, HT
   Bryant, C
   Tse, CK
   Swift-Scanlan, T
   Geradts, J
   Troester, MA
   Millikan, RC
AF Conway, Kathleen
   Edmiston, Sharon N.
   May, Ryan
   Kuan, Pei Fen
   Chu, Haitao
   Bryant, Christopher
   Tse, Chiu-Kit
   Swift-Scanlan, Theresa
   Geradts, Joseph
   Troester, Melissa A.
   Millikan, Robert C.
TI DNA methylation profiling in the Carolina Breast Cancer Study defines
   cancer subclasses differing in clinicopathologic characteristics and
   survival
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ABERRANT METHYLATION; CPG ISLANDS; PHENOTYPE; CELL; PATTERNS; SUBTYPES;
   REVEALS; GENES; RISK; RACE
AB Introduction: Breast cancer is a heterogeneous disease, with several intrinsic subtypes differing by hormone receptor (HR) status, molecular profiles, and prognosis. However, the role of DNA methylation in breast cancer development and progression and its relationship with the intrinsic tumor subtypes are not fully understood.
   Methods: A microarray targeting promoters of cancer-related genes was used to evaluate DNA methylation at 935 CpG sites in 517 breast tumors from the Carolina Breast Cancer Study, a population-based study of invasive breast cancer.
   Results: Consensus clustering using methylation (beta) values for the 167 most variant CpG loci defined four clusters differing most distinctly in HR status, intrinsic subtype (luminal versus basal-like), and p53 mutation status. Supervised analyses for HR status, subtype, and p53 status identified 266 differentially methylated CpG loci with considerable overlap. Genes relatively hypermethylated in HR+, luminal A, or p53 wild-type breast cancers included FABP3, FGF2, FZD9, GAS7, HDAC9, HOXA11, MME, PAX6, POMC, PTGS2, RASSF1, RBP1, and SCGB3A1, whereas those more highly methylated in HR-, basal-like, or p53 mutant tumors included BCR, C4B, DAB2IP, MEST, RARA, SEPT5, TFF1, THY1, and SERPINA5. Clustering also defined a hypermethylated luminal-enriched tumor cluster 3 that gene ontology analysis revealed to be enriched for homeobox and other developmental genes (ASCL2, DLK1, EYA4, GAS7, HOXA5, HOXA9, HOXB13, IHH, IPF1, ISL1, PAX6, TBX1, SOX1, and SOX17). Although basal-enriched cluster 2 showed worse short-term survival, the luminal-enriched cluster 3 showed worse long-term survival but was not independently prognostic in multivariate Cox proportional hazard analysis, likely due to the mostly early stage cases in this dataset.
   Conclusions: This study demonstrates that epigenetic patterns are strongly associated with HR status, subtype, and p53 mutation status and may show heterogeneity within tumor subclass. Among HR+ breast tumors, a subset exhibiting a gene signature characterized by hypermethylation of developmental genes and poorer clinicopathologic features may have prognostic value and requires further study. Genes differentially methylated between clinically important tumor subsets have roles in differentiation, development, and tumor growth and may be critical to establishing and maintaining tumor phenotypes and clinical outcomes.
C1 [Conway, Kathleen; Tse, Chiu-Kit; Troester, Melissa A.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Conway, Kathleen; Edmiston, Sharon N.; Swift-Scanlan, Theresa; Troester, Melissa A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [May, Ryan] EMMES Corp, Rockville, MD 20850 USA.
   [Kuan, Pei Fen] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.
   [Chu, Haitao] Univ Minnesota, MMC Sch Publ Hlth 303, Div Biostat, Minneapolis, MN 55455 USA.
   [Bryant, Christopher] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA.
   [Swift-Scanlan, Theresa] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
   [Geradts, Joseph] Duke Univ, Med Ctr, Sch Med, Dept Pathol, Durham, NC 27710 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Emmes Corporation; State University of New York (SUNY) System; Stony
   Brook University; University of Minnesota System; University of
   Minnesota Twin Cities; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina; University of North
   Carolina Chapel Hill; Duke University
RP Conway, K (通讯作者)，Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Campus Box 7435, Chapel Hill, NC 27599 USA.
EM kconway@med.unc.edu
RI Chu, Haitao/J-7576-2012; Kuan, Pei Fen/GRX-4622-2022
OI Chu, Haitao/0000-0003-0932-598X
FU Susan G. Komen for the Cure [KG081397]; University Cancer Research Fund
   of North Carolina; National Cancer Institute Specialized Program of
   Research Excellence (SPORE) in Breast Cancer [NIH/NCI P50-CA58223]
FX This work was supported by a grant to KC from the Susan G. Komen for the
   Cure (grant #KG081397). The CBCS was funded by the University Cancer
   Research Fund of North Carolina and the National Cancer Institute
   Specialized Program of Research Excellence (SPORE) in Breast Cancer
   (NIH/NCI P50-CA58223). We acknowledge support of Jason Luo and staff of
   the Mammalian Genotyping Core Facility in performance of the Illumina
   methylation array assays and of the Tissue Procurement Core for making
   available normal breast tissue specimens. We thank Lin Wu and Nancy
   Patten of Roche Molecular Systems for providing p53 AmpliChip arrays. We
   are grateful to the participants of the CBCS for their continuing
   support of the study. This work is dedicated to the memory of our
   colleague, the late Robert Millikan, principal investigator of the CBCS.
CR ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976
   [Anonymous], J PATHOL
   [Anonymous], PACKAGE SURVIVAL ANA
   ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Cohen AL, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-35
   Conway K, 2011, PIGM CELL MELANOMA R, V24, P352, DOI 10.1111/j.1755-148X.2011.00828.x
   Dressler LG, 1999, BREAST CANCER RES TR, V58, P31, DOI 10.1023/A:1006354627669
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jithesh PV, 2013, BRIT J CANCER, V108, P370, DOI 10.1038/bjc.2012.568
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Killian JK, 2011, AM J PATHOL, V179, P55, DOI 10.1016/j.ajpath.2011.03.022
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Li JCA, 2003, SOCIOL METHOD RES, V32, P117, DOI 10.1177/0049124103031004005
   Li Y, 1998, CANCER EPIDEM BIOMAR, V7, P303
   Lynch AG, 2009, STAT METHODS MED RES, V18, P437, DOI 10.1177/0962280208099451
   Maier S, 2007, EUR J CANCER, V43, P1679, DOI 10.1016/j.ejca.2007.04.025
   Marsit CJ, 2009, CARCINOGENESIS, V30, P416, DOI 10.1093/carcin/bgp006
   Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Moorman PG, 1999, ANN EPIDEMIOL, V9, P188, DOI 10.1016/S1047-2797(98)00057-X
   NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Nosho K, 2009, CLIN CANCER RES, V15, P3663, DOI 10.1158/1078-0432.CCR-08-2383
   Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Piotrowski A, 2006, GENE CHROMOSOME CANC, V45, P656, DOI 10.1002/gcc.20331
   Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479
   Polyak K, 2009, BREAST CANCER RES, V11, pS8, DOI 10.1186/bcr2279
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Shinjo K, 2012, CARCINOGENESIS, V33, P1277, DOI 10.1093/carcin/bgs154
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Toyota M, 1999, CANCER RES, V59, P5438
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V131, P859, DOI 10.1007/s10549-011-1485-3
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Wilkerson M, 2013, PACKAGE CONSENSUSCLU
   Xu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-243
   Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160
   Zhang QY, 2011, GYNECOL OBSTET INVES, V72, P183, DOI 10.1159/000324496
NR 65
TC 66
Z9 70
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2014
VL 16
IS 5
AR 450
DI 10.1186/s13058-014-0450-6
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CA1II
UT WOS:000348665600025
PM 25287138
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Tan, XH
   Peng, J
   Fu, YB
   An, SJ
   Rezaei, K
   Tabbara, S
   Teal, CB
   Man, YG
   Brem, RF
   Fu, SW
AF Tan, Xiaohui
   Peng, Jin
   Fu, Yebo
   An, Shejuan
   Rezaei, Katayoon
   Tabbara, Sana
   Teal, Christine B.
   Man, Yan-gao
   Brem, Rachel F.
   Fu, Sidney W.
TI miR-638 mediated regulation of <i>BRCA1</i> affects DNA repair and
   sensitivity to UV and cisplatin in triple-negative breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID GENE-EXPRESSION; MICRORNA; DAMAGE; CELLS; EPIGENETICS; ER
AB Introduction: Triple-negative breast cancer (TNBC) represents 15 to 20% of all types of breast cancer; however, it accounts for a large number of metastatic cases and deaths, and there is still no effective treatment. The deregulation of microRNAs (miRNAs) in breast cancer has been widely reported. We previously identified that miR-638 was one of the most deregulated miRNAs in breast cancer progression. Bioinformatics analysis revealed that miR-638 directly targets BRCA1. The aim of this study was to investigate the role of miR-638 in breast cancer prognosis and treatment.
   Methods: Formalin-fixed, paraffin-embedded (FFPE) breast cancer samples were microdissected into normal epithelial and invasive ductal carcinoma (IDC) cells, and total RNA was isolated. Several breast cancer cell lines were used for the functional analysis. miR-638 target genes were identified by TARGETSCAN-VERT 6.2 and miRanda. The expression of miR-638 and its target genes was analyzed by real-time qRT-PCR and Western blotting. Dual-luciferase reporter assay was employed to confirm the specificity of miR-638 target genes. The biological function of miR-638 was analyzed by MTT chemosensitivity, matrigel invasion and host cell reactivation assays.
   Results: The expression of miR-638 was decreased in IDC tissue samples compared to their adjacent normal controls. The decreased miR-638 expression was more prevalent in non-TNBC compared with TNBC cases. miR-638 expression was significantly downregulated in breast cancer cell lines compared to the immortalized MCF-10A epithelial cells. BRCA1 was predicted as one of the direct targets of miR-638, which was subsequently confirmed by dual-luciferase reporter assay. Forced expression of miR-638 resulted in a significantly reduced proliferation rate as well as decreased invasive ability in TNBC cells. Furthermore, miR-638 overexpression increased sensitivity to DNA-damaging agents, ultraviolet (UV) and cisplatin, but not to 5-fluorouracil (5-FU) and epirubicin exposure in TNBC cells. Host cell reactivation assays showed that miR-638 reduced DNA repair capability in post UV/cisplatin-exposed TNBC cells. The reduced proliferation, invasive ability, and DNA repair capabilities are associated with downregulated BRCA1 expression.
   Conclusions: Our findings suggest that miR-638 plays an important role in TNBC progression via BRCA1 deregulation. Therefore, miR-638 might serve as a potential prognostic biomarker and therapeutic target for breast cancer.
C1 [Tan, Xiaohui; Peng, Jin; Fu, Yebo; An, Shejuan; Fu, Sidney W.] George Washington Univ, Sch Med & Hlth Sci, Dept Med, Div Genom Med, 2300 Eye St NW,Ross Hall 402C, Washington, DC 20037 USA.
   [Rezaei, Katayoon; Tabbara, Sana] George Washington Univ, Sch Med & Hlth Sci, Dept Pathol, Washington, DC 20037 USA.
   [Teal, Christine B.] George Washington Univ, Sch Med & Hlth Sci, Dept Surg, Washington, DC 20037 USA.
   [Man, Yan-gao] Bon Secours Hlth Syst, Bon Secours Canc Inst, Res Lab, Richmond, VA 23226 USA.
   [Man, Yan-gao] Bon Secours Hlth Syst, Bon Secours Canc Inst, Int Collaborat, Richmond, VA 23226 USA.
   [Brem, Rachel F.] George Washington Univ, Sch Med & Hlth Sci, Dept Radiol, Washington, DC 20037 USA.
   [Fu, Sidney W.] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA.
C3 George Washington University; George Washington University; George
   Washington University; George Washington University; George Washington
   University
RP Fu, SW (通讯作者)，George Washington Univ, Sch Med & Hlth Sci, Dept Med, Div Genom Med, 2300 Eye St NW,Ross Hall 402C, Washington, DC 20037 USA.
EM sfu@gwu.edu
RI An, Shejuan/A-9573-2014; Xiaohui, Tan/HTR-5450-2023; Peng,
   Jin/P-4752-2017
FU Dr. Cyrus and Myrtle Katzen Cancer Research Center Grant at The George
   Washington University; National Cancer Institute [1R21 CA159103-01]; Hao
   Foundation; Elaine H. Snyder Cancer Research Award
FX We would like to thank Dr. Kenneth H. Kraemer (NCI/NIH) for providing us
   with the pCMVLuc reporter gene plasmid and Dr. Wen Chen (Faculty of
   Preventive Medicine, School of Public Health, Sun Yat-sen University,
   China) for the pGL3 plasmid. We thank Woojin Lee, the W. T. Gill, Jr.,
   Summer Research Fellow at GW School of Medicine and Health Science for
   qRT-PCR technical assistance. This research was supported by the Dr.
   Cyrus and Myrtle Katzen Cancer Research Center Grant at The George
   Washington University (to SWF and RFB), the National Cancer Institute
   Grant (1R21 CA159103-01) (to SWF), the Hao Foundation grant (to SWF) and
   the Elaine H. Snyder Cancer Research Award (to SWF).
CR Alli Elizabeth, 2011, BMC Pharmacology, V11, P7, DOI 10.1186/1471-2210-11-7
   Alli E, 2009, CANCER RES, V69, P3589, DOI 10.1158/0008-5472.CAN-08-4016
   Berger F, 2013, THERANOSTICS, V3, P932, DOI 10.7150/thno.7445
   Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187
   Chen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054213
   Costa PM, 2013, PHARMACEUTICALS, V6, P1195, DOI 10.3390/ph6101195
   Crown J, 2012, ANN ONCOL, V23, P56, DOI 10.1093/annonc/mds196
   Deng CX, 2003, HUM MOL GENET, V12, pR113, DOI 10.1093/hmg/ddg082
   Fu SW, 2011, J CANCER, V2, P116, DOI 10.7150/jca.2.116
   Fu YB, 2010, J CANCER, V1, P54
   Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Husain A, 1998, CANCER RES, V58, P1120
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kahlert C, 2011, CANCER SCI, V102, P1799, DOI 10.1111/j.1349-7006.2011.02023.x
   Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312
   Li DC, 2012, TOXICOL SCI, V125, P382, DOI 10.1093/toxsci/kfr299
   Li P, 2013, CARDIOVASC RES, V99, P185, DOI 10.1093/cvr/cvt082
   Lin Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069230
   Mascaux C, 2009, EUR RESPIR J, V33, P352, DOI 10.1183/09031936.00084108
   Moulis S, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1853
   Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557
   Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541
   Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105
   Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415
   Sand M, 2012, BRIT J DERMATOL, V167, P847, DOI 10.1111/j.1365-2133.2012.11022.x
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Slezak-Prochazka I, 2010, RNA, V16, P1087, DOI 10.1261/rna.1804410
   Subik K, 2010, BREAST CANCER-BASIC, V4, P35
   Tan XH, 2013, HUM MUTAT, V34, P1250, DOI 10.1002/humu.22354
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Wang JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073683
   Wang YM, 2013, CELL CYCLE, V12, P32, DOI 10.4161/cc.23051
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zhang XJ, 2013, CARCINOGENESIS, V34, P2309, DOI 10.1093/carcin/bgt213
   Zhu DX, 2012, CARCINOGENESIS, V33, P1294, DOI 10.1093/carcin/bgs179
NR 38
TC 106
Z9 112
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2014
VL 16
IS 5
AR 435
DI 10.1186/s13058-014-0435-5
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CA1II
UT WOS:000348665600010
PM 25228385
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Shah, P
   Gau, Y
   Sabnis, G
AF Shah, Preeti
   Gau, Yael
   Sabnis, Gauri
TI Histone deacetylase inhibitor entinostat reverses epithelial to
   mesenchymal transition of breast cancer cells by reversing the
   repression of E-cadherin
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Epithelial to mesenchymal transition; E-cadherin; HDAC inhibitor
ID IN-VIVO; TUBULIN DETYROSINATION; GENE-EXPRESSION; TUMOR CELLS;
   MECHANISMS; VIMENTIN; PROMOTER; MICROTENTACLES; MICROTUBULES;
   RECRUITMENT
AB Loss of ER alpha in breast cancer correlates with poor prognosis, increased recurrence rates, and higher incidence of metastasis. Epigenetic silencing of E-cadherin (loss of which is associated with more invasive phenotype) is observed in metastatic cell lines and invasive breast cancers. Here, we are showing that entinostat (ENT) can reverse epithelial to mesenchymal transition (EMT), which is considered to be a first step in the process of metastases formation. Triple-negative breast cancer cells such as MDA-MB-231 and Hs578T show a basal phenotype characterized by loss of E-cadherin expression and higher expression of mesenchymal markers such as N-cadherin and vimentin along with transcriptional repressors such as twist and snail. When MDA-MB-231 and Hs578T cells or tumors were treated with ENT, E-cadherin transcription was increased along with reduction in N-cadherin mRNA expression. Chromatin immunoprecipitation assay showed that treatment of MDA-MB-231 and Hs578T cells increased the activation of E-cadherin promoter by reducing the association of twist and snail with the E-cadherin (CDH1) promoter and downregulated both the snail and twist. ENT also inhibited cell migration in vitro. In addition, phosphorylation of vimentin was increased, as well as remodeling of vimentin filaments. ENT treatment also reduced formation of tubulin-based microtentacles, which help floating cells attach to other surfaces. These findings suggest that ENT can reverse EMT and may reduce the formation of metastasis.
C1 [Shah, Preeti; Gau, Yael; Sabnis, Gauri] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore
RP Sabnis, G (通讯作者)，Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 685 W Baltimore St,HSF 1 580-1, Baltimore, MD 21201 USA.
EM gsabn001@umaryland.edu
OI Sabnis, Gauri/0000-0001-8703-9394
FU Susan G Komen for the Cure [KG10037]
FX This work was supported by Grants to G Sabnis (KG10037) from Susan G
   Komen for the Cure.
CR Barak V, 2004, CLIN BIOCHEM, V37, P529, DOI 10.1016/j.clinbiochem.2004.05.009
   Baranwal S, 2009, BIOCHEM BIOPH RES CO, V384, P6, DOI 10.1016/j.bbrc.2009.04.051
   Behrens J, 2000, ANN NY ACAD SCI, V910, P21
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Brady-West DC, 2011, ASIAN PAC J CANCER P, V12, P2139
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9
   Curigliano Giuseppe, 2011, Journal of the National Cancer Institute Monographs, P108, DOI 10.1093/jncimonographs/lgr038
   Eriksson JE, 2004, J CELL SCI, V117, P919, DOI 10.1242/jcs.00906
   Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4
   Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388
   Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320
   KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Matrone MA, 2010, ONCOGENE, V29, P3217, DOI 10.1038/onc.2010.68
   Mialhe A, 2001, CANCER RES, V61, P5024
   Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peris L, 2009, J CELL BIOL, V185, P1159, DOI 10.1083/jcb.200902142
   Sabnis G, 2009, CANCER RES, V69, P1416, DOI 10.1158/0008-5472.CAN-08-0857
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Sabnis GJ, 2005, CANCER RES, V65, P3903, DOI 10.1158/0008-5472.CAN-04-4092
   Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1
   Schech AJ, 2013, MOL CANCER THER, V12, P1356, DOI 10.1158/1535-7163.MCT-12-0304
   Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215
   Ungefroren H, 2011, INT J ONCOL, V38, P797, DOI 10.3892/ijo.2011.897
   van Horssen R, 2012, BREAST CANCER RES TR, V136, P365, DOI 10.1007/s10549-012-2261-8
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151
   Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509
   WEBSTER DR, 1987, P NATL ACAD SCI USA, V84, P9040, DOI 10.1073/pnas.84.24.9040
   Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589
   Whipple RA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3477
   Whipple RA, 2010, CANCER RES, V70, P8127, DOI 10.1158/0008-5472.CAN-09-4613
   Zou DH, 2009, J PATHOL, V218, P265, DOI 10.1002/path.2541
NR 40
TC 69
Z9 76
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2014
VL 143
IS 1
BP 99
EP 111
DI 10.1007/s10549-013-2784-7
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 284DE
UT WOS:000329295500010
PM 24305977
DA 2025-01-12
ER

PT J
AU Schwimmer, H
   Metzer, A
   Pilosof, Y
   Szyf, M
   Machnes, ZM
   Fares, F
   Harel, O
   Haim, A
AF Schwimmer, Hagit
   Metzer, Avishag
   Pilosof, Yonit
   Szyf, Moshe
   Machnes, Ziv M.
   Fares, Fuad
   Harel, Orna
   Haim, Abraham
TI Light at night and melatonin have opposite effects on breast cancer
   tumors in mice assessed by growth rates and global DNA methylation
SO CHRONOBIOLOGY INTERNATIONAL
LA English
DT Article
DE Breast cancer; epigenetic modifications; global methylation state; light
   at night; melatonin
ID CO-DISTRIBUTES; PINEAL-GLAND; AT-NIGHT; RISK; CARCINOGENESIS;
   TUMORIGENESIS; CONSEQUENCES; PROGRESSION; DISRUPTION; MECHANISMS
AB Light-at-night (LAN) is a worldwide problem co-distributed with breast cancer prevalence. We hypothesized that exposure to LAN is coincided with a decreased melatonin (MLT) secretion level, followed by epigenetic modifications and resulted in higher breast cancer tumors growth-rate. Accordingly, we studied the effect of LAN exposure and exogenous MLT on breast cancer tumors growth-rate. 4T1 cells were inoculated into BALB/c short day-acclimated mice, resulting in tumors growth. Growth rates were followed under various light exposures and global DNA methylations were measured. Results demonstrated the positive effect of LAN on tumors growth-rate, reversed by MLT through global DNA methylation.
C1 [Schwimmer, Hagit; Metzer, Avishag; Fares, Fuad; Harel, Orna; Haim, Abraham] Univ Haifa, Israeli Ctr Interdisciplinary Res Chronobiol, IL-31905 Haifa, Israel.
   [Pilosof, Yonit; Fares, Fuad; Haim, Abraham] Univ Haifa, Dept Human Biol, IL-31999 Haifa, Israel.
   [Szyf, Moshe; Machnes, Ziv M.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
C3 University of Haifa; University of Haifa; McGill University
RP Schwimmer, H (通讯作者)，Univ Haifa, Israeli Ctr Interdisciplinary Res Chronobiol, IL-31905 Haifa, Israel.
EM hagit.sch@gmail.com
FU University of Haifa
FX The authors declare no conflict of interests. Authors are thankful to
   the Research Authority, the University of Haifa, for their partial
   financial support.
CR AMA, 2012, AMA AD NEW PUBL HLTH
   [Anonymous], 2008, WORLD CANC REPORT
   Arendt J, 1995, J SLEEP RES, V4, P74, DOI 10.1111/j.1365-2869.1995.tb00232.x
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   Blask DE, 2011, J PINEAL RES, V51, P259, DOI 10.1111/j.1600-079X.2011.00888.x
   Blask DE, 2009, SLEEP MED REV, V13, P257, DOI 10.1016/j.smrv.2008.07.007
   Blask David E., 2002, Current Topics in Medicinal Chemistry, V2, P113, DOI 10.2174/1568026023394407
   Blask DE, 2005, CANCER RES, V65, P11174, DOI 10.1158/0008-5472.CAN-05-1945
   Brainard GC, 1997, J BIOL RHYTHM, V12, P537, DOI 10.1177/074873049701200608
   Cajochen C, 2005, J CLIN ENDOCR METAB, V90, P1311, DOI 10.1210/jc.2004-0957
   Conti A, 1996, J PINEAL RES, V20, P138, DOI 10.1111/j.1600-079X.1996.tb00249.x
   Cos S, 2006, CANCER LETT, V235, P266, DOI 10.1016/j.canlet.2005.04.025
   Erren TC, 2008, NATURWISSENSCHAFTEN, V95, P273, DOI 10.1007/s00114-007-0315-2
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Filipski E, 2004, CANCER RES, V64, P7879, DOI 10.1158/0008-5472.CAN-04-0674
   Haim A., 2010, Sleep Science, V3, P32
   Haim A, 2011, CHRONOBIOL INT, V28, P734, DOI 10.3109/07420528.2011.604591
   Haim A, 2011, CHRONOBIOL INT, V28, P379, DOI 10.3109/07420528.2011.566090
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Kloog I, 2008, CHRONOBIOL INT, V25, P65, DOI 10.1080/07420520801921572
   Kloog I, 2011, CHRONOBIOL INT, V28, P76, DOI 10.3109/07420528.2010.531490
   Kloog I, 2010, CANCER CAUSE CONTROL, V21, P2059, DOI 10.1007/s10552-010-9624-4
   Korkmaz A, 2008, J PINEAL RES, V44, P41, DOI 10.1111/j.1600-079X.2007.00509.x
   Nelson RJ, 1999, REPROD NUTR DEV, V39, P383, DOI 10.1051/rnd:19990310
   Portaluppi F, 2010, CHRONOBIOL INT, V27, P1911, DOI 10.3109/07420528.2010.516381
   Redondo P, 2000, BRIT J DERMATOL, V143, P741, DOI 10.1046/j.1365-2133.2000.03769.x
   Reiter RJ, 2002, NEUROENDOCRINOL LETT, V23, P9
   REITER RJ, 1969, NEUROENDOCRINOLOGY, V5, P219, DOI 10.1159/000121862
   Schernhammer ES, 2001, J NATL CANCER I, V93, P1563, DOI 10.1093/jnci/93.20.1563
   SHAH PN, 1984, CANCER RES, V44, P3403
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Srinivasan V, 2008, INTEGR CANCER THER, V7, P189, DOI 10.1177/1534735408322846
   Stevens RG, 2002, NEUROENDOCRINOL LETT, V23, P57
   Stevens RG, 2009, INT J EPIDEMIOL, V38, P963, DOI 10.1093/ije/dyp178
   SUBRAMANIAN A, 1991, ANTI-CANCER DRUG, V2, P297, DOI 10.1097/00001813-199106000-00013
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Verkasalo PK, 1999, BRIT J CANCER, V80, P1459, DOI 10.1038/sj.bjc.6690544
   Vijayalaxmi, 2002, J CLIN ONCOL, V20, P2575, DOI 10.1200/JCO.2002.11.004
   Zubidat AE, 2007, CHRONOBIOL INT, V24, P269, DOI 10.1080/07420520701284675
NR 42
TC 59
Z9 66
U1 0
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0742-0528
EI 1525-6073
J9 CHRONOBIOL INT
JI Chronobiol. Int.
PY 2014
VL 31
IS 1
BP 144
EP 150
DI 10.3109/07420528.2013.842925
PG 7
WC Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA 291JW
UT WOS:000329826000014
PM 24131150
DA 2025-01-12
ER

PT J
AU Pinto, R
   De Summa, S
   Pilato, B
   Tommasi, S
AF Pinto, R.
   De Summa, S.
   Pilato, B.
   Tommasi, S.
TI DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer:
   Epigenetic Changes, Players in Transcriptional and Post-Transcriptional
   Regulation in Hereditary Breast Cancer
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Basal-like breast cancer; BRCA1; hereditary breast cancer; methylation;
   miRNA; triple-negative breast cancer
ID ESTROGEN-RECEPTOR-ALPHA; BRCA1 PROMOTER METHYLATION; BLOOD-BASED
   MARKERS; FAMILIAL BREAST; SPORADIC BREAST; CIRCULATING MICRORNAS;
   TAMOXIFEN RESISTANCE; EXPRESSION ANALYSIS; GENE METHYLATION;
   DOWN-REGULATION
AB The genetic alterations associated with breast carcinogenesis are well known. On the contrary epigenetic alterations in hereditary breast cancer are a new field. Two epigenetic mechanisms have emerged as the most critical players in transcriptional regulation in breast cancer: the methylation of DNA and microRNA interference.
   In this review we will focus on recent findings on gene silencing caused by DNA methylation and microRNA to explore the potential role of these epigenetic changes in the understanding of hereditary breast cancer. Moreover we will describe the same alterations in basal-like breast cancer and in triple-negative breast cancer, since their phenotypes have similarities with BRCA1-mutated tumors. To underline the possibility that some epigenetic alterations could also be used as potential epigenetic biomarkers of drug sensitivity or resistance, we will discuss the more common therapies in hereditary breast cancer that could also be applied to breast cancer with basal-like or triple negative phenotypes.
C1 [Pinto, R.; De Summa, S.; Pilato, B.; Tommasi, S.] IRCCS Giovanni Paolo II, Mol Genet Lab, I-70124 Bari, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica
   Molecolare (IGM-CNR)
RP Tommasi, S (通讯作者)，IRCCS Giovanni Paolo II, Vle Orazio Flacco 65, I-70124 Bari, Italy.
EM s.tommasi@oncologico.bari.it
RI Pilato, Brunella/AAH-7365-2020; Tommasi, Stefania/J-6732-2012; De Summa,
   Simona/K-2582-2018
OI Tommasi, Stefania/0000-0002-2157-2978; De Summa,
   Simona/0000-0001-9607-3754; pilato, brunella/0000-0001-6067-3977
CR Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004
   Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Castilla MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047709
   Anker P, 2000, MEDICINA-BUENOS AIRE, V60, P699
   Antill YC, 2010, CANCER EPIDEM BIOMAR, V19, P265, DOI 10.1158/1055-9965.EPI-09-0359
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Cascione L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055910
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Catucci I, 2012, BREAST CANCER RES TR, V133, P805, DOI 10.1007/s10549-012-2011-y
   Catucci I, 2010, HUM MUTAT, V31, pE1052, DOI 10.1002/humu.21141
   Chang HG, 2005, J MOL MED, V83, P132, DOI 10.1007/s00109-004-0596-2
   Chen PS, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-90
   Chen Y, 2006, GENET TEST, V10, P281, DOI 10.1089/gte.2006.10.281
   Cittelly DM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-317
   Cortez MA, 2010, ADV CANCER RES, V108, P113, DOI [10.1016/S0065.230X(10)08001.2, 10.1016/B978-0-12-380888-2.00004-2]
   Dallol A, 2002, CANCER RES, V62, P5874
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Farazi TA, 2013, ADV EXP MED BIOL, V774, P1, DOI 10.1007/978-94-007-5590-1_1
   Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Friedman LM, 2009, MAMM GENOME, V20, P581, DOI 10.1007/s00335-009-9230-5
   Fumagalli C, 2012, BREAST CANCER RES TR, V134, P131, DOI 10.1007/s10549-011-1945-9
   Gal S, 2004, BRIT J CANCER, V90, P1211, DOI 10.1038/sj.bjc.6601609
   Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Guler G, 2007, CLIN CANCER RES, V13, P6115, DOI 10.1158/1078-0432.CCR-07-1282
   He YJ, 2013, EXP THER MED, V5, P813, DOI 10.3892/etm.2013.915
   Heneghan HM, 2010, ANN SURG, V251, P499, DOI 10.1097/SLA.0b013e3181cc939f
   Heyn H, 2011, INT J CANCER, V129, P2797, DOI 10.1002/ijc.25962
   HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230
   Honrado E, 2007, MODERN PATHOL, V20, P1298, DOI 10.1038/modpathol.3800969
   Ibragimova I, 2011, METHODS MOL BIOL, V780, P277, DOI 10.1007/978-1-61779-270-0_17
   Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Joosse SA, 2011, GENE CHROMOSOME CANC, V50, P71, DOI 10.1002/gcc.20833
   Kawai S, 2012, J CELL BIOL, V197, P201, DOI 10.1083/jcb.201110008
   King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251
   Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180
   Kong W., 2013, Oncogene
   Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Lee JS, 2010, CANCER BIOL THER, V9, P1017, DOI 10.4161/cbt.9.12.11804
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Matuschek C, 2010, EUR J MED RES, V15, P277
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Osin P, 2003, INT J SURG PATHOL, V11, P153, DOI 10.1177/106689690301100301
   Pang D, 2012, MED ONCOL, V29, P1561, DOI 10.1007/s12032-011-0100-0
   Pastrello C, 2010, CARCINOGENESIS, V31, P2124, DOI 10.1093/carcin/bgq184
   Pilato B, 2013, J HUM GENET, V58, P51, DOI 10.1038/jhg.2012.118
   Pinto R, 2013, J CELL PHYSIOL, V228, P1264, DOI 10.1002/jcp.24281
   Piovan C, 2012, MOL ONCOL, V6, P458, DOI 10.1016/j.molonc.2012.03.003
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487
   Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Rodríguez-González FG, 2011, BREAST CANCER RES TR, V127, P43, DOI 10.1007/s10549-010-0940-x
   Roth C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2766
   Ru Peng, 2011, Genes Cancer, V2, P720, DOI 10.1177/1947601911425832
   Sachdeva M, 2011, ONCOGENE, V30, P822, DOI 10.1038/onc.2010.463
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shen J, 2008, CARCINOGENESIS, V29, P1963, DOI 10.1093/carcin/bgn172
   Shen J, 2009, INT J CANCER, V124, P1178, DOI 10.1002/ijc.24008
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334
   Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002258
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Svoboda M, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-31
   Swift-Scanlan T, 2011, CANCER BIOL THER, V11, P853, DOI 10.4161/cbt.11.10.15177
   Tanic M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038847
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Thaler S, 2012, ONCOGENE, V31, P4912, DOI 10.1038/onc.2011.658
   Tjensvoll K, 2012, BIOMARKERS, V17, P463, DOI 10.3109/1354750X.2012.686061
   Toyama T, 2012, JPN J CLIN ONCOL, V42, P256, DOI 10.1093/jjco/hys001
   Trifa F, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0418-2
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876
   Van der Auwera I, 2010, BRIT J CANCER, V102, P276, DOI 10.1038/sj.bjc.6605472
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang C, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-58
   Wang HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034210
   Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128
   Wei J, 2012, TUMOR BIOL, V33, P413, DOI 10.1007/s13277-011-0234-x
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wu HC, 2011, EPIGENETICS-US, V6, P29, DOI 10.4161/epi.6.1.13393
   Wu Q, 2012, CLIN CHIM ACTA, V413, P1058, DOI 10.1016/j.cca.2012.02.016
   Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753
   Yang RX, 2010, BREAST CANCER RES TR, V121, P693, DOI 10.1007/s10549-009-0633-5
   Yao EL, 2011, MOL CELL, V41, P135, DOI 10.1016/j.molcel.2011.01.005
   Young SR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-86
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
NR 110
TC 20
Z9 21
U1 1
U2 27
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PD JAN
PY 2014
VL 14
IS 1
BP 45
EP 57
DI 10.2174/1566524013666131203101405
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 282QQ
UT WOS:000329187800005
PM 24295492
DA 2025-01-12
ER

PT J
AU Ferraro, A
   Kontos, CK
   Boni, T
   Bantounas, I
   Siakouli, D
   Kosmidou, V
   Vlassi, M
   Spyridakis, Y
   Tsipras, I
   Zografos, G
   Pintzas, A
AF Ferraro, Angelo
   Kontos, Christos K.
   Boni, Themis
   Bantounas, Ioannis
   Siakouli, Dimitra
   Kosmidou, Vivian
   Vlassi, Margarita
   Spyridakis, Yannis
   Tsipras, Iraklis
   Zografos, George
   Pintzas, Alexander
TI Epigenetic regulation of miR-21 in colorectal cancer ITGB4 as a novel
   miR-21 target and a three-gene network (miR-21-ITGB4-PDCD4) as predictor
   of metastatic tumor potential
SO EPIGENETICS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITIONS; II COLON-CANCER; MICRORNA
   EXPRESSION; CELL DIFFERENTIATION; GLIOBLASTOMA CELLS; PROGNOSTIC VALUE;
   CARCINOMA CELLS; BREAST-CANCER; RAS ONCOGENES; AP-1
C1 [Ferraro, Angelo; Kontos, Christos K.; Boni, Themis; Bantounas, Ioannis; Siakouli, Dimitra; Kosmidou, Vivian; Vlassi, Margarita; Pintzas, Alexander] Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Med Chem & Biotechnol, Athens, Greece.
   [Spyridakis, Yannis; Tsipras, Iraklis; Zografos, George] Gen Hosp Athens G Gennimatas, Dept Surg 3, Athens, Greece.
C3 National Hellenic Research Foundation
RP Pintzas, A (通讯作者)，Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Med Chem & Biotechnol, Athens, Greece.
EM apint@eie.gr
RI Ferraro, Angelo/H-3193-2019; Kontos, Christos/C-2757-2012; Ferraro,
   Angelo/A-4172-2014
OI Kontos, Christos/0000-0002-9935-8461; Ferraro,
   Angelo/0000-0002-2044-7569; Bantounas, Ioannis/0000-0001-7899-1068
FU EU FP7 Project [241783 EpiDiaCan]; GSRT
FX This study was funded by EU FP7 Project 241783 EpiDiaCan and support by
   GSRT to Pintzas A.
CR [Anonymous], 2004, SEER cancer statistic review. 1975-2001
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Beaulieu Jean-Francois, 2010, World J Gastrointest Pathophysiol, V1, P3, DOI 10.4291/wjgp.v1.i1.3
   Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1
   Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17
   Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069
   Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597
   Dydensborg AB, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-223
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   FALCIONI R, 1994, INT J ONCOL, V5, P573
   Fassan M, 2011, VIRCHOWS ARCH, V458, P413, DOI 10.1007/s00428-011-1046-5
   Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015
   Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08
   Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013
   Huang HY, 2006, NUCLEIC ACIDS RES, V34, pW429, DOI 10.1093/nar/gkl333
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kjaer-Frifeldt S, 2012, BRIT J CANCER, V107, P1169, DOI 10.1038/bjc.2012.365
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Leung CL, 2002, TRENDS CELL BIOL, V12, P37, DOI 10.1016/S0962-8924(01)02180-8
   Li XQ, 2010, BRIT J HAEMATOL, V148, P69, DOI 10.1111/j.1365-2141.2009.07920.x
   Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741
   Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900
   Mei Y, 2013, J CELL BIOCHEM, V114, P1374, DOI 10.1002/jcb.24479
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Nielsen BS, 2011, CLIN EXP METASTAS, V28, P27, DOI 10.1007/s10585-010-9355-7
   Nordlinger B, 2002, J CLIN ONCOL, V20, P1442, DOI 10.1200/JCO.2002.20.6.1442
   Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759
   Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305
   Peláez IM, 2010, INT J BIOCHEM CELL B, V42, P911, DOI 10.1016/j.biocel.2010.01.024
   Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769
   Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012
   Ribas J, 2012, NUCLEIC ACIDS RES, V40, P6821, DOI 10.1093/nar/gks308
   Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448
   Roberts ML, 2006, INT J CANCER, V118, P616, DOI 10.1002/ijc.21386
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Sayed D, 2010, J BIOL CHEM, V285, P20281, DOI 10.1074/jbc.M110.109207
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Shibuya H, 2010, ONCOLOGY-BASEL, V79, P313, DOI 10.1159/000323283
   Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A
   STALLMACH A, 1992, GUT, V33, P342, DOI 10.1136/gut.33.3.342
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076
   Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370
   Teller I C, 2001, Expert Rev Mol Med, V3, P1, DOI 10.1017/S1462399401003623
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406
   Vaiopoulos AG, 2010, INT J BIOCHEM CELL B, V42, P1061, DOI 10.1016/j.biocel.2010.03.018
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang N, 2008, INT J CANCER, V122, P963, DOI 10.1002/ijc.23325
   Yu PT, 2012, INT J CANCER, V131, P1744, DOI 10.1002/ijc.27447
   Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105
   Zhang ZH, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-155
NR 67
TC 90
Z9 95
U1 0
U2 8
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JAN 1
PY 2014
VL 9
IS 1
SI SI
BP 129
EP 141
DI 10.4161/epi.26842
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AA8WC
UT WOS:000331374700015
PM 24149370
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Moutinho, C
   Martinez-Cardús, A
   Santos, C
   Navarro-Pérez, V
   Martínez-Balibrea, E
   Musulen, E
   Carmona, FJ
   Sartore-Bianchi, A
   Cassingena, A
   Siena, S
   Elez, E
   Tabernero, J
   Salazar, R
   Abad, A
   Esteller, M
AF Moutinho, Catia
   Martinez-Cardus, Anna
   Santos, Cristina
   Navarro-Perez, Valentin
   Martinez-Balibrea, Eva
   Musulen, Eva
   Javier Carmona, F.
   Sartore-Bianchi, Andrea
   Cassingena, Andrea
   Siena, Salvatore
   Elez, Elena
   Tabernero, Josep
   Salazar, Ramon
   Abad, Albert
   Esteller, Manel
TI Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to
   Oxaliplatin in Colorectal Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; PREDICTS SENSITIVITY;
   OVARIAN-CANCER; BREAST-CANCER; LUNG CANCERS; CHEMOTHERAPY; COLON;
   DETERMINANTS; EXPRESSION
AB Background A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause.
   Methods A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant colorectal cancer cells. The candidate gene SRBC was validated by single-locus DNA methylation and expression techniques. Transfection and short hairpin experiments were used to assess oxaliplatin sensitivity. Progression-free survival (PFS) and overall survival (OS) in metastasic colorectal cancer patients were explored with Kaplan-Meier and Cox regression analyses. All statistical tests were two-sided.
   Results We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene. SRBC overexpression or depletion gives rise to sensitivity or resistance to oxaliplatin, respectively. SRBC epigenetic inactivation occurred in primary tumors from a discovery cohort of colorectal cancer patients (29.8%; n = 39 of 131), where it predicted shorter PFS (hazard ratio [HR] = 1.83; 95% confidence interval [CI] = 1.15 to 2.92; log-rank P = .01), particularly in oxaliplatin-treated case subjects for which metastasis surgery was not indicated (HR = 1.96; 95% CI = 1.13 to 3.40; log-rank P = .01). In a validation cohort of unresectable colorectal tumors treated with oxaliplatin (n = 58), SRBC hypermethylation was also associated with shorter PFS (HR = 1.90; 95% CI = 1.01 to 3.60; log-rank P = .045).
   Conclusions These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.
C1 [Moutinho, Catia; Martinez-Cardus, Anna; Javier Carmona, F.; Esteller, Manel] Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program, Barcelona, Spain.
   [Martinez-Cardus, Anna; Martinez-Balibrea, Eva; Abad, Albert] Germans Trias & Pujol Fdn, Med Oncol Serv, Catalan Inst Oncol, Hlth Sci Res Inst, Barcelona, Spain.
   [Santos, Cristina; Salazar, Ramon] Bellvitge Biomed Res Inst, Dept Med Oncol, Catalan Inst Oncol, Barcelona, Spain.
   [Navarro-Perez, Valentin] Bellvitge Biomed Res Inst, Clin Informat Unit, Catalan Inst Oncol, Barcelona, Spain.
   [Musulen, Eva] Germans Trias & Pujol Fdn, Dept Pathol, Barcelona, Spain.
   [Sartore-Bianchi, Andrea; Cassingena, Andrea; Siena, Salvatore] Osped Niguarda Ca Granda, Dept Hematol & Oncol, Milan, Italy.
   [Elez, Elena; Tabernero, Josep] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.
   [Esteller, Manel] Univ Barcelona, Dept Physiol Sci 2, Sch Med, Barcelona, Spain.
   [Esteller, Manel] ICREA, Barcelona, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut
   Catala d'Oncologia; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Institut Catala d'Oncologia; Institut Catala d'Oncologia;
   Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Ospedale
   Niguarda Ca' Granda; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia
   (VHIO); University of Barcelona; ICREA
RP Esteller, M (通讯作者)，Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, 3rd Fl,Av Gran Via Hospitalet 199-203, Barcelona 08908, Catalonia, Spain.
EM mesteller@idibell.cat
RI Martinez-Balibrea, Eva/HHS-5710-2022; Cassingena, Andrea/AGD-7137-2022;
   Tabernero, Josep/AAG-5026-2019; Musulen, Eva/AAI-9169-2020;
   Sartore-Bianchi, Andrea/AAB-9848-2019; Élez, Elena/AAH-2945-2019; SIENA,
   SALVATORE/AAC-5806-2019; Martinez, Anna/AAA-4939-2020; Moutinho,
   Cátia/ABS-8506-2022; Esteller, Manel/L-5956-2014
OI Elez, Elena/0000-0002-4653-6324; Cassingena, Andrea/0000-0003-4116-3992;
   Esteller, Manel/0000-0003-4490-6093; Martinez Cardus,
   Anna/0000-0002-3937-8794; Musulen, Eva/0000-0002-9667-6464;
   Martinez-Balibrea, Eva/0000-0002-4501-7100; Carmona Sanz, F
   Javier/0000-0001-7904-8493; Moutinho, Catia/0000-0003-3885-0847; SIENA,
   SALVATORE/0000-0002-2681-2846; Sartore-Bianchi,
   Andrea/0000-0003-0780-0409; Tabernero, Josep/0000-0002-2495-8139
FU European Community [HEALTH-F2-2011-259015-COLTHERES,
   HEALTH-F5-2010-258236-SYSCOL]; Cellex Foundation; Botin Foundation;
   Fundacion Olga Torres; Institute of Health Carlos III (ISCIII) under the
   Spanish Cancer Research Network (RTICC) [RD12/0036/0039]; Health and
   Science Departments of the Catalan Government (Generalitat de
   Catalunya); ICREA Funding Source: Custom
FX This work was supported by the European Community's Seventh Framework
   Programme (FP7/2007-2013) under grant agreements
   HEALTH-F2-2011-259015-COLTHERES project and HEALTH-F5-2010-258236-SYSCOL
   project; the Cellex Foundation; the Botin Foundation; the Fundacion Olga
   Torres; the Institute of Health Carlos III (ISCIII) under the Spanish
   Cancer Research Network (RTICC) RD12/0036/0039; and the Health and
   Science Departments of the Catalan Government (Generalitat de
   Catalunya). M. Esteller is an ICREA Research Professor.
CR Arnould S, 2003, EUR J CANCER, V39, P112, DOI 10.1016/S0959-8049(02)00411-2
   Atipairin A, 2011, BREAST CANCER RES TR, V126, P203, DOI 10.1007/s10549-010-1182-7
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Compton CC, 2004, CA-CANCER J CLIN, V54, P295, DOI 10.3322/canjclin.54.6.295
   Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fedier A, 2003, INT J ONCOL, V22, P1169
   Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Jemal A, 2012, LANCET, V380, P1797, DOI 10.1016/S0140-6736(12)61688-2
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Lee JH, 2011, CLIN CANCER RES, V17, P7551, DOI 10.1158/1078-0432.CCR-11-1026
   Martinez-Cardús A, 2009, MOL CANCER THER, V8, P194, DOI 10.1158/1535-7163.MCT-08-0659
   McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   Pang SK, 2008, ONCOL REP, V20, P1269, DOI 10.3892/or_00000140
   Park YJ, 2011, PROG DRUG RES, V67, P25, DOI 10.1007/978-3-7643-8989-5_2
   Peeters M, 2013, J CLIN ONCOL, V31, P759, DOI 10.1200/JCO.2012.45.1492
   Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006
   Raymond E, 2002, MOL CANCER THER, V1, P227
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Turner NC, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3332
   Wang YQ, 2013, J OBSTET GYNAECOL RE, V39, P549, DOI 10.1111/j.1447-0756.2012.01979.x
   Weller M, 2012, NEURO-ONCOLOGY, V14, P100, DOI 10.1093/neuonc/nos206
   Xu XL, 2001, CANCER RES, V61, P7943
   Xu Y, 2013, ANN ONCOL, V24, P1498, DOI 10.1093/annonc/mdt011
   Zöchbauer-Müller S, 2005, ONCOGENE, V24, P6249, DOI 10.1038/sj.onc.1208775
NR 33
TC 67
Z9 71
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JAN
PY 2014
VL 106
IS 1
AR djt322
DI 10.1093/jnci/djt322
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB6IV
UT WOS:000331891900013
PM 24273214
OA Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Lin, YC
   Lee, YC
   Li, LH
   Cheng, CJ
   Yang, RB
AF Lin, Yuh-Charn
   Lee, Yi-Ching
   Li, Ling-Hui
   Cheng, Chien-Jui
   Yang, Ruey-Bing
TI Tumor suppressor <i>SCUBE2</i> inhibits breast-cancer cell migration and
   invasion through the reversal of epithelial-mesenchymal transition
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE Breast cancer; Tumor suppressor; Epithelial-mesenchymal transition;
   Epigenetic regulation; DNA hypermethylation; DNA methyltransferase
ID E-CADHERIN EXPRESSION; LONG-RANGE REGULATION; GENE-EXPRESSION; SURFACE
   GLYCOPROTEIN; FOXA1 EXPRESSION; CPG METHYLATION; PROTEIN; TRANSCRIPTION;
   CARCINOMA; ZEBRAFISH
AB Signal peptide-CUB-EGF domain-containing protein 2 (SCUBE2) belongs to a secreted and membrane-associated multi-domain SCUBE protein family. We previously demonstrated that SCUBE2 is a novel breast-tumor suppressor and could be a useful prognostic marker. However, the role of SCUBE2 in breast-cancer cell migration and invasion and how it is regulated during the epithelial-mesenchymal transition (EMT) remain undefined. In this study, we showed that ectopic SCUBE2 overexpression could enhance the formation of E-cadherin-containing adherens junctions by beta-catenin-SOX-mediated induction of forkhead box A1 (a positive regulator of E-cadherin) and upregulation of E-cadherin, which in turn led to epithelial transition and inhibited migration and invasion of aggressive MDA-MB-231 breast-carcinoma cells. SCUBE2 expression was repressed together with that of E-cadherin in TGF-beta-induced EMT; direct expression of SCUBE2 alone was sufficient to inhibit the TGF-beta-induced EMT. Furthermore, quantitative DNA methylation, methylation-specific PCR, and chromatin immunoprecipitation analyses revealed that SCUBE2 expression was inactivated by DNA hypermethylation at the CpG islands by recruiting and binding DNA methyltransferase 1 during TGF-beta-induced EMT. Together, our results suggest that SCUBE2 plays a key role in suppressing breast-carcinoma-cell mobility and invasiveness by increasing the formation of the epithelial E-cadherin-containing adherens junctions to promote epithelial differentiation and drive the reversal of EMT.
C1 [Lin, Yuh-Charn; Yang, Ruey-Bing] Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.
   [Lin, Yuh-Charn; Li, Ling-Hui; Yang, Ruey-Bing] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
   [Lee, Yi-Ching] Natl Tsing Hua Univ, Inst Mol Med, Hsinchu 300, Taiwan.
   [Lee, Yi-Ching] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
   [Cheng, Chien-Jui] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei 110, Taiwan.
   [Cheng, Chien-Jui] Taipei Med Univ Hosp, Dept Pathol, Taipei 110, Taiwan.
   [Yang, Ruey-Bing] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan.
C3 National Defense Medical Center; Academia Sinica - Taiwan; National
   Tsing Hua University; Academia Sinica - Taiwan; Taipei Medical
   University; Taipei Medical University Hospital; Taipei Medical
   University; National Yang Ming Chiao Tung University
RP Yang, RB (通讯作者)，Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan.
EM rbyang@ibms.sinica.edu.tw
RI Lin, Yuh-Charn/P-2520-2018; Li, Ling-Hui/AAR-7444-2021; Lee,
   Yi-Ching/AAE-6900-2022; Yang, Ruey-Bing/O-1494-2018
OI Lee, Yi-Ching/0000-0002-7734-5619; Yang, Ruey-Bing/0000-0003-3017-3714;
   Lin, Yuh-Charn/0000-0002-8501-4596
FU Taiwan National Science Council [NSC 101-2325-B-001-030,
   102-2325-B-001-028, 102-2320-B-001-015-MY3, NSC 100-2320-B-038-029];
   National Core Facility Program for Biotechnology, National Science
   Council, Taiwan [NSC 101-2319-B-001-001, 102-2319-B-001-001]
FX This work was supported by the Taiwan National Science Council [grant
   numbers NSC 101-2325-B-001-030, 102-2325-B-001-028,
   102-2320-B-001-015-MY3 to R.B.Y., and NSC 100-2320-B-038-029 to C.J.C.].
   The National Center for Genome Medicine at Academia Sinica, Taiwan is
   supported by grants from the National Core Facility Program for
   Biotechnology, National Science Council, Taiwan [grant numbers NSC
   101-2319-B-001-001 and 102-2319-B-001-001].
CR Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122
   Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cheng CJ, 2009, CANCER RES, V69, P3634, DOI 10.1158/0008-5472.CAN-08-3615
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933
   Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050
   Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Grimmond S, 2000, GENOMICS, V70, P74, DOI 10.1006/geno.2000.6370
   Grimmond S, 2001, MECH DEVELOP, V102, P209, DOI 10.1016/S0925-4773(00)00586-4
   Hisamatsu Y, 2012, ANN SURG ONCOL, V19, P1145, DOI 10.1245/s10434-011-2094-4
   Hollway GE, 2006, DEV BIOL, V294, P104, DOI 10.1016/j.ydbio.2006.02.032
   Kawakami A, 2005, CURR BIOL, V15, P480, DOI 10.1016/j.cub.2005.02.018
   Kim C, 2010, NAT REV CLIN ONCOL, V7, P340, DOI 10.1038/nrclinonc.2010.61
   Kim SK, 2008, CARCINOGENESIS, V29, P1623, DOI 10.1093/carcin/bgn110
   Koizume S, 2002, NUCLEIC ACIDS RES, V30, P4770, DOI 10.1093/nar/gkf593
   Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046
   Lin YC, 2011, J BIOL CHEM, V286, P27039, DOI 10.1074/jbc.M111.244418
   Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991
   Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668
   MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623
   Medvedeva YA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-48
   Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176
   Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06
   Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979
   Sparano JA, 2008, J CLIN ONCOL, V26, P721, DOI 10.1200/JCO.2008.16.7528
   Strumane K, 2004, HANDB EXP PHARM, V165, P69, DOI 10.1007/978-3-540-68170-0_4
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274
   Tsai MT, 2009, BIOCHEM J, V422, P119, DOI 10.1042/BJ20090341
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M
   Wang GY, 2008, LUNG CANCER, V62, P162, DOI 10.1016/j.lungcan.2008.03.023
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Woods IG, 2005, PLOS BIOL, V3, P476, DOI 10.1371/journal.pbio.0030066
   Wu BT, 2004, J BIOL CHEM, V279, P37485, DOI 10.1074/jbc.M405912200
   Yang RB, 2002, J BIOL CHEM, V277, P46364, DOI 10.1074/jbc.M207410200
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zajchowski DA, 2001, CANCER RES, V61, P5168
NR 49
TC 56
Z9 62
U1 0
U2 12
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD JAN 1
PY 2014
VL 127
IS 1
BP 85
EP 100
DI 10.1242/jcs.132779
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 281SY
UT WOS:000329122500010
PM 24213532
OA Bronze
DA 2025-01-12
ER

PT J
AU Boidot, R
   Végran, F
   Lizard-Nacol, S
AF Boidot, Romain
   Vegran, Frederique
   Lizard-Nacol, Sarab
TI Transcriptional regulation of the <i>survivin</i> gene
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Transcription factors; Genetic alterations; Signalling pathways;
   survivin gene; Transcription regulation
ID INHIBITOR-INDUCED APOPTOSIS; BREAST-CANCER CELLS; WILD-TYPE P53;
   NF-KAPPA-B; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; MULTIPLE-MYELOMA CELLS;
   GROWTH-FACTOR RECEPTOR; NORMAL CORD BLOOD; UP-REGULATION;
   DOWN-REGULATION
AB Survivin, a small member of the inhibitors of the apoptosis protein family, is highly deregulated in cancer. It is weakly expressed in normal tissues but very strongly expressed in malignant lesions. Survivin is involved in cell-cycle progression, especially in the G2/M transition, and has anti-apoptotic activity, which correlates with its strong expression in cases with a poor cancer treatment response and poor outcomes. Several therapies that target the survivin transcript or protein are currently being tested in clinical trials. However, focusing new therapies on the origins of survivin overexpression and targeting these upstream deregulations could be more effective. For this reason, it seems important to make an inventory of the transcriptional (de)regulation of survivin. This review will gather the important points concerning the regulation of survivin mRNA expression: structure of the survivin promoter, epigenetic modifications and genetic abnormalities, transcription factors, and signalling pathways that affect survivin mRNA expression.
C1 [Boidot, Romain; Vegran, Frederique; Lizard-Nacol, Sarab] Ctr Georges Francois Leclerc, Mol Biol Unit, F-21079 Dijon, France.
   [Vegran, Frederique] Fac Med, Equipe AVENIR, INSERM, U866, Dijon, France.
C3 UNICANCER; Centre Georges-Francois Leclerc; Universite de Bourgogne;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut Agro; AgroSup Dijon
RP Boidot, R (通讯作者)，Ctr Georges Francois Leclerc, Mol Biol Unit, 1 Rue Prof Marion, F-21079 Dijon, France.
EM rboidot@cgfl.fr
RI VEGRAN, Frederique/O-9986-2018
OI VEGRAN, Frederique/0000-0002-4377-1441
FU Ligue contre le Cancer de Cote d'Or and Ligue contre le Cancer de
   l'Yonne; Ligue nationale contre le Cancer
FX We thank Philip Bastable (CHU Le Bocage, Dijon, France) for editing the
   manuscript. RB was financially supported by the Ligue contre le Cancer
   de Cote d'Or and Ligue contre le Cancer de l'Yonne and FV was granted by
   the Ligue nationale contre le Cancer.
CR Ahn KS, 2007, J BIOL CHEM, V282, P809, DOI 10.1074/jbc.M610028200
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491
   Athanassiadou P, 2008, PATHOL RES PRACT, V204, P241, DOI 10.1016/j.prp.2007.11.004
   Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988
   Boidot R, 2010, ONCOGENE, V29, P2577, DOI 10.1038/onc.2009.525
   Boidot R, 2008, GENE CHROMOSOME CANC, V47, P299, DOI 10.1002/gcc.20533
   Cao J, 2006, SURG ONCOL, V15, P223, DOI 10.1016/j.suronc.2007.01.006
   Cao J, 2007, WORLD J GASTROENTERO, V13, P1018, DOI 10.3748/wjg.v13.i7.1018
   Carter BZ, 2006, BLOOD, V107, P1555, DOI 10.1182/blood-2004-12-4704
   Chen MS, 2007, J CELL SCI, V120, P468, DOI 10.1242/jcs.03348
   Chen YQ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-29
   Cosgrave N, 2006, J MOL ENDOCRINOL, V37, P377, DOI 10.1677/jme.1.02118
   Dalwadi H, 2005, CLIN CANCER RES, V11, P7674, DOI 10.1158/1078-0432.CCR-05-1205
   Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171
   Di Stefano AB, 2010, J CELL PHYSIOL, V225, P555, DOI 10.1002/jcp.22238
   Erkanli S, 2007, GYNECOL ONCOL, V104, P320, DOI 10.1016/j.ygyno.2006.08.044
   Estève PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200
   Fang ZH, 2009, J CELL MOL MED, V13, P2039, DOI 10.1111/j.1582-4934.2008.00549.x
   Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833
   Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463
   Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091
   Glaros TG, 2012, CANCER CHEMOTH PHARM, V70, P207, DOI 10.1007/s00280-012-1868-0
   Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752
   Gu LB, 2007, EXP HEMATOL, V35, P957, DOI 10.1016/j.exphem.2007.03.007
   Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2
   Hino R, 2008, CANCER RES, V68, P1427, DOI 10.1158/0008-5472.CAN-07-3027
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   Jacob NK, 2012, ONCOTARGETS THER, V5, DOI 10.2147/OTT.S28147
   Jiang HP, 2008, BIOCHEM BIOPH RES CO, V368, P1, DOI 10.1016/j.bbrc.2007.04.004
   Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200
   Kaneko R, 2007, J BIOL CHEM, V282, P19273, DOI 10.1074/jbc.M610350200
   Kumar P, 2007, CANCER RES, V67, P1193, DOI 10.1158/0008-5472.CAN-06-2265
   Lee CW, 2008, CANCER RES, V68, P5273, DOI 10.1158/0008-5472.CAN-07-6673
   Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395
   Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141
   Li Y, 2006, ONCOGENE, V25, P3296, DOI 10.1038/sj.onc.1209363
   Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008-5472.CAN-07-2295
   Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433
   Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241
   Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353
   Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664
   Mori F, 2007, HISTOL HISTOPATHOL, V22, P61, DOI 10.14670/HH-22.61
   Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343
   Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699
   Otaki M, 2000, BBA-GENE STRUCT EXPR, V1493, P188, DOI 10.1016/S0167-4781(00)00142-1
   Papanikolaou V, 2011, J CELL MOL MED, V15, P1542, DOI 10.1111/j.1582-4934.2010.01149.x
   Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200
   Punga T, 2003, FEBS LETT, V552, P214, DOI 10.1016/S0014-5793(03)00927-X
   Quillard T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008244
   Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200
   Scheper MA, 2007, INT J ORAL MAX SURG, V36, P632, DOI 10.1016/j.ijom.2007.04.003
   Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323
   Sethi G, 2007, J IMMUNOL, V179, P1926, DOI 10.4049/jimmunol.179.3.1926
   Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509
   Tajiri T, 2001, CANCER LETT, V166, P89, DOI 10.1016/S0304-3835(01)00434-7
   Takezawa K, 2011, CLIN CANCER RES, V17, P2140, DOI 10.1158/1078-0432.CCR-10-2798
   Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103
   Vaira V, 2007, ONCOGENE, V26, P2678, DOI 10.1038/sj.onc.1210094
   Végran F, 2007, ONCOGENE, V26, P290, DOI 10.1038/sj.onc.1209784
   Vegran F, 2005, INT J ONCOL, V27, P1151
   Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487
   Wagner M, 2008, LEUKEMIA RES, V32, P1054, DOI 10.1016/j.leukres.2007.11.013
   Xu R, 2007, BIOCHEM BIOPH RES CO, V356, P286, DOI 10.1016/j.bbrc.2007.02.140
   Xu Y, 2004, DNA CELL BIOL, V23, P527, DOI 10.1089/dna.2004.23.527
   Yang XY, 2009, DIS ESOPHAGUS, V22, P223, DOI 10.1111/j.1442-2050.2008.00885.x
   Zhang T, 2001, CANCER RES, V61, P8664
   Zhu NX, 2006, J BIOL CHEM, V281, P14711, DOI 10.1074/jbc.M513810200
   Zu XY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2843
NR 71
TC 59
Z9 71
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JAN
PY 2014
VL 41
IS 1
BP 233
EP 240
DI 10.1007/s11033-013-2856-0
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 281KP
UT WOS:000329100500027
PM 24197699
DA 2025-01-12
ER

PT J
AU Liu, C
   Srihari, S
   Cao, KAL
   Chenevix-Trench, G
   Simpson, PT
   Ragan, MA
   Khanna, KK
AF Liu, Chao
   Srihari, Sriganesh
   Cao, Kim-Anh Le
   Chenevix-Trench, Georgia
   Simpson, Peter T.
   Ragan, Mark A.
   Khanna, Kum Kum
TI A fine-scale dissection of the DNA double-strand break repair machinery
   and its implications for breast cancer therapy
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HOMOLOGOUS RECOMBINATION REPAIR; HOLLIDAY JUNCTION RESOLUTION;
   END-JOINING PATHWAYS; UBIQUITIN E3 LIGASE; POLY(ADP-RIBOSE) POLYMERASE;
   DAMAGE RESPONSE; MUTATIONAL PROCESSES; GENOMIC INSTABILITY; BINDING
   PROTEIN; PARP INHIBITOR
AB DNA-damage response machinery is crucial to maintain the genomic integrity of cells, by enabling effective repair of even highly lethal lesions such as DNA double-strand breaks (DSBs). Defects in specific genes acquired through mutations, copy-number alterations or epigenetic changes can alter the balance of these pathways, triggering cancerous potential in cells. Selective killing of cancer cells by sensitizing them to further DNA damage, especially by induction of DSBs, therefore requires careful modulation of DSB-repair pathways.
   Here, we review the latest knowledge on the two DSB-repair pathways, homologous recombination and non-homologous end joining in human, describing in detail the functions of their components and the key mechanisms contributing to the repair. Such an in-depth characterization of these pathways enables a more mechanistic understanding of how cells respond to therapies, and suggests molecules and processes that can be explored as potential therapeutic targets. One such avenue that has shown immense promise is via the exploitation of synthetic lethal relationships, for which the BRCA1-PARP1 relationship is particularly notable. Here, we describe how this relationship functions and the manner in which cancer cells acquire therapy resistance by restoring their DSB repair potential.
C1 [Liu, Chao; Srihari, Sriganesh; Cao, Kim-Anh Le; Ragan, Mark A.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
   [Cao, Kim-Anh Le] Univ Queensland, Queensland Facil Adv Bioinformat, St Lucia, Qld 4072, Australia.
   [Chenevix-Trench, Georgia; Khanna, Kum Kum] QIMR Berghofer Med Res Inst, Brisbane, Qld 4029, Australia.
   [Simpson, Peter T.] Univ Queensland, Clin Res Ctr, Brisbane, Qld 4029, Australia.
C3 University of Queensland; University of Queensland; QIMR Berghofer
   Medical Research Institute; University of Queensland
RP Khanna, KK (通讯作者)，QIMR Berghofer Med Res Inst, Brisbane, Qld 4029, Australia.
EM m.ragan@uq.edu.au; kumkum.khanna@qimrberghofer.edu.au
RI Khanna, Kum/I-1747-2013; Chenevix-Trench, Georgia/AAV-2014-2020;
   Srihari, Sriganesh/H-1740-2013; Simpson, Peter/F-1225-2010; Le Cao,
   Kim-Anh/B-6637-2013; Ragan, Mark/A-9825-2014
OI Khanna, Kum Kum/0000-0001-8650-5381; Srihari,
   Sriganesh/0000-0002-0713-6723; Simpson, Peter/0000-0002-4816-8289; Le
   Cao, Kim-Anh/0000-0003-3923-1116; Ragan, Mark/0000-0003-1672-7020;
   Chenevix-Trench, Georgia/0000-0002-1878-2587
FU National Health and Medical Research Council (NHMRC) [1024612, 613638,
   1028742]; National Breast Cancer Foundation Fellowship, Australia
   [ECF-10-12]; National Health and Medical Research Council of Australia
   [613638] Funding Source: NHMRC
FX National Health and Medical Research Council (NHMRC) Senior Principal
   Research Fellowships [1024612 to G. C. T. and 613638 to K. K. K.];
   National Breast Cancer Foundation Fellowship, Australia [ECF-10-12 to P.
   T. S.]; NHMRC Project Grant [1028742 to P. T. S. and M.A.R.].
CR Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401
   Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026
   Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321
   Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164
   Al-Ejeh F, 2010, ONCOGENE, V29, P6085, DOI 10.1038/onc.2010.407
   Al-Minawi AZ, 2008, NUCLEIC ACIDS RES, V36, P1, DOI 10.1093/nar/gkm888
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Alt FW, 2013, CELL, V152, P417, DOI 10.1016/j.cell.2013.01.007
   Altmeyer M, 2013, CURR OPIN GENET DEV, V23, P156, DOI 10.1016/j.gde.2012.11.001
   [Anonymous], SEER Cancer Statistics Review, 1975-2017
   Bachrati CZ, 2006, NUCLEIC ACIDS RES, V34, P2269, DOI 10.1093/nar/gkl258
   Bacquin A, 2013, NUCLEIC ACIDS RES, V41, P6501, DOI 10.1093/nar/gkt397
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Bao YH, 2011, EPIGENOMICS-UK, V3, P307, DOI [10.2217/EPI.11.14, 10.2217/epi.11.14]
   Barabási AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Barber LJ, 2008, CELL, V135, P261, DOI 10.1016/j.cell.2008.08.016
   Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268
   Bartocci Cristina, 2013, Frontiers in Genetics, V4, P128, DOI 10.3389/fgene.2013.00128
   Bekker-Jensen S, 2010, NAT CELL BIOL, V12, P80, DOI 10.1038/ncb2008
   Bennetzen MV, 2013, CELL CYCLE, V12, P1688, DOI 10.4161/cc.24758
   Bennetzen MV, 2010, MOL CELL PROTEOMICS, V9, P1314, DOI 10.1074/mcp.M900616-MCP200
   Bensimon A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001034
   Bernstein NK, 2005, MOL CELL, V17, P657, DOI 10.1016/j.molcel.2005.02.012
   Bhatti S, 2011, CELL MOL LIFE SCI, V68, P2977, DOI 10.1007/s00018-011-0683-9
   Blank M, 2012, NAT MED, V18, P227, DOI 10.1038/nm.2596
   Boboila C, 2012, ADV IMMUNOL, V116, P1, DOI 10.1016/B978-0-12-394300-2.00001-6
   Bolderson E, 2010, NUCLEIC ACIDS RES, V38, P1821, DOI 10.1093/nar/gkp1164
   Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096
   Bologna Serena, 2013, Frontiers in Genetics, V4, P106, DOI 10.3389/fgene.2013.00106
   Boone C, 2007, NAT REV GENET, V8, P437, DOI 10.1038/nrg2085
   Bothmer A, 2011, MOL CELL, V42, P319, DOI 10.1016/j.molcel.2011.03.019
   Bothmer A, 2010, J EXP MED, V207, P855, DOI 10.1084/jem.20100244
   Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043
   Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342
   Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831
   Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206
   Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012
   Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881
   Bussen W, 2007, J BIOL CHEM, V282, P31484, DOI 10.1074/jbc.M706116200
   Callen E, 2013, CELL, V153, P1266, DOI 10.1016/j.cell.2013.05.023
   Cerbinskaite A, 2012, CANCER TREAT REV, V38, P89, DOI 10.1016/j.ctrv.2011.04.015
   Chang JH, 2008, GENE DEV, V22, P1093, DOI 10.1101/gad.1618708
   Chapman JR, 2008, EMBO REP, V9, P795, DOI 10.1038/embor.2008.103
   Chapman JR, 2013, MOL CELL, V49, P858, DOI 10.1016/j.molcel.2013.01.002
   Chen LC, 2008, J BIOL CHEM, V283, P7713, DOI 10.1074/jbc.M710245200
   Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066
   Chen XQ, 2013, NUCLEIC ACIDS RES, V41, P9325, DOI 10.1093/nar/gkt672
   Cheng Q, 2011, NUCLEIC ACIDS RES, V39, P9605, DOI 10.1093/nar/gkr656
   Cheung-Ong K, 2013, CHEM BIOL, V20, P648, DOI 10.1016/j.chembiol.2013.04.007
   Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107
   Ciccia A, 2008, ANNU REV BIOCHEM, V77, P259, DOI 10.1146/annurev.biochem.77.070306.102408
   Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Cortizas EM, 2013, J IMMUNOL, V191, P5751, DOI 10.4049/jimmunol.1301300
   Curtin Nicola J., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S146239940500904X
   Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Danielsen JR, 2012, J CELL BIOL, V197, P179, DOI 10.1083/jcb.201106152
   Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02
   Della-Maria J, 2011, J BIOL CHEM, V286, P33845, DOI 10.1074/jbc.M111.274159
   deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303
   Drost R., 2013, ONCOGENE, V10, P1
   Drost R, 2011, CANCER CELL, V20, P797, DOI 10.1016/j.ccr.2011.11.014
   Dueva R, 2013, TRANSL CANCER RES, V2, P163, DOI 10.3978/j.issn.2218-676X.2013.05.02
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Escribano-Díaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evers B, 2010, TRENDS PHARMACOL SCI, V31, P372, DOI 10.1016/j.tips.2010.06.001
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fekairi S, 2009, CELL, V138, P78, DOI 10.1016/j.cell.2009.06.029
   Feng L, 2013, J BIOL CHEM, V288, P11135, DOI 10.1074/jbc.M113.457440
   Feng ZH, 2011, P NATL ACAD SCI USA, V108, P686, DOI 10.1073/pnas.1010959107
   Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255
   Fojo T, 2001, J NATL CANCER I, V93, P1434, DOI 10.1093/jnci/93.19.1434
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318
   French JD, 2013, AM J HUM GENET, V92, P489, DOI 10.1016/j.ajhg.2013.01.002
   Fugger K, 2009, J CELL BIOL, V186, P655, DOI 10.1083/jcb.200812138
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Galanty Y, 2012, GENE DEV, V26, P1179, DOI 10.1101/gad.188284.112
   Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657
   Garner E, 2013, CELL REP, V5, P207, DOI 10.1016/j.celrep.2013.08.041
   Geng LY, 2010, J CELL BIOL, V191, P249, DOI 10.1083/jcb.201005101
   Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994
   Gilljam KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049199
   Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10
   Goodarzi AA, 2012, INT J MOL SCI, V13, P11844, DOI 10.3390/ijms130911844
   Gottipati P, 2010, CANCER RES, V70, P5389, DOI 10.1158/0008-5472.CAN-09-4716
   Göttlich B, 1998, EUR J BIOCHEM, V258, P387, DOI 10.1046/j.1432-1327.1998.2580387.x
   Gottschalk AJ, 2009, P NATL ACAD SCI USA, V106, P13770, DOI 10.1073/pnas.0906920106
   Grabarz A, 2012, AM J CANCER RES, V2, P249
   Greenberg RA, 2006, GENE DEV, V20, P34, DOI 10.1101/gad.1381306
   Grimme JM, 2010, NUCLEIC ACIDS RES, V38, P2917, DOI 10.1093/nar/gkp1249
   Grotsky DA, 2013, J CELL BIOL, V200, P187, DOI 10.1083/jcb.201204053
   Grundy GJ, 2013, EMBO J, V32, P112, DOI 10.1038/emboj.2012.304
   Hahn MA, 2012, HUM MOL GENET, V21, P559, DOI 10.1093/hmg/ddr490
   Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harris JL, 2011, AGING-US, V3, P461, DOI 10.18632/aging.100334
   Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Holloman WK, 2011, NAT STRUCT MOL BIOL, V18, P748, DOI 10.1038/nsmb.2096
   Hu Y, 2007, GENE DEV, V21, P3073, DOI 10.1101/gad.1609107
   Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831
   Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200
   Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034
   Ismail IH, 2013, J BIOL CHEM, V288, P26944, DOI 10.1074/jbc.M113.461699
   Iwakawa R, 2013, GENE CHROMOSOME CANC, V52, P802, DOI 10.1002/gcc.22076
   Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049
   Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337
   Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155
   Johnson N, 2013, P NATL ACAD SCI USA, V110, P17041, DOI 10.1073/pnas.1305170110
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Kaidi A, 2013, NATURE, V498, DOI 10.1038/nature12201
   Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X
   Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798
   Khanna KK, 2004, J MAMMARY GLAND BIOL, V9, P247, DOI 10.1023/B:JOMG.0000048772.92326.a1
   Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621
   Kloosterman WP, 2011, HUM MOL GENET, V20, P1916, DOI 10.1093/hmg/ddr073
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koito A, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00028
   Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270
   KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491
   Lamarche BJ, 2010, FEBS LETT, V584, P3682, DOI 10.1016/j.febslet.2010.07.029
   Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106
   Lee-Theilen M, 2011, NAT STRUCT MOL BIOL, V18, P75, DOI 10.1038/nsmb.1942
   LI FP, 1988, CANCER RES, V48, P5358
   Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153
   Li SC, 2011, J BIOL CHEM, V286, P36368, DOI 10.1074/jbc.M111.287797
   Li YJ, 2009, J BIOL CHEM, V284, P23525, DOI 10.1074/jbc.C109.039586
   Liang L, 2008, NUCLEIC ACIDS RES, V36, P3297, DOI 10.1093/nar/gkn184
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131
   Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904
   Liu PF, 2012, CURR OPIN GENET DEV, V22, P211, DOI 10.1016/j.gde.2012.02.012
   Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760
   Luijsterburg MS, 2012, EMBO J, V31, P2511, DOI 10.1038/emboj.2012.104
   Luo KT, 2012, EMBO J, V31, P3008, DOI 10.1038/emboj.2012.158
   Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017
   Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2
   MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935
   Malhotra A, 2013, GENOME RES, V23, P762, DOI 10.1101/gr.143677.112
   Malivert L, 2010, J BIOL CHEM, V285, P26475, DOI 10.1074/jbc.M110.138156
   Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021
   Mansour WY, 2010, NUCLEIC ACIDS RES, V38, P6065, DOI 10.1093/nar/gkq387
   Marees T, 2008, J NATL CANCER I, V100, P1771, DOI 10.1093/jnci/djn394
   Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103
   Masciari S, 2012, BREAST CANCER RES TR, V133, P1125, DOI 10.1007/s10549-012-1993-9
   Matsumoto Y, 2001, PROG NUCLEIC ACID RE, V68, P129
   Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321
   Mazin AV, 2010, DNA REPAIR, V9, P286, DOI 10.1016/j.dnarep.2009.12.006
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000
   Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879
   Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mladenov E, 2011, MUTAT RES-FUND MOL M, V711, P61, DOI 10.1016/j.mrfmmm.2011.02.005
   Modesti M, 2007, MOL CELL, V28, P468, DOI 10.1016/j.molcel.2007.08.025
   Moldovan GL, 2012, MOL CELL, V45, P75, DOI 10.1016/j.molcel.2011.11.010
   Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593
   Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015
   Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753
   Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811
   Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980
   O'Connor KW, 2013, CANCER RES, V73, P2529, DOI 10.1158/0008-5472.CAN-12-3313
   O'Neil NJ, 2013, TRENDS GENET, V29, P290, DOI 10.1016/j.tig.2012.12.004
   Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277
   Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108
   Paul K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059505
   Perry JJP, 2006, NAT STRUCT MOL BIOL, V13, P414, DOI 10.1038/nsmb1088
   Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974
   Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311
   Povirk LF, 2007, J BIOL CHEM, V282, P3547, DOI 10.1074/jbc.M607745200
   Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011
   Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009
   Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959
   Rass E, 2009, NAT STRUCT MOL BIOL, V16, P819, DOI 10.1038/nsmb.1641
   Rass U, 2010, GENE DEV, V24, P1559, DOI 10.1101/gad.585310
   Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013
   Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717
   Richard DJ, 2008, NATURE, V453, P677, DOI 10.1038/nature06883
   Roberts SA, 2010, NATURE, V464, P1214, DOI 10.1038/nature08926
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Sandmann T, 2012, CURR OPIN GENET DEV, V22, P36, DOI 10.1016/j.gde.2012.02.001
   Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337
   Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902
   Sebesta M, 2013, DNA REPAIR, V12, P691, DOI 10.1016/j.dnarep.2013.05.001
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1
   Shibata A, 2014, MOL CELL, V53, P7, DOI 10.1016/j.molcel.2013.11.003
   Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546
   Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4
   Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516
   Soubeyrand S, 2006, J MOL BIOL, V358, P1200, DOI 10.1016/j.jmb.2006.02.061
   Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013
   Spycher C, 2008, J CELL BIOL, V181, P227, DOI 10.1083/jcb.200709008
   Srihari S., 2013, SYSTEMATIC TRACKING
   Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004
   Steger M, 2013, MOL CELL, V50, P333, DOI 10.1016/j.molcel.2013.03.023
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645
   Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047
   Ström CE, 2012, BIOMOLECULES, V2, P635, DOI 10.3390/biom2040635
   Su GC, 2014, NUCLEIC ACIDS RES, V42, P349, DOI 10.1093/nar/gkt879
   Sun YL, 2010, CELL CYCLE, V9, P930, DOI 10.4161/cc.9.5.10931
   Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982
   Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102
   Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556
   Suwaki N, 2011, SEMIN CELL DEV BIOL, V22, P898, DOI 10.1016/j.semcdb.2011.07.019
   SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101
   Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088
   Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106
   Symington LS, 2011, ANNU REV GENET, V45, P247, DOI 10.1146/annurev-genet-110410-132435
   Tang JB, 2013, NAT STRUCT MOL BIOL, V20, P317, DOI 10.1038/nsmb.2499
   Tavtigian SV, 2009, AM J HUM GENET, V85, P427, DOI 10.1016/j.ajhg.2009.08.018
   Tomimatsu N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4561
   Tomimatsu N, 2012, DNA REPAIR, V11, P441, DOI 10.1016/j.dnarep.2012.01.006
   Truong LN, 2013, P NATL ACAD SCI USA, V110, P7720, DOI 10.1073/pnas.1213431110
   Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1
   Uematsu N, 2007, J CELL BIOL, V177, P219, DOI 10.1083/jcb.200608077
   Ulrich HD, 2012, J CELL SCI, V125, P249, DOI 10.1242/jcs.091801
   Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9
   van Attikum H, 2009, TRENDS CELL BIOL, V19, P207, DOI 10.1016/j.tcb.2009.03.001
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000
   Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476
   Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055
   Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840
   Wang X, 2011, CELL DEATH DIFFER, V18, P5, DOI 10.1038/cdd.2010.106
   Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347
   Warmerdam DO, 2013, J CELL SCI, V126, P1923, DOI 10.1242/jcs.118265
   Wiese C, 2007, MOL CELL, V28, P482, DOI 10.1016/j.molcel.2007.08.027
   Wiesner T, 2012, J CLIN ONCOL, V30, pE337, DOI 10.1200/JCO.2011.41.2965
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Wyatt HDM, 2013, MOL CELL, V52, P234, DOI 10.1016/j.molcel.2013.08.035
   Xie AY, 2009, NAT STRUCT MOL BIOL, V16, P814, DOI 10.1038/nsmb.1640
   Xu DY, 2008, GENE DEV, V22, P2843, DOI 10.1101/gad.1708608
   Xu Y, 2012, MOL CELL, V48, P723, DOI 10.1016/j.molcel.2012.09.026
   Xu Y, 2010, J CELL BIOL, V191, P31, DOI 10.1083/jcb.201001160
   Yang J, 2010, J BIOL CHEM, V285, P21426, DOI 10.1074/jbc.M110.123216
   Yang LX, 2013, CELL, V153, P919, DOI 10.1016/j.cell.2013.04.010
   Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491
   Yin YL, 2012, GENE DEV, V26, P1196, DOI 10.1101/gad.189274.112
   Ying SM, 2012, CANCER RES, V72, P2814, DOI 10.1158/0008-5472.CAN-11-3417
   Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004
   Yuan JS, 2011, J BIOL CHEM, V286, P9888, DOI 10.1074/jbc.M110.207290
   Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897
   Zhang CZ, 2013, GENE DEV, V27, P2513, DOI 10.1101/gad.229559.113
   Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123
   Zhang Y, 2011, NAT STRUCT MOL BIOL, V18, P80, DOI 10.1038/nsmb.1940
   Zhao Y, 2014, TRENDS CELL BIOL, V24, P426, DOI 10.1016/j.tcb.2014.01.005
   Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200
   Zimmermann M, 2013, SCIENCE, V339, P700, DOI 10.1126/science.1231573
NR 261
TC 57
Z9 74
U1 0
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PY 2014
VL 42
IS 10
BP 6106
EP 6127
DI 10.1093/nar/gku284
PG 22
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AK9SW
UT WOS:000338768100009
PM 24792170
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Tomiyasu, H
   Goto-Koshino, Y
   Fujino, Y
   Ohno, K
   Tsujimoto, H
AF Tomiyasu, Hirotaka
   Goto-Koshino, Yuko
   Fujino, Yasuhito
   Ohno, Koichi
   Tsujimoto, Hajime
TI Epigenetic regulation of the <i>ABCB1</i> gene in drug-sensitive and
   drug-resistant lymphoid tumour cell lines obtained from canine patients
SO VETERINARY JOURNAL
LA English
DT Article
DE DNA methylation; Dog; Histone H3 acetylation; MDR1; Multidrug resistance
ID P-GLYCOPROTEIN EXPRESSION; BREAST-CANCER CELLS; PROMOTER REGION; MDR1
   PROMOTER; DOGS; HYPERMETHYLATION; HYPOMETHYLATION; CHEMORESISTANCE;
   OVEREXPRESSION; ESTABLISHMENT
AB Multidrug resistance (MDR) is a major obstacle in the treatment of cancer. Overexpression of P-glycoprotein (P-gp), encoded by the ABCB1 (MDR1) gene, is an important factor in determining the MDR phenotype of a tumour. Although recent studies have revealed the epigenetic transcriptional regulation of the human ABCB1 gene, such regulation of this gene has not been examined in dogs. The aim of the current study was to evaluate differences in epigenetic regulation of the ABCB1 gene, between drug-sensitive and drug-resistant canine lymphoid tumour cell lines.
   In two drug-sensitive cell lines, GL-1 and CLBL-1, ABCB1 mRNA expression was significantly lower than in two drug-resistant cell lines, UL-1 and Ema, using real-time quantitative polymerase chain reaction (QPCR). Bisulphite sequencing and real-time methylation-specific PCR revealed that the CpG island present in the upstream region of exon 2 was hypermethylated in GL-1 and CLBL-1, but hypomethylated in UL-1 and Ema. Chromatin immunoprecipitation and QPCR revealed that histone H3 acetylation in the same CpG island was significantly increased in UL-1 and Ema compared to GL-1 and CLBL-1. Treatment with 5-aza 2'-deoxycytidine or trichostatin A increased ABCB1 mRNA expression in GL-1 and CLBL-1. DNA methylation and histone H3 acetylation were shown to be involved in ABCB1 gene expression and associated with an MDR phenotype in these canine lymphoid tumour cell lines. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Tomiyasu, Hirotaka; Goto-Koshino, Yuko; Fujino, Yasuhito; Ohno, Koichi; Tsujimoto, Hajime] Univ Tokyo, Dept Vet Internal Med, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan.
C3 University of Tokyo
RP Tsujimoto, H (通讯作者)，Univ Tokyo, Dept Vet Internal Med, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan.
EM atsuji@mail.ecc.u-tokyo.ac.jp
RI Tsujimoto, Hisashi/A-5914-2016
OI Tsujimoto, Hajime/0000-0002-3771-6235; Tomiyasu,
   Hirotaka/0000-0001-7708-6218; Goto-Koshino, Yuko/0000-0002-5228-7125
FU Japan Society for the Promotion of Science [KAKENHI 23380182, 24658265];
   Grants-in-Aid for Scientific Research [24658265, 23380182, 10J40178]
   Funding Source: KAKEN
FX This study was supported by Japan Society for the Promotion of Science,
   KAKENHI 23380182 and 24658265. The authors are indebted to Dr. Barbara
   C. Rutgen (University of Veterinary Medicine Vienna, Austria) for
   providing the CLBL-1 cell line and to Dr. Takuya Mizuno (Yamaguchi
   University, Japan) for providing the Ema cell line.
CR Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Bergman PJ, 1996, J VET INTERN MED, V10, P354, DOI 10.1111/j.1939-1676.1996.tb02080.x
   Bergman PJ, 2003, VET CLIN N AM-SMALL, V33, P651, DOI 10.1016/S0195-5616(03)00004-4
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Chekhun VF, 2006, CANCER LETT, V231, P87, DOI 10.1016/j.canlet.2005.01.038
   Chen KG, 2005, CANCER RES, V65, P9388, DOI 10.1158/0008-5472.CAN-04-4133
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   Desiderato L, 1997, SOMAT CELL MOLEC GEN, V23, P391, DOI 10.1007/BF02673749
   Dobson JM, 2001, J SMALL ANIM PRACT, V42, P377, DOI 10.1111/j.1748-5827.2001.tb02485.x
   El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002
   Garrett LD, 2002, J VET INTERN MED, V16, P704, DOI 10.1111/j.1939-1676.2002.tb02411.x
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Hiraoka H, 2009, J VET MED SCI, V71, P769, DOI 10.1292/jvms.71.769
   Kantharidis P, 1997, CLIN CANCER RES, V3, P2025
   KELLER ET, 1993, J VET INTERN MED, V7, P289, DOI 10.1111/j.1939-1676.1993.tb01021.x
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Lee JJ, 1996, CANCER, V77, P1892, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U
   Lee TB, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-33
   Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411
   Marconato L, 2011, VET J, V188, P34, DOI 10.1016/j.tvjl.2010.04.027
   Matsuura S, 2007, AM J VET RES, V68, P95, DOI 10.2460/ajvr.68.1.95
   MOORE AS, 1995, CANCER INVEST, V13, P475, DOI 10.3109/07357909509024910
   Moore AS, 2001, J VET INTERN MED, V15, P348, DOI 10.1892/0891-6640(2001)015<0348:EOADTP>2.3.CO;2
   Nakaichi M, 1996, J VET MED SCI, V58, P469, DOI 10.1292/jvms.58.469
   Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307
   O'Connor R, 2007, ANTICANCER RES, V27, P1267
   Reed K, 2008, EPIGENETICS-US, V3, P270, DOI 10.4161/epi.3.5.6868
   Rütgen BC, 2010, LEUKEMIA RES, V34, P932, DOI 10.1016/j.leukres.2010.01.021
   Skolnik JM, 2006, CANCER CHEMOTH PHARM, V57, P458, DOI 10.1007/s00280-005-0065-9
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tada Y, 2000, CLIN CANCER RES, V6, P4618
   Tomiyasu H, 2013, LEUKEMIA LYMPHOMA, V54, P1309, DOI 10.3109/10428194.2012.751529
   Tomiyasu H, 2010, J VET MED SCI, V72, P1165, DOI 10.1292/jvms.09-0575
   Xiao JJ, 2005, J PHARMACOL EXP THER, V314, P467, DOI 10.1124/jpet.105.083956
   Yamazaki J, 2008, VET IMMUNOL IMMUNOP, V126, P321, DOI 10.1016/j.vetimm.2008.09.004
NR 36
TC 38
Z9 42
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090-0233
EI 1532-2971
J9 VET J
JI Vet. J.
PD JAN
PY 2014
VL 199
IS 1
BP 103
EP 109
DI 10.1016/j.tvjl.2013.10.022
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA AB3GR
UT WOS:000331679800020
PM 24332606
DA 2025-01-12
ER

PT J
AU Wu, L
   Wang, FL
   Xu, RB
   Zhang, SM
   Peng, XZ
   Feng, Y
   Wang, JM
   Lu, C
AF Wu, Liang
   Wang, Fengliang
   Xu, Ruobing
   Zhang, Simin
   Peng, Xianzhen
   Feng, Yan
   Wang, Jianming
   Lu, Cheng
TI Promoter methylation of <i>BRCA1</i> in the prognosis of breast cancer:
   a meta-analysis
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; BRCA1; Methylation; Prognosis; Survival; Meta-analysis
ID CELL-FREE DNA; PREDICTS SENSITIVITY; HYPERMETHYLATION; GENES; SERUM;
   INACTIVATION; CARCINOMAS; MORTALITY; REPAIR; TUMOR
AB The inactivation of BRCA1 by epigenetic alterations is a critical event in breast tumorigenesis, which may potentially be used as a prognostic marker for patients with breast cancer. The present study systematically reviewed the promoter methylation of BRCA1 and its relationship to the clinical outcomes of breast cancer patients. We performed a meta-analysis following the PRISMA guideline. Relevant articles were identified by searching PubMed, Web of Science and Embase database until August 2013. The pooled hazard ratio (HR) and 95 % confidence interval (CI) were applied to estimate the effect of BRCA1 methylation. Random or fixed effect model was chosen based on the heterogeneity analysis. A total of 3,205 patients from nine eligible studies were included in the meta-analysis. BRCA1 methylation was found to be significantly correlated with a poor overall survival of breast cancer, with the combined HR (95 % CI) of 2.02 (1.35-3.03). After adjusting for potential confounders using the Cox regression model, the pooled HR (95 % CI) of BRCA1 methylation on patients' overall survival was 1.38 (1.04-1.84). If we used the disease-free survival as the outcome, the combined HR (95 % CI) was 2.89 (1.73-4.83) for univariate analysis and 3.92 (95 % CI 1.49-10.32) for multivariate analysis, respectively. Subgroup analysis of specimen types revealed that the pooled HR (95 % CI) for overall survival was 1.48 (1.22-1.81) when using formalin-fixed paraffin-embedded (FFPE) specimen and 1.38 (0.16-11.84) when using fresh frozen tissues. As for the disease-free survival, the pooled HR (95 % CI) was 2.47 (1.33-4.58) when using FFPE specimen and 2.78 (1.47-5.28) when using fresh frozen tissues. As a conclusion, the present meta-analysis provides evidence that BRCA1 methylation is associated with a poor survival of breast cancer patients. Our findings underscore the clinical relevance of aberrant epigenetic alteration as a promising biomarker for the prognosis of human cancers.
C1 [Wu, Liang; Xu, Ruobing; Zhang, Simin; Peng, Xianzhen; Feng, Yan; Wang, Jianming] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
   [Wang, Fengliang; Lu, Cheng] Nanjing Med Univ, Dept Breast, Nanjing Matern & Child Hlth Hosp, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Wang, JM (通讯作者)，Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Jiangsu, Peoples R China.
EM jmwang@njmu.edu.cn; lucheng66@126.com
RI Wang, Jianming/HGA-5239-2022
OI Wang, Jianming/0000-0002-9151-284X; Lu, Cheng/0000-0002-0974-9697
FU National Natural Science Foundation of China [81172268, 81172501]; Key
   University Science Research Project of Jiangsu Province [12KJA330001];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD)
FX This study is supported by the National Natural Science Foundation of
   China (81172268, 81172501), Key University Science Research Project of
   Jiangsu Province (12KJA330001), and Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD).
CR Bax L, 2009, AM J EPIDEMIOL, V169, P249, DOI 10.1093/aje/kwn340
   Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460
   Ben Gacem R, 2012, CANCER EPIDEMIOL, V36, P190, DOI 10.1016/j.canep.2011.09.001
   Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518
   Chen YL, 2009, CANCER SCI, V100, P1663, DOI 10.1111/j.1349-7006.2009.01225.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N
   Dumitrescu Ramona G, 2012, Methods Mol Biol, V863, P3, DOI 10.1007/978-1-61779-612-8_1
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Hamilton MG, 2011, J NEURO-ONCOL, V102, P255, DOI 10.1007/s11060-010-0307-5
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsu NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056256
   Ignatiadis M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2906
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780
   Jing F, 2008, ONCOLOGY-BASEL, V75, P60, DOI 10.1159/000155145
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Karray-Chouayekh S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/369129
   Kennedy RD, 2002, LANCET, V360, P1007, DOI 10.1016/S0140-6736(02)11087-7
   Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c
   Kim DC, 2012, CANCER BIOMARK, V11, P75, DOI 10.3233/CBM-2012-0266
   Kohler C, 2011, ANTICANCER RES, V31, P2623
   Krasteva ME, 2012, NEOPLASMA, V59, P85, DOI 10.4149/neo_2012_011
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   MANTEL N, 1959, JNCI-J NATL CANCER I, V22, P719
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299]
   Mukherjee A, 2012, WOMENS HEALTH, V8, P99, DOI [10.2217/WHE.11.81, 10.2217/whe.11.81]
   Nasir A, 2009, MINERVA ENDOCRINOL, V34, P295
   Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607
   Ralhan R, 2007, CANCER LETT, V248, P1, DOI 10.1016/j.canlet.2006.06.004
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Toh Y, 2013, GEN THORAC CARDIOVAS, V61, P262, DOI 10.1007/s11748-013-0235-3
   Van de Voorde L, 2012, MUTAT RES-REV MUTAT, V751, P304, DOI 10.1016/j.mrrev.2012.06.001
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Xu Y, 2013, ANN ONCOL, V24, P1498, DOI 10.1093/annonc/mdt011
NR 46
TC 37
Z9 40
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2013
VL 142
IS 3
BP 619
EP 627
DI 10.1007/s10549-013-2774-9
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 269CP
UT WOS:000328218500015
PM 24258259
DA 2025-01-12
ER

PT J
AU Roll, JD
   Rivenbark, AG
   Sandhu, R
   Parker, JS
   Jones, WD
   Carey, LA
   Livasy, CA
   Coleman, WB
AF Roll, J. Devon
   Rivenbark, Ashley G.
   Sandhu, Rupninder
   Parker, Joel S.
   Jones, Wendell D.
   Carey, Lisa A.
   Livasy, Chad A.
   Coleman, William B.
TI Dysregulation of the epigenome in triple-negative breast cancers:
   Basal-like and claudin-low breast cancers express aberrant DNA
   hypermethylation
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article
DE Triple-negative breast cancer; Basal-like breast cancer; Claudin-low
   breast cancer; Aberrant DNA hypermethylation
ID ISLAND METHYLATOR PHENOTYPE; TUMOR-SUPPRESSOR GENES; MOLECULAR
   PORTRAITS; CELL-LINES; PREOPERATIVE CHEMOTHERAPY; PROMOTER
   HYPERMETHYLATION; EPIGENETIC THERAPY; COLORECTAL-CANCER; MULTIPLE GENES;
   CARCINOMAS
AB A subset of human breast cancer cell lines exhibits aberrant DNA hypermethylation that is characterized by hyperactivity of the DNA methyltransferase enzymes, overexpression of DNMT3b, and concurrent methylation-dependent silencing of numerous epigenetic biomarker genes. The objective of this study was to determine if this aberrant DNA hypermethylation (i) is found in primary breast cancers, (ii) is associated with specific breast cancer molecular subtypes, and (iii) influences patient outcomes. Analysis of epigenetic biomarker genes (CDH1, CEAC4M6, CST6, ESR1, GNA11, MUC1, MYB, SCNN1A, and TFF3) identified a gene expression signature characterized by reduced expression levels or loss of expression among a cohort of primary breast cancers. The breast cancers that express this gene expression signature are enriched for triple-negative subtypes basal-like and claudin-low breast cancers. Methylation analysis of primary breast cancers showed extensive promoter hypermethylation of epigenetic biomarker genes among triple-negative breast cancers, compared to other breast cancer subclasses where promoter hypermethylation events were less frequent. Furthermore, triple-negative breast cancers either did not express or expressed significantly reduced levels of protein corresponding to methylation-sensitive biomarker gene products. Together, these findings suggest strongly that loss of epigenetic biomarker gene expression is frequently associated with gene promoter hypermethylation events. We propose that aberrant DNA hypermethylation is a common characteristic of triple-negative breast cancers and may represent a fundamental biological property of basal-like and claudin-low breast cancers. Kaplan-Meier analysis of relapse-free survival revealed a survival disadvantage for patients with breast cancers that exhibit aberrant DNA hypermethylation. Identification of this distinguishing trait among triple-negative breast cancers forms the basis for development of new rational therapies that target the epigenome in patients with basal-like and claudin-low breast cancers. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Roll, J. Devon; Rivenbark, Ashley G.; Sandhu, Rupninder; Jones, Wendell D.; Livasy, Chad A.; Coleman, William B.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   [Roll, J. Devon; Rivenbark, Ashley G.; Sandhu, Rupninder; Parker, Joel S.; Carey, Lisa A.; Livasy, Chad A.; Coleman, William B.] Univ N Carolina, Sch Med, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Carey, Lisa A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA.
   [Jones, Wendell D.] Express Anal, Durham, NC 27713 USA.
C3 University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill
RP Coleman, WB (通讯作者)，Univ N Carolina, Sch Med, Dept Pathol & Lab Med, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM droll@esquaredcommunications.net; ashley_rivenbark@med.unc.edu;
   sandhu@email.unc.edu; parkerjs@email.unc.edu;
   wjones@expressionanalysis.com; lisa_carey@med.unc.edu;
   chad_livasy@med.unc.edu; wbcolemn@med.unc.edu
RI Parker, Joel/AAG-1108-2019; Jones, Wendell/JAC-5247-2023
OI Jones, Wendell/0000-0002-9676-5387
FU NCI NIH HHS [P30 CA016086] Funding Source: Medline
CR Abe M, 2005, CANCER RES, V65, P828
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   Asch BB, 2001, J MAMMARY GLAND BIOL, V6, P151, DOI 10.1023/A:1011306222533
   Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Banerjee S, 2006, J CLIN PATHOL, V59, P729, DOI 10.1136/jcp.2005.033043
   Baylin S, 2001, Dev Biol (Basel), V106, P85
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Benito M, 2004, BIOINFORMATICS, V20, P105, DOI 10.1093/bioinformatics/btg385
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brueckner B, 2007, CANCER J, V13, P17, DOI 10.1097/PPO.0b013e31803c7245
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Carey Lisa A, 2011, Clin Adv Hematol Oncol, V9, P678
   Carey LA, 2010, ONCOLOGIST, V15, P49, DOI 10.1634/theoncologist.2010-S5-49
   Carey LA, 2010, J CLIN ONCOL, V28, P361, DOI 10.1200/JCO.2009.24.0838
   Chavez-Blanco A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-2
   Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175
   Eads CA, 2000, CANCER RES, V60, P5021
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf
   FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6
   FEINBERG AP, 1987, SEMIN SURG ONCOL, V3, P149, DOI 10.1002/ssu.2980030304
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kaneko Y, 2003, GUT, V52, P641, DOI 10.1136/gut.52.5.641
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502
   Melki JR, 1999, CANCER RES, V59, P3730
   Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Perreard L, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1399
   Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748
   Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Sandhu R, 2012, INT J ONCOL, V41, P721, DOI 10.3892/ijo.2012.1505
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr433
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P5438
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Ueki T, 2000, CANCER RES, V60, P1835
   van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van Engeland M, 2003, CANCER RES, V63, P3133
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   WETZELS RHW, 1989, AM J PATHOL, V134, P571
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Yu YC, 2006, CLIN EXP METASTAS, V23, P65, DOI 10.1007/s10585-006-9020-3
   Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44
NR 83
TC 50
Z9 58
U1 0
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD DEC
PY 2013
VL 95
IS 3
BP 276
EP 287
DI 10.1016/j.yexmp.2013.09.001
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 266EZ
UT WOS:000328007500005
PM 24045095
DA 2025-01-12
ER

PT J
AU Karakas, B
   Colak, D
   Kaya, N
   Ghebeh, H
   Al-Qasem, A
   Hendrayani, F
   Toulimat, M
   Al-Tweigeri, T
   Park, B
   Aboussekhra, A
AF Karakas, Bedri
   Colak, Dilek
   Kaya, Namik
   Ghebeh, Hazem
   Al-Qasem, Abeer
   Hendrayani, Fawziah
   Toulimat, Mohamed
   Al-Tweigeri, Taher
   Park, Ben Ho
   Aboussekhra, Abdelilah
TI Prevalence of <i>PIK3CA</i> mutations and the SNP rs17849079 in Arab
   breast cancer patients
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE PI3K; PIK3CA; mutation; breast cancer; SNP; CAF
ID CLINICOPATHOLOGICAL ANALYSIS; HIGH-FREQUENCY; FIBROBLASTS; GENE;
   CARCINOMA; PATHWAY; CELLS; PI3K; GROWTH; TP53
AB Carcinomas initiate and progress due to genetic and epigenetic alterations in epithelial cells. However, recently, these alterations have also been reported in stromal fibroblasts. The gain-of-function mutations in the PI3K p110 catalytic subunit (PIK3CA) have been identified in many cancers with a current global incidence of 26% (18-40%) in breast carcinomas. We analyzed the mutational frequency of PIK3CA of three hotspots (exons 1, 9, and 20) in 81 primary invasive breast cancers (BC) and 25 cultured breast cancer-associated fibroblast (CAF) samples by Sanger sequencing in Arab breast cancer patients. Associations between the incidence of any PIK3CA mutation and several clinicopathologic characteristics were assessed using chi-square tests for categorical or t test for continuous variables. Furthermore, survival curves were estimated using the Kaplan-Meier method with the log rank test to evaluate the significance of their differences. We identified a total of 21 PIK3CA missense mutations with a frequency of 25.9%. The majority of the mutations, 17 out of 21 (81%), were in exon 20 (p.His1047Arg, p.His1047Lys, p.Thr1025Ala, p.Gly1049Arg, p.Asp1056Asn) while the remainder, 4 out of 21 (19%) were in exon 9 (p.Glu545Lys). PIK3CA mutations were significantly associated with lower grade and hormone receptor positivity. Although there was a favorable trend in overall survival for patients whose tumor harbored PIK3CA mutations, the difference was not statistically significant (P = 0.10). However, we did not detect any somatic mutations in CAFs. Furthermore, we have shown a high prevalence (8.2-fold) of a silent variant (SNP, rs17849079) in the Arab breast cancer population compared with disease-free individuals.
C1 [Karakas, Bedri; Al-Qasem, Abeer; Hendrayani, Fawziah; Aboussekhra, Abdelilah] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh 11211, Saudi Arabia.
   [Colak, Dilek] King Faisal Specialist Hosp & Res Ctr, Dept Biostat Epidemiol & Sci Comput, Riyadh 11211, Saudi Arabia.
   [Kaya, Namik] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia.
   [Ghebeh, Hazem] King Faisal Specialist Hosp & Res Ctr, Dept Stem Cell Therapy & Tissue Regenerat, Riyadh 11211, Saudi Arabia.
   [Toulimat, Mohamed] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia.
   [Al-Tweigeri, Taher] King Faisal Specialist Hosp & Res Ctr, Dept Oncol, Riyadh 11211, Saudi Arabia.
   [Park, Ben Ho] Johns Hopkins Univ, Dept Oncol, Breast Canc Program, Baltimore, MD USA.
C3 King Faisal Specialist Hospital & Research Center; King Faisal
   Specialist Hospital & Research Center; King Faisal Specialist Hospital &
   Research Center; King Faisal Specialist Hospital & Research Center; King
   Faisal Specialist Hospital & Research Center; King Faisal Specialist
   Hospital & Research Center; Johns Hopkins University
RP Karakas, B (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh 11211, Saudi Arabia.
EM bkarakas@kfshrc.edu.sa
RI Colak, Dilek/IQT-4246-2023; Kaya, Namik/GQA-7857-2022; Aboussekhra,
   Abdelilah/JCD-8138-2023; Karakas, Bedri/KIH-4149-2024; Ghebeh,
   Hazem/AAR-1453-2021
OI Alqasem, Abeer/0000-0003-1710-0908; Karakas, Bedri/0000-0002-5893-3212;
   Colak, Dilek/0000-0001-6485-8768; Ghebeh, Hazem/0000-0002-3297-3996
FU King Faisal Specialist and Research Centre (KFSHRC)
FX This project was funded by King Faisal Specialist and Research Centre
   (KFSH&RC). This work was performed under the RAC proposal #2100017 of
   KFSH&RC. We also thank M. Mohammed Rajab and Abdelmoneim Eldali
   (KFSH&RC) for assistance with the sequencing of our samples and data
   analysis.
CR Abubaker J, 2008, ONCOGENE, V27, P3539, DOI 10.1038/sj.onc.1211013
   Abubaker J, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-51
   Al-Eid HS, 2004, CANC INCIDENCE REPOR
   Allison M, 2008, NAT BIOTECHNOL, V26, P509, DOI 10.1038/nbt0508-509
   [Anonymous], 2007, Global Cancer Facts Figures American Cancer Society
   Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994
   Barbareschi M, 2007, CLIN CANCER RES, V13, P6064, DOI 10.1158/1078-0432.CCR-07-0266
   Campbell I, 2011, J PATHOL, V223, P450, DOI 10.1002/path.2842
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chavez-MacGregor M, 2012, EXPERT OPIN INV DRUG, V21, P1835, DOI 10.1517/13543784.2012.726218
   Cohen Y, 2009, INVEST OPHTH VIS SCI, V50, P5054, DOI 10.1167/iovs.09-3617
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641
   Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003
   Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539
   Eng C, 2009, CANCER RES, V69, P6759, DOI 10.1158/0008-5472.CAN-09-0985
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Goff LA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007192
   Gustin JP, 2009, P NATL ACAD SCI USA, V106, P2835, DOI 10.1073/pnas.0813351106
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192
   Hosein AN, 2010, CANCER RES, V70, P5770, DOI 10.1158/0008-5472.CAN-10-0673
   Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632
   Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970
   Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013
   Lerma E, 2008, VIRCHOWS ARCH, V453, P133, DOI 10.1007/s00428-008-0643-4
   Li SY, 2006, BREAST CANCER RES TR, V96, P91, DOI 10.1007/s10549-005-9048-0
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107
   Maira SM, 2011, CURR TOP MICROBIOL, V347, P209, DOI 10.1007/82_2010_60
   Maruyama N, 2007, CLIN CANCER RES, V13, P408, DOI 10.1158/1078-0432.CCR-06-0267
   Michelucci A, 2009, DIAGN MOL PATHOL, V18, P200, DOI 10.1097/PDM.0b013e31818e5fa4
   Mohseni M, 2010, J CLIN INVEST, V120, P2655, DOI 10.1172/JCI44026
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825
   Porter P, 2008, NEW ENGL J MED, V358, P213, DOI 10.1056/NEJMp0708307
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
NR 45
TC 20
Z9 24
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD OCT 1
PY 2013
VL 14
IS 10
BP 888
EP 896
DI 10.4161/cbt.25945
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 257XI
UT WOS:000327420700009
PM 23982433
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Sato, Y
   Marzese, DM
   Ohta, K
   Huang, SK
   Sim, MS
   Chong, K
   Hoon, DSB
AF Sato, Yusuke
   Marzese, Diego M.
   Ohta, Katsuya
   Huang, Sharon K.
   Sim, Myung Shin
   Chong, Kelly
   Hoon, Dave S. B.
TI Epigenetic regulation of <i>REG1A</i> and chemosensitivity of cutaneous
   melanoma
SO EPIGENETICS
LA English
DT Article
DE REG1A; melanoma; methylation; metastasis; chemosensitivity
ID ESOPHAGEAL CANCER-PATIENTS; MALIGNANT-MELANOMA; COLORECTAL-CANCER;
   ADJUVANT THERAPY; POOR-PROGNOSIS; BREAST-CANCER; I-ALPHA; EXPRESSION;
   CELL; GENES
AB Regenerating gene 1A (REG1A) plays an important role in tissue regeneration and in cell proliferation in epithelium origin tumors; however, its role in melanoma has not been explored in details. The objective of this study was to identify whether REG1A is expressed in cutaneous melanoma and if REG1A expression status can predict prognosis in cutaneous melanoma patients with metastasis. We also determined whether epigenetic regulation of the promoter region regulates REG1A expression. AJCC stage III cutaneous melanoma specimens with clinically well annotated stage III lymph node melanoma metastasis tissue microarray were assessed by IHC. MALDI-TOF-mass spectrometry and HM450K array were used to identify REG1A promoter region CpG site methylation. Chemotherapeutic agent response by melanoma cells as related to REG1A protein expression was assessed. Post-surgery melanoma patients followed by adjuvant chemotherapy with high REG1A expression had a significantly better prognosis (disease-specific survival) compared with patients with low REG1A expression (log rank test; p = 0.0013). The demethylating reagent 5-Aza-2-deoxycytidine activated REG1A promoter region resulting in enhanced REG1A mRNA and protein expression in melanoma cell lines. Promoter region CpG methylation was shown to regulate REG1A expression in melanoma cells. Moreover, melanoma lines with high REG1A mRNA expression were more susceptible to Dacarbazine and Cisplatin, as compared with those with low REG1A mRNA expression. In conclusion, REG1A expression status may be useful as a biomarker in melanoma patients for sensitivity to these chemotherapeutic agents. The epigenetic regulation of the REG1A promoter region may offer a potential therapeutic approach to improve chemotherapy for metastatic melanoma patients.
C1 [Sato, Yusuke; Marzese, Diego M.; Ohta, Katsuya; Huang, Sharon K.; Chong, Kelly; Hoon, Dave S. B.] John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA USA.
   [Sim, Myung Shin] John Wayne Canc Inst, Div Biostat, Santa Monica, CA USA.
C3 John Wayne Cancer Institute; John Wayne Cancer Institute
RP Hoon, DSB (通讯作者)，John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA USA.
EM hoon@jwci.org
RI Marzese, Diego/AAA-3547-2022; Hoon, Dave/C-7146-2018; Chong,
   Kelly/JXN-8770-2024
OI Hoon, Dave/0000-0003-1915-3683
FU NIH [P0 CA029605]; NCI; Leslie and Susan Gonda (Goldschmied) Foundation;
   Dr Miriam and Sheldon G. Adelson Medical Research Foundation; Ruth and
   Martin H. Weil Fund
FX This work was supported by P0 CA029605 from the NIH, NCI, the Leslie and
   Susan Gonda (Goldschmied) Foundation (DH), The Dr Miriam and Sheldon G.
   Adelson Medical Research Foundation (DH), and Ruth and Martin H. Weil
   Fund (DH).
CR Astrosini C, 2008, INT J CANCER, V123, P409, DOI 10.1002/ijc.23466
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cavard C, 2006, ONCOGENE, V25, P599, DOI 10.1038/sj.onc.1208860
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Geng J, 2009, EJSO-EUR J SURG ONC, V35, P852, DOI 10.1016/j.ejso.2008.12.007
   Greenberg ES, 2012, CANC LETT, DOI [10.1016\j.canlet.2010.01.020, 10. 1016/j. canlet. 2012. 01. 020 22289720]
   Hayashi K, 2008, ANN SURG ONCOL, V15, P1224, DOI 10.1245/s10434-008-9810-8
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   KIMURA N, 1992, CANCER, V70, P1857, DOI 10.1002/1097-0142(19921001)70:7<1857::AID-CNCR2820700708>3.0.CO;2-8
   Kirkwood JM, 2006, CLIN CANCER RES, V12, p2331S, DOI 10.1158/1078-0432.CCR-05-2538
   Kitago M, 2009, CLIN CANCER RES, V15, P2988, DOI 10.1158/1078-0432.CCR-08-3172
   Lee WS, 2008, J SURG RES, V144, P29, DOI 10.1016/j.jss.2007.02.005
   McShane LM, 2005, EUR J CANCER, V41, P1690, DOI 10.1016/j.ejca.2005.03.032
   Minamiya Y, 2008, LUNG CANCER, V60, P98, DOI 10.1016/j.lungcan.2007.09.012
   Miyaoka Y, 2004, ONCOGENE, V23, P3572, DOI 10.1038/sj.onc.1207333
   Miyata H, 2000, CLIN CANCER RES, V6, P4859
   Mocellin S, 2010, JNCI-J NATL CANCER I, V102, P493, DOI 10.1093/jnci/djq009
   Morton DL, 2006, NEW ENGL J MED, V355, P1307, DOI 10.1056/NEJMoa060992
   Motoyama S, 2006, ANN SURG ONCOL, V13, P1724, DOI 10.1245/s10434-006-9075-z
   Narita N, 2009, ONCOGENE, V28, P3058, DOI 10.1038/onc.2009.164
   Neyns B, 2010, CANCER-AM CANCER SOC, V116, P2868, DOI 10.1002/cncr.25035
   Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Sasaki Y, 2008, ANN SURG ONCOL, V15, P3244, DOI 10.1245/s10434-008-0137-2
   Sato Y, 2013, ANN SURG ONCOL, DOI 10. 1245/s10434-013-2983-9 23645481
   Sekikawa A, 2008, CARCINOGENESIS, V29, P76, DOI 10.1093/carcin/bgm250
   Takasawa S, 2006, FEBS LETT, V580, P585, DOI 10.1016/j.febslet.2005.12.070
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   TERAZONO K, 1988, J BIOL CHEM, V263, P2111
   Triche TJ, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt090
   UNNO M, 1992, ADV EXP MED BIOL, V321, P61
   Unno M, 1992, ADV EXP MED BIOL, V321, P67
   WATANABE T, 1990, J BIOL CHEM, V265, P7432
   Yoshimura T, 2011, EPIGENETICS-US, V6, P1001, DOI 10.4161/epi.6.8.16063
   Yoshino N, 2005, AM J GASTROENTEROL, V100, P2157, DOI 10.1111/j.1572-0241.2005.41915.x
NR 38
TC 16
Z9 16
U1 0
U2 3
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD OCT 1
PY 2013
VL 8
IS 10
BP 1043
EP 1052
DI 10.4161/epi.25810
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 260UJ
UT WOS:000327619700006
PM 23903855
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Kabro, A
   Lachance, H
   Marcoux-Archambault, I
   Perrier, V
   Doré, V
   Gros, C
   Masson, V
   Gregoire, JM
   Ausseil, F
   Cheishvili, D
   Laulan, NB
   St-Pierre, Y
   Szyf, M
   Arimondo, PB
   Gagnon, A
AF Kabro, Anzhelika
   Lachance, Hugo
   Marcoux-Archambault, Iris
   Perrier, Valerie
   Dore, Vicky
   Gros, Christina
   Masson, Veronique
   Gregoire, Jean-Marc
   Ausseil, Frederic
   Cheishvili, David
   Laulan, Nathalie Bibens
   St-Pierre, Yves
   Szyf, Moshe
   Arimondo, Paola B.
   Gagnon, Alexandre
TI Preparation of phenylethylbenzamide derivatives as modulators of DNMT3
   activity
SO MEDCHEMCOMM
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; DNA METHYLTRANSFERASE INHIBITORS; SMALL-MOLECULE
   INHIBITORS; DE-NOVO METHYLATION; MYELODYSPLASTIC SYNDROMES; CANCER;
   EPIGENETICS; HYPOMETHYLATION; DISCOVERY; AGENTS
AB DNA-methyltransferases (DNMTs) are a class of epigenetic enzymes that catalyze the transfer of a methyl moiety from the methyl donor S-adenosyl-L-methionine onto the C5 position of cytosine in DNA. This process is dysregulated in cancers and leads to the hypermethylation and silencing of tumor suppressor genes. The development of potent and selective inhibitors of DNMTs is of utmost importance for the discovery of new therapies for the treatment of cancer. We report herein the synthesis and DNMT inhibitory activity of 29 analogues derived from NSC 319745. The effect of selected compounds on the methylation level in the MDA-MB-231 human breast cancer cell line was evaluated using a luminometric methylation assay. Molecular docking studies have been conducted to propose a binding mode for this series.
C1 [Kabro, Anzhelika; Lachance, Hugo; Marcoux-Archambault, Iris; Perrier, Valerie; Dore, Vicky; Gagnon, Alexandre] Univ Quebec, Dept Chim, Montreal, PQ H3C 3P8, Canada.
   [Lachance, Hugo; St-Pierre, Yves; Gagnon, Alexandre] Pharmaqam, Dept Chim, Montreal, PQ H3C 3P8, Canada.
   [Gros, Christina; Masson, Veronique; Gregoire, Jean-Marc; Ausseil, Frederic; Arimondo, Paola B.] USR CNRS Pierre Fabre 3388 ETaC Epigenet Targetin, F-31035 Toulouse 01, France.
   [Cheishvili, David; Szyf, Moshe] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
   [Laulan, Nathalie Bibens; St-Pierre, Yves] Ctr INRS Inst Armand Frappier, Laval, PQ H7V 1B7, Canada.
C3 University of Quebec; University of Quebec Montreal; Centre National de
   la Recherche Scientifique (CNRS); McGill University; University of
   Quebec; Institut national de la recherche scientifique (INRS)
RP Arimondo, PB (通讯作者)，USR CNRS Pierre Fabre 3388 ETaC Epigenet Targetin, CRDPF 3 Ave Hubert Curien, F-31035 Toulouse 01, France.
EM yves.st-pierre@iaf.inrs.ca; moshe.szyf@mcgill.ca;
   paola.arimondo@etac.cnrs.fr; gagnon.alexandre@uqam.ca
RI Arimondo, Paola/R-9095-2017; Cheishvili, David/AAL-1915-2020
OI St-Pierre, Yves/0000-0002-1948-2041; Cheishvili,
   David/0000-0001-9136-8967
FU Pharmaqam; Natural Sciences and Engineering Research Council of Canada
   (NSERC); Universite du Quebec a Montreal (UQAM); Canadian Institute of
   Health Research; Region Midi-Pyrenees (Equipe d'Excellence) et FEDER
   (CNRS-Region Midi-Pyrenees); UQAM; Israel Cancer Research Fund
FX This work was supported by Pharmaqam, the Natural Sciences and
   Engineering Research Council of Canada (NSERC), the Universite du Quebec
   a Montreal (UQAM), and a grant from the Canadian Institute of Health
   Research to MS. PBA was funded by Region Midi-Pyrenees (Equipe
   d'Excellence) et FEDER (CNRS-Region Midi-Pyrenees). We thank
   Constellation Pharmaceuticals for generously testing our compounds
   against EZH2 and DOT1L. AG would like to thank Dr Brian Albrecht, Dr
   Richard Cummings, and Pr. Steve Bourgault for useful discussion. IMA
   thanks UQAM for an undergraduate scholarship, DC thanks the Israel
   Cancer Research Fund for a post-doctoral fellowship.
CR Auclair G, 2012, BIOCHIMIE, V94, P2202, DOI 10.1016/j.biochi.2012.05.016
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Bissinger EM, 2010, MEDCHEMCOMM, V1, P114, DOI 10.1039/c0md00062k
   Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   BROWN GR, 1984, J MED CHEM, V27, P79, DOI 10.1021/jm00367a016
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Carey N, 2012, MEDCHEMCOMM, V3, P162, DOI 10.1039/c1md00264c
   Castellano S, 2008, J MED CHEM, V51, P2321, DOI 10.1021/jm7015705
   Castellano S, 2011, J MED CHEM, V54, P7663, DOI 10.1021/jm2010404
   Ceccaldi A, 2013, ACS CHEM BIOL, V8, P543, DOI 10.1021/cb300565z
   Ceccaldi A, 2011, CHEMBIOCHEM, V12, P1337, DOI 10.1002/cbic.201100130
   Cherblanc FL, 2013, NAT PROD REP, V30, P605, DOI 10.1039/c3np20097c
   Copeland RA, 2010, CURR OPIN CHEM BIOL, V14, P505, DOI 10.1016/j.cbpa.2010.06.174
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fahy J, 2012, EXPERT OPIN THER PAT, V22, P1427, DOI 10.1517/13543776.2012.729579
   Fang MZ, 2003, CANCER RES, V63, P7563
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6
   Foulks JM, 2012, J BIOMOL SCREEN, V17, P2, DOI 10.1177/1087057111421212
   Garcia JS, 2010, ONCOTARGETS THER, V3, P1
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Halby L, 2012, CHEMBIOCHEM, V13, P157, DOI 10.1002/cbic.201100522
   Hassler MR, 2012, BIOCHIMIE, V94, P2219, DOI 10.1016/j.biochi.2012.05.007
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Itoh Y, 2013, MOL BIOSYST, V9, P873, DOI 10.1039/c3mb25410k
   Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones P, 2012, MEDCHEMCOMM, V3, P135, DOI 10.1039/c1md00199j
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401
   Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuck D, 2010, BIOORGAN MED CHEM, V18, P822, DOI 10.1016/j.bmc.2009.11.050
   Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216
   Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074/jbc.M505593200
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Lin YS, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-3
   Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007
   Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041
   Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016/j.biocel.2008.08.020
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Martinet N, 2012, MEDCHEMCOMM, V3, P263, DOI 10.1039/c1md00194a
   McGinty RK, 2008, NATURE, V453, P812, DOI 10.1038/nature06906
   Medina-Franco JL, 2013, MOL DIVERS, V17, P337, DOI 10.1007/s11030-013-9428-z
   Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4
   Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pilsner JR, 2010, MOL ECOL, V19, P307, DOI 10.1111/j.1365-294X.2009.04452.x
   Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Schaefer M, 2010, CHROMOSOMA, V119, P35, DOI 10.1007/s00412-009-0240-6
   Segura-Pacheco B, 2003, CLIN CANCER RES, V9, P1596
   Seidel C, 2012, BIOCHIMIE, V94, P2264, DOI 10.1016/j.biochi.2012.05.012
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Siedlecki P, 2006, J MED CHEM, V49, P678, DOI 10.1021/jm050844z
   Steensma DP, 2009, J CLIN ONCOL, V27, P3842, DOI 10.1200/JCO.2008.19.6550
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Suzuki T, 2010, BIOORG MED CHEM LETT, V20, P1124, DOI 10.1016/j.bmcl.2009.12.016
   Svedruzic ZM, 2008, CURR MED CHEM, V15, P92, DOI 10.2174/092986708783330700
   SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4
   Szyf M, 2011, J NEURODEV DISORD, V3, P238, DOI 10.1007/s11689-011-9079-2
   Szyf M, 2010, BBA-GENE REGUL MECH, V1799, P750, DOI 10.1016/j.bbagrm.2010.09.002
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Therrien E, 2012, J CHEM INF MODEL, V52, P210, DOI 10.1021/ci2004779
   Villar-Garea A, 2003, CANCER RES, V63, P4984
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Yoo J, 2012, CURR MED CHEM, V19, P3475, DOI 10.2174/092986712801323289
NR 75
TC 21
Z9 23
U1 0
U2 30
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PD DEC
PY 2013
VL 4
IS 12
BP 1562
EP 1570
DI 10.1039/c3md00214d
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 258LR
UT WOS:000327461300004
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Nabilsi, NH
   Ryder, DJ
   Peraza-Penton, AC
   Poudyal, R
   Loose, DS
   Kladde, MP
AF Nabilsi, Nancy H.
   Ryder, Daniel J.
   Peraza-Penton, Ashley C.
   Poudyal, Rosha
   Loose, David S.
   Kladde, Michael P.
TI Local Depletion of DNA Methylation Identifies a Repressive p53
   Regulatory Region in the <i>NEK2</i> Promoter
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Chromatin Regulation; Chromatin Structure; DNA Methylation; Epigenetics;
   Nucleosome; p53; MAPit; NEK2
ID METHYLTRANSFERASE ACCESSIBILITY PROTOCOL; CELL-CYCLE; INDIVIDUAL
   TEMPLATES; CPG METHYLATION; PROTEIN-KINASE; SURVIVIN GENE;
   BREAST-CANCER; EXPRESSION; PATTERNS; TARGET
AB Background: NEK2 is a mammalian kinase that promotes centrosome separation during the cell cycle. Results: Agents that demethylate the NEK2 promoter or induce DNA damage repress NEK2 expression in a p53-dependent manner. Conclusion: p53 represses NEK2 expression and protects its binding region from accumulating DNA methylation. Significance: Knowledge regarding novel mechanisms of NEK2 regulation may help inform clinical application of NEK2-based anticancer therapeutics.
   Genome-scale mapping suggests that the function of DNA methylation varies with genomic context beyond transcriptional repression. However, the use of DNA-demethylating agents (e.g. 5-aza-2-deoxycytidine (5aza-dC)) to study epigenetic regulation often focuses on gene activation and ignores repression elicited by 5aza-dC. Here, we show that repression of NEK2, which encodes the never in mitosis A (NIMA)-related kinase, by 5aza-dC is context-specific as NEK2 transcript levels were reduced in HCT116 colon cancer cells but not in isogenic p53(-/-) cells. Bisulfite sequencing showed that DNA methylation was restricted to the distal region of the NEK2 promoter. Demethylation by 5aza-dC was associated with increased accessibility to micrococcal nuclease, i.e. nucleosome depletion. Conversely, methyltransferase accessibility protocol for individual templates (MAPit) methylation footprinting showed that nucleosome occupancy and DNA methylation at the distal promoter were significantly increased in p53(-/-) cells, suggesting dynamic regulation of chromatin structure at this region by p53 in HCT116 cells. Stabilization of endogenous p53 by doxorubicin or ectopic expression of p53, but not a p53 DNA-binding mutant, decreased NEK2 expression. Chromatin immunoprecipitation demonstrated direct and specific association of p53 with the distal NEK2 promoter, which was enhanced by doxorubicin. Luciferase reporters confirmed that this region is required for p53-mediated repression of NEK2 promoter activity. Lastly, modulation of p53 abundance altered nucleosome occupancy and DNA methylation at its binding region. These results identify NEK2 as a novel p53-repressed gene, illustrate that its repression by 5aza-dC is specific and associated with nucleosome reorganization, and provide evidence that identification of partially methylated regions can reveal novel p53 target genes.
C1 [Nabilsi, Nancy H.; Peraza-Penton, Ashley C.; Poudyal, Rosha; Kladde, Michael P.] Univ Florida, Coll Med, Hlth Canc Ctr, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   [Ryder, Daniel J.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Phys Therapy, Gainesville, FL 32610 USA.
   [Loose, David S.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; University of Texas
   System; University of Texas Health Science Center Houston
RP Loose, DS (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA.
EM David.S.Loose@uth.tmc.edu; kladde@ufl.edu
OI Kladde, Michael/0000-0001-7951-9291
FU National Institutes of Health [CA098258, CA155390]; Bankhead-Coley
   Florida Cancer Research Program Postdoctoral Fellowship [BD-03]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants CA098258 (to D. S. L.) and CA155390 (to M. P. K.). This
   work was also supported by Bankhead-Coley Florida Cancer Research
   Program Postdoctoral Fellowship BD-03 (to N. H. N.). We thank Dr. Lei
   Deng and Dr. Russell Broaddus for providing the p53-luciferase reporter
   and RNA from doxo-treated breast cancer cells and Dr. Lawrence Donehower
   for the p53-EGFP construct. We also thank Dr. Carolina Pardo for
   critical reading of the manuscript.
CR Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Barbagallo F, 2009, J PATHOL, V217, P431, DOI 10.1002/path.2471
   Barletta JM, 1997, CANCER RES, V57, P48
   Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Botcheva K, 2011, CELL CYCLE, V10, P4237, DOI 10.4161/cc.10.24.18383
   Brendle A, 2009, EUR J CANCER, V45, P435, DOI 10.1016/j.ejca.2008.10.001
   Broude EV, 2007, CELL CYCLE, V6, P1468
   Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237
   Cui KR, 2012, METHODS MOL BIOL, V833, P413, DOI 10.1007/978-1-61779-477-3_24
   Darst RP, 2012, METHOD ENZYMOL, V513, P185, DOI 10.1016/B978-0-12-391938-0.00008-2
   Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620
   Feng Z, 2006, ONCOGENE, V25, P1, DOI 10.1038/sj.onc.1209021
   Fletcher L, 2004, RADIAT RES, V162, P128, DOI 10.1667/RR3211
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711
   Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301
   Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Herbert BS, 2010, ONCOTARGET, V1, P405
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hsieh CL, 1999, MOL CELL BIOL, V19, P46
   Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83
   Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268
   Kilgore JA, 2007, METHODS, V41, P320, DOI 10.1016/j.ymeth.2006.08.008
   Kokuryo T, 2007, CANCER RES, V67, P9637, DOI 10.1158/0008-5472.CAN-07-1489
   Lai AY, 2010, J EXP MED, V207, P1939, DOI 10.1084/jem.20100204
   Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217
   Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020
   Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946
   Lin IG, 2000, MOL CELL BIOL, V20, P2343, DOI 10.1128/MCB.20.7.2343-2349.2000
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Löffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Nabilsi NH, 2010, J ENDOCRINOL, V207, P237, DOI 10.1677/JOE-10-0128
   Pang LY, 2011, CELL CYCLE, V10, P932, DOI 10.4161/cc.10.6.15012
   Pardo Carolina E, 2011, Curr Protoc Mol Biol, VChapter 21, DOI 10.1002/0471142727.mb2122s95
   Pardo CE, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq716
   Peltonen K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012996
   Petrovich M, 2009, J MOL BIOL, V386, P72, DOI 10.1016/j.jmb.2008.11.054
   Qiu XL, 2009, J MED CHEM, V52, P1757, DOI 10.1021/jm8015969
   Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   Rishi V, 2010, P NATL ACAD SCI USA, V107, P20311, DOI 10.1073/pnas.1008688107
   SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Suzuki K, 2010, CANCER SCI, V101, P1163, DOI 10.1111/j.1349-7006.2010.01504.x
   Troester MA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-276
   Tsunoda N, 2009, CANCER SCI, V100, P111, DOI 10.1111/j.1349-7006.2008.01007.x
   Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030
   Wu GK, 2008, CANCER RES, V68, P8393, DOI 10.1158/0008-5472.CAN-08-1915
   Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485
   Xie R, 2007, MODERN PATHOL, V20, P1045, DOI 10.1038/modpathol.3800940
   Xu M, 1998, NUCLEIC ACIDS RES, V26, P3961, DOI 10.1093/nar/26.17.3961
   Yang F, 2013, CURR BIOL, V23, P782, DOI 10.1016/j.cub.2013.03.043
NR 58
TC 14
Z9 16
U1 3
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 13
PY 2013
VL 288
IS 50
BP 35940
EP 35951
DI 10.1074/jbc.M113.523837
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 291FZ
UT WOS:000329814700030
PM 24163369
OA Green Published
DA 2025-01-12
ER

PT J
AU Guo, L
   Chen, C
   Shi, M
   Wang, F
   Chen, X
   Diao, D
   Hu, M
   Yu, M
   Qian, L
   Guo, N
AF Guo, L.
   Chen, C.
   Shi, M.
   Wang, F.
   Chen, X.
   Diao, D.
   Hu, M.
   Yu, M.
   Qian, L.
   Guo, N.
TI Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate
   and maintain oncostatin M-driven epithelial-mesenchymal transition
SO ONCOGENE
LA English
DT Article
DE OSM; EMT; Stat3; let-7; miR-200
ID DOUBLE-EDGED-SWORD; NF-KAPPA-B; SELF-RENEWAL; FEEDBACK LOOP; CELL
   MOTILITY; TGF-BETA; CANCER; INFLAMMATION; EXPRESSION; EMT
AB Inflammation can act as a crucial mediator of epithelial-to-mesenchymal transition (EMT). In this study, we show that oncostatin M (OSM) is expressed in an autocrine/paracrine fashion in invasive breast carcinoma. OSM stimulation promotes spontaneous lung metastasis of MCF-7 xenografts in nude mice. A conspicuous epigenetic transition was induced by OSM stimulation not only in breast cancer cell lines but also in MCF-7 xenografts in nude mice. The expression of miR-200 and let-7 family members in response to OSM stimulation was downregulated in a signal transducer and activator of transcription factor 3 (Stat3)-dependent manner, resulting in comprehensive alterations of the transcription factors and oncoproteins targeted by these microRNAs. Inhibition of Stat3 activation or the ectopic expression of let-7 and miR-200 effectively reversed the mesenchymal phenotype of breast cancer cells. Stat3 promotes the transcription of Lin-28 by directly binding to the Lin-28 promoter, resulting in the repression of let-7 expression and concomitant upregulation of the let-7 target, high-mobility group A protein 2 (HMGA2). Knock down of HMGA2 significantly impairs OSM-driven EMT. Our data indicate that downregulation of let-7 and miR-200 levels initiates and maintains OSM-induced EMT phenotypes, and HMGA2 acts as a master switch of OSM-induced EMT. These findings highlight the importance of Stat3-coordinated Lin-28B-let-7-HMGA2 and miR-200-ZEB1 circuits in the cytokine-mediated phenotypic reprogramming of breast cancer cells.
C1 [Guo, L.; Chen, C.; Shi, M.; Diao, D.; Hu, M.; Yu, M.; Qian, L.; Guo, N.] Beijing Inst Basic Med Sci, Dept Mol Immunol, Beijing, Peoples R China.
   [Wang, F.] Inst Basic Med Sci, Dept Brain Protect & Plast Res, Beijing 100850, Peoples R China.
   [Chen, X.] 307 Hosp, Beijing, Peoples R China.
   [Diao, D.] Henan Univ, Lab Cellular & Mol Immunol, Sch Med, Kaifeng, Peoples R China.
C3 Academy of Military Medical Sciences - China; Fifth Medical Center of
   Chinese PLA General Hospital; Henan University
RP Qian, L (通讯作者)，Inst Basic Med Sci, Dept Mol Immunol, Beijing 100850, Peoples R China.
EM qianlubj@sohu.com; ningguo@nic.bmi.ac.cn
OI , Liang/0000-0002-8748-5770
FU National Basic Research Program of China (973 Program) [2010CB911904];
   National Natural Science Foundation of China [30972690, 31271440,
   81272232]
FX We are grateful to Dr Xuemin Zhang (National Center of Biomedical
   Analysis, Beijing) for kindly providing us the plasmids
   pRc/CMV-Stat3C-Flag and luciferase reporter vectors containing the
   binding sequences for Stat3, NF-kappa B, AP-1 and Smad. We also thank Dr
   Xiaofei Zheng (Beijing Institute of Radiation Medicine, Beijing) for the
   gift of the modified pGL3-control plasmid. This work is supported by
   National Basic Research Program of China (973 Program, No. 2010CB911904)
   and National Natural Science Foundation of China (Nos. 30972690,
   31271440 and 81272232).
CR Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06
   Bhaumik D, 2009, CELL CYCLE, V8, P1822
   Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0
   Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172
   Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200
   Chiappetta G, 1996, ONCOGENE, V13, P2439
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Dahéron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770
   Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156
   Gómez-Lechón MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024-3205(99)00296-9
   Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14
   Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004
   Jun C, 2007, PROG BIOCHEM BIOPHYS, V34, P389
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675
   Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101
   Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   López-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043
   Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108
   Nightingale J, 2004, J AM SOC NEPHROL, V15, P21, DOI 10.1097/01.ASN.0000102479.92582.43
   Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907
   Pfannkuche K, 2009, STEM CELL REV REP, V5, P224, DOI 10.1007/s12015-009-9078-9
   Pollack V, 2007, AM J PHYSIOL-RENAL, V293, pF1714, DOI 10.1152/ajprenal.00130.2007
   Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008-5472.CAN-05-1734
   Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007
   Shi M, 2011, BREAST CANCER RES TR, V125, P351, DOI 10.1007/s10549-010-0822-2
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3
   Strippoli R, 2010, J CELL SCI, V123, P4321, DOI 10.1242/jcs.071647
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   Tan EJ, 2012, J BIOL CHEM, V287, P7134, DOI 10.1074/jbc.M111.291385
   Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200
   Winder DM, 2011, J PATHOL, V225, P448, DOI 10.1002/path.2968
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964
   Yang L, 2010, CANCER METAST REV, V29, P263, DOI 10.1007/s10555-010-9226-3
   Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
   Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200
   Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123
NR 53
TC 171
Z9 188
U1 0
U2 34
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD NOV 7
PY 2013
VL 32
IS 45
BP 5272
EP 5282
DI 10.1038/onc.2012.573
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 251IS
UT WOS:000326922100003
PM 23318420
OA hybrid
DA 2025-01-12
ER

PT J
AU Bardowell, SA
   Parker, J
   Fan, C
   Crandell, J
   Perou, CM
   Swift-Scanlan, T
AF Bardowell, Sabrina A.
   Parker, Joel
   Fan, Cheng
   Crandell, Jamie
   Perou, Charles M.
   Swift-Scanlan, Theresa
TI Differential methylation relative to breast cancer subtype and matched
   normal tissue reveals distinct patterns
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Epigenetic; Methylation; Breast cancer; Illumina; BRCA1; Basal-like
ID BRCA1 PROMOTER; DNA METHYLATION; GENE-EXPRESSION; TUMORS;
   HYPERMETHYLATION; EPIGENETICS; DISEASE
AB Due to the heterogeneous nature of breast cancer and the widespread use of single-gene studies, there is limited knowledge of multi-gene, locus-specific DNA methylation patterns in relation to molecular subtype and clinical features. We, therefore, quantified DNA methylation of 70 candidate gene loci in 140 breast tumors and matched normal tissues and determined associations with gene expression and tumor subtype. Using Sequenom's EpiTYPER platform, approximately 1,200 CpGs were interrogated and revealed six DNA methylation patterns in breast tumors relative to matched normal tissue. Differential methylation of several gene loci was observed within all molecular subtypes, while other patterns were subtype-dependent. Methylation of numerous gene loci was inversely correlated with gene expression, and in some cases, this correlation was only observed within specific breast tumor subtypes. Our findings were validated on a larger set of tumors and matched adjacent normal tissue from The Cancer Genome Atlas dataset, which utilized methylation data derived from both Illumina Infinium 27 and 450 k arrays. These findings highlight the need to control for subtype when interpreting DNA methylation results, and the importance of interrogating multiple CpGs across varied gene regions.
C1 [Bardowell, Sabrina A.; Crandell, Jamie; Swift-Scanlan, Theresa] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
   [Parker, Joel; Fan, Cheng; Perou, Charles M.; Swift-Scanlan, Theresa] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Parker, Joel; Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Swift-Scanlan, T (通讯作者)，Univ N Carolina, Sch Nursing, Off 5102,Carrington Hall,CB 7460, Chapel Hill, NC 27599 USA.
EM tswift@unc.edu
RI FAN, CHENG/KVY-9602-2024; Parker, Joel/AAG-1108-2019; Crandell,
   Jamie/KCX-8061-2024; Perou, Charles/H-9934-2014
OI Gardner, Sabrina/0000-0003-2566-3743; Perou, Charles/0000-0001-9827-2247
FU National Center for Research Resources [KL2RR025746]; NIH/NINR
   [T32NR007091-17]; NIH/NCI Breast SPORE [CA058823]; Susan G. Komen
   Foundation [KG090180]
FX We wish to acknowledge the TCGA Research Network and publically
   available TCGA breast cancer datasets. Without this rich resource we
   would not have been able to validate our findings. We are grateful for
   the support of the KL2RR025746 to T. Swift-Scanlan from the National
   Center for Research Resources, the NIH/NINR T32NR007091-17 to S. A.
   Bardowell, the NIH/NCI Breast SPORE CA058823 to C. M. Perou, and the
   Susan G. Komen Foundation KG090180 to T. Swift-Scanlan.
CR Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Ehrich M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni038
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Gardner KE, 2011, J MOL BIOL, V409, P36, DOI 10.1016/j.jmb.2011.01.040
   Hasan TN, 2013, CLIN TRANSL ONCOL, V15, P555, DOI 10.1007/s12094-012-0968-y
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lu YH, 2011, MOL CELL BIOL, V31, P3339, DOI 10.1128/MCB.01121-10
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Swift-Scanlan T, 2011, CANCER BIOL THER, V11, P853, DOI 10.4161/cbt.11.10.15177
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   Wilcox CB, 2005, CANCER GENET CYTOGEN, V159, P114, DOI 10.1016/j.cancergencyto.2004.12.017
   Wu JM, 2008, CLIN CANCER RES, V14, P1938, DOI 10.1158/1078-0432.CCR-07-4082
   Xu JH, 2010, BREAST CANCER RES TR, V120, P593, DOI 10.1007/s10549-009-0422-1
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
NR 25
TC 27
Z9 28
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD NOV
PY 2013
VL 142
IS 2
BP 365
EP 380
DI 10.1007/s10549-013-2738-0
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 253JB
UT WOS:000327079800011
PM 24212716
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Estal, RM
   Suela, SP
   Jiménez, ID
   Rojas, CE
   García-Casado, Z
   Fita, MJJ
   Heras, ABS
   Huerta, AS
   González, IC
   Sánchez-Izquierdo, D
   García, ML
   González, EB
   Gilabert, PB
AF Murria Estal, Rosa
   Palanca Suela, Sarai
   de Juan Jimenez, Inmaculada
   Egoavil Rojas, Cecilia
   Garcia-Casado, Zaida
   Juan Fita, Maria Jose
   Sanchez Heras, Ana Beatriz
   Segura Huerta, Angel
   Chirivella Gonzalez, Isabel
   Sanchez-Izquierdo, Dolors
   Llop Garcia, Marta
   Barragan Gonzalez, Eva
   Bolufer Gilabert, Pascual
TI MicroRNA signatures in hereditary breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Sporadic breast cancer; Hereditary breast cancer; miR expression
   profile; BRCA1; BRCA2; Mutations; Molecular markers
ID EXPRESSION PROFILES; GENE; IDENTIFICATION; SEQUENCES; ESTROGEN; MIR-155;
   BRCA1
AB This study aims to identify signatures of miR associated with hereditary, BRCA1 or BRCA2 mutation positive breast cancer (BC), and non-hereditary BC, either sporadic (SBC) or non-informative (BRCAX). Moreover, we search for signatures associated with tumor stage, immunohistochemistry and tumor molecular profile. Twenty formalin fixed paraffin embedded (FFPE) BCs, BRCA1, BRCA2, BRCAX and SBC, five per group were studied. Affymetrix platform miRNA v.3.0 was used to perform miR expression analysis. ER, PR, HER2 and Ki67 protein expression was analyzed by immunohistochemistry. BRCA1, BRCA2 and RASSF1 methylation analysis, AURKA copy number variations, and BRCA1 and BRCA2 deletions, were studied by MLPA. We validated eight of the miR selected by the arrays in 77 BCs by qRT-PCR. The miR profiles associated with tumor features were studied applying the Sparse Partial Least Squares Discriminant Analysis. MiR discrimination capability to distinguish hereditary and non-hereditary BC was analyzed by the discriminant function. With 15 out of 1,733 hsa-miRs, it was possible to differentiate the four groups. BRCA1, BRCA2 and SBC were associated with clusters of hyper-expressed miRs, and BRCAX with hypo-expressed miRs. Hsa-miR-4417 and hsa-miR-423-3p expressions (included among the eight validated miRs) differentiated 70.1 % of hereditary and non-hereditary BCs. We found miR profiles associated with tumor features like node involvement, histological grade, ER, PR and HER2 expression. Regarding molecular parameters, we only found a weak association of miRs in BC harboring losses in AURKA. We conclude that array miR expression profiles can differentiate the four study groups using FFPE BC. However, miRs expression estimated by qRT-PCR differentiates only hereditary and non-inherited BCs. The miR expression array is a simple and rapid approach that could be useful to facilitate the identification of those SBC carrying genetic or epigenetic changes in BRCA genes responsible of BRCA-like phenotype. These patients could benefit from the treatment with PARP inhibitors.
C1 [Murria Estal, Rosa; Palanca Suela, Sarai; de Juan Jimenez, Inmaculada; Llop Garcia, Marta; Barragan Gonzalez, Eva; Bolufer Gilabert, Pascual] Univ Hosp La Fe, Serv Clin Anal, Mol Biol Lab, Valencia 46009, Spain.
   [Egoavil Rojas, Cecilia] Univ Gen Hosp, Dept Pathol, Alicante, Spain.
   [Garcia-Casado, Zaida] IVO, Mol Biol Lab, Valencia, Spain.
   [Juan Fita, Maria Jose] IVO, Dept Oncol, Valencia, Spain.
   [Sanchez Heras, Ana Beatriz] Elche Hosp, Genet Counseling Unit, Alicante, Spain.
   [Segura Huerta, Angel] Univ Hosp La Fe, Genet Counseling Unit, Valencia 46009, Spain.
   [Chirivella Gonzalez, Isabel] Clin Univ Hosp, Genet Counseling Unit, Valencia, Spain.
   [Sanchez-Izquierdo, Dolors] Hlth Res Inst La Fe, Arrays Serv, Valencia, Spain.
C3 General University Hospital of Alicante; Instituto Valenciano De
   Oncologia; Instituto Valenciano De Oncologia; Hospital Universitari i
   Politecnic La Fe; Instituto de Investigacion Sanitaria La Fe (IIS La Fe)
RP Gilabert, PB (通讯作者)，Univ Hosp La Fe, Serv Clin Anal, Mol Biol Lab, Escuela Enfermeria 7 Planta Avd Campanar 21, Valencia 46009, Spain.
EM bolufer_pas@gva.es
RI Garcia-Casado, Zaida/Z-2125-2019; Egoavil, Cecilia/X-5134-2018;
   Sanchez-Heras, Ana Beatriz/KSP-5768-2024
OI Egoavil, Cecilia/0000-0003-0166-4901; GARCIA-CASADO,
   ZAIDA/0000-0001-6592-6099; Sanchez-Heras, Ana
   Beatriz/0000-0003-1742-5374
FU Carlos III Health Institute [PI10/00347]
FX We would like to thank the Carlos III Health Institute for having
   granted this project PI10/00347. We also would like to thank the Health
   Research Institute La Fe for having granted Rosa Murria Estal which made
   possible her participation in the study. We should thank the effort to
   perform this work to the pathologists, Cristina Alenda Gonzalez,
   Francisco Javier Segui Ivanez (University Hospital of Alicante) and Ana
   Garcia Martinez (University Hospital La Fe). We also should thank the
   oncologist, Ana Santaballa Bertran (Medical Oncolgy University Hospital
   La Fe); the molecular biologist, Jose Antonio Lopez Guerrero (Valencia
   Institute of Oncology); the laboratory technicians, Gema Perez Simo
   (University Hospital La Fe) and Estefania Rojas Calvente (University
   Hospital of Alicante); the statistician, David Hervas Marin (Health
   Research Institute La Fe) and Mercedes Goicoechea Saez, Dolores Salas
   Trejo and Jacobo Martinez Santamaria (General Department of Public
   Health, Conselleria de Sanitat, Generalitat Valenciana).
CR [Anonymous], 2008, Ethical principles for medical research involving human subjects
   Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812
   Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098
   Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253
   Casciano DA, 2006, NAT BIOTECHNOL, V24, P1103, DOI 10.1038/nbt0906-1103
   Chang SW, 2012, ONCOTARGET, V3, P5, DOI 10.18632/oncotarget.433
   Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Conselleria de Sanitat Generalitat Valenciana, 2008, CANC COL HER POL CCH, P60
   Dahlgaard Jesper, 2011, BMC Res Notes, V4, P424, DOI 10.1186/1756-0500-4-424
   Cardeñosa EE, 2008, MED CLIN-BARCELONA, V130, P121, DOI 10.1157/13115767
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Hall JS, 2012, BRIT J CANCER, V107, P684, DOI 10.1038/bjc.2012.294
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Henken FE, 2007, BRIT J CANCER, V97, P1457, DOI 10.1038/sj.bjc.6604055
   Hui ABY, 2009, LAB INVEST, V89, P597, DOI 10.1038/labinvest.2009.12
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kheir TB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-29
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kolbert, 2013, PLOS ONE, V8, DOI [10.1371/0052517, DOI 10.1371/0052517]
   Lizé M, 2011, CELL CYCLE, V10, P2874, DOI 10.4161/cc.10.17.17181
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu ZD, 2012, ONCOL LETT, V4, P1027, DOI 10.3892/ol.2012.841
   Luo W, 2013, PLOS ONE, DOI [10.1371/0064759, DOI 10.1371/0064759]
   Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Milanezi F, 2008, EXPERT REV MOL DIAGN, V8, P417, DOI 10.1586/14737159.8.4.417
   Moelans CB, 2011, CELL ONCOL, V34, P475, DOI 10.1007/s13402-011-0043-7
   Ng EKO, 2013, PLOS ONE, DOI [10.1371/.005314, DOI 10.1371/.005314]
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Piñol V, 2005, JAMA-J AM MED ASSOC, V293, P1986, DOI 10.1001/jama.293.16.1986
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239
   Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53
   Swami M, 2010, NAT REV CANCER, V10, P238, DOI 10.1038/nrc2828
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
NR 44
TC 36
Z9 39
U1 0
U2 27
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD NOV
PY 2013
VL 142
IS 1
BP 19
EP 30
DI 10.1007/s10549-013-2723-7
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 248HA
UT WOS:000326687600003
PM 24129975
DA 2025-01-12
ER

PT J
AU Tan, DY
   Tan, S
   Zhang, J
   Tang, PZ
   Huang, JJ
   Zhou, WH
   Wu, SJ
AF Tan, Dunyong
   Tan, Si
   Zhang, Jie
   Tang, Peizhi
   Huang, Jianjun
   Zhou, Weihua
   Wu, Shijun
TI Histone Trimethylation of the p53 Gene by Expression of a Constitutively
   Active Prolactin Receptor in Prostate Cancer Cells
SO CHINESE JOURNAL OF PHYSIOLOGY
LA English
DT Article
DE constitutively active prolactin receptor; delta S2; histone
   modification; p53 gene; prostate cancer
ID AGGRESSIVE BREAST-CANCER; HUMAN PRL RECEPTORS; EPITHELIAL-CELLS; EZH2;
   PATHWAY; METHYLTRANSFERASE; PROLIFERATION; INVASIVENESS; METHYLATION;
   ANTAGONISTS
AB Prolactin (PRL) is a pituitary polypeptide hormone characterized by multiple biological actions including stimulation of growth in the prostate, breast and ovarian epithelial cells. A sizable body of reports has presented evidences to indicate the involvement of PRL in the pathogenic process of cancers of the reproductive system, such as prostate and breast cancers. PRL exerts its effects by dimerizing its receptor (PRLR) on the plasma membrane, and initiating cellular Jak-Stat signal pathway. We have previously cloned from prostate cancer cells a natural variant of PRLR in which the S2 subdomain of the extracellular domain is missing (Delta S2). Our preliminary data showed that Delta S2 PRLR was able to dimerize and to constitutively activate the beta-casein promoter (in the absence of its ligand, PRL) in breast and prostate epithelial cells. Enhancer of zeste homologue 2 (EZH2), an important histone-modifying enzyme, is able to trimethylate histone 3 on lysine 27 (H3K27Me3), consequently leading to gene silencing, especially silencing of tumor suppressor genes such as p53. We hypothesized that Delta S2 PRLR played an important pathogenic role in prostate cancer through, at least partly, alterations in the expression of EZH2 and the trimethylation of histone 3 on lysine 27. In the present study, overexpression of Delta S2 PRLR in prostate epithelial cells was achieved by infection with an adenoviral vector carrying the cDNA. The viable cell number overexpressing Delta S2 PRLR was assessed using MTS reagent. Western blot, chromatin immunoprecipitation (ChIP) assay and acid histone extraction were applied to detect expression of EZH2 as well as trimethylation of histone 3, respectively. In prostate epithelial cells, overexpression of Delta S2 PRLR increased the levels of EZH2 methyltransferase mRNA and protein, induced EZH2 methyltransferase recruitment to chromatin, increased the trimethylation of histone 3 on lysine 27, and decreased expression of the p53 gene. We concluded that Delta S2 PRLR plays an important pathogenic role in prostate cancer through epigenetic covalent modification leading to chromatin remodeling. Hypertrimethylation on H3K27 of the p53 gene promoter region due to elevated expression of Delta S2 PRLR by alternative splicing of the pre-mRNA in its full-length form might serve as a new mechanism underlying human prostate cancer.
C1 [Tan, Dunyong; Zhang, Jie; Tang, Peizhi; Huang, Jianjun; Zhou, Weihua; Wu, Shijun] Jishou Univ, Coll Med, Inst Med Sci, Jishou 416000, Hunan, Peoples R China.
   [Tan, Si] Univ Calif Riverside, Coll Engn, Riverside, CA 92521 USA.
C3 Jishou University; University of California System; University of
   California Riverside
RP Tan, DY (通讯作者)，Jishou Univ, Coll Med, Inst Med Sci, Datianwan Campus, Jishou 416000, Hunan, Peoples R China.
EM naturet2002@yahoo.com
FU National Natural Science Foundation of PRC [81172497, 81260396]; Jishou
   University Research Grant [jsdxkyzz101010]
FX This work was supported by the National Natural Science Foundation of
   PRC (No. 81172497 and No. 81260396) and a Jishou University Research
   Grant (No.jsdxkyzz101010).
CR Akkers RC, 2009, DEV CELL, V17, P425, DOI 10.1016/j.devcel.2009.08.005
   Bachmann J.M., 2008, J CLIN ONCOL, V24, P268
   Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Broutin I, 2010, J BIOL CHEM, V285, P8422, DOI 10.1074/jbc.M109.089128
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Dagvadorj A, 2007, ENDOCRINOLOGY, V148, P3089, DOI 10.1210/en.2006-1761
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Gourdou I, 1996, MOL ENDOCRINOL, V10, P45, DOI 10.1210/me.10.1.45
   Hahn MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018844
   He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474
   Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242
   Jacobson EM, 2011, DISCOV MED, V11, P315
   Johansson EM, 2005, MOL ENDOCRINOL, V19, P992, DOI 10.1210/me.2004-0359
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuo CB, 1998, ENDOCRINE, V9, P121, DOI 10.1385/ENDO:9:2:121
   Lee RCH, 1999, J BIOL CHEM, V274, P10024, DOI 10.1074/jbc.274.15.10024
   NAGANO M, 1994, J BIOL CHEM, V269, P13337
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tan D, 2008, BIOCHEMISTRY-US, V47, P479, DOI 10.1021/bi7013882
   Tan DY, 2011, CANCER LETT, V310, P101, DOI 10.1016/j.canlet.2011.06.014
   Tan DY, 2005, MOL ENDOCRINOL, V19, P1291, DOI 10.1210/me.2004-0304
   Tan DY, 2009, J MOL ENDOCRINOL, V42, P1
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389
   Wierod L, 2008, ONCOGENE, V27, P2763, DOI 10.1038/sj.onc.1210937
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
NR 32
TC 9
Z9 12
U1 0
U2 15
PU CHINESE PHYSIOLOGICAL SOC
PI TAIPEI
PA CHINA MEDICAL UNIVERSITY HOSPITAL, UNIV MEDICAL CENTER OF AGING
   RESEARCH, TAIPEI, TAICHUNG 40402, TAIWAN
SN 0304-4920
J9 CHINESE J PHYSIOL
JI Chin. J. Physiol.
PD OCT 31
PY 2013
VL 56
IS 5
BP 282
EP 290
DI 10.4077/CJP.2013.BAB139
PG 9
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA 249HB
UT WOS:000326767200005
PM 24032713
DA 2025-01-12
ER

PT J
AU Meier, JL
AF Meier, Jordan L.
TI Metabolic Mechanisms of Epigenetic Regulation
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID ATP-CITRATE LYASE; HISTONE ACETYLTRANSFERASE ACTIVITY; NICOTINAMIDE
   N-METHYLTRANSFERASE; NAD(+) SALVAGE PATHWAY; ADENOSYL-L-METHIONINE;
   CHEMICAL PROBE; BREAST-CANCER; TRANSCRIPTIONAL COACTIVATOR;
   ALPHA-KETOGLUTARATE; DNA METHYLATION
AB Chromatin modifications have been well-established to play a critical role in the regulation of genome function. Many of these modifications are introduced and removed by enzymes that utilize cofactors derived from primary metabolism. Recently, it has been shown that endogenous cofactors and metabolites can regulate the activity of chromatin-modifying enzymes, providing a direct link between the metabolic state of the cell and epigenetics. Here we review metabolic mechanisms of epigenetic regulation with an emphasis on their role in cancer. Focusing on three core mechanisms, we detail and draw parallels between metabolic and chemical strategies to modulate epigenetic signaling, and highlight opportunities for chemical biologists to help shape our knowledge of this emerging phenomenon. Continuing to integrate our understanding of metabolic and genomic regulatory mechanisms may help elucidate the role of nutrition in diseases such as cancer, while also providing a basis for new approaches to modulate epigenetic signaling for therapeutic benefit.
C1 NCI, Chem Genom Sect, Biol Chem Lab, Frederick, MD 21702 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Meier, JL (通讯作者)，NCI, Chem Genom Sect, Biol Chem Lab, Frederick, MD 21702 USA.
RI Meier, Jordan/N-2608-2014
OI Meier, Jordan/0000-0002-0537-7101
FU Intramural Research Program of the National Institutes of Health,
   National Cancer Institute, Center for Cancer Research
FX We apologize to colleagues whose work could not be cited here due to
   space limitations. We thank members of the Meier laboratory (D.
   Montgomery, A. Sorum) and colleagues in the Chemical Biology Laboratory
   for careful reading of this manuscript and many helpful comments. J.L.M.
   is supported by the Intramural Research Program of the National
   Institutes of Health, National Cancer Institute, Center for Cancer
   Research.
CR Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006
   Albaugh BN, 2011, CHEMBIOCHEM, V12, P290, DOI 10.1002/cbic.201000438
   Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039
   Baba R, 2012, J AM CHEM SOC, V134, P14310, DOI 10.1021/ja306045j
   Bacolla A, 2001, J BIOL CHEM, V276, P18605, DOI 10.1074/jbc.M100404200
   Barth TK, 2010, TRENDS BIOCHEM SCI, V35, P618, DOI 10.1016/j.tibs.2010.05.006
   Becher I, 2013, ACS CHEM BIOL, V8, P599, DOI 10.1021/cb3005879
   Benayoun BA, 2009, TRENDS CELL BIOL, V19, P189, DOI 10.1016/j.tcb.2009.02.003
   Bennett BD, 2009, NAT CHEM BIOL, V5, P593, DOI 10.1038/nchembio.186
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010
   Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004
   Cebrat M, 2003, BIOORGAN MED CHEM, V11, P3307, DOI 10.1016/S0968-0896(03)00265-7
   Cen YN, 2011, ORG BIOMOL CHEM, V9, P987, DOI 10.1039/c0ob00774a
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Christopher SA, 2002, CANCER RES, V62, P6639
   Cole PA, 2008, NAT CHEM BIOL, V4, P590, DOI 10.1038/nchembio.111
   Cooney CA, 2002, J NUTR, V132, p2393S
   Copeland RA, 2010, CURR OPIN CHEM BIOL, V14, P505, DOI 10.1016/j.cbpa.2010.06.174
   Corson TW, 2008, ACS CHEM BIOL, V3, P677, DOI 10.1021/cb8001792
   Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644
   Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009
   Dalhoff C, 2010, CHEMBIOCHEM, V11, P256, DOI 10.1002/cbic.200900349
   Dancy BM, 2012, CHEMBIOCHEM, V13, P2113, DOI 10.1002/cbic.201200381
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dhall A, 2011, ACS CHEM BIOL, V6, P987, DOI 10.1021/cb200142c
   Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438
   Donohoe DR, 2012, MOL CELL, V48, P612, DOI 10.1016/j.molcel.2012.08.033
   Donohoe DR, 2012, J CELL PHYSIOL, V227, P3169, DOI 10.1002/jcp.24054
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Evans MJ, 2006, CHEM REV, V106, P3279, DOI 10.1021/cr050288g
   Eychène A, 2008, NAT REV CANCER, V8, P683, DOI 10.1038/nrc2460
   Fang MZ, 2003, CANCER RES, V63, P7563
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100
   Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4
   Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004
   Galli U, 2013, J MED CHEM, V56, P6279, DOI 10.1021/jm4001049
   Gao L, 2007, J CHROMATOGR B, V853, P303, DOI 10.1016/j.jchromb.2007.03.029
   Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002
   GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006-291X(86)90048-3
   Guan KL, 2011, TRENDS BIOCHEM SCI, V36, P108, DOI 10.1016/j.tibs.2010.09.003
   GUERINOT F, 1977, EUR J CANCER, V13, P1257, DOI 10.1016/0014-2964(77)90033-0
   Hasmann M, 2003, CANCER RES, V63, P7436
   Hathaway NA, 2012, CELL, V149, P1447, DOI 10.1016/j.cell.2012.03.052
   Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008
   He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488
   Henikoff S, 2011, TRENDS GENET, V27, P389, DOI 10.1016/j.tig.2011.06.006
   Hwang Y, 2007, ANGEW CHEM INT EDIT, V46, P7621, DOI 10.1002/anie.200702485
   Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017
   Islam K, 2012, J AM CHEM SOC, V134, P5909, DOI 10.1021/ja2118333
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   James LI, 2013, NAT CHEM BIOL, V9, P184, DOI [10.1038/nchembio.1157, 10.1038/NCHEMBIO.1157]
   Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004
   Katoh Y, 2011, MOL CELL, V41, P554, DOI 10.1016/j.molcel.2011.02.018
   Kemp CD, 2012, CLIN CANCER RES, V18, P77, DOI 10.1158/1078-0432.CCR-11-0962
   Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092
   King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200
   Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898
   Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]
   Krejcí A, 2012, BIOCHEM SOC T, V40, P311, DOI 10.1042/BST20110767
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Langer MR, 2002, J BIOL CHEM, V277, P27337, DOI 10.1074/jbc.M203251200
   Larson DR, 2011, SCIENCE, V332, P475, DOI 10.1126/science.1202142
   Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9
   Lee HM, 2009, ACS CHEM BIOL, V4, P409, DOI 10.1021/cb900036s
   Letouzé E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018
   Lin CW, 2004, J AM CHEM SOC, V126, P5982, DOI 10.1021/ja038854h
   Lin HN, 2012, ACS CHEM BIOL, V7, P947, DOI 10.1021/cb3001793
   Lin RT, 2013, MOL CELL, V51, P506, DOI 10.1016/j.molcel.2013.07.002
   Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47
   Liu X, 2008, NATURE, V451, P846, DOI 10.1038/nature06546
   Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677
   Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Luo XL, 2011, J AM CHEM SOC, V133, P9451, DOI 10.1021/ja201597b
   Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840
   Mason E. F., 2013, MODERN PATHOL, DOI [10.1038/modpa-thol.2013.86, DOI 10.1038/M0DPA-TH0L.2013.86]
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Moellering RE, 2013, SCIENCE, V341, P549, DOI 10.1126/science.1238327
   Momparler RL, 2012, LEUKEMIA RES, V36, P1049, DOI 10.1016/j.leukres.2012.03.001
   Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(01)00269-0
   Nakahata Y, 2009, SCIENCE, V324, P654, DOI 10.1126/science.1170803
   Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Oermann EK, 2012, SEMIN CELL DEV BIOL, V23, P370, DOI 10.1016/j.semcdb.2012.01.013
   Paige JS, 2012, SCIENCE, V335, P1194, DOI 10.1126/science.1218298
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Patricelli MP, 2011, CHEM BIOL, V18, P699, DOI 10.1016/j.chembiol.2011.04.011
   Phang JM, 2013, EPIGENETICS-US, V8, P231, DOI 10.4161/epi.24042
   Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200
   Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227
   Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350
   Ptashne M, 2013, P NATL ACAD SCI USA, V110, P7101, DOI 10.1073/pnas.1305399110
   Richon VM, 2011, CHEM BIOL DRUG DES, V78, P199, DOI 10.1111/j.1747-0285.2011.01135.x
   Roessler M, 2005, CLIN CANCER RES, V11, P6550, DOI 10.1158/1078-0432.CCR-05-0983
   Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062
   Rose NR, 2011, CHEM SOC REV, V40, P4364, DOI 10.1039/c0cs00203h
   Rotili D, 2011, CHEM BIOL, V18, P642, DOI 10.1016/j.chembiol.2011.03.007
   Rowling MJ, 2002, J NUTR, V132, P365, DOI 10.1093/jn/132.3.365
   Sack JS, 2011, BIOCHEM J, V436, P331, DOI 10.1042/BJ20102161
   Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323
   Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022
   Siudeja K, 2011, EMBO MOL MED, V3, P755, DOI 10.1002/emmm.201100180
   Smith BC, 2009, ANAL BIOCHEM, V394, P101, DOI 10.1016/j.ab.2009.07.019
   Smith EH, 2007, HUM MOL GENET, V16, P3136, DOI 10.1093/hmg/ddm275
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Szczepankiewicz BG, 2012, J ORG CHEM, V77, P7319, DOI 10.1021/jo301067e
   Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040
   Tang SW, 2011, CARCINOGENESIS, V32, P138, DOI 10.1093/carcin/bgq225
   Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200
   Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h
   Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157
   Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769
   Wang P, 2013, ONCOGENE, V32, P3091, DOI 10.1038/onc.2012.315
   Wang R, 2013, J AM CHEM SOC, V135, P1048, DOI 10.1021/ja309412s
   Wang R, 2011, J AM CHEM SOC, V133, P7648, DOI 10.1021/ja2006719
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097
   Whitehouse I, 2013, CURR OPIN GENET DEV, V23, P140, DOI 10.1016/j.gde.2012.12.007
   Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108
   Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111
   Wu J, 2009, BIOORGAN MED CHEM, V17, P1381, DOI 10.1016/j.bmc.2008.12.014
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Yang C, 2013, J AM CHEM SOC, V135, P7791, DOI 10.1021/ja311636b
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018
   Yang YY, 2010, J AM CHEM SOC, V132, P3640, DOI 10.1021/ja908871t
   Yao Y, 2011, J AM CHEM SOC, V133, P16746, DOI 10.1021/ja206312b
   Hung YP, 2011, CELL METAB, V14, P545, DOI 10.1016/j.cmet.2011.08.012
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
   Zhang T, 2009, J BIOL CHEM, V284, P20408, DOI 10.1074/jbc.M109.016469
   Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944
   Zheng GQ, 2013, RNA BIOL, V10, P915, DOI 10.4161/rna.24711
   Zheng YJ, 2005, J AM CHEM SOC, V127, P17182, DOI 10.1021/ja0558544
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 155
TC 54
Z9 60
U1 0
U2 50
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD DEC
PY 2013
VL 8
IS 12
BP 2607
EP 2621
DI 10.1021/cb400689r
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 281CW
UT WOS:000329078100002
PM 24228614
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Nakagawa, S
   Okabe, H
   Sakamoto, Y
   Hayashi, H
   Hashimoto, D
   Yokoyama, N
   Sakamoto, K
   Kuroki, H
   Mima, K
   Nitta, H
   Imai, K
   Chikamoto, A
   Watanabe, M
   Beppu, T
   Baba, H
AF Nakagawa, Shigeki
   Okabe, Hirohisa
   Sakamoto, Yasuo
   Hayashi, Hiromitsu
   Hashimoto, Daisuke
   Yokoyama, Naomi
   Sakamoto, Keita
   Kuroki, Hideyuki
   Mima, Kosuke
   Nitta, Hidetoshi
   Imai, Katsunori
   Chikamoto, Akira
   Watanabe, Masayuki
   Beppu, Toru
   Baba, Hideo
TI Enhancer of Zeste Homolog 2 (EZH2) Promotes Progression of
   Cholangiocarcinoma Cells by Regulating Cell Cycle and Apoptosis
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID EMBRYONIC STEM-CELLS; GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE;
   DEVELOPMENTAL REGULATORS; BILIARY EPITHELIA; PROSTATE-CANCER;
   BREAST-CANCER; POLYCOMB; PROLIFERATION; EXPRESSION
AB Background. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2). When present in PRC2, EZH2 catalyzes trimethylation on lysine 27 residue of histone H3, resulting in epigenetic silencing of gene expression and cancer progression. We investigated the expression and function of EZH2 in intrahepatic and extrahepatic cholangiocarcinoma (ICC and ECC).
   Methods. The influence of EZH2 on cell growth and apoptosis was assessed by knockdown experiments. Target gene of EZH2 was searched by quantitative RT-PCR. Clinical significance of EZH2 in 86 cholangiocarcinoma patients (45 ICC and 41 ECC) who underwent curative surgery was examined by immunohistochemistry.
   Results. In vitro analysis, knockdown of EZH2 reduced cell growth, induced G1 arrest, and induced apoptosis, as confirmed by Annexin V staining and increased sub-G1 populations in cholangiocarcinoma cell lines. The expression levels of p16(INK4a) and p27(KIP1) were remarkably increased by knockdown of EZH2 in these cell lines. In immunohistochemical study, EZH2 upregulation correlated with tumor diameter (p = 0.0103) in ICC, lymph node metastasis (p = 0.0292) in ECC, and Ki67 index in both ICC (p = 0.0364) and ECC (p = 0.0017). In addition, EZH2 expression was correlated with poor prognosis in both ICC (p = 0.0447) and ECC (p = 0.0227).
   Conclusions. The current study demonstrated relationships between EZH2 expression and acceleration of the cell cycle and antiapoptosis, and poor prognosis in cholangiocarcinoma. These results suggest that EZH2 may represent a potential therapeutic target in patients with cholangiocarcinoma.
C1 [Nakagawa, Shigeki; Okabe, Hirohisa; Sakamoto, Yasuo; Hayashi, Hiromitsu; Hashimoto, Daisuke; Yokoyama, Naomi; Sakamoto, Keita; Kuroki, Hideyuki; Mima, Kosuke; Nitta, Hidetoshi; Imai, Katsunori; Chikamoto, Akira; Watanabe, Masayuki; Beppu, Toru; Baba, Hideo] Kumamoto Univ, Grad Sch Life Sci, Dept Surg Gastroenterol, Kumamoto, Japan.
   [Sakamoto, Yasuo; Beppu, Toru] Kumamoto Univ Hosp, Dept Multidisciplinary Treatment Gastroenterol Ca, Kumamoto, Japan.
C3 Kumamoto University; Kumamoto University
RP Baba, H (通讯作者)，Kumamoto Univ, Grad Sch Life Sci, Dept Surg Gastroenterol, Kumamoto, Japan.
EM hdobaba@kumamoto-u.ac.jp
RI Hashimoto, Daisuke/AAE-7134-2020
FU Grants-in-Aid for Scientific Research [24592008] Funding Source: KAKEN
CR Alpini G, 2002, HEPATOLOGY, V35, P1256, DOI 10.1053/jhep.2002.33541
   Avan A, 2012, MOL CANCER THER, V11, P1735, DOI 10.1158/1535-7163.MCT-12-0037
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a
   Huang WY, 2011, BIOCHEM PHARMACOL, V81, P510, DOI 10.1016/j.bcp.2010.11.014
   Ketel CS, 2005, MOL CELL BIOL, V25, P6857, DOI 10.1128/MCB.25.16.6857-6868.2005
   Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Nakanuma Y, 2009, WORLD J HEPATOL, V1, P35, DOI 10.4254/wjh.v1.i1.35
   Nakeeb A, 1996, ANN SURG, V224, P463, DOI 10.1097/00000658-199610000-00005
   Ohno I, 2009, INTERNAL MED, V48, P415, DOI 10.2169/internalmedicine.48.1817
   Okabe H, 2012, INT J CANC
   Okabe H, 2011, ANN SURG ONCOL, V18, P1175, DOI 10.1245/s10434-010-1391-7
   Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013
   Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106
   Roberts SK, 1997, GASTROENTEROLOGY, V112, P269, DOI 10.1016/S0016-5085(97)70244-0
   Saramäki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327
   Sasaki M, 2008, J PATHOL, V215, P175, DOI 10.1002/path.2345
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   Sasaki M, 2013, HISTOPATHOLOGY, V62, P446, DOI 10.1111/his.12016
   Schuettengruber B, 2009, PLOS BIOL, V7, P146, DOI 10.1371/journal.pbio.1000013
   Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817
   Shaib YH, 2007, AM J GASTROENTEROL, V102, P1016, DOI 10.1111/j.1572-0241.2007.01104.x
   Shiojiri N, 1997, MICROSC RES TECHNIQ, V39, P328, DOI 10.1002/(SICI)1097-0029(19971115)39:4<328::AID-JEMT3>3.0.CO;2-D
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162
   Yamaguchi J, 2010, CANCER SCI, V101, P355, DOI 10.1111/j.1349-7006.2009.01387.x
   Zhang B, 2011, CARCINOGENESIS, V32, P2, DOI 10.1093/carcin/bgq209
NR 36
TC 53
Z9 59
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD DEC
PY 2013
VL 20
SU 3
BP S667
EP S675
DI 10.1245/s10434-013-3135-y
PG 9
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 268VB
UT WOS:000328197600042
PM 23887863
DA 2025-01-12
ER

PT J
AU Citro, S
   Jaffray, E
   Hay, RT
   Seiser, C
   Chiocca, S
AF Citro, Simona
   Jaffray, Ellis
   Hay, Ronald T.
   Seiser, Christian
   Chiocca, Susanna
TI A role for paralog-specific sumoylation in histone deacetylase 1
   stability
SO JOURNAL OF MOLECULAR CELL BIOLOGY
LA English
DT Article
DE breast cancer; HDAC1; PIAS; SUMO; ubiquitin
ID IN-VIVO IDENTIFICATION; TRANSCRIPTIONAL ACTIVITY; PROTEASOME INHIBITORS;
   MASS-SPECTROMETRY; SUMO; EXPRESSION; CANCER; HDAC1; ACTIVATION;
   PROGNOSIS
AB Histone deacetylase 1 (HDAC1) is an essential epigenetic regulator belonging to a highly conserved family of deacetylases. Increased HDAC1 activity and expression often correlates with neoplastic transformation. Here we show how specific modification of HDAC1 by SUMO1, but not by SUMO2, facilitates HDAC1 degradation. Our findings reveal that SUMO1, but not SUMO2, conjugation to HDAC1 promotes HDAC1 ubiquitination and degradation. This is suggested by the observation that in non-tumorigenic mammary epithelial cells HDAC1 is preferentially conjugated to SUMO1 leading to HDAC1 proteolysis, whereas in breast cancer cells HDAC1 is more conjugated to SUMO2, promoting HDAC1 protein stability. SUMO E3 ligases play an important role in paralog-specific conjugation; in particular, the SUMO E3 ligase PIASy, which is overexpressed in breast cancer cells, selectively promotes the conjugation of HDAC1 to SUMO2. Therefore, cell environment affects paralog-specific sumoylation of HDAC1, whose conjugation to SUMO1 but not to SUMO2 facilitates its protein turnover. Our findings uncover a role for paralog-specific sumoylation of HDAC1 whose significance is emphasized by the use of HDAC inhibitors as anticancer drugs.
C1 [Citro, Simona; Chiocca, Susanna] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy.
   [Jaffray, Ellis; Hay, Ronald T.] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee DD1 5EH, Scotland.
   [Seiser, Christian] Med Univ Vienna, Max F Perutz Labs, Dept Med Biochem, A-1030 Vienna, Austria.
C3 IRCCS European Institute of Oncology (IEO); University of Dundee;
   Medical University of Vienna; University of Vienna; Vienna Biocenter
   (VBC); Max F. Perutz Laboratories (MFPL)
RP Chiocca, S (通讯作者)，European Inst Oncol, Dept Expt Oncol, IFOM IEO Campus, I-20139 Milan, Italy.
EM susanna.chiocca@ieo.eu
RI Citro, Simona/K-4994-2016; Chiocca, Susanna/AAC-8863-2019; Hay,
   Ronald/F-9338-2011
OI Hay, Ronald/0000-0001-7113-9024; Seiser, Christian/0000-0002-7046-9352;
   citro, simona/0000-0003-3561-1824; Chiocca, Susanna/0000-0002-9721-0850
FU Associazione Italiana per la Ricerca sul Cancro [AIRC IG5732, AIRC
   IG12075]; Italian Ministry of Health; Austrian Science Fund [P 22340]
FX This work was supported by grants from Associazione Italiana per la
   Ricerca sul Cancro to S.Ch. (AIRC IG5732, AIRC IG12075) and from the
   Italian Ministry of Health. C.S. was supported by the Austrian Science
   Fund (P 22340).
CR Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5
   Blomster HA, 2010, J BIOL CHEM, V285, P19324, DOI 10.1074/jbc.M110.106955
   Boggio R, 2004, MOL CELL, V16, P549, DOI 10.1016/j.molcel.2004.11.007
   Borrell B, 2010, NATURE, V463, P858, DOI 10.1038/463858a
   Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618
   Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893
   Cai QL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009720
   Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045
   Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004
   Citro Simona, 2013, Front Biosci (Schol Ed), V5, P544
   Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213
   Coppola D, 2009, J CANCER RES CLIN, V135, P1287, DOI 10.1007/s00432-009-0570-z
   David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200
   Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7
   Dovey OM, 2013, BLOOD, V121, P1335, DOI 10.1182/blood-2012-07-441949
   Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107
   Galisson F, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004796
   Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293
   Geoffroy MC, 2009, NAT REV MOL CELL BIO, V10, P564, DOI 10.1038/nrm2707
   Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004
   Grant C, 2010, EXPERT REV ANTICANC, V10, P997, DOI [10.1586/era.10.88, 10.1586/ERA.10.88]
   Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227
   Guo B, 2007, BIOCHEM SOC T, V35, P1414, DOI 10.1042/BST0351414
   Heideman MR, 2013, BLOOD, V121, P2038, DOI 10.1182/blood-2012-08-450916
   Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387
   Jurkin J, 2011, CELL CYCLE, V10, P406, DOI 10.4161/cc.10.3.14712
   Kisselev AF, 2012, CHEM BIOL, V19, P99, DOI 10.1016/j.chembiol.2012.01.003
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717
   Li YM, 2010, CANCER RES, V70, P646, DOI 10.1158/0008-5472.CAN-09-1924
   Ma PP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003377
   Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458
   Martin N, 2009, EMBO J, V28, P3534, DOI 10.1038/emboj.2009.279
   Matic I, 2008, MOL CELL PROTEOMICS, V7, P132, DOI 10.1074/mcp.M700173-MCP200
   Meulmeester E, 2008, MOL CELL, V30, P610, DOI 10.1016/j.molcel.2008.03.021
   Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019
   Nakagawa M, 2007, ONCOL REP, V18, P769
   Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236
   Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198
   Patani N, 2011, ANTICANCER RES, V31, P4115
   Pedrioli PGA, 2006, NAT METHODS, V3, P533, DOI 10.1038/NMETH891
   Rangwala S, 2012, FUTURE MED CHEM, V4, P471, DOI [10.4155/fmc.12.6, 10.4155/FMC.12.6]
   Rosas-Acosta G, 2005, MOL CELL PROTEOMICS, V4, P56, DOI 10.1074/mcp.M400149-MCP200
   Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252
   Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988
   Saydmohammed M, 2010, J CELL BIOCHEM, V110, P447, DOI 10.1002/jcb.22558
   Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07
   Spiegel S, 2012, ONCOGENE, V31, P537, DOI 10.1038/onc.2011.267
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Tatham MH, 2005, NAT STRUCT MOL BIOL, V12, P67, DOI 10.1038/nsmb878
   Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200
   Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716
   Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200
   Warleta F, 2010, FOOD CHEM TOXICOL, V48, P1092, DOI 10.1016/j.fct.2010.01.031
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Weisshaar SR, 2008, FEBS LETT, V582, P3174, DOI 10.1016/j.febslet.2008.08.008
   Yang XJ, 2006, MOL CELL, V23, P779, DOI 10.1016/j.molcel.2006.08.009
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhu JM, 2008, J BIOL CHEM, V283, P29405, DOI 10.1074/jbc.M803632200
   Zhu SS, 2009, MOL CELL, V33, P570, DOI 10.1016/j.molcel.2009.02.008
NR 63
TC 36
Z9 38
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1674-2788
EI 1759-4685
J9 J MOL CELL BIOL
JI J. Mol. Cell Biol.
PD DEC
PY 2013
VL 5
IS 6
BP 416
EP 427
DI 10.1093/jmcb/mjt032
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 303ZV
UT WOS:000330715900007
PM 24068740
OA Bronze
DA 2025-01-12
ER

PT J
AU Sabnis, GJ
   Goloubeva, OG
   Kazi, AA
   Shah, P
   Brodie, AH
AF Sabnis, Gauri J.
   Goloubeva, Olga G.
   Kazi, Armina A.
   Shah, Preeti
   Brodie, Angela H.
TI HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant
   MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITOR; POSITIVE
   BREAST-CANCER; CHAPERONE FUNCTION; PROTEASOMAL DEGRADATION;
   POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; GENE-EXPRESSION; MESSENGER-RNA;
   TAMOXIFEN
AB We previously showed that in innately resistant tumors, silencing of the estrogen receptor (ER) could be reversed by treatment with a histone deacetylase (HDAC) inhibitor, entinostat. Tumors were then responsive to aromatase inhibitor (AI) letrozole. Here, we investigated whether ER in the acquired letrozole-resistant tumors could be restored with entinostat. Ovariectomized athymic mice were inoculated with MCF-7Ca cells, supplemented with androstenedione (Delta(4)Delta), the aromatizable substrate. When the tumors reached about 300 mm(3), the mice were treated with letrozole. After initial response to letrozole, the tumors eventually became resistant (doubled their initial volume). The mice then were grouped to receive letrozole, exemestane (250 mu g/d), entinostat (50 mu g/d), or the combination of entinostat with letrozole or exemestane for 26 weeks. The growth rates of tumors of mice treated with the combination of entinostat with letrozole or exemestane were significantly slower than with the single agent (P < 0.05). Analysis of the letrozole-resistant tumors showed entinostat increased ER alpha expression and aromatase activity but downregulated Her-2, p-Her-2, p-MAPK, and p-Akt. However, the mechanism of action of entinostat in reversing acquired resistance did not involve epigenetic silencing but rather included posttranslational as well as transcriptional modulation of Her-2. Entinostat treatment reduced the association of the Her-2 protein with HSP-90, possibly by reducing the stability of Her-2 protein. In addition, entinostat also reduced Her-2 mRNA levels and its stability. Our results suggest that the HDAC inhibitor may reverse letrozole resistance in cells and tumors by modulating Her-2 expression and activity. (C)2013 AACR.
C1 [Sabnis, Gauri J.; Kazi, Armina A.; Shah, Preeti; Brodie, Angela H.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.
   [Goloubeva, Olga G.] Univ Maryland, Sch Med, Div Biostat, Baltimore, MD 21201 USA.
   [Goloubeva, Olga G.] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
   [Kazi, Armina A.] Loyola Univ, Baltimore, MD USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore; Loyola
   University Maryland
RP Sabnis, GJ (通讯作者)，Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 685 W Baltimore St,HSF I 580, Baltimore, MD 21201 USA.
EM gsabn001@umaryland.edu
OI Sabnis, Gauri/0000-0001-8703-9394
FU Susan G. Komen [KG10037, SAC100010]; NCI/NIH [CA-62483]
FX This work was supported by grants to G.J. Sabnis (KG10037 from Susan G.
   Komen) and to A.H. Brodie (CA-62483 from NCI/NIH and SAC100010 from
   Susan G. Komen).
CR Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Brodie A, 2005, CLIN CANCER RES, V11, p884S
   Brodie A, 1999, ENDOCR-RELAT CANCER, V6, P205, DOI 10.1677/erc.0.0060205
   Buzdar Aman, 2003, Clin Breast Cancer, V4 Suppl 1, pS42, DOI 10.3816/CBC.2003.s.014
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Goss PE, 2006, SEMIN ONCOL, V33, pS8, DOI 10.1053/j.seminoncol.2006.03.025
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Jelovac D, 2005, CANCER RES, V65, P5380, DOI 10.1158/0008-5472.CAN-04-4502
   Jelovac D, 2004, CLIN CANCER RES, V10, P7375, DOI 10.1158/1078-0432.CCR-04-0565
   Kazi AA, 2005, MOL ENDOCRINOL, V19, P2006, DOI 10.1210/me.2004-0388
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006
   Long BJ, 1998, J STEROID BIOCHEM, V67, P293, DOI 10.1016/S0960-0760(98)00122-8
   Long BJ, 2004, JNCI-J NATL CANCER I, V96, P456, DOI 10.1093/jnci/djh076
   Long BJ, 2002, CLIN CANCER RES, V8, P2378
   Nishioka C, 2008, LEUKEMIA RES, V32, P1382, DOI 10.1016/j.leukres.2008.02.018
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Sabnis G, 2009, END SOC ANN M WASH D
   Sabnis G, 2010, MOL CANCER THER, V9, P46, DOI 10.1158/1535-7163.MCT-09-0696
   Sabnis G, 2009, CANCER RES, V69, P1416, DOI 10.1158/0008-5472.CAN-08-0857
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Sabnis GJ, 2012, P 103 ANN M AACR MAR
   Salnis GJ, 2008, CANCER RES, V68, P4518, DOI 10.1158/0008-5472.CAN-07-5999
   Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110
   Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Swain SM, 2005, NEW ENGL J MED, V353, P2807, DOI 10.1056/NEJMe058273
   Wardley AM, 2010, J CLIN ONCOL, V28
   Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251
   YUE W, 1995, CANCER RES, V55, P3073
   YUE W, 1993, J STEROID BIOCHEM, V44, P671, DOI 10.1016/0960-0760(93)90278-5
   YUE W, 1994, CANCER RES, V54, P5092
   Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8
   ZHOU D, 1990, CANCER RES, V50, P6949
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
NR 37
TC 51
Z9 58
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD DEC
PY 2013
VL 12
IS 12
BP 2804
EP 2816
DI 10.1158/1535-7163.MCT-13-0345
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 272UK
UT WOS:000328486600017
PM 24092810
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Forn, M
   Muñoz, M
   Tauriello, DVF
   Merlos-Suárez, A
   Rodilla, V
   Bigas, A
   Batlle, E
   Jordà, M
   Peinado, MA
AF Forn, Marta
   Munoz, Mar
   Tauriello, Daniele V. F.
   Merlos-Suarez, Anna
   Rodilla, Veronica
   Bigas, Anna
   Batlle, Eduard
   Jorda, Mireia
   Peinado, Miguel A.
TI Long range epigenetic silencing is a trans-species mechanism that
   results in cancer specific deregulation by overriding the chromatin
   domains of normal cells
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Gene silencing; DNA methylation; Colorectal cancer; Chromatin marks;
   Histone modification; Long range epigenetic silencing; Cell
   differentiation
ID COLORECTAL-CANCER; DNA METHYLATION; STEM-CELLS; HISTONE MODIFICATIONS;
   GENE-EXPRESSION; BREAST-CANCER; COLON-CANCER; HUMAN GENOME;
   HYPERMETHYLATION; CTCF
AB DNA methylation and chromatin remodeling are frequently implicated in the silencing of genes involved in carcinogenesis. Long Range Epigenetic Silencing (LRES) is a mechanism of gene inactivation that affects multiple contiguous CpG islands and has been described in different human cancer types. However, it is unknown whether there is a coordinated regulation of the genes embedded in these regions in normal cells and in early stages of tumor progression. To better characterize the molecular events associated with the regulation and remodeling of these regions we analyzed two regions undergoing LRES in human colon cancer in the mouse model. We demonstrate that LRES also occurs in murine cancer in vivo and mimics the molecular features of the human phenomenon, namely, downregulation of gene expression, acquisition of inactive histone marks, and DNA hypermethylation of specific CpG islands. The genes embedded in these regions showed a dynamic and autonomous regulation during mouse intestinal cell differentiation, indicating that, in the framework considered here, the coordinated regulation in LRES is restricted to cancer. Unexpectedly, benign adenomas in Apc(Min/+) mice showed overexpression of most of the genes affected by LRES in cancer, which suggests that the repressive remodeling of the region is a late event. Chromatin immunoprecipitation analysis of the transcriptional insulator CTCF in mouse colon cancer cells revealed disrupted chromatin domain boundaries as compared with normal cells. Malignant regression of cancer cells by in vitro differentiation resulted in partial reversion of LRES and gain of CTCF binding. We conclude that genes in LRES regions are plastically regulated in cell differentiation and hyperproliferation, but are constrained to a coordinated repression by abolishing boundaries and the autonomous regulation of chromatin domains in cancer cells. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Forn, Marta; Munoz, Mar; Jorda, Mireia; Peinado, Miguel A.] Inst Predict & Personalized Med Canc, Badalona 08916, Barcelona, Spain.
   [Tauriello, Daniele V. F.; Merlos-Suarez, Anna; Batlle, Eduard] Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain.
   [Rodilla, Veronica] Inst Hosp Mar Invest Med IMIM, Barcelona 08003, Spain.
   [Batlle, Eduard] ICREA, Barcelona, Spain.
C3 Barcelona Institute of Science & Technology; Institute for Research in
   Biomedicine - IRB Barcelona; Hospital del Mar Research Institute; ICREA
RP Peinado, MA (通讯作者)，Inst Predict & Personalized Med Canc, Badalona 08916, Barcelona, Spain.
EM map@imppc.org
RI Jordà, Mireia/Z-4519-2019; Forn, Marta/R-2808-2016; Peinado, Miguel
   A./A-5591-2008; Benito, Verónica/A-5171-2018; Tauriello, Daniele V.
   F./H-4644-2018; Batlle, Eduard/K-8080-2014; Bigas, Anna/A-7457-2014
OI Tauriello, Daniele V. F./0000-0003-1522-3496; Batlle,
   Eduard/0000-0003-2422-0326; Peinado, Miguel A./0000-0002-4090-793X;
   Jorda, Mireia/0000-0003-3709-1850; Bigas, Anna/0000-0003-4801-6899;
   RODILLA BENITO, VERONICA/0000-0003-0512-4179
FU Ministry of Science and Innovation [FPI BES2007-16580, SAF2008/1409,
   SAF2011/23638, CSD2006/49]; Juan de la Cierva postdoctoral fellowship;
   Generalitat de Catalunya [2009 SGR 1356]; ERC Starting grant; ICREA
   Funding Source: Custom
FX We thank Marta Vives and Rosa Ampudia (Laboratori d'Immunobiologia per a
   la Recerca i les Aplicacions Diagnostiques -LIRAD, Badalona) and Pura
   Munoz-Canoves (Universitat Pompeu Fabra, Barcelona) for kindly providing
   mouse tissues; and Marcus Buschbeck for helpful advices and Sergio
   Palomo for technical assistance. MF was supported by a fellowship from
   the Ministry of Science and Innovation (FPI BES2007-16580), DVFT holds a
   Juan de la Cierva postdoctoral fellowship and AM-S held an AECC
   postdoctoral fellowship. This work was supported by grants from the
   Ministry of Science and Innovation (SAF2008/1409, SAF2011/23638 and
   CSD2006/49), and the Generalitat de Catalunya (2009 SGR 1356) to MAP;
   and an ERC Starting grant to EB.
CR Acosta D, 2011, MAMM GENOME, V22, P249, DOI 10.1007/s00335-011-9318-6
   ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Choi SC, 2011, VITAM HORM, V85, P79, DOI 10.1016/B978-0-12-385961-7.00005-6
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Dallosso AR, 2012, ONCOGENE, V31, P4409, DOI 10.1038/onc.2011.609
   Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745
   Delgado MD, 1999, FEBS LETT, V444, P5, DOI 10.1016/S0014-5793(99)00013-7
   Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Docquier F, 2009, CLIN CANCER RES, V15, P5762, DOI 10.1158/1078-0432.CCR-09-0329
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Farrar D, 2010, MOL CELL BIOL, V30, P1199, DOI 10.1128/MCB.00827-09
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Grimm C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003250
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Iliou MS, 2011, EPIGENETICS-US, V6, P1344, DOI 10.4161/epi.6.11.18021
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Javierre BM, 2011, MOL CANCER RES, V9, P1139, DOI 10.1158/1541-7786.MCR-10-0515
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Kondo Y, 2003, J BIOL CHEM, V278, P27658, DOI 10.1074/jbc.M304072200
   Krahn MP, 2010, J BIOL CHEM, V285, P13193, DOI 10.1074/jbc.M109.080051
   Long SH, 2007, J CLIN ENDOCR METAB, V92, P4394, DOI 10.1210/jc.2007-0986
   Mayor R, 2009, BRIT J CANCER, V100, P1534, DOI 10.1038/sj.bjc.6605045
   Mayor R, 2011, EPIGENETICS-US, V6, P1138, DOI 10.4161/epi.6.9.16066
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Merlos-Suárez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ose R, 2009, MOL ONCOL, V3, P54, DOI 10.1016/j.molonc.2008.10.005
   Park JH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-82
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Raevskaya NM, 2005, GENE, V359, P127, DOI 10.1016/j.gene.2005.07.005
   Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106
   Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105
   Rosa-Garrido M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039371
   Sääf AM, 2007, MOL BIOL CELL, V18, P4245, DOI 10.1091/mbc.E07-04-0309
   Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   Tarafa G, 2003, CANCER RES, V63, P5731
   Torrano V, 2005, J BIOL CHEM, V280, P28152, DOI 10.1074/jbc.M501481200
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Xiao S, 2012, CELL, V149, P1381, DOI 10.1016/j.cell.2012.04.029
NR 54
TC 11
Z9 13
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD DEC
PY 2013
VL 7
IS 6
BP 1129
EP 1141
DI 10.1016/j.molonc.2013.08.008
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 268NA
UT WOS:000328176400012
PM 24035705
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Fu, Y
   Wei, XF
   Tang, CY
   Li, JP
   Liu, R
   Shen, A
   Wu, ZJ
AF Fu, Yu
   Wei, Xufu
   Tang, Chengyong
   Li, Jianping
   Liu, Rui
   Shen, Ai
   Wu, Zhongjun
TI Circulating microRNA-101 as a potential biomarker for hepatitis B
   virus-related hepatocellular carcinoma
SO ONCOLOGY LETTERS
LA English
DT Article
DE miR-101; serum; monitor; HBV-related HCC
ID BREAST-CANCER; HEALTHY-SUBJECTS; SERUM; SUPPRESSOR; EXPRESSION; MARKERS;
   PLASMA; RNAS
AB Circulating microRNAs (miRNAs) are emerging as promising biomarkers for cancer; however, the significance of circulating miRNAs in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains largely unknown. Based on our prior observations that miRNA-101 (miR-101) is downregulated by HBV and induces epigenetic modification, we sought to test whether circulating miR-101 may serve as a potential biomarker for HCC. The expression of miR-101 in HCCs and serum was evaluated by real-time polymerase chain reaction. Tissue and serum miR-101 levels were assessed in samples from patients with HBV-related HCC and healthy controls. A potential correlation was also evaluated between miR-101 expression and the clinicopathological features and prognosis of HCC patients. miR-101 was downregulated in HBV-related HCC tissues compared with adjacent noncancerous tissues. Furthermore, the miR-101 levels in these tissues from HCC patients were significantly lower than those in tissues from control subjects. Notably, serum miR-101 levels were found to have an inverse correlation with tissue miR-101 expression levels. The expression of serum miR-101 in patients with HBV-related HCC was significantly higher than that in the healthy controls, and this increase correlated with hepatitis B surface antigen positivity, HBV DNA levels and tumor size. These results indicate that different factors govern the levels of miR-101 in the tissue and serum of HCC patients. Given the marked and consistent increase in serum miR-101 levels in HCC patients, circulating miR-101 may serve as a promising biochemical marker for monitoring the progression of tumor development in HBV-related HCC.
C1 [Fu, Yu; Wei, Xufu; Liu, Rui; Shen, Ai; Wu, Zhongjun] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing 400016, Peoples R China.
   [Tang, Chengyong] Chongqing Med Univ, Affiliated Hosp 1, Dept Clin Pharmacol, Chongqing 400016, Peoples R China.
   [Li, Jianping] Chongqing Med Univ, Dept Histol & Embryol, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University
RP Wu, ZJ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM wzjtcy@126.com
RI Fu, Yu/AAP-6707-2020; tang, cheng/KLD-8823-2024
OI Shen, Ai/0000-0002-6966-0168
FU National Natural Science Foundation of China [81171562]; Chongqing
   Health Bureau [2011-1-010]
FX This study was supported by the National Natural Science Foundation of
   China (no. 81171562) and the Chongqing Health Bureau grant (no.
   2011-1-010).
CR Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1111/j.1365-2613.2001.iep178.x
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bianchi F, 2011, EMBO MOL MED, V3, P495, DOI 10.1002/emmm.201100154
   Brase JC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-306
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cortez MA, 2009, EXPERT OPIN BIOL TH, V9, P703, DOI [10.1517/14712590902932889, 10.1517/14712590902932889 ]
   Croci S, 2002, ANTICANCER RES, V22, P2903
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x
   Jackson DB, 2009, P NATL ACAD SCI USA, V106, pE5, DOI 10.1073/pnas.0809999106
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Ji X, 2009, CLIN CHEM, V55, P1944, DOI 10.1373/clinchem.2009.125310
   Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256
   Liu SP, 2012, J HEPATOL, V56, P389, DOI 10.1016/j.jhep.2011.08.008
   Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Mott JL, 2009, HEPATOLOGY, V50, P630, DOI 10.1002/hep.23010
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   OKA H, 1994, HEPATOLOGY, V19, P61, DOI 10.1002/hep.1840190111
   Pain SJ, 2004, J NUCL MED, V45, P789
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Qi P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028486
   Qu KZ, 2011, J CLIN GASTROENTEROL, V45, P355, DOI 10.1097/MCG.0b013e3181f18ac2
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347
   Visone R, 2008, GASTROENTEROLOGY, V135, P1866, DOI 10.1053/j.gastro.2008.10.074
   Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106
   Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405
   Wei XF, 2013, CELL SIGNAL, V25, P439, DOI 10.1016/j.cellsig.2012.10.013
   Wittmann J, 2010, BBA-REV CANCER, V1806, P200, DOI 10.1016/j.bbcan.2010.07.002
   WURZ H, 1983, ARCH GYNECOL, V233, P267, DOI 10.1007/BF02133801
   Zhu Weizhu, 2009, BMC Res Notes, V2, P89, DOI 10.1186/1756-0500-2-89
   Zinkin NT, 2008, CLIN CANCER RES, V14, P470, DOI 10.1158/1078-0432.CCR-07-0586
NR 35
TC 46
Z9 51
U1 0
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2013
VL 6
IS 6
BP 1811
EP 1815
DI 10.3892/ol.2013.1638
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AA0LQ
UT WOS:000330787000050
PM 24260081
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Fontana, L
   Adelaiye, RM
   Rastelli, AL
   Miles, KM
   Ciamporcero, E
   Longo, VD
   Nguyen, H
   Vessella, R
   Pili, R
AF Fontana, Luigi
   Adelaiye, Remi M.
   Rastelli, Antonella L.
   Miles, Kiersten Marie
   Ciamporcero, Eric
   Longo, Valter D.
   Nguyen, Holly
   Vessella, Robert
   Pili, Roberto
TI Dietary protein restriction inhibits tumor growth in human xenograft
   models of prostate and breast cancer
SO ONCOTARGET
LA English
DT Article
DE protein restriction; mTOR; prostate and breast cancer
ID FACTOR-I; AMINO-ACIDS; RISK; PROGRESSION; PATHWAY; METAANALYSIS;
   THERAPY; BALANCE; RATES; MICE
AB Purpose: Data from epidemiological and experimental studies suggest that dietary protein intake may play a role in inhibiting prostate and breast cancer by modulating the IGF/AKT/mTOR pathway. In this study we investigated the effects of diets with different protein content or quality on prostate and breast cancer.
   Experimental Design: To test our hypothesis we assessed the inhibitory effect of protein diet restriction on prostate and breast cancer growth, serum PSA and IGF-1 concentrations, mTOR activity and epigenetic markers, by using human xenograft cancer models.
   Results: Our results showed a 70% inhibition of tumor growth in the castrate-resistant LuCaP23.1 prostate cancer model and a 56% inhibition in the WHIM16 breast cancer model fed with a 7% protein diet when compared to an isocaloric 21% protein diet. Inhibition of tumor growth correlated, in the LuCaP23.1 model, with decreased serum PSA and IGF-1 levels, down-regulation of mTORC1 activity, decreased cell proliferation as indicated by Ki67 staining, and reduction in epigenetic markers of prostate cancer progression, including the histone methyltransferase EZH2 and the associated histone mark H3K27me3. In addition, we observed that modifications of dietary protein quality, independently of protein quantity, decreased tumor growth. A diet containing 20% plant protein inhibited tumor weight by 37% as compared to a 20% animal dairy protein diet.
   Conclusions: Our findings suggest that a reduction in dietary protein intake is highly effective in inhibiting tumor growth in human xenograft prostate and breast cancer models, possibly through the inhibition of the IGF/AKT/mTOR pathway and epigenetic modifications.
C1 [Fontana, Luigi; Rastelli, Antonella L.] Washington Univ, Dept Med, St Louis, MO 63130 USA.
   [Fontana, Luigi] Univ Salerno, Sch Med, Dept Med, I-84100 Salerno, Italy.
   [Fontana, Luigi] CEINGE Biotecnol Avanzate, Naples, Italy.
   [Adelaiye, Remi M.; Miles, Kiersten Marie; Ciamporcero, Eric; Pili, Roberto] Roswell Pk Canc Inst, Genitourinary Program, Buffalo, NY USA.
   [Adelaiye, Remi M.; Pili, Roberto] SUNY Buffalo, Roswell Pk Canc Inst Div, Dept Canc Pathol & Prevent, Buffalo, NY 14260 USA.
   [Ciamporcero, Eric] Univ Turin, Turin, Italy.
   [Longo, Valter D.] Univ So Calif, Longev Inst, Sch Gerontol, Los Angeles, CA USA.
   [Longo, Valter D.] Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA.
   [Nguyen, Holly; Vessella, Robert] Univ Washington, Med Ctr, Dept Urol, Seattle, WA 98195 USA.
C3 Washington University (WUSTL); University of Salerno; CEINGE
   Biotecnologie Avanzate; Roswell Park Comprehensive Cancer Center; State
   University of New York (SUNY) System; University at Buffalo, SUNY;
   Roswell Park Comprehensive Cancer Center; University of Turin;
   University of Southern California; University of Southern California;
   University of Washington; University of Washington Seattle
RP Fontana, L (通讯作者)，Washington Univ, Dept Med, St Louis, MO 63130 USA.
EM LFontana@dom.wustl.edu; Roberto.Pili@RoswellPark.org
RI Longo, Valter D./JXM-3545-2024; Fontana, Luigi/K-4773-2013; Ciamporcero,
   Eric/M-6580-2017
OI Fontana, Luigi/0000-0001-8500-5537; Adelaiye-Ogala,
   Remi/0000-0002-6581-7359; Ciamporcero, Eric/0000-0002-3856-6435
FU National Cancer Institute; National Institutes of Health [P30CA016056];
   Glenn Foundation for Medical Research; Bakewell Foundation; Richard M
   Lucas Foundation [LuCaP23.1-AS, LuCaP23.1-CR, LuCaP35V-CR]; Prostate
   Cancer Foundation
FX This research was supported in part by the National Cancer Institute,
   National Institutes of Health (P30CA016056) (RP), Glenn Foundation for
   Medical Research (LF), and the Bakewell Foundation (LF). LuCaP23.1-AS,
   LuCaP23.1-CR and LuCaP35V-CR were generated with support from the
   Richard M Lucas Foundation and the Prostate Cancer Foundation (RV).
CR Blando J, 2011, CANCER PREV RES, V4, P2002, DOI 10.1158/1940-6207.CAPR-11-0182
   Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563
   Chan JM, 2005, J CLIN ONCOL, V23, P8152, DOI 10.1200/JCO.2005.03.1492
   CLEMMONS DR, 1985, METABOLISM, V34, P391, DOI 10.1016/0026-0495(85)90230-6
   Cong RH, 2012, J NUTR BIOCHEM, V23, P1647, DOI 10.1016/j.jnutbio.2011.11.007
   Corey Eva, 2007, P3, DOI 10.1007/978-1-59745-224-3_1
   Dai B, 2009, BJU INT, V104, P1009, DOI 10.1111/j.1464-410X.2009.08538.x
   Donohoe DR, 2012, J CELL PHYSIOL, V227, P3169, DOI 10.1002/jcp.24054
   Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x
   Freedland SJ, 2008, PROSTATE, V68, P11, DOI 10.1002/pros.20683
   Gao X, 2005, JNCI-J NATL CANCER I, V97, P1768, DOI 10.1093/jnci/dji402
   Giovannucci E, 2003, CANCER EPIDEM BIOMAR, V12, P84
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Key TJ, 2010, LANCET ONCOL, V11, P530, DOI 10.1016/S1470-2045(10)70095-4
   Kolonel LN, 2004, NAT REV CANCER, V4, P519, DOI 10.1038/nrc1389
   Kuroishi T, 2003, JPN J CLIN ONCOL, V33, P241
   Lloyd JC, 2010, J UROLOGY, V183, P1619, DOI 10.1016/j.juro.2009.12.003
   Ma CX, 2011, STEROIDS, V76, P750, DOI 10.1016/j.steroids.2011.02.023
   Morgan TM, 2009, CURR CANCER DRUG TAR, V9, P237, DOI 10.2174/156800909787580999
   Moshfegh A.G., 2005, WHAT WE EAT AM NHANE
   Nardella C, 2011, CURR TOP MICROBIOL, V347, P135, DOI 10.1007/82_2010_62
   Norat T, 2007, EUR J CLIN NUTR, V61, P91, DOI 10.1038/sj.ejcn.1602494
   Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021
   Pollak Michael N, 2004, Novartis Found Symp, V262, P84
   Rand WM, 2003, AM J CLIN NUTR, V77, P109, DOI 10.1093/ajcn/77.1.109
   Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080
   SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210
   U.S. Department of the Office of the Civil Administrator of the Ryukyu Islands, 1949, REC HLTH ED WELF
   UNDERWOOD LE, 1994, HORM RES, V42, P145, DOI 10.1159/000184187
   WANG Y, 1995, J NATL CANCER I, V87, P1456, DOI 10.1093/jnci/87.19.1456
   Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
   Zheng SS, 2012, BRIT J NUTR, V108, P998, DOI 10.1017/S0007114511006222
NR 36
TC 97
Z9 107
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC
PY 2013
VL 4
IS 12
BP 2451
EP 2461
DI 10.18632/oncotarget.1586
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 279CK
UT WOS:000328936800026
PM 24353195
OA hybrid, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Alves, CP
   Fonseca, AS
   Muys, BR
   Bueno, RDEL
   Bürger, MC
   de Souza, JES
   Valente, V
   Zago, MA
   Silva, WA
AF Alves, Cleidson Padua
   Fonseca, Aline Simoneti
   Muys, Bruna Rodrigues
   Bueno, Rafaela de Barros e Lima
   Buerger, Matheus Carvalho
   de Souza, Jorge E. S.
   Valente, Valeria
   Zago, Marco Antonio
   Silva, Wilson Araujo, Jr.
TI Brief Report: The lincRNA Hotair Is Required for
   Epithelial-to-Mesenchymal Transition and Stemness Maintenance of Cancer
   Cell Lines
SO STEM CELLS
LA English
DT Article
DE Cancer stem cell; Epithelial-to-mesenchymal transition; LincRNA; Hotair
ID NONCODING RNAS; GENE-EXPRESSION; BREAST-CANCER; TGF-BETA; METASTASIS;
   REVEALS
AB Hotair is a member of the recently described class of noncoding RNAs called lincRNA (large intergenic noncoding RNA). Various studies suggest that Hotair acts regulating epigenetic states by recruiting chromatin-modifying complexes to specific target sequences that ultimately leads to suppression of several genes. Although Hotair has been associated with metastasis and poor prognosis in different tumor types, a deep characterization of its functions in cancer is still needed. Here, we investigated the role of Hotair in the scenario of epithelial-to-mesenchymal transition (EMT) and in the arising and maintenance of cancer stem cells (CSCs). We found that treatment with TGF-1 resulted in increased Hotair expression and triggered the EMT program. Interestingly, ablation of Hotair expression by siRNA prevented the EMT program stimulated by TGF-1, and also the colony-forming capacity of colon and breast cancer cells. Furthermore, we observed that the colon CSC subpopulation (CD133(+)/CD44(+)) presents much higher levels of Hotair when compared with the non-stem cell subpopulation. These results indicate that Hotair acts as a key regulator that controls the multiple signaling mechanisms involved in EMT. Altogether, our data suggest that the role of Hotair in tumorigenesis occurs through EMT triggering and stemness acquisition.
C1 [Alves, Cleidson Padua; Fonseca, Aline Simoneti; Muys, Bruna Rodrigues; Bueno, Rafaela de Barros e Lima; Buerger, Matheus Carvalho; de Souza, Jorge E. S.; Silva, Wilson Araujo, Jr.] Univ Sao Paulo, Dept Genet, Ribeirao Preto Med Sch, Sao Paulo, Brazil.
   [Zago, Marco Antonio] Univ Sao Paulo, Dept Internal Med, Ribeirao Preto Med Sch, Sao Paulo, Brazil.
   [Alves, Cleidson Padua; Fonseca, Aline Simoneti; Muys, Bruna Rodrigues; Bueno, Rafaela de Barros e Lima; Buerger, Matheus Carvalho; de Souza, Jorge E. S.; Valente, Valeria; Zago, Marco Antonio; Silva, Wilson Araujo, Jr.] Natl Inst Sci & Technol Stem Cell & Cell Therapy, Sao Paulo, Brazil.
   [Alves, Cleidson Padua; Fonseca, Aline Simoneti; Muys, Bruna Rodrigues; Bueno, Rafaela de Barros e Lima; Buerger, Matheus Carvalho; de Souza, Jorge E. S.; Valente, Valeria; Zago, Marco Antonio; Silva, Wilson Araujo, Jr.] Ctr Cell Based Therapy, Sao Paulo, Brazil.
   [Valente, Valeria] Univ Estadual Paulista, Fac Pharmaceut Sci Araraquara, Sao Paulo, Brazil.
   [Alves, Cleidson Padua; Buerger, Matheus Carvalho; de Souza, Jorge E. S.; Valente, Valeria; Silva, Wilson Araujo, Jr.] Univ Sao Paulo, Ctr Integrat Syst Biolo CISBi, NAP, BR-09500900 Sao Paulo, Brazil.
   [Buerger, Matheus Carvalho; de Souza, Jorge E. S.] Inst Bioinformat & Biotechnol 2Bio, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade
   Estadual Paulista; Universidade de Sao Paulo
RP Silva, WA (通讯作者)，Ctr Reg Hemoterapia Ribeirao Preto, Rua Catao Roxo 2501, BR-14051140 Sao Paulo, Brazil.
EM wilsonjr@usp.br
RI ZAGO, MARCO/E-9442-2017; Fonseca, Aline/AAG-5306-2019; Bürger,
   Matheus/P-6045-2014; Silva Jr, Wilson Araujo/E-9487-2011; Valente,
   Valeria/F-1301-2014
OI Silva Jr, Wilson Araujo/0000-0001-9364-2886; Valente,
   Valeria/0000-0002-3942-7744; Rodrigues Muys, Bruna/0000-0002-3963-0865;
   Simoneti Fonseca, Aline/0000-0002-0840-8487
FU Sao Paulo Research Foundation (FAPESP); CNPQ; CAPES; FUNDHERP; 
   [2012/00588-5];  [1998/14247-6]; Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) [98/14247-6] Funding Source: FAPESP
FX We thank Anemari Ramos Dinarte dos Santos, Cristiane Ayres Ferreira,
   Flow Cytometry Core at National Institute of Science and Technology in
   Stem Cell and Cell Therapy for the technical support and Claudia
   Marchini Alves for critical review of the manuscript. This work was
   supported by grants 2012/00588-5 and 1998/14247-6 , Sao Paulo Research
   Foundation (FAPESP), CNPQ, CAPES, and FUNDHERP.
CR Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Ferrand A, 2009, BBA-MOL CELL RES, V1793, P477, DOI 10.1016/j.bbamcr.2009.01.004
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Haraguchi N, 2008, ANN SURG ONCOL, V15, P2927, DOI 10.1245/s10434-008-0074-0
   Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ocaña OH, 2010, CELL RES, V20, P1086, DOI 10.1038/cr.2010.127
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rubin MA, 2000, CLIN CANCER RES, V6, P1038
   Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Xue CS, 2003, CANCER RES, V63, P3386
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
NR 30
TC 185
Z9 202
U1 1
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD DEC
PY 2013
VL 31
IS 12
BP 2827
EP 2832
DI 10.1002/stem.1547
PG 6
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 262LF
UT WOS:000327736000022
PM 24022994
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhu, JW
   Liu, F
   Liu, XC
   Bai, EZ
   Li, S
   Li, C
AF Zhu Jianwei
   Liu Fan
   Liu Xiancheng
   Bai Enzhong
   Li Shuai
   Li Can
TI MicroRNA 181a improves proliferation and invasion, suppresses apoptosis
   of osteosarcoma cell
SO TUMOR BIOLOGY
LA English
DT Article
DE Osteosarcoma; MicroRNA; Proliferation; Apoptosis; Invasion
ID EPIGENETIC REGULATION; GASTRIC-CANCER; BREAST-CANCER; EXPRESSION;
   METASTASIS; MIGRATION; KLF6
AB MicroRNA 181a (miR-181a) was found dysregulated in a variety of human cancers and significantly associated with clinical outcome of cancer patients. However, the direct role of miR-181a has not yet been characterized in osteosarcoma progression. This study was aimed at investigating the effects of miR-181a on osteosarcoma cell biological behavior. First, the expression of miR-181a in osteosarcoma cell lines (MG63, HOS, SaOS-2, and U2OS) and a human osteoblastic cell line (hFOB1.19) was detected by qRT-PCR. Results showed that miR-181a was overexpressed in osteosarcoma cell lines compared to human osteoblastic cell line (hFOB1.19). To investigate the effects of miR-181a on proliferation, apoptosis, and invasion of osteosarcoma cells, we generated human osteosarcoma MG63 cells in which miR-181a was either overexpressed or depleted. The MG63 cell viability, cycle, apoptosis, and invasive ability were analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide staining, propidium iodide (PI) staining, Annexin V-FITC/PI double staining, and Transwell invasion experiment, respectively. The results showed that MG63 cell viability, proliferation, and invasive abilities were suppressed, and the apoptosis was enhanced in the group with underexpression of miR-181a. The viability, proliferation, and invasive abilities were improved, and the apoptosis was inhibited in the group with overexpression of miR-181a. The results from Western blotting indicated that miR-181a might be associated with the up-regulation of bcl-2 and matrix metalloproteinase 9 and the down-regulation of tissue inhibitor of metalloproteinases-3 and p21 in MG63 cells. Taken together, our results suggested that miR-181a might facilitate proliferation and invasion and suppress apoptosis of osteosarcoma cells, which might be a potential target for the treatment of osteosarcoma.
C1 [Zhu Jianwei; Liu Fan; Li Shuai] Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong 226001, Jiangsu, Peoples R China.
   [Liu Xiancheng] Nantong Univ, Affiliated Hosp, Dept Oncol, Nantong 226001, Jiangsu, Peoples R China.
   [Bai Enzhong] Feicheng Hosp Tradit Chinese Med, Dept Orthoped, Feicheng 271608, Shandong, Peoples R China.
   [Li Can] Shanghai Jiao Tong Univ, Bio X Ctr, Shanghai 200030, Peoples R China.
C3 Nantong University; Nantong University; Shanghai Jiao Tong University
RP Zhu, JW (通讯作者)，Nantong Univ, Affiliated Hosp, Dept Orthoped, 20 Xishi Rd, Nantong 226001, Jiangsu, Peoples R China.
EM zhujianwei_nt@163.com
FU "Six Talent Peaks Program" of Jiangsu Province of China
FX This study was supported by The "Six Talent Peaks Program" of Jiangsu
   Province of China.
CR Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Ciafrè SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030
   Cui JC, 2011, B CANCER, V98, pE62, DOI 10.1684/bdc.2011.1400
   Endo-Munoz L, 2012, BBA-REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Gaal Zsuzsanna, 2012, Orvosi Hetilap, V153, P2051, DOI 10.1556/OH.2012.29511
   Gao W, 2010, BIOMED PHARMACOTHER, V64, P399, DOI 10.1016/j.biopha.2010.01.018
   Harting Matthew T, 2006, Semin Pediatr Surg, V15, P25, DOI 10.1053/j.sempedsurg.2005.11.005
   HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0
   Hu H, 2012, ONCOL LETT, V4, P1037, DOI 10.3892/ol.2012.866
   Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663
   Lin SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059532
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Meng FY, 2012, J CELL MOL MED, V16, P160, DOI 10.1111/j.1582-4934.2011.01282.x
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Narla G, 2003, AM J PATHOL, V162, P1047, DOI 10.1016/S0002-9440(10)63901-6
   Neel JC, 2013, CELL SIGNAL, V25, P1556, DOI 10.1016/j.cellsig.2013.03.013
   Poletajew Slawomir, 2011, Ortop Traumatol Rehabil, V13, P537
   Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085
   Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468
   Wang HJ, 2010, EUR J CANCER, V46, P2295, DOI 10.1016/j.ejca.2010.05.012
   Wang ZF, 2013, CANCER LETT, V331, P1, DOI 10.1016/j.canlet.2012.12.006
   Yang CC, 2011, J ORAL PATHOL MED, V40, P397, DOI 10.1111/j.1600-0714.2010.01003.x
   Yao C, 2013, CELL BIOCHEM BIOPHYS, V65, P217, DOI 10.1007/s12013-012-9423-5
   Zhang XY, 2012, TUMOR BIOL, V33, P1589, DOI 10.1007/s13277-012-0414-3
NR 25
TC 47
Z9 50
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2013
VL 34
IS 6
BP 3331
EP 3337
DI 10.1007/s13277-013-0902-0
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 270BP
UT WOS:000328292100008
PM 23740615
DA 2025-01-12
ER

PT J
AU Fang, M
   Yuan, JP
   Peng, CW
   Liu, SP
   Li, Y
AF Fang Min
   Yuan Jing-Ping
   Peng Chun-Wei
   Liu Shao-Ping
   Li Yan
TI Dynamic Changes of Collagen IV During Cancer Invasion and Migration:
   Pulse Mode
SO PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
LA Chinese
DT Article
DE cancer; collagen IV; ECM remodeling; quantum dots
ID TARGETING EPIGENETIC READERS; LYSYL OXIDASE; QUANTUM-DOTS; MATRIX
   METALLOPROTEINASES; CELL INVASION; MICROENVIRONMENT; MECHANISMS; FORCE
AB Cancer invasion and metastasis remain two root causes of mortality. This process involves alterations of tumor microenvironment, particularly the remodeling of extracellular matrix(ECM), characterized by collagen IV uncoiling, degradation, fragments deposition and cross-linking. This study was aimed to reveal the cancer invasion mode based on dynamic changes of collagen IV by novel quantum dots (QDs) imaging technology. Cancer tissues of hepatocellular carcinoma, gastric cancer, breast cancer and cervical carcinoma were collected and stained by traditional immunohistochemistry and novel QDs-based imaging technology. Several key molecules representing of cancer cells and tumor microenvironment were studied, including Ki67, representing of proliferation of cancer cells, macrophages, representing of monocytes infiltration and collagen IV, representing of tumor stroma remodeling during cancer invasion and migration. During cancer invasion and migration, collagen IV had structural and functional changes. In different cancer tissues, 4 types of collagen IV could be observed, consisting of linear, irregular, fragmented and disappeared. However, several common features were evident during the dynamic process of cancer progression. First, collagen IV at basement membrane increased, presenting an irregular sheath surrounding cancer nests; then, collagen IV was degraded to form invasion fronts at several sites accompanied with linear re-deposition of collagen IV and increased macrophages in ECM. Second, cancer cells escaped from large cancer nests to seed in ECM. And also the dynamic changes of collagen IV were accompanied with the recruitment of macrophages, together to regulate and affect biological behaviors of cancer cells. A series changes caused by dynamic changes of collagen IV provide a proper tumor microenvironment for cancer invasion and migration. In this dysfunctional tumor microenvironment, tumor mass becomes increasingly harder with tumor stroma stiffening causing high ECM stress. With cancer cells proliferation, tension becomes increasingly higher, till reaching a critical point, where large tumor nests "burst", releasing many tiny seeding nests and reducing the central ECM tension. The resulting seeding tumor nests repeat the same process of tumor mass growth -> prominent central hypoxia -> collagen IV cross-linking and deposition -> ECM remodeling -> ECM stress buildup -> tumor nest bursts, leading to accelerated cancer progression in this rich "soil" of dysfunctional tumor microenvironment, presenting a "pulse mode".
C1 [Li Yan] Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Zhongnan Hosp, Dept Oncol, Wuhan 430071, Peoples R China.
   Hubei Canc Clin Study Ctr, Wuhan 430071, Peoples R China.
C3 Wuhan University
RP Li, Y (通讯作者)，Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Zhongnan Hosp, Dept Oncol, Wuhan 430071, Peoples R China.
EM liyansd2@163.com
RI Yang, Litao/ABE-8170-2020
FU The National Natural Science Foundation of China [81230031/H18,
   81171396]; The National Science and Technology Major Project
   [2012ZX10002012-12]; The National University Students Innovation
   Training Project of China [111048673]
FX This work was supported by grants from The National Natural Science
   Foundation of China (81230031/H18, 81171396), The National Science and
   Technology Major Project (2012ZX10002012-12) and The National University
   Students Innovation Training Project of China (111048673).
CR Bignon M, 2011, BLOOD, V118, P3979, DOI 10.1182/blood-2010-10-313296
   Chen C, 2009, BIOMATERIALS, V30, P2912, DOI 10.1016/j.biomaterials.2009.02.010
   Chen LD, 2008, BIOMATERIALS, V29, P4170, DOI 10.1016/j.biomaterials.2008.07.025
   Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635
   Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015
   Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548
   Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016
   Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Giovannetti E, 2012, NEW ENGL J MED, V366, P966, DOI 10.1056/NEJMc1201170
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hoon DSB, 2006, CANCER METAST REV, V25, P203, DOI 10.1007/s10555-006-8500-x
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109
   Nerenberg Paul S., 2007, Cancer Genomics & Proteomics, V4, P319
   Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Peng CW, 2012, BIOMATERIALS, V33, P5742, DOI 10.1016/j.biomaterials.2012.04.034
   POSTLETHWAITE AE, 1976, J EXP MED, V143, P1299, DOI 10.1084/jem.143.6.1299
   Resch-Genger U, 2008, NAT METHODS, V5, P763, DOI 10.1038/NMETH.1248
   Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175
   Rosner M, 2012, NEW ENGL J MED, V367, P1764, DOI 10.1056/NEJMc1211175
   Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195
   Torzilli PA, 2012, SEMIN CANCER BIOL, V22, P385, DOI 10.1016/j.semcancer.2012.05.002
   Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639
   Wu SD, 2012, CANCER TREAT REV, V38, P218, DOI 10.1016/j.ctrv.2011.06.010
   Xiao Q, 2012, CANCER MICROENVIRON, V5, P261, DOI 10.1007/s12307-012-0105-z
NR 32
TC 1
Z9 1
U1 0
U2 12
PU CHINESE ACAD SCIENCES, INST BIOPHYSICS
PI BEIJING
PA 15 DATUN RD, CHAOYAND DISTRICT, BEIJING, 100101, PEOPLES R CHINA
SN 1000-3282
J9 PROG BIOCHEM BIOPHYS
JI Prog. Biochem. Biophys.
PD OCT
PY 2013
VL 40
IS 10
BP 1056
EP 1062
DI 10.3724/SP.J.1206.2013.00242
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 243JK
UT WOS:000326312500020
OA Bronze
DA 2025-01-12
ER

PT J
AU Attema, JL
   Bert, AG
   Lim, YY
   Kolesnikoff, N
   Lawrence, DM
   Pillman, KA
   Smith, E
   Drew, PA
   Khew-Goodall, Y
   Shannon, F
   Goodall, GJ
AF Attema, Joanne L.
   Bert, Andrew G.
   Lim, Yat-Yuen
   Kolesnikoff, Natasha
   Lawrence, David M.
   Pillman, Katherine A.
   Smith, Eric
   Drew, Paul A.
   Khew-Goodall, Yeesim
   Shannon, Frances
   Goodall, Gregory J.
TI Identification of an Enhancer That Increases miR-200b∼200a∼429 Gene
   Expression in Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; MIR-200 FAMILY; ACTIVE CHROMATIN;
   REPRESSORS ZEB1; NONCODING RNAS; FEEDBACK LOOP; TRANSCRIPTION;
   MICRORNAS; REGULATORS; PROMOTERS
AB The miR-200b similar to 200a similar to 429 gene cluster is a key regulator of EMT and cancer metastasis, however the transcription-based mechanisms controlling its expression during this process are not well understood. We have analyzed the miR-200b similar to 200a similar to 429 locus for epigenetic modifications in breast epithelial and mesenchymal cell lines using chromatin immunoprecipitation assays and DNA methylation analysis. We discovered a novel enhancer located approximately 5.1kb upstream of the miR-200b similar to 200a similar to 429 transcriptional start site. This region was associated with the active enhancer chromatin signature comprising H3K4me1, H3K27ac, RNA polymerase II and CpG dinucleotide hypomethylation. Luciferase reporter assays revealed the upstream enhancer stimulated the transcription of the miR-200b similar to 200a similar to 429 minimal promoter region approximately 27-fold in breast epithelial cells. Furthermore, we found that a region of the enhancer was transcribed, producing a short, GC-rich, mainly nuclear, non-polyadenylated RNA transcript designated miR-200b eRNA. Over-expression of miR-200b eRNA had little effect on miR-200b similar to 200a similar to 429 promoter activity and its production did not correlate with miR-200b similar to 200a similar to 429 gene expression. While additional investigations of miR-200b eRNA function will be necessary, it is possible that miR-200b eRNA may be involved in the regulation of miR-200b similar to 200a similar to 429 gene expression and silencing. Taken together, these findings reveal the presence of a novel enhancer, which contributes to miR-200b similar to 200a similar to 429 transcriptional regulation in epithelial cells.
C1 [Attema, Joanne L.; Bert, Andrew G.; Lim, Yat-Yuen; Kolesnikoff, Natasha; Pillman, Katherine A.; Khew-Goodall, Yeesim; Goodall, Gregory J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.
   [Lim, Yat-Yuen; Goodall, Gregory J.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia.
   [Lim, Yat-Yuen] Univ Malaya, Inst Biol Sci, Fac Sci, Kuala Lumpur, Malaysia.
   [Lawrence, David M.] Ctr Canc Biol, ACRF Canc Genom Facil, Adelaide, SA, Australia.
   [Smith, Eric] Univ Adelaide, Discipline Surg, Adelaide, SA, Australia.
   [Drew, Paul A.] Flinders Univ S Australia, Sch Nursing & Midwifery, Bedford Pk, SA 5042, Australia.
   [Shannon, Frances] Univ Canberra, Off Deputy Vice Chancellor Res, Bruce, ACT, Australia.
   [Attema, Joanne L.; Lawrence, David M.; Khew-Goodall, Yeesim; Goodall, Gregory J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia.
C3 Centre for Cancer Biology; SA Pathology; University of Adelaide;
   Universiti Malaya; Centre for Cancer Biology; University of Adelaide;
   Flinders University South Australia; University of Canberra; University
   of Adelaide
RP Attema, JL (通讯作者)，SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.
EM joanne.attema@health.sa.gov.au; greg.goodall@health.sa.gov.au
RI Lim, Yat/I-6495-2013; Pillman, Katherine/M-5723-2019; Smith,
   Eric/ABG-7104-2020
OI Lawrence, David/0000-0001-5464-5830; Drew, Paul/0000-0001-5661-4771;
   Smith, Eric/0000-0003-2958-3492; Pillman, Katherine
   A./0000-0002-5869-889X; Bert, Andrew/0000-0003-3876-1537
FU National Health and Medical Research Council [APP1008440]; Swedish
   Medical Research Council (Vetenskapsradet) [521-2009-2873]; Lund
   University Faculty of Medicine; Hemato-Linne Program
FX This work was supported by a Project Grant APP1008440 from the National
   Health and Medical Research Council to GG and FS, and by funds from the
   Swedish Medical Research Council (Vetenskapsradet, 521-2009-2873), Lund
   University Faculty of Medicine and The Hemato-Linne Program to JA. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bertani S, 2011, MOL CELL, V43, P1040, DOI 10.1016/j.molcel.2011.08.019
   Blow MJ, 2010, NAT GENET, V42, P806, DOI 10.1038/ng.650
   Boussouar F, 2008, CELL CYCLE, V7, P3499, DOI 10.4161/cc.7.22.6975
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   De Santa F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000384
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Ebisuya M, 2008, NAT CELL BIOL, V10, P1106, DOI 10.1038/ncb1771
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Flynn RA, 2012, CURR OPIN GENET DEV, V22, P172, DOI 10.1016/j.gde.2011.11.002
   Frith MC, 2008, GENOME RES, V18, P1, DOI 10.1101/gr.6831208
   Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621
   Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, CURR OPIN GENET DEV, V19, P541, DOI 10.1016/j.gde.2009.09.006
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812
   Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   Jin FL, 2011, TRANSCR-AUSTIN, V2, P226, DOI 10.4161/trns.2.5.17712
   Kanhere A, 2010, MOL CELL, V38, P675, DOI 10.1016/j.molcel.2010.03.019
   Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Kowalczyk MS, 2012, MOL CELL, V45, P447, DOI 10.1016/j.molcel.2011.12.021
   Lefevre P, 2008, MOL CELL, V32, P129, DOI 10.1016/j.molcel.2008.07.023
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021
   Orom UA, 2011, CURR OPIN GENET DEV, V21, P194, DOI 10.1016/j.gde.2011.01.020
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295
   Pike JW, 2011, J BONE MINER RES, V26, P1155, DOI 10.1002/jbmr.317
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Sandelin A, 2007, NAT REV GENET, V8, P424, DOI 10.1038/nrg2026
   Smallwood A, 2013, CURR OPIN CELL BIOL, V25, P387, DOI 10.1016/j.ceb.2013.02.005
   Van Bortle K, 2012, ANNU REV CELL DEV BI, V28, P163, DOI 10.1146/annurev-cellbio-101011-155824
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819
   Weake VM, 2010, NAT REV GENET, V11, P426, DOI 10.1038/nrg2781
   Zentner GE, 2012, J BIOL CHEM, V287, P30888, DOI 10.1074/jbc.R111.296491
NR 49
TC 18
Z9 19
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 25
PY 2013
VL 8
IS 9
AR e75517
DI 10.1371/journal.pone.0075517
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 228VC
UT WOS:000325218700094
PM 24086551
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Demetriou, CA
   Chen, J
   Polidoro, S
   van Veldhoven, K
   Cuenin, C
   Campanella, G
   Brennan, K
   Clavel-Chapelon, F
   Dossus, L
   Kvaskoff, M
   Drogan, D
   Boeing, H
   Kaaks, R
   Risch, A
   Trichopoulos, D
   Lagiou, P
   Masala, G
   Sieri, S
   Tumino, R
   Panico, S
   Quirós, JR
   Perez, MJS
   Amiano, P
   Castaño, JMH
   Ardanaz, E
   Onland-Moret, C
   Peeters, P
   Khaw, KT
   Wareham, N
   Key, TJ
   Travis, RC
   Romieu, I
   Gallo, V
   Gunter, M
   Herceg, Z
   Kyriacou, K
   Riboli, E
   Flanagan, JM
   Vineis, P
AF Demetriou, Christiana A.
   Chen, Jia
   Polidoro, Silvia
   van Veldhoven, Karin
   Cuenin, Cyrille
   Campanella, Gianluca
   Brennan, Kevin
   Clavel-Chapelon, Francoise
   Dossus, Laure
   Kvaskoff, Marina
   Drogan, Dagmar
   Boeing, Heiner
   Kaaks, Rudolf
   Risch, Angela
   Trichopoulos, Dimitrios
   Lagiou, Pagona
   Masala, Giovanna
   Sieri, Sabina
   Tumino, Rosario
   Panico, Salvatore
   Ramon Quiros, J.
   Sanchez Perez, Maria-Jose
   Amiano, Pilar
   Huerta Castano, Jose Maria
   Ardanaz, Eva
   Onland-Moret, Charlotte
   Peeters, Petra
   Khaw, Kay-Tee
   Wareham, Nick
   Key, Timothy J.
   Travis, Ruth C.
   Romieu, Isabelle
   Gallo, Valentina
   Gunter, Marc
   Herceg, Zdenko
   Kyriacou, Kyriacos
   Riboli, Elio
   Flanagan, James M.
   Vineis, Paolo
TI Methylome Analysis and Epigenetic Changes Associated with Menarcheal Age
SO PLOS ONE
LA English
DT Article
ID GENOMIC DNA HYPOMETHYLATION; BREAST-CANCER; METHYLATION PATTERNS;
   COLORECTAL ADENOMA; LEUKOCYTE DNA; BLOOD-CELLS; RISK; IMPACT; LUMA;
   HYPERMETHYLATION
AB Reproductive factors have been linked to both breast cancer and DNA methylation, suggesting methylation as an important mechanism by which reproductive factors impact on disease risk. However, few studies have investigated the link between reproductive factors and DNA methylation in humans. Genome-wide methylation in peripheral blood lymphocytes of 376 healthy women from the prospective EPIC study was investigated using LUminometric Methylation Assay (LUMA). Also, methylation of 458877 CpG sites was additionally investigated in an independent group of 332 participants of the EPIC-Italy sub-cohort, using the Infinium HumanMethylation 450 BeadChip. Multivariate logistic regression and linear models were used to investigate the association between reproductive risk factors and genome wide and CpG-specific DNA methylation, respectively. Menarcheal age was inversely associated with global DNA methylation as measured with LUMA. For each yearly increase in age at menarche, the risk of having genome wide methylation below median level was increased by 32% (OR: 1.32, 95% CI: 1.14-1.53). When age at menarche was treated as a categorical variable, there was an inverse dose-response relationship with LUMA methylation levels (OR12-14vs.<= 11 yrs: 1.78, 95% CI: 1.01-3.17 and OR >= 15vs.<= 11 yrs: 4.59, 95% CI: 2.04-10.33; P for trend<0.0001). However, average levels of global methylation as measured by the Illumina technology were not significantly associated with menarcheal age. In locus by locus comparative analyses, only one CpG site had significantly different methylation depending on the menarcheal age category examined, but this finding was not replicated by pyrosequencing in an independent data set. This study suggests a link between age at menarche and genome wide DNA methylation, and the difference in results between the two arrays suggests that repetitive element methylation has a role in the association. Epigenetic changes may be modulated by menarcheal age, or the association may be a mirror of other important changes in early life that have a detectable effect on both methylation levels and menarcheal age.
C1 [Demetriou, Christiana A.; Kyriacou, Kyriacos] Cyprus Inst Neurol & Genet, Dept Electron Microscopy & Mol Pathol, Nicosia, Cyprus.
   [Demetriou, Christiana A.; van Veldhoven, Karin; Campanella, Gianluca; Gallo, Valentina; Gunter, Marc; Vineis, Paolo] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.
   [Chen, Jia] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Paediat, New York, NY USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY USA.
   [Polidoro, Silvia; Herceg, Zdenko] Human Genet Fdn, Mol & Genet Epidemiol Unit, Turin, Italy.
   [Cuenin, Cyrille] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon, France.
   [Brennan, Kevin; Flanagan, James M.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London, England.
   [Clavel-Chapelon, Francoise; Dossus, Laure; Kvaskoff, Marina] Inst Gustave Roussy, INSERM, Ctr Res Epidemiol & Populat Hlth, F-94805 Villejuif, France.
   [Clavel-Chapelon, Francoise; Dossus, Laure; Kvaskoff, Marina] Paris South Univ, Nutr Hormones & Canc Unit, Villejuif, France.
   [Drogan, Dagmar; Boeing, Heiner] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Nuthetal, Germany.
   [Kaaks, Rudolf] German Canc Res Ctr, Dept Canc Epidemiol, Heidelberg, Germany.
   [Risch, Angela] German Canc Res Ctr, Dept Epigen & Canc Risk Factors, Heidelberg, Germany.
   [Trichopoulos, Dimitrios; Lagiou, Pagona] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Trichopoulos, Dimitrios; Lagiou, Pagona] Acad Athens, Bur Epidemiol Res, Athens, Greece.
   [Trichopoulos, Dimitrios] Hellen Hlth Fdn, Athens, Greece.
   [Lagiou, Pagona] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, WHO Collaborating Ctr Food & Nutr Policies, GR-11527 Athens, Greece.
   [Masala, Giovanna] Canc Res & Prevent Inst ISPO, Mol & Nutr Epidemiol Unit, Florence, Italy.
   [Sieri, Sabina] Fdn IRCCS Ist Nazl Tumori, Epidemiol & Prevent Unit, Milan, Italy.
   [Tumino, Rosario] ASP Ragusa, Civile MP Arezzo Hosp, Canc Registry, Ragusa, Italy.
   [Tumino, Rosario] ASP Ragusa, Civile MP Arezzo Hosp, Histopathol Unit, Ragusa, Italy.
   [Panico, Salvatore] Univ Naples Federico II, Dept Clin & Expt Med, Naples, Italy.
   [Ramon Quiros, J.] Publ Hlth & Planning Directorate, Asturias, Spain.
   [Sanchez Perez, Maria-Jose] Andalusian Sch Publ Hlth, Granada, Spain.
   [Sanchez Perez, Maria-Jose; Amiano, Pilar; Huerta Castano, Jose Maria; Ardanaz, Eva] CIBERESP, Madrid, Spain.
   [Amiano, Pilar] BioDonostia Res Inst, Hlth Dept Basque Reg, Publ Hlth Div Gipuzkoa, San Sebastian, Spain.
   [Huerta Castano, Jose Maria] Murcia Reg Hlth Council, Dept Epidemiol, Murcia, Spain.
   [Ardanaz, Eva] Navarre Publ Hlth Inst, Pamplona, Spain.
   [Onland-Moret, Charlotte; Peeters, Petra] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Khaw, Kay-Tee; Wareham, Nick] Cambridge Inst Publ Hlth, MRC Epidemiol Unit, Cambridge, England.
   [Key, Timothy J.; Travis, Ruth C.] Univ Oxford, Nuffield Dept Clin Med, Canc Epidemiol Unit, Oxford, England.
   [Romieu, Isabelle] Int Agcy Res Canc, Nutr & Metab Sect, F-69372 Lyon, France.
   [Gallo, Valentina] Univ London, Barts & London Sch Med, Ctr Primary Care & Publ Hlth, London, England.
   [Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England.
C3 Cyprus Institute of Neurology & Genetics; Imperial College London; Icahn
   School of Medicine at Mount Sinai; Icahn School of Medicine at Mount
   Sinai; Icahn School of Medicine at Mount Sinai; World Health
   Organization; International Agency for Research on Cancer (IARC);
   Imperial College London; UNICANCER; Gustave Roussy; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Leibniz Association;
   Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE);
   Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); Harvard University;
   Harvard T.H. Chan School of Public Health; Academy of Athens; Athens
   Medical School; World Health Organization; National & Kapodistrian
   University of Athens; ISPRO Istituto per lo studio, la prevenzione e la
   rete oncologica; Fondazione IRCCS Istituto Nazionale Tumori Milan;
   Civile M.P. Arezzo Hospital; Civile M.P. Arezzo Hospital; University of
   Naples Federico II; Escuela Andaluza de Salud Publica; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERESP; Murcia Regional Health
   Council; Public Health Institute of Navarra; Utrecht University; Utrecht
   University Medical Center; University of Cambridge; University of
   Oxford; World Health Organization; International Agency for Research on
   Cancer (IARC); University of London; Queen Mary University London;
   Imperial College London
RP Demetriou, CA (通讯作者)，Cyprus Inst Neurol & Genet, Dept Electron Microscopy & Mol Pathol, Nicosia, Cyprus.
EM christiana.demetriou08@imperial.ac.uk
RI Polidoro, Silvia/GYJ-3517-2022; Trichopoulos, Dimitrios/G-6825-2012;
   Khaw, Kay-Tee/AAZ-3209-2021; Sánchez, María/JTS-8758-2023; Riboli,
   Elio/A-4357-2009; Panico, Salvatore/K-6506-2016; Herceg,
   Zdenko/JOZ-6188-2023; Gunter, Marc/AAP-8621-2020; Onland-Moret,
   N./G-9185-2011; Clavel-Chapelon, Francoise/G-6733-2014; Masala,
   Giovanna/AAC-5474-2022; Dossus, Laure/AAW-9097-2021; Huerta, Jose
   Maria/N-8654-2015; Campanella, Gianluca/G-2617-2010; Gallo,
   Valentina/X-1139-2018; SANCHEZ-PEREZ, MARIA JOSE/D-1087-2011; Sieri,
   Sabina/K-4667-2016; Kvaskoff, Marina/E-7981-2017; Risch,
   Angela/H-2669-2013
OI Polidoro, Silvia/0000-0003-2968-0575; Panico,
   Salvatore/0000-0002-5498-8312; van Veldhoven, Karin/0000-0001-5298-6148;
   Masala, Giovanna/0000-0002-5758-9069; Huerta, Jose
   Maria/0000-0002-9637-3869; Ardanaz, Eva/0000-0001-8434-2013; Flanagan,
   James/0000-0003-4955-1383; Demetriou, Christiana A./0000-0003-4002-2880;
   Campanella, Gianluca/0000-0002-5411-6338; Gunter,
   Marc/0000-0001-5472-6761; Riboli, Elio/0000-0001-6795-6080; Gallo,
   Valentina/0000-0002-1268-8629; SANCHEZ-PEREZ, MARIA
   JOSE/0000-0003-4817-0757; tumino, rosario/0000-0003-2666-414X; Sieri,
   Sabina/0000-0001-5201-172X; Herceg, Zdenko/0000-0003-4109-3154;
   Kvaskoff, Marina/0000-0002-4557-3772; Risch, Angela/0000-0002-8026-5505
FU EU-Europe aid grant [CRIS 2009/223-507]; Europe Against Cancer Program
   of the European Commission (SANCO); Denmark (Danish Cancer Society);;
   France (Ligue centre le Cancer); France (Institut Gustave Roussy,
   Mutuelle Generale de l'Education Nationale); France (Institut National
   de la Santeet de la Recherche Medicale (INSERM)); Greece (Hellenic
   Ministry of Health); Greece (Stavros Niarchos Foundation ); Greece
   (Hellenic Health Foundation); Germany (German Cancer Aid); Germany
   (German Cancer Research Center); Germany (Federal Ministry of Education
   and Research) [01-EA-9401]; Italy (Italian Association for Research on
   Cancer); Italy (National Research Council); The Netherlands (Dutch
   Ministry of Public Health, Welfare and Sports (VWS)); The Netherlands
   (Netherlands Cancer Registry (NKR)); The Netherlands (LK Research
   Funds); The Netherlands (Dutch Prevention Funds); The Netherlands (Dutch
   ZON (Zorg Onderzoek Nederland)); The Netherlands (World Cancer Research
   Fund (WCRF)); Spain (Health Research Fund (FIS) of the Spanish Ministry
   of Health) [Exp 96/0032]; Sweden (Swedish Cancer Society); Sweden
   (Swedish Scientific Council); Sweden (Regional Government of Skane);
   United Kingdom (Cancer Research UK); United Kingdom (Medical Research
   Council UK); United Kingdom (Breast Cancer Campaign)
FX CAD received funding from EU-Europe aid grant CRIS 2009/223-507. The
   EPIC cohort is supported by the Europe Against Cancer Program of the
   European Commission (SANCO). The individual centres also received
   funding from: Denmark (Danish Cancer Society); France (Ligue centre le
   Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education
   Nationale, and Institut National de la Santeet de la Recherche Medicale
   (INSERM)); Greece (Hellenic Ministry of Health, the Stavros Niarchos
   Foundation and the Hellenic Health Foundation); Germany (German Cancer
   Aid, German Cancer Research Center, and Federal Ministry of Education
   and Research (Grant 01-EA-9401)); Italy (Italian Association for
   Research on Cancer and the National Research Council); The Netherlands
   (Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands
   Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, and
   Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund
   (WCRF)); Spain (Health Research Fund (FIS) of the Spanish Ministry of
   Health (Exp 96/0032) and the participating regional governments and
   institutions); Sweden (Swedish Cancer Society, Swedish Scientific
   Council, and Regional Government of Skane); and the United Kingdom
   (Cancer Research UK and Medical Research Council UK and Breast Cancer
   Campaign). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ahmed ML, 2009, TRENDS ENDOCRIN MET, V20, P237, DOI 10.1016/j.tem.2009.02.004
   Barouki R, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-42
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Esteller M, 2001, CANCER RES, V61, P3225
   Feber A, 2011, GENOME RES, V21, P515, DOI 10.1101/gr.109678.110
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Piyathilake C, 2011, CANCER EPIDEM BIOMAR, V20, P719, DOI 10.1158/1055-9965.EPI-11-0094
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394
   Scoccianti C, 2011, EPIGENETICS-US, V6, P1114, DOI 10.4161/epi.6.9.16515
   Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488
   Starlard-Davenport A, 2010, CARCINOGENESIS, V31, P376, DOI 10.1093/carcin/bgp304
   Tanner JM, 1973, TREND EARLIER MENARC, V243, P95, DOI [101038/243095a0, DOI 10.1038/243095A0]
   Teegarden D, 2012, NUTR RES REV, V25, P68, DOI 10.1017/S0954422411000199
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Triche TJ, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt090
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Zhang FF, 2011, J NUTR, V141, P1165, DOI 10.3945/jn.110.134536
NR 43
TC 30
Z9 37
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 20
PY 2013
VL 8
IS 11
AR e79391
DI 10.1371/journal.pone.0079391
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 256LY
UT WOS:000327313100020
PM 24278132
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Khan, F
   Ruterbusch, JJ
   Gomez, SL
   Schwartz, K
AF Khan, Fatima
   Ruterbusch, Julie J.
   Gomez, Scarlett L.
   Schwartz, Kendra
TI Differences in the cancer burden among foreign-born and US-born Arab
   Americans living in metropolitan Detroit
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Arab Americans; Migrant groups; Cancer incidence; Proportional incidence
   ratios
ID MIDDLE-EASTERN POPULATION; PHARYNGEAL CANCER; 1ST-GENERATION IMMIGRANTS;
   THYROID-CANCER; BREAST-CANCER; URINARY-TRACT; RISK; EPIDEMIOLOGY;
   MIGRANTS; NETHERLANDS
AB Migrant studies often provide clues for cancer etiology. We estimated the cancer burden among Arab Americans (ArA) by immigrant status in the metropolitan Detroit area, home to one of the highest concentrations of ArA in USA.
   A validated name algorithm was used to identify ArA cancer cases diagnosed 1990-2009 in the Detroit SEER database. Recorded birthplace was supplemented with imputation of nativity using birthdate and social security number. Age-adjusted, gender-specific proportional incidence ratios and 95 % confidence intervals were calculated comparing all ArA, foreign-born ArA, and US-born ArA, to non-Hispanic Whites (NHW).
   Foreign-born ArA males had higher proportions of multiple myeloma, leukemia, kidney, liver, stomach, and bladder cancer than NHW, while bladder cancer and leukemia were higher among US-born ArA males. For ArA women, gall bladder and thyroid cancers were proportionally higher among both foreign- and US-born compared with NHW. Stomach cancer was proportionally higher only among foreign-born women.
   Cancer proportional incidence patterns among ArA show some similarity to other migrant groups, with higher proportional incidences of stomach and liver cancers among foreign-born than US-born. Other patterns, such as tobacco-related cancers among ArA men and gall bladder and thyroid cancers among ArA women, will require more investigation of genetic, epigenetic, and environmental factors.
C1 [Khan, Fatima] Univ Minnesota, Sch Med, Dept Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA.
   [Ruterbusch, Julie J.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA.
   [Gomez, Scarlett L.] Canc Prevent Inst Calif, Fremont, CA USA.
   [Gomez, Scarlett L.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA.
   [Schwartz, Kendra] Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, Detroit, MI 48202 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   Barbara Ann Karmanos Cancer Institute; Wayne State University; Cancer
   Prevention Institute of California; Stanford University; Wayne State
   University
RP Schwartz, K (通讯作者)，Wayne State Univ, Sch Med, Dept Family Med & Publ Hlth Sci, 3939 Woodward Ave, Detroit, MI 48202 USA.
EM kensch@med.wayne.edu
RI Khan, Fatima/HKM-9535-2023
FU National Cancer Institute at National Institutes of Health
   [HHSN261201000028C]
FX This project was supported by funds from the National Cancer Institute
   at National Institutes of Health (HHSN261201000028C).
CR Al-Dahir S, 2013, J HEALTH CARE POOR U, V24, P47, DOI 10.1353/hpu.2013.0038
   Andreeva Valentina A, 2007, J Immigr Minor Health, V9, P307, DOI 10.1007/s10903-007-9037-y
   [Anonymous], 2007, IARC Scientific Publications
   Arab American Institute Foundation, 2012, NAT AR AM DEM
   BLOCK G, 1983, AM J EPIDEMIOL, V118, P377, DOI 10.1093/oxfordjournals.aje.a113645
   BLOT WJ, 1988, CANCER RES, V48, P3282
   Breslow N, 1989, IARC SCI PUBLICATION, V82
   de la Cruz P., 2003, ARAB POPULATION 2000
   El-Sayed AM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-272
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Falkenstein M, 2002, JOINT STAT M NEW YOR
   FREEDMAN L, 2006, NIH PUB
   Hemminki K, 2002, INT J CANCER, V99, P218, DOI 10.1002/ijc.10322
   Hemminki K, 2002, INT J CANCER, V99, P229, DOI 10.1002/ijc.10323
   Hemminki K, 2011, CURR OPIN UROL, V21, P386, DOI 10.1097/MOU.0b013e32834958ff
   IARC, 1994, IARC MON, V61
   Jadalla A, 2012, J TRANSCULT NURS, V23, P159, DOI 10.1177/1043659611434058
   Kato I, 2009, J REGISTRY MANAG, V36, P101
   Kato Ikuko, 2009, J Registry Manag, V36, P71
   MCCREDIE M, 1994, CANCER CAUSE CONTROL, V5, P414, DOI 10.1007/BF01694755
   McCredie M, 1998, RECENT RES CANCER, V154, P298
   Memon A, 2002, INT J CANCER, V97, P82, DOI 10.1002/ijc.1573
   Mousavi SM, 2011, GASTRIC CANCER, V14, P285, DOI 10.1007/s10120-011-0033-5
   Mueller CM, 2008, UROL ONCOL-SEMIN ORI, V26, P451, DOI 10.1016/j.urolonc.2008.02.016
   Nanchahal K, 2001, J PUBLIC HEALTH MED, V23, P278, DOI 10.1093/pubmed/23.4.278
   Nasseri K, 2008, CANCER CAUSE CONTROL, V19, P1183, DOI 10.1007/s10552-008-9185-y
   Nasseri K, 2007, ASIAN PAC J CANCER P, V8, P405
   Nasseri K, 2009, BREAST J, V15, P182, DOI 10.1111/j.1524-4741.2009.00694.x
   Novis BH, 1998, YALE J BIOL MED, V71, P135
   Perkins RC, 1993, 4 US BUR CENS POP DI
   Peterson L, 2011, J IMMIGR MINOR HEALT, V13, P1033, DOI 10.1007/s10903-011-9485-2
   Pinelli NR, 2011, ETHNIC DIS, V21, P480
   RICE VH, 1992, PUBLIC HEALTH REP, V107, P589
   Rodriguez T, 2004, ORAL ONCOL, V40, P207, DOI 10.1016/j.oraloncology.2003.08.014
   Salim EI, 2010, ASIAN PAC J CANCER P, V11, P33
   Schwartz K, 2008, J IMMIGR MINOR HEALT, V10, P541, DOI 10.1007/s10903-008-9140-8
   Schwartz KL, 2004, ETHNIC DIS, V14, P141
   Stirbu I, 2006, INT J CANCER, V119, P2665, DOI 10.1002/ijc.22200
   Talaat N, 2013, J COMMUN HEALTH, V38, P619, DOI 10.1007/s10900-013-9688-7
   TALAMINI R, 1990, INT J CANCER, V46, P391, DOI 10.1002/ijc.2910460310
   Tarabeia J, 2010, CANCER EPIDEMIOL, V34, P226, DOI 10.1016/j.canep.2010.01.002
   Visser O, 2007, EUR J CANCER, V43, P901, DOI 10.1016/j.ejca.2006.12.010
   Visser O, 2004, BRIT J CANCER, V90, P2135, DOI 10.1038/sj.bjc.6601821
   Zeegers MPA, 2000, CANCER-AM CANCER SOC, V89, P630, DOI 10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.3.CO;2-H
NR 44
TC 16
Z9 21
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD NOV
PY 2013
VL 24
IS 11
BP 1955
EP 1961
DI 10.1007/s10552-013-0271-4
PG 7
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 238JJ
UT WOS:000325942000006
PM 24013772
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Theodorou, M
   Speletas, M
   Mamara, A
   Papachristopoulou, G
   Lazou, V
   Scorilas, A
   Katsantoni, E
AF Theodorou, Marina
   Speletas, Matthaios
   Mamara, Antigoni
   Papachristopoulou, Georgia
   Lazou, Vassiliki
   Scorilas, Andreas
   Katsantoni, Eleni
TI Identification of a STAT5 Target Gene, <i>Dpf3</i>, Provides Novel
   Insights in Chronic Lymphocytic Leukemia
SO PLOS ONE
LA English
DT Article
ID B-CELLS; TRANSCRIPTION FACTORS; TRANSGENIC MICE; HISTONE ACETYLATION;
   SIGNAL TRANSDUCERS; PROSTATE-CANCER; BREAST-CANCER; IN-VIVO; EXPRESSION;
   ACTIVATION
AB STAT5 controls essential cellular functions and is encoded by two genes, Stat5a and Stat5b. To provide insight to the mechanisms linking hematologic malignancy to STAT5 activation/regulation of target genes, we identified STAT5 target genes and focused on Dpf3 gene, which encodes for an epigenetic factor. Dpf3 expression was induced upon IL-3 stimulation in Ba/F3 cells, while strong binding of both STAT5a and STAT5b was detected in its promoter. Reduced expression of Dpf3 was detected in Ba/F3 cells with Stat5a and Stat5b knock-down, suggesting that this gene is positively regulated by STAT5, upon IL-3 stimulation. Furthermore, this gene was significantly up-regulated in CLL patients, where DPF3 gene/protein up-regulation and strong STAT5 binding to the DPF3 promoter, correlated with increased STAT5 activation, mainly in non-malignant myeloid cells (granulocytes). Our findings provide insights in the STAT5 dependent transcriptional regulation of Dpf3, and demonstrate for the first time increased STAT5 activation in granulocytes of CLL patients. Novel routes of investigation are opened to facilitate the understanding of the role of STAT5 activation in the communication between non-malignant myeloid and malignant B-cells, and the functions of STAT5 target genes networks in CLL biology.
C1 [Theodorou, Marina; Lazou, Vassiliki; Katsantoni, Eleni] Acad Athens, Biomed Res Fdn, Div Hematol Oncol, Athens, Greece.
   [Speletas, Matthaios; Mamara, Antigoni] Univ Thessaly, Sch Med, Dept Immunol & Histocompatibil, Larisa, Greece.
   [Papachristopoulou, Georgia; Scorilas, Andreas] Univ Athens, Fac Biol, Dept Biochem & Mol Biol, Athens, Greece.
C3 Academy of Athens; University of Thessaly; National & Kapodistrian
   University of Athens
RP Katsantoni, E (通讯作者)，Acad Athens, Biomed Res Fdn, Div Hematol Oncol, Athens, Greece.
EM ekatsantoni@bioacademy.gr
RI Katsantoni, Eleni/JVP-2743-2024
OI Katsantoni, Eleni/0000-0001-8249-6035; Theodorou,
   Marina/0000-0002-1354-8863; Scorilas, Andreas/0000-0003-2427-4949
FU EU; BRFAA
FX This work was supported by research funding from the EU (European
   Reintegration Grant) and BRFAA to EK. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Basham B, 2008, NUCLEIC ACIDS RES, V36, P3802, DOI 10.1093/nar/gkn271
   Bojarska-Junak A, 2009, LEUKEMIA RES, V33, P1319, DOI 10.1016/j.leukres.2009.03.030
   Buettner R, 2002, CLIN CANCER RES, V8, P945
   BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213
   CHAOUCHI N, 1994, CLIN IMMUNOL IMMUNOP, V73, P197, DOI 10.1006/clin.1994.1188
   Choi YP, 2005, PROTEOMICS, V5, P1481, DOI 10.1002/pmic.200401021
   Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7
   DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319
   Dawson M, 2012, EDITH WHARTON IN CONTEXT, P41
   de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100
   de Totero D, 2008, BLOOD, V111, P517, DOI 10.1182/blood-2007-04-087882
   diCelle PF, 1996, BLOOD, V87, P4382, DOI 10.1182/blood.V87.10.4382.bloodjournal87104382
   Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768
   Gamberale R, 2001, LEUKEMIA, V15, P1860, DOI 10.1038/sj.leu.2402288
   Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8
   Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5
   Kang K, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-4
   Kato Y, 2005, J EXP MED, V202, P169, DOI 10.1084/jem.20042541
   Katsantoni E, 2012, SCI SIGNAL, V5, ppt13
   Katsantoni EZ, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-108
   Katsantoni EZ, 2004, EXP HEMATOL, V32, P224, DOI 10.1016/j.exphem.2003.11.001
   Lange M, 2008, GENE DEV, V22, P2370, DOI 10.1101/gad.471408
   Lanvin O, 2004, ONCOGENE, V23, P3040, DOI 10.1038/sj.onc.1207450
   Li HZ, 2005, CLIN CANCER RES, V11, P5863, DOI 10.1158/1078-0432.CCR-05-0562
   Li HZ, 2004, CANCER RES, V64, P4774, DOI 10.1158/0008-5472.CAN-03-3499
   Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656
   Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224
   Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179
   Lo KC, 2007, GENE CHROMOSOME CANC, V46, P875, DOI 10.1002/gcc.20474
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Malin S, 2010, CURR OPIN IMMUNOL, V22, P168, DOI 10.1016/j.coi.2010.02.004
   Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148
   Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367
   MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413
   PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2
   Pestina TI, 2003, EXP HEMATOL, V31, P1198, DOI 10.1016/j.exphem.2003.09.002
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   PISTOIA V, 1987, BLOOD, V69, P1340
   Planelles L, 2007, HAEMATOLOGICA, V92, P1284, DOI 10.3324/haematol.10317
   SALTMAN D, 1990, LEUKEMIA RES, V14, P381, DOI 10.1016/0145-2126(90)90167-8
   Schwaller J, 2007, BLOOD, V109, P331, DOI 10.1182/blood-2006-02-001800
   Siapati EK, 2005, MOL THER, V12, P537, DOI 10.1016/j.ymthe.2005.01.022
   Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165
   Speletas M, 2007, LEUKEMIA RES, V31, P1053, DOI 10.1016/j.leukres.2006.09.005
   Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0
   Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239
   Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238
   Weissman B, 2009, CANCER RES, V69, P8223, DOI 10.1158/0008-5472.CAN-09-2166
   Xu R, 2007, J BIOL CHEM, V282, P14992, DOI 10.1074/jbc.M610316200
   Yamaji D, 2012, NUCL ACIDS RES
   Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323
   Zhang YJ, 2012, MOL CELL BIOL, V32, P880, DOI 10.1128/MCB.06312-11
   Zhu BM, 2012, NUCLEIC ACIDS RES, V40, P4461, DOI 10.1093/nar/gks056
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 54
TC 16
Z9 18
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 14
PY 2013
VL 8
IS 10
AR e76155
DI 10.1371/journal.pone.0076155
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 237RD
UT WOS:000325887300024
PM 24155890
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Cong, BH
   Zhu, XY
   Cao, BQ
   Xiao, J
   Wang, ZN
   Ni, X
AF Cong, Binhai
   Zhu, Xiaoyan
   Cao, Buqing
   Xiao, Jian
   Wang, Zhinong
   Ni, Xin
TI Estrogens protect myocardium against ischemia/reperfusion insult by
   up-regulation of CRH receptor type 2 in female rats
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Estrogen; Corticotropin-releasing hormone receptors; Myocardium;
   Epigenetic; Methylation
ID HORMONE-THERAPY; CARDIOMYOCYTE APOPTOSIS; UROCORTIN PROTECTS; CARDIAC
   MYOCYTES; BREAST-CANCER; ACTIVATION; HEART; EXPRESSION; INJURY;
   CARDIOPROTECTION
AB Background: The mechanism underlying estrogen cardioprotection remains largely unknown. Urocortin (UCN), a member of corticotropin-releasing hormone (CRH) family, is one of endogenous cardioprotective factors. The goal of present study is to investigate whether estrogens regulate UCN and its receptor CRH receptor type 2 (CRHR2) in female rat heart.
   Methods: 17 beta-estradiol (E2) was subcutaneously administrated to ovariectomized (OVX) rats for eight weeks. UCN was administrated before simulated myocardial ischemia/reperfusion (I/R). Cell damage was assessed by measurement of infarct size, activity of serum creatine kinase (CK) and lactate dehydrogenase (LDH) and percentage of TUNEL staining in myocardium. The mRNA and protein levels of UCN and CRHR2 were determined in sham operated and OVX rats with or without E2 replacement. DNA methylation frequency of CRHR2 gene promoter was determined by bisulfite-sequencing.
   Results: UCN administration reduced infarct size, LDH and CK level and percentage of TUNEL staining upon I/R injury. The cardioprotective effects of UCN were abrogated in OVX rats and E2 replacement restored UCN-induced cardioprotection. CRHR2 mRNA and protein expression were down-regulated more than 40% in OVX rats, both of which were restored by E2 replacement. UCN mRNA and protein levels were not affected by ovariectomy and E2 replacement. Hypermethylation in CRHR2 promoter was found in OVX rats, and two of the methylated CpG sites were seated at cis-acting elements. Hypermethylation induced by OVX could also be ameliorated by E2 replacement.
   Conclusion: Estrogens maintain CRHR2 expression in myocardium, which may through an epigenetic mechanism, and enhance UCN-induced cardioprotective effects against I/R injury. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Cong, Binhai; Zhu, Xiaoyan; Cao, Buqing; Ni, Xin] Second Mil Med Univ, Dept Physiol, Shanghai 200433, Peoples R China.
   [Cong, Binhai; Zhu, Xiaoyan; Cao, Buqing; Ni, Xin] Second Mil Med Univ, Minist Educ, Key Lab Mol Neurobiol, Shanghai 200433, Peoples R China.
   [Xiao, Jian; Wang, Zhinong] Changzheng Hosp, Dept Thorac Surg, Shanghai 200041, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University
RP Ni, X (通讯作者)，Second Mil Med Univ, Dept Physiol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.
EM nixinsmmu@hotmail.com
RI Cong, Binhai/LSK-3661-2024; Wang, Zhinong/HTR-6440-2023; zhu,
   xiaoyan/AAQ-6601-2021
OI Cong, Binhai/0000-0001-6913-1779
FU Major State Basic Research Program of China [2013CB967404]; Natural
   Science Foundation of China and Science [31000516]
FX This work is supported by Major State Basic Research Program of China
   (No. 2013CB967404) and Natural Science Foundation of China (No.
   31000516) and Science.
CR Åkerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938
   BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861
   Boonprasert P, 2008, INT J CARDIOL, V127, P307, DOI 10.1016/j.ijcard.2007.11.026
   Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508
   Brar BK, 2002, J MOL CELL CARDIOL, V34, P483, DOI 10.1006/jmcc.2002.1529
   Brar BK, 1999, MOL CELL ENDOCRINOL, V158, P55, DOI 10.1016/S0303-7207(99)00183-5
   Coste SC, 2001, ENDOCRINOLOGY, V142, P3537, DOI 10.1210/en.142.8.3537
   Davis C. E., 1994, Annals of Epidemiology, V4, P445
   Fujii G, 2006, BIOCHEM J, V395, P203, DOI 10.1042/BJ20051802
   Gann PH, 2003, JAMA-J AM MED ASSOC, V289, P3304, DOI 10.1001/jama.289.24.3304
   Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49
   Haeger P, 2006, J NEUROSCI, V26, P4908, DOI 10.1523/JNEUROSCI.0476-06.2006
   Hamilton KL, 2008, PHYSIOL GENOMICS, V32, P254, DOI 10.1152/physiolgenomics.00039.2007
   Hausenloy DJ, 2009, CARDIOVASC RES, V83, P179, DOI 10.1093/cvr/cvp062
   Hodis HN, 2003, NEW ENGL J MED, V349, P535, DOI 10.1056/NEJMoa030830
   ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X
   Jeanes HL, 2008, J ENDOCRINOL, V197, P493, DOI 10.1677/JOE-08-0071
   Jonassen AK, 2012, REGUL PEPTIDES, V174, P90, DOI 10.1016/j.regpep.2011.12.005
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Knight RA, 2008, FEBS LETT, V582, P984, DOI 10.1016/j.febslet.2008.02.035
   Lagranha CJ, 2010, CIRC RES, V106, P1681, DOI 10.1161/CIRCRESAHA.109.213645
   Lawrence KM, 2003, FASEB J, V17, P2313, DOI 10.1096/fj.02-0832fje
   Liu H, 2011, CARDIOVASC RES, V89, P119, DOI 10.1093/cvr/cvq265
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062
   Newton KM, 1997, AM J EPIDEMIOL, V145, P269
   Ordovás JM, 2010, NAT REV CARDIOL, V7, P510, DOI 10.1038/nrcardio.2010.104
   Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89
   Shinohara T, 2004, J MOL CELL CARDIOL, V37, P1053, DOI 10.1016/j.yjmcc.2004.09.006
   Shlipak MG, 2001, CIRCULATION, V104, P2300, DOI 10.1161/hc4401.98414
   Singh KP, 2012, CANCER LETT, V316, P62, DOI 10.1016/j.canlet.2011.10.022
   Smani T, 2010, CARDIOVASC RES, V87, P459, DOI 10.1093/cvr/cvq063
   Tomikawa J, 2012, PNAS, V109, P1294
   Wang S, 2012, ENDOCRINOLOGY, V153, P1915, DOI 10.1210/en.2011-1939
   Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673
NR 35
TC 27
Z9 30
U1 0
U2 18
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 12
PY 2013
VL 168
IS 5
BP 4755
EP 4760
DI 10.1016/j.ijcard.2013.07.231
PG 6
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 242EI
UT WOS:000326219800034
PM 23962778
DA 2025-01-12
ER

PT J
AU Wang, ZQ
   Keita, M
   Bachvarova, M
   Gobeil, S
   Morin, C
   Plante, M
   Gregoire, J
   Renaud, MC
   Sebastianelli, A
   Trinh, XB
   Bachvarov, D
AF Wang, Zhi-Qiang
   Keita, Mamadou
   Bachvarova, Magdalena
   Gobeil, Stephane
   Morin, Chantale
   Plante, Marie
   Gregoire, Jean
   Renaud, Marie-Claude
   Sebastianelli, Alexandra
   Trinh, Xuan Bich
   Bachvarov, Dimcho
TI Inhibition of RUNX2 Transcriptional Activity Blocks the Proliferation,
   Migration and Invasion of Epithelial Ovarian Carcinoma Cells
SO PLOS ONE
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; BREAST-CANCER;
   DOWN-REGULATION; EXPRESSION; TARGET; APOPTOSIS; BETA; HEMATOPOIESIS;
   METHYLATION
AB Previously, we have identified the RUNX2 gene as hypomethylated and overexpressed in post-chemotherapy (CT) primary cultures derived from serous epithelial ovarian cancer (EOC) patients, when compared to primary cultures derived from matched primary (prior to CT) tumors. However, we found no differences in the RUNX2 methylation in primary EOC tumors and EOC omental metastases, suggesting that DNA methylation-based epigenetic mechanisms have no impact on RUNX2 expression in advanced (metastatic) stage of the disease. Moreover, RUNX2 displayed significantly higher expression not only in metastatic tissue, but also in high-grade primary tumors and even in low malignant potential tumors. Knockdown of the RUNX2 expression in EOC cells led to a sharp decrease of cell proliferation and significantly inhibited EOC cell migration and invasion. Gene expression profiling and consecutive network and pathway analyses confirmed these findings, as various genes and pathways known previously to be implicated in ovarian tumorigenesis, including EOC tumor invasion and metastasis, were found to be downregulated upon RUNX2 suppression, while a number of pro-apoptotic genes and some EOC tumor suppressor genes were induced. Taken together, our data are indicative for a strong oncogenic potential of the RUNX2 gene in serous EOC progression and suggest that RUNX2 might be a novel EOC therapeutic target. Further studies are needed to more completely elucidate the functional implications of RUNX2 and other members of the RUNX gene family in ovarian tumorigenesis.
C1 [Wang, Zhi-Qiang; Keita, Mamadou; Gobeil, Stephane; Bachvarov, Dimcho] Univ Laval, Dept Mol Med, Quebec City, PQ, Canada.
   [Wang, Zhi-Qiang; Keita, Mamadou; Bachvarova, Magdalena; Morin, Chantale; Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude; Sebastianelli, Alexandra; Trinh, Xuan Bich; Bachvarov, Dimcho] Hop Hotel Dieu, Ctr Rech CHU Quebec, Quebec City, PQ, Canada.
   [Gobeil, Stephane] CHUL, Ctr Rech CHU Quebec, Quebec City, PQ, Canada.
   [Plante, Marie; Gregoire, Jean; Renaud, Marie-Claude; Sebastianelli, Alexandra] Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ, Canada.
   [Trinh, Xuan Bich] Univ Antwerp Hosp, Dept Gynecol Oncol, Antwerp, Belgium.
C3 Laval University; Laval University; Laval University; University of
   Antwerp
RP Bachvarov, D (通讯作者)，Univ Laval, Dept Mol Med, Quebec City, PQ, Canada.
EM dimtcho.batchvarov@crhdq.ulaval.ca
OI Bachvarov, Dimcho/0000-0001-6509-9599
FU Cancer Research Society of Canada
FX This study was sustained by a grant to D. B. from the Cancer Research
   Society of Canada. Clinical specimens were provided by the Banque de
   tissus et de donnees of the Reseau de recherche sur le cancer of the
   Fonds de recherche du Quebec - Sante which is affiliated with the
   Canadian Tumor Repository Network. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agarwal A, 2010, CANCER RES, V70, P5880, DOI 10.1158/0008-5472.CAN-09-4341
   Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123
   Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Alouini S, 2012, GYNECOL ONCOL, V126, P313, DOI 10.1016/j.ygyno.2012.04.044
   Alper Ö, 2001, MOL CELL BIOCHEM, V218, P55, DOI 10.1023/A:1007205205131
   [Anonymous], J CELL BIOCH
   Balch C, 2009, ENDOCRINOLOGY, V150, P4003, DOI 10.1210/en.2009-0404
   Barnholtz-Sloan JS, 2003, AM J OBSTET GYNECOL, V189, P1120, DOI 10.1067/S0002-9378(03)00579-9
   Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Blyth K, 2010, BLOOD CELL MOL DIS, V45, P117, DOI 10.1016/j.bcmd.2010.05.007
   Bock AJ, 2010, INT J GYNECOL CANCER, V20, P1448, DOI 10.1111/IGC.0b013e3181f7d6be
   Brard L, 2011, GYNECOL ONCOL, V123, P370, DOI 10.1016/j.ygyno.2011.07.002
   Cano CE, 2011, J CELL PHYSIOL, V226, P1439, DOI 10.1002/jcp.22324
   Capparelli C, 2012, CELL CYCLE, V11, P2272, DOI 10.4161/cc.20717
   Casaburi I, 2012, CELL CYCLE, V11, P2699, DOI 10.4161/cc.21029
   Daikoku T, 2005, CANCER RES, V65, P3735, DOI 10.1158/0008-5472.CAN-04-3814
   Daikoku T, 2007, CANCER RES, V67, P5285, DOI 10.1158/0008-5472.CAN-07-0828
   Duprez E, 2004, CELL CYCLE, V3, P389
   Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085
   Fridman JS, 1998, ONCOGENE, V17, P2981, DOI 10.1038/sj.onc.1202224
   Hantke B, 2003, BIOL CHEM, V384, P1247, DOI 10.1515/BC.2003.137
   Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461
   Huang XM, 1999, NAT STRUCT BIOL, V6, P624
   Huang Z, 2012, ONCOGENE, V31, P3709, DOI 10.1038/onc.2011.529
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kanamori Y, 1999, CANCER RES, V59, P4225
   Karnezis T, 2012, ONCOTARGET, V3, P893, DOI 10.18632/oncotarget.593
   Kayed H, 2007, BRIT J CANCER, V97, P1106, DOI 10.1038/sj.bjc.6603984
   Keita M, 2013, CELL CYCLE, V12, P972, DOI 10.4161/cc.23963
   Keita M, 2013, GYNECOL ONCOL, V128, P356, DOI 10.1016/j.ygyno.2012.11.036
   Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200
   Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991
   L'Espérance S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-99
   Lecomte C, 2005, CELL CYCLE, V4, P1862, DOI 10.4161/cc.4.12.2300
   Lee CWL, 2011, GYNECOL ONCOL, V122, P410, DOI 10.1016/j.ygyno.2011.04.044
   Lehtinen L, 2013, ONCOTARGET, V4, P48, DOI 10.18632/oncotarget.756
   Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370
   Li H, 2013, TUMOUR BIOL
   Li H, 2012, CANCER PREV RES, V5, P484, DOI 10.1158/1940-6207.CAPR-11-0414
   Li W, 2010, CELL CYCLE, V9, P4433, DOI 10.4161/cc.9.22.13838
   Li WP, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/456534
   Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409
   Madsen CV, 2012, ANTICANCER RES, V32, P3817
   Maier S, 2005, AM J PHARMACOGENOMIC, V5, P223, DOI 10.2165/00129785-200505040-00003
   Mann AP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013050
   Mansour M, 2011, J VIROL, V85, P6015, DOI 10.1128/JVI.01537-10
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Mercier PL, 2011, MOL ONCOL, V5, P438, DOI 10.1016/j.molonc.2011.07.003
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Morrow KA, 2011, J BIOL CHEM, V286, P40376, DOI 10.1074/jbc.M111.250035
   Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0
   Niu DF, 2012, LAB INVEST, V92, P1181, DOI 10.1038/labinvest.2012.84
   Ofek P, 2003, J BIOL CHEM, V278, P14299, DOI 10.1074/jbc.M211699200
   Okada-Ban M, 1999, ONCOGENE, V18, P6719, DOI 10.1038/sj.onc.1203092
   Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7
   Papacleovoulou G, 2011, J ENDOCRINOL, V211, P273, DOI 10.1530/JOE-11-0081
   Planagumà J, 2011, HUM PATHOL, V42, P57, DOI 10.1016/j.humpath.2010.01.025
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005
   Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357
   Purcell DJ, 2012, J CELL BIOCHEM, V113, P2406, DOI 10.1002/jcb.24114
   Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140
   Sandi MJ, 2011, J CELL PHYSIOL, V226, P3442, DOI 10.1002/jcp.22702
   Sasaki H, 2000, CANCER RES, V60, P5659
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Stone B, 2003, INT J CANCER, V104, P73, DOI 10.1002/ijc.10900
   Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004
   Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199
   Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742
   Taraboletti G, 2010, ONCOTARGET, V1, P662
   Tetu B, 2008, MODERN PATHOL, V21, P1002, DOI 10.1038/modpathol.2008.80
   van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771
   Vergote I, 2000, J NATL CANCER I, V92, P1534, DOI 10.1093/jnci/92.18.1534
   Wang CQ, 2010, BLOOD CELL MOL DIS, V44, P275, DOI 10.1016/j.bcmd.2010.01.006
   Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444
   Wotton S, 2002, CANCER RES, V62, P7181
   Yamaoka T, 2011, J DERMATOL SCI, V64, P99, DOI 10.1016/j.jdermsci.2011.07.005
   Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714
   Yang MH, 2012, ONCOGENE, V31, P2401, DOI 10.1038/onc.2011.423
   Zhang SQ, 2009, OMICS, V13, P307, DOI 10.1089/omi.2009.0030
   Zhao HX, 2012, EXP MOL MED, V44, P633, DOI 10.3858/emm.2012.44.11.072
NR 82
TC 24
Z9 28
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 4
PY 2013
VL 8
IS 10
AR e74384
DI 10.1371/journal.pone.0074384
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 232JF
UT WOS:000325489100007
PM 24124450
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Chan, KCA
   Jiang, PY
   Chan, CWM
   Sun, K
   Wong, J
   Hui, EP
   Chan, SL
   Chan, WC
   Hui, DSC
   Ng, SSM
   Chan, HLY
   Wong, CSC
   Ma, BBY
   Chan, ATC
   Lai, PBS
   Sun, H
   Chiu, RWK
   Lo, YMD
AF Chan, K. C. Allen
   Jiang, Peiyong
   Chan, Carol W. M.
   Sun, Kun
   Wong, John
   Hui, Edwin P.
   Chan, Stephen L.
   Chan, Wing Cheong
   Hui, David S. C.
   Ng, Simon S. M.
   Chan, Henry L. Y.
   Wong, Cesar S. C.
   Ma, Brigette B. Y.
   Chan, Anthony T. C.
   Lai, Paul B. S.
   Sun, Hao
   Chiu, Rossa W. K.
   Lo, Y. M. Dennis
TI Noninvasive detection of cancer-associated genome-wide hypomethylation
   and copy number aberrations by plasma DNA bisulfite sequencing
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE epigenomics; epigenetics; next-generation sequencing; tumor markers;
   global hypomethylation
ID MATERNAL PLASMA; NUCLEIC-ACIDS; FETAL DNA; SERUM; RNA; METHYLATION;
   ANEUPLOIDY
AB We explored the detection of genome-wide hypomethylation in plasma using shotgun massively parallel bisulfite sequencing as a marker for cancer. Tumor-associated copy number aberrations (CNAs) could also be observed from the bisulfite DNA sequencing data. Hypomethylation and CNAs were detected in the plasma DNA of patients with hepatocellular carcinoma, breast cancer, lung cancer, nasopharyngeal cancer, smooth muscle sarcoma, and neuroendocrine tumor. For the detection of nonmetastatic cancer cases, plasma hypomethylation gave a sensitivity and specificity of 74% and 94%, respectively, when a mean of 93 million reads per case were obtained. Reducing the sequencing depth to 10 million reads per case was found to have no adverse effect on the sensitivity and specificity for cancer detection, giving respective figures of 68% and 94%. This characteristic thus indicates that analysis of plasma hypomethylation by this sequencing-based method may be a relatively cost-effective approach for cancer detection. We also demonstrated that plasma hypomethylation had utility for monitoring hepatocellular carcinoma patients following tumor resection and for detecting residual disease. Plasma hypomethylation can be combined with plasma CNA analysis for further enhancement of the detection sensitivity or specificity using different diagnostic algorithms. Using the detection of at least one type of aberration to define an abnormality, a sensitivity of 87% could be achieved with a specificity of 88%. These developments have thus expanded the applications of plasma DNA analysis for cancer detection and monitoring.
C1 [Chan, K. C. Allen; Jiang, Peiyong; Chan, Carol W. M.; Sun, Kun; Chan, Henry L. Y.; Sun, Hao; Chiu, Rossa W. K.; Lo, Y. M. Dennis] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Chan, K. C. Allen; Jiang, Peiyong; Chan, Carol W. M.; Sun, Kun; Sun, Hao; Chiu, Rossa W. K.; Lo, Y. M. Dennis] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China.
   [Chan, K. C. Allen; Hui, Edwin P.; Chan, Stephen L.; Ng, Simon S. M.; Ma, Brigette B. Y.; Chan, Anthony T. C.; Lai, Paul B. S.; Lo, Y. M. Dennis] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Oncol South China, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China.
   [Wong, John; Ng, Simon S. M.; Lai, Paul B. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
   [Hui, Edwin P.; Chan, Stephen L.; Ma, Brigette B. Y.; Chan, Anthony T. C.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.
   [Chan, Wing Cheong] North Dist Hosp, Dept Surg, Sheung Shui, Hong Kong, Peoples R China.
   [Hui, David S. C.; Chan, Henry L. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
   [Wong, Cesar S. C.] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; State Key Lab Oncology South China; Chinese
   University of Hong Kong; Prince of Wales Hospital; Chinese University of
   Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong;
   Prince of Wales Hospital; Chinese University of Hong Kong; Prince of
   Wales Hospital; Hong Kong Polytechnic University
RP Lo, YMD (通讯作者)，Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
EM loym@cuhk.edu.hk
RI Ng, Simon/M-1219-2018; Hui, David/O-2754-2015; Sun, Hao/T-5576-2019;
   Chan, Carol/JBS-1978-2023; Lo, Yuk/D-4468-2011; Peiyong,
   JIANG,/AAZ-9898-2020; Chan, Henry/B-9636-2008; Hui, Edwin/ABC-1818-2021;
   Chan, Stephen/F-9149-2011; Ma, Brigette/H-4681-2017; Chan, Anthony Tak
   Cheung/R-3940-2018; sun, hao/J-9964-2013; LAI, Paul Bo-San/K-8556-2015;
   Sun, Kun/Q-6479-2018
OI Chan, Stephen/0000-0001-8998-5480; Ma, Brigette/0000-0003-4802-1102;
   WONG, Sze Chuen Cesar/0000-0003-0058-140X; Chan, Anthony Tak
   Cheung/0000-0002-6912-8091; sun, hao/0000-0002-5547-9501; LAI, Paul
   Bo-San/0000-0002-9469-6728; Hui, David/0000-0003-4382-2445; Sun,
   Kun/0000-0002-9883-1616; Jiang, Peiyong/0000-0003-4523-3476
FU Hong Kong Research Grants Council Theme-Based Research Scheme
   [T12-CUHK05/10]; S. K. Yee Foundation; Innovation and Technology Fund
   under the State Key Laboratory Programme; Li Ka Shing Foundation
FX This work is supported by the Hong Kong Research Grants Council
   Theme-Based Research Scheme (T12-CUHK05/10), the S. K. Yee Foundation,
   and the Innovation and Technology Fund under the State Key Laboratory
   Programme. Y.M.D.L. is supported by an endowed chair from the Li Ka
   Shing Foundation.
CR Bianchi DW, 2012, OBSTET GYNECOL, V119, P890, DOI 10.1097/AOG.0b013e31824fb482
   Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014
   Chen EZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021791
   Chen XQ, 1996, NAT MED, V2, P1033
   Chim SSC, 2005, P NATL ACAD SCI USA, V102, P14753, DOI 10.1073/pnas.0503335102
   Chiu RWK, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7401
   Chiu RWK, 2008, P NATL ACAD SCI USA, V105, P20458, DOI 10.1073/pnas.0810641105
   Edge S.B., 2010, AJCC cancer staging manual, V649
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm434
   Kopreski MS, 1999, CLIN CANCER RES, V5, P1961
   Korlach J, 2012, CURR OPIN STRUC BIOL, V22, P251, DOI 10.1016/j.sbi.2012.04.002
   Leary RJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004742
   Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Lo KW, 1999, CLIN CHEM, V45, P1292
   Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800
   Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0
   Lo YMD, 2012, ANNU REV GENOM HUM G, V13, P285, DOI 10.1146/annurev-genom-090711-163806
   Lun FMF, 2013, CLIN CHEM, V59, P1583, DOI 10.1373/clinchem.2013.212274
   Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
   Palomaki GE, 2011, GENET MED, V13, P913, DOI 10.1097/GIM.0b013e3182368a0e
   Poon LLM, 2000, CLIN CHEM, V46, P1832
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Ross JP, 2010, EPIGENOMICS-UK, V2, P245, DOI 10.2217/EPI.10.2
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Srinivasan A, 2013, AM J HUM GENET, V92, P167, DOI 10.1016/j.ajhg.2012.12.006
   Tangkijvanich P, 2007, CLIN CHIM ACTA, V379, P127, DOI 10.1016/j.cca.2006.12.029
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Wong IHN, 1999, CANCER RES, V59, P71
   Yu SCY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060968
NR 31
TC 328
Z9 384
U1 1
U2 93
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 19
PY 2013
VL 110
IS 47
BP 18761
EP 18768
DI 10.1073/pnas.1313995110
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 253PD
UT WOS:000327100600029
PM 24191000
OA Green Published
DA 2025-01-12
ER

PT J
AU Jansen, MPHM
   Knijnenburg, T
   Reijm, EA
   Simon, I
   Kerkhoven, R
   Droog, M
   Velds, A
   van Laere, S
   Dirix, L
   Alexi, X
   Foekens, JA
   Wessels, L
   Linn, SC
   Berns, EMJJ
   Zwart, W
AF Jansen, Maurice P. H. M.
   Knijnenburg, Theo
   Reijm, Esther A.
   Simon, Iris
   Kerkhoven, Ron
   Droog, Marjolein
   Velds, Arno
   van Laere, Steven
   Dirix, Luc
   Alexi, Xanthippi
   Foekens, John A.
   Wessels, Lodewyk
   Linn, Sabine C.
   Berns, Els M. J. J.
   Zwart, Wilbert
TI Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic
   Profiling in Breast Cancer
SO CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR BINDING; GENE-EXPRESSION; CHROMATIN STATE; PPAR-GAMMA;
   CELLS; SIX1; OVEREXPRESSION; PROLIFERATION; METHYLATION; PROGRESSION
AB Aromatase inhibitors are the major first-line treatment of estrogen receptor-positive breast cancer, but resistance to treatment is common. To date, no biomarkers have been validated clinically to guide subsequent therapy in these patients. In this study, we mapped the genome-wide chromatin-binding profiles of estrogen receptor alpha (ER alpha), along with the epigenetic modifications H3K4me3 and H3K27me3, that are responsible for determining gene transcription (n = 12). Differential binding patterns of ER alpha, H3K4me3, and H3K27me3 were enriched between patients with good or poor outcomes after aromatase inhibition. ER alpha and H3K27me3 patterns were validated in an additional independent set of breast cancer cases (n = 10). We coupled these patterns to array-based proximal gene expression and progression-free survival data derived from a further independent cohort of 72 aromatase inhibitor-treated patients. Through this approach, we determined that the ER alpha and H3K27me3 profiles predicted the treatment outcomes for first-line aromatase inhibitors. In contrast, the H3K4me3 pattern identified was not similarly informative. The classification potential of these genes was only partially preserved in a cohort of 101 patients who received first-line tamoxifen treatment, suggesting some treatment selectivity in patient classification. (C) 2013 AACR.
C1 [Jansen, Maurice P. H. M.; Reijm, Esther A.; Foekens, John A.; Berns, Els M. J. J.] Erasmus Univ, Med Ctr, Dept Med Oncol, Inst Canc, Rotterdam, Netherlands.
   [Knijnenburg, Theo; Wessels, Lodewyk] Netherlands Canc Inst, Dept Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands.
   [Droog, Marjolein; Alexi, Xanthippi; Linn, Sabine C.; Zwart, Wilbert] Netherlands Canc Inst, Dept Mol Pathol, NL-1066 CX Amsterdam, Netherlands.
   [Kerkhoven, Ron; Velds, Arno] Netherlands Canc Inst, Cent Genom Facil, NL-1066 CX Amsterdam, Netherlands.
   [Simon, Iris] Agendia NV, Amsterdam, Netherlands.
   [van Laere, Steven; Dirix, Luc] Univ Antwerp, Translat Canc Res Unit, Pathol Lab, Oncol Ctr,GZA Hosp St Augustinus, B-2020 Antwerp, Belgium.
C3 Erasmus University Rotterdam; Erasmus MC; Netherlands Cancer Institute;
   Netherlands Cancer Institute; Netherlands Cancer Institute; Agendia;
   University of Antwerp
RP Zwart, W (通讯作者)，Netherlands Canc Inst, Dept Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM w.zwart@nki.nl
RI jansen, maurice/E-9927-2013; Simón Sáez, Iris/JWA-2431-2024; Van Laere,
   Steven/GQA-8872-2022; Dirix, Luc/AAI-8880-2020
OI Van Laere, Steven/0000-0002-2640-0040; Velds, Arno/0000-0003-4333-8872;
   Zwart, Wilbert/0000-0002-9823-7289
FU KWF Dutch Cancer Society; A Sisters Hope; Top Institute Pharma [T3-108,
   T3-502]
FX This work was supported by grants from the KWF Dutch Cancer Society, A
   Sisters Hope and Top Institute Pharma, grants T3-108 and T3-502.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499
   Bertelli G, 2005, BRIT J CANCER, V93, pS6, DOI 10.1038/sj.bjc.6602689
   Bonofiglio D, 2009, AM J PATHOL, V175, P1270, DOI 10.2353/ajpath.2009.081078
   Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cobleigh MA, 2005, CLIN CANCER RES, V11, P8623, DOI 10.1158/1078-0432.CCR-05-0735
   Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101
   Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Iwanaga R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3219
   Kirmizis A, 2007, NATURE, V449, P928, DOI 10.1038/nature06160
   Kok M, 2012, BREAST, V21, P769, DOI 10.1016/j.breast.2012.04.010
   Kok M, 2009, BREAST CANCER RES TR, V113, P275, DOI 10.1007/s10549-008-9939-y
   Liu H, 2003, BREAST CANCER RES TR, V79, P63, DOI 10.1023/A:1023366117157
   Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Makeyev AV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044443
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Miller WR, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2611
   Miller WR, 2009, J CLIN ONCOL, V27, P1382, DOI 10.1200/JCO.2008.16.8849
   Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Ramirez-Ardila DE, 2013, BREAST CANCER RES TR, V139, P39, DOI 10.1007/s10549-013-2529-7
   Ravindranath A, 2011, BRIT J CANCER, V105, P542, DOI 10.1038/bjc.2011.269
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Salero E, 2001, J BIOL CHEM, V276, P1881, DOI 10.1074/jbc.M007008200
   Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001
   Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Varadi V, 2009, EUR J CANCER, V45, P3008, DOI 10.1016/j.ejca.2009.08.012
   Vlaeminck-Guillem V, 2003, ONCOGENE, V22, P8072, DOI 10.1038/sj.onc.1207094
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Williams CMJ, 2009, EMBO J, V28, P3591, DOI 10.1038/emboj.2009.290
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368
NR 50
TC 69
Z9 77
U1 0
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2013
VL 73
IS 22
BP 6632
EP 6641
DI 10.1158/0008-5472.CAN-13-0704
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 256NY
UT WOS:000327321700010
PM 24242068
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Rizzolo, P
   Silvestri, V
   Tommasi, S
   Pinto, R
   Danza, K
   Falchetti, M
   Gulino, M
   Frati, P
   Ottini, L
AF Rizzolo, P.
   Silvestri, V.
   Tommasi, S.
   Pinto, R.
   Danza, K.
   Falchetti, M.
   Gulino, M.
   Frati, P.
   Ottini, L.
TI Male breast cancer: genetics, epigenetics, and ethical aspects
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE epigenetic alterations; ethics; genetic susceptibility; male breast
   cancer; methylation; miRNAs
ID GENOME-WIDE ASSOCIATION; BRCA2 REARRANGEMENTS; GERMLINE MUTATIONS;
   COMMON MUTATIONS; FANCONI-ANEMIA; CHEK2 1100DELC; SUSCEPTIBILITY; RISK;
   MICRORNA; GENES
AB Male breast cancer (MBC) is a rare disease compared with female BC and our current understanding regarding breast carcinogenesis in men has been largely extrapolated from the female counterpart. We focus on differences between the ethical issues related to male and female BC patients. A systematic literature search by using PubMed (), was carried out to provide a synopsis of the current research in the field of MBC genetics, epigenetics and ethics. Original articles and reviews published up to September 2012 were selected by using the following search key words to query the PubMed website: 'male breast cancer', 'male breast cancer and genetic susceptibility', 'male breast cancer and epigenetics', 'male breast cancer and methylation', 'male breast cancer and miRNA', 'male breast cancer and ethics'.
   As in women, three classes of breast cancer genetic susceptibility (high, moderate, and low penetrance) are recognized in men. However, genes involved and their impact do not exactly overlap in female and male BC. Epigenetic alterations are currently scarcely investigated in MBC, however, the different methylation and miRNA expression profiles identified to date in female and male BCs suggest a potential role for epigenetic alterations as diagnostic biomarkers. Overall, much still needs to be learned about MBC and, because of its rarity, the main effort is to develop large consortia for moving forward in understanding MBC and improving the management of MBC patients on a perspective of gender medicine.
C1 [Rizzolo, P.; Silvestri, V.; Falchetti, M.; Ottini, L.] Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy.
   [Tommasi, S.; Pinto, R.; Danza, K.] Ist Tumori Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy.
   [Gulino, M.; Frati, P.] Univ Roma La Sapienza, Dept Anat Histol Forens & Orthopaed Sci, I-00161 Rome, Italy.
   [Frati, P.] IRCSS Neuromed, Pozzilli, Italy.
C3 Sapienza University Rome; IRCCS Istituto Tumori Bari Giovanni Paolo II;
   Sapienza University Rome; IRCCS Neuromed
RP Ottini, L (通讯作者)，Univ Roma La Sapienza, Dept Mol Med, Viale Regina Elena 324, I-00161 Rome, Italy.
EM laura.ottini@uniroma1.it
RI Danza, Katia/K-3182-2018; Silvestri, Valentina/AAR-8552-2020; Tommasi,
   Stefania/J-6732-2012; Gulino, Matteo/T-2318-2018
OI Silvestri, Valentina/0000-0003-0712-9379; Tommasi,
   Stefania/0000-0002-2157-2978; Gulino, Matteo/0000-0002-0146-1314;
   Rizzolo, Piera/0000-0002-3421-1485; OTTINI, LAURA/0000-0001-8030-0449;
   Frati, Paola/0000-0002-0358-7965
CR Adank MA, 2011, BREAST CANCER RES TR, V127, P357, DOI 10.1007/s10549-010-1001-1
   [Anonymous], CHIN J CANC
   [Anonymous], CLIN CANC RES
   [Anonymous], PATHOLOGY GENE EXPRE
   Antoniou AC, 2008, AM J HUM GENET, V82, P937, DOI 10.1016/j.ajhg.2008.02.008
   Bane AL, 2007, AM J SURG PATHOL, V31, P121, DOI 10.1097/01.pas.0000213351.49767.0f
   Bonifaci N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014078
   Bunnik EM, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-4
   Caligo MA, 2004, HUM MUTAT, V24, P100, DOI 10.1002/humu.20051
   Capalbo C, 2007, J CLIN ONCOL, V25, P2632, DOI 10.1200/JCO.2007.11.4330
   Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958
   Corcoran C, 2011, CLIN CHEM, V57, P18, DOI 10.1373/clinchem.2010.150730
   Cox A, 2007, NAT GENET, V39, P352, DOI 10.1038/ng1981
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Da Silva L, 2010, MODERN PATHOL, V23, pS46, DOI 10.1038/modpathol.2010.37
   de Chalon AS, 2010, BREAST CANCER RES TR, V121, P253, DOI 10.1007/s10549-009-0673-x
   Ding YC, 2011, BREAST CANCER RES TR, V126, P771, DOI 10.1007/s10549-010-1195-2
   Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Falchetti M, 2008, BREAST CANCER RES TR, V110, P161, DOI 10.1007/s10549-007-9689-2
   Fassan M, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2348
   Fletcher O, 2010, NAT REV CANCER, V10, P353, DOI 10.1038/nrc2840
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   France L, 2000, BREAST, V9, P343, DOI 10.1054/brst.2000.0173
   Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480
   García MJ, 2009, BREAST CANCER RES TR, V113, P545, DOI 10.1007/s10549-008-9945-0
   Garcia-Closas M, 2008, CLIN CANCER RES, V14, P8000, DOI 10.1158/1078-0432.CCR-08-0975
   Ghoussaini M, 2008, JNCI-J NATL CANCER I, V100, P962, DOI 10.1093/jnci/djn190
   Ghoussaini M, 2012, NAT GENET, V44, P312, DOI 10.1038/ng.1049
   Giannini G, 2008, J CLIN ONCOL, V26, P4212, DOI 10.1200/JCO.2008.18.2089
   Giordano SH, 2005, ONCOLOGIST, V10, P471, DOI 10.1634/theoncologist.10-7-471
   Hansen TV, 2009, BREAST CANCER RES TR, V115, P315, DOI 10.1007/s10549-008-0088-0
   HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230
   Issabekova A, 2012, BIOINFORMATION, V8, P513, DOI 10.6026/97320630008513
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Karhu R, 2006, CANCER DETECT PREV, V30, P530, DOI 10.1016/j.cdp.2006.10.002
   Korde LA, 2010, J CLIN ONCOL, V28, P2114, DOI 10.1200/JCO.2009.25.5729
   Kornegoor R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3220
   Kumar A, 2012, GENOMICS, V100, P352, DOI 10.1016/j.ygeno.2012.08.006
   Lehmann U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-109
   Levy-Lahad E, 2010, NAT GENET, V42, P368, DOI 10.1038/ng0510-368
   Li MF, 2010, AAPS J, V12, P309, DOI 10.1208/s12248-010-9194-0
   Ling Hui, 2011, Chin J Cancer, V30, P739, DOI 10.5732/cjc.011.10243
   Ly D, 2013, INT J CANCER, V132, P1918, DOI 10.1002/ijc.27841
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Martínez-Bouzas C, 2007, BREAST CANCER RES TR, V103, P111, DOI 10.1007/s10549-006-9351-4
   Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775
   Mavaddat N, 2010, MOL ONCOL, V4, P174, DOI 10.1016/j.molonc.2010.04.011
   Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879
   Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569
   Narod SA, 2007, J CLIN ONCOL, V25, P6, DOI 10.1200/JCO.2006.08.8229
   Neuhausen S, 2004, INT J CANCER, V108, P477, DOI 10.1002/ijc.11385
   Offit K, 2011, HUM GENET, V130, P3, DOI 10.1007/s00439-011-1028-3
   Ohayon T, 2004, INT J CANCER, V108, P479, DOI 10.1002/ijc.11603
   Orr N, 2012, NAT GENET, V44, P1182, DOI 10.1038/ng.2417
   Orr N, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002290
   Ottini L, 2012, BREAST CANCER RES TR, V134, P411, DOI 10.1007/s10549-012-2062-0
   Ottini L, 2010, CRIT REV ONCOL HEMAT, V73, P141, DOI 10.1016/j.critrevonc.2009.04.003
   Ottini L, 2009, BREAST CANCER RES TR, V116, P577, DOI 10.1007/s10549-008-0194-z
   Palli D, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-170
   Papi L, 2009, BREAST CANCER RES TR, V117, P497, DOI 10.1007/s10549-008-0190-3
   Park DJ, 2012, AM J HUM GENET, V90, P734, DOI 10.1016/j.ajhg.2012.02.027
   Pharoah P, 2006, JNCI-J NATL CANCER I, V98, P1382, DOI 10.1093/jnci/djj374
   Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853
   Pinto R, 2013, J CELL PHYSIOL, V228, P1264, DOI 10.1002/jcp.24281
   Qiu LX, 2010, BREAST CANCER RES TR, V123, P487, DOI 10.1007/s10549-010-0767-5
   Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959
   Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Shen J, 2009, INT J CANCER, V124, P1178, DOI 10.1002/ijc.24008
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Silvestri V, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2823
   Silvestri V, 2011, BREAST CANCER RES TR, V126, P539, DOI 10.1007/s10549-010-1289-x
   Silvestri V, 2010, BREAST CANCER RES TR, V122, P299, DOI 10.1007/s10549-010-0797-z
   Sluiter MD, 2011, BREAST CANCER RES TR, V125, P325, DOI 10.1007/s10549-010-0817-z
   Speirs V, 2009, BREAST CANCER RES TR, V115, P429, DOI 10.1007/s10549-008-0053-y
   Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131
   Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53
   Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001
   Syrjäkoski K, 2004, INT J CANCER, V108, P475, DOI 10.1002/ijc.11384
   Tan DSP, 2008, J CLIN PATHOL, V61, P1073, DOI 10.1136/jcp.2008.057950
   Thaler S, 2012, ONCOGENE, V31, P4912, DOI 10.1038/onc.2011.658
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b
   Tirkkonen M, 1999, GENE CHROMOSOME CANC, V24, P56, DOI 10.1002/(SICI)1098-2264(199901)24:1<56::AID-GCC8>3.0.CO;2-X
   Tommasi S, 2010, ANAL CELL PATHOL, V33, P113, DOI [10.1155/2010/468280, 10.3233/ACP-CLO-2010-0544]
   Tournier I, 2004, CANCER RES, V64, P8143, DOI 10.1158/0008-5472.CAN-04-2467
   Tsai NP, 2009, BIOCHEM J, V424, P411, DOI 10.1042/BJ20090915
   Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586
   Vargas AC, 2011, J MAMMARY GLAND BIOL, V16, P27, DOI 10.1007/s10911-011-9204-6
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wasserman NF, 2010, GENOME RES, V20, P1191, DOI 10.1101/gr.105361.110
   Willems PJ, 2007, CLIN GENET, V72, P493, DOI 10.1111/j.1399-0004.2007.00909.x
   Wokolorczyk D, 2009, JNCI-J NATL CANCER I, V101, DOI 10.1093/jnci/djn472
   Wokolorczyk D, 2008, CANCER RES, V68, P9982, DOI 10.1158/0008-5472.CAN-08-1838
   Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318
NR 99
TC 72
Z9 75
U1 0
U2 28
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD NOV
PY 2013
VL 24
SU 8
BP 75
EP 82
DI 10.1093/annonc/mdt316
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 239AX
UT WOS:000325994900015
PM 24131976
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Yang, CS
   Wang, H
   Hu, B
AF Yang, Chung S.
   Wang, Hong
   Hu, Bing
TI Combination of Chemopreventive Agents in Nanoparticles for Cancer
   Prevention
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID DRUG-DELIVERY; LIPID NANOPARTICLES; PANCREATIC-CANCER; BREAST-CANCER;
   SULFORAPHANE; CURCUMIN; ASPIRIN; NUTRACEUTICALS; ATORVASTATIN; SLN
AB Carcinogenesis involves multiple genetic and epigenetic alterations, and a single chemopreventive agent may not be sufficient to prevent these events. Therefore, the use of a combination of agents is an attractive approach for cancer chemoprevention. In this issue of the journal, Prabhu and colleagues examined a combination of aspirin, curcumin, and sulforaphane for the prevention of pancreatic cancer in hamsters (beginning page 1015). The novelty of this work is that when aspirin and curcumin were incorporated in nanoparticles and administered orally, in combination with sulforaphane, the effective dosages were decreased by 10-fold in comparison with the free form mixture. In this commentary, the possible mechanisms of synergistic action among multiple chemopreventive agents and the use of stable nanoparticles for oral delivery are discussed. Also discussed is the importance of measuring tissue levels of the chemopreventive agents to understand the mode of action of these nanoparticles and to avoid toxicity. (c)2013 AACR.
C1 [Yang, Chung S.; Wang, Hong] Rutgers State Univ, Dept Biol Chem, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA.
   [Hu, Bing] Nanjing Agr Univ, Coll Food Sci & Technol, Nanjing, Jiangsu, Peoples R China.
C3 Rutgers University System; Rutgers University New Brunswick; Nanjing
   Agricultural University
RP Yang, CS (通讯作者)，Rutgers State Univ, Dept Biol Chem, Ernest Mario Sch Pharm, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM csyang@pharmacy.rutgers.edu
CR Bansal SS, 2011, CANCER PREV RES, V4, P1158, DOI 10.1158/1940-6207.CAPR-10-0006
   Bargoni A, 1998, PHARMACEUT RES, V15, P745, DOI 10.1023/A:1011975120776
   Chan AT, 2012, CANCER PREV RES, V5, P164, DOI 10.1158/1940-6207.CAPR-11-0391
   Garcia-Fuentes M, 2012, J CONTROL RELEASE, V161, P496, DOI 10.1016/j.jconrel.2012.03.017
   Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015
   Gradishar WJ, 2005, J CLIN ONCOL, V23, P7794, DOI 10.1200/JCO.2005.04.937
   Grandhi BK, 2013, CANCER PREV RES, V6, P1015, DOI 10.1158/1940-6207.CAPR-13-0172
   Hu B, 2012, CHEM COMMUN, V48, P2421, DOI 10.1039/c2cc17295j
   Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339
   Kumazoe M, 2013, J CLIN INVEST, V123, P787, DOI 10.1172/JCI64768
   Lambert JD, 2010, FOOD CHEM TOXICOL, V48, P409, DOI 10.1016/j.fct.2009.10.030
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Lu G, 2008, CLIN CANCER RES, V14, P4981, DOI 10.1158/1078-0432.CCR-07-1860
   Mazzanti G, 2009, EUR J CLIN PHARMACOL, V65, P331, DOI 10.1007/s00228-008-0610-7
   Muchow M, 2008, DRUG DEV IND PHARM, V34, P1394, DOI 10.1080/03639040802130061 
   Nair HB, 2010, BIOCHEM PHARMACOL, V80, P1833, DOI 10.1016/j.bcp.2010.07.021
   Parhi P, 2012, DRUG DISCOV TODAY, V17, P1044, DOI 10.1016/j.drudis.2012.05.010
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Sung BK, 2012, NUTR CANCER, V64, P173, DOI 10.1080/01635581.2012.630551
   Sutaria D, 2012, INT J ONCOL, V41, P2260, DOI 10.3892/ijo.2012.1636
   Thakkar A, 2013, ONCOL REP, V29, P1671, DOI 10.3892/or.2013.2276
   Thorley AJ, 2013, PHARM THER
   Veeranki OL, 2013, BRIT J NUTR, V109, P25, DOI 10.1017/S0007114512000657
   Yallapu MM, 2012, DRUG DISCOV TODAY, V17, P71, DOI 10.1016/j.drudis.2011.09.009
   Yang ZH, 2010, INT J CANCER, V126, P852, DOI 10.1002/ijc.24766
   Yuan H, 2007, COLLOID SURFACE B, V58, P157, DOI 10.1016/j.colsurfb.2007.03.002
NR 26
TC 9
Z9 13
U1 0
U2 35
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD OCT
PY 2013
VL 6
IS 10
BP 1011
EP 1014
DI 10.1158/1940-6207.CAPR-13-0312
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 229NE
UT WOS:000325272400002
PM 24072675
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhao, WT
   Wang, YT
   Huang, ZW
   Fang, J
AF Zhao, Wen-Ting
   Wang, Yu-Tian
   Huang, Zhao-Wei
   Fang, Jing
TI BRCA2 affects the efficiency of DNA double-strand break repair in
   response to N-nitroso compounds with differing carcinogenic potentials
SO ONCOLOGY LETTERS
LA English
DT Article
DE DNA double strand breaks; BRCA2; N-nitroso compounds; DNA damage repair
ID CANCER SUSCEPTIBILITY; H2A PHOSPHORYLATION; CELLULAR-RESPONSE;
   ANTICANCER AGENT; IN-VIVO; RECOMBINATION; GENE; CHEMORESISTANCE;
   MUTATIONS; NITROSAMINES
AB The tumor suppressor gene breast cancer susceptibility gene 2 (BRCA2) is frequently mutated or epigenetically repressed in human cancer and has a significant role in the homologous recombination (HR) of DNA double-strand breaks (DSBs). Although N-nitrosodiethylamine (NDEA), N-nitrosodiethanolamine (NDELA) and N-nitrosodipropylamine (NDPA) have similar chemical structures and are able to induce DNA damage, they have varying carcinogenic risks. We hypothesized that the DNA damage repair pathways that are induced by these N-nitroso compounds (NOCs) may differ and that this may contribute to the genotoxic-carcinogenic effect of the NOCs. The present study aimed to characterize the formation of DSBs by NDEA, NDELA and NDPA and also to investigate whether BRCA2 is involved in the DNA damage response. The NOCs were observed to time-dependently induce DSBs and the expression of gamma-H2AX in gastric cancer SGC7901 cells. It was observed that the DNA damage induced by NDEA, the most potent carcinogen, was not repaired as efficiently as that caused by NDELA or NDPA. The expression of BRCA2 and RAD51 was demonstrated to be inhibited by NDEA treatment but upregulated by NDELA or NDPA treatment. Furthermore, the knock down of BRCA2 expression impaired the DNA damage repair induced by NDELA or NDPA. The cells with this knock down exhibited an increased sensitivity to NDELA or NDPA treatment, but not to NDEA. These findings suggest that a BRCA2-mediated pathway contributes to differential DSB repair and sensitivity in response to NOC exposure and that it may be associated with the genotoxic-carcinogenic potential of NOCs.
C1 [Zhao, Wen-Ting; Fang, Jing] Chinese Acad Sci, SIBS, Inst Nutr Sci, Key Lab Nutr & Metab, Shanghai 200031, Peoples R China.
   [Wang, Yu-Tian; Huang, Zhao-Wei] Second Mil Med Univ, Changzheng Hosp, Dept Gastroenterol, Shanghai 200003, Peoples R China.
C3 Chinese Academy of Sciences; Naval Medical University
RP Wang, YT (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Gastroenterol, 415 Fengyang Rd, Shanghai 200031, Peoples R China.
EM yutianwangcn@yeah.net; fangj586@126.com
RI ZHAO, Wenting/AAB-5269-2019
FU Natural Science Foundation of China [81170385]; Shanghai Pujiang Talent
   Plan [07pj14003]; Chinese Ministry of Science and Technology
   [2007BAC27B02]; Chinese Academy of Sciences [KSCX2-YW-R-114]
FX The present study was supported by grants from the Natural Science
   Foundation of China (Grant No. 81170385), the Shanghai Pujiang Talent
   Plan (07pj14003), the Chinese Ministry of Science and Technology
   (2007BAC27B02) and the Chinese Academy of Sciences (KSCX2-YW-R-114).
CR [Anonymous], 1985, IARC Monogr Eval Carcinog Risk Chem Hum, V37, P1
   [Anonymous], 1978, IARC Monogr Eval Carcinog Risk Chem Man, V17, P1
   [Anonymous], 1987, IARC Monogr Eval Carcinog Risks Hum Suppl, V7, P1
   BRADLEY MO, 1982, CANCER RES, V42, P2592
   Brambilla G, 2007, MUTAT RES-REV MUTAT, V635, P17, DOI 10.1016/j.mrrev.2006.09.003
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7
   Dickey JS, 2009, CHROMOSOMA, V118, P683, DOI 10.1007/s00412-009-0234-4
   Esashi F, 2007, NAT STRUCT MOL BIOL, V14, P468, DOI 10.1038/nsmb1245
   Fillingham J, 2006, BIOCHEM CELL BIOL, V84, P568, DOI 10.1139/O06-072
   Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x
   Hecht SS, 1997, P SOC EXP BIOL MED, V216, P181
   Hefferin ML, 2005, DNA REPAIR, V4, P639, DOI 10.1016/j.dnarep.2004.12.005
   Jakubowska A, 2002, BRIT J CANCER, V87, P888, DOI 10.1038/sj.bjc.6600562
   Liede A, 2004, J CLIN ONCOL, V22, P735, DOI 10.1200/JCO.2004.05.055
   Loeppky RN, 2002, CHEM RES TOXICOL, V15, P470, DOI 10.1021/tx0101393
   Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5
   O'Donovan PJ, 2010, CARCINOGENESIS, V31, P961, DOI 10.1093/carcin/bgq069
   Ohnishi T, 2009, MUTAT RES-FUND MOL M, V669, P8, DOI 10.1016/j.mrfmmm.2009.06.010
   Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0
   Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009
   Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230
   Philip S, 2008, CANCER RES, V68, P9973, DOI 10.1158/0008-5472.CAN-08-1179
   Phillips ER, 2007, ONCOGENE, V26, P7799, DOI 10.1038/sj.onc.1210877
   Pinto LFR, 2001, CARCINOGENESIS, V22, P1877
   Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Sanches PJ, 2003, WATER RES, V37, P3837, DOI 10.1016/S0043-1354(03)00347-6
   Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004
   Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008
   Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333
   Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4
   van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Visoni S, 2008, TOXICOL LETT, V183, P90, DOI 10.1016/j.toxlet.2008.10.004
   Wang WX, 2008, CANCER BIOL THER, V7, P1004, DOI 10.4161/cbt.7.7.6409
   Wang YT, 2006, MOL CANCER THER, V5, P3153, DOI 10.1158/1535-7163.MCT-06-0427
   Williams GM, 1999, ARCH TOXICOL, V73, P394, DOI 10.1007/s002040050679
   Wiltshire T, 2007, MOL PHARMACOL, V71, P1051, DOI 10.1124/mol.106.029504
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
NR 40
TC 4
Z9 4
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUN
PY 2013
VL 5
IS 6
BP 1948
EP 1954
DI 10.3892/ol.2013.1269
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 223OT
UT WOS:000324816500038
PM 23833673
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Hosseini, SA
   Horton, S
   Saldivar, JC
   Miuma, S
   Stampfer, MR
   Heerema, NA
   Huebner, K
AF Hosseini, Seyed Ali
   Horton, Susan
   Saldivar, Joshua C.
   Miuma, Satoshi
   Stampfer, Martha R.
   Heerema, Nyla A.
   Huebner, Kay
TI Common Chromosome Fragile Sites in Human and Murine Epithelial Cells and
   <i>FHIT</i>/<i>FRA3B</i> Loss-Induced Global Genome Instability
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; BREAST-CANCER; LUNG-CANCER; CARCINOMA; DELETION;
   FHIT; REGIONS; TRANSFORMATION; PROGRESSION; FRA3B
AB Chromosomal positions of common fragile sites differ in lymphoblasts and fibroblasts, with positions dependent on the epigenetically determined density of replication origins at these loci. Because rearrangement of fragile loci and associated loss of fragile gene products are hallmarks of cancers, we aimed to map common fragile sites in epithelial cells, from which most cancers derive. Among the five most frequently activated sites in human epithelial cells were chromosome bands 2q33 and Xq22.1, which are not among top fragile sites identified in lymphoblasts or fibroblasts. FRA16D at 16q23 was among the top three fragile sites in the human epithelial cells examined, as it is in lymphoblasts and fibroblasts, while FRA3B at 3p14.2, the top fragile locus in lymphoblasts, was not fragile in most epithelial cell lines tested. Epithelial cells exhibited varying hierarchies of fragile sites; some frequent epithelial cell fragile sites are apparently not frequently altered in epithelial cancers and sites that are frequently deleted in epithelial cancers are not necessarily among the most fragile. Since we have reported that loss of expression of the FRA3B-encoded FHIT protein causes increased replication stress-induced DNA damage, we also examined the effect of FHIT-deficiency on markers of genome instability in epithelial cells. FHIT-deficient cells exhibited increases in fragile breaks and in H2AX and 53BP1 foci in G1 phase cells, confirming in epithelial cells that the FHIT gene and encompassing FRA3B, is a caretaker gene necessary for maintenance of genome stability. (c) 2013 Wiley Periodicals, Inc.
C1 [Hosseini, Seyed Ali; Saldivar, Joshua C.; Miuma, Satoshi; Huebner, Kay] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Horton, Susan; Heerema, Nyla A.] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Stampfer, Martha R.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; University of California System; University
   of California Berkeley; United States Department of Energy (DOE);
   Lawrence Berkeley National Laboratory
RP Huebner, K (通讯作者)，Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Wexner Med Ctr, Biomed Res Tower,Rm 916,460 W 12th Ave, Columbus, OH 43210 USA.
EM kay.huebner@osumc.edu
OI Saldivar, Joshua/0000-0001-7821-1615
FU US National Institutes of Health [CA120516, CA154200, CA132453,
   F31CA157150, T32GM068412]; Pelotonia Postdoctoral Fellowship, Ohio State
   University Comprehensive Cancer Center; Office of Science, Office of
   Biological and Environmental Research, of the U.S. Department of Energy
   [DE-AC02-05CH11231]
FX Supported by: US National Institutes of Health, Grant numbers: CA120516,
   CA154200, and CA132453 (to K. H.); Pelotonia Postdoctoral Fellowship,
   Ohio State University Comprehensive Cancer Center (to S. A. H.); US
   National Institutes of Health, Grant numbers: F31CA157150 and
   T32GM068412 (to J.C.S.); Director, Office of Science, Office of
   Biological and Environmental Research, of the U.S. Department of Energy,
   Grant numbers: DE-AC02-05CH11231 (to M.R.S.).
CR [Anonymous], 2011, PLoS Biol, V9, pe1001046
   Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482
   Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768
   Boberg DR, 2013, CHEM-BIOL INTERACT, V203, P344, DOI 10.1016/j.cbi.2012.09.020
   Brown KK, 2009, AM J MED GENET A, V149A, P931, DOI 10.1002/ajmg.a.32764
   Cengiz B, 2007, ORAL ONCOL, V43, P241, DOI 10.1016/j.oraloncology.2006.03.004
   Chien J, 2008, ONCOGENE, V27, P7223, DOI 10.1038/onc.2008.360
   Debatisse M, 2012, TRENDS GENET, V28, P22, DOI 10.1016/j.tig.2011.10.003
   DJALALI M, 1987, HUM GENET, V77, P157, DOI 10.1007/BF00272384
   Dohi O, 2010, INT J ONCOL, V36, P85, DOI 10.3892/ijo_00000478
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Finch R, 2005, DIS COLON RECTUM, V48, P2148, DOI 10.1007/s10350-005-0177-7
   Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485
   Grady B, 2001, J UROLOGY, V166, P1088, DOI 10.1016/S0022-5347(05)65927-7
   Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137
   Hagmar L, 1998, CANCER RES, V58, P4117
   Hansen RS, 2010, P NATL ACAD SCI USA, V107, P139, DOI 10.1073/pnas.0912402107
   Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058
   Huebner K, 2011, NATURE, V470, P46, DOI 10.1038/470046a
   Iarmarcovai G, 2008, MUTAT RES-REV MUTAT, V658, P215, DOI 10.1016/j.mrrev.2007.10.001
   Jongsma APM, 2002, J CLIN PATHOL-MOL PA, V55, P305, DOI 10.1136/mp.55.5.305
   Kadota M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009201
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Kim YH, 2011, BRAIN PATHOL, V21, P645, DOI 10.1111/j.1750-3639.2011.00492.x
   Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421
   Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047
   Lee SH, 1999, CANCER RES, V59, P5674
   Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745
   Mori M, 2000, CANCER RES, V60, P1177
   Mrasek K, 2010, INT J ONCOL, V36, P929, DOI 10.3892/ijo_00000572
   MURANO I, 1989, HUM GENET, V83, P45, DOI 10.1007/BF00274145
   MURANO I, 1989, HUM GENET, V84, P71, DOI 10.1007/BF00210675
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X
   Ozeri-Galai E, 2012, TRENDS GENET, V28, P295, DOI 10.1016/j.tig.2012.02.006
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002
   Rao PH, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-5
   Rothenberg SM, 2010, CANCER RES, V70, P2158, DOI 10.1158/0008-5472.CAN-09-3458
   Saldivar JC, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003077
   SEABRIGH.M, 1971, LANCET, V2, P971
   Simoneau M, 2000, ONCOGENE, V19, P6317, DOI 10.1038/sj.onc.1204022
   Sonoda E, 1999, MOL CELL BIOL, V19, P5166
   SOULE HD, 1990, CANCER RES, V50, P6075
   Sozzi G, 1998, CANCER RES, V58, P5032
   Stankov K, 2004, INT J CANCER, V111, P463, DOI 10.1002/ijc.20259
   Turner BC, 2002, CANCER RES, V62, P4054
   Wistuba II, 2000, CANCER RES, V60, P1949
   Worsham MJ, 2006, BREAST CANCER RES TR, V96, P177, DOI 10.1007/s10549-005-9077-8
   WORSHAM MJ, 1993, GENE CHROMOSOME CANC, V6, P58, DOI 10.1002/gcc.2870060111
   Zhu Y, 2006, ONCOGENE, V25, P2901, DOI 10.1038/sj.onc.1209314
NR 51
TC 50
Z9 55
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD NOV
PY 2013
VL 52
IS 11
BP 1017
EP 1029
DI 10.1002/gcc.22097
PG 13
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 227IS
UT WOS:000325106700003
PM 23929738
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Bose, P
   Thakur, S
   Thalappilly, S
   Ahn, BY
   Satpathy, S
   Feng, X
   Kim, SW
   Riabowol, K
AF Bose, P.
   Thakur, S.
   Thalappilly, S.
   Ahn, B. Y.
   Satpathy, S.
   Feng, X.
   Kim, S. W.
   Riabowol, K.
TI ING1 induces apoptosis through direct effects at the mitochondria
SO CELL DEATH & DISEASE
LA English
DT Article
DE apoptosis; ING1; mitochondria; BAX
ID CANDIDATE TUMOR-SUPPRESSOR; CELL-DEATH; REPLICATIVE SENESCENCE;
   DECREASED EXPRESSION; REDUCED EXPRESSION; BREAST-CANCER; P33(ING1);
   PROTEINS; P53; BINDING
AB The ING family of tumor suppressors acts as readers and writers of the histone epigenetic code, affecting DNA repair, chromatin remodeling, cellular senescence, cell cycle regulation and apoptosis. The best characterized member of the ING family, ING1, interacts with the proliferating cell nuclear antigen (PCNA) in a UV-inducible manner. ING1 also interacts with members of the 14-3-3 family leading to its cytoplasmic relocalization. Overexpression of ING1 enhances expression of the Bax gene and was reported to alter mitochondrial membrane potential in a p53-dependent manner. Here we show that ING1 translocates to the mitochondria of primary fibroblasts and established epithelial cell lines in response to apoptosis inducing stimuli, independent of the cellular p53 status. The ability of ING1 to induce apoptosis in various breast cancer cell lines correlates well with its degree of translocation to the mitochondria after UV treatment. Endogenous ING1 protein specifically interacts with the pro-apoptotic BCL2 family member BAX, and colocalizes with BAX in a UV-inducible manner. Ectopic expression of a mitochondria-targeted ING1 construct is more proficient in inducing apoptosis than the wild type ING1 protein. Bioinformatic analysis of the yeast interactome indicates that yeast ING proteins interact with 64 mitochondrial proteins. Also, sequence analysis of ING1 reveals the presence of a BH3-like domain. These data suggest a model in which stress-induced cytoplasmic relocalization of ING1 by 14-3-3 induces ING1-BAX interaction to promote mitochondrial membrane permeability and represent a paradigm shift in our understanding of ING1 function in the cytoplasm and its contribution to apoptosis.
C1 [Bose, P.; Thakur, S.; Thalappilly, S.; Ahn, B. Y.; Satpathy, S.; Feng, X.; Kim, S. W.] Univ Calgary, Southern Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.
   [Riabowol, K.] Univ Calgary, Southern Alberta Canc Res Inst, Dept Oncol, Calgary, AB T2N 4N1, Canada.
C3 University of Calgary; University of Calgary
RP Riabowol, K (通讯作者)，Univ Calgary, Fac Med, Dept Biochem & Mol Biol, HMRB,Room 311,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM karl@ucalgary.ca
RI Feng, Xiaolan/J-9997-2019
OI Feng, Xiaolan/0000-0002-7333-8198; Thalappilly,
   Subhash/0000-0003-1766-3057
CR Abad M, 2011, AGING CELL, V10, P158, DOI 10.1111/j.1474-9726.2010.00651.x
   Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413
   Boland D, 2000, HYBRIDOMA, V19, P161, DOI 10.1089/02724570050031202
   Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004
   Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028
   Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610
   Cheung KJ, 2001, CANCER RES, V61, P4974
   CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x
   Coles AH, 2007, CANCER RES, V67, P2054, DOI 10.1158/0008-5472.CAN-06-3558
   Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007
   Eapen SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040684
   Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06
   Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7
   Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014
   Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415
   Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675
   Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006
   Gordon PMK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-426
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256
   Helbing CC, 1997, CANCER RES, V57, P1255
   Kameyama K, 2003, CLIN CANCER RES, V9, P4926
   Kataoka H, 2003, CANCER RES, V63, P5785
   Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670
   Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003
   Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002
   Larrieu D, 2010, CELL CYCLE, V9, P3984, DOI 10.4161/cc.9.19.13208
   Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297
   Li N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.22
   Li XH, 2011, HISTOL HISTOPATHOL, V26, P597, DOI 10.14670/HH-26.597
   Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000
   Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Mulder KW, 2012, NAT CELL BIOL, V14, P753, DOI 10.1038/ncb2520
   Ohmori M, 1999, AM J HEMATOL, V62, P118
   Oki E, 1999, CANCER LETT, V147, P157, DOI 10.1016/S0304-3835(99)00288-8
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005
   Pena PV, 2008, J MOL BIOL, V380, P303, DOI 10.1016/j.jmb.2008.04.061
   Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052
   Scott M, 2001, J CELL SCI, V114, P3455
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176
   Shinoura N, 1999, CANCER RES, V59, P5521
   Simpson F, 2006, EXP CELL RES, V312, P73, DOI 10.1016/j.yexcr.2005.09.020
   Soliman MA, 2007, TRENDS BIOCHEM SCI, V32, P509, DOI 10.1016/j.tibs.2007.08.006
   Soliman MA, 2008, AGING CELL, V7, P783, DOI 10.1111/j.1474-9726.2008.00427.x
   Takahashi M, 2004, ONCOL REP, V12, P811
   Tallen G, 2004, INT J CANCER, V109, P476, DOI 10.1002/ijc.11715
   Tamannai M, 2010, ONCOL RES, V18, P469, DOI 10.3727/096504010X12704916124828
   Thakur S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043671
   Thalappilly S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021065
   Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905
   Vieyra D, 2002, CANCER RES, V62, P4445
   Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wei QJ, 2012, ONCOL LETT, V4, P438, DOI 10.3892/ol.2012.744
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281
   Wong RPC, 2011, NUCLEIC ACIDS RES, V39, P3632, DOI 10.1093/nar/gkq1337
   Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
   Zhang X, 2004, FEBS LETT, V570, P7, DOI 10.1016/j.febslet.2004.06.010
NR 62
TC 24
Z9 26
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP
PY 2013
VL 4
AR e788
DI 10.1038/cddis.2013.321
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 230VC
UT WOS:000325370300005
PM 24008732
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, XH
   Song, N
   Matsumoto, K
   Nanashima, A
   Nagayasu, T
   Hayashi, T
   Ying, MG
   Endo, D
   Wu, ZR
   Koji, T
AF Chen, Xiaohui
   Song, Ning
   Matsumoto, Keitaro
   Nanashima, Atsushi
   Nagayasu, Takeshi
   Hayashi, Tomayoshi
   Ying, Mingang
   Endo, Daisuke
   Wu, Zhiren
   Koji, Takehiko
TI High expression of trimethylated histone H3 at lysine 27 predicts better
   prognosis in non-small cell lung cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE non-small cell lung cancer; trimethylated histone H3 at lysine 27;
   epigenetics; enhancer of zeste homolog 2; DNA methylation
ID H3K27 METHYLATION LEVELS; GROUP PROTEIN EZH2; BREAST-CANCER; THERAPEUTIC
   TARGET; DNA METHYLATION; CARCINOMA; PROSTATE; GENE; METHYLTRANSFERASE;
   HYPERMETHYLATION
AB Epigenetic parameters such as DNA methylation and histone modifications play pivotal roles in carcinogenesis. Global histone modification patterns have been implicated as possible predictors of cancer recurrence and prognoses in a great variety of tumor entities. Our study was designed to evaluate the association among trimethylated histone H3 at lysine 27 (H3K27me3), clinicopathological variables and outcome in early-stage non-small cell lung cancer (NSCLC). The expression of H3K27me3 and its methyl-transferase, enhancer of zeste homolog 2 (EZH2) together with proliferating cell nuclear antigen (PCNA) were evaluated by immunohistochemistry in normal lung tissue (n=5) and resected NSCLC patients (n=42). In addition, the specificity of antibody for H3K27me3 was tested by western blot analysis. The optimal cut-off point of H3K27me3 expression for prognosis was determined by the X-tile program. The prognostic significance was determined by means of Kaplan-Meier survival estimates and log-rank tests. As a result, enhanced trimethylation of H3K27me3 was correlated with longer overall survival (OS) and better prognosis (P<0.05). Moreover, both univariate and multivariate analyses indicated that H3K27me3 level was a significant and independent predictor of better survival (hazard ratio, 0.187; 95% confidence interval, 0.066-0.531, P=0.002). Furthermore, H3K27me3 expression was positively correlated with DNA methylation level at CCGG sites while reversely related to EZH2 expression (P<0.05). In conclusion, H3K27me3 level defines unrecognized subgroups of NSCLC patients with distinct epigenetic phenotype and clinical outcome, and can probably be used as a novel predictor for better prognosis in NSCLC patients.
C1 [Chen, Xiaohui; Song, Ning; Endo, Daisuke; Wu, Zhiren; Koji, Takehiko] Nagasaki Univ, Dept Histol & Cell Biol, Grad Sch Biomed Sci, Nagasaki 8528523, Japan.
   [Matsumoto, Keitaro; Nanashima, Atsushi; Nagayasu, Takeshi] Nagasaki Univ, Dept Translat Med Sci, Div Surg Oncol, Grad Sch Biomed Sci, Nagasaki 8528523, Japan.
   [Hayashi, Tomayoshi] Nagasaki Univ Hosp, Dept Pathol, Nagasaki, Japan.
   [Chen, Xiaohui; Ying, Mingang] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Div Oncol Surg, Fujian, Peoples R China.
C3 Nagasaki University; Nagasaki University; Nagasaki University; Fujian
   Medical University
RP Koji, T (通讯作者)，Nagasaki Univ, Dept Histol & Cell Biol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM tkoji@nagasaki-u.ac.jp
RI chen, hongyu/HHS-4314-2022; Koji, Takehiko/JJF-3367-2023
OI Chen, Xiaohui/0000-0003-3035-3360
FU Japan Society for the Promotion of Science [18390060]; Grants-in-Aid for
   Scientific Research [18390060] Funding Source: KAKEN
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research from the Japan Society for the Promotion of Science (no.
   18390060 to T.K.).
CR ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134
   Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2
   An SC, 2005, HISTOCHEM CELL BIOL, V123, P249, DOI 10.1007/s00418-005-0765-6
   Anderton JA, 2011, ONCOGENE, V30, P2037, DOI 10.1038/onc.2010.579
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Cai MY, 2011, MOL MED, V17, P1137, DOI 10.2119/molmed.2011.00054
   Cai MY, 2011, MOL MED, V17, P12, DOI 10.2119/molmed.2010.00103
   Camp Robert L, 2004, Clin Cancer Res, V10, P7252
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002
   Ellinger J, 2012, CANCER INVEST, V30, P92, DOI 10.3109/07357907.2011.636117
   Fujii S, 2012, BIOCHEM BIOPH RES CO, V417, P1074, DOI 10.1016/j.bbrc.2011.12.099
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Guo JF, 2011, CANCER SCI, V102, P530, DOI 10.1111/j.1349-7006.2010.01836.x
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Huqun, 2012, CANCER-AM CANCER SOC, V118, P1599, DOI 10.1002/cncr.26441
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Karlic R, 2010, P NATL ACAD SCI USA, V107, P2926, DOI 10.1073/pnas.0909344107
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koji T, 2008, HISTOCHEM CELL BIOL, V130, P917, DOI 10.1007/s00418-008-0487-7
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kunju LP, 2011, MODERN PATHOL, V24, P786, DOI 10.1038/modpathol.2011.8
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mitani Y, 2005, J PATHOL, V205, P65, DOI 10.1002/path.1684
   MOLLOY PL, 1990, PHILOS T R SOC B, V326, P267, DOI 10.1098/rstb.1990.0010
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Prystowsky MB, 2009, J PATHOL, V218, P467, DOI 10.1002/path.2554
   Rogenhofer S, 2012, BJU INT, V109, P459, DOI 10.1111/j.1464-410X.2011.10278.x
   Ross JP, 2010, EPIGENOMICS-UK, V2, P245, DOI 10.2217/EPI.10.2
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shirendeb U, 2009, ACTA HISTOCHEM CYTOC, V42, P181, DOI 10.1267/ahc.09030
   Song N, 2011, ACTA HISTOCHEM CYTOC, V44, P183, DOI 10.1267/ahc.11027
   Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x
   Taniguchi H, 2007, J PATHOL, V213, P131, DOI 10.1002/path.2216
   Tzao C, 2009, MODERN PATHOL, V22, P252, DOI 10.1038/modpathol.2008.172
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Yamayoshi T, 2004, J PATHOL, V204, P110, DOI 10.1002/path.1617
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Zhang C, 2007, J PATHOL, V212, P134, DOI 10.1002/path.2173
NR 46
TC 51
Z9 55
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD NOV
PY 2013
VL 43
IS 5
BP 1467
EP 1480
DI 10.3892/ijo.2013.2062
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 225SN
UT WOS:000324982700016
PM 23969945
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Jeong, YJ
   Jeong, HY
   Lee, SM
   Bong, JG
   Park, SH
   Oh, HK
AF Jeong, Young Ju
   Jeong, Hye Yeon
   Lee, Sang Min
   Bong, Jin Gu
   Park, Sung Hwan
   Oh, Hoon Kyu
TI Promoter methylation status of the <i>FHIT</i> gene and Fhit expression:
   Association with HER2/neu status in breast cancer patients
SO ONCOLOGY REPORTS
LA English
DT Article
DE breast cancer; methylation; fragile histidine triad; human epidermal
   growth factor receptor 2; epigenetics
ID PROGESTERONE-RECEPTOR STATUS; DNA METHYLATION; CLINICOPATHOLOGICAL
   FEATURES; ISLAND METHYLATION; CARCINOMAS; PROFILES; PROTEIN; CELLS;
   HYPERMETHYLATION; CARCINOGENESIS
AB Aberrant DNA methylation has been recognized to contribute to breast carcinogenesis, and promoter hypermethylation of several tumor suppressor genes has been correlated with decreased gene expression. The fragile histidine triad (FHIT) gene is a putative tumor suppressor gene in breast and other types of cancer, and loss of Fhit expression has been observed in breast cancer. The aim of the present study was to evaluate the association between methylation of the FHIT gene and its expression in breast cancer, and to investigate whether methylation and expression of the FHIT gene correlates with clinicopathological characteristics in relation to human epidermal growth factor receptor 2 (HER2) status. Pyrosequencing of bisulfite-treated DNA was performed to study the methylation status of the FHIT gene in 60 breast cancer samples. We examined the expression of Fhit using tissue microarrays by immunohistochemical staining. FHIT methylation was detected in 96.7% and the positive expression rate of Fhit was 87.3% of the patients. The mean methylation level of the FHIT gene was associated with intratumoral inflammation. Methylation level of the FHIT gene had no significant differences according to molecular subtypes. Loss of Fhit expression was associated with large tumor size, basal-like subtype and positive expression of EGFR. In HER2-negative breast cancer, loss of Fhit expression was significantly associated with tumor size, estrogen receptor status and Ki-67 proliferation index. No significant correlation between methylation of the FHIT gene and its expression was observed in the present study. Our results suggest that loss of Fhit expression in breast cancer is associated with poor prognostic features, and it is also relevant to the results in HER2-negative breast cancer. Further studies with larger sample sizes and longer follow-up are required to clarify the predictive and prognostic value of Fhit expression and the FHIT gene methylation status in breast cancer.
C1 [Jeong, Young Ju; Jeong, Hye Yeon; Lee, Sang Min; Bong, Jin Gu; Park, Sung Hwan] Catholic Univ Daegu, Dept Surg, Coll Med, Taegu 705718, South Korea.
   [Oh, Hoon Kyu] Catholic Univ Daegu, Dept Pathol, Coll Med, Taegu 705718, South Korea.
C3 Catholic University of Daegu; Catholic University of Daegu
RP Jeong, YJ (通讯作者)，Catholic Univ Daegu, Dept Surg, Coll Med, 3056-6 Daemyoung 4 Dong, Taegu 705718, South Korea.
EM yjjeong@cu.ac.kr
FU Catholic University of Daegu
FX The present study was supported by research grants from the Catholic
   University of Daegu in 2011.
CR Ahmadian M, 1997, CANCER RES, V57, P3664
   Arun B, 2005, CANCER EPIDEM BIOMAR, V14, P1681, DOI 10.1158/1055-9965.EPI-04-0278
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Bianchi F, 2007, CELL CYCLE, V6, P643, DOI 10.4161/cc.6.6.4033
   Bianchi F, 2006, P NATL ACAD SCI USA, V103, P18981, DOI 10.1073/pnas.0605821103
   Campan M, 2006, CURR TOP MICROBIOL, V310, P141
   Campiglio M, 1999, CANCER RES, V59, P3866
   Creighton CJ, 2009, BREAST CANCER RES TR, V114, P287, DOI 10.1007/s10549-008-0017-2
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Hayashi S, 1997, CANCER RES, V57, P1981
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Ingvarsson S, 1999, CANCER RES, V59, P2682
   Ingvarsson S, 2001, CANCER DETECT PREV, V25, P292
   Ingvarsson S, 2001, SEMIN CANCER BIOL, V11, P361, DOI 10.1006/scbi.2001.0391
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3
   Kim H, 2004, J CLIN ONCOL, V22, P2363, DOI 10.1200/JCO.2004.10.077
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Maruyama R, 2001, CANCER RES, V61, P8659
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Ménard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E
   Naqvi RA, 2008, DNA CELL BIOL, V27, P517, DOI 10.1089/dna.2007.0660
   Negrini M, 1996, CANCER RES, V56, P3173
   Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101
   Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5
   Raish M, 2009, TRANSL ONCOL, V2, P264, DOI 10.1593/tlo.09148
   Syeed N, 2011, MUTAT RES-FUND MOL M, V707, P1, DOI 10.1016/j.mrfmmm.2010.11.001
   Tost Jorg, 2007, V373, P89
   Virmani AK, 2001, CLIN CANCER RES, V7, P584
   Wali A, 2010, THESCIENTIFICWORLDJO, V10, P1142, DOI 10.1100/tsw.2010.110
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang QF, 2002, CLIN CANCER RES, V8, P2890
   Yang QF, 2001, CLIN CANCER RES, V7, P3869
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 38
TC 14
Z9 14
U1 0
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2013
VL 30
IS 5
BP 2270
EP 2278
DI 10.3892/or.2013.2668
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 219VW
UT WOS:000324540300033
PM 23969757
OA Bronze
DA 2025-01-12
ER

PT J
AU Sio, A
   Chehal, MK
   Tsai, K
   Fan, XL
   Roberts, ME
   Nelson, BH
   Grembecka, J
   Cierpicki, T
   Krebs, DL
   Harder, KW
AF Sio, Alexander
   Chehal, Manreet K.
   Tsai, Kevin
   Fan, Xueling
   Roberts, Morgan E.
   Nelson, Brad H.
   Grembecka, Jolanta
   Cierpicki, Tomasz
   Krebs, Danielle L.
   Harder, Kenneth W.
TI Dysregulated Hematopoiesis Caused by Mammary Cancer Is Associated with
   Epigenetic Changes and <i>Hox</i> Gene Expression in Hematopoietic Cells
SO CANCER RESEARCH
LA English
DT Article
ID COLONY-STIMULATING FACTOR; BONE-MARROW CELLS; BREAST-CANCER; STEM-CELLS;
   MYELOID CELLS; POLYCOMB; INFLAMMATION; ERYTHROPOIESIS; LEUKEMOGENESIS;
   TRANSFORMATION
AB Cancer is associated with immune dysfunction characterized by the presence of proinflammatory and immunosuppressive cells and factors that contribute to tumor growth and progression. Here we show that mammary tumor growth is associated with defects in hematopoiesis, leading to myeloproliferative-like disease (leukemoid reaction), anemia, and disruption of the bone marrow stem/progenitor compartment. The defects we characterized included impaired erythropoiesis, leukocytosis, loss of early progenitor cells in the bone marrow, and splenic extramedullary hematopoiesis. We established an in vitro model to dissect interactions between mammary cancers and the hematopoietic system. Investigations in this model revealed that granulocyte colonystimulating factor (G-CSF) produced by mammary tumors can synergize with FLT3L and granulocyte macrophage CSF (GM-CSF) to expand myeloid progenitors and their progeny in culture. Mammary tumor growth was associated with histone methylation changes within lineage-negative c-Kit-positive hematopoietic cells within the bone marrow of tumor-bearing mice. Similarly, parallel histone methylation patterns occurred in cultured bone marrow cells exposed to mammary tumor-conditioned cell culture media. Notably, changes in histone methylation in these cell populations correlated with dysregulated expression of genes controlling hematopoietic lineage commitment and differentiation, including Hox family genes and members of the Polycomb repressive complex 2 (PRC2) chromatin-remodeling complex. Together, our results show that mammary tumor-secreted factors induce profound perturbations in hematopoiesis and expression of key hematopoietic regulatory genes. (C) 2013 AACR.
C1 [Sio, Alexander; Chehal, Manreet K.; Tsai, Kevin; Fan, Xueling; Roberts, Morgan E.; Krebs, Danielle L.; Harder, Kenneth W.] Univ British Columbia, Res Grp I3, Dept Microbiol & Immunol, Inst Life Sci, Vancouver, BC V5Z 1M9, Canada.
   [Nelson, Brad H.] British Columbia Canc Agcy, Trev & Joyce Deeley Res Ctr, Victoria, BC, Canada.
   [Grembecka, Jolanta; Cierpicki, Tomasz] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
C3 University of British Columbia; British Columbia Cancer Agency;
   University of Michigan System; University of Michigan
RP Harder, KW (通讯作者)，Life Sci Ctr, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.
EM kharder@mail.ubc.ca
RI Tsai, Kevin/GQR-1990-2022; Nelson, Brad/K-2622-2014; Fan,
   Xueling/B-2861-2015
OI Tsai, Kevin/0000-0001-5966-6542; Nelson, Brad/0000-0002-4445-5539;
   Krebs, Danielle/0000-0002-6522-7308; Roberts, Morgan/0000-0002-5850-7985
FU Canadian Breast Cancer Foundation; Canadian Institutes of Health
   Research (CIHR) [CIHRMOP-86694]; Michael Smith Foundation; University of
   British Columbia/4YF
FX This work is supported by grants from the Canadian Breast Cancer
   Foundation (K.W. Harder, D.L. Krebs) and Canadian Institutes of Health
   Research (CIHR; K.W. Harder; CIHRMOP-86694). K.W. Harder holds a Tier-II
   Canada Research Chair. Studentships to M.K. Chehal (Michael Smith
   Foundation and CIHR), M.E. Roberts (CIHR Training Program in
   Transplantation), and X. Fan (University of British Columbia/4YF) helped
   support these studies.
CR Argiropoulos B, 2007, ONCOGENE, V26, P6766, DOI 10.1038/sj.onc.1210760
   Asano Touko, 2002, Hinyokika Kiyo, V48, P495
   Bach C, 2010, BLOOD, V115, P2910, DOI 10.1182/blood-2009-04-216606
   Baldridge MT, 2010, NATURE, V465, P793, DOI 10.1038/nature09135
   Brasel K, 1997, BLOOD, V90, P3781, DOI 10.1182/blood.V90.9.3781
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P
   Cedar H, 2011, NAT REV IMMUNOL, V11, P478, DOI 10.1038/nri2991
   Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648
   Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103
   Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   DEHAAN G, 1992, EXP HEMATOL, V20, P600
   Dehqanzada ZA, 2007, ONCOL REP, V17, P687
   DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   duPre' SA, 2007, EXP MOL PATHOL, V82, P12, DOI 10.1016/j.yexmp.2006.06.007
   Elkabets M, 2011, J CLIN INVEST, V121, P784, DOI 10.1172/JCI43757
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815
   Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Grembecka J, 2012, NAT CHEM BIOL, V8, P277, DOI [10.1038/nchembio.773, 10.1038/NCHEMBIO.773]
   He H, 2011, ONCOGENE, V30, P379, DOI 10.1038/onc.2010.484
   Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585
   Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099
   Lawicki Slawomir, 2007, Pol Merkur Lekarski, V23, P259
   Majewski IJ, 2008, PLOS BIOL, V6, P796, DOI 10.1371/journal.pbio.0060093
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Matsumoto Y, 2010, INT J GYNECOL CANCER, V20, P417, DOI 10.1111/IGC.0b013e3181d15a11
   McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425
   Park S, 2011, CYTOKINE, V55, P126, DOI 10.1016/j.cyto.2011.03.002
   Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024
   Qiu MZ, 2010, TUMOR BIOL, V31, P633, DOI 10.1007/s13277-010-0079-8
   Quezada SA, 2008, J EXP MED, V205, P2125, DOI 10.1084/jem.20080099
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261
   Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034
   Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121
   TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892
   van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562
   Waight JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027690
   Wall EM, 2007, CANCER RES, V67, P6442, DOI 10.1158/0008-5472.CAN-07-0622
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Wilcox RA, 2010, MAYO CLIN PROC, V85, P656, DOI 10.4065/mcp.2010.0077
   Yang TM, 2009, CANCER IMMUNOL IMMUN, V58, P1867, DOI 10.1007/s00262-009-0698-3
   Yoshino Tateki, 2008, Hinyokika Kiyo, V54, P775
NR 50
TC 38
Z9 41
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2013
VL 73
IS 19
BP 5892
EP 5904
DI 10.1158/0008-5472.CAN-13-0842
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 229NJ
UT WOS:000325273000006
PM 23913828
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Sabherwal, Y
   Mahajan, N
   Zhang, M
AF Sabherwal, Yamini
   Mahajan, Nitin
   Zhang, Ming
TI Epigenetic modifications of prostate-derived Ets transcription factor in
   breast cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE epigenetics; prostate-derived Ets factor; p21; DNA methylation; breast
   cancer
ID ANDROGEN RECEPTOR; GENE-EXPRESSION; DNA METHYLATION; IN-VITRO; PDEF;
   TUMORS; PROGRESSION; INHIBITORS; THERAPY; TARGETS
AB The importance of epigenetic alterations such as DNA methylation, histone modification and nucleosome remodeling in breast cancer is well established. Epigenetic alterations are reversible, and much research has been focused on understanding these alterations with the aim of developing effective therapies. Prostate-derived Ets factor (PDEF) is a member of the Ets family of transcription factors and has long been under investigation for its key role in tumor development and progression. To date, no studies have been conducted to elucidate the epigenetic modifications of PDEF in cancer progression. Using breast and prostate cancer cells, we investigated the effect of the methylation inhibitor 5' azacytidine (AZA) on the expression of PDEF in these cells. The inhibition of methylation observed was specific to breast cancer cells as experiments with prostate cells did not exhibit any significant change. Notably, the expression of p21, a cyclin-dependent kinase (CDK) inhibitor 1 and also a target gene of PDEF, was found to be positively correlated with PDEF expression following 5' AZA treatment. Inhibition of methylation led to a decrease in the proliferation rate of MDA-MB-468 cells as revealed by MTT proliferation assay. Other epigenetic alterations such as histone modifications were not observed in these breast cancer cells following treatment with specific HDAC inhibitors. Our data suggest the possibility of epigenetic modification of PDEF due to DNA methylation and involvement of the cell cycle inhibitor p21. Future studies on the epigenetic alterations of PDEF in correlation with p21 or other targets may facilitate the development of effective therapies for the treatment of breast cancer.
C1 [Sabherwal, Yamini; Mahajan, Nitin; Zhang, Ming] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
   [Sabherwal, Yamini; Mahajan, Nitin; Zhang, Ming] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
C3 Northwestern University; Northwestern University; Ann & Robert H. Lurie
   Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer
   Center
RP Zhang, M (通讯作者)，Northwestern Univ, Dept Mol Pharmacol & Biol Chem, 303 E Super St, Chicago, IL 60611 USA.
EM m-zhang@northwestern.edu
RI Mahajan, Nitin/A-9144-2015
OI Mahajan, Nitin/0000-0002-0907-6410
FU Northwestern Prostate Cancer SPORE pilot project fund
FX The authors would like to thank Dr Asish K. Ghosh and Dr George P.
   Tuszynski for their helpful discussions and comments. The present study
   was supported by a Northwestern Prostate Cancer SPORE pilot project fund
   to M.Z.
CR Acharya MR, 2005, MOL PHARMACOL, V68, P917, DOI 10.1124/mol.105.014167
   Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Feldman RJ, 2003, CANCER RES, V63, P4626
   Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200
   Ghadersohi A, 2004, ONCOL REP, V11, P453
   Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731
   Ghadersohi A, 2007, BREAST CANCER RES TR, V102, P19, DOI 10.1007/s10549-006-9314-9
   Ghoshal K, 2007, DRUG TODAY, V43, P395, DOI 10.1358/dot.2007.43.6.1062666
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012
   Karahoca M, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-3
   Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035
   Locke WJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3237
   Lustberg MB, 2011, CURR BREAST CANCER R, V3, P34, DOI 10.1007/s12609-010-0034-0
   Marks PW, 2012, EXPERT REV ANTICANC, V12, P299, DOI [10.1586/era.11.207, 10.1586/ERA.11.207]
   Matsuzaki Youichirou, 2003, Environ Health Prev Med, V8, P157, DOI 10.1007/BF02897908
   Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004
   Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216
   Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Sabherwal Y, 2012, INT J ONCOL, V40, P1889, DOI 10.3892/ijo.2012.1392
   Schaefer JS, 2010, J BIOL CHEM, V285, P11258, DOI 10.1074/jbc.M109.073932
   Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013
   Siegel R, 2012, CA-CANCER J CLIN, V62, P220, DOI 10.3322/caac.21149
   Sood AK, 2007, HUM PATHOL, V38, P1628, DOI 10.1016/j.humpath.2007.03.010
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673
   Zhang M, 1997, CELL GROWTH DIFFER, V8, P179
NR 31
TC 3
Z9 5
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD OCT
PY 2013
VL 30
IS 4
BP 1985
EP 1988
DI 10.3892/or.2013.2661
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 219VR
UT WOS:000324539700060
PM 23921628
OA Bronze
DA 2025-01-12
ER

PT J
AU Zheng, Q
   Zeng, TT
   Chen, J
   Liu, H
   Zhang, H
   Su, J
AF Zheng, Qin
   Zeng, Ting-ting
   Chen, Jiao
   Liu, Hua
   Zhang, He
   Su, Jun
TI Association between DNA Methyltransferases 3B Gene Polymorphisms and the
   Susceptibility to Acute Myeloid Leukemia in Chinese Han Population
SO PLOS ONE
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISM; T PROMOTER POLYMORPHISM; LUNG-CANCER;
   DNMT3B POLYMORPHISMS; EPIGENETIC CHANGES; BREAST-CANCER; RISK;
   METHYLATION; MALIGNANCIES; ADENOCARCINOMA
AB DNMT3B plays a crucial role in the generation of aberrant methylation during carcinogenesis. Polymorphisms in the DNMT3B gene may influence the DNA methylation enzymatic activity of DNMT3B, thereby modulating the susceptibility to AML. Thus, we investigated the association between SNPs in the DNMT3B gene and their haplotypes with the risk of AML in the Chinese Han population. The DNMT3B genotype was determined by HRM in 317 de novo AML patients and 406 healthy control subjects matched for age and gender. Among the 5 SNPs investigated in this study, rs2424913 demonstrated no polymorphisms in the Chinese Han populations, rs1569686 and rs2424908 were significantly associated with AML risk. The GG genotype of rs1569686 was associated with increased AML risk (OR: 5.76; 95% CI: 2.60-12.73; P<0.01) compared with the TT genotype, and individuals with a G allele had a significantly increased risk (OR: 1.89; 95% CI: 1.41-2.52; P<0.01) for AML compared with those harboring a C allele, this polymorphism can predict the risk of AML in a minority of patients. While the CC genotype of rs2424908 appeared to reduce the AML risk (OR: 0.57; 95% CI: 0.36-0.91; P=0.01) compared with the TT genotype, individuals with a C allele were associated with a lower risk (OR: 0.79, 95% CI: 0.64-0.97, P=0.03) for developing AML compared with those harboring a T allele. The other 2 SNPs, rs6087990 and rs6119954, had no significant association with AML risk in the study population. The CGGT, CTAT, TGAT, and CGAT haplotypes of rs6087990, rs1569686, rs6119954, and rs2424908 appeared to significantly increase the AML risk, and the TTGC haplotype appeared to significantly reduce the risk. These results suggest that DNMT3B polymorphisms may contribute to the genetic susceptibility to AML; in particular, the G allele of rs1569686 serves as a risk factor for AML, whereas the C allele of rs2424908 represents a potential protective factor.
C1 [Zheng, Qin; Zeng, Ting-ting; Chen, Jiao; Liu, Hua; Zhang, He; Su, Jun] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu 610064, Peoples R China.
C3 Sichuan University
RP Su, J (通讯作者)，Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu 610064, Peoples R China.
EM sjhuaxi1667@163.com
RI tingting, zeng/ISB-4993-2023; CHEN, JIAO/GZA-5784-2022
OI Zeng, Tingting/0000-0002-0436-2733
FU National Natural Science Foundation of China [81201343]; science and
   technology project of Sichuan Province of China [2011SZ0206]
FX This work received financial support from the National Natural Science
   Foundation of China (Grant no. 81201343) and the science and technology
   project of Sichuan Province of China (Grant no. 2011SZ0206). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aung PP, 2005, ONCOL REP, V14, P1151
   Bao Q, 2011, INT J COLORECTAL DIS, V26, P1107, DOI 10.1007/s00384-011-1199-3
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bheemanaik S, 2006, BIOCHEM J, V399, P177, DOI 10.1042/BJ20060854
   Chang KP, 2007, ORAL ONCOL, V43, P345, DOI 10.1016/j.oraloncology.2006.04.006
   Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8
   Fan H, 2008, WORLD J GASTROENTERO, V14, P2230, DOI 10.3748/wjg.14.2230
   Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020
   Greif PA, 2012, BLOOD, V120, P395, DOI 10.1182/blood-2012-01-403220
   Gronbæk K, 2012, HAEMATOL-HEMATOL J, V97, P1380, DOI 10.3324/haematol.2011.058305
   Hong YS, 2007, BIOCHEM GENET, V45, P155, DOI 10.1007/s10528-006-9047-9
   Juhl-Christensen C, 2012, PEDIATR BLOOD CANCER, V58, P525, DOI 10.1002/pbc.23397
   Khalade A, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-31
   Khandanpour C, 2012, BLOOD, V120, P4006, DOI 10.1182/blood-2011-02-334722
   Khorshied MM, 2012, GENE, V511, P34, DOI 10.1016/j.gene.2012.09.024
   Lee ST, 2012, NUCLEIC ACIDS RES, V40, P11339, DOI 10.1093/nar/gks957
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Liu H, 2012, EXP THER MED, V3, P525, DOI 10.3892/etm.2011.420
   Lugthart S, 2011, BLOOD, V117, P234, DOI 10.1182/blood-2010-04-281337
   McCabe DC, 2005, NUTR REV, V63, P183, DOI 10.1111/j.1753-4887.2005.tb00136.x
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Rithidech KN, 2007, EXP HEMATOL, V35, P117, DOI 10.1016/j.exphem.2007.01.019
   Schaefer M, 2010, CHROMOSOMA, V119, P35, DOI 10.1007/s00412-009-0240-6
   Schoofs T, 2013, BLOOD, V121, P178, DOI 10.1182/blood-2012-08-448860
   Shen HB, 2002, CANCER RES, V62, P4992
   Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343
   Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1
   Thomas A, 2012, BLOOD, V119, P2731, DOI 10.1182/blood-2011-12-381426
   Wang J, 2006, CANCER RES, V66, P8361, DOI 10.1158/0008-5472.CAN-06-2031
   Wang YM, 2005, WORLD J GASTROENTERO, V11, P3623, DOI 10.3748/wjg.v11.i23.3623
   Wienholz BL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001106
   Yan P, 2012, BLOOD, V120, P2466, DOI 10.1182/blood-2012-05-429175
NR 32
TC 11
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 17
PY 2013
VL 8
IS 9
AR e74626
DI 10.1371/journal.pone.0074626
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 219YJ
UT WOS:000324547300047
PM 24069326
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Walters, RJ
   Williamson, EJ
   English, DR
   Young, JP
   Rosty, C
   Clendenning, M
   Walsh, MD
   Parry, S
   Ahnen, DJ
   Baron, JA
   Win, AK
   Giles, GG
   Hopper, JL
   Jenkins, MA
   Buchanan, DD
AF Walters, Rhiannon J.
   Williamson, Elizabeth J.
   English, Dallas R.
   Young, Joanne P.
   Rosty, Christophe
   Clendenning, Mark
   Walsh, Michael D.
   Parry, Susan
   Ahnen, Dennis J.
   Baron, John A.
   Win, Aung Ko
   Giles, Graham G.
   Hopper, John L.
   Jenkins, Mark A.
   Buchanan, Daniel D.
TI Association between hypermethylation of DNA repetitive elements in white
   blood cell DNA and early-onset colorectal cancer
SO EPIGENETICS
LA English
DT Article
DE colorectal cancer; DNA methylation; repetitive sequence; peripheral
   blood; epigenetics
ID LINE-1 METHYLATION; LYNCH-SYNDROME; COLON-CANCER; MICROSATELLITE
   INSTABILITY; PERIPHERAL LEUKOCYTES; BREAST-CANCER; HYPOMETHYLATION;
   RISK; IMMUNOHISTOCHEMISTRY; BIOMARKER
AB Changes in the methylation levels of DNA from white blood cells (WBCs) are putatively associated with an elevated risk for several cancers. The aim of this study was to investigate the association between colorectal cancer (CRC) and the methylation status of three DNA repetitive elements in DNA from peripheral blood. WBC DNA from 539 CRC cases diagnosed before 60 years of age and 242 sex and age frequency-matched healthy controls from the Australasian Colorectal Cancer Family Registry were assessed for methylation across DNA repetitive elements Alu, LINE-1 and Sat2 using MethyLight. The percentage of methylated reference (PMR) of cases and controls was calculated for each marker. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression adjusted for potential confounders. CRC cases demonstrated a significantly higher median PMR for LINE-1 (p < 0.001), Sat2 (p < 0.001) and Alu repeats (p = 0.02) when compared with controls. For each of the DNA repetitive elements, individuals with PMR values in the highest quartile were significantly more likely to have CRC compared with those in the lowest quartile (LINE-1 OR = 2.34, 95%CI = 1.48-3.70; p < 0.001, Alu OR = 1.83, 95%CI = 1.17-2.86; p = 0.01, Sat2 OR = 1.72, 95%CI = 1.10-2.71; p = 0.02). When comparing the OR for the PMR of each marker across subgroups of CRC, only the Alu marker showed a significant difference in the 5-fluoruracil treated and nodal involvement subgroups (both p = 0.002). This association between increasing methylation levels of three DNA repetitive elements in WBC DNA and early-onset CRC is novel and may represent a potential epigenetic biomarker for early CRC detection.
C1 [Walters, Rhiannon J.; Young, Joanne P.; Rosty, Christophe; Clendenning, Mark; Walsh, Michael D.; Buchanan, Daniel D.] Queensland Inst Med Res, Canc & Populat Studies Grp, Herston, Qld 4006, Australia.
   [Williamson, Elizabeth J.; English, Dallas R.; Win, Aung Ko; Giles, Graham G.; Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Carlton, Vic 3053, Australia.
   [Williamson, Elizabeth J.; English, Dallas R.; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia.
   [Rosty, Christophe] Univ Queensland, Herston, Qld, Australia.
   [Rosty, Christophe] Envoi Pathol, Herston, Qld, Australia.
   [Walsh, Michael D.] Sullivan Nicolaides Pathol, Dept Histopathol, Taringa, Qld, Australia.
   [Parry, Susan] Auckland City Hosp Private Bag, Dept Gastroenterol & Hepatol, Auckland, New Zealand.
   [Parry, Susan] Auckland City Hosp, New Zealand Familial Gastrointestinal Canc Serv, Auckland, New Zealand.
   [Ahnen, Dennis J.] VA Eastern Colorado Healthcare Syst, Sect Gastroenterol & Hepatol, Denver, CO USA.
   [Baron, John A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
C3 QIMR Berghofer Medical Research Institute; University of Melbourne;
   Cancer Council Victoria; University of Queensland; Auckland City
   Hospital; Auckland City Hospital; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina
   School of Medicine
RP Buchanan, DD (通讯作者)，Queensland Inst Med Res, Canc & Populat Studies Grp, Bramston Terrace, Herston, Qld 4006, Australia.
EM daniel.buchanan@qimr.edu.au
RI Giles, Graham/LCD-5671-2024; English, Dallas/AAH-5005-2019; Rosty,
   Christophe/F-1796-2010; Williamson, Elizabeth/H-3876-2019; Win,
   Aung/J-6204-2015; Young, Joanne/H-7774-2014; Jenkins, Mark/P-7803-2015
OI Giles, Graham/0000-0003-4946-9099; Buchanan, Daniel/0000-0003-2225-6675;
   Williamson, Elizabeth/0000-0001-6905-876X; Young,
   Joanne/0000-0002-1514-1522; Jenkins, Mark/0000-0002-8964-6160; Rosty,
   Christophe/0000-0001-7671-2651; Win, Aung/0000-0002-2794-5261; English,
   Dallas/0000-0001-7828-8188
FU NHMRC [1025799]; National Cancer Institute at the National Institutes of
   Health (RFA) [CA-95-011]
FX This work was supported by NHMRC project grant 1025799 and by the
   National Cancer Institute at the National Institutes of Health (RFA
   #CA-95-011) and through cooperative agreements with members of the Colon
   Cancer Family Registry and Principal Investigators of Australasian
   Colorectal Cancer Family Registry (U01 CA097735). CR is a Jass Pathology
   Fellow. MAJ is a NHMRC Senior Research Fellow and JLH is a NHMRC
   Australia Fellow.
CR Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316
   Buchanan DD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011636
   Candelaria M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029181
   Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Cicek MS, 2011, J MOL DIAGN, V13, P271, DOI 10.1016/j.jmoldx.2010.12.004
   Cleary SP, 2009, GASTROENTEROLOGY, V136, P1251, DOI 10.1053/j.gastro.2008.12.050
   Clendenning M, 2006, HUM MUTAT, V27, P490, DOI 10.1002/humu.20318
   Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Fuke C, 2004, ANN HUM GENET, V68, P196, DOI 10.1046/j.1529-8817.2004.00081.x
   Gao Y, 2012, BRIT J CANCER, V106, P585, DOI 10.1038/bjc.2011.562
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9
   Kitkumthorn N, 2012, CLIN CHIM ACTA, V413, P869, DOI 10.1016/j.cca.2012.01.024
   Langevin SM, 2012, EPIGENETICS-US, V7, P291, DOI 10.4161/epi.7.3.19134
   Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018
   Liao LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027361
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Nan H, 2013, PLOS ONE, V8, DOI 10. 1371/journal. pone. 0059455 23560049
   Newcomb PA, 2007, CANCER EPIDEM BIOMAR, V16, P2331, DOI 10.1158/1055-9965.EPI-07-0648
   Pornthanakasem W, 2008, NUCLEIC ACIDS RES, V36, P3667, DOI 10.1093/nar/gkn261
   Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Ren J, 2011, CELL SIGNAL, V23, P1082, DOI 10.1016/j.cellsig.2011.02.003
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Senter L, 2008, GASTROENTEROLOGY, V135, P419, DOI 10.1053/j.gastro.2008.04.026
   Siegel RL, 2009, CANCER EPIDEM BIOMAR, V18, P1695, DOI 10.1158/1055-9965.EPI-09-0186
   Smith RA, 2009, CA-CANCER J CLIN, V59, P27, DOI 10.3322/caac.20008
   Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849
   Suzuki K, 2006, CANCER CELL, V9, P199, DOI 10.1016/j.ccr.2006.02.016
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   TOFT P, 1993, ACTA ANAESTH SCAND, V37, P245, DOI 10.1111/j.1399-6576.1993.tb03708.x
   Walsh MD, 2008, CLIN CANCER RES, V14, P1692, DOI 10.1158/1078-0432.CCR-07-1849
   Walsh MD, 2010, CLIN CANCER RES, V16, P2214, DOI 10.1158/1078-0432.CCR-09-3058
   Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
   Zhang YK, 2011, EPIGENETICS-US, V6, P888, DOI 10.4161/epi.6.7.16315
   Zhu ZZ, 2011, CANCER CAUSE CONTROL, V22, P437, DOI 10.1007/s10552-010-9715-2
NR 50
TC 34
Z9 34
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JUL 1
PY 2013
VL 8
IS 7
BP 748
EP 755
DI 10.4161/epi.25178
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 222OU
UT WOS:000324741500010
PM 23804018
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Stovall, DB
   Wan, MM
   Miller, LD
   Cao, P
   Maglic, D
   Zhang, Q
   Stampfer, MR
   Liu, WN
   Xu, JF
   Sui, GC
AF Stovall, Daniel B.
   Wan, Meimei
   Miller, Lance D.
   Cao, Paul
   Maglic, Dejan
   Zhang, Qiang
   Stampfer, Martha R.
   Liu, Wennuan
   Xu, Jianfeng
   Sui, Guangchao
TI The Regulation of SOX7 and Its Tumor Suppressive Role in Breast Cancer
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID SEX-DETERMINING REGION; COLORECTAL-CANCER; EPITHELIAL-CELLS;
   MAMMALIAN-CELLS; RNAI TECHNOLOGY; GENE-EXPRESSION; REDUNDANT ROLES;
   POOR-PROGNOSIS; VECTOR; TRANSFORMATION
AB Both epigenetic silencing and genetic deletion of tumor suppressors contribute to the development and progression of breast cancer. SOX7 is a transcription factor important to development, and its downregulation has been reported in tumor tissues and cell lines of prostate, colon, and lung cancers. However, the regulation of SOX7 expression and its functional role in breast cancer have not been reported. The current study demonstrates that SOX7 mRNA and protein expression are down-regulated in breast cancer tissues and cell Lines compared with adjacent normal tissues and nontumorigenic cells, respectively. The SOX7 promoter is hypermethylated in breast cancer cell lines compared with nontumorigenic cells, and the inhibition of DNA methylation increases SOX7 mRNA Levels. With shRNAmediated SOX7 silencing, nontumorigenic immortal breast cells display increased proliferation, migration, and invasion and form structures that resemble that of breast cancer cells in a threedimensional culture system. Conversely, ectopic SOX7 expression inhibits proliferation, migration, and invasion of breast cancer cells in vitro and tumor growth in vivo. Importantly, we discovered that SOX7 transcript levels positively correlated with clinical outcome of 674 breast cancer patients. Overall, our data suggest that SOX7 acts as a tumor suppressor in breast cancer. SOX7 expression is likely regulated by multiple mechanisms and potentially serves as a prognostic marker for breast cancer patients.
C1 [Stovall, Daniel B.; Wan, Meimei; Miller, Lance D.; Cao, Paul; Maglic, Dejan; Zhang, Qiang; Sui, Guangchao] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA.
   [Stovall, Daniel B.; Wan, Meimei; Miller, Lance D.; Cao, Paul; Maglic, Dejan; Zhang, Qiang; Sui, Guangchao] Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC USA.
   [Maglic, Dejan] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27103 USA.
   [Liu, Wennuan; Xu, Jianfeng; Sui, Guangchao] Wake Forest Univ, Bowman Gray Sch Med, Ctr Canc Genom, Winston Salem, NC 27103 USA.
   [Stampfer, Martha R.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
C3 Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest
   University; Wake Forest Baptist Medical Center; Wake Forest University;
   Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest
   Baptist Medical Center; United States Department of Energy (DOE);
   Lawrence Berkeley National Laboratory; University of California System;
   University of California Berkeley
RP Sui, GC (通讯作者)，Hanes Bldg,Room 5055,Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM gsui@wakehealth.edu
RI Xu, Jianfeng/P-6421-2016; Miller, Lance/A-5633-2009; Zhang,
   Qiang/K-8476-2017
OI Sui, Guangchao/0000-0002-8164-5585; Miller, Lance/0000-0003-3799-2528
FU American Cancer Society [116403-RSG-09-082-01-MGO]; National Cancer
   Institute [5T32CA079448]; Office of Science, Office of Biological and
   Environmental Research, US Department of Energy [DE-AC02-05CH11231];
   National Cancer Institute Cancer Center [P30CA012197];  [5R01CA106314]
FX Supported in part by Research Scholars grant 116403-RSG-09-082-01-MGO
   from the American Cancer Society and grant 5R01CA106314 (G.S.); National
   Cancer Institute training grant 5T32CA079448 (D.B.S.); and contract
   DE-AC02-05CH11231 from the Office of Science, Office of Biological and
   Environmental Research, US Department of Energy. The Cell & Virus Vector
   Core Laboratory and the Tumor Tissue Core Laboratory at the
   Comprehensive Cancer Center of Wake Forest University School of Medicine
   are supported by National Cancer Institute Cancer Center Support grant
   P30CA012197.
CR Anbazhagan R, 1998, AM J PATHOL, V152, P815
   Castillo SD, 2012, EXPERT OPIN THER TAR, V16, P903, DOI 10.1517/14728222.2012.709239
   Cermenati S, 2008, BLOOD, V111, P2657, DOI 10.1182/blood-2007-07-100412
   Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y
   Chen Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022930
   Costa G, 2012, DEVELOPMENT, V139, P1587, DOI 10.1242/dev.071282
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Deng ZY, 2007, MOL CELL BIOL, V27, P3780, DOI 10.1128/MCB.01761-06
   Fan R, 2012, TOHOKU J EXP MED, V227, P119, DOI 10.1620/tjem.227.119
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0
   Guo LH, 2008, MOL CANCER RES, V6, P1421, DOI 10.1158/1541-7786.MCR-07-2175
   Herpers R, 2008, CIRC RES, V102, P12, DOI 10.1161/CIRCRESAHA.107.166066
   Katoh M, 2002, INT J MOL MED, V9, P363
   Li B, 2012, PATHOL ONCOL RES, V18, P1039, DOI 10.1007/s12253-012-9542-8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870
   Murakami A, 2004, J BIOL CHEM, V279, P28564, DOI 10.1074/jbc.M313814200
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Niimi T, 2004, J BIOL CHEM, V279, P38055, DOI 10.1074/jbc.M403724200
   NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D
   Pendeville H, 2008, DEV BIOL, V317, P405, DOI 10.1016/j.ydbio.2008.01.028
   Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117
   SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0
   Stovall DB, 2012, JOVE-J VIS EXP, DOI 10.3791/4129
   Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004
   Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599
   Sui G, 2005, METH MOL B, V309, P205
   TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234
   Wan MM, 2012, AM J PATHOL, V180, P2120, DOI 10.1016/j.ajpath.2012.01.037
   Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409
   Zhang C, 2005, DEV DYNAM, V234, P878, DOI 10.1002/dvdy.20565
   Zhang Y, 2009, CANCER LETT, V277, P29, DOI 10.1016/j.canlet.2008.11.014
   Zhong WD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-248
   Zhou X, 2011, WORLD J GASTROENTERO, V17, P4922, DOI 10.3748/wjg.v17.i44.4922
   Zientek-Targosz H, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-51
NR 37
TC 53
Z9 58
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD NOV
PY 2013
VL 183
IS 5
BP 1645
EP 1653
DI 10.1016/j.ajpath.2013.07.025
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 246QE
UT WOS:000326553400029
PM 24012678
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Jung, EJ
   Kim, IS
   Lee, EY
   Kang, JE
   Lee, SM
   Kim, DC
   Kim, JY
   Park, ST
AF Jung, Eun-Jung
   Kim, In-Suk
   Lee, Eun Yup
   Kang, Jeong-Eun
   Lee, Sun-Min
   Kim, Dong Chul
   Kim, Ju-Yeon
   Park, Soon-Tae
TI Comparison of Methylation Profiling in Cancerous and Their Corresponding
   Normal Tissues from Korean Patients with Breast Cancer
SO ANNALS OF LABORATORY MEDICINE
LA English
DT Article
DE Breast cancer; Epigenetics; Carcinogenesis; Methylation
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; CPG ISLAND;
   CLINICOPATHOLOGICAL FEATURES; HIGH-FREQUENCY; TUMOR; ASSOCIATION;
   RASSF1A; GENES; P15(INK4B)
AB Background: Aberrant DNA hypermethylation plays a pivotal role in carcinogenesis and disease progression; therefore, accurate measurement of differential gene methylation patterns among many genes is likely to reveal biomarkers for improved risk assessment. We evaluated the gene hypermethylation profiles of primary breast tumors and their corresponding normal tissues and investigated the association between major clinicopathological features and gene hypermethylation.
   Methods: A single reaction using methylation-specific multiplex ligation-dependent probe amplification was used to analyze the DNA methylation status of 24 tumor suppressor genes in 60 cancerous tissues and their corresponding normal tissues from patients with primary breast cancer.
   Results: In cancerous breast tissues, 21 of 24 genes displayed promoter methylation in one or more samples. The most frequently methylated genes included RASSF1 (43.3%), APC (31.7%), CDKN2B (25.0%), CDH13 (23.3%), GSTP1 (16.7%), and BRCA1 (10%). APC was associated with lymph node metastasis, and BRCA1 was associated with negative estrogen receptor and negative progesterone receptor expression. In normal breast tissues, 8 of 24 tumor suppressor genes displayed promoter hypermethylation; CDKN2B (28.3%) and RASSF1 (8.3%) hypermethylation were most frequently observed.
   Conclusions: RASSF1 and CDKN2B hypermethylation in Korean breast cancer patients were the most frequent in cancerous tissue and corresponding normal tissue, respectively. Our data indicates that methylation of specific genes is a frequent event in morphologically normal breast tissues adjacent to breast tumors as well as the corresponding breast cancers. This study also suggests that gene methylation is linked to various pathological features of breast cancer; however, this requires confirmation in a larger study.
C1 [Jung, Eun-Jung; Kim, Ju-Yeon; Park, Soon-Tae] Gyeongsang Natl Univ Hosp, Dept Surg, Div Surg Oncol, Jinju, South Korea.
   [Kim, In-Suk; Lee, Eun Yup] Pusan Natl Univ Hosp, Dept Lab Med, Biomed Res Inst, Pusan 602739, South Korea.
   [Kang, Jeong-Eun; Lee, Sun-Min] Pusan Natl Univ, Yangsan Hosp, Dept Lab Med, Yangsan, South Korea.
   [Kim, Dong Chul] Gyeongsang Natl Univ Hosp, Dept Pathol, Jinju, South Korea.
C3 Gyeongsang National University; Gyeongsang National University Hospital;
   Pusan National University; Pusan National University Hospital; Pusan
   National University; Pusan National University Hospital; Gyeongsang
   National University; Gyeongsang National University Hospital
RP Kim, IS (通讯作者)，Pusan Natl Univ Hosp, Dept Lab Med, 305 Gudeok Ro, Pusan 602739, South Korea.
EM iskim0710@gmail.com
RI Kim, Yeon Ji/AAE-1906-2022; Hong, Young Joon/IYT-1369-2023; Lee, Sang
   Yeub/AEQ-6658-2022; Lee, Sun Min/R-7717-2019
OI Kim, In-Suk/0000-0002-7243-9173
FU Biomedical Research Institute Grant [2010-02]; Pusan National University
   Hospital; Research Foundation of Gyeongsang National University Hospital
   [GNUHCRF-2010-005]
FX This study was supported by a Biomedical Research Institute Grant
   (2010-02), Pusan National University Hospital, and grants from the
   Research Foundation of Gyeongsang National University Hospital,
   GNUHCRF-2010-005.
CR Aggerholm A, 1999, CANCER RES, V59, P436
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054
   Dammann R, 2001, CANCER RES, V61, P3105
   Dodge JE, 2001, LEUKEMIA RES, V25, P917, DOI 10.1016/S0145-2126(01)00053-4
   Elston C W, 2002, Histopathology, V41, P154
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2003, ADV EXP MED BIOL, V532, P39
   Herman JG, 1996, CANCER RES, V56, P722
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Ishiguro A, 2006, J GASTROEN HEPATOL, V21, P1334, DOI 10.1111/j.1440-1746.2006.04137.x
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Kim DC, 2012, CANCER BIOMARK, V11, P75, DOI 10.3233/CBM-2012-0266
   Kim JH, 2010, GYNECOL ONCOL, V118, P176, DOI 10.1016/j.ygyno.2010.04.016
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Marzese DM, 2012, J MOL DIAGN, V14, P613, DOI 10.1016/j.jmoldx.2012.07.001
   Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Müller HM, 2003, CANCER RES, V63, P7641
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Qin Y, 2004, WORLD J GASTROENTERO, V10, P1276
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   The Korea Central Cancer Registry National Cancer Center, 2011, ANN REP CANC STAT KO
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   Van de Voorde L, 2012, MUTAT RES-REV MUTAT, V751, P304, DOI 10.1016/j.mrrev.2012.06.001
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V131, P859, DOI 10.1007/s10549-011-1485-3
   Wang SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037928
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Xu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-243
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
   Zhu WZ, 2010, INT J CANCER, V126, P474, DOI 10.1002/ijc.24728
NR 34
TC 23
Z9 23
U1 0
U2 4
PU KOREAN SOC LABORATORY MEDICINE
PI SEOUL
PA A505-ASTERIUM SEOUL, 372 HANGANG-DAERO, YONGSAN-GU, SEOUL, 04323, SOUTH
   KOREA
SN 2234-3806
EI 2234-3814
J9 ANN LAB MED
JI Ann. Lab. Med.
PD NOV
PY 2013
VL 33
IS 6
BP 431
EP 440
DI 10.3343/alm.2013.33.6.431
PG 10
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 251TP
UT WOS:000326953900008
PM 24205493
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Wang, YF
   Shi, J
   Chai, KQ
   Ying, XH
   Zhou, BHP
AF Wang, Yifan
   Shi, Jian
   Chai, Kequn
   Ying, Xuhua
   Zhou, Binhua P.
TI The Role of Snail in EMT and Tumorigenesis
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Breast cancer; EMT; metastasis; signaling pathway; snail
ID NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN REPRESSION;
   CANCER STEM-CELLS; TGF-BETA; TRANSCRIPTION FACTORS; TUMOR PROGRESSION;
   INDUCED APOPTOSIS; MASTER REGULATOR; DOWN-REGULATION
AB Epithelial-mesenchymal transition (EMT) is a highly conserved process in which polarized, immobile epithelial cells lose tight junctions, associated adherence, and become migratory mesenchymal cells. Several transcription factors, including the Snail/Slug family, Twist, delta EF1/ZEB1, SIP1/ZEB2 and E12/E47 respond to microenvironmental stimuli and function as molecular switches for the EMT program. Snail is a zinc-finger transcriptional repressor controlling EMT during embryogenesis and tumor progression. Through its N-terminal SNAG domain, Snail interacts with several co-repressors and epigenetic remodeling complexes to repress specific target genes, such as the E-cadherin gene (CDH1). An integrated and complex signaling network, including the RTKs, TGF-beta, Notch, Wnt, TNF-alpha, and BMPs pathways, activates Snail, thereby inducing EMT. Snail expression correlates with the tumor grade, nodal metastasis of many types of tumor and predicts a poor outcome in patients with metastatic cancer. Emerging evidences indicate that Snail causes a metabolic reprogramming, bestows tumor cells with cancer stem cell-like traits, and additionally, promotes drug resistance, tumor recurrence and metastasis. Despite many new and exciting developments, several challenges remain to be addressed in order to understand more thoroughly the role of Snail in metastasis. Additional investigations are required to disclose the contribution of microenvironmental factors on tumor progression. This information will lead to a comprehensive understanding of Snail in cancer and will provide us with novel approaches for preventing and treating metastatic cancers.
C1 [Wang, Yifan; Shi, Jian; Zhou, Binhua P.] Univ Kentucky, Sch Med, Dept Mol, Lexington, KY 40506 USA.
   [Wang, Yifan; Shi, Jian; Zhou, Binhua P.] Univ Kentucky, Sch Med, Dept Cellular Biochem, Lexington, KY 40506 USA.
   [Wang, Yifan; Shi, Jian; Zhou, Binhua P.] Univ Kentucky, Sch Med, Markey Canc Ctr, Lexington, KY 40506 USA.
   [Wang, Yifan; Chai, Kequn; Ying, Xuhua] Zhejiang Acad Chinese Med, Canc Inst Integrat Med, Hangzhou 310007, Zhejiang, Peoples R China.
C3 University of Kentucky; University of Kentucky; University of Kentucky
RP Wang, YF (通讯作者)，Univ Kentucky, Sch Med, Dept Mol, Lexington, KY 40506 USA.
EM yifan.wang11@foxmail.com; peter.zhou@uky.edu
RI SHI, JIAN/GQR-1712-2022
FU NIH [2RO1CA125454]; Susan G Komen Foundation [KG081310]; Mary Kay Ash
   Foundation
FX We thank Cathy Anthony for editorial support in the preparation of this
   manuscript. This work was supported by grants from NIH (2RO1CA125454),
   Susan G Komen Foundation (KG081310), and Mary Kay Ash Foundation (to
   B.P. Zhou).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   ALBERGA A, 1991, DEVELOPMENT, V111, P983
   Amin Rupen, 2008, Gastrointest Cancer Res, V2, pS27
   Barberà MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Bruyere F, 2010, UROL ONCOL-SEMIN ORI, V28, P591, DOI 10.1016/j.urolonc.2008.11.005
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330
   Chen SU, 2001, J STEROID BIOCHEM, V79, P35, DOI 10.1016/S0960-0760(01)00132-7
   Chen Wei-Juan, 2010, Chin J Cancer, V29, P151
   Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010
   Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X
   De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011
   Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293
   Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9
   Domínguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Franco DL, 2010, J CELL SCI, V123, P3467, DOI 10.1242/jcs.068692
   Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004
   Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4
   GRAU Y, 1984, GENETICS, V108, P347
   Grego-Bessa J, 2004, CELL CYCLE, V3, P718
   Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harney AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032318
   Harney AS, 2009, P NATL ACAD SCI USA, V106, P13667, DOI 10.1073/pnas.0906423106
   Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3
   Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07
   Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070
   IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518
   Jin HY, 2010, INT J CANCER, V126, P2102, DOI 10.1002/ijc.24901
   Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546
   Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Katsman A, 2009, CURR PHARM DESIGN, V15, P792, DOI 10.2174/138161209787582156
   Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023
   Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154
   Lee SH, 2010, ONCOGENE, V29, P4576, DOI 10.1038/onc.2010.208
   Lee SH, 2009, ONCOGENE, V28, P2005, DOI 10.1038/onc.2009.67
   Lee SY, 2012, CANCER RES, V72, P3607, DOI 10.1158/0008-5472.CAN-12-0006
   Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Liebner S, 2004, J CELL BIOL, V166, P359, DOI 10.1083/jcb.200403050
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   MASOOD S, 1992, CANCER, V70, P2109, DOI 10.1002/1097-0142(19921015)70:8<2109::AID-CNCR2820700817>3.0.CO;2-C
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Okubo T, 2001, CANCER RES, V61, P1338
   Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318
   Ozes ON, 1999, NATURE, V401, P82
   Palmer MB, 2007, CANCER RES, V67, P6113, DOI 10.1158/0008-5472.CAN-06-4256
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Peiró S, 2006, NUCLEIC ACIDS RES, V34, P2077, DOI 10.1093/nar/gkl141
   Piedra ME, 2002, DEVELOPMENT, V129, P3431
   MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474
   Rudolph T, 2007, MOL CELL, V26, P103, DOI 10.1016/j.molcel.2007.02.025
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105
   Sakai D, 2006, DEVELOPMENT, V133, P1323, DOI 10.1242/dev.02297
   Scherbakov AM, 2012, J CELL BIOCHEM, V113, P2147, DOI 10.1002/jcb.24087
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110
   Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200
   Vernon AE, 2006, DEVELOPMENT, V133, P3359, DOI 10.1242/dev.02504
   Viñas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995
   Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905
   Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40
   Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480
   Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433
   Ye Y, 2008, BIOCHEM J, V416, P179, DOI 10.1042/BJ20080328
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
   Zhang K, 2012, EMBO J, V31, P29, DOI 10.1038/emboj.2011.357
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
   Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027
NR 114
TC 698
Z9 779
U1 3
U2 128
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD NOV
PY 2013
VL 13
IS 9
BP 963
EP 972
DI 10.2174/15680096113136660102
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 273TY
UT WOS:000328560400008
PM 24168186
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Martin, SL
   Hardy, TM
   Tollefsbol, TO
AF Martin, S. L.
   Hardy, T. M.
   Tollefsbol, T. O.
TI Medicinal Chemistry of the Epigenetic Diet and Caloric Restriction
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Age related diseases; caloric restriction; dietary polyphenols;
   epigenetics and epigenetic diet
ID NF-KAPPA-B; BREAST-CANCER; LIFE-SPAN; TRANSCRIPTION FACTORS; COGNITIVE
   FUNCTION; OXIDATIVE STRESS; DNA METHYLATION; GENE-EXPRESSION; TEA
   CONSUMPTION; ENERGY-BALANCE
AB The pronounced effects of the epigenetic diet (ED) and caloric restriction (CR) have on epigenetic gene regulation have been documented in many pre-clinical and clinical studies. Understanding epigenetics is of high importance because of the concept that external factors such as nutrition and diet may possess the ability to alter gene expression without modifying the DNA sequence. The ED introduces bioactive medicinal chemistry compounds such as sulforaphane (SFN), curcumin (CCM), epigallocatechin gallate (EGCG) and resveratrol (RSV) that are thought to aid in extending the human lifespan. CR, although similar to ED in the target of longevity, mildly reduces the total daily calorie intake while concurrently providing all beneficial nutrients. Both CR and ED may act as epigenetic modifiers to slow the aging process through histone modification, DNA methylation, and by modulating microRNA expression. CR and ED have been proposed as two important mechanisms that modulate and potentially slow the progression of age-related diseases such as cardiovascular disease (CVD), cancer, obesity, Alzheimer's and osteoporosis to name a few. While many investigators have examined CR and ED as separate entities, this review will primarily focus on both as they relate to age-related diseases, their epigenetic effects and their medicinal chemistry.
C1 [Martin, S. L.; Hardy, T. M.; Tollefsbol, T. O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, T. O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, T. O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, T. O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Tollefsbol, T. O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，CH175,1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
FU University of Alabama at Birmingham [2006478, HRD-0-09-25056]; National
   Cancer Institute [CA 129415]; American Institute for Cancer Research;
   Institutional Research and Academic Career Development Awards (IRACDA)
   program [5k126M088010]
FX SLM was supported in part by a Bridge to Doctorate fellowship (2006478)
   program HRD-0-09-25056 at the University of Alabama at Birmingham.
   Additional support is provided by the National Cancer Institute (CA
   129415) and the American Institute for Cancer Research. TMH is supported
   in part by Institutional Research and Academic Career Development Awards
   (IRACDA) program 5k126M088010 (Dr. Bryan Noe (PI). The authors would
   like to thank Natalie Mitchell, Sabita Saldanha, Rishabh Kala and Dr.
   Yuanyuan Li for helpful comments in preparation of this manuscript.
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530
   American Cancer Society, CANC INCR INC TRENDS
   [Anonymous], 1999, MMWR-MORBID MORTAL W, V48, P48
   AUSTAD SN, 1989, EXP GERONTOL, V24, P83, DOI 10.1016/0531-5565(89)90037-5
   Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Bhamre S, 2009, PROSTATE, V69, P181, DOI 10.1002/pros.20869
   Bloomer RJ, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-94
   Buchowski MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047079
   Calvanese V, 2009, AGEING RES REV, V8, P268, DOI 10.1016/j.arr.2009.03.004
   Chandra V, 2001, NEUROLOGY, V57, P985, DOI 10.1212/WNL.57.6.985
   Checkoway H, 2002, AM J EPIDEMIOL, V155, P732, DOI 10.1093/aje/155.8.732
   Choi JH, 2010, BIOCHEM BIOPH RES CO, V391, P449, DOI 10.1016/j.bbrc.2009.11.078
   Choi SW, 2010, ADV NUTR, V1, P8, DOI 10.3945/an.110.1004
   Cleary Margot P, 2011, J Carcinog, V10, P21, DOI 10.4103/1477-3163.85181
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Cooper C, 2005, RHEUMATOLOGY, V44, P36, DOI 10.1093/rheumatology/kei060
   Cooper C, 1998, AM J EPIDEMIOL, V147, P516
   Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049
   Cruzen C, 2009, CLIN GERIATR MED, V25, P733, DOI 10.1016/j.cger.2009.07.001
   Dashwood RH, 2008, NUTR REV, V66, pS36, DOI 10.1111/j.1753-4887.2008.00065.x
   Davinelli S, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-9
   Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147
   Dirks AJ, 2006, MECH AGEING DEV, V127, P1, DOI 10.1016/j.mad.2005.09.001
   Dixit VD, 2008, J LEUKOCYTE BIOL, V84, P882, DOI 10.1189/jlb.0108028
   Dolinsky VW, 2010, HYPERTENSION, V56, P412, DOI 10.1161/HYPERTENSIONAHA.110.154732
   Duthie SJ, 2011, P NUTR SOC, V70, P47, DOI 10.1017/S0029665110003952
   Edwards AG, 2010, MECH AGEING DEV, V131, P739, DOI 10.1016/j.mad.2010.09.007
   Edwards IJ, 1998, J GERONTOL A-BIOL, V53, pB443, DOI 10.1093/gerona/53A.6.B443
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Fraser GE, 1999, PREV MED, V29, pS18, DOI 10.1006/pmed.1998.0415
   Gandhy SU, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-564
   Giacosa A, 2013, EUR J CANCER PREV, V22, P90, DOI 10.1097/CEJ.0b013e328354d2d7
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361
   Hill JO, 2006, ENDOCR REV, V27, P750, DOI 10.1210/er.2006-0032
   Ho VW, 2011, CANCER RES, V71, P4484, DOI 10.1158/0008-5472.CAN-10-3973
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3
   Hu G, 2007, MOVEMENT DISORD, V22, P2242, DOI 10.1002/mds.21706
   Huffman Kelly, 2012, Frontiers in Genetics, V3, P212, DOI 10.3389/fgene.2012.00212
   Johnson JB, 2007, FREE RADICAL BIO MED, V42, P665, DOI 10.1016/j.freeradbiomed.2006.12.005
   Kabil H, 2011, P NATL ACAD SCI USA, V108, P16831, DOI 10.1073/pnas.1102008108
   Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898
   KROMHOUT D, 1989, ANN MED, V21, P237, DOI 10.3109/07853898909149942
   Kuriyama S, 2006, AM J CLIN NUTR, V83, P355
   Kyo S, 2008, CANCER SCI, V99, P1528, DOI 10.1111/j.1349-7006.2008.00878.x
   LANE MA, 1995, AM J PHYSIOL-ENDOC M, V268, pE941, DOI 10.1152/ajpendo.1995.268.5.E941
   Lanzilli G, 2006, INT J ONCOL, V28, P641
   Lawler DF, 2008, BRIT J NUTR, V99, P793, DOI 10.1017/S0007114507871686
   Lee IM, 2001, J GERONTOL A-BIOL, V56, P7, DOI 10.1093/gerona/56.suppl_1.7
   Lefevre M, 2009, ATHEROSCLEROSIS, V203, P206, DOI 10.1016/j.atherosclerosis.2008.05.036
   Li YY, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-98
   Long JR, 2005, DRUG TODAY, V41, P205, DOI 10.1358/dot.2005.41.3.892525
   Lorch Steven M, 2007, J Cardiometab Syndr, V2, P30, DOI 10.1111/j.1559-4564.2007.06001.x
   Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059
   Mandel SA, 2008, J NUTR, V138, P1578
   Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509
   Marshall WG, 2010, VET RES COMMUN, V34, P241, DOI 10.1007/s11259-010-9348-7
   Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012
   MCCAY CM, 1989, NUTRITION, V5, P155
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mesquita A, 2010, P NATL ACAD SCI USA, V107, P15123, DOI 10.1073/pnas.1004432107
   Messier SP, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-93
   Meydani M, 2011, J NUTR HEALTH AGING, V15, P456, DOI 10.1007/s12603-011-0002-z
   Morimoto T, 2008, J CLIN INVEST, V118, P868, DOI 10.1172/JCI33160
   Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Nagao K, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-8
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Oliveria SA, 1999, EPIDEMIOLOGY, V10, P161, DOI 10.1097/00001648-199903000-00013
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Queen Brannon L, 2010, Curr Aging Sci, V3, P34
   Rajendran P, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-4
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Redman LM, 2011, ANTIOXID REDOX SIGN, V14, P275, DOI 10.1089/ars.2010.3253
   Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Rizzo NS, 2011, DIABETES CARE, V34, P1225, DOI 10.2337/dc10-1221
   Rogozina OP, 2011, CANCER PREV RES, V4, P568, DOI 10.1158/1940-6207.CAPR-10-0140
   Ross SA, 2008, NUTR REV, V66, pS1, DOI 10.1111/j.1753-4887.2008.00055.x
   Sancarlo D, 2011, J NUTR HEALTH AGING, V15, P169, DOI 10.1007/s12603-010-0293-5
   Schulte DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032437
   Shelton LM, 2010, ASN NEURO, V2, DOI 10.1042/AN20100002
   Soetikno V, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-35
   SPECTOR TD, 1994, ANN RHEUM DIS, V53, P565, DOI 10.1136/ard.53.9.565
   Tang HY, 2006, MOL CANCER THER, V5, P2034, DOI 10.1158/1535-7163.MCT-06-0216
   Teeuwisse WM, 2012, DIABETES, V61, P3255, DOI 10.2337/db11-1835
   Telang U, 2009, EXP BIOL MED, V234, P287, DOI 10.3181/0808-RM-241
   Thakur VS, 2012, INT J ONCOL, V41, P353, DOI 10.3892/ijo.2012.1449
   Valenzano DR, 2006, CURR BIOL, V16, P296, DOI 10.1016/j.cub.2005.12.038
   Van Speybroeck L, 2002, ANN NY ACAD SCI, V981, P61
   Vasto S, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-10
   Vlaming H, 2012, EPIGENOMICS-UK, V4, P5, DOI [10.2217/epi.11.113, 10.2217/EPI.11.113]
   Wang HM, 2010, J ALZHEIMERS DIS, V20, P1189, DOI 10.3233/JAD-2010-091336
   Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618
   WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641
   Weisberg SP, 2008, ENDOCRINOLOGY, V149, P3549, DOI 10.1210/en.2008-0262
   Wengreen HJ, 2007, J NUTR HEALTH AGING, V11, P230
   Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037
   Willett W, 2003, AM J CLIN NUTR, V78, p539S, DOI 10.1093/ajcn/78.3.539S
   Witte AV, 2009, P NATL ACAD SCI USA, V106, P1255, DOI 10.1073/pnas.0808587106
   Zhang C, 2010, J BIOL CHEM, V285, P28472, DOI 10.1074/jbc.M110.133520
   Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024486
   Zhang SF, 2012, MECH AGEING DEV, V133, P387, DOI 10.1016/j.mad.2012.04.005
   Zhang X, 2011, PHARMACOL REP, V63, P1101, DOI 10.1016/S1734-1140(11)70629-6
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 114
TC 50
Z9 54
U1 1
U2 62
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD OCT
PY 2013
VL 20
IS 32
BP 4050
EP 4059
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 214WS
UT WOS:000324168900005
PM 23895687
DA 2025-01-12
ER

PT J
AU Pan, YZ
   Zhou, A
   Hu, ZH
   Yu, AM
AF Pan, Yu-Zhuo
   Zhou, Amy
   Hu, Zihua
   Yu, Ai-Ming
TI Small Nucleolar RNA-Derived MicroRNA hsa-miR-1291 Modulates Cellular
   Drug Disposition through Direct Targeting of ABC Transporter ABCC1
SO DRUG METABOLISM AND DISPOSITION
LA English
DT Article
ID MULTIDRUG-RESISTANCE PROTEIN-1; PSEUDOURIDYLATION GUIDE RNA;
   BREAST-CANCER; NONCODING RNAS; LUNG-CANCER; BOX C/D; EXPRESSION; CELLS;
   CARCINOMA; SNORNA
AB Multidrug resistance-associated protein 1 (MRP1/ABCC1) is an important membrane transporter that contributes to cellular disposition of many endobiotic and xenobiotic agents, and it can also confer multidrug resistance. This study aimed to investigate the role of human noncoding microRNA-1291 (hsa-miR-1291) in regulation of ABCC1 and drug disposition. Bioinformatics analyses indicated that hsa-miR-1291, localized within the small nucleolar RNA H/ACA box 34 (SNORA34), might target ABCC1 3'-untranslated region (3'UTR). Using splinted ligation small RNA detection method, we found that SNORA34 was processed into hsa-miR-1291 in human pancreatic carcinoma PANC-1 cells. Luciferase reporter assays showed that ABCC1 3'-UTRluciferase activity was decreased by 20% in cells transfected with hsa-miR-1291 expression plasmid, and increased by 40% in cells transfected with hsa-miR-1291 antagomir. Furthermore, immunoblot study revealed that ABCC1 protein expression was sharply reduced in hsa-miR-1291-stably transfected PANC-1 cells, which was attenuated by hsa-miR-1291 antagomir. The change of ABCC1 protein expression was associated with an alternation in mRNA expression. In addition, hsa-miR-1291-directed downregulation of ABCC1 led to a greater intracellular drug accumulation and sensitized the cells to doxorubicin. Together, our results indicate that hsa-miR-1291 is derived from SNORA34 and modulates cellular drug disposition and chemosensitivity through regulation of ABCC1 expression. These findings shall improve the understanding of microRNA-controlled epigenetic regulatory mechanisms underlying multidrug resistance and interindividual variability in pharmacokinetics.
C1 [Pan, Yu-Zhuo; Zhou, Amy; Yu, Ai-Ming] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA.
   [Hu, Zihua] SUNY Buffalo, Ctr Computat Res, Buffalo, NY 14260 USA.
   [Yu, Ai-Ming] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY;
   State University of New York (SUNY) System; University at Buffalo, SUNY;
   University of California System; University of California Davis
RP Yu, AM (通讯作者)，UC Davis Sch Med, Dept Biochem & Mol Med, 2700 Stockton Blvd, Sacramento, CA 95817 USA.
EM aimyu@ucdavis.edu
OI Yu, Aiming/0000-0003-1441-4012
FU National Institutes of Health National Institute on Drug Abuse
   [R01-DA021172]
FX This project was supported in part by the National Institutes of Health
   National Institute on Drug Abuse [Grant R01-DA021172].
CR Borel F, 2012, HEPATOLOGY, V55, P821, DOI 10.1002/hep.24682
   Brameier M, 2011, NUCLEIC ACIDS RES, V39, P675, DOI 10.1093/nar/gkq776
   Cho S, 2011, P NATL ACAD SCI USA, V108, P20778, DOI 10.1073/pnas.1019452108
   Darzacq X, 2002, EMBO J, V21, P2746, DOI 10.1093/emboj/21.11.2746
   Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017
   Faggad A, 2009, HISTOPATHOLOGY, V54, P657, DOI 10.1111/j.1365-2559.2009.03297.x
   Filipits M, 2005, J CLIN ONCOL, V23, P1161, DOI 10.1200/JCO.2005.03.033
   Gomez A, 2009, CLIN PHARMACOL THER, V85, P426, DOI 10.1038/clpt.2009.2
   Guo LL, 2010, EUR J CANCER, V46, P1692, DOI 10.1016/j.ejca.2010.02.043
   Haber M, 2006, J CLIN ONCOL, V24, P1546, DOI 10.1200/JCO.2005.01.6196
   Haenisch S, 2011, MOL PHARMACOL, V80, P314, DOI 10.1124/mol.110.070714
   Hidaka H, 2012, ONCOTARGET, V3, P44
   Hill CR, 2013, BIOCHEM PHARMACOL, V85, P29, DOI 10.1016/j.bcp.2012.10.004
   Ingelman-Sundberg M, 2010, PHARMACOGENOMICS, V11, P625, DOI 10.2217/PGS.10.59
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Kiss AM, 2004, MOL CELL BIOL, V24, P5797, DOI 10.1128/MCB.24.13.5797-5807.2004
   Kiss AM, 2002, NUCLEIC ACIDS RES, V30, P4643, DOI 10.1093/nar/gkf592
   Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704
   Li X, 2011, BIOCHEM PHARMACOL, V81, P783, DOI 10.1016/j.bcp.2010.12.018
   Liang ZX, 2010, BIOCHEM PHARMACOL, V79, P817, DOI 10.1016/j.bcp.2009.10.017
   Maeno K, 2009, DRUG METAB DISPOS, V37, P1411, DOI 10.1124/dmd.109.026633
   Maroney PA, 2008, NAT PROTOC, V3, P279, DOI 10.1038/nprot.2007.530
   Meder B, 2011, BASIC RES CARDIOL, V106, P13, DOI 10.1007/s00395-010-0123-2
   Mohri T, 2010, BIOCHEM PHARMACOL, V79, P1045, DOI 10.1016/j.bcp.2009.11.015
   Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508
   Nakajima M, 2011, PHARMACOL THERAPEUT, V131, P330, DOI 10.1016/j.pharmthera.2011.04.009
   Pajic M, 2011, PHARMACOGENET GENOM, V21, P270, DOI 10.1097/FPC.0b013e328343dd5f
   Pan YZ, 2009, DRUG METAB DISPOS, V37, P2112, DOI 10.1124/dmd.109.027680
   Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163
   Rodrigues AC, 2011, BIOPHARM DRUG DISPOS, V32, P355, DOI 10.1002/bdd.764
   Saraiya AA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000224
   Scott MS, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000507
   To KKW, 2008, MOL CELL BIOL, V28, P5147, DOI 10.1128/MCB.00331-08
   Triller N, 2006, LUNG CANCER, V54, P235, DOI 10.1016/j.lungcan.2006.06.019
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   Wang F, 2010, BRIT J CANCER, V103, P567, DOI 10.1038/sj.bjc.6605724
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Watkins NJ, 2012, WIRES RNA, V3, P397, DOI 10.1002/wrna.117
   Yokoi T, 2013, ANNU REV PHARMACOL, V53, P377, DOI 10.1146/annurev-pharmtox-011112-140250
   Yu AM, 2012, ACTA PHARM SIN B, V2, P93, DOI 10.1016/j.apsb.2012.02.011
   Yu AM, 2009, EXPERT OPIN DRUG MET, V5, P1513, DOI 10.1517/17425250903307448
   Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007
NR 44
TC 72
Z9 80
U1 0
U2 20
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0090-9556
EI 1521-009X
J9 DRUG METAB DISPOS
JI Drug Metab. Dispos.
PD OCT
PY 2013
VL 41
IS 10
BP 1744
EP 1751
DI 10.1124/dmd.113.052092
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 219QK
UT WOS:000324523100005
PM 23686318
OA Green Published
DA 2025-01-12
ER

PT J
AU Falahi, F
   Huisman, C
   Kazemier, HG
   van der Vlies, P
   Kok, K
   Hospers, GAP
   Rots, MG
AF Falahi, Fahimeh
   Huisman, Christian
   Kazemier, Hinke G.
   van der Vlies, Pieter
   Kok, Klaas
   Hospers, Geke A. P.
   Rots, Marianne G.
TI Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; TRANSCRIPTION FACTORS; MONOCLONAL-ANTIBODY; THERAPY;
   TRASTUZUMAB; HER-2; OVEREXPRESSION; METHYLATION; PROMOTER; EXPRESSION
AB The human epidermal growth factor receptor-2 (HER2/neu/ERBB2) is overexpressed in several cancer types. Although therapies targeting the HER2/neu protein result in inhibition of cell proliferation, the anticancer effect might be further optimized by limiting HER2/neu expression at the DNA level. Towards this aim, epigenetic editing was performed to suppress HER2/neu expression by inducing epigenetic silencing marks on the HER2/neu promoter. HER2/neu expression and HER2/neu promoter epigenetic modification status were determined in a panel of ovarian and breast cancer cell lines. HER2/neu-overexpressing cancer cells were transduced to express a zinc finger protein (ZFP), targeting the HER2/neu gene, fused to histone methyltransferases (G9a, SUV39-H1)/super KRAB domain (SKD). Epigenetic assessment of the HER2/neu promoter showed that HER2/neu-ZFP fused to G9a efficiently induced the intended silencing histone methylation mark (H3K9me2). Importantly, H3K9me2 induction was associated with a dramatic downregulation of HER2/neu expression in HER2/neu- overexpressing cells. Downregulation by SKD, traditionally considered transient in nature, was associated with removal of the histone acetylation mark (H3ac). The downregulation of HER2/neu by induced H3K9 methylation and/or reduced H3 acetylation was sufficient to effectively inhibit cellular metabolic activity and clonogenicity. Furthermore, genome-wide analysis indicated preferential binding of the ZFP to its target sequence. These results not only show that H3K9 methylation can be induced but also that this epigenetic mark was instructive in promoting downregulation of HER2/neu expression. (C) 2013 AACR.
C1 [Falahi, Fahimeh; Huisman, Christian; Kazemier, Hinke G.; Rots, Marianne G.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Biol & Pathol, Groningen, Netherlands.
   [Hospers, Geke A. P.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands.
   [van der Vlies, Pieter; Kok, Klaas] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
C3 University of Groningen; University of Groningen; University of
   Groningen
RP Rots, MG (通讯作者)，Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands.
EM m.g.rots@umcg.nl
OI Hospers, Geke/0000-0002-3047-7892
FU National Dutch Scientific Research Organization [NWO/VIDI/91786373]; KWF
   Dutch Cancer Society [RUG 2009-4529];  [UMCG-601005]
FX This study was supported by The National Dutch Scientific Research
   Organization (NWO/VIDI/91786373; to M.G. Rots), UMCG-601005 (to F.
   Falahi), and KWF Dutch Cancer Society (RUG 2009-4529; to G.A.P.
   Hospers).
CR Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628
   Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697
   Beyer I, 2011, CANCER RES, V71, P7080, DOI 10.1158/0008-5472.CAN-11-2009
   Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437
   Camilleri-Broët S, 2004, ANN ONCOL, V15, P104, DOI 10.1093/annonc/mdh021
   de Groote ML, 2012, NUCLEIC ACIDS RES, V40, P10596, DOI 10.1093/nar/gks863
   Estève PO, 2005, NUCLEIC ACIDS RES, V33, P3211, DOI 10.1093/nar/gki635
   Federico M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/475641
   Fuino L, 2003, MOL CANCER THER, V2, P971
   Goldenberg MM, 1999, CLIN THER, V21, P309, DOI 10.1016/S0149-2918(00)88288-0
   Groner AC, 2012, J BIOL CHEM, V287, P25361, DOI 10.1074/jbc.M112.350884
   Hechtman JF, 2012, ARCH PATHOL LAB MED, V136, P691, DOI 10.5858/arpa.2011-0168-RS
   Huisman C, 2013, MOL ONCOL, V7, P669, DOI 10.1016/j.molonc.2013.02.017
   Hurst HC, 2001, BREAST CANCER RES, V3, P395, DOI 10.1186/bcr329
   Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010
   Jeyakumar A, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S6460
   Juárez-Moreno K, 2013, EPIGENETICS-US, V8, P164, DOI 10.4161/epi.23503
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Lara H, 2012, J BIOL CHEM, V287, P29873, DOI 10.1074/jbc.M112.360768
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lund CV, 2005, MOL CELL BIOL, V25, P9082, DOI 10.1128/MCB.25.20.9082-9091.2005
   Lund CV, 2004, J MOL BIOL, V340, P599, DOI 10.1016/j.jmb.2004.04.057
   Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9
   Munnink THO, 2010, J CLIN ONCOL, V28, pE355, DOI 10.1200/JCO.2010.28.4604
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nahta R, 2004, CANCER RES, V64, P2343, DOI 10.1158/0008-5472.CAN-03-3856
   Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612
   Olayioye MA, 2001, BREAST CANCER RES, V3, P385, DOI 10.1186/bcr327
   Pegram MD, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.27_suppl.98
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Quenneville S, 2012, CELL REP, V2, P766, DOI 10.1016/j.celrep.2012.08.043
   Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507
   Scheuer W, 2009, CANCER RES, V69, P9330, DOI 10.1158/0008-5472.CAN-08-4597
   Sera T, 2009, ADV DRUG DELIVER REV, V61, P513, DOI 10.1016/j.addr.2009.03.012
   Siddique A, 2013, J MOL BIOL, V425, P479, DOI 10.1016/j.jmb.2012.11.038
   Smyth EC, 2012, CURR TREAT OPTION ON, V13, P377, DOI 10.1007/s11864-012-0192-6
   Snowden AW, 2002, CURR BIOL, V12, P2159, DOI 10.1016/S0960-9822(02)01391-X
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Tapia C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1676
   Tapia C, 2007, MODERN PATHOL, V20, P192, DOI 10.1038/modpathol.3800729
   Uil TG, 2003, NUCLEIC ACIDS RES, V31, P6064, DOI 10.1093/nar/gkg815
   van der Gun BTF, 2013, BRIT J CANCER, V108, P881, DOI 10.1038/bjc.2013.45
   van der Gun BTF, 2011, BRIT J CANCER, V105, P312, DOI 10.1038/bjc.2011.231
   Visser AE, 2006, ADV GENET, V56, P131, DOI 10.1016/S0065-2660(06)56004-3
   Wong ALA, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/415170
   Yip AYS, 2010, ANTI-CANCER DRUG, V21, P487, DOI 10.1097/CAD.0b013e3283388eaf
   Yu YL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012710
NR 48
TC 61
Z9 67
U1 1
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD SEP
PY 2013
VL 11
IS 9
BP 1029
EP 1039
DI 10.1158/1541-7786.MCR-12-0567
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 219RE
UT WOS:000324525500007
PM 23814024
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Zeng, L
   Jarrett, C
   Brown, K
   Gillespie, KM
   Holly, JMP
   Perks, CM
AF Zeng, Li
   Jarrett, Caroline
   Brown, Keith
   Gillespie, Kathleen M.
   Holly, Jeff M. P.
   Perks, Claire M.
TI Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in
   the anti-tumorigenic effects of 5-Aza-2′-deoxycytidine (AZA) in breast
   cancer cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE IGFBP-3; AZA; Breast cancer; Cell survival
ID ESTROGEN-RECEPTOR-ALPHA; PROMOTER METHYLATION; EPITHELIAL-CELLS; DNA
   METHYLATION; THERAPEUTIC TARGETS; IGF-I; EXPRESSION; METHYLTRANSFERASE;
   APOPTOSIS; GENES
AB Breast cancer progression is associated with loss of estrogen receptor (ER-alpha), often due to epigenetic silencing. IGFBP genes have consistently been identified among the most common to be aberrantly methylated in tumours. To understand the impact of losing IGFBP-3 tumour expression via DNA methylation, we treated four breast cancer cell lines (MCF-7, T47D, Hs578T and MDA-MB-231) with a DNA methyltransferase inhibitor, 5-Aza-2'-deoxycytidine (AZA) to determine IGFBP-3's role in the effects of AZA on total cell number and survival relative to changes in the ER. AZA induced cell growth inhibition, death and a reduction in the formation of colonies, despite increasing ER-alpha expression in ER-negative cells but reducing ER-alpha in ER-positive cells. Regardless of the differential effects on the ER-alpha, AZA consistently increased the abundance of IGFBP-3 and negating this increase in IGFBP-3 with siRNA reduced the AZA-induced growth inhibition and induction of cell death and virtually negated the AZA-induced inhibition of colony formation. With ER-alpha positive cells AZA increased the abundance of the tumour suppressor gene, p53 and induced demethylation of the IGFBP-3 promoter, whereas with ER negative cells, AZA epigenetically increased the transcription factor AP2-alpha, which when silenced prevented the increase in IGFBP-3. IGFBP-3 plays an important role in the anti-tumorigenic effects of AZA on breast cancer cells. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Zeng, Li; Jarrett, Caroline; Holly, Jeff M. P.; Perks, Claire M.] Univ Bristol, Southmead Hosp, IGFs, Bristol BS10 5NB, Avon, England.
   [Zeng, Li; Jarrett, Caroline; Holly, Jeff M. P.; Perks, Claire M.] Univ Bristol, Southmead Hosp, Metab Endocrinol Grp, Bristol BS10 5NB, Avon, England.
   [Brown, Keith] Univ Bristol, Sch Med Sci, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England.
   [Gillespie, Kathleen M.] Univ Bristol, Southmead Hosp, Sch Clin Sci, Bristol BS10 5NB, Avon, England.
C3 University of Bristol; Southmead Hospital; University of Bristol;
   Southmead Hospital; University of Bristol; Southmead Hospital;
   University of Bristol
RP Perks, CM (通讯作者)，Univ Bristol, Southmead Hosp, IGFs, Learning & Res Bldg, Bristol BS10 5NB, Avon, England.
EM claire.m.perks@bristol.ac.uk
RI Brown, Keith/C-3355-2009
OI Zeng, Li/0009-0004-9357-3904; Perks, Claire/0000-0003-1562-891X
CR Anttila MA, 2000, BRIT J CANCER, V82, P1974
   BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0
   Burrows C, 2006, ENDOCRINOLOGY, V147, P3484, DOI 10.1210/en.2006-0005
   Campbell MJ, 2001, J CLIN PATHOL-MOL PA, V54, P307
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679
   Colston KW, 1998, J MOL ENDOCRINOL, V20, P157, DOI 10.1677/jme.0.0200157
   DAVIES SC, 1991, CLIN ENDOCRINOL, V34, P501, DOI 10.1111/j.1365-2265.1991.tb00331.x
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Fowler CA, 2000, INT J CANCER, V88, P448, DOI 10.1002/1097-0215(20001101)88:3<448::AID-IJC18>3.3.CO;2-M
   Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602
   Gomyo Y, 2004, ONCOGENE, V23, P6779, DOI 10.1038/sj.onc.1207381
   Hollowood AD, 2000, INT J CANCER, V88, P336, DOI 10.1002/1097-0215(20001101)88:3<336::AID-IJC3>3.3.CO;2-1
   Hurtubise A, 2006, CANCER CHEMOTH PHARM, V58, P618, DOI 10.1007/s00280-006-0225-6
   Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365
   Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI 10.3322/caac.20105
   Jenkins PJ, 2004, EUR J ENDOCRINOL, V151, pS17, DOI 10.1530/eje.0.151S017
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kalebic T, 2003, ANN NY ACAD SCI, V983, P278, DOI 10.1111/j.1749-6632.2003.tb05982.x
   Kuo HK, 2007, CANCER RES, V67, P8248, DOI 10.1158/0008-5472.CAN-07-1038
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   McCaig C, 2002, BRIT J CANCER, V86, P1963, DOI 10.1038/sj.bjc.6600355
   McIntosh J, 2010, J BIOL CHEM, V285, P38788, DOI 10.1074/jbc.M110.177311
   Mirza S., 2010, MOL CELL BIOCH
   Orso F, 2008, FASEB J, V22, P2702, DOI 10.1096/fj.08-106492
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Perks C, 2003, HORM METAB RES, V35, P828
   Perks Claire M, 2003, Breast Dis, V18, P45
   Perks C, 2008, J MAMMARY GLAND BIOL, V13, P455, DOI 10.1007/s10911-008-9106-4
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Renehan AG, 2006, ENDOCR-RELAT CANCER, V13, P273, DOI 10.1677/erc.1.01219
   Ricort JM, 2001, ENDOCRINOLOGY, V142, P108, DOI 10.1210/en.142.1.108
   Sadikovic B, 2008, CURR GENOMICS, V9, P394, DOI 10.2174/138920208785699580
   Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Suh YA, 2013, CANCER LETT, V332, P102, DOI 10.1016/j.canlet.2013.01.022
   Thomas F, 2010, PROSTATE, V70, P856, DOI 10.1002/pros.21119
   Wajapeyee N, 2005, CANCER RES, V65, P8628, DOI 10.1158/0008-5472.CAN-05-1059
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   Wolf I, 2007, BREAST CANCER RES TR, V105, P139, DOI 10.1007/s10549-006-9440-4
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yang XW, 2001, CANCER RES, V61, P7025
   YATEMAN ME, 1993, J ENDOCRINOL, V137, P151, DOI 10.1677/joe.0.1370151
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zeng L, 2010, ENDOCR-RELAT CANCER, V17, P539, DOI 10.1677/ERC-09-0221
NR 49
TC 14
Z9 19
U1 0
U2 6
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD AUG 15
PY 2013
VL 319
IS 14
BP 2282
EP 2295
DI 10.1016/j.yexcr.2013.06.011
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 196VG
UT WOS:000322804900015
PM 23810988
DA 2025-01-12
ER

PT J
AU Yamamoto, M
   Taguchi, Y
   Ito-Kureha, T
   Semba, K
   Yamaguchi, N
   Inoue, J
AF Yamamoto, Mizuki
   Taguchi, Yuu
   Ito-Kureha, Taku
   Semba, Kentaro
   Yamaguchi, Noritaka
   Inoue, Jun-ichiro
TI NF-κB non-cell-autonomously regulates cancer stem cell populations in
   the basal-like breast cancer subtype
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; SIGNALING PATHWAY; EXPRESSION; GENE;
   IDENTIFICATION; KINASE; FATE; JAG1; POOR; PROLIFERATION
AB Patients with triple-negative breast cancer display the highest rates of early relapse of all patients with breast cancer. The basal-like subtype, a subgroup of triple-negative breast cancer, exhibits high levels of constitutively active NF-kappa B signalling. Here we show that NF-kappa B activation, induced by inflammatory cytokines or by epigenetically dysregulated NIK expression, cell-autonomously upregulates JAG1 expression in non-cancer stem cells. This upregulation stimulates NOTCH signalling in cancer stem cells in trans, leading to an expansion of cancer stem cell populations. Among breast cancers, the NF-kappa B-dependent induction of JAG1 and the NOTCH-dependent expansion of the cancer stem cell population occur only in the basal-like subtype. Collectively, our results indicate that NF-kappa B has a non-cell-autonomous role in regulating cancer stem cell populations by forming intratumoural microenvironments composed of JAG1-expressing non-cancer stem cells with a basal-like subtype.
C1 [Yamamoto, Mizuki; Taguchi, Yuu; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Dept Canc Biol,Div Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan.
   [Yamamoto, Mizuki; Semba, Kentaro] Waseda Univ, Dept Life Sci & Med Bio Sci, Shinjuku Ku, Tokyo 1628480, Japan.
   [Ito-Kureha, Taku] Grad Univ, Okinawa Inst Sci & Technol, Cell Signal Unit, Onna, Okinawa 9040495, Japan.
   [Yamaguchi, Noritaka] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Cell Biol, Chiba 2608675, Japan.
C3 University of Tokyo; Waseda University; Okinawa Institute of Science &
   Technology Graduate University; Chiba University
RP Inoue, J (通讯作者)，Univ Tokyo, Inst Med Sci, Dept Canc Biol,Div Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan.
EM jun-i@ims.u-tokyo.ac.jp
RI Yamaguchi, Noritaka/HKN-7206-2023; Yamamoto, Mizuki/AAW-1688-2020;
   Kureha, Taku/JDW-3219-2023
OI Yamamoto, Mizuki/0000-0003-3731-1702
FU contract research fund for the Program of Japan Initiative for Global
   Research Network on Infectious Diseases from the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan; Takeda Science
   Foundation; Grants-in-Aid for Scientific Research [25861297, 25670100]
   Funding Source: KAKEN
FX We thank T. Akiyama, J. Gohda and A. Niida for their helpful input and
   K. Miyazaki for secretarial assistance. This work was partially
   supported by a grant-in-aid for Scientific Research on Innovative Areas
   and by a contract research fund for the Program of Japan Initiative for
   Global Research Network on Infectious Diseases from the Ministry of
   Education, Culture, Sports, Science, and Technology of Japan (J-i.I.),
   by the Takeda Science Foundation (J.-i.I.). M.Y. is a research fellow of
   the Japan Society for the Promotion of Science.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785
   Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13
   Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001
   Johnston DA, 2009, GENE, V435, P36, DOI 10.1016/j.gene.2009.01.003
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102
   LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200
   Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu M, 2010, CANCER RES, V70, P10464, DOI 10.1158/0008-5472.CAN-10-0732
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468
   Niida A, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-71
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Pratt MAC, 2009, ONCOGENE, V28, P2710, DOI 10.1038/onc.2009.131
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun SC, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3123pe18
   Tian B, 2005, J BIOL CHEM, V280, P17435, DOI 10.1074/jbc.M500437200
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597
   Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x
   Yamamoto M, 2010, CANCER SCI, V101, P2391, DOI 10.1111/j.1349-7006.2010.01685.x
   Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007/s10549-007-9798-y
NR 49
TC 141
Z9 171
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG
PY 2013
VL 4
AR 2299
DI 10.1038/ncomms3299
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 209JN
UT WOS:000323752000015
PM 23934482
OA Bronze
DA 2025-01-12
ER

PT J
AU May, T
   Yang, JZ
   Shoni, M
   Liu, SB
   He, HS
   Gali, R
   Ng, SK
   Crum, C
   Berkowitz, RS
   Ng, SW
AF May, Taymaa
   Yang, Junzheng
   Shoni, Melina
   Liu, Shubai
   He, Housheng
   Gali, Reddy
   Ng, Shu-Kay
   Crum, Christopher
   Berkowitz, Ross S.
   Ng, Shu-Wing
TI BRCA1 Expression Is Epigenetically Repressed in Sporadic Ovarian Cancer
   Cells by Overexpression of C-Terminal Binding Protein 2
SO NEOPLASIA
LA English
DT Article
ID TRANSCRIPTIONAL COREPRESSOR; BREAST-CANCER; GENE; CTBP; SURVIVAL;
   COMPLEX
AB INTRODUCTION: Ovarian cancer is the leading cause of mortality from gynecological malignancy despite advancements in novel therapeutics. We have recently demonstrated that the transcriptional co-repressor C-terminal binding protein 2 (CtBP2) is overexpressed in epithelial ovarian carcinoma. MATERIALS AND METHODS: Reverse-transcribed cDNA from CtBP2 wild-type and knockdown ovarian cancer cell lines was hybridized to Affymetrix Gene 1.0 ST microarrays, and differentially expressed genes were studied. Immunohistochemical analysis of CtBP2 and BRCA1 staining of ovarian tissues was performed. Chromatin immunoprecipitation (ChIP) and luciferase assays were carried out. The effect of the drugs 4-methylthio-2-oxobutyric acid (MTOB) and poly(ADP-ribose) polymerase (PARP) inhibitor Olaparib on CtBP2 wild-type and knockdown cell lines was examined using methylthiazol tetrazolium assays and an xCELLigence System. RESULTS: Eighty-five genes involved in DNA repair, mitotic checkpoint, nucleosome assembly, and the BRCA1 network were differentially regulated by CtBP2 expression. ChIP and luciferase reporter assays using a BRCA1 promoter-regulated luciferase construct indicated that the CtBP2 complex binds the BRCA1 promoter and represses BRCA1 transcription. Immunohistochemistry illustrated a significant inverse CtBP2 and BRCA1 expression in a panel of malignant ovarian tumor tissues. The CtBP2 inhibitor MTOB suppressed ovarian cancer cell survival in a CtBP2-dependent manner. Ovarian cancer cells with CtBP2 knockdown did not display increased sensitivity to the PARP inhibitor Olaparib. CONCLUSION: CtBP2 is an ovarian cancer oncogene that may play a significant role in epigenetically silencing BRCA1 function in sporadic epithelial ovarian cancer. CtBP2-specific inhibitors, such as MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.
C1 [May, Taymaa; Yang, Junzheng; Shoni, Melina; Liu, Shubai; Berkowitz, Ross S.; Ng, Shu-Wing] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol,Div Gynecol Onc, Boston, MA 02115 USA.
   [He, Housheng] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
   [Gali, Reddy] Harvard Univ, Sch Med, Ctr Biomed Informat Countway, Boston, MA USA.
   [Ng, Shu-Kay] Griffith Univ, Sch Med, Griffith Hlth Inst, Meadowbrook, Qld 4131, Australia.
   [Crum, Christopher] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Brigham & Women's Hospital;
   Harvard University; Harvard Medical School; Dana-Farber Cancer
   Institute; Harvard University; Harvard Medical School; Menzies Health
   Institute Queensland; Griffith University; Griffith University - Logan
   Campus; Harvard University; Brigham & Women's Hospital
RP Ng, SW (通讯作者)，Brigham & Womens Hosp, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.
EM sng@partners.org
RI Shoni, Melina/AAT-3007-2021
OI Ng, Shu Kay/0000-0002-6865-9384; liu, shubai/0000-0001-8929-4209
FU Ruth N. White Gynecologic Oncology Research Fellowship; Robert and
   Deborah First Fund; Sperling Family Fund Foundation; Women's Cancer
   Program; Gillette Center for Women's Cancer from Dana-Farber Cancer
   Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc;
   Friends of Dana-Farber Cancer Institute to the Laboratory of Gynecologic
   Oncology
FX T.M. was partially supported by the Ruth N. White Gynecologic Oncology
   Research Fellowship. We also acknowledge the support of the Robert and
   Deborah First Fund, the Sperling Family Fund Foundation, Women's Cancer
   Program and Gillette Center for Women's Cancer from Dana-Farber Cancer
   Institute, Ovarian Cancer Research Foundation, Adler Foundation, Inc,
   and the Friends of Dana-Farber Cancer Institute to the Laboratory of
   Gynecologic Oncology. The authors have no conflicts of interests to
   disclose.
CR [Anonymous], 2010, CANCER
   Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Barroilhet L., 2012, ONCOGENE
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4
   Bergman LM, 2009, MOL CELL BIOL, V29, P4539, DOI 10.1128/MCB.00439-09
   Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119
   Birts CN, 2011, BIOL CELL, V103, P1, DOI 10.1042/BC20100067
   Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025
   Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4
   Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349
   Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941
   Fang M, 2006, EMBO J, V25, P2735, DOI 10.1038/sj.emboj.7601153
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100
   Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Joo JH, 2010, DEV BIOL, V345, P191, DOI 10.1016/j.ydbio.2010.07.009
   Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719
   Lacour RA, 2011, GYNECOL ONCOL, V121, P358, DOI 10.1016/j.ygyno.2010.12.354
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Straza MW, 2010, CELL CYCLE, V9, P3740, DOI 10.4161/cc.9.18.12936
   Tang LD, 2010, EUR J CANCER, V46, P170, DOI 10.1016/j.ejca.2009.10.003
   Varma AK, 2005, BIOCHEMISTRY-US, V44, P10941, DOI 10.1021/bi0509651
   Wysham WZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030042
NR 27
TC 23
Z9 30
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD JUN
PY 2013
VL 15
IS 6
BP 600
EP +
DI 10.1593/neo.121674
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 219DW
UT WOS:000324486800003
PM 23730208
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhang, X
   Tanaka, K
   Yan, JS
   Li, J
   Peng, DN
   Jiang, YY
   Yang, Z
   Barton, MC
   Wen, H
   Shi, XB
AF Zhang, Xi
   Tanaka, Kaori
   Yan, Jiusheng
   Li, Jing
   Peng, Danni
   Jiang, Yuanyuan
   Yang, Zhe
   Barton, Michelle C.
   Wen, Hong
   Shi, Xiaobing
TI Regulation of estrogen receptor a by histone methyltransferase
   SMYD2-mediated protein methylation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ER alpha hinge region; lysine methylation; LSD1
ID ALPHA HINGE-REGION; BREAST-CANCER; PHOSPHORYLATION; DEMETHYLATION;
   SMYD2; COACTIVATOR; ACTIVATION; LSD1; TRANSACTIVATION; TRANSCRIPTION
AB Estrogen receptor alpha (ER alpha) is a ligand-activated transcription factor. Upon estrogen stimulation, ER alpha recruits a number of coregulators, including both coactivators and corepressors, to the estrogen response elements, modulating gene activation or repression. Most coregulator complexes contain histone-modifying enzymes to control ER alpha target gene expression in an epigenetic manner. In addition to histones, these epigenetic modifiers can modify nonhistone proteins including ER alpha, thereby constituting another layer of transcriptional regulation. Here we show that SET and MYND domain containing 2 (SMYD2), a histone H3K4 and H3K36 methyltransferase, directly methylates ER alpha protein at lysine 266 (K266) both in vitro and in cells. In breast cancer MCF7 cells, SMYD2 attenuates the chromatin recruitment of ER alpha to prevent ER alpha target gene activation under an estrogen-depleted condition. Importantly, the SMYD2-mediated repression of ER alpha target gene expression is mediated by the methylation of ER alpha at K266 in the nucleus, but not the methylation of histone H3K4. Upon estrogen stimulation, ER alpha-K266 methylation is diminished, thereby enabling p300/cAMP response element-binding protein-binding protein to acetylate ER alpha at K266, which is known to promote ERa transactivation activity. Our study identifies a previously undescribed inhibitory methylation event on ER alpha. Our data suggest that the dynamic cross-talk between SMYD2-mediated ER alpha protein methylation and p300/cAMP response element-binding protein-binding protein-dependent ER alpha acetylation plays an important role in fine-tuning the functions of ER alpha at chromatin and the estrogen-induced gene expression profiles.
C1 [Zhang, Xi; Tanaka, Kaori; Li, Jing; Peng, Danni; Barton, Michelle C.; Wen, Hong; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Yan, Jiusheng] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA.
   [Zhang, Xi; Tanaka, Kaori; Li, Jing; Peng, Danni; Barton, Michelle C.; Wen, Hong; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Houston, TX 77030 USA.
   [Zhang, Xi; Tanaka, Kaori; Li, Jing; Peng, Danni; Barton, Michelle C.; Wen, Hong; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX 77030 USA.
   [Zhang, Xi; Tanaka, Kaori; Li, Jing; Peng, Danni; Barton, Michelle C.; Wen, Hong; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Ctr Genet & Genom, Houston, TX 77030 USA.
   [Li, Jing; Barton, Michelle C.; Shi, Xiaobing] Univ Texas Grad Sch Biomed Sci, Genes & Dev Grad Program, Houston, TX 77030 USA.
   [Jiang, Yuanyuan; Yang, Zhe] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center;
   Wayne State University
RP Shi, XB (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
EM xbshi@mdanderson.org
RI Jiang, Yuanyuan/IQS-5599-2023
OI Shi, Xiaobing/0000-0001-5242-8189; Wen, Hong/0000-0001-8739-4572;
   Barton, Michelle/0000-0002-4042-1374
FU American Cancer Society [RSG-13-290-01-TBE]; Cancer Prevention Research
   Institute of Texas [RP110471]; Welch [G1719]; National Institutes of
   Health/MD Anderson; Cancer Center [CA016672]; MDA Institutional Research
   Grant; Leukemia Research Foundation; Aplastic Anemia & Myelodysplastic
   Syndromes International Foundation; MDA Center for Cancer Epigenetics
   Postdoc Scholar Award; Kimmel Scholar Award
FX We thank M. T. Bedford, W. L. Kraus, C. M. Chiang, J. Sage, M. Lee, and
   L. Ma for reagents; D. Weber (University of California Davis Proteomics
   Facility) for MS data collection; and Joseph Munch for editing the
   manuscript. This work was supported by American Cancer Society Grant
   RSG-13-290-01-TBE (to X. S.) Cancer Prevention Research Institute of
   Texas Grant RP110471 (to X. S.), Welch Grant G1719 (to X. S.), National
   Institutes of Health/MD Anderson (MDA) Cancer Center Support Grant
   CA016672 (to X. S.), MDA Institutional Research Grant (to H. W.), the
   Leukemia Research Foundation (Z.Y.), and Aplastic Anemia &
   Myelodysplastic Syndromes International Foundation (Z.Y.). X.Z. is a
   recipient of an MDA Center for Cancer Epigenetics Postdoc Scholar Award,
   and X. S. is a recipient of a Kimmel Scholar Award.
CR Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200
   Abu-Farha M, 2011, J MOL CELL BIOL, V3, P301, DOI 10.1093/jmcb/mjr025
   Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449
   Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26
   Cho HS, 2012, NEOPLASIA, V14, P476, DOI 10.1593/neo.12656
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287
   Jiang J, 2007, CLIN CANCER RES, V13, P5769, DOI 10.1158/1078-0432.CCR-07-0822
   Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485
   Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531
   Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200
   Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025
   Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839
   Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016
   Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736
   Pratt William B., 1994, Seminars in Cell Biology, V5, P83
   Qian C, 2006, CELL MOL LIFE SCI, V63, P2755, DOI 10.1007/s00018-006-6274-5
   Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612
   Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9
   Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200
   Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781
   Wen H, 2010, J BIOL CHEM, V285, P9322, DOI 10.1074/jbc.C109.097667
   Wu SC, 2009, MOL ENDOCRINOL, V23, P1323, DOI 10.1210/me.2009-0131
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5
   Yamashita H, 2008, ENDOCR-RELAT CANCER, V15, P755, DOI 10.1677/ERC-08-0078
   Yang YZ, 2010, MOL CELL, V40, P1016, DOI 10.1016/j.molcel.2010.11.024
NR 35
TC 122
Z9 144
U1 0
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 22
PY 2013
VL 110
IS 43
BP 17284
EP 17289
DI 10.1073/pnas.1307959110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 238JU
UT WOS:000325943300036
PM 24101509
OA Bronze, Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Gumireddy, K
   Li, AP
   Yan, JC
   Setoyama, T
   Johannes, GJ
   Orom, UA
   Tchou, J
   Liu, Q
   Zhang, L
   Speicher, DW
   Calin, GA
   Huang, QH
AF Gumireddy, Kiranmai
   Li, Anping
   Yan, Jinchun
   Setoyama, Tetsuro
   Johannes, Gregg J.
   Orom, Ulf A.
   Tchou, Julia
   Liu, Qin
   Zhang, Lin
   Speicher, David W.
   Calin, George A.
   Huang, Qihong
TI Identification of a long non-coding RNA-associated RNP complex
   regulating metastasis at the translational step
SO EMBO JOURNAL
LA English
DT Article
DE non-coding RNA; translation; metastasis
ID EPITHELIAL-MESENCHYMAL TRANSITION; NUCLEAR RIBONUCLEOPROTEIN-K;
   X-RELATED PROTEINS; HNRNP K; BINDING PROTEINS; GENE-EXPRESSION;
   MESSENGER-RNAS; MEDIATED PHOSPHORYLATION; MOLECULAR-MECHANISMS;
   TUMOR-METASTASIS
AB Long non-coding RNAs (lncRNAs) are a novel class of regulatory genes that play critical roles in various processes ranging from normal development to human diseases such as cancer progression. Recent studies have shown that lncRNAs regulate the gene expression by chromatin remodelling, transcription, splicing and RNA decay control, enhancer function, and epigenetic regulation. However, little is known about translation regulation by lncRNAs. We identified a translational regulatory lncRNA (treRNA) through genome-wide computational analysis. We found that treRNA is upregulated in paired clinical breast cancer primary and lymph-node metastasis samples, and that its expression stimulates tumour invasion in vitro and metastasis in vivo. Interestingly, we found that treRNA downregulates the expression of the epithelial marker E-cadherin by suppressing the translation of its mRNA. We identified a novel ribonucleoprotein (RNP) complex, consisting of RNA-binding proteins (hnRNP K, FXR1, and FXR2), PUF60 and SF3B3, that is required for this treRNA functions. Translational suppression by treRNA is dependent on the 3'UTR of the E-cadherin mRNA. Taken together, our study indicates a novel mechanism of gene regulation by lncRNAs in cancer progression.
C1 [Gumireddy, Kiranmai; Li, Anping; Liu, Qin; Speicher, David W.; Huang, Qihong] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
   [Yan, Jinchun] Univ Washington, Med Ctr, Seattle, WA 98195 USA.
   [Setoyama, Tetsuro; Calin, George A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Johannes, Gregg J.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.
   [Orom, Ulf A.] Max Planck Inst Mol Genet, D-14195 Berlin, Germany.
   [Tchou, Julia] Univ Penn, Dept Surg, Div Endocrine & Oncol Surg, Abramson Canc Ctr,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Tchou, Julia] Univ Penn, Abramson Canc Ctr, Rena Rowan Breast Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Zhang, Lin] Univ Penn, Ctr Res Early Detect & Cure Ovarian Canc, Philadelphia, PA 19104 USA.
   [Zhang, Lin] Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA.
C3 The Wistar Institute; University of Washington; University of Washington
   Seattle; University of Texas System; UTMD Anderson Cancer Center; Drexel
   University; Max Planck Society; University of Pennsylvania; University
   of Pennsylvania; University of Pennsylvania; University of Pennsylvania
RP Huang, QH (通讯作者)，Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
EM qhuang@wistar.org
RI Calin, George/E-9390-2011; Zhang, Lin/K-8478-2012; Orom, Ulf/G-1327-2010
OI Calin, George/0000-0001-6704-5615; Calin, George/0000-0002-7427-0578;
   Orom, Ulf/0000-0002-0643-0592
FU Breast Cancer Alliance; WW Smith Foundation; Edward Mallinckrodt Jr
   Foundation; National Natural Science Foundation of China [81372328]; 
   [NCIR01CA148759-01]
FX We would like to thank Drs Melissa J Moore and Ngan Vo for generously
   providing the plasmids; Drs Gain Tartaglia and Federico Agostini for the
   catRAPID analysis. This work was supported by NCIR01CA148759-01; Breast
   Cancer Alliance; WW Smith Foundation; Edward Mallinckrodt Jr Foundation;
   National Natural Science Foundation of China (81372328).
CR Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182
   Bánfai B, 2012, GENOME RES, V22, P1646, DOI 10.1101/gr.134767.111
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bellucci M, 2011, NAT METHODS, V8, P444, DOI 10.1038/nmeth.1611
   Beltran M, 2008, GENE DEV, V22, P756, DOI 10.1101/gad.455708
   Benetatos L, 2010, LEUKEMIA RES, V34, P148, DOI 10.1016/j.leukres.2009.06.019
   Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199
   Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Ceman S, 1999, MOL CELL BIOL, V19, P7925
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chang XB, 2008, J CELL SCI, V121, P2814, DOI 10.1242/jcs.028951
   Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029
   Cook LM, 2011, SEMIN CANCER BIOL, V21, P113, DOI 10.1016/j.semcancer.2010.12.005
   Corsini L, 2009, J BIOL CHEM, V284, P630, DOI 10.1074/jbc.M805395200
   Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052
   Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007
   Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491
   Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Flynn RL, 2011, NATURE, V471, P532, DOI 10.1038/nature09772
   Friend K, 2012, NAT STRUCT MOL BIOL, V19, P176, DOI 10.1038/nsmb.2214
   Fukaya T, 2012, MOL CELL, V48, P825, DOI 10.1016/j.molcel.2012.09.024
   Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488
   Glisovic T, 2008, FEBS LETT, V582, P1977, DOI 10.1016/j.febslet.2008.03.004
   Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701
   Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2013, CELL, V154, P240, DOI 10.1016/j.cell.2013.06.009
   Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398
   Harismendy O, 2011, NATURE, V470, P264, DOI 10.1038/nature09753
   He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232
   Heo JB, 2011, SCIENCE, V331, P76, DOI 10.1126/science.1197349
   Hoogeveen AT, 2002, MICROSC RES TECHNIQ, V57, P148, DOI 10.1002/jemt.10064
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003
   Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838
   Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901
   Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080
   Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105
   Khalil AM, 2011, SEMIN CELL DEV BIOL, V22, P359, DOI 10.1016/j.semcdb.2011.02.016
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kielkopf CL, 2004, GENE DEV, V18, P1513, DOI 10.1101/gad.1206204
   Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687
   Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033
   Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568
   Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568
   Li L, 2009, P NATL ACAD SCI USA, V106, P12956, DOI 10.1073/pnas.0906005106
   Liu FQ, 2010, SCIENCE, V327, P94, DOI 10.1126/science.1180278
   Maison C, 2011, NAT GENET, V43, P220, DOI 10.1038/ng.765
   Mancini-DiNardo D, 2006, GENE DEV, V20, P1268, DOI 10.1101/gad.1416906
   Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519
   Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459
   Meijer HA, 2013, SCIENCE, V340, P82, DOI 10.1126/science.1231197
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373
   Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X
   Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002
   Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2
   Ostrowski J, 2003, NUCLEIC ACIDS RES, V31, P3954, DOI 10.1093/nar/gkg452
   Perez DS, 2008, HUM MOL GENET, V17, P642, DOI 10.1093/hmg/ddm336
   Petrovics G, 2004, ONCOGENE, V23, P605, DOI 10.1038/sj.onc.1207069
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Prigge JR, 2009, BBA-GENE REGUL MECH, V1789, P487, DOI 10.1016/j.bbagrm.2009.06.002
   Reed, 2003, CURRENT PROTOCOLS MO, P22
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Schmitz KM, 2010, GENE DEV, V24, P2264, DOI 10.1101/gad.590910
   Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498
   Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824
   Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5
   Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Tian D, 2010, CELL, V143, P390, DOI 10.1016/j.cell.2010.09.049
   TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Ule J, 2005, METHODS, V37, P376, DOI 10.1016/j.ymeth.2005.07.018
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Valverde R, 2008, FEBS J, V275, P2712, DOI 10.1111/j.1742-4658.2008.06411.x
   van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107
   Vasudevan S, 2007, CELL, V128, P1105, DOI 10.1016/j.cell.2007.01.038
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021
   Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027
NR 92
TC 144
Z9 158
U1 1
U2 63
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD OCT 16
PY 2013
VL 32
IS 20
BP 2672
EP 2684
DI 10.1038/emboj.2013.188
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 235JJ
UT WOS:000325714100004
PM 23974796
OA Green Published
DA 2025-01-12
ER

PT J
AU Bhan, A
   Hussain, I
   Ansari, KI
   Kasiri, S
   Bashyal, A
   Mandal, SS
AF Bhan, Arunoday
   Hussain, Imran
   Ansari, Khairul I.
   Kasiri, Sahba
   Bashyal, Aarti
   Mandal, Subhrangsu S.
TI Antisense Transcript Long Noncoding RNA (lncRNA) HOTAIR is
   Transcriptionally Induced by Estradiol
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE long noncoding RNA; HOTAIR; estrogen receptors; epigenetics; MLL histone
   methylases
ID NUCLEAR RECEPTOR COREGULATORS; ESTROGEN-RECEPTOR; HISTONE METHYLASES;
   GENE-EXPRESSION; BREAST-CANCER; XIST GENE; CELL; APOPTOSIS; GROWTH;
   ROLES
AB HOTAIR (HOX antisense intergenic RNA) is a long noncoding RNA (lncRNA) that is transcribed from the antisense strand of homeobox C gene locus in chromosome 12. HOTAIR coordinates with chromatin-modifying enzymes and regulates gene silencing. It is overexpressed in various carcinomas including breast cancer. Herein, we demonstrated that HOTAIR is crucial for cell growth and viability and its knockdown induced apoptosis in breast cancer cells. We also demonstrated that HOTAIR is transcriptionally induced by estradiol (E2). Its promoter contains multiple functional estrogen response elements (EREs). Estrogen receptors (ERs) along with various ER coregulators such as histone methylases MLL1 (mixed lineage leukemia 1) and MLL3 and CREB-binding protein/p300 bind to the promoter of HOTAIR in an E2-dependent manner. Level of histone H3 lysine-4 trimethylation, histone acetylation, and RNA polymerase II recruitment is enriched at the HOTAIR promoter in the presence of E2. Knockdown of ERs and MLLs downregulated the E2-induced HOTAIR expression. Thus, similar to protein-coding gene transcription, E2-induced transcription of antisense transcript HOTAIR is coordinated via ERs and ER coregulators, and this mechanism of HOTAIR overexpression potentially contributes towards breast cancer progression. Published by Elsevier Ltd.
C1 [Bhan, Arunoday; Hussain, Imran; Ansari, Khairul I.; Kasiri, Sahba; Bashyal, Aarti; Mandal, Subhrangsu S.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
C3 University of Texas System; University of Texas Arlington
RP Mandal, SS (通讯作者)，Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
EM smandal@uta.edu
RI bhan, arunoday/F-1066-2011; Kasiri, Sahba/F-1064-2011; Ansari,
   Khairul/C-9791-2011
OI Ansari, Khairul I/0000-0002-9564-2107; Hussain,
   Imran/0000-0003-1563-7656
FU National Institutes of Health [1R15 ES019129-01, 2R15 CA113747-02];
   National Science Foundation [0821969]; American Heart Association
   [0765160Y]; Direct For Mathematical & Physical Scien; Division Of
   Chemistry [0821969] Funding Source: National Science Foundation;
   American Heart Association (AHA) [0765160Y] Funding Source: American
   Heart Association (AHA)
FX We thank all the Mandal laboratory members for helpful discussions.
   Research in the Mandal laboratory is supported in part by grants from
   the National Institutes of Health (1R15 ES019129-01 and 2R15
   CA113747-02), the National Science Foundation (0821969), and the
   American Heart Association (0765160Y).
CR Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263
   Ansari K. I., 2012, ONCOGENE, DOI DOI 10.1038/0NC.2012.352
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x
   Ansari KI, 2009, DALTON T, P8525, DOI 10.1039/b905276c
   Ansari KI, 2009, ORG BIOMOL CHEM, V7, P926, DOI 10.1039/b816858j
   Ansari KI, 2009, FEBS J, V276, P3299, DOI 10.1111/j.1742-4658.2009.07055.x
   Ansari KI, 2009, FRONT BIOSCI-LANDMRK, V14, P3483, DOI 10.2741/3466
   BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0
   BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I
   BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707
   Carninci P, 2007, CURR OPIN GENET DEV, V17, P139, DOI 10.1016/j.gde.2007.02.008
   Denger S, 2001, MOL CELL ENDOCRINOL, V178, P155, DOI 10.1016/S0303-7207(01)00417-8
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Dreijerink KMA, 2009, MOL CELL BIOL, V29, P5060, DOI 10.1128/MCB.01001-08
   Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784
   Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331
   Geng YJ, 2011, J INT MED RES, V39, P2119, DOI 10.1177/147323001103900608
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398
   Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6
   Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005
   Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167
   Hüttenhofer A, 2005, TRENDS GENET, V21, P289, DOI 10.1016/j.tig.2005.03.007
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Kok M, 2010, NETH J MED, V68, P291
   Lebeau A, 2003, BREAST CANCER RES TR, V79, P187, DOI 10.1023/A:1023958324448
   Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734
   Lee S, 2008, MOL ENDOCRINOL, V22, P1312, DOI 10.1210/me.2008-0012
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   McKenna NJ, 2009, MOL ENDOCRINOL, V23, P740, DOI 10.1210/me.2009-0135
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185
   Moseley ML, 2006, NAT GENET, V38, P758, DOI 10.1038/ng1827
   Naik MU, 2008, CANCER RES, V68, P2194, DOI 10.1158/0008-5472.CAN-07-3057
   Nettles KW, 2008, MOL ENDOCRINOL, V22, P263, DOI 10.1210/me.2007-0324
   Nie L, 2012, AM J TRANSL RES, V4, P127
   Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803
   Niland Courtney N., 2012, Frontiers in Genetics, V3, P25, DOI 10.3389/fgene.2012.00025
   Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266
   Özgür E, 2013, CLIN EXP MED, V13, P119, DOI 10.1007/s10238-012-0181-x
   Poole RL, 2012, EUR J HUM GENET, V20, P240, DOI 10.1038/ejhg.2011.166
   Ranum LPW, 2006, ANNU REV NEUROSCI, V29, P259, DOI 10.1146/annurev.neuro.29.051605.113014
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200
   Shrestha B, 2012, FEBS J, V279, P3715, DOI 10.1111/j.1742-4658.2012.08733.x
   Tahira AC, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-141
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157
   Wall NR, 1999, LEUKEMIA RES, V23, P881, DOI 10.1016/S0145-2126(99)00108-3
   Woldemariam GA, 2008, J INORG BIOCHEM, V102, P740, DOI 10.1016/j.jinorgbio.2007.11.008
   Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y
   Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045
NR 64
TC 213
Z9 241
U1 0
U2 86
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD OCT 9
PY 2013
VL 425
IS 19
BP 3707
EP 3722
DI 10.1016/j.jmb.2013.01.022
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 226MP
UT WOS:000325040800011
PM 23375982
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Carey, JP
   Knowell, AE
   Chinaranagari, S
   Chaudhary, J
AF Carey, Jason P.
   Knowell, Ashley Evans
   Chinaranagari, Swathi
   Chaudhary, Jaideep
TI Id4 Promotes Senescence and Sensitivity to Doxorubicin-induced Apoptosis
   in DU145 Prostate Cancer Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Id4; senescence; E2F1; apoptosis; DU145
ID CELLULAR SENESCENCE; GENE-EXPRESSION; BREAST-CANCER; INHIBITOR;
   ACCUMULATION; FIBROBLASTS; INDUCTION; PROTEINS; PATHWAY
AB Inhibitor of differentiation proteins (Id1, 2, 3 and 4) are dominant negative regulators of basic helix loop helix transcription factors and play dominant roles in cancer cells, spanning several molecular pathways including senescence, invasion, metastasis, proliferation and apoptosis. In contrast to high Idl, Id2 and Id3 expression, the expression of Id4 is epigenetically silenced in prostate cancer. In the present study we demonstrated a novel role of Id4, that of promotion of cellular senescence in prostate cancer cells. Materials and Methods: Id4 was ectopically expressed in DU145 cells (DU145+Id4). The cells treated with Doxorubicin (0-500 nm) or vehicle control were analyzed for apoptosis, senescence (SA-beta Galactosidase), and expression of CDKN1A (p21), CDKN1B(p27), CDKN2A (p16), E2F1, vimentin and E-cadherin by immuno-histochemistry and/or Western blot. Results: In the present study we demonstrated that Id4 promotes cellular senescence in prostate cancer cell line DU145. Ectopic overexpression of Id4 in androgen receptor-negative DU145 prostate cancer cells resulted in increased expression of p16, p21, p27, E-cadherin and vimentin but down-regulated E2F1 expression. Id4 also potentiated the effect of doxorubicin induced senescence and apoptosis. Conclusion: The absence of functional p16, pRB and p53 in DU145 suggests that Id4 could alter additional molecular pathways such as those involving E2F1 to promote senescence and increased sensitivity to doxorubicin-induced apoptosis. The results of the present study support the role of Id4 as a tumor suppressor in prostate cancer.
C1 [Carey, Jason P.; Knowell, Ashley Evans; Chinaranagari, Swathi; Chaudhary, Jaideep] Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Atlanta, GA 30314 USA.
C3 Clark Atlanta University
RP Chaudhary, J (通讯作者)，Ctr Canc Res & Therapeut Dev, 223 James P Brawley Dr SW, Atlanta, GA 30314 USA.
EM jchaudhary@cau.edu
OI Carey, Jason PW/0000-0002-9729-1742
FU NIH/NCI [CA128914]; NIH/NCRR/RCMI [G12RR03062]
FX The research was supported by NIH/NCI CA128914 to IC. Support for core
   facilities and additional resources were funded in part by NIH/NCRR/RCMI
   G12RR03062.
CR Asirvatham AJ, 2006, PROSTATE, V66, P921, DOI 10.1002/pros.20366
   BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762
   Carey JPW, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-173
   Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923
   DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Elston MS, 2009, J CLIN ENDOCR METAB, V94, P1436, DOI 10.1210/jc.2008-2075
   Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   Ewald JA, 2009, J BIOMOL SCREEN, V14, P853, DOI 10.1177/1087057109340314
   Jia LJ, 2011, NEOPLASIA, V13, P561, DOI 10.1593/neo.11420
   KATZ ML, 1984, MECH AGEING DEV, V25, P149, DOI 10.1016/0047-6374(84)90137-4
   Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477
   Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34
   Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693
   Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002
   MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9
   Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699
   Nishio K, 2001, HISTOCHEM CELL BIOL, V116, P321, DOI 10.1007/s004180100325
   Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880
   Park C, 2006, INT J MOL MED, V17, P715
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Sharma P, 2012, CANCER MED-US, V1, P187, DOI 10.1002/cam4.19
   Sharma P, 2012, CANCER MED-US, V1, P176, DOI 10.1002/cam4.16
   Sliwinska MA, 2009, MECH AGEING DEV, V130, P24, DOI 10.1016/j.mad.2008.04.011
   Sun BH, 2010, CELL CYCLE, V9, P1122, DOI 10.4161/cc.9.6.10990
   Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Vergel M, 2010, J AGING RES, V2011, P1
   Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042
NR 29
TC 17
Z9 17
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD OCT
PY 2013
VL 33
IS 10
BP 4271
EP 4278
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 241YK
UT WOS:000326204400016
PM 24122992
DA 2025-01-12
ER

PT J
AU Wu, YD
   Wang, YF
   Yang, XWH
   Kang, TB
   Zhao, YX
   Wang, C
   Evers, BM
   Zhou, BHP
AF Wu, Yadi
   Wang, Yifan
   Yang, Xiuwei H.
   Kang, Tiebang
   Zhao, Yongxiang
   Wang, Chi
   Evers, B. Mark
   Zhou, Binhua P.
TI The Deubiquitinase USP28 Stabilizes LSD1 and Confers Stem-Cell-like
   Traits to Breast Cancer Cells
SO CELL REPORTS
LA English
DT Article
ID DEMETHYLASE 1; PROGENITOR CELLS; SILENCED GENES; SELF-RENEWAL; HISTONE;
   DIFFERENTIATION; OSTEOSARCOMA; REEXPRESSION; METHYLATION; INHIBITION
AB LSD1 is a critical chromatin modulator that controls cellular pluripotency and differentiation through the demethylation of H3K4me1/2. Overexpression of LSD1 has been observed in many types of tumors and is correlated with its oncogenic effects in tumorigenesis. However, the mechanism leading to LSD1 upregulation in tumors remains unclear. Using an unbiased siRNA screening against all the human deubiquitinases, we identified USP28 as a bona fide deubiquitinase of LSD1. USP28 interacted with and stabilized LSD1 via deubiquitination. USP28 overexpression correlated with LSD1 upregulation in multiple cancer cell lines and breast tumor samples. Knockdown of USP28 resulted in LSD1 destabilization, leading to the suppression of cancer stem cell (CSC)-like characteristics in vitro and inhibition of tumorigenicity in vivo, which can be rescued by ectopic LSD1 expression. Our study reveals a critical mechanism underlying the epigenetic regulation by USP28 and provides another treatment approach against breast cancer.
C1 [Wu, Yadi; Yang, Xiuwei H.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA.
   [Wang, Yifan; Evers, B. Mark; Zhou, Binhua P.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   [Wang, Chi] Univ Kentucky, Coll Med, Dept Biostat, Lexington, KY 40506 USA.
   [Evers, B. Mark] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA.
   [Wu, Yadi; Wang, Yifan; Yang, Xiuwei H.; Wang, Chi; Evers, B. Mark; Zhou, Binhua P.] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA.
   [Kang, Tiebang] State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhao, Yongxiang] Guangxi Med Univ, Biol Targeting Diag & Therapy Res Ctr, Nanning 530021, Guangxi, Peoples R China.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Kentucky; University of Kentucky; State Key Lab Oncology
   South China; Guangxi Medical University
RP Wu, YD (通讯作者)，Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA.
EM yadi.wu@uky.edu; peter.zhou@uky.edu
RI WANG, YIFAN/AAW-1973-2021
FU NIH [2RO1CA125454]; Susan G. Komen Foundation [KG081310]; Mary Kay Ash
   Foundation; American Cancer Society Research Scholar Award [RSG13187-01]
FX We thank Cathy Anthony for critical reading and editing of this
   manuscript. This work was supported by grants from NIH (2RO1CA125454),
   Susan G. Komen Foundation (KG081310), Mary Kay Ash Foundation (to
   B.P.Z.), and American Cancer Society Research Scholar Award (RSG13187-01
   to Y.W.).
CR Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246
   Bennani-Baiti IM, 2012, HUM PATHOL, V43, P1300, DOI 10.1016/j.humpath.2011.10.010
   Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811
   Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471
   Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051
   Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673
   Foster CT, 2010, MOL CELL BIOL, V30, P4851, DOI 10.1128/MCB.00521-10
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101
   Luise C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015891
   Magerl C, 2010, HUM PATHOL, V41, P181, DOI 10.1016/j.humpath.2009.08.007
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Nicholson TB, 2009, EPIGENETICS-US, V4, P129, DOI 10.4161/epi.4.3.8443
   Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017
   Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601
   Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040
   Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039
NR 35
TC 136
Z9 159
U1 1
U2 29
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD OCT
PY 2013
VL 5
IS 1
BP 224
EP 236
DI 10.1016/j.celrep.2013.08.030
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 241FP
UT WOS:000326152100023
PM 24075993
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Xiang, TX
   Li, LL
   Yin, XD
   Zhong, L
   Peng, WY
   Qiu, Z
   Ren, GS
   Tao, Q
AF Xiang, Tingxiu
   Li, Lili
   Yin, Xuedong
   Zhong, Lan
   Peng, Weiyan
   Qiu, Zhu
   Ren, Guosheng
   Tao, Qian
TI Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal
   Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE DKK3; breast cancer; methylation; Wnt; -catenin
ID FACTOR-I WIF1; TUMOR-SUPPRESSOR; PROMOTER METHYLATION; BETA-CATENIN;
   FAMILY GENES; CPG METHYLATION; REIC/DKK-3 GENE; EXPRESSION; DKK3;
   INACTIVATION
AB Dickkopf-related protein 3 (DKK3) is an antagonist of Wnt ligand activity. Reduced DKK3 expression has been reported in various types of cancers, but its functions and related molecular mechanisms in breast tumorigenesis remain unclear. We examined the expression and promoter methylation of DKK3 in 10 breast cancer cell lines, 96 primary breast tumours, 43 paired surgical margin tissues and 16 normal breast tissues. DKK3 was frequently silenced in breast cell lines (5/10) by promoter methylation, compared with human normal mammary epithelial cells and tissues. DKK3 methylation was detected in 78% of breast tumour samples, whereas only rarely methylated in normal breast and surgical margin tissues, suggesting tumour-specific methylation of DKK3 in breast cancer. Ectopic expression of DKK3 suppressed cell colony formation through inducing G0/G1 cell cycle arrest and apoptosis of breast tumour cells. DKK3 also induced changes of cell morphology, and inhibited breast tumour cell migration through reversing epithelial-mesenchymal transition (EMT) and down-regulating stem cell markers. DKK3 inhibited canonical Wnt/-catenin signalling through mediating -catenin translocation from nucleus to cytoplasm and membrane, along with reduced active--catenin, further activating non-canonical JNK signalling. Thus, our findings demonstrate that DKK3 could function as a tumour suppressor through inducing apoptosis and regulating Wnt signalling during breast tumorigenesis.
C1 [Xiang, Tingxiu; Yin, Xuedong; Peng, Weiyan; Qiu, Zhu; Ren, Guosheng; Tao, Qian] Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing, Peoples R China.
   [Li, Lili; Zhong, Lan; Tao, Qian] Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China.
   [Li, Lili; Zhong, Lan; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Li, Lili; Zhong, Lan; Tao, Qian] CUHK Shenzhen Res Inst, Shatin, Hong Kong, Peoples R China.
C3 Chongqing Medical University; Chinese University of Hong Kong; Chinese
   University of Hong Kong; CUHK Shenzhen Research Institute
RP Tao, Q (通讯作者)，Chinese Univ Hong Kong, Dept Clin Oncol, PWH, Ctr Canc, Rm 315, Shatin, Hong Kong, Peoples R China.
EM rgs726@163.com; qtao@clo.cuhk.edu.hk
RI Xiang, Tingxiu/E-6157-2016; Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018
OI Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808
FU Chongqing Natural Science Fund [2010AB5012]; Chongqing Health Bureau
   Grant; National Natural Science Foundation of China [81072148, 81071634,
   81172582]
FX We thank Sun Young Rha for the YCC cell lines. This study was supported
   by the Chongqing Natural Science Fund (#CSTC, 2010AB5012), Chongqing
   Health Bureau Grant, and National Natural Science Foundation of China
   (#81072148, #81071634 and #81172582).
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002
   Candidus S, 1996, CANCER RES, V56, P49
   Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547
   Dellinger TH, 2012, GYNECOL ONCOL, V126, P259, DOI 10.1016/j.ygyno.2012.04.026
   Ding Z, 2009, WORLD J GASTROENTERO, V15, P2595, DOI 10.3748/wjg.15.2595
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   Hayashi T, 2012, J CANCER RES CLIN, V138, P799, DOI 10.1007/s00432-012-1158-6
   Hirata H, 2009, CLIN CANCER RES, V15, P5678, DOI 10.1158/1078-0432.CCR-09-0558
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952
   Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138
   Kawano Y, 2006, ONCOGENE, V25, P6528, DOI 10.1038/sj.onc.1209661
   Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58
   Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1
   Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0
   Kuphal S, 2006, ONCOGENE, V25, P5027, DOI 10.1038/sj.onc.1209508
   Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4
   Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913
   Li JS, 2010, CANCER BIOL THER, V10, P617, DOI 10.4161/cbt.10.6.12609
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X
   Nakamura REI, 2010, GROWTH FACTORS, V28, P232, DOI 10.3109/08977191003738832
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Pinho S, 2007, DIFFERENTIATION, V75, P957, DOI 10.1111/j.1432-0436.2007.00185.x
   Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999
   Redston M, 1998, NAT GENET, V20, P13, DOI 10.1038/1666
   Roman-Gomez J, 2005, J CLIN ONCOL, V23, P7043, DOI 10.1200/JCO.2005.01.4944
   Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008
   Román-Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Ueno K, 2011, MOL CARCINOGEN, V50, P449, DOI 10.1002/mc.20729
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194
   van der Meide WF, 2011, GYNECOL ONCOL, V123, P116, DOI 10.1016/j.ygyno.2011.06.015
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2011, BIOCHIM BIOPHYS ACTA, V1825, P18
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694
   Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443
   Xiang TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029783
   Xiang TX, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12726
   Xue L, 2007, DEV CELL, V13, P446, DOI 10.1016/j.devcel.2007.07.012
   Yang B, 2010, WORLD J GASTROENTERO, V16, P755, DOI 10.3748/wjg.v16.i6.755
   Yang D, 2011, ONCOGENE, V30, P4590, DOI [10.1038/onc.2011.166, 10.1038/onc.2011.541]
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
   Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371
   Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989
   Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267
NR 58
TC 56
Z9 65
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2013
VL 17
IS 10
BP 1236
EP 1246
DI 10.1111/jcmm.12099
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 257GD
UT WOS:000327370700004
PM 23890219
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Divyya, S
   Naushad, SM
   Murthy, PVLN
   Reddy, CR
   Kutala, VK
AF Divyya, Shree
   Naushad, Shaik Mohammad
   Murthy, P. V. L. N.
   Reddy, Ch Ram
   Kutala, Vijay Kumar
TI <i>GCPII</i> modulates oxidative stress and prostate cancer
   susceptibility through changes in methylation of <i>RASSF1</i>,
   <i>BNIP3</i>, <i>GSTP1</i> and <i>Ec</i>-<i>SOD</i>
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Glutamate carboxypeptidase II; BCL2/adenovirus E1B 19 kDa
   protein-interacting protein 3; Ras association domain family 1 isoform
   A; Extracellular superoxide dismutase; Prostate cancer; Haplotypes
ID ONE-CARBON METABOLISM; GLUTAMATE-CARBOXYPEPTIDASE; DNA-DAMAGE;
   FOLIC-ACID; BREAST-CANCER; EXPRESSION; FOLATE; HYPERMETHYLATION; GENE;
   POLYMORPHISMS
AB Glutamate carboxypeptidase II (GCPII) haplotypes were found to influence susceptibility to prostate cancer. In the current study, we have elucidated the impact of these haplotypes on the expression of PSMA, BNIP3, Ec-SOD, GSTP1 and RASSF1 genes to understand the epigenetic basis of oxidative stress and prostate cancer risk. Expression analysis was carried out by RT-PCR. Bisulphite treated DNA was subjected to MS-PCR and COBRA for epigenetic studies. Plasma MDA and glutathione levels were measured. In prostate cancer, upregulation of BNIP3 (204.4 +/- A 23.77 vs. 143.9 +/- A 16.42 %, p = 0.03); and downregulation of Ec-SOD (105.8 +/- A 13.69 vs. 176.3 +/- A 21.1 %, p = 0.027) and RASSF1A (16.67 +/- A 16.0 vs. 90.8 +/- A 8.5 %, p = 0.0048) was observed. Hypomethylation of BNIP3 (31.25 +/- A 16.19 vs. 45.70 +/- A 2.42 %, p < 0.0001), hypermethylation of Ec-SOD (71.4 +/- A 6.75 vs. 10.0 +/- A 3.78 %, p < 0.0001) and RASSF1 (76.25 +/- A 12.53 vs. 30.0 +/- A 8.82 %, p = 0.0077) was observed in prostate cancer. The gene expression signature of PSMA, BNIP3, Ec-SOD, GSTP1, clearly demarcated cases and controls (AUC = 0.89 in the ROC curve). D191V variant of GCPII showed positive association with oxidative stress and inverse association with Ec-SOD expression. H475Y variant showed positive association with Ec-SOD expression and inverse association with oxidative stress. R190W variant was found to reduce oxidative stress by increasing glutathione levels. GCPII genetic variants contribute to increased oxidative stress and prostate cancer risk by modulating the CpG island methylation of Ec-SOD.
C1 [Divyya, Shree; Naushad, Shaik Mohammad; Kutala, Vijay Kumar] Nizams Inst Med Sci, Dept Clin Pharmacol, Hyderabad 500082, Andhra Pradesh, India.
   [Divyya, Shree; Naushad, Shaik Mohammad; Kutala, Vijay Kumar] Nizams Inst Med Sci, Dept Therapeut, Hyderabad 500082, Andhra Pradesh, India.
   [Murthy, P. V. L. N.; Reddy, Ch Ram] Nizams Inst Med Sci, Dept Urol, Hyderabad 500082, Andhra Pradesh, India.
C3 Nizam's Institute of Medical Sciences; Nizam's Institute of Medical
   Sciences; Nizam's Institute of Medical Sciences
RP Kutala, VK (通讯作者)，Nizams Inst Med Sci, Dept Clin Pharmacol, Hyderabad 500082, Andhra Pradesh, India.
EM vijaykutala@gmail.com
RI Naushad, Shaik Mohammad/C-3094-2012
OI Naushad, Shaik Mohammad/0000-0001-8952-9581; Kutala, Vijay
   Kumar/0000-0002-7253-8999
FU Indian Council of Medical Research (ICMR), New Delhi [5/13/32/2007];
   Lady Tata Junior Research Fellowship
FX This work was supported by the grant funded by Indian Council of Medical
   Research (ICMR), New Delhi (Ref No. 5/13/32/2007), and Lady Tata Junior
   Research Fellowship awarded to Ms. Shree Divyya. We would also like to
   thank all the patients and the family members who participated in the
   study.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Ahmed Hafiz, 2010, Biomark Cancer, V2010, P17, DOI 10.4137/BIC.S3187
   Ambrosone CB, 2000, ANTIOXID REDOX SIGN, V2, P903, DOI 10.1089/ars.2000.2.4-903
   Amin KS, 2012, J CARCINOG, V11, P13
   Bagnyukova TV, 2008, BRAIN RES, V1237, P44, DOI 10.1016/j.brainres.2008.07.073
   Camilo E, 1996, GASTROENTEROLOGY, V110, P991, DOI 10.1053/gast.1996.v110.pm8613033
   Cavallaro RA, 2010, J ALZHEIMERS DIS, V20, P997, DOI 10.3233/JAD-2010-091666
   Cutler R G, 1992, EXS, V62, P31
   Daniunaite K, 2011, MEDICINA-LITHUANIA, V47, P147, DOI 10.3390/medicina47030020
   Divyya S, 2013, GENE, V516, P76, DOI 10.1016/j.gene.2012.11.047
   Divyya S, 2012, GENE, V497, P273, DOI 10.1016/j.gene.2012.01.055
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Gezginci-Oktayoglu S, 2012, APOPTOSIS, V17, P14, DOI 10.1007/s10495-011-0657-2
   Gordon IO, 2008, MODERN PATHOL, V21, P1421, DOI 10.1038/modpathol.2008.143
   Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131
   Halsted CH, 1998, J BIOL CHEM, V273, P20417, DOI 10.1074/jbc.273.32.20417
   Halsted CH, 2007, AM J CLIN NUTR, V86, P514, DOI 10.1093/ajcn/86.2.514
   Hayashi M, 2012, ADV EXP MED BIOL, V724, P278, DOI 10.1007/978-1-4614-0653-2_21
   Iynem Alkan Hacer, 2004, Int Urol Nephrol, V36, P57
   Kim YI, 2006, GUT, V55, P1387, DOI 10.1136/gut.2006.095463
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Kraft P, 2009, NAT REV GENET, V10, P264, DOI 10.1038/nrg2516
   Krebs J, 2002, COMPOSITION FOODS SU
   Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008
   Kuzmin I, 2002, CANCER RES, V62, P3498
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Majumdar S, 2009, ENVIRON TOXICOL, V24, P377, DOI 10.1002/tox.20442
   Mao WM, 2011, ARCH MED RES, V42, P182, DOI 10.1016/j.arcmed.2011.04.002
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Metukuri MR, 2009, AM J PHYSIOL-GASTR L, V296, pG499, DOI 10.1152/ajpgi.90526.2008
   Murphy TM, 2011, PROSTATE, V71, P1, DOI 10.1002/pros.21212
   Naushad SM, 2012, MOL CELL BIOCHEM, V361, P189, DOI 10.1007/s11010-011-1103-z
   Naushad SM, 2011, CELL BIOCHEM BIOPHYS, V61, P715, DOI 10.1007/s12013-011-9245-x
   PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9
   RONG N, 1991, J NUTR, V121, P1955, DOI 10.1093/jn/121.12.1955
   Siow YL, 2006, BIOCHEM J, V398, P73, DOI 10.1042/BJ20051810
   Smith AD, 2008, AM J CLIN NUTR, V87, P517
   Smith TR, 2003, CARCINOGENESIS, V24, P883, DOI 10.1093/carcin/bgg037
   Sowter HM, 2001, CANCER RES, V61, P6669
   Stroes ESG, 2000, CIRC RES, V86, P1129
   Sunami E, 2009, CLIN CHEM, V55, P559, DOI 10.1373/clinchem.2008.108498
   Suzuki H, 2012, J CLIN BIOCHEM NUTR, V50, P35, DOI [10.3164/jcbn.11-11SSR, 10.3164/jcbn.11-115SR]
   Tian YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017017
   *USDA, 2006, USDA NAT NUTR DAT ST, V18
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Xu XR, 2007, CARCINOGENESIS, V28, P1504, DOI 10.1093/carcin/bgm061
   Yoo NJ, 2010, TUMORI J, V96, P138, DOI 10.1177/030089161009600122
   Yoon HY, 2012, KOREAN J UROL, V53, P200, DOI 10.4111/kju.2012.53.3.200
NR 48
TC 14
Z9 20
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2013
VL 40
IS 10
BP 5541
EP 5550
DI 10.1007/s11033-013-2655-7
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 238LQ
UT WOS:000325948400003
PM 23979608
DA 2025-01-12
ER

PT J
AU Murray-Stewart, T
   Hanigan, CL
   Woster, PM
   Marton, LJ
   Casero, RA
AF Murray-Stewart, Tracy
   Hanigan, Christin L.
   Woster, Patrick M.
   Marton, Laurence J.
   Casero, Robert A., Jr.
TI Histone Deacetylase Inhibition Overcomes Drug Resistance through a
   miRNA-Dependent Mechanism
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID LUNG-CARCINOMA CELLS; SPERMIDINE SPERMINE N1-ACETYLTRANSFERASE;
   POLYAMINE ANALOG PG-11047; BREAST-CANCER CELLS; MESSENGER-RNA;
   N-1-ACETYLTRANSFERASE; GENE; TRANSCRIPTION; OXIDASE; LINES
AB The treatment of specific tumor cell lines with poly- and oligoamine analogs results in a superinduction of polyamine catabolism that is associated with cytotoxicity; however, other tumor cells show resistance to analog treatment. Recent data indicate that some of these analogs also have direct epigenetic effects. We, therefore, sought to determine the effects of combining specific analogs with an epigenetic targeting agent in phenotypically resistant human lung cancer cell lines. We show that the histone deacetylase inhibitor MS-275, when combined with (N-1, N-11)-bisethylnorspermine (BENSpm) or (N-1, N-12)-bis(ethyl)-cis-6,7-dehydrospermine tetrahydrochloride (PG-11047), synergistically induces the polyamine catabolic enzyme spermidine/spermine N-1-acetyltransferase (SSAT), a major determinant of sensitivity to the antitumor analogs. Evidence indicates that the mechanism of this synergy includes reactivation of miR-200a, which targets and destabilizes kelch-like ECH-associated protein 1 (KEAP1) mRNA, resulting in the translocation and binding of nuclear factor (erythroid-derived 2)-like 2 (NRF2) to the polyamine-responsive element of the SSAT promoter. This transcriptional stimulation, combined with positive regulation of SSAT mRNA and protein by the analogs, results in decreased intracellular concentrations of natural polyamines and growth inhibition. The finding that an epigenetic targeting agent is capable of inducing a rate-limiting step in polyamine catabolism to overcome resistance to the antitumor analogs represents a completely novel chemotherapeutic approach. In addition, this is the first demonstration of miRNA-mediated regulation of the polyamine catabolic pathway. Furthermore, the individual agents used in this study have been investigated clinically; therefore, translation of these combinations into the clinical setting holds promise. (c) 2013 AACR.
C1 [Murray-Stewart, Tracy; Hanigan, Christin L.; Casero, Robert A., Jr.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.
   [Woster, Patrick M.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
   [Marton, Laurence J.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Medical University of
   South Carolina; University of California System; University of
   California San Francisco
RP Casero, RA (通讯作者)，Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, CRB 1 Room 551,1650 Orleans St,Bunting Blaustein, Baltimore, MD 21287 USA.
EM rcasero@jhmi.edu
RI Woster, Patrick/A-5604-2010; Murray Stewart, Tracy/B-6137-2017
OI Woster, Patrick/0000-0002-9471-1916; Casero, Robert/0000-0001-5653-3306;
   Murray Stewart, Tracy/0000-0001-8679-6414
FU National Institutes of Health [CA51085, CA98454, CA149095]; Samuel
   Waxman Cancer Research Foundation
FX This work was financially supported by the National Institutes of Health
   (CA51085 and CA98454 to R.A. Casero; CA149095 to P.M. Woster) and the
   Samuel Waxman Cancer Research Foundation (to R.A. Casero).
CR Babbar N, 2006, J BIOL CHEM, V281, P24182, DOI 10.1074/jbc.M601871200
   BALASUNDARAM D, 1991, MOL CELL BIOCHEM, V100, P129
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CASERO RA, 1992, CANCER RES, V52, P5359
   CASERO RA, 1989, CANCER RES, V49, P3829
   Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243
   Casero RA, 2009, BIOCHEM J, V421, P323, DOI 10.1042/BJ20090598
   Cirenajwis H, 2010, ANTI-CANCER DRUG, V21, P897, DOI 10.1097/CAD.0b013e32833f2f77
   COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020
   Devereux W, 2003, CANCER CHEMOTH PHARM, V52, P383, DOI 10.1007/s00280-003-0662-4
   Dredge K, 2009, CANCER CHEMOTH PHARM, V65, P191, DOI 10.1007/s00280-009-1105-7
   Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495
   Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401
   Feuerstein B G, 1988, Adv Exp Med Biol, V250, P517
   FEUERSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271, DOI 10.1093/nar/18.5.1271
   FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118
   Hacker A, 2008, CANCER CHEMOTH PHARM, V63, P45, DOI 10.1007/s00280-008-0706-x
   Hahm HA, 2002, CLIN CANCER RES, V8, P684
   Holst CM, 2006, TOXICOLOGY, V223, P71, DOI 10.1016/j.tox.2006.03.009
   Ignatenko Natalia A., 2009, Cancer Genomics & Proteomics, V6, P161
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X
   Kuo WL, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-77
   Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493
   LIBBY PR, 1989, BIOCHEM PHARMACOL, V38, P1435, DOI 10.1016/0006-2952(89)90182-2
   McCloskey DE, 2003, J BIOL CHEM, V278, P13881, DOI 10.1074/jbc.M205689200
   Mitchell JLA, 2007, AMINO ACIDS, V33, P291, DOI 10.1007/s00726-007-0523-2
   Murray-Stewart T, 2003, BIOCHEM J, V373, P629, DOI 10.1042/BJ20021895
   Murray-Stewart T, 2008, FEBS J, V275, P2795, DOI 10.1111/j.1742-4658.2008.06419.x
   Nowotarski SL, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.3
   Piekarz RL, 2009, CLIN CANCER RES, V15, P3918, DOI 10.1158/1078-0432.CCR-08-2788
   Pledgie A, 2005, J BIOL CHEM, V280, P39843, DOI 10.1074/jbc.M508177200
   PORTER CW, 1988, ADV ENZYME REGUL, V27, P57
   PORTER CW, 1986, ANTICANCER RES, V6, P525
   Reddy VK, 1998, J MED CHEM, V41, P4723, DOI 10.1021/jm980172v
   Seiler N, 2005, PHARMACOL THERAPEUT, V107, P99, DOI 10.1016/j.pharmthera.2005.02.001
   Seiler N, 1998, INT J ONCOL, V13, P993
   Silva RLE, 2006, EXP EYE RES, V83, P1260, DOI 10.1016/j.exer.2006.07.003
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   Smith M, 2011, POSTHUMANITIES, V16, P1
   SNYDER RD, 1989, BIOCHEM J, V260, P697, DOI 10.1042/bj2600697
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006
   Wang YL, 1999, J BIOL CHEM, V274, P22095, DOI 10.1074/jbc.274.31.22095
   Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623
   Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3
   Wolff AC, 2003, CLIN CANC RES, V9, P5922
   Xiao L, 1996, BIOCHEM J, V313, P691, DOI 10.1042/bj3130691
NR 52
TC 18
Z9 19
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2013
VL 12
IS 10
BP 2088
EP 2099
DI 10.1158/1535-7163.MCT-13-0418
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 233EG
UT WOS:000325548400015
PM 23943804
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Rhee, JK
   Kim, K
   Chae, H
   Evans, J
   Yan, P
   Zhang, BT
   Gray, J
   Spellman, P
   Huang, THM
   Nephew, KP
   Kim, S
AF Rhee, Je-Keun
   Kim, Kwangsoo
   Chae, Heejoon
   Evans, Jared
   Yan, Pearlly
   Zhang, Byoung-Tak
   Gray, Joe
   Spellman, Paul
   Huang, Tim H. -M.
   Nephew, Kenneth P.
   Kim, Sun
TI Integrated analysis of genome-wide DNA methylation and gene expression
   profiles in molecular subtypes of breast cancer
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITIONS; CPG ISLAND METHYLATION; CELL-LINES;
   BASAL-LIKE; PATTERNS; HYPERMETHYLATION; EPIGENETICS; CAVEOLIN-1;
   DISEASE; TUMORS
AB Aberrant DNA methylation of CpG islands, CpG island shores and first exons is known to play a key role in the altered gene expression patterns in all human cancers. To date, a systematic study on the effect of DNA methylation on gene expression using high resolution data has not been reported. In this study, we conducted an integrated analysis of MethylCap-sequencing data and Affymetrix gene expression microarray data for 30 breast cancer cell lines representing different breast tumor phenotypes. As well-developed methods for the integrated analysis do not currently exist, we created a series of four different analysis methods. On the computational side, our goal is to develop methylome data analysis protocols for the integrated analysis of DNA methylation and gene expression data on the genome scale. On the cancer biology side, we present comprehensive genome-wide methylome analysis results for differentially methylated regions and their potential effect on gene expression in 30 breast cancer cell lines representing three molecular phenotypes, luminal, basal A and basal B. Our integrated analysis demonstrates that methylation status of different genomic regions may play a key role in establishing transcriptional patterns in molecular subtypes of human breast cancer.
C1 [Rhee, Je-Keun; Zhang, Byoung-Tak; Kim, Sun] Seoul Natl Univ, Interdisciplinary Program Bioinformat, Seoul 151742, South Korea.
   [Kim, Kwangsoo; Kim, Sun] Seoul Natl Univ, Bioinformat Inst, Seoul 151744, South Korea.
   [Chae, Heejoon] Indiana Univ, Sch Informat & Comp, Bloomington, IN 47408 USA.
   [Evans, Jared] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA.
   [Yan, Pearlly] Ohio State Univ, Ctr Comprehens Canc, Nucle Acid Shared Resource Illumina Core, Columbus, OH 43210 USA.
   [Zhang, Byoung-Tak; Kim, Sun] Seoul Natl Univ, Sch Comp Sci & Engn, Seoul 151742, South Korea.
   [Gray, Joe; Spellman, Paul] OHSU Knight Canc Inst, Portland, OR 97239 USA.
   [Huang, Tim H. -M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78229 USA.
   [Nephew, Kenneth P.] Indiana Univ Sch Med, Bloomington, IN 47405 USA.
   [Nephew, Kenneth P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
C3 Seoul National University (SNU); Seoul National University (SNU);
   Indiana University System; Indiana University Bloomington; Mayo Clinic;
   University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; Seoul National University (SNU); Oregon
   Health & Science University; University of Texas System; University of
   Texas Health Science Center at San Antonio; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington
RP Kim, S (通讯作者)，Seoul Natl Univ, Interdisciplinary Program Bioinformat, Seoul 151742, South Korea.
EM sunkim.bioinfo@snu.ac.kr
RI Gray, Joe/AAX-9549-2020; Yan, Pearlly/E-4339-2011
OI Rhee, Je-Keun/0000-0003-4811-8895
FU Next-Generation Information Computing Development Program
   [2012M3C4A7033341]; National Research Foundation of Korea (NRF);
   Ministry of Science, ICT & Future Planning (MSIP) [2012M3A9D1054622];
   Next-Generation BioGreen 21 Program [PJ009037022012]; Rural Development
   Administration, Republic of Korea; Interrogating Epigenetic Changes in
   Cancer Genomes [U54 CA113001]; NRF by MSIP [2010-0017734]; Seoul
   National University
FX Next-Generation Information Computing Development Program [No.
   2012M3C4A7033341]; the National Research Foundation of Korea (NRF)
   funded by the Ministry of Science, ICT & Future Planning (MSIP)
   [2012M3A9D1054622]; Next-Generation BioGreen 21 Program
   [PJ009037022012]; Rural Development Administration, Republic of Korea;
   This work is also part of National Cancer Institute, Integrated Cancer
   Biology Program, Center for Cancer Systems Biology, funded by [U54
   CA113001] (Interrogating Epigenetic Changes in Cancer Genomes); NRF
   grant funded by MSIP [No. 2010-0017734 to J.K.R and B.T.Z.] (in part).
   Funding for open access charge: Seoul National University.
CR Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Brinkman AB, 2010, METHODS, V52, P232, DOI 10.1016/j.ymeth.2010.06.012
   Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540
   Chavez L, 2010, GENOME RES, V20, P1441, DOI 10.1101/gr.110114.110
   Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fadare O, 2008, NAT CLIN PRACT ONCOL, V5, P149, DOI 10.1038/ncponc1038
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Hall M., 2009, ACM SIGKDD EXPLOR NE, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Pai AA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001316
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Rauch TA, 2010, METHODS, V52, P213, DOI 10.1016/j.ymeth.2010.03.004
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Savage K, 2007, CLIN CANCER RES, V13, P90, DOI 10.1158/1078-0432.CCR-06-1371
   Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Toft DJ, 2011, MOL ENDOCRINOL, V25, P199, DOI 10.1210/me.2010-0164
   Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275
   Werth M, 2010, DEVELOPMENT, V137, P3835, DOI 10.1242/dev.055483
   Xiang XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050781
   Zuo T, 2009, EPIGENOMICS-UK, V1, P331, DOI 10.2217/epi.09.31
NR 44
TC 53
Z9 66
U1 1
U2 31
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD OCT
PY 2013
VL 41
IS 18
BP 8464
EP 8474
DI 10.1093/nar/gkt643
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 236EG
UT WOS:000325776600014
PM 23887935
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Cohen, AL
   Piccolo, SR
   Cheng, L
   Soldi, R
   Han, B
   Johnson, WE
   Bild, AH
AF Cohen, Adam L.
   Piccolo, Stephen R.
   Cheng, Luis
   Soldi, Rafaella
   Han, Bing
   Johnson, W. Evan
   Bild, Andrea H.
TI Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually
   exclusive epigenetic pathways across human cancers
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Epigenetics; Histone acetylation; Histone methylation; mRNA microarray
ID BREAST-CANCER; GENE-EXPRESSION; MESSENGER-RNA; POLYCOMB; SUBTYPES;
   IDENTIFICATION; PROGRESSION; H3K27ME3; TARGET; GROWTH
AB Background: Alterations in epigenetic marks, including methylation or acetylation, are common in human cancers. For many epigenetic pathways, however, direct measures of activity are unknown, making their role in various cancers difficult to assess. Gene expression signatures facilitate the examination of patterns of epigenetic pathway activation across and within human cancer types allowing better understanding of the relationships between these pathways.
   Methods: We used Bayesian regression to generate gene expression signatures from normal epithelial cells before and after epigenetic pathway activation. Signatures were applied to datasets from TCGA, GEO, CaArray, ArrayExpress, and the cancer cell line encyclopedia. For TCGA data, signature results were correlated with copy number variation and DNA methylation changes. GSEA was used to identify biologic pathways related to the signatures.
   Results: We developed and validated signatures reflecting downstream effects of enhancer of zeste homolog 2 (EZH2), histone deacetylase( HDAC) 1, HDAC4, sirtuin 1(SIRT1), and DNA methyltransferase 2(DNMT2). By applying these signatures to data from cancer cell lines and tumors in large public repositories, we identify those cancers that have the highest and lowest activation of each of these pathways. Highest EZH2 activation is seen in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and melanoma, while highest HDAC activity is seen in pharyngeal cancer, kidney cancer, and pancreatic cancer. Across all datasets studied, activation of both EZH2 and HDAC4 is significantly underrepresented. Using breast cancer and glioblastoma as examples to examine intrinsic subtypes of particular cancers, EZH2 activation was highest in luminal breast cancers and proneural glioblastomas, while HDAC4 activation was highest in basal breast cancer and mesenchymal glioblastoma. EZH2 and HDAC4 activation are associated with particular chromosome abnormalities: EZH2 activation with aberrations in genes from the TGF and phosphatidylinositol pathways and HDAC4 activation with aberrations in inflammatory and chemokine related genes.
   Conclusion: Gene expression patterns can reveal the activation level of epigenetic pathways. Epigenetic pathways define biologically relevant subsets of human cancers. EZH2 activation and HDAC4 activation correlate with growth factor signaling and inflammation, respectively, and represent two distinct states for cancer cells. This understanding may allow us to identify targetable drivers in these cancer subsets.
C1 [Cohen, Adam L.; Soldi, Rafaella; Bild, Andrea H.] Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [Piccolo, Stephen R.; Cheng, Luis; Bild, Andrea H.] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA.
   [Piccolo, Stephen R.; Han, Bing; Johnson, W. Evan] Boston Univ, Sch Med, Div Computat Biomed, Boston, MA 02118 USA.
C3 Utah System of Higher Education; University of Utah; Huntsman Cancer
   Institute; Utah System of Higher Education; University of Utah; Boston
   University
RP Cohen, AL (通讯作者)，Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.
EM adam.cohen@hci.utah.edu
OI Johnson, W. Evan/0000-0002-6247-6595
FU National Institute of Health [R01GM085601, R01HG00569];
   Multidisciplinary Cancer Research Training Program award [T32 CA93247]
FX This study was supported by the National Institute of Health
   (R01GM085601, AB and R01HG00569 WEJ) and a Multidisciplinary Cancer
   Research Training Program award (T32 CA93247, AC). The funding agencies
   had no role in the design, in the collection, analysis, and
   interpretation of data, in the writing of the manuscript, or in the
   decision to submit the manuscript for publication. The authors
   acknowledge Patricia Bild and Jessica Jennifer Cohen for inspiring this
   work.
CR Angrisano T, 2011, NUCLEIC ACIDS RES, V39, P1993, DOI 10.1093/nar/gkq864
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Beier CP, 2012, STEM CELLS DEV, V21, P2753, DOI 10.1089/scd.2011.0660
   Benito M, 2004, BIOINFORMATICS, V20, P105, DOI 10.1093/bioinformatics/btg385
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Bondgaard ALRO, 2012, CANCER BIOMARK, V11, P123, DOI 10.3233/CBM-2012-0269
   Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112
   Cai MY, 2011, MOL MED, V17, P12, DOI 10.2119/molmed.2010.00103
   Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Chiba T, 2012, INT J CANCER, V130, P2557, DOI 10.1002/ijc.26264
   Cohen AL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.47
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055
   He LR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-461
   Herrera ACSA, 2012, CANCER IMMUNOL IMMUN, V61, P2193, DOI 10.1007/s00262-012-1283-8
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hussein YR, 2012, HUM PATHOL, V43, P1638, DOI 10.1016/j.humpath.2011.12.004
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Lei WW, 2010, INT J BIOCHEM CELL B, V42, P1489, DOI 10.1016/j.biocel.2010.05.006
   Majdzadeh N, 2008, DEV NEUROBIOL, V68, P1076, DOI 10.1002/dneu.20637
   Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rustici G, 2013, NUCLEIC ACIDS RES, V41, pD987, DOI 10.1093/nar/gks1174
   Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x
   Velasco-Velázquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   Wong JC, 2012, J MED CHEM, V55, P8903, DOI 10.1021/jm3011838
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160
   Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129
   Zheng SC, 2011, NEURO-ONCOLOGY, V13, P280, DOI 10.1093/neuonc/noq190
NR 46
TC 36
Z9 40
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD SEP 30
PY 2013
VL 6
AR 35
DI 10.1186/1755-8794-6-35
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 235ET
UT WOS:000325700000001
PM 24079712
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Schmitt, ML
   Hauser, AT
   Carlino, L
   Pippel, M
   Schulz-Fincke, J
   Metzger, E
   Willmann, D
   Yiu, T
   Barton, M
   Schüle, R
   Sippl, W
   Jung, M
AF Schmitt, Martin L.
   Hauser, Alexander-Thomas
   Carlino, Luca
   Pippel, Martin
   Schulz-Fincke, Johannes
   Metzger, Eric
   Willmann, Dominica
   Yiu, Teresa
   Barton, Michelle
   Schuele, Roland
   Sippl, Wolfgang
   Jung, Manfred
TI Nonpeptidic Propargylamines as Inhibitors of Lysine Specific Demethylase
   1 (LSD1) with Cellular Activity
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HISTONE DEMETHYLASE; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; MECHANISM;
   TARGET
AB Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders. As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer. Here, we report on the discovery of new small molecule inhibitors of LSD1 containing a propargylamine warhead, starting out from lysine containing substrate analogues. On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.
C1 [Schmitt, Martin L.; Hauser, Alexander-Thomas; Schulz-Fincke, Johannes; Jung, Manfred] Univ Freiburg, Inst Pharmaceut Sci, D-79104 Freiburg, Germany.
   [Carlino, Luca; Pippel, Martin; Sippl, Wolfgang] Univ Halle Wittenberg, Dept Pharmaceut Chem, D-06120 Halle, Germany.
   [Metzger, Eric; Willmann, Dominica; Schuele, Roland] Univ Freiburg, Med Ctr, Womens Hosp, Dept Urol, D-79106 Freiburg, Germany.
   [Metzger, Eric; Willmann, Dominica; Schuele, Roland] Univ Freiburg, Med Ctr, Clin Res Ctr, D-79106 Freiburg, Germany.
   [Yiu, Teresa] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Yiu, Teresa; Barton, Michelle] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
C3 University of Freiburg; Martin Luther University Halle Wittenberg;
   University of Freiburg; University of Freiburg; Baylor College of
   Medicine; University of Texas System; UTMD Anderson Cancer Center
RP Jung, M (通讯作者)，Univ Freiburg, Inst Pharmaceut Sci, Albertstr 25, D-79104 Freiburg, Germany.
EM manfred.jung@pharmazie.uni-freiburg.de
RI Pippel, Martin/AGA-8156-2022; Sippl, Wolfgang/P-5944-2014; Schüle,
   Rebecca/B-5763-2019; Jung, Manfred/Q-8029-2016
OI Jung, Manfred/0000-0002-6361-7716; Sippl, Wolfgang/0000-0002-5985-9261;
   Barton, Michelle/0000-0002-4042-1374
FU Deutsche Forschungsgemeinschaft [Ju295/7-1, Si868/4-1, Schu688/11-1]
FX We thank Karin Schmidtkunz for performing the experiements for the
   GI<INF>50</INF> values on MCF7 cells. The authors thank the Deutsche
   Forschungsgemeinschaft for funding (Grants Ju295/7-1, Si868/4-1,
   Schu688/11-1).
CR Benelkebir H, 2011, BIOORGAN MED CHEM, V19, P3709, DOI 10.1016/j.bmc.2011.02.017
   Biel M, 2005, ANGEW CHEM INT EDIT, V44, P3186, DOI 10.1002/anie.200461346
   Binda C, 2010, J AM CHEM SOC, V132, P6827, DOI 10.1021/ja101557k
   Chen Y, 2006, P NATL ACAD SCI USA, V103, P13956, DOI 10.1073/pnas.0606381103
   Culhane JC, 2006, J AM CHEM SOC, V128, P4536, DOI 10.1021/ja0602748
   Culhane JC, 2007, CURR OPIN CHEM BIOL, V11, P561, DOI 10.1016/j.cbpa.2007.07.014
   Forneris F, 2007, J BIOL CHEM, V282, P20070, DOI 10.1074/jbc.C700100200
   Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9
   Hauser AT, 2012, J BIOMOL SCREEN, V17, P18, DOI 10.1177/1087057111423968
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mimasu S, 2008, BIOCHEM BIOPH RES CO, V366, P15, DOI 10.1016/j.bbrc.2007.11.066
   Mimasu S, 2010, BIOCHEMISTRY-US, V49, P6494, DOI 10.1021/bi100299r
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Stavropoulos P, 2006, NAT STRUCT MOL BIOL, V13, P626, DOI 10.1038/nsmb1113
   Suzuki T, 2011, J MED CHEM, V54, P8236, DOI 10.1021/jm201048w
   Ueda R, 2009, J AM CHEM SOC, V131, P17536, DOI 10.1021/ja907055q
   Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896
   Willmann D, 2012, INT J CANCER, V131, P2704, DOI 10.1002/ijc.27555
   Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012
   Yang MJ, 2007, BIOCHEMISTRY-US, V46, P8058, DOI 10.1021/bi700664y
   Yang MJ, 2007, NAT STRUCT MOL BIOL, V14, P535, DOI 10.1038/nsmb1255
   Zhu QS, 2012, AMINO ACIDS, V42, P887, DOI 10.1007/s00726-011-1004-1
NR 25
TC 65
Z9 71
U1 1
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 26
PY 2013
VL 56
IS 18
BP 7334
EP 7342
DI 10.1021/jm400792m
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 295DV
UT WOS:000330097700016
PM 24007511
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Tang, M
   Shen, HX
   Jin, Y
   Lin, T
   Cai, QS
   Pinard, MA
   Biswas, S
   Tran, Q
   Li, GY
   Shenoy, AK
   Tongdee, E
   Lin, SB
   Gu, YM
   Law, BK
   Zhou, L
   Mckenna, R
   Wu, LZ
   Lu, JR
AF Tang, Ming
   Shen, Huangxuan
   Jin, Yue
   Lin, Tong
   Cai, Qingsong
   Pinard, Melissa A.
   Biswas, Shyamasri
   Quyen Tran
   Li, Guangyao
   Shenoy, Anitha K.
   Tongdee, Emily
   Lin, Shuibin
   Gu, Yumei
   Law, Brian K.
   Zhou, Lei
   Mckenna, Robert
   Wu, Lizi
   Lu, Jianrong
TI The Malignant Brain Tumor (MBT) Domain Protein SFMBT1 Is an Integral
   Histone Reader Subunit of the LSD1 Demethylase Complex for Chromatin
   Association and Epithelial-to-mesenchymal Transition
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID GENE-EXPRESSION; BREAST-CANCER; STEM-CELLS; DIFFERENTIATION; REPRESSION;
   SNAIL; TRANSCRIPTION; COREST; DISCOVERY; BINDING
AB Chromatin readers decipher the functional readouts of histone modifications by recruiting specific effector complexes for subsequent epigenetic reprogramming. The LSD1 (also known as KDM1A) histone demethylase complex modifies chromatin and represses transcription in part by catalyzing demethylation of dimethylated histone H3 lysine 4 (H3K4me2), a mark for active transcription. However, none of its currently known subunits recognizes methylated histones. The Snai1 family transcription factors are central drivers of epithelial-to-mesenchymal transition (EMT) by which epithelial cells acquire enhanced invasiveness. Snai1-mediated transcriptional repression of epithelial genes depends on its recruitment of the LSD1 complex and ensuing demethylation of H3K4me2 at its target genes. Through biochemical purification, we identified the MBT domain-containing protein SFMBT1 as a novel component of the LSD1 complex associated with Snai1. Unlike other mammalian MBT domain proteins characterized to date that selectively recognize mono- and dimethylated lysines, SFMBT1 binds di- and trimethyl H3K4, both of which are enriched at active promoters. We show that SFMBT1 is essential for Snai1-dependent recruitment of LSD1 to chromatin, demethylation of H3K4me2, transcriptional repression of epithelial markers, and induction of EMT by TGF beta. Carcinogenic metal nickel is a widespread environmental and occupational pollutant. Nickel alters gene expression and induces EMT. We demonstrate the nickel-initiated effects are dependent on LSD1-SFMBT1-mediated chromatin modification. Furthermore, in human cancer, expression of SFMBT1 is associated with mesenchymal markers and unfavorable prognosis. These results highlight a critical role of SFMBT1 in epigenetic regulation, EMT, and cancer.
C1 [Tang, Ming; Jin, Yue; Lin, Tong; Cai, Qingsong; Pinard, Melissa A.; Biswas, Shyamasri; Shenoy, Anitha K.; Tongdee, Emily; Mckenna, Robert; Lu, Jianrong] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Hlth Canc Ctr, Gainesville, FL 32610 USA.
   [Shen, Huangxuan; Li, Guangyao; Lin, Shuibin; Gu, Yumei; Zhou, Lei; Wu, Lizi] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Hlth Canc Ctr, Gainesville, FL 32610 USA.
   [Law, Brian K.] Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Hlth Canc Ctr, Gainesville, FL 32610 USA.
   [Tang, Ming; Lin, Tong; Li, Guangyao; Zhou, Lei; Wu, Lizi; Lu, Jianrong] Univ Florida, Genet & Genom Grad Program, Genet Inst, Gainesville, FL 32610 USA.
   [Shen, Huangxuan] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [Quyen Tran] Agnes Scott Coll, Decatur, GA 30030 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida; Sun Yat Sen University
RP Wu, LZ (通讯作者)，Univ Florida, Genet & Genom Grad Program, Genet Inst, Gainesville, FL 32610 USA.
EM lzwu@ufl.edu; jrlu@ufl.edu
RI Li, Guangyao/I-8241-2015; Law, Brian/L-6043-2019; Lu,
   Jianrong/F-5240-2013
OI Law, Brian/0000-0002-8411-6531; Lu, Jianrong/0000-0002-4969-6040; Wu,
   Lizi/0000-0002-0076-2617
FU National Institutes of Health [R01CA137021]; Florida Bankhead-Coley
   Cancer Research Program [09BN-12-23092, 2BT01]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01CA137021 (NCI; to J. L.). This work was also supported
   by the Florida Bankhead-Coley Cancer Research Program (09BN-12-23092 and
   2BT01).
CR Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246
   Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Batlle R, 2013, ONCOGENE, V32, P3381, DOI 10.1038/onc.2012.342
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bonasio R, 2010, SEMIN CELL DEV BIOL, V21, P221, DOI 10.1016/j.semcdb.2009.09.010
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Chervona Y, 2012, FREE RADICAL BIO MED, V53, P1041, DOI 10.1016/j.freeradbiomed.2012.07.020
   Cui SAY, 2011, MOL CELL BIOL, V31, P3298, DOI 10.1128/MCB.05310-11
   Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635
   de Frutos CA, 2009, EMBO J, V28, P686, DOI 10.1038/emboj.2009.23
   Ding J, 2013, DIGEST DIS SCI, V58, P1581, DOI 10.1007/s10620-012-2552-2
   Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593
   Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   James LI, 2013, NAT CHEM BIOL, V9, P184, DOI [10.1038/nchembio.1157, 10.1038/NCHEMBIO.1157]
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Koester-Eiserfunke N, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002017
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lan F, 2007, NATURE, V448, P718, DOI 10.1038/nature06034
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Lee SH, 2009, NEOPLASIA, V11, P22, DOI 10.1593/neo.81006
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin SB, 2013, J BIOL CHEM, V288, P6238, DOI 10.1074/jbc.M112.429605
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11
   Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020
   Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436
   Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Su ST, 2009, MOL CELL BIOL, V29, P1421, DOI 10.1128/MCB.01158-08
   Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tsai WW, 2008, MOL CELL BIOL, V28, P5139, DOI 10.1128/MCB.00287-08
   Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Wu CH, 2012, J BIOL CHEM, V287, P25292, DOI 10.1074/jbc.M111.291195
   Wu SM, 2007, FEBS LETT, V581, P3289, DOI 10.1016/j.febslet.2007.06.025
   Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109
   Xu J, 2013, P NATL ACAD SCI USA, V110, P6518, DOI 10.1073/pnas.1303976110
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012
   Yatim A, 2012, MOL CELL, V48, P445, DOI 10.1016/j.molcel.2012.08.022
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   Zhang J, 2013, GENE DEV, V27, P749, DOI 10.1101/gad.210963.112
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 56
TC 38
Z9 45
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 20
PY 2013
VL 288
IS 38
BP 27680
EP 27691
DI 10.1074/jbc.M113.482349
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 302IG
UT WOS:000330597300061
PM 23928305
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Lewis, JR
   McNab, TJ
   Liew, LJ
   Tan, J
   Hudson, P
   Wang, JZ
   Prince, RL
AF Lewis, Joshua R.
   McNab, Tegan J.
   Liew, Lawrence J.
   Tan, Jeremy
   Hudson, Phillip
   Wang, Jenny Z.
   Prince, Richard L.
TI DNA methylation within the I.4 promoter region correlates with CYPl19A1
   gene expression in human <i>ex vivo</i> mature omental and subcutaneous
   adipocytes
SO BMC MEDICAL GENETICS
LA English
DT Article
DE Aromatase gene expression; DNA methylation; Circulating estradiol; Bone
   structure; Epigenetics
ID CYP19 AROMATASE GENE; BREAST-CANCER; ADIPOSE-TISSUE; BONE-STRUCTURE;
   MESSENGER-RNA; CPG ISLANDS; P450 GENE; CELLS; ESTROGEN; CLONING
AB Background: DNA methylation at specific CpG sites within gene promoter regions is known to regulate transcriptional activity in vitro. In human adipose tissue, basal transcription of the aromatase (CYP19A1) gene is driven primarily by the I.4 promoter however the role of DNA methylation in regulating expression in ex vivo mature adipocytes is unknown. This observational study reports the correlation of DNA methylation within the I.4 promoter region of human mature subcutaneous and omental adipocytes with aromatase expression and body composition measures.
   Methods: Omental and subcutaneous adipose tissue were collected from 25 obese subjects undergoing bariatric surgery and the mature adipocyte fraction purified. DNA methylation status of 5 CpG sites within a 550 base pair region encompassing the transcription start site (TSS) of promoter I.4 was determined using pyrosequencing. Relative aromatase and I.4 promoter specific mRNA expression was determined by qRT-PCR and whole body DXA performed in 25 participants.
   Results: Site-specific DNA methylation varied from 21 +/- 10% to 81 +/- 11%. In omental adipocytes percentage methylation at the I.4.1 and I.4.2 CpG sites, but not other nearby sites, was negatively correlated with relative aromatase mRNA expression (R = -0.52, P = 0.017 and R = -0.52, P = 0.015). In contrast subcutaneous adipocytes percentage DNA methylation at the I.4.3 and I.4.5 sites were positively correlated with relative aromatase mRNA expression (R = 0.47, P = 0.022 and R = 0.55, P = 0.004). In a small subset of patients DNA methylation at the I.4.5 site was also positively correlated with whole body lean mass, bone mineral content and density.
   Conclusions: In conclusion in mature adipocytes, the primary source of estradiol after menopause, increasing DNA methylation was correlated with aromatase mRNA expression and thus estradiol biosynthesis. These findings support a tissue-specific epigenetic regulation of the basal promoter activity in mature adipocytes; the mechanisms influencing this regulation and its physiological role remain to be elucidated.
C1 [Lewis, Joshua R.; McNab, Tegan J.; Liew, Lawrence J.; Wang, Jenny Z.; Prince, Richard L.] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia.
   [Lewis, Joshua R.; McNab, Tegan J.; Liew, Lawrence J.; Wang, Jenny Z.; Prince, Richard L.] Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia.
   [Tan, Jeremy] Sir Charles Gairdner Hosp, Dept Gen Surg, Nedlands, WA 6009, Australia.
   [Hudson, Phillip] QIAGEN Pty Ltd, Doncaster, Vic, Australia.
C3 University of Western Australia; Sir Charles Gairdner Hospital;
   University of Western Australia; University of Western Australia; Sir
   Charles Gairdner Hospital; QIAGEN Pty Ltd
RP Lewis, JR (通讯作者)，Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia.
EM joshua.lewis@uwa.edu.au
RI Liew, Lawrence/ABB-7259-2020; Lewis, Joshua/D-5077-2013
OI Liew, Lawrence/0000-0002-5962-3240
FU National Health and Medical Research Council (NHMRC) [513472]; Sir
   Charles Gairdner Hospital Research Advisory Committee Grant; Raine
   Medical Research Foundation Priming Grant
FX We would like to thank all the participants and surgery staff for
   providing the samples for this study. We acknowledge the Australian
   Genome Research Facility (AGRF) for additional pyrosequencing. This work
   was supported by National Health and Medical Research Council (NHMRC)
   grant (Project grant 513472) and a Sir Charles Gairdner Hospital
   Research Advisory Committee Grant. The salary of JRL is supported by a
   Raine Medical Research Foundation Priming Grant. These funding agencies
   had no input into any aspect of the design and management of this study.
CR Agarwal VR, 1997, J CLIN ENDOCR METAB, V82, P70, DOI 10.1210/jc.82.1.70
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Blouin K, 2009, AM J PHYSIOL-ENDOC M, V296, pE244, DOI 10.1152/ajpendo.00039.2008
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5
   Chen D, 2009, CANCER LETT, V273, P15, DOI 10.1016/j.canlet.2008.05.038
   Chen K, 2011, MOL PHARMACOL, V79, P308, DOI 10.1124/mol.110.067439
   CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Demura M, 2008, REPROD SCI, V15, P1044, DOI 10.1177/1933719108322441
   Dick IM, 2005, AM J PHYSIOL-ENDOC M, V288, pE989, DOI 10.1152/ajpendo.00550.2004
   Dubois Severine G., 2008, V449, P69, DOI 10.1007/978-1-60327-169-1_5
   Fürbass R, 2008, MOL REPROD DEV, V75, P1, DOI 10.1002/mrd.20756
   Fürbass R, 2001, EUR J BIOCHEM, V268, P1222, DOI 10.1046/j.1432-1327.2001.01988.x
   Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292
   HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066
   Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004
   Jeong JH, 2010, MOL CELL BIOL, V30, P2365, DOI 10.1128/MCB.00672-09
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456
   Knower KC, 2010, MOL CELL ENDOCRINOL, V321, P123, DOI 10.1016/j.mce.2010.02.035
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Luco RF, 2011, CELL, V144, P16, DOI 10.1016/j.cell.2010.11.056
   MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Mullin BH, 2011, CALCIFIED TISSUE INT, V89, P464, DOI 10.1007/s00223-011-9535-8
   Narasimhan Supraja, 2009, BMC Res Notes, V2, P104, DOI 10.1186/1756-0500-2-104
   PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244
   Pogribny IP, 2000, CANCER RES, V60, P588
   Prince RL, 2007, BONE, V41, P33, DOI 10.1016/j.bone.2007.03.014
   Riancho JA, 2007, J CLIN ENDOCR METAB, V92, P660, DOI 10.1210/jc.2006-1616
   Riancho JA, 2009, J BONE MINER RES, V24, P1709, DOI [10.1359/JBMR.090404, 10.1359/jbmr.090404]
   Rivière G, 2011, EPIGENETICS-US, V6, P479, DOI 10.4161/epi.6.4.14961
   RYAN KJ, 1959, J BIOL CHEM, V234, P268
   Sebastian S, 2002, MOL ENDOCRINOL, V16, P2243, DOI 10.1210/me.2002-0123
   Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600
   Shigematsu M, 1999, CELL STRUCT FUNCT, V24, P89, DOI 10.1247/csf.24.89
   Shukla S, 2011, NATURE, V479, P74, DOI 10.1038/nature10442
   Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059
   Spitschak M, 2012, GEN COMP ENDOCR, V178, P37, DOI 10.1016/j.ygcen.2012.04.001
   THOMPSON EA, 1974, J BIOL CHEM, V249, P5364
   TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Vanselow J, 2008, EXP CLIN ENDOCR DIAB, V116, P437, DOI 10.1055/s-2008-1058083
   Vanselow J, 2005, MOL CELL ENDOCRINOL, V233, P57, DOI 10.1016/j.mce.2005.01.007
   Wang J, 2011, EURASIP J WIREL COMM, DOI 10.1155/2011/785437
   ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340
NR 50
TC 10
Z9 12
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD AUG 30
PY 2013
VL 14
AR 87
DI 10.1186/1471-2350-14-87
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 209VJ
UT WOS:000323788300001
PM 24128150
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Sun, SY
   Noviski, A
   Yu, XQ
AF Sun, Shuying
   Noviski, Aaron
   Yu, Xiaoqing
TI MethyQA: a pipeline for bisulfite-treated methylation sequencing quality
   assessment
SO BMC BIOINFORMATICS
LA English
DT Article
DE DNA methylation; Next generation sequencing; Alignment; BRAT; Quality
   assessment
ID DNA METHYLATION; BREAST-CANCER; CPG ISLANDS; HYPERMETHYLATION;
   PLURIPOTENT; EFFICIENT; ALIGNMENT; MARKERS; COLON; MAPS
AB Background: DNA methylation is an epigenetic event that adds a methyl-group to the 5' cytosine. This epigenetic modification can significantly affect gene expression in both normal and diseased cells. Hence, it is important to study methylation signals at the single cytosine site level, which is now possible utilizing bisulfite conversion technique (i.e., converting unmethylated Cs to Us and then to Ts after PCR amplification) and next generation sequencing (NGS) technologies. Despite the advances of NGS technologies, certain quality issues remain. Some of the more prevalent quality issues involve low per-base sequencing quality at the 3' end, PCR amplification bias, and bisulfite conversion rates. Therefore, it is important to conduct quality assessment before downstream analysis. To the best of our knowledge, no existing software packages can generally assess the quality of methylation sequencing data generated based on different bisulfite-treated protocols.
   Results: To conduct the quality assessment of bisulfite methylation sequencing data, we have developed a pipeline named MethyQA. MethyQA combines currently available open-source software packages with our own custom programs written in Perl and R. The pipeline can provide quality assessment results for tens of millions of reads in under an hour. The novelty of our pipeline lies in its examination of bisulfite conversion rates and of the DNA sequence structure of regions that have different conversion rates or coverage.
   Conclusions: MethyQA is a new software package that provides users with a unique insight into the methylation sequencing data they are researching. It allows the users to determine the quality of their data and better prepares them to address the research questions that lie ahead. Due to the speed and efficiency at which MethyQA operates, it will become an important tool for studies dealing with bisulfite methylation sequencing data.
C1 [Sun, Shuying; Yu, Xiaoqing] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Sun, Shuying] Texas State Univ, Dept Math, San Marcos, TX 78666 USA.
   [Noviski, Aaron] Case Western Reserve Univ, Dept Elect Engn & Comp Sci, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; Texas State
   University System; Texas State University San Marcos; University System
   of Ohio; Case Western Reserve University
RP Sun, SY (通讯作者)，Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
EM ssun5211@yahoo.com
RI Yu, Xiaoqing/E-2388-2013
FU Case Comprehensive Cancer Center, Case Western Reserve University
FX This work was supported by Dr. Sun's start-up funds provided by Case
   Comprehensive Cancer Center, Case Western Reserve University. The
   authors appreciate the three reviewers' comments and suggestions, which
   have helped us to improve the manuscript greatly.
CR [Anonymous], 2009, Fastx-toolkit
   [Anonymous], 2010, FASTQC
   Brunner AL, 2009, GENOME RES, V19, P1044, DOI 10.1101/gr.088773.108
   Chen PY, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-203
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Ecker JR, 2010, NAT METHODS, V7, P435, DOI 10.1038/nmeth0610-435
   Esteller M, 2001, CANCER RES, V61, P3225
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Harris EY, 2012, BIOINFORMATICS, V28, P1795, DOI 10.1093/bioinformatics/bts264
   Harris EY, 2010, BIOINFORMATICS, V26, P572, DOI 10.1093/bioinformatics/btp706
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Khalili A, 2007, CANCER INFORM, V3, P43
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144
   Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Martin M, 2011, EMBnet J, V17, P10, DOI [DOI 10.14806/EJ.17.1.200, 10.1089/cmb.2017.0096, 10.14806/ej.17.1.200]
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Pedersen B, 2011, BIOINFORMATICS, V27, P2435, DOI 10.1093/bioinformatics/btr394
   Strathdee G, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004222
   Suijkerbuijk KPM, 2011, ANN ONCOL, V22, P24, DOI 10.1093/annonc/mdq305
   Sun SY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-54
   Sun ZF, 2012, BIOINFORMATICS, V28, P2180, DOI 10.1093/bioinformatics/bts337
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Wei SH, 2003, ANN NY ACAD SCI, V983, P243, DOI 10.1111/j.1749-6632.2003.tb05979.x
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2006, CLIN CANCER RES, V12, P7205, DOI 10.1158/1078-0432.CCR-06-2531
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
   Xi YP, 2009, BMC BIOINFORMATICS, V10, DOI [10.1186/1471-2105-10-S1-S58, 10.1186/1471-2105-10-232]
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yu XQ, 2012, BIODATA MIN, V5, DOI 10.1186/1756-0381-5-6
   Zhu WZ, 2010, INT J CANCER, V126, P474, DOI 10.1002/ijc.24728
   Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967
NR 43
TC 17
Z9 18
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD AUG 23
PY 2013
VL 14
AR 259
DI 10.1186/1471-2105-14-259
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 209WL
UT WOS:000323791200001
PM 23968174
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Alakhova, DY
   Zhao, Y
   Li, S
   Kabanov, AV
AF Alakhova, Daria Y.
   Zhao, Yi
   Li, Shu
   Kabanov, Alexander V.
TI Effect of Doxorubicin/Pluronic SP1049C on Tumorigenicity,
   Aggressiveness, DNA Methylation and Stem Cell Markers in Murine Leukemia
SO PLOS ONE
LA English
DT Article
ID PLURONIC BLOCK-COPOLYMERS; TUMOR-INITIATING CELLS; BREAST-CANCER CELLS;
   ACUTE MYELOID-LEUKEMIA; ALDEHYDE DEHYDROGENASE; EPIGENETIC CHANGES;
   CD133; MDR; PATHWAY; IDENTIFICATION
AB Purpose: Pluronic block copolymers are potent sensitizers of multidrug resistant cancers. SP1049C, a Pluronic-based micellar formulation of doxorubicin (Dox) has completed Phase II clinical trial and demonstrated safety and efficacy in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. This study elucidates the ability of SP1049C to deplete cancer stem cells (CSC) and decrease tumorigenicity of cancer cells in vivo.
   Experimental Design: P388 murine leukemia ascitic tumor was grown in BDF1 mice. The animals were treated with: (a) saline, (b) Pluronics alone, (c) Dox or (d) SP1049C. The ascitic cancer cells were isolated at different passages and examined for 1) in vitro colony formation potential, 2) in vivo tumorigenicity and aggressiveness, 3) development of drug resistance and Wnt signaling activation 4) global DNA methylation profiles, and 5) expression of CSC markers.
   Results: SP1049C treatment reduced tumor aggressiveness, in vivo tumor formation frequency and in vitro clonogenic potential of the ascitic cells compared to drug, saline and polymer controls. SP1049C also prevented overexpression of BCRP and activation of Wnt-beta-catenin signaling observed with Dox alone. Moreover, SP1049C significantly altered the DNA methylation profiles of the cells. Finally, SP1049C decreased CD133(+) P388 cells populations, which displayed CSC-like properties and were more tumorigenic compared to CD133(-) cells.
   Conclusions: SP1049C therapy effectively suppresses the tumorigenicity and aggressiveness of P388 cells in a mouse model. This may be due to enhanced activity of SP1049C against CSC and/or altered epigenetic regulation restricting appearance of malignant cancer cell phenotype.
C1 [Alakhova, Daria Y.; Zhao, Yi; Li, Shu; Kabanov, Alexander V.] Univ Nebraska Med Ctr, Coll Pharm, Ctr Drug Delivery & Nanomed, Omaha, NE USA.
   [Alakhova, Daria Y.; Zhao, Yi; Li, Shu; Kabanov, Alexander V.] Univ Nebraska Med Ctr, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE USA.
   [Kabanov, Alexander V.] Moscow MV Lomonosov State Univ, Fac Chem, Lab Chem Design Bionanomat, Moscow 117234, Russia.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   Lomonosov Moscow State University
RP Kabanov, AV (通讯作者)，Univ N Carolina, Ctr Nanotechnol Drug Delivery, Chapel Hill, NC 27515 USA.
EM kabanov@email.unc.edu
RI Zhao, Yi/O-9117-2015; Kabanov, Alexander/N-3356-2013
OI Kabanov, Alexander/0000-0002-3665-946X
FU National Institutes of Health [2RO1 CA89225, UO1 CA151806]; Center of
   Biomedical Research Excellence (COBRE) Nebraska Center for Nanomedicine
   [1P20RR021937]; China Scholarship Council PhD Scholarship
FX This study was supported by the National Institutes of Health 2RO1
   CA89225, UO1 CA151806, Center of Biomedical Research Excellence (COBRE)
   Nebraska Center for Nanomedicine 1P20RR021937, and a China Scholarship
   Council PhD Scholarship (Yi Zhao). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alakhov V, 1999, COLLOID SURFACE B, V16, P113, DOI 10.1016/S0927-7765(99)00064-8
   Alakhov VY, 1996, BIOCONJUGATE CHEM, V7, P209, DOI 10.1021/bc950093n
   Alakhova DY, 2010, J CONTROL RELEASE, V142, P89, DOI 10.1016/j.jconrel.2009.09.026
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Batrakova E, 1999, PHARM RES-DORDR, V16, P1373, DOI 10.1023/A:1018942823676
   Batrakova EV, 2006, MOL PHARMACEUT, V3, P113, DOI 10.1021/mp050050g
   Batrakova EV, 2004, PHARM RES-DORDR, V21, P2226, DOI 10.1007/s11095-004-7675-5
   Batrakova EV, 2003, J PHARMACOL EXP THER, V304, P845, DOI 10.1124/jpet.102.043307
   Batrakova EV, 2001, BRIT J CANCER, V85, P1987, DOI 10.1054/bjoc.2001.2165
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Burger PE, 2009, STEM CELLS, V27, P2220, DOI 10.1002/stem.135
   Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)02125-0
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440
   Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011
   Cox CV, 2009, BLOOD, V113, P3287, DOI 10.1182/blood-2008-04-154187
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Danson S, 2004, BRIT J CANCER, V90, P2085, DOI 10.1038/sj.bjc.6601856
   DAWE CJ, 1957, AM J PATHOL, V33, P603
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Doré BT, 1998, CANCER CHEMOTH PHARM, V41, P275, DOI 10.1007/s002800050740
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Goldman SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018269
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599
   HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lin J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049277
   Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67
   Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526
   Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317
   Minko T, 2005, J CONTROL RELEASE, V105, P269, DOI 10.1016/j.jconrel.2005.03.019
   Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283
   Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Rappa G, 2008, STEM CELLS, V26, P3008, DOI 10.1634/stemcells.2008-0601
   Rattis FM, 2004, CURR OPIN HEMATOL, V11, P88, DOI 10.1097/01.moh.0000133649.61121.ec
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rieger ME, 2010, MOL CELL BIOL, V30, P4267, DOI 10.1128/MCB.01418-09
   Robinson MD, 2007, BIOINFORMATICS, V23, P2881, DOI 10.1093/bioinformatics/btm453
   Rodenhiser DI, 2009, CLIN EXP METASTAS, V26, P5, DOI 10.1007/s10585-008-9166-2
   Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017
   Sharma AK, 2008, J CONTROL RELEASE, V131, P220, DOI 10.1016/j.jconrel.2008.07.031
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994
   TODOROVA N, 2003, BIOTECHNOL BIOTECHNO, V17, P151
   Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949
   Valle JW, 2011, INVEST NEW DRUG, V29, P1029, DOI 10.1007/s10637-010-9399-1
   Venne A, 1996, CANCER RES, V56, P3626
   Waud WR, 2011, CANCER DRUG DISCOV D, P23, DOI 10.1007/978-1-60761-968-0_2
   Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353
   Zöller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023
NR 65
TC 66
Z9 73
U1 0
U2 42
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2013
VL 8
IS 8
AR e72238
DI 10.1371/journal.pone.0072238
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 205ER
UT WOS:000323425700154
PM 23977261
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Askari, M
   Sobti, RC
   Nikbakht, M
   Sharma, SC
AF Askari, Marjan
   Sobti, Ranbir Chander
   Nikbakht, Mohsen
   Sharma, Suresh C.
TI Promoter hypermethylation of tumour suppressor genes (<i>p14/ARF</i> and
   <i>p16/INK4a</i>): case-control study in North Indian population
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Breast cancer; Hypermethylation; Tumour suppressor genes; p14/ARF;
   p16/INK4a
ID SQUAMOUS-CELL CARCINOMA; CPG ISLAND HYPERMETHYLATION; BREAST-CANCER
   PATIENTS; DNA METHYLATION; P16 HYPERMETHYLATION; P16(INK4A) GENES;
   LUNG-CANCER; FHIT GENE; P14(ARF); INACTIVATION
AB The epigenetic modifications have been reported to be key factors in breast carcinogenesis. In the current study, it has been tried to determine the methylation status of two tumour suppressor genes p14/ARF and p16/INK4a in 150 breast cancer patients as well as 150 controls by using MSP-PCR. There was, highly significant difference in methylation of p14/ARF and p16/INK4a (P = 0.000) between patients and controls. Methylation of both the genes together significantly increased the risk of breast cancer by 12.31 folds. The present study concludes that hypermethylation of p14/ARF and p16/INK4a promoters demonstrate significant association with the risk of breast cancer, hence indicating these as important tumour suppressor genes involved in the pathogenesis of breast cancer in North Indian population (i.e. Punjab, Haryana, Uttar Pradesh, Himachal Pradesh as well as Union Territory of Chandigarh).
C1 [Askari, Marjan; Sobti, Ranbir Chander; Nikbakht, Mohsen] Panjab Univ, Dept Biotechnol, Chandigarh 160014, India.
   [Nikbakht, Mohsen] Post Grad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh, India.
   [Sharma, Suresh C.] Post Grad Inst Med Educ & Res, Dept Radiotherapy & Oncol, Chandigarh, India.
C3 Panjab University; Post Graduate Institute of Medical Education &
   Research (PGIMER), Chandigarh; Post Graduate Institute of Medical
   Education & Research (PGIMER), Chandigarh
RP Sobti, RC (通讯作者)，Panjab Univ, Dept Biotechnol, Chandigarh 160014, India.
EM rcsobti@pu.ac.in
RI sobti, ranbir/AAX-8037-2021; nikbakht, mohsen/O-9391-2016
OI nikbakht, mohsen/0000-0001-6621-5424
CR Agarwal G, 2008, BREAST CARE, V3, P21, DOI 10.1159/000115288
   Agarwal G, 2009, WORLD J SURG, V33, P2069, DOI 10.1007/s00268-009-0150-z
   Badal V, 2008, CELL CYCLE, V7, P112, DOI 10.4161/cc.7.1.5137
   Bagadi SAR, 2008, LIFE SCI, V82, P1288, DOI 10.1016/j.lfs.2008.04.020
   Brown VL, 2004, J INVEST DERMATOL, V122, P1284, DOI 10.1111/j.0022-202X.2004.22501.x
   Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230
   Chang-Claude J, 2007, CANCER EPIDEM BIOMAR, V16, P740, DOI 10.1158/1055-9965.EPI-06-0829
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Ding Y, 2003, WORLD J GASTROENTERO, V9, P423, DOI 10.3748/wjg.v9.i3.423
   Dominguez G, 2003, MUTAT RES-FUND MOL M, V530, P9, DOI 10.1016/S0027-5107(03)00133-7
   Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098
   Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133
   Elisei R, 1998, CANCER, V83, P2185, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Hsu HS, 2004, CLIN CANCER RES, V10, P4734, DOI 10.1158/1078-0432.CCR-03-0704
   Ishida E, 2005, ORAL ONCOL, V41, P614, DOI 10.1016/j.oraloncology.2005.02.003
   Kawamoto K, 2006, BIOCHEM BIOPH RES CO, V339, P790, DOI 10.1016/j.bbrc.2005.11.072
   Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8
   Maeda K, 2003, ONCOL REP, V10, P935
   McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624
   Murphy N, 2004, VIRCHOWS ARCH, V445, P610, DOI 10.1007/s00428-004-1111-4
   QUELLE DE, 1995, CELL, V83, P993
   Raish M, 2009, TRANSL ONCOL, V2, P264, DOI 10.1593/tlo.09148
   Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457
   Roman-Gomez J, 2006, LEUKEMIA, V20, P1445, DOI 10.1038/sj.leu.2404257
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072
   Shim YH, 2003, CANCER LETT, V190, P213, DOI 10.1016/S0304-3835(02)00613-4
   Vallian S, 2009, J CANCER RES CLIN, V135, P991, DOI 10.1007/s00432-008-0534-8
   Worm J, 2002, J ORAL PATHOL MED, V31, P443, DOI 10.1034/j.1600-0714.2002.00034.x
   Xing EP, 1999, CLIN CANCER RES, V5, P2704
   Zhao Ying-fang, 2010, Chinese Journal of Pathology, V39, P377, DOI 10.3760/cma.j.issn.0529-5807.2010.06.004
   Zheng SC, 2004, CANCER RES, V64, P2000, DOI 10.1158/0008-5472.CAN-03-2387
NR 44
TC 15
Z9 15
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD AUG
PY 2013
VL 40
IS 8
BP 4921
EP 4928
DI 10.1007/s11033-013-2592-5
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 191DH
UT WOS:000322392300030
PM 23712779
DA 2025-01-12
ER

PT J
AU Hsu, PY
   Hsu, HK
   Lan, X
   Juan, LR
   Yan, PS
   Labanowska, J
   Heerenna, N
   Hsiao, TH
   Chiu, YC
   Chen, YD
   Liu, YL
   Li, L
   Li, R
   Thompson, IM
   Nephew, KP
   Sharp, ZD
   Kirma, NB
   Jin, VX
   Huang, THM
AF Hsu, Pei-Yin
   Hsu, Hang-Kai
   Lan, Xun
   Juan, Liran
   Yan, Pearlly S.
   Labanowska, Jadwiga
   Heerenna, Nyla
   Hsiao, Tzu-Hung
   Chiu, Yu-Chiao
   Chen, Yidong
   Liu, Yunlong
   Li, Lang
   Li, Rong
   Thompson, Ian M.
   Nephew, Kenneth P.
   Sharp, Zelton D.
   Kirma, Nameer B.
   Jin, Victor X.
   Huang, Tim H. -M.
TI Amplification of Distant Estrogen Response Elements Deregulates Target
   Genes Associated with Tamoxifen Resistance in Breast Cancer
SO CANCER CELL
LA English
DT Article
ID COPY NUMBER; 17Q23 AMPLICON; DNA; HYBRIDIZATION; TRANSCRIPTION;
   EPIGENETICS; SENSITIVITY; DISRUPTION; EVOLUTION; GENETICS
AB A causal role of gene amplification in tumorigenesis is well known, whereas amplification of DNA regulatory elements as an oncogenic driver remains unclear. In this study, we integrated next-generation sequencing approaches to map distant estrogen response elements (DEREs) that remotely control the transcription of target genes through chromatin proximity. Two densely mapped DERE regions located on chromosomes 17q23 and 20q13 were frequently amplified in estrogen receptor-alpha-positive luminal breast cancer. These aberrantly amplified DEREs deregulated target gene expression potentially linked to cancer development and tamoxifen resistance. Progressive accumulation of DERE copies was observed in normal breast progenitor cells chronically exposed to estrogenic chemicals. These findings may extend to other DNA regulatory elements, the amplification of which can profoundly alter target transcriptome during tumorigenesis.
C1 [Hsu, Pei-Yin; Hsu, Hang-Kai; Li, Rong; Sharp, Zelton D.; Kirma, Nameer B.; Huang, Tim H. -M.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.
   [Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Urol, San Antonio, TX 78245 USA.
   [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Epidemiol & Biostat, San Antonio, TX 78245 USA.
   [Hsiao, Tzu-Hung; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Greehey Childrens Canc Res Inst, San Antonio, TX 78245 USA.
   [Chiu, Yu-Chiao] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 106, Taiwan.
   [Lan, Xun] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA.
   [Yan, Pearlly S.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Labanowska, Jadwiga; Heerenna, Nyla] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA.
   [Liu, Yunlong; Li, Lang] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
   [Liu, Yunlong; Li, Lang] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Nephew, Kenneth P.] Indiana Univ Sch Med, Bloomington, IN 47405 USA.
C3 Cancer Therapy & Research Center; University of Texas System; University
   of Texas Health Science Center at San Antonio; Cancer Therapy & Research
   Center; University of Texas System; University of Texas Health Science
   Center at San Antonio; University of Texas System; University of Texas
   Health Science Center at San Antonio; Cancer Therapy & Research Center;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; Cancer Therapy & Research Center; National Taiwan
   University; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; University System of Ohio; Ohio
   State University; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Bloomington
RP Huang, THM (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.
EM huangt3@uthscsa.edu
RI Yan, Pearlly/E-4339-2011
OI Chiu, Yu-Chiao/0000-0003-1647-8634; Lan, Xun/0000-0002-6523-046X;
   Thompson, Ian/0000-0003-0833-952X
FU Gene and Environment Initiative [R01 CA069065, R01 ES017594, U01
   ES015986]; Integrative Cancer Biology Program [U54 CA113001]; Cancer
   Center Support Grant at the US National Institutes of Health [P30
   CA054174]
FX We would like to thank the Genomic Sequencing Facility of the Greehey
   Children's Cancer Research Institute, University of Texas Health Science
   Center at San Antonio for next-generation sequencing. This work was
   supported by grants R01 CA069065, R01 ES017594, U01 ES015986 (Gene and
   Environment Initiative), U54 CA113001 (Integrative Cancer Biology
   Program), and P30 CA054174 (Cancer Center Support Grant) at the US
   National Institutes of Health and by generous gifts from the Cancer
   Therapy and Research Center Foundation and the Voelcker Fund.
CR Almstrup K, 2002, ENVIRON HEALTH PERSP, V110, P743, DOI 10.1289/ehp.02110743
   Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2
   Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744
   Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547
   Bilal E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038575
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   De S, 2011, NAT BIOTECHNOL, V29, P1103, DOI 10.1038/nbt.2030
   De S, 2011, NAT STRUCT MOL BIOL, V18, P950, DOI 10.1038/nsmb.2089
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339
   Hagège H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243
   Hampton OA, 2009, GENOME RES, V19, P167, DOI 10.1101/gr.080259.108
   Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200
   Han W, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-92
   Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914
   Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105
   Jiang XG, 2006, ENDOCRINOLOGY, V147, P1419, DOI 10.1210/en.2005-0996
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Kim J, 2004, GENOMICS, V84, P47, DOI 10.1016/j.ygeno.2004.02.007
   Knuesel MT, 2009, MOL CELL BIOL, V29, P650, DOI 10.1128/MCB.00993-08
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Li L, 2007, J MOL ENDOCRINOL, V38, P569, DOI 10.1677/JME-07-0003
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030
   Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049
   Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124
   Mitchell JA, 2008, GENE DEV, V22, P20, DOI 10.1101/gad.454008
   Mohr J, 2011, BLOOD, V117, P1622, DOI 10.1182/blood-2010-08-300160
   Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298
   Nikolsky Y, 2008, CANCER RES, V68, P9532, DOI 10.1158/0008-5472.CAN-08-3082
   Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771
   SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0
   Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126
   Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273
   Vandenberg LN, 2006, J STEROID BIOCHEM, V101, P263, DOI 10.1016/j.jsbmb.2006.06.028
   Visel A, 2009, NATURE, V461, P199, DOI 10.1038/nature08451
   Wang LH, 2006, CANCER CELL, V10, P487, DOI 10.1016/j.ccr.2006.09.015
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
NR 49
TC 44
Z9 52
U1 0
U2 27
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD AUG 12
PY 2013
VL 24
IS 2
BP 197
EP 212
DI 10.1016/j.ccr.2013.07.007
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 201KT
UT WOS:000323141200009
PM 23948299
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Deb, G
   Thakur, VS
   Gupta, S
AF Deb, Gauri
   Thakur, Vijay S.
   Gupta, Sanjay
TI Multifaceted role of EZH2 in breast and prostate tumorigenesis:
   Epigenetics and beyond
SO EPIGENETICS
LA English
DT Article
DE EZH2; PRC2 complex; breast cancer; prostate cancer; H3K27
   trimethylation; androgen receptor; estrogen receptor
ID GROUP PROTEIN EZH2; POLYCOMB-REPRESSIVE COMPLEX; H3 LYSINE 27; HISTONE
   METHYLTRANSFERASE EZH2; TUMOR-SUPPRESSOR GENES; ANDROGEN RECEPTOR;
   ESTROGEN-RECEPTOR; SOMATIC MUTATIONS; DOWN-REGULATION; NONCODING RNA
AB Overexpression of EZH2 and other PRC2 subunits, such as SUZ12, is associated with tumor progression and poor prognosis in several human malignancies. Nevertheless, the underlying mechanisms driving aberrant EZH2 expression are poorly understood. This review provides molecular insights into the essential role of EZH2 in breast and prostate tumorigenesis. We addressed the current understanding on the oncogenic role of EZH2, with an emphasis on: (1) the less known PRC2-independent role of EZH2 in gene activation, in addition to its canonical role in transcriptional silencing as a histone methyltransferase catalyzing the trimethylation of histone H3 at lysine 27; (2) causes and consequences of its deregulation in tumor cells and; (3) collaboration of EZH2 with other epigenetic and hormone receptor-mediated oncogenic signaling pathways. We also summarize how EZH2 has emerged as a promising therapeutic target in hormone-refractory cancers and the prospects for integrating EZH2 blockade with available pharmacological inhibitors.
C1 [Deb, Gauri; Thakur, Vijay S.; Gupta, Sanjay] Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA.
   [Deb, Gauri] Indian Inst Technol, Dept Biotechnol, Gauhati, India.
   [Thakur, Vijay S.; Gupta, Sanjay] Univ Hosp Case Med Ctr, Dept Urol, Cleveland, OH USA.
   [Gupta, Sanjay] Case Comprehens Canc Ctr, Div Gen Med Sci, Cleveland, OH USA.
C3 University System of Ohio; Case Western Reserve University; Indian
   Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati; University System of Ohio; Case Western
   Reserve University; Case Western Reserve University Hospital; University
   System of Ohio; Case Western Reserve University
RP Gupta, S (通讯作者)，Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA.
EM sanjay.gupta@case.edu
RI Deb, Gauri/T-8429-2019
OI Gupta, Sanjay/0000-0002-9492-3249
FU United States Public Health Service [RO1CA115491, RO1CA108512,
   R21109424]; Council of Scientific and Industrial Research (CSIR), India;
   United States - India Educational Foundation (USIEF)
FX This work was partially supported by funds from the United States Public
   Health Service Grants RO1CA115491, RO1CA108512 and R21109424 to SG. We
   acknowledge Shyama Prasad Mukherjee (SPM) fellowship provided to GD by
   the Council of Scientific and Industrial Research (CSIR), India and
   Fulbright-Nehru Doctoral and Professional Research fellowship provided
   by United States - India Educational Foundation (USIEF) for her work in
   the US.
CR Abel KJ, 1996, GENOMICS, V37, P161, DOI 10.1006/geno.1996.0537
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Barrand S, 2010, BIOCHEM BIOPH RES CO, V401, P611, DOI 10.1016/j.bbrc.2010.09.116
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248
   Bell O, 2007, EMBO J, V26, P4974, DOI 10.1038/sj.emboj.7601926
   Bohrer LR, 2010, ENDOCRINOLOGY, V151, P5136, DOI 10.1210/en.2010-0436
   Borbone E, 2011, J CLIN ENDOCR METAB, V96, P1029, DOI 10.1210/jc.2010-1784
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cai HJ, 2012, CANCER RES, V72, P4672, DOI 10.1158/0008-5472.CAN-12-0228
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cardoso C, 2000, EUR J HUM GENET, V8, P174, DOI 10.1038/sj.ejhg.5200439
   Cavalli G, 2012, SCIENCE, V338, P1430, DOI 10.1126/science.1232332
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116
   Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   Cromer MK, 2012, J CLIN ENDOCR METAB, V97, pE1774, DOI 10.1210/jc.2012-1743
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Dimri M, 2010, CARCINOGENESIS, V31, P489, DOI 10.1093/carcin/bgp305
   Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3
   Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Eskeland R, 2010, MOL CELL, V38, P452, DOI 10.1016/j.molcel.2010.02.032
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Fujii S, 2012, BIOCHEM BIOPH RES CO, V417, P1074, DOI 10.1016/j.bbrc.2011.12.099
   Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861
   Gehani SS, 2010, MOL CELL, V39, P886, DOI 10.1016/j.molcel.2010.08.020
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hayes DF, 1998, BREAST CANCER RES TR, V52, P305, DOI 10.1023/A:1006197805041
   Hayes DF, 2000, EUR J CANCER, V36, P302, DOI 10.1016/S0959-8049(99)00303-2
   Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Hua WF, 2010, EUR J PHARMACOL, V637, P16, DOI 10.1016/j.ejphar.2010.03.051
   Hwang C, 2008, BREAST CANCER RES TR, V107, P235, DOI 10.1007/s10549-007-9542-7
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kim H, 2009, NUCLEIC ACIDS RES, V37, P2940, DOI 10.1093/nar/gkp149
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Ko S, 2011, MOL ENDOCRINOL, V25, P433, DOI 10.1210/me.2010-0482
   Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Lau PNI, 2011, P NATL ACAD SCI USA, V108, P2801, DOI 10.1073/pnas.1012798108
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002
   LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0
   Maenner S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000276
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Nekrasov M, 2007, EMBO J, V26, P4078, DOI 10.1038/sj.emboj.7601837
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   O'Meara MM, 2012, CHROMOSOMA, V121, P221, DOI 10.1007/s00412-012-0361-1
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022
   Pasini D, 2010, NUCLEIC ACIDS RES, V38, P4958, DOI 10.1093/nar/gkq244
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110
   Rau KM, 2005, ENDOCR-RELAT CANCER, V12, P511, DOI 10.1677/erc.1.01026
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Riising EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002704
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Ross, 1998, Oncologist, V3, P237
   Rush Margaret, 2009, Epigenetics, V4, P404
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025
   Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Schulz WA, 2009, SEMIN CANCER BIOL, V19, P172, DOI 10.1016/j.semcancer.2009.02.006
   Schwartz YB, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000805
   Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2
   Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Shin YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030393
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005
   Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387
   Tie F, 2009, DEVELOPMENT, V136, P3131, DOI 10.1242/dev.037127
   Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714
   Truax AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036013
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Walker E, 2010, CELL STEM CELL, V6, P153, DOI 10.1016/j.stem.2009.12.014
   Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wilkinson FH, 2006, P NATL ACAD SCI USA, V103, P19296, DOI 10.1073/pnas.0603564103
   Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Xi HL, 2007, GENOME RES, V17, P798, DOI 10.1101/gr.5754707
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018
   Yu M, 2012, MOL CELL, V45, P330, DOI 10.1016/j.molcel.2011.11.032
   Yuan W, 2011, J BIOL CHEM, V286, P7983, DOI 10.1074/jbc.M110.194027
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
   Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111
NR 128
TC 62
Z9 77
U1 0
U2 20
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD MAY 1
PY 2013
VL 8
IS 5
BP 464
EP 476
DI 10.4161/epi.24532
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 205VU
UT WOS:000323473700003
PM 23644490
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Vidi, PA
   Leary, JF
   Lelièvre, SA
AF Vidi, Pierre-Alexandre
   Leary, James F.
   Lelievre, Sophie A.
TI Building risk-on-a-chip models to improve breast cancer risk assessment
   and prevention
SO INTEGRATIVE BIOLOGY
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE; EXTRACELLULAR-MATRIX; TISSUE
   POLARITY; DIFFERENTIATION; METHYLATION; CULTURE; PROTEIN; REPAIR; EZH2
AB Preventive actions for chronic diseases hold the promise of improving lives and reducing healthcare costs. For several diseases, including breast cancer, multiple risk and protective factors have been identified by epidemiologists. The impact of most of these factors has yet to be fully understood at the organism, tissue, cellular and molecular levels. Importantly, combinations of external and internal risk and protective factors involve cooperativity thus, synergizing or antagonizing disease onset. Models are needed to mechanistically decipher cancer risks under defined cellular and microenvironmental conditions. Here, we briefly review breast cancer risk models based on 3D cell culture and propose to improve risk modeling with lab-on-a-chip approaches. We suggest epithelial tissue polarity, DNA repair and epigenetic profiles as endpoints in risk assessment models and discuss the development of 'risks-on-chips' integrating biosensors of these endpoints and of general tissue homeostasis. Risks-on-chips will help identify biomarkers of risk, serve as screening platforms for cancer preventive agents, and provide a better understanding of risk mechanisms, hence resulting in novel developments in disease prevention.
C1 [Vidi, Pierre-Alexandre; Leary, James F.; Lelievre, Sophie A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
   [Vidi, Pierre-Alexandre; Leary, James F.; Lelievre, Sophie A.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.
   [Leary, James F.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University; Purdue University System; Purdue University
RP Vidi, PA (通讯作者)，Purdue Univ, Dept Basic Med Sci, 625 Harrison St,Lynn Hall, W Lafayette, IN 47907 USA.
EM lelievre@purdue.edu
RI Leary, James/H-8554-2014
OI Leary, James/0000-0002-0250-4427; LELIEVRE, Sophie/0000-0001-6606-2501;
   Vidi, Pierre-Alexandre/0000-0002-9117-8896
FU National Institute of Health [R01CA112017, 1K99CA163957]; Purdue Center
   for Cancer Research Obesity and Cancer Discovery Group; Medical Research
   Award from the Keck Foundation
FX We thank Dr Kurt Hodges (Indiana University School of Medicine) for
   providing microscopic illustrations of normal breast tissue. The
   authors' work is supported by the National Institute of Health
   (R01CA112017 to SAL, 1K99CA163957 to PAV), the Purdue Center for Cancer
   Research Obesity and Cancer Discovery Group (incentive award to SAL) and
   a Medical Research Award from the Keck Foundation. SAL and JFL are
   members of the International Breast Cancer & Nutrition (IBCN) group for
   the development of primary prevention research.
CR Akyüz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002
   Ballard-Barbash R, 2009, JNCI-J NATL CANCER I, V101, P630, DOI 10.1093/jnci/djp068
   Bischel LL, 2013, BIOMATERIALS, V34, P1471, DOI 10.1016/j.biomaterials.2012.11.005
   BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5
   Boyd NF, 2007, NEW ENGL J MED, V356, P227, DOI 10.1056/NEJMoa062790
   BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578
   Campbell JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025661
   Chandramouly G, 2007, J CELL SCI, V120, P1596, DOI 10.1242/jcs.03439
   Chang R, 2008, TISSUE ENG PART C-ME, V14, P157, DOI 10.1089/ten.tec.2007.0392
   Chen JJ, 2012, J CELL SCI, V125, P2954, DOI 10.1242/jcs.101592
   Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019
   de Assis S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2058
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112
   Dumitrescu Ramona G, 2012, Methods Mol Biol, V863, P3, DOI 10.1007/978-1-61779-612-8_1
   Fan XD, 2008, ANAL CHIM ACTA, V620, P8, DOI 10.1016/j.aca.2008.05.022
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Grafton MMG, 2011, INTEGR BIOL-UK, V3, P451, DOI [10.1039/c0ib00132e, 10.1039/c0ib00132c]
   Henderson TO, 2010, ANN INTERN MED, V152, P444, DOI 10.7326/0003-4819-152-7-201004060-00009
   Hernandez L, 2010, DEV CELL, V19, P413, DOI 10.1016/j.devcel.2010.08.013
   Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360
   Jakab K, 2008, TISSUE ENG PT A, V14, P413, DOI 10.1089/tea.2007.0173
   Jakab K, 2010, BIOFABRICATION, V2, DOI 10.1088/1758-5082/2/2/022001
   JENSEN HM, 1986, AM J OBSTET GYNECOL, V154, P1280, DOI 10.1016/0002-9378(86)90713-1
   Jones IL, 2011, ANAL BIOANAL CHEM, V399, P2313, DOI 10.1007/s00216-010-3968-1
   Ker EDF, 2011, BIOMATERIALS, V32, P8097, DOI 10.1016/j.biomaterials.2011.07.025
   Khalil S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3128729
   Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004
   Krause S, 2012, TISSUE ENG PT A, V18, P520, DOI [10.1089/ten.tea.2011.0317, 10.1089/ten.TEA.2011.0317]
   Kunju LP, 2011, MODERN PATHOL, V24, P786, DOI 10.1038/modpathol.2011.8
   Lam LL, 2012, P NATL ACAD SCI USA, V109, P17253, DOI 10.1073/pnas.1121249109
   Lelièvre SA, 2010, J MAMMARY GLAND BIOL, V15, P49, DOI 10.1007/s10911-010-9168-y
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Lewis CM, 2006, BREAST CANCER RES TR, V99, P103, DOI 10.1007/s10549-006-9189-9
   Lopez JI, 2011, INTEGR BIOL-UK, V3, P910, DOI 10.1039/c1ib00043h
   Maxwell CA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001199
   Mishra GD, 2011, CANCER CAUSE CONTROL, V22, P227, DOI 10.1007/s10552-010-9690-7
   Montanez-Sauri SI, 2013, INTEGR BIOL-UK, V5, P631, DOI 10.1039/c3ib20225a
   Montanez-Sauri SI, 2011, JALA-J LAB AUTOM, V16, P171, DOI 10.1016/j.jala.2011.02.003
   Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284
   Norotte C, 2009, BIOMATERIALS, V30, P5910, DOI 10.1016/j.biomaterials.2009.06.034
   Ozasa K, 2012, RADIAT RES, V177, P229, DOI 10.1667/RR2629.1
   PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323
   Pal T, 2012, CANCER CONTROL, V19, P255, DOI 10.1177/107327481201900402
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Pemberton RM, 2013, BIOSENS BIOELECTRON, V42, P668, DOI 10.1016/j.bios.2012.11.032
   PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064
   Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Plachot C, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-77
   Prakash S, 2012, PHILOS T R SOC A, V370, P2269, DOI 10.1098/rsta.2011.0498
   Ralhan R, 2007, CANCER LETT, V248, P1, DOI 10.1016/j.canlet.2006.06.004
   Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60
   Saitakis M, 2012, CELL MOL LIFE SCI, V69, P357, DOI 10.1007/s00018-011-0854-8
   Schwartz GF, 2008, CANCER, V113, P2627, DOI 10.1002/cncr.23903
   Sherman ME, 2012, CANCER PREV RES, V5, P528, DOI 10.1158/1940-6207.CAPR-11-0234
   Singletary SE, 2003, ANN SURG, V237, P474, DOI 10.1097/00000658-200304000-00007
   SOULE HD, 1990, CANCER RES, V50, P6075
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Steinberg MS, 2007, CURR OPIN GENET DEV, V17, P281, DOI 10.1016/j.gde.2007.05.002
   Su Y, 2011, J NUTR BIOCHEM, V22, P605, DOI 10.1016/j.jnutbio.2010.09.008
   Teegarden D, 2012, NUTR RES REV, V25, P68, DOI 10.1017/S0954422411000199
   Teixeira AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072419
   The Interagency Breast Cancer and Environmental Research Coordinating Committee (IBCERCC), 2013, INTERAGENCY BREAST C
   Tse JR., 2010, CURR PROTOC CELL BIO, V10, P16, DOI [10.1002/0471143030.cb1016-47, DOI 10.1002/0471143030.CB1016-47]
   Underwood JM, 2006, J CELL PHYSIOL, V208, P141, DOI 10.1002/jcp.20639
   Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13
   Vidi PA, 2012, J CELL SCI, V125, P350, DOI 10.1242/jcs.089177
   Yue SH, 2012, BIOPHYS J, V102, P1215, DOI 10.1016/j.bpj.2012.01.023
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
   Zeng L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002329
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
NR 74
TC 19
Z9 22
U1 0
U2 27
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1757-9694
EI 1757-9708
J9 INTEGR BIOL-UK
JI Integr. Biol.
PY 2013
VL 5
IS 9
BP 1110
EP 1118
DI 10.1039/c3ib40053k
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 203EA
UT WOS:000323272300002
PM 23681255
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ari, F
   Napieralski, R
   Ulukaya, E
AF Ari, Ferda
   Napieralski, Rudolf
   Ulukaya, Engin
TI Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell
   Lines
SO TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
LA English
DT Article
DE DNA methylation; breast cancer; apoptosis; decitabine; FEC
ID O-6-METHYLGUANINE DNA METHYLTRANSFERASE; PROMOTER HYPERMETHYLATION;
   PROTEIN-KINASE; CLINICAL-SIGNIFICANCE; LUMINESCENCE ASSAY; REPAIR GENES;
   SERUM DNA; EXPRESSION; TUMOR; DEMETHYLATION
AB Objective: Epigenetic modulation of gene expression by DNA promoter methylation may contribute to acquired resistance to chemotherapy in cancer cells. Decitabine (5-aza-2'-deoxycytidine), a demethylating agent, may act synergistically with standard chemotherapy regimens to activate epigenetically silenced genes. In the present in vitro study, it was investigated the effect of gene methylation level after treatment with decitabine and combination of decitabine with anthracycline-based therapeutics (5-fluorouracil plus epirubicine plus cyclophosphamide; FEC) on breast cancer cells (MCF-7 and MDA-MB-231).
   Methods: The effect of decitabine and its combination with FEC on different genes methylation level has been tested in MDA-MB-231 and MCF-7 human breast cancer cell lines. The effect of decitabine on the cell viability was assayed by MTT assay. Methylight real-time PCR and methylation specific PCR were carried out to determine the methylation status of certain genes: DAPK, TMS1, MGMT and the global methylation marker LINE-1.
   Results: The LINE-1 methylation status significantly decreased in both cell lines after treatment with the combination of decitabine with FEC. In MDA-MB-231 cells, methylation of the TMS1 and the MGMT gene promoter was significantly reduced by FEC plus decitabine while no effect was observed in MCF-7 cells.
   Conclusion: Anthracycline-based therapy regimens in combination with demethylating agents such as decitabine may affect chemotherapy outcome by modulation of apoptosis-relevant genes by methylation. More importantly, this modulation seems to be dependent on the cell type.
C1 [Ari, Ferda] Uludag Univ, Sci & Arts Fac, Dept Biol, TR-16059 Bursa, Turkey.
   [Ulukaya, Engin] Uludag Univ, Fac Med, Dept Med Biochem, TR-16059 Bursa, Turkey.
   [Napieralski, Rudolf] Tech Univ Munich, M Rechts Isar, Dept Obstet & Gynecol, D-80290 Munich, Germany.
C3 Uludag University; Uludag University; Technical University of Munich
RP Ari, F (通讯作者)，Uludag Univ, Sci & Arts Fac, Dept Biol, TR-16059 Bursa, Turkey.
EM ferdaoz@uludag.edu.tr
RI Arı, Ferda/AAG-7012-2021; Ulukaya, Engin/K-5792-2018
OI Ulukaya, Engin/0000-0003-4875-5472
FU TUBITAK (The Scientific and Technical Research Council of Turkey)
   [106S349]
FX We thank TUBITAK (The Scientific and Technical Research Council of
   Turkey) to support this project numbered 106S349.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   ANDREOTTI PE, 1995, CANCER RES, V55, P5276
   Ari F, 2011, CELL BIOCHEM FUNCT, V29, P651, DOI 10.1002/cbf.1801
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brabender J, 2003, CLIN CANCER RES, V9, P223
   Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799
   Cheema B, 2008, BREAST CANCER RES TR, V109, P9, DOI 10.1007/s10549-007-9638-0
   Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Conway KE, 2000, CANCER RES, V60, P6236
   Deng T, 2009, BIOMED PHARMACOTHER, V63, P492, DOI 10.1016/j.biopha.2008.08.013
   Dumitrescu Ramona G, 2012, Methods Mol Biol, V863, P3, DOI 10.1007/978-1-61779-612-8_1
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Hattermann K, 2008, ANAL BIOCHEM, V377, P62, DOI 10.1016/j.ab.2008.03.014
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hupp TR, 2010, FEBS J, V277, P47, DOI 10.1111/j.1742-4658.2009.07410.x
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Kato K, 2008, INT J CANCER, V122, P603, DOI 10.1002/ijc.23143
   Kitkumthorn N, 2012, CLIN CHIM ACTA, V413, P869, DOI 10.1016/j.cca.2012.01.024
   Kreklau EL, 2001, NUCLEIC ACIDS RES, V29, P2558, DOI 10.1093/nar/29.12.2558
   Kurbacher CM, 1998, ANTI-CANCER DRUG, V9, P51, DOI 10.1097/00001813-199801000-00006
   Lehmann U, 2002, CANCER RES, V62, P6634
   Levine JJ, 2003, ONCOGENE, V22, P3475, DOI 10.1038/sj.onc.1206430
   Lévy D, 2004, CLIN CANCER RES, V10, P3124, DOI 10.1158/1078-0432.CCR-03-0213
   Lewandowska J, 2011, MUTAGENESIS, V26, P475, DOI 10.1093/mutage/ger019
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Liu J, 2012, ONCOL REP, V28, P545, DOI 10.3892/or.2012.1838
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mirza S, 2012, ANN SURG ONCOL, V19, P3107, DOI 10.1245/s10434-012-2323-5
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Morandi L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-48
   Napieralski R, 2007, CLIN CANCER RES, V13, P5095, DOI 10.1158/1078-0432.CCR-07-0241
   PEGG AE, 1990, CANCER RES, V50, P6119
   Poláková K, 2009, LEUKEMIA RES, V33, P518, DOI 10.1016/j.leukres.2008.08.003
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Schulz WA, 2006, CURR TOP MICROBIOL, V310, P211
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Singh KP, 2012, CANCER LETT, V316, P62, DOI 10.1016/j.canlet.2011.10.022
   Song YH, 2009, CANCER CHEMOTH PHARM, V63, P605, DOI 10.1007/s00280-008-0773-z
   Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932
   Swift-Scanlan T, 2011, CANCER BIOL THER, V11, P853, DOI 10.4161/cbt.11.10.15177
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   Ulukaya E, 2008, TOXICOL IN VITRO, V22, P232, DOI 10.1016/j.tiv.2007.08.006
   Van de Voorde L, 2012, MUTAT RES-REV MUTAT, V751, P304, DOI 10.1016/j.mrrev.2012.06.001
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wethkamp N, 2006, EUR J CANCER, V42, P264, DOI 10.1016/j.ejca.2005.10.019
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yoo HJ, 2012, CELL SIGNAL, V24, P1471, DOI 10.1016/j.cellsig.2012.03.010
   Zhang XT, 2006, CANCER SCI, V97, P938, DOI 10.1111/j.1349-7006.2006.00253.x
NR 57
TC 2
Z9 2
U1 0
U2 20
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0250-4685
EI 1303-829X
J9 TURK J BIOCHEM
JI Turk. J. Biochem.
PY 2013
VL 38
IS 2
BP 154
EP 162
DI 10.5505/tjb.2013.46320
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 201ZM
UT WOS:000323181600005
DA 2025-01-12
ER

PT J
AU Shen, Z
   Chen, L
   Yang, XJ
   Zhao, Y
   Pier, E
   Zhang, X
   Yang, XC
   Xiong, Y
AF Shen, Zhu
   Chen, Ling
   Yang, Xiaojun
   Zhao, Yun
   Pier, Eric
   Zhang, Xia
   Yang, Xichuan
   Xiong, Ya
TI Downregulation of Ezh2 methyltransferase by FOXP3: New insight of FOXP3
   into chromatin remodeling?
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
LA English
DT Article
DE FOXP3; Ezh2; Praja1; Transcription; Ubiquitination
ID GROUP PROTEIN EZH2; BREAST-CANCER; T-CELLS; TARGET GENES; DNA-DAMAGE;
   STEM-CELLS; C-MYC; EXPRESSION; ROLES; HYPERMETHYLATION
AB Transcription factor FOXP3 (forkhead box P3) is found initially as a key regulator in regulatoiy T cells. Recently its expression has been demonstrated in some non-lymphoid normal and cancerous cells. Now FOXP3 has been proven to regulate cancer-related genes, especially suppressor genes in breast cancer. But the mechanisms by which FOXP3 regulates suppressor genes are not fully determined. In this study, we found the inverse correlation between FOXP3 and Ezh2, an enzyme for histone H3K27 trimethylation (H3K27me3) and a central epigenetic regulator in cancer. The overexpression of FOXP3 weakened Ezh2's enhancement on the mammosphere formation, cell proliferation, directional migration, and colony forming ability of T47D cells. We demonstrated that FOXP3 could downregulate Ezh2 protein level and this depended on not only the FOXP3 expression amount, but also the nuclear localization of FOXP3. More importantly, we demonstrated FOXP3 accelerated Ezh2 protein degradation through the polyubiquitination-proteasome pathway by enhancing the transcription of E3 ligase Praja1 directly. These results provided a new mechanism for FOXP3 in histone modifications as an Ezh2 suppressor and supported new evidence for FOXP3 as a tumor suppressor in breast cancer. 2013 Elsevier B.V. All rights reserved.
C1 [Shen, Zhu; Yang, Xichuan; Xiong, Ya] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing 400038, Peoples R China.
   [Chen, Ling] Third Mil Med Univ, Daping Hosp, Dept Dermatol, Chongqing 400042, Peoples R China.
   [Yang, Xiaojun; Zhang, Xia] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China.
   [Yang, Xiaojun; Zhang, Xia] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.
   [Yang, Xiaojun; Zhang, Xia] Minist Educ China, Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China.
   [Zhao, Yun] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Pier, Eric] Tufts Univ, Sch Med, Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA.
C3 Army Medical University; Army Medical University; Army Medical
   University; Army Medical University; Harvard University; Massachusetts
   General Hospital; Harvard Medical School; Tufts University; Tufts
   Medical Center
RP Shen, Z (通讯作者)，Third Mil Med Univ, Southwest Hosp, Dept Dermatol, 30 Gaotanyan Main St, Chongqing 400038, Peoples R China.
EM zhushencq@gmail.com
RI Zhao, Yun/HNB-6660-2023; Zhang, Xia/B-8152-2008
FU National Natural Science Foundation of China [30801013, 81072502];
   Natural Science Foundation Project of CQ CSTC [CSTC 2009BA5010]; project
   for the Medical Science Development of PLA [CWS12J027]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30801013, Ling Chen; and No. 81072502, Zhu Shen), the Natural
   Science Foundation Project of CQ CSTC (No. CSTC 2009BA5010, Zhu Shen),
   and the project for the Medical Science Development of PLA (No.
   CWS12J027, Ling Chen).
CR Alimova I, 2012, INT J CANCER, V131, P1800, DOI 10.1002/ijc.27455
   Balasubramanian S, 2011, MOL PHARMACOL, V80, P870, DOI 10.1124/mol.111.072363
   Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen B, 2000, CANCER RES, V60, P3290
   de Haan G, 2007, ANN NY ACAD SCI, V1106, P233, DOI 10.1196/annals.1392.008
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Gregg R, 2005, CLIN EXP IMMUNOL, V140, P540, DOI 10.1111/j.1365-2249.2005.02798.x
   Han GM, 2009, CELL IMMUNOL, V258, P188, DOI 10.1016/j.cellimm.2009.05.003
   Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Katoh H, 2011, MOL CELL, V44, P770, DOI 10.1016/j.molcel.2011.10.012
   Katoh H, 2010, INT J BIOCHEM CELL B, V42, P1784, DOI 10.1016/j.biocel.2010.07.015
   Koh KP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008109
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104
   Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106
   Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717
   Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478
   Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174
   McInnes N, 2012, ONCOGENE, V31, P1045, DOI 10.1038/onc.2011.293
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5
   Pan F, 2009, SCIENCE, V325, P1142, DOI 10.1126/science.1176077
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Satoh Y, 2004, J BIOL CHEM, V279, P24986, DOI 10.1074/jbc.M400407200
   Semaan A, 2011, PHARM RES-DORDR, V28, P3079, DOI 10.1007/s11095-011-0547-x
   Shen Z, 2009, MED RES REV, V29, P742, DOI 10.1002/med.20152
   SOULE HD, 1990, CANCER RES, V50, P6075
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016
   Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48
   Ying JM, 2004, BLOOD, V103, P743, DOI 10.1182/blood-2003-09-3193
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Yu P, 2002, GENOMICS, V79, P869, DOI 10.1006/geno.2002.6770
   Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563
   Zheng YG, 2008, MED RES REV, V28, P645, DOI 10.1002/med.20120
   Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538
   Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034
NR 45
TC 22
Z9 24
U1 0
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4889
J9 BBA-MOL CELL RES
JI Biochim. Biophys. Acta-Mol. Cell Res.
PD OCT
PY 2013
VL 1833
IS 10
BP 2190
EP 2200
DI 10.1016/j.bbamcr.2013.05.014
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 197OA
UT WOS:000322859300009
PM 23688634
OA Bronze
DA 2025-01-12
ER

PT J
AU Pitta, CA
   Papageorgis, P
   Charalambous, C
   Constantinou, AI
AF Pitta, Chara A.
   Papageorgis, Panagiotis
   Charalambous, Christiana
   Constantinou, Andreas I.
TI Reversal of ER-β silencing by chromatin modifying agents overrides
   acquired tamoxifen resistance
SO CANCER LETTERS
LA English
DT Article
DE Tamoxifen resistance; Breast cancer; Estrogen receptors; Epigenetics
ID ESTROGEN-RECEPTOR-BETA; BREAST-CANCER CELLS; MESSENGER-RNA;
   TRANSCRIPTIONAL ACTIVATION; EXPRESSION; ALPHA; PROLIFERATION;
   MECHANISMS; BINDING; PROTEIN
AB The purpose of this work is to determine the molecular mechanisms underlying tamoxifen resistance. We show here that ER-beta is epigenetically silenced in a cell line with acquired tamoxifen resistance (MCF-7/TAM-R) and this could be reversed by 5-AZA-deoxycytidine (5-AZA) and trichostatin-A (TSA) pre-treatment. Subsequent treatment with 4-hydroxy-tamoxifen (4-OHT) induced ER-beta nuclear translocation, upregulated pS2 and p21 levels and reduced cell viability. Transfection with an ER-beta expression vector sensitized MCF-7/TAM-R cells to the growth inhibitory and pro-apoptotic effects of 4-OHT, indicating that ER-beta re-expression alone is sufficient to restore sensitivity to tamoxifen. This novel finding reveals that ER-beta is fundamental in overcoming acquired tamoxifen resistance and provides insights for new therapeutic protocols against breast cancer. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Pitta, Chara A.; Papageorgis, Panagiotis; Charalambous, Christiana; Constantinou, Andreas I.] Univ Cyprus, Dept Biol Sci, CY-1678 Nicosia, Cyprus.
C3 University of Cyprus
RP Constantinou, AI (通讯作者)，Univ Cyprus, Dept Biol Sci, 75 Kallipoleos Ave,POB 20537, CY-1678 Nicosia, Cyprus.
EM andreasc@ucy.ac.cy
RI Papageorgis, Panagiotis/J-5711-2019
OI Constantinou, Andreas/0000-0003-0365-1821; Papageorgis,
   Panagiotis/0000-0002-7595-5616
FU Cyprus Research Promotion Foundation (CRPF) [PENEK/ENISHISI/0308/028]
FX The authors thank Dr. IanHutcheson for kindly providing the MCF-7/TAM-R
   cell line. The authors also thank Dr. Antonis Kirmizis for helpful
   discussion, Dr. Paris Skourides and Dr. Panayiota Stylianou for advice
   and technical assistance with the immunofluoresence microscopy, Eleni G.
   Koumeni, Christiana Neophytou and Christiana Savva for other technical
   assistance. This work was partially supported by funding from the Cyprus
   Research Promotion Foundation (CRPF Grant: PENEK/ENISHISI/0308/028).
CR Arpino G, 2004, CLIN CANCER RES, V10, P5670, DOI 10.1158/1078-0432.CCR-04-0110
   Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800
   Cannings E, 2007, BREAST CANCER RES TR, V102, P173, DOI 10.1007/s10549-006-9323-8
   Chang CY, 1999, MOL CELL BIOL, V19, P8226
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Duong V, 2006, ONCOGENE, V25, P1799, DOI 10.1038/sj.onc.1209102
   Esslimani-Sahla M, 2004, CLIN CANCER RES, V10, P5769, DOI 10.1158/1078-0432.CCR-04-0389
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x
   Fixemer T, 2003, PROSTATE, V54, P79, DOI 10.1002/pros.10171
   Foley EF, 2000, CANCER RES, V60, P245
   Fürst RW, 2012, J STEROID BIOCHEM, V130, P96, DOI 10.1016/j.jsbmb.2012.01.009
   Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172
   Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114
   Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M
   Järvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   KLINGE CM, 1987, CANCER RES, V47, P2852
   Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620
   Kumar R, 1996, CLIN CANCER RES, V2, P1215
   Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722
   Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120
   Linja MJ, 2003, PROSTATE, V55, P180, DOI 10.1002/pros.10242
   Loven MA, 2001, J BIOL CHEM, V276, P45282, DOI 10.1074/jbc.M106211200
   LYKKESFELDT AE, 1984, BRIT J CANCER, V49, P717, DOI 10.1038/bjc.1984.113
   Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508
   Papoutsi Z, 2009, J MOL ENDOCRINOL, V43, P65, DOI 10.1677/JME-08-0177
   Planas-Silva MD, 2007, EXP MOL PATHOL, V82, P85, DOI 10.1016/j.yexmp.2006.09.001
   Ramsey TL, 2004, ENDOCRINOLOGY, V145, P149, DOI 10.1210/en.2003-1043
   Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Roger P, 2001, CANCER RES, V61, P2537
   Saji S, 2005, CANCER CHEMOTH PHARM, V56, pS21, DOI 10.1007/s0028-005-0107-3
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Speirs V, 1999, CANCER RES, V59, P5421
   Sweeney EE, 2012, HORM MOL BIOL CLIN I, V9, P143, DOI 10.1515/hmbci-2011-0004
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
NR 44
TC 13
Z9 16
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 1
PY 2013
VL 337
IS 2
BP 167
EP 176
DI 10.1016/j.canlet.2013.05.031
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 201JP
UT WOS:000323138200003
PM 23752064
DA 2025-01-12
ER

PT J
AU Muñoz, DP
   Lee, EL
   Takayama, S
   Coppé, JP
   Heo, SJ
   Boffelli, D
   Di Noia, JM
   Martin, DIK
AF Munoz, Denise P.
   Lee, Elbert L.
   Takayama, Sachiko
   Coppe, Jean-Philippe
   Heo, Seok-Jin
   Boffelli, Dario
   Di Noia, Javier M.
   Martin, David I. K.
TI Activation-induced cytidine deaminase (AID) is necessary for the
   epithelial-mesenchymal transition in mammary epithelial cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID THYMINE-DNA GLYCOSYLASE; GENE-EXPRESSION; ESTROGEN-RECEPTOR; HUMAN
   HEPATOCYTES; GERM-CELLS; METHYLATION; DEMETHYLATION; LINKS;
   5-METHYLCYTOSINE; ASSOCIATION
AB Activation-induced cytidine deaminase (AID), which functions in antibody diversification, is also expressed in a variety of germ and somatic cells. Evidence that AID promotes DNA demethylation in epigenetic reprogramming phenomena, and that it is induced by inflammatory signals, led us to investigate its role in the epithelial-mesenchymal transition (EMT), a critical process in normal morphogenesis and tumor metastasis. We find that expression of AID is induced by inflammatory signals that induce the EMT in nontransformed mammary epithelial cells and in ZR75.1 breast cancer cells. shRNA-mediated knockdown of AID blocks induction of the EMT and prevents cells from acquiring invasive properties. Knockdown of AID suppresses expression of several key EMT transcriptional regulators and is associated with increased methylation of CpG islands proximal to the promoters of these genes; furthermore, the DNA demethylating agent 5 aza-2'deoxycytidine (5-Aza-dC) antagonizes the effects of AID knockdown on the expression of EMT factors. We conclude that AID is necessary for the EMT in this breast cancer cell model and in nontransformed mammary epithelial cells. Our results suggest that AID may act near the apex of a hierarchy of regulatory steps that drive the EMT, and are consistent with this effect being mediated by cytosine demethylation. This evidence links our findings to other reports of a role for AID in epigenetic reprogramming and control of gene expression.
C1 [Munoz, Denise P.; Lee, Elbert L.; Takayama, Sachiko; Heo, Seok-Jin; Boffelli, Dario; Martin, David I. K.] Childrens Hosp Oakland Res Inst, Oakland, CA 94609 USA.
   [Coppe, Jean-Philippe] Univ Calif San Francisco, Sch Med, Dept Lab Med, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94115 USA.
   [Di Noia, Javier M.] Inst Rech Clin Montreal, Div Immun & Viral Infect, Montreal, PQ H2J 3T3, Canada.
   [Di Noia, Javier M.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
C3 Children's Hospital Oakland Research Institute; University of California
   System; University of California San Francisco; UCSF Medical Center;
   UCSF Benioff Children's Hospital Oakland; University of California
   System; University of California San Francisco; UCSF Medical Center;
   UCSF Helen Diller Family Comprehensive Cancer Center; Universite de
   Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite
   de Montreal
RP Muñoz, DP (通讯作者)，Childrens Hosp Oakland Res Inst, Oakland, CA 94609 USA.
EM dmunoz@chori.org
RI Boffelli, Dario/K-3959-2014; Di Noia, Javier Marcelo/D-2285-2012
OI Heo, Seok-Jin/0009-0004-4830-8319; Di Noia, Javier
   Marcelo/0000-0003-2896-0321
FU National Institutes of Health [5K22CA163969-02, CA115768-05,
   1R21ES016581-02, DK080428-02]; Pink Pumpkin Patch grant; Canadian
   Research Chair tier 2
FX We thank Pierre-Yves Desprez for the kind gift of multiple reagents and
   for helpful comments and discussions, Jennifer Yamtich for help with
   statistical analysis, and Wendy Magis for technical assistance. This
   work was supported by National Institutes of Health Grants
   5K22CA163969-02 (to D.P.M.), CA115768-05, 1R21ES016581-02, and
   DK080428-02 (to D.I.K.M.) and a Pink Pumpkin Patch grant (to D.P.M.).
   J.M.D.N. is supported by a Canadian Research Chair tier 2.
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Babbage G, 2006, CANCER RES, V66, P3996, DOI 10.1158/0008-5472.CAN-05-3704
   Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411
   Bhutani N, 2013, FASEB J, V27, P1107, DOI 10.1096/fj.12-222125
   Bhutani N, 2011, CELL, V146, P866, DOI 10.1016/j.cell.2011.08.042
   Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Câmara J, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-2
   Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529
   Chaudhuri Jayanta, 2007, Adv Immunol, V94, P157, DOI 10.1016/S0065-2776(06)94006-1
   Chen DS, 2003, J BIOL CHEM, V278, P38586, DOI 10.1074/jbc.M304286200
   Conticello SG, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-229
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Cortázar D, 2011, NATURE, V470, P419, DOI 10.1038/nature09672
   Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020
   Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042
   Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344
   Endo Y, 2008, GASTROENTEROLOGY, V135, P889, DOI 10.1053/j.gastro.2008.06.091
   Feng SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020599
   Franchini DM, 2012, ANNU REV GENET, V46, P419, DOI 10.1146/annurev-genet-110711-155451
   Gonda H, 2003, J EXP MED, V198, P1427, DOI 10.1084/jem.20030802
   Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223
   Imbalzano KM, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-7
   Kamitani S, 2011, INT ARCH ALLERGY IMM, V155, P119, DOI 10.1159/000318854
   Komori J, 2008, HEPATOLOGY, V47, P888, DOI 10.1002/hep.22125
   Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292
   Kumar R, 2013, NATURE, V500, P89, DOI 10.1038/nature12299
   Kuraoka M, 2011, P NATL ACAD SCI USA, V108, P11560, DOI 10.1073/pnas.1102571108
   Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154
   Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li YQ, 2007, NUCLEIC ACIDS RES, V35, P390, DOI 10.1093/nar/gkl1052
   Lin CY, 2011, CANCER SCI, V102, P815, DOI 10.1111/j.1349-7006.2011.01861.x
   Lindley LE, 2010, BIOCHEM BIOPH RES CO, V399, P659, DOI 10.1016/j.bbrc.2010.07.138
   MacDuff DA, 2009, NUCLEIC ACIDS RES, V37, P1854, DOI 10.1093/nar/gkp030
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566
   MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185
   Meyers G, 2011, P NATL ACAD SCI USA, V108, P11554, DOI 10.1073/pnas.1102600108
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200
   Muñoz DP, 2013, NUCLEIC ACIDS RES, V41, P2894, DOI 10.1093/nar/gks1478
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631
   Ooi SKT, 2009, J CELL SCI, V122, P2787, DOI 10.1242/jcs.015123
   Orthwein A, 2012, SEMIN IMMUNOL, V24, P246, DOI 10.1016/j.smim.2012.05.001
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Park SR, 2009, NAT IMMUNOL, V10, P540, DOI 10.1038/ni.1725
   Patenaude AM, 2009, NAT STRUCT MOL BIOL, V16, P517, DOI 10.1038/nsmb.1598
   Pauklin S, 2009, J EXP MED, V206, P99, DOI 10.1084/jem.20080521
   Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017
   Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp
   Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829
   Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042
   REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0
   RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315
   Schreck S, 2006, J PATHOL, V210, P26, DOI 10.1002/path.2014
   Slattery C, 2006, FEBS LETT, V580, P4021, DOI 10.1016/j.febslet.2006.06.039
   Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027
   THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314
   Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110
   Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200
   Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7
   Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416
   Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728
   Willmann KL, 2012, J EXP MED, V209, P2099, DOI 10.1084/jem.20112145
   Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090
   Wu XS, 2008, BLOOD, V112, P4675, DOI 10.1182/blood-2008-03-145995
NR 84
TC 58
Z9 66
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 6
PY 2013
VL 110
IS 32
BP E2977
EP E2986
DI 10.1073/pnas.1301021110
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 196JQ
UT WOS:000322771100010
PM 23882083
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Janzen, DM
   Rosales, MA
   Paik, DY
   Lee, DS
   Smith, DA
   Witte, ON
   Iruela-Arispe, ML
   Memarzadeh, S
AF Janzen, Deanna M.
   Rosales, Miguel A.
   Paik, Daniel Y.
   Lee, Daniel S.
   Smith, Daniel A.
   Witte, Owen N.
   Iruela-Arispe, M. Luisa
   Memarzadeh, Sanaz
TI Progesterone Receptor Signaling in the Microenvironment of Endometrial
   Cancer Influences Its Response to Hormonal Therapy
SO CANCER RESEARCH
LA English
DT Article
ID PROSTATE-CANCER; BREAST-CANCER; ESTROGEN; CARCINOMA; HYPERPLASIA;
   EXPRESSION; MOUSE; ADENOCARCINOMA; AKT
AB Progesterone, an agonist for the progesterone receptor (PR), can be an efficacious and well-tolerated treatment in endometrial cancer. The clinical use of progesterone is limited because of the lack of biomarkers that predict hormone sensitivity. Despite its efficacy in cancer therapy, mechanisms and site of action for progesterone remain unknown. Using an in vivo endometrial cancer mouse model driven by clinically relevant genetic changes but dichotomous responses to hormonal therapy, we show that signaling through stromal PR is necessary and sufficient for progesterone antitumor effects. Endometrial cancers resulting from epithelial loss of PTEN (PTENKO) were hormone sensitive and had abundant expression of stromal PR. Stromal deletion of PR as a single genetic change in these tumors induced progesterone resistance indicating that paracrine signaling through the stroma is essential for the progesterone therapeutic effects. A hormone-refractory endometrial tumor with low levels of stromal PR developed when activation of KRAS was coupled with PTEN-loss (PTENKO/Kras). The innate progesterone resistance in PTENKO/Kras tumors stemmed from methylation of PR in the tumor microenvironment. Add-back of stromal PR expressed from a constitutively active promoter sensitized these tumors to progesterone therapy. Results show that signaling through stromal PR is sufficient for inducing hormone responsiveness. Our findings suggest that epigenetic derepression of stromal PR could be a potential therapeutic target for sensitizing hormone-refractory endometrial tumors to progesterone therapy. On the basis of these results, stromal expression of PR may emerge as a reliable biomarker in predicting response to hormonal therapy. (C)2013 AACR.
C1 [Janzen, Deanna M.; Rosales, Miguel A.; Paik, Daniel Y.; Lee, Daniel S.; Memarzadeh, Sanaz] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA.
   [Witte, Owen N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
   [Iruela-Arispe, M. Luisa] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.
   [Smith, Daniel A.; Witte, Owen N.; Iruela-Arispe, M. Luisa] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
   [Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.
   [Witte, Owen N.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA.
   [Smith, Daniel A.; Witte, Owen N.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Memarzadeh, Sanaz] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of California System; University of California Los
   Angeles; University of California System; University of California Los
   Angeles; Howard Hughes Medical Institute; University of California
   System; University of California Los Angeles; University of California
   System; University of California Los Angeles; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles
   Healthcare System
RP Memarzadeh, S (通讯作者)，Univ Calif Los Angeles, 555 Westwood Plaza,Level B,Box 957243,1015 Terasa, Los Angeles, CA 90095 USA.
EM smemarzadeh@mednet.ucla.edu
RI Iruela-Arispe, M./AAJ-1297-2020
FU VA CDA-2 Award; Scholars in Translational Medicine Program; Mary Kay
   Award; CDU/UCLA NIH/NCI [U54-CA-143931]; Sidney Kimmel Foundation; UCLA
   Cancer Research Coordinating Committee; Concern foundation
FX S. Memarzadeh is supported by a VA CDA-2 Award, Scholars in
   Translational Medicine Program, Mary Kay Award, the CDU/UCLA NIH/NCI
   Grant #U54-CA-143931 award, a Sidney Kimmel Foundation award, the UCLA
   Cancer Research Coordinating Committee grant, and the Concern
   foundation.
CR ACKEN HS, 1969, OBSTET GYNECOL, V34, P46
   Azueta A, 2010, SEMIN DIAGN PATHOL, V27, P226, DOI 10.1053/j.semdp.2010.09.001
   CHARLES D, 1964, J CLIN PATHOL, V17, P205, DOI 10.1136/jcp.17.3.205
   CLELAND WH, 1985, J CLIN ENDOCR METAB, V60, P174, DOI 10.1210/jcem-60-1-174
   Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339
   Cramer DW, 2012, HEMATOL ONCOL CLIN N, V26, P1, DOI 10.1016/j.hoc.2011.10.009
   Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417
   Decruze SB, 2007, INT J GYNECOL CANCER, V17, P964, DOI 10.1111/j.1525-1438.2007.00897.x
   Franco HL, 2012, FASEB J, V26, P1218, DOI 10.1096/fj.11-193334
   Fyles A, 2008, GYNECOL ONCOL, V108, P395, DOI 10.1016/j.ygyno.2007.10.033
   Gabriel EM, 2012, EXPERT REV ANTICANC, V12, P223, DOI [10.1586/era.11.206, 10.1586/ERA.11.206]
   Hammerer Peter, 2012, BJU Int, V110 Suppl 1, P23, DOI 10.1111/j.1464-410X.2012.11431.x
   Hashimoto-Partyka MK, 2006, GENESIS, V44, P391, DOI 10.1002/dvg.20227
   Hecht JL, 2006, J CLIN ONCOL, V24, P4783, DOI 10.1200/JCO.2006.06.7173
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Janzen DM, 2013, STEM CELLS, V31, P808, DOI 10.1002/stem.1337
   Joshi A, 2011, EXP CELL RES, V317, P1580, DOI 10.1016/j.yexcr.2011.03.006
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Kim JJ, 2010, SEMIN REPROD MED, V28, P81, DOI 10.1055/s-0029-1242998
   Kim TH, 2010, J ONCOL, V2010, DOI 10.1155/2010/139087
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   Kurita T, 1998, ENDOCRINOLOGY, V139, P4708, DOI 10.1210/en.139.11.4708
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Li QX, 2011, SCIENCE, V331, P912, DOI 10.1126/science.1197454
   Markman M, 2005, EUR J CANCER, V41, P673, DOI 10.1016/j.ejca.2004.12.008
   MARTIN L, 1973, J ENDOCRINOL, V56, P133, DOI 10.1677/joe.0.0560133
   Memarzadeh S, 2007, CANCER CELL, V12, P572, DOI 10.1016/j.ccr.2007.11.002
   Memarzadeh S, 2010, P NATL ACAD SCI USA, V107, P17298, DOI 10.1073/pnas.1012548107
   Milam MR, 2008, INT J GYNECOL CANCER, V18, P146, DOI 10.1111/j.1525-1438.2007.00958.x
   Minaguchi T, 2007, CANCER LETT, V248, P112, DOI 10.1016/j.canlet.2006.06.013
   Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924
   Orbo A, 2006, CANCER RES, V66, P5613, DOI 10.1158/0008-5472.CAN-05-4321
   Puhalla S, 2012, MOL ONCOL, V6, P222, DOI 10.1016/j.molonc.2012.02.003
   Rauh-Hain JA, 2010, ONCOLOGIST, V15, P852, DOI 10.1634/theoncologist.2010-0091
   Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540
   Sasaki M, 2001, CANCER RES, V61, P97
   SCHRADER WT, 1972, J BIOL CHEM, V247, P51
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302
   SNIJDERS MP, 1992, J PATHOL, V166, P171, DOI 10.1002/path.1711660214
   Tanwar PS, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002906
   Thigpen JT, 1999, J CLIN ONCOL, V17, P1736, DOI 10.1200/JCO.1999.17.6.1736
   Wargon V, 2011, BREAST CANCER RES TR, V126, P319, DOI 10.1007/s10549-010-0908-x
   Wheeler DT, 2007, AM J SURG PATHOL, V31, P988, DOI 10.1097/PAS.0b013e31802d68ce
   Wright JD, 2012, LANCET, V379, P1352, DOI 10.1016/S0140-6736(12)60442-5
   Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Zheng WX, 2004, GYNECOL ONCOL, V92, P1008, DOI 10.1016/j.ygyno.2003.11.026
   Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109
NR 49
TC 55
Z9 64
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2013
VL 73
IS 15
BP 4697
EP 4710
DI 10.1158/0008-5472.CAN-13-0930
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 194HC
UT WOS:000322620800012
PM 23744837
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Huang, ZB
   Li, SZ
   Song, W
   Li, X
   Li, QS
   Zhang, ZY
   Han, YQ
   Zhang, XD
   Miao, SY
   Du, RL
   Wang, LF
AF Huang, Zebin
   Li, Shangze
   Song, Wei
   Li, Xin
   Li, Qinshan
   Zhang, Zeyan
   Han, Yongqing
   Zhang, Xiaodong
   Miao, Shiying
   Du, Runlei
   Wang, Linfang
TI Lysine-Specific Demethylase 1 (LSD1/KDM1A) Contributes to Colorectal
   Tumorigenesis via Activation of the Wnt/<i>B</i>-Catenin Pathway by
   Down-Regulating Dickkopf-1 (DKK1)
SO PLOS ONE
LA English
DT Article
ID FREQUENT EPIGENETIC INACTIVATION; COLON-CANCER CELLS; BREAST-CANCER;
   CARCINOMA CELLS; SOMATIC-CELLS; LSD1; METHYLATION; GENE; PROLIFERATION;
   TRANSCRIPTION
AB We collected paired samples of tumor and adjacent normal colorectal tissues from 22 patients with colorectal carcinoma to compare the differences in the expression of lysine specific demethylase 1 (LSD1) in these two tissues. The results showed that in 19 paired samples (86.4%), LSD1 is more highly expressed in tumor tissue than in normal tissue. To explore the role of LSD1 in colorectal tumorigenesis, we used somatic cell gene targeting to generate an LSD1 knockout (KO) HCT 116 human colorectal cancer cell line as a research model. The analysis of phenotypic changes showed that LSD1 KO colorectal cancer cells are less tumorigenic, both in vivo and in vitro. The differential expression analysis of the cells by mRNA sequencing (RNA-Seq) yielded 2,663 differentially expressed genes, and 28 of these genes had highly significant differences (Q<0.01). We then selected the 4 colorectal cancer-related genes ADM, DKK1, HAS3 and SMURF2 for quantitative real-time PCR verification. The results showed that the differences in the expression of ADM, DKK1 and HAS3 were consistent with those measured using the RNA-Seq data. As DKK1 was the gene with the most significant differential expression, we analyzed the key proteins of the DKK1-related Wnt/beta-catenin signaling pathway and found that, after knocking out LSD1, the amount of free beta-catenin translocated to the nucleus was significantly reduced and that the transcription of the signaling pathway target gene c-Myc was down-regulated. Our studies show that LSD1 activates the Wnt/beta-catenin signaling pathway by down-regulating the pathway antagonist DKK1, which may be one of the mechanisms leading to colorectal tumorigenesis.
C1 [Huang, Zebin; Song, Wei; Li, Qinshan; Han, Yongqing; Miao, Shiying; Wang, Linfang] Chinese Acad Med Sci, Tsinghua Univ, Peking Union Med Coll,Natl Lab Med Mol Biol, Dept Biochem & Mol Biol,Inst Basic Med Sci, Beijing 100084, Peoples R China.
   [Li, Shangze; Li, Xin; Zhang, Zeyan; Zhang, Xiaodong; Du, Runlei] Wuhan Univ, Coll Life Sci, Dept Cellular & Dev Biol, Wuhan 430072, Peoples R China.
C3 Institute of Basic Medical Sciences - CAMS; Tsinghua University; Chinese
   Academy of Medical Sciences - Peking Union Medical College; Peking Union
   Medical College; Wuhan University
RP Du, RL (通讯作者)，Wuhan Univ, Coll Life Sci, Dept Cellular & Dev Biol, Wuhan 430072, Peoples R China.
EM runleidu@whu.edu.cn; wang.linfang@imicams.ac.cn
RI Zhang, Xiaodong/GQQ-6363-2022; li, shangze/AAW-6317-2021; Zhang,
   Ze-Yan/ABB-4948-2021; Li, Xin/L-2237-2019
OI Li, Xin/0000-0002-3914-9377; Zhang, Zeyan/0000-0002-7896-3013
FU National Basic Research Program of China [2011CB944302, 2011CB944404];
   State Key Laboratory Special Fund [2060204]; National Natural Science
   Foundation of China [81270306, 30971499]
FX This research was supported by the National Basic Research Program of
   China (2011CB944302, 2011CB944404, http://www.973.gov.cn), the State Key
   Laboratory Special Fund (2060204, http://www.chinalab.gov.cn), and the
   National Natural Science Foundation of China (81270306, 30971499,
   http://www.nsfc.gov.cn). The experimental study was performed in
   compliance with the laws of the People's Republic of China. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446
   Chosed R, 2007, MOL CELL, V26, P160, DOI 10.1016/j.molcel.2007.04.009
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101
   Dornhoff H, 2012, GASTROENTEROLOGY, V142, P1183, DOI 10.1053/j.gastro.2012.02.005
   Foster CT, 2010, MOL CELL BIOL, V30, P4851, DOI 10.1128/MCB.00521-10
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Godmann M, 2007, BIOL REPROD, V77, P754, DOI 10.1095/biolreprod.107.062265
   Gonzálex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hirata H, 2011, INT J CANCER, V128, P1793, DOI 10.1002/ijc.25507
   Hirata R, 2002, NAT BIOTECHNOL, V20, P735, DOI 10.1038/nbt0702-735
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Ilyas M, 2005, J PATHOL, V205, P130, DOI 10.1002/path.1692
   Jin LH, 2013, BIOCHEM J, V449, P459, DOI 10.1042/BJ20121360
   Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kocemba KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030359
   Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Li Y, 2012, ONCOGENE, V31, P5007, DOI 10.1038/onc.2012.8
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lv SA, 2010, EUR J CELL BIOL, V89, P557, DOI 10.1016/j.ejcb.2010.01.004
   Lv TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035065
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549-007-9867-2
   Musri MM, 2010, J BIOL CHEM, V285, P30034, DOI 10.1074/jbc.M110.151209
   Qi LS, 2012, CANCER SCI, V103, P828, DOI 10.1111/j.1349-7006.2012.02222.x
   Qin XR, 2007, TRANSL RES, V150, P281, DOI 10.1016/j.trsl.2007.06.005
   Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Scoumanne A, 2007, J BIOL CHEM, V282, P15471, DOI 10.1074/jbc.M701023200
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Talero E, 2011, INFLAMM BOWEL DIS, V17, P696, DOI 10.1002/ibd.21420
   Teng BP, 2011, ANTI-CANCER AGENT ME, V11, P620
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   Wu CY, 2012, INT J CANCER, V131, P1423, DOI 10.1002/ijc.27343
   Yang P, 2011, STEM CELLS, V29, P791, DOI 10.1002/stem.634
   Zhang P, 2011, MOL CANCER RES, V9, P1418, DOI 10.1158/1541-7786.MCR-11-0147
   Zhang XD, 2008, NAT METHODS, V5, P163, DOI 10.1038/NMETH1170
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
   Zhou HY, 2010, J BIOL CHEM, V285, P29676, DOI 10.1074/jbc.C110.150599
   Zhou XL, 2010, ACTA PHARMACOL SIN, V31, P202, DOI 10.1038/aps.2009.200
NR 58
TC 65
Z9 78
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 26
PY 2013
VL 8
IS 7
AR e70077
DI 10.1371/journal.pone.0070077
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 197GU
UT WOS:000322838900143
PM 24040375
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Kutanzi, K
   Kovalchuk, O
AF Kutanzi, Kristy
   Kovalchuk, Olga
TI Exposure to estrogen and ionizing radiation causes epigenetic
   dysregulation, activation of mitogen-activated protein kinase pathways,
   and genome instability in the mammary gland of ACI rats
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE epigenetics; estrogen; ionizing radiation; DNA methylation; histones;
   breast cancer; mitogen-activated protein kinase pathways
ID INDUCED BREAST-CANCER; DOUBLE-STRAND BREAKS; HISTONE H3; DNA
   METHYLATION; OXIDATIVE STRESS; MAP KINASE; PHOSPHORYLATION;
   CARCINOGENESIS; CELLS; METHYLTRANSFERASE
AB The impact of environmental mutagens and carcinogens on the mammary gland has recently received a lot of attention. Among the most generally accepted carcinogenic agents identified as factors that may increase breast cancer incidence are ionizing radiation and elevated estrogen levels. However, the molecular mechanisms of mammary gland aberrations associated with radiation and estrogen exposure still need to be further elucidated, especially the interplay between elevated hormone levels and radiation. Therefore, in the present study, we investigated molecular changes induced in rat mammary gland tissue by estrogen, ionizing radiation, and the combined action of these two carcinogens using a well-established ACI rat model. We found that continuous exposure of intact female ACI rats to elevated levels of estrogen or to both estrogen and radiation resulted in significant hyperproliferative changes in rat mammary glands. In contrast, radiation exposure alone did not induce hyperplasia. Interestingly, despite the obvious disparity in mammary gland morphology, we did not detect significant differences in the levels of genomic methylation among animals exposed to estrogen, radiation, or both agents together. Specifically, we observed a significant global genomic hypomethylation at 6 weeks of exposure. However, by 12 and 18 weeks, the levels of global DNA methylation returned to those of age-matched controls. We also found that combined exposure to radiation and estrogen significantly altered the levels of histone H3 and H4 methylation and acetylation. Most importantly, we for the first time demonstrated that estrogen and radiation exposure caused a significant induction of p42/44 MAPK and p38 pathways that was paralleled by elevated levels of H3S10 phosphorylation, a well-established biomarker of genome and chromosome instability. The precise role of MAPK pathways and their inter-relationship with H3S10 phosphorylation and genome instability in mammary gland tissues needs to be explored further.
C1 [Kutanzi, Kristy; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 University of Lethbridge
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca
FU Alberta Cancer Research Institute; Canadian Breast Cancer Foundation;
   Vanier Canada Graduate Scholarship; National Science and Engineering
   Research Council Graduate Scholarship; Queen Elizabeth II Graduate
   Scholarship; Alberta Heritage for Medical Research Scholarship
FX Work was supported by the Alberta Cancer Research Institute and Canadian
   Breast Cancer Foundation Operating grants to OK. KK was a recipient of
   the Vanier Canada Graduate Scholarship, National Science and Engineering
   Research Council Graduate Scholarship, Queen Elizabeth II Graduate
   Scholarship, and the Alberta Heritage for Medical Research Scholarship.
   We are thankful to Rocio Rodriguez-Juarez and Igor Koturbash for
   technical assistance, to Dr Roderick T Bronson and Dr Langxing Pan for
   their help and advice with histopathology, to Dr Igor Pogribny for
   useful discussions, and to Dr Valentina Titova for careful proofreading
   of this manuscript.
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781
   Bhat HK, 2003, P NATL ACAD SCI USA, V100, P3913, DOI 10.1073/pnas.0437929100
   BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890
   Brody JG, 2007, CANCER-AM CANCER SOC, V109, P2667, DOI 10.1002/cncr.22655
   Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914
   Choi HS, 2005, CANCER RES, V65, P5818, DOI 10.1158/0008-5472.CAN-05-0197
   Chou CH, 2009, INT J RADIAT ONCOL, V75, P1553, DOI 10.1016/j.ijrobp.2009.08.034
   Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z
   Dyson MH, 2005, J CELL SCI, V118, P2247, DOI 10.1242/jcs.02373
   Ellsworth DL, 2004, LANCET ONCOL, V5, P753, DOI 10.1016/S1470-2045(04)01653-5
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fischle W, 2008, GENE DEV, V22, P3375, DOI 10.1101/gad.1759708
   Gould KA, 2004, GENETICS, V168, P2113, DOI 10.1534/genetics.104.033878
   Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076
   Harvell DME, 2000, P NATL ACAD SCI USA, V97, P2779, DOI 10.1073/pnas.050569097
   Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johansen KM, 2006, CHROMOSOME RES, V14, P393, DOI 10.1007/s10577-006-1063-4
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082
   Li JJ, 2002, MOL CARCINOGEN, V33, P56, DOI 10.1002/mc.10022
   Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101
   Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003
   MacMahon B, 2006, INT J CANCER, V118, P2373, DOI 10.1002/ijc.21404
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679
   Mobley JA, 2004, CARCINOGENESIS, V25, P3, DOI 10.1093/carcin/bgg175
   Moss TJ, 2007, MUTAT RES-FUND MOL M, V618, P163, DOI 10.1016/j.mrfmmm.2006.05.038
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588
   Okitsu CY, 2007, MOL CELL BIOL, V27, P2746, DOI 10.1128/MCB.02291-06
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Ota T, 2002, CANCER RES, V62, P5168
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Powell CL, 2005, CANCER LETT, V229, P1, DOI 10.1016/j.canlet.2004.12.002
   Prise KM, 2001, RADIAT RES, V156, P572, DOI 10.1667/0033-7587(2001)156[0572:AROSOI]2.0.CO;2
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Ronckers CM, 2005, BREAST CANCER RES, V7, P21, DOI 10.1186/bcr970
   Ruhlen RL, 2009, BREAST CANCER RES TR, V117, P517, DOI 10.1007/s10549-008-0169-0
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   Russo J, 2006, J STEROID BIOCHEM, V102, P89, DOI 10.1016/j.jsbmb.2006.09.004
   Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267
   Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002
   Schaffer BS, 2006, CANCER RES, V66, P7793, DOI 10.1158/0008-5472.CAN-06-0143
   Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253
   Shull James D, 2007, Breast Dis, V28, P69
   Shull JD, 1997, CARCINOGENESIS, V18, P1595, DOI 10.1093/carcin/18.8.1595
   Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309
   Smith SS, 1998, INT J MOL MED, V1, P147
   Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116
   Starlard-Davenport A, 2010, CARCINOGENESIS, V31, P376, DOI 10.1093/carcin/bgp304
   STORM HH, 1992, J NATL CANCER I, V84, P1245, DOI 10.1093/jnci/84.16.1245
   Subramanian A, 2008, BREAST CANCER RES TR, V111, P191, DOI 10.1007/s10549-007-9788-0
   Szyf M, 2003, AGEING RES REV, V2, P299, DOI 10.1016/S1568-1637(03)00012-6
   TOMATIS L, 1979, ANNU REV PHARMACOL, V19, P511, DOI 10.1146/annurev.pa.19.040179.002455
   Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   TURK PW, 1995, CARCINOGENESIS, V16, P1253, DOI 10.1093/carcin/16.5.1253
   Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   WEITZMAN SA, 1994, P NATL ACAD SCI USA, V91, P1261, DOI 10.1073/pnas.91.4.1261
   Weyandt J, 2008, CURR MED CHEM, V15, P2680, DOI 10.2174/092986708786242930
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
NR 70
TC 10
Z9 11
U1 2
U2 10
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JUL 1
PY 2013
VL 14
IS 7
BP 564
EP 573
DI 10.4161/cbt.24599
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 200BT
UT WOS:000323042400002
PM 23792640
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Wang, B
   Li, DP
   Kovalchuk, O
AF Wang, Bo
   Li, Dongping
   Kovalchuk, Olga
TI p53 Ser15 phosphorylation and histone modifications contribute to
   IR-induced miR-34a transcription in mammary epithelial cells
SO CELL CYCLE
LA English
DT Article
DE ionizing radiation; mammary epithelial cells; p53 phosphorylation;
   histone modification; miR-34a transcription
ID DNA METHYLATION; BREAST-CANCER; GENE-EXPRESSION; NEOPLASTIC
   TRANSFORMATION; ONCOPROTEIN EXPRESSION; EPIGENETIC REGULATION; STRONG
   DEPENDENCE; TUMOR-SUPPRESSOR; CYCLE ARREST; X-RAYS
AB Previous studies have demonstrated that miR-34a is a direct transcriptional target of tumor suppressor p53 and plays a crucial role in p53-mediated biological processes, such as cell cycle arrest, apoptosis and senescence. However, the role of p53 phosphorylation at Ser15 and histone modifications in ionizing radiation (IR)-induced miR-34a transcription in human mammary epithelial cells remains unknown. The present study showed that IR triggers miR-34a induction in rat mammary gland tissue and human mammary epithelial cells in a dose- and time-dependent fashion. Gene copy number and CpG methylation exhibit no effect on IR-inducible miR-34a expression, while the levels of phosphorylated p53 at Ser15 are markedly elevated in human mammary epithelial cells 96 h post-IR, which correlates with IR-inducible miR-34a transcription and the p38 MAPK pathway. Conversely, suppression of p38 MAPK with SB239063 inhibits IR-induced p53 phosphorylation at Ser15 and miR-34a expression in a dose-dependent manner. Our study found that wild-type p53 is enriched at miR-34a promoter, and luciferase activity of miR-34a promoter reporter is attenuated by either mutant p53 (Ser15Ala) or mutant miR-34a promoter. Furthermore, IR also triggers phosphorylation, tri-methylation and acetylation of histone H3 and acetylation of histone H4, which correlates with IR-inducible miR-34a transcription, while SAHA potentiates IR-inducible miR-34a expression. Moreover, acetyl-histone H3 is significantly enriched at miR-34a promoter in IR-exposed HMEC cells. Yet, we show that there is no correlation between IR-inducible miR-34a expression and IR-induced rapid and transient G(2)/M arrest. In sum, our novel data for the first time demonstrate that IR-induced p53 Ser15 phosphorylation via p38 MAPK is essential for its functional regulation of IR-inducible miR-34a transcription in human mammary epithelial cells, and that histone modifications may also play a key role in IR-inducible miR-34a expression.
C1 [Wang, Bo; Li, Dongping; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 University of Lethbridge
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca
OI Wang, Bo/0000-0001-7260-1938
FU Alberta Cancer Foundation/Alberta Innovates-Health Solutions grant;
   Alberta Innovates-Health Solutions Postdoctoral Fellow ship
FX This study was supported by Alberta Cancer Foundation/Alberta
   Innovates-Health Solutions grant to O. Kovalchuk. B. Wang is a recipient
   of the Alberta Innovates-Health Solutions Postdoctoral Fellow ship. We
   thank Ms Lidia Luzhna and Ms Dorothy McRae for providing IR-exposed rat
   mammary gland tissue; we are grateful to Prof Moshe Oren (Department of
   Molecular Cell Biology, The Weizmann Institute of Science) for providing
   EST-Prom-Luc and EST-Prom-M-Luc reporters. We also thank Mr Julian St.
   Hilaire for performing flow cytometry experiments.
CR BRENNER DJ, 1989, BRIT J RADIOL, V62, P910, DOI 10.1259/0007-1285-62-742-910
   Brenner DJ, 2002, INT J RADIAT BIOL, V78, P1065, DOI 10.1080/0955300021000016576
   Calaf G, 2001, INT J RADIAT BIOL, V77, P31, DOI 10.1080/095530001453096
   Calaf GM, 2005, ONCOL REP, V14, P885
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Cheung P, 2005, MOL ENDOCRINOL, V19, P563, DOI 10.1210/me.2004-0496
   Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033
   Cho HN, 2001, INT J RADIAT BIOL, V77, P225, DOI 10.1080/09553000010001024
   Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109
   Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]
   Doody MM, 2000, SPINE, V25, P2052
   Eccles LJ, 2011, MUTAT RES-FUND MOL M, V711, P134, DOI 10.1016/j.mrfmmm.2010.11.003
   Esteller M, 2011, GENES CANC, V2, p604 6, DOI 10.1177/1947601911423096 21941616
   Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Frankenberg D, 2002, RADIAT PROT DOSIM, V99, P261, DOI 10.1093/oxfordjournals.rpd.a006779
   Frankenberg D, 2002, RADIAT RES, V157, P99, DOI 10.1667/0033-7587(2002)157[0099:ENTBMX]2.0.CO;2
   Frankenberg D, 2002, J RADIOL PROT, V22, p3AA17, DOI 10.1088/0952-4746/22/3A/303 12400941
   Gentile M, 2003, NUCLEIC ACIDS RES, V31, P4779, DOI 10.1093/nar/gkg675
   Georgakilas AG, 2008, MOL BIOSYST, V4, P30, DOI 10.1039/b713178j
   Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Healy S, 2012, BIOCHEM CELL BIOL, V90, P39, DOI [10.1139/O11-092, 10.1139/o11-092]
   Herceg Z, 2010, ADV GENET, V70, P1, DOI [10.1016/S0065-2660(10)70001-8, 10.1016/B978-0-12-380866-0.60001-0]
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   Hutvágner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3
   Hutvágner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Ilnytskyy Y, 2011, MUTAT RES-FUND MOL M, V714, P113, DOI 10.1016/j.mrfmmm.2011.06.014
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Koturbash I, 2008, CELL CYCLE, V7, P1658, DOI 10.4161/cc.7.11.5981
   Koturbash I, 2011, MUTAT RES-GEN TOX EN, V722, P94, DOI 10.1016/j.mrgentox.2010.05.006
   Kovalchuk O, 2008, ENVIRON MOL MUTAGEN, V49, P16, DOI 10.1002/em.20361
   Kruger RL, 2001, MED PHYS, V28, P1449, DOI 10.1118/1.1382606
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529
   Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Loree J, 2006, INT J RADIAT BIOL, V82, P805, DOI 10.1080/09553000600960027
   MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935
   MATTSSON A, 1993, J NATL CANCER I, V85, P1679, DOI 10.1093/jnci/85.20.1679
   Munshi A, 2009, J GENET GENOMICS, V36, P75, DOI 10.1016/S1673-8527(08)60094-6
   Piao HL, 2012, J MAMMARY GLAND BIOL, V17, P33, DOI 10.1007/s10911-012-9245-5
   Pogribny IP, 2009, CELL MOL LIFE SCI, V66, P2249, DOI 10.1007/s00018-009-0015-5
   Raver-Shapira N, 2007, CELL CYCLE, V6, P2656, DOI 10.4161/cc.6.21.4915
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Ronckers CM, 2005, BREAST CANCER RES, V7, P21, DOI 10.1186/bcr970
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200
   Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Shames DS, 2007, CURR MOL MED, V7, P85, DOI 10.2174/156652407779940413
   Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436
   Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104
   Valerie K, 2007, MOL CANCER THER, V6, P789, DOI 10.1158/1535-7163.MCT-06-0596
   VANBEKKUM DW, 1991, RADIAT ENVIRON BIOPH, V30, P217, DOI 10.1007/BF01226623
   Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Weidman JR, 2007, CANCER J, V13, P9, DOI 10.1097/PPO.0b013e31803c71f2
   Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293
NR 64
TC 23
Z9 23
U1 1
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD JUL 1
PY 2013
VL 12
IS 13
BP 2073
EP 2083
DI 10.4161/cc.25135
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 201VI
UT WOS:000323170700021
PM 23759592
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU You, YJ
   Yang, WJ
   Wang, ZZ
   Zhu, HM
   Li, HJ
   Lin, CF
   Ran, YG
AF You, Yanjie
   Yang, Wenjun
   Wang, Zhizhong
   Zhu, Huimin
   Li, Haijun
   Lin, Canfeng
   Ran, Yonggang
TI Promoter hypermethylation contributes to the frequent suppression of the
   <i>CDK10</i> gene in human nasopharyngeal carcinomas
SO CELLULAR ONCOLOGY
LA English
DT Article
DE CDK10; DNA methylation; Nasopharyngeal carcinoma; Cancer surveillance
   and screening; Tumor suppressor gene
ID TUMOR-SUPPRESSOR; BREAST-CANCER; ABERRANT METHYLATION; PERIPHERAL-BLOOD;
   PROTEIN-KINASE; PISSLRE; BIOMARKER; FAMILY; FLUID; CELLS
AB Previous studies have shown a down-regulation of the gene encoding cyclin-dependent kinase 10 (CDK10) in hepatocellular carcinomas. Here we provide evidence that down-regulation of the CDK10 gene is mediated by promoter hypermethylation in primary human nasopharyngeal carcinomas (NPC) and NPC-derived cell lines.
   RT-PCR, Western blotting, methylation-specific PCR and bisulfite sequencing were performed to assess the expression and methylation status of the CDK10 gene in primary NPC samples, NPC-derived cell lines and patient-derived peripheral blood samples. The NPC-derived cell line CNE-2 was selected for treatment with a methylation inhibitor to restore CDK10 expression. In addition, cell proliferation, invasion and colony formation assays were performed to assess the inhibitory effects of ectopic CDK10 expression in CNE-2 cells.
   Down-regulation of CDK10 expression in primary NPC samples (23/40, 57.5 %) was found to be significantly correlated with the methylation status of its promoter CpG island (21/40, 52.5 %). Demethylation by 5-aza-dC treatment led to reactivation of the CDK10 gene in the CNE-2 cell line. Additionally, exogenous expression of CDK10 in CNE-2 cells strongly suppressed its growth, invasion and colony formation capacities. The high sensitivity (15/40, 37.5 %) and specificity (0 % false positives) of detecting CDK10 promoter hypermethylation in NPC patient-derived peripheral blood samples suggest that it could be employed as an epigenetic marker for noninvasive cancer diagnosis and recurrence screening.
   Our findings implicate that aberrant methylation of the CDK10 gene promoter occurs frequently in NPC, and that reactivation of CDK10 might be utilized as a novel epigenetic strategy for the treatment of NPC patients.
C1 [You, Yanjie] Luohe Med Coll, Dept Pharm, Luohe 462002, Peoples R China.
   [Yang, Wenjun] Ningxia Med Univ, Inst Canc Res, Yinchuan 750004, Peoples R China.
   [Yang, Wenjun] Ningxia Med Univ, Sch Basic Med Sci, Yinchuan 750004, Peoples R China.
   [Wang, Zhizhong] Ningxia Med Univ, Dept Stat & Epidemiol, Yinchuan 750004, Peoples R China.
   [Zhu, Huimin] Luohe Med Coll, Affiliated Hosp 3, Dept Gynaecol, Luohe 462002, Peoples R China.
   [Li, Haijun] Second Peoples Hosp Neijiang City, Dept Radiat Oncol, Neijaing 641000, Peoples R China.
   [Lin, Canfeng] Shantou Cent Hosp, Dept Radiat Oncol, Shantou 515041, Peoples R China.
   [Ran, Yonggang] Bethune Mil Med NCO Acad PLA, Dept Teaching & Training, Shijiazhuang 050081, Peoples R China.
C3 Ningxia Medical University; Ningxia Medical University; Ningxia Medical
   University
RP You, YJ (通讯作者)，Luohe Med Coll, Dept Pharm, 148 Daxue Rd, Luohe 462002, Peoples R China.
EM youyanjie@163.com
RI zhu, huimin/ITV-5615-2023
OI Wang, zhizhong/0000-0002-0612-3218; Yang, Wenjun/0000-0001-5671-1344
FU Annual Natural Science Foundation of Luohe Medical College
FX We thank Mr. Zhen Zhang (Department of Biochemistry and Molecular
   Biology, University of Kansas Medical Center) for his careful reading of
   the manuscript and kind suggestions. This work was supported by the 2013
   Annual Natural Science Foundation of Luohe Medical College (Y.-J. You).
CR Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332
   Bae Young Kyung, 2005, Cancer Res Treat, V37, P233, DOI 10.4143/crt.2005.37.4.233
   Baek YH, 2009, DIS COLON RECTUM, V52, P1452, DOI 10.1007/DCR.0b013e3181a79533
   BRAMBILLA R, 1994, ONCOGENE, V9, P3037
   BULLRICH F, 1995, CANCER RES, V55, P1199
   Chang HW, 2003, INT J CANCER, V105, P851, DOI 10.1002/ijc.11162
   Crawford J, 1999, GENOMICS, V56, P90, DOI 10.1006/geno.1998.5676
   GRANA X, 1994, ONCOGENE, V9, P2097
   Guo MZ, 2008, EPIGENETICS-US, V3, P336, DOI 10.4161/epi.3.6.7158
   Heller G, 2009, ANTICANCER RES, V29, P3939
   Hoffmann AC, 2009, J CANCER RES CLIN, V135, P1231, DOI 10.1007/s00432-009-0564-x
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Niedobitek G, 2000, J CLIN PATHOL-MOL PA, V53, P248, DOI 10.1136/mp.53.5.248
   Ran YG, 2011, J BIOCHEM, V149, P49, DOI 10.1093/jb/mvq128
   Rosas SLB, 2001, CANCER RES, V61, P939
   Sanguineti G, 1997, INT J RADIAT ONCOL, V37, P985, DOI 10.1016/S0360-3016(97)00104-1
   Sun D, 2007, ORAL ONCOL, V43, P82, DOI 10.1016/j.oraloncology.2006.01.007
   You YJ, 2012, CANCER LETT, V315, P138, DOI 10.1016/j.canlet.2011.08.032
   You Y, 2008, CYTOTECHNOLOGY, V56, P97, DOI 10.1007/s10616-007-9117-9
   Yu JH, 2012, ONCOL REP, V27, P1266, DOI 10.3892/or.2011.1617
   Zhong XY, 2012, GENE, V498, P68, DOI 10.1016/j.gene.2012.01.022
   Zhu WZ, 2010, INT J CANCER, V126, P474, DOI 10.1002/ijc.24728
NR 22
TC 20
Z9 23
U1 1
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD JUL
PY 2013
VL 36
IS 4
BP 323
EP 331
DI 10.1007/s13402-013-0137-5
PG 9
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA 200GG
UT WOS:000323055400006
PM 23740091
DA 2025-01-12
ER

PT J
AU Meng, XQ
   Wu, JX
   Pan, CC
   Wang, H
   Ying, XF
   Zhou, Y
   Yu, HY
   Zuo, YF
   Pan, ZZ
   Liu, RY
   Huang, WL
AF Meng, Xiangqi
   Wu, Jiangxue
   Pan, Changchuan
   Wang, Hui
   Ying, Xiaofang
   Zhou, Yi
   Yu, Hongyan
   Zuo, Yufang
   Pan, Zhizhong
   Liu, Ran-Yi
   Huang, Wenlin
TI Genetic and Epigenetic Down-regulation of MicroRNA-212 Promotes
   Colorectal Tumor Metastasis via Dysregulation of MnSOD
SO GASTROENTEROLOGY
LA English
DT Article
DE Gene Expression; Epigenetic Regulation; Genetic Alteration; Colorectal
   Cancer
ID MANGANESE-SUPEROXIDE-DISMUTASE; BREAST-CANCER CELLS; MIR-212 EXPRESSION;
   LUNG-CANCER; LIVER; ACTIVATION; MECHANISM; APOPTOSIS; OVEREXPRESSION;
   INDUCTION
AB BACKGROUND & AIMS: Altered functions of microRNAs (miRNAs) have been associated with colorectal cancer (CRC). miR-212 is transcribed from a stable intron of a non-protein coding gene, and is reportedly down-regulated in different tumor types. We investigated the role of miR-212 in colorectal carcinogenesis and progression. METHODS: We analyzed the expression of miR-212 by real-time polymerase chain reaction (PCR) analysis of colorectal cell lines and 180 paired tumor samples and surrounding healthy tissue. We overexpressed and knocked down miR-212 in CRC cell lines and assessed the in vitro effects. We also studied the effects of miR-212 overexpression on metastasis of tumors grown from HCT116 cells in nude mice. RESULTS: Overexpression of miR-212 inhibited CRC cell migration and invasion in vitro and formation of intrahepatic and pulmonary metastasis in vivo. We identified manganese superoxide dismutase (MnSOD) messenger RNA as a direct target of miR-212, and observed an inverse correlation between the level of miR-212 and MnSOD protein in colorectal tumor samples. MnSOD was required for down-regulation of epithelial markers and up-regulation of mesenchymal markers in CRC cells, indicating that it promoted the epithelial-mesenchymal transition. Overexpression of miR-212 reduced the levels of MnSOD to block the epithelial-mesenchymal transition process. Loss of heterozygosity and promoter hypermethylation each contributed to the down-regulation of miR-212. Reduced levels of miR-212 were associated with a more aggressive tumor phenotype and short disease-free survival times of patients (P = .0045; overall survival, P = .0015). CONCLUSIONS: miR-212 is down-regulated in human CRC tissues via genetic and epigenetic mechanisms. miR-212 might prevent tumor progression by targeting MnSOD messenger RNA; reduction of miR-212 could be a prognostic marker for patients with CRC. miR-212 and MnSOD might also be therapeutic targets for cancer.
C1 [Meng, Xiangqi; Wu, Jiangxue; Wang, Hui; Ying, Xiaofang; Zhou, Yi; Yu, Hongyan; Zuo, Yufang; Pan, Zhizhong; Liu, Ran-Yi; Huang, Wenlin] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
   [Pan, Changchuan] Second Peoples Hosp Sichuan Prov, Sichuan Canc Hosp & Inst, Chengdu, Peoples R China.
   [Huang, Wenlin] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.
C3 State Key Lab Oncology South China; Sun Yat Sen University; Chinese
   Academy of Sciences; Institute of Microbiology, CAS
RP Huang, WL (通讯作者)，Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, No 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM hwenl@mail.sysu.edu.cn
RI Jiang, Senwei/HSE-5278-2023; Liu, Ran-yi/L-1008-2019; Zhang,
   Changlin/ABI-4611-2020; huang, wenlin/H-7572-2016; zuo,
   yufang/AAH-7155-2021; Han, Yutong/ISU-4638-2023
OI Meng, Xiangqi/0000-0002-6407-6122
FU National High Technology Research and Development Program of China
   (project 863) [2012AA02A204]; National Basic Research Program of China
   (973 Program) [2011CB504805, 2010CB912201, 2010CB529904]; National
   Natural Science Foundation of China [81272638, 30973448]; Guangdong
   Innovative Research Team Program [2009010058]
FX This work was supported by grants from the National High Technology
   Research and Development Program of China (project 863, no.
   2012AA02A204), the National Basic Research Program of China (973
   Program, no. 2011CB504805, 2010CB912201, 2010CB529904), the National
   Natural Science Foundation of China (no. 81272638, 30973448) and
   Guangdong Innovative Research Team Program (no. 2009010058).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018
   Cheng ZX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023752
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ghetie C, 2008, CLIN COLORECTAL CANC, V7, P283, DOI 10.3816/CCC.2008.n.037
   Goyal P, 2004, FREE RADICAL BIO MED, V36, P1279, DOI 10.1016/j.freeradbiomed.2004.02.071
   Hitchiler MJ, 2008, FREE RADICAL BIO MED, V45, P1573, DOI 10.1016/j.freeradbiomed.2008.09.005
   Holdhoff M, 2011, CLIN CANCER RES, V17, P3551, DOI 10.1158/1078-0432.CCR-10-3087
   Hu YM, 2005, J BIOL CHEM, V280, P39485, DOI 10.1074/jbc.M503296200
   Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358
   Hur K., 2012, GUT
   Incoronato M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027722
   Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341
   Kaewpila S, 2008, CANCER RES, V68, P2781, DOI 10.1158/0008-5472.CAN-07-2635
   KALLIONIEMI A, 1992, CYTOGENET CELL GENET, V60, P190, DOI 10.1159/000133333
   Kato M, 2008, BIOL CELL, V100, P71, DOI 10.1042/BC20070078
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li SJ, 2000, CANCER RES, V60, P3927
   Li Y, 2012, MOL BIOL CELL, V23, P1423, DOI 10.1091/mbc.E11-09-0777
   Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mohr A, 2008, ONCOGENE, V27, P763, DOI 10.1038/sj.onc.1210673
   Okamoto K, 2012, EMBO J, V31, P1752, DOI 10.1038/emboj.2012.25
   Risio M, 2003, CANCER GENET CYTOGEN, V147, P44, DOI 10.1016/S0165-4608(03)00188-2
   Saeed M, 2011, J BIOL CHEM, V286, P33872, DOI 10.1074/jbc.M111.275446
   Saeki H, 2011, CLIN CANCER RES, V17, P1731, DOI 10.1158/1078-0432.CCR-10-1996
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   SIDDIQUI KM, 1984, IN VITRO CELL DEV B, V20, P859
   Sun SM, 2013, LEUKEMIA, V27, P100, DOI 10.1038/leu.2012.158
   Sureban SM, 2009, GASTROENTEROLOGY, V137
   Sureban SM, 2009, GASTROENTEROLOGY, V137, P649, DOI 10.1053/j.gastro.2009.05.004
   Tang YM, 2008, ALCOHOL CLIN EXP RES, V32, P355, DOI 10.1111/j.1530-0277.2007.00584.x
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Toh Y, 2000, INT J ONCOL, V17, P107
   Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126
   Wang H, 2011, CARCINOGENESIS, V32, P1033, DOI 10.1093/carcin/bgr081
   Wang TL, 2004, P NATL ACAD SCI USA, V101, P3089, DOI 10.1073/pnas.0308716101
   Yoo YG, 2011, CANCER RES, V71, P1244, DOI 10.1158/0008-5472.CAN-10-2360
   Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200
   Zhang YH, 2006, CANCER RES, V66, P4291, DOI 10.1158/0008-5472.CAN-05-1834
   Zhou J, 2011, J CLIN ONCOL, V29, P4781, DOI 10.1200/JCO.2011.38.2697
   Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338
NR 43
TC 94
Z9 100
U1 0
U2 23
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD AUG
PY 2013
VL 145
IS 2
BP 426
EP +
DI 10.1053/j.gastro.2013.04.004
PG 17
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 194KC
UT WOS:000322630600032
PM 23583431
OA Bronze
DA 2025-01-12
ER

PT J
AU Bond, WS
   Akinfenwa, PY
   Perlaky, L
   Hurwitz, MY
   Hurwitz, RL
   Chévez-Barrios, P
AF Bond, Wesley S.
   Akinfenwa, Patricia Y.
   Perlaky, Laszlo
   Hurwitz, Mary Y.
   Hurwitz, Richard L.
   Chevez-Barrios, Patricia
TI Tumorspheres but Not Adherent Cells Derived from Retinoblastoma Tumors
   Are of Malignant Origin
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; STEM-CELLS; GENE; IDENTIFICATION; EXPRESSION; LINES;
   MISIDENTIFICATION; PRECURSORS; CULTURE; BRAIN
AB Verification that cell lines used for cancer research are derived from malignant cells in primary tumors is imperative to avoid invalidation of study results. Retinoblastoma is a childhood ocular tumor that develops from loss of functional retinoblastoma protein (pRb) as a result of genetic or epigenetic changes that affect both alleles of the RB1 gene. These patients contain unique identifiable genetic signatures specifically present in malignant cells. Primary cultures derived from retinoblastoma tumors can be established as non-adherent tumorspheres when grown in defined media or as attached monolayers when grown in serum-containing media. While the RB1 genotypes of tumorspheres match those of the primary tumor, adherent cultures have the germline RB1 genotype. Tumorspheres derived from pRb-negative tumors do not express pRb and express the neuroendocrine tumor markers synaptophysin and microtubule-associated protein 2 (MAP2). Adherent cells are synaptophysin-negative and express pRb, the epithelial cell marker cytokeratin that is expressed in the retinal pigmented epithelium and the vascular endothelial cell marker CD34. While tumorspheres are of malignant origin, our results cast doubt on the assumption that adherent tumor-derived cultures are always valid in vitro models of malignant cells and emphasize the need for validation of primary tumor cultures.
C1 [Bond, Wesley S.; Akinfenwa, Patricia Y.; Hurwitz, Richard L.; Chevez-Barrios, Patricia] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA.
   [Bond, Wesley S.; Akinfenwa, Patricia Y.; Perlaky, Laszlo; Hurwitz, Mary Y.; Hurwitz, Richard L.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Bond, Wesley S.; Akinfenwa, Patricia Y.; Hurwitz, Mary Y.; Hurwitz, Richard L.] Ctr Cell & Gene Therapy, Houston, TX USA.
   [Bond, Wesley S.; Akinfenwa, Patricia Y.; Perlaky, Laszlo; Hurwitz, Mary Y.; Hurwitz, Richard L.] Texas Childrens Canc & Hematol Cts, Houston, TX USA.
   [Chevez-Barrios, Patricia] Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA.
   [Hurwitz, Richard L.; Chevez-Barrios, Patricia] Retinoblastoma Ctr Houston, Houston, TX USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine; Baylor College Medical Hospital; Texas Children's Cancer
   Center; Houston Methodist
RP Chévez-Barrios, P (通讯作者)，Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA.
EM pchevez-barrios@tmhs.org
OI Bond, Wesley/0000-0001-9715-0336
FU Retina Research Foundation; Golfers Against Cancer; National Institutes
   of Health grant [T32 EY007001-37]
FX This work was supported by the Retina Research Foundation (RLH), Golfers
   Against Cancer (RLH) and National Institutes of Health grant T32
   EY007001-37 (PYA). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bond WS, 2011, JOVE-J VIS EXP, DOI 10.3791/2644
   Chatterjee R, 2007, SCIENCE, V315, P928, DOI 10.1126/science.315.5814.928
   Dimaras H, 2008, HUM MOL GENET, V17, P1363, DOI 10.1093/hmg/ddn024
   Dimaras H, 2012, LANCET, V379, P1436, DOI 10.1016/S0140-6736(11)61137-9
   FINA L, 1990, BLOOD, V75, P2417
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   GOULD VE, 1987, AM J PATHOL, V126, P243
   HERMAN MM, 1989, AM J PATHOL, V134, P115
   Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152
   Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012
   HISCOTT PS, 1984, BRIT J OPHTHALMOL, V68, P708, DOI 10.1136/bjo.68.10.708
   HISCOTT PS, 1984, BRIT J OPHTHALMOL, V68, P698, DOI 10.1136/bjo.68.10.698
   HURWITZ RL, 1990, J CLIN INVEST, V85, P1872, DOI 10.1172/JCI114648
   LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017
   Liscovitch M, 2007, CANCER LETT, V245, P350, DOI 10.1016/j.canlet.2006.01.013
   Mardis ER, 2009, HUM MOL GENET, V18, pR163, DOI 10.1093/hmg/ddp396
   McCallum HM, 1996, BREAST CANCER RES TR, V39, P247, DOI 10.1007/BF01806153
   Nardone RM, 2008, BIOTECHNIQUES, V45, P221, DOI 10.2144/000112925
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347
   Seaberg RM, 2004, NAT BIOTECHNOL, V22, P1115, DOI 10.1038/nbt1004
   Singh SK, 2003, CANCER RES, V63, P5821
   Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   TUCKER RP, 1988, DEV BIOL, V130, P423, DOI 10.1016/0012-1606(88)90338-7
   Valverde JR, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-53
   Wadhwa L, 2012, INVEST OPHTH VIS SCI, V53, P3454, DOI 10.1167/iovs.12-9549
   Zhong XF, 2007, INT J CANCER, V121, P2125, DOI 10.1002/ijc.22880
NR 29
TC 19
Z9 19
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2013
VL 8
IS 6
AR e63519
DI 10.1371/journal.pone.0063519
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 182JP
UT WOS:000321738400002
PM 23826078
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Li, H
   Sheridan, R
   Williams, T
AF Li, Hong
   Sheridan, Ryan
   Williams, Trevor
TI Analysis of <i>TFAP2A</i> mutations in Branchio-Oculo-Facial Syndrome
   indicates functional complexity within the AP-2 DNA-binding domain
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID TRANSCRIPTION FACTOR AP-2; NUCLEAR-LOCALIZATION SIGNAL; PATENT
   DUCTUS-ARTERIOSUS; CAUSE CHAR-SYNDROME; BREAST-CANCER; LENS VESICLE;
   AP-2-ALPHA; PHENOTYPE; DEFECTS; IDENTIFICATION
AB Multiple lines of evidence indicate that the AP-2 transcription factor family has an important regulatory function in human craniofacial development. Notably, mutations in TFAP2A, the gene encoding AP-2, have been identified in patients with Branchio-Oculo-Facial Syndrome (BOFS). BOFS is an autosomal-dominant trait that commonly presents with facial clefting, eye defects and branchial skin anomalies. Examination of multiple cases has suggested either simple haploinsufficiency or more complex genetic causes for BOFS, especially as the clinical manifestations are variable, with no clear genotypephenotype correlation. Mutations occur throughout TFAP2A, but mostly within conserved sequences within the DNA contact domain of AP-2. However, the consequences of the various mutations for AP-2 protein function have not been evaluated. Therefore, it remains unclear if all BOFS mutations result in similar changes to the AP-2 protein or if they each produce specific alterations that underlie the spectrum of phenotypes. Here, we have investigated the molecular consequences of the mutations that localize to the DNA-binding region. We show that although individual mutations have different effects on DNA binding, they all demonstrate significantly reduced transcriptional activities. Moreover, all mutant derivatives have an altered nuclear:cytoplasmic distribution compared with the predominantly nuclear localization of wild-type AP-2 and several can exert a dominant-negative activity on the wild-type AP-2 protein. Overall, our data suggest that the individual TFAP2A BOFS mutations can generate null, hypomorphic or antimorphic alleles and that these differences in activity, combined with a role for AP-2 in epigenetic events, may influence the resultant pathology and the phenotypic variability.
C1 [Li, Hong; Sheridan, Ryan; Williams, Trevor] Univ Colorado Denver, Dept Craniofacial Biol & Cell & Dev Biol, Aurora, CO 80045 USA.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus
RP Williams, T (通讯作者)，Univ Colorado Denver, Dept Craniofacial Biol & Cell & Dev Biol, Mailstop 8120,12801 East 17th Ave,POB 6511, Aurora, CO 80045 USA.
EM trevor.williams@ucdenver.edu
RI Li, Hong/R-8843-2016; Sheridan, Ryan/LWK-8532-2024
OI Sheridan, Ryan/0000-0003-4012-3147
FU National Institutes of Health [DE 012728]
FX This research was supported by the National Institutes of Health (grant
   number DE 012728 to T.W.).
CR Ahituv N, 2004, MAMM GENOME, V15, P424, DOI 10.1007/s00335-004-2334-z
   Al-Dosari MS, 2010, MOL VIS, V16, P813
   Aliferis K, 2011, OPHTHALMIC GENET, V32, P250, DOI 10.3109/13816810.2011.592176
   Arcidiacono MV, 2008, J AM SOC NEPHROL, V19, P1919, DOI 10.1681/ASN.2007111216
   Ba ANN, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-202
   Bassett EA, 2010, HUM MOL GENET, V19, P1791, DOI 10.1093/hmg/ddq060
   Brewer S, 2004, DEV BIOL, V267, P135, DOI 10.1016/j.ydbio.2003.10.039
   Brewer S, 2002, MECH DEVELOP, V110, P139, DOI 10.1016/S0925-4773(01)00579-2
   Britto R, 2007, CANCER BIOL THER, V6, P413, DOI 10.4161/cbt.6.3.3756
   Davies SJ, 2004, CYTOGENET GENOME RES, V105, P47, DOI 10.1159/000078008
   Ding XF, 2006, NUCLEIC ACIDS RES, V34, P2570, DOI 10.1093/nar/gkl319
   Dixon MJ, 2011, NAT REV GENET, V12, P167, DOI 10.1038/nrg2933
   Dumitrescu AV, 2012, OPHTHALMIC GENET, V33, P100, DOI 10.3109/13816810.2011.634878
   Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246
   Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913
   Feng WG, 2003, MOL CELL NEUROSCI, V24, P460, DOI 10.1016/S1044-7431(03)00209-4
   Frascari F, 2012, ANN DERMATOL VENER, V139, P550, DOI 10.1016/j.annder.2012.05.006
   Galliani E, 2012, CLEFT PALATE-CRAN J, V49, P357, DOI 10.1597/10-203
   García MA, 1999, FEBS LETT, V444, P27, DOI 10.1016/S0014-5793(99)00021-6
   García MA, 2000, J MOL BIOL, V301, P807, DOI 10.1006/jmbi.2000.4019
   GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x
   Gestri G, 2009, HUM GENET, V126, P791, DOI 10.1007/s00439-009-0730-x
   Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6
   Iwamoto N, 2008, ARTERIOSCL THROM VAS, V28, P2282, DOI 10.1161/ATVBAHA.108.174714
   Kosugi S, 2009, P NATL ACAD SCI USA, V106, P10171, DOI 10.1073/pnas.0900604106
   la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062
   Lange A, 2010, TRAFFIC, V11, P311, DOI 10.1111/j.1600-0854.2009.01028.x
   Lin AE, 2011, GENEREVIEWS
   Mani A, 2005, P NATL ACAD SCI USA, V102, P2975, DOI 10.1073/pnas.0409852102
   Marfori M, 2011, BBA-MOL CELL RES, V1813, P1562, DOI 10.1016/j.bbamcr.2010.10.013
   MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7
   Mazina OM, 2001, J INVEST DERMATOL, V117, P864, DOI 10.1046/j.0022-202x.2001.01472.x
   Milunsky JM, 2008, AM J HUM GENET, V82, P1171, DOI 10.1016/j.ajhg.2008.03.005
   Milunsky JM, 2011, AM J MED GENET A, V155A, P22, DOI 10.1002/ajmg.a.33783
   Mirza G, 2004, EUR J HUM GENET, V12, P718, DOI 10.1038/sj.ejhg.5201194
   Nelson DK, 2004, DEV BIOL, V267, P72, DOI 10.1016/j.ydbio.2003.10.033
   Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714
   Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648
   Pontoriero GF, 2008, DEV DYNAM, V237, P602, DOI 10.1002/dvdy.21445
   Rahimov F, 2012, CLEFT PALATE-CRAN J, V49, P73, DOI 10.1597/10-178
   Reiber J, 2010, AM J MED GENET A, V152A, P994, DOI 10.1002/ajmg.a.33331
   Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578
   Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0
   Stoetzel C, 2009, AM J MED GENET A, V149A, P2141, DOI 10.1002/ajmg.a.33015
   Tekin M, 2009, AM J MED GENET A, V149A, P427, DOI 10.1002/ajmg.a.32619
   Thomeer HGXM, 2010, ANN OTO RHINOL LARYN, V119, P806, DOI 10.1177/000348941011901204
   Turner BC, 1998, CANCER RES, V58, P5466
   West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132
   WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122
   WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670
   WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557
   Wu F, 2002, J CELL BIOCHEM, V84, P699, DOI 10.1002/jcb.10094
   Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200
   Zaidi SK, 2010, NAT REV GENET, V11, P583, DOI 10.1038/nrg2827
   Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0
   Zhao F, 2001, AM J HUM GENET, V69, P695, DOI 10.1086/323410
NR 56
TC 30
Z9 36
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2013
VL 22
IS 16
BP 3195
EP 3206
DI 10.1093/hmg/ddt173
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 190LK
UT WOS:000322341300002
PM 23578821
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Au, SLK
   Wong, CCL
   Lee, JMF
   Wong, CM
   Ng, IOL
AF Au, Sandy Leung-Kuen
   Wong, Carmen Chak-Lui
   Lee, Joyce Man-Fong
   Wong, Chun-Ming
   Ng, Irene Oi-Lin
TI EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted
   in Liver Cancer 1 in Human Cancers
SO PLOS ONE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HEPATOCELLULAR-CARCINOMA CELLS; HISTONE
   METHYLTRANSFERASE EZH2; TUMOR-SUPPRESSOR GENES; GROUP PROTEIN EZH2;
   PROSTATE-CANCER; LYSINE-27 METHYLATION; DEVELOPMENTAL GENES;
   BREAST-CANCER; DLC-1 GENE
AB Enhancer of zeste homolog 2 (EZH2), the histone methyltransferase of the Polycomb Repressive complex 2 catalyzing histone H3 lysine 27 tri-methylation (H3K27me3), is frequently up-regulated in human cancers. In this study, we identified the tumor suppressor Deleted in liver cancer 1 (DLC1) as a target of repression by EZH2-mediated H3K27me3. DLC1 is a GTPase-activating protein for Rho family proteins. Inactivation of DLC1 results in hyper-activated Rho/ROCK signaling and is implicated in actin cytoskeleton reorganization to promote cancer metastasis. By chromatin immunoprecipitation assay, we demonstrated that H3K27me3 was significantly enriched at the DLC1 promoter region of a DLC1-nonexpressing HCC cell line, MHCC97L. Depletion of EZH2 in MHCC97L by shRNA reduced H3K27me3 level at DLC1 promoter and induced DLC1 gene re-expression. Conversely, transient overexpression of GFP-EZH2 in DLC1-expressing Huh7 cells reduced DLC1 mRNA level with a concomitant enrichment of EZH2 on DLC1 promoter. An inverse relation between EZH2 and DLC1 expression was observed in the liver, lung, breast, prostate, and ovarian cancer tissues. Treating cancer cells with the EZH2 small molecular inhibitor, 3-Deazaneplanocin A (DZNep), restored DLC1 expression in different cancer cell lines, indicating that EZH2-mediated H3K27me3 epigenetic regulation of DLC1 was a common mechanism in human cancers. Importantly, we found that DZNep treatment inhibited HCC cell migration through disrupting actin cytoskeleton network, suggesting the therapeutic potential of DZNep in targeting cancer metastasis. Taken together, our study has shed mechanistic insight into EZH2-H3K27me3 epigenetic repression of DLC1 and advocated the significant pro-metastatic role of EZH2 via repressing tumor and metastasis suppressors.
C1 [Ng, Irene Oi-Lin] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Ng, IOL (通讯作者)，Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China.
EM iolng@hkucc.hku.hk
RI WONG, Chun-Ming/A-6739-2009; Wong, Carmen Chak Lui/C-4660-2009
OI Wong, Carmen Chak Lui/0000-0001-5866-4705; WONG,
   Chun-Ming/0000-0002-2497-7858; Ng, Irene Oi-lin/0000-0001-7532-2029
FU University of Hong Kong Seed Funding Program for Basic Research
   [200811159061, 201011159045]; Hong Kong Research Grants Council General
   Research Fund [HKU 782411M]; Hong Kong Research Grants Council
   Collaborative Research Fund [HKU 1/06C, HKU 7/CRG/09]
FX The study was supported by The University of Hong Kong Seed Funding
   Program for Basic Research (200811159061 and 201011159045 to CMW), Hong
   Kong Research Grants Council General Research Fund (HKU 782411M to CMW)
   and Hong Kong Research Grants Council Collaborative Research Fund (HKU
   1/06C and HKU 7/CRG/09 to IN). IN is Loke Yew Professor in Pathology.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998
   Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chiba T, 2012, INT J CANCER, V130, P2557, DOI 10.1002/ijc.26264
   Durkin ME, 2005, FEBS LETT, V579, P1191, DOI 10.1016/j.febslet.2004.12.090
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li Y, 2001, WORLD J GASTROENTERO, V7, P630
   Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004
   Plimack ER, 2007, LEUKEMIA LYMPHOMA, V48, P1472, DOI 10.1080/10428190701471981
   Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   Shih YP, 2010, CANCER RES, V70, P8270, DOI 10.1158/0008-5472.CAN-10-1174
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387
   Ullmannova V, 2006, INT J ONCOL, V29, P1127
   Vanaja DK, 2003, CANCER RES, V63, P3877
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836
   Wong CC, 2008, PLOS ONE, V3, pe2779, DOI [10.1371/journal.pone.0002779, DOI 10.1371/J0URNAL.P0NE.0002779.PUBMED:18648664]
   Wong CM, 2003, CANCER RES, V63, P7646
   Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850
   Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269
   Yuan BZ, 1998, CANCER RES, V58, P2196
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246
NR 49
TC 47
Z9 51
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 27
PY 2013
VL 8
IS 6
AR e68226
DI 10.1371/journal.pone.0068226
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 174IX
UT WOS:000321150000134
PM 23826380
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Guan, D
   Factor, D
   Liu, Y
   Wang, Z
   Kao, HY
AF Guan, D.
   Factor, D.
   Liu, Yu
   Wang, Z.
   Kao, H-Y
TI The epigenetic regulator UHRF1 promotes ubiquitination-mediated
   degradation of the tumor-suppressor protein promyelocytic leukemia
   protein
SO ONCOGENE
LA English
DT Article
DE UHRF1; PML; ubiquitination; cell migration; capillary tube formation
ID HEMI-METHYLATED DNA; BREAST-CANCER; SRA DOMAIN; PML; LIGASE;
   RECOGNITION; GENE; ICBP90; ALPHA; ACETYLATION
AB The promyelocytic leukemia (PML) protein is a tumor suppressor originally identified in acute promyelocytic leukemia and implicated in tumorigenesis in multiple forms of cancer. Here, we demonstrate that the PML protein undergoes ubiquitination-mediated degradation facilitated by an E3 ligase UHRF1 (ubiquitin-like with PHD and RING finger domains 1), which is commonly upregulated in various human malignancies. Furthermore, UHRF1 negatively regulates PML protein accumulation in primary human umbilical vein endothelial cells (HUVECs), HEK 293 cells and cancer cells. Knockdown of UHRF1 upregulates whereas ectopic overexpression of UHRF1 downregulates protein abundance of endogenous or exogenous PML, doing so through its binding to the N-terminus of PML. Overexpression of wild-type UHRF1 shortens PML protein half-life and promotes PML polyubiquitination, whereas deletion of the RING domain or coexpression of the dominant-negative E2 ubiquitin-conjugating enzyme, E2D2, attenuates this modification to PML. Finally, knockdown of UHRF1 prolongs PML half-life and increases PML protein accumulation, yet inhibits cell migration and in vitro capillary tube formation, whereas co-knockdown of PML compromises this inhibitory effect. These findings suggest that UHRF1 promotes the turnover of PML protein, and thus targeting UHRF1 to restore PML-mediated tumor suppression represents a promising, novel, anticancer strategy.
C1 [Guan, D.; Factor, D.; Liu, Yu; Kao, H-Y] Dept Biochem, Cleveland, OH 44106 USA.
   [Guan, D.; Factor, D.; Liu, Yu; Kao, H-Y] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Wang, Z.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA.
   [Wang, Z.; Kao, H-Y] Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH USA.
   [Wang, Z.; Kao, H-Y] Univ Hosp Cleveland, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University; University Hospitals of Cleveland
RP Kao, HY (通讯作者)，Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM hxk43@cwru.edu
OI Factor, Daniel/0000-0002-3200-7560
FU NIH [R01 DK078965, HL093269]; Case Comprehensive Cancer Center Program
   in Aging and Energy Balance, NCI [P20 CA103767, CA127590];  [T32HD07104]
FX We thank Dr David Samols for his comments on the manuscript. D Factor is
   supported by training Grant T32HD07104. This project is supported by the
   NIH through R01 DK078965, HL093269 and Case Comprehensive Cancer Center
   Program in Aging and Energy Balance, NCI P20 CA103767 to H-Y Kao and
   CA127590 to Z Wang.
CR Alhosin M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-41
   Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249
   Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273
   Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Boutell C, 2005, J VIROL, V79, P12342, DOI 10.1128/JVI.79.19.12342-12354.2005
   Canning M, 2004, J BIOL CHEM, V279, P38160, DOI 10.1074/jbc.M402885200
   Cheng XW, 2012, J BIOL CHEM, V287, P23356, DOI 10.1074/jbc.M112.340505
   Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004
   Daskalos Alexandros, 2011, Cancer, V117, P1027, DOI 10.1002/cncr.25531
   DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0
   Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462
   Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200
   Felle M, 2011, NUCLEIC ACIDS RES, V39, P8355, DOI 10.1093/nar/gkr528
   Gao CZ, 2008, MOL BIOL CELL, V19, P3020, DOI 10.1091/mbc.E07-11-1203
   Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043
   Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280
   Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715
   Hu LL, 2011, CELL RES, V21, P1374, DOI 10.1038/cr.2011.124
   Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878
   Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194
   Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765
   Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2
   Khurana S, 2011, J BIOL CHEM, V286, P1850, DOI 10.1074/jbc.M110.162107
   Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961
   Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717
   Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4
   Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335
   Lim JH, 2011, J BIOL CHEM, V286, P44403, DOI 10.1074/jbc.M111.289512
   Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31
   Ma HH, 2012, P NATL ACAD SCI USA, V109, P4828, DOI 10.1073/pnas.1116349109
   Nady N, 2011, J BIOL CHEM, V286, P24300, DOI 10.1074/jbc.M111.234104
   Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127
   Rajakumara E, 2011, MOL CELL, V43, P275, DOI 10.1016/j.molcel.2011.07.006
   Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07
   Reineke EL, 2010, J BIOL CHEM, V285, P9485, DOI 10.1074/jbc.M109.063362
   Reineke EL, 2009, INT J BIOL SCI, V5, P366
   Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3
   Sarkari F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016598
   Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716
   TERRIS B, 1995, CANCER RES, V55, P1590
   Un F, 2006, ANTICANCER RES, V26, P2761
   Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053
   Unoki M, 2010, BRIT J CANCER, V103, P217, DOI 10.1038/sj.bjc.6605717
   Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123
   Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035
   van Wijk SJL, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.55
   Wang DY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3017
   Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1
   Xie S, 2012, J MOL BIOL, V415, P318, DOI 10.1016/j.jmb.2011.11.012
   Yan F, 2011, CANCER BIOTHER RADIO, V26, P183, DOI 10.1089/cbr.2010.0886
   Yang GL, 2012, MED ONCOL, V29, P842, DOI 10.1007/s12032-011-9983-z
   Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008
NR 53
TC 56
Z9 70
U1 0
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 15
PY 2013
VL 32
IS 33
BP 3819
EP 3828
DI 10.1038/onc.2012.406
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 202JH
UT WOS:000323210200004
PM 22945642
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Coe, BP
   Thu, KL
   Aviel-Ronen, S
   Vucic, EA
   Gazdar, AF
   Lam, S
   Tsao, MS
   Lam, WL
AF Coe, Bradley P.
   Thu, Kelsie L.
   Aviel-Ronen, Sarit
   Vucic, Emily A.
   Gazdar, Adi F.
   Lam, Stephen
   Tsao, Ming-Sound
   Lam, Wan L.
TI Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the
   Oncogene EZH2 in Small Cell Lung Cancer
SO PLOS ONE
LA English
DT Article
ID POLYCOMB GROUP PROTEIN; DNA METHYLATION; GENE-EXPRESSION;
   HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR;
   MICROARRAY ANALYSIS; DRIVER MUTATIONS; EPITHELIAL-CELLS; BREAST-CANCER
AB Small cell lung cancer (SCLC) is a highly aggressive lung neoplasm with extremely poor clinical outcomes and no approved targeted treatments. To elucidate the mechanisms responsible for driving the SCLC phenotype in hopes of revealing novel therapeutic targets, we studied copy number and methylation profiles of SCLC. We found disruption of the E2F/Rb pathway was a prominent feature deregulated in 96% of the SCLC samples investigated and was strongly associated with increased expression of EZH2, an oncogene and core member of the polycomb repressive complex 2 (PRC2). Through its catalytic role in the PRC2 complex, EZH2 normally functions to epigenetically silence genes during development, however, it aberrantly silences genes in human cancers. We provide evidence to support that EZH2 is functionally active in SCLC tumours, exerts pro-tumourigenic functions in vitro, and is associated with aberrant methylation profiles of PRC2 target genes indicative of a "stem-cell like'' hypermethylator profile in SCLC tumours. Furthermore, lentiviral-mediated knockdown of EZH2 demonstrated a significant reduction in the growth of SCLC cell lines, suggesting EZH2 has a key role in driving SCLC biology. In conclusion, our data confirm the role of EZH2 as a critical oncogene in SCLC, and lend support to the prioritization of EZH2 as a potential therapeutic target in clinical disease.
C1 [Coe, Bradley P.; Thu, Kelsie L.; Vucic, Emily A.; Lam, Stephen; Lam, Wan L.] BC Canc Res Ctr, Integrat Oncol Dept, Vancouver, BC, Canada.
   [Aviel-Ronen, Sarit] Chaim Sheba Med Ctr, Dept Pathol, IL-52621 Tel Hashomer, Israel.
   [Gazdar, Adi F.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   [Gazdar, Adi F.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   [Tsao, Ming-Sound] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Tsao, Ming-Sound] Princess Margaret Hosp Univ Hlth Network, Dept Pathol, Toronto, ON, Canada.
C3 British Columbia Cancer Agency; Chaim Sheba Medical Center; University
   of Texas System; University of Texas Southwestern Medical Center Dallas;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Toronto; University of Toronto; University
   Health Network Toronto; Princess Margaret Cancer Centre
RP Thu, KL (通讯作者)，BC Canc Res Ctr, Integrat Oncol Dept, Vancouver, BC, Canada.
EM kthu@bccrc.ca
RI Gazdar, Adi/F-7496-2010; Tsao, Ming/M-3503-2017; Coe,
   Bradley/A-2878-2009
OI Vucic, Emily/0000-0002-2728-8708; Coe, Bradley/0000-0001-8471-4016; Thu,
   Kelsie/0000-0001-9262-7238; Tsao, Ming/0000-0002-9160-5405
FU Canadian Institutes for Health Research (CIHR)
FX This work was supported by grants from the Canadian Institutes for
   Health Research (CIHR). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804
   Arriola E, 2008, CLIN TRANSL ONCOL, V10, P189, DOI 10.1007/s12094-008-0181-1
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Bondzi C, 2000, CELL GROWTH DIFFER, V11, P305
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112
   Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424
   Chari R, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-32
   Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668
   Coe BP, 2006, BRIT J CANCER, V94, P1927, DOI 10.1038/sj.bjc.6603167
   Coe BP, 2005, GENES CHROM IN PRESS
   Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Eppig JT, 2012, NUCLEIC ACIDS RES, V40, pD881, DOI 10.1093/nar/gkr974
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Grimaud C, 2006, CHROMOSOME RES, V14, P363, DOI 10.1007/s10577-006-1069-y
   Hinz S, 2007, J CANC RES CLIN ONCO
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913
   Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6
   Kalari S, 2012, ONCOGENE
   Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585
   Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Lally BE, 2007, ONCOLOGIST, V12, P1096, DOI 10.1634/theoncologist.12-9-1096
   Lee J, 2008, CLIN CANCER RES, V14, P82, DOI 10.1158/1078-0432.CCR-07-0612
   LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813
   Lockwood WW, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000315
   Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891
   Lonergan KM, 2006, AM J RESP CELL MOL, V35, P651, DOI 10.1165/rcmb.2006-0056OC
   Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884
   MORI N, 1990, ONCOGENE, V5, P1713
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5
   Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703
   Rossi A, 2004, CRIT REV ONCOL HEMAT, V51, P45, DOI 10.1016/j.critrevonc.2004.02.003
   Rostad H, 2004, EUR J CARDIO-THORAC, V26, P782, DOI 10.1016/j.ejcts.2004.06.011
   Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116
   Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shan L, 2007, AM J PHYSIOL-LUNG C, V292, pL500, DOI 10.1152/ajplung.00052.2006
   Simon GR, 2003, CHEST, V123, p259S, DOI 10.1378/chest.123.1_suppl.259S
   Socinski MA, 2007, J CLIN ONCOL, V25, P4137, DOI 10.1200/JCO.2007.11.5303
   Thu KL, 2011, J THORAC ONCOL, V6, P1521, DOI 10.1097/JTO.0b013e3182289479
   Vestergaard J, 2006, LUNG CANCER, V52, P281, DOI 10.1016/j.lungcan.2005.12.014
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Walker Suzanne, 2003, Clin J Oncol Nurs, V7, P563, DOI 10.1188/03.CJON.563-568
   Weinmann M, 2003, LUNG CANCER, V40, P1, DOI 10.1016/S0169-5002(02)00524-X
   XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
NR 60
TC 73
Z9 86
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 15
PY 2013
VL 8
IS 8
AR e71670
DI 10.1371/journal.pone.0071670
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 204OU
UT WOS:000323378000064
PM 23967231
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Lerebours, F
   Cizeron-Clairac, G
   Susini, A
   Vacher, S
   Mouret-Fourme, E
   Belichard, C
   Brain, E
   Alberini, JL
   Spyratos, F
   Lidereau, R
   Bieche, I
AF Lerebours, Florence
   Cizeron-Clairac, Geraldine
   Susini, Aurelie
   Vacher, Sophie
   Mouret-Fourme, Emmanuelle
   Belichard, Catherine
   Brain, Etienne
   Alberini, Jean-Louis
   Spyratos, Frederique
   Lidereau, Rosette
   Bieche, Ivan
TI miRNA expression profiling of inflammatory breast cancer identifies a
   5-miRNA signature predictive of breast tumor aggressiveness
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE inflammatory breast cancer; miRNA profiles; miRNA signature; breast
   cancer prognosis
ID FARNESOID X RECEPTOR; ESTROGEN-RECEPTOR; DOWN-REGULATION; GROWTH-FACTOR;
   SURVIVAL; CARCINOMA; MICRORNAS; DIAGNOSIS; GENES; TRENDS
AB IBC (inflammatory breast cancer) is a rare but very aggressive form of breast cancer with a particular phenotype. The molecular mechanisms responsible for IBC remain largely unknown. In particular, genetic and epigenetic alterations specific to IBC remain to be identified. MicroRNAs, a class of small noncoding RNAs able to regulate gene expression, are deregulated in breast cancer and may therefore serve as tools for diagnosis and prediction. This study was designed to determine miRNA expression profiling (microRNAome) in IBC. Quantitative RT-PCR was used to determine expression levels of 804 miRNAs in a screening series of 12 IBC compared to 31 non-stage-matched non-IBC and 8 normal breast samples. The differentially expressed miRNAs were then validated in a series of 65 IBC and 95 non-IBC. From a set of 18 miRNAs of interest selected from the screening series, 13 were differentially expressed with statistical significance in the validation series of IBC compared to non-IBC. Among these, a 5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 was shown to be predictive for IBC phenotype with an overall accuracy of 89%. Moreover, multivariate analysis showed that this signature was an independent predictor of poor Metastasis-Free Survival in non-IBC patients.
   What's new? Inflammatory breast cancer (IBC) is a very aggressive type of breast cancer that most often originates from ductal epithelial cells and rapidly invades and blocks lymphoid vessels. To identify new diagnostic and causative leads in this disease, the authors performed a global expression profiling of microRNAs. They found 13 out of 804 miRNAs were differentially expressed in IBC compared to non-IBC tumors. Among the 13 miRNAs, a 5-miRNA signature was highly predictive of IBC, thus raising the hope for a new diagnostic and prognostic marker in this deadly disease.
C1 [Lerebours, Florence; Cizeron-Clairac, Geraldine; Susini, Aurelie; Vacher, Sophie; Mouret-Fourme, Emmanuelle; Belichard, Catherine; Brain, Etienne; Alberini, Jean-Louis; Spyratos, Frederique; Lidereau, Rosette; Bieche, Ivan] Hop Rene Huguenin, Inst Curie, Lab Oncogenet, F-92210 St Cloud, France.
C3 Rene Huguenin Hospital; UNICANCER; Universite PSL; Institut Curie
RP Lerebours, F (通讯作者)，Hop Rene Huguenin, Inst Curie, 35 Rue Dailly, F-92210 St Cloud, France.
EM florence.lerebours@curie.net
RI ; Bieche, Ivan/O-7399-2017
OI VACHER, Sophie/0000-0002-0042-6023; Bieche, Ivan/0000-0002-2430-5429
FU Comite departemental des Hauts-de-Seine de la Ligue Nationale Contre la
   Cancer; Asssociation pour la Recherche en Cancerologie de Saint-Cloud
   (ARCS)
FX Grant sponsors: Comite departemental des Hauts-de-Seine de la Ligue
   Nationale Contre la Cancer; Asssociation pour la Recherche en
   Cancerologie de Saint-Cloud (ARCS)
CR Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006
   Awadelkarim KD, 2012, INT J CANCER, V131, P2852, DOI 10.1002/ijc.27600
   Bekhouche I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016950
   Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115
   Bertucci F, 2004, CANCER RES, V64, P8558, DOI 10.1158/0008-5472.CAN-04-2696
   Bièche I, 2004, CLIN CANCER RES, V10, P6789, DOI 10.1158/1078-0432.CCR-04-0306
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628
   Cabioglu N, 2007, ANN ONCOL, V18, P1021, DOI 10.1093/annonc/mdm060
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Charafe-Jaufrret E, 2004, J PATHOL, V202, P265, DOI 10.1002/path.1515
   Dawood S, 2012, ANN ONCOL, V23, P870, DOI 10.1093/annonc/mdr319
   Dawood S, 2011, ANN ONCOL, V22, P515, DOI 10.1093/annonc/mdq345
   Dressman HK, 2006, CLIN CANCER RES, V12, P819, DOI 10.1158/1078-0432.CCR-05-1447
   Ferretti E, 2008, EMBO J, V27, P2616, DOI 10.1038/emboj.2008.172
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   Giordano C, 2011, ONCOGENE, V30, P4129, DOI 10.1038/onc.2011.124
   Gonzalez-Angulo AM, 2007, ONCOLOGIST, V12, P904, DOI 10.1634/theoncologist.12-8-904
   Greco D, 2011, PLOS ONE, V6
   Greene FL, 2002, AJCC CANC STAGING MA, P225
   Hance KW, 2005, JNCI-J NATL CANCER I, V97, P966, DOI 10.1093/jnci/dji172
   Hao J, 2011, BIOCHEM BIOPH RES CO, V406, P552, DOI 10.1016/j.bbrc.2011.02.086
   Hu HL, 2010, P NATL ACAD SCI USA, V107, P1506, DOI 10.1073/pnas.0907763107
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Iwamoto T, 2011, BREAST CANCER RES TR, V125, P785, DOI 10.1007/s10549-010-1280-6
   Jiang Q, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-194
   Kleer CG, 2005, BREAST CANCER RES TR, V93, P101, DOI 10.1007/s10549-005-4170-6
   Lerebours F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-41
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Mosakhani N, 2012, GENE CHROMOSOME CANC, V51, P1, DOI 10.1002/gcc.20925
   Narducci MG, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.32
   Navon R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008003
   Nguyen DM, 2006, CLIN CANCER RES, V12, P5047, DOI 10.1158/1078-0432.CCR-05-2248
   Oh HK, 2011, CLIN CANCER RES, V17, P2657, DOI 10.1158/1078-0432.CCR-10-3152
   Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7
   Ragusa M, 2010, MOL CANCER THER, V9, P3396, DOI 10.1158/1535-7163.MCT-10-0137
   Shi W, 2011, CANCER RES, V71, P2926, DOI 10.1158/0008-5472.CAN-10-3369
   Shirakawa K, 2002, INT J CANCER, V99, P821, DOI 10.1002/ijc.10423
   Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419
   Van der Auwera I, 2010, BRIT J CANCER, V103, P532, DOI 10.1038/sj.bjc.6605787
   Van der Auwera I, 2004, CLIN CANCER RES, V10, P7965, DOI 10.1158/1078-0432.CCR-04-0063
   Van Laere S, 2007, BRIT J CANCER, V97, P1165, DOI 10.1038/sj.bjc.6603967
   Van Laere S, 2005, BREAST CANCER RES TR, V93, P237, DOI 10.1007/s10549-005-5157-z
   Van Laere S, 2008, CLIN CANCER RES, V14, P7452, DOI 10.1158/1078-0432.CCR-08-1077
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109
   Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200
   Yamauchi H, 2009, NAT REV CLIN ONCOL, V6, P387, DOI 10.1038/nrclinonc.2009.73
   Zhang Y, 2012, MOL CANCER RES, V10, P516, DOI 10.1158/1541-7786.MCR-11-0473
   Zhong XY, 2012, GENE, V493, P44, DOI 10.1016/j.gene.2011.11.028
NR 50
TC 61
Z9 70
U1 2
U2 52
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 1
PY 2013
VL 133
IS 7
BP 1614
EP 1623
DI 10.1002/ijc.28171
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 182RR
UT WOS:000321762200010
PM 23526361
OA Bronze
DA 2025-01-12
ER

PT J
AU Nappi, RE
   Domoney, C
AF Nappi, R. E.
   Domoney, C.
TI Pharmacogenomics and sexuality: a vision
SO CLIMACTERIC
LA English
DT Article
DE PHARMACOGENOMICS; FEMALE SEXUAL DYSFUNCTION; SEXUAL MEDICINE
ID HORMONE REPLACEMENT THERAPY; BREAST-CANCER RISK; DESIRE DISORDER;
   GENETIC EPIDEMIOLOGY; POSTMENOPAUSAL WOMEN; VULVAR VESTIBULITIS;
   UNITED-STATES; DYSFUNCTION; PREVALENCE; AROUSAL
AB Female sexual dysfunction (FSD) is multidimensional with a complex interplay of biopsychosocial factors modulating the clinical expression of sexual symptoms and associated distress. During the entire reproductive lifespan, intra-and interpersonal experiences shape human neuroendocrine and neurovascular sexual pathways. These are dependent on genetic and epigenetic mechanisms, including acquired medical conditions. Understanding the genetic basis of FSD can help to determine clinical phenotypes of women and therefore postulate the most effective intervention according to biological, psychological or environmental determinants. However, there is a paucity of studies demonstrating a genetic contribution to FSD and a diverse modulation of innate and acquired factors on discrete domains of sexual response and distress. This is evident from menarche to menopause. Pharmacogenomics is still in its infancy in the field of sexual medicine and most data regarding genetic polymorphisms of drug targets associated with susceptibility to sexual dysfunction have been obtained in males. Pharmacogenomics may be the future of medical practice in women with FSD and may guide an individualized approach by predicting both therapeutic effects at varying dosages of hormonal and non-hormonal agents, and disadvantageous side-effects and drug interactions.
C1 [Nappi, R. E.] IRCCS S Matteo Fdn, Res Ctr Reprod Med Gynecol Endocrinol & Menopause, Pavia, Italy.
   [Nappi, R. E.] Univ Pavia, Dept Clin Surg Diagnost & Paediat Sci, I-27100 Pavia, Italy.
   [Domoney, C.] Chelsea & Westminster Hosp, Dept Obstet & Gynaecol, London, England.
C3 IRCCS Fondazione San Matteo; University of Pavia; Imperial College
   London
RP Nappi, RE (通讯作者)，IRCCS Policlin San Matteo, Res Ctr Reprod Med, Sect Obstet & Gynecol, Piazzale Golgi 2, I-27100 Pavia, Italy.
RI Nappi, Rossella/AAC-1793-2022
OI Nappi, Rossella/0000-0003-1713-6396
CR Abdel-Hamid IA, 2009, PHARMACOGENOMICS, V10, P1625, DOI [10.2217/pgs.09.104, 10.2217/PGS.09.104]
   [Anonymous], 2000, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425787, DOI 10.1176/APPI.BOOKS.9780890425787]
   Atlantis E, 2012, J SEX MED, V9, P1497, DOI 10.1111/j.1743-6109.2012.02709.x
   BACHMANN GA, 1989, OBSTET GYNECOL, V73, P425
   Bancroft J, 2002, ARCH SEX BEHAV, V31, P451, DOI 10.1023/A:1019800426980
   Basson R, 2004, MENOPAUSE, V11, P714, DOI 10.1097/01.GME.0000138542.65917.FB
   Basson R, 2004, J SEX MED, V1, P24, DOI 10.1111/j.1743-6109.2004.10105.x
   Basson R, 2007, LANCET, V369, P409, DOI 10.1016/S0140-6736(07)60197-4
   Basson R, 2010, J SEX MED, V7, P374, DOI 10.1111/j.1743-6109.2009.01621.x
   Basson R, 2010, J SEX MED, V7, P314, DOI 10.1111/j.1743-6109.2009.01617.x
   Ben Zion IZ, 2006, MOL PSYCHIATR, V11, P782, DOI 10.1038/sj.mp.4001832
   Bishop JR, 2006, NEUROPSYCHOPHARMACOL, V31, P2281, DOI 10.1038/sj.npp.1301090
   Brotto LA, 2010, J SEX MED, V7, P586, DOI 10.1111/j.1743-6109.2009.01630.x
   Burnett AL, 2010, J SEX MED, V7, P3269, DOI 10.1111/j.1743-6109.2010.02025.x
   Burri A, 2011, PSYCHOL MED, V41, P2435, DOI 10.1017/S0033291711000493
   Burri A, 2013, J SEX RES, V50, P318, DOI 10.1080/00224499.2012.753027
   Burri A, 2012, J SEX MED, V9, P2671, DOI 10.1111/j.1743-6109.2012.02861.x
   Burri A, 2012, J SEX MED, V9, P1887, DOI 10.1111/j.1743-6109.2012.02710.x
   Burri A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035041
   Burri AV, 2009, J SEX MED, V6, P646, DOI 10.1111/j.1743-6109.2008.01144.x
   Clayton AH, 2013, WOMENS HEALTH, V9, P135, DOI 10.2217/whe.13.6
   Cooke GE, 2008, FUTUR CARDIOL, V4, P19, DOI 10.2217/14796678.4.1.19
   Dawood K, 2005, TWIN RES HUM GENET, V8, P27, DOI 10.1375/1832427053435427
   Dunn KM, 2005, BIOL LETT-UK, V1, P260, DOI 10.1098/rsbl.2005.0308
   Elaut E, 2012, CONTRACEPTION, V85, P470, DOI 10.1016/j.contraception.2011.10.007
   Fooladi E, 2012, CLIMACTERIC, V15, P306, DOI 10.3109/13697137.2012.658461
   Gerber S, 2003, EUR J OBSTET GYN R B, V107, P74, DOI 10.1016/S0301-2115(02)00276-2
   Giraldi A, 2004, J SEX MED, V1, P237, DOI 10.1111/j.1743-6109.04037.x
   Hayes RD, 2006, J SEX MED, V3, P589, DOI 10.1111/j.1743-6109.2006.00241.x
   Herrington DM, 2003, PHARMACOGENOMICS, V4, P269, DOI 10.1517/phgs.4.3.269.22686
   Hettema JM, 2001, AM J PSYCHIAT, V158, P1568, DOI 10.1176/appi.ajp.158.10.1568
   Jang KL, 1996, J PERS, V64, P577, DOI 10.1111/j.1467-6494.1996.tb00522.x
   Jeremias J, 2000, AM J OBSTET GYNECOL, V182, P283, DOI 10.1016/S0002-9378(00)70212-2
   Justenhoven C, 2012, PHARMACOGENOMICS, V13, P659, DOI [10.2217/pgs.11.144, 10.2217/PGS.11.144]
   Kalow W, 2006, PHARMACOGENOMICS J, V6, P162, DOI 10.1038/sj.tpj.6500361
   Kingsberg S, 2007, J SEX MED, V4, P1001, DOI 10.1111/j.1743-6109.2007.00526.x
   Kobayashi N, 2002, MATURITAS, V41, P193, DOI 10.1016/S0378-5122(01)00287-0
   Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537
   Leiblum SR, 2006, MENOPAUSE, V13, P46, DOI 10.1097/01.gme.0000172596.76272.06
   Majdic G, 2011, FRONT NEUROENDOCRIN, V32, P137, DOI 10.1016/j.yfrne.2011.02.009
   Massart F, 2005, GYNECOL ENDOCRINOL, V20, P36, DOI 10.1080/09513590400019437
   McCabe M, 2010, J SEX MED, V7, P327, DOI 10.1111/j.1743-6109.2009.01618.x
   McDevitta MA, 2008, MOL CELL ENDOCRINOL, V290, P24, DOI 10.1016/j.mce.2008.04.003
   Nappi R, 2005, J SEX MED, V2, P4, DOI 10.1111/j.1743-6109.2005.20102.x
   Nappi RE, 2007, CLIMACTERIC, V10, P105, DOI 10.1080/13697130701599876
   Nappi RE, 2009, J SEX MED, V6, P603, DOI 10.1111/j.1743-6109.2008.01198.x
   Nappi RE, 2009, MATURITAS, V63, P138, DOI 10.1016/j.maturitas.2009.03.021
   Nicolosi A, 2004, UROLOGY, V64, P991, DOI 10.1016/j.urology.2004.06.055
   NORBURY TA, 2007, BRAIN, V13, P27
   Notelovitz Morris, 2006, MedGenMed, V8, P85
   Perlis RH, 2009, NEUROPSYCHOPHARMACOL, V34, P1819, DOI 10.1038/npp.2009.4
   Pfaff D, 2002, TRENDS NEUROSCI, V25, P45, DOI 10.1016/S0166-2236(00)02084-1
   Pfaff DW, 2006, BRAIN AROUSAL INF TH
   Pfaus JG, 2009, J SEX MED, V6, P1506, DOI 10.1111/j.1743-6109.2009.01309.x
   Portman D.J., 2013, MENOPAUSE
   Rebbeck TR, 2007, AM J EPIDEMIOL, V166, P1392, DOI 10.1093/aje/kwm239
   Salonia A, 2010, J SEX MED, V7, P2637, DOI 10.1111/j.1743-6109.2010.01810.x
   Schober JM, 2007, BEST PRACT RES CL EN, V21, P445, DOI 10.1016/j.beem.2007.04.006
   Shastry BS, 2005, J HUM GENET, V50, P321, DOI 10.1007/s10038-005-0264-6
   Shiften JL, 2008, OBSTET GYNECOL, V112, P970, DOI 10.1097/AOG.0b013e3181898cdb
   Sobecki JN, 2012, J SEX MED, V9, P1285, DOI 10.1111/j.1743-6109.2012.02702.x
   SPECTOR IP, 1990, ARCH SEX BEHAV, V19, P389, DOI 10.1007/BF01541933
   Stahl SM, 2011, J SEX MED, V8, P15, DOI 10.1111/j.1743-6109.2010.02032.x
   Sullivan PF, 2000, AM J PSYCHIAT, V157, P1552, DOI 10.1176/appi.ajp.157.10.1552
   Tempfer CB, 2004, PHARMACOGENOMICS, V5, P57, DOI 10.1517/phgs.5.1.57.25687
   Traish AM, 2010, J SEX MED, V7, P2925, DOI 10.1111/j.1743-6109.2010.01903.x
   Visvanathan K, 2005, OBSTET GYNECOL, V106, P1372, DOI 10.1097/01.AOG.0000187308.67021.98
   West SL, 2008, ARCH INTERN MED, V168, P1441, DOI 10.1001/archinte.168.13.1441
   Wierman ME, 2010, J SEX MED, V7, P561, DOI 10.1111/j.1743-6109.2009.01629.x
   WITTING K, 2009, PSYCHOL MED, V26, P1
   Yu KD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015649
   Zhang XQ, 2013, J STEROID BIOCHEM, V134, P51, DOI 10.1016/j.jsbmb.2012.10.015
NR 72
TC 11
Z9 12
U1 0
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1369-7137
J9 CLIMACTERIC
JI Climacteric
PD AUG
PY 2013
VL 16
SU 1
BP 25
EP 30
DI 10.3109/13697137.2013.806402
PG 6
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 183BB
UT WOS:000321787500005
PM 23848488
DA 2025-01-12
ER

PT J
AU Natsume, A
   Ito, M
   Katsushima, K
   Ohka, F
   Hatanaka, A
   Shinjo, K
   Sato, S
   Takahashi, S
   Ishikawa, Y
   Takeuchi, I
   Shimogawa, H
   Uesugi, M
   Okano, H
   Kim, SU
   Wakabayashi, T
   Issa, JPJ
   Sekido, Y
   Kondo, Y
AF Natsume, Atsushi
   Ito, Motokazu
   Katsushima, Keisuke
   Ohka, Fumiharu
   Hatanaka, Akira
   Shinjo, Keiko
   Sato, Shinya
   Takahashi, Satoru
   Ishikawa, Yuta
   Takeuchi, Ichiro
   Shimogawa, Hiroki
   Uesugi, Motonari
   Okano, Hideyuki
   Kim, Seung U.
   Wakabayashi, Toshihiko
   Issa, Jean-Pierre J.
   Sekido, Yoshitaka
   Kondo, Yutaka
TI Chromatin Regulator PRC2 Is a Key Regulator of Epigenetic Plasticity in
   Glioblastoma
SO CANCER RESEARCH
LA English
DT Article
ID CANCER STEM-CELLS; GROUP PROTEIN EZH2; SELF-RENEWAL; INITIATING CELLS;
   DNA METHYLATION; HISTONE METHYLTRANSFERASE; DEVELOPMENTAL REGULATORS;
   BREAST-CANCER; POLYCOMB; DIFFERENTIATION
AB Tumor cell plasticity contributes to functional and morphologic heterogeneity. To uncover the underlying mechanisms of this plasticity, we examined glioma stem-like cells (GSC) where we found that the biologic interconversion between GSCs and differentiated non-GSCs is functionally plastic and accompanied by gain or loss of polycomb repressive complex 2 (PRC2), a complex that modifies chromatin structure. PRC2 mediates lysine 27 trimethylation on histone H3 and in GSC it affected pluripotency or development-associated genes (e. g., Nanog, Wnt1, and BMP5) together with alterations in the subcellular localization of EZH2, a catalytic component of PRC2. Intriguingly, exogenous expression of EZH2-dNLS, which lacks nuclear localization sequence, impaired the repression of Nanog expression under differentiation conditions. RNA interference (RNAi)-mediated attenuation or pharmacologic inhibition of EZH2 had little to no effect on apoptosis or bromodeoxyuridine incorporation in GSCs, but it disrupted morphologic interconversion and impaired GSC integration into the brain tissue, thereby improving survival of GSC-bearing mice. Pathologic analysis of human glioma specimens revealed that the number of tumor cells with nuclear EZH2 is larger around tumor vessels and the invasive front, suggesting that nuclear EZH2 may help reprogram tumor cells in close proximity to this microenvironment. Our results indicate that epigenetic regulation by PRC2 is a key mediator of tumor cell plasticity, which is required for the adaptation of glioblastoma cells to their microenvironment. Thus, PRC2-targeted therapy may reduce tumor cell plasticity and tumor heterogeneity, offering a new paradigm for glioma treatment.
C1 [Natsume, Atsushi; Ito, Motokazu; Wakabayashi, Toshihiko] Nagoya Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi 4648601, Japan.
   [Ito, Motokazu; Katsushima, Keisuke; Ohka, Fumiharu; Hatanaka, Akira; Shinjo, Keiko; Kondo, Yutaka] Nagoya City Univ, Grad Sch Med Sci, Div Epigenom, Nagoya, Aichi, Japan.
   [Sekido, Yoshitaka; Kondo, Yutaka] Nagoya City Univ, Grad Sch Med Sci, Dept Mol Oncol, Aichi Canc Ctr,Res Inst, Nagoya, Aichi, Japan.
   [Sato, Shinya; Takahashi, Satoru] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Aichi, Japan.
   [Ishikawa, Yuta; Takeuchi, Ichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Sci & Engn Simulat, Grad Sch Engn,Nagoya Inst Technol, Nagoya, Aichi, Japan.
   [Sekido, Yoshitaka] Nagoya City Univ, Grad Sch Med Sci, Dept Canc Genet, Nagoya, Aichi, Japan.
   [Shimogawa, Hiroki; Uesugi, Motonari] Kyoto Univ, Inst Chem Res, Inst Integrated Cell Mat Sci, Kyoto, Japan.
   [Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Keio, Japan.
   [Kondo, Yutaka] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Tokyo, Japan.
   [Kim, Seung U.] Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC V6T 1W5, Canada.
   [Kim, Seung U.] Chung Ang Univ, Coll Med, Med Res Inst, Seoul, South Korea.
   [Issa, Jean-Pierre J.] Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA.
C3 Nagoya University; Nagoya City University; Nagoya City University; Aichi
   Cancer Center; Nagoya City University; Nagoya City University; Nagoya
   Institute of Technology; Nagoya City University; Kyoto University; Keio
   University; Japan Science & Technology Agency (JST); University of
   British Columbia; Chung Ang University; Chung Ang University Hospital;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University
RP Kondo, Y (通讯作者)，Aichi Canc Ctr, Res Inst, Div Epigenom, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.
EM ykondo@aichi-cc.jp
RI Uesugi, Motonari/AAM-9777-2020; Wakabayashi, Toshihiko/I-3526-2012;
   Ohka, Fumiharu/A-3420-2016; Okano, Hideyuki/I-7584-2019; Sekido,
   Yoshitaka/P-9756-2015; Kim, Sun/L-4239-2013; Natsume,
   Atsushi/I-7364-2014; katsushima, keisuke/AAD-5945-2019
OI Sekido, Yoshitaka/0000-0002-2428-3848; Issa,
   Jean-Pierre/0000-0003-2258-5030; Natsume, Atsushi/0000-0002-9113-0470;
   katsushima, keisuke/0000-0001-7770-432X; Sato,
   Shinya/0000-0002-2155-2379; Ohka, Fumiharu/0000-0002-5569-5626; Okano,
   Hideyuki/0000-0001-7482-5935
FU PRESTO of JST [4219]; Japan Society for the Promotion of Science
   [23300344, 24390341]; Uehara Memorial Foundation; Takeda Science
   Foundation; Grants-in-Aid for Scientific Research [24390341, 23300344]
   Funding Source: KAKEN
FX This work was supported by grant from PRESTO of JST (Y. Kondo; 4219),
   Grant-in-Aid for Scientific Research from the Japan Society for the
   Promotion of Science (Y. Kondo, 23300344; A. Natsume, 24390341), the
   Uehara Memorial Foundation (Y. Kondo), and Takeda Science Foundation (Y.
   Kondo).
CR Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Cadieux B, 2006, CANCER RES, V66, P8469, DOI 10.1158/0008-5472.CAN-06-1547
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Chung S, 2009, CELL STEM CELL, V5, P646, DOI 10.1016/j.stem.2009.09.015
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Estécio MRH, 2007, GENOME RES, V17, P1529, DOI 10.1101/gr.6417007
   Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929
   Gao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hirabayashi Y, 2010, NAT REV NEUROSCI, V11, P377, DOI 10.1038/nrn2810
   Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Katsushima K, 2012, J BIOL CHEM, V287, P27396, DOI 10.1074/jbc.M112.359109
   Kawaguchi A, 2001, MOL CELL NEUROSCI, V17, P259, DOI 10.1006/mcne.2000.0925
   Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060
   Ohnishi T, 1998, CANCER RES, V58, P2935
   Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013
   Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Peñuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011
   Pereira JD, 2010, P NATL ACAD SCI USA, V107, P15957, DOI 10.1073/pnas.1002530107
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343
   Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   TSENG CKH, 1989, J MED CHEM, V32, P1442, DOI 10.1021/jm00127a007
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Yuki K, 2009, CANCER LETT, V284, P71, DOI 10.1016/j.canlet.2009.04.020
NR 48
TC 83
Z9 99
U1 0
U2 29
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2013
VL 73
IS 14
BP 4559
EP 4570
DI 10.1158/0008-5472.CAN-13-0109
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 183NR
UT WOS:000321823600036
PM 23720055
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Kong, ANT
   Zhang, CY
   Su, ZY
AF Kong, Ah-Ng Tony
   Zhang, Chengyue
   Su, Zheng-Yuan
TI Targeting Epigenetics for Cancer Prevention By Dietary Cancer Preventive
   Compounds-The Case of miRNA
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID HUMAN BREAST-CANCER; GRAPE SEED EXTRACT; MICRORNA; METHYLATION;
   EXPRESSION; CELLS; PROANTHOCYANIDINS; PHYTOCHEMICALS; POLYPHENOLS;
   PROGRESSION
AB In cancer, genetic mutations have long been considered to be the only driver of neoplasia. However, there is increasing evidence that epigenetic alterations could also play a major role in carcinogenesis and cancer. A number of experimental and epidemiologic studies have shown that many classes of dietary phytochemicals possess cancer-preventive and epigenetic-modifying properties. The report by Derry and colleagues in this issue of the journal shows that grape seed extract (GSE) prevents azoxymethane (AOM)-induced colon colitis via epigenetic microRNA (miRNA) regulation. Although the precise mechanism underlying the control of miRNA expression is not well understood currently, epigenetic changes could play a major role. This report, along with increasing evidence showing the impact of dietary phytochemicals on epigenetic activities, offers new perspectives on miRNA and epigenetic regulation in cancer prevention. (c) 2013 AACR.
C1 [Kong, Ah-Ng Tony; Zhang, Chengyue; Su, Zheng-Yuan] Rutgers State Univ, Ctr Canc Prevent Res, Piscataway, NJ 08854 USA.
   [Kong, Ah-Ng Tony; Zhang, Chengyue; Su, Zheng-Yuan] Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University System; Rutgers University New Brunswick
RP Kong, ANT (通讯作者)，Rutgers State Univ, Ctr Canc Prevent Res, Dept Pharmaceut, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM KongT@pharmacy.rutgers.edu
RI Zhang, Chengyue/L-1185-2017; Su, Zheng-Yuan/J-7238-2019; Kong,
   Ah-Ng/AAX-2828-2020; Su, Zheng-Yuan/D-5431-2019
OI Su, Zheng-Yuan/0000-0003-2624-9181
FU NCCIH NIH HHS [R01 AT007065] Funding Source: Medline; NCI NIH HHS [R01
   CA152826, R01 CA118947] Funding Source: Medline
CR Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Arola-Arnal A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025982
   Derry MM, 2013, CANCER PREV RES, V6, P625, DOI 10.1158/1940-6207.CAPR-13-0053
   Engelbrecht AM, 2007, CANCER LETT, V258, P144, DOI 10.1016/j.canlet.2007.08.020
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2003, CANCER RES, V63, P7563
   Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005
   Gantier MP, 2012, NUCLEIC ACIDS RES, V40, P8048, DOI 10.1093/nar/gks521
   Gao Y, 2013, CARCINOGENESIS
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Ho E, 2011, ADV NUTR, V2, P497, DOI 10.3945/an.111.001032
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kaur M, 2009, J NUTR, V139, p1806S, DOI 10.3945/jn.109.106864
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Khor TO, 2011, BIOCHEM PHARMACOL, V82, P1073, DOI 10.1016/j.bcp.2011.07.065
   Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003
   Lee JH, 2013, PHARMACOL THERAPEUT, V137, P153, DOI 10.1016/j.pharmthera.2012.09.008
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Raina K, 2007, CANCER RES, V67, P5976, DOI 10.1158/0008-5472.CAN-07-0295
   Rossato M, 2012, P NATL ACAD SCI USA, V109, pE3101, DOI 10.1073/pnas.1209100109
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tsang WP, 2010, J NUTR BIOCHEM, V21, P140, DOI 10.1016/j.jnutbio.2008.12.003
   Vaid M, 2012, TOXICOL APPL PHARM, V263, P122, DOI 10.1016/j.taap.2012.06.013
   Wilting SM, 2013, EPIGENETICS-US, V8, P220, DOI 10.4161/epi.23605
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003
   Zhao X., 2013, LEUKEMIA, DOI 10.1038/leu.2013.94
NR 33
TC 10
Z9 10
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD JUL
PY 2013
VL 6
IS 7
BP 622
EP 624
DI 10.1158/1940-6207.CAPR-13-0202
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 174YR
UT WOS:000321195000002
PM 23773911
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Mann, M
   Cortez, V
   Vadlamudi, R
AF Mann, Monica
   Cortez, Valerie
   Vadlamudi, Ratna
TI PELP1 oncogenic functions involve CARM1 regulation
SO CARCINOGENESIS
LA English
DT Article
ID BREAST-CANCER; EPIGENETIC REGULATION; ESTROGEN; HISTONE; METHYLATION;
   COREGULATOR
AB Estrogen receptor alpha (ER) is implicated in the initiation and progression of breast cancer and its transcription depends on the modulation of epigenetic changes at target gene promoters via coregulators. There is a critical need to understand the molecular mechanism(s) by which deregulation of epigenetic changes occurs during breast cancer progression. The ER coregulator PELP1 plays an important role in ER signaling and is a proto-oncogene with aberrant expression in breast cancer. PELP1 interacts with histones and may be a reader of chromatin modifications. We profiled PELP1s epigenetic interactome using a histone peptide array. Our results show that PELP1 recognizes histones modified by arginine and lysine dimethylation. PELP1 functionally interacts with the arginine methyltransferase CARM1 and their interaction is enhanced by ER. PELP1CARM1 interactions synergistically enhance ER transactivation. Chromatin immunoprecipitation assays revealed that PELP1 alters histone H3 arginine methylation status at ER target gene promoters. Pharmacological inhibition or small interfering RNA knockdown of CARM1 substantially reduced PELP1 oncogenic functions. The critical role of PELP1 status in modulating arginine methylation status was also observed through in vivo studies where PELP1 knockdown mediated decreased tumorigenesis correlated with decreased arginine dimethylation. Further, immunohistochemical analysis of human breast tumor tissues revealed co-overexpression of PELP1 and CARM1 in a subset of ER-positive breast tumors. Our findings show PELP1 is a reader of histone arginine methyl modifications and deregulation promotes tumor proliferation via epigenetic alterations at ER target promoters. Targeting these epigenetic alterations through inhibition of PELP1 and the arginine methyltransferases could be a promising cancer therapeutic.
C1 [Mann, Monica; Cortez, Valerie] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Mann, Monica; Cortez, Valerie; Vadlamudi, Ratna] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
   [Vadlamudi, Ratna] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio; Cancer Therapy & Research
   Center
RP Vadlamudi, R (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Div Reprod Res, Dept Obstet & Gynecol, 7703 Floyd Curl Dr,Mail Code 7836, San Antonio, TX 78229 USA.
EM vadlamudi@uthscsa.edu
FU National Institute of Health [CA095681, 1F31CA173909, 1F31CA165814];
   Cancer Prevention and Research Institute of Texas [RP101491]
FX National Institute of Health (CA095681 to R. V.); Cancer Prevention and
   Research Institute of Texas (RP101491 to M. M.); F31 training grants of
   the National Institute of Health (1F31CA173909 to M. M., 1F31CA165814 to
   V.C.).
CR Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Bock I., 2011, BMC BIOCH, V12, P1471
   Chakravarty D, 2010, CANCER RES, V70, P4092, DOI 10.1158/0008-5472.CAN-09-3834
   Chakravarty D, 2010, IUBMB LIFE, V62, P163, DOI 10.1002/iub.287
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229
   El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103
   Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983
   Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lan F, 2009, SCI CHINA SER C, V52, P311, DOI 10.1007/s11427-009-0054-z
   Le Romancer M, 2011, ENDOCR REV, V32, P597, DOI 10.1210/er.2010-0016
   Mann Monica, 2011, Cancers (Basel), V3, P1691, DOI 10.3390/cancers3021691
   Nair BC, 2010, CANCER RES, V70, P7166, DOI 10.1158/0008-5472.CAN-10-0628
   Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786
   Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62
   O'Brien KB, 2010, DEVELOPMENT, V137, P2147, DOI 10.1242/dev.037150
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Phillips T, 2007, APPL IMMUNOHISTO M M, V15, P325, DOI 10.1097/01.pai.0000213135.16783.bc
   Rajhans R, 2007, CANCER RES, V67, P5505, DOI 10.1158/0008-5472.CAN-06-3647
   Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272
   Vallabhaneni S, 2011, BREAST CANCER RES TR, V130, P377, DOI 10.1007/s10549-010-1312-2
   Wysocka J, 2006, METHODS, V40, P339, DOI 10.1016/j.ymeth.2006.05.028
NR 25
TC 46
Z9 57
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2013
VL 34
IS 7
BP 1468
EP 1475
DI 10.1093/carcin/bgt091
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 182OI
UT WOS:000321753000007
PM 23486015
OA Green Published
DA 2025-01-12
ER

PT J
AU Yu, Y
   Wu, JZ
   Guan, LZ
   Qi, LH
   Tang, Y
   Ma, B
   Zhan, J
   Wang, YL
   Fang, WG
   Zhang, HQ
AF Yu, Yu
   Wu, Junzhou
   Guan, Lizhao
   Qi, Lihua
   Tang, Yan
   Ma, Bo
   Zhan, Jun
   Wang, Yunling
   Fang, Weigang
   Zhang, Hongquan
TI Kindlin 2 promotes breast cancer invasion via epigenetic silencing of
   the microRNA200 gene family
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; DNA methyltransferase; Kindlins; MicroRNA-200 family
ID MITOGEN-INDUCIBLE GENE-2; MIR-200 FAMILY; MESENCHYMAL TRANSITION; DNA
   METHYLTRANSFERASE; MIRNA PROMOTERS; CELL INVASION; ZEB1; METHYLATION;
   EXPRESSION; IDENTIFICATION
AB Kindlin 2, as a focal adhesion protein, controls integrin activation and regulates Wnt signaling in an integrin-binding independent manner. However, the association of Kindlin 2 with cancer-related microRNAs is unknown. Here, we report that Kindlin 2 markedly downregulates the expression of miR-200 family by inducing CpG island hypermethylation. Mechanistically, Kindlin 2 forms a complex with DNMT3A in the cell nucleus and the two proteins co-occupy the promoter of miRNA-200b. Functionally, repression of miR-200b is required for Kindlin 2-induced breast cancer cell invasion and tumor formation. Our data indicate that Kindlin 2 plays a novel role in epigenetic repression of miR-200 family, a mechanism that promotes breast cancer invasion.
   What's new? Recent studies have implicated Kindlin 2, a focal adhesion protein, in boosting tumor progression. This study investigated the association of Kindlin 2 with microRNAs (miRNAs), which are frequently altered in cancer. The authors showed that Kindlin 2 forms a complex with DNA methyltransferase 3A, and this complex then blocks the miR-200b promoter. MicroRNAs in the miR-200 family function as tumor repressors, and their loss is crucial for cell invasion and tumor progression. These new results demonstrate for the first time that Kindlin 2 promotes breast cancer invasion by working together with DNA methyltransferase 3A to stifle miR-200b expression.
C1 [Yu, Yu; Wu, Junzhou; Guan, Lizhao; Qi, Lihua; Tang, Yan; Ma, Bo; Zhan, Jun; Wang, Yunling; Fang, Weigang; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, Minist Educ China, Key Lab Carcinogenesis & Translat Res, Beijing 100191, Peoples R China.
   [Yu, Yu; Wu, Junzhou; Guan, Lizhao; Qi, Lihua; Tang, Yan; Ma, Bo; Zhan, Jun; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, Lab Mol Cell Biol & Tumor Biol, Dept Anat, Beijing 100191, Peoples R China.
   [Yu, Yu; Wu, Junzhou; Guan, Lizhao; Qi, Lihua; Tang, Yan; Ma, Bo; Zhan, Jun; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, Dept Histol, Beijing 100191, Peoples R China.
   [Yu, Yu; Wu, Junzhou; Guan, Lizhao; Qi, Lihua; Tang, Yan; Ma, Bo; Zhan, Jun; Zhang, Hongquan] Peking Univ, Hlth Sci Ctr, Dept Embryol, Beijing 100191, Peoples R China.
   [Fang, Weigang] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100191, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University; Peking University
RP Zhang, HQ (通讯作者)，Peking Univ, Hlth Sci Ctr, Dept Anat Histol & Embryol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.
EM Hongquan.Zhang@bjmu.edu.cn
RI zhang, ying/HJB-1230-2022
OI Yu, Yu/0000-0001-6751-5349
FU Ministry of Science and Technology of China [2010CB912203,
   2010CB529402]; National Natural Science Foundation of China [30830048,
   81230051, 31170711, 81101495]; 111 Project of the Ministry of Education;
   Beijing Natural Science Foundation [7120002]; Peking University
   [BMU20120314]; Leading Academic Discipline Project of Beijing Education
   Bureau
FX This work was supported by grants from the Ministry of Science and
   Technology of China 2010CB912203 and 2010CB529402, the National Natural
   Science Foundation of China 30830048, 81230051, 31170711 and 81101495,
   the 111 Project of the Ministry of Education, Beijing Natural Science
   Foundation 7120002 and a Peking University grant BMU20120314 and Leading
   Academic Discipline Project of Beijing Education Bureau to H.Z.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   An ZW, 2010, INT J CANCER, V127, P1999, DOI 10.1002/ijc.25223
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Gong XW, 2010, CANCER LETT, V299, P54, DOI 10.1016/j.canlet.2010.08.003
   Gozgit JM, 2006, MOL CANCER RES, V4, P905, DOI 10.1158/1541-7786.MCR-06-0147
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Jorda MA, 2003, ANN NY ACAD SCI, V996, P10, DOI 10.1111/j.1749-6632.2003.tb03227.x
   Kato K, 2004, HUM PATHOL, V35, P55, DOI 10.1016/j.humpath.2003.08.019
   LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P
   Li B, 2007, BIOCHEM J, V405, P369, DOI 10.1042/BJ20061873
   Ling Y, 2004, NUCLEIC ACIDS RES, V32, P598, DOI 10.1093/nar/gkh195
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005
   Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219
   Montanez E, 2008, GENE DEV, V22, P1325, DOI 10.1101/gad.469408
   Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Roybal JD, 2011, MOL CANCER RES, V9, P25, DOI 10.1158/1541-7786.MCR-10-0497
   Shi XH, 2008, MOL CANCER RES, V6, P715, DOI 10.1158/1541-7786.MCR-07-2026
   Shi XH, 2007, J BIOL CHEM, V282, P20455, DOI 10.1074/jbc.M611680200
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wee EJH, 2012, ONCOGENE, V31, P4182, DOI 10.1038/onc.2011.584
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wiklund ED, 2010, EPIGENOMICS-UK, V2, P823, DOI 10.2217/EPI.10.51
   Wu LP, 2008, MOL CELL BIOL, V28, P3219, DOI 10.1128/MCB.01516-07
   Yu Y, 2012, EMBO REP, V13, P750, DOI 10.1038/embor.2012.88
   Yu Y, 2009, J BIOL CHEM, V284, P19310, DOI 10.1074/jbc.M109.015289
NR 36
TC 56
Z9 69
U1 0
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 15
PY 2013
VL 133
IS 6
BP 1368
EP 1379
DI 10.1002/ijc.28151
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 178HH
UT WOS:000321436300010
PM 23483548
OA Bronze
DA 2025-01-12
ER

PT J
AU Tzadok, S
   Caspin, Y
   Hachmo, Y
   Canaani, D
   Dotan, I
AF Tzadok, Sivan
   Caspin, Yarden
   Hachmo, Yafit
   Canaani, Dan
   Dotan, Iris
TI Directionality of noncoding human RNAs: How to avoid artifacts
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE RT-PCR; Epigenetic gene silencing; Long noncoding RNAs
ID TUMOR-SUPPRESSOR; REVERSE TRANSCRIPTION; GENE-EXPRESSION; DNA
   METHYLATION; REVEALS; COMPLEXES; GENCODE; CELLS
AB Inactivation of tumor suppressor and metastasis suppressor genes via epigenetic silencing is a frequent event in human cancers. Recent work has shown new mechanisms of epigenetic silencing, based on the occurrence of long noncoding promoter-spanning antisense and/or sense RNAs (lncRNAs), which constitute part of chromatin silencing complexes. Using reverse transcription polymerase chain reaction (RT-PCR), we have started to scan "triple negative" and Her2-overexpressing breast cancer cell lines for directional/bidirectional transcription through promoters of tumor suppressor and metastasis suppressor genes known to be epigenetically silenced in vivo. Surprisingly, we found that RT-PCR-amplified products were obtained at high frequency in the absence of exogenous primers. These amplified products resulted from RT priming via transcripts originating from promoter or upstream spanning regions. Consequently, this priming overruled directionality determination and led to false detection-identification of such IncRNAs. We show that this prevalent "no primer" artifact can be eliminated by treating the RNA preparations with periodate, performing RT reactions at highly elevated temperatures, or a combination of both. These experimental improvements enabled determination of the presence and directionality of individual promoter-spanning long noncoding RNAs with certainty. Examples for the BRMS1 metastasis suppressor gene, as well as RAR-32 and CST6 human tumor suppressor genes, in breast carcinoma cell lines are presented. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Tzadok, Sivan; Caspin, Yarden; Hachmo, Yafit; Canaani, Dan; Dotan, Iris] Tel Aviv Univ, Fac Life Sci, Dept Biochem & Mol Biol, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University
RP Dotan, I (通讯作者)，Tel Aviv Univ, Fac Life Sci, Dept Biochem & Mol Biol, IL-69978 Tel Aviv, Israel.
EM irisd@tauex.tau.ac.il
FU David Orgler Fund for Cancer Research; TAU Rector fellowship; van Baytes
   Cancer Research fellowship
FX We thank J. Price for a biological reagent and G. Kaufmann for his
   thoughtful suggestion in treating RNA preparations with periodate. This
   work was supported by a grant from the David Orgler Fund for Cancer
   Research to Dan Canaani. Sivan Tzadok was supported by a TAU Rector
   fellowship. Yafit Hachmo was supported by a van Baytes Cancer Research
   fellowship.
CR Adrover MF, 2010, BIOCHIMIE, V92, P1839, DOI 10.1016/j.biochi.2010.07.019
   Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   CROPP CS, 1994, JNCI-J NATL CANCER I, V86, P1167, DOI 10.1093/jnci/86.15.1167
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Haddad F, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-21
   Han J, 2007, P NATL ACAD SCI USA, V104, P12422, DOI 10.1073/pnas.0701635104
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hawkins PG, 2009, NUCLEIC ACIDS RES, V37, P2984, DOI 10.1093/nar/gkp127
   He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853
   Ho ECH, 2010, METHODS MOL BIOL, V630, P125, DOI 10.1007/978-1-60761-629-0_9
   Hoque MO, 2008, CANCER RES, V68, P2661, DOI 10.1158/0008-5472.CAN-07-5913
   Ideue T, 2009, RNA, V15, P1578, DOI 10.1261/rna.1657609
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Knowling S, 2011, PROG MOL BIOL TRANSL, V102, P1, DOI 10.1016/B978-0-12-415795-8.00003-9
   Kowalczyk MS, 2012, NATURE, V482, P310, DOI 10.1038/482310a
   Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Morris KV, 2009, RNA BIOL, V6, P242, DOI 10.4161/rna.6.3.8353
   Morris KV, 2009, EPIGENETICS-US, V4, P296, DOI 10.4161/epi.4.5.9282
   Morris KV, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000258
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802
   NEU HC, 1964, J BIOL CHEM, V239, P2927
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105
   Preker P, 2008, SCIENCE, V322, P1851, DOI 10.1126/science.1164096
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594
   Ståhlberg A, 2004, CLIN CHEM, V50, P509, DOI 10.1373/clinchem.2003.026161
   Vaidya KS, 2007, J MAMMARY GLAND BIOL, V12, P175, DOI 10.1007/s10911-007-9049-1
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468
NR 46
TC 5
Z9 5
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD AUG 1
PY 2013
VL 439
IS 1
BP 23
EP 29
DI 10.1016/j.ab.2013.03.031
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 172UA
UT WOS:000321029200007
PM 23583907
DA 2025-01-12
ER

PT J
AU Akulenko, R
   Helms, V
AF Akulenko, Ruslan
   Helms, Volkhard
TI DNA co-methylation analysis suggests novel functional associations
   between gene pairs in breast cancer samples
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SIMILARITY; INTEGRATION; PATHWAY
AB Localized promoter hypermethylation and overall DNA hypomethylation have been associated with the presence of tumor in humans. Yet, despite the large amount of recently produced epigenetic data, there is still a lack of understanding on how several genes behave in tumor cells with respect to their epigenetic alterations such as DNA methylation. Here we performed a novel type of analysis that measures the correlation of DNA methylation levels between two genes across many samples. We linked this so-called co-methylation to the genomic distance of these genes, their functional similarity and their expression levels. Co-methylation analysis of more than 300 breast cancer samples from the TCGA portal yielded 187 pairs of genes showing Pearson correlation coefficients |r| 0.75. These pairs were formed by 133 genes. Less than half of these pairs are located on the same chromosome. For these, we found that the level of co-methylation is weakly anti-correlated with genomic distance (r 0.29). Linking co-methylation with the functional similarity of genes showed that genes with r 0.8 tend to have similar molecular function and to be involved in the same biological process as described in the Gene Ontology project. Clustering of highly co-methylated genes identified four enriched KEGG pathways. Hence we have introduced co-methylation as a new indicator to discover functional associations between gene pairs in breast cancer and furthermore to discover new candidate genes that should be inspected more closely in the context of the studied disease.
C1 [Akulenko, Ruslan; Helms, Volkhard] Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany.
C3 Saarland University
RP Helms, V (通讯作者)，Ctr Bioinformat, Bldg E2 1,R-315,POB 15 11 50, D-66041 Saarbrucken, Germany.
EM volkhard.helms@bioinformatik.uni-saarland.de
OI Helms, Volkhard/0000-0002-2180-9154
FU Saarbrucken Graduate School of Computer Science; Deutsche
   Forschungsgemeinschaft [GK 1276]
FX R.A. was supported by the Saarbrucken Graduate School of Computer
   Science and by the Deutsche Forschungsgemeinschaft via GK 1276.
CR [Anonymous], 1996, EPIGENETIC MECH GENE
   Azuaje FJ, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-46
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bock C, 2008, BIOINFORMATICS, V24, P1, DOI 10.1093/bioinformatics/btm546
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Chan MF, 2000, CURR TOP MICROBIOL, V249, P75
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Fiegl H, 2008, CLIN CANCER RES, V14, P3494, DOI 10.1158/1078-0432.CCR-07-4557
   Golmoghaddam H, 2011, PATHOL ONCOL RES, V17, P669, DOI 10.1007/s12253-011-9367-x
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Horan K, 2008, PLANT PHYSIOL, V147, P41, DOI 10.1104/pp.108.117366
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kriaucionis S, 2003, HUM MOL GENET, V12, pR221, DOI 10.1093/hmg/ddg286
   Krupp M, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-53
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   La Rocca G, 2008, HISTOPATHOLOGY, V52, P203, DOI 10.1111/j.1365-2559.2007.02919.x
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Li YR, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000533
   Lin D., 1998, Machine Learning. Proceedings of the Fifteenth International Conference (ICML'98), P296
   Mosca E, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-76
   Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6
   Resnik P, 1999, J ARTIF INTELL RES, V11, P95, DOI 10.1613/jair.514
   Schlicker A, 2008, NUCLEIC ACIDS RES, V36, pD434, DOI 10.1093/nar/gkm806
   Schlicker A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-302
   Tessema M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034850
   Xiao X, 2012, COMPUT BIOL MED, V42, P624, DOI 10.1016/j.compbiomed.2012.02.008
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
NR 35
TC 29
Z9 31
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2013
VL 22
IS 15
BP 3016
EP 3022
DI 10.1093/hmg/ddt158
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 178MR
UT WOS:000321452600005
PM 23571108
OA Bronze
DA 2025-01-12
ER

PT J
AU Wong, RLY
   Walker, CL
AF Wong, Rebecca Lee Yean
   Walker, Cheryl Lyn
TI Molecular Pathways: Environmental Estrogens Activate Nongenomic
   Signaling to Developmentally Reprogram the Epigenome
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID VASCULAR ENDOTHELIAL-CELLS; NON-GENOMIC ACTIVATION; NITRIC-OXIDE
   SYNTHASE; BREAST-CANCER CELLS; HISTONE METHYLTRANSFERASE; ANDROGEN
   RECEPTOR; PHOSPHATIDYLINOSITOL-3-OH KINASE; TRANSCRIPTIONAL ACTIVITY;
   DYNAMIC REGULATION; CYCLE PROGRESSION
AB Exposure to environmental xenoestrogens is a major health concern because of the ability of these compounds to perturb estrogen receptor (ER) signaling and act as endocrine disrupting compounds (EDC). Inappropriate exposure to EDCs during development, even at low doses, can predispose individuals to an increased lifetime risk of disease, including cancer. Recent data indicate that perinatal exposure to EDCs increases cancer risk by (re) programming the epigenome via alterations in DNA and histone methylation. We and others have begun to dissect the mechanisms by which xenoestrogens disrupt the epigenetic machinery to reprogram the epigenome and induce developmental reprogramming. Our studies revealed that xenoestrogens induce nongenomic ER signaling to activate PI3K/AKT, resulting in AKT phosphorylation and inactivation of the histone methyltransferase EZH2, thus providing a direct link to disruption of the epigenome. Other epigenetic "readers, writers, and erasers" may also be targeted by nongenomic signaling, suggesting this is a central mechanism by which xenoestrogens and other EDCs disrupt the epigenome to induce developmental reprogramming. Elucidating mechanisms of developmental reprogramming of the epigenome is important for understanding how environmental exposures increase cancer risk, and provides a rationale for developing epigenetic interventions that can reverse the effects of environmental exposures to reduce cancer risk. (C) 2013 AACR.
C1 [Wong, Rebecca Lee Yean; Walker, Cheryl Lyn] Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; University of Texas System; University of
   Texas Health Science Center Houston
RP Walker, CL (通讯作者)，Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.
EM walker@ibt.tamhsc.edu
FU National Institute of Environmental Health Sciences [R01ES008263,
   RC2ES018789]
FX This work is supported by grants from the National Institute of
   Environmental Health Sciences (to C.L. Walker; R01ES008263 and
   RC2ES018789).
CR Acconcia F, 2005, MOL BIOL CELL, V16, P231, DOI 10.1091/mbc.e04-07-0547
   Acconcia F, 2006, CANCER LETT, V238, P1, DOI 10.1016/j.canlet.2005.06.018
   Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875
   Baba A, 2011, NAT CELL BIOL, V13, P668, DOI 10.1038/ncb2228
   Boeke J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010042
   Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5
   Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Bulayeva NN, 2004, STEROIDS, V69, P181, DOI 10.1016/j.steroids.2003.12.003
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44
   Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102
   De Coster S, 2012, J ENVIRON PUBLIC HEA, V2012, DOI 10.1155/2012/713696
   Dong B, 2011, BBA-GEN SUBJECTS, V1810, P427, DOI 10.1016/j.bbagen.2010.11.007
   Faivre EJ, 2007, MOL CELL BIOL, V27, P466, DOI 10.1128/MCB.01539-06
   Feng Q, 2009, J BIOL CHEM, V284, P36167, DOI 10.1074/jbc.M109.065524
   Gardner OS, 2005, MOL PHARMACOL, V68, P933, DOI 10.1124/mol.105.012260
   Gilad LA, 2007, J MOL ENDOCRINOL, V38, P603, DOI 10.1677/JME-06-0040
   Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440
   Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605
   Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070
   Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jiménez R, 2010, J PHARMACOL EXP THER, V332, P554, DOI 10.1124/jpet.109.159806
   Keung W, 2011, PHARMACOL RES, V64, P509, DOI 10.1016/j.phrs.2011.05.010
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9
   Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004
   Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018
   Liang CY, 2011, NUCLEIC ACIDS RES, V39, P4151, DOI 10.1093/nar/gkr040
   Liu DM, 2005, ENDOCRINOLOGY, V146, P1312, DOI 10.1210/en.2004-1221
   Liu DM, 2004, ENDOCRINOLOGY, V145, P5532, DOI 10.1210/en.2004-0102
   Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272
   Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383
   Lösel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003
   Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200
   Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406
   Ogawa M, 2003, IMMUNOL LETT, V86, P57, DOI 10.1016/S0165-2478(02)00293-6
   Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200
   Sciullo EM, 2008, ARCH BIOCHEM BIOPHYS, V480, P143, DOI 10.1016/j.abb.2008.09.017
   Sen N, 2011, P NATL ACAD SCI USA, V108, P20178, DOI 10.1073/pnas.1117820108
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200
   Sun M, 2001, CANCER RES, V61, P5985
   Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Verkasalo PK, 2001, NUTR CANCER, V40, P79, DOI 10.1207/S15327914NC402_1
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220
   Watson CS, 2007, MOL CELL ENDOCRINOL, V274, P1, DOI 10.1016/j.mce.2007.05.011
   Watson CS, 2007, STEROIDS, V72, P124, DOI 10.1016/j.steroids.2006.11.002
   Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159
   Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210
   Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515
   Yu J, 2012, BIOCHEM BIOPH RES CO, V424, P538, DOI 10.1016/j.bbrc.2012.06.151
   Zassadowski F, 2012, CELL SIGNAL, V24, P2369, DOI 10.1016/j.cellsig.2012.08.003
NR 57
TC 41
Z9 48
U1 1
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2013
VL 19
IS 14
BP 3732
EP 3737
DI 10.1158/1078-0432.CCR-13-0021
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 183NE
UT WOS:000321822000003
PM 23549878
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Hasan, TN
   Grace, BL
   Shafi, G
   Syed, R
AF Hasan, Tarique N.
   Grace, B. Leena
   Shafi, Gowhar
   Syed, Rabbani
TI Association of <i>BRCA1</i> promoter methylation with rs11655505
   (c.2265C&gt;T) variants and decreased gene expression in sporadic breast
   cancer
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Sporadic breast cancer; BRCA1 promoter; Methylation; Gene expression;
   rs11655505 (c.-2265C/T)
ID SAUDI POPULATION; RISK; MUTATIONS; WOMEN; HYPERMETHYLATION; PROFILES;
   DNA
AB Breast cancer is the most common cancer and the main cause of cancer morbidity for women worldwide and is manifestation of abnormal genetic as well as epigenetic changes. Therefore, our aim was to study the association of BRCA1 promoter methylation with rs11655505 (c.-2265C/T) variants and gene expression in sporadic breast cancer.
   Twenty-nine sporadic breast cancer tissues and 26 normal biopsies were used for this study. Genomic DNA and total RNA were extracted from paraffin-embedded tissue and SNP analysis performed. Methylation status of the BRCA1 promoter region was determined by methylation-specific PCR after sodium bisulfite modification of DNA.
   Among all clinical-pathological parameters only estrogen receptor -ve and +ve samples were significantly different for methylation status (P = 0.04). The genotypic (CC, CT and TT), allelic frequencies and methylation status had not been found to be significantly different from that of healthy controls (P = 0.67, 0.71 and 0.17, respectively). Similarly, methylated BRCA1 promoter was not found to be significantly different in different genotypes from unmethylated promoters between patients and controls. Interestingly, only heterozygous (CT) genotypes with low and normal expression of BRCA1 were significantly different for the differential expression of BRCA1 compared to controls (P = 0.004). However, in tumor samples decreased expression of gene is associated with methylated state of BRCA1 promoter [OR (95 % CI) = 25.09 (2.17-29.75); P = 0.01].
   Our data suggest that both single nucleotide variations rs11655505 (c.-2265C/T) and the methylation status of BRCA1 are not associated significantly with the occurrence of sporadic breast cancer in studied population. However, decreased expression of gene is associated with the CT genotypes and the disease. But, in case of tumor samples, an association of methylation of the promoter to the decreased expression of BRCA1 gene suggests the possible role of methylation in gene silencing.
C1 [Hasan, Tarique N.] Bharathiar Univ, R&D Ctr, Coimbatore 641046, Tamil Nadu, India.
   [Grace, B. Leena] Vinayaka Missions Univ, Dept Biotechnol, Salem, Tamil Nadu, India.
   [Shafi, Gowhar] Inst Genet, Dept Mol Biol, Hyderabad, Andhra Pradesh, India.
   [Shafi, Gowhar] Hosp Genet Dis, Hyderabad, Andhra Pradesh, India.
   [Syed, Rabbani] Mahavir Hosp & Res Ctr, Dept Genet, Hyderabad, Andhra Pradesh, India.
C3 Bharathiar University; Vinayaka Mission's Research Foundation
RP Hasan, TN (通讯作者)，Bharathiar Univ, R&D Ctr, Coimbatore 641046, Tamil Nadu, India.
EM tariquenh@gmail.com
RI Hasan, Tarique/F-4701-2011; Syed, Rabbani/AAW-4246-2021; BESLIN, LEENA
   GRACE/J-4439-2014
OI Syed, Rabbani/0000-0003-4695-0645; Noorul Hasan,
   Tarique/0000-0002-7744-9637; BESLIN, LEENA GRACE/0000-0002-7987-0572
CR Alshatwi AA, 2012, BREAST J, V18, P383, DOI 10.1111/j.1524-4741.2012.01260.x
   Alshatwi AA, 2012, FUND CLIN PHARMACOL, V26, P438, DOI 10.1111/j.1472-8206.2011.00939.x
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bin Amer SM, 2008, SAUDI MED J, V29, P507
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bosviel R, 2012, CANCER EPIDEMIOL, V36, pE177, DOI 10.1016/j.canep.2012.02.001
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Chan KYK, 2009, J MED GENET, V46, P32, DOI 10.1136/jmg.2007.057174
   Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054
   Freedman ML, 2005, CANCER RES, V65, P7516, DOI 10.1158/0008-5472.CAN-05-0132
   FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Indian Council of Medical Research, 2002, NAT CANC REG PROGR I
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Murthy N. S., 2009, Indian Journal of Cancer, V46, P73, DOI 10.4103/0019-509X.48603
   Parkin D., 2005, Cancer Incidence in Five Continents, V1-8
   Parkin DM, 2010, INT J CANCER, V126, P1187, DOI 10.1002/ijc.24838
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Verderio P, 2010, J MED GENET, V47, P268, DOI 10.1136/jmg.2009.073544
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Yu CY, 2004, CANCER RES, V64, P7622, DOI 10.1158/0008-5472.CAN-04-1521
NR 30
TC 9
Z9 9
U1 0
U2 9
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1699-048X
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD JUL
PY 2013
VL 15
IS 7
BP 555
EP 562
DI 10.1007/s12094-012-0968-y
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 173WO
UT WOS:000321112900008
PM 23263908
DA 2025-01-12
ER

PT J
AU Yakulov, T
   Raggioli, A
   Franz, H
   Kemler, R
AF Yakulov, Toma
   Raggioli, Angelo
   Franz, Henriette
   Kemler, Rolf
TI Wnt3a-dependent and -independent Protein Interaction Networks of
   Chromatin-bound β-catenin in Mouse Embryonic Stem Cells
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; DNA-BINDING; PLURIPOTENCY;
   SALL4; WNT; IDENTIFICATION; COMPLEX; LSD1; TRANSACTIVATION
AB Canonical Wnt signaling is repeatedly used during development to control cell fate, and it is often implicated in human cancer. beta-catenin, the effector of Wnt signaling, has a dual function in the cell and is involved in both cell adhesion and transcription. Nuclear beta-catenin controls transcription through association with transcription factors of the TCF family and the recruitment of epigenetic modifiers. In this study, we used a strategy combining the genetic manipulation of mouse embryonic stem cells with affinity purification and quantitative mass spectroscopy utilizing stable isotope labeling with amino acids in cell culture to study the interactome of chromatin-bound beta-catenin with and without Wnt3a stimulation. We uncovered previously unknown interactions of beta-catenin with transcription factors and chromatin-modifying complexes. Our proof-of-principle experiments show that beta-catenin can recruit the H3K4me2/1 demethylase LSD1 to regulate the expression of the tumor suppressor Lefty1 in mouse embryonic stem cells. The mRNA levels of LSD1 and beta-catenin are inversely correlated with the levels of Lefty1 in pancreas and breast tumors, implying that this mechanism is common to mouse embryonic stem cells and cancer cells.
C1 [Yakulov, Toma; Raggioli, Angelo; Kemler, Rolf] Max Planck Inst Immunobiol & Epigenet, Dept Mol Embryol, D-79108 Freiburg, Germany.
   [Franz, Henriette] Univ Freiburg Klinikum, Urol Klin, Frauenklin & Zent Klin Forsch, D-79106 Freiburg, Germany.
C3 Max Planck Society; University of Freiburg
RP Kemler, R (通讯作者)，Max Planck Inst Immunobiol & Epigenet, Dept Mol Embryol, D-79108 Freiburg, Germany.
EM kemler@ie-freiburg.mpg.de
RI Yakulov, Toma/GNO-9211-2022
OI Yakulov, Toma Antonov/0000-0002-3160-0944; Franz,
   Henriette/0000-0001-9358-7442; Raggioli, Angelo/0000-0002-6748-0307
CR Abu-Remaileh M, 2010, EMBO J, V29, P3236, DOI 10.1038/emboj.2010.200
   [Anonymous], 2005, R: a language and environment for statistical computing
   Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016
   Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121
   Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Blagoev B, 2004, NAT BIOTECHNOL, V22, P1139, DOI 10.1038/nbt1005
   Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611
   Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103
   Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124
   Foster CT, 2010, MOL CELL BIOL, V30, P4851, DOI 10.1128/MCB.00521-10
   Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473
   Graham K, 2010, BRIT J CANCER, V102, P1284, DOI 10.1038/sj.bjc.6605576
   Gullberg M, 2004, P NATL ACAD SCI USA, V101, P8420, DOI 10.1073/pnas.0400552101
   Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370
   Kelly KF, 2011, CELL STEM CELL, V8, P214, DOI 10.1016/j.stem.2010.12.010
   Kon C, 2005, GENETICS, V169, P2087, DOI 10.1534/genetics.104.034595
   Li M, 2012, NAT REV MOL CELL BIO, V13, P524, DOI 10.1038/nrm3393
   Lorenz M, 1999, BIOCHEMISTRY-US, V38, P12150, DOI 10.1021/bi990459+
   Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7
   Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Miyata N, 2012, PANCREAS, V41, P745, DOI 10.1097/MPA.0b013e31823b66d3
   Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654
   Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06
   Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9
   Niwa H, 2002, MOL CELL BIOL, V22, P1526, DOI 10.1128/MCB.22.5.1526-1536.2002
   Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127
   OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x
   PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521
   Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007
   Rudloff S, 2012, DEVELOPMENT, V139, P3711, DOI 10.1242/dev.085597
   Saijoh Y, 1996, GENES CELLS, V1, P239, DOI 10.1046/j.1365-2443.1996.d01-237.x
   Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457
   SHELTON KR, 1981, BIOCHEM BIOPH RES CO, V103, P975, DOI 10.1016/0006-291X(81)90905-0
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Söderberg O, 2008, METHODS, V45, P227, DOI 10.1016/j.ymeth.2008.06.014
   Sokol SY, 2011, DEVELOPMENT, V138, P4341, DOI 10.1242/dev.066209
   Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Taniguchi N, 2009, P NATL ACAD SCI USA, V106, P16817, DOI 10.1073/pnas.0904414106
   Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200
   Yi F, 2011, NAT CELL BIOL, V13, P762, DOI 10.1038/ncb2283
   Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481
NR 60
TC 15
Z9 20
U1 1
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD JUL
PY 2013
VL 12
IS 7
BP 1980
EP 1994
DI 10.1074/mcp.M112.026914
PG 15
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 179YM
UT WOS:000321559000018
PM 23592333
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Sun, M
   Song, CX
   Huang, H
   Frankenberger, CA
   Sankarasharma, D
   Gomes, S
   Chen, P
   Chen, JJ
   Chada, KK
   He, C
   Rosner, MR
AF Sun, Miao
   Song, Chun-Xiao
   Huang, Hao
   Frankenberger, Casey A.
   Sankarasharma, Devipriya
   Gomes, Suzana
   Chen, Ping
   Chen, Jianjun
   Chada, Kiran K.
   He, Chuan
   Rosner, Marsha R.
TI HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and
   metastasis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID ACTIVE DNA DEMETHYLATION; GENE-EXPRESSION; TET PROTEINS;
   5-HYDROXYMETHYLCYTOSINE; MOUSE; 5-METHYLCYTOSINE; MLL; SUPPRESSES;
   CONVERSION; EXCISION
AB The ten-eleven translocation (TET) family of methylcytosine dioxygenases initiates demethylation of DNA and is associated with tumorigenesis in many cancers; however, the mechanism is mostly unknown. Here we identify upstream activators and downstream effectors of TET1 in breast cancer using human breast cancer cells and a genetically engineered mouse model. We show that depleting the architectural transcription factor high mobility group AT-hook 2 (HMGA2) induces TET1. TET1 binds and demethylates its own promoter and the promoter of homeobox A (HOXA) genes, enhancing its own expression and stimulating expression of HOXA genes including HOXA7 and HOXA9. Both TET1 and HOXA9 suppress breast tumor growth and metastasis in mouse xenografts. The genes comprising the HMGA2-TET1-HOXA9 pathway are coordinately regulated in breast cancer and together encompass a prognostic signature for patient survival. These results implicate the HMGA2-TET1-HOX signaling pathway in the epigenetic regulation of human breast cancer and highlight the importance of targeting methylation in specific subpopulations as a potential therapeutic strategy.
C1 [Sun, Miao; Frankenberger, Casey A.; Gomes, Suzana; Rosner, Marsha R.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.
   [Sun, Miao; Rosner, Marsha R.] Univ Chicago, Comm Genet Genom & Syst Biol, Chicago, IL 60637 USA.
   [Song, Chun-Xiao; He, Chuan] Univ Chicago, Dept Chem, Chicago, IL 60637 USA.
   [Song, Chun-Xiao; He, Chuan] Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA.
   [Huang, Hao; Chen, Ping; Chen, Jianjun] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Sankarasharma, Devipriya; Chada, Kiran K.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   University of Chicago; University of Chicago; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences
RP Rosner, MR (通讯作者)，Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.
EM m-rosner@uchicago.edu
RI Song, Chunxiao/GXH-8050-2022; chen, JJ/HGB-6029-2022; He,
   Chuan/HZJ-6319-2023; Sun, Hao/T-5576-2019
OI Chen, Jianjun/0000-0003-3749-2902; Song, Chun-Xiao/0000-0002-7781-6521;
   HUANG, HAO/0000-0002-6687-6967
FU National Institutes of Health (NIH) [GM087630, GM071440, P50
   CA125183-05, CA127277]; Department of Defense [W81XWH-10-1-0396]
FX We thank Alex Rothenberg and Eva Eves for helpful discussions; Huiping
   Liu for sharing her invasion assay; and Xi Jiang for sharing plasmids.
   This work was supported by National Institutes of Health (NIH) Grant
   GM087630 (to M. R. R.), NIH Grant GM071440 (to C. H.), NIH Specialized
   Programs of Research Excellence Grant P50 CA125183-05 (Developmental
   Research Program) (to M. R. R. and C. H.), and NIH Grant CA127277 (to
   J.C.). M. S. was supported by Department of Defense Predoctoral
   Traineeship Award W81XWH-10-1-0396.
CR Abe N, 2003, BRIT J CANCER, V89, P2104, DOI 10.1038/sj.bjc.6601391
   BENSON KF, 1994, GENET RES, V64, P27, DOI 10.1017/S0016672300032511
   Bhutani N, 2011, CELL, V146, P866, DOI 10.1016/j.cell.2011.08.042
   Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020
   Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294
   Dreszer TR, 2012, NUCLEIC ACIDS RES, V40, pD918, DOI 10.1093/nar/gkr1055
   Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915
   Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597
   Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Inoue A, 2011, SCIENCE, V334, P194, DOI 10.1126/science.1212483
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008
   Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Meyer B, 2007, MOL CARCINOGEN, V46, P503, DOI 10.1002/mc.20235
   Miyazawa J, 2004, CANCER RES, V64, P2024, DOI 10.1158/0008-5472.CAN-03-1855
   Morishita A, 2013, CANC RES IN PRESS
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ono R, 2002, CANCER RES, V62, P4075
   Rogalla P, 1997, MOL CARCINOGEN, V19, P153, DOI 10.1002/(SICI)1098-2744(199707)19:3<153::AID-MC2>3.0.CO;2-F
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Winter N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018837
   Wu H, 2011, CELL CYCLE, V10, P2428, DOI 10.4161/cc.10.15.16930
   Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312
NR 40
TC 230
Z9 251
U1 0
U2 28
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 11
PY 2013
VL 110
IS 24
BP 9920
EP 9925
DI 10.1073/pnas.1305172110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 171LM
UT WOS:000320930100073
PM 23716660
OA Green Published
DA 2025-01-12
ER

PT J
AU Rhie, SK
   Coetzee, SG
   Noushmehr, H
   Yan, CL
   Kim, JM
   Haiman, CA
   Coetzee, GA
AF Rhie, Suhn Kyong
   Coetzee, Simon G.
   Noushmehr, Houtan
   Yan, Chunli
   Kim, Jae Mun
   Haiman, Christopher A.
   Coetzee, Gerhard A.
TI Comprehensive Functional Annotation of Seventy-One Breast Cancer Risk
   Loci
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GENE-EXPRESSION; REGULATORY ELEMENTS;
   ANDROGEN-RECEPTOR; DIFFERENTIAL EXPRESSION; SUSCEPTIBILITY LOCUS; COMMON
   VARIANTS; DATA SETS; DATABASE; PROTEIN
AB Breast Cancer (BCa) genome-wide association studies revealed allelic frequency differences between cases and controls at index single nucleotide polymorphisms (SNPs). To date, 71 loci have thus been identified and replicated. More than 320,000 SNPs at these loci define BCa risk due to linkage disequilibrium (LD). We propose that BCa risk resides in a subgroup of SNPs that functionally affects breast biology. Such a shortlist will aid in framing hypotheses to prioritize a manageable number of likely disease-causing SNPs. We extracted all the SNPs, residing in 1 Mb windows around breast cancer risk index SNP from the 1000 genomes project to find correlated SNPs. We used FunciSNP, an R/Bioconductor package developed in-house, to identify potentially functional SNPs at 71 risk loci by coinciding them with chromatin biofeatures. We identified 1,005 SNPs in LD with the index SNPs (r(2) >= 0.5) in three categories; 21 in exons of 18 genes, 76 in transcription start site (TSS) regions of 25 genes, and 921 in enhancers. Thirteen SNPs were found in more than one category. We found two correlated and predicted non-benign coding variants (rs8100241 in exon 2 and rs8108174 in exon 3) of the gene, ANKLE1. Most putative functional LD SNPs, however, were found in either epigenetically defined enhancers or in gene TSS regions. Fifty-five percent of these non-coding SNPs are likely functional, since they affect response element (RE) sequences of transcription factors. Functionality of these SNPs was assessed by expression quantitative trait loci (eQTL) analysis and allele-specific enhancer assays. Unbiased analyses of SNPs at BCa risk loci revealed new and overlooked mechanisms that may affect risk of the disease, thereby providing a valuable resource for follow-up studies.
C1 [Rhie, Suhn Kyong; Coetzee, Simon G.; Noushmehr, Houtan; Yan, Chunli; Haiman, Christopher A.; Coetzee, Gerhard A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Rhie, Suhn Kyong; Coetzee, Simon G.; Noushmehr, Houtan; Yan, Chunli; Haiman, Christopher A.; Coetzee, Gerhard A.] Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA.
   [Kim, Jae Mun] Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA.
   [Coetzee, Gerhard A.] Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; University of Southern California
RP Coetzee, GA (通讯作者)，Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
EM coetzee@usc.edu
RI Coetzee, Gerhard/AAG-8439-2019; Lee, Sang-Jun/A-3892-2015; Haiman,
   Christopher/HGC-5586-2022; Coetzee, Simon Gert/C-1218-2014; Noushmehr,
   Houtan/C-9692-2013
OI Rhie, Suhn/0000-0002-5522-5296; Kim, Hugo/0000-0002-8610-9677; Coetzee,
   Simon Gert/0000-0003-4267-5930; Coetzee, Gerhard/0000-0001-8820-8364;
   Noushmehr, Houtan/0000-0003-4051-8114
FU National Institutes of Health [R01 CA136924, T32CA009320]; Genetic
   Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer
   Post-GWAS Initiative
FX This work was supported by the National Institutes of Health [R01
   CA136924 to GAC and T32CA009320 to HN). The scientific development and
   funding of this project were in part supported by the Genetic
   Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer
   Post-GWAS Initiative. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adiseshaiah P, 2003, J BIOL CHEM, V278, P47423, DOI 10.1074/jbc.M303505200
   Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354
   Albers M, 2005, MOL CELL PROTEOMICS, V4, P205, DOI 10.1074/mcp.M400169-MCP200
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   [Anonymous], NATURE GENETICS
   [Anonymous], NATURE GENETICS
   Antoniou AC, 2010, NAT GENET, V42, P885, DOI 10.1038/ng.669
   Babu MM, 2004, CURR OPIN STRUC BIOL, V14, P283, DOI 10.1016/j.sbi.2004.05.004
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bedell VM, 2012, NATURE, V491, P114, DOI 10.1038/nature11537
   Bolton KL, 2010, NAT GENET, V42, P880, DOI 10.1038/ng.666
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Brachner A, 2012, J CELL SCI, V125, P1048, DOI 10.1242/jcs.098392
   Chen F, 2013, HUM GENET, V132, P39, DOI 10.1007/s00439-012-1214-y
   Coetzee SG, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks542
   Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416
   D'Amato NC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045684
   Degner JF, 2012, NATURE, V482, P390, DOI 10.1038/nature10808
   Dreszer TR, 2012, NUCLEIC ACIDS RES, V40, pD918, DOI 10.1093/nar/gkr1055
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Ecker JR, 2012, NATURE, V489, P52, DOI 10.1038/489052a
   Eswarakumar VP, 2002, DEVELOPMENT, V129, P3783
   Evert BO, 2000, CELL TISSUE RES, V301, P189, DOI 10.1007/s004410000228
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fletcher O, 2011, JNCI-J NATL CANCER I, V103, P425, DOI 10.1093/jnci/djq563
   Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840
   Garcia-Closas M, 2013, NAT GENET, V45, P392, DOI 10.1038/ng.2561
   Gibson G, 2012, NAT REV GENET, V13, P135, DOI 10.1038/nrg3118
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999
   Haiman CA, 2011, NAT GENET, V43, P1210, DOI 10.1038/ng.985
   Hansson A, 2003, BIOCHEM BIOPH RES CO, V312, P1073, DOI 10.1016/j.bbrc.2003.11.030
   Hardison RC, 2012, J BIOL CHEM, V287, P30932, DOI 10.1074/jbc.R112.352427
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Jia L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000597
   Kalhor R, 2012, NAT BIOTECHNOL, V30, P90, DOI 10.1038/nbt.2057
   Kim HW, 2010, MOL CELL BIOL, V30, P5406, DOI 10.1128/MCB.00217-10
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002-9440(10)64139-9
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li QY, 2013, CELL, V152, P633, DOI 10.1016/j.cell.2012.12.034
   Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231
   Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Mavaddat N, 2010, MOL ONCOL, V4, P174, DOI 10.1016/j.molonc.2010.04.011
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903
   Myers AJ, 2007, NAT GENET, V39, P1494, DOI 10.1038/ng.2007.16
   Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Palii CG, 2011, EMBO J, V30, P494, DOI 10.1038/emboj.2010.342
   Parkhomchuk D, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp596
   Peng SH, 2011, BREAST CANCER RES TR, V127, P309, DOI 10.1007/s10549-011-1459-5
   Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872
   Pickrell JK, 2010, NATURE, V464, P768, DOI 10.1038/nature08872
   Qi W, 2007, EMBO J, V26, P65, DOI 10.1038/sj.emboj.7601483
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Rosenbloom KR, 2012, NUCLEIC ACIDS RES, V40, pD912, DOI 10.1093/nar/gkr1012
   Schaub MA, 2012, GENOME RES, V22, P1748, DOI 10.1101/gr.136127.111
   Seelan RS, 2004, ARCH BIOCHEM BIOPHYS, V431, P95, DOI 10.1016/j.abb.2004.08.002
   Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100
   Siddiq A, 2012, HUM MOL GENET, V21, P5373, DOI 10.1093/hmg/dds381
   Smith AJP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002908
   Song LY, 2011, GENOME RES, V21, P1757, DOI 10.1101/gr.121541.111
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131
   Stevens KN, 2012, CANCER RES, V72, P1795, DOI 10.1158/0008-5472.CAN-11-3364
   Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142
   Tapias A, 2008, CELL CYCLE, V7, P2856, DOI 10.4161/cc.7.18.6671
   Tarlac V, 2003, J NEUROSCI RES, V74, P406, DOI 10.1002/jnr.10746
   Ting MC, 2012, DIS MODEL MECH, V5, P366, DOI 10.1242/dmm.008458
   Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586
   van Berkum Nynke L, 2010, J Vis Exp, DOI 10.3791/1869
   Veyrieras JB, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000214
   VISVADER J, 1991, ONCOGENE, V6, P187
   Volders PJ, 2013, NUCLEIC ACIDS RES, V41, pD246, DOI 10.1093/nar/gks915
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158
   Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262
   Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693
   Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318
NR 95
TC 37
Z9 38
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR e63925
DI 10.1371/journal.pone.0063925
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700080
PM 23717510
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Birts, CN
   Nijjar, SK
   Mardle, CA
   Hoakwie, F
   Duriez, PJ
   Blaydes, JP
   Tavassoli, A
AF Birts, Charles N.
   Nijjar, Sharandip K.
   Mardle, Charlotte A.
   Hoakwie, Franciane
   Duriez, Patrick J.
   Blaydes, Jeremy P.
   Tavassoli, Ali
TI A cyclic peptide inhibitor of C-terminal binding protein dimerization
   links metabolism with mitotic fidelity in breast cancer cells
SO CHEMICAL SCIENCE
LA English
DT Article
ID TRANSCRIPTIONAL COREPRESSOR; CTBP; PROLIFERATION; GLYCOLYSIS; ROLES;
   TUMORIGENESIS; COACTIVATOR; INSTABILITY; ACTIVATION; CTBP/BARS
AB Identification of direct modulators of transcription factor protein-protein interactions is a key challenge for ligand discovery that promises to significantly advance current approaches to cancer therapy. Here, we report an inhibitor of NADH-dependent dimerization of the C-terminal binding protein (CtBP) transcriptional repressor, identified by screening genetically encoded cyclic peptide libraries of up to 64 million members. CtBP dimers form the core of transcription complexes associated with epigenetic regulation of multiple genes that control many characteristics of cancer cells, including proliferation, survival and migration. CtBP monomers also have distinct and critical cellular function, thus current experimental tools that deplete all forms of a targeted protein (e.g. siRNA) do not allow the cellular consequences of this metabolically regulated transcription factor to be deciphered. The most potent inhibitor from our screen (cyclo-SGWTVVRMY) is demonstrated to disrupt CtBP dimerization in vitro and in cells. This compound is used as a chemical tool to establish that the NADH-dependent dimerization of CtBPs regulates the maintenance of mitotic fidelity in cancer cells. Treatment of highly glycolytic breast cancer cell lines with the identified inhibitor significantly reduced their mitotic fidelity, proliferation and colony forming potential, whereas the compound does not affect mitotic fidelity of cells with lower glycolytic flux. This work not only links the altered metabolic state of transformed cells to a key determinant of the tumor cell phenotype, but the uncovered compound also serves as the starting point for the development of potential therapeutic agents that target tumors by disrupting the CtBP chromatin-modifying complex.
C1 [Birts, Charles N.; Nijjar, Sharandip K.; Mardle, Charlotte A.; Hoakwie, Franciane; Tavassoli, Ali] Univ Southampton, Southampton SO17 1BJ, Hants, England.
   [Birts, Charles N.; Nijjar, Sharandip K.; Mardle, Charlotte A.; Duriez, Patrick J.; Blaydes, Jeremy P.; Tavassoli, Ali] Univ Southampton, Fac Med, Southampton SO16 6YD, Hants, England.
   [Blaydes, Jeremy P.; Tavassoli, Ali] Univ Southampton, Inst Life Sci, Southampton SO9 5NH, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton
RP Blaydes, JP (通讯作者)，Univ Southampton, Fac Med, Southampton SO16 6YD, Hants, England.
EM j.p.blaydes@soton.ac.uk; a.tavassoli@soton.ac.uk
RI Birts, Charles/N-9845-2013; Tavassoli, Ali/N-8908-2018; Blaydes,
   Jeremy/AAC-6939-2019
OI Duriez, Patrick/0000-0003-1814-2552; Birts, Charles/0000-0002-0368-8766;
   Blaydes, Jeremy/0000-0001-8525-0209; Tavassoli, Ali/0000-0002-7420-5063
FU Cancer Research UK [A10263]; Breast Cancer Campaign [2010NovPR12];
   Biotechnology and Biological Sciences Research Council; University of
   Southampton Life Science Interface Forum
FX The authors are grateful to Matthew Darley for generating plasmid
   reagents, and the Southampton Faculty of Medicine Bioimaging Unit for
   assistance with live cell imaging. We thank Dr Bruno Linclau and Dr
   Josephine Corsi for helpful discussions. This work was funded by Cancer
   Research UK (Career Establishment Award A10263 to A.T.), Breast Cancer
   Campaign (Project Grant 2010NovPR12 to J.P.B.), Biotechnology and
   Biological Sciences Research Council (studentship for S.K.N. to A.T.),
   and the University of Southampton Life Science Interface Forum.
CR Achouri Y, 2007, BIOCHEM BIOPH RES CO, V352, P903, DOI 10.1016/j.bbrc.2006.11.111
   Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107
   Berg T, 2008, CURR OPIN CHEM BIOL, V12, P464, DOI 10.1016/j.cbpa.2008.07.023
   Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4
   Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35
   Bergman LM, 2009, MOL CELL BIOL, V29, P4539, DOI 10.1128/MCB.00439-09
   Bhambhani C, 2011, EMBO J, V30, P2031, DOI 10.1038/emboj.2011.100
   Birts CN, 2011, ONCOGENE, V30, P1272, DOI 10.1038/onc.2010.507
   Buchakjian MR, 2010, NAT REV MOL CELL BIO, V11, P715, DOI 10.1038/nrm2972
   Chiarugi A, 2012, NAT REV CANCER, V12, P741, DOI 10.1038/nrc3340
   Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4
   Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349
   Corda D, 2006, TRENDS CELL BIOL, V16, P167, DOI 10.1016/j.tcb.2006.01.007
   Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906
   Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438
   Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718
   Horswill AR, 2004, P NATL ACAD SCI USA, V101, P15591, DOI 10.1073/pnas.0406999101
   Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004
   Kim JH, 2009, CELL DEATH DIFFER, V16, P584, DOI 10.1038/cdd.2008.186
   Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924
   Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0
   Ladurner AG, 2006, MOL CELL, V24, P1, DOI 10.1016/j.molcel.2006.09.002
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Mazurek S, 1997, J BIOL CHEM, V272, P4941, DOI 10.1074/jbc.272.8.4941
   Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8
   Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543
   Mullard A, 2012, NAT REV DRUG DISCOV, V11, P172, DOI 10.1038/nrd3680
   Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571
   Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283
   Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06
   REITZER LJ, 1979, J BIOL CHEM, V254, P2669
   Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Spurr IB, 2012, CHEMBIOCHEM, V13, P1628, DOI 10.1002/cbic.201200279
   Straza MW, 2010, CELL CYCLE, V9, P3740, DOI 10.4161/cc.9.18.12936
   Tavassoli A, 2005, ANGEW CHEM INT EDIT, V44, P2760, DOI 10.1002/anie.200500417
   Tavassoli A, 2007, NAT PROTOC, V2, P1126, DOI 10.1038/nprot.2007.152
   Tavassoli A, 2008, ACS CHEM BIOL, V3, P757, DOI 10.1021/cb800193n
   Vazquez-Martin A, 2009, CELL CYCLE, V8, P3679, DOI 10.4161/cc.8.22.9905
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
   Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x
   Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103
   Zhao LJ, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-89
   Zhao LZ, 2010, CELL CYCLE, V9, P3645, DOI 10.4161/cc.9.18.13221
   Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X
NR 50
TC 51
Z9 65
U1 1
U2 26
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
EI 2041-6539
J9 CHEM SCI
JI Chem. Sci.
PY 2013
VL 4
IS 8
BP 3046
EP 3057
DI 10.1039/c3sc50481f
PG 12
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 176LV
UT WOS:000321307000006
PM 30450179
OA Green Submitted, Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Hussain, Z
   Khan, MI
   Shahid, M
   Almajhdi, FN
AF Hussain, Z.
   Khan, M. I.
   Shahid, M.
   Almajhdi, F. N.
TI S-adenosylmethionine, a methyl donor, up regulates tissue inhibitor of
   metalloproteinase-2 in colorectal cancer
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE Colorectal cancer; Epigenetics; DNA hypomethylation; Gene expression;
   Metastasis
ID DNA METHYLATION; BREAST-CANCER; IN-VIVO; GROWTH-FACTOR; TUMOR-GROWTH;
   TIMP-2 GENE; EXPRESSION; INVASION; HYPERMETHYLATION; ANGIOGENESIS
AB DNA methylation is a fundamental epigenetic mechanism in regulating the expression of genes controlling crucial cell functions in cancer development. Gene silencing via CpG island methylation/ demethylation in the promoter region is one of the mechanisms by which different genes are inactivated/activated in human cancers. Tissue inhibitor of metalloproteinase-2 (TIMP-2) is known to antagonize matrix metalloproteinase (MMP) activity and to suppress tumor growth, angiogenesis, invasion, and metastasis. TIMP-2 expression has been found to be both upregulated and downregulated in various cancers. The inconsistent TIMP-2 expression and unclear epigenetic regulation lead us to investigate its role in colorectal cancer in the presence of a methylating agent. Highly invasive human colorectal cells SW-620 were treated with the methyl donor S-adenosylmethionine (SAM) and its effect was evaluated by cell proliferation, cell cycle, invasion and migration assay. The ability of SAM to down regulate a panel of activated prometastatic, angiogenesis and growth-and cell cycle-regulatory genes was evaluated using end-point and real-time PCR. Treatment of SW-620 with SAM diminished cell proliferation and altered cell cycle kinetic G2/M phase cell cycle arrest. An in vitro matrigel invasion assay of SAM-treated cells showed a significant reduction in the invasive potential compared to untreated SW-620 cells. Treatment of SW-620 cells with SAM resulted in activation of TIMP-2 and inhibition of the expression of genes such as MMP (MMP-2, MT1-MMP), urokinase plasminogen activator, and vascular endothelial growth factors. The level of expression of tumor suppressor and apoptotic genes was not significantly higher compared to the untreated control. No changes in the levels of expression of genes (growth and cell cycle regulator), such as TGF-alpha, Smad2, Smad4, and p21 were observed. Our data support the hypothesis that TIMP-2, along with other prometastatic genes, is hypomethylated and expressed differently in colorectal cancer. Further in-depth analysis is warranted to confirm the promoter region CpG methylation pattern of the TIMP-2 gene.
C1 [Hussain, Z.] King Saud Univ, Ctr Excellence Biotechnol Res, Riyadh, Saudi Arabia.
   [Khan, M. I.] Med Univ Innsbruck, Dept Inner Med 1, A-6020 Innsbruck, Austria.
   [Shahid, M.] Salman bin Abdul Aziz Univ, Coll Dent, Dept Oral & Maxillofacial Surg & Diagnost Sci, Alkharj, Saudi Arabia.
   [Almajhdi, F. N.] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia.
C3 King Saud University; Medical University of Innsbruck; Prince Sattam Bin
   Abdulaziz University; King Saud University
RP Hussain, Z (通讯作者)，King Saud Univ, Ctr Excellence Biotechnol Res, Riyadh, Saudi Arabia.
EM hussainzahep@gmail.com
RI MOHAMMAD, SHAHID/CAH-3217-2022; Hussain, Zahid/HGU-8912-2022; Almajhdi,
   Fahad/AAM-4403-2020
OI Almajhdi, Fahad/0000-0002-0135-7015; Shahid, PhD., Professor
   Mohammad/0000-0002-9659-2041; Hussain, Zahid/0000-0002-1076-9484
FU Deanship of Scientific Research at King Saud University [RGP-VPP-136]
FX Research supported by the Deanship of Scientific Research at King Saud
   University (Project #RGP-VPP-136).
CR Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bird NC, 2006, J SURG ONCOL, V94, P68, DOI 10.1002/jso.20558
   Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   DECLERCK YA, 1992, CANCER RES, V52, P701
   Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10
   Esteller M, 2001, CANCER RES, V61, P3225
   Futschik M., 2002, Genome Lett, V1, P26, DOI 10.1166/gl.2002.005
   Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599
   Gokaslan ZL, 1998, CLIN EXP METASTAS, V16, P721, DOI 10.1023/A:1006580728338
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   Hajitou A, 2001, CANCER RES, V61, P3450
   Imren S, 1996, CANCER RES, V56, P2891
   Ivanova T, 2004, INT J CANCER, V108, P882, DOI 10.1002/ijc.11652
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42
   LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C
   LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0
   Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561
   McMillan DC, 2007, SURG ONCOL, V16, P3, DOI 10.1016/j.suronc.2007.04.008
   Mollabashy A, 2000, ORTHOP CLIN N AM, V31, P529, DOI 10.1016/S0030-5898(05)70172-3
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Pulukuri SM, 2007, ONCOGENE, V26, P5229, DOI 10.1038/sj.onc.1210329
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121
   RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B
   van de Velde CJH, 2005, ANN ONCOL, V16, P144, DOI 10.1093/annonc/mdi702
   Yamamoto M, 1996, CANCER RES, V56, P384
   Yi JM, 2012, TUMOR BIOL, V33, P363, DOI 10.1007/s13277-011-0302-2
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200
NR 40
TC 17
Z9 18
U1 0
U2 3
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
EI 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2013
VL 12
IS 2
BP 1106
EP 1118
DI 10.4238/2013.April.10.6
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 159FI
UT WOS:000320030100025
PM 23661436
OA Bronze
DA 2025-01-12
ER

PT J
AU Korah, R
   Healy, JM
   Kunstman, JW
   Fonseca, AL
   Ameri, AH
   Prasad, ML
   Carling, T
AF Korah, Reju
   Healy, James M.
   Kunstman, John W.
   Fonseca, Annabelle L.
   Ameri, Amir H.
   Prasad, Manju L.
   Carling, Tobias
TI Epigenetic silencing of <i>RASSF1A</i> deregulates cytoskeleton and
   promotes malignant behavior of adrenocortical carcinoma
SO MOLECULAR CANCER
LA English
DT Article
DE Adrenal cortex; Carcinoma; Adenoma; RASSF1A; Hypermethylation;
   Epigenetic silencing; Cytoskeleton
ID TUMOR-SUPPRESSOR RASSF1A; P53 MUTATIONS; MOLECULAR MARKERS;
   BREAST-CANCER; METHYLATION; HYPERMETHYLATION; GENE; INACTIVATION;
   ASSOCIATION; EXPRESSION
AB Background: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with high mutational heterogeneity and a generally poor clinical outcome. Despite implicated roles of deregulated TP53, IGF-2 and Wnt signaling pathways, a clear genetic association or unique mutational link to the disease is still missing. Recent studies suggest a crucial role for epigenetic modifications in the genesis and/or progression of ACC. This study specifically evaluates the potential role of epigenetic silencing of RASSF1A, the most commonly silenced tumor suppressor gene, in adrenocortical malignancy.
   Results: Using adrenocortical tumor and normal tissue specimens, we show a significant reduction in expression of RASSF1A mRNA and protein in ACC. Methylation-sensitive and -dependent restriction enzyme based PCR assays revealed significant DNA hypermethylation of the RASSF1A promoter, suggesting an epigenetic mechanism for RASSF1A silencing in ACC. Conversely, the RASSF1A promoter methylation profile in benign adrenocortical adenomas (ACAs) was found to be very similar to that found in normal adrenal cortex. Enforced expression of ectopic RASSF1A in the SW-13 ACC cell line reduced the overall malignant behavior of the cells, which included impairment of invasion through the basement membrane, cell motility, and solitary cell survival and growth. On the other hand, expression of RASSF1A/A133S, a loss-of-function mutant form of RASSF1A, failed to elicit similar malignancy-suppressing responses in ACC cells. Moreover, association of RASSF1A with the cytoskeleton in RASSF1A-expressing ACC cells and normal adrenal cortex suggests a role for RASSF1A in modulating microtubule dynamics in the adrenal cortex, and thereby potentially blocking malignant progression.
   Conclusions: Downregulation of RASSF1A via promoter hypermethylation may play a role in the malignant progression of adrenocortical carcinoma possibly by abrogating differentiation-promoting RASSF1A- microtubule interactions.
C1 [Korah, Reju; Healy, James M.; Kunstman, John W.; Fonseca, Annabelle L.; Ameri, Amir H.; Carling, Tobias] Yale Univ, Sch Med, Yale Endocrine Neoplasia Lab, Dept Surg, New Haven, CT 06520 USA.
   [Korah, Reju; Healy, James M.; Kunstman, John W.; Fonseca, Annabelle L.; Carling, Tobias] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA.
   [Prasad, Manju L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
C3 Yale University; Yale University; Yale University
RP Carling, T (通讯作者)，Yale Univ, Sch Med, Yale Endocrine Neoplasia Lab, Dept Surg, 333 Cedar St,TMP202,Box 208062, New Haven, CT 06520 USA.
EM tobias.carling@yale.edu
OI Healy, James/0000-0002-1941-4452; Kunstman, John/0000-0002-2618-4173;
   Ameri, Amir H./0000-0003-0284-8286; Fonseca,
   Annabelle/0000-0002-4972-5139
FU Ohse Research Award; Damon Runyon Cancer Research Foundation; Doris Duke
   Charitable Foundation
FX This work was supported by an Ohse Research Award. T.C. is a Doris
   Duke-Damon Runyon Clinical Investigator supported in part by the Damon
   Runyon Cancer Research Foundation and the Doris Duke Charitable
   Foundation.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968
   Avruch J, 2009, J BIOL CHEM, V284, P11001, DOI 10.1074/jbc.R800073200
   Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010
   Barreau O, 2013, J CLIN ENDOCR METAB, V98, pE174, DOI 10.1210/jc.2012-2993
   Bertherat J, 2003, CANCER RES, V63, P5308
   Berthon A, 2012, MOL CELL ENDOCRINOL, V351, P87, DOI 10.1016/j.mce.2011.09.009
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Catalano Maria Graziella, 2012, Front Endocrinol (Lausanne), V3, P40, DOI 10.3389/fendo.2012.00040
   Dackiw APB, 2001, WORLD J SURG, V25, P914, DOI 10.1007/s00268-001-0030-7
   Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247
   Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Dumitrescu Ramona G, 2012, Methods Mol Biol, V863, P3, DOI 10.1007/978-1-61779-612-8_1
   El-Kalla M, 2010, ONCOGENE, V29, P5729, DOI 10.1038/onc.2010.316
   Fassnacht M, 2012, NEW ENGL J MED, V366, P2189, DOI 10.1056/NEJMoa1200966
   Fausti Francesca, 2012, Mol Biol Int, V2012, P307628, DOI 10.1155/2012/307628
   Fernandes MS, 2013, INT J CANCER, V132, P251, DOI 10.1002/ijc.27696
   Fonseca AL, 2012, GENE CHROMOSOME CANC, V51, P949, DOI 10.1002/gcc.21978
   Gao BN, 2008, CANCER RES, V68, P22, DOI 10.1158/0008-5472.CAN-07-5183
   Gao ZH, 2002, J CLIN ENDOCR METAB, V87, P1170, DOI 10.1210/jc.87.3.1170
   Geli J, 2008, CLIN CANCER RES, V14, P2551, DOI 10.1158/1078-0432.CCR-07-1867
   Geli J, 2007, ENDOCR-RELAT CANCER, V14, P125, DOI 10.1677/ERC-06-0031
   Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026
   Jain M, 2012, J SURG ONCOL, V106, P549, DOI 10.1002/jso.23119
   Korah R, 2004, BREAST CANCER RES TR, V88, P17, DOI 10.1007/s10459-004-6006-2
   Lee SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016180
   Lehmann T, 2012, CANCER GENET-NY, V205, P131, DOI 10.1016/j.cancergen.2012.02.009
   Libè R, 2007, CLIN CANCER RES, V13, P844, DOI 10.1158/1078-0432.CCR-06-2085
   Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984
   Malpeli G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-351
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Ng L, 2003, J UROLOGY, V169, P5, DOI 10.1016/S0022-5347(05)64023-2
   OHGAKI H, 1993, INT J CANCER, V54, P408, DOI 10.1002/ijc.2910540310
   Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Rechache NS, 2012, J CLIN ENDOCR METAB, V97, pE1004, DOI 10.1210/jc.2011-3298
   REINCKE M, 1994, J CLIN ENDOCR METAB, V78, P790, DOI 10.1210/jc.78.3.790
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901
   Schagdarsurengin U, 2002, CANCER RES, V62, P3698
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Soon PSH, 2008, ONCOLOGIST, V13, P548, DOI 10.1634/theoncologist.2007-0243
   Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593
   Tommasi S, 2005, CANCER RES, V65, P92
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466
   Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707
   Wajchenberg BL, 2000, CANCER-AM CANCER SOC, V88, P711, DOI 10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.3.CO;2-N
   Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Yu MY, 2003, INT J CANCER, V105, P204, DOI 10.1002/ijc.11051
NR 55
TC 20
Z9 21
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD AUG 5
PY 2013
VL 12
AR 87
DI 10.1186/1476-4598-12-87
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 199XX
UT WOS:000323030000001
PM 23915220
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kim, Y
   Othmer, HG
AF Kim, Yangjin
   Othmer, Hans G.
TI A Hybrid Model of Tumor-Stromal Interactions in Breast Cancer
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Microenvironment invasion
ID EPIDERMAL-GROWTH-FACTOR; TGF-BETA; IN-VITRO; MATHEMATICAL-MODEL;
   RECEPTOR; CELLS; PROTEOLYSIS; MICROENVIRONMENT; PHOSPHORYLATION;
   MECHANISMS
AB Ductal carcinoma in situ (DCIS) is an early stage noninvasive breast cancer that originates in the epithelial lining of the milk ducts, but it can evolve into comedo DCIS and ultimately, into the most common type of breast cancer, invasive ductal carcinoma. Understanding the progression and how to effectively intervene in it presents a major scientific challenge. The extracellular matrix (ECM) surrounding a duct contains several types of cells and several types of growth factors that are known to individually affect tumor growth, but at present the complex biochemical and mechanical interactions of these stromal cells and growth factors with tumor cells is poorly understood. Here we develop a mathematical model that incorporates the cross-talk between stromal and tumor cells, which can predict how perturbations of the local biochemical and mechanical state influence tumor evolution. We focus on the EGF and TGF-beta signaling pathways and show how up- or down-regulation of components in these pathways affects cell growth and proliferation. We then study a hybrid model for the interaction of cells with the tumor microenvironment (TME), in which epithelial cells (ECs) are modeled individually while the ECM is treated as a continuum, and show how these interactions affect the early development of tumors. Finally, we incorporate breakdown of the epithelium into the model and predict the early stages of tumor invasion into the stroma. Our results shed light on the interactions between growth factors, mechanical properties of the ECM, and feedback signaling loops between stromal and tumor cells, and suggest how epigenetic changes in transformed cells affect tumor progression.
C1 [Kim, Yangjin] Konkuk Univ, Dept Math, Seoul 143701, South Korea.
   [Othmer, Hans G.] Univ Minnesota, Sch Math, Minneapolis, MN 55455 USA.
   [Othmer, Hans G.] Univ Minnesota, Digital Technol Ctr, Minneapolis, MN 55455 USA.
C3 Konkuk University; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities
RP Othmer, HG (通讯作者)，Univ Minnesota, Sch Math, Minneapolis, MN 55455 USA.
EM othmer@math.umn.edu
RI Kim, Yangjin/C-9681-2014
FU University of Michigan-Dearborn; Konkuk University; NSF [DMS-0517884];
   NIH [GM-29123]
FX Y.J.K. was supported by a Faculty research grant from the University of
   Michigan-Dearborn and the faculty research fund of Konkuk University in
   2012. H.G.O. was supported in part by NSF grant DMS-0517884, and NIH
   grant GM-29123.
CR Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678
   Adams S, 2004, CANCER RES, V64, P5471, DOI 10.1158/0008-5472.CAN-04-0447
   ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   Alexander S, 2012, TRENDS MOL MED, V18, P13, DOI 10.1016/j.molmed.2011.11.003
   Almholt K, 2007, J MAMMARY GLAND BIOL, V12, P83, DOI 10.1007/s10911-007-9040-x
   Annabi B, 2005, CLIN EXP METASTAS, V22, P429, DOI 10.1007/s10585-005-2669-1
   [Anonymous], P NATL ACAD SCI
   [Anonymous], MOL SYST BIOL
   Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5
   Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003
   Brown DR, 1999, J NEUROCHEM, V72, P943, DOI 10.1046/j.1471-4159.1999.0720943.x
   Burrai GP, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-156
   Chen ST, 2008, J PROTEOME RES, V7, P1379, DOI 10.1021/pr700745n
   Cheng G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004632
   Cheng JD, 2003, CLIN CANCER RES, V9, P1590
   Chivukula M, 2009, AM J CLIN PATHOL, V131, P802, DOI 10.1309/AJCPLDG6TT7VAHPH
   Chung SW, 2009, BIOPHYS J, V96, P1733, DOI 10.1016/j.bpj.2008.11.050
   Dallon JC, 2004, J THEOR BIOL, V231, P203, DOI 10.1016/j.jtbi.2004.06.015
   Dallon JC, 1997, PHILOS T R SOC B, V352, P391, DOI 10.1098/rstb.1997.0029
   Danielsen T, 1998, INT J CANCER, V76, P836, DOI 10.1002/(SICI)1097-0215(19980610)76:6<836::AID-IJC12>3.0.CO;2-0
   DAVIS RJ, 1993, J BIOL CHEM, V268, P14553
   Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016
   Geho DH, 2005, PHYSIOLOGY, V20, P194, DOI 10.1152/physiol.00009.2005
   Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4
   Helmlinger G, 1997, NAT BIOTECHNOL, V15, P778, DOI 10.1038/nbt0897-778
   Hendriks BS, 2005, J BIOL CHEM, V280, P6157, DOI 10.1074/jbc.M410491200
   Hillen T, 2006, J MATH BIOL, V53, P585, DOI 10.1007/s00285-006-0017-y
   Hillen T, 2010, DISCRETE CONT DYN-B, V14, P1055, DOI 10.3934/dcdsb.2010.14.1055
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Ilina O, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/1/015010
   Kaufman LJ, 2005, BIOPHYS J, V89, P635, DOI 10.1529/biophysj.105.061994
   Kim Y, 2007, MATH MOD METH APPL S, V17, P1773, DOI 10.1142/S0218202507002479
   Kim Y, 2011, PROG BIOPHYS MOL BIO, V106, P353, DOI 10.1016/j.pbiomolbio.2011.06.006
   Kim Y, 2010, B MATH BIOL, V72, P1029, DOI 10.1007/s11538-009-9481-z
   Kim Y, 2009, J THEOR BIOL, V260, P359, DOI 10.1016/j.jtbi.2009.06.025
   Kloft C, 2004, INVEST NEW DRUG, V22, P39, DOI 10.1023/B:DRUG.0000006173.72210.1c
   Koka S, 1995, J West Soc Periodontol Periodontal Abstr, V43, P97
   Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804
   Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348
   Krouskop TA, 1998, ULTRASONIC IMAGING, V20, P260, DOI 10.1177/016173469802000403
   KUDLOW JE, 1986, J BIOL CHEM, V261, P4134
   Kunz-Schughart LA, 2003, AM J PHYSIOL-CELL PH, V284, pC209, DOI 10.1152/ajpcell.00557.2001
   Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669
   Mantzaris NV, 2004, J MATH BIOL, V49, P111, DOI 10.1007/s00285-003-0262-2
   Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mercapide J, 2003, INT J CANCER, V106, P676, DOI 10.1002/ijc.11286
   Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x
   Preziosi L, 2011, MATH MOD METH APPL S, V21, P1901, DOI 10.1142/S0218202511005593
   Provenzano PP, 2009, ONCOGENE, V28, P4326, DOI 10.1038/onc.2009.299
   Renkawitz J, 2010, EMBO REP, V11, P744, DOI 10.1038/embor.2010.147
   Renkawitz J, 2009, NAT CELL BIOL, V11, P1438, DOI 10.1038/ncb1992
   Saffarian S, 2004, SCIENCE, V306, P108, DOI 10.1126/science.1099179
   Samoszuk M, 2005, BREAST CANCER RES, V7, pR274, DOI 10.1186/bcr995
   Santos SDM, 2007, NAT CELL BIOL, V9, P324, DOI 10.1038/ncb1543
   SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512
   Schmierer B, 2008, P NATL ACAD SCI USA, V105, P6608, DOI 10.1073/pnas.0710134105
   SHERRATT JA, 1990, P ROY SOC B-BIOL SCI, V241, P29, DOI 10.1098/rspb.1990.0061
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107
   Stein AM, 2007, BIOPHYS J, V92, P356, DOI 10.1529/biophysj.106.093468
   Stein AM, 2011, COMPLEXITY, V16, P22, DOI 10.1002/cplx.20332
   Thorne RG, 2004, J NEUROPHYSIOL, V92, P3471, DOI 10.1152/jn.00352.2004
   Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361
   VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6
   WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965
   Wells CA, 2007, J CLIN PATHOL, V60, P1313, DOI 10.1136/jcp.2006.040626
   Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616
   WOODCOCK EA, 1993, CLIN EXP PHARMACOL P, V20, P331, DOI 10.1111/j.1440-1681.1993.tb01697.x
NR 71
TC 50
Z9 56
U1 1
U2 32
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD AUG
PY 2013
VL 75
IS 8
SI SI
BP 1304
EP 1350
DI 10.1007/s11538-012-9787-0
PG 47
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 200GD
UT WOS:000323055100005
PM 23292359
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Padi, SKR
   Zhang, QS
   Rustum, YM
   Morrison, C
   Guo, B
AF Padi, Sathish K. R.
   Zhang, Qunshu
   Rustum, Youcef M.
   Morrison, Carl
   Guo, Bin
TI MicroRNA-627 Mediates the Epigenetic Mechanisms of Vitamin D to Suppress
   Proliferation of Human Colorectal Cancer Cells and Growth of Xenograft
   Tumors in Mice
SO GASTROENTEROLOGY
LA English
DT Article
DE Gene Regulation; Messenger RNA Processing; Apoptosis; Cancer Prevention
ID COVALENT HISTONE MODIFICATIONS; HYPOXIA-INDUCIBLE FACTORS;
   COLON-CARCINOMA CELLS; BREAST-CANCER; D-RECEPTOR; DIFFERENTIATION;
   TUMORIGENESIS; POLYMORPHISMS; DEMETHYLASES; METASTASIS
AB BACKGROUND & AIMS: Vitamin D protects against colorectal cancer through unclear mechanisms. We investigated the effects of calcitriol (1 alpha,25-dihydroxyvitamin D-3; the active form of vitamin D) on levels of different microRNAs (miRNAs) in colorectal cancer cells from humans and xenograft tumors in mice. METHODS: Expression of miRNAs in colorectal cancer cell lines was examined using the Ambion mirVana miRNA Bioarray. The effects of calcitriol on expression of miR-627 and cell proliferation were determined by real-time polymerase chain reaction and WST-1 assay, respectively; growth of colorectal xenograft tumors was examined in nude mice. Real-time polymerase chain reaction was used to analyze levels of miR-627 in human colon adenocarcinoma samples and nontumor colon mucosa tissues (controls). RESULTS: In HT-29 cells, miR-627 was the only miRNA significantly up-regulated by calcitriol. Jumonji domain containing 1A (JMJD1A), which encodes a histone demethylase, was found to be a target of miR-627. By down-regulating JMJD1A, miR-627 increased methylation of histone H3K9 and suppressed expression of proliferative factors, such as growth and differentiation factor 15. Calcitriol induced expression of miR-627, which down-regulated JMJD1A and suppressed growth of xenograft tumors from HCT-116 cells in nude mice. Overexpression of miR-627 prevented proliferation of colorectal cancer cell lines in culture and growth of xenograft tumors in mice. Conversely, blocking the activity of miR-627 inhibited the tumor suppressive effects of calcitriol in cultured colorectal cancer cells and in mice. Levels of miR-627 were decreased in human colon adenocarcinoma samples compared with controls. CONCLUSIONS: miR-627 mediates tumor-suppressive epigenetic activities of vitamin D on colorectal cancer cells and xenograft tumors in mice. The messenger RNA that encodes the histone demethylase JMJD1A is a direct target of miR-627. Reagents designed to target JMJD1A or its messenger RNA, or increase the function of miR-627, might have the same antitumor activities of vitamin D without the hypercalcemic side effects.
C1 [Padi, Sathish K. R.; Zhang, Qunshu; Guo, Bin] N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Fargo, ND 58108 USA.
   [Rustum, Youcef M.] Roswell Pk Canc Inst, Dept Canc Biol, Buffalo, NY 14263 USA.
   [Morrison, Carl] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.
C3 North Dakota State University Fargo; Roswell Park Comprehensive Cancer
   Center; Roswell Park Comprehensive Cancer Center
RP Guo, B (通讯作者)，N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Fargo, ND 58108 USA.
EM Bin.Guo@ndsu.edu
RI Guo, Bin/AAA-2445-2019; Padi, Sathish/L-1587-2019
OI Padi, Sathish K. R./0000-0002-5526-4287; GUO, BIN/0000-0003-3296-9177
FU National Institutes of Health [CA130062, RR015566]; North Dakota EPSCoR
   [EPS-0814442]; EPSCoR; Office Of The Director [0814442] Funding Source:
   National Science Foundation
FX This work was supported by the National Institutes of Health (CA130062
   and RR015566 to B.G.), and North Dakota EPSCoR (EPS-0814442 to B.G.).
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501
   Cooper G.M, 2000, The Cell: A Molecular Approach, V2nd
   Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110
   Egan JB, 2010, CANCER RES, V70, P1496, DOI 10.1158/0008-5472.CAN-09-3264
   Evans SRT, 1998, CLIN CANCER RES, V4, P2869
   Feskanich D, 2004, CANCER EPIDEM BIOMAR, V13, P1502
   GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227
   GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140-6736(89)91789-3
   Gorham ED, 2005, J STEROID BIOCHEM, V97, P179, DOI 10.1016/j.jsbmb.2005.06.018
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   HERMEKING H, 2009, CELL DEATH DIFFER
   Jenab M, 2009, CANCER EPIDEM BIOMAR, V18, P2485, DOI 10.1158/1055-9965.EPI-09-0319
   Kluiver J, 2012, METHODS, V58, P113, DOI 10.1016/j.ymeth.2012.07.019
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09
   Lee JE, 2011, CANCER PREV RES, V4, P735, DOI 10.1158/1940-6207.CAPR-10-0289
   Lim S, 2010, INT J CANCER, V127, P1991, DOI 10.1002/ijc.25538
   Liu GM, 2010, INT J CANCER, V126, P631, DOI 10.1002/ijc.24762
   Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Maynard MA, 2007, CELL MOL LIFE SCI, V64, P2170, DOI 10.1007/s00018-007-7082-2
   Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Muindi JR, 2004, ONCOLOGY-BASEL, V66, P62, DOI 10.1159/000076336
   Pálmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
   Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21
   Robsahm TE, 2004, CANCER CAUSE CONTROL, V15, P149, DOI 10.1023/B:CACO.0000019494.34403.09
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Wactawski-Wende J, 2006, NEW ENGL J MED, V354, P684, DOI 10.1056/NEJMoa055222
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Zhang J, 2009, BLOOD, V113, P4586, DOI 10.1182/blood-2008-09-178186
NR 39
TC 99
Z9 104
U1 1
U2 28
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD AUG
PY 2013
VL 145
IS 2
BP 437
EP 446
DI 10.1053/j.gastro.2013.04.012
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 194KC
UT WOS:000322630600033
PM 23619147
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Jordan, NV
   Prat, A
   Abell, AN
   Zawistowski, JS
   Sciaky, N
   Karginova, OA
   Zhou, BY
   Golitz, BT
   Perou, CM
   Johnson, GL
AF Jordan, Nicole Vincent
   Prat, Aleix
   Abell, Amy N.
   Zawistowski, Jon S.
   Sciaky, Noah
   Karginova, Olga A.
   Zhou, Bingying
   Golitz, Brian T.
   Perou, Charles M.
   Johnson, Gary L.
TI SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls
   Epithelial-Mesenchymal Transition by Inducing Wnt5a Signaling
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID EPH RECEPTORS; COMPLEX; METASTASIS; PROTEIN; ACTIVATION; EXPRESSION;
   PHENOTYPE; RESPONSES; MELANOMA; EPHRINS
AB We previously identified a gene signature predicted to regulate the epithelial-mesenchymal transition (EMT) in both epithelial tissue stem cells and breast cancer cells. A phenotypic RNA interference (RNAi) screen identified the genes within this 140-gene signature that promoted the conversion of mesenchymal epithelial cell adhesion molecule-negative (EpCAM(-)) breast cancer cells to an epithelial EpCAM(+/high) phenotype. The screen identified 10 of the 140 genes whose individual knockdown was sufficient to promote EpCAM and E-cadherin expression. Among these 10 genes, RNAi silencing of the SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c in EpCAM(-) breast cancer cells gave the most robust transition from the mesenchymal to epithelial phenotype. Conversely, expression of Smarcd3/Baf60c in immortalized human mammary epithelial cells induced an EMT. The mesenchymal-like phenotype promoted by Smarcd3/Baf60c expression resulted in gene expression changes in human mammary epithelial cells similar to that of claudin-low triple-negative breast cancer cells. These mammary epithelial cells expressing Smarcd3/Baf60c had upregulated Wnt5a expression. Inhibition of Wnt5a by either RNAi knockdown or blocking antibody reversed Smarcd3/Baf60c-induced EMT. Thus, Smarcd3/Baf60c epigenetically regulates EMT by activating WNT signaling pathways.
C1 [Jordan, Nicole Vincent; Abell, Amy N.; Zawistowski, Jon S.; Sciaky, Noah; Zhou, Bingying; Golitz, Brian T.; Johnson, Gary L.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.
   [Jordan, Nicole Vincent; Prat, Aleix; Abell, Amy N.; Zawistowski, Jon S.; Sciaky, Noah; Karginova, Olga A.; Zhou, Bingying; Perou, Charles M.; Johnson, Gary L.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
   [Prat, Aleix; Karginova, Olga A.; Perou, Charles M.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC USA.
   [Golitz, Brian T.] Univ N Carolina, Sch Med, RNAi Screening Facil, Chapel Hill, NC USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine; University of North Carolina School of Medicine; University of
   North Carolina; University of North Carolina Chapel Hill
RP Johnson, GL (通讯作者)，Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.
EM gary_johnson@med.unc.edu
RI Perou, Charles/H-9934-2014; Prat, Aleix/P-8561-2014
OI Perou, Charles/0000-0001-9827-2247; Prat, Aleix/0000-0003-2377-540X
FU NIH [GM101141, GM007040]; University Cancer Research Fund; NCI Center
   Core Support Grant [P30CA06086]
FX G.L.J. is supported by NIH grant GM101141 and the University Cancer
   Research Fund. N.V.J. was supported by NIH training grant GM007040. We
   thank the UNC Flow Cytometry and RNAi Core Facilities, which are
   supported in part by an NCI Center Core Support Grant (P30CA06086) to
   the UNC Lineberger Comprehensive Cancer Center.
CR Abell AN, 2011, CELL STEM CELL, V8, P525, DOI 10.1016/j.stem.2011.03.008
   Abell AN, 2009, MOL CELL BIOL, V29, P2748, DOI 10.1128/MCB.01391-08
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Banerjee S, 2006, J CLIN PATHOL, V59, P729, DOI 10.1136/jcp.2005.033043
   Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554
   CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282
   Ding LH, 2009, J CLIN INVEST, V119, P349, DOI 10.1172/JCI35930
   Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200
   Dissanayake SK, 2008, CANCER RES, V68, P10205, DOI 10.1158/0008-5472.CAN-08-2149
   Dominguez MG, 2007, P NATL ACAD SCI USA, V104, P3243, DOI 10.1073/pnas.0611510104
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Forcales SV, 2012, EMBO J, V31, P301, DOI 10.1038/emboj.2011.391
   Fulford LG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1636
   Gaedcke J, 2007, MODERN PATHOL, V20, P864, DOI 10.1038/modpathol.3800830
   Guais A, 2006, GENE, V374, P112, DOI 10.1016/j.gene.2006.01.028
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911
   Holder N, 1999, DEVELOPMENT, V126, P2033
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014
   Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824
   Mori M, 2010, J CELL PHYSIOL, V224, P195, DOI 10.1002/jcp.22122
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007
   Rafael MS, 2012, BIOCHIMIE, V94, P1128, DOI 10.1016/j.biochi.2012.01.013
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200
   Sheikh F, 2008, J CLIN INVEST, V118, P3870, DOI 10.1172/JCI34472
   Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037
   Takeuchi JK, 2007, P NATL ACAD SCI USA, V104, P846, DOI 10.1073/pnas.0608118104
   Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217
   Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823
NR 47
TC 52
Z9 70
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2013
VL 33
IS 15
BP 3011
EP 3025
DI 10.1128/MCB.01443-12
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 180SD
UT WOS:000321615500017
PM 23716599
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Méndez-Catalá, CF
   Gretton, S
   Vostrov, A
   Pugacheva, E
   Farrar, D
   Ito, Y
   Docquier, F
   Kita, GX
   Murrell, A
   Lobanenkov, V
   Klenova, E
AF Mendez-Catala, Claudia Fabiola
   Gretton, Svetlana
   Vostrov, Alexander
   Pugacheva, Elena
   Farrar, Dawn
   Ito, Yoko
   Docquier, France
   Kita, Georgia-Xanthi
   Murrell, Adele
   Lobanenkov, Victor
   Klenova, Elena
TI A Novel Mechanism for CTCF in the Epigenetic Regulation of <i>Bax</i> in
   Breast Cancer Cells
SO NEOPLASIA
LA English
DT Article
ID PROTEIN EXPRESSION; BINDING-PROTEIN; BCL-2 FAMILY; GENE; APOPTOSIS; P53;
   DIFFERENTIATION; SENSITIVITY; CARCINOMA; PATHWAYS
AB We previously reported the association of elevated levels of the multifunctional transcription factor, CCCTC binding factor (CTCF), in breast cancer cells with the specific anti-apoptotic function of CTCF. To understand the molecular mechanisms of this phenomenon, we investigated regulation of the human Bax gene by CTCF in breast and non-breast cells. Two CTCF binding sites (CTSs) within the Bax promoter were identified. In all cells, breast and non-breast, active histone modifications were present at these CTSs, DNA harboring this region was unmethylated, and levels of Bax mRNA and protein were similar. Nevertheless, up-regulation of Bax mRNA and protein and apoptotic cell death were observed only in breast cancer cells depleted of CTCF. We proposed that increased CTCF binding to the Bax promoter in breast cancer cells, by comparison with non-breast cells, may be mechanistically linked to the specific apoptotic phenotype in CTCF-depleted breast cancer cells. In this study, we show that CTCF binding was enriched at the Bax CTSs in breast cancer cells and tumors; in contrast, binding of other transcription factors (SP1, WT1, EGR1, and c-Myc) was generally increased in non-breast cells and normal breast tissues. Our findings suggest a novel mechanism for CTCF in the epigenetic regulation of Bax in breast cancer cells, whereby elevated levels of CTCF support preferential binding of CTCF to the Bax CTSs. In this context, CTCF functions as a transcriptional repressor counteracting influences of positive regulatory factors; depletion of breast cancer cells from CTCF therefore results in the activation of Bax and apoptosis.
C1 [Mendez-Catala, Claudia Fabiola; Gretton, Svetlana; Farrar, Dawn; Kita, Georgia-Xanthi; Klenova, Elena] Univ Essex, Sch Biol Sci, Colchester CO4 3SQ, Essex, England.
   [Vostrov, Alexander; Pugacheva, Elena; Lobanenkov, Victor] NIAID, Mol Pathol Sect, Immunopathol Lab, NIH, Rockville, MD USA.
   [Ito, Yoko; Murrell, Adele] Canc Res UK Cambridge Res Inst, Cambridge, England.
   [Docquier, France] Anglia Ruskin Univ, Helen Rollason Res Lab, PMI 208, PMI, Chelmsford, Essex, England.
C3 University of Essex; National Institutes of Health (NIH) - USA; NIH
   National Institute of Allergy & Infectious Diseases (NIAID); Cancer
   Research UK; CRUK Cambridge Institute; Anglia Ruskin University
RP Klenova, E (通讯作者)，Univ Essex, Sch Biol Sci, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.
EM klenovae@essex.ac.uk
RI Lobanenkov, Victor/ABD-5710-2021; Pugacheva, Elena M./GNH-1756-2022
OI Mendez-Catala, Claudia Fabiola/0000-0003-3444-1085; Pugacheva, Elena
   M./0000-0001-9693-9853; Lobanenkov, Victor/0000-0001-6665-3635; Murrell,
   adele/0000-0003-2647-3511
FU CONACyT, Mexico; Breast Cancer Campaign; Breast Cancer Research Trust;
   Helen Rollason Cancer Charity; Medical Research Council; Cancer Research
   UK; Research Promotion Fund from the University of Essex; Intramural
   Research Program of the National Institutes of Health, National
   Institute of Allergy and Infectious Diseases; Cancer Research UK Senior
   Cancer Research Fellowship; Association for International Cancer
   Research; University of Cambridge; Hutchison Whampoa Limited
FX This work was supported by the Postgraduate Scholarship from CONACyT,
   Mexico (C.F.M.-C.), Breast Cancer Campaign (F.D. and E.K.), Breast
   Cancer Research Trust (G.-X.K. and E.K.), Helen Rollason Cancer Charity
   (F.D.), Medical Research Council and Cancer Research UK (D.F. and E.K.),
   Research Promotion Fund from the University of Essex (F.D., D.F., and
   E.K.), the Intramural Research Program of the National Institutes of
   Health, National Institute of Allergy and Infectious Diseases (A.V.,
   E.P., and V.L.), Cancer Research UK Senior Cancer Research Fellowship
   (A.M.), and Association for International Cancer Research (A.M. and
   Y.I.), as well as the support of the University of Cambridge, Cancer
   Research UK, and Hutchison Whampoa Limited (A.M. and Y.I.).
CR Abrmofff MD., 2005, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1201/9781420005615.AX4
   [Anonymous], GENE REGULATION AIDS
   [Anonymous], THESIS U ESSEX UK
   Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Burns Timothy F, 2003, Cancer Treat Res, V115, P319
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Chernukhin I, 2011, ANAL BIOCHEM, V412, P183, DOI 10.1016/j.ab.2011.01.036
   Cianfrocca R, 2008, CELL DEATH DIFFER, V15, P354, DOI 10.1038/sj.cdd.4402264
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cuddapah S, 2009, GENOME RES, V19, P24, DOI 10.1101/gr.082800.108
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Docquier F, 2009, CLIN CANCER RES, V15, P5762, DOI 10.1158/1078-0432.CCR-09-0329
   Farrar D, 2010, MOL CELL BIOL, V30, P1199, DOI 10.1128/MCB.00827-09
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Fiorentino FP, 2012, J CELL PHYSIOL, V227, P479, DOI 10.1002/jcp.22780
   Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981
   García-Sáez AJ, 2012, CELL DEATH DIFFER, V19, P1733, DOI 10.1038/cdd.2012.105
   Handoko L, 2011, NAT GENET, V43, P630, DOI 10.1038/ng.857
   Jürgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   Koh SWM, 2007, NEUROSCI LETT, V423, P89, DOI 10.1016/j.neulet.2007.05.067
   LOBANENKOV VV, 1990, ONCOGENE, V5, P1743
   Loeb DM, 2006, CELL CYCLE, V5, P1249, DOI 10.4161/cc.5.12.2807
   Mitchell KO, 2000, CANCER RES, V60, P6318
   MIYASHITA T, 1995, CELL, V80, P293
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Ohlsson R, 2010, BIOESSAYS, V32, P37, DOI 10.1002/bies.200900118
   Peled A, 1996, CANCER RES, V56, P2148
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315
   Pugacheva EM, 2005, HUM MOL GENET, V14, P953, DOI 10.1093/hmg/ddi089
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x
   Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989
   Roberts J, 2007, J NEUROSCI, V27, P2793, DOI 10.1523/JNEUROSCI.0892-06.2007
   Sacha T, 2005, BBA-MOL BASIS DIS, V1740, P206, DOI 10.1016/j.bbadis.2004.12.005
   Saldaña-Meyer R, 2011, EPIGENETICS-US, V6, P1068, DOI 10.4161/epi.6.9.16683
   Schelwies K, 2002, INT J CANCER, V99, P589, DOI 10.1002/ijc.10380
   Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B
   Torrano V, 2005, J BIOL CHEM, V280, P28152, DOI 10.1074/jbc.M501481200
   van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028
   van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20
   Wallace JA, 2007, CURR OPIN GENET DEV, V17, P400, DOI 10.1016/j.gde.2007.08.005
   Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154
   Zagurovskaya M, 2009, ONCOGENE, V28, P1121, DOI 10.1038/onc.2008.461
   Zhivotovsky B, 2006, CARCINOGENESIS, V27, P1939, DOI 10.1093/carcin/bgl035
NR 53
TC 20
Z9 25
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD AUG
PY 2013
VL 15
IS 8
BP 898
EP +
DI 10.1593/neo.121948
PG 25
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 219EM
UT WOS:000324488800004
PM 23908591
OA Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Lee, SH
   Um, SJ
   Kim, EJ
AF Lee, Sang Hyup
   Um, Soo-Jong
   Kim, Eun-Joo
TI CBX8 suppresses Sirtinol-induced premature senescence in human breast
   cancer cells <i>via</i> cooperation with SIRT1
SO CANCER LETTERS
LA English
DT Article
DE CBX8; SIRT1; p53; Senescence; Cancer; Epigenetics
ID CELLULAR SENESCENCE; LIFE-SPAN; CALORIE RESTRICTION; DNA-DAMAGE;
   IN-VIVO; P53; INHIBITION; P16(INK4A); INTERACTS
AB Stress-induced premature senescence (SIPS) has been implicated in the suppression of carcinogenesis. We identified chromodomain protein 8 (CBX8), a Polycomb group (PcG) protein, as a novel binding partner of SIRT1. The interaction between CBX8 and SIRT1 was demonstrated by immunoprecipitation, GST pull-down, fluorescence microscopy, and cooperation for transcriptional repression. Like SIRT1, CBX8 repressed premature senescence and growth arrest induced by the SIRT1 inhibitor Sirtinol in MCF7 cells, which was reversed by depleting CBX8. CBX8 cooperated with SIRT1 for suppressing p53 acetylation induced by Sirtinol and etoposide/TSA. Upon ectopic expression, CBX8 or SIRT1 repressed the expression of p21(WAF1) by inhibiting p53 binding to the promoter. We provide the first evidence that CBX8 plays a potential role in regulating premature senescence in human breast cancer cells through cooperation with SIRT1. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Lee, Sang Hyup; Kim, Eun-Joo] Dankook Univ, Dept Mol Biol, Grad Program BK21, Yongin 448701, Gyeonggi Do, South Korea.
   [Um, Soo-Jong] Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Grad Program BK21, Seoul 143747, South Korea.
C3 Dankook University; Sejong University
RP Kim, EJ (通讯作者)，Dankook Univ, Dept Mol Biol, Grad Program BK21, Yongin 448701, Gyeonggi Do, South Korea.
EM nbrejk@dankook.ac.kr
RI Lee, sujeong/KUD-4735-2024; Kim, Eun Joo/AAQ-7273-2020
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [2011-0022309, 2012R1A2A2A01003013]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (2011-0022309: E-J.
   Kim) and (2012R1A2A2A01003013: E-J. Kim).
CR Back JH, 2011, J BIOL CHEM, V286, P19100, DOI 10.1074/jbc.M111.240598
   Bárdos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200
   Chien WW, 2010, CELL CYCLE, V9, P3286, DOI 10.4161/cc.9.16.12600
   Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   García-Cuéllar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108
   Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077
   Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458
   HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478
   Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015
   Kerppola TK, 2009, TRENDS CELL BIOL, V19, P692, DOI 10.1016/j.tcb.2009.10.001
   Kim BC, 2012, EMBO J, V31, P4289, DOI 10.1038/emboj.2012.286
   Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030
   Kim EJ, 2008, BMB REP, V41, P751, DOI 10.5483/BMBRep.2008.41.11.751
   Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383
   Lee HK, 2007, EMBO J, V26, P3545, DOI 10.1038/sj.emboj.7601797
   Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126
   Ogrunc M, 2011, EUR J CANCER, V47, P1616, DOI 10.1016/j.ejca.2011.04.003
   Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0
   te Poele RH, 2002, CANCER RES, V62, P1876
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wojcik M, 2009, MINI-REV MED CHEM, V9, P386, DOI 10.2174/1389557510909030386
   Yao HW, 2012, J CLIN INVEST, V122, P2032, DOI 10.1172/JCI60132
NR 33
TC 41
Z9 48
U1 3
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD JUL 28
PY 2013
VL 335
IS 2
BP 397
EP 403
DI 10.1016/j.canlet.2013.02.051
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 168CE
UT WOS:000320682500017
PM 23474493
DA 2025-01-12
ER

PT J
AU Farzanehfar, M
   Vossoughinia, H
   Jabini, R
   Tavassoli, A
   Saadatnia, H
   Khorashad, AK
   Ahadi, M
   Afzalaghaee, M
   Karimiani, EG
   Mirzaei, F
   Ayatollahi, H
AF Farzanehfar, Mohammadreza
   Vossoughinia, Hasan
   Jabini, Raheleh
   Tavassoli, Alireza
   Saadatnia, Hasan
   Khorashad, Ahmad Khosravi
   Ahadi, Mitra
   Afzalaghaee, Monavvar
   Karimiani, Ehsan Ghayoor
   Mirzaei, Farzaneh
   Ayatollahi, Hossein
TI Evaluation of Methylation of MGMT
   (<i>O<SUP>6</SUP></i>-Methylguanine-DNA Methyltransferase) Gene Promoter
   in Sporadic Colorectal Cancer
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; HUMAN-TUMOR-CELLS; DNA METHYLATION; MULTIPLE
   GENES; LUNG-CANCER; CPG ISLAND; PCR ASSAY; GSTP1 METHYLATION;
   BREAST-CANCER; HYPERMETHYLATION
AB The DNA repair gene O-6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer (CRC). The aim of this study was to demonstrate that MGMT methylation may be one of the candidate mediators of field cancerization in the colon mucosa. Therefore, quantitative methylation-specific polymerase chain reaction was performed on tumor itself and additional samples of 5 and 10 cm away from the tumor in 40 CRC patients. Moreover, colon mucosa was examined from 30 cases with no evidence of cancer as a control. MGMT promoter methylation was present in 27.5% of colorectal tumor specimens. Tumors that showed MGMT promoter methylation had substantial MGMT promoter methylation in their normal adjacent mucosa. The methylation was also observed in 36.36% (4/11) of normal samples with MGMT promoter methylation in the adjacent tumors, in 20.79% (6/29) of samples without MGMT methylation in the adjacent tumors, and in 6.66% (2/30) of control samples (p < 0.006 and p < 0.001 respectively). Finally, the mean of MGMT methylation levels was significantly higher in the cancerous group than in the control group (6.25 +/- 1.702 vs. 0.086 +/- 0.036, p < 0.001). Some CRCs arise from a field defect defined by epigenetic inactivation of MGMT. Detection of such abnormality may ultimately be useful in risk assessment for CRCs.
C1 [Farzanehfar, Mohammadreza; Vossoughinia, Hasan; Saadatnia, Hasan; Khorashad, Ahmad Khosravi; Ahadi, Mitra] Mashhad Univ Med Sci, Ghaem Hosp, Sch Med, Dept Internal Med, Mashhad 917669199, Iran.
   [Jabini, Raheleh] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, Mashhad 917669199, Iran.
   [Tavassoli, Alireza] Mashhad Univ Med Sci, Ghaem Hosp, Sch Med, Endoscop & Minimally Invas Surg Res Ctr, Mashhad 917669199, Iran.
   [Afzalaghaee, Monavvar] Mashhad Univ Med Sci, Sch Hlth, Dept Biostat, Mashhad 917669199, Iran.
   [Karimiani, Ehsan Ghayoor] Mashhad Univ Med Sci, Sch Med, Dept New Sci & Technol, Mashhad 917669199, Iran.
   [Mirzaei, Farzaneh; Ayatollahi, Hossein] Mashhad Univ Med Sci, Ghaem Hosp, Sch Med, Canc Mol Pathol Res Ctr, Mashhad 917669199, Iran.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; Mashhad University of Medical Sciences; Mashhad University of
   Medical Sciences; Mashhad University of Medical Sciences; Mashhad
   University of Medical Sciences
RP Ayatollahi, H (通讯作者)，Mashhad Univ Med Sci, Ghaem Hosp, Sch Med, Canc Mol Pathol Res Ctr, Mashhad 917669199, Iran.
EM ayatollahih@mums.ac.ir
RI Ghayoor Karimiani, Ehsan/AFS-7844-2022
OI Farzanehfar, Mohammadreza/0000-0003-3135-930X; Jabini,
   Raheleh/0000-0002-9483-9370; afzalaghaee, monnavar/0000-0003-2029-6577
FU Mashhad University of Medical Sciences, Mashhad, Iran
FX The authors are thankful for the financial support of the Mashhad
   University of Medical Sciences, Mashhad, Iran. They are grateful to the
   volunteers involved in the study, laboratory staff, and all those who
   contributed in terms of time and effort.
CR An Q, 2002, CANCER LETT, V188, P109, DOI 10.1016/S0304-3835(02)00496-2
   Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408
   Candiloro ILM, 2009, CANCER PREV RES, V2, P862, DOI 10.1158/1940-6207.CAPR-09-0056
   Cankovic M, 2007, LAB INVEST, V87, P392, DOI 10.1038/labinvest.3700520
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   COSTELLO JF, 1994, J BIOL CHEM, V269, P17228
   COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6
   DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0
   Derks S, 2004, CELL ONCOL, V26, P291
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0
   Esteller M, 1999, CANCER RES, V59, P793
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2001, CANCER RES, V61, P3225
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   FORNACE AJ, 1990, CANCER RES, V50, P7908
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082
   Havik AB, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-36
   Hawkins NJ, 2009, MODERN PATHOL, V22, P1588, DOI 10.1038/modpathol.2009.130
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Issa JP, 2002, J NUTR, V132, p2388S, DOI 10.1093/jn/132.8.2388S
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258
   Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41
   Kamimae S, 2011, CANCER PREV RES, V4, P674, DOI 10.1158/1940-6207.CAPR-10-0214
   Lo YMD, 1999, CANCER RES, V59, P3899
   Mellai Marta, 2009, Cancer Genomics & Proteomics, V6, P219
   Mikeska T, 2007, J MOL DIAGN, V9, P368, DOI 10.2353/jmoldx.2007.060167
   Ogino S, 2006, AM J SURG PATHOL, V30, P1175
   Pawan Prakash Pawan Prakash, 2012, Journal of Pharmacy Research, V5, P355
   Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X
   PEGG AE, 1990, CANCER RES, V50, P6119
   PIEPER RO, 1990, CANCER COMMUN-US, V2, P13, DOI 10.3727/095535490820874812
   Povey AC, 2002, J NUTR, V132, p3518S, DOI 10.1093/jn/132.11.3518S
   QIAN XL, 1995, CARCINOGENESIS, V16, P1385, DOI 10.1093/carcin/16.6.1385
   Qian XLC, 1997, CANCER RES, V57, P3672
   Reesink-Peters N, 2004, MOL CANCER RES, V2, P289
   Schmiemann V, 2005, CLIN CANCER RES, V11, P7728, DOI 10.1158/1078-0432.CCR-05-0999
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P687, DOI 10.1093/nar/18.3.687
   van Engeland M, 2003, CANCER RES, V63, P3133
   Villalva C, 2012, INT J MOL SCI, V13, P6983, DOI 10.3390/ijms13066983
   Vlassenbroeck I, 2008, J MOL DIAGN, V10, P332, DOI 10.2353/jmoldx.2008.070169
   Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612
NR 49
TC 16
Z9 18
U1 0
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD JUL
PY 2013
VL 32
IS 7
BP 371
EP 377
DI 10.1089/dna.2012.1949
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 174VY
UT WOS:000321186100005
PM 23705976
DA 2025-01-12
ER

PT J
AU Yegin, Z
   Gunes, S
   Buyukalpelli, R
AF Yegin, Zeynep
   Gunes, Sezgin
   Buyukalpelli, Recep
TI Hypermethylation of <i>TWIST1</i> and <i>NID2</i> in Tumor Tissues and
   Voided Urine in Urinary Bladder Cancer Patients
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID BREAST-CANCER; CPG ISLAND; PROMOTER HYPERMETHYLATION; COLORECTAL TUMORS;
   DNA METHYLATION; GENES; NIDOGEN-2; CARCINOMAS; EXPRESSION; APOPTOSIS
AB Bladder cancer like other cancers arises from the accumulation of many genetic and epigenetic changes that lead to the activation of proto-oncogenes or inactivation of tumor suppressor genes. We aimed to investigate the methylation patterns of Twist homolog 1 (TWIST1) and nidogen-2 (NID2) genes in bladder cancer. Fifty six histologically confirmed bladder tumor samples and paired 24 urine samples constituted the study group and was compared with 15 age-and gender-matched noncancerous individuals. DNA was purified from both tumor and urine samples. The methylation status of the two genes was analyzed by methylation-specific polymerase chain reaction (MSP) in both urinary bladder cell carcinoma samples and urine samples. Sensitivity and specificity values of the method were assessed and compared with the results of the cytology test. Methylation of TWIST1 and NID2 was detected in 98.2% and 96.4% of the tumor samples, and in 87.5% and 95.8% of the urine samples, respectively. The sensitivity of TWIST1 and NID2 genes (87.5% and 95.8% in urine samples, respectively), was higher compared with urine cytology (62.5%) for cancer detection. The sensitivity of any of the two genes was 88.8% (8/9) for low-grade cases. The sensitivity of urine cytology was 33.3% for the same low-grade cases. To be used in the early noninvasive diagnosis of bladder cancer, the combined methylation analysis of TWIST1 and NID2 genes may be a simple, noninvasive, sensitive, and specific method for detecting cancer cells in urine.
C1 [Yegin, Zeynep; Gunes, Sezgin] Ondokuz Mayis Univ, Dept Med Biol, Samsun, Turkey.
   [Buyukalpelli, Recep] Ondokuz Mayis Univ, Dept Urol, Samsun, Turkey.
C3 Ondokuz Mayis University; Ondokuz Mayis University
RP Gunes, S (通讯作者)，Ondokuz Mayis Univ, Dept Med Biol, TR-55139 Kurupelit, Turkey.
EM sgunes@omu.edu.tr
RI Gunes, Sezgin/AFK-0596-2022
OI Gunes, Sezgin/0000-0002-3103-6482
FU Ondokuz Mayis University Research Foundation [PYO.TIP.1904. 11.003]
FX This study was supported by the Ondokuz Mayis University Research
   Foundation (Project No. PYO.TIP.1904. 11.003).
CR [Anonymous], 2010, AJCC CANC STAGING MA
   Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005
   Cebrian V, 2008, J PATHOL, V216, P111, DOI 10.1002/path.2390
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Cheng ZX, 2012, J SURG ONCOL, V105, P71, DOI 10.1002/jso.22047
   Christoph F, 2007, J CANCER RES CLIN, V133, P343, DOI 10.1007/s00432-006-0174-9
   Enokida H, 2008, INT J CLIN ONCOL, V13, P298, DOI 10.1007/s10147-008-0811-1
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265
   Jarmalaite S, 2008, ONCOLOGY-BASEL, V75, P145, DOI 10.1159/000158665
   Kang Ho-Jin, 2012, J Prev Med Public Health, V45, P251, DOI 10.3961/jpmph.2012.45.4.251
   Karnes RJ, 2012, MAYO CLIN PROC, V87, P835, DOI 10.1016/j.mayocp.2012.04.013
   Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353
   Kim JH, 2010, GYNECOL ONCOL, V118, P176, DOI 10.1016/j.ygyno.2010.04.016
   Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647
   Kim YK, 2009, INT J UROL, V16, P17, DOI 10.1111/j.1442-2042.2008.02143.x
   Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49
   Lin HH, 2010, UROL ONCOL-SEMIN ORI, V28, P597, DOI 10.1016/j.urolonc.2008.12.008
   Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Miraoui H, 2010, GENE, V468, P1, DOI 10.1016/j.gene.2010.07.013
   Mokkapati S, 2008, J INVEST DERMATOL, V128, P2259, DOI 10.1038/jid.2008.65
   Navarro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033284
   Nischt R, 2007, J INVEST DERMATOL, V127, P545, DOI 10.1038/sj.jid.5700562
   Okada T, 2010, GENE CHROMOSOME CANC, V49, P452, DOI 10.1002/gcc.20755
   Phé V, 2009, BJU INT, V104, P896, DOI 10.1111/j.1464-410X.2009.08696.x
   Reinert T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046297
   Renard Isabelle, 2010, Eur Urol, V58, P96, DOI 10.1016/j.eururo.2009.07.041
   Sen-Yo M, 2013, BIOMED REP, V1, P31, DOI 10.3892/br.2012.25
   Sun JF, 2009, J CANCER RES CLIN, V135, P1717, DOI 10.1007/s00432-009-0619-z
   Toyota M, 2000, CANCER RES, V60, P4044
   Ulazzi L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-17
   Wallerand H, 2010, UROL ONCOL-SEMIN ORI, V28, P473, DOI 10.1016/j.urolonc.2008.12.018
   Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861
   Zhang JJ, 2001, J NATL CANCER I, V93, P45, DOI 10.1093/jnci/93.1.45
NR 38
TC 34
Z9 37
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD JUL
PY 2013
VL 32
IS 7
BP 386
EP 392
DI 10.1089/dna.2013.2030
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 174VY
UT WOS:000321186100007
PM 23682613
DA 2025-01-12
ER

PT J
AU Lim, YY
   Wright, JA
   Attema, JL
   Gregory, PA
   Bert, AG
   Smith, E
   Thomas, D
   Lopez, AF
   Drew, PA
   Khew-Goodall, Y
   Goodall, GJ
AF Lim, Yat-Yuen
   Wright, Josephine A.
   Attema, Joanne L.
   Gregory, Philip A.
   Bert, Andrew G.
   Smith, Eric
   Thomas, Daniel
   Lopez, Angel F.
   Drew, Paul A.
   Khew-Goodall, Yeesim
   Goodall, Gregory J.
TI Epigenetic modulation of the miR-200 family is associated with
   transition to a breast cancer stem-cell-like state
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE Epithelial-mesenchymal transition; Breast cancer stem cells; miR-200;
   DNA methylation; Histone modifications; Gene regulation
ID TO-MESENCHYMAL TRANSITION; IN-VITRO PROPAGATION; DNA METHYLATION;
   IDENTIFICATION; MICRORNAS; ZEB1; REPRESSION; EMT; TUMORIGENICITY;
   MAINTENANCE
AB The miR-200 family is a key regulator of the epithelial-mesenchymal transition, however, its role in controlling the transition between cancer stem-cell-like and non-stem-cell-like phenotypes is not well understood. We utilized immortalized human mammary epithelial (HMLE) cells to investigate the regulation of the miR-200 family during their conversion to a stem-like phenotype. HMLE cells were found to be capable of spontaneous conversion from a non-stem to a stem-like phenotype and this conversion was accompanied by the loss of miR-200 expression. Stem-like cell fractions isolated from metastatic breast cancers also displayed loss of miR-200 indicating similar molecular changes may occur during breast cancer progression. The phenotypic change observed in HMLE cells was directly controlled by miR-200 because restoration of its expression decreased stem-like properties while promoting a transition to an epithelial phenotype. Investigation of the mechanisms controlling miR-200 expression revealed both DNA methylation and histone modifications were significantly altered in the stem-like and non-stem phenotypes. In particular, in the stem-like phenotype, the miR-200b-200a-429 cluster was silenced primarily through polycomb group-mediated histone modifications whereas the miR-200c-141 cluster was repressed by DNA methylation. These results indicate that the miR-200 family plays a crucial role in the transition between stem-like and non-stem phenotypes and that distinct epigenetic-based mechanisms regulate each miR-200 gene in this process. Therapy targeted against miR-200 family members and epigenetic modifications might therefore be applicable to breast cancer.
C1 [Lim, Yat-Yuen; Wright, Josephine A.; Attema, Joanne L.; Gregory, Philip A.; Bert, Andrew G.; Thomas, Daniel; Lopez, Angel F.; Khew-Goodall, Yeesim; Goodall, Gregory J.] SA Pathol, Ctr Canc Biol, Div Human Immunol, Adelaide, SA 5000, Australia.
   [Lim, Yat-Yuen; Wright, Josephine A.; Attema, Joanne L.; Gregory, Philip A.; Lopez, Angel F.; Goodall, Gregory J.] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia.
   [Lim, Yat-Yuen] Univ Malaya, Inst Biol Sci, Fac Sci, Kuala Lumpur, Malaysia.
   [Smith, Eric] Univ Adelaide, Discipline Surg, Adelaide, SA 5005, Australia.
   [Drew, Paul A.] Flinders Univ S Australia, Sch Nursing & Midwifery, Bedford Pk, SA 5042, Australia.
   [Khew-Goodall, Yeesim; Goodall, Gregory J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.
C3 SA Pathology; Centre for Cancer Biology; University of Adelaide;
   Universiti Malaya; University of Adelaide; Flinders University South
   Australia; University of Adelaide
RP Goodall, GJ (通讯作者)，SA Pathol, Ctr Canc Biol, Div Human Immunol, Adelaide, SA 5000, Australia.
EM greg.goodall@health.sa.gov.au
RI Smith, Eric/ABG-7104-2020; Lopez, Angel/E-2260-2011; Lim,
   Yat/I-6495-2013; Gregory, Philip/F-4089-2013
OI Khew-Goodall, Yeesim/0000-0002-0473-5392; Drew,
   Paul/0000-0001-5661-4771; Bert, Andrew/0000-0003-3876-1537; Goodall,
   Gregory/0000-0003-1294-0692; Wright, Josephine/0000-0003-4588-8827;
   Smith, Eric/0000-0003-2958-3492; Gregory, Philip/0000-0002-0999-0632;
   Lopez, Angel F/0000-0001-7430-0135
FU National Cancer Foundation Australia [ECF-09-08]; University of Malaya
   Skim Latihan Akademik IPTA program; National Health and Medical Research
   Council [626918, 1008440]; Cancer Council South Australia [626956,
   1005078]
FX This work was supported by a fellowship from the National Cancer
   Foundation Australia [grant number ECF-09-08 to P. A. G.]; a scholarship
   from the University of Malaya Skim Latihan Akademik IPTA program [to
   Y.-Y.L.]; and grants from the National Health and Medical Research
   Council [grant numbers 626918 and 1008440 to G.J.G. and Y.K.-G.]; and
   the Cancer Council South Australia [grant number 626956 to G.J.G.,
   Y.K.-G. and P. A. G. and 1005078 to P.A.D.].
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   BERGE DT, 2011, NAT CELL BIOL, V13, P1070, DOI DOI 10.1038/NCB2314
   Bracken CP, 2009, CELL MOL LIFE SCI, V66, P1682, DOI 10.1007/s00018-009-8750-1
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106
   Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327
   Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490
   Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495
   Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Prezioso C, 2011, FEBS LETT, V585, P2067, DOI 10.1016/j.febslet.2011.04.062
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Shackleton M, 2010, SEMIN CANCER BIOL, V20, P85, DOI 10.1016/j.semcancer.2010.04.002
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Smith E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-123
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
NR 57
TC 155
Z9 170
U1 0
U2 23
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD MAY 15
PY 2013
VL 126
IS 10
BP 2256
EP 2266
DI 10.1242/jcs.122275
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 157RG
UT WOS:000319916200013
PM 23525011
DA 2025-01-12
ER

PT J
AU Stuopelyte, K
   Daniunaite, K
   Laurinaviciene, A
   Ostapenko, V
   Jarmalaite, S
AF Stuopelyte, Kristina
   Daniunaite, Kristina
   Laurinaviciene, Aida
   Ostapenko, Valerijus
   Jarmalaite, Sonata
TI High-Resolution Melting-Based Quantitative Analysis of <i>RASSF1</i>
   Methylation in Breast Cancer
SO MEDICINA-LITHUANIA
LA English
DT Article
DE DNA methylation; breast cancer; HRM; QMSP; RASSF1 gene
ID DNA METHYLATION; POOR-PROGNOSIS; IMMUNOHISTOCHEMISTRY; HYPERMETHYLATION;
   METHYLIGHT; CARCINOMA; TUMOR; ASSAY; GENE; PCR
AB Background and Objective. Breast cancer is the leading cause of death from cancer among women worldwide. The aberrant promoter methylation of tumor suppressor genes is a typical epigenetic alteration for breast cancer and can be detected in early carcinogenesis. High-throughput and cost-effective methods are needed for the early and sensitive detection of epigenetic changes in clinical material. The main purpose of our study was to optimize a high-resolution melting (HRM) assay for the reliable and quantitative assessment of RASSF1 gene met hylation, which is considered one of the earliest epigenetic alterations in breast cancer.
   Material and Methods. A total of 76 breast carcinomas and 10 noncancerous breast tissues were studied by means of HRM and compared with the results obtained by means of quantitative methylation-specific polymerase chain reaction (QMSP) and methylation-specific polymerase chain reaction (MSP).
   Results. Both quantitative methods, HRM and QMSP, showed a similar specificity and sensitivity for the detection of RASSF1 methylation in breast cancer (about 80% and 70%, respectively). In breast cancer, the mean methylation intensity of RASSF1 was 42.5% and 48.6% according to HRM and QMSP, respectively. Both methods detected low levels of methylation (less than 5%) in noncancerous breast tissues. In comparison with quantitative methods, MSP showed a lower sensitivity (70%), but a higher specificity (80%) for the detection of RASSF1 methylation in breast cancer.
   Conclusions. HRM is as a simple, cost-effective method for the reliable high-throughput quantification of DNA methylation in clinical material.
C1 [Stuopelyte, Kristina; Daniunaite, Kristina; Jarmalaite, Sonata] Vilnius State Univ, Fac Nat Sci, Div Human Genome, Res Ctr, LT-03101 Vilnius, Lithuania.
   [Laurinaviciene, Aida] Vilnius Univ Hosp, Santariskiu Klin, Natl Ctr Pathol, Vilnius, Lithuania.
   [Ostapenko, Valerijus] Vilnius State Univ, Inst Oncol, LT-03101 Vilnius, Lithuania.
C3 Vilnius University; Vilnius University Hospital Santariskiu Klinikos;
   Vilnius University
RP Jarmalaite, S (通讯作者)，Vilnius State Univ, Fac Nat Sci, Div Human Genome, Res Ctr, MK Ciurlionio 21, LT-03101 Vilnius, Lithuania.
EM sonata.jarmalaite@gf.vu.lt
RI Jarmalaite, Sonata/CAI-0675-2022; Daniunaite, Kristina/JXL-5926-2024;
   Laurinaviciene, Aida/P-3046-2015; Snipaitiene, Kristina/AAS-9035-2021
OI Snipaitiene, Kristina/0000-0001-9766-7108; Jarmalaite,
   Sonata/0000-0003-3719-0891; Daniunaite, Kristina/0000-0002-4527-0624
FU Research Council of Lithuania [MIP 109/2010]; Lithuanian State Science
   and Studies Foundation [C-03/2007]
FX We thank Ms. Justina Tverkuviene for technical assistance in QMSP
   analysis. This study was funded by a grant (No. MIP 109/2010) from the
   Research Council of Lithuania. The biosample collection was funded by a
   grant (No. C-03/2007) from the Lithuanian State Science and Studies
   Foundation.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Amin K. S, 2012, J CARCINOG, V11, P31
   Amornpisutt R, 2012, CLIN BIOCHEM, V45, P1092, DOI 10.1016/j.clinbiochem.2012.04.027
   [Anonymous], 2011, LITHUANIAN CANC REGI
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Buhmeida A, 2011, ANTICANCER RES, V31, P2975
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Ehrich M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni038
   Goedecke S, 2009, ELECTROPHORESIS, V30, P3063, DOI 10.1002/elps.200900204
   Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322
   Gonzalgo ML, 2004, CLIN CANCER RES, V10, P7276, DOI 10.1158/1078-0432.CCR-03-0692
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang Katie T, 2009, BMC Res Notes, V2, P194, DOI 10.1186/1756-0500-2-194
   Laurinavicius A, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-27
   Lettini AA, 2007, HISTOL HISTOPATHOL, V22, P1413, DOI 10.14670/HH-22.1413
   Martins AT, 2011, BREAST CANCER RES TR, V129, P1, DOI 10.1007/s10549-010-1160-0
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   [Пфайфер Г.П. Pfeifer G.P.], 2005, [Биохимия, BIOCHEMISTRY (MOSCOW), Biokhimiya], V70, P699
   Quillien V, 2012, CANCER-AM CANCER SOC, V118, P4201, DOI 10.1002/cncr.27392
   Reed K, 2010, ANAL BIOCHEM, V397, P96, DOI 10.1016/j.ab.2009.10.021
   Van der Auwera I, 2009, CANCER BIOL THER, V8, P2252
   Vinci S, 2013, METHODS, V59, P138, DOI 10.1016/j.ymeth.2012.09.002
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Wojdacz TK, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-116
NR 25
TC 7
Z9 9
U1 0
U2 7
PU KAUNAS UNIV MEDICINE & VILNIUS UNIV
PI KAUNAS
PA KAUNAS UNIV MEDICINE, A MICKEVICIAUS 9, KAUNAS, LT-44307, LITHUANIA
SN 1010-660X
J9 MED LITH
JI Med. Lith.
PY 2013
VL 49
IS 2
BP 78
EP 83
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 171CZ
UT WOS:000320904000006
PM 23888343
DA 2025-01-12
ER

PT J
AU Yu, YY
   Wang, B
   Zhang, K
   Lei, ZJ
   Guo, Y
   Xiao, HL
   Wang, J
   Fan, LL
   Lan, CH
   Wei, YL
   Ma, Q
   Lin, L
   Mao, CY
   Yang, X
   Chen, XD
   Li, Y
   Bai, Y
   Chen, DF
AF Yu, Yanyan
   Wang, Bin
   Zhang, Kun
   Lei, Zengjie
   Guo, Yan
   Xiao, Hualiang
   Wang, Jun
   Fan, Lilin
   Lan, Chunhui
   Wei, Yanling
   Ma, Qiang
   Lin, Li
   Mao, Chengyi
   Yang, Xin
   Chen, Xiaodi
   Li, Yan
   Bai, Yun
   Chen, Dongfeng
TI High expression of lysine-specific demethylase 1 correlates with poor
   prognosis of patients with esophageal squamous cell carcinoma
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE LSD1; Esophageal squamous cell carcinoma; Invasion
ID PROSTATE-CANCER; BREAST-CANCER; LSD1; STATISTICS; RISK
AB Recent studies have elucidated the role of lysine-specific demethylase 1 (LSD1), a member of the histone demethylases, in epigenetic regulation of tumor suppressing/promoting genes and neoplastic growth. However, the expression of LSD1 in patients with esophageal squamous cell carcinoma (ESCC) is still unknown. Here, we reported that LSDI expression was elevated in cancerous tissue and correlated with lymph node metastasis and poorer overall survival in patients with ESCC. Compared to EC109 cells, LSD1 expression was unregulated in aggressive cancer cell lines KYSE450 and KYSE150. Knockdown of LSD1 using lentivirus delivery of LSD1-specific shRNA abrogated the migration and invasion of ESCC cells in vitro. Further, a LSD1 inhibitor, tranylcypromine, suppressed H3K4me2 demethylation and attenuated cellular motility and invasiveness in a dose-dependent manner. Taken together, these data suggested that LSD1 was a potential prognostic maker and may be a molecular target for inhibiting invasion and metastasis in ESCC. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Yu, Yanyan; Wang, Bin; Lei, Zengjie; Guo, Yan; Wang, Jun; Fan, Lilin; Lan, Chunhui; Wei, Yanling; Chen, Xiaodi; Li, Yan; Chen, Dongfeng] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Gastroenterol, Chongqing 400042, Peoples R China.
   [Zhang, Kun; Bai, Yun] Third Mil Med Univ, Coll Basic Med Sci, Dept Med Genet, Chongqing 400038, Peoples R China.
   [Xiao, Hualiang; Ma, Qiang; Lin, Li; Mao, Chengyi; Yang, Xin] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Pathol, Chongqing 400042, Peoples R China.
C3 Army Medical University; Army Medical University; Army Medical
   University
RP Bai, Y (通讯作者)，Third Mil Med Univ, Coll Basic Med Sci, Dept Med Genet, Chongqing 400038, Peoples R China.
EM baiyungene@gmail.com; chendf1981@126.com
RI Wang, Bin/W-9917-2019; Lei, Zengjie/KIK-7206-2024
OI Wang, Bin/0000-0001-5574-1760
FU National Natural Science Foundation of China (NSFC) [81101631,
   81201949]; Natural Science Foundation [CSTC2012JJA10124]; Science
   Foundation of the Third Military Medical University [2012XJQ22,
   2012XJQ21]
FX We would like to thank Miss Xiewan Chen and Ms. Xiaoqing Zhan (Medical
   English Department, Third Military Medical University, China) for a
   critical reading of the manuscript. This project was supported by the
   National Natural Science Foundation of China (NSFC Nos. 81101631 and
   81201949), the Natural Science Foundation Project of CQ CSTC
   (CSTC2012JJA10124), and the Science Foundation of the Third Military
   Medical University (Nos. 2012XJQ22 and 2012XJQ21).
CR Cheung WY, 2009, GASTROENTEROL CLIN N, V38, P75, DOI 10.1016/j.gtc.2009.01.009
   Fang Y, 2011, ASIAN PAC J CANCER P, V12, P1861
   Gao L, 2010, EPIGENETICS-US, V5, P100, DOI 10.4161/epi.5.2.10778
   Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349
   Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kaz AM, 2012, CANC LETT
   Kolahdoozan S, 2010, ARCH IRAN MED, V13, P143
   Lambert R, 2012, WORLD J GASTRO ENDOS, V4, P518, DOI 10.4253/wjge.v4.i12.518
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lv SA, 2010, EUR J CELL BIOL, V89, P557, DOI 10.1016/j.ejcb.2010.01.004
   Lv T., 2012, PLOS ONE, V7
   Lynch JT, 2012, EXPERT OPIN THER TAR, V16, P1239, DOI 10.1517/14728222.2012.722206
   REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323
   Sakane N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002184
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Siegel R, 2012, CA-CANCER J CLIN, V62, P220, DOI 10.3322/caac.21149
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Spannhoff A, 2009, CHEMMEDCHEM, V4, P1568, DOI 10.1002/cmdc.200900301
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang Q, 2011, CELL RES, V21, P1424, DOI 10.1038/cr.2011.108
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x
NR 26
TC 52
Z9 79
U1 1
U2 26
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 26
PY 2013
VL 437
IS 2
BP 192
EP 198
DI 10.1016/j.bbrc.2013.05.123
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 199TJ
UT WOS:000323018100002
PM 23747727
OA hybrid
DA 2025-01-12
ER

PT J
AU Balic, M
   Schwarzenbacher, D
   Stanzer, S
   Heitzer, E
   Auer, M
   Geigl, JB
   Cote, RJ
   Datar, RH
   Dandachi, N
AF Balic, Marija
   Schwarzenbacher, Daniela
   Stanzer, Stefanie
   Heitzer, Ellen
   Auer, Martina
   Geigl, Jochen B.
   Cote, Richard J.
   Datar, Ram H.
   Dandachi, Nadia
TI Genetic and epigenetic analysis of putative breast cancer stem cell
   models
SO BMC CANCER
LA English
DT Article
ID TIME PCR PRIMER; IDENTIFICATION; AMPLIFICATION; RTPRIMERDB; GENERATION;
   PREDICTOR
AB Background: Cancer stem cell model hypothesizes existence of a small proportion of tumor cells capable of sustaining tumor formation, self-renewal and differentiation. In breast cancer, these cells were found to be associated with CD44(+)CD24(-low) and ALDH(+) phenotype. Our study was performed to evaluate the suitability of current approaches for breast cancer stem cell analyses to evaluate heterogeneity of breast cancer cells through their extensive genetic and epigenetic characterization.
   Methods: Breast cancer cell lines MCF7 and SUM159 were cultured in adherent conditions and as mammospheres. Flow cytometry sorting for CD44, CD24 and ALDH was performed. Sorted and unsorted populations, mammospheres and adherent cell cultures were subjected to DNA profiling by array CGH and methylation profiling by Epitect Methyl qPCR array. Methylation status of selected genes was further evaluated by pyrosequencing. Functional impact of methylation was evaluated by mRNA analysis for selected genes.
   Results: Array CGH did not reveal any genomic differences. In contrast, putative breast cancer stem cells showed altered methylation levels of several genes compared to parental tumor cells.
   Conclusions: Our results underpin the hypothesis that epigenetic mechanisms seem to play a major role in the regulation of CSCs. However, it is also clear that more efficient methods for CSC enrichment are needed. This work underscores requirement of additional approaches to reveal heterogeneity within breast cancer.
C1 [Balic, Marija; Schwarzenbacher, Daniela; Stanzer, Stefanie; Dandachi, Nadia] Med Univ Graz, Dept Internal Med, Div Oncol, A-8036 Graz, Austria.
   [Heitzer, Ellen; Auer, Martina; Geigl, Jochen B.] Med Univ Graz, Inst Human Genet, A-8036 Graz, Austria.
   [Cote, Richard J.; Datar, Ram H.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA.
C3 Medical University of Graz; Medical University of Graz; University of
   Miami
RP Dandachi, N (通讯作者)，Med Univ Graz, Dept Internal Med, Div Oncol, Auenbruggerpl 15, A-8036 Graz, Austria.
EM nadia.dandachi@medunigraz.at
RI Balic, Marija/LPQ-3522-2024; Heitzer, Ellen/B-7354-2017
OI Heitzer, Ellen/0000-0002-8815-7859
FU Oesterreichische Nationalbank (Anniversary Fund) [14001]
FX This work was supported by funds of the Oesterreichische Nationalbank
   (Anniversary Fund, project number 14001).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Azizi E, 2013, CLIN CHEM, V59, P205, DOI 10.1373/clinchem.2012.195990
   Balic M, 2013, ANNU REV MED, V64, P31, DOI 10.1146/annurev-med-050311-163404
   Balic M, 2011, APPL IMMUNOHISTO M M, V19, P33, DOI 10.1097/PAI.0b013e3181ebf4e8
   Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169
   Barlow DP, 2011, ANNU REV GENET, V45, P379, DOI 10.1146/annurev-genet-110410-132459
   Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106
   Cipak A, 2010, ACTA BIOCHIM POL, V57, P165
   Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Geigl JB, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp526
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Hampton OA, 2009, GENOME RES, V19, P167, DOI 10.1101/gr.080259.108
   Hardt O, 2012, CANCER LETT, V325, P165, DOI 10.1016/j.canlet.2012.06.010
   Hernandez-Vargas H, 2011, EPIGENETICS-US, V6, P429, DOI 10.4161/epi.6.4.14515
   Huang MZ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-80
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Kaur P, 2012, TUMOR BIOL, V33, P325, DOI 10.1007/s13277-012-0331-5
   Liu SL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002751
   Liu SL, 2012, J MAMMARY GLAND BIOL, V17, P15, DOI 10.1007/s10911-012-9242-8
   Lorico A, 2011, J ONCOL, V2011, DOI 10.1155/2011/135039
   Ly D, 2013, INT J CANCER, V132, P1918, DOI 10.1002/ijc.27841
   Malik F, 2012, CELL CYCLE, V11, P2780, DOI 10.4161/cc.21395
   Malinowsky K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040285
   Muñoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006
   Oak PS, 2012, INT J CANCER, V131, P2808, DOI 10.1002/ijc.27595
   Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011
   Pattyn F, 2006, NUCLEIC ACIDS RES, V34, pD684, DOI 10.1093/nar/gkj155
   Raychaudhuri M, 2012, J MOL DIAGN, V14, P376, DOI 10.1016/j.jmoldx.2012.01.016
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Stanzer S, 2010, CLIN BIOCHEM, V43, P1443, DOI 10.1016/j.clinbiochem.2010.09.013
   Tang Y, 2012, STEM CELLS, V30, P2645, DOI 10.1002/stem.1225
   van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889
   Venugopal C, 2012, STEM CELL RES, V8, P141, DOI 10.1016/j.scr.2011.09.008
   Vincent A, 2012, BBA-REV CANCER, V1826, P83, DOI 10.1016/j.bbcan.2012.03.009
   Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160
NR 41
TC 20
Z9 23
U1 0
U2 22
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 24
PY 2013
VL 13
AR 358
DI 10.1186/1471-2407-13-358
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 191AI
UT WOS:000322384600001
PM 23883436
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Song, SJ
   Poliseno, L
   Song, MS
   Ala, U
   Webster, K
   Ng, C
   Beringer, G
   Brikbak, NJ
   Yuan, X
   Cantley, LC
   Richardson, AL
   Pandolfi, PP
AF Song, Su Jung
   Poliseno, Laura
   Song, Min Sup
   Ala, Ugo
   Webster, Kaitlyn
   Ng, Christopher
   Beringer, Gary
   Brikbak, Nicolai J.
   Yuan, Xin
   Cantley, Lewis C.
   Richardson, Andrea L.
   Pandolfi, Pier Paolo
TI MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via
   TET-Family-Dependent Chromatin Remodeling
SO CELL
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; MESENCHYMAL TRANSITION; 5-HYDROXYMETHYLCYTOSINE
   CONTENT; EPITHELIAL PHENOTYPE; DOWN-REGULATION; MIR-200 FAMILY;
   MESSENGER-RNA; HUMAN GENES; TGF-BETA; CELLS
AB Tumor cells metastasize to distant organs through genetic and epigenetic alterations, including changes in microRNA (miR) expression. Here we find miR-22 triggers epithelial-mesenchymal transition (EMT), enhances invasiveness and promotes metastasis in mouse xenografts. In a conditional mammary gland-specific transgenic (TG) mouse model, we show that miR-22 enhances mammary gland side-branching, expands the stem cell compartment, and promotes tumor development. Critically, miR-22 promotes aggressive metastatic disease in MMTV-miR-22 TG mice, as well as compound MMTV-neu or -PyVT-miR-22 TG mice. We demonstrate that miR-22 exerts its metastatic potential by silencing antimetastatic miR-200 through direct targeting of the TET (Ten eleven translocation) family of methylcytosine dioxygenases, thereby inhibiting demethylation of the mir-200 promoter. Finally, we show that miR-22 overexpression correlates with poor clinical outcomes and silencing of the TET-miR-200 axis in patients. Taken together, our findings implicate miR-22 as a crucial epigenetic modifier and promoter of EMT and breast cancer stemness toward metastasis.
C1 [Song, Su Jung; Poliseno, Laura; Song, Min Sup; Ala, Ugo; Webster, Kaitlyn; Ng, Christopher; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program,Div Genet,Dept Med & Pathol, Boston, MA 02115 USA.
   [Ng, Christopher; Cantley, Lewis C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct,Dept Med, Boston, MA 02115 USA.
   [Yuan, Xin] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Hematol Oncol Div,Dept Med, Boston, MA 02115 USA.
   [Beringer, Gary; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
   [Brikbak, Nicolai J.; Richardson, Andrea L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Beth Israel Deaconess
   Medical Center; Harvard University; Harvard Medical School; Beth Israel
   Deaconess Medical Center; Harvard University; Beth Israel Deaconess
   Medical Center; Harvard Medical School; Harvard University; Harvard
   Medical School; Harvard University; Harvard Medical School; Brigham &
   Women's Hospital
RP Pandolfi, PP (通讯作者)，Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program,Div Genet,Dept Med & Pathol, Boston, MA 02115 USA.
EM ppandolf@bidmc.harvard.edu
RI yuan, xin/HOF-1618-2023; Van Loo, Peter/A-3287-2012; Cantley,
   Lewis/D-1800-2014; Poliseno, Laura/B-5711-2012; Ala, Ugo/K-2029-2016
OI Ng, Christopher/0000-0001-8815-7958; Cantley, Lewis/0000-0002-1298-7653;
   Pandolfi, Pier Paolo/0000-0002-5352-5295; Webster,
   Kaitlyn/0000-0001-9902-0500; Poliseno, Laura/0000-0001-6557-955X; Ala,
   Ugo/0000-0001-5408-6397; Birkbak, Nicolai/0000-0003-1613-9587
FU NIH [CA 082328-14]
FX We are grateful to all members of the Pandolfi lab and in particular to
   Keisuke Ito and Leonardo Salmena for advice and discussion. We thank
   Thomas Garvey for critical editing of the manuscript as well as Yvonne
   Tay, Luo Man-Lee, April Greene-Colozzi, and Soon Jung Kim for
   experimental and technical support. This work was supported by NIH grant
   CA 082328-14 awarded to P.P.P.
CR Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bendoraite A, 2010, GYNECOL ONCOL, V116, P117, DOI 10.1016/j.ygyno.2009.08.009
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Breving K, 2010, INT J BIOCHEM CELL B, V42, P1316, DOI 10.1016/j.biocel.2009.09.016
   Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Haffner MC, 2011, ONCOTARGET, V2, P627
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307
   Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013
   Ito K, 2009, CURR OPIN GENET DEV, V19, P51, DOI 10.1016/j.gde.2009.01.004
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586
   Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227
   Ling B, 2012, J CANCER RES CLIN, V138, P1355, DOI 10.1007/s00432-012-1194-2
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   MCCARTHY JB, 1985, CANCER METAST REV, V4, P125, DOI 10.1007/BF00050692
   Melisi D, 2008, MOL CANCER THER, V7, P829, DOI 10.1158/1535-7163.MCT-07-0337
   Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109
   Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594
   Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shorning BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016209
   Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732
   Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Vuoristo M, 2007, MELANOMA RES, V17, P215, DOI 10.1097/CMR.0b013e328270b935
   Wang T, 2012, INT J BIOCHEM CELL B, V44, P366, DOI 10.1016/j.biocel.2011.11.012
   Withana NP, 2012, CANCER RES, V72, P1199, DOI 10.1158/0008-5472.CAN-11-2759
   Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Yoshimoto N, 2011, BREAST CANCER RES TR, V130, P331, DOI 10.1007/s10549-011-1672-2
NR 60
TC 381
Z9 415
U1 1
U2 94
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JUL 18
PY 2013
VL 154
IS 2
BP 311
EP 324
DI 10.1016/j.cell.2013.06.026
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 185FF
UT WOS:000321950700009
PM 23830207
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Goldstein, TC
   Paull, EO
   Ellis, MJ
   Stuart, JM
AF Goldstein, Theodore C.
   Paull, Evan O.
   Ellis, Matthew J.
   Stuart, Joshua M.
TI Molecular Pathways: Extracting Medical Knowledge from High-Throughput
   Genomic Data
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; SUBTYPE
AB High-throughput genomic data that measures RNA expression, DNA copy number, mutation status, and protein levels provide us with insights into the molecular pathway structure of cancer. Genomic lesions (amplifications, deletions, mutations) and epigenetic modifications disrupt biochemical cellular pathways. Although the number of possible lesions is vast, different genomic alterations may result in concordant expression and pathway activities, producing common tumor subtypes that share similar phenotypic outcomes. How can these data be translated into medical knowledge that provides prognostic and predictive information? First-generation mRNA expression signatures such as Genomic Health's Oncotype DX already provide prognostic information, but do not provide therapeutic guidance beyond the current standard of care, which is often inadequate in high-risk patients. Rather than building molecular signatures based on gene expression levels, evidence is growing that signatures based on higher-level quantities such as from genetic pathways may provide important prognostic and diagnostic cues. We provide examples of how activities for molecular entities can be predicted from pathway analysis and how the composite of all such activities, referred to here as the "activitome," helps connect genomic events to clinical factors to predict the drivers of poor outcome. (C)2013 AACR.
C1 [Goldstein, Theodore C.; Paull, Evan O.; Stuart, Joshua M.] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.
   [Goldstein, Theodore C.; Paull, Evan O.; Stuart, Joshua M.] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.
   [Ellis, Matthew J.] Washington Univ, Dept Internal Med, Div Oncol, Sect Breast Oncol, St Louis, MO 63110 USA.
   [Ellis, Matthew J.] Washington Univ, Breast Canc Program, Siteman Canc Ctr, St Louis, MO 63110 USA.
C3 University of California System; University of California Santa Cruz;
   University of California System; University of California Santa Cruz;
   Washington University (WUSTL); Washington University (WUSTL); Siteman
   Cancer Center
RP Ellis, MJ (通讯作者)，Washington Univ, Sch Med, Sect Breast Oncol,Dept Med, Siteman Canc Ctr,Breast Canc Program,Div Oncol, Campus Box 8056,660 South Euclid Ave, St Louis, MO 63110 USA.
EM mellis@wustl.edu; jstuart@soe.ucsc.edu
RI Pearson, John/AAT-4211-2020
OI Stuart, Joshua/0000-0002-2171-565X
FU NIH [U24 CA160035, R01 CA095614, P30 CA91842]; Susan G Komen for the
   Cure Promise Grant; BCRP-Idea Award [BC112014]; Breast Cancer Research
   Fund; NSF CAREER Award; TCGA project; Direct For Biological Sciences;
   Div Of Biological Infrastructure [0845783] Funding Source: National
   Science Foundation
FX M.J. Ellis is supported by NIH grants U24 CA160035, R01 CA095614, P30
   CA91842, a Susan G Komen for the Cure Promise Grant, a BCRP-Idea
   Award-BC112014, and the Breast Cancer Research Fund. J.M. Stuart is
   supported by an NSF CAREER Award and coleads a genome data analysis
   center supported by the TCGA project.
CR Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Chen R, 2007, NAT METHODS, V4, P879, DOI 10.1038/nmeth1107-879
   Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Huang HY, 2010, P NATL ACAD SCI USA, V107, P6823, DOI 10.1073/pnas.0912043107
   Kschischang FR, 2001, IEEE T INFORM THEORY, V47, P498, DOI 10.1109/18.910572
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Vandin F, 2011, J COMPUT BIOL, V18, P507, DOI 10.1089/cmb.2010.0265
   Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182
NR 11
TC 12
Z9 15
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 15
PY 2013
VL 19
IS 12
BP 3114
EP 3120
DI 10.1158/1078-0432.CCR-12-2093
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 164AL
UT WOS:000320381000002
PM 23430023
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Jeschke, J
   O'Hagan, HM
   Zhang, W
   Vatapalli, R
   Calmon, MF
   Danilova, L
   Nelkenbrecher, C
   Van Neste, L
   Bijsmans, ITGW
   Van Engeland, M
   Gabrielson, E
   Schuebel, KE
   Winterpacht, A
   Baylin, SB
   Herman, JG
   Ahuja, N
AF Jeschke, Jana
   O'Hagan, Heather M.
   Zhang, Wei
   Vatapalli, Rajita
   Calmon, Marilia Freitas
   Danilova, Ludmila
   Nelkenbrecher, Claudia
   Van Neste, Leander
   Bijsmans, Ingrid T. G. W.
   Van Engeland, Manon
   Gabrielson, Edward
   Schuebel, Kornel E.
   Winterpacht, Andreas
   Baylin, Stephen B.
   Herman, James G.
   Ahuja, Nita
TI Frequent Inactivation of <i>Cysteine Dioxygenase Type 1</i> Contributes
   to Survival of Breast Cancer Cells and Resistance to Anthracyclines
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CYSTEINE DIOXYGENASE; COLORECTAL-CANCER; GENE-EXPRESSION; ONCOGENIC
   TRANSFORMATION; METHYLATION; MECHANISM; DNA; TUMOR; ROS; HYPERMETHYLOME
AB Purpose: Genome-wide DNA methylation analyses have identified hundreds of candidate DNA-hypermethylated genes in cancer. Comprehensive functional analyses provide an understanding of the biologic significance of this vast amount of DNA methylation data that may allow the determination of key epigenetic events associated with tumorigenesis.
   Experimental Design: To study mechanisms of cysteine dioxygenase type 1 (CDO1) inactivation and its functional significance in breast cancer in a comprehensive manner, we screened for DNA methylation and gene mutations in primary breast cancers and analyzed growth, survival, and reactive oxygen species (ROS) production in breast cancer cells with restored CDO1 function in the context of anthracycline treatment.
   Results: DNA methylation-associated silencing of CDO1 in breast cancer is frequent (60%), cancer specific, and correlates with disease progression and outcome. CDO1 function can alternatively be silenced by repressive chromatin, and we describe protein-damaging missense mutations in 7% of tumors without DNA methylation. Restoration of CDO1 function in breast cancer cells increases levels of ROS and leads to reduced viability and growth, as well as sensitization to anthracycline treatment. Priming with 5-azacytidine of breast cancer cells with epigenetically silenced CDO1 resulted in restored expression and increased sensitivity to anthracyclines.
   Conclusion: We report that silencing of CDO1 is a critical epigenetic event that contributes to the survival of oxidative-stressed breast cancer cells through increased detoxification of ROS and thus leads to the resistance to ROS-generating chemotherapeutics including anthracyclines. Our study shows the importance of CDO1 inactivation in breast cancer and its clinical potential as a biomarker and therapeutic target to overcome resistance to anthracyclines. (C)2013 AACR.
C1 [Jeschke, Jana; Vatapalli, Rajita; Calmon, Marilia Freitas; Ahuja, Nita] Johns Hopkins Univ, Dept Surg, Baltimore, MD 21287 USA.
   [Jeschke, Jana; O'Hagan, Heather M.; Zhang, Wei; Vatapalli, Rajita; Calmon, Marilia Freitas; Danilova, Ludmila; Schuebel, Kornel E.; Baylin, Stephen B.; Herman, James G.; Ahuja, Nita] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA.
   [Gabrielson, Edward] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21287 USA.
   [Jeschke, Jana; Nelkenbrecher, Claudia; Winterpacht, Andreas] Univ Erlangen Nurnberg, Inst Human Genet, Univ Hosp Erlangen, Erlangen, Germany.
   [Van Neste, Leander] MDxHeatlth SA, Liege, Belgium.
   [Bijsmans, Ingrid T. G. W.; Van Engeland, Manon] Maastricht Univ, Med Ctr, Dept Pathol, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; University of Erlangen Nuremberg; Maastricht University
RP Ahuja, N (通讯作者)，Johns Hopkins Univ, CRB1,Suite 541,1650 Orleans St, Baltimore, MD 21287 USA.
EM hermaji@jhmi.edu; nahuja@jhmi.edu
RI Calmon, Marilia/H-3150-2012; Vatapalli, Rajita/AAN-1397-2021; zhang,
   wei/A-7015-2011; O'Hagan, Heather/AAF-5385-2020; van Engeland,
   Manon/A-7479-2009
OI O'Hagan, Heather/0000-0001-9750-5088; Jeschke, Jana/0000-0002-6047-2558
FU Susan G. Komen Foundation; German Academic Exchange Service (DAAD); Dr.
   Jost Henkel Stiftung
FX This study was supported by the Susan G. Komen Foundation, German
   Academic Exchange Service (DAAD), and Dr. Jost Henkel Stiftung.
CR Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Behrend L, 2003, BIOCHEM SOC T, V31, P1441
   BRADLEY H, 1994, J RHEUMATOL, V21, P1192
   Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137
   Clements EG, 2012, NUCLEIC ACIDS RES, V40, P4334, DOI 10.1093/nar/gks031
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Dietrich D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-247
   Dominy JE, 2007, AM J PHYSIOL-ENDOC M, V293, pE62, DOI 10.1152/ajpendo.00053.2007
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025
   Glöckner SC, 2009, CANCER RES, V69, P4691, DOI 10.1158/0008-5472.CAN-08-0142
   GORDON C, 1992, LANCET, V339, P25, DOI 10.1016/0140-6736(92)90144-R
   GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558
   HEAFIELD MT, 1990, NEUROSCI LETT, V110, P216, DOI 10.1016/0304-3940(90)90814-P
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Jeschke J, 2012, EPIGENETICS-US, V7, P701, DOI 10.4161/epi.20445
   Joseph CA, 2007, CHEM COMMUN, P3338, DOI 10.1039/b702158e
   Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552
   Martínez-Sánchez G, 2007, J EXP CLIN CANC RES, V26, P39
   Maschietto M, 2011, EUR J CANCER, V47, P2715, DOI 10.1016/j.ejca.2011.05.024
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mossman D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023127
   Oltra AM, 2001, FREE RADICAL BIO MED, V30, P1286, DOI 10.1016/S0891-5849(01)00521-4
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Ray G, 2000, BREAST CANCER RES TR, V59, P163, DOI 10.1023/A:1006357330486
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Schneider BL, 2004, CARCINOGENESIS, V25, P2033, DOI 10.1093/carcin/bgh204
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6
   Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015
   Stipanuk MH, 2009, AMINO ACIDS, V37, P55, DOI 10.1007/s00726-008-0202-y
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8
   Ye S, 2007, J BIOL CHEM, V282, P3391, DOI 10.1074/jbc.M609337200
   Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222
   Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349
NR 40
TC 64
Z9 76
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 15
PY 2013
VL 19
IS 12
BP 3201
EP 3211
DI 10.1158/1078-0432.CCR-12-3751
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 164AL
UT WOS:000320381000010
PM 23630167
OA Green Published, Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Lee, C
   Zhang, Q
   Kozlowski, J
   Brendler, C
   Soares, MB
   Dash, A
   McClelland, M
   McClelland, M
   Mercola, D
AF Lee, Chung
   Zhang, Qiang
   Kozlowski, James
   Brendler, Charles
   Soares, Marcelo B.
   Dash, Atrya
   McClelland, Michael
   McClelland, Michael
   Mercola, Dan
TI Natural Products and Transforming Growth Factor-beta (TGF-β) Signaling
   in Cancer Development and Progression
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Dietary components; DNA methylation; non-Smad pathways; Smad pathways;
   TGF-beta signaling; Tumor development and progression
ID DNA METHYLATION; BREAST-CANCER; DIETARY POLYPHENOLS; GENE-EXPRESSION;
   EPIGENETIC REGULATION; FACTOR-BETA/SMAD; IN-VITRO; CELL; EXTRACT;
   PROMOTER
AB Actions of many herbal medicine products for cancer treatment are linked to an altered production of TGF-beta in the target cells. An altered TGF-beta production in the target cells will have profound effects on the patients. Therefore, it is important that we review the pros and cons of these products on cancer development and progression in terms of TGF-beta signaling. It has been well established that TGF-beta is growth inhibitory to benign cells or early stages of cancer cells but it is tumor promoting and metastatic for advanced malignancies. Further, many dietary components can alter gene-specific DNA methylation levels in systemic and in target tissues. Since TGF-beta signaling in cancer is closely linked to the DNA methylation profiles, we also review the effect of dietary components on DNA methylation. In light of this knowledge, it is important to note that many natural products that can induce TGF-beta production in the target cells may be beneficial in preventing cancer development but may be harmful for cancer patients, especially when they harbor advanced stage cancer.
   A discussion of the effect of herbal natural products on cancer can be divided into three categories. The first category of herbal medicine products will be those related to the induction of cancer as far as TGF-beta is concerned. Since TGF-beta is growth inhibitory and pro-apoptosis to benign cells, any herbal medication that can induce the production of TGF-beta in the target cells will be beneficial to the patients. However, such herbal medicine may not necessarily be beneficial for patients with established and advanced cancer. The second category of herbal products will inhibit TGF-beta signaling and will reduce TGF-beta mediated growth promotion and metastasis in advanced cancers. For patients with established and advanced cancer, agents that can inhibit the production of TGF-beta may also inhibit cancer growth and metastasis. Finally, the third category of herbal products has no impact on TGF-beta signaling, such as lycopene.
C1 [Lee, Chung; Zhang, Qiang; Kozlowski, James] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.
   [Lee, Chung; McClelland, Michael; Mercola, Dan] Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA.
   [Lee, Chung; Dash, Atrya] Univ Calif Irvine, Dept Urol, Irvine, CA 92697 USA.
   [Brendler, Charles] NorthShore Univ HealthSyst, Dept Surg, Evanston, IL 60201 USA.
   [Soares, Marcelo B.] Childrens Mem Res Ctr, Canc Biol & Epigen Program, Chicago, IL 60614 USA.
   [McClelland, Michael] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 Northwestern University; Feinberg School of Medicine; University of
   California System; University of California Irvine; University of
   California System; University of California Irvine; NorthShore
   University Health System; University of California System; University of
   California Irvine
RP Lee, C (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.
EM c-lee7@northwestern.edu
RI McClelland, Michael/A-8583-2011; mercola, dan/L-4182-2013
OI McClelland, Michael/0000-0003-1788-9347; , dan/0000-0002-0281-9840
FU NIH/NCI [Prostate Cancer SPORE P50 CA90386, EDRN U01 CA152738, UO1
   CA114810, CA122558]; Department of Defense [W81XWH-08-1-0720,
   W81XWH-09-1-0311]; Northshore University Healthsystem
FX This report was presented before the International Conference on Natural
   Products and Cancer Targets: Progress and Promises (August 24-25, 2011,
   Zhengzhou University, Zhengzhou (Henan Province), China. The work
   performed by the authors was supported in part by NIH/NCI grants
   (Prostate Cancer SPORE P50 CA90386, EDRN U01 CA152738, and SPECS grant
   UO1 CA114810, and CA122558), grants from the Department of Defense
   (W81XWH-08-1-0720, W81XWH-09-1-0311), a grant from Northshore University
   Healthsystem, and a gift from the Fred Turner Foundation,
CR Adjakly M, 2011, EPIGENOMICS-UK, V3, P795, DOI [10.2217/EPI.11.103, 10.2217/epi.11.103]
   Bajracharya P, 2009, ARCH PHARM RES, V32, P1555, DOI 10.1007/s12272-009-2107-z
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev-biochem-052610-091920
   Chiam K, 2012, CANC LETT
   Chou CC, 2003, EUR J PHARM SCI, V19, P403, DOI 10.1016/S0928-0987(03)00144-1
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Funahashi H, 1999, JPN J CANCER RES, V90, P922, DOI 10.1111/j.1349-7006.1999.tb00836.x
   Gunasekera RS, 2007, NUTR CANCER, V58, P171, DOI 10.1080/01635580701328339
   Han G, 2006, RADIAT RES, V165, P546, DOI 10.1667/RR3543.1
   Jang M, 1999, DRUG EXP CLIN RES, V25, P65
   Ji GY, 2011, INT IMMUNOPHARMACOL, V11, P762, DOI 10.1016/j.intimp.2011.01.036
   Khor TO, 2011, BIOCHEM PHARMACOL, V82, P1073, DOI 10.1016/j.bcp.2011.07.065
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kitano A, 2006, J CATARACT REFR SURG, V32, P1727, DOI 10.1016/j.jcrs.2006.05.015
   Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42
   Kwak KG, 2011, HUM EXP TOXICOL, V30, P1322, DOI 10.1177/0960327110389502
   Lee CY, 2008, LIVER INT, V28, P841, DOI 10.1111/j.1478-3231.2008.01698.x
   Lee S, 2011, J ETHNOPHARMACOL, V133, P973, DOI 10.1016/j.jep.2010.07.018
   Lee TK, 2005, INT J GYNECOL CANCER, V15, P349, DOI 10.1111/j.1525-1438.2005.15228.x
   Lee TK, 2004, IMMUNOPHARM IMMUNOT, V26, P315, DOI 10.1081/IPH-200026840
   Li GS, 2010, PHYTOMEDICINE, V17, P282, DOI 10.1016/j.phymed.2009.05.002
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Lim Unhee, 2012, Methods Mol Biol, V863, P359, DOI 10.1007/978-1-61779-612-8_23
   Lin HH, 2011, TOXICOL APPL PHARM, V250, P336, DOI 10.1016/j.taap.2010.11.014
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   Liu AG, 2011, BIOCHEM BIOPH RES CO, V412, P479, DOI 10.1016/j.bbrc.2011.07.124
   Liu X, 2010, J GASTROEN HEPATOL, V25, P420, DOI 10.1111/j.1440-1746.2009.05981.x
   Liu YL, 2011, MOL MED REP, V4, P675, DOI 10.3892/mmr.2011.473
   Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P
   Luo XR, 2008, J IMMUNOL, V180, P2757, DOI 10.4049/jimmunol.180.5.2757
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   Manabe M, 2003, BIOSCI BIOTECH BIOCH, V67, P2512, DOI 10.1271/bbb.67.2512
   Mandal D, 2007, NUTR CANCER, V58, P213, DOI 10.1080/01635580701328503
   Massagué J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051
   MASSAGUE J, 1992, CANCER SURV, V12, P81
   Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110
   McCarty MF, 2006, MED HYPOTHESES, V66, P1093, DOI 10.1016/j.mehy.2004.11.046
   Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y
   Nantz MP, 2006, J NUTR, V136, P2606, DOI 10.1093/jn/136.10.2606
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Papoutsis AJ, 2012, J NUTR BIOCHEM, V23, P1324, DOI 10.1016/j.jnutbio.2011.08.001
   Park EY, 2005, PLANTA MED, V71, P393, DOI 10.1055/s-2005-864131
   Pavese JM, 2010, CANCER METAST REV, V29, P465, DOI 10.1007/s10555-010-9238-z
   Philips N, 2009, ANTICANCER RES, V29, P3233
   Philips N, 2009, ARCH DERMATOL RES, V301, P487, DOI 10.1007/s00403-009-0950-x
   Pitchakarn P, 2010, CANCER SCI, V101, P2234, DOI 10.1111/j.1349-7006.2010.01669.x
   Roomi MW, 2005, ONCOL REP, V14, P807
   Ruiz-Torres MP, 2007, INT J BIOCHEM CELL B, V39, P133, DOI 10.1016/j.biocel.2006.07.012
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Shin JW, 2006, WORLD J GASTROENTERO, V12, P6142, DOI 10.3748/wjg.v12.i38.6142
   Tamura T, 2007, PEDIATR SURG INT, V23, P343, DOI 10.1007/s00383-007-1887-9
   Teicher BA, 2001, CANCER METAST REV, V20, P133, DOI 10.1023/A:1013177011767
   Vittal R, 2004, MOL CANCER THER, V3, P1091
   Wertz K, 2004, ARCH BIOCHEM BIOPHYS, V430, P127, DOI 10.1016/j.abb.2004.04.023
   Whyte L, 2007, CANCER RES, V67, P12007, DOI 10.1158/0008-5472.CAN-07-2464
   Xiao ZY, 2006, INT J RADIAT ONCOL, V65, P882, DOI 10.1016/j.ijrobp.2006.01.031
   Yamamoto M, 1996, HEPATOLOGY, V23, P552
   You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544
   Yu HM, 2008, LUNG CANCER, V59, P219, DOI 10.1016/j.lungcan.2007.08.007
   Yu NW, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.061
   Zhang D, 2010, FERTIL STERIL, V94, P1887, DOI 10.1016/j.fertnstert.2009.08.065
   Zhang Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025168
   Zhang Q, 2009, CLIN CANCER RES, V15, P3557, DOI 10.1158/1078-0432.CCR-08-1656
   Zhu WZ, 2012, NUTR CANCER, V64, P393, DOI 10.1080/01635581.2012.654926
NR 66
TC 8
Z9 8
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD JUN
PY 2013
VL 13
IS 5
BP 500
EP 505
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 161KK
UT WOS:000320191600003
PM 23597196
DA 2025-01-12
ER

PT J
AU Wang, YJ
   Li, Y
   Liu, XM
   Cho, WCS
AF Wang, Yujiong
   Li, Yong
   Liu, Xiaoming
   Cho, William C. S.
TI Genetic and Epigenetic Studies for Determining Molecular Targets of
   Natural Product Anticancer Agents
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Cancer stem cells; epigenetics; genetics; microRNA; natural product
ID PROSTATE-CANCER CELLS; HISTONE DEACETYLASE INHIBITORS; GREEN TEA
   POLYPHENOL; MAMMARY EPITHELIAL-CELLS; SOY ISOFLAVONE GENISTEIN;
   TUMOR-SUPPRESSOR GENES; STEM-LIKE CELLS; FACTOR-KAPPA-B; BREAST-CANCER;
   MICRORNA EXPRESSION
AB Cancer is a disease caused by a series of genetic and epigenetic alterations. Therefore, agents targeting the genetic and/or epigenetic machinery offer potential for the development of anticancer drugs. Accumulating evidence has demonstrated that some common natural products [such as epigallocatechin-3-gallate (EGCG), curcumin, genistein, sulforaphane (SFN) and resveratrol] have anticancer properties through the mechanisms of altering epigenetic processes [including DNA methylation, histone modification, chromatin remodeling, microRNA (miRNA) regulation] and targeting cancer stem cells (CSCs). These bioactive compounds are able to revert epigenetic alterations in a variety of cancers in vitro and in vivo. They exert anticancer effects by targeting various signaling pathways related to the initiation, progression and metastasis of cancer. It appears that natural products hold great promise for cancer prevention and treatment by altering various epigenetic modifications. This review aims to discuss our current understanding of genetic and epigenetic targets of natural products and the effects of some common natural products on cancer chemoprevention and treatment.
C1 [Wang, Yujiong; Li, Yong; Liu, Xiaoming] Ningxia Univ, Minist Educ Conservat & Utilizat Special Biol Res, Key Lab, Ningxia 750021, Peoples R China.
   [Wang, Yujiong; Li, Yong; Liu, Xiaoming] Ningxia Univ, Coll Life Sci, Ningxia 750021, Peoples R China.
   [Cho, William C. S.] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
C3 Ningxia University; Ningxia University
RP Liu, XM (通讯作者)，Ningxia Univ, Coll Life Sci, Ningxia 750021, Peoples R China.
EM lxm1966@nxu.edu.cn; williamcscho@gmail.com
RI Cho, William/H-7429-2019; Liu, Xiaoyan/ACD-3429-2022
OI LIU, XIAOMING/0000-0002-3902-9105
FU National Key Basic Research Program of China [2012CB126300,
   2012CB518801]; National Natural Science Foundation of China [31172278,
   31160515, 31260615]
FX This work was supported by grants (Nos. 2012CB126300 and 2012CB518801)
   from National Key Basic Research Program of China and grants (Nos.
   31172278, 31160515 and 31260615) from National Natural Science
   Foundation of China.
CR Aggarwal BB, 2009, TRENDS PHARMACOL SCI, V30, P85, DOI 10.1016/j.tips.2008.11.002
   Almanaa TN, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-195
   Anand P, 2008, BIOCHEM PHARMACOL, V76, P1590, DOI 10.1016/j.bcp.2008.08.008
   Anand P, 2008, PHARM RES-DORDR, V25, P2097, DOI 10.1007/s11095-008-9661-9
   Aravindaram K, 2010, PLANTA MED, V76, P1103, DOI 10.1055/s-0030-1249859
   Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797
   Banerjee S, 2011, MUTAT RES-REV MUTAT, V728, P47, DOI 10.1016/j.mrrev.2011.06.001
   Bao B, 2012, CANCER RES, V72, P335, DOI 10.1158/0008-5472.CAN-11-2182
   Beaver LM, 2012, TOXICOL APPL PHARM, V263, P345, DOI 10.1016/j.taap.2012.07.007
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Bhamre S, 2009, PROSTATE, V69, P181, DOI 10.1002/pros.20869
   Bishayee A, 2009, CANCER PREV RES, V2, P409, DOI 10.1158/1940-6207.CAPR-08-0160
   Blaskovich MA, 2003, CANCER RES, V63, P1270
   Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147
   Bryant CS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-47
   Chang CJ, 2012, CHILD NERV SYST, V28, P363, DOI 10.1007/s00381-011-1672-x
   Chen D, 2012, BIOORGAN MED CHEM, V20, P3031, DOI 10.1016/j.bmc.2012.03.002
   Chen M, 2010, CANCER PREV RES, V3, P1235, DOI 10.1158/1940-6207.CAPR-10-0035
   Chen Y, 2007, BASIC CLIN PHARMACOL, V101, P427, DOI 10.1111/j.1742-7843.2007.00142.x
   Chen Y, 2011, CANCER PREV RES, V4, P76, DOI 10.1158/1940-6207.CAPR-10-0167
   Chen YW, 2010, MOL CANCER THER, V9, P2879, DOI 10.1158/1535-7163.MCT-10-0504
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365
   Choi KC, 2009, CANCER RES, V69, P583, DOI 10.1158/0008-5472.CAN-08-2442
   Collett NP, 2010, SEMIN ONCOL, V37, P258, DOI 10.1053/j.seminoncol.2010.06.014
   Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z
   Danilenko M, 2004, EXP CELL RES, V298, P339, DOI 10.1016/j.yexcr.2004.04.029
   Dashwood RH, 2008, NUTR REV, V66, pS36, DOI 10.1111/j.1753-4887.2008.00065.x
   Davis CD, 2008, NUTR REV, V66, P477, DOI 10.1111/j.1753-4887.2008.00080.x
   de Bono JS, 2010, NATURE, V467, P543, DOI 10.1038/nature09339
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Dubrovska A, 2010, CLIN CANCER RES, V16, P5692, DOI 10.1158/1078-0432.CCR-10-1601
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller Manel, 2011, Genes Cancer, V2, P604, DOI 10.1177/1947601911423096
   Fang Douglas D, 2012, Front Med, V6, P112, DOI 10.1007/s11684-012-0199-1
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fix Lindsey N., 2010, Cancer Genomics & Proteomics, V7, P261
   Fong D, 2010, CANCER LETT, V293, P65, DOI 10.1016/j.canlet.2009.12.018
   Fu SQ, 2010, CANCER-AM CANCER SOC, V116, P4670, DOI 10.1002/cncr.25414
   Gaedicke S, 2008, FEBS LETT, V582, P3542, DOI 10.1016/j.febslet.2008.09.032
   Ganesan A, 2009, CURR CANCER DRUG TAR, V9, P963, DOI 10.2174/156800909790192428
   Gao Z, 2009, ANTICANCER RES, V29, P2025
   Gong HY, 2005, CANCER BIOTHER RADIO, V20, P155, DOI 10.1089/cbr.2005.20.155
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F
   Gu B, 2009, ONCOL REP, V21, P635, DOI 10.3892/or_00000266
   Gu Y, 2005, WORLD J GASTROENTERO, V11, P6512, DOI 10.3748/wjg.v11.i41.6512
   Han KC, 2011, BRIT J NUTR, V105, P171, DOI 10.1017/S0007114510003211
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Hauser AT, 2008, PLANTA MED, V74, P1593, DOI 10.1055/s-2008-1081347
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   HOFFMAN DR, 1979, CAN J BIOCHEM CELL B, V57, P56, DOI 10.1139/o79-007
   Hope C, 2008, MOL NUTR FOOD RES, V52, pS52, DOI 10.1002/mnfr.200700448
   Hossain MM, 2012, NEUROCHEM INT, V61, P1102, DOI 10.1016/j.neuint.2012.08.002
   Hsiao WC, 2012, MOL PHARMACEUT, V9, P1396, DOI 10.1021/mp200649g
   Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P2970, DOI 10.1002/cncr.25869
   Hu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016221
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029
   Izzotti A, 2012, MUTAT RES-REV MUTAT, V751, P287, DOI 10.1016/j.mrrev.2012.05.004
   Izzotti A, 2012, J CHILD NEUROL, V27, P51, DOI 10.1177/0883073811413582
   Izzotti A, 2010, CARCINOGENESIS, V31, P894, DOI 10.1093/carcin/bgq037
   Izzotti A, 2010, CANCER PREV RES, V3, P62, DOI 10.1158/1940-6207.CAPR-09-0202
   Jensen MB, 2012, NEOPLASIA, V14, P952, DOI 10.1593/neo.121164
   Jin YC, 2010, ANTI-CANCER DRUG, V21, P814, DOI 10.1097/CAD.0b013e32833e53ea
   Johnson IT, 2008, FOOD CHEM TOXICOL, V46, P1346, DOI 10.1016/j.fct.2007.09.101
   Joshua B, 2012, HEAD NECK-J SCI SPEC, V34, P42, DOI 10.1002/hed.21699
   Ju J, 2005, CANCER RES, V65, P10623, DOI 10.1158/0008-5472.CAN-05-1949
   Kakarala M, 2010, BREAST CANCER RES TR, V122, P777, DOI 10.1007/s10549-009-0612-x
   Kallifatidis G, 2009, GUT, V58, P949, DOI 10.1136/gut.2008.149039
   Kanai M, 2011, CANCER CHEMOTH PHARM, V68, P157, DOI 10.1007/s00280-010-1470-2
   Kang SK, 2006, STEM CELLS DEV, V15, P165, DOI 10.1089/scd.2006.15.165
   Kanwar SS, 2011, PHARM RES-DORDR, V28, P827, DOI 10.1007/s11095-010-0336-y
   Kao CL, 2009, INT J RADIAT ONCOL, V74, P219, DOI 10.1016/j.ijrobp.2008.12.035
   Karius T, 2012, BIOCHEM PHARMACOL, V83, P1591, DOI 10.1016/j.bcp.2012.02.004
   Kato K, 2008, BRIT J CANCER, V99, P647, DOI 10.1038/sj.bjc.6604521
   Khan N, 2010, CANCER METAST REV, V29, P435, DOI 10.1007/s10555-010-9236-1
   Khor TO, 2006, BIOPHARM DRUG DISPOS, V27, P407, DOI 10.1002/bdd.522
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200
   Kim YS, 2012, J NUTR BIOCHEM, V23, P691, DOI 10.1016/j.jnutbio.2012.03.002
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kotsopoulos J, 2008, J NUTR, V138, P703, DOI 10.1093/jn/138.4.703
   Lee AH, 2006, EXPERT REV ANTICANC, V6, P507, DOI 10.1586/14737140.6.4.507
   Lee DH, 2010, THESCIENTIFICWORLDJO, V10, P413, DOI 10.1100/tsw.2010.44
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2011, J NUTR BIOCHEM, V22, P799, DOI 10.1016/j.jnutbio.2010.11.001
   Li Y, 2008, J BIOL CHEM, V283, P27707, DOI 10.1074/jbc.M802759200
   Li YW, 2010, PHARM RES-DORDR, V27, P1027, DOI 10.1007/s11095-010-0105-y
   Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Lim KJ, 2011, CANCER BIOL THER, V11, P464, DOI 10.4161/cbt.11.5.14410
   Lin JK, 2002, ARCH PHARM RES, V25, P561, DOI 10.1007/BF02976924
   Lin L, 2011, BRIT J CANCER, V105, P212, DOI 10.1038/bjc.2011.200
   Liu HL, 2005, ACTA PHARMACOL SIN, V26, P603, DOI 10.1111/j.1745-7254.2005.00081.x
   Liu PL, 2010, MOL NUTR FOOD RES, V54, pS196, DOI 10.1002/mnfr.200900550
   Liu Z, 2011, MOLECULES, V16, P5283, DOI 10.3390/molecules16065283
   Lu KH, 2009, CHILD NERV SYST, V25, P543, DOI 10.1007/s00381-009-0826-6
   Lukiw WJ, 2008, J BIOL CHEM, V283, P31315, DOI 10.1074/jbc.M805371200
   Luo Q, 2009, J MED FOOD, V12, P695, DOI 10.1089/jmf.2008.1232
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Mao QQ, 2010, MOL NUTR FOOD RES, V54, P1574, DOI 10.1002/mnfr.200900392
   Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Meeran SM, 2008, FRONT BIOSCI-LANDMRK, V13, P2191, DOI 10.2741/2834
   Melkamu T, 2010, CARCINOGENESIS, V31, P252, DOI 10.1093/carcin/bgp208
   Messina M, 2009, AM J CLIN NUTR, V89, pS1673, DOI 10.3945/ajcn.2009.26736V
   Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841
   MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463
   Montales MTE, 2012, CARCINOGENESIS, V33, P652, DOI 10.1093/carcin/bgr317
   Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Myzak MC, 2007, EXP BIOL MED, V232, P227
   Myzak MC, 2006, MOL CARCINOGEN, V45, P443, DOI 10.1002/mc.20224
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Pálmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Pan JX, 2010, CANCER LETT, V292, P149, DOI 10.1016/j.canlet.2009.11.018
   Pandey M, 2010, INT J CANCER, V126, P2520, DOI 10.1002/ijc.24988
   Papoutsis AJ, 2012, J NUTR BIOCHEM, V23, P1324, DOI 10.1016/j.jnutbio.2011.08.001
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Parasramka MA, 2012, MOL CARCINOGEN, V51, P213, DOI 10.1002/mc.20822
   Parker LP, 2009, EUR J GYNAECOL ONCOL, V30, P616
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Rabiau N, 2011, IN VIVO, V25, P917
   Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031
   Ryu MJ, 2008, BIOCHEM BIOPH RES CO, V377, P1304, DOI 10.1016/j.bbrc.2008.10.171
   Salerno E, 2009, MOL CANCER THER, V8, P2684, DOI 10.1158/1535-7163.MCT-09-0127
   Semov A, 2012, BIOCHEM BIOPH RES CO, V424, P45, DOI 10.1016/j.bbrc.2012.06.062
   Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828
   Siddiqui IA, 2011, FASEB J, V25, P1198, DOI 10.1096/fj.10-167924
   Singh AV, 2006, CANCER RES, V66, P1851, DOI 10.1158/0008-5472.CAN-05-1332
   Slusarz A, 2010, CANCER RES, V70, P3382, DOI 10.1158/0008-5472.CAN-09-3012
   Soltanian S, 2011, TUMOR BIOL, V32, P425, DOI 10.1007/s13277-011-0155-8
   Su Y, 2009, CARCINOGENESIS, V30, P331, DOI 10.1093/carcin/bgn279
   Subramanian B, 2006, J EXP THER ONCOL, V5, P195
   Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272
   Sun QM, 2009, ONCOL REP, V22, P563, DOI 10.3892/or_00000472
   Suter MA, 2009, SEMIN REPROD MED, V27, P380, DOI 10.1055/s-0029-1237426
   Tachibana H, 2009, FORUM NUTR, V61, P156, DOI 10.1159/000212748
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Tang FY, 2008, MOL NUTR FOOD RES, V52, P646, DOI 10.1002/mnfr.200700272
   Tang SN, 2012, INT J CANCER, V131, P30, DOI 10.1002/ijc.26323
   Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682
   Telang U, 2009, EXP BIOL MED, V234, P287, DOI 10.3181/0808-RM-241
   Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003
   Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143
   Traka M, 2005, J NUTR, V135, P1865, DOI 10.1093/jn/135.8.1865
   Tsang WP, 2010, J NUTR BIOCHEM, V21, P140, DOI 10.1016/j.jnutbio.2008.12.003
   Tsuda Hiroyuki, 2004, Drug Metab Pharmacokinet, V19, P245, DOI 10.2133/dmpk.19.245
   Wang H, 2011, CARCINOGENESIS, V32, P1881, DOI 10.1093/carcin/bgr218
   Wang L, 2009, MOL PHARMACOL, V76, P1238, DOI 10.1124/mol.109.059105
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Wang ZW, 2006, CANCER-AM CANCER SOC, V106, P2503, DOI 10.1002/cncr.21904
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-12
   Wu N, 2011, ACTA PHARMACOL SIN, V32, P345, DOI 10.1038/aps.2010.220
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   Yang J, 2010, MED ONCOL, V27, P1114, DOI 10.1007/s12032-009-9344-3
   Yaseen A, 2012, MOL PHARMACOL, V82, P1030, DOI 10.1124/mol.112.079624
   YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666
   Zhang J, 2010, ONCOL REP, V24, P1217, DOI 10.3892/or_00000975
   Zhang J, 2010, BIOCHEM BIOPH RES CO, V399, P1, DOI 10.1016/j.bbrc.2010.07.013
   Zhang LL, 2012, CANCER LETT, V323, P48, DOI 10.1016/j.canlet.2012.03.037
   Zhang ZP, 2011, CELL BIOL TOXICOL, V27, P107, DOI 10.1007/s10565-010-9174-2
   Zhang ZP, 2011, ARCH PHARM RES, V34, P801, DOI 10.1007/s12272-011-0514-4
   Zhao F, 2010, TOXICOLOGY, V267, P70, DOI 10.1016/j.tox.2009.10.023
NR 173
TC 29
Z9 33
U1 0
U2 50
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD JUN
PY 2013
VL 13
IS 5
BP 506
EP 518
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 161KK
UT WOS:000320191600004
PM 23597195
DA 2025-01-12
ER

PT J
AU Qian, BY
   Nag, SA
   Su, YL
   Voruganti, S
   Qin, JJ
   Zhang, RW
   Cho, WCS
AF Qian, Biyun
   Nag, Subhasree A.
   Su, Yuliang
   Voruganti, Sukesh
   Qin, Jiang-Jiang
   Zhang, Ruiwen
   Cho, William C. S.
TI miRNAs in Cancer Prevention and Treatment and as Molecular Targets for
   Natural Product Anticancer Agents
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Biomarker; cancer diagnosis; cancer prognosis; cancer therapy;
   chemoprevention; epigenetics; microRNA; natural product; oncogene; tumor
   suppressor gene
ID MICRORNA EXPRESSION PROFILE; BINDING-SITE POLYMORPHISMS;
   TUMOR-SUPPRESSOR GENE; BREAST-CANCER; LUNG-CANCER; DOWN-REGULATION;
   PROSTATE-CANCER; UP-REGULATION; COLORECTAL-CANCER; CIGARETTE-SMOKE
AB MicroRNAs (miRNAs) are endogenous small non-coding RNAs that regulate gene expression by binding to the 3 untranslated region of target mRNA, resulting in posttranscriptional gene silencing via mRNA degradation or translation inhibition. miRNAs are involved in many biological processes including carcinogenesis. They can act as oncogenes or tumor suppressors and their aberrant expressions are intimately linked with cancer development and progression. Therefore, miRNAs have been utilized as potential biomarkers for cancer diagnosis, prognosis, as well as cancer therapeutic targets. Recently, it has been demonstrated that dietary and natural chemopreventive agents exert their anticancer activities through the regulation of one or more miRNAs. In addition to expounding the latest findings of miRNAs in cancer, this review also discusses the recent efforts on the translational research of miRNAs, with an emphasis on natural products in the treatment of cancer.
C1 [Qian, Biyun; Su, Yuliang] Tianjin Med Univ, Canc Inst & Hosp, Dept Epidemiol & Biostat, Tianjin 300060, Peoples R China.
   [Nag, Subhasree A.; Voruganti, Sukesh; Qin, Jiang-Jiang; Zhang, Ruiwen] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.
   [Zhang, Ruiwen] Texas Tech Univ, Hlth Sci Ctr, Canc Biol Ctr, Sch Pharm, Amarillo, TX 79106 USA.
   [Cho, William C. S.] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
C3 Tianjin Medical University; Texas Tech University System; Texas Tech
   University Health Science Center; Texas Tech University Health Sciences
   Center Amarillo; Texas Tech University System; Texas Tech University
   Health Science Center; Texas Tech University Health Sciences Center
   Amarillo
RP Qian, BY (通讯作者)，Tianjin Med Univ, Canc Inst & Hosp, Dept Epidemiol & Biostat, Huan Hu Xi Rd, Tianjin 300060, Peoples R China.
EM qianbiyun@126.com; williamcscho@gmail.com
RI Nag, Subhasree/JCE-1320-2023; Cho, William/H-7429-2019; voruganti,
   sukesh/B-1524-2016; Qin, Jiangjiang/AAM-9553-2020; Nag,
   Subhasree/K-1807-2016
OI Qin, Jiangjiang/0000-0002-8559-616X; Nag, Subhasree/0000-0001-6933-4349
FU National Natural Science Foundation of China [81071914]; National
   Institutes of Health (NIH) [R01 CA112029, R01 CA121211]; Susan G Komen
   Foundation [BCTR0707731]
FX This work was supported by National Natural Science Foundation of China
   (No. 81071914 to B. Q.). This work also was supported by the National
   Institutes of Health (NIH) grants R01 CA112029 and R01 CA121211 and a
   Susan G Komen Foundation grant BCTR0707731 (to R.Z.).
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Ahn J, 2012, MOL NUTR FOOD RES, V56, P1665, DOI 10.1002/mnfr.201200182
   Akkiz H, 2011, J VIRAL HEPATITIS, V18, pE399, DOI 10.1111/j.1365-2893.2010.01414.x
   Ali S, 2011, AM J TRANSL RES, V3, P28
   Alpers DH, 2009, CURR OPIN GASTROEN, V25, P116, DOI 10.1097/MOG.0b013e32831ef221
   Anand P, 2008, CANCER LETT, V267, P133, DOI 10.1016/j.canlet.2008.03.025
   [Anonymous], PLOS ONE
   [Anonymous], PLOS ONE
   [Anonymous], CAN UROL ASS J
   Arola-Arnal A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025982
   Asaga S, 2011, CLIN CHEM, V57, P84, DOI 10.1373/clinchem.2010.151845
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131
   Aypar U, 2011, MUTAT RES-FUND MOL M, V707, P24, DOI 10.1016/j.mrfmmm.2010.12.003
   Bae S, 2011, MOL CELLS, V32, P243, DOI 10.1007/s10059-011-1037-z
   Banaudha K, 2011, HEPATOLOGY, V53, P53, DOI 10.1002/hep.24016
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Barh D, 2010, CURR ONCOL, V17, P70
   Beveridge NJ, 2009, CELL SIGNAL, V21, P1837, DOI 10.1016/j.cellsig.2009.07.019
   Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880
   Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349
   Braconi C, 2010, CLIN CANCER RES, V16, P957, DOI 10.1158/1078-0432.CCR-09-2123
   Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595
   Büssing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Cao Z, 2012, J CANCER RES CLIN, V138, P611, DOI 10.1007/s00432-011-1140-8
   Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chan LS, 2009, EUR J PHARM SCI, V38, P370, DOI 10.1016/j.ejps.2009.08.008
   Chang KH, 2011, INT J COLORECTAL DIS, V26, P1415, DOI 10.1007/s00384-011-1279-4
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Chen JQ, 2012, MED ONCOL, V29, P2527, DOI 10.1007/s12032-011-0117-4
   Chen LT, 2012, MED ONCOL, V29, P1673, DOI 10.1007/s12032-011-0083-x
   Chen WS, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-17
   Chen X, 2012, INT J CANCER, V130, P1620, DOI 10.1002/ijc.26177
   Chen Y, 2011, CANCER PREV RES, V4, P76, DOI 10.1158/1940-6207.CAPR-10-0167
   Cheng HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017745
   Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129
   Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60
   Christensen BC, 2010, CLIN CANCER RES, V16, P3713, DOI 10.1158/1078-0432.CCR-10-0657
   Christensen BC, 2009, CARCINOGENESIS, V30, P1003, DOI 10.1093/carcin/bgp099
   Chu YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039777
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102
   Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069
   Cui E. H., 2012, ACTA PHARM SIN
   Dai XN, 2012, MOL MED REP, V5, P1299, DOI 10.3892/mmr.2012.815
   Davidson LA, 2009, CARCINOGENESIS, V30, P2077, DOI 10.1093/carcin/bgp245
   Davidson MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012560
   Davis CD, 2011, J NUTRIGENET NUTRIGE, V4, P1, DOI 10.1159/000324175
   Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855
   Dhar S, 2011, MOL NUTR FOOD RES, V55, P1219, DOI 10.1002/mnfr.201100141
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Fix Lindsey N., 2010, Cancer Genomics & Proteomics, V7, P261
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Frezzetti D, 2011, ONCOGENE, V30, P275, DOI 10.1038/onc.2010.416
   Gaedicke S, 2008, FEBS LETT, V582, P3542, DOI 10.1016/j.febslet.2008.09.032
   Gao G., 2012, CANCER
   Gao LB, 2011, BREAST CANCER RES TR, V125, P571, DOI 10.1007/s10549-010-0993-x
   Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170
   Giovannetti E, 2012, CRIT REV ONCOL HEMAT, V81, P103, DOI 10.1016/j.critrevonc.2011.03.010
   Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104
   Gocek E, 2011, CANCER RES, V71, P6230, DOI 10.1158/0008-5472.CAN-11-1717
   Gong M, 2012, NEURO-ONCOLOGY, V14, P1007, DOI 10.1093/neuonc/nos124
   Greenberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027400
   Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687
   Guo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030585
   Guo LJ, 2012, INT J MOL MED, V30, P680, DOI 10.3892/ijmm.2012.1021
   Habbe N, 2009, CANCER BIOL THER, V8, P340, DOI 10.4161/cbt.8.4.7338
   Haider KH, 2010, CARDIOVASC RES, V88, P168, DOI 10.1093/cvr/cvq151
   Han ZY, 2012, CARCINOGENESIS, V33, P131, DOI 10.1093/carcin/bgr226
   Han ZB, 2012, J CANCER RES CLIN, V138, P153, DOI 10.1007/s00432-011-1076-z
   Hennessey PT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032307
   Hoffman AE, 2009, CANCER RES, V69, P5970, DOI 10.1158/0008-5472.CAN-09-0236
   Horikawa Y, 2008, CLIN CANCER RES, V14, P7956, DOI 10.1158/1078-0432.CCR-08-1199
   Hu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016221
   Hur K., 2012, GUT
   Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111
   Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630
   Inoue T, 2012, ONCOL REP, V27, P1759, DOI 10.3892/or.2012.1709
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Issabekova A, 2012, BIOINFORMATION, V8, P513, DOI 10.6026/97320630008513
   Ivanovska I, 2008, CELL CYCLE, V7, P3137, DOI 10.4161/cc.7.20.6923
   Izzotti A, 2012, MUTAT RES-REV MUTAT, V751, P287, DOI 10.1016/j.mrrev.2012.05.004
   Izzotti A, 2010, CARCINOGENESIS, V31, P894, DOI 10.1093/carcin/bgq037
   Izzotti A, 2010, CANCER PREV RES, V3, P62, DOI 10.1158/1940-6207.CAPR-09-0202
   Izzotti A, 2009, FASEB J, V23, P3243, DOI 10.1096/fj.09-135251
   Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384
   Jay C, 2007, DNA CELL BIOL, V26, P293, DOI 10.1089/dna.2006.0554
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Jung EJ, 2012, CANCER-AM CANCER SOC, V118, P2603, DOI 10.1002/cncr.26565
   Karaayvaz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035158
   Kato M, 2009, ONCOGENE, V28, P2419, DOI 10.1038/onc.2009.106
   Kawasaki Hiroaki, 2003, Nucleic Acids Res Suppl, P243
   Keklikoglou I, 2012, ONCOGENE, V31, P4150, DOI 10.1038/onc.2011.571
   Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Kunte DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045591
   Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982
   Landi MT, 2010, CLIN CANCER RES, V16, P430, DOI 10.1158/1078-0432.CCR-09-1736
   Lanza G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-54
   Le XF, 2010, CANCER MICROENVIRON, V3, P137, DOI 10.1007/s12307-010-0037-4
   Lee JA, 2011, J BREAST CANCER, V14, P269, DOI 10.4048/jbc.2011.14.4.269
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Li C, 2012, ANN SURG ONCOL
   Li LQ, 2012, CELL PHYSIOL BIOCHEM, V30, P631, DOI 10.1159/000341444
   Li YZ, 2011, ONCOL LETT, V2, P991, DOI 10.3892/ol.2011.351
   Li Y, 2009, BRAIN RES, V1286, P13, DOI 10.1016/j.brainres.2009.06.053
   Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792
   Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298
   Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X
   Liang D, 2010, CANCER RES, V70, P9765, DOI 10.1158/0008-5472.CAN-10-0130
   Lin D, 2011, J INT MED RES, V39, P1870, DOI 10.1177/147323001103900530
   Lin LF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043304
   Link A, 2010, CANCER EPIDEM BIOMAR, V19, P1766, DOI 10.1158/1055-9965.EPI-10-0027
   Liu DC, 2011, IEEE INT C BIO BIO W, P440, DOI 10.1109/BIBMW.2011.6112411
   Liu HS, 2012, CANCER LETT, V316, P196, DOI 10.1016/j.canlet.2011.10.034
   Liu K, 2011, J INT MED RES, V39, P2288, DOI 10.1177/147323001103900626
   Liu LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019139
   Liu R, 2011, EUR J CANCER, V47, P784, DOI 10.1016/j.ejca.2010.10.025
   Liu XG, 2012, MED ONCOL, V29, P618, DOI 10.1007/s12032-011-9923-y
   Liu ZL, 2013, MOL CELL BIOCHEM, V372, P35, DOI 10.1007/s11010-012-1443-3
   Lopez-Camarillo C, 2012, INT J MOL SCI, V13, P1347, DOI 10.3390/ijms13021347
   Lu YZ, 2011, J BIOL CHEM, V286, P42292, DOI 10.1074/jbc.M111.270926
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Majid S, 2010, CANCER RES, V70, P2809, DOI 10.1158/0008-5472.CAN-09-4176
   Marsit CJ, 2006, CANCER RES, V66, P10843, DOI 10.1158/0008-5472.CAN-06-1894
   Mascaux C, 2009, EUR RESPIR J, V33, P352, DOI 10.1183/09031936.00084108
   Mavrakis KJ, 2010, NAT CELL BIOL, V12, P372, DOI 10.1038/ncb2037
   Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284
   Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Miah S, 2012, BRIT J CANCER, V107, P123, DOI 10.1038/bjc.2012.221
   Michael A, 2010, ORAL DIS, V16, P34, DOI 10.1111/j.1601-0825.2009.01604.x
   Mohri T, 2009, INT J CANCER, V125, P1328, DOI 10.1002/ijc.24459
   Moltzahn F, 2011, CANCER RES, V71, P550, DOI 10.1158/0008-5472.CAN-10-1229
   Moretti F, 2010, RNA, V16, P2493, DOI 10.1261/rna.2384610
   Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065
   Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900
   Noratto GD, 2011, FITOTERAPIA, V82, P557, DOI 10.1016/j.fitote.2011.01.013
   Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710
   Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001
   Papaconstantinou IG, 2012, PANCREAS
   Parasramka MA, 2012, MOL CARCINOGEN, V51, P213, DOI 10.1002/mc.20822
   Park NJ, 2009, CLIN CANCER RES, V15, P5473, DOI 10.1158/1078-0432.CCR-09-0736
   Parker LP, 2009, EUR J GYNAECOL ONCOL, V30, P616
   Pelletier C, 2010, EXPERT REV MOL DIAGN, V10, P817, DOI [10.1586/erm.10.59, 10.1586/ERM.10.59]
   Peng S, 2010, DIGEST DIS SCI, V55, P2288, DOI 10.1007/s10620-009-1007-x
   Peng XJ, 2010, J CELL BIOCHEM, V110, P1324, DOI 10.1002/jcb.22646
   Permuth-Wey J, 2011, CANCER EPIDEM BIOMAR, V20, P1793, DOI 10.1158/1055-9965.EPI-11-0397
   Pichler M, 2012, BRIT J CANCER, V106, P1826, DOI 10.1038/bjc.2012.175
   Preis M, 2011, CLIN CANCER RES, V17, P5812, DOI 10.1158/1078-0432.CCR-11-0695
   Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7
   Qiu LX, 2011, CYTOKINE, V56, P695, DOI 10.1016/j.cyto.2011.09.001
   Ranade AR, 2010, J THORAC ONCOL, V5, P1273, DOI 10.1097/JTO.0b013e3181dea6be
   Rao AV, 2002, EXP BIOL MED, V227, P908, DOI 10.1177/153537020222701011
   Raponi M, 2009, CANCER RES, V69, P5776, DOI 10.1158/0008-5472.CAN-09-0587
   Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698
   Ren Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-27
   Resnick KE, 2009, GYNECOL ONCOL, V112, P55, DOI 10.1016/j.ygyno.2008.08.036
   Rimbach G, 2010, MOLECULES, V15, P1746, DOI 10.3390/molecules15031746
   Rossi Annalisa, 2010, BMC Res Notes, V3, P24, DOI 10.1186/1756-0500-3-24
   Rothé F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020980
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007
   Russ R, 2012, PULM MED, V2012, DOI 10.1155/2012/791234
   Saini S, 2011, CANCER PREV RES, V4, P1698, DOI 10.1158/1940-6207.CAPR-11-0267
   Saito M, 2011, CLIN CANCER RES, V17, P1875, DOI 10.1158/1078-0432.CCR-10-2961
   Saleem M, 2009, CANCER LETT, V285, P109, DOI 10.1016/j.canlet.2009.04.033
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Sarveswaran S, 2010, INT J ONCOL, V36, P1419, DOI 10.3892/ijo_00000627
   Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106
   Schrauder MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029770
   Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106
   Shin VY, 2011, CARCINOGENESIS, V32, P240, DOI 10.1093/carcin/bgq240
   Shukla Y, 2007, ASIAN PAC J CANCER P, V8, P155
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Slaby O, 2012, J CELL MOL MED, V16, P8, DOI 10.1111/j.1582-4934.2011.01359.x
   Smits KM, 2011, CLIN CANCER RES, V17, P7723, DOI 10.1158/1078-0432.CCR-11-0990
   Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1
   Song YX, 2012, INT J CANCER, V131, P1042, DOI 10.1002/ijc.26485
   Stenvang Jan, 2012, Silence, V3, P1, DOI 10.1186/1758-907X-3-1
   Sun GH, 2009, RNA, V15, P1640, DOI 10.1261/rna.1560209
   Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272
   Sun QM, 2009, ONCOL REP, V22, P563, DOI 10.3892/or_00000472
   Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207
   Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419
   Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029
   Terao M, 2011, J BIOL CHEM, V286, P4027, DOI 10.1074/jbc.M110.184994
   Tian T, 2010, INT J MOL EPIDEMIOL, V1, P358
   Tian T, 2009, CANCER EPIDEM BIOMAR, V18, P1183, DOI 10.1158/1055-9965.EPI-08-0814
   Tili E, 2011, J NUCLEIC ACIDS, V2011, DOI 10.4061/2011/102431
   Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108
   Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003
   Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143
   Tomimaru Y, 2012, J HEPATOL, V56, P167, DOI 10.1016/j.jhep.2011.04.026
   Tsang WP, 2010, J NUTR BIOCHEM, V21, P140, DOI 10.1016/j.jnutbio.2008.12.003
   Tzur G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003726
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2
   Verbrugge I, 2011, EPIGENOMICS-UK, V3, P547, DOI [10.2217/EPI.11.82, 10.2217/epi.11.82]
   Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181
   Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109
   Wang B, 2012, J CANCER RES CLIN, V138, P1659, DOI 10.1007/s00432-012-1244-9
   Wang F, 2012, PLOS ONE, V7
   Wang F, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039623, DOI 10.1371/J0URNAL.P0NE.0039623.PUBMED:22761848]
   Wang F, 2012, MOL BIOL REP, V39, P269, DOI 10.1007/s11033-011-0735-0
   Wang HK, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029452, 10.1371/journal.pone.0041330, 10.1371/journal.pone.0038619]
   Wang H, 2011, CARCINOGENESIS, V32, P1881, DOI 10.1093/carcin/bgr218
   Wang J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-227
   Wang JB, 2012, MUTAGENESIS, V27, P779, DOI 10.1093/mutage/ges052
   Wang J, 2012, MOL BIOL REP, V39, P4571, DOI 10.1007/s11033-011-1247-7
   Wang LL, 2009, HUM REPROD, V24, P562, DOI 10.1093/humrep/den439
   Wang LN, 2012, GENE, V508, P9, DOI 10.1016/j.gene.2012.08.005
   Wang LG, 2012, CANCER EPIDEMIOL, V36, pE61, DOI 10.1016/j.canep.2011.05.002
   Wang PY, 2012, EXP THER MED, V3, P324, DOI 10.3892/etm.2011.399
   Wang TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043268
   Wang V, 2009, BIODRUGS, V23, P15, DOI 10.2165/00063030-200923010-00002
   Wang XC, 2011, LUNG CANCER, V72, P92, DOI 10.1016/j.lungcan.2010.07.014
   Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309
   Wang XN, 2009, CELL CYCLE, V8, P736, DOI 10.4161/cc.8.5.7870
   Wang Y, 2012, GENE, V509, P267, DOI 10.1016/j.gene.2012.08.008
   Wang Z, 2012, PLOS ONE, V7, DOI DOI 10.1371/J0URNAL.P0NE.0040039.PUBMED:22768213
   Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405
   Wei Juan, 2011, Chin J Cancer, V30, P407
   Weiss GJ, 2008, ANN ONCOL, V19, P1053, DOI 10.1093/annonc/mdn006
   Wen XY, 2009, PHYTOTHER RES, V23, P778, DOI 10.1002/ptr.2616
   White NMA, 2011, NAT REV CLIN ONCOL, V8, P75, DOI 10.1038/nrclinonc.2010.173
   Whitlock NC, 2012, NUTR CANCER, V64, P493, DOI 10.1080/01635581.2012.667862
   WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4
   Wilting SM, 2013, ONCOGENE, V32, P106, DOI 10.1038/onc.2012.20
   Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   Wu N, 2011, ACTA PHARMACOL SIN, V32, P345, DOI 10.1038/aps.2010.220
   Wulfken LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025787
   Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764
   Xie Y, 2010, LUNG CANCER, V67, P170, DOI 10.1016/j.lungcan.2009.04.004
   Xu WM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019120
   Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang CH, 2013, INT J CANCER, V132, P116, DOI 10.1002/ijc.27657
   Yang J, 2010, MED ONCOL, V27, P1114, DOI 10.1007/s12032-009-9344-3
   Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954
   Yin KJ, 2012, J BIOL CHEM, V287, P27055, DOI 10.1074/jbc.M112.364414
   Young DD, 2010, J AM CHEM SOC, V132, P7976, DOI 10.1021/ja910275u
   Yu HB, 2012, J VIROL, V86, P3088, DOI 10.1128/JVI.05901-11
   Yu ZB, 2007, NUCLEIC ACIDS RES, V35, P4535, DOI 10.1093/nar/gkm480
   Zhang AM, 2011, UROLOGY, V78, DOI 10.1016/j.urology.2011.03.030
   Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246
   Zhang J, 2010, ONCOL REP, V24, P1217, DOI 10.3892/or_00000975
   Zhang Siyuan, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P239, DOI 10.2174/1568011053765976
   Zhang SY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/936030
   Zhang T, 2012, MOL CARCINOG
   Zhang W, 2011, ANN ONCOL, V22, P104, DOI 10.1093/annonc/mdq315
   Zhang XJ, 2012, TUMOR BIOL, V33, P2349, DOI 10.1007/s13277-012-0497-x
   Zhang Y, 2012, Hepatology
   Zhao FL, 2012, J INT MED RES, V40, P859, DOI 10.1177/147323001204000304
   Zhao LQ, 2012, CARCINOGENESIS, V33, P2220, DOI 10.1093/carcin/bgs235
   Zhou X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039011, 10.1371/journal.pone.0043230]
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
   Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4
NR 267
TC 32
Z9 33
U1 0
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD JUN
PY 2013
VL 13
IS 5
BP 519
EP 541
PG 23
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 161KK
UT WOS:000320191600005
PM 23597193
DA 2025-01-12
ER

PT J
AU Sonaglio, V
   de Carvalho, AC
   Toledo, SRC
   Salinas-Souza, C
   Carvalho, AL
   Petrilli, AS
   de Camargo, B
   Vettore, AL
AF Sonaglio, Viviane
   de Carvalho, Ana C.
   Toledo, Silvia R. C.
   Salinas-Souza, Carolina
   Carvalho, Andre L.
   Petrilli, Antonio S.
   de Camargo, Beatriz
   Vettore, Andre L.
TI Aberrant DNA methylation of <i>ESR1</i> and <i>p14ARF</i> genes could be
   useful as prognostic indicators in osteosarcoma
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE DNA methylation; ESR1; hypermethylation; osteosarcoma; p14ARF
ID HIGH-GRADE OSTEOSARCOMA; PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR;
   BREAST-CANCER; LUNG-CANCER; CPG ISLAND; OSTEOGENIC-SARCOMA; MULTIPLE
   GENES; SURVIVAL; ESTROGEN
AB Osteosarcoma (OS) is the eighth most common form of childhood and adolescence cancer. Approximately 10%-20% of patients present metastatic disease at diagnosis and the 5-year overall survival remains around 70% for nonmetastatic patients and around 30% for metastatic patients. Metastatic disease at diagnosis and the necrosis grade induced by preoperative treatment are the only well-established prognostic factors for osteosarcoma. The DNA aberrant methylation is a frequent epigenetic alteration in humans and has been described as a molecular marker in different tumor types. This study evaluated the DNA aberrant methylation status of 18 genes in 34 OS samples without previous chemotherapy treatment and in four normal bone specimens and compared the methylation profile with clinicopathological characteristics of the patients. We were able to define a three-gene panel (AIM1, p14ARF, and ESR1) in which methylation was correlated with OS cases. The hypermethylation of p14ARF showed a significant association with the absence of metastases at diagnoses, while ESR1 hypermethylation was marginally associated with worse overall survival. This study demonstrated that aberrant promoter methylation is a common event in OS and provides evidence that p14ARF and ESR1 hypermethylation could be useful as a prognostic indicator for this disease.
C1 [Sonaglio, Viviane] AC Camargo Hosp, Dept Pediat, Sao Paulo, Brazil.
   [de Carvalho, Ana C.; Vettore, Andre L.] Univ Fed Sao Paulo, Dept Biol Sci, Diadema, Brazil.
   [Toledo, Silvia R. C.; Salinas-Souza, Carolina; Petrilli, Antonio S.] Univ Fed Sao Paulo, GRAACC, Dept Pediat, Pediat Oncol Inst, Sao Paulo, Brazil.
   [Toledo, Silvia R. C.; Salinas-Souza, Carolina] Univ Fed Sao Paulo, Dept Morphol & Genet, Sao Paulo, Brazil.
   [Carvalho, Andre L.] Barretos Canc Hosp, Dept Head & Neck Surg, PIO Fdn 12, Sao Paulo, Brazil.
   [de Camargo, Beatriz] Inst Nacl Canc, Res Program Pediat Oncol Program, CPNq, Rio De Janeiro, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); A.C.Camargo Cancer Center;
   Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Hospital
   de Cancer de Barretos; National Cancer Institute (Inca)
RP Vettore, AL (通讯作者)，Univ Fed Sao Paulo, Lab Mol Canc Biol, Rua Pedro Toledo,669-11 Andar, BR-04039032 Sao Paulo, Brazil.
EM andre.vettore@gmail.com
RI Petrilli, Antonio/B-7906-2012; Vettore, Andre/J-5168-2012; Toledo,
   Silvia/C-2470-2012; de Camargo, Beatriz/I-8414-2014; de Carvalho, Ana
   Carolina/Q-4055-2019; Lopes Carvalho, Andre/S-7053-2016; Salinas-Souza,
   Carolina/I-5351-2012
OI de Camargo, Beatriz/0000-0002-5794-1042; de Carvalho, Ana
   Carolina/0000-0002-0114-7659; INCT de Optica Basica e Aplicada as
   Ciencias da Vida (CNPq), CePOF (FAPESP)/0000-0002-6403-4037; Lopes
   Carvalho, Andre/0000-0001-7214-6402; Salinas-Souza,
   Carolina/0000-0002-9489-7888
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Edital
   Universal (CNPq) [472193/2004-0]; Fundacao Antonio Prudente (FAP); CNPq
   [472193/2004-0]
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Edital Universal (CNPq) grant 472193/2004-0
   (to ALV). VS was the recipient of a fellowship from Fundacao Antonio
   Prudente (FAP). ALV received a fellowship from CNPq, grant
   472193/2004-0. The authors thank the tumor bank of A C Camargo Hospital
   for kindly providing tumor samples to be examined in this study.
CR Batanian JR, 2002, J CLIN PATHOL-MOL PA, V55, P389, DOI 10.1136/mp.55.6.389
   Begum S, 2011, CLIN CANCER RES, V17, P4494, DOI 10.1158/1078-0432.CCR-10-3436
   Benassi MS, 2001, CANCER-AM CANCER SOC, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X
   Bielack S, 2008, ANN ONCOL, V19, P94, DOI 10.1093/annonc/mdn102
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455
   Brait M, 2008, CANCER EPIDEM BIOMAR, V17, P2786, DOI 10.1158/1055-9965.EPI-08-0192
   Buddingh EP, 2010, PEDIATR BLOOD CANCER, V54, P216, DOI 10.1002/pbc.22293
   Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581-200810050-00005
   Cui Q, 2011, PATHOL ONCOL RES, V17, P587, DOI 10.1007/s12253-010-9354-7
   de Carvalho F, 2009, INT J CANCER, V125, P1985, DOI 10.1002/ijc.24431
   Eads CA, 2001, CANCER RES, V61, P3410
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferrari S, 2007, CURR OPIN ONCOL, V19, P341, DOI 10.1097/CCO.0b013e328122d73f
   FLETCHER JA, 1994, CANCER GENET CYTOGEN, V77, P81, DOI 10.1016/0165-4608(94)90154-6
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Gorlick R, 2009, CANC TREAT, V152, P467, DOI 10.1007/978-1-4419-0284-9_27
   Harden SV, 2003, CLIN CANCER RES, V9, P1370
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hou P, 2006, CANCER-AM CANCER SOC, V106, P1602, DOI 10.1002/cncr.21762
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jaffe N, 2009, CANCER TREAT RES, V152, P219, DOI 10.1007/978-1-4419-0284-9_11
   Jerónimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292
   Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lewis IJ, 2007, JNCI-J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015
   Lim G, 2005, GENE CHROMOSOME CANC, V42, P392, DOI 10.1002/gcc.20157
   Lim S, 2003, ONCOL REP, V10, P897
   Lima F, 2004, BONE, V35, P1127, DOI 10.1016/j.bone.2004.07.005
   Loyo M, 2011, INT J CANCER, V128, P1393, DOI 10.1002/ijc.25443
   Mankin HJ, 2004, CLIN ORTHOP RELAT R, P286, DOI 10.1097/01.blo.0000145991.65770.e6
   Müller HM, 2003, CANCER RES, V63, P7641
   Oh JH, 2006, CLIN ORTHOP RELAT R, P216, DOI 10.1097/01.blo.0000188063.56091.69
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1
   Patiño-García A, 2003, J PEDIAT HEMATOL ONC, V25, P362, DOI 10.1097/00043426-200305000-00003
   Petrilli AS, 2006, J CLIN ONCOL, V24, P1161, DOI 10.1200/JCO.2005.03.5352
   QUELLE DE, 1995, CELL, V83, P993
   Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229
   Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457
   Sailasree R, 2008, CANCER EPIDEM BIOMAR, V17, P414, DOI 10.1158/1055-9965.EPI-07-0284
   Sakamoto A, 2008, REV RECENT CLIN TRIA, V3, P228, DOI 10.2174/157488708785700267
   Selvarajah S, 2007, CANCER GENET CYTOGEN, V179, P52, DOI 10.1016/j.cancergencyto.2007.08.003
   Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682
   Susman E, 2005, ONCOL TIMES, V27, P37
   Tarkkanen M, 1999, INT J CANCER, V84, P114, DOI 10.1002/(SICI)1097-0215(19990420)84:2<114::AID-IJC4>3.0.CO;2-Q
   Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1
   Vidal DO, 2007, LEUKEMIA RES, V31, P175, DOI 10.1016/j.leukres.2006.06.013
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
NR 54
TC 17
Z9 20
U1 0
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2013
VL 6
BP 713
EP 723
DI 10.2147/OTT.S44918
PG 11
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA 164VC
UT WOS:000320437500001
PM 23836983
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Lu, D
   Dong, D
   Zhou, Y
   Lu, M
   Pang, XW
   Li, Y
   Tian, XJ
   Zhang, Y
   Zhang, J
AF Lu, Dan
   Dong, Dong
   Zhou, Yu
   Lu, Min
   Pang, Xue-Wen
   Li, Yan
   Tian, Xiao-Jun
   Zhang, Yu
   Zhang, Jun
TI The Tumor-Suppressive Function of <i>UNC5D</i> and Its Repressed
   Expression in Renal Cell Carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID EPIGENETIC INACTIVATION; CANCER SUSCEPTIBILITY; DEPENDENCE RECEPTORS;
   NETRIN-1 RECEPTOR; BLADDER-CANCER; BREAST-CANCER; KIDNEY CANCER;
   GROWTH-FACTOR; LUNG-CANCER; SFRP GENES
AB Purpose: As a newly added member of the UNC5H receptors, the function of UNC5D/H4 in tumorigenesis remains poorly defined. The aim of this study was to examine the expression of UNC5D in primary renal cell carcinomas (RCC), analyze the mechanisms responsible for its downregulation in RCC, and assess its functional relevance to tumor growth and migration.
   Experimental Design: Forty-four paired primary RCCs and corresponding adjacent noncancerous tissues were collected. The mRNA and protein expression level of UNC5D was assessed by reverse transcriptase-PCR, real-time PCR, or immunohistochemistry. Epigenetic alterations in UNC5D promoter and LOH in the UNC5D locus were also analyzed. Ectopic expression of UNC5D in renal cancer cells with silenced expression of UNC5D was used for analysis of the biologic functions of UNC5D.
   Results: UNC5D expression was attenuated in multiple carcinoma cell lines including renal cancer cells. Similar reduction was also observed in primary RCC tissues as compared with paired adjacent noncancerous tissues. Methylation-specific PCR showed hypermethylation in UNC5D promoter in a significant proportion (18 of 44) of tumor tissue (40.9%). LOH of UNC5D was observed in 13 of 44 patients with RCCs (29.5%). Restoration of UNC5D expression in renal cancer cells significantly inhibited cell proliferation, anchorage-dependent and -independent growth, as well as migration and invasion, whereas knockdown of UNC5D promoted cell growth. Furthermore, ectopic expression of UNC5D induced G(2)-M cell-cycle arrest.
   Conclusions: UNC5D is a functional tumor suppressor that is frequently downregulated in RCCs due to promoter hypermethylation and LOH. (c) 2013 AACR.
C1 [Lu, Dan; Dong, Dong; Zhou, Yu; Pang, Xue-Wen; Li, Yan; Zhang, Yu; Zhang, Jun] Peking Univ, Hlth Sci Ctr, Dept Immunol, Key Lab Med Immunol,Minist Hlth, Beijing 100191, Peoples R China.
   [Lu, Min] Peking Univ, Hlth Sci Ctr, Dept Pathol, Sch Basic Med Sci, Beijing 100191, Peoples R China.
   [Tian, Xiao-Jun] Peking Univ, Hosp 3, Dept Urol, Beijing 100191, Peoples R China.
C3 Peking University; Peking University; Peking University
RP Zhang, J (通讯作者)，Peking Univ, Hlth Sci Ctr, Dept Immunol, Beijing 100191, Peoples R China.
EM zhangyu007@hsc.pku.edu.cn; junzhang@bjmu.edu.cn
RI dong, Dong/JFJ-3808-2023; Tian, Xiaojun/M-9242-2014
OI Lu, Dan/0000-0002-3000-5094
FU National Basic Research Program of China [2011CB946103]; Beijing
   Municipal Natural Science Foundation [7122104]; National Natural Science
   Foundation of China [81072395]
FX This work received support from the National Basic Research Program of
   China (2011CB946103), Beijing Municipal Natural Science Foundation
   (7122104), and the National Natural Science Foundation of China
   (81072395).
CR Ando K, 2012, MOL CELL, V47, P681, DOI 10.1016/j.molcel.2012.06.024
   Atschekzei F, 2012, EPIGENETICS-US, V7, P447, DOI 10.4161/epi.19614
   Baldewijns MML, 2008, BBA-REV CANCER, V1785, P133, DOI 10.1016/j.bbcan.2007.12.002
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bernet A, 2007, GASTROENTEROLOGY, V133, P1840, DOI 10.1053/j.gastro.2007.08.009
   Bosque A, 2008, J LEUKOCYTE BIOL, V84, P488, DOI 10.1189/jlb.0108043
   Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629
   Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172
   Dancey JE, 2012, CELL, V148, P409, DOI 10.1016/j.cell.2012.01.014
   Delloye-Bourgeois C, 2009, J EXP MED, V206, P833, DOI 10.1084/jem.20082299
   Delloye-Bourgeois C, 2009, JNCI-J NATL CANCER I, V101, P237, DOI 10.1093/jnci/djn491
   Doostzadeh-Cizeron J, 2001, J BIOL CHEM, V276, P1127, DOI 10.1074/jbc.M006944200
   Eisen T, 2012, JNCI-J NATL CANCER I, V104, P93, DOI 10.1093/jnci/djr511
   Engelkamp D, 2002, MECH DEVELOP, V118, P191, DOI 10.1016/S0925-4773(02)00248-4
   Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741
   Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128
   George DJ, 2003, NEW ENGL J MED, V349, P419, DOI 10.1056/NEJMp030061
   GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85
   Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13
   Goode EL, 2011, CANCER EPIDEM BIOMAR, V20, P1638, DOI 10.1158/1055-9965.EPI-11-0455
   Hibi K, 2009, WORLD J SURG, V33, P1053, DOI 10.1007/s00268-008-9909-x
   Hoffman AM, 2011, EPIGENOMICS-UK, V3, P19, DOI 10.2217/EPI.10.64
   Jin HF, 2007, NEOPLASIA, V9, P471, DOI 10.1593/neo.07175
   Kagara I, 2008, J UROLOGY, V180, P343, DOI 10.1016/j.juro.2008.02.044
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Liu PY, 2012, MOL CANCER RES, V10, P66, DOI 10.1158/1541-7786.MCR-10-0540
   Loginov VI, 2009, MOL BIOL+, V43, P1014, DOI 10.1134/S0026893309060156
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Lv D, 2011, EUR J CANCER, V47, P2068, DOI 10.1016/j.ejca.2011.04.021
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Mehlen Patrick, 2005, Journal de la Societe de Biologie, V199, P211, DOI 10.1051/jbio:2005022
   Melchor L, 2007, INT J CANCER, V120, P714, DOI 10.1002/ijc.22354
   Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064
   Pantuck AJ, 2003, CLIN CANCER RES, V9, P4641
   Paradisi A, 2010, CELL CYCLE, V9, P1253, DOI 10.4161/cc.9.7.11072
   Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4
   Sogabe Y, 2008, INT J ONCOL, V32, P1253
   Thiébault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100
   Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220
   Wang H, 2008, BIOCHEM BIOPH RES CO, V370, P594, DOI 10.1016/j.bbrc.2008.03.152
   Williams SV, 2010, GENE CHROMOSOME CANC, V49, P642, DOI 10.1002/gcc.20775
NR 43
TC 15
Z9 19
U1 0
U2 23
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2013
VL 19
IS 11
BP 2883
EP 2892
DI 10.1158/1078-0432.CCR-12-2978
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 155FF
UT WOS:000319732000014
PM 23589179
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Moestue, SA
   Dam, CG
   Gorad, SS
   Kristian, A
   Bofin, A
   Mælandsmo, GM
   Engebråten, O
   Gribbestad, IS
   Bjorkoy, G
AF Moestue, Siver A.
   Dam, Cornelia G.
   Gorad, Saurabh S.
   Kristian, Alexandr
   Bofin, Anna
   Maelandsmo, Gunhild M.
   Engebraten, Olav
   Gribbestad, Ingrid S.
   Bjorkoy, Geir
TI Metabolic biomarkers for response to PI3K inhibition in basal-like
   breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID PHOSPHATIDYLINOSITOL 3-KINASE PATHWAY; CHOLINE KINASE;
   PHOSPHOLIPID-METABOLISM; LUMINAL-LIKE; LUNG-CANCER; PTEN; MUTATIONS;
   GROWTH; TISSUE; CELLS
AB Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in cancer cells through numerous mutations and epigenetic changes. The recent development of inhibitors targeting different components of the PI3K pathway may represent a valuable treatment alternative. However, predicting efficacy of these drugs is challenging, and methods for therapy monitoring are needed. Basal-like breast cancer (BLBC) is an aggressive breast cancer subtype, frequently associated with PI3K pathway activation. The objectives of this study were to quantify the PI3K pathway activity in tissue sections from xenografts representing basal-like and luminal-like breast cancer before and immediately after treatment with PI3K inhibitors, and to identify metabolic biomarkers for treatment response.
   Methods: Tumor-bearing animals (n = 8 per treatment group) received MK-2206 (120 mg/kg/day) or BEZ235 (50 mg/kg/day) for 3 days. Activity in the PI3K/Akt/mammalian target of rapamycin pathway in xenografts and human biopsies was evaluated using a novel method for semiquantitative assessment of Akt(ser473) phosphorylation. Metabolic changes were assessed by ex vivo high-resolution magic angle spinning magnetic resonance spectroscopy.
   Results: Using a novel dual near-infrared immunofluorescent imaging method, basal-like xenografts had a 4.5-fold higher baseline level of pAkt(ser473) than luminal-like xenografts. Following treatment, basal-like xenografts demonstrated reduced levels of pAkt(ser473) and decreased proliferation. This correlated with metabolic changes, as both MK-2206 and BEZ235 reduced lactate concentration and increased phosphocholine concentration in the basal-like tumors. BEZ235 also caused increased glucose and glycerophosphocholine concentrations. No response to treatment or change in metabolic profile was seen in luminal-like xenografts. Analyzing tumor sections from five patients with BLBC demonstrated that two of these patients had an elevated pAkt(ser473) level.
   Conclusion: The activity of the PI3K pathway can be determined in tissue sections by quantitative imaging using an antibody towards pAkt(ser473). Long-term treatment with MK-2206 or BEZ235 resulted in significant growth inhibition in basal-like, but not luminal-like, xenografts. This indicates that PI3K inhibitors may have selective efficacy in basal-like breast cancer with increased PI3K signaling, and identifies lactate, phosphocholine and glycerophosphocholine as potential metabolic biomarkers for early therapy monitoring. In human biopsies, variable pAkt(ser473) levels were observed, suggesting heterogeneous PI3K signaling activity in BLBC.
C1 [Moestue, Siver A.; Gorad, Saurabh S.; Gribbestad, Ingrid S.] NTNU, MI Lab, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway.
   [Moestue, Siver A.] St Olavs Univ Hosp, N-7006 Trondheim, Norway.
   [Dam, Cornelia G.; Bofin, Anna] NTNU, Dept Lab Med Childrens & Womens Hlth, N-7491 Trondheim, Norway.
   [Kristian, Alexandr; Maelandsmo, Gunhild M.; Engebraten, Olav] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, N-0310 Oslo, Norway.
   [Engebraten, Olav] Univ Oslo, Dept Oncol, N-0318 Oslo, Norway.
   [Bjorkoy, Geir] Univ Coll Sor Trondelag HiST, Dept Technol, N-7004 Trondheim, Norway.
C3 Norwegian University of Science & Technology (NTNU); Norwegian
   University of Science & Technology (NTNU); Norwegian University of
   Science & Technology (NTNU); University of Oslo; University of Oslo;
   Norwegian University of Science & Technology (NTNU)
RP Moestue, SA (通讯作者)，NTNU, MI Lab, Dept Circulat & Med Imaging, POB 8905, N-7491 Trondheim, Norway.
EM siver.a.moestue@ntnu.no
RI Moestue, Siver/F-2369-2015; Mælandsmo, Gunhild Mari/AFV-4446-2022
OI Bjorkoy, Geir/0000-0003-0031-8361; Maelandsmo, Gunhild
   Mari/0000-0002-4797-1600; Moestue, Siver Andreas/0000-0002-1940-5695
FU Research Council of Norway [183379, 186479]; Liaison Committee between
   St. Olavs University Hospital; Faculty of Medicine, NTNU; Norwegian
   Cancer Society; Norwegian Breast Cancer Society [171656 PR-2009-270,
   2209215-2011]; Dutch VSB funds
FX The authors wish to thank Heike Immervoll for discussion and material
   for the initial set-up of the Akt immunostaining method, and Borgny
   Ytterhus, Unn Granli and Jostein Halgunset for training and access both
   to their laboratory and expertise in histology. Kristine Pettersen, Anna
   van der Vein and Sonja Andersen are thanked for their excellent
   laboratory assistance. Per Eystein Lonning and Ragnhild Lothe are
   thanked for valuable discussions and access to clinical material for
   development of the NIR scanning method. The work presented was supported
   by the Research Council of Norway (grants 183379 and 186479), the
   Liaison Committee between St. Olavs University Hospital and the Faculty
   of Medicine, NTNU, the Norwegian Cancer Society and the Norwegian Breast
   Cancer Society (grants 171656 PR-2009-270 and 2209215-2011) and a
   student grant to CGD from the Dutch VSB funds.
CR Aboagye EO, 1999, CANCER RES, V59, P80
   Al-Saffar NMS, 2010, CANCER RES, V70, P5507, DOI 10.1158/0008-5472.CAN-09-4476
   Baker AF, 2005, CLIN CANCER RES, V11, P4338, DOI 10.1158/1078-0432.CCR-05-0422
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Beckner ME, 2005, LAB INVEST, V85, P1457, DOI 10.1038/labinvest.3700355
   Beloueche-Babari M, 2006, MOL CANCER THER, V5, P187, DOI 10.1158/1535-7163.MCT-03-0220
   Beloueche-Babari M, 2011, CELL CYCLE, V10, P2883, DOI 10.4161/cc.10.17.17192
   Beloueche-Babari M, 2010, ONCOTARGET, V1, P185
   Bergamaschi A, 2009, MOL ONCOL, V3, P469, DOI 10.1016/j.molonc.2009.07.003
   Chung YL, 2008, NEOPLASIA, V10, P303, DOI 10.1593/neo.07834
   Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162
   Glunde K, 2011, NMR BIOMED, V24, P673, DOI 10.1002/nbm.1751
   Glunde K, 2010, CHEM REV, V110, P3043, DOI 10.1021/cr9004007
   Grinde MT, 2011, NMR BIOMED, V24, P1243, DOI 10.1002/nbm.1683
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012
   Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317
   Huuse EM, 2012, J MAGN RESON IMAGING, V35, P1098, DOI 10.1002/jmri.23507
   JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114
   Keshari KR, 2011, NMR BIOMED, V24, P691, DOI 10.1002/nbm.1738
   Klawitter J, 2009, BRIT J PHARMACOL, V158, P588, DOI 10.1111/j.1476-5381.2009.00345.x
   Koul D, 2010, NEURO-ONCOLOGY, V12, P559, DOI 10.1093/neuonc/nop058
   Kurhanewicz J, 2011, NEOPLASIA, V13, P81, DOI 10.1593/neo.101102
   López-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Marty B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2204
   Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039
   Moestue SA, 2011, MOL ONCOL, V5, P224, DOI 10.1016/j.molonc.2011.04.001
   Moestue S, 2009, CONTRAST MEDIA MOL I, V4, P73, DOI 10.1002/cmmi.264
   Moestue SA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-433
   Moestue SA, 2012, P NATL ACAD SCI USA, V109, pE2506, DOI 10.1073/pnas.1208226109
   Moulder SL, 2010, CLIN BREAST CANCER, V10, pS66, DOI 10.3816/CBC.2010.s.014
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Panupinthu N, 2010, BRIT J CANCER, V102, P941, DOI 10.1038/sj.bjc.6605588
   Park JB, 2012, NAT REV CANCER, V12, P782, DOI 10.1038/nrc3379
   Podo F, 2011, NMR BIOMED, V24, P648, DOI 10.1002/nbm.1658
   Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510
   Ramírez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489
   Rodríguez-González A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062
   Sankaranarayanapillai M, 2006, MOL CANCER THER, V5, P1325, DOI 10.1158/1535-7163.MCT-05-0494
   Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706
   Serganova I, 2011, CLIN CANCER RES, V17, P6250, DOI 10.1158/1078-0432.CCR-11-0397
   Sitter B, 2006, NMR BIOMED, V19, P30, DOI 10.1002/nbm.992
   Skaland I, 2007, MODERN PATHOL, V20, P1307, DOI 10.1038/modpathol.3800972
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854
   Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   WARBURG O, 1956, SCIENCE, V124, P269
   Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42
   Wen ZH, 2013, ONCOGENE, V32, P160, DOI 10.1038/onc.2012.47
   Wijnen JP, 2010, NMR BIOMED, V23, P968, DOI 10.1002/nbm.1523
   Yalcin A, 2010, ONCOGENE, V29, P139, DOI 10.1038/onc.2009.317
   Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x
NR 61
TC 41
Z9 45
U1 1
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2013
VL 15
IS 1
AR R16
DI 10.1186/bcr3391
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 160ZC
UT WOS:000320158100025
PM 23448424
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Choudhury, S
   Almendro, V
   Merino, VF
   Wu, ZH
   Maruyama, R
   Su, Y
   Martins, FC
   Fackler, MJ
   Bessarabova, M
   Kowalczyk, A
   Conway, T
   Beresford-Smith, B
   Macintyre, G
   Cheng, YK
   Lopez-Bujanda, Z
   Kaspi, A
   Hu, R
   Robens, J
   Nikolskaya, T
   Haakensen, VD
   Schnitt, SJ
   Argani, P
   Ethington, G
   Panos, L
   Grant, M
   Clark, J
   Herlihy, W
   Lin, SJ
   Chew, G
   Thompson, EW
   Greene-Colozzi, A
   Richardson, AL
   Rosson, GD
   Pike, M
   Garber, JE
   Nikolsky, Y
   Blum, JL
   Au, A
   Hwang, ES
   Tamimi, RM
   Michor, F
   Haviv, I
   Liu, XS
   Sukumar, S
   Polyak, K
AF Choudhury, Sibgat
   Almendro, Vanessa
   Merino, Vanessa F.
   Wu, Zhenhua
   Maruyama, Reo
   Su, Ying
   Martins, Filipe C.
   Fackler, Mary Jo
   Bessarabova, Marina
   Kowalczyk, Adam
   Conway, Thomas
   Beresford-Smith, Bryan
   Macintyre, Geoff
   Cheng, Yu-Kang
   Lopez-Bujanda, Zoila
   Kaspi, Antony
   Hu, Rong
   Robens, Judith
   Nikolskaya, Tatiana
   Haakensen, Vilde D.
   Schnitt, Stuart J.
   Argani, Pedram
   Ethington, Gabrielle
   Panos, Laura
   Grant, Michael
   Clark, Jason
   Herlihy, William
   Lin, S. Joyce
   Chew, Grace
   Thompson, Erik W.
   Greene-Colozzi, April
   Richardson, Andrea L.
   Rosson, Gedge D.
   Pike, Malcolm
   Garber, Judy E.
   Nikolsky, Yuri
   Blum, Joanne L.
   Au, Alfred
   Hwang, E. Shelley
   Tamimi, Rulla M.
   Michor, Franziska
   Haviv, Izhak
   Liu, X. Shirley
   Sukumar, Saraswati
   Polyak, Kornelia
TI Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a
   p27<SUP>+</SUP> Cell Population with Progenitor Characteristics
SO CELL STEM CELL
LA English
DT Article
ID HORMONE-INDUCED PROTECTION; GENE-EXPRESSION; STEM-CELLS; MUTATION
   CARRIERS; GENOMIC SIGNATURE; PREGNANCY; P27(KIP1); INHIBITOR; GROWTH;
   TUMORIGENESIS
AB Early full-term pregnancy is one of the most effective natural protections against breast cancer. To investigate this effect, we have characterized the global gene expression and epigenetic profiles of multiple cell types from normal breast tissue of nulliparous and parous women and carriers of BRCA1 or BRCA2 mutations. We found significant differences in CD44(+) progenitor cells, where the levels of many stem cell-related genes and pathways, including the cell-cycle regulator p27, are lower in parous women without BRCA1/BRCA2 mutations. We also noted a significant reduction in the frequency of CD44(+)p27(+) cells in parous women and showed, using explant cultures, that parity-related signaling pathways play a role in regulating the number of p27(+) cells and their proliferation. Our results suggest that pathways controlling p27(+) mammary epithelial cells and the numbers of these cells relate to breast cancer risk and can be explored for cancer risk assessment and prevention.
C1 [Choudhury, Sibgat; Almendro, Vanessa; Maruyama, Reo; Su, Ying; Martins, Filipe C.; Garber, Judy E.; Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
   [Wu, Zhenhua; Cheng, Yu-Kang; Michor, Franziska; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
   [Greene-Colozzi, April; Richardson, Andrea L.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
   [Garber, Judy E.] Dana Farber Canc Inst, Ctr Clin Canc Genet, Boston, MA 02215 USA.
   [Choudhury, Sibgat; Almendro, Vanessa; Maruyama, Reo; Su, Ying; Hu, Rong; Garber, Judy E.; Tamimi, Rulla M.; Polyak, Kornelia] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Richardson, Andrea L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Choudhury, Sibgat; Almendro, Vanessa; Maruyama, Reo; Su, Ying; Garber, Judy E.; Polyak, Kornelia] Harvard Univ, Dept Med, Boston, MA 02115 USA.
   [Robens, Judith; Schnitt, Stuart J.; Richardson, Andrea L.] Harvard Univ, Dept Pathol, Boston, MA 02115 USA.
   [Wu, Zhenhua; Cheng, Yu-Kang; Tamimi, Rulla M.; Michor, Franziska; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Almendro, Vanessa] Hosp Clin Barcelona, Dept Med, Inst Invest Biomed August Pi & Sunyer, E-08036 Barcelona, Spain.
   [Merino, Vanessa F.; Fackler, Mary Jo; Lopez-Bujanda, Zoila; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
   [Argani, Pedram] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA.
   [Rosson, Gedge D.] Johns Hopkins Univ, Sch Med, Dept Plast Surg, Baltimore, MD 21231 USA.
   [Martins, Filipe C.] Coimbra Univ Hosp, Dept Obstet & Gynaecol, P-3000354 Coimbra, Portugal.
   [Martins, Filipe C.] Programa Gulbenkian Formacao Med Avancada, P-1067001 Lisbon, Portugal.
   [Bessarabova, Marina; Nikolskaya, Tatiana; Nikolsky, Yuri] Thomson Reuters Healthcare & Sci, Encinitas, CA 92024 USA.
   [Kowalczyk, Adam; Conway, Thomas; Beresford-Smith, Bryan; Macintyre, Geoff; Haviv, Izhak] Univ Melbourne, NICTA Victoria Res Lab, Parkville, Vic 3010, Australia.
   [Kowalczyk, Adam] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic 3010, Australia.
   [Kowalczyk, Adam; Conway, Thomas; Beresford-Smith, Bryan; Macintyre, Geoff] Univ Melbourne, Dept Comp Sci & Software Engn, Parkville, Vic 3010, Australia.
   [Lin, S. Joyce; Haviv, Izhak] Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia.
   [Chew, Grace; Thompson, Erik W.] Univ Melbourne, Dept Surg, Parkville, Vic 3010, Australia.
   [Thompson, Erik W.] Univ Melbourne, Dept Biochem, Parkville, Vic 3010, Australia.
   [Kaspi, Antony; Haviv, Izhak] Baker IDI Heart & Diabet Inst, Prahran, Vic 3004, Australia.
   [Robens, Judith; Schnitt, Stuart J.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA.
   [Haakensen, Vilde D.] Univ Oslo, Oslo Univ Hosp, Dept Genet, Inst Canc Res, N-0424 Oslo, Norway.
   [Haakensen, Vilde D.] Univ Oslo, Oslo Univ Hosp, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, N-0424 Oslo, Norway.
   [Ethington, Gabrielle; Panos, Laura; Grant, Michael; Clark, Jason; Herlihy, William; Blum, Joanne L.] Baylor Charles A Sammons Canc Ctr, Dallas, TX 75246 USA.
   [Thompson, Erik W.] St Vincents Inst, Fitzroy, Vic 3065, Australia.
   [Pike, Malcolm] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
   [Au, Alfred; Hwang, E. Shelley] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   [Haviv, Izhak] Peter MacCallum Canc Ctr, East Melbourne, Vic 3002, Australia.
   [Polyak, Kornelia] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Dana-Farber Cancer Institute; Harvard
   University; Brigham & Women's Hospital; Harvard University; Brigham &
   Women's Hospital; Harvard University; Harvard University; Harvard
   University; Harvard T.H. Chan School of Public Health; University of
   Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Clarivate; University of Melbourne; University of Melbourne;
   University of Melbourne; University of Melbourne; University of
   Melbourne; University of Melbourne; Baker Heart and Diabetes Institute;
   Harvard University; Beth Israel Deaconess Medical Center; University of
   Oslo; University of Oslo; Baylor University Medical Center; Texas
   Oncology-Baylor Charles A Sammons Cancer Center; St. Vincent's Institute
   of Medical Research; University of Southern California; University of
   California System; University of California San Francisco; UCSF Medical
   Center; UCSF Helen Diller Family Comprehensive Cancer Center; Peter
   Maccallum Cancer Center; Harvard University
RP Sukumar, S (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
EM saras@jhmi.edu; kornelia_polyak@dfci.harvard.edu
RI Haviv, Izhak/E-3782-2015; Rosson, Gedge/I-5918-2013; Nikolskaya,
   Tatiana/M-5008-2013; Liu, X Shirley/JQI-9418-2023; Polyak,
   Kornelia/ACJ-5837-2022; Chen, yafang/GVS-0304-2022; WU,
   ZHEN/GRN-7688-2022; Thompson, Erik Walter/A-1425-2009
OI Su, Ying/0000-0003-0462-3865; Thompson, Erik Walter/0000-0002-9723-4924;
   WU, ZHEN/0000-0001-8719-057X; Lopez Bujanda, Zoila/0000-0001-5729-7309;
   Kaspi, Antony/0000-0001-6576-5862; Correia Martins,
   Filipe/0000-0001-6459-8206; Rosson, Gedge/0000-0003-1817-9443;
   Macintyre, Geoff/0000-0003-3906-467X; Haakensen, Vilde
   Drageset/0000-0003-0864-3628
FU Avon Foundation; National Cancer Institute [P50 CA89383, P01 CA080111,
   CA116235-04S1, CA087969]; Susan G. Komen Foundation; Terri Brodeur
   Foundation; US Army Congressionally Directed Research
   [W81XWH-07-1-0294]; Victorian Breast Cancer Research Consortium; St.
   Vincent's Hospital Research Endowment Fund; Victorian Government's OIS
   Program; Programme for Advanced Medical Education; Fundacao Calouste
   Gulbenkian; Cellex Foundation
FX We thank Lisa Cameron in the DFCI Confocal and Light Microscopy Core
   Facility, members of Dr. Massimo Loda's lab for technical assistance,
   members of our laboratories and Drs. Elgene Lim and David Livingston for
   their critical reading of this manuscript, Jonathan Yingling (Eli Lilly)
   for providing the LY2109761 TGF-beta receptor kinase inhibitor, Drs.
   Sally Knox, Jeffrey Lamont, and Dao Tuoc (Baylor University Medical
   Center-Baylor Sammons Cancer Center), Erin Bowlby (University of
   California San Francisco, San Francisco), and Drs. Eli Golomg and
   Pikarski (Hadassah Medical Centre) for their help with collecting tissue
   samples from patients with BRCA1/BRCA2 germline mutation. Samples from
   the Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer
   Center were used in this study. We thank contributors, including Indiana
   University who collected samples used in this study, as well as donors
   and their families, whose help and participation made this work
   possible. This work was supported by the Avon Foundation (to K. P. and
   S. S.), the National Cancer Institute P50 CA89383 and P01 CA080111 (to
   S.J.S., K. P., and A. L. R.), CA116235-04S1 (to K. P.), and CA087969 (to
   R. M. T.), the Susan G. Komen Foundation (to R. M., Y.S., I. H., J.E.G.,
   and K. P.), the Terri Brodeur Foundation (to S. C.), US Army
   Congressionally Directed Research W81XWH-07-1-0294 (to K. P.), the
   Victorian Breast Cancer Research Consortium (to S.J.L., G. C., and E. W.
   T.), the St. Vincent's Hospital Research Endowment Fund and the
   Victorian Government's OIS Program (to E. W. T.), the Programme for
   Advanced Medical Education funded by Fundacao Calouste Gulbenkian (to F.
   M.), and the Cellex Foundation (to V.A.).
CR Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Asztalos S, 2010, CANCER PREV RES, V3, P301, DOI 10.1158/1940-6207.CAPR-09-0069
   Belitskaya-Lévy I, 2011, CANCER PREV RES, V4, P1457, DOI 10.1158/1940-6207.CAPR-11-0021
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Blakely CM, 2006, CANCER RES, V66, P6421, DOI 10.1158/0008-5472.CAN-05-4235
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019
   Boyd NF, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2423
   Brisken C, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003178
   Britt KL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2245
   Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335
   Chung K, 2012, BREAST CANCER RES TR, V132, P653, DOI 10.1007/s10549-011-1870-y
   Colditz GA, 2004, JNCI-J NATL CANCER I, V96, P218, DOI 10.1093/jnci/djh025
   Cox A, 2007, NAT GENET, V39, P352, DOI 10.1038/ng1981
   Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273
   D'Cruz CM, 2002, MOL ENDOCRINOL, V16, P2034, DOI 10.1210/me.2002-0073
   Davison EA, 2003, MOL ENDOCRINOL, V17, P2436, DOI 10.1210/me.2003-0199
   Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Ginger MR, 2003, BREAST CANCER RES, V5, P192, DOI 10.1186/bcr603
   GOING JJ, 1988, AM J PATHOL, V130, P193
   Haakensen VD, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-77
   Haakensen VD, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-332
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Key TJ, 2010, LANCET ONCOL, V11, P530, DOI 10.1016/S1470-2045(10)70095-4
   Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6
   Kowalczyk A, 2011, J COMPUT BIOL, V18, P391, DOI 10.1089/cmb.2010.0272
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Maruyama R, 2012, P NATL ACAD SCI USA, V109, P2820, DOI 10.1073/pnas.1010559107
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Maxwell KN, 2012, NAT REV CLIN ONCOL, V9, P520, DOI 10.1038/nrclinonc.2012.123
   Mitsuhashi T, 2001, P NATL ACAD SCI USA, V98, P6435, DOI 10.1073/pnas.111051398
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917
   Nikolsky Y, 2008, CANCER RES, V68, P9532, DOI 10.1158/0008-5472.CAN-08-3082
   Nikolsky Y, 2009, METHODS MOL BIOL, V563, P177, DOI 10.1007/978-1-60761-175-2_10
   Oesterle EC, 2011, CELL CYCLE, V10, P1237, DOI 10.4161/cc.10.8.15301
   Ohtsubo M, 2008, P NATL ACAD SCI USA, V105, P10396, DOI 10.1073/pnas.0800672105
   POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9
   Poynter JN, 2010, CANCER CAUSE CONTROL, V21, P839, DOI 10.1007/s10552-010-9510-0
   Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366
   Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181
   Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x
   Russo J, 2005, BREAST CANCER RES, V7, P131, DOI 10.1186/bcr1029
   Russo J, 2008, CANCER EPIDEM BIOMAR, V17, P51, DOI 10.1158/1055-9965.EPI-07-0678
   Russo J, 2012, INT J CANCER, V131, P1059, DOI 10.1002/ijc.27323
   Scollen S, 2011, CANCER EPIDEM BIOMAR, V20, P1112, DOI 10.1158/1055-9965.EPI-11-0062
   Shinde SS, 2010, CANCER-AM CANCER SOC, V116, P4933, DOI 10.1002/cncr.25443
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sivaraman L, 2002, J MAMMARY GLAND BIOL, V7, P77, DOI 10.1023/A:1015774524076
   Siwko SK, 2008, STEM CELLS, V26, P3205, DOI 10.1634/stemcells.2008-0103
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Taylor D, 2009, BREAST CANCER RES TR, V118, P161, DOI 10.1007/s10549-009-0322-4
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wu ZJ, 2010, GENOME RES, V20, P1730, DOI 10.1101/gr.108217.110
NR 58
TC 71
Z9 80
U1 1
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD JUL 3
PY 2013
VL 13
IS 1
BP 117
EP 130
DI 10.1016/j.stem.2013.05.004
PG 14
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 287VJ
UT WOS:000329570100017
PM 23770079
OA Green Accepted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Di Cello, F
   Cope, L
   Li, HL
   Jeschke, J
   Wang, W
   Baylin, SB
   Zahnow, CA
AF Di Cello, Francescopaolo
   Cope, Leslie
   Li, Huili
   Jeschke, Jana
   Wang, Wei
   Baylin, Stephen B.
   Zahnow, Cynthia A.
TI Methylation of the Claudin 1 Promoter Is Associated with Loss of
   Expression in Estrogen Receptor Positive Breast Cancer
SO PLOS ONE
LA English
DT Article
ID INVASIVE DUCTAL CARCINOMA; EPITHELIAL-CELLS; DNA-METHYLATION; JUNCTIONS;
   FEATURES; OCCLUDIN; SUBTYPE; BENIGN; TUMORS; GRADE
AB Downregulation of the tight junction protein claudin 1 is a frequent event in breast cancer and is associated with recurrence, metastasis, and reduced survival, suggesting a tumor suppressor role for this protein. Tumor suppressor genes are often epigenetically silenced in cancer. Downregulation of claudin 1 via DNA promoter methylation may thus be an important determinant in breast cancer development and progression. To investigate if silencing of claudin 1 has an epigenetic etiology in breast cancer we compared gene expression and methylation data from 217 breast cancer samples and 40 matched normal samples available through the Cancer Genome Atlas (TCGA). Moreover, we analyzed claudin 1 expression and methylation in 26 breast cancer cell lines. We found that methylation of the claudin 1 promoter CpG island is relatively frequent in estrogen receptor positive (ER+) breast cancer and is associated with low claudin 1 expression. In contrast, the claudin 1 promoter was not methylated in most of the ER-breast cancers samples and some of these tumors overexpress claudin 1. In addition, we observed that the demethylating agents, azacitidine and decitabine can upregulate claudin 1 expression in breast cancer cell lines that have a methylated claudin 1 promoter. Taken together, our results indicate that DNA promoter methylation is causally associated with downregulation of claudin 1 in a subgroup of breast cancer that includes mostly ER+ tumors, and suggest that epigenetic therapy to restore claudin 1 expression might represent a viable therapeutic strategy in this subtype of breast cancer.
C1 [Di Cello, Francescopaolo; Cope, Leslie; Li, Huili; Jeschke, Jana; Wang, Wei; Baylin, Stephen B.; Zahnow, Cynthia A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins, Sch Med, Baltimore, MD 21218 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Zahnow, CA (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins, Sch Med, Baltimore, MD 21218 USA.
EM zahnoci@jhmi.edu
RI cope, leslie/LTE-4234-2024
OI Wang, Wei/0000-0003-1339-4080; Jeschke, Jana/0000-0002-6047-2558
FU Flight Attendant Medical Research Institute [062544_YCSA, 072156_CIA];
   Safeway Foundation; Irving Hansen Foundation; Johns Hopkins Center in
   Urban Environmental Health Pilot Project Program; National Institutes of
   Health [P30 ES003819, P30 CA006973]
FX This study was supported by the Flight Attendant Medical Research
   Institute (062544_YCSA, 072156_CIA), the Safeway Foundation, the Irving
   Hansen Foundation, the Johns Hopkins Center in Urban Environmental
   Health Pilot Project Program, and The National Institutes of Health (P30
   ES003819, P30 CA006973). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Blanchard AA, 2009, VIRCHOWS ARCH, V454, P647, DOI 10.1007/s00428-009-0770-6
   Boireau S, 2007, CARCINOGENESIS, V28, P246, DOI 10.1093/carcin/bgl120
   Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433
   Cataldo VD, 2009, EXPERT REV ANTICANC, V9, P875, DOI 10.1586/ERA.09.61
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419
   Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391
   Gerhard R, 2012, BREAST, V21, P354, DOI 10.1016/j.breast.2012.03.001
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Gupta IR, 2010, CLIN GENET, V77, P314, DOI 10.1111/j.1399-0004.2010.01397.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Hoevel T, 2004, INT J CANCER, V108, P374, DOI 10.1002/ijc.11571
   Ignatoski KMW, 1999, BREAST CANCER RES TR, V54, P173, DOI 10.1023/A:1006135331912
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199
   Krämer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375
   Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Lu SL, 2013, MODERN PATHOL, V26, P485, DOI 10.1038/modpathol.2012.187
   Martínez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591
   Mineta K, 2011, FEBS LETT, V585, P606, DOI 10.1016/j.febslet.2011.01.028
   Morohashi S, 2007, INT J MOL MED, V20, P139
   Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897
   Ogoshi K, 2011, GENOMICS, V98, P280, DOI 10.1016/j.ygeno.2011.07.003
   Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x
   Ricardo S, 2012, HISTOL HISTOPATHOL, V27, P1283, DOI 10.14670/HH-27.1283
   Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397
   Santos FPS, 2010, EXPERT REV ANTICANC, V10, P9, DOI [10.1586/era.09.164, 10.1586/ERA.09.164]
   Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Stresemann C, 2008, MOL CANCER THER, V7, P2998, DOI 10.1158/1535-7163.MCT-08-0411
   Szasz AM, 2011, CLIN EXP METASTAS, V28, P55, DOI 10.1007/s10585-010-9357-5
   Tokés AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 39
TC 41
Z9 43
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 3
PY 2013
VL 8
IS 7
AR e68630
DI 10.1371/journal.pone.0068630
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 182HT
UT WOS:000321733000019
PM 23844228
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Nizialek, EA
   Peterson, C
   Mester, JL
   Downes-Kelly, E
   Eng, C
AF Nizialek, Emily A.
   Peterson, Charissa
   Mester, Jessica L.
   Downes-Kelly, Erinn
   Eng, Charis
TI Germline and somatic <i>KLLN</i> alterations in breast cancer
   dysregulate G2 arrest
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID EPIGENETIC REGULATION; SYNONYMOUS MUTATIONS; PTEN GENE; CHK1;
   SUSCEPTIBILITY; STABILITY; COWDEN; KILLIN; CHECKPOINT; EXPRESSION
AB PTEN is a well-described predisposition gene for Cowden syndrome (CS), a familial cancer syndrome characterized by a high risk of breast and other cancers. KLLN, which shares a bidirectional promoter with PTEN, causes cell cycle arrest and apoptosis. We previously identified germline hypermethylation of the KLLN promoter in 37 of PTEN mutation-negative CS/CS-like (CSL) patients. Patients with germline KLLN hypermethylation have an increased prevalence of breast and renal cancers when compared with PTEN mutation carriers. We have consequently sought to identify and characterize germline KLLN variants/mutations in CS/CSL and in apparently sporadic breast cancer patients. KLLN variants in CS/CSL patients are rare (1 of 136, 0.007). Interestingly, among 438 breast cancer patients, 13 (3) have germline KLLN variants when compared with none in 128 controls (P 0.049). Patients with KLLN variants have a family history of breast cancer when compared with those without (P 0.02). We demonstrate that germline KLLN variants dysregulate the cell cycle at G2. Of 24 breast carcinomas analyzed, 3 (13) have somatic KLLN hemizygous deletions, with somatic loss of the wild-type allele in a patient with germline KLLN p.Leu119Leu. Of 452 breast carcinomas in The Cancer Genome Atlas project, 93 (21) have KLLN hemizygous or homozygous deletions. This is the first study to associate germline KLLN variants with sporadic breast cancer and to recognize somatic KLLN deletions in breast carcinomas. Our observations suggest that KLLN may be a low penetrance susceptibility factor for apparently sporadic breast cancer.
C1 [Nizialek, Emily A.; Peterson, Charissa; Mester, Jessica L.; Eng, Charis] Cleveland Clin, Genom Med Inst, Cleveland, OH 44195 USA.
   [Nizialek, Emily A.; Peterson, Charissa; Mester, Jessica L.; Eng, Charis] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Mester, Jessica L.; Eng, Charis] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA.
   [Downes-Kelly, Erinn] Cleveland Clin, Dept Anat Pathol, Pathol & Lab Med Inst, Cleveland, OH 44195 USA.
   [Nizialek, Emily A.; Eng, Charis] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.
   [Eng, Charis] Case Western Reserve Univ, CASE Comprehens Canc Ctr, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation; Cleveland Clinic Foundation; University System of
   Ohio; Case Western Reserve University; University System of Ohio; Case
   Western Reserve University
RP Eng, C (通讯作者)，Cleveland Clin, Genom Med Inst, 9500 Euclid Ave,NE 50, Cleveland, OH 44195 USA.
EM engc@ccf.org
OI Eng, Charis/0000-0002-3693-5145
FU Breast Cancer Research Foundation
FX This work was supported, in part, by a grant from the Breast Cancer
   Research Foundation.
CR Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7
   Bennett KL, 2011, GENE CHROMOSOME CANC, V50, P654, DOI 10.1002/gcc.20887
   Bennett KL, 2010, JAMA-J AM MED ASSOC, V304, P2724, DOI 10.1001/jama.2010.1877
   Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chamary JV, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r75
   Cho YJ, 2008, P NATL ACAD SCI USA, V105, P5396, DOI 10.1073/pnas.0705410105
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dent P, 2011, MOL INTERV, V11, P133, DOI 10.1124/mi.11.2.11
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Feilotter HE, 1999, BRIT J CANCER, V79, P718, DOI 10.1038/sj.bjc.6690115
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976
   Gingold H, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.14
   Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177
   Han W, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-92
   He X, 2011, HUM MOL GENET, V20, P80, DOI 10.1093/hmg/ddq434
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Hemminki K, 2003, BREAST CANCER RES TR, V82, P17, DOI 10.1023/B:BREA.0000003871.38587.8b
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kuiper RP, 2010, CURR OPIN GENET DEV, V20, P282, DOI 10.1016/j.gde.2010.03.005
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Liu QH, 2000, GENE DEV, V14, P1448
   Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765
   McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238
   Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292
   Narod SA, 2006, ONCOGENE, V25, P5832, DOI 10.1038/sj.onc.1209870
   Nathanson KL, 2001, HUM MOL GENET, V10, P715, DOI 10.1093/hmg/10.7.715
   Ni Y, 2008, AM J HUM GENET, V83, P261, DOI 10.1016/j.ajhg.2008.07.011
   Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Schug J, 2002, CURRENT PROTOCOLS BI
   Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076
   Shukla SJ, 2005, PHARMACOGENOMICS, V6, P303, DOI 10.1517/14622416.6.3.303
   Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53
   Tan MH, 2012, CLIN CANCER RES, V18, P400, DOI 10.1158/1078-0432.CCR-11-2283
   Tan MH, 2011, AM J HUM GENET, V88, P42, DOI 10.1016/j.ajhg.2010.11.013
   Tang YF, 2006, CANCER RES, V66, P6139, DOI 10.1158/0008-5472.CAN-06-0772
   Thompson ER, 2012, BREAST CANCER RES TR, V134, P543, DOI 10.1007/s10549-012-2088-3
   Tsutsui S, 2005, ONCOLOGY-BASEL, V68, P398, DOI 10.1159/000086981
   Venkatachalam R, 2010, GASTROENTEROLOGY, V139, P2221, DOI 10.1053/j.gastro.2010.08.063
   Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657
   Weigman VJ, 2012, BREAST CANCER RES TR, V133, P865, DOI 10.1007/s10549-011-1846-y
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837
   Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037
   Zhang B, 2011, LANCET ONCOL, V12, P477, DOI 10.1016/S1470-2045(11)70076-6
NR 53
TC 17
Z9 19
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 15
PY 2013
VL 22
IS 12
BP 2451
EP 2461
DI 10.1093/hmg/ddt097
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 151AK
UT WOS:000319432800011
PM 23446638
OA Green Published
DA 2025-01-12
ER

PT J
AU Wang, SS
   Zhu, Y
   He, HY
   Liu, J
   Xu, L
   Zhang, H
   Liu, HO
   Liu, WS
   Liu, YD
   Pan, D
   Chen, L
   Wu, Q
   Xu, JJ
   Gu, JX
AF Wang, Shanshan
   Zhu, Yu
   He, Hongyong
   Liu, Jing
   Xu, Le
   Zhang, Heng
   Liu, Haiou
   Liu, Weisi
   Liu, Yidong
   Pan, Deng
   Chen, Lin
   Wu, Qian
   Xu, Jiejie
   Gu, Jianxin
TI Sorafenib suppresses growth and survival of hepatoma cells by
   accelerating degradation of enhancer of zeste homolog 2
SO CANCER SCIENCE
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA CELLS; AGGRESSIVE BREAST-CANCER;
   TRANSCRIPTIONAL REPRESSOR; TARGETED THERAPIES; PROSTATE-CANCER; HISTONE
   H3; EZH2; POLYCOMB; EXPRESSION; PATHWAY
AB Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing of target genes that regulate cancer cell growth and survival. It is overexpressed in hepatocellular carcinoma (HCC) with a clinical significance that remains obscure. Sorafenib, a multikinase inhibitor, has been used as a first-line therapeutic drug and shown clinical efficiency for advanced-stage HCC patients. In the present study, we found that sorafenib lowered the protein level of EZH2 through accelerating proteasome-mediated EZH2 degradation in hepatoma cells. Overexpression of EZH2 reversed sorafenib-induced cell growth arrest, cell cycle arrest, and cell apoptosis dependent on histone methyltransferase activity in hepatoma cells. More importantly, shRNA-mediated EZH2 knockdown or EZH2 inhibition with 3-deazaneplanocin A treatment promoted sorafenib-induced hepatoma cell growth arrest and apoptosis. Sorafenib altered the hepatoma epigenome by reducing EZH2 and H3K27 trimethylation. These results revealed a novel therapeutic mechanism underlying sorafenib treatment in suppressing hepatoma growth and survival by accelerating EZH2 degradation. Genetic deletion or pharmacological ablation of EZH2 made hepatoma cells more sensitive to sorafenib, which helps provide a strong framework for exploring innovative combined therapies for advanced-stage HCC patients.
C1 [Wang, Shanshan; Liu, Haiou; Liu, Weisi; Liu, Yidong; Pan, Deng; Chen, Lin; Wu, Qian; Xu, Jiejie; Gu, Jianxin] Fudan Univ, Shanghai Med Coll, Zhongshan Hosp, Dept Biochem & Mol Biol,Sch Basic Med Sci, Shanghai 200433, Peoples R China.
   [Zhu, Yu; Xu, Le] Fudan Univ, Shanghai Med Coll, Zhongshan Hosp, Dept Urol, Shanghai 200433, Peoples R China.
   [He, Hongyong; Zhang, Heng] Fudan Univ, Shanghai Med Coll, Zhongshan Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
   [Liu, Jing] Nantong Univ, Sch Med, Nantong, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Nantong University
RP Xu, JJ (通讯作者)，Fudan Univ, Shanghai Med Coll, Zhongshan Hosp, Dept Biochem & Mol Biol,Sch Basic Med Sci, Shanghai 200433, Peoples R China.
EM jjxufdu@fudan.edu.cn
RI Wang, Shanshan/D-2283-2014; Liu, Yidong/A-5855-2014; Liu,
   Haiou/AFS-2886-2022; Xu, Le/HDN-9623-2022; wu, qian/JOL-0074-2023; He,
   Hang/ABF-4074-2020
OI liu, weisi/0000-0002-4730-5448; HE, HONGYONG/0000-0001-7371-4133
FU State Key Project Specialized for Infectious Diseases of China
   [2012ZX10002-008, 2012ZX10002-012]; National Basic Research Program of
   China 973 Program [2012CB822104, 2010CB912104]; National High-Tech RD
   863 Program [2012AA020203]; National Natural Science Fund [30930025,
   31010103906, 31170766, 31100629, 31270863]
FX This work was supported by grants from the State Key Project Specialized
   for Infectious Diseases of China (Grant Nos. 2012ZX10002-008,
   2012ZX10002-012), the National Basic Research Program of China 973
   Program (Grant Nos. 2012CB822104, 2010CB912104), the National High-Tech
   R&D 863 Program (Grant No. 2012AA020203), and the National Natural
   Science Fund (Grant Nos. 30930025, 31010103906, 31170766, 31100629,
   31270863).
CR [Anonymous], CANC CELL
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen HN, 2011, NATURE, V478, P349, DOI 10.1038/nature10502
   Chen KF, 2010, CLIN CANCER RES, V16, P5189, DOI 10.1158/1078-0432.CCR-09-3389
   Chen Y, 2007, PROTEOMICS, V7, P3097, DOI 10.1002/pmic.200700019
   Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668
   Chen YL, 2011, HEPATOLOGY, V53, P1708, DOI 10.1002/hep.24254
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Chiba T, 2012, INT J CANCER, V130, P2557, DOI 10.1002/ijc.26264
   Coriat R, 2012, MOL CANCER THER, V11, P2284, DOI 10.1158/1535-7163.MCT-12-0093
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Liu HO, 2011, CANCER RES, V71, P7547, DOI 10.1158/0008-5472.CAN-11-2260
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Ma WW, 2009, CA-CANCER J CLIN, V59, P111, DOI 10.3322/caac.20003
   Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   Testoni B, 2011, ONCOGENE, V30, P2670, DOI 10.1038/onc.2010.635
   Thomas MB, 2005, J CLIN ONCOL, V23, P8093, DOI 10.1200/JCO.2004.00.1537
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623
   Weikert S, 2005, INT J MOL MED, V16, P349
   Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236
   Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515
   Xu JJ, 2012, GASTROENTEROLOGY, V143, P199, DOI 10.1053/j.gastro.2012.03.053
   Xu JJ, 2010, HEPATOLOGY, V52, P142, DOI 10.1002/hep.23613
   Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Zhang WJ, 2011, J IMMUNOL, V187, P1764, DOI 10.4049/jimmunol.1002315
   Zhang WJ, 2010, J IMMUNOL, V184, P6465, DOI 10.4049/jimmunol.0904016
   Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145
   Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30
NR 46
TC 26
Z9 30
U1 0
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD JUN
PY 2013
VL 104
IS 6
BP 750
EP 759
DI 10.1111/cas.12132
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 150PZ
UT WOS:000319404600014
PM 23421437
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Wang, L
   Zeng, XZ
   Chen, S
   Ding, LY
   Zhong, J
   Zhao, JC
   Wang, LG
   Sarver, A
   Koller, A
   Zhi, JZ
   Ma, YP
   Yu, JD
   Chen, JJ
   Huang, HJ
AF Wang, Lan
   Zeng, Xianzhuo
   Chen, Shuai
   Ding, Liya
   Zhong, Jian
   Zhao, Jonathan C.
   Wang, Liguo
   Sarver, Aaron
   Koller, Antonius
   Zhi, Jizu
   Ma, Yupo
   Yu, Jindan
   Chen, Junjie
   Huang, Haojie
TI BRCA1 is a negative modulator of the PRC2 complex
SO EMBO JOURNAL
LA English
DT Article
DE BRCA1; breast cancer; embryonic stem cell; epigenetic gene silencing;
   PRC2
ID EMBRYONIC STEM-CELLS; HISTONE METHYLTRANSFERASE ACTIVITY; EZH2
   SUPPRESSES METHYLATION; DNA-DAMAGE RESPONSE; H3 LYSINE 27;
   BREAST-CANCER; GENE-EXPRESSION; PROSTATE-CANCER; DEVELOPMENTAL
   REGULATORS; OVARIAN-CANCER
AB The Polycomb-repressive complex 2 (PRC2) is important for maintenance of stem cell pluripotency and suppression of cell differentiation by promoting histone H3 lysine 27 trimethylation (H3K27me3) and transcriptional repression of differentiation genes. Here we show that the tumour-suppressor protein BRCA1 interacts with the Polycomb protein EZH2 in mouse embryonic stem (ES) and human breast cancer cells. The BRCA1-binding region in EZH2 overlaps with the noncoding RNA (ncRNA)-binding domain, and BRCA1 expression inhibits the binding of EZH2 to the HOTAIR ncRNA. Decreased expression of BRCA1 causes genome-wide EZH2 re-targeting and elevates H3K27me3 levels at PRC2 target loci in both mouse ES and human breast cancer cells. BRCA1 deficiency blocks ES cell differentiation and enhances breast cancer migration and invasion in an EZH2-dependent manner. These results reveal that BRCA1 is a key negative modulator of PRC2 and that loss of BRCA1 inhibits ES cell differentiation and enhances an aggressive breast cancer phenotype by affecting PRC2 function.
C1 [Wang, Lan; Zeng, Xianzhuo; Ding, Liya; Zhong, Jian; Huang, Haojie] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
   [Wang, Lan; Zeng, Xianzhuo; Ding, Liya; Zhong, Jian; Huang, Haojie] Mayo Clin, Coll Med, Ctr Canc, Rochester, MN 55905 USA.
   [Chen, Shuai; Sarver, Aaron] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
   [Zhao, Jonathan C.; Yu, Jindan] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Wang, Liguo] Mayo Clin, Coll Med, Dept Biomed Stat & Informat, Rochester, MN 55905 USA.
   [Koller, Antonius; Zhi, Jizu; Ma, Yupo] SUNY Stony Brook, Dept Pathol, Med Ctr, Stony Brook, NY 11794 USA.
   [Chen, Junjie] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.
C3 Mayo Clinic; Mayo Clinic; University of Minnesota System; University of
   Minnesota Twin Cities; Northwestern University; Feinberg School of
   Medicine; Mayo Clinic; State University of New York (SUNY) System; Stony
   Brook University; University of Texas System; UTMD Anderson Cancer
   Center
RP Huang, HJ (通讯作者)，Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
EM huang.haojie@mayo.edu
RI Chen, Junjie/AAF-8762-2019; Zhong, Jian/H-8289-2015
OI Zhong, Jian/0000-0001-7157-603X; Ding, Liya/0000-0002-8106-1918; Wang,
   Liguo/0000-0003-2072-4826
FU National Institutes of Health [CA134514, CA130908, K99/R00CA129565];
   Department of Defense [W81XWH-09-1-622]; American Cancer Society
   [RSG-12-085-01]
FX We thank Mien-Chie Hung, Yi Zhang, Zhenkun Lou, Xiaohua Shen and Fergus
   Couch for plasmids and reagents; Shyam Sharan for matched Brca1
   wild-type, deficient and rescued mouse ES cells; and Jeffrey Simon and
   Aswathy Rai for providing purified PRC2 complexes. This work was
   supported in part by grants from the National Institutes of Health
   (CA134514 and CA130908 to HH and K99/R00CA129565 to JY), the Department
   of Defense (W81XWH-09-1-622 to HH) and the American Cancer Society (the
   Research Scholar Award RSG-12-085-01 to JY).
CR Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   Bohrer LR, 2010, ENDOCRINOLOGY, V151, P5136, DOI 10.1210/en.2010-0436
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chang SW, 2009, J CLIN INVEST, V119, P3160, DOI 10.1172/JCI39836
   Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0
   Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116
   Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107
   Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043
   Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2
   Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512
   Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831
   Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810
   Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r
   Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424
   Landeira D, 2010, NAT CELL BIOL, V12, P618, DOI 10.1038/ncb2065
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040
   Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105
   Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104
   Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Murphy M, 2010, AUK, V127, P1, DOI 10.1525/auk.2010.127.1.1
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788
   Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002
   Pereira CF, 2010, CELL STEM CELL, V6, P547, DOI 10.1016/j.stem.2010.04.013
   Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007
   Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Schorderet P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002071
   Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981
   Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6
   Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646
   Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Vassilopoulos A, 2008, INT J BIOL SCI, V4, P133, DOI 10.7150/ijbs.4.133
   Vissers JHA, 2012, J CELL SCI, V125, P3939, DOI 10.1242/jcs.107375
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284
   Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515
   Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021
   Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753
   Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
   Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371
NR 83
TC 97
Z9 103
U1 1
U2 32
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD MAY 29
PY 2013
VL 32
IS 11
BP 1584
EP 1597
DI 10.1038/emboj.2013.95
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 152WQ
UT WOS:000319562800010
PM 23624935
OA Green Published
DA 2025-01-12
ER

PT J
AU van Hoesel, AQ
   Sato, Y
   Elashoff, DA
   Turner, RR
   Giuliano, AE
   Shamonki, JM
   Kuppen, PJK
   van de Velde, CJH
   Hoon, DSB
AF van Hoesel, A. Q.
   Sato, Y.
   Elashoff, D. A.
   Turner, R. R.
   Giuliano, A. E.
   Shamonki, J. M.
   Kuppen, P. J. K.
   van de Velde, C. J. H.
   Hoon, D. S. B.
TI Assessment of DNA methylation status in early stages of breast cancer
   development
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; DNA methylation; premalignant; malignant potential
ID CARCINOMA IN-SITU; MIXED-EFFECTS MODEL; DUCTAL CARCINOMA; TUMOR; RISK;
   PROGRESSION; DISEASE; EXPRESSION; PHENOTYPE; PROMOTER
AB Background: Molecular pathways determining the malignant potential of premalignant breast lesions remain unknown. In this study, alterations in DNA methylation levels were monitored during benign, premalignant and malignant stages of ductal breast cancer development.
   Methods: To study epigenetic events during breast cancer development, four genomic biomarkers (Methylated-IN-Tumour (MINT) 17, MINT31, RAR beta 2 and RASSF1A) shown to represent DNA hypermethylation in tumours were selected. Laser capture microdissection was employed to isolate DNA from breast lesions, including normal breast epithelia (n = 52), ductal hyperplasia (n = 23), atypical ductal hyperplasia (n = 31), ductal carcinoma in situ (DCIS, n = 95) and AJCC stage I invasive ductal carcinoma (IDC, n = 34). Methylation Index (MI) for each biomarker was calculated based on methylated and unmethylated copy numbers measured by Absolute Quantitative Assessment Of Methylated Alleles (AQAMA). Trends in MI by developmental stage were analysed.
   Results: Methylation levels increased significantly during the progressive stages of breast cancer development; P-values are 0.0012, 0.0003, 0.012, <0.0001 and <0.0001 for MINT17, MINT31, RAR beta 2, RASSF1A and combined biomarkers, respectively. In both DCIS and IDC, hypermethylation was associated with unfavourable characteristics.
   Conclusion: DNA hypermethylation of selected biomarkers occurs early in breast cancer development, and may present a predictor of malignant potential.
C1 [van Hoesel, A. Q.; Sato, Y.; Hoon, D. S. B.] John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   [Elashoff, D. A.] Univ Calif Los Angeles, Dept Med, Stat Core, Los Angeles, CA 90095 USA.
   [Turner, R. R.; Shamonki, J. M.] Dept Pathol, Santa Monica, CA 90404 USA.
   [Giuliano, A. E.] St Johns Hlth Ctr, Margie Robert Petersen Breast Ctr, Santa Monica, CA 90404 USA.
   [Kuppen, P. J. K.; van de Velde, C. J. H.] Leiden Univ, Med Ctr, Dept Surg, NL-2333 ZA Leiden, Netherlands.
C3 John Wayne Cancer Institute; University of California System; University
   of California Los Angeles; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC
RP Hoon, DSB (通讯作者)，John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI van de Velde, Cornelis/AAY-8360-2020; Hoon, Dave/C-7146-2018; Kuppen,
   Peter/J-2342-2016
OI Kuppen, Peter/0000-0002-0294-3251; Hoon, Dave/0000-0003-1915-3683
FU Susan G. Komen Breast Cancer Foundation [BCTR0707528]; Leslie and Susan
   Gonda (Goldschmied) Foundation (Los Angeles, CA, USA); Associates of
   Breast and Prostate Cancer Studies (Los Angeles, CA, USA); Fashion
   Footwear Association of New York; Ruth and Martin H. Weil Fund
FX This study was supported by funding from Susan G. Komen Breast Cancer
   Foundation Grant# BCTR0707528 (DSBH), the Leslie and Susan Gonda
   (Goldschmied) Foundation (Los Angeles, CA, USA) (DSBH), Associates of
   Breast and Prostate Cancer Studies (Los Angeles, CA, USA) (DSBH), and
   Fashion Footwear Association of New York (DSBH), Ruth and Martin H. Weil
   Fund (DSBH). We thank the staff at the Department of Molecular Oncology,
   JWCI, for technical support.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Allred DC, 2012, J CLIN ONCOL, V30, P1268, DOI 10.1200/JCO.2010.34.0141
   Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675
   Allred DC, 2009, J NATL COMPR CANC S, V7, p6S1
   Bastogne T, 2010, J THEOR BIOL, V262, P544, DOI 10.1016/j.jtbi.2009.10.008
   BEITLER PJ, 1985, BIOMETRICS, V41, P991, DOI 10.2307/2530970
   Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L
   Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301
   Carlson RW, 2009, J NATL COMPR CANC NE, V7, P122, DOI 10.6004/jnccn.2009.0012
   Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6
   de Maat MFG, 2007, MOL CANCER RES, V5, P461, DOI 10.1158/1541-7786.MCR-06-0358
   Degnim AC, 2007, J CLIN ONCOL, V25, P2671, DOI 10.1200/JCO.2006.09.0217
   Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026
   Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457
   DUPONT WD, 1993, CANCER, V71, P1258, DOI 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I
   DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303
   Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Hartmann LC, 2005, NEW ENGL J MED, V353, P229, DOI 10.1056/NEJMoa044383
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Jeffrey SS, 2003, BREAST CANCER RES, V5, P320, DOI 10.1186/bcr655
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   JENSEN HM, 1976, SCIENCE, V191, P295, DOI 10.1126/science.1246614
   Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Meijnen P, 2008, BRIT J CANCER, V98, P137, DOI 10.1038/sj.bjc.6604112
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   MURPHY WA, 1978, RADIOLOGY, V127, P335, DOI 10.1148/127.2.335
   O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697
   PAGE DL, 1985, CANCER-AM CANCER SOC, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A
   PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0
   Rakovitch E, 2012, BRIT J CANCER, V106, P1160, DOI 10.1038/bjc.2012.41
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Roses RE, 2009, CANCER EPIDEM BIOMAR, V18, P1386, DOI 10.1158/1055-9965.EPI-08-1101
   Roy A, 2009, J BIOPHARM STAT, V19, P150, DOI 10.1080/10543400802535141
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sunami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018884
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V131, P859, DOI 10.1007/s10549-011-1485-3
   WELLINGS SR, 1973, J NATL CANCER I, V50, P1111, DOI 10.1093/jnci/50.5.1111
   WELLINGS SR, 1975, J NATL CANCER I, V55, P231
NR 47
TC 65
Z9 74
U1 7
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 28
PY 2013
VL 108
IS 10
BP 2033
EP 2038
DI 10.1038/bjc.2013.136
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 152WE
UT WOS:000319561300016
PM 23652305
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Ludwig, K
   Tse, ES
   Wang, JYJ
AF Ludwig, Kirsten
   Tse, Edison S.
   Wang, Jean Y. J.
TI Colon cancer cells adopt an invasive phenotype without mesenchymal
   transition in 3-D but not 2-D culture upon combined stimulation with EGF
   and crypt growth factors
SO BMC CANCER
LA English
DT Article
ID COLORECTAL CANCERS; DOWN-REGULATION; BREAST-CANCER; STEM-CELLS;
   EXPRESSION; PROLIFERATION; STIFFNESS; FLAT
AB Background: The intestinal crypt homeostasis is maintained by a combination of growth factors including Wnt, R-Spondin1, Noggin and the epidermal growth factor (EGF). In human colorectal cancer, the Wnt pathway is constitutively activated through genetic and epigenetic alterations in as many as 11 genes encoding components of this crypt stem-cell maintenance mechanism. Although the proliferation of colon cancer cells does not require Wnt, it is possible that colon cancer cells can still respond to the crypt growth factors in the colonic microenvironment. A number of studies have shown that epithelial cells behave differently in 3-D versus 2-D cultures. Because the 3-D conditions more closely mimic the in vivo environment, we examined the effects of Wnt and other crypt growth factors on colon cancer cell growth in 3-D culture.
   Methods: Colon cancer cells were grown in 3-D matrigel supplemented with different combinations of crypt growth factors and colonies were examined for morphology and pathways.
   Results: When colon cancer cells were cultured in 3-D with EGF, they grew as round spheroid colonies. However, colon cancer cells also grew as flat, disc-like colonies when cultured with EGF plus Wnt, R-Spondin1 and Noggin. Disc colonies were found to have comparable levels of E-cadherin as the spheroid colonies, but showed decreased E-cadherin at the cell-matrix contact sites. Disc colonies also elaborated F-actin rich protrusions (FRP) at the cell-matrix edge, reminiscent of an invasive phenotype but without the expression of vimentin. These E-cadherin and F-actin alterations were not induced by the four growth factors in 2-D culture. Formation of the disc colonies was inhibited by the knockdown of beta-catenin and by protein kinase inhibitors such as gefitinib, imatinib and MK-2206. Furthermore, withdrawal of the crypt growth factors was able to revert the disc colonies to spheroid growth, showing that the invasive phenotype was reversible dependent on the availability of growth factors.
   Conclusions: These findings show that colon cancer cells remain responsive to the growth factors in the crypt microenvironment and can be induced to undergo morphological transformation in the more physiologically relevant 3-D culture.
C1 [Ludwig, Kirsten; Tse, Edison S.; Wang, Jean Y. J.] Moores UCSD Canc Ctr, La Jolla, CA 92093 USA.
   [Wang, Jean Y. J.] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego
RP Wang, JYJ (通讯作者)，Moores UCSD Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.
EM jywang@ucsd.edu
RI Ludwig, Kirsten/LXB-2452-2024
FU NIH Cancer Cell Biology Training Grant [2T32CA067754-16A1]; NIH
   [CA058320]
FX We thank Dr. Tony Burgess at the Ludwig Cancer Research Institute in
   Melbourne, Australia for the generous gifts of the LIM1215, 1899, and
   2551 cells [12], Dr. Karl Willert for the 293 Wnt3a and R-Spondin1 cells
   [34], and the UCSD Neuroscience Microscopy Facility. KL was supported by
   the NIH Cancer Cell Biology Training Grant (2T32CA067754-16A1). This
   work was supported by an NIH RO1 (CA058320) to JYJW.
CR Bowman A, 2011, CANCER CELL, V20, P415, DOI 10.1016/j.ccr.2011.10.003
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Bujanda L, 2010, WORLD J GASTROENTERO, V16, P3103, DOI 10.3748/wjg.v16.i25.3103
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Feng Y, 2012, CELL PROLIFERAT, V45, P413, DOI 10.1111/j.1365-2184.2012.00837.x
   Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001
   Gao Y, 2006, CANCER RES, V66, P11623, DOI 10.1158/0008-5472.CAN-06-2629
   Gerber B, 2001, J CLIN ONCOL, V19, P960, DOI 10.1200/JCO.2001.19.4.960
   Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355
   Hu TH, 2010, J BIOL CHEM, V285, P13561, DOI 10.1074/jbc.M109.075945
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104
   Küntzer J, 2010, HUM MUTAT, V31, P407, DOI 10.1002/humu.21207
   Levental I, 2007, SOFT MATTER, V3, P299, DOI 10.1039/b610522j
   Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002
   Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nishioka M, 2013, MOL CARCINOGEN, V52, P207, DOI 10.1002/mc.21845
   Planutis K, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-12
   Qi LS, 2012, CANCER SCI, V103, P828, DOI 10.1111/j.1349-7006.2012.02222.x
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066
   Soetikno RM, 2008, JAMA-J AM MED ASSOC, V299, P1027, DOI 10.1001/jama.299.9.1027
   Solon J, 2007, BIOPHYS J, V93, P4453, DOI 10.1529/biophysj.106.101386
   Symons M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-213
   Takahashi T, 2007, MODERN PATHOL, V20, P139, DOI 10.1038/modpathol.3800722
   Ueno K, 2009, BRIT J CANCER, V101, P1374, DOI 10.1038/sj.bjc.6605307
   Uronis JM, 2007, CANCER RES, V67, P11594, DOI 10.1158/0008-5472.CAN-07-3242
   Wei Q, 2007, J BIOL CHEM, V282, P15903, DOI 10.1074/jbc.M701927200
   Zhang HH, 2009, INT J CANCER, V125, P297, DOI 10.1002/ijc.24289
NR 34
TC 18
Z9 21
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 2
PY 2013
VL 13
AR 221
DI 10.1186/1471-2407-13-221
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 154HD
UT WOS:000319663600001
PM 23638973
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lin, CY
   Hsiao, WC
   Wright, DE
   Hsu, CL
   Lo, YC
   Hsu, GSW
   Kao, CF
AF Lin, Chia-Yeh
   Hsiao, Wei-Chun
   Wright, Duncan Edward
   Hsu, Chia-Ling
   Lo, Yi-Chen
   Hsu, Guoo-Shyng Wang
   Kao, Cheng-Fu
TI Resveratrol activates the histone H2B ubiquitin ligase, RNF20, in
   MDA-MB-231 breast cancer cells
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Resveratrol; RNF20; H2B ubiquitylation; Breast cancer; p21; Cell growth
ID NF-KAPPA-B; GENE-EXPRESSION; EPIGENOMICS; RECEPTOR; GROWTH; SIRT1;
   CHEMOPREVENTION; TRANSCRIPTION; METHYLATION; PREVENTION
AB Resveratrol, a polyphenolic compound found in grapes, has been shown to partially exert its anti-cancer function through the modulation of epigenetic events. However, the epigenetic targets of resveratrol in breast cancer are not yet fully understood. Here, we identified that the gene encoding the histone H2B ubiquitin ligase RNF20 (ring finger protein 20), a chromatin modifying enzyme and putative tumour suppressor, is up-regulated by resveratrol in MDA-MB-231 breast cancer cells. Up-regulation of RNF20 is achieved through an increase of active histone marks around its promoter. The increase in RNF20 in MDA-MB-231 likely contributes to p21 regulation and the anti-growth effects of resveratrol, as RNF20 knockdown diminished these effects. Our findings suggest that RNF20 is a novel epigenetic target of resveratrol, and increase our understanding of how it contributes to the chemopreventive effect of resveratrol in a more aggressive breast cancer cell line, MDA-MB-231. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Lin, Chia-Yeh; Hsu, Guoo-Shyng Wang] Fu Jen Catholic Univ, Grad Inst Nutr & Food Sci, New Taipei City 24205, Taiwan.
   [Lin, Chia-Yeh; Hsiao, Wei-Chun; Wright, Duncan Edward; Hsu, Chia-Ling; Kao, Cheng-Fu] Acad Sinica, Inst Cellular & Organism Biol, Taipei 11529, Taiwan.
   [Lo, Yi-Chen] Natl Taiwan Univ, Inst Food Sci & Technol, Taipei 10617, Taiwan.
C3 Fu Jen Catholic University; Academia Sinica - Taiwan; National Taiwan
   University
RP Hsu, GSW (通讯作者)，Fu Jen Catholic Univ, Grad Inst Nutr & Food Sci, 510 Zhongzheng Rd, New Taipei City 24205, Taiwan.
EM leaflin@gate.sinica.edu.tw; carol1228_1@hotmail.com;
   dwright@gate.sinica.edu.tw; plusohsu@gmail.com; loyichen@ntu.edu.tw;
   002613@mail.fju.edu.tw; ckao@gate.sinica.e-du.tw
RI tang, cheng/KLD-8823-2024; Kao, Cheng-Fu/AAE-8400-2022
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bishayee A, 2009, CANCER PREV RES, V2, P409, DOI 10.1158/1940-6207.CAPR-08-0160
   Bourguignon LYW, 2009, J BIOL CHEM, V284, P2657, DOI 10.1074/jbc.M806708200
   Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970
   Buro LJ, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-16
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   Chang CY, 2012, J FUNCT FOODS, V4, P727, DOI 10.1016/j.jff.2012.04.012
   Chung EY, 2011, J NUTR BIOCHEM, V22, P902, DOI 10.1016/j.jnutbio.2010.07.012
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Espinosa JM, 2008, GENE DEV, V22, P2743, DOI 10.1101/gad.1732108
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Gao Z, 2011, BIOCHEM BIOPH RES CO, V407, P271, DOI 10.1016/j.bbrc.2011.02.008
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   Harikumar KB, 2008, CELL CYCLE, V7, P1020, DOI 10.4161/cc.7.8.5740
   Hoshino I, 2010, SURG TODAY, V40, P809, DOI 10.1007/s00595-010-4300-6
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604
   Katayose D, 1995, CLIN CANCER RES, V1, P889
   Kim J, 2005, MOL CELL, V20, P759, DOI 10.1016/j.molcel.2005.11.012
   Kundu JK, 2004, MUTAT RES-FUND MOL M, V555, P65, DOI 10.1016/j.mrfmmm.2004.05.019
   Kundu JK, 2008, CANCER LETT, V269, P243, DOI 10.1016/j.canlet.2008.03.057
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Le Corre L, 2005, MOL NUTR FOOD RES, V49, P462, DOI 10.1002/mnfr.200400094
   Lee MF, 2011, J AGR FOOD CHEM, V59, P11853, DOI 10.1021/jf202426k
   Lin JN, 2010, J AGR FOOD CHEM, V58, P1584, DOI 10.1021/jf9035782
   Liu PL, 2010, MOL NUTR FOOD RES, V54, pS196, DOI 10.1002/mnfr.200900550
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P
   Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016/j.biocel.2008.08.020
   Mao QQ, 2010, MOL NUTR FOOD RES, V54, P1574, DOI 10.1002/mnfr.200900392
   MICHEL E, 1988, MOL CELL ENDOCRINOL, V56, P71, DOI 10.1016/0303-7207(88)90010-X
   Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8
   Neven P, 2006, J CLIN ONCOL, V24, P2595, DOI 10.1200/JCO.2005.05.1334
   Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pennock S, 2008, MOL CELL BIOL, V28, P3020, DOI 10.1128/MCB.01809-07
   Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0
   Reid G, 2009, INT J BIOCHEM CELL B, V41, P155, DOI 10.1016/j.biocel.2008.08.028
   Ross SA, 2008, NUTR REV, V66, pS1, DOI 10.1111/j.1753-4887.2008.00055.x
   Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008
   Shema E, 2011, MOL CELL, V42, P477, DOI 10.1016/j.molcel.2011.03.011
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883
   Vanamala J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-238
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Youlden DR, 2012, CANCER EPIDEMIOL, V36, P237, DOI 10.1016/j.canep.2012.02.007
   Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403
   Zhu B, 2005, MOL CELL, V20, P601, DOI 10.1016/j.molcel.2005.09.025
NR 60
TC 14
Z9 14
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756-4646
EI 2214-9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD APR
PY 2013
VL 5
IS 2
BP 790
EP 800
DI 10.1016/j.jff.2013.01.025
PG 11
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 152MV
UT WOS:000319536700028
DA 2025-01-12
ER

PT J
AU Gertych, A
   Oh, JH
   Wawrowsky, KA
   Weisenberger, DJ
   Tajbakhsh, J
AF Gertych, Arkadiusz
   Oh, Jin Ho
   Wawrowsky, Kolja A.
   Weisenberger, Daniel J.
   Tajbakhsh, Jian
TI 3-D DNA methylation phenotypes correlate with cytotoxicity levels in
   prostate and liver cancer cell models
SO BMC PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE DNA methylation phenotype; Chromatin distribution; High-throughput cell
   assay; 3D image analysis; MethyLight; Repetitive element; Epigenetic
   drug
ID METHYLTRANSFERASE INHIBITORS; EPIGENETIC REGULATION; CPG ISLANDS;
   IN-VITRO; NUCLEAR-ORGANIZATION; MYELOID-LEUKEMIA; BREAST-CANCER; HISTONE
   H3; ZEBULARINE; HYPOMETHYLATION
AB Background: The spatial organization of the genome is being evaluated as a novel indicator of toxicity in conjunction with drug-induced global DNA hypomethylation and concurrent chromatin reorganization. 3D quantitative DNA methylation imaging (3D-qDMI) was applied as a cell-by-cell high-throughput approach to investigate this matter by assessing genome topology through represented immunofluorescent nuclear distribution patterns of 5-methylcytosine (MeC) and global DNA (4,6-diamidino-2-phenylindole = DAPI) in labeled nuclei.
   Methods: Differential progression of global DNA hypomethylation was studied by comparatively dosing zebularine (ZEB) and 5-azacytidine (AZA). Treated and untreated (control) human prostate and liver cancer cells were subjected to confocal scanning microscopy and dedicated 3D image analysis for the following features: differential nuclear MeC/DAPI load and codistribution patterns, cell similarity based on these patterns, and corresponding differences in the topology of low-intensity MeC (LIM) and low in intensity DAPI (LID) sites.
   Results: Both agents generated a high fraction of similar MeC phenotypes across applied concentrations. ZEB exerted similar effects at 10-100-fold higher drug concentrations than its AZA analogue: concentration-dependent progression of global cytosine demethylation, validated by measuring differential MeC levels in repeat sequences using MethyLight, and the concurrent increase in nuclear LIM densities correlated with cellular growth reduction and cytotoxicity.
   Conclusions: 3D-qDMI demonstrated the capability of quantitating dose-dependent drug-induced spatial progression of DNA demethylation in cell nuclei, independent from interphase cell-cycle stages and in conjunction with cytotoxicity. The results support the notion of DNA methylation topology being considered as a potential indicator of causal impacts on chromatin distribution with a conceivable application in epigenetic drug toxicology.
C1 [Gertych, Arkadiusz; Oh, Jin Ho; Wawrowsky, Kolja A.; Tajbakhsh, Jian] Cedars Sinai Med Ctr, Dept Surg, Translat Cyt Grp, Los Angeles, CA 90048 USA.
   [Oh, Jin Ho; Tajbakhsh, Jian] Cedars Sinai Med Ctr, Dept Surg, Chromatin Biol Lab, Los Angeles, CA 90048 USA.
   [Gertych, Arkadiusz] Cedars Sinai Med Ctr, Dept Surg, Bioinformat Lab, Los Angeles, CA 90048 USA.
   [Wawrowsky, Kolja A.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.
   [Weisenberger, Daniel J.] Univ So Calif, Keck Sch Med, USC Epigenome Ctr, Los Angeles, CA 90089 USA.
C3 Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai
   Medical Center; Cedars Sinai Medical Center; University of Southern
   California
RP Tajbakhsh, J (通讯作者)，Cedars Sinai Med Ctr, Dept Surg, Translat Cyt Grp, Los Angeles, CA 90048 USA.
EM tajbakhshj@cshs.org
RI Weisenberger, Daniel/AAA-8314-2020; Gertych, Arkadiusz/AAW-2572-2021
OI Tajbakhsh, Jian/0009-0005-0293-3490; Gertych,
   Arkadiusz/0000-0002-3107-602X
FU DOD-CDMRP Award [W81XWH-10-1-0939]; NIH [1R21CA143618-01A1]; Department
   of Surgery at CSMC
FX We thank Patricia Lin (CSMC Research Flow Cytometry Core) for helping us
   with flow cytometry and Vaithilingaraja Arumugaswami (CSMC) for Huh-7
   cells. This work was supported by the DOD-CDMRP Award W81XWH-10-1-0939
   (to JT), the NIH grant 1R21CA143618-01A1 (to AG), and institutional
   grants from the Department of Surgery at CSMC.
CR Ammerpohl O, 2009, BBA-GEN SUBJECTS, V1790, P847, DOI 10.1016/j.bbagen.2009.02.001
   Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338
   Bender CM, 1999, MOL CELL BIOL, V19, P6690
   Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Champion C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012388
   Chen M, 2012, MOL CANCER THER, V11, P370, DOI 10.1158/1535-7163.MCT-11-0458
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Cheng JC, 2004, MOL CELL BIOL, V24, P1270, DOI 10.1128/MCB.24.3.1270-1278.2004
   Chiam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025634
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8
   Csoka AB, 2009, MED HYPOTHESES, V73, P770, DOI 10.1016/j.mehy.2008.10.039
   D'Alessio AC, 2006, BIOCHEM CELL BIOL, V84, P463, DOI 10.1139/O06-090
   Deal RB, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-218
   deCapoa A, 1996, CHROMOSOME RES, V4, P271, DOI 10.1007/BF02263676
   Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864
   Dostie J, 2006, GENOME RES, V16, P1299, DOI 10.1101/gr.5571506
   Dote H, 2005, CLIN CANCER RES, V11, P4571, DOI 10.1158/1078-0432.CCR-05-0050
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich Melanie, 2000, P273
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Espada J, 2007, CELL MOL LIFE SCI, V64, P449, DOI 10.1007/s00018-007-6358-x
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ewald JA, 2008, BRIT J CANCER, V98, P1244, DOI 10.1038/sj.bjc.6604288
   Fatemi M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni180
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016
   Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Gertych A, 2010, EXP CELL RES, V316, P3150, DOI 10.1016/j.yexcr.2010.08.013
   Gertych A, 2009, CYTOM PART A, V75A, P569, DOI 10.1002/cyto.a.20740
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Gilbert N, 2007, J CELL BIOL, V177, P401, DOI 10.1083/jcb.200607133
   Gore SD, 2006, NAT REV DRUG DISCOV, V5, P891, DOI 10.1038/nrd2180
   Goren A, 2010, NAT METHODS, V7, P47, DOI [10.1038/nmeth.1404, 10.1038/NMETH.1404]
   HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6
   Hagemann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017388
   Heinemann L, 2010, MOL THER, V18, P2085, DOI 10.1038/mt.2010.189
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herranz M, 2006, BLOOD, V107, P1174, DOI 10.1182/blood-2005-05-2033
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Huang J, 2011, CURR DRUG TARGETS, V12, P1925, DOI 10.2174/138945011798184155
   Issa JP., 2005, Nat Rev Drug Discov Suppl, pS6, DOI DOI 10.1038/NRD1726
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kang MI, 2006, GENOMICS, V87, P580, DOI 10.1016/j.ygeno.2006.01.002
   Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112
   Khan R, 2008, EXP HEMATOL, V36, P149, DOI 10.1016/j.exphem.2007.10.002
   Komashko Vitalina M, 2010, Epigenetics, V5, P229
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Lang P, 2006, NAT REV DRUG DISCOV, V5, P343, DOI 10.1038/nrd2008
   Li GH, 2011, CURR OPIN GENET DEV, V21, P175, DOI 10.1016/j.gde.2011.01.022
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Marquez VE, 2005, ANN NY ACAD SCI, V1058, P246, DOI 10.1196/annals.1359.037
   Misteli T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000794
   Nguyen CT, 2002, CANCER RES, V62, P6456
   Patra A, 2011, CLIN EPIGENETICS, V2, P339, DOI 10.1007/s13148-010-0019-x
   Patra SK, 2009, BIOCHEMISTRY-MOSCOW+, V74, P613, DOI 10.1134/S0006297909060042
   Patra SK, 2008, CANCER METAST REV, V27, P315, DOI 10.1007/s10555-008-9118-y
   Peng JC, 2008, CURR OPIN GENET DEV, V18, P204, DOI 10.1016/j.gde.2008.01.021
   Peng JC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000435
   Putiri EL, 2011, CLIN EPIGENETICS, V2, P299, DOI 10.1007/s13148-010-0017-z
   Ruiz-Magaña MJ, 2012, INT J CANCER, V130, P1195, DOI 10.1002/ijc.26107
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Santos AP, 2002, J CELL SCI, V115, P4597, DOI 10.1242/jcs.00160
   Schwarze SR, 2005, NEOPLASIA, V7, P816, DOI 10.1593/neo.05250
   Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005
   Shvachko L. P., 2008, Experimental Oncology, V30, P230
   Si J, 2010, CANCER RES, V70, P6968, DOI 10.1158/0008-5472.CAN-09-4474
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Stresemann C, 2008, MOL CANCER THER, V7, P2998, DOI 10.1158/1535-7163.MCT-08-0411
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Tajbakhsh J., 2010, DRUG DISCOV WORLD, P27
   Tajbakhsh J, 2008, P SPIE
   Tajbakhsh J, 2012, EPIGENOMICS CHROMATI, P273
   Tajbakhsh J, 2011, EPIGENOMICS-UK, V3, P761, DOI [10.2217/EPI.11.101, 10.2217/epi.11.101]
   Tárnok A, 2010, CYTOM PART A, V77A, P1, DOI 10.1002/cyto.a.20845
   Tong Wei-Gang, 2010, Epigenetics, V5, P499
   van Bemmel DM, 2009, BIOCHEM PHARMACOL, V78, P633, DOI 10.1016/j.bcp.2009.05.017
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   Venturelli S, 2007, CANCER, V109, P2132, DOI 10.1002/cncr.22652
   Vera E, 2008, ONCOGENE, V27, P6817, DOI 10.1038/onc.2008.289
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
   Whitfield ML, 2000, MOL CELL BIOL, V20, P4188, DOI 10.1128/MCB.20.12.4188-4198.2000
   Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6
   Yang XJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002604
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200
NR 101
TC 17
Z9 18
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2050-6511
J9 BMC PHARMACOL TOXICO
JI BMC Pharmacol. Toxicol.
PD FEB 11
PY 2013
VL 14
AR 11
DI 10.1186/2050-6511-14-11
PG 21
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 154ST
UT WOS:000319696900001
PM 23394161
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Royo, H
   Prosser, H
   Ruzankina, Y
   Mahadevaiah, SK
   Cloutier, JM
   Baumann, M
   Fukuda, T
   Höög, C
   Tóth, A
   de Rooij, DG
   Bradley, A
   Brown, EJ
   Turner, JMA
AF Royo, Helene
   Prosser, Haydn
   Ruzankina, Yaroslava
   Mahadevaiah, Shantha K.
   Cloutier, Jeffrey M.
   Baumann, Marek
   Fukuda, Tomoyuki
   Hoog, Christer
   Toth, Attila
   de Rooij, Dirk G.
   Bradley, Allan
   Brown, Eric J.
   Turner, James M. A.
TI ATR acts stage specifically to regulate multiple aspects of mammalian
   meiotic silencing
SO GENES & DEVELOPMENT
LA English
DT Article
DE ATR; meiosis; sex chromosomes
ID SEX-CHROMOSOME INACTIVATION; HISTONE UBIQUITINATION;
   ATAXIA-TELANGIECTASIA; DNA-DAMAGE; MEIOSIS; CHROMATIN; MOUSE; MICE;
   ASYNAPSIS; H2AX
AB In mammals, homologs that fail to synapse during meiosis are transcriptionally inactivated. This process, meiotic silencing, drives inactivation of the heterologous XY bivalent in male germ cells (meiotic sex chromosome inactivation [MSCI]) and is thought to act as a meiotic surveillance mechanism. The checkpoint protein ATM and Rad3-related (ATR) localizes to unsynapsed chromosomes, but its role in the initiation and maintenance of meiotic silencing is unknown. Here we show that ATR has multiple roles in silencing. ATR first regulates HORMA (Hop1, Rev7, and Mad2) domain protein HORMAD1/2 phosphorylation and localization of breast cancer I (BRCA1) and ATR cofactors ATR-interacting peptide (ATRIP)/topoisomerase 2-binding protein 1 (TOPBP1) at unsynapsed axes. Later, it acts as an adaptor, transducing signaling at unsynapsed axes into surrounding chromatin in a manner that requires interdependence with mediator of DNA damage checkpoint 1 (MDC1) and H2AFX. Finally, ATR catalyzes histone H2AFX phosphorylation, the epigenetic event leading to gene inactivation. Using a novel genetic strategy in which MSCI is used to silence a chosen gene in pachytene, we show that ATR depletion does not disrupt the maintenance of silencing and that silencing comprises two phases: The first is dynamic and reversible, and the second is stable and irreversible. Our work identifies a role for ATR in the epigenetic regulation of gene expression and presents a new technique for ablating gene function in the germline.
C1 [Royo, Helene; Mahadevaiah, Shantha K.; Cloutier, Jeffrey M.; Turner, James M. A.] Natl Inst Med Res, MRC, Div Stem Cell Biol & Dev Genet, London NW7 1AA, England.
   [Prosser, Haydn; Bradley, Allan] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   [Ruzankina, Yaroslava; Brown, Eric J.] Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Baumann, Marek; Toth, Attila] Tech Univ Dresden, Inst Physiol Chem, D-01307 Dresden, Germany.
   [Fukuda, Tomoyuki; Hoog, Christer] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.
   [de Rooij, Dirk G.] Univ Amsterdam, Acad Med Ctr, Ctr Reprod Med, NL-1105 AZ Amsterdam, Netherlands.
C3 MRC National Institute for Medical Research; Wellcome Trust Sanger
   Institute; University of Pennsylvania; Technische Universitat Dresden;
   Karolinska Institutet; University of Amsterdam; Academic Medical Center
   Amsterdam
RP Turner, JMA (通讯作者)，Natl Inst Med Res, MRC, Div Stem Cell Biol & Dev Genet, London NW7 1AA, England.
EM jturner@nimr.mrc.ac.uk
RI Fukuda, Tomoyuki/AAV-2062-2021; de Rooij, D.G./JAC-8489-2023; Toth,
   Attila/C-9624-2013
OI Fukuda, Tomoyuki/0000-0003-2069-7127; Bradley,
   Allan/0000-0002-2349-8839; Cloutier, Jeffrey/0000-0002-8630-8609; de
   Rooij, Dirk/0000-0003-3932-4419; Toth, Attila/0000-0001-5744-3847
FU Medical Research Council [U117588498]; National Institute on Aging
   [2R01AG027376]; Deutsche Forschungsgemeinschaft [TO 421/3-1, 421/3-2,
   421/4-1, 421/5-1]; Wellcome Trust [WT098051]; Swedish Cancer Society;
   Swedish Research Council; Karolinska Institutet
FX We thank Karlene Cimprich and Junjie Chen for providing the ATRIP and
   TOPBP1 antibodies, respectively; Grzegorz Polikiewicz for genotyping;
   and Paul Burgoyne and members of Turner laboratory for critical reading
   of the manuscript. This work was funded by the Medical Research Council
   (U117588498), the National Institute on Aging (2R01AG027376), the
   Deutsche Forschungsgemeinschaft (TO 421/3-1, 421/3-2, 421/4-1, and
   421/5-1), the Wellcome Trust (WT098051), the Swedish Cancer Society, the
   Swedish Research Council, and the Karolinska Institutet.
CR An JY, 2010, P NATL ACAD SCI USA, V107, P1912, DOI 10.1073/pnas.0910267107
   Baarends WM, 2005, MOL CELL BIOL, V25, P1041, DOI 10.1128/MCB.25.3.1041-1053.2005
   Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155
   Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0
   Bellani MA, 2005, J CELL SCI, V118, P3233, DOI 10.1242/jcs.02466
   Brown EJ, 2000, GENE DEV, V14, P397
   Burgoyne PS, 2009, NAT REV GENET, V10, P207, DOI 10.1038/nrg2505
   Burrows AE, 2008, GENE DEV, V22, P1416, DOI 10.1101/gad.1685108
   Carballo JA, 2007, CHROMOSOME RES, V15, P539, DOI 10.1007/s10577-007-1145-y
   Carballo JA, 2008, CELL, V132, P758, DOI 10.1016/j.cell.2008.01.035
   Daniel K, 2011, NAT CELL BIOL, V13, P599, DOI 10.1038/ncb2213
   Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5
   Fukuda T, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002485
   Greaves IK, 2006, MOL CELL BIOL, V26, P5394, DOI 10.1128/MCB.00519-06
   Hamer G, 2004, BIOL REPROD, V70, P1206, DOI 10.1095/biolreprod.103.024950
   Handel MA, 2010, NAT REV GENET, V11, P124, DOI 10.1038/nrg2723
   Ichijima Y, 2012, CELL MOL LIFE SCI, V69, P2559, DOI 10.1007/s00018-012-0941-5
   Ichijima Y, 2011, GENE DEV, V25, P959, DOI 10.1101/gad.2030811
   Inagaki A, 2010, EPIGENETICS-US, V5, P255, DOI 10.4161/epi.5.4.11518
   Kauppi L, 2011, SCIENCE, V331, P916, DOI 10.1126/science.1195774
   Kouznetsova A, 2009, J CELL SCI, V122, P2446, DOI 10.1242/jcs.049353
   Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025
   Mahadevaiah SK, 2008, J CELL BIOL, V182, P263, DOI 10.1083/jcb.200710195
   Mahadevaiah SK, 2009, METHODS MOL BIOL, V558, P433, DOI 10.1007/978-1-60761-103-5_25
   MCKEE BD, 1993, CHROMOSOMA, V102, P71, DOI 10.1007/BF00356023
   Modzelewski AJ, 2012, DEV CELL, V23, P251, DOI 10.1016/j.devcel.2012.07.003
   Nagaoka SI, 2012, NAT REV GENET, V13, P493, DOI 10.1038/nrg3245
   Namekawa SH, 2006, CURR BIOL, V16, P660, DOI 10.1016/j.cub.2006.01.066
   Prosser HM, 2008, MOL CELL BIOL, V28, P1702, DOI 10.1128/MCB.01282-07
   Refolio E, 2011, J CELL SCI, V124, P2488, DOI 10.1242/jcs.081711
   Royo H, 2010, CURR BIOL, V20, P2117, DOI 10.1016/j.cub.2010.11.010
   Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002
   Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233
   SOLARI AJ, 1974, INT REV CYTOL, V38, P273, DOI 10.1016/S0074-7696(08)60928-6
   Song R, 2009, NAT GENET, V41, P488, DOI 10.1038/ng.338
   Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207
   Turner JMA, 2005, NAT GENET, V37, P41, DOI 10.1038/ng1484
   Turner JMA, 2006, DEV CELL, V10, P521, DOI 10.1016/j.devcel.2006.02.009
   Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032
   van der Heijden GW, 2007, NAT GENET, V39, P251, DOI 10.1038/ng1949
   Vigodner M, 2005, DEV BIOL, V282, P480, DOI 10.1016/j.ydbio.2005.03.034
   Vigodner M, 2009, CHROMOSOME RES, V17, P37, DOI 10.1007/s10577-008-9006-x
   Wojtasz L, 2012, GENE DEV, V26, P958, DOI 10.1101/gad.187559.112
   Wojtasz L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000702
   Yan W, 2009, EPIGENETICS-US, V4, P452, DOI 10.4161/epi.4.7.9923
NR 45
TC 107
Z9 122
U1 0
U2 17
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD JUL 1
PY 2013
VL 27
IS 13
BP 1484
EP 1494
DI 10.1101/gad.219477.113
PG 11
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 176KR
UT WOS:000321303600006
PM 23824539
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Newburger, DE
   Kashef-Haghighi, D
   Weng, ZM
   Salari, R
   Sweeney, RT
   Brunner, AL
   Zhu, SX
   Guo, XQ
   Varma, S
   Troxell, ML
   West, RB
   Batzoglou, S
   Sidow, A
AF Newburger, Daniel E.
   Kashef-Haghighi, Dorna
   Weng, Ziming
   Salari, Raheleh
   Sweeney, Robert T.
   Brunner, Alayne L.
   Zhu, Shirley X.
   Guo, Xiangqian
   Varma, Sushama
   Troxell, Megan L.
   West, Robert B.
   Batzoglou, Serafim
   Sidow, Arend
TI Genome evolution during progression to breast cancer
SO GENOME RESEARCH
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; COLUMNAR CELL LESIONS; DNA-SEQUENCING DATA;
   MUTATIONAL EVOLUTION; HIGH-FREQUENCY; GENE; ARCHITECTURE; METASTASIS;
   SIGNATURES; FRAMEWORK
AB Cancer evolution involves cycles of genomic damage, epigenetic deregulation, and increased cellular proliferation that eventually culminate in the carcinoma phenotype. Early neoplasias, which are often found concurrently with carcinomas and are histologically distinguishable from normal breast tissue, are less advanced in phenotype than carcinomas and are thought to represent precursor stages. To elucidate their role in cancer evolution we performed comparative whole-genome sequencing of early neoplasias, matched normal tissue, and carcinomas from six patients, for a total of 31 samples. By using somatic mutations as lineage markers we built trees that relate the tissue samples within each patient. On the basis of these lineage trees we inferred the order, timing, and rates of genomic events. In four out of six cases, an early neoplasia and the carcinoma share a mutated common ancestor with recurring aneuploidies, and in all six cases evolution accelerated in the carcinoma lineage. Transition spectra of somatic mutations are stable and consistent across cases, suggesting that accumulation of somatic mutations is a result of increased ancestral cell division rather than specific mutational mechanisms. In contrast to highly advanced tumors that are the focus of much of the current cancer genome sequencing, neither the early neoplasia genomes nor the carcinomas are enriched with potentially functional somatic point mutations. Aneuploidies that occur in common ancestors of neoplastic and tumor cells are the earliest events that affect a large number of genes and may predispose breast tissue to eventual development of invasive carcinoma.
C1 [Newburger, Daniel E.] Biomed Informat Training Program, Stanford, CA 94305 USA.
   [Kashef-Haghighi, Dorna; Salari, Raheleh; Batzoglou, Serafim] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA.
   [Weng, Ziming; Sweeney, Robert T.; Brunner, Alayne L.; Zhu, Shirley X.; Guo, Xiangqian; Varma, Sushama; West, Robert B.; Sidow, Arend] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.
   [Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
   [Troxell, Megan L.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
   [Sidow, Arend] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Oregon Health & Science
   University; Oregon Health & Science University; Stanford University
RP West, RB (通讯作者)，Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.
EM rbwest@stanford.edu; serafim@cs.stanford.edu; arend@stanford.edu
RI Guo, Xiangqian/AAN-4599-2020
OI Guo, Xiangqian/0000-0001-6645-5786; West, Robert/0000-0002-8330-8283
FU Sequencing Initiative of the Stanford Department of Pathology;
   California Breast Cancer Research Program; NIH/NCI; KAUST;
   STMicroelectronics Stanford Graduate Fellowship; NIH/NLM; Bio-X Stanford
   Interdisciplinary Graduate Fellowship
FX This work was supported by the Sequencing Initiative of the Stanford
   Department of Pathology, grants from the California Breast Cancer
   Research Program and NIH/NCI to R.B.W. and a grant from KAUST to S.B.
   D.K.H. was supported by a STMicroelectronics Stanford Graduate
   Fellowship, and D.E.N. by a training grant from NIH/NLM and a Bio-X
   Stanford Interdisciplinary Graduate Fellowship. This study is the result
   of an equal collaboration among the Batzoglou, Sidow, and West groups.
   Listed order of corresponding authors was determined by a series of coin
   flips.
CR Abdel-Fatah TMA, 2007, AM J SURG PATHOL, V31, P417, DOI 10.1097/01.pas.0000213368.41251.b9
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768
   Bombonati A, 2011, J PATHOL, V223, P307, DOI 10.1002/path.2808
   Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837
   Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hwang DG, 2004, P NATL ACAD SCI USA, V101, P13994, DOI 10.1073/pnas.0404142101
   Kong A, 2012, NATURE, V488, P471, DOI 10.1038/nature11396
   Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105
   Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485
   Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042
   Lopez-Garcia MA, 2010, HISTOPATHOLOGY, V57, P171, DOI 10.1111/j.1365-2559.2010.03568.x
   Maher CA, 2012, CELL, V148, P29, DOI 10.1016/j.cell.2012.01.006
   Mardis ER, 2012, CURR OPIN GENET DEV, V22, P245, DOI 10.1016/j.gde.2012.03.005
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Meyerson M, 2011, CELL, V144, P9, DOI 10.1016/j.cell.2010.12.025
   Mills RE, 2006, GENOME RES, V16, P1182, DOI 10.1101/gr.4565806
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Simpson PT, 2005, AM J SURG PATHOL, V29, P734, DOI 10.1097/01.pas.0000157295.93914.3b
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692
   Troxell ML, 2012, MODERN PATHOL, V25, P930, DOI 10.1038/modpathol.2012.55
   Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111
   Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968
   Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
NR 45
TC 85
Z9 94
U1 0
U2 21
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD JUL
PY 2013
VL 23
IS 7
BP 1097
EP 1108
DI 10.1101/gr.151670.112
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 173YO
UT WOS:000321119900007
PM 23568837
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Ho, AS
   Kannan, K
   Roy, DM
   Morris, LGT
   Ganly, I
   Katabi, N
   Ramaswami, D
   Walsh, LA
   Eng, S
   Huse, JT
   Zhang, JN
   Dolgalev, I
   Huberman, K
   Heguy, A
   Viale, A
   Drobnjak, M
   Leversha, MA
   Rice, CE
   Singh, B
   Iyer, NG
   Leemans, CR
   Bloemena, E
   Ferris, RL
   Seethala, RR
   Gross, BE
   Liang, YP
   Sinha, R
   Peng, LK
   Raphael, BJ
   Turcan, S
   Gong, YX
   Schultz, N
   Kim, S
   Chiosea, S
   Shah, JP
   Sander, C
   Lee, W
   Chan, TA
AF Ho, Allen S.
   Kannan, Kasthuri
   Roy, David M.
   Morris, Luc G. T.
   Ganly, Ian
   Katabi, Nora
   Ramaswami, Deepa
   Walsh, Logan A.
   Eng, Stephanie
   Huse, Jason T.
   Zhang, Jianan
   Dolgalev, Igor
   Huberman, Kety
   Heguy, Adriana
   Viale, Agnes
   Drobnjak, Marija
   Leversha, Margaret A.
   Rice, Christine E.
   Singh, Bhuvanesh
   Iyer, N. Gopalakrishna
   Leemans, C. Rene
   Bloemena, Elisabeth
   Ferris, Robert L.
   Seethala, Raja R.
   Gross, Benjamin E.
   Liang, Yupu
   Sinha, Rileen
   Peng, Luke
   Raphael, Benjamin J.
   Turcan, Sevin
   Gong, Yongxing
   Schultz, Nikolaus
   Kim, Seungwon
   Chiosea, Simion
   Shah, Jatin P.
   Sander, Chris
   Lee, William
   Chan, Timothy A.
TI The mutational landscape of adenoid cystic carcinoma
SO NATURE GENETICS
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMATIN REMODELING GENES; SOMATIC POINT
   MUTATIONS; SQUAMOUS-CELL CARCINOMA; DNA-SEQUENCING DATA; BREAST-CANCER;
   TUMOR-GROWTH; INACTIVATING MUTATIONS; MISSENSE MUTATIONS;
   PROSTATE-CANCER
AB Adenoid cystic carcinomas (ACCs) are among the most enigmatic of human malignancies. These aggressive salivary gland cancers frequently recur and metastasize despite definitive treatment, with no known effective chemotherapy regimen. Here we determined the ACC mutational landscape and report the exome or whole-genome sequences of 60 ACC tumor-normal pairs. These analyses identified a low exonic somatic mutation rate (0.31 non-silent events per megabase) and wide mutational diversity. Notably, we found mutations in genes encoding chromatin-state regulators, such as SMARCA2, CREBBP and KDM6A, suggesting that there is aberrant epigenetic regulation in ACC oncogenesis. Mutations in genes central to the DNA damage response and protein kinase A signaling also implicate these processes. We observed MYB-NFIB translocations and somatic mutations in MYB-associated genes, solidifying the role of these aberrations as critical events in ACC. Lastly, we identified recurrent mutations in the FGF-IGF-PI3K pathway (30% of tumors) that might represent new avenues for therapy. Collectively, our observations establish a molecular foundation for understanding and exploring new treatments for ACC.
C1 [Ho, Allen S.; Kannan, Kasthuri; Roy, David M.; Morris, Luc G. T.; Ganly, Ian; Ramaswami, Deepa; Walsh, Logan A.; Eng, Stephanie; Huse, Jason T.; Zhang, Jianan; Dolgalev, Igor; Huberman, Kety; Heguy, Adriana; Peng, Luke; Turcan, Sevin; Gong, Yongxing; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
   [Ho, Allen S.; Morris, Luc G. T.; Ganly, Ian; Singh, Bhuvanesh; Shah, Jatin P.] Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA.
   [Katabi, Nora; Huse, Jason T.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Viale, Agnes] Mem Sloan Kettering Canc Ctr, Genom Core, New York, NY 10021 USA.
   [Drobnjak, Marija] Mem Sloan Kettering Canc Ctr, Pathol Core, New York, NY 10021 USA.
   [Leversha, Margaret A.; Rice, Christine E.] Mem Sloan Kettering Canc Ctr, Mol Cytogenet Core, New York, NY 10021 USA.
   [Iyer, N. Gopalakrishna] Natl Canc Ctr Singapore, Dept Surg Oncol, Singapore, Singapore.
   [Leemans, C. Rene] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, Amsterdam, Netherlands.
   [Bloemena, Elisabeth] Vrije Univ Amsterdam, Med Ctr, Acad Ctr Dent, Dept Oral & Maxillofacial Surg & Oral Pathol, Amsterdam, Netherlands.
   [Ferris, Robert L.; Kim, Seungwon] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA.
   [Seethala, Raja R.; Chiosea, Simion] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA.
   [Gross, Benjamin E.; Liang, Yupu; Sinha, Rileen; Sander, Chris; Lee, William] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA.
   [Raphael, Benjamin J.] Brown Univ, Dept Comp Sci, Providence, RI 02912 USA.
   [Schultz, Nikolaus; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering
   Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan
   Kettering Cancer Center; National Cancer Centre Singapore (NCCS); Vrije
   Universiteit Amsterdam; Academic Center for Dentistry Amsterdam; Vrije
   Universiteit Amsterdam; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh; Memorial
   Sloan Kettering Cancer Center; Brown University; Memorial Sloan
   Kettering Cancer Center
RP Chan, TA (通讯作者)，Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.
EM chant@mskcc.org
RI Chan, Timothy/ABD-5850-2021; Kannan, Kasthuri/A-5403-2013; Dolgalev,
   Igor/AAY-6406-2020; Schultz, Nikolaus/ABE-6347-2020; Wang,
   Jun/C-8434-2016; Heguy, Adriana/GPP-3907-2022; Bloemena,
   Elisabeth/V-1095-2018; Turcan, Sevin/AAF-1095-2019
OI Dolgalev, Igor/0000-0003-4451-126X; Gong, Yongxing/0000-0003-1071-0375;
   Bloemena, Elisabeth/0000-0002-0221-9538; Ho, Allen/0000-0001-5423-509X;
   Iyer, N. Gopalakrishna/0000-0002-8812-6219; Ferris,
   Robert/0000-0001-6605-2071; Leemans, C. Rene/0000-0001-7887-083X; Shah,
   Jatin/0000-0002-6444-6592; Drobnjak, Marija/0000-0003-0676-4709; Kannan,
   Kasthuri/0000-0002-8479-0657; Chiosea, Simion/0000-0002-5766-8779;
   Walsh, Logan/0000-0001-8771-2577; Lee, William/0000-0001-9582-4413;
   Schultz, Nikolaus/0000-0002-0131-4904; Sinha,
   Rileen/0000-0001-5497-5055; Ganly, Ian/0000-0001-7636-5426; Turcan,
   Sevin/0000-0002-0885-5607
FU US National Institutes of Health (NIH) [RO1CA154767, R21DE023229,
   5T32CA009685]; Geoffrey Beene Foundation; Starr Cancer Consortium; Louis
   Gerstner Foundation; American Head and Neck Society/American Academy of
   Otolaryngology-Head and Neck Surgery Foundation Young Investigator
   Combined Award; Howard Hughes Medical Institute Medical Research Fellows
   Program; NIH National Resource for Network Biology [GM103504]; Adenoid
   Cystic Carcinoma Research Foundation
FX We thank A. Kayserian and S. Thomas for technical assistance. We are
   indebted to R.J. Wong (Memorial Sloan-Kettering Cancer Center), P. K.
   Brindle (St. Jude Children's Research Hospital) and O.J. Baker (State
   University of New York at Buffalo) for generously providing cell lines
   and constructs. We are additionally grateful to J.O. Boyle, S. G. Patel,
   A. R. Shaha, R.J. Wong, A. L. Ho, M. C. Mariano and L. Lopez for
   facilitating tissue procurement and contributing valuable input. This
   work was supported by the US National Institutes of Health (NIH)
   (RO1CA154767 (T. A. C.), R21DE023229 (T. A. C.), 5T32CA009685 (A. S.
   H.)), the Geoffrey Beene Foundation (T. A. C.), the Starr Cancer
   Consortium (T. A. C.) and the Louis Gerstner Foundation (T. A. C.). A.
   S. H. was supported by an American Head and Neck Society/American
   Academy of Otolaryngology-Head and Neck Surgery Foundation Young
   Investigator Combined Award. D. M. R. was supported by the Howard Hughes
   Medical Institute Medical Research Fellows Program. The cBio Portal was
   supported in part by the NIH National Resource for Network Biology
   (GM103504). T. A. C. would like to thank Jeff and Marnie Kaufman and the
   Adenoid Cystic Carcinoma Research Foundation for support of the work and
   inspiration to see it
CR Abdul M, 2008, PATHOL ONCOL RES, V14, P157, DOI 10.1007/s12253-008-9045-9
   Adelstein DJ, 2012, SEMIN RADIAT ONCOL, V22, P245, DOI 10.1016/j.semradonc.2012.03.009
   Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923
   Agulnik M, 2007, J CLIN ONCOL, V25, P3978, DOI 10.1200/JCO.2007.11.8612
   Allen TD, 2011, CANCER RES, V71, P6010, DOI 10.1158/0008-5472.CAN-11-0595
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0
   Bengtsson H, 2008, BIOINFORMATICS, V24, P759, DOI 10.1093/bioinformatics/btn016
   Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744
   Binmadi NO, 2012, AM J PATHOL, V180, P1232, DOI 10.1016/j.ajpath.2011.12.009
   Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699
   Carter H, 2009, CANCER RES, V69, P6660, DOI 10.1158/0008-5472.CAN-09-1133
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Cerami EG, 2011, NUCLEIC ACIDS RES, V39, pD685, DOI 10.1093/nar/gkq1039
   CHENG J, 1992, CANCER, V69, P2631, DOI 10.1002/1097-0142(19920601)69:11<2631::AID-CNCR2820691103>3.0.CO;2-P
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479
   Egloff AM, 2012, CLIN CANCER RES, V18, P5188, DOI 10.1158/1078-0432.CCR-11-2258
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gopalan A, 2009, CANCER RES, V69, P1400, DOI 10.1158/0008-5472.CAN-08-2467
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Holst VA, 1999, MODERN PATHOL, V12, P956
   Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2
   Hu Y, 2007, GENE DEV, V21, P3073, DOI 10.1101/gad.1609107
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059
   Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101
   Janakiraman M, 2010, CANCER RES, V70, P5901, DOI 10.1158/0008-5472.CAN-10-0192
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Kimura S, 2000, VIRCHOWS ARCH, V437, P122, DOI 10.1007/s004280000209
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Larson DE, 2012, BIOINFORMATICS, V28, P311, DOI 10.1093/bioinformatics/btr665
   Laurie SA, 2011, LANCET ONCOL, V12, P815, DOI 10.1016/S1470-2045(10)70245-X
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Masse JE, 2002, J MOL BIOL, V323, P263, DOI 10.1016/S0022-2836(02)00938-5
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910
   Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727
   Munakata R, 1996, J ORAL PATHOL MED, V25, P441, DOI 10.1111/j.1600-0714.1996.tb00294.x
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730
   Persson M, 2012, GENE CHROMOSOME CANC, V51, P805, DOI 10.1002/gcc.21965
   Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106
   Phuchareon J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006040
   Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Rodrigues S, 2007, ONCOGENE, V26, P5615, DOI 10.1038/sj.onc.1210347
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Sarmento LM, 2011, EXPERT REV ANTICANC, V11, P1403, DOI [10.1586/ERA.11.73, 10.1586/era.11.73]
   Sathirapongsasuti JF, 2011, BIOINFORMATICS, V27, P2648, DOI 10.1093/bioinformatics/btr462
   Savorè C, 2005, CLIN EXP METASTAS, V22, P377, DOI 10.1007/s10585-005-2339-3
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Spangle JM, 2010, J VIROL, V84, P9398, DOI 10.1128/JVI.00974-10
   Staaf J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-409
   Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036
   Tien AL, 2011, BIOCHEM J, V435, P175, DOI 10.1042/BJ20100840
   Tran PK, 2004, CIRC RES, V94, P550, DOI 10.1161/01.RES.0000117772.86853.34
   Tsurusaki Y, 2012, NAT GENET, V44, P376, DOI 10.1038/ng.2219
   Van Houdt JKJ, 2012, NAT GENET, V44, P445, DOI 10.1038/ng.1105
   Véekony H, 2007, CLIN CANCER RES, V13, P3133, DOI 10.1158/1078-0432.CCR-06-2555
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023
   Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261
   Wang JM, 2011, NAT METHODS, V8, P652, DOI [10.1038/NMETH.1628, 10.1038/nmeth.1628]
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Yang RB, 2003, J BIOL CHEM, V278, P33232, DOI 10.1074/jbc.M305022200
   Yau C, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-9-r92
   Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246
   Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725
   Zhang LN, 2011, P NATL ACAD SCI USA, V108, P13653, DOI 10.1073/pnas.1103360108
   Zhou ZJ, 2004, CANCER RES, V64, P4699, DOI 10.1158/0008-5472.CAN-04-0810
   2012, ORAL ONCOL, V48, P95
NR 97
TC 357
Z9 392
U1 1
U2 52
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUL
PY 2013
VL 45
IS 7
BP 791
EP +
DI 10.1038/ng.2643
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 172LQ
UT WOS:000321005200014
PM 23685749
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Anwar, SL
   Albat, C
   Krech, T
   Hasemeier, B
   Schipper, E
   Schweitzer, N
   Vogel, A
   Kreipe, H
   Lehmann, U
AF Anwar, Sumadi Lukman
   Albat, Cord
   Krech, Till
   Hasemeier, Britta
   Schipper, Elisa
   Schweitzer, Nora
   Vogel, Arndt
   Kreipe, Hans
   Lehmann, Ulrich
TI Concordant hypermethylation of intergenic microRNA genes in human
   hepatocellular carcinoma as new diagnostic and prognostic marker
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE microRNA; DNA methylation; hepatocellular carcinoma; liver; epigenetics
ID DNA METHYLATION PATTERNS; BREAST-CANCER; MYELODYSPLASTIC-SYNDROME;
   CELLS; EXPRESSION; RESOLUTION; LIVER; QUANTIFICATION; IDENTIFICATION;
   PROLIFERATION
AB Epigenetic inactivation by aberrant DNA methylation has been reported for many microRNA genes in various human malignancies. However, relatively little is known about microRNA gene methylation in hepatocellular carcinoma (HCC). Therefore, a systematic screen for identification of aberrantly hypermethylated microRNA genes in HCC was initiated. The methylation status of 39 intergenic CpG island associated microRNA genes was analyzed in HCC cell lines (n=7), immortalized hepatocytes (n=2) and normal liver samples (n=5). Subsequently, 13 differentially methylated microRNA genes were analyzed in primary human HCC samples (n=40), benign liver tumors (n=15) and the adjacent liver tissues employing pyrosequencing. Expression of microRNA genes was measured using quantitative real-time polymerase chain reaction (RT-PCR). In addition, DNA methylation and expression of microRNA genes were measured after DNMT1 knockdown or DNMT inhibition. Aberrant hypermethylation and concomitant reduction in expression of intergenic microRNA genes is a frequent event in human HCC: hsa-mir-9-2 (23%), hsa-mir-9-3 (50 %), hsa-mir-124-1 (20%), hsa-mir-124-2 (13%), hsa-mir-124-3 (43%), hsa-mir-129-2 (58%), hsa-mir-596 (28%) and hsa-mir-1247 (38%). Altogether, it affects 90% of the HCC specimens under study. MicroRNA gene methylation is not found in hepatocellular adenoma (n=10) and focal nodular hyperplasia (n=5). DNMT1 knockdown or DNMT inhibition reduced microRNA gene methylation and stimulated expression. In primary human HCC specimens hypermethylation and expression of microRNA genes showed an inverse correlation. Concordant hypermethylation of three or more microRNA genes is a highly specific marker for the detection of HCC and for poor prognosis.
C1 [Anwar, Sumadi Lukman; Albat, Cord; Krech, Till; Hasemeier, Britta; Schipper, Elisa; Kreipe, Hans; Lehmann, Ulrich] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany.
   [Schweitzer, Nora; Vogel, Arndt] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany.
C3 Hannover Medical School; Hannover Medical School
RP Lehmann, U (通讯作者)，Hannover Med Sch, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM Lehmann.Ulrich@MH-Hannover.de
RI Vogel, Arndt/A-8437-2012
OI anwar, sumadi lukman/0000-0002-2607-6682; Vogel,
   Arndt/0000-0003-0560-5538
FU German Research Council (DFG) [SFB-TRR77]
FX Grant sponsor: German Research Council (DFG), SFB-TRR77 "Liver cancer"
   (Project B1)
CR Alpini G, 2011, J HEPATOL, V55, P1339, DOI 10.1016/j.jhep.2011.04.015
   Ammerpohl O, 2012, INT J CANCER, V130, P1319, DOI 10.1002/ijc.26136
   Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Brakensiek K, 2004, BLOOD, V104, P1586, DOI 10.1182/blood-2004-03-0898
   Brakensiek K, 2007, CLIN CHEM, V53, P17, DOI 10.1373/clinchem.2007.072629
   Capel E, 2007, ONCOGENE, V26, P7596, DOI 10.1038/sj.onc.1210581
   Cekaite L, 2012, NEOPLASIA, V14, P868, DOI 10.1593/neo.121094
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Christgen M, 2013, GENE CHROMOSOME CANC, V52, P69, DOI 10.1002/gcc.22007
   Claus R, 2012, EPIGENETICS-US, V7, P772, DOI 10.4161/epi.20299
   Claus R, 2012, INT J CANCER, V131, pE138, DOI 10.1002/ijc.26429
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Hennessey PT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020584
   Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499
   Huss S, HISTOPATHOL IN PRESS
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Kim JK, HEPATOLOGY IN PRESS
   Kozaki K, 2012, CANCER SCI, V103, P837, DOI 10.1111/j.1349-7006.2012.02236.x
   Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lehmann U, 2005, CLIN CANCER RES, V11, P3654, DOI 10.1158/1078-0432.CCR-04-2462
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Nahm CB, 2011, J GASTROINTEST SURG, V15, P2275, DOI 10.1007/s11605-011-1680-x
   Neumann O, 2012, HEPATOLOGY, V56, P1817, DOI 10.1002/hep.25870
   Potapova A, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-6
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Selcuklu SD, 2012, J BIOL CHEM, V287, P29516, DOI 10.1074/jbc.M111.335943
   Shen J, 2012, EPIGENETICS-US, V7, P1230, DOI 10.4161/epi.22140
   Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569
   Stoot JHMB, 2010, HPB, V12, P509, DOI 10.1111/j.1477-2574.2010.00222.x
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tao R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019862
   Tränkenschuh W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013688
   Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Wang XW, 2012, GASTROENTEROLOGY, V142, P1431, DOI 10.1053/j.gastro.2012.04.007
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yan HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020628
   Yang JD, 2011, J KOREAN MED SCI, V26, P1428, DOI 10.3346/jkms.2011.26.11.1428
   Zhang HY, 2012, MOL CANCER THER, V11, P1454, DOI 10.1158/1535-7163.MCT-12-0001
NR 45
TC 67
Z9 72
U1 0
U2 38
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 1
PY 2013
VL 133
IS 3
BP 660
EP 670
DI 10.1002/ijc.28068
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 149AC
UT WOS:000319289400015
PM 23364900
OA Bronze
DA 2025-01-12
ER

PT J
AU Davis, MB
   Liu, XY
   Wang, SY
   Reeves, J
   Khramtsov, A
   Huo, DZ
   Olopade, OI
AF Davis, Melissa B.
   Liu, Xinyu
   Wang, Shiyao
   Reeves, Jaxk
   Khramtsov, Andrey
   Huo, Dezheng
   Olopade, Olufunmilayo I.
TI Expression and sub-cellular localization of an epigenetic regulator,
   co-activator arginine methyltransferase 1 (CARM1), is associated with
   specific breast cancer subtypes and ethnicity
SO MOLECULAR CANCER
LA English
DT Article
DE Tissue-microarray; Breast cancer; Molecular subtypes; CARM1; Epigenetic
   regulator; Subcellular localization; Ethnic disparities
ID INVASIVE DUCTAL CARCINOMA; ESTROGEN-RECEPTOR-ALPHA; HISTONE
   MODIFICATION; ANDROGEN RECEPTOR; AFRICAN-AMERICAN; DNA METHYLATION;
   TRANSCRIPTIONAL COACTIVATOR; CELL-LINES; DISPARITIES; WOMEN
AB Background: Co-Activator Arginine Methyltransferase 1(CARM1) is an Estrogen Receptor (ER) cofactor that remodels chromatin for gene regulation via methylation of Histone3. We investigated CARM1 levels and localization across breast cancer tumors in a cohort of patients of either European or African ancestry.
   Methods: We analyzed CARM1 levels using tissue microarrays with over 800 histological samples from 549 female cancer patients from the US and Nigeria, Africa. We assessed associations between CARM1 expression localized to the nucleus and cytoplasm for 11 distinct variables, including; ER status, Progesterone Receptor status, molecular subtypes, ethnicity, HER2+ status, other clinical variables and survival.
   Results: We found that levels of cytoplasmic CARM1 are distinct among tumor sub-types and increased levels are associated with ER-negative (ER-) status. Higher nuclear CARM1 levels are associated with HER2 receptor status. EGFR expression also correlates with localization of CARM1 into the cytoplasm. This suggests there are distinct functions of CARM1 among molecular tumor types. Our data reveals a basal-like subtype association with CARM1, possibly due to expression of Epidermal Growth Factor Receptor (EGFR). Lastly, increased cytoplasmic CARM1, relative to nuclear levels, appear to be associated with self-identified African ethnicity and this result is being further investigated using quantified genetic ancestry measures.
   Conclusions: Although it is known to be an ER cofactor in breast cancer, CARM1 expression levels are independent of ER. CARM1 has distinct functions among molecular subtypes, as is indicative of its sub-cellular localization and it may function in subtype etiology. These sub-cellular localization patterns, indicate a novel role beyond its ER cofactor function in breast cancer. Differential localization among ethnic groups may be due to ancestry-specific polymorphisms which alter the gene product.
C1 [Davis, Melissa B.] Univ Chicago, Div Biol Sci, Inst Genom & Syst Biol, Chicago, IL 60637 USA.
   [Davis, Melissa B.] Univ Chicago, Div Biol Sci, Dept Human Genet, Chicago, IL 60637 USA.
   [Khramtsov, Andrey; Olopade, Olufunmilayo I.] Univ Chicago Med, Dept Med, Ctr Clin Canc Genet & Global Hlth, Chicago, IL 60637 USA.
   [Huo, Dezheng] Univ Chicago, Dept Hlth Studies, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
   [Davis, Melissa B.] Georgia Hlth Sci Univ, Athens, GA 30602 USA.
   [Davis, Melissa B.] Univ Georgia Med Partnership, Athens, GA 30602 USA.
   [Davis, Melissa B.] Univ Georgia, Dept Genet, Athens, GA 30602 USA.
   [Liu, Xinyu; Wang, Shiyao; Reeves, Jaxk] Univ Georgia, Dept Stat, Athens, GA 30602 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   University System of Georgia; Augusta University; University System of
   Georgia; University of Georgia; University System of Georgia; University
   of Georgia; University System of Georgia; University of Georgia
RP Davis, MB (通讯作者)，Univ Chicago, Div Biol Sci, Inst Genom & Syst Biol, Chicago, IL 60637 USA.
EM mbdavis@uga.edu
RI Liu, Xinyu/HKN-1981-2023; Wang, Shiyao/JLL-7826-2023; Khramtsov,
   Andrey/H-8701-2018
OI Davis, Melissa/0000-0002-6124-6923; Khramtsov,
   Andrey/0000-0001-6301-4619
FU UofC Institute for Genomics and Systems Biology
FX Special thanks to Kevin White at the UofC Institute for Genomics and
   Systems Biology for financial support and lab space during this
   postdoctoral work. Tremendous thanks to Olufunmilayo Olopade for
   mentorship and access to tumor samples. Special thanks to Andrey
   Khramastov for histological staining and scoring. Special thanks to
   Sarah Gehlert and the Center of Interdisciplinary Health Disparities
   Research at UofC for guidance and involvement on experimental direction.
CR Agurs-Collins T, 2010, SEMIN ONCOL, V37, P384, DOI 10.1053/j.seminoncol.2010.05.002
   Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426
   Albert R, 1996, CYTOMETRY, V24, P140
   Baek SH, 2006, P NATL ACAD SCI USA, V103, P3100, DOI 10.1073/pnas.0510842103
   Baquet CR, 2008, J NATL MED ASSOC, V100, P480, DOI 10.1016/S0027-9684(15)31294-3
   Barr FD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006766
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Benn-Torres J, 2008, ANN HUM GENET, V72, P90, DOI 10.1111/j.1469-1809.2007.00398.x
   Blackman DJ, 2006, J CLIN ONCOL, V24, P2170, DOI 10.1200/JCO.2005.05.4734
   Bowen RL, 2008, BRIT J CANCER, V98, P277, DOI 10.1038/sj.bjc.6604174
   Carascossa S, 2010, GENE DEV, V24, P708, DOI 10.1101/gad.568410
   Ceschin DG, 2011, GENE DEV, V25, P1132, DOI 10.1101/gad.619211
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   Cheng DH, 2011, CHEMBIOCHEM, V12, P323, DOI 10.1002/cbic.201000522
   Chernov AV, 2010, J BIOL CHEM, V285, P19647, DOI 10.1074/jbc.M109.088153
   Chernov AV, 2009, J BIOL CHEM, V284, P12727, DOI 10.1074/jbc.M900273200
   Choi YL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-507
   Clark SE, 2011, BRIT J CANCER, V104, P120, DOI 10.1038/sj.bjc.6606021
   Curtis E, 2008, CANCER-AM CANCER SOC, V112, P171, DOI 10.1002/cncr.23131
   Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z
   Daujat S, 2002, CURR BIOL, V12, P2090, DOI 10.1016/S0960-9822(02)01387-8
   De Laurentiis M, 2010, CANCER TREAT REV, V36, pS80, DOI 10.1016/S0305-7372(10)70025-6
   El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103
   ELSTON EW, 1993, J CLIN PATHOL, V46, P189
   Fejerman L, 2008, PHARMACOGENOMICS, V9, P323, DOI 10.2217/14622416.9.3.323
   Feng Q, 2006, MOL CELL BIOL, V26, P7846, DOI 10.1128/MCB.00568-06
   Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983
   Fujiwara T, 2006, MOL CELL BIOL, V26, P2273, DOI 10.1128/MCB.26.6.2273-2285.2006
   Fulford LG, 2006, HISTOPATHOLOGY, V49, P22, DOI 10.1111/j.1365-2559.2006.02453.x
   Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hong H, 2004, CANCER-AM CANCER SOC, V101, P83, DOI 10.1002/cncr.20327
   Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158
   Huo D, 2008, BRIT J CANCER, V98, P992, DOI 10.1038/sj.bjc.6604275
   Huo DZ, 2009, J CLIN ONCOL, V27, P4515, DOI 10.1200/JCO.2008.19.6873
   Ishihara A, 2009, BREAST CANCER-TOKYO, V16, P179, DOI 10.1007/s12282-009-0108-x
   Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125
   Kim YR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-197
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Lavasani MA, 2012, J BIOPHOTONICS, DOI [10.1002/jbio.201100097, DOI 10.1002/JBI0.201100097]
   Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lu TY, 2009, J CELL BIOCHEM, V108, P315, DOI 10.1002/jcb.22256
   Majumder S, 2006, PROSTATE, V66, P1292, DOI 10.1002/pros.20438
   Miljkovic-Gacic I, 2005, HUM HERED, V60, P129, DOI 10.1159/000089553
   Morgan DK, 2008, MAMM GENOME, V19, P394, DOI 10.1007/s00335-008-9124-y
   Pazaiti A, 2011, WOMENS HEALTH, V7, P181, DOI [10.2217/WHE.11.5, 10.2217/whe.11.5]
   Prando ED, 2011, EPIGENETICS-US, V6, P1413, DOI 10.4161/epi.6.12.18271
   Reiner AP, 2007, HUM GENET, V121, P565, DOI 10.1007/s00439-007-0350-2
   Ruiz-Narvaez EA, 2010, BREAST CANCER RES TR, V123, P525, DOI 10.1007/s10549-010-0775-5
   Rybicki BA, 2011, GENES IMMUN, V12, P67, DOI 10.1038/gene.2010.56
   Shirley SH, 2009, CANCER RES, V69, P3405, DOI 10.1158/0008-5472.CAN-08-3628
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Tawfik O, 2007, VIRCHOWS ARCH, V450, P627, DOI 10.1007/s00428-007-0400-0
   Tawfik O, 2010, ANN CLIN LAB SCI, V40, P315
   Tawfik OW, 2006, HISTOPATHOLOGY, V48, P258, DOI 10.1111/j.1365-2559.2005.02322.x
   Vainshtein J, 2008, J NATL MED ASSOC, V100, P833, DOI 10.1016/S0027-9684(15)31378-X
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Xu H, 2008, BIOINFORMATICS, V24, P2344, DOI 10.1093/bioinformatics/btn402
   Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961
   Zika E, 2005, P NATL ACAD SCI USA, V102, P16321, DOI 10.1073/pnas.0505045102
NR 66
TC 27
Z9 31
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 10
PY 2013
VL 12
AR 40
DI 10.1186/1476-4598-12-40
PG 17
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 150WN
UT WOS:000319422300001
PM 23663560
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Xu, ZL
   Bolick, SCE
   DeRoo, LA
   Weinberg, CR
   Sandler, DP
   Taylor, JA
AF Xu, Zongli
   Bolick, Sophia C. E.
   DeRoo, Lisa A.
   Weinberg, Clarice R.
   Sandler, Dale P.
   Taylor, Jack A.
TI Epigenome-wide Association Study of Breast Cancer Using Prospectively
   Collected Sister Study Samples
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID PERIPHERAL-BLOOD DNA; METHYLATION PROFILES; GENETIC-VARIANTS; BRCA1
   PROMOTER; RISK; MODEL; ATM
AB Background Previous studies have suggested DNA methylation in blood is a potential epigenetic marker of cancer risk, but this has not been evaluated on a genome-wide scale in prospective studies for breast cancer.
   Methods We measured DNA methylation at 27 578 CpGs in blood samples from 298 women who developed breast cancer 0 to 5 years after enrollment in the Sister Study cohort and compared them with a random sample of 612 cohort women who remained cancer free. We also genotyped women for nine common polymorphisms associated with breast cancer.
   Results We identified 250 differentially methylated CpGs (dmCpGs) between case subjects and noncase subjects (false discovery rate [FDR] Q < 0.05). Of these dmCpGs, 75.2% were undermethylated in case subjects relative to noncase subjects. Women diagnosed within 1 year of blood draw had small but consistently greater divergence from noncase subjects than did women diagnosed at more than 1 year. Gene set enrichment analysis identified Kyoto Encyclopedia of Genes and Genomes cancer pathways at the recommended FDR of Q less than 0.25. Receiver operating characteristic analysis estimated a prediction accuracy of 65.8% (95% confidence interval = 61.0% to 70.5%) for methylation, compared with 56.0% for the Gail model and 58.8% for genome-wide association study polymorphisms. The prediction accuracy of just five dmCpGs (64.1%) was almost as good as the larger panel and was similar (63.1%) when replicated in a small sample of 81 women with diverse ethnic backgrounds.
   Conclusions Methylation profiling of blood holds promise for breast cancer detection and risk prediction.
C1 [Xu, Zongli; DeRoo, Lisa A.; Sandler, Dale P.; Taylor, Jack A.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
   [Bolick, Sophia C. E.; Taylor, Jack A.] NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.
   [Weinberg, Clarice R.] NIEHS, Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS); National Institutes of Health (NIH) - USA; NIH National
   Institute of Environmental Health Sciences (NIEHS)
RP Taylor, JA (通讯作者)，NIEHS, MD A3-05,111 TW Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.
EM taylor@niehs.nih.gov
RI Christina E. Weinberg, née/AAV-1839-2020; Sandler, Dale/E-5110-2019;
   taylor, jack/C-7154-2019
OI Sandler, Dale/0000-0002-6776-0018; taylor, jack/0000-0001-5303-6398;
   Weinberg, Clarice/0000-0002-7713-8556; xu, zongli/0000-0002-9034-8902
FU Intramural Research Program of the National Institutes of Health,
   National Institute of Environmental Health Sciences [Z01 ES044005, Z01
   ES044032, Z01 ES049033]
FX This research was supported by the Intramural Research Program of the
   National Institutes of Health, National Institute of Environmental
   Health Sciences (Z01 ES044005, Z01 ES044032, and Z01 ES049033).
CR American Cancer Society, 2011, CANC FACTS FIG 2011, P9
   [Anonymous], TNM CLASSIFICATION M
   Bosviel R, 2011, CLIN CHIM ACTA, V412, P1472, DOI 10.1016/j.cca.2011.04.027
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Campa D, 2011, JNCI-J NATL CANCER I, V103, P1252, DOI 10.1093/jnci/djr265
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Decarli A, 2006, J NATL CANCER I, V98, P1686, DOI 10.1093/jnci/djj463
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Koestler DC, 2012, CANCER EPIDEM BIOMAR, V21, P1293, DOI 10.1158/1055-9965.EPI-12-0361
   Langevin SM, 2012, EPIGENETICS-US, V7, P291, DOI 10.4161/epi.7.3.19134
   Lewandowska J, 2011, MUTAGENESIS, V26, P475, DOI 10.1093/mutage/ger019
   Lynch HT, 2008, BREAST J, V14, P3, DOI 10.1111/j.1524-4741.2007.00515.x
   Marsit CJ, 2011, J CLIN ONCOL, V29, P1133, DOI 10.1200/JCO.2010.31.3577
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   SELF SG, 1988, ANN STAT, V16, P64, DOI 10.1214/aos/1176350691
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Therneau TM, 1999, LIFETIME DATA ANAL, V5, P99, DOI 10.1023/A:1009691327335
   Wacholder S, 2010, NEW ENGL J MED, V362, P986, DOI 10.1056/NEJMoa0907727
   Wessels LFA, 2005, BIOINFORMATICS, V21, P3755, DOI 10.1093/bioinformatics/bti429
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Wu HC, 2011, EPIGENETICS-US, V6, P29, DOI 10.4161/epi.6.1.13393
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
NR 31
TC 107
Z9 119
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD MAY
PY 2013
VL 105
IS 10
BP 694
EP 700
DI 10.1093/jnci/djt045
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 149JS
UT WOS:000319315700008
PM 23578854
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Maekawa, R
   Sato, S
   Yamagata, Y
   Asada, H
   Tamura, I
   Lee, L
   Okada, M
   Tamura, H
   Takaki, E
   Nakai, A
   Sugino, N
AF Maekawa, Ryo
   Sato, Shun
   Yamagata, Yoshiaki
   Asada, Hiromi
   Tamura, Isao
   Lee, Lifa
   Okada, Maki
   Tamura, Hiroshi
   Takaki, Eiichi
   Nakai, Akira
   Sugino, Norihiro
TI Genome-Wide DNA Methylation Analysis Reveals a Potential Mechanism for
   the Pathogenesis and Development of Uterine Leiomyomas
SO PLOS ONE
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; GLUTATHIONE-S-TRANSFERASE; BREAST-CANCER;
   GENE-EXPRESSION; X-CHROMOSOME; EPIGENETIC REGULATION; INACTIVE-X; IRS-1;
   DAPK1; HYPERMETHYLATION
AB Background: The pathogenesis of uterine leiomyomas, the most common benign tumor in women, remains unclear. Since acquired factors such as obesity, hypertension and early menarche place women at greater risk for uterine leiomyomas, uterine leiomyomas may be associated with epigenetic abnormalities that are caused by unfavorable environmental exposures.
   Principal Findings: Profiles of genome-wide DNA methylation and mRNA expression were investigated in leiomyomas and in myometrium with and without leiomyomas. Profiles of DNA methylation and mRNA expression in the myometrium with and without leiomyomas were quite similar while those in leiomyomas were distinct. We identified 120 genes whose DNA methylation and mRNA expression patterns differed between leiomyomas and the adjacent myometrium. The biological relevance of the aberrantly methylated and expressed genes was cancer process, including IRS1 that is related to transformation, and collagen-related genes such as COL4A1, COL4A2 and COL6A3. We also detected 22 target genes of estrogen receptor (ER) alpha, including apoptosis-related genes, that have aberrant DNA methylation in the promoter, suggesting that the aberrant epigenetic regulation of ER alpha-target genes contributes to the aberrant response to estrogen.
   Conclusions: Aberrant DNA methylation and its related transcriptional aberration were associated with cancer processes, which may represent a critical initial mechanism that triggers transformation of a single tumor stem cell that will eventually develop into a monoclonal leiomyoma tumor. The aberrant epigenetic regulation of ER alpha-target genes also may contribute to the aberrant response to estrogen, which is involved in the development of uterine leiomyomas after menarche.
C1 [Maekawa, Ryo; Sato, Shun; Yamagata, Yoshiaki; Asada, Hiromi; Tamura, Isao; Lee, Lifa; Okada, Maki; Tamura, Hiroshi; Sugino, Norihiro] Yamaguchi Univ, Grad Sch Med, Dept Obstet & Gynecol, Ube, Yamaguchi 755, Japan.
   [Takaki, Eiichi; Nakai, Akira] Yamaguchi Univ, Dept Biochem & Mol Biol, Grad Sch Med, Ube, Yamaguchi 755, Japan.
C3 Yamaguchi University; Yamaguchi University
RP Sugino, N (通讯作者)，Yamaguchi Univ, Grad Sch Med, Dept Obstet & Gynecol, Ube, Yamaguchi 755, Japan.
EM sugino@yamaguchi-u.ac.jp
RI Maekawa, Ryo/AAR-4233-2020
OI Maekawa, Ryo/0000-0003-0923-376X
FU Japan Society for the Promotion of Science KAKENHI [23791846, 23890140,
   24592471]; Ministry of Education, Science, and Culture, Japan
   [24791704]; Grants-in-Aid for Scientific Research [23791846, 24791704,
   23890140, 24592471] Funding Source: KAKEN
FX This work was supported in part by Japan Society for the Promotion of
   Science KAKENHI Grant Number 23791846, 23890140, 24592471, and 24791704
   for Scientific Research from the Ministry of Education, Science, and
   Culture, Japan (http://www.jsps.go.jp/j-grantsinaid/index.html). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Asada H, 2008, MOL HUM REPROD, V14, P539, DOI 10.1093/molehr/gan045
   Bajekal N, 2000, HUM REPROD UPDATE, V6, P614, DOI 10.1093/humupd/6.6.614
   Bell A, 2011, CANCER-AM CANCER SOC, V117, P2898, DOI 10.1002/cncr.25818
   Bernard D, 2010, AGING-US, V2, P317, DOI 10.18632/aging.100153
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   Cesarone G, 2006, J CELL BIOCHEM, V98, P440, DOI 10.1002/jcb.20817
   Chiaffarino F, 1999, OBSTET GYNECOL, V94, P395, DOI 10.1016/S0029-7844(99)00305-1
   Claus R, 2012, INT J CANCER, V131, pE138, DOI 10.1002/ijc.26429
   DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557
   DeAngelis T, 2006, ONCOGENE, V25, P32, DOI 10.1038/sj.onc.1209013
   del Rincón SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104
   Esposito DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036190
   Etcheverry A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-701
   Faerstein E, 2001, AM J EPIDEMIOL, V153, P1, DOI 10.1093/aje/153.1.1
   FAERSTEIN E, 2001, AM J EPIDEMIOL, V153, P11
   Feng Gang, 2010, BMC Res Notes, V3, P10, DOI 10.1186/1756-0500-3-10
   Gilden M, 2012, FERTIL STERIL
   Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605
   Hitchler MJ, 2006, EPIGENETICS-US, V1, P163, DOI 10.4161/epi.1.4.3401
   Hou X, 2011, ONCOGENE, V30, P2933, DOI 10.1038/onc.2011.19
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Iwatani M, 2006, STEM CELLS, V24, P2549, DOI 10.1634/stemcells.2005-0427
   Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808
   Kearns PR, 2003, BRIT J HAEMATOL, V120, P80, DOI 10.1046/j.1365-2141.2003.04039.x
   Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294
   Lieb JD, 2006, CYTOGENET GENOME RES, V114, P1, DOI 10.1159/000091922
   Maekawa R, 2011, J REPROD DEVELOP, V57, P604, DOI 10.1262/jrd.11-035A
   Marinescu VD, 2005, NUCLEIC ACIDS RES, V33, pD91, DOI 10.1093/nar/gki103
   Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256
   Missaoui N, 2011, PATHOL RES PRACT, V207, P37, DOI 10.1016/j.prp.2010.11.001
   Morelli C, 2004, ONCOGENE, V23, P7517, DOI 10.1038/sj.onc.1208014
   Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436
   Navarro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033284
   Ono M, 2007, P NATL ACAD SCI USA, V104, P18700, DOI 10.1073/pnas.0704472104
   Ono M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036935
   Peng DF, 2009, GUT, V58, P5, DOI 10.1136/gut.2007.146290
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Reiss K, 2012, J CELL PHYSIOL, V227, P2992, DOI 10.1002/jcp.24019
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Shiota K, 2002, GENES CELLS, V7, P961, DOI 10.1046/j.1365-2443.2002.00574.x
   Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   Skubitz KM, 2003, CANCER, V98, P1029, DOI 10.1002/cncr.11586
   Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Sun M, 2001, CANCER RES, V61, P5985
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940
   Tseng YH, 2005, NAT CELL BIOL, V7, P601, DOI 10.1038/ncb1259
   Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423
   Vanharanta S, 2005, ONCOGENE, V24, P6545, DOI 10.1038/sj.onc.1208784
   Weston G, 2003, MOL HUM REPROD, V9, P541, DOI 10.1093/molehr/gag066
   White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001
   Wu Q, 2004, BIOL REPROD, V70, P1790, DOI 10.1095/biolreprod.103.025387
   Yamagata Y, 2009, MOL HUM REPROD, V15, P259, DOI 10.1093/molehr/gap010
   Zhang P, 2006, HUM PATHOL, V37, P1350, DOI 10.1016/j.humpath.2006.05.005
NR 56
TC 80
Z9 90
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2013
VL 8
IS 6
AR e66632
DI 10.1371/journal.pone.0066632
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 190LY
UT WOS:000322342800087
PM 23818951
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU White, AJ
   Sandler, DP
   Bolick, SCE
   Xu, ZL
   Taylor, JA
   DeRoo, LA
AF White, Alexandra J.
   Sandler, Dale P.
   Bolick, Sophia C. E.
   Xu, Zongli
   Taylor, Jack A.
   DeRoo, Lisa A.
TI Recreational and household physical activity at different time points
   and DNA global methylation
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; LINE-1; Physical activity; Pyrosequencing; Sister Study
ID MODERATE FOLATE-DEPLETION; ASSOCIATION; EPIGENETICS; MECHANISMS;
   DECREASES; PATTERNS; ESTROGEN; GENDER; RISK
AB Background: DNA methylation patterns are heritable but can change over time and in response to exposures. Lower global DNA methylation, which may result in increased genomic and chromosomal instability, has been associated with increased cancer risk. Physical activity is a modifiable factor that has been inversely related to the risk of cancer. Changes in DNA methylation may be a mechanism by which lifestyle and environment factors influence disease. We investigated the relationship between DNA methylation and physical activity in a sample of women enroled in The Sister Study, a large United States (U.S.) cohort study of women aged 35-74 years with a family history of breast cancer.
   Methods: Global DNA methylation was measured using bisulphite-converted DNA and pyrosequencing of a LINE-1 repetitive sequence in the peripheral blood of 647 non-Hispanic white women. Physical activity (average hours per week) was retrospectively assessed for three time periods: childhood (ages 5-12), teenage years (ages 13-19) and the previous 12 months.
   Findings: Compared with women with physical activity levels below the median for all three time periods, those at or above the median physical activity for one (beta = 0.20, 95% confidence interval (CI): -0.10, 0.49), two (beta = 0.22, 95% CI: - 0.08, 0.52) or all three (beta = 0.33, 95% CI: 0.01, 0.66) time periods had increased global methylation.
   Interpretation: Maintaining higher levels of physical activity over these three time periods was associated with increased global DNA methylation, consistent with reported associations between exercise and decreased cancer risk. Published by Elsevier Ltd.
C1 [White, Alexandra J.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
   [Sandler, Dale P.; Xu, Zongli; Taylor, Jack A.; DeRoo, Lisa A.] NIEHS, Epidemiol Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
   [Bolick, Sophia C. E.; Taylor, Jack A.] NIEHS, Mol Carcinogenesis Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS)
RP DeRoo, LA (通讯作者)，NIEHS, Epidemiol Branch, POB 12233,Mail Drop A3-05 111,TW Alexander Dr, Res Triangle Pk, NC 27709 USA.
EM DeRooL@niehs.nih.gov
RI Sandler, Dale/E-5110-2019; White, Alexandra/D-9687-2019; taylor,
   jack/C-7154-2019
OI Sandler, Dale/0000-0002-6776-0018; White, Alexandra/0000-0003-2455-2945;
   xu, zongli/0000-0002-9034-8902; taylor, jack/0000-0001-5303-6398
FU Intramural Research Program of the NIH, National Institute of
   Environmental Health Sciences [Z01 ES044005]; NIEHS [ES07018]
FX This research was supported by the Intramural Research Program of the
   NIH, National Institute of Environmental Health Sciences, (Z01
   ES044005). Alexandra J. White was also supported in part by NIEHS
   training Grant ES07018. We thank Ms. Karen Baldwin for assisting with
   the laboratory assays and Drs. Anne Marie Jukic and Abee Boyles for
   helpful comments on an earlier draft of this paper.
CR Ainsworth B.E., 2002, COMPENDIUM PHYS ACTI
   Alegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/EPI.11.22, 10.2217/epi.11.22]
   Bertone-Johnson ER, 2009, AM J EPIDEMIOL, V170, P1095, DOI 10.1093/aje/kwp254
   Bryan AD, 2013, ANN BEHAV MED, V45, P89, DOI 10.1007/s12160-012-9411-4
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI 10.1177/0192623309354108
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Friedenreich CM, 2010, EUR J CANCER, V46, P2593, DOI 10.1016/j.ejca.2010.07.028
   Friedenreich CM, 2010, J CLIN ONCOL, V28, P1458, DOI 10.1200/JCO.2009.24.9557
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Hodge DR, 2005, CANCER RES, V65, P4673, DOI 10.1158/0008-5472.CAN-04-3589
   Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jung MM, 2011, CANCER CAUSE CONTROL, V22, P1297, DOI 10.1007/s10552-011-9803-y
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961
   Klein Cb LJ, 2005, P AM ASSOC CANC RES, V46, P2744
   Lim Unhee, 2012, Methods Mol Biol, V863, P359, DOI 10.1007/978-1-61779-612-8_23
   Luttropp K, 2012, SCAND J CLIN LAB INV
   McTiernan A, 2008, NAT REV CANCER, V8, P205, DOI 10.1038/nrc2325
   Nagy C, 2012, EPIGENOMICS-UK, V4, P445, DOI [10.2217/EPI.12.37, 10.2217/epi.12.37]
   Nakajima K, 2010, INT J SPORTS MED, V31, P671, DOI 10.1055/s-0029-1246140
   Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56
   Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998
   Russo J, 2000, J Natl Cancer Inst Monogr, P17
   Shephard RJ, 2003, BRIT J SPORT MED, V37, P197, DOI 10.1136/bjsm.37.3.197
   Taylor WC, 1999, MED SCI SPORT EXER, V31, P118, DOI 10.1097/00005768-199901000-00019
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yue W, 2013, STEROIDS, V78, P161, DOI 10.1016/j.steroids.2012.11.001
   Zeng HM, 2012, BREAST CANCER RES TR, V133, P127, DOI 10.1007/s10549-011-1716-7
   Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
   Zhang FF, 2012, EPIGENETICS, V7
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 39
TC 69
Z9 79
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JUN
PY 2013
VL 49
IS 9
BP 2199
EP 2206
DI 10.1016/j.ejca.2013.02.013
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 144YG
UT WOS:000318978000015
PM 23473616
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Cuddington, BP
   Dyer, AL
   Workenhe, ST
   Mossman, KL
AF Cuddington, B. P.
   Dyer, A. L.
   Workenhe, S. T.
   Mossman, K. L.
TI Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells
   and breast cancer-initiating cells irrespective of tumor subtype
SO CANCER GENE THERAPY
LA English
DT Article
DE oncolytic virus; breast cancer therapy; cancer-initiating cells
ID SIDE POPULATION CELLS; STEM-LIKE CELLS; VIRUSES; ALPHAHERPESVIRUSES;
   EPIGENETICS; MICRORNAS; GROWTH; ENTRY; HOST
AB Oncolytic viruses are attractive cancer therapeutics because of their unique mechanisms of tumor cell targeting and the absence of toxic side effects associated with current treatments. Bovine herpesvirus type 1 (BHV-1) is a species-specific herpesvirus that fails to induce cytopathic effects in normal human cells, but is capable of infecting and killing a variety of immortalized and transformed human cell types, including human breast tumor cell lines from luminal, basal A and basal B subtypes, representing a variety of receptor expression profiles. BHV-1 is capable of initiating replication in and killing both bulk and side population cells, the latter of which have enhanced tumor-initiating capacity. Despite the lack of a productive infection or secretion of cytotoxic factors, BHV-1 infection decreases cellular viability in long-term culture following low multiplicity of infection. Moreover, BHV-1-infected MCF7 cells are significantly diminished in their capacity to form tumors in vivo. Overall, these studies suggest that oncolytic BHV-1 targets bulk breast cancer cells and cancer-initiating cells from luminal and basal subtypes by a novel mechanism that is not contingent upon cellular receptor expression status.
C1 [Cuddington, B. P.; Dyer, A. L.; Workenhe, S. T.; Mossman, K. L.] McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada.
C3 McMaster University
RP Mossman, KL (通讯作者)，McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West,MDCL 5026, Hamilton, ON L8S 4K1, Canada.
EM mossk@mcmaster.ca
FU Natural Sciences and Engineering Research Council; Canadian Breast
   Cancer Foundation; Cancer Research Society; Canadian Cancer Society
   Research Institute
FX We thank Vikram Misra (University of Saskatchewan, Canada), Gunther Keil
   (Friedrich-Loeffler-Institut, Germany) and Clinton Jones (University of
   Nebraska, USA) for reagents and Derek Cummings for technical assistance.
   AD held a Natural Sciences and Engineering Research Council studentship.
   BC holds a fellowship from the Canadian Breast Cancer Foundation. This
   work was sponsored by operating grants from the Cancer Research Society
   and the Canadian Cancer Society Research Institute (formerly the
   Canadian Breast Cancer Research Alliance). We acknowledge there are no
   financial conflicts of interest related to this research.
CR Abril C, 2004, J VIROL, V78, P3644, DOI 10.1128/JVI.78.7.3644-3653.2004
   Adhya D, 2010, J BIOSCIENCES, V35, P647, DOI 10.1007/s12038-010-0072-9
   Ahtiainen L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013859
   Bauerschmitz GJ, 2008, CANCER RES, V68, P5533, DOI 10.1158/0008-5472.CAN-07-5288
   Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T
   Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103
   Cervantes-García D, 2008, ANN HEPATOL, V7, P34
   Cheng XY, 2009, J CELL MOL MED, V13, P4377, DOI 10.1111/j.1582-4934.2008.00664.x
   Cripe TP, 2009, MOL THER, V17, P1677, DOI 10.1038/mt.2009.193
   Cullen BR, 2011, GENE DEV, V25, P1881, DOI 10.1101/gad.17352611
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dey M, 2011, STEM CELL REV REP, V7, P119, DOI 10.1007/s12015-010-9132-7
   Engelmann K, 2008, CANCER RES, V68, P2419, DOI 10.1158/0008-5472.CAN-07-2249
   Eriksson M, 2007, MOL THER, V15, P2088, DOI 10.1038/sj.mt.6300300
   Fernandez AF, 2010, ONCOGENE, V29, P1405, DOI 10.1038/onc.2009.517
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Geevarghese SK, 2010, HUM GENE THER, V21, P1119, DOI 10.1089/hum.2010.020
   Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618
   Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797
   Han JS, 2009, INT J ONCOL, V34, P1449, DOI 10.3892/ijo_00000273
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hemmings C, 2010, PATHOLOGY, V42, P105, DOI 10.3109/00313020903488773
   Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108
   Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101
   Hushur O, 2004, J VET MED SCI, V66, P453, DOI 10.1292/jvms.66.453
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596
   Lal R, 2009, CURR OPIN MOL THER, V11, P532
   Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035
   Lu F, 2010, J VIROL, V84, P2697, DOI 10.1128/JVI.01997-09
   Marcato P, 2009, MOL THER, V17, P972, DOI 10.1038/mt.2009.58
   Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228
   Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236
   Mastrangelo MJ, 2000, ADV EXP MED BIOL, V465, P391
   Melcher A, 2011, MOL THER, V19, P1008, DOI 10.1038/mt.2011.65
   Nakao A, 2011, CANCER GENE THER, V18, P167, DOI 10.1038/cgt.2010.65
   Niller HH, 2009, SEMIN CANCER BIOL, V19, P158, DOI 10.1016/j.semcancer.2009.02.012
   Paschos K, 2010, TRENDS MICROBIOL, V18, P439, DOI 10.1016/j.tim.2010.07.003
   Patel SA, 2010, BREAST CANCER-TARGET, V2, P1
   Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592
   Rodrigues R, 2010, CANCER GENE THER, V17, P344, DOI 10.1038/cgt.2009.77
   Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73
   Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24
   Vähä-Koskela MJV, 2007, CANCER LETT, V254, P178, DOI 10.1016/j.canlet.2007.02.002
   Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048
   Yamada Y, 2010, ADV GENET, V70, P177, DOI [10.1016/B978-0-12-380866-0.60007-1, 10.1016/S0065-2660(10)70007-9]
   Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104
NR 50
TC 18
Z9 18
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD MAY
PY 2013
VL 20
IS 5
BP 282
EP 289
DI 10.1038/cgt.2013.18
PG 8
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA 145QH
UT WOS:000319031400003
PM 23618948
OA Bronze
DA 2025-01-12
ER

PT J
AU Franci, C
   Zhou, J
   Jiang, ZS
   Modrusan, Z
   Good, Z
   Jackson, E
   Kouros-Mehr, H
AF Franci, Christian
   Zhou, Jenny
   Jiang, Zhaoshi
   Modrusan, Zora
   Good, Zinaida
   Jackson, Erica
   Kouros-Mehr, Hosein
TI Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases
   in the MMTV-PyMT Breast Cancer Model
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION PROFILES; MOLECULAR PORTRAITS; TRANSCRIPTION FACTORS;
   TARGETING NOTCH; STAT FAMILY; RESISTANCE; DISTINCT; INTERLEUKIN-6;
   SIGNATURE; PATHWAY
AB Cancer metastases arise in part from disseminated tumor cells originating from the primary tumor and from residual disease persisting after therapy. The identification of biomarkers on micro-metastases, disseminated tumors, and residual disease may yield novel tools for early detection and treatment of these disease states prior to their development into metastases and recurrent tumors. Here we describe the molecular profiling of disseminated tumor cells in lungs, lung metastases, and residual tumor cells in the MMTV-PyMT breast cancer model. MMTV-PyMT mice were bred with actin-GFP mice, and focal hyperplastic lesions from pubertal MMTV-PyMT;actin-GFP mice were orthotopically transplanted into FVB/n mice to track single tumor foci. Tumor-bearing mice were treated with TAC chemotherapy (docetaxel, doxorubicin, cyclophosphamide), and residual and relapsed tumor cells were sorted and profiled by mRNA microarray analysis. Data analysis revealed enrichment of the Jak/Stat pathway, Notch pathway, and epigenetic regulators in residual tumors. Stat1 was significantly up-regulated in a DNA-damage-resistant population of residual tumor cells, and a pre-existing Stat1 sub-population was identified in untreated tumors. Tumor cells from adenomas, carcinomas, lung disseminated tumor cells, and lung metastases were also sorted from MMTV-PyMT transplant mice and profiled by mRNA microarray. Whereas disseminated tumors cells appeared similar to carcinoma cells at the mRNA level, lung metastases were genotypically very different from disseminated cells and primary tumors. Lung metastases were enriched for a number of chromatin-modifying genes and stem cell-associated genes. Histone analysis of H3K4 and H3K9 suggested that lung metastases had been reprogrammed during malignant progression. These data identify novel biomarkers of residual tumor cells and disseminated tumor cells and implicate pathways that may mediate metastasis formation and tumor relapse after therapy.
C1 [Franci, Christian; Zhou, Jenny; Jiang, Zhaoshi; Modrusan, Zora; Good, Zinaida; Jackson, Erica; Kouros-Mehr, Hosein] Genentech Inc, Res Oncol Dept, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Kouros-Mehr, H (通讯作者)，Eli Lilly & Co, Indianapolis, IN 46285 USA.
EM kouros.mehr@gmail.com
OI Good, Zinaida/0000-0003-2343-5771
FU Genentech, Inc.
FX Funding was provided by Genentech, Inc. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007
   Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Carmo CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019861
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Clarke M, 2008, LANCET, V371, P29, DOI 10.1016/S0140-6736(08)60069-0
   Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7
   Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3
   Ezponda T., 2012, ONCOGENE
   FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927
   Fryknäs M, 2007, INT J CANCER, V120, P189, DOI 10.1002/ijc.22291
   Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349
   Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043
   Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Hall C, 2012, CANCER-AM CANCER SOC, V118, P342, DOI 10.1002/cncr.26202
   Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Khodarev NN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005821
   Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100
   Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0
   Knüpfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3
   Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7
   Lucci A, 2012, LANCET ONCOL, V13, P688, DOI 10.1016/S1470-2045(12)70209-7
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Martin M, 2006, ANN ONCOL, V17, P1205, DOI 10.1093/annonc/mdl135
   McAuliffe SM, 2012, P NATL ACAD SCI USA, V109, pE2939, DOI 10.1073/pnas.1206400109
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Montel V, 2005, AM J PATHOL, V166, P1565, DOI 10.1016/S0002-9440(10)62372-3
   Naumov GN, 2001, SEMIN CANCER BIOL, V11, P271, DOI 10.1006/scbi.2001.0382
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823
   Patterson SG, 2006, ONCOGENE, V25, P6113, DOI 10.1038/sj.onc.1209632
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Popovic R, 2012, CANCER DISCOV, V2, P405, DOI 10.1158/2159-8290.CD-12-0076
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004
   Rickardson L, 2005, BRIT J CANCER, V93, P483, DOI 10.1038/sj.bjc.6602699
   Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412
   Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447
   Rodriguez-Viciana P, 2006, P NATL ACAD SCI USA, V103, P19290, DOI 10.1073/pnas.0609343103
   Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833
   Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Sheen-Chen SM, 2007, ANTICANCER RES, V27, P2481
   Slade MJ, 2007, NAT CLIN PRACT ONCOL, V4, P30, DOI 10.1038/ncponc0685
   Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021
   Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Townsend PA, 2005, J CELL SCI, V118, P1629, DOI 10.1242/jcs.01728
   Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250
   van Attikum H, 2009, TRENDS CELL BIOL, V19, P207, DOI 10.1016/j.tcb.2009.03.001
   Vecchi M, 2008, ONCOGENE, V27, P2148, DOI 10.1038/sj.onc.1210858
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162
   Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100
   Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217
   Zhang GJ, 1999, ANTICANCER RES, V19, P1427
   Zhang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020965
NR 73
TC 30
Z9 40
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 8
PY 2013
VL 8
IS 3
AR e58183
DI 10.1371/journal.pone.0058183
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 140TZ
UT WOS:000318679900052
PM 23520493
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Liu, K
   Cang, SD
   Ma, YH
   Chiao, JW
AF Liu, Katherine
   Cang, Shundong
   Ma, Yuehua
   Chiao, Jen Wei
TI Synergistic effect of paclitaxel and epigenetic agent phenethyl
   isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in
   breast cancer cells
SO CANCER CELL INTERNATIONAL
LA English
DT Article
ID PHASE-I TRIAL; HISTONE DEACETYLASE INHIBITOR; PHENYLHEXYL
   ISOTHIOCYANATE; TAXOL; MECHANISM; ACETYLATION; TRANSCRIPTION;
   METHYLATION; REPRESSION; CHROMATIN
AB This study examined whether combining paclitaxel (taxol) with a novel epigenetic agent phenethyl isothiocyanate (PEITC) will yield a synergistic effect on inhibiting breast cancer cells. Two drug-resistant breast cancer cell lines, MCF7 and MDA-MB-231, were treated with PEITC and taxol. Cell growth, cell cycle, and apoptosis were examined. The combination of PEITC and taxol significantly decreased the IC50 of PEITC and taxol over each agent alone. The combination also increased apoptosis by more than two fold over each single agent in both cell lines. A significant increase of cells in the G2/M phases was detected. In conclusion, the combination of PEITC and taxol exhibits a synergistic effect on growth inhibition in breast cancer cells. This combination deserves further study in vivo.
C1 [Liu, Katherine; Chiao, Jen Wei] New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
   [Cang, Shundong; Ma, Yuehua] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Peoples R China.
C3 New York Medical College; Zhengzhou University
RP Chiao, JW (通讯作者)，New York Med Coll, Dept Med, Valhalla, NY 10595 USA.
EM jen-wei_chiao@nymc.edu
RI Liu, Katherine/GQA-3751-2022
CR Badia E, 2007, CURR MED CHEM, V14, P3035, DOI 10.2174/092986707782794023
   Beklemisheva AA, 2006, ANTICANCER RES, V26, P1225
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BROWN T, 1991, J CLIN ONCOL, V9, P1261, DOI 10.1200/JCO.1991.9.7.1261
   Cang SD, 2009, INT J ONCOL, V35, P1417, DOI 10.3892/ijo_00000459
   CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x
   DONEHOWER RC, 1987, CANCER TREAT REP, V71, P1171
   Elbaz HA, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-4
   FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892
   Firer MA, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-70
   FUCHS DA, 1978, CANCER TREAT REP, V62, P1219
   GREM JL, 1987, CANCER TREAT REP, V71, P1179
   Guo Y, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-72
   HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507
   Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55
   HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a
   Jordan MA, 2007, CURR CANCER DRUG TAR, V7, P730, DOI 10.2174/156800907783220417
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   Kelly WK, 2003, CLIN CANCER RES, V9, P3578
   KUMAR N, 1981, J BIOL CHEM, V256, P435
   Lamba G, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-14
   LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488
   Lu LL, 2006, ONCOL REP, V16, P1363
   Lu QY, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-6
   Ma XD, 2006, INT J ONCOL, V28, P1287
   MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Munster PN, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3501
   Rafiyath SM, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-10
   SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041
   SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0
   SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629
   Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5
   Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096
   Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693
   Wang KM, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-36
   Wang LG, 2008, INT J ONCOL, V33, P375, DOI 10.3892/ijo_00000018
   Wang LG, 2007, MOL CARCINOGEN, V46, P24, DOI 10.1002/mc.20258
   WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045
   Weiss L, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-38
   WIERNIK PH, 1987, CANCER RES, V47, P2486
   WIERNIK PH, 1987, J CLIN ONCOL, V5, P1232, DOI 10.1200/JCO.1987.5.8.1232
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545
   Xu BH, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-3
   Yuan Y, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-16
   Zou Y, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-36
NR 49
TC 63
Z9 72
U1 0
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD FEB 7
PY 2013
VL 13
AR 10
DI 10.1186/1475-2867-13-10
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 139US
UT WOS:000318611000001
PM 23388416
OA gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Galli, R
   Paone, A
   Fabbri, M
   Zanesi, N
   Calore, F
   Cascione, L
   Acunzo, M
   Stoppacciaro, A
   Tubaro, A
   Lovat, F
   Gasparini, P
   Fadda, P
   Alder, H
   Volinia, S
   Filippini, A
   Ziparo, E
   Riccioli, A
   Croce, CM
AF Galli, Roberta
   Paone, Alessio
   Fabbri, Muller
   Zanesi, Nicola
   Calore, Federica
   Cascione, Luciano
   Acunzo, Mario
   Stoppacciaro, Antonella
   Tubaro, Andrea
   Lovat, Francesca
   Gasparini, Pierluigi
   Fadda, Paolo
   Alder, Hansjuerg
   Volinia, Stefano
   Filippini, Antonio
   Ziparo, Elio
   Riccioli, Anna
   Croce, Carlo M.
TI Toll-like receptor 3 (TLR3) activation induces microRNA-dependent
   reexpression of functional RARβ and tumor regression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE inflammation; combined chemotherapy
ID GENE-EXPRESSION; PROSTATE-CANCER; CELLS; METHYLATION; BREAST;
   STIMULATION; APOPTOSIS; PROMOTER; IMMUNITY
AB Toll-like receptor 3 (TLR3) is a key effector of the innate immune system against viruses. Activation of TLR3 exerts an antitumoral effect through a mechanism of action still poorly understood. Here we show that TLR3 activation by polyinosinic: polycytidylic acid induces up-regulation of microRNA-29b, -29c, -148b, and -152 in tumor-derived cell lines and primary tumors. In turn, these microRNAs induce reexpression of epigenetically silenced genes by targeting DNA methyltransferases. In DU145 and TRAMP-C1 prostate and MDA-MB-231 breast cancer cells, we demonstrated that polyinosinic: polycytidylic acid-mediated activation of TLR3 induces microRNAs targeting DNA methyltransferases, leading to demethylation and reexpression of the oncosuppressor retinoic acid receptor beta (RAR beta). As a result, cancer cells become sensitive to retinoic acid and undergo apoptosis both in vitro and in vivo. This study provides evidence of an antitumoral mechanism of action upon TLR3 activation and the biological rationale for a combined TLR3 agonist/retinoic acid treatment of prostate and breast cancer.
C1 [Galli, Roberta; Filippini, Antonio; Ziparo, Elio; Riccioli, Anna] Univ Roma La Sapienza, Unit Histol & Med Embryol, Dept Anat Histol Forens & Orthopaed Sci DAHFMO, Ist Pasteur,Fdn Cenci Bolognetti, I-00161 Rome, Italy.
   [Galli, Roberta; Paone, Alessio; Zanesi, Nicola; Calore, Federica; Cascione, Luciano; Acunzo, Mario; Lovat, Francesca; Gasparini, Pierluigi; Fadda, Paolo; Alder, Hansjuerg; Volinia, Stefano; Croce, Carlo M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
   [Galli, Roberta; Paone, Alessio; Zanesi, Nicola; Calore, Federica; Cascione, Luciano; Acunzo, Mario; Lovat, Francesca; Gasparini, Pierluigi; Fadda, Paolo; Alder, Hansjuerg; Volinia, Stefano; Croce, Carlo M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Fabbri, Muller] Univ So Calif, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90089 USA.
   [Fabbri, Muller] Univ So Calif, Dept Mol Microbiol & Immunol, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
   [Fabbri, Muller] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA.
   [Fabbri, Muller] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA.
   [Cascione, Luciano] Univ Catania, Dept Clin & Mol Biomed, I-95122 Catania, Italy.
   [Stoppacciaro, Antonella; Tubaro, Andrea] Univ Roma La Sapienza, Osped St Andrea, Dept Clin & Mol Med, I-00185 Rome, Italy.
   [Volinia, Stefano] Univ Ferrara, Dept Morphol & Embryol, I-44100 Ferrara, Italy.
C3 Fondazione Cenci Bolognetti; Sapienza University Rome; University System
   of Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; Children's
   Hospital Los Angeles; University of Southern California; University of
   Southern California; University of Southern California; Children's
   Hospital Los Angeles; University of Catania; Sapienza University Rome;
   Azienda Ospedaliera Sant'Andrea; University of Ferrara
RP Croce, CM (通讯作者)，Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
EM carlo.croce@osumc.edu
RI Acunzo, Mario/ABE-1739-2020; Gasparini, Pierluigi/AEW-6133-2022; Paone,
   Alessio/AAB-4957-2019; Cascione, Luciano/X-3115-2019; Volinia,
   Stefano/A-3029-2010
OI Volinia, Stefano/0000-0003-0910-3893; Gasparini,
   Pierluigi/0000-0001-8311-8845; Acunzo, Mario/0000-0002-3942-9061;
   riccioli, anna/0000-0002-9792-4933; stoppacciaro,
   antonella/0000-0002-8506-3363; filippini, antonio/0000-0001-8453-287X;
   Ziparo, Elio/0000-0002-8776-3515; Paone, Alessio/0000-0001-9406-3982;
   Cascione, Luciano/0000-0002-4606-0637
FU National Institutes of Health [UO1CA152758, RC2CA148302]; Fondazione
   Roma
FX We thank Prof. Kay Huebner for critical reading of the manuscript and
   Dorothee Wernicke for helpful scientific discussion. This study was
   supported by National Institutes of Health Grants UO1CA152758 and
   RC2CA148302 to C. M. C. and by a grant from Fondazione Roma to E.Z.
CR ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30
   Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381
   Chin AI, 2010, CANCER RES, V70, P2595, DOI 10.1158/0008-5472.CAN-09-1162
   Cittelly DM, 2013, ONCOGENE, V32, P2555, DOI 10.1038/onc.2012.275
   Conforti R, 2010, CANCER RES, V70, P490, DOI 10.1158/0008-5472.CAN-09-1890
   Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Galli R, 2010, J IMMUNOL, V184, P6658, DOI 10.4049/jimmunol.0902401
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Inao T, 2012, BREAST CANCER RES TR, V134, P89, DOI 10.1007/s10549-011-1930-3
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Larsen Peter H, 2007, Sci STKE, V2007, ppe47, DOI 10.1126/stke.4022007pe47
   Liu XG, 2010, J IMMUNOL, V185, P7244, DOI 10.4049/jimmunol.1001573
   López-Otín C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634
   Michelsen KS, 2007, CURR OPIN HEMATOL, V14, P48, DOI 10.1097/00062752-200701000-00010
   Moschos SA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-240
   Motsch N, 2007, RNA BIOL, V4, P131, DOI 10.4161/rna.4.3.5206
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957
   Paone A, 2008, CARCINOGENESIS, V29, P1334, DOI 10.1093/carcin/bgn149
   Salaun B, 2007, EUR J IMMUNOL, V37, P3311, DOI 10.1002/eji.200737744
   Salaun B, 2006, J IMMUNOL, V176, P4894, DOI 10.4049/jimmunol.176.8.4894
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   SODERLUND MB, 1995, BIOCHEM J, V308, P353, DOI 10.1042/bj3080353
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Wang C, 2011, MOL CELL BIOCHEM, V352, P197, DOI 10.1007/s11010-011-0755-z
   Yamanaka M, 2003, INT J CANCER, V106, P382, DOI 10.1002/ijc.11227
   Zhou BY, 2007, P NATL ACAD SCI USA, V104, P7080, DOI 10.1073/pnas.0702409104
NR 31
TC 55
Z9 61
U1 0
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 11
PY 2013
VL 110
IS 24
BP 9812
EP 9817
DI 10.1073/pnas.1304610110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 171LM
UT WOS:000320930100054
PM 23716670
OA Green Published, Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Tiwari, N
   Tiwari, VK
   Waldmeier, L
   Balwierz, PJ
   Arnold, P
   Pachkov, M
   Meyer-Schaller, N
   Schübeler, D
   van Nimwegen, E
   Christofori, G
AF Tiwari, Neha
   Tiwari, Vijay K.
   Waldmeier, Lorenz
   Balwierz, Piotr J.
   Arnold, Phil
   Pachkov, Mikhail
   Meyer-Schaller, Nathalie
   Schuebeler, Dirk
   van Nimwegen, Erik
   Christofori, Gerhard
TI Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by
   Controlling Ezh2 Expression and Epigenetic Reprogramming
SO CANCER CELL
LA English
DT Article
ID CARDIAC OUTFLOW TRACT; CANCER STEM-CELLS; BREAST-CANCER; TRANSCRIPTION
   FACTORS; GENE-EXPRESSION; E-CADHERIN; POLYCOMB; REPRESSION;
   OVEREXPRESSION; CARCINOMA
AB Gene expression profiling has uncovered the transcription factor Sox4 with upregulated activity during TGF-beta-induced epithelial-mesenchymal transition (EMT) in normal and cancerous breast epithelial cells. Sox4 is indispensable for EMT and cell survival in vitro and for primary tumor growth and metastasis in vivo. Among several EMT-relevant genes, Sox4 directly regulates the expression of Ezh2, encoding the Polycomb group histone methyltransferase that trimethylates histone 3 lysine 27 (H3K27me3) for gene repression. Ablation of Ezh2 expression prevents EMT, whereas forced expression of Ezh2 restores EMT in Sox4-deficient cells. Ezh2-mediated H3K27me3 marks associate with key EMT genes, representing an epigenetic EMT signature that predicts patient survival. Our results identify Sox4 as a master regulator of EMT by governing the expression of the epigenetic modifier Ezh2.
C1 [Tiwari, Neha; Waldmeier, Lorenz; Meyer-Schaller, Nathalie; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.
   [Tiwari, Vijay K.; Schuebeler, Dirk] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland.
   [Balwierz, Piotr J.; Arnold, Phil; Pachkov, Mikhail; van Nimwegen, Erik] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland.
   [Balwierz, Piotr J.; Arnold, Phil; Pachkov, Mikhail; van Nimwegen, Erik] Swiss Inst Bioinformat, CH-4056 Basel, Switzerland.
C3 University of Basel; Friedrich Miescher Institute for Biomedical
   Research; University of Basel; Swiss Institute of Bioinformatics
RP Christofori, G (通讯作者)，Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.
EM gerhard.christofori@unibas.ch
RI van Nimwegen, Erik/ABF-1085-2021; Schübeler, Dirk/JMR-1336-2023; TIWARI,
   VINOD/L-9595-2019; Balwierz, Piotr/AAG-4187-2020
OI Tiwari, Neha/0000-0001-7931-4085; Tiwari, Vijay/0000-0003-0292-6635;
   Balwierz, Piotr Jan/0000-0002-1548-4605; van Nimwegen,
   Erik/0000-0001-6338-1312
FU Swiss National Science Foundation; Swiss Initiative for Systems Biology
   (RTD Cellplasticity); EU-FP7 framework program TuMIC [2008-201662];
   Swiss Cancer League; Deutsche Forschungsgemeinschaft (DFG) [TI 799/1-1];
   EpiGeneSys RISE1 program; Marie Curie CIG [322210]; Wilhelm Sander
   Stiftung [2012.009.1]; Novartis Research Foundation; European Union (NoE
   "EpiGeneSys" FP7) [HEALTH-2010-257082]; "Blueprint" consortium
   [FP7-282510]; European Research Council (EpiGePlas); SNF Sinergia
   program
FX We are grateful to H. Antoniadis, I. Galm, and P. Schmidt for technical
   support and A. Fantozzi for critical comments. We thank I. Nissen
   (Laboratory of Quantitative Genomics at D-BSSE, ETH Zurich) and S.
   Dessus-Babus (FMI, Basel) for Illumina sequencing. We thank A.P. Tsou
   (National Yang-Ming University, Taipei), A.H. Peters (FMI, Basel), N.
   Goldfinger and V. Rotter (Weizmann Institute, Rehovot), and G. Berx
   (VIB, Ghent) for providing important reagents and P. Demougin for gene
   expression profiling. This research has been supported by the Swiss
   National Science Foundation, the Swiss Initiative for Systems Biology
   (RTD Cellplasticity), the EU-FP7 framework program TuMIC 2008-201662,
   and the Swiss Cancer League. Research in the laboratory of V.K.T. is
   supported by Deutsche Forschungsgemeinschaft (DFG) grant TI 799/1-1,
   EpiGeneSys RISE1 program, Marie Curie CIG 322210, and Wilhelm Sander
   Stiftung 2012.009.1. Research in the laboratory of D.S. is supported by
   the Novartis Research Foundation, the European Union (NoE "EpiGeneSys"
   FP7- HEALTH-2010-257082 and the "Blueprint" consortium FP7-282510), the
   European Research Council (EpiGePlas), and the SNF Sinergia program.
CR Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456
   Acloque H, 2011, DEV CELL, V21, P546, DOI 10.1016/j.devcel.2011.07.005
   Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1
   Chew LJ, 2009, J NEUROSCI RES, V87, P3277, DOI 10.1002/jnr.22128
   Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872
   Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40
   Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043
   Grünert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hong CS, 2005, SEMIN CELL DEV BIOL, V16, P694, DOI 10.1016/j.semcdb.2005.06.005
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Hur W, 2010, CARCINOGENESIS, V31, P1298, DOI 10.1093/carcin/bgq072
   Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kloeker S, 2004, J BIOL CHEM, V279, P6824, DOI 10.1074/jbc.M307978200
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178
   Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168
   Lioubinski O, 2003, DEV DYNAM, V227, P402, DOI 10.1002/dvdy.10311
   Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055
   Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Penzo-Méndez AI, 2010, INT J BIOCHEM CELL B, V42, P425, DOI 10.1016/j.biocel.2009.07.018
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566
   Restivo A, 2006, ANAT REC PART A, V288A, P936, DOI 10.1002/ar.a.20367
   Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415
   Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0
   Schilham MW, 1997, EUR J IMMUNOL, V27, P1292, DOI 10.1002/eji.1830270534
   Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206
   Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121
   Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885
   Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876
   Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Thiery JP, 2004, NAT MED, V10, P777, DOI 10.1038/nm0804-777
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254
   VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Wilson ME, 2005, DIABETES, V54, P3402, DOI 10.2337/diabetes.54.12.3402
   Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148
   Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045
NR 65
TC 406
Z9 432
U1 1
U2 53
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD JUN 10
PY 2013
VL 23
IS 6
BP 768
EP 783
DI 10.1016/j.ccr.2013.04.020
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 163QB
UT WOS:000320350900010
PM 23764001
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Hansberg-Pastor, V
   González-Arenas, A
   Peña-Ortiz, MA
   García-Gómez, E
   Rodríguez-Dorantes, M
   Camacho-Arroyo, I
AF Hansberg-Pastor, Valeria
   Gonzalez-Arenas, Aliesha
   Pena-Ortiz, Miguel A.
   Garcia-Gomez, Elizabeth
   Rodriguez-Dorantes, Mauricio
   Camacho-Arroyo, Ignacio
TI The role of DNA methylation and histone acetylation in the regulation of
   progesterone receptor isoforms expression in human astrocytoma cell
   lines
SO STEROIDS
LA English
DT Article
DE Progesterone receptor isoforms; Astrocytomas; DNA methylation; 5-Aza-2
   '-deoxycytidine; Histone acetylation; Trichostatin A
ID BREAST-CANCER CELLS; PROMOTER METHYLATION; DEACETYLASE INHIBITORS; GENE
   INACTIVATION; DOWN-REGULATION; CYCLE ARREST; B GENE;
   5-AZA-2'-DEOXYCYTIDINE; GROWTH; ESTROGEN
AB Many progesterone (P4) effects are mediated by its intracellular receptor (PR), which has two isoforms, PR-A and PR-B, each of them with different function and regulation. Differential PR expression in cancer cells has been associated to a PR isoform-specific promoter methylation. In astrocytomas, the most frequent and aggressive brain tumors, PR isoforms expression is directly correlated to the tumor's evolution grade. However, there is no evidence of the role of epigenetic regulation of PR expression in astrocytomas. We evaluated the effect of the demethylating agent 5-aza-2'-deoxycytidine (5AzadC) and the histone deacetylase inhibitor trichostatin A (TSA) on PR expression in human astrocytoma cell lines U373 (grade III) and D54 (grade IV) by RT-PCR and Western blot. Total PR expression increased with 5 mu M 5AzadC treatment, whereas PR-B expression increased with 5 and 10 mu M 5AzadC treatment in U373 cells, but not in D54 cells. In U373 cells, PR-A protein content augmented with 10 mu M 5AzadC treatment, while PR-B content increased with 5 and 10 mu M 5AzadC. PR-B expression was not modified by the TSA concentrations that were used, and the combination with 5AzadC did not change the effects of the latter. The study of 5AzadC effects on the number of astrocytoma cells showed that P4 treatment increased the number of U373 cells, whereas 5AzadC and the combined treatment with P4 reduced it. Our results suggest that PR-B expression is regulated by methylation and not by histone acetylation in U373 cells, and that DNA demethylation reduced the number of U373 cells. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Hansberg-Pastor, Valeria; Gonzalez-Arenas, Aliesha; Pena-Ortiz, Miguel A.; Garcia-Gomez, Elizabeth; Camacho-Arroyo, Ignacio] Univ Nacl Autonoma Mexico, Dept Biol, Fac Quim, Mexico City 04510, DF, Mexico.
   [Rodriguez-Dorantes, Mauricio] Inst Nacl Med Genom, Mexico City, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Instituto Nacional de Medicina
   Genomica
RP Camacho-Arroyo, I (通讯作者)，Univ Nacl Autonoma Mexico, Dept Biol, Fac Quim, Av Univ 3000,Ciudad Univ, Mexico City 04510, DF, Mexico.
EM camachoarroyo@gmail.com
RI RODRIGUEZ-DORANTES, MAURICIO/T-5738-2019; García-Gómez,
   Elizabeth/AAG-1293-2020; Camacho-Arroyo, Ignacio/AAM-4654-2021
OI Garcia-Gomez, Elizabeth/0000-0002-7350-0386; RODRIGUEZ-DORANTES,
   MAURICIO/0000-0003-4249-7222; Hansberg-Pastor,
   Valeria/0000-0002-9136-3995
FU CONACYT [100645]
FX The authors would like to thank CONACYT for its financial support (Grant
   No. 100645) to I.C.A., a scholarship to V.H.P. and a post-doctoral
   support to E.G.G.
CR [Anonymous], 2004, Molecular Endocrinology
   Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6
   Assimakopoulou M, 1998, CLIN NEUROPATHOL, V17, P27
   Bender CM, 1998, CANCER RES, V58, P95
   Brait M, 2011, TOXICOL MECH METHOD, V21, P275, DOI 10.3109/15376516.2011.562671
   Cabrera-Muñoz E, 2009, J STEROID BIOCHEM, V113, P80, DOI 10.1016/j.jsbmb.2008.11.009
   CARROLL RS, 1995, NEUROSURGERY, V37, P496, DOI 10.1227/00006123-199509000-00019
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chang J, 2012, BRIT J CANCER, V106, P116, DOI 10.1038/bjc.2011.532
   Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Chu SH, 2012, MOL MED REP, V5, P138, DOI 10.3892/mmr.2011.620
   Daskalakis M, 2010, RECENT RESULTS CANC, V184, P131, DOI 10.1007/978-3-642-01222-8_10
   DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fjelldal R, 2010, ANTICANCER RES, V30, P4835
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Geiger K, 2012, MOL BIOL CELL, V23, P2226, DOI 10.1091/mbc.E11-06-0535
   Götze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981
   Gonzalez-Agüero G, 2007, ENDOCRINE, V32, P129, DOI 10.1007/s12020-007-9023-0
   González-Agüero G, 2001, BRAIN RES BULL, V56, P43, DOI 10.1016/S0361-9230(01)00590-1
   GRUNBERG SM, 1991, J NEUROSURG, V74, P861, DOI 10.3171/jns.1991.74.6.0861
   Hagemann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017388
   Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356
   Hartung T, 2012, EPIGENETICS, V7
   Horiuchi S, 2005, EXP CELL RES, V305, P233, DOI 10.1016/j.yexcr.2005.01.003
   Hsu YF, 2011, BBA-GEN SUBJECTS, V1810, P504, DOI 10.1016/j.bbagen.2011.02.006
   Hulleman E, 2005, ADV CANCER RES, V94, P1, DOI 10.1016/S0065-230X(05)94001-3
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Kabat GC, 2010, CANCER EPIDEM BIOMAR, V19, P2421, DOI 10.1158/1055-9965.EPI-10-0658
   Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Kesari S, 2011, SEMIN ONCOL, V38, pS2, DOI 10.1053/j.seminoncol.2011.09.005
   Khalid H, 1997, CANCER, V80, P2133, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2133::AID-CNCR13>3.0.CO;2-#
   Kim JK, 2009, CELL MOL LIFE SCI, V66, P596, DOI 10.1007/s00018-008-8432-4
   Kumar Hari R, 2008, Expert Rev Neurother, V8, P1497, DOI 10.1586/14737175.8.10.1497
   Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7
   Liu QY, 2011, ENVIRON TOXICOL PHAR, V32, P423, DOI 10.1016/j.etap.2011.08.008
   Liu ZJ, 2004, FEBS LETT, V567, P327, DOI 10.1016/j.febslet.2004.04.044
   Liu ZJ, 2003, LIFE SCI, V73, P1963, DOI 10.1016/S0024-3205(03)00544-7
   Mc Cormack O, 2008, BREAST CANCER RES TR, V111, P45, DOI 10.1007/s10549-007-9757-7
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Neubauer Nikki L., 2011, Hormones & Cancer, V2, P170, DOI 10.1007/s12672-011-0065-7
   Nie JC, 2010, REPROD SCI, V17, P995, DOI 10.1177/1933719110377118
   Nieto M, 2004, ONCOGENE, V23, P735, DOI 10.1038/sj.onc.1207175
   Pathiraja TN, 2011, CLIN CANCER RES, V17, P4177, DOI 10.1158/1078-0432.CCR-10-2950
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Ren Y, 2007, CANCER GENET CYTOGEN, V175, P107, DOI 10.1016/j.cancergencyto.2007.02.002
   Rokhlin OW, 2006, MOL CANCER RES, V4, P113, DOI 10.1158/1541-7786.MCR-05-0085
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Sasaki M, 2001, CANCER RES, V61, P97
   Sasaki M, 2003, MOL CELL ENDOCRINOL, V202, P201, DOI 10.1016/S0303-7207(03)00084-4
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Skildum A, 2005, MOL ENDOCRINOL, V19, P327, DOI 10.1210/me.2004-0306
   Tang Bo, 2005, Zhonghua Wai Ke Za Zhi, V43, P1545
   Waha A, 2010, CANCER RES, V70, P1689, DOI 10.1158/0008-5472.CAN-09-3218
   Wang Rui, 2006, Zhonghua Zhongliu Zazhi, V28, P894
   Wargon V, 2011, BREAST CANCER RES TR, V126, P319, DOI 10.1007/s10549-010-0908-x
   Wee EJH, 2012, ONCOGENE, V31, P4182, DOI 10.1038/onc.2011.584
   Xiong YN, 2005, GYNECOL ONCOL, V99, P135, DOI 10.1016/j.ygyno.2005.05.035
   Xue Q, 2007, BIOL REPROD, V77, P681, DOI 10.1095/biolreprod.107.061804
   Zhang ZP, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-99
   Zheng ZX, 2012, FASEB J, V26, P449, DOI 10.1096/fj.11-190025
   Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200
NR 68
TC 11
Z9 14
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-128X
EI 1878-5867
J9 STEROIDS
JI Steroids
PD MAY
PY 2013
VL 78
IS 5
BP 500
EP 507
DI 10.1016/j.steroids.2013.02.010
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 136TG
UT WOS:000318385700008
PM 23474171
DA 2025-01-12
ER

PT J
AU Cao, J
   Yan, Q
AF Cao, Jian
   Yan, Qin
TI Histone Demethylases Set the Stage for Cancer Metastasis
SO SCIENCE SIGNALING
LA English
DT Article
ID BREAST-CANCER
AB Metastasis is the major cause of cancer-related mortality. It is increasingly evident that epigenetic alterations in tumor cells enable them to overcome various barriers in this multistage process of cell spreading, and insight into the molecular roles of epigenetic regulators in tumor metastasis are just beginning to emerge. Histone demethylases appear to have critical roles in creating suitable epigenetic states for tumor cells to gain metastatic potential. These studies shed light on the roles of histone demethylases in tumor metastasis and highlight the importance of targeting these enzymes to suppress metastatic disease.
C1 [Cao, Jian; Yan, Qin] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
C3 Yale University
RP Yan, Q (通讯作者)，Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
EM qin.yan@yale.edu
RI Cao, Jian/K-2440-2014; Yan, Qin/E-8893-2012
OI Cao, Jian/0000-0003-3424-6802; Yan, Qin/0000-0003-4077-453X
FU Alexander and Margaret Stewart Trust Fellowship
FX This work was supported by the Alexander and Margaret Stewart Trust
   Fellowship to Q.Y.
CR Blair LP, 2012, DNA CELL BIOL, V31, pS49, DOI 10.1089/dna.2012.1654
   Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Sayegh J, 2013, J BIOL CHEM, V288, P9408, DOI 10.1074/jbc.M112.419861
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107
NR 13
TC 10
Z9 12
U1 0
U2 4
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD APR 30
PY 2013
VL 6
IS 273
AR pe15
DI 10.1126/scisignal.2004188
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 136GJ
UT WOS:000318350100004
PM 23633674
DA 2025-01-12
ER

PT J
AU Gu, F
   Doderer, MS
   Huang, YW
   Roa, JC
   Goodfellow, PJ
   Kizer, EL
   Huang, THM
   Chen, YD
AF Gu, Fei
   Doderer, Mark S.
   Huang, Yi-Wen
   Roa, Juan C.
   Goodfellow, Paul J.
   Kizer, E. Lynette
   Huang, Tim H. M.
   Chen, Yidong
TI CMS: A Web-Based System for Visualization and Analysis of Genome-Wide
   Methylation Data of Human Cancers
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; BREAST-CANCER; GENE-EXPRESSION; HIGH-THROUGHPUT; CELLS;
   HOXB2; METHYLOME; PATTERNS; GROWTH
AB Background: DNA methylation of promoter CpG islands is associated with gene suppression, and its unique genome-wide profiles have been linked to tumor progression. Coupled with high-throughput sequencing technologies, it can now efficiently determine genome-wide methylation profiles in cancer cells. Also, experimental and computational technologies make it possible to find the functional relationship between cancer-specific methylation patterns and their clinicopathological parameters.
   Methodology/Principal Findings: Cancer methylome system (CMS) is a web-based database application designed for the visualization, comparison and statistical analysis of human cancer-specific DNA methylation. Methylation intensities were obtained from MBDCap-sequencing, pre-processed and stored in the database. 191 patient samples (169 tumor and 22 normal specimen) and 41 breast cancer cell-lines are deposited in the database, comprising about 6.6 billion uniquely mapped sequence reads. This provides comprehensive and genome-wide epigenetic portraits of human breast cancer and endometrial cancer to date. Two views are proposed for users to better understand methylation structure at the genomic level or systemic methylation alteration at the gene level. In addition, a variety of annotation tracks are provided to cover genomic information. CMS includes important analytic functions for interpretation of methylation data, such as the detection of differentially methylated regions, statistical calculation of global methylation intensities, multiple gene sets of biologically significant categories, interactivity with UCSC via custom-track data. We also present examples of discoveries utilizing the framework.
   Conclusions/Significance: CMS provides visualization and analytic functions for cancer methylome datasets. A comprehensive collection of datasets, a variety of embedded analytic functions and extensive applications with biological and translational significance make this system powerful and unique in cancer methylation research. CMS is freely accessible at: http://cbbiweb.uthscsa.edu/KMethylomes/.
C1 [Gu, Fei; Huang, Tim H. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78229 USA.
   [Doderer, Mark S.; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
   [Huang, Yi-Wen] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA.
   [Roa, Juan C.] Univ La Frontera, Dept Pathol, Temuco, Fono, Chile.
   [Goodfellow, Paul J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
   [Goodfellow, Paul J.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Goodfellow, Paul J.] Siteman Canc Ctr, St Louis, MO USA.
   [Kizer, E. Lynette; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
   [Gu, Fei; Huang, Tim H. M.; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; Medical College of Wisconsin; Universidad
   de La Frontera; University of Texas System; University of Texas Health
   Science Center at San Antonio; Washington University (WUSTL); Siteman
   Cancer Center; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio; Cancer Therapy & Research
   Center
RP Huang, THM (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78229 USA.
EM huangt3@uthscsa.edu; cheny8@uthscsa.edu
RI Huang, Yiwen/KPB-2034-2024; Roa, Juan/K-4749-2014; Doderer,
   Mark/D-5835-2017
OI Doderer, Mark/0000-0003-4386-4602; Roa, Juan Carlos/0000-0001-8313-8774;
   Gu, Fei/0000-0002-7725-3909
FU Integrative Cancer Biology Program [R01 CA069065, U54 CA113001]; Cancer
   Center Support Grant [P30 CA054174]; U.S. National Institutes of Health,
   Texas [NCATS 8UL1TR000149 (CTSA), CPRIT RP101195-C04]
FX This work was supported by R01 CA069065, U54 CA113001 (Integrative
   Cancer Biology Program), P30 CA054174 (Cancer Center Support Grant),
   NCATS 8UL1TR000149 (CTSA) of the U.S. National Institutes of Health,
   Texas CPRIT RP101195-C04, and by generous gifts from the Cancer Therapy
   and Research Center Foundation. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Becker M, 2005, MOL CANCER THER, V4, P151
   Boimel PJ, 2011, GENOMICS, V98, P164, DOI 10.1016/j.ygeno.2011.05.011
   Doderer Mark S, 2011, BMC Res Notes, V4, P182, DOI 10.1186/1756-0500-4-182
   Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8
   Gao JG, 2002, DNA CELL BIOL, V21, P819, DOI 10.1089/104454902320908469
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Inamura K, 2008, ANTICANCER RES, V28, P2121
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708
   Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330
   Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nishimura D, 2001, Internet Rep., V2, P117, DOI [DOI 10.1089/152791601750294344, 10.1089/152791601750294344]
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Pico AR, 2008, PLOS BIOL, V6, P1403, DOI 10.1371/journal.pbio.0060184
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Romero P, 2005, GENOME BIOL, V6
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653
   Segara D, 2005, CLIN CANCER RES, V11, P3587, DOI 10.1158/1078-0432.CCR-04-1813
   Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Vastrik I, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-r39
NR 26
TC 29
Z9 32
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2013
VL 8
IS 4
AR e60980
DI 10.1371/journal.pone.0060980
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 130JR
UT WOS:000317911500011
PM 23630576
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Skryabin, NA
   Tolmacheva, EN
   Lebedev, IN
   Zavyalova, MV
   Slonimskaya, EM
   Cherdyntseva, NV
AF Skryabin, N. A.
   Tolmacheva, E. N.
   Lebedev, I. N.
   Zavyalova, M. V.
   Slonimskaya, E. M.
   Cherdyntseva, N. V.
TI Dynamics of aberrant methylation of functional groups of genes in
   progression of breast cancer
SO MOLECULAR BIOLOGY
LA English
DT Article
DE DNA methylation; DNA Methylation Microarray GoldenGate Cancer Panel I;
   breast cancer
ID DNA METHYLATION; TUMOR-SUPPRESSOR; METASTASIS; EXPRESSION; EPIGENETICS;
   CARCINOMA; CELLS
AB For the first time, the epigenetic status of breast benign proliferative processes, malignant breast tumors, and metastases to regional lymph nodes has been studied using the GoldenGate Cancer Panel I DNA methylation microarray (Illumina, United States). The functional groups of differentially methylated genes were identified in each set of samples. The aberrant methylation of genes that regulate cell proliferation and mobility was found in the samples of benign proliferative breast processes. The aberrant methylation of genes responsible for cell differentiation and proliferation, as well as protein phosphorylation and cell mobility, was observed in the samples of malignant breast tumors. The differential methylation of the genes that regulate cell adhesion, the formation of anatomical structures, angiogenesis, immune response, signal transduction, and protein phosphorylation were found in samples with metastases to regional lymph nodes compared to the unaltered breast epithelium. It was found that tissues that range from benign proliferative processes and metastases to regional lymph nodes were generally characterized by a relatively lower level of epigenetic variability compared to the tissues of the primary tumor.
C1 [Skryabin, N. A.; Tolmacheva, E. N.; Lebedev, I. N.] Russian Acad Med Sci, Siberian Branch, Inst Med Genet, Tomsk 634050, Russia.
   [Zavyalova, M. V.; Slonimskaya, E. M.; Cherdyntseva, N. V.] Russian Acad Med Sci, Siberian Branch, Inst Oncol, Tomsk 634050, Russia.
   [Lebedev, I. N.; Zavyalova, M. V.; Slonimskaya, E. M.; Cherdyntseva, N. V.] Siberian State Med Univ, Tomsk 634050, Russia.
C3 Russian Academy of Sciences; Tomsk National Research Medical Center;
   Research Institute of Medical Genetics - Tomsk; Russian Academy of
   Medical Sciences; Russian Academy of Sciences; Tomsk National Research
   Medical Center; Cancer Research Institute of the RAS; Russian Academy of
   Medical Sciences; Siberian State Medical University
RP Skryabin, NA (通讯作者)，Russian Acad Med Sci, Siberian Branch, Inst Med Genet, Tomsk 634050, Russia.
EM Nukulay@gmail.com
RI Slonimskaya, Elena/C-7405-2012; Zavyalova, Marina/C-8580-2012; Lebedev,
   Igor/O-2470-2019; Cherdyntseva, Nadezda/C-7943-2012; Lebedev,
   Igor/K-7454-2012; Tolmacheva, Ekaterina/P-5379-2014; Skryabin,
   Nikolay/A-7862-2014
OI Cherdyntseva, Nadezda/0000-0003-1526-9013; Lebedev,
   Igor/0000-0002-0482-8046; Zavyalova, Marina/0000-0001-9429-9813;
   Tolmacheva, Ekaterina/0000-0001-6427-3276; Skryabin,
   Nikolay/0000-0002-2491-3141
FU Siberian Branch of the Academy of Medical Sciences; Federal Target
   Program "Research and Scientific-Pedagogical Staff of Innovative Russia"
   [8602]
FX The authors would like to thank employees of Genoanalitika (Moscow) for
   carrying out microarray hybridization. This work was supported by
   integration project of the Siberian Branch of the Academy of Medical
   Sciences "Molecular and Genetic Mechanisms of the Formation and
   Progression of Breast Cancer: Development of Criteria for Risk,
   Prediction of Clinical Course, and Sensitivity to Chemotherapy Based on
   the Detection of Informative Markers of Tumors and the Body" and the
   Federal Target Program "Research and Scientific-Pedagogical Staff of
   Innovative Russia, 2009-2013" (No. 8602).
CR Chen D, 2011, CLIN CANCER RES, V17, P6693, DOI 10.1158/1078-0432.CCR-10-2774
   Chien WW, 2011, INT J ONCOL, V38, P1741, DOI 10.3892/ijo.2011.985
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2010, VIRCHOWS ARCH, V456, P13, DOI 10.1007/s00428-009-0847-2
   Getsios S, 2004, DIFFERENTIATION, V72, P419, DOI 10.1111/j.1432-0436.2004.07208008.x
   Hartman AR, 2005, RECENT RESULTS CANC, V166, P125
   Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623
   Menashe I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029396
   Nagaraju GPC, 2011, CANCER TREAT REV, V37, P559, DOI 10.1016/j.ctrv.2010.12.001
   O'Riain C, 2009, LEUKEMIA, V23, P1858, DOI 10.1038/leu.2009.114
   Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768
   Said N, 2012, J CLIN INVEST, V122, P1503, DOI 10.1172/JCI61392
   Skryabin N. A., 2011, Voprosy Onkologii (St. Petersburg), V57, P717
   Zaletaev DV, 2004, MOL BIOL+, V38, P174, DOI 10.1023/B:MBIL.0000023731.25512.fa
   Zemlyakova VV, 2003, MOL BIOL+, V37, P591, DOI 10.1023/A:1025195512841
   Zhen L., 2007, CHINESE J CANC, V26, P586
NR 18
TC 4
Z9 4
U1 0
U2 5
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0026-8933
J9 MOL BIOL+
JI Mol. Biol.
PD MAR
PY 2013
VL 47
IS 2
BP 267
EP 274
DI 10.1134/S0026893313020131
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 131JN
UT WOS:000317989300014
DA 2025-01-12
ER

PT J
AU Abu-Asab, MS
   Abu-Asab, N
   Loffredo, CA
   Clarke, R
   Amri, H
AF Abu-Asab, M. S.
   Abu-Asab, N.
   Loffredo, C. A.
   Clarke, R.
   Amri, H.
TI Identifying Early Events of Gene Expression in Breast Cancer with
   Systems Biology Phylogenetics
SO CYTOGENETIC AND GENOME RESEARCH
LA English
DT Article
DE Cancer; Early events; Heterogeneity; Parsimony; Phylogenetics;
   Synapomorphies; Systems biology
ID EPIGENETIC HETEROGENEITY; MEDICINE; ACCUMULATION; EPITHELIUM; MUTATIONS;
   THERAPY; GENOME
AB Advanced omics technologies such as deep sequencing and spectral karyotyping are revealing more of cancer heterogeneity at the genetic, genomic, gene expression, epigenetic, proteomic, and metabolomic levels. With this increasing body of emerging data, the task of data analysis becomes critical for mining and modeling to better understand the relevant underlying biological processes. However, the multiple levels of heterogeneity evident within and among populations, healthy and diseased, complicate the mining and interpretation of biological data, especially when dealing with hundreds to tens of thousands of variables. Heterogeneity occurs in many diseases, such as cancers, autism, macular degeneration, and others. In cancer, heterogeneity has hampered the search for validated biomarkers for early detection, and it has complicated the task of finding clonal (driver) and nonclonal (nonexpanded or passenger) aberrations. We show that subtyping of cancer (classification of specimens) should be an a priori step to the identification of early events of cancers. Studying early events in oncogenesis can be done on histologically normal tissues from diseased individuals (HNTDI), since they most likely have been exposed to the same mutagenic insults that caused the cancer in their neighboring tissues. Polarity assessment of HNTDI data variables by using healthy specimens as outgroup(s), followed by the application of parsimony phylogenetic analysis, produces a hierarchical classification of specimens that reveals the early events of the disease ontogeny within its subtypes as shared derived changes (abnormal changes) or synapomorphies in phylogenetic terminology. Copyright (C) 2013 S. Karger AG, Basel
C1 [Abu-Asab, M. S.] NEI, Immunopathol Sect, NIH, Bethesda, MD 20892 USA.
   [Loffredo, C. A.] Georgetown Univ, Sch Med, Dept Biostat Bioinformat & Biomath, Washington, DC USA.
   [Loffredo, C. A.; Clarke, R.] Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20005 USA.
   [Amri, H.] Georgetown Univ, Sch Med, Dept Biochem Cellular & Mol Biol, Washington, DC 20057 USA.
   [Abu-Asab, N.] Univ New England, Armidale Rural Referral Hosp, Armidale, NSW, Australia.
   [Abu-Asab, N.] Univ Newcastle, Armidale, NSW, Australia.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Georgetown University; Georgetown University; Georgetown
   University; University of New England; University of Newcastle
RP Amri, H (通讯作者)，Georgetown Univ, Sch Med, Dept Biochem Cellular & Mol Biol, 217 Basic Sci Bldg,3900 Reservoir Rd, Washington, DC 20057 USA.
EM amrih@georgetown.edu
RI ; Clarke, Robert/A-6485-2008
OI Abu-Asab, Mones/0000-0002-4047-1232; Clarke, Robert/0000-0002-9278-0854
FU Intramural NIH HHS [Z99 EY999999] Funding Source: Medline; NCI NIH HHS
   [U54 CA149147] Funding Source: Medline
CR Abu-Asab M, 2008, PROTEOM CLIN APPL, V2, P122, DOI 10.1002/prca.200780047
   Abu-Asab M, 2006, J PROTEOME RES, V5, P2236, DOI 10.1021/pr0504485
   Abu-Asab MS, 2008, OMICS, V12, P183, DOI 10.1089/omi.2008.0010
   Abu-Asab MS, 2011, OMICS, V15, P105, DOI 10.1089/omi.2010.0023
   Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107
   Buchen L, 2011, NATURE, V471, P428, DOI 10.1038/471428a
   Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y
   Clarke R, 2008, NAT REV CANCER, V8, P37, DOI 10.1038/nrc2294
   Couzin-Frankel J, 2011, SCIENCE, V333, P1569, DOI 10.1126/science.333.6049.1569
   Daley GQ, 2008, COLD SH Q B, V73, P171, DOI 10.1101/sqb.2008.73.041
   Diamandis EP, 2010, J NATL CANCER I, V102, P1462, DOI 10.1093/jnci/djq306
   Fendt L, 2011, BREAST CANCER RES TR, V128, P327, DOI 10.1007/s10549-010-1092-8
   Ganeshan B, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00033
   Goldstein DB, 2007, AM J MED, V120, P21, DOI 10.1016/j.amjmed.2007.02.004
   Graham K, 2010, BRIT J CANCER, V102, P1284, DOI 10.1038/sj.bjc.6605576
   Heng HH, 2010, CURR DRUG TARGETS, V11, P1304
   Heng HHO, 2011, ADV CANCER RES, V112, P217, DOI 10.1016/B978-0-12-387688-1.00008-9
   Heng HHQ, 2011, GENOMICS, V98, P242, DOI 10.1016/j.ygeno.2011.05.008
   Heng HHQ, 2009, J CELL PHYSIOL, V220, P538, DOI 10.1002/jcp.21799
   HEPPNER GH, 1983, CANCER METAST REV, V2, P5, DOI 10.1007/BF00046903
   Isozaki A., 2010, END BUILDINGS BEGINN
   Koturbash I, 2011, TOXICOL MECH METHOD, V21, P289, DOI 10.3109/15376516.2011.557881
   Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970
   Loeb LA, 2008, CANCER RES, V68, P3551, DOI 10.1158/0008-5472.CAN-07-5835
   Lyons-Weiler J, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-110
   Michor F, 2010, CANCER PREV RES, V3, P1361, DOI 10.1158/1940-6207.CAPR-10-0234
   Plotree D, 1989, CLADISTICS, V5, P6, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Pogribny I. P., 2010, Experimental Oncology, V32, P132
   RANZANI GN, 1995, CANCER EPIDEM BIOMAR, V4, P223
   Sumer B, 2008, NANOMEDICINE-UK, V3, P137, DOI 10.2217/17435889.3.2.137
   Tripathi A, 2008, INT J CANCER, V122, P1557, DOI 10.1002/ijc.23267
NR 31
TC 11
Z9 13
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1424-8581
J9 CYTOGENET GENOME RES
JI Cytogenet. Genome Res.
PY 2013
VL 139
IS 3
BP 206
EP 214
DI 10.1159/000348433
PG 9
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 137YS
UT WOS:000318475100009
PM 23548567
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU An, J
   Kim, K
   Rhee, SM
   Chae, H
   Nephew, KP
   Kim, S
AF An, Jaehyun
   Kim, Kwangsoo
   Rhee, Sung-Min
   Chae, Heejoon
   Nephew, Kenneth P.
   Kim, Sun
TI GENOME-WIDE ANALYSIS AND MODELING OF DNA METHYLATION SUSCEPTIBILITY IN
   30 BREAST CANCER CELL LINES BY USING CpG FLANKING SEQUENCES
SO JOURNAL OF BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
LA English
DT Article
DE DNA methylation; CpG flanking sequence; classification; genome-wide
   analysis
ID EPIGENETICS; ISLANDS; LOGO
AB DNA methylation is an epigenetic modification of DNA that adds a methyl group to cytosine. Aberrant DNA methylation in the CpG context is frequently observed in cancer cells and it is known that aberrant DNA methylation silences tumor repressor genes. However, the mechanism of DNA methylation is not well understood. A widely accepted hypothesis is that DNA methylation does not randomly occur and may be controlled by some instructive mechanisms. In this paper, we conducted an extensive study on this important question by using proprietary sequencing data from methyl-binding domain protein (MBD)-Cap ChIP sequencing experiments for 30 breast cancer cell lines. The goal of our study is to investigate difference in nucleotide composition around CpG sites, where high levels of methylation are observed, and use the information for modeling DNA methylation susceptibility. First, we observed that DNA methylation is not uniform in the whole-genome region and also that the character composition of CpG flanking sequences are significantly different between hyper- and hypo-methylated groups. In an in-depth study, we used information theoretic approaches such as entropy and relative entropy to delineate character composition features and found enrichment of A (Adenine) and T (Thymine) in specific positions around hyper- methylated sites. As the methylation level is increased, A, T proportions in specific positions around hypermethylated sites are increased while A, T proportions in other positions around hypermethylated sites are decreased. Second, we built predictive models for methylation susceptibility by using characters flanking CpG sites as features and hyper-/hypo-methylation status as class. Third, we constructed predictive models using a log odds score of two profiles from DNA sequences surrounding CpG sites of hyper- and hypo-methylated groups. This analysis showed that distribution of profile scores of hyper-/hypo-methylated sites sequences is quite distinct. Our genome-wide CpG methylation study shows that nucleotides around CpG sites caries information for cytosine methylation. This is consistent with the seminal work on the instructive evidence of DNA methylation by Keshet et al. (Nature Genetics, 38(2), 149-153 2006). Our study is on the full genome scale and used the sequencing data, thus our study is significantly different in terms of resolution of data and analysis methods used for the study by Keshet et al.
C1 [An, Jaehyun; Kim, Kwangsoo; Rhee, Sung-Min] Seoul Natl Univ, Dept Comp Sci & Engn, Seoul, South Korea.
   [Chae, Heejoon] Indiana Univ, Sch Informat & Comp, Bloomington, IN USA.
   [Nephew, Kenneth P.] Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA.
   [Kim, Sun] Seoul Natl Univ, Bioinformat Inst, Dept Comp Sci & Engn, Interdisciplinary Program Bioinformat, Seoul, South Korea.
C3 Seoul National University (SNU); Indiana University System; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Seoul National University (SNU)
RP Kim, S (通讯作者)，Seoul Natl Univ, Bioinformat Inst, Dept Comp Sci & Engn, Interdisciplinary Program Bioinformat, Seoul, South Korea.
EM starjh@snu.ac.kr; kksoo@snu.ac.kr; lars@snu.ac.kr;
   heechae@cs.indiana.edu; knephew@indiana.edu; sunkim.bioinfo@snu.ac.kr
FU Brain Korea 21 Project; Next-Generation Information Computing
   Development Program through the National Research Foundation of Korea
   (NRF); Ministry of Education, Science and Technology [2012M3C4A7033341];
   Next-Generation BioGreen 21 Program, Rural Development Administration,
   Republic of Korea [PJ009037022012]
FX This work was supported by the Brain Korea 21 Project in 2012. This work
   is supported by Next-Generation Information Computing Development
   Program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education, Science and Technology (No.
   2012M3C4A7033341). This work is also supported by a grant from the
   Next-Generation BioGreen 21 Program (No. PJ009037022012), Rural
   Development Administration, Republic of Korea.
CR Brinkman AB, 2010, METHODS, V52, P232, DOI 10.1016/j.ymeth.2010.06.012
   Choi JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013020
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Hall M., 2009, ACM SIGKDD EXPLOR NE, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Handa V, 2005, J MOL BIOL, V348, P1103, DOI 10.1016/j.jmb.2005.02.044
   Jones PA, 2005, SEMIN HEMATOL, V42, pS3, DOI 10.1053/j.seminhematol.2005.05.001
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Kim S, 2008, Pac Symp Biocomput, P315
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992
   Vacic V, 2006, BIOINFORMATICS, V22, P1536, DOI 10.1093/bioinformatics/btl151
NR 17
TC 1
Z9 1
U1 0
U2 9
PU IMPERIAL COLLEGE PRESS
PI LONDON
PA 57 SHELTON ST, COVENT GARDEN, LONDON WC2H 9HE, ENGLAND
SN 0219-7200
J9 J BIOINF COMPUT BIOL
JI J. Bioinform. Comput. Biol.
PD JUN
PY 2013
VL 11
IS 3
SI SI
AR 1341003
DI 10.1142/S0219720013410035
PG 20
WC Biochemical Research Methods; Computer Science, Interdisciplinary
   Applications; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Computer Science; Mathematical &
   Computational Biology
GA 172LS
UT WOS:000321005400003
PM 23796180
DA 2025-01-12
ER

PT J
AU Hosein, AN
   Song, S
   Reed, AEM
   Jayanthan, J
   Reid, LE
   Kutasovic, JR
   Cummings, MC
   Waddell, N
   Lakhani, SR
   Chenevix-Trench, G
   Simpson, PT
AF Hosein, Abdel Nasser
   Song, Sarah
   Reed, Amy E. McCart
   Jayanthan, Janani
   Reid, Lynne E.
   Kutasovic, Jamie R.
   Cummings, Margaret C.
   Waddell, Nic
   Lakhani, Sunil R.
   Chenevix-Trench, Georgia
   Simpson, Peter T.
TI Evaluating the repair of DNA derived from formalin-fixed
   paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis
SO LABORATORY INVESTIGATION
LA English
DT Article
DE array CGH; breast cancer; DNA restoration; DNA copy number alterations;
   formalin fixed; paraffin-embedded tissue; SNP array
ID FFPE TUMOR-TISSUES; COPY-NUMBER; BREAST-CANCER; ARRAY CGH; MICROARRAY
   PLATFORMS; MOLECULAR PORTRAITS; HYBRIDIZATION; RESOLUTION; SAMPLES;
   IDENTIFICATION
AB Pathology archives contain vast resources of clinical material in the form of formalin-fixed paraffin-embedded (FFPE) tissue samples. Owing to the methods of tissue fixation and storage, the integrity of DNA and RNA available from FFPE tissue is compromized, which means obtaining informative data regarding epigenetic, genomic, and expression alterations can be challenging. Here, we have investigated the utility of repairing damaged DNA derived from FFPE tumors prior to single-nucleotide polymorphism (SNP) arrays for whole-genome DNA copy number analysis. DNA was extracted from FFPE samples spanning five decades, involving tumor material obtained from surgical specimens and postmortems. Various aspects of the protocol were assessed, including the method of DNA extraction, the role of Quality Control quantitative PCR (qPCR) in predicting sample success, and the effect of DNA restoration on assay performance, data quality, and the prediction of copy number aberrations (CNAs). DNA that had undergone the repair process yielded higher SNP call rates, reduced log R ratio variance, and improved calling of CNAs compared with matched FFPE DNA not subjected to repair. Reproducible mapping of genomic break points and detection of focal CNAs representing high-level gains and homozygous deletions (HD) were possible, even on autopsy material obtained in 1974. For example, DNA amplifications at the ERBB2 and EGFR gene loci and a HD mapping to 13q14.2 were validated using immunohistochemistry, in situ hybridization, and qPCR. The power of SNP arrays lies in the detection of allele-specific aberrations; however, this aspect of the analysis remains challenging, particularly in the distinction between loss of heterozygosity (LOH) and copy neutral LOH. In summary, attempting to repair DNA that is damaged during fixation and storage may be a useful pretreatment step for genomic studies of large archival FFPE cohorts with long-term follow-up or for understanding rare cancer types, where fresh frozen material is scarce.
C1 [Hosein, Abdel Nasser; Chenevix-Trench, Georgia] Queensland Inst Med Res, Canc Genet Lab, Herston, Qld 4006, Australia.
   [Song, Sarah; Waddell, Nic] Univ Queensland, Queensland Ctr Med Genom, Inst Mol Biosci, Brisbane, Qld, Australia.
   [Song, Sarah; Reed, Amy E. McCart; Jayanthan, Janani; Reid, Lynne E.; Kutasovic, Jamie R.; Cummings, Margaret C.; Lakhani, Sunil R.; Simpson, Peter T.] Univ Queensland, Royal Brisbane & Womens Hosp, UQ Ctr Clin Res, Herston, Qld 4029, Australia.
   [Cummings, Margaret C.; Lakhani, Sunil R.] Royal Brisbane & Womens Hosp, Pathol Queensland, Brisbane, Qld, Australia.
   [Lakhani, Sunil R.] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
C3 QIMR Berghofer Medical Research Institute; University of Queensland;
   Royal Brisbane & Women's Hospital; University of Queensland; Royal
   Brisbane & Women's Hospital; University of Queensland
RP Simpson, PT (通讯作者)，Univ Queensland, Royal Brisbane & Womens Hosp, UQ Ctr Clin Res, Bldg 71-918, Herston, Qld 4029, Australia.
EM p.simpson@uq.edu.au
RI Waddell, Nicola/H-4929-2015; Cummings, Margaret/B-5747-2011;
   Chenevix-Trench, Georgia/AAV-2014-2020; Hosein, Abdel/KGM-7325-2024;
   McCart Reed, Amy/C-6192-2011; Lakhani, Sunil/I-1970-2018; Simpson,
   Peter/F-1225-2010; Kutasovic, Jamie/M-2137-2018
OI McCart Reed, Amy/0000-0001-5387-2791; Lakhani,
   Sunil/0000-0003-4067-2760; Waddell, Nicola/0000-0002-3950-2476; Hosein,
   Abdel/0000-0003-1567-6700; Simpson, Peter/0000-0002-4816-8289;
   Kutasovic, Jamie/0000-0001-5410-3636; Chenevix-Trench,
   Georgia/0000-0002-1878-2587
FU National Breast Cancer Foundation, Australia; National Health and
   Medical Research, Australia-Program [1017028]
FX We would like to express our thanks to Sibylle Cocciardi (Queensland
   Institute for Medical Research) and Dr Brian Fritz (Illumina) for
   technical assistance. We would also like to acknowledge the contribution
   of tissue donors and research groups to the generation of the Brisbane
   Breast Bank and TCGA data resource. Peter Simpson is a recipient of a
   fellowship from the National Breast Cancer Foundation, Australia. This
   work was funded by National Health and Medical Research,
   Australia-Program Grant # 1017028.
CR Alvarez K, 2010, DIAGN MOL PATHOL, V19, P127, DOI 10.1097/PDM.0b013e3181d527c5
   Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Curtis C, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-588
   DeVries S, 2005, J MOL DIAGN, V7, P65, DOI 10.1016/S1525-1578(10)60010-4
   Halper-Stromberg E, 2011, BIOINFORMATICS, V27, P1052, DOI 10.1093/bioinformatics/btr106
   Hostetter G, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp881
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Jacobs S, 2007, CANCER RES, V67, P2544, DOI 10.1158/0008-5472.CAN-06-3597
   Johnson CE, 2012, BREAST CANCER RES TR, V133, P889, DOI 10.1007/s10549-011-1835-1
   Jönsson G, 2012, CANCER RES, V72, P4028, DOI 10.1158/0008-5472.CAN-12-0097
   KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641
   Kerick M, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-68
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krijgsman O, 2012, GENE CHROMOSOME CANC, V51, P344, DOI 10.1002/gcc.21920
   Lips EH, 2005, CANCER RES, V65, P10188, DOI 10.1158/0008-5472.CAN-05-2486
   Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673
   Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992
   Nasri S, 2010, CANCER GENET CYTOGEN, V198, P1, DOI 10.1016/j.cancergencyto.2009.12.002
   Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878
   Oosting J, 2007, GENOME RES, V17, P368, DOI 10.1101/gr.5686107
   Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569
   Schweiger MR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005548
   Simpson PT, 2008, J PATHOL, V215, P231, DOI 10.1002/path.2358
   Simpson PT, 2005, AM J SURG PATHOL, V29, P734, DOI 10.1097/01.pas.0000157295.93914.3b
   Song S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045835
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Sun W, 2009, NUCLEIC ACIDS RES, V37, P5365, DOI 10.1093/nar/gkp493
   Thompson ER, 2005, HUM MUTAT, V26, P384, DOI 10.1002/humu.20220
   Tuefferd M, 2008, GENE CHROMOSOME CANC, V47, P957, DOI 10.1002/gcc.20599
   van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889
   Waddell N, 2010, BREAST CANCER RES TR, V123, P661, DOI 10.1007/s10549-009-0653-1
   Wicker N, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-84
   Wood HM, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq510
   Yost SE, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks299
NR 35
TC 25
Z9 28
U1 1
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD JUN
PY 2013
VL 93
IS 6
BP 701
EP 710
DI 10.1038/labinvest.2013.54
PG 10
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 155HY
UT WOS:000319739800007
PM 23568031
OA Bronze
DA 2025-01-12
ER

PT J
AU Min, A
   Im, SA
   Yoon, YK
   Song, SH
   Nam, HJ
   Hur, HS
   Kim, HP
   Lee, KH
   Han, SW
   Oh, DY
   Kim, TY
   O'Connor, MJ
   Kim, WH
   Bang, YJ
AF Min, Ahrum
   Im, Seock-Ah
   Yoon, Young-Kwang
   Song, Sang-Hyun
   Nam, Hyun-Jin
   Hur, Hyung-Seok
   Kim, Hwang-Phill
   Lee, Kyung-Hun
   Han, Sae-Won
   Oh, Do-Youn
   Kim, Tae-You
   O'Connor, Mark J.
   Kim, Woo-Ho
   Bang, Yung-Jue
TI RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor
   Olaparib
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID POLY(ADP-RIBOSE) POLYMERASE; DNA-REPAIR; HOMOLOGOUS RECOMBINATION;
   GERMLINE MUTATIONS; BREAST-CANCER; RAD51C DEFICIENCY; MAMMARY-TUMORS;
   OVARIAN-CANCER; IN-VIVO; BRCA1
AB A PARP inhibitor is a rationally designed targeted therapy for cancers with impaired DNA repair abilities. RAD51C is a paralog of RAD51 that has an important role in the DNA damage response. We found that cell lines sensitive to a novel oral PARP inhibitor, olaparib, had low levels of RAD51C expression using microarray analysis, and we therefore hypothesized that low expression of RAD51C may hamper the DNA repair process, resulting in increased sensitivity to olaparib. Compared with the cells with normal RAD51C expression levels, RAD51C-deficient cancer cells were more sensitive to olaparib, and a higher proportion underwent cell death by inducing G(2)-M cell-cycle arrest and apoptosis. The restoration of RAD51C in a sensitive cell line caused attenuation of olaparib sensitivity. In contrast, silencing of RAD51C in a resistant cell line enhanced the sensitivity to olaparib, and the number of RAD51 foci decreased with ablated RAD51C expression. We also found the expression of RAD51C was downregulated in cancer cells due to epigenetic changes and RAD51C expression was low in some gastric cancer tissues. Furthermore, olaparib significantly suppressed RAD51C-deficient tumor growth in a xenograft model. In summary, RAD51C-deficient cancer cells are highly sensitive to olaparib and offer preclinical proof-of-principle that RAD51C deficiency may be considered a biomarker for predicting the antitumor effects of olaparib.
C1 [Min, Ahrum; Im, Seock-Ah; Yoon, Young-Kwang; Song, Sang-Hyun; Nam, Hyun-Jin; Hur, Hyung-Seok; Kim, Hwang-Phill; Lee, Kyung-Hun; Han, Sae-Won; Oh, Do-Youn; Kim, Tae-You; Kim, Woo-Ho; Bang, Yung-Jue] Seoul Natl Univ, Canc Res Inst, Seoul 110744, South Korea.
   [Im, Seock-Ah; Lee, Kyung-Hun; Han, Sae-Won; Oh, Do-Youn; Kim, Tae-You; Bang, Yung-Jue] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea.
   [Kim, Woo-Ho] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110744, South Korea.
   [Kim, Tae-You] Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.
   [O'Connor, Mark J.] AstraZeneca UK Ltd, Macclesfield, Cheshire, England.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); AstraZeneca
RP Im, SA (通讯作者)，Seoul Natl Univ, Coll Med, Dept Internal Med, 101 Daehak Ro, Seoul 110744, South Korea.
EM moisa@snu.ac.kr; bangyj@snu.ac.kr
RI Bang, Yung Jue/J-2759-2012; Kim, Chang Gon/IAP-6721-2023; Im,
   Seock-Ah/J-5620-2012
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF); Ministry of Education, Science and Technology
   [2010-0022299]; Oncology Research collaboration of AstraZeneca Korean
   Cancer Study Group [06-2007-301-0]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2010-0022299; S.-A. Im); and
   supported by research grants from the Oncology Research collaboration of
   AstraZeneca Korean Cancer Study Group (06-2007-301-0; Y.-J. Bang).
CR Abe K, 2005, PLANT PHYSIOL, V139, P896, DOI 10.1104/pp.105.065243
   Ahn SH, 2007, CANCER LETT, V245, P90, DOI 10.1016/j.canlet.2005.12.031
   Stefansson OA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2871
   Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Badie S, 2009, J CELL BIOL, V185, P587, DOI 10.1083/jcb.200811079
   Bae Young Kyung, 2005, Cancer Res Treat, V37, P233, DOI 10.4143/crt.2005.37.4.233
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   French CA, 2002, J BIOL CHEM, V277, P19322, DOI 10.1074/jbc.M201402200
   Füllgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Hay T, 2009, CANCER RES, V69, P3850, DOI 10.1158/0008-5472.CAN-08-2388
   Horton JK, 2011, DNA REPAIR, V10, P225, DOI 10.1016/j.dnarep.2010.11.003
   Ibragimova I, 2011, METHODS MOL BIOL, V780, P277, DOI 10.1007/978-1-61779-270-0_17
   Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377
   Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1
   Kuznetsov S, 2007, J CELL BIOL, V176, P581, DOI 10.1083/jcb.200608130
   Kuznetsov SG, 2009, CANCER RES, V69, P863, DOI 10.1158/0008-5472.CAN-08-3057
   Lio YC, 2004, J BIOL CHEM, V279, P42313, DOI 10.1074/jbc.M405212200
   Liu YL, 2007, J BIOL CHEM, V282, P1973, DOI 10.1074/jbc.M609066200
   Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569
   Nam HJ, 2012, INVEST NEW DRUG, V30, P2148, DOI 10.1007/s10637-011-9782-6
   Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108
   Plummer ER, 2007, CLIN CANCER RES, V13, P6252, DOI 10.1158/1078-0432.CCR-07-0617
   Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260
   Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914
   Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105
   Smeenk G, 2010, MUTAT RES-FUND MOL M, V689, P50, DOI 10.1016/j.mrfmmm.2010.05.001
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
   Zeidler M, 2006, J MOL HISTOL, V37, P219, DOI 10.1007/s10735-006-9042-9
NR 37
TC 105
Z9 116
U1 1
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2013
VL 12
IS 6
BP 865
EP 877
DI 10.1158/1535-7163.MCT-12-0950
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 160HT
UT WOS:000320110500004
PM 23512992
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Trifa, F
   Karray-Chouayekh, S
   Jmal, E
   Ben Jmaa, Z
   Khabir, A
   Sellami-Boudawara, T
   Frikha, M
   Daoud, J
   Mokdad-Gargouri, R
AF Trifa, Fatma
   Karray-Chouayekh, Sondes
   Jmal, Emna
   Ben Jmaa, Zeineb
   Khabir, Abdelmajid
   Sellami-Boudawara, Tahia
   Frikha, Mounir
   Daoud, Jamel
   Mokdad-Gargouri, Raja
TI Loss of WIF-1 and Wnt5a expression is related to aggressiveness of
   sporadic breast cancer in Tunisian patients
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; WIF-1; Methylation; Transcriptional silencing; Wnt5a;
   Tumor suppressor
ID INHIBITORY FACTOR-I; FREQUENT EPIGENETIC INACTIVATION; CELL LUNG-CANCER;
   BETA-CATENIN; TUMOR-SUPPRESSOR; UP-REGULATION; WNT-5A; PATHWAY;
   ACTIVATION; PROTEIN
AB Activation of the Wnt/beta-catenin signaling pathway is common in various human cancers. The aim of this study was to investigate the expression of 2 members of the Wnt family (WIF-1 and Wnt5a) in sporadic and hereditary breast cancer tissues. WIF-1, is a secreted antagonist that binds Wnt ligands, and therefore inhibits the canonical Wnt/beta-catenin pathway. Wnt5a is one of the members of the noncanonical Wnt family that mainly acts through calcium signaling pathway. The expression of WIF-1 was analyzed by methylation-specific PCR and RT-PCR, and the level of Wnt5a ligand was quantified by RT-QPCR in breast cancer tissues. Methylation of WIF-1 was detected in 71.3 % and 81.8 % of sporadic and hereditary cases, respectively. Aberrant methylation of WIF-1 was associated with advanced TNM stage and triple negative cases in sporadic breast carcinoma (p = 0.001 and p = 0.037, respectively). In hereditary cases, methylation of WIF-1 correlated with age at diagnosis (p = 0.027) and p53 status (p = 0.035). Regarding patients' survival, WIF-1 methylated promoter conferred a reduced overall survival rate, and particularly in a group of patients with advanced TNM stage (p log rank = 0.006). Furthermore, aberrant CpG methylation of the WIF-1 promoter was significantly associated with transcriptional silencing of this tumor suppressor gene in sporadic breast cancer tissues (p = 0.036). On the other hand, in sporadic tumor tissues, the level of Wnt5a mRNA was significantly lower compared to normal tissues (p = 0.031) and lower still in those showing more aggressive behavior, suggesting that Wnt5a, a ligand involved in the noncanonical Wnt/beta-catenin pathway, could act as a tumor suppressor gene in breast cancer.
C1 [Trifa, Fatma; Karray-Chouayekh, Sondes; Jmal, Emna; Ben Jmaa, Zeineb; Mokdad-Gargouri, Raja] Univ Sfax, Ctr Biotechnol Sfax, Lab Biomass Valorisat & Prod Eukaryot Prot, Sfax 3018, Tunisia.
   [Khabir, Abdelmajid; Sellami-Boudawara, Tahia; Frikha, Mounir; Daoud, Jamel] Ctr Hosp Univ Habib Bourguiba Sfax, Sfax 3000, Tunisia.
C3 Centre de Biotechnologie de Sfax; Universite de Sfax; Universite de
   Sfax; Hopital Habib Bourguiba
RP Mokdad-Gargouri, R (通讯作者)，Univ Sfax, Ctr Biotechnol Sfax, Lab Biomass Valorisat & Prod Eukaryot Prot, Sidi Mansour St,BP K 1177, Sfax 3018, Tunisia.
EM raja.gargouri@cbs.rnrt.tn
OI ABDELMAJID, KHABIR/0000-0003-0031-2242
FU Tunisian Ministry of High Education and Scientific Research
FX This work was supported by a grant of the Tunisian Ministry of High
   Education and Scientific Research. We thank technicians at CHU Habib
   Bourguiba at Sfax-Tunisia for assistance.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Blanc E, 2005, ONCOGENE, V24, P1277, DOI 10.1038/sj.onc.1208255
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232
   Dejmek J, 2003, INT J CANCER, V103, P344, DOI 10.1002/ijc.10752
   Fendri A, 2010, CANCER INVEST, V28, P896, DOI 10.3109/07357907.2010.494324
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jönsson M, 2002, CANCER RES, V62, P409
   Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957
   Karray-Chouayekh S, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/369129
   Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370
   LEJEUNE S, 1995, CLIN CANCER RES, V1, P215
   Leris ACA, 2005, ANTICANCER RES, V25, P731
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   McDonald SL, 2009, BRIT J CANCER, V101, P209, DOI 10.1038/sj.bjc.6605174
   Medrek C, 2009, J BIOL CHEM, V284, P10968, DOI 10.1074/jbc.M804923200
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Polakis P, 2000, GENE DEV, V14, P1837
   Pukrop T, 2008, J MOL MED, V86, P259, DOI 10.1007/s00109-007-0266-2
   Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920
   Roarty K, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2244
   Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793
   Saitoh T, 2002, INT J MOL MED, V9, P515
   Surmann-Schmitt C, 2009, J CELL SCI, V122, P3627, DOI 10.1242/jcs.048926
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
NR 45
TC 22
Z9 24
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2013
VL 34
IS 3
BP 1625
EP 1633
DI 10.1007/s13277-013-0694-2
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 149YI
UT WOS:000319356900038
PM 23417837
DA 2025-01-12
ER

PT J
AU Zeng, H
   Wu, JC
   Bedford, MT
   Sbardella, G
   Hoffmann, FM
   Bi, K
   Xu, W
AF Zeng, Hao
   Wu, Jiacai
   Bedford, Mark T.
   Sbardella, Gianluca
   Hoffmann, F. Michael
   Bi, Kun
   Xu, Wei
TI A TR-FRET-Based Functional Assay for Screening Activators of CARM1
SO CHEMBIOCHEM
LA English
DT Article
DE arginine; CARM1; FRET; methylation; PABP1
ID ARGININE METHYLTRANSFERASE CARM1; HISTONE H3; PROTEIN; METHYLATION;
   DIFFERENTIATION; REGULATOR; PROLIFERATION; TRANSCRIPTION; CARM1/PRMT4;
   NUCLEUS
AB Epigenetics is an emerging field that demands selective cell-permeable chemical probes to perturb, especially in vivo, the activity of specific enzymes involved in modulating the epigenetic codes. Coactivator-associated arginine methyltransferase 1 (CARM1) is a coactivator of estrogen receptor (ER), the main target in human breast cancer. We previously showed that twofold overexpression of CARM1 in MCF7 breast cancer cells increased the expression of ER-target genes involved in differentiation and reduced cell proliferation, thus leading to the hypothesis that activating CARM1 by chemical activators might be therapeutically effective in breast cancer. Selective, potent, cell-permeable CARM1 activators will be essential to test this hypothesis. Here we report the development of a cell-based, time-resolved (TR) FRET assay that uses poly(A) binding protein 1 (PABP1) methylation to monitor cellular activity of CARM1. The LanthaScreen TR-FRET assay uses MCF7 cells expressing GFP-PABP1 fusion protein through BacMam gene delivery system, methyl-PABP1 specific antibody, and terbium-labeled secondary antibody. This assay has been validated as reflecting the expression and/or activity of CARM1 and optimized for high throughput screening to identify CARM1 allosteric activators. This TR-FRET platform serves as a generic tool for functional screening of cell-permeable, chemical modulators of CARM1 for elucidation of its in vivo functions.
C1 [Zeng, Hao; Wu, Jiacai; Hoffmann, F. Michael; Xu, Wei] Univ Wisconsin, Grad Program Cellular & Mol Biol, McArdle Lab Canc Res, Madison, WI 53706 USA.
   [Zeng, Hao; Wu, Jiacai; Hoffmann, F. Michael; Xu, Wei] Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI 53706 USA.
   [Bedford, Mark T.] Univ Texas MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA.
   [Sbardella, Gianluca] Univ Salerno, Dipartimento Farm, Epigenet Med Chem Lab, I-84084 Fisciano, SA, Italy.
   [Bi, Kun] Life Technol Corp, Primary & Stem Cell Syst, Madison, WI 53719 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Salerno; Thermo Fisher Scientific
RP Xu, W (通讯作者)，Univ Wisconsin, Grad Program Cellular & Mol Biol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.
EM wxu@oncology.wisc.edu
RI ; Sbardella, Gianluca/E-2823-2010
OI Zeng, Hao/0000-0003-4967-9555; Sbardella, Gianluca/0000-0003-0748-1145;
   Hoffmann, F. Michael/0000-0002-2770-9656
FU National Institutes of Health [RO1A125387]; Shaw Scientist Award; Villas
   Associate Award; DOD ERA of HOPE Scholar Award
FX We thank Jeanne Dudek and Leisha Kopp (Life Technologies Corporation)
   for technical support on BacMam virus production and TR-FRET assay
   development. We would like to thank Song Guo at SMSSF of UW-Madison for
   help with the pilot screen. This project is supported by the National
   Institutes of Health RO1A125387, Shaw Scientist Award, Villas Associate
   Award, and DOD ERA of HOPE Scholar Award to W.X.
CR Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015
   Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426
   Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003
   Castellano S, 2012, J MED CHEM, V55, P9875, DOI 10.1021/jm301097p
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200
   Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019
   Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548
   Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500
   Dorgan KM, 2006, ANAL BIOCHEM, V350, P249, DOI 10.1016/j.ab.2006.01.004
   El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103
   Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983
   Fujiwara T, 2006, MOL CELL BIOL, V26, P2273, DOI 10.1128/MCB.26.6.2273-2285.2006
   Heightman TD, 2011, EXPERT OPIN THER TAR, V15, P729, DOI 10.1517/14728222.2011.561786
   Ito T, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-47
   [Anonymous], 2010, Drug Discov Today Technol, V7, pe1, DOI 10.1016/j.ddtec.2010.07.004
   Kim D, 2010, J BIOL CHEM, V285, P1147, DOI 10.1074/jbc.M109.035865
   Kost TA, 2007, DRUG DISCOV TODAY, V12, P396, DOI 10.1016/j.drudis.2007.02.017
   Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052
   Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200
   Li J, 2013, J IMMUNOL, V190, P597, DOI 10.4049/jimmunol.1102513
   Luo MK, 2012, ACS CHEM BIOL, V7, P443, DOI 10.1021/cb200519y
   Machleidt T, 2011, J BIOMOL SCREEN, V16, P1236, DOI 10.1177/1087057111422943
   O'Brien KB, 2010, DEVELOPMENT, V137, P2147, DOI 10.1242/dev.037150
   ODEA RF, 1987, CANCER RES, V47, P3656
   Ou CY, 2011, MOL CANCER RES, V9, P660, DOI 10.1158/1541-7786.MCR-10-0223
   Quinn AM, 2010, MOL BIOSYST, V6, P782, DOI 10.1039/b921912a
   Rangwala S, 2012, FUTURE MED CHEM, V4, P471, DOI [10.4155/fmc.12.6, 10.4155/FMC.12.6]
   Robers MB, 2011, MOL BIOSYST, V7, P59, DOI 10.1039/c0mb00026d
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Salaun C, 2010, J VIROL, V84, P8539, DOI 10.1128/JVI.00668-10
   Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b
   Sims RJ, 2011, SCIENCE, V332, P99, DOI 10.1126/science.1202663
   Teyssier C, 2010, TRENDS ENDOCRIN MET, V21, P181, DOI 10.1016/j.tem.2009.11.002
   Wang SCM, 2012, BIOCHEM J, V444, P323, DOI 10.1042/BJ20112033
   Wigle TJ, 2010, CHEM BIOL, V17, P695, DOI 10.1016/j.chembiol.2010.04.014
   Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100
   Yadav N, 2008, EMBO REP, V9, P193, DOI 10.1038/sj.embor.7401151
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zorn JA, 2010, NAT CHEM BIOL, V6, P179, DOI 10.1038/NCHEMBIO.318
NR 42
TC 18
Z9 23
U1 0
U2 29
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4227
EI 1439-7633
J9 CHEMBIOCHEM
JI ChemBioChem
PD MAY 10
PY 2013
VL 14
IS 7
BP 827
EP 835
DI 10.1002/cbic.201300029
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 135HZ
UT WOS:000318280500008
PM 23585185
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Pierzchalski, K
   Yu, JS
   Norman, V
   Kane, MA
AF Pierzchalski, Keely
   Yu, Jianshi
   Norman, Victoria
   Kane, Maureen A.
TI CrbpI regulates mammary retinoic acid homeostasis and the mammary
   microenvironment
SO FASEB JOURNAL
LA English
DT Article
DE vitamin A; breast cancer; Rbp1; retinoids
ID ADENOMATOUS POLYPOSIS-COLI; BINDING-PROTEIN-I; BREAST-CANCER; OXIDATIVE
   STRESS; LIGAND-BINDING; DIFFERENTIAL RECOGNITION; 9-CIS-RETINOIC ACID;
   MATRIX-HOMEOSTASIS; CELLULAR UPTAKE; HOLO-CRBP
AB Cellular retinol-binding protein, type I (CrbpI), encoded by retinol-binding protein, type 1 (Rbp1), is a chaperone of vitamin A (retinol) that is epigenetically silenced in similar to 25% of human breast cancers. CrbpI delivers vitamin A to enzymes for metabolism into an active metabolite, all-trans retinoic acid (atRA), where atRA is essential to cell proliferation, apoptosis, differentiation, and migration. Here, we show the effect of CrbpI loss on mammary atRA homeostasis using the Rbp1(-/-) mouse model. Rbp1(-/-) mouse mammary tissue has disrupted retinoid homeostasis that results in 40% depleted endogenous atRA. CrbpI loss and atRA depletion precede defects in atRA biosynthesis enzyme expression. Compensation by CrbpIII as a retinoid chaperone does not functionally replace CrbpI. Mammary subcellular fractions isolated from Rbp1(-/-) mice have altered retinol dehydrogenase/reductase (Rdh) enzyme activity that results in 24-42% less atRA production. Rbp1(-/-) mammary tissue has epithelial hyperplasia, stromal hypercellularity, increased collagen, and increased oxidative stress characteristic of atRA deficiency and early tissue dysfunction that precedes tumor formation. Consistent with the findings from the Rbp1(-/-) mouse, tumorigenic epithelial cells lacking CrbpI expression produce 51% less atRA. Together, these data show that CrbpI loss disrupts atRA homeostasis in mammary tissue, resulting in microenvironmental defects similar to those observed at the early stages of tumorigenesis.-Pierzchalski, K., Yu, J., Norman, V., Kane, M. A. CrbpI regulates mammary retinoic acid homeostasis and the mammary microenvironment. FASEB J. 27, 1904-1916 (2013). www.fasebj.org
C1 [Pierzchalski, Keely; Yu, Jianshi; Kane, Maureen A.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Norman, Victoria] Bryn Mawr Sch, Baltimore, MD USA.
C3 University System of Maryland; University of Maryland Baltimore
RP Kane, MA (通讯作者)，Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St,PH 723N, Baltimore, MD 21201 USA.
EM mkane@rx.umaryland.edu
RI Norman, Victoria/KPB-1138-2024
OI Norman, Victoria/0000-0002-7093-607X; Pierzchalski,
   Keely/0000-0002-2456-0382
FU University of Maryland, Department of Pharmaceutical Sciences New
   Faculty Start-Up funds
FX This work was supported by University of Maryland, Department of
   Pharmaceutical Sciences New Faculty Start-Up funds. The authors are very
   grateful to Norbert Ghyselinck and Pierre Chambon (Institut de Genetique
   et de Biologie Moleculaire et Cellulaire, Institut National de la Sante
   et de la Recherche Medicale, Illkirch, France) for the
   Rbp1<SUP>-/-</SUP> mice. The authors thank Elizabeth Smith (Center for
   Vascular and Inflammatory Diseases Histology Core, University of
   Maryland School of Medicine) for mammary histology.
CR Aiello EJ, 2005, CANCER EPIDEM BIOMAR, V14, P662, DOI 10.1158/1055-9965.EPI-04-0327
   [Anonymous], 2009, Breast cancer facts and figures 2009
   Arapshian A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-13
   Ashique AM, 2012, GENESIS, V50, P415, DOI 10.1002/dvg.22002
   BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273
   Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610
   BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415
   Boyd N F, 2001, Curr Oncol Rep, V3, P314, DOI 10.1007/s11912-001-0083-7
   Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301
   Carén H, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-66
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen N, 2008, J BIOL CHEM, V283, P20841, DOI 10.1074/jbc.M802314200
   Chen N, 2008, FASEB J, V22, P236, DOI 10.1096/fj.07-8739com
   Chiu HJ, 2008, FASEB J, V22, P3878, DOI 10.1096/fj.08-112375
   CHOPRA DP, 1976, JNCI-J NATL CANCER I, V56, P583, DOI 10.1093/jnci/56.3.583
   Cichon MA, 2010, J MAMMARY GLAND BIOL, V15, P389, DOI 10.1007/s10911-010-9195-8
   COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x
   Dupé V, 2003, P NATL ACAD SCI USA, V100, P14036, DOI 10.1073/pnas.2336223100
   Esteller M, 2002, CANCER RES, V62, P5902
   Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003
   Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004
   Feng L, 2010, DEV BIOL, V338, P1, DOI 10.1016/j.ydbio.2009.10.029
   Fleming JM, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-46
   Folli C, 2002, J BIOL CHEM, V277, P41970, DOI 10.1074/jbc.M207124200
   Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898
   Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157
   Gallego O, 2006, BIOCHEM J, V399, P101, DOI 10.1042/BJ20051988
   Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903
   HARRISON EH, 1987, J LIPID RES, V28, P973
   HERR F, 1992, FASEB J, V6, pA1783
   JAMISON RS, 1994, BIOCHEMISTRY-US, V33, P2873, DOI 10.1021/bi00176a017
   Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200
   Kane MA, 2005, BIOCHEM J, V388, P363, DOI 10.1042/BJ20041867
   Kane MA, 2008, ANAL BIOCHEM, V378, P71, DOI 10.1016/j.ab.2008.03.038
   Kane MA, 2008, ANAL CHEM, V80, P1702, DOI 10.1021/ac702030f
   Kane MA, 2011, MOL CELL BIOL, V31, P3277, DOI 10.1128/MCB.05516-11
   Kane MA, 2011, BBA-GEN SUBJECTS, V1810, P514, DOI 10.1016/j.bbagen.2011.02.009
   Kane MA, 2010, P NATL ACAD SCI USA, V107, P21884, DOI 10.1073/pnas.1008859107
   Kane MA, 2010, METHODS MOL BIOL, V652, P1, DOI 10.1007/978-1-60327-325-1_1
   Kane MA, 2010, FASEB J, V24, P823, DOI 10.1096/fj.09-141572
   Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244
   Kunju LP, 2011, MODERN PATHOL, V24, P786, DOI 10.1038/modpathol.2011.8
   Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475
   Kupumbati TS, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-12
   Lapshina EA, 2003, BIOCHEMISTRY-US, V42, P776, DOI 10.1021/bi026836r
   Lee SA, 2007, J BIOL CHEM, V282, P35621, DOI 10.1074/jbc.M706372200
   Lei Z, 2003, BIOCHEMISTRY-US, V42, P4190, DOI 10.1021/bi026948i
   Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225
   LI E, 1991, J BIOL CHEM, V266, P3622
   Lidén M, 2006, J BIOL CHEM, V281, P13001, DOI 10.1074/jbc.R500027200
   Lim R, 2011, BIOCHEM BIOPH RES CO, V406, P408, DOI 10.1016/j.bbrc.2011.02.056
   Lotan R, 2005, JNCI-J NATL CANCER I, V97, P3, DOI 10.1093/jnci/dji031
   Maeda A, 2007, P NATL ACAD SCI USA, V104, P19565, DOI 10.1073/pnas.0707477104
   Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439
   Malins DC, 2006, CELL CYCLE, V5, P1629, DOI 10.4161/cc.5.15.3098
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   Markova NG, 2006, J INVEST DERMATOL, V126, P2019, DOI 10.1038/sj.jid.5700347
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048
   McArthur MJ, 1999, J LIPID RES, V40, P1371
   Mic FA, 2002, DEVELOPMENT, V129, P2271
   Nadauld LD, 2004, J BIOL CHEM, V279, P51581, DOI 10.1074/jbc.M408830200
   Nakles RE, 2011, MOL ENDOCRINOL, V25, P549, DOI 10.1210/me.2010-0114
   NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362
   NAPOLI JL, 1992, BIOCHIM BIOPHYS ACTA, V1120, P183, DOI 10.1016/0167-4838(92)90267-H
   NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7
   Napoli JL, 2000, NUTR REV, V58, P230, DOI 10.1111/j.1753-4887.2000.tb01870.x
   Napoli JL, 2012, BBA-MOL CELL BIOL L, V1821, P152, DOI 10.1016/j.bbalip.2011.05.004
   Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788
   ONG DE, 1988, J BIOL CHEM, V263, P5789
   Parmar H, 2004, ENDOCR-RELAT CANCER, V11, P437, DOI 10.1677/erc.1.00659
   PEEHL DM, 1993, PROSTATE, V23, P69, DOI 10.1002/pros.2990230107
   Penzes P, 1999, BIOCHEMISTRY-US, V38, P2088, DOI 10.1021/bi982228t
   Piantedosi R, 2005, J BIOL CHEM, V280, P24286, DOI 10.1074/jbc.M503906200
   POSCH KC, 1992, J BIOL CHEM, V267, P19676
   Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11
   Rexer BN, 2001, CANCER RES, V61, P7065
   RONG D, 1994, BBA-PROTEIN STRUCT M, V1208, P136, DOI 10.1016/0167-4838(94)90170-8
   ROSS AC, 1982, J LIPID RES, V23, P133
   Sandell LL, 2007, GENE DEV, V21, P1113, DOI 10.1101/gad.1533407
   Shaw N, 2003, J BIOL CHEM, V278, P41589, DOI 10.1074/jbc.C300368200
   Shih MYS, 2009, J BIOL CHEM, V284, P4292, DOI 10.1074/jbc.M807503200
   Siegenthaler JA, 2009, CELL, V139, P597, DOI 10.1016/j.cell.2009.10.004
   Singh R, 2007, J BACTERIOL, V189, P6665, DOI 10.1128/JB.00555-07
   Sun FF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034525
   Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200
   Wang C, 2011, J BIOL CHEM, V286, P6542, DOI 10.1074/jbc.M110.198382
   Wang YA, 2005, DEV DYNAM, V234, P892, DOI 10.1002/dvdy.20570
   Williams JA, 2010, J BIOL CHEM, V285, P36674, DOI 10.1074/jbc.M110.151878
   Williams JA, 2009, DEV BIOL, V328, P315, DOI 10.1016/j.ydbio.2009.01.031
   Zhang M, 2007, FASEB J, V21, P2886, DOI 10.1096/fj.06-7964com
   Zizola CF, 2008, AM J PHYSIOL-ENDOC M, V295, pE1358, DOI 10.1152/ajpendo.90464.2008
NR 92
TC 29
Z9 33
U1 1
U2 17
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2013
VL 27
IS 5
BP 1904
EP 1916
DI 10.1096/fj.12-219410
PG 13
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 134PU
UT WOS:000318226100011
PM 23362116
DA 2025-01-12
ER

PT J
AU Wang, JJ
   Yu, LL
   Cai, J
   Jia, JH
   Gao, YP
   Liang, ML
   Wang, ZH
AF Wang, Junjie
   Yu, Lili
   Cai, Jing
   Jia, Jinghui
   Gao, Yanping
   Liang, Minglin
   Wang, Zehua
TI The role of EZH2 and DNA methylation in hMLH1 silencing in epithelial
   ovarian cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE EZH2; hMLH1; Methylation; Epigenetics; Ovarian cancer
ID TUMOR-SUPPRESSOR GENES; MICROSATELLITE INSTABILITY; MISMATCH REPAIR;
   FRAMESHIFT MUTATIONS; DRUG-RESISTANCE; ZESTE HOMOLOG-2; BREAST-CANCER;
   COLON-CANCER; EXPRESSION; PROMOTER
AB Enhancer of zeste homolog 2 (EZH2) is overexpressed in various malignancies and associated with poor prognosis and drug-resistance. A recent study suggested that there is a link between EZH2 expression and the mediation of gene silencing in association with aberrant DNA methylation. In the present study, we showed an inverse correlation between EZH2 and human mutL homolog 1 gene (hMLH1) expression in 30 epithelial ovarian cancer (EOC) tissues. Moreover, we found that EZH2 downregulation could induce the re-expression of the unmethylated, basally expressed hMLH1 gene without affecting DNA methylation in the hMLH1 promoter. These results suggest that EZH2 can modulate the transcription of basally expressed hMLH1 via a non-DNA-methylation-dependent pathway, but it has no effect on hMLH1 silencing that is mediated by DNA hypermethylation. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Wang, Junjie; Yu, Lili; Cai, Jing; Jia, Jinghui; Liang, Minglin; Wang, Zehua] Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Gao, Yanping] First Hosp Datong, Dept Obstet & Gynecol, Datong, Peoples R China.
C3 Huazhong University of Science & Technology
RP Wang, ZH (通讯作者)，Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
EM zehuawang@163.net
OI Wang, Junjie/0000-0003-3586-6675
FU National Natural Science Foundation of China [30901585]; Scientific
   Research Items of Bureau of Health of Shanxi Province of China
   [201202013]
FX This work was supported by Grant No. 30901585 from the National Natural
   Science Foundation of China and No. 201202013 from the Scientific
   Research Items of Bureau of Health of Shanxi Province of China.
CR Aebi S, 1996, CANCER RES, V56, P3087
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Colella G, 1998, CARCINOGENESIS, V19, P691, DOI 10.1093/carcin/19.4.691
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Geisler JP, 2003, CANCER-AM CANCER SOC, V98, P2199, DOI 10.1002/cncr.11770
   Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933
   Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO;2-3
   Guo JF, 2011, CANCER SCI, V102, P530, DOI 10.1111/j.1349-7006.2010.01836.x
   Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Murphy MA, 2011, INT J CANCER, V129, P1914, DOI 10.1002/ijc.25835
   PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
   Plumb JA, 2000, CANCER RES, V60, P6039
   Rush Margaret, 2009, Epigenetics, V4, P404
   Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540
   Strathdee G, 2001, AM J PATHOL, V158, P1121, DOI 10.1016/S0002-9440(10)64059-X
   Swisher EM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-48
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Vikhanskaya F, 1999, CLIN CANCER RES, V5, P937
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
NR 29
TC 8
Z9 11
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 19
PY 2013
VL 433
IS 4
BP 470
EP 476
DI 10.1016/j.bbrc.2013.03.037
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 135AT
UT WOS:000318259100020
PM 23523787
DA 2025-01-12
ER

PT J
AU Magnani, L
   Stoeck, A
   Zhang, XY
   Lánczky, A
   Mirabella, AC
   Wang, TL
   Gyorffy, B
   Lupien, M
AF Magnani, Luca
   Stoeck, Alexander
   Zhang, Xiaoyang
   Lanczky, Andras
   Mirabella, Anne C.
   Wang, Tian-Li
   Gyorffy, Balazs
   Lupien, Mathieu
TI Genome-wide reprogramming of the chromatin landscape underlies endocrine
   therapy resistance in breast cancer
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE open chromatin; histone modification; drug resistance; epigenetic;
   transcriptional regulation
ID ESTROGEN-RECEPTOR BINDING; GENE-EXPRESSION; POSTMENOPAUSAL WOMEN;
   AROMATASE INHIBITOR; HISTOLOGIC GRADE; EPIGENETIC SIGNATURES; REGULATORY
   ELEMENTS; ACQUIRED-RESISTANCE; MOLECULAR-CHANGES; DOUBLE-BLIND
AB The estrogen receptor (ER)alpha drives growth in two-thirds of all breast cancers. Several targeted therapies, collectively termed endocrine therapy, impinge on estrogen-induced ER alpha activation to block tumor growth. However, half of ER alpha-positive breast cancers are tolerant or acquire resistance to endocrine therapy. We demonstrate that genome-wide reprogramming of the chromatin landscape, defined by epigenomic maps for regulatory elements or transcriptional activation and chromatin openness, underlies resistance to endocrine therapy. This annotation reveals endocrine therapy-response specific regulatory networks where NOTCH pathway is overactivated in resistant breast cancer cells, whereas classical ER alpha signaling is epigenetically disengaged. Blocking NOTCH signaling abrogates growth of resistant breast cancer cells. Its activation state in primary breast tumors is a prognostic factor of resistance in endocrine treated patients. Overall, our work demonstrates that chromatin landscape reprogramming underlies changes in regulatory networks driving endocrine therapy resistance in breast cancer.
C1 [Magnani, Luca; Zhang, Xiaoyang; Mirabella, Anne C.; Lupien, Mathieu] Dartmouth Coll, Geisel Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA.
   [Stoeck, Alexander; Wang, Tian-Li] Johns Hopkins Univ, Dept Gynecol, Baltimore, MD USA.
   [Stoeck, Alexander; Wang, Tian-Li] Johns Hopkins Univ, Dept Obstet & Oncol, Baltimore, MD USA.
   [Lanczky, Andras; Gyorffy, Balazs] Hungarian Acad Sci, Res Lab Pediat & Nephrol, H-1083 Budapest, Hungary.
   [Lupien, Mathieu] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario Canc Inst, Toronto, ON M5G 1L7, Canada.
   [Lupien, Mathieu] Ontario Inst Canc Res, Toronto, ON M5G 1L7, Canada.
   [Lupien, Mathieu] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.
C3 Norris Cotton Cancer Center; Dartmouth College; Johns Hopkins
   University; Johns Hopkins University; Hungarian Academy of Sciences;
   University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; Ontario Institute for Cancer Research;
   University of Toronto; University of Toronto
RP Gyorffy, B (通讯作者)，Hungarian Acad Sci, Res Lab Pediat & Nephrol, H-1083 Budapest, Hungary.
EM gyorffy@kmplot.com; mlupien@uhnres.utoronto.ca
RI Gyorffy, Balazs/AAA-9135-2021; magnani, luca/N-1094-2015; Lupien,
   Mathieu/KFB-6691-2024
OI Gyorffy, Balazs/0000-0002-5772-3766; Mirabella, Anne
   Catherine/0000-0002-2137-1455; magnani, luca/0000-0002-7534-0785;
   Lupien, Mathieu/0000-0003-0929-9478
FU National Cancer Institute [R01CA155004]; American Cancer Society
   [IRG-82-003-27]; Princess Margaret Foundation
FX We thank Walter Taylor from the Genomics Core at Dartmouth College for
   the development of an epigenomic mapper tool and Carol Ringelberg for
   assistance with analyzing the microarray-based expression profiles. We
   thank Swenke Bailey and Kinjal Desai for bioinformatic support. We thank
   Matt Ellis, Kenneth Nephew, and Kathleen Arcaro for sharing ET-resistant
   cell lines, Francesco Blasi for sharing pcDNA 3.1 PBX1 plasmids, and
   Till Barkte for reagents. This work was supported by National Cancer
   Institute Grant R01CA155004 (to M.L.), American Cancer Society Grant
   IRG-82-003-27 (to M.L.), and the Princess Margaret Foundation.
CR Aguilar H, 2010, ONCOGENE, V29, P6071, DOI 10.1038/onc.2010.333
   Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Ali S, 2011, ANNU REV MED, V62, P217, DOI 10.1146/annurev-med-052209-100305
   Aulisa L, 2009, ACTA BIOMATER, V5, P842, DOI 10.1016/j.actbio.2008.11.002
   Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89
   Bourdeau V, 2008, NUCLEIC ACIDS RES, V36, P76, DOI 10.1093/nar/gkm945
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Brodie A, 2005, J STEROID BIOCHEM, V95, P41, DOI 10.1016/j.jsbmb.2005.04.026
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2
   Chen ST, 2011, JPN J CLIN ONCOL, V41, P1327, DOI 10.1093/jjco/hyr157
   Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822
   CONTESSO G, 1987, J CLIN ONCOL, V5, P1378, DOI 10.1200/JCO.1987.5.9.1378
   Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106
   Creighton CJ, 2008, CANCER RES, V68, P7493, DOI 10.1158/0008-5472.CAN-08-1404
   Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415
   Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108
   Efferson CL, 2010, CANCER RES, V70, P2476, DOI 10.1158/0008-5472.CAN-09-3114
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fasco MJ, 2003, MOL CELL ENDOCRINOL, V206, P33, DOI 10.1016/S0303-7207(03)00256-9
   Flanagan JM, 2009, MOL CANCER THER, V8, P249, DOI 10.1158/1535-7163.MCT-08-0636
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067
   Gozgit JM, 2007, BRIT J CANCER, V97, P809, DOI 10.1038/sj.bjc.6603926
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hajkova P, 2010, CURR OPIN CELL BIOL, V22, P342, DOI 10.1016/j.ceb.2010.04.011
   Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108
   He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111
   Hebenstreit D, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1226
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Holmes KA, 2012, P NATL ACAD SCI USA, V109, P2748, DOI 10.1073/pnas.1018863108
   Hoskins JM, 2009, NAT REV CANCER, V9, P576, DOI 10.1038/nrc2683
   Howell A, 2004, J CLIN ONCOL, V22, P1605, DOI 10.1200/JCO.2004.02.112
   Howell A, 2002, J CLIN ONCOL, V20, P3396, DOI 10.1200/JCO.2002.10.057
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jelovac D, 2005, CANCER RES, V65, P5439, DOI 10.1158/0008-5472.CAN-04-2782
   Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164
   Ji T, 2004, BIOORG MED CHEM LETT, V14, P3875, DOI 10.1016/j.bmcl.2004.05.068
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Kiba T, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-323
   Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Martin LA, 2011, STEROIDS, V76, P772, DOI 10.1016/j.steroids.2011.02.035
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101
   Miller WR, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2611
   Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Pan L, 2005, J BIOL CHEM, V280, P20860, DOI 10.1074/jbc.M414618200
   Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517
   Park S, 2012, BREAST, V21, P50, DOI 10.1016/j.breast.2011.07.008
   Perey L, 2007, ANN ONCOL, V18, P64, DOI 10.1093/annonc/mdl341
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744
   Rodríguez-Ubreva J, 2012, NUCLEIC ACIDS RES, V40, P1954, DOI 10.1093/nar/gkr1015
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Sabo PJ, 2004, P NATL ACAD SCI USA, V101, P16837, DOI 10.1073/pnas.0407387101
   Sanchez CG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2833
   Santen RJ, 2008, ADV EXP MED BIOL, V630, P19
   Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Sengupta S, 2010, HORM MOL BIOL CLIN I, V2, P235, DOI 10.1515/HMBCI.2010.025
   Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Song RX, 2002, MOL CELL ENDOCRINOL, V193, P29, DOI 10.1016/S0303-7207(02)00093-X
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sorlie T, 2010, LANCET ONCOL, V11, P719, DOI 10.1016/S1470-2045(10)70174-1
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305
   Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Watters JW, 2009, CANCER RES, V69, P8949, DOI 10.1158/0008-5472.CAN-09-1544
   Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c
   Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111
NR 97
TC 129
Z9 154
U1 0
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 16
PY 2013
VL 110
IS 16
BP E1490
EP E1499
DI 10.1073/pnas.1219992110
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 132BA
UT WOS:000318041500009
PM 23576735
OA Green Published, Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Shen, XP
   Li, S
   Zhang, L
   Li, HD
   Hong, GN
   Zhou, XX
   Zheng, TT
   Zhang, WJ
   Hao, CX
   Shi, TW
   Liu, CY
   Guo, Z
AF Shen, Xiaopei
   Li, Shan
   Zhang, Lin
   Li, Hongdong
   Hong, Guini
   Zhou, XianXiao
   Zheng, Tingting
   Zhang, Wenjing
   Hao, Chunxiang
   Shi, Tongwei
   Liu, Chunyang
   Guo, Zheng
TI An Integrated Approach to Uncover Driver Genes in Breast Cancer
   Methylation Genomes
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; TUMOR-SUPPRESSOR; EXPRESSION; HYPOMETHYLATION;
   DATABASE; CELLS; PROGRESSION; COMPONENT; NETWORK
AB Background: Cancer cells typically exhibit large-scale aberrant methylation of gene promoters. Some of the genes with promoter methylation alterations play "driver" roles in tumorigenesis, whereas others are only "passengers".
   Results: Based on the assumption that promoter methylation alteration of a driver gene may lead to expression alternation of a set of genes associated with cancer pathways, we developed a computational framework for integrating promoter methylation and gene expression data to identify driver methylation aberrations of cancer. Applying this approach to breast cancer data, we identified many novel cancer driver genes and found that some of the identified driver genes were subtype-specific for basal-like, luminal-A and HER2+ subtypes of breast cancer.
   Conclusion: The proposed framework proved effective in identifying cancer driver genes from genome-wide gene methylation and expression data of cancer. These results may provide new molecular targets for potential targeted and selective epigenetic therapy.
C1 [Shen, Xiaopei; Li, Shan; Zhang, Lin; Li, Hongdong; Hong, Guini; Zhou, XianXiao; Zheng, Tingting; Zhang, Wenjing; Hao, Chunxiang; Shi, Tongwei; Guo, Zheng] Univ Elect Sci & Technol China, Sch Life Sci, Bioinformat Ctr, Chengdu 610054, Peoples R China.
   [Liu, Chunyang; Guo, Zheng] Fujian Med Univ, Sch Basic Med Sci, Dept Bioinformat, Fuzhou, Peoples R China.
C3 University of Electronic Science & Technology of China; Fujian Medical
   University
RP Guo, Z (通讯作者)，Univ Elect Sci & Technol China, Sch Life Sci, Bioinformat Ctr, Chengdu 610054, Peoples R China.
EM guoz@ems.hrbmu.edu.cn
RI Zhang, Wenjing/AAN-4349-2020; Li, Hongdong/B-4476-2015; Shen,
   Xiaopei/B-2773-2017
OI Shen, Xiaopei/0000-0002-0004-4228
FU National Natural Science Foundation of China [30970668, 81201702,
   81071646, 91029717]
FX This work was supported in part by the National Natural Science
   Foundation of China (30970668, 81201702, 81071646 and 91029717). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. No additional
   external funding received for this study.
CR Akavia UD, 2010, CELL, V143, P1005, DOI 10.1016/j.cell.2010.11.013
   Ambatipudi S, 2012, GENE CHROMOSOME CANC, V51, P161, DOI 10.1002/gcc.20940
   Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056
   Ben-Dor A, 1999, J COMPUT BIOL, V6, P281, DOI 10.1089/106652799318274
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bertucci Francois, 2008, J Biol, V7, P6, DOI 10.1186/jbiol67
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Efroni S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000425
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Esteller M, 2000, CANCER RES, V60, P4366
   Fan HZ, 1998, CANCER RES, V58, P1650
   Finetti P, 2008, CANCER RES, V68, P767, DOI 10.1158/0008-5472.CAN-07-5516
   Frau M, 2012, HEPATOLOGY, V56, P165, DOI 10.1002/hep.25643
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Gong X, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-76
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hermjakob H, 2004, NUCLEIC ACIDS RES, V32, pD452, DOI 10.1093/nar/gkh052
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Joshi-Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072
   Kalari S, 2010, ADV GENET, V70, P277, DOI [10.1016/B978-0-12-380866-0.60010-1, 10.1016/S0065-2660(10)70010-9]
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Kim YA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001095
   Lage K, 2007, NAT BIOTECHNOL, V25, P309, DOI 10.1038/nbt1295
   Mewes HW, 2008, NUCLEIC ACIDS RES, V36, pD196, DOI 10.1093/nar/gkm980
   Peri S, 2004, NUCLEIC ACIDS RES, V32, pD497, DOI 10.1093/nar/gkh070
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Potter C, 2004, CELL CYCLE, V3, P164
   Pulukuri SMK, 2007, CANCER RES, V67, P930, DOI 10.1158/0008-5472.CAN-06-2892
   Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086
   Sawan C, 2010, ADV GENET, V70, P57, DOI [10.1016/S0065-2660(10)70003-1, 10.1016/B978-0-12-380866-0.60003-4]
   Shen XP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044822
   Son KS, 2010, BREAST, V19, P484, DOI 10.1016/j.breast.2010.05.011
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Ushijima T, 2010, CANCER SCI, V101, P300, DOI 10.1111/j.1349-7006.2009.01434.x
   Vince JE, 2009, J BIOL CHEM, V284, P35906, DOI 10.1074/jbc.M109.072256
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wang ZQ, 2006, INT J CANCER, V118, P1436, DOI 10.1002/ijc.21499
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496
   Yang YM, 2003, BIOINFORMATICS, V19, P2311, DOI 10.1093/bioinformatics/btg300
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
   Zanzoni A, 2002, FEBS LETT, V513, P135, DOI 10.1016/S0014-5793(01)03293-8
   Zeller C., 2012, Oncogene
   Zhang M, 2008, BIOINFORMATICS, V24, P2057, DOI 10.1093/bioinformatics/btn365
   Zhang Y, 2011, HISTOL HISTOPATHOL, V26, P87, DOI 10.14670/HH-26.87
   Zou JF, 2012, COMPUT BIOL CHEM, V39, P1, DOI 10.1016/j.compbiolchem.2012.04.002
NR 54
TC 13
Z9 15
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 8
PY 2013
VL 8
IS 4
AR e61214
DI 10.1371/journal.pone.0061214
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 130FG
UT WOS:000317898000113
PM 23579546
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Herst, PM
   Berridge, MV
AF Herst, Patries M.
   Berridge, Michael V.
TI Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer
   Treatment
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Cancer paradigms; cell hierarchy; drug targeting; metabolic flexibility;
   stem cells; tissue organization
ID MEMBRANE ELECTRON-TRANSPORT; SESQUITERPENE LACTONE PARTHENOLIDE; ACUTE
   PROMYELOCYTIC LEUKEMIA; SURFACE OXYGEN-CONSUMPTION; CHRONIC
   MYELOID-LEUKEMIA; PLASMA-MEMBRANE; GLUCOSE-TRANSPORT; STEM-CELLS;
   BREAST-CANCER; MITOCHONDRIAL-DNA
AB The proliferative cancer cell paradigm that has driven cancer drug development for the past 50 years has failed to generate treatments that cure most metastatic adult cancers. This view is supported not only by cumulative experience with conventional cytotoxic anticancer drugs, but also by the application of highly-targeted anticancer compounds against, for example, BCR-ABL in CML and mutant BRAF in metastatic melanoma. Such drugs often send their respective cancers into complete molecular remission but fail to effect cures because a small population of quiescent or slowly self-renewing cancer cells that are drug and radiation resistant survive treatment indefinitely. This review explores the grounds for an emerging cancer paradigm that views cancer as a disorganized tissue with hierarchical cellular compartments in which the boudaries are less well-defined than in normal tissues with plasticity controlled by epigenetic changes mediated by the local microenvironment. Increased metabolic flexibility and adaptability give cancer cells an additional survival advantage that may be able to be targeted with drugs like metformin. Combining approaches that target the increased metabolic flexibility of cancer cells as well as ablating rapidly-proliferating cells and self-renewing cancer stem cells in individual cancers are needed to address the holy grail of cancer cure.
C1 [Herst, Patries M.; Berridge, Michael V.] Malaghan Inst Med Res, Wellington 6242, New Zealand.
C3 Malaghan Institute; Victoria University Wellington
RP Berridge, MV (通讯作者)，Malaghan Inst Med Res, POB 7060, Wellington 6242, New Zealand.
EM mberridge@malaghan.org.nz
RI Berridge, Michael/I-3969-2013
OI Herst, Patries/0000-0002-2173-2513; Berridge,
   Michael/0000-0003-2619-7473
FU New Zealand Breast Cancer Research Trust; Genesis Oncology Trust; Child
   Health Research Foundation; Melanoma Research Alliance; Department of
   Radiation Therapy, University of Otago
FX The authors acknowledge the support of the New Zealand Breast Cancer
   Research Trust, Genesis Oncology Trust, the Child Health Research
   Foundation, the Melanoma Research Alliance and the Department of
   Radiation Therapy, University of Otago.
CR Abollo-Jiménez F, 2010, SEMIN CANCER BIOL, V20, P98, DOI 10.1016/j.semcancer.2010.02.002
   Ahmed N, 1998, LIFE SCI, V63, P1887, DOI 10.1016/S0024-3205(98)00465-2
   Ahmed N, 1999, BIOCHEM PHARMACOL, V57, P387, DOI 10.1016/S0006-2952(98)00267-6
   Ahn GO, 2007, FRONT BIOSCI-LANDMRK, V12, P3483, DOI 10.2741/2329
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Andreani A, 2008, J MED CHEM, V51, P4563, DOI 10.1021/jm800194k
   Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592
   Berridge M. V., 2009, REJUV RES, V13, P139
   Berridge MV, 2000, ANTIOXID REDOX SIGN, V2, P231, DOI 10.1089/ars.2000.2.2-231
   Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7
   Berridge MV, 1998, PROTOPLASMA, V205, P74, DOI 10.1007/BF01279296
   BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843
   BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870
   Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Brahimi-Horn Christiane, 2006, Bull Cancer, V93, pE73
   Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367
   Campoli M, 2010, CLIN CANCER RES, V16, P11, DOI 10.1158/1078-0432.CCR-09-2345
   Cárdenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387
   Cerundolo V, 2004, NAT IMMUNOL, V5, P7, DOI 10.1038/ni0104-7
   CRANE FL, 1991, J BIOENERG BIOMEMBR, V23, P773, DOI 10.1007/BF00786001
   de Groof AJC, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-54
   De Luca T, 2005, BIOFACTORS, V25, P43
   DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643
   del Castillo-Olivares A, 2000, CRIT REV BIOCHEM MOL, V35, P197
   Dellapasqua S, 2010, EXPERT OPIN DRUG MET, V6, P251, DOI 10.1517/17425250903540246
   Deng T, 2009, CLIN CANCER RES, V15, P119, DOI 10.1158/1078-0432.CCR-08-1708
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   DEWHIRST MW, 1994, CANCER RES, V54, P3333
   Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568
   Elstrom RL, 2004, CLIN LYMPHOMA, V5, P62, DOI 10.3816/CLM.2004.n.012
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Facey K, 2007, HEALTH TECHNOL ASSES, V11, P1
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023
   Fausel Christopher, 2007, J Manag Care Pharm, V13, P8
   Fiorentini D, 2004, FREE RADICAL BIO MED, V37, P1402, DOI 10.1016/j.freeradbiomed.2004.07.022
   FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217
   Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Geschwind JFH, 2002, CANCER RES, V62, P3909
   Godinot C, 2007, J BIOENERG BIOMEMBR, V39, P235, DOI 10.1007/s10863-007-9088-8
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135
   Guzman ML, 2007, BLOOD, V110, P4436, DOI 10.1182/blood-2007-05-088815
   Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621
   Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x
   Hardie DG, 2008, FEBS LETT, V582, P81, DOI 10.1016/j.febslet.2007.11.018
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177
   Hersey P, 2009, ANN ONCOL, V20, P35, DOI 10.1093/annonc/mdp254
   Herst PM, 2007, BBA-BIOENERGETICS, V1767, P170, DOI 10.1016/j.bbabio.2006.11.018
   Herst PM, 2006, CURR MOL MED, V6, P895, DOI 10.2174/156652406779010777
   Herst PM, 2004, BBA-BIOENERGETICS, V1656, P79, DOI 10.1016/j.bbabio.2004.01.008
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x
   Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491
   Indo HP, 2007, MITOCHONDRION, V7, P106, DOI 10.1016/j.mito.2006.11.026
   Janni W, 2010, CANCER TREAT REV, V36, P249, DOI 10.1016/j.ctrv.2009.12.010
   Jezek P, 2010, INT J BIOCHEM CELL B, V42, P604, DOI 10.1016/j.biocel.2009.11.008
   Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410
   Jorgensen HG, 2007, BIOCHEM SOC T, V35, P1347, DOI 10.1042/BST0351347
   Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014
   Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226
   Kawasaki BT, 2009, PROSTATE, V69, P827, DOI 10.1002/pros.20931
   Kulawiec M, 2008, CANCER BIOL THER, V7, P1732, DOI 10.4161/cbt.7.11.6729
   Kunkel M, 2003, CANCER, V97, P1015, DOI 10.1002/cncr.11159
   LARM JA, 1994, J BIOL CHEM, V269, P30097
   Larsson SC, 2007, INT J CANCER, V121, P856, DOI 10.1002/ijc.22717
   Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105
   Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
   Mamede M, 2005, NEOPLASIA, V7, P369, DOI 10.1593/neo.04577
   Marin D, 2002, HAEMATOLOGICA, V87, P979
   Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613
   McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276
   Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669
   Michor F, 2007, STEM CELLS, V25, P1114, DOI 10.1634/stemcells.2006-0638
   Moreno-Sánchez R, 2009, BIOFACTORS, V35, P209, DOI 10.1002/biof.31
   Morré DJ, 2003, FREE RADICAL RES, V37, P795, DOI 10.1080/1071576031000083107
   Murdoch D, 2008, CURR OPIN ONCOL, V20, P104, DOI 10.1097/CCO.0b013e3282f44b12
   NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827
   Neller MA, 2008, SEMIN IMMUNOL, V20, P286, DOI 10.1016/j.smim.2008.09.006
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Palit V, 2005, ONCOL REP, V14, P909
   Palucka AK, 2008, J IMMUNOTHER, V31, P793, DOI 10.1097/CJI.0b013e31818403bc
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190
   Poage GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009651
   Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387
   Prata C., 2010, LEUK RES, V22
   Puhalla S, 2009, BREAST, V18, pS122, DOI 10.1016/S0960-9776(09)70286-3
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Raghunand N, 2003, BRIT J RADIOL, V76, pS11, DOI 10.1259/bjr/12913493
   Red-Horse K, 2010, NATURE, V464, P549, DOI 10.1038/nature08873
   Redout EM, 2007, CARDIOVASC RES, V75, P770, DOI 10.1016/j.cardiores.2007.05.012
   Reske SN, 1997, J NUCL MED, V38, P1344
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Robbins RJ, 2006, J CLIN ENDOCR METAB, V91, P498, DOI 10.1210/jc.2005-1534
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355
   Salih HR, 2004, LEUKEMIA LYMPHOMA, V45, P55, DOI 10.1080/1042819031000139684
   Sattler UGA, 2009, INT J RADIAT BIOL, V85, P963, DOI 10.3109/09553000903258889
   Scarlett DJ, 2004, BIOFACTORS, V20, P199
   Scarlett DJG, 2005, BBA-BIOENERGETICS, V1708, P108, DOI 10.1016/j.bbabio.2005.03.006
   Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
   Schatton T, 2009, BIOESSAYS, V31, P1038, DOI 10.1002/bies.200900058
   Schornack PA, 2003, NEOPLASIA, V5, P135, DOI 10.1016/S1476-5586(03)80005-2
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Singh SK, 2003, CANCER RES, V63, P5821
   Smolková K, 2010, J BIOENERG BIOMEMBR, V42, P55, DOI 10.1007/s10863-009-9267-x
   Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843
   Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324
   Tan AS, 2004, REDOX REP, V9, P302, DOI 10.1179/135100004225006777
   Thorel F, 2010, NATURE, V464, P1149, DOI 10.1038/nature08894
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307
   Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yu M, 2007, TOXICOL LETT, V170, P83, DOI 10.1016/j.toxlet.2007.02.013
   Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972
   Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007/s10549-007-9798-y
   Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136
NR 130
TC 13
Z9 13
U1 1
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2010
EI 1873-4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD MAR
PY 2013
VL 14
IS 3
BP 289
EP 299
PG 11
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 133TD
UT WOS:000318162300005
PM 22201593
DA 2025-01-12
ER

PT J
AU Gawish, HH
   Hagrass, HA
   Bary, EHA
AF Gawish, Heba H.
   Hagrass, Hoda A.
   Bary, Eman H. Abdel
TI RASSF1A Gene Hypermethylation in Tissue and Serum Together with Tissue
   Protein Expression in Breast Cancer Patients
SO LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION
LA English
DT Article
DE RASSF1A; hypermethylation; MSP; cancer breast
ID FREQUENT EPIGENETIC INACTIVATION; METHYLATION-SPECIFIC PCR;
   TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; DNA METHYLATION; CPG
   ISLAND; ABERRANT METHYLATION; ESTROGEN-RECEPTOR; MULTIPLE GENES; LUNG
AB Background: Recently genetics and epigenetics alterations have been found to be characteristic of malignancy and hence can be used as targets for detection of neoplasms. RASSF1A genehypermethylation has been a subject of interest in recent researches on cancer breast patients. Design and methods: We investigated 30 breast cancer patients and 10 control subjects diagnosed with benign lesions of the breast for RASSF1A methylation status in paired tissue and serum samples using MSP and we evaluated RASSF1A protein expression in tissues by IHC. Results were studied in relation to known prognostic clinicopathplogical features in breast cancer. Results: We evaluated 30 breast cancer patients mean age (50.9 +/- 7.7) years and 10 control patients mean age (38.4 +/- 8.6 years). Frequency of RASSF1A methylation in tissues, serum were 73% and 63.3% respectively and RASSF1A protein expression showed frequency of 46.7%. There was an association between RASSF1A methylation in tissues, serum and loss of protein expression in tissues with invasive carcinoma, advanced stage breast cancer, L.N metastasis, ER/PR negativity and HER2 positivity. RASSF1A methylation in serum showed high degree of concordance with methylation in tissues (Kappa = 0.851, P < 0.001). Conclusion: RASSF1A hypermethylation in tissues and serum and its protein expression may be a valid, reliable and sensitive tool for detection and follow up of breast cancer patients. [Heba H. Gawish, Hoda A. Hagrass and Eman H. Abdel Bary RASSF1A Gene Hypermethylation in Tissue and Serum Together with Tissue Protein Expression in Breast Cancer Patients. Life Sci J 2012;9(3):667675] (ISSN: 1097-8135). http://www.lifesciencesite.com. 93
C1 [Gawish, Heba H.; Hagrass, Hoda A.] Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig, Egypt.
   [Bary, Eman H. Abdel] Zagazig Univ, Fac Med, Dept Pathol, Zagazig, Egypt.
C3 Egyptian Knowledge Bank (EKB); Zagazig University; Egyptian Knowledge
   Bank (EKB); Zagazig University
RP Gawish, HH (通讯作者)，Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig, Egypt.
EM hebagawish@yahoo.com
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   [Anonymous], CA CANC J CLIN
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Byun DS, 2001, CANCER RES, V61, P7034
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Göbel G, 2011, BREAST CANCER RES TR, V130, P109, DOI 10.1007/s10549-010-1335-8
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jeronimo C, 2008, BREAST CANCER RES TR, V109, P27, DOI 10.1007/s10549-007-9620-x
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Karray-Chouayekh Sondes, 2010, J CANCER RES CLIN, V136, P203
   Kassim SK, 2001, CLIN BIOCHEM, V34, P499, DOI 10.1016/S0009-9120(01)00253-3
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee MG, 2001, CANCER RES, V61, P6688
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li YM, 2008, ONCOL REP, V19, P1149
   Lo KW, 2001, CANCER RES, V61, P3877
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Müller HM, 2003, CANCER RES, V63, P7641
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Tavassoeli FA, 2003, WHO CLASSIFICATION T, P10
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651
   Yamamoto N, 2012, BREAST CANCER RES TR, V132, P165, DOI 10.1007/s10549-011-1575-2
NR 45
TC 1
Z9 1
U1 0
U2 2
PU MARSLAND PRESS
PI LANSING
PA PO BOX 21126, LANSING, MI 48909 USA
SN 1097-8135
J9 LIFE SCI J
JI Life Sci. J.
PY 2012
VL 9
IS 3
BP 667
EP 675
PG 9
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA 100SX
UT WOS:000315724100092
DA 2025-01-12
ER

PT J
AU Del Vecchio, CA
   Giacomini, CP
   Vogel, H
   Jensen, KC
   Florio, T
   Merlo, A
   Pollack, JR
   Wong, AJ
AF Del Vecchio, C. A.
   Giacomini, C. P.
   Vogel, H.
   Jensen, K. C.
   Florio, T.
   Merlo, A.
   Pollack, J. R.
   Wong, A. J.
TI <i>EGFRvIII</i> gene rearrangement is an early event in glioblastoma
   tumorigenesis and expression defines a hierarchy modulated by epigenetic
   mechanisms
SO ONCOGENE
LA English
DT Article
DE EGFRvIII; glioblastoma; HDAC; methylation; amplification
ID GROWTH-FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITORS; TUMOR-INITIATING
   CELLS; TRICHOSTATIN-A; IN-VIVO; LUNG CARCINOMAS; HDAC INHIBITORS;
   BREAST-CANCER; VALPROIC ACID; BRAIN-TUMORS
AB Amplification and rearrangements of the epidermal growth factor receptor (EGFR) gene are frequently found in glioblastoma multiforme (GBM). The most common variant is EGFR variant III (EGFRvIII). Research suggests that EGFRvIII could be a marker for a cancer stem cell or tumor-initiating population. If amplification and rearrangement are early events in tumorigenesis, this implies that they should be preserved throughout the tumor. However, in primary GBM, EGFRvIII expression is focal and sporadic. Unexpectedly, we found EGFR amplification and rearrangement throughout the tumor, including regions with no EGFRvIII expression, suggesting that mechanisms exist to modulate EGFRvIII expression even in the presence of high gene amplification. To study this phenomenon, we characterized three GBM cell lines with endogenous EGFRvIII. EGFRvIII expression was heterogeneous, with both positive and negative populations maintaining the genetic alterations, akin to primary tumors. Furthermore, EGFRvIII defined a hierarchy where EGFRvIII-positive cells gave rise to additional positive and negative cells. Only cells that had recently lost EGFRvIII expression could re-express EGFRvIII, providing an important buffer for maintaining EGFRvIII-positive cell numbers. Epigenetic mechanisms had a role in maintaining heterogeneous EGFRvIII expression. Demethylation induced a 20-60% increase in the percentage of EGFRvIII-positive cells, indicating that some cells could re-express EGFRvIII. Surprisingly, inhibition of histone deacetylation resulted in a 50-80% reduction in EGFRvIII expression. Collectively, this data demonstrates that EGFR amplification and rearrangement are early events in tumorigenesis and EGFRvIII follows a model of hierarchical expression. Furthermore, EGFRvIII expression is restricted by epigenetic mechanisms, suggesting that drugs that modulate the epigenome might be used successfully in glioblastoma tumors.
C1 [Del Vecchio, C. A.; Wong, A. J.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.
   [Del Vecchio, C. A.; Giacomini, C. P.; Pollack, J. R.; Wong, A. J.] Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA.
   [Giacomini, C. P.; Vogel, H.; Jensen, K. C.; Pollack, J. R.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.
   [Jensen, K. C.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
   [Florio, T.] Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy.
   [Merlo, A.] Univ Basel, Lab Mol Neurooncol, Dept Clin & Biol Sci, Basel, Switzerland.
C3 Stanford University; Stanford University; Stanford University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Palo Alto Health Care System; University of Genoa; University of Basel
RP Wong, AJ (通讯作者)，Stanford Univ, Med Ctr, Dept Neurosurg, Canc Biol Program, 1201 Welch Rd,MSLS P108, Stanford, CA 94305 USA.
EM ajwong@stanford.edu
RI Florio, Tullio/A-2211-2012
OI Vogel, Otto Hannes/0000-0002-0960-3508; Jensen,
   Kristin/0000-0003-1177-9104; FLORIO, TULLIO/0000-0002-2394-996X; Del
   Vecchio Fitz, Catherine/0000-0002-9554-411X
FU National Defense Science and Engineering Graduate Research Fellowship;
   National Science Foundation Graduate Research Fellowship; NIH [CA124832,
   RC2 CA14891]; Lucille Packard Children's Foundation; National Brain
   Tumor Foundation
FX We thank Dr Neethan Lobo, Dr Siddhartha Mitra, Dr A Hunter Shain and the
   Stanford FACS facility for technical advice. Additionally, we thank Dana
   Bangs and Dr Athena Cherry at the Stanford Cytogenetics Laboratory for
   their assistance with FISH staining and analysis. This work was
   supported by the National Defense Science and Engineering Graduate
   Research Fellowship, the National Science Foundation Graduate Research
   Fellowship, NIH Grants CA124832, RC2 CA14891, the Lucille Packard
   Children's Foundation and a research grant from the National Brain Tumor
   Foundation.
CR Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700
   Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bialer M, 2007, NEUROTHERAPEUTICS, V4, P130, DOI 10.1016/j.nurt.2006.11.007
   Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x
   BIGNER SH, 1990, CANCER RES, V50, P8017
   Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774
   Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001
   Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1
   DEPALAZZO IEG, 1993, CANCER RES, V53, P3217
   Frederick L, 2000, NEURO-ONCOLOGY, V2, P159, DOI 10.1093/neuonc/2.3.159
   Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821
   Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675
   HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207
   HUMPHREY PA, 1988, CANCER RES, V48, P2231
   Jones G, 2001, CANCER RES, V61, P4978
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   MOSCATELLO DK, 1995, CANCER RES, V55, P5536
   Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724
   Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472
   Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510
   Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186
   Porter KR, 2010, NEURO-ONCOLOGY, V12, P520, DOI 10.1093/neuonc/nop066
   Schulte A, 2012, CLIN CANCER RES, V18, P1901, DOI 10.1158/1078-0432.CCR-11-3084
   Shabason JE, 2011, J CELL MOL MED, V15, P2735, DOI 10.1111/j.1582-4934.2011.01296.x
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Solomon DA, 2009, CANCER RES, V69, P5630, DOI 10.1158/0008-5472.CAN-09-1055
   Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003
   Stockhausen MT, 2011, EXP CELL RES, V317, P1513, DOI 10.1016/j.yexcr.2011.04.001
   SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602
   Svechnikova I, 2008, INT J ONCOL, V32, P821
   Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5
   Tang CK, 2000, CANCER RES, V60, P3081
   Thomas C, 2001, ACTA NEUROPATHOL, V101, P605
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Vogt N, 2004, P NATL ACAD SCI USA, V101, P11368, DOI 10.1073/pnas.0402979101
   VONHOFF DD, 1991, CANCER RES, V51, P6273
   Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x
   WIKSTRAND CJ, 1995, CANCER RES, V55, P3140
   Witusik-Perkowska M, 2011, J NEURO-ONCOL, V102, P395, DOI 10.1007/s11060-010-0352-0
   WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965
   WONG AJ, 2008, J CLIN ONCOL S, V26, P2002
   YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
NR 45
TC 96
Z9 104
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAY 23
PY 2013
VL 32
IS 21
BP 2670
EP 2681
DI 10.1038/onc.2012.280
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 156FH
UT WOS:000319806700008
PM 22797070
OA Bronze
DA 2025-01-12
ER

PT J
AU Alvarez, C
   Tapia, T
   Cornejo, V
   Fernandez, W
   Muñoz, A
   Camus, M
   Alvarez, M
   Devoto, L
   Carvallo, P
AF Alvarez, Carolina
   Tapia, Teresa
   Cornejo, Valeria
   Fernandez, Wanda
   Munoz, Alex
   Camus, Mauricio
   Alvarez, Manuel
   Devoto, Luigi
   Carvallo, Pilar
TI Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter
   hypermethylation in hereditary breast cancer
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE hereditary breast cancer; BRCAX; biopsies; tumor suppressor gene;
   promoter hypermethylation; protein expression
ID INHIBITORY FACTOR-I; FREQUENT EPIGENETIC INACTIVATION; BRCA1 PROMOTER;
   METHYLATION STATUS; DNA METHYLATION; BLADDER-CANCER; LUNG; EXPRESSION;
   PATHWAY; PROTEIN
AB Promoter hypermethylation is gaining strength as one of the main mechanisms through which tumor suppressor genes are silenced during tumor progression. Three tumor suppressor genes are frequently found methylated in their promoter, in concordance with absence of expression, RASSF1A, SLIT2, and WIF1. In addition, a previous array-CGH analysis from our group showed that these genes are found in deleted genomic regions observed in hereditary breast cancer tumors. In the present work we analyzed the methylation status of these three tumor suppressor gene promoters in 47 hereditary breast cancer tumors. Promoter methylation status analysis of hereditary breast tumors revealed high methylation frequencies for the three genes (67% RASSF1A, 80% SLIT2, and 72% WIF1). Additionally, the presence of methylated PCR products was associated with absence of protein expression for the three genes and statistically significant for RASSF1A and WIF1. Interestingly, methylation of all the three genes was found in 4 out of 6 grade I invasive ductal carcinoma tumors. Association between RASSF1A methylation and DCIS tumors was found. These results suggest that silencing of these tumor suppressor genes is an early event in hereditary breast cancer, and could be a marker for pre-malignant phenotypes. (c) 2012 Wiley Periodicals, Inc.
C1 [Alvarez, Carolina; Tapia, Teresa; Carvallo, Pilar] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Santiago, Chile.
   [Cornejo, Valeria; Fernandez, Wanda] Hosp San Borja Arriaran, Unidad Anat Patol, Santiago, Chile.
   [Munoz, Alex; Devoto, Luigi] Univ Santiago Chile, Fac Med, Inst Invest Materno Infantil IDIMI, Santiago, Chile.
   [Camus, Mauricio] Pontificia Univ Catolica Chile, Fac Med, Ctr Canc, Santiago, Chile.
   [Alvarez, Manuel] Clin Las Condes, Ctr Clin Canc, Santiago, Chile.
C3 Pontificia Universidad Catolica de Chile; Universidad de Chile;
   Universidad de Santiago de Chile; Pontificia Universidad Catolica de
   Chile; Clinica Las Condes
RP Carvallo, P (通讯作者)，Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Casilla 114-D, Santiago, Chile.
FU FONDECYT [1080595]; CONICYT
FX We are grateful to FONDECYT grant 1080595 and to CONICYT for providing
   scholarships to Carolina Alvarez.
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Antill YC, 2010, CANCER EPIDEM BIOMAR, V19, P265, DOI 10.1158/1055-9965.EPI-09-0359
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chen YL, 2009, CANCER SCI, V100, P1663, DOI 10.1111/j.1349-7006.2009.01225.x
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   Dallol A, 2002, CANCER RES, V62, P5874
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2001, CANCER RES, V61, P3225
   Gallardo M, 2006, BREAST CANCER RES TR, V95, P81, DOI 10.1007/s10549-005-9047-1
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022
   Jing F, 2007, ONKOLOGIE, V30, P14, DOI 10.1159/000096892
   Karray-Chouayekh S, 2010, J CANCER RES CLIN, V136, P203, DOI 10.1007/s00432-009-0649-6
   Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li YM, 2008, ONCOL REP, V19, P1149
   Licchesi JDF, 2010, ONCOGENE, V29, P5923, DOI 10.1038/onc.2010.322
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Pfeifer GP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P576, DOI 10.1007/s10541-005-0151-y
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Strickland P, 2006, DEVELOPMENT, V133, P823, DOI 10.1242/dev.02261
   Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Vallian S, 2009, J CANCER RES CLIN, V135, P991, DOI 10.1007/s00432-008-0534-8
   Vasilatos SN, 2009, CANCER EPIDEM BIOMAR, V18, P901, DOI 10.1158/1055-9965.EPI-08-0875
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616
   Xian J, 2004, CANCER RES, V64, P6432, DOI 10.1158/0008-5472.CAN-04-2561
   Ye M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-120
NR 43
TC 49
Z9 52
U1 0
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD JUN
PY 2013
VL 52
IS 6
BP 475
EP 487
DI 10.1002/mc.21881
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 131HV
UT WOS:000317984500006
PM 22315090
DA 2025-01-12
ER

PT J
AU Lesma, E
   Ancona, S
   Orpianesi, E
   Grande, V
   Di Giulio, AM
   Gorio, A
AF Lesma, Elena
   Ancona, Silvia
   Orpianesi, Emanuela
   Grande, Vera
   Di Giulio, Anna Maria
   Gorio, Alfredo
TI Chromatin Remodeling by Rosuvastatin Normalizes TSC2<SUP>-/meth</SUP>
   Cell Phenotype through the Expression of Tuberin
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID HMG-COA REDUCTASE; CYTOKINE PRODUCTION; SCLEROSIS COMPLEX; RENAL
   ANGIOMYOLIPOMA; COLORECTAL-CANCER; BREAST-CANCER; GROWTH-FACTOR;
   STATINS; INHIBITION; RAPAMYCIN
AB Tuberous sclerosis complex (TSC) is a multi-systemic syndrome caused by mutations in TSC1 or TSC2 gene. In TSC2-null cells, Rheb, a member of the Ras family of GTPases, is constitutively activated. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase and block the synthesis of isoprenoid lipids with inhibition of Rheb farnesylation and RhoA geranylgeranylation. The effects of rosuvastatin on the function of human TSC2(-/-) and TSC2(-/meth) alpha-actin smooth muscle (ASM) cells have been investigated. The TSC2(-/-) and TSC2(-/meth) ASM cells, previously isolated in our laboratory from the renal angiomyolipoma of two TSC patients, do not express tuberin and bear loss of heterozigosity caused by a double hit on TSC2 and methylation of TSC2 promoter, respectively. Exposure to rosuvastatin affected TSC2(-/meth) ASM cell growth and promoted tuberin expression by acting as a demethylating agent. This occurred without changes in interleukin release. Rosuvastatin also reduced RhoA activation in TSC2(-/meth) ASM cells, and it required coadministration with the specific mTOR (mammalian target of rapamycin) inhibitor rapamycin to be effective in TSC2(-/-) ASM cells. Rapamycin enhanced rosuvastatin effect in inhibiting cell proliferation in TSC2(-/-) and TSC2(-/meth) ASM cells. Rosuvastatin alone did not alter phosphorylation of S6 and extracellular signal-regulated kinase (ERK), and at the higher concentration, rosuvastatin and rapamycin slightly decreased ERK phosphorylation. These results suggest that rosuvastatin may potentially represent a treatment adjunct to the therapy with mTOR inhibitors now in clinical development for TSC. In particular, rosuvastatin appears useful when the disease is originated by epigenetic defects.
C1 [Lesma, Elena; Ancona, Silvia; Orpianesi, Emanuela; Grande, Vera; Di Giulio, Anna Maria; Gorio, Alfredo] Univ Milan, Labs Pharmacol, Dept Hlth Sci, I-20142 Milan, Italy.
C3 University of Milan
RP Lesma, E (通讯作者)，Univ Milan, Labs Pharmacol, Dept Hlth Sci, Via Rudini 8, I-20142 Milan, Italy.
EM elena.lesma@unimi.it
OI Di Giulio, Anna Maria/0000-0002-5702-4623; Lesma,
   Elena/0000-0002-9096-713X; ancona, silvia/0000-0003-1999-129X
FU Associazione Italiana Linfangioleiomiomatosi AILAM; Associazione
   Sclerosi Tuberosa; Accordo Quadro di Collaborazione tra Universita
   Lombarde from Lombardy Region
FX This work was supported by Associazione Italiana Linfangioleiomiomatosi
   AILAM (to A.G. and E.L.); Associazione Sclerosi Tuberosa (to E.L.); and
   Accordo Quadro di Collaborazione tra Universita Lombarde from Lombardy
   Region (Research Collaborative Program between Lombard Universities and
   Region; to A.G.).
CR Ai M, 2008, AM J CARDIOL, V101, P315, DOI 10.1016/j.amjcard.2007.08.035
   Arbiser JL, 2001, AM J PATHOL, V159, P483, DOI 10.1016/S0002-9440(10)61720-8
   Bessler H, 2005, CLIN IMMUNOL, V117, P73, DOI 10.1016/j.clim.2005.06.014
   Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564
   Bulhak A, 2007, AM J PHYSIOL-HEART C, V292, pH3158, DOI 10.1152/ajpheart.01354.2006
   Carelli S, 2007, MOL MED, V13, P166, DOI 10.2119/2006-00091.Carelli
   Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200
   Chan KKW, 2003, CLIN CANCER RES, V9, P10
   Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751
   Finlay GA, 2007, CANCER RES, V67, P9878, DOI 10.1158/0008-5472.CAN-07-1394
   Finlay GA, 2009, MOL CANCER THER, V8, P1799, DOI 10.1158/1535-7163.MCT-09-0055
   Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Goncharova E, 2004, J CELL BIOL, V167, P1171, DOI 10.1083/jcb.200405130
   Goncharova EA, 2011, MOL CELL BIOL, V31, P2484, DOI 10.1128/MCB.01061-10
   Gorio A, 2007, J PHARMACOL EXP THER, V322, P973, DOI 10.1124/jpet.107.123679
   Greenwood J, 2007, TRENDS IMMUNOL, V28, P88, DOI 10.1016/j.it.2006.12.003
   GRUNDY SM, 1988, NEW ENGL J MED, V319, P24
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344
   Iwata A, 2012, CLIN EXP IMMUNOL, V168, P234, DOI 10.1111/j.1365-2249.2012.04564.x
   Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901
   Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kim YC, 2010, IMMUNOLOGY, V130, P484, DOI 10.1111/j.1365-2567.2010.03269.x
   Kodach LL, 2011, GUT, V60, P1544, DOI 10.1136/gut.2011.237495
   Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550
   Lee Nancy, 2009, BMC Pharmacology, V9, P8, DOI 10.1186/1471-2210-9-8
   Lesma E, 2005, AM J PATHOL, V167, P1093, DOI 10.1016/S0002-9440(10)61198-4
   Lesma E, 2009, AM J PATHOL, V174, P2150, DOI 10.2353/ajpath.2009.080799
   Lesma E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003558
   Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691
   Liu L, 2010, J BIOL CHEM, V285, P38362, DOI 10.1074/jbc.M110.141168
   Ma ZH, 2011, BIOL PHARM BULL, V34, P1684
   Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38
   Rosenson RS, 1999, LANCET, V353, P983, DOI 10.1016/S0140-6736(98)05917-0
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3
NR 41
TC 3
Z9 3
U1 0
U2 7
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAY
PY 2013
VL 345
IS 2
BP 180
EP 188
DI 10.1124/jpet.113.203141
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 128AT
UT WOS:000317741100002
PM 23426956
DA 2025-01-12
ER

PT J
AU Jeong, YJ
   Jeong, HY
   Bong, JG
   Park, SH
   Oh, HK
AF Jeong, Young Ju
   Jeong, Hye Yeon
   Bong, Jin Gu
   Park, Sung Hwan
   Oh, Hoon Kyu
TI Low methylation levels of the <i>SFRP1</i> gene are associated with the
   basal-like subtype of breast cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE breast cancer; basal-like; methylation; secreted frizzled-related
   protein 1; epigenetics
ID DNA METHYLATION; RECEPTOR STATUS; EXPRESSION; HYPERMETHYLATION;
   ANTAGONIST; PROGNOSIS; PROFILES; CELLS
AB Epigenetic analyses have shown that aberrant DNA methylation signatures are associated with breast cancer molecular subtypes. In this study, we analyzed the methylation status of breast cancer-related genes in relation to the molecular subtypes and investigated whether the basal-like subtype displays distinct methylation profiles. By using pyrosequencing, we analyzed the DNA methylation status of 5 candidate genes in 60 breast cancer samples. We compared the methylation frequency across the molecular subtypes and analyzed the correlation between methylation levels and clinicopathological characteristics. A total of 59 cases displayed aberrant methylation. Amplification during polymerase chain reaction analysis failed in 1 case. The median methylation levels of the secreted frizzled-related protein 1 (SFRP1) gene were significantly lower in the basal-like subtype compared to the luminal A, luminal B and human epidermal growth factor receptor 2 (HER2) subtypes. Cadherin 13 (H-cadherin; CDH13) methylation levels were significantly higher in the HER2 tumors compared to the luminal A and basal-like subtypes. A comparison of the methylation status with clinicopathological characteristics revealed that the expression of Bcl-2, progesterone receptor and epidermal growth factor receptor were associated with SFRP1 gene methylation status. Our results indicate that the basal-like subtype is associated with low methylation levels of the SFRP1 gene, suggesting that the methylation levels of specific breast cancer genes may potentially serve as epigenetic biomarkers and prognostic factors.
C1 [Jeong, Young Ju; Jeong, Hye Yeon; Bong, Jin Gu; Park, Sung Hwan] Catholic Univ Daegu, Coll Med, Dept Surg, Taegu 705718, South Korea.
   [Oh, Hoon Kyu] Catholic Univ Daegu, Coll Med, Dept Pathol, Taegu 705718, South Korea.
C3 Catholic University of Daegu; Catholic University of Daegu
RP Jeong, YJ (通讯作者)，Catholic Univ Daegu, Coll Med, Dept Surg, 3056-6 Daemyoung-4-Dong, Taegu 705718, South Korea.
EM yjjeong@cu.ac.kr
FU Korea Breast Cancer Foundation
FX The present research has been supported by Korea Breast Cancer
   Foundation.
CR Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Celebiler A, 2009, CANCER SCI, V100, P2341, DOI 10.1111/j.1349-7006.2009.01333.x
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Du Y, 2001, CANCER RES, V61, P8094
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Liedtke C, 2009, CANC RES S, V69, P4047
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Polakis P, 2000, GENE DEV, V14, P1837
   Raish M, 2009, TRANSL ONCOL, V2, P264, DOI 10.1593/tlo.09148
   Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wang S, 2012, PLOS ONE, V7
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yuan YF, 2001, CANCER RES, V61, P5558
NR 30
TC 19
Z9 21
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2013
VL 29
IS 5
BP 1946
EP 1954
DI 10.3892/or.2013.2335
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 125MC
UT WOS:000317542900038
PM 23467623
OA Bronze
DA 2025-01-12
ER

PT J
AU Gombos, K
   Horváth, R
   Szele, E
   Juhász, K
   Gocze, K
   Somlai, K
   Pajkos, G
   Ember, I
   Olasz, L
AF Gombos, Katalin
   Horvath, Robert
   Szele, Eszter
   Juhasz, Krisztina
   Gocze, Katalin
   Somlai, Karoly
   Pajkos, Gabor
   Ember, Istvan
   Olasz, Lajos
TI miRNA Expression Profiles of Oral Squamous Cell Carcinomas
SO ANTICANCER RESEARCH
LA English
DT Article
DE Oral cancer; squamous cell carcinoma; miRNA expression; genomics
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; DOWN-REGULATION; BREAST-CANCER; MICRORNA;
   HEAD; GENE; SIGNATURE; INVASION; IDENTIFICATION; LEUKOPLAKIA
AB Background: Oral squamous cell carcinoma (OSCC) development involves complex machinery of genomic and epigenetic regulations including microRNA (miRNA) expression changes. We aimed to analyze the expression patterns of a set of miRNAs in human TNM stage I and II OSCC samples in an autologous normal mucosa-controlled experimental design. Materials and Methods: Forty samples of OSCC and 40 matched normal tissues were evaluated for miR-21, miR-155, miR-191, miR-146a, miR-221 and miR-222 expression in a LightCycler 480(PCR) system. Results: Our results showed significant overexpression of miR-21, miR-155, miR-191 and miR-221 in paired-sample t-test and the sensitivity/specificity of tests were over 90% in the case of miR-21 and miR-155 on the receiver operating characteristic curve (ROC) analysis. Conclusion: Our results underline the role of miR-21 in OSCC and support the possible causal role of miR-155 and miR-221 in oral carcino genesis. The overexpression of miR-191 is a novel finding in squamous cell carcinoma.
C1 [Gombos, Katalin; Szele, Eszter; Juhasz, Krisztina; Gocze, Katalin; Ember, Istvan] Univ Pecs, Fac Med, Inst Publ Hlth, H-7624 Pecs, Hungary.
   [Horvath, Robert; Olasz, Lajos] Univ Pecs, Ctr Clin, Dept Dent Oral & Maxillofacial Surg, H-7624 Pecs, Hungary.
   [Somlai, Karoly] Csolnok Ferenc Cty Hosp, Dept Dent & Maxillofacial Surg, Veszprem, Hungary.
   [Pajkos, Gabor] Bacs Kiskun Cty Hosp, Oncoradiol Ctr, Kecskemet, Hungary.
C3 University of Pecs; University of Pecs
RP Gombos, K (通讯作者)，Univ Pecs, Fac Med, Inst Publ Hlth, 12 Szigeti Str, H-7624 Pecs, Hungary.
EM katalin_gombos@yahoo.com
RI Horvath, Robert/P-2541-2019
CR Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X
   Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131
   Babu JM, 2011, BBA-REV CANCER, V1816, P67, DOI 10.1016/j.bbcan.2011.04.003
   Boldrup L, 2012, J CARCINOG, V11, P1
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Cervigne NK, 2009, HUM MOL GENET, V18, P4818, DOI 10.1093/hmg/ddp446
   Chang SS, 2008, INT J CANCER, V123, P2791, DOI 10.1002/ijc.23831
   Chen L, 2010, INT J ANTENN PROPAG, V2010, DOI 10.1155/2010/564357
   Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014
   Hui ABY, 2010, CLIN CANCER RES, V16, P1129, DOI 10.1158/1078-0432.CCR-09-2166
   Iorio MV, 2012, CARCINOGENESIS, V33, P1126, DOI 10.1093/carcin/bgs140
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kawaguchi H, 2008, J CLIN ONCOL, V26, P354, DOI 10.1200/JCO.2007.13.4072
   Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Lee JJ, 2000, CLIN CANCER RES, V6, P1702
   Li J, 2012, CLIN CANCER RES, V15, P3998
   Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792
   Liu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034773
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72
   Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682
   Mascolo M, 2012, INT J MOL SCI, V13, P2331, DOI 10.3390/ijms13022331
   Mehrotra R, 2011, HEAD NECK ONCOL, V3, P1
   Mydlarz Wojciech K, 2010, Expert Opin Med Diagn, V4, P53
   Park NJ, 2009, CLIN CANCER RES, V15, P5473, DOI 10.1158/1078-0432.CCR-09-0736
   Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198
   Ramdas L, 2009, HEAD NECK-J SCI SPEC, V31, P642, DOI 10.1002/hed.21017
   Raveche ES, 2007, BLOOD, V109, P5079, DOI 10.1182/blood-2007-02-071225
   Reis PP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-238
   Saintigny P, 2011, CANCER PREV RES, V4, P218, DOI 10.1158/1940-6207.CAPR-10-0155
   Saintigny P, 2009, CLIN CANCER RES, V15, P6284, DOI 10.1158/1078-0432.CCR-09-0498
   Schee K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-505
   Stewart BW, 2003, LANCET, V361, P1300, DOI 10.1016/S0140-6736(03)13003-6
   Tagawa H, 2005, LEUKEMIA, V19, P2013, DOI 10.1038/sj.leu.2403942
   Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wald AI, 2011, HEAD NECK-J SCI SPEC, V33, P504, DOI 10.1002/hed.21475
   Warner GC, 2004, INT J CANCER, V110, P857, DOI 10.1002/ijc.20197
   Wise-Draper TM, 2012, TRANSL RES, V160, P167, DOI 10.1016/j.trsl.2012.02.002
   Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583
   Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666
   Woolgar JA, 2009, ORAL ONCOL, V45, P361, DOI 10.1016/j.oraloncology.2008.07.016
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
NR 47
TC 63
Z9 66
U1 0
U2 9
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD APR
PY 2013
VL 33
IS 4
BP 1511
EP 1517
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 126PD
UT WOS:000317632200031
PM 23564792
DA 2025-01-12
ER

PT J
AU Chen, HF
   Mai, JR
   Wan, JX
   Gao, YF
   Lin, LN
   Wang, SZ
   Chen, YX
   Zhang, CZ
   Zhang, YJ
   Xia, B
   Liao, K
   Lin, YC
   Lin, ZN
AF Chen, Hui-Feng
   Mai, Jian-Rong
   Wan, Jian-Xin
   Gao, Yan-fang
   Lin, Li-Na
   Wang, Song-Zi
   Chen, Yu-Xi
   Zhang, Chen-Zi
   Zhang, Yu-Jing
   Xia, Bin
   Liao, Kun
   Lin, Yu-Chun
   Lin, Zhong-Ning
TI Role of a Novel Functional Variant in the <i>PPP2R1A</i> Promoter on the
   Regulation of PP2A-Aalpha and the Risk of Hepatocellular Carcinoma
SO PLOS ONE
LA English
DT Article
ID PROTEIN PHOSPHATASE 2A; NF-KAPPA-B; VIRUS-X-PROTEIN; ALPHA ER
   EXPRESSION; BREAST-CANCER; CELL-TRANSFORMATION; TUMOR-SUPPRESSOR; DNA
   METHYLATION; JNK ACTIVATION; PP2A COMPLEXES
AB Previously, we identified the genetic variant -241 (-/G) (rs11453459) in the PP2A-A alpha gene (PPP2R1A) promoter and demonstrated that this variant influences the DNA-binding affinity of nuclear factor-kappa B (NF-kappa B). In this study, we further confirmed that the transcriptional activity of PPP2R1A may be regulated by NF-kappa B through the functional genetic variant -241 (-/G). Moreover, we also demonstrated that the methylation status of CpG islands in the promoter of PPP2R1A influences the activity of this gene promoter. Few studies have examined the role of this -241 (-/G) variant in genetic or epigenetic regulation in hepatocellular carcinoma (HCC). To investigate whether this functional variant in the PPP2R1A promoter is associated with the risk of HCC and confirm the function of the -241 (-/G) variant in the HCC population, we conducted a case-control study involving 251 HCC cases and 252 cancer-free controls from a Han population in southern China. Compared with the -241 (--) homozygote, the heterozygous -241 (-G) genotype (adjusted OR = 0.32, 95% confidence interval (CI) = 0.17-0.58, P<0.001) and the -241 (-G)/(GG) genotypes (adjusted OR = 0.38, 95% CI = 0.22-0.67, P = 0.001) were both significantly associated with a reduced risk of HCC. Stratification analysis indicated that the protective role of -241 (-G) was more pronounced in individuals who were <= 40 years of age, female and HBV-negative. Our data suggest that the transcriptional activity of PPP2R1A is regulated by NF-kappa B through the -241 (-/G) variant and by the methylation of the promoter region. Moreover, the functional -241 (-/G) variant in the PPP2R1A promoter contributes to the decreased risk of HCC. These findings contribute novel information regarding the gene transcription of PPP2R1A regulated by the polymorphism and methylation in the promoter region through genetic and epigenetic mechanisms in hepatocarcinogenesis.
C1 [Lin, Yu-Chun; Lin, Zhong-Ning] Xiamen Univ, Sch Publ Hlth, Xiamen, Fujian, Peoples R China.
   [Chen, Hui-Feng; Mai, Jian-Rong; Gao, Yan-fang; Lin, Li-Na; Chen, Yu-Xi; Zhang, Chen-Zi; Zhang, Yu-Jing; Xia, Bin; Liao, Kun; Lin, Yu-Chun; Lin, Zhong-Ning] Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Prov Key Lab Food Nutr & Hlth, Guangzhou 510275, Guangdong, Peoples R China.
   [Wan, Jian-Xin; Wang, Song-Zi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Lab Med, Guangzhou 510275, Guangdong, Peoples R China.
   [Chen, Hui-Feng] Guangdong Prevent & Treatment Ctr Occupat Dis, Guangzhou, Guangdong, Peoples R China.
C3 Xiamen University; Sun Yat Sen University; Sun Yat Sen University
RP Lin, YC (通讯作者)，Xiamen Univ, Sch Publ Hlth, Xiamen, Fujian, Peoples R China.
EM linych@mail.sysu.edu.cn; linzhn@mail.sysu.edu.cn
RI Mai, Jianrong/IUO-3858-2023; fang, gao/GLU-2575-2022; Zhang, Y
   J/HLG-1022-2023
OI Chen, Huifeng/0000-0002-5381-1793; Mai, Jianrong/0000-0003-0866-7646
FU National Natural Science Foundation of China [NSFC 81172705, 81072334];
   Specialized Research Fund for the Doctoral Program of Higher Education
   of China [20090171110052]; Natural Science Foundation of Guangdong
   Province [S2011020002769]; Key Program of NSFC [81130052]
FX This work was supported by National Natural Science Foundation of China
   (NSFC 81172705, 81072334), Key Program (81130052) of NSFC, the
   Specialized Research Fund for the Doctoral Program of Higher Education
   of China (20090171110052) and the Key Project of Natural Science
   Foundation of Guangdong Province (S2011020002769). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Arsura M, 2005, CANCER LETT, V229, P157, DOI 10.1016/j.canlet.2005.07.008
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Boumber YA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000162
   Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X
   Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389
   Chen HG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007019
   Chen HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035524
   Chen HP, 2007, INT J CANCER, V120, P1684, DOI 10.1002/ijc.22406
   Chen KF, 2010, J HEPATOL, V52, P88, DOI 10.1016/j.jhep.2009.10.011
   Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1
   Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103
   De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560
   Duong FHT, 2010, HEPATOLOGY, V51, P741, DOI 10.1002/hep.23388
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Dupont WD, 2010, CANCER, V116, P8, DOI 10.1002/cncr.24702
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Esplin ED, 2006, GENE CHROMOSOME CANC, V45, P182, DOI 10.1002/gcc.20284
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ezzikouri S, 2009, INFECT GENET EVOL, V9, P877, DOI 10.1016/j.meegid.2009.05.012
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434
   HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002
   HENDRIX P, 1993, J BIOL CHEM, V268, P15267
   Huang W, 2005, J CELL PHYSIOL, V205, P37, DOI 10.1002/jcp.20372
   Hudson TJ, 2003, NAT GENET, V33, P439, DOI 10.1038/ng0403-439
   Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004
   Kane MA, 2003, CANCER EPIDEM BIOMAR, V12, P2
   Keen JC, 2005, J BIOL CHEM, V280, P29519, DOI 10.1074/jbc.M505317200
   Keen JC, 2004, CANCER BIOL THER, V3, P1304, DOI 10.4161/cbt.3.12.1458
   Kloth M, 2012, INT J CANCER, V131, pE897, DOI 10.1002/ijc.27628
   Lin YC, 2011, MUTAT RES-FUND MOL M, V716, P66, DOI 10.1016/j.mrfmmm.2011.08.004
   Lin ZN, 2008, HUM MUTAT, V29, P113, DOI 10.1002/humu.20610
   Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9
   Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016
   Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4
   Moorhead GBG, 2007, NAT REV MOL CELL BIO, V8, P234, DOI 10.1038/nrm2126
   Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001
   Nijhara R, 2001, FEBS LETT, V504, P59, DOI 10.1016/S0014-5793(01)02773-9
   Ogino S, 2007, CARCINOGENESIS, V28, P1985, DOI 10.1093/carcin/bgm160
   Park JY, 2006, HUM MOL GENET, V15, P1963, DOI 10.1093/hmg/ddl119
   Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047
   Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855
   Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103
   Schütte K, 2009, DIGEST DIS, V27, P80, DOI 10.1159/000218339
   Stepanova M, 2006, MOL CELL PROBE, V20, P348, DOI 10.1016/j.mcp.2006.03.007
   Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886
   Sun T, 2007, NAT GENET, V39, P605, DOI 10.1038/ng2030
   Sunahori K, 2009, J IMMUNOL, V182, P1500, DOI 10.4049/jimmunol.182.3.1500
   Suzuki K, 2006, BIOCHEM BIOPH RES CO, V349, P255, DOI 10.1016/j.bbrc.2006.08.037
   Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268
   Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568
   Tarn C, 2001, J BIOL CHEM, V276, P34671, DOI 10.1074/jbc.M104105200
   Dung TD, 2012, INT J MOL MED, V29, P1045, DOI 10.3892/ijmm.2012.938
   Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Xiong XD, 2008, MUTAT RES-FUND MOL M, V643, P70, DOI 10.1016/j.mrfmmm.2008.06.006
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu MW, 2001, J NATL CANCER I, V93, P1644, DOI 10.1093/jnci/93.21.1644
   Zhang SY, 2004, CARCINOGENESIS, V25, P2191, DOI 10.1093/carcin/bgh234
NR 61
TC 15
Z9 15
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 29
PY 2013
VL 8
IS 3
AR e59574
DI 10.1371/journal.pone.0059574
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 121SG
UT WOS:000317263900017
PM 23555712
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Mirza, S
   Sharma, G
   Parshad, R
   Gupta, SD
   Pandya, P
   Ralhan, R
AF Mirza, Sameer
   Sharma, Gayatri
   Parshad, Rajinder
   Gupta, Sidhartha Datta
   Pandya, Pranav
   Ralhan, Ranju
TI Expression of DNA Methyltransferases in Breast Cancer Patients and to
   Analyze the Effect of Natural Compounds on DNA Methyltransferases and
   Associated Proteins
SO JOURNAL OF BREAST CANCER
LA English
DT Article
DE Breast neoplasms; Chemoprevention; DNA methylation; Epigenomics
ID TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; HISTONE ACETYLATION;
   TEA CATECHINS; METHYLATION; CELLS; POLYPHENOLS; EPIGENETICS; INHIBITION;
   SERUM
AB Purpose: The DNA methylation mediated by specific DNA methyltransferases (DNMTs), results in the epigenetic silencing of multiple genes which are implicated in human breast cancer. We hypothesized that the natural compounds modulate the expression of DNMTs and their associated proteins in the breast cancer cell lines and affect the methylation mediated gene silencing. Methods: The DNMTs transcript expression was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) in the tumors and the adjacent normal breast tissues of the patients with invasive ductal breast carcinoma. We tested the hypothesis that the natural compounds, viz., epigallocatechin gallate (EGCG), genistein, withaferin A, curcumin, resveratrol, and guggulsterone, have demethylation potential. To investigate this hypothesis, we analyzed the DNMTs expression at the transcript levels, followed by the analysis of DNMT1 and its associated proteins (HDAC1, MeCP2, and MBD2). Results: The increased DNMTs transcripts expression, viz., DNMT1, DNMT3a, and DNMT3b, in the breast cancer tissues suggest involvement of the DNMTs in the breast carcinogenesis. Quantitative RT-PCR analysis revealed that the treatment with natural compounds, viz., EGCG, genistein, withaferin A, curcumin, resveratrol, and guggulsterone, resulted in a significant decrease in the transcript levels of all the DNMTs investigated. Importantly, these natural compounds decreased the protein levels of DNMT1, HDAC1, and MeCP2. Conclusion: Our results demonstrate that the natural compounds, EGCG, genistein, withaferin A, curcumin, resveratrol, and guggulsterone, have the potential to reverse the epigenetic changes. Moreover, their lack of toxicity makes these natural compounds promising candidates for the chemoprevention of the breast cancer. In-depth future mechanistic studies aimed to elucidate how these compounds affect the gene transcription are warranted.
C1 [Mirza, Sameer; Sharma, Gayatri; Ralhan, Ranju] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   [Sharma, Gayatri; Pandya, Pranav] Dev Sanskrit Vishwa Vidhyalaya, Hardwar, India.
   [Parshad, Rajinder] All India Inst Med Sci, Dept Surg, New Delhi 110029, India.
   [Gupta, Sidhartha Datta] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.
   [Ralhan, Ranju] Mt Sinai Hosp, Alex & Simona Shnaider Lab Mol Oncol, Toronto, ON M5G 1X5, Canada.
   [Ralhan, Ranju] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada.
   [Ralhan, Ranju] Mt Sinai Hosp, Sonshine Family Ctr Head & Neck Dis, Toronto, ON M5G 1X5, Canada.
   [Ralhan, Ranju] Mt Sinai Hosp, Dept Otolaryngol, Toronto, ON M5G 1X5, Canada.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dev Sanskriti
   Vishwavidyalaya; All India Institute of Medical Sciences (AIIMS) New
   Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi;
   University of Toronto; Sinai Health System Toronto; University of
   Toronto; Sinai Health System Toronto; Lunenfeld Tanenbaum Research
   Institute; University of Toronto; Sinai Health System Toronto;
   University of Toronto; Sinai Health System Toronto; Lunenfeld Tanenbaum
   Research Institute
RP Ralhan, R (通讯作者)，Mt Sinai Hosp, Alex & Simona Shnaider Lab Mol Oncol, Dept Pathol & Lab Med, Room 6-500,Joseph & Wolf Lebovic Hlth Complex,600, Toronto, ON M5G 1X5, Canada.
EM ralhanr@gmail.com
FU UGC; Canadian Institutes of Health Research for the Chair in the
   Advanced Cancer Diagnostics
FX S.M. is thankful to UGC for providing him with the SRF Fellowship. The
   authors thank Dr. Fayaz Malik, the Indian Institute of Integrative
   Medicine (Council of Scientific and Industrial Research), for the kind
   gift of withaferin A. R.R. gratefully acknowledges the financial support
   from Canadian Institutes of Health Research for the Chair in the
   Advanced Cancer Diagnostics.
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Berger J, 2005, BIOCHEM SOC T, V33, P1537, DOI 10.1042/BST0331537
   Chen D, 2005, BIOCHEM PHARMACOL, V69, P1523, DOI 10.1016/j.bcp.2005.01.024
   Chen D, 2008, HISTOL HISTOPATHOL, V23, P487, DOI 10.14670/HH-23.487
   Choi JS, 2004, J NUTR, V134, P1013, DOI 10.1093/jn/134.5.1013
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fini L, 2007, J NUTR, V137, P2622, DOI 10.1093/jn/137.12.2622
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Moiseeva EP, 2007, MOL CANCER THER, V6, P3071, DOI 10.1158/1535-7163.MCT-07-0117
   Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822
   Prokhortchouk E, 2002, ONCOGENE, V21, P5394, DOI 10.1038/sj.onc.1205631
   Ptak C, 2008, ANNU REV PHARMACOL, V48, P257, DOI 10.1146/annurev.pharmtox.48.113006.094731
   Ramos S, 2007, J NUTR BIOCHEM, V18, P427, DOI 10.1016/j.jnutbio.2006.11.004
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245
   Sim GS, 2007, ARCH PHARM RES, V30, P290, DOI 10.1007/BF02977608
NR 29
TC 162
Z9 177
U1 2
U2 16
PU KOREAN BREAST CANCER SOC
PI SEOUL
PA 163 SINMUNRO 1-GA JONGRO-GU, OFFICIA  BUILDING, SUITE 2024, SEOUL,
   110-999, SOUTH KOREA
SN 1738-6756
J9 J BREAST CANCER
JI J. Breast Canc.
PD MAR
PY 2013
VL 16
IS 1
BP 23
EP 31
DI 10.4048/jbc.2013.16.1.23
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 124CC
UT WOS:000317440400004
PM 23593078
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Kang, HF
   Dai, ZJ
   Bai, HP
   Lu, WF
   Ma, XB
   Bao, X
   Lin, S
   Wang, XJ
AF Kang, Hua-Feng
   Dai, Zhi-Jun
   Bai, He-Ping
   Lu, Wang-Feng
   Ma, Xiao-Bin
   Bao, Xing
   Lin, Shuai
   Wang, Xi-Jing
TI RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in
   breast cancer MCF-7 cell line
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE breast cancer; RUNX3; methylation; apoptosis
ID DNA METHYLATION; HYPERMETHYLATION; INACTIVATION; EPIGENETICS;
   EXPRESSION; MARKER
AB Runt-related transcription factor 3 (RUNX3) is a tumor suppressor gene, its inactivation due to hypermethylation related to carcinogenesis. The aim of this study was to investigate the effects of 5-aza-2'-deoxycytidine (5-Aza-CdR) on cell proliferation and apoptosis by demethylation of the promoter region and restoring the expression of RUNX3 in the breast cancer MCF-7 cell line. MCF-7 cells were cultured with different concentrations (0.4-102.4 mu mol/L) of 5-Aza-CdR in vitro. MTT assay was used to determine the proliferation of MCF-7 cells. Flow cytometry and Hoechst staining were used for analyzing cell apoptosis. The methylation status and expression of RUNX3 in mRNA and protein levels were measured by methylation-specific polymerase chain reaction (PCR [MSP]), reverse transcription (RT)-PCR, and Western blot. It was shown that the RUNX3 gene downregulated and hypermethylated in MCF-7 cells. 5-Aza-CdR induced demethylation, upregulated the expression of RUNX3 on both mRNA and protein levels in cancer cells, and induced growth suppression and apoptosis in vitro in a dose-and time-dependent manner. The results demonstrate that RUNX3 downregulation in breast cancer is frequently due to hypermethylation, and that 5-Aza-CdR can inhibit cell proliferation and induce apoptosis by eliminating the methylation status of RUNX3 promoter and restoring its expression.
C1 [Kang, Hua-Feng; Dai, Zhi-Jun; Bai, He-Ping; Lu, Wang-Feng; Ma, Xiao-Bin; Bao, Xing; Lin, Shuai; Wang, Xi-Jing] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian 710004, Peoples R China.
C3 Xi'an Jiaotong University
RP Wang, XJ (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Oncol, Xian 710004, Peoples R China.
EM wangxijing@21cn.com
RI Ma, Xiaobin/O-7422-2017; Dai, Zhi-Jun/O-6826-2014
OI Dai, Zhi-Jun/0000-0001-5209-8626
FU Fundamental Research Funds for the Central Universities, People's
   Republic of China; International Cooperative Project of Shaanxi
   province, People's Republic of China; Science and Technology Foundation
   of Shanxi Province, People's Republic of China [2011 K03-[08]]
FX This study was supported by the Fundamental Research Funds for the
   Central Universities, People's Republic of China; 2013 International
   Cooperative Project of Shaanxi province, People's Republic of China; and
   The Science and Technology Foundation of Shanxi Province, People's
   Republic of China (No 2011 K03-[08]).
CR Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Chen W, 2007, GENE CHROMOSOME CANC, V46, P288, DOI 10.1002/gcc.20411
   Dai ZJ, 2013, INT J MOL SCI, V14, P273, DOI 10.3390/ijms14010273
   Dai ZJ, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-28
   Gore SD, 2006, NAT REV DRUG DISCOV, V5, P891, DOI 10.1038/nrd2180
   Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029
   Ito K, 2011, GASTROENTEROLOGY, V140, P1536, DOI 10.1053/j.gastro.2011.01.043
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385
   Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162
   Kantarjian HM, 2007, CANCER-AM CANCER SOC, V109, P1133, DOI 10.1002/cncr.22508
   Kim EJ, 2008, J UROLOGY, V180, P1141, DOI 10.1016/j.juro.2008.05.002
   Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Nomoto S, 2008, BRIT J CANCER, V98, P1690, DOI 10.1038/sj.bjc.6604333
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Schübeler D, 2009, NATURE, V462, P296, DOI 10.1038/462296a
   Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4
   Suzuki M, 2005, BRIT J CANCER, V93, P1029, DOI 10.1038/sj.bjc.6602837
   Tycko B, 2011, ONCOLOGY-NY, V25, P228
   Watanabe T, 2011, CLIN COLORECTAL CANC, V10, P134, DOI 10.1016/j.clcc.2011.03.011
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Yanagawa N, 2007, LUNG CANCER, V58, P131, DOI 10.1016/j.lungcan.2007.05.011
   Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385
   Zheng Ying, 2011, Zhonghua Yu Fang Yi Xue Za Zhi, V45, P150
   Zhong ZQ, 2012, ASIAN PAC J CANCER P, V13, P3781, DOI 10.7314/APJCP.2012.13.8.3781
NR 30
TC 16
Z9 22
U1 0
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2013
VL 6
BP 411
EP 417
DI 10.2147/OTT.S43744
PG 7
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA 126EX
UT WOS:000317596400001
PM 23723708
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Mrema, EJ
   Rubino, FM
   Brambilla, G
   Moretto, A
   Tsatsakis, AM
   Colosio, C
AF Mrema, Ezra J.
   Rubino, Federico M.
   Brambilla, Gabri
   Moretto, Angelo
   Tsatsakis, Aristidis M.
   Colosio, Claudio
TI Persistent organochlorinated pesticides and mechanisms of their toxicity
SO TOXICOLOGY
LA English
DT Article
DE Human exposure; Adverse health effect; Organochlorinated pesticides;
   Mechanisms of action
ID ESTROGEN-RECEPTOR-ALPHA; EPIGENETIC TRANSGENERATIONAL ACTIONS;
   BREAST-CANCER RISK; POLYCHLORINATED-BIPHENYLS; HAIR ANALYSIS; IN-VITRO;
   BETA-HEXACHLOROCYCLOHEXANE; ORGANIC POLLUTANTS; SERUM-LEVELS; TESTICULAR
   APOPTOSIS
AB Persistent organic pollutants comprised of organic chemicals like polychlorinated biphenyls, dibenzo-p-dioxins, dibenzofurans and organochlorinated pesticides which have many characteristics in common. Once released in the environment they resist physical, biological, chemical and photochemical breakdown processes and thus persist in the environment. They are subject to long transboundary air pollution transport. They accumulate in the food chain due to their lipophilicity, bioaccumulation and biomagnification properties Human exposure occurs through inhalation of air, ingestion of food and skin contact. Because most of them bioaccumulate and remain preferentially in fat, their long-term effects are still a matter of public health concern. They are condemned for health adverse effects such as cancer, reproductive defects, neurobehavioral abnormalities, endocrine and immunological toxicity. These effects can be elicited via a number of mechanisms among others include disruption of endocrine system, oxidation stress and epigenetic. However most of the mechanisms are not clear thus a number of studies are ongoing trying to elucidate them. In this review, the underlying possible mechanisms of action and their possible roles in adverse developmental and reproductive processes are discussed and where possible a linkage is made to some existing epidemiological data. Both genomic and nongenomic pathways are used to describe these effects. Understanding of these mechanisms will enable development of strategies to protect the public by reducing these adverse effects. This review is limited to persistent organochlorinated pesticides (OCPs) such as dichlorodiphenyltrichloroethane (DDT) and its metabolites, hexachlorobenzene (HCB), beta-hexachlorocyclohexane (beta-HCH) and endosulfan. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Mrema, Ezra J.; Rubino, Federico M.; Brambilla, Gabri; Colosio, Claudio] Univ Milan, Univ Hosp San Paolo, Int Ctr Rural Hlth, Dept Hlth Sci,Occupat Hlth Unit, I-20142 Milan, Italy.
   [Mrema, Ezra J.; Rubino, Federico M.; Brambilla, Gabri; Colosio, Claudio] Lab Analyt Toxicol & Metabol, I-20142 Milan, Italy.
   [Mrema, Ezra J.] Muhimbili Univ Hlth & Allied Sci, Dept Environm & Occupat Hlth, Dar Es Salaam, Tanzania.
   [Moretto, Angelo] Luigi Sacco Univ Milan, Dept Biomed & Clin Sci, I-20157 Milan, Italy.
   [Moretto, Angelo] Univ Hosp Luigi Sacco, Int Ctr Pesticides & Hlth Risk Prevent ICPS, I-20157 Milan, Italy.
   [Tsatsakis, Aristidis M.] Univ Crete, Sch Med, Ctr Toxicol Sci & Res, Div Morphol, Iraklion 71003, Crete, Greece.
C3 University of Milan; Muhimbili University of Health & Allied Sciences;
   University of Milan; Luigi Sacco Hospital; University of Crete
RP Mrema, EJ (通讯作者)，Univ Milan, Dept Hlth Sci, Via San Vigilio 43, I-20142 Milan, Italy.
EM ezra.mrema@unimi.it
RI Rubino, Federico/A-6277-2008; Moretto, Angelo/GPP-6199-2022; TSATSAKIS,
   ARISTIDIS/H-2890-2013; Moretto, Angelo/F-1581-2017; Colosio,
   Claudio/O-3173-2017
OI TSATSAKIS, ARISTIDIS/0000-0003-3824-2462; Rubino, Federico
   Maria/0000-0001-9620-1883; Moretto, Angelo/0000-0003-4386-5736; Colosio,
   Claudio/0000-0002-3643-0681; Mrema, Ezra/0000-0003-1471-6002; BRAMBILLA,
   GABRI/0000-0002-3485-3170
CR García MA, 2010, TOXICOL LETT, V192, P195, DOI 10.1016/j.toxlet.2009.10.026
   Alison MR, 1995, HUM EXP TOXICOL, V14, P935, DOI 10.1177/096032719501401201
   ALLAN DJ, 1992, CELL PROLIFERAT, V25, P241, DOI 10.1111/j.1365-2184.1992.tb01399.x
   Ameisen JC, 1996, SCIENCE, V272, P1278, DOI 10.1126/science.272.5266.1278
   Andersen HH, 2002, NUCL INSTRUM METH B, V187, P1
   Androutsopoulos V, 2009, CANCER LETT, V274, P54, DOI 10.1016/j.canlet.2008.08.032
   Androutsopoulos V, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2090
   Androutsopoulos VP, 2011, BIOORGAN MED CHEM, V19, P2842, DOI 10.1016/j.bmc.2011.03.042
   Androutsopoulos VP, 2010, PHARMACOL THERAPEUT, V126, P9, DOI 10.1016/j.pharmthera.2010.01.009
   Androutsopoulos VP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-187
   [Anonymous], 2002, Toxicological profile for DDT, DDE, and DDD
   [Anonymous], 2003, JOINT WHO CONV TASK
   Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640
   Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Appenzeller BMR, 2012, TOXICOL LETT, V210, P119, DOI 10.1016/j.toxlet.2011.10.021
   Arcaro KF, 1998, ENVIRON HEALTH PERSP, V106, P1041
   Aronson KJ, 2000, CANCER EPIDEM BIOMAR, V9, P55
   Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc
   Badawi AF, 2000, CARCINOGENESIS, V21, P1593, DOI 10.1093/carcin/21.8.1593
   Ben Rhouma K, 2001, HUM EXP TOXICOL, V20, P393, DOI 10.1191/096032701682692946
   Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55
   Bornman R, 2010, BJU INT, V106, P405, DOI 10.1111/j.1464-410X.2009.09003.x
   BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141, DOI 10.1080/15287399109531514
   Bouwman H, 2011, ENVIRON HEALTH PERSP, V119, P744, DOI 10.1289/ehp.1002127
   BRADLOW HL, 1995, ENVIRON HEALTH PERSP, V103, P147, DOI 10.2307/3432525
   Briz V, 2011, TOXICOL SCI, V120, P413, DOI 10.1093/toxsci/kfr019
   CAMPBELL MA, 1983, GEN PHARMACOL-VASC S, V14, P445, DOI 10.1016/0306-3623(83)90028-9
   Carpenter DO, 2008, ANN NY ACAD SCI, V1140, P155, DOI 10.1196/annals.1454.004
   Chiappini F, 2009, TOXICOL SCI, V108, P301, DOI 10.1093/toxsci/kfp016
   Claessens F, 2004, ESSAYS BIOCHEM, V40, P59, DOI 10.1042/bse0400059
   Cohn BA, 2007, ENVIRON HEALTH PERSP, V115, P1406, DOI 10.1289/ehp.10260
   COOSEN R, 1989, TOXICOL APPL PHARM, V101, P310, DOI 10.1016/0041-008X(89)90279-2
   Covaci A, 2002, CHEMOSPHERE, V46, P413, DOI 10.1016/S0045-6535(01)00065-0
   Cupp AS, 2003, J ANDROL, V24, P736
   Davis DL, 1998, ENVIRON HEALTH PERSP, V106, P523, DOI 10.2307/3434225
   Desaulniers D, 2009, INT J TOXICOL, V28, P294, DOI 10.1177/1091581809337918
   DEWAILLY E, 1993, ENVIRON HEALTH PERSP, V101, P618, DOI 10.2307/3431646
   Dewailly É, 1999, ENVIRON HEALTH PERSP, V107, P823, DOI 10.2307/3454581
   Di Lorenzo D, 2002, ENDOCRINOLOGY, V143, P4544, DOI 10.1210/en.2002-220448
   Engeler E., 2009, UN TREATY EXPANDED 9
   Geisz HN, 2008, ENVIRON SCI TECHNOL, V42, P3958, DOI 10.1021/es702919n
   GELLERT RJ, 1978, ENVIRON RES, V16, P131, DOI 10.1016/0013-9351(78)90150-0
   Giribaldi L, 2011, TOXICOLOGY, V289, P19, DOI 10.1016/j.tox.2011.07.004
   Gladen BC, 2003, ANN EPIDEMIOL, V13, P151, DOI 10.1016/S1047-2797(02)00268-5
   Gougeon ML, 1996, J IMMUNOL, V156, P3509
   Grünfeld HT, 2004, TOXICOL LETT, V151, P467, DOI 10.1016/j.toxlet.2004.03.021
   HAHN ME, 1989, ARCH BIOCHEM BIOPHYS, V270, P344, DOI 10.1016/0003-9861(89)90037-4
   Hankinson O, 2005, ARCH BIOCHEM BIOPHYS, V433, P379, DOI 10.1016/j.abb.2004.09.031
   Hatakeyama M, 2002, J BIOCHEM MOL TOXIC, V16, P209, DOI 10.1002/jbt.10047
   Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776
   Hoekstra PF, 2001, TOXICOL LETT, V125, P75, DOI 10.1016/S0378-4274(01)00410-6
   Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86
   Jakszyn P, 2009, CHEMOSPHERE, V76, P1518, DOI 10.1016/j.chemosphere.2009.05.048
   Jung D, 1997, J TOXICOL ENV HEALTH, V51, P23, DOI 10.1080/009841097160203
   KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0
   Khan PK, 1996, MUTAGENESIS, V11, P33, DOI 10.1093/mutage/11.1.33
   Khan SM, 2000, BIOCHEM BIOPH RES CO, V269, P542, DOI 10.1006/bbrc.2000.2321
   Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131
   Kleanthi G., 2008, HLTH SCI J, V2, P89
   Lemaire G, 2006, LIFE SCI, V79, P1160, DOI 10.1016/j.lfs.2006.03.023
   LI HC, 1995, J BIOCHEM TOXICOL, V10, P51
   Li J, 2008, TOXICOL LETT, V183, P65, DOI 10.1016/j.toxlet.2008.10.002
   Li XR, 2006, J STEROID BIOCHEM, V98, P122, DOI 10.1016/j.jsbmb.2005.08.018
   Liang Xian-min, 2008, Zhonghua Yufang Yixue Zazhi, V42, P648
   Longnecker MP, 2007, AM J EPIDEMIOL, V165, P1015, DOI 10.1093/aje/kwk109
   LUBET RA, 1990, ARCH ENVIRON CON TOX, V19, P157, DOI 10.1007/BF01056082
   LUBET RA, 1992, BIOCHEM PHARMACOL, V43, P1067, DOI 10.1016/0006-2952(92)90614-O
   MAHER VMG, 1992, Q J MED, V84, P671
   Mathur V, 2002, ENVIRON INT, V28, P331, DOI 10.1016/S0160-4120(02)00031-4
   Mazzetti MB, 2004, ARCH TOXICOL, V78, P25, DOI 10.1007/s00204-003-0470-y
   MCBLAIN WA, 1987, LIFE SCI, V40, P215, DOI 10.1016/0024-3205(87)90361-4
   McGlynn KA, 2008, JNCI-J NATL CANCER I, V100, P663, DOI 10.1093/jnci/djn101
   McGlynn KA, 2006, JNCI-J NATL CANCER I, V98, P1005, DOI 10.1093/jnci/djj266
   Mortensen H.M., TOXICOL APP IN PRESS
   Mrema E.J., 2011, TOXICOL LETT S, V205S, pS60
   MUSSALORAUHAMAA H, 1990, CANCER-AM CANCER SOC, V66, P2124, DOI 10.1002/1097-0142(19901115)66:10<2124::AID-CNCR2820661014>3.0.CO;2-A
   Nakamura YK, 2008, NUTR RES, V28, P671, DOI 10.1016/j.nutres.2008.07.002
   Nativelle-Serpentini C, 2003, TOXICOL IN VITRO, V17, P413, DOI 10.1016/S0887-2333(03)00046-8
   Navas JM, 2004, LIFE SCI, V76, P699, DOI 10.1016/j.lfs.2004.09.015
   Nicolopoulou-Stamati P, 2001, HUM REPROD UPDATE, V7, P323, DOI 10.1093/humupd/7.3.323
   Ozanne SE, 2007, NAT CLIN PRACT ENDOC, V3, P539, DOI 10.1038/ncpendmet0531
   Peña D, 2012, TOXICOLOGY, V293, P68, DOI 10.1016/j.tox.2011.12.012
   Perera FP, 2005, NEUROTOXICOLOGY, V26, P573, DOI 10.1016/j.neuro.2004.07.007
   Pérez-Maldonado IN, 2005, ENVIRON RES, V98, P177, DOI 10.1016/j.envres.2004.11.001
   Pérez-Maldonado IN, 2004, ENVIRON RES, V94, P38, DOI 10.1016/S0013-9351(03)00112-9
   Pérez-Maldonado IN, 2006, SCI TOTAL ENVIRON, V370, P343, DOI 10.1016/j.scitotenv.2006.06.026
   Picard D, 2006, TRENDS ENDOCRIN MET, V17, P229, DOI 10.1016/j.tem.2006.06.003
   Pontillo CA, 2011, TOXICOL SCI, V120, P284, DOI 10.1093/toxsci/kfq390
   Porta M, 2006, LANCET, V368, P558, DOI 10.1016/S0140-6736(06)69174-5
   RAIZADA RB, 1991, NATL ACAD SCI LETT, V14, P103
   Randi AS, 2006, TOXICOL SCI, V89, P83, DOI 10.1093/toxsci/kfj023
   RAPPOLT RT, 1969, CLIN TOXICOL, V2, P55, DOI 10.3109/15563656908990914
   Recio-Vega R, 2011, J APPL TOXICOL, V31, P270, DOI 10.1002/jat.1672
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Said TM, 2004, HUM REPROD UPDATE, V10, P39, DOI 10.1093/humupd/dmh003
   Saiyed H, 2003, ENVIRON HEALTH PERSP, V111, P1958, DOI 10.1289/ehp.6271
   Samanta L, 1997, COMP BIOCHEM PHYS C, V118, P319, DOI 10.1016/S0742-8413(97)00132-1
   Saradha B, 2009, TOXICOLOGY, V255, P131, DOI 10.1016/j.tox.2008.10.016
   SCHNEIDER J, 1982, P NATL ACAD SCI-BIOL, V79, P3047, DOI 10.1073/pnas.79.9.3047
   Scippo ML, 2004, ANAL BIOANAL CHEM, V378, P664, DOI 10.1007/s00216-003-2251-0
   Shelby MD, 1996, ENVIRON HEALTH PERSP, V104, P1296, DOI 10.2307/3432965
   Shi YQ, 2010, TOXICOL LETT, V193, P79, DOI 10.1016/j.toxlet.2009.12.008
   Shi YQ, 2011, ENVIRON TOXICOL, V26, P124, DOI 10.1002/tox.20536
   Shi YQ, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/181282
   Shinomiya N, 2003, TOXICOL LETT, V137, P175, DOI 10.1016/S0378-4274(02)00401-0
   Shutoh Y, 2009, J TOXICOL SCI, V34, P469, DOI 10.2131/jts.34.469
   Silva E, 2007, ENVIRON HEALTH PERSP, V115, P91, DOI 10.1289/ehp.9363
   Silva E, 2010, TOXICOL APPL PHARM, V245, P159, DOI 10.1016/j.taap.2010.02.015
   Sinha N, 1999, REPROD TOXICOL, V13, P291, DOI 10.1016/S0890-6238(99)00020-9
   Sinha N, 2001, ENVIRON TOXICOL PHAR, V10, P29, DOI 10.1016/S1382-6689(01)00066-7
   Sinha N, 2001, B ENVIRON CONTAM TOX, V67, P821, DOI 10.1007/s001280196
   SINHA N, 1995, VET HUM TOXICOL, V37, P547
   Sinha N, 1997, B ENVIRON CONTAM TOX, V58, P79, DOI 10.1007/s001289900303
   Song MO, 2012, TOXICOLOGY, V292, P23, DOI 10.1016/j.tox.2011.11.013
   Song Y, 2008, TOXICOLOGY, V253, P53, DOI 10.1016/j.tox.2008.08.013
   Song Y, 2011, TOXICOL LETT, V202, P55, DOI 10.1016/j.toxlet.2011.01.020
   SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519
   SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626
   Steinmetz R, 1996, CANCER RES, V56, P5403
   Sujatha R, 2001, ASIAN J ANDROL, V3, P135
   Swanson HI, 2002, CHEM-BIOL INTERACT, V141, P63, DOI 10.1016/S0009-2797(02)00066-2
   Swedenborg E, 2009, J MOL ENDOCRINOL, V43, P1, DOI 10.1677/JME-08-0132
   Tebourbi O, 2010, ENVIRON TOXICOL PHAR, V29, P271, DOI 10.1016/j.etap.2010.03.002
   TELANG NT, 1992, J NATL CANCER I, V84, P634, DOI 10.1093/jnci/84.8.634
   ToFigueras J, 1997, ENVIRON HEALTH PERSP, V105, P78, DOI 10.2307/3433066
   Tsang HL, 2011, ENVIRON INT, V37, P142, DOI 10.1016/j.envint.2010.08.010
   Tsatsakis A, 2004, FORENSIC SCI INT, V145, P195, DOI 10.1016/j.forsciint.2004.04.036
   Tsatsakis AM, 2008, FORENSIC SCI INT, V176, P67, DOI 10.1016/j.forsciint.2007.07.017
   Tsatsakis AM, 2009, TOXICOL LETT, V186, P66, DOI 10.1016/j.toxlet.2008.10.018
   Tsatsakis AM, 1998, VET HUM TOXICOL, V40, P200
   Tutudaki M, 2003, HUM EXP TOXICOL, V22, P159, DOI 10.1191/0960327103ht334oa
   UNEP, 2010, 6 EXP M END RISK MAN
   UNEP, 2010, 3 EXP GROUP M ASS PR
   Vaithinathan S, 2010, CHEM-BIOL INTERACT, V185, P110, DOI 10.1016/j.cbi.2010.03.014
   van Ommen B, 1989, Drug Metabol Drug Interact, V7, P213
   Van Tonder J.J., 2011, THESIS U PRETORIA PR
   Wade MG, 1997, REPROD TOXICOL, V11, P791, DOI 10.1016/S0890-6238(97)00062-2
   Wang LM, 2009, ENVIRON TOXICOL CHEM, V28, P1, DOI 10.1897/08-055.1
   WHO, 1992, 123 WHO EHC
   WHO, 2011, 241 WHO EHC
   Wójtowicz AK, 2011, PHARMACOL REP, V63, P1460, DOI 10.1016/S1734-1140(11)70710-1
   Wu YJ, 2006, REPRODUCTION, V131, P299, DOI 10.1530/rep.1.00922
   YOSHIOKA H, 1984, J BIOCHEM, V95, P937, DOI 10.1093/oxfordjournals.jbchem.a134721
   Yu Hai-Ge, 2008, Zhonghua Nan Ke Xue, V14, P311
   Zala SM, 2004, ANIM BEHAV, V68, P649, DOI 10.1016/j.anbehav.2004.01.005
NR 147
TC 338
Z9 374
U1 6
U2 707
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD MAY 10
PY 2013
VL 307
BP 74
EP 88
DI 10.1016/j.tox.2012.11.015
PG 15
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 165IK
UT WOS:000320476900011
PM 23219589
DA 2025-01-12
ER

PT J
AU Liu, XY
   Wang, Y
   Qu, HL
   Hou, MH
   Cao, WH
   Ma, ZL
   Wang, HB
AF Liu, Xiaoyi
   Wang, Yu
   Qu, Huili
   Hou, Minghui
   Cao, Weihong
   Ma, Zhongliang
   Wang, Haibo
TI Associations of Polymorphisms of rs693 and rs1042031 in Apolipoprotein B
   Gene With Risk of Breast Cancer in Chinese
SO JAPANESE JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE lipids; apolipoprotein B; breast cancer; polymorphisms; risk
ID FATTY-ACID SYNTHASE; APO-B; POSTMENOPAUSAL WOMEN; GALLSTONE FORMATION;
   GALLBLADDER CANCER; LIPID-METABOLISM; CELLS; LIPOPROTEINS; PATHWAYS;
   RECEPTOR
AB Lipid synthesis is an integrated result of genetic, epigenetic and environmental factors, and also can promote growth and survival of cancer cells. Apolipoprotein B plays a central role in lipid metabolism as the major protein component of very-low-density lipoprotein and low-density lipoprotein.
   We investigated the associations of polymorphisms of rs693 (7673CT) and rs1042031 (12669 GA) in the APOB gene with risk of breast cancer in 675 blood-unrelated Chinese patients with breast cancer and 712 healthy controls.
   Polymorphisms of 12669 GA and 7673CT in the APOB gene were significantly associated with an increased risk of breast cancer (P 0.000), especially for postmenopausal women (P 0.000, 0.023). The positive associations still remained after further analysis of the two polymorphisms distribution according to body mass index. However, no statistical associations were found between 12669 GA and 7673CT polymorphisms and other clinical characteristics, including tumor size, lymph node metastasis, histological grade, estrogen and progesterone receptor status and Her-2 status.
   rs693 and rs1042031 polymorphisms in the APOB gene increased the risk of breast cancer in Chinese, and this role of the two polymorphisms in connection with breast cancer was not dependent on body mass index.
C1 [Liu, Xiaoyi; Wang, Yu; Qu, Huili; Hou, Minghui; Cao, Weihong; Ma, Zhongliang; Wang, Haibo] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Galactophore, Qingdao 266071, Peoples R China.
C3 Qingdao University
RP Wang, HB (通讯作者)，Qingdao Univ, Coll Med, Affiliated Hosp, Dept Galactophore, 59 Haier Rd, Qingdao 266071, Peoples R China.
EM qdyxywhb@163.com
RI Chen, Yuanyuan/GXG-2130-2022; liu, yichen/GVT-6262-2022
CR Adachi M, 2009, CHILD NERV SYST, V25, P669, DOI 10.1007/s00381-009-0837-3
   Andreotti G, 2008, CANCER EPIDEM BIOMAR, V17, P525, DOI 10.1158/1055-9965.EPI-07-2704
   Apostolou F, 2010, ATHEROSCLEROSIS, V212, P607, DOI 10.1016/j.atherosclerosis.2010.06.006
   Ashur-Fabian O, 2010, CELL CYCLE, V9, P3761, DOI 10.4161/cc.9.18.12993
   Báez S, 2010, WORLD J GASTROENTERO, V16, P372, DOI 10.3748/wjg.v16.i3.372
   Bhatt AP, 2012, P NATL ACAD SCI USA, V109, P11818, DOI 10.1073/pnas.1205995109
   Borén J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847
   Campbell KL, 2012, J ACAD NUTR DIET, V112, P559, DOI 10.1016/j.jada.2011.10.022
   Chang SJ, 2007, CLIN CHEM LAB MED, V45, P1219, DOI 10.1515/CCLM.2007.263
   Choong SS, 2011, INT J LAB HEMATOL, V33, P182, DOI 10.1111/j.1751-553X.2010.01264.x
   Cohen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014540
   Dawood S, 2012, CLIN BREAST CANCER, V12, P364, DOI 10.1016/j.clbc.2012.07.013
   Dumitrescu L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002138
   Fredrikson GN, 2007, STROKE, V38, P1495, DOI 10.1161/STROKEAHA.106.474577
   Gallegos-Arreola MP, 2012, ASIA PAC J CLIN NUTR, V21, P312
   Gaudreault N, 2011, AM J CARDIOL, V108, P1305, DOI 10.1016/j.amjcard.2011.06.050
   Gautier T, 2010, J LIPID RES, V51, P2245, DOI 10.1194/jlr.M005181
   Guerra Cristina Tosti, 2007, Dig Liver Dis, V39 Suppl 1, pS76, DOI 10.1016/S1590-8658(07)80016-8
   Han CZ, 2008, BIOL TRACE ELEM RES, V126, P38, DOI 10.1007/s12011-008-8182-z
   Inamdar P, 2011, INDIA J SURG ONCOL, V2, P118, DOI 10.1007/s13193-011-0070-x
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Kamdem LK, 2008, PHARMACOGENET GENOM, V18, P507, DOI 10.1097/FPC.0b013e3282fc5801
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673
   Lafontan M, 2012, AM J PHYSIOL-CELL PH, V302, pC327, DOI 10.1152/ajpcell.00168.2011
   Li N, 2012, NUTR CANCER, V64, P864, DOI 10.1080/01635581.2012.701704
   Liu FL, 2010, WORLD J GASTROENTERO, V16, P2549, DOI 10.3748/wjg.v16.i20.2549
   Llanos AA, 2012, ETHNIC DIS, V22, P281
   Maiti B, 2010, BREAST CANCER RES TR, V121, P479, DOI 10.1007/s10549-009-0591-y
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Mukherjee A, 2012, J BIOL CHEM, V287, P24990, DOI 10.1074/jbc.M112.340083
   Nagel G, 2009, INT ARCH ALLERGY IMM, V149, P259, DOI 10.1159/000199722
   Pandey SN, 2007, LIVER INT, V27, P1008, DOI 10.1111/j.1478-3231.2007.01516.x
   Phipps AI, 2008, CANCER EPIDEM BIOMAR, V17, P2078, DOI 10.1158/1055-9965.EPI-08-0206
   Reddavide R, 2011, ANTICANCER RES, V31, P555
   Ronco AL, 2012, ASIAN PAC J CANCER P, V13, P139, DOI 10.7314/APJCP.2012.13.1.139
   Sekine Y, 2007, CLIN CHIM ACTA, V383, P78, DOI 10.1016/j.cca.2007.04.016
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Tsunoda K, 2012, BIOCHEM GENET, V50, P249, DOI 10.1007/s10528-011-9468-y
   Yadav NK, 2012, ASIAN PAC J CANCER P, V13, P3385, DOI 10.7314/APJCP.2012.13.7.3385
   Yang XR, 2007, CANCER EPIDEM BIOMAR, V16, P439, DOI 10.1158/1055-9965.EPI-06-0806
   Zaman Khalil, 2012, Rev Med Suisse, V8, P1101
NR 42
TC 17
Z9 18
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0368-2811
EI 1465-3621
J9 JPN J CLIN ONCOL
JI Jpn. J. Clin. Oncol.
PD APR
PY 2013
VL 43
IS 4
BP 362
EP 368
DI 10.1093/jjco/hyt018
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 117QE
UT WOS:000316967400004
PM 23444115
DA 2025-01-12
ER

PT J
AU Schirmer, U
   Fiegl, H
   Pfeifer, M
   Zeimet, AG
   Müller-Holzner, E
   Bode, PK
   Tischler, V
   Altevogt, P
AF Schirmer, Uwe
   Fiegl, Heidi
   Pfeifer, Marco
   Zeimet, Alain G.
   Mueller-Holzner, Elisabeth
   Bode, Peter K.
   Tischler, Verena
   Altevogt, Peter
TI Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to
   cancer-testis (CT-X) antigens
SO BMC CANCER
LA English
DT Article
ID CELL-ADHESION MOLECULE; GENE-EXPRESSION; DNA METHYLATION; BREAST-CANCER;
   L1 EXPRESSION; CPG ISLAND; PROMOTER; PROGRESSION; DEMETHYLATION;
   INHIBITOR
AB Background: L1CAM was originally identified as an adhesion molecule involved in neural development. In many human carcinomas L1CAM is over-expressed and is associated with a bad prognosis. We previously reported that L1CAM was absent in the vast majority of endometrioid endometrial carcinomas (ECs) (type 1) but was strongly expressed in the more aggressive serous and clear-cell ECs (termed type 2). The differential regulation of L1CAM in ECs is not well understood. Recent evidence suggests that it can be regulated by epigenetic mechanisms. Here we investigated the role of DNA-methylation of the L1CAM promoter for expression. We also studied the relationship to cancer testis (CT-X) antigens that co-localize with L1CAM on chromosome Xq28, a region that is often activated in human tumors.
   Methods: We used EC cell lines and primary tumor tissues for our analysis. For expression analysis we employed RT-PCR and Western blotting. DNA-Methylation of the L1CAM promoter was determined after bisulfite conversation and DNA sequencing. Tumor tissues were examined by immunohistochemical (IHC) staining.
   Results: We demonstrate that the treatment of L1CAM low/negative expressing EC cell lines with 5'-Azacytidine (5-AzaC) or knock-down of DNMT1 (DNA methyltransferase 1) as well as the HDAC (histone deacetylase) inhibitor Trichostatin A (TSA) up-regulated L1CAM at the mRNA and protein level. The L1CAM gene has two promoter regions with two distinct CpG islands. We observed that the expression of L1CAM correlated with hypermethylation in promoter 1 and 5-AzaC treatment affected the DNA-methylation pattern in this region. The CT-X antigens NY-ESO-1, MAGE-A3 and MAGE-A4 were also strongly up-regulated by 5-AzaC or knock-down of DNMT1 but did not respond to treatment with TSA. Primary EC tumor tissues showed a variable methylation pattern of the L1CAM promoter. No striking differences in promoter methylation were observed between tumor areas with L1CAM expression and those without expression.
   Conclusions: L1CAM expression correlated with methylation of the L1CAM promoter in EC cell lines. In negative cell lines L1CAM expression is up-regulated by epigenetic mechanism. Although genes localized on Xq28 are often re-expressed by human tumors, L1CAM and CT-X antigens show distinct regulation in response to HADC inhibitors and 5-AzaC.
C1 [Schirmer, Uwe; Pfeifer, Marco; Altevogt, Peter] German Canc Res Ctr, Dept Translat Immunol, D-69120 Heidelberg, Germany.
   [Fiegl, Heidi; Zeimet, Alain G.; Mueller-Holzner, Elisabeth] Med Univ Innsbruck, Dept Gynecol & Obstet, A-6020 Innsbruck, Austria.
   [Bode, Peter K.; Tischler, Verena] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Medical
   University of Innsbruck; University of Zurich; University Zurich
   Hospital
RP Altevogt, P (通讯作者)，German Canc Res Ctr, Dept Translat Immunol, D015, D-69120 Heidelberg, Germany.
EM p.altevogt@dkfz.de
RI Tischler, Verena/Q-7263-2017; Fiegl, Heidi/K-4445-2017
OI Bode, Peter/0000-0002-9633-4042; Fiegl, Heidi/0000-0002-1236-6806
FU Deutsche Krebshilfe [108739]; Wilhelm-Sander Stiftung, Munich; Academy
   of Finland (AKA) [108739] Funding Source: Academy of Finland (AKA)
FX We acknowledge the competent help of Natalie Erbe-Hofmann and John Hazin
   for critically reading of the manuscript. We thank Inge Gaugg and
   Martina Fleischer for their excellent technical assistance. This work
   was supported by grants from Deutsche Krebshilfe (grant Nr. 108739 to
   P.A.), and Wilhelm-Sander Stiftung, Munich.
CR Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Bondong S, 2012, ANN ONCOL, V23, P1795, DOI 10.1093/annonc/mdr568
   Boo YJ, 2007, ANN SURG ONCOL, V14, P1703, DOI 10.1245/s10434-006-9281-8
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5
   Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X
   Gast D, 2008, ONCOGENE, V27, P1281, DOI 10.1038/sj.onc.1210747
   Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051
   Gavert N, 2008, EXPERT OPIN BIOL TH, V8, P1749, DOI 10.1517/14712598.8.11.1749 
   Geismann C, 2011, INT J ONCOL, V38, P257, DOI 10.3892/ijo_00000846
   Huszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673
   Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343
   Kato K, 2009, INT J ONCOL, V35, P467, DOI 10.3892/ijo_00000358
   Kiefel H, 2012, CELL ADHES MIGR, V6, P374, DOI 10.4161/cam.20832
   KOHL A, 1992, J NEUROSCI RES, V32, P167, DOI 10.1002/jnr.490320206
   Konecny GE, 2008, BRIT J CANCER, V98, P1076, DOI 10.1038/sj.bjc.6604278
   Kuwajima A, 2007, ANTICANCER RES, V27, P4163
   Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099
   Müller HM, 2003, CANCER RES, V63, P7641
   OTTO SP, 1990, GENETICS, V124, P429
   Pfeifer M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-64
   Sahin U, 1998, INT J CANCER, V78, P387, DOI 10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2
   Schäfer MKE, 2010, CELL MOL LIFE SCI, V67, P2425, DOI 10.1007/s00018-010-0339-1
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Wischnewski F, 2006, MOL CANCER RES, V4, P339, DOI 10.1158/1541-7786.MCR-05-0229
NR 27
TC 15
Z9 18
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAR 26
PY 2013
VL 13
AR 156
DI 10.1186/1471-2407-13-156
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 123NX
UT WOS:000317398100001
PM 23530769
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Giovinazzi, S
   Morozov, VM
   Summers, MK
   Reinhold, WC
   Ishov, AM
AF Giovinazzi, S.
   Morozov, V. M.
   Summers, M. K.
   Reinhold, W. C.
   Ishov, A. M.
TI USP7 and Daxx regulate mitosis progression and taxane sensitivity by
   affecting stability of Aurora-A kinase
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
DE Daxx; USP7; mitosis; taxanes; Aurora-A; CHFR
ID SPINDLE-ASSEMBLY CHECKPOINT; TRANSCRIPTION REPRESSOR DAXX; MITOTIC
   STRESS CHECKPOINT; HUMAN CANCER-CELLS; BREAST-CANCER; EPIGENETIC
   INACTIVATION; PROTEIN; CHFR; P53; RESISTANCE
AB A large number of patients are resistant to taxane-based chemotherapy. Functional mitotic checkpoints are essential for taxane sensitivity. Thus, mitotic regulators are potential markers for therapy response and could be targeted for anticancer therapy. In this study, we identified a novel function of ubiquitin (Ub)-specific processing protease-7 (USP7) that interacts and cooperates with protein death domain-associated protein (Daxx) in the regulation of mitosis and taxane resistance. Depletion of USP7 impairs mitotic progression, stabilizes cyclin B and reduces stability of the mitotic E3 Ub ligase, checkpoint with forkhead and Ring-finger (CHFR). Consequently, cells with depleted USP7 accumulate Aurora-A kinase, a CHFR substrate, thus elevating multipolar mitoses. We further show that these effects are independent of the USP7 substrate p53. Thus, USP7 and Daxx are necessary to regulate proper execution of mitosis, partially via regulation of CHFR and Aurora-A kinase stability. Results from colony formation assay, in silico analysis across the NCI60 platform and in breast cancer patients suggest that USP7 levels inversely correlate with response to taxanes, pointing at the USP7 protein as a potential predictive factor for taxane response in cancer patients. In addition, we demonstrated that inhibition of Aurora-A attenuates USP7-mediated taxane resistance, suggesting that combinatorial drug regimens of Taxol and Aurora-A inhibitors may improve the outcome of chemotherapy response in cancer patients resistant to taxane treatment. Finally, our study offers novel insights on USP7 inhibition as cancer therapy. Cell Death and Differentiation (2013) 20, 721-731; doi:10.1038/cdd.2012.169; published online 25 January 2013
C1 [Giovinazzi, S.; Morozov, V. M.; Ishov, A. M.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
   [Giovinazzi, S.; Morozov, V. M.; Ishov, A. M.] Univ Florida Shands Canc Ctr, Gainesville, FL USA.
   [Summers, M. K.] Lerner Res Inst, Dept Canc Biol, Cleveland, OH USA.
   [Reinhold, W. C.] NIH, Genom & Bioinformat Grp, Mol Pharmacol Lab, NCI, Bethesda, MD 20892 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; Cleveland Clinic
   Foundation; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI)
RP Ishov, AM (通讯作者)，Univ Florida, Dept Anat & Cell Biol, 2033 Mowry Rd, Gainesville, FL 32610 USA.
EM ishov@ufl.edu
RI Ishov, Alexander/E-4912-2010; Reinhold, William/J-6704-2017
OI Morozov, Viacheslav/0000-0002-4901-7722; Reinhold,
   William/0000-0001-5513-9323
FU NIH/NCI [R01 CA127378-01A1]; Shula Foundation; Cleveland Clinic; Center
   for Cancer Research; NCI; DTP, Division of Cancer Treatment and
   Diagnosis (DCTD), NCI
FX We thank Bert Vogelstein for the generous gift of HCT116 p53 WT and -/-
   cells. This work was supported by NIH/NCI R01 CA127378-01A1 for SG, VMM
   and AMI and Shula Foundation for SG, by seed funding from the Cleveland
   Clinic for MKS and by the Center for Cancer Research, the intramural
   program of NCI and the DTP, Division of Cancer Treatment and Diagnosis
   (DCTD), NCI for WCR.
CR Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967
   Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0
   Banno K, 2007, INT J ONCOL, V31, P713
   Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136
   Bonneterre J, 1999, EUR J CANCER, V35, P1431, DOI 10.1016/S0959-8049(99)00174-4
   Boutell C, 2005, J VIROL, V79, P12342, DOI 10.1128/JVI.79.19.12342-12354.2005
   Brito DA, 2008, J CELL BIOL, V182, P623, DOI 10.1083/jcb.200805072
   Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043
   Carvajal RD, 2006, CLIN CANCER RES, V12, P6869, DOI 10.1158/1078-0432.CCR-06-1405
   Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726
   Chien AJ, 2008, SEMIN ONCOL, V35, pS1, DOI 10.1053/j.seminoncol.2008.02.010
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924
   Faesen AC, 2011, MOL CELL, V44, P147, DOI 10.1016/j.molcel.2011.06.034
   Giovinazzi S, 2012, ONCOGENE, V31, P13, DOI 10.1038/onc.2011.211
   Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981
   Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313
   Higa GM, 2011, BREAST CANCER-TOKYO, V18, P103, DOI 10.1007/s12282-010-0224-7
   Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1
   Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06
   Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230
   Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385
   Kon N, 2011, CELL DEATH DIFFER, V18, P1366, DOI 10.1038/cdd.2011.12
   Kon N, 2010, ONCOGENE, V29, P1270, DOI 10.1038/onc.2009.427
   Lee EA, 2004, MOL CANCER THER, V3, P661
   Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737
   Lindsay CR, 2008, FRONT BIOSCI-LANDMRK, V13, P7132, DOI 10.2741/3216
   Lindsay CR, 2007, CELL CYCLE, V6, P1200, DOI 10.4161/cc.6.10.4244
   Lindsay CR, 2009, CELL CYCLE, V8, P1544, DOI 10.4161/cc.8.10.8379
   Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965
   Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435
   LUNA RMD, 1995, NATURE, V378, P203
   Mantel C, 2008, CELL CYCLE, V7, P484, DOI 10.4161/cc.7.4.5316
   Matson DR, 2011, MOL INTERV, V11, P141, DOI 10.1124/mi.11.2.12
   Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006
   Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483
   Morozov VM, 2008, ONCOGENE, V27, P2177, DOI 10.1038/sj.onc.1210865
   Morse DL, 2005, MOL CANCER THER, V4, P1495, DOI 10.1158/1535-7163.MCT-05-0130
   Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163
   Nakatani Y, 2003, METHOD ENZYMOL, V370, P430
   Nicholson B, 2011, CELL BIOCHEM BIOPHYS, V60, P61, DOI 10.1007/s12013-011-9185-5
   O'Shaughnessy J, 2005, ONCOLOGIST, V10, P20, DOI 10.1634/theoncologist.10-90003-20
   Oh YM, 2007, BIOCHEM BIOPH RES CO, V357, P615, DOI 10.1016/j.bbrc.2007.03.193
   Qina L, 2009, CANCER LETT, V275, P77, DOI 10.1016/j.canlet.2008.10.011
   Reinhold WC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025991
   Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002
   Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575
   RUBINSTEIN LV, 1990, JNCI-J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113
   Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Staff S, 2010, ONCOL REP, V23, P307, DOI 10.3892/or_00000637
   Sun CB, 2007, BIOCHEM BIOPH RES CO, V352, P220, DOI 10.1016/j.bbrc.2006.11.004
   Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106
   Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442
   Tang J, 2010, BIOCHEM BIOPH RES CO, V393, P542, DOI 10.1016/j.bbrc.2010.02.051
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Wysong DR, 2009, CELL CYCLE, V8, P876, DOI 10.4161/cc.8.6.7897
   Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322
   Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538
   Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569
NR 60
TC 50
Z9 55
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD MAY
PY 2013
VL 20
IS 5
BP 721
EP 731
DI 10.1038/cdd.2012.169
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 121SP
UT WOS:000317264800006
PM 23348568
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Connolly, RM
   Nguyen, NK
   Sukumar, S
AF Connolly, Roisin M.
   Nguyen, Nguyen K.
   Sukumar, Saraswati
TI Molecular Pathways: Current Role and Future Directions of the Retinoic
   Acid Pathway in Cancer Prevention and Treatment
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BETA-CAROTENE SUPPLEMENTATION; SQUAMOUS-CELL CARCINOMA; LOW-DOSE
   ISOTRETINOIN; 2ND PRIMARY TUMORS; PHASE-III TRIAL; BREAST-CANCER;
   RECEPTOR-BETA; LUNG-CANCER; HIGH-RISK; STAGE-I
AB Retinoids and their naturally metabolized and synthetic products (e. g., all-trans retinoic acid, 13-cis retinoic acid, bexarotene) induce differentiation in various cell types. Retinoids exert their actions mainly through binding to the nuclear retinoic acid receptors (alpha, beta, gamma), which are transcriptional and homeostatic regulators with functions that are often compromised early in neoplastic transformation. The retinoids have been investigated extensively for their use in cancer prevention and treatment. Success has been achieved with their use in the treatment of subtypes of leukemia harboring chromosomal translocations. Promising results have been observed in the breast cancer prevention setting, where fenretinide prevention trials have provided a strong rationale for further investigation in young women at high risk for breast cancer. Ongoing phase III randomized trials investigating retinoids in combination with chemotherapy in non-small cell lung cancer aim to definitively characterize the role of retinoids in this tumor type. The limited treatment success observed to date in the prevention and treatment of solid tumors may relate to the frequent epigenetic silencing of RAR beta. Robust evaluation of RAR beta and downstream genes may permit optimized use of retinoids in the solid tumor arena. Clin Cancer Res; 19(7); 1651-9. (C) 2013 AACR.
C1 [Connolly, Roisin M.; Nguyen, Nguyen K.; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Breast Canc Program, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Sukumar, S (通讯作者)，Johns Hopkins Univ, Sch Med, 1650 Orleans St,Room 143, Baltimore, MD 21287 USA.
EM rconnol2@jhmi.edu; saras@jhmi.edu
RI Nguyen, Duy/HDO-8098-2022
FU Sidney Kimmel Comprehensive Cancer Center (SKCCC) [P30 CA006973]; DOD
   COE [W81XWH-04-1-0595]
FX This study was supported by the Sidney Kimmel Comprehensive Cancer
   Center (SKCCC) Core grant P30 CA006973 and DOD COE W81XWH-04-1-0595.
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Alvarez S, 2007, INT J BIOCHEM CELL B, V39, P1406, DOI 10.1016/j.biocel.2007.02.010
   [Anonymous], P 101 ANN M AM ASS C
   Arrieta O, 2010, J CLIN ONCOL, V28, P3463, DOI 10.1200/JCO.2009.26.6452
   Bonanni B, 2009, RECENT RES CANCER, V181, P77
   Bryan M, 2011, INVEST NEW DRUG, V29, P1482, DOI 10.1007/s10637-010-9478-3
   Bushue N, 2010, ADV DRUG DELIVER REV, V62, P1285, DOI 10.1016/j.addr.2010.07.003
   CASSIDY J, 1982, EUR J CANCER CLIN ON, V18, P925, DOI 10.1016/0277-5379(82)90239-5
   Catalano A, 2007, BLOOD, V110, P4073, DOI 10.1182/blood-2007-06-095554
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chiesa Matteo Dalla, 2007, Acta Biomed, V78, P204
   Cras A, 2012, CLIN CANCER RES, V18, P442, DOI 10.1158/1078-0432.CCR-11-0510
   Decensi A, 2009, J CLIN ONCOL, V27, P3749, DOI 10.1200/JCO.2008.19.3797
   Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329
   Duong V, 2011, BBA-MOL BASIS DIS, V1812, P1023, DOI 10.1016/j.bbadis.2010.10.007
   Duvic M, 2001, J CLIN ONCOL, V19, P2456, DOI 10.1200/JCO.2001.19.9.2456
   Esteva FJ, 2003, J CLIN ONCOL, V21, P999, DOI 10.1200/JCO.2003.05.068
   Fenaux P, 2007, CURR TOP MICROBIOL, V313, P101
   Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936
   Gillespie RF, 2007, J MOL BIOL, V372, P298, DOI 10.1016/j.jmb.2007.06.079
   Goodman GE, 2004, J NATL CANCER I, V96, P1743, DOI 10.1093/jnci/djh320
   HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Kelly K, 2009, CANCER PREV RES, V2, P440, DOI 10.1158/1940-6207.CAPR-08-0136
   Khuri FR, 2006, JNCI-J NATL CANCER I, V98, P441, DOI 10.1093/jnci/djj091
   Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626
   Kucukzeybek Y, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-37
   Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206
   Kurie JM, 2000, CLIN CANCER RES, V6, P2973
   Lee ER, 2007, STEM CELLS, V25, P2191, DOI 10.1634/stemcells.2007-0203
   Lee HY, 1999, MOL CELL BIOL, V19, P1973
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   LEE JS, 1994, J CLIN ONCOL, V12, P937, DOI 10.1200/JCO.1994.12.5.937
   Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8
   Lin LM, 2005, WORLD J GASTROENTERO, V11, P5633, DOI 10.3748/wjg.v11.i36.5633
   LIPPMAN SM, 1995, CANCER RES, V55, P16
   LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103
   Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Lodi G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001829.pub3
   LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103
   Lu TY, 2011, CHINESE MED J-PEKING, V124, P2708, DOI 10.3760/cma.j.issn.0366-6999.2011.17.026
   McPherson LA, 2007, J SURG RES, V138, P71, DOI 10.1016/j.jss.2006.07.002
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   MEHTA RG, 1991, EUR J CANCER, V27, P138, DOI 10.1016/0277-5379(91)90471-O
   MOGHAL N, 1995, MOL CELL BIOL, V15, P3945
   MOON RC, 1979, CANCER RES, V39, P1339
   Njar VCO, 2006, BIOORGAN MED CHEM, V14, P4323, DOI 10.1016/j.bmc.2006.02.041
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Orfanos CE, 1997, DRUGS, V53, P358, DOI 10.2165/00003495-199753030-00003
   Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769
   Papi A, 2012, CELL DEATH DIFFER, V19, P1208, DOI 10.1038/cdd.2011.207
   Pappas JJ, 2011, GENE CHROMOSOME CANC, V50, P700, DOI 10.1002/gcc.20892
   PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216
   Pili R, 2012, BRIT J CANCER, V106, P77, DOI 10.1038/bjc.2011.527
   Piskunov A, 2012, ONCOGENE, V31, P3333, DOI 10.1038/onc.2011.499
   Qian DZ, 2005, PROSTATE, V64, P20, DOI 10.1002/pros.20209
   Raffoux E, 2010, ONCOTARGET, V1, P34, DOI 10.18632/oncotarget.106
   Ramlau R, 2008, J CLIN ONCOL, V26, P1886, DOI 10.1200/JCO.2007.12.2614
   RATKO TA, 1989, CANCER RES, V49, P4472
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508
   Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666
   Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Theodosiou M, 2010, CELL MOL LIFE SCI, V67, P1423, DOI 10.1007/s00018-010-0268-z
   van Zandwijk N, 2000, JNCI-J NATL CANCER I, V92, P977, DOI 10.1093/jnci/92.12.977
   Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847
   Virtamo J, 2003, JAMA-J AM MED ASSOC, V290, P476, DOI 10.1001/jama.290.4.476
   Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000
   Wang Q, 2001, BREAST CANCER RES TR, V67, P157, DOI 10.1023/A:1010643323268
   White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538
   Widschwendter M, 1997, CANCER RES, V57, P4158
   WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033
   Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58
NR 80
TC 170
Z9 196
U1 0
U2 30
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 1
PY 2013
VL 19
IS 7
BP 1651
EP 1659
DI 10.1158/1078-0432.CCR-12-3175
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 118BH
UT WOS:000316996900005
PM 23322901
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Roulston, A
   Muller, WJ
   Shore, GC
AF Roulston, Anne
   Muller, William J.
   Shore, Gordon C.
TI BIM, PUMA, and the Achilles' Heel of Oncogene Addiction
SO SCIENCE SIGNALING
LA English
DT Article
ID BREAST-CANCER CELLS; KINASE INHIBITORS; APOPTOSIS; EXPRESSION;
   INDUCTION; MYC; PROTEIN; FAMILY; DEATH; HER2
AB Cancer cells undergo extensive genetic and epigenetic rewiring to support the malignant phenotype, and yet cell survival and proliferation often remain dependent on one or a limited number of driver mutations. This is the concept of oncogene addiction, the elucidation of which has led to substantial progress in therapeutic interventions. However, because resistance mechanisms often emerge, explicating the pathways that connect therapeutic oncogene inactivation to the cell death machinery is critical to exploiting additional synthetic lethal opportunities.
C1 [Shore, Gordon C.] McGill Univ, Dept Biochem, Montreal, PQ H3G 2J7, Canada.
   McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3G 2J7, Canada.
C3 McGill University; McGill University
RP Shore, GC (通讯作者)，McGill Univ, Dept Biochem, Montreal, PQ H3G 2J7, Canada.
EM gordon.shore@mcgill.ca
CR Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Amente S, 2011, NUCLEIC ACIDS RES, V39, P9498, DOI 10.1093/nar/gkr638
   ASKEW DS, 1991, ONCOGENE, V6, P1915
   Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483
   Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106
   Campone M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-110
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315
   Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961
   Dunn L, 2009, MOL DIAGN THER, V13, P73, DOI 10.2165/01250444-200913020-00002
   Ertel F, 2013, EMBO REP, V14, P328, DOI 10.1038/embor.2013.20
   EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T
   Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106
   Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777
   Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294
   Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086
   Guo SQ, 2004, MOL CELL BIOL, V24, P8681, DOI 10.1128/MCB.24.19.8681-8690.2004
   Khatri S, 2010, J BIOL CHEM, V285, P15960, DOI 10.1074/jbc.M110.121871
   Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499
   Letai AG, 2008, NAT REV CANCER, V8, P121, DOI 10.1038/nrc2297
   Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688
   Martin AP, 2009, CANCER BIOL THER, V8, P2084
   Mikse OR, 2010, CANCER RES, V70, P6205, DOI 10.1158/0008-5472.CAN-09-4008
   Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X
   Nielsen DL, 2013, BREAST, V22, P1, DOI 10.1016/j.breast.2012.09.008
   Obrador-Hevia A, 2012, BRIT J HAEMATOL, V156, P334, DOI 10.1111/j.1365-2141.2011.08951.x
   Quadros MR, 2006, CANCER BIOL THER, V5, P498, DOI 10.4161/cbt.5.5.2567
   Sawyers CL, 2009, NAT MED, V15, P1158, DOI 10.1038/nm1009-1158
   She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065
   Shiu KK, 2014, ONCOGENE, V33, P619, DOI 10.1038/onc.2012.625
   Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200
   Wang XW, 2012, J CELL PHYSIOL, V227, P1168, DOI 10.1002/jcp.22839
   Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293
   Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
   You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
NR 39
TC 19
Z9 21
U1 0
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD MAR 26
PY 2013
VL 6
IS 268
AR pe12
DI 10.1126/scisignal.2004113
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 115EJ
UT WOS:000316795100004
PM 23532333
DA 2025-01-12
ER

PT J
AU Alanazi, MS
   Parine, NR
   Shaik, JP
   Alabdulkarim, HA
   Ajaj, SA
   Khan, Z
AF Alanazi, Mohammad Saud
   Parine, Narasimha Reddy
   Shaik, Jilani Purusottapatnam
   Alabdulkarim, Huda A.
   Ajaj, Sana Abdulla
   Khan, Zahid
TI Association of Single Nucleotide Polymorphisms in Wnt Signaling Pathway
   Genes with Breast Cancer in Saudi Patients
SO PLOS ONE
LA English
DT Article
ID BETA-CATENIN; COLORECTAL-CANCER; SUPPRESSOR GENE; TCF7L2 VARIANT; APC
   GENE; RISK; EXPRESSION; SUSCEPTIBILITY; LUNG; AXIN
AB Breast cancer is a complex heterogeneous disease involving genetic and epigenetic alterations in genes encoding proteins that are components of various signaling pathways. Candidate gene approach have identified association of genetic variants in the Wnt signaling pathway genes and increased susceptibility to several diseases including breast cancer. Due to the rarity of somatic mutations in key genes of Wnt pathway, we investigated the association of genetic variants in these genes with predisposition to breast cancers. We performed a case-control study to identify risk variants by examining 15 SNPs located in 8 genes associated with Wnt signaling. Genotypic analysis of individual locus showed statistically significant association of five SNPs located in beta-catenin, AXIN2, DKK3, SFRP3 and TCF7L2 with breast cancers. Increased risk was observed only with the SNP in b-catenin while the other four SNPs conferred protection against breast cancers. Majority of these associations persisted after stratification of the cases based on estrogen receptor status and age of on-set of breast cancer. The rs7775 SNP in exon 6 of SFRP3 gene that codes for either arginine or glycine exhibited very strong association with breast cancer, even after Bonferroni's correction. Apart from these five variants, rs3923086 in AXIN2 and rs3763511 in DKK4 that did not show any association in the overall population were significantly associated with early on-set and estrogen receptor negative breast cancers, respectively. This is the first study to utilize pathway based approach to identify association of risk variants in the Wnt signaling pathway genes with breast cancers. Confirmation of our findings in larger populations of different ethnicities would provide evidence for the role of Wnt pathway as well as screening markers for early detection of breast carcinomas.
C1 [Alanazi, Mohammad Saud; Parine, Narasimha Reddy; Shaik, Jilani Purusottapatnam; Khan, Zahid] King Saud Univ, Coll Sci, Dept Biochem, Genome Res Chair, Riyadh 11451, Saudi Arabia.
   [Alabdulkarim, Huda A.] Comprehens Canc Ctr King Fahad Med City, Riyadh, Saudi Arabia.
   [Ajaj, Sana Abdulla] King Saud Univ, Coll Med, Dept Family Med, Riyadh 11461, Saudi Arabia.
C3 King Saud University; King Fahad Medical City; King Saud University
RP Khan, Z (通讯作者)，King Saud Univ, Coll Sci, Dept Biochem, Genome Res Chair, Riyadh 11451, Saudi Arabia.
EM zahidatkhan@yahoo.com
RI Parine, Narasimha/B-7975-2011
OI PARINE, NARASIMHA REDDY/0000-0002-0765-9022
FU National Science, Technology and Innovation Plan strategic technologies
   program [10BIO897-2]
FX This study was financially supported by a grant from National Science,
   Technology and Innovation Plan strategic technologies program number
   10BIO897-2 in the Kingdom. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Anderson WF, 2006, BREAST CANCER RES TR, V100, P121, DOI 10.1007/s10549-006-9231-y
   Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103
   Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596
   Burwinkel B, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-268
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Connor AE, 2012, BREAST CANCER RES TR, V136, P593, DOI 10.1007/s10549-012-2299-7
   Cuilliere-Dartigues P, 2006, ONCOGENE, V25, P4441, DOI 10.1038/sj.onc.1209471
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Ferlay J., 2010, IARC CANCERBASE
   Fernández-Rozadilla C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012673
   Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Goode EL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-312
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379
   Hazra A, 2008, CANCER CAUSE CONTROL, V19, P975, DOI 10.1007/s10552-008-9164-3
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Kanzaki H, 2006, INT J MOL MED, V18, P279
   Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859
   Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   Naidu R, 2012, MED ONCOL, V29, P411, DOI 10.1007/s12032-011-9837-8
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polakis P, 2000, GENE DEV, V14, P1837
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Saudi National Cancer Registry, 2011, CANC INC SURV REP SA
   Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131
   Tong Y, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-15
   Tseng RC, 2008, ONCOGENE, V27, P4488, DOI 10.1038/onc.2008.83
   Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Wang SZ, 2012, MUTAGENESIS, V27, P623, DOI 10.1093/mutage/ges027
   Wang XS, 2008, CANCER EPIDEM BIOMAR, V17, P2101, DOI 10.1158/1055-9965.EPI-08-0134
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
NR 45
TC 43
Z9 48
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 14
PY 2013
VL 8
IS 3
AR 0059555
DI 10.1371/journal.pone.0059555
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 109YM
UT WOS:000316407400115
PM 23516639
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Li, BQ
   Yu, H
   Wang, Z
   Ding, GH
   Liu, L
AF Li, Bi-Qing
   Yu, Hui
   Wang, Zhen
   Ding, Guo-Hui
   Liu, Lei
TI MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
DE Colorectal cancer; microRNA; DNA methylation; regulatory network
ID PTEN EXPRESSION; PROMOTER HYPERMETHYLATION; HMLH1 PROMOTER;
   COLON-CANCER; FREQUENT INACTIVATION; SYSTEMS BIOLOGY; MISMATCH REPAIR;
   MIR-17 FAMILY; CELL-SURVIVAL; KAPPA-B
AB Colorectal cancer (CRC) is one of the most malignant cancers. A growing number of studies have shown that both genetic and epigenetic play important roles in the etiology of CRC. Both microRNA (miRNA) and DNA methylation belong to the scope of epigenetic and there are complex regulatory mechanisms within miRNA and DNA methylation.
   We compiled 71 CRC related genes and 134 CRC related miRNAs. Then we identified 417 feed forward loops (FFLs) and 37 feedback loops (FBLs) among these genes, miRNAs and transcription factors (TFs). We constructed a network of miRNAs and TFs mediation for CRC utilizing these FFLs and FBLs. Statistical tests proved that these FFLs were significantly enriched in the CRC comparing to the esophageal cancer, breast cancer and randomly selected CRCmiRNA-gene pairs. Analysis of the network singled out 3 core genes, 2 core miRNAs and 5 core TFs. The KEGG enrichment and GO enrichment for the 2 core miRNA target genes indicated that they were significantly enriched in CRC related pathways. (Ex. MARK pathway, TGF beta pathway and cell cycle) Through the investigation on methylation, we found that most of the CRC related genes and miRNAs were prone to be regulated by methylation.
   This study sheds lights on the regulatory mechanisms in CRC and we provide some insights on the epigenetic of CRC.
C1 [Li, Bi-Qing; Yu, Hui; Wang, Zhen; Ding, Guo-Hui; Liu, Lei] Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Syst Biol, Shanghai 200031, Peoples R China.
   [Li, Bi-Qing; Yu, Hui; Wang, Zhen; Ding, Guo-Hui; Liu, Lei] Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China.
C3 Chinese Academy of Sciences; Chinese Academy of Sciences
RP Liu, L (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Syst Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.
EM leiliu@sibs.ac.cn
CR Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296
   Aguda BD, 2008, P NATL ACAD SCI USA, V105, P19678, DOI 10.1073/pnas.0811166106
   [Anonymous], 2008, R LANG ENV STAT COMP
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Bramis J, 2004, ANTICANCER RES, V24, P3041
   Brosh R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.65
   Cairns P, 1997, CANCER RES, V57, P4997
   Carraro G, 2009, DEV BIOL, V333, P238, DOI 10.1016/j.ydbio.2009.06.020
   Chandrasekar B, 2008, J BIOL CHEM, V283, P24889, DOI 10.1074/jbc.M804236200
   Chen Shu-Hwa, 2009, GEN INF WORKSH
   Coller HA, 2007, PLOS GENET, V3, P1319, DOI 10.1371/journal.pgen.0030146
   Cunningham JM, 1998, CANCER RES, V58, P3455
   Dicuonzo G, 2001, CLIN CANCER RES, V7, P4049
   Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612
   Dong YB, 2003, CANCER GENE THER, V10, P168, DOI 10.1038/sj.cgt.7700565
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Elliott MJ, 2001, CLIN CANCER RES, V7, P3590
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2000, CANCER RES, V60, P4366
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2
   Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283
   Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418
   Haider S, 2009, NUCLEIC ACIDS RES, V37, pW23, DOI 10.1093/nar/gkp265
   Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555
   Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hood L, 2004, SCIENCE, V306, P640, DOI 10.1126/science.1104635
   Hornberg JJ, 2006, BIOSYSTEMS, V83, P81, DOI 10.1016/j.biosystems.2005.05.014
   Huang T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010972
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jordan IK, 2004, MOL BIOL EVOL, V21, P2058, DOI 10.1093/molbev/msh222
   Kane MF, 1997, CANCER RES, V57, P808
   Kanehisa M, 2002, NOVART FDN SYMP, V247, P91
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li J, 1998, CANCER RES, V58, P5667
   Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Mao XM, 2006, NAT CELL BIOL, V8, P516, DOI 10.1038/ncb1404
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5
   Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909
   Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924
   Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951
   Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059
   Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195
   Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409
   Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003
   Rhead B, 2010, NUCLEIC ACIDS RES, V38, pD613, DOI 10.1093/nar/gkp939
   Roberts RJ, 2001, P NATL ACAD SCI USA, V98, P381, DOI 10.1073/pnas.98.2.381
   Sawai H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-56
   Schenck A, 2008, CELL, V133, P486, DOI 10.1016/j.cell.2008.02.044
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Shalgi R, 2007, PLOS COMPUT BIOL, V3, P1291, DOI 10.1371/journal.pcbi.0030131
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sinha AU, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-88
   Snyder M, 2008, J BIOL CHEM, V283, P3791, DOI 10.1074/jbc.M706976200
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107
   Varsano T, 2006, MOL CELL BIOL, V26, P8942, DOI 10.1128/MCB.00305-06
   Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang SI, 1997, CANCER RES, V57, P4183
   Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294
   Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587
   Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575
   Yang HS, 2009, CLIN CANCER RES, V15, P5744, DOI 10.1158/1078-0432.CCR-09-0385
   Zhou R, 2010, NUCLEIC ACIDS RES, V38, P3222, DOI 10.1093/nar/gkq056
   Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9
NR 80
TC 5
Z9 5
U1 0
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8665
EI 1875-5305
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PD MAR
PY 2013
VL 20
IS 3
BP 352
EP 363
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 116CT
UT WOS:000316860900014
PM 22591477
DA 2025-01-12
ER

PT J
AU Di, LJ
   Byun, JS
   Wong, MM
   Wakano, C
   Taylor, T
   Bilke, S
   Baek, S
   Hunter, K
   Yang, H
   Lee, M
   Zvosec, C
   Khramtsova, G
   Cheng, F
   Perou, CM
   Miller, CR
   Raab, R
   Olopade, OI
   Gardner, K
AF Di, Li-Jun
   Byun, Jung S.
   Wong, Madeline M.
   Wakano, Clay
   Taylor, Tara
   Bilke, Sven
   Baek, Songjoon
   Hunter, Kent
   Yang, Howard
   Lee, Maxwell
   Zvosec, Cecilia
   Khramtsova, Galina
   Cheng, Fan
   Perou, Charles M.
   Miller, C. Ryan
   Raab, Rachel
   Olopade, Olufunmilayo I.
   Gardner, Kevin
TI Genome-wide profiles of CtBP link metabolism with genome stability and
   epithelial reprogramming in breast cancer
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MESENCHYMAL TRANSITION; MOLECULAR PORTRAITS; NADH CONCENTRATION;
   COREPRESSOR CTBP; CO-REPRESSOR; EXPRESSION; LSD1; SUBTYPE; PROTEIN;
   CELLS
AB The C-terminal binding protein (CtBP) is a NADH-dependent transcriptional repressor that links carbohydrate metabolism to epigenetic regulation by recruiting diverse histone-modifying complexes to chromatin. Here global profiling of CtBP in breast cancer cells reveals that it drives epithelial-to-mesenchymal transition, stem cell pathways and genome instability. CtBP expression induces mesenchymal and stem cell-like features, whereas CtBP depletion or caloric restriction reverses gene repression and increases DNA repair. Multiple members of the CtBP-targeted gene network are selectively downregulated in aggressive breast cancer subtypes. Differential expression of CtBP-targeted genes predicts poor clinical outcome in breast cancer patients, and elevated levels of CtBP in patient tumours predict shorter median survival. Finally, both CtBP promoter targeting and gene repression can be reversed by small molecule inhibition. These findings define broad roles for CtBP in breast cancer biology and suggest novel chromatin-based strategies for pharmacologic and metabolic intervention in cancer.
C1 [Di, Li-Jun; Byun, Jung S.; Wong, Madeline M.; Wakano, Clay; Taylor, Tara; Bilke, Sven; Gardner, Kevin] NCI, Genet Branch, Bethesda, MD 20892 USA.
   [Baek, Songjoon] NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA.
   [Hunter, Kent] NCI, Lab Canc Biol & Genet, Bethesda, MD 20892 USA.
   [Yang, Howard; Lee, Maxwell] NCI, Lab Populat Genet, Bethesda, MD 20892 USA.
   [Zvosec, Cecilia; Khramtsova, Galina; Olopade, Olufunmilayo I.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Cheng, Fan; Perou, Charles M.; Miller, C. Ryan] Univ N Carolina, Lineberger Comprehens Canc Care Ctr, Chapel Hill, NC 27599 USA.
   [Raab, Rachel] E Carolina Univ, Leo W Jenkins Canc Ctr, Greenville, NC 27834 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); University of Chicago; University of
   North Carolina; University of North Carolina Chapel Hill; University of
   North Carolina; East Carolina University
RP Gardner, K (通讯作者)，NCI, Genet Branch, Bethesda, MD 20892 USA.
EM gardnerk@mail.nih.gov
RI Di, Li-jun/B-3352-2011; Cheng, Fan/JXX-8930-2024; Wong,
   Madeline/HTL-3557-2023; Khramtsova, Galina/N-3423-2018; Perou,
   Charles/H-9934-2014; Miller, Christopher/B-9365-2008
OI Byun, Jung Shin/0000-0001-9049-9594; Khramtsova,
   Galina/0000-0001-9625-1549; Perou, Charles/0000-0001-9827-2247; Miller,
   Christopher/0000-0002-0096-8762
FU US National Institutes of Health; US National Cancer Institute; US
   National Institute on Aging; US National Institute on Minority Health
   and Health Disparities; University of Chicago Breast Cancer SPORE [P50
   CA125183]
FX This research was supported by the Intramural Research Program of the US
   National Institutes of Health, the US National Cancer Institute, the US
   National Institute on Aging, the US National Institute on Minority
   Health and Health Disparities, and the University of Chicago Breast
   Cancer SPORE P50 CA125183.
CR Achouri Y, 2007, BIOCHEM BIOPH RES CO, V352, P903, DOI 10.1016/j.bbrc.2006.11.111
   Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246
   Alexander BM, 2010, CLIN CANCER RES, V16, P5796, DOI 10.1158/1078-0432.CCR-10-0292
   Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122
   Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bergman LM, 2009, MOL CELL BIOL, V29, P4539, DOI 10.1128/MCB.00439-09
   Bernardo GM, 2013, ONCOGENE, V32, P554, DOI 10.1038/onc.2012.62
   Bhambhani C, 2011, EMBO J, V30, P2031, DOI 10.1038/emboj.2011.100
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349
   Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038
   Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   De Siervi A, 2010, CANCER RES, V70, P532, DOI 10.1158/0008-5472.CAN-09-1477
   Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941
   Ewertz M, 2011, J CLIN ONCOL, V29, P25, DOI 10.1200/JCO.2010.29.7614
   Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108
   Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002
   Issa JPJ, 2011, CANCER PREV RES, V4, P6, DOI 10.1158/1940-6207.CAPR-10-0348
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0
   Li J, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1033
   Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Ram O, 2011, CELL, V147, P1628, DOI 10.1016/j.cell.2011.09.057
   SCHWARTZ JP, 1974, J BIOL CHEM, V249, P4138
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Sinicrope FA, 2011, J CLIN ONCOL, V29, P4, DOI 10.1200/JCO.2010.32.1752
   Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040
   Straza MW, 2010, CELL CYCLE, V9, P3740, DOI 10.4161/cc.9.18.12936
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Taubes G, 2012, SCIENCE, V335, P286, DOI [10.1126/science.335.6064.28, 10.1126/science.335.6064.29]
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Uppal A, 2003, BIOTECHNOL APPL BIOC, V37, P45, DOI 10.1042/BA20020052
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wakano C, 2012, BBA-GENE REGUL MECH, V1819, P688, DOI 10.1016/j.bbagrm.2012.02.006
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Werth M, 2010, DEVELOPMENT, V137, P3835, DOI 10.1242/dev.055483
   Yu QR, 2009, J PHOTOCH PHOTOBIO B, V95, P46, DOI 10.1016/j.jphotobiol.2008.12.010
   Zhang QH, 2002, SCIENCE, V295, P1895
   Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103
   Zhao LJ, 2007, ONCOGENE, V26, P7544, DOI 10.1038/sj.onc.1210569
NR 56
TC 103
Z9 118
U1 0
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB
PY 2013
VL 4
AR 1449
DI 10.1038/ncomms2438
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 112TL
UT WOS:000316616400025
PM 23385593
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Zhang, L
   Szulwach, KE
   Hon, GC
   Song, CX
   Park, B
   Yu, M
   Lu, XY
   Dai, Q
   Wang, X
   Street, CR
   Tan, HP
   Min, JH
   Ren, B
   Jin, P
   He, C
AF Zhang, Liang
   Szulwach, Keith E.
   Hon, Gary C.
   Song, Chun-Xiao
   Park, Beomseok
   Yu, Miao
   Lu, Xingyu
   Dai, Qing
   Wang, Xiao
   Street, Craig R.
   Tan, Huiping
   Min, Jung-Hyun
   Ren, Bing
   Jin, Peng
   He, Chuan
TI Tet-mediated covalent labelling of 5-methylcytosine for its genome-wide
   detection and sequencing
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DNA IMMUNOPRECIPITATION MEDIP; SINGLE-BASE RESOLUTION; BREAST-CANCER;
   MAMMALIAN DNA; METHYLATION; 5-HYDROXYMETHYLCYTOSINE; METHYLOME; CELLS;
   5-CARBOXYLCYTOSINE; 5-FORMYLCYTOSINE
AB 5-methylcytosine is an epigenetic mark that affects a broad range of biological functions in mammals. The chemically inert methyl group prevents direct labelling for subsequent affinity purification and detection. Therefore, most current approaches for the analysis of 5-methylcytosine still have limitations of being either density-biased, lacking in robustness and consistency, or incapable of analysing 5-methylcytosine specifically. Here we present an approach, TAmC-Seq, which selectively tags 5-methylcytosine with an azide functionality that can be further labelled with a biotin for affinity purification, detection and genome-wide mapping. Using this covalent labelling approach, we demonstrate high sensitivity and specificity for known methylated loci, as well as increased CpG dinucleotide coverage at lower sequencing depth as compared with antibody-based enrichment, providing an improved efficiency in the 5-methylcytosine enrichment and genome-wide profiling.
C1 [Zhang, Liang; Song, Chun-Xiao; Yu, Miao; Lu, Xingyu; Dai, Qing; Wang, Xiao; He, Chuan] Univ Chicago, Dept Chem, Chicago, IL 60637 USA.
   [Zhang, Liang; Song, Chun-Xiao; Yu, Miao; Lu, Xingyu; Dai, Qing; Wang, Xiao; He, Chuan] Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA.
   [Szulwach, Keith E.; Street, Craig R.; Tan, Huiping; Jin, Peng] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.
   [Hon, Gary C.; Ren, Bing] Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Cellular & Mol Med,UCSD,Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Hon, Gary C.; Ren, Bing] Univ Calif San Diego, Sch Med, Inst Genome Med, La Jolla, CA 92093 USA.
   [Park, Beomseok; Min, Jung-Hyun] Univ Illinois, Dept Chem, Chicago, IL 60606 USA.
C3 University of Chicago; University of Chicago; Emory University;
   University of California System; University of California San Diego;
   Ludwig Institute for Cancer Research; University of California System;
   University of California San Diego; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP He, C (通讯作者)，Univ Chicago, Dept Chem, 929 E 57th St, Chicago, IL 60637 USA.
EM chuanhe@uchicago.edu
RI Dai, Qing/ABD-8444-2021; Song, Chunxiao/GXH-8050-2022; He,
   Chuan/HZJ-6319-2023; Zhang, Liang/F-8064-2013
OI Min, Jung-Hyun/0000-0002-4221-9321; Song, Chun-Xiao/0000-0002-7781-6521;
   Hon, Gary/0000-0002-5728-4433; Zhang, Liang/0000-0002-7672-1168; Wang,
   Xiao/0000-0002-3090-9894
FU National Institutes of Health [GM071440, NS051630, MH076090, U01
   ES017166]; Chicago Biomedical Consortium; Chicago Community Trust;
   Ludwig Institute for Cancer Research; Emory Genetics Discovery Fund
FX This study was supported by National Institutes of Health (GM071440 to
   C. H., NS051630 and MH076090 to P.J., U01 ES017166 to B. R.), a Catalyst
   Award (C. H. and J.-H.M.) from the Chicago Biomedical Consortium, with
   support from the Searle Funds at The Chicago Community Trust, the Ludwig
   Institute for Cancer Research (B. R.) and the Emory Genetics Discovery
   Fund (P.J.). We thank S. F. Reichard, MA, for editing the manuscript.
CR Beck S, 2008, TRENDS GENET, V24, P231, DOI 10.1016/j.tig.2008.01.006
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bhutani N, 2011, CELL, V146, P866, DOI 10.1016/j.cell.2011.08.042
   Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681
   Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Ficz G, 2011, NATURE, V473, P398, DOI 10.1038/nature10008
   Harris RA, 2010, NAT BIOTECHNOL, V28, P1097, DOI 10.1038/nbt.1682
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Huang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008888
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708
   Jin SG, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq223
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KORNBERG S, 1961, J BIOL CHEM, V236, P1487
   Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719
   Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Nair SS, 2011, EPIGENETICS-US, V6, P34, DOI 10.4161/epi.6.1.13313
   Pastor WA, 2011, NATURE, V473, P394, DOI 10.1038/nature10102
   Pfaffeneder T, 2011, ANGEW CHEM INT EDIT, V50, P7008, DOI 10.1002/anie.201103899
   Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Song CX, 2012, NAT METHODS, V9, P75, DOI [10.1038/NMETH.1779, 10.1038/nmeth.1779]
   Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027
NR 34
TC 43
Z9 52
U1 0
U2 55
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB
PY 2013
VL 4
AR 1517
DI 10.1038/ncomms2527
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 112TL
UT WOS:000316616400087
PM 23443545
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Ni, C
   Huang, J
AF Ni, Chao
   Huang, Jian
TI Dynamic regulation of cancer stem cells and clinical challenges
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Cancer stem cells; Reprogramming; Dedifferentiation; Epigenetics;
   Microenvironment
ID GLIOMA-INITIATING CELLS; BREAST-CANCER; SELF-RENEWAL; HUMAN FIBROBLASTS;
   TUMORIGENICITY; PROMOTES; CARCINOMA; GROWTH; OCT4; RNA
AB A small population of cancer cells referred to as cancer stem cells (CSCs) have received particular attention, as they have been revealed to acquire stem cell-like properties and become the main cause of tumor propagation, metastasis and drug resistance. The CSC theory of tumor formation was believed to follow the hierarchical model initially, and therefore many CSC-targeted therapy methods were expected to cure cancer by eradicating CSCs. However, subsequent CSC research has revealed that rather than a distinct entity, the CSC is a dynamic status that can be continually dedifferentiated from progenitor or differentiated cancer cells. Elucidation of this bidirectional transition mechanism would help perfect the CSC theory and be of great value in the development of more effective anti-cancer drugs. Here, we reviewed the mechanisms of reciprocal conversion between non-CSCs and CSCs. Moreover, several approaches of target CSCs and non-CSCs together with unbiased eradication of all cancer cells are also discussed.
C1 [Ni, Chao; Huang, Jian] Zhejiang Univ, Prov Key Lab Mol Biol Med Sci, Key Lab Canc Prevent & Intervent, Canc Inst,Natl Minist Educ,Sch Med,Affiliated Hos, Hangzhou 310009, Zhejiang, Peoples R China.
   [Huang, Jian] Zhejiang Univ, Dept Oncol, Sch Med, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Huang, J (通讯作者)，Zhejiang Univ, Prov Key Lab Mol Biol Med Sci, Key Lab Canc Prevent & Intervent, Canc Inst,Natl Minist Educ,Sch Med,Affiliated Hos, Hangzhou 310009, Zhejiang, Peoples R China.
EM drhuangjian@zju.edu.cn
RI ni, chao/Q-9565-2017
OI ni, chao/0000-0002-2724-8896
CR Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Azzi S, 2011, J NATL CANCER I, V103, P1884, DOI 10.1093/jnci/djr451
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chang HH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-6
   Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638
   Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Elaraj DM, 2006, CLIN CANCER RES, V12, P1088, DOI 10.1158/1078-0432.CCR-05-1603
   Farthing CR, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000116
   Freberg CT, 2007, MOL BIOL CELL, V18, P1543, DOI 10.1091/mbc.E07-01-0029
   Fulciniti M, 2009, CLIN CANCER RES, V15, P7144, DOI 10.1158/1078-0432.CCR-09-1483
   Gill JG, 2011, STEM CELLS, V29, P764, DOI 10.1002/stem.628
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701
   Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235
   Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429
   Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012
   Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863
   Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016
   Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114
   Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29
   Jullien J, 2010, P NATL ACAD SCI USA, V107, P5483, DOI 10.1073/pnas.1000599107
   Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436
   Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656
   Kyle AH, 2012, CANCER RES, V72, P801, DOI 10.1158/0008-5472.CAN-11-3059
   Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040
   Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108
   Li ZH, 2011, EMBO J, V30, P823, DOI 10.1038/emboj.2011.2
   Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320
   Melton C, 2010, NATURE, V463, P621, DOI 10.1038/nature08725
   Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108
   Motohara T, 2011, CARCINOGENESIS, V32, P1597, DOI 10.1093/carcin/bgr183
   Närvä E, 2012, STEM CELLS, V30, P452, DOI 10.1002/stem.1013
   Ramachandran R, 2010, NAT CELL BIOL, V12, P1101, DOI 10.1038/ncb2115
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Subramanyam D, 2011, NAT BIOTECHNOL, V29, P443, DOI 10.1038/nbt.1862
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Taranger CK, 2005, MOL BIOL CELL, V16, P5719, DOI 10.1091/mbc.e05-06-0572
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Todaro M, 2008, CELL CYCLE, V7, P309, DOI 10.4161/cc.7.3.5389
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392
   Wang K, 2011, INT J NANOMED, V6, P3207, DOI 10.2147/IJN.S26268
   Wang YK, 2010, CARCINOGENESIS, V31, P1376, DOI 10.1093/carcin/bgq120
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Xie GZ, 2012, INT J ONCOL, V40, P1171, DOI 10.3892/ijo.2011.1275
   Yang P, 2011, STEM CELLS, V29, P791, DOI 10.1002/stem.634
   Yao C, 2007, INT J CANCER, V121, P1949, DOI 10.1002/ijc.22930
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang Y, 2012, BIOMATERIALS, V33, P679, DOI 10.1016/j.biomaterials.2011.09.072
   Zhu YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035147
NR 63
TC 20
Z9 24
U1 0
U2 20
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1699-048X
EI 1699-3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD APR
PY 2013
VL 15
IS 4
BP 253
EP 258
DI 10.1007/s12094-012-0927-7
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 107ZS
UT WOS:000316260600001
PM 22926945
DA 2025-01-12
ER

PT J
AU Katase, N
   Lefeuvre, M
   Tsujigiwa, H
   Fujii, M
   Ito, S
   Tamamura, R
   Buery, RR
   Gunduz, M
   Nagatsuka, H
AF Katase, Naoki
   Lefeuvre, Mathieu
   Tsujigiwa, Hidetsugu
   Fujii, Masae
   Ito, Satoshi
   Tamamura, Ryo
   Buery, Rosario Rivera
   Gunduz, Mehmet
   Nagatsuka, Hitoshi
TI Knockdown of Dkk-3 decreases cancer cell migration and invasion
   independently of the Wnt pathways in oral squamous cell
   carcinoma-derived cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE head and neck cancer; oral cancer; squamous cell carcinoma; Dkk-3;
   functional analysis; migration; invasion
ID BETA-CATENIN PATHWAY; PROMOTER METHYLATION; DICKKOPF (DKK)-3;
   PROSTATE-CANCER; BREAST-CANCER; EPIGENETIC INACTIVATION; TUMOR-GROWTH;
   REIC/DKK-3; OVEREXPRESSION; METASTASIS
AB Oral squamous cell carcinoma (OSCC) is thought to arise as the result of cumulative genetic or epigenetic alterations in cancer-associated genes. We focused on the Dickkopf-3 (Dkk-3) gene as a candidate tumor suppressor in OSCC. Dkk-3 is a potential tumor suppressor, and its downregulation has been reported in various types of malignancies. However, our previous data demonstrated that the Dkk-3 protein was dominantly expressed in OSCC tissue, and its expression was correlated with a high incidence of metastasis and with poor prognosis. In order to explain this paradox, we performed functional analyses of the Dkk-3 gene in cancer cell lines. RT-PCR revealed that Dkk-3 mRNA expression was observed in OSCC-derived cell lines but not in gastrointestinal or colorectal adenocarcinoma-derived cell lines. The siRNA for Dkk-3 was transfected into Dkk-3-expressing cells, and the changes in cell proliferation, invasion and migration were assessed. The knockdown of Dkk-3 mRNA by siRNA transfection did not affect cell proliferation, but it significantly decreased cell migration and invasion. To further investigate the precise mechanism that contributes to the potential oncogenic function of Dkk-3, the Wnt canonical pathway and non-canonical pathways were assessed. Western blotting demonstrated that the effect of Dkk-3 knockdown on cell migration or invasion was not caused by activation of the Wnt pathways. These data demonstrated that Dkk-3 expression in OSCC was different than that in adenocarcinomas. Dkk-3 may possess an oncogenic function that is independent of Wnt signaling.
C1 [Katase, Naoki; Lefeuvre, Mathieu; Tsujigiwa, Hidetsugu; Fujii, Masae; Ito, Satoshi; Tamamura, Ryo; Buery, Rosario Rivera; Gunduz, Mehmet; Nagatsuka, Hitoshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Pathol & Med, Okayama 7008525, Japan.
   [Gunduz, Mehmet] Fatih Univ, Fac Med, Dept Otolaryngol Head & Neck Surg, Ankara, Turkey.
C3 Okayama University; Fatih University
RP Katase, N (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Pathol & Med, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008525, Japan.
EM katase-n@cc.okayama-u.ac.jp
RI KATASE, Naoki/B-2344-2011
OI Katase, Naoki/0000-0002-5486-6630
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [22791766, 22791977, 24592766, 24659891]; Grants-in-Aid for Scientific
   Research [22791977, 24592766, 24659891, 22791766] Funding Source: KAKEN
FX This study was partially supported by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Culture, Sports, Science and
   Technology, Japan to N.K. (22791766), H.T. (22791977), R.T. (24592766)
   and H.N. (24659891).
CR Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829
   Ding Z, 2009, WORLD J GASTROENTERO, V15, P2595, DOI 10.3748/wjg.15.2595
   Edamura K, 2007, CANCER GENE THER, V14, P765, DOI 10.1038/sj.cgt.7701071
   Fujii M, 2011, J MOL HISTOL, V42, P499, DOI 10.1007/s10735-011-9357-z
   Götze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981
   Gu YM, 2011, WORLD J GASTROENTERO, V17, P3810, DOI 10.3748/wjg.v17.i33.3810
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952
   Hughes L, 2008, CLIN EXP METASTAS, V25, P549, DOI 10.1007/s10585-008-9169-z
   Ishida-Takagishi M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1861
   Iwai S, 2010, INT J ONCOL, V37, P1095, DOI 10.3892/ijo_00000761
   Johnson N., 2005, WHO CLASSIFICATION T, P168
   Katase N, 2012, ONCOL LETT, V3, P273, DOI 10.3892/ol.2011.473
   Katase N, 2010, CANCER INVEST, V28, P103, DOI 10.3109/07357900903095680
   Katase N, 2008, ONCOL RES, V17, P273, DOI 10.3727/096504008786991594
   Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58
   Kawauchi K, 2012, ACTA MED OKAYAMA, V66, P7
   Laxmidevi Lankesh B, 2010, J Oral Sci, V52, P633, DOI 10.2334/josnusd.52.633
   Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702
   Pannone G, 2010, ONCOL REP, V24, P1035, DOI 10.3892/or_00000952
   Sakaguchi M, 2009, J BIOL CHEM, V284, P14236, DOI 10.1074/jbc.M808002200
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Tanimoto R, 2007, INT J MOL MED, V19, P363
   Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772
   Than SS, 2011, ONCOL REP, V25, P989, DOI 10.3892/or.2011.1149
   Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067
   van der Meide WF, 2011, GYNECOL ONCOL, V123, P116, DOI 10.1016/j.ygyno.2011.06.015
   Veeck J, 2012, BBA-REV CANCER, V1825, P18, DOI 10.1016/j.bbcan.2011.09.003
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   You A, 2011, J CANCER RES CLIN, V137, P621, DOI 10.1007/s00432-010-0916-6
   Yu ZW, 2005, CLIN CANCER RES, V11, P2471, DOI 10.1158/1078-0432.CCR-04-2199
NR 30
TC 25
Z9 30
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD APR
PY 2013
VL 29
IS 4
BP 1349
EP 1355
DI 10.3892/or.2013.2251
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 111GU
UT WOS:000316510600012
PM 23354949
OA hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Duan, ZJ
   Zou, JX
   Yang, P
   Wang, YZ
   Borowsky, AD
   Gao, AC
   Chen, HW
AF Duan, Zhijian
   Zou, June X.
   Yang, Ping
   Wang, Yuzhuo
   Borowsky, Alexander D.
   Gao, Allen C.
   Chen, Hong-Wu
TI Developmental and androgenic regulation of chromatin regulators EZH2 and
   ANCCA/ATAD2 in the prostate Via MLL histone methylase complex
SO PROSTATE
LA English
DT Article
DE epigenetic regulators; prostate development; androgen; EZH2; ANCCA
ID GROUP PROTEIN EZH2; EMBRYONIC STEM-CELLS; BREAST-CANCER CELLS;
   METHYLTRANSFERASE EZH2; MICE LACKING; EPITHELIAL DEVELOPMENT; GLAND
   DEVELOPMENT; FAMILY PROTEINS; RECEPTOR; POLYCOMB
AB BACKGROUND Chromatin regulators ANCCA and EZH2 are overexpressed in prostate cancer and play crucial roles in androgen-stimulated and castration-refractory prostate tumor growth and survival. However, how their expression is regulated in the tumors and whether they play a role in prostate development remains unclear. METHODS Prostate tissue from different developmental stages of mouse and human were examined by IHC, qRT-PCR and Western for expression of ANCCA, EZH2, and Ki-67. Animals were castrated and T-implanted for the expression response in normal prostate and tumors. siRNA knockdown and ChIP were performed for the mechanism of ANCCA regulation of EZH2. RESULTS In contrast to their very low level expression in adult prostate, ANCCA and EZH2 are strongly expressed in the epithelium and mesenchyme of mouse and human UGS. Their expression becomes more restricted to epithelial cells during later development and displays a second peak during puberty, which correlates with the proliferative status of the epithelium. Importantly, their expression in normal prostate and tumors is strongly suppressed by castration and markedly induced by testosterone replacement. While androgen suppresses EZH2 in CRPC cells, in LNCaP cells, physiological concentrations of androgen stimulate expression of PRC2 genes (EZH2, SUZ12, and EED), which is mediated by androgen-induced ANCCA and involves E2F and histone H3K4me3 methylase MLL1 complex. CONCLUSION EZH2 and ANCCA are androgen regulated and strongly expressed in early prostate morphogenesis and during puberty, suggesting their important role in prostate development. Regulation of EZH2 by ANCCA emphasizes bromodomain protein ANCCA as a potential therapeutic target against prostate cancer. Prostate 73: 455466, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Duan, Zhijian; Yang, Ping; Chen, Hong-Wu] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA.
   [Duan, Zhijian] Univ Calif Davis, Grad Program Pharmacol & Toxicol, Sacramento, CA 95817 USA.
   [Zou, June X.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA.
   [Wang, Yuzhuo] BC Canc Agcy, Dept Expt Therapeut, Vancouver, BC, Canada.
   [Wang, Yuzhuo] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada.
   [Wang, Yuzhuo] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada.
   [Borowsky, Alexander D.] Univ Calif Davis, Dept Pathol, Sacramento, CA 95817 USA.
   [Gao, Allen C.] Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA.
   [Chen, Hong-Wu] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis; British
   Columbia Cancer Agency; University of British Columbia; University of
   British Columbia; University of California System; University of
   California Davis; University of California System; University of
   California Davis; University of California System; University of
   California Davis
RP Chen, HW (通讯作者)，Univ Calif Davis, Ctr Canc, UCDMC Res 3, Rm 1400B,4645 2nd Ave, Sacramento, CA 95817 USA.
EM hwzchen@ucdavis.edu
RI Wang, Yangyang/GXH-5679-2022; Zou, June/LDF-4772-2024; Borowsky,
   Alexander/S-5404-2017
OI Wang, Yuzhuo/0000-0002-9749-8591
FU NIH [R01DK060019, R01CA134766]
FX Grant sponsor: NIH; Grant numbers: R01DK060019. R01CA134766.
CR Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027
   Bohrer LR, 2010, ENDOCRINOLOGY, V151, P5136, DOI 10.1210/en.2010-0436
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Caron C, 2010, ONCOGENE, V29, P5171, DOI 10.1038/onc.2010.259
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Chung ACK, 2007, CANCER RES, V67, P5965, DOI 10.1158/0008-5472.CAN-06-3168
   Chung CW, 2011, J BIOMOL SCREEN, V16, P1170, DOI 10.1177/1087057111421372
   Ciró M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131
   Cunha GR, 2004, J STEROID BIOCHEM, V92, P221, DOI 10.1016/j.jsbmb.2004.10.017
   CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338
   Denmeade SR, 2010, PROSTATE, V70, P1600, DOI 10.1002/pros.21196
   Gao N, 2005, DEVELOPMENT, V132, P3431, DOI 10.1242/dev.01917
   Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019
   Hofman K, 2001, BIOCHEM BIOPH RES CO, V283, P97, DOI 10.1006/bbrc.2001.4738
   Hu PZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028670
   Huang LW, 2009, DEV BIOL, V328, P188, DOI 10.1016/j.ydbio.2009.01.003
   Kalashnikova EV, 2010, CANCER RES, V70, P9402, DOI 10.1158/0008-5472.CAN-10-1199
   Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112
   Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547
   Lai KP, 2012, MOL ENDOCRINOL, V26, P52, DOI 10.1210/me.2011-1189
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Marker PC, 2008, DIFFERENTIATION, V76, P736, DOI 10.1111/j.1432-0436.2008.00297.x
   Memarzadeh S, 2011, P NATL ACAD SCI USA, V108, P7962, DOI 10.1073/pnas.1105243108
   Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131
   Muller S, 2011, EXPERT REV MOL MED, V13, P1, DOI 10.1017/S1462399411001992
   Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11
   Prins GS, 2008, DIFFERENTIATION, V76, P641, DOI 10.1111/j.1432-0436.2008.00277.x
   Revenko AS, 2010, MOL CELL BIOL, V30, P5260, DOI 10.1128/MCB.00484-10
   Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723
   Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   SONNENSCHEIN C, 1989, CANCER RES, V49, P3474
   Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369
   Tyagi S, 2007, MOL CELL, V27, P107, DOI 10.1016/j.molcel.2007.05.030
   Vander Griend DJ, 2010, PROSTATE, V70, P90, DOI 10.1002/pros.21043
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107
   Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x
   Wu CT, 2007, P NATL ACAD SCI USA, V104, P12679, DOI 10.1073/pnas.0704940104
   Wu XY, 2011, MOL ENDOCRINOL, V25, P1018, DOI 10.1210/me.2010-0513
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018
   Yu SQ, 2012, PROSTATE, V72, P437, DOI 10.1002/pros.21445
   Zou JX, 2007, P NATL ACAD SCI USA, V104, P18067, DOI 10.1073/pnas.0705814104
   Zou JX, 2009, CANCER RES, V69, P3339, DOI 10.1158/0008-5472.CAN-08-3440
NR 57
TC 39
Z9 49
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
EI 1097-0045
J9 PROSTATE
JI Prostate
PD APR
PY 2013
VL 73
IS 5
BP 455
EP 466
DI 10.1002/pros.22587
PG 12
WC Endocrinology & Metabolism; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Urology & Nephrology
GA 108IZ
UT WOS:000316287600002
PM 23038103
DA 2025-01-12
ER

PT J
AU Rinner, B
   Weinhaeusel, A
   Lohberger, B
   Froehlich, EV
   Pulverer, W
   Fischer, C
   Meditz, K
   Scheipl, S
   Trajanoski, S
   Guelly, C
   Leithner, A
   Liegl, B
AF Rinner, Beate
   Weinhaeusel, Andreas
   Lohberger, Birgit
   Froehlich, Elke Verena
   Pulverer, Walter
   Fischer, Carina
   Meditz, Katharina
   Scheipl, Susanne
   Trajanoski, Slave
   Guelly, Christian
   Leithner, Andreas
   Liegl, Bernadette
TI Chordoma Characterization of Significant Changes of the DNA Methylation
   Pattern
SO PLOS ONE
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; PROMOTER
   HYPERMETHYLATION; BREAST-CANCER; KLOTHO; EXPRESSION; ASSOCIATION;
   BIOMARKERS
AB Chordomas are rare mesenchymal tumors occurring exclusively in the midline from clivus to sacrum. Early tumor detection is extremely important as these tumors are resistant to chemotherapy and irradiation. Despite continuous research efforts surgical excision remains the main treatment option. Because of the often challenging anatomic location early detection is important to enable complete tumor resection and to reduce the high incidence of local recurrences. The aim of this study was to explore whether DNA methylation, a well known epigenetic marker, may play a role in chordoma development and if hypermethylation of specific CpG islands may serve as potential biomarkers correlated with SNP analyses in chordoma. The study was performed on tumor samples from ten chordoma patients. We found significant genomic instability by Affymetrix 6.0. It was interesting to see that all chordomas showed a loss of 3q26.32 (PIK 3CA) and 3q27.3 (BCL6) thus underlining the potential importance of the PI3K pathway in chordoma development. By using the AITCpG360 methylation assay we elucidated 20 genes which were hyper/hypomethylated compared to normal blood. The most promising candidates were nine hyper/ hypomethylated genes C3, XIST, TACSTD2, FMR1, HIC1, RARB, DLEC1, KL, and RASSF1. In summary, we have shown that chordomas are characterized by a significant genomic instability and furthermore we demonstrated a characteristic DNA methylation pattern. These findings add new insights into chordoma development, diagnosis and potential new treatment options.
C1 [Rinner, Beate; Fischer, Carina; Meditz, Katharina; Trajanoski, Slave; Guelly, Christian] Med Univ Graz, Med Res Ctr, Graz, Austria.
   [Weinhaeusel, Andreas; Pulverer, Walter] AIT Austrian Inst Technol, Hlth & Environm Dept, Mol Diagnost Unit, Vienna, Austria.
   [Lohberger, Birgit; Froehlich, Elke Verena; Scheipl, Susanne; Leithner, Andreas] Med Univ Graz, Dept Orthopaed Surg, Graz, Austria.
   [Liegl, Bernadette] Med Univ Graz, Inst Pathol, Graz, Austria.
C3 Medical University of Graz; Austrian Institute of Technology (AIT);
   Medical University of Graz; Medical University of Graz
RP Rinner, B (通讯作者)，Med Univ Graz, Med Res Ctr, Graz, Austria.
EM beate.rinner@medunigraz.at; bernadette.liegl-atzwanger@medunigraz.at
RI Leithner, Andreas/JBI-9805-2023; Weinhaeusel, Andreas/A-7644-2018
OI Rinner, Beate/0000-0002-6340-4905; Weinhaeusel,
   Andreas/0000-0002-9318-1204
FU Jubilee Fund of the Austrian National Bank [OENB 13459]
FX Financial support by the Jubilee Fund of the Austrian National Bank
   (OENB 13459) is gratefully acknowledged. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Catton C, 1996, RADIOTHER ONCOL, V41, P67, DOI 10.1016/S0167-8140(96)91805-8
   CAVENEE WK, 1991, CANCER, V67, P2431, DOI 10.1002/1097-0142(19910515)67:10<2431::AID-CNCR2820671005>3.0.CO;2-#
   Chamdin A, 2009, TRANSL ONCOL, V2, P128, DOI 10.1593/tlo.08220
   Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947
   Chugh R, 2007, ONCOLOGIST, V12, P1344, DOI 10.1634/theoncologist.12-11-1344
   Dalprà L, 1999, INT J CANCER, V81, P24, DOI 10.1002/(SICI)1097-0215(19990331)81:1<24::AID-IJC5>3.0.CO;2-O
   Dhe-Paganon Sirano, 2011, Int J Biochem Mol Biol, V2, P58
   Fletcher C.D.M., 2002, PATHOLOGY GENETICS T, V5
   Hallor KH, 2008, BRIT J CANCER, V98, P434, DOI 10.1038/sj.bjc.6604130
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Kurosu H, 2008, CURR OPIN NEPHROL HY, V17, P368, DOI 10.1097/MNH.0b013e3282ffd994
   Le LP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018846
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Naumann RW, 2011, GYNECOL ONCOL, V123, P411, DOI 10.1016/j.ygyno.2011.08.002
   Neumann LC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-380
   Nikolaidis G, 2012, CANCER RES, V72, P5692, DOI 10.1158/0008-5472.CAN-12-2309
   Ransohoff DF, 2003, SCIENCE, V299, P1679, DOI 10.1126/science.1083158
   Scheil S, 2001, GENE CHROMOSOME CANC, V32, P203, DOI 10.1002/gcc.1184
   Scheipl S, 2012, HISTOPATHOLOGY, V60, P999, DOI 10.1111/j.1365-2559.2012.04186.x
   Simon R, 2007, CANCER INFORM, V3, P11
   Sommer J, 2010, J PATHOL, V220, P608, DOI 10.1002/path.2679
   Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wang YA, 2006, CANCER BIOL THER, V5, P20, DOI 10.4161/cbt.5.1.2430
   Weinhaeusel A, 2010, Lung cancer methylation markers, Patent No. [PCT/EP2010/051032, 2010051032]
   Weinhaeusel A, 2010, [No title captured], Patent No. [2010086388, WO2010086388 A1]
   Weinhaeusel A, 2010, [No title captured], Patent No. [WO2010086389 A1, 2010086389]
   Weinhaeusel A, 2008, CLIN CHEM, V54, P1537, DOI 10.1373/clinchem.2008.104216
   Weinhausel A, 2009, European Patent Application, Patent No. [EP 09450020.4, 09450020]
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
NR 35
TC 33
Z9 33
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 22
PY 2013
VL 8
IS 3
AR e56609
DI 10.1371/journal.pone.0056609
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 111VQ
UT WOS:000316549400007
PM 23533570
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Yigit, MV
   Ghosh, SK
   Kumar, M
   Petkova, V
   Kavishwar, A
   Moore, A
   Medarova, Z
AF Yigit, M. V.
   Ghosh, S. K.
   Kumar, M.
   Petkova, V.
   Kavishwar, A.
   Moore, A.
   Medarova, Z.
TI Context-dependent differences in miR-10b breast oncogenesis can be
   targeted for the prevention and arrest of lymph node metastasis
SO ONCOGENE
LA English
DT Article
DE imaging; miRNA; metastasis; miR-10b; nanoparticle; therapy
ID SUPERPARAMAGNETIC IRON-OXIDE; CANCER; MICRORNA; THERAPEUTICS; LNA
AB Metastases, and not the primary tumor from which they originate, are the main reason for mortality from carcinoma. Although the molecular mechanisms behind metastasis are poorly understood, it is clear that epigenetic dysregulation at the level of microRNA expression is a key characteristic of the metastatic process that can be exploited for therapy. Here, we describe an miRNA-targeted therapeutic approach for the prevention and arrest of lymph node metastasis. Therapy relies on the inhibition of the pro-metastatic microRNA-10b. It is delivered to primary and lymph node metastatic tumor cells using an imaging-capable nanodrug that is designed to specifically home to these tissues. Treatment of invasive human breast tumor cells (MDA-MB-231) with the nanodrug in vitro downregulates miR-10b and abolishes the invasion and migration of the tumor cells. After intravenous delivery to mice bearing orthotopic MDA-MB-231-luc-D3H2LN tumors, the nanodrug accumulates in the primary tumor and lymph nodes. When treatment is initiated before metastasis to lymph nodes, metastasis is prevented. Treatment after the formation of lymph node metastases arrests the metastatic process without a concomitant effect on primary tumor growth raising the possibility of a context-dependent variation in miR-10b breast oncogenesis. Oncogene (2013) 32, 1530-1538; doi:10.1038/onc.2012.173; published online 14 May 2012
C1 [Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Kavishwar, A.; Moore, A.; Medarova, Z.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Mol Imaging Lab, Dept Radiol, Charlestown, MA USA.
   [Yigit, M. V.; Ghosh, S. K.; Kumar, M.; Kavishwar, A.; Moore, A.; Medarova, Z.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
   [Petkova, V.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard University; Harvard Medical School; Beth Israel Deaconess
   Medical Center
RP Moore, A (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Mol Imaging Lab,MGH MIT HMS Athinoula, Bldg 75,13th St, Charlestown, MA 02129 USA.
EM amoore@helix.mgh.harvard.edu; zmedarova@partners.org
RI Yiğit, Mehmet/HLQ-7874-2023
OI Kavishwar, Amol/0000-0001-8214-6625
FU National Cancer Institute [R00CA129070]; Breast Cancer Alliance
FX We thank Pamela Pantazopoulos and Alana Ross for help with the in-vitro,
   in-vivo and ex-vivo studies and Marytheresa Ifediba for proofreading the
   manuscript. Confocal microscopy was performed at the Confocal Microscopy
   Core at MGH with technical assistance from Igor A Bagayev, MS Work at
   the Martinos Center for Biomedical Imaging was supported in part under
   Grant R00CA129070 from the National Cancer Institute and a Research
   Grant from the Breast Cancer Alliance.
CR Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Beer AJ, 2008, J NUCL MED, V49, P255, DOI 10.2967/jnumed.107.045526
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181
   Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783
   Gabriely G, 2011, AUTOPHAGY, V7, P1384, DOI 10.4161/auto.7.11.17371
   Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008-5472.CAN-10-3568
   Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749
   Jepsen JS, 2004, OLIGONUCLEOTIDES, V14, P130, DOI 10.1089/1545457041526317
   Kenny LM, 2008, J NUCL MED, V49, P879, DOI 10.2967/jnumed.107.049452
   Kumar M, 2010, CANCER RES, V70, P7553, DOI 10.1158/0008-5472.CAN-10-2070
   Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004
   Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Medarova Z, 2006, NAT PROTOC, V1, P429, DOI 10.1038/nprot.2006.63
   Medarova Z, 2007, NAT MED, V13, P372, DOI 10.1038/nm1486
   Medarova Z, 2009, CANCER RES, V69, P1182, DOI 10.1158/0008-5472.CAN-08-2001
   Michel SCA, 2002, RADIOLOGY, V225, P527, DOI 10.1148/radiol.2252011605
   Nathanson SD, 2009, ANN SURG ONCOL, V16, P3396, DOI 10.1245/s10434-009-0659-2
   Petersen M, 2003, TRENDS BIOTECHNOL, V21, P74, DOI 10.1016/S0167-7799(02)00038-0
   WEISSLEDER R, 1990, RADIOLOGY, V175, P494, DOI 10.1148/radiology.175.2.2326475
   Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54
   Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499
NR 26
TC 77
Z9 88
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 21
PY 2013
VL 32
IS 12
BP 1530
EP 1538
DI 10.1038/onc.2012.173
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 110PC
UT WOS:000316456000006
PM 22580603
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Korkina, LG
   Pastore, S
   Dellambra, E
   De Luca, C
AF Korkina, L. G.
   Pastore, S.
   Dellambra, E.
   De Luca, C.
TI New Molecular and Cellular Targets for Chemoprevention and Treatment of
   Skin Tumors by Plant Polyphenols: A Critical Review
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE AhR; skin cancers; EGFR; epigenetics; melanoma; plant polyphenols;
   cellular senescence; stem cells
ID GROWTH-FACTOR RECEPTOR; ARYL-HYDROCARBON RECEPTOR; NF-KAPPA-B; CANCER
   STEM-CELLS; HISTONE DEACETYLASE INHIBITORS; TYROSINE-PHOSPHATASE-KAPPA;
   HUMAN KERATINOCYTES; BREAST-CANCER; PHOTODYNAMIC THERAPY; SQUAMOUS-CELL
AB As the incidence of skin tumors has been steadily growing, there is an urgent need for the preventive measures as well as the improved therapeutic approaches. In the last two decades, natural plant derived polyphenols (PPs, resveratrol, silibinin, green tea polyphenols, flavonoids, anthocyanins, etc.) have been drawing particular interest as emerging active substances in dermatological/cosmeceutical compositions for the prevention, slowing, or reversion of skin tumorigenesis (chemoprevention). When chronically applied to the skin, they supposedly would not damage normal skin cells or negatively affect their functions while they would suppress tumorigenic cell transformation, inhibit tumor cell proliferation, and activate tumor cell apoptosis. PPs are also reported to synergize with conventional anti-cancer therapies. The major aim of this critical review is to provide recent updates on the molecular and cellular targets for the prevention and therapy of skin tumors with a special focus on the crossroad between inflammation and carcinogenesis as the most promising approach to chemoprevention. Novel therapeutic targets as different as epidermal stem cells, cellular senescence, epigenetic enzymes involved in carcinogenesis, epidermal growth factor and aryl hydrocarbon receptors, and metabolic CYP1 subfamily enzymes are highlighted. The mechanisms of PPs interaction with these molecular and cellular targets are reviewed. The feasibility of PPs to prevent/cure specific cutaneous toxicity connected to anti-EGFR therapy and to reduce multidrug resistance of skin tumors is also discussed.
C1 [Korkina, L. G.; Pastore, S.; Dellambra, E.; De Luca, C.] IDI IRCCS, Dermatol Inst Ist Dermopat Immacolata, Lab Tissue Engn & Skin Pathophysiol, I-00167 Rome, Italy.
C3 IRCCS Istituto Dermopatico dell'Immacolata (IDI)
RP Korkina, LG (通讯作者)，Dermatol Inst IDI IRCCS, Lab Tissue Engn & Skin Pathophysiol, Via Monti di Creta 104, I-00167 Rome, Italy.
EM l.korkina@idi.it
RI Dellambra, Elena/A-4005-2014
OI Dellambra, Elena/0000-0002-4329-3312
FU Italian Ministry for Health [IDI IRCCS-2011]
FX The work was financed by the Italian Ministry for Health grant (IDI
   IRCCS-2011).
CR Afaq F, 2011, MINI-REV MED CHEM, V11, P1200
   Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Albanesi C, 2010, CURR DRUG METAB, V11, P210, DOI 10.2174/138920010791196328
   Allison RR, 2010, PHOTODIAGN PHOTODYN, V7, P61, DOI 10.1016/j.pdpdt.2010.02.001
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Androutsopoulos VP, 2011, EUR J MED CHEM, V46, P2586, DOI 10.1016/j.ejmech.2011.03.049
   Androutsopoulos VP, 2010, PHARMACOL THERAPEUT, V126, P9, DOI 10.1016/j.pharmthera.2010.01.009
   Archier E, 2012, J EUR ACAD DERMATOL, V26, P22, DOI 10.1111/j.1468-3083.2012.04520.x
   Asensi M, 2011, CRIT REV CL LAB SCI, V48, P197, DOI 10.3109/10408363.2011.631268
   Atta M, 2012, TRANSFUS APHER SCI, V46, P195, DOI 10.1016/j.transci.2011.10.016
   Aziz MH, 2005, FASEB J, V19, P1193, DOI 10.1096/fj.04-3582fje
   Babich H, 2008, BASIC CLIN PHARMACOL, V103, P66, DOI 10.1111/j.1742-7843.2008.00232.x
   Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217
   Balagula Y, 2011, INT J DERMATOL, V50, P129, DOI 10.1111/j.1365-4632.2010.04791.x
   Balasubramanian S, 2008, NUTR REV, V66, pS65, DOI 10.1111/j.1753-4887.2008.00071.x
   Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314
   Balcerczyk A, 2010, BIOFACTORS, V36, P383, DOI 10.1002/biof.112
   Balducci L, 2005, NAT REV CANCER, V5, P655, DOI 10.1038/nrc1675
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Beedanagari SR, 2009, TOXICOL SCI, V110, P61, DOI 10.1093/toxsci/kfp079
   Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013
   Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056
   Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988
   Bhattacharya S, 2008, BIOORG MED CHEM LETT, V18, P5856, DOI 10.1016/j.bmcl.2008.06.029
   Bickford PC, 2006, STEM CELLS DEV, V15, P118, DOI 10.1089/scd.2006.15.118
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5
   Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Bonafè M, 2012, BIOESSAYS, V34, P40, DOI 10.1002/bies.201100104
   Brohem CA, 2012, PIGM CELL MELANOMA R, V25, P354, DOI 10.1111/j.1755-148X.2012.00992.x
   Brooks J, 2011, CURR CANCER DRUG TAR, V11, P654, DOI 10.2174/156800911795655967
   Cabarcas SM, 2011, INT J CANCER, V129, P2315, DOI 10.1002/ijc.26312
   Cabello CM, 2012, INVEST NEW DRUG, V30, P1289, DOI 10.1007/s10637-011-9676-7
   Canguilhem B, 2005, J BIOL CHEM, V280, P43257, DOI 10.1074/jbc.M508650200
   CANTI G, 1994, ANTI-CANCER DRUG, V5, P443, DOI 10.1097/00001813-199408000-00009
   Casanova ML, 2002, CANCER RES, V62, P3402
   Checinska A, 2011, PIGM CELL MELANOMA R, V24, P1116, DOI 10.1111/j.1755-148X.2011.00927.x
   Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752
   Chen D, 2011, ADV CLIN CHEM, V53, P155, DOI 10.1016/S0065-2423(11)53007-0
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Cho MY, 2012, ARCH PHARM RES, V35, P911, DOI 10.1007/s12272-012-0517-9
   Chung SW, 2010, ARCH BIOCHEM BIOPHYS, V501, P79, DOI 10.1016/j.abb.2010.05.003
   Ciolino HP, 1999, BIOCHEM J, V340, P715, DOI 10.1042/0264-6021:3400715
   Ciolino HP, 1998, CANCER RES, V58, P5707
   Conforti F, 2012, CELL PROLIFERAT, V45, P279, DOI 10.1111/j.1365-2184.2012.00816.x
   Coppé JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Coppé JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009188
   Cosme-Blanco W, 2007, EMBO REP, V8, P497, DOI 10.1038/sj.embor.7400937
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Crea F, 2009, ANTI-CANCER AGENT ME, V9, P1105, DOI 10.2174/187152009789735053
   Daniela L, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/498373
   Das M, 2010, MOL ASPECTS MED, V31, P503, DOI 10.1016/j.mam.2010.09.001
   Dash R, 2011, P NATL ACAD SCI USA, V108, P8785, DOI 10.1073/pnas.1100769108
   Davids LM, 2009, CELL BIOL INT, V33, P1065, DOI 10.1016/j.cellbi.2009.06.026
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Delmas D, 2011, CURR MED CHEM, V18, P1100, DOI 10.2174/092986711795029708
   Dever DP, 2012, MOL PHARMACOL, V81, P669, DOI 10.1124/mol.111.077305
   Devi P. Uma, 2000, Indian Journal of Experimental Biology, V38, P432
   Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025
   Dlugosz AA, 1997, CANCER RES, V57, P3180
   DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071
   El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220
   El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204
   Enjuanes A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019736
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026
   Fernández Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686
   Fogarty GB, 2007, BRIT J DERMATOL, V156, P92, DOI 10.1111/j.1365-2133.2006.07603.x
   Garg AD, 2010, APOPTOSIS, V15, P1050, DOI 10.1007/s10495-010-0479-7
   Garg AK, 2005, ANTIOXID REDOX SIGN, V7, P1630, DOI 10.1089/ars.2005.7.1630
   Gatouillat G, 2010, J CELL BIOCHEM, V110, P893, DOI 10.1002/jcb.22601
   Goldman R, 1997, ADV EXP MED BIOL, V433, P41
   Gollnick SO, 2010, IMMUNOL RES, V46, P216, DOI 10.1007/s12026-009-8119-4
   Gopalakrishnan A, 2008, FOOD CHEM TOXICOL, V46, P1257, DOI 10.1016/j.fct.2007.09.082
   Haarmann-Stemmann T, 2009, BIOCHEM PHARMACOL, V77, P508, DOI 10.1016/j.bcp.2008.09.013
   Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hansen LA, 2000, CANCER RES, V60, P3328
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221
   Hayeshi R, 2007, FOOD CHEM TOXICOL, V45, P286, DOI 10.1016/j.fct.2006.07.027
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Hei Tom K, 2011, Curr Mol Pharmacol, V4, P96
   Hermans N, 2007, CURR MED CHEM, V14, P417, DOI 10.2174/092986707779941005
   Hofseth LJ, 2010, AGING-US, V2, P183, DOI 10.18632/aging.100143
   Honigsmann H., 2012, PHOTOCHEM PHOTOBIOL
   Howell PM, 2009, CANCER CONTROL, V16, P200, DOI 10.1177/107327480901600302
   Hsieh TH, 2012, FASEB J, V26, P778, DOI 10.1096/fj.11-191742
   Hwang YP, 2011, MOL NUTR FOOD RES, V55, P594, DOI 10.1002/mnfr.201000292
   Ibbotson SH, 2011, PHOTODERMATOL PHOTO, V27, P116, DOI 10.1111/j.1600-0781.2010.00560.x
   Ikuta T, 2009, BIOCHEM PHARMACOL, V77, P588, DOI 10.1016/j.bcp.2008.10.003
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158
   Kabingu E, 2009, CLIN CANCER RES, V15, P4460, DOI 10.1158/1078-0432.CCR-09-0400
   Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200
   Kalmes M, 2011, BIOL CHEM, V392, P643, DOI 10.1515/BC.2011.067
   Kalthoff S, 2010, J BIOL CHEM, V285, P5993, DOI 10.1074/jbc.M109.075770
   Kane RC, 2006, CLIN CANCER RES, V12, P2955, DOI 10.1158/1078-0432.CCR-06-0170
   Kasten-Pisula U, 2007, RADIOTHER ONCOL, V83, P296, DOI 10.1016/j.radonc.2007.04.024
   Katiyar SK, 2007, CANCER LETT, V255, P1, DOI 10.1016/j.canlet.2007.02.010
   Katiyar SK, 2011, ARCH BIOCHEM BIOPHYS, V508, P152, DOI 10.1016/j.abb.2010.11.015
   Katiyar SK, 2000, J INVEST DERMATOL, V114, P328, DOI 10.1046/j.1523-1747.2000.00876.x
   Kato K, 2008, BRIT J CANCER, V99, P647, DOI 10.1038/sj.bjc.6604521
   Kawasaki BT, 2008, MOL INTERV, V8, P174, DOI 10.1124/mi.8.4.9
   Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231
   Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200
   Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962
   Kondapalli L, 2005, J AM ACAD DERMATOL, V53, P291, DOI 10.1016/j.jaad.2005.02.011
   Kong Y., 2011, J AGING RES, P1
   Korbelik M, 2011, PHOTOCH PHOTOBIO SCI, V10, P664, DOI 10.1039/c0pp00343c
   Korkaya H, 2011, CLIN CANCER RES, V17, P6125, DOI 10.1158/1078-0432.CCR-10-2743
   Korkina L, 2011, MINI-REV MED CHEM, V11, P823, DOI 10.2174/138955711796575489
   Korkina LG, 2007, CELL MOL BIOL, V53, P84, DOI 10.1170/T822
   Korkina LG, 2009, CURR MED CHEM, V16, P3943, DOI 10.2174/092986709789352312
   Korkina LG, 2008, CURR DRUG METAB, V9, P710, DOI 10.2174/138920008786049267
   Kostyuk V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044472
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Kumar G, 2012, FREE RADICAL BIO MED, V53, P1358, DOI 10.1016/j.freeradbiomed.2012.07.017
   Kyrylenko S, 2010, CURR MED CHEM, V17, P2921, DOI 10.2174/092986710792065009
   Labrecque MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029545
   Lacouture ME, 2006, NAT REV CANCER, V6, P803, DOI 10.1038/nrc1970
   Lafon-Hughes L, 2008, MUTAT RES-REV MUTAT, V658, P191, DOI 10.1016/j.mrrev.2008.01.008
   Landis-Piwowar KR, 2007, J CELL PHYSIOL, V213, P252, DOI 10.1002/jcp.21124
   Landis-Piwowar KR, 2006, DRUG RESIST UPDATE, V9, P263, DOI 10.1016/j.drup.2006.11.001
   Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003
   Lee K, 2008, J INVEST DERMATOL, V128, P9, DOI 10.1038/sj.jid.5700949
   Lee Y, 2011, SEMIN CUTAN MED SURG, V30, P199, DOI 10.1016/j.sder.2011.08.001
   Li TH, 2009, TARGET ONCOL, V4, P107, DOI 10.1007/s11523-009-0114-0
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YW, 2010, PHARM RES-DORDR, V27, P1027, DOI 10.1007/s11095-010-0105-y
   Lin SS, 2009, CANCER LETT, V285, P127, DOI 10.1016/j.canlet.2009.04.037
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   Liu FT, 2008, BLOOD, V112, P3835, DOI 10.1182/blood-2008-04-150227
   Luecke S, 2010, PIGM CELL MELANOMA R, V23, P828, DOI 10.1111/j.1755-148X.2010.00762.x
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Maher J, 2010, TOXICOL APPL PHARM, V244, P4, DOI 10.1016/j.taap.2010.01.011
   Martens UM, 2000, EXP CELL RES, V256, P291, DOI 10.1006/excr.2000.4823
   Martin Olga A, 2011, Commun Integr Biol, V4, P78, DOI 10.4161/cib.4.1.13942
   Martínez-Carpio PA, 2010, PHOTODERMATOL PHOTO, V26, P250, DOI 10.1111/j.1600-0781.2010.00534.x
   Mascia F, 2003, AM J PATHOL, V163, P303, DOI 10.1016/S0002-9440(10)63654-1
   Maund SL, 2011, STEM CELL REV REP, V7, P307, DOI 10.1007/s12015-010-9205-7
   Meeran SM, 2009, TOXICOL APPL PHARM, V241, P303, DOI 10.1016/j.taap.2009.09.003
   Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003
   Menichini G, 2012, CELL PROLIFERAT, V45, P39, DOI 10.1111/j.1365-2184.2011.00791.x
   Mercader AG, 2012, CURR MED CHEM, V19, P4324
   Millington GWM, 2008, PHARMACOGENOMICS, V9, P1835, DOI 10.2217/14622416.9.12.1835
   Morton CA, 2008, BRIT J DERMATOL, V159, P1245, DOI 10.1111/j.1365-2133.2008.08882.x
   Mukai R, 2010, ARCH BIOCHEM BIOPHYS, V501, P134, DOI 10.1016/j.abb.2010.05.002
   Munro J, 2004, EXP CELL RES, V295, P525, DOI 10.1016/j.yexcr.2004.01.017
   Muntoni A, 2005, HUM MOL GENET, V14, pR191, DOI 10.1093/hmg/ddi266
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965
   Niestroy J, 2011, TOXICOL IN VITRO, V25, P671, DOI 10.1016/j.tiv.2011.01.008
   Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104
   Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   Olaharski AJ, 2005, PLOS GENET, V1, P689, DOI 10.1371/journal.pgen.0010077
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pahlke G, 2006, J AGR FOOD CHEM, V54, P7075, DOI 10.1021/jf0612530
   Palumbo A, 2011, BRIT J CANCER, V104, P1106, DOI 10.1038/bjc.2011.78
   Pastore S, 2005, J IMMUNOL, V174, P5047, DOI 10.4049/jimmunol.174.8.5047
   Pastore S, 2008, J INVEST DERMATOL, V128, P1365, DOI 10.1038/sj.jid.5701184
   Pastore S, 2012, PHOTOCHEM PHOTOBIOL, V88, P1522, DOI 10.1111/j.1751-1097.2012.01195.x
   Pastore S, 2012, ANTIOXID REDOX SIGN, V16, P314, DOI 10.1089/ars.2011.4053
   Pastore S, 2011, J DERMATOL SCI, V63, P104, DOI 10.1016/j.jdermsci.2011.04.011
   Pavek P, 2008, CURR DRUG METAB, V9, P129, DOI 10.2174/138920008783571774
   Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095
   Pivarcsi A, 2007, P NATL ACAD SCI USA, V104, P19055, DOI 10.1073/pnas.0705673104
   Potapovich AI, 2011, TOXICOL APPL PHARM, V255, P138, DOI 10.1016/j.taap.2011.06.007
   Potthoff K, 2011, ANN ONCOL, V22, P524, DOI 10.1093/annonc/mdq387
   Prado R, 2011, DERMATOL SURG, V37, P1566, DOI 10.1111/j.1524-4725.2011.02108.x
   Prasad V. Satya, 1996, Indian Journal of Experimental Biology, V34, P857
   Pratt MAC, 2009, ONCOGENE, V28, P2710, DOI 10.1038/onc.2009.131
   Psahoulia FH, 2007, CARCINOGENESIS, V28, P1021, DOI 10.1093/carcin/bgl232
   Puga A.Ma., 2009, Biochem Pharmacol, V77, P13
   Puppala D, 2007, CARCINOGENESIS, V28, P639, DOI 10.1093/carcin/bgl169
   Quan F, 2008, BIOMED PHARMACOTHER, V62, P622, DOI 10.1016/j.biopha.2008.07.089
   Queen Brannon L, 2010, Curr Aging Sci, V3, P34
   Rajaraman G, 2009, CAN J PHYSIOL PHARM, V87, P674, DOI [10.1139/Y09-061, 10.1139/y09-061]
   Rannug A, 2006, BIOL CHEM, V387, P1149, DOI 10.1515/BC.2006.143
   Rauser CL, 2006, AGEING RES REV, V5, P14, DOI 10.1016/j.arr.2005.06.003
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866
   Roninson IB, 2002, DRUG RESIST UPDATE, V5, P204, DOI 10.1016/S1368764602001103
   Scarlatti F, 2007, CANCER LETT, V253, P124, DOI 10.1016/j.canlet.2007.01.014
   Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1
   Schneider MR, 2008, AM J PATHOL, V173, P14, DOI 10.2353/ajpath.2008.070942
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   Shimamoto K, 2011, TOXICOLOGY, V283, P109, DOI 10.1016/j.tox.2011.03.003
   Shimizu T, 2001, DERMATOLOGY, V202, P203, DOI 10.1159/000051637
   Shytle RD, 2007, REJUV RES, V10, P173, DOI 10.1089/rej.2006.0515
   Siddens LK, 2012, TOXICOL APPL PHARM, V264, P377, DOI 10.1016/j.taap.2012.08.014
   Sigalotti L, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-56
   Slusarz A, 2010, CANCER RES, V70, P3382, DOI 10.1158/0008-5472.CAN-09-3012
   Sorensen OE, 2003, J IMMUNOL, V170, P5583, DOI 10.4049/jimmunol.170.11.5583
   Sorensen OE, 2006, J CLIN INVEST, V116, P1878, DOI 10.1172/JCI28422
   Spink BC, 2013, MOL CARCINOGEN, V52, P544, DOI 10.1002/mc.21889
   Stejskalova L, 2011, CURR DRUG METAB, V12, P198, DOI 10.2174/138920011795016818
   Stern RS, 2012, J AM ACAD DERMATOL, V66, P553, DOI 10.1016/j.jaad.2011.04.004
   Sticozzi C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033592
   Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Suttana W, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-99
   Swanson HI, 2004, CHEM-BIOL INTERACT, V149, P69, DOI 10.1016/j.cbi.2004.08.006
   Szic KSV, 2010, BIOCHEM PHARMACOL, V80, P1816, DOI 10.1016/j.bcp.2010.07.029
   Tan AC, 2011, NUTR CANCER, V63, P495, DOI 10.1080/01635581.2011.538953
   Tauchi M, 2005, MOL CELL BIOL, V25, P9360, DOI 10.1128/MCB.25.21.9360-9368.2005
   Teillet F, 2008, MED RES REV, V28, P715, DOI 10.1002/med.20122
   Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023
   Tiong CT, 2012, CARCINOGENESIS, V33, P1089, DOI 10.1093/carcin/bgs110
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Vaid M, 2012, TOXICOL APPL PHARM, V263, P122, DOI 10.1016/j.taap.2012.06.013
   Van Lanen SG, 2012, ANTICANCER AGENTS FROM NATURAL PRODUCTS, 2ND EDITION, P671
   Vanden Berghe W, 2012, PHARMACOL RES, V65, P565, DOI 10.1016/j.phrs.2012.03.007
   Vanden Berghe W, 2010, CURR DRUG METAB, V11, P436, DOI 10.2174/138920010791526079
   Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099
   VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643
   Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541
   Wang T, 2011, TOXICOL SCI, V124, P291, DOI 10.1093/toxsci/kfr247
   Wang Y, 2008, CLIN GENET, V74, P307, DOI 10.1111/j.1399-0004.2008.01075.x
   Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173
   Willmore-Payne C, 2006, MODERN PATHOL, V19, P634, DOI 10.1038/modpathol.3800552
   Wincent E, 2009, J BIOL CHEM, V284, P2690, DOI 10.1074/jbc.M808321200
   Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104
   Wu DS, 2011, ANN OPER RES, V185, P1, DOI 10.1007/s10479-010-0822-y
   Wu YX, 2010, PLANTA MED, V76, P128, DOI 10.1055/s-0029-1186004
   Xu YR, 2006, J BIOL CHEM, V281, P27389, DOI 10.1074/jbc.M602355200
   Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200
   Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529
   Yang H, 2008, CURR PROTEIN PEPT SC, V9, P227, DOI 10.2174/138920308784533998
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Ye MX, 2012, INT J MOL SCI, V13, P3959, DOI 10.3390/ijms13033959
   Yerlikaya A, 2010, MOL MED REP, V3, P333, DOI 10.3892/mmr_00000262
   Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642
   Yoshii H, 2012, BIOCHEM BIOPH RES CO, V417, P640, DOI 10.1016/j.bbrc.2011.12.024
   Zhan YH, 2009, ARCH PHARM, V342, P223, DOI 10.1002/ardp.200800185
   Zhang ZY, 2005, BBA-PROTEINS PROTEOM, V1754, P100, DOI 10.1016/j.bbapap.2005.09.005
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 242
TC 28
Z9 29
U1 1
U2 68
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD MAR
PY 2013
VL 20
IS 7
BP 852
EP 868
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 112RN
UT WOS:000316610600002
PM 23210776
DA 2025-01-12
ER

PT J
AU Rebucci, M
   Michiels, C
AF Rebucci, Magali
   Michiels, Carine
TI Molecular aspects of cancer cell resistance to chemotherapy
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Cancer; Resistance; Anti-cancer agents; Targeted therapies; Hypoxia;
   Cancer stem cells
ID DNA-DAMAGE RESPONSE; MEDIATED DRUG-RESISTANCE; MULTIDRUG-RESISTANCE;
   BREAST-CANCER; TUMOR MICROENVIRONMENT; STEM-CELLS; SIGNALING PATHWAYS;
   CHEMORESISTANCE; MECHANISMS; P53
AB Cancer cell resistance to chemotherapy is still a heavy burden that impairs treatment of cancer patients. Both intrinsic and acquired resistance results from the numerous genetic and epigenetic changes occurring in cancer cells. Most of the hallmarks of cancer cells provide general mechanisms to sustain stresses such as the ones induced by chemotherapeutic drugs. Moreover, specific changes in the target bring resistance to specific drugs like modification in nucleotide synthesis enzymes upon anti-metabolite exposure, in microtubule composition upon spindle poison treatment, in topoisomerase activity upon topoisomerase inhibitor incubation or in intracellular signaling pathways when targeting tyrosine kinase receptors.
   Finally, the stemness properties of a few cancer cells as well as components of the tumor stroma, like fibroblasts and tumor-associated macrophages but also hypoxia, also help tumor to resist to anticancer agents. These processes provide an additional level of complexity to the understanding of the tumor resistance phenomenon.
   This review aims to describe the different general mechanisms as well as some examples of specific on target modifications inducing cancer cell resistance to chemotherapy at the molecular level. Perspectives to develop more efficient treatment, using genomic signature or more specific biomarkers to characterize putative resistance mechanisms in patients before choosing the more appropriate treatment, will also be discussed. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Rebucci, Magali; Michiels, Carine] Univ Namur FUNDP, URBC NARILIS, Namur, Belgium.
C3 University of Namur
RP Michiels, C (通讯作者)，Univ Namur, URBC, 61 Rue Bruxelles, B-5000 Namur, Belgium.
EM carine.michiels@fundp.ac.be
RI Michiels, Carine/HMO-9983-2023
FU FNRS (National Funds for Scientific Research, Brussels, Belgium)
FX Magali Rebucci is recipient of a mobility post-doc grant from the FNRS
   (National Funds for Scientific Research, Brussels, Belgium).
CR Annunziata CM, 2010, CLIN CANCER RES, V16, P4517, DOI 10.1158/1078-0432.CCR-10-0526
   Azmi AS, 2009, J CELL PHYSIOL, V218, P13, DOI 10.1002/jcp.21567
   Baba H, 2003, CANCER CHEMOTH PHARM, V52, P469, DOI 10.1007/s00280-003-0695-8
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Basu B, 2012, CURR OPIN ONCOL, V24, P316, DOI 10.1097/CCO.0b013e32835280c6
   BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251
   Beier D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-128
   Bennewith KL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-504
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Borst P, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120066
   Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342
   Breier A, 2012, ANTICANCER AGENTS ME
   Brown JM, 1998, CANCER RES, V58, P1408
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Cao L, 2009, MOL CELL, V35, P534, DOI 10.1016/j.molcel.2009.06.037
   Castells M, 2012, INT J MOL SCI, V13, P9545, DOI 10.3390/ijms13089545
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chatterjee M, 2008, BLOOD, V111, P3714, DOI 10.1182/blood-2007-05-089151
   Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566
   Chen KG, 2012, CLIN CANCER RES, V18, P1863, DOI 10.1158/1078-0432.CCR-11-1590
   Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019
   Coffelt SB, 2009, BBA-REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004
   Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127
   Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798
   Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399
   de Hoon JPJ, 2012, BBA-REV CANCER, V1825, P197, DOI 10.1016/j.bbcan.2012.01.001
   De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dempke WCM, 2009, EUR J CANCER, V45, P1117, DOI 10.1016/j.ejca.2008.11.038
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   Dimberg LY., 2012, ONCOGENE
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Faber AC, 2012, ADV PHARMACOL, V65, P519, DOI 10.1016/B978-0-12-397927-8.00016-6
   Farrell A, 2011, NAT MED, V17, P262, DOI 10.1038/nm0311-262
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Ganguly A, 2011, BBA-REV CANCER, V1816, P164, DOI 10.1016/j.bbcan.2011.06.001
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944
   Gonen N, 2012, DRUG RESIST UPDATE, V15, P183, DOI 10.1016/j.drup.2012.07.002
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156
   Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hilgeroth A, 2012, MINI-REV MED CHEM, V12, P1127, DOI 10.2174/138955712802762130
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Karamboulas C, 2012, BIOCH BIOPHYS ACTA
   Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803
   Knappskog S, 2012, EXPERT OPIN THER TAR, V16, pS23, DOI 10.1517/14728222.2011.640322
   Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401
   Lai D, 2012, BIOSCIENCE REP, V32, P361, DOI 10.1042/BSR20110125
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005
   Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760
   Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366
   Manning AL, 2011, TRENDS CELL BIOL, V21, P433, DOI 10.1016/j.tcb.2011.05.003
   Mao Y, 2012, CANC METASTASIS REV
   Marin JJG, 2012, CURR CANCER DRUG TAR, V12, P402
   Matson DR, 2011, MOL INTERV, V11, P141, DOI 10.1124/mi.11.2.12
   McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Mocellin S, 2012, CURR MED CHEM, V19, P3893, DOI 10.2174/092986712802002509
   Monzó M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713
   Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015
   O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259
   Park S, 2010, HAEMATOL-HEMATOL J, V95, P819, DOI 10.3324/haematol.2009.013797
   Pilati P, 2012, CURR MED CHEM, V19, P3900, DOI 10.2174/092986712802002473
   Plati J, 2008, J CELL BIOCHEM, V104, P1124, DOI 10.1002/jcb.21707
   Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662
   Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001
   Rosenzweig SA, 2012, BIOCHEM PHARMACOL, V83, P1041, DOI 10.1016/j.bcp.2011.12.025
   Scartozzi M, 2011, PHARMACOGENOMICS, V12, P251, DOI 10.2217/PGS.10.167
   Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366
   Shindoh N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049201
   Showalter SL, 2008, CANCER BIOL THER, V7, P986, DOI 10.4161/cbt.7.7.6181
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   SMITH K, 1993, ONCOGENE, V8, P933
   Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645
   Strano S, 2007, HEAD NECK-J SCI SPEC, V29, P488, DOI 10.1002/hed.20531
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890
   Tomicic MT, 2013, BBA-REV CANCER, V1835, P11, DOI 10.1016/j.bbcan.2012.09.002
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368
   Vasey PA, 1996, MOL PHARMACOL, V50, P1536
   Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1
   Wang L, 2012, MOL CANCER THER, V11, P2401, DOI 10.1158/1535-7163.MCT-12-0448
   Ward RJ, 2007, ANNU REV PATHOL-MECH, V2, P175, DOI 10.1146/annurev.pathol.2.010506.091847
   Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249
   Wu CP, 2011, MOL PHARMACEUT, V8, P1996, DOI 10.1021/mp200261n
   Xia CQ, 2012, MOL PHARMACOL, V82, P1008, DOI 10.1124/mol.112.079129
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
NR 100
TC 315
Z9 353
U1 0
U2 151
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY 1
PY 2013
VL 85
IS 9
BP 1219
EP 1226
DI 10.1016/j.bcp.2013.02.017
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 122LZ
UT WOS:000317320900002
PM 23435357
DA 2025-01-12
ER

PT J
AU Sproul, D
   Meehan, RR
AF Sproul, Duncan
   Meehan, Richard R.
TI Genomic insights into cancer-associated aberrant CpG island
   hypermethylation
SO BRIEFINGS IN FUNCTIONAL GENOMICS
LA English
DT Article
DE epigenetics; epigenomics; cancer; DNA methylation; CpG islands
ID DNA METHYLATION PATTERNS; DE-NOVO METHYLATION; TUMOR-SUPPRESSOR GENE;
   ACUTE MYELOID-LEUKEMIA; X-CHROMOSOME INACTIVATION; EMBRYONIC STEM-CELLS;
   HUMAN COLON-CANCER; BREAST-CANCER; PROMOTER HYPERMETHYLATION;
   CHROMATIN-STRUCTURE
AB Carcinogenesis is thought to occur through a combination of mutational and epimutational events that disrupt key pathways regulating cellular growth and division. The DNA methylomes of cancer cells can exhibit two striking differences from normal cells; a global reduction of DNA methylation levels and the aberrant hypermethylation of some sequences, particularly CpG islands (CGIs). This aberrant hypermethylation is often invoked as a mechanism causing the transcriptional inactivation of tumour suppressor genes that directly drives the carcinogenic process. Here, we review our current understanding of this phenomenon, focusing on how global analysis of cancer methylomes indicates that most affected CGI genes are already silenced prior to aberrant hypermethylation during cancer development. We also discuss how genome-scale analyses of both normal and cancer cells have refined our understanding of the elusive mechanism(s) that may underpin aberrant CGI hypermethylation.
C1 [Meehan, Richard R.] Univ Edinburgh, Western Gen Hosp, MRC Human Genet Unit, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh
RP Meehan, RR (通讯作者)，Univ Edinburgh, Western Gen Hosp, MRC Human Genet Unit, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
EM Duncan.Sproul@igmm.ed.ac.uk; Richard.Meehan@igmm.ed.ac.uk
OI Meehan, Richard/0000-0001-6471-6882
FU Medical Research Council; Biotechnology and Biological Sciences Research
   Council; Innovative Medicine Initiative Joint Undertaking (IMI JU) [115
   001]; Breakthrough Breast Cancer; Breast Cancer Campaign; MRC
   [MC_PC_U127574433] Funding Source: UKRI
FX Work in R.M.'s lab is supported by the Medical Research Council, the
   Biotechnology and Biological Sciences Research Council and by the
   Innovative Medicine Initiative Joint Undertaking (IMI JU) under grant
   agreement number 115 001 (MARCAR project). D. S. is supported by the
   Medical Research Council, Breakthrough Breast Cancer and Breast Cancer
   Campaign.
CR Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039
   Adams PD, 2007, GENE, V397, P84, DOI 10.1016/j.gene.2007.04.020
   [Anonymous], 2007, BIOL CANC
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   BAYLIN SB, 1986, CANCER RES, V46, P2917
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bestor TH, 2003, ANN NY ACAD SCI, V983, P22, DOI 10.1111/j.1749-6632.2003.tb05959.x
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499
   Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019
   Boumber YA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000162
   BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Brookes E, 2012, CELL STEM CELL, V10, P157, DOI 10.1016/j.stem.2011.12.017
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev-biochem-052610-091920
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Clouaire T, 2012, GENE DEV, V26, P1714, DOI 10.1101/gad.194209.112
   Conerly ML, 2010, GENOME RES, V20, P1383, DOI 10.1101/gr.106542.110
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cunningham JM, 1998, CANCER RES, V58, P3455
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   De Gobbi M, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-9
   Deaton AM, 2011, GENOME RES, V21, P1074, DOI 10.1101/gr.118703.110
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1
   Eads CA, 1999, CANCER RES, V59, P2302
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470
   Enderle D, 2011, GENOME RES, V21, P216, DOI 10.1101/gr.114348.110
   Epsztejn-Litman S, 2008, NAT STRUCT MOL BIOL, V15, P1176, DOI 10.1038/nsmb.1476
   Estécio MRH, 2010, GENOME RES, V20, P1369, DOI 10.1101/gr.107318.110
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2001, CANCER RES, V61, P3225
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Fournier A, 2012, BRIEF FUNCT GENOMICS, V11, P251, DOI 10.1093/bfgp/elr040
   Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011
   Franchini DM, 2012, ANNU REV GENET, V46, P419, DOI 10.1146/annurev-genet-110711-155451
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gebhard C, 2010, CANCER RES, V70, P1398, DOI 10.1158/0008-5472.CAN-09-3406
   Gendrel AV, 2012, DEV CELL, V23, P265, DOI 10.1016/j.devcel.2012.06.011
   Gertz J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002228
   Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987
   Gilbertson RJ, 2012, NATURE, V488, P462, DOI 10.1038/nature11480
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   GREGER V, 1994, HUM GENET, V94, P491
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Helman E, 2012, ONCOGENE, V31, P1181, DOI 10.1038/onc.2011.307
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Hitchins MP, 2011, CANCER CELL, V20, P200, DOI 10.1016/j.ccr.2011.07.003
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hosoya K, 2009, CANCER LETT, V285, P182, DOI 10.1016/j.canlet.2009.05.016
   Houshdaran S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009359
   Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602
   Illingworth RS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001134
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kalari S, 2010, ADV GENET, V70, P277, DOI [10.1016/B978-0-12-380866-0.60010-1, 10.1016/S0065-2660(10)70010-9]
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010
   Kodzius R, 2006, NAT METHODS, V3, P211, DOI 10.1038/nmeth0306-211
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lakhani SR, 1997, LANCET, V349, P1505
   Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442
   Levanon D, 2011, EMBO MOL MED, V3, P593, DOI 10.1002/emmm.201100168
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006
   Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007
   LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9
   Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760
   Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   McDermott U, 2011, NEW ENGL J MED, V364, P340, DOI 10.1056/NEJMra0907178
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056
   MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095
   Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Myöhänen SK, 1998, CANCER RES, V58, P591
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   O'Riain C, 2009, LEUKEMIA, V23, P1858, DOI 10.1038/leu.2009.114
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0
   OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063
   Okamoto I, 2009, CHROMOSOME RES, V17, P659, DOI 10.1007/s10577-009-9057-7
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Patel K, 2010, NUCLEIC ACIDS RES, V38, P4313, DOI 10.1093/nar/gkq187
   Pike BL, 2008, LEUKEMIA, V22, P1035, DOI 10.1038/leu.2008.18
   Prokhortchouk A, 2006, MOL CELL BIOL, V26, P199, DOI 10.1128/MCB.26.1.199-208.2006
   Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Ribeiro AFT, 2012, BLOOD, V119, P5824, DOI 10.1182/blood-2011-07-367961
   RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   Ruiz S, 2012, P NATL ACAD SCI USA, V109, P16196, DOI 10.1073/pnas.1202352109
   Rush Margaret, 2009, Epigenetics, V4, P404
   Sado T, 2000, DEV BIOL, V225, P294, DOI 10.1006/dbio.2000.9823
   Sado T, 2004, DEVELOPMENT, V131, P975, DOI 10.1242/dev.00995
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155
   Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112
   Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323
   Sato S, 2011, GENOMICS, V98, P120, DOI 10.1016/j.ygeno.2011.05.003
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shah MY, 2010, CANCER RES, V70, P5840, DOI 10.1158/0008-5472.CAN-10-0847
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111
   Steine EJ, 2011, J CLIN INVEST, V121, P1748, DOI 10.1172/JCI43169
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109
   Teodoridis JM, 2008, CANCER LETT, V268, P177, DOI 10.1016/j.canlet.2008.03.022
   Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tung ND, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2776
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Van Emburgh BO, 2011, NUCLEIC ACIDS RES, V39, P4984, DOI 10.1093/nar/gkr116
   Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Walter MJ, 2011, LEUKEMIA, V25, P1153, DOI 10.1038/leu.2011.44
   Weigelt B, 2010, MOL ONCOL, V4, P192, DOI 10.1016/j.molonc.2010.04.004
   Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wild L, 2010, BBA-REV CANCER, V1806, P50, DOI 10.1016/j.bbcan.2010.03.003
   Williams K, 2012, EMBO REP, V13, P28, DOI 10.1038/embor.2011.233
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934
   Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366
   Zilberman D, 2008, NATURE, V456, P125, DOI 10.1038/nature07324
   Ziller MJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002389
NR 183
TC 91
Z9 98
U1 0
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2041-2649
EI 2041-2657
J9 BRIEF FUNCT GENOMICS
JI Brief. Funct. Genomics
PD MAY
PY 2013
VL 12
IS 3
SI SI
BP 174
EP 190
DI 10.1093/bfgp/els063
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 150ZK
UT WOS:000319430200003
PM 23341493
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU O'Brien, K
   Rani, S
   Corcoran, C
   Wallace, R
   Hughes, L
   Friel, AM
   McDonnell, S
   Crown, J
   Radomski, MW
   O'Driscoll, L
AF O'Brien, Keith
   Rani, Sweta
   Corcoran, Claire
   Wallace, Robert
   Hughes, Linda
   Friel, Anne M.
   McDonnell, Susan
   Crown, John
   Radomski, Marek W.
   O'Driscoll, Lorraine
TI Exosomes from triple-negative breast cancer cells can transfer
   phenotypic traits representing their cells of origin to secondary cells
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Exosomes; Breast cancer; Triple-negative breast cancer; Cell-to-cell
   communication; Epigenetic
ID MEMBRANE-VESICLES; CARCINOMA-CELLS; MATRIX ADHESION; ANOIKIS;
   TUMORIGENESIS; GLIOBLASTOMA; RECURRENCE; MECHANISMS; APOPTOSIS; PATTERNS
AB Background: Triple-negative breast cancer (TNBC) accounts for 15-20% of breast cancers but is responsible for a disproportionate number of deaths. We investigated the relevance, in TNBC, of nano-sized exosomes expelled from cells. Specifically, we compared effects of exosomes derived from the claudin-low TNBC cell line Hs578T and its more invasive Hs578Ts(i)(8) variant, as well as exosomes from TNBC patient sera compared to normal sera.
   Methods: Exosomes were isolated from conditioned media (CM) of Hs578T and Hs578Ts(i)(8) cells and from sera by filtration and ultracentrifugation. Successful isolation was confirmed by transmission electron microscopy and immunoblotting. Subsequent analysis, of secondary/recipient cells in response to exosomes, included proliferation; motility/migration; invasion; anoikis assays and endothelial tubule formation assays.
   Results: Hs578Ts(i)(8)-exosomes versus Hs578T-exosomes significantly increased the proliferation, migration and invasion capacity of all three recipient cell lines evaluated i. e. SKBR3, MDA-MB-231 and HCC1954. Exosomes from Hs578Ts(i)(8) cells also conferred increased invasiveness to parent Hs578T cells. Hs578Ts(i)(8)-exosomes increased sensitivity of SKBR3, MDA-MB-231 and HCC1954 to anoikis when compared to the effects of Hs578T-exosomes reflecting the fact that Hs578Ts(i)(8) cells are themselves innately more sensitive to anoikis. In relation to vasculogenesis and subsequent angiogenesis, Hs578Ts(i)(8)-exosomes versus Hs578T-exosomes stimulated significantly more endothelial tubules formation. Finally, our pilot translational study showed that exosomes from TNBC patients' sera significantly increased recipient cells' invasion when compared to those derived from age- and gender-matched healthy control sera.
   Conclusion: This study supports the hypothesis that TNBC exosomes may be involved in cancer cell-to-cell communication, conferring phenotypic traits to secondary cells that reflect those of their cells of origin. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [O'Brien, Keith; Rani, Sweta; Corcoran, Claire; Wallace, Robert; Friel, Anne M.; Radomski, Marek W.; O'Driscoll, Lorraine] Univ Dublin Trinity Coll, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland.
   [O'Brien, Keith; Rani, Sweta; Corcoran, Claire; Wallace, Robert; Friel, Anne M.; Radomski, Marek W.; O'Driscoll, Lorraine] Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Dublin 2, Ireland.
   [Hughes, Linda; McDonnell, Susan] Univ Coll Dublin, Sch Chem & Bioproc Engn, Dublin 4, Ireland.
   [Crown, John] Dublin City Univ, Mol Therapeut Canc Ireland, Dublin 9, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; University College
   Dublin; Dublin City University
RP O'Driscoll, L (通讯作者)，Univ Dublin Trinity Coll, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland.
EM lodrisc@tcd.ie
RI O'Driscoll, Lorraine/HNS-2826-2023; Crown, John/AAL-3367-2020; Radomski,
   Marek/C-5195-2014
OI Rani, Sweta/0000-0003-0937-0094; O'Driscoll,
   Lorraine/0000-0002-9860-8262; Crown, John/0000-0002-3125-7613; Friel,
   Anne/0000-0001-9876-5332
FU Marie Keating Foundation PhD Scholarship at Trinity College Dublin;
   Trinity Foundation; Trinity College Dublin; Science Foundation Ireland
   [08/SRC/B1410]; Irish Research Council for Science, Engineering
   Technology; Higher Education Authorities Programme for Research in
   Third-Level Institutions Cycle 5; Science Foundation Ireland (SFI)
   [08/SRC/B1410] Funding Source: Science Foundation Ireland (SFI)
FX The authors wish to thank Mr. Neal Leddy Chief Technical Officer
   Specialist for his microscopy expertise. We also gratefully acknowledge
   funding support in the form of the Marie Keating Foundation PhD
   Scholarship at Trinity College Dublin (LOD); Trinity Foundation, Trinity
   College Dublin (LOD); Science Foundation Ireland's funding of Strategic
   Research Cluster, Molecular Therapeutics for Cancer Ireland 08/SRC/B1410
   (JC, LOD); the Irish Research Council for Science, Engineering &
   Technology (RW, LOD) and the Higher Education Authorities Programme for
   Research in Third-Level Institutions Cycle 5 support for Trinity
   Biomedical Sciences Institute (MWR, LOD). The sponsors had no
   involvement in the study design through to manuscript preparation.
CR Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008
   Arnedos M, 2012, THER ADV MED ONCOL, V4, P195, DOI 10.1177/1758834012444711
   Battke C, 2011, CANCER IMMUNOL IMMUN, V60, P639, DOI 10.1007/s00262-011-0979-5
   Bondar VM, 2002, PROSTATE, V51, P42, DOI 10.1002/pros.10070
   Carey LA, 2010, CLIN BREAST CANCER, V10, P188, DOI 10.3816/CBC.2010.n.026
   Ciravolo V, 2012, J CELL PHYSIOL, V227, P658, DOI 10.1002/jcp.22773
   Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2
   Gangopadhyay S, 2012, CLIN BREAST CANC
   Ge R, 2012, CANCER MICROENVIRON, V5, P323, DOI 10.1007/s12307-012-0110-2
   Germano S, 2012, INT J CANCER, V130, P1991, DOI 10.1002/ijc.26200
   Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693
   György B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3
   Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455
   Hughes L, 2008, CLIN EXP METASTAS, V25, P549, DOI 10.1007/s10585-008-9169-z
   Kharaziha P, 2012, BBA-REV CANCER, V1826, P103, DOI 10.1016/j.bbcan.2012.03.006
   Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283
   Lau CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033037
   Li JH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-244
   Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930
   Ludwig AK, 2012, INT J BIOCHEM CELL B, V44, P11, DOI 10.1016/j.biocel.2011.10.005
   Noda T, 2009, APOPTOSIS, V14, P287, DOI 10.1007/s10495-009-0319-9
   Pap E, 2011, CRIT REV ONCOL HEMAT, V79, P213, DOI 10.1016/j.critrevonc.2010.07.015
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rani S, 2011, METHODS MOL BIOL, V784, P181, DOI 10.1007/978-1-61779-289-2_13
   Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3
   Roomi MW, 2009, ONCOL REP, V21, P1323, DOI 10.3892/or_00000358
   Simionescu Dan T., 2011, Vasculogenesis and Angiogenesis - from Embryonic Development to Regenerative Medicine
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Taylor DD, 2009, GYNECOL ONCOL, V115, P112, DOI 10.1016/j.ygyno.2009.06.031
   Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3-15
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Wang J, 2012, J MED CHEM, V55, P2154, DOI 10.1021/jm201352k
   Wicha MS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3338
   Zhan M, 2004, HISTOL HISTOPATHOL, V19, P973, DOI 10.14670/HH-19.973
NR 39
TC 181
Z9 196
U1 2
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2013
VL 49
IS 8
BP 1845
EP 1859
DI 10.1016/j.ejca.2013.01.017
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 139UN
UT WOS:000318610500006
PM 23453937
OA Green Published
DA 2025-01-12
ER

PT J
AU Li, CH
   To, KF
   Tong, JHM
   Xiao, ZG
   Xia, T
   Lai, PBS
   Chow, SC
   Zhu, YX
   Chan, SL
   Marquez, VE
   Chen, YC
AF Li, Chi Han
   To, Ka-Fai
   Tong, Joanna Hung-Man
   Xiao, Zhangang
   Xia, Tian
   Lai, Paul B. S.
   Chow, Sheung Ching
   Zhu, Yin-Xin
   Chan, Stephen L.
   Marquez, Victor E.
   Chen, Yangchao
TI Enhancer of Zeste Homolog 2 Silences MicroRNA-218 in Human Pancreatic
   Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin
SO GASTROENTEROLOGY
LA English
DT Article
DE Pancreatic Cancer; Gene Regulation; Epigenetic; Messenger RNA Processing
ID HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; IN-VIVO; DE-NOVO; EXPRESSION;
   METHYLATION; GENE; ASSOCIATION; PROGRESSION; METASTASIS
AB BACKGROUND & AIMS: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is overexpressed by pancreatic ductal adenocarcinoma (PDAC) cells and increases their aggressiveness. We identified microRNAs (miRs) that are regulated by EZH2 and studied their functions in PDAC cells. METHODS: We performed miR profile analysis of PDAC cells incubated with EZH2 inhibitor 3-deazaneplanocin A, and pancreatic ductal epithelial cells that overexpressed EZH2. Expression levels of miRs and the targets of miRs were analyzed by quantitative reverse transcription polymerase chain reaction and immunohistochemistry. We expressed different forms of EZH2 to analyze functional domains and used small interfering RNAs to reduce its level in PDAC cells. RESULTS: Expression of miR-218 was repressed by EZH2 in PDAC cells. Levels of miR-218 were significantly reduced in primary PDAC tumor samples compared with paired, adjacent nontumor tissue. Overexpression of miR-218 in SW1990 cells reduced their proliferation and tumor formation and metastasis in nude mice. Loss of miR-218 from SW1990 cells increased levels of UDP-glycosyltransferase 8 and miR-218 was found to bind to its 3'-UTR. Levels of UDP-glycosyltransferase protein and messenger RNA were associated with the metastatic potential of PDAC cell lines and progression of tumors in patients. EZH2 was found to silence miR-218 by binding to its promoter, promoting heterochromatin formation, and recruiting the DNAs methyltransferase 1, 3A, and 3B. CONCLUSIONS: EZH2 is up-regulated in PDAC samples from patients and silences miR-218. MicroRNA-218 prevents proliferation of PDAC cells in culture, and tumor growth and metastasis in nude mice. MicroRNA-218 reduces levels of UDP-glycosyltransferase, which is associated with the metastatic potential of PDAC tumors in mice and progression of human PDAC.
C1 [Li, Chi Han; Xiao, Zhangang; Xia, Tian; Chow, Sheung Ching; Zhu, Yin-Xin; Chen, Yangchao] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
   [To, Ka-Fai; Tong, Joanna Hung-Man] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China.
   [Lai, Paul B. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.
   [Chan, Stephen L.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.
   [Marquez, Victor E.] NCI, Ctr Canc Res, Chem Biol Lab, Frederick, MD 21701 USA.
   [Chen, Yangchao] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Chinese University of Hong Kong; Prince of Wales
   Hospital; Chinese University of Hong Kong; Prince of Wales Hospital;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); CUHK Shenzhen Research Institute; The Chinese University of Hong
   Kong, Shenzhen
RP Chen, YC (通讯作者)，Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
EM frankch@cuhk.edu.hk
RI Zhang, Xiao-Hua/AAI-8899-2021; Marquez, Victor/KWD-9188-2024; Chan,
   Stephen/F-9149-2011; Chen, Yangchao/AAG-2127-2019; To, Ka
   Fai/JTT-7693-2023; LAI, Paul Bo-San/K-8556-2015
OI Chan, Stephen/0000-0001-8998-5480; Chen, Yangchao/0000-0002-0249-3414;
   To, Ka Fai/0000-0003-4919-3707; LAI, Paul Bo-San/0000-0002-9469-6728
FU Research Grants Council-General Research Fund of Hong Kong Special
   Administrative Region, China [CUHK462109, CUHK462211]; National Natural
   Science Foundation of China [81101888]; Shenzhen Basic Research Program
   [JC201105201092A]; CUHK; National Institutes of Health, National Cancer
   Institute, Center for Cancer Research
FX This work was supported by grants from the Research Grants
   Council-General Research Fund of Hong Kong Special Administrative
   Region, China (CUHK462109 and CUHK462211), National Natural Science
   Foundation of China (81101888), Shenzhen Basic Research Program
   (JC201105201092A), Direct Grant from CUHK to YC. This research was
   supported in part by the Intramural Research Program of the National
   Institutes of Health, National Cancer Institute, Center for Cancer
   Research.
CR Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641
   Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Chen Y, 2007, PROTEOMICS, V7, P3097, DOI 10.1002/pmic.200700019
   Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668
   Chen YC, 2010, CANCER LETT, V297, P109, DOI 10.1016/j.canlet.2010.05.003
   Culhane AC, 2009, CANCER RES, V69, P7480, DOI 10.1158/0008-5472.CAN-08-3350
   Davidson MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012560
   Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036
   Dziegiel P, 2010, BRIT J CANCER, V103, P524, DOI 10.1038/sj.bjc.6605750
   Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289
   Furukawa T, 1996, AM J PATHOL, V148, P1763
   Gao CP, 2010, CANCER-AM CANCER SOC, V116, P41, DOI 10.1002/cncr.24743
   Grzenda Adrienne, 2011, J Gastrointest Cancer, V42, P100, DOI 10.1007/s12029-011-9262-4
   Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6
   Hruban RH, 2000, CLIN CANCER RES, V6, P2969
   Kim K., 2012, Oncogene
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227
   Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792
   Lomberk G, 2009, PANCREATIC CANC, P143
   Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020
   Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919
   Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220
   Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Peng DF, 2005, CANCER SCI, V96, P403, DOI 10.1111/j.1349-7006.2005.00071.x
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002
   Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9
   Ruckhäberle E, 2008, BREAST CANCER RES TR, V112, P41, DOI 10.1007/s10549-007-9836-9
   Sakurai Y, 1997, CLIN EXP METASTAS, V15, P307, DOI 10.1023/A:1018429600437
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Song LB, 2010, BIOCHEM BIOPH RES CO, V402, P135, DOI 10.1016/j.bbrc.2010.10.003
   Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wald AI, 2011, HEAD NECK-J SCI SPEC, V33, P504, DOI 10.1002/hed.21475
   WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706
   Zhang JJ, 2012, CLIN TRANSL ONCOL, V14, P116, DOI 10.1007/s12094-012-0770-x
NR 40
TC 48
Z9 57
U1 0
U2 27
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2013
VL 144
IS 5
BP 1086
EP +
DI 10.1053/j.gastro.2013.01.058
PG 21
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 129BR
UT WOS:000317813900037
PM 23395645
OA Bronze
DA 2025-01-12
ER

PT J
AU Teh, MT
   Hutchison, IL
   Costea, DE
   Neppelberg, E
   Liavaag, PG
   Purdie, K
   Harwood, C
   Wan, H
   Odell, EW
   Hackshaw, A
   Waseem, A
AF Teh, Muy-Teck
   Hutchison, Iain L.
   Costea, Daniela Elena
   Neppelberg, Evelyn
   Liavaag, Per Gunnar
   Purdie, Karin
   Harwood, Catherine
   Wan, Hong
   Odell, Edward W.
   Hackshaw, Allan
   Waseem, Ahmad
TI Exploiting FOXM1-orchestrated molecular network for early squamous cell
   carcinoma diagnosis and prognosis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE molecular diagnostics; early cancer biomarkers; qPCR; squamous cell
   carcinoma; FOXM1 diagnostic biomarkers; prognostic biomarkers; clinical
   translation; personalised medicine; early detection
ID BREAST-CANCER; ORAL-CANCER; UP-REGULATION; FOXM1; EXPRESSION;
   DIFFERENTIATION; PROLIFERATION; SIGNATURE; INSTABILITY; RESISTANCE
AB Histopathological discordance with molecular phenotype of many human cancers poses clinically challenging tasks for accurate cancer diagnosis, which impacts on treatment strategy and patient outcome. Hence, an objective, accurate and quantitative method is needed. A quantitative Malignancy Index Diagnostic System (qMIDS) was developed based on 14 FOXM1 (isoform B)-associated genes implicated in the regulation of the cell cycle, differentiation, ageing, genomic stability, epigenetic and stem cell renewal, and two reference genes. Their mRNA expression levels were translated via a prospectively designed algorithm, into a metric scoring system. Subjects from UK and Norway (n = 299) provided 359 head and neck tissue specimens. Diagnostic test performance was assessed using detection rate (DR) and false-positive rate (FPR). The median qMIDS scores were 1.3, 2.9 and 6.7 in healthy tissue, dysplasia and head and neck squamous cell carcinomas (HNSCC), respectively (UK prospective dataset, p<0.001); 1.4, 2.3 and 7.6 in unaffected, oral lichen planus, or HNSCC, respectively (Norwegian retrospective dataset with up to 19 years survival data, p<0.001). At a qMIDS cut-off of 4.0, DR was 94% and FPR was 3.2% (Norwegian dataset); and DR was 91% and FPR was 1.3% (UK dataset). We further demonstrated the transferability of qMIDS for diagnosing premalignant human vulva (n = 58) and skin (n = 21) SCCs, illustrating its potential clinical use for other cancer types. This study provided evidence that qMIDS was able to quantitatively diagnose and objectively stratify cancer aggressiveness. With further validation, qMIDS could enable early HNSCC detection and guide appropriate treatment. Early treatment intervention can lead to long-term reduction in healthcare costs and improve patient outcome.
C1 [Teh, Muy-Teck; Wan, Hong; Waseem, Ahmad] Queen Mary Univ London, Ctr Clin & Diagnost Oral Sci, Barts & London Sch Med & Dent, Inst Dent, London E1 2AT, England.
   [Hutchison, Iain L.] Barts & London NHS Trust, Dept Oral & Maxillofacial Surg, London, England.
   [Costea, Daniela Elena] Univ Bergen, Sect Pathol, Gade Inst, Bergen, Norway.
   [Costea, Daniela Elena] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
   [Neppelberg, Evelyn] Haukeland Hosp, Dept Oral Surg, N-5021 Bergen, Norway.
   [Neppelberg, Evelyn] Univ Bergen, Inst Clin Dent, Bergen, Norway.
   [Liavaag, Per Gunnar] Haukeland Hosp, Dept Otolaryngol & Head & Neck Surg, Head & Neck Clin, N-5021 Bergen, Norway.
   [Purdie, Karin; Harwood, Catherine] Queen Mary Univ London, Ctr Cutaneous Res, Blizard Inst, Barts & London Sch Med & Dent, London E1 2AT, England.
   [Odell, Edward W.] Kings Coll London, Dept Clin & Diagnost Sci, London SE1 9RT, England.
   [Hackshaw, Allan] Canc Res UK, London W1T 4TJ, England.
   [Hackshaw, Allan] UCL, Canc Trials Ctr, London W1T 4TJ, England.
C3 University of London; Queen Mary University London; Barts Health NHS
   Trust; University of Bergen; University of Bergen; Haukeland University
   Hospital; University of Bergen; Haukeland University Hospital;
   University of Bergen; University of Bergen; Haukeland University
   Hospital; University of London; Queen Mary University London; University
   of London; King's College London; Cancer Research UK; University of
   London; University College London
RP Teh, MT (通讯作者)，Queen Mary Univ London, Ctr Clin & Diagnost Oral Sci, Barts & London Sch Med & Dent, Blizard Bldg,4,Newark St, London E1 2AT, England.
EM m.t.teh@qmul.ac.uk
RI Costea, Daniela Elena/AAB-9705-2020; Teh, Muy-Teck/B-9284-2016; Odell,
   Edward/E-9920-2012
OI Harwood, Catherine/0000-0002-1375-0965; Hutchison,
   Iain/0000-0002-4894-4049; Costea, Daniela-Elena/0000-0001-7673-0358;
   Teh, Muy-Teck/0000-0002-7725-8355; Odell, Edward/0000-0001-8435-0048
FU Facial Surgery Research Foundation-Saving Faces; Bergen Medical Research
   Foundation [20/2009]; Norwegian Cancer Research Association
   [515970/2011]; British Skin Foundation [S535]; Cancer Research UK
FX Grant sponsor: Facial Surgery Research Foundation-Saving Faces; Grant
   sponsor: Bergen Medical Research Foundation; Grant number: 20/2009;
   Grant sponsor: Norwegian Cancer Research Association; Grant number:
   515970/2011; Grant sponsor: British Skin Foundation; Grant number: S535;
   Grant sponsor: Cancer Research UK
CR Baron RC, 2010, AM J PREV MED, V38, P110, DOI 10.1016/j.amepre.2009.09.031
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768
   Bose A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038599
   Bossuyt PM, 2003, LANCET, V361, P71, DOI 10.1016/S0140-6736(03)12122-8
   Braakhuis BJM, 2003, CANCER RES, V63, P1727
   Braakhuis BJM, 2010, ORAL ONCOL, V46, P485, DOI 10.1016/j.oraloncology.2010.01.019
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545
   Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861
   CHANG SE, 1992, INT J CANCER, V52, P896, DOI 10.1002/ijc.2910520612
   Chen CH, 2009, ONCOGENE, V28, P2723, DOI 10.1038/onc.2009.128
   Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174
   Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gaballah K, 2008, J PATHOL, V215, P280, DOI 10.1002/path.2360
   Gemenetzidis E, 2010, CANCER RES, V70, P9515, DOI 10.1158/0008-5472.CAN-10-2173
   Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849
   Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975
   Hu S, 2008, CLIN CANCER RES, V14, P6246, DOI 10.1158/1078-0432.CCR-07-5037
   Juul N, 2010, LANCET ONCOL, V11, P358, DOI 10.1016/S1470-2045(10)70018-8
   Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004
   Kratz JR, 2012, LANCET, V379, P823, DOI 10.1016/S0140-6736(11)61941-7
   KULKARNI PS, 1995, CARCINOGENESIS, V16, P2515, DOI 10.1093/carcin/16.10.2515
   Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432
   Ledford H, 2010, NATURE, V464, P972, DOI 10.1038/464972a
   Lingen MW, 2008, ORAL ONCOL, V44, P10, DOI 10.1016/j.oraloncology.2007.06.011
   Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912
   Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994
   Mehrotra R, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-33
   Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47
   Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Priller M, 2011, CLIN CANCER RES, V17, P6791, DOI 10.1158/1078-0432.CCR-11-1214
   REISS M, 1985, JNCI-J NATL CANCER I, V74, P1015
   Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002
   RHEINWALD JG, 1981, CANCER RES, V41, P1657
   Scully C, 2008, AM J DENT, V21, P199
   Teh MT, 2002, CANCER RES, V62, P4773
   Teh MT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034329
   Teh MT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-45
   Tompkins DH, 2011, AM J RESP CELL MOL, V45, P101, DOI 10.1165/rcmb.2010-0149OC
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Warnakulasuriya S, 2007, J ORAL PATHOL MED, V36, P575, DOI 10.1111/j.1600-0714.2007.00582.x
   Waseem A, 2010, ORAL ONCOL, V46, P536, DOI 10.1016/j.oraloncology.2010.03.022
   Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159
   Woolgar JA, 2009, ORAL ONCOL, V45, P361, DOI 10.1016/j.oraloncology.2008.07.016
   Xia JT, 2012, PANCREAS, V41, P629, DOI 10.1097/MPA.0b013e31823bcef2
   Xie ZQ, 2010, NUCLEIC ACIDS RES, V38, P8027, DOI 10.1093/nar/gkq715
   Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047
   Ziober BL, 2008, HEAD NECK-J SCI SPEC, V30, P111, DOI 10.1002/hed.20680
NR 56
TC 30
Z9 35
U1 0
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 1
PY 2013
VL 132
IS 9
BP 2095
EP 2106
DI 10.1002/ijc.27886
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 092KV
UT WOS:000315121100013
PM 23034676
OA Bronze
DA 2025-01-12
ER

PT J
AU Pogribny, IP
   Tryndyak, VP
   Pogribna, M
   Shpyleva, S
   Surratt, G
   Da Costa, GG
   Beland, FA
AF Pogribny, Igor P.
   Tryndyak, Volodymyr P.
   Pogribna, Marta
   Shpyleva, Svitlana
   Surratt, Gordon
   Da Costa, Goncalo Gamboa
   Beland, Frederick A.
TI Modulation of intracellular iron metabolism by iron chelation affects
   chromatin remodeling proteins and corresponding epigenetic modifications
   in breast cancer cells and increases their sensitivity to
   chemotherapeutic agents
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE breast cancer; iron metabolism; histone modifications; DNA methylation
ID DNA-DAMAGE; HISTONE DEMETHYLATION; METHYLATION; APOPTOSIS; FAMILY;
   MECHANISMS; GROWTH; DP44MT; LSD1
AB Iron plays a vital role in the normal functioning of cells via the regulation of essential cellular metabolic reactions, including several DNA and histone-modifying proteins. The metabolic status of iron and the regulation of epigenetic mechanisms are well-balanced and tightly controlled in normal cells; however, in cancer cells these processes are profoundly disturbed. Cancer-related abnormalities in iron metabolism have been corrected through the use of iron-chelating agents, which cause an inhibition of DNA synthesis, G(1)-S phase arrest, an inhibition of epithelial-to-mesenchymal transition, and the activation of apoptosis. In the present study, we show that, in addition to these well-studied molecular mechanisms, the treatment of wild-type TP53 MCF-7 and mutant TP53 MDA-MB-231 human breast cancer cells with desferrioxamine (DFO), a model iron chelator, causes significant epigenetic alterations at the global and gene-specific levels. Specifically, DFO treatment decreased the protein levels of the histone H3 lysine 9 demethylase, Jumonji domain-containing protein 2A (JMJD2A), in the MCF-7 and MDA-MB-231 cells and down-regulated the levels of the histone H3 lysine 4 demethylase, lysine-specific demethylase 1 (LSD1), in the MDA-MB-231 cells. These changes were accompanied by alterations in corresponding metabolically sensitive histone marks. Additionally, we demonstrate that DFO treatment activates apoptotic programs in MCF-7 and MDA-MB-231 cancer cells and enhances their sensitivity to the chemotherapeutic agents, doxorubicin and cisplatin; however, the mechanisms underlying this activation differ. The induction of apoptosis in wild-type TP53 MCF-7 cells was p53-dependent, triggered mainly by the down-regulation of the JMJD2A histone demethylase, while in mutant TP53 MDA-MB-231 cells, the activation of the p53-independent apoptotic program was driven predominantly by the epigenetic up-regulation of p21.
C1 [Pogribny, Igor P.; Tryndyak, Volodymyr P.; Pogribna, Marta; Shpyleva, Svitlana; Surratt, Gordon; Da Costa, Goncalo Gamboa; Beland, Frederick A.] US FDA, Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA)
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, 3900 NCTR Rd, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
RI Shpyleva, Svitlana/KVZ-0200-2024
OI Tryndyak, Volodymyr/0000-0002-8319-2954; Beland,
   Frederick/0000-0002-2113-6260
CR Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Binda O, 2010, EPIGENETICS-US, V5, P767, DOI 10.4161/epi.5.8.13278
   Black JC, 2010, MOL CELL, V40, P736, DOI 10.1016/j.molcel.2010.11.008
   Burgio G, 2010, BBA-GENE REGUL MECH, V1799, P671, DOI 10.1016/j.bbagrm.2010.05.007
   Buss JL, 2003, CURR MED CHEM, V10, P1021, DOI 10.2174/0929867033457638
   Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   Chen ZQ, 2012, J BIOL CHEM, V287, P17016, DOI 10.1074/jbc.M112.350470
   Culhane JC, 2007, CURR OPIN CHEM BIOL, V11, P561, DOI 10.1016/j.cbpa.2007.07.014
   Escoubet-Lozach L, 2009, CANCER RES, V69, P7347, DOI 10.1158/0008-5472.CAN-08-4898
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HILETI D, 1995, BRIT J HAEMATOL, V89, P181, DOI 10.1111/j.1365-2141.1995.tb08927.x
   Hoke EM, 2005, FREE RADICAL BIO MED, V39, P403, DOI 10.1016/j.freeradbiomed.2005.03.029
   Hou HF, 2010, CURR OPIN STRUC BIOL, V20, P739, DOI 10.1016/j.sbi.2010.09.006
   Huang X, 2008, LANCET ONCOL, V9, P803, DOI 10.1016/S1470-2045(08)70200-6
   Iyer LM, 2011, PROG MOL BIOL TRANSL, V101, P25, DOI 10.1016/B978-0-12-387685-0.00002-0
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kawamoto M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-359
   Kim TD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034618
   Kim TD, 2012, J CELL BIOCHEM, V113, P1368, DOI 10.1002/jcb.24009
   Kovacevic Z, 2011, CARCINOGENESIS, V32, P732, DOI 10.1093/carcin/bgr046
   Luka Z, 2011, BIOCHEMISTRY-US, V50, P4750, DOI 10.1021/bi200247b
   Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47
   McDonough MA, 2010, CURR OPIN STRUC BIOL, V20, P659, DOI 10.1016/j.sbi.2010.08.006
   Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008-5472.CAN-11-1870
   Pan YJ, 2004, BBA-MOL CELL RES, V1691, P41, DOI 10.1016/j.bbamcr.2003.12.003
   Pinnix ZK, 2010, SCI TRANSL MED, V2, DOI [10.1126/scitranslmed.3001127, 10.1126/scisignal.3001127]
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Rao VA, 2009, CANCER RES, V69, P948, DOI 10.1158/0008-5472.CAN-08-1437
   Saletta F, 2011, J BIOL CHEM, V286, P35396, DOI 10.1074/jbc.M111.273060
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shpyleva SI, 2011, BREAST CANCER RES TR, V126, P63, DOI 10.1007/s10549-010-0849-4
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   So EY, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.9
   Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005
   Teperino R, 2010, CELL METAB, V12, P321, DOI 10.1016/j.cmet.2010.09.004
   Torti SV, 2011, CANCER RES, V71, P1511, DOI 10.1158/0008-5472.CAN-10-3614
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103
   Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Yu Y, 2012, CURR MED CHEM, V19, P2689, DOI 10.2174/092986712800609706
   Zhang JJ, 2011, ANAL BIOCHEM, V413, P164, DOI 10.1016/j.ab.2011.01.029
NR 46
TC 46
Z9 51
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAY
PY 2013
VL 42
IS 5
BP 1822
EP 1832
DI 10.3892/ijo.2013.1855
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 132FN
UT WOS:000318053400037
PM 23483119
OA Bronze
DA 2025-01-12
ER

PT J
AU Su, XW
   Wang, ZH
   Li, LL
   Zheng, MB
   Zheng, CF
   Gong, P
   Zhao, PF
   Ma, YF
   Tao, Q
   Cai, LT
AF Su, Xianwei
   Wang, Zhaohui
   Li, Lili
   Zheng, Mingbin
   Zheng, Cuifang
   Gong, Ping
   Zhao, Pengfei
   Ma, Yifan
   Tao, Qian
   Cai, Lintao
TI Lipid-Polymer Nanoparticles Encapsulating Doxorubicin and
   2′-Deoxy-5-azacytidine Enhance the Sensitivity of Cancer Cells to
   Chemical Therapeutics
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE drug delivery; chemotherapeutic drug; epigenetic drug; cancer therapy;
   combined therapy
ID TUMOR-SUPPRESSOR GENE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE;
   BREAST-CANCER; DNA METHYLTRANSFERASE; RNA INTERFERENCE; CHEMOTHERAPY;
   METHYLATION; MECHANISM; CARCINOMA
AB Nanomedcine holds great potential in cancer therapy due to its flexibility on drug delivery, protection, releasing, and targeting. Epigenetic drugs, such as 2'-deoxy-5-azacytidine (DAC), are able to cause reactive expression of tumor suppressor genes (TSG) in human cancers and, therefore, might be able to enhance the sensitivity of cancer cells to chemotherapy. In this report, we fabricated a lipid-polymer nanoparticle for codelivery of epigenetic drug DAC and traditional chemotherapeutic drug (DOX) to cancer cells and monitored the growth inhibition of the hybrid nanoparticles (NPs) on cancer cells. Our results showed that NPs encapsulating DAC, DOX, or both, could be effectively internalized by cancer cells. More importantly, incorporating DAC into NPs significantly enhanced the sensitivity of cancer cells to DOX by inhibiting cell growth rate and inducing cell apoptosis. Further evidence indicated that DAC encapsulated by NPs was able to rescue the expression of silenced TSG in cancer cells. Overall our work clearly suggested that the resulting lipid-polymer nanoparticle is a potential tool for combining epigenetic therapy and chemotherapy.
C1 [Su, Xianwei; Wang, Zhaohui; Li, Lili; Zheng, Mingbin; Zheng, Cuifang; Gong, Ping; Zhao, Pengfei; Ma, Yifan; Tao, Qian; Cai, Lintao] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen Key Lab Canc Nanotechnol, Guangdong Key Lab Nanomed,Inst Biomed & Biotechno, Shenzhen 518055, Peoples R China.
   [Zheng, Mingbin] Guangdong Med Coll, Dept Chem, Dongguan 523808, Peoples R China.
   [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong, Hong Kong, Peoples R China.
   [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Li, Lili; Tao, Qian] CUHK Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology,
   CAS; Guangdong Medical University; Chinese University of Hong Kong;
   Chinese University of Hong Kong; CUHK Shenzhen Research Institute
RP Tao, Q (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen Key Lab Canc Nanotechnol, Guangdong Key Lab Nanomed,Inst Biomed & Biotechno, Shenzhen 518055, Peoples R China.
EM qtao@clo.cuhk.edu.hk; lt.cai@siat.ac.cn
RI Zhao, Pengfei/IVH-5715-2023; Gong, Ping/J-4378-2014; Wang,
   Zhaohui/C-9795-2016; Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018
OI Zhao, Pengfei/0000-0003-2034-7696; Li, Lili/0000-0002-0292-5889; Tao,
   Qian/0000-0001-5383-4808; Cai, Lintao/0000-0002-2461-6390
FU National Natural Science Foundation of China [81071634, 81101492,
   81071249, 81171446]; Guangdong Innovation Research Team Fund for
   Low-cost Healthcare Technologies (GIRTF-LCHT); Key Project of Science
   and Technology of Guangdong [2009A030301010]; Shenzhen Science and
   Technology Program [JC20100570328A, JC201005260247A, CXB201005250029A];
   "Hundred Talents Program" of Chinese Academy of Sciences
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81071634, 81101492, 81071249, 81171446), Guangdong
   Innovation Research Team Fund for Low-cost Healthcare Technologies
   (GIRTF-LCHT), the Key Project of Science and Technology of Guangdong
   (2009A030301010), the Shenzhen Science and Technology Program (Grant No.
   JC20100570328A, JC201005260247A, CXB201005250029A) and the "Hundred
   Talents Program" of Chinese Academy of Sciences.
CR Abbasi M, 2011, PHARM RES-DORDR, V28, P2516, DOI 10.1007/s11095-011-0480-z
   Arnold CN, 2003, INT J CANCER, V106, P66, DOI 10.1002/ijc.11176
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022
   Chen AM, 2009, SMALL, V5, P2673, DOI 10.1002/smll.200900621
   Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951
   George RE, 2010, PEDIATR BLOOD CANCER, V55, P629, DOI 10.1002/pbc.22607
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaminskyy VO, 2011, CARCINOGENESIS, V32, P1450, DOI 10.1093/carcin/bgr135
   Kuendgen A, 2008, ANN HEMATOL, V87, P601, DOI 10.1007/s00277-008-0477-9
   Lage H, 2006, CURR DRUG TARGETS, V7, P813, DOI 10.2174/138945006777709566
   Lai D, 2012, BIOSCIENCE REP, V32, P361, DOI 10.1042/BSR20110125
   Li B, 2012, INT J NANOMED, V7, P187, DOI 10.2147/IJN.S27864
   LIN KT, 1981, J PHARM SCI, V70, P1228, DOI 10.1002/jps.2600701112
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Mund C, 2010, BIOESSAYS, V32, P949, DOI 10.1002/bies.201000061
   Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313
   Perez J, 2011, ANTICANCER RES, V31, P2813
   Plumb JA, 2000, CANCER RES, V60, P6039
   Qiu GH, 2008, J HEPATOL, V48, P433, DOI 10.1016/j.jhep.2007.11.015
   Reid GK, 2002, CURR OPIN MOL THER, V4, P130
   Seng TJ, 2007, ONCOGENE, V26, P934, DOI 10.1038/sj.onc.1209839
   Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794
   Shang DH, 2009, CANCER LETT, V278, P82, DOI 10.1016/j.canlet.2008.12.034
   Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c
   Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307
   Wei GL, 2008, BIOMED CHROMATOGR, V22, P1252, DOI 10.1002/bmc.1054
   Xia ZS, 2008, ONCOL REP, V20, P1433, DOI 10.3892/or_00000163
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Zhang Q, 2007, CANCER LETT, V249, P220, DOI 10.1016/j.canlet.2006.08.019
   Zheng CF, 2012, BIOMATERIALS, V33, P5603, DOI 10.1016/j.biomaterials.2012.04.044
NR 36
TC 51
Z9 57
U1 0
U2 83
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD MAY
PY 2013
VL 10
IS 5
BP 1901
EP 1909
DI 10.1021/mp300675c
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 140QI
UT WOS:000318669600038
PM 23570548
DA 2025-01-12
ER

PT J
AU Müller, BM
   Jana, L
   Kasajima, A
   Lehmann, A
   Prinzler, J
   Budczies, J
   Winzer, KJ
   Dietel, M
   Weichert, W
   Denkert, C
AF Mueller, Berit Maria
   Jana, Lisa
   Kasajima, Atsuko
   Lehmann, Annika
   Prinzler, Judith
   Budczies, Jan
   Winzer, Klaus-Juergen
   Dietel, Manfred
   Weichert, Wilko
   Denkert, Carsten
TI Differential expression of histone deacetylases HDAC1, 2 and 3 in human
   breast cancer - overexpression of HDAC2 and HDAC3 is associated with
   clinicopathological indicators of disease progression
SO BMC CANCER
LA English
DT Article
DE HDAC; Breast cancer; Immunohistochemistry
ID ESTROGEN-RECEPTOR-ALPHA; ER-ALPHA; THERAPY; CELLS; INHIBITION;
   ACTIVATION; ACID
AB Background: In breast cancer, the role of epigenetic alterations including modifications of the acetylation status of histones in carcinogenesis has been an important research focus during the last years. An increased deacetylation of histones leads to increased cell proliferation, cell migration, angiogenesis and invasion. Class 1 histone deacetylases (HDAC) seem to be most important during carcinogenesis.
   Methods: The immunhistochemical expression of HDAC1, 2 and 3 was analyzed on tissue microarrays (TMAs) from 238 patients with primary breast cancer. We analyzed the nuclear staining intensity (negative, weak, moderate, strong) as well as the percentage of positive tumor cells and calculated the immunoreactivity score (0-12). Expression was correlated with clinicopathological parameters and patient survival.
   Results: In this cohort, we found a differential positive expression of HDAC1, HDAC2 and HDAC3. HDAC2 and HDAC3 expression was significantly higher in less differentiated tumors: HDAC2 (n=207), p<0.001 and HDAC3 (n=220), p<0.001 and correlated with negative hormone receptor status: HDAC2 (n=206), p=0.02 and HDAC3 (n=219),p=0.04. Additionally, a high HDAC2 expression was significantly associated with an overexpression of HER2 (n=203, p=0.005) and the presence of nodal metastasis (n=200, p=0.04).
   HDAC1 was highly expressed in hormone receptor positive tumors (n=203; p<0.001).
   Conclusion: As a conclusion, our results show that the class-1 HDAC isoenzymes 1, 2 and 3 are differentially expressed in breast cancer. HDAC2 and HDAC3 are strongly expressed in subgroups of tumor with features of a more aggressive tumor type.
C1 [Mueller, Berit Maria; Jana, Lisa; Lehmann, Annika; Prinzler, Judith; Budczies, Jan; Dietel, Manfred; Denkert, Carsten] Charite, Inst Pathol, D-10117 Berlin, Germany.
   [Weichert, Wilko] Heidelberg Univ, Inst Pathol, Heidelberg, Germany.
   [Winzer, Klaus-Juergen] Charite, Breast Canc Ctr, D-10117 Berlin, Germany.
   [Kasajima, Atsuko] Tohoku Univ Hosp, Depat Pathol, Sendai, Miyagi 9808574, Japan.
C3 Berlin Institute of Health; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls
   University Heidelberg; Berlin Institute of Health; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Tohoku University
RP Müller, BM (通讯作者)，Charite, Inst Pathol, Campus Mitte,Charitepl 1, D-10117 Berlin, Germany.
EM berit.mueller@charite.de
RI Budczies, Jan/AAG-8122-2020; Denkert, Carsten/AHE-2675-2022
OI Lehmann, Annika/0000-0001-9424-5882; Denkert,
   Carsten/0000-0002-2249-0982; Lindner, Judith Lea/0000-0003-2223-4468;
   Budczies, Jan/0000-0002-6668-5327
CR Bali P, 2005, CLIN CANCER RES, V11, P6382, DOI 10.1158/1078-0432.CCR-05-0344
   Biçaku E, 2008, CANCER RES, V68, P1513, DOI 10.1158/0008-5472.CAN-07-2822
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Duong V, 2006, ONCOGENE, V25, P1799, DOI 10.1038/sj.onc.1209102
   Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Higgins MJ, 2011, ANNU REV MED, V62, P281, DOI 10.1146/annurev-med-070909-182545
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kurebayashi J, 2005, CANCER CHEMOTH PHARM, V56, pS39, DOI 10.1007/s00280-005-0099-z
   Linares A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/856985
   Marchion DC, 2009, MOL CANCER THER, V8, P794, DOI 10.1158/1535-7163.MCT-08-0985
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Sangha R, 2009, CURR OPIN ONCOL, V21, P116, DOI 10.1097/CCO.0b013e3283210489
   Schneider Gunter, 2011, J Gastrointest Cancer, V42, P85, DOI 10.1007/s12029-011-9257-1
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Thomas S, 2009, CANCER LETT, V280, P184, DOI 10.1016/j.canlet.2008.12.026
   Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]
   Travaglini L, 2009, INT J BIOCHEM CELL B, V41, P225, DOI 10.1016/j.biocel.2008.08.019
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 28
TC 177
Z9 198
U1 2
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 30
PY 2013
VL 13
AR 215
DI 10.1186/1471-2407-13-215
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 138FI
UT WOS:000318493800001
PM 23627572
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ding, XM
   Pan, HY
   Li, J
   Zhong, Q
   Chen, XH
   Dry, SM
   Wang, CY
AF Ding, Xiangming
   Pan, Hongya
   Li, Jiong
   Zhong, Qi
   Chen, Xiaohong
   Dry, Sarah M.
   Wang, Cun-Yu
TI Epigenetic Activation of AP1 Promotes Squamous Cell Carcinoma Metastasis
SO SCIENCE SIGNALING
LA English
DT Article
ID NF-KAPPA-B; FACTOR INHIBITS ANOIKIS; GROWTH-FACTOR; HISTONE
   DEMETHYLASES; MET ONCOGENE; TYROSINE KINASE; NECK-CANCER; HEAD;
   EXPRESSION; INVASION
AB The transcription factor AP1 (activating protein 1), a heterodimer of the JUN and FOS proteins, promotes the invasive growth and metastasis of various tumors such as squamous cell carcinoma (SCC), breast cancer, and melanoma. AP1 activity is transcriptionally induced through a positive feedback loop. We identified the histone demethylase KDM4A (lysine-specific demethylase 4A) as a key epigenetic priming factor in this positive feedback loop. KDM4A contributed to the induction of genes encoding the AP1 transcription factors and the invasive growth and metastasis of SCC. KDM4A knockdown decreased the growth factor-induced mRNA expression and protein abundance of AP1 family members, including JUN and FOSL1. Mechanistically, histone demethylation by KDM4A facilitated the binding of the AP1 complex to the promoters of JUN and FOSL1, thereby promoting the positive feedback loop that maintains activation of AP1. In a mouse model of SCC, KDM4A knockdown inhibited lymph node metastasis. Moreover, the abundance of KDM4A correlated with the abundance of JUN and FOSL1 in human SCC tissues, and KDM4A expression was increased in human lymph node metastases. Our studies provide insights into the epigenetic control of AP1 and tumor invasion and suggest that KDM4A could be an important therapeutic target for inhibiting invasive SCC growth and metastasis.
C1 [Ding, Xiangming; Pan, Hongya; Li, Jiong; Zhong, Qi; Chen, Xiaohong; Wang, Cun-Yu] Univ Calif Los Angeles, Sch Dent, Lab Mol Signaling, Div Oral Biol & Med, Los Angeles, CA 90095 USA.
   [Pan, Hongya] Shanghai Jiao Tong Univ, Shanghai Hosp 9, Dept Oral & Maxillofacial Surg, Shanghai 200011, Peoples R China.
   [Zhong, Qi; Chen, Xiaohong] Capital Univ Med Sci, Affiliated Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing 100730, Peoples R China.
   [Dry, Sarah M.; Wang, Cun-Yu] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Dry, Sarah M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.
   [Wang, Cun-Yu] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA 90095 USA.
   [Wang, Cun-Yu] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   Shanghai Jiao Tong University; Capital Medical University; UCLA Jonsson
   Comprehensive Cancer Center; University of California System; University
   of California Los Angeles; University of California System; University
   of California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California System; University of California Los Angeles
RP Wang, CY (通讯作者)，Univ Calif Los Angeles, Sch Dent, Lab Mol Signaling, Div Oral Biol & Med, Los Angeles, CA 90095 USA.
EM cunywang@ucla.edu
RI Chen, Haoda/KHT-7533-2024; Wang, Chunlei/F-3593-2012
OI ding, xiangming/0000-0003-1169-5998
FU National Institute of Dental and Craniofacial Research [R37DE13848,
   R01DE15964]; Shapiro Family Charitable Foundation
FX This work was supported by the National Institute of Dental and
   Craniofacial Research grants (R37DE13848 and R01DE15964 to C.-Y.W.) and
   the Shapiro Family Charitable Foundation.
CR Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583
   ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2
   Blumenschein GR, 2012, J CLIN ONCOL, V30, P3287, DOI 10.1200/JCO.2011.40.3774
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392
   Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L
   DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921
   Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455
   Dong G, 2001, CANCER RES, V61, P5911
   Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975
   Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Li J, 2008, NAT CELL BIOL, V10, P160, DOI 10.1038/ncb1684
   Lopez-Bergami P, 2010, NAT REV CANCER, V10, P65, DOI 10.1038/nrc2681
   Mangone FRR, 2005, INT J EXP PATHOL, V86, P205, DOI 10.1111/j.0959-9673.2005.00423.x
   Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031
   Myers JN, 2002, CLIN CANCER RES, V8, P293
   Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N
   Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379
   Qian CN, 2002, CANCER RES, V62, P589
   Rehman AO, 2009, INT J ORAL SCI, V1, P105, DOI 10.4248/IJOS.09059
   Seiwert TY, 2009, CANCER RES, V69, P3021, DOI 10.1158/0008-5472.CAN-08-2881
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Ye H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-69
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004
   Zeng QH, 2002, J BIOL CHEM, V277, P50137, DOI 10.1074/jbc.M208952200
   Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200
   Zhang L, 2010, J ORAL PATHOL MED, V39, P470, DOI 10.1111/j.1600-0714.2009.00869.x
NR 37
TC 90
Z9 98
U1 0
U2 11
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD APR 30
PY 2013
VL 6
IS 273
AR ra28
DI 10.1126/scisignal.2003884
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 136GJ
UT WOS:000318350100001
PM 23633675
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ajj, H
   Chesnel, A
   Pinel, S
   Plenat, F
   Flament, S
   Dumond, H
AF Ajj, Hussein
   Chesnel, Amand
   Pinel, Sophie
   Plenat, Francois
   Flament, Stephane
   Dumond, Helene
TI An Alkylphenol Mix Promotes Seminoma Derived Cell Proliferation through
   an ERalpha36-Mediated Mechanism
SO PLOS ONE
LA English
DT Article
ID ESTROGEN-RECEPTOR GPER; BREAST-CANCER CELLS; GERM-CELLS; DNA
   METHYLATION; BISPHENOL-A; TESTICULAR-TUMORS; EXPRESSION; NONYLPHENOL;
   RISK; RATS
AB Long chain alkylphenols are man-made compounds still present in industrial and agricultural processes. Their main use is domestic and they are widespread in household products, cleansers and cosmetics, leading to a global environmental and human contamination. These molecules are known to exert estrogen-like activities through binding to classical estrogen receptors. In vitro, they can also interact with the G-protein coupled estrogen receptor. Testicular germ cell tumor etiology and progression are proposed to be stimulated by lifelong estrogeno-mimetic exposure. We studied the transduction signaling pathways through which an alkyphenol mixture triggers testicular cancer cell proliferation in vitro and in vivo. Proliferation assays were monitored after exposure to a realistic mixture of 4-tert-octylphenol and 4-nonylphenol of either TCam-2 seminoma derived cells, NT2/D1 embryonal carcinoma cells or testis tumor in xenografted nude mice. Specific pharmacological inhibitors and gene-silencing strategies were used in TCam-2 cells in order to demonstrate that the alkylphenol mix triggers CREB-phosphorylation through a rapid, ER alpha 36-PI3kinase non genomic pathway. Microarray analysis of the mixture target genes revealed that this pathway can modulate the expression of the DNA-methyltransferase-3 (Dnmt3) gene family which is involved in DNA methylation control. Our results highlight a key role for ER alpha 36 in alkylphenol non genomic signaling in testicular germ cell tumors. Hence, ER alpha 36-dependent control of the epigenetic status opens the way for the understanding of the link between endocrine disruptor exposure and the burden of hormone sensitive cancers.
C1 [Ajj, Hussein; Chesnel, Amand; Pinel, Sophie; Plenat, Francois; Flament, Stephane; Dumond, Helene] Univ Lorraine, CNRS, Ctr Rech Automat Nancy, UMR 7039, Vandoeuvre Les Nancy, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de
   Lorraine
RP Dumond, H (通讯作者)，Univ Lorraine, CNRS, Ctr Rech Automat Nancy, UMR 7039, Vandoeuvre Les Nancy, France.
EM helene.dumond@univ-lorraine.fr
OI Dumond, Helene/0000-0002-9697-3901
FU ANSES [APR EST 08-09]; Syrian Government fellowship
FX This work was supported by ANSES (APR EST 08-09). HA is the recipient of
   a Syrian Government fellowship. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anway MD, 2008, GENOMICS, V91, P30, DOI 10.1016/j.ygeno.2007.10.002
   Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640
   Barton M, 2012, STEROIDS, V77, P935, DOI 10.1016/j.steroids.2012.04.001
   Beiki O, 2010, CANCER EPIDEM BIOMAR, V19, P1053, DOI 10.1158/1055-9965.EPI-09-1190
   Berner C, 2011, ANN NUTR METAB, V57, P183, DOI 10.1159/000321514
   Beyrouthy MJ, 2009, CANCER RES, V69, P9360, DOI 10.1158/0008-5472.CAN-09-1490
   Biswal BK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053003
   Borghese B, 2012, AM J PATHOL, V180, P1781, DOI 10.1016/j.ajpath.2012.01.009
   Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886
   Bouskine A, 2009, ENVIRON HEALTH PERSP, V117, P1053, DOI 10.1289/ehp.0800367
   Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391, DOI 10.1289/ehp.7534
   Chédin F, 2011, PROG MOL BIOL TRANSL, V101, P255, DOI 10.1016/B978-0-12-387685-0.00007-X
   Chevalier N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034672
   Cyriac Sanju, 2012, Indian J Hum Genet, V18, P119, DOI 10.4103/0971-6866.96679
   Dobrzynska MM, 2012, DRUG CHEM TOXICOL, V35, P36, DOI 10.3109/01480545.2011.586036
   Frassinetti S, 2011, ECOTOX ENVIRON SAFE, V74, P253, DOI 10.1016/j.ecoenv.2010.10.039
   Fucic A, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-S1-S8
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Hashimoto H, 2010, EPIGENOMICS-UK, V2, P657, DOI 10.2217/EPI.10.44
   Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883
   Imura M, 2006, CANCER LETT, V241, P213, DOI 10.1016/j.canlet.2005.10.010
   Kang LG, 2010, MOL ENDOCRINOL, V24, P709, DOI 10.1210/me.2009-0317
   Kilian E, 2007, ANDROLOGIA, V39, P128, DOI 10.1111/j.1439-0272.2007.00777.x
   Kristensen DG, 2012, CANCER GENET-NY, V205, P425, DOI 10.1016/j.cancergen.2012.05.003
   Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154
   Li ZY, 2012, TOXICOL IN VITRO, V26, P769, DOI 10.1016/j.tiv.2012.05.017
   Liao HF, 2012, BIOL CELL, V104, P571, DOI 10.1111/boc.201100109
   Long Fan, 2004, In Silico Biology, V4, P395
   Main KM, 2010, BEST PRACT RES CL EN, V24, P279, DOI 10.1016/j.beem.2009.10.003
   McClusky LM, 2007, TOXICOL SCI, V95, P249, DOI 10.1093/toxsci/kfl141
   Meyts ERD, 2007, ANN NY ACAD SCI, V1120, P168, DOI 10.1196/annals.1411.013
   Minami K, 2010, CLIN CANCER RES, V16, P2751, DOI 10.1158/1078-0432.CCR-09-3338
   Mizuno Y, 1993, Nihon Hinyokika Gakkai Zasshi, V84, P1211
   Müller S, 1998, ENVIRON TOXICOL PHAR, V5, P257, DOI 10.1016/S1382-6689(98)00009-X
   Okamoto K, 2012, INT J UROL, V19, P504, DOI 10.1111/j.1442-2042.2012.02986.x
   Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122
   Pupo M, 2012, ENVIRON HEALTH PERSP, V120, P1177, DOI 10.1289/ehp.1104526
   Raecker T, 2011, CHEMOSPHERE, V82, P1533, DOI 10.1016/j.chemosphere.2010.11.065
   SKAKKEBAEK NE, 1975, ACTA PATH MICRO IM A, VA 83, P127
   Skakkebæk NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972
   Sonne SB, 2009, CANCER RES, V69, P5241, DOI 10.1158/0008-5472.CAN-08-4554
   Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1
   Thomas P, 2006, J STEROID BIOCHEM, V102, P175, DOI 10.1016/j.jsbmb.2006.09.017
   Tong JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015408
   Ushida H, 2012, MOL CARCINOGEN, V51, P711, DOI 10.1002/mc.20831
   Vega Aurelie, 2012, Front Endocrinol (Lausanne), V3, P150, DOI 10.3389/fendo.2012.00150
   Wallacides A, 2012, MOL CELL ENDOCRINOL, V350, P61, DOI 10.1016/j.mce.2011.11.021
   Walton EL, 2011, EPIGENETICS-US, V6, P1373, DOI 10.4161/epi.6.11.17978
   Wang L, 2010, ONCOL REP, V23, P1109, DOI 10.3892/or_00000739
   Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289
   Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103
   Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226
   Willoughby KN, 2005, ENDOCRINE, V26, P161, DOI 10.1385/ENDO:26:2:161
   Xue Q, 2007, BIOL REPROD, V77, P681, DOI 10.1095/biolreprod.107.061804
   Yang XX, 2012, INT J MOL SCI, V13, P8364, DOI 10.3390/ijms13078364
   Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458
   Zhang XT, 2012, ONCOL REP, V27, P2057, DOI 10.3892/or.2012.1722
   Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102
NR 58
TC 33
Z9 39
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2013
VL 8
IS 4
AR e61758
DI 10.1371/journal.pone.0061758
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 131QH
UT WOS:000318008400087
PM 23626723
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, JH
   Rozek, LS
   Soliman, AS
   Sartor, MA
   Hablas, A
   Seifeldin, IA
   Colacino, JA
   Weinhouse, C
   Nahar, MS
   Dolinoy, DC
AF Kim, Jung H.
   Rozek, Laura S.
   Soliman, Amr S.
   Sartor, Maureen A.
   Hablas, Ahmed
   Seifeldin, Ibrahim A.
   Colacino, Justin A.
   Weinhouse, Caren
   Nahar, Muna S.
   Dolinoy, Dana C.
TI Bisphenol A-associated epigenomic changes in prepubescent girls: a
   cross-sectional study in Gharbiah, Egypt
SO ENVIRONMENTAL HEALTH
LA English
DT Article
DE Bead array; Bisphenol A; Egypt; Epigenetics; DNA methylation
ID COMPARATIVE TOXICOGENOMICS DATABASE; X-CHROMOSOME INACTIVATION; DNA
   METHYLATION; ENDOCRINE DISRUPTORS; DEVELOPMENTAL EXPOSURE; PRENATAL
   EXPOSURE; GENE-EXPRESSION; BREAST-CANCER; MOUSE UTERUS; NECDIN GENE
AB Background: There is now compelling evidence that epigenetic modifications link adult disease susceptibility to environmental exposures during specific life stages, including pre-pubertal development. Animal studies indicate that bisphenol A (BPA), the monomer used in epoxy resins and polycarbonate plastics, may impact health through epigenetic mechanisms, and epidemiological data associate BPA levels with metabolic disorders, behavior changes, and reproductive effects. Thus, we conducted an environmental epidemiology study of BPA exposure and CpG methylation in pre-adolescent girls from Gharbiah, Egypt hypothesizing that methylation profiles exhibit exposure-dependent trends.
   Methods: Urinary concentrations of total (free plus conjugated) species of BPA in spot samples were quantified for 60 girls aged 10 to 13. Genome-wide CpG methylation was concurrently measured in bisulfite-converted saliva DNA using the Infinium HumanMethylation27 BeadChip (N = 46). CpG sites from four candidate genes were validated via quantitative bisulfite pyrosequencing.
   Results: CpG methylation varied widely among girls, and higher urinary BPA concentrations were generally associated with less genomic methylation. Based on pathway analyses, genes exhibiting reduced methylation with increasing urinary BPA were involved in immune function, transport activity, metabolism, and caspase activity. In particular, hypomethylation of CpG targets on chromosome X was associated with higher urinary BPA. Using the Comparative Toxicogenomics Database, we identified a number of candidate genes in our sample that previously have been associated with BPA-related expression change.
   Conclusions: These data indicate that BPA may affect human health through specific epigenomic modification of genes in relevant pathways. Thus, epigenetic epidemiology holds promise for the identification of biomarkers from previous exposures and the development of epigenetic-based diagnostic strategies.
C1 [Kim, Jung H.; Rozek, Laura S.; Colacino, Justin A.; Weinhouse, Caren; Nahar, Muna S.; Dolinoy, Dana C.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
   [Rozek, Laura S.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA.
   [Soliman, Amr S.] Univ Nebraska Med Ctr, Dept Epidemiol, Omaha, NE USA.
   [Sartor, Maureen A.] Univ Michigan, Ctr Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
   [Hablas, Ahmed; Seifeldin, Ibrahim A.] Tanta Canc Ctr, Tanta, Egypt.
   [Hablas, Ahmed; Seifeldin, Ibrahim A.] Gharbiah Canc Soc, Tanta, Egypt.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Nebraska System;
   University of Nebraska Medical Center; University of Michigan System;
   University of Michigan; Egyptian Knowledge Bank (EKB); Tanta University
RP Dolinoy, DC (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
EM ddolinoy@umich.edu
RI Hablas, Ahmed/AFK-5458-2022; Sartor, Maureen/L-2902-2019
OI Weinhouse, Caren/0000-0002-1257-7267; kim, julie/0000-0001-8300-6448
FU University of Michigan NIEHS Center of excellence [P30 ES017885]; NIH
   [ES017524]; NIEHS Institutional Training Grant [T32 ES007062]; NHGRI
   Institutional Training Grant [T32 HG00040]; Cancer Epidemiology
   Education in Special Population Program Grant [R25 CA112383]; National
   Human Genome Research Institute [T32HG000040] Funding Source: NIH
   RePORTER; National Institute of Environmental Health Sciences
   [P30ES017885, T32ES007062] Funding Source: NIH RePORTER
FX This work was supported by the University of Michigan NIEHS Center of
   excellence P30 ES017885 and by NIH grant ES017524. Support for CW, JAC,
   and MSN was provided by NIEHS Institutional Training Grant T32 ES007062.
   Support for JAC was also provided by NHGRI Institutional Training Grant
   T32 HG00040. We would like to acknowledge Dr. Antonia Calafat and her
   team at the National Center for Environmental Health, Centers for
   Disease Control and Prevention, Atlanta, GA for their part in the
   analysis of BPA concentrations. We would also like to acknowledge Ms.
   Stacy Endres for her effort in part of the data collection in Egypt and
   the Cancer Epidemiology Education in Special Population Program Grant
   R25 CA112383. The authors have no conflicts of interest and declare no
   competing financial interests.
CR Anderson OS, 2012, ENVIRON MOL MUTAGEN, V53, P334, DOI 10.1002/em.21692
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Antonopoulos A, 2011, BIOCHEM SOC T, V39, P1334, DOI 10.1042/BST0391334
   Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Banister CE, 2011, EPIGENETICS-US, V6, P920, DOI 10.4161/epi.6.7.16079
   Barker DJP, 1997, ACTA PAEDIATR, V86, P178
   BARKER DJP, 1998, MOTHERS BABIES HLTH, P13
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Brody JG, 2007, CANCER-AM CANCER SOC, V109, P2627, DOI 10.1002/cncr.22656
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Chang HS, 2006, ENDOCRINOLOGY, V147, P5524, DOI 10.1210/en.2006-0987
   Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z
   Colacino JA, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-40
   Cotton AM, 2011, HUM GENET, V130, P187, DOI 10.1007/s00439-011-1007-8
   Crews D, 2012, P NATL ACAD SCI USA, V109, P9143, DOI 10.1073/pnas.1118514109
   Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773
   Daniel CW, 1987, MAMMARY GLAND DEV RE, V1
   Davis AP, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-48
   Davis AP, 2011, NUCLEIC ACIDS RES, V39, pD1067, DOI 10.1093/nar/gkq813
   Davis AP, 2009, NUCLEIC ACIDS RES, V37, pD786, DOI 10.1093/nar/gkn580
   Dey S, 2011, CANCER EPIDEMIOL, V35, P254, DOI 10.1016/j.canep.2010.09.010
   Dey S, 2010, BREAST, V19, P417, DOI 10.1016/j.breast.2010.04.005
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Elston C.W., 1998, BREAST, P1
   Gérard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828
   Ghaly I., 2008, Eastern Mediterranean Health Journal, V14, P1391
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357
   Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412
   Kang ER, 2011, EPIGENETICS-US, V6, P937, DOI 10.4161/epi.6.7.16067
   Kim JH, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-526
   Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131
   Kriegel AM, 2006, ENVIRON HEALTH PERSP, V114, P113, DOI 10.1289/ehp.8035
   Lang IA, 2008, JAMA-J AM MED ASSOC, V300, P1303, DOI 10.1001/jama.300.11.1303
   Li SF, 1997, CANCER RES, V57, P4356
   Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147
   Maffini MV, 2006, MOL CELL ENDOCRINOL, V254, P179, DOI 10.1016/j.mce.2006.04.033
   Mcnally S, 2011, ANN MED, V43, P212, DOI 10.3109/07853890.2011.554425
   Moriyama K, 2002, J CLIN ENDOCR METAB, V87, P5185, DOI 10.1210/jc.2002-020209
   Naciff JM, 2010, TOXICOLOGY, V270, P137, DOI 10.1016/j.tox.2010.02.008
   Naderi A, 2007, CANCER RES, V67, P6725, DOI 10.1158/0008-5472.CAN-06-4394
   Nahar MS, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-20
   Nilsson E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036129
   Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Russo J., 1987, The mammary gland. Development, regulation, and function., P67
   Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011
   Sartor MA, 2011, EPIGENETICS-US, V6, P777, DOI 10.4161/epi.6.6.16216
   Sartor MA, 2009, BIOINFORMATICS, V25, P211, DOI 10.1093/bioinformatics/btn592
   Schairer C, 2013, CANCER MED-US, V2, P178, DOI 10.1002/cam4.48
   Soliman AS, 2012, CANCER MED-US, V1, P338, DOI 10.1002/cam4.36
   Sparrow LG, 2008, PROTEINS, V71, P426, DOI 10.1002/prot.21768
   Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Thayer KA, 2012, ENVIRON HEALTH PERSP, V120, P779, DOI 10.1289/ehp.1104597
   Thirlwell C, 2010, METHODS, V52, P248, DOI 10.1016/j.ymeth.2010.04.012
   Tobi EW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037933
   Trasande L, 2012, JAMA-J AM MED ASSOC, V308, P1113, DOI 10.1001/2012.jama.11461
   vom Saal FS, 2008, JAMA-J AM MED ASSOC, V300, P1353, DOI 10.1001/jama.300.11.1353
   Waterland RA, 2006, HUM MOL GENET, V15, P705, DOI 10.1093/hmg/ddi484
   Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9
   Wojtyla A, 2011, ANN AGR ENV MED, V18, P355
   Woodruff TJ, 2011, ENVIRON HEALTH PERSP, V119, P878, DOI 10.1289/ehp.1002727
   Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028
   Ye XY, 2005, ANAL BIOANAL CHEM, V383, P638, DOI 10.1007/s00216-005-0019-4
   Yoshino S, 2004, IMMUNOLOGY, V112, P489, DOI 10.1111/j.1365-2567.2004.01900.x
   Zoeller RT, 2005, ENDOCRINOLOGY, V146, P607, DOI 10.1210/en.2004-1018
NR 71
TC 53
Z9 55
U1 0
U2 37
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-069X
J9 ENVIRON HEALTH-GLOB
JI Environ. Health
PD APR 16
PY 2013
VL 12
AR 33
DI 10.1186/1476-069X-12-33
PG 15
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 146UX
UT WOS:000319120400001
PM 23590724
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Perry, AS
   O'Hurley, G
   Raheem, OA
   Brennan, K
   Wong, S
   O'Grady, A
   Kennedy, AM
   Marignol, L
   Murphy, TM
   Sullivan, L
   Barrett, C
   Loftus, B
   Thornhill, J
   Hewitt, SM
   Lawler, M
   Kay, E
   Lynch, T
   Hollywood, D
AF Perry, Antoinette S.
   O'Hurley, Gillian
   Raheem, Omer A.
   Brennan, Kevin
   Wong, Simon
   O'Grady, Anthony
   Kennedy, Anne-Marie
   Marignol, Laure
   Murphy, Therese M.
   Sullivan, Linda
   Barrett, Ciara
   Loftus, Barbara
   Thornhill, John
   Hewitt, Stephen M.
   Lawler, Mark
   Kay, Elaine
   Lynch, Thomas
   Hollywood, Donal
TI Gene expression and epigenetic discovery screen reveal methylation of
   SFRP2 in prostate cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE SFRP2; prostate cancer; hypermethylation; Wnt signaling
ID PROTEIN-KINASE CK2; ANDROGEN RECEPTOR; WNT-ANTAGONIST; DNA METHYLATION;
   NEGATIVE REGULATOR; TUMOR PROGRESSION; BREAST-CANCER; BETA-CATENIN;
   CELL-GROWTH; FAMILY
AB Aberrant activation of Wnts is common in human cancers, including prostate. Hypermethylation associated transcriptional silencing of Wnt antagonist genes SFRPs (Secreted Frizzled-Related Proteins) is a frequent oncogenic event. The significance of this is not known in prostate cancer. The objectives of our study were to (i) profile Wnt signaling related gene expression and (ii) investigate methylation of Wnt antagonist genes in prostate cancer. Using TaqMan Low Density Arrays, we identified 15 Wnt signaling related genes with significantly altered expression in prostate cancer; the majority of which were upregulated in tumors. Notably, histologically benign tissue from men with prostate cancer appeared more similar to tumor (r = 0.76) than to benign prostatic hyperplasia (BPH; r = 0.57, p < 0.001). Overall, the expression profile was highly similar between tumors of high ( 7) and low ( 6) Gleason scores. Pharmacological demethylation of PC-3 cells with 5-Aza-CdR reactivated 39 genes ( 2-fold); 40% of which inhibit Wnt signaling. Methylation frequencies in prostate cancer were 10% (2/20) (SFRP1), 64.86% (48/74) (SFRP2), 0% (0/20) (SFRP4) and 60% (12/20) (SFRP5). SFRP2 methylation was detected at significantly lower frequencies in high-grade prostatic intraepithelial neoplasia (HGPIN; 30%, (6/20), p = 0.0096), tumor adjacent benign areas (8.82%, (7/69), p < 0.0001) and BPH (11.43% (4/35), p < 0.0001). The quantitative level of SFRP2 methylation (normalized index of methylation) was also significantly higher in tumors (116) than in the other samples (HGPIN = 7.45, HB = 0.47, and BPH = 0.12). We show that SFRP2 hypermethylation is a common event in prostate cancer. SFRP2 methylation in combination with other epigenetic markers may be a useful biomarker of prostate cancer.
C1 [Perry, Antoinette S.; Brennan, Kevin; Kennedy, Anne-Marie; Marignol, Laure; Murphy, Therese M.; Sullivan, Linda; Lawler, Mark; Hollywood, Donal] Trinity Coll Dublin, Inst Mol Med, Dept Clin Med, Dublin, Ireland.
   [O'Hurley, Gillian; O'Grady, Anthony; Kay, Elaine] RCSI ERC Beaumont Hosp, Dept Pathol, Dublin, Ireland.
   [Raheem, Omer A.; Lynch, Thomas] St James Hosp, Dept Urol, Dublin 8, Ireland.
   [Wong, Simon] Irish Ctr High End Comp, Dublin, Ireland.
   [Barrett, Ciara] St James Hosp, Dept Histopathol, Dublin 8, Ireland.
   [Loftus, Barbara] Adelaide & Meath Inc Natl Childrens Hosp, Dept Lab Med, Dublin, Ireland.
   [Thornhill, John] Adelaide & Meath Inc Natl Childrens Hosp, Dept Urol, Dublin, Ireland.
   [Hewitt, Stephen M.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 Trinity College Dublin; Royal College of Surgeons - Ireland; Trinity
   College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity
   College Dublin; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI)
RP Perry, AS (通讯作者)，St James Hosp, Trinity Ctr Hlth Sci, Inst Mol Med, Dublin 8, Ireland.
EM aperry@tcd.ie
RI Kay, Elaine/D-8539-2013; Marignol, Laure/AAE-1407-2020; Murphy,
   Therese/C-7481-2014
OI Perry, Antoinette/0000-0002-6108-512X; Lawler, Mark/0000-0002-3930-8470;
   Marignol, Laure/0000-0002-2680-6200; Hewitt,
   Stephen/0000-0001-8283-1788; Murphy, Therese/0000-0002-7647-2798
FU Irish Cancer Society; Prostate Cancer Foundation
FX Grant sponsors: the Irish Cancer Society, the Prostate Cancer Foundation
CR Barrett T, 2011, NUCLEIC ACIDS RES, V39, pD1005, DOI 10.1093/nar/gkq1184
   Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008-5472.CAN-07-6541
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004
   Garnis C, 2005, HUM MOL GENET, V14, P475, DOI 10.1093/hmg/ddi043
   Goetz C, 2007, PROSTATE, V67, P125, DOI 10.1002/pros.20471
   Hayward SW, 1997, BRIT J UROL, V79, P18, DOI 10.1111/j.1464-410X.1997.tb16917.x
   Henrique R, 2006, MOL CANCER RES, V4, P1, DOI 10.1158/1541-7786.MCR-05-0113
   Horvath LG, 2007, PROSTATE, V67, P1081, DOI 10.1002/pros.20607
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002
   Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824
   Kawakami K, 2011, INT J CANCER, V128, P541, DOI 10.1002/ijc.25357
   Kawamoto K, 2008, INT J CANCER, V123, P535, DOI 10.1002/ijc.23514
   Kawano Y, 2009, BRIT J CANCER, V100, P1165, DOI 10.1038/sj.bjc.6604976
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32
   Laramas M, 2007, EUR J CANCER, V43, P928, DOI 10.1016/j.ejca.2006.11.021
   Lavergne E, 2011, ONCOGENE, V30, P423, DOI 10.1038/onc.2010.432
   Li YR, 2009, CANCER RES, V69, P3332, DOI 10.1158/0008-5472.CAN-08-3380
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603
   Mehrotra J, 2008, PROSTATE, V68, P152, DOI 10.1002/pros.20675
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Nonn L, 2009, PROSTATE, V69, P1470, DOI 10.1002/pros.20983
   O'Hurley G, 2011, HISTOPATHOLOGY, V59, P1240, DOI 10.1111/j.1365-2559.2011.04073.x
   Olumi AF, 1999, CANCER RES, V59, P5002
   Perry AS, 2007, BRIT J CANCER, V96, P1587, DOI 10.1038/sj.bjc.6603767
   Perry AS, 2006, ENDOCR-RELAT CANCER, V13, P357, DOI 10.1677/erc.1.01184
   Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185
   R Core Team, 2019, R Found. Stat. Comput.
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Tabesh A, 2007, IEEE T MED IMAGING, V26, P1366, DOI 10.1109/TMI.2007.898536
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Wang BE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002186
   Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718
   Wang GX, 2008, MOL CELL BIOCHEM, V316, P91, DOI 10.1007/s11010-008-9810-9
   Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200
   Wei Q, 2008, LUNG CANCER, V62, P181, DOI 10.1016/j.lungcan.2008.06.018
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103
NR 49
TC 37
Z9 45
U1 1
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2013
VL 132
IS 8
BP 1771
EP 1780
DI 10.1002/ijc.27798
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 090OE
UT WOS:000314987800006
PM 22915211
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Ding, XM
   Park, SI
   McCauley, LK
   Wang, CY
AF Ding, Xiangming
   Park, Serk In
   McCauley, Laurie K.
   Wang, Cun-Yu
TI Signaling between Transforming Growth Factor β (TGF-β) and Transcription
   Factor SNAI2 Represses Expression of MicroRNA miR-203 to Promote
   Epithelial-Mesenchymal Transition and Tumor Metastasis
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER CELLS; E-CADHERIN; ZEB1; FAMILY; SLUG; CARCINOMA;
   INVASION; PHENOTYPE; MIGRATION; PROFILES
AB TGF-beta promotes tumor invasion and metastasis by inducing an epithelial-mesenchymal transition (EMT). Understanding the molecular and epigenetic mechanisms by which TGF-beta induces EMT may facilitate the development of new therapeutic strategies for metastasis. Here, we report that TGF-beta induced SNAI2 to promote EMT by repressing miR-203. Although miR-203 targeted SNAI2, SNAI2 induced by TGF-beta could directly bind to the miR-203 promoter to inhibit its transcription. SNAI2 and miR-203 formed a double negative feedback loop to inhibit each other's expression, thereby controlling EMT. Moreover, we found that miR-203 was significantly down-regulated in highly metastatic breast cancer cells. The restoration of miR-203 in highly metastatic breast cancer cells inhibited tumor cell invasion in vitro and lung metastatic colonization in vivo by repressing SNAI2. Taken together, our results suggest that the SNAI2 and miR-203 regulatory loop plays important roles in EMT and tumor metastasis.
C1 [Ding, Xiangming; Wang, Cun-Yu] Univ Calif Los Angeles, Sch Dent, Lab Mol Signaling, Div Oral Biol & Med, Los Angeles, CA 90095 USA.
   [Ding, Xiangming; Wang, Cun-Yu] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Ding, Xiangming; Wang, Cun-Yu] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA.
   [Park, Serk In; McCauley, Laurie K.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Park, Serk In; McCauley, Laurie K.] Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   UCLA Jonsson Comprehensive Cancer Center; University of California
   System; University of California Los Angeles; University of Michigan
   System; University of Michigan; University of Michigan System;
   University of Michigan
RP Wang, CY (通讯作者)，Univ Calif Los Angeles, Sch Dent, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM cunywang@ucla.edu
RI Wang, Chunlei/F-3593-2012; McCauley, Laurie/G-4041-2012; Park, Serk
   In/D-2840-2011
OI Park, Serk In/0000-0001-8643-5096; ding, xiangming/0000-0003-1169-5998
FU National Institutes of Health from the NIDCR [R01 CA132134, R37
   DE013848, R01 DE15964]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants R01 CA132134 and R37 DE013848 and R01 DE15964 from the
   NIDCR (to C.-Y.W.).
CR Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102
   Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200
   Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699
   Hajra KM, 2002, CANCER RES, V62, P1613
   Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108
   Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010
   Moes M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035440
   Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pérez-Caro M, 2008, BRIT J CANCER, V98, P480, DOI 10.1038/sj.bjc.6604084
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   Ramadoss S, 2011, MOL CELL BIOL, V31, P924, DOI 10.1128/MCB.00576-10
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619
   Shalgi R, 2009, AGING-US, V1, P762, DOI 10.18632/aging.100085
   Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650
   Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687
   Takeshita N, 2012, INT J ONCOL, V41, P1653, DOI 10.3892/ijo.2012.1614
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Volinia S, 2010, GENOME RES, V20, P589, DOI 10.1101/gr.098046.109
   Wang C, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-58
   Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408
   Wels C, 2011, J INVEST DERMATOL, V131, P1877, DOI 10.1038/jid.2011.142
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
NR 48
TC 148
Z9 164
U1 0
U2 21
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 12
PY 2013
VL 288
IS 15
BP 10241
EP 10253
DI 10.1074/jbc.M112.443655
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 125TU
UT WOS:000317565000006
PM 23447531
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Santos, EMM
   Edwards, QT
   Floria-Santos, M
   Rogatto, SR
   Achatz, MIW
   MacDonald, DJ
AF Monteiro Santos, Erika Maria
   Edwards, Quannetta T.
   Floria-Santos, Milena
   Rogatto, Silvia Regina
   Waddington Achatz, Maria Isabel
   MacDonald, Deborah J.
TI Integration of Genomics in Cancer Care
SO JOURNAL OF NURSING SCHOLARSHIP
LA English
DT Article
DE Genetics; genomics; cancer; risk assessment
ID BREAST-CANCER; MICROSATELLITE INSTABILITY; LYNCH-SYNDROME; PERSONALIZED
   MEDICINE; EXPRESSION PROFILES; SUSCEPTIBILITY LOCI; RISK;
   IMMUNOHISTOCHEMISTRY; POLYMORPHISMS; GENETICS
AB Purpose: The article aims to introduce nurses to how genetics-genomics is currently integrated into cancer care from prevention to treatment and influencing oncology nursing practice. Organizing Construct: An overview of genetics-genomics is described as it relates to cancer etiology, hereditary cancer syndromes, epigenetics factors, and management of care considerations. Methods: Peer-reviewed literature and expert professional guidelines were reviewed to address concepts of genetics-genomics in cancer care. Findings: Cancer is now known to be heterogeneous at the molecular level, with genetic and genomic factors underlying the etiology of all cancers. Understanding how these factors contribute to the development and treatment of both sporadic and hereditary cancers is important in cancer risk assessment, prevention, diagnosis, treatment, and long-term management and surveillance. Conclusions: Rapidly developing advances in genetics-genomics are changing all aspects of cancer care, with implications for nursing practice. Clinical Relevance: Nurses can educate cancer patients and their families about genetic-genomic advances and advocate for use of evidence-based genetic-genomic practice guidelines to reduce cancer risk and improve outcomes in cancer management.
C1 [Monteiro Santos, Erika Maria; Waddington Achatz, Maria Isabel] Hosp AC Camargo Fund Antonio Prudente, CIPE Ctr Res & Teaching, Sao Paulo, Brazil.
   [Monteiro Santos, Erika Maria] Natl Inst Oncogen, Sao Paulo, Brazil.
   [Edwards, Quannetta T.] Western Univ Hlth Sci, Pomona, CA USA.
   [Floria-Santos, Milena] Univ Sao Paulo Ribeirao Preto, Coll Nursing, WHO Collaborating Ctr Dev Nursing Res, Dept Maternal Child Nursing & Publ Hlth, Sao Paulo, Brazil.
   [Rogatto, Silvia Regina] Sao Paulo State Univ, Univ Estadual Paulista UNESP, Coll Med, Botucatu, SP, Brazil.
   [Waddington Achatz, Maria Isabel] Hosp AC Camargo Fund Antonio Prudente, Oncogenet Dept, Sao Paulo, Brazil.
   [MacDonald, Deborah J.] City Hope Comprehens Canc Ctr, Div Clin Canc Genet, Duarte, CA USA.
C3 A.C.Camargo Cancer Center; Western University of Health Sciences;
   Universidade de Sao Paulo; Universidade Estadual Paulista; A.C.Camargo
   Cancer Center; City of Hope
RP MacDonald, DJ (通讯作者)，City Hope Natl Med Ctr, Div Clin Canc Genet, Dept Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM deborahmac@outlook.com
RI Flória, Milena/E-3319-2013; Rogatto, Silvia/E-6535-2012; Achatz, Maria
   Isabel/C-5751-2013; , Erika/H-1654-2012
OI Achatz, Maria Isabel/0000-0001-6894-1219; , Erika/0000-0002-7315-9843;
   /0000-0002-0656-1736; Rogatto, Silvia/0000-0003-4637-5687
CR Aiello-Laws Lisa, 2011, Semin Oncol Nurs, V27, P13, DOI 10.1016/j.soncn.2010.11.003
   Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127
   [Anonymous], 2012, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer
   Badzek L, 2013, J NURS SCHOLARSHIP, V45, P15, DOI 10.1111/jnu.12000
   Beamer LC, 2012, J CLIN ONCOL, V30, P1058, DOI 10.1200/JCO.2011.38.4719
   Boland CR, 2008, FAM CANCER, V7, P41, DOI 10.1007/s10689-007-9145-9
   Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189
   Cleator S, 2004, BRIT J CANCER, V90, P1120, DOI 10.1038/sj.bjc.6601667
   Dacic S, 2011, ARCH PATHOL LAB MED, V135, P535, DOI 10.1043/2011-0017-EDI.1
   Dancey JE, 2012, CELL, V148, P409, DOI 10.1016/j.cell.2012.01.014
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   de Matos LL, 2010, BIOMARK INSIGHTS, V5, P9
   Diamandis M, 2010, MOL CANCER RES, V8, P1175, DOI 10.1158/1541-7786.MCR-10-0264
   Fletcher O, 2010, NAT REV CANCER, V10, P353, DOI 10.1038/nrc2840
   Gallagher DJ, 2010, CLIN CANCER RES, V16, P2819, DOI 10.1158/1078-0432.CCR-10-0028
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913
   Jain SJ, 2004, CANCER RES, V64, P3907, DOI 10.1158/0008-5472.CAN-03-3801
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kiyotani K, 2010, J CLIN ONCOL, V28, P1287, DOI 10.1200/JCO.2009.25.7246
   Kohlmann Wendy., 2004, GeneReviews
   Krepischi ACV, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3109
   MacDonald Deborah J, 2011, Semin Oncol Nurs, V27, P21, DOI 10.1016/j.soncn.2010.11.004
   Maradiegue A, 2008, J AM ACAD NURSE PRAC, V20, P76, DOI 10.1111/j.1745-7599.2007.00282.x
   Marrs J, 2009, CLIN J ONCOL NURS, V13, P564, DOI 10.1188/09.CJON.564-572
   Mehta R, 2011, CLIN BREAST CANCER, V11, P20, DOI 10.3816/CBC.2011.n.004
   National Cancer Institute, PERS MED DICT CANC T
   Newman B, 2012, LYMPHAT RES BIOL, V10, P2, DOI 10.1089/lrb.2011.0024
   Ng K, 2010, J CLIN ONCOL, V28, P3207, DOI 10.1200/JCO.2010.28.9314
   O'Donnell PH, 2012, MOL ONCOL, V6, P251, DOI 10.1016/j.molonc.2012.01.005
   Pasche B, 2011, JAMA-J AM MED ASSOC, V305, P1596, DOI 10.1001/jama.2011.484
   Prows Cynthia A, 2011, Semin Oncol Nurs, V27, P45, DOI 10.1016/j.soncn.2010.11.006
   Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133
   Olivieri EHR, 2009, ORAL ONCOL, V45, pE73, DOI 10.1016/j.oraloncology.2009.03.004
   Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825
   Schroth W, 2007, J CLIN ONCOL, V25, P5187, DOI 10.1200/JCO.2007.12.2705
   Schwartz GF, 2008, CANCER, V113, P2627, DOI 10.1002/cncr.23903
   Speicher MR, 2010, LANCET ONCOL, V11, P890, DOI 10.1016/S1470-2045(09)70359-6
   Walsh CS, 2010, GYNECOL ONCOL, V116, P516, DOI 10.1016/j.ygyno.2009.11.021
   Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600
   Weitzel JN, 2011, CA-CANCER J CLIN, V61, P327, DOI 10.3322/caac.20128
NR 41
TC 18
Z9 24
U1 3
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6546
EI 1547-5069
J9 J NURS SCHOLARSHIP
JI J. Nurs. Scholarsh.
PD MAR
PY 2013
VL 45
IS 1
BP 43
EP 51
DI 10.1111/j.1547-5069.2012.01465.x
PG 9
WC Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Nursing
GA 099RV
UT WOS:000315639800007
PM 23294839
OA Bronze
DA 2025-01-12
ER

PT J
AU Wang, JB
   Lan, X
   Hsu, PY
   Hsu, HK
   Huang, K
   Parvin, J
   Huang, THM
   Jin, VX
AF Wang, Junbai
   Lan, Xun
   Hsu, Pei-Yin
   Hsu, Hang-Kai
   Huang, Kun
   Parvin, Jeffrey
   Huang, Tim H-M
   Jin, Victor X.
TI Genome-wide analysis uncovers high frequency, strong differential
   chromosomal interactions and their associated epigenetic patterns in
   E2-mediated gene regulation
SO BMC GENOMICS
LA English
DT Article
ID BREAST-CANCER; CHIP-SEQ; CHROMATIN; ALPHA; BINDING; ACETYLATION;
   ELEMENTS; MODEL; MARKS
AB Background: An emerging Hi-C protocol has the ability to probe three-dimensional (3D) architecture and capture chromatin interactions in a genome-wide scale. It provides informative results to address how chromatin organization changes contribute to disease/tumor occurrence and progression in response to stimulation of environmental chemicals or hormones.
   Results: In this study, using MCF7 cells as a model system, we found estrogen stimulation significantly impact chromatin interactions, leading to alteration of gene regulation and the associated histone modification states. Many chromosomal interaction regions at different levels of interaction frequency were identified. In particular, the top 10 hot regions with the highest interaction frequency are enriched with breast cancer specific genes. Furthermore, four types of E2-mediated strong differential (gain- or loss-) chromosomal (intra- or inter-) interactions were classified, in which the number of gain-chromosomal interactions is less than the number of loss-chromosomal interactions upon E2 stimulation. Finally, by integrating with eight histone modification marks, DNA methylation, regulatory elements regions, ER alpha and Pol-II binding activities, associations between epigenetic patterns and high chromosomal interaction frequency were revealed in E2-mediated gene regulation.
   Conclusions: The work provides insight into the effect of chromatin interaction on E2/ER alpha regulated downstream genes in breast cancer cells.
C1 [Wang, Junbai] Norwegian Radium Hosp, Dept Pathol, Oslo Univ Hosp, N-0310 Oslo, Norway.
   [Lan, Xun; Huang, Kun; Parvin, Jeffrey; Jin, Victor X.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA.
   [Hsu, Pei-Yin; Hsu, Hang-Kai; Huang, Tim H-M] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.
C3 University of Oslo; University System of Ohio; Ohio State University;
   University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Wang, JB (通讯作者)，Norwegian Radium Hosp, Dept Pathol, Oslo Univ Hosp, N-0310 Oslo, Norway.
EM junbai.wang@rr-research.no; Victor.Jin@osumc.edu
RI wang, junbai/B-2093-2008; Huang, Kun/E-3272-2011; Parvin,
   Jeffrey/C-8955-2009
OI Lan, Xun/0000-0002-6523-046X
FU Norwegian Cancer Society [DNK 2192630-2012-33376]; NOTUR project
   [nn4605k]; Ohio Cancer Research Associate; Department of Biomedical
   Informatics, The Ohio State University
FX JW is supported by Norwegian Cancer Society (DNK 2192630-2012-33376) and
   NOTUR project (nn4605k). VXJ is supported by Ohio Cancer Research
   Associate and Department of Biomedical Informatics, The Ohio State
   University.
CR Baù D, 2011, NAT STRUCT MOL BIOL, V18, P107, DOI 10.1038/nsmb.1936
   Botta M, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.79
   Chen Z, 2011, EMBO J, V30, P2405, DOI 10.1038/emboj.2011.154
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   de Laat W, 2012, METHODS, V58, P189, DOI 10.1016/j.ymeth.2012.11.005
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gheldof N, 2010, NUCLEIC ACIDS RES, V38, P4325, DOI 10.1093/nar/gkq175
   Herz HM, 2009, DEV CELL, V17, P301, DOI 10.1016/j.devcel.2009.08.014
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Kutanzi KR, 2010, CELL CYCLE, V9, P3078, DOI 10.4161/cc.9.15.12516
   Lan X, 2012, NUCLEIC ACIDS RES, V40, P7690, DOI 10.1093/nar/gks501
   Lan X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022226
   Lan X, 2011, BIOINFORMATICS, V27, P428, DOI 10.1093/bioinformatics/btq669
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Rodriguez BAT, 2011, CARCINOGENESIS, V32, P812, DOI 10.1093/carcin/bgr017
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Stein T, 2010, AM J PATHOL, V177, P2323, DOI 10.2353/ajpath.2010.100209
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   van Steensel B, 2010, NAT BIOTECHNOL, V28, P1089, DOI 10.1038/nbt.1680
   Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020
   Wang JB, 2002, BIOINFORMATICS, V18, P1139, DOI 10.1093/bioinformatics/18.8.1139
   Wang JB, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-172
   Wang JB, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-36
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Wu DY, 2011, TRENDS ENDOCRIN MET, V22, P474, DOI 10.1016/j.tem.2011.07.006
   Zhang Y, 2012, CELL, V148, P908, DOI 10.1016/j.cell.2012.02.002
NR 34
TC 27
Z9 34
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD JAN 31
PY 2013
VL 14
AR 70
DI 10.1186/1471-2164-14-70
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 107GJ
UT WOS:000316202800001
PM 23368971
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lu, S
   Labhasetwar, V
AF Lu, Shan
   Labhasetwar, Vinod
TI Drug-resistant breast cancer cell line displays cancer stem cell
   phenotype and responds sensitively to epigenetic drug SAHA
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Article
DE Drug resistance; Breast cancer stem cell; Surface markers; Epithelial
   mesenchymal transition; Epigenetic therapy; Cancer therapy
ID TUMOR-GROWTH; CD44(+)/CD24(-/LOW); IDENTIFICATION; CARCINOMA
AB Cancer stem cell (CSC) population in solid human breast tumor is identified by CD44(+)/CD24(-) phenotype, characterized by high tumorigenicity, invasiveness, and drug resistance. In this study, we characterized drug-resistant breast cancer cell line-MCF-7/Adr and a number of other breast cancer cell lines using flow cytometry, immunofluorescence, mammosphere formation assay, and migration assay, examining their CSC immunophenotypes, presence of CSC proteins, tumorigenicity in vitro, and migratory rates, respectively. Our results show that MCF-7/Adr cells uniformly display CSC characteristics yet retain low migratory rate. They are also able to self-renew and differentiate under floating culture conditions. Furthermore, MCF-7/Adr is selectively sensitive to epigenetic drug, suberoylanilide hydroxamic acid, losing drug resistance and changes morphology yet retaining CSC immunophenotypes. In conclusion, we show that resistant breast cancer cell line MCF-7/Adr demonstrates uniform CSC-like characteristics and are sensitive to epigenetic drug treatment.
C1 [Lu, Shan; Labhasetwar, Vinod] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA.
   [Lu, Shan] Univ Akron, Integrated Biosci Program, Akron, OH 44325 USA.
   [Labhasetwar, Vinod] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA.
   [Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; University System of Ohio; University of
   Akron; Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Labhasetwar, V (通讯作者)，Cleveland Clin, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
RI Labhasetwar, Vinod/J-9660-2016
FU National Cancer Institute of the National Institutes of Health [R01
   CA149359-03]
FX This study was funded by grant R01 CA149359-03 (to VL) from the National
   Cancer Institute of the National Institutes of Health.
CR Abraham BK, 2005, CLIN CANCER RES, V11, P1154
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   An ZH, 2010, CANCER LETT, V292, P215, DOI 10.1016/j.canlet.2009.12.006
   Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Bauerschmitz GJ, 2008, CANCER RES, V68, P5533, DOI 10.1158/0008-5472.CAN-07-5288
   Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202
   Chuthapisith S, 2010, SURG ONCOL, V19, P27, DOI 10.1016/j.suronc.2009.01.004
   Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100
   Dick JE, 2003, NATURE, V423, P231, DOI 10.1038/423231a
   Dontu G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2130
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   GRIFFIN JD, 1986, BLOOD, V68, P1185
   Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y
   Hill RP, 2007, JNCI-J NATL CANCER I, V99, P1435, DOI 10.1093/jnci/djm136
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Iseri ÖD, 2011, BIOMED PHARMACOTHER, V65, P40, DOI 10.1016/j.biopha.2010.10.004
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596
   Li WD, 2010, PATHOL RES PRACT, V206, P828, DOI 10.1016/j.prp.2010.09.008
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   MCCULLOCH EA, 1983, BLOOD, V62, P1
   Morrison BJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2111
   Mylona E, 2008, HUM PATHOL, V39, P1096, DOI 10.1016/j.humpath.2007.12.003
   Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754
   Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Snyder EL, 2009, LAB INVEST, V89, P857, DOI 10.1038/labinvest.2009.54
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
NR 32
TC 19
Z9 24
U1 1
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD APR
PY 2013
VL 3
IS 2
BP 183
EP 194
DI 10.1007/s13346-012-0113-z
PG 12
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA V39QB
UT WOS:000209424400007
PM 23543868
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Mitchell, NE
   Wilson, ML
   Bray, MS
   Crossman, DK
   Tollefsbol, TO
AF Mitchell, Natalie E.
   Wilson, MacKenzie L.
   Bray, Molly S.
   Crossman, David K.
   Tollefsbol, Trygve O.
TI Real-time methylomic aberrations during initiation and progression of
   induced human mammary epithelial cell tumorigenesis
SO EPIGENOMICS
LA English
DT Article
DE breast cancer; DNA methylation; epigenetics; Illumina Infinium
   HumanMethylation27 BeadChip; neoplastic reprogramming
ID GENOME-WIDE ANALYSIS; DNA METHYLATION; LUNG-CANCER; GENE;
   HYPERMETHYLATION; POLYCOMB; IMMUNOPRECIPITATION; INACTIVATION; SIGNATURE
AB Aim: Neoplastic transformation provides one of the few existing opportunities to analyze molecular changes in real time during the initiation and progression of breast cancer. Materials & methods: Human mammary epithelial cells underwent neoplastic reprogramming, generating one line of semitransformed, premalignant cells and two separate, temporal lines of fully transformed human mammary epithelial cells (THMECs). An Illumina Infinium HumanMethylation27 BeadChip was used to analyze DNA methylation alterations in 27,578 CpG loci at three consecutive time points over an 80-day (d) transformation period. Results: The mean b value for semitransformed human mammary epithelial cells CpG loci (0.245) was much greater than for either THMEC-40d (0.055) or THMEC-80d (0.066), indicating a large loss of methylation after neoplastic induction. In addition, 54% of CpG loci were hypermethylated during the THMEC-40d to THMEC-80d transition. We observed that the CpG loci exhibiting DNA methylation changes during early oncogenesis were enriched for biological functions like cellular movement; this was distinctly different than in the later, more progressive stages of the transformation process enriched for processes involving differentiation. Conclusion: The timing of major methylomic changes may be important in directing the cell toward a more cancerous phenotype. In addition, gene-specific hypermethylation appears to silence developmentally related genes, leading to dedifferentiation.
C1 [Mitchell, Natalie E.; Wilson, MacKenzie L.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Bray, Molly S.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Crossman, David K.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，Univ Alabama Birmingham, Dept Biol, 1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
OI Crossman, David/0000-0002-0981-169X
FU American Institute for Cancer Research; National Institutes of Health
   [CA 129415]; UAB Comprehensive Cancer Center Heflin Center for Genomic
   Sciences Genomics Core [P30-CA013148]
FX This work was funded by grants to TO Tollefsbol from the American
   Institute for Cancer Research and the National Institutes of Health (CA
   129415). The authors acknowledge the support of the UAB Comprehensive
   Cancer Center (P30-CA013148) Heflin Center for Genomic Sciences Genomics
   Core and its personnel for assisting with all portions of the Illumina
   Infinium HumanMethylation27 BeadChip experiments. The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356
   Anderson RM, 2009, DEV BIOL, V334, P213, DOI 10.1016/j.ydbio.2009.07.017
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X
   DeAngelis JT, 2011, J PROTEOME RES, V10, P447, DOI 10.1021/pr100533k
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Hanna CW, 2012, HUM REPROD, V27, P1401, DOI 10.1093/humrep/des038
   Helman E, 2012, ONCOGENE, V31, P1181, DOI 10.1038/onc.2011.307
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holliday R, 2006, EPIGENETICS-US, V1, P76, DOI 10.4161/epi.1.2.2762
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Katto J, 2011, CARCINOGENESIS, V32, P1414, DOI 10.1093/carcin/bgr120
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380
   Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Rajendram R, 2011, EPIGENETICS-US, V6, P410, DOI 10.4161/epi.6.4.14763
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Sun ZF, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-84
   Tan JX, 2013, CLIN EXP MED, V13, P1, DOI 10.1007/s10238-011-0173-2
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
NR 39
TC 3
Z9 4
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD APR
PY 2013
VL 5
IS 2
BP 155
EP 165
DI 10.2217/EPI.13.6
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 122VN
UT WOS:000317346400011
PM 23566093
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Moison, C
   Senamaud-Beaufort, C
   Fourrière, L
   Champion, C
   Ceccaldi, A
   Lacomme, S
   Daunay, A
   Tost, J
   Arimondo, PB
   Guieysse-Peugeot, AL
AF Moison, Celine
   Senamaud-Beaufort, Catherine
   Fourriere, Lou
   Champion, Christine
   Ceccaldi, Alexandre
   Lacomme, Stephanie
   Daunay, Antoine
   Tost, Joerg
   Arimondo, Paola B.
   Guieysse-Peugeot, Anne-Laure
TI DNA methylation associated with polycomb repression in retinoic acid
   receptor β silencing
SO FASEB JOURNAL
LA English
DT Article
DE prostate cancer; epigenetic silencing; tumor supressor gene; DNA
   hypermethylation; EZH2
ID BREAST-CANCER CELLS; GROUP PROTEIN EZH2; PROSTATE-CANCER; TARGET GENES;
   CARCINOMA-CELLS; GROWTH ARREST; EXPRESSION; CHROMATIN; ISOFORM;
   HYPERMETHYLATION
AB Retinoic acid receptor beta 2 (RAR beta 2) is a tumor suppressor gene whose loss of expression is recurrent in prostate cancers. Here we studied the epigenetic mechanisms leading to its stable silencing. First, we characterized all RAR beta isoforms in 6 human tumor cell lines (prostate DU145, LNCaP, PC3, lung A549, breast Hs578T, and colon HCT116) by RT-PCR and Western blot. We excluded loss of heterozygosity (2D-FISH) and loss of RARa expression, an upstream regulator, as origin of RAR beta 2 silencing. All data concluded to an epigenetic silencing. In agreement, a DNA methylation inhibitor restored its expression. Second RAR beta 2 loss of expression was found associated with different epigenetic profiles in LNCaP and DU145 cells. According to bisulfite sequencing and ChIP analysis, we observed heavy methylation (97%) of the RAR beta 2 promoter with repressive histone mark H3K9me3 in LNCaP. While DNA methylation and polycomb repression are described to be mutually exclusive at CpG-rich promoters, we observed that in DU145, moderate DNA methylation (36%) and H3K9me3 mark were present concomitantly with H3K27me3, a signature of polycomb repression. In summary, we provide new insights on how the RAR beta 2 promoter is silenced, reveal the existence of two distinct repressive chromatin profiles at the same locus, and support a polycomb-mediated epigenetic repression process in prostate cancer.-Moison, C., Senamaud-Beaufort, C., Fourriere, L., Champion, C., Ceccaldi, A., Lacomme, S., Daunay, A., Tost, J. Arimondo, P. B., Guieysse-Peugeot, A.-L. DNA methylation associated with polycomb repression in retinoic acid receptor beta silencing. FASEB J. 27, 1468-1478 (2013). www.fasebj.org
C1 [Moison, Celine; Arimondo, Paola B.] CRDPF, CNRS Pierre Fabre, USR ETaC 3388, F-31100 Toulouse, France.
   [Moison, Celine; Senamaud-Beaufort, Catherine; Fourriere, Lou; Champion, Christine; Ceccaldi, Alexandre; Guieysse-Peugeot, Anne-Laure] Museum Natl Hist Nat, CNRS, UMR7196, Paris, France.
   [Moison, Celine; Senamaud-Beaufort, Catherine; Fourriere, Lou; Champion, Christine; Ceccaldi, Alexandre; Guieysse-Peugeot, Anne-Laure] INSERM, U565, Paris, France.
   [Moison, Celine; Fourriere, Lou; Champion, Christine; Ceccaldi, Alexandre] Univ Paris 06, Paris, France.
   [Lacomme, Stephanie] Hop Cent, Ctr Ressources Biol, Serv Anat & Cytol Pathol, Nancy, France.
   [Daunay, Antoine; Tost, Joerg] Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, Lab Funct Genom, F-75010 Paris, France.
   [Tost, Joerg] Commissariat Energie Atom & Energies Alternat CEA, Inst Genom, Ctr Natl Genotypage, Lab Epigenet, Evry, France.
C3 Centre National de la Recherche Scientifique (CNRS); Museum National
   d'Histoire Naturelle (MNHN); Centre National de la Recherche
   Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut
   National de la Sante et de la Recherche Medicale (Inserm); Sorbonne
   Universite; CHU de Nancy; Foundation Jean Dausset-CEPH; Universite Paris
   Saclay; CEA
RP Arimondo, PB (通讯作者)，CRDPF, CNRS Pierre Fabre, USR ETaC 3388, 3 Ave Hubert Curien, F-31100 Toulouse, France.
EM paola.arimondo@etac.cnrs.fr; guieysse@mnhn.fr
RI Arimondo, Paola/R-9095-2017; Tost, Jorg/H-7129-2019
OI Tost, Jorg/0000-0002-2683-0817
FU Agence Nationale de la Recherche [ANR-06 JCJCJ-0080]; Ministry of
   Education, Research, and Technology; Institut National de la Sante et de
   la Recherche Medicale-Centre National de la Recherche Scientifique
   Bourse de Doctorat pour Ingenieurs; ARC
FX The authors acknowledge the Service d'Anatomie et Cytologie
   Pathologiques des Hopitaux de Toulouse for the tumor samples. The
   authors thank Helene Gondelle and Jean Ollion for technical help in FISH
   experiments and Laurent Lacroix, Christophe Escude, Loic Ponger, and
   Pierre-Antoine Defossez for helpful discussions. This work was supported
   by Agence Nationale de la Recherche (ANR-06 JCJCJ-0080) and Region
   Midi-Pyrenees. C. M. was the recipient of a Ministry of Education,
   Research, and Technology fellowship, C. C. of an Institut National de la
   Sante et de la Recherche Medicale-Centre National de la Recherche
   Scientifique Bourse de Doctorat pour Ingenieurs, and A.C. of an ARC
   fellowship. The authors declare no conflicts of interest.
CR Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005
   BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0
   Berezovska OP, 2006, CELL CYCLE, V5, P1886
   BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen LI, 2002, J BIOL CHEM, V277, P35411, DOI 10.1074/jbc.M202717200
   Cote S, 1997, ANTI-CANCER DRUG, V8, P56
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0
   Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329
   Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312
   Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gillespie RF, 2007, J MOL BIOL, V372, P298, DOI 10.1016/j.jmb.2007.06.079
   HOULE B, 1994, CANCER RES, V54, P365
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Kanhere A, 2010, MOL CELL, V38, P675, DOI 10.1016/j.molcel.2010.03.019
   Karamouzis MV, 2007, CELL ONCOL, V29, P183
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A
   LaTulippe E, 2002, CANCER RES, V62, P4499
   Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065
   NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Peng XJ, 2004, CANCER RES, V64, P8911, DOI 10.1158/0008-5472.CAN-04-1810
   Petty WJ, 2005, J NATL CANCER I, V97, P1645, DOI 10.1093/jnci/dji371
   Poulain S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-423
   Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005
   Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230
   Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Sun J., 2010, MED ONCOL, P1311
   Swift ME, 2006, J CELL PHYSIOL, V209, P718, DOI 10.1002/jcp.20788
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Toulouse A, 1996, BBA-GENE STRUCT EXPR, V1309, P1, DOI 10.1016/S0167-4781(96)00126-1
   van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591
   ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x
   Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045
NR 61
TC 29
Z9 31
U1 0
U2 17
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2013
VL 27
IS 4
BP 1468
EP 1478
DI 10.1096/fj.12-210971
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 117GF
UT WOS:000316940800019
PM 23299856
OA Bronze
DA 2025-01-12
ER

PT J
AU Bianco, C
   Castro, NP
   Baraty, C
   Rollman, K
   Held, N
   Rangel, MC
   Karasawa, H
   Gonzales, M
   Strizzi, L
   Salomon, DS
AF Bianco, Caterina
   Castro, Nadia P.
   Baraty, Christina
   Rollman, Kelly
   Held, Natalie
   Rangel, Maria Cristina
   Karasawa, Hideaki
   Gonzales, Monica
   Strizzi, Luigi
   Salomon, David S.
TI Regulation of human Cripto-1 expression by nuclear receptors and DNA
   promoter methylation in human embryonal and breast cancer cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; MAMMARY EPITHELIAL-CELLS; DIFFERENTIAL
   RECRUITMENT; OCT4 EXPRESSION; COLON-CANCER; LRH-1; REPRESSION; LIVER;
   GENE; GCNF
AB Human Cripto-1 (CR-1) plays an important role in regulating embryonic development while also regulating various stages of tumor progression. However, mechanisms that regulate CR-1 expression during embryogenesis and tumorigenesis are still not well defined. In the present study, we investigated the effects of two nuclear receptors, liver receptor homolog (LRH)-1 and germ cell nuclear factor receptor (GCNF) and epigenetic modifications on CR-1 gene expression in NTERA-2 human embryonal carcinoma cells and in breast cancer cells. CR-1 expression in NTERA-2 cells was positively regulated by LRH-1 through direct binding to a DR0 element within the CR-1 promoter, while GCNF strongly suppressed CR-1 expression in these cells. In addition, the CR-1 promoter was unmethylated in NTERA-2 cells, while T47D, ZR75-1, and MCF7 breast cancer cells showed high levels of CR-1 promoter methylation and low CR-1 mRNA and protein expression. Treatment of breast cancer cells with a demethylating agent and histone deacetylase inhibitors reduced methylation of the CR-1 promoter and reactivated CR-1 mRNA and protein expression in these cells, promoting migration and invasion of breast cancer cells. Analysis of a breast cancer tissue array revealed that CR-1 was highly expressed in the majority of human breast tumors, suggesting that CR-1 expression in breast cancer cell lines might not be representative of in vivo expression. Collectively, these findings offer some insight into the transcriptional regulation of CR-1 gene expression and its critical role in the pathogenesis of human cancer. J. Cell. Physiol. 228: 11741188, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Bianco, Caterina; Castro, Nadia P.; Baraty, Christina; Rollman, Kelly; Held, Natalie; Rangel, Maria Cristina; Karasawa, Hideaki; Gonzales, Monica; Salomon, David S.] Frederick Natl Lab Canc Res, Lab Canc Prevent, Frederick, MD USA.
   [Strizzi, Luigi] Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Frederick National Laboratory for Cancer Research; Northwestern
   University; Feinberg School of Medicine; Robert H. Lurie Comprehensive
   Cancer Center; Ann & Robert H. Lurie Children's Hospital of Chicago
RP Salomon, DS (通讯作者)，Lab Canc Prevent, 1050 Boyles Dr,Bldg 560 Room 1246, Frederick, MD 21701 USA.
EM biancoc@mail.nih.gov; salomond@mail.nih.gov
RI Strizzi, Luigi/LWI-5313-2024; Karasawa, Hideaki/AAQ-2771-2021; Rangel,
   Maria Cristina/P-7216-2014
OI Rangel, Maria Cristina/0000-0002-8002-9617; Karasawa,
   Hideaki/0000-0003-0358-3398
FU NIH, National Cancer Institute, Center for Cancer Research; Eisenberg
   Research Scholar Fund
FX Contract grant sponsor: Intramural Research Program, NIH, National
   Cancer Institute, Center for Cancer Research.Contract grant sponsor:
   Eisenberg Research Scholar Fund.
CR Aasen T, 2008, NAT BIOTECHNOL, V26, P1276, DOI 10.1038/nbt.1503
   Annicotte JS, 2005, ONCOGENE, V24, P8167, DOI 10.1038/sj.onc.1208950
   Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884
   Assou S, 2007, STEM CELLS, V25, P961, DOI 10.1634/stemcells.2006-0352
   Bianco C, 2005, J NATL CANCER I, V97, P132, DOI 10.1093/jnci/dji011
   Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002
   Bianco C, 2008, AM J PATHOL, V172, P345, DOI 10.2353/ajpath.2008.070696
   Bianco C, 2006, CLIN CANCER RES, V12, P5158, DOI 10.1158/1078-0432.CCR-06-0274
   Bianco C, 2010, AM J PATHOL, V177, P532, DOI 10.2353/ajpath.2010.100102
   Bianco C, 2009, AM J PATHOL, V175, P2146, DOI 10.2353/ajpath.2009.090218
   Chand AL, 2010, ENDOCR-RELAT CANCER, V17, P965, DOI 10.1677/ERC-10-0179
   Chang CW, 2009, STEM CELLS, V27, P1042, DOI 10.1002/stem.39
   Clyne CD, 2004, MOL CELL ENDOCRINOL, V215, P39, DOI 10.1016/j.mce.2003.11.001
   de Castro NP, 2010, FUTURE ONCOL, V6, P1127, DOI 10.2217/FON.10.68
   Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215
   Gong YP, 2007, EJSO-EUR J SURG ONC, V33, P438, DOI 10.1016/j.ejso.2006.10.014
   Gu PL, 2006, MOL CELL BIOL, V26, P9471, DOI 10.1128/MCB.00898-06
   Gu PL, 2011, STEM CELLS, V29, P1041, DOI 10.1002/stem.652
   Gu PL, 2005, MOL CELL BIOL, V25, P8507, DOI 10.1128/MCB.25.19.8507-8519.2005
   Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005
   Hamada S, 2007, BIOCHEM BIOPH RES CO, V355, P240, DOI 10.1016/j.bbrc.2007.01.143
   Hentschke M, 2006, J BIOL CHEM, V281, P33497, DOI 10.1074/jbc.M606975200
   Koohi MK, 2005, J NEUROENDOCRINOL, V17, P197, DOI 10.1111/j.1365-2826.2005.01298.x
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Mancino M, 2008, J CELL PHYSIOL, V215, P192, DOI 10.1002/jcp.21301
   Miharada K, 2011, CELL STEM CELL, V9, P330, DOI 10.1016/j.stem.2011.07.016
   Miki Y, 2006, CANCER LETT, V244, P24, DOI 10.1016/j.canlet.2005.11.038
   Mullen EM, 2007, PPAR RES, V2007, DOI 10.1155/2007/61563
   Nagaoka T, 2012, GROWTH FACTORS, V30, P13, DOI 10.3109/08977194.2011.641962
   Normanno N, 2004, J CELL PHYSIOL, V198, P31, DOI 10.1002/jcp.10375
   Rangel MC, 2012, AM J PATHOL, V180, P2188, DOI 10.1016/j.ajpath.2012.02.031
   Sato N, 2006, BIOCHEM BIOPH RES CO, V344, P845, DOI 10.1016/j.bbrc.2006.04.007
   Strizzi L, 2008, CELL CYCLE, V7, P1931, DOI 10.4161/cc.7.13.6236
   Sun C, 2008, BIOCHEM BIOPH RES CO, V377, P215, DOI 10.1016/j.bbrc.2008.09.113
   Thiruchelvam PTR, 2011, BREAST CANCER RES TR, V127, P385, DOI 10.1007/s10549-010-0994-9
   Vallier L, 2009, DEVELOPMENT, V136, P1339, DOI 10.1242/dev.033951
   Watanabe K, 2010, STEM CELLS, V28, P1303, DOI 10.1002/stem.463
   Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162
   Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862
   Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0
NR 41
TC 30
Z9 35
U1 1
U2 105
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2013
VL 228
IS 6
BP 1174
EP 1188
DI 10.1002/jcp.24271
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 096OL
UT WOS:000315414000007
PM 23129342
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Pinto, R
   Pilato, B
   Ottini, L
   Lambo, R
   Simone, G
   Paradiso, A
   Tommasi, S
AF Pinto, Rosamaria
   Pilato, Brunella
   Ottini, Laura
   Lambo, Rossana
   Simone, Giovanni
   Paradiso, Angelo
   Tommasi, Stefania
TI Different methylation and MicroRNA expression pattern in male and female
   familial breast cancer
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID GENETIC-VARIANTS; HYPERMETHYLATION; RASSF1A; BRCA1; CELLS; LET-7; DNA
AB Epigenetic regulation, has been very scarcely explored in familial breast cancer (BC). In the present study RASSF1A and RAR beta promoter methylation and miR17, miR21, miR 124, and let-7a expression were investigated to highlight possible differences of epigenetic regulation between male and female familial BC, also in comparison with sporadic BC. These epigenetic alterations were studied in 56 familial BC patients (27 males and 29 females) and in 16 female sporadic cases. RASSF1A resulted more frequently methylated in men than women (76% vs. 28%, respectively, P=0.0001), while miR17 and let-7a expression frequency was higher in women than in men (miR17: 66% in women vs. 41% in men, P<0.05; let-7a: 45% in women vs. 15% in men, P=0.015). RASSF1A methylation affected 27.6% of familial BC while 83% of familial cases showed high expression of the gene (P=0.025); on the contrary, only 17% of familial BC presented RAR beta methylation and 55% of familial cases overexpressed this gene (P=0.005). Moreover, miR17, miR21, and let-7a resulted significantly overexpressed in familial compared to sporadic BC. RASSF1A overexpression (86% vs. 65%, P=0.13) and RAR beta overexpression (57% vs. 32%, P=0.11) were higher in BRCA1/2 carriers even if not statistical significance was reached. BRCA mutation carriers also demonstrated significant overexpression of: miR17 (93% vs. 35%, P=0.0001), let-7a (64% vs. 16%, P=0.002), and of miR21 (100% vs. 65%, P=0.008). In conclusion, the present data suggest the involvement of RASSF1A in familial male BC, while miR17 and let-7a seem to be implied in familial female BC. J. Cell. Physiol. 228: 12641269, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Pinto, Rosamaria; Pilato, Brunella; Tommasi, Stefania] NCRC Giovanni Paolo II, Mol Genet Lab, Bari, Italy.
   [Ottini, Laura] Univ Roma La Sapienza, Dept Mol Med, Rome, Italy.
   [Lambo, Rossana] NCRC Giovanni Paolo II, Genet Outpatient Clin, Bari, Italy.
   [Simone, Giovanni] NCRC Giovanni Paolo II, Anatomopathol Unit, Bari, Italy.
   [Paradiso, Angelo] NCRC Giovanni Paolo II, Bari, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica
   Molecolare (IGM-CNR); Sapienza University Rome
RP Tommasi, S (通讯作者)，Ist Tumori Giovanni Paolo II, Mol Genet Lab, Vle Orazio Flacco 65, I-70124 Bari, Italy.
EM s.tommasi@oncologico.bari.it
RI Pilato, Brunella/AAH-7365-2020; paradiso, angelo/J-9457-2018; Tommasi,
   Stefania/J-6732-2012
OI OTTINI, LAURA/0000-0001-8030-0449; pilato, brunella/0000-0001-6067-3977;
   Tommasi, Stefania/0000-0002-2157-2978
FU Progetto Regione Puglia [DIEF 2007]
FX Contract grant sponsor: Progetto Regione Puglia;Contract grant number:
   DIEF 2007.
CR Alvarez C, 2012, MOL CARCINOG
   Barh D, 2010, CURR ONCOL, V17, P70
   Bergqvist J, 2010, FAM CANCER, V9, P263, DOI 10.1007/s10689-010-9335-8
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Choi CH, 2007, CANCER LETT, V255, P26, DOI 10.1016/j.canlet.2007.03.015
   de Oliveira PEQ, 2009, CELL CYCLE, V8, P3157
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Foerster R, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-335
   Fu XN, 2011, EUR J CLIN INVEST, V41, P1245, DOI 10.1111/j.1365-2362.2011.02535.x
   Gao BN, 2008, CANCER RES, V68, P22, DOI 10.1158/0008-5472.CAN-07-5183
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kanwal R, 2012, CLIN GENET, V81, P303, DOI 10.1111/j.1399-0004.2011.01809.x
   Kodama T, 2011, J CLIN INVEST, V121, P3343, DOI 10.1172/JCI44957
   Lehmann U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-109
   O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484
   Ottini L, 2010, CRIT REV ONCOL HEMAT, V73, P141, DOI 10.1016/j.critrevonc.2009.04.003
   Schrauder MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029770
   Shen J, 2009, INT J CANCER, V124, P1178, DOI 10.1002/ijc.24008
   Shukla S, 2006, EPIGENETICS-US, V1, P88, DOI 10.4161/epi.1.2.2679
   Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Thaler S., 2012, ONCOGENE
   Tommasi S, 2005, MUTAT RES-FUND MOL M, V578, P395, DOI 10.1016/j.mrfmmm.2005.06.010
   Tommasi S, 2008, MUTAT RES-FUND MOL M, V644, P64, DOI 10.1016/j.mrfmmm.2008.07.005
   Tommasi S, 2011, OMICS, V15, P125, DOI 10.1089/omi.2010.0080
   Tommasi S, 2011, J CELL PHYSIOL, V226, P1934, DOI 10.1002/jcp.22524
   Trompeter HI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016138
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wang ZX, 2011, ARCH MED RES, V42, P281, DOI 10.1016/j.arcmed.2011.06.008
   Zhao YC, 2011, MOL MED, V17, P1233, DOI 10.2119/molmed.2010.00225
   Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145
   Zheng H, 2011, INT J ONCOL, V38, P1153, DOI 10.3892/ijo.2011.940
NR 34
TC 32
Z9 33
U1 0
U2 88
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2013
VL 228
IS 6
BP 1264
EP 1269
DI 10.1002/jcp.24281
PG 6
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 096OL
UT WOS:000315414000016
PM 23160909
DA 2025-01-12
ER

PT J
AU Vijayaraghavalu, S
   Labhasetwar, V
AF Vijayaraghavalu, Sivakumar
   Labhasetwar, Vinod
TI Efficacy of decitabine-loaded nanogels in overcoming cancer drug
   resistance is mediated via sustained DNA methyltransferase 1 (DNMT1)
   depletion
SO CANCER LETTERS
LA English
DT Article
DE Hypermethylation; Epigenetic drugs; Nanoparticles; Cell-cycle analysis;
   Drug delivery; Cancer therapy
ID IN-VITRO; THERAPEUTIC TARGET; GENE-EXPRESSION; METHYLATION; CELL;
   5-AZA-2'-DEOXYCYTIDINE; HYPERMETHYLATION; CHEMOTHERAPY; AZACITIDINE;
   SENSITIVITY
AB DNA methyltransferase 1 (DNMT1) promotes DNA methylation to maintain cancer drug resistance. The epigenetic drug, decitabine (DAC) is a potent hypomethylating agent, but its effect is transient because of its instability. We tested the efficacy of DAC-loaded nanogels in doxorubicin-resistant breast cancer cells, DAC-resistant melanoma cells, and leukemia cells. DAC in nanogel sustained DNMT1 depletion, prolonged cell arrest in the G2/M cell-cycle phase, and significantly enhanced antiproliferative effect of DAC. The efficacy of DAC-loaded nanogels was more significant in resistant than sensitive cells. Our data suggest that effective delivery of DAC and prolonged DNMT1 depletion are critical to overcoming drug resistance. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Vijayaraghavalu, Sivakumar; Labhasetwar, Vinod] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA.
   [Labhasetwar, Vinod] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Labhasetwar, V (通讯作者)，Cleveland Clin, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
RI Labhasetwar, Vinod/J-9660-2016; Vijayaraghavalu, Sivakumar/IZE-6423-2023
OI Vijayaraghavalu, Sivakumar/0000-0002-6770-6716
FU National Cancer Institute of the National Institutes of Health [R01
   CA149359-01]
FX This study was funded by Grant R01 CA149359-01 (to V.L.) from the
   National Cancer Institute of the National Institutes of Health. We thank
   our colleague Yogen Saunthararajah, MD, Taussig Cancer Institute,
   Cleveland Clinic, for providing DAC-resistant melanoma and leukemia
   cells.
CR Abraham GA, 2001, BIOMATERIALS, V22, P1971, DOI 10.1016/S0142-9612(00)00381-1
   Ahmed Z, 2009, J PHYS CHEM B, V113, P4248, DOI 10.1021/jp810685g
   Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   Brown Robert, 2004, Expert Rev Anticancer Ther, V4, P501, DOI 10.1586/14737140.4.4.501
   BRUNNER N, 1989, CANCER RES, V49, P1515
   Chan CK, 2004, MATER CHEM PHYS, V88, P59, DOI 10.1016/j.matchemphys.2004.06.009
   Cherblanc F, 2012, FUTURE MED CHEM, V4, P425, DOI [10.4155/FMC.12.7, 10.4155/fmc.12.7]
   Cheung HH, 2009, BIRTH DEFECTS RES C, V87, P335, DOI 10.1002/bdrc.20163
   Clements EG, 2012, NUCLEIC ACIDS RES, V40, P4334, DOI 10.1093/nar/gks031
   COVEY JM, 1984, CANCER TREAT REP, V68, P1475
   Damaraju VL, 2012, NUCLEOS NUCLEOT NUCL, V31, P236, DOI 10.1080/15257770.2011.652330
   Daniel FI, 2011, CANCER-AM CANCER SOC, V117, P677, DOI 10.1002/cncr.25482
   Daskalakis M, 2010, RECENT RESULTS CANC, V184, P131, DOI 10.1007/978-3-642-01222-8_10
   Dhe-Paganon Sirano, 2011, Int J Biochem Mol Biol, V2, P58
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025
   HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6
   Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001
   Hubeek I, 2005, BRIT J CANCER, V93, P1388, DOI 10.1038/sj.bjc.6602881
   Jabbour E, 2008, CANCER-AM CANCER SOC, V112, P2341, DOI 10.1002/cncr.23463
   Jansen RS, 2012, CANCER CHEMOTH PHARM, V69, P1457, DOI 10.1007/s00280-012-1850-x
   Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008
   Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695
   Mutze K, 2011, EUR J CANCER, V47, P1817, DOI 10.1016/j.ejca.2011.02.024
   Oki Y, 2007, CRIT REV ONCOL HEMAT, V61, P140, DOI 10.1016/j.critrevonc.2006.07.010
   Oloumi A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2592
   Onda K, 2012, ANTICANCER RES, V32, P4439
   Reddy MK, 2008, CIRC-CARDIOVASC INTE, V1, P209, DOI 10.1161/CIRCINTERVENTIONS.108.830018
   Ren J, 2011, CELL SIGNAL, V23, P1082, DOI 10.1016/j.cellsig.2011.02.003
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Tan HH, 2009, BIOCHEM BIOPH RES CO, V382, P171, DOI 10.1016/j.bbrc.2009.03.001
   TARATINA TM, 1990, BIOPHYS CHEM, V38, P1, DOI 10.1016/0301-4622(90)80034-5
   Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005
   TERRY NHA, 1995, BRIT J CANCER, V72, P435, DOI 10.1038/bjc.1995.351
   Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Vijayaraghavalu S, 2013, MOL PHARMACEUT, V10, P337, DOI 10.1021/mp3004622
   Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008
   Yallapu MM, 2008, J BIOMED NANOTECHNOL, V4, P16, DOI 10.1166/jbn.2008.006
   Zhu X, 2007, LANGMUIR, V23, P162, DOI 10.1021/la061577i
NR 41
TC 31
Z9 35
U1 0
U2 71
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 30
PY 2013
VL 331
IS 1
BP 122
EP 129
DI 10.1016/j.canlet.2012.12.009
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 099GS
UT WOS:000315610100016
PM 23305699
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Tao, MH
   Marian, C
   Shields, PG
   Potischman, N
   Nie, J
   Krishnan, SS
   Berry, DL
   Kallakury, BV
   Ambrosone, C
   Edge, SB
   Trevisan, M
   Winston, J
   Freudenheim, JL
AF Tao, M-H
   Marian, C.
   Shields, P. G.
   Potischman, N.
   Nie, J.
   Krishnan, S. S.
   Berry, D. L.
   Kallakury, B. V.
   Ambrosone, C.
   Edge, S. B.
   Trevisan, M.
   Winston, J.
   Freudenheim, J. L.
TI Exposures in early life: associations with DNA promoter methylation in
   breast tumors
SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE
LA English
DT Article
DE breast cancer; early-life exposure; epidemiology; epigenetics; promoter
   methylation
ID NEW-YORK EXPOSURES; CANCER-RISK; BIRTH-WEIGHT; SMOKE EXPOSURE;
   BODY-MASS; METAANALYSIS; HYPERMETHYLATION; INFANCY; COHORT; MILK
AB There is evidence that epigenetic changes occur early in breast carcinogenesis. We hypothesized that early-life exposures associated with breast cancer would be associated with epigenetic alterations in breast tumors. In particular, we examined DNA methylation patterns in breast tumors in association with several early-life exposures in a population-based case-control study. Promoter methylation of E-cadherin, p16 and RAR-beta(2) genes was assessed in archived tumor blocks from 803 cases with real-time methylation-specific PCR. Unconditional logistic regression was used for case-case comparisons of those with and without promoter methylation. We found no differences in the prevalence of DNA methylation of the individual genes by age at menarche, age at first live birth and weight at age 20. In case-case comparisons of premenopausal breast cancer, lower birth weight was associated with increased likelihood of E-cadherin promoter methylation (OR = 2.79, 95% CI, 1.15-6.82, for <= 2.5 v. 2.6-2.9 kg); higher adult height with RAR-beta(2) methylation (OR = 3.34, 95% CI, 1.19-9.39, for >= 1.65 v. <1.60 m); and not having been breastfed with p16 methylation (OR = 2.75, 95% CI, 1.14-6.62). Among postmenopausal breast cancers, birth order was associated with increased likelihood of p16 promoter methylation. Being other than first in the birth order was inversely associated with likelihood of >= 1 of the three genes being methylated for premenopausal breast cancers, but positively associated with methylation in postmenopausal women. These results suggest that there may be alterations in methylation associated with early-life exposures that persist into adulthood and affect breast cancer risk.
C1 [Tao, M-H] Mt Sinai Sch Med, Inst Translat Epidemiol, New York, NY 10029 USA.
   [Marian, C.; Shields, P. G.; Krishnan, S. S.] Ohio State Univ, Ctr Canc, Columbus, OH 43210 USA.
   [Potischman, N.] NCI, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
   [Nie, J.; Trevisan, M.; Freudenheim, J. L.] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA.
   [Berry, D. L.; Kallakury, B. V.] Georgetown Univ, Lombardi Canc Ctr, Washington, DC USA.
   [Ambrosone, C.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
   [Edge, S. B.] Roswell Pk Canc Inst, Dept Surg, Buffalo, NY 14263 USA.
   [Trevisan, M.] CUNY, Sch Biomed Educ, New York, NY 10021 USA.
   [Winston, J.] Potomac Hosp, Woodbridge, VA USA.
C3 Icahn School of Medicine at Mount Sinai; University System of Ohio; Ohio
   State University; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI); State University of New York (SUNY)
   System; University at Buffalo, SUNY; Georgetown University; Roswell Park
   Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center;
   City University of New York (CUNY) System
RP Tao, MH (通讯作者)，Mt Sinai Sch Med, Inst Translat Epidemiol, POB 1057, New York, NY 10029 USA.
EM menghua.tao@mssm.edu
RI Marian, Catalin/KHU-8477-2024; Shields, Peter/I-1644-2012; Marian,
   Catalin/P-2885-2019
OI Marian, Catalin/0000-0002-7749-1384; Freudenheim, Jo/0000-0002-9301-0499
FU National Institute on Alcohol Abuse and Alcoholism [P50-AA09802];
   Department of Defense [DAMD 179616202, DAMD 17030446]; National Cancer
   Institute [R01CA 092040]
FX This study would not have been possible without the support of all the
   study participants and the research staff of the WEB Study. This work
   was supported in part by the National Institute on Alcohol Abuse and
   Alcoholism (P50-AA09802), the Department of Defense (DAMD 179616202,
   DAMD 17030446) and the National Cancer Institute (R01CA 092040).
CR Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Attig L, 2010, CURR OPIN CLIN NUTR, V13, P284, DOI 10.1097/MCO.0b013e328338aa61
   Barba M, 2006, CANCER CAUSE CONTROL, V17, P395, DOI 10.1007/s10552-005-0481-5
   Bernal AJ, 2010, BIRTH DEFECTS RES A, V88, P938, DOI 10.1002/bdra.20685
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Burdge GC, 2009, BRIT J NUTR, V101, P619, DOI 10.1017/S0007114508145883
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Desaulniers D, 2009, INT J TOXICOL, V28, P294, DOI 10.1177/1091581809337918
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fernandez SV, 2010, TOXICOL PATHOL, V38, P110, DOI 10.1177/0192623309354108
   Flom JD, 2011, CANCER EPIDEM BIOMAR, V20, P2518, DOI 10.1158/1055-9965.EPI-11-0553
   Forman MR, 2005, CANCER INVEST, V23, P609, DOI 10.1080/07357900500283093
   FREUDENHEIM JL, 1994, EPIDEMIOLOGY, V5, P324, DOI 10.1097/00001648-199405000-00011
   Fryer AA, 2011, EPIGENETICS-US, V6, P86, DOI 10.4161/epi.6.1.13392
   Green J, 2011, LANCET ONCOL, V12, P785, DOI 10.1016/S1470-2045(11)70154-1
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   HERMAN JG, 1995, CANCER RES, V55, P4525
   HSIEH CC, 1991, CANCER CAUSE CONTROL, V2, P95, DOI 10.1007/BF00053127
   Hughes LAE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007951
   Innes K, 2000, AM J EPIDEMIOL, V152, P1121, DOI 10.1093/aje/152.12.1121
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Knip M, 2010, AM J CLIN NUTR, V91, p1506S, DOI 10.3945/ajcn.2010.28701C
   La Merrill M, 2011, ANN EPIDEMIOL, V21, P413, DOI 10.1016/j.annepidem.2010.11.012
   Lee ES, 2008, CLIN CANCER RES, V14, P2664, DOI 10.1158/1078-0432.CCR-07-1232
   Li L, 2004, AM J CLIN NUTR, V80, P185
   Martin RM, 2005, JNCI-J NATL CANCER I, V97, P1446, DOI 10.1093/jnci/dji291
   Mellemkjær L, 2003, CANCER CAUSE CONTROL, V14, P61, DOI 10.1023/A:1022570305704
   Michels KB, 2001, AM J EPIDEMIOL, V153, P275, DOI 10.1093/aje/153.3.275
   Okasha M, 2003, BREAST CANCER RES TR, V78, P223, DOI 10.1023/A:1022988918755
   Park SK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1850
   Rodriguez-Palmero M, 1999, CLIN PERINATOL, V26, P335, DOI 10.1016/S0095-5108(18)30056-3
   Ruder EH, 2008, CLIN BREAST CANCER, V8, P334, DOI 10.3816/CBC.2008.n.038
   Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011
   Shah PS, 2009, CAN MED ASSOC J, V180, pE99, DOI 10.1503/cmaj.081777
   Slanger T, 2007, ANN EPIDEMIOL, V17, P993, DOI 10.1016/j.annepidem.2007.07.094
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tao MH, 2009, BREAST CANCER RES TR, V114, P559, DOI 10.1007/s10549-008-0028-z
   Tao MH, 2011, AM J CLIN NUTR, V94, P831, DOI 10.3945/ajcn.110.009365
   Titus-Ernstoff L, 1998, J NATL CANCER I, V90, P921, DOI 10.1093/jnci/90.12.921
   Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4
   Waterland RA, 2009, HORM RES, V71, P13, DOI 10.1159/000178030
   Wise LA, 2009, CANCER CAUSE CONTROL, V20, P1083, DOI 10.1007/s10552-009-9332-0
   Xu XH, 2009, J WOMENS HEALTH, V18, P1169, DOI 10.1089/jwh.2008.1034
   Xue F, 2007, LANCET ONCOL, V8, P1088, DOI 10.1016/S1470-2045(07)70377-7
NR 46
TC 11
Z9 13
U1 0
U2 13
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 2040-1744
J9 J DEV ORIG HLTH DIS
JI J. Dev. Orig. Health Dis.
PD APR
PY 2013
VL 4
IS 2
BP 182
EP 190
DI 10.1017/S2040174412000694
PG 9
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 100GO
UT WOS:000315685800009
PM 25054684
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Xiang, YQ
   Cheng, Y
   Li, XT
   Li, QL
   Xu, JW
   Zhang, JY
   Liu, Y
   Xing, QH
   Wang, L
   He, L
   Zhao, XZ
AF Xiang, Yuqian
   Cheng, Yan
   Li, Xiaotian
   Li, Qiaoli
   Xu, Jiawei
   Zhang, Junyu
   Liu, Yun
   Xing, Qinghe
   Wang, Lei
   He, Lin
   Zhao, Xinzhi
TI Up-Regulated Expression and Aberrant DNA Methylation of <i>LEP</i> and
   <i>SH3PXD2A</i> in Pre-Eclampsia
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; PROMOTER HYPOMETHYLATION; EPIGENETIC MECHANISMS;
   PLACENTAL LEPTIN; BREAST-CANCER; FOLIC-ACID; PROTEIN; INVASION;
   HYPERTENSION; HOMOCYSTEINE
AB The primary mechanism underlying pre-eclampsia (PE) remains one of the most burning problems in the obstetrics and gynecology. In this study, we performed an expression profiling screen and detected 1312 genes that were differentially expressed (p<0.05 and fold change >1.5) in PE placentas, including LEP and SH3PXD2A. After validating the microarray results, we conducted the quantitative methylation analysis of LEP and SH3PXD2A in preeclamptic (n=16) versus normal placentas (n = 16) Our results showed that many CpG sites close to the transcriptional start site (TSS) of LEP gene were hypomethylated in placentas from pregnancies with PE compared with those of in controls, including the TSS position (p = 0.001), the binding sites of Sp1 (p = 1.57 x 10(-4)), LP1 (p=0.023) and CEBP alpha (p=0.031). Luciferase reporter analysis confirmed the aberrant methylation of LEP promoter and CEBP alpha co-transfection had a role in the regulation of gene expression. Our results indicated the aberrant LEP promoter methylation was involved in the development of PE. We did not find a significant methylation differences between groups in the promoter region of SH3PXD2A, however, a CGI region in the gene body (CGI34) presented a higher methylation in preeclamptic placentas (p = 1.57 x 10(-4)), which might promote the efficiency of gene transcription. We speculated that SH3PXD2A may take part in the pathogenesis of PE through its role in the regulation of trophoblast cell invasion in the period of placenta formation.
C1 [Xiang, Yuqian; Li, Qiaoli; Xu, Jiawei; Zhang, Junyu; Liu, Yun; Xing, Qinghe; Wang, Lei; He, Lin; Zhao, Xinzhi] Fudan Univ, Childrens Hosp, Shanghai 200433, Peoples R China.
   [Xiang, Yuqian; Li, Qiaoli; Xu, Jiawei; Zhang, Junyu; Liu, Yun; Xing, Qinghe; Wang, Lei; He, Lin; Zhao, Xinzhi] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
   [Cheng, Yan; Li, Xiaotian] Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China.
   [He, Lin] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200030, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong
   University
RP He, L (通讯作者)，Fudan Univ, Childrens Hosp, Shanghai 200433, Peoples R China.
EM helin@bio-x.cn; xzzhao@fudan.edu.cn
RI Liu, Yun/I-5755-2012; li, qiaoli/HNR-9746-2023; xu,
   jiawei/JCD-7577-2023; HE, Lin/KZU-4337-2024; Li, Xiaotian/ABI-3309-2020;
   Zhang, Juan/GRX-2638-2022
OI Zhang, Junyu/0000-0003-0239-6670; Li, Xiaotian/0000-0002-2051-4581
FU 973 Program [2009825606, 2010CB529600]; National Key Technology RD
   Program [2012BAI01B09]; National Natural Science Foundation of China
   [30800616, 81000256, 81121001]; Shanghai Municipal Commission of Science
   and Technology Program [09DJ1400601]; Shanghai Rising-Star Program
   [09QA1400500]; Mingdao Program of Medical Student [MDJH2012027]
FX This work was supported by the 973 Program (2009825606, 2010CB529600),
   the National Key Technology R&D Program (2012BAI01B09), the National
   Natural Science Foundation of China (30800616, 81000256, 81121001), the
   Shanghai Municipal Commission of Science and Technology Program
   (09DJ1400601), the Shanghai Rising-Star Program (09QA1400500) and the
   Mingdao Program of Medical Student (MDJH2012027). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200
   BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A
   Cervero A, 2005, REPROD BIOMED ONLINE, V10, P217, DOI 10.1016/S1472-6483(10)60943-1
   Chelbi ST, 2007, HYPERTENSION, V49, P76, DOI 10.1161/01.HYP.0000250831.52876.cb
   Chim SSC, 2005, P NATL ACAD SCI USA, V102, P14753, DOI 10.1073/pnas.0503335102
   Eiland E, 2012, J PREGNANCY, V2012, DOI 10.1155/2012/586578
   Enquobahrie DA, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.020
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102
   Gopalakrishnan S, 2008, MUTAT RES-FUND MOL M, V647, P30, DOI 10.1016/j.mrfmmm.2008.08.006
   Guven MA, 2009, HYPERTENS PREGNANCY, V28, P190, DOI 10.1080/10641950802601179
   Hennessy A, 1999, J IMMUNOL, V163, P3491
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jarvenpaa J, 2007, GYNECOL ENDOCRINOL, V23, P351, DOI 10.1080/09513590701350291
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kang JH, 2011, J HYPERTENS, V29, P928, DOI 10.1097/HJH.0b013e328344a82c
   Kaufmann P, 2003, BIOL REPROD, V69, P1, DOI 10.1095/biolreprod.102.014977
   Knox KS, 2007, MOL HUM REPROD, V13, P251, DOI 10.1093/molehr/gal116
   Kulkarni A, 2011, DNA CELL BIOL, V30, P79, DOI 10.1089/dna.2010.1084
   Levine RJ, 2004, AM J OBSTET GYNECOL, V190, P707, DOI 10.1016/j.ajog.2003.12.019
   Louwen F, 2012, ONCOTARGET, V3, P759
   Makedos Georgios, 2007, Archives of Gynecology and Obstetrics, V275, P121, DOI 10.1007/s00404-006-0223-2
   Maymó JL, 2011, PLACENTA, V32, pS146, DOI 10.1016/j.placenta.2011.01.004
   Maymó JL, 2010, ENDOCRINOLOGY, V151, P3738, DOI 10.1210/en.2010-0064
   Maymó JL, 2009, ENDOCRINOLOGY, V150, P304, DOI 10.1210/en.2008-0522
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   Melzner I, 2002, J BIOL CHEM, V277, P45420, DOI 10.1074/jbc.M208511200
   Mousa AA, 2012, AM J PATHOL, V181, P1455, DOI 10.1016/j.ajpath.2012.06.019
   Müller HM, 2004, CLIN CHEM, V50, P1065, DOI 10.1373/clinchem.2003.030387
   Nakatsukasa H, 2008, ENDOCR J, V55, P565, DOI 10.1507/endocrj.K07E-136
   Nelissen ECM, 2011, HUM REPROD UPDATE, V17, P397, DOI 10.1093/humupd/dmq052
   O'Neil JS, 2001, MOL CELL ENDOCRINOL, V176, P67, DOI 10.1016/S0303-7207(01)00473-7
   Patel A, 2012, EUR J CELL BIOL, V91, P171, DOI 10.1016/j.ejcb.2011.11.006
   Ramma W, 2012, ANGIOGENESIS, V15, P333, DOI 10.1007/s10456-012-9261-5
   Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726
   Richardson B, 2007, NAT CLIN PRACT RHEUM, V3, P521, DOI 10.1038/ncprheum0573
   Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248
   Saito S, 2007, MOL ASPECTS MED, V28, P192, DOI 10.1016/j.mam.2007.02.006
   Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006
   Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5
   Singh Urmila, 2008, J Indian Med Assoc, V106, P503
   Sitras V, 2009, PLACENTA, V30, P424, DOI 10.1016/j.placenta.2009.01.012
   Stylli SS, 2012, J CLIN NEUROSCI, V19, P436, DOI 10.1016/j.jocn.2011.11.013
   Toft JH, 2008, J MATERN-FETAL NEO M, V21, P267, DOI 10.1080/14767050801924118
   Tsai S, 2011, PLACENTA, V32, P175, DOI 10.1016/j.placenta.2010.11.014
   Urdinguio RG, 2009, LANCET NEUROL, V8, P1056, DOI 10.1016/S1474-4422(09)70262-5
   Várkonyi T, 2011, PLACENTA, V32, pS21, DOI 10.1016/j.placenta.2010.04.014
   Wang W, 2012, J CLIN ENDOCR METAB, V97, pE1051, DOI 10.1210/jc.2011-3131
   Weaver AM, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.288pe56
   Xiang Y, 2012, MOL HUM REP IN PRESS
   Yuen RKC, 2010, EUR J HUM GENET, V18, P1006, DOI 10.1038/ejhg.2010.63
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   Zhao AM, 2011, MOL HUM REPROD, V17, P199, DOI 10.1093/molehr/gaq092
NR 55
TC 34
Z9 39
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 27
PY 2013
VL 8
IS 3
AR e59753
DI 10.1371/journal.pone.0059753
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 124QO
UT WOS:000317480700053
PM 23544093
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ghimenti, C
   Mello-Grand, M
   Grosso, E
   Scatolini, M
   Regolo, L
   Zambelli, A
   Chiorino, G
AF Ghimenti, Chiara
   Mello-Grand, Maurizia
   Grosso, Enrico
   Scatolini, Maria
   Regolo, Lea
   Zambelli, Alberto
   Chiorino, Giovanna
TI Regulation of aromatase expression in breast cancer treated with
   anastrozole neoadjuvant therapy
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE breast neoplasms; aromatase inhibitors; genetic polymorphism; aromatase
   targeting microRNAs; intrinsic resistance
ID GENE; POLYMORPHISM; INHIBITORS; LETROZOLE
AB Aromatase inhibitors (AIs), such as anastrozole, are established in the treatment of hormone-dependent breast cancer. However, similar to 20% of patients with hormone receptor-positive breast tumors treated with anastrozole do not respond and it remains impossible to accurately predict sensitivity. Since polymorphisms in the aromatase gene may influence the response to inhibitory drugs, we evaluated the presence of rs6493497 and rs7176005 polymorphisms (mapping in the 5'-flanking region of the CYP19A1 gene coding for the aromatase protein) in a cohort of 37 patients with postmenopausal breast cancer who received three-month neoadjuvant treatment with anastrozole. We then investigated any association of the polymorphisms with changes in aromatase mRNA expression change and/or response to treatment. We also analyzed five miRNAs computationally predicted to target aromatase, to observe any association between their expression and sensitivity to anastrozole. Three samples carried the two polymorphisms and the remaining samples were wild-type for both, however, no association with response or with aromatase mRNA basal expression level or expression difference after therapy was observed. Polymorphic samples that were resistant to anastrozole showed no change or decrease in aromatase expression following AI treatment, whereas an increase in expression was observed for the polymorphic responsive samples. No statistically significant correlation was observed between miRNA and aromatase mRNA expression, or with response to anastrozole neoadjuvant treatment. These data indicate that the polymorphisms analyzed are not involved in aromatase activity and that other epigenetic mechanisms may regulate aromatase protein expression.
C1 [Ghimenti, Chiara; Mello-Grand, Maurizia; Grosso, Enrico; Scatolini, Maria; Chiorino, Giovanna] Fdn Edo & Elvo Tempia Valenta, Canc Genom Lab, I-13900 Biella, Italy.
   [Regolo, Lea] IRCCS Fdn Salvatore Maugeri, Unit Senol, Pavia, Italy.
   [Zambelli, Alberto] IRCCS Fdn Salvatore Maugeri, Unit Med Oncol, Pavia, Italy.
C3 Istituti Clinici Scientifici Maugeri IRCCS; Istituti Clinici Scientifici
   Maugeri IRCCS
RP Chiorino, G (通讯作者)，Fdn Edo & Elvo Tempia Valenta, Canc Genom Lab, 3 Via Malta, I-13900 Biella, Italy.
EM giovanna.chiorino@fondazionetempia.org
RI regolo, lea/AAE-3104-2020; Scatolini, Maria/ABA-7311-2020; Chiorino,
   Giovanna/K-5037-2016; Zambelli, Alberto/HGB-1572-2022
OI Chiorino, Giovanna/0000-0002-9502-6400; Zambelli,
   Alberto/0000-0002-1374-1831
CR Brueggemeier RW, 2005, ENDOCR REV, V26, P331, DOI 10.1210/er.2004-0015
   Colomer R, 2008, CLIN CANCER RES, V14, P811, DOI 10.1158/1078-0432.CCR-07-1923
   Garcia-Casado Z, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-36
   Ghimenti C, 2010, EXP THER MED, V1, P939, DOI 10.3892/etm.2010.151
   Mello-Grand M, 2010, BREAST CANCER RES TR, V121, P399, DOI 10.1007/s10549-010-0887-y
   Park IH, 2011, CANCER CHEMOTH PHARM, V68, P1263, DOI 10.1007/s00280-011-1615-y
   Shibahara Y, 2012, J PATHOL, V227, P357, DOI 10.1002/path.4019
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Wang LW, 2010, CANCER RES, V70, P319, DOI 10.1158/0008-5472.CAN-09-3224
   Xu SY, 2011, ENDOCRINOLOGY, V152, P3941, DOI 10.1210/en.2011-1147
   Yue W, 1998, CANCER RES, V58, P927
NR 11
TC 15
Z9 16
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
J9 EXP THER MED
JI Exp. Ther. Med.
PD MAR
PY 2013
VL 5
IS 3
BP 902
EP 906
DI 10.3892/etm.2012.878
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 096SB
UT WOS:000315423500045
PM 23408108
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Momose, K
   Minami, A
   Shimono, Y
   Mizutani, K
   Nobutani, K
   Azuma, T
   Takai, Y
AF Momose, Kenji
   Minami, Akihiro
   Shimono, Yohei
   Mizutani, Kiyohito
   Nobutani, Kentaro
   Azuma, Takeshi
   Takai, Yoshimi
TI miR-214 and hypoxia down-regulate Necl-2/CADM1 and enhance ErbB2/ErbB3
   signaling
SO GENES TO CELLS
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR4; CELL-ADHESION MOLECULE; TUMOR-SUPPRESSOR;
   IMMUNOGLOBULIN SUPERFAMILY; OVARIAN-CANCER; INDUCIBLE FACTOR;
   BREAST-CANCER; LUNG-CANCER; GENE; EXPRESSION
AB Necl-2/CADM1 is down-regulated by the promoter hypermethylation and/or the loss of heterozygosity at chromosome 11q23.2 in many types of cancers and serves as a tumor suppressor by interacting in cis with ErbB3 and suppressing the ligand-induced ErbB2/ErbB3 signaling for cell movement and death. However, the incidence of these epigenetic and genetic abnormalities of Necl-2 is 3060% in these cancers. We investigated here other mechanisms that down-regulate Necl-2. miR-214, that is frequently up-regulated in a variety of cancers, targeted the 3UTR of the Necl-2 mRNA directly, suppressed the translation of Necl-2 and enhanced the ligand-induced ErbB2/ErbB3 signaling in human colon cancer Caco-2 cells. Hypoxia reduced the Necl-2 protein level in a manner independent of miR-214 or hypoxia-inducible factor-1 in Caco-2 cells. These results indicate that miR-214 and hypoxia are novel regulators that down-regulate Necl-2 and enhance ErbB2/ErbB3 signaling.
C1 [Momose, Kenji; Minami, Akihiro; Shimono, Yohei; Mizutani, Kiyohito; Nobutani, Kentaro; Takai, Yoshimi] Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol & Cellular Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
   [Momose, Kenji; Minami, Akihiro; Nobutani, Kentaro; Azuma, Takeshi] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Gastroenterol,Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Kobe University
RP Takai, Y (通讯作者)，Kobe Univ, Grad Sch Med, Dept Biochem & Mol Biol, Div Mol & Cellular Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM ytakai@med.kobe-u.ac.jp
RI AZUMA, TAKESHI/ADS-9307-2022; Mizutani, Kiyohito/L-8474-2019
OI Shimono, Yohei/0000-0002-6256-4704
FU Global COE Program 'Global Center for Education and Research in
   Integrative Membrane Biology'; Targeted Proteins Research Program from
   the Ministry of Education, Culture, Sports, Science and Technology,
   Japan; Japan Society for the Promotion of Science; Core Research for
   Evolutional Science and Technology from the Japanese Science and
   Technology Agency; Naito Foundation; Sagawa Foundation; Yasuda Medical
   Foundation; Cell Science Research Foundation; Grants-in-Aid for
   Scientific Research [23501268, 23130510, 24790284] Funding Source: KAKEN
FX This work was supported by the Global COE Program 'Global Center for
   Education and Research in Integrative Membrane Biology' and the Targeted
   Proteins Research Program from the Ministry of Education, Culture,
   Sports, Science and Technology, Japan, by Grants-in-Aid from the Japan
   Society for the Promotion of Science, by the Core Research for
   Evolutional Science and Technology from the Japanese Science and
   Technology Agency, and by the grants from the Naito Foundation, the
   Sagawa Foundation, the Yasuda Medical Foundation, and the Cell Science
   Research Foundation.
CR Abaan OD, 2008, CANCER METAST REV, V27, P205, DOI 10.1007/s10555-008-9114-2
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356
   Chen PJ, 2012, HEPATOLOGY, V56, P632, DOI 10.1002/hep.25695
   Galanis A, 2008, CANCER LETT, V266, P12, DOI 10.1016/j.canlet.2008.02.028
   Galibert L, 2005, J BIOL CHEM, V280, P21955, DOI 10.1074/jbc.M502095200
   Gomyo H, 1999, GENOMICS, V62, P139, DOI 10.1006/geno.1999.6001
   Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125
   Kawano S, 2009, J BIOL CHEM, V284, P23793, DOI 10.1074/jbc.M109.025155
   Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934
   Lahiry P, 2010, NAT REV GENET, V11, P60, DOI 10.1038/nrg2707
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li QJ, 2012, TUMOR BIOL, V33, P1455, DOI 10.1007/s13277-012-0396-1
   Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200
   Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0
   Mizutani K, 2011, J BIOL CHEM, V286, P36667, DOI 10.1074/jbc.M110.200535
   Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x
   Penna E, 2011, EMBO J, V30, P1990, DOI 10.1038/emboj.2011.102
   Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267
   Schraml P, 1999, CLIN CANCER RES, V5, P1966
   Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shingai T, 2003, J BIOL CHEM, V278, P35421, DOI 10.1074/jbc.M305387200
   Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874
   Takai Y, 2008, ANNU REV CELL DEV BI, V24, P309, DOI 10.1146/annurev.cellbio.24.110707.175339
   Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457
   Taylor CT, 2009, ANN NY ACAD SCI, V1177, P178, DOI 10.1111/j.1749-6632.2009.05024.x
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2
   Urase K, 2001, NEUROREPORT, V12, P3217, DOI 10.1097/00001756-200110290-00015
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wakayama T, 2001, MOL REPROD DEV, V60, P158, DOI 10.1002/mrd.1072
   Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Xu CX, 2012, J BIOL CHEM, V287, P34970, DOI 10.1074/jbc.M112.374611
   Yageta M, 2002, CANCER RES, V62, P5129
   Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488
   Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111
   Zhang XJ, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-46
NR 43
TC 19
Z9 22
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-9597
J9 GENES CELLS
JI Genes Cells
PD MAR
PY 2013
VL 18
IS 3
BP 195
EP 202
DI 10.1111/gtc.12027
PG 8
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 096IQ
UT WOS:000315397800003
PM 23301758
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Li, YY
   Meeran, SM
   Patel, SN
   Chen, HP
   Hardy, TM
   Tollefsbol, TO
AF Li, Yuanyuan
   Meeran, Syed M.
   Patel, Shweta N.
   Chen, Huaping
   Hardy, Tabitha M.
   Tollefsbol, Trygve O.
TI Epigenetic reactivation of estrogen receptor-α (ERα) by genistein
   enhances hormonal therapy sensitivity in ERα-negative breast cancer
SO MOLECULAR CANCER
LA English
DT Article
DE Genistein; ER alpha; Tamoxifen; Epigenetic; Breast cancer
ID HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN-A; IN-VITRO; EXPRESSION;
   TAMOXIFEN; METHYLATION; ACTIVATION; GROWTH; GENES; CELLS
AB Background: Estrogen receptor-alpha (ER alpha)-negative breast cancer is clinically aggressive and normally does not respond to conventional estrogen target-directed therapies. The soybean isoflavone, genistein (GE), has been shown to prevent and inhibit breast cancer and recent studies have suggested that GE can enhance the anticancer capacity of an estrogen antagonist, tamoxifen (TAM), especially in ER alpha-positive breast cancer cells. However, the role of GE in ER alpha-negative breast cancer remains unknown.
   Methods: We have evaluated the in vitro and in vivo epigenetic effects of GE on ER alpha reactivation by using MTT assay, real-time reverse transcription-polymerase chain reaction (RT-PCR) assay, western-blot assay, immunoprecipitation (ChIP) assay, immunohistochemistry and epigenetic enzymatic activity analysis. Preclinical mouse models including xenograft and spontaneous breast cancer mouse models were used to test the efficacy of GE in vivo.
   Results: We found that GE can reactivate ER alpha expression and this effect was synergistically enhanced when combined with a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), in ER alpha-negative MDA-MB-231 breast cancer cells. GE treatment also re-sensitized ER alpha-dependent cellular responses to activator 17 beta-estradiol (E-2) and antagonist TAM. Further studies revealed that GE can lead to remodeling of the chromatin structure in the ER alpha promoter thereby contributing to ER alpha reactivation. Consistently, dietary GE significantly prevented cancer development and reduced the growth of ER alpha-negative mouse breast tumors. Dietary GE further enhanced TAM-induced anti-cancer efficacy due at least in part to epigenetic ER alpha reactivation.
   Conclusions: Our studies suggest that soybean genistein can epigenetically restore ER alpha expression, which in turn increases TAM-dependent anti-estrogen therapeutic sensitivity in vitro and in vivo. The results from our studies reveal a novel therapeutic combination approach using bioactive soybean product and anti-hormone therapy in refractory ER alpha-negative breast cancer which will provide more effective options in breast cancer therapy.
C1 [Li, Yuanyuan; Chen, Huaping; Hardy, Tabitha M.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL USA.
   [Patel, Shweta N.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Meeran, Syed M.] Cent Drug Res Inst, Div Endocrinol, Lucknow 226001, Uttar Pradesh, India.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Council
   of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug
   Research Institute (CDRI)
RP Li, YY (通讯作者)，Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
EM lyy@uab.edu
RI Meeran, Syed/AAG-2157-2020; Chen, Huaping/O-3096-2014
OI Chen, Huaping/0000-0002-9835-5138
FU American Institute for Cancer Research (AICR); National Cancer Institute
   [CA 129415]; Susan G Komen for the Cure; American Cancer Society Award
   [IRG-60-001-47]; AICR; UAB Comprehensive Cancer Center [CA 13148-31]
FX This work was supported by grants from the American Institute for Cancer
   Research (AICR); the National Cancer Institute (CA 129415); Susan G
   Komen for the Cure and the American Cancer Society Award
   (IRG-60-001-47). YL was supported by a Postdoctoral Award (PDA)
   sponsored by AICR; a Junior Faculty Development Grant by American Cancer
   Society Award and UAB Comprehensive Cancer Center (CA 13148-31). We
   would like to thank Dr. Stephen Barnes (Departments of Biochemistry and
   Molecular Genetics) for providing insightful consultation in study
   design.
CR Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358
   [Anonymous], 1983, Cancer Res, V43, P3018
   BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S
   Belguise K, 2007, CANCER RES, V67, P5763, DOI 10.1158/0008-5472.CAN-06-4327
   Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294
   Cassidy A, 2000, P NUTR SOC, V59, P489, DOI 10.1017/S0029665100000719
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Dickson R B, 2000, J Natl Cancer Inst Monogr, P135
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Dong JY, 2011, BREAST CANCER RES TR, V125, P315, DOI 10.1007/s10549-010-1270-8
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690
   Fritz WA, 2002, MOL CELL ENDOCRINOL, V186, P89, DOI 10.1016/S0303-7207(01)00663-3
   Gadducci A, 2005, GYNECOL ENDOCRINOL, V20, P343, DOI 10.1080/09513590500128492
   Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280
   HENDERSON BE, 1991, BREAST CANCER RES TR, V18, pS11, DOI 10.1007/BF02633520
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mai ZM, 2007, MOL CARCINOGEN, V46, P534, DOI 10.1002/mc.20300
   Mai ZM, 2007, CARCINOGENESIS, V28, P1217, DOI 10.1093/carcin/bgm004
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Mentor-Marcel R, 2001, CANCER RES, V61, P6777
   Messina M, 2006, JNCI-J NATL CANCER I, V98, P1275, DOI 10.1093/jnci/djj356
   MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mourits MJE, 2001, OBSTET GYNECOL, V97, P855, DOI 10.1016/S0029-7844(00)01196-0
   OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5
   Olaharski AJ, 2006, TOXICOL SCI, V93, P341, DOI 10.1093/toxsci/kfl068
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446
   Shao WL, 2004, BREAST CANCER RES, V6, P39, DOI 10.1186/bcr742
   Shon YH, 2006, J BIOCHEM MOL BIOL, V39, P448
   Sui M, 2011, CURR MED CHEM, V18, P4674, DOI 10.2174/092986711797379348
   Tryndyak VP, 2006, CARCINOGENESIS, V27, P1713, DOI 10.1093/carcin/bgl050
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 45
TC 135
Z9 145
U1 1
U2 41
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD FEB 4
PY 2013
VL 12
AR 9
DI 10.1186/1476-4598-12-9
PG 17
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 097WC
UT WOS:000315503200002
PM 23379261
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Junk, DJ
   Cipriano, R
   Stampfer, M
   Jackson, MW
AF Junk, Damian J.
   Cipriano, Rocky
   Stampfer, Martha
   Jackson, Mark W.
TI Constitutive CCND1/CDK2 Activity Substitutes for p53 Loss, or MYC or
   Oncogenic RAS Expression in the Transformation of Human Mammary
   Epithelial Cells
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; CYCLIN D1; INDUCED SENESCENCE; GROWTH; AMPLIFICATION;
   GENES; CDK2; PHOSPHORYLATION; OVEREXPRESSION; PROLIFERATION
AB Cancer develops following the accumulation of genetic and epigenetic alterations that inactivate tumor suppressor genes and activate proto-oncogenes. Dysregulated cyclin-dependent kinase (CDK) activity has oncogenic potential in breast cancer due to its ability to inactivate key tumor suppressor networks and drive aberrant proliferation. Accumulation or over-expression of cyclin D1 (CCND1) occurs in a majority of breast cancers and over-expression of CCND1 leads to accumulation of activated CCND1/CDK2 complexes in breast cancer cells. We describe here the role of constitutively active CCND1/CDK2 complexes in human mammary epithelial cell (HMEC) transformation. A genetically-defined, stepwise HMEC transformation model was generated by inhibiting p16 and p53 with shRNA, and expressing exogenous MYC and mutant RAS. By replacing components of this model, we demonstrate that constitutive CCND1/CDK2 activity effectively confers anchorage independent growth by inhibiting p53 or replacing MYC or oncogenic RAS expression. These findings are consistent with several clinical observations of luminal breast cancer sub-types that show elevated CCND1 typically occurs in specimens that retain wild-type p53, do not amplify MYC, and contain no RAS mutations. Taken together, these data suggest that targeted inhibition of constitutive CCND1/CDK2 activity may enhance the effectiveness of current treatments for luminal breast cancer.
C1 [Junk, Damian J.; Cipriano, Rocky; Jackson, Mark W.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   [Stampfer, Martha] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Jackson, Mark W.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University
   of California System; University of California Berkeley; United States
   Department of Energy (DOE); Lawrence Berkeley National Laboratory;
   University System of Ohio; Case Western Reserve University
RP Jackson, MW (通讯作者)，Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
EM mark.w.jackson@case.edu
OI Junk, Damian/0000-0002-9251-3799
FU U.S. Department of Energy [DE-AC02-05CH11231]; NIH [T32 CA059366]
FX Martha Stampfer was supported under the U.S. Department of Energy
   contract No. DE-AC02-05CH11231. Damian Junk was supported by NIH T32
   CA059366. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aggarwal BB, 2005, CELL CYCLE, V4, P1201, DOI 10.4161/cc.4.9.1993
   Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945
   BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   BUCKLEY MF, 1993, ONCOGENE, V8, P2127
   Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409
   Chytil A, 2004, J BIOL CHEM, V279, P47688, DOI 10.1074/jbc.M405938200
   Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108
   Corsino P, 2007, CANCER RES, V67, P3135, DOI 10.1158/0008-5472.CAN-06-3815
   Corsino P, 2009, J BIOL CHEM, V284, P29945, DOI 10.1074/jbc.M109.055251
   Cuny M, 2000, CANCER RES, V60, P1077
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499
   FILMUS J, 1994, ONCOGENE, V9, P3627
   Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419
   Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X
   Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q
   GILLETT C, 1994, CANCER RES, V54, P1812
   Guedj M., 2011, Oncogene
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hydbring P, 2010, CANCER RES, V70, P6687, DOI 10.1158/0008-5472.CAN-10-1383
   Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106
   Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307
   Kan CE, 2007, CANCER RES, V67, P9862, DOI 10.1158/0008-5472.CAN-07-0259
   KATO J, 1993, GENE DEV, V7, P331
   LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0
   Mani S, 2000, EXPERT OPIN INV DRUG, V9, P1849, DOI 10.1517/13543784.9.8.1849
   MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O
   Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Olsen CL, 2002, ONCOGENE, V21, P6328, DOI 10.1038/sj.onc.1205780
   PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0
   Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009
   RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0
   STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415
   Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814
NR 39
TC 22
Z9 29
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 4
PY 2013
VL 8
IS 2
AR e53776
DI 10.1371/journal.pone.0053776
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 086NH
UT WOS:000314691100008
PM 23390492
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Dagdemir, A
   Durif, J
   Ngollo, M
   Bignon, YJ
   Bernard-Gallon, D
AF Dagdemir, Aslihan
   Durif, Julie
   Ngollo, Marjolaine
   Bignon, Yves-Jean
   Bernard-Gallon, Dominique
TI Histone lysine trimethylation or acetylation can be modulated by
   phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines
SO EPIGENOMICS
LA English
DT Article
DE acetylation; breast cancer; histone; methylation; soy phytoestrogens
ID SOY PHYTOESTROGENS; GENE-EXPRESSION; SPORADIC BREAST; DNA METHYLATION;
   BRCA1; ISOFLAVONES; EQUOL; GENISTEIN; PATTERNS; BINDING
AB Aim: The isoflavones genistein, daidzein and equol (daidzein metabolite) have been reported to interact with epigenetic modifications, specifically hypermethylation of tumor suppressor genes. The objective of this study was to analyze and understand the mechanisms by which phytoestrogens act on chromatin in breast cancer cell lines. Materials & methods: Two breast cancer cell lines, MCF-7 and MDA-MB 231, were treated with genistein (18.5 mu M), daidzein (78.5 mu M), equol (12.8 mu M), 17 beta-estradiol (10 nM) and suberoylanilide hydroxamic acid (1 mu M) for 48 h. A control with untreated cells was performed. 17 beta-estradiol and an anti-HDAC were used to compare their actions with phytoestrogens. The chromatin immunoprecipitation coupled with quantitative PCR was used to follow soy phytoestrogen effects on H3 and H4 histones on H3K27me3, H3K9me3, H3K4me3, H4K8ac and H3K4ac marks, and we selected six genes (EZH2, BRCA1, ER alpha, ER beta, SRC3 and P300) for analysis. Results: Soy phytoestrogens induced a decrease in trimethylated marks and an increase in acetylating marks studied at six selected genes. Conclusion: We demonstrated that soy phytoestrogens tend to modify transcription through the demethylation and acetylation of histones in breast cancer cell lines.
C1 [Dagdemir, Aslihan; Durif, Julie; Ngollo, Marjolaine; Bignon, Yves-Jean; Bernard-Gallon, Dominique] CBRV, Dept Oncogenet, Ctr Jean Perrin, F-63001 Clermont Ferrand, France.
   [Dagdemir, Aslihan; Durif, Julie; Ngollo, Marjolaine; Bignon, Yves-Jean; Bernard-Gallon, Dominique] Univ Auvergne, ERTICA, EA 4677, F-63001 Clermont Ferrand, France.
   [Dagdemir, Aslihan; Durif, Julie; Ngollo, Marjolaine; Bignon, Yves-Jean; Bernard-Gallon, Dominique] CRNH, F-63009 Clermont Ferrand, France.
C3 UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA)
RP Bignon, YJ (通讯作者)，CBRV, Dept Oncogenet, Ctr Jean Perrin, 28 Pl Henri Dunant,BP 38, F-63001 Clermont Ferrand, France.
EM yves-jean.bignon@cjp.fr
RI Bernard-Gallon, Dominique/L-6079-2015
FU La Ligue Nationale Contre le Cancer, Comite de la Region Auvergne;
   Protema Saglik Hizm
FX This work was supported by La Ligue Nationale Contre le Cancer, Comite
   de la Region Auvergne. The authors are indebted to P Dechelotte who
   contributed to this study. The authors also thank C Picard for
   immunohistochemical technique. A Dagdemir received a grant from Protema
   Saglik Hizm. A.S. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Adjakly M, 2011, EPIGENOMICS-UK, V3, P795, DOI [10.2217/EPI.11.103, 10.2217/epi.11.103]
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bosviel R, 2012, BRIT J NUTR, V108, P1187, DOI 10.1017/S000711451100657X
   Bosviel R, 2012, CANCER EPIDEMIOL, V36, pE177, DOI 10.1016/j.canep.2012.02.001
   Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Hedlund TE, 2003, PROSTATE, V54, P68, DOI 10.1002/pros.10137
   Hong T, 2004, BIOCHEM BIOPH RES CO, V317, P259, DOI 10.1016/j.bbrc.2004.03.041
   Jackson RL, 2011, MENOPAUSE, V18, P185, DOI 10.1097/gme.0b013e3181e9779c
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Keinan-Boker L, 2004, AM J CLIN NUTR, V79, P282
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844
   Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492
   Muthyala RS, 2004, BIOORGAN MED CHEM, V12, P1559, DOI 10.1016/j.bmc.2003.11.035
   Nadal-Serrano M, 2012, J CELL BIOCHEM, V113, P3178, DOI 10.1002/jcb.24192
   Pasqualini JR, 2004, BBA-REV CANCER, V1654, P123, DOI 10.1016/j.bbcan.2004.03.001
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007
   Pfitscher A, 2008, J STEROID BIOCHEM, V112, P87, DOI 10.1016/j.jsbmb.2008.08.007
   Plomley JB, 2011, J PHARMACEUT BIOMED, V55, P125, DOI 10.1016/j.jpba.2010.12.031
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Satih S, 2008, CURR NUTR FOOD SCI, V4, P259, DOI 10.2174/157340108786263658
   Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Ström A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100
   Takeuchi S, 2009, BIOL PHARM BULL, V32, P195, DOI 10.1248/bpb.32.195
   Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025
   Trock BJ, 2006, JNCI-J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102
   Vissac-Sabatier C, 2003, NUTR CANCER, V45, P247, DOI 10.1207/S15327914NC4502_15
   Völkel P, 2007, BIOCHIMIE, V89, P1, DOI 10.1016/j.biochi.2006.07.009
   Wolff MS, 1997, ENVIRON HEALTH PERSP, V105, P891, DOI 10.2307/3433299
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145
   Yerbes R, 2012, INVEST NEW DRUG, V30, P541, DOI 10.1007/s10637-010-9597-x
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368
NR 46
TC 65
Z9 69
U1 1
U2 36
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD FEB
PY 2013
VL 5
IS 1
BP 51
EP 63
DI 10.2217/EPI.12.74
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 093CD
UT WOS:000315168400014
PM 23414320
DA 2025-01-12
ER

PT J
AU Ferraro, A
   Mourtzoukou, D
   Kosmidou, V
   Avlonitis, S
   Kontogeorgos, G
   Zografos, G
   Pintzas, A
AF Ferraro, Angelo
   Mourtzoukou, Despoina
   Kosmidou, Vivian
   Avlonitis, Spiros
   Kontogeorgos, George
   Zografos, George
   Pintzas, Alexander
TI EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control
   Epithelial-Mesenchymal Transition and anoikis in colon cancer cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE EZH2; ITG alpha 2; EMT; Metastasis; Anoikis
ID RAS-INDUCED TRANSFORMATION; AGGRESSIVE BREAST-CANCER; GROUP PROTEIN
   EZH2; COLORECTAL-CANCER; PROSTATE-CANCER; ALPHA(2)BETA(1) INTEGRIN;
   METASTASIS SUPPRESSOR; MICROARRAY ANALYSIS; CARCINOMA CELLS; ERK PATHWAY
AB Epithelial-Mesenchymal Transition is a good example of cell plasticity. In tumorigenesis, this process has been associated with metastasis. Overexpression of EZH2 has been detected in most malignant human tumors, including colorectal carcinomas. Herein, we provide evidence supporting the idea that oncogenic Epithelial-Mesenchymal Transition in colon cancer cell models is partially controlled by epigenetic factors such as the transcription regulator EZH2. Evaluation of EZH2 mRNA and protein levels revealed overexpression in cell lines with metastatic traits. Analysis of EZH2 mRNA expression was expanded in clinical samples of colon cancer, and high level of EZH2 correlates with appearance of metastasis. Furthermore, inhibition of ERK and AKT pathways in metastatic colon cancer cell lines attenuates EZH2 overexpression. EZH2 promoter analysis illustrates presence of putative AP-1 binding sites and occupancy of transcription factors such as FRA-1 and C-JUN is demonstrated here on EZH2 promoter. Abrogation of EZH2 expression impairs the ability of colon cancer cells to move associated with anoikis in three-dimensional environment. Integrin alpha2 was identified to be a novel EZH2 target by chromatin immunoprecipitation and short hairpin RNA analysis. This study proposes that activation of ERK/AKT pathways and FRA1/C-JUN induce EZH2 overexpression, which results in Integrin alpha2 silencing. Our results show how deregulation of epigenetic factors and mechanisms can affect cancer cell aggressiveness and propose EZH2 as a potential metastasis marker and/or therapeutic target for colorectal cancer treatment. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Ferraro, Angelo; Kosmidou, Vivian; Pintzas, Alexander] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Lab Signal Mediated Gene Express, Athens 11635, Greece.
   [Avlonitis, Spiros; Zografos, George] Gen Hosp Athens G Gennimatas, Dept Surg 3, Athens 11527, Greece.
   [Mourtzoukou, Despoina; Kontogeorgos, George] Gen Hosp Athens G Gennimatas, Dept Pathol, Athens 11527, Greece.
C3 National Hellenic Research Foundation
RP Pintzas, A (通讯作者)，Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Lab Signal Mediated Gene Express, Athens 11635, Greece.
EM apint@eie.gr
RI KONTOGEORGOS, GEORGE/ABH-1156-2021; Ferraro, Angelo/H-3193-2019;
   Ferraro, Angelo/A-4172-2014
OI Ferraro, Angelo/0000-0002-2044-7569
FU FP7 EU [FP7-241783 EpiDia-Can]
FX This study was supported by FP7 EU grant FP7-241783 EpiDia-Can to A.P.
CR Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chandran UR, 2007, BMC CANCER, V12, P7
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002
   Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Joyce T, 2009, CLIN EXP METASTAS, V26, P569, DOI 10.1007/s10585-009-9256-9
   Kalogeropoulou M, 2010, MOL CANCER RES, V8, P554, DOI 10.1158/1541-7786.MCR-09-0159
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Mazon-Pelaez I, 2010, INT J BIOCHEM CELL B, V42, P911
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Morris EJA, 2007, GUT, V56, P1419, DOI 10.1136/gut.2006.116830
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   POTTEN CS, 1975, B CANCER, V62, P419
   Provenzani A, 2006, CARCINOGENESIS, V27, P1323, DOI 10.1093/carcin/bgi377
   Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Roberts ML, 2006, INT J CANCER, V118, P616, DOI 10.1002/ijc.21386
   Shaikhibrahim Z, 2011, INT J MOL MED, V28, P605, DOI 10.3892/ijmm.2011.746
   Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9
   Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020
   Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029
   Smith E, 2010, MOL CELL, V40, P689, DOI 10.1016/j.molcel.2010.11.031
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Voulgari A, 2008, MOL CANCER RES, V6, P1071, DOI 10.1158/1541-7786.MCR-07-0375
   Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632
   Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411
NR 45
TC 59
Z9 71
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD FEB
PY 2013
VL 45
IS 2
BP 243
EP 254
DI 10.1016/j.biocel.2012.10.009
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 094GR
UT WOS:000315251500005
PM 23116973
DA 2025-01-12
ER

PT J
AU Zheng, JH
   Wang, JL
   Sun, XQ
   Hao, MG
   Ding, T
   Xiong, D
   Wang, XM
   Zhu, Y
   Xiao, G
   Cheng, GC
   Zhao, MZ
   Zhang, J
   Wang, JH
AF Zheng, Jianghua
   Wang, Jinglong
   Sun, Xueqing
   Hao, Mingang
   Ding, Tao
   Xiong, Dan
   Wang, Xiumin
   Zhu, Yu
   Xiao, Gang
   Cheng, Guangcun
   Zhao, Meizhong
   Zhang, Jian
   Wang, Jianhua
TI HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; CHEMOKINE RECEPTOR; DNA HYPERMETHYLATION;
   BREAST-CANCER; D17S5 LOCUS; CELLS; CXCR7; METHYLATION; EXPRESSION;
   HYPERMETHYLATED-IN-CANCER-1
AB Purpose: Prostate cancer is the second leading cause of cancer deaths among men in Western counties, which has also occurred in Chinese male with markedly increasing incidence in recent years. Although the mechanism underlying its progression still remains unclear, epigenetic modifications are important ethological parameters. The purpose of this study is to determine the methylation status and function of hypermethylatioted in cancer 1 (HIC1) in prostate cancer progression.
   Experimental Design: The methylation status of HIC1 promoter was assayed in cell lines, tissues, and plasma of patients with prostate cancer by using methylation-specific PCR and bisulfate sequencing PCR. The ability of HIC1 to regulate proliferation, migration, and invasion was assessed by MTT, scratch-healing assay, and reconstituted extracellular matrices in porous culture chambers. Tumorigenesis, metastases, and bone destruction were analyzed in mice bearing prostate cancer cells restoring HIC1 by using Xenogen IVIS with radiographic system and small-animal positron emission tomography computed tomographic images. Microarrays were searched for genes that had correlated expression with HIC1 mRNA. Reporter gene assays were used to determine whether HIC1 affected the expression of CXCR7, and chromatin immuno-precipitation was used to determine whether HIC1 bound to CXCR7 promoters. All P values were determined using 2-sided tests.
   Results: The methylation status of 11 CpG sites within HIC1 promoter was abundantly methylated in cell lines, tissues, and plasma of patients with prostate cancer compared with those of respective normal controls. Restoring HIC1 expression in prostate cancer cells markedly inhibited proliferation, migration, and invasion and induced the apoptosis in these cells. Moreover, mice bearing prostate cancer-restoring HIC1 cells had a marked effect on reducing tumor growth, multiple tissue metastases, and bone destruction. Notably, we also identified that the chemokine receptor CXCR7 is a direct downstream target gene of HIC1. Finally, we showed that CXCR7 promoter in prostate cancer cells is negatively regulated by HIC1, which may be responsible for prostate cancer progression.
   Conclusions: Our data show for the first time that hypermethylation of HIC1 promoter results in loss of its repressive function, responsible for prostate cancer progression and invasion. These findings suggest that therapies targeting epigenetic events regulating HIC1 expression may provide a more effective strategy for prostate cancer treatment. Clin Cancer Res; 19(6); 1400-10. (C) 2012 AACR.
C1 [Zheng, Jianghua; Wang, Jinglong; Sun, Xueqing; Hao, Mingang; Xiong, Dan; Wang, Xiumin; Xiao, Gang; Cheng, Guangcun; Wang, Jianhua] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai 200025, Peoples R China.
   [Zheng, Jianghua] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 200433, Peoples R China.
   [Ding, Tao] Shanghai Tradit Chinese Med Univ, Dept Urol, Shanghai Putuo Hosp, Shanghai, Peoples R China.
   [Zhu, Yu] Shanghai Ruijin Hosp, Dept Urol, Shanghai, Peoples R China.
   [Zhao, Meizhong] Shanghai Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai, Peoples R China.
   [Zhang, Jian] Guangxi Med Univ, Nanning, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong
   University; Shanghai Jiao Tong University; Guangxi Medical University
RP Wang, JH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China.
EM jianhuaw2007@gmail.com
RI ZHANG, JIAN/Q-6334-2018; zhang, ying/HJB-1230-2022; Hao,
   Mingang/X-2317-2018; Zhang, Yu/JQW-8689-2023; Xiao, Gang/IQU-8191-2023
OI Hao, Mingang/0000-0001-6456-1710; Xiao, Gang/0000-0001-7784-4963
FU National Natural funding of China [81071747, 81272404]; National key
   program (973) for Basic Research of China [2011CB510106, 2011CB504300];
   Shanghai Education Committee Key Discipline and Specialties Foundation
   [J50208]; Program for Professor of Special Appointment at Shanghai
   Institutions of Higher Learning; Program for Professor of Special
   Appointment at Shanghai Pujiang Program [10PJ1406400]; Shanghai
   Committee of Science and Technology [11DZ2260200]; Shanghai Municipal
   Health Bureau Subject Chief Scientist [XBR20110052]
FX Research in the authors' laboratory is supported by the National Natural
   funding of China (81071747, 81272404), National key program (973) for
   Basic Research of China (2011CB510106, 2011CB504300), Shanghai Education
   Committee Key Discipline and Specialties Foundation (J50208), the
   Program for Professor of Special Appointment (Eastern Scholar to J.
   Wang) at Shanghai Institutions of Higher Learning, and Shanghai Pujiang
   Program (10PJ1406400), Shanghai Committee of Science and Technology
   (11DZ2260200), and Program of Shanghai Municipal Health Bureau Subject
   Chief Scientist (XBR20110052).
CR Brawley OW, 2012, WORLD J UROL, V30, P195, DOI 10.1007/s00345-012-0824-2
   Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908
   Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144
   Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Fleuriel C, 2009, INT J BIOCHEM CELL B, V41, P26, DOI 10.1016/j.biocel.2008.05.028
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Hao MG, 2012, BIOCHEM PHARMACOL, V84, P204, DOI 10.1016/j.bcp.2012.04.007
   Issa JPJ, 1997, CANCER RES, V57, P1678
   Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338
   Kanai Y, 1998, CANCER LETT, V122, P135, DOI 10.1016/S0304-3835(97)00380-7
   Ke ZJ, 2006, INT J CANCER, V119, P8, DOI 10.1002/ijc.21769
   Luker KE, 2012, ONCOGENE, V31, P4750, DOI 10.1038/onc.2011.633
   Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104
   Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0
   Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002
   Parrella P, 2005, CANCER LETT, V222, P75, DOI 10.1016/j.canlet.2004.08.026
   Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822
   Stankovic-Valentin N, 2007, MOL CELL BIOL, V27, P2661, DOI 10.1128/MCB.01098-06
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x
   Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470
   Van Rechem C, 2010, MOL CELL BIOL, V30, P4045, DOI 10.1128/MCB.00582-09
   Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200
   Wang Yi, 2009, Zhonghua Yi Xue Za Zhi, V89, P1681
   Yoon SO, 2003, J BIOCHEM MOL BIOL, V36, P128
   Zawlik I, 2006, CANCER GENET CYTOGEN, V170, P24, DOI 10.1016/j.cancergencyto.2006.04.014
   Zheng JH, 2012, CANCER MICROENVIRON, V5, P285, DOI 10.1007/s12307-012-0103-1
NR 32
TC 47
Z9 52
U1 1
U2 26
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2013
VL 19
IS 6
BP 1400
EP 1410
DI 10.1158/1078-0432.CCR-12-2888
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 107BE
UT WOS:000316188900012
PM 23340301
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Dong, C
   Wu, Y
   Wang, Y
   Wang, C
   Kang, T
   Rychahou, PG
   Chi, YI
   Evers, BM
   Zhou, BP
AF Dong, C.
   Wu, Y.
   Wang, Y.
   Wang, C.
   Kang, T.
   Rychahou, P. G.
   Chi, Y-I
   Evers, B. M.
   Zhou, B. P.
TI Interaction with Suv39H1 is critical for Snail-mediated E-cadherin
   repression in breast cancer
SO ONCOGENE
LA English
DT Article
DE metastasis; EMT; chromatin modifications; transcription; Snail
ID EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; HISTONE H3; DNA
   METHYLATION; GENE-EXPRESSION; G9A; METHYLTRANSFERASES; DOMAIN;
   INFLAMMATION; SUPERFAMILY
AB Expression of E-cadherin, a hallmark of epithelial-mesenchymal transition (EMT), is often lost due to promoter DNA methylation in basal-like breast cancer (BLBC), which contributes to the metastatic advantage of this disease; however, the underlying mechanism remains unclear. Here, we identified that Snail interacted with Suv39H1 (suppressor of variegation 3-9 homolog 1), a major methyltransferase responsible for H3K9me3 that intimately links to DNA methylation. We demonstrated that the SNAG domain of Snail and the SET domain of Suv39H1 were required for their mutual interactions. We found that H3K9me3 and DNA methylation on the E-cadherin promoter were higher in BLBC cell lines. We showed that Snail interacted with Suv39H1 and recruited it to the E-cadherin promoter for transcriptional repression. Knockdown of Suv39H1 restored E-cadherin expression by blocking H3K9me3 and DNA methylation and resulted in the inhibition of cell migration, invasion and metastasis of BLBC. Our study not only reveals a critical mechanism underlying the epigenetic regulation of EMT, but also paves a way for the development of new treatment strategies against this disease. Oncogene (2013) 32, 1351-1362; doi:10.1038/onc.2012.169; published online 7 May 2012
C1 [Dong, C.; Wang, Y.; Chi, Y-I; Evers, B. M.; Zhou, B. P.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA.
   [Dong, C.; Wu, Y.; Wang, Y.; Wang, C.; Rychahou, P. G.; Evers, B. M.; Zhou, B. P.] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA.
   [Wu, Y.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA.
   [Wang, C.] Univ Kentucky, Coll Med, Dept Biostat, Lexington, KY 40506 USA.
   [Kang, T.] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.
   [Rychahou, P. G.; Evers, B. M.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA.
C3 University of Kentucky; University of Kentucky; University of Kentucky;
   University of Kentucky; State Key Lab Oncology South China; University
   of Kentucky
RP Zhou, BP (通讯作者)，Univ Kentucky, Coll Med, Markey Canc Ctr, Dept Mol & Cellular Biochem, BBSRB Room B336,741 South Limestone, Lexington, KY 40506 USA.
EM peter.zhou@uky.edu
RI Dong, Chenfang/B-1164-2013
OI Rychahou, Piotr/0000-0001-7352-9122; Chi, Young-In/0000-0001-9220-9511
FU NIH [RO1CA125454]; Susan G Komen Foundation [KG081310]; Mary Kay Ash
   Foundation
FX We thank Dr Nathan L Vanderford for critical reading and editing of this
   manuscript. This work was supported by grants from NIH (RO1CA125454),
   Susan G Komen Foundation (KG081310), and Mary Kay Ash Foundation (to BP
   Zhou).
CR Barrallo-Gimeno A, 2009, TRENDS GENET, V25, P248, DOI 10.1016/j.tig.2009.04.001
   Bergamaschi A, 2009, MOL ONCOL, V3, P469, DOI 10.1016/j.molonc.2009.07.003
   Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X
   Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227
   Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004
   Eissenberg JC, 2010, DEV BIOL, V339, P240, DOI 10.1016/j.ydbio.2009.08.017
   Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/0471250953.bi0506s15, 10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/0471250953.bi0506s47, 10.1002/cpbi.3]
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003
   Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   López-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Mullins M, 2007, CLIN CHEM, V53, P1273, DOI 10.1373/clinchem.2006.083725
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Rudolph T, 2007, MOL CELL, V26, P103, DOI 10.1016/j.molcel.2007.02.025
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254
   Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Wang Yifan, 2011, Chin J Cancer, V30, P603, DOI 10.5732/cjc.011.10226
   Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433
   Wu H, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008570, 10.1371/journal.pone.0013316]
   Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x
   Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016
   Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200
   Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527
   Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 65
TC 164
Z9 179
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 14
PY 2013
VL 32
IS 11
BP 1351
EP 1362
DI 10.1038/onc.2012.169
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 110OZ
UT WOS:000316455600002
PM 22562246
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Clarke, JM
   Armstrong, AJ
AF Clarke, J. M.
   Armstrong, A. J.
TI Novel Therapies for the Treatment of Advanced Prostate Cancer
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
DE Prostate cancer; Novel; Treatments; Castration-resistant; Androgen
   receptor; Metastatic; PI3 kinase inhibitors; Androgen synthesis
   inhibitors; Immunotherapies; Epigenetic; Epithelial mesenchymal
   transition
ID EPITHELIAL-MESENCHYMAL TRANSITION; RANDOMIZED PHASE-II; ANDROGEN
   RECEPTOR; TRANSGENIC ADENOCARCINOMA; BREAST-CANCER; DOUBLE-BLIND;
   DOCETAXEL; TRIAL; METASTASIS; SURVIVAL
AB In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.
C1 [Clarke, J. M.] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Duke Prostate Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Clarke, JM (通讯作者)，Duke Univ, Med Ctr, Duke Canc Inst, DUMCBox 102002, Durham, NC 27710 USA.
EM andrew.armstrong@duke.edu
FU Dendreon; Sanofi Aventis; Janssen; Pfizer
FX J.M. Clarke: none. A.J. Armstrong: Consultancy for Amgen, Active
   Biotech/Ipsen, Sanofi Aventis, Dendreon, BMS, and Bayer, received
   honoraria from Sanofi Aventis, Dendreon, Pfizer, and Janssen, received
   payment for development of educational presentations from Dendreon,
   Sanofi Aventis, Janssen, and Pfizer, and had travel/accommodations
   expenses covered or reimbursed from Active Biotech, Dendreon, Sanofi
   Aventis, Pfizer, BMS, and Bayer.
CR Agarwal N, 2012, EUR UROL, V61, P950, DOI 10.1016/j.eururo.2011.12.028
   Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027
   [Anonymous], J CLIN ONCOL
   [Anonymous], 2012 EUROPEAN SOCIET
   Antonarakis ES, 2011, PROSTATE CANCER P D, V14, P206, DOI 10.1038/pcan.2011.24
   Araujo JC, 2012, CANCER-AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204
   Armstrong AJ, 2012, J CLIN ONCOL, V30, P3402, DOI 10.1200/JCO.2011.40.9631
   Armstrong AJ, 2012, EUR UROL, V61, P549, DOI 10.1016/j.eururo.2011.11.009
   Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490
   Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744
   Bradley D, 2009, CANCER-AM CANCER SOC, V115, P5541, DOI 10.1002/cncr.24597
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010
   Bruno RD, 2011, STEROIDS, V76, P1268, DOI 10.1016/j.steroids.2011.06.002
   Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595
   Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008
   Cecchi F, 2010, EUR J CANCER, V46, P1260, DOI 10.1016/j.ejca.2010.02.028
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Chi KN, 2012, J CLIN ONCOL, V30
   Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771
   Chou R, 2011, TREATMENTS FOR LOCAL
   Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
   Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265
   DiPaola RS, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-1
   Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016
   Ferrari A.C., 2011, ASCO M, V29, P156
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6
   Friedlander TW, 2012, CANCER RES, V72, P616, DOI 10.1158/0008-5472.CAN-11-2079
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Gulley JL, 2011, CLIN CANCER RES, V17, P3884, DOI 10.1158/1078-0432.CCR-10-2656
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892
   Hussain M, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.4516
   Kaku T, 2011, BIOORGAN MED CHEM, V19, P6383, DOI 10.1016/j.bmc.2011.08.066
   Källberg E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034207
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597
   Kelly WK, 2012, J CLIN ONCOL, V30, P1534, DOI 10.1200/JCO.2011.39.4767
   Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105
   Kottke T, 2011, NAT MED, V17, P854, DOI 10.1038/nm.2390
   LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745
   Lu-Yao GL, 2009, JAMA-J AM MED ASSOC, V302, P1202, DOI 10.1001/jama.2009.1348
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   May KF, 2011, CLIN CANCER RES, V17, P5233, DOI 10.1158/1078-0432.CCR-10-3402
   Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834
   Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249
   Montgomery Robert B., 2012, J CLIN ONCOL
   Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728
   Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132
   Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006
   Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444
   Olsson A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-107
   Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482
   Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185
   Pili R, 2011, J CLIN ONCOL, V29, P4022, DOI 10.1200/JCO.2011.35.6295
   Rathkopf D, 2010, CANCER CHEMOTH PHARM, V66, P181, DOI 10.1007/s00280-010-1289-x
   Rathkopf DE, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.5_suppl.43
   Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916
   Ryan C, 2012, CANCER RES, V72
   Ryan CJ, 2012, ASCO M, V30
   Saad F, 2011, CLIN CANCER RES, V17, P5765, DOI 10.1158/1078-0432.CCR-11-0859
   Sadar MD, 2011, CANCER RES, V71, P1208, DOI 10.1158/0008-5472.CAN_10-3398
   Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125
   Saylor PJ, 2012, EUR UROL
   Scher HI, 2012, N ENGL J MED
   Seidenfeld J, 2000, ANN INTERN MED, V132, P566, DOI 10.7326/0003-4819-132-7-200004040-00009
   Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713
   Shiota M., 2012, CANC RES
   Singh RP, 2008, CLIN CANCER RES, V14, P7773, DOI 10.1158/1078-0432.CCR-08-1309
   Slovin SF, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.5_suppl.25
   Smith MR, 2012, J CLIN ONCOL, V30
   Sonpavde G, 2008, ASCO M, V26, P5172
   Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000
   Sun Y, 2012, NAT MED
   Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004
   Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701
   Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236
   Tatarov O, 2009, CLIN CANCER RES, V15, P3540, DOI 10.1158/1078-0432.CCR-08-1857
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   Verheul HMW, 2007, CANCER CHEMOTH PHARM, V60, P329, DOI 10.1007/s00280-006-0379-2
   Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216
   Wu KJ, 2010, ONCOL REP, V23, P1545, DOI 10.3892/or_00000794
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264
   Yu EY, 2011, UROLOGY, V77, P1166, DOI 10.1016/j.urology.2011.01.006
   Zorn CS, 2007, CLIN CANCER RES, V13, P2136, DOI 10.1158/1078-0432.CCR-06-2381
   Zoubeidi A, 2010, CLIN CANCER RES, V16, P1088, DOI 10.1158/1078-0432.CCR-09-2917
   Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057
NR 94
TC 15
Z9 19
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD MAR
PY 2013
VL 14
IS 1
BP 109
EP 126
DI 10.1007/s11864-012-0222-4
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 087MM
UT WOS:000314765700010
PM 23322116
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Alimova, I
   Birks, DK
   Harris, PS
   Knipstein, JA
   Venkataraman, S
   Marquez, VE
   Foreman, NK
   Vibhakar, R
AF Alimova, Irina
   Birks, Diane K.
   Harris, Peter S.
   Knipstein, Jeffrey A.
   Venkataraman, Sujatha
   Marquez, Victor E.
   Foreman, Nicholas K.
   Vibhakar, Rajeev
TI Inhibition of EZH2 suppresses self-renewal and induces radiation
   sensitivity in atypical rhabdoid teratoid tumor cells
SO NEURO-ONCOLOGY
LA English
DT Article
DE atypical teratoid/rhabdoid tumor; DZNep; EZH2; histone lysine
   methylation; Polycomb repressive complex 2
ID HISTONE METHYLTRANSFERASE ACTIVITY; GROUP PROTEIN EZH2; ZESTE HOMOLOG 2;
   TERATOID/RHABDOID TUMORS; CYCLIN D1; POLYCOMB; CANCER; ENHANCER; GENE;
   METHYLATION
AB Introduction. Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid/rhabdoid tumor (ATRT) is a rare, high-grade embryonal brain tumor that occurs most commonly in young children and carries a very poor prognosis. ATRTs are characterized by absence of the chromatin remodeling protein SMARCB1. Given the role of EZH2 in regulating epigenetic changes, we investigated the role of EZH2 in ATRT.
   Methods. Microarray analysis was used to evaluate expression of EZH2 in ATRT tumor samples. We used shRNA and a chemical inhibitor of EZH2 to examine the impact of EZH2 inhibition on cell growth, proliferation, and tumor cell self-renewal.
   Results. Here, we show that targeted disruption of EZH2 by RNAi or pharmacologic inhibition strongly impairs ATRT cell growth, suppresses tumor cell self-renewal, induces apoptosis, and potently sensitizes these cells to radiation. Using functional analysis of transcription factor activity, we found the cyclin D1-E2F axis to be repressed after EZH2 depletion in ATRT cells.
   Conclusions. Our observations provide evidence that EZH2 disruption alters cell cycle progression and may be an important new therapeutic target, particularly in combination with radiation, in ATRT.
C1 [Alimova, Irina; Harris, Peter S.; Knipstein, Jeffrey A.; Venkataraman, Sujatha; Foreman, Nicholas K.; Vibhakar, Rajeev] Univ Colorado Denver, Dept Pediat, Aurora, CO 80045 USA.
   [Alimova, Irina; Harris, Peter S.; Knipstein, Jeffrey A.; Venkataraman, Sujatha; Foreman, Nicholas K.; Vibhakar, Rajeev] Univ Colorado Denver, Childrens Hosp Colorado, Sect Pediat Hematol Oncol BMT, Aurora, CO 80045 USA.
   [Birks, Diane K.] Childrens Hosp Colorado, Dept Neurosurg, Denver, CO USA.
   [Birks, Diane K.] Univ Colorado Denver, Denver, CO USA.
   [Marquez, Victor E.] Natl Canc Inst Frederick, Med Chem Lab, Ctr Canc Res, NIH, Frederick, MD USA.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus; University of Colorado System;
   University of Colorado Anschutz Medical Campus; Children's Hospital
   Colorado; Children's Hospital Colorado; Children's Hospital Colorado;
   University of Colorado System; University of Colorado Denver; University
   of Colorado Anschutz Medical Campus; National Institutes of Health (NIH)
   - USA; NIH National Cancer Institute (NCI)
RP Vibhakar, R (通讯作者)，Univ Colorado Denver, Dept Pediat, 12800 E 19th Ave,Mail Stop 4103 Aurora, Aurora, CO 80045 USA.
EM rajeev.vibhakar@ucdenver.edu
RI Alimova, Irina/R-9457-2016; Marquez, Victor/KWD-9188-2024
OI Foreman, Nicholas/0000-0003-4848-4801; Knipstein,
   Jeffrey/0000-0002-0632-2751
FU NINDS [K08 NS059790]; Morgan Adams Foundation
FX This work was supported by NINDS K08 NS059790 (to R.V.) and the Morgan
   Adams Foundation (to R.V. and N.K.F.).
CR Alarcon-Vargas D, 2006, ONCOGENE, V25, P722, DOI 10.1038/sj.onc.1209112
   Alimova I, 2012, INT J CANCER, V131, P1800, DOI 10.1002/ijc.27455
   Aoki R, 2010, J HEPATOL, V52, P854, DOI 10.1016/j.jhep.2010.01.027
   Biegel JA, 2002, CLIN CANCER RES, V8, P3461
   Biegel JA, 1999, CANCER RES, V59, P74
   Birks DK, 2011, NEURO-ONCOLOGY, V13, P1296, DOI 10.1093/neuonc/nor140
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Buscariollo DL, 2012, CANCER-AM CANCER SOC, V118, P4212, DOI 10.1002/cncr.27373
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chi SN, 2009, J CLIN ONCOL, V27, P385, DOI 10.1200/JCO.2008.18.7724
   Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Fujisawa H, 2005, J NEURO-ONCOL, V73, P117, DOI 10.1007/s11060-004-4276-4
   Gardner SL, 2008, PEDIATR BLOOD CANCER, V51, P235, DOI 10.1002/pbc.21578
   Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073
   Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398
   Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Oka H, 1999, NEUROL MED-CHIR, V39, P510, DOI 10.2176/nmc.39.510
   OLSON TA, 1995, J PEDIAT HEMATOL ONC, V17, P71, DOI 10.1097/00043426-199502000-00013
   Orzan F, 2011, NEUROPATH APPL NEURO, V37, P381, DOI 10.1111/j.1365-2990.2010.01132.x
   Pereira JD, 2010, P NATL ACAD SCI USA, V107, P15957, DOI 10.1073/pnas.1002530107
   Rorke LB, 1996, J NEUROSURG, V85, P56, DOI 10.3171/jns.1996.85.1.0056
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Smits M, 2010, ONCOTARGET, V1, P710, DOI 10.18632/oncotarget.205
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   Tsang DPF, 2011, J GASTROEN HEPATOL, V26, P19, DOI 10.1111/j.1440-1746.2010.06447.x
   Tsikitis M, 2005, P NATL ACAD SCI USA, V102, P12129, DOI 10.1073/pnas.0505300102
   van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vibhakar R, 2007, NEURO-ONCOLOGY, V9, P135, DOI 10.1215/15228517-2006-038
   Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x
   Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
NR 49
TC 104
Z9 119
U1 0
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD FEB
PY 2013
VL 15
IS 2
BP 149
EP 160
DI 10.1093/neuonc/nos285
PG 12
WC Oncology; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Neurosciences & Neurology
GA 093DL
UT WOS:000315171800003
PM 23190500
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Kobayashi, Y
   Banno, K
   Shimizu, T
   Ueki, A
   Tsuji, K
   Masuda, K
   Kisu, I
   Nomura, H
   Tominaga, E
   Nagano, O
   Saya, H
   Aoki, D
AF Kobayashi, Y.
   Banno, K.
   Shimizu, T.
   Ueki, A.
   Tsuji, K.
   Masuda, K.
   Kisu, I.
   Nomura, H.
   Tominaga, E.
   Nagano, O.
   Saya, H.
   Aoki, D.
TI Gene expression profile of a newly established choriocarcinoma cell
   line, iC<SUP>3</SUP>-1, compared to existing choriocarcinoma cell lines
   and normal placenta
SO PLACENTA
LA English
DT Article
DE Choriocarcinoma; iC(3)-1; HAS2; CD44; S100; SOX3
ID EPIGENETIC INACTIVATION; BREAST-CANCER; MICROARRAY ANALYSIS; TROPHOBLAST
   CELLS; OVER-EXPRESSION; WORKSHOP REPORT; CULTURE MODELS; GROWTH; CD44;
   CHFR
AB Gestational choriocarcinoma is a malignant trophoblastic tumor that usually occurs in the uterus after pregnancy. The tumor is curable with advanced chemotherapy, but the molecular mechanism of choriocarcinoma tumorigenesis remains unclear. This is partly because the low incidence makes it difficult to obtain clinical samples for investigation and because an appropriate choriocarcinoma cell model to study the tumorigenesis has not been developed. We have established a new choriocarcinoma cell line, induced choriocarcinoma cell-1 (iC(3)-1), that possesses unique characteristics compared to other choriocarcinoma cell lines, including production of tumors that consist of the two types of cells commonly found in choriocarcinoma and mimicking of the clinical pathology. Existing trophoblast cell lines utilized in previous choriocarcinoma studies have had significantly dissimilar gene expression profiles. Therefore, it is important to choose an appropriate cell line for a particular study based on the characteristics of the cell line. In this study, to clarify the genetic characteristics of iC(3)-1 and to explore the tumorigenesis mechanism, we examined the gene profile of iC(3)-1 compared to those of existing cell lines and normal placental tissue. Bioinformatics analysis showed that several characteristic genes, IGF1R, CHFR, MUC3A, TAF7, PARK7, CDC123 and PSMD8, were significantly upregulated in iC(3)-1 compared to BeWo and JEG3 cells. Interestingly, HAS2, CD44 and S100P were significantly upregulated in iC(3)-1 compared to parental HTR8/SVneo cells and normal third trimester placenta. Choriocarcinoma samples also showed immunoreactivity to HAS2, CD44 and S100. In summary, the gene expression profile of iC(3)-1 suggests that studies using this cell line can make an important contribution to improved understanding of choriocarcinoma tumorigenesis. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Kobayashi, Y.; Banno, K.; Ueki, A.; Tsuji, K.; Masuda, K.; Kisu, I.; Nomura, H.; Tominaga, E.; Aoki, D.] Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, Tokyo 1608582, Japan.
   [Shimizu, T.; Ueki, A.; Masuda, K.; Nagano, O.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan.
   [Shimizu, T.; Ueki, A.; Masuda, K.; Nagano, O.; Saya, H.] Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol CREST, Tokyo, Japan.
C3 Keio University; Keio University; Japan Science & Technology Agency
   (JST)
RP Kobayashi, Y (通讯作者)，Keio Univ, Sch Med, Dept Obstet & Gynecol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM kobax@a2.keio.jp
RI Aoki, Daisuke/E-6650-2014; Saya, Hideyuki/J-4325-2013; Nomura,
   Hiroyuki/G-2668-2014; Banno, Kouji/C-9638-2014; Kobayashi,
   Yusuke/M-5174-2019; Nagano, Osamu/J-5874-2013
OI Nagano, Osamu/0000-0002-7630-142X; Saya, Hideyuki/0000-0001-6610-1902;
   Kobayashi, Yusuke/0000-0002-4503-2845
FU Grants-in-Aid for Scientific Research [24592530] Funding Source: KAKEN
CR Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Altieri A, 2003, LANCET ONCOL, V4, P670, DOI 10.1016/S1470-2045(03)01245-2
   Arumugam T, 2006, J NATL CANCER I, V98, P1806, DOI 10.1093/jnci/djj498
   Arumugam T, 2011, AMINO ACIDS, V41, P893, DOI 10.1007/s00726-010-0496-4
   Bagley RG, 2012, INT J ONCOL, V40, P479, DOI 10.3892/ijo.2011.1257
   Banno K, 2007, INT J ONCOL, V31, P713
   Burleigh DW, 2007, PLACENTA, V28, P383, DOI 10.1016/j.placenta.2006.05.001
   Davidson B, 2008, HUM PATHOL, V39, P87, DOI 10.1016/j.humpath.2007.05.014
   Deng SS, 2007, BREAST CANCER RES TR, V104, P21, DOI 10.1007/s10549-006-9393-7
   Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Gallagher EJ, 2011, ENDOCRINOLOGY, V152, P2546, DOI 10.1210/en.2011-0231
   GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139
   Grümmer R, 1999, PLACENTA, V20, P547, DOI 10.1053/plac.1999.0406
   Hannan NJ, 2010, BIOL REPROD, V82, P235, DOI 10.1095/biolreprod.109.077800
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Itano N, 2004, J BIOL CHEM, V279, P18679, DOI 10.1074/jbc.M313178200
   Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337
   Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893
   Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010
   King A, 2000, PLACENTA, V21, pS113, DOI 10.1053/plac.1999.0526
   Klingbeil P, 2009, MOL CANCER RES, V7, P168, DOI 10.1158/1541-7786.MCR-08-0207
   Kobayashi Y, 2011, AM J PATHOL, V179, P1471, DOI 10.1016/j.ajpath.2011.05.019
   Kosaki R, 1999, CANCER RES, V59, P1141
   Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9
   Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200
   Nishizawa H, 2007, PLACENTA, V28, P487, DOI 10.1016/j.placenta.2006.05.010
   Novakovic B, 2011, MOL HUM REPROD, V17, P344, DOI 10.1093/molehr/gar005
   Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445
   Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001
   Satoh A, 2003, CANCER RES, V63, P8606
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Shiverick KT, 2001, PLACENTA, V22, pS104, DOI 10.1053/plac.2001.0647
   Sullivan MHF, 2004, MOL CELL ENDOCRINOL, V228, P103, DOI 10.1016/j.mce.2003.03.001
   Takao T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021990
   TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026
   Wang RQ, 2003, J CLIN PATHOL, V56, P378, DOI 10.1136/jcp.56.5.378
   Wang YL, 2002, CURR CANCER DRUG TAR, V2, P191, DOI 10.2174/1568009023333863
   Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892
   Yanokura M, 2007, ONCOL REP, V17, P41
   Zhao RH, 2009, CARCINOGENESIS, V30, P2117, DOI 10.1093/carcin/bgp254
NR 45
TC 8
Z9 8
U1 1
U2 13
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0143-4004
J9 PLACENTA
JI Placenta
PD FEB
PY 2013
VL 34
IS 2
BP 110
EP 118
DI 10.1016/j.placenta.2012.11.003
PG 9
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA 088SJ
UT WOS:000314857100005
PM 23199791
DA 2025-01-12
ER

PT J
AU Horvat, T
   Dezeljin, M
   Redzic, I
   Barisic, D
   Bosnar, MH
   Lauc, G
   Zoldos, V
AF Horvat, Tomislav
   Dezeljin, Martina
   Redzic, Irma
   Barisic, Darko
   Bosnar, Maja Herak
   Lauc, Gordan
   Zoldos, Vlatka
TI Reversibility of Membrane <i>N</i>-Glycome of HeLa Cells upon Treatment
   with Epigenetic Inhibitors
SO PLOS ONE
LA English
DT Article
ID HUMAN BREAST-CANCER; DNA METHYLATION; PERICENTRIC HETEROCHROMATIN;
   MOLECULAR-BASIS; EXPRESSION; ZEBULARINE; GLYCOSYLATION; TRICHOSTATIN;
   GLYCANS; REACTIVATION
AB Glycans are essential regulators of protein function and are now in the focus of research in many physiological and pathophysiological processes. There are numerous modes of regulating their biosynthesis, including epigenetic mechanisms implicated in the expression of glyco-genes. Since N-glycans located at the cell membrane define intercellular communication as well as a cellular response to a given environment, we developed a method to preferentially analyze this fraction of glycans. The method is based on incorporation of living cells into polyacrylamide gels, partial denaturation of membrane proteins with 3 M urea and subsequent release of N-glycans with PNGase F followed by HPLC analysis. Using this newly developed method, we revealed multiple effects of epigenetic inhibitors Trichostatin A, sodium butyrate and zebularine on the composition of N-glycans in human cells. The induced changes were found to be reversible after inhibitor removal. Given that many epigenetic inhibitors are currently explored as a therapeutic strategy in treatment of cancer, wherein surface glycans play an important role, the presented work contributes to our understanding of their efficiency in altering the N-glycan profile of cancer cells in culture.
C1 [Horvat, Tomislav; Barisic, Darko; Zoldos, Vlatka] Univ Zagreb, Fac Sci, Zagreb 41000, Croatia.
   [Dezeljin, Martina; Bosnar, Maja Herak] Rudjer Boskovic Inst, Zagreb, Croatia.
   [Redzic, Irma; Lauc, Gordan] Univ Zagreb, Fac Pharm & Biochem, Zagreb 41000, Croatia.
   [Lauc, Gordan] Genos Ltd, Glycobiol Lab, Zagreb, Croatia.
   [Lauc, Gordan] Edith Cowan Univ, Perth, WA, Australia.
C3 University of Zagreb; Rudjer Boskovic Institute; University of Zagreb;
   Edith Cowan University
RP Lauc, G (通讯作者)，Univ Zagreb, Fac Pharm & Biochem, Zagreb 41000, Croatia.
EM glauc@pharma.hr; vzoldos@biol.pmf.hr
RI Barisic, Darko/JSL-1345-2023; Bosnar, Maja/AAN-6122-2020; Lauc,
   Gordan/K-5864-2012
OI Lauc, Gordan/0000-0003-1840-9560; Barisic, Darko/0000-0001-7007-9138
FU Croatian Ministry of Science, Education and Sport [309-0061194-2023,
   119-1191196-1224, 098-0982464-2513]; European Commission GlycoBioM
   [259869]; European Commission HighGlycan [278535]; AUF PSCI Grant
   (Agence universitaire de la Francophonie)
FX This work was supported by the Croatian Ministry of Science, Education
   and Sport grants #309-0061194-2023 (to GL), #119-1191196-1224 (to VZ)
   and #098-0982464-2513 (to MHB); by the European Commission GlycoBioM
   (contract #259869) and HighGlycan (contract #278535) grants and by AUF
   PSCI Grant (Agence universitaire de la Francophonie). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abbott KL, 2008, PROTEOMICS, V8, P3210, DOI 10.1002/pmic.200800157
   Alavi A, 2008, RHEUMATOLOGY, V47, P760, DOI 10.1093/rheumatology/ken081
   Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338
   Balch C, 2005, MOL CANCER THER, V4, P1505, DOI 10.1158/1535-7163.MCT-05-0216
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Champion C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012388
   Chen M, 2012, MOL CANCER THER, V11, P370, DOI 10.1158/1535-7163.MCT-11-0458
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   Chiurazzi P, 1999, HUM MOL GENET, V8, P2317, DOI 10.1093/hmg/8.12.2317
   Craig JM, 2003, EMBO J, V22, P2495, DOI 10.1093/emboj/cdg232
   Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   Dennis JW, 2009, CELL, V139, P1229, DOI 10.1016/j.cell.2009.12.008
   Dennis JW, 2009, TRAFFIC, V10, P1569, DOI 10.1111/j.1600-0854.2009.00981.x
   Diehl GE, 2004, IMMUNITY, V21, P877, DOI 10.1016/j.immuni.2004.11.008
   Gornik O, 2009, GLYCOBIOLOGY, V19, P1547, DOI 10.1093/glycob/cwp134
   Gornik O, 2008, DIS MARKERS, V25, P267, DOI 10.1155/2008/493289
   Hellebrekers DMEI, 2006, MOL CANCER THER, V5, P467, DOI 10.1158/1535-7163.MCT-05-0417
   Herranz M, 2006, BLOOD, V107, P1174, DOI 10.1182/blood-2005-05-2033
   Horvat T, 2012, BBA-GEN SUBJECTS, V1820, P1412, DOI 10.1016/j.bbagen.2011.12.007
   Horvat T, 2011, CLIN EPIGENETICS, V2, P425, DOI 10.1007/s13148-011-0039-1
   Ide Y, 2006, BIOCHEM BIOPH RES CO, V341, P478, DOI 10.1016/j.bbrc.2005.12.208
   Jitsuhara Y, 2002, J BIOCHEM, V132, P803, DOI 10.1093/oxfordjournals.jbchem.a003290
   Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594
   Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041
   Kawamura YI, 2008, GASTROENTEROLOGY, V135, P142, DOI 10.1053/j.gastro.2008.03.031
   Knezevic A, 2009, J PROTEOME RES, V8, P694, DOI 10.1021/pr800737u
   Lebrilla CB, 2009, MOL BIOSYST, V5, P17, DOI 10.1039/b811781k
   Listinsky JJ, 2011, AM J TRANSL RES, V3, P292
   Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843
   MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237
   Mariadason JM, 2000, CANCER RES, V60, P4561
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Miyoshi E, 2012, BIOMOLECULES, V2, P34, DOI 10.3390/biom2010034
   Moriwaki K, 2010, GLYCOCONJUGATE J, V27, P649, DOI 10.1007/s10719-010-9310-5
   Moriwaki K, 2009, GASTROENTEROLOGY, V137, P188, DOI 10.1053/j.gastro.2009.04.002
   Nairn AV, 2008, J BIOL CHEM, V283, P17298, DOI 10.1074/jbc.M801964200
   Packer NH, 2008, PROTEOMICS, V8, P8, DOI 10.1002/pmic.200700917
   Pajak B, 2007, ADV MED SCI-POLAND, V52, P83
   Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109
   Pucic M, 2010, GLYCOBIOLOGY, V20, P970, DOI 10.1093/glycob/cwq052
   RADEMACHER TW, 1994, P NATL ACAD SCI USA, V91, P6123, DOI 10.1073/pnas.91.13.6123
   Royle L, 2008, ANAL BIOCHEM, V376, P1, DOI 10.1016/j.ab.2007.12.012
   Schraen-Maschke S, 2003, BIOCHIMIE, V85, P219, DOI 10.1016/S0300-9084(03)00018-X
   Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430
   Serpa J, 2006, CANCER LETT, V242, P191, DOI 10.1016/j.canlet.2005.11.009
   Sharma V, 2011, J BIOL CHEM, V286, P10193, DOI 10.1074/jbc.M110.194241
   Syrbe U, 2004, BLOOD, V104, P3243, DOI 10.1182/blood-2003-09-3047
   Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010
   Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441
   Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6
   Taniguchi N., 2002, HDB GLYCOSYLTRANSFER
   Tempel W, 2004, J BIOL CHEM, V279, P29774, DOI 10.1074/jbc.M403065200
   Vanderschaeghe D, 2010, ANAL CHEM, V82, P7408, DOI 10.1021/ac101560a
   VanLint C, 1996, GENE EXPRESSION, V5, P245
   Wuhrer M, 2007, EXPERT REV PROTEOMIC, V4, P135, DOI 10.1586/14789450.4.2.135
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Zoldos V, 2012, EPIGENETICS-US, V7, P164, DOI 10.4161/epi.7.2.18918
   Zoldos Vlatka, 2010, Biomol Concepts, V1, P253, DOI 10.1515/bmc.2010.027
NR 61
TC 20
Z9 23
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2013
VL 8
IS 1
AR e54672
DI 10.1371/journal.pone.0054672
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 086SQ
UT WOS:000314707700070
PM 23336012
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ellis, HL
   Shioda, K
   Rosenthal, NF
   Coser, KR
   Shioda, T
AF Ellis, Haley L.
   Shioda, Keiko
   Rosenthal, Noel F.
   Coser, Kathryn R.
   Shioda, Toshi
TI Masculine Epigenetic Sex Marks of the <i>CYP19A1</i>/<i>Aromatase</i>
   Promoter in Genetically Male Chicken Embryonic Gonads Are Resistant to
   Estrogen-Induced Phenotypic Sex Conversion
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE embryo; endocrine disruptors; epigenetics; gene regulation; sex
   determination
ID PRIMORDIAL GERM-CELLS; BREAST-CANCER CELLS; BISPHENOL-A; DNA
   METHYLATION; TRANSGENERATIONAL ACTIONS; OVARIAN DEVELOPMENT;
   VITELLOGENIN GENE; ORGAN DEVELOPMENT; FEMALE CHICKENS; AROMATASE GENES
AB Sex of birds is genetically determined through inheritance of the ZW sex chromosomes (ZZ males and ZW females). Although the mechanisms of avian sex determination remains unknown, the genetic sex is experimentally reversible by in ovo exposure to exogenous estrogens (ZZ-male feminization) or aromatase inhibitors (ZW-female masculinization). Expression of various testis-and ovary-specific marker genes during the normal and reversed gonadal sex differentiation in chicken embryos has been extensively studied, but the roles of sex-specific epigenetic marks in sex differentiation are unknown. In this study, we show that a 170-nt region in the promoter of CYP19A1/aromatase, a key gene required for ovarian estrogen biosynthesis and feminization of chicken embryonic gonads, contains highly quantitative, nucleotide base-level epigenetic marks that reflect phenotypic gonadal sex differentiation. We developed a protocol to feminize ZZ-male chicken embryonic gonads in a highly quantitative manner by direct injection of emulsified ethynylestradiol into yolk at various developmental stages. Taking advantage of this experimental sex reversal model, we show that the epigenetic sex marks in the CYP19A1/aromatase promoter involving DNA methylation and histone lysine methylation are feminized significantly but only partially in sex-converted gonads even when morphological and transcriptional marks of sex differentiation show complete feminization, being indistinguishable from gonads of normal ZW females. Our study suggests that the epigenetic sex of chicken embryonic gonads is more stable than the morphologically or transcriptionally characterized sex differentiation, suggesting the importance of the nucleotide base-level epigenetic sex in gonadal sex differentiation.
C1 [Shioda, Toshi] Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA USA.
   Harvard Univ, Sch Med, Charlestown, MA USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University
RP Shioda, T (通讯作者)，Massachusetts Gen Hosp, Mol Profiling Lab, Ctr Canc Res, Charlestown, MA USA.
EM tshioda@partners.org
RI Ellis, Haley/IUM-8312-2023
FU NIH National Cancer Institute (NCI) Federal Share/Program Income Grant
   [R7963]; Friends of Mels grant
FX Supported by the NIH National Cancer Institute (NCI) Federal
   Share/Program Income Grant (R7963) and the Friends of Mels grant to T.S.
CR Andrews JE, 1997, GEN COMP ENDOCR, V108, P182, DOI 10.1006/gcen.1997.6978
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Bannister SC, 2011, BIOL REPROD, V85, P22, DOI 10.1095/biolreprod.110.088476
   Bannister SC, 2009, BIOL REPROD, V81, P165, DOI 10.1095/biolreprod.108.074005
   Berg C, 1999, SCI TOTAL ENVIRON, V233, P57, DOI 10.1016/S0048-9697(99)00179-5
   Berg C, 2001, ENVIRON TOXICOL CHEM, V20, P2836, DOI 10.1002/etc.5620201224
   Branco MR, 2012, NAT REV GENET, V13, P7, DOI 10.1038/nrg3080
   Bretschneider N, 2008, MOL ONCOL, V2, P182, DOI 10.1016/j.molonc.2008.05.004
   Chue J, 2011, FEBS J, V278, P1027, DOI 10.1111/j.1742-4658.2011.08032.x
   Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106
   Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100
   Deng J, 2009, NAT BIOTECHNOL, V27, P353, DOI 10.1038/nbt.1530
   Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   ELBRECHT A, 1992, SCIENCE, V255, P467, DOI 10.1126/science.1734525
   Govoroun MS, 2004, DEV DYNAM, V231, P859, DOI 10.1002/dvdy.20189
   Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100
   Halldin K, 1999, ENVIRON HEALTH PERSP, V107, P861, DOI 10.2307/3454472
   Hudson QJ, 2005, DEV DYNAM, V233, P1052, DOI 10.1002/dvdy.20388
   Inawaka K, 2009, TOXICOL APPL PHARM, V237, P178, DOI 10.1016/j.taap.2009.03.004
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   JOST JP, 1984, P NATL ACAD SCI-BIOL, V81, P429, DOI 10.1073/pnas.81.2.429
   Jung JS, 2005, STEM CELLS, V23, P689, DOI 10.1634/stemcells.2004-0208
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Kent J, 1996, DEVELOPMENT, V122, P2813
   Kim H, 2007, PHYSIOL GENOMICS, V29, P253, DOI 10.1152/physiolgenomics.00067.2006
   Kim JN, 2010, BIOL REPROD, V82, P257, DOI 10.1095/biolreprod.109.079723
   Kim JN, 2004, MOL REPROD DEV, V68, P81, DOI 10.1002/mrd.20051
   Korshunova Y, 2008, GENOME RES, V18, P19, DOI 10.1101/gr.6883307
   Lawson C, 2011, BIOL REPROD, V84, P79, DOI 10.1095/biolreprod.110.084814
   Lee EJ, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr598
   Loffler KA, 2003, ENDOCRINOLOGY, V144, P3237, DOI 10.1210/en.2002-0095
   MATSUMINE H, 1991, J BIOL CHEM, V266, P19900
   Mckernan MA, 2007, ENVIRON TOXICOL CHEM, V26, P2724, DOI 10.1897/07-291.1
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Nakabayashi O, 1998, J MOL ENDOCRINOL, V20, P193, DOI 10.1677/jme.0.0200193
   Nishikimi H, 2000, MOL REPROD DEV, V55, P20, DOI 10.1002/(SICI)1098-2795(200001)55:1<20::AID-MRD4>3.0.CO;2-E
   Pelizzola M, 2008, GENOME RES, V18, P1652, DOI 10.1101/gr.080721.108
   PESCE M, 1995, DEV BIOL, V170, P722, DOI 10.1006/dbio.1995.1250
   Rosenthal NF, 2010, POULTRY SCI, V89, P1451, DOI 10.3382/ps.2010-00638
   SCHEIB D, 1983, DIFFERENTIATION, V23, pS87
   Schneider S, 2008, REPROD TOXICOL, V25, P352, DOI 10.1016/j.reprotox.2008.04.001
   Shioda T, 2006, P NATL ACAD SCI USA, V103, P12033, DOI 10.1073/pnas.0605341103
   Skinner M.K., 2005, Sertoli cell biology
   Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007
   Smith CA, 2007, CYTOGENET GENOME RES, V117, P165, DOI 10.1159/000103177
   Smith CA, 2004, BIOESSAYS, V26, P120, DOI 10.1002/bies.10400
   Smith CA, 2003, BIOL REPROD, V68, P560, DOI 10.1095/biolreprod.102.007294
   Smith CA, 1997, J STEROID BIOCHEM, V60, P295, DOI 10.1016/S0960-0760(96)00196-3
   Smith CA, 2009, NATURE, V461, P267, DOI 10.1038/nature08298
   Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005
   TENG CS, 1985, BIOCHEM J, V228, P689, DOI 10.1042/bj2280689
   Vaillant S, 2001, DEV DYNAM, V222, P228, DOI 10.1002/dvdy.1190
   Vaillant S, 2001, J EXP ZOOL, V290, P727, DOI 10.1002/jez.1123
   vom Saal FS, 2007, REPROD TOXICOL, V24, P131, DOI 10.1016/j.reprotox.2007.07.005
   WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163
   WILKS AF, 1982, P NATL ACAD SCI-BIOL, V79, P4252, DOI 10.1073/pnas.79.14.4252
   Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301
   Yang X, 2011, SEX DEV, V5, P147, DOI 10.1159/000327712
   Yang XR, 2010, MOL BIOL REP, V37, P1841, DOI 10.1007/s11033-009-9619-y
   Yu Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002672
NR 64
TC 26
Z9 26
U1 0
U2 24
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD JUL
PY 2012
VL 87
IS 1
AR 23
DI 10.1095/biolreprod.112.099747
PG 12
WC Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology
GA 080EN
UT WOS:000314224200004
PM 22539680
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Jiao, X
   Hooper, SD
   Djureinovic, T
   Larsson, C
   Wärnberg, F
   Tellgren-Roth, C
   Botling, J
   Sjöblom, T
AF Jiao, Xiang
   Hooper, Sean D.
   Djureinovic, Tatjana
   Larsson, Chatarina
   Warnberg, Fredrik
   Tellgren-Roth, Christian
   Botling, Johan
   Sjoblom, Tobias
TI Gene rearrangements in hormone receptor negative breast cancers revealed
   by mate pair sequencing
SO BMC GENOMICS
LA English
DT Article
ID MUTATIONAL EVOLUTION; MOLECULAR PORTRAITS; COLORECTAL CANCERS; HUMAN
   GENOME; TRANSLOCATIONS; LANDSCAPES; EXPRESSION; TUMORS
AB Background: Chromosomal rearrangements in the form of deletions, insertions, inversions and translocations are frequently observed in breast cancer genomes, and a subset of these rearrangements may play a crucial role in tumorigenesis. To identify novel somatic chromosomal rearrangements, we determined the genome structures of 15 hormone-receptor negative breast tumors by long-insert mate pair massively parallel sequencing.
   Results: We identified and validated 40 somatic structural alterations, including the recurring fusion between genes DDX10 and SKA3 and translocations involving the EPHA5 gene. Other rearrangements were found to affect genes in pathways involved in epigenetic regulation, mitosis and signal transduction, underscoring their potential role in breast tumorigenesis. RNA interference-mediated suppression of five candidate genes (DDX10, SKA3, EPHA5, CLTC and TNIK) led to inhibition of breast cancer cell growth. Moreover, downregulation of DDX10 in breast cancer cells lead to an increased frequency of apoptotic nuclear morphology.
   Conclusions: Using whole genome mate pair sequencing and RNA interference assays, we have discovered a number of novel gene rearrangements in breast cancer genomes and identified DDX10, SKA3, EPHA5, CLTC and TNIK as potential cancer genes with impact on the growth and proliferation of breast cancer cells.
C1 [Jiao, Xiang; Hooper, Sean D.; Djureinovic, Tatjana; Larsson, Chatarina; Tellgren-Roth, Christian; Botling, Johan; Sjoblom, Tobias] Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
   [Warnberg, Fredrik] Uppsala Univ, Dept Surg Sci, SE-75185 Uppsala, Sweden.
C3 Uppsala University; Uppsala University
RP Sjöblom, T (通讯作者)，Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
EM Tobias.Sjoblom@igp.uu.se
RI Botling, Johan/ABA-2586-2020
OI Warnberg, Fredrik/0000-0002-0130-7296; Botling,
   Johan/0000-0003-2226-3517; Tellgren-Roth, Christian/0000-0003-0502-3693;
   Larsson, Chatarina/0000-0002-5250-3617
FU Swedish Cancer Foundation
FX The authors would like to thank the Uppsala Biobank and Uppsala Genome
   Center for their contributions in sample handling and sequencing. This
   work was supported by the Swedish Cancer Foundation.
CR Abdelhak S, 1997, HUM MOL GENET, V6, P2247, DOI 10.1093/hmg/6.13.2247
   Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936
   Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615
   Daum JR, 2009, CURR BIOL, V19, P1467, DOI 10.1016/j.cub.2009.07.017
   Debacker K, 2007, HUM MOL GENET, V16, pR150, DOI 10.1093/hmg/ddm136
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Hampton OA, 2009, GENOME RES, V19, P167, DOI 10.1101/gr.080259.108
   Howarth KD, 2008, ONCOGENE, V27, P3345, DOI 10.1038/sj.onc.1210993
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Jiao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022250
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li WQ, 2004, J BIOL CHEM, V279, P32824, DOI 10.1074/jbc.M401878200
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   Otto AM, 1996, J CANCER RES CLIN, V122, P603, DOI 10.1007/BF01221192
   Ottoboni C, 2001, MUTAGENESIS, V16, P423, DOI 10.1093/mutage/16.5.423
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645
   Theis M, 2009, EMBO J, V28, P1453, DOI 10.1038/emboj.2009.114
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567
   Wolf SS, 2007, ARCH BIOCHEM BIOPHYS, V460, P56, DOI 10.1016/j.abb.2007.01.017
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
NR 36
TC 33
Z9 38
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAR 12
PY 2013
VL 14
AR 165
DI 10.1186/1471-2164-14-165
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 107HY
UT WOS:000316207800001
PM 23496902
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Guo, W
   Dong, ZM
   Dong, YR
   Guo, YL
   Kuang, G
   Yang, ZB
AF Guo, Wei
   Dong, Zhiming
   Dong, Yuran
   Guo, Yanli
   Kuang, Gang
   Yang, Zhibin
TI Genetic and epigenetic alterations of <i>WWOX</i> in the development of
   gastric cardia adenocarcinoma
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE WWOX; gastric cardia adenocarcinoma; polymorphism; LOH; methylation;
   expression
ID TUMOR-SUPPRESSOR GENE; DOMAIN-CONTAINING OXIDOREDUCTASE; BREAST-CANCER;
   EXPRESSION; DNA; HYPERMETHYLATION; FRA16D; ASSOCIATION; METHYLATION;
   POPULATION
AB WWOX is a tumor suppressor gene that maps to the common fragile site FRA16D and is involved in carcinogenesis and cancer progression in many different carcinomas. Reduced WWOX expression is associated with more aggressive phenotypes and poor patient outcomes in several cancers. The present study was conducted in order to elucidate more precisely the genetic and epigenetic alterations of WWOX that play a role in gastric cardia adenocarcinoma (GCA) carcinogenesis in a population from Northern China. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), PCR-simple sequence length polymorphism (PCR-SSLP), and methylation specific PCR (MSP) methods were used to characterize polymorphisms in the rs3764340, rs2548861, and rs1079635 loci, the level of loss of heterozygosity (LOH), and methylation status of WWOX, respectively. Protein and mRNA expression of WWOX in GCA tissues was quantified by immunohistochemistry and reverse transcription-PCR (RT-PCR). Family history of upper gastrointestinal cancer (UGIC) significantly increased the risk of developing GCA. The CG+GG genotype of rs3764340 and GT or TT genotype of rs2548861 significantly elevated the risk of developing GCA. LOH at the WWOX locus was observed in 45.6% tumors. The promoter and exon 1 methylation frequency of WWOX in GCA tissues was significantly higher than in corresponding normal tissues and was associated with UGIC family history. Protein and mRNA expression of WWOX was reduced in GCA tumor tissues and was associated with LOH and methylation of the gene. These results indicate that WWOX may play an important role in GCA especially in individuals with UGIC family history. Environ. Mol. Mutagen., 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Guo, Wei; Dong, Zhiming; Dong, Yuran; Guo, Yanli; Kuang, Gang; Yang, Zhibin] Hebei Med Univ, Hosp 4, Hebei Canc Inst, Dept Lab Pathol, Shijiazhuang 050011, Hebei, Peoples R China.
C3 Hebei Medical University
RP Dong, ZM (通讯作者)，Hebei Med Univ, Hosp 4, Hebei Canc Inst, Jiankanglu 12, Shijiazhuang 050011, Hebei, Peoples R China.
EM dddzzzmmm@yahoo.com.cn
FU National Natural Science Foundation [81101854]
FX Grant sponsor: National Natural Science Foundation; Grant Number
   81101854.
CR Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150
   Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101
   Bednarek AK, 2000, CANCER RES, V60, P2140
   Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726
   Bouras T, 2001, CANCER RES, V61, P903
   Cancemi L, 2011, INT J CANCER, V129, P2816, DOI 10.1002/ijc.25937
   Dong ZM, 2008, J CLIN GASTROENTEROL, V42, P910, DOI 10.1097/MCG.0b013e3180f6262c
   Esteller M, 2001, CANCER RES, V61, P3225
   Guo W, 2009, CANCER INVEST, V27, P459, DOI 10.1080/07357900802620828
   Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350
   Hezova Renata, 2007, Biomedical Papers (Olomouc), V151, P11
   Hsu LJ, 2009, J BIOL CHEM, V284, P16049, DOI 10.1074/jbc.M806688200
   Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398
   Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038
   Ishii H, 2003, MOL CANCER RES, V1, P940
   Kosla K, 2011, J NEURO-ONCOL, V101, P207, DOI 10.1007/s11060-010-0254-1
   Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096
   Kuroki T, 2002, CANCER RES, V62, P2258
   Lange EM, 2009, PROSTATE, V69, P385, DOI 10.1002/pros.20891
   Lee JC, 2008, AM J HUM GENET, V83, P180, DOI 10.1016/j.ajhg.2008.07.002
   Lewandowska U, 2009, J PHYSIOL PHARMACOL, V60, P47
   Maeda N, 2010, VIRCHOWS ARCH, V457, P423, DOI 10.1007/s00428-010-0956-y
   Mangelsdorf M, 2000, CANCER RES, V60, P1683
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Nakayama S, 2009, BRIT J CANCER, V100, P1438, DOI 10.1038/sj.bjc.6604986
   Nakayama S, 2008, CANCER SCI, V99, P1370, DOI 10.1111/j.1349-7006.2008.00841.x
   Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898
   Pikor L. A., 2011, J VIS EXP, V26
   Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616
   Wang X, 2009, TUMOR BIOL, V30, P8, DOI 10.1159/000197911
   Yendamuri S, 2003, CANCER RES, V63, P878
   Zelazowski MJ, 2011, TUMOR BIOL, V32, P551, DOI 10.1007/s13277-010-0150-5
NR 32
TC 17
Z9 18
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0893-6692
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PD MAR
PY 2013
VL 54
IS 2
BP 112
EP 123
DI 10.1002/em.21748
PG 12
WC Environmental Sciences; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA 085EB
UT WOS:000314595400004
PM 23197378
DA 2025-01-12
ER

PT J
AU Arabsolghar, R
   Azimi, T
   Rasti, M
AF Arabsolghar, Rita
   Azimi, Tayebeh
   Rasti, Mozhgan
TI Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and
   HDAC1 in MDA-MB-468 breast cancer cells
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE p53; MDA-MB-468 cells; ESR1; HDAC1; DNMT1; MeCP2
ID HISTONE DEACETYLASE INHIBITION; DE-NOVO METHYLATION; ALPHA ER; DNA
   METHYLATION; GENE-EXPRESSION; PROTEIN; METHYLTRANSFERASE;
   HYPERMETHYLATION; ACTIVATION; DEMETHYLATION
AB DNA methylation and histone deacetylation are two epigenetic mechanisms involved in the lack of estrogen receptor (ER) expression. Our previous studies demonstrated that mutant p53 along with repression complex proteins including DNMT1, HDAC1 and MeCP2 is associated with ER-negative promoter in MDA-MB-468 cells. To elucidate the molecular mechanism of estrogen receptor 1 (ESR1) gene silencing in these cells, we down-regulated DNMT1 and HDAC1 expression using siRNAs and studied the ability of DNMT1, HDAC1, MeCP2 and p53 in binding to ESR1 promoter CpG island. Our results showed that DNMT1 or HDAC1 down-regulation disassembled the repression complex proteins and mutant p53 from ER-negative promoter. The partial demethylation of ESR1 promoter and ER re-expression in down-regulated cells supports these findings. In vivo binding studies demonstrated that mutation of p53 protein in this cell line did not affect its binding capacity to DNMT1, HDAC1 and MeCP2 proteins. Our observations suggest that not only histone deacetylase activity of HDAC1 contributes to inactivation of methylated ESR1 gene but also HDAC1 presence on ESR1 promoter is important for assembly of DNMT1 in repression complex. In addition, our data revealed that mutant p53 protein binds to the promoter of ESR1 through direct interaction with HDAC1 and indirect interaction with DNMT1, MeCP2 proteins in the ER-negative MDA-MB-468 cells.
C1 [Arabsolghar, Rita; Azimi, Tayebeh; Rasti, Mozhgan] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Recombinant Prot Lab, Shiraz, Iran.
C3 Shiraz University of Medical Science
RP Rasti, M (通讯作者)，Shiraz Univ Med Sci, Sch Med, Dept Biochem, Recombinant Prot Lab, Shiraz, Iran.
EM rasti31@yahoo.com
RI Arabsolghar, Rita/S-3994-2017
OI Arabsolghar, Rita/0000-0001-9725-8005
FU Shiraz University of Medical Sciences, Iran [89-5176, 90-5620]; School
   of Advanced Medical Sciences and Technologies
FX This work was supported by Grants No: 89-5176 and 90-5620 from the
   Shiraz University of Medical Sciences, Iran for Ms Rita Arabsolghar's
   thesis and Ms Tayebe Azimi's thesis, respectively. The authors would
   like to thank the School of Advanced Medical Sciences and Technologies
   for their support in performing this project.
CR Akaogi K, 2009, ONCOGENE, V28, P2894, DOI 10.1038/onc.2009.151
   Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497
   Böhlig L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/464916
   Chédin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999
   Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316
   Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895
   Estève PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784
   Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4
   Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Keshelava N, 2007, JNCI-J NATL CANCER I, V99, P1107, DOI 10.1093/jnci/djm044
   Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200
   Lai JC, 2008, DNA REPAIR, V7, P1352, DOI 10.1016/j.dnarep.2008.04.016
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Le Gac G, 2006, J BIOL CHEM, V281, P24161, DOI 10.1074/jbc.M603724200
   Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Qin WH, 2011, NUCLEUS-PHILA, V2, P392, DOI 10.4161/nucl.2.5.17928
   Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005
   Rasti M, 2012, PATHOL ONCOL RES, V18, P169, DOI 10.1007/s12253-011-9423-6
   Rasti Mozhgan, 2009, Iranian Biomedical Journal, V13, P199
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Saxena Neeraj K, 2010, Mol Cell Pharmacol, V2, P191
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Shirley SH, 2009, CANCER RES, V69, P3405, DOI 10.1158/0008-5472.CAN-08-3628
   Sui M, 2011, CURR MED CHEM, V18, P4674, DOI 10.2174/092986711797379348
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Tajima S, 1998, J BIOCHEM-TOKYO, V123, P993, DOI 10.1093/oxfordjournals.jbchem.a022066
   Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 43
TC 10
Z9 11
U1 1
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAR
PY 2013
VL 40
IS 3
BP 2617
EP 2625
DI 10.1007/s11033-012-2348-7
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 084JQ
UT WOS:000314535600061
PM 23242655
DA 2025-01-12
ER

PT J
AU Harada, H
   Miyamoto, K
   Yamashita, Y
   Nakano, K
   Taniyama, K
   Miyata, Y
   Ohdan, H
   Okada, M
AF Harada, Hiroaki
   Miyamoto, Kazuaki
   Yamashita, Yoshinori
   Nakano, Kikuo
   Taniyama, Kiyomi
   Miyata, Yoshihiro
   Ohdan, Hideki
   Okada, Morihito
TI Methylation of breast cancer susceptibility gene 1 (<i>BRCA1</i>)
   predicts recurrence in patients with curatively resected stage I
   nonsmall cell lung cancer
SO CANCER
LA English
DT Article
DE BRCA1; methylation; epigenetics; prognosis; nonsmall cell lung cancer
ID MESSENGER-RNA EXPRESSION; PROMOTER HYPERMETHYLATION; DNA METHYLATION;
   EPIGENETIC INACTIVATION; SPORADIC BREAST; SURVIVAL; ASSOCIATION;
   MECHANISMS; CHEMORESISTANCE; RESISTANCE
AB BACKGROUND: Even after early detection and curative resection of early stage nonsmall cell lung cancer (NSCLC), a significant fraction of patients develop recurrent disease. Molecular biomarkers that can predict the risk of recurrence thus need to be identified to improve clinical outcomes. METHODS: Using the methylation-specific polymerase chain reaction assay, promoter methylation of the breast cancer susceptibility gene 1 (BRCA1) was assessed in cancer tissues from 70 patients with curatively resected stage I NSCLC. The clinical relevance of BRCA1 methylation status was evaluated in terms of outcome of the disease. RESULTS: Methylation of the BRCA1 promoter was detected in 13 of 70 patients (18.6%). Multiple logistic regression analysis revealed that BRCA1 methylation was an independent risk factor for recurrence (P = .0197) and that patients with BRCA1 methylation demonstrated significantly poorer recurrence-free survival compared to those without (P = .0139). Cox's proportional hazard regression analysis revealed that BRCA1 methylation was an independent risk factor for recurrence-free survival (P = .0155). CONCLUSIONS: Methylated BRCA1 can be a potential biomarker that predicts the prognosis after curative resection of stage I NSCLC. Considering that BRCA1 plays a role in chemotherapy-induced apoptosis, it is plausible that identification of methylated BRCA1 could provide information that is clinically relevant to tailored adjuvant therapy. Cancer 2013. (c) 2013 American Cancer Society.
C1 [Harada, Hiroaki; Miyata, Yoshihiro; Okada, Morihito] Hiroshima Univ, Grad Sch Biomed Sci, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan.
   [Harada, Hiroaki; Miyamoto, Kazuaki; Yamashita, Yoshinori; Taniyama, Kiyomi] Natl Hosp Org, Kure Med Ctr, Inst Clin Res, Kure, Hiroshima 7370023, Japan.
   [Harada, Hiroaki; Miyamoto, Kazuaki; Yamashita, Yoshinori; Nakano, Kikuo; Taniyama, Kiyomi] Chugoku Canc Ctr, Kure, Hiroshima 7370023, Japan.
   [Harada, Hiroaki; Yamashita, Yoshinori] Natl Hosp Org, Kure Med Ctr, Dept Resp Surg, Kure, Hiroshima 7370023, Japan.
   [Miyamoto, Kazuaki] Natl Hosp Org, Kure Med Ctr, Dept Surg, Kure, Hiroshima 7370023, Japan.
   [Nakano, Kikuo] Natl Hosp Org, Kure Med Ctr, Dept Resp Med, Kure, Hiroshima 7370023, Japan.
   [Ohdan, Hideki] Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Surg,Programs Biomed Res, Hiroshima, Japan.
C3 Hiroshima University; Hiroshima University
RP Miyamoto, K (通讯作者)，Natl Hosp Org, Kure Med Ctr, 3-1 Aoyama Cho, Kure, Hiroshima 7370023, Japan.
EM miyamotoka@mopera.net
RI Okada, Morihito/H-1495-2019; Ohdan, Hideki/G-4719-2019
OI Ohdan, Hideki/0000-0002-9066-1288
FU Ministry of Health, Labour and Welfare of Japan; Ministry of Education,
   Culture, Science, Sports, and Technology of Japan; Kyowa Hakko; Daiwa
   Securities Health Foundation
FX This work was supported, in part, by Grants-in-Aid for the Third-term
   Comprehensive 10-Year Strategy for Cancer Control from the Ministry of
   Health, Labour and Welfare of Japan; Grants-in-Aid for Cancer Research
   from the Ministry of Education, Culture, Science, Sports, and Technology
   of Japan; Research Funding from Kyowa Hakko; and Research Funding from
   Daiwa Securities Health Foundation.
CR Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   Campan M, 2006, CURR TOP MICROBIOL, V310, P141
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Dominioni L, 2000, CANCER-AM CANCER SOC, V89, P2334, DOI 10.1002/1097-0142(20001201)89:11+<2334::AID-CNCR4>3.0.CO;2-I
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x
   Goodgame Boone, 2009, J Thorac Oncol, V4, P1293, DOI 10.1097/JTO.0b013e3181b7ef95
   Gu J, 2006, CLIN CANCER RES, V12, P7329, DOI 10.1158/1078-0432.CCR-06-0894
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Husain A, 1998, CANCER RES, V58, P1120
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kennedy RD, 2002, LANCET, V360, P1007, DOI 10.1016/S0140-6736(02)11087-7
   Kim JS, 2006, CANCER RES, V66, P4049, DOI 10.1158/0008-5472.CAN-05-3813
   Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Reguart N, 2008, CLIN LUNG CANCER, V9, P331, DOI 10.3816/CLC.2008.n.048
   Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012
   Rosell R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005133
   Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260
   Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Wang Y, 2008, CANCER-AM CANCER SOC, V112, P1325, DOI 10.1002/cncr.23312
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
NR 36
TC 16
Z9 16
U1 0
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 15
PY 2013
VL 119
IS 4
BP 792
EP 798
DI 10.1002/cncr.27754
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 086BC
UT WOS:000314657000014
PM 23335114
OA Bronze
DA 2025-01-12
ER

PT J
AU Tan, JX
   Gu, YM
   Zhang, XM
   You, SH
   Lu, XW
   Chen, SQ
   Han, X
   Sun, YJ
AF Tan, Jianxin
   Gu, Yumei
   Zhang, Xiaomei
   You, Sihong
   Lu, Xiaowei
   Chen, Senqing
   Han, Xiao
   Sun, Yujie
TI Hypermethylation of CpG islands is more prevalent than hypomethylation
   across the entire genome in breast carcinogenesis
SO CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE DNA methylation; Breast cancer; Carcinogenesis; MSRF; DHPLC
ID DNA METHYLATION MARKERS; ABERRANT PROMOTER METHYLATION; SQUAMOUS-CELL
   CARCINOMA; CLINICOPATHOLOGICAL FEATURES; COLORECTAL-CANCER; MULTIPLE
   GENES; EPIGENETICS; PATTERNS; IDENTIFICATION; DISEASE
AB This study aimed to establish a high-throughput, genome-wide and non-gene-specific approach to assess the methylation status of multiple CpG islands in parallel and employ it to detect the CpG island methylation profiling alterations in breast carcinogenesis. We used methylation-sensitive restriction fingerprint (MSRF) to screen the permutations of primers that could detect varied and specific methylation profiling in genomic DNA isolated from four different cell lines. Five permutations of nine arbitrary primers were determined for the following experiments based on the above test. We then examined the methylation profiling alterations of CpG islands in 31 breast cancer tissue samples relative to their adjacent non-neoplastic tissues with modified MSRF that replaced silver staining with denatured high-performance liquid chromatography for size fraction. We found that two pairs of primers could reveal specific alterations of CpG methylation in the examined tissues, and 83.9% (26/31) of breast cancer tissues exhibited specific CpG island methylation profiling relative to their adjacent non-neoplastic tissues. Size fraction analysis revealed that hypermethylation of CpG islands was responsible for the aberrant methylation profiling in breast cancer tissues. Our work not only established a relative high-throughput, genome-wide and economic method to detect methylation alterations of CpG island profiling, but also revealed that hypermethylation of CpG islands was more prevalent than hypomethylation across the entire genome in our examined cancer tissues. The methylation profiling alterations revealed by two primer pairs used in the present study might be a novel marker for breast cancer.
C1 [Tan, Jianxin; Gu, Yumei; Zhang, Xiaomei; You, Sihong; Han, Xiao; Sun, Yujie] Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhang, Xiaomei; Chen, Senqing] Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China.
   [Lu, Xiaowei] Maternal & Child Hlth Hosp, Dept Breast Surg, Wuxi 214002, Peoples R China.
   [Sun, Yujie] Nanjing Med Univ, Dept Cell Biol, Nanjing 210029, Jiangsu, Peoples R China.
   [Sun, Yujie] Nanjing Med Univ, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University
RP Sun, YJ (通讯作者)，Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu Prov, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM tanjianxin1019@163.com; yujiesun@njmu.edu.cn
RI Lu, Xiaowei/AAS-6701-2020; 韩, 晓/GXV-2361-2022; Sun, Yujie/HHZ-7619-2022
FU National Natural Science Foundation of China [30870978]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 30870978).
CR Anglim PP, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-62
   Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Brait M, 2008, CANCER EPIDEM BIOMAR, V17, P2786, DOI 10.1158/1055-9965.EPI-08-0192
   Breault JE, 2005, CLIN CANCER RES, V11, P557
   Brena RM, 2006, J MOL MED, V84, P365, DOI 10.1007/s00109-005-0034-0
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523
   Hayward AL, 1998, NUCLEIC ACIDS RES, V26, P2511, DOI 10.1093/nar/26.11.2511
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004
   Huang THM, 1997, CANCER RES, V57, P1030
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Hurd Paul J., 2009, Briefings in Functional Genomics & Proteomics, V8, P174, DOI 10.1093/bfgp/elp013
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Killian JK, 2009, CANCER RES, V69, P758, DOI 10.1158/0008-5472.CAN-08-2984
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Lv ZL, 2006, AM J CLIN PATHOL, V125, P740, DOI 10.1309/09B452V7R76K7D6K
   Marsit CJ, 2009, CARCINOGENESIS, V30, P416, DOI 10.1093/carcin/bgp006
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Ogi K, 2002, CLIN CANCER RES, V8, P3164
   Paluszczak J, 2006, J APPL GENET, V47, P365, DOI 10.1007/BF03194647
   Toyota M, 1999, CANCER RES, V59, P2307
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wu MC, 2004, ONCOGENE, V23, P250, DOI 10.1038/sj.onc.1207076
   Zilberman D, 2007, DEVELOPMENT, V134, P3959, DOI 10.1242/dev.001131
NR 37
TC 8
Z9 10
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1591-8890
J9 CLIN EXP MED
JI Clin. Exper. Med.
PD FEB
PY 2013
VL 13
IS 1
BP 1
EP 9
DI 10.1007/s10238-011-0173-2
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 086TT
UT WOS:000314710800001
PM 22212995
DA 2025-01-12
ER

PT J
AU Harris, RA
   Nagy-Szakal, D
   Kellermayer, R
AF Harris, R. Alan
   Nagy-Szakal, Dorottya
   Kellermayer, Richard
TI Human metastable epiallele candidates link to common disorders
SO EPIGENETICS
LA English
DT Article
DE epigenetics; DNA methylation; nutrition; developmental origins;
   metastable epiallele
ID DNA METHYLATION; PROMOTER METHYLATION; GENE; SUPPLEMENTATION;
   EPIGENETICS; EXPRESSION
AB Metastable epialleles (MEs) are mammalian genomic loci where epigenetic patterning occurs before gastrulation in a stochastic fashion leading to systematic interindividual variation within one species. Importantly, periconceptual nutritional influences may modulate the establishment of epigenetic changes, such as DNA methylation at MEs. Based on these characteristics, we exploited Infinium HumanMethylation450 BeadChip kits in a 2-tissue parallel screen on peripheral blood leukocyte and colonic mucosal DNA from 10 children without identifiable large intestinal disease. This approach led to the delineation of 1776 CpG sites meeting our criteria for MEs, which associated with 1013 genes. The list of ME candidates exhibited overlaps with recently identified human genes (including CYP2E1 and MGMT, where methylation has been associated with Parkinson disease and glioblastoma, respectively) in which perinatal DNA methylation levels where linked to maternal periconceptual nutrition. One hundred 18 (11.6%) of the ME candidates overlapped with genes where DNA methylation correlated (r > 0.871; p < 0.055) with expression in the colon mucosa of 5 independent control children. Genes involved in homophilic cell adhesion (including cadherin-associated genes) and developmental processes were significantly overrepresented in association with MEs. Additional filtering of gene expression-correlated MEs defined 35 genes, associated with 2 or more CpG sites within a 10 kb genomic region, fulfilling the ME criteria. DNA methylation changes at a number of these genes have been linked to various forms of human disease, including cancers, such as asthma and acute myeloid leukemia (ALOX12), gastric cancer (EBF3), breast cancer (NAV1), colon cancer and acute lymphoid leukemia (KCNK15), Wilms tumor (protocadherin gene cluster; PCDHAs) and colorectal cancer (TCERG1L), suggesting a potential etiologic role for MEs in tumorigenesis and underscoring the possible developmental origins of these malignancies. The presented compendium of ME candidates may accelerate our understanding of the epigenetic origins of common human disorders.
C1 [Harris, R. Alan] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Nagy-Szakal, Dorottya; Kellermayer, Richard] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Pediat Gastroenterol, Houston, TX 77030 USA.
   [Nagy-Szakal, Dorottya; Kellermayer, Richard] ARS, USDA, Childrens Nutr Res Ctr, Houston, TX USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   Medical Hospital; United States Department of Agriculture (USDA)
RP Kellermayer, R (通讯作者)，Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Pediat Gastroenterol, Houston, TX 77030 USA.
EM kellerma@bcm.edu
RI Harris, Ronald/AAI-2784-2020
OI Harris, Ronald/0000-0002-7333-4752
FU NIDDK [DK56338]
FX The authors would like to acknowledge the patients for providing
   samples, and all of our colleagues who contributed to the successful
   banking of the tissues. This study utilized the NIDDK supported
   Pediatric Inflammatory Bowel Disease Consortium Registry of the
   BaylorCollege of Medicine (DK56338; Texas Medical Center Digestive
   Disease Center (PI: Estes, MK)
CR Barouki R, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-42
   Cooney CA, 2002, J NUTR, V132, p2393S
   Cortessis VK, 2012, HUM GENET, V131, P1565, DOI 10.1007/s00439-012-1189-8
   DesRochers TM, 2012, EPIGENETICS-US, V7, P34, DOI 10.4161/epi.7.1.18546
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Etcheverry A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-701
   Harris RA, 2012, INFLAMM BOWEL DIS, V18, P2334, DOI 10.1002/ibd.22956
   Kaminsky Z, 2012, MOL PSYCHIATR, V17, P728, DOI 10.1038/mp.2011.64
   Katsamba P, 2009, P NATL ACAD SCI USA, V106, P11594, DOI 10.1073/pnas.0905349106
   Kaut O, 2012, NEUROGENETICS, V13, P87, DOI 10.1007/s10048-011-0308-3
   Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174
   Khulan B, 2012, HUM MOL GENET, V21, P2086, DOI 10.1093/hmg/dds026
   Kim J, 2012, INT J CANCER, V130, P817, DOI 10.1002/ijc.26038
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Naghibalhossaini F, 2011, PATHOL ONCOL RES, V17, P819, DOI 10.1007/s12253-011-9388-5
   Nimmo ER, 2012, INFLAMM BOWEL DIS, V18, P889, DOI 10.1002/ibd.21912
   Ohgaki Hiroko, 2009, V472, P323, DOI 10.1007/978-1-60327-492-0_14
   Pan H, 2012, EPIGENETICS-US, V7, P1173, DOI 10.4161/epi.22102
   Petronis A, 2003, AM J MED GENET C, V123C, P65, DOI 10.1002/ajmg.c.20015
   Rakyan VK, 2002, TRENDS GENET, V18, P348, DOI 10.1016/S0168-9525(02)02709-9
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629
   Skiriute D, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-218
   Veerla S, 2008, GENE CHROMOSOME CANC, V47, P368, DOI 10.1002/gcc.20542
   Wang ZP, 2012, MOL CELL BIOCHEM, V362, P35, DOI 10.1007/s11010-011-1125-6
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   Weksberg R, 2002, HUM MOL GENET, V11, P1317, DOI 10.1093/hmg/11.11.1317
   Winkler AS, 2010, J NEUROL, V257, P799, DOI 10.1007/s00415-009-5420-z
   Wirdefeldt K, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.02.017
NR 32
TC 47
Z9 50
U1 0
U2 21
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB
PY 2013
VL 8
IS 2
BP 157
EP 163
DI 10.4161/epi.23438
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 086JQ
UT WOS:000314680300004
PM 23321599
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Juárez-Moreno, K
   Erices, R
   Beltran, AS
   Stolzenburg, S
   Cuello-Fredes, M
   Owen, GI
   Qian, HL
   Blancafort, P
AF Juarez-Moreno, Karla
   Erices, Rafaela
   Beltran, Adriana S.
   Stolzenburg, Sabine
   Cuello-Fredes, Mauricio
   Owen, Gareth I.
   Qian, Haili
   Blancafort, Pilar
TI Breaking through an epigenetic wall Re-activation of <i>Oct4</i> by
   KRAB-containing designer zinc finger transcription factors
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; artificial transcription factors; Zinc Finger Proteins;
   KRAB domain; epigenetics; breast cancer; serous epithelial ovarian
   cancer; Oct4
ID PLURIPOTENT STEM-CELLS; OVARIAN-CANCER; DNA METHYLATION;
   GENE-EXPRESSION; BREAST-CANCER; FACTORS ATFS; INTERACTION NETWORK; HUMAN
   FIBROBLASTS; SELF-RENEWAL; TARGET GENES
AB The gene Oct4 encodes a transcription factor critical for the maintenance of pluripotency and self-renewal in embryonic stem cells. In addition, improper re-activation of Oct4 contributes to oncogenic processes. Herein, we describe a novel designer zinc finger protein (ZFP) capable of upregulating the endogenous Oct4 promoter in a panel of breast and ovarian cell lines carrying a silenced gene. In some ovarian tumor lines, the ZFP triggered a strong reactivation of Oct4, with levels of expression comparable with exogenous Oct4 cDNA delivery. Surprisingly, the reactivation of Oct4 required a KRAB domain for effective upregulation of the endogenous gene. While KRAB-containing ZFPs are traditionally described as transcriptional repressors, our results suggest that these proteins could, in certain genomic contexts, function as potent activators and, thus, outline an emerging novel function of KRAB-ZFPs. In addition, we document a novel ZFP that could be used for the epigenetic reprograming of cancer cells.
C1 [Juarez-Moreno, Karla; Erices, Rafaela; Beltran, Adriana S.; Stolzenburg, Sabine; Qian, Haili; Blancafort, Pilar] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 28401 USA.
   [Juarez-Moreno, Karla] UNAM, Ctr Nanociencias & Nanotecnol, Ensenada, Baja California, Mexico.
   [Erices, Rafaela; Owen, Gareth I.] Pontificia Univ Catolica Chile, Biomed Res Consortium Chile, Santiago, Chile.
   [Erices, Rafaela] Univ Nacl Andres Bello Santiago, Santiago, Chile.
   [Stolzenburg, Sabine; Blancafort, Pilar] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA, Australia.
   [Cuello-Fredes, Mauricio] Pontificia Univ Catolica Chile, Lab Obstet & Ginecol, Ctr Invest Med, Santiago, Chile.
   [Qian, Haili] Chinese Acad Med Sci, State Key Lab Mol Oncol, Beijing 100730, Peoples R China.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; Universidad Nacional
   Autonoma de Mexico; Pontificia Universidad Catolica de Chile; University
   of Western Australia; Pontificia Universidad Catolica de Chile; Chinese
   Academy of Medical Sciences - Peking Union Medical College
RP Blancafort, P (通讯作者)，Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 28401 USA.
EM pilar.blancafort@uwa.edu.au
RI Owen, Gareth/A-5100-2013; Blancafort, Pilar/K-9029-2012; Qian,
   Haili/H-5290-2019; Cuello, Mauricio/M-9817-2015; Juarez-Moreno,
   Karla/E-2730-2016
OI qian, haili/0000-0003-0652-4801; Blancafort, Pilar/0000-0002-3881-7396;
   Cuello, Mauricio/0000-0003-2812-0015; Juarez-Moreno,
   Karla/0000-0002-6171-8601
FU UNC University Cancer Research Fund (UCRF); National Cancer
   Institute/National Institutes of Health [1R01CA125273,
   3R01CA125273-03S1]; Department of Defense (DoD) [W81XWH-10-1-0265];
   Chilean grant BMRC [CTU06]; Chilean grant FONDECYT [1120292]; Chilean
   government science and technology grant [CONICYT 21100327]; Fulbright
   Garcia-Robles Foundation (COMEXUS)
FX We thank Michelle Mathews at the UNC Anatomic Pathology Translational
   Core Laboratory (APTCL) for expert technical assistance, and to Irina
   Tikhonova at the Yale Center for Genome Analysis (YCGA) for the
   assistance and analysis of DNA methylation. The UNC APTCL is supported,
   in part, by grants from the UNC University Cancer Research Fund (UCRF).
   This work was supported by National Cancer Institute/National Institutes
   of Health grants 1R01CA125273, 3R01CA125273-03S1, the Department of
   Defense (DoD) W81XWH-10-1-0265 (P.B.), the Chilean grants BMRC CTU06
   (G.O.) and FONDECYT 1120292 (M.C.), the Chilean government science and
   technology grant CONICYT 21100327 (R.E.), and the Researcher Professor
   Grant by the Fulbright Garcia-Robles Foundation (COMEXUS) (K.J.M.).
CR Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006-0426
   Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628
   Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072
   Beltran AS, 2008, MOL CANCER THER, V7, P1080, DOI 10.1158/1535-7163.MCT-07-0526
   Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019
   Beltran AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024595
   Beltran AS, 2011, EPIGENETICS-US, V6, P224, DOI 10.4161/epi.6.2.13700
   Beltran AS, 2010, METHODS MOL BIOL, V649, P163, DOI 10.1007/978-1-60761-753-2_10
   Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752
   Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758
   Blancafort P, 2008, COMB CHEM HIGH T SCR, V11, P146, DOI 10.2174/138620708783744453
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Bultmann S, 2012, NUCLEIC ACIDS RES, V40, P5368, DOI 10.1093/nar/gks199
   Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   de Groote ML, 2012, NUCLEIC ACIDS RES, V40, P10596, DOI 10.1093/nar/gks863
   Doege CA, 2012, NATURE, V488, P652, DOI 10.1038/nature11333
   Dyce PW, 2010, HISTOL HISTOPATHOL, V25, P505, DOI 10.14670/HH-25.505
   Epsztejn-Litman S, 2008, NAT STRUCT MOL BIOL, V15, P1176, DOI 10.1038/nsmb.1476
   Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353
   Feng B, 2009, CELL STEM CELL, V4, P301, DOI 10.1016/j.stem.2009.03.005
   Frietze S, 2010, J BIOL CHEM, V285, P1393, DOI 10.1074/jbc.M109.063032
   Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35
   Gentilini O, 2005, EJSO-EUR J SURG ONC, V31, P232, DOI 10.1016/j.ejso.2004.11.012
   Gu PL, 2011, STEM CELLS, V29, P1041, DOI 10.1002/stem.652
   Hassiotou F, 2012, STEM CELLS, V30, P2164, DOI 10.1002/stem.1188
   Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867
   Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626
   Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642
   Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569
   Iyengar S, 2011, MOL CELL BIOL, V31, P1833, DOI 10.1128/MCB.01331-10
   Keleher AJ, 2002, J AM COLL SURGEONS, V194, P54, DOI 10.1016/S1072-7515(01)01105-X
   Kim JB, 2008, NATURE, V454, P646, DOI 10.1038/nature07061
   Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Kobolak J, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-88
   Lara H, 2012, J BIOL CHEM, V287, P29873, DOI 10.1074/jbc.M112.360768
   Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858
   Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Mak VCY, 2012, HISTOL HISTOPATHOL, V27, P1121, DOI 10.14670/HH-27.1121
   Mandell JG, 2006, NUCLEIC ACIDS RES, V34, pW516, DOI 10.1093/nar/gkl209
   Meilinger D, 2009, EMBO REP, V10, P1259, DOI 10.1038/embor.2009.201
   Pardo M, 2010, CELL STEM CELL, V6, P382, DOI 10.1016/j.stem.2010.03.004
   Park JT, 2010, AM J PATHOL, V177, P1087, DOI 10.2353/ajpath.2010.100316
   Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500
   Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507
   Samardzija C, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-37
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Sera T, 2009, ADV DRUG DELIVER REV, V61, P513, DOI 10.1016/j.addr.2009.03.012
   Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004
   Sterneckert J, 2012, STEM CELLS, V30, P15, DOI 10.1002/stem.765
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Topisirovic I, 2005, MOL CELL BIOL, V25, P1100, DOI 10.1128/MCB.25.3.1100-1112.2005
   Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231
   Walker E, 2007, CELL STEM CELL, V1, P71, DOI 10.1016/j.stem.2007.04.002
   Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284
   Wang ZX, 2008, STEM CELLS, V26, P2791, DOI 10.1634/stemcells.2008-0443
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   Yu HB, 2009, J BIOL CHEM, V284, P31327, DOI 10.1074/jbc.M109.016162
   Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111
   Zhang J, 2010, J CLIN PATHOL, V63, P879, DOI 10.1136/jcp.2009.073593
NR 65
TC 19
Z9 20
U1 0
U2 16
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD FEB
PY 2013
VL 8
IS 2
BP 164
EP 176
DI 10.4161/epi.23503
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 086JQ
UT WOS:000314680300005
PM 23314702
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Lee, SE
   Kim, SJ
   Yoon, HJ
   Yu, SY
   Yang, H
   Jeong, SI
   Hwang, SY
   Park, CS
   Park, YS
AF Lee, Seung Eun
   Kim, Seung Jun
   Yoon, Hyo-Jeong
   Yu, So Yeon
   Yang, Hana
   Jeong, Seong Il
   Hwang, Seung Yong
   Park, Cheung-Seog
   Park, Yong Seek
TI Genome-wide profiling in melatonin-exposed human breast cancer cell
   lines identifies differentially methylated genes involved in the
   anticancer effect of melatonin
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Article
DE anticancer effect; breast cancer; gene expression; melatonin;
   methylation profiling
ID DNA METHYLATION; EPIGENETIC REGULATION; EXPRESSION; MECHANISMS; GROWTH;
   INHIBITION; HYPERMETHYLATION; GLYPICAN-3; INVASION; DISEASE
AB Epigenetic alterations have emerged as an important mechanism involved in tumorigenesis. The epigenetic impact of DNA methylation in various types of human cancer is not completely understood. Previously, we observed melatonin-induced differential expression of miRNA and miRNA-related genes in human breast cancer cell lines that indicated an anticancer effect of melatonin. In this report, we further characterized epigenetic changes in melatonin-exposed MCF-7 cells through the analysis of DNA methylation profiles in breast cancer cells to provide new insights into the potential mechanisms of the anticancer effect of melatonin. Microarray-based DNA methylation and gene expression profiling were carried out using human breast cancer cell lines. We further identified a number of mRNAs whose expression levels show an inverse correlation with DNA methylation levels. The mRNA expression levels and methylation status of candidate genes in melatonin-exposed cells were confirmed by real-time quantitative PCR and bisulfite PCR. This approach led to the detection of cancer-related genes, which were oncogenic genes, including EGR3 and POU4F2/Brn-3b were down-regulated, while the tumor suppressor gene, GPC3, was up-regulated by 1 nM melatonin-treated MCF-7 cells. Our results provide detailed insights into the DNA methylation patterns induced by melatonin and suggest a potential mechanism of the anticancer effect of aberrant DNA methylation in melatonin-treated breast cancer cells.
C1 [Lee, Seung Eun; Yang, Hana; Jeong, Seong Il; Park, Cheung-Seog; Park, Yong Seek] Kyung Hee Univ, Dept Microbiol, Sch Med, 1 Hoegi Dong, Seoul 130701, South Korea.
   [Kim, Seung Jun; Yoon, Hyo-Jeong; Yu, So Yeon; Hwang, Seung Yong] Genocheck Co Ltd, Ansan, South Korea.
   [Yoon, Hyo-Jeong] Hankyong Natl Univ, Genom Informat Ctr, Anseong, South Korea.
   [Yu, So Yeon; Hwang, Seung Yong] Hanyang Univ, Dept Biochem, Ansan, South Korea.
C3 Kyung Hee University; GenoCheck Co. Ltd; Hankyong National University;
   Hanyang University
RP Park, YS (通讯作者)，Kyung Hee Univ, Dept Microbiol, Sch Med, 1 Hoegi Dong, Seoul 130701, South Korea.
EM yongseek@khu.ac.kr
RI Park, Yong Seek/ABG-6398-2021
OI Park, Yong Seek/0000-0002-9260-3102
FU Ministry of Health and Welfare, Republic of Korea [A111834]
FX This study was supported by a grant of the Korean Health Technology R
   and D Project, Ministry of Health and Welfare, Republic of Korea
   (A111834).
CR BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I
   Blask DE, 2005, ENDOCRINE, V27, P179, DOI 10.1385/ENDO:27:2:179
   Blask DE, 2005, CANCER RES, V65, P11174, DOI 10.1158/0008-5472.CAN-05-1945
   Carrillo-Vico A, 2005, J PINEAL RES, V39, P400, DOI 10.1111/j.1600-079X.2005.00265.x
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   Cini G, 2005, J PINEAL RES, V39, P12, DOI 10.1111/j.1600-079X.2004.00206.x
   COS S, 1994, J PINEAL RES, V17, P25, DOI 10.1111/j.1600-079X.1994.tb00110.x
   Cos S, 1998, CANCER RES, V58, P4383
   Cos S, 2005, J PINEAL RES, V38, P136, DOI 10.1111/j.1600-079X.2004.00186.x
   Cucina A, 2009, J PINEAL RES, V46, P172, DOI 10.1111/j.1600-079X.2008.00645.x
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dennis JH, 2001, ONCOGENE, V20, P4961, DOI 10.1038/sj.onc.1204491
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Groom A, 2012, DIABETES, V61, P391, DOI 10.2337/db11-1039
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hill SM, 2009, INTEGR CANCER THER, V8, P337, DOI 10.1177/1534735409353332
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Joo SS, 2009, J PINEAL RES, V47, P8, DOI 10.1111/j.1600-079X.2009.00682.x
   Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0
   Korkmaz A, 2009, BREAST CANCER RES TR, V115, P13, DOI 10.1007/s10549-008-0103-5
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Lee SE, 2011, J PINEAL RES, V51, P345, DOI 10.1111/j.1600-079X.2011.00896.x
   Mediavilla MD, 2010, CURR MED CHEM, V17, P4462, DOI 10.2174/092986710794183015
   Mills E, 2005, J PINEAL RES, V39, P360, DOI 10.1111/j.1600-079X.2005.00258.x
   Mukherjee D, 2010, J PINEAL RES, V48, P251, DOI 10.1111/j.1600-079X.2010.00749.x
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   PATWARDHAN S, 1991, ONCOGENE, V6, P917
   Peters MG, 2003, BREAST CANCER RES TR, V80, P221, DOI 10.1023/A:1024549729256
   Petrosillo G, 2010, J PINEAL RES, V48, P340, DOI 10.1111/j.1600-079X.2010.00758.x
   Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2
   REITER RJ, 1973, ENDOCRINOLOGY, V92, P423, DOI 10.1210/endo-92-2-423
   Reiter RJ, 2004, J PINEAL RES, V37, P213, DOI 10.1111/j.1600-079X.2004.00165.x
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Stehle JH, 2011, J PINEAL RES, V51, P17, DOI 10.1111/j.1600-079X.2011.00856.x
   Stigliano I, 2009, BREAST CANCER RES TR, V114, P251, DOI 10.1007/s10549-008-0009-2
   Suzuki T, 2007, ENDOCR-RELAT CANCER, V14, P279, DOI 10.1677/ERC-06-0005
   Swarnakar S, 2011, J PINEAL RES, V50, P8, DOI 10.1111/j.1600-079X.2010.00812.x
   Uddin M, 2011, DIS MARKERS, V30, P111, DOI [10.3233/DMA-2011-0750, 10.1155/2011/513659]
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 45
TC 50
Z9 54
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD JAN
PY 2013
VL 54
IS 1
BP 80
EP 88
DI 10.1111/j.1600-079X.2012.01027.x
PG 9
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA 088PV
UT WOS:000314848500008
PM 22856590
DA 2025-01-12
ER

PT J
AU Wang, YQ
   Yan, Q
   Zhang, JR
   Li, SD
   Yang, YX
   Wan, XP
AF Wang, Yan-Qiu
   Yan, Qin
   Zhang, Jia-Rong
   Li, Shuang-Di
   Yang, Yi-Xia
   Wan, Xiao-Ping
TI Epigenetic inactivation of BRCA1 through promoter hypermethylation in
   ovarian cancer progression
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article
DE biomarker; BRCA1; cancer progression; early diagnosis; ovarian cancer
ID SPORADIC BREAST-CANCER; ABERRANT METHYLATION; GENE-EXPRESSION; CPG
   METHYLATION; DNA METHYLATION; CELLS; SURVIVAL; TUMORS; CISPLATIN;
   PATHWAYS
AB Aim: The BRCA1 promoter is hypermethylated in ovarian cancer patients. We postulated that this hypermethylation might be involved in ovarian cancer progression. Methods: To confirm our hypothesis, tissue and serum samples were collected from ovarian carcinoma patients and categorized according to tumor stage. Healthy or benign ovarian disease tissue samples and corresponding serum samples were used as controls. Breast and ovarian cancer susceptibility gene 1 (BRCA1) promoter methylation levels were detected by real-time polymerase chain reaction (PCR). Real-time PCR was also used to evaluate BRCA1 gene expression, and Western blot was performed to assay the expression of BRCA1 protein. Results: BRCA1 showed hypomethylation in 30 normal ovarian and 30 benign ovarian tumors, but showed hypermethylation or methylation in ovarian cancer patients. There was also a significant difference in the BRCA1 promoter methylation levels between different ovarian cancer stages. Compared to stage I and the control groups, there were higher BRCA1 promoter methylation frequencies in stage II and III ovarian cancers. BRCA1 methylation correlated with the loss of BRCA1 expression. BRCA1 promoter in stage I tumors showed hypomethylated. Conclusion: Promoter hypermethylation may act as a biomarker for sporadic ovarian cancer progression, but is unlikely to be helpful in the early diagnosis of ovarian cancer.
C1 [Wang, Yan-Qiu; Yan, Qin; Zhang, Jia-Rong; Li, Shuang-Di; Yang, Yi-Xia] Shanghai Jiao Tong Univ, Sch Med, Shanghai Hosp 1, Dept Obstet & Gynecol, Shanghai 200030, Peoples R China.
   [Wan, Xiao-Ping] Shanghai Jiao Tong Univ, Int Peace Matern & Children Hlth Care Hosp, Dept Obstet & Gynecol, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Wan, XP (通讯作者)，Shanghai Jiao Tong Univ, Int Peace Matern & Children Hlth Care Hosp, Dept Obstet & Gynecol, 910 Hengshan Rd, Shanghai 200030, Peoples R China.
EM wanxp61@126.com
OI li, shuangdi/0000-0002-7524-5753
FU Shanghai Committee of Science and Technology, China [10JC1415600];
   Shanghai Foundation for Excellent Leaders of Disciplines in Science,
   China [08XD1403200]
FX This work was supported by grants from the Key Project of Shanghai
   Committee of Science and Technology, China (Grant no. 10JC1415600) and
   the Shanghai Foundation for Excellent Leaders of Disciplines in Science,
   China (Grant no. 08XD1403200).
CR Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310
   Chan KYK, 2002, CANCER RES, V62, P4151
   Davis PL, 1999, ONCOGENE, V18, P6000, DOI 10.1038/sj.onc.1202990
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Ibragimova I, 2011, METHODS MOL BIOL, V780, P277, DOI 10.1007/978-1-61779-270-0_17
   Kissel CK, 2006, MELANOMA RES, V16, P527, DOI 10.1097/CMR.0b013e3280103a7c
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Ludwig DL, 1997, GENE, V199, P181, DOI 10.1016/S0378-1119(97)00366-1
   Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177
   Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431
   Quinn JE, 2009, GYNECOL ONCOL, V113, P134, DOI 10.1016/j.ygyno.2008.12.015
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183
   Wang YQ, 2010, CANCER SCI, V101, P1618, DOI 10.1111/j.1349-7006.2010.01568.x
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Zhong Q, 2008, ANN ONCOL, V19, P1584, DOI 10.1093/annonc/mdn167
NR 25
TC 20
Z9 22
U1 0
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD FEB
PY 2013
VL 39
IS 2
BP 549
EP 554
DI 10.1111/j.1447-0756.2012.01979.x
PG 6
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA 079ZU
UT WOS:000314211800013
PM 23006047
DA 2025-01-12
ER

PT J
AU Soldi, R
   Cohen, AL
   Cheng, L
   Sun, Y
   Moos, PJ
   Bild, AH
AF Soldi, R.
   Cohen, A. L.
   Cheng, L.
   Sun, Y.
   Moos, P. J.
   Bild, A. H.
TI A genomic approach to predict synergistic combinations for breast cancer
   treatment
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article
DE histone deacetylase inhibitors; cyclin-dependent kinase inhibitors; drug
   synergy; breast cancer
ID HISTONE DEACETYLASE INHIBITORS; TUMOR-SUPPRESSOR GENE; VALPROIC ACID;
   CELL-LINES; EPIGENETIC THERAPY; PROSTATE-CANCER; SOLID TUMORS;
   EXPRESSION; METHYLATION; P57(KIP2)
AB We leverage genomic and biochemical data to identify synergistic drug regimens for breast cancer. In order to study the mechanism of the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) in breast cancer, we generated and validated genomic profiles of drug response using a series of breast cancer cell lines sensitive to each drug. These genomic profiles were then used to model drug response in human breast tumors and show significant correlation between VPA and SAHA response profiles in multiple breast tumor data sets, highlighting their similar mechanism of action. The genes deregulated by VPA and SAHA converge on the cell cycle pathway (Bayes factor 5.21 and 5.94, respectively; P-value 10(-8.6) and 10(-9), respectively). In particular, VPA and SAHA upregulate key cyclin-dependent kinase (CDK) inhibitors. In two independent datasets, cancer cells treated with CDK inhibitors have similar gene expression profile changes to the cellular response to HDAC inhibitors. Together, these results led us to hypothesize that VPA and SAHA may interact synergistically with CDK inhibitors such as PD-033299. Experiments show that HDAC and CDK inhibitors have statistically significant synergy in both breast cancer cell lines and primary 3-dimensional cultures of cells from pleural effusions of patients. Therefore, synergistic relationships between HDAC and CDK inhibitors may provide an effective combinatorial regimen for breast cancer. Importantly, these studies provide an example of how genomic analysis of drug-response profiles can be used to design rational drug combinations for cancer treatment. The Pharmacogenomics Journal (2013) 13, 94-104; doi:10.1038/tpj.2011.48; published online 15 November 2011
C1 [Soldi, R.; Cheng, L.; Moos, P. J.; Bild, A. H.] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA.
   [Cohen, A. L.] Univ Utah, Dept Internal Med, Oncol Div, Salt Lake City, UT 84112 USA.
   [Cohen, A. L.; Sun, Y.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah; Huntsman Cancer Institute
RP Bild, AH (通讯作者)，Univ Utah, Dept Pharmacol & Toxicol, 112 Skaggs Hall, Salt Lake City, UT 84112 USA.
EM andreab@genetics.utah.edu
OI Moos, Philip/0000-0002-8223-442X
FU National Institute of Health [R01GM085601]; Pharmaceutical Research and
   Manufacturers of America; Multidisciplinary Cancer Research Training
   Program award [T32 CA93247]; MIDT cancer center
FX This study was funded by the National Institute of Health (R01GM085601,
   AHB); the Pharmaceutical Research and Manufacturers of America (AHB); a
   Multidisciplinary Cancer Research Training Program award (T32 CA93247,
   RS and AC) and an award from the MIDT cancer center support grant. The
   Breast Interdisciplinary Group of the University of Utah is acknowledged
   for their assistance in breast tumor collection.
CR Algar EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004482
   [Anonymous], 2010, CANCER
   [Anonymous], 2011, Cancer facts and figures
   Arce C, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000098
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Berkofsky-Fessler W, 2009, MOL CANCER THER, V8, P2517, DOI 10.1158/1535-7163.MCT-09-0083
   Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Buzdar AU, 2009, ANN ONCOL, V20, P993, DOI 10.1093/annonc/mdn739
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Chavez-Blanco A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-2
   Cucciolla V, 2008, CARCINOGENESIS, V29, P560, DOI 10.1093/carcin/bgn010
   Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005
   Fry DW, 2004, MOL CANCER THER, V3, P1427
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hayslip J, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-44
   Iorio F, 2010, P NATL ACAD SCI USA, V107, P14621, DOI 10.1073/pnas.1000138107
   Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695
   Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Larson PS, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-68
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Marks P.A., 2004, NOVARTIS FDN S, V259, P281
   Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564
   Marks Paul A, 2004, Novartis Found Symp, V259, P269
   Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x
   Monks A, 2009, ANTI-CANCER DRUG, V20, P682, DOI 10.1097/CAD.0b013e32832e14e1
   Münster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165
   Munster P, 2009, CLIN CANCER RES, V15, P2488, DOI 10.1158/1078-0432.CCR-08-1930
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Pateras IS, 2006, INT J CANCER, V119, P2546, DOI 10.1002/ijc.22214
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865
   Travaglini L, 2009, INT J BIOCHEM CELL B, V41, P225, DOI 10.1016/j.biocel.2008.08.019
   Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Wood JR, 2005, PHYSIOL GENOMICS, V20, P233, DOI 10.1152/physiolgenomics.00193.2004
   Woodcock J, 2011, NEW ENGL J MED, V364, P985, DOI 10.1056/NEJMp1101548
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
NR 48
TC 14
Z9 18
U1 1
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470-269X
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD FEB
PY 2013
VL 13
IS 1
BP 94
EP 104
DI 10.1038/tpj.2011.48
PG 11
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 079ZI
UT WOS:000314210400011
PM 22083351
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Vrba, L
   Muñoz-Rodríguez, JL
   Stampfer, MR
   Futscher, BW
AF Vrba, Lukas
   Munoz-Rodriguez, Jose L.
   Stampfer, Martha R.
   Futscher, Bernard W.
TI miRNA Gene Promoters Are Frequent Targets of Aberrant DNA Methylation in
   Human Breast Cancer
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR; FEEDBACK LOOP; EARLY EVENT; HYPERMETHYLATION;
   EXPRESSION; MICRORNA-34B/C; INACTIVATION; MIR-34A; P53
AB miRNAs are important regulators of gene expression that are frequently deregulated in cancer, with aberrant DNA methylation being an epigenetic mechanism involved in this process. We previously identified miRNA promoter regions active in normal mammary cell types and here we analyzed which of these promoters are targets of aberrant DNA methylation in human breast cancer cell lines and breast tumor specimens. Using 5-methylcytosine immunoprecipitation coupled to miRNA tiling microarray hybridization, we performed comprehensive evaluation of DNA methylation of miRNA gene promoters in breast cancer. We found almost one third (55/167) of miRNA promoters were targets for aberrant methylation in breast cancer cell lines. Breast tumor specimens displayed DNA methylation of majority of these miRNA promoters, indicating that these changes in DNA methylation might be clinically relevant. Aberrantly methylated miRNA promoters were, similar to protein coding genes, enriched for promoters targeted by polycomb in normal cells. Detailed analysis of selected miRNA promoters revealed decreased expression of miRNA linked to increased promoter methylation for mir-31, mir-130a, let-7a-3/let-7b, mir-155, mir-137 and mir-34b/mir-34c genes. The proportion of miRNA promoters we found aberrantly methylated in breast cancer is several fold larger than that observed for protein coding genes, indicating an important role of DNA methylation in miRNA deregulation in cancer.
C1 [Vrba, Lukas; Munoz-Rodriguez, Jose L.; Stampfer, Martha R.; Futscher, Bernard W.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
   [Munoz-Rodriguez, Jose L.; Futscher, Bernard W.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   [Stampfer, Martha R.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Vrba, Lukas] Acad Sci Czech Republ, Inst Plant Mol Biol, Ctr Biol, Vvi, CR-37005 Ceske Budejovice, Czech Republic.
C3 University of Arizona; Arizona Center Cancer Care; University of
   Arizona; University of California System; University of California
   Berkeley; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory; Czech Academy of Sciences; Biology Centre of the
   Czech Academy of Sciences
RP Futscher, BW (通讯作者)，Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
EM bfutscher@azcc.arizona.edu
RI Munoz Rodriguez, Jose Manuel/A-7323-2016; Vrba, Lukas/J-9268-2015
OI Munoz Rodriguez, Jose Manuel/0000-0002-4688-6420; Vrba,
   Lukas/0000-0003-3042-6275
FU Margaret E. and Fenton L. Maynard Endowment for Breast Cancer Research; 
   [1U01CA153086];  [P30 CA023074];  [P30 ES006694]
FX This work was supported by grant 1U01CA153086; center grants P30
   CA023074 and P30 ES006694; and Margaret E. and Fenton L. Maynard
   Endowment for Breast Cancer Research. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], 2011, R: A language and enviroment for statistical computing
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Fury Wen, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5531
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957
   Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jönsson G, 2007, GENE CHROMOSOME CANC, V46, P543, DOI 10.1002/gcc.20438
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907
   Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318
   Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435
NR 39
TC 105
Z9 127
U1 0
U2 35
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 16
PY 2013
VL 8
IS 1
AR e54398
DI 10.1371/journal.pone.0054398
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 072OV
UT WOS:000313682700112
PM 23342147
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Lubecka-Pietruszewska, K
   Kaufman-Szymczyk, A
   Stefanska, B
   Fabianowska-Majewska, K
AF Lubecka-Pietruszewska, Katarzyna
   Kaufman-Szymczyk, Agnieszka
   Stefanska, Barbara
   Fabianowska-Majewska, Krystyna
TI Folic acid enforces DNA methylation-mediated transcriptional silencing
   of <i>PTEN</i>, <i>APC</i> and <i>RARbeta2</i> tumour suppressor genes
   in breast cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Folic acid; Epigenetic regulation of gene transcription; DNA
   methylation; Breast cancer
ID RETINOIC ACID; FOLATE INTAKE; PROMOTER METHYLATION; COLORECTAL ADENOMAS;
   ADENOSINE-ANALOGS; RISK; SUPPLEMENTATION; HYPOMETHYLATION; EXPRESSION;
   PROSTATE
AB Folate, one of the most studied dietary compounds, has recently become the main topic of debates on food fortification. Although low folate levels may be associated with increased risk of cancer development, simultaneously several reports indicate a detrimental effects mediated by high folate concentrations. Using the methylation sensitive restriction analysis (MSRA) and real-time RT-PCR we tested the effect of folic acid on DNA promoter methylation and expression of PTEN, APC and RARbeta2 tumour suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines with different invasive capacity. The tested genes encode proteins involved in regulation of oncogenic intracellular signaling pathways. The results show that the increasing concentrations of folic acid lead to a dose-dependent down-regulation of tumour suppressor genes which may be linked to the increased DNA methylation detected within their promoter regions. The effects were more remarkable in non-invasive MCF-7 cells where we also observed 30% up-regulation of DNMT1 expression at the highest folate concentration used. Our findings show that caution need to be used when introducing folic acid supplementation since it may lead to cancer progression. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lubecka-Pietruszewska, Katarzyna; Kaufman-Szymczyk, Agnieszka; Fabianowska-Majewska, Krystyna] Med Univ Lodz, Dept Biomed Chem, PL-92215 Lodz, Poland.
   [Stefanska, Barbara] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
C3 Medical University Lodz; McGill University
RP Lubecka-Pietruszewska, K (通讯作者)，Med Univ Lodz, Dept Biomed Chem, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.
EM katarzyna.lubecka-pietruszewska@umed.lodz.pl
RI Kaufman-Szymczyk, Agnieszka/S-9624-2016; Lubecka, Katarzyna/S-9731-2016;
   Stefańska, Barbara/ABD-1161-2021
OI Kaufman-Szymczyk, Agnieszka/0000-0001-6014-7280; Lubecka-Gajewska,
   Katarzyna/0000-0002-4250-0922
FU Medical University of Lodz [503/6-099-01/503-01,
   502-03/6-099-01/502-64-057]
FX The research was supported by the Medical University of Lodz - grants
   nos. 503/6-099-01/503-01 and 502-03/6-099-01/502-64-057. The authors are
   grateful to Professor Piotr Smolewski and Dr Barbara Cebula (Department
   of Experimental Haematology, Medical University of Lodz, Poland) for the
   possibility to perform the flow cytometry analysis.
CR Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779
   Bazzano LA, 2006, JAMA-J AM MED ASSOC, V296, P2720, DOI 10.1001/jama.296.22.2720
   Berner C, 2011, ANN NUTR METAB, V57, P183, DOI 10.1159/000321514
   Choi SW, 2005, CLIN CHEM LAB MED, V43, P1151, DOI 10.1515/CCLM.2005.200
   Choi SW, 2005, BRIT J NUTR, V93, P31, DOI 10.1079/BJN20041283
   Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351
   Fang JY, 1998, J GASTROENTEROL, V33, P656, DOI 10.1007/s005350050152
   Figueiredo JC, 2009, JNCI-J NATL CANCER I, V101, P432, DOI 10.1093/jnci/djp019
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Jaszewski R, 2008, WORLD J GASTROENTERO, V14, P4492, DOI 10.3748/wjg.14.4492
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Kim YI, 2003, J NUTR, V133, p3731S, DOI 10.1093/jn/133.11.3731S
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Kim YI, 2006, NUTR REV, V64, P468, DOI 10.1301/nr.2006.oct.468-475
   Krawczyk B, 2007, NUCLEOS NUCLEOT NUCL, V26, P1043, DOI 10.1080/15257770701509594
   Larsson SC, 2007, JNCI-J NATL CANCER I, V99, P64, DOI 10.1093/jnci/djk006
   Larsson SC, 2006, GASTROENTEROLOGY, V131, P1271, DOI 10.1053/j.gastro.2006.08.010
   Ly A, 2012, ANTIOXID REDOX SIGN, V17, P302, DOI 10.1089/ars.2012.4554
   Ly A, 2011, CANCER RES, V71, P988, DOI 10.1158/0008-5472.CAN-10-2379
   Mills JL, 2004, BIRTH DEFECTS RES A, V70, P844, DOI 10.1002/bdra.20075
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266
   Selhub J, 2002, J Nutr Health Aging, V6, P39
   Stefanska B, 2012, BRIT J PHARMACOL, V167, P279, DOI 10.1111/j.1476-5381.2012.02002.x
   Stefanska B, 2012, BRIT J NUTR, V107, P781, DOI 10.1017/S0007114511003631
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wu K, 2009, AM J CLIN NUTR, V90, P1623, DOI 10.3945/ajcn.2009.28319
NR 34
TC 42
Z9 45
U1 0
U2 32
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 11
PY 2013
VL 430
IS 2
BP 623
EP 628
DI 10.1016/j.bbrc.2012.11.103
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 080QH
UT WOS:000314257800030
PM 23219837
DA 2025-01-12
ER

PT J
AU Wang, S
   Huang, J
   Lyu, H
   Lee, CK
   Tan, J
   Wang, J
   Liu, B
AF Wang, S.
   Huang, J.
   Lyu, H.
   Lee, C-K
   Tan, J.
   Wang, J.
   Liu, B.
TI Functional cooperation of miR-125a, miR-125b, and miR-205 in
   entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast
   cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
DE entinostat; HDAC; miRNA; erbB2; erbB3; breast cancer
ID HISTONE DEACETYLASE INHIBITORS; EPIGENETIC ALTERATIONS; EXPRESSION;
   MICRORNAS; ERBB3; RESISTANCE; TRASTUZUMAB; THERAPY; GROWTH; SUPPRESSION
AB We reported that the class I HDAC inhibitor entinostat induced apoptosis in erbB2-overexpressing breast cancer cells via downregulation of erbB2 and erbB3. Here, we study the molecular mechanism by which entinostat dual-targets erbB2/erbB3. Treatment with entinostat had no effect on erbB2/erbB3 mRNA, suggesting a transcription-independent mechanism. Entinostat decreased endogenous but not exogenous erbB2/erbB3, indicating it did not alter their protein stability. We hypothesized that entinostat might inhibit erbB2/erbB3 protein translation via specific miRNAs. Indeed, entinostat significantly upregulated miR-125a, miR-125b, and miR-205, that have been reported to target erbB2 and/or erbB3. Specific inhibitors were then used to determine whether these miRNAs had a causal role in entinostat-induced downregulation of erbB2/erbB3 and apoptosis. Transfection with a single inhibitor dramatically abrogated entinostat induction of miR-125a, miR-125b, or miR-205; however, none of the inhibitors blocked entinostat action on erbB2/erbB3. In contrast, co-transfection with two inhibitors not only reduced their corresponding miRNAs, but also significantly abrogated entinostat-mediated reduction of erbB2/erbB3. Moreover, simultaneous inhibition of two, but not one miRNA significantly attenuated entinostat-induced apoptosis. Interestingly, although the other HDAC inhibitors, such as SAHA and panobinostat, exhibited activity as potent as entinostat to induce growth inhibition and apoptosis in erbB2-overexpressing breast cancer cells, they had no significant effects on the three miRNAs. Instead, both SAHA- and panobinostat-decreased erbB2/erbB3 expression correlated with the reduction of their mRNA levels. Collectively, we demonstrate that entinostat specifically induces expression of miR-125a, miR-125b, and miR-205, which act in concert to downregulate erbB2/erbB3 in breast cancer cells. Our data suggest that epigenetic regulation via miRNA-dependent or -independent mechanisms may represent a novel approach to treat breast cancer patients with erbB2-overexpressing tumors. Cell Death and Disease (2013) 4, e556; doi:10.1038/cddis.2013.79; published online 21 March 2013
C1 [Wang, S.; Huang, J.; Lyu, H.; Liu, B.] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA.
   [Wang, S.; Tan, J.] Fuzhou Gen Hosp, Fujian Key Lab Transplant Biol, Fuzhou, Fujian, Peoples R China.
   [Huang, J.; Wang, J.] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China.
   [Huang, J.; Wang, J.] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China.
   [Huang, J.; Wang, J.] Peking Union Med Coll, Tianjin 300020, Peoples R China.
   [Lee, C-K] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Chinese Academy of Medical Sciences - Peking Union Medical
   College; Institute of Hematology & Blood Diseases Hospital - CAMS;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese
   Academy of Medical Sciences - Peking Union Medical College; Peking Union
   Medical College; University of Colorado System; University of Colorado
   Anschutz Medical Campus
RP Wang, J (通讯作者)，Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
EM wangjx@ihcams.ac.cn; bolin.liu@ucdenver.edu
RI Tan, Ming-Jen/A-3862-2011
OI Tan, Ming-Jen/0000-0002-3583-1723; Liu, Bolin/0000-0003-0150-8650
FU Cancer League of Colorado [AWD-102888, AWD-122695]
FX We are grateful to Dr. Peter Ordentlich (Syndax Pharmaceuticals, Inc.,
   Waltham, MA, USA) for providing entinostat, to Dr. Dihua Yu (MD Anderson
   Cancer Center) for providing 435.eB1 cells, and to Ms. Lisa Litzenberger
   for her excellent assistance in arts preparation. This work was
   supported in part by research grants (AWD-102888 and AWD-122695) from
   the Cancer League of Colorado (to BL).
CR Adams BD, 2008, SEMIN REPROD MED, V26, P522, DOI 10.1055/s-0028-1096132
   Åstrand C, 2009, EXP CELL RES, V315, P2604, DOI 10.1016/j.yexcr.2009.05.012
   Aurisicchio L, 2012, ONCOTARGET, V3, P744, DOI 10.18632/oncotarget.550
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741
   Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   Chumsri S, 2011, STEROIDS, V76, P730, DOI 10.1016/j.steroids.2011.02.033
   Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Hofmann MH, 2009, MOL CANCER RES, V7, P1635, DOI 10.1158/1541-7786.MCR-09-0043
   Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100
   Huang XP, 2011, CANCER LETT, V307, P72, DOI 10.1016/j.canlet.2011.03.019
   Huang XP, 2009, CANCER RES, V69, P8403, DOI 10.1158/0008-5472.CAN-09-2146
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010
   Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920
   Kasman L, 2012, PROSTATE CANCER, V2012, DOI 10.1155/2012/137163
   Knipstein J, 2011, EXPERT OPIN INV DRUG, V20, P1455, DOI 10.1517/13543784.2011.613822
   Lai MD, 2010, CANCER GENE THER, V17, P203, DOI 10.1038/cgt.2009.65
   Lee BI, 2001, CANCER RES, V61, P931
   Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380
   Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423
   Liu BL, 2009, MOL CANCER RES, V7, P1882, DOI 10.1158/1541-7786.MCR-08-0509
   Mahlknecht U, 2000, MOL MED, V6, P623, DOI 10.1007/BF03402044
   Mestdagh P, 2010, MOL CELL, V40, P762, DOI 10.1016/j.molcel.2010.11.038
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mottet D, 2008, CLIN EXP METASTAS, V25, P183, DOI 10.1007/s10585-007-9131-5
   Mulholland NM, 2003, ONCOGENE, V22, P4807, DOI 10.1038/sj.onc.1206722
   Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379
   Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509
   Nelson KM, 2008, MOL CANCER THER, V7, P3655, DOI 10.1158/1535-7163.MCT-08-0586
   Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145
   Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632
   Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107
   Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   THOR AD, 1989, CANCER RES, V49, P7147
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wang S, 2010, ONCOGENE, V29, P4225, DOI 10.1038/onc.2010.180
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18
   Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34
   Xu J, 2008, CANCER RES, V68, P6718, DOI 10.1158/0008-5472.CAN-08-0657
   Yang N, 2008, INT J CANCER, V122, P963, DOI 10.1002/ijc.23325
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Yu DH, 1996, ONCOGENE, V13, P1359
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
NR 60
TC 102
Z9 117
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR
PY 2013
VL 4
AR e556
DI 10.1038/cddis.2013.79
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 116FR
UT WOS:000316868700035
PM 23519125
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Do, K
   Chen, AP
AF Do, Khanh
   Chen, Alice P.
TI Molecular Pathways: Targeting PARP in Cancer Treatment
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ADP-RIBOSE POLYMERASE; REFRACTORY SOLID TUMORS; NEGATIVE BREAST-CANCER;
   POLY(ADP-RIBOSE) POLYMERASE; DNA-DAMAGE; PHASE-I; PROMOTER
   HYPERMETHYLATION; SPORADIC BREAST; INHIBITOR ABT-888; OVARIAN-CANCER
AB Poly (ADP-ribose) polymerases (PARP) are a family of nuclear protein enzymes involved in the DNA damage response. The role of PARP-1 in base excisional repair has been extensively characterized. More recent in vitro studies additionally implicate a role for PARP-1 in facilitating homologous recombination and nonhomologous end-joining. The more faithful process of homologous recombination repair of double-stranded DNA breaks involves localization of BRCA-1 and BRCA-2 to sites of DNA damage, resection of the double-stranded break, and gap-filling DNA synthesis using the homologous sister chromatid as a template. Simultaneous dysfunction of both DNA repair pathways decreases the ability of cells to compensate, and forms the basis for the concept of synthetic lethality. Treatment strategies, thus far, have focused on two main principles: (i) exploitation of the concept of synthetic lethality in homologous recombination-deficient tumors, primarily in breast and ovarian cancer patients with BRCA mutation, and (ii) as radiosensitizers and chemosensitizers. BRCA deficiency accounts for only a fraction of dysfunction in homologous recombination repair. Epigenetic alterations of BRCA function and defects within the Fanconi anemia pathway also result in defective DNA repair. Rational therapeutic combinations exploiting alternate mechanisms of defective DNA repair, abrogation of cell-cycle checkpoints, and additional functions of PARP-1 present novel opportunities for further clinical development of PARP inhibitors. On the basis of the results of clinical studies of PARP inhibitors thus far, it is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting. Clin Cancer Res; 19(5); 977-84. (C) 2012 AACR.
C1 [Do, Khanh] NCI, Med Oncol Branch, Ctr Canc Res, Bethesda, MD 20852 USA.
   [Chen, Alice P.] NCI, Canc Therapy Evaluat Program, Div Canc Treatment & Diag, Bethesda, MD 20852 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI)
RP Chen, AP (通讯作者)，NCI, 6130 Executive Blvd,Suite 7130, Bethesda, MD 20852 USA.
EM chenali@mail.nih.gov
RI Chen, Alice/AAG-9400-2020
FU Intramural NIH HHS [Z99 CA999999] Funding Source: Medline; NCI NIH HHS
   [Y99 CA999999] Funding Source: Medline
CR Albert JM, 2007, CLIN CANCER RES, V13, P3033, DOI 10.1158/1078-0432.CCR-06-2872
   [Anonymous], J CLIN ONCOL S
   [Anonymous], J CLIN ONCOL S
   Beckert S, 2006, BIOCHEM BIOPH RES CO, V341, P67, DOI 10.1016/j.bbrc.2005.12.148
   Bhargava S, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.9559
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566
   Chuang HC, 2012, BREAST CANCER RES TR, V134, P649, DOI 10.1007/s10549-012-2106-5
   Cotter MB, 2012, J CLIN ONCOL, V30
   El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Giaccone G, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3027
   Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200
   Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001
   Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232
   Houtgraaf JH, 2006, CARDIOVASC REVASCULA, V7, P165, DOI 10.1016/j.carrev.2006.02.002
   HUGGINSPUHALLA SL, 2012, J CLIN ONCOL S, V30
   Hunter JE, 2012, ONCOGENE, V31, P251, DOI 10.1038/onc.2011.229
   Isakoff SJ, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.1019
   Ji JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026152
   Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377
   Kapoor P, 2012, J CLIN ONCOL, V30
   Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248
   Khan OA, 2011, BRIT J CANCER, V104, P750, DOI 10.1038/bjc.2011.8
   Kinders RJ, 2008, CLIN CANCER RES, V14, P6877, DOI 10.1158/1078-0432.CCR-08-0214
   Kummar S, 2012, CLIN CANCER RES, V18, P1726, DOI 10.1158/1078-0432.CCR-11-2821
   Kummar S, 2011, CANCER RES, V71, P5626, DOI 10.1158/0008-5472.CAN-11-1227
   Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535
   Liu J, 2011, J CLIN ONCOL S, V29
   LUNEC J, 1984, BRIT J CANCER, V49, P19
   Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   Middleton M, 2011, ECCO ESMO 2011
   Naing A, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.10031
   Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245
   Nowsheen S, 2011, RADIOTHER ONCOL, V99, P331, DOI 10.1016/j.radonc.2011.05.084
   O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418
   Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890
   Petrovics G, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e15171
   Plummer R, 2006, J CLIN ONCOL, V24, P8013
   Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223
   Rajesh M, 2006, BIOCHEM BIOPH RES CO, V350, P352, DOI 10.1016/j.bbrc.2006.09.049
   Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812
   Russo AL, 2009, CLIN CANCER RES, V15, P607, DOI 10.1158/1078-0432.CCR-08-2079
   Schaefer NG, 2011, NUCL MED COMMUN, V32, P1046, DOI 10.1097/MNM.0b013e32834a369b
   Schelman WR, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3102
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   Sinha S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-84
   Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6
   Villalona-Calero MA, 2011, J CLIN ONCOL S, V29
   Wan Y, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.27_suppl.74
   Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840
   Wang XZ, 2004, DNA REPAIR, V3, P1063, DOI 10.1016/j.dnarep.2004.04.005
   Wang ZH, 2006, CANCER BIOL THER, V5, P256, DOI 10.4161/cbt.5.3.2380
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Yang ES, 2012, J CLIN ONCOL S, V30
NR 61
TC 76
Z9 81
U1 0
U2 37
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 1
PY 2013
VL 19
IS 5
BP 977
EP 984
DI 10.1158/1078-0432.CCR-12-0163
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 100YB
UT WOS:000315740200005
PM 23269547
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Jacobs, DI
   Hansen, J
   Fu, A
   Stevens, RG
   Tjonneland, A
   Vogel, UB
   Zheng, TZ
   Zhu, Y
AF Jacobs, Daniel I.
   Hansen, Johnni
   Fu, Alan
   Stevens, Richard G.
   Tjonneland, Anne
   Vogel, Ulla B.
   Zheng, Tongzhang
   Zhu, Yong
TI Methylation alterations at imprinted genes detected among long-term
   shiftworkers
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article
DE loss of imprinting; shiftwork; differential methylation
ID DNA METHYLATION; BREAST-CANCER; EPIGENETICS; GENOME; NIGHT; RISK;
   EXPRESSION; MUTATIONS; EXPOSURE; DENMARK
AB Exposure to light at night through shiftwork has been linked to alterations in DNA methylation and increased risk of cancer development. Using an Illumina Infinium Methylation Assay, we analyzed methylation levels of 397 CpG sites in the promoter regions of 56 normally imprinted genes to investigate whether shiftwork is associated with alteration of methylation patterns. Methylation was significantly higher at 20 CpG sites and significantly lower at 30 CpG sites (P < 0.05) in 10 female long-term shiftworkers as compared to 10 female age- and folate intake-matched day workers. The strongest evidence for altered methylation patterns in shiftworkers was observed for DLX5, IGF2AS, and TP73 based on the magnitude of methylation change and consistency in the direction of change across multiple CpG sites, and consistent results were observed using quantitative DNA methylation analysis. We conclude that long-term shiftwork may alter methylation patterns at imprinted genes, which may be an important mechanism by which shiftwork has carcinogenic potential and warrants further investigation. Environ. Mol. Mutagen., 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Jacobs, Daniel I.; Fu, Alan; Zheng, Tongzhang; Zhu, Yong] Yale Univ, Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
   [Hansen, Johnni; Tjonneland, Anne] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
   [Stevens, Richard G.] Univ Connecticut, Dept Community Med & Hlth Care, Ctr Hlth, Farmington, CT USA.
   [Vogel, Ulla B.] Natl Res Ctr Working Environm, Copenhagen, Denmark.
C3 Yale University; Danish Cancer Society; University of Connecticut;
   National Research Centre for the Working Environment
RP Zhu, Y (通讯作者)，Yale Univ, Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
EM yong.zhu@yale.edu
RI Vogel, Ulla/ABC-2212-2020; Tjonneland, Anne/AGU-0320-2022; Vogel,
   Ulla/I-5048-2012
OI Vogel, Ulla/0000-0001-6807-1524; Tjonneland, Anne/0000-0003-4385-2097;
   Hansen, Johnni/0000-0002-9342-2725
FU National Institute of Environmental Health Sciences (NIEHS) [ES018915];
   Yale University; Danish Cancer Society
FX Grant sponsor: The National Institute of Environmental Health Sciences
   (NIEHS); Grant Number ES018915; Grant sponsor: Yale University; Grant
   sponsor: The Danish Cancer Society.
CR Alegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/EPI.11.22, 10.2217/epi.11.22]
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2
   Bollati V, 2010, CHRONOBIOL INT, V27, P1093, DOI 10.3109/07420528.2010.490065
   Davis S, 2001, JNCI-J NATL CANCER I, V93, P1557, DOI 10.1093/jnci/93.20.1557
   Fang F, 2012, P NATL ACAD SCI USA, V109, P7332, DOI 10.1073/pnas.1201310109
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7
   Fustinoni S, 2012, MED LAV, V103, P84
   Hansen J, 2001, JNCI-J NATL CANCER I, V93, P1513, DOI 10.1093/jnci/93.20.1513
   Hansen J, 2011, OCCUP ENVIRON MED, V68, P236, DOI 10.1136/oem.2010.061630
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Hoffman AE, 2009, CANCER RES, V69, P3605, DOI 10.1158/0008-5472.CAN-08-4572
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Kacem S, 2009, MAMM GENOME, V20, P544, DOI 10.1007/s00335-009-9223-4
   Kato T, 2008, CLIN CANCER RES, V14, P2363, DOI 10.1158/1078-0432.CCR-07-1523
   Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649
   Okutsu T, 2000, J BIOCHEM-TOKYO, V127, P475, DOI 10.1093/oxfordjournals.jbchem.a022630
   OVERVAD K, 1991, INT J EPIDEMIOL, V20, P900, DOI 10.1093/ije/20.4.900
   Parle-McDermott A, 2011, ADV NUTR, V2, P463, DOI 10.3945/an.111.001008
   Pavanello S, 2009, INT J CANCER, V125, P1692, DOI 10.1002/ijc.24492
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002
   Schernhammer ES, 2001, J NATL CANCER I, V93, P1563, DOI 10.1093/jnci/93.20.1563
   Sigal A, 2000, CANCER RES, V60, P6788
   Tan YF, 2010, CANCER RES, V70, P9197, DOI 10.1158/0008-5472.CAN-10-1568
   Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986
   Yang P, 2012, CANCER EPIDEM BIOMAR, V21, P182, DOI 10.1158/1055-9965.EPI-11-0784
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
   Zhu Y, 2009, CANCER RES, V69, P9315, DOI 10.1158/0008-5472.CAN-09-0648
NR 30
TC 24
Z9 27
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0893-6692
EI 1098-2280
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PD MAR
PY 2013
VL 54
IS 2
BP 141
EP 146
DI 10.1002/em.21752
PG 6
WC Environmental Sciences; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA 085EB
UT WOS:000314595400007
PM 23193016
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Grzenda, A
   Lomberk, G
   Svingen, P
   Mathison, A
   Calvo, E
   Iovanna, J
   Xiong, YN
   Faubion, W
   Urrutia, R
AF Grzenda, Adrienne
   Lomberk, Gwen
   Svingen, Phyllis
   Mathison, Angela
   Calvo, Ezequiel
   Iovanna, Juan
   Xiong, Yuning
   Faubion, William
   Urrutia, Raul
TI Functional characterization of EZH2β reveals the increased complexity of
   EZH2 isoforms involved in the regulation of mammalian gene expression
SO EPIGENETICS & CHROMATIN
LA English
DT Article
DE Chromatin; Enhancer of zeste homologue 2; Epigenetics; EZH2; Histone
   methyltransferase; Polycomb; Polycomb repressive complex 2; PRC2
ID GROUP PROTEIN EZH2; HISTONE H3; TRANSCRIPTIONAL REPRESSION;
   METHYLTRANSFERASE ACTIVITY; BREAST-CANCER; DNA-REPAIR; E-CADHERIN; CELL
   FATE; POLYCOMB; METHYLATION
AB Background: Histone methyltransferase enhancer of zeste homologue 2 (EZH2) forms an obligate repressive complex with suppressor of zeste 12 and embryonic ectoderm development, which is thought, along with EZH1, to be primarily responsible for mediating Polycomb-dependent gene silencing. Polycomb-mediated repression influences gene expression across the entire gamut of biological processes, including development, differentiation and cellular proliferation. Deregulation of EZH2 expression is implicated in numerous complex human diseases. To date, most EZH2-mediated function has been primarily ascribed to a single protein product of the EZH2 locus.
   Results: We report that the EZH2 locus undergoes alternative splicing to yield at least two structurally and functionally distinct EZH2 methyltransferases. The longest protein encoded by this locus is the conventional enzyme, which we refer to as EZH2 alpha, whereas EZH2 beta, characterized here, represents a novel isoform. We find that EZH2 beta localizes to the cell nucleus, complexes with embryonic ectoderm development and suppressor of zeste 12, trimethylates histone 3 at lysine 27, and mediates silencing of target promoters. At the cell biological level, we find that increased EZH2 beta induces cell proliferation, demonstrating that this protein is functional in the regulation of processes previously attributed to EZH2 alpha. Biochemically, through the use of genome-wide expression profiling, we demonstrate that EZH2 beta governs a pattern of gene repression that is often ontologically redundant from that of EZH2 alpha, but also divergent for a wide variety of specific target genes.
   Conclusions: Combined, these results demonstrate that an expanded repertoire of EZH2 writers can modulate histone code instruction during histone 3 lysine 27-mediated gene silencing. These data support the notion that the regulation of EZH2-mediated gene silencing is more complex than previously anticipated and should guide the design and interpretation of future studies aimed at understanding the biochemical and biological roles of this important family of epigenomic regulators.
C1 [Grzenda, Adrienne; Lomberk, Gwen; Svingen, Phyllis; Mathison, Angela; Xiong, Yuning; Faubion, William; Urrutia, Raul] Mayo Clin, Lab Epigenet & Chromatin Dynam, Rochester, MN 55905 USA.
   [Calvo, Ezequiel] CHUL Res Ctr, Mol Endocrinol & Oncol Res Ctr, Quebec City, PQ, Canada.
   [Iovanna, Juan; Urrutia, Raul] INSERM U624, F-13288 Marseille 9, France.
   [Urrutia, Raul] Mayo Clin, CIM, Translat Epigenom Program, Rochester, MN 55905 USA.
   [Urrutia, Raul] Mayo Clin, Dept Med, Rochester, MN 55905 USA.
   [Urrutia, Raul] Mayo Clin, Dept Physiol, Rochester, MN 55905 USA.
   [Urrutia, Raul] Mayo Clin, Dept Biochem, Rochester, MN 55905 USA.
C3 Mayo Clinic; Laval University; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo
   Clinic
RP Urrutia, R (通讯作者)，Mayo Clin, Lab Epigenet & Chromatin Dynam, Rochester, MN 55905 USA.
EM urrutia.raul@mayo.edu
RI Iovanna, Juan/M-9805-2017; Grzenda, Adrienne/K-4421-2019; Lomberk,
   Gwen/AAL-8490-2020
OI Lomberk, Gwen/0000-0001-5463-789X; Grzenda, Adrienne/0000-0001-5952-6953
FU National Institutes of Health [DK52913]; Fraternal Order of Eagles
   Cancer Award [T32CA148073]; Mayo Clinic Center for Cell Signaling in
   Gastroenterology [P30DK084567]; Mayo Foundation; National Institute of
   Diabetes and Digestive and Kidney Diseases [R01DK052913] Funding Source:
   NIH RePORTER
FX This work was supported by funding from National Institutes of Health
   grants DK52913 (RU), Fraternal Order of Eagles Cancer Award (GL),
   T32CA148073 (AG), the Mayo Clinic Center for Cell Signaling in
   Gastroenterology (P30DK084567), and the Mayo Foundation.
CR Bao YH, 2005, PROSTATE, V64, P401, DOI 10.1002/pros.20265
   Bohrer LR, 2010, ENDOCRINOLOGY, V151, P5136, DOI 10.1210/en.2010-0436
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cardoso C, 2000, EUR J HUM GENET, V8, P174, DOI 10.1038/sj.ejhg.5200439
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001
   Han ZF, 2007, STRUCTURE, V15, P1306, DOI 10.1016/j.str.2007.08.007
   Hobert O, 1996, MOL CELL BIOL, V16, P3066
   Hyland PL, 2011, J VIROL, V85, P10999, DOI 10.1128/JVI.00160-11
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Lomberk G, 2012, J BIOL CHEM, V287, P13026, DOI 10.1074/jbc.M112.342634
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367
   Nolz JC, 2005, TRENDS CELL BIOL, V15, P514, DOI 10.1016/j.tcb.2005.08.003
   Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255
   Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876
   Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706
   Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029
   Thierry-Mieg D, 2006, GENOME BIOL S1, V7
   Tie F, 2001, DEVELOPMENT, V128, P275
   Tie F, 2007, MOL CELL BIOL, V27, P2014, DOI 10.1128/MCB.01822-06
   Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wettenhall JM, 2006, BIOINFORMATICS, V22, P897, DOI 10.1093/bioinformatics/btl025
   Xiong YN, 2012, J BIOL CHEM, V287, P34372, DOI 10.1074/jbc.M111.325332
   Yamamoto K, 2004, J BIOL CHEM, V279, P401, DOI 10.1074/jbc.M307344200
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
   Zeidler M, 2006, J MOL HISTOL, V37, P219, DOI 10.1007/s10735-006-9042-9
   Zeng XZ, 2011, CELL CYCLE, V10, P579, DOI 10.4161/cc.10.4.14722
NR 52
TC 26
Z9 31
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD FEB 28
PY 2013
VL 6
AR 3
DI 10.1186/1756-8935-6-3
PG 20
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 114HF
UT WOS:000316731000001
PM 23448518
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Dohi, O
   Yasui, K
   Gen, Y
   Takada, H
   Endo, M
   Tsuji, K
   Konishi, C
   Yamada, N
   Mitsuyoshi, H
   Yagi, N
   Naito, Y
   Tanaka, S
   Arii, S
   Yoshikawa, T
AF Dohi, Osamu
   Yasui, Kohichiroh
   Gen, Yasuyuki
   Takada, Hisashi
   Endo, Mio
   Tsuji, Kazuhiro
   Konishi, Chika
   Yamada, Nobuhisa
   Mitsuyoshi, Hironori
   Yagi, Nobuaki
   Naito, Yuji
   Tanaka, Shinji
   Arii, Shigeki
   Yoshikawa, Toshikazu
TI Epigenetic silencing of <i>miR</i>-<i>335</i> and its host gene
   <i>MEST</i> in hepatocellular carcinoma
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE miR-335; MEST; methylation; hepatocellular carcinoma
ID BREAST-CANCER; MICRORNAS; CELLS; DIFFERENTIATION; METHYLATION; GROWTH
AB MicroRNAs (miRNAs) are small non-coding RNAs that function as endogenous silencers of target genes. Some tumor-suppressive miRNAs are known to be epigenetically silenced by promoter DNA methylation in cancer. In the present study, we aimed to identify miRNA genes that are silenced by DNA hypermethylation in hepatocellular carcinoma (HCC). We screened for miRNA genes with promoter DNA hypermethylation using a genome-wide methylation microarray analysis in HCC cells. It was found that miR-335, which is harbored within an intron of its protein-coding host gene, MEST, was downregulated by aberrant promoter hypermethylation via further methylation assays, including methylation-specific PCR, combined bisulfite and restriction analysis, bisulfite sequencing analysis and 5-aza-2'-deoxycytidine treatment. The expression levels of miR-335 significantly correlated with those of MEST, supporting the notion that the intronic miR-335 is co-expressed with its host gene. The levels of miR-335/MEST methylation were significantly higher in 18 (90%) out of 20 primary HCC tumors, compared to their non-tumor tissue counterparts (P<0.001). The expression levels of miR-335 were significantly lower in 25 (78%) out of 32 primary HCC tumors, compared to their non-tumor tissue counterparts (P=0.001). Furthermore, the expression levels of miR-335 were significantly lower in HCC tumors with distant metastasis compared to those without distant metastasis (P=0.02). In conclusion, our results indicate that expression of miR-335 is reduced by aberrant DNA methylation in HCC.
C1 [Yasui, Kohichiroh] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kamigyo Ku, Kyoto 6028566, Japan.
   [Tanaka, Shinji; Arii, Shigeki] Tokyo Med & Dent Univ, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan.
C3 Kyoto Prefectural University of Medicine; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU)
RP Yasui, K (通讯作者)，Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kamigyo Ku, 465 Kawaramachi, Kyoto 6028566, Japan.
EM yasuik@koto.kpu-m.ac.jp
RI Dohi, Osamu/AAA-1634-2020
FU Grants-in-Aid for Scientific Research [22130005, 23590470, 25253081]
   Funding Source: KAKEN
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Borel F, 2012, J HEPATOL, V56, P1371, DOI 10.1016/j.jhep.2011.11.026
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Dohi O, 2010, INT J ONCOL, V36, P85, DOI 10.3892/ijo_00000478
   Hatada I, 2006, ONCOGENE, V25, P3059, DOI 10.1038/sj.onc.1209331
   Hatada I, 2008, J HUM GENET, V53, P185, DOI 10.1007/s10038-007-0228-0
   Hatada I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003189
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512
   Kozaki K, 2012, CANCER SCI, V103, P837, DOI 10.1111/j.1349-7006.2012.02236.x
   Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104
   Scarola M, 2010, CANCER RES, V70, P6925, DOI 10.1158/0008-5472.CAN-10-0141
   Shu MF, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-59
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010
   Zen K, 2009, GENE CHROMOSOME CANC, V48, P109, DOI 10.1002/gcc.20624
NR 24
TC 67
Z9 72
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2013
VL 42
IS 2
BP 411
EP 418
DI 10.3892/ijo.2012.1724
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 077AT
UT WOS:000314001000005
PM 23229728
OA Green Submitted, Green Accepted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Thaler, R
   Spitzer, S
   Karlic, H
   Berger, C
   Klaushofer, K
   Varga, F
AF Thaler, R.
   Spitzer, S.
   Karlic, H.
   Berger, C.
   Klaushofer, K.
   Varga, F.
TI Ibandronate increases the expression of the pro-apoptotic gene FAS by
   epigenetic mechanisms in tumor cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Bisphosphonates; Ibandronate; Epigenetic DNA-methylation; Small GTPases;
   FAS apoptosis
ID CONTAINING BISPHOSPHONATES INHIBIT; FARNESYL-PROTEIN TRANSFERASE;
   PROSTATE-CANCER PATIENTS; DNA METHYLATION; ZOLEDRONIC ACID; IN-VITRO;
   OSTEOCLAST FORMATION; BONE-RESORPTION; FARNESYLTRANSFERASE INHIBITOR;
   ORAL BISPHOSPHONATES
AB There is growing evidence that aminobisphosphonates like ibandronate show anticancer activity by an unknown mechanism. Biochemically, they prevent posttranslational isoprenylation of small GTPases, thus inhibiting their activity. In tumor cells, activated RAS-GTPase, the founding member of the gene family, down-regulates the expression of the pro-apoptotic gene FAS via epigenetic DNA-methylation by DNMT1. We compared ibandronate treatment in neoplastic human U-2 osteosarcoma and in mouse CCL-51 breast cancer cells as well as in the immortalized non-neoplastic MC3T3-E1 osteoblastic cells. Ibandronate attenuated cell proliferation in all cell lines tested. In the neoplastic cells we found upregulation of caspases suggesting apoptosis. Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by reisoprenylation by both geranylgeranyl-pyrophosphate and farnesylpyrophosphate. In contrast, ibandronate did not affect FAS and DNMT1 expression in MC3T3-E1 non-neoplastic cells. Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression. In conclusion the shown epigenetic mechanism underlying the anti-neoplastic activity of farnesyl-transferase-inhibition, also explains the clinical success of other drugs, which target this pathway. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Thaler, R.; Spitzer, S.; Klaushofer, K.; Varga, F.] Hanusch Hosp, Dept Med 1, WGKK & AUVA Trauma Ctr Meidling, Ludwig Boltzmann Inst Osteol, A-1140 Vienna, Austria.
   [Karlic, H.] Hanusch Hosp, Inst Leukemia Res & Hematol, A-1140 Vienna, Austria.
   [Berger, C.] Danube Hosp, SMZ OST, Dept Orthoped, Vienna, Austria.
C3 Ludwig Boltzmann Institute; WGKK - Hanusch Hospital; WGKK - Hanusch
   Hospital; Donauspital
RP Varga, F (通讯作者)，Hanusch Hosp, Dept Med 1, WGKK & AUVA Trauma Ctr Meidling, Ludwig Boltzmann Inst Osteol, Heinrich Collin Str 30, A-1140 Vienna, Austria.
EM franz.varga@osteologie.at
RI Varga, Franz/HOH-9148-2023
FU Fonds zur Foerderung der Wissenschaftlichen Forschung (FWF)
   [P24370-B19]; Medical Scientific Fund of the Mayor of the City of Vienna
   [2565]; WORK (Social Health Insurance Vienna); AUVA (Austrian Social
   Insurance for Occupational Risks); Austrian Science Fund (FWF) [P24370]
   Funding Source: Austrian Science Fund (FWF)
FX This study was supported by the Fonds zur Foerderung der
   Wissenschaftlichen Forschung (FWF; The Austrian Science Fund) Project
   P24370-B19, the Medical Scientific Fund of the Mayor of the City of
   Vienna (Project 2565), the WORK (Social Health Insurance Vienna), and
   the AUVA (Austrian Social Insurance for Occupational Risks).
CR Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255
   ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   Bundred N, 2012, CANCER TREAT REV, V38, P776, DOI 10.1016/j.ctrv.2012.02.002
   Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155
   Caraglia M, 2006, ENDOCR-RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Cardwell CR, 2012, INT J CANCER, V131, pE717, DOI 10.1002/ijc.27389
   Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Corrado A, 2010, CLIN EXP RHEUMATOL, V28, P873
   Coxon FP, 1998, MOL PHARMACOL, V54, P631
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Daubine F, 2011, ANTICANCER RES, V31, P4141
   Delcuve GP, 2009, J CELL PHYSIOL, V219, P243, DOI 10.1002/jcp.21678
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Epling-Burnette PK, 2010, EXPERT OPIN INV DRUG, V19, P689, DOI 10.1517/13543781003801076
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Fujita H, 2011, BASIC CLIN PHARMACOL, V109, P78, DOI 10.1111/j.1742-7843.2011.00685.x
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Ghanim V, 2012, BLOOD, V119, P4242, DOI 10.1182/blood-2011-09-382770
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010
   Halasy-Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756-3282(01)00615-9
   Hopfer O, 2009, LEUKEMIA RES, V33, P434, DOI 10.1016/j.leukres.2008.08.014
   Huang K, 2010, REGEN MED, V5, P531, DOI 10.2217/RME.10.35
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Kaneda A, 2004, CANCER RES, V64, P6410, DOI 10.1158/0008-5472.CAN-04-1543
   Karlic H, 2011, BLOOD, V118, P1479, DOI 10.1182/blood.V118.21.3463.3463
   Kinoshita H, 2000, CANCER RES, V60, P3623
   Kubista B, 2006, J ORTHOP RES, V24, P1145, DOI 10.1002/jor.20129
   Kucukzeybek Y, 2010, J INT MED RES, V38, P1663, DOI 10.1177/147323001003800511
   Lane SW, 2012, BLOOD, V119, P736, DOI 10.1182/blood-2011-07-368753
   Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743
   Lee MV, 2001, CANCER RES, V61, P2602
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Moasser MM, 2002, BREAST CANCER RES TR, V73, P135, DOI 10.1023/A:1015209123900
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Nilsson S, 2011, CANCER LETT, V304, P60, DOI 10.1016/j.canlet.2010.12.022
   Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A
   Ohtsuka Y, 2005, BLOOD, V106, P3134, DOI 10.1182/blood-2005-03-0972
   Oki Y, 2010, CANCER TREAT RES, V145, P19, DOI 10.1007/978-0-387-69259-3_2
   Omerovic J, 2007, CELL MOL LIFE SCI, V64, P2575, DOI 10.1007/s00018-007-7133-8
   Patra SK, 2008, FEBS J, V275, P5217, DOI 10.1111/j.1742-4658.2008.06658.x
   Pazianas M, 2012, OSTEOPOROSIS INT, V23, P2693, DOI 10.1007/s00198-012-1902-4
   Pazianas M, 2011, ANN NY ACAD SCI, V1240, pE19, DOI 10.1111/j.1749-6632.2011.06372.x
   Petak I, 2003, CELL DEATH DIFFER, V10, P211, DOI 10.1038/sj.cdd.4401132
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528
   Reibenwein J, 2007, PROSTATE, V67, P427, DOI 10.1002/pros.20533
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Rodrigues P, 2011, CANCER RES TREAT, V43, P231, DOI 10.4143/crt.2011.43.4.231
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Santourlidis S, 2001, MOL CARCINOGEN, V32, P36, DOI 10.1002/mc.1062
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Thaler R, 2011, J BIOL CHEM, V286, P5578, DOI 10.1074/jbc.M110.166181
   Thaler R, 2010, APOPTOSIS, V15, P728, DOI 10.1007/s10495-010-0462-3
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
   Wang J, 2011, BIOCHEM PHARMACOL, V81, P1036, DOI 10.1016/j.bcp.2011.01.025
   Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wu JQ, 2011, ARCH DERMATOL, V147, P443, DOI 10.1001/archdermatol.2010.376
   Zhang FL, 1997, J BIOL CHEM, V272, P10232
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 87
TC 18
Z9 19
U1 12
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JAN 15
PY 2013
VL 85
IS 2
BP 173
EP 185
DI 10.1016/j.bcp.2012.10.016
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 079AU
UT WOS:000314143400005
PM 23103563
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Ray, BK
   Dhar, S
   Henry, C
   Rich, A
   Ray, A
AF Ray, Bimal K.
   Dhar, Srijita
   Henry, Carolyn
   Rich, Alexander
   Ray, Alpana
TI Epigenetic Regulation by Z-DNA Silencer Function Controls
   Cancer-Associated ADAM-12 Expression in Breast Cancer: Cross-talk
   between MeCP2 and NF1 Transcription Factor Family
SO CANCER RESEARCH
LA English
DT Article
ID CPG-BINDING PROTEIN; POLYMORPHIC DINUCLEOTIDE REPEAT;
   EPIDERMAL-GROWTH-FACTOR; HISTONE DEACETYLASE; FORMING SEQUENCES; TUMOR
   PROGRESSION; GENE-EXPRESSION; MELTRIN-ALPHA; BAF COMPLEX; IN-VIVO
AB A disintegrin and metalloprotease domain-containing protein 12 (ADAM-12) is upregulated in many human cancers and promotes cancer metastasis. Increased urinary level of ADAM-12 in breast and bladder cancers correlates with disease progression. However, the mechanism of its induction in cancer remains less understood. Previously, we reported a Z-DNA-forming negative regulatory element (NRE) in ADAM-12 that functions as a transcriptional suppressor to maintain a low-level expression of ADAM-12 in most normal cells. We now report here that overexpression of ADAM-12 in triple-negative MDA-MB-231 breast cancer cells and breast cancer tumors is likely due to a marked loss of this Z-DNA-mediated transcriptional suppression function. We show that Z-DNA suppressor operates by interaction with methyl-CpG-binding protein, MeCP2, a prominent epigenetic regulator, and two members of the nuclear factor 1 family of transcription factors, NF1C and NF1X. While this tripartite interaction is highly prevalent in normal breast epithelial cells, both in vitro and in vivo, it is significantly lower in breast cancer cells. Western blot analysis has revealed significant differences in the levels of these 3 proteins between normal mammary epithelial and breast cancer cells. Furthermore, we show, by NRE mutation analysis, that interaction of these proteins with the NRE is necessary for effective suppressor function. Our findings unveil a new epigenetic regulatory process in which Z-DNA/MeCP2/NF1 interaction leads to transcriptional suppression, loss of which results in ADAM-12 overexpression in breast cancer cells. Cancer Res; 73(2); 736-44. (C) 2012 AACR.
C1 [Ray, Bimal K.; Dhar, Srijita; Ray, Alpana] Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.
   [Henry, Carolyn] Univ Missouri, Dept Vet Med & Surg, Columbia, MO 65211 USA.
   [Rich, Alexander] MIT, Dept Biol, Cambridge, MA USA.
C3 University of Missouri System; University of Missouri Columbia;
   University of Missouri System; University of Missouri Columbia;
   Massachusetts Institute of Technology (MIT)
RP Ray, A (通讯作者)，Univ Missouri, Dept Vet Pathobiol, 126A Connaway Hall, Columbia, MO 65211 USA.
EM rayb@missouri.edu; rayal@missouri.edu
OI , Carolyn/0000-0002-2761-5203
FU U.S. Army Medical Research and Materiel Command; University of Missouri
   Research Board; University of Missouri, College of Veterinary Medicine
FX This study was supported partly by grants from U.S. Army Medical
   Research and Materiel Command, University of Missouri Research Board,
   and University of Missouri, College of Veterinary Medicine.
CR Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051
   ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958
   Dyczynska E, 2008, INT J CANCER, V122, P2634, DOI 10.1002/ijc.23405
   Fröhlich C, 2006, CLIN CANCER RES, V12, P7359, DOI 10.1158/1078-0432.CCR-06-1066
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176
   Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516
   Hebbar PB, 2003, MOL CELL BIOL, V23, P887, DOI 10.1128/MCB.23.3.887-898.2003
   Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421
   Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kane R, 2002, J BIOL CHEM, V277, P25893, DOI 10.1074/jbc.M202469200
   Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200
   Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3
   Kriaucionis S, 2004, NUCLEIC ACIDS RES, V32, P1818, DOI 10.1093/nar/gkh349
   Kumar D, 2009, J BIOL CHEM, V284, P1853, DOI 10.1074/jbc.M806289200
   Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262
   Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205
   Liu H, 2006, MOL CELL BIOL, V26, P2550, DOI 10.1128/MCB.26.7.2550-2559.2006
   Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9
   Müller K, 2000, J BIOL CHEM, V275, P1645, DOI 10.1074/jbc.275.3.1645
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0
   Oh DB, 2002, P NATL ACAD SCI USA, V99, P16666, DOI 10.1073/pnas.262672699
   Peduto L, 2006, ONCOGENE, V25, P5462, DOI 10.1038/sj.onc.1209536
   Pories SE, 2008, CANCER EPIDEM BIOMAR, V17, P1034, DOI 10.1158/1055-9965.EPI-07-0365
   Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327
   Ray BK, 2011, P NATL ACAD SCI USA, V108, P103, DOI 10.1073/pnas.1008831108
   Rich A, 2003, NAT REV GENET, V4, P566, DOI 10.1038/nrg1115
   Rothenburg S, 2001, P NATL ACAD SCI USA, V98, P8985, DOI 10.1073/pnas.121176998
   Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200
   Roy R, 2011, J BIOL CHEM, V286, P20758, DOI 10.1074/jbc.M110.216036
   SCHROTH GP, 1992, J BIOL CHEM, V267, P11846
   Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761
   Singh U, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005050
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Tian BL, 2002, J CLIN PATHOL-MOL PA, V55, P394, DOI 10.1136/mp.55.6.394
   Wang GL, 2006, P NATL ACAD SCI USA, V103, P2677, DOI 10.1073/pnas.0511084103
   Wang GL, 2007, FRONT BIOSCI-LANDMRK, V12, P4424, DOI 10.2741/2399
   Zhao LH, 2005, ACTA BIOCH BIOPH SIN, V37, P440, DOI 10.1111/j.1745-7270.2005.00061.x
NR 40
TC 42
Z9 49
U1 1
U2 27
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JAN 15
PY 2013
VL 73
IS 2
BP 736
EP 744
DI 10.1158/0008-5472.CAN-12-2601
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 073JO
UT WOS:000313739500032
PM 23135915
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Pilato, B
   Pinto, R
   De Summa, S
   Lambo, R
   Paradiso, A
   Tommasi, S
AF Pilato, Brunella
   Pinto, Rosamaria
   De Summa, Simona
   Lambo, Rossana
   Paradiso, Angelo
   Tommasi, Stefania
TI <i>HOX</i> gene methylation status analysis in patients with hereditary
   breast cancer
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE BRCA1; BRCA2; HOX genes; familial breast cancer
ID OVARIAN-CANCER; EXPRESSION; ESTROGEN; P53
AB Cancer development is related not only to genetic alterations but also to aberrant epigenetic changes that could lead to heritable gene patterns critical for neoplastic initiation and progression. Knowledge of epigenetic regulation in cancer cells is useful for both the understanding of carcinogenesis and for the possibility of using epigenetic drugs. HOX genes deregulation have a crucial role in oncogenesis process and tumor suppression. In this report, the methylation of HOXA1, HOXA9, HOXA10, HOXB13, HNF1B, OTX1, TLX1 genes have been analyzed in patients with hereditary breast cancer. This is the first study analyzing BRCA mutational status of patients with respect to methylation of HOX genes. HOXA10 has been found to be methylated in all patients analyzed but never in healthy subjects. With respect to clinical pathological information, hypermethylation of all studied genes, with the exception of OTX1, was significantly associated with absence of HER2 neu expression (P<0.05). Moreover, hypermethylation of HOXB13, HOXA10 and HOXA1 was associated with a high proliferation index (Mib1 >= 10%, P<0.05) and hypermethylation of HOXB13 and HOXA10 also with high expression of estrogen and progesterone receptors. These preliminary data suggest a possible involvement of HOX genes in familial breast cancer as marker helpful to identify high-risk patients. Journal of Human Genetics (2013) 58, 51-53; doi: 10.1038/jhg.2012.118; published online 11 October 2012
C1 [Tommasi, Stefania] Natl Canc Res Ctr, Mol Genet Lab, Ist Tumori Giovanni Paolo 2, I-70124 Bari, Italy.
C3 IRCCS Istituto Tumori Bari Giovanni Paolo II; Consiglio Nazionale delle
   Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)
RP Tommasi, S (通讯作者)，Natl Canc Res Ctr, Mol Genet Lab, Ist Tumori Giovanni Paolo 2, Viale Orazio Flacco 65, I-70124 Bari, Italy.
EM s.tommasi@oncologico.bari.it
RI Pilato, Brunella/AAH-7365-2020; paradiso, angelo/J-9457-2018; Tommasi,
   Stefania/J-6732-2012; De Summa, Simona/K-2582-2018
OI Tommasi, Stefania/0000-0002-2157-2978; pilato,
   brunella/0000-0001-6067-3977; De Summa, Simona/0000-0001-9607-3754
FU Progetto Regione Puglia DIEF
FX We thank Dr Caroline Oakley for language revision. This work is
   partially supported by Progetto Regione Puglia DIEF 2007.
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Avraham A, 2010, EPIGENETICS-US, V5, P41, DOI 10.4161/epi.5.1.10724
   Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Kelly ZL, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-16
   Martin R, 2007, J CLIN ENDOCR METAB, V92, P1920, DOI 10.1210/jc.2006-1694
   Miao J, 2007, P NATL ACAD SCI USA, V104, P17093, DOI 10.1073/pnas.0707938104
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014
   Terrinoni A, 2011, ONCOGENE, V30, P3096, DOI 10.1038/onc.2011.31
   Tommasi S, 2008, MUTAT RES-FUND MOL M, V644, P64, DOI 10.1016/j.mrfmmm.2008.07.005
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
NR 14
TC 31
Z9 32
U1 0
U2 27
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
J9 J HUM GENET
JI J. Hum. Genet.
PD JAN
PY 2013
VL 58
IS 1
BP 51
EP 53
DI 10.1038/jhg.2012.118
PG 3
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 078KW
UT WOS:000314098700011
PM 23051705
OA Bronze
DA 2025-01-12
ER

PT J
AU Jiang, M
   Huang, O
   Zhang, X
   Xie, ZQ
   Shen, AJ
   Liu, HC
   Geng, MY
   Shen, KW
AF Jiang, Min
   Huang, Ou
   Zhang, Xi
   Xie, Zuoquan
   Shen, Aijun
   Liu, Hongchun
   Geng, Meiyu
   Shen, Kunwei
TI Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the
   Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and
   MCF-7/LCC9
SO MOLECULES
LA English
DT Article
DE curcumin; endocrine resistance; tamoxifen; NF-kappa B; Src/FAK;
   Akt/mTOR; EZH2; cyclin D1; c-Myc
ID NF-KAPPA-B; ESTROGEN-RECEPTOR; CLINICAL-IMPLICATIONS; ENDOCRINE
   RESISTANCE; GENE-EXPRESSION; GROWTH-FACTOR; IN-VITRO; PATHWAY;
   INHIBITION; EZH2
AB Curcumin, a principal component of turmeric (Curcuma longa), has potential therapeutic activities against breast cancer through multiple signaling pathways. Increasing evidence indicates that curcumin reverses chemo-resistance and sensitizes cancer cells to chemotherapy and targeted therapy in breast cancer. To date, few studies have explored its potential antiproliferation effects and resistance reversal in antiestrogen-resistant breast cancer. In this study, we therefore investigated the efficacy of curcumin alone and in combination with tamoxifen in the established antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. We discovered that curcumin treatment displayed anti-proliferative and pro-apoptotic activities and induced cell cycle arrest at G2/M phase. Of note, the combination of curcumin and tamoxifen resulted in a synergistic survival inhibition in MCF-7/LCC2 and MCF-7/LCC9 cells. Moreover, we found that curcumin targeted multiple signals involved in growth maintenance and resistance acquisition in endocrine resistant cells. In our cell models, curcumin could suppress expression of pro-growth and anti-apoptosis molecules, induce inactivation of NF-kappa B, Src and Akt/mTOR pathways and downregulate the key epigenetic modifier EZH2. The above findings suggested that curcumin alone and combinations of curcumin with endocrine therapy may be of therapeutic benefit for endocrine-resistant breast cancer.
C1 [Jiang, Min; Huang, Ou; Zhang, Xi; Shen, Kunwei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai 200025, Peoples R China.
   [Xie, Zuoquan; Shen, Aijun; Liu, Hongchun; Geng, Meiyu] Chinese Acad Sci, Div Antitumor Pharmacol, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Materia Medica, CAS
RP Geng, MY (通讯作者)，Chinese Acad Sci, Div Antitumor Pharmacol, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
EM jiangmin1023@126.com; ou_huang@163.com; zhangxi0714@yeah.net;
   zuoquan_xie@163.com; aijun_shen@163.com; hongchun_liu@126.com;
   meiyu_geng@yeah.net; kunwei_shen@yeah.net
RI zhang, xi/AAD-7224-2021
OI Jiang, Min/0000-0003-1530-6830; Zhang, Xi/0000-0002-8865-0045; xie,
   zuoquan/0000-0002-1613-3321
FU National Natured Science Foundation of China [81172520]
FX We thank Robert Clarke for kindly providing MCF-7, MCF-7/LCC2 and
   MCF-7/LCC9 cell lines. This study was supported by National Natured
   Science Foundation of China (81172520).
CR Abukhdeir AM, 2008, P NATL ACAD SCI USA, V105, P288, DOI 10.1073/pnas.0710887105
   Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721
   Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510
   Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045
   Bachmeier BE, 2008, CARCINOGENESIS, V29, P779, DOI 10.1093/carcin/bgm248
   Block M, 2012, INT J ONCOL, V41, P1845, DOI 10.3892/ijo.2012.1591
   BRUNNER N, 1993, CANCER RES, V53, P3229
   Brunner N, 1997, CANCER RES, V57, P3486
   Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen Y, 2011, BREAST CANCER RES TR, V128, P69, DOI 10.1007/s10549-010-1024-7
   Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941
   Clark CA, 2010, CANCER PREV RES, V3, P1586, DOI 10.1158/1940-6207.CAPR-09-0244
   Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233
   Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429
   Granit RZ, 2013, ONCOGENE, V32, P3886, DOI 10.1038/onc.2012.390
   Hiscox S, 2009, BREAST CANCER RES TR, V115, P57, DOI 10.1007/s10549-008-0058-6
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Hua WF, 2010, EUR J PHARMACOL, V637, P16, DOI 10.1016/j.ejphar.2010.03.051
   Jansen MPHM, 2012, BREAST CANCER RES TR, V133, P937, DOI 10.1007/s10549-011-1877-4
   Johnson SM, 2009, ANTICANCER RES, V29, P3185
   Kim SR, 2012, ENDOCRINOLOGY, V153, P554, DOI 10.1210/en.2011-1413
   Lai HW, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/486568
   Larsen MS, 2012, ACTA ONCOL, V51, P781, DOI 10.3109/0284186X.2011.653009
   Leary AF, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1763
   Leung E, 2011, CANCER BIOL THER, V11, P938, DOI 10.4161/cbt.11.11.15527
   Lin HJ, 2010, ONCOL REP, V23, P665, DOI 10.3892/or_00000682
   Masuda N, 2012, LANCET ONCOL, V13, P345, DOI 10.1016/S1470-2045(11)70373-4
   Morgan L, 2009, CANCER BIOL THER, V8, P1550, DOI 10.4161/cbt.8.16.8954
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Nagaraju GP, 2012, INTEGR BIOL-UK, V4, P996, DOI 10.1039/c2ib20088k
   Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204
   Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9
   Riggins RB, 2005, MOL CANCER THER, V4, P33
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Saini S, 2011, CANCER PREV RES, V4, P1698, DOI 10.1158/1940-6207.CAPR-11-0267
   Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926
   Sen GS, 2011, J BIOL CHEM, V286, P42232, DOI 10.1074/jbc.M111.262295
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Steelman LS, 2011, CELL CYCLE, V10, P3003, DOI 10.4161/cc.10.17.17119
   Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137
   Vallabhaneni S, 2011, BREAST CANCER RES TR, V130, P377, DOI 10.1007/s10549-010-1312-2
   Yde CW, 2012, BREAST CANCER RES TR, V135, P67, DOI 10.1007/s10549-012-2053-1
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
   Zhou QM, 2011, EUR J CANCER, V47, P2240, DOI 10.1016/j.ejca.2011.04.032
   Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977
NR 47
TC 85
Z9 88
U1 0
U2 36
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD JAN
PY 2013
VL 18
IS 1
BP 701
EP 720
DI 10.3390/molecules18010701
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 077MX
UT WOS:000314032900044
PM 23299550
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Cao, W
   Ribeiro, RD
   Liu, DA
   Saintigny, P
   Xia, RH
   Xue, YW
   Lin, RX
   Mao, L
   Ren, HN
AF Cao, Wei
   Ribeiro, Rachel de Oliveira
   Liu, Diane
   Saintigny, Pierre
   Xia, Ronghui
   Xue, Yuwen
   Lin, Ruxian
   Mao, Li
   Ren, Hening
TI EZH2 Promotes Malignant Behaviors via Cell Cycle Dysregulation and Its
   mRNA Level Associates with Prognosis of Patient with Non-Small Cell Lung
   Cancer
SO PLOS ONE
LA English
DT Article
ID POLYCOMB GROUP GENE; ZESTE HOMOLOG 2; AGGRESSIVE BREAST-CANCER; GROUP
   PROTEINS BMI1; DNA METHYLATION; PROSTATE-CANCER; CLINICAL-IMPLICATIONS;
   INCREASED EXPRESSION; HISTONE DEACETYLASE; DOWN-REGULATION
AB Background: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesis. Enhancer of Zeste 2 (EZH2) is the histone methyltransferase subunit in polycomb repressive complex 2 which mediates transcriptional repression through histone methylation. EZH2 overexpression has been linked to aggressive phenotypes of certain cancers. However, the mechanism that EZH2 played in promoting malignancy in non-small cell lung cancer (NSCLC) remains unclear. In addition, the correlation of EZH2 overexpression and the prognosis of NSCLC patients in non-Asian cohort need to be determined.
   Methodology/Principal Findings: Up-regulation of EZH2 was found in NSCLC cells compared with normal human bronchial epithelial cells by western blot assay. Upon EZH2 knockdown using small interfering RNA (siRNA), the proliferation, anchorage-independent growth and invasion of NSCLC cells were remarkably suppressed with profound induction of G1 arrest. Furthermore, the expression of cyclin D1 was notably reduced whereas p15(INK4B), p21(Waf1/Cip1) and p27(Kip1) were increased in NSCLC cells after EZH2-siRNA delivery. To determine whether EZH2 expression contributes to disease progression in patients with NSCLC, Taqman quantitative real-time RT-PCR was used to measure the expression of EZH2 in paired tumor and normal samples. Univariate analysis revealed that patients with NSCLC whose tumors had a higher EZH2 expression had significantly inferior overall, disease-specific, and disease-free survivals compared to those whose tumors expressed lower EZH2 (P = 0.005, P = 0.001 and P = 0.003, respectively). In multivariate analysis, EZH2 expression was an independent predictor of disease-free survival (hazard ratio = 0.450, 95% CI: 0.270 to 0.750, P = 0.002).
   Conclusions/Significance: Our results demonstrate that EZH2 overexpression is critical for NSCLC progression. EZH2 mRNA levels may serve as a prognostic predictor for patients with NSCLC.
C1 [Cao, Wei; Xia, Ronghui] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Stomatol, Dept Oral Maxillofacial Head & Neck Oncol,Hosp 9, Shanghai 200030, Peoples R China.
   [Cao, Wei; Xia, Ronghui; Lin, Ruxian; Mao, Li; Ren, Hening] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
   [Ribeiro, Rachel de Oliveira; Saintigny, Pierre; Xue, Yuwen; Mao, Li; Ren, Hening] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
C3 Shanghai Jiao Tong University; University System of Maryland; University
   of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer
   Center
RP Ren, HN (通讯作者)，Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
EM Hren@umaryland.edu
RI Mao, Li/C-7570-2011; Li, Xiaoqiang/P-4087-2019; Cao, Wei/ABE-1035-2021
OI Saintigny, Pierre/0000-0002-8090-9323; Cao, Wei/0000-0003-2184-9380
FU NIH [R01 CA126818, R01 CA136635]; National Natural Science Foundation of
   China [81202130]
FX The work is supported by NIH grants R01 CA126818 and R01 CA136635. WC is
   supported in part by the National Natural Science Foundation of China
   (Grant No. 81202130). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622
   Aoki R, 2010, J HEPATOL, V52, P854, DOI 10.1016/j.jhep.2010.01.027
   Custodio AB, 2009, J THORAC ONCOL, V4, P891, DOI 10.1097/JTO.0b013e3181a4b8fb
   Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao W, 2012, CANCER-AM CANCER SOC, V118, P2858, DOI 10.1002/cncr.26575
   Cao W, 2011, CANCER PREV RES, V4, P1816, DOI 10.1158/1940-6207.CAPR-11-0130
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Choi JH, 2010, APMIS, V118, P196, DOI 10.1111/j.1600-0463.2009.02579.x
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40
   Delgado-Olguín P, 2012, NAT GENET, V44, P343, DOI 10.1038/ng.1068
   Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333
   Gieni RS, 2009, BIOCHEM CELL BIOL, V87, P711, DOI 10.1139/O09-057
   Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695
   Herbst RS, 2007, NEW ENGL J MED, V356, P76, DOI 10.1056/NEJMe068218
   Hinz S, 2009, J UROLOGY, V182, P2920, DOI 10.1016/j.juro.2009.08.014
   Huqun, 2012, CANCER-AM CANCER SOC, V118, P1599, DOI 10.1002/cncr.26441
   Juan AH, 2009, MOL CELL, V36, P61, DOI 10.1016/j.molcel.2009.08.008
   Karanikolas BDW, 2009, MOL CANCER RES, V7, P1456, DOI 10.1158/1541-7786.MCR-09-0121
   Kia SK, 2008, MOL CELL BIOL, V28, P3457, DOI 10.1128/MCB.02019-07
   Kikuchi J, 2010, CANCER-AM CANCER SOC, V116, P3015, DOI 10.1002/cncr.25128
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Mao L, 2001, LUNG CANCER, V34, pS27, DOI 10.1016/S0169-5002(01)00341-5
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Mok Tony, 2009, Discov Med, V8, P227
   Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c
   Siegel R, 2012, CA-CANCER J CLIN, V62, P220, DOI 10.3322/caac.21149
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Toll AD, 2010, HUM PATHOL, V41, P1205, DOI 10.1016/j.humpath.2010.03.004
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z
   Wang J, 2007, CANCER RES, V67, P10647, DOI 10.1158/0008-5472.CAN-07-1337
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Wen J, 2011, MODERN PATHOL, V24, P932, DOI 10.1038/modpathol.2011.46
   Zhang J, 2006, CANCER RES, V66, P18, DOI 10.1158/0008-5472.CAN-04-3905
NR 47
TC 61
Z9 69
U1 0
U2 51
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2012
VL 7
IS 12
AR e52984
DI 10.1371/journal.pone.0052984
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 075GO
UT WOS:000313872600044
PM 23300840
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, J
   Gao, L
   Tan, K
AF Kim, Jongkwang
   Gao, Long
   Tan, Kai
TI Multi-Analyte Network Markers for Tumor Prognosis
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; BREAST-CANCER; DNA METHYLATION; GLIOBLASTOMA;
   CLASSIFICATION; GLIOMAS; HYPERMETHYLATION; EPIGENETICS; INTERACTOME;
   MODULARITY
AB Deregulation of gene expression, a hallmark of cancer, is caused by both genetic and epigenetic mechanisms. The rapid accumulation of epigenome maps of various cancers suggests a new avenue of research, namely integrating epigenomic data with other types of omic data for cancer diagnosis, prognosis, and biomarker discovery. We introduce the MAPIT algorithm (Multi Analyte Pathway Inference Tool), to enable principled integration of epigenomic, transcriptomic, and protein interactome data. As a proof-of-principle, we apply MAPIT to glioblastoma multiforme (GBM), the most common and aggressive form of brain tumor. Few predictive markers were reported for the prognosis of GBM patients. By integrating mRNA transcriptome, promoter DNA methylome and protein-protein physical interactome, we find ten expression-and three methylation-based network markers, involving 118 genes. When tested on additional GBM patient samples, the prognostic accuracy of the multi-analyte network markers (73.5%) is 9.7% and 8.6% higher than previous prognostic signatures built on gene expression or DNA methylation alone. Our results highlight the critical role of two novel pathways in the prognosis of GBM patients, small GTPase-mediated protein trafficking and ubiquitination-dependent protein degradation. A better understanding of these two pathways could lead to personalized therapies for subgroups of GBM patients. Our study demonstrates that integrating epigenomic, transcriptomic, and interactomic data can improve the accuracy network-based prognosis markers and lead to novel mechanistic understanding of cancer.
C1 [Kim, Jongkwang; Tan, Kai] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
   [Gao, Long; Tan, Kai] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Tan, K (通讯作者)，Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
EM kai-tan@uiowa.edu
RI Kim, Hyung/J-5451-2012
OI Tan, Kai/0000-0002-9104-5567; Gao, Long/0000-0002-2631-6914; Kim, Jong
   K./0000-0001-9290-0820
FU American Brain Tumor Association Discovery grant; National Institutes of
   Health [HG006130, HL110349]
FX This work was supported by an American Brain Tumor Association Discovery
   grant and the National Institutes of Health grants HG006130 and HL110349
   (to KT). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bandyopadhyay S, 2010, NAT METHODS, V7, P801, DOI 10.1038/NMETH.1506
   Buonerba C., 2010, Crit Rev Oncol Hematol
   Castaldi PJ, 2011, BRIEF BIOINFORM, V12, P189, DOI 10.1093/bib/bbq073
   Chia WJ, 2009, BBA-REV CANCER, V1795, P110, DOI 10.1016/j.bbcan.2008.10.001
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan SC, 2009, BIOCHEM BIOPH RES CO, V383, P421, DOI 10.1016/j.bbrc.2009.04.023
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011
   Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452
   Garcia BA, 2007, NAT METHODS, V4, P487, DOI 10.1038/nmeth1052
   Guillaud M, 2008, CANCER RES, V68, P3099, DOI 10.1158/0008-5472.CAN-07-2113
   Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797
   Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   IARC, 2007, WHO CLASSIFICATION T
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim J, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-521
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31
   Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120
   Liu HQ, 2005, BIOINFORMATICS, V21, P3377, DOI 10.1093/bioinformatics/bti544
   Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007
   Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Nutt CL, 2003, CANCER RES, V63, P1602
   Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295
   Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019
   Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2
   Razick S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-405
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Siegfried Z, 2010, WIRES SYST BIOL MED, V2, P362, DOI 10.1002/wsbm.64
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522
   Torkamani A, 2009, GENOME RES, V19, P1570, DOI 10.1101/gr.092833.109
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Unterkircher T, 2011, CLIN CANCER RES, V17, P4019, DOI 10.1158/1078-0432.CCR-11-0075
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Wen Z, 2012, J AM MED INFORM ASS
   Wu WKK, 2010, CANCER LETT, V293, P15, DOI 10.1016/j.canlet.2009.12.002
   Xu L, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-125
   Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225
NR 48
TC 14
Z9 15
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2012
VL 7
IS 12
AR e52973
DI 10.1371/journal.pone.0052973
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 071TV
UT WOS:000313618800164
PM 23300836
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Hettiarachchi, K
   Kim, H
   Faris, GW
AF Hettiarachchi, Kanaka
   Kim, Hanyoup
   Faris, Gregory W.
TI Optical manipulation and control of real-time PCR in cell encapsulating
   microdroplets by IR laser
SO MICROFLUIDICS AND NANOFLUIDICS
LA English
DT Article
DE Breast cancer; Epigenetics; Lab on a chip; Microdroplet; Optical
   microfluidics; Polymerase chain reaction
ID POLYMERASE-CHAIN-REACTION; SINGLE-COPY DNA; REACTION AMPLIFICATION;
   METHYLATION; SYSTEM; BREAST; CANCER; CPG
AB This study presents an optical microfluidic platform and method for performing real-time polymerase chain reactions of MDA-MB-231 breast cancer cell DNA within droplet-in-oil micro-reactors. Illumination of the droplets using a low-power (20-40 mW) infrared (IR) laser at 1,460 nm provides a simple approach for droplet manipulation and rapid thermal cycling. The nanoliter droplet volumes allow for extremely fast amplification times, from cell lysis to assay completion in 15 min or less. Droplets containing lysis buffer and subsequently master mix solutions are optically positioned in mineral oil to coalesce with droplets containing live cells on a Petri dish surface for reverse-transcription polymerase chain reactions (RT-PCR). The optical PCR setup is also shown to amplify DNA in droplets containing single or multiple cells and distinguish between methylated and unmethylated BRCA1 promoters in microdroplets containing sample at the single-cell level. Melting curves generated using IR heating indicates a melting temperature of 86 degrees C for the 255-bp amplicon. The results are consistent with standard PCR and methylation-specific protocols performed in a commercial system. The simplicity of the droplet-in-oil Petri dish platform provides an easy and efficient tool for DNA analysis from live cells, and can be integrated with other microfluidic technologies for complex and large-scale assays.
C1 [Hettiarachchi, Kanaka; Kim, Hanyoup; Faris, Gregory W.] SRI Int, Div Phys Sci, Menlo Pk, CA 94025 USA.
C3 SRI International
RP Faris, GW (通讯作者)，SRI Int, Div Phys Sci, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA.
EM khettiar@gmail.com; gregory.faris@sri.com
OI Hettiarachchi, Kanaka/0000-0001-8102-2997
FU DOD Breast Cancer Research Program [W81XWH-09-1-0298]
FX We thank Nahid Waleh for technical assistance, and acknowledge the
   thoughtful discussions with Keith Laderoute, Christopher Green, and
   Sanhita Dixit. This work was supported by the DOD Breast Cancer Research
   Program, Grant Number W81XWH-09-1-0298. The US Army Medical Research
   Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is
   the awarding and administering acquisition office. The content of this
   paper does not necessarily reflect the position or the policy of the
   government, and no official endorsement should be inferred.
CR Abate AR, 2009, LAB CHIP, V9, P2628, DOI 10.1039/b909386a
   Abrmofff MD., 2005, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1201/9781420005615.AX4
   Basu AS, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/11/115031
   Beer NR, 2007, ANAL CHEM, V79, P8471, DOI 10.1021/ac701809w
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499
   Dixit SS, 2012, LANGMUIR, V28, P7442, DOI 10.1021/la3005739
   Dixit SS, 2010, LANGMUIR, V26, P6193, DOI 10.1021/la1010067
   Dorfman KD, 2005, ANAL CHEM, V77, P3700, DOI 10.1021/ac050031i
   Edd JF, 2008, LAB CHIP, V8, P1262, DOI 10.1039/b805456h
   ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872
   Hatch AC, 2011, LAB CHIP, V11, P2509, DOI 10.1039/c0lc00553c
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hu WQ, 2011, MICROFLUID NANOFLUID, V11, P307, DOI 10.1007/s10404-011-0797-2
   Hühmer AFR, 2000, ANAL CHEM, V72, P5507, DOI 10.1021/ac000423j
   Hunt HC, 2008, MICROFLUID NANOFLUID, V4, P53, DOI 10.1007/s10404-007-0223-y
   Kim H, 2009, OPT EXPRESS, V17, P218, DOI 10.1364/OE.17.000218
   Kim H, 2009, LAB CHIP, V9, P1230, DOI 10.1039/b817288a
   Kiss MM, 2008, ANAL CHEM, V80, P8975, DOI 10.1021/ac801276c
   Kotz KT, 2005, J AM CHEM SOC, V127, P5736, DOI 10.1021/ja050249m
   Kotz KT, 2004, APPL PHYS LETT, V85, P2658, DOI 10.1063/1.1797538
   Kumaresan P, 2008, ANAL CHEM, V80, P3522, DOI 10.1021/ac800327d
   Lee D, 2010, BIOSENS BIOELECTRON, V25, P1820, DOI 10.1016/j.bios.2009.11.021
   Liu RH, 2004, ANAL CHEM, V76, P1824, DOI 10.1021/ac0353029
   Marcus JS, 2006, ANAL CHEM, V78, P3084, DOI 10.1021/ac0519460
   Mazutis L, 2009, ANAL CHEM, V81, P4813, DOI 10.1021/ac900403z
   Morimoto Y, 2009, LAB CHIP, V9, P2217, DOI 10.1039/b900035f
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   Nakano M, 2003, J BIOTECHNOL, V102, P117, DOI 10.1016/S0168-1656(03)00023-3
   Nishimura T, 2012, MICROFLUID NANOFLUID, V13, P1, DOI 10.1007/s10404-012-0934-6
   Northrup MA, 1998, ANAL CHEM, V70, P918, DOI 10.1021/ac970486a
   Oda RP, 1998, ANAL CHEM, V70, P4361, DOI 10.1021/ac980452i
   Ohashi T, 2007, BIOMED MICRODEVICES, V9, P695, DOI 10.1007/s10544-007-9078-y
   Roper MG, 2005, ANAL CHEM, V77, P3887, DOI 10.1021/ac050756m
   Schaerli Y, 2009, ANAL CHEM, V81, P302, DOI 10.1021/ac802038c
   Shi WW, 2008, LAB CHIP, V8, P1432, DOI 10.1039/b808753a
   Sundberg SO, 2010, ANAL CHEM, V82, P1546, DOI 10.1021/ac902398c
   Tan YC, 2006, J AM CHEM SOC, V128, P5656, DOI 10.1021/ja056641h
   Teh SY, 2008, LAB CHIP, V8, P198, DOI 10.1039/b715524g
   Terazono H, 2008, JPN J APPL PHYS, V47, P5212, DOI 10.1143/JJAP.47.5212
   Tewhey R, 2009, NAT BIOTECHNOL, V27, P1025, DOI 10.1038/nbt.1583
   Thakur S, 2003, MOL CELL BIOL, V23, P3774, DOI 10.1128/MCB.23.11.3774-3787.2003
   Wang F, 2009, BIOMED MICRODEVICES, V11, P1071, DOI 10.1007/s10544-009-9324-6
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   WEIS JH, 1992, TRENDS GENET, V8, P263, DOI 10.1016/0168-9525(92)90242-V
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Yu YJ, 2012, ANAL CHEM, V84, P2825, DOI 10.1021/ac203307h
   Zamorano PL, 1996, NEUROENDOCRINOLOGY, V63, P397, DOI 10.1159/000127065
   Zhang Y, 2009, LAB CHIP, V9, P1059, DOI 10.1039/b821780g
NR 49
TC 26
Z9 27
U1 2
U2 80
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1613-4982
EI 1613-4990
J9 MICROFLUID NANOFLUID
JI Microfluid. Nanofluid.
PD DEC
PY 2012
VL 13
IS 6
BP 967
EP 975
DI 10.1007/s10404-012-1016-5
PG 9
WC Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics,
   Fluids & Plasmas
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Instruments & Instrumentation;
   Physics
GA 074FJ
UT WOS:000313798000010
DA 2025-01-12
ER

PT J
AU Cheng, SP
   Liu, CL
   Hsu, YC
   Chang, YC
   Huang, SY
   Lee, JJ
AF Cheng, Shih-Ping
   Liu, Chien-Liang
   Hsu, Yi-Chiung
   Chang, Yuan-Ching
   Huang, Shih-Yuan
   Lee, Jie-Jen
TI Regulation of leptin receptor expression in human papillary thyroid
   cancer cells
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Leptin receptor; Insulin; Epigenetic regulation
ID SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITORS;
   BREAST-CANCER; SIGNALING PATHWAYS; UP-REGULATION; CYCLIN D1; HYPOXIA;
   OBESITY; CARCINOMA; PROMOTER
AB Epidemiological studies suggest an important link between obesity and thyroid cancer. The adipose tissue-derived polypeptide leptin acting via leptin receptor may modulate cell migration of thyroid cancer cells. Previously we have demonstrated that leptin receptor is overexpressed in papillary thyroid cancer and is associated with tumor aggressiveness. The present study was undertaken to explore the possible regulatory factors which would influence leptin receptor expression in papillary thyroid cancer cells. We found that DNA methyltransferase inhibitor (5-Aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) reduced leptin receptor expression. Conversely, insulin upregulated leptin receptor expression in a time-and dose-dependent manner. Hypoxia-mimicking agent (cobalt chloride) had no effect on leptin receptor expression. Taken together, our study provides evidence that epigenetic events and insulin stimulation take part in regulation of leptin receptor expression in papillary thyroid cancer cells. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Cheng, Shih-Ping; Liu, Chien-Liang; Chang, Yuan-Ching; Huang, Shih-Yuan; Lee, Jie-Jen] Mackay Mem Hosp, Dept Surg, Taipei 10449, Taiwan.
   [Cheng, Shih-Ping; Lee, Jie-Jen] Mackay Med Coll, New Taipei City 25245, Taiwan.
   [Liu, Chien-Liang] Mackay Med Nursing & Management Coll, Taipei 11260, Taiwan.
   [Cheng, Shih-Ping; Lee, Jie-Jen] Taipei Med Univ, Inst Pharmacol, Taipei 11031, Taiwan.
   [Hsu, Yi-Chiung] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan.
C3 Mackay Memorial Hospital; Mackay Medical College; Mackay Junior College
   of Medicine, Nursing & Management; Taipei Medical University; Academia
   Sinica - Taiwan
RP Lee, JJ (通讯作者)，Mackay Mem Hosp, Dept Surg, 92 Zhongshan N Rd,Sec 2, Taipei 10449, Taiwan.
EM surg.mmh@gmail.com
RI Cheng, Shih-Ping/Q-3014-2018; Liu, Chien-Liang/D-9497-2013
OI Cheng, Shih-Ping/0000-0002-6301-5096
FU Mackay Memorial Hospital [MMH-9946, MMH-E-100-08-01]
FX This work was supported by research grants from Mackay Memorial Hospital
   (MMH-9946 and MMH-E-100-08-01).
CR Alvarez-Nuñez F, 2006, THYROID, V16, P17, DOI 10.1089/thy.2006.16.17
   Aschebrook-Kilfoy B, 2011, THYROID, V21, P957, DOI 10.1089/thy.2010.0396
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Carroll PA, 2011, MOL CARCINOGEN, V50, P643, DOI 10.1002/mc.20764
   Chen CC, 2007, ENDOCR-RELAT CANCER, V14, P513, DOI 10.1677/ERC-06-0027
   Chen CC, 2006, BREAST CANCER RES TR, V98, P121, DOI 10.1007/s10549-005-9139-y
   Cheng SP, 2011, ONCOL REP, V26, P1265, DOI 10.3892/or.2011.1388
   Cheng SP, 2011, MED HYPOTHESES, V76, P94, DOI 10.1016/j.mehy.2010.08.039
   Cheng SP, 2010, SURGERY, V147, P847, DOI 10.1016/j.surg.2009.11.004
   Cheng SP, 2010, ONCOL REP, V23, P1721, DOI 10.3892/or_00000817
   Codd R, 2009, INT J BIOCHEM CELL B, V41, P736, DOI 10.1016/j.biocel.2008.05.026
   Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I
   Frühbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578
   Garofalo C, 2006, CLIN CANCER RES, V12, P1447, DOI 10.1158/1078-0432.CCR-05-1913
   Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200
   Hikita M, 2000, BIOCHEM BIOPH RES CO, V271, P703, DOI 10.1006/bbrc.2000.2692
   Hsu HT, 2006, J CLIN ENDOCR METAB, V91, P2761, DOI 10.1210/jc.2005-2383
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kitahara CM, 2011, CANCER EPIDEM BIOMAR, V20, P464, DOI 10.1158/1055-9965.EPI-10-1220
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Koda M, 2007, ANN ONCOL, V18, P116, DOI 10.1093/annonc/mdm238
   Koda M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-320
   Liu CL, 2007, ONCOLOGY-BASEL, V72, P75, DOI 10.1159/000111097
   Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549
   Mathew OP, 2010, BIOMED PHARMACOTHER, V64, P733, DOI 10.1016/j.biopha.2010.09.017
   Momparler RL, 2005, SEMIN HEMATOL, V42, pS9, DOI 10.1053/j.seminhematol.2005.05.002
   Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142
   Otvos L, 2011, EUR J CANCER, V47, P1578, DOI 10.1016/j.ejca.2011.01.018
   Paik SS, 2009, ANN SURG ONCOL, V16, P297, DOI 10.1245/s10434-008-0221-7
   Puppin C, 2005, ENDOCRINOLOGY, V146, P3967, DOI 10.1210/en.2005-0128
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Russo D, 2011, J MOL ENDOCRINOL, V46, pR73, DOI 10.1530/JME-10-0150
   Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102
   Sheffield L, 2008, ENDOCR RES, V33, P111, DOI 10.1080/07435800802539976
   Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5
   van Kruijsdijk RCM, 2009, CANCER EPIDEM BIOMAR, V18, P2569, DOI 10.1158/1055-9965.EPI-09-0372
   Vivaldi A, 2009, MOL CELL ENDOCRINOL, V307, P142, DOI 10.1016/j.mce.2009.03.020
   Woyach JA, 2009, J CLIN ENDOCR METAB, V94, P164, DOI 10.1210/jc.2008-1631
   Xing MZ, 2007, ENDOCRINOLOGY, V148, P948, DOI 10.1210/en.2006-0927
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
NR 41
TC 17
Z9 18
U1 0
U2 10
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2012
VL 66
IS 6
BP 469
EP 473
DI 10.1016/j.biopha.2012.03.008
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 070MT
UT WOS:000313512400014
PM 22560341
DA 2025-01-12
ER

PT J
AU Alvi, MA
   Liu, XX
   O'Donovan, M
   Newton, R
   Wernisch, L
   Shannon, NB
   Shariff, K
   di Pietro, M
   Bergman, JJGHM
   Ragunath, K
   Fitzgerald, RC
AF Alvi, Muhammad A.
   Liu, Xinxue
   O'Donovan, Maria
   Newton, Richard
   Wernisch, Lorenz
   Shannon, Nicholas B.
   Shariff, Kareem
   di Pietro, Massimiliano
   Bergman, Jacques J. G. H. M.
   Ragunath, Krish
   Fitzgerald, Rebecca C.
TI DNA Methylation as an Adjunct to Histopathology to Detect Prevalent,
   Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's Esophagus
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HIGH-GRADE DYSPLASIA; PROMOTER HYPERMETHYLATION; BREAST-CANCER;
   RISK-FACTORS; PROGRESSION; ADENOCARCINOMA; MANAGEMENT; PATHOLOGISTS;
   EPIGENETICS; REGUCALCIN
AB Purpose: Endoscopic surveillance of Barrett's esophagus is problematic because dysplasia/early-stage neoplasia is frequently invisible and likely to be missed because of sampling bias. Molecular abnormalities may be more diffuse than dysplasia. The aim was therefore to test whether DNA methylation, especially on imprinted and X-chromosome genes, is able to detect dysplasia/early-stage neoplasia.
   Experimental design: 27K methylation arrays were used to find genes best able to differentiate between 22 Barrett's esophagus and 24 esophageal adenocarcinoma (EAC) samples. These were validated using pyrosequencing on a retrospective cohort (60 Barrett's esophagus, 36 dysplastic, and 90 EAC) and then in a prospective multicenter study (98 Barrett's esophagus patients, including 28 dysplastic and 9 early EAC) designed to utilize biomarkers to stratify patients according to their prevalent dysplasia/EAC status.
   Results: Genes (23%) on the array, including 7% of X-linked and 69% of imprinted genes, have shown statistically significant changes in methylation in EAC versus Barrett's esophagus (Wilcoxon P < 0.05). 6/7 selected candidate genes were successfully internally (Pearson's P < 0.01) and externally validated(ANOVAP < 0.001). Four genes (SLC22A18, PIGR, GJA12, and RIN2) showed the greatest area under curve (0.988) to distinguish between Barrett's esophagus and dysplasia/EAC in the retrospective cohort. This methylation panel was able to stratify patients from the prospective cohort into three risk groups based on the number of genes methylated (low risk: < 2 genes, intermediate: 2, and high: > 2).
   Conclusion: Widespread DNA methylation changes were observed in Barrett's carcinogenesis including approximate to 70% of known imprinted genes. A four-gene methylation panel stratified patients with Barrett's esophagus into three risk groups with potential clinical utility. Clin Cancer Res; 19(4); 878-88. (C) 2012 AACR.
C1 [Alvi, Muhammad A.; Liu, Xinxue; Shannon, Nicholas B.; Shariff, Kareem; di Pietro, Massimiliano; Fitzgerald, Rebecca C.] Hutchison MRC Res Ctr, MRC Canc Cell Unit, Cambridge CB2 0XZ, England.
   [O'Donovan, Maria] Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England.
   [Newton, Richard; Wernisch, Lorenz] MRC, Biostat Unit, Cambridge CB2 2BW, England.
   [Ragunath, Krish] Univ Nottingham Hosp, Nottingham NG7 2UH, England.
   [Bergman, Jacques J. G. H. M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
C3 Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's
   Hospital; University of Cambridge; MRC Biostatistics Unit; University of
   Nottingham; University of Amsterdam; Academic Medical Center Amsterdam
RP Fitzgerald, RC (通讯作者)，Hutchison MRC Res Ctr, MRC Canc Cell Unit, Hills Rd, Cambridge CB2 0XZ, England.
EM rcf29@hutchison-mrc.cam.ac.uk
RI Bergman, Jacques/AAS-2500-2021; Ragunath, Krish/ACQ-0721-2022; Shariff,
   Mohammed Kareem/JYO-8651-2024
OI Fitzgerald, Rebecca/0000-0002-3434-3568; Shannon, Nicholas
   Brian/0000-0001-8742-8285; Ragunath, Krish/0000-0001-6571-5435; Shariff,
   Mohammed Kareem/0000-0001-9561-5830; Liu, Xinxue/0000-0003-1107-0365
FU Trinity College Cambridge; NHS National Institute for Health Research;
   Experimental Cancer Medicine Centre Network; National Institute for
   Health Research Cambridge Biomedical Research Centre; Cambridge
   Commonwealth Trust; MRC programme grant; MRC [MC_U105365007,
   MC_U105260799, MC_UU_12022/2] Funding Source: UKRI
FX M.A. Alvi was funded by Trinity College Cambridge and Cambridge
   Commonwealth Trust for his PhD. The laboratory work was funded by an MRC
   programme grant to R.C. Fitzgerald with additional clinical research
   infrastructure funding from the NHS National Institute for Health
   Research, Experimental Cancer Medicine Centre Network, and the National
   Institute for Health Research Cambridge Biomedical Research Centre.
CR Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356
   Belshaw NJ, 2008, BRIT J CANCER, V99, P136, DOI 10.1038/sj.bjc.6604432
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Chien J, 2005, ONCOGENE, V24, P5089, DOI 10.1038/sj.onc.1208700
   Chu SH, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-156
   Clément G, 2006, ONCOGENE, V25, P3084, DOI 10.1038/sj.onc.1209338
   Crane SJ, 2008, MAYO CLIN PROC, V83, P1087, DOI 10.4065/83.10.1087
   Curvers WL, 2010, AM J GASTROENTEROL, V105, P1523, DOI 10.1038/ajg.2010.171
   DeMeester SR, 2010, J GASTROINTEST SURG, V14, P94, DOI 10.1007/s11605-009-1025-1
   Desai TK, 2012, GUT, V61, P970, DOI 10.1136/gutjnl-2011-300730
   Downs-Kelly E, 2008, AM J GASTROENTEROL, V103, P2333, DOI 10.1111/j.1572-0241.2008.02020.x
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Finegold DN, 2012, CLIN CANCER RES, V18, P2382, DOI 10.1158/1078-0432.CCR-11-2303
   Gallagher E, 2006, GENOMICS, V88, P12, DOI 10.1016/j.ygeno.2006.02.004
   Goldblum JR, 2010, ARCH PATHOL LAB MED, V134, P1479, DOI 10.1043/2010-0249-RA.1
   Gologan A, 2008, ARCH PATHOL LAB MED, V132, P1295, DOI 10.1043/1543-2165(2008)132[1295:PIRTRA]2.0.CO;2
   Huang Y, 2009, J CELL MOL MED, V13, P398, DOI 10.1111/j.1582-4934.2008.00336.x
   Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042
   Jin Z, 2008, INT J CANCER, V123, P2331, DOI 10.1002/ijc.23804
   Jin Z, 2008, CANCER EPIDEM BIOMAR, V17, P111, DOI 10.1158/1055-9965.EPI-07-0407
   Jin Z, 2007, CLIN CANCER RES, V13, P6293, DOI 10.1158/1078-0432.CCR-07-0818
   Jin Z, 2009, CANCER RES, V69, P4112, DOI 10.1158/0008-5472.CAN-09-0028
   Kahrilas PJ, 2011, NEW ENGL J MED, V365, P1437, DOI 10.1056/NEJMe1108435
   Kaz AM, 2011, EPIGENETICS-US, V6, P1403, DOI 10.4161/epi.6.12.18199
   Kerkhof M, 2007, HISTOPATHOLOGY, V50, P920, DOI 10.1111/j.1365-2559.2007.02706.x
   Kuester D, 2009, CANCER LETT, V275, P117, DOI 10.1016/j.canlet.2008.10.009
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Leedham SJ, 2008, GUT, V57, P1041, DOI 10.1136/gut.2007.143339
   Maia C, 2009, J CELL BIOCHEM, V107, P667, DOI 10.1002/jcb.22158
   Merlo LMF, 2010, CANCER PREV RES, V3, P1388, DOI 10.1158/1940-6207.CAPR-10-0108
   Pohl H, 2010, CANCER EPIDEM BIOMAR, V19, P1468, DOI 10.1158/1055-9965.EPI-10-0012
   Rattan R, 2010, ONCOGENE, V29, P1362, DOI 10.1038/onc.2009.431
   Reid BJ, 2011, CLIN CANCER RES, V17, P3512, DOI 10.1158/1078-0432.CCR-09-2358
   Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598
   Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497
   Shaheen NJ, 2009, NEW ENGL J MED, V360, P2277, DOI 10.1056/NEJMoa0808145
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Spechler SJ, 2011, GASTROENTEROLOGY, V140, P1084, DOI 10.1053/j.gastro.2011.01.030
   Spechler SJ, 2011, GASTROENTEROLOGY, V140, pE18, DOI 10.1053/j.gastro.2011.01.031
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Wang JS, 2009, AM J GASTROENTEROL, V104, P2153, DOI 10.1038/ajg.2009.300
   Wani S, 2011, GASTROENTEROLOGY, V141, P1179, DOI 10.1053/j.gastro.2011.06.055
   Yamaguchi M, 2005, J CELL BIOCHEM, V95, P1169, DOI 10.1002/jcb.20490
   Yousef F, 2008, AM J EPIDEMIOL, V168, P237, DOI 10.1093/aje/kwn121
   Zhai RH, 2012, NEOPLASIA, V14, P29, DOI 10.1593/neo.111626
NR 46
TC 54
Z9 58
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2013
VL 19
IS 4
BP 878
EP 888
DI 10.1158/1078-0432.CCR-12-2880
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 091CJ
UT WOS:000315026200013
PM 23243219
OA Bronze, Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Wang, L
   Zhang, Y
   Li, RQ
   Chen, Y
   Pan, XY
   Li, GY
   Dai, F
   Yang, JL
AF Wang, Li
   Zhang, Yong
   Li, RongQing
   Chen, Yue
   Pan, XinYan
   Li, GuiYun
   Dai, Fang
   Yang, JuLun
TI 5-aza-2′-Deoxycytidine Enhances the Radiosensitivity of Breast Cancer
   Cells
SO CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
LA English
DT Article
DE breast cancer; DAC; radiosensitivity; radiotherapy
ID HISTONE DEACETYLASE INHIBITION; DNA METHYLATION; EXPRESSION;
   METHYLTRANSFERASE; HYPERMETHYLATION; RADIORESISTANCE; SENSITIVITY;
   EPIGENETICS; 5-AZA-CDR; PROMOTER
AB Purpose: To investigate the effect of the DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine (DAC), on radiosensitivity in breast cancer cells. Materials and methods: Two breast cancer cell lines, MDA-MB-231 and MDA-MB-435, were evaluated. The methylation status and the mRNA expression of three genes (ER, PR, and HIC-1) that were frequently hypermethylated in these cell lines were determined as a function of DAC exposure. 3-(4,5)-dimethylthiahiazo-(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) absorbance and a colony-forming assay were used to estimate cell viability and radiosensitivity. Using cell-cycle analysis, gamma-histone H2A (gamma-H2AX) formation assays and methylation-specific polymerase chain reaction (MSP) analysis of three genes correlated with radiosensitivity (BRCA1, 14-3-3 sigma, and E-cadherin), the mechanism of DAC enhancement of radiosensitivity was explored. Results: DAC induced the demethylation and reactivation of silent genes in both cell lines. The combination of DAC and irradiation induced growth suppression in vitro. DAC, 5 mu M, enhanced sensitivity to ionizing radiation. DAC followed by irradiation correlated with G2/M arrest and the retardation of repair of radiation-induced double strand breaks. DAC reversed the methylation status of genes connected with radiosensitization. The different radiosensitization effects observed with different breast cancers cells may correlate with the primary methylation status of radiosensitizing genes. Conclusions: Treatment strategies that include DAC present promising options for sensitizing breast cancer cells to irradiation.
C1 [Wang, Li; Chen, Yue; Pan, XinYan; Li, GuiYun; Dai, Fang; Yang, JuLun] Kunming Gen Hosp, Dept Pathol, Kunming 650032, Yunnan, Peoples R China.
   [Zhang, Yong; Li, RongQing] Kunming Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Kunming, Yunnan, Peoples R China.
C3 Kunming General Hospital; Kunming Medical University
RP Yang, JL (通讯作者)，Kunming Gen Hosp, Dept Pathol, 212 Daguan Rd, Kunming 650032, Yunnan, Peoples R China.
EM yangjulun@yahoo.com
FU Applied and Basic Research Funds of Yunnan Province, China [2008ZC075M,
   2009ZC148M]
FX This work was supported by the Applied and Basic Research Funds of
   Yunnan Province, China (No. 2008ZC075M and 2009ZC148M).
CR Blakely EA, 1998, ACTA ONCOL, V37, P127, DOI 10.1080/028418698429676
   Cho HJ, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-49
   De Schutter H, 2009, INT J RADIAT ONCOL, V73, P904, DOI 10.1016/j.ijrobp.2008.10.032
   Dote H, 2005, CLIN CANCER RES, V11, P4571, DOI 10.1158/1078-0432.CCR-05-0050
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Garcia JS, 2010, ONCOTARGETS THER, V3, P1
   GRAFF JR, 1995, CANCER RES, V55, P5195
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Martin NT, 2011, RADIOTHER ONCOL, V101, P35, DOI 10.1016/j.radonc.2011.05.065
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695
   Nam JS, 2004, CLIN EXP METASTAS, V21, P49, DOI 10.1023/B:CLIN.0000017180.19881.c1
   Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163
   Nome RV, 2005, MOL CANCER THER, V4, P1231, DOI 10.1158/1535-7163.MCT-04-0304
   Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07
   Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005
   Qi WQ, 2003, RADIAT RES, V160, P217, DOI 10.1667/RR3038
   Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x
   Roy K, 2006, BIOCHEM BIOPH RES CO, V344, P821, DOI 10.1016/j.bbrc.2006.03.222
   Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Schübeler D, 2009, NATURE, V462, P296, DOI 10.1038/462296a
   Theys J, 2011, RADIOTHER ONCOL, V99, P392, DOI 10.1016/j.radonc.2011.05.044
   Tycko B, 2011, ONCOLOGY-NY, V25, P228
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Yang XW, 2001, CANCER RES, V61, P7025
   Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251
   Zhang B, 2007, J HUAZHONG U SCI-MED, V27, P543, DOI 10.1007/s11596-007-0517-z
   Zhang Y, 2010, INT J RADIAT BIOL, V86, P964, DOI 10.3109/09553002.2010.496032
NR 34
TC 28
Z9 31
U1 0
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1084-9785
EI 1557-8852
J9 CANCER BIOTHER RADIO
JI Cancer Biother. Radiopharm.
PD FEB
PY 2013
VL 28
IS 1
BP 34
EP 44
DI 10.1089/cbr.2012.1170
PG 11
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
GA 070ZS
UT WOS:000313555000004
PM 22917213
DA 2025-01-12
ER

PT J
AU Berdel, B
   Nieminen, K
   Soini, Y
   Tengström, M
   Malinen, M
   Kosma, VM
   Palvimo, JJ
   Mannermaa, A
AF Berdel, Bozena
   Nieminen, Kaisa
   Soini, Ylermi
   Tengstrom, Maria
   Malinen, Marjo
   Kosma, Veli-Matti
   Palvimo, Jorma J.
   Mannermaa, Arto
TI Histone demethylase GASC1 - a potential prognostic and predictive marker
   in invasive breast cancer
SO BMC CANCER
LA English
DT Article
DE Epigenetics; GASC1; Breast cancer; Survival; Tissue microarrays
ID ANDROGEN RECEPTOR; CLINICAL-SIGNIFICANCE; CELL-PROLIFERATION;
   EXPRESSION; GENE; IDENTIFICATION; JMJD2C; ASSOCIATION; METHYLATION;
   PROSTATE
AB Background: The histone demethylase GASC1 (JMJD2C) is an epigenetic factor suspected of involvement in development of different cancers, including breast cancer. It is thought to be overexpressed in the more aggressive breast cancer types based on mRNA expression studies on cell lines and meta analysis of human breast cancer sets. This study aimed to evaluate the prognostic and predictive value of GASC1 for women with invasive breast cancer.
   Methods: All the 355 cases were selected from a cohort enrolled in the Kuopio Breast Cancer Project between April 1990 and December 1995. The expression of GASC1 was studied by immunohistochemistry (IHC) on tissue microarrays. Additionally relative GASC1 mRNA expression was measured from available 57 cases.
   Results: In our material, 56% of the cases were GASC1 negative and 44% positive in IHC staining. Women with GASC1 negative tumors had two years shorter breast cancer specific survival and time to relapse than the women with GASC1 positive tumors (p=0.017 and p=0.034 respectively). The majority of GASC1 negative tumors were ductal cases (72%) of higher histological grade (84% of grade II and III altogether). When we evaluated estrogen receptor negative and progesterone receptor negative cases separately, there was 2 times more GASC1 negative than GASC1 positive tumors in each group (chi2, p= 0.033 and 0.001 respectively). In the HER2 positive cases, there was 3 times more GASC1 negative cases than GASC1 positives (chi2, p= 0.029). Patients treated with radiotherapy (n=206) and hormonal treatment (n=62) had better breast cancer specific survival, when they were GASC1 positive (Cox regression: HR=0.49, p=0.007 and HR=0.33, p=0.015, respectively). The expression of GASC1 mRNA was in agreement with the protein analysis.
   Conclusions: This study indicates that the GASC1 is both a prognostic and a predictive factor for women with invasive breast cancer. GASC1 negativity is associated with tumors of more aggressive histopathological types (ductal type, grade II and III, ER negative, PR negative). Patients with GASC1 positive tumors have better breast cancer specific survival and respond better to radiotherapy and hormonal treatment.
C1 [Berdel, Bozena; Nieminen, Kaisa; Soini, Ylermi; Kosma, Veli-Matti; Mannermaa, Arto] Univ Eastern Finland, Canc Ctr Eastern Finland, Inst Clin Med, Dept Pathol & Forens Med, FI-70211 Kuopio, Finland.
   [Soini, Ylermi; Kosma, Veli-Matti; Mannermaa, Arto] Kuopio Univ Hosp, Imaging Ctr, Dept Clin Pathol, FI-70211 Kuopio, Finland.
   [Soini, Ylermi; Malinen, Marjo; Kosma, Veli-Matti; Palvimo, Jorma J.; Mannermaa, Arto] Univ Eastern Finland, Bioctr Kuopio, FI-70211 Kuopio, Finland.
   [Tengstrom, Maria] Kuopio Univ Hosp, Ctr Canc, FI-70211 Kuopio, Finland.
   [Malinen, Marjo; Palvimo, Jorma J.] Univ Eastern Finland, Inst Biomed Med Biochem, FI-70211 Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland; University of Eastern Finland
RP Mannermaa, A (通讯作者)，Univ Eastern Finland, Canc Ctr Eastern Finland, Inst Clin Med, Dept Pathol & Forens Med, POB 1627, FI-70211 Kuopio, Finland.
EM arto.mannermaa@uef.fi
RI Nieminen, Kaisa/AAB-5355-2021
OI Palvimo, Jorma/0000-0003-2373-0578
FU Special Government Funding (EVO) of Kuopio University Hospital; Kuopio
   Northern Savo Cancer Society; Finnish Cancer Organization; University of
   Eastern Finland; Academy of Finland
FX We thank Helena Kemilainen for her skilful laboratory assistance. This
   study was supported by grants from Special Government Funding (EVO) of
   Kuopio University Hospital, Kuopio Northern Savo Cancer Society, Finnish
   Cancer Organization, the strategic funding of the University of Eastern
   Finland and Academy of Finland.
CR Amit D, 2012, INT J CLIN EXP MED, V5, P296
   Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Chen YX, 2006, BIOCHEM BIOPH RES CO, V340, P758, DOI 10.1016/j.bbrc.2005.12.068
   Chiam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025634
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Collins LC, 2011, MODERN PATHOL, V24, P924, DOI 10.1038/modpathol.2011.54
   DEKONING L, 2009, FMBO MOL MED, V1, P178, DOI DOI 10.1002/EMMM.200900022
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x
   Dumont AG, 2012, CARCINOGENESIS, V33, P1674, DOI 10.1093/carcin/bgs221
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Gebeshuber CA, 2013, ONCOGENE, V32, P3306, DOI 10.1038/onc.2012.372
   Gömöri É, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-8
   Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322
   Hartikainen JM, 2005, CANCER EPIDEM BIOMAR, V14, P75
   Hoffmann I, 2012, MOL ONCOL, V6, P683, DOI 10.1016/j.molonc.2012.07.004
   Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021
   Katoh Y, 2007, INT J MOL MED, V20, P269
   Kauppinen JM, 2010, CANCER EPIDEM BIOMAR, V19, P2133, DOI 10.1158/1055-9965.EPI-10-0418
   Khau T, 2011, FASEB J, V25, P483, DOI 10.1096/fj.09-154096
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855
   Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207
   McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107
   Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159
   Pellikainen MJ, 2003, J CLIN PATHOL, V56, P214, DOI 10.1136/jcp.56.3.214
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787
   Qiu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036497
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Soini Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-73
   Stefanska B, 2012, BRIT J PHARMACOL, V167, P279, DOI 10.1111/j.1476-5381.2012.02002.x
   Takahashi M, 2005, INT J ONCOL, V27, P1483
   Tang DB, 2012, MED ONCOL, V29, P526, DOI 10.1007/s12032-011-9948-2
   Tavassoeli FA, 2003, IARC WHO CLASS TUM, P432
   Van Neste L, 2012, PROSTATE, V72, P1248, DOI 10.1002/pros.22459
   Wang Y, 2011, ONCOGENE, V30, P4327, DOI 10.1038/onc.2011.144
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227
   Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x
   Yang ZQ, 2000, CANCER RES, V60, P4735
   Yom CK, 2011, J BREAST CANCER, V14, P262, DOI 10.4048/jbc.2011.14.4.262
   Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825
NR 51
TC 25
Z9 31
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD NOV 14
PY 2012
VL 12
AR 516
DI 10.1186/1471-2407-12-516
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 074GC
UT WOS:000313799900001
PM 23148692
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ulirsch, J
   Fan, C
   Knafl, G
   Wu, MJ
   Coleman, B
   Perou, CM
   Swift-Scanlan, T
AF Ulirsch, Jacob
   Fan, Cheng
   Knafl, George
   Wu, Ming Jing
   Coleman, Brett
   Perou, Charles M.
   Swift-Scanlan, Theresa
TI Vimentin DNA methylation predicts survival in breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE DNA methylation; Breast cancer; Vimentin; Epigenetic; Survival
ID EPITHELIAL-MESENCHYMAL TRANSITION; BASE-SPECIFIC CLEAVAGE; CELL-LINES;
   FECAL DNA; IN-VITRO; GENES; SUBTYPE; RISK; STRATIFICATION; TRANSCRIPTION
AB The Vimentin gene plays a pivotal role in epithelial-to-mesenchymal transition and is known to be overexpressed in the prognostically poor basal-like breast cancer subtype. Recent studies have reported Vimentin DNA methylation in association with poor clinical outcomes in other solid tumors, but not in breast cancer. We therefore quantified Vimentin DNA methylation using MALDI-TOF mass spectrometry in breast tumors and matched normal pairs in association with gene expression and survival in a hospital-based study of breast cancer patients. Gene expression data via qRT-PCR in cell lines and oligomicroarray data from breast tissues were correlated with percent methylation in the Vimentin promoter. A threshold of 20 percent average methylation compared with matched normal pairs was set for bivariate and multivariate tests of association between methylation and tumor subtype, tumor histopathology, and survival. Vimentin was differentially methylated in luminal breast cancer cell lines, and in luminal A, luminal B, and HER2-enriched breast tumor subtypes, but was rare in basal-like cell lines and tumors. Increased methylation was strongly correlated with decreased mRNA expression in cell lines, and had a moderate inverse correlation in breast tumors. Vimentin methylation predicted poor overall survival independent of race, subtype, stage, nodal status, or metastatic disease and holds promise as a new prognostic biomarker for breast cancer patients.
C1 [Ulirsch, Jacob; Wu, Ming Jing] Univ N Carolina, Chapel Hill Sch Nursing, Lab 013, Chapel Hill, NC 27599 USA.
   [Fan, Cheng; Perou, Charles M.; Swift-Scanlan, Theresa] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Knafl, George] Univ N Carolina, Chapel Hill Sch Nursing, Off 5014, Chapel Hill, NC 27599 USA.
   [Coleman, Brett] Univ N Carolina, Chapel Hill Sch Nursing, Off 301B, Chapel Hill, NC 27599 USA.
   [Perou, Charles M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
   [Swift-Scanlan, Theresa] Univ N Carolina, Chapel Hill Sch Nursing, Off 503, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Swift-Scanlan, T (通讯作者)，Univ N Carolina, Chapel Hill Sch Nursing, Off 503, Carrington Hall,CB 7460, Chapel Hill, NC 27599 USA.
EM tswift@unc.edu
RI FAN, CHENG/KVY-9602-2024; Perou, Charles/H-9934-2014
OI Ulirsch, Jacob/0000-0002-7947-0827; Perou, Charles/0000-0001-9827-2247
FU NIH/NCI Breast SPORE [CA058823]; National Center for Research Resources
   [KL2RR025746]; Susan G. Komen Foundation [KG090180]
FX The authors thank Dr. Tim Wiltshire and the Lineberger Cancer Center for
   permitting the use of the Mass Array Platform to carry out the
   methylation studies; Dr. Lisa Carey and Amy Drobish for clinical updates
   and medical records abstraction; and Dr. Scott Bultman for his
   thoughtful review of the paper. The authors gratefully acknowledge the
   support of the NIH/NCI Breast SPORE CA058823 to C. M. Perou, and the
   KL2RR025746 from the National Center for Research Resources and the
   Susan G. Komen Foundation KG090180 to T. Swift-Scanlan.
CR [Anonymous], 2011, PLOS CURR-TREE LIFE, DOI DOI 10.1371/CURRENTS.RRN1220
   Challa AA, 2011, MOL CELL BIOL, V31, P3773, DOI 10.1128/MCB.05263-11
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Costa VL, 2010, CLIN CANCER RES, V16, P5842, DOI 10.1158/1078-0432.CCR-10-1312
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Ehrich M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni038
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Itzkowitz SH, 2007, CLIN GASTROENTEROL H, V5, P111, DOI 10.1016/j.cgh.2006.10.006
   Ivaska Johanna, 2011, Small GTPases, V2, P51
   Jung S, 2011, MOL CELLS, V31, P405, DOI 10.1007/s10059-011-0229-x
   Katz E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017083
   Kisiel JB, 2012, CANCER-AM CANCER SOC, V118, P2623, DOI 10.1002/cncr.26558
   Kitamura YH, 2009, ANTICANCER RES, V29, P2227
   Kitamura Y, 2011, ANTICANCER RES, V31, P1289
   Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252
   Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639
   Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898
   Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1
   Shirahata A, 2010, ANTICANCER RES, V30, P5015
   Shirahata A, 2009, ANTICANCER RES, V29, P279
   Sousa B, 2010, HISTOL HISTOPATHOL, V25, P963, DOI 10.14670/HH-25.963
   Swift-Scanlan T, 2011, CANCER BIOL THER, V11, P853, DOI 10.4161/cbt.11.10.15177
   Vanaja DK, 2009, CANCER INVEST, V27, P549, DOI 10.1080/07357900802620794
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 43
TC 47
Z9 53
U1 2
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2013
VL 137
IS 2
BP 383
EP 396
DI 10.1007/s10549-012-2353-5
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 066DT
UT WOS:000313201100006
PM 23239149
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Vijayaraghavalu, S
   Dermawan, JK
   Cheriyath, V
   Labhasetwar, V
AF Vijayaraghavalu, Sivakumar
   Dermawan, Josephine Kamtai
   Cheriyath, Venugopalan
   Labhasetwar, Vinod
TI Highly Synergistic Effect of Sequential Treatment with Epigenetic and
   Anticancer Drugs To Overcome Drug Resistance in Breast Cancer Cells Is
   Mediated via Activation of <i>p21</i> Gene Expression Leading to G2/M
   Cycle Arrest
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE epigenetic drugs; drug resistance; breast cancer; combination therapy;
   cell-cycle analysis; gene expression
ID TOPOISOMERASE-II-ALPHA; TUMOR-SUPPRESSOR GENE; DOWN-REGULATION; DNA
   METHYLATION; DOXORUBICIN; GROWTH; OVARIAN; TARGET; NETWORKS;
   HYPERMETHYLATION
AB Epigenetic alterations such as aberrant DNA methylation and histone modifications contribute substantially to both the cause and maintenance of drug resistance. These epigenetic changes lead to silencing of tumor suppressor genes involved in key DNA damage-response pathways, making drug-resistant cancer cells nonresponsive to conventional anticancer drug therapies. Our hypothesis is that treating drug-resistant cells with epigenetic drugs could restore the sensitivity to anticancer drugs by reactivating previously silenced genes. To test our hypothesis, we used drug-resistant breast cancer cells (MCF-7/ADR) and two epigenetic drugs that act via different mechanisms-5-aza-2'-deoxycytidine (decitabine, DAC), a demethylating agent, and suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor-in combination with doxorubicin. We show that the sequential treatment of resistant cells, first with an epigenetic drug (DAC), and then with doxorubicin, induces a highly synergistic effect, thus reducing the IC50 of doxorubicin by several thousand fold. The sequential treatment caused over 90% resistant cells to undergo G2/M cell cycle arrest, determined to be due to upregulation of p21(WAFI/CIPI) expression, which is responsible for cell-cycle regulation. The induction of p21(WAFI/CIPI) correlated well with the depletion of DNA methyltransferase 1 (DNMT1), an enzyme that promotes methylation of DNA, suggesting that the p21(WAFI/CIPI) gene may have been methylated and hence is inactive in MCF-7/ADR cells. Microarray analysis shows expression of several tumor suppressor genes and downregulation of tumor promoter genes, particularly in sequentially treated resistant cells. Sequential treatment was found to be significantly more effective than simultaneous treatment, and DAC was more effective than SAHA in overcoming doxorubicin resistance. Synergistic effect with sequential treatment was also seen in drug-sensitive breast cancer cells, but the effect was significantly more pronounced in resistant cells. In conclusion, the sequential treatment of an epigenetic drug in combination with doxorubicin induces a highly synergistic effect that overcomes doxorubicin resistance in breast cancer cells.
C1 [Vijayaraghavalu, Sivakumar; Dermawan, Josephine Kamtai; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Cheriyath, Venugopalan; Labhasetwar, Vinod] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Labhasetwar, V (通讯作者)，Cleveland Clin, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@cci.org
RI Dermawan, Josephine/AAD-2077-2019; Labhasetwar, Vinod/J-9660-2016;
   Vijayaraghavalu, Sivakumar/IZE-6423-2023
OI Vijayaraghavalu, Sivakumar/0000-0002-6770-6716
FU National Cancer Institute of the National Institutes of Health [R01
   CA149359-01]
FX This study was funded by Grant R01 CA149359-01 (to V.L.) from the
   National Cancer Institute of the National Institutes of Health. We thank
   Na Jie, Biostatistician, and Banu Gopalan, Core manager, Bioinformatics
   Core, Lerner Research Institute, Cleveland Clinic, Ohio, for carrying
   out statistical and functional analysis of gene expression data.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Abeysinghe HR, 2004, CANCER GENET CYTOGEN, V149, P1, DOI 10.1016/S0165-4608(03)00234-6
   Alelu-Paz R., 2012, J SIGNAL TRANSDUCT, DOI 10.1155/2012/956958
   Ando T, 2000, LEUKEMIA, V14, P1915, DOI 10.1038/sj.leu.2401914
   Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896
   Basile L, 2012, CURR DRUG DELIV, V9, P255, DOI 10.2174/156720112800389089
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bjelogrlic SK, 2005, BASIC CLIN PHARMACOL, V97, P311, DOI 10.1111/j.1742-7843.2005.pto_166.x
   Blum C, 2008, INT J ONCOL, V33, P579, DOI 10.3892/ijo_00000043
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   Brown Robert, 2004, Expert Rev Anticancer Ther, V4, P501, DOI 10.1586/14737140.4.4.501
   Cheung AKL, 2011, P NATL ACAD SCI USA, V108, P8390, DOI 10.1073/pnas.1101747108
   COVEY JM, 1984, CANCER TREAT REP, V68, P1475
   Daskalakis M, 2010, RECENT RESULTS CANC, V184, P131, DOI 10.1007/978-3-642-01222-8_10
   Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620
   Drenzek JG, 2011, GYNECOL ONCOL, V122, P396, DOI 10.1016/j.ygyno.2011.04.027
   DUSRE L, 1989, CANCER RES, V49, P511
   Efferth T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000693
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735
   Garg M, 2010, EUR J CANCER, V46, P207, DOI 10.1016/j.ejca.2009.10.020
   Ghadjar P, 2009, INT J CANCER, V125, P741, DOI 10.1002/ijc.24468
   Gianni L, 2009, J CLIN ONCOL, V27, P4798, DOI 10.1200/JCO.2008.21.4791
   Gray J, 2012, CANCER BIOL THER, V13, P614, DOI 10.4161/cbt.19848
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222
   Kallio H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027152
   Kanda M, 2009, INT J ONCOL, V35, P477, DOI 10.3892/ijo_00000359
   Kang MR, 2002, MOL PHARMACOL, V61, P879, DOI 10.1124/mol.61.4.879
   Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012
   KIM R, 1991, ANTICANCER RES, V11, P429
   Kimura J, 2011, INT J CANCER, V128, P1524, DOI 10.1002/ijc.25475
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046264
   Li Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-121
   Liang Y, 2008, EXP CELL RES, V314, P1962, DOI 10.1016/j.yexcr.2008.01.032
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812
   Mahmoud MS, 1999, BLOOD, V94, P3551, DOI 10.1182/blood.V94.10.3551.422k08_3551_3558
   Martinez Ramon, 2012, J Signal Transduct, V2012, P519807, DOI 10.1155/2012/519807
   Mason CW, 2006, AM J OBSTET GYNECOL, V194, P1513, DOI 10.1016/j.ajog.2005.12.044
   Melixetian MB, 2000, LEUKEMIA RES, V24, P831, DOI 10.1016/S0145-2126(00)00054-0
   Menna P, 2012, EXPERT OPIN DRUG SAF, V11, pS21, DOI 10.1517/14740338.2011.589834
   Mir RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020768
   Mund C, 2010, BIOESSAYS, V32, P949, DOI 10.1002/bies.201000061
   Nikolsky Y, 2005, TOXICOL LETT, V158, P20, DOI 10.1016/j.toxlet.2005.02.004
   Octavia Y, 2012, J MOL CELL CARDIOL, V52, P1213, DOI 10.1016/j.yjmcc.2012.03.006
   Parise RA, 2006, J CHROMATOGR B, V840, P108, DOI 10.1016/j.jchromb.2006.04.044
   Park HJ, 2011, CANCER LETT, V312, P117, DOI 10.1016/j.canlet.2011.08.014
   Patil RR, 2008, CRIT REV THER DRUG, V25, P1
   Peetla C, 2010, MOL PHARMACEUT, V7, P2334, DOI 10.1021/mp100308n
   Petrelli F, 2012, BREAST CANCER RES TR, V135, P335, DOI 10.1007/s10549-012-2121-6
   Quan ZW, 2008, CHEMOTHERAPY, V54, P431, DOI 10.1159/000158662
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rohozinski J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005064
   Rosebeck S, 2008, APOPTOSIS, V13, P562, DOI 10.1007/s10495-008-0190-0
   Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537
   Sabatier R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027656
   Sato A, 2012, ONCOTARGETS THER, V5, P67, DOI 10.2147/OTT.S23874
   Segura-Pacheco B, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-32
   Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340
   Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338
   Song SH, 2011, DRUGS, V71, P2391, DOI 10.2165/11596690-000000000-00000
   Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813
   Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787
   TAN KB, 1989, JNCI-J NATL CANCER I, V81, P1732, DOI 10.1093/jnci/81.22.1732
   Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005
   TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249
   Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]
   Ueda K, 2003, ONCOGENE, V22, P5586, DOI 10.1038/sj.onc.1206845
   Ueda S, 2004, CANCER RES, V64, P5672, DOI 10.1158/0008-5472.CAN-04-0985
   Vaidyanathan G, 2004, ONCOGENE, V23, P5858, DOI 10.1038/sj.onc.1207774
   Vijayaraghavalu S, 2012, MOL PHARMACEUT, V9, P2730, DOI 10.1021/mp300281t
   Waha A, 2010, CANCER RES, V70, P1689, DOI 10.1158/0008-5472.CAN-09-3218
   Walker JV, 2002, CANCER INVEST, V20, P570, DOI 10.1081/CNV-120002156
   Wehbe-Janek H, 2007, ANTICANCER RES, V27, P3143
   Xu DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037811
   Xu XJ, 2009, INT J CANCER, V124, P1330, DOI 10.1002/ijc.24078
   Yan DW, 2012, BBA-MOL BASIS DIS, V1822, P918, DOI 10.1016/j.bbadis.2012.02.021
   Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105
   Young JI, 2003, J BIOL CHEM, V278, P19904, DOI 10.1074/jbc.M301685200
   Zhang J, 2006, CANCER RES, V66, P18, DOI 10.1158/0008-5472.CAN-04-3905
NR 82
TC 67
Z9 75
U1 1
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JAN
PY 2013
VL 10
IS 1
BP 337
EP 352
DI 10.1021/mp3004622
PG 16
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 065NV
UT WOS:000313156100034
PM 23215027
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Diaz, RJ
   Guduk, M
   Romagnuolo, R
   Smith, CA
   Northcott, P
   Shih, D
   Berisha, F
   Flanagan, A
   Munoz, DG
   Cusimano, MD
   Pamir, MN
   Rutka, JT
AF Diaz, Roberto Jose
   Guduk, Mustafa
   Romagnuolo, Rocco
   Smith, Christian A.
   Northcott, Paul
   Shih, David
   Berisha, Fitim
   Flanagan, Adrienne
   Munoz, David G.
   Cusimano, Michael D.
   Pamir, M. Necmettin
   Rutka, James T.
TI High-resolution Whole-Genome Analysis of Skull Base Chordomas Implicates
   FHIT Loss in Chordoma Pathogenesis
SO NEOPLASIA
LA English
DT Article
ID COMMON FRAGILE SITE; CELL LUNG-CANCER; DAMAGE CHECKPOINT RESPONSE;
   TUMOR-SUPPRESSOR GENE; BREAST-CANCER; EXPRESSION; FRA3B; DELETION;
   REPLICATION; CARCINOMAS
AB Chordoma is a rare tumor arising in the sacrum, clivus, or vertebrae. It is often not completely resectable and shows a high incidence of recurrence and progression with shortened patient survival and impaired quality of life. Chemo-therapeutic options are limited to investigational therapies at present. Therefore, adjuvant therapy for control of tumor recurrence and progression is of great interest, especially in skull base lesions where complete tumor resection is often not possible because of the proximity of cranial nerves. To understand the extent of genetic instability and associated chromosomal and gene losses or gains in skull base chordoma, we undertook whole-genome single-nucleotide polymorphism microarray analysis of flash frozen surgical chordoma specimens, 21 from the clivus and 1 from C1 to C2 vertebrae. We confirm the presence of a deletion at 9p involving CDKN2A, CDKN2B, and MTAP but at a much lower rate (22%) than previously reported for sacral chordoma. At a similar frequency (21%), we found aneuploidy of chromosome 3. Tissue microarray immunohistochemistry demonstrated absent or reduced fragile histidine triad (FHIT) protein expression in 98% of sacral chordomas and 67% of skull base chordomas. Our data suggest that chromosome 3 aneuploidy and epigenetic regulation of FHIT contribute to loss of the FHIT tumor suppressor in chordoma. The finding that FHIT is lost in a majority of chordomas provides new insight into chordoma pathogenesis and points to a potential new therapeutic target for this challenging neoplasm. Neoplasia (2012) 14, 788-798
C1 [Rutka, James T.] Hosp Sick Children, Dept Surg, Div Neurosurg, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada.
   [Diaz, Roberto Jose; Rutka, James T.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Diaz, Roberto Jose; Cusimano, Michael D.; Rutka, James T.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
   [Guduk, Mustafa; Pamir, M. Necmettin] Acibadem Univ, Dept Neurosurg, Istanbul, Turkey.
   [Berisha, Fitim; Flanagan, Adrienne] Royal Natl Orthopaed Hosp, Dept Histopathol, Stanmore HA7 4LP, Middx, England.
   [Flanagan, Adrienne] UCL Canc Inst, London, England.
   [Munoz, David G.] St Michaels Hosp, Dept Pathol, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada.
   [Cusimano, Michael D.] St Michaels Hosp, Dept Surg, Div Neurosurg, Toronto, ON M5B 1W8, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto; University of Toronto; Acibadem University; University of
   London; University College London; Royal National Orthopaedic Hospital
   NHS Trust; University of London; University College London; University
   of Toronto; Saint Michaels Hospital Toronto; University of Toronto;
   Saint Michaels Hospital Toronto
RP Rutka, JT (通讯作者)，Hosp Sick Children, Dept Surg, Div Neurosurg, Arthur & Sonia Labatt Brain Tumor Res Ctr, Suite 1503,555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM james.rutka@sickkids.ca
RI Cusimano, Michael/X-4059-2019; Munoz, David/AAQ-8003-2020; Shih,
   David/AAE-8726-2019; Northcott, Paul/N-4022-2018; Guduk,
   Mustafa/X-9556-2018; Shih, David J. H./H-3186-2011
OI Pamir, M Necmettin/0000-0002-5958-8625; Guduk,
   Mustafa/0000-0002-0751-1802; Northcott, Paul/0000-0002-1220-5252;
   Cusimano, Michael/0000-0002-9989-0650; Munoz, David/0000-0003-0957-6244;
   Shih, David J. H./0000-0002-9802-4937
FU Wiley Fund at the Hospital for Sick Children; Laurie Berman fund for
   brain tumor research; Canadian Institutes of Health Research
FX Tumor database support was provided by Jim Loukides, Arthur and Sonia
   Labatt Brain Tumor Research Centre, The Hospital for Sick Children.
   Tissue microarray material was made available from the Royal National
   Orthopaedic Hospital Musculoskeletal Research Programme and Bio-bank.
   Assistance received from Josh Sommer, Chordama Foundation. This work was
   supported by the Wiley Fund at the Hospital for Sick Children, and the
   Laurie Berman fund for brain tumor research.This work was supported by
   the Canadian Institutes of Health Research. Dr Diaz is a Canada Vanier
   Graduate Scholar at the University of Toronto.
CR Almefty KK, 2009, J NEUROSURG, V110, P715, DOI 10.3171/2008.9.JNS08285
   Ares C, 2009, INT J RADIAT ONCOL, V75, P1111, DOI 10.1016/j.ijrobp.2008.12.055
   Aydemir E, 2012, J NEUROSURG, V116, P810, DOI 10.3171/2011.12.JNS11430
   Baratti D, 2003, ANN SURG ONCOL, V10, P291, DOI 10.1245/ASO.2003.06.002
   Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t
   Bayrakli F, 2007, SURG NEUROL, V68, P425, DOI 10.1016/j.surneu.2006.11.046
   Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870
   Catton C, 1996, RADIOTHER ONCOL, V41, P67, DOI 10.1016/S0167-8140(96)91805-8
   Cecener G, 2010, CELL MOL NEUROBIOL, V30, P301, DOI 10.1007/s10571-009-9452-9
   CHAMBERS PW, 1979, AM J CLIN PATHOL, V72, P765
   Diaz RJ, 2011, J NEURO-ONCOL, V104, P411, DOI 10.1007/s11060-011-0559-8
   DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V
   Druck T, 1997, CANCER RES, V57, P504
   Dumon KR, 2001, CANCER RES, V61, P4827
   Eisenberg MB, 1997, SURG NEUROL, V47, P156, DOI 10.1016/S0090-3019(96)00432-6
   ERIKSSON B, 1981, ACTA ORTHOP SCAND, V52, P49, DOI 10.3109/17453678108991758
   Fong KM, 1997, CANCER RES, V57, P2256
   Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.0.CO;2-I
   Gil Z, 2004, CANCER GENET CYTOGEN, V154, P124, DOI 10.1016/j.cancergencyto.2004.01.031
   Hallor KH, 2008, BRIT J CANCER, V98, P434, DOI 10.1038/sj.bjc.6604130
   Hayashi S, 1997, CANCER RES, V57, P1981
   HEFFELFINGER MJ, 1973, CANCER-AM CANCER SOC, V32, P410, DOI 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S
   Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013
   HIBI K, 1992, ONCOGENE, V7, P445
   HIGINBOTHAM NL, 1967, CANCER-AM CANCER SOC, V20, P1841, DOI 10.1002/1097-0142(196711)20:11<1841::AID-CNCR2820201107>3.0.CO;2-2
   HRUBAN RH, 1990, AM J PATHOL, V137, P435
   Hsu W, 2011, J NEUROSURG, V115, P760, DOI 10.3171/2011.5.JNS11185
   Hu BC, 2005, J CELL PHYSIOL, V202, P518, DOI 10.1002/jcp.20139
   Huebner K, 1997, BBA-REV CANCER, V1332, pM65, DOI 10.1016/S0304-419X(97)00009-7
   Ishii H, 2001, CANCER RES, V61, P1578
   Ishii H, 2007, CELL CYCLE, V6, P1044, DOI 10.4161/cc.6.9.4213
   Ishii H, 2006, CANCER RES, V66, P11287, DOI 10.1158/0008-5472.CAN-06-2503
   Ji L, 1999, CANCER RES, V59, P3333
   KOHNO T, 1993, ONCOGENE, V8, P1825
   Kuzniacka A, 2004, CANCER GENET CYTOGEN, V151, P178, DOI 10.1016/j.cancergencyto.2003.09.015
   Kvasha S, 2008, CANCER LETT, V265, P250, DOI 10.1016/j.canlet.2008.02.036
   Le LP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018846
   Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069
   Long Fei, 2011, Zhonghua Yixue Yichuanxue Zazhi, V28, P699, DOI 10.3760/cma.j.issn.1003-9406.2011.06.023
   Longoni M, 2008, NEURO-ONCOLOGY, V10, P52, DOI 10.1215/15228517-2007-048
   MAESTRO R, 1993, CANCER RES, V53, P5775
   Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Michael D, 1997, ONCOGENE, V15, P1653
   NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0
   Nishizaki M, 2004, CANCER RES, V64, P5745, DOI 10.1158/0008-5472.CAN-04-0195
   Noël G, 2005, ACTA ONCOL, V44, P700, DOI 10.1080/02841860500326257
   Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336
   Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C
   Ozeri-Galai E, 2012, TRENDS GENET, V28, P295, DOI 10.1016/j.tig.2012.02.006
   Palakodeti A, 2010, HUM MOL GENET, V19, P99, DOI 10.1093/hmg/ddp470
   Pamir MN, 2008, ADV TECH STAND NEURO, V33, P35, DOI 10.1007/978-3-211-72283-1_2
   Presneau N, 2011, J PATHOL, V223, P327, DOI 10.1002/path.2816
   Rimessi A, 2009, P NATL ACAD SCI USA, V106, P12753, DOI 10.1073/pnas.0906484106
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   ROSENBERG AE, 1994, AM J CLIN PATHOL, V101, P36, DOI 10.1093/ajcp/101.1.36
   SATO T, 1991, CANCER RES, V51, P5794
   Sawyer J R, 2001, Neurosurg Focus, V10, pE6
   Scheil S, 2001, GENE CHROMOSOME CANC, V32, P203, DOI 10.1002/gcc.1184
   SCHOEDEL KE, 1995, ACTA NEUROPATHOL, V89, P139
   Sevignani C, 2003, CANCER RES, V63, P1183
   Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771
   Sozzi G, 1997, CANCER RES, V57, P5207
   Sükösd F, 2003, CANCER RES, V63, P455
   Tanaka H, 1998, CANCER RES, V58, P3429
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770
   Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431
   YAMAKAWA K, 1991, CANCER RES, V51, P4707
   Yamamoto G, 2007, AM J HUM GENET, V81, P114, DOI 10.1086/518809
   Yang XHR, 2009, NAT GENET, V41, P1176, DOI 10.1038/ng.454
   Zandi R, 2011, CANCER INVEST, V29, P683, DOI 10.3109/07357907.2011.626475
   Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898
   Zawacka-Pankau J, 2009, TOXICOL APPL PHARM, V241, P246, DOI 10.1016/j.taap.2009.08.023
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 77
TC 34
Z9 35
U1 0
U2 4
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
   USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD SEP
PY 2012
VL 14
IS 9
BP 788
EP U141
DI 10.1593/neo.12526
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 068DR
UT WOS:000313345200002
PM 23019410
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Bentires-Alj, M
   Glukhova, M
   Hynes, N
   Vivanco, MD
AF Bentires-Alj, Mohamed
   Glukhova, Marina
   Hynes, Nancy
   Vivanco, Maria dM
TI New methods in mammary gland development and cancer: proteomics,
   epigenetics, symmetric division and metastasis
SO BREAST CANCER RESEARCH
LA English
DT Article
ID CARCINOMA IN-SITU; BREAST-TUMORS; STEM-CELLS; CYTOMETRY; PATHOLOGY;
   MODEL
AB The European Network for Breast Development and Cancer (ENBDC) meeting on 'Methods in Mammary Gland Development and Cancer' has become an annual international rendezvous for scientists with interests in the normal and neoplastic breast. The fourth meeting in this series, held in April in Weggis, Switzerland, focused on proteomics, epigenetics, symmetric division, and metastasis.
C1 [Bentires-Alj, Mohamed; Hynes, Nancy] Friedrich Miescher Inst Biomed Res FMI, CH-4058 Basel, Switzerland.
   [Glukhova, Marina] CNRS, UMR144, Inst Curie, Ctr Rech, F-75248 Paris 05, France.
   [Vivanco, Maria dM] CIC bioGUNE, Cell Biol & Stem Cells Unit, Derio 48160, Bizkaia, Spain.
C3 Friedrich Miescher Institute for Biomedical Research; Universite PSL;
   UNICANCER; Institut Curie; Centre National de la Recherche Scientifique
   (CNRS); CIC bioGUNE
RP Vivanco, MD (通讯作者)，CIC bioGUNE, Cell Biol & Stem Cells Unit, Technol Pk Bizkaia,801 A, Derio 48160, Bizkaia, Spain.
EM mdmvivanco@cicbiogune.es
RI Bentires-Alj, Mohamed/F-4484-2015; Vivanco, Maria/G-2393-2011
OI Bentires-Alj, Mohamed/0000-0001-6344-1127; Vivanco,
   Maria/0000-0002-9540-247X
FU Novartis Research Foundation; European Research Council (ERC)
   [243211-PTPsBDC]; Institute of Health Carlos III (FIS); Department of
   Health of the Government of the Autonomous Community of the Basque
   Country
FX Research in the lab of MB-A is supported by the Novartis Research
   Foundation and the European Research Council (ERC starting grant
   243211-PTPsBDC). NH is supported by the Novartis Research Foundation. MV
   is supported by grants from the Institute of Health Carlos III (FIS) and
   the Department of Health of the Government of the Autonomous Community
   of the Basque Country.
CR Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358
   Bendall SC, 2012, TRENDS IMMUNOL, V33, P323, DOI 10.1016/j.it.2012.02.010
   Braakman RBH, 2011, METHODS MOL BIOL, V755, P143, DOI 10.1007/978-1-61779-163-5_11
   Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048
   Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Fienberg HG, 2012, CYTOM PART A, V81A, P467, DOI 10.1002/cyto.a.22067
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Nola S, 2012, J MAMMARY GLAND BIOL
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290
   Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016
   Valdez KE, 2011, J PATHOL, V225, P565, DOI 10.1002/path.2969
   WELLINGS SR, 1975, J NATL CANCER I, V55, P231
NR 15
TC 0
Z9 0
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2012
VL 14
IS 4
AR 314
DI 10.1186/bcr3216
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 065ZP
UT WOS:000313189600032
PM 22809213
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Cortez, V
   Mann, M
   Tekmal, S
   Suzuki, T
   Miyata, N
   Rodriguez-Aguayo, C
   Lopez-Berestein, G
   Sood, AK
   Vadlamudi, RK
AF Cortez, Valerie
   Mann, Monica
   Tekmal, Seshidhar
   Suzuki, Takayoshi
   Miyata, Naoki
   Rodriguez-Aguayo, Cristian
   Lopez-Berestein, Gabriel
   Sood, Anil K.
   Vadlamudi, Ratna K.
TI Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for
   breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID NUCLEAR RECEPTOR COREGULATORS; INTERFERING RNA DELIVERY;
   GLUTAMIC-ACID-RICH; AROMATASE INHIBITORS; ESTROGEN-RECEPTOR; IN-VIVO;
   OVARIAN-CARCINOMA; PROLINE-RICH; CELLS; METHYLATION
AB Introduction: The estrogen receptor (ER) co-regulator proline glutamic acid and leucine-rich protein 1 (PELP1) is a proto-oncogene that modulates epigenetic changes on ER target gene promoters via interactions with lysine-specific histone demethylase 1 (KDM1). In this study, we assessed the therapeutic potential of targeting the PELP1-KDM1 axis in vivo using liposomal (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; DOPC) siRNA to downregulate PELP1 expression and KDM1 inhibitors, pargyline and N-((1S)-3-(3-(trans-2-aminocyclopropyl)phenoxy)-1-(benzylcarbamoyl)propyl) benzamide using preclinical models.
   Methods: Preclinical xenograft models were used to test the efficacy of drugs in vivo. Ki-67 and terminal deoxynucleotidyl transferase dUTP nick end-labeling immunohistochemical analysis of epigenetic markers was performed on tumor tissues. The in vitro effect of PELP1-KDM axis blockers was tested using proliferation, reporter gene, chromatin immunoprecipitation and real-time RT-PCR assays. The efficacy of the KDM1 targeting drugs alone or in combination with letrozole and tamoxifen was tested using therapy-resistant model cells.
   Results: Treatment of ER-positive xenograft-based breast tumors with PELP1-siRNA-DOPC or pargyline reduced tumor volume by 58.6% and 62%, respectively. In a postmenopausal model, in which tumor growth is stimulated solely by local estrogen synthesis, daily pargyline treatment reduced tumor volume by 78%. Immunohistochemical analysis of excised tumors revealed a combined decrease in cellular proliferation, induction of apoptosis and upregulation of inhibitory epigenetic modifications. Pharmacological inhibition of KDM1 in vitro increased inhibitory histone mark dimethylation of histone H3 at lysine 9 (H3K9me2) and decreased histone activation mark acetylation of H3K9 (H3K9Ac) on ER target gene promoters. Combining KDM1 targeting drugs with current endocrine therapies substantially impeded growth and restored sensitivity of therapy-resistant breast cancer cells to treatment.
   Conclusion: Our results suggest inhibition of PELP1-KDM1-mediated histone modifications as a potential therapeutic strategy for blocking breast cancer progression and therapy resistance.
C1 [Cortez, Valerie; Mann, Monica; Tekmal, Seshidhar; Vadlamudi, Ratna K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
   [Cortez, Valerie; Mann, Monica] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA.
   [Suzuki, Takayoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kita Ku, Kyoto 4038334, Japan.
   [Suzuki, Takayoshi] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan.
   [Miyata, Naoki] Nagoya City Univ, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678673, Japan.
   [Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 78030 USA.
   [Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 78030 USA.
   [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 78030 USA.
   [Vadlamudi, Ratna K.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; Kyoto Prefectural University of Medicine;
   Japan Science & Technology Agency (JST); Nagoya City University;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; University of
   Texas Health Science Center at San Antonio; Cancer Therapy & Research
   Center
RP Vadlamudi, RK (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
EM vadlamudi@uthscsa.edu
OI RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723
FU RGK Foundation; Komen grant [KG090447];  [NIH-CA095681]; 
   [NIH-1F31CA165814];  [NIH-CA165814-01];  [U54 CA151668]
FX The authors thank the Pathology Core Facility, University of Texas
   Health Science Center, San Antonio for performing IHC analysis, Dr
   Rajeshwar Rao Tekmal for nude mice studies, Dr Dimple Chakravarty for
   siRNA preparation/transfection and Dr Sujit Nair for help with MTT
   assays. This study was supported by grants NIH-CA095681,
   NIH-1F31CA165814, NIH-CA165814-01 and U54 CA151668, the RGK Foundation,
   and Komen grant KG090447
CR Bennani-Baiti IM, 2012, HUM PATHOL, V43, P1300, DOI 10.1016/j.humpath.2011.10.010
   BULUN SE, 1994, BREAST CANCER RES TR, V30, P19, DOI 10.1007/BF00682738
   Chakravarty D, 2011, CLIN CANCER RES, V17, P2250, DOI 10.1158/1078-0432.CCR-10-2718
   Chakravarty D, 2010, IUBMB LIFE, V62, P163, DOI 10.1002/iub.287
   Chumsri S, 2011, J STEROID BIOCHEM, V125, P13, DOI 10.1016/j.jsbmb.2011.02.001
   Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9
   Halder J, 2006, CLIN CANCER RES, V12, P4916, DOI 10.1158/1078-0432.CCR-06-0021
   Howlader N., 2011, SEER cancer statistics review, 1975-2008
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179
   Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745
   Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004
   Landen CN, 2006, CANCER BIOL THER, V5, P1708, DOI 10.4161/cbt.5.12.3468
   Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530
   Leary A, 2006, BRIT J CANCER, V95, P661, DOI 10.1038/sj.bjc.6603316
   Lewis-Wambi Joan S, 2005, Breast Dis, V24, P93
   Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413
   Lonard DM, 2007, ENDOCR REV, V28, P575, DOI 10.1210/er.2007-0012
   Long BJ, 2004, JNCI-J NATL CANCER I, V96, P456, DOI 10.1093/jnci/djh076
   Lydon JP, 2011, ENDOCRINOLOGY, V152, P19, DOI 10.1210/en.2010-1012
   Macedo LF, 2008, CANCER, V112, P679, DOI 10.1002/cncr.23191
   Mangala LS, 2009, CLIN CANCER RES, V15, P3770, DOI 10.1158/1078-0432.CCR-08-2306
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321
   Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502
   Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786
   Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62
   Natoli G, 2009, CURR OPIN DRUG DISC, V12, P607
   Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   Pietras RJ, 2006, ONCOLOGIST, V11, P704, DOI 10.1634/theoncologist.11-7-704
   Rajhans R, 2008, MOL ENDOCRINOL, V22, P649, DOI 10.1210/me.2007-0350
   Rajhans R, 2007, CANCER RES, V67, P5505, DOI 10.1158/0008-5472.CAN-06-3647
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Subbaramaiah K, 2006, CANCER RES, V66, P5504, DOI 10.1158/0008-5472.CAN-05-4076
   Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027
   Ueda R, 2009, J AM CHEM SOC, V131, P17536, DOI 10.1021/ja907055q
   Utsumi Toshiaki, 2007, Breast Cancer, V14, P194, DOI 10.2325/jbcs.959
   Vadlamudi Ratna K, 2007, Nucl Recept Signal, V5, pe004
   Vadlamudi RK, 2010, J STEROID BIOCHEM, V118, P211, DOI 10.1016/j.jsbmb.2009.09.009
   Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614
   Vallabhaneni S, 2011, BREAST CANCER RES TR, V130, P377, DOI 10.1007/s10549-010-1312-2
   Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896
   Yang L, 2012, MOL ENDOCRINOL, V26, P550, DOI 10.1210/me.2011-1101
NR 48
TC 66
Z9 76
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2012
VL 14
IS 4
AR R108
DI 10.1186/bcr3229
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 065ZP
UT WOS:000313189600011
PM 22812534
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kornegoor, R
   Moelans, CB
   Verschuur-Maes, AHJ
   Hogenes, MCH
   de Bruin, PC
   Oudejans, JJ
   van Diest, PJ
AF Kornegoor, Robert
   Moelans, Cathy B.
   Verschuur-Maes, Anoek H. J.
   Hogenes, Marieke C. H.
   de Bruin, Peter C.
   Oudejans, Joost J.
   van Diest, Paul J.
TI Promoter hypermethylation in male breast cancer: analysis by multiplex
   ligation-dependent probe amplification
SO BREAST CANCER RESEARCH
LA English
DT Article
ID CARCINOMA IN-SITU; PROGNOSTIC RELEVANCE; DNA HYPERMETHYLATION;
   POOR-PROGNOSIS; METHYLATION; GENE; ASSOCIATION; EPIGENETICS; EXPRESSION;
   PATTERNS
AB Introduction: Epigenetic events are, along with genetic alteration, important in the development and progression of cancer. Promoter hypermethylation causes gene silencing and is thought to be an early event in carcinogenesis. The role of promoter hypermethylation in male breast cancer has not yet been studied.
   Methods: In a group of 108 male breast cancers, the methylation status of 25 genes was studied using methylation-specific multiplex ligation-dependent probe amplification. Methylation of more than 15% was regarded indicative for promoter hypermethylation. Methylation status was correlated with clinicopathological features, with patients' outcome and with 28 female breast cancer cases.
   Results: Promoter hypermethylation of the genes MSH6, WT1, PAX5, CDH13, GATA5 and PAX6 was seen in more than 50% of the cases, but was uncommon or absent in normal male breast tissue. High overall methylation status was correlated with high grade (P = 0.003) and was an independent predictor of poor survival (P = 0.048; hazard ratio 2.5). ESR1 and GSTP1 hypermethylation were associated with high mitotic count (P = 0.037 and P = 0.002, respectively) and high grade (both P = 0.001). No correlation with survival was seen for individual genes. Compared with female breast cancers (logistic regression), promoter hypermethylation was less common in a variety of genes, particularly ESR1 (P = 0.005), BRCA1 (P = 0.010) and BRCA2 (P < 0.001). The most frequently hypermethylated genes (MSH6, CDH13, PAX5, PAX6 and WT1) were similar for male and female breast cancer.
   Conclusion: Promoter hypermethylation is common in male breast cancer and high methylation status correlates with aggressive phenotype and poor survival. ESR1 and GSTP1 promoter hypermethylation seem to be involved in development and/or progression of high-grade male breast cancer. Although female and male breast cancer share a set of commonly methylated genes, many of the studied genes are less frequently methylated in male breast cancer, pointing towards possible differences between male and female breast carcinogenesis.
C1 [Kornegoor, Robert; Moelans, Cathy B.; Verschuur-Maes, Anoek H. J.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, NL-3584 CX Utrecht, Netherlands.
   [Hogenes, Marieke C. H.] Lab Pathol E Netherlands, NL-7512 AD Enschede, Netherlands.
   [de Bruin, Peter C.] St Antonius Hosp, Dept Pathol, NL-3435 CM Nieuwegein, Netherlands.
   [Oudejans, Joost J.] Diakonessen Hosp, Dept Pathol, Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; St. Antonius
   Hospital Utrecht; Diakonessenhuis
RP van Diest, PJ (通讯作者)，Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
EM p.j.vandiest@umcutrecht.nl
OI Moelans, Cathy/0000-0001-9992-8703; Oudejans, Joost/0000-0003-3162-5516
CR Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945
   Anderson WF, 2010, J CLIN ONCOL, V28, P232, DOI 10.1200/JCO.2009.23.8162
   Andreeva AV, 2010, GENE CHROMOSOME CANC, V49, P775, DOI 10.1002/gcc.20787
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Buerger H, 2001, J PATHOL, V194, P165, DOI 10.1002/path.875
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Coles BF, 2003, BIOFACTORS, V17, P115, DOI 10.1002/biof.5520170112
   Dikow N, 2007, MOL CELL PROBE, V21, P208, DOI 10.1016/j.mcp.2006.12.002
   Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Giordano SH, 2004, CANCER, V101, P51, DOI 10.1002/cncr.20312
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Gylling A, 2007, GUT, V56, P926, DOI 10.1136/gut.2006.114876
   Hayashi SI, 2003, ENDOCR-RELAT CANCER, V10, P193, DOI 10.1677/erc.0.0100193
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Hwang ES, 2004, CLIN CANCER RES, V10, P5160, DOI 10.1158/1078-0432.CCR-04-0165
   Johansson I, 2011, BREAST CANCER RES TR, V129, P747, DOI 10.1007/s10549-010-1262-8
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Korde LA, 2010, J CLIN ONCOL, V28, P2114, DOI 10.1200/JCO.2009.25.5729
   Kornegoor R, 2012, MODERN PATHOL, V25, P398, DOI 10.1038/modpathol.2011.174
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lasabova Z, 2010, NEOPLASMA, V57, P35, DOI 10.4149/neo_2010_01_035
   Martin SA, 2010, CLIN CANCER RES, V16, P5107, DOI 10.1158/1078-0432.CCR-10-0821
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Moelans CB, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-4
   Muir D, 2003, ARCH PATHOL LAB MED, V127, P36
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Palmisano WA, 2003, CANCER RES, V63, P4620
   Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Suijkerbuijk KPM, 2010, ANAL CELL PATHOL, V33, P133, DOI [10.1155/2010/185219, 10.3233/ACP-CLO-2010-0542]
   Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3
   van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648
   VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223
NR 42
TC 43
Z9 45
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2012
VL 14
IS 4
AR R101
DI 10.1186/bcr3220
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 065ZP
UT WOS:000313189600004
PM 22765268
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Peschiaroli, A
   Giacobbe, A
   Formosa, A
   Markert, EK
   Bongiorno-Borbone, L
   Levine, AJ
   Candi, E
   D'Alessandro, A
   Zolla, L
   Agrò, AF
   Melino, G
AF Peschiaroli, A.
   Giacobbe, A.
   Formosa, A.
   Markert, E. K.
   Bongiorno-Borbone, L.
   Levine, A. J.
   Candi, E.
   D'Alessandro, A.
   Zolla, L.
   Agro, A. Finazzi
   Melino, G.
TI miR-143 regulates hexokinase 2 expression in cancer cells
SO ONCOGENE
LA English
DT Article
DE miRNAs; hexokinases; prostate cancer; breast cancer; glucose metabolism
ID DOWN-REGULATION; II HEXOKINASE; GLUCOSE CATABOLISM; GENE; METABOLISM;
   WARBURG; MICRORNAS; CARCINOMA; TARGET; MITOCHONDRIA
AB Tumor cells activate pathways that facilitate and stimulate glycolysis even in the presence of adequate levels of oxygen in order to satisfy their continuous need of molecules, such as nucleotides, ATP and fatty acids, necessary to support their rapid proliferation. Accordingly, a variety of human tumors are characterized by elevated expression levels of the hexokinase 2 isoform (HK2). Although different molecular mechanisms, including genetic and epigenetic mechanisms, have been suggested to account for the altered expression of HK2 in tumors, the potential role of microRNAs (miRNAs) in the regulation of HK2 expression has not been evaluated. Here, we report that miR-143 inhibits HK2 expression via a conserved miR-143 recognition motif located in the 3'-untranslated region (3'UTR) of HK2 mRNA. We demonstrate that miR143 inhibits HK2 expression both in primary keratinocytes and in head and neck squamous cell carcinoma (HNSCC)-derived cell lines. Importantly, we found that miR-143 inversely correlates with HK2 expression in HNSCC-derived cell lines and in primary tumors. We also report that the miRNA-dependent regulation of hexokinase expression is not limited to HK2 as miR-138 targets HK1 via a specific recognition motif located in its 3'UTR. All these data unveil a new miRNA-dependent mechanism of regulation of hexokinase expression potentially important in the regulation of glucose metabolism of cancer cells.
C1 [Peschiaroli, A.] CNR, Inst Cellular Biol & Neurobiol, Rome, Italy.
   [Peschiaroli, A.; Formosa, A.; Melino, G.] Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy.
   [Giacobbe, A.; Bongiorno-Borbone, L.; Candi, E.; Agro, A. Finazzi] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy.
   [Markert, E. K.; Levine, A. J.] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA.
   [D'Alessandro, A.; Zolla, L.] Univ Tuscia, Dept Environm Sci, Viterbo, Italy.
   [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England.
C3 Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor
   Vergata; University of Rome Tor Vergata; Institute for Advanced Study -
   USA; Tuscia University; University of Leicester
RP Melino, G (通讯作者)，Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.
EM peschiaroli@med.uniroma2.it; melino@uniroma2.it
RI D'Alessandro, Angelo/AAA-4695-2019
OI PESCHIAROLI, ANGELO/0000-0001-6311-2382; Giacobbe,
   Arianna/0000-0002-5874-1851; Candi, Eleonora/0000-0001-8332-4825;
   D'Alessandro, Angelo/0000-0002-2258-6490
FU Medical Research Council, UK; Alleanza contro il Cancro [ACC12];
   MIUR/PRIN [20078P7T3K_001)/FIRB, RBIP06LCA9_0023, RBIP06LCA9_0C,
   2008MRLSNZ_004]; AIRC [5471, 2011-IG11955]; Telethon Grant [GGPO9133];
   AIRC 5xmille [9979, RF06, c.73, RF08 c.15, RF07 c.57]; Ric. Finalizzata
   [08-GIOV_RIC]; MRC [MC_U132670600] Funding Source: UKRI
FX This work has been supported by the Medical Research Council, UK; grants
   from 'Alleanza contro il Cancro' Grant (ACC12), MIUR/PRIN
   (20078P7T3K_001)/FIRB (RBIP06LCA9_0023, RBIP06LCA9_0C), AIRC grant no.
   5471; 2011-IG11955), Telethon Grant GGPO9133 to GM, MIUR/PRIN
   2008MRLSNZ_004, AIRC 5xmille (no. 9979), RF06 c.73, RF08 c.15, RF07 c.57
   awarded to GM and EC. Research described in this article was also
   supported by Ric. Finalizzata 08-GIOV_RIC awarded to AP.
CR Aberdam D, 2008, TRENDS BIOCHEM SCI, V33, P583, DOI 10.1016/j.tibs.2008.09.002
   Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85
   Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864
   Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787
   Cook CC, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.141
   Davis-Dusenbery BN, 2011, J BIOL CHEM, V286, P28097, DOI 10.1074/jbc.M111.236950
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Israël M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-70
   Jiang L, 2011, HUM GENET, V129, P189, DOI 10.1007/s00439-010-0915-3
   Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69
   Liu XQ, 2009, CANCER LETT, V286, P217, DOI 10.1016/j.canlet.2009.05.030
   Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025
   Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006
   Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200
   MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918
   Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918
   Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x
   Morton SU, 2008, P NATL ACAD SCI USA, V105, P17830, DOI 10.1073/pnas.0804673105
   Muñoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123
   Noguchi S, 2011, CANCER LETT, V307, P211, DOI 10.1016/j.canlet.2011.04.005
   Pedersen PL, 2008, J BIOENERG BIOMEMBR, V40, P123, DOI 10.1007/s10863-008-9165-7
   Rempel A, 1996, CANCER RES, V56, P2468
   Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013
   Siegel G, 2009, NAT CELL BIOL, V11, P705, DOI 10.1038/ncb1876
   Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang Chunmei, 2007, Journal of Genetics and Genomics, V34, P966, DOI 10.1016/S1673-8527(07)60109-X
   WARBURG O, 1956, SCIENCE, V124, P269
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470
NR 40
TC 150
Z9 162
U1 0
U2 37
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB 7
PY 2013
VL 32
IS 6
BP 797
EP 802
DI 10.1038/onc.2012.100
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 101AF
UT WOS:000315746700013
PM 22469988
DA 2025-01-12
ER

PT J
AU Lakshmi, SVV
   Naushad, SM
   Reddy, CA
   Saumya, K
   Rao, DS
   Kotamraju, S
   Kutala, VK
AF Lakshmi, Sana Venkata Vijaya
   Naushad, Shaik Mohammad
   Reddy, Cheruku Apoorva
   Saumya, Kankanala
   Rao, Damera Seshagiri
   Kotamraju, Srigiridhar
   Kutala, Vijay Kumar
TI Oxidative stress in coronary artery disease: epigenetic perspective
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Bcl2/adenovirus E1B interacting protein-3 (BNIP3); Extracellular
   superoxide dismutase (EC-SOD); Glutathione-S-transferase pi (GSTP1);
   Homocysteine; Coronary artery disease (CAD)
ID ONE-CARBON METABOLISM; DNA-DAMAGE; SUPEROXIDE DISMUTASE; BREAST-CANCER;
   BNIP3 GENE; HOMOCYSTEINE; SUSCEPTIBILITY; EXPRESSION; METHYLATION;
   POLYMORPHISM
AB The association between oxidative stress and coronary artery disease (CAD) is well documented. However, the role of epigenetic factors contributing to oxidative stress is relatively unexplored. In this study, we aimed to explore the impact of DNA methylation profile in BCL2/E1B adenovirus interacting protein 3 (BNIP3), extracellular superoxide dismutase (EC-SOD) and glutathione-S-transferase P1 (GSTP1) on the oxidative stress in CAD. Further, the contribution of folate pathway genetic polymorphisms in regulating epigenome was elucidated. The expression of BNIP3, EC-SOD, and GSTP1 were studied by using Maxima@SYBR-green based real-time qPCR approach in peripheral blood samples. Combined bisulfite restriction analysis and methylation-specific PCR were used to study promoter CpG island methylation. Further, the effect of homocysteine on BNIP3 gene expression was studied in human aortic endothelial cells in vitro. CAD cases exhibited upregulation of BNIP3, downregulation of EC-SOD and GSTP1. Hypomethylation of BNIP3 and hypermethylation of EC-SOD were observed in CAD cases. The expression of BNIP3 was positively correlated with homocysteine, MDA, protein carbonyls, and methylene tetrahydrofolate reductase C677T, while showing inverse association with cytosolic serine hydroxymethyl transferase C1420T. The expressions of EC-SOD and GSTP1 showed positive association with thymidylate synthase (TYMS) 2R3R, while inverse association with MDA, protein carbonyls, and methionine synthase reductase (MTRR) A66G. In vitro analysis showed homocysteine-dependent upregulation of BNIP3. The results of this study suggest that the aberrations in one-carbon metabolism appear to induce altered gene expression of EC-SOD, GSTP1, and BNIP3, and thus contribute to the increased oxidative stress and increased susceptibility to CAD.
C1 [Lakshmi, Sana Venkata Vijaya; Naushad, Shaik Mohammad; Reddy, Cheruku Apoorva; Saumya, Kankanala; Kutala, Vijay Kumar] Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad 500082, Andhra Pradesh, India.
   [Rao, Damera Seshagiri] Nizams Inst Med Sci, Dept Cardiol, Hyderabad 500082, Andhra Pradesh, India.
   [Kotamraju, Srigiridhar] Indian Inst Chem Technol, Chem Biol Div, Hyderabad 500007, Andhra Pradesh, India.
C3 Nizam's Institute of Medical Sciences; Nizam's Institute of Medical
   Sciences; Council of Scientific & Industrial Research (CSIR) - India;
   CSIR - Indian Institute of Chemical Technology (IICT)
RP Kutala, VK (通讯作者)，Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad 500082, Andhra Pradesh, India.
EM vijaykutala@gmail.com
RI Naushad, Shaik Mohammad/C-3094-2012
OI Naushad, Shaik Mohammad/0000-0001-8952-9581; Kutala, Vijay
   Kumar/0000-0002-7253-8999
FU Council of Scientific and Industrial Research (CSIR), New Delhi;
   Department of Science and Technology, Government of India
FX We acknowledge Council of Scientific and Industrial Research (CSIR), New
   Delhi for providing Senior Research Fellowship (SRF) to SVV. VKK and KS
   are recipients of Ramanujan Fellowship awarded by Department of Science
   and Technology, Government of India.
CR Alvarez-Maqueda M, 2004, ATHEROSCLEROSIS, V172, P229, DOI 10.1016/j.atherosclerosis.2003.11.005
   Bagnyukova TV, 2008, BRAIN RES, V1237, P44, DOI 10.1016/j.brainres.2008.07.073
   Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082
   CHENG KC, 1992, J BIOL CHEM, V267, P166
   Divyya S, 2012, GENE, V497, P273, DOI 10.1016/j.gene.2012.01.055
   Ghassibe-Sabbagh M, 2012, ATHEROSCLEROSIS, V222, P180, DOI 10.1016/j.atherosclerosis.2012.02.035
   Govindaiah V, 2009, CLIN BIOCHEM, V42, P380, DOI 10.1016/j.clinbiochem.2008.12.003
   Guay SP, 2012, EPIGENETICS-US, V7, P464, DOI 10.4161/epi.19633
   Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008
   Lakshmi SVV, 2013, CELL BIOCHEM BIOPHYS, V67, P353, DOI 10.1007/s12013-011-9322-1
   Lakshmi SVV, 2011, J ATHEROSCLER THROMB, V18, P56, DOI 10.5551/jat.5702
   Lee SJ, 2005, J BIOL CHEM, V280, P5781, DOI 10.1074/jbc.M411224200
   Lin HC, 2011, TOXICOLOGY, V290, P342, DOI 10.1016/j.tox.2011.10.016
   Majumdar S, 2009, ENVIRON TOXICOL, V24, P377, DOI 10.1002/tox.20442
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   Mohammad NS, 2011, MOL CELL BIOCHEM, V349, P159, DOI 10.1007/s11010-010-0670-8
   Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Nagayoshi Y, 2009, FREE RADICAL RES, V43, P1159, DOI 10.3109/10715760903214470
   Naushad SM, 2012, MOL CELL BIOCHEM, V361, P189, DOI 10.1007/s11010-011-1103-z
   Naushad SM, 2011, CELL BIOCHEM BIOPHYS, V61, P715, DOI 10.1007/s12013-011-9245-x
   Naushad SM, 2011, MOL BIOL REP, V38, P4893, DOI 10.1007/s11033-010-0631-z
   Nihei S, 2004, CIRC J, V68, P822, DOI 10.1253/circj.68.822
   Nomani H, 2011, MOL CELL BIOCHEM, V354, P181, DOI 10.1007/s11010-011-0817-2
   Oikawa S, 2001, CARCINOGENESIS, V22, P1239, DOI 10.1093/carcin/22.8.1239
   Park E, 2009, J CLIN BIOCHEM NUTR, V45, P341, DOI 10.3164/jcbn.09-44
   Pogribny IP, 2012, MOL NUTR FOOD RES, V56, P116, DOI 10.1002/mnfr.201100524
   Rajesh KG, 2011, SINGAP MED J, V52, P283
   Ramprasath T, 2011, BIOCHEM BIOPH RES CO, V407, P49, DOI 10.1016/j.bbrc.2011.02.097
   Roberts R, 2012, CURR OPIN CARDIOL, V27, P221, DOI 10.1097/HCO.0b013e3283515b4b
   Siow YL, 2006, BIOCHEM J, V398, P73, DOI 10.1042/BJ20051810
   Su XD, 2011, ARCH MED RES, V42, P596, DOI 10.1016/j.arcmed.2011.11.001
   Tayal D, 2012, CARDIOVASC J AFR, V23, P23, DOI 10.5830/CVJA-2010-092
   Turunen MP, 2009, BBA-GEN SUBJECTS, V1790, P886, DOI 10.1016/j.bbagen.2009.02.008
   van Diest PJ, 2010, ANAL CELL PATHOL, V33, P175, DOI [10.1155/2010/852197, 10.3233/ACP-CLO-2010-0543]
   Welch GN, 1997, HOSP PRACT, V32, P81, DOI 10.1080/21548331.1997.11443510
   Zhang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017998
NR 37
TC 35
Z9 44
U1 0
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD FEB
PY 2013
VL 374
IS 1-2
BP 203
EP 211
DI 10.1007/s11010-012-1520-7
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 062QR
UT WOS:000312936500021
PM 23160801
DA 2025-01-12
ER

PT J
AU Bonneville, R
   Jin, VX
AF Bonneville, Russell
   Jin, Victor X.
TI A hidden Markov model to identify combinatorial epigenetic regulation
   patterns for estrogen receptor α target genes
SO BIOINFORMATICS
LA English
DT Article
ID CHIP-SEQ; BREAST-CANCER; HISTONE MODIFICATIONS; DNA METHYLATION;
   DISCOVERY
AB Motivation: Many studies have shown that epigenetic changes, such as altered DNA methylation and histone modifications, are linked to estrogen receptor alpha (ER alpha)-positive tumors and disease prognoses. Several recent studies have applied high-throughput technologies such as ChIP-seq and MBD-seq to interrogate the altered architectures of ER alpha regulation in tamoxifen (Tam)-resistant breast cancer cells. However, the details of combinatorial epigenetic regulation of ER alpha target genes in breast cancers with acquired Tam resistance have not yet been fully examined.
   Results: We developed a computational approach to identify and analyze epigenetic patterns associated with Tam resistance in the MCF7-T cell line as opposed to the Tam-sensitive MCF7 cell line, with the goal of understanding the underlying mechanisms of epigenetic regulatory influence on resistance to Tam treatment in breast cancer. In this study, we used ChIP-seq of ER alpha, RNA polymerase II, three histone modifications and MBD-seq data of DNA methylation in MCF7 and MCF7-T cells to train hidden Markov models (HMMs). We applied the Bayesian information criterion to determine that a 20-state HMM was best, which was reduced to a 14-state HMM with a Bayesian information criterion score of 1.21291 x 10(7). We further identified four classes of biologically meaningful states in this breast cancer cell model system, and a set of ER alpha combinatorial epigenetic regulated target genes. The correlated gene expression level and gene ontology analyses showed that different gene ontology terms were enriched with Tam-resistant versus sensitive breast cancer cells. Our study illustrates the applicability of HMM-based analysis of genome-wide high-throughput genomic data to study epigenetic influences on E2/ER alpha regulation in breast cancer.
C1 [Bonneville, Russell; Jin, Victor X.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA.
C3 University System of Ohio; Ohio State University
RP Jin, VX (通讯作者)，Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA.
EM victor.jin@osumc.edu
FU PhRMA foundation; Department of Biomedical Informatics, Wexner Medical
   Center at the Ohio State University, Columbus, OH, USA
FX The PhRMA foundation and the Department of Biomedical Informatics,
   Wexner Medical Center at the Ohio State University, Columbus, OH, USA.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   BAUM LE, 1970, ANN MATH STAT, V41, P164, DOI 10.1214/aoms/1177697196
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Clarke M, 1998, LANCET, V351, P1451
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fischer B, 2005, ANAL CHEM, V77, P7265, DOI 10.1021/ac0508853
   Gu F, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-170
   Henderson J, 1997, J COMPUT BIOL, V4, P127, DOI 10.1089/cmb.1997.4.127
   Hinrichs AS, 2006, NUCLEIC ACIDS RES, V34, pD590, DOI 10.1093/nar/gkj144
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Kutanzi KR, 2010, CELL CYCLE, V9, P3078, DOI 10.4161/cc.9.15.12516
   Lan X, 2011, BIOINFORMATICS, V27, P428, DOI 10.1093/bioinformatics/btq669
   Qin ZHS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-369
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rodriguez BAT, 2011, CARCINOGENESIS, V32, P812, DOI 10.1093/carcin/bgr017
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136
   Shen CY, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-67
   Smit A, 1996, REPEATMASKER
   VITERBI AJ, 1967, IEEE T INFORM THEORY, V13, P260, DOI 10.1109/TIT.1967.1054010
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Xu H, 2008, BIOINFORMATICS, V24, P2344, DOI 10.1093/bioinformatics/btn402
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 30
TC 9
Z9 15
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1367-4811
J9 BIOINFORMATICS
JI Bioinformatics
PD JAN
PY 2013
VL 29
IS 1
BP 22
EP 28
DI 10.1093/bioinformatics/bts639
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA 058SP
UT WOS:000312654600004
PM 23104890
OA Bronze
DA 2025-01-12
ER

PT J
AU Kim, WG
   Zhu, XG
   Kim, DW
   Zhang, LS
   Kebebew, E
   Cheng, SY
AF Kim, Won Gu
   Zhu, Xuguang
   Kim, Dong Wook
   Zhang, Lisa
   Kebebew, Electron
   Cheng, Sheue-yann
TI Reactivation of the Silenced Thyroid Hormone Receptor β Gene Expression
   Delays Thyroid Tumor Progression
SO ENDOCRINOLOGY
LA English
DT Article
ID CARCINOMA CELL-LINES; BREAST-CANCER; NUCLEAR RECEPTORS; RETINOIC ACID;
   MOUSE MODEL; TR-BETA; GROWTH; MUTATION; 5-AZA-2'-DEOXYCYTIDINE;
   HYPERMETHYLATION
AB That a knock-in mouse harboring a dominant-negative thyroid hormone receptor (TR)-beta (Thrb) mutation develops metastatic thyroid cancer strongly suggests the involvement of TR beta in carcinogenesis. Epigenetic silencing of the THRB gene is common in human cancers. The aim of the present study was to determine how DNA methylation affected the expression of the THRB gene in differentiated thyroid cancer (DTC) and how reexpression of the THRB gene attenuated the cancer phenotypes. We used methylation-specific PCR to examine the expression and promoter methylation of the THRB gene in DTC tissues. Thyroid cancer cells with hypermethylated THRB were treated with the demethylating agents 5'-aza-2'-deoxycytidine (5'-aza-CdR) and zebularine to evaluate their impact on the cancer cell phenotypes. THRB mRNA expression in DTC was 90% lower than in normal controls, and this decrease was associated with a higher tumor/lymph node staging. The promoter methylation level of the THRB gene had a significant negative correlation with the expression level of the THRB gene. Treatment of FTC-236 cells with 5'-aza-CdR or zebularine induced reexpression of the THRB gene and inhibited cell proliferation and migration. FTC-236 cells stably expressing TR beta exhibited lower cell proliferation and migration through inhibition of beta-catenin signaling pathways compared with FTC-236 without TR beta. 5'-Aza-CdR also led to suppression of tumor growth in an in vivo xenograft model using FTC-236 cells consistent with the cell-based studies. These finding indicate that TR beta is a tumor suppressor and could be tested as a potential therapeutic target. (Endocrinology 154: 25-35, 2013)
C1 [Kim, Won Gu; Zhu, Xuguang; Kim, Dong Wook; Cheng, Sheue-yann] NCI, Mol Biol Lab, Surg Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Zhang, Lisa; Kebebew, Electron] NCI, Endocrine Oncol Sect, Surg Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI)
RP Cheng, SY (通讯作者)，NCI, Mol Biol Lab, Surg Branch, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.
EM chengs@mail.nih.gov
RI Kim, Won Gu/AAG-2096-2019
OI Kim, Won Gu/0000-0002-8404-7759
FU Center for Cancer Research, National Cancer Institute, National
   Institutes of Health
FX This work was supported by the Intramural Research Program at the Center
   for Cancer Research, National Cancer Institute, National Institutes of
   Health.
CR Ambroziak M, 2005, THYROID, V15, P1137, DOI 10.1089/thy.2005.15.1137
   Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572
   BHAT MK, 1995, BIOCHEM BIOPH RES CO, V210, P464, DOI 10.1006/bbrc.1995.1683
   Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023
   Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007
   Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752
   Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005
   Garcia-Rostan G, 1999, CANCER RES, V59, P1811
   Guigon CJ, 2008, MOL CELL BIOL, V28, P4598, DOI 10.1128/MCB.02192-07
   Hörkkö TT, 2006, INT J CANCER, V118, P1653, DOI 10.1002/ijc.21556
   Iwasaki Y, 2010, ANN SURG ONCOL, V17, P2222, DOI 10.1245/s10434-010-0956-9
   Jazdzewski K, 2011, J CLIN ENDOCR METAB, V96, pE546, DOI 10.1210/jc.2010-1594
   Joseph B, 2007, J CLIN ENDOCR METAB, V92, P4766, DOI 10.1210/jc.2007-0812
   Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25
   Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997
   Kilfoy BA, 2009, CANCER CAUSE CONTROL, V20, P525, DOI 10.1007/s10552-008-9260-4
   Kim WG, 2012, CLIN CANCER RES, V18, P1281, DOI 10.1158/1078-0432.CCR-11-2892
   Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836
   Kondo T, 2009, LAB INVEST, V89, P791, DOI 10.1038/labinvest.2009.50
   Li Z, 2002, CANCER RES, V62, P1939
   Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z
   Ling YQ, 2010, CANCER GENET CYTOGEN, V196, P140, DOI 10.1016/j.cancergencyto.2009.09.010
   Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001
   Miasaki FY, 2008, J ENDOCRINOL INVEST, V31, P724, DOI 10.1007/BF03346422
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Russo D, 2011, J MOL ENDOCRINOL, V46, pR73, DOI 10.1530/JME-10-0150
   Sigalotti L, 2007, J CELL PHYSIOL, V212, P330, DOI 10.1002/jcp.21066
   Silva JM, 2002, ONCOGENE, V21, P4307, DOI 10.1038/sj.onc.1205534
   VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831
   Vivaldi A, 2009, MOL CELL ENDOCRINOL, V307, P142, DOI 10.1016/j.mce.2009.03.020
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
   Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097
   Ying H, 2006, J CLIN INVEST, V116, P2972, DOI 10.1172/JCI28598
   Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9
   Zhu XG, 2010, ONCOGENE, V29, P1909, DOI 10.1038/onc.2009.476
   Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812
NR 36
TC 42
Z9 49
U1 0
U2 5
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0013-7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD JAN
PY 2013
VL 154
IS 1
BP 25
EP 35
DI 10.1210/en.2012-1728
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 061SO
UT WOS:000312868500005
PM 23183175
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Gomes, MVM
   Toffoli, LV
   Arruda, DW
   Soldera, LM
   Pelosi, GG
   Neves-Souza, RD
   Freitas, ER
   Castro, DT
   Marquez, AS
AF Gomes, Marcus V. M.
   Toffoli, Leandro V.
   Arruda, Douglas W.
   Soldera, Larissa M.
   Pelosi, Gislaine G.
   Neves-Souza, Rejane D.
   Freitas, Eliane R.
   Castro, Denilson T.
   Marquez, Audrey S.
TI Age-Related Changes in the Global DNA Methylation Profile of Leukocytes
   Are Linked to Nutrition but Are Not Associated with the MTHFR C677T
   Genotype or to Functional Capacities
SO PLOS ONE
LA English
DT Article
ID MINI-MENTAL-STATE; GASTRIC-CANCER RISK; EPIGENETIC REGULATION; GENOMIC
   METHYLATION; COLORECTAL ADENOMA; BLADDER-CANCER; BREAST-CANCER; FOLATE
   STATUS; GENE; HYPOMETHYLATION
AB Global DNA methylation of peripheral blood leukocytes has been recently proposed as a potential biomarker for disease risk. However, the amplitude of the changes in DNA methylation associated with normal aging and the impacts of environmental changes on this variation are still unclear. In this context, we evaluated the association of global DNA methylation with nutritional habits, tobacco smoking, body mass index (BMI), clinical laboratory parameters, polymorphism C677T MTHFR, functional cognition and the daily practice of physical activity in a cancer-free older population. Leukocyte global DNA methylation from 126 older individuals was quantified using a high-throughput ELISA-based method. Global DNA hypomethylation was observed in older individuals when compared to a younger population (p = 0.0469), confirming changes in DNA methylation in the aging process. Furthermore, the methylation profile of elders was correlated with the daily ingestion of carbohydrates (p = 0.0494), lipids (p = 0.0494), vitamin B6 (p = 0.0421), magnesium (p = 0.0302), and also to the serum levels of total protein (p = 0.0004), alpha 2 globulin (p = 0.0013) and albumin (p = 0.0015). No statistically significant difference was observed when global DNA methylation were stratified according to C677T MTHFR genotypes (p = 0.7200), BMI (p = 0.1170), smoking habit (p = 0.4382), physical activity in daily life (p = 0.8492), scored cognitive function (p = 0.7229) or depression state (p = 0.8301). Our data indicate that age-related variations in the global DNA methylation profile of leukocytes might be modulated by the daily intake of carbohydrates, lipids, vitamin B6, and magnesium and be associated with serum protein levels, however it is independent of C677T MTHFR genotype and not correlated with BMI, smoking habit, cognitive function or the routine physical activities.
C1 [Gomes, Marcus V. M.; Toffoli, Leandro V.; Arruda, Douglas W.; Soldera, Larissa M.; Neves-Souza, Rejane D.; Freitas, Eliane R.; Castro, Denilson T.; Marquez, Audrey S.] Univ No Parana UNOPAR, Res Ctr Hlth Sci, Londrina, Parana, Brazil.
   [Pelosi, Gislaine G.] State Univ Londrina UEL, Dept Physiol Sci, Ctr Biol Sci, Londrina, Parana, Brazil.
C3 University Norte Parana; Universidade Estadual de Londrina
RP Gomes, MVM (通讯作者)，Univ No Parana UNOPAR, Res Ctr Hlth Sci, Londrina, Parana, Brazil.
EM mvmgomes@gmail.com
RI Pelosi, Gislaine/AAF-8585-2021
FU National Foundation for Development of Private Education (Funadesp)
   [5300665]
FX This work was supported by a grant from the National Foundation for
   Development of Private Education (Funadesp) (no.5300665). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Avanutrionline, 2012, SOFTW WIND
   Axume J, 2007, NUTR RES, V27, P13, DOI 10.1016/j.nutres.2006.12.006
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   Bell JT, 2012, PLOS GENET, V8, P189, DOI 10.1371/journal.pgen.1002629
   BERDYSHEV G. D., 1967, BIOKHIMIYA, V32, P988
   Bestor TH, 1998, CIBA F SYMP, V214, P187
   Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014
   Calvanese V, 2009, AGEING RES REV, V8, P268, DOI 10.1016/j.arr.2009.03.004
   Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Chouliaras L, 2011, BRAIN BEHAV IMMUN, V25, P616, DOI 10.1016/j.bbi.2010.11.016
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Fraga MF, 2009, CURR OPIN IMMUNOL, V21, P446, DOI 10.1016/j.coi.2009.04.003
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Fuke C, 2004, ANN HUM GENET, V68, P196, DOI 10.1046/j.1529-8817.2004.00081.x
   Gao Y, 2012, BRIT J CANCER, V106, P585, DOI 10.1038/bjc.2011.562
   Gräff J, 2009, EUR J NEUROSCI, V30, P1, DOI 10.1111/j.1460-9568.2009.06787.x
   Guerrero-Preston R, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12378
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jung AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024976
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Li YY, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-98
   Li YY, 2010, FASEB J, V24, P1442, DOI 10.1096/fj.09-149328
   Liao LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027361
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   MURDEN RA, 1991, J AM GERIATR SOC, V39, P149, DOI 10.1111/j.1532-5415.1991.tb01617.x
   OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x
   Ono H, 2012, CANC SCI, V7
   Pallavi R, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00318
   Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1
   Penner MR, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00009
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rönn T, 2008, DIABETOLOGIA, V51, P1159, DOI 10.1007/s00125-008-1018-8
   Schiepers OJG, 2012, BRIT J NUTR, V107, P744, DOI 10.1017/S0007114511003576
   Slimani N, 1999, COMPUT METH PROG BIO, V58, P251, DOI 10.1016/S0169-2607(98)00088-1
   So K, 2006, PATHOL INT, V56, P571, DOI 10.1111/j.1440-1827.2006.02010.x
   Spirduso W.W., 1995, PHYS DIMENSIONS AGIN
   Thompson RF, 2010, AGING CELL, V9, P506, DOI 10.1111/j.1474-9726.2010.00577.x
   Tohgi H, 1999, MOL BRAIN RES, V70, P288, DOI 10.1016/S0169-328X(99)00163-1
   Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132
   VANYUSHI.BF, 1973, GERONTOLOGY, V19, P138, DOI 10.1159/000211967
   Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Wilhelm CS, 2010, CLIN CANCER RES, V16, P1682, DOI 10.1158/1078-0432.CCR-09-2983
   WILSON VL, 1987, J BIOL CHEM, V262, P9948
   Wong CCY, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12226
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Wu HC, 2011, EPIGENETICS-US, V6, P29, DOI 10.4161/epi.6.1.13393
   Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335
NR 60
TC 50
Z9 53
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2012
VL 7
IS 12
AR e52570
DI 10.1371/journal.pone.0052570
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 060RA
UT WOS:000312794500200
PM 23285094
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Novak, P
   Stampfer, MR
   Munoz-Rodriguez, JL
   Garbe, JC
   Ehrich, M
   Futscher, BW
   Jensen, TJ
AF Novak, Petr
   Stampfer, Martha R.
   Munoz-Rodriguez, Jose L.
   Garbe, James C.
   Ehrich, Mathias
   Futscher, Bernard W.
   Jensen, Taylor J.
TI Cell-Type Specific DNA Methylation Patterns Define Human Breast Cellular
   Identity
SO PLOS ONE
LA English
DT Article
ID MAMMARY EPITHELIAL-CELLS; DIFFERENTIAL METHYLATION; EPIGENETIC
   INACTIVATION; HYPERMETHYLATION; PLURIPOTENT; EXPRESSION; GROWTH; GENES;
   BARRIERS; CLUSTER
AB DNA methylation plays a role in a variety of biological processes including embryonic development, imprinting, X-chromosome inactivation, and stem cell differentiation. Tissue specific differential methylation has also been well characterized. We sought to extend these studies to create a map of differential DNA methylation between different cell types derived from a single tissue. Using three pairs of isogenic human mammary epithelial and fibroblast cells, promoter region DNA methylation was characterized using MeDIP coupled to microarray analysis. Comparison of DNA methylation between these cell types revealed nearly three thousand cell-type specific differentially methylated regions (ctDMRs). MassARRAY was performed upon 87 ctDMRs to confirm and quantify differential DNA methylation. Each of the examined regions exhibited statistically significant differences ranging from 10-70%. Gene ontology analysis revealed the overrepresentation of many transcription factors involved in developmental processes. Additionally, we have shown that ctDMRs are associated with histone related epigenetic marks and are often aberrantly methylated in breast cancer. Overall, our data suggest that there are thousands of ctDMRs which consistently exhibit differential DNA methylation and may underlie cell type specificity in human breast tissue. In addition, we describe the pathways affected by these differences and provide insight into the molecular mechanisms and physiological overlap between normal cellular differentiation and breast carcinogenesis.
C1 [Novak, Petr; Stampfer, Martha R.; Munoz-Rodriguez, Jose L.; Futscher, Bernard W.; Jensen, Taylor J.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
   [Munoz-Rodriguez, Jose L.; Futscher, Bernard W.; Jensen, Taylor J.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   [Stampfer, Martha R.; Garbe, James C.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
   [Novak, Petr] Acad Sci Czech Republ, Inst Plant Mol Biol, Vvi, Biol Ctr ASCR, CR-37005 Ceske Budejovice, Czech Republic.
   [Ehrich, Mathias] Sequenom Inc, San Diego, CA USA.
   [Jensen, Taylor J.] John Hopkins Ct, Sequenom Ctr Mol Med, San Diego, CA USA.
C3 Arizona Center Cancer Care; University of Arizona; University of
   Arizona; University of California System; University of California
   Berkeley; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory; Czech Academy of Sciences; Biology Centre of the
   Czech Academy of Sciences; Sequenom; Sequenom
RP Novak, P (通讯作者)，Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA.
EM petr@umbr.cas.cz
RI Munoz Rodriguez, Jose Manuel/A-7323-2016; Novak, Petr/A-3059-2013
OI Munoz Rodriguez, Jose Manuel/0000-0002-4688-6420; Novak,
   Petr/0000-0002-5068-9681
FU BIO5 interdisciplinary biotechnology center at the UA; DOD [BCRP
   BC060444]; National Institutes of Health [U54 CA112970]; Office of
   Energy Research, Office of Health and Biological Research, U.S.
   Department of Energy [DE-AC03-76SF00098]; NIEHS [ES06694]; Academy of
   Sciences of the Czech Republic [AVOZ50510513];  [R01CA65662]; 
   [R33CA091351];  [P30ES06694];  [P30CA023074];  [CA09213]
FX Grants R01CA65662 and R33CA091351 to BWF supported this work. Center
   Grants P30ES06694 and P30CA023074, and the BIO5 interdisciplinary
   biotechnology center at the UA supported the Genomics Shared Service.
   Training grant CA09213 helped support TJJ. JCG and MRS were supported by
   DOD BCRP BC060444, National Institutes of Health U54 CA112970, and the
   Office of Energy Research, Office of Health and Biological Research,
   U.S. Department of Energy under Contract No. DE-AC03-76SF00098. NIEHS
   Grant ES06694 and Grant AVOZ50510513 from the Academy of Sciences of the
   Czech Republic support PN. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alexa A, 2006, BIOINFORMATICS, V22, P1600, DOI 10.1093/bioinformatics/btl140
   Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3
   BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519
   Garbe JC, 2012, CANCER RES, V72, P3687, DOI 10.1158/0008-5472.CAN-12-0157
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018
   Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jensen TJ, 2008, CARCINOGENESIS, V29, P1500, DOI 10.1093/carcin/bgn102
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   LaBarge MA, 2012, J VISUALIZE IN PRESS
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   MAKOS M, 1993, CANCER RES, V53, P2715
   MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Oshiro MM, 2005, NEOPLASIA, V7, P799, DOI 10.1593/neo.05274
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415
   Strathdee G, 2007, CLIN CANCER RES, V13, P5048, DOI 10.1158/1078-0432.CCR-07-0919
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598
   Zhang JM, 2006, CANCER RES, V66, P10325, DOI 10.1158/0008-5472.CAN-06-1594
NR 50
TC 17
Z9 21
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2012
VL 7
IS 12
AR e52299
DI 10.1371/journal.pone.0052299
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 060RA
UT WOS:000312794500139
PM 23284978
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Kresse, SH
   Rydbeck, H
   Skårn, M
   Namlos, HM
   Barragan-Polania, AH
   Cleton-Jansen, AM
   Serra, M
   Liestol, K
   Hogendoorn, PCW
   Hovig, E
   Myklebost, O
   Meza-Zepeda, LA
AF Kresse, Stine H.
   Rydbeck, Halfdan
   Skarn, Magne
   Namlos, Heidi M.
   Barragan-Polania, Ana H.
   Cleton-Jansen, Anne-Marie
   Serra, Massimo
   Liestol, Knut
   Hogendoorn, Pancras C. W.
   Hovig, Eivind
   Myklebost, Ola
   Meza-Zepeda, Leonardo A.
TI Integrative Analysis Reveals Relationships of Genetic and Epigenetic
   Alterations in Osteosarcoma
SO PLOS ONE
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; CELL-LINES; BREAST-CANCER;
   COPY-NUMBER; EXPRESSION; IDENTIFICATION; DISEASE; BONE; BIOINFORMATICS;
   OVEREXPRESSION
AB Background: Osteosarcomas are the most common non-haematological primary malignant tumours of bone, and all conventional osteosarcomas are high-grade tumours showing complex genomic aberrations. We have integrated genome-wide genetic and epigenetic profiles from the EuroBoNeT panel of 19 human osteosarcoma cell lines based on microarray technologies.
   Principal Findings: The cell lines showed complex patterns of DNA copy number changes, where genomic copy number gains were significantly associated with gene-rich regions and losses with gene-poor regions. By integrating the datasets, 350 genes were identified as having two types of aberrations (gain/over-expression, hypo-methylation/over-expression, loss/under-expression or hyper-methylation/under-expression) using a recurrence threshold of 6/19 (>30%) cell lines. The genes showed in general alterations in either DNA copy number or DNA methylation, both within individual samples and across the sample panel. These 350 genes are involved in embryonic skeletal system development and morphogenesis, as well as remodelling of extracellular matrix. The aberrations of three selected genes, CXCL5, DLX5 and RUNX2, were validated in five cell lines and five tumour samples using PCR techniques. Several genes were hyper-methylated and under-expressed compared to normal osteoblasts, and expression could be reactivated by demethylation using 5-Aza-2'-deoxycytidine treatment for four genes tested; AKAP12, CXCL5, EFEMP1 and IL11RA. Globally, there was as expected a significant positive association between gain and over-expression, loss and under-expression as well as hyper-methylation and under-expression, but gain was also associated with hyper-methylation and under-expression, suggesting that hyper-methylation may oppose the effects of increased copy number for detrimental genes.
   Conclusions: Integrative analysis of genome-wide genetic and epigenetic alterations identified dependencies and relationships between DNA copy number, DNA methylation and mRNA expression in osteosarcomas, contributing to better understanding of osteosarcoma biology.
C1 [Kresse, Stine H.; Rydbeck, Halfdan; Skarn, Magne; Namlos, Heidi M.; Barragan-Polania, Ana H.; Hovig, Eivind; Myklebost, Ola; Meza-Zepeda, Leonardo A.] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Tumour Biol, Oslo, Norway.
   [Rydbeck, Halfdan; Liestol, Knut; Hovig, Eivind] Univ Oslo, Dept Informat, N-0316 Oslo, Norway.
   [Barragan-Polania, Ana H.; Myklebost, Ola; Meza-Zepeda, Leonardo A.] Univ Oslo, Norwegian Microarray Consortium, Dept Mol Biosci, Oslo, Norway.
   [Cleton-Jansen, Anne-Marie; Hogendoorn, Pancras C. W.] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands.
   [Serra, Massimo] Ist Ortoped Rizzoli, Expt Oncol Lab, Bologna, Italy.
C3 University of Oslo; University of Oslo; University of Oslo; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; IRCCS Istituto Ortopedico Rizzoli
RP Meza-Zepeda, LA (通讯作者)，Oslo Univ Hosp, Norwegian Radium Hosp, Dept Tumour Biol, Oslo, Norway.
EM leonardm@rr-research.no
RI Namløs, Heidi/AAB-2843-2021; Meza-Zepeda, Leonardo/CAG-5229-2022;
   Myklebost, Ola/E-9335-2010; Hovig, Eivind/H-2474-2011; Hogendoorn,
   Pancras C W/H-5859-2015; Serra, Massimo/J-4878-2016
OI Hovig, Eivind/0000-0002-9103-1077; Hogendoorn, Pancras C
   W/0000-0002-1513-8104; rydbeck, halfdan/0000-0003-1606-3842; Serra,
   Massimo/0000-0003-0742-1177
FU European Network to Promote Research into Uncommon Cancers in Adults and
   Children: Pathology, Biology and Genetics of Bone Tumours (EuroBoNeT);
   Norwegian Cancer Society (Ragnvarda F. Sorvik and Hakon Starheim's
   legacy); Norwegian Research Council
FX This work was supported by the European Network to Promote Research into
   Uncommon Cancers in Adults and Children: Pathology, Biology and Genetics
   of Bone Tumours (EuroBoNeT), the Norwegian Cancer Society (Ragnvarda F.
   Sorvik and Hakon Starheim's legacy) and the Norwegian Research Council.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aksnes LH, 2006, ACTA ONCOL, V45, P38, DOI 10.1080/02841860500466624
   Bacci G, 2003, ANN ONCOL, V14, P1126, DOI 10.1093/annonc/mdg286
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078-0432.CCR-10-2047
   Toledo SRC, 2011, J ORTHOP SCI, V16, P458, DOI 10.1007/s00776-011-0106-7
   Chari R, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-67
   Cui JC, 2011, B CANCER, V98, pE62, DOI 10.1684/bdc.2011.1400
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Epping MT, 2006, CANCER RES, V66, P10639, DOI 10.1158/0008-5472.CAN-06-2522
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Hattinger CM, 2010, EXPERT OPIN EMERG DR, V15, P615, DOI 10.1517/14728214.2010.505603
   Hogan LE, 2011, BLOOD, V118, P5218, DOI 10.1182/blood-2011-04-345595
   Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132
   Kawamura M, 2011, EUR J CANC IN PRESS
   Kresse Stine H, 2010, BMC Res Notes, V3, P223, DOI 10.1186/1756-0500-3-223
   Kresse SH, 2009, GENE CHROMOSOME CANC, V48, P679, DOI 10.1002/gcc.20675
   Kristensen VN, 2012, P NATL ACAD SCI USA, V109, P2802, DOI 10.1073/pnas.1108781108
   Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956
   Kuijjer ML, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-66
   Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291
   Lee MH, 2009, ANN NY ACAD SCI, V1171, P87, DOI 10.1111/j.1749-6632.2009.04909.x
   Lewis IJ, 2007, JNCI-J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015
   Li AH, 2011, AM J PATHOL, V178, P1340, DOI 10.1016/j.ajpath.2010.11.058
   Li Y, 2008, EXP MOL PATHOL, V84, P234, DOI 10.1016/j.yexmp.2008.03.013
   Lin SM, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1075
   Lockwood WW, 2011, J MOL DIAGN, V13, P289, DOI 10.1016/j.jmoldx.2010.11.020
   Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115
   Man TK, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-45
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   Nishimura R, 2012, J BIOCHEM, V151, P247, DOI 10.1093/jb/mvs004
   Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717
   Ozaki T, 2002, INT J CANCER, V102, P355, DOI 10.1002/ijc.10709
   Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004
   Patschan O, 2012, EPIGENETICS, V7
   PosthumaDeBoer J, 2011, CLIN EXP METASTAS, V28, P493, DOI 10.1007/s10585-011-9384-x
   Rao-Bindal Krithi, 2011, Sarcoma, V2011, P679457, DOI 10.1155/2011/679457
   Raymond AK, 2002, WHO CLASSIFICATION T
   Revill K, 2009, ENDOCR-RELAT CANCER, V16, P537, DOI 10.1677/ERC-09-0008
   Sadikovic B, 2009, HUM MOL GENET, V18, P1962, DOI 10.1093/hmg/ddp117
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   Sandve GK, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-12-r121
   Schenk T, 2007, GENE CHROMOSOME CANC, V46, P796, DOI 10.1002/gcc.20465
   SCHULZ A, 1993, CALCIFIED TISSUE INT, V52, P30
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Smida J, 2010, CLIN CANCER RES, V16, P4256, DOI 10.1158/1078-0432.CCR-10-0284
   Speetjens FM, 2008, CLIN CANCER RES, V14, P2276, DOI 10.1158/1078-0432.CCR-07-4045
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Tessema M, 2010, ONCOGENE, V29, P5159, DOI 10.1038/onc.2010.255
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
   Yen CC, 2009, INT J ONCOL, V35, P775, DOI 10.3892/ijo_00000390
   Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733
   Zou C, 2011, CANCER, V118, P1845
NR 57
TC 79
Z9 82
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 7
PY 2012
VL 7
IS 11
AR e48262
DI 10.1371/journal.pone.0048262
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 048TK
UT WOS:000311935800042
PM 23144859
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Gao, C
   Devarajan, K
   Zhou, Y
   Slater, CM
   Daly, MB
   Chen, XW
AF Gao, Chuan
   Devarajan, Karthik
   Zhou, Yan
   Slater, Carolyn M.
   Daly, Mary B.
   Chen, Xiaowei
TI Identifying breast cancer risk loci by global differential
   allele-specific expression (DASE) analysis in mammary epithelial
   transcriptome
SO BMC GENOMICS
LA English
DT Article
DE Differential allele-specific expression; Breast cancer susceptibility;
   SNP array; DMBT1
ID GENOME-WIDE ASSOCIATION; GENE-EXPRESSION; SUSCEPTIBILITY GENE; BRCA2;
   MUTATIONS; CANDIDATE; DMBT1; INFORMATION; TUMORS; CELLS
AB Background: The significant mortality associated with breast cancer (BCa) suggests a need to improve current research strategies to identify new genes that predispose women to breast cancer. Differential allele-specific expression (DASE) has been shown to contribute to phenotypic variables in humans and recently to the pathogenesis of cancer. We previously reported that nonsense-mediated mRNA decay (NMD) could lead to DASE of BRCA1/2, which is associated with elevated susceptibility to breast cancer. In addition to truncation mutations, multiple genetic and epigenetic factors can contribute to DASE, and we propose that DASE is a functional index for cis-acting regulatory variants and pathogenic mutations, and that global analysis of DASE in breast cancer precursor tissues can be used to identify novel causative alleles for breast cancer susceptibility.
   Results: To test our hypothesis, we employed the Illumina (R) Omni1-Quad BeadChip in paired genomic DNA (gDNA) and double-stranded cDNA (ds-cDNA) samples prepared from eight BCa patient-derived normal mammary epithelial lines (HMEC). We filtered original array data according to heterozygous genotype calls and calculated DASE values using the Log ratio of cDNA allele intensity, which was normalized to the corresponding gDNA. We developed two statistical methods, SNP-and gene-based approaches, which allowed us to identify a list of 60 candidate DASE loci (DASE >= 2.00, P <= 0.01, FDR <= 0.05) by both methods. Ingenuity Pathway Analysis of DASE loci revealed one major breast cancer-relevant interaction network, which includes two known cancer causative genes, ZNF331 (DASE = 2.31, P = 0.0018, FDR = 0.040) and USP6 (DASE = 4.80, P = 0.0013, FDR = 0.013), and a breast cancer causative gene, DMBT1 (DASE = 2.03, P = 0.0017, FDR = 0.014). Sequence analysis of a 5' RACE product of DMBT1 demonstrated that rs2981745, a putative breast cancer risk locus, appears to be one of the causal variants leading to DASE in DMBT1.
   Conclusions: Our study demonstrated for the first time that global DASE analysis is a powerful new approach to identify breast cancer risk allele(s).
C1 [Gao, Chuan; Slater, Carolyn M.; Chen, Xiaowei] Fox Chase Canc Ctr, Canc Epigenet Program, Philadelphia, PA 19111 USA.
   [Devarajan, Karthik; Zhou, Yan] Fox Chase Canc Ctr, Dept Biostat & Bioinformat, Philadelphia, PA 19111 USA.
   [Daly, Mary B.] Fox Chase Canc Ctr, Dept Clin Genet, Philadelphia, PA 19111 USA.
C3 Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer
   Center
RP Chen, XW (通讯作者)，Fox Chase Canc Ctr, Canc Epigenet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.
EM Xiaowei.Chen@fccc.edu
FU Susan G. Komen for the Cure [KG100274]; Eileen Stein Jacoby Fund; Risk
   Assessment and Presentation Keystone Program at Fox Chase Cancer Center
FX This work was kindly supported by the Susan G. Komen for the Cure
   (KG100274 to X.C.), the Eileen Stein Jacoby Fund, and the Risk
   Assessment and Presentation Keystone Program at Fox Chase Cancer Center.
CR [Anonymous], 2005, R LANG ENV STAT COMP
   [Anonymous], NUCL ACIDS RES
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bjornsson HT, 2008, GENOME RES, V18, P771, DOI 10.1101/gr.073254.107
   Blackburn AC, 2007, AM J PATHOL, V170, P2030, DOI 10.2353/ajpath.2007.060512
   Bove BA, 2002, BREAST CANCER: PROGNOSIS, TREATMENT, AND PREVENTION, P555
   Braidotti P, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-46
   Buckland PR, 2004, HUM MOL GENET, V13, pR255, DOI 10.1093/hmg/ddh227
   Chen XW, 2008, HUM MOL GENET, V17, P1336, DOI 10.1093/hmg/ddn022
   Chen XW, 2006, HUM MUTAT, V27, P427, DOI 10.1002/humu.20319
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Daelemans C, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-25
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Easton DF, 2008, HUM MOL GENET, V17, pR109, DOI 10.1093/hmg/ddn287
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Ge B, 2009, NAT GENET, V41, P1216, DOI 10.1038/ng.473
   Ghoussaini M, 2012, NAT GENET, V44, P312, DOI 10.1038/ng.1049
   GODWIN AK, 1994, AM J HUM GENET, V55, P666
   Gunderson KL, 2006, METHOD ENZYMOL, V410, P359, DOI 10.1016/S0076-6879(06)10017-8
   Gunderson Kevin L., 2009, V529, P197, DOI 10.1007/978-1-59745-538-1_13
   Heikkinen K, 2006, CARCINOGENESIS, V27, P1593, DOI 10.1093/carcin/bgi360
   Howlader N., 2011, SEER cancer statistics review, 1975-2008
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Klee EW, 2011, EXPERT REV MOL DIAGN, V11, P703, DOI [10.1586/ERM.11.58, 10.1586/erm.11.58]
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Lei HX, 2007, INT J CANCER, V120, P447, DOI 10.1002/ijc.22182
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Mavaddat N, 2010, MOL ONCOL, V4, P174, DOI 10.1016/j.molonc.2010.04.011
   McCarthy MI, 2008, HUM MOL GENET, V17, pR156, DOI 10.1093/hmg/ddn289
   Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879
   Meyer KB, 2008, PLOS BIOL, V6, P1098, DOI 10.1371/journal.pbio.0060108
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mollenhauer J, 2004, GENE CHROMOSOME CANC, V39, P185, DOI 10.1002/gcc.10309
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902
   Serre D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000006
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Song MY, 2012, GENE, V493, P211, DOI 10.1016/j.gene.2011.11.058
   Spencer C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001337
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Steffen J, 2006, INT J CANCER, V119, P472, DOI 10.1002/ijc.21853
   Tchatchou S, 2010, HUM MUTAT, V31, P60, DOI 10.1002/humu.21134
   Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141
   Tycko B, 2010, AM J HUM GENET, V86, P109, DOI 10.1016/j.ajhg.2010.01.021
   van't Veer LJ, 2005, J CLIN ONCOL, V23, P1631, DOI 10.1200/JCO.2005.12.005
   Wagner JR, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000849
   Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022
NR 52
TC 22
Z9 22
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD OCT 30
PY 2012
VL 13
AR 570
DI 10.1186/1471-2164-13-570
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 062XM
UT WOS:000312957800001
PM 23107584
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zama, AM
   Uzumcu, M
AF Zama, Aparna Mahakali
   Uzumcu, Mehmet
TI Targeted Genome-Wide Methylation and Gene Expression Analyses Reveal
   Signaling Pathways Involved in Ovarian Dysfunction after Developmental
   EDC Exposure in Rats
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE development; endocrine-disrupting chemicals; epigenetics;
   folliculogenesis; functional annotation; gene expression; methylation;
   ovary
ID ENDOCRINE-DISRUPTING CHEMICALS; ESTROGEN-RECEPTOR-ALPHA; ANTI-MULLERIAN
   HORMONE; FACTOR-BINDING-PROTEIN; OOCYTE NEST BREAKDOWN; NEONATAL MOUSE
   OVARY; BREAST-CANCER CELLS; GRANULOSA-CELLS; METHOXYCHLOR EXPOSURE; DNA
   METHYLATION
AB Transient exposure to methoxychlor (MXC), an environmental endocrine-disrupting chemical, during fetal and neonatal stages causes ovarian dysfunction in pubertal, adult, and aging animals. Adult animals have reduced number of ovulations and abnormal follicular composition associated with altered gene expression and DNA methylation patterns. To test the hypothesis that the ovarian epigenomic changes induced by MXC are detectable following the exposure period, leading to altered gene expression by adulthood, we conducted a targeted genome-wide methylation study using Nimblegen 3x720K CpG Island Plus RefSeq Promoter Arrays. Control (vehicle), low-dose MXC (20 mu g/kg/day), or high-dose MXC (100 mg/kg/day) treatments were administered between Embryonic Day 19 and Postnatal Day (PND) 7. Ovaries were collected at PND 7 immediately after exposure or at adulthood, PND 60. Array hybridizations were conducted with genomic DNA after methylated DNA immuno-precipitation and the array data were analyzed. DNA methylation events were functionally annotated, and candidate loci common to all the treatments or unique to some treatments were identified. Specific loci encoding signaling molecules such as the regulatory subunit p85 of phosphoinositide-3-kinase, insulin-like growth factor-1 receptor, Harvey rat sarcoma viral oncogene, insulin receptor, and forkhead box protein O3 were identified to be hypermethylated in MXC-treated ovaries at PND 7 and/or PND 60. Examination of gene expression changes with TaqMan low-density arrays revealed that nearly 25% of the genes that were assayed were downregulated. These data demonstrate that key molecules in specific signaling pathways such as PTEN signaling, IGF-1 signaling, or rapid estrogen signaling are epigenetically altered in MXC-exposed ovaries, which is associated with ovarian dysfunction and female infertility.
C1 [Zama, Aparna Mahakali; Uzumcu, Mehmet] Rutgers State Univ, Sch Environm & Biol Sci, Dept Anim Sci, New Brunswick, NJ 08901 USA.
C3 Rutgers University System; Rutgers University New Brunswick
RP Uzumcu, M (通讯作者)，Rutgers State Univ, Sch Environm & Biol Sci, Dept Anim Sci, 84 Lipman Dr, New Brunswick, NJ 08901 USA.
EM uzumcu@aesop.rutgers.edu
FU National Institutes of Health [ES013854, ES017059, P30ES005022]
FX Supported by National Institutes of Health grants ES013854, ES017059,
   and P30ES005022. Presented in part at the 44th Annual Meeting of the
   Society for the Study of Reproduction, July 31-August 4, 2011, Portland,
   Oregon.
CR Alworth LC, 2002, TOXICOL APPL PHARM, V183, P10, DOI 10.1006/taap.2002.9459
   Armenti AE, 2008, TOXICOL APPL PHARM, V233, P286, DOI 10.1016/j.taap.2008.09.010
   Barker DJP, 2003, EUR J EPIDEMIOL, V18, P733, DOI 10.1023/A:1025388901248
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336
   CATALDO NA, 1993, J CLIN ENDOCR METAB, V76, P207, DOI 10.1210/jc.76.1.207
   Chapin RE, 1997, FUND APPL TOXICOL, V40, P138, DOI 10.1006/faat.1997.2381
   Chen Y, 2007, ENDOCRINOLOGY, V148, P3580, DOI 10.1210/en.2007-0088
   Chen Y, 2009, J ENDOCRINOL, V202, P407, DOI 10.1677/JOE-09-0109
   Coffigny H, 1999, CYTOGENET CELL GENET, V87, P175, DOI 10.1159/000015460
   Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155
   Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100
   Crain DA, 2008, FERTIL STERIL, V90, P911, DOI 10.1016/j.fertnstert.2008.08.067
   Cummings AM, 1997, CRIT REV TOXICOL, V27, P367, DOI 10.3109/10408449709089899
   deMoura MD, 1997, BIOL REPROD, V56, P946, DOI 10.1095/biolreprod56.4.946
   Deroo BJ, 2009, MOL REPROD DEV, V76, P733, DOI 10.1002/mrd.21041
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Edson MA, 2009, ENDOCR REV, V30, P624, DOI 10.1210/er.2009-0012
   Fan HY, 2008, MOL ENDOCRINOL, V22, P2128, DOI 10.1210/me.2008-0095
   Fuortes L, 1997, AM J IND MED, V31, P445, DOI 10.1002/(SICI)1097-0274(199704)31:4<445::AID-AJIM11>3.0.CO;2-#
   Gaido KW, 2000, MOL PHARMACOL, V58, P852, DOI 10.1124/mol.58.4.852
   Gaido KW, 1999, ENDOCRINOLOGY, V140, P5746, DOI 10.1210/en.140.12.5746
   Gore AC, 2011, MOL ENDOCRINOL, V25, P2157, DOI 10.1210/me.2011-1210
   GRAY LE, 1989, FUND APPL TOXICOL, V12, P92, DOI 10.1016/0272-0590(89)90065-1
   Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605
   GUERRIER D, 1990, J REPROD FERTIL, V88, P695
   Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8
   Hewitt SC, 2009, MOL ENDOCRINOL, V23, P2111, DOI 10.1210/me.2009-0356
   Hoivik EA, 2008, ENDOCRINOLOGY, V149, P5599, DOI 10.1210/en.2008-0104
   IGUCHI T, 1986, ANAT EMBRYOL, V175, P53, DOI 10.1007/BF00315455
   Ikeda Y, 2002, ENDOCRINOLOGY, V143, P304, DOI 10.1210/en.143.1.304
   Ikeda Y, 2001, DEV DYNAM, V221, P443, DOI 10.1002/dvdy.1162
   Jagarlamudi K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006186
   Jefferson W, 2006, BIOL REPROD, V74, P161, DOI 10.1095/biolreprod.105.045724
   Kezele P, 2003, ENDOCRINOLOGY, V144, P3329, DOI 10.1210/en.2002-0131
   Kirigaya A, 2009, ZOOL SCI, V26, P704, DOI 10.2108/zsj.26.704
   Kouzmenko A, 2010, EPIGENOMICS-UK, V2, P765, DOI 10.2217/EPI.10.58
   Kwintkiewicz J, 2009, SEMIN REPROD MED, V27, P43, DOI 10.1055/s-0028-1108009
   Levin ER, 2011, MOL ENDOCRINOL, V25, P377, DOI 10.1210/me.2010-0284
   Liu ZL, 2009, MOL ENDOCRINOL, V23, P649, DOI 10.1210/me.2008-0412
   Luense LJ, 2011, ENDOCRINOLOGY, V152, P4974, DOI 10.1210/en.2011-1182
   Mazerbourg S, 2003, REPROD DOMEST ANIM, V38, P247, DOI 10.1046/j.1439-0531.2003.00440.x
   McDevitta MA, 2008, MOL CELL ENDOCRINOL, V290, P24, DOI 10.1016/j.mce.2008.04.003
   Nilsson E, 2001, MOL CELL ENDOCRINOL, V175, P123, DOI 10.1016/S0303-7207(01)00391-4
   Obata Y, 2002, J BIOL CHEM, V277, P5285, DOI 10.1074/jbc.M108586200
   Ohyama K, 2005, XENOBIOTICA, V35, P331, DOI 10.1080/00498250500087309
   Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200
   Pedram A, 2009, J BIOL CHEM, V284, P3488, DOI 10.1074/jbc.M806249200
   Powell E, 2010, J BIOL CHEM, V285, P16125, DOI 10.1074/jbc.M110.104356
   Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004-0115
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580
   Rodríguez HA, 2010, REPROD TOXICOL, V30, P550, DOI 10.1016/j.reprotox.2010.07.008
   Rüegg J, 2008, MOL ENDOCRINOL, V22, P304, DOI 10.1210/me.2007-0128
   Sanchez ER, 2012, BBA-MOL CELL RES, V1823, P722, DOI 10.1016/j.bbamcr.2011.11.006
   Santen RJ, 2009, STEROIDS, V74, P586, DOI 10.1016/j.steroids.2008.11.020
   Schwarz JM, 2010, ENDOCRINOLOGY, V151, P4871, DOI 10.1210/en.2010-0142
   Simoncini T, 2003, ARTERIOSCL THROM VAS, V23, P198, DOI 10.1161/01.ATV.0000053846.71621.93
   Skinner MK, 2005, HUM REPROD UPDATE, V11, P461, DOI 10.1093/humupd/dmi020
   Song RXD, 2010, J STEROID BIOCHEM, V118, P219, DOI 10.1016/j.jsbmb.2009.09.018
   Stouder C, 2011, REPRODUCTION, V141, P207, DOI 10.1530/REP-10-0400
   Swedenborg E, 2010, TOXICOLOGY, V268, P132, DOI 10.1016/j.tox.2009.09.007
   Tian J, 2012, J CLIN INVEST, V122, P192, DOI 10.1172/JCI42204
   Ueda T, 2000, GENES CELLS, V5, P649, DOI 10.1046/j.1365-2443.2000.00351.x
   UI M, 1989, ENDOCRINOLOGY, V125, P912, DOI 10.1210/endo-125-2-912
   Uzumcu M, 2006, J ENDOCRINOL, V191, P549, DOI 10.1677/joe.1.06592
   Younglai EV, 2005, HUM REPROD UPDATE, V11, P43, DOI 10.1093/humupd/dmh055
   Zama AM, 2010, FRONT NEUROENDOCRIN, V31, P420, DOI 10.1016/j.yfrne.2010.06.003
   Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499
NR 69
TC 25
Z9 30
U1 0
U2 18
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA
SN 0006-3363
J9 BIOL REPROD
JI Biol. Reprod.
PD FEB
PY 2013
VL 88
IS 2
AR 52
DI 10.1095/biolreprod.112.104802
PG 13
WC Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology
GA 103ZP
UT WOS:000315958600012
PM 23303685
OA Green Published
DA 2025-01-12
ER

PT J
AU Doig, CL
   Singh, PK
   Dhiman, VK
   Thorne, JL
   Battaglia, S
   Sobolewski, M
   Maguire, O
   O'Neill, LP
   Turner, BM
   McCabe, CJ
   Smiraglia, DJ
   Campbell, MJ
AF Doig, Craig L.
   Singh, Prashant K.
   Dhiman, Vineet K.
   Thorne, James L.
   Battaglia, Sebastiano
   Sobolewski, Michelle
   Maguire, Orla
   O'Neill, Laura P.
   Turner, Bryan M.
   McCabe, Christopher J.
   Smiraglia, Dominic J.
   Campbell, Moray J.
TI Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer
   cells and associates with altered DNA methylation patterns
SO CARCINOGENESIS
LA English
DT Article
ID VITAMIN-D-RECEPTOR; MYELOID-LEUKEMIA CELLS; BREAST-CANCER;
   1-ALPHA,25-DIHYDROXYVITAMIN D-3; ANDROGEN RECEPTOR; TRANSCRIPTIONAL
   REPRESSION; HISTONE METHYLATION; GROWTH-INHIBITION; MASS-SPECTROMETRY;
   NUCLEAR RECEPTORS
AB The current study investigated transcriptional distortion in prostate cancer cells using the vitamin D receptor (VDR) as a tool to examine how epigenetic events driven by corepressor binding and CpG methylation lead to aberrant gene expression. These relationships were investigated in the non-malignant RWPE-1 cells that were 1 alpha,25(OH)(2)D-3 responsive (RWPE-1) and malignant cell lines that were 1 alpha, 25(OH)(2)D-3 partially responsive (RWPE-2) and resistant (PC-3). These studies revealed that selective attenuation and repression of VDR transcriptional responses in the cancer cell lines reflected their loss of antiproliferative sensitivity. This was evident in VDR target genes including VDR, CDKN1A (encodes p21(waf1/cip1)) and GADD45A; NCOR1 knockdown alleviated this malignant transrepression. ChIP assays in RWPE-1 and PC-3 cells revealed that transrepression of CDKN1A was associated with increased NCOR1 enrichment in response to 1 alpha, 25(OH)(2)D-3 treatment. These findings supported the concept that retained and increased NCOR1 binding, associated with loss of H3K9ac and increased H3K9me2, may act as a beacon for the initiation and recruitment of DNA methylation. Overexpressed histone methyltransferases (KMTs) were detectable in a wide panel of prostate cancer cell lines compared with RWPE-1 and suggested that generation of H3K9me2 states would be favored. Cotreatment of cells with the KMT inhibitor, chaetocin, increased 1 alpha,25(OH)(2)D-3 - mediated induction of CDKN1A expression supporting a role for this event to disrupt CDKN1A regulation. Parallel surveys in PC-3 cells of CpG methylation around the VDR binding regions on CDKN1A revealed altered basal and VDR-regulated DNA methylation patterns that overlapped with VDR-induced recruitment of NCOR1 and gene transrepression. Taken together, these findings suggest that sustained corepressor interactions with nuclear-resident transcription factors may inappropriately transform transient-repressive histone states into more stable and repressive DNA methylation events.
C1 [Doig, Craig L.; Singh, Prashant K.; Battaglia, Sebastiano; Sobolewski, Michelle; Maguire, Orla; Campbell, Moray J.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.
   [Dhiman, Vineet K.; Smiraglia, Dominic J.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
   [Thorne, James L.] Univ Leeds, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England.
   [O'Neill, Laura P.; Turner, Bryan M.; McCabe, Christopher J.] Univ Birmingham, Inst Biomed Res, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.
C3 Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive
   Cancer Center; University of Leeds; University of Birmingham
RP Campbell, MJ (通讯作者)，Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.
EM Moray.campbell@roswellpark.org
RI Smiraglia, Dominic/R-2069-2019; thorne, james/R-9878-2019; Campbell,
   Moray/ABF-1264-2021; SINGH, PRASHANT/K-5405-2014; Doig,
   Craig/AAU-7601-2021
OI Campbell, Moray/0000-0002-3355-0928; Smiraglia,
   Dominic/0000-0001-8852-1510; Doig, Craig/0000-0001-9694-4230; Thorne,
   James/0000-0002-3037-8528; Dhiman, Vineet/0000-0002-6867-5034
FU NucSys, a European Community FP6-Marie Curie Research Training Network;
   Biotechnology and Biological Sciences Research Council; National
   Institute of Health [R01 CA095367-06, 2R01-CA-095045-06]; NCI Cancer
   Center Support Grant [CA016056]; Cancer Research UK [C1015/A9077]; MRC
   [MR/J001414/1] Funding Source: UKRI
FX NucSys, a European Community FP6-Marie Curie Research Training Network,
   the Biotechnology and Biological Sciences Research Council; National
   Institute of Health (R01 CA095367-06 and 2R01-CA-095045-06) to M.J.C.;
   NCI Cancer Center Support Grant to the Roswell Park Cancer Institute
   (CA016056) to M.J.C.; Cancer Research UK (C1015/A9077) to B.M.T.
CR ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990
   Abedin SA, 2009, CARCINOGENESIS, V30, P449, DOI 10.1093/carcin/bgp005
   Ahonen MH, 2000, CANCER CAUSE CONTROL, V11, P847, DOI 10.1023/A:1008923802001
   Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985
   Altintas DM, 2011, MOL CELL ENDOCRINOL, V332, P149, DOI 10.1016/j.mce.2010.10.007
   Banach-Petrosky W, 2006, CLIN CANCER RES, V12, P5895, DOI 10.1158/1078-0432.CCR-06-1039
   Banwell CM, 2006, CLIN CANCER RES, V12, P2004, DOI 10.1158/1078-0432.CCR-05-1218
   Battaglia S, 2010, CARCINOGENESIS, V31, P1650, DOI 10.1093/carcin/bgq086
   Battaglia S, 2010, INT J CANCER, V126, P2511, DOI 10.1002/ijc.25181
   Blutt SE, 2000, CANCER RES, V60, P779
   Camoriano M, 2008, CANCER RES, V68, P4173, DOI 10.1158/0008-5472.CAN-07-6715
   Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888
   Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015
   Chang TH, 2002, CLIN CANCER RES, V8, P1206
   Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567
   Chen TC, 2003, J CELL BIOCHEM, V88, P315, DOI 10.1002/jcb.10342
   Chêne G, 2007, BBA-MOL CELL BIOL L, V1771, P576, DOI 10.1016/j.bbalip.2007.02.014
   Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t
   Cherrier T, 2009, ONCOGENE, V28, P3380, DOI 10.1038/onc.2009.193
   COLSTON K, 1981, ENDOCRINOLOGY, V108, P1083, DOI 10.1210/endo-108-3-1083
   COLSTON K, 1982, CANCER RES, V42, P856
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Elstner E, 1999, PROSTATE, V40, P141, DOI 10.1002/(SICI)1097-0045(19990801)40:3<141::AID-PROS1>3.0.CO;2-C
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200
   GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227
   GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091-7435(90)90058-R
   Giovannucci E, 2005, CANCER CAUSE CONTROL, V16, P83, DOI 10.1007/s10552-004-1661-4
   Girault I, 2003, CLIN CANCER RES, V9, P1259
   Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200
   Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200
   Hsu JY, 2001, CANCER RES, V61, P2852
   John EM, 2005, CANCER RES, V65, P5470, DOI 10.1158/0008-5472.CAN-04-3134
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Khanim FL, 2004, ONCOGENE, V23, P6712, DOI 10.1038/sj.onc.1207772
   Kim JY, 2009, MOL ENDOCRINOL, V23, P251, DOI 10.1210/me.2008-0426
   Lakshmikuttyamma A, 2010, ONCOGENE, V29, P576, DOI 10.1038/onc.2009.361
   Le May N, 2010, MOL CELL, V38, P54, DOI 10.1016/j.molcel.2010.03.004
   Liao GQ, 2003, J BIOL CHEM, V278, P5052, DOI 10.1074/jbc.M206374200
   Luscombe CJ, 2001, BRIT J CANCER, V85, P1504, DOI 10.1054/bjoc.2001.2097
   Matilainen M, 2005, NUCLEIC ACIDS RES, V33, P5521, DOI 10.1093/nar/gki872
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4
   Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005
   Pálmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095
   PEEHL DM, 1994, CANCER RES, V54, P805
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Qiu X, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-50
   Saramäki A, 2006, NUCLEIC ACIDS RES, V34, P543, DOI 10.1093/nar/gkj460
   Saramäki A, 2009, J BIOL CHEM, V284, P8073, DOI 10.1074/jbc.M808090200
   SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307
   Seuter S, 2007, BBA-MOL CELL BIOL L, V1771, P864, DOI 10.1016/j.bbalip.2007.04.007
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Thorne J, 2008, P NUTR SOC, V67, P115, DOI 10.1017/S0029665108006964
   Thorne JL, 2011, NUCLEIC ACIDS RES, V39, P2045, DOI 10.1093/nar/gkq875
   Toropainen S, 2010, J MOL BIOL, V400, P284, DOI 10.1016/j.jmb.2010.05.031
   Towsend K, 2006, ONCOLOGY-BASEL, V71, P111, DOI 10.1159/000100989
   Webber MM, 1997, CARCINOGENESIS, V18, P1225, DOI 10.1093/carcin/18.6.1225
   Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008
   Zella LA, 2007, J STEROID BIOCHEM, V103, P435, DOI 10.1016/j.jsbmb.2006.12.019
   Zhang ZH, 2006, CANCER LETT, V237, P123, DOI 10.1016/j.canlet.2005.05.046
NR 65
TC 45
Z9 51
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 2013
VL 34
IS 2
BP 248
EP 256
DI 10.1093/carcin/bgs331
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 099NH
UT WOS:000315627900002
PM 23087083
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Garagnani, P
   Pirazzini, C
   Franceschi, C
AF Garagnani, Paolo
   Pirazzini, Chiara
   Franceschi, Claudio
TI Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota,
   Inflammation and Epigenetics
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Colorectal cancer; inflammation; aging; gut microbiota; epigenetic;
   nutrition
ID TUMOR-NECROSIS-FACTOR; MODERATE FOLATE-DEPLETION; GENOMIC DNA
   METHYLATION; NF-KAPPA-B; COLON-CANCER; DIETARY POLYPHENOLS;
   BREAST-CANCER; BETA-CATENIN; T-CELLS; EVOLUTIONARY PERSPECTIVE
AB Colorectal cancer (CRC) is a major health problem causing significant morbidity and mortality. During the last decade, results from different studies indicate that the pathogenetic mechanisms of CRC encompass tumour microenvironment, emphasizing a tight correlation with aging, inflammation, nutrition, gut microbiome composition and epigenetic modifications. Aging is one of the most important risk factors for the development of a wide range of neoplasies, including CRC, as it represents the general framework in which the tumor environment evolves. Together, these elements likely contribute to the carcinogenic process with specific effects, impacts and roles in the different stages of the tumor progression. CRCs evolve through loops of deregulated inflammatory stimuli which are sustained by DNA damage signaling pathways, dysbiosis of gut microbiota (GM) and epigenetic re-modelling (DNA methylation). To date no studies address those elements simultaneously. The synergic analysis of such parameters could provide new biological insights and effective biomarkers that could have applications in prevention, molecular diagnosis, prognosis and treatment of CRC.
C1 [Garagnani, Paolo; Pirazzini, Chiara; Franceschi, Claudio] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy.
   [Garagnani, Paolo; Pirazzini, Chiara; Franceschi, Claudio] Univ Bologna, Interdept Ctr Bioinformat Biophys & Biocomplex L, I-40126 Bologna, Italy.
C3 University of Bologna; University of Bologna
RP Pirazzini, C (通讯作者)，Univ Bologna, Dept Expt Pathol, Via S Giacomo 14, I-40126 Bologna, Italy.
EM chiara.pirazzini5@unibo.it
RI Pirazzini, Chiara/AAD-9318-2021; Franceschi, Claudio/L-4484-2017
OI Garagnani, Paolo/0000-0002-4161-3626
CR Andreoli F, 2013, CURR PHARM DESIGN, V19, P578, DOI 10.2174/138161213804581918
   Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X
   [Anonymous], 2011, TNM CLASSIFICATION M
   Araújo JR, 2011, NUTR RES, V31, P77, DOI 10.1016/j.nutres.2011.01.006
   Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Arthur JC., 2012, Science
   Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X
   Atreya I, 2008, EXPERT REV ANTICANC, V8, P561, DOI 10.1586/14737140.8.4.561
   Baggio G, 1998, FASEB J, V12, P433, DOI 10.1096/fasebj.12.6.433
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
   Bauer C, 2010, GUT, V59, P1192, DOI 10.1136/gut.2009.197822
   Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020
   Belluco C, 2003, CLIN CANCER RES, V9, P2173
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Biagi E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010667
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Biswas S, 2004, CANCER RES, V64, P4687, DOI 10.1158/0008-5472.CAN-03-3255
   Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002
   Bonafè M, 2012, BIOESSAYS, V34, P40, DOI 10.1002/bies.201100104
   BRENTNALL TA, 1994, GASTROENTEROLOGY, V107, P369, DOI 10.1016/0016-5085(94)90161-9
   Bretthauer M, 2010, BEST PRACT RES CL GA, V24, P417, DOI 10.1016/j.bpg.2010.06.005
   Brittan M, 2004, GUT, V53, P899, DOI 10.1136/gut.2003.025478
   BROKLEHU.JC, 1972, P ROY SOC MED, V65, P66, DOI 10.1177/003591577206500126
   Calvanese V, 2009, AGEING RES REV, V8, P268, DOI 10.1016/j.arr.2009.03.004
   Candela M, 2011, CRIT REV MICROBIOL, V37, P1, DOI 10.3109/1040841X.2010.501760
   Capri M, 2006, ARTIF ORGANS, V30, P730, DOI 10.1111/j.1525-1594.2006.00295.x
   CARMAN RJ, 1988, MUTAT RES, V206, P335, DOI 10.1016/0165-1218(88)90119-X
   Cea M, 2013, CURR PHARM DESIGN, V19, P734, DOI 10.2174/138161213804581945
   Cevenini E, 2010, CURR PHARM DESIGN, V16, P609, DOI 10.2174/138161210790883840
   Chang E, 2010, HEPATO-GASTROENTEROL, V57, P720
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Chung YC, 2003, J SURG ONCOL, V83, P222, DOI 10.1002/jso.10269
   Cirri P, 2011, AM J CANCER RES, V1, P482
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335
   Costarelli V., 2009, INT J FOOD SCI NUTR, P1
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dall'olio F, 2012, AGEING RES REV
   Dall'Olio F, 2012, FRONT BIOSCI-LANDMRK, V17, P670, DOI 10.2741/3951
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   Davis CD, 2009, J NUTR BIOCHEM, V20, P743, DOI 10.1016/j.jnutbio.2009.06.001
   de Vogel J, 2005, CARCINOGENESIS, V26, P387, DOI 10.1093/carcin/bgh331
   Dolara P, 2005, MUTAT RES-FUND MOL M, V591, P237, DOI 10.1016/j.mrfmmm.2005.04.022
   Duthie GG, 2000, NUTR RES REV, V13, P79, DOI 10.1079/095442200108729016
   Duthie SJ, 2007, MOL NUTR FOOD RES, V51, P665, DOI 10.1002/mnfr.200600257
   Duthie SJ, 2011, P NUTR SOC, V70, P47, DOI 10.1017/S0029665110003952
   Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Feldmann M, 2009, ANNU REV IMMUNOL, V27, P1, DOI 10.1146/annurev-immunol-082708-100732
   Ferguson LR, 2001, MUTAT RES-FUND MOL M, V475, P89, DOI 10.1016/S0027-5107(01)00073-2
   Flint HJ, 2007, ENVIRON MICROBIOL, V9, P1101, DOI 10.1111/j.1462-2920.2007.01281.x
   Foran E, 2010, MOL CANCER RES, V8, P471, DOI 10.1158/1541-7786.MCR-09-0496
   Foster Anthony D, 2011, Aging health, V7, P707
   Franceschi C, 2000, VACCINE, V18, P1717, DOI 10.1016/S0264-410X(99)00513-7
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Franceschi C, 1999, EXP GERONTOL, V34, P911, DOI 10.1016/S0531-5565(99)00068-6
   Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016
   Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102
   Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Galizia G, 2002, CLIN IMMUNOL, V102, P169, DOI 10.1006/clim.2001.5163
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Grivennikov SI, 2006, INT REV CYTOL, V252, P129, DOI 10.1016/S0074-7696(06)52002-9
   Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005
   Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0
   Guigoz Y, 2008, CURR OPIN CLIN NUTR, V11, P13, DOI 10.1097/MCO.0b013e3282f2bfdf
   Habito RC, 2001, METABOLISM, V50, P505, DOI 10.1053/meta.2001.20973
   HALL PA, 1994, J CELL SCI, V107, P3569
   He QO, 2010, CANCER GENET CYTOGEN, V202, P1, DOI 10.1016/j.cancergencyto.2010.05.018
   Herbst A, 2011, AM J GASTROENTEROL, V106, P1110, DOI 10.1038/ajg.2011.6
   Hope ME, 2005, FEMS MICROBIOL LETT, V244, P1, DOI 10.1016/j.femsle.2005.01.029
   Hsu RYC, 2011, CANCER RES, V71, P1989, DOI 10.1158/0008-5472.CAN-10-2833
   Humblot C, 2004, J CHROMATOGR B, V802, P231, DOI 10.1016/j.jchromb.2003.11.018
   Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046
   Huycke MM, 2004, EXP BIOL MED, V229, P586, DOI 10.1177/153537020422900702
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204
   Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14
   Jia W, 2008, NAT REV DRUG DISCOV, V7, P123, DOI 10.1038/nrd2505
   Kai H, 2005, ANTICANCER RES, V25, P709
   Kamiyama H, 2012, ONCOGENE
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213
   Kemp RA, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-78
   Key TJ, 2003, BREAST, V12, P412, DOI 10.1016/S0960-9776(03)00145-0
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Kim MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006555
   Kojima M, 2004, ANTICANCER RES, V24, P675
   Kollias G, 2002, CYTOKINE GROWTH F R, V13, P315, DOI 10.1016/S1359-6101(02)00019-9
   Kolonel LN, 2004, NAT REV CANCER, V4, P519, DOI 10.1038/nrc1389
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006
   Kruglov AA, 2008, CYTOKINE GROWTH F R, V19, P231, DOI 10.1016/j.cytogfr.2008.04.010
   Kryston TB, 2011, MUTAT RES-FUND MOL M, V711, P193, DOI 10.1016/j.mrfmmm.2010.12.016
   Kurdi P, 2000, J BACTERIOL, V182, P6525, DOI 10.1128/JB.182.22.6525-6528.2000
   Kurdi P, 2003, MICROBIOL-SGM, V149, P2031, DOI 10.1099/mic.0.26376-0
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lakatos PL, 2008, WORLD J GASTROENTERO, V14, P3937, DOI 10.3748/wjg.14.3937
   Larbi A, 2008, PHYSIOLOGY, V23, P64, DOI 10.1152/physiol.00040.2007
   Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725
   Lind GE, 2011, ONCOGENE, V30, P3967, DOI 10.1038/onc.2011.109
   Lind GE, 2007, GASTROENTEROLOGY, V132, P1631, DOI 10.1053/j.gastro.2007.03.003
   Lind GE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-85
   Lind GE, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-13
   Louis P, 2009, FEMS MICROBIOL LETT, V294, P1, DOI 10.1111/j.1574-6968.2009.01514.x
   MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442
   MACFARLANE GT, 1989, J APPL BACTERIOL, V67, P521, DOI 10.1111/j.1365-2672.1989.tb02524.x
   Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200
   Mai V, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-49
   Mammano E, 2009, EJSO-EUR J SURG ONC, V35, P415, DOI 10.1016/j.ejso.2008.03.003
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Matsumoto S, 2010, J IMMUNOL, V184, P1543, DOI 10.4049/jimmunol.0801217
   Matthews CP, 2007, CURR CANCER DRUG TAR, V7, P317, DOI 10.2174/156800907780809723
   Matthews VB, 2010, DIABETOLOGIA, V53, P2431, DOI 10.1007/s00125-010-1865-y
   Maynard CL, 2009, IMMUNITY, V31, P389, DOI 10.1016/j.immuni.2009.08.012
   McMahon B, 2007, PATHOPHYSIOL HAEMO T, V36, P184, DOI 10.1159/000175156
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Mishto M, 2003, AGEING RES REV, V2, P419, DOI 10.1016/S1568-1637(03)00030-8
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Motta M, 2010, ARCH GERONTOL GERIAT, V50, P48, DOI 10.1016/j.archger.2009.01.008
   Müller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9
   Naito Y, 1998, CANCER RES, V58, P3491
   Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020
   Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080
   Neri S, 2005, J GERONTOL A-BIOL, V60, P285, DOI 10.1093/gerona/60.3.285
   Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698
   O'Keefe SJD, 2008, CURR OPIN GASTROEN, V24, P51, DOI 10.1097/MOG.0b013e3282f323f3
   O'Keefe SJD, 2009, J NUTR, V139, P2044, DOI 10.3945/jn.109.104380
   OBE G, 1987, MUTAT RES, V186, P177, DOI 10.1016/0165-1110(87)90003-0
   Oldani A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000603
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P245, DOI 10.1159/000334813
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P275, DOI 10.1159/000334585
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Ostan R, 2008, NEUROIMMUNOMODULAT, V15, P224, DOI 10.1159/000156466
   Pagès F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424
   Paluszczak J, 2010, TOXICOL LETT, V192, P119, DOI 10.1016/j.toxlet.2009.10.010
   Passeri G, 2003, J CLIN ENDOCR METAB, V88, P5109, DOI 10.1210/jc.2003-030515
   Pédron T, 2008, CELL HOST MICROBE, V3, P344, DOI 10.1016/j.chom.2008.05.010
   Peltomäki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060
   Pennesi G, 1999, HUM IMMUNOL, V60, P291, DOI 10.1016/S0198-8859(98)00134-7
   Pierre F, 2004, J NUTR, V134, P2711, DOI 10.1093/jn/134.10.2711
   Pierre F, 2003, CARCINOGENESIS, V24, P1683, DOI 10.1093/carcin/bgg130
   Potten CS, 2002, J CELL SCI, V115, P2381
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998
   Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237
   Rawls JF, 2007, CELL HOST MICROBE, V2, P73, DOI 10.1016/j.chom.2007.07.006
   Reed K, 2010, ANAL BIOCHEM, V397, P96, DOI 10.1016/j.ab.2009.10.021
   Ridlon JM, 2006, J LIPID RES, V47, P241, DOI 10.1194/jlr.R500013-JLR200
   Ross SA, 2008, NUTR REV, V66, pS1, DOI 10.1111/j.1753-4887.2008.00055.x
   Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515
   Rowland IR, 1996, NUTR CANCER, V26, P37, DOI 10.1080/01635589609514461
   Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107
   Sansonetti PJ, 2008, CURR OPIN GASTROEN, V24, P435, DOI 10.1097/MOG.0b013e32830007f7
   Sansonetti PJ, 2007, IMMUNITY, V26, P149, DOI 10.1016/j.immuni.2007.02.004
   Scanlan PD, 2008, ENVIRON MICROBIOL, V10, P789, DOI 10.1111/j.1462-2920.2007.01503.x
   Schneider MR, 2000, CANCER LETT, V151, P31, DOI 10.1016/S0304-3835(99)00401-2
   Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1
   Sesink ALA, 1999, CANCER RES, V59, P5704
   Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280
   Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105
   Solvioli Stefano, 2008, Biotechnology Journal, V3, P740, DOI 10.1002/biot.200800046
   Sonnenburg JL, 2006, PLOS BIOL, V4, P2213, DOI 10.1371/journal.pbio.0040413
   STEMMERMANN GN, 1991, JPN J CANCER RES, V82, P1366, DOI 10.1111/j.1349-7006.1991.tb01807.x
   Stoll BA, 1996, BREAST CANCER RES TR, V38, P239, DOI 10.1007/BF01806141
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   Suzuki M, 2009, CELL HOST MICROBE, V5, P23, DOI 10.1016/j.chom.2008.11.010
   Tänzer M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009061
   Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0
   Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9
   Tang D, 2011, CLIN INVEST MED, V34, pE88
   Tenesa A, 2009, NAT REV GENET, V10, P353, DOI 10.1038/nrg2574
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008
   Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Uronis JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006026
   van Dam L, 2010, BEST PRACT RES CL GA, V24, P479, DOI 10.1016/j.bpg.2010.03.009
   Vanhooren V, 2010, EXP GERONTOL, V45, P738, DOI 10.1016/j.exger.2010.08.009
   Vescovini R, 2010, J IMMUNOL, V184, P3242, DOI 10.4049/jimmunol.0902890
   Wack A, 1998, INT IMMUNOL, V10, P1281, DOI 10.1093/intimm/10.9.1281
   Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118
   Westbrook AM, 2009, CANCER RES, V69, P4827, DOI 10.1158/0008-5472.CAN-08-4416
   Willett W C, 2000, Oncologist, V5, P393, DOI 10.1634/theoncologist.5-5-393
   Willett WC, 2001, J INTERN MED, V249, P395, DOI 10.1046/j.1365-2796.2001.00822.x
   Williams RO, 2007, CURR OPIN PHARMACOL, V7, P412, DOI 10.1016/j.coph.2007.06.001
   Yagi S, 2008, GENOME RES, V18, P1969, DOI 10.1101/gr.074070.107
   YOUNG GP, 1990, J GASTROEN HEPATOL, V5, P194, DOI 10.1111/j.1440-1746.1990.tb01824.x
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Yu Y, 2012, MOL BIOL REP, V39, P8457, DOI 10.1007/s11033-012-1699-4
   Zaki MH, 2011, TRENDS IMMUNOL, V32, P171, DOI 10.1016/j.it.2011.02.002
   Zeisberg M, 2000, J NEPHROL, V13, pS111
   Zhang W, 2007, DIS COLON RECTUM, V50, P1618, DOI 10.1007/s10350-007-0286-6
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 204
TC 33
Z9 41
U1 2
U2 73
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD FEB
PY 2013
VL 19
IS 4
BP 765
EP 778
DI 10.2174/138161213804581981
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 110MS
UT WOS:000316448200014
PM 23016865
DA 2025-01-12
ER

PT J
AU Doi, T
   Hamaguchi, T
   Shirao, K
   Chin, K
   Hatake, K
   Noguchi, K
   Otsuki, T
   Mehta, A
   Ohtsu, A
AF Doi, Toshihiko
   Hamaguchi, Tetsuya
   Shirao, Kuniaki
   Chin, Kensho
   Hatake, Kiyohiko
   Noguchi, Kazuo
   Otsuki, Tetsuya
   Mehta, Anish
   Ohtsu, Atsushi
TI Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a
   histone deacetylase inhibitor, in the treatment of gastrointestinal (GI)
   cancer in a phase I clinical trial
SO INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE Histone deacetylase inhibitor (HDACi); Gastrointestinal cancer;
   Vorinostat; Suberoylanilide hydroxamic acid (SAHA)
ID SUBEROYLANILIDE HYDROXAMIC ACID; T-CELL LYMPHOMA; GASTRIC-CANCER;
   ABERRANT METHYLATION; BREAST-CANCER; SOLID TUMORS; GROWTH; SAHA; BETA;
   ACETYLATION
AB Control of epigenetic changes using histone deacetylase inhibitors (HDACi) is thought to be a promising target in therapy of gastrointestinal (GI) cancer. In this study, we evaluated the safety, pharmacokinetics, and efficacy of two dosing regimens of vorinostat, an oral HDACi, in patients with GI tumors.
   Patients received either vorinostat 300 mg bid for 3 consecutive days followed by 4 rest days per cycle (n = 10) or vorinostat 400 mg qd for 21 consecutive days per cycle (n = 6). Pharmacokinetic parameters were assessed for the first treatment cycle. Efficacy was determined through evaluation of tumors and assessment of treatment response.
   The median treatment duration of 300 mg bid was 52.0 days and of 400 mg qd was 51.5 days. The most common drug-related adverse events were anorexia, nausea, fatigue, and hyperglycemia. Two patients taking 400 mg qd had dose-limiting toxicities (DLTs) of thrombocytopenia. No patients taking 300 mg bid experienced DLT. Five patients taking 300 mg bid and 2 patients taking 400 mg qd maintained stable disease for > 8 weeks, with the maximum duration of 245 days. Mean drug exposure (+/- SD) was generally higher with 400 mg qd (area under the curve [AUC(0-a)] of 7.75 +/- A 2.79 mu M h on Day 1 post-dose) compared with 300 mg bid (AUC(0-a) of 3.94 +/- A 1.56 mu M h on Day 1 post-dose).
   Vorinostat 300 mg bid for 3 consecutive days followed by 4 days of rest was better tolerated in patients with GI cancer than a higher once daily dose. Additionally, there were patients in both groups who achieved stable disease, most maintaining it for longer than 8 weeks, suggesting vorinostat as a possible active agent in the treatment of GI cancer.
C1 [Doi, Toshihiko; Ohtsu, Atsushi] Natl Canc Ctr Hosp E, Chiba, Japan.
   [Hamaguchi, Tetsuya] Natl Canc Ctr, Tokyo 104, Japan.
   [Shirao, Kuniaki] Oita Univ, Oita 87011, Japan.
   [Chin, Kensho; Hatake, Kiyohiko] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan.
   [Noguchi, Kazuo; Otsuki, Tetsuya] MSD KK, Tokyo, Japan.
   [Mehta, Anish] Merck Sharpe & Dohme Corp, Whitehouse Stn, NJ USA.
C3 National Cancer Center - Japan; National Cancer Center - Japan; Oita
   University; Japanese Foundation for Cancer Research; Merck & Company;
   Merck & Company
RP Doi, T (通讯作者)，Natl Canc Ctr Hosp E, Chiba, Japan.
EM doi.toshi3@gmail.com
CR Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200
   Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926
   Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2
   Butler LM, 2000, CANCER RES, V60, P5165
   Dummer R, 2006, J CUTAN PATHOL, V33, P52, DOI 10.1111/j.0303-6987.2006.00497.x
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Fujiwara Y, 2009, CANCER SCI, V100, P1728, DOI 10.1111/j.1349-7006.2009.01237.x
   Galanis E, 2009, J CLIN ONCOL, V27, P2052, DOI 10.1200/JCO.2008.19.0694
   Gehan EA, 2000, JNCI-J NATL CANCER I, V92, P179, DOI 10.1093/jnci/92.3.179
   Gordon KJ, 2008, BBA-MOL BASIS DIS, V1782, P197, DOI 10.1016/j.bbadis.2008.01.006
   Huang CH, 2007, BIOCHEM PHARMACOL, V73, P990, DOI 10.1016/j.bcp.2006.12.013
   Kawamura YI, 2008, GASTROENTEROLOGY, V135, P142, DOI 10.1053/j.gastro.2008.03.031
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Krug LM, 2006, CLIN LUNG CANCER, V7, P257, DOI 10.3816/CLC.2006.n.003
   Lobjois V, 2009, EUR J CANCER, V45, P2402, DOI 10.1016/j.ejca.2009.05.026
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Marson CM, 2009, ANTI-CANCER AGENT ME, V9, P661, DOI 10.2174/187152009788679976
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Nishiyama M, 2009, ADV DRUG DELIVER REV, V61, P402, DOI 10.1016/j.addr.2008.09.004
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   Richon VM, 2009, CANCER LETT, V280, P201, DOI 10.1016/j.canlet.2009.01.002
   Rubin EH, 2006, CLIN CANCER RES, V12, P7039, DOI 10.1158/1078-0432.CCR-06-1802
   Secrist J Paul, 2003, Curr Opin Investig Drugs, V4, P1422
   Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896
   Ueno M, 2004, TUMOR BIOL, V25, P134, DOI 10.1159/000079145
   Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1
   Woyach JA, 2009, J CLIN ENDOCR METAB, V94, P164, DOI 10.1210/jc.2008-1631
NR 30
TC 31
Z9 33
U1 0
U2 9
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 1341-9625
J9 INT J CLIN ONCOL
JI Int. J. Clin. Oncol.
PD FEB
PY 2013
VL 18
IS 1
BP 87
EP 95
DI 10.1007/s10147-011-0348-6
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 093TF
UT WOS:000315214200013
PM 22234637
DA 2025-01-12
ER

PT J
AU Xu, Q
   Jiang, Y
   Yin, Y
   Li, Q
   He, J
   Jing, Y
   Qi, YT
   Xu, Q
   Li, W
   Lu, B
   Peiper, SS
   Jiang, BH
   Liu, LZ
AF Xu, Qing
   Jiang, Yue
   Yin, Yu
   Li, Qi
   He, Jun
   Jing, Yi
   Qi, Yan-Ting
   Xu, Qian
   Li, Wei
   Lu, Bo
   Peiper, Stephen S.
   Jiang, Bing-Hua
   Liu, Ling-Zhi
TI A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell
   transformation and tumor angiogenesis through IGF-IR and IRS1
SO JOURNAL OF MOLECULAR CELL BIOLOGY
LA English
DT Article
DE miR-148a; miR-152; DNMT1; IGF-IR; IRS1; breast cancer; tumor
   angiogenesis
ID DNA METHYLTRANSFERASES; BREAST-CANCER; PROMOTER HYPERMETHYLATION; EARLY
   EVENT; METHYLATION; EXPRESSION; MICRORNA; PATHWAY; INSULIN; GROWTH
AB Dysregulation of microRNAs is a common feature in human cancers, including breast cancer (BC). Here we describe the epigenetic regulation of miR-148a and miR-152 and their impact on BC cells. Due to the hypermethylation of CpG island, the expression levels of both miR-148a and miR-152 (miR-148a/152) are decreased in BC tissues and cells. DNMT1, the DNA methyltransferase 1 for the maintenance methylation, is aberrantly up-regulated in BC and its overexpression is responsible for hypermethylation of miR-148a and miR-152 promoters. Intriguingly, we found that DNMT1 expression, which is one of the targets of miR-148a/152, is inversely correlated with the expression levels of miR-148a/152 in BC tissues. Those results lead us to propose a negative feedback regulatory loop between miR-148a/152 and DNMT1 in BC. More importantly, we demonstrate that IGF-IR and IRS1, often overexpressed in BC, are two novel targets of miR-148a/152. Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation, and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways. Our results suggest a novel miR-148a/152-DNMT1 regulatory circuit and reveal that miR-148a and miR-152 act as tumor suppressors by targeting IGF-IR and IRS1, and that restoration of miR-148a/152 expression may provide a strategy for therapeutic application to treat BC patients.
C1 [Xu, Qing; Yin, Yu; Li, Qi; Xu, Qian; Li, Wei; Jiang, Bing-Hua] Nanjing Med Univ, Ctr Canc, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.
   [Xu, Qing; Yin, Yu; Li, Qi; Xu, Qian; Li, Wei; Jiang, Bing-Hua] Nanjing Med Univ, Ctr Canc, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China.
   [Jiang, Yue; He, Jun; Jing, Yi; Qi, Yan-Ting; Peiper, Stephen S.; Jiang, Bing-Hua; Liu, Ling-Zhi] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.
   [Jiang, Yue] Fujian Normal Univ, Fac Software, Fuzhou 350007, Peoples R China.
   [Yin, Yu] Anhui Med Univ, Dept Pathol, Hefei 230032, Peoples R China.
   [Lu, Bo] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA.
C3 Nanjing Medical University; Nanjing Medical University; Thomas Jefferson
   University; Fujian Normal University; Anhui Medical University; Thomas
   Jefferson University
RP Jiang, BH (通讯作者)，Nanjing Med Univ, Ctr Canc, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China.
EM binghjiang@yahoo.com; ling-zhi.liu@jefferson.edu
RI He, jun/LCW-1246-2024; liu, xy/JEP-3175-2023; Yin, Yu/AAM-4895-2021
OI Hartl, Carla/0000-0001-9769-7462; Liu, Ling-Zhi/0000-0001-9234-457X; He,
   Jun/0000-0002-5162-6041; Jiang, Bing-Hua/0000-0003-4526-2031
FU National Key Basic Research Program of China [2011CB504003]; National
   Natural Science Foundation of China [81071642, 30871296]; National
   Cancer Institute, NIH [R01CA109460]
FX This work was supported in part by the National Key Basic Research
   Program of China (2011CB504003), by National Natural Science Foundation
   of China (81071642 and 30871296), and by National Cancer Institute, NIH
   (R01CA109460).
CR Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Campan M, 2006, CURR TOP MICROBIOL, V310, P141
   Chang Q, 2002, CANCER RES, V62, P6035
   Chen PS, 2011, J CLIN INVEST, V121, P3442, DOI 10.1172/JCI45390
   Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2
   De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]
   De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917
   Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06
   del Rincón SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305
   Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   La Rocca G, 2009, CELL CYCLE, V8, P2255, DOI 10.4161/cc.8.14.9026
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Liu XG, 2010, J IMMUNOL, V185, P7244, DOI 10.4049/jimmunol.1001573
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060
   Park BH, 2007, CANCER CELL, V12, P297, DOI 10.1016/j.ccr.2007.10.004
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Stumpel DJPM, 2011, LEUKEMIA, V25, P429, DOI 10.1038/leu.2010.282
   Sui M, 2007, CANCER RES, V67, P5337, DOI 10.1158/0008-5472.CAN-06-4582
   SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0
   Tamimi RM, 2011, BREAST CANCER RES TR, V128, P243, DOI 10.1007/s10549-010-1313-1
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Visvanathan K, 2006, CLIN CANCER RES, V12, P6591, DOI 10.1158/1078-0432.CCR-06-2001
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783
   Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730
   Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714
NR 51
TC 228
Z9 257
U1 0
U2 39
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1674-2788
EI 1759-4685
J9 J MOL CELL BIOL
JI J. Mol. Cell Biol.
PD FEB
PY 2013
VL 5
IS 1
BP 3
EP 13
DI 10.1093/jmcb/mjs049
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 093WN
UT WOS:000315223900002
PM 22935141
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Achyut, BR
   Bader, DA
   Robles, AI
   Wangsa, D
   Harris, CC
   Ried, T
   Yang, L
AF Achyut, B. R.
   Bader, David A.
   Robles, Ana I.
   Wangsa, Darawalee
   Harris, Curtis C.
   Ried, Thomas
   Yang, Li
TI Inflammation-Mediated Genetic and Epigenetic Alterations Drive Cancer
   Development in the Neighboring Epithelium upon Stromal Abrogation of
   TGF-β Signaling
SO PLOS GENETICS
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE;
   DNA-DAMAGE RESPONSE; BREAST-CANCER; COLON-CANCER; MOUSE MODEL;
   EXPRESSION; MICE; MICROENVIRONMENT
AB Deletion of tumor suppressor genes in stromal fibroblasts induces epithelial cancer development, suggesting an important role of stroma in epithelial homoeostasis. However, the underlying mechanisms remain to be elucidated. Here we report that deletion of the gene encoding TGF beta receptor 2 (Tgfbr2) in the stromal fibroblasts (Tgfbr2(fspKO)) induces inflammation and significant DNA damage in the neighboring epithelia of the forestomach. This results in loss or down-regulation of cyclin-dependent kinase inhibitors p15, p16, and p21, which contribute to the development of invasive squamous cell carcinoma (SCC). Anti-inflammation treatment restored p21 expression, delayed tumorigenesis, and increased survival of Tgfbr2(fspKO) mice. Our data demonstrate for the first time that inflammation is a critical player in the epigenetic silencing of p21 in tumor progression. Examination of human esophageal SCC showed a down-regulation of TGF beta receptor 2 (T beta RII) in the stromal fibroblasts, as well as increased inflammation, DNA damage, and loss or decreased p15/p16 expression. Our study suggests anti-inflammation may be a new therapeutic option in treating human SCCs with down-regulation of T beta RII in the stroma.
C1 [Achyut, B. R.; Yang, Li] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Bader, David A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Robles, Ana I.; Harris, Curtis C.] NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Wangsa, Darawalee; Ried, Thomas] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Baylor College of Medicine; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI)
RP Achyut, BR (通讯作者)，NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM yangl3@mail.nih.gov
OI Robles, Ana/0000-0001-5019-4374
FU NCI
FX This work was supported by NCI intramural funding to LY. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Achyut BR, 2011, GASTROENTEROLOGY, V141, P1167, DOI 10.1053/j.gastro.2011.07.048
   Bacman D, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-156
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597
   Bierie B, 2009, J CLIN INVEST, V119, P1571, DOI 10.1172/JCI37480
   Blanco D, 2007, NEOPLASIA, V9, P840, DOI 10.1593/neo.07517
   Boomershine CS, 2009, GUT, V58, P1267, DOI 10.1136/gut.2008.170779
   Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854
   Cheng N, 2008, MOL CANCER RES, V6, P1521, DOI 10.1158/1541-7786.MCR-07-2203
   Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802
   Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016
   Engle SJ, 2002, CANCER RES, V62, P6362
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Franco OE, 2011, CANCER RES, V71, P1272, DOI 10.1158/0008-5472.CAN-10-3142
   Fukai Y, 2003, INT J CANCER, V104, P161, DOI 10.1002/ijc.10929
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   GARTNER K, 1979, ZBL VET MED A, V26, P530
   Glick AB, 2011, SIGNALING PATHWAYS IN SQUAMOUS CANCER, P1, DOI 10.1007/978-1-4419-7203-3
   Hashimoto N, 2007, HEPATO-GASTROENTEROL, V54, P758
   HERZOG CR, 1994, CANCER RES, V54, P4007
   Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030
   Hu N, 2004, GENE CHROMOSOME CANC, V39, P205, DOI 10.1002/gcc.10315
   Hu N, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-576
   Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754
   Inoue T, 2005, KIDNEY INT, V67, P2488, DOI 10.1111/j.1523-1755.2005.00358.x
   Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214
   Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846
   Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084
   Li X, 2008, ONCOGENE, V27, P7118, DOI 10.1038/onc.2008.293
   Ling Y, 2011, J CLIN PATHOL, V64, P246, DOI 10.1136/jcp.2010.082875
   Liu Y, 2011, J BIOL CHEM, V286, P25007, DOI 10.1074/jbc.M110.213108
   Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344
   Mathé EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Méndez-Acuña L, 2010, CYTOGENET GENOME RES, V128, P28, DOI 10.1159/000296275
   Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146
   Monteleone G, 2004, J BIOL CHEM, V279, P3925, DOI 10.1074/jbc.M303654200
   Österreicher CH, 2011, P NATL ACAD SCI USA, V108, P308, DOI 10.1073/pnas.1017547108
   Padilla-Nash HM, 2012, GENE CHROMOSOME CANC, V51, P353, DOI 10.1002/gcc.21921
   Pang B, 2007, CARCINOGENESIS, V28, P1807, DOI 10.1093/carcin/bgm037
   Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825
   Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003
   Resta-Lenert S, 2006, GASTROENTEROLOGY, V130, P731, DOI 10.1053/j.gastro.2005.12.015
   Scholten D, 2010, GASTROENTEROLOGY, V139, P987, DOI 10.1053/j.gastro.2010.05.005
   Stairs DB, 2011, CANCER CELL, V19, P470, DOI 10.1016/j.ccr.2011.02.007
   STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393
   Su H, 2011, CLIN CANCER RES, V17, P2955, DOI 10.1158/1078-0432.CCR-10-2724
   Tanwar PS, 2011, CANCER RES, V71, P1584, DOI 10.1158/0008-5472.CAN-10-3166
   Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507
   Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486
   Wallace JA, 2011, CANCER RES, V71, P1203, DOI 10.1158/0008-5472.CAN-10-3263
   Xing EP, 1999, CLIN CANCER RES, V5, P2704
   Xing EP, 1999, CARCINOGENESIS, V20, P77, DOI 10.1093/carcin/20.1.77
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
   Yang L, 2010, CANCER METAST REV, V29, P263, DOI 10.1007/s10555-010-9226-3
   Yang LY, 2012, CLIN CANCER RES, V18, P2138, DOI 10.1158/1078-0432.CCR-11-0934
NR 57
TC 60
Z9 65
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD FEB
PY 2013
VL 9
IS 2
AR e1003251
DI 10.1371/journal.pgen.1003251
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 099RG
UT WOS:000315638300015
PM 23408900
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Sang, Q
   Zhang, SZ
   Zou, S
   Wang, H
   Feng, RZ
   Li, QL
   Jin, L
   He, L
   Xing, QH
   Wang, L
AF Sang, Qing
   Zhang, Shaozhen
   Zou, Shien
   Wang, Huan
   Feng, Ruizhi
   Li, Qiaoli
   Jin, Li
   He, Lin
   Xing, Qinghe
   Wang, Lei
TI Quantitative analysis of <i>follistatin</i> (<i>FST</i>) promoter
   methylation in peripheral blood of patients with polycystic ovary
   syndrome
SO REPRODUCTIVE BIOMEDICINE ONLINE
LA English
DT Article
DE follistatin; FST; PCOS; quantitative methylation analysis
ID DNA METHYLATION; CANDIDATE GENES; BREAST-CANCER; CPG ISLANDS; MASS
   ARRAY; WOMEN; ENDOMETRIUM; ACTIVIN; SUSCEPTIBILITY; TRANSCRIPTION
AB Epigenetic mechanisms may contribute to polycystic ovary syndrome (PCOS). To date, however, no studies have associated CpG methylation levels of any candidate gene with PCOS susceptibility. Follistatin (FST), an activin-binding protein, is expressed in numerous tissues and is shown to have linkage with PCOS. However, results from case-control association analyses between this gene and PCOS are inconsistent. Thus, this study investigated possible association of methylation levels in the promoter and 5'-untranscribed region (UTR) of the FST gene with PCOS incidence in peripheral blood leukocytes and endometrial tissue. Using mass array quantitative methylation analysis, first the 5'-UTR methylation in FST was analysed in 130 PCOS patients and 120 controls. The methylation level of the FST gene was further studied in endometrium from 24 controls and 24 PCOS patients. This study demonstrates that methylation levels of CpG sites in the FST promoter and 5'-UTR are not associated with PCOS. Nonetheless, this was the first study to quantitatively evaluate the methylation levels of a candidate gene in association with PCOS. Further studies should be performed to examine methylation in other candidate genes. Understanding the epigenetic mechanisms involved in PCOS may yield new insights into the pathophysiology of the disorder. RBMOnline (C) 2012, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
C1 [Sang, Qing; Wang, Huan; Feng, Ruizhi; Jin, Li; Wang, Lei] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China.
   [Sang, Qing; Wang, Huan; Feng, Ruizhi; Jin, Li; Wang, Lei] Fudan Univ, Sch Life Sci, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China.
   [Sang, Qing; Wang, Huan; Feng, Ruizhi; Li, Qiaoli; He, Lin; Xing, Qinghe; Wang, Lei] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China.
   [He, Lin; Xing, Qinghe; Wang, Lei] Shanghai Jiao Tong Univ, Minist Educ, Bio X Ctr, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai 200030, Peoples R China.
   [Zhang, Shaozhen] Shanghai Ninth Hosp, Shanghai, Peoples R China.
   [Zou, Shien] Fudan Univ, Dept Gynecol Obstet & Gynecol, Shanghai 200433, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong
   University; Fudan University
RP Xing, QH (通讯作者)，Fudan Univ, Inst Biomed Sci, 138 Yixueyuan Rd, Shanghai 200433, Peoples R China.
EM xingqinghe@hotmail.com; wanglei2004sjtu@gmail.com
RI HE, Lin/KZU-4337-2024; Jin, Li/M-5063-2019; li, qiaoli/HNR-9746-2023
OI Jin, Li/0000-0001-9201-2321
FU National High Technology Research and Development Program of China (863
   Program) [2011AA02A112]; National Natural Science Foundation of China
   [8100467, 81270747, 81200415]; Shanghai City Board of Education
   Scientific Research Innovation Key Projects [13ZZ001]; Fundamental
   Research Fund for Central University; Shanghai Educational Development
   Foundation
FX This work was supported by the National High Technology Research and
   Development Program of China (863 Program) (No. 2011AA02A112), National
   Natural Science Foundation of China (Nos. 8100467, 81270747, 81200415),
   Shanghai City Board of Education Scientific Research Innovation Key
   Projects (No. 13ZZ001) and the Fundamental Research Fund for Central
   University. It was also sponsored by Shanghai Educational Development
   Foundation.
CR Bilezikjian LM, 2004, MOL CELL ENDOCRINOL, V225, P29, DOI 10.1016/j.mce.2004.02.010
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Calvo RM, 2001, FERTIL STERIL, V75, P1020, DOI 10.1016/S0015-0282(01)01697-1
   Carmina E, 1999, J CLIN ENDOCR METAB, V84, P1897, DOI 10.1210/jc.84.6.1897
   Chen ZJ, 2011, NAT GENET, V43, P55, DOI 10.1038/ng.732
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Eldar-Geva T, 2001, HUM REPROD, V16, P2552, DOI 10.1093/humrep/16.12.2552
   Escobar-Morreale HF, 2005, ENDOCR REV, V26, P251, DOI 10.1210/er.2004-0004
   Franks S, 1997, HUM REPROD, V12, P2641, DOI 10.1093/humrep/12.12.2641
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Giudice LC, 2006, BEST PRACT RES CL EN, V20, P235, DOI 10.1016/j.beem.2006.03.005
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
   Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053
   Hickey TE, 2006, J CLIN ENDOCR METAB, V91, P2789, DOI 10.1210/jc.2006-0069
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Jones MR, 2007, MOL HUM REPROD, V13, P237, DOI 10.1093/molehr/gal120
   Kim JY, 2009, J CLIN ENDOCR METAB, V94, P1416, DOI 10.1210/jc.2008-1612
   Li ZX, 2008, MED HYPOTHESES, V70, P638, DOI 10.1016/j.mehy.2006.09.076
   Liao WX, 2000, MOL HUM REPROD, V6, P587, DOI 10.1093/molehr/6.7.587
   Bellido ML, 2010, BIOL REPROD, V82, P745, DOI 10.1095/biolreprod.109.082271
   Maliqueo M, 2003, FERTIL STERIL, V80, P812, DOI 10.1016/S0015-0282(03)00987-7
   Norman RJ, 2001, HUM REPROD, V16, P668, DOI 10.1093/humrep/16.4.668
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   ROBERTS VJ, 1994, J CLIN ENDOCR METAB, V79, P1434, DOI 10.1210/jc.79.5.1434
   Sakamoto Y, 1996, EUR J ENDOCRINOL, V135, P345, DOI 10.1530/eje.0.1350345
   Sasaki M, 2001, CANCER RES, V61, P97
   Stanssens P, 2004, GENOME RES, V14, P126
   Sullivan SD, 2004, P NATL ACAD SCI USA, V101, P7129, DOI 10.1073/pnas.0308058101
   Talbi S, 2006, ENDOCRINOLOGY, V147, P1097, DOI 10.1210/en.2005-1076
   Urbanek M, 1999, P NATL ACAD SCI USA, V96, P8573, DOI 10.1073/pnas.96.15.8573
   Xu N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027286
   Xu N, 2010, FERTIL STERIL, V94, P781, DOI 10.1016/j.fertnstert.2009.10.020
   Yamada N, 2009, BRIT J CANCER, V100, P344, DOI 10.1038/sj.bjc.6604845
   Zhao AM, 2011, MOL HUM REPROD, V17, P199, DOI 10.1093/molehr/gaq092
   Zhu JQ, 2010, MOL HUM REPROD, V16, P260, DOI 10.1093/molehr/gap089
NR 37
TC 20
Z9 21
U1 0
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1472-6483
J9 REPROD BIOMED ONLINE
JI Reprod. Biomed. Online
PD FEB
PY 2013
VL 26
IS 2
BP 157
EP 163
DI 10.1016/j.rbmo.2012.10.011
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 086DU
UT WOS:000314664400009
PM 23265961
DA 2025-01-12
ER

PT J
AU Zhang, XY
   Sun, Q
   Shan, M
   Niu, M
   Liu, T
   Xia, BS
   Liang, XS
   Wei, W
   Sun, SS
   Zhang, YX
   Liu, XS
   Song, QB
   Yang, YM
   Ma, YY
   Liu, Y
   Yang, L
   Ren, YL
   Zhang, GQ
   Pang, D
AF Zhang, Xianyu
   Sun, Qian
   Shan, Ming
   Niu, Ming
   Liu, Tong
   Xia, Bingshu
   Liang, Xiaoshuan
   Wei, Wei
   Sun, Shanshan
   Zhang, Youxue
   Liu, Xiaolong Sean
   Song, Qingbin
   Yang, Yanmei
   Ma, Yuyan
   Liu, Yang
   Yang, Long
   Ren, Yanlv
   Zhang, Guoqiang
   Pang, Da
TI Promoter Hypermethylation of ARID1A Gene Is Responsible for Its Low mRNA
   Expression in Many Invasive Breast Cancers
SO PLOS ONE
LA English
DT Article
ID SOMATIC MUTATIONS; PROTEIN P270; COMPLEXES; EPIGENETICS; COMPONENT
AB ARID1A (AT-rich interactive domain 1A) has recently been identified as a tumor suppressor gene. Its mRNA expression is significantly low in many breast cancers; this is often associated with more aggressive phenotypes. However, the underlying molecular mechanism for its low expression has not been fully understood. This study was undertaken to evaluate the contribution of gene copy number variation, mutations, promoter methylation and histone modification to ARID1A's low expression. 38 pairs of breast invasive ductal carcinomas and their normal breast tissue counterparts from the same patients were randomly selected for gene expression and copy number variation detection. Promoter methylation and histone modification levels were evaluated by MeDIP-qPCR and ChIP-qPCR, respectively. PCR product Sanger sequencing was carried out to detect the exon mutation rate. Twenty-two out of 38 invasive ductal carcinomas in the study (57.9%) revealed ARID1A mRNA low expression by realtime RT-PCR. The relative promoter methylation level was, significantly higher in ARID1A mRNA low expression group compared with its high expression group (p<0.001). In the low expression group, nineteen out of 22 invasive ductal carcinomas (86.4%) exhibited ARID1A promoter hypermthylation. In addition, the promoter hypermethylation was accompanied with repressive histone modification (H3K27Me3). Although five out of 38 invasive ductal carcinomas (13.2%) exhibited loss of ARID1A gene copy number by realtime PCR and nine exon novel mutations are seen from eight out of 33 invasive ductal carcinomas (24.2%), there was no statistically significant difference in both ARID1A mRNA low and high expression groups (p = 0.25, and p = 0.68, respectively). We demonstrate that promoter hypermethylation was the main culprit for ARID1A mRNA low expression in invasive ductal carcinomas. The influence of mutation and copy number variation on the expression were statistically insignificant at mRNA level, and were, therefore, not considered the main causes for ARID1A mRNA low expression in invasive breast cancer.
C1 [Zhang, Xianyu; Sun, Qian; Shan, Ming; Niu, Ming; Liu, Tong; Xia, Bingshu; Liang, Xiaoshuan; Wei, Wei; Sun, Shanshan; Zhang, Youxue; Ren, Yanlv; Zhang, Guoqiang; Pang, Da] Harbin Med Univ, Dept Breast Surg, Affiliated Hosp 3, Harbin, Heilongjiang, Peoples R China.
   [Liu, Xiaolong Sean] Harbin Med Univ, Dept Pathol, Affiliated Hosp 3, Harbin, Heilongjiang, Peoples R China.
   [Song, Qingbin] Mt Sinai Sch Med, Dept Med, New York, NY USA.
   [Yang, Yanmei; Ma, Yuyan; Pang, Da] Heilongjiang Inst Canc Res, Key Lab, Harbin, Heilongjiang, Peoples R China.
   [Yang, Long] Life Technol Corp, ICFC Custom Serv, Beijing, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Icahn School of
   Medicine at Mount Sinai; Thermo Fisher Scientific
RP Pang, D (通讯作者)，Harbin Med Univ, Dept Breast Surg, Affiliated Hosp 3, Harbin, Heilongjiang, Peoples R China.
EM pangda@ems.hrbmu.edu.cn
RI zhang, xiaoping/G-9688-2013; Zhang, Guo-Qiang/AAG-6817-2019; Wu,
   Guangyu/AAI-6122-2020; Ma, Yuyan/LKM-3343-2024
FU National Natural Science Foundation of China [81172498/H1622]; Harbin
   Science and Technology bureau [2011RFXYS056]; Postgraduate Innovation
   Research Fund of Heilongjiang Province [YJSCX2011-332-HLJ]; Research
   initiation Fund of the Third Affiliated Hospital of Harbin Medical
   University [JJ2010-24]
FX This work was supported by National Natural Science Foundation of China
   (81172498/H1622), Harbin Science and Technology bureau (2011RFXYS056),
   Postgraduate Innovation Research Fund of Heilongjiang Province
   (YJSCX2011-332-HLJ) and Research initiation Fund of the Third Affiliated
   Hospital of Harbin Medical University (JJ2010-24). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR [Anonymous], ONCOGENE
   Cancer Genome Atlas Network, 2012, Nature (London), V487, P330, DOI 10.1038/nature11252
   Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000
   Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596
   DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256
   Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Katagiri A, 2012, MODERN PATHOL, V25, P282, DOI 10.1038/modpathol.2011.161
   Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105
   Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386
   Nagl NG, 2005, CANCER RES, V65, P9236, DOI 10.1158/0008-5472.CAN-05-1225
   Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541
   Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109
   Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24
   Wang XM, 2004, INT J CANCER, V112, P636, DOI 10.1002/ijc.20450
   Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911
   Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433
   Zhang XY, 2012, CANCER EPIDEMIOL, V36, P288, DOI 10.1016/j.canep.2011.07.006
NR 21
TC 679
Z9 707
U1 1
U2 27
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 21
PY 2013
VL 8
IS 1
AR e53931
DI 10.1371/journal.pone.0053931
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 076FX
UT WOS:000313943000021
PM 23308293
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU van Roon, EH
   Boot, A
   Dihal, AA
   Ernst, RF
   van Wezel, T
   Morreau, H
   Boer, JM
AF van Roon, Eddy H.
   Boot, Arnoud
   Dihal, Ashwin A.
   Ernst, Robert F.
   van Wezel, Tom
   Morreau, Hans
   Boer, Judith M.
TI <i>BRAF</i> mutation-specific promoter methylation of <i>FOX</i> genes
   in colorectal cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE BRAF mutation; Colorectal cancer; DNA methylation; Histone pre-marking
ID TUMOR-SUPPRESSOR GENES; EMBRYONIC STEM-CELLS; DNA METHYLATION;
   COLON-CANCER; BREAST-CANCER; MICROSATELLITE INSTABILITY; SERRATED
   POLYPS; CPG; HYPERMETHYLATION; PHENOTYPE
AB Background: Cancer-specific hypermethylation of (promoter) CpG islands is common during the tumorigenesis of colon cancer. Although associations between certain genetic aberrations, such as BRAF mutation and microsatellite instability, and the CpG island methylator phenotype (CIMP), have been found, the mechanisms by which these associations are established are still unclear. We studied genome-wide DNA methylation differences between colorectal tumors carrying a BRAF mutation and BRAF wildtype tumors.
   Results: Using differential methylation hybridization on oligonucleotide microarrays representing 32,171 CpG-rich regions, we identified 1,770 regions with differential methylation between colorectal tumor and paired normal colon. Next, we compared the tumor/normal methylation ratios between different groups of patients. Related to CIMP, we identified 749 differentially methylated regions, of which 86% had a higher tumor/normal methylation ratio in the CIMP-positive group. We identified 758 regions with a BRAF mutation-specific methylation change, of which 96% had a higher tumor/normal methylation ratio in the BRAF mutant group. Among the genes affected by BRAF mutation-specific methylation changes, we found enrichment of several cancer-related pathways, including the PI3 kinase and Wnt signaling pathways. To focus on genes that are silenced in a tumor-specific rather than a lineage-specific manner, we used information on the epigenetic silencing mark H3K27me(3) in embryonic stem (ES) cells. Among the genes showing BRAF mutation-specific promoter methylation but no H3K27me(3) mark in ES cells were forkhead box (FOX) transcription factors associated with the PI3 kinase pathway, as well as MLH1 and SMO. Repression of FOXD3 gene expression in tumors could be related to its promoter hypermethylation.
   Conclusions: We identified new BRAF mutation-specific methylation changes in colorectal cancer. Epigenetic downregulation of these targets may contribute to mutationally active BRAF-driven tumorigenesis, explaining its association with aberrant DNA methylation.
C1 [van Roon, Eddy H.; Boot, Arnoud; Dihal, Ashwin A.; Boer, Judith M.] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands.
   [van Roon, Eddy H.; Boot, Arnoud; Dihal, Ashwin A.; van Wezel, Tom; Morreau, Hans] Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands.
   [Ernst, Robert F.; Boer, Judith M.] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol, Rotterdam, Netherlands.
   [Boer, Judith M.] Netherlands Bioinformat Ctr, Nijmegen, Netherlands.
C3 Leiden University - Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; Erasmus University
   Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital
RP Boer, JM (通讯作者)，Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands.
EM j.m.boer@erasmusmc.nl
RI Boer, Judith/A-7546-2010; van Wezel, Tom/AAL-5626-2021
OI Boot, Arnoud/0000-0002-7717-7416; van Wezel, Tom/0000-0001-5773-7730;
   Boer, Judith/0000-0003-4848-7789
CR Abel EV, 2010, CANCER RES, V70, P2891, DOI 10.1158/0008-5472.CAN-09-3139
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Carmona FJ, 2010, MUTAT RES-FUND MOL M, V693, P53, DOI 10.1016/j.mrfmmm.2010.07.007
   Celniker SE, 2009, NATURE, V459, P927, DOI 10.1038/459927a
   Core-Team R.-D., 2008, R LANG ENV STAT COMP
   de Keizer PLJ, 2010, CANCER RES, V70, P8526, DOI 10.1158/0008-5472.CAN-10-1563
   Deng GR, 1999, CANCER RES, V59, P2029
   Hinoue T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008357
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lewin J, 2004, BIOINFORMATICS, V20, P3005, DOI 10.1093/bioinformatics/bth346
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144
   Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576
   Margaritis T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.21
   Minoo P, 2007, J PATHOL, V212, P124, DOI 10.1002/path.2160
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nagasaka T, 2008, GASTROENTEROLOGY, V134, P1950, DOI 10.1053/j.gastro.2008.02.094
   Nakshatri H, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001008
   Nelms BL, 2011, SCI REP-UK, V1, DOI 10.1038/srep00106
   Niv Y, 2007, WORLD J GASTROENTERO, V13, P1767
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Parsons MT, 2012, J MED GENET, V49, P151, DOI 10.1136/jmedgenet-2011-100714
   Rada-Iglesias A, 2009, EPIGENETICS-US, V4, P107, DOI 10.4161/epi.4.2.8038
   Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   van Roon EHJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-180
   van Wezel T, 2005, BREAST CANCER RES, V7, pR998, DOI 10.1186/bcr1337
   Velho S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-255
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Xu XL, 2003, CANCER RES, V63, P4561
   Yamauchi M, 2012, GUT, V61, P794, DOI 10.1136/gutjnl-2012-302014
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yan PS, 2001, CANCER RES, V61, P8375
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
NR 45
TC 27
Z9 30
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JAN 16
PY 2013
VL 5
AR 2
DI 10.1186/1868-7083-5-2
PG 10
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 286FM
UT WOS:000329451700001
PM 23324568
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yuan, XY
   Yuan, ZT
   Jiang, DD
   Li, FN
AF Yuan Xunyi
   Yuan Zhentao
   Jiang Dandan
   Li Funian
TI Clinicopathological significance of PTPN12 expression in human breast
   cancer
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Breast cancer; Tumor suppressor gene; PTPN12; Prognosis; Methylation
ID PEST; MOTILITY
AB Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a recently identified tumor suppressor gene (TSG) that is frequently compromised in human triple-negative breast cancer. In the present study, we investigated the expression of PTPN12 protein by patients with breast cancer in a Chinese population and the relationship between PTPN12 expression levels and patient clinicopathological features and prognosis. Additionally, we explored the underlying down-regulation mechanism from the perspective of an epigenetic alteration. We examined PTPN12 mRNA expression in five breast cancer cell lines using semi-quantitative reverse-transcription PCR, and detected PTPN12 protein expression using immunohistochemistry in 150 primary invasive breast cancer cases and paired adjacent non-tumor tissues. Methylation-specific PCR was performed to analyze the promoter CpG island methylation status of PTPN12. PTPN12 was significantly down-regulated in breast cancer cases (48/150) compared to adjacent noncancerous tissues (17/150; P < 0.05). Furthermore, low expression of PTPN12 showed a significant positive correlation with tumor size (P = 0.047), lymph node metastasis (P = 0.001), distant metastasis (P = 0.009), histological grade (P = 0.012), and survival time (P = 0.019). Additionally, promoter CpG island hypermethylation occurs more frequently in breast cancer cases and breast cancer cell lines with low PTPN12 expression. Our findings suggest that PTPN12 is potentially a methylation-silenced TSG for breast cancer that may play an important role in breast carcinogenesis and could potentially serve as an independent prognostic factor for invasive breast cancer patients.
C1 [Yuan Xunyi; Jiang Dandan; Li Funian] Qingdao Univ, Affiliated Hosp, Coll Med, Breast Dis Diag & Treatment Ctr, Qingdao 266003, Shandong, Peoples R China.
   [Yuan Zhentao] Shengli Oilfield Cent Hosp, Dept Anesthesiol, Dongying, Shandong, Peoples R China.
C3 Qingdao University
RP Li, FN (通讯作者)，Qingdao Univ, Affiliated Hosp, Coll Med, Breast Dis Diag & Treatment Ctr, Qingdao 266003, Shandong, Peoples R China.
EM yzhtyxy@163.com
RI wang, jiaqi/JSL-7112-2023
FU Natural Science Foundation of Shandong China [Y2007C124]
FX Research supported by the Natural Science Foundation of Shandong China
   Grant (#Y2007C124).
CR Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chae BJ, 2011, PATHOLOGY, V43, P248, DOI 10.1097/PAT.0b013e328344e2c4
   Espejo R, 2010, AM J PHYSIOL-CELL PH, V299, pC454, DOI 10.1152/ajpcell.00148.2010
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275
   Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC2288, DOI 10.1152/ajpcell.00503.2006
   Streit S, 2006, CANCER GENET CYTOGEN, V170, P48, DOI 10.1016/j.cancergencyto.2006.05.013
   Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003
   Villa-Moruzzi E, 2011, ANAL CELL PATHOL, V34, P101, DOI [10.1155/2011/870459, 10.3233/ACP-2011-0008]
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
NR 13
TC 17
Z9 21
U1 0
U2 6
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD DEC
PY 2012
VL 45
IS 12
BP 1334
EP 1340
DI 10.1590/S0100-879X2012007500163
PG 7
WC Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 056BK
UT WOS:000312461700033
PM 23044628
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, YY
   Chen, HP
   Hardy, TM
   Tollefsbol, TO
AF Li, Yuanyuan
   Chen, Huaping
   Hardy, Tabitha M.
   Tollefsbol, Trygve O.
TI Epigenetic Regulation of Multiple Tumor-Related Genes Leads to
   Suppression of Breast Tumorigenesis by Dietary Genistein
SO PLOS ONE
LA English
DT Article
ID CHROMATIN MODIFICATIONS; CANCER PREVENTION; DNA METHYLATION; CELLS; SOY;
   IMPACT; HYPERMETHYLATION; ISOFLAVONES; MECHANISMS; MUTATIONS
AB Breast cancer is one of the most lethal diseases in women; however, the precise etiological factors are still not clear. Genistein (GE), a natural isoflavone found in soybean products, is believed to be a potent chemopreventive agent for breast cancer. One of the most important mechanisms for GE inhibition of breast cancer may involve its potential in impacting epigenetic processes allowing reversal of aberrant epigenetic events during breast tumorigenesis. To investigate epigenetic regulation for GE impedance of breast tumorigenesis, we monitored epigenetic alterations of several key tumor-related genes in an established breast cancer transformation system. Our results show that GE significantly inhibited cell growth in a dose-dependent manner in precancerous breast cells and breast cancer cells, whereas it exhibited little effect on normal human mammary epithelial cells. Furthermore, GE treatment increased expression of two crucial tumor suppressor genes, p21(WAF1) (p21) and p16(INK4a) (p16), although it decreased expression of two tumor promoting genes, BMI1 and c-MYC. GE treatment led to alterations of histone modifications in the promoters of p21 and p16 as well as the binding ability of the c-MYC-BMI1 complex to the p16 promoter contributing to GE-induced epigenetic activation of these tumor suppressor genes. In addition, an orally-fed GE diet prevented breast tumorigenesis and inhibited breast cancer development in breast cancer mice xenografts. Our results suggest that genistein may repress early breast tumorigenesis by epigenetic regulation of p21 and p16 by impacting histone modifications as well as the BMI1-c-MYC complex recruitment to the regulatory region in the promoters of these genes. These studies will facilitate more effective use of soybean product in breast cancer prevention and also help elucidate the mechanisms during the process of early breast tumorigenesis.
C1 [Li, Yuanyuan; Chen, Huaping; Hardy, Tabitha M.; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Aging, Birmingham, AL USA.
   [Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Li, YY (通讯作者)，Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
EM lyy@uab.edu
RI Chen, Huaping/O-3096-2014
FU American Institute for Cancer Research (AICR); National Cancer Institute
   [CA 129415]; Susan G Komen for the Cure; American Cancer Society Award
   [IRG-60-001-47]; AICR; American Cancer Society Award; UAB Comprehensive
   Cancer Center [CA 13148-31]
FX This work was supported by grants from the American Institute for Cancer
   Research (AICR), the National Cancer Institute (CA 129415), Susan G
   Komen for the Cure and the American Cancer Society Award
   (IRG-60-001-47). YL was supported by a Postdoctoral Award sponsored by
   AICR and a Junior Faculty Development Grant by American Cancer Society
   Award and UAB Comprehensive Cancer Center (CA 13148-31). The authors
   declare that they have no financial interests. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Bradbury AR, 2007, REV ENDOCR METAB DIS, V8, P255, DOI 10.1007/s11154-007-9038-0
   Casillas MA, 2003, MOL CELL BIOCHEM, V252, P33, DOI 10.1023/A:1025548623524
   DeAngelis JT, 2011, J PROTEOME RES, V10, P447, DOI 10.1021/pr100533k
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Fritz WA, 2002, MOL CELL ENDOCRINOL, V186, P89, DOI 10.1016/S0303-7207(01)00663-3
   Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   HARPER JW, 1993, CELL, V75, P805
   HENDERSON BE, 1991, BREAST CANCER RES TR, V18, pS11, DOI 10.1007/BF02633520
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678
   King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li Y, 2012, MOL CANC
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Li YY, 2010, FASEB J, V24, P1442, DOI 10.1096/fj.09-149328
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Mai ZM, 2007, CARCINOGENESIS, V28, P1217, DOI 10.1093/carcin/bgm004
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Mentor-Marcel R, 2001, CANCER RES, V61, P6777
   Messina M, 2006, JNCI-J NATL CANCER I, V98, P1275, DOI 10.1093/jnci/djj356
   MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746
   Nielsen ILF, 2007, NUTR CANCER, V57, P1, DOI 10.1080/01635580701267677
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Papp B, 2006, GENE DEV, V20, P2041, DOI 10.1101/gad.388706
   Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Shon YH, 2006, J BIOCHEM MOL BIOL, V39, P448
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Wiklund ED, 2010, EPIGENOMICS-UK, V2, P823, DOI 10.2217/EPI.10.51
NR 44
TC 25
Z9 27
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2013
VL 8
IS 1
AR e54369
DI 10.1371/journal.pone.0054369
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 087KE
UT WOS:000314759400156
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Montenegro, MF
   Sáez-Ayala, M
   Piñero-Madrona, A
   Cabezas-Herrera, J
   Rodríguez-López, JN
AF Montenegro, Maria F.
   Saez-Ayala, Magali
   Pinero-Madrona, Antonio
   Cabezas-Herrera, Juan
   Neptuno Rodriguez-Lopez, Jose
TI Reactivation of the Tumour Suppressor <i>RASSF1A</i> in Breast Cancer by
   Simultaneous Targeting of DNA and E2F1 Methylation
SO PLOS ONE
LA English
DT Article
ID TAMOXIFEN RESISTANCE; PHOSPHATASE 2A; MST2 PATHWAY; CELL-DEATH; PROTEIN;
   DAMAGE; RAS; 3-O-(3,4,5-TRIMETHOXYBENZOYL)-(-)-EPICATECHIN;
   METHOTREXATE; ACETYLATION
AB Background: Tumour suppressor genes are often transcriptionally silenced by promoter hypermethylation, and recent research has implicated alterations in chromatin structure as the mechanistic basis for this repression. In addition to DNA methylation, other epigenetic post-translational modifications that modulate the stability and binding of specific transcription factors to gene promoters have emerged as important mechanisms for controlling gene expression. The aim of this study was to analyse the implications of these mechanisms and their molecular connections in the reactivation of RASSF1A in breast cancer.
   Methods: Compounds that modulate the intracellular concentration of adenosine, such as dipyridamole (DIPY), greatly increase the antiproliferative effects of 3-O-(3,4,5-trimethoxybenzoyl)-(-)-catechin (TMCG), a synthetic antifolate derived from the structure of tea catechins. Quantitative real-time PCR arrays and MALDI-TOF mass spectrometry indicated that this combination (TMCG/DIPY) induced apoptosis in breast cancer cells by modulating the methylation levels of DNA and proteins (such as E2F1), respectively. Chromatin immunoprecipitation (ChIP) assays were employed to confirm that this combination induced chromatin remodelling of the RASSF1A promoter and increased the occupancy of E2F1 at the promoter of this tumour suppressor gene.
   Results: The TMCG/DIPY combination acted as an epigenetic treatment that reactivated RASSF1A expression and induced apoptosis in breast cancer cells. In addition to modulating DNA methylation and chromatin remodelling, this combination also induced demethylation of the E2F1 transcription factor. The ChIP assay showed enhancement of E2F1 occupancy at the unmethylated RASSF1A promoter after TMCG/DIPY treatment. Interestingly, inhibition of E2F1 demethylation using an irreversible inhibitor of lysine-specific demethylase 1 reduced both TMCG/DIPY-mediated RASSF1A expression and apoptosis in MDA-MB-231 cells, suggesting that DNA and protein demethylation may act together to control these molecular and cellular processes.
   Conclusions/Significance: This study demonstrates that simultaneous targeting of DNA and E2F1 methylation is an effective epigenetic treatment that reactivates RASSF1A expression and induces apoptosis in breast cancer cells. Citation: Montenegro MF, Saez-Ayala M, Pinero-Madrona A, Cabezas-Herrera J, Rodriguez-Lopez JN (2012) Reactivation of the Tumour Suppressor RASSF1A in Breast Cancer by Simultaneous Targeting of DNA and E2F1 Methylation. PLoS ONE 7(12): e52231. doi: 10.1371/journal.pone.0052231
C1 [Montenegro, Maria F.; Saez-Ayala, Magali; Neptuno Rodriguez-Lopez, Jose] Univ Murcia, Dept Biochem & Mol Biol A, Sch Biol, Murcia, Spain.
   [Pinero-Madrona, Antonio] Univ Hosp Virgen Arrixaca, Inst Murciano Invest Biomed, Dept Surg, Murcia, Spain.
   [Cabezas-Herrera, Juan] Univ Hosp Virgen Arrixaca, Inst Murciano Invest Biomed, Translat Canc Res Grp, Murcia, Spain.
C3 University of Murcia; Hospital Clinico Universitario Virgen de la
   Arrixaca; Hospital Clinico Universitario Virgen de la Arrixaca
RP Rodríguez-López, JN (通讯作者)，Univ Murcia, Dept Biochem & Mol Biol A, Sch Biol, Reg Campus Int Excellence,Campus Mare Nostrum, Murcia, Spain.
EM neptuno@um.es
RI Piñero-Madrona, Antonio/AAB-5138-2022; Montenegro, Maria/AAF-2695-2021;
   CABEZAS-HERRERA, JUAN/J-9434-2015; Neptuno, Jose/F-5012-2016;
   Cabezas-Herrera, Juan/F-3850-2016; Saez Ayala, Magali/T-9810-2017
OI Cabezas-Herrera, Juan/0000-0001-9053-5380; Cabezas-Herrera,
   Juan/0000-0002-6833-4977; Saez Ayala, Magali/0000-0002-8726-0053;
   Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173; Pinero-Madrona,
   Antonio/0000-0002-7718-8318; Montenegro, Maria
   Fernanda/0000-0002-0064-0484
FU Ministerio de Ciencia e Innovacion (MICINN) [SAF2009-12043-C02-01];
   Fundacion Seneca, Region de Murcia (FS-RM) [15230/PI/10]; EU
   [ERA293514]; Fundacion para la Formacion e Investigacion Sanitaria de la
   region de Murcia (FFIS); Fundacion Cientifica de la Asociacion Espanola
   contra el Cancer (FCAECC)
FX This work was supported by grants from Ministerio de Ciencia e
   Innovacion (MICINN) (SAF2009-12043-C02-01), Fundacion Seneca, Region de
   Murcia (FS-RM) (15230/PI/10), and EU ERA293514. J.C-H is contracted by
   the Fundacion para la Formacion e Investigacion Sanitaria de la region
   de Murcia (FFIS). M.F.M is contracted by Fundacion Cientifica de la
   Asociacion Espanola contra el Cancer (FCAECC). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Cellarier E, 2003, CANCER TREAT REV, V29, P489, DOI 10.1016/S0305-7372(03)00118-X
   Chang JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012847
   Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004
   Guo C, 2011, J BIOL CHEM, V286, P6253, DOI 10.1074/jbc.M110.178210
   Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076
   Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359
   Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780
   Kawamoto K, 2007, CLIN CANCER RES, V13, P2541, DOI 10.1158/1078-0432.CCR-06-2225
   Kontaki H, 2010, CELL CYCLE, V9, P3836, DOI 10.4161/cc.9.19.13384
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025
   Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043
   Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255
   Lin WC, 2001, GENE DEV, V15, P1833
   Liu L, 2008, ONCOGENE, V27, P6175, DOI 10.1038/onc.2008.220
   Louie MC, 2010, MOL CANCER RES, V8, P343, DOI 10.1158/1541-7786.MCR-09-0395
   Martínez-Balbás MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662
   Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008
   Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016
   Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121
   Sáez-Ayala M, 2012, EXP CELL RES, V318, P1146, DOI 10.1016/j.yexcr.2012.03.022
   Sáez-Ayala M, 2011, CHEMMEDCHEM, V6, P440, DOI 10.1002/cmdc.201000482
   Sánchez-del-Campo L, 2008, INT J CANCER, V123, P2446, DOI 10.1002/ijc.23813
   Sánchez-del-Campo L, 2009, MOL PHARMACEUT, V6, P883, DOI 10.1021/mp800259k
   Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Tian YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017017
   Tommasi S, 2005, CANCER RES, V65, P92
   Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004
   Winter-Vann AM, 2003, P NATL ACAD SCI USA, V100, P6529, DOI 10.1073/pnas.1135239100
   Xie Q, 2011, J RECEPT SIG TRANSD, V31, P139, DOI 10.3109/10799893.2011.552914
   Yan PS, 2003, CANCER RES, V63, P6178
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 41
TC 24
Z9 27
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 14
PY 2012
VL 7
IS 12
AR e52231
DI 10.1371/journal.pone.0052231
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 055AJ
UT WOS:000312386800153
PM 23251702
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Yu, HX
   Simons, DL
   Segall, I
   Carcamo-Cavazos, V
   Schwartz, EJ
   Yan, N
   Zuckerman, NS
   Dirbas, FM
   Johnson, DL
   Holmes, SP
   Lee, PP
AF Yu, Hongxiang
   Simons, Diana L.
   Segall, Ilana
   Carcamo-Cavazos, Valeria
   Schwartz, Erich J.
   Yan, Ning
   Zuckerman, Neta S.
   Dirbas, Frederick M.
   Johnson, Denise L.
   Holmes, Susan P.
   Lee, Peter P.
TI PRC2/EED-EZH2 Complex Is Up-Regulated in Breast Cancer Lymph Node
   Metastasis Compared to Primary Tumor and Correlates with Tumor
   Proliferation <i>In Situ</i>
SO PLOS ONE
LA English
DT Article
ID EXPRESSION PROFILES; EZH2 EXPRESSION; GENE; SIGNATURE; PATHWAY;
   OVEREXPRESSION; TRANSFORMATION; DEREGULATION; PROGRESSION; PROSTATE
AB Background: Lymph node metastasis is a key event in the progression of breast cancer. Therefore it is important to understand the underlying mechanisms which facilitate regional lymph node metastatic progression.
   Methodology/Principal Findings: We performed gene expression profiling of purified tumor cells from human breast tumor and lymph node metastasis. By microarray network analysis, we found an increased expression of polycomb repression complex 2 (PRC2) core subunits EED and EZH2 in lymph node metastatic tumor cells over primary tumor cells which were validated through real-time PCR. Additionally, immunohistochemical (IHC) staining and quantitative image analysis of whole tissue sections showed a significant increase of EZH2 expressing tumor cells in lymph nodes over paired primary breast tumors, which strongly correlated with tumor cell proliferation in situ. We further explored the mechanisms of PRC2 gene up-regulation in metastatic tumor cells and found up-regulation of E2F genes, MYC targets and down-regulation of tumor suppressor gene E-cadherin targets in lymph node metastasis through GSEA analyses. Using IHC, the expression of potential EZH2 target, E-cadherin was examined in paired primary/lymph node samples and was found to be significantly decreased in lymph node metastases over paired primary tumors.
   Conclusions/Significance: This study identified an over expression of the epigenetic silencing complex PRC2/EED-EZH2 in breast cancer lymph node metastasis as compared to primary tumor and its positive association with tumor cell proliferation in situ. Concurrently, PRC2 target protein E-cadherin was significant decreased in lymph node metastases, suggesting PRC2 promotes epithelial mesenchymal transition (EMT) in lymph node metastatic process through repression of E-cadherin. These results indicate that epigenetic regulation mediated by PRC2 proteins may provide additional advantage for the outgrowth of metastatic tumor cells in lymph nodes. This opens up epigenetic drug development possibilities for the treatment and prevention of lymph node metastasis in breast cancer. Citation: Yu H, Simons DL, Segall I, Carcamo-Cavazos V, Schwartz EJ, et al. (2012) PRC2/EED-EZH2 Complex Is Up-Regulated in Breast Cancer Lymph Node Metastasis Compared to Primary Tumor and Correlates with Tumor Proliferation In Situ. PLoS ONE 7(12): e51239. doi:10.1371/journal.pone.0051239
C1 [Yu, Hongxiang; Simons, Diana L.; Carcamo-Cavazos, Valeria; Yan, Ning; Zuckerman, Neta S.; Lee, Peter P.] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA.
   [Segall, Ilana; Holmes, Susan P.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
   [Schwartz, Erich J.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA.
   [Dirbas, Frederick M.; Johnson, Denise L.] Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA.
   [Simons, Diana L.; Zuckerman, Neta S.; Lee, Peter P.] City Hope Canc Ctr, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA USA.
C3 Stanford University; Stanford University; Stanford University; Stanford
   University; City of Hope
RP Lee, PP (通讯作者)，Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA.
EM plee@coh.org
RI Holmes, Susan P./JGL-6344-2023; Yan, Ning/HTT-1384-2023
FU Department of Defense Congressionally Directed Medical Research Programs
   [BC01560]; NIH [R01GM086884]
FX This work was supported by grants from the Department of Defense
   Congressionally Directed Medical Research Programs grant no. BC01560 to
   P.P.L. S.H. was supported by NIH grant no. R01GM086884. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Agiostratidou G, 2007, J MAMMARY GLAND BIOL, V12, P127, DOI 10.1007/s10911-007-9044-6
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Becker KF, 2007, CELLS TISSUES ORGANS, V185, P204, DOI 10.1159/000101321
   Bossi A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.17
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Carvalho J, 2012, J PATHOL, V228, P31, DOI 10.1002/path.4032
   Ellsworth RE, 2009, CLIN EXP METASTAS, V26, P205, DOI 10.1007/s10585-008-9232-9
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feng YM, 2007, BREAST CANCER RES TR, V103, P319, DOI 10.1007/s10549-006-9385-7
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Halsted W S, 1898, Ann Surg, V28, P557
   Hao XS, 2004, CANCER-AM CANCER SOC, V100, P1110, DOI 10.1002/cncr.20095
   Jatoi I, 1999, J CLIN ONCOL, V17, P2334, DOI 10.1200/JCO.1999.17.8.2334
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327
   Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Nacu S, 2007, BIOINFORMATICS, V23, P850, DOI 10.1093/bioinformatics/btm019
   Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Rodenhiser DI, 2009, CLIN EXP METASTAS, V26, P5, DOI 10.1007/s10585-008-9166-2
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Setiadi AF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012420
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vecchi M, 2008, ONCOGENE, V27, P2148, DOI 10.1038/sj.onc.1210858
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wu SC, 2011, J BIOL CHEM, V286, P28511, DOI 10.1074/jbc.M111.240515
NR 35
TC 36
Z9 37
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2012
VL 7
IS 12
AR e51239
DI 10.1371/journal.pone.0051239
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 052ML
UT WOS:000312201900057
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Raviraj, V
   Fok, S
   Zhao, JF
   Chien, HY
   Lyons, JG
   Thompson, EW
   Soon, L
AF Raviraj, Vanisri
   Fok, Sandra
   Zhao, Jifei
   Chien, Hsin-Ya
   Lyons, J. Guy
   Thompson, Erik W.
   Soon, Lilian
TI Regulation of ROCK1 via Notch1 during breast cancer cell migration into
   dense matrices
SO BMC CELL BIOLOGY
LA English
DT Article
DE Breast cancer; High-density matrix; Cancer cell migration; ROCK
   expression; Histone deacetylase inhibitors
ID HISTONE DEACETYLASE; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; VALPROIC
   ACID; GROWTH-FACTOR; EPITHELIAL-CELL; MAMMARY-GLAND; COLLAGEN; RHO;
   INVASION
AB Background: The behaviour of tumour cells depends on factors such as genetics and the tumour microenvironment. The latter plays a crucial role in normal mammary gland development and also in breast cancer initiation and progression. Breast cancer tissues tend to be highly desmoplastic and dense matrix as a pre-existing condition poses one of the highest risk factors for cancer development. However, matrix influence on tumour cell gene expression and behaviour such as cell migration is not fully elucidated.
   Results: We generated high-density (HD) matrices that mimicked tumour collagen content of 20 mg/cm(3) that were similar to 14-fold stiffer than low-density (LD) matrix of 1 mg/cm(3). Live-cell imaging showed breast cancer cells utilizing cytoplasmic streaming and cell body contractility for migration within HD matrix. Cell migration was blocked in the presence of both the ROCK inhibitor, Y-27632, and the MMP inhibitor, GM6001, but not by the drugs individually. This suggests roles for ROCK1 and MMP in cell migration are complicated by compensatory mechanisms. ROCK1 expression and protein activity, were significantly upregulated in HD matrix but these were blocked by treatment with a histone deacetylase (HDAC) inhibitor, MS-275. In HD matrix, the inhibition of ROCK1 by MS-275 was indirect and relied upon protein synthesis and Notch1. Inhibition of Notch1 using pooled siRNA or DAPT abrogated the inhibition of ROCK1 by MS-275.
   Conclusion: Increased matrix density elevates ROCK1 activity, which aids in cell migration via cell contractility. The upregulation of ROCK1 is epigenetically regulated in an indirect manner involving the repression of Notch1. This is demonstrated from inhibition of HDACs by MS-275, which caused an upregulation of Notch1 levels leading to blockade of ROCK1 expression.
C1 [Raviraj, Vanisri; Fok, Sandra; Zhao, Jifei; Chien, Hsin-Ya; Soon, Lilian] Univ Sydney, AMMRF, ACMM, Sydney, NSW 2006, Australia.
   [Lyons, J. Guy] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia.
   [Thompson, Erik W.] St Vincents Inst Med Res, Invas & Metastasis Unit, Melbourne, Vic, Australia.
   [Thompson, Erik W.] Univ Melbourne, St Vincents Hosp, Dept Surg, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; St. Vincent's Institute of
   Medical Research; NSW Health; St Vincents Hospital Sydney; St Vincent's
   Health; St Vincent's Hospital Melbourne; University of Melbourne
RP Soon, L (通讯作者)，Univ Sydney, AMMRF, ACMM, Sydney, NSW 2006, Australia.
EM lilian.soon@sydney.edu.au
RI Thompson, Erik Walter/A-1425-2009; Lyons, Guy/B-1319-2012
OI Thompson, Erik Walter/0000-0002-9723-4924; Lyons,
   Guy/0000-0002-4835-4663; Raviraj, Vanisri/0000-0003-4646-8576
FU NHMRC [402510, 571200]; ARC [DP0881012]; St Vincent's Hospital Research
   Endowment Fund; VBCRC; FABLS; Australian Research Council [DP0881012]
   Funding Source: Australian Research Council
FX This work was supported by the NHMRC (#402510), ARC (#DP0881012), St
   Vincent's Hospital Research Endowment Fund, VBCRC and FABLS, and was
   conducted with human ethics approvals (USyd #09-2009/12168 and Peter
   MacCallum #08/21). VR is funded by the NHMRC biomedical scholarship
   (#571200). We gratefully acknowledge AMMRF, AKCMM, EMU, Sydney,
   Australia for use of the facility and Dr Renee Whan and Mr Dennis Dwarte
   for technical assistance. We thank Prof. John Condeelis for kindly
   providing the MTLn3 cells, Ms Joyce Lin, Dexing Huang and the Peter
   MacCallum Tissue Bank for assistance with the mammary tissue accrual and
   Assoc. Prof Jenny Cawson, and others at Breast Screen, Vic, for
   mammography imaging. We also thank Assoc. Prof. Prue Hill, St. Vincent's
   Pathology, Melbourne, for assistance with histopathological assessments
   of tissues.
CR Adler JT, 2008, SURGERY, V144, P956, DOI 10.1016/j.surg.2008.08.027
   Albini A, 2005, CANCER RES, V65, P10637, DOI 10.1158/0008-5472.CAN-05-3473
   Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090
   Alowami S, 2003, BREAST CANCER RES, V5, pR129, DOI 10.1186/bcr622
   Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418
   Anderson RB, 2010, INT J DEV BIOL, V54, P63, DOI 10.1387/ijdb.082667ra
   ANGERVO M, 1993, J MOL ENDOCRINOL, V10, P7, DOI 10.1677/jme.0.0100007
   Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002
   Besseau L, 2002, BIOMATERIALS, V23, P27, DOI 10.1016/S0142-9612(01)00075-8
   Cai FF, 2011, INT J MOL SCI, V12, P4465, DOI 10.3390/ijms12074465
   CAPALDI MJ, 1982, BIOPOLYMERS, V21, P2291, DOI 10.1002/bip.360211115
   Clementz AG, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2407
   del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238
   ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476
   Falzon G, 2008, PHYS MED BIOL, V53, P6641, DOI 10.1088/0031-9155/53/23/001
   Fan SS, 2005, J VIROL METHODS, V125, P23, DOI 10.1016/j.jviromet.2004.11.023
   Friedl P, 2001, J LEUKOCYTE BIOL, V70, P491
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Gadea G, 2008, CURR BIOL, V18, P1456, DOI 10.1016/j.cub.2008.08.053
   Greenblatt DY, 2008, ANN SURG, V247, P1036, DOI 10.1097/SLA.0b013e3181758d0e
   Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541
   Ilunga K, 2004, INT J EXP PATHOL, V85, P373, DOI 10.1111/j.0959-9673.2004.00406.x
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025
   Kim HG, 2011, J BIOL CHEM, V286, P17672, DOI 10.1074/jbc.M111.236612
   Kim YB, 2005, J BIOL CHEM, V280, P28357, DOI 10.1074/jbc.M412608200
   Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245
   Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3
   Lämmermann T, 2008, NATURE, V453, P51, DOI 10.1038/nature06887
   Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170
   Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707
   Leung T, 1996, MOL CELL BIOL, V16, P5313
   LIAN JB, 1973, BIOCHIM BIOPHYS ACTA, V328, P193, DOI 10.1016/0005-2795(73)90345-0
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9
   Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299
   Mongan NP, 2005, MOL CANCER THER, V4, P477
   Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960
   Nervi C, 2001, CANCER RES, V61, P1247
   OBRIG TG, 1971, J BIOL CHEM, V246, P174
   Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825
   Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7
   Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11
   Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   ROLLINS BJ, 1989, ADV CANCER RES, V53, P1
   Ruppender NS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015451
   Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188
   Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028
   Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019
   Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592
   Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043
   Shabason JE, 2010, ONCOLOGY-NY, V24, P180
   Srivastava RK, 2010, MOL CANCER THER, V9, P3254, DOI 10.1158/1535-7163.MCT-10-0582
   Suzuki T, 1999, J MED CHEM, V42, P3001, DOI 10.1021/jm980565u
   Ursin G, 2005, BREAST CANCER RES, V7, pR605, DOI 10.1186/bcr1260
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230
   Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431
   Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006
   Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616
   Wolf K, 2009, SEMIN CELL DEV BIOL, V20, P931, DOI 10.1016/j.semcdb.2009.08.005
   Wozniak MA, 2003, J CELL BIOL, V163, P583, DOI 10.1083/jcb.200305010
   Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065
   Yim JH, 2008, SURGERY, V144, P961
   Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06
   Zaman MH, 2006, P NATL ACAD SCI USA, V103, P10889, DOI 10.1073/pnas.0604460103
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 72
TC 25
Z9 29
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD MAY 14
PY 2012
VL 13
AR 12
DI 10.1186/1471-2121-13-12
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 054AW
UT WOS:000312317400001
PM 22583596
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Verschuur-Maes, AHJ
   de Bruin, PC
   Diest, PJ
AF Verschuur-Maes, Anoek H. J.
   de Bruin, Peter C.
   van Diest, Paul J.
TI Epigenetic progression of columnar cell lesions of the breast to
   invasive breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Columnar cell lesions; Flat epithelial atypia; MS-MLPA; Methylation;
   Breast
ID CARCINOMA IN-SITU; FLAT EPITHELIAL ATYPIA; PROMOTER METHYLATION;
   SPORADIC BREAST; DNA METHYLATION; ABERRANT METHYLATION; CPG ISLANDS;
   HYPERMETHYLATION; INACTIVATION; EXPRESSION
AB Promoter hypermethylation of several tumour suppressor genes often occurs during breast carcinogenesis, but little is known about epigenetic silencing in the possible precursor columnar cell lesion (CCL). Promoter hypermethylation of 50 different tumour suppressor genes was assessed in normal breast tissue (N = 10), CCL (N = 15), ductal carcinoma in situ (DCIS) grade I originating in CCL (N = 5) and paired CCL (N = 15) with DCIS (N = 7) and/or invasive carcinoma (N = 14) by Methylation-specific multiplex ligation-dependent probe amplification. Increasing mean cumulative methylation levels were found from normal breast tissue to CCL to DCIS and invasive carcinoma (P < 0.001) with similar methylation levels in DCIS and invasive carcinoma. Methylation levels and frequencies (in the overall analysis and analysis of only the synchronous lesions) were the highest for RASSF1, CCND2, ID4, SCGB3A1 and CDH13. The methylation levels of ID4, CCND2, and CDH13 increased significantly from normal breast tissue to CCL and to DCIS/invasive carcinoma. RASSF1, SCGB3A1 and SFRP5 had significant higher methylation levels in CCL compared to normal breast tissue, but showed no significant differences between CCL, DCIS and invasive carcinoma. Also, no difference was found between CCLs with and without atypia, or CCLs with or without synchronous cancer. In conclusion, promoter hypermethylation for several established tumour suppressor genes is already present in CCLs, underlining that promoter hypermethylation is an early event in breast carcinogenesis. Atypia in CCL or the presence of synchronous more advanced lesions does not seem to be accompanied by higher methylation levels.
C1 [Verschuur-Maes, Anoek H. J.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, Ctr Canc, NL-3508 GA Utrecht, Netherlands.
   [de Bruin, Peter C.] St Antonius Hosp Nieuwegein, Dept Pathol, Nieuwegein, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; St. Antonius
   Hospital Utrecht
RP Diest, PJ (通讯作者)，Univ Med Ctr Utrecht, Dept Pathol, Ctr Canc, POB 85500, NL-3508 GA Utrecht, Netherlands.
EM p.j.vandiest@umcutrecht.nl
FU Oncology Centre of St. Antonius Hospital Nieuwegein
FX This work was supported by The Oncology Centre of St. Antonius Hospital
   Nieuwegein.
CR Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047
   [Anonymous], 2003, WHO CLASSIFICATION T
   Aulmann S, 2009, AM J SURG PATHOL, V33, P1646, DOI 10.1097/PAS.0b013e3181adfdcf
   Bertolo C, 2008, AM J CLIN PATHOL, V130, P414, DOI 10.1309/J3QV9763DYPV338D
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Chen CM, 2003, AM J PATHOL, V163, P37, DOI 10.1016/S0002-9440(10)63628-0
   Dabbs DJ, 2006, MODERN PATHOL, V19, P344, DOI 10.1038/modpathol.3800538
   Ellsworth RE, 2010, ANN SURG ONCOL, V17, P1688, DOI 10.1245/s10434-010-0910-x
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evron E, 2001, CANCER RES, V61, P2782
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Feeley L, 2008, HISTOPATHOLOGY, V52, P11, DOI 10.1111/j.1365-2559.2007.02890.x
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Gylling A, 2007, GUT, V56, P926, DOI 10.1136/gut.2006.114876
   Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Joensuu EI, 2008, CANCER RES, V68, P4597, DOI 10.1158/0008-5472.CAN-07-6645
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Lee S, 2007, AM J PATHOL, V171, P252, DOI 10.2353/ajpath.2007.061010
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Liu TJ, 2008, HUM PATHOL, V39, P1637, DOI 10.1016/j.humpath.2008.04.001
   Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002
   Moelans CB, 2010, ANAL CELL PATHOL, V33, P165, DOI [10.1155/2010/829358, 10.3233/ACP-CLO-2010-0546]
   Moinfar F, 2000, CANCER-AM CANCER SOC, V88, P2072, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2072::AID-CNCR13>3.3.CO;2-8
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Qi LQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-163
   Schnitt SJ, 2003, ADV ANAT PATHOL, V10, P113, DOI 10.1097/00125480-200305000-00001
   Seeber LMS, 2010, ENDOCR-RELAT CANCER, V17, P663, DOI 10.1677/ERC-10-0014
   Shigematsu H, 2005, INT J CANCER, V113, P600, DOI 10.1002/ijc.20622
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Simpson PT, 2005, AM J SURG PATHOL, V29, P734, DOI 10.1097/01.pas.0000157295.93914.3b
   Sinn HP, 2009, J MOL MED, V87, P113, DOI 10.1007/s00109-008-0435-y
   Subramaniam MM, 2010, HISTOPATHOLOGY, V57, P555, DOI 10.1111/j.1365-2559.2010.03675.x
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Suijkerbuijk KPM, 2010, ANAL CELL PATHOL, V33, P133, DOI [10.1155/2010/185219, 10.3233/ACP-CLO-2010-0542]
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   van Diest PJ, 2010, ANAL CELL PATHOL, V33, P175, DOI [10.1155/2010/852197, 10.3233/ACP-CLO-2010-0543]
   van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Verschuur-Maes AHJ, 2012, ANN SURG, V255, P259, DOI 10.1097/SLA.0b013e318233523f
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
NR 52
TC 36
Z9 42
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2012
VL 136
IS 3
BP 705
EP 715
DI 10.1007/s10549-012-2301-4
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 050RF
UT WOS:000312071000008
PM 23104224
DA 2025-01-12
ER

PT J
AU Hansmann, T
   Pliushch, G
   Leubner, M
   Kroll, P
   Endt, D
   Gehrig, A
   Preisler-Adams, S
   Wieacker, P
   Haaf, T
AF Hansmann, Tamara
   Pliushch, Galyna
   Leubner, Monika
   Kroll, Patricia
   Endt, Daniela
   Gehrig, Andrea
   Preisler-Adams, Sabine
   Wieacker, Peter
   Haaf, Thomas
TI Constitutive promoter methylation of <i>BRCA1</i> and <i>RAD51C</i> in
   patients with familial ovarian cancer and early-onset sporadic breast
   cancer
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PERIPHERAL-BLOOD DNA; GENE-EXPRESSION; GERMLINE MUTATIONS; RISK;
   HYPERMETHYLATION; EPIGENETICS; PATTERNS; ATM; INACTIVATION; ASSOCIATION
AB Genetic defects in breast cancer (BC) susceptibility genes, most importantly BRCA1 and BRCA2, account for approximate to 40 of hereditary BC and ovarian cancer (OC). Little is known about the contribution of constitutive (soma-wide) epimutations to the remaining cases. We developed bisulfite pyrosequencing assays to screen 600 affected BRCA1/BRCA2 mutation-negative patients from the German Consortium for Hereditary Breast and Ovarian Cancer for constitutive hypermethylation of ATM, BRCA1, BRCA2, RAD51C, PTEN and TP53 in blood cells. In a second step, patients with epsilon 6 promoter methylation were analyzed by bisulfite plasmid sequencing to demonstrate the presence of hypermethylated alleles (epimutations), indicative of epigenetic gene silencing. Altogether we identified nine (1.4) patients with constitutive BRCA1 and three (0.5) with RAD51C hypermethylation. Epimutations were found in both sporadic cases, in particular in 2 (5.5) of 37 patients with early-onset BC, and familial cases, in particular 4 (10) of 39 patients with OC. Hypermethylation was always confined to one of the two parental alleles in a subset (1240) of the analyzed cells. Because epimutations occurred in cell types from different embryonal layers, they most likely originated in single cells during early somatic development. We propose that analogous to germline genetic mutations constitutive epimutations may serve as the first hit of tumor development. Because the role of constitutive epimutations in cancer development is likely to be largely underestimated, future strategies for effective testing of susceptibility to BC and OC should include an epimutation screen.
C1 [Hansmann, Tamara; Pliushch, Galyna; Leubner, Monika; Kroll, Patricia; Endt, Daniela; Gehrig, Andrea; Haaf, Thomas] Univ Wurzburg, Inst Human Genet, D-97074 Wurzburg, Germany.
   [Preisler-Adams, Sabine; Wieacker, Peter] Univ Munster, Inst Human Genet, D-48149 Munster, Germany.
C3 University of Wurzburg; University of Munster
RP Haaf, T (通讯作者)，Univ Wurzburg, Inst Human Genet, D-97074 Wurzburg, Germany.
EM thomas.haaf@uni-wuerzburg.de
FU Wurzburg University Institute of Human Genetics
FX Funding to pay the Open Access publication charges for this article was
   provided by the operating revenues of the Wurzburg University Institute
   of Human Genetics.
CR Al-Moghrabi N, 2011, INT J ONCOL, V39, P129, DOI 10.3892/ijo.2011.1021
   Alegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/EPI.11.22, 10.2217/epi.11.22]
   Antoniou AC, 2010, CURR OPIN GENET DEV, V20, P299, DOI 10.1016/j.gde.2010.03.010
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Bock C, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn122
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Chen Y, 2006, GENET TEST, V10, P281, DOI 10.1089/gte.2006.10.281
   Dobrovic A, 2009, INT J BIOCHEM CELL B, V41, P34, DOI 10.1016/j.biocel.2008.09.006
   Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1
   Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251
   El Hajj N, 2011, EPIGENETICS-US, V6, P1176, DOI 10.4161/epi.6.10.17202
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Galetzka D, 2012, EPIGENETICS-US, V7, P47, DOI 10.4161/epi.7.1.18814
   Ghoussaini M, 2012, NAT GENET, V44, P312, DOI 10.1038/ng.1049
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hitchins MP, 2009, J MED GENET, V46, P793, DOI 10.1136/jmg.2009.068122
   Hitchins MP, 2011, CANCER CELL, V20, P200, DOI 10.1016/j.ccr.2011.07.003
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   Jackson K, 2011, DIGEST DIS SCI, V56, P125, DOI 10.1007/s10620-010-1422-z
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Kontorovich T, 2009, BREAST CANCER RES TR, V116, P195, DOI 10.1007/s10549-008-0121-3
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585
   Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569
   O'Donovan PJ, 2010, CARCINOGENESIS, V31, P961, DOI 10.1093/carcin/bgq069
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Schneider E, 2010, NUCLEIC ACIDS RES, V38, P3880, DOI 10.1093/nar/gkq126
   Seeber L M S, 2012, Methods Mol Biol, V863, P253, DOI 10.1007/978-1-61779-612-8_15
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Sontag LB, 2006, J THEOR BIOL, V242, P890, DOI 10.1016/j.jtbi.2006.05.012
   Thompson ER, 2012, HUM MUTAT, V33, P95, DOI 10.1002/humu.21625
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wilcox CB, 2005, CANCER GENET CYTOGEN, V159, P114, DOI 10.1016/j.cancergencyto.2004.12.017
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Xie HH, 2011, NUCLEIC ACIDS RES, V39, P4099, DOI 10.1093/nar/gkr017
NR 48
TC 85
Z9 90
U1 1
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 1
PY 2012
VL 21
IS 21
BP 4669
EP 4679
DI 10.1093/hmg/dds308
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 025DN
UT WOS:000310165500008
PM 22843497
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Conte, M
   Altucci, L
AF Conte, Mariarosaria
   Altucci, Lucia
TI Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent
   Clinical Advances
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; ACUTE-MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR
   GENES; BREAST-CANCER; LYSINE-METHYLTRANSFERASES; DIFFERENTIAL
   EXPRESSION; CELL-PROLIFERATION; PROSTATE-CANCER; POOR-PROGNOSIS;
   COLON-CANCER
AB Human cancer is causally linked to genomic and epigenomic deregulations. Epigenetic abnormalities occurring within signaling pathways regulating proliferation, migration, growth, differentiation, transcription, and death signals may be critical in the progression of malignancies. Consequently, identification of epigenetic marks and their bioimplications in tumors represents a crucial step toward defining new therapeutic strategies both in cancer treatment and prevention. Alterations of writers, readers, and erasers in cancer may affect, for example, the methylation and acetylation state of huge areas of chromatin, suggesting that epi-based treatments may require "distinct" therapeutic strategies compared with "canonical" targeted treatments. Whereas anticancer treatments targeting histone deacetylase and DNA methylation have entered the clinic, additional chromatin modification enzymes have not yet been pharmacologically targeted for clinical use in patients. Thus, a greater insight into alterations occurring on chromatin modifiers and their impact in tumorigenesis represents a crucial advancement in exploiting epigenetic targeting in cancer prevention and treatment. Here, the interplay of the best known epi-mutations and how their targeting might be optimized are addressed. Clin Cancer Res; 18(20); 5526-34. (C) 2012 AACR.
C1 [Conte, Mariarosaria; Altucci, Lucia] Univ Naples 2, Dipartimento Patol Gen, I-80138 Naples, Italy.
   [Altucci, Lucia] CNR, IGB, I-80125 Naples, Italy.
C3 Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso"
   (IGB-CNR)
RP Altucci, L (通讯作者)，Univ Naples 2, Dipartimento Patol Gen, Vico L De Crecchio 7, I-80138 Naples, Italy.
EM lucia.altucci@unina2.it
RI Altucci, Lucia/S-8031-2019; Conte, Mariarosaria/K-7352-2016
OI Conte, Mariarosaria/0000-0002-3622-1476; altucci,
   lucia/0000-0002-7312-5387
FU EU: Blueprint [282510]; EU: ATLAS [221952]; Epigenomics Flagship Project
   EPIGEN (MIUR-CNR); Italian Association for Cancer Research [AIRC 11812];
   Italian Ministry of University and Research [PRIN_2009PX2T2E_004]; 
   [PON002782];  [PON0101227]
FX This work was supported by EU: Blueprint (282510), ATLAS (221952);
   Epigenomics Flagship Project EPIGEN (MIUR-CNR); the Italian Association
   for Cancer Research (AIRC 11812); Italian Ministry of University and
   Research (PRIN_2009PX2T2E_004); PON002782; PON0101227.
CR Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001
   Aniello F, 2006, ANTICANCER RES, V26, P2063
   Armas-Pineda C, 2007, J EXP CLIN CANC RES, V26, P269
   Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Binda C, 2010, J AM CHEM SOC, V132, P6827, DOI 10.1021/ja101557k
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Bryan EJ, 2002, INT J CANCER, V102, P137, DOI 10.1002/ijc.10682
   Carafa V, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00004
   Chang HH, 2009, ORAL ONCOL, V45, P610, DOI 10.1016/j.oraloncology.2008.08.011
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642
   Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dell'Aversana C, 2012, EXP CELL RES, V318, P1229, DOI 10.1016/j.yexcr.2012.01.025
   Dickinson M, 2010, INVEST NEW DRUG, V28, pS3, DOI 10.1007/s10637-010-9596-y
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Gloghini A, 2009, BRIT J HAEMATOL, V147, P515, DOI 10.1111/j.1365-2141.2009.07887.x
   Hong J, 2007, FREE RADICAL BIO MED, V42, P1211, DOI 10.1016/j.freeradbiomed.2007.01.016
   Hsia DA, 2010, P NATL ACAD SCI USA, V107, P9671, DOI 10.1073/pnas.1000401107
   Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood-2006-07-027326
   Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118
   [Anonymous], 2010, Drug Discov Today Technol, V7, pe1, DOI 10.1016/j.ddtec.2010.07.004
   Jinawath A, 2005, BIOCHEM J, V385, P557, DOI 10.1042/BJ20040684
   Kast RE, 2011, ANTI-CANCER AGENT ME, V11, P756
   Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107
   Klisovic RB, 2008, CLIN CANCER RES, V14, P2444, DOI 10.1158/1078-0432.CCR-07-1320
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Kuendgen A, 2008, ANN HEMATOL, V87, P601, DOI 10.1007/s00277-008-0477-9
   Liu X, 2008, NATURE, V451, P846, DOI 10.1038/nature06546
   Matarese F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.95
   Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x
   Muraoka M, 1996, ONCOGENE, V12, P1565
   Nebbioso A, 2011, MOL CANCER THER, V10, P2394, DOI 10.1158/1535-7163.MCT-11-0525
   Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004
   Papadokostopoulou A, 2009, ANTICANCER RES, V29, P1361
   Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S
   Ribeiro AFT, 2012, BLOOD, V119, P5824, DOI 10.1182/blood-2011-07-367961
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773
   Sakuma T, 2006, INT J ONCOL, V29, P117
   Sapountzi V, 2011, CELL MOL LIFE SCI, V68, P1147, DOI 10.1007/s00018-010-0599-9
   Schausberger E, 2004, BRIT J CANCER, V91, P1955, DOI 10.1038/sj.bjc.6602191
   Schildhaus HU, 2011, HUM PATHOL, V42, P1667, DOI 10.1016/j.humpath.2010.12.025
   Schultz DJ, 2010, MOL CANCER THER, V9, P594, DOI 10.1158/1535-7163.MCT-09-0978
   Selvi BR, 2010, BBA-GENE REGUL MECH, V1799, P810, DOI 10.1016/j.bbagrm.2010.09.005
   Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732
   Stavropoulos P, 2008, P NATL ACAD SCI USA, V105, P12236, DOI 10.1073/pnas.0805813105
   Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896
   Toyota M, 2011, PROG MOL BIOL TRANSL, V101, P447, DOI 10.1016/B978-0-12-387685-0.00014-7
   Venugopal B, 2011, CURR MED CHEM, V18, P1658, DOI 10.2174/092986711795471284
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139
   Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008
   Yildirim E, 2003, NEUROSCI LETT, V345, P141, DOI 10.1016/S0304-3940(03)00490-7
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
NR 68
TC 25
Z9 25
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2012
VL 18
IS 20
BP 5526
EP 5534
DI 10.1158/1078-0432.CCR-12-2037
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 048JW
UT WOS:000311908500003
PM 22904103
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Simms, NAK
   Rajput, A
   Sharratt, EA
   Ongchin, M
   Teggart, CA
   Wang, J
   Brattain, MG
AF Simms, Neka A. K.
   Rajput, Ashwani
   Sharratt, Elizabeth A.
   Ongchin, Melanie
   Teggart, Carol A.
   Wang, Jing
   Brattain, Michael G.
TI Transforming growth factor-β suppresses metastasis in a subset of human
   colon carcinoma cells
SO BMC CANCER
LA English
DT Article
ID SURVIVIN GENE-EXPRESSION; ANTI-APOPTOSIS GENE; BREAST-CANCER CELLS; LINE
   MIA PACA-2; TGF-BETA; COLORECTAL-CANCER; FACTOR RECEPTOR; FACTOR-ALPHA;
   INHIBITS APOPTOSIS; DOWN-REGULATION
AB Background: TGF beta signaling has typically been associated with suppression of tumor initiation while the role it plays in metastasis is generally associated with progression of malignancy. However, we present evidence here for an anti-metastatic role of TGF beta signaling.
   Methods: To test the importance of TGF beta signaling to cell survival and metastasis we compared human colon carcinoma cell lines that are either non-tumorigenic with TGF beta response (FET), or tumorigenic with TGF beta response (FET alpha) or tumorigenic with abrogated TGF beta response via introduction of dominant negative TGF beta RII (FET alpha/DN) and their ability to metastasize. Metastatic competency was assessed by orthotopic transplantation. Metastatic colony formation was assessed histologically and by imaging.
   Results: Abrogation of TGF beta signaling through introduction of a dominant negative TGF beta receptor II (TGF beta RII) in non-metastatic FET alpha human colon cancer cells permits metastasis to distal organs, but importantly does not reduce invasive behavior at the primary site. Loss of TGF beta signaling in FET alpha-DN cells generated enhanced cell survival capabilities in response to cellular stress in vitro. We show that enhanced cellular survival is associated with increased AKT phosphorylation and cytoplasmic expression of inhibitor of apoptosis (IAP) family members (survivin and XIAP) that elicit a cytoprotective effect through inhibition of caspases in response to stress. To confirm that TGF beta signaling is a metastasis suppressor, we rescued TGF beta signaling in CBS metastatic colon cancer cells that had lost TGF beta receptor expression due to epigenetic repression. Restoration of TGF beta signaling resulted in the inhibition of metastatic colony formation in distal organs by these cells. These results indicate that TGF beta signaling has an important role in the suppression of metastatic potential in tumors that have already progressed to the stage of an invasive carcinoma.
   Conclusions: The observations presented here indicate a metastasis suppressor role for TGF beta signaling in human colon cancer cells. This raises the concern that therapies targeting inhibition of TGF beta signaling may be imprudent in some patient populations with residual TGF beta tumor suppressor activity.
C1 [Simms, Neka A. K.; Teggart, Carol A.; Wang, Jing; Brattain, Michael G.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA.
   [Rajput, Ashwani] Univ New Mexico, Div Surg Oncol, Dept Surg, Albuquerque, NM 87131 USA.
   [Sharratt, Elizabeth A.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.
   [Ongchin, Melanie] SUNY Buffalo, Dept Surg, Buffalo, NY 14260 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of New Mexico; Roswell Park Comprehensive Cancer Center;
   State University of New York (SUNY) System; University at Buffalo, SUNY
RP Brattain, MG (通讯作者)，Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA.
EM mbrattain@unmc.edu
FU NCI [CA38173, 54807, 72001, 34432, T32-CA036727]
FX This work was supported by NCI grants CA38173, 54807, 72001, 34432 and
   T32-CA036727.
CR Ahmed MM, 2002, J BIOL CHEM, V277, P2234, DOI 10.1074/jbc.M110168200
   Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527
   Ammanamanchi S, 2004, J BIOL CHEM, V279, P32620, DOI 10.1074/jbc.M402691200
   Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200
   Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200
   Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200
   Andersen MH, 2007, CLIN CANCER RES, V13, P5991, DOI 10.1158/1078-0432.CCR-07-0686
   Awwad RA, 2003, CANCER RES, V63, P4731
   Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006
   Borczuk AC, 2005, AM J RESP CRIT CARE, V172, P729, DOI 10.1164/rccm.200504-615OC
   Buck MB, 2004, CLIN CANCER RES, V10, P491, DOI 10.1158/1078-0432.CCR-0320-03
   CHANTRET I, 1988, CANCER RES, V48, P1936
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Chowdhury S, 2011, J BIOL CHEM, V286, P30937, DOI 10.1074/jbc.M110.212035
   Connell CM, 2008, J BIOL CHEM, V283, P3289, DOI 10.1074/jbc.M704461200
   Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200
   Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200
   Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222
   Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004
   Endl E, 2001, METHOD CELL BIOL, V63, P399
   Freeman JW, 2004, FRONT BIOSCI-LANDMRK, V9, P1889, DOI 10.2741/1388
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973
   Gobbi H, 1999, J NATL CANCER I, V91, P2096, DOI 10.1093/jnci/91.24.2096
   Gobbi H, 2000, HISTOPATHOLOGY, V36, P168
   Guo XN, 2007, CANCER RES, V67, P5851, DOI 10.1158/0008-5472.CAN-07-0049
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hasegawa Y., 2001, Cancer, V91, P64
   HAYASHI K, 1983, BIOCHEM BIOPH RES CO, V112, P102, DOI 10.1016/0006-291X(83)91803-X
   Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214
   Hu YP, 2008, CANCER RES, V68, P8004, DOI 10.1158/0008-5472.CAN-08-0280
   Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200
   Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009
   Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2
   Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471
   Kawasaki H, 1998, CANCER RES, V58, P5071
   Kim IY, 1996, CLIN CANCER RES, V2, P1255
   Li FZ, 2005, INT J CANCER, V114, P509, DOI 10.1002/ijc.20768
   MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852
   Matsushita M, 1999, BRIT J CANCER, V80, P194, DOI 10.1038/sj.bjc.6690339
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   Miller M, 2001, GUT, V48, P137, DOI 10.1136/gut.48.1.137
   Montorsi M, 2007, HEPATO-GASTROENTEROL, V54, P2040
   Monzó M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100
   Ongchin M, 2009, J SURG RES, V156, P250, DOI 10.1016/j.jss.2009.02.002
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Rajput A, 2008, J SURG RES, V147, P276, DOI 10.1016/j.jss.2007.04.021
   Rajput A, 2007, CANCER RES, V67, P665, DOI 10.1158/0008-5472.CAN-06-2773
   Saito H, 1999, CANCER, V86, P1455, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1455::AID-CNCR11>3.0.CO;2-L
   SHARKEY RM, 1980, HISTOCHEMISTRY, V66, P35, DOI 10.1007/BF00493243
   Tanaka K, 2000, CLIN CANCER RES, V6, P127
   Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583
   Venkatasubbarao K, 2001, CANCER RES, V61, P6239
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348
   Wang J, 2009, J BIOL CHEM, V284, P10912, DOI 10.1074/jbc.M809551200
   Welm AL, 2008, CELL, V133, P27, DOI 10.1016/j.cell.2008.03.012
   WOOD CB, 1981, BRIT J SURG, V68, P326, DOI 10.1002/bjs.1800680512
   Yantiss RK, 2009, AM J SURG PATHOL, V33, P572, DOI 10.1097/PAS.0b013e31818afd6b
   Ye SC, 1999, CANCER RES, V59, P4725
   Zhou YF, 2005, CANCER RES, V65, P5848, DOI 10.1158/0008-5472.CAN-04-3509
NR 63
TC 13
Z9 14
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 6
PY 2012
VL 12
AR 221
DI 10.1186/1471-2407-12-221
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 051AJ
UT WOS:000312096000001
PM 22672900
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wang, X
   Zhang, SJ
   Zhang, JB
   Lam, E
   Liu, X
   Sun, J
   Feng, LF
   Lu, HQ
   Yu, J
   Jin, HC
AF Wang, Xian
   Zhang, Shengjie
   Zhang, Jianbin
   Lam, Emily
   Liu, Xin
   Sun, Jie
   Feng, Lifeng
   Lu, Haiqi
   Yu, Jun
   Jin, Hongchuan
TI Annexin A6 is down-regulated through promoter methylation in gastric
   cancer
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE ANXA6; methylation; gastric cancer; Ras signaling
ID TUMOR-SUPPRESSOR; RAS ACTIVATION; CELLS; GROWTH; HYPERMETHYLATION;
   CARCINOMA; GENE
AB Background: The aberrant activation of oncogenic signaling such as Ras/MAPK signaling is a frequent event in human cancers. In addition to genetic changes, epigenetic silencing of inhibitors in Ras/MAPK signaling contributes to the activation of Ras/MAPK signaling. Recently, ANXA6 has been shown to interact with Ras-GAP1 and inhibit Ras activation in human breast cancer. However, whether and how it is involved in human cancers remain unknown. Methods: Real-time PCR was used to determine ANXA6 expression in gastric cancer cells and primary gastric carcinomas. Next, we explored the methylation of ANXA6 promoter in cell lines and tumor tissues with methylation-specific PCR and bisulfite genomic sequencing. We also investigated the function of ANXA6 in gastric cancer cells with colony formation assay and western blotting analysis. Results: ANXA6 was down-regulated in gastric cancer cells and primary gastric carcinomas. Ectopic ANXA6 expression inhibited the growth of gastric cancer cells and the activity of Ras/MAPK signaling. Its expression was restored after pharmaceutical demethylation. ANXA6 promoter was methylated in gastric cancer cell lines (6/6) and primary gastric carcinoma tissues (29/156). Interestingly, the knockdown of oncoprotein Yin Yang 1 (YY1) also restored ANXA6 expression and promoted the demethylation of ANXA6 promoter. However, ANXA6 methylation was not associated with clinical parameters such as differentiation, and TNM staging. Neither Kaplan-Meier Curve nor Cox regression analysis revealed a significant role of ANXA methylation to predict the survival of gastric cancer patients. Conclusions: We firstly reported that ANXA6 is epigenetically silenced through promoter methylation in human cancers and YY1 is important to initiate or maintain ANXA6 promoter methylation in gastric cancer cells. ANXA6 functions as a tumor suppressor in gastric cancer cells through the inhibition of Ras/MAPK signaling. ANXA6 methylation is not a prognostic factor for gastric cancer patients.
C1 [Wang, Xian; Zhang, Shengjie; Sun, Jie; Feng, Lifeng; Lu, Haiqi; Jin, Hongchuan] Zhejiang Univ, Sch Med, Sir Runrun Shaw Hosp, Dept Med Oncol,Lab Canc Biol,Inst Clin Sci, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhang, Jianbin; Lam, Emily; Liu, Xin; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.
C3 Zhejiang University; Chinese University of Hong Kong
RP Jin, HC (通讯作者)，Zhejiang Univ, Sch Med, Sir Runrun Shaw Hosp, Dept Med Oncol,Lab Canc Biol,Inst Clin Sci, Hangzhou 310003, Zhejiang, Peoples R China.
EM jinhc@zju.edu.cn
RI Yu, Shi-Tong/H-3747-2018; Jun, Yu/D-8569-2015
OI Liu, Michelle Xin/0000-0002-5795-2948; Wang, Xian/0000-0003-0041-7589;
   Jin, Hongchuan/0000-0002-6697-3097; Jun, Yu/0000-0001-5008-2153
FU National Natural Science Foundation of China [81071652, 81071963];
   Qianjiang Scholarship of Zhejiang Province [2011R10061, 2011R10073]; 973
   project [2012CB526604]; Key Innovation Teams of Science and Technology
   in Zhejiang Province [2012R10046]
FX The project was supported by National Natural Science Foundation of
   China (81071652; 81071963), Qianjiang Scholarship of Zhejiang Province
   (2011R10061; 2011R10073), 973 project (2012CB526604) and Key Innovation
   Teams of Science and Technology in Zhejiang Province (2012R10046).
CR Arcuri C, 2002, NEUROSCIENCE, V109, P371, DOI 10.1016/S0306-4522(01)00330-X
   BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Grewal T, 2005, ONCOGENE, V24, P5809, DOI 10.1038/sj.onc.1208743
   Grewal T, 2010, INT J BIOCHEM CELL B, V42, P580, DOI 10.1016/j.biocel.2009.12.020
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200
   Kim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x
   Koese M, 2013, ONCOGENE, V32, P2858, DOI 10.1038/onc.2012.303
   Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017
   Lam EKY, 2011, AM J TRANSL RES, V3, P209
   Liu XD, 2009, STUD FUZZ SOFT COMP, V244, P3
   Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608
   Sakwe AM, 2011, EXP CELL RES, V317, P823, DOI 10.1016/j.yexcr.2010.12.008
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   de Muga SV, 2009, ONCOGENE, V28, P363, DOI 10.1038/onc.2008.386
   Wang LJ, 2012, MOL MED, V18, P389, DOI 10.2119/molmed.2011.00172
   Wang LJ, 2011, AM J CANCER RES, V1, P111
   Wang X, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-95
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343
   Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050
NR 26
TC 30
Z9 36
U1 0
U2 8
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2013
VL 5
IS 5
BP 555
EP 562
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 206RF
UT WOS:000323539100008
PM 23977414
DA 2025-01-12
ER

PT J
AU Anaya-Ruiz, M
   Cebada, J
   Delgado-López, G
   Sánchez-Vázquez, ML
   Pérez-Santos, JLM
AF Anaya-Ruiz, Maricruz
   Cebada, Jorge
   Delgado-Lopez, Guadalupe
   Luisa Sanchez-Vazquez, Maria
   Martin Perez-Santos, Jose Luis
TI miR-153 Silencing Induces Apoptosis in the MDA-MB-231 Breast Cancer Cell
   Line
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Breast cancer; microRNA; apoptosis; triple negative; miR-153 silencing
ID TUMOR-SUPPRESSOR; DOWN-REGULATION; MICRORNAS; EXPRESSION; EPIGENETICS;
   GENE
AB MicroRNAs (miRNAs) are small, non-coding RNAs (18-25 nucleotides) that post-transcriptionally modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs. In this context, the present study aimed to evaluate the in vitro effects of miR-153 inhibition in the breast carcinoma cell line MDA-MB-231. Forty-eight hours after MDA-MB-231 cells were transfected with the miR-153 inhibitor, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to determine the effects of miR-153 on cell viability. Flow cytometry analysis and assessment of caspase 3/7 activity were adopted to determine whether miR-153 affects the proliferation rates and apoptosis levels of MDA-MB-231 cells. Our results showed that silencing of miR-153 significantly inhibited growth when compared to controls at 48 hours, reducing proliferation by 37.6%, and inducing apoptosis. Further studies are necessary to corroborate our findings and examine the potential use of this microRNA in future diagnostic and therapeutic interventions.
C1 [Anaya-Ruiz, Maricruz; Delgado-Lopez, Guadalupe] Benemerita Univ Autonoma Puebla, Lab Cellular Biol, Puebla, Mexico.
   [Luisa Sanchez-Vazquez, Maria] Benemerita Univ Autonoma Puebla, Lab Reprod Biol, Ctr Invest Biomed Oriente, Inst Mexicano Seguro Social, Puebla, Mexico.
   [Cebada, Jorge] Benemerita Univ Autonoma Puebla, Escuela Biol, Puebla, Mexico.
   [Martin Perez-Santos, Jose Luis] Benemerita Univ Autonoma Puebla, Puebla, Mexico.
C3 Benemerita Universidad Autonoma de Puebla; Benemerita Universidad
   Autonoma de Puebla; Instituto Mexicano del Seguro Social; Benemerita
   Universidad Autonoma de Puebla; Benemerita Universidad Autonoma de
   Puebla
RP Pérez-Santos, JLM (通讯作者)，Benemerita Univ Autonoma Puebla, Puebla, Mexico.
EM martin.perez@correo.buap.mx
RI ; Perez-Santos, Martin/F-7229-2017
OI Anaya Ruiz, Maricruz/0000-0002-3193-3730; Perez-Santos,
   Martin/0000-0001-5074-2000
CR Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Haghighat S, 2012, ASIAN PAC J CANCER P, V13, P5525, DOI 10.7314/APJCP.2012.13.11.5525
   Harquail J, 2012, CANCER BIOMARK, V11, P269, DOI 10.3233/CBM-120291
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Kala Rishabh, 2013, J Clin Bioinforma, V3, P6, DOI 10.1186/2043-9113-3-6
   Kim TH, 2010, HISTOPATHOLOGY, V57, P734, DOI 10.1111/j.1365-2559.2010.03686.x
   Lages E, 2012, FRONT BIOSCI-LANDMRK, V17, P2508, DOI 10.2741/4068
   Lee S, 2013, ADV EXP MED BIOL, V768, P97, DOI 10.1007/978-1-4614-5107-5_7
   Li S, 2013, PATHOL RES PRACT, V209, P179, DOI 10.1016/j.prp.2012.12.002
   Lindström LS, 2012, J CLIN ONCOL, V30, P2601, DOI 10.1200/JCO.2011.37.2482
   Mar-Aguilar F, 2013, ASIA-PAC J CLIN ONCO, V9, P53, DOI 10.1111/j.1743-7563.2012.01548.x
   Özgün A, 2013, ONKOLOGIE, V36, P115, DOI 10.1159/000348678
   Parpart Sonya, 2013, Curr Pathobiol Rep, V1, P71
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Singh R, 2013, CANCER BIOL THER, V14, P201, DOI 10.4161/cbt.23296
   Tang J, 2012, INT J MOL SCI, V13, P13414, DOI 10.3390/ijms131013414
   Wu ZQ, 2013, PROSTATE, V73, P596, DOI 10.1002/pros.22600
   Xu JZ, 2011, INT J CANCER, V129, P2527, DOI 10.1002/ijc.25917
   Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823
   Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374
   Yang Lei, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P1009
   Zhao SG, 2013, MOL BIOL REP, V40, P2789, DOI 10.1007/s11033-012-2278-4
NR 22
TC 28
Z9 31
U1 0
U2 5
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2013
VL 14
IS 5
BP 2983
EP 2986
DI 10.7314/APJCP.2013.14.5.2983
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB0HU
UT WOS:000331473400051
PM 23803066
OA gold
DA 2025-01-12
ER

PT J
AU Borges, S
   Döppler, H
   Perez, EA
   Andorfer, CA
   Sun, ZF
   Anastasiadis, PZ
   Thompson, EA
   Geiger, XJ
   Storz, P
AF Borges, Sahra
   Doeppler, Heike
   Perez, Edith A.
   Andorfer, Cathy A.
   Sun, Zhifu
   Anastasiadis, Panos Z.
   Thompson, E. Aubrey
   Geiger, Xochiquetzal J.
   Storz, Peter
TI Pharmacologic reversion of epigenetic silencing of the <i>PRKD1</i>
   promoter blocks breast tumor cell invasion and metastasis
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Decitabine; Invasion; Metastasis; PKD1; Protein kinase D1
ID PROTEIN-KINASE D1; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER METASTASIS;
   DNA METHYLATION; IN-SITU; GENE; PHOSPHORYLATION; EXPRESSION; MIGRATION;
   GROWTH
AB Introduction: DNA methylation-induced silencing of genes encoding tumor suppressors is common in many types of cancer, but little is known about how such epigenetic silencing can contribute to tumor metastasis. The PRKD1 gene encodes protein kinase D1 (PKD1), a serine/threonine kinase that is expressed in cells of the normal mammary gland, where it maintains the epithelial phenotype by preventing epithelial-to-mesenchymal transition.
   Methods: The status of PRKD1 promoter methylation was analyzed by reduced representation bisulfite deep sequencing, methylation-specific PCR (MSP-PCR) and in situ MSP-PCR in invasive and noninvasive breast cancer lines, as well as in humans in 34 cases of "normal" tissue, 22 cases of ductal carcinoma in situ, 22 cases of estrogen receptor positive, HER2-negative (ER+/HER2-) invasive lobular carcinoma, 43 cases of ER+/HER2-invasive ductal carcinoma (IDC), 93 cases of HER2+ IDC and 96 cases of triple-negative IDC. A reexpression strategy using the DNA methyltransferase inhibitor decitabine was used in vitro in MDA-MB-231 cells as well as in vivo in a tumor xenograft model and measured by RT-PCR, immunoblotting and immunohistochemistry. The effect of PKD1 reexpression on cell invasion was analyzed in vitro by transwell invasion assay. Tumor growth and metastasis were monitored in vivo using the IVIS Spectrum Pre-clinical In Vivo Imaging System.
   Results: Herein we show that the gene promoter of PRKD1 is aberrantly methylated and silenced in its expression in invasive breast cancer cells and during breast tumor progression, increasing with the aggressiveness of tumors. Using an animal model, we show that reversion of PRKD1 promoter methylation with the DNA methyltransferase inhibitor decitabine restores PKD1 expression and blocks tumor spread and metastasis to the lung in a PKD1-dependent fashion.
   Conclusions: Our data suggest that the status of epigenetic regulation of the PRKD1 promoter can provide valid information on the invasiveness of breast tumors and therefore could serve as an early diagnostic marker. Moreover, targeted upregulation of PKD1 expression may be used as a therapeutic approach to reverse the invasive phenotype of breast cancer cells.
C1 [Borges, Sahra; Doeppler, Heike; Anastasiadis, Panos Z.; Thompson, E. Aubrey; Storz, Peter] Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA.
   [Perez, Edith A.; Andorfer, Cathy A.] Mayo Clin, Dept Hematol Oncol, Jacksonville, FL 32224 USA.
   [Sun, Zhifu] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA.
   [Geiger, Xochiquetzal J.] Mayo Clin, Jacksonville, FL 32224 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Storz, P (通讯作者)，Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA.
EM storz.peter@mayo.edu
RI Perez, Edith/ACA-8756-2022
OI Sun, Zhifu/0000-0001-8461-7523
FU National Institutes of Health [GM086435, CA140182]; Bankhead-Coley
   Program of the Florida Department of Health [1BG11]; Mayo Clinic Breast
   Cancer SPORE [CA116201-03DR4, R21 NS070117]; Breast Cancer Research
   Foundation; Donna Foundation
FX This work was supported by grants from the National Institutes of Health
   (GM086435 and CA140182) and the Bankhead-Coley Program of the Florida
   Department of Health (1BG11) to PS, as well as a pilot project grant
   from the Mayo Clinic Breast Cancer SPORE (CA116201-03DR4) to PS, an R21
   NS070117 grant to PZA, a grant from the Breast Cancer Research
   Foundation to EAP and partial support from the 26.2 with Donna
   Foundation to EAT. We thank our colleagues in the Storz laboratory for
   helpful discussions. We also thank Brandy H Edenfield and Pamela
   Kreinest of the Mayo Clinic Florida Histopathology Facility for
   immunohistochemistry and assembly of TMAs. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Cancer Institute or the National
   Institutes of Health. The funders had no role in study design, data
   collection and analysis, decision to publish or preparation of the
   manuscript.
CR Asmann YW, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr362
   Bastea LI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030459
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Beaudet AL, 2002, AM J HUM GENET, V70, P1389, DOI 10.1086/340969
   Bender CM, 1998, CANCER RES, V58, P95
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Chabottaux V, 2007, CLIN EXP METASTAS, V24, P647, DOI 10.1007/s10585-007-9113-7
   De Kimpe L, 2009, CELL SIGNAL, V21, P253, DOI 10.1016/j.cellsig.2008.10.015
   Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Eiseler T, 2007, FEBS LETT, V581, P4279, DOI 10.1016/j.febslet.2007.07.079
   Eiseler T, 2012, J BIOL CHEM, V287, P32367, DOI 10.1074/jbc.M112.370999
   Eiseler T, 2010, J BIOL CHEM, V285, P18672, DOI 10.1074/jbc.M109.093880
   Eiseler T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2232
   Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Hao Q, 2013, ANTICANCER RES, V33, P393
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jaggi M, 2003, BIOCHEM BIOPH RES CO, V307, P254, DOI 10.1016/S0006-291X(03)01161-6
   Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kim M, 2008, CARCINOGENESIS, V29, P629, DOI 10.1093/carcin/bgm291
   Lehmann U, 2002, CANCER RES, V62, P6634
   Liang G, 2002, CANCER RES, V62, P961
   McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Onishi Y, 2012, INT J ONCOL, V40, P1839, DOI 10.3892/ijo.2012.1400
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Peterburs P, 2009, CANCER RES, V69, P5634, DOI 10.1158/0008-5472.CAN-09-0718
   Pusapati GV, 2012, J BIOL CHEM, V287, P9473, DOI 10.1074/jbc.M112.339564
   Rozengurt E, 2011, PHYSIOLOGY, V26, P23, DOI 10.1152/physiol.00037.2010
   Shin DY, 2012, INT J ONCOL, V41, P910, DOI 10.3892/ijo.2012.1546
   Singh B, 2007, ONCOGENE, V26, P3789, DOI 10.1038/sj.onc.1210154
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Spratley SJ, 2011, J BIOL CHEM, V286, P34254, DOI 10.1074/jbc.M111.259424
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915
   WOLF SF, 1982, NATURE, V295, P667, DOI 10.1038/295667a0
   Yang AS, 2003, SCIENCE, V302
   Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825
   Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200
NR 52
TC 63
Z9 70
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2013
VL 15
IS 2
AR R66
DI 10.1186/bcr3460
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 302NU
UT WOS:000330612000020
PM 23971832
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Eccles, SA
   Aboagye, EO
   Ali, S
   Anderson, AS
   Armes, J
   Berditchevski, F
   Blaydes, JP
   Brennan, K
   Brown, NJ
   Bryant, HE
   Bundred, NJ
   Burchell, JM
   Campbell, AM
   Carroll, JS
   Clarke, RB
   Coles, CE
   Cook, GJR
   Cox, A
   Curtin, NJ
   Dekker, LV
   Silva, ID
   Duffy, SW
   Easton, DF
   Eccles, DM
   Edwards, DR
   Edwards, J
   Evans, DG
   Fenlon, DF
   Flanagan, JM
   Foster, C
   Gallagher, WM
   Garcia-Closas, M
   Gee, JMW
   Gescher, AJ
   Goh, V
   Groves, AM
   Harvey, AJ
   Harvie, M
   Hennessy, BT
   Hiscox, S
   Holen, I
   Howell, SJ
   Howell, A
   Hubbard, G
   Hulbert-Williams, N
   Hunter, MS
   Jasani, B
   Jones, LJ
   Key, TJ
   Kirwan, CC
   Kong, A
   Kunkler, IH
   Langdon, SP
   Leach, MO
   Mann, DJ
   Marshall, JF
   Martin, LA
   Martin, SG
   Macdougall, JE
   Miles, DW
   Miller, WR
   Morris, JR
   Moss, SM
   Mullan, P
   Natrajan, R
   O'Connor, JPB
   O'Connor, R
   Palmieri, C
   Pharoah, PDP
   Rakha, EA
   Reed, E
   Robinson, SP
   Sahai, E
   Saxton, JM
   Schmid, P
   Smalley, MJ
   Speirs, V
   Stein, R
   Stingl, J
   Streuli, CH
   Tutt, ANJ
   Velikova, G
   Walker, RA
   Watson, CJ
   Williams, KJ
   Young, LS
   Thompson, AM
AF Eccles, Suzanne A.
   Aboagye, Eric O.
   Ali, Simak
   Anderson, Annie S.
   Armes, Jo
   Berditchevski, Fedor
   Blaydes, Jeremy P.
   Brennan, Keith
   Brown, Nicola J.
   Bryant, Helen E.
   Bundred, Nigel J.
   Burchell, Joy M.
   Campbell, Anna M.
   Carroll, Jason S.
   Clarke, Robert B.
   Coles, Charlotte E.
   Cook, Gary J. R.
   Cox, Angela
   Curtin, Nicola J.
   Dekker, Lodewijk V.
   Silva, Isabel dos Santos
   Duffy, Stephen W.
   Easton, Douglas F.
   Eccles, Diana M.
   Edwards, Dylan R.
   Edwards, Joanne
   Evans, D. Gareth
   Fenlon, Deborah F.
   Flanagan, James M.
   Foster, Claire
   Gallagher, William M.
   Garcia-Closas, Montserrat
   Gee, Julia M. W.
   Gescher, Andy J.
   Goh, Vicky
   Groves, Ashley M.
   Harvey, Amanda J.
   Harvie, Michelle
   Hennessy, Bryan T.
   Hiscox, Stephen
   Holen, Ingunn
   Howell, Sacha J.
   Howell, Anthony
   Hubbard, Gill
   Hulbert-Williams, Nick
   Hunter, Myra S.
   Jasani, Bharat
   Jones, Louise J.
   Key, Timothy J.
   Kirwan, Cliona C.
   Kong, Anthony
   Kunkler, Ian H.
   Langdon, Simon P.
   Leach, Martin O.
   Mann, David J.
   Marshall, John F.
   Martin, Lesley Ann
   Martin, Stewart G.
   Macdougall, Jennifer E.
   Miles, David W.
   Miller, William R.
   Morris, Joanna R.
   Moss, Sue M.
   Mullan, Paul
   Natrajan, Rachel
   O'Connor, James P. B.
   O'Connor, Rosemary
   Palmieri, Carlo
   Pharoah, Paul D. P.
   Rakha, Emad A.
   Reed, Elizabeth
   Robinson, Simon P.
   Sahai, Erik
   Saxton, John M.
   Schmid, Peter
   Smalley, Matthew J.
   Speirs, Valerie
   Stein, Robert
   Stingl, John
   Streuli, Charles H.
   Tutt, Andrew N. J.
   Velikova, Galina
   Walker, Rosemary A.
   Watson, Christine J.
   Williams, Kaye J.
   Young, Leonie S.
   Thompson, Alastair M.
TI Critical research gaps and translational priorities for the successful
   prevention and treatment of breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; CIRCULATING TUMOR-CELLS;
   EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-BETA; MAMMARY-GLAND
   DEVELOPMENT; TREATMENT MENOS 1; STEM-CELLS; PHYSICAL-ACTIVITY;
   GENE-EXPRESSION
AB Introduction: Breast cancer remains a significant scientific, clinical and societal challenge. This gap analysis has reviewed and critically assessed enduring issues and new challenges emerging from recent research, and proposes strategies for translating solutions into practice.
   Methods: More than 100 internationally recognised specialist breast cancer scientists, clinicians and healthcare professionals collaborated to address nine thematic areas: genetics, epigenetics and epidemiology; molecular pathology and cell biology; hormonal influences and endocrine therapy; imaging, detection and screening; current/ novel therapies and biomarkers; drug resistance; metastasis, angiogenesis, circulating tumour cells, cancer `stem' cells; risk and prevention; living with and managing breast cancer and its treatment. The groups developed summary papers through an iterative process which, following further appraisal from experts and patients, were melded into this summary account.
   Results: The 10 major gaps identified were: (1) understanding the functions and contextual interactions of genetic and epigenetic changes in normal breast development and during malignant transformation; (2) how to implement sustainable lifestyle changes (diet, exercise and weight) and chemopreventive strategies; (3) the need for tailored screening approaches including clinically actionable tests; (4) enhancing knowledge of molecular drivers behind breast cancer subtypes, progression and metastasis; (5) understanding the molecular mechanisms of tumour heterogeneity, dormancy, de novo or acquired resistance and how to target key nodes in these dynamic processes; (6) developing validated markers for chemosensitivity and radiosensitivity; (7) understanding the optimal duration, sequencing and rational combinations of treatment for improved personalised therapy; (8) validating multimodality imaging biomarkers for minimally invasive diagnosis and monitoring of responses in primary and metastatic disease; (9) developing interventions and support to improve the survivorship experience; (10) a continuing need for clinical material for translational research derived from normal breast, blood, primary, relapsed, metastatic and drug-resistant cancers with expert bioinformatics support to maximise its utility. The proposed infrastructural enablers include enhanced resources to support clinically relevant in vitro and in vivo tumour models; improved access to appropriate, fully annotated clinical samples; extended biomarker discovery, validation and standardisation; and facilitated cross-discipline working.
   Conclusions: With resources to conduct further high-quality targeted research focusing on the gaps identified, increased knowledge translating into improved clinical care should be achievable within five years.
C1 [Aboagye, Eric O.; Ali, Simak; Flanagan, James M.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.
   [Anderson, Annie S.; Campbell, Anna M.; Mann, David J.; Thompson, Alastair M.] Univ Dundee, Dundee DD1 4HN, Scotland.
   [Blaydes, Jeremy P.; Eccles, Diana M.; Fenlon, Deborah F.; Foster, Claire] Univ Southampton, Southampton SO17 1BJ, Hants, England.
   [Berditchevski, Fedor; Morris, Joanna R.] Univ Birmingham, Birmingham B15 2TT, W Midlands, England.
   [Brennan, Keith; Bundred, Nigel J.; Clarke, Robert B.; Evans, D. Gareth; Harvie, Michelle; Howell, Sacha J.; Howell, Anthony; Kirwan, Cliona C.; O'Connor, James P. B.; Streuli, Charles H.; Williams, Kaye J.] Univ Manchester, Manchester M13 9PL, Lancs, England.
   [Brown, Nicola J.; Bryant, Helen E.; Cox, Angela; Holen, Ingunn] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England.
   [Armes, Jo; Burchell, Joy M.; Cook, Gary J. R.; Goh, Vicky; Hunter, Myra S.; Miles, David W.; Tutt, Andrew N. J.] Kings Coll London, London WC2R 2LS, England.
   [Groves, Ashley M.; Stein, Robert] UCL, London WC1E 6BT, England.
   [Carroll, Jason S.; Easton, Douglas F.; Pharoah, Paul D. P.; Stingl, John; Watson, Christine J.] Univ Cambridge, Cambridge Res Inst, Canc Res UK, Cambridge CB2 1TN, England.
   [Curtin, Nicola J.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Dekker, Lodewijk V.; Martin, Stewart G.; Rakha, Emad A.] Univ Nottingham, Nottingham NG7 2RD, England.
   [Silva, Isabel dos Santos] Univ London London Grad Sch Business Studies, London WC1E 2HT, England.
   [Duffy, Stephen W.; Jones, Louise J.; Marshall, John F.; Moss, Sue M.] Queen Mary Univ London, London E1 4NS, England.
   [Edwards, Joanne] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland.
   [Edwards, Dylan R.; Saxton, John M.] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England.
   [Gallagher, William M.] Univ Coll Dublin, Dublin 4, Ireland.
   [Eccles, Suzanne A.; Garcia-Closas, Montserrat; Leach, Martin O.; Martin, Lesley Ann; Natrajan, Rachel; Robinson, Simon P.] Inst Canc Res, London SM2 5MG, England.
   [Gee, Julia M. W.; Hiscox, Stephen; Jasani, Bharat; Smalley, Matthew J.] Cardiff Univ, Cardiff CF10 3AT, S Glam, Wales.
   [Speirs, Valerie; Velikova, Galina] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England.
   [Hennessy, Bryan T.; Young, Leonie S.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
   [Hubbard, Gill] Univ Stirling, Stirling FK9 4LA, Scotland.
   [Hulbert-Williams, Nick] Univ Chester, Chester CH1 4BJ, Cheshire, England.
   [Key, Timothy J.; Kong, Anthony] Univ Oxford, Oxford OX1 2JD, England.
   [Kunkler, Ian H.; Langdon, Simon P.; Miller, William R.] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland.
   [Macdougall, Jennifer E.] Natl Canc Res Inst, London EC1V 4AD, England.
   [Mullan, Paul] Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland.
   [O'Connor, Rosemary] Natl Univ Ireland Univ Coll Cork, Cork, Ireland.
   [Gescher, Andy J.; Walker, Rosemary A.] Univ Leicester, Leicester LE1 4RH, Leics, England.
   [Schmid, Peter] Univ Sussex, Brighton & Sussex Med Sch, Brighton BN1 9PX, E Sussex, England.
   [Palmieri, Carlo] Univ Liverpool, Liverpool L69 7ZX, Merseyside, England.
   [Sahai, Erik] London Res Inst, London WC2A 3LY, England.
   [Harvey, Amanda J.] Brunel Univ, Uxbridge UB8 3PH, Middx, England.
   [Coles, Charlotte E.] Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 0QQ, England.
C3 Imperial College London; University of Dundee; University of
   Southampton; University of Birmingham; University of Manchester;
   University of Sheffield; University of London; King's College London;
   University of London; University College London; CRUK Cambridge
   Institute; University of Cambridge; Cancer Research UK; Newcastle
   University - UK; University of Nottingham; University of London; London
   Business School; University of London; Queen Mary University London;
   University of Glasgow; University of East Anglia; University College
   Dublin; University of London; Institute of Cancer Research - UK; Cardiff
   University; University of Leeds; Royal College of Surgeons - Ireland;
   University of Stirling; University of Chester; University of Oxford;
   University of Edinburgh; Queens University Belfast; University College
   Cork; University of Leicester; University of Brighton; University of
   Sussex; University of Liverpool; Brunel University; University of
   Cambridge
RP Eccles, SA (通讯作者)，Inst Canc Res, 15 Cotswold Rd, London SM2 5MG, England.
EM Sue.Eccles@icr.ac.uk; a.m.thompson@dundee.ac.uk
RI bryant, helen/AHB-1139-2022; Pharoah, Paul/V-6658-2019; Goh,
   Vicky/AAG-2708-2020; Kirwan, Cliona/HHZ-8872-2022; Schmid,
   Peter/AAE-2788-2019; Martin, Lesley-Ann/AAA-1841-2020; Clarke,
   Robert/AAA-3442-2021; Morris, Joanna/AAK-3388-2021; Rakha,
   Emad/Q-5554-2019; Young, Leonie/D-5631-2012; Eccles, Diana/K-6327-2019;
   Armes, Jo/AAH-8812-2021; Burchell, Joy/G-4560-2012; Marshall,
   J/LBH-2002-2024; Ali, Simak/N-4740-2019; Hunter, Myra/F-2133-2010;
   Evans, D/AAB-4308-2022; Miller, William/AAY-5398-2020; Speirs,
   Valerie/ABE-7377-2021; howell, sacha/K-8770-2015; Blaydes,
   Jeremy/AAC-6939-2019; Martin, Stewart/F-5999-2012; Ali,
   Simak/M-6912-2018; Gee, Julia/N-3995-2014; Stein, Robert/N-6679-2015;
   O'Connor, Rosemary/B-7902-2014; Edwards, Dylan/B-4734-2009; Edwards,
   Joanne/J-1903-2015; Garcia-Closas, Montserrat/F-3871-2015; Dekker,
   Lodewijk/J-6934-2013; Smalley, Matthew/M-7000-2015; Foster,
   Claire/N-6223-2016; leach, martin/C-2248-2008; Hiscox, Steve/N-3968-2014
OI howell, sacha/0000-0001-8141-6515; Brennan, Keith/0000-0002-9384-125X;
   Robinson, Simon/0000-0003-4101-7274; Blaydes,
   Jeremy/0000-0001-8525-0209; Eccles, Diana M/0000-0002-9935-3169; Martin,
   Stewart/0000-0002-2810-2338; Ali, Simak/0000-0002-1320-0816; Natrajan,
   Rachael/0000-0002-9987-2946; Gee, Julia/0000-0001-6483-2015; Evans,
   Gareth/0000-0002-8482-5784; Brown, Nicola/0000-0002-2100-1905; Clarke,
   Robert/0000-0001-5407-3123; Kirwan, Cliona/0000-0002-1725-4790; Howell,
   Anthony/0000-0002-6233-719X; Hubbard, Gill/0000-0003-2165-5770; ABOAGYE,
   Eric/0000-0003-2276-6771; O'Connor, James/0000-0002-4044-8497; Stein,
   Robert/0000-0003-2969-0415; O'Connor, Rosemary/0000-0002-0687-3422;
   Edwards, Dylan/0000-0002-3292-2064; Fenlon, Deborah/0000-0001-7347-8919;
   Edwards, Joanne/0000-0002-7192-6906; Garcia-Closas,
   Montserrat/0000-0003-1033-2650; Dekker, Lodewijk/0000-0001-5247-3297;
   Holen, Ingunn/0000-0002-8759-6913; Smalley, Matthew/0000-0001-9540-1146;
   Foster, Claire/0000-0002-4703-8378; anderson, annie/0000-0002-0047-4500;
   Flanagan, James/0000-0003-4955-1383; Carroll, Jason/0000-0003-3643-0080;
   Cox, Angela/0000-0002-5138-1099; Marshall, John/0000-0002-0494-2295;
   Tutt, Andrew/0000-0001-8715-2901; Curtin, Nicola/0000-0003-1369-1843;
   leach, martin/0000-0002-0756-5368; Hulbert-Williams, Nicholas
   James/0000-0001-9041-5485; Rakha, Emad/0000-0002-5009-5525; Gallagher,
   William/0000-0002-4307-5999; Burchell, Joy/0000-0003-0413-3823; Coombes,
   Raoul Charles/0000-0002-4811-1100; Young, Leonie/0000-0002-4904-0367;
   Hennessy, Bryan/0000-0002-7871-6477; Sahai, Erik/0000-0002-3932-5086;
   Armes, Jo/0000-0002-7994-0796; Hiscox, Steve/0000-0002-3535-3100; Goh,
   Vicky/0000-0002-2321-8091; Cook, Gary/0000-0002-8732-8134; Morris,
   Joanna/0000-0001-9762-8133
FU NIHR RM/ICR; MRC [MR/K011014/1, G0400170] Funding Source: UKRI
FX We would like to acknowledge the helpful contributions to the final
   manuscript from the Executive Advisory Board: Kevin Brindle, Robert E
   Coleman, Charles Coombes, Jack Cuzick, Mitchell Dowsett, Lesley
   Fallowfield, Christine Friedenreich, William J Gullick, Barry Gusterson,
   Craig Jordan, Sunil Lakhani, Bettina Meiser, Emma Pennery, Rebecca
   Riggins and Stephen Johnston. We would also like to acknowledge the
   contributions of the patient advocate representatives Mairead McKenzie
   and Marion Lewis from Breast Cancer Care's Service User Research Panel.
   SAE acknowledges support from the NIHR RM/ ICR Biomedical Research
   Centre, ICR and Cancer Research UK. AMT acknowledges support from Breast
   Cancer Campaign, Breakthrough Breast Cancer and CR-UK. Breast Cancer
   Campaign staff Lisa Wilde, Phyllis Quinn and Stuart Griffiths assisted
   in the design and implementation of the gap analysis initiative and
   acted as facilitators throughout the process. Geraldine Byrne was
   responsible for co-ordinating and delivering the logistics and acted as
   a facilitator at the nine gap analysis workshops that were held at the
   Breast Cancer Campaign offices. We thank Dr Alexis Willet who provided
   editorial assistance on behalf of Punch Consulting.
CR Ablett MP, 2012, EUR J CANCER, V48, P2104, DOI 10.1016/j.ejca.2012.03.019
   Absolom K, 2009, BRIT J CANCER, V101, P561, DOI 10.1038/sj.bjc.6605213
   Adams S, 2011, CANCER IMMUNOL IMMUN, V60, P999, DOI 10.1007/s00262-011-1005-7
   Akhtar N, 2013, NAT CELL BIOL, V15, P17, DOI 10.1038/ncb2646
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Albada A, 2011, J COMMUN GENET, V2, P233, DOI 10.1007/s12687-011-0061-1
   Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5
   Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6
   Amir E, 2012, CANCER TREAT REV, V38, P708, DOI 10.1016/j.ctrv.2011.11.006
   Amir E, 2010, JNCI-J NATL CANCER I, V102, P680, DOI 10.1093/jnci/djq088
   Anderson AS, 2013, CANCER PREV RES, V6, P165, DOI 10.1158/1940-6207.CAPR-12-0385
   Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X
   Andre F, 2013, CLIN CANCER RES, V19, P28, DOI 10.1158/1078-0432.CCR-11-2701
   Andrechek ER, 2010, J MOL MED, V88, P1095, DOI 10.1007/s00109-010-0644-z
   Anisimov VN, 2011, CELL CYCLE, V10, P4230, DOI 10.4161/cc.10.24.18486
   Antoniou AC, 2010, CANCER RES, V70, P9742, DOI 10.1158/0008-5472.CAN-10-1907
   Aranda S, 2005, EUR J CANCER CARE, V14, P211, DOI 10.1111/j.1365-2354.2005.00541.x
   Armes J, 2007, CANCER-AM CANCER SOC, V110, P1385, DOI 10.1002/cncr.22923
   Armes J, 2009, J CLIN ONCOL, V27, P6172, DOI 10.1200/JCO.2009.22.5151
   Arslan UY, 2011, BREAST, V20, P562, DOI 10.1016/j.breast.2011.07.017
   Asola R, 2006, BREAST CANCER RES TR, V100, P77, DOI 10.1007/s10549-006-9224-x
   Asselin MC, 2012, EUR J CANCER, V48, P447, DOI 10.1016/j.ejca.2011.12.025
   Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Aupperlee MD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3431
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Azim HA, 2013, ANN ONCOL, V24, P647, DOI 10.1093/annonc/mds645
   Azim H, 2013, EXPERT REV ANTICANC, V13, P195, DOI [10.1586/ERA.12.177, 10.1586/era.12.177]
   Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576
   Badve S, 2012, LANCET ONCOL, V13, pE43, DOI 10.1016/S1470-2045(11)70191-7
   Bailey KM, 2012, ADV PHARMACOL, V65, P63, DOI 10.1016/B978-0-12-397927-8.00004-X
   Baird RD, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-151
   Balic M, 2012, EXPERT REV MOL DIAGN, V12, P303, DOI [10.1586/ERM.12.12, 10.1586/erm.12.12]
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319
   Barrière G, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-114
   Bartelink H, 2007, J CLIN ONCOL, V25, P3259, DOI 10.1200/JCO.2007.11.4991
   Bartlett JMS, 2011, J CLIN ONCOL, V29, P1531, DOI 10.1200/JCO.2010.30.3677
   Basch E, 2009, JNCI-J NATL CANCER I, V101, P1624, DOI 10.1093/jnci/djp386
   Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
   Bazzoun D, 2013, PHARMACOL THERAPEUT, V138, P418, DOI 10.1016/j.pharmthera.2013.02.004
   Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7
   Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]
   Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725
   Blamey RW, 2013, EUR J CANCER, V49, P2294, DOI 10.1016/j.ejca.2013.02.031
   Bloom Joan R, 2008, J Cancer Surviv, V2, P190, DOI 10.1007/s11764-008-0058-x
   Borowsky AD, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a009670
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Brower V, 2010, J NATL CANCER I, V102, P843, DOI 10.1093/jnci/djq230
   Caligiuri I, 2012, J CELL PHYSIOL, V227, P2988, DOI 10.1002/jcp.24031
   Calvo F, 2011, CURR OPIN CELL BIOL, V23, P621, DOI 10.1016/j.ceb.2011.04.010
   Campbell KL, 2012, BRIT J SPORT MED, V46, P909, DOI [10.1136/bjsm.2010.082719, 10.1136/bjsports-2010-082719]
   Capala J, 2010, CURR OPIN ONCOL, V22, P559, DOI 10.1097/CCO.0b013e32833f8c3a
   Capozzo MA, 2010, CANCER NURS, V33, P228, DOI 10.1097/NCC.0b013e3181c1acd6
   Carlson RW, 2012, BREAST CANCER RES TR, V133, P1049, DOI 10.1007/s10549-012-1997-5
   Castellon SA, 2004, J CLIN EXP NEUROPSYC, V26, P955, DOI 10.1080/13803390490510905
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chen YL, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0023237, 10.1371/journal.pone.0017876]
   Cheville AL, 2008, J CLIN ONCOL, V26, P2621, DOI 10.1200/JCO.2007.12.3075
   Chew V, 2012, J ONCOL, V2012, DOI 10.1155/2012/608406
   Chlebowski RT, 2012, ANTI-CANCER AGENT ME, V12, P144
   Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500
   CHLEBOWSKI RT, 1992, BREAST CANCER RES TR, V20, P73
   Chui MH, 2013, INT J CANCER, V132, P1487, DOI 10.1002/ijc.27745
   Cimprich B, 2005, PSYCHO-ONCOLOGY, V14, P704, DOI 10.1002/pon.891
   Classen C, 2001, ARCH GEN PSYCHIAT, V58, P494, DOI 10.1001/archpsyc.58.5.494
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Coates PJ, 2010, CANCER RES, V70, P9808, DOI 10.1158/0008-5472.CAN-10-1118
   Coleman RE, 2012, CURR OPIN SUPPORT PA, V6, P322, DOI 10.1097/SPC.0b013e32835689cd
   Coles CE, 2013, CLIN ONCOL-UK, V25, P127, DOI 10.1016/j.clon.2012.10.013
   Comen Elizabeth, 2012, Recent Results Cancer Res, V195, P13, DOI 10.1007/978-3-642-28160-0_2
   Comen E, 2011, NAT REV CLIN ONCOL, V8, P369, DOI 10.1038/nrclinonc.2011.64
   Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1
   Corcoran C, 2011, CLIN CHEM, V57, P18, DOI 10.1373/clinchem.2010.150730
   Corner J, 2007, BRIT J CANCER, V96, P875, DOI 10.1038/sj.bjc.6603662
   Courneya KS, 2012, J PHYS ACT HEALTH, V9, P857, DOI 10.1123/jpah.9.6.857
   Criscitiello C, 2013, ANN ONCOL, V24, P1980, DOI 10.1093/annonc/mdt129
   Critchley AC, 2013, CLIN ONCOL-UK, V25, P101, DOI 10.1016/j.clon.2012.10.009
   Csaba P, 2010, RADIOTHER ONCOL, V94, P264, DOI 10.1016/j.radonc.2010.01.014
   Cuzick J, 2013, LANCET, V381, P1827, DOI 10.1016/S0140-6736(13)60140-3
   Cuzick J, 2011, J NATL CANCER I, V103, P744, DOI 10.1093/jnci/djr079
   D'Agostino RB, 2011, NEW ENGL J MED, V365, DOI [10.1056/nejmp1106984, 10.1056/NEJMp1106984]
   Dale David C, 2003, J Support Oncol, V1, P11
   Darabi H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3110
   Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938
   Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   Davies C, 2013, LANCET, V381, P805, DOI 10.1016/S0140-6736(12)61963-1
   Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19
   De Amicis F, 2010, BREAST CANCER RES TR, V121, P1, DOI 10.1007/s10549-009-0436-8
   De Mattos-Arruda L, 2013, NAT REV CLIN ONCOL, V10, P377, DOI 10.1038/nrclinonc.2013.80
   de Visser KE, 2012, J PATHOL, V228, P300, DOI 10.1002/path.4096
   Decensi A, 2007, J CLIN ONCOL, V25, P4201, DOI 10.1200/JCO.2006.09.4318
   Denkert C, 2012, GENOME MED, V4, DOI 10.1186/gm336
   DeRose Yoko S, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1423s60
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Dietel M, 2013, CANCER GENE THER, V20, P211, DOI 10.1038/cgt.2013.13
   Dite GS, 2013, BREAST CANCER RES TR, V139, P887, DOI 10.1007/s10549-013-2610-2
   Dittmer J, 2013, HISTOL HISTOPATHOL, V28, P827, DOI 10.14670/HH-28.827
   dos Santos CO, 2013, P NATL ACAD SCI USA, V110, P7123, DOI 10.1073/pnas.1303919110
   Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393
   Dowsett M, 2010, J CLIN ONCOL, V28, P1829, DOI 10.1200/JCO.2009.24.4798
   Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037
   Drooger JC, 2013, EUR J PHARMACOL, V717, P12, DOI 10.1016/j.ejphar.2013.03.034
   Duijts SFA, 2012, J CLIN ONCOL, V30, P4124, DOI 10.1200/JCO.2012.41.8525
   Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Dunn BK, 2011, RECENT RESULTS CANC, V188, P21, DOI 10.1007/978-3-642-10858-7_3
   Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2
   Eccles, 2011, CANC METASTASIS BIOL, P204
   Eccles SA, 2005, LANCET, V365, P1006, DOI 10.1016/S0140-6736(05)71116-8
   Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8
   Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372
   El Turabi A, 2013, BRIT J CANCER, V109, P780, DOI 10.1038/bjc.2013.316
   Eliassen AH, 2006, JAMA-J AM MED ASSOC, V296, P193, DOI 10.1001/jama.296.2.193
   Elsberger B, 2012, J CANCER RES CLIN, V138, P327, DOI 10.1007/s00432-011-1096-8
   Emilsson S, 2012, EUR J CANCER CARE, V21, P591, DOI 10.1111/j.1365-2354.2012.01343.x
   Eriksson L, 2012, BRIT J CANCER, V107, P18, DOI 10.1038/bjc.2012.234
   Evans DGR, 2012, CANCER PREV RES, V5, P943, DOI 10.1158/1940-6207.CAPR-11-0458
   Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8
   Fan P, 2009, ENDOCRINOLOGY, V150, P2036, DOI 10.1210/en.2008-1195
   Fang YZ, 2013, JNCI-J NATL CANCER I, V105, P47, DOI 10.1093/jnci/djs485
   Farhat GN, 2011, JNCI-J NATL CANCER I, V103, P562, DOI 10.1093/jnci/djr031
   Favaro E, 2011, GENOME MED, V3, DOI 10.1186/gm271
   Fenlon DR, 2009, EUR J CANCER CARE, V18, P140, DOI 10.1111/j.1365-2354.2007.00902.x
   Fenlon D, 2013, EUR J ONCOL NURS, V17, P311, DOI 10.1016/j.ejon.2012.08.004
   Fenlon DR, 2008, J PAIN SYMPTOM MANAG, V35, P397, DOI 10.1016/j.jpainsymman.2007.05.014
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ferris RL, 2012, CLIN EXP METASTAS, V29, P729, DOI 10.1007/s10585-012-9520-2
   Fidler IJ, 2011, SEMIN CANCER BIOL, V21, P107, DOI 10.1016/j.semcancer.2010.12.009
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fleissig A, 2006, BREAST CANCER RES TR, V95, P279, DOI 10.1007/s10549-005-9025-7
   Fong Daniel Y T, 2012, BMJ, V344, pe70, DOI 10.1136/bmj.e70
   Fontein DBY, 2013, CANCER TREAT REV, V39, P958, DOI 10.1016/j.ctrv.2013.03.008
   Fontein DBY, 2013, J CLIN ONCOL, V31, P2257, DOI 10.1200/JCO.2012.45.3068
   Formenti SC, 2012, INT J RADIAT ONCOL, V84, P879, DOI 10.1016/j.ijrobp.2012.06.020
   Foster C, 2007, BRIT J CANCER, V96, P718, DOI 10.1038/sj.bjc.6603610
   Foster C, 2011, BRIT J CANCER, V105, pS21, DOI 10.1038/bjc.2011.419
   Foster C, 2009, EUR J CANCER CARE, V18, P223, DOI 10.1111/j.1365-2354.2008.01001.x
   Fourie WJ, 2009, PHYSIOTHERAPY, V95, P314, DOI 10.1016/j.physio.2009.05.001
   Francia G, 2011, NAT REV CANCER, V11, P135, DOI 10.1038/nrc3001
   Friedenreich CM, 2011, RECENT RESULTS CANC, V188, P125, DOI 10.1007/978-3-642-10858-7_11
   Gagnon B, 2004, J CLIN ONCOL, V22, P3458, DOI 10.1200/JCO.2004.06.111
   Ganz PA, 2011, J CLIN ONCOL, V29, P1101, DOI 10.1200/JCO.2010.28.8043
   Garay JP, 2012, AM J CANCER RES, V2, P434
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351
   Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973
   Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9
   Gielissen MFM, 2007, BRIT J CANCER, V97, P612, DOI 10.1038/sj.bjc.6603899
   Giordano A, 2013, ANN ONCOL
   Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460
   Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90
   Glukhova MA, 2013, CURR OPIN CELL BIOL, V25, P633, DOI 10.1016/j.ceb.2013.06.010
   Gnant M, 2012, EXPERT REV ANTICANC, V12, P1579, DOI [10.1586/ERA.12.138, 10.1586/era.12.138]
   Gnant M, 2012, RECENT RESULTS CANC, V192, P65, DOI 10.1007/978-3-642-21892-7_3
   Goldhirsch A, 2012, CANCER RES, V72, DOI 10.1158/0008-5472.SABCS12-S5-2
   Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322
   Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008
   Goodwin PJ, 2012, J CLIN ONCOL, V30, P2812, DOI 10.1200/JCO.2012.42.3319
   Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178
   Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Grunfeld EA, 2006, J CLIN ONCOL, V24, P1090, DOI 10.1200/JCO.2005.01.9208
   Guerin E, 2013, CANCER RES, V73, P2743, DOI 10.1158/0008-5472.CAN-12-4183
   Hadad S, 2011, BREAST CANCER RES TR, V128, P783, DOI 10.1007/s10549-011-1612-1
   Hallowell N, 2012, FAM CANCER, V11, P215, DOI 10.1007/s10689-011-9504-4
   Hamilton-Burke W, 2010, AM J PATHOL, V177, P1079, DOI 10.2353/ajpath.2010.090886
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hannoun-Levi JM, 2013, RADIOTHER ONCOL, DOI 1016/j.radonc.2013.03.026
   Hansen J, 2012, EUR J CANCER, V48, P1722, DOI 10.1016/j.ejca.2011.07.005
   Harder H, 2013, PSYCHO-ONCOLOGY, V22, P2729, DOI 10.1002/pon.3338
   Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681
   Harvie M, 2005, CANCER EPIDEM BIOMAR, V14, P656, DOI 10.1158/1055-9965.EPI-04-0001
   He WS, 2012, ONCOL RES, V20, P251, DOI 10.3727/096504013X13589503483012
   Headley JA, 2004, ONCOL NURS FORUM, V31, P977, DOI 10.1188/04.ONF.977-983
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Hendrix A, 2011, INT J DEV BIOL, V55, P879, DOI 10.1387/ijdb.113391ah
   Hewitt M, 2003, J GERONTOL A-BIOL, V58, P82
   Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152
   Hilgart JS, 2012, COCHRANE DB SYST REV, V2
   Ho KS, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-579
   Hoelder S, 2012, MOL ONCOL, V6, P155, DOI 10.1016/j.molonc.2012.02.004
   Hoey LM, 2008, PATIENT EDUC COUNS, V70, P315, DOI 10.1016/j.pec.2007.11.016
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Honma N, 2008, J CLIN ONCOL, V26, P3727, DOI 10.1200/JCO.2007.14.2968
   HOPWOOD P, 1991, BRIT J CANCER, V64, P349, DOI 10.1038/bjc.1991.304
   Hsieh SM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2412
   Hu GH, 2009, J MOL CELL BIOL, V1, P3, DOI 10.1093/jmcb/mjp005
   Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407
   Hubbard G, 2013, BMJ SUPPORT PALLIAT, V3, P1
   Hughes KS, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.507
   Hulbert-Williams N, 2012, PSYCHO-ONCOLOGY, V21, P857, DOI 10.1002/pon.1980
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Ingham SL, 2013, CLIN GENET, V84, P37, DOI 10.1111/cge.12035
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Ito Y, 2012, BREAST CANCER-TOKYO, V19, P206, DOI 10.1007/s12282-011-0266-5
   Jacobsen PB, 2007, J CLIN ONCOL, V25, P4526, DOI 10.1200/JCO.2007.13.1367
   Jakesz R, 2005, LANCET, V366, P455, DOI 10.1016/S0140-6736(05)67059-6
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734
   Jung S, 2013, JNCI-J NATL CANCER I, V105, P219, DOI 10.1093/jnci/djs635
   Kabos P, 2012, BREAST CANCER RES TR, V135, P415, DOI 10.1007/s10549-012-2164-8
   Kaimala S, 2012, J BIOSCIENCES, V37, P349, DOI 10.1007/s12038-012-9200-z
   Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Karamouzis MV, 2007, EUR J CANCER CARE, V16, P433, DOI 10.1111/j.1365-2354.2006.00771.x
   Kasimir-Bauer S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3099
   Kauselmann G, 2012, CURR CANCER DRUG TAR, V12, P1
   Kelly CM, 2013, DRUGS, V73, P505, DOI 10.1007/s40265-013-0044-0
   Kerbel RS, 2012, J MAMMARY GLAND BIOL, V17, P229, DOI 10.1007/s10911-012-9266-0
   Key TJ, 2011, STEROIDS, V76, P812, DOI 10.1016/j.steroids.2011.02.029
   Khoury T, 2012, APPL IMMUNOHISTO M M, V20, P531, DOI 10.1097/PAI.0b013e318248bf6d
   Kievit FM, 2012, ACS NANO, V6, P2591, DOI 10.1021/nn205070h
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Kirkbride P, 2012, CLIN ONCOL-UK, V24, P627, DOI 10.1016/j.clon.2012.06.001
   Kirma NB, 2012, J STEROID BIOCHEM, V131, P76, DOI 10.1016/j.jsbmb.2011.11.005
   Kissane DW, 2004, AUST NZ J PSYCHIAT, V38, P320, DOI 10.1080/j.1440-1614.2004.01358.x
   Knowles SM, 2012, J CLIN ONCOL, V30, P3884, DOI 10.1200/JCO.2012.42.4887
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krishnan V, 2011, J CELL PHYSIOL, V226, P2150, DOI 10.1002/jcp.22550
   Kunkler I, 2010, EJSO-EUR J SURG ONC, V36, P331, DOI 10.1016/j.ejso.2009.11.004
   La Porta Caterina Am, 2012, World J Stem Cells, V4, P17, DOI 10.4252/wjsc.v4.i3.17
   LaCroix AZ, 2010, JNCI-J NATL CANCER I, V102, P1706, DOI 10.1093/jnci/djq415
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Lambin P, 2012, EUR J CANCER, V48, P441, DOI 10.1016/j.ejca.2011.11.036
   Larionov AFD, 2009, CANCER RES, V69, P809
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Leal J, 2012, P NAT CANC RES I C 4
   Leary AF, 2009, J CLIN ONCOL, V27, P1694, DOI 10.1200/JCO.2008.17.3989
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lelièvre SA, 2010, J MAMMARY GLAND BIOL, V15, P49, DOI 10.1007/s10911-010-9168-y
   Lenzer J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4244
   Lewis CE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1679
   Li CI, 2010, J NATL CANCER I, V102, P1422, DOI 10.1093/jnci/djq316
   Liauw SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005148
   Lindell KO, 2006, PLOS MED, V3, P953, DOI 10.1371/journal.pmed.0030234
   Lindor NM, 2013, ONCOLOGIST, V18, P518, DOI 10.1634/theoncologist.2012-0452
   Lipkus IM, 2010, MED DECIS MAKING, V30, P464, DOI 10.1177/0272989X09360371
   Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Longo VD, 2011, AGING-US, V3, P1039, DOI 10.18632/aging.100401
   Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773
   Lundgren K, 2007, CELL MOL LIFE SCI, V64, P3233, DOI 10.1007/s00018-007-7390-6
   Macaskill EJ, 2011, BREAST CANCER RES TR, V128, P725, DOI 10.1007/s10549-010-0967-z
   Maddams J, 2012, BRIT J CANCER, V107, P1195, DOI 10.1038/bjc.2012.366
   Maddams J, 2009, BRIT J CANCER, V101, P541, DOI 10.1038/sj.bjc.6605148
   Maguire P, 2002, ABC BREAST DIS, P150
   Makarem M, 2013, J MAMMARY GLAND BIOL, V18, P209, DOI 10.1007/s10911-013-9284-6
   Makubate B, 2013, BRIT J CANCER, V108, P1515, DOI 10.1038/bjc.2013.116
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mann E, 2012, LANCET ONCOL, V13, P309, DOI 10.1016/S1470-2045(11)70364-3
   Mann E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-44
   Mannino M, 2009, RADIOTHER ONCOL, V90, P14, DOI 10.1016/j.radonc.2008.05.002
   Mao Q, 2013, J CANCER RES CLIN, V139, P211, DOI 10.1007/s00432-012-1310-3
   Marchini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014131
   Marleau AM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-134
   Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1
   Martin LJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1831
   Martinez-Outschoorn UE, 2011, CANCER BIOL THER, V12, P924, DOI 10.4161/cbt.12.10.17780
   Melchor L, 2013, HUM GENET
   Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Michalak EM, 2011, J MAMMARY GLAND BIOL, V16, P41, DOI 10.1007/s10911-011-9199-z
   Milani M, 2008, EUR J CANCER, V44, P2766, DOI 10.1016/j.ejca.2008.09.025
   Milas L, 2009, SEMIN RADIAT ONCOL, V19, P96, DOI 10.1016/j.semradonc.2008.11.004
   Miller WR, 2012, PHARMACOGENOMICS J, V12, P10, DOI 10.1038/tpj.2010.67
   Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004
   Mina LA, 2011, NAT REV CLIN ONCOL, V8, P325, DOI 10.1038/nrclinonc.2011.59
   Mireskandari S, 2007, GENET MED, V9, P311, DOI 10.1097/GIM.0b013e3180534293
   Modur V, 2013, CLIN CHEM, V59, P102, DOI 10.1373/clinchem.2012.191072
   Molina R, 2012, CLIN CHEM LAB MED, V50, P5, DOI [10.1515/CCLM.2011.822, 10.1515/cclm.2011.822]
   Mollard S, 2011, CANCER BIOL THER, V12, P855, DOI 10.4161/cbt.12.10.18139
   Molyneux G, 2011, J MAMMARY GLAND BIOL, V16, P51, DOI 10.1007/s10911-011-9202-8
   Moulder S, 2011, J CLIN ONCOL, V29, pE572, DOI 10.1200/JCO.2010.34.0604
   Mouridsen H, 2009, NEW ENGL J MED, V361, P766, DOI 10.1056/NEJMoa0810818
   Moussa O, 2012, CANCER BIOMARK, V12, P231, DOI 10.3233/CBM-130314
   Müller HM, 2003, CANCER RES, V63, P7641
   Muller V, 2012, BCR, V14, pR118
   Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
   Mutrie N, 2012, J CANCER SURVIV, V6, P420, DOI 10.1007/s11764-012-0233-y
   Naba A, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014647
   Nagy JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z
   Neal R. D., 2008, COCHRANE DB SYST REV, V16, P3
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Niraula S, 2012, BREAST CANCER RES TR, V134, P769, DOI 10.1007/s10549-012-2073-x
   O'Hara J, 2012, CLIN CANCER RES, V18, P3305, DOI 10.1158/1078-0432.CCR-11-3300
   Obeid E, 2013, INT J ONCOL, V43, P5, DOI 10.3892/ijo.2013.1938
   Oliveri Jill M, 2008, J Cancer Surviv, V2, P233, DOI 10.1007/s11764-008-0065-y
   Osborn RL, 2006, INT J PSYCHIAT MED, V36, P13, DOI 10.2190/EUFN-RV1K-Y3TR-FK0L
   Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078-0432.CCR-10-1869
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985
   Palmieri C, 2011, CLIN BREAST CANCER, V11, P93, DOI 10.1016/j.clbc.2011.03.001
   Palmieri D, 2009, CLIN CANCER RES, V15, P6148, DOI 10.1158/1078-0432.CCR-09-1039
   Parkin DM, 2011, J EPIDEMIOL COMMUN H, V65, pA143, DOI 10.1136/jech.2011.142976e.69
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470-2045(12)70226-7
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002
   Pierce JP, 2007, JAMA-J AM MED ASSOC, V298, P289, DOI 10.1001/jama.298.3.289
   PINDER KL, 1993, EUR J CANCER, V29A, P524
   Pivot X, 2013, LANCET ONCOL, V14, P741, DOI 10.1016/S1470-2045(13)70225-0
   Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Pontiggia O, 2012, BREAST CANCER RES TR, V133, P459, DOI 10.1007/s10549-011-1766-x
   Postovit LM, 2008, J CELL BIOCHEM, V103, P1369, DOI 10.1002/jcb.21517
   Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629
   Quail DF, 2012, J BIOMOL SCREEN, V17, P1088, DOI 10.1177/1087057112449863
   Rack B, 2010, BREAST CARE, V5, P395, DOI 10.1159/000322677
   Rampinelli C, 2011, TECHNOL CANCER RES T, V10, P323, DOI 10.7785/tcrt.2012.500209
   Ran Sophia, 2010, Pathophysiology, V17, P229, DOI 10.1016/j.pathophys.2009.11.003
   Rausch R, 2003, NEUROLOGY, V60, P951, DOI 10.1212/01.WNL.0000048203.23766.A1
   Reed E, 2012, J PAIN SYMPTOM MANAG, V43, P747, DOI 10.1016/j.jpainsymman.2011.05.005
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Reisfeld Ralph A., 2013, Critical Reviews in Oncogenesis, V18, P115
   Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113
   Richardson A, 2011, BRIT J CANCER, V105, pS82, DOI 10.1038/bjc.2011.425
   Ring A, 2013, ANN ONCOL, V24, P1211, DOI 10.1093/annonc/mds642
   Riou O, 2012, INT J SURG ONCOL, V2012, DOI 10.1155/2012/748196
   Ritterband LM, 2012, PSYCHO-ONCOLOGY, V21, P695, DOI 10.1002/pon.1969
   Rosner B, 2013, AM J EPIDEMIOL, V178, P296, DOI 10.1093/aje/kws457
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105
   Rundqvist H, 2010, CURR TOP MICROBIOL, V345, P121, DOI 10.1007/82_2010_77
   Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088
   Rutgers EJ, 2013, J CLIN ONCOLOGY
   Sakoda LC, 2013, NAT GENET, V45, P345, DOI 10.1038/ng.2587
   Sampieri K, 2012, SEMIN CANCER BIOL, V22, P187, DOI 10.1016/j.semcancer.2012.03.002
   Samuel N, 2013, CLIN CHEM, V59, P127, DOI 10.1373/clinchem.2012.184580
   Santen RJ, 2007, ENDOCR-RELAT CANCER, V14, P169, DOI 10.1677/ERC-06-0045
   Santen RJ, 2009, STEROIDS, V74, P586, DOI 10.1016/j.steroids.2008.11.020
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Sceneay J, 2013, CANC METASTASIS REV
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Scheel C, 2011, INT J CANCER, V129, P2310, DOI 10.1002/ijc.26311
   Seah MDW, 2009, ASIAN J SURG, V32, P71, DOI 10.1016/S1015-9584(09)60013-0
   Segal E, 2007, NAT BIOTECHNOL, V25, P675, DOI 10.1038/nbt1306
   Senkus E, 2013, ANN ONCOL, V24, P7, DOI 10.1093/annonc/mdt284
   Seymour KC, 2010, J GENET COUNS, V19, P330, DOI 10.1007/s10897-010-9296-y
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shennan C, 2011, PSYCHO-ONCOLOGY, V20, P681, DOI 10.1002/pon.1819
   Shojaei F, 2012, CANCER LETT, V320, P130, DOI 10.1016/j.canlet.2012.03.008
   Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406
   Smalley M, 2013, CANCER LETT, V338, P57, DOI 10.1016/j.canlet.2012.04.023
   Smith BD, 2012, J CLIN ONCOL, V30, P3913, DOI 10.1200/JCO.2012.44.4539
   Smith BD, 2009, INT J RADIAT ONCOL, V74, P987, DOI 10.1016/j.ijrobp.2009.02.031
   Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067
   Somaiah N, 2013, RADIOTHER ONCOL, V108, P155, DOI 10.1016/j.radonc.2013.05.012
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Speck RM, 2010, J CANCER SURVIV, V4, P87, DOI 10.1007/s11764-009-0110-5
   SPIEGEL D, 1989, LANCET, V2, P888
   Stanton AL, 2013, J CONSULT CLIN PSYCH, V81, P318, DOI 10.1037/a0028833
   Steeg PS, 2012, NATURE, V485, pS58, DOI 10.1038/485S58a
   Sultana R, 2013, CANCER RES, V73, P1621, DOI 10.1158/0008-5472.CAN-12-2929
   Swain SM, 2013, LANCET ONCOL, V14, P461, DOI 10.1016/S1470-2045(13)70130-X
   Swerdlow AJ, 2012, J CLIN ONCOL, V30, P2745, DOI 10.1200/JCO.2011.38.8835
   Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876
   Tan EY, 2009, BRIT J CANCER, V100, P405, DOI 10.1038/sj.bjc.6604844
   Tenori L, 2012, MOL ONCOL, V6, P437, DOI 10.1016/j.molonc.2012.05.003
   Teras LR, 2011, CANCER CAUSE CONTROL, V22, P573, DOI 10.1007/s10552-011-9730-y
   Thompson AM, 2012, ANN ONCOL, V23, P231, DOI 10.1093/annonc/mds324
   Thompson A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1983
   Thompson AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2771
   Thompson AM, 2011, BREAST CANCER RES TR, V125, P279, DOI 10.1007/s10549-010-1139-x
   Thompson J, 2009, PSYCHOONCOLOGY S3, V19, pS1
   Thureau S, 2012, ANTICANCER RES, V32, P1429
   Tinterri C, 2009, BREAST, V18, P373, DOI 10.1016/j.breast.2009.09.013
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Turnbull C, 2012, HUM MOL GENET, V21, P958, DOI 10.1093/hmg/ddr525
   Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746
   Uhra JW, 2011, P NATL ACAD SCI USA, V108, P12396, DOI 10.1073/pnas.1106613108
   Uray IP, 2011, RECENT RESULTS CANC, V188, P147, DOI 10.1007/978-3-642-10858-7_13
   Vaidya JS, 2010, LANCET, V376, P91, DOI 10.1016/S0140-6736(10)60837-9
   van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573
   Villarini A, 2012, TUMORI J, V98, P1, DOI 10.1700/1053.11494
   Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Wakefield CE, 2008, BREAST CANCER RES TR, V107, P289, DOI 10.1007/s10549-007-9539-2
   Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004
   Waterton JC, 2012, EUR J CANCER, V48, P409, DOI 10.1016/j.ejca.2011.11.037
   Watson EK, 2012, BRIT J CANCER, V106, P1, DOI 10.1038/bjc.2011.535
   Watts K, 2011, ONCOL NURS FORUM, V38, P627, DOI 10.1188/11.ONF.627-631
   Watts KJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-320
   Wei SW, 2013, MOL ONCOL, V7, P297, DOI 10.1016/j.molonc.2012.10.003
   Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2
   Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260
   Willis L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062320
   Wilson C, 2012, CANCER TREAT REV, V38, P877, DOI 10.1016/j.ctrv.2012.02.007
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
   Witzel I, 2010, BREAST CANCER RES TR, V123, P437, DOI 10.1007/s10549-010-1030-9
   Wong ALA, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/415170
   Xia TS, 2010, ONCOL REP, V24, P203, DOI 10.3892/or_00000847
   Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663
   Yan Y, 2013, ANN ONCOL, V24, P1986, DOI 10.1093/annonc/mdt132
   Yarnold J, 2011, INT J RADIAT ONCOL, V79, P1, DOI 10.1016/j.ijrobp.2010.08.035
   Yazici H, 2009, CANCER EPIDEM BIOMAR, V18, P2723, DOI 10.1158/1055-9965.EPI-08-1237
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
   Yuan H, 2012, NEW ENGL J MED, V367, P1220, DOI 10.1056/NEJMoa1203055
   Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29
   Zhang F, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-S1-S6
   Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081
NR 403
TC 296
Z9 331
U1 1
U2 131
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2013
VL 15
IS 5
AR R92
DI 10.1186/bcr3493
PG 37
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 290NA
UT WOS:000329763800020
PM 24286369
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lin, X
   Li, J
   Yin, GL
   Zhao, Q
   Elias, D
   Lykkesfeldt, AE
   Stenvang, J
   Bruenner, N
   Wang, J
   Yang, HM
   Bolund, L
   Ditzel, HJ
AF Lin, Xue
   Li, Jian
   Yin, Guangliang
   Zhao, Qian
   Elias, Daniel
   Lykkesfeldt, Anne E.
   Stenvang, Jan
   Bruenner, Nils
   Wang, Jun
   Yang, Huanming
   Bolund, Lars
   Ditzel, Henrik J.
TI Integrative analyses of gene expression and DNA methylation profiles in
   breast cancer cell line models of tamoxifen-resistance indicate a
   potential role of cells with stem-like properties
SO BREAST CANCER RESEARCH
LA English
DT Article
ID HORMONE-INDEPENDENT GROWTH; ESTROGEN-RECEPTOR FUNCTION; ANTIESTROGEN
   RESISTANCE; IN-VITRO; STEM/PROGENITOR CELLS; ENDOCRINE RESISTANCE;
   REGULATED GENES; MCF-7 CELLS; FOXA1; TRANSCRIPTION
AB Introduction: Development of resistance to tamoxifen is an important clinical issue in the treatment of breast cancer. Tamoxifen resistance may be the result of acquisition of epigenetic regulation within breast cancer cells, such as DNA methylation, resulting in changed mRNA expression of genes pivotal for estrogen-dependent growth. Alternatively, tamoxifen resistance may be due to selection of pre-existing resistant cells, or a combination of the two mechanisms.
   Methods: To evaluate the contribution of these possible tamoxifen resistance mechanisms, we applied modified DNA methylation-specific digital karyotyping (MMSDK) and digital gene expression (DGE) in combination with massive parallel sequencing to analyze a well-established tamoxifen-resistant cell line model (TAM(R)), consisting of 4 resistant and one parental cell line. Another tamoxifen-resistant cell line model system (LCC1/LCC2) was used to validate the DNA methylation and gene expression results.
   Results: Significant differences were observed in global gene expression and DNA methylation profiles between the parental tamoxifen-sensitive cell line and the 4 tamoxifen-resistant TAM(R) sublines. The 4 TAM(R) cell lines exhibited higher methylation levels as well as an inverse relationship between gene expression and DNA methylation in the promoter regions. A panel of genes, including NRIP1, HECA and FIS1, exhibited lower gene expression in resistant vs. parental cells and concurrent increased promoter CGI methylation in resistant vs. parental cell lines. A major part of the methylation, gene expression, and pathway alterations observed in the TAM(R) model were also present in the LCC1/LCC2 cell line model. More importantly, high expression of SOX2 and alterations of other SOX and E2F gene family members, as well as RB-related pocket protein genes in TAM(R) highlighted stem cell-associated pathways as being central in the resistant cells and imply that cancer-initiating cells/cancer stem-like cells may be involved in tamoxifen resistance in this model.
   Conclusion: Our data highlight the likelihood that resistant cells emerge from cancer-initiating cells/cancer stem-like cells and imply that these cells may gain further advantage in growth via epigenetic mechanisms. Illuminating the expression and DNA methylation features of putative cancer-initiating cells/cancer stem cells may suggest novel strategies to overcome tamoxifen resistance.
C1 [Lin, Xue; Li, Jian; Yin, Guangliang; Elias, Daniel; Lykkesfeldt, Anne E.; Stenvang, Jan; Bruenner, Nils; Wang, Jun; Yang, Huanming; Bolund, Lars; Ditzel, Henrik J.] Sino Danish Breast Canc Res Ctr, Copenhagen, Denmark.
   [Lin, Xue; Li, Jian; Bolund, Lars] Univ Aarhus, Dept Biomed, DK-8000 Aarhus, Denmark.
   [Li, Jian; Yin, Guangliang; Wang, Jun; Yang, Huanming; Bolund, Lars] BGI Shenzhen, Shenzhen 518083, Peoples R China.
   [Li, Jian; Elias, Daniel; Ditzel, Henrik J.] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, DK-5000 Odense, Denmark.
   [Zhao, Qian] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
   [Lykkesfeldt, Anne E.] Danish Canc Soc Res Ctr, DK-2100 Copenhagen, Denmark.
   [Stenvang, Jan; Bruenner, Nils] Univ Copenhagen, Dept Vet Dis Biol, Fac Hlth & Med Sci, DK-2100 Copenhagen, Denmark.
   [Yang, Huanming] James D Watson Inst Genome Sci, Hangzhou, Zhejiang, Peoples R China.
   [Ditzel, Henrik J.] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark.
C3 Aarhus University; Beijing Genomics Institute (BGI); University of
   Southern Denmark; Tongji University; Danish Cancer Society; University
   of Copenhagen; University of Southern Denmark; Odense University
   Hospital
RP Bolund, L (通讯作者)，Sino Danish Breast Canc Res Ctr, Copenhagen, Denmark.
EM bolundlars@gmail.com; hditzel@health.sdu.dk
RI Elias, Daniel/KBD-3896-2024; Wang, Jun/A-7261-2013; Wang,
   Jun/B-9503-2016; Yang, Huanming/C-6513-2013; Wang, Jun/C-8434-2016
OI Wang, Jun/0000-0002-2113-5874; Stenvang, Jan/0000-0001-5647-4828;
   Ditzel, Henrik J./0000-0003-3927-5135; Yang,
   Huanming/0000-0002-0858-3410; Wang, Jun/0000-0002-8540-8931
FU Sino-Danish Breast Cancer Research Centre; Danish National Research
   Foundation (Grundforskningsfonden); National Natural Science Foundation
   of China [30890032, 31161130357]; Chinese 863 Program [2012AA02A201,
   2012AA02A502]; Guangdong Innovative Research Team Program [2009010016];
   Danish Cancer Society; Danish Research Council; Danish Center for
   Translational Breast Cancer Research; A Race Against Breast Cancer
FX This study was supported by the Sino-Danish Breast Cancer Research
   Centre, financed by the Danish National Research Foundation
   (Grundforskningsfonden) and the National Natural Science Foundation of
   China (30890032, 31161130357). Further support was obtained from the
   Chinese 863 Program (2012AA02A201, 2012AA02A502), the Guangdong
   Innovative Research Team Program (2009010016), the Danish Cancer
   Society, the Danish Research Council, the Danish Center for
   Translational Breast Cancer Research and A Race Against Breast Cancer.
   The authors thank MK Occhipinti-Bender for editorial assistance.
CR Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007
   Alles MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004710
   Augello MA, 2011, EMBO J, V30, P3885, DOI 10.1038/emboj.2011.340
   Becker KA, 2007, J CELL PHYSIOL, V210, P517, DOI 10.1002/jcp.20903
   Bernard P, 2010, INT J BIOCHEM CELL B, V42, P400, DOI 10.1016/j.biocel.2009.10.017
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   BRIAND P, 1986, ANTICANCER RES, V6, P85
   Brockdorff BL, 2003, ENDOCR-RELAT CANCER, V10, P579, DOI 10.1677/erc.0.0100579
   BRUNNER N, 1993, CANCER RES, V53, P3229
   BRUNNER N, 1993, CANCER RES, V53, P283
   Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200
   CLARK GM, 1984, J CLIN ONCOL, V2, P1102, DOI 10.1200/JCO.1984.2.10.1102
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649
   Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   de Cremoux P, 2003, ENDOCR-RELAT CANCER, V10, P409, DOI 10.1677/erc.0.0100409
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dowejko A, 2012, EXP CELL RES, V318, P489, DOI 10.1016/j.yexcr.2011.11.004
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946
   Frogne T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2230
   Fu XY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2849
   Ghoussaini M, 2012, NAT GENET, V44, P312, DOI 10.1038/ng.1049
   Gjerstorff MF, 2006, BRIT J CANCER, V94, P1864, DOI 10.1038/sj.bjc.6603163
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Ivanova IA, 2005, INT J BIOL SCI, V1, P87
   Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886
   Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li J, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-223
   Li ZL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020526
   LIPPMAN M, 1976, CANCER RES, V36, P4595
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   LYKKESFELDT AE, 1994, CANCER RES, V54, P1587
   LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5
   Madsen MW, 1997, CANCER RES, V57, P585
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502
   O'Brien C, 2009, CANC RES S, V69
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240
   Pérez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126
   Petersen OW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003160
   Rasmussen BB, 2008, LANCET ONCOL
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442
   Sastre-Serra J, 2012, INT J BIOCHEM CELL B, V44, P1901, DOI 10.1016/j.biocel.2012.07.012
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Talman MLM, 2008, ACTA ONCOL, V47, P789, DOI 10.1080/02841860801982741
   Tempel Sebastien, 2012, Methods Mol Biol, V859, P29, DOI 10.1007/978-1-61779-603-6_2
   Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2
   Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200
   VANAGTHOVEN T, 1994, MOL ENDOCRINOL, V8, P1474, DOI 10.1210/me.8.11.1474
   Wong J, 2007, FRONT BIOSCI, V12, P2085, DOI 10.2741/2213
   Xu J, 2007, P NATL ACAD SCI USA, V104, P12377, DOI 10.1073/pnas.0704579104
NR 66
TC 43
Z9 51
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2013
VL 15
IS 6
AR R119
DI 10.1186/bcr3588
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB1IH
UT WOS:000331544200015
PM 24355041
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yin, XD
   Xiang, TX
   Li, LL
   Su, XW
   Shu, XS
   Luo, XR
   Huang, JB
   Yuan, Y
   Peng, WY
   Oberst, M
   Kelly, K
   Ren, GS
   Tao, Q
AF Yin, Xuedong
   Xiang, Tingxiu
   Li, LiLi
   Su, Xianwei
   Shu, Xingsheng
   Luo, Xinrong
   Huang, Jianbo
   Yuan, Ying
   Peng, Weiyan
   Oberst, Michael
   Kelly, Kathleen
   Ren, Guosheng
   Tao, Qian
TI <i>DACT1</i>, an antagonist to Wnt/β-catenin signaling, suppresses tumor
   cell growth and is frequently silenced in breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID BETA-CATENIN; METHYLATION PATTERNS; HDPR1; DNA; ESOPHAGEAL; MECHANISM;
   CARCINOMA; DAPPER1; PATHWAY
AB Introduction: Aberrant activation of Wnt/beta-catenin signaling plays an important role in the pathogenesis of breast cancer. DACT1 (Dapper/Frodo) has been identified as involved in antagonizing Wnt/beta-catenin signaling through interacting with Dishevelled (Dvl), a central mediator of Wnt signaling, whereas its role in breast tumorigenesis remains unclear.
   Methods: We examined DACT1 expression in breast cancer cell lines and primary tumors with semiquantitative or quantitative RT-PCR and immunochemistry, and further evaluated the promoter methylation of DACT1 with methylation-specific PCR (MSP). We also explored the tumor-suppressive functions of DACT1 in vivo and in vitro, and its related mechanism in breast cancer.
   Results: We identified DACT1 as a methylated target in our breast cancer epigenome study. Here, we further investigated DACT1 expression in multiple breast cell lines and primary tumors, and further studied its function and molecular mechanisms. We found that DACT1 expression was silenced in eight (88.9%) of nine breast cancer cell lines, and its protein levels were obviously reduced in breast tumors compared with paired surgical-margin tissues. Promoter CpG methylation of DACT1 was detected in five (55.6%) of nine breast cancer cell lines and 40 (29.9%) of 134 primary tumors, but not in surgical-margin tissues and normal breast tissues. Demethylation treatment of breast cancer cell lines restored DACT1 expression along with promoter demethylation, suggesting that an epigenetic mechanism mediates DACT1 silencing in breast cancer. Functional assays showed that ectopic expression of DACT1 could inhibit breast tumor cell proliferation in vivo and in vitro through inducing apoptosis, and further suppress tumor cell migration through antagonizing the Wnt/beta-catenin signaling pathway.
   Conclusions: Our study demonstrates that DACT1 could function as a tumor suppressor but was frequently downregulated in breast cancer.
C1 [Yin, Xuedong; Xiang, Tingxiu; Luo, Xinrong; Huang, Jianbo; Yuan, Ying; Peng, Weiyan; Ren, Guosheng; Tao, Qian] Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing 400016, Peoples R China.
   [Li, LiLi; Su, Xianwei; Shu, Xingsheng; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China.
   [Li, LiLi; Su, Xianwei; Shu, Xingsheng; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China.
   [Li, LiLi; Su, Xianwei; Shu, Xingsheng; Tao, Qian] CUHK Shenzhen Res Inst, Shatin, Hong Kong, Peoples R China.
   [Oberst, Michael; Kelly, Kathleen] NCI, Signal Transduct Sect, NIH, Bethesda, MD 20892 USA.
   [Tao, Qian] Dalian Med Univ, Ctr Canc, Dalian 116044, Peoples R China.
C3 Chongqing Medical University; Chinese University of Hong Kong; Chinese
   University of Hong Kong; CUHK Shenzhen Research Institute; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   Dalian Medical University
RP Ren, GS (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM rgs726@163.com; qtao@clo.cuhk.edu.hk
RI Xiang, Tingxiu/E-6157-2016; Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018
OI Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808; Huang,
   Jianbo/0000-0002-1662-2969
FU National Natural Science Foundation of China [31171243, 81072148,
   81172582]; Natural Science Foundation of Chongqing [2010BB5101]; Group
   Research Scheme of The Chinese University of Hong Kong [3110085]
FX We thank Dr. Sun Y. Rha for some breast cancer cell lines. This study
   was supported by National Natural Science Foundation of China (31171243,
   81072148, and 81172582), Natural Science Foundation of Chongqing
   (2010BB5101) and the Group Research Scheme of The Chinese University of
   Hong Kong (3110085).
CR Astolfi A, 2010, LAB INVEST, V90, P1285, DOI 10.1038/labinvest.2010.110
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Chen H, 2011, J BIOL CHEM, V286, P14870, DOI 10.1074/jbc.M110.211607
   Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fisher DA, 2006, DEV DYNAM, V235, P2620, DOI 10.1002/dvdy.20917
   Gloy J, 2002, NAT CELL BIOL, V4, P351, DOI 10.1038/ncb784
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Hou J, 2011, J HISTOCHEM CYTOCHEM, V59, P711, DOI 10.1369/0022155411409941
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Katoh M, 2003, INT J ONCOL, V22, P907
   Oda T, 2007, BLOOD, V109, P5016, DOI 10.1182/blood-2006-08-038638
   Okerlund ND, 2010, J NEUROSCI, V30, P4362, DOI 10.1523/JNEUROSCI.0354-10.2010
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Skvortsova TE, 2006, BRIT J CANCER, V94, P1492, DOI 10.1038/sj.bjc.6603117
   Suriben R, 2006, DEV DYNAM, V235, P3177, DOI 10.1002/dvdy.20968
   Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Waxman JS, 2004, DEVELOPMENT, V131, P5909, DOI 10.1242/dev.01520
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Xiang TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029783
   Xiang TX, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12726
   Yang ZQ, 2010, MOL CARCINOGEN, V49, P508, DOI 10.1002/mc.20622
   Yau TO, 2005, ONCOGENE, V24, P1607, DOI 10.1038/sj.onc.1208340
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371
   Yuan GH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034004
   Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200
NR 34
TC 74
Z9 91
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2013
VL 15
IS 2
AR R23
DI 10.1186/bcr3399
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 302NU
UT WOS:000330612000006
PM 23497530
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ferrari-Amorotti, G
   Fragliasso, V
   Esteki, R
   Prudente, Z
   Soliera, AR
   Cattelani, S
   Manzotti, G
   Grisendi, G
   Dominici, M
   Pieraccioli, M
   Raschellà, G
   Chiodoni, C
   Colombo, MP
   Calabretta, B
AF Ferrari-Amorotti, Giovanna
   Fragliasso, Valentina
   Esteki, Roza
   Prudente, Zelia
   Soliera, Angela Rachele
   Cattelani, Sara
   Manzotti, Gloria
   Grisendi, Giulia
   Dominici, Massimo
   Pieraccioli, Marco
   Raschella, Giuseppe
   Chiodoni, Claudia
   Colombo, Mario Paolo
   Calabretta, Bruno
TI Inhibiting Interactions of Lysine Demethylase LSD1 with Snail/Slug
   Blocks Cancer Cell Invasion
SO CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR SNAIL;
   E-CADHERIN EXPRESSION; TUMOR-METASTASIS; DUCTAL CARCINOMA;
   BREAST-CANCER; STEM-CELLS; IN-VIVO; SLUG; PROGRESSION
AB The process of epithelial-mesenchymal transition (EMT) which is required for cancer cell invasion is regulated by a family of E-box-binding transcription repressors, which include Snail (SNAIL1) and Slug (SNAI2). Snail appears to repress the expression of the EMT marker E-cadherin by epigenetic mechanisms dependent on the interaction of its N-terminal SNAG domain with chromatin-modifying proteins including lysine-specific demethylase 1 (LSD1/KDM1A). We assessed whether blocking Snail/Slug-LSD1 interaction by treatment with Parnate, an enzymatic inhibitor of LSD1, or TAT-SNAG, a cell-permeable peptide corresponding to the SNAG domain of Slug, suppresses the motility and invasiveness of cancer cells of different origin and genetic background. We show here that either treatment blocked Slug-dependent repression of the E-cadherin promoter and inhibited the motility and invasion of tumor cell lines without any effect on their proliferation. These effects correlated with induction of epithelial and repression of mesenchymal markers and were phenocopied by LSD1 or Slug downregulation. Parnate treatment also inhibited bone marrow homing/engraftment of Slug-expressing K562 cells. Together, these studies support the concept that targeting Snail/Slug-dependent transcription repression complexes may lead to the development of novel drugs selectively inhibiting the invasive potential of cancer cells. Cancer Res; 73(1); 235-45. (C) 2012 AACR.
C1 [Calabretta, Bruno] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.
   [Calabretta, Bruno] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [Ferrari-Amorotti, Giovanna; Fragliasso, Valentina; Esteki, Roza; Prudente, Zelia; Soliera, Angela Rachele; Cattelani, Sara; Manzotti, Gloria; Calabretta, Bruno] Univ Modena & R Emilia, Dept Clin & Diagnost Med & Publ Hlth, Modena, Italy.
   [Grisendi, Giulia; Dominici, Massimo] Univ Modena & R Emilia, Dept Med & Surg Sci, Modena, Italy.
   [Pieraccioli, Marco; Raschella, Giuseppe] ENEA Res Ctr Casaccia, Lab Radiat Biol & Biomed, Rome, Italy.
   [Chiodoni, Claudia; Colombo, Mario Paolo] Fdn IRCCS Ist Nazl Tumori, Mol Immunol Unit, Dept Expt Oncol & Mol Med, Milan, Italy.
C3 Thomas Jefferson University; Thomas Jefferson University; Universita di
   Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Italian
   National Agency New Technical Energy & Sustainable Economics
   Development; Fondazione IRCCS Istituto Nazionale Tumori Milan
RP Calabretta, B (通讯作者)，Thomas Jefferson Univ, Dept Canc Biol, 233 South, Philadelphia, PA 19107 USA.
EM B_Calabretta@mail.jci.tju.edu
RI Dominici, Massimo/K-8014-2016; Pieraccioli, Marco/K-4294-2018;
   fragliasso, valentina/AAA-2291-2022; Grisendi, Giulia/J-6360-2016;
   Fragliasso, Valentina/K-4657-2016; Chiodoni, Claudia/C-2172-2017;
   Manzotti, Gloria/J-7235-2016; Colombo, Mario Paolo/V-7166-2017
OI Pieraccioli, Marco/0000-0003-3995-535X; Grisendi,
   Giulia/0000-0002-0120-6129; Fragliasso, Valentina/0000-0002-4189-0316;
   Chiodoni, Claudia/0000-0002-7644-9969; Manzotti,
   Gloria/0000-0002-0639-3605; Colombo, Mario Paolo/0000-0003-0042-7955;
   Dominici, Massimo/0000-0002-4007-1503
FU Fondazione Cassa di Risparmio di Modena; Fondazione Guido Berlucchi;
   Amici di Lino; NCI [CA095111]; Associazione Italiana Ricerca sul Cancro
   (AIRC); Fondazione Angela Serra; Fondazione Cassa di Risparmio di
   Vignola
FX This work was supported by grants of the Fondazione Cassa di Risparmio
   di Modena, Fondazione Guido Berlucchi, Amici di Lino, and by NCI grant
   CA095111. G. Ferrari-Amorotti was supported by Fellowship of the
   Associazione Italiana Ricerca sul Cancro (AIRC) and is currently
   supported by Fondazione Angela Serra. A. R. Soliera and G. Manzotti are
   supported by a fellowship of AIRC. S. Cattelani was supported by
   fellowships of AIRC and the Fondazione Cassa di Risparmio di Vignola and
   is currently supported by a fellowship of the Fondazione Cassa di
   Risparmio di Modena.
CR Ahmad KF, 2003, MOL CELL, V12, P1551, DOI 10.1016/S1097-2765(03)00454-4
   Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433
   Baron R, 2011, STRUCTURE, V19, P212, DOI 10.1016/j.str.2011.01.001
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330
   Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200
   Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883
   Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004
   Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634
   Hajra KM, 2002, CANCER RES, V62, P1613
   HENNIG G, 1995, ONCOGENE, V11, P475
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235
   Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Logullo AF, 2010, ONCOL REP, V23, P313, DOI 10.3892/or_00000638
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691
   Nakamura M, 2011, J DERMATOL SCI, V61, P7, DOI 10.1016/j.jdermsci.2010.11.015
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325
   Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621
   Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687
   Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Tanno B, 2010, J BIOL CHEM, V285, P29434, DOI 10.1074/jbc.M109.089045
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148
   Usami Y, 2008, J PATHOL, V215, P330, DOI 10.1002/path.2365
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017
   Vitali R, 2008, CLIN CANCER RES, V14, P4622, DOI 10.1158/1078-0432.CCR-07-5210
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
NR 44
TC 118
Z9 131
U1 0
U2 25
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 1
PY 2013
VL 73
IS 1
BP 235
EP 245
DI 10.1158/0008-5472.CAN-12-1739
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 063SF
UT WOS:000313019800024
PM 23054398
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Heyn, H
   Carmona, FJ
   Gomez, A
   Ferreira, HJ
   Bell, JT
   Sayols, S
   Ward, K
   Stefansson, OA
   Moran, S
   Sandoval, J
   Eyfjord, JE
   Spector, TD
   Esteller, M
AF Heyn, Holger
   Javier Carmona, F.
   Gomez, Antonio
   Ferreira, Humberto J.
   Bell, Jordana T.
   Sayols, Sergi
   Ward, Kirsten
   Stefansson, Olafur A.
   Moran, Sebastian
   Sandoval, Juan
   Eyfjord, Jorunn E.
   Spector, Tim D.
   Esteller, Manel
TI DNA methylation profiling in breast cancer discordant identical twins
   identifies <i>DOK7</i> as novel epigenetic biomarker
SO CARCINOGENESIS
LA English
DT Article
ID CPG ISLAND HYPERMETHYLATION; PLURIPOTENT STEM-CELLS; SPORADIC BREAST;
   GENE; BRCA1; TISSUE; HYPOMETHYLATION; MICRORNA-145; POLYMERASE;
   ASSOCIATE
AB Using whole blood from 15 twin pairs discordant for breast cancer and high-resolution (450K) DNA methylation analysis, we identified 403 differentially methylated CpG sites including known and novel potential breast cancer genes. Confirming the results in an independent validation cohort of 21 twin pairs determined the docking protein DOK7 as a candidate for blood-based cancer diagnosis. DNA hypermethylation of the promoter region was also seen in primary breast cancer tissues and cancer cell lines. Hypermethylation of DOK7 occurs years before tumor diagnosis, suggesting a role as a powerful epigenetic blood-based biomarker as well as providing insights into breast cancer pathogenesis.
C1 [Heyn, Holger; Javier Carmona, F.; Gomez, Antonio; Ferreira, Humberto J.; Sayols, Sergi; Stefansson, Olafur A.; Moran, Sebastian; Sandoval, Juan; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Catalonia, Spain.
   [Ferreira, Humberto J.] Univ Coimbra, Programme Expt Biol & Biomed, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.
   [Bell, Jordana T.; Ward, Kirsten; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London SE1 7EH, England.
   [Eyfjord, Jorunn E.] Iceland Canc Soc, Mol & Cell Biol Res Lab, IS-101 Reykjavik, Iceland.
   [Eyfjord, Jorunn E.] Univ Iceland, Dept Med, IS-101 Reykjavik, Iceland.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, E-08007 Barcelona, Catalonia, Spain.
   [Esteller, Manel] ICREA, Barcelona 08010, Catalonia, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidade
   de Coimbra; University of London; King's College London; University of
   Iceland; University of Barcelona; ICREA
RP Esteller, M (通讯作者)，Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Catalonia, Spain.
EM tim.spector@kcl.ac.uk; mesteller@idibell.cat
RI Bell, Jordana/AAH-7312-2019; sandoval, juan/M-4593-2015; Esteller,
   Manel/L-5956-2014; Moran, Sebastian/G-5293-2013; Gomez Moruno,
   Antonio/H-7574-2015
OI Heyn, Holger/0000-0002-3276-1889; Bell, Jordana/0000-0002-3858-5986;
   Ferreira, Humberto/0000-0003-0834-2956; Esteller,
   Manel/0000-0003-4490-6093; Moran, Sebastian/0000-0003-4192-8983; Carmona
   Sanz, F Javier/0000-0001-7904-8493; Sayols, Sergi/0000-0002-3877-4170;
   Kelly, Kirsten/0000-0003-4234-543X; Gomez Moruno,
   Antonio/0000-0001-5308-981X; sandoval, juan/0000-0002-5100-973X
FU Ministerio de Ciencia e Innovacion [SAF2011-22803]; European Research
   Council (ERC); Cellex Foundation; Health Department of the Catalan
   Government (Generalitat de Catalunya); Science Department of the Catalan
   Government (Generalitat de Catalunya); Fondo de Investigaciones
   Sanitarias [PI08-1345]; Fundacion Sandra Ibarra de Solidaridad frente al
   Cancer; ERC [250157]; NIHR BRC; European Research Council (ERC) [250157]
   Funding Source: European Research Council (ERC); ICREA Funding Source:
   Custom
FX Ministerio de Ciencia e Innovacion (grant SAF2011-22803 to M. E.); the
   European Research Council (ERC) (advanced grant EPINORC to M. E.);
   Cellex Foundation, the Health and Science Departments of the Catalan
   Government (Generalitat de Catalunya), Fondo de Investigaciones
   Sanitarias (grant PI08-1345 to M. E.) and Fundacion Sandra Ibarra de
   Solidaridad frente al Cancer. M. E. is an ICREA Research Professor. T.
   D. S. is an European Research Council Principal Investigator. This work
   was also supported in part by the ERC (250157) as well as core support
   from the Wellcome Trust and the NIHR BRC award to Guys and St Thomas'
   foundation Trust and KCL. The funders had no role in study design, data
   collection and analysis, decision to publish or preparation of the
   manuscript.
CR Bell JT, 2012, PLOS GENET, V8, P189, DOI 10.1371/journal.pgen.1002629
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Bell JT, 2011, TRENDS GENET, V27, P116, DOI 10.1016/j.tig.2010.12.005
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bergamin E, 2010, MOL CELL, V39, P100, DOI 10.1016/j.molcel.2010.06.007
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Campan M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028141
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Hall M.A., 1999, THESIS WAIKATO U WAI
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109
   Kim SJ, 2011, J CONTROL RELEASE, V155, P427, DOI 10.1016/j.jconrel.2011.06.026
   Korshunova Y, 2008, GENOME RES, V18, P19, DOI 10.1101/gr.6883307
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Molaro A, 2011, CELL, V146, P1028, DOI 10.1016/j.cell.2011.08.016
   Rakyan VK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002300
   Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Smith ZD, 2012, NATURE, V484, P339, DOI 10.1038/nature10960
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
NR 40
TC 115
Z9 125
U1 0
U2 37
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2013
VL 34
IS 1
BP 102
EP 108
DI 10.1093/carcin/bgs321
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 065DQ
UT WOS:000313128600013
PM 23054610
OA Green Published
DA 2025-01-12
ER

PT J
AU Zhao, CH
   Ma, HY
   Bu, XM
   Wang, W
   Zhang, N
AF Zhao, Chenghai
   Ma, Haiying
   Bu, Xianmin
   Wang, Wei
   Zhang, Ning
TI SFRP5 inhibits gastric epithelial cell migration induced by
   macrophage-derived Wnt5a
SO CARCINOGENESIS
LA English
DT Article
ID EPIGENETIC INACTIVATION; TUMOR PROGRESSION; BREAST-CANCER;
   UP-REGULATION; EXPRESSION; INVASION; GENES; HYPERMETHYLATION;
   AGGRESSIVENESS; ACTIVATION
AB Secreted frizzled-related protein 5 (SFRP5) is frequently found downregulated in gastric cancer due to SFRP5 gene hypermethylation, and there is a great necessity to elucidate the role of its downregulation in gastric cancer. By binding Wnt molecules, SFRP5 is generally supposed to exert negative effects on Wnt signal pathways widely linked to human cancers. This study found that macrophages over-produced Wnt5a under the stimulation of Lipopolysaccharide (LPS) or Helicobacter pylori, the most common infectious agent in human stomach. Wnt5a-conditioned medium from macrophages enhanced cell migration and CXCR4 expression in either SFRP5-negative gastric epithelial cells (GEC) harboring SFRP5 methylation or SFRP5-positive cells treated with SFRP5 small interfering RNA (siRNA). However, such induced effect was remarkably eliminated by either Wnt5a siRNA in macrophages or treatment with recombinant SFRP5. We also found that Wnt5a-conditioned medium stimulated phosphorylation of c-jun N-terminal kinase (JNK) and c-Jun, and JNK inhibitor SP600125 blocked Wnt5a-induced CXCR4 expression and cell migration in SFRP5-negative cells. Taken together, these findings suggest that epithelium-derived SFRP5 may play a probable defensive role in impeding gastric cancer progression, characteristically by inhibiting GEC migration induced by macrophage-derived Wnt5a via JNK signaling activation.
C1 [Zhao, Chenghai; Ma, Haiying; Wang, Wei; Zhang, Ning] China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110001, Peoples R China.
   [Bu, Xianmin] China Med Univ, Shengjing Hosp, Dept Gen Surg, Shenyang 110001, Peoples R China.
C3 China Medical University; China Medical University
RP Zhao, CH (通讯作者)，China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110001, Peoples R China.
EM zhaochenghai2005@yahoo.com.cn
RI Zhang, Ning/IZR-2419-2023; Zhao, Cheng-Hai/O-6990-2019
FU Division of Science and Technology, Liaoning Province, China [20092125]
FX Division of Science and Technology, Liaoning Province, China (20092125).
CR Aman A, 2008, DEV CELL, V15, P749, DOI 10.1016/j.devcel.2008.10.002
   Blumenthal A, 2006, BLOOD, V108, P965, DOI 10.1182/blood-2005-12-5046
   Bu XM, 2008, WORLD J GASTROENTERO, V14, P3421, DOI 10.3748/wjg.14.3421
   Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175
   Ghosh MC, 2009, BLOOD, V114, P1366, DOI 10.1182/blood-2008-08-175869
   Götze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190
   Kim J, 2010, J IMMUNOL, V185, P1274, DOI 10.4049/jimmunol.1000181
   Kitadai Y, 2003, BIOCHEM BIOPH RES CO, V311, P809, DOI 10.1016/j.bbrc.2003.10.077
   Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370
   Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Li B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022920
   Li Y, 2008, GENE DEV, V22, P3050, DOI 10.1101/gad.1687308
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X
   Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7
   Matsuo T, 2012, DIGESTION, V85, P61, DOI 10.1159/000335260
   Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660
   O'Connell MP, 2010, ONCOGENE, V29, P34, DOI 10.1038/onc.2009.305
   Oliveira MJ, 2006, J BIOL CHEM, V281, P34888, DOI 10.1074/jbc.M607067200
   Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007
   Ouchi N, 2010, SCIENCE, V329, P454, DOI 10.1126/science.1188280
   Pereira C, 2008, ARTERIOSCL THROM VAS, V28, P504, DOI 10.1161/ATVBAHA.107.157438
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103
   Ripka S, 2007, CARCINOGENESIS, V28, P1178, DOI 10.1093/carcin/bgl255
   Schumacher MA, 2012, GASTROENTEROLOGY, V142, P1150, DOI 10.1053/j.gastro.2012.01.029
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721
   Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tamura M, 2011, INT J BIOCHEM CELL B, V43, P760, DOI 10.1016/j.biocel.2011.01.021
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Wang Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010456
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496
   Zhao CH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-419
   Zhao CH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-224
NR 40
TC 26
Z9 29
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2013
VL 34
IS 1
BP 146
EP 152
DI 10.1093/carcin/bgs309
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 065DQ
UT WOS:000313128600019
PM 23054609
OA Bronze
DA 2025-01-12
ER

PT J
AU Barbano, R
   Muscarella, LA
   Pasculli, B
   Valori, VM
   Fontana, A
   Coco, M
   la Torre, A
   Balsamo, T
   Poeta, ML
   Marangi, GF
   Maiello, E
   Castelvetere, M
   Pellegrini, F
   Murgo, R
   Fazio, VM
   Parrella, P
AF Barbano, Raffaela
   Muscarella, Lucia Anna
   Pasculli, Barbara
   Valori, Vanna Maria
   Fontana, Andrea
   Coco, Michelina
   la Torre, Annamaria
   Balsamo, Teresa
   Poeta, Maria Luana
   Marangi, Giovanni Francesco
   Maiello, Evaristo
   Castelvetere, Marina
   Pellegrini, Fabio
   Murgo, Roberto
   Fazio, Vito Michele
   Parrella, Paola
TI Aberrant <i>Keap1</i> methylation in breast cancer and association with
   clinicopathological features
SO EPIGENETICS
LA English
DT Article
DE breast cancer; KEAP1; prognosis; oxidative stress; methylation; estrogen
ID PROMOTER METHYLATION; NRF2 PATHWAY; MUTATIONS; GENE; ACTIVATION; INRF2;
   BETA
AB Keap1 (Kelch-like ECH-associated protein 1) is an adaptor protein that mediates the ubiquitination/degradation of genes regulating cell survival and apoptosis under oxidative stress conditions. We determined methylation status of the KEAP1 promoter in 102 primary breast cancers, 14 pre-invasive lesions, 38 paired normal breast tissues and 6 normal breast from reductive mammoplasty by quantitative methylation specific PCR (QMSP). Aberrant promoter methylation was detected in 52 out of the 102 primary breast cancer cases (51%) and 10 out of 14 pre-invasive lesions (71%). No mutations of the KEAP1 gene were identified in the 20 breast cancer cases analyzed by fluorescence based direct sequencing. Methylation was more frequent in the subgroup of patients identified as ER positive-HER2 negative tumors (66.7%) as compared with triple-negative breast cancers (35%) (p = 0.05, Chi-square test). The impact of the interactions between Er, PgR, Her2 expression and KEAP1 methylation on mortality was investigated by RECPA M multivariable statistical analysis, identifying four prognostic classes at different mortality risks. Triple-negative breast cancer patients with KEAP1 methylation had higher mortality risk than patients without triple-negative breast cancer (HR = 14.73, 95% CI: 3.65-59.37). Both univariable and multivariable COX regressions analyses showed that KEAP1 methylation was associated with a better progression free survival in patients treated with epirubicin/cyclophosfamide and docetaxel as sequential chemotherapy (HR = 0.082; 95% CI: 0.007-0.934). These results indicate that aberrant promoter methylation of the KEAP1 gene is involved in breast cancerogenesis. In addition, identifying patients with KEAP1 epigenetic abnormalities may contribute to disease progression prediction in breast cancer patients.
C1 [Barbano, Raffaela; Muscarella, Lucia Anna; Pasculli, Barbara; Coco, Michelina; la Torre, Annamaria; Balsamo, Teresa; Fazio, Vito Michele; Parrella, Paola] IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, Italy.
   [Pasculli, Barbara; Poeta, Maria Luana] Univ Bari, Dept Biosci Biotecnol & Pharmacol Sci, Bari, Italy.
   [Valori, Vanna Maria; Maiello, Evaristo] IRCCS Casa Sollievo Sofferenza, Dept Oncohaematol, San Giovanni Rotondo, Italy.
   [Fontana, Andrea; Pellegrini, Fabio] IRCCS Casa Sollievo Sofferenza, Biostat Unit, San Giovanni Rotondo, Italy.
   [Marangi, Giovanni Francesco] Univ Campus BioMed, Dept Plast & Reconstruct Surg, Rome, Italy.
   [Castelvetere, Marina] IRCCS Casa Sollievo Sofferenza, Dept Pathol, San Giovanni Rotondo, Italy.
   [Pellegrini, Fabio] Consorzio Mario Negri S, Dept Clin Pharmacol & Epidemiol, Biostat Unit, Santa Maria Imbaro, Italy.
   [Murgo, Roberto] IRCCS Casa Sollievo Sofferenza, Breast Unit, San Giovanni Rotondo, Italy.
   [Fazio, Vito Michele] Univ Campus BioMed, Mol Med & Biotechnol Lab, Rome, Italy.
C3 IRCCS Casa Sollievo Della Sofferenza; Universita degli Studi di Bari
   Aldo Moro; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo
   Della Sofferenza; University Campus Bio-Medico - Rome Italy; IRCCS Casa
   Sollievo Della Sofferenza; Consorzio Mario Negri Sud; IRCCS Casa
   Sollievo Della Sofferenza; University Campus Bio-Medico - Rome Italy
RP Fazio, VM (通讯作者)，IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, Italy.
EM fazio@unicampus.it; pparrella@operapadrepio.it
RI poeta, maria/G-6014-2015; Marangi, Giovanni/AAW-4723-2020; Barbano,
   Raffaela/H-3640-2016; Fontana, Andrea/J-8584-2016; Fazio, Vito
   Michele/H-3007-2016; Maiello, Evaristo/C-5224-2017; PARRELLA,
   PAOLA/D-8895-2011; Pasculli, Barbara/H-3646-2016; Muscarella, Lucia
   Anna/K-5979-2016; la Torre, Annamaria/B-2717-2017
OI Barbano, Raffaela/0000-0002-4533-4157; Fontana,
   Andrea/0000-0002-6660-5315; Fazio, Vito Michele/0000-0002-7751-1867;
   POETA, Maria Luana/0000-0002-6364-727X; Maiello,
   Evaristo/0000-0003-3890-3435; PARRELLA, PAOLA/0000-0001-6031-9636;
   Pasculli, Barbara/0000-0002-3333-0255; Muscarella, Lucia
   Anna/0000-0002-1866-8151; la Torre, Annamaria/0000-0003-4199-1077;
   Marangi, Giovanni Francesco/0000-0002-7179-3533; la Torre,
   Annamaria/0000-0002-7017-0879
FU Ricerca Corrente; Italian Ministry of Health; Progetto Operativo
   Nazionale, PON VIRTUALAB [PON01_0129]; Reti Laboratori pubblici di
   Ricerca: Progetto BioBOP; AIRC
FX This study was supported by the "Ricerca Corrente 2012" funding granted
   by the Italian Ministry of Health and by the "5 x 1,000" voluntary
   contributions" and partially funded by the "Progetto Operativo
   Nazionale, PON 2011-2014 VIRTUALAB (PON01_01297), "Reti Laboratori
   pubblici di Ricerca: Progetto BioBOP" and AIRC Investigator Grant
   2005-2007.
CR Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   CIAMPI A, 1995, J CLIN EPIDEMIOL, V48, P675, DOI 10.1016/0895-4356(94)00164-L
   De Berardis G, 2007, J UROLOGY, V177, P252, DOI 10.1016/j.juro.2006.08.102
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   Hanada N, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-66
   Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008
   Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713
   Karihtala P, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-262
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Konstantinopoulos PA, 2011, CANCER RES, V71, P5081, DOI 10.1158/0008-5472.CAN-10-4668
   Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025
   MacLeod AK, 2009, CARCINOGENESIS, V30, P1571, DOI 10.1093/carcin/bgp176
   Montano MM, 2007, ONCOGENE, V26, P3587, DOI 10.1038/sj.onc.1210144
   Muscarella LA, 2011, EPIGENETICS-US, V6, P710, DOI 10.4161/epi.6.6.15773
   Muscarella LA, 2011, EPIGENETICS-US, V6, P317, DOI 10.4161/epi.6.3.14408
   Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051
   Niture SK, 2011, CELL DEATH DIFFER, V18, P439, DOI 10.1038/cdd.2010.114
   Niture SK, 2011, J BIOL CHEM, V286, P44542, DOI 10.1074/jbc.M111.275073
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Ronkainen H, 2009, ONCOL REP, V21, P1519, DOI 10.3892/or_00000383
   Shen GX, 2009, BIOPHARM DRUG DISPOS, V30, P345, DOI 10.1002/bdd.680
   Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082
   Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420
   SKILLINGS JH, 1981, TECHNOMETRICS, V23, P171, DOI 10.2307/1268034
   Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352
   Sripathy SP, 2008, ONCOGENE, V27, P6376, DOI 10.1038/onc.2008.235
   Takahashi T, 2010, J SURG ONCOL, V101, P500, DOI 10.1002/jso.21520
   Tian H, 2012, CANCER LETT, V325, P26, DOI 10.1016/j.canlet.2012.06.007
   Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Wong TF, 2011, INT J GYNECOL CANCER, V21, P1428, DOI 10.1097/IGC.0b013e31822d0eb2
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yao YA, 2010, BREAST CANCER RES TR, V124, P585, DOI 10.1007/s10549-010-1023-8
   Yoo NJ, 2012, HISTOPATHOLOGY, V60, P943, DOI 10.1111/j.1365-2559.2012.04178.x
   Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974
NR 39
TC 65
Z9 75
U1 0
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JAN
PY 2013
VL 8
IS 1
BP 105
EP 112
DI 10.4161/epi.23319
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 067GT
UT WOS:000313282900012
PM 23249627
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Huntriss, JD
   Hemmings, KE
   Hinkins, M
   Rutherford, AJ
   Sturmey, RG
   Elder, K
   Picton, HM
AF Huntriss, John D.
   Hemmings, Karen E.
   Hinkins, Matthew
   Rutherford, Anthony J.
   Sturmey, Roger G.
   Elder, Kay
   Picton, Helen M.
TI Variable imprinting of the <i>MEST</i> gene in human preimplantation
   embryos
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE imprinting; PEG1/MEST; assisted reproduction; imprinted; epigenetic;
   preimplantation
ID SILVER-RUSSELL-SYNDROME; MESODERM-SPECIFIC TRANSCRIPT; ABERRANT DNA
   METHYLATION; INVASIVE BREAST-CANCER; STEM-CELL LINES; IN-VITRO; HUMAN
   PEG1/MEST; MICROSATELLITE INSTABILITY; ADIPOSE-TISSUE; HUMAN SPERM
AB There is evidence that expression and methylation of the imprinted paternally expressed gene 1/mesoderm-specific transcript homologue (PEG1/MEST) gene may be affected by assisted reproductive technologies (ARTs) and infertility. In this study, we sought to assess the imprinting status of the MEST gene in a large cohort of in vitro-derived human preimplantation embryos, in order to characterise potentially adverse effects of ART and infertility on this locus in early human development. Embryonic genomic DNA from morula or blastocyst stage embryos was screened for a transcribed AflIII polymorphism in MEST and imprinting analysis was then performed in cDNA libraries derived from these embryos. In 10 heterozygous embryos, MEST expression was monoallelic in seven embryos, predominantly monoallelic in two embryos, and biallelic in one embryo. Screening of cDNA derived from 61 additional human preimplantation embryos, for which DNA for genotyping was unavailable, identified eight embryos with expression originating from both alleles (biallelic or predominantly monoallelic). In some embryos, therefore, the onset of imprinted MEST expression occurs during late preimplantation development. Variability in MEST imprinting was observed in both in vitro fertilization and intracytoplasmic sperm injection-derived embryos. Biallelic or predominantly monoallelic MEST expression was not associated with any one cause of infertility. Characterisation of the main MEST isoforms revealed that isoform 2 was detected in early development and was itself variably imprinted between embryos. To our knowledge, this report constitutes the largest expression study to date of genomic imprinting in human preimplantation embryos and reveals that for some imprinted genes, contrasting imprinting states exist between embryos. European Journal of Human Genetics (2013) 21, 40-47; doi: 10.1038/ejhg.2012.102; published online 4 July 2012
C1 [Huntriss, John D.; Hemmings, Karen E.; Hinkins, Matthew; Picton, Helen M.] Univ Leeds, Leeds Inst Genet Hlth & Therapeut, LIGHT Labs, Div Reprod & Early Dev, Leeds LS2 9JT, W Yorkshire, England.
   [Rutherford, Anthony J.] Seacroft Hosp, Leeds Teaching Hosp NHS Trust, Leeds Ctr Reprod Med, Leeds, W Yorkshire, England.
   [Sturmey, Roger G.] Univ Hull, Hull York Med Sch, Ctr Cardiovasc & Metab Res, Kingston Upon Hull HU6 7RX, N Humberside, England.
   [Elder, Kay] Bourn Hall Clin, Cambridge CB3 7TR, England.
C3 University of Leeds; University of Leeds; University of York - UK;
   University of Hull
RP Huntriss, JD (通讯作者)，Univ Leeds, Leeds Inst Genet Hlth & Therapeut, LIGHT Labs, Div Reprod & Early Dev, Clarendon Way, Leeds LS2 9JT, W Yorkshire, England.
EM j.huntriss@leeds.ac.uk
OI Hemmings, Karen/0000-0002-4967-6314; Sturmey, Roger/0000-0003-4423-5058;
   Elder, Kay/0000-0003-3510-8268
FU Newlife Foundation; MRC [G0701388]; MRC [G0701388] Funding Source: UKRI
FX This work was supported by the Newlife Foundation and the MRC (Grant no.
   G0701388). We thank Judith A Hawkhead (University of York) for
   assistance with sample collection.
CR Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318
   Anckaert E, 2010, BIOL REPROD, V83, P377, DOI 10.1095/biolreprod.109.082164
   Beechey CV, 2000, CYTOGENET CELL GENET, V90, P309, DOI 10.1159/000056794
   Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260
   Diplas AI, 2009, EPIGENETICS-US, V4, P235, DOI 10.4161/epi.9019
   EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010
   Frost JM, 2011, EPIGENETICS-US, V6, P52, DOI 10.4161/epi.6.1.13361
   Ghassemifar MR, 2003, MOL HUM REPROD, V9, P245, DOI 10.1093/molehr/gag033
   Hammoud SS, 2010, FERTIL STERIL, V94, P1728, DOI 10.1016/j.fertnstert.2009.09.010
   Houghton FD, 2002, HUM REPROD, V17, P999, DOI 10.1093/humrep/17.4.999
   Houshdaran S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001289
   Huntriss J, 1998, AM J HUM GENET, V63, P1009, DOI 10.1086/302039
   Huntriss J, 2011, FERTIL STERIL, V95, P2564, DOI 10.1016/j.fertnstert.2011.04.035
   Huntriss John, 2008, Hum Fertil (Camb), V11, P85, DOI 10.1080/14647270802116250
   Imamura T, 2005, J BIOL CHEM, V280, P20171, DOI 10.1074/jbc.M501749200
   Jung H, 2011, BIOCHEM J, V436, P263, DOI 10.1042/BJ20101512
   Kagami M, 2007, J ASSIST REPROD GEN, V24, P131, DOI 10.1007/s10815-006-9096-3
   Kamei Y, 2007, FEBS LETT, V581, P91, DOI 10.1016/j.febslet.2006.12.002
   Katari S, 2009, HUM MOL GENET, V18, P3769, DOI 10.1093/hmg/ddp319
   Kerjean A, 2003, EUR J HUM GENET, V11, P493, DOI 10.1038/sj.ejhg.5200990
   Kim KP, 2007, GENOME RES, V17, P1731, DOI 10.1101/gr.6609207
   Kobayashi H, 2007, HUM MOL GENET, V16, P2542, DOI 10.1093/hmg/ddm187
   Kobayashi S, 1997, HUM MOL GENET, V6, P781, DOI 10.1093/hmg/6.5.781
   Kobayashi S, 2001, AM J MED GENET, V104, P225, DOI 10.1002/ajmg.10022.abs
   Kosaki K, 2000, AM J HUM GENET, V66, P309, DOI 10.1086/302712
   Koza RA, 2006, PLOS GENET, V2, P769, DOI 10.1371/journal.pgen.0020081
   Koza RA, 2009, EPIGENETICS-US, V4, P512, DOI 10.4161/epi.4.7.10031
   Lee YS, 2008, PHYSIOL GENOMICS, V35, P145, DOI 10.1152/physiolgenomics.90281.2008
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Li T, 2002, J BIOL CHEM, V277, P13518, DOI 10.1074/jbc.M200458200
   Lighten AD, 1997, NAT GENET, V15, P122, DOI 10.1038/ng0297-122
   MacIsaac JL, 2012, NUCLEIC ACIDS RES, V40, P1523, DOI 10.1093/nar/gkr871
   Marques CJ, 2008, MOL HUM REPROD, V14, P67, DOI 10.1093/molehr/gam093
   McElroy SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010979
   McMinn J, 2006, PLACENTA, V27, P119, DOI 10.1016/j.placenta.2004.12.003
   Monk M, 2001, MOL CELL ENDOCRINOL, V183, pS35, DOI 10.1016/S0303-7207(01)00575-5
   Nakabayashi K, 2002, HUM MOL GENET, V11, P1743, DOI 10.1093/hmg/11.15.1743
   Nakanishi H, 2004, ONCOL REP, V12, P1273
   Nikonova L, 2008, FASEB J, V22, P3925, DOI 10.1096/fj.08-108266
   Nishihara S, 2000, INT J ONCOL, V17, P317
   Obata Y, 2011, J REPROD DEVELOP, V57, P327, DOI 10.1262/jrd.10-145A
   Pedersen IS, 2002, HUM MOL GENET, V11, P1449, DOI 10.1093/hmg/11.12.1449
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Poplinski A, 2010, INT J ANDROL, V33, P642, DOI 10.1111/j.1365-2605.2009.01000.x
   Riesewijk AM, 1998, EUR J HUM GENET, V6, P114, DOI 10.1038/sj.ejhg.5200164
   Riesewijk AM, 1997, GENOMICS, V42, P236, DOI 10.1006/geno.1997.4731
   Salpekar A, 2001, MOL HUM REPROD, V7, P839, DOI 10.1093/molehr/7.9.839
   Sato A, 2007, HUM REPROD, V22, P26, DOI 10.1093/humrep/del316
   Schöherr N, 2008, EUR J MED GENET, V51, P322, DOI 10.1016/j.ejmg.2008.05.001
   Shi W, 2004, GENESIS, V39, P65, DOI 10.1002/gene.20027
   Takahashi M, 2005, AM J PHYSIOL-ENDOC M, V288, pE117, DOI 10.1152/ajpendo.00244.2004
   Tay JI, 1997, HUM REPROD, V12, P2451, DOI 10.1093/humrep/12.11.2451
   Tierling S, 2010, J MED GENET, V47, P371, DOI 10.1136/jmg.2009.073189
   Wang E, 2000, NAT BIOTECHNOL, V18, P457, DOI 10.1038/74546
NR 54
TC 34
Z9 38
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JAN
PY 2013
VL 21
IS 1
BP 40
EP 47
DI 10.1038/ejhg.2012.102
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 056LX
UT WOS:000312492500011
PM 22763377
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Aure, MR
   Leivonen, SK
   Fleischer, T
   Zhu, Q
   Overgaard, J
   Alsner, J
   Tramm, T
   Louhimo, R
   Alnæs, GIG
   Perälä, M
   Busato, F
   Touleimat, N
   Tost, J
   Borresen-Dale, AL
   Hautaniemi, S
   Troyanskaya, OG
   Lingjærde, OC
   Sahlberg, KK
   Kristensen, VN
AF Aure, Miriam Ragle
   Leivonen, Suvi-Katri
   Fleischer, Thomas
   Zhu, Qian
   Overgaard, Jens
   Alsner, Jan
   Tramm, Trine
   Louhimo, Riku
   Alnaes, Grethe I. Grenaker
   Perala, Merja
   Busato, Florence
   Touleimat, Nizar
   Tost, Joerg
   Borresen-Dale, Anne-Lise
   Hautaniemi, Sampsa
   Troyanskaya, Olga G.
   Lingjaerde, Ole Christian
   Sahlberg, Kristine Kleivi
   Kristensen, Vessela N.
TI Individual and combined effects of DNA methylation and copy number
   alterations on miRNA expression in breast tumors
SO GENOME BIOLOGY
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN CELL-LINE; POSTOPERATIVE
   RADIOTHERAPY; MICRORNA DYSREGULATION; MOLECULAR SUBTYPES;
   ESTROGEN-RECEPTOR; NONCODING RNAS; BONE-MARROW; CANCER; GENES
AB Background: The global effect of copy number and epigenetic alterations on miRNA expression in cancer is poorly understood. In the present study, we integrate genome-wide DNA methylation, copy number and miRNA expression and identify genetic mechanisms underlying miRNA dysregulation in breast cancer.
   Results: We identify 70 miRNAs whose expression was associated with alterations in copy number or methylation, or both. Among these, five miRNA families are represented. Interestingly, the members of these families are encoded on different chromosomes and are complementarily altered by gain or hypomethylation across the patients. In an independent breast cancer cohort of 123 patients, 41 of the 70 miRNAs were confirmed with respect to aberration pattern and association to expression. In vitro functional experiments were performed in breast cancer cell lines with miRNA mimics to evaluate the phenotype of the replicated miRNAs. let-7e-3p, which in tumors is found associated with hypermethylation, is shown to induce apoptosis and reduce cell viability, and low let-7e-3p expression is associated with poorer prognosis. The overexpression of three other miRNAs associated with copy number gain, miR-21-3p, miR-148b-3p and miR-151a-5p, increases proliferation of breast cancer cell lines. In addition, miR-151a-5p enhances the levels of phosphorylated AKT protein.
   Conclusions: Our data provide novel evidence of the mechanisms behind miRNA dysregulation in breast cancer. The study contributes to the understanding of how methylation and copy number alterations influence miRNA expression, emphasizing miRNA functionality through redundant encoding, and suggests novel miRNAs important in breast cancer.
C1 [Aure, Miriam Ragle; Leivonen, Suvi-Katri; Fleischer, Thomas; Alnaes, Grethe I. Grenaker; Borresen-Dale, Anne-Lise; Sahlberg, Kristine Kleivi; Kristensen, Vessela N.] Norwegian Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
   [Aure, Miriam Ragle; Leivonen, Suvi-Katri; Alnaes, Grethe I. Grenaker; Borresen-Dale, Anne-Lise; Lingjaerde, Ole Christian; Sahlberg, Kristine Kleivi; Kristensen, Vessela N.] Univ Oslo, Fac Med, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, N-0318 Oslo, Norway.
   [Zhu, Qian; Troyanskaya, Olga G.] Princeton Univ, Dept Comp Sci, Princeton, NJ 08540 USA.
   [Overgaard, Jens; Alsner, Jan; Tramm, Trine] Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark.
   [Louhimo, Riku; Hautaniemi, Sampsa] Univ Helsinki, Syst Biol Lab, Inst Biomed, FIN-00014 Helsinki, Finland.
   [Louhimo, Riku; Hautaniemi, Sampsa] Univ Helsinki, Genome Scale Biol Res Program, FIN-00014 Helsinki, Finland.
   [Perala, Merja] VTT Tech Res Ctr Finland, Turku 20521, Finland.
   [Busato, Florence; Touleimat, Nizar; Tost, Joerg] CEA, Inst Genom, Lab Epigenet & Environm, Ctr Natl Genotypage, F-91000 Evry, France.
   [Troyanskaya, Olga G.] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.
   [Lingjaerde, Ole Christian] Univ Oslo, Dept Informat, Biomed Informat Res Grp, N-0316 Oslo, Norway.
   [Lingjaerde, Ole Christian] Univ Oslo, Ctr Canc Biomed, N-0424 Oslo, Norway.
   [Sahlberg, Kristine Kleivi] Vestre Viken Hosp Trust, Dept Res, N-3004 Drammen, Norway.
   [Kristensen, Vessela N.] Akershus Univ Hosp, Div Med, Dept Clin Mol Biol & Lab Sci EpiGen, N-1478 Akershus, Norway.
C3 University of Oslo; University of Oslo; Princeton University; Aarhus
   University; University of Helsinki; University of Helsinki; VTT
   Technical Research Center Finland; Universite Paris Saclay; CEA;
   Princeton University; University of Oslo; University of Oslo; University
   of Oslo
RP Kristensen, VN (通讯作者)，Norwegian Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
EM v.n.kristensen@medisin.uio.no
RI Leivonen, Suvi-Katri/AAK-3096-2021; Troyanskaya, Olga/B-1968-2010;
   Busato, Fabio/LIC-8043-2024; Alsner, Jan/A-3056-2009; Hautaniemi,
   Sampsa/A-3122-2009; Tost, Jorg/H-7129-2019; Fleischer,
   Thomas/T-8066-2017
OI Leivonen, Suvi-Katri/0000-0003-3224-0757; Hautaniemi,
   Sampsa/0000-0002-7749-2694; Kleivi Sahlberg,
   Kristine/0000-0002-7281-2759; Tramm, Trine/0000-0003-3894-4552; Tost,
   Jorg/0000-0002-2683-0817; Lingjaerde, Ole Christian/0000-0003-3565-4912;
   Fleischer, Thomas/0000-0003-0985-8460; Alsner, Jan/0000-0002-5395-3193;
   Troyanskaya, Olga/0000-0002-5676-5737
FU Norwegian Research Council [193387/V50, 183621/S10, 175240/S10];
   Norwegian Cancer Society [419616, 419628]; KG Jebsen Center for Breast
   Cancer Research
FX MRA had a PhD fellowship from the Norwegian Research Council (grant
   number 193387/V50). This work was supported by grants from the Norwegian
   Research Council (grant numbers 183621/S10 and 175240/S10), the
   Norwegian Cancer Society (grant numbers 419616 and 419628) and the KG
   Jebsen Center for Breast Cancer Research. We thank Hilde Johnsen and
   Eldri U Due for performing array experiments. We would like to
   acknowledge Dr Pekka Kohonen for normalizing the CellTiter-Glo data and
   Rami Makela for performing the protein lysate arrays. We would like to
   thank Prof. Junichi Kurebayashi (Department of Breast and Thyroid
   Surgery, Kawasaki Medical School, Kurashiki-City, Japan) for kindly
   providing the KPL-4 breast cancer cell line. We would also like to thank
   Daniel Nebdal for excellent help in making the figures.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   [Anonymous], MOL ONCOL
   [Anonymous], 2011, R: A language and environment for statistical computing
   [Anonymous], CARCINOGENE IN PRESS
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Biasiolo M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023854
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Boutros M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r66
   BROOKS SC, 1973, J BIOL CHEM, V248, P6251
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054213
   Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505
   Cimino D, 2013, FASEB J, V27, P1223, DOI 10.1096/fj.12-214692
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Cuk K, 2013, INT J CANCER, V132, P1602, DOI 10.1002/ijc.27799
   Ding J, 2010, NAT CELL BIOL, V12, P390, DOI 10.1038/ncb2039
   Ding XC, 2009, TRENDS BIOTECHNOL, V27, P27, DOI 10.1016/j.tibtech.2008.09.006
   Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4
   Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915
   Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608
   Ferraro L, 2012, HORM CANCER-US, V3, P65, DOI 10.1007/s12672-012-0102-1
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   Git A, 2010, RNA, V16, P991, DOI 10.1261/rna.1947110
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Han M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032383
   Haverty PM, 2008, GENE CHROMOSOME CANC, V47, P530, DOI 10.1002/gcc.20558
   Hertel J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-25
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296
   Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384
   Kozaki K, 2012, CANCER SCI, V103, P837, DOI 10.1111/j.1349-7006.2012.02236.x
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Kurebayashi J, 1999, BRIT J CANCER, V79, P707, DOI 10.1038/sj.bjc.6690114
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992
   Louhimo R, 2011, BIOINFORMATICS, V27, P887, DOI 10.1093/bioinformatics/btr019
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206
   Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108
   Mitra D, 2011, J BIOL CHEM, V286, P40531, DOI 10.1074/jbc.M111.304865
   Mukherji S, 2011, NAT GENET, V43, P854, DOI 10.1038/ng.905
   Myhre S, 2013, MOL ONCOL, V7, P704, DOI 10.1016/j.molonc.2013.02.018
   Myhre S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014002
   Nadiminty N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032832
   Nakao M, 2011, ONCOL REP, V25, P1603, DOI 10.3892/or.2011.1246
   Naume B, 2001, CLIN CANCER RES, V7, P4122
   Naume B, 2007, MOL ONCOL, V1, P160, DOI 10.1016/j.molonc.2007.03.004
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Nilsen G, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-591
   Nordgard SH, 2008, GENE CHROMOSOME CANC, V47, P680, DOI 10.1002/gcc.20569
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Overgaard M, 1999, LANCET, V353, P1641, DOI 10.1016/S0140-6736(98)09201-0
   Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401
   Qian PX, 2011, CANCER RES, V71, P6463, DOI 10.1158/0008-5472.CAN-11-1322
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027355
   Riis MLH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-686
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007
   Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200
   Serrano NA, 2012, OTOLARYNG HEAD NECK, V147, P501, DOI 10.1177/0194599812442490
   Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080
   Shi W, 2011, CANCER RES, V71, P2926, DOI 10.1158/0008-5472.CAN-10-3369
   Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693
   Tanner M, 2004, MOL CANCER THER, V3, P1585
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Touleimat N, 2012, EPIGENOMICS-UK, V4, P325, DOI [10.2217/EPI.12.21, 10.2217/epi.12.21]
   Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019
   Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398
   Wee EJH, 2012, ONCOGENE, V31, P4182, DOI 10.1038/onc.2011.584
   Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167
   Yu FY, 2012, J BIOL CHEM, V287, P465, DOI 10.1074/jbc.M111.280768
   Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435
   Zhao ZN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045133
NR 92
TC 74
Z9 84
U1 1
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2013
VL 14
IS 11
AR R126
DI 10.1186/gb-2013-14-11-r126
PG 20
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 302PA
UT WOS:000330616200005
PM 24257477
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Horvath, S
AF Horvath, Steve
TI DNA methylation age of human tissues and cell types
SO GENOME BIOLOGY
LA English
DT Article
ID GENE-EXPRESSION; PROFILING REVEALS; STEM-CELLS; WIDE ASSOCIATION;
   HISTONE H3.3; MUTATIONS; CANCER; BLOOD; RISK; EPIGENOME
AB Background: It is not yet known whether DNA methylation levels can be used to accurately predict age across a broad spectrum of human tissues and cell types, nor whether the resulting age prediction is a biologically meaningful measure.
   Results: I developed a multi-tissue predictor of age that allows one to estimate the DNA methylation age of most tissues and cell types. The predictor, which is freely available, was developed using 8,000 samples from 82 Illumina DNA methylation array datasets, encompassing 51 healthy tissues and cell types. I found that DNA methylation age has the following properties: first, it is close to zero for embryonic and induced pluripotent stem cells; second, it correlates with cell passage number; third, it gives rise to a highly heritable measure of age acceleration; and, fourth, it is applicable to chimpanzee tissues. Analysis of 6,000 cancer samples from 32 datasets showed that all of the considered 20 cancer types exhibit significant age acceleration, with an average of 36 years. Low age-acceleration of cancer tissue is associated with a high number of somatic mutations and TP53 mutations, while mutations in steroid receptors greatly accelerate DNA methylation age in breast cancer. Finally, I characterize the 353 CpG sites that together form an aging clock in terms of chromatin states and tissue variance.
   Conclusions: I propose that DNA methylation age measures the cumulative effect of an epigenetic maintenance system. This novel epigenetic clock can be used to address a host of questions in developmental biology, cancer and aging research.
C1 [Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Horvath, Steve] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA.
   [Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Gonda Res Ctr, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Horvath, S (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM shorvath@mednet.ucla.edu
FU NIA NIH HHS [R01 AG042511] Funding Source: Medline
CR Adkins RM, 2011, BIRTH DEFECTS RES A, V91, P728, DOI 10.1002/bdra.20770
   Alisch RS, 2012, GENOME RES, V22, P623, DOI 10.1101/gr.125187.111
   Bell JT, 2012, PLOS GENET, V8, P189, DOI 10.1371/journal.pgen.1002629
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Berdyshev G., 1967, Biokhimiia, V31, P88
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Blair JD, 2013, MOL HUM REPROD, V19, P697, DOI 10.1093/molehr/gat044
   Bocklandt S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014821
   Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003
   Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474-9726.2009.00535.x
   Calvanese V, 2012, NUCLEIC ACIDS RES, V40, P116, DOI 10.1093/nar/gkr685
   Campisi J, 2009, J GERONTOL A-BIOL, V64, P175, DOI 10.1093/gerona/gln065
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Essex MJ, 2013, CHILD DEV, V84, P58, DOI 10.1111/j.1467-8624.2011.01641.x
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fernandez-Tajes J., 2013, Ann Rheum Dis
   Fraga MF, 2007, ANN NY ACAD SCI, V1100, P60, DOI 10.1196/annals.1395.005
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Gibbs JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000952
   Ginsberg MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044736
   Gordon L, 2012, GENOME RES, V22, P1395, DOI 10.1101/gr.136598.111
   Grönniger E, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000971
   Guintivano J, 2013, EPIGENETICS-US, V8, P290, DOI 10.4161/epi.23924
   Haas J, 2013, EMBO MOL MED, V5, P413, DOI 10.1002/emmm.201201553
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Harris RA, 2013, EPIGENETICS-US, V8, P157, DOI 10.4161/epi.23438
   Harris RA, 2012, INFLAMM BOWEL DIS, V18, P2334, DOI 10.1002/ibd.22956
   Hernandez DG, 2011, HUM MOL GENET, V20, P1164, DOI 10.1093/hmg/ddq561
   Hernando-Herraez I, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003763
   Heyn H, 2013, EPIGENETICS-US, V8, P28, DOI 10.4161/epi.23366
   Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Horvath S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r97
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Jacobsen SC, 2012, DIABETOLOGIA, V55, P3341, DOI 10.1007/s00125-012-2717-8
   Jones MJ, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-126
   Khulan B, 2012, HUM MOL GENET, V21, P2086, DOI 10.1093/hmg/dds026
   Kim JY, 2005, P NATL ACAD SCI USA, V102, P17739, DOI 10.1073/pnas.0503976102
   Kobayashi Y, 2011, GENOME RES, V21, P1017, DOI 10.1101/gr.119487.110
   Koch CM, 2011, AGING-US, V3, P1018, DOI 10.18632/aging.100395
   Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322
   Krausz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044479
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lam LL, 2012, P NATL ACAD SCI USA, V109, P17253, DOI 10.1073/pnas.1121249109
   Langfelder P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061505
   Lauss M, 2012, EPIGENETICS-US, V7, P858, DOI 10.4161/epi.20837
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li YR, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000533
   Liu JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010028
   Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487
   Martino D, 2012, GENES IMMUN, V13, P388, DOI 10.1038/gene.2012.7
   Martino D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r42
   Martino DJ, 2011, EPIGENETICS-US, V6, P1085, DOI 10.4161/epi.6.9.16401
   Miller JA, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-322
   Murgatroyd C, 2010, AGING-US, V2, P107
   Nazor KL, 2012, CELL STEM CELL, V10, P620, DOI 10.1016/j.stem.2012.02.013
   Numata S, 2012, AM J HUM GENET, V90, P260, DOI 10.1016/j.ajhg.2011.12.020
   Oberdoerffer P, 2007, NAT REV MOL CELL BIO, V8, P692, DOI 10.1038/nrm2238
   Pacheco SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020280
   Pai AA, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001316
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Ramos-Mejía V, 2012, STEM CELLS DEV, V21, P1549, DOI 10.1089/scd.2011.0400
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Ribel-Madsen R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051302
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2
   Rodríguez-Rodero S, 2010, DISCOV MED, V10, P225
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]
   Shao KF, 2013, MOL THER, V21, P240, DOI 10.1038/mt.2012.207
   Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569
   Shibata D, 2006, CELL CYCLE, V5, P610, DOI 10.4161/cc.5.6.2570
   Song HL, 2009, NAT GENET, V41, P996, DOI 10.1038/ng.424
   Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Thompson RF, 2010, AGING CELL, V9, P506, DOI 10.1111/j.1474-9726.2010.00577.x
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   van Eijk KR, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-636
   VANYUSHI.BF, 1973, GERONTOLOGY, V19, P138, DOI 10.1159/000211967
   WILSON VL, 1987, J BIOL CHEM, V262, P9948
   Zhuang J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002517
   Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504
NR 89
TC 4059
Z9 4406
U1 18
U2 390
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2013
VL 14
IS 10
AR R115
DI 10.1186/gb-2013-14-10-r115
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 285IN
UT WOS:000329387500008
PM 24138928
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Malouf, GG
   Taube, JH
   Lu, Y
   Roysarkar, T
   Panjarian, S
   Estecio, MRH
   Jelinek, J
   Yamazaki, J
   Raynal, NJM
   Long, H
   Tahara, T
   Tinnirello, A
   Ramachandran, P
   Zhang, XY
   Liang, SD
   Mani, SA
   Issa, JPJ
AF Malouf, Gabriel G.
   Taube, Joseph H.
   Lu, Yue
   Roysarkar, Tapasree
   Panjarian, Shoghag
   Estecio, Marcos R. H.
   Jelinek, Jaroslav
   Yamazaki, Jumpei
   Raynal, Noel J-M
   Long, Hai
   Tahara, Tomomitsu
   Tinnirello, Agata
   Ramachandran, Priyanka
   Zhang, Xiu-Ying
   Liang, Shoudan
   Mani, Sendurai A.
   Issa, Jean-Pierre J.
TI Architecture of epigenetic reprogramming following Twist1-mediated
   epithelial-mesenchymal transition
SO GENOME BIOLOGY
LA English
DT Article
ID BREAST-CANCER; DNA METHYLATION; GENE-EXPRESSION; E-CADHERIN; CELLS;
   EZH2; METASTASIS; DOMAINS; IDENTIFICATION; REGULATOR
AB Background: Epithelial-mesenchymal transition (EMT) is known to impart metastasis and stemness characteristics in breast cancer. To characterize the epigenetic reprogramming following Twist1-induced EMT, we characterized the epigenetic and transcriptome landscapes using whole-genome transcriptome analysis by RNA-seq, DNA methylation by digital restriction enzyme analysis of methylation (DREAM) and histone modifications by CHIP-seq of H3K4me3 and H3K27me3 in immortalized human mammary epithelial cells relative to cells induced to undergo EMT by Twist1.
   Results: EMT is accompanied by focal hypermethylation and widespread global DNA hypomethylation, predominantly within transcriptionally repressed gene bodies. At the chromatin level, the number of gene promoters marked by H3K4me3 increases by more than one fifth; H3K27me3 undergoes dynamic genomic redistribution characterized by loss at half of gene promoters and overall reduction of peak size by almost half. This is paralleled by increased phosphorylation of EZH2 at serine 21. Among genes with highly altered mRNA expression, 23.1% switch between H3K4me3 and H3K27me3 marks, and those point to the master EMT targets and regulators CDH1, PDGFRa and ESRP1. Strikingly, Twist1 increases the number of bivalent genes by more than two fold. Inhibition of the H3K27 methyltransferases EZH2 and EZH1, which form part of the Polycomb repressive complex 2 (PRC2), blocks EMT and stemness properties.
   Conclusions: Our findings demonstrate that the EMT program requires epigenetic remodeling by the Polycomb and Trithorax complexes leading to increased cellular plasticity. This suggests that inhibiting epigenetic remodeling and thus decrease plasticity will prevent EMT, and the associated breast cancer metastasis.
C1 [Malouf, Gabriel G.; Lu, Yue; Estecio, Marcos R. H.; Jelinek, Jaroslav; Yamazaki, Jumpei; Raynal, Noel J-M; Long, Hai; Tahara, Tomomitsu; Issa, Jean-Pierre J.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   [Malouf, Gabriel G.] Inst Univ Cancorol, Fac Med Pierre & Marie Curie, Grp Hosp Pitie Salpetriere, Dept Med Oncol,AP HP, Paris, France.
   [Taube, Joseph H.; Roysarkar, Tapasree; Tinnirello, Agata; Ramachandran, Priyanka; Mani, Sendurai A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
   [Zhang, Xiu-Ying; Liang, Shoudan] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat, Houston, TX 77030 USA.
   [Taube, Joseph H.; Roysarkar, Tapasree; Mani, Sendurai A.] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX 77030 USA.
   [Panjarian, Shoghag; Issa, Jean-Pierre J.] Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Sorbonne
   Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Pitie-Salpetriere - APHP; University of Texas System; UTMD
   Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; UTMD Anderson Cancer Center;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University
RP Mani, SA (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
EM smani@mdanderson.org; jpissa@temple.edu
RI Yamazaki, Jumpei/A-3360-2012; yue, lu/KMY-6349-2024; Jelinek,
   Jaroslav/O-6876-2019; Mani, Sendurai/A-7244-2009; Jelinek,
   Jaroslav/D-2282-2012; Malouf, Gabriel/Q-7012-2018
OI Lu, Yue/0000-0002-5479-9095; Mani, Sendurai/0000-0002-5918-4276;
   Estecio, Marcos/0000-0002-6874-7413; Panjarian,
   Shoghag/0000-0003-0861-9767; Taube, Joseph/0000-0002-3636-5189; Issa,
   Jean-Pierre/0000-0003-2258-5030; Jelinek, Jaroslav/0000-0002-2533-0220;
   Malouf, Gabriel/0000-0003-3527-0417
FU MD Anderson Research Trust; George and Barbara Bush Endowment for
   Innovative Cancer Research; DOD Breast Cancer Research Postdoctoral
   Fellowship; Fondation Nadine Midy; Foundation Nelia et Amadeo Barletta
   (FNAB); Association pour l'Aide a'la Recherche et l'Enseignement en
   Cancerologie (AAREC)
FX This work was supported in part by an MD Anderson Research Trust Fellow
   Award, funded by the George and Barbara Bush Endowment for Innovative
   Cancer Research (SAM) and DOD Breast Cancer Research Postdoctoral
   Fellowship (JHT). GGM was also funded by the following non-for-profit
   organizations: Fondation Nadine Midy, Foundation Nelia et Amadeo
   Barletta (FNAB) and the Association pour l'Aide a'la Recherche et
   l'Enseignement en Cancerologie (AAREC).
CR Aran D, 2011, HUM MOL GENET, V20, P670, DOI 10.1093/hmg/ddq513
   Bapat SA, 2010, EPIGENETICS-US, V5, P716, DOI 10.4161/epi.5.8.13014
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Challen GA, 2012, NAT GENET, V44, P23, DOI 10.1038/ng.1009
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036
   Ghoul A, 2009, CANCER RES, V69, P4260, DOI 10.1158/0008-5472.CAN-08-2837
   Hader C, 2010, ONCOGENE, V29, P1031, DOI 10.1038/onc.2009.397
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hiraguri S, 1998, CANCER RES, V58, P1972
   Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Jelinek J, 2012, EPIGENETICS-US, V7, P1368, DOI 10.4161/epi.22552
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829
   Pujadas E, 2012, CELL, V148, P1123, DOI 10.1016/j.cell.2012.02.045
   Reinke LM, 2012, J BIOL CHEM, V287, P36435, DOI 10.1074/jbc.M112.397125
   Rosty C, 2005, ONCOGENE, V24, P7094, DOI 10.1038/sj.onc.1208854
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Schroeder DI, 2011, GENOME RES, V21, P1583, DOI 10.1101/gr.119131.110
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Walter K, 2012, CLIN CANCER RES, V18, P2360, DOI 10.1158/1078-0432.CCR-11-2635-T
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312
   Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 55
TC 69
Z9 82
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2013
VL 14
IS 12
AR R144
DI 10.1186/gb-2013-14-12-r144
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AA8WR
UT WOS:000331376200012
PM 24367927
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Dulla, B
   Kirla, KT
   Rathore, V
   Deora, GS
   Kavela, S
   Maddika, S
   Chatti, K
   Reiser, O
   Iqbal, J
   Pal, M
AF Dulla, Balakrishna
   Kirla, Krishna Tulasi
   Rathore, Vandana
   Deora, Girdhar Singh
   Kavela, Sridhar
   Maddika, Subbareddy
   Chatti, Kiranam
   Reiser, Oliver
   Iqbal, Javed
   Pal, Manojit
TI Synthesis and evaluation of 3-amino/guanidine substituted phenyl
   oxazoles as a novel class of LSD1 inhibitors with anti-proliferative
   properties
SO ORGANIC & BIOMOLECULAR CHEMISTRY
LA English
DT Article
ID HISTONE; ANALOGS; DEMETHYLATION; REEXPRESSION; INACTIVATOR; CHROMATIN
AB A series of functionalized phenyl oxazole derivatives was designed, synthesized and screened in vitro for their activities against LSD1 and for effects on viability of cervical and breast cancer cells, and in vivo for effects using zebrafish embryos. These compounds are likely to act via multiple epigenetic mechanisms specific to cancer cells including LSD1 inhibition.
C1 [Dulla, Balakrishna; Reiser, Oliver] Univ Regensburg, Inst Organ Chem, D-93053 Regensburg, Germany.
   [Dulla, Balakrishna; Deora, Girdhar Singh; Iqbal, Javed; Pal, Manojit] Dr Reddys Inst Life Sci, Dept Med Chem, Hyderabad 500046, Andhra Pradesh, India.
   [Kirla, Krishna Tulasi; Rathore, Vandana; Chatti, Kiranam] Dr Reddys Inst Life Sci, Dept Biol, Hyderabad 500046, Andhra Pradesh, India.
   [Kavela, Sridhar; Maddika, Subbareddy] Ctr DNA Fingerprinting & Diagnost, Lab Cell Death & Cell Survival, Hyderabad 500001, Andhra Pradesh, India.
C3 University of Regensburg; Department of Biotechnology (DBT) India;
   Centre for DNA Fingerprinting & Diagnostics (CDFD)
RP Reiser, O (通讯作者)，Univ Regensburg, Inst Organ Chem, Univ Str 31, D-93053 Regensburg, Germany.
EM Oliver.Reiser@chemie.uni-regensburg.de; JIqbal@drils.org;
   manojitpal@rediffmail.com
RI Reiser, Oliver/B-7743-2008; Iqbal, Javed/H-9604-2015; Kavela,
   Sridhar/KZU-1742-2024; Pal, Manojit/H-9106-2019; Chatti,
   Kiranam/M-8808-2017; Deora, Girdhar Singh/C-1152-2013; Kirla, Krishna
   Tulasi/U-5041-2017
OI Chatti, Kiranam/0000-0002-1234-5271; Deora, Girdhar
   Singh/0000-0001-9857-101X; kavela, sridhar/0000-0003-3676-4822; Kirla,
   Krishna Tulasi/0000-0001-5191-3748; Reiser, Oliver/0000-0003-1430-573X
FU DAAD (Indigo)
FX The authors thank the management of DRILS for support and B. D. thanks
   the DAAD (Indigo) for providing a fellowship.
CR Bi XD, 2006, BIOORG MED CHEM LETT, V16, P3229, DOI 10.1016/j.bmcl.2006.03.048
   Culhane J. C., 2007, CURR OPIN CHEM BIOL
   Culhane JC, 2006, J AM CHEM SOC, V128, P4536, DOI 10.1021/ja0602748
   Culhane JC, 2010, J AM CHEM SOC, V132, P3164, DOI 10.1021/ja909996p
   Donelson JL, 2006, BIOORG MED CHEM LETT, V16, P4420, DOI 10.1016/j.bmcl.2006.05.029
   Dulla B, 2012, BIOORG MED CHEM LETT, V22, P4629, DOI 10.1016/j.bmcl.2012.05.096
   Ettmayer P, 2003, J COMB CHEM, V5, P253, DOI 10.1021/cc020100w
   Forneris F, 2007, J BIOL CHEM, V282, P20070, DOI 10.1074/jbc.C700100200
   Gelato KA, 2008, BIOL CHEM, V389, P353, DOI 10.1515/BC.2008.048
   Gillenwater AM, 2007, MOL CANCER THER, V6, P2967, DOI 10.1158/1535-7163.MCT-04-0344
   Godfrey AG, 2003, J ORG CHEM, V68, P2623, DOI 10.1021/jo026655v
   Gooden DM, 2008, BIOORG MED CHEM LETT, V18, P3047, DOI 10.1016/j.bmcl.2008.01.003
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Loenarz C, 2008, NAT CHEM BIOL, V4, P152, DOI 10.1038/nchembio0308-152
   McGrath P, 2008, DRUG DISCOV TODAY, V13, P394, DOI 10.1016/j.drudis.2008.03.002
   Neelamegam R, 2012, ACS CHEM NEUROSCI, V3, P120, DOI 10.1021/cn200104y
   Powell DA, 2003, J ORG CHEM, V68, P2300, DOI 10.1021/jo0265535
   Reddy MA, 2008, CIRC RES, V103, P615, DOI 10.1161/CIRCRESAHA.108.175190
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Suzuki T, 2011, J MED CHEM, V54, P8236, DOI 10.1021/jm201048w
   Szewczuk LM, 2007, BIOCHEMISTRY-US, V46, P6892, DOI 10.1021/bi700414b
   Tahtaoui C, 2004, J MED CHEM, V47, P4300, DOI 10.1021/jm040800a
   THOMAS JO, 1984, J CELL SCI, P1
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Wu Y, 2012, BIOCHEM J, V442, P693, DOI 10.1042/BJ20111271
   Zhou XF, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-294
   Zhu QJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001446
NR 29
TC 47
Z9 53
U1 0
U2 36
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-0520
EI 1477-0539
J9 ORG BIOMOL CHEM
JI Org. Biomol. Chem.
PY 2013
VL 11
IS 19
BP 3103
EP 3107
DI 10.1039/c3ob40217g
PG 5
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Chemistry
GA 130RZ
UT WOS:000317938200005
PM 23575971
DA 2025-01-12
ER

PT J
AU van Vlerken, LE
   Kiefer, CM
   Morehouse, C
   Li, Y
   Groves, C
   Wilson, SD
   Ya, YH
   Hollingsworth, RE
   Hurt, EM
AF van Vlerken, Lilian E.
   Kiefer, Christine M.
   Morehouse, Chris
   Li, Ying
   Groves, Chris
   Wilson, Susan D.
   Ya, Yihong
   Hollingsworth, Robert E.
   Hurt, Elaine M.
TI EZH2 Is Required for Breast and Pancreatic Cancer Stem Cell Maintenance
   and Can Be Used as a Functional Cancer Stem Cell Reporter
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Cancer stem cells; Epigenetics; Selectable marker; Technology
ID TO-MESENCHYMAL TRANSITION; HISTONE H3; PROSTATE-CANCER; TRITHORAX
   PROTEINS; TUMOR-GROWTH; IN-VIVO; POLYCOMB; IDENTIFICATION; METASTASIS;
   METHYLATION
AB Although cancer is largely seen as a disease stemming from genetic mutations, evidence has implicated epigenetic regulation of gene expression as a driving force for tumorigenesis. Epigenetic regulation by histone modification, specifically through polycomb group (PcG) proteins such as EZH2 and BMI-1, is a major driver in stem cell biology and is found to be correlated with poor prognosis in many tumor types. This suggests a role for PcG proteins in cancer stem cells (CSCs). We hypothesized that epigenetic modification by EZH2, specifically, helps maintain the CSC phenotype and that in turn this epigenetic modifier can be used as a reporter for CSC activity in an in vitro high-throughput screening assay. CSCs isolated from pancreatic and breast cancer lines had elevated EZH2 levels over non-CSCs. Moreover, EZH2 knockdown by RNA interference significantly reduced the frequency of CSCs in all models tested, confirming the role of EZH2 in maintenance of the CSC population. Interestingly, genes affected by EZH2 loss, and therefore CSC loss, were inversely correlated with genes identified by CSC enrichment, further supporting the function of EZH2 CSC regulation. We translated these results into a novel assay whereby elevated EZH2 staining was used as a reporter for CSCs. Data confirmed that this assay could effectively measure changes, both inhibition and enrichment, in the CSC population, providing a novel approach to look at CSC activity. This assay provides a unique, rapid way to facilitate CSC screening across several tumor types to aid in further CSC-related research. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:43-52
C1 [van Vlerken, Lilian E.; Hollingsworth, Robert E.; Hurt, Elaine M.] Medimmune Inc, Dept Oncol Res, Gaithersburg, MD 20878 USA.
   [Kiefer, Christine M.; Wilson, Susan D.] Medimmune Inc, Dept Antibody Discovery & Prot Engn, Gaithersburg, MD 20878 USA.
   [Morehouse, Chris; Ya, Yihong] Medimmune Inc, Dept Translat Sci, Gaithersburg, MD 20878 USA.
   [Li, Ying; Groves, Chris] Medimmune Inc, Dept Resp Inflammat & Autoimmune, Gaithersburg, MD 20878 USA.
C3 AstraZeneca; Medimmune; AstraZeneca; Medimmune; AstraZeneca; Medimmune;
   AstraZeneca; Medimmune
RP Hurt, EM (通讯作者)，Medimmune Inc, Dept Oncol Res, 1 MedImmune Way, Gaithersburg, MD 20878 USA.
EM HurtE@MedImmune.com
OI Groves, Christopher/0009-0007-1667-4869; Kiefer,
   Christine/0000-0003-0823-9502
CR Akunuru S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016951
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793
   Anania MC, 2011, ONCOGENE, V30, P3011, DOI 10.1038/onc.2011.18
   Barry F, 2001, BIOCHEM BIOPH RES CO, V289, P519, DOI 10.1006/bbrc.2001.6013
   Beider K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005125
   Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579
   Blumenthal RD, 2005, CANCER RES, V65, P8809, DOI 10.1158/0008-5472.CAN-05-0420
   Bourseau-Guilmain E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025515
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chen YC, 2010, CANCER LETT, V297, P109, DOI 10.1016/j.canlet.2010.05.003
   Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40
   Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012
   Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002
   Du ZY, 2011, DIGEST DIS SCI, V56, P741, DOI 10.1007/s10620-010-1340-0
   Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184
   Gautier P, 2008, DEV DYNAM, V237, P3295, DOI 10.1002/dvdy.21729
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012
   Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3
   Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573
   Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104
   Koutsourakis M, 1999, DEVELOPMENT, V126, P723
   Kume T, 2000, DEVELOPMENT, V127, P1387
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027
   Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Mizuma M, 2012, MOL CANCER THER, V11, P1999, DOI 10.1158/1535-7163.MCT-12-0017
   Nitzki F, 2010, CANCER RES, V70, P2739, DOI 10.1158/0008-5472.CAN-09-3743
   Ohkuma M, 2012, ANN SURG ONCOL, V19, P1357, DOI 10.1245/s10434-011-1739-7
   Paron I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021684
   Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004
   Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214
   Qi H, 2007, CELL RES, V17, P578, DOI 10.1038/cr.2007.59
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Song K, 2011, BIOCHEM J, V436, P271, DOI 10.1042/BJ20110297
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Sripichai O, 2009, BLOOD, V114, P2299, DOI 10.1182/blood-2009-05-219386
   Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Toll AD, 2010, HUM PATHOL, V41, P1205, DOI 10.1016/j.humpath.2010.03.004
   Tsang DPF, 2011, J GASTROEN HEPATOL, V26, P19, DOI 10.1111/j.1440-1746.2010.06447.x
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Xing ZQ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-162
   Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591
   Zhang GN, 2011, CANCER LETT, V313, P137, DOI 10.1016/j.canlet.2011.05.030
   Zhi QM, 2011, BIOMED PHARMACOTHER, V65, P509, DOI 10.1016/j.biopha.2011.06.006
   Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129
NR 56
TC 89
Z9 98
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD JAN
PY 2013
VL 2
IS 1
BP 43
EP 52
DI 10.5966/sctm.2012-0036
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 072IV
UT WOS:000313665500010
PM 23283488
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Ramadoss, S
   Chen, XH
   Wang, CY
AF Ramadoss, Sivakumar
   Chen, Xiaohong
   Wang, Cun-Yu
TI Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER; JMJD3 CONTRIBUTES; GENE-EXPRESSION; H3K27ME3 DEMETHYLASE;
   STEM-CELLS; PROGRESSION; SNAIL; EZH2; TRANSCRIPTION; UTX
AB Epithelial-mesenchymal transition (EMT) is a critical event that occurs in embryonic development, tissue repair control, organ fibrosis, and carcinoma invasion and metastasis. Although significant progress has been made in understanding the molecular regulation of EMT, little is known about how chromatin is modified in EMT. Chromatin modifications through histone acetylation and methylation determine the precise control of gene expression. Recently, histone demethylases were found to play important roles in gene expression through demethylating mono-, di-, or trimethylated lysines. KDM6B (also known as JMJD3) is a histone demethylase that might activate gene expression by removing repressive histone H3 lysine 27 trimethylation marks from chromatin. Here we report that KDM6B played a permissive role in TGF-beta-induced EMT in mammary epithelial cells by stimulating SNAI1 expression. KDM6B was induced by TGF-beta, and the knockdown of KDM6B inhibited EMT induced by TGF-beta. Conversely, overexpression of KDM6B induced the expression of mesenchymal genes and promoted EMT. Chromatin immunoprecipitation (ChIP) assays revealed that KDM6B promoted SNAI1 expression by removing histone H3 lysine trimethylation marks. Consistently, our analysis of the Oncomine database found that KDM6B expression was significantly increased in invasive breast carcinoma compared with normal breast tissues. The knockdown of KDM6B significantly inhibited breast cancer cell invasion. Collectively, our study uncovers a novel epigenetic mechanism regulating EMT and tumor cell invasion, and has important implication in targeting cancer metastasis.
C1 [Ramadoss, Sivakumar; Chen, Xiaohong; Wang, Cun-Yu] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles
RP Wang, CY (通讯作者)，Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, 33-030A CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM cwang@dentistry.ucla.edu
RI Wang, Chunlei/F-3593-2012; Chen, Haoda/KHT-7533-2024
OI Ramadoss, Sivakumar/0000-0001-7943-7501
FU National Institutes of Health [CA132134, R3713848, DE15964]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants CA132134, R3713848, and DE15964.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Anderton JA, 2011, ONCOGENE, V30, P2037, DOI 10.1038/onc.2010.579
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298
   Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179
   Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104
   Hübner MR, 2010, COLD SH Q B, V75, P43, DOI 10.1101/sqb.2010.75.020
   Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004
   Kim SW, 2011, DEV BIOL, V357, P492, DOI 10.1016/j.ydbio.2011.06.009
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651
   Kunju LP, 2011, MODERN PATHOL, V24, P786, DOI 10.1038/modpathol.2011.8
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010
   Massagué J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789
   Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028
   Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997
   Pereira F, 2011, HUM MOL GENET, V20, P4655, DOI 10.1093/hmg/ddr399
   Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Ramadoss S, 2011, MOL CELL BIOL, V31, P924, DOI 10.1128/MCB.00576-10
   Schuettengruber B, 2009, DEVELOPMENT, V136, P3531, DOI 10.1242/dev.033902
   Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104
   Wendt MK, 2012, CELL TISSUE RES, V347, P85, DOI 10.1007/s00441-011-1199-1
   Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045
NR 47
TC 140
Z9 152
U1 0
U2 31
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 28
PY 2012
VL 287
IS 53
BP 44508
EP 44517
DI 10.1074/jbc.M112.424903
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 062RI
UT WOS:000312938600047
PM 23152497
OA Green Published
DA 2025-01-12
ER

PT J
AU DeBono, AJ
   Xie, JH
   Ventura, S
   Pouton, CW
   Capuano, B
   Scammells, PJ
AF DeBono, Aaron J.
   Xie, Jin Han
   Ventura, Sabatino
   Pouton, Colin W.
   Capuano, Ben
   Scammells, Peter J.
TI Synthesis and Biological Evaluation of <i>N</i>-Substituted Noscapine
   Analogues
SO CHEMMEDCHEM
LA English
DT Article
DE antitumor agents; cytotoxic activity; natural products; noscapine
   analogues; structure-activity relationships
ID TUMOR-SUPPRESSOR GENES; DNA METHYLTRANSFERASE; EPIGENETIC MODIFICATIONS;
   HISTONE DEACETYLASE; INHIBITORS; MECHANISMS; DISCOVERY;
   HYPERMETHYLATION; PEYSSONENYNES; EPIGENOMICS
AB Noscapine is a phthalideisoquinoline alkaloid isolated from the opium poppy Papaver somniferum. It has long been used as an antitussive agent, but has more recently been found to possess microtubule-modulating properties and anticancer activity. Herein we report the synthesis and pharmacological evaluation of a series of 6'-substituted noscapine derivatives. To underpin this structure-activity study, an efficient synthesis of N-nornoscapine and its subsequent reduction to the cyclic ether derivative of N-nornoscapine was developed. Reaction of the latter with a range of alkyl halides, acid chlorides, isocyanates, thio-isocyanates, and chloroformate reagents resulted in the formation of the corresponding N-alkyl, N-acyl, N-carbamoyl, N-thiocarbamoyl, and N-carbamate derivatives, respectively. The ability of these compounds to inhibit cell proliferation was assessed in cell-cycle cytotoxicity assays using prostate cancer (PC3), breast cancer (MCF-7), and colon cancer (Caco-2) cell lines. Compounds that showed activity in the cell-cycle assay were further evaluated in cell viability assays using PC3 and MCF-7 cells.
C1 [DeBono, Aaron J.; Xie, Jin Han; Ventura, Sabatino; Pouton, Colin W.; Capuano, Ben; Scammells, Peter J.] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia.
C3 Monash University
RP DeBono, AJ (通讯作者)，Monash Univ, Monash Inst Pharmaceut Sci, 381 Royal Parade, Parkville, Vic 3052, Australia.
EM peter.scammells@monash.edu
RI Capuano, Ben/AAC-2541-2019; Pouton, Colin/M-2049-2016
OI Pouton, Colin/0000-0003-0224-3308; Scammells, Peter/0000-0003-2930-895X
FU GSK Australia
FX The authors thank GSK Australia for financial support. We also thank Dr.
   Jason Dang (Monash University) for the acquisition of MS data.
CR Adcock Ian M, 2005, COPD, V2, P445
   Alami M, 1996, TETRAHEDRON LETT, V37, P2763, DOI 10.1016/0040-4039(96)00414-5
   Alvarez R, 2011, CURR TOP MED CHEM, V11, P2749, DOI 10.2174/156802611798184436
   Andrianasolo EH, 2006, J NAT PROD, V69, P576, DOI 10.1021/np0503956
   Aoki S, 2002, TETRAHEDRON, V58, P5417, DOI 10.1016/S0040-4020(02)00519-7
   Ates A, 2003, TETRAHEDRON, V59, P8989, DOI 10.1016/j.tet.2003.03.002
   Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135
   Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078
   Brown R, 2002, TRENDS MOL MED, V8, pS43, DOI 10.1016/S1471-4914(02)02314-6
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Compernolle F, 2006, EUR J ORG CHEM, V2006, P1586, DOI 10.1002/ejoc.200500796
   Crews P, 2003, PHARM BIOL, V41, P39, DOI 10.1080/1388020039051743
   Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fang MZ, 2003, CANCER RES, V63, P7563
   García P, 2010, MAGN RESON CHEM, V48, P543, DOI 10.1002/mrc.2618
   García-Domínguez P, 2011, ORG BIOMOL CHEM, V9, P6979, DOI 10.1039/c1ob05932g
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902
   Hang CT, 2010, NATURE, V466, P62, DOI 10.1038/nature09130
   Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109
   Johnstone SE, 2010, NAT REV GENET, V11, P806, DOI 10.1038/nrg2881
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Krishnamurthy VV, 1996, J MAGN RESON SER A, V121, P33, DOI 10.1006/jmra.1996.0132
   Kuck D, 2010, MOL CANCER THER, V9, P3015, DOI 10.1158/1535-7163.MCT-10-0609
   Kuck D, 2010, BIOORGAN MED CHEM, V18, P822, DOI 10.1016/j.bmc.2009.11.050
   Kwan JC, 2010, CHEM-EUR J, V16, P13020, DOI 10.1002/chem.201001562
   Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006
   Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   McPhail KL, 2004, J NAT PROD, V67, P1010, DOI 10.1021/np0400252
   NAHM S, 1981, TETRAHEDRON LETT, V22, P3815, DOI 10.1016/S0040-4039(01)91316-4
   Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009
   Piña IC, 2003, J ORG CHEM, V68, P3866, DOI 10.1021/jo034248t
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602
   Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rosato RR, 2003, CANCER BIOL THER, V2, P30
   Schaefer M, 2010, CHROMOSOMA, V119, P35, DOI 10.1007/s00412-009-0240-6
   Siedlecki P, 2006, J MED CHEM, V49, P678, DOI 10.1021/jm050844z
   Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410
   Singh N, 2009, CHEMMEDCHEM, V4, P792, DOI 10.1002/cmdc.200900017
   Song JK, 2011, SCIENCE, V331, P1036, DOI 10.1126/science.1195380
   Sun AM, 2009, BIOORG MED CHEM LETT, V19, P6627, DOI 10.1016/j.bmcl.2009.10.023
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Urdinguio RG, 2009, LANCET NEUROL, V8, P1056, DOI 10.1016/S1474-4422(09)70262-5
   Villeneuve LM, 2010, AM J PHYSIOL-RENAL, V299, pF14, DOI 10.1152/ajprenal.00200.2010
   Yadav JS, 2003, J ORG CHEM, V68, P7098, DOI 10.1021/jo034335l
   Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102
NR 59
TC 46
Z9 49
U1 1
U2 50
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD DEC
PY 2012
VL 7
IS 12
BP 2122
EP 2133
DI 10.1002/cmdc.201200365
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)
SC Pharmacology & Pharmacy
GA 045HK
UT WOS:000311685800009
PM 23055449
DA 2025-01-12
ER

PT J
AU Zhang, S
   Bai, JQ
   Ren, SY
   Wang, R
   Zhang, L
   Zuo, YF
AF Zhang, Shuai
   Bai, Jingqiao
   Ren, Shuangyi
   Wang, Ran
   Zhang, Li
   Zuo, Yunfei
TI Sodium butyrate restores ASC expression and induces apoptosis in LS174T
   cells
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE sodium butyrate; apoptosis-associated speck-like protein; LS174T cells
ID HISTONE DEACETYLASE INHIBITION; EMBRYONIC STEM-CELLS; BREAST-CANCER
   CELLS; HUMAN COLON-CANCER; COLORECTAL-CANCER; DNA METHYLATION; ABERRANT
   METHYLATION; GENE-EXPRESSION; DIFFERENTIATION; RECEPTOR
AB Sodium butyrate (NaBu) is a short-chain fatty acid (SCFA), which has been proposed as a potential anticancer agent. Apoptosis-associated speck-like protein (ASC) is a pro-apoptotic signaling factor that is subjected to epigenetic silencing in human cancers. Modulation by the aberrant methylation of CpG islands of ASC is a well-characterized epigenetic mechanism, and the methylation-induced silencing of ASC has been observed in several types of tumors. NaBu induces cell cycle arrest, markers of cell differentiation and apoptosis in colon cancer. NaBu promotes transcriptional activation by relaxing the DNA conformation and displays anti-proliferative and differentiating activity in a wide variety of cancers. Thus, we used NaBu to investigate the relationship between the status of cell proliferation and the re-expression of ASC in colon carcinoma LS174T cells. Our experiments determined ASC re-expression at the protein level using western blotting. In addition, we used reverse transcription-polymerase chain reaction to detect the expression levels of ASC mRNA and an MTT assay to detect the inhibitory rate of cell growth. The apoptosis rate was also detected for further validation of the re-expression of ASC. The results showed that ASC re-expression was significantly increased in the LS174 cells following NaBu treatment in a time- and dose-dependent manner. The expression of ASC also induced the apoptosis of LS174T cells. These results suggest that NaBu plays a role in the reactivation of ASC expression and that the latter promotes the apoptosis of LS174T cells.
C1 [Zhang, Shuai; Bai, Jingqiao; Wang, Ran; Zhang, Li; Zuo, Yunfei] Dalian Med Univ, Dept Clin Biochem, Dalian 116044, Peoples R China.
   [Zhang, Shuai; Ren, Shuangyi] Dalian Med Univ, Affiliated Hosp 2, Dept Surg, Dalian 116023, Peoples R China.
C3 Dalian Medical University; Dalian Medical University
RP Zuo, YF (通讯作者)，Dalian Med Univ, Dept Clin Biochem, Dalian 116044, Peoples R China.
EM rsydl@yahoo.com.cn; zyf04112002@yahoo.com.cn
FU Chinese National Natural Science Foundation Projects [31270867]; Chinese
   State Key Program in Basic Research [2012CB822103]
FX This study was supported by grants from the Chinese National Natural
   Science Foundation Projects (31270867) and the Chinese State Key Program
   in Basic Research (2012CB822103).
CR Archer SY, 2005, AM J PHYSIOL-GASTR L, V289, pG696, DOI 10.1152/ajpgi.00575.2004
   Bartels M, 2010, HAEMATOL-HEMATOL J, V95, P1052, DOI 10.3324/haematol.2009.008870
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bordonaro M, 2008, CELL CYCLE, V7, P1178, DOI 10.4161/cc.7.9.5818
   Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139
   Boyle P, 2000, BRIT MED J, V321, P805, DOI 10.1136/bmj.321.7264.805
   Bukreeva E I, 2009, Tsitologiia, V51, P697
   Cayo MA, 2009, AM J TRANSL RES, V1, P178
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cho HJ, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-49
   Chopin V, 2004, ONCOGENE, V23, P21, DOI 10.1038/sj.onc.1207020
   Du W, 2010, WORLD J GASTROENTERO, V16, P921, DOI 10.3748/wjg.v16.i8.921
   Fearnhead NS, 2002, BRIT MED BULL, V64, P27, DOI 10.1093/bmb/64.1.27
   Ferrante RJ, 2003, J NEUROSCI, V23, P9418
   Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11<1677::AID-ELPS1677>3.0.CO;2-Z
   Fukasawa K, 2008, BBA-REV CANCER, V1786, P15, DOI 10.1016/j.bbcan.2008.04.002
   Heerdt BG, 1999, CANCER RES, V59, P1584
   Heinzel T., 2007, DRUG DISCOV TODAY DI, V4, P277
   Jullumstro E, 2011, COLORECTAL DIS, V13, P512, DOI 10.1111/j.1463-1318.2010.02191.x
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Küster K, 2010, CANCER INVEST, V28, P268, DOI 10.3109/07357900902783195
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c
   Meinke PT, 2001, CURR MED CHEM, V8, P211, DOI 10.2174/0929867013373787
   Nimmanapalli R, 2002, CANCER RES, V62, P5761
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Pan LN, 2010, FEBS J, V277, P989, DOI 10.1111/j.1742-4658.2009.07542.x
   Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980
   Ren M, 2010, J CELL BIOCHEM, V109, P236, DOI 10.1002/jcb.22401
   Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7
   Sung JJY, 2005, LANCET ONCOL, V6, P871, DOI 10.1016/S1470-2045(05)70422-8
   Uchida Hiroshi, 2005, Reprod Med Biol, V4, P115, DOI 10.1111/j.1447-0578.2005.00101.x
   Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206
   Wang L, 2009, J INT MED RES, V37, P803, DOI 10.1177/147323000903700323
   Weidle UH, 2000, ANTICANCER RES, V20, P1471
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhou MM, 2010, J CELL BIOCHEM, V109, P606, DOI 10.1002/jcb.22442
NR 42
TC 10
Z9 10
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD DEC
PY 2012
VL 30
IS 6
BP 1431
EP 1437
DI 10.3892/ijmm.2012.1156
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 046NJ
UT WOS:000311771400024
PM 23064206
OA Bronze
DA 2025-01-12
ER

PT J
AU Gray, SG
   Baird, AM
   O'Kelly, F
   Nikolaidis, G
   Almgren, M
   Meunier, A
   Dockry, E
   Hollywood, D
   Ekström, TJ
   Perry, AS
   O'Byrne, KJ
AF Gray, Steven G.
   Baird, Anne-Marie
   O'Kelly, Fardod
   Nikolaidis, Georgios
   Almgren, Malin
   Meunier, Armelle
   Dockry, Eilis
   Hollywood, Donal
   Ekstrom, Tomas J.
   Perry, Antoinetie S.
   O'Byrne, Kenneth J.
TI Gemcitabine reactivates epigenetically silenced genes and functions as a
   DNA methyltransferase inhibitor
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE cancer; gemcitabine; DNA methyltransferase; epigenetics; DNMT inhibitor
ID CELL LUNG-CANCER; MALIGNANT PLEURAL MESOTHELIOMA; PANCREATIC-CANCER;
   PROSTATE-CANCER; BREAST-CANCER; METHYLATION; GROWTH; CHEMOTHERAPY;
   EXPRESSION; APOPTOSIS
AB Gemcitabi ne is indicated in combination with cisplatin as first-line therapy for solid tumours including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma. Gemcitabinc is an analogue of pyrimidine cytosine and functions as an anti-metabolite. Structurally, however, gemcitabine has similarities to 5-aza-2-deoxycytidine (decitabine/Dacogen (R)), a DNA methyltransferase inhibitor (DNMTi). NSCLC, mesothelioma and prostate cancer cell lines were treated with decitabine and gemcitabine. Reactivation of epigenetically silenced genes was examined by RT-PCR/qPCR. DNA methyltransferase activity in nuclear extracts and recombinant proteins was measured using a DNA methyltransferase assay, and alterations in DNA methylation status were examined using methylation-specific PCR (MS-PCR) and pyrosequencing. We observe a reactivation of several epigenetically silenced genes including GSTP1, IGFBP3 and RASSFIA. Gemcitabine functionally inhibited DNA methyltransferase activity in both nuclear extracts and recombinant Proteins. Gemcitabinc dramatically destabilised DNMT1 protein. However, DNA CpG methylation was for the most part unaffected by gemcitabine. In conclusion, gemcitabine both inhibits and destabilises DNA methyltransferases and reactivates epigenetically silenced genes having activity equivalent to decitabine at concentrations significantly lower than those achieved in the treatment of patients with solid tumours. This property may contribute to the anticancer activity of gemcitabine.
C1 [Gray, Steven G.; Baird, Anne-Marie; Dockry, Eilis; O'Byrne, Kenneth J.] Trinity Coll Dublin, Inst Mol Med, Thorac Oncol Res Grp, Dublin 2, Ireland.
   [O'Kelly, Fardod; Meunier, Armelle; Hollywood, Donal; Perry, Antoinetie S.] St James Hosp, Trinity Ctr Hlth Sci, Dublin 8, Ireland.
   [Nikolaidis, Georgios] Univ Liverpool, Canc Res Ctr, Dept Mol & Clin Canc Med, Roy Castle Lung Canc Res Program, Liverpool L3 9TA, Merseyside, England.
   [Almgren, Malin; Ekstrom, Tomas J.] Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, SE-17176 Stockholm, Sweden.
   [O'Byrne, Kenneth J.] St James Hosp, HOPE Directorate, Dublin 8, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; University of Liverpool;
   Karolinska Institutet; Trinity College Dublin
RP Gray, SG (通讯作者)，Trinity Coll Dublin, Inst Mol Med, Thorac Oncol Res Grp, Dublin 2, Ireland.
EM sgray@stjames.ie
RI Gray, Steven/I-3081-2019; O’Kelly, Fardod/JFJ-2563-2023; Ekström,
   Tomas/B-7764-2013
OI O'Byrne, Kenneth/0000-0002-6754-5633; Gray, Steven/0000-0002-5850-6392;
   Baird, Anne-Marie/0000-0001-7501-1159; Perry,
   Antoinette/0000-0002-6108-512X; O'Kelly, Fardod/0000-0002-4992-7689
FU Irish Cancer Society
FX Funding support for this project was provided by the Irish Cancer
   Society to Antoinette Perry.
CR Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Cai D, 2010, CANCER RES, V70, P6477, DOI 10.1158/0008-5472.CAN-10-0005
   Daskalos A, 2011, CANCER LETT, V300, P79, DOI 10.1016/j.canlet.2010.09.009
   Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   de Lange SM, 2005, EUR J CLIN PHARMACOL, V61, P843, DOI 10.1007/s00228-005-0033-7
   DeVita V, 2006, NAT CLIN PRACT ONCOL, V3, P641, DOI 10.1038/ncponc0669
   Endoh H, 2003, INT J CANCER, V106, P45, DOI 10.1002/ijc.11184
   Fennell DA, 2008, NAT CLIN PRACT ONCOL, V5, P136, DOI 10.1038/ncponc1039
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Goffin J, 2010, J THORAC ONCOL, V5, P260, DOI 10.1097/JTO.0b013e3181c6f035
   Gore SD, 2006, NAT REV DRUG DISCOV, V5, P891, DOI 10.1038/nrd2180
   Gray SG, 2009, EUR J CANCER, V45, P3087, DOI 10.1016/j.ejca.2009.09.006
   Hajji N, 2010, ONCOGENE, V29, P2192, DOI 10.1038/onc.2009.505
   He B, 2005, CANCER RES, V65, P743
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Jantscheff P, 2009, CLIN EXP METASTAS, V26, P981, DOI 10.1007/s10585-009-9288-1
   Jantscheff P, 2009, PROSTATE, V69, P1151, DOI 10.1002/pros.20964
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   Kuzmin I, 2002, CANCER RES, V62, P3498
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Lawless MW, 2009, J CELL MOL MED, V13, P826, DOI 10.1111/j.1582-4934.2008.00571.x
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Levenson VV, 2010, EXPERT REV MOL DIAGN, V10, P481, DOI 10.1586/ERM.10.17
   McLaren BR, 2000, CANCER CHEMOTH PHARM, V45, P502, DOI 10.1007/s002800051026
   Nagel S, 2007, EXPERT OPIN PHARMACO, V8, P3265, DOI 10.1517/14656566.8.18.3265
   Nelson WG, 2009, ENDOCRINOLOGY, V150, P3991, DOI 10.1210/en.2009-0573
   O'Byrne Kenneth J, 2011, Cancers (Basel), V3, P1426, DOI 10.3390/cancers3011426
   Perry AS, 2007, BRIT J CANCER, V96, P1587, DOI 10.1038/sj.bjc.6603767
   Perry Antoinette S, 2007, Epigenetics, V2, P43
   PLUNKETT W, 1995, SEMIN ONCOL, V22, P3
   Ramachandran K, 2010, ANTICANCER RES, V30, P3919
   Ray M, 2009, CHEST, V136, P888, DOI 10.1378/chest.08-2665
   Salazar F, 2011, LUNG CANCER, V72, P84, DOI 10.1016/j.lungcan.2010.07.008
   Schäfer A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014060
   Tkaczuk KHR, 2009, CLIN THER, V31, P2273, DOI 10.1016/j.clinthera.2009.11.011
   Toyooka S, 2001, CANCER RES, V61, P5727
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Yokochi T, 2004, MOL PHARMACOL, V66, P1415, DOI 10.1124/mol.104.002634
   Zhao WH, 2009, BIOCHEM BIOPH RES CO, V380, P699, DOI 10.1016/j.bbrc.2009.01.155
NR 40
TC 32
Z9 35
U1 0
U2 20
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD DEC
PY 2012
VL 30
IS 6
BP 1505
EP 1511
DI 10.3892/ijmm.2012.1138
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 046NJ
UT WOS:000311771400035
PM 23007409
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Katoh, M
AF Katoh, Masaru
TI Function and cancer genomics of <i>FAT</i> family genes (Review)
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE FAT; YAP; TAZ; actin dynamics; G-protein-coupled receptor; receptor
   tyrosine kinase; WNT; beta-catenin; cancer stem cells; whole-genome
   sequence
ID TUMOR-SUPPRESSOR GENE; PLANAR CELL POLARITY; SIGNALING PATHWAY;
   INACTIVATING MUTATIONS; PROTOCADHERIN FAT1; DROSOPHILA ENCODES; ACTIN
   DYNAMICS; CYCLE EXIT; CADHERIN; PROTEIN
AB FAT 1, FAT2, FAT3 and FAT4 are human homologs of Drosophila Fat, which is involved in tumor suppression and planar cell polarity (PCP). FAT1 and FAT4 undergo the first proteolytic cleavage by Furin and are predicted to undergo the second cleavage by gamma-secretase to release intracellular domain (ICD). Ena/VAPS-binding to FAT1 induces actin polymerization at lamellipodia and filopodia to promote cell migration, while Scribble-binding to FAT1 induces phosphorylation and functional inhibition of YAP1 to suppress cell growth. FAT1 is repressed in oral cancer owing to homozygous deletion or epigenetic silencing and is preferentially downregulated in invasive breast cancer. On the other hand, FAT1 is upregulated in leukemia and prognosis of preB-ALL patients with FAT1 upregulation is poor. FAT4 directly interacts with MPDZ/MUPP1 to recruit membrane-associated guanylate kinase MPP5/PALS1. FAT4 is involved in the maintenance of PCP and inhibition of cell proliferation. FAT4 mRNA is repressed in breast cancer and lung cancer due to promoter hypermethylation. FAT4 gene is recurrently mutated in several types of human cancers, such as melanoma, pancreatic cancer, gastric cancer and hepatocellular carcinoma. FAT1 and FAT4 suppress tumor growth via activation of Hippo signaling, whereas FAT1 promotes tumor migration via induction of actin polymerization. FAT1 is tumor suppressive or oncogenic in a context-dependent manner, while FAT4 is tumor suppressive. Copy number aberration, translocation and point mutation of FAT1, FAT2, FAT3, FAT4, FRMD1, FRMD6, NF2, WWC1, WWC2, SAV1, STK3, STK4, MOB1A, MOB1B, LATS1, LATS2, YAP1 and WWTRI/TAZ genes should be comprehensively investigated in various types of human cancers to elucidate the mutation landscape of the FAT-Hippo signaling cascades. Because YAP1 and WWTR1 are located at the crossroads of adhesion, GPCR, RTK and stem-cell signaling network, cancer genomics of the FAT signaling cascades could be applied for diagnostics, prognostics and therapeutics in the era of personalized medicine.
C1 Natl Canc Ctr, Div Integrat Omics & Bioinformat, Chuo Ward, Tokyo 1040045, Japan.
C3 National Cancer Center - Japan
RP Katoh, M (通讯作者)，Natl Canc Ctr, Div Integrat Omics & Bioinformat, Chuo Ward, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM mkatoh-kkr@umin.ac.jp
OI Katoh, Masaru/0000-0003-3274-4066
FU National Cancer Center Research and Development Fund
FX This study was supported in part by National Cancer Center Research and
   Development Fund.
CR Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923
   Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610
   Axelrod JD, 2009, SEMIN CELL DEV BIOL, V20, P964, DOI 10.1016/j.semcdb.2009.08.001
   Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108
   Bosveld F, 2012, SCIENCE, V336, P724, DOI 10.1126/science.1221071
   BRYANT PJ, 1993, DEVELOPMENT, P239
   BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5
   Chosdol K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-5
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   de Bock CE, 2012, LEUKEMIA, V26, P918, DOI 10.1038/leu.2011.319
   Djiane A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011228
   DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884
   Genevet A, 2011, BIOCHEM J, V436, P213, DOI 10.1042/BJ20110217
   Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738
   Höng JC, 2004, J MOL BIOL, V337, P307, DOI 10.1016/j.jmb.2004.01.026
   Hou R, 2006, J CELL BIOL, V173, P417, DOI 10.1083/jcb.200508121
   Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036
   Hulpiau P, 2009, INT J BIOCHEM CELL B, V41, P349, DOI 10.1016/j.biocel.2008.09.027
   Imajo M, 2012, EMBO J, V31, P1109, DOI 10.1038/emboj.2011.487
   Ishikawa HO, 2008, SCIENCE, V321, P401, DOI 10.1126/science.1158159
   Ishiuchi T, 2009, J CELL BIOL, V185, P959, DOI 10.1083/jcb.200811030
   Jones C, 2007, BIOESSAYS, V29, P120, DOI 10.1002/bies.20526
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534
   Katoh M, 2004, INT J MOL MED, V13, P333
   Katoh M, 2005, ONCOL REP, V14, P1583
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   Katoh Y, 2006, INT J MOL MED, V18, P523
   Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081
   Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636
   Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903
   Magg T, 2005, EXP CELL RES, V307, P100, DOI 10.1016/j.yexcr.2005.03.006
   MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7
   Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1
   Moeller MJ, 2004, EMBO J, V23, P3769, DOI 10.1038/sj.emboj.7600380
   Nakaya K, 2007, ONCOGENE, V26, P5300, DOI 10.1038/sj.onc.1210330
   Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051
   Qi C, 2009, INT J CANCER, V124, P793, DOI 10.1002/ijc.23775
   Rauch TA, 2012, TUMOR BIOL, V33, P287, DOI 10.1007/s13277-011-0282-2
   Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974
   Rohrbeck A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007315
   Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179
   Sadeqzadeh E, 2011, J BIOL CHEM, V286, P28181, DOI 10.1074/jbc.M111.234419
   Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221
   Schreiner D, 2006, FEBS LETT, V580, P5295, DOI 10.1016/j.febslet.2006.08.079
   Settakorn J, 2005, J CLIN PATHOL, V58, P1249, DOI 10.1136/jcp.2005.026575
   Skouloudaki K, 2009, P NATL ACAD SCI USA, V106, P8579, DOI 10.1073/pnas.0811691106
   Sopko R, 2009, CURR OPIN CELL BIOL, V21, P717, DOI 10.1016/j.ceb.2009.07.001
   STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361
   Strutt H, 2002, DEV CELL, V3, P851, DOI 10.1016/S1534-5807(02)00363-5
   Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398
   Tanoue T, 2004, J CELL BIOL, V165, P517, DOI 10.1083/jcb.200403006
   Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3
   Thomas C, 2012, DEV DYNAM, V241, P27, DOI 10.1002/dvdy.22736
   Van Hateren NJ, 2011, DEVELOPMENT, V138, P1893, DOI 10.1242/dev.064204
   WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X
   Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397
   Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X
   Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037
   Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246
NR 62
TC 162
Z9 195
U1 1
U2 47
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD DEC
PY 2012
VL 41
IS 6
BP 1913
EP 1918
DI 10.3892/ijo.2012.1669
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 043YZ
UT WOS:000311587900002
PM 23076869
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Rossa, C
   Sommer, G
   Spolidorio, LC
   Rosenzweig, SA
   Watson, DK
   Kirkwood, KL
AF Rossa, Carlos, Jr.
   Sommer, Gunhild
   Spolidorio, Luis C.
   Rosenzweig, Steven A.
   Watson, Dennis K.
   Kirkwood, Keith L.
TI Loss of Expression and Function of SOCS3 Is an Early Event in HNSCC:
   Altered Subcellular Localization as a Possible Mechanism Involved in
   Proliferation, Migration and Invasion
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; CYTOKINE SIGNALING-3; CONSTITUTIVE EXPRESSION;
   GROWTH-INHIBITION; BREAST-CANCER; IFN-ALPHA; SUPPRESSOR; LYMPHOMA; SITE;
   RESISTANCE
AB Background: Suppressor of cytokine signaling 3 (SOCS3) is an inducible endogenous negative regulator of signal transduction and activator of transcription 3 (STAT3). Epigenetic silencing of SOCS3 has been shown in head and neck squamous cell carcinoma (HNSCC), which is associated with increased activation of STAT3. There is scarce information on the functional role of the reduction of SOCS3 expression and no information on altered subcellular localization of SOCS3 in HNSCC.
   Methodology/Principal Findings: We assessed endogenous SOCS3 expression in different HNSCC cell lines by RT-qPCR and western blot. Immunofluorescence and western blot were used to study the subcellular localization of endogenous SOCS3 induced by IL-6. Overexpression of SOCS3 by CMV-driven plasmids and siRNA-mediated inhibition of endogenous SOCS3 were used to verify the role of SOCS3 on tumor cell proliferation, viability, invasion and migration in vitro. In vivo relevance of SOCS3 expression in HNSCC was studied by quantitative immunohistochemistry of commercially-available tissue microarrays. Endogenous expression of SOCS3 was heterogeneous in four HNSCC cell lines and surprisingly preserved in most of these cell lines. Subcellular localization of endogenous SOCS3 in the HNSCC cell lines was predominantly nuclear as opposed to cytoplasmic in non-neoplasic epithelial cells. Overexpression of SOCS3 produced a relative increase of the protein in the cytoplasmic compartment and significantly inhibited proliferation, migration and invasion, whereas inhibition of endogenous nuclear SOCS3 did not affect these events. Analysis of tissue microarrays indicated that loss of SOCS3 is an early event in HNSCC and was correlated with tumor size and histological grade of dysplasia, but a considerable proportion of cases presented detectable expression of SOCS3.
   Conclusion: Our data support a role for SOCS3 as a tumor suppressor gene in HNSCC with relevance on proliferation and invasion processes and suggests that abnormal subcellular localization impairs SOCS3 function in HNSCC cells.
C1 [Rossa, Carlos, Jr.] Araraquara Univ Estadual Paulista UNESP, Dept Diag & Surg, Sch Dent, Sao Paulo, Brazil.
   [Sommer, Gunhild; Watson, Dennis K.] Med Univ S Carolina MUSC, Dept Biochem & Mol Biol, Charleston, SC USA.
   [Spolidorio, Luis C.] Araraquara Univ Estadual Paulista UNESP, Dept Physiol & Pathol, Sch Dent, Sao Paulo, Brazil.
   [Rosenzweig, Steven A.] Med Univ S Carolina MUSC, Dept Pharmacol, Charleston, SC USA.
   [Watson, Dennis K.] Med Univ S Carolina MUSC, Dept Pathol & Lab Med, Charleston, SC USA.
   [Kirkwood, Keith L.] Med Univ S Carolina MUSC, Dept Craniofacial Biol, Charleston, SC USA.
   [Kirkwood, Keith L.] Med Univ S Carolina MUSC, Ctr Oral Hlth, Charleston, SC USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Medical University of South Carolina; Medical University of
   South Carolina; Medical University of South Carolina
RP Rossa, C (通讯作者)，Araraquara Univ Estadual Paulista UNESP, Dept Diag & Surg, Sch Dent, Sao Paulo, Brazil.
EM crossajr@foar.unesp.br
RI Rosenzweig, Steven/O-5062-2018; Kirkwood, Keith/L-4728-2018; Spolidorio,
   Luis Carlos/G-1857-2012; Rossa Jr, Carlos/D-8328-2012
OI Spolidorio, Luis Carlos/0000-0002-0592-542X; Rossa Jr,
   Carlos/0000-0003-1705-5481; Sommer, Gunhild/0000-0002-3776-4181;
   Kirkwood, Keith/0000-0003-4519-8973; Rosenzweig,
   Steven/0000-0002-7022-6086
FU National Institutes of Health -National Center for Research Resources
   [P20RR017696]; National Institute of Dental and Craniofacial Research
   [1R01DE018290]
FX This work was supported by the National Institutes of Health -National
   Center for Research Resources (P20RR017696) and National Institute of
   Dental and Craniofacial Research (1R01DE018290 to KLK). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130
   Babon JJ, 2006, MOL CELL, V22, P205, DOI 10.1016/j.molcel.2006.03.024
   Baetz A, 2008, FASEB J, V22, P4296, DOI 10.1096/fj.08-116079
   Brender C, 2005, LEUKEMIA, V19, P209, DOI 10.1038/sj.leu.2403610
   Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056
   Chen JYF, 2004, CARCINOGENESIS, V25, P269, DOI 10.1093/carcin/bgh006
   Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010
   Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101
   Evans MK, 2007, ONCOGENE, V26, P1941, DOI 10.1038/sj.onc.1209993
   Flowers LO, 2004, J IMMUNOL, V172, P7510, DOI 10.4049/jimmunol.172.12.7510
   Frobose H, 2006, MOL ENDOCRINOL, V20, P1587, DOI 10.1210/me.2005-0301
   He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100
   Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872
   Kuppens IELM, 2006, CURR CLIN PHARMACOL, V1, P57, DOI 10.2174/157488406775268200
   Lee KH, 2008, FEBS LETT, V582, P2319, DOI 10.1016/j.febslet.2008.05.039
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Liu SY, 2008, BIOCHEM BIOPH RES CO, V366, P520, DOI 10.1016/j.bbrc.2007.11.179
   Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489
   Masuda M, 2002, CANCER RES, V62, P3351
   Meng FY, 2007, J BIOL CHEM, V282, P8256, DOI 10.1074/jbc.M607712200
   Neuwirt H, 2007, ENDOCR-RELAT CANCER, V14, P1007, DOI 10.1677/ERC-07-0172
   Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197
   Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025
   Pierconti F, 2011, PROSTATE, V71, P318, DOI 10.1002/pros.21245
   Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8
   Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073
   Sasi W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-178
   Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848
   Tokita T, 2007, INT J ONCOL, V30, P689
   Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004
   Waiboci LW, 2007, J IMMUNOL, V178, P5058, DOI 10.4049/jimmunol.178.8.5058
   Wang YM, 2011, CURR PROTEIN PEPT SC, V12, P68
   Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818
   Yang SF, 2008, PATHOLOGY, V40, P558, DOI 10.1080/00313020802320432
   Ying MZ, 2010, J CANCER RES CLIN, V136, P1617, DOI 10.1007/s00432-010-0819-6
   Zou TT, 2008, FEBS LETT, V582, P4015, DOI 10.1016/j.febslet.2008.10.055
NR 36
TC 23
Z9 25
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2012
VL 7
IS 9
AR e45197
DI 10.1371/journal.pone.0045197
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 040HS
UT WOS:000311313900098
PM 23028842
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Prieto-Remón, I
   Sánchez-Carrera, D
   López-Duarte, M
   Richard, C
   Pipaón, C
AF Prieto-Remon, Ines
   Sanchez-Carrera, Damaso
   Lopez-Duarte, Monica
   Richard, Carlos
   Pipaon, Carlos
TI BIK (NBK) is a mediator of the sensitivity of Fanconi anaemia group C
   lymphoblastoid cell lines to interstrand DNA cross-linking agents
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE apoptosis; Bcl-2-interacting killer (BIK); Fanconi Anaemia (FA);
   interstrand DNA cross-linking agents; Delta Np73
ID INDUCED APOPTOTIC RESPONSES; OXIDATIVE STRESS; GENE-EXPRESSION;
   HEMATOPOIETIC-CELLS; FAMILY PROTEINS; BREAST-CANCER; BCL-2 FAMILY;
   TNF-ALPHA; IN-VITRO; INDUCTION
AB FA (Fanconi anaemia) is a rare hereditary disorder characterized by congenital malformations, progressive bone marrow failure and an extraordinary predisposition to develop cancer. At present, 15 genes have been related to this condition and mutations of them have also been found in different types of cancer. Bone marrow failure threatens the life of FA patients during the first decade of their life, but the mechanisms underlying this process are not completely understood. In the present study we investigate a possible imbalance between the expression of pro-and anti-apoptotic proteins as a cause for the hypersensitivity of FANCC (FA, complementation group C)-deficient cells to genotoxic stress. We found a BIK (Bcl-2 interacting killer) over-expression in lymphoblastoid cell lines derived from FA-C patients when compared with their phenotypically corrected counterparts. This overexpression has a transcriptional basis since the regulatory region of the gene shows higher activity in FANCC-deficient cells. We demonstrate the involvement of BIK in the sensitivity of FA-C lymphoblasts to interstrand DNA cross-linking agents as it is induced by these drugs and interference of its expression in these cells preserves their viability and reduces apoptosis. We investigate the mechanism of BIK overexpression in FANCC-deficient cells by analysing the activity of many different signalling pathways in these cells. Finally, we provide evidence of a previously undescribed indirect epigenetic regulation of BIK in FA-C lymphoblasts mediated by Delta Np73, an isoform of p73 lacking its transactivation domain that activates BIK through a proximal element in its promoter.
C1 [Prieto-Remon, Ines; Sanchez-Carrera, Damaso; Lopez-Duarte, Monica; Richard, Carlos; Pipaon, Carlos] Inst Formac & Invest Marques Valdecilla IFIMAV, Serv Hematol, Santander, Spain.
C3 Hospital Universitario Marques de Valdecilla (HUMV)
RP Pipaón, C (通讯作者)，Hosp Univ Marques Valdecilla, Lab Hematol Mol, Pabellon 20,Bajo Avda Valdecilla S-N, Santander 39008, Spain.
EM cpipaon@humv.es
RI Pipaon, Carlos/L-4922-2014
OI Pipaon, Carlos/0000-0002-3851-6710
FU Instituto de Salud Carlos III [PS09/01533]; Fundacion Marques de
   Valdecilla-IFIMAV and Universidad de Cantabria [UC08/03]; Instituto de
   Formacion e Investigacion Marques de Valdecilla-IFIMAV
FX This work was supported by the Instituto de Salud Carlos III [grant
   number PS09/01533] and the Fundacion Marques de Valdecilla-IFIMAV and
   Universidad de Cantabria [grant number UC08/03]. I.P.-R. and D.S.-C. are
   recipients of a contract from Instituto de Formacion e Investigacion
   Marques de Valdecilla-IFIMAV.
CR Bijangi-Vishehsaraei K, 2005, BLOOD, V106, P4124, DOI 10.1182/blood-2005-05-2096
   Bodet L, 2010, BRIT J CANCER, V103, P1808, DOI 10.1038/sj.bjc.6605981
   BOYD JM, 1995, ONCOGENE, V11, P1921
   Brigati C, 2011, MOL IMMUNOL, V48, P408, DOI 10.1016/j.molimm.2010.09.001
   Castells A, 2000, CANCER RES, V60, P2836
   Chinnadurai G, 2008, ONCOGENE, V27, pS20, DOI 10.1038/onc.2009.40
   CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x
   D'Andrea AD, 2010, NEW ENGL J MED, V362, P1909, DOI 10.1056/NEJMra0809889
   Dai ZY, 2006, BIOCHEM BIOPH RES CO, V351, P455, DOI 10.1016/j.bbrc.2006.10.055
   Du W, 2008, ANTIOXID REDOX SIGN, V10, P1909, DOI 10.1089/ars.2008.2129
   Dufour C, 2003, BLOOD, V102, P2053, DOI 10.1182/blood-2003-01-0114
   Ferrer M, 2003, EXP CELL RES, V286, P381, DOI 10.1016/S0014-4827(03)00112-5
   Haneline LS, 1998, BLOOD, V91, P4092
   Hur J, 2006, CANCER RES, V66, P10153, DOI 10.1158/0008-5472.CAN-05-3696
   Ibáñez A, 2009, BIOCHEM J, V422, P161, DOI 10.1042/BJ20082118
   Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025
   Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7
   Li YM, 2003, CANCER RES, V63, P7630
   Lyakhovich A, 2010, MOL CANCER RES, V8, P46, DOI 10.1158/1541-7786.MCR-09-0373
   Maiani E, 2011, BIOCHEM PHARMACOL, V82, P1269, DOI 10.1016/j.bcp.2011.07.001
   Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340
   McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5
   Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200
   Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200
   Pipaon C, 2005, FEBS LETT, V579, P4610, DOI 10.1016/j.febslet.2005.07.026
   Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985
   Rathbun RK, 2000, BLOOD, V96, P4204
   Real PJ, 2006, FEBS LETT, V580, P5905, DOI 10.1016/j.febslet.2006.08.088
   Río P, 2002, BLOOD, V100, P2032
   Ritchie A, 2009, CELL DEATH DIFFER, V16, P838, DOI 10.1038/cdd.2009.13
   Rosenberg PS, 2003, BLOOD, V101, P822, DOI 10.1182/blood-2002-05-1498
   Spender LC, 2009, CELL DEATH DIFFER, V16, P593, DOI 10.1038/cdd.2008.183
   Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782
   Tanaka Y, 2004, BIOCHEM BIOPH RES CO, V317, P865, DOI 10.1016/j.bbrc.2004.03.124
   Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852
   Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016
   Valeri A, 2011, CLIN TRANSL ONCOL, V13, P215, DOI 10.1007/s12094-011-0645-6
   Verma S, 2000, GENE, V254, P157, DOI 10.1016/S0378-1119(00)00276-6
   Zhang XL, 2007, J CELL SCI, V120, P1572, DOI 10.1242/jcs.003152
NR 39
TC 6
Z9 7
U1 0
U2 2
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD NOV 15
PY 2012
VL 448
BP 153
EP 163
DI 10.1042/BJ20120327
PN 1
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 042HP
UT WOS:000311462600015
PM 22873408
DA 2025-01-12
ER

PT J
AU Mullins, CS
   Linnebacher, M
AF Mullins, Christina S.
   Linnebacher, Michael
TI Human endogenous retroviruses and cancer: Causality and therapeutic
   possibilities
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Human endogenous retroviruses; Gastrointestinal cancer; Therapeutic
   targets; Tumor-specific antigens; Tumorigenesis
ID LONG TERMINAL REPEATS; HERV-K; BREAST-CANCER; MOBILE ELEMENTS; HUMAN
   GENOME; ENVELOPE; EXPRESSION; MELANOMA; SEQUENCE; IDENTIFICATION
AB A substantial part of the human genome is derived from transposable elements; remnants of ancient retroviral infections. Conservative estimates set the percentage of human endogenous retroviruses (HERVs) in the genome at 8%. For the most part, the interplay between mutations, epigenetic mechanisms and post-transcriptional regulations silence HERVs in somatic cells. We first highlight mechanisms by which activation of members of several HERV families may be associated with tumor development before discussing the arising chances for both diagnosis and therapy. It has been shown that at least in some cases, tumor cells expressing HERV open reading frames (ORFs) thus gain tumor-promoting functions. However, since these proteins are not expressed in healthy tissues, they become prime target structures. Of potential pharmacological interest are the prevention of HERV transposition, the inhibition of HERV-encoded protein expression and the interference with these proteins' activities. Evidence from recent studies unequivocally proves that HERV ORFs represent a very interesting source of novel tumor-specific antigens with even the potential to surpass entity boundaries. The development of new tumor (immune-) therapies is a very active field and true tumor-specific targets are of outstanding interest since they minimize the risk of autoimmunity and could reduce side effects. Finally, we postulate on main future research streams in order to stimulate discussion on this hot topic. (C) 2012 Baishideng. All rights reserved.
C1 [Mullins, Christina S.; Linnebacher, Michael] Univ Rostock, Dept Gen Thorac Vasc & Transplantat Surg, Sect Mol Oncol & Immunotherapy, D-18057 Rostock, Germany.
C3 University of Rostock
RP Linnebacher, M (通讯作者)，Univ Rostock, Dept Gen Thorac Vasc & Transplantat Surg, Sect Mol Oncol & Immunotherapy, Schillingallee 35, D-18057 Rostock, Germany.
EM michael.linnebacher@med.uni-rostock.de
RI Linnebacher, Michael/AAT-3763-2021; Mullins, Christina/ABG-4821-2021
OI Linnebacher, Christina/0000-0003-2296-2027
FU State Mecklenburg-Vorpommem; Deutsche Krebshilfe [108446]
FX Supported by Grants from the State Mecklenburg-Vorpommem and from
   Deutsche Krebshilfe, No. 108446
CR Argyris EG, 2007, VIROLOGY, V367, P440, DOI 10.1016/j.virol.2007.06.010
   Balaj L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1180
   Bannert N, 2004, P NATL ACAD SCI USA, V101, P14572, DOI 10.1073/pnas.0404838101
   Bannert N, 2006, ANNU REV GENOM HUM G, V7, P149, DOI 10.1146/annurev.genom.7.080505.115700
   Blaise S, 2001, J GEN VIROL, V82, P1597, DOI 10.1099/0022-1317-82-7-1597
   Blikstad V, 2008, CELL MOL LIFE SCI, V65, P3348, DOI 10.1007/s00018-008-8495-2
   Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000
   Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997
   BOLLER K, 1993, VIROLOGY, V196, P349, DOI 10.1006/viro.1993.1487
   Braoudaki M, 2011, J INFECT DEV COUNTR, V5, P751, DOI 10.3855/jidc.1773
   Büscher K, 2006, MELANOMA RES, V16, P223
   Carlini F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014221
   COHEN M, 1988, BIOESSAYS, V9, P191, DOI 10.1002/bies.950090603
   Contreras-Galindo R, 2008, J VIROL, V82, P9329, DOI 10.1128/JVI.00646-08
   de Parseval N, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-117
   Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402
   Dittmar T, 2011, CLIN EXP METASTAS, V28, P75, DOI 10.1007/s10585-010-9359-3
   Dunn CA, 2003, P NATL ACAD SCI USA, V100, P12841, DOI 10.1073/pnas.2134464100
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Feng WJN, 2007, INT J CANCER, V120, P81, DOI 10.1002/ijc.22256
   Garbe Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026517
   Goff SP, 2004, MOL CELL, V16, P849, DOI 10.1016/j.molcel.2004.12.001
   Gotzinger N, 1996, J GEN VIROL 12, V77, P2983
   Hahn S, 2008, AIDS RES HUM RETROV, V24, P717, DOI 10.1089/aid.2007.0286
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harris R, 2008, NAT BIOTECHNOL, V26, P1089, DOI 10.1038/nbt1008-1089
   Hedges DJ, 2005, BIOESSAYS, V27, P785, DOI 10.1002/bies.20268
   Herbst H, 1997, Verh Dtsch Ges Pathol, V81, P464
   Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631
   Ishida Toshiaki, 2008, Cancer Immun, V8, P15
   Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670
   Kim C, 2001, GENE, V276, P127, DOI 10.1016/S0378-1119(01)00639-4
   Kim DS, 2011, BIOINFORMATICS, V27, P14, DOI 10.1093/bioinformatics/btq612
   Kim DS, 2010, INT J MOL MED, V26, P151, DOI 10.3892/ijmm_00000447
   Kozeretska I. A., 2011, Experimental Oncology, V33, P198
   Krueger F, 2012, NAT METHODS, V9, P145, DOI [10.1038/nmeth.1828, 10.1038/NMETH.1828]
   Lamprecht B, 2010, CELL CYCLE, V9, P4276, DOI 10.4161/cc.9.21.13682
   Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lazova R, 2011, ADV EXP MED BIOL, V714, P151, DOI 10.1007/978-94-007-0782-5_8
   Ling JH, 2002, J VIROL, V76, P2410, DOI 10.1128/JVI.76.5.2410-2423.2002
   Linnebacher M, 2001, INT J CANCER, V93, P6, DOI 10.1002/ijc.1298
   LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480
   Maeda N, 2008, REV MED VIROL, V18, P387, DOI 10.1002/rmv.592
   Maksakova IA, 2008, CELL MOL LIFE SCI, V65, P3329, DOI 10.1007/s00018-008-8494-3
   Mallet F, 2004, P NATL ACAD SCI USA, V101, P1731, DOI 10.1073/pnas.0305763101
   Mangeney M, 1998, P NATL ACAD SCI USA, V95, P14920, DOI 10.1073/pnas.95.25.14920
   Mbisa JL, 2010, J VIROL, V84, P5250, DOI 10.1128/JVI.02358-09
   Medstrand P, 2001, J BIOL CHEM, V276, P1896, DOI 10.1074/jbc.M006557200
   Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12
   Mizuuchi M, 2012, EXP MOL PATHOL, V92, P185, DOI 10.1016/j.yexmp.2011.10.002
   Morgan D, 2004, EXP HEMATOL, V32, P520, DOI 10.1016/j.exphem.2004.03.003
   Mullins CS, 2012, CANCER IMMUNOL IMMUN, V61, P1093, DOI 10.1007/s00262-011-1183-3
   Muster T, 2003, CANCER RES, V63, P8735
   Nelson PN, 2003, J CLIN PATHOL-MOL PA, V56, P11, DOI 10.1136/mp.56.1.11
   Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214
   Pötgens AJG, 2004, HUM REPROD UPDATE, V10, P487, DOI 10.1093/humupd/dmh039
   Rappa G, 2012, AM J PATHOL, V180, P2504, DOI 10.1016/j.ajpath.2012.02.020
   Ripberger E, 2003, J CLIN IMMUNOL, V23, P415, DOI 10.1023/A:1025329819121
   Romanish MT, 2010, SEMIN CANCER BIOL, V20, P246, DOI 10.1016/j.semcancer.2010.05.005
   Rowe HM, 2011, VIROLOGY, V411, P273, DOI 10.1016/j.virol.2010.12.007
   Ruprecht K, 2008, CELL MOL LIFE SCI, V65, P3366, DOI 10.1007/s00018-008-8496-1
   SAUTER M, 1995, J VIROL, V69, P414, DOI 10.1128/JVI.69.1.414-421.1995
   Sawyer SL, 2005, P NATL ACAD SCI USA, V102, P2832, DOI 10.1073/pnas.0409853102
   Schiavetti F, 2002, CANCER RES, V62, P5510
   Schulz WA, 2006, CURR TOP MICROBIOL, V310, P211
   SEIFARTH W, 1995, J VIROL, V69, P6408, DOI 10.1128/JVI.69.10.6408-6416.1995
   SenGupta D, 2011, J VIROL, V85, P6977, DOI 10.1128/JVI.00179-11
   Sensi M, 2006, CLIN CANCER RES, V12, P5023, DOI 10.1158/1078-0432.CCR-05-2682
   Serafino A, 2009, EXP CELL RES, V315, P849, DOI 10.1016/j.yexcr.2008.12.023
   Stocking C, 2008, CELL MOL LIFE SCI, V65, P3383, DOI 10.1007/s00018-008-8497-0
   Sun C, 2000, HUM MOL GENET, V9, P2291, DOI 10.1093/oxfordjournals.hmg.a018920
   Takahashi Y, 2008, J CLIN INVEST, V118, P1099, DOI 10.1172/JCI34409
   Volff JN, 2006, BIOESSAYS, V28, P913, DOI 10.1002/bies.20452
   Wang-Johanning F, 2008, CANCER RES, V68, P5869, DOI 10.1158/0008-5472.CAN-07-6838
   Wang-Johanning F, 2012, JNCI-J NATL CANCER I, V104, P189, DOI 10.1093/jnci/djr540
   Wentzensen N, 2007, INT J CANCER, V121, P1417, DOI 10.1002/ijc.22826
NR 79
TC 23
Z9 29
U1 0
U2 18
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD NOV 14
PY 2012
VL 18
IS 42
BP 6027
EP 6035
DI 10.3748/wjg.v18.i42.6027
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 042LW
UT WOS:000311473700003
PM 23155332
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Izadi, P
   Noruzinia, M
   Fereidooni, F
   Nateghi, MR
AF Izadi, Pantea
   Noruzinia, Mehrdad
   Fereidooni, Foruzandeh
   Nateghi, Mohammad Reza
TI Association of Poor Prognosis Subtypes of Breast Cancer with Estrogen
   Receptor Alpha Methylation in Iranian Women
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Estrogen receptor alpha; promoter methylation; breast cancer subtypes;
   Iranian patients
ID CPG ISLAND METHYLATION; ER-ALPHA; PROMOTER HYPERMETHYLATION; GENE; DNA;
   CLASSIFICATION; CARCINOMA; PATTERNS; BRCA1; HER2
AB Breast cancer is a prevalent heterogeneous malignant disease. Gene expression profiling by DNA microarray can classify breast tumors into five different molecular subtypes: luminal A, luminal B, HER-2, basal and normal-like which have differing prognosis. Recently it has been shown that immunohistochemistry (IHC) markers including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2), can divide tumors to main subtypes: luminal A (ER+; PR+/-; HER-2-), luminal B (ER+; PR+/-; HER-2+), basal-like (ER-; PR-; HER2-) and Her2+ (ER-; PR-; HER-2+). Some subtypes such as basal-like subtype have been characterized by poor prognosis and reduced overall survival. Due to the importance of the ER signaling pathway in mammary cell proliferation; it appears that epigenetic changes in the ER alpha gene as a central component of this pathway, may contribute to prognostic prediction. Thus this study aimed to clarify the correlation of different IHC-based subtypes of breast tumors with ER alpha methylation in Iranian breast cancer patients. For this purpose one hundred fresh breast tumors obtained by surgical resection underwent DNA extraction for assessedment of their ER methylation status by methylation specific PCR (MSP). These tumors were classified into main subtypes according to IHC markers and data were collected on pathological features of the patients. ER alpha methylation was found in 25 of 28 (89.3%) basal tumors, 21 of 24 (87.5%) Her2+ tumors, 18 of 34 (52.9%) luminal A tumors and 7 of 14 (50%) luminal B tumors. A strong correlation was found between ER alpha methylation and poor prognosis tumor subtypes (basal and Her2+) in patients (P<0.001). Our findings show that ER alpha methylation is correlated with poor prognosis subtypes of breast tumors in Iranian patients and may play an important role in pathogenesis of the more aggressive breast tumors.
C1 [Izadi, Pantea; Noruzinia, Mehrdad] Tarbiat Modares Univ, Sch Med Sci, Dept Med Genet, Tehran, Iran.
   [Izadi, Pantea] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
   [Fereidooni, Foruzandeh] Univ Tehran Med Sci, Inst Canc, Dept Pathol, Tehran, Iran.
   [Nateghi, Mohammad Reza] ACECR, IBRC, Tehran, Iran.
C3 Tarbiat Modares University; Tehran University of Medical Sciences;
   Tehran University of Medical Sciences; Academic Center for Education,
   Culture & Research (ACECR)
RP Noruzinia, M (通讯作者)，Tarbiat Modares Univ, Sch Med Sci, Dept Med Genet, Tehran, Iran.
EM noruzinia@modares.ac.ir
RI ; Nateghi, Mohammad Reza/ABD-8638-2020
OI noruzinia, mehrdad/0000-0002-1325-3758; Nateghi, Mohammad
   Reza/0000-0001-5754-0516
FU Cancer Institute of Tehran University
FX The authors are grateful to Dr. Zahra Mostakhdemine Hosseini, Dr.
   Fatemeh Kamali and Mr. Ahmad Joulaie for their valuable collaborations
   in gathering clinicopathological information. Biological materials were
   provided by the IRAN NATIONAL TUMOR BANK which is funded by Cancer
   Institute of Tehran University, for Cancer Research.
CR Badve S, 2009, J CLIN PATHOL, V62, P6, DOI 10.1136/jcp.2008.059899
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chen XS, 2010, TUMORI J, V96, P103, DOI 10.1177/030089161009600117
   Chuthapisith S, 2012, ASIAN PAC J CANCER P, V13, P459, DOI 10.7314/APJCP.2012.13.2.459
   Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639
   Fallahazad V, 2004, J TEHRAN MED FACULTY, V62, P745
   Gown AM, 2008, MODERN PATHOL, V21, pS8, DOI 10.1038/modpathol.2008.34
   Harirchi Iraj, 2004, Asian Pac J Cancer Prev, V5, P24
   Hayashi S, 2009, CANCER SCI, V100, P1773, DOI 10.1111/j.1349-7006.2009.01243.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hines LM, 2011, J WOMENS HEALTH, V20, P1543, DOI 10.1089/jwh.2010.2558
   Ihemelandu CU, 2007, J SURG RES, V143, P109, DOI 10.1016/j.jss.2007.03.085
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Killian JK, 2011, AM J PATHOL, V179, P55, DOI 10.1016/j.ajpath.2011.03.022
   Kolahdoozan S, 2010, ARCH IRAN MED, V13, P143
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lee JS, 2010, CANCER BIOL THER, V9, P1017, DOI 10.4161/cbt.9.12.11804
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mousavi SM, 2009, ANN ONCOL, V20, P556, DOI 10.1093/annonc/mdn642
   Mousavi SM, 2007, BREAST J, V13, P383, DOI 10.1111/j.1524-4741.2007.00446.x
   Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Post WS, 1999, CARDIOVASC RES, V43, P985, DOI 10.1016/S0008-6363(99)00153-4
   Ramezani F, 2012, ASIAN PAC J CANCER P, V13, P451, DOI 10.7314/APJCP.2012.13.2.451
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Sandhu R, 2010, LABMEDICINE, V41, P364, DOI 10.1309/LMLIK0VIE3CJK0WD
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Travis RC, 2003, BREAST CANCER RES, V5, P239, DOI 10.1186/bcr628
   Vahdaninia Mariam, 2004, Asian Pac J Cancer Prev, V5, P223
   Vallejos CS, 2010, CLIN BREAST CANCER, V10, P294, DOI 10.3816/CBC.2010.n.038
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 40
TC 10
Z9 10
U1 0
U2 3
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2012
VL 13
IS 8
BP 4113
EP 4117
DI 10.7314/APJCP.2012.13.8.4113
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 042GJ
UT WOS:000311459400097
PM 23098526
OA gold
DA 2025-01-12
ER

PT J
AU Brinkhuizen, T
   van den Hurk, K
   Winnepenninckx, VJL
   de Hoon, JP
   van Marion, AM
   Veeck, J
   van Engeland, M
   van Steensel, MAM
AF Brinkhuizen, Tjinta
   van den Hurk, Karin
   Winnepenninckx, Veronique J. L.
   de Hoon, Joep P.
   van Marion, Arienne M.
   Veeck, Juergen
   van Engeland, Manon
   van Steensel, Maurice A. M.
TI Epigenetic Changes in Basal Cell Carcinoma Affect SHH and WNT Signaling
   Components
SO PLOS ONE
LA English
DT Article
ID METHYLATION-SPECIFIC PCR; NONMELANOMA SKIN-CANCER; BETA-CATENIN
   EXPRESSION; PROMOTER METHYLATION; TUMOR-SUPPRESSOR; DNA METHYLATION;
   CUTANEOUS MALIGNANCIES; COLORECTAL-CANCER; BREAST-CANCER; E-CADHERIN
AB Background: The genetic background of Basal Cell Carcinoma (BCC) has been studied extensively, while its epigenetic makeup has received comparatively little attention. Epigenetic alterations such as promoter hypermethylation silence tumor suppressor genes (TSG) in several malignancies.
   Objective: We sought to analyze the promoter methylation status of ten putative (tumor suppressor) genes that are associated with Sonic Hedgehog (SHH), WNT signaling and (hair follicle) tumors in a large series of 112 BCC and 124 healthy control samples by methylation-specific PCR.
   Results: Gene promoters of SHH (P = 0.016), adenomatous polyposis coli (APC) (P = 0.003), secreted frizzled-related protein 5 (SFRP5) (P = 0.004) and Ras association domain family 1A (RASSF1A) (P = 0.023) showed significantly more methylation in BCC versus normal skin. mRNA levels of these four genes were reduced for APC and SFRP5 in BCC (n = 6) vs normal skin (n = 6). Down regulation of SHH, APC and RASSF1A could be confirmed on protein level as well (P < 0.001 for all genes) by immunohistochemical staining. Increased canonical WNT activity was visualized by beta-catenin staining, showing nuclear beta-catenin in only 28/101 (27.7%) of BCC. Absence of nuclear beta-catenin in some samples may be due to high levels of membranous E-cadherin (in 94.1% of the samples).
   Conclusions: We provide evidence that promoter hypermethylation of key players within the SHH and WNT pathways is frequent in BCC, consistent with their known constitutive activation in BCC. Epigenetic gene silencing putatively contributes to BCC tumorigenesis, indicating new venues for treatment.
C1 [Brinkhuizen, Tjinta; van Steensel, Maurice A. M.] Maastricht Univ, Med Ctr, Dept Dermatol, Maastricht, Netherlands.
   [van den Hurk, Karin; Winnepenninckx, Veronique J. L.; de Hoon, Joep P.; Veeck, Juergen; van Engeland, Manon] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands.
   [van Steensel, Maurice A. M.] Maastricht Univ, Med Ctr, Dept Clin Genet, Maastricht, Netherlands.
   [Brinkhuizen, Tjinta; van den Hurk, Karin; Winnepenninckx, Veronique J. L.; de Hoon, Joep P.; Veeck, Juergen; van Engeland, Manon; van Steensel, Maurice A. M.] Maastricht Univ, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands.
   [de Hoon, Joep P.; Veeck, Juergen] Maastricht Univ, Med Ctr, Div Med Oncol, Dept Internal Med, Maastricht, Netherlands.
   [van Marion, Arienne M.] VieCuri Med Ctr, Dept Pathol, Venlo, Netherlands.
   [Veeck, Juergen] Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, D-52062 Aachen, Germany.
C3 Maastricht University; Maastricht University; Maastricht University;
   Maastricht University; Maastricht University; VieCuri Medical Center;
   RWTH Aachen University; RWTH Aachen University Hospital
RP Brinkhuizen, T (通讯作者)，Maastricht Univ, Med Ctr, Dept Dermatol, Maastricht, Netherlands.
EM t.brinkhuizen@mumc.nl
RI van Engeland, Manon/A-7479-2009; van Steensel, Maurice/V-3852-2019;
   Veeck, Jurgen/B-9256-2008
OI Veeck, Jurgen/0000-0002-2952-6159; van Steensel,
   Maurice/0000-0002-7507-2442
FU Dutch Cancer Society [KWF UM2009-4609, KWF UM2009-4352]
FX This work was supported by the Dutch Cancer Society, grants to TB (KWF
   UM2009-4609) and MVS (KWF UM2009-4352). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdulla FR, 2005, PEDIATR DERMATOL, V22, P501, DOI 10.1111/j.1525-1470.2005.00129.x
   Bezdekova Michala, 2007, Biomedical Papers (Olomouc), V151, P251
   BONIFAS JM, 1994, HUM MOL GENET, V3, P447, DOI 10.1093/hmg/3.3.447
   Borkowska J, 2011, INT J DERMATOL, V50, P13, DOI 10.1111/j.1365-4632.2010.04727.x
   Chhibber A, 2008, ANAL BIOCHEM, V377, P46, DOI 10.1016/j.ab.2008.02.026
   Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918
   Derks S, 2004, CELL ONCOL, V26, P291
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Donovan J, 2009, DERMATOL SURG, V35, P1311, DOI 10.1111/j.1524-4725.2009.01236.x
   El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x
   Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503
   Fukumaru K, 2007, J DERMATOL, V34, P746, DOI 10.1111/j.1346-8138.2007.00376.x
   Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78
   Giacinti L, 2008, CLIN TER, V159, P347
   Goldberg M, 2006, BRIT J DERMATOL, V155, P1154, DOI 10.1111/j.1365-2133.2006.07433.x
   Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472
   Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018
   Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z
   Heitzer E, 2010, EXP DERMATOL, V19, P926, DOI 10.1111/j.1600-0625.2010.01120.x
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holterhues C, 2010, J INVEST DERMATOL, V130, P1807, DOI 10.1038/jid.2010.58
   House MG, 2003, CARCINOGENESIS, V24, P193, DOI 10.1093/carcin/24.2.193
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Kundel HL, 2003, RADIOLOGY, V228, P303, DOI 10.1148/radiol.2282011860
   Lee DA, 2005, J MED GENET, V42, P811, DOI 10.1136/jmg.2004.025577
   Li L, 2011, GRAEF ARCH CLIN EXP, V249, P1867, DOI 10.1007/s00417-011-1729-2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Madan V, 2010, LANCET, V375, P673, DOI 10.1016/S0140-6736(09)61196-X
   Mosterd K, 2009, ACTA DERM-VENEREOL, V89, P454, DOI 10.2340/00015555-0710
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nandakumar V, 2011, CARCINOGENESIS, V32, P597, DOI 10.1093/carcin/bgq282
   Pourreyron C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031827
   Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X
   Reifenberger J, 1998, CANCER RES, V58, P1798
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Roewert-Huber J, 2007, BRIT J DERMATOL, V157, P47, DOI 10.1111/j.1365-2133.2007.08273.x
   Rosner B., 2006, Fundamentals of Biostatistics, V7th
   Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x
   Sathyanarayana UG, 2007, CANCER LETT, V245, P112, DOI 10.1016/j.canlet.2005.12.042
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Smeets NWJ, 2004, LANCET, V364, P1766, DOI 10.1016/S0140-6736(04)17399-6
   Szeimies RM, 2006, BRIT J DERMATOL, V154, P16, DOI 10.1111/j.1365-2133.2006.07232.x
   Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305
   Tilli CMLJ, 2005, BRIT J DERMATOL, V152, P1108, DOI 10.1111/j.1365-2133.2005.06587.x
   van Doorn R, 2005, SEMIN ONCOL, V32, P479, DOI 10.1053/j.seminoncol.2005.07.001
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466
   van Steensel MAM, 2009, EXP DERMATOL, V18, P185, DOI 10.1111/j.1600-0625.2008.00808.x
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   VONDOMARUS H, 1984, J AM ACAD DERMATOL, V10, P1043
   Wu W, 2011, CLIN EXP DERMATOL, V36, P381, DOI 10.1111/j.1365-2230.2010.03968.x
   Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201
   Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192
   Zedan W, 2001, J PATHOL, V194, P473, DOI 10.1002/path.940
NR 56
TC 35
Z9 39
U1 2
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 17
PY 2012
VL 7
IS 12
AR e51710
DI 10.1371/journal.pone.0051710
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 055RZ
UT WOS:000312435900048
PM 23284750
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Saxena, A
   Dhillon, VS
   Shahid, M
   Khalil, HS
   Rani, M
   Das, TP
   Hedau, S
   Hussain, A
   Naqvi, RA
   Deo, SVS
   Shukla, NK
   Das, BC
   Husain, SA
AF Saxena, Anubha
   Dhillon, Varinderpal S.
   Shahid, Mohammad
   Khalil, Hesham Saleh
   Rani, Madhu
   Das, Trinath Prasad
   Hedau, Suresh
   Hussain, Arif
   Naqvi, Raza Ali
   Deo, S. V. S.
   Shukla, N. K.
   Das, B. C.
   Husain, Syed Akhtar
TI <i>GSTP1</i> methylation and polymorphism increase the risk of breast
   cancer and the effects of diet and lifestyle in breast cancer patients
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE GSTP1; polymorphism; methylation; expression
ID GLUTATHIONE-S-TRANSFERASE; ABERRANT DNA METHYLATION; PROMOTER
   METHYLATION; PROSTATE ADENOCARCINOMA; GENETIC POLYMORPHISMS; P1 GENE;
   HYPERMETHYLATION; PI; CARCINOGENESIS; ASSOCIATION
AB Glutathione S-transferases (GSTs) are an important group of isoenzymes that play an essential role in the detoxification of carcinogens. Polymorphism at exon 5 of the GST pi family decreases the catalytic activity and affects the detoxification ability of the enzyme, GSTP1. GSTP1 promoter hypermethylation and loss of expression are frequently observed in various types of carcinoma. We hypothesized that somatic epigenetic modification in homozygous mutants increases the degree to which breast cancer risk is affected by lifestyle factors and dietary habits. The present study used tumor biopsies and blood samples from 215 breast cancer patients and 215 blood samples from healthy donors. GSTP1 polymorphism was studied using PCR-restriction fragment length polymorphism, methylation using methylation-specific PCR and loss of expression using immunohistochemistry and western blotting. No significant increase was observed in the breast cancer risk of individuals with the mutant (Val) allele [odds ratio (OR), 1.48; 95% confidence interval (CI), 0.97-2.26 for heterozygotes; OR, 1.42; 95% CI, 0.86-2.42 homozygous mutants]. GSTP1 promoter hypermethylation was detected in one-third of tumor biopsies (74/215) and was found to be associated with a loss of expression. Genotype and tumor methylation associations were not observed. Estrogen (ER) and progesterone (PR) receptor-positive tumors had a higher methylation frequency. GSTP1 polymorphism was not associated with increased promoter hypermethylation. The results suggest that GSTP1 methylation is a major event in breast carcinogenesis and may act as a tumor-specific biomarker.
C1 [Saxena, Anubha; Shahid, Mohammad; Naqvi, Raza Ali; Husain, Syed Akhtar] Jamia Millia Islamia, Dept Biosci, Human Genet Lab, New Delhi, India.
   [Saxena, Anubha] Catholic Univ Louvain, Unit Expt Med, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium.
   [Dhillon, Varinderpal S.] CSIRO Food & Nutr Sci, Adelaide, SA 5000, Australia.
   [Shahid, Mohammad] Salman bin Abdulaziz Univ, Dept Oral & Maxillofacial Surg & Diagnost Sci, Coll Dent, Dent Genet Lab, Alkharj 11942, Saudi Arabia.
   [Shahid, Mohammad] Salman bin Abdulaziz Univ, Dept Biochem & Mol Biol, Coll Med, Alkharj 11942, Saudi Arabia.
   [Khalil, Hesham Saleh] King Saud Univ, Coll Dent, Riyadh, Saudi Arabia.
   [Rani, Madhu; Das, Trinath Prasad] Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.
   [Hedau, Suresh; Das, B. C.] Inst Cytol & Prevent Oncol, Noida, Uttar Pradesh, India.
   [Hussain, Arif] Manipal Univ, Dept Biotechnol, Dubai, U Arab Emirates.
   [Deo, S. V. S.; Shukla, N. K.] All India Inst Med Sci, Dept Surg Oncol, Inst Rotary Canc Hosp, New Delhi, India.
C3 Jamia Millia Islamia; Universite Catholique Louvain; Commonwealth
   Scientific & Industrial Research Organisation (CSIRO); Prince Sattam Bin
   Abdulaziz University; Prince Sattam Bin Abdulaziz University; King Saud
   University; Jawaharlal Nehru University, New Delhi; Indian Council of
   Medical Research (ICMR); ICMR - National Institute of Cancer Prevention
   & Research (NICPR); All India Institute of Medical Sciences (AIIMS) New
   Delhi; DR. B.R.A. Institute Rotary Cancer Hospital
RP Shahid, M (通讯作者)，Salman bin Abdulaziz Univ, Dept Oral & Maxillofacial Surg & Diagnost Sci, Coll Dent, Dent Genet Lab, King Fahd Rd, Alkharj 11942, Saudi Arabia.
EM varinderpal.dhillon@csiro.au; dr.shahid90@yahoo.com
RI MOHAMMAD, SHAHID/CAH-3217-2022; Naqvi, Raza/AAE-5550-2022; Das,
   Bhudev/IVH-2052-2023; Dhillon, varinderpal/H-4622-2013; Shukla,
   Neeraj/ABD-4938-2020; Almoallim, Hesham/H-7795-2014; Hussain,
   Arif/H-6286-2018
OI husain, syed akhtar/0000-0002-6513-7759; Almoallim,
   Hesham/0000-0002-1455-1095; Hussain, Arif/0000-0002-0851-4845; Shahid,
   PhD., Professor Mohammad/0000-0002-9659-2041
FU Council of Scientific and Industrial Research, New Delhi (CSIR) [9=466
   [87]-EMR-II]
FX The authors would like to thank the Council of Scientific and Industrial
   Research, New Delhi (CSIR; Grant No. 9=466 [87]-EMR-II) for financial
   assistance.
CR Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321
   [Anonymous], BREAST CANC RES TREA
   Antognelli C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-115
   Arai T, 2006, BREAST CANCER RES TR, V100, P169, DOI 10.1007/s10549-006-9241-9
   Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460
   Bernardini S, 2005, CLIN CHEM, V51, P944, DOI 10.1373/clinchem.2004.045955
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   Chan QKY, 2005, J MOL DIAGN, V7, P8, DOI 10.1016/S1525-1578(10)60003-7
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Esteller M, 1998, CANCER RES, V58, P4515
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   Gazzoli I, 2002, CANCER RES, V62, P3925
   Henderson CJ, 1998, CHEM-BIOL INTERACT, V112, P69, DOI 10.1016/S0009-2797(97)00176-2
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hu X, 1998, CANCER RES, V58, P5340
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jerónimo C, 2002, CANCER EPIDEM BIOMAR, V11, P445
   Johansson AS, 1998, J MOL BIOL, V278, P687, DOI 10.1006/jmbi.1998.1708
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0
   Kopps S, 2008, J TOXICOL ENV HEAL A, V71, P898, DOI 10.1080/15287390801988483
   Lee JS, 2007, CANCER BIOL THER, V6, P1114, DOI 10.4161/cbt.6.7.4331
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Lu S, 2011, BREAST CANCER RES TR, V125, P253, DOI 10.1007/s10549-010-0969-x
   Matuschek C, 2010, EUR J MED RES, V15, P277
   Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pongtheerat T, 2011, ASIAN PAC J CANCER P, V12, P2731
   Reding KW, 2009, CANCER EPIDEM BIOMAR, V18, P1461, DOI 10.1158/1055-9965.EPI-08-0917
   Saxena A, 2009, BREAST CANCER RES TR, V115, P537, DOI 10.1007/s10549-008-0098-y
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Silvestrini R, 1997, J NATL CANCER I, V89, P639, DOI 10.1093/jnci/89.9.639
   Singletary SE, 2002, J CLIN ONCOL, V20, P3628, DOI 10.1200/JCO.2002.02.026
   Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Tokumaru Y, 2004, CLIN CANCER RES, V10, P5518, DOI 10.1158/1078-0432.CCR-04-0108
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Zhang BL, 2011, CHINESE MED J-PEKING, V124, P199, DOI 10.3760/cma.j.issn.0366-6999.2011.02.008
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
NR 44
TC 28
Z9 32
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2012
VL 4
IS 6
BP 1097
EP 1103
DI 10.3892/etm.2012.710
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 036HD
UT WOS:000311016100027
PM 23226781
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Marzese, DM
   Hoon, DSB
   Chong, KK
   Gago, FE
   Orozco, JI
   Tello, OM
   Vargas-Roig, LM
   Roqué, M
AF Marzese, Diego M.
   Hoon, Dave S. B.
   Chong, Kelly K.
   Gago, Francisco E.
   Orozco, Javier I.
   Tello, Olga M.
   Vargas-Roig, Laura M.
   Roque, Maria
TI DNA Methylation Index and Methylation Profile of Invasive Ductal Breast
   Tumors
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Article
ID GENE-EXPRESSION; HYPERMETHYLATION PROFILE; PROGNOSTIC-FACTORS;
   HISTOLOGIC GRADE; CANCER-CELLS; ASSOCIATION; EPIGENETICS;
   CARCINOGENESIS; CLASSIFICATION; DEFICIENT
AB Breast carcinogenesis is a multistep process that involves both genetic and epigenetic alterations. Identification of aberrantly methylated genes in breast tumors and their relation to clinical parameters can contribute to improved diagnostic, prognostic, and therapeutic decision making. Our objective in the present study was to identify the methylation status of 34 cancer-involved genes in invasive ductal carcinomas (MC). Each of the 70 MC cases analyzed had a unique methylation profile. The highest methylation frequency was detected in the WT1 (95.7%) and RASSF1 (71.4%) genes. Hierarchical cluster analysis revealed three clusters with different distribution of the prognostic factors tumor grade, lymph node metastasis, and proliferation rate. Methylation of TP73 was associated with high histological grade and high proliferation rate; methylation of RARB was associated with lymph node metastasis. Concurrent methylation of TP73 and RARB was associated with high histological grade, high proliferation rate, increased tumor size, and lymph node metastasis. Patients with more than six methylated genes had higher rates of relapse events and cancer deaths. In multivariate analysis, TP73 methylation and the methylation index were associated with disease outcome. Our results indicate that methylation index and methylation of TP73 and/or RARB are related to unfavorable prognostic factors in patients with MC. These epigenetic markers should be validated in further studies to improve breast cancer management. 0 Mol Diagn 2012, 14:613-622; http://dx.doi.mg/10.1016/j.jmoldx.2012.07.001)
C1 [Marzese, Diego M.; Roque, Maria] Inst Histol & Embryol IHEM CCT CONICET, Lab Cellular & Mol Biol, Mendoza, Argentina.
   [Marzese, Diego M.; Gago, Francisco E.; Orozco, Javier I.; Vargas-Roig, Laura M.; Roque, Maria] Natl Univ Cuyo, Sch Med Sci, RA-5500 Mendoza, Argentina.
   [Tello, Olga M.] Natl Univ Cuyo, Sch Odontol, Mendoza, Argentina.
   [Hoon, Dave S. B.; Chong, Kelly K.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA USA.
   [Gago, Francisco E.; Orozco, Javier I.] Med Ctr Mendoza, Dept Gynecol & Obstet, Mendoza, Argentina.
   [Gago, Francisco E.; Orozco, Javier I.] Med Ctr Mendoza, Inst Ginecomamario, Mendoza, Argentina.
   [Vargas-Roig, Laura M.] Inst Med & Expt Biol Cuyo IMBECU CCT CONICET, Lab Tumor Biol, Mendoza, Argentina.
C3 University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza; John
   Wayne Cancer Institute
RP Roqué, M (通讯作者)，Natl Univ Cuyo, Lab Cellular & Mol Biol, IHEM CCT CONICET, Sch Med Sci, Parque Gen San Martin ZC, RA-5500 Mendoza, Argentina.
EM mroque@mendoza-conicet.gob.ar
RI Marzese, Diego/AAA-3547-2022; Chong, Kelly/JXN-8770-2024; Hoon,
   Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683; Roque, Maria/0000-0002-9564-1032;
   Marzese, Diego/0000-0002-3258-8852
FU National University of Cuyo; School of Medical Sciences [06/J343 2009]
FX Supported by the National University of Cuyo with grants for the
   development of clinical and basic research, School of Medical Sciences
   (2009 and 06/J343 2009).
CR BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   Cianfrocca M, 2004, ONCOLOGIST, V9, P606, DOI 10.1634/theoncologist.9-6-606
   ELSTON CW, 1982, BRIT J CANCER, V45, P655, DOI 10.1038/bjc.1982.106
   Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Farias EF, 2002, CELL GROWTH DIFFER, V13, P335
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   FISHER B, 1969, CANCER, V24, P1071, DOI 10.1002/1097-0142(196911)24:5<1071::AID-CNCR2820240533>3.0.CO;2-H
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107
   HARVEY JM, 1992, PATHOLOGY, V24, P63, DOI 10.3109/00313029209063625
   Hilsenbeck SG, 1998, BREAST CANCER RES TR, V52, P227, DOI 10.1023/A:1006133418245
   Hu XC, 2003, ONCOL REP, V10, P1811
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Killick R, 2011, MOL NEUROBIOL, V43, P139, DOI 10.1007/s12035-011-8172-6
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Liebetrau A. M., 1983, Measures of Association
   Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002
   McGowan PO, 2008, BRAIN RES, V1237, P12, DOI 10.1016/j.brainres.2008.07.074
   Minamoto T, 1999, CARCINOGENESIS, V20, P519, DOI 10.1093/carcin/20.4.519
   Nygren AOH, 2008, J MOL DIAGN, V10, P496, DOI 10.2353/jmoldx.2008.080053
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Ohgane J, 2008, PLACENTA, V29, pS29, DOI 10.1016/j.placenta.2007.09.011
   Rakha EA, 2008, J CLIN ONCOL, V26, P3153, DOI 10.1200/JCO.2007.15.5986
   ROSEN PP, 1979, ANN CLIN LAB SCI, V9, P144
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5
   Serizawa RR, 2010, J MOL DIAGN, V12, P402, DOI 10.2353/jmoldx.2010.090152
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   SHIVAPURKAR N, 1986, JNCI-J NATL CANCER I, V77, P213
   Siegmund KD, 2004, BIOINFORMATICS, V20, P1896, DOI 10.1093/bioinformatics/bth176
   Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039-6109(03)00034-3
   Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   SUNDBLAD AS, 1992, MEDICINA-BUENOS AIRE, V52, P333
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Van der Auwera I, 2009, CANCER BIOL THER, V8, P2252
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Villar-Garea A, 2003, CANCER RES, V63, P4984
   Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   WILSON MJ, 1984, BIOCHEM J, V218, P987, DOI 10.1042/bj2180987
   Yan PS, 2000, CLIN CANCER RES, V6, P1432
NR 46
TC 29
Z9 35
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-1578
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD NOV
PY 2012
VL 14
IS 6
BP 613
EP 622
DI 10.1016/j.jmoldx.2012.07.001
PG 10
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 025HG
UT WOS:000310178600010
PM 22925694
OA Green Published
DA 2025-01-12
ER

PT J
AU Diaz, E
   Machutta, CA
   Chen, S
   Jiang, Y
   Nixon, C
   Hofmann, G
   Key, D
   Sweitzer, S
   Patel, M
   Wu, ZN
   Creasy, CL
   Kruger, RG
   LaFrance, L
   Verma, SK
   Pappalardi, MB
   Le, B
   Van Aller, GS
   McCabe, MT
   Tummino, PJ
   Pope, AJ
   Thrall, SH
   Schwartz, B
   Brandt, M
AF Diaz, Elsie
   Machutta, Carl A.
   Chen, Stephanie
   Jiang, Yong
   Nixon, Christopher
   Hofmann, Glenn
   Key, Danielle
   Sweitzer, Sharon
   Patel, Mehul
   Wu, Zining
   Creasy, Caretha L.
   Kruger, Ryan G.
   LaFrance, Louis
   Verma, Sharad K.
   Pappalardi, Melissa B.
   Le, Baochau
   Van Aller, Glenn S.
   McCabe, Michael T.
   Tummino, Peter J.
   Pope, Andrew J.
   Thrall, Sara H.
   Schwartz, Benjamin
   Brandt, Martin
TI Development and Validation of Reagents and Assays for EZH2 Peptide and
   Nucleosome High-Throughput Screens
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE epigenetics; histone methyltransferase; EZH2; HTS
ID DOMAIN PROTEIN METHYLTRANSFERASES; HISTONE LYSINE METHYLATION;
   AGGRESSIVE BREAST-CANCER; TUMOR-CELL PROLIFERATION; PROSTATE-CANCER; H3;
   EXPRESSION; MECHANISM; HYPERTRIMETHYLATION; SPECIFICITY
AB Histone methyltransferases (HMT) catalyze the methylation of histone tail lysines, resulting in changes in gene transcription. Misregulation of these enzymes has been associated with various forms of cancer, making this target class a potential new area for the development of novel chemotherapeutics. EZH2 is the catalytic component of the polycomb group repressive complex (PRC2), which selectively methylates histone H3 lysine 27 (H3K27). EZH2 is overexpressed in prostate, breast, bladder, brain, and other tumor types and is recognized as a molecular marker for cancer progression and aggressiveness. Several new reagents and assays were developed to aid in the identification of EZH2 inhibitors, and these were used to execute two high-throughput screening campaigns. Activity assays using either an H3K27 peptide or nucleosomes as substrates for methylation are described. The strategy to screen EZH2 with either a surrogate peptide or a natural substrate led to the identification of the same tractable series. Compounds from this series are reversible, are [H-3]-S-adenosyl-L-methionine competitive, and display biochemical inhibition of H3K27 methylation.
C1 [Diaz, Elsie; Machutta, Carl A.; Chen, Stephanie; Jiang, Yong; Nixon, Christopher; Hofmann, Glenn; Key, Danielle; Sweitzer, Sharon; Patel, Mehul; Wu, Zining; Pope, Andrew J.; Thrall, Sara H.; Schwartz, Benjamin; Brandt, Martin] GlaxoSmithKline, Platform Technol & Sci, Collegeville, PA 19426 USA.
   [Creasy, Caretha L.; Kruger, Ryan G.; LaFrance, Louis; Verma, Sharad K.; Pappalardi, Melissa B.; Le, Baochau; Van Aller, Glenn S.; McCabe, Michael T.; Tummino, Peter J.] GlaxoSmithKline, Canc Epigenet Discovery Performance Unit, Collegeville, PA 19426 USA.
C3 GlaxoSmithKline; GlaxoSmithKline
RP Brandt, M (通讯作者)，GlaxoSmithKline, Platform Technol & Sci, UP12-105,1250 S Collegeville Rd, Collegeville, PA 19426 USA.
EM martin.brandt@gsk.com
RI zining, wu/AEP-5141-2022; Brandt, Martin/E-4598-2015
CR Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007
   Bays NW, 2009, J BIOMOL SCREEN, V14, P636, DOI 10.1177/1087057109335746
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Blackledge NP, 2010, EPIGENOMICS-UK, V2, P151, DOI 10.2217/EPI.09.42
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Coma I, 2009, METHODS MOL BIOL, V565, P69, DOI 10.1007/978-1-60327-258-2_4
   Coma I, 2009, J BIOMOL SCREEN, V14, P66, DOI 10.1177/1087057108326664
   Cottom J, 2011, J BIOMOL SCREEN, V16, P53, DOI 10.1177/1087057110384133
   Couture JF, 2008, P NATL ACAD SCI USA, V105, P20659, DOI 10.1073/pnas.0806712105
   Crea F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-265
   Dhayalan A, 2009, J BIOMOL SCREEN, V14, P1129, DOI 10.1177/1087057109345528
   Dirk LMA, 2007, BIOCHEMISTRY-US, V46, P3905, DOI 10.1021/bi6023644
   Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107
   Glickman JF, 2008, ASSAY DRUG DEV TECHN, V6, P433, DOI 10.1089/adt.2008.135
   Hemeon I, 2011, ANAL CHEM, V83, P4996, DOI 10.1021/ac200816m
   Horowitz S, 2011, J BIOL CHEM, V286, P18658, DOI 10.1074/jbc.M111.232876
   Jiang Y, 2011, ANAL BIOCHEM, V415, P84, DOI 10.1016/j.ab.2011.03.037
   Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lakowski TM, 2008, J BIOL CHEM, V283, P10015, DOI 10.1074/jbc.M710176200
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Margueron R, 2010, NAT REV GENET, V11, P285, DOI 10.1038/nrg2752
   Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013
   Patnaik D, 2004, J BIOL CHEM, V279, P53248, DOI 10.1074/jbc.M409604200
   Quinn AM, 2010, MOL BIOSYST, V6, P782, DOI 10.1039/b921912a
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07
   Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107
   Suh-Lailam BB, 2010, ANAL BIOCHEM, V398, P218, DOI 10.1016/j.ab.2009.09.005
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378
   Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208
   Young NL, 2009, MOL CELL PROTEOMICS, V8, P2266, DOI 10.1074/mcp.M900238-MCP200
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 38
TC 51
Z9 59
U1 0
U2 29
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0571
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD DEC
PY 2012
VL 17
IS 10
BP 1279
EP 1292
DI 10.1177/1087057112453765
PG 14
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA 034QA
UT WOS:000310886800001
PM 22904200
OA hybrid
DA 2025-01-12
ER

PT J
AU Cascella, B
   Mirica, LM
AF Cascella, Barbara
   Mirica, Liviu M.
TI Kinetic Analysis of Iron-Dependent Histone Demethylases: α-Ketoglutarate
   Substrate Inhibition and Potential Relevance to the Regulation of
   Histone Demethylation in Cancer Cells
SO BIOCHEMISTRY
LA English
DT Article
ID DOMAIN-CONTAINING PROTEINS; BREAST-CANCER; ONCOMETABOLITE
   2-HYDROXYGLUTARATE; LYSINE DEMETHYLASES; 2-OXOGLUTARATE; SPECIFICITY;
   SELECTIVITY; ACTIVATION; OXIDASE; FAMILY
AB The Jumonji C domain-containing histone demethylases (JmjC-HDMs) are alpha-ketoglutarate (alpha KG)-dependent, O-2-activating, non-heme iron enzymes that play an important role in epigenetics. Reported herein is a detailed kinetic analysis of three JmjC-HDMs, including the cancer-relevant JMJD2C, that was achieved by employing three enzyme activity assays. A continuous 02 consumption assay reveals that HDMs have low affinities for O-2, suggesting that these enzymes can act as oxygen sensors in vivo. An interesting case of alpha KG substrate inhibition was found, and the kinetic data suggest that alpha KG inhibits JMJD2C competitively with respect to O-2 center dot JMJD2C displays an optimal activity in vitro at alpha KG concentrations similar to those found in cancer cells, with implications for the regulation of histone demethylation activity in cancer versus normal cells.
C1 [Cascella, Barbara; Mirica, Liviu M.] Washington Univ, Dept Chem, St Louis, MO 63130 USA.
C3 Washington University (WUSTL)
RP Mirica, LM (通讯作者)，Washington Univ, Dept Chem, 1 Brookings Dr, St Louis, MO 63130 USA.
EM mirica@wustl.edu
RI Mirica, Liviu/R-1978-2017
FU Department of Defense through Breast Cancer Research Program Concept
   Award [W81XWH-10-1-0442]
FX This work was supported by the Department of Defense through a Breast
   Cancer Research Program Concept Award (W81XWH-10-1-0442).
CR Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337
   Chang KH, 2011, CHEMMEDCHEM, V6, P759, DOI 10.1002/cmdc.201100026
   Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n
   Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Dubus A, 2001, CELL MOL LIFE SCI, V58, P835, DOI 10.1007/PL00000904
   Gross S, 2010, J EXP MED, V207, P339, DOI 10.1084/jem.20092506
   Hamada S, 2010, J MED CHEM, V53, P5629, DOI 10.1021/jm1003655
   Hamada S, 2009, BIOORG MED CHEM LETT, V19, P2852, DOI 10.1016/j.bmcl.2009.03.098
   Hirsilä M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200
   HOLME E, 1975, BIOCHEMISTRY-US, V14, P4999, DOI 10.1021/bi00693a033
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853
   Krishnan S, 2012, ANAL BIOCHEM, V420, P48, DOI 10.1016/j.ab.2011.08.034
   Kristensen LH, 2012, FEBS J, V279, P1905, DOI 10.1111/j.1742-4658.2012.08567.x
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Loenarz C, 2011, TRENDS BIOCHEM SCI, V36, P7, DOI 10.1016/j.tibs.2010.07.002
   Lohse B., 2011, Angewandte Chemie, International Edition in English, V123, P9266
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Luo XL, 2011, J AM CHEM SOC, V133, P9451, DOI 10.1021/ja201597b
   Mirica LM, 2008, P NATL ACAD SCI USA, V105, P1814, DOI 10.1073/pnas.0711626105
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Ng SS, 2007, NATURE, V448, P87, DOI 10.1038/nature05971
   Rose NR, 2008, J MED CHEM, V51, P7053, DOI 10.1021/jm800936s
   Rose NR, 2011, CHEM SOC REV, V40, P4364, DOI 10.1039/c0cs00203h
   Rose NR, 2010, J MED CHEM, V53, P1810, DOI 10.1021/jm901680b
   Roy TW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm1031
   Sakurai M, 2010, MOL BIOSYST, V6, P357, DOI 10.1039/b912993f
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Thirstrup K, 2011, PHARMACOL RES, V64, P268, DOI 10.1016/j.phrs.2011.03.017
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Welford RWD, 2003, J BIOL CHEM, V278, P10157, DOI 10.1074/jbc.M211058200
   Woon ECY, 2012, ANGEW CHEM INT EDIT, V51, P1631, DOI 10.1002/anie.201107833
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zhang Y., 2007, NAT REV MOL CELL BIO, V8, P307
NR 39
TC 46
Z9 56
U1 1
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD NOV 6
PY 2012
VL 51
IS 44
BP 8699
EP 8701
DI 10.1021/bi3012466
PG 3
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 031TC
UT WOS:000310664200001
PM 23067339
DA 2025-01-12
ER

PT J
AU Zhang, DJ
   Zhao, W
   Liao, XH
   Bi, TQ
   Li, HJ
   Che, XM
AF Zhang, Danjie
   Zhao, Wei
   Liao, Xinhua
   Bi, Tieqiang
   Li, Haijun
   Che, Xiangming
TI Frequent silencing of protocadherin 8 by promoter methylation, a
   candidate tumor suppressor for human gastric cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE protocadherin 8; gene methylation; 5-aza-2 '-deoxycytidine; gastric
   cancer
ID SQUAMOUS-CELL CARCINOMA; PARAXIAL PROTOCADHERIN; BREAST-CANCER;
   HYPERMETHYLATION; ESOPHAGEAL; EPIDEMIOLOGY; PCDH8
AB The cadherins are a family of cell surface glycoproteins responsible for cell adhesion which play an important role in cell morphology, contact inhibition and signal transduction during tumorigenesis. Protocadherin 8 (PCDH8), a member of the cadherin family, has been reported to act as a tumor suppressor involved in oncogenesis in breast cancer. In this study, we aimed to investigate the epigenetic inactivation of PCDH8 and its tumor suppressor function in gastric cancer. The expression of PCDH8 was markedly reduced or silenced in gastric cancer cell lines compared with normal gastric cells or tissues. Methylation of the PCDH8 gene promoter was observed in 100% (4/4) of cell lines and 55.38% (36/65) of the primary gastric cancer by methylation-specific PCR, but not in normal gastric mucosa (0/10). Methylated PCDH8 was significantly associated with lymph node metastasis in a logistic regression analysis. The demethylation reagent 5-aza-2'-deoxycytidine was able to restore or upregulate PCDH8 expression in gastric cancer cell lines. Ectopic expression of PCDH8 in silenced gastric cancer cells significantly inhibited cell migration and induced apoptosis. For the first time, our study demonstrates the epigenetic inactivation of PCDH8 by promoter methylation and its tumor suppressor function in human gastric cancer. Thus, PCDH8 could be identified as a candidate tumor suppressor in human gastric cancer.
C1 [Zhang, Danjie; Zhao, Wei; Liao, Xinhua; Bi, Tieqiang; Li, Haijun; Che, Xiangming] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Gen Surg, Xian 710061, Peoples R China.
C3 Xi'an Jiaotong University
RP Che, XM (通讯作者)，Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Dept Gen Surg, Yanta W Rd 277, Xian 710061, Peoples R China.
EM renpengyu2001@163.com
CR Arkenau HT, 2009, J CANCER RES CLIN, V135, P855, DOI 10.1007/s00432-009-0583-7
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23
   Buffart TE, 2008, BRIT J CANCER, V99, P1802, DOI 10.1038/sj.bjc.6604777
   Chang YLC, 2010, J CLIN LAB ANAL, V24, P167, DOI 10.1002/jcla.20385
   Esteller M, 2001, CANCER RES, V61, P3225
   Franko J, 2008, J GASTROINTEST SURG, V12, P1664, DOI 10.1007/s11605-008-0577-9
   Gorringe KL, 2009, GENE CHROMOSOME CANC, V48, P931, DOI 10.1002/gcc.20694
   Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699
   Haruki S, 2010, CARCINOGENESIS, V31, P1027, DOI 10.1093/carcin/bgq053
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Herszényi L, 2010, EUR REV MED PHARMACO, V14, P249
   Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2
   Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437
   Machado JC, 2001, ONCOGENE, V20, P1525, DOI 10.1038/sj.onc.1204234
   Medina A, 2004, EMBO J, V23, P3249, DOI 10.1038/sj.emboj.7600329
   Nishikawa Y, 2011, ONCOL REP, V26, P587, DOI 10.3892/or.2011.1324
   Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467
   Tian KG, 2005, CANCER RES, V65, P10024, DOI 10.1158/0008-5472.CAN-05-1944
   Unterseher F, 2004, EMBO J, V23, P3259, DOI 10.1038/sj.emboj.7600332
   Wang LF, 2007, WORLD J GASTROENTERO, V13, P5692, DOI 10.3748/wjg.v13.i43.5692
   Yasui W, 2006, SCAND J SURG, V95, P225, DOI 10.1177/145749690609500403
   Ye Y, 2009, CANCER RES, V69, P8482, DOI 10.1158/0008-5472.CAN-09-1153
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101
NR 26
TC 26
Z9 29
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2012
VL 28
IS 5
BP 1785
EP 1791
DI 10.3892/or.2012.1997
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 031QV
UT WOS:000310657900037
PM 22941331
OA Bronze
DA 2025-01-12
ER

PT J
AU Bawa-Khalfe, T
   Lu, LS
   Zuo, Y
   Huang, C
   Dere, R
   Lin, FM
   Yeh, ETH
AF Bawa-Khalfe, Tasneem
   Lu, Long-Sheng
   Zuo, Yong
   Huang, Chao
   Dere, Ruhee
   Lin, Feng-Ming
   Yeh, Edward T. H.
TI Differential expression of SUMO-specific protease 7 variants regulates
   epithelial-mesenchymal transition
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE posttranslational-modification; epigenetics; dedifferentiation
ID E2F TARGET GENES; CELLULAR SENESCENCE; BREAST-CANCER; PERICENTRIC
   HETEROCHROMATIN; DOWN-REGULATION; E-CADHERIN; SENP7; HP1(HS-ALPHA);
   SUPPRESSION; HP1-ALPHA
AB Two Sentrin/small ubiquitin-like modifier (SUMO)-specific protease 7 (SENP7) variants are naturally expressed in breast epithelia. Breast cancer (BCa) onset down-regulates the short SENP7 splice variant (SENP7S) and enhances the long transcript (SENP7L). Here, we show that SENP7L induction promotes gene expression profiles that favor aberrant proliferation and initiate epithelial-mesenchymal transition (EMT). SENP7L exhibits an interaction domain for the epigenetic remodeler heterochromatin protein 1 alpha (HP1 alpha) and isopeptidase activity against SUMO-modified HP1 alpha. Loss of this interaction domain, as observed with SENP7S, favors HP1 alpha SUMOylation. SUMOylated HP1 alpha is enriched at E2F-responsive and mesenchymal gene promoters, silences transcription of these genes, and promotes cellular senescence. Elevated SENP7L renders HP1 alpha hypo-SUMOylated, which relieves transcriptional repression of the same genes and concurrently decreases transcription of epithelial-promoting genes via an HP1 alpha-independent mechanism. Consequently, SENP7L levels correlate with EMT, motility, and invasiveness of BCa cells. Stable knockdown of elevated SENP7L levels lessens the dissemination of highly metastatic BCa cells to the lungs from primary implantation sites in in vivo studies. Thus, differential splicing of the SENP7 regulates either tumor suppression or progression.
C1 [Bawa-Khalfe, Tasneem; Yeh, Edward T. H.] Univ Texas MD Anderson Canc Ctr, Dept Chem, Houston, TX 77030 USA.
   [Lu, Long-Sheng; Huang, Chao; Lin, Feng-Ming; Yeh, Edward T. H.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA.
   [Zuo, Yong] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Sch Med, Shanghai 200025, Peoples R China.
   [Dere, Ruhee] Texas A&M Hlth Canc Ctr, Inst Biosci & Technol, Ctr Translat Canc Res, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Texas Heart
   Institute; Saint Lukes Episcopal Hospital; Shanghai Jiao Tong University
RP Bawa-Khalfe, T (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Chem, Houston, TX 77030 USA.
EM tbawa@mdanderson.org; etyeh@mdanderson.org
RI chen, renhua/GYE-3650-2022
OI huang, chao/0000-0002-4913-921X
FU National Institutes of Health [RO1 CA239520]
FX SENP7 and HP1 alpha interaction was originally identified by Fei Gao. We
   thank Runsheng Wang for his great contribution to the manuscript. This
   project is supported in part by National Institutes of Health Grant RO1
   CA239520 (to E.T.H.Y.). E.T.H.Y. is the McNair Scholar of the Texas
   Heart Institute.
CR Alegre KO, 2011, J BIOL CHEM, V286, P36142, DOI 10.1074/jbc.M111.268847
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Bawa-Khalfe Tasneem, 2010, Genes Cancer, V1, P748
   Bawa-Khalfe T, 2010, J BIOL CHEM, V285, P25859, DOI 10.1074/jbc.M110.134874
   De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022
   Guan F, 2009, P NATL ACAD SCI USA, V106, P7461, DOI 10.1073/pnas.0902368106
   Hu JJ, 2011, BIOCHEM BIOPH RES CO, V411, P786, DOI 10.1016/j.bbrc.2011.07.025
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang XL, 2010, MOL CELL, V38, P191, DOI 10.1016/j.molcel.2010.03.005
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Kokura K, 2010, EMBO J, V29, P3673, DOI 10.1038/emboj.2010.239
   Lima CD, 2008, J BIOL CHEM, V283, P32045, DOI 10.1074/jbc.M805655200
   Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047
   Maehara K, 2005, J CELL BIOL, V168, P553, DOI 10.1083/jcb.200411093
   Maison C, 2012, NAT STRUCT MOL BIOL, V19, P458, DOI 10.1038/nsmb.2244
   Maison C, 2011, NAT GENET, V43, P220, DOI 10.1038/ng.765
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Norwood LE, 2006, J BIOL CHEM, V281, P18668, DOI 10.1074/jbc.M512454200
   Panteleeva I, 2007, EMBO J, V26, P3616, DOI 10.1038/sj.emboj.7601789
   Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05
   Sánchez-Tilló E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102
   Shin JA, 2005, MOL CELL, V19, P817, DOI 10.1016/j.molcel.2005.08.021
   Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6
NR 24
TC 61
Z9 69
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 23
PY 2012
VL 109
IS 43
BP 17466
EP 17471
DI 10.1073/pnas.1209378109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 038AO
UT WOS:000311147800037
PM 23045645
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Cooper, SJ
   von Roemeling, CA
   Kang, KH
   Marlow, LA
   Grebe, SK
   Menefee, ME
   Tun, HW
   Colon-Otero, G
   Perez, EA
   Copland, JA
AF Cooper, Simon J.
   von Roemeling, Christina A.
   Kang, Kylie H.
   Marlow, Laura A.
   Grebe, Stefan K.
   Menefee, Michael E.
   Tun, Han W.
   Colon-Otero, Gerardo
   Perez, Edith A.
   Copland, John A.
TI Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of
   Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID FRIZZLED-RELATED PROTEIN-5; WNT ANTAGONIST SFRP1; PHASE-I TRIAL; HISTONE
   DEACETYLASE; DNA METHYLATION; BREAST-CANCER; EPIGENETIC INACTIVATION;
   PROMOTER HYPERMETHYLATION; 5-AZA-2'-DEOXYCYTIDINE; GENE
AB Metastatic solid tumors are aggressive and mostly drug resistant, leading to few treatment options and poor prognosis as seen with clear cell renal cell carcinoma (ccRCC) and triple-negative breast cancer (TNBC). Therefore, the identification of new therapeutic regimes for the treatment of metastatic disease is desirable. ccRCC and TNBC cell lines were treated with the HDAC inhibitor romidepsin and the methyltransferase inhibitor decitabine, two epigenetic modifying drugs approved by the U. S. Food and Drug Administration for the treatment of various hematologic malignancies. Cell proliferation analysis, flow cytometry, quantitative PCR, and immunoblotting techniques were used to evaluate the antitumor synergy of this drug combination and identify the reexpression of epigenetically silenced tumor suppressor genes. Combinatorial treatment of metastatic TNBC and stage IV ccRCC cell lines with romidepsin/decitabine leads to synergistic inhibition of cell growth and induction of apoptosis above levels of individual drug treatments alone. Synergistic reexpression of the tumor suppressor gene secreted frizzled-related protein one (sFRP1) was observed in combinatorial drug-treated groups. Silencing sFRP1 (short hairpin RNA) before combinatorial drug treatment showed that sFRP1 mediates the growth inhibitory and apoptotic activity of combined romidepsin/decitabine. Furthermore, addition of recombinant sFRP1 to ccRCC or TNBC cells inhibits cell growth in a dose-dependent manner through the induction of apoptosis, identifying that epigenetic silencing of sFRP1 contributes to renal and breast cancer cell survival. Combinatorial treatment with romidepsin and decitabine in drug resistant tumors is a promising treatment strategy. Moreover, recombinant sFRP1 may be a novel therapeutic strategy for cancers with suppressed sFRP1 expression. Mol Cancer Ther; 11(10); 2105-15. (C) 2012 AACR.
C1 [Cooper, Simon J.; von Roemeling, Christina A.; Kang, Kylie H.; Marlow, Laura A.; Copland, John A.] Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA.
   [Grebe, Stefan K.] Mayo Clin, Dept Med, Rochester, MN USA.
   [Grebe, Stefan K.] Mayo Clin, Lab Med & Pathol, Rochester, MN USA.
   [Menefee, Michael E.; Tun, Han W.; Colon-Otero, Gerardo; Perez, Edith A.] Mayo Clin, Dept Internal Med, Div Hematol Oncol, Jacksonville, FL 32224 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Copland, JA (通讯作者)，Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM copland.john@mayo.edu
RI Cooper, Simon/K-5732-2013; Colon-Otero, Gerardo/AAH-1275-2019; Perez,
   Edith/ACA-8756-2022
OI Marlow, Laura/0000-0002-4726-9889; von Roemeling,
   Christina/0000-0002-3754-5544
FU NIH/NCI [R01CA104505, R01CA104505-05S1, 2K12CA090628]; David & Lois
   Stulberg Endowed Fund for Kidney Cancer Research; Kidney Cancer Research
   at Mayo Clinic in Florida; Breast Cancer Research Foundation; James C.
   and Sarah K. Kennedy Mayo Clinic Research Career Development Award for
   Clinicians; Tallahassee Memorial HealthCare Foundation; RITA Foundation;
   Scheidel Foundation
FX This work was funded in part from NIH/NCI grants R01CA104505 (J.A.
   Copland) and R01CA104505-05S1 and 2K12CA090628 (M. E. Menefee); a
   generous gift from the David & Lois Stulberg Endowed Fund for Kidney
   Cancer Research (J.A. Copland); Kidney Cancer Research at Mayo Clinic in
   Florida (J.A. Copland); the Breast Cancer Research Foundation (E. A.
   Perez and J.A. Copland); James C. and Sarah K. Kennedy Mayo Clinic
   Research Career Development Award for Clinicians (H. W. Tun); The Brenda
   E. and Roger S. Luca Family Endowment at The Tallahassee Memorial
   HealthCare Foundation (J.A. Copland and G. Colon-Otero); RITA Foundation
   (Research Is The Answer; J.A. Copland); Scheidel Foundation (J.A.
   Copland); and a grant for rare cancers from Dr. Ellis and Dona Brunton
   (J.A. Copland and G. Colon-Otero).
CR ABELE R, 1987, EUR J CANCER CLIN ON, V23, P1921, DOI 10.1016/0277-5379(87)90060-5
   Awakura Y, 2008, ONCOL REP, V20, P1257, DOI 10.3892/or_00000138
   Banumathy G, 2010, CANCER BIOL THER, V10, P658, DOI 10.4161/cbt.10.7.13247
   Bender CM, 1998, CANCER RES, V58, P95
   Berrada N, 2010, ANN ONCOL, V21, P30, DOI 10.1093/annonc/mdq279
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Cooper SJ, 2010, ONCOGENE, V29, P2905, DOI 10.1038/onc.2010.64
   Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267
   Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Geutjes EJ, 2012, BREAST CANCER RES TR, V131, P809, DOI 10.1007/s10549-011-1477-3
   Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883
   Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Jung M, 2001, CURR MED CHEM, V8, P1505, DOI 10.2174/0929867013372058
   Kawakami K, 2011, INT J CANCER, V128, P541, DOI 10.1002/ijc.25357
   Kawamoto K, 2008, INT J CANCER, V123, P535, DOI 10.1002/ijc.23514
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Konstantinopoulos PA, 2006, CANCER CHEMOTH PHARM, V58, P711, DOI 10.1007/s00280-005-0182-5
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Liu SZ, 2008, MOL CANCER THER, V7, P1751, DOI 10.1158/1535-7163.MCT-07-0560
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Marlow LA, 2010, J CLIN ENDOCR METAB, V95, P5338, DOI 10.1210/jc.2010-1421
   Marlow LA, 2009, CANCER RES, V69, P1536, DOI 10.1158/0008-5472.CAN-08-3718
   Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1
   Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07
   Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6
   Reu FJ, 2006, J CLIN ONCOL, V24, P3771, DOI 10.1200/JCO.2005.03.4074
   Sandor V, 2002, CLIN CANCER RES, V8, P718
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579
   Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194
   van Spronsen DJ, 2005, CRIT REV ONCOL HEMAT, V55, P177, DOI 10.1016/j.critrevonc.2005.04.002
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Widelitz R, 2005, GROWTH FACTORS, V23, P111, DOI 10.1080/08977190500125746
   Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X
   Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200
   Zhu WG, 2001, CANCER RES, V61, P1327
NR 50
TC 45
Z9 51
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2012
VL 11
IS 10
BP 2105
EP 2115
DI 10.1158/1535-7163.MCT-11-0873
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 031KP
UT WOS:000310638600004
PM 22826467
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Luo, WB
   Chang, R
   Zhong, J
   Pandey, A
   Semenza, GL
AF Luo, Weibo
   Chang, Ryan
   Zhong, Jun
   Pandey, Akhilesh
   Semenza, Gregg L.
TI Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor
   1 that is required for breast cancer progression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE H3K9me3; SILAC; chromatin immunoprecipitation; gene expression
ID TRANSACTIVATION DOMAIN; GENE; EXPRESSION; METHYLATION; PROTEIN;
   HIF-1-ALPHA; MODULATION; RESPONSES; PATTERNS; TARGETS
AB Hypoxia-inducible factor 1 (HIF-1) activates transcription of genes encoding proteins that play key roles in breast cancer biology. We hypothesized that interaction of HIF-1 with epigenetic regulators may increase HIF-1 transcriptional activity, and thereby promote breast cancer progression. We report that the histone demethylase jumonji domain containing protein 2C (JMJD2C) selectively interacts with HIF-1 alpha, but not HIF-2 alpha, and that HIF-1 alpha mediates recruitment of JMJD2C to the hypoxia response elements of HIF-1 target genes. JMJD2C decreases trimethylation of histone H3 at lysine 9, and enhances HIF-1 binding to hypoxia response elements, thereby activating transcription of BNIP3, LDHA, PDK1, and SLC2A1, which encode proteins that are required for metabolic reprogramming, as well as LOXL2 and L1CAM, which encode proteins that are required for lung metastasis. JMJD2C expression is significantly associated with expression of GLUT1, LDHA, PDK1, LOX, LOXL2, and L1CAM mRNA in human breast cancer biopsies. JMJD2C knockdown inhibits breast tumor growth and spontaneous metastasis to the lungs of mice following mammary fat pad injection. Taken together, these findings establish an important epigenetic mechanism that stimulates HIF-1-mediated transactivation of genes encoding proteins involved in metabolic reprogramming and lung metastasis in breast cancer.
C1 [Luo, Weibo; Chang, Ryan; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vasc Program, Baltimore, MD 21205 USA.
   [Luo, Weibo; Zhong, Jun; Pandey, Akhilesh; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.
   [Pandey, Akhilesh; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Pandey, Akhilesh] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
   [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA.
   [Pandey, Akhilesh; Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins University; Johns Hopkins University; Johns Hopkins University
RP Semenza, GL (通讯作者)，Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vasc Program, Baltimore, MD 21205 USA.
EM gsemenza@jhmi.edu
RI Semenza, Gregg/ABW-5102-2022; Zhong, Jun/D-1662-2010; Pandey,
   Akhilesh/B-4127-2009
OI Zhong, Jun/0000-0003-3148-4143; Luo, Weibo/0000-0002-1992-0320; Pandey,
   Akhilesh/0000-0001-9943-6127
FU National Heart, Lung, and Blood Institute [N01-HV28180,
   HHS-N268201000032C]; Johns Hopkins Institute for Cell Engineering;
   Fowler Foundation for Advanced Research in the Medical Sciences
FX We thank Karen Padgett (Novus Biologicals) for providing antibodies
   against HIF-1 beta, HIF-2 alpha, JMJD2A, JMJD2C, JMJD2D, GLUT1, PDK1,
   LDHA, histone H3, and rabbit IgG and Carmen Wong for advice on the
   orthotopic mouse model of breast cancer. This work was supported by
   National Heart, Lung, and Blood Institute Contracts N01-HV28180 and
   HHS-N268201000032C and by funds from the Johns Hopkins Institute for
   Cell Engineering. W. L. was supported by a fellowship from the Fowler
   Foundation for Advanced Research in the Medical Sciences. G. L. S. is
   the C. Michael Armstrong Professor at The Johns Hopkins University
   School of Medicine and an American Cancer Society Research Professor.
CR Agger K, 2008, CURR OPIN GENET DEV, V18, P159, DOI 10.1016/j.gde.2007.12.003
   Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969
   Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3
   Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956
   Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055
   Gu YZ, 1998, GENE EXPRESSION, V7, P205
   Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419
   Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200
   Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592
   Lee JS, 2011, P NATL ACAD SCI USA, V108, P13510, DOI 10.1073/pnas.1106106108
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054
   Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11
   Nangaku M, 2007, J MOL MED, V85, P1325, DOI 10.1007/s00109-007-0278-y
   Onnis B, 2009, J CELL MOL MED, V13, P2780, DOI 10.1111/j.1582-4934.2009.00876.x
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Porter GJR, 2004, CLIN RADIOL, V59, P1094, DOI 10.1016/j.crad.2004.05.001
   Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013
   Semenza GL, 2011, COLD SH Q B, V76, P347, DOI 10.1101/sqb.2011.76.010678
   Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Semenza GL, 2010, WIRES SYST BIOL MED, V2, P336, DOI 10.1002/wsbm.69
   Shohet RV, 2007, J MOL MED, V85, P1309, DOI 10.1007/s00109-007-0279-x
   Tan HD, 2008, MOL BIOL REP, V35, P551, DOI 10.1007/s11033-007-9121-3
   Taylor CT, 2007, J MOL MED, V85, P1295, DOI 10.1007/s00109-007-0277-z
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
   Vaupel P, 2004, METHOD ENZYMOL, V381, P335
   Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Wong CCL, 2012, J MOL MED, V90, P803, DOI 10.1007/s00109-011-0855-y
   Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108
   Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227
   Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054
   Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
   Zinkernagel AS, 2007, J MOL MED, V85, P1339, DOI 10.1007/s00109-007-0282-2
NR 58
TC 188
Z9 215
U1 0
U2 40
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 4
PY 2012
VL 109
IS 49
BP E3367
EP E3376
DI 10.1073/pnas.1217394109
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 054MF
UT WOS:000312347200010
PM 23129632
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Ivanov, M
   Kacevska, M
   Ingelman-Sundberg, M
AF Ivanov, M.
   Kacevska, M.
   Ingelman-Sundberg, M.
TI Epigenomics and Interindividual Differences in Drug Response
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID BREAST-CANCER PATIENTS; EMBRYONIC STEM-CELLS; LONG NONCODING RNA; DNA
   METHYLATION; GENE-EXPRESSION; PROMOTER HYPERMETHYLATION; RESISTANCE
   PHENOTYPE; EPIGENETIC CHANGES; BET BROMODOMAINS; LEUKEMIA-CELLS
AB Epigenomics is a rapidly growing field. New developments in epigenetics, such as the recently described modified cytosine variants (e.g., 5-hydroxymethylcytosine, 5hmC) and an arsenal of novel noncoding forms of RNA, can be applied in the area of drug pharmacokinetics and pharmacodynamics. Epigenetic aberrations can affect drug treatment by modulating the expressions of key genes involved in the metabolism and distribution of drugs as well as drug targets, thereby contributing to interindividual variation in drug response. These epigenetic alterations, along with the epigenetic profiles of circulating nucleic acids, have great potential to be used as biomarkers for personalized therapy, particularly in the treatment of cancer. In this review we present an update of pharmacoepigenetics with respect to epigenetic regulation of ADME genes (genes related to drug absorption, distribution, metabolism, and excretion) and drug targets, and we illustrate how this information can be used for predicting interindividual variations in drug response.
C1 [Ivanov, M.; Kacevska, M.; Ingelman-Sundberg, M.] Karolinska Inst, Dept Physiol & Pharmacol, Sect Pharmacogenet, Stockholm, Sweden.
C3 Karolinska Institutet
RP Ingelman-Sundberg, M (通讯作者)，Karolinska Inst, Dept Physiol & Pharmacol, Sect Pharmacogenet, Stockholm, Sweden.
EM magnus.ingelman-sundberg@ki.se
RI Ingelman-Sundberg, Magnus/ABD-9302-2021
OI Ingelman-Sundberg, Magnus/0000-0002-7255-9079; Ivanov,
   Maxim/0000-0001-7548-3316
FU Swedish Cancer Foundation; Swedish Research Council; European Union;
   Innovative Medicines Initiative
FX The authors' research is supported by grants from the Swedish Cancer
   Foundation and the Swedish Research Council, and also from the European
   Union and the Innovative Medicines Initiative.
CR Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103
   Aguilo F, 2011, CANCER RES, V71, P5365, DOI 10.1158/0008-5472.CAN-10-4379
   Amato RJ, 2007, CLIN GENITOURIN CANC, V5, P422, DOI 10.3816/CGC.2007.n.029
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Begum S, 2011, CLIN CANCER RES, V17, P4494, DOI 10.1158/1078-0432.CCR-10-3436
   Boddy JL, 2005, CLIN CANCER RES, V11, P1394, DOI 10.1158/1078-0432.CCR-04-1237
   Bram EE, 2009, NEOPLASIA, V11, P1359, DOI 10.1593/neo.91314
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427
   Chang YQ, 2010, J MOL BIOL, V400, P1, DOI 10.1016/j.jmb.2010.04.048
   Chen HY, 2010, INT J CANCER, V126, P1944, DOI 10.1002/ijc.24772
   Choi SH, 2011, NUCLEIC ACIDS RES, V39, P104, DOI 10.1093/nar/gkq774
   Cortese R, 2012, HUM MOL GENET, V21, P3619, DOI 10.1093/hmg/dds192
   Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
   Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009
   Dekker FJ, 2009, DRUG DISCOV TODAY, V14, P942, DOI 10.1016/j.drudis.2009.06.008
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   El-Khoury V, 2007, BRIT J CANCER, V97, P562, DOI 10.1038/sj.bjc.6603914
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002
   Giovannetti E, 2010, CANCER RES, V70, P4528, DOI 10.1158/0008-5472.CAN-09-4467
   Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hauswald S, 2009, CLIN CANCER RES, V15, P3705, DOI 10.1158/1078-0432.CCR-08-2048
   Hawkins PG, 2009, NUCLEIC ACIDS RES, V37, P2984, DOI 10.1093/nar/gkp127
   Hibi K, 2011, CANCER LETT, V311, P96, DOI 10.1016/j.canlet.2011.07.006
   Hong SJ, 2010, J KOREAN MED SCI, V25, P405, DOI 10.3346/jkms.2010.25.3.405
   Hung ECW, 2009, J CLIN PATHOL, V62, P308, DOI 10.1136/jcp.2007.048470
   Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630
   Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Kacevska M, 2011, CLIN PHARMACOL THER, V89, P902, DOI 10.1038/clpt.2011.21
   Kaut O, 2012, NEUROGENETICS, V13, P87, DOI 10.1007/s10048-011-0308-3
   Kim GE, 2011, VIRCHOWS ARCH, V459, P383, DOI 10.1007/s00428-011-1143-5
   Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586
   Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008
   Kuramochi-Miyagawa S, 2008, GENE DEV, V22, P908, DOI 10.1101/gad.1640708
   Liggett TE, 2011, INT J CANCER, V128, P492, DOI 10.1002/ijc.25363
   Lin YL, 2011, J INT MED RES, V39, P179, DOI 10.1177/147323001103900119
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu FS, 2009, TAIWAN J OBSTET GYNE, V48, P239, DOI 10.1016/S1028-4559(09)60296-5
   Lohse B, 2011, BIOORGAN MED CHEM, V19, P3625, DOI 10.1016/j.bmc.2011.01.046
   Marmorstein R, 2009, BBA-GENE REGUL MECH, V1789, P58, DOI 10.1016/j.bbagrm.2008.07.009
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Münzel M, 2011, ANGEW CHEM INT EDIT, V50, P6460, DOI 10.1002/anie.201101547
   Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   Pasmant E, 2011, FASEB J, V25, P444, DOI 10.1096/fj.10-172452
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Pontier DB, 2011, HUM GENET, V130, P223, DOI 10.1007/s00439-011-1008-7
   Rukov JL, 2011, TRENDS MOL MED, V17, P412, DOI 10.1016/j.molmed.2011.04.003
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Sim SC, 2011, TRENDS PHARMACOL SCI, V32, P72, DOI 10.1016/j.tips.2010.11.008
   Song SH, 2011, DRUGS, V71, P2391, DOI 10.2165/11596690-000000000-00000
   Szulwach KE, 2011, NAT NEUROSCI, V14, P1607, DOI 10.1038/nn.2959
   Tekpli X, 2012, INT J CANCER, V131, P1509, DOI 10.1002/ijc.27421
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035
   Urbanova M, 2010, CELL MOL BIOL LETT, V15, P242, DOI 10.2478/s11658-010-0004-6
   Wang Q, 2011, EXP LUNG RES, V37, P427, DOI 10.3109/01902148.2011.584263
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Wu Y, 2012, J PHARMACEUT BIOMED, V58, P78, DOI 10.1016/j.jpba.2011.09.017
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yamamoto Y, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-135
   Yildirim O, 2011, CELL, V147, P1498, DOI 10.1016/j.cell.2011.11.054
   Yu W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029450
   Zeller C., 2012, Oncogene
   Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4
NR 74
TC 95
Z9 106
U1 0
U2 37
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD DEC
PY 2012
VL 92
IS 6
BP 727
EP 736
DI 10.1038/clpt.2012.152
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 039YE
UT WOS:000311283400014
PM 23093317
DA 2025-01-12
ER

PT J
AU Fumagalli, D
   Andre, F
   Piccart-Gebhart, MJ
   Sotiriou, C
   Desmedt, C
AF Fumagalli, Debora
   Andre, Fabrice
   Piccart-Gebhart, Martine J.
   Sotiriou, Christos
   Desmedt, Christine
TI Molecular biology in breast cancer: Should molecular classifiers be
   assessed by conventional tools or by gene expression arrays?
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Article
DE Breast cancer; lmmunohistochemistry; Gene expression profiles; Molecular
   classifiers; Breast cancer subtypes; Prognostic signatures; Predictive
   signatures; Reproducibility
ID RETRACTED ARTICLE. SEE; POLYMERASE CHAIN-REACTION; ESTROGEN-RECEPTOR;
   GRADE INDEX; PROGESTERONE-RECEPTOR; MUTATIONAL PROCESSES; PROGNOSTIC
   UTILITY; 21-GENE ASSAY; TUMOR; CLASSIFICATION
AB Breast cancer is a complex disease, with heterogeneous presentations and clinical courses. Standard clinico-pathological parameters, relying on single gene or protein characterization determined with sometimes poorly-reproducible technologies, have shown limitations in the classification of the disease and in the prediction of individual patient outcomes and responses to therapy. Gene-expression profiling has revealed great potential to accurately classify breast cancer and define patient prognosis and prediction to anti-cancer therapy. Nevertheless, the performance of molecular classifiers remains sub-optimal, and both technical and conceptual improvements are needed. It is likely that determining the ideal strategy for tailoring treatment of breast cancer will require a more systematic, structured and multi-dimensional approach than in the past. Besides implementing cutting-edge technologies to detect genetic and epigenetic cancer alterations, the future of breast cancer research will in all probability rely on the innovative and multilevel integration of molecular profiles with clinical parameters of the disease and patient-related factors. (C) 2012 Published by Elsevier Ireland Ltd.
C1 [Fumagalli, Debora; Sotiriou, Christos; Desmedt, Christine] Univ Libre Bruxelles, Inst Jules Bordet, Breast Canc Translat Res Unit, Brussels, Belgium.
   [Andre, Fabrice] Inst Gustave Roussy, Breast Canc Unit, Villejuif, France.
   [Andre, Fabrice] Inst Gustave Roussy, Translat Res Unit, Villejuif, France.
   [Piccart-Gebhart, Martine J.] Inst Jules Bordet, Breast Int Grp, B-1000 Brussels, Belgium.
C3 Institut Jules Bordet; Universite Libre de Bruxelles; UNICANCER; Gustave
   Roussy; UNICANCER; Gustave Roussy; Breast International Group; Institut
   Jules Bordet
RP Desmedt, C (通讯作者)，Inst Jules Bordet, Breast Canc Translat Res Unit, 125 Blvd Waterloo, B-1000 Brussels, Belgium.
EM christine.desmedt@bordet.be
RI ANDRE, Fabrice/AAL-2683-2020; Desmedt, Christine/P-7438-2017
OI Desmedt, Christine/0000-0002-5223-5579; andre,
   fabrice/0000-0001-5795-8357
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Aleskandarany MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3084
   Alexe G, 2007, CANCER RES, V67, P10669, DOI 10.1158/0008-5472.CAN-07-0539
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Andre F, 2006, BBA-REV CANCER, V1766, P197, DOI 10.1016/j.bbcan.2006.08.002
   Andre F, 2006, NAT CLIN PRACT ONCOL, V3, P621, DOI 10.1038/ncponc0636
   Andre F, 2009, CLIN CANCER RES, V15, P441, DOI 10.1158/1078-0432.CCR-08-1791
   Augustine CK, 2009, CLIN CANCER RES, V15, P502, DOI 10.1158/1078-0432.CCR-08-1916
   Badve SS, 2008, J CLIN ONCOL, V26, P2473, DOI 10.1200/JCO.2007.13.6424
   Baggerly KA, 2009, ANN APPL STAT, V3, P1309, DOI 10.1214/09-AOAS291
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Berezhnaya N. M., 2010, Experimental Oncology, V32, P159
   Betensky RA, 2002, J CLIN ONCOL, V20, P2495, DOI 10.1200/JCO.2002.06.140
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5
   Buerger H, 2001, J PATHOL, V194, P165, DOI 10.1002/path.875
   Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329
   Canales RD, 2006, NAT BIOTECHNOL, V24, P1115, DOI 10.1038/nbt1236
   Cardoso F, 2008, J CLIN ONCOL, V26, P729, DOI 10.1200/JCO.2007.14.3222
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Cleator SJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1506
   Collingridge D, 2010, LANCET ONCOL, V11, P813, DOI 10.1016/S1470-2045(10)70185-6
   Coombes KR, 2007, NAT MED, V13, P1276, DOI 10.1038/nm1107-1276b
   Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429
   Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835
   Dabbs DJ, 2011, J CLIN ONCOL, V29, P4279, DOI 10.1200/JCO.2011.34.7963
   Denkert C, 2012, VIRCHOWS ARCH, V460, P251, DOI 10.1007/s00428-012-1204-4
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Desmedt C, 2012, CLIN CANCER RES, V18, P1004, DOI 10.1158/1078-0432.CCR-11-0383
   Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Filipits M, 2011, CLIN CANCER RES, V17, P6012, DOI 10.1158/1078-0432.CCR-11-0926
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Folgueira MAAK, 2005, CLIN CANCER RES, V11, P7434
   Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316
   GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834
   Geyer FC, 2012, ADV ANAT PATHOL, V19, P39, DOI 10.1097/PAP.0b013e31823fafa0
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Goldstein LJ, 2008, J CLIN ONCOL, V26, P4063, DOI 10.1200/JCO.2007.14.4501
   Guo L, 2006, NAT BIOTECHNOL, V24, P1162, DOI 10.1038/nbt1238
   Habel LA, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1412
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JOP.777003, 10.5858/134.6.907, 10.1200/JCO.2009.25.6529]
   Harbeck N, 2007, CRIT REV CL LAB SCI, V44, P179, DOI 10.1080/10408360601040970
   Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   Horlings HM, 2010, CLIN CANCER RES, V16, P651, DOI 10.1158/1078-0432.CCR-09-0709
   Hsu DS, 2007, J CLIN ONCOL, V25, P4350, DOI 10.1200/JCO.2007.11.0593
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Ioannidis JPA, 2009, NAT GENET, V41, P149, DOI 10.1038/ng.295
   Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756
   Jerevall PL, 2011, BRIT J CANCER, V104, P1762, DOI 10.1038/bjc.2011.145
   Jönsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596
   Li QY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015031
   Liedtke C, 2009, J CLIN ONCOL, V27, P3185, DOI 10.1200/JCO.2008.18.5934
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Loi S, 2012, J CLIN ONCOL, V30
   Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107
   Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6
   Lusa L, 2007, JNCI-J NATL CANCER I, V99, P1715, DOI 10.1093/jnci/djm216
   Ma XJ, 2008, CLIN CANCER RES, V14, P2601, DOI 10.1158/1078-0432.CCR-07-5026
   Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015
   Martin Vittoria, 2012, Patholog Res Int, V2012, P261857, DOI 10.1155/2012/261857
   Melchor L, 2008, ONCOGENE, V27, P3165, DOI 10.1038/sj.onc.1210975
   Michiels S, 2007, BRIT J CANCER, V96, P1155, DOI 10.1038/sj.bjc.6603673
   Mook S, 2009, BREAST CANCER RES TR, V116, P295, DOI 10.1007/s10549-008-0130-2
   Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379
   Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878
   Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   Noske A, 2011, BREAST CANCER RES TR, V126, P109, DOI 10.1007/s10549-010-1316-y
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Patterson TA, 2006, NAT BIOTECHNOL, V24, P1140, DOI 10.1038/nbt1242
   Peppercorn J, 2008, CANCER INVEST, V26, P1, DOI 10.1080/07357900701784238
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Potti A, 2008, NAT MED, V14, P889, DOI 10.1038/nm0808-889
   Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Pusztai L, 2006, ONCOLOGIST, V11, P868, DOI 10.1634/theoncologist.11-8-868
   Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607
   Rhodes A, 2000, J CLIN PATHOL, V53, P125, DOI 10.1136/jcp.53.2.125
   Rody A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2234
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Russnes HG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000611
   Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239
   Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665
   Shippy R, 2006, NAT BIOTECHNOL, V24, P1123, DOI 10.1038/nbt1241
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Sparano JA, 2008, J CLIN ONCOL, V26, P721, DOI 10.1200/JCO.2008.16.7528
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Strauss E, 2006, CELL, V127, P657, DOI 10.1016/j.cell.2006.11.005
   Straver ME, 2010, BREAST CANCER RES TR, V119, P551, DOI 10.1007/s10549-009-0333-1
   Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273
   Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157
   Tong WD, 2006, NAT BIOTECHNOL, V24, P1132, DOI 10.1038/nbt1237
   Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Weigelt B, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2734
   Weigelt B, 2010, LANCET ONCOL, V11, P339, DOI 10.1016/S1470-2045(10)70008-5
   Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648
   Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124
   Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
NR 120
TC 8
Z9 10
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD DEC 1
PY 2012
VL 84
SU 1
BP E58
EP E69
DI 10.1016/j.critrevonc.2012.08.003
PG 12
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA V40VS
UT WOS:000209506700009
PM 22964299
DA 2025-01-12
ER

PT J
AU Simpson, NE
   Tryndyak, VP
   Pogribna, M
   Beland, FA
   Pogribny, IP
AF Simpson, Natalie E.
   Tryndyak, Volodymyr P.
   Pogribna, Marta
   Beland, Frederick A.
   Pogribny, Igor P.
TI Modifying metabolically sensitive histone marks by inhibiting glutamine
   metabolism affects gene expression and alters cancer cell phenotype
SO EPIGENETICS
LA English
DT Article
DE breast cancer; glutamine metabolism; histone modifications; gene
   expression
ID DOWN-REGULATION; BREAST-CANCER; MEDIATED APOPTOSIS; TUMOR; PATHWAY;
   GROWTH; RETINOBLASTOMA; TUMORIGENESIS; DEMETHYLASES; TRASTUZUMAB
AB The interplay of metabolism and epigenetic regulatory mechanisms has become a focal point for a better understanding of cancer development and progression. In this study, we have acquired data supporting previous observations that demonstrate glutamine metabolism affects histone modifications in human breast cancer cell lines. Treatment of non-invasive epithelial (T-47D and MDA-MB-361) and invasive mesenchymal (MDA-MB-231 and Hs-578T) breast cancer cell lines with the glutaminase inhibitor, compound 968, resulted in cytotoxicity in all cell lines, with the greatest effect being observed in MDA-MB-231 breast cancer cells. Compound 968 treatment induced significant downregulation of 20 critical cancer-related genes, the majority of which are anti-apoptotic and/or promote metastasis, including AKT, BCL2, BCL2L1, CCND1, CDKN3, ERBB2, ETS1, E2F1, JUN, KITLG, MYB and MYC. Histone H3K4me3, a mark of transcriptional activation, was reduced at the promoters of all but one of these critical cancer genes. The decrease in histone H3K4me3 at global and gene-specific levels correlated with reduced expression of SETD1 and ASH2L, genes encoding the histone H3K4 methyltransferase complex. Further, the expression of other epigenetic regulatory genes, known to be downregulated during apoptosis (e.g., DNMT1, DNMT3B, SETD1 and SIRT1), was also downregulated by compound 968. These changes in gene expression and histone modifications were accompanied by the activation of apoptosis, and decreased invasiveness and resistance of MDA-MB-231 cells to chemotherapeutic drug doxorubicin. The results of this study provide evidence to a link between cytotoxicity caused by inhibiting glutamine metabolism with alterations of the epigenome of breast cancer cells and suggest that modification of intracellular metabolism may enhance the efficiency of epigenetic therapy.
C1 [Simpson, Natalie E.; Tryndyak, Volodymyr P.; Pogribna, Marta; Beland, Frederick A.; Pogribny, Igor P.] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA)
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
OI Tryndyak, Volodymyr/0000-0002-8319-2954; Beland,
   Frederick/0000-0002-2113-6260
CR Asiago VM, 2010, CANCER RES, V70, P8309, DOI 10.1158/0008-5472.CAN-10-1319
   Burgio G, 2010, BBA-GENE REGUL MECH, V1799, P671, DOI 10.1016/j.bbagrm.2010.05.007
   Carbone GM, 2004, NUCLEIC ACIDS RES, V32, P4358, DOI 10.1093/nar/gkh744
   Cuello M, 2001, CANCER RES, V61, P4892
   Daye D, 2012, SEMIN CELL DEV BIOL, V23, P362, DOI 10.1016/j.semcdb.2012.02.002
   DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358
   Dubská L, 2005, FEBS LETT, V579, P4149, DOI 10.1016/j.febslet.2005.06.047
   Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575
   Erickson JW, 2010, ONCOTARGET, V1, P734, DOI 10.18632/oncotarget.208
   Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x
   Hitchler MJ, 2009, FREE RADICAL BIO MED, V47, P115, DOI 10.1016/j.freeradbiomed.2009.04.010
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kassis ES, 2006, J THORAC CARDIOV SUR, V131, P298, DOI 10.1016/j.jtcvs.2005.05.022
   Katt WP, 2012, MOL CANCER THER, V11, P1269, DOI 10.1158/1535-7163.MCT-11-0942
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kwon MJ, 2010, CARCINOGENESIS, V31, P974, DOI 10.1093/carcin/bgp336
   Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194
   Lee JH, 2010, J BIOL CHEM, V285, P24466, DOI 10.1074/jbc.M110.109801
   Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494
   Lin Y, 2012, ONCOL REP, V27, P1976, DOI 10.3892/or.2012.1717
   Lüscher-Firzlaff J, 2008, CANCER RES, V68, P749, DOI 10.1158/0008-5472.CAN-07-3158
   Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109
   Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090
   Park EJ, 2009, CANCER LETT, V277, P133, DOI 10.1016/j.canlet.2008.11.029
   Rajendran P, 2011, CRIT REV BIOCHEM MOL, V46, P181, DOI 10.3109/10409238.2011.557713
   Robin P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-12-r270
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666
   Simpson NE, 2012, BREAST CANCER RES TR, V133, P959, DOI 10.1007/s10549-011-1871-x
   Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206
   Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131
   Tate CM, 2010, FEBS J, V277, P210, DOI 10.1111/j.1742-4658.2009.07475.x
   Teperino R, 2010, CELL METAB, V12, P321, DOI 10.1016/j.cmet.2010.09.004
   Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950
   Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617
   Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097
   Zhang MC, 2003, CANCER LETT, V195, P201, DOI 10.1016/S0304-3835(03)00148-4
   Zhang Y, 2007, ONCOL REP, V18, P1207
NR 45
TC 63
Z9 79
U1 0
U2 14
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD DEC
PY 2012
VL 7
IS 12
BP 1413
EP 1420
DI 10.4161/epi.22713
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 048UK
UT WOS:000311938500008
PM 23117580
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Faryna, M
   Konermann, C
   Aulmann, S
   Bermejo, JL
   Brugger, M
   Diederichs, S
   Rom, J
   Weichenhan, D
   Claus, R
   Rehli, M
   Schirmacher, P
   Sinn, HP
   Plass, C
   Gerhauser, C
AF Faryna, Marta
   Konermann, Carolin
   Aulmann, Sebastian
   Bermejo, Justo Lorenzo
   Brugger, Markus
   Diederichs, Sven
   Rom, Joachim
   Weichenhan, Dieter
   Claus, Rainer
   Rehli, Michael
   Schirmacher, Peter
   Sinn, Hans-Peter
   Plass, Christoph
   Gerhauser, Clarissa
TI Genome-wide methylation screen in low-grade breast cancer identifies
   novel epigenetically altered genes as potential biomarkers for tumor
   diagnosis
SO FASEB JOURNAL
LA English
DT Article
DE estrogen receptor-positive; EpiTyper MassArray; CpG island array;
   methyl-CpG immunoprecipitation; DMR; ductal carcinoma in situ
ID CARCINOMA IN-SITU; DNA METHYLATION; PROMOTER HYPERMETHYLATION;
   PROTOCADHERIN PCDH10; RECEPTOR STATUS; EARLY EVENT; FREQUENT;
   SUPPRESSOR; PATTERNS; EXPRESSION
AB Aberrant DNA methylation constitutes a well-established epigenetic marker for breast cancer. Changes in methylation early in cancer development may be clinically relevant for cancer detection and prognosis-based therapeutic decisions. In the present study, a combination of methyl-CpG immunoprecipitation (MCIp) and human CpG island (CGI) arrays was applied to compare genome-wide DNA methylation profiles in 10 low-grade in situ and invasive breast cancers against 10 normal breast samples. In total, 214 CGIs were found to be hypermethylated in >= 6 of 10 tumors. Functional term enrichment analyses revealed an overrepresentation of homeobox genes and genes involved in transcription and regulation of transcription. Significant hypermethylation of 11 selected genes in tumor vs. normal tissue was validated in two independent sample sets (45 tumors and 11 controls, 43 tumors and 8 controls) using quantitative EpiTyper technology. In tumors, median methylation levels of BCAN, HOXD1, KCTD8, KLF11, NXPH1, POU4F1, SIM1, and TCF7L1 were >= 30% higher than in normal samples, representing potential biomarkers for tumor diagnosis. Using the 90th percentile of methylation levels in normal tissue as cutoff value, 62-92% of in situ samples (n = 13), 72-97% of invasive samples from the first validation set (n = 32), and 86-100% of invasive samples from the second validation set (n = 43) were classified as hypermethylated. Hypermethylation of KLF11 and SIM1 might also be associated with increased risk of developing metastases. In summary, early methylation changes are frequent in the low-grade pathway of breast cancer and may be useful in the development of differential diagnostic and possibly also prognostic markers.-Faryna, M., Konermann, C., Aulmann, S., Bermejo, J. L., Brugger, M., Diederichs, S., Rom, J., Weichenhan, D., Claus, R., Rehli, M., Schirmacher, P., Sinn, H.-P., Plass, C., Gerhauser, C. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 26, 4937-4950 (2012). www.fasebj.org
C1 [Faryna, Marta; Konermann, Carolin; Weichenhan, Dieter; Claus, Rainer; Plass, Christoph; Gerhauser, Clarissa] German Canc Res Ctr, Div Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany.
   [Diederichs, Sven] German Canc Res Ctr, Helmholtz Univ Grp Mol RNA Biol & Canc, D-69120 Heidelberg, Germany.
   [Konermann, Carolin; Aulmann, Sebastian; Diederichs, Sven; Schirmacher, Peter; Sinn, Hans-Peter] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany.
   [Bermejo, Justo Lorenzo; Brugger, Markus] Univ Heidelberg Hosp, Inst Med Biometry & Informat, Heidelberg, Germany.
   [Rom, Joachim] Univ Heidelberg Hosp, Dept Gynecol & Obstet, Heidelberg, Germany.
   [Claus, Rainer] Univ Freiburg, Med Ctr, Div Hematol & Oncol, Dept Med, D-79106 Freiburg, Germany.
   [Rehli, Michael] Univ Hosp Regensburg, Dept Hematol & Oncol, Regensburg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); Ruprecht Karls
   University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht
   Karls University Heidelberg; University of Freiburg; University of
   Regensburg
RP Gerhauser, C (通讯作者)，German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
EM c.gerhauser@dkfz-heidelberg.de
RI Rehli, Michael/E-9093-2011; Claus, Rainer/AAZ-5606-2020; GIL BERMEJO,
   JOSE LUIS/ABA-7839-2021; Plass, Christoph/H-7192-2014; Diederichs,
   Sven/J-6237-2012; Sinn, Hans-Peter/C-5661-2008
OI Diederichs, Sven/0000-0001-7901-4752; Sinn,
   Hans-Peter/0000-0003-2836-6699; Gerhauser, Clarissa/0000-0002-5792-3901;
   Claus, Rainer/0000-0003-2617-8766
FU FRONTIER Innovation Fund, Excellence Initiative of Heidelberg
   University; Deutsche Forschungsgemeinschaft (DFG) [SFB/TRR77, CL
   427/2-1]; Helmholtz Society [VH-NG-504]; German Research Foundation [DFG
   Transregio TRR77, TP B03]; Marie Curie Program of the European
   Commission
FX The authors thank Manuela Zucknick for statistical support in array
   analysis and Julia Strathmann for providing DNA from MCF7 cells. The
   authors thank Oliver Mucke, Sandra Hahn, and Tina Philipp for excellent
   technical assistance. This project was funded by the FRONTIER Innovation
   Fund as part of the Excellence Initiative of Heidelberg University.
   J.L.B. and M. B. were supported by a grant of the Deutsche
   Forschungsgemeinschaft (DFG; SFB/TRR77, project Z2). Research in the S.
   D. laboratory is supported by the Helmholtz Society (VH-NG-504), the
   German Research Foundation (DFG Transregio TRR77, TP B03) and the Marie
   Curie Program of the European Commission. R. C. was supported by a DFG
   grant (CL 427/2-1). The authors declare no conflicts of interest.
CR [Anonymous], 2010, GLOBOCAN 2008 V1 2 C
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dedeurwaerder S, 2011, CURR OPIN ONCOL, V23, P559, DOI 10.1097/CCO.0b013e32834bd481
   Deli T, 2007, INT J CANCER, V121, P55, DOI 10.1002/ijc.22621
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376
   Goeppert B, 2010, HEPATOLOGY, V52, P2023, DOI 10.1002/hep.23939
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Holleczek B, 2011, CANCER EPIDEMIOL, V35, P399, DOI 10.1016/j.canep.2011.01.008
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Killian JK, 2011, AM J PATHOL, V179, P55, DOI 10.1016/j.ajpath.2011.03.022
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Narayan G, 2011, GENE CHROMOSOME CANC, V50, P1043, DOI 10.1002/gcc.20922
   Narayan G, 2009, GENE CHROMOSOME CANC, V48, P983, DOI 10.1002/gcc.20703
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Pasquali L, 2007, CANCER LETT, V257, P136, DOI 10.1016/j.canlet.2007.07.010
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   Schilling E, 2007, GENOMICS, V90, P314, DOI 10.1016/j.ygeno.2007.04.011
   Schilling E, 2009, GENOME RES, V19, P2028, DOI 10.1101/gr.095562.109
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   VOLLENWEIDERZERARGUI L, 1986, CANCER-AM CANCER SOC, V57, P1171, DOI 10.1002/1097-0142(19860315)57:6<1171::AID-CNCR2820570618>3.0.CO;2-X
   Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050
NR 58
TC 74
Z9 83
U1 0
U2 28
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2012
VL 26
IS 12
BP 4937
EP 4950
DI 10.1096/fj.12-209502
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 047KD
UT WOS:000311838300017
PM 22930747
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Liu, JF
   Lee, W
   Jiang, ZS
   Chen, ZQ
   Jhunjhunwala, S
   Haverty, PM
   Gnad, F
   Guan, YH
   Gilbert, HN
   Stinson, J
   Klijn, C
   Guillory, J
   Bhatt, D
   Vartanian, S
   Walter, K
   Chan, J
   Holcomb, T
   Dijkgraaf, P
   Johnson, S
   Koeman, J
   Minna, JD
   Gazdar, AF
   Stern, HM
   Hoeflich, KP
   Wu, TD
   Settleman, J
   de Sauvage, FJ
   Gentleman, RC
   Neve, RM
   Stokoe, D
   Modrusan, Z
   Seshagiri, S
   Shames, DS
   Zhang, ZM
AF Liu, Jinfeng
   Lee, William
   Jiang, Zhaoshi
   Chen, Zhongqiang
   Jhunjhunwala, Suchit
   Haverty, Peter M.
   Gnad, Florian
   Guan, Yinghui
   Gilbert, Houston N.
   Stinson, Jeremy
   Klijn, Christiaan
   Guillory, Joseph
   Bhatt, Deepali
   Vartanian, Steffan
   Walter, Kimberly
   Chan, Jocelyn
   Holcomb, Thomas
   Dijkgraaf, Peter
   Johnson, Stephanie
   Koeman, Julie
   Minna, John D.
   Gazdar, Adi F.
   Stern, Howard M.
   Hoeflich, Klaus P.
   Wu, Thomas D.
   Settleman, Jeff
   de Sauvage, Frederic J.
   Gentleman, Robert C.
   Neve, Richard M.
   Stokoe, David
   Modrusan, Zora
   Seshagiri, Somasekar
   Shames, David S.
   Zhang, Zemin
TI Genome and transcriptome sequencing of lung cancers reveal diverse
   mutational and splicing events
SO GENOME RESEARCH
LA English
DT Article
ID BREAST-CANCER; CELL-LINES; SOMATIC MUTATIONS; GENE; VARIANTS; COMPLEX;
   FUSION; EPIGENOMICS; EXPRESSION; DISCOVERY
AB Lung cancer is a highly heterogeneous disease in terms of both underlying genetic lesions and response to therapeutic treatments. We performed deep whole-genome sequencing and transcriptome sequencing on 19 lung cancer cell lines and three lung tumor/normal pairs. Overall, our data show that cell line models exhibit similar mutation spectra to human tumor samples. Smoker and never-smoker cancer samples exhibit distinguishable patterns of mutations. A number of epigenetic regulators, including KDM6A, ASH1L, SMARCA4, and ATAD2, are frequently altered by mutations or copy number changes. A systematic survey of splice-site mutations identified 106 splice site mutations associated with cancer specific aberrant splicing, including mutations in several known cancer-related genes. RAC1b, an isoform of the RAC1 GTPase that includes one additional exon, was found to be preferentially up-regulated in lung cancer. We further show that its expression is significantly associated with sensitivity to a MAP2K (MEK) inhibitor PD-0325901. Taken together, these data present a comprehensive genomic landscape of a large number of lung cancer samples and further demonstrate that cancer-specific alternative splicing is a widespread phenomenon that has potential utility as therapeutic biomarkers. The detailed characterizations of the lung cancer cell lines also provide genomic context to the vast amount of experimental data gathered for these lines over the decades, and represent highly valuable resources for cancer biology.
C1 [Liu, Jinfeng; Lee, William; Jiang, Zhaoshi; Chen, Zhongqiang; Jhunjhunwala, Suchit; Haverty, Peter M.; Gnad, Florian; Klijn, Christiaan; Wu, Thomas D.; Gentleman, Robert C.; Zhang, Zemin] Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
   [Guan, Yinghui; Stinson, Jeremy; Guillory, Joseph; Bhatt, Deepali; Dijkgraaf, Peter; de Sauvage, Frederic J.; Modrusan, Zora; Seshagiri, Somasekar] Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.
   [Gilbert, Houston N.] Genentech Inc, Dept Nonclin Biostat, San Francisco, CA 94080 USA.
   [Vartanian, Steffan; Settleman, Jeff; Neve, Richard M.; Stokoe, David] Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA.
   [Walter, Kimberly; Holcomb, Thomas; Shames, David S.] Genentech Inc, Dept Dev Oncol Diagnost, San Francisco, CA 94080 USA.
   [Chan, Jocelyn; Hoeflich, Klaus P.] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA.
   [Johnson, Stephanie; Stern, Howard M.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Koeman, Julie] Van Andel Res Inst, Cytogenet Core, Grand Rapids, MI 49503 USA.
   [Minna, John D.; Gazdar, Adi F.] UT SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche
   Holding; Genentech; Roche Holding; Genentech; Van Andel Institute;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas
RP Zhang, ZM (通讯作者)，Genentech Inc, Dept Bioinformat & Computat Biol, San Francisco, CA 94080 USA.
EM zhang.zemin@gene.com
RI de Sauvage, Frederic/ABE-8400-2020; Minna, John/AAB-1036-2022;
   Jhunjhunwala, Suchit/GNH-2256-2022; Gazdar, Adi/F-7496-2010
OI Gnad, Florian/0000-0002-2287-2251; Liu, Jinfeng/0000-0002-0343-8222;
   Shames, David/0000-0002-5900-1177; Klijn, Christiaan/0000-0003-0878-4121
FU NCI SPORE [P50CA70907]; CPRIT [RP101251, RP110709]; Early Detection
   Research Network [U01 CA086402]; NCI; Canary Foundation
FX We thank Jens Reeder, Cory Barr, Melanie Huntley, Meg Green, Michael
   Lawrence, and Jeremiah Degenhardt for development of the transcriptome
   sequencing analysis pipeline and assistance in processing the
   transcriptome data; Richard Bourgon, Kiran Mukhyala, Oleg Mayba, Robert
   Yauch, David Dornan, Krishna Pant, and Dennis Ballinger for constructive
   discussions. J.D.M. is supported by NCI SPORE P50CA70907, CPRIT
   (RP101251, RP110709). A.F.G. is supported by U01 CA086402 from the Early
   Detection Research Network, NCI and the Canary Foundation.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Argani P, 2003, ONCOGENE, V22, P5374, DOI 10.1038/sj.onc.1206686
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Barrow J, 2011, NEURO-ONCOLOGY, V13, P212, DOI 10.1093/neuonc/noq158
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Borrell B, 2010, NATURE, V463, P858, DOI 10.1038/463858a
   Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x
   Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006
   Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7
   Chang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021097
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Clark MJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000832
   De Paepe P, 2003, BLOOD, V102, P2638, DOI 10.1182/blood-2003-04-1050
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Diskin SJ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn556
   Dominissini D, 2011, CARCINOGENESIS, V32, P1569, DOI 10.1093/carcin/bgr124
   Drmanac R, 2010, SCIENCE, V327, P78, DOI 10.1126/science.1181498
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Gazdar AF, 2010, JNCI-J NATL CANCER I, V102, P1310, DOI 10.1093/jnci/djq279
   Gonçalves V, 2009, HUM MOL GENET, V18, P3696, DOI 10.1093/hmg/ddp317
   Greenman CD, 2010, BIOSTATISTICS, V11, P164, DOI 10.1093/biostatistics/kxp045
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441
   Iyer MK, 2011, BIOINFORMATICS, V27, P2903, DOI 10.1093/bioinformatics/btr467
   Jiang ZS, 2012, GENOME RES, V22, P593, DOI 10.1101/gr.133926.111
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233
   Kalashnikova EV, 2010, CANCER RES, V70, P9402, DOI 10.1158/0008-5472.CAN-10-1199
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004
   Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485
   Lin E, 2009, MOL CANCER RES, V7, P1466, DOI 10.1158/1541-7786.MCR-08-0522
   Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638
   McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056
   Peiffer DA, 2006, GENOME RES, V16, P1136, DOI 10.1101/gr.5402306
   Phelps RM, 1996, J CELL BIOCHEM, P32
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Revenko AS, 2010, MOL CELL BIOL, V30, P5260, DOI 10.1128/MCB.00484-10
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044
   Salgia R, 2011, SEMIN ONCOL, V38, P274, DOI 10.1053/j.seminoncol.2011.01.012
   Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659
   Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Stallings-Mann ML, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004062
   Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982
   Wang LH, 2012, GENOME RES, V22, P208, DOI 10.1101/gr.123109.111
   Weinstein JN, 2012, NATURE, V483, P544, DOI 10.1038/483544a
   Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
   Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825
   Yue P, 2010, HUM MUTAT, V31, P264, DOI 10.1002/humu.21194
   Zandi R, 2011, CANCER INVEST, V29, P683, DOI 10.3109/07357907.2011.626475
   Zhao Q, 2009, P NATL ACAD SCI USA, V106, P1886, DOI 10.1073/pnas.0812945106
   Zhou C, 2013, ONCOGENE, V32, P903, DOI 10.1038/onc.2012.99
NR 68
TC 154
Z9 180
U1 0
U2 70
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD DEC
PY 2012
VL 22
IS 12
BP 2315
EP 2327
DI 10.1101/gr.140988.112
PG 13
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 048FK
UT WOS:000311895500001
PM 23033341
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Duncan, CG
   Barwick, BG
   Jin, GL
   Rago, C
   Kapoor-Vazirani, P
   Powell, DR
   Chi, JT
   Bigner, DD
   Vertino, PM
   Yan, H
AF Duncan, Christopher G.
   Barwick, Benjamin G.
   Jin, Genglin
   Rago, Carlo
   Kapoor-Vazirani, Priya
   Powell, Doris R.
   Chi, Jen-Tsan
   Bigner, Darell D.
   Vertino, Paula M.
   Yan, Hai
TI A heterozygous <i>IDH1<SUP>R132H/WT</SUP></i> mutation induces
   genome-wide alterations in DNA methylation
SO GENOME RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HUMAN CANCER-CELLS; ISOCITRATE DEHYDROGENASE 1;
   ACUTE MYELOID-LEUKEMIA; IDH1 CODON 132; CELLULAR
   RETINOL-BINDING-PROTEIN-1; ONCOMETABOLITE 2-HYDROXYGLUTARATE;
   GENE-EXPRESSION; MAMMALIAN DNA; BREAST-CANCER
AB Monoallelic point mutations of the NADP(+)-dependent isocitrate dehydrogenases IDH1 and IDH2 occur frequently in gliomas, acute myeloid leukemias, and chondromas, and display robust association with specific DNA hypermethylation signatures. Here we show that heterozygous expression of the IDH1(R132H) allele is sufficient to induce the genome-wide alterations in DNA methylation characteristic of these tumors. Using a gene-targeting approach, we knocked-in a single copy of the most frequently observed IDH1 mutation, R132H, into a human cancer cell line and profiled changes in DNA methylation at over 27,000 CpG dinucleotides relative to wild- type parental cells. We find that IDH1(R132H/WT) mutation induces widespread alterations in DNA methylation, including hypermethylation of 2010 and hypomethylation of 842 CpG loci. We demonstrate that many of these alterations are consistent with those observed in IDH1-mutant and G-CIMP+ primary gliomas and can segregate IDH wild- type and mutated tumors as well as those exhibiting the G-CIMP phenotype in unsupervised analysis of two primary glioma cohorts. Further, we show that the direction of IDH1(R132H/WT)-mediated DNA methylation change is largely dependent upon preexisting DNA methylation levels, resulting in depletion of moderately methylated loci. Additionally, whereas the levels of multiple histone H3 and H4 methylation modifications were globally increased, consistent with broad inhibition of histone demethylation, hypermethylation at H3K9 in particular accompanied locus-specific DNA hypermethylation at several genes down-regulated in IDH1R(132H/WT) knock-in cells. These data provide insight on epigenetic alterations induced by IDH1 mutations and support a causal role for IDH1R132H/WT mutants in driving epigenetic instability in human cancer cells.
C1 [Kapoor-Vazirani, Priya; Powell, Doris R.; Vertino, Paula M.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Kapoor-Vazirani, Priya; Powell, Doris R.; Vertino, Paula M.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Duncan, Christopher G.; Jin, Genglin; Bigner, Darell D.; Yan, Hai] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Pediat Brain Tumor Fdn Inst,Dept Pathol, Durham, NC 27710 USA.
   [Barwick, Benjamin G.] Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA.
   [Rago, Carlo] Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.
   [Rago, Carlo] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA.
   [Chi, Jen-Tsan] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA.
   [Chi, Jen-Tsan] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27708 USA.
C3 Emory University; Emory University; Duke University; Emory University;
   Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins
   Medicine; Duke University; Duke University
RP Vertino, PM (通讯作者)，Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
EM pvertin@emory.edu; hai.yan@dm.duke.edu
RI Jin, Genglin/F-6868-2011; Chi, Jen-Tsan/AAI-4125-2020; Barwick,
   Benjamin/O-5185-2019
OI Duncan, Christopher/0000-0001-7205-2414; Barwick,
   Benjamin/0000-0001-9810-3566; Chi, Jen-Tsan/0000-0003-3433-903X
FU American Cancer Society Research Scholar Award [RSG-10-126-01-CCE];
   Pediatric Brain Tumor Foundation Institute; Southeastern Brain Tumor
   Foundation; NCI [5R01-CA140316, 2R01-CA077337, 5R01-CA132065]; NIH [5P50
   NS20023, 5P50 CA108786]; NCI Merit Award [R37 CA 011898]; Sanofi-aventis
FX We thank members of the Yan and Vertino Labs for technical help and
   helpful discussions. We thank I. Spasojevic, P. Fan, and the DUCC
   Clinical Pharmacology Lab for quantitative analysis of D-2-HG; K.
   Abramson and the Duke CHG Molecular Genetics Core for their assistance
   with the Methylation Array Studies; and the Duke Microarray Core
   Facility for their assistance with the microarray studies. This project
   was supported by American Cancer Society Research Scholar Award
   RSG-10-126-01-CCE, The Pediatric Brain Tumor Foundation Institute Grant,
   The Southeastern Brain Tumor Foundation Grant, and NCI Grant
   5R01-CA140316 (to H.Y.), NCI Grants 2R01-CA077337 and 5R01-CA132065 (to
   P.M.V.), as well as by the following NIH grants: NINDS Grant 5P50
   NS20023 (to D.D.B.), NCI SPORE Grant 5P50 CA108786 (to D.D.B.), and NCI
   Merit Award R37 CA 011898 (to D.D.B.). H.Y. received a research grant
   and consulting fee from Sanofi-aventis.
CR Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913
   Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2
   Barbus S, 2011, JNCI-J NATL CANCER I, V103, P598, DOI 10.1093/jnci/djr036
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937
   Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386
   Bralten LBC, 2011, ANN NEUROL, V69, P455, DOI 10.1002/ana.22390
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497
   Chu LC, 2006, INT J CANCER, V119, P2487, DOI 10.1002/ijc.22124
   Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020
   Dahl C, 2011, CLIN CHIM ACTA, V412, P831, DOI 10.1016/j.cca.2011.02.013
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Esteller M, 2002, CANCER RES, V62, P5902
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Farias EF, 2005, ONCOGENE, V24, P1598, DOI 10.1038/sj.onc.1208347
   Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004
   Ficz G, 2011, NATURE, V473, P398, DOI 10.1038/nature10008
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gravendeel LAM, 2010, HUM MUTAT, V31, pE1186, DOI 10.1002/humu.21201
   Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022
   Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957
   Hartmann C, 2009, ACTA NEUROPATHOL, V118, P469, DOI 10.1007/s00401-009-0561-9
   Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155
   Hashimoto H, 2010, EPIGENOMICS-UK, V2, P657, DOI 10.2217/EPI.10.44
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Ichimura K, 2009, NEURO-ONCOLOGY, V11, P341, DOI 10.1215/15228517-2009-025
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303
   Jin GL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016812
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Jin SG, 2011, NUCLEIC ACIDS RES, V39, P5015, DOI 10.1093/nar/gkr120
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379
   Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141
   Karimi MM, 2011, CELL STEM CELL, V8, P676, DOI 10.1016/j.stem.2011.04.004
   Kinney SM, 2011, J BIOL CHEM, V286, P24685, DOI 10.1074/jbc.M110.217083
   Kipp BR, 2012, HUM PATHOL, V43, P1552, DOI 10.1016/j.humpath.2011.12.007
   Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586
   Koh KP, 2011, CELL STEM CELL, V8, P200, DOI 10.1016/j.stem.2011.01.008
   Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009
   Laffaire J, 2011, NEURO-ONCOLOGY, V13, P84, DOI 10.1093/neuonc/noq110
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Li A, 2009, CANCER RES, V69, P2091, DOI 10.1158/0008-5472.CAN-08-2100
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Loenarz C, 2008, NAT CHEM BIOL, V4, P152, DOI 10.1038/nchembio0308-152
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730
   Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Mizuiri H, 2005, CANCER SCI, V96, P571, DOI 10.1111/j.1349-7006.2005.00082.x
   Nestor C, 2010, BIOTECHNIQUES, V48, P317, DOI 10.2144/000113403
   Nestor CE, 2012, GENOME RES, V22, P467, DOI 10.1101/gr.126417.111
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762
   Pastor WA, 2011, NATURE, V473, P394, DOI 10.1038/nature10102
   Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019
   Pike BL, 2008, LEUKEMIA, V22, P1035, DOI 10.1038/leu.2008.18
   Rago C, 2007, NAT PROTOC, V2, P2734, DOI 10.1038/nprot.2007.408
   Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106
   Reitman ZJ, 2011, P NATL ACAD SCI USA, V108, P3270, DOI 10.1073/pnas.1019393108
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Ruzov A, 2011, CELL RES, V21, P1332, DOI 10.1038/cr.2011.113
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Stroud H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r54
   Struys EA, 2004, CLIN CHEM, V50, P1391, DOI 10.1373/clinchem.2004.033399
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Szulwach KE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002154
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Toki K, 2010, INT J ONCOL, V37, P1379, DOI 10.3892/ijo_00000789
   Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160
   Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Wagner K, 2010, J CLIN ONCOL, V28, P2356, DOI 10.1200/JCO.2009.27.6899
   WALDMAN T, 1995, CANCER RES, V55, P5187
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Watanabe T, 2009, AM J PATHOL, V174, P1149, DOI 10.2353/ajpath.2009.080958
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240
   Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934
   Wu H, 2011, GENE DEV, V25, P679, DOI 10.1101/gad.2036011
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yan H, 2009, CANCER RES, V69, P9157, DOI 10.1158/0008-5472.CAN-09-2650
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944
NR 114
TC 145
Z9 165
U1 0
U2 39
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD DEC
PY 2012
VL 22
IS 12
BP 2339
EP 2355
DI 10.1101/gr.132738.111
PG 17
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 048FK
UT WOS:000311895500003
PM 22899282
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Rojas-Atencio, A
   Yamarte, L
   Urdaneta, K
   Soto-Alvarez, M
   Nava, FA
   Cañizalez, J
   Quintero, M
   Atencio, R
   González, R
AF Rojas-Atencio, Alicia
   Yamarte, Leonard
   Urdaneta, Karelis
   Soto-Alvarez, Marisol
   Alvarez Nava, Francisco
   Canizalez, Jenny
   Quintero, Maribel
   Atencio, Raquel
   Gonzalez, Richard
TI Utility of chromosome banding with ALU I enzyme for identifying
   methylated areas in breast cancer
SO INVESTIGACION CLINICA
LA Spanish
DT Article
DE breast cancer; methylation of DNA; restriction enzymes ALU I; chromosome
   banding
ID DNA METHYLATION; IDENTIFICATION; GENE; ASSIGNMENT; ESTROGEN; PATTERN;
   1Q32
AB Cancer is a group of disorders characterized by uncontrolled cell growth which is produced by two successive events: increased cell proliferation (tumor or neoplasia) and the invasive capacity of these cells (metastasis). DNA methylation is an epigenetic process which has been involved as an important pathogenic factor of cancer. DNA methylation participates in the regulation of gene expression, directly, by preventing the union of transcription factors, and indirectly, by promoting the "closed" structure of the chromatine. The objectives of this study were to identify hypermethyled chromosomal regions through the use of restriction Alu I endonuclease, and to relate cytogenetically these regions with tumor suppressive gene loci. Sixty peripheral blood samples of females with breast cancer were analyzed. Cell cultures were performed and cytogenetic spreads, previously digested with Alu I enzyme, were stained with Giemsa. Chromosomal centromeric and not centromeric regions were stained in 37% of cases. About 96% of stained hypermethyled chromosomal regions (1q, 2q, 6q) were linked with methylated genes associated with breast cancer. In addition, centromeric regions in chromosomes 3, 4, 8, 13, 14, 15 and 17, usually unstained, were found positive to digestion with Alu I enzime and Giemsa staining. We suggest the importance of this technique for the global visualization of the genome which can find methylated genes related to breast cancer, and thus lead to a specific therapy, and therefore a better therapeutic response.
C1 [Rojas-Atencio, Alicia; Yamarte, Leonard; Urdaneta, Karelis; Soto-Alvarez, Marisol; Alvarez Nava, Francisco; Canizalez, Jenny; Quintero, Maribel; Atencio, Raquel; Gonzalez, Richard] Univ Zulia, Fac Med, Inst Invest Genet, Maracaibo 4011, Venezuela.
RP Rojas-Atencio, A (通讯作者)，Univ Zulia, Fac Med, Inst Invest Genet, Maracaibo 4011, Venezuela.
EM arojasa26@gmail.com
RI Soto, Marisol/AAR-6689-2021; Gonzalez, Richard/B-6449-2008
OI Soto, Marisol/0000-0003-4213-9273
CR Adonis R Waldo, 2006, Rev. chil. enferm. respir., V22, P7
   BIANCHI MS, 1985, CHROMOSOMA, V91, P131, DOI 10.1007/BF00294057
   BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993
   Bozcuk H, 2001, BREAST CANCER RES TR, V68, P239, DOI 10.1023/A:1012269804578
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   COUCH FJ, 2001, METABOLIC MOL BASIS, P999
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Fabianowska-Majewska K, 2006, NUCLEOS NUCLEOT NUCL, V25, P1025, DOI 10.1080/15257770600890640
   Feng W, 2007, BREAST CANCER RES, V94, P50
   Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007
   Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966
   GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938
   Hekimian K, 2012, INT SCHOLARLY RES NE, V2012
   Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51
   Hong SJ, 2005, J KOREAN MED SCI, V20, P790, DOI 10.3346/jkms.2005.20.5.790
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   KAELBLING M, 1984, CHROMOSOMA, V90, P128, DOI 10.1007/BF00292449
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Leslie MC, 2005, J CELL BIOCHEM, V94, P25, DOI 10.1002/jcb.20296
   Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245
   Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7
   Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06
   Maniotis AJ, 2005, AM J PATHOL, V166, P1187, DOI 10.1016/S0002-9440(10)62338-3
   MEZZANOTTE R, 1983, J HISTOCHEM CYTOCHEM, V31, P553, DOI 10.1177/31.4.6298309
   Ministerio Del Poder Popular Para La Salud, 2007, AN EP 2006
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   Müller HM, 2003, CANCER RES, V63, P7641
   Orsetti B, 2006, BRIT J CANCER, V95, P1439, DOI 10.1038/sj.bjc.6603433
   OZAWA K, 1991, GENOMICS, V10, P1103, DOI 10.1016/0888-7543(91)90210-6
   Pandis N, 1996, INT J CANCER, V66, P191, DOI 10.1002/(SICI)1097-0215(19960410)66:2<191::AID-IJC9>3.0.CO;2-Y
   Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684
   Riemenschneider MJ, 1999, CANCER RES, V59, P6091
   Roa S Juan Carlos, 2004, Rev. méd. Chile, V132, P1069
   Rojas-Atencio A, 1999, Invest Clin, V40, P179
   Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058
   Shaffer LG., 2005, INT SYSTEM HUMAN CYT
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Shimizu F, 1997, CYTOGENET CELL GENET, V77, P261, DOI 10.1159/000134591
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Tommasi S, 2009, BREAST CANCER RES, V1, P1
   Verma RS, 1995, HUMAN CHROMOSOMES PR, P235
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xiang S, 2010, BMC CANCER, V17, P1
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yunis J, 1975, HUMAN GENET, V2, P1
   YUNIS JJ, 1981, HUM PATHOL, V12, P540, DOI 10.1016/S0046-8177(81)80068-8
NR 48
TC 0
Z9 0
U1 0
U2 6
PU INST INVESTIGACION CLINICA
PI MARACAIBO
PA APARTADO 23, MARACAIBO 4001-A, VENEZUELA
SN 0535-5133
J9 INVEST CLIN
JI Invest. Clin.
PD DEC
PY 2012
VL 53
IS 4
BP 331
EP 341
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 079BB
UT WOS:000314144100002
PM 23513484
DA 2025-01-12
ER

PT J
AU Connolly, R
   Stearns, V
AF Connolly, Roisin
   Stearns, Vered
TI Epigenetics as a Therapeutic Target in Breast Cancer
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE Epigenetics; Breast cancer; DNA methyltransferase inhibitor (DNMT);
   Histone deacetylase inhibitor (HDAC)
ID SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITOR; CPG
   ISLAND HYPERMETHYLATION; PHASE-II TRIAL; DNA METHYLATION; SOLID TUMORS;
   MYELODYSPLASTIC SYNDROMES; HDAC INHIBITOR; CELLS; EXPRESSION
AB Epigenetics refers to alterations in gene expression due to modifications in histone acetylation and DNA methylation at the promoter regions of genes. Unlike genetic mutations, epigenetic alterations are not due to modifications in the gene primary nucleotide sequence. The importance of epigenetics in the initiation and progression of breast cancer has led many investigators to incorporate this novel and exciting field in breast cancer drug development. Several drugs that target epigenetic alterations, including inhibitors of histone deacetylase (HDAC) and DNA methyltransferase (DNMT), are currently approved for treatment of hematological malignancies and are available for clinical investigation in solid tumors. In this manuscript, we review the critical role of epigenetics in breast cancer including the potential for epigenetic alterations to serve as biomarkers determining breast cancer prognosis and response to therapy. We highlight initial promising results to date with use of epigenetic modifiers in patients with breast cancer and the ongoing challenges involved in the successful establishment of these agents for the treatment of breast cancer.
C1 [Connolly, Roisin; Stearns, Vered] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Stearns, V (通讯作者)，Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB 1,Room 145, Baltimore, MD 21231 USA.
EM rconnol2@jhmi.edu; vstearn1@jhmi.edu
FU Specialized Program Of Research Excellence in Breast Cancer [P50
   CA88843]; Stand Up To Cancer; QVC; Fashion Footwear Association of New
   York (FFANY); Abraxis; Merck; Novartis; Pfizer
FX Supported by Specialized Program Of Research Excellence in Breast Cancer
   (P50 CA88843), Stand Up To Cancer, and QVC and Fashion Footwear
   Association of New York (FFANY).Dr. Stearns has received
   investigator-initiated grants from Abraxis, Merck, Novartis, and Pfizer.
CR Arts J, 2003, CURR MED CHEM, V10, P2343, DOI 10.2174/0929867033456657
   Bali P, 2005, CLIN CANCER RES, V11, P6382, DOI 10.1158/1078-0432.CCR-05-0344
   Brock MV, 2008, NEW ENGL J MED, V358, P1118, DOI 10.1056/NEJMoa0706550
   CASSIDY J, 1982, EUR J CANCER CLIN ON, V18, P925, DOI 10.1016/0277-5379(82)90239-5
   Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048
   Cohen LA, 1999, ANTICANCER RES, V19, P4999
   Connolly RM, SABCS 2011 ONG TRIAL
   Connolly RM, 2012, J CLIN ONCOL, V30
   Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fackler MJ, 2009, CLIN CANCER RES, V15, P3802, DOI 10.1158/1078-0432.CCR-08-1981
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Ferracin M, 2011, SEMIN ONCOL, V38, P764, DOI 10.1053/j.seminoncol.2011.08.005
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Foulks JM, 2012, J BIOMOL SCREEN, V17, P2, DOI 10.1177/1087057111421212
   Fu SQ, 2011, CANCER-AM CANCER SOC, V117, P1661, DOI 10.1002/cncr.25701
   Fuino L, 2003, MOL CANCER THER, V2, P971
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080
   Gore SD, 2001, CLIN CANCER RES, V7, P2330
   Gray R, 2009, J CLIN ONCOL, V27, P4966, DOI 10.1200/JCO.2008.21.6630
   Gupta A, 2003, CANCER RES, V63, P664
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hodges-Gallagher L, 2007, BREAST CANCER RES TR, V105, P297, DOI 10.1007/s10549-006-9459-6
   Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823
   Huang XP, 2011, CANCER LETT, V307, P72, DOI 10.1016/j.canlet.2011.03.019
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Kim MS, 2003, CANCER RES, V63, P7291
   Krawczyk B, 2007, NUCLEOS NUCLEOT NUCL, V26, P1043, DOI 10.1080/15257770701509594
   Krawczyk B, 2006, NUCLEOS NUCLEOT NUCL, V25, P1029, DOI 10.1080/15257770600890764
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Licchesi Julien D. F., 2009, V507, P305, DOI 10.1007/978-1-59745-522-0_22
   Lujambio A, 2007, CELL CYCLE, V6, P1455
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Metzeler KH, 2012, LEUKEMIA, V26, P1106, DOI 10.1038/leu.2011.342
   Miyake K, 2008, PANCREAS, V36, pE1, DOI 10.1097/MPA.0b013e31815f2c2a
   Munshi A, 2009, J GENET GENOMICS, V36, P75, DOI 10.1016/S1673-8527(08)60094-6
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Munster PN, 2009, BRIT J CANCER, V101, P1044, DOI 10.1038/sj.bjc.6605293
   Munster PN, 2001, CANCER RES, V61, P8492
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   Ordentlich P, 2011, AACR MOL TARG C 2011
   PEDRALINOY G, 1986, J BIOL CHEM, V261, P7600
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182/blood-2010-10-312603
   Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150
   Pomraning KR, 2009, METHODS, V47, P142, DOI 10.1016/j.ymeth.2008.09.022
   Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785
   Pu RT, 2003, MODERN PATHOL, V16, P1095, DOI 10.1097/01.MP.0000095782.79895.E2
   Qin T, 2007, CLIN CANCER RES, V13, P4225, DOI 10.1158/1078-0432.CCR-06-2762
   Raffoux E, 2010, ONCOTARGET, V1, P34, DOI 10.18632/oncotarget.106
   Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162
   Ramaswamy B, 2012, BREAST CANCER RES TR, V132, P1063, DOI 10.1007/s10549-011-1928-x
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Said TK, 2001, BREAST CANCER RES, V3, P122, DOI 10.1186/bcr284
   Scandura JM, 2011, BLOOD, V118, P1472, DOI 10.1182/blood-2010-11-320093
   Schrauder MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029770
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Stathis A, 2011, CLIN CANCER RES, V17, P1582, DOI 10.1158/1078-0432.CCR-10-1893
   Stearns V, 2010, J CLIN ONCOLOGY S, P28
   Steensma DP, 2009, J CLIN ONCOL, V27, P3842, DOI 10.1200/JCO.2008.19.6550
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Tserga A, 2012, ONCOL REP, V27, P1630, DOI 10.3892/or.2011.1576
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047
   WEISS AJ, 1972, CANCER CHEMOTH REP 1, V56, P413
   WEISS AJ, 1977, CANCER TREAT REP, V61, P55
   Whittaker SJ, 2010, J CLIN ONCOL, V28, P4485, DOI 10.1200/JCO.2010.28.9066
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624
   Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   Yang XW, 2001, CANCER RES, V61, P7025
   Yao Y, 2011, J AM CHEM SOC, V133, P16746, DOI 10.1021/ja206312b
   Yardley DA, 2011, SAN ANT BREAST CANC
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5
NR 95
TC 83
Z9 98
U1 1
U2 62
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083-3021
EI 1573-7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD DEC
PY 2012
VL 17
IS 3-4
SI SI
BP 191
EP 204
DI 10.1007/s10911-012-9263-3
PG 14
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 061YN
UT WOS:000312886300002
PM 22836913
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Lobikin, M
   Chernet, B
   Lobo, D
   Levin, M
AF Lobikin, Maria
   Chernet, Brook
   Lobo, Daniel
   Levin, Michael
TI Resting potential, oncogene-induced tumorigenesis, and metastasis: the
   bioelectric basis of cancer <i>in vivo</i>
SO PHYSICAL BIOLOGY
LA English
DT Article
ID SODIUM-CHANNEL EXPRESSION; CENTRAL-NERVOUS-SYSTEM; HUMAN
   PROSTATE-CANCER; SEROTONIN-LIKE IMMUNOREACTIVITY; SOMATIC MUTATION
   THEORY; HERG K+ CHANNEL; CELL-PROLIFERATION; POTASSIUM CHANNELS;
   BREAST-CANCER; ION CHANNELS
AB Cancer may result from localized failure of instructive cues that normally orchestrate cell behaviors toward the patterning needs of the organism. Steady-state gradients of transmembrane voltage (V-mem) in non-neural cells are instructive, epigenetic signals that regulate pattern formation during embryogenesis and morphostatic repair. Here, we review molecular data on the role of bioelectric cues in cancer and present new findings in the Xenopus laevis model on how the microenvironment's biophysical properties contribute to cancer in vivo. First, we investigated the melanoma-like phenotype arising from serotonergic signaling by 'instructor' cells-a cell population that is able to induce a metastatic phenotype in normal melanocytes. We show that when these instructor cells are depolarized, blood vessel patterning is disrupted in addition to the metastatic phenotype induced in melanocytes. Surprisingly, very few instructor cells need to be depolarized for the hyperpigmentation phenotype to occur; we present a model of antagonistic signaling by serotonin receptors that explains the unusual all-or-none nature of this effect. In addition to the body-wide depolarization-induced metastatic phenotype, we investigated the bioelectrical properties of tumor-like structures induced by canonical oncogenes and cancer-causing compounds. Exposure to carcinogen 4-nitroquinoline 1-oxide (4NQO) induces localized tumors, but has a broad (and variable) effect on the bioelectric properties of the whole body. Tumors induced by oncogenes show aberrantly high sodium content, representing a non-invasive diagnostic modality. Importantly, depolarized transmembrane potential is not only a marker of cancer but is functionally instructive: susceptibility to oncogene-induced tumorigenesis is significantly reduced by forced prior expression of hyperpolarizing ion channels. Importantly, the same effect can be achieved by pharmacological manipulation of endogenous chloride channels, suggesting a strategy for cancer suppression that does not require gene therapy. Together, these data extend our understanding of the recently demonstrated role of transmembrane potential in tumor formation and metastatic cell behavior. V-mem is an important non-genetic biophysical aspect of the microenvironment that regulates the balance between normally patterned growth and carcinogenesis.
C1 [Levin, Michael] Tufts Univ, Dept Biol, Medford, MA 02155 USA.
   Tufts Univ, Tufts Ctr Regenerat & Dev Biol, Medford, MA 02155 USA.
C3 Tufts University; Tufts University
RP Levin, M (通讯作者)，Tufts Univ, Dept Biol, 200 Boston Ave, Medford, MA 02155 USA.
EM michael.levin@tufts.edu
RI Levin, Michael/A-5918-2011
OI Lobo, Daniel/0000-0003-4666-6118; Levin, Michael/0000-0001-7292-8084
FU NIH [AR061988, AR055993]; G Harold and Leila Y Mathers Charitable
   Foundation
FX We thank Paul Mead for his kind assistance and gift of the transgenic
   flk1-GFP frogs, John Adelman for the Kir4.1 construct, Ruiz I Altaba for
   the Gli1 construct, Leonard Zon for the KRAS mutant construct, Punita
   Koustubhan and Amber Currier for general lab assistance and frog
   husbandry, Joan Lemire and Claire Stevenson for molecular biology
   assistance, Vaibhav Pai for advice on serotonergic signaling pathways,
   Joan Lemire for valuable comments on the manuscript, and the members of
   the Levin lab and the bioelectricity community for many useful
   discussions. ML is grateful for support of the NIH (awards AR061988,
   AR055993) and the G Harold and Leila Y Mathers Charitable Foundation.
CR Åberg P, 2004, IEEE T BIO-MED ENG, V51, P2097, DOI 10.1109/TBME.2004.836523
   Adams DS, 2007, DEVELOPMENT, V134, P1323, DOI 10.1242/dev.02812
   Adams DS, 2006, GENESIS, V44, P530, DOI 10.1002/dvg.20246
   Adams DS, 2013, CELL TISSUE RES, V352, P95, DOI 10.1007/s00441-012-1329-4
   Adams DS, 2006, DEVELOPMENT, V133, P1657, DOI 10.1242/dev.02341
   Adams DS, 2012, COLD SPRING IN PRESS
   Adams SV, 2002, BIOPHYS J, V83, P3268, DOI 10.1016/S0006-3495(02)75328-9
   Antonyak MA, 2011, P NATL ACAD SCI USA, V108, P4852, DOI 10.1073/pnas.1017667108
   Arcangeli A, 2009, CURR MED CHEM, V16, P66, DOI 10.2174/092986709787002835
   Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065
   Arcangeli Annarosa, 2005, V266, P225
   Aw S, 2008, MECH DEVELOP, V125, P353, DOI 10.1016/j.mod.2007.10.011
   Baker SG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-89
   Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6
   Beane WS, 2011, CHEM BIOL, V18, P77, DOI 10.1016/j.chembiol.2010.11.012
   Becchetti A, 2011, AM J PHYSIOL-CELL PH, V301, pC255, DOI 10.1152/ajpcell.00047.2011
   Bianchi L, 1998, CANCER RES, V58, P815
   BINGGELI R, 1986, J THEOR BIOL, V123, P377, DOI 10.1016/S0022-5193(86)80209-0
   Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013
   Bizzarri M, 2008, ACTA BIOTHEOR, V56, P173, DOI 10.1007/s10441-008-9047-8
   Bizzarri M, 2011, CURR PHARM BIOTECHNO, V12, P243, DOI 10.2174/138920111794295701
   Blackiston D, 2011, DIS MODEL MECH, V4, P67, DOI 10.1242/dmm.005561
   Blackiston DJ, 2009, CELL CYCLE, V8, P3527, DOI 10.4161/cc.8.21.9888
   Borgens R.B., 1986, Progress in Clinical and Biological Research, V210, P239
   Boroughs LK, 2011, J BIOL CHEM, V286, P37094, DOI 10.1074/jbc.M111.242438
   Brackenbury WJ, 2006, J PHYSIOL-LONDON, V573, P343, DOI 10.1113/jphysiol.2006.106906
   Brackenbury WJ, 2008, NEUROSCIENTIST, V14, P571, DOI 10.1177/1073858408320293
   BRANDES LJ, 1992, CANCER RES, V52, P3796
   Brink PR, 2012, BBA-BIOMEMBRANES, V1818, P2076, DOI 10.1016/j.bbamem.2011.09.025
   Burr H S, 1938, Yale J Biol Med, V10, P539
   BURR H. S., 1941, YALE JOUR BIOL AND MED, V13, P783
   Burr H S, 1940, Yale J Biol Med, V12, P277
   Buznikov GA, 2001, CELL TISSUE RES, V305, P177, DOI 10.1007/s004410100408
   CAMERON I L, 1980, Scanning Electron Microscopy, P463
   CAMERON IL, 1979, J CELL PHYSIOL, V101, P493, DOI 10.1002/jcp.1041010315
   CAMERON IL, 1979, J CELL BIOL, V80, P444, DOI 10.1083/jcb.80.2.444
   CAMERON IL, 1980, CANCER RES, V40, P1493
   CAMERON IL, 1989, MAGNESIUM, V8, P31
   Carneiro K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-29
   Chernet B, 2012, TRANSMEMBRANE UNPUB
   Chernet Brook T, 2012, Cold Spring Harb Protoc, V2012, P447, DOI 10.1101/pdb.prot067694
   CONE CD, 1976, SCIENCE, V192, P155, DOI 10.1126/science.56781
   CONE CD, 1974, ANN NY ACAD SCI, V238, P420, DOI 10.1111/j.1749-6632.1974.tb26808.x
   Conti Matteo, 2004, J Exp Ther Oncol, V4, P161
   Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918
   Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a
   Dinicola S, 2011, OMICS, V15, P93, DOI 10.1089/omi.2010.0091
   Diss JKJ, 2005, PROSTATE CANCER P D, V8, P266, DOI 10.1038/sj.pcan.4500796
   Dizeyi N, 2004, PROSTATE, V59, P328, DOI 10.1002/pros.10374
   Doherty JR, 2007, DEV DYNAM, V236, P2808, DOI 10.1002/dvdy.21321
   DONALDSON DJ, 1975, GROWTH, V39, P475
   ENGLISH KB, 1992, ANAT REC, V232, P112, DOI 10.1002/ar.1092320112
   Fakler B, 1996, PFLUG ARCH EUR J PHY, V433, P77, DOI 10.1007/s004240050251
   Fan Y, 2008, TRENDS CELL BIOL, V18, P467, DOI 10.1016/j.tcb.2008.08.001
   Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795
   Farias LMB, 2004, CANCER RES, V64, P6996, DOI 10.1158/0008-5472.CAN-04-1204
   Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894
   Fraser SP, 2000, PROSTATE, V44, P61, DOI 10.1002/1097-0045(20000615)44:1<61::AID-PROS9>3.0.CO;2-3
   Fraser SP, 2005, CLIN CANCER RES, V11, P5381, DOI 10.1158/1078-0432.CCR-05-0327
   Fukumoto T, 2005, CURR BIOL, V15, P794, DOI 10.1016/j.cub.2005.03.044
   Gallaher J, 2010, BIOSYSTEMS, V101, P149, DOI 10.1016/j.biosystems.2010.05.007
   Gupta D, 2004, AM J CLIN NUTR, V80, P1634, DOI 10.1093/ajcn/80.6.1634
   Gupta N, 2006, LIFE SCI, V78, P2419, DOI 10.1016/j.lfs.2005.10.028
   Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734
   Habela CW, 2008, J NEUROSCI, V28, P9205, DOI 10.1523/JNEUROSCI.1897-08.2008
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092
   Hilber B, 2005, NEUROPHARMACOLOGY, V49, P811, DOI 10.1016/j.neuropharm.2005.08.008
   HIROSE M, 1976, GANN, V67, P365
   House CD, 2010, CANCER RES, V70, P6957, DOI 10.1158/0008-5472.CAN-10-1169
   Huang S, 2009, SEMIN CELL DEV BIOL, V20, P869, DOI 10.1016/j.semcdb.2009.07.003
   Ingber DE, 2008, SEMIN CANCER BIOL, V18, P356, DOI 10.1016/j.semcancer.2008.03.016
   Jaffe L.F., 1979, Membrane Transduction Mechanisms
   JETER JR, 1982, CYTOBIOS, V35, P47
   JIRSCH J, 1993, CANCER RES, V53, P4156
   Johansson O, 1998, J INVEST DERMATOL, V111, P1010, DOI 10.1046/j.1523-1747.1998.00460.x
   Kannen V, 2011, TOXICOL LETT, V204, P134, DOI 10.1016/j.toxlet.2011.04.024
   Kasemeier-Kulesa JC, 2008, DEV DYNAM, V237, P2657, DOI 10.1002/dvdy.21613
   Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039
   Kim CJ, 2004, APMIS, V112, P588, DOI 10.1111/j.1600-0463.2004.apm1120905.x
   Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105
   KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7
   Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302
   Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103
   Lange C, 2011, STEM CELLS DEV, V20, P843, DOI 10.1089/scd.2010.0484
   Lastraioli E, 2004, CANCER RES, V64, P606, DOI 10.1158/0008-5472.CAN-03-2360
   Le XN, 2007, P NATL ACAD SCI USA, V104, P9410, DOI 10.1073/pnas.0611302104
   Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471
   Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282
   Leffert H L, 1980, Ann N Y Acad Sci, V339, P201, DOI 10.1111/j.1749-6632.1980.tb15979.x
   Levin M, 2002, CELL, V111, P77, DOI 10.1016/S0092-8674(02)00939-X
   Levin M, 1998, DEV BIOL, V203, P90, DOI 10.1006/dbio.1998.9024
   Levin M, 2011, BIOESSAYS IN PRESS
   Levin M, 2006, DEV NEUROSCI-BASEL, V28, P171, DOI 10.1159/000091915
   Levin M, 2011, REGEN MED, V6, P667, DOI [10.2217/rme.11.69, 10.2217/RME.11.69]
   Levin M, 2009, SEMIN CELL DEV BIOL, V20, P543, DOI 10.1016/j.semcdb.2009.04.013
   Li Bo, 2011, Adv Enzymol Relat Areas Mol Biol, V78, P247
   Lin HX, 2007, J CELL PHYSIOL, V212, P137, DOI 10.1002/jcp.21015
   Lund E., 1947, Bioelectric fields and growth
   Lynagh T, 2010, J BIOL CHEM, V285, P14890, DOI 10.1074/jbc.M110.107789
   MANDA T, 1988, CANCER RES, V48, P4250
   Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5
   McCaig CD, 2005, PHYSIOL REV, V85, P943, DOI 10.1152/physrev.00020.2004
   McCaig CD, 2009, J CELL SCI, V122, P4267, DOI 10.1242/jcs.023564
   Meredith EJ, 2005, FASEB J, V19, P1187, DOI 10.1096/fj.04-3477fje
   Meyer R, 1999, J MEMBRANE BIOL, V171, P107, DOI 10.1007/s002329900563
   Moiseiwitsch JRD, 2000, CRIT REV ORAL BIOL M, V11, P230, DOI 10.1177/10454411000110020601
   MONACHON MA, 1972, N-S ARCH PHARMACOL, V274, P192, DOI 10.1007/BF00501854
   Morokuma J, 2008, P NATL ACAD SCI USA, V105, P16608, DOI 10.1073/pnas.0808328105
   Mu D, 2003, CANCER CELL, V3, P297, DOI 10.1016/S1535-6108(03)00054-0
   Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397
   Needham J, 1963, CHEM EMBRYOLOGY
   NEEDHAM JOSEPH, 1936, PROC ROY SOC MED, V29, P1577
   Nguyen L, 2001, CELL TISSUE RES, V305, P187, DOI 10.1007/s004410000343
   Nieuwkoop PD., 1967, Normal Table of Xenopus Laevis (Daudin)
   O'Grady SM, 2005, INT J BIOCHEM CELL B, V37, P1578, DOI 10.1016/j.biocel.2005.04.002
   Onganer PU, 2005, BRIT J CANCER, V93, P1197, DOI 10.1038/sj.bjc.6602857
   Onganer PU, 2005, J MEMBRANE BIOL, V204, P67, DOI 10.1007/s00232-005-0747-6
   Onkal R, 2009, EUR J PHARMACOL, V625, P206, DOI 10.1016/j.ejphar.2009.08.040
   OTTESEN EA, 1994, J ANTIMICROB CHEMOTH, V34, P195, DOI 10.1093/jac/34.2.195
   Ousingsawat J, 2008, PFLUG ARCH EUR J PHY, V456, P847, DOI 10.1007/s00424-008-0451-3
   Pai VP, 2008, J BIOL CHEM, V283, P30901, DOI 10.1074/jbc.M802476200
   Pai VP, 2012, DEVELOPMENT, V139, P313, DOI 10.1242/dev.073759
   Pai VP, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2448
   Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540
   Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004
   Paulmann N, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000229
   Pei L, 2003, P NATL ACAD SCI USA, V100, P7803, DOI 10.1073/pnas.1232448100
   PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0
   Potter JD, 2001, CANCER EPIDEM BIOMAR, V10, P161
   Potter JD, 2007, NAT REV CANCER, V7, P464, DOI 10.1038/nrc2146
   Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005
   Pu J, 2007, J CELL SCI, V120, P3395, DOI 10.1242/jcs.002774
   Pullar CE, 2007, J CELL PHYSIOL, V211, P261, DOI 10.1002/jcp.20934
   Roepke TK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011451
   ROSE SM, 1948, SCIENCE, V107, P457
   Roskelley CD, 2002, SEMIN CANCER BIOL, V12, P97, DOI 10.1006/scbi.2001.0417
   Rowlatt C., 1994, New Frontiers in Cancer Causation, P45
   Rozengurt E, 1980, Ann N Y Acad Sci, V339, P175, DOI 10.1111/j.1749-6632.1980.tb15977.x
   RUBIN H, 1985, CANCER RES, V45, P2935
   RUBIN H, 1990, CANCER METAST REV, V9, P1, DOI 10.1007/BF00047585
   Sachdeva G, 2010, BIOL CYBERN, V102, P109, DOI 10.1007/s00422-009-0352-3
   Saito T, 1998, ONCOGENE, V17, P1673, DOI 10.1038/sj.onc.1202092
   Seilern-Aspang F., 1965, Regeneration in animals and related problems, P452
   Shan Q, 2001, J BIOL CHEM, V276, P12556, DOI 10.1074/jbc.M011264200
   Shuba YM, 2000, AM J PHYSIOL-CELL PH, V279, pC1144, DOI 10.1152/ajpcell.2000.279.4.C1144
   Sive H.L., 2000, Early Development of Xenopus Laevis: A Laboratory Manual
   Slominski A, 2004, BBA-GENE STRUCT EXPR, V1680, P67, DOI 10.1016/j.bbaexp.2004.09.002
   Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287
   Slominski A, 2009, EXP DERMATOL, V18, P760, DOI 10.1111/j.1600-0625.2009.00892.x
   SMITH NR, 1978, CANCER RES, V38, P1952
   Sonnenschein C., 1999, SOC CELLS CANC CONTR
   Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087
   SPARKS RL, 1983, CANCER RES, V43, P73
   Stojadinovic A, 2005, J CLIN ONCOL, V23, P2703, DOI 10.1200/JCO.2005.06.155
   Stull MA, 2007, P NATL ACAD SCI USA, V104, P16708, DOI 10.1073/pnas.0708136104
   Sundelacruz S, 2009, STEM CELL REV REP, V5, P231, DOI 10.1007/s12015-009-9080-2
   Sundelacruz S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003737
   Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2
   Tseng A-S, 2012, ANAT REC IN PRESS
   Tseng AS, 2010, J NEUROSCI, V30, P13192, DOI 10.1523/JNEUROSCI.3315-10.2010
   TSONIS PA, 1987, ANTICANCER RES, V7, P617
   Vaux DL, 2011, BIOESSAYS, V33, P660, DOI 10.1002/bies.201100063
   Vicaut E, 2000, ANN MED, V32, P187, DOI 10.3109/07853890008998826
   Volkov AG, 2012, PLANT SIGNAL BEHAV, V7, P282, DOI 10.4161/psb.18798
   Volkov AG, 2011, J PLANT PHYSIOL, V168, P1753, DOI 10.1016/j.jplph.2011.03.012
   Volkov AG, 2011, BIOELECTROCHEMISTRY, V81, P39, DOI 10.1016/j.bioelechem.2011.01.004
   Waddington CH, 1935, NATURE, V135, P606, DOI 10.1038/135606a0
   Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2
   Walther DJ, 2003, CELL, V115, P851, DOI 10.1016/S0092-8674(03)01014-6
   Wang HZ, 2002, CANCER RES, V62, P4843
   Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5
   Weissenberger S, 2011, J NEUROCHEM, V116, P616, DOI 10.1111/j.1471-4159.2010.07148.x
   Williams SR, 2002, J PHYSIOL-LONDON, V539, P469, DOI 10.1113/jphysiol.2001.013136
   Wimalasena K, 2011, MED RES REV, V31, P483, DOI 10.1002/med.20187
   WOLSKY A, 1978, GROWTH, V42, P425
   Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089
   Yang SS, 1998, J BIOL CHEM, V273, P13746, DOI 10.1074/jbc.273.22.13746
   Yasuda T, 2010, J NEUROCHEM, V114, P946, DOI 10.1111/j.1471-4159.2010.06822.x
   Zhao M, 2006, NATURE, V442, P457, DOI 10.1038/nature04925
NR 183
TC 129
Z9 139
U1 2
U2 39
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1478-3967
EI 1478-3975
J9 PHYS BIOL
JI Phys. Biol.
PD DEC
PY 2012
VL 9
IS 6
AR 065002
DI 10.1088/1478-3975/9/6/065002
PG 22
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 047KN
UT WOS:000311839500003
PM 23196890
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Acar, M
   Çora, T
   Toy, H
   Acar, H
AF Acar, Muradiye
   Cora, Tulin
   Toy, Hatice
   Acar, Hasan
TI Analysis of promoter methylation of <i>Dickkopf1</i> (<i>DKK1</i>) gene
   in breast cancer
SO TURKISH JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Breast cancer; Dickkopf1; DNA methylation
ID WNT SIGNALING PATHWAY; FREQUENT EPIGENETIC INACTIVATION; ACUTE
   MYELOID-LEUKEMIA; BETA-CATENIN/TCF; DNA METHYLATION; NORMAL-TISSUES;
   HYPERMETHYLATION; TUMOR; EXPRESSION; CARCINOMAS
AB Aim: Breast cancer is the most common malignancy in women worldwide. The Dickkopf1 (DKK1) gene product is a potent inhibitor of the Wnt pathway. DKK1 methylation status and its protein expression were examined in normal and cancer tissues of breast cancer patients.
   Materials and methods: We examined methylation changes in 83 tumor and adjacent normal tissues, and also in 9 normal breast tissues from unaffected women (no breast cancer history) as controls. DKK1 promoter methylation was assessed by methylation-specific polymerase chain reaction. Immunohistochemical staining was used to investigate DKK1 protein expression in the 9 controls and in 70 out of the 83 tumors as well as their adjacent normal tissues. Immunohistochemical results were categorized as positive or negative for DKK1.
   Results: DKK1 gene methylation was detected in 3 out of the 9 (33%) normal breast tissue samples of unaffected women. The DKK1 gene was hypermethylated in 58 out of the 83 (70%) tumor samples and 51 out of the 83 (61%) adjacent normal tissue samples. In immunohistochemistry, 33% of normal breast tissue from unaffected women, 31% of the tumors, and 17% of the adjacent normal tissues in the breast cancer patients were found to be DKK1-positive. DKK1 promoter methylation and protein expression were not associated with age, tumor size, lymph node status, histological grade, estrogen/progesterone receptor status, or HER2 positivity.
   Conclusion: Our results indicate that there is a concordant DKK1 methylation change between normal and cancerous breast tissue.
C1 [Acar, Muradiye; Cora, Tulin; Acar, Hasan] Selcuk Univ, Dept Med Genet, Fac Med, Konya, Turkey.
   [Acar, Muradiye; Toy, Hatice] Fatih Univ, Dept Med Genet, Fac Med, Ankara, Turkey.
   Selcuk Univ, Dept Pathol, Fac Med, Konya, Turkey.
C3 Selcuk University; Fatih University; Selcuk University
RP Acar, M (通讯作者)，Fatih Univ, Dept Med Genet, Fac Med, Anadolu Bulvari,Camlica Mah 16-A, Ankara, Turkey.
EM acarmuradiye@hotmail.com
RI acar, muradiye/B-6537-2019
OI acar, muradiye/0000-0003-4357-5229
CR Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128
   Belshaw NJ, 2008, BRIT J CANCER, V99, P136, DOI 10.1038/sj.bjc.6604432
   Bozkurt C, 2011, TURK J MED SCI, V41, P633, DOI 10.3906/sag-0909-296
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057
   Esteller M, 2001, CANCER RES, V61, P3225
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gonzálex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Griffiths EA, 2010, LEUKEMIA LYMPHOMA, V51, P1711, DOI 10.3109/10428194.2010.496505
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0
   Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702
   Makino T, 2009, ANN SURG ONCOL, V16, P2058, DOI 10.1245/s10434-009-0476-7
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki R, 2007, BRIT J HAEMATOL, V138, P624, DOI 10.1111/j.1365-2141.2007.06702.x
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Tokatli ZF, 2011, TURK J MED SCI, V41, P769, DOI 10.3906/sag-0909-257
   Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   Van der Auwera I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-97
   Wang SZ, 2009, INT J BIOL MARKER, V24, P165, DOI 10.1177/172460080902400306
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD
   Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
   Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020
   Zhou YX, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-138
   Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8
NR 41
TC 4
Z9 4
U1 0
U2 10
PU Tubitak Scientific & Technological Research Council Turkey
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, TR-06100 ANKARA, TURKIYE
SN 1300-0144
EI 1303-6165
J9 TURK J MED SCI
JI Turk. J. Med. Sci.
PD DEC
PY 2012
VL 42
SU 2
BP 1379
EP 1387
DI 10.3906/sag-1204-30
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 175JH
UT WOS:000321226500004
OA Bronze
DA 2025-01-12
ER

PT J
AU Gu, S
   Tian, YF
   Chlenski, A
   Salwen, HR
   Lu, ZY
   Raj, JU
   Yang, QW
AF Gu, Song
   Tian, Yufeng
   Chlenski, Alexandre
   Salwen, Helen R.
   Lu, Ziyan
   Raj, J. Usha
   Yang, Qiwei
TI Valproic acid shows a potent antitumor effect with alteration of DNA
   methylation in neuroblastoma
SO ANTI-CANCER DRUGS
LA English
DT Article
DE cell cycle; cell proliferation; DNA methylation; histone acetylation;
   histone deacetylase; neuroblastoma; valproic acid
ID DEPENDENT KINASE INHIBITORS; CELL-CYCLE ARREST; N-MYC; SODIUM VALPROATE;
   POOR-PROGNOSIS; BREAST-CANCER; GROWTH; GENE; EXPRESSION; APOPTOSIS
AB Epigenetic aberrations and a CpG island methylator phenotype are associated with poor outcome in children with neuroblastoma (NB). Previously, we have shown that valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, exerts antitumor effects in an NB xenograft model. However, the underlying antitumor molecular mechanisms are largely unknown. In this study, we examined the role of HDAC in cell proliferation, cell cycle progression, gene expression patterns, and epigenome in NB. Cell proliferation, cell cycle progression, caspase activity, RNA and protein expression, quantitative methylation, and global DNA methylation were examined in NBL-W-N and LA1-55n NB cell lines. Our studies showed that inhibition of HDAC decreased NB proliferation, and induced caspase activity and G(1) growth arrest. Expression patterns of cancer-related genes were modulated by VPA. The expression of THBS1, CASP8, SPARC, CDKN1A, HIC1, CDKN1B, and HIN1 was upregulated, and that of MYCN and TIG1 was downregulated. HDAC inhibition decreased methylation levels of THBS1 and RASSF1A promoters. Inhibition of HDAC increased acetylation of histone 4 and overall DNA methylation levels. Our studies showed that inhibition of HDAC blocked cell proliferation and cell cycle progression in relation to alteration in cancer-related genes, increased overall DNA methylation, and decreased methylation of tumor suppressor genes. Further studies examining the antitumor effects of VPA in NB are warranted. Anti-Cancer Drugs 23:1054-1066 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Lu, Ziyan; Raj, J. Usha; Yang, Qiwei] Univ Illinois, Dept Pediat, Chicago, IL 60612 USA.
   [Gu, Song] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Pediat Surg, Shanghai 200030, Peoples R China.
   [Tian, Yufeng] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Gu, Song; Tian, Yufeng; Chlenski, Alexandre; Salwen, Helen R.; Yang, Qiwei] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Shanghai Jiao Tong University;
   University of Chicago; University of Chicago
RP Yang, QW (通讯作者)，Univ Illinois, Dept Pediat, 840 S Wood St,Mailcode 856, Chicago, IL 60612 USA.
EM qiwei@uic.edu
RI Yang, Qiwei/AAI-7414-2021
OI , Qiwei Yang/0000-0001-7131-8946
FU Children's Neuroblastoma Cancer Foundation; Comer Kids Classic Grant of
   University of Chicago; National Institutes of Health [R01 HL075187, R01
   HL059435]
FX This work was supported in part by Children's Neuroblastoma Cancer
   Foundation (Q.Y.), Comer Kids Classic Grant of University of Chicago
   (Q.Y.), and National Institutes of Health Grants R01 HL075187 (J.U.R.)
   and R01 HL059435 (J.U.R.).
CR Abe M, 2005, CANCER RES, V65, P828
   Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158
   Bidabadi Elham, 2010, Paediatr Drugs, V12, P269, DOI 10.2165/11316270-000000000-00000
   Cabello CM, 2009, BIOCHEM PHARMACOL, V77, P1125, DOI 10.1016/j.bcp.2008.12.002
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Chlenski A, 2002, CANCER RES, V62, P7357
   Cho YJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-91
   Cinatl J, 1996, ANTI-CANCER DRUG, V7, P766, DOI 10.1097/00001813-199609000-00008
   Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785
   Dong E, 2007, P NATL ACAD SCI USA, V104, P4676, DOI 10.1073/pnas.0700529104
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fortson WS, 2011, INT J ONCOL, V39, P111, DOI 10.3892/ijo.2011.1014
   Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028
   Georgiou E, 2011, CURR MED CHEM, V18, P1757, DOI 10.2174/092986711795496791
   Hsu YF, 2011, BBA-GEN SUBJECTS, V1810, P504, DOI 10.1016/j.bbagen.2011.02.006
   Janardhanan R, 2009, BRAIN RES, V1268, P142, DOI 10.1016/j.brainres.2009.02.064
   Krop I, 2005, CANCER RES, V65, P9659, DOI 10.1158/0008-5472.CAN-05-1663
   Liu NA, 2011, P NATL ACAD SCI USA, V108, P8414, DOI 10.1073/pnas.1018091108
   Lovell BV, 2010, EXPERT OPIN DRUG MET, V6, P495, DOI 10.1517/17425251003693547
   Michaelis M, 2004, INT J ONCOL, V25, P1795
   Mossman D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023127
   Peverali FA, 1996, ONCOGENE, V12, P457
   Ramos EAS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-23
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Rocchi P, 2005, ONCOL REP, V13, P1139
   SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171
   SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0
   Shah MY, 2010, CANCER RES, V70, P5840, DOI 10.1158/0008-5472.CAN-10-0847
   Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007
   THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0
   Tom M, 2009, J CLIN ONCOL, V27, P298
   Venkataramani V, 2010, J BIOL CHEM, V285, P10678, DOI 10.1074/jbc.M109.057836
   WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504
   Witt O, 2009, CURR PHARM DESIGN, V15, P436, DOI 10.2174/138161209787315774
   Wojdacz Tomasz K, 2008, BMC Res Notes, V1, P54, DOI 10.1186/1756-0500-1-54
   Wojdacz TK, 2009, EPIGENETICS-US, V4, P231, DOI 10.4161/epi.9020
   Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846
   Yang QW, 2007, CANCER RES, V67, P1716, DOI 10.1158/0008-5472.CAN-06-2595
   Yang QW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-286
   Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331
   Yang QW, 2004, CANCER RES, V64, P4531, DOI 10.1158/0008-5472.CAN-04-0956
   Yang QW, 2003, CANCER RES, V63, P6299
   Yao MY, 2011, PHARMACOL RES, V63, P13, DOI 10.1016/j.phrs.2010.10.014
   Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12
NR 44
TC 42
Z9 48
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4973
J9 ANTI-CANCER DRUG
JI Anti-Cancer Drugs
PD NOV
PY 2012
VL 23
IS 10
BP 1054
EP 1066
DI 10.1097/CAD.0b013e32835739dd
PG 13
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 016UH
UT WOS:000309544500007
PM 22863973
OA Green Accepted
DA 2025-01-12
ER

PT J
AU To, SQ
   Takagi, K
   Miki, Y
   Suzuki, K
   Abe, E
   Yang, Y
   Sasano, H
   Simpson, ER
   Knower, KC
   Clyne, CD
AF To, Sarah Q.
   Takagi, Kiyoshi
   Miki, Yasuhiro
   Suzuki, Koyu
   Abe, Eriko
   Yang, Yang
   Sasano, Hironobu
   Simpson, Evan R.
   Knower, Kevin C.
   Clyne, Colin D.
TI Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast
   cancer
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Aromatase; EP2; DNA methylation; Breast cancer; Epigenetics
ID CYTOCHROME-P450 CYP19 GENE; ADIPOSE STROMAL CELLS; DNA METHYLATION;
   PROMOTER HYPERMETHYLATION; AROMATASE EXPRESSION; TISSUE; PTGER2;
   FIBROBLASTS; TRANSCRIPTS; PROGRESSION
AB The increase in local oestrogen production seen in oestrogen receptor positive (ER+) breast cancers is driven by increased activity of the aromatase enzyme. CYP19A1, the encoding gene for aromatase, is often overexpressed in the oestrogen-producing cells of the breast adipose fibroblasts (BAFs) surrounding an ER+ tumour, and the molecular processes underlying this upregulation is important in the development of breast-specific aromatase inhibitors for breast cancer therapy. Prostaglandin E2 (PGE2), a factor secreted by tumours, is known to stimulate CYP19A1 expression in human BAFs. The hormonal regulation of this process has been examined: however, what is less well understood is the emerging role of epigenetic mechanisms and how they modulate PGE2 signalling. This present study characterises the epigenetic processes underlying expression of the prostanoid receptor EP2 in the context of ER+ breast cancer. Sodium bisulphite sequencing of CpG methylation within the promoter region of EP2 revealed that an inverse correlation existed between methylation levels and relative EP2 expression in breast cancer cell lines MDA-MB-231, MCF7 and MCF10A but not in HS578t and T47D. Inhibition of DNA methylation with 5-aza-2'-deoxycytidine (5aza) and histone deacetylation with Trichostatin A (TSA) resulted in upregulation of EP2 mRNA in all cell lines with varying influences of each epigenetic process observed. Expression of EP2 was detected in human BAFs despite a natively methylated promoter, and this expression was further increased upon 5aza treatment. An examination of 3 triple negative, 3 ductal carcinoma in situ and 3 invasive ductal carcinoma samples revealed that there was no change in EP2 promoter methylation status between normal and cancer associated stroma, despite observed differences in relative mRNA levels. Although EP2 methylation status is inversely correlated to expression levels in established breast cancer cell lines, we could not identify that such a correlation existed in tumour-associated stroma cells. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [To, Sarah Q.; Knower, Kevin C.; Clyne, Colin D.] Prince Henrys Inst Med Res, Canc Drug Discovery Lab, Clayton, Vic 3168, Australia.
   [To, Sarah Q.; Simpson, Evan R.; Clyne, Colin D.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.
   [Takagi, Kiyoshi; Miki, Yasuhiro; Sasano, Hironobu] Tohoku Grad Sch Med, Dept Pathol, Sendai, Miyagi, Japan.
   [Suzuki, Koyu; Abe, Eriko; Yang, Yang] St Lukes Int Hosp, Dept Pathol, Tokyo, Japan.
   [Simpson, Evan R.] Prince Henrys Inst Med Res, Metab & Canc Lab, Clayton, Vic 3168, Australia.
C3 Prince Henry's Institute of Medical Research; Monash University; Tohoku
   University; St. Luke's International Hospital; Prince Henry's Institute
   of Medical Research
RP Knower, KC (通讯作者)，Prince Henrys Inst Med Res, Canc Drug Discovery Lab, POB 5152, Clayton, Vic 3168, Australia.
EM kevin.knower@princehenrys.org
RI Miki, Yasuhiro/AFQ-3410-2022; Takagi, Kiyoshi/ABJ-3265-2022; Knower,
   Kevin/C-2869-2014
OI To, Sarah Quynh Giao/0000-0002-7198-484X
FU Australian Postgraduate Award; U.S. Department of Defense Post-doctoral
   Training Award [W81XWH-08-BCRP-POSTDOC]; National Health and Medical
   Research Council of Australia [338518, 550900]; Victoria Breast Cancer
   Research Consortium Inc.; Victorian Government's Operational
   Infrastructure Support Program
FX ST is supported by an Australian Postgraduate Award. KCK is supported by
   a U.S. Department of Defense Post-doctoral Training Award
   (W81XWH-08-BCRP-POSTDOC). This work was supported by the National Health
   and Medical Research Council of Australia through fellowships to CDC
   (#338518) and ERS (#550900); the Victoria Breast Cancer Research
   Consortium Inc.; and the Victorian Government's Operational
   Infrastructure Support Program. PHI Data Audit #12-01.
CR ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412
   Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843
   Agarwal VR, 1995, MOL CELL PROBE, V9, P453, DOI 10.1006/mcpr.1995.0069
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Brock MV, 2003, CLIN CANCER RES, V9, P2912
   BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622
   BULUN SE, 1994, TRENDS ENDOCRIN MET, V5, P113, DOI 10.1016/1043-2760(94)90092-2
   BULUN SE, 1994, BREAST CANCER RES TR, V30, P19, DOI 10.1007/BF00682738
   Czajka-Oraniec I, 2010, ENDOKRYNOL POL, V61, P126
   Dannenberg LO, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-181
   Demura M, 2008, MOL CELL ENDOCRINOL, V283, P127, DOI 10.1016/j.mce.2007.12.003
   DOERFLER W, 1988, GENE, V74, P129, DOI 10.1016/0378-1119(88)90268-5
   Fürbass R, 2008, MOL REPROD DEV, V75, P1, DOI 10.1002/mrd.20756
   Fürbass R, 2001, EUR J BIOCHEM, V268, P1222, DOI 10.1046/j.1432-1327.2001.01988.x
   Gray SG, 2009, EUR J CANCER, V45, P3087, DOI 10.1016/j.ejca.2009.09.006
   Graziano F, 2004, CLIN CANCER RES, V10, P2784, DOI 10.1158/1078-0432.CCR-03-0320
   HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   Huang SK, 2010, AM J PATHOL, V177, P2245, DOI 10.2353/ajpath.2010.100446
   Izawa M., 2007, FERTILITY STERILITY
   Knower KC, 2010, MOL CELL ENDOCRINOL, V321, P123, DOI 10.1016/j.mce.2010.02.035
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   LESHIN M, 1985, P NATL ACAD SCI USA, V82, P3005, DOI 10.1073/pnas.82.9.3005
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Miki Y, 2007, CANCER RES, V67, P3945, DOI 10.1158/0008-5472.CAN-06-3105
   Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031
   Richards JA, 2003, J CLIN ENDOCR METAB, V88, P2810, DOI 10.1210/jc.2002-021475
   ROBBINS P, 1995, HUM PATHOL, V26, P873, DOI 10.1016/0046-8177(95)90010-1
   Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230
   Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954
   SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342
   Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703
   Subbaramaiah K, 2008, J BIOL CHEM, V283, P3433, DOI 10.1074/jbc.M705409200
   Sugino Y, 2007, ONCOGENE, V26, P7401, DOI 10.1038/sj.onc.1210550
   Thorat MA, 2008, MODERN PATHOL, V21, P15, DOI 10.1038/modpathol.3800970
   Tian L, 2008, CANCER-AM CANCER SOC, V113, P1396, DOI 10.1002/cncr.23694
   Vanselow J, 2008, EXP CLIN ENDOCR DIAB, V116, P437, DOI 10.1055/s-2008-1058083
   Vanselow J, 2005, MOL CELL ENDOCRINOL, V233, P57, DOI 10.1016/j.mce.2005.01.007
   Watts GS, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-47
   Wolf I, 2007, BREAST CANCER RES TR, V105, P139, DOI 10.1007/s10549-006-9440-4
   Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
   ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449
   Zhao Y, 1997, J STEROID BIOCHEM, V61, P203, DOI 10.1016/S0960-0760(97)80013-1
   Zhao Y, 1996, ENDOCRINOLOGY, V137, P5739, DOI 10.1210/en.137.12.5739
NR 44
TC 9
Z9 10
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD NOV
PY 2012
VL 132
IS 3-5
BP 331
EP 338
DI 10.1016/j.jsbmb.2012.07.007
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 028HL
UT WOS:000310413300017
PM 22929011
DA 2025-01-12
ER

PT J
AU Castilla, MA
   Díaz-Martín, J
   Sarrió, D
   Romero-Pérez, L
   López-García, MA
   Vieites, B
   Biscuola, M
   Ramiro-Fuentes, S
   Isacke, CM
   Palacios, J
AF Angeles Castilla, Maria
   Diaz-Martin, Juan
   Sarrio, David
   Romero-Perez, Laura
   Angeles Lopez-Garcia, Maria
   Vieites, Begona
   Biscuola, Michele
   Ramiro-Fuentes, Susana
   Isacke, Clare M.
   Palacios, Jose
TI MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-INITIATING CELLS; E-CADHERIN
   EXPRESSION; GENE-EXPRESSION; METAPLASTIC CARCINOMA; MIR-200 FAMILY;
   FEEDBACK LOOP; CLAUDIN-LOW; PROGRESSION; SUBTYPES
AB The epithelial to mesenchymal transition (EMT) contributes to tumor invasion and metastasis in a variety of cancer types. In human breast cancer, gene expression studies have determined that basal-B/claudin-low and metaplastic cancers exhibit EMT-related characteristics, but the molecular mechanisms underlying this observation are unknown. As the family of miR-200 microRNAs has been shown to regulate EMT in normal tissues and cancer, here we evaluated whether the expression of the miR-200 family (miR-200f) and their epigenetic state correlate with EMT features in human breast carcinomas. We analyzed by qRT-PCR the expression of miR-200f members and various EMT-transcriptional inducers in a series of 70 breast cancers comprising an array of phenotypic subtypes: estrogen receptor positive (ER+), HER2 positive (HER2+), and triple negative (TN), including a subset of metaplastic breast carcinomas (MBCs) with sarcomatous (homologous or heterologous) differentiation. No MBCs with squamous differentiation were included. The DNA methylation status of miR-200f loci in tumor samples were inspected using Sequenom MassArray (R) MALDI-TOF platform. We also used two non-tumorigenic breast basal cell lines that spontaneously undergo EMT to study the modulation of miR-200f expression during EMT in vitro. We demonstrate that miR-200f is strongly decreased in MBCs compared with other cancer types. TN and HER2+ breast cancers also exhibited lower miR-200f expression than ER+ tumors. Significantly, the decreased miR-200f expression found in MBCs is accompanied by an increase in the expression levels of EMT-transcriptional inducers, and hypermethylation of the miR-200c-141 locus. Similar to tumor samples, we demonstrated that downregulation of miR-200f and hypermethylation of the miR-200c-141 locus, together with upregulation of EMT-transcriptional inducers also occur in an in vitro cellular model of spontaneous EMT. Thus, the expression and methylation status of miR-200f could be used as hypothetical biomarkers to assess the occurrence of EMT in breast cancer.
C1 [Angeles Castilla, Maria; Diaz-Martin, Juan; Romero-Perez, Laura; Angeles Lopez-Garcia, Maria; Vieites, Begona; Biscuola, Michele; Ramiro-Fuentes, Susana; Palacios, Jose] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Dept Pathol,Inst Biomed Sevilla, Seville, Spain.
   [Angeles Castilla, Maria; Diaz-Martin, Juan; Romero-Perez, Laura; Angeles Lopez-Garcia, Maria; Vieites, Begona; Biscuola, Michele; Palacios, Jose] RTICC, Madrid, Spain.
   [Sarrio, David; Isacke, Clare M.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
   [Palacios, Jose] Hosp Univ Ramon Y Cajal, Dept Pathol, Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); University of
   Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS);
   Virgen del Rocio University Hospital; University of London; Institute of
   Cancer Research - UK; Royal Marsden NHS Foundation Trust; Hospital
   Universitario Ramon y Cajal
RP Díaz-Martín, J (通讯作者)，Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Dept Pathol,Inst Biomed Sevilla, Seville, Spain.
EM jdiaz-ibis@us.es; jose.palacios@salud.madrid.org
RI Palacios, Jose/AAV-3765-2020; SARRIO, DAVID/Y-8903-2019; Castilla,
   Mª/C-9454-2015; Diaz-Martin, Juan/F-4765-2015; Romero-Perez,
   Laura/C-8314-2015
OI Diaz-Martin, Juan/0000-0002-3985-6434; Romero-Perez,
   Laura/0000-0003-3196-4382; Sarrio, David/0000-0003-4886-8290; Isacke,
   Clare/0000-0002-9222-3345
FU Instituto de Salud Carlos III (ISCIII) [PI07/90324, PI080971];
   Ministerio de Ciencia e Innovacion (MCINN); European Development
   Regional Fund, "A way to achieve Europe" EDRF [RD06/0020/0013]; Junta de
   Andalucia (Consejeria de Salud) [PI-0384/2007, PI0581/2009]; Consejeria
   de Innovacion (Proyecto de Excelencia) [P07-CVI-03100]; Sandra Ibarra
   Foundation [2011/088]; ISCIII [PI080971, RD06/0020/0013]; Consejeria de
   Salud, Junta de Andalucia [PI0581/2009]; EU Marie Curie Intra-European
   Fellowship [PIEF-GA-2008-221083]; Breakthrough Breast Cancer; PFIS
   fellowship [F109/00193]; ISCIII-Red de Biobancos [RD09/0076/00085]
FX This work was supported by grants from: the Instituto de Salud Carlos
   III (ISCIII; Grant Nos PI07/90324 and PI080971) and the Ministerio de
   Ciencia e Innovacion (MCINN), co-financed by the European Development
   Regional Fund, "A way to achieve Europe" EDRF (Grant No.
   RD06/0020/0013); the Junta de Andalucia (Consejeria de Salud, Grant No.
   PI-0384/2007, PI0581/2009); the Consejeria de Innovacion (Proyecto de
   Excelencia, Grant No. P07-CVI-03100); and Sandra Ibarra Foundation
   (Grant No. 2011/088) to JP. MAC and JDM are PhD researchers funded by
   the ISCIII (Grant No. RD06/0020/0013) and the Consejeria de Salud, Junta
   de Andalucia (PI0581/2009), respectively. DS was funded by an EU Marie
   Curie Intra-European Fellowship (PIEF-GA-2008-221083) and by
   Breakthrough Breast Cancer. LRP is a PhD student recipient of a PFIS
   fellowship (Grant No. F109/00193). MB is a researcher funded by the
   ISCIII-Red de Biobancos RD09/0076/00085. SR works as a lab technician
   supported by the ISCIII (PI080971). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Bockmeyer CL, 2011, BREAST CANCER RES TR, V130, P735, DOI 10.1007/s10549-010-1303-3
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Bracken CP, 2009, CELL MOL LIFE SCI, V66, P1682, DOI 10.1007/s00018-009-8750-1
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cano A, 2008, TRENDS CELL BIOL, V18, P357, DOI 10.1016/j.tcb.2008.05.005
   Davalos V, 2011, ONCOGENE
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108
   Holliday DL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2218
   Howe EN., 2012, J Mammary Gland Biol Neoplasia
   Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867
   Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675
   Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545
   Lien HC, 2007, ONCOGENE, V26, P7859, DOI 10.1038/sj.onc.1210593
   Lien HC, 2004, J PATHOL, V204, P131, DOI 10.1002/path.1624
   Liu Y.N., 2012, ONCOGENE
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007
   Reis JS, 2006, HISTOPATHOLOGY, V49, P10, DOI 10.1111/j.1365-2559.2006.02467.x
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sossey-Alaoui K, 2009, J BIOL CHEM, V284, P33019, DOI 10.1074/jbc.M109.034553
   Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Toft DJ, 2011, MOL ENDOCRINOL, V25, P199, DOI 10.1210/me.2010-0164
   Vrba L, 2011, GENOME RES
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wee EJ, 2012, ONCOGENE
   Wiklund ED, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027840
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Yuan JH, 2011, HEPATOLOGY, V54, P2025, DOI 10.1002/hep.24606
   Zhang YH, 2012, MODERN PATHOL, V25, P178, DOI 10.1038/modpathol.2011.167
NR 50
TC 90
Z9 97
U1 0
U2 35
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2012
VL 7
IS 10
AR e47709
DI 10.1371/journal.pone.0047709
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 026VC
UT WOS:000310310200071
PM 23112837
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Balasubramanian, S
   Kanade, S
   Han, BS
   Eckert, RL
AF Balasubramanian, Sivaprakasam
   Kanade, Santosh
   Han, Bingshe
   Eckert, Richard L.
TI A Proteasome Inhibitor-stimulated Nrf1 Protein-dependent Compensatory
   Increase in Proteasome Subunit Gene Expression Reduces Polycomb Group
   Protein Level
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID EZH2 HISTONE METHYLTRANSFERASE; SKIN-CANCER CELLS; BMI-1 ONCOPROTEIN;
   COLORECTAL-CANCER; MULTIPLE-MYELOMA; INK4A-ARF LOCUS; BREAST-CANCER;
   SULFORAPHANE; PROLIFERATION; MECHANISM
AB The polycomb group (PcG) proteins, Bmi-1 and Ezh2, are important epigenetic regulators that enhance skin cancer cell survival. We recently showed that Bmi-1 and Ezh2 protein level is reduced by treatment with the dietary chemopreventive agents, sulforaphane and green tea polyphenol, and that this reduction involves ubiquitination of Bmi-1 and Ezh2, suggesting a key role of the proteasome. In the present study, we observe a surprising outcome that Bmi-1 and Ezh2 levels are reduced by treatment with the proteasome inhibitor, MG132. We show that this is associated with a compensatory increase in the level of mRNA encoding proteasome protein subunits in response to MG132 treatment and an increase in proteasome activity. The increase in proteasome subunit level is associated with increased Nrf1 and Nrf2 level. Moreover, knockdown of Nrf1 attenuates the MG132-dependent increase in proteasome subunit expression and restores Bmi-1 and Ezh2 expression. The MG132-dependent loss of Bmi-1 and Ezh2 is associated with reduced cell proliferation, accumulation of cells in G(2), and increased apoptosis. These effects are attenuated by forced expression of Bmi-1, suggesting that PcG proteins, consistent with a prosurvival action, may antagonize the action of MG132. These studies describe a compensatory Nrf1-dependent, and to a lesser extent Nrf2-dependent, increase in proteasome subunit level in proteasome inhibitor-treated cells and confirm that PcG protein levels are regulated by proteasome activity.
C1 [Balasubramanian, Sivaprakasam; Kanade, Santosh; Han, Bingshe; Eckert, Richard L.] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA.
   [Eckert, Richard L.] Univ Maryland, Dept Dermatol, Sch Med, Baltimore, MD 21201 USA.
   [Eckert, Richard L.] Univ Maryland, Dept Obstet & Gynecol, Sch Med, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Eckert, RL (通讯作者)，Univ Maryland, Dept Biochem & Mol Biol, Sch Med, 108 N Greene St, Baltimore, MD 21201 USA.
EM reckert@umaryland.edu
RI Kanade, Santosh/V-7054-2019
FU National Institutes of Health [R01 AR053851, R01 CA131074]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants R01 AR053851 and R01 CA131074 (to R. L. E.).
CR Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Balasubramanian S, 2008, NUTR REV, V66, pS65, DOI 10.1111/j.1753-4887.2008.00071.x
   Balasubramanian S, 2011, MOL PHARMACOL, V80, P870, DOI 10.1124/mol.111.072363
   Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752
   Chew YC, 2011, J BIOL CHEM, V286, P28772, DOI 10.1074/jbc.M110.205245
   Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624
   Dinkova-Kostova AT, 2006, CANCER LETT, V240, P243, DOI 10.1016/j.canlet.2005.09.012
   Eckert RL, 2011, J INVEST DERMATOL, V131, P295, DOI 10.1038/jid.2010.318
   Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607
   Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7
   Hatano A, 2010, BIOCHEM BIOPH RES CO, V397, P93, DOI 10.1016/j.bbrc.2010.05.074
   Jans R, 2008, J INVEST DERMATOL, V128, P517, DOI 10.1038/sj.jid.5701035
   Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016
   Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010
   Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009
   Kwak MK, 2007, FREE RADICAL BIO MED, V43, P809, DOI 10.1016/j.freeradbiomed.2007.05.029
   Kwak MK, 2010, TOXICOL APPL PHARM, V244, P66, DOI 10.1016/j.taap.2009.08.028
   Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003
   Lancet JE, 2011, CLIN CANCER RES, V17, P1140, DOI 10.1158/1078-0432.CCR-10-1878
   Laubach J, 2011, ANNU REV MED, V62, P249, DOI 10.1146/annurev-med-070209-175325
   Lee K, 2008, J INVEST DERMATOL, V128, P9, DOI 10.1038/sj.jid.5700949
   Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200
   Ling SCW, 2012, HAEMATOL-HEMATOL J, V97, P64, DOI 10.3324/haematol.2011.043331
   Lundgren J, 2005, MOL CELL BIOL, V25, P4662, DOI 10.1128/MCB.25.11.4662-4675.2005
   Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Mimori K, 2005, EJSO-EUR J SURG ONC, V31, P376, DOI 10.1016/j.ejso.2004.11.001
   Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2007, EXP BIOL MED, V232, P227
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Radhakrishnan SK, 2010, MOL CELL, V38, P17, DOI 10.1016/j.molcel.2010.02.029
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Singh SV, 2005, J BIOL CHEM, V280, P19911, DOI 10.1074/jbc.M412443200
   Steffen J, 2010, MOL CELL, V40, P147, DOI 10.1016/j.molcel.2010.09.012
   Sturniolo MT, 2005, ONCOGENE, V24, P2963, DOI 10.1038/sj.onc.1208392
   Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7
   Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791
   Weikert S, 2005, INT J MOL MED, V16, P349
   Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300
NR 48
TC 23
Z9 25
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 19
PY 2012
VL 287
IS 43
BP 36179
EP 36189
DI 10.1074/jbc.M112.359281
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 027PA
UT WOS:000310364000039
PM 22932898
OA Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Yoshida, GJ
   Fuchimoto, Y
   Osumi, T
   Shimada, H
   Hosaka, S
   Morioka, H
   Mukai, M
   Masugi, Y
   Sakamoto, M
   Kuroda, T
AF Yoshida, Go J.
   Fuchimoto, Yasushi
   Osumi, Tomoo
   Shimada, Hiroyuki
   Hosaka, Seiichi
   Morioka, Hideo
   Mukai, Makio
   Masugi, Yohei
   Sakamoto, Michiie
   Kuroda, Tatsuo
TI Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer:
   Increased expression of a CD44 variant isoform after chemotherapy
SO BMC CANCER
LA English
DT Article
DE Li-Fraumeni syndrome (LFS); cancer stem cells (CSCs); CD44 variant
   isoforms
ID FAMILIAL SYNDROME; BREAST-CANCER; MUTATIONS; NEOPLASMS; SARCOMAS; GROWTH
AB Background: Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome that is commonly associated with a germline mutation in the tumor suppressor gene p53. Loss of p53 results in increased expression of CD44, a cancer stem cell (CSC) marker, which is involved in the scavenging of reactive oxygen species (ROS). Here, we report a change in the expression of a CD44 variant isoform (CD44v8-10) in an 8-year-old female LFS patient with osteosarcoma and atypical liver cancer after chemotherapy.
   Case presentation: The patient visited a clinic with a chief complaint of chronic pain in a bruise on her right knee. Magnetic resonance imaging (MRI) raised the possibility of a bone malignancy. Biochemical testing also revealed significantly elevated levels of AFP, which strongly suggested the existence of a primary malignancy in the liver. MRI imaging showed the simultaneous development of osteosarcoma and liver cancer, both of which were confirmed upon biopsy. Combined therapy with surgical resection after chemotherapy was successful in this patient. Regardless of the absence of a familial history of hereditary cancer, a germline mutation in p53 was identified (a missense mutation defined as c.722 C>T, p.Ser241Phe). To better understand the cancer progression and response to treatment, immunohistochemical (IHC) analysis of biopsy specimens obtained before and after chemotherapy was performed using a specific antibody against CD44v8-10.
   Conclusion: This case demonstrates the ectopic up-regulation of CD44v8-10 in a biopsy sample obtained after cytotoxic chemotherapy, which confers high levels of oxidative stress on cancer cells. Because the alternative splicing of CD44 is tightly regulated epigenetically, it is possible that micro-environmental stress resulting from chemotherapy caused the ectopic induction of CD44v8-10 in vivo.
C1 [Fuchimoto, Yasushi] Natl Ctr Child Hlth & Dev, Dept Surg Subspecial, Div Surg, Setagaya Ku, Tokyo 1578535, Japan.
   [Kuroda, Tatsuo] Keio Univ, Sch Med, Dept Pediat Surg, Shinjuku Ku, Tokyo 1608582, Japan.
   [Yoshida, Go J.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo 1608582, Japan.
   [Mukai, Makio] Keio Univ Hosp, Div Diagnost Pathol, Shinjuku Ku, Tokyo 1608582, Japan.
   [Osumi, Tomoo; Shimada, Hiroyuki] Keio Univ, Sch Med, Dept Pediat, Shinjuku Ku, Tokyo 1608582, Japan.
   [Masugi, Yohei; Sakamoto, Michiie] Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan.
   [Hosaka, Seiichi; Morioka, Hideo] Keio Univ, Sch Med, Dept Orthoped Surg, Shinjuku Ku, Tokyo 1608582, Japan.
C3 National Center for Child Health & Development - Japan; Keio University;
   Keio University; Keio University; Keio University; Keio University; Keio
   University
RP Fuchimoto, Y (通讯作者)，Natl Ctr Child Hlth & Dev, Dept Surg Subspecial, Div Surg, Setagaya Ku, 2-10-1 Okura, Tokyo 1578535, Japan.
EM yfuchimoto@z5.keio.jp
RI Osumi, Tomoo/AAH-9925-2020; Masugi, Yohei/E-6980-2014
OI Osumi, Tomoo/0000-0001-5536-6788; Yoshida, Go/0000-0002-1472-892X;
   Masugi, Yohei/0000-0002-6952-4043
FU Grants-in-Aid for Scientific Research [21249085, 24390397] Funding
   Source: KAKEN
CR BIRCH JM, 1994, CANCER RES, V54, P1298
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006
   Gonzalez KD, 2009, J MED GENET, V46, P689, DOI 10.1136/jmg.2008.058958
   Hisada M, 1998, JNCI-J NATL CANCER I, V90, P606, DOI 10.1093/jnci/90.8.606
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Jothy S, 2003, CLIN EXP METASTAS, V20, P195, DOI 10.1023/A:1022931016285
   Kuryu M, 1999, J CANCER RES CLIN, V125, P646, DOI 10.1007/s004320050329
   LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x
   Prokurat A, 2002, MED PEDIATR ONCOL, V39, P510, DOI 10.1002/mpo.10177
   Varley JM, 2003, HUM MUTAT, V21, P313, DOI 10.1002/humu.10185
   Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606
   Yamada H, 2009, INT J CANCER, V125, P973, DOI 10.1002/ijc.24432
NR 15
TC 17
Z9 18
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD OCT 2
PY 2012
VL 12
AR 444
DI 10.1186/1471-2407-12-444
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 031ME
UT WOS:000310644200001
PM 23031740
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Rudnick, JA
   Kuperwasser, C
AF Rudnick, Jenny A.
   Kuperwasser, Charlotte
TI Stromal biomarkers in breast cancer development and progression
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Breast; Stroma; Biomarkers; Cancer
ID FIBROBLAST ACTIVATION PROTEIN; TUMOR-ASSOCIATED MACROPHAGES; TENASCIN-C;
   GENE-EXPRESSION; TGF-BETA; SERINE-PROTEASE; LYSYL OXIDASE; IN-SITU;
   MAMMARY CARCINOMAS; INVASIVE-CARCINOMA
AB Breast cancer is a heterogeneous, multi-factorial disease of aberrant breast development whose etiology relies upon several microenvironmental changes within the tissue. Within the last decade, it has become widely accepted that tumor cells frequently rely on signals from an activated microenvironment in order to proliferate and survive within a tissue. This activated tissue microenvironment involves the appearance of alpha SMA + fibroblasts (referred to as "cancer associated fibroblasts"), the recruitment of various immune cells (macrophages, T cells, B cells, T regulatory cells), enhanced collagen I deposition, and epigenetic modifications of stromal cells. These stromal changes can predict patient survival and correlate with distinct breast tumor subtypes. Characterizing these stromal changes will facilitate their use as clinical biomarkers in breast cancer, and may facilitate their use as potential drug targets for adjuvant breast cancer therapy.
C1 [Rudnick, Jenny A.; Kuperwasser, Charlotte] Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Dept Anat & Cellular Biol, Boston, MA 02111 USA.
   [Kuperwasser, Charlotte] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA.
C3 Tufts University; Tufts Medical Center
RP Kuperwasser, C (通讯作者)，Tufts Univ, Sch Med, Sackler Sch Grad Biomed Sci, Dept Anat & Cellular Biol, 136 Harrison Ave, Boston, MA 02111 USA.
EM charlotte.kuperwasser@tufts.edu
FU Department of Defense Breast Cancer Research Program Pre-doctoral
   Traineeship Award; Breast Cancer Research Foundation; Silvian
   Foundation; NIH/NCI [CA125554, CA092644]
FX This work was supported by grants from the Department of Defense Breast
   Cancer Research Program Pre-doctoral Traineeship Award (to J.A.R.), the
   Breast Cancer Research Foundation, the Silvian Foundation, and the
   NIH/NCI (CA125554, CA092644).
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Baglole CJ, 2006, IMMUNOL INVEST, V35, P297, DOI 10.1080/08820130600754960
   Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208
   Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Boland GP, 2004, BRIT J CANCER, V90, P423, DOI 10.1038/sj.bjc.6601534
   Bolat F, 2006, J EXP CLIN CANC RES, V25, P365
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Calabrò A, 2009, BREAST CANCER RES TR, V116, P69, DOI 10.1007/s10549-008-0105-3
   Campbell I, 2009, CANCER RES, V69, P6765, DOI 10.1158/0008-5472.CAN-08-4253
   Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y
   Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8
   Cheng N, 2007, CANCER RES, V67, P4869, DOI 10.1158/0008-5472.CAN-06-3381
   Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V
   Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   Davis-Dusenbery Brandi N, 2010, Genes Cancer, V1, P1100, DOI 10.1177/1947601910396213
   de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014
   Decitre M, 1998, LAB INVEST, V78, P143
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018
   Denkert C, 2003, CANCER-AM CANCER SOC, V97, P2978, DOI 10.1002/cncr.11437
   Denkert Carsten, 2004, Clin Breast Cancer, V4, P428, DOI 10.3816/CBC.2004.n.006
   Desmoulière A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x
   Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439
   DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Enkelmann A, 2011, J CANCER RES CLIN, V137, P751, DOI 10.1007/s00432-010-0932-6
   Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Fazi F, 2008, CARDIOVASC RES, V79, P553, DOI 10.1093/cvr/cvn151
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fujimoto H, 2009, INT J CANCER, V125, P1276, DOI 10.1002/ijc.24378
   Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621
   Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040
   Gottfried E, 2008, SCAND J IMMUNOL, V67, P453, DOI 10.1111/j.1365-3083.2008.02091.x
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Guttery DS, 2010, CANCER METAST REV, V29, P595, DOI 10.1007/s10555-010-9249-9
   Hancox RA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2251
   Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037
   Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524
   HOWEEDY AA, 1990, LAB INVEST, V63, P798
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106
   Huang S, 2005, CANCER CELL, V8, P175, DOI 10.1016/j.ccr.2005.08.009
   Huang Y, 2011, CLIN EXP METASTAS, V28, P567, DOI 10.1007/s10585-011-9392-x
   Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jahkola T, 1996, INT J CANCER, V69, P445, DOI 10.1002/(SICI)1097-0215(19961220)69:6<445::AID-IJC4>3.3.CO;2-G
   Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714
   Jahkola T, 1998, EUR J CANCER, V34, P1687, DOI 10.1016/S0959-8049(98)00215-9
   Jazbutyte V, 2010, CURR DRUG TARGETS, V11, P926, DOI 10.2174/138945010791591403
   Jiang L, 2008, CANCER RES, V68, P9900, DOI 10.1158/0008-5472.CAN-08-1319
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   KAWAKATSU H, 1992, JPN J CANCER RES, V83, P1073, DOI 10.1111/j.1349-7006.1992.tb02724.x
   Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101
   Kirschmann DA, 1999, BREAST CANCER RES TR, V55, P127
   Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107
   Koo JS, 2011, TUMOR BIOL, V32, P787, DOI 10.1007/s13277-011-0181-6
   Krenning G, 2010, J CELL PHYSIOL, V225, P631, DOI 10.1002/jcp.22322
   Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101
   LeBeau AM, 2009, MOL CANCER THER, V8, P1378, DOI 10.1158/1535-7163.MCT-08-1170
   Lee AHS, 1997, J CLIN PATHOL, V50, P669, DOI 10.1136/jcp.50.8.669
   Lee J, 2005, CANCER RES, V65, P11156, DOI 10.1158/0008-5472.CAN-05-2805
   Leek RD, 1996, CANCER RES, V56, P4625
   Leung AKL, 2006, COLD SPRING HARB SYM, V71, P29, DOI 10.1101/sqb.2006.71.049
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   LIGHTNER VA, 1994, EXP CELL RES, V210, P177, DOI 10.1006/excr.1994.1027
   Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278
   Liu G, 2010, J EXP MED, V207, P1589, DOI 10.1084/jem.20100035
   Liu R, 2012, CANCER BIOL THER, V13, P123, DOI 10.4161/cbt.13.3.18696
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72
   Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
   Mahmoud SMA, 2012, BREAST CANCER RES TR, V132, P545, DOI 10.1007/s10549-011-1620-1
   Mahmoud SMA, 2012, J CLIN PATHOL, V65, P159, DOI 10.1136/jclinpath-2011-200355
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Menard S, 1997, CLIN CANCER RES, V3, P817
   Méric JB, 2006, CRIT REV ONCOL HEMAT, V59, P51, DOI 10.1016/j.critrevonc.2006.01.003
   Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Mori L, 2005, EXP CELL RES, V304, P81, DOI 10.1016/j.yexcr.2004.11.011
   Mukhtar RA, 2011, EXPERT REV MOL DIAGN, V11, P91, DOI [10.1586/erm.10.97, 10.1586/ERM.10.97]
   Nakahara H, 2006, EUR J IMMUNOL, V36, P3334, DOI 10.1002/eji.200636271
   O'Connell JT, 2011, P NATL ACAD SCI USA, V108, P16002, DOI 10.1073/pnas.1109493108
   Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87
   Olumi AF, 1999, CANCER RES, V59, P5002
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505
   Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010
   Perrone G, 2005, HISTOPATHOLOGY, V46, P561, DOI 10.1111/j.1365-2559.2005.02132.x
   Peyrol S, 1997, AM J PATHOL, V150, P497
   Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11
   Qian BY, 2009, BREAST CANCER RES TR, V117, P131, DOI 10.1007/s10549-008-0219-7
   Radisky DC, 2011, CANCER PREV RES, V4, P1953, DOI 10.1158/1940-6207.CAPR-11-0282
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736
   RONNOVJESSEN L, 1993, LAB INVEST, V68, P696
   Rudnick JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024605
   Ruffell B, 2012, P NATL ACAD SCI USA, V109, P2796, DOI 10.1073/pnas.1104303108
   SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657
   Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29
   Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856
   STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217
   Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400
   Suwiwat S, 2004, CLIN CANCER RES, V10, P2491, DOI 10.1158/1078-0432.CCR-03-0146
   Tahtis K, 2003, MOL CANCER THER, V2, P729
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511
   Tiscornia G, 2010, GENE DEV, V24, P2732, DOI 10.1101/gad.1982910
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486
   Tsutsui S, 2005, ONCOL REP, V14, P425
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   Witkiewicz AK, 2011, CELL CYCLE, V10, P1794, DOI 10.4161/cc.10.11.15675
   Witkiewicz AK, 2010, CANCER BIOL THER, V10, P135, DOI 10.4161/cbt.10.2.11983
   Witkiewicz AK, 2009, AM J PATHOL, V174, P2023, DOI 10.2353/ajpath.2009.080873
   Wixler V, 2007, J CELL BIOL, V177, P163, DOI 10.1083/jcb.200606043
   Wolf BB, 2008, MINI-REV MED CHEM, V8, P719, DOI 10.2174/138955708784567449
   Wülfing P, 2003, J CANCER RES CLIN, V129, P375, DOI 10.1007/s00432-003-0459-1
   Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
   Yang WT, 2010, BREAST CANCER RES TR, V119, P305, DOI 10.1007/s10549-009-0350-0
   Yao Q, 2011, INT J CANCER, V128, P1783, DOI 10.1002/ijc.25506
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
NR 139
TC 30
Z9 40
U1 1
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD OCT
PY 2012
VL 29
IS 7
BP 663
EP 672
DI 10.1007/s10585-012-9499-8
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 028ZO
UT WOS:000310464700006
PM 22684404
DA 2025-01-12
ER

PT J
AU Huynh, KT
   Hoon, DSB
AF Huynh, Kelly T.
   Hoon, Dave S. B.
TI Epigenetics of regional lymph node metastasis in solid tumors
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Methylation; microRNA; Lymph node; Biomarker; Melanoma; Breast cancer
ID ISLAND METHYLATOR PHENOTYPE; EARLY COLON-CANCER; BREAST-CANCER;
   PHASE-II; DEACETYLASE INHIBITOR; SUPPRESSOR GENES; RUNX3 EXPRESSION;
   SENTINEL; HYPERMETHYLATION; MULTICENTER
AB Regional nodal status remains one of the most important prognostic factors in several solid tumors including melanoma, breast cancer, and gastrointestinal malignancies. However, despite the accuracy of lymph node (LN) staging, patients who are LN negative are still at risk for development of recurrence and distant metastasis. As such, numerous molecular studies have focused on genetic and transcriptome changes in primary and metastatic tumors to discover molecular determinants that can predict aggressive metastatic disease and/or correlated to clinical outcomes. More recently, epigenetic aberrations have been investigated in solid cancers and are associated with tumorigenesis and disease progression. These epigenetic alterations have demonstrated potential utility as diagnostic and prognostic biomarkers and are being developed into novel targeted treatment strategies, as epigenetic changes can be reversed by appropriate drugs. If patients who are at increased risk of developing metastases or recurrence can be accurately identified, this will help stratify patients into more appropriate treatment and follow-up. This review discusses some of the recent studies on regional LN metastases in melanoma, breast cancer, and colorectal cancer, focusing on the potential clinicopathological utility of epigenetic aberrations in the management of cancer patients.
C1 [Huynh, Kelly T.; Hoon, Dave S. B.] John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
C3 John Wayne Cancer Institute
RP Hoon, DSB (通讯作者)，John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Hoon, Dave/C-7146-2018
OI Hoon, Dave/0000-0003-1915-3683
FU Dr. Miriam & Sheldon G. Adelson Medical Research Foundation; Ruth and
   Martin H. Weil Fund; Associates for Breast and Prostate Cancer (ABC)
   Studies; Fashion Footwear Association of New York (FFA-NY); NIH, NCI [P0
   CA029605]
FX This study was supported by Dr. Miriam & Sheldon G. Adelson Medical
   Research Foundation, the Ruth and Martin H. Weil Fund, Associates for
   Breast and Prostate Cancer (ABC) Studies, Fashion Footwear Association
   of New York (FFA-NY), the Award Number P0 CA029605 from the NIH, NCI.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official view of the National Cancer Institute
   or the National Institutes of Health.
CR Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6
   Bilchik AJ, 2002, EUR J CANCER, V38, P977, DOI 10.1016/S0959-8049(02)00058-8
   Bilchik AJ, 2001, J CLIN ONCOL, V19, P1128, DOI 10.1200/JCO.2001.19.4.1128
   Cabanas R, 2009, CURR CLIN ONCOL, P347, DOI 10.1007/978-1-60327-087-8_30
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Chen SL, 2006, ANN SURG, V244, P602, DOI 10.1097/01.sla.0000237655.11717.50
   Cho NY, 2009, VIRCHOWS ARCH, V454, P17, DOI 10.1007/s00428-008-0706-6
   Civantos FJ, 2010, J CLIN ONCOL, V28, P1395, DOI 10.1200/JCO.2008.20.8777
   Davis-Dusenbery Brandi N, 2010, Genes Cancer, V1, P1100, DOI 10.1177/1947601910396213
   de Maat MFG, 2010, CLIN CANCER RES, V16, P2811, DOI 10.1158/1078-0432.CCR-09-2717
   Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fabbri M, 2007, EXPERT OPIN BIOL TH, V7, P1009, DOI 10.1517/14712598.7.7.1009
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   GIULIANO AE, 1995, ANN SURG, V222, P394, DOI 10.1097/00000658-199509000-00016
   Giuliano AE, 2011, JAMA-J AM MED ASSOC, V306, P385, DOI 10.1001/jama.2011.1034
   Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90
   Hansen NM, 2009, J CLIN ONCOL, V27, P4679, DOI 10.1200/JCO.2008.19.0686
   Hauschild A, 2008, MELANOMA RES, V18, P274, DOI 10.1097/CMR.0b013e328307c248
   Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016
   Hoon DSB, 2011, J SURG ONCOL, V103, P508, DOI 10.1002/jso.21690
   Hoshimoto S, 2012, J INVEST DERMATOL, V132, P1689, DOI 10.1038/jid.2012.36
   Howell PM, 2009, CANCER CONTROL, V16, P200, DOI 10.1177/107327480901600302
   Howlader N., 2011, SEER cancer statistics review, 1975-2008
   Howman-Giles R, 2010, ANN SURG ONCOL, V17, P138, DOI 10.1245/s10434-009-0657-4
   Huynh KT, 2012, BRIT J DERMATOL, V166, P1319, DOI 10.1111/j.1365-2133.2012.10867.x
   Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783
   Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755
   Carmona FJ, 2012, J PATHOL, V228, P230, DOI 10.1002/path.4011
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kitago M, 2009, CLIN CANCER RES, V15, P2988, DOI 10.1158/1078-0432.CCR-08-3172
   Klein A, 2012, INT J CANCER, V131, P2509, DOI 10.1002/ijc.27552
   Koyanagi K, 2008, CLIN CANCER RES, V14, P7391, DOI 10.1158/1078-0432.CCR-08-0290
   Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008
   Leong Stanley P L, 2004, Curr Treat Options Oncol, V5, P185, DOI 10.1007/s11864-004-0010-x
   Leong SPL, 2011, J SURG ONCOL, V103, P518, DOI 10.1002/jso.21815
   Li J, 2004, J CLIN PATHOL, V57, P294, DOI 10.1136/jcp.2003.013011
   Li Q, 2011, EPIGENETICS-US, V6, P849, DOI 10.4161/epi.6.7.16314
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Livestro DP, 2007, CANCER, V110, P614, DOI 10.1002/cncr.22818
   Lombardi L, 2010, CANCER TREAT REV, V36, pS34, DOI 10.1016/S0305-7372(10)70018-9
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Maaskant-Braat AJ, 2011, BREAST CANCER RES TR, V127, P195, DOI 10.1007/s10549-010-1086-6
   Martinez SR, 2006, SURG ONCOL CLIN N AM, V15, P331, DOI 10.1016/j.soc.2005.12.012
   Morton DL, 2005, ANN SURG, V242, P302, DOI 10.1097/01.sla.0000181092.50141.fa
   MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392
   Morton DL, 2006, NEW ENGL J MED, V355, P1307, DOI 10.1056/NEJMoa060992
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056
   Nicholl MB, 2011, ANN SURG, V253, P116, DOI 10.1097/SLA.0b013e3181fca894
   Ogino S, 2008, J NATL CANCER I, V100, P1734, DOI 10.1093/jnci/djn359
   Park SY, 2009, J PATHOL, V219, P410, DOI 10.1002/path.2596
   Pass HI, 2010, CANCER RES, V70, P1916, DOI 10.1158/0008-5472.CAN-09-3993
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Sassen S, 2008, ANN SURG ONCOL, V15, P630, DOI 10.1245/s10434-007-9684-1
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sunami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018884
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Viehl CT, 2012, ANN SURG ONCOL, V19, P1959, DOI 10.1245/s10434-012-2233-6
   Witz IP, 2009, CANCER MICROENVIRON, V2, pS9, DOI 10.1007/s12307-009-0025-8
   Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zou DH, 2009, J PATHOL, V218, P265, DOI 10.1002/path.2541
NR 71
TC 11
Z9 12
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD OCT
PY 2012
VL 29
IS 7
BP 747
EP 756
DI 10.1007/s10585-012-9491-3
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 028ZO
UT WOS:000310464700015
PM 22684433
DA 2025-01-12
ER

PT J
AU Leurs, U
   Clausen, RP
   Kristensen, JL
   Lohse, B
AF Leurs, Ulrike
   Clausen, Rasmus P.
   Kristensen, Jesper L.
   Lohse, Brian
TI Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C)
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE KDM4C/JMJD2C; FDH assay; Small molecule inhibitors; Heterocyclic ring
   systems; Histone lysine demethylases
ID MECHANISM
AB The human histone demethylases of the KDM4 (JMJD2) family have been associated to diseases such as prostate and breast cancer, as well as X-linked mental retardation. Therefore, these enzymes are considered oncogenes and their selective inhibition might be a possible therapeutic approach to treat cancer. Here we describe a heterocyclic ring system library screened against the histone demethylase KDM4C (JMJD2C) in the search for novel inhibitory scaffolds. A 4-hydroxypyrazole scaffold was identified as an inhibitor of KDM4C; this scaffold could be employed in the further development of novel therapeutics, as well as for the elucidation of the biological roles of KDM4C on epigenetic regulation. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Leurs, Ulrike; Clausen, Rasmus P.; Kristensen, Jesper L.; Lohse, Brian] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, DK-2100 Copenhagen, Denmark.
C3 University of Copenhagen
RP Lohse, B (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, Univ Pk 2, DK-2100 Copenhagen, Denmark.
EM bril@farma.ku.dk
RI Kristensen, Jesper/AAP-4439-2021; Clausen, Rasmus/A-6812-2008;
   Kristensen, Jesper/E-3581-2010
OI Clausen, Rasmus/0000-0001-9466-9431; Kristensen,
   Jesper/0000-0002-5613-1267; Leurs, Ulrike/0000-0002-8828-3505; Lohse,
   Brian/0000-0003-0479-8980
CR BEGTRUP M, 1968, ACTA CHEM SCAND, V22, P2476, DOI 10.3891/acta.chem.scand.22-2476
   BEGTRUP M, 1985, J CHEM SOC PERK T 1, P81, DOI 10.1039/p19850000081
   Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273
   Culhane JC, 2006, J AM CHEM SOC, V128, P4536, DOI 10.1021/ja0602748
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Hafez HN, 2008, BIOORG MED CHEM LETT, V18, P5222, DOI 10.1016/j.bmcl.2008.08.071
   Jenuwein T., 2001, SCIENCE, V1074, P293
   Kristensen J. B., 1951, FEBS LETT, V2011, P585
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Lohse B, 2011, ANGEW CHEM INT EDIT, V50, P9100, DOI 10.1002/anie.201101849
   Lohse B, 2011, BIOORGAN MED CHEM, V19, P3625, DOI 10.1016/j.bmc.2011.01.046
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Rose NR, 2008, J MED CHEM, V51, P7053, DOI 10.1021/jm800936s
   Rostom SAF, 2010, BIOORGAN MED CHEM, V18, P2767, DOI 10.1016/j.bmc.2010.02.006
   Woon ECY, 2012, ANGEW CHEM INT EDIT, V51, P1631, DOI 10.1002/anie.201107833
NR 17
TC 18
Z9 22
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 15
PY 2012
VL 22
IS 18
BP 5811
EP 5813
DI 10.1016/j.bmcl.2012.07.091
PG 3
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 995WY
UT WOS:000308046800009
PM 22917519
DA 2025-01-12
ER

PT J
AU Zopf, S
   Ocker, M
   Neureiter, D
   Alinger, B
   Gahr, S
   Neurath, MF
   Di Fazio, P
AF Zopf, Steffen
   Ocker, Matthias
   Neureiter, Daniel
   Alinger, Beate
   Gahr, Susanne
   Neurath, Markus F.
   Di Fazio, Pietro
TI Inhibition of DNA methyltransferase activity and expression by treatment
   with the pan-deacetylase inhibitor panobinostat in hepatocellular
   carcinoma cell lines
SO BMC CANCER
LA English
DT Article
DE DNA methyltransferase; Deacetylase inhibitor; Epigenetics;
   Transcriptional control; Hepatocellular carcinoma
ID BREAST-CANCER CELLS; VIRUS-X PROTEIN; HISTONE-DEACETYLASE;
   TUMOR-SUPPRESSOR; MULTISTEP HEPATOCARCINOGENESIS; PROMOTER
   HYPERMETHYLATION; METHYLATION STATUS; HEPATOMA-CELLS; LUNG-CANCER; GENES
AB Background: Hepatocellular carcinoma (HCC) still represents an unmet medical need. Epigenetic inactivation of tumor suppressor genes like RASSF1A or APC by overexpression of DNA methyltransferases (DNMTs) has been shown to be common in HCC and to be linked to the overall prognosis of patients. Inhibitors of protein and histone deacetylases (DACi) have been demonstrated to possess strong anti-tumor effects in HCC models.
   Methods: We therefore investigated whether DACi also has any influence on the expression and activity of DNMTs and methylated target genes in HepG2 and Hep3B cell culture systems and in a xenograft model by immunohistochemistry, westernblotting, RT-qPCR and methylation-specific PCR.
   Results: Our findings demonstrate a rapid inhibition of DNMT activity 6 h after treatment with 0.1 mu M of the pan-DACi panobinostat. A downregulation of DNMT mRNAs and protein were also observed at later points in time. This loss of DNMT activity and expression was paralleled by a diminished methylation of the target genes RASSF1A and APC and a concomitant re-expression of APC mRNA and protein. Analysis of HepG2 xenograft specimens confirmed these results in vivo.
   Conclusion: We suggest a dual mode of action of DACi on DNA methylation status: a rapid inhibition of enzyme activity due to interference with posttranslational acetylation and a delayed effect on transcriptional control of DNMT genes by HDAC or miRNA mechanisms.
C1 [Zopf, Steffen; Gahr, Susanne; Neurath, Markus F.] Univ Hosp Erlangen, Dept Med 1, D-91054 Erlangen, Germany.
   [Neureiter, Daniel; Alinger, Beate] Paracelsus Med Univ, Inst Pathol, Salzburg, Austria.
   [Gahr, Susanne] Klinikum Nuremberg Nord, Dept Pneumol, Nurnberg, Germany.
   [Ocker, Matthias; Di Fazio, Pietro] Univ Marburg, Inst Surg Res, Marburg, Germany.
C3 University of Erlangen Nuremberg; Paracelsus Private Medical University;
   Klinikum Nurnberg Nord; Philipps University Marburg
RP Zopf, S (通讯作者)，Univ Hosp Erlangen, Dept Med 1, Ulmenweg 18, D-91054 Erlangen, Germany.
EM steffen.zopf@uk-erlangen.de
RI Ocker, Matthias/IUN-5769-2023; Di Fazio, Pietro/AAU-4575-2020
OI Di Fazio, Pietro/0000-0003-0091-8498; Ocker,
   Matthias/0000-0001-8263-6288
FU ELAN fund of the Faculty of Medicine, Friedrich-Alexander University of
   Erlangen-Nuremberg [09.03.16.1.]; University Hospital Medical Center
   Giessen and Marburg (UKGM); EASL Dame Sheila Sherlock post-doctoral
   fellowship
FX We are grateful for the excellent technical assistance of Astrid Taut,
   Christina Lindner and Isabel Zeittrager. This study was supported by a
   grant from the ELAN fund of the Faculty of Medicine, Friedrich-Alexander
   University of Erlangen-Nuremberg to S.Z. (09.03.16.1.), a grant of the
   University Hospital Medical Center Giessen and Marburg (UKGM) to M.O.
   and an EASL Dame Sheila Sherlock post-doctoral fellowship to P.D.F.
CR Arora P, 2008, CANCER LETT, V261, P244, DOI 10.1016/j.canlet.2007.11.033
   Bosetti C, 2008, HEPATOLOGY, V48, P137, DOI 10.1002/hep.22312
   Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381
   Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006
   Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5
   Csepregi A, 2008, J CANCER RES CLIN, V134, P579, DOI 10.1007/s00432-007-0321-y
   Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5
   Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110
   Di Fazio P, 2012, EXP CELL RES, V318, P1832, DOI 10.1016/j.yexcr.2012.04.018
   Di Fazio P, 2010, CELL ONCOL, V32, P285, DOI 10.3233/CLO-2010-0511
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462
   Duffy A, 2010, EXPERT REV GASTROENT, V4, P551, DOI 10.1586/EGH.10.58
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fiskus W, 2009, CANCER BIOL THER, V8, P939, DOI 10.4161/cbt.8.10.8213
   Gahr S, 2012, J CANCER, V3, P158, DOI 10.7150/jca.4211
   Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z
   Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4
   Hirasawa Y, 2006, ONCOLOGY-BASEL, V71, P77, DOI 10.1159/000100475
   Honda S, 2008, INT J CANCER, V123, P1117, DOI 10.1002/ijc.23613
   Hu L, 2010, HEPATOL INT, V4, P423, DOI 10.1007/s12072-010-9164-8
   Jain S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026799
   Januchowski R, 2007, CANCER LETT, V246, P313, DOI 10.1016/j.canlet.2006.03.010
   Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x
   Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027
   Lee EM, 2009, INT J MOL MED, V24, P45, DOI 10.3892/ijmm_00000204
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71
   Liu JB, 2011, WORLD J GASTROENTERO, V17, P4718, DOI 10.3748/wjg.v17.i42.4718
   Moribe T, 2009, INT J CANCER, V125, P388, DOI 10.1002/ijc.24394
   Neureiter D, 2007, SCAND J GASTROENTERO, V42, P103, DOI 10.1080/00365520600874198
   Ocker M, 2005, J CANCER RES CLIN, V131, P385, DOI 10.1007/s00432-004-0664-6
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Ocker Matthias, 2010, World J Biol Chem, V1, P55, DOI 10.4331/wjbc.v1.i5.55
   Oh BK, 2007, INT J MOL MED, V20, P65
   Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060
   Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017
   Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034
   Peng LR, 2011, MOL CELL BIOL, V31, P4720, DOI 10.1128/MCB.06147-11
   Peng Lirong, 2011, Handb Exp Pharmacol, V206, P39, DOI 10.1007/978-3-642-21631-2_3
   Prince HM, 2009, FUTURE ONCOL, V5, P601, DOI 10.2217/FON.09.36
   Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Rhodes LV, 2012, ONCOL REP, V27, P10, DOI 10.3892/or.2011.1488
   Saelee P, 2010, ASIAN PAC J CANCER P, V11, P1677
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510
   Schneider-Stock R, 2007, IDRUGS, V10, P557
   Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Um TH, 2011, J HEPATOL, V54, P939, DOI 10.1016/j.jhep.2010.08.021
   Venturelli S, 2011, GUT, V60, P156, DOI 10.1136/gut.2010.208041
   Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Yeo W, 2005, LIVER INT, V25, P266, DOI 10.1111/j.1478-3231.2005.01084.x
   You JS, 2008, ONCOGENE, V27, P1376, DOI 10.1038/sj.onc.1210776
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124
   Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
   Zopf S, 2007, INT J ONCOL, V31, P1391
NR 63
TC 37
Z9 39
U1 1
U2 24
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD SEP 3
PY 2012
VL 12
AR 386
DI 10.1186/1471-2407-12-386
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 029XM
UT WOS:000310530900001
PM 22943463
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Fu, A
   Leaderer, D
   Zheng, TZ
   Hoffman, AE
   Stevens, RG
   Zhu, Y
AF Fu, Alan
   Leaderer, Derek
   Zheng, Tongzhang
   Hoffman, Aaron E.
   Stevens, Richard G.
   Zhu, Yong
TI Genetic and epigenetic associations of circadian gene TIMELESS and
   breast cancer risk
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE TIMELESS; circadian genetics; breast cancer; genetic variants;
   epigenetic variants
ID CLOCK; NIGHT; WOMEN; DISRUPTION; EXPRESSION; LIGHT; WORK
AB Results from recent molecular epidemiologic studies suggest that the core circadian genes play a role in breast tumorigenesis, possibly by influencing hormone regulation or other pathways relevant to cancer. In order to further evaluate this hypothesis, we conducted a genetic and epigenetic association study of the circadian regulator TIMELESS in breast carcinogenesis. We detected significant associations between two tagging SNPs (rs2291738 and rs7302060) in the TIMELESS gene and breast cancer among 441 breast cancer cases and 479 cancer-free controls, with apparent effect modification by ER/PR status. The presence of the C allele of rs7302060 was found to be associated with reduced breast cancer risk (OR, 0.54; 95% CI, 0.54-0.99). In addition, both the G/G genotype of rs2291738 and the C/C genotype of rs7302060 were associated with reduced risk of breast cancer among ER- or PR-positive breast cancer cases (OR, 0.46; 95% CI, 0.22-0.97 and OR, 0.36; 95% CI, 0.17-0.78, respectively). We also observed a significant association between stage II, III, and IV breast cancers and TIMELESS promoter hypomethylation in peripheral blood lymphocytes (OR, 0.35; 95% CI, 0.13-0.96) in 80 breast cancer cases and 80 age-matched controls, which is corroborated by documented overexpression of TIMELESS in breast tumor tissue compared to adjacent normal tissue. Our findings support the hypothesized role of circadian genes in breast tumorigenesis, and identify a set of circadian biomarkers for breast cancer susceptibility. (c) 2011 Wiley Periodicals, Inc.
C1 [Fu, Alan; Leaderer, Derek; Zheng, Tongzhang; Hoffman, Aaron E.; Zhu, Yong] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Stevens, Richard G.] Univ Connecticut, Ctr Hlth, Dept Community Med & Hlth Care, Farmington, CT USA.
C3 Yale University; University of Connecticut
RP Zhu, Y (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
FU National Institutes of Health [CA122676, ES018915]
FX This work was supported by the National Institutes of Health (grants
   CA122676 and ES018915). We would also like to thank Irina Tikhonova at
   Yale University's W. M. Keck Foundation Biotechnology Research
   Laboratory for performing the Sequenom genotyping analysis.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Davis S, 2001, JNCI-J NATL CANCER I, V93, P1557, DOI 10.1093/jnci/93.20.1557
   Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072
   Hansen J, 2001, EPIDEMIOLOGY, V12, P74, DOI 10.1097/00001648-200101000-00013
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Schernhammer ES, 2001, J NATL CANCER I, V93, P1563, DOI 10.1093/jnci/93.20.1563
   Stevens RG, 2005, EPIDEMIOLOGY, V16, P254, DOI 10.1097/01.ede.0000152525.21924.54
   Stevens RG, 2001, CANCER CAUSE CONTROL, V12, P279, DOI 10.1023/A:1011237000609
   STEVENS RG, 1987, AM J EPIDEMIOL, V125, P556, DOI 10.1093/oxfordjournals.aje.a114569
   Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744
   Ünsal-Kaçmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005
   Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576
   Zheng TZ, 2000, CANCER EPIDEM BIOMAR, V9, P167
   Zhu Y, 2005, CANCER EPIDEM BIOMAR, V14, P268
NR 19
TC 52
Z9 59
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD DEC
PY 2012
VL 51
IS 12
BP 923
EP 929
DI 10.1002/mc.20862
PG 7
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 021YV
UT WOS:000309922900001
PM 22006848
DA 2025-01-12
ER

PT J
AU Gao, W
   Chan, JYW
   Wei, WI
   Wong, TS
AF Gao, Wei
   Chan, Jimmy Yu-Wai
   Wei, William Ignance
   Wong, Thian-Sze
TI Anti-cancer Effects of Curcumin on Head and Neck Cancers
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Chemotherapeutic agent; Curcumin; Epigenetics regulation; Head and neck
   cancer
ID SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; ADVANCED PANCREATIC-CANCER; I
   CLINICAL-TRIAL; NASOPHARYNGEAL CARCINOMA; CONSTITUTIVE ACTIVATION;
   CHEMOPREVENTIVE AGENT; DOWN-REGULATION; BREAST-CANCER; UP-REGULATION
AB Head and neck cancer is the sixth large type of cancer in the world. The treatment regimens for head and neck cancer encompass surgery, radiotherapy and chemotherapy. However, all current treatment regimens for head and neck cancer have adverse effects. Therefore, continuing investigations have been undertaken to seek less toxic therapies to reduce treatment morbidity for head and neck cancer. Substantial evidence has demonstrated that curcumin inhibited proliferation, migration, invasion and metastasis and induced apoptosis via modulating multiple signaling pathways in head and neck cancer. Curcumin also suppressed the growth of xenograft derived from head and neck cancer in vivo in animal models. This review summarizes the evidence demonstrating potential use of curcumin as a single chemotherapeutic agent or in combination with other chemotherapeutic agents and radiation to minimize their toxicity in head and neck cancer. Although curcumin has been shown to be safe at doses of 8 g/d in both phase I and phase II clinical trials, its bioavailability is poor. Overcoming the poor bioavailability of curcumin in the near future would facilitate its clinical use.
C1 [Gao, Wei; Chan, Jimmy Yu-Wai; Wei, William Ignance; Wong, Thian-Sze] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong
RP Wong, TS (通讯作者)，Queen Mary Hosp, Dept Surg, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM thiansze@graduate.hku.hk
RI Wong, Thian/C-4447-2009
OI gao, wei/0000-0002-7426-1874; Wong, Thian Sze/0000-0002-8245-4019
FU Li Shu Pui Professorship, The University of Hong Kong
FX The study was supported by Li Shu Pui Professorship, The University of
   Hong Kong
CR Abuzeid WM, 2011, ARCH OTOLARYNGOL, V137, P499, DOI 10.1001/archoto.2011.63
   Aftab N, 2010, PHYTOTHER RES, V24, P500, DOI 10.1002/ptr.2960
   Aggarwal BB, 2007, BIOCHEM PHARMACOL, V73, P1024, DOI 10.1016/j.bcp.2006.12.010
   Aggarwal S, 2004, INT J CANCER, V111, P679, DOI 10.1002/ijc.20333
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   [Anonymous], CURR PHARM BIOTECHNO
   Argiris A, 2003, CANC TREAT, V114, P15
   Argiris A, 2004, CLIN CANCER RES, V10, P1956, DOI 10.1158/1078-0432.CCR-03-1077
   Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X
   Bayet-Robert M, 2010, CANCER BIOL THER, V9, P8, DOI 10.4161/cbt.9.1.10392
   Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793
   Bora-Tatar G, 2009, BIOORGAN MED CHEM, V17, P5219, DOI 10.1016/j.bmc.2009.05.042
   Burz C, 2009, ACTA ONCOL, V48, P811, DOI 10.1080/02841860902974175
   Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098
   Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196
   Chakravarti N, 2006, INT J CANCER, V119, P1268, DOI 10.1002/ijc.21967
   Chakravarti N, 2010, CANCER PREV RES, V3, P331, DOI 10.1158/1940-6207.CAPR-09-0076
   Chang KW, 2010, INT J CANCER, V127, P9, DOI 10.1002/ijc.25220
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Choi HY, 2010, PROSTATE CANCER P D, V13, P343, DOI 10.1038/pcan.2010.26
   Clark CA, 2010, CANCER PREV RES, V3, P1586, DOI 10.1158/1940-6207.CAPR-09-0244
   D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
   Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906
   De R, 2009, ANTIMICROB AGENTS CH, V53, P1592, DOI 10.1128/AAC.01242-08
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Duarte VM, 2010, MOL CANCER THER, V9, P2665, DOI 10.1158/1535-7163.MCT-10-0064
   Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802
   Estilo CL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-11
   Garcea G, 2005, CANCER EPIDEM BIOMAR, V14, P120
   Gottschlich S, 2006, INT J ONCOL, V29, P605
   Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hua WF, 2010, EUR J PHARMACOL, V637, P16, DOI 10.1016/j.ejphar.2010.03.051
   Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697
   Ji CH, 1999, ENDOCRINOLOGY, V140, P4564, DOI 10.1210/en.140.10.4564
   Jurenka JS, 2009, ALTERN MED REV, V14, P141
   Kang HJ, 2009, BREAST J, V15, P223, DOI 10.1111/j.1524-4741.2009.00709.x
   Khafif A, 2005, OTOLARYNG HEAD NECK, V132, P317, DOI 10.1016/j.otohns.2004.09.006
   Khafif A, 2009, LARYNGOSCOPE, V119, P2019, DOI 10.1002/lary.20582
   Kim KC, 2010, KOREAN J PHYSIOL PHA, V14, P391, DOI 10.4196/kjpp.2010.14.6.391
   Kim SG, 2011, CLIN CANCER RES, V17, P5953, DOI 10.1158/1078-0432.CCR-11-1272
   Kuo CL, 2011, INT J ONCOL, V39, P319, DOI 10.3892/ijo.2011.1057
   Li Y, 2011, CANCER CHEMOTH PHARM, V68, P603, DOI 10.1007/s00280-010-1515-6
   Liao SK, 2011, J CELL BIOCHEM, V112, P1055, DOI 10.1002/jcb.23019
   Lin H.P., 2011, PHYTOTHER RES
   Lin SC, 2002, J PATHOL, V198, P317, DOI 10.1002/path.1220
   Lin YT, 2009, J AGR FOOD CHEM, V57, P3765, DOI 10.1021/jf803758x
   Liu HL, 2005, ACTA PHARMACOL SIN, V26, P603, DOI 10.1111/j.1745-7254.2005.00081.x
   Liu SL, 2011, J HUAZHONG U SCI-MED, V31, P530, DOI 10.1007/s11596-011-0485-1
   Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041
   López-Jornet P, 2011, ACTA ODONTOL SCAND, V69, P269, DOI 10.3109/00016357.2011.554864
   LoTempio MM, 2005, CLIN CANCER RES, V11, P6994, DOI 10.1158/1078-0432.CCR-05-0301
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003
   Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133
   Marur S, 2008, MAYO CLIN PROC, V83, P489, DOI 10.4065/83.4.489
   Massarelli E, 2005, CANCER-AM CANCER SOC, V104, P2430, DOI 10.1002/cncr.21476
   Mitra A, 2006, J ENVIRON PATHOL TOX, V25, P679, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i4.70
   Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041
   Molinolo AA, 2009, ORAL ONCOL, V45, P324, DOI 10.1016/j.oraloncology.2008.07.011
   Morimoto T, 2008, J CLIN INVEST, V118, P868, DOI 10.1172/JCI33160
   Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065
   Narayan S, 2004, J MOL HISTOL, V35, P301, DOI 10.1023/B:HIJO.0000032361.98815.bb
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8
   Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N
   Park MT, 2003, J BIOCHEM MOL BIOL, V36, P60
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508
   Reich NC, 2006, NAT REV IMMUNOL, V6, P602, DOI 10.1038/nri1885
   Saha A, 2010, BIOL PHARM BULL, V33, P1291, DOI 10.1248/bpb.33.1291
   Saini S, 2011, CANCER PREV RES, V4, P1698, DOI 10.1158/1940-6207.CAPR-11-0267
   Saydmohammed M, 2010, J CELL BIOCHEM, V110, P447, DOI 10.1002/jcb.22558
   Scott DW, 2004, CARCINOGENESIS, V25, P2155, DOI 10.1093/carcin/bgh239
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Shen HM, 2009, APOPTOSIS, V14, P348, DOI 10.1007/s10495-009-0315-0
   Shin HK, 2010, PHYTOTHER RES, V24, P577, DOI 10.1002/ptr.2989
   Sriuranpong V, 2003, CANCER RES, V63, P2948
   Ströfer M, 2011, STRAHLENTHER ONKOL, V187, P393, DOI 10.1007/s00066-011-2248-0
   Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656
   Vermorken JB, 2008, CANCER-AM CANCER SOC, V112, P2710, DOI 10.1002/cncr.23442
   Vissink A, 2003, CRIT REV ORAL BIOL M, V14, P199, DOI 10.1177/154411130301400305
   Wang D, 2008, CLIN CANCER RES, V14, P6228, DOI 10.1158/1078-0432.CCR-07-5177
   Wong SJ, 2011, CANCER-AM CANCER SOC, V117, P1679, DOI 10.1002/cncr.25721
   Wong TS, 2010, ANTICANCER RES, V30, P2851
   Wu SH, 2010, ANTICANCER RES, V30, P2125
   Yallapu MM, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-11
   Yang J, 2010, MED ONCOL, V27, P1114, DOI 10.1007/s12032-009-9344-3
   Yu ZW, 2007, CANCER EPIDEM BIOMAR, V16, P553, DOI 10.1158/1055-9965.EPI-06-0121
   Zhang J, 2010, BIOCHEM BIOPH RES CO, V399, P1, DOI 10.1016/j.bbrc.2010.07.013
   Zheng Z, 1999, HUM PATHOL, V30, P458, DOI 10.1016/S0046-8177(99)90123-5
NR 92
TC 26
Z9 29
U1 0
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PD NOV
PY 2012
VL 12
IS 9
BP 1110
EP 1116
DI 10.2174/187152012803529736
PG 7
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 023SG
UT WOS:000310055000010
PM 22583425
DA 2025-01-12
ER

PT J
AU de Oliveira, MMC
   de Oliveira, SFV
   Lima, RS
   Urban, CD
   Cavalli, LR
   Ribeiro, EMDF
   Cavalli, IJ
AF Costa de Oliveira, Marcia Maria
   Vieira de Oliveira, Sarah Franco
   Lima, Rubens Silveira
   Urban, Cicero de Andrade
   Cavalli, Luciane Regina
   de Souza Fonseca Ribeiro, Enilze Maria
   Cavalli, Iglenir Joao
TI Differential loss of heterozygosity profile on chromosome 3p in ductal
   and lobular breast carcinomas
SO HUMAN PATHOLOGY
LA English
DT Article
DE LOH; 3p; Ductal breast carcinoma; Lobular breast carcinoma
ID TUMOR-SUPPRESSOR; FHIT GENE; EPIGENETIC INACTIVATION; CANCER;
   EXPRESSION; ASSOCIATION; LUNG; LESIONS; REGION; BRCA1
AB The 2 main histologic types of infiltrating breast cancer, invasive lobular and invasive ductal carcinoma, are morphologically and clinically distinct. Studies revealed that different patterns of gene expression and loss of heterozygosity can also distinguish these 2 subtypes. A whole-genome study using single nucleotide polymorphism array found a significantly higher frequency of loss of heterozygosity on 3p in invasive ductal carcinoma when compared with invasive lobular carcinoma. In this study, we performed a loss of heterozygosity analysis of the 3p chromosome region in ductal and lobular breast tumors. Seven microsatellite markers were evaluated in a series of 136 sporadic breast cancer cases (118 invasive ductal carcinoma and 18 invasive lobular carcinoma) and correlated with clinical-histopathologic parameters from the patients. A significantly higher frequency of loss of heterozygosity was observed in invasive ductal carcinoma (65.3%) when compared with invasive lobular carcinoma (38.9%). When the markers were analyzed separately, loss of heterozygosity at 3 of them, D351307 in 3p26.3, D3SI286 in 3p24.3, and D3SI300 in 3p14.2, were significantly more frequent in ductal than in lobular tumors. D3SI307 marker showed the highest frequency of loss of heterozygosity in invasive ductal carcinoma (46.2%), and associations between loss of this marker and loss of estrogen and progesterone receptors were found in these samples. Our results confirm the observations that invasive ductal carcinoma has a higher frequency of loss of heterozygosity events across the 3p region than invasive lobular carcinoma and show that specific losses on 3p26.3, 3p24.3, and 3p14.2 regions are more frequent in ductal than in lobular tumors. We discuss our data in relation to the known tumor suppressor genes that are mapped at the 3p loci investigated and their present relevant roles in breast cancer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Costa de Oliveira, Marcia Maria; Vieira de Oliveira, Sarah Franco; de Souza Fonseca Ribeiro, Enilze Maria; Cavalli, Iglenir Joao] Univ Fed Parana, Dept Genet, BR-81531970 Curitiba, Parana, Brazil.
   [Lima, Rubens Silveira] Clin Hosp, BR-80060150 Curitiba, Parana, Brazil.
   [Lima, Rubens Silveira; Urban, Cicero de Andrade] Nossa Senhora Gracas Hosp, BR-80810120 Curitiba, Parana, Brazil.
   [Urban, Cicero de Andrade] Univ Posit, BR-81280330 Curitiba, Parana, Brazil.
   [Cavalli, Luciane Regina] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
C3 Universidade Federal do Parana; Georgetown University
RP Cavalli, IJ (通讯作者)，Univ Fed Parana, Dept Genet, BR-81531970 Curitiba, Parana, Brazil.
EM cavalli@ufpr.br
RI Ribeiro, Enilze/K-7319-2012; Urban, Cicero/D-1578-2011; Maciel,
   Sarah/KDP-1986-2024; Cavalli, Luciane/J-6100-2012
OI Franco Vieira de Oliveira Maciel, Sarah/0000-0002-5746-7109; Cavalli,
   Luciane Regina/0000-0001-5619-9037
FU National Research Council for Scientific and Technologic Development
   (CNPq), Brazil
FX This work was supported, in part, by the National Research Council for
   Scientific and Technologic Development (CNPq), Brazil. We thank the
   staff of the Hospital Nossa Senhora das Gracas and Hospital das
   Clinicas, Curitiba, PR, Brazil, for providing all necessary information
   for this study.
CR Ahmadian M, 1997, CANCER RES, V57, P3664
   Arun B, 2005, CANCER EPIDEM BIOMAR, V14, P1681, DOI 10.1158/1055-9965.EPI-04-0278
   Barroso E, 2006, CARCINOGENESIS, V27, P1930, DOI 10.1093/carcin/bgl062
   Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Campiglio M, 1999, CANCER RES, V59, P3866
   Cavalli LR, 2004, CANCER GENET CYTOGEN, V149, P38, DOI 10.1016/S0165-4608(03)00282-6
   Chikman B, 2010, ISR MED ASSOC J, V12, P697
   Dammann R, 2001, CANCER RES, V61, P3105
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Guigon CJ, 2011, ONCOGENE, V30, P3381, DOI 10.1038/onc.2011.50
   Huiping C, 2000, EUR J CANCER, V36, P1552, DOI 10.1016/S0959-8049(00)00143-X
   Hwang ES, 2004, CANCER, V100, P2562, DOI 10.1002/cncr.20273
   Ingvarsson S, 2001, CANCER DETECT PREV, V25, P292
   Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861
   Korkola JE, 2003, CANCER RES, V63, P7167
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Lerman MI, 2000, CANCER RES, V60, P6116
   Loo LWM, 2008, GENE CHROMOSOME CANC, V47, P1049, DOI 10.1002/gcc.20610
   Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Rao Y, 2002, GENE DEV, V16, P2973, DOI 10.1101/gad.1005802
   Rintala-Maki ND, 2004, CELL BIOCHEM FUNCT, V22, P307, DOI 10.1002/cbf.1106
   Rosen PP, 1997, BREAST PATHOLOGY, P545
   Roylance R, 2006, ONCOGENE, V25, P6544, DOI 10.1038/sj.onc.1209659
   Santos SCL, 2004, J CLIN PATHOL, V57, P374, DOI 10.1136/jcp.2003.013490
   Schwarzenbach H, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1772
   Silva JM, 2002, ONCOGENE, V21, P4307, DOI 10.1038/sj.onc.1205534
   Soares EWS, 2010, CANCER GENET CYTOGEN, V199, P24, DOI 10.1016/j.cancergencyto.2010.01.019
   Terry G, 2007, BRIT J CANCER, V96, P110, DOI 10.1038/sj.bjc.6603512
   Turashvili Gulisa, 2005, Biomedical Papers (Olomouc), V149, P63, DOI 10.5507/bp.2005.006
   van der Groep P, 2008, BREAST CANCER RES TR, V107, P41, DOI 10.1007/s10549-007-9534-7
   Ventii KH, 2008, CANCER RES, V68, P6953, DOI 10.1158/0008-5472.CAN-08-0365
   de Oliveira SFV, 2010, CANCER GENET CYTOGEN, V200, P23, DOI 10.1016/j.cancergencyto.2010.03.002
   Yang QF, 2002, J HUM GENET, V47, P453, DOI 10.1007/s100380200064
   Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
   Zia MK, 2007, INT J MOL MED, V20, P605
NR 38
TC 1
Z9 1
U1 2
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD OCT
PY 2012
VL 43
IS 10
BP 1661
EP 1667
DI 10.1016/j.humpath.2011.12.008
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 018VC
UT WOS:000309693600018
PM 22503535
DA 2025-01-12
ER

PT J
AU Beckman, RA
   Schemmann, GS
   Yeang, CH
AF Beckman, Robert A.
   Schemmann, Gunter S.
   Yeang, Chen-Hsiang
TI Impact of genetic dynamics and single-cell heterogeneity on development
   of nonstandard personalized medicine strategies for cancer
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE systems biology; evolution; treatment strategy; targeted therapy;
   combinations
ID LUNG-CANCER; LYMPHOBLASTIC-LEUKEMIA; MUTATIONAL EVOLUTION;
   PANCREATIC-CANCER; DRUG-SENSITIVITY; CLONAL SELECTION; GENOMIC ANALYSIS;
   BREAST-CANCER; EGFR; RESISTANCE
AB Cancers are heterogeneous and genetically unstable. Current practice of personalized medicine tailors therapy to heterogeneity between cancers of the same organ type. However, it does not yet systematically address heterogeneity at the single-cell level within a single individual's cancer or the dynamic nature of cancer due to genetic and epigenetic change as well as transient functional changes. We have developed a mathematical model of personalized cancer therapy incorporating genetic evolutionary dynamics and single-cell heterogeneity, and have examined simulated clinical outcomes. Analyses of an illustrative case and a virtual clinical trial of over 3 million evaluable "patients" demonstrate that augmented (and sometimes counterintuitive) nonstandard personalized medicine strategies may lead to superior patient outcomes compared with the current personalized medicine approach. Current personalized medicine matches therapy to a tumor molecular profile at diagnosis and at tumor relapse or progression, generally focusing on the average, static, and current properties of the sample. Nonstandard strategies also consider minor subclones, dynamics, and predicted future tumor states. Our methods allow systematic study and evaluation of nonstandard personalized medicine strategies. These findings may, in turn, suggest global adjustments and enhancements to translational oncology research paradigms.
C1 [Beckman, Robert A.; Yeang, Chen-Hsiang] Inst Adv Study, Sch Nat Sci, Simons Ctr Syst Biol, Princeton, NJ 08540 USA.
   [Beckman, Robert A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Ctr Evolut & Canc, San Francisco, CA 94158 USA.
   [Schemmann, Gunter S.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
   [Schemmann, Gunter S.] World Water & Solar Technol, Princeton, NJ 08540 USA.
   [Yeang, Chen-Hsiang] Acad Sinica, Inst Stat Sci, Taipei 115, Taiwan.
C3 Institute for Advanced Study - USA; University of California System;
   University of California San Francisco; UCSF Medical Center; UCSF Helen
   Diller Family Comprehensive Cancer Center; Princeton University;
   Academia Sinica - Taiwan
RP Beckman, RA (通讯作者)，Inst Adv Study, Sch Nat Sci, Simons Ctr Syst Biol, Olden Lane, Princeton, NJ 08540 USA.
EM eniac1@snip.net
RI Yeang, Chen-Hsiang/AAP-2962-2021
CR Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Beckman RA, 2005, GENETICS, V171, P2123, DOI 10.1534/genetics.105.040840
   Beckman RA, 2006, P NATL ACAD SCI USA, V103, P14140, DOI 10.1073/pnas.0606271103
   Beckman RA, 2011, NAT REV DRUG DISCOV, V10, P735, DOI 10.1038/nrd3550
   Beckman RA, 2010, SEMIN CANCER BIOL, V20, P340, DOI 10.1016/j.semcancer.2010.10.004
   Beckman RA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005860
   Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Dutta PK, 2005, STRATEGIES GAMES THE
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fox EJ, 2009, CANCER RES, V69, P4948, DOI 10.1158/0008-5472.CAN-09-1231
   Fujii H, 1996, CANCER RES, V56, P1493
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727
   Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Jiang H, 2011, NAT CHEM BIOL, V7, P92, DOI 10.1038/NCHEMBIO.503
   Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316
   Klein CA, 2006, CELL CYCLE, V5, P1788, DOI 10.4161/cc.5.16.3097
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   LOEB LA, 1974, CANCER RES, V34, P2311
   Loeb LA, 2008, CANCER RES, V68, P3551, DOI 10.1158/0008-5472.CAN-07-5835
   Longo DL, 2012, NEW ENGL J MED, V366, P956, DOI 10.1056/NEJMe1200656
   Lovly CM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003728
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266
   NORTON L, 1977, CANCER TREAT REP, V61, P1307
   Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733
   Orlova A, 2007, CANCER RES, V67, P2178, DOI 10.1158/0008-5472.CAN-06-2887
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Riely GJ, 2007, CLIN CANCER RES, V13, P5150, DOI 10.1158/1078-0432.CCR-07-0560
   Shah NP, 2007, J CLIN INVEST, V117, P2562, DOI 10.1172/JCI30890
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Solit DB, 2012, NATURE, V483, P44, DOI 10.1038/483044a
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Wang SH, 2010, CLIN CANCER RES, V16, P1324, DOI 10.1158/1078-0432.CCR-09-2672
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733
NR 43
TC 81
Z9 90
U1 0
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 4
PY 2012
VL 109
IS 36
BP 14586
EP 14591
DI 10.1073/pnas.1203559109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 007TZ
UT WOS:000308912600061
PM 22891318
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Vijayaraghavalu, S
   Peetla, C
   Lu, S
   Labhasetwar, V
AF Vijayaraghavalu, Sivakumar
   Peetla, Chiranjeevi
   Lu, Shan
   Labhasetwar, Vinod
TI Epigenetic Modulation of the Biophysical Properties of Drug-Resistant
   Cell Lipids to Restore Drug Transport and Endocytic Functions
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE cancer cell membrane; sphingomyelin; drug resistance; membrane rigidity;
   P-glycoprotein; cancer therapy; epigenetic
ID P-GLYCOPROTEIN ACTIVITY; BREAST-CANCER CELLS; CHOLESTEROL; MEMBRANES;
   SPHINGOMYELIN; DOXORUBICIN; APOPTOSIS; PROTEINS; ORGANIZATION;
   POLYMORPHISM
AB In our recent studies exploring the biophysical characteristics of resistant cell lipids, and the role they play in drug transport, we demonstrated the difference of drug-resistant breast cancer cells from drug-sensitive cells in lipid composition and biophysical properties, suggesting that cancer cells acquire a drug-resistant phenotype through the alteration of lipid synthesis to inhibit intracellular drug transport to protect from cytotoxic effect. In cancer cells, epigenetic changes (e.g., DNA hypermethylation) are essential to maintain this drug-resistant phenotype. Thus, altered lipid synthesis may be linked to epigenetic mechanisms of drug resistance. We hypothesize that reversing DNA hypermethylation in resistant cells with an epigenetic drug could alter lipid synthesis, changing the cell membrane's biophysical properties to facilitate drug delivery to overcome drug resistance. Herein we show that treating drug-resistant breast cancer cells (MCF-7/ADR) with the epigenetic drug 5-aza-2'-deoxycytidine (decitabine) significantly alters cell lipid composition and biophysical properties, causing the resistant cells to acquire biophysical characteristics similar to those of sensitive cell (MCF-7) lipids. Following decitabine treatment, resistant cells demonstrated increased sphingomyelinase activity, resulting in a decreased sphingomyelin level that influenced lipid domain structures, increased membrane fluidity, and reduced P-glycoprotein expression. Changes in the biophysical characteristics of resistant cell lipids facilitated doxorubicin transport and restored endocytic function for drug delivery with a lipid-encapsulated form of doxorubicin, enhancing the drug efficacy. In conclusion, we have established a new mechanism for efficacy of an epigenetic drug, mediated through changes in lipid composition and biophysical properties, in reversing cancer drug resistance.
C1 [Vijayaraghavalu, Sivakumar; Peetla, Chiranjeevi; Lu, Shan; Labhasetwar, Vinod] Cleveland Clin, Dept Biomed Engn, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Labhasetwar, Vinod] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Labhasetwar, V (通讯作者)，ND20 Cleveland Clin, Dept Biomed Engn, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
RI Vijayaraghavalu, Sivakumar/IZE-6423-2023; Labhasetwar,
   Vinod/J-9660-2016; Peetla, Chiranjeevi/E-4916-2010
OI Vijayaraghavalu, Sivakumar/0000-0002-6770-6716; Peetla,
   Chiranjeevi/0000-0002-9471-7322
FU National Cancer Institute of the National Institutes of Health [R01
   CA149359-01]
FX This study was funded by Grant R01 CA149359-01 (to V.L.) from the
   National Cancer Institute of the National Institutes of Health.
CR Brzustowicz MR, 2002, BIOPHYS J, V82, P285, DOI 10.1016/S0006-3495(02)75394-0
   Chachaty C, 2005, BIOPHYS J, V88, P4032, DOI 10.1529/biophysj.104.054155
   Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583
   Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771
   COVEY JM, 1984, CANCER TREAT REP, V68, P1475
   CULLIS PR, 1986, CHEM PHYS LIPIDS, V40, P127, DOI 10.1016/0009-3084(86)90067-8
   CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1
   Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620
   Escribá PV, 2008, J CELL MOL MED, V12, P829, DOI 10.1111/j.1582-4934.2008.00281.x
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Frolov VA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004747
   Gayet L, 2005, BIOCHEMISTRY-US, V44, P4499, DOI 10.1021/bi048669w
   Ghetie MA, 2004, BLOOD, V104, P178, DOI 10.1182/blood-2003-12-4255
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gouazé V, 2001, MOL PHARMACOL, V60, P488
   ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645
   Kiziltepe T, 2007, MOL CANCER THER, V6, P1718, DOI 10.1158/1535-7163.MCT-07-0010
   Kopecka J, 2011, J CONTROL RELEASE, V149, P196, DOI 10.1016/j.jconrel.2010.10.003
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315
   Narváez-Rivas M, 2011, J CHROMATOGR A, V1218, P3453, DOI 10.1016/j.chroma.2011.03.067
   Peetla C, 2010, MOL PHARMACEUT, V7, P2334, DOI 10.1021/mp100308n
   Rauch C, 2000, BIOPHYS J, V78, P3036, DOI 10.1016/S0006-3495(00)76842-1
   Rosetti CM, 2008, BBA-BIOMEMBRANES, V1778, P1665, DOI 10.1016/j.bbamem.2008.02.007
   Schulz WA, 2011, WORLD J CLIN ONCOL, V2, P1, DOI 10.5306/wjco.v2.i1.1
   SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653
   Solyanik G. I., 2010, Experimental Oncology, V32, P181
   Troost J, 2004, MOL PHARMACOL, V66, P1332, DOI 10.1124/mol.104.002329
   van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330
   Vance JE, 2004, BIOCHEM CELL BIOL, V82, P113, DOI 10.1139/o03-073
   VANDIJCK PWM, 1979, BIOCHIM BIOPHYS ACTA, V555, P89, DOI 10.1016/0005-2736(79)90074-9
   vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7
   Wehbe-Janek H, 2007, ANTICANCER RES, V27, P3143
   Xu J, 2007, CANCER RES, V67, P1203, DOI 10.1158/0008-5472.CAN-06-2310
   ZWAAL RFA, 1976, TRENDS BIOCHEM SCI, V1, P112, DOI 10.1016/0968-0004(76)90322-4
NR 36
TC 59
Z9 64
U1 2
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2012
VL 9
IS 9
BP 2730
EP 2742
DI 10.1021/mp300281t
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 998TQ
UT WOS:000308263700036
PM 22817326
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Wu, HC
   Delgado-Cruzata, L
   Flom, JD
   Perrin, M
   Liao, YY
   Ferris, JS
   Santella, RM
   Terry, MB
AF Wu, Hui-Chen
   Delgado-Cruzata, Lissette
   Flom, Julie D.
   Perrin, Mary
   Liao, Yuyan
   Ferris, Jennifer S.
   Santella, Regina M.
   Terry, Mary Beth
TI Repetitive element DNA methylation levels in white blood cell DNA from
   sisters discordant for breast cancer from the New York site of the
   Breast Cancer Family Registry
SO CARCINOGENESIS
LA English
DT Article
ID CHROMOSOME ANALYSIS; GLOBAL METHYLATION; HYPOMETHYLATION; RISK;
   BIOMARKER; TISSUES; ASSOCIATION; CARCINOMAS; PATTERNS; EXPOSURE
AB Global decreases in DNA methylation, particularly in repetitive elements, have been associated with genomic instability and human cancer. Emerging, though limited, data suggest that in white blood cell (WBC) DNA levels of methylation, overall or in repetitive elements, may be associated with cancer risk. We measured methylation levels of three repetitive elements [Satellite 2 (Sat2)], long interspersed nuclear element-1 (LINE-1) and Alu) by MethyLight, and LINE-1 by pyrosequencing in a total of 282 breast cancer cases and 347 unaffected sisters from the New York site of the Breast Cancer Family Registry (BCFR) using DNA from both granulocytes and total WBC. We found that methylation levels in all markers were correlated between sisters (Spearman correlation coefficients ranged from 0.17 to 0.55). Sat2 methylation was statistically significantly associated with increased breast cancer risk [odds ratio (OR) = 2.09, 95% confidence interval (CI) = 1.094.03; for each unit decrease in the natural log of the methylation level, OR = 2.12, 95% CI = 0.885.11 for the lowest quartile compared with the highest quartile]. These associations were only observed in total WBC but not granulocyte DNA. There was no association between breast cancer and LINE-1 and Alu methylation. If replicated in larger prospective studies, these findings support that selected markers of epigenetic changes measured in WBC, such as Sat2, may be potential biomarkers of breast cancer risk.
C1 [Wu, Hui-Chen; Delgado-Cruzata, Lissette; Flom, Julie D.; Liao, Yuyan; Ferris, Jennifer S.; Terry, Mary Beth] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.
   [Wu, Hui-Chen; Delgado-Cruzata, Lissette; Santella, Regina M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Perrin, Mary] NYU, Sch Med, Dept Psychiat, New York, NY USA.
   [Perrin, Mary] NYU, Sch Med, Dept Environm Med, New York, NY USA.
   [Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA.
C3 Columbia University; Columbia University; New York University; New York
   University; Columbia University
RP Terry, MB (通讯作者)，Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 W 168th St,724A, New York, NY 10032 USA.
EM mt146@columbia.edu
RI Wu, Lisa/JPA-4139-2023
OI Terry, Mary Beth/0000-0002-4106-5033; Delgado-Cruzata,
   Lissette/0000-0002-2884-0234
FU Breast Cancer Research Foundation; NIH [U01 CA69398, P30 CA13696, P30
   ES009089, K07 CA131094]; National Cancer Institute, National Institutes
   of Health, under RFA [CA-06-503]; Columbia University [U01 CA69398]
FX This work was supported by an award from the Breast Cancer Research
   Foundation and NIH grants U01 CA69398, P30 CA13696, P30 ES009089 and K07
   CA131094. This work was also supported by the National Cancer Institute,
   National Institutes of Health, under RFA #CA-06-503 and through
   cooperative agreements with members of the BCFR and Principal
   Investigators, including Columbia University (U01 CA69398). The content
   of this manuscript does not necessarily reflect the views or policies of
   the National Cancer Institute or any of the collaborating centers in the
   BCFR, nor does mention of trade names, commercial products or
   organizations imply endorsement by the United States Government or the
   BCFR.
CR Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Choi SH, 2009, INT J CANCER, V125, P723, DOI 10.1002/ijc.24384
   Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x
   EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ewing AD, 2010, GENOME RES, V20, P1262, DOI 10.1101/gr.106419.110
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Frühwald MC, 2002, MOL GENET METAB, V75, P1, DOI 10.1006/mgme.2001.3265
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   John EM, 2004, BREAST CANCER RES, V6, pR375, DOI 10.1186/bcr801
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kennedy DO, 2005, JNCI-J NATL CANCER I, V97, P127, DOI 10.1093/jnci/dji013
   Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   LU YJ, 1993, CANCER GENET CYTOGEN, V69, P91, DOI 10.1016/0165-4608(93)90081-V
   Machella N, 2008, CARCINOGENESIS, V29, P1367, DOI 10.1093/carcin/bgn140
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423
   PANDIS N, 1995, GENE CHROMOSOME CANC, V12, P173, DOI 10.1002/gcc.2870120304
   Patel A, 2003, ANN NY ACAD SCI, V983, P286, DOI 10.1111/j.1749-6632.2003.tb05983.x
   Pavanello S, 2009, INT J CANCER, V125, P1692, DOI 10.1002/ijc.24492
   Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P1466, DOI 10.1289/ehp.0800497
   Rusiecki JA, 2009, ENVIRON HEALTH PERSP, V117, P581, DOI 10.1289/ehp.11318
   Steinhoff C, 2004, MOL GENET GENOMICS, V270, P394, DOI 10.1007/s00438-003-0931-2
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Tycko B, 2003, ANN NY ACAD SCI, V983, P43, DOI 10.1111/j.1749-6632.2003.tb05961.x
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wright RO, 2010, ENVIRON HEALTH PERSP, V118, P790, DOI 10.1289/ehp.0901429
   Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zhu ZZ, 2011, CANCER CAUSE CONTROL, V22, P437, DOI 10.1007/s10552-010-9715-2
   Zipprich J, 2009, CANCER RES, V69, P2966, DOI 10.1158/0008-5472.CAN-08-3418
NR 48
TC 50
Z9 53
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2012
VL 33
IS 10
BP 1946
EP 1952
DI 10.1093/carcin/bgs201
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 018XJ
UT WOS:000309700900014
PM 22678115
OA Green Published
DA 2025-01-12
ER

PT J
AU Holm, K
   Grabau, D
   Lövgren, K
   Aradottir, S
   Gruvberger-Saal, S
   Howlin, J
   Saal, LH
   Ethier, SP
   Bendahl, PO
   Stål, O
   Malmström, P
   Fernö, M
   Rydén, L
   Hegardt, C
   Borg, Å
   Ringnér, M
AF Holm, Karolina
   Grabau, Dorthe
   Lovgren, Kristina
   Aradottir, Steina
   Gruvberger-Saal, Sofia
   Howlin, Jillian
   Saal, Lao H.
   Ethier, Stephen P.
   Bendahl, Par-Ola
   Stal, Olle
   Malmstrom, Per
   Ferno, Marten
   Ryden, Lisa
   Hegardt, Cecilia
   Borg, Ake
   Ringner, Markus
TI Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Breast cancer; Epigenetics; EZH2; H3K27me3; Molecular subtypes; Polycomb
ID GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE EZH2; COPY NUMBER
   ALTERATIONS; GENE-EXPRESSION; ADJUVANT TAMOXIFEN; DNA METHYLATION;
   PREMENOPAUSAL PATIENTS; MOLECULAR PORTRAITS; CELL-PROLIFERATION; SOMATIC
   MUTATIONS
AB Polycomb repressive complex 2 (PRC2) and its core member enhancer of zeste homolog 2 (EZH2) mediate the epigenetic gene silencing mark: trimethylation of lysine 27 on histone 3 (H3K27me3). H3K27me3 is characteristic of the chromatin at genes involved in developmental regulation in undifferentiated cells. Overexpression of EZH2 has been found in several cancer types such as breast, prostate, melanoma and bladder cancer. Moreover, overexpression is associated with highly proliferative and aggressive types of breast and prostate tumors. We have analyzed the abundance of EZH2 and H3K27me3 using immunohistochemistry in two large and Well-characterized breast tumor data sets encompassing more than 400 tumors. The results have been analyzed in relation to the molecular subtypes of breast tumors (basal-like, luminal A, luminal B, HER2-enriched and normal-like), as well as in subtypes defined by clinical markers (triple negative, ER+/HER2-/Ki67low, ER+/HER2-/Ki67high and HER2+), and were validated in representative breast cancer cell lines by western blot. We found significantly different expression of both EZH2 and H3K27me3 across all subtypes with high abundance of EZH2 in basal-like, triple negative and HER2-enriched tumors, and high H3K27me3 in luminal A, HER2-enriched and normal-like tumors. Intriguingly, the two markers show an inverse correlation, particularly for the basal-like and triple negative tumors. Consequently, high expression of EZH2 was associated with poor distant disease-free survival whereas high expression of H3K27me3 was associated with better survival. Additionally, none of 182 breast tumors was found to carry a previously described EZH2 mutation affecting Tyr641. Our observation that increased expression of EZH2 does not necessarily correlate with increased abundance of H3K27me3 supports the idea that EZH2 can have effects beyond epigenetic silencing of target genes in breast cancer. (c) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Ringner, Markus] Lund Univ, Dept Oncol, CREATE Hlth Strateg Ctr Translat Canc Res, SE-22184 Lund, Sweden.
   [Holm, Karolina; Lovgren, Kristina; Aradottir, Steina; Gruvberger-Saal, Sofia; Howlin, Jillian; Saal, Lao H.; Bendahl, Par-Ola; Malmstrom, Per; Ferno, Marten; Hegardt, Cecilia; Borg, Ake; Ringner, Markus] Lund Univ, Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.
   [Grabau, Dorthe] Skane Univ Hosp, Dept Clin Pathol, Lab Med, SE-22185 Lund, Sweden.
   [Ethier, Stephen P.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
   [Stal, Olle] Linkoping Univ, Div Oncol, Dept Clin & Expt Med, Fac Hlth Sci, SE-58185 Linkoping, Sweden.
   [Ryden, Lisa] Lund Univ, Skane Univ Hosp, Dept Surg, SE-22185 Lund, Sweden.
C3 Lund University; Lund University; Skane University Hospital; Lund
   University; Skane University Hospital; Medical University of South
   Carolina; Linkoping University; Lund University; Skane University
   Hospital
RP Ringnér, M (通讯作者)，Lund Univ, Dept Oncol, CREATE Hlth Strateg Ctr Translat Canc Res, BMC C13, SE-22184 Lund, Sweden.
EM karolina.holm@med.lu.se; dorthe.grabau@med.lu.se;
   kristina.lovgren@med.lu.se; steina.aradottir@med.lu.se;
   sofia.gruvberger@med.lu.se; jillian.howlin@med.lu.se;
   lao.saal@med.lu.se; ethier@musc.edu; par-ola.bendahl@med.lu.se;
   olle.stal@liu.se; per.malm-strom@med.lu.se; marten.ferno@med.lu.se;
   lisa.ryden@med.lu.se; cecilia.hegardt@med.lu.se; ake.borg@med.lu.se;
   markus.ringner@med.lu.se
RI Ringnér, Markus/G-3641-2011; Howlin, Jill/G-9665-2011; Saal,
   Lao/A-2919-2011
OI Ryden, Lisa/0000-0001-7515-3130; Howlin, Jill/0000-0002-2766-3002; Saal,
   Lao/0000-0002-0815-1896; Ringner, Markus/0000-0001-5469-8940
FU Swedish Cancer Society; Foundation for Strategic Research through the
   Lund Strategic Centre for Translational Cancer Research (CREATE Health);
   Gunnar Nilsson Cancer Foundation; Mrs. Berta Kamprad Foundation; Swedish
   Research Council
FX The present study was supported by the Swedish Cancer Society, the
   Foundation for Strategic Research through the Lund Strategic Centre for
   Translational Cancer Research (CREATE Health), the Gunnar Nilsson Cancer
   Foundation, the Mrs. Berta Kamprad Foundation, and the Swedish Research
   Council.
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bödör C, 2011, LEUKEMIA, V25, P726, DOI 10.1038/leu.2010.311
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cai MY, 2011, MOL MED, V17, P12, DOI 10.2119/molmed.2010.00103
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Derfoul A, 2011, CARCINOGENESIS, V32, P1607, DOI 10.1093/carcin/bgr184
   Fernö M, 1997, ACTA ONCOL, V36, P793, DOI 10.3109/02841869709001359
   Fernö M, 2000, BREAST CANCER RES TR, V59, P69, DOI 10.1023/A:1006332423620
   FERNO M, 1995, BREAST CANCER RES TR, V36, P23, DOI 10.1007/BF00690181
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933
   Gruvberger-Saal SK, 2007, CLIN CANCER RES, V13, P1987, DOI 10.1158/1078-0432.CCR-06-1823
   Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787
   Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018
   He LR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-461
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Jirström K, 2005, J CLIN PATHOL, V58, P1135, DOI 10.1136/jcp.2005.027185
   Jones A, 2010, PROTEIN CELL, V1, P1056, DOI 10.1007/s13238-010-0142-7
   Jonsson G., CANC RES IN PRESS
   Jönsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klintman M, 2010, MODERN PATHOL, V23, P251, DOI 10.1038/modpathol.2009.167
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Makishima H, 2010, LEUKEMIA, V24, P1799, DOI 10.1038/leu.2010.167
   Malmström P, 2001, J CLIN ONCOL, V19, P2010, DOI 10.1200/JCO.2001.19.7.2010
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rada-Iglesias A, 2009, EPIGENETICS-US, V4, P107, DOI 10.4161/epi.4.2.8038
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Roepman P, 2009, CLIN CANCER RES, V15, P7003, DOI 10.1158/1078-0432.CCR-09-0449
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Rydén L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030
   Rydén L, 2008, BREAST CANCER RES TR, V109, P351, DOI 10.1007/s10549-007-9660-2
   Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   Staaf J, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3075
   Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568
   Staaf J, 2010, J CLIN ONCOL, V28, P1813, DOI 10.1200/JCO.2009.22.8775
   Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Weigelt B, 2010, LANCET ONCOL, V11, P339, DOI 10.1016/S1470-2045(10)70008-5
   Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208
NR 70
TC 132
Z9 155
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1574-7891
J9 MOL ONCOL
JI Mol. Oncol.
PD OCT
PY 2012
VL 6
IS 5
BP 494
EP 506
DI 10.1016/j.molonc.2012.06.002
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 020GB
UT WOS:000309795900003
PM 22766277
OA Green Published
DA 2025-01-12
ER

PT J
AU Asangani, IA
   Harms, PW
   Dodson, L
   Pandhi, M
   Kunju, LP
   Maher, CA
   Fullen, DR
   Johnson, TM
   Giordano, TJ
   Palanisamy, N
   Chinnaiyan, AM
AF Asangani, Irfan A.
   Harms, Paul W.
   Dodson, Lois
   Pandhi, Mithil
   Kunju, Lakshmi P.
   Maher, Christopher A.
   Fullen, Douglas R.
   Johnson, Timothy M.
   Giordano, Thomas J.
   Palanisamy, Nallasivam
   Chinnaiyan, Arul M.
TI Genetic and epigenetic loss of microRNA-31 leads to feed-forward
   expression of EZH2 in melanoma
SO ONCOTARGET
LA English
DT Article
DE microRNA-31; melanoma; tumor suppressor; EZH2; DZNep
ID AGGRESSIVE BREAST-CANCER; COLORECTAL-CANCER; MALIGNANT-MELANOMA;
   SIGNALING PATHWAY; PROSTATE-CANCER; REGULATES EZH2; MIR-31; CELLS;
   METASTASIS; OVEREXPRESSION
AB MicroRNAs (miRs) play a key role in cancer etiology by coordinately repressing numerous target genes involved in cell proliferation, migration and invasion. The genomic region in chromosome 9p21 that encompasses miR-31 is frequently deleted in solid cancers including melanoma; however the expression and functional role of miR-31 has not been previously studied in melanoma. Here, we queried the expression status and performed functional characterization of miR-31 in melanoma tissues and cell lines. We found that down-regulation of miR-31 was a common event in melanoma tumors and cell lines and was associated with genomic loss in a subset of samples. Down-regulation of miR-31 gene expression was also a result of epigenetic silencing by DNA methylation, and via EZH2-mediated histone methylation. Ectopic overexpression of miR-31 in various melanoma cell lines inhibited cell migration and invasion. miR-31 targets include oncogenic kinases such as SRC, MET, NIK (MAP3K14) and the melanoma specific oncogene RAB27a. Furthermore, miR-31 overexpression resulted in down-regulation of EZH2 and a de-repression of its target gene rap1GAP; increased expression of EZH2 was associated with melanoma progression and overall patient survival. Taken together, our study supports a tumor suppressor role for miR-31 in melanoma and identifies novel therapeutic targets.
C1 [Asangani, Irfan A.; Harms, Paul W.; Kunju, Lakshmi P.; Maher, Christopher A.; Fullen, Douglas R.; Giordano, Thomas J.; Palanisamy, Nallasivam; Chinnaiyan, Arul M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Harms, Paul W.; Fullen, Douglas R.; Johnson, Timothy M.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA.
   [Palanisamy, Nallasivam; Chinnaiyan, Arul M.] Univ Michigan, Ctr Comprehens Canc, Sch Med, Ann Arbor, MI 48109 USA.
   [Chinnaiyan, Arul M.] Univ Michigan, Howard Hughes Med Inst, Sch Med, Ann Arbor, MI 48109 USA.
   [Chinnaiyan, Arul M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Howard Hughes Medical Institute; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
EM arul@umich.edu
RI Palanisamy, Nallasivam/ABC-8844-2020; Thomas, George/HSI-4053-2023;
   Chinnaiyan, Arul/LCE-5288-2024
OI Palanisamy, Nallasivam/0000-0002-0633-9772; Harms,
   Paul/0000-0002-0802-2883; Giordano, Thomas/0000-0003-0641-8873;
   asangani, irfan/0000-0001-5381-1702; Dodson, Lois/0000-0002-3126-8873
FU Doris Duke Charitable Foundation Clinical Scientist Award; Development
   award form Melanoma Research Alliance
FX A.M.C. is supported by the Doris Duke Charitable Foundation Clinical
   Scientist Award. A.M.C. is an American Cancer Society Research Professor
   and A. Alfred Taubman Scholar. N.P. is supported by Development award
   form Melanoma Research Alliance.
CR Akavia UD, 2010, CELL, V143, P1005, DOI 10.1016/j.cell.2010.11.013
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bandrés E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29
   Banerjee R, 2011, ONCOGENE, V30, P4339, DOI 10.1038/onc.2011.141
   Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Cottonham CL, 2010, J BIOL CHEM, V285, P35293, DOI 10.1074/jbc.M110.160069
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200
   Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511
   Flores JF, 1996, CANCER RES, V56, P5023
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Fujii S, 2012, BIOCHEM BIOPH RES CO, V417, P1074, DOI 10.1016/j.bbrc.2011.12.099
   Gao W, 2011, J CANCER RES CLIN, V137, P557, DOI 10.1007/s00432-010-0918-4
   Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Homsi J, 2007, EXPERT OPIN THER TAR, V11, P91, DOI 10.1517/14728222.11.1.91
   Ivanov SV, 2010, J BIOL CHEM, V285, P22807, DOI 10.1074/jbc.M110.100354
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lindor NM, 2007, AM J MED GENET A, V143A, P95, DOI 10.1002/ajmg.a.31545
   Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566
   Lonigro RJ, 2011, NEOPLASIA, V13, P1019, DOI 10.1593/neo.111252
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Nikolaou VA, 2012, J INVEST DERMATOL, V132, P854, DOI 10.1038/jid.2011.421
   Otsuka T, 1998, CANCER RES, V58, P5157
   Oy GF, 2010, INT J CANCER, V126, P350, DOI 10.1002/ijc.24727
   Peinado H., 2012, Nat Med
   Perera RJ, 2012, EPIGENOMICS-UK, V4, P81, DOI [10.2217/EPI.11.114, 10.2217/epi.11.114]
   Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827
   Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Thu YM, 2012, ONCOGENE, V31, P2580, DOI 10.1038/onc.2011.427
   Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341
   Valastyan S, 2010, CELL CYCLE, V9, P2124, DOI 10.4161/cc.9.11.11843
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183
   Wang CJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-616
   Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015
   Zhang YY, 2010, MED ONCOL, V27, P685, DOI 10.1007/s12032-009-9269-x
NR 45
TC 114
Z9 123
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP
PY 2012
VL 3
IS 9
BP 1011
EP 1025
DI 10.18632/oncotarget.622
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 020MR
UT WOS:000309815300013
PM 22948084
OA hybrid, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Grigoriadis, A
   Mackay, A
   Noel, E
   Wu, PJ
   Natrajan, R
   Frankum, J
   Reis, JS
   Tutt, A
AF Grigoriadis, Anita
   Mackay, Alan
   Noel, Elodie
   Wu, Pei Jun
   Natrajan, Rachel
   Frankum, Jessica
   Reis-Filho, Jorge S.
   Tutt, Andrew
TI Molecular characterisation of cell line models for triple-negative
   breast cancers
SO BMC GENOMICS
LA English
DT Article
DE Microarray; Gene expression profiling; Comparative genomic
   hybridisation; Methylation arrays; Triple negative; Breast cancer
ID BASAL-LIKE; EXPRESSION; TUMORS; CARCINOMAS; SUBTYPES; IDENTIFICATION;
   PROGENITORS; METASTASIS; SIGNATURES; PORTRAITS
AB Background: Triple-negative breast cancers (BC) represent a heterogeneous subtype of BCs, generally associated with an aggressive clinical course and where targeted therapies are currently limited. Target validation studies for all BC subtypes have largely employed established BC cell lines, which have proven to be effective tools for drug discovery.
   Results: Given the lines of evidence suggesting that BC cell lines are effective tools for drug discovery, we assessed the similarities between triple-negative BCs and cell lines, to identify in vitro representatives, modelling the diversity within this BC subtype. 25 BC cell lines, enriched for those lacking ER, PR and HER2 expression, were subjected to transcriptomic, genomic and epigenomic profiling analyses and comparisons were made to existing knowledge of corresponding perturbations in triple-negative BCs. Transcriptional analysis segregated ER-negative BC cell lines into three groups, displaying distinctive abundances for genes involved in epithelial-mesenchymal transition, apocrine and high-grade carcinomas. DNA copy number aberrations of triple-negative BCs were well represented in cell lines and genes with coordinately altered gene expression showed similar patterns in tumours and cell lines. Methylation events in triple-negative BCs were mostly retained in epigenomes of cell lines. Combined methylation and gene expression analyses revealed a subset of genes characteristic of the Claudin-low BC subtype, exhibiting epigenetic-regulated gene expression in BC cell lines and tumours, suggesting that methylation patterns are likely to underpin subtype-specificity.
   Conclusion: Here, we provide a comprehensive analysis of triple-negative BC features on several molecular levels in BC cell lines, thereby creating an in-depth resource to access the suitability of individual lines as experimental models for studying BC tumour biology, biomarkers and possible therapeutic targets in the context of preclinical target validation.
C1 [Grigoriadis, Anita; Noel, Elodie; Wu, Pei Jun; Tutt, Andrew] Kings Coll London, Breakthrough Breast Canc Res Unit, Guys Hosp, Kings Hlth Partners AHSC,Sch Med, London SE1 9RT, England.
   [Mackay, Alan; Natrajan, Rachel; Frankum, Jessica; Reis-Filho, Jorge S.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
C3 Guy's & St Thomas' NHS Foundation Trust; King's Health Partners;
   University of London; King's College London; Royal Marsden NHS
   Foundation Trust; University of London; Institute of Cancer Research -
   UK
RP Grigoriadis, A (通讯作者)，Kings Coll London, Breakthrough Breast Canc Res Unit, Guys Hosp, Kings Hlth Partners AHSC,Sch Med, London SE1 9RT, England.
EM Anita.grigoriadis@kcl.ac.uk
OI Grigoriadis, Anita/0000-0003-3434-201X; Natrajan,
   Rachael/0000-0002-9987-2946; Tutt, Andrew/0000-0001-8715-2901
FU Breakthrough Breast Cancer; Experimental Cancer Medicine Centre at
   King's College London; National Institute for Health Research (NIHR)
   Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation
   Trust and King's College; NIHR Biomedical Research Centre
FX This study was funded by Breakthrough Breast Cancer. This research was
   supported by the Experimental Cancer Medicine Centre at King's College
   London and also by the National Institute for Health Research (NIHR)
   Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation
   Trust and King's College. RN, JT and JSR-F acknowledge NHS funding for
   the NIHR Biomedical Research Centre. The views expressed are those of
   the author(s) and not necessarily those of the NHS, the NIHR or the
   Department of Health. We would like to thank Dr. Alice Gao and Prof.
   Marketa Zevlebil for providing access to the ROCK database. We are also
   grateful to Dr Olorunsola Agbaje for advise in statistical analysis.
CR Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   BRENNAN RL, 1981, EDUC PSYCHOL MEAS, V41, P687, DOI 10.1177/001316448104100307
   Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Duprez R, 2012, J PATHOL, V226, P427, DOI 10.1002/path.3032
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Frye M, 2010, CANCER LETT, V289, P71, DOI 10.1016/j.canlet.2009.08.004
   Garber K, 2012, J NATL CANCER I, V104, P174, DOI 10.1093/jnci/djs021
   Geyer FC, 2010, J PATHOL, V220, P562, DOI 10.1002/path.2675
   Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301
   Haibe-Kains B, 2012, JNCI-J NATL CANCER I, V104, P311, DOI 10.1093/jnci/djr545
   Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hu XL, 2009, MOL CANCER RES, V7, P511, DOI 10.1158/1541-7786.MCR-08-0107
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236
   Klingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Lacroix-Triki M, 2010, J PATHOL, V222, P282, DOI 10.1002/path.2763
   Lai WR, 2005, BIOINFORMATICS, V21, P3763, DOI 10.1093/bioinformatics/bti611
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Linderholm BK, 2009, ANN ONCOL, V20, P1639, DOI 10.1093/annonc/mdp062
   Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3
   Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510
   Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x
   Reis JS, 2006, MODERN PATHOL, V19, P999, DOI 10.1038/modpathol.3800621
   Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200
   Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349
   Savage K, 2008, BREAST CANCER RES TR, V110, P245, DOI 10.1007/s10549-007-9718-1
   Savage K, 2007, CLIN CANCER RES, V13, P90, DOI 10.1158/1078-0432.CCR-06-1371
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117
   Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157
   Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Voduc D, 2008, CLIN BREAST CANCER, V8, pS171, DOI 10.3816/CBC.2008.s.014
   Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115
   Weigelt B, 2010, LANCET ONCOL, V11, P339, DOI 10.1016/S1470-2045(10)70008-5
   West RB, 2005, PLOS BIOL, V3, P1101, DOI 10.1371/journal.pbio.0030187
NR 69
TC 62
Z9 76
U1 1
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD NOV 14
PY 2012
VL 13
AR 619
DI 10.1186/1471-2164-13-619
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 054LM
UT WOS:000312345100001
PM 23151021
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zeng, B
   Li, ZH
   Chen, RF
   Guo, N
   Zhou, JJ
   Zhou, QB
   Lin, Q
   Cheng, D
   Liao, QF
   Zheng, LP
   Gong, YF
AF Zeng, Bing
   Li, Zhihua
   Chen, Rufu
   Guo, Ning
   Zhou, Jiajia
   Zhou, Quanbo
   Lin, Qing
   Cheng, Di
   Liao, Qiaofang
   Zheng, Liping
   Gong, Yuanfeng
TI Epigenetic regulation of miR-124 by Hepatitis C Virus core protein
   promotes migration and invasion of intrahepatic cholangiocarcinoma cells
   by targeting SMYD3
SO FEBS LETTERS
LA English
DT Article
DE miR-124; Hepatitis C Virus core protein; DNMT1; SMYD3; Intrahepatic
   cholangiocarcinoma
ID HEPATOCELLULAR-CARCINOMA; MICRORNA EXPRESSION; DNA METHYLATION;
   BREAST-CANCER; GENE; DIFFERENTIATION; INVOLVEMENT; ACTIVATION;
   INFECTION; ABUNDANCE
AB Hepatitis C Virus core protein (HCVc) plays important roles in the development of intrahepatic cholangiocarcinoma (ICC). MicroRNAs (miRNAs) contribute to tumor progression by interacting with downstream target genes. However, the regulation and role of miRNAs in HCV-related intrahepatic cholangiocarcinoma (HCV-ICC) is poorly understood. In this study, we found that miR-124 was down-regulated in HCV-ICC and the induction of DNMT1 by HCVc mediated the suppression of miR-124. Over-expression of miR-124 suppressed cell migration and invasion in vitro, and reduced the protein levels of SMYD3 and downstream target genes (c-Myc and MMP9). Knockdown of SMYD3 inhibited cell migration and invasion resembling that of miR-124 over-expression. In conclusion, our studies indicate that low miR-124 levels mediated by HCVc via DNMT1 promote ICC cell migration and invasion by targeting SMYD3. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Zeng, Bing; Cheng, Di; Liao, Qiaofang; Zheng, Liping] Sun Yat Sen Univ, Dept Oncol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China.
   [Zeng, Bing; Chen, Rufu; Guo, Ning; Zhou, Jiajia; Zhou, Quanbo; Lin, Qing; Gong, Yuanfeng] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Li, ZH (通讯作者)，Sun Yat Sen Univ, Dept Oncol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China.
EM zhihuali2002@163.com; chenrf63@163.com
RI Li, Zh/GLR-2952-2022; zhou, bolin/KHX-0072-2024
FU National Natural Science Foundation of China [30872485]
FX We wish to thank colleagues at the Department of General Surgery and
   Department of Oncology of Sun Yat-sen Memorial Hospital of Sun Yat-sen
   University for their cooperation in our experiments. This work was
   supported by the National Natural Science Foundation of China (No.
   30872485).
CR Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   Arora P, 2008, CANCER LETT, V261, P244, DOI 10.1016/j.canlet.2007.11.033
   Bandyopadhyay S, 2011, J INFECT DIS, V203, P1753, DOI 10.1093/infdis/jir186
   Baudet ML, 2012, NAT NEUROSCI, V15, P29, DOI 10.1038/nn.2979
   Braconi C, 2010, CLIN CANCER RES, V16, P957, DOI 10.1158/1078-0432.CCR-09-2123
   Chen L, 2009, J HEPATOL, V50, P358, DOI 10.1016/j.jhep.2008.09.015
   Chen RF, 2007, ONCOL REP, V17, P105
   Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Dickstein J, 2010, P NATL ACAD SCI USA, V107, P9783, DOI 10.1073/pnas.1004297107
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   El-Serag HB, 2009, HEPATOLOGY, V49, P116, DOI 10.1002/hep.22606
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022
   Guo N, 2011, ACTA BIOCH BIOPH SIN, V43, P354, DOI 10.1093/abbs/gmr021
   Hou WH, 2010, HEPATOLOGY, V51, P1494, DOI 10.1002/hep.23401
   Huang TC, 2011, FEBS LETT, V585, P3582, DOI 10.1016/j.febslet.2011.10.025
   Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038
   Ishida H, 2011, BIOCHEM BIOPH RES CO, V412, P92, DOI 10.1016/j.bbrc.2011.07.049
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329
   Kincaid RP, 2012, P NATL ACAD SCI USA, V109, P3077, DOI 10.1073/pnas.1116107109
   Lee CH, 2009, BRIT J CANCER, V100, P1765, DOI 10.1038/sj.bjc.6605063
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015
   Murakami Y, 2009, J HEPATOL, V50, P453, DOI 10.1016/j.jhep.2008.06.010
   Park SH, 2011, CANCER LETT, V310, P61, DOI 10.1016/j.canlet.2011.06.012
   Pfeffer Sebastien, 2009, J Hepatol, V51, P606, DOI 10.1016/j.jhep.2009.03.018
   Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798
   Shin HR, 2010, CANCER SCI, V101, P579, DOI 10.1111/j.1349-7006.2009.01458.x
   Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749
   Wong KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019027
   Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627
   Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145
   Zheng H, 2011, INT J ONCOL, V38, P1153, DOI 10.3892/ijo.2011.940
   Zou JN, 2009, CANCER LETT, V280, P78, DOI 10.1016/j.canlet.2009.02.015
NR 39
TC 90
Z9 104
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD SEP 21
PY 2012
VL 586
IS 19
BP 3271
EP 3278
DI 10.1016/j.febslet.2012.06.049
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 013OH
UT WOS:000309314200042
PM 22819820
OA Bronze
DA 2025-01-12
ER

PT J
AU Gao, TY
   Wang, SK
   He, BS
   Pan, YQ
   Song, GQ
   Gu, L
   Chen, LP
   Nie, ZL
   Xu, YQ
   Li, R
AF Gao, Tianyi
   Wang, Shukui
   He, Bangshun
   Pan, Yuqin
   Song, Guoqi
   Gu, Ling
   Chen, Liping
   Nie, Zhenling
   Xu, Yeqiong
   Li, Rui
TI The Association of RAS Association Domain Family Protein1A (RASSF1A)
   Methylation States and Bladder Cancer Risk: A Systematic Review and
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; PROMOTER HYPERMETHYLATION; EPIGENETIC
   INACTIVATION; CELL CARCINOMA; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE;
   VOIDED URINE; LUNG; DNA; PHENOTYPE
AB RAS association domain family protein 1a (RASSF1A) is a putative tumor suppressor gene located on 3p21, has been regarded playing important roles in the regulation of different types of human tumors. Previous reports demonstrated that the frequency of RASSF1A methylation was significantly higher in patients group compared with controls, but the relationship between RASSF1A promoter methylation and pathological features or the tumor grade of bladder cancer remains controversial. Therefore, A meta-analysis of published studies investigating the effects of RASSF1A methylation status in bladder cancer occurrence and association with both pTNM (p, pathologic stage; T, tumor size; N, node status; M, metastatic status) and tumor grade in bladder cancer was performed in the study. A total of 10 eligible studies involving 543 cases and 217 controls were included in the pooled analyses. Under the fixed-effects model, the OR of RASSF1A methylation in bladder cancer patients, compared to non-cancer controls, was 8.40 with 95% CI = 4.96-14.23. The pooled OR with the random-effects model of pTNM and tumor grade in RASSF1A methylated patients, compared to unmethylated patients, was 0.75 (95% CI = 0.28-1.99) and 0.39 (95% CI = 0.14-1.09). This study showed that RASSF1A methylation appears to be an independent prognostic factor for bladder cancer. The present findings also require confirmation through adequately designed prospective studies.
C1 [Gao, Tianyi; Wang, Shukui; He, Bangshun; Pan, Yuqin; Song, Guoqi; Gu, Ling; Chen, Liping; Nie, Zhenling; Xu, Yeqiong; Li, Rui] Nanjing Univ, Nanjing Hosp 1, Cent Lab, Nanjing 210008, Jiangsu, Peoples R China.
   [Gu, Ling; Chen, Liping; Li, Rui] Nanjing Normal Univ, Dept Life Sci, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing Normal University
RP Wang, SK (通讯作者)，Nanjing Univ, Nanjing Hosp 1, Cent Lab, Nanjing 210008, Jiangsu, Peoples R China.
EM sk_wang@njmu.edu.cn
RI He, Bangshun/S-6164-2017
OI He, Bangshun/0000-0002-4731-0167
FU National nature science foundation of China [81172141/H1611]
FX The study was supported by National nature science foundation of China
   (81172141/H1611; http://isisn.nsfc.gov.cn/egrantweb/). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Agathanggelou A, 2003, CANCER RES, V63, P5344
   Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Allen NPC, 2007, ONCOGENE, V26, P6203, DOI 10.1038/sj.onc.1210440
   BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Cairns P, 2007, NAT REV CANCER, V7, P531, DOI 10.1038/nrc2170
   Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163
   Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971
   Chen PC, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-45
   Chen WT, 2007, HISTOPATHOLOGY, V51, P785, DOI 10.1111/j.1365-2559.2007.02871.x
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fleshner NE, 1996, AIDCNGR19 3 0 CO, P2
   Handoll HH, 2006, ARCH PHYS MED REHAB, V87, P875, DOI 10.1016/j.apmr.2006.04.006
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Jarmalaite S, 2008, ONCOLOGY-BASEL, V75, P145, DOI 10.1159/000158665
   Jo H, 2006, ONCOL RES, V16, P205, DOI 10.3727/000000006783981125
   KANTOR AF, 1988, CANCER RES, V48, P3853
   Kawai Y, 2010, ANN ONCOL, V21, P1612, DOI 10.1093/annonc/mdp577
   Kioulafa M, 2009, CLIN BIOCHEM, V42, P970, DOI 10.1016/j.clinbiochem.2009.04.003
   Lee MG, 2001, CANCER RES, V61, P6688
   Lin HH, 2010, UROL ONCOL-SEMIN ORI, V28, P597, DOI 10.1016/j.urolonc.2008.12.008
   MANTEL N, 1959, JNCI-J NATL CANCER I, V22, P719
   Marsit CJ, 2006, CANCER RES, V66, P10621, DOI 10.1158/0008-5472.CAN-06-1687
   Martins AT, 2011, BREAST CANCER RES TR, V129, P1, DOI 10.1007/s10549-010-1160-0
   Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812
   Misawa A, 2009, BRIT J CANCER, V100, P399, DOI 10.1038/sj.bjc.6604887
   Negraes PD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-238
   Ploeg M, 2009, WORLD J UROL, V27, P289, DOI 10.1007/s00345-009-0383-3
   Serizawa RR, 2011, INT J CANCER, V129, P78, DOI 10.1002/ijc.25651
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Wang J, 2011, CARCINOGENESIS, V32, P411, DOI 10.1093/carcin/bgq266
   Yates DR, 2006, ONCOGENE, V25, P1984, DOI 10.1038/sj.onc.1209209
   Yu J, 2007, CLIN CANCER RES, V13, P7296, DOI 10.1158/1078-0432.CCR-07-0861
NR 40
TC 18
Z9 23
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 6
PY 2012
VL 7
IS 11
AR e48300
DI 10.1371/journal.pone.0048300
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 040IE
UT WOS:000311315300024
PM 23139773
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Pulverer, W
   Wielscher, M
   Panzer-Grümayer, R
   Plessl, T
   Kriegner, A
   Vierlinger, K
   Weinhäusel, A
AF Pulverer, Walter
   Wielscher, Matthias
   Panzer-Gruemayer, Renate
   Plessl, Tanja
   Kriegner, Albert
   Vierlinger, Klemens
   Weinhaeusel, Andreas
TI The stem cell signature of CHH/CHG methylation is not present in 271
   cancer associated 5′UTR gene regions
SO BIOCHIMIE
LA English
DT Article
DE Non-CpG methylation; Cancer stem cell; qPCR; Neoplasia; Microarray
ID NON-CPG METHYLATION; DNA METHYLATION; COLORECTAL-CANCER; PROMOTER
   METHYLATION; HUMAN GENOME; EXPRESSION; CCWGG; EPIGENETICS; HYPOTHESIS;
   MARKERS
AB Non-CpG methylation is frequently present in stem cell DNA. We investigated the value of this epigenetic modification in cancerous DNA in order to establish the implications of CHH/CHG methylation for biomarker development. Therefore we used the restriction enzymes BstNI and PspGI within a combined multiplex PCR and targeted microarray approach for the elucidation of non-CpG (CCWGG) methylation. Targeting 544 CCWGG sites in 271 5' gene regions, the CHH/CHG methylation status of the MCF7 breast cancer cell line and blood from healthy volunteers and childhood ALL was analyzed. Statistical analysis of microarray data and subsequent SYBR green based qPCR on DNA digests was applied to confirm the results from the microarray screen.
   Result/conclusion: The microarray experiments identified for the MCF7 cell line the genes MSH2 (p < 0.001), EREG (p < 0.001) and HSPA2 (p = 0.029) with CHH/CHG methylation, and in childhood ALL the genes HIST1H2AG (p = 0.003), PGF (p = 0.02), CPEB4 (p = 0.039) and TJP2 (p = 0.04). Validation using qPCR upon restriction digestion did not confirm the presence of CHH/CHG methylation in MCF7 DNA. In ALL samples only TJP2 was found harboring CHH/CHG methylation (p = 0.02). However, applying Bonferroni-correction for multiple testing that qPCR-result was not rated as statistically significant anymore. We concluded that non-CpG methylation in 544 CCWGG sites analyzed did not change in tumor cells. Thus any change of the CHH/CHG methylation pattern is a minor event in tumorigenesis, even if the stem cell markers OCT4, NANOG, STELLAR and GDF3 are expressed like in the MCF7 breast cancer cell line. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Pulverer, Walter; Wielscher, Matthias; Plessl, Tanja; Kriegner, Albert; Vierlinger, Klemens; Weinhaeusel, Andreas] AIT Austrian Inst Technol GmbH, Hlth & Environm Dept, Mol Diagnost, A-1190 Vienna, Austria.
   [Panzer-Gruemayer, Renate] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria.
C3 Austrian Institute of Technology (AIT); Saint Anna Children's Hospital;
   St. Anna Children's Cancer Research Institute (CCRI)
RP Weinhäusel, A (通讯作者)，AIT Austrian Inst Technol GmbH, Hlth & Environm Dept, Mol Diagnost, Muthgasse 11-2, A-1190 Vienna, Austria.
EM walter.pulverer@ait.ac.at; matthias.wielscher@ait.ac.at;
   renate.panzer@ccri.at; a1007599@univie.ac.at; albert.kriegner@ait.ac.at;
   klemens.vierlinger@ait.ac.at; andreas.weinhaeusel@ait.ac.at
RI Weinhaeusel, Andreas/A-7644-2018; Wielscher, Matthias/GLS-8316-2022
OI Wielscher, Matthias/0000-0003-4138-1383; Weinhaeusel,
   Andreas/0000-0002-9318-1204; Vierlinger, Klemens/0000-0001-6038-5895
FU project RESOLVE; European Commission [202047]; Academy of Finland (AKA)
   [202047] Funding Source: Academy of Finland (AKA)
FX Grant/Funding Support: This work was partially supported by the project
   RESOLVE funded by the European Commission under FP7-HEALTH-F4-2008,
   Contract no. 202047 (http://resolve.punkt-international.eu/).
CR Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236
   [Anonymous], 2010, R: A language and environment for statistical computing
   Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Cheung HH, 2009, BIRTH DEFECTS RES C, V87, P335, DOI 10.1002/bdrc.20163
   Denisova OV, 2007, ANAL BIOCHEM, V369, P154, DOI 10.1016/j.ab.2007.06.048
   Dulac C, 2010, NATURE, V465, P728, DOI 10.1038/nature09231
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432
   He X.J., 2011, CELL RES
   Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964
   Ideraabdullah FY, 2008, MUTAT RES-FUND MOL M, V647, P77, DOI 10.1016/j.mrfmmm.2008.08.008
   Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Kneip C, 2011, J THORAC ONCOL, V6, P1632, DOI 10.1097/JTO.0b013e318220ef9a
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Mathews LA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-267
   MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P3640, DOI 10.1093/nar/22.17.3640
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Nishino K., 2011, J REPROD DEV
   Qureshi SA, 2010, INT J SURG, V8, P194, DOI 10.1016/j.ijsu.2010.02.001
   Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237
   Schär P, 2011, PROG DRUG RES, V67, P51, DOI 10.1007/978-3-7643-8989-5_3
   Senner CE, 2009, CURR OPIN GENET DEV, V19, P122, DOI 10.1016/j.gde.2009.03.003
   Shipitsin M, 2008, LAB INVEST, V88, P459, DOI 10.1038/labinvest.2008.14
   Szyf M, 2003, DRUG RESIST UPDATE, V6, P341, DOI 10.1016/j.drup.2003.10.002
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488
   Venkatachalam R, 2010, CANCER GENET CYTOGEN, V203, P1, DOI 10.1016/j.cancergencyto.2010.08.013
   Warren JD, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-133
   Watanabe D, 2002, MECH DEVELOP, V118, P187, DOI 10.1016/S0925-4773(02)00242-3
   Watson B, 2007, EPIGENETICS, V2, P151, DOI 10.4161/epi.2.3.4748
   Weinhaeusel A, 2008, CLIN CHEM, V54, P1537, DOI 10.1373/clinchem.2008.104216
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Yan J, 2011, EXP CELL RES, V317, P2555, DOI 10.1016/j.yexcr.2011.08.019
NR 37
TC 16
Z9 20
U1 0
U2 11
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300-9084
J9 BIOCHIMIE
JI Biochimie
PD NOV
PY 2012
VL 94
IS 11
BP 2345
EP 2352
DI 10.1016/j.biochi.2012.06.023
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 035FQ
UT WOS:000310929200014
PM 22750649
DA 2025-01-12
ER

PT J
AU Stefansson, OA
   Villanueva, A
   Vidal, A
   Martí, L
   Esteller, M
AF Stefansson, Olafur A.
   Villanueva, Alberto
   Vidal, August
   Marti, Lola
   Esteller, Manel
TI BRCA1 epigenetic inactivation predicts sensitivity to platinum-based
   chemotherapy in breast and ovarian cancer
SO EPIGENETICS
LA English
DT Article
DE BRCA1; DNA methylation; epigenetics; breast cancer; ovarian cancer;
   cisplatin; carboplatin
ID DNA METHYLATION PATTERNS; SPORADIC BREAST; PROMOTER; HYPERMETHYLATION;
   POLYMERASE; MUTATIONS; ASSOCIATION; SURVIVAL; OLAPARIB; EFFICACY
AB Germline mutations in the BRCA1 or BRCA2 genes are associated with an increased risk of breast and ovarian cancer development. Both genes are involved in DNA repair, and tumors harboring genetic defects in them are thought to be more sensitive to DNA-damaging agents used in chemotherapy. However, as only a minority of breast and ovarian cancer patients carry BRCA1 or BRCA2 mutations, few patients are likely to benefit from these pharmacogenetic biomarkers. Herein, we show that, in cancer cell lines and xenografted tumors, BRCA1 CpG island promoter hypermethylation-associated silencing also predicts enhanced sensitivity to platinum-derived drugs to the same extent as BRCA1 mutations. Most importantly, BRCA1 hypermethylation proves to be a predictor of longer time to relapse and improved overall survival in ovarian cancer patients undergoing chemotherapy with cisplatin.
C1 [Stefansson, Olafur A.; Esteller, Manel] Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program, Barcelona, Catalonia, Spain.
   [Villanueva, Alberto] Bellvitge Biomed Res Inst, Translat Res Lab, Catalan Inst Oncol, Barcelona, Catalonia, Spain.
   [Vidal, August] Univ Hosp Bellvitge, Bellvitge Biomed Res Inst, Pathol Dept, Barcelona, Catalonia, Spain.
   [Marti, Lola] Univ Hosp Bellvitge, Bellvitge Biomed Res Inst, Gynecol Dept, Barcelona, Catalonia, Spain.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain.
   [Esteller, Manel] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut Catala
   d'Oncologia; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   Bellvitge University Hospital; Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); Bellvitge University Hospital; University of
   Barcelona; ICREA
RP Esteller, M (通讯作者)，Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program, Barcelona, Catalonia, Spain.
EM mesteller@idibell.cat
RI Esteller, Manel/L-5956-2014; Vidal, August/N-4662-2016
OI Esteller, Manel/0000-0003-4490-6093; Vidal, August/0000-0001-5727-2099
FU Lilly Foundation; Botin Foundation; Dr. Josef Steiner Cancer Research
   Foundation; Fundacion Sandra Ibarra de Solidaridad frente al Cancer;
   Junta de Barcelona of the Asociacion Espanola Contra el Cancer (AECC);
   Health and Science Departments of the Catalan Government (Generalitat de
   Catalunya);  [SAF2011-22803]; ICREA Funding Source: Custom
FX Supported by Grants SAF2011-22803, Lilly Foundation, Botin Foundation,
   Dr. Josef Steiner Cancer Research Foundation, Fundacion Sandra Ibarra de
   Solidaridad frente al Cancer, Junta de Barcelona of the Asociacion
   Espanola Contra el Cancer (AECC), and the Health and Science Departments
   of the Catalan Government (Generalitat de Catalunya). M.E. is an ICREA
   Research Professor.
CR Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bleeker FE, 2012, J NEURO-ONCOL, V108, P11, DOI 10.1007/s11060-011-0793-0
   Bolton KL, 2012, JAMA-J AM MED ASSOC, V307, P382, DOI 10.1001/jama.2012.20
   Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61
   Grushko TA, 2004, CLIN CANCER RES, V10, P499, DOI 10.1158/1078-0432.CCR-0976-03
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Kang J, 2012, JNCI-J NATL CANCER I, V104, P670, DOI 10.1093/jnci/djs177
   Kaye SB, 2012, J CLIN ONCOL, V30, P372, DOI 10.1200/JCO.2011.36.9215
   Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Roukos DH, 2007, NAT CLIN PRACT ONCOL, V4, P578, DOI 10.1038/ncponc0930
   Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456
NR 28
TC 100
Z9 114
U1 0
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD NOV
PY 2012
VL 7
IS 11
BP 1225
EP 1229
DI 10.4161/epi.22561
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 030PO
UT WOS:000310582800002
PM 23069641
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Nagathihalli, NS
   Massion, PP
   Gonzalez, AL
   Lu, PC
   Datta, PK
AF Nagathihalli, Nagaraj S.
   Massion, Pierre P.
   Gonzalez, Adriana L.
   Lu, Pengcheng
   Datta, Pran K.
TI Smoking Induces Epithelial-to-Mesenchymal Transition in Non-Small Cell
   Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; GROWTH-FACTOR RECEPTOR; CIGARETTE-SMOKE;
   TISSUE MICROARRAY; BREAST-CANCER; FACTOR-BETA; EXPRESSION; METASTASIS;
   SURVIVAL; PROGNOSIS
AB Epidemiological studies have shown that most cases of lung cancers (85%-90%) are directly attributable to tobacco smoking. Although association between cigarette smoking and lung cancer is well documented, surprisingly little is known about the molecular mechanisms of how smoking is involved in epithelial-to-mesenchymal transition (EMT) through epigenetic changes. Here, we show that lung cancer patients with a smoking history have low E-cadherin levels and loss of E-cadherin is a poor prognostic factor in smokers. Moreover, the downregulation of E-cadherin correlates with the number of pack years. In an attempt to determine the role of long-term cigarette smoking on EMT, we observed that treatment of lung cell lines with cigarette smoke condensate (CSC) induces EMT through downregulation of epithelial markers, including E-cadherin and upregulation of mesenchymal markers. CSC decreases E-cadherin expression at the transcriptional level through upregulation of LEF1 and Slug, and knockdown of these two proteins increases E-cadherin expression. Importantly, chromatin immunoprecipitation assays suggest that LEF-1 and Slug binding to E-cadherin promoter is important for CSC-mediated downregulation of E-cadherin. The histone deacetylase (HDAC) inhibitor MS-275 reverses CSC-induced EMT, migration, and invasion through the restoration of E-cadherin expression. These results suggest that recruitment of HDACs by transcriptional repressors LEF-1 and Slug is responsible for E-cadherin suppression and EMT in cigarette smokers and provide a potential drug target toward the treatment of lung cancer. Mol Cancer Ther; 11(11); 2362-72. (c) 2012 AACR.
C1 [Datta, Pran K.] Univ Alabama Birmingham, Dept Med, WTI, Birmingham, AL 35294 USA.
   [Datta, Pran K.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA.
   [Datta, Pran K.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA.
   [Nagathihalli, Nagaraj S.; Massion, Pierre P.; Datta, Pran K.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   [Nagathihalli, Nagaraj S.; Datta, Pran K.] Vanderbilt Univ, Dept Surg, Sch Med, Nashville, TN 37240 USA.
   [Nagathihalli, Nagaraj S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA.
   [Massion, Pierre P.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
   [Gonzalez, Adriana L.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA.
   [Lu, Pengcheng] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
C3 University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Tennessee Valley Healthcare System; University of Alabama System;
   University of Alabama Birmingham; Vanderbilt University; Vanderbilt
   University; Vanderbilt University; Vanderbilt University; Vanderbilt
   University; Vanderbilt University
RP Datta, PK (通讯作者)，Univ Alabama Birmingham, Dept Med, WTI, 1720 2nd Ave S,520 C, Birmingham, AL 35294 USA.
EM dattapk@uab.edu
RI Gonzalez, Adriana/KFB-1711-2024
FU NIH [R01 CA95195, CA113519]; National Cancer Institute Specialized
   Program of Research Excellence grant in lung cancer [5P50CA90949];
   Veterans Affairs Merit Review Award;  [R01 CA102353]
FX This work was supported by NIH Grants R01 CA95195 and CA113519, National
   Cancer Institute Specialized Program of Research Excellence grant in
   lung cancer (5P50CA90949, project 4), a Veterans Affairs Merit Review
   Award (P.K. Datta) and R01 CA102353 (P.P. Massion).
CR [Anonymous], GASTROENTEROLOGY
   Baum SL, 2003, ANAL CHIM ACTA, V481, P1, DOI 10.1016/S0003-2670(03)00078-3
   Bhalla K, 2004, BEST PRACT RES CL HA, V17, P595, DOI 10.1016/j.beha.2004.08.011
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bosken CH, 2002, JNCI-J NATL CANCER I, V94, P1091
   Bremnes RM, 2002, J CLIN ONCOL, V20, P2417, DOI 10.1200/JCO.2002.08.159
   Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8
   Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4
   Dasgupta P, 2009, INT J CANCER, V124, P36, DOI 10.1002/ijc.23894
   Deeb G, 2004, MODERN PATHOL, V17, P430, DOI 10.1038/modpathol.3800041
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Fei QY, 2002, LUNG CANCER, V37, P147, DOI 10.1016/S0169-5002(02)00077-6
   Fondrevelle ME, 2009, UROL ONCOL-SEMIN ORI, V27, P268, DOI 10.1016/j.urolonc.2007.12.012
   Haider SK, 2006, CANCER RES, V66, P6156, DOI 10.1158/0008-5472.CAN-05-3261
   Hajra KM, 2002, CANCER RES, V62, P1613
   Halder SK, 2005, NEOPLASIA, V7, P509, DOI 10.1593/neo.04640
   Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037
   Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389
   Ji XD, 1997, CELL GROWTH DIFFER, V8, P773
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Kase S, 2000, CLIN CANCER RES, V6, P4789
   Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129
   Massion PP, 2003, CANCER RES, V63, P7113
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Nagaraj NS, 2006, TOXICOL LETT, V165, P182, DOI 10.1016/j.toxlet.2006.03.008
   Nagaraj NS, 2011, CLIN CANCER RES, V17, P483, DOI 10.1158/1078-0432.CCR-10-1670
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900
   Pérez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200
   Planchard D, 2012, CANCER
   Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162
   Ratschiller D, 2003, J CLIN ONCOL, V21, P2085, DOI 10.1200/JCO.2003.03.103
   Samanta D, 2012, CANCER PREV RES, V5, P453, DOI 10.1158/1940-6207.CAPR-11-0313
   Shiou SR, 2006, J BIOL CHEM, V281, P33971, DOI 10.1074/jbc.M607010200
   Stimson L, 2009, ANN ONCOL, V20, P1293, DOI 10.1093/annonc/mdn792
   Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yoshino I, 2007, CANCER-AM CANCER SOC, V110, P369, DOI 10.1002/cncr.22728
NR 41
TC 74
Z9 84
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD NOV
PY 2012
VL 11
IS 11
BP 2362
EP 2372
DI 10.1158/1535-7163.MCT-12-0107
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 049VN
UT WOS:000312011600006
PM 22933707
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Cowper-Sal-lari, R
   Zhang, XY
   Wright, JB
   Bailey, SD
   Cole, MD
   Eeckhoute, J
   Moore, JH
   Lupien, M
AF Cowper-Sal-lari, Richard
   Zhang, Xiaoyang
   Wright, Jason B.
   Bailey, Swneke D.
   Cole, Michael D.
   Eeckhoute, Jerome
   Moore, Jason H.
   Lupien, Mathieu
TI Breast cancer risk-associated SNPs modulate the affinity of chromatin
   for FOXA1 and alter gene expression
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; EPIGENETIC SIGNATURES; SUSCEPTIBILITY;
   ENHANCERS; DISTINCT; DEFINES; PROMOTERS; RS6983267; PROTEINS; DYNAMICS
AB Genome-wide association studies (GWAS) have identified thousands of SNPs that are associated with human traits and diseases. But, because the vast majority of these SNPs are located in non-coding regions of the genome, the mechanisms by which they promote disease risk have remained elusive. Employing a new methodology that combines cistromics, epigenomics and genotype imputation, we annotate the non-coding regions of the genome in breast cancer cells and systematically identify the functional nature of SNPs associated with breast cancer risk. Our results show that breast cancer risk-associated SNPs are enriched in the cistromes of FOXA1 and ESR1 and the epigenome of histone H3 lysine 4 monomethylation (H3K4me1) in a cancer- and cell type-specific manner. Furthermore, the majority of the risk-associated SNPs modulate the affinity of chromatin for FOXA1 at distal regulatory elements, thereby resulting in allele-specific gene expression, which is exemplified by the effect of the rs4784227 SNP on the TOX3 gene within the 16q12.1 risk locus.
C1 [Bailey, Swneke D.; Lupien, Mathieu] Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada.
   [Cowper-Sal-lari, Richard; Zhang, Xiaoyang; Wright, Jason B.; Cole, Michael D.; Moore, Jason H.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH USA.
   [Cowper-Sal-lari, Richard; Zhang, Xiaoyang; Moore, Jason H.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Inst Quantitat Biomed Sci, Lebanon, NH USA.
   [Bailey, Swneke D.; Lupien, Mathieu] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   [Eeckhoute, Jerome] Univ Lille Nord France, UMR 1011, INSERM, Lille, France.
   [Eeckhoute, Jerome] Inst Pasteur, F-59019 Lille, France.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; Dartmouth College; Norris Cotton Cancer Center;
   Norris Cotton Cancer Center; Dartmouth College; University of Toronto;
   Universite de Lille; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Pasteur Network; Universite de Lille; Institut
   Pasteur Lille
RP Lupien, M (通讯作者)，Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada.
EM jason.h.moore@dartmouth.edu; mlupien@uhnres.utoronto.ca
RI Eeckhoute, Jerome/AAN-8219-2021; Moore, Jason/AAV-9645-2021; zhang, xiao
   yu/JMA-9767-2023; Lupien, Mathieu/KFB-6691-2024
OI Eeckhoute, Jerome/0000-0002-7222-9264; Moore, Jason/0000-0002-5015-1099;
   Zhang, Xiaoyang/0000-0002-0031-0290; Lupien, Mathieu/0000-0003-0929-9478
FU US National Cancer Institute (NCI) [2P30CA023108-32]; American Cancer
   Society (ACS) [1RG-82-003-27]; US National Institutes of Health (NIH)
   [R01LM009012, R01CA155004]; Princess Margaret Hospital Foundation; Div
   Of Biological Infrastructure; Direct For Biological Sciences [0923008]
   Funding Source: National Science Foundation
FX We thank M. Brown, M.L. Freedman and M. Lemaire for discussions, as well
   as B.G. Neel and R. Marcotte for technical assistance. We acknowledge
   support from the US National Cancer Institute (NCI; 2P30CA023108-32),
   the American Cancer Society (ACS; 1RG-82-003-27 to M.L.), the US
   National Institutes of Health (NIH; R01LM009012 to J.H.M. and
   R01CA155004 to M.L.) and the Princess Margaret Hospital Foundation
   (M.L.).
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Antoniou AC, 2008, AM J HUM GENET, V82, P937, DOI 10.1016/j.ajhg.2008.02.008
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   De Gobbi M, 2006, SCIENCE, V312, P1215, DOI 10.1126/science.1126431
   Dittmer S, 2011, J CELL SCI, V124, P252, DOI 10.1242/jcs.068759
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554
   Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840
   Gaulton KJ, 2010, NAT GENET, V42, P255, DOI 10.1038/ng.530
   Grant SFA, 2008, CLIN CHEM, V54, P1116, DOI 10.1373/clinchem.2008.105395
   He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Hutter CM, 2011, CANCER EPIDEM BIOMAR, V20, P1950, DOI 10.1158/1055-9965.EPI-11-0524
   Jia L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000597
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Long JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001002
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Lupien M, 2009, ENDOCR-RELAT CANCER, V16, P381, DOI 10.1677/ERC-09-0038
   Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002
   McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032
   McDaniell R, 2010, SCIENCE, V328, P235, DOI 10.1126/science.1184655
   O'Flaherty E, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-13
   Park JH, 2010, NAT GENET, V42, P570, DOI 10.1038/ng.610
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Reddy TE, 2012, GENOME RES, V22, P860, DOI 10.1101/gr.131201.111
   Riaz M, 2012, BREAST CANCER RES TR, V133, P843, DOI 10.1007/s10549-011-1663-3
   Ruiz-Narváez EA, 2010, CANCER EPIDEM BIOMAR, V19, P1320, DOI 10.1158/1055-9965.EPI-09-1250
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Sekiya T, 2007, MOL CELL, V28, P291, DOI 10.1016/j.molcel.2007.10.002
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064
   Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406
   Udler MS, 2010, HUM MOL GENET, V19, P2507, DOI 10.1093/hmg/ddq122
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Wright JB, 2010, MOL CELL BIOL, V30, P1411, DOI 10.1128/MCB.01384-09
   Zentner GE, 2011, GENOME RES, V21, P1273, DOI 10.1101/gr.122382.111
   Zhang XY, 2012, GENOME RES, V22, P1437, DOI 10.1101/gr.135665.111
NR 47
TC 295
Z9 335
U1 0
U2 38
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD NOV
PY 2012
VL 44
IS 11
BP 1191
EP 1198
DI 10.1038/ng.2416
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 029KZ
UT WOS:000310495800009
PM 23001124
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Pluciennik, E
   Nowakowska, M
   Wujcicka, WI
   Sitkiewicz, A
   Kazanowska, B
   Zielinska, E
   Bednarek, AK
AF Pluciennik, Elzbieta
   Nowakowska, Magdalena
   Wujcicka, Wioletta I.
   Sitkiewicz, Anna
   Kazanowska, Bernarda
   Zielinska, Elzbieta
   Bednarek, Andrzej K.
TI Genetic alterations of <i>WWOX</i> in Wilms' tumor are involved in its
   carcinogenesis
SO ONCOLOGY REPORTS
LA English
DT Article
DE Wilms' tumor; WWOX gene
ID BREAST-CANCER; SUPPRESSOR PROTEIN; CYCLIN-E; EXPRESSION; DOMAIN; 16Q;
   HETEROZYGOSITY; NEPHROBLASTOMA; ASSOCIATION; CARCINOMA
AB Loss of heterozygosity (LOH) in 16q appears in similar to 20-30% cases of Wilms' tumor. Within this region, known as common fragile site FRA16D, the WWOX tumor suppressor gene is located. Abnormalities of WWOX gene expression levels were observed in many tumor types and were associated with worse prognosis. The purpose of this study was to investigate the role of the WWOX tumor suppressor gene in Wilms' tumor samples. We evaluated the correlation between expression of WWOX and genes involved in proliferation (Ki67), apoptosis (BCL2, BAX), signal transduction (ERBB4, ERBB2, EGFR), cell cycle (CCNE1, CCND1), cell adhesion (CDH1) and transcription (TP73) using real-time RT-PCR in 23 tumor samples. We also analyzed the potential causes of WWOX gene expression reduction i.e., promoter methylation status (Methyl Screen method) and loss of heterozygosity (LOH) status. We revealed a positive correlation between WWOX expression and BCL2, BCL2/BAX ratio, EGFR, ERBB4 isoform JM-a, TP73 and negative correlation with both cyclins. Loss of heterozygosity of the WWOX gene was observed only at intron 8, however, it had no influence on the reduction of its expression levels. Contrary to LOH, methylation of the region covering the 3' end of the promoter and part of exon 1 was associated with statistically significant reduction of WWOX gene expression levels. In the present study we reveal that in Wilms' tumors the WWOX expression levels are positively associated with the process of apoptosis, signal transduction through the ERBB4 pathway and EGFR and negatively with the regulation of the cell cycle (by cyclin El and DD. Moreover, our analysis indicates that in this type of tumor the expression of the WWOX gene can be regulated by an epigenetic mechanism - its promoter methylation.
C1 [Pluciennik, Elzbieta; Nowakowska, Magdalena; Wujcicka, Wioletta I.; Bednarek, Andrzej K.] Med Univ Lodz, Dept Mol Cancerogenesis, PL-90752 Lodz, Poland.
   [Sitkiewicz, Anna] Med Univ Lodz, Dept Pediat Surg & Oncol, PL-91738 Lodz, Poland.
   [Zielinska, Elzbieta] Med Univ Lodz, Dept Pediat Oncol & Hematol, PL-91738 Lodz, Poland.
   [Kazanowska, Bernarda] Univ Med, Dept Bone Marrow Transplantat Pediat Oncol & Hema, PL-50345 Wroclaw, Poland.
C3 Medical University Lodz; Medical University Lodz; Medical University
   Lodz; Wroclaw Medical University
RP Pluciennik, E (通讯作者)，Med Univ Lodz, Dept Mol Cancerogenesis, PL-90752 Lodz, Poland.
EM elzbieta.pluciennik@umed.lodz.pl
RI Nowakowska, Magdalena/S-9639-2016; Wujcicka, Wioletta/N-3601-2014;
   Pluciennik, Elzbieta/S-9636-2016; Bednarek, Andrzej/S-9664-2016
OI Pluciennik, Elzbieta/0000-0002-6682-0402; Bednarek,
   Andrzej/0000-0002-4570-4154; Nowakowska, Magdalena/0000-0002-5854-484X;
   Wujcicka, Wioletta/0000-0002-2907-1414
FU Polish Ministry of Science and Higher Education [2670/B/P01/2008/34,
   0757/B/P01/2009/37]
FX The authors wish to thank Ewa Latkowska for her excellent technical
   support. This study was supported by the Polish Ministry of Science and
   Higher Education 2670/B/P01/2008/34 and 0757/B/P01/2009/37. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aqeilan RI, 2008, J BIOL CHEM, V283, P21629, DOI 10.1074/jbc.M800855200
   Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104
   Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150
   Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101
   Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594
   Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055
   Aqeilian RI, 2007, CANCER RES, V67, P9330, DOI 10.1158/0008-5472.CAN-07-2147
   Bednarek AK, 2000, CANCER RES, V60, P2140
   Berrebi D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002216
   Chen TP, 1996, CANCER RES, V56, P5605
   Faussillon M, 2005, CANCER LETT, V221, P67, DOI 10.1016/j.canlet.2004.08.010
   Feinberg AP, 1999, CANCER RES, V59, p1743S
   Gaudio E, 2006, CANCER RES, V66, P11585, DOI 10.1158/0008-5472.CAN-06-3376
   Ghanems MA, 2001, BRIT J CANCER, V85, P1557, DOI 10.1054/bjoc.2001.2146
   Green DM, 1996, CA-CANCER J CLIN, V46, P46, DOI 10.3322/canjclin.46.1.46
   GRUNDY PE, 1994, CANCER RES, V54, P2331
   Grundy PE, 2005, J CLIN ONCOL, V23, P7312, DOI 10.1200/JCO.2005.01.2799
   Guler G, 2009, CANCER-AM CANCER SOC, V115, P899, DOI 10.1002/cncr.24103
   Holemon H, 2007, BIOTECHNIQUES, V43, P683, DOI 10.2144/000112597
   Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398
   Ishii H, 2003, MOL CANCER RES, V1, P940
   Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096
   Kuroki T, 2002, CANCER RES, V62, P2258
   Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532
   Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200
   Maeda N, 2010, VIRCHOWS ARCH, V457, P423, DOI 10.1007/s00428-010-0956-y
   Messahel B, 2009, EUR J CANCER, V45, P819, DOI 10.1016/j.ejca.2009.01.005
   Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202
   Skotnicka-Klonowicz G, 2000, EUR J SURG ONCOL, V26, P61, DOI 10.1053/ejso.1999.0742
   Tanaka K, 1999, PEDIATR SURG INT, V15, P243, DOI 10.1007/s003830050567
   Vasei M, 2009, CANCER GENET CYTOGEN, V194, P88, DOI 10.1016/j.cancergencyto.2009.06.003
   Vujanic GM, 2002, MED PEDIATR ONCOL, V38, P79, DOI 10.1002/mpo.1276.abs
   Wetli SC, 2008, VIRCHOWS ARCH, V452, P637, DOI 10.1007/s00428-008-0605-x
   Yendamuri S, 2003, CANCER RES, V63, P878
NR 34
TC 27
Z9 30
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
J9 ONCOL REP
JI Oncol. Rep.
PD OCT
PY 2012
VL 28
IS 4
BP 1417
EP 1422
DI 10.3892/or.2012.1940
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 013OT
UT WOS:000309315400042
PM 22842668
OA Bronze
DA 2025-01-12
ER

PT J
AU de Assis, S
   Warri, A
   Cruz, MI
   Laja, O
   Tian, Y
   Zhang, B
   Wang, Y
   Huang, THM
   Hilakivi-Clarke, L
AF de Assis, Sonia
   Warri, Anni
   Cruz, M. Idalia
   Laja, Olusola
   Tian, Ye
   Zhang, Bai
   Wang, Yue
   Huang, Tim Hui-Ming
   Hilakivi-Clarke, Leena
TI High-fat or ethinyl-oestradiol intake during pregnancy increases mammary
   cancer risk in several generations of offspring
SO NATURE COMMUNICATIONS
LA English
DT Article
ID EPIGENETIC TRANSGENERATIONAL ACTIONS; PRIMORDIAL GERM-CELLS; IN-UTERO;
   DNA METHYLTRANSFERASES; BREAST-CANCER; DIETHYLSTILBESTROL ALTERS;
   GENETIC SUSCEPTIBILITY; NEONATAL EXPOSURE; BIRTH-WEIGHT; GENOMIC DNA
AB Maternal exposures to environmental factors during pregnancy influence the risk of many chronic adult-onset diseases in the offspring. Here we investigate whether feeding pregnant rats a high-fat (HF)- or ethinyl-oestradiol (EE2)-supplemented diet affects carcinogen-induced mammary cancer risk in daughters, granddaughters and great-granddaughters. We show that mammary tumourigenesis is higher in daughters and granddaughters of HF rat dams and in daughters and great-granddaughters of EE2 rat dams. Outcross experiments suggest that the increase in mammary cancer risk is transmitted to HF granddaughters equally through the female or male germ lines, but it is only transmitted to EE2 granddaughters through the female germ line. The effects of maternal EE2 exposure on offspring's mammary cancer risk are associated with changes in the DNA methylation machinery and methylation patterns in mammary tissue of all three EE2 generations. We conclude that dietary and oestrogenic exposures in pregnancy increase breast cancer risk in multiple generations of offspring, possibly through epigenetic means.
C1 [de Assis, Sonia; Warri, Anni; Cruz, M. Idalia; Laja, Olusola; Hilakivi-Clarke, Leena] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA.
   [Warri, Anni] Univ Turku, Inst Biomed, Fac Med, Turku, Finland.
   [Tian, Ye; Zhang, Bai; Wang, Yue] Virginia Tech, Bradley Dept Elect & Comp Engn, Arlington, VA USA.
   [Zhang, Bai] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA.
   [Huang, Tim Hui-Ming] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA.
   [Huang, Tim Hui-Ming] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Mol Med, San Antonio, TX 78229 USA.
C3 Georgetown University; University of Turku; Virginia Polytechnic
   Institute & State University; Johns Hopkins University; Johns Hopkins
   Medicine; University of Texas System; University of Texas Health Science
   Center at San Antonio; University of Texas System; University of Texas
   Health Science Center at San Antonio; Cancer Therapy & Research Center
RP de Assis, S (通讯作者)，Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, 3970 Reservoir Rd NW,Res Bldg,Room E407, Washington, DC 20057 USA.
EM deassiss@georgetown.edu
RI Assis, Sonia/N-8274-2013
OI Warri, Anni/0000-0002-0535-847X; de Assis, Sonia/0000-0001-5053-0614
FU American Cancer Society [116602-PF-09-018-01-CNE]; National Institutes
   of Health [R03CA150040, U54CA100970, U54CA149147, P30CA051668,
   R21GM085665, CA160036, R01CA069065, R01ES017594, P30CA054174,
   U54CA113001]
FX This study was supported by the American Cancer Society
   (116602-PF-09-018-01-CNE to S.deA.), the National Institutes of Health
   (R03CA150040 to S.deA.; U54CA100970, U54CA149147 and P30CA051668 to
   L.H.-C.; R21GM085665 and CA160036 to Y.W.; R01CA069065, R01ES017594,
   P30CA054174 and U54CA113001 to T.H.-M.H.) and by generous gifts from the
   Cancer Therapy and Research Center Foundation at University of Texas
   Health Science Center, San Antonio, to T.H. M.H. We thank Dr Jianhua
   Xuan of Virginia Tech and Dr Guoqiang Yu of Stanford University for
   suggestions to the data analysis, and Dr Pasi Pollanen of University of
   Helsinki, Finland, and Robert Clarke of Georgetown University for
   suggestions to the manuscript. We also thank the following Lombardi
   Cancer Center Shared Resources (SR) for their assistance: Animal SR,
   Histopathology and Tissue SR and Genomics and Epigenomics SR.
CR Aflatoonian B, 2006, REPRODUCTION, V132, P699, DOI 10.1530/REP-06-0022
   [Anonymous], BMC WOMENS HLTH, DOI [DOI 10.1186/1472-6874-9-10), DOI 10.1186/1472-6874-11-37]
   Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879
   Anway MD, 2006, J ANDROL, V27, P868, DOI 10.2164/jandrol.106.000349
   Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708
   BOYLAN ES, 1983, CANCER RES, V43, P4879
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Cowin PA, 2010, ENDOCRINOLOGY, V151, P783, DOI 10.1210/en.2009-0982
   de Assis S., 2010, J VIS EXP, V44, P2260
   de Assis S, 2006, INT J CANCER, V119, P1537, DOI 10.1002/ijc.21936
   Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002
   Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Ghoshal K, 2006, J NUTR, V136, P1522, DOI 10.1093/jn/136.6.1522
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961
   Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751
   Huang THM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004515
   Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980
   Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385
   Jimenez-Chillaron JC, 2009, DIABETES, V58, P460, DOI 10.2337/db08-0490
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kawaguchi H, 2009, J VET MED SCI, V71, P1309, DOI 10.1292/jvms.001309
   LaPlant Q, 2010, NAT NEUROSCI, V13, P1137, DOI 10.1038/nn.2619
   Larson PS, 2006, CANCER-AM CANCER SOC, V107, P2122, DOI 10.1002/cncr.22223
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   McLaren A, 2003, DEV BIOL, V262, P1, DOI 10.1016/S0012-1606(03)00214-8
   Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114
   Nakatsuji N, 2001, INT J DEV BIOL, V45, P541
   National Research Council, 2012, BREAST CANC ENV LIF
   Oldenburg RA, 2007, CRIT REV ONCOL HEMAT, V63, P125, DOI 10.1016/j.critrevonc.2006.12.004
   Olivo SE, 2005, CARCINOGENESIS, V26, P1563, DOI 10.1093/carcin/bgi118
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   RUSSO J, 1990, LAB INVEST, V62, P244
   Sato K, 2006, ENDOCR J, V53, P331, DOI 10.1507/endocrj.K06-009
   Sato K, 2009, ENDOCR J, V56, P131, DOI 10.1507/endocrj.K08E-239
   Schulz R, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001214
   Skinner MK, 2008, REPROD TOXICOL, V25, P2, DOI 10.1016/j.reprotox.2007.09.001
   Skinner MK, 2011, BIRTH DEFECTS RES C, V93, P51, DOI 10.1002/bdrc.20199
   Skinner MK, 2010, TRENDS ENDOCRIN MET, V21, P214, DOI 10.1016/j.tem.2009.12.007
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631
   Wang XY, 2008, MOL CELL BIOL, V28, P3589, DOI 10.1128/MCB.00040-08
   Zuo T, 2011, CANCER RES, V71, P1752, DOI 10.1158/0008-5472.CAN-10-3573
NR 56
TC 105
Z9 112
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP
PY 2012
VL 3
AR 1053
DI 10.1038/ncomms2058
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 013XA
UT WOS:000309338100020
PM 22968699
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Izadi, P
   Noruzinia, M
   Karimipoor, M
   Karbassian, MH
   Akbari, MT
AF Izadi, Pantea
   Noruzinia, Mehrdad
   Karimipoor, Morteza
   Karbassian, Mohammad Hamid
   Akbari, Mohammad Taghi
TI Promoter Hypermethylation of Estrogen Receptor Alpha Gene Is Correlated
   to Estrogen Receptor Negativity in Iranian Patients with Sporadic Breast
   Cancer
SO CELL JOURNAL
LA English
DT Article
DE Estrogen Receptor; Methylation; Breast Cancer
ID ER-ALPHA; DNA HYPERMETHYLATION; CPG ISLANDS; METHYLATION; EXPRESSION;
   CELLS; DEMETHYLATION; REEXPRESSION; BRCA1
AB Objective: Breast Cancer is the most common cancer in Iranian women. Breast tumors are classified based on the estrogen receptor alpha (ER alpha) expression status into ER negative and ER positive tumors. ER negative tumors tend to have worse prognosis and less likely to respond to endocrine therapy. Aberrant methylation of gene promoter is one of the mechanisms for gene silencing in breast tumors. Because of its reversible nature, promoter methylation is a good target for new therapeutic strategies. We aimed to evaluate the frequency of this epigenetic event in ER alpha gene and its association to clinicopathological features in Iranian breast cancer patients.
   Materials and Methods: In this case control study the patient series consisted of 100 sporadic primary breast cancer cases (51 ER negative and 49 ER positive tumors). None of the participants had chemo or radiotherapy before surgery. In breast tumors ER alpha promoter methylation were assessed with methylation specific polymerase chain reaction (MSP). Data was collected on clinicopathological features of the patients. Correlation between ERa methylation and clinicopathological characteristics of the patients was investigated by Pearson Chi-Square and Fisher's exact test.
   Results: ER alpha methylation was detected in 98% of ER negative and 65% of ER positive breast tumors. A strong correlation was found between ER alpha methylation and ER negativity in tumors (p<0.0001). Also, ER alpha methylation has associated to progesterone receptor negativity (p<0.008) and double receptor negative status (p<0.0001) in breast tumors.
   Conclusion: ER alpha methylation occurs with high frequency in the breast tumors of Iranian breast cancer patients and may play a considerable role in pathogenesis of ER alpha negative tumors as a poor prognosis and more aggressive category. The reversible nature of DNA methylation may provide new therapeutic possibilities in ER negative breast tumors.
C1 [Izadi, Pantea; Noruzinia, Mehrdad; Akbari, Mohammad Taghi] Tarbiat Modares Univ, Sch Med Sci, Dept Med Genet, Tehran, Iran.
   [Karimipoor, Morteza] Pasteur Inst Iran, Biotechnol Res Ctr, Dept Mol Med, Tehran, Iran.
   [Karbassian, Mohammad Hamid] Day Hosp, Tehran, Iran.
C3 Tarbiat Modares University; Pasteur Network; Pasteur Institute of Iran
RP Noruzinia, M (通讯作者)，Tarbiat Modares Univ, Sch Med Sci, Dept Med Genet, POB 14115-111, Tehran, Iran.
EM noruzinia@modares.ac.ir
RI Karimipoor, Morteza/ABG-4882-2021
OI noruzinia, mehrdad/0000-0002-1325-3758
FU faculty of Medical Sciences of Tarbiat Modares University
FX This study was a part of a PhD thesis in Medical Genetics delivered by
   the first author and supported by a grant from faculty of Medical
   Sciences of Tarbiat Modares University.
CR Ariazi EA, 2006, CURR TOP MED CHEM, V6, P181, DOI 10.2174/156802606776173483
   Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   deGraffenried LA, 2004, BREAST CANCER RES TR, V85, P111, DOI 10.1023/B:BREA.0000025398.93829.78
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Gown AM, 2008, MODERN PATHOL, V21, pS8, DOI 10.1038/modpathol.2008.34
   Harirchi Iraj, 2004, Asian Pac J Cancer Prev, V5, P24
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Lopez-Tarruella S, 2007, CLIN CANCER RES, V13, P6921, DOI 10.1158/1078-0432.CCR-07-1399
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mousavi SM, 2009, ANN ONCOL, V20, P556, DOI 10.1093/annonc/mdn642
   Mousavi SM, 2007, BREAST J, V13, P383, DOI 10.1111/j.1524-4741.2007.00446.x
   Nass SJ, 2000, CANCER RES, V60, P4346
   Panahi M, 2011, CELL J YAKHTEH S2, V13, P30
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004
   Pirouzpanah S, 2010, CANCER CAUSE CONTROL, V21, P2101, DOI 10.1007/s10552-010-9629-z
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Wang Rui, 2006, Zhonghua Zhongliu Zazhi, V28, P894
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 28
TC 14
Z9 14
U1 0
U2 3
PU ROYAN INST
PI TEHRAN
PA PO BOX 19395-4644, TEHRAN, 00000, IRAN
SN 2228-5806
EI 2228-5814
J9 CELL J
JI Cell J.
PD SUM
PY 2012
VL 14
IS 2
BP 102
EP 109
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 016GF
UT WOS:000309504800005
PM 23508069
DA 2025-01-12
ER

PT J
AU Putnik, M
   Zhao, CY
   Gustafsson, JA
   Dahlman-Wright, K
AF Putnik, Milica
   Zhao, Chunyan
   Gustafsson, Jan-Ake
   Dahlman-Wright, Karin
TI Global identification of genes regulated by estrogen signaling and
   demethylation in MCF-7 breast cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Estrogen; Estrogen receptor; 5-Aza-2 '-deoxycytidine; DNA methylation;
   Breast cancer; Microarray
ID DNA METHYLATION PROFILES; HUMAN-DISEASE; RECEPTOR; EPIGENETICS;
   HYPERMETHYLATION; EXPRESSION; ANTIESTROGENS; GENISTEIN; BIOLOGY; BTG3
AB Estrogen signaling and epigenetic modifications, in particular DNA methylation, are involved in regulation of gene expression in breast cancers. Here we investigated a potential regulatory cross-talk between these two pathways by identifying their common target genes and exploring underlying molecular mechanisms in human MCF-7 breast cancer cells. Gene expression profiling revealed that the expression of approximately 140 genes was influenced by both 17 beta-estradiol (E2) and a demethylating agent 5-aza-2'-deoxycytidine (DAC). Gene ontology (GO) analysis suggests that these genes are involved in intracellular signaling cascades, regulation of cell proliferation and apoptosis. Based on previously reported association with breast cancer, estrogen signaling and/or DNA methylation, CpG island prediction and GO analysis, we selected six genes (BIG3, FHL2, PMAIP1, BTG2, CDKN1A and TGFB2) for further analysis. Tamoxifen reverses the effect of E2 on the expression of all selected genes, suggesting that they are direct targets of estrogen receptor. Furthermore, DAC treatment reactivates the expression of all selected genes in a dose-dependent manner. Promoter CpG island methylation status analysis revealed that only the promoters of BTG3 and FHL2 genes are methylated, with DAC inducing demethylation, suggesting DNA methylation directs repression of these genes in MCF-7 cells. In a further analysis of the potential interplay between estrogen signaling and DNA methylation, E2 treatment showed no effect on the methylation status of these promoters. Additionally, we show that the ER alpha recruitment occurs at the FHL2 promoter in an E2- and DAC-independent fashion. In conclusion, we identified a set of genes regulated by both estrogen signaling and DNA methylation. However, our data does not support a direct molecular interplay of mediators of estrogen and epigenetic signaling at promoters of regulated genes. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Putnik, Milica; Zhao, Chunyan; Gustafsson, Jan-Ake; Dahlman-Wright, Karin] Karolinska Inst, Dept Biosci & Nutr, Novum, S-14183 Huddinge, Sweden.
   [Gustafsson, Jan-Ake] Univ Houston, Dept Biol & Biochem, Sci & Engn Res Ctr Bldg, Houston, TX 77204 USA.
C3 Karolinska Institutet; University of Houston System; University of
   Houston
RP Putnik, M (通讯作者)，Karolinska Inst, Dept Biosci & Nutr, Novum, Halsovagen 7, S-14183 Huddinge, Sweden.
EM milica.putnik@ki.se; chunyan.zhao@ki.se; jan-ake.gustafsson@ki.se;
   karin.dahlman-wright@ki.se
RI Putnik, Goran/B-1428-2014
OI Putnik, Goran/0000-0003-3378-6866
FU Cancerfonden, Karolinska Institute's faculty funds; Karolinska
   Institute's Center for Biosciences; EU
FX The study was supported by Cancerfonden, Karolinska Institute's faculty
   funds for partial financing of doctoral students (KID), Karolinska
   Institute's Center for Biosciences and the EU integrated project
   CRESCENDO. We are grateful to the Bioinformatic and Expression Analysis
   core facility at the Karolinska Institute (BEA, www.bea.ki.se) for
   performing the microarray assay.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   Akamine R, 2007, J BIOCHEM BIOPH METH, V70, P481, DOI 10.1016/j.jbbm.2006.11.008
   Ali S, 2011, ANNU REV MED, V62, P217, DOI 10.1146/annurev-med-052209-100305
   Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fujikane T, 2010, BREAST CANCER RES TR, V122, P699, DOI 10.1007/s10549-009-0600-1
   Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Matthews J, 2006, MOL ENDOCRINOL, V20, P534, DOI 10.1210/me.2005-0140
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Ramaswamy B, 2009, MOL ENDOCRINOL, V23, P176, DOI 10.1210/me.2008-0211
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389
   Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
   Yu JW, 2008, GENE EXPRESSION, V14, P173
NR 36
TC 31
Z9 33
U1 0
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 14
PY 2012
VL 426
IS 1
BP 26
EP 32
DI 10.1016/j.bbrc.2012.08.007
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 013NO
UT WOS:000309312300005
PM 22902638
DA 2025-01-12
ER

PT J
AU Zare, M
   Jazii, FR
   Soheili, ZS
   Moghanibashi, MM
AF Zare, Maryam
   Jazii, Ferdous Rastgar
   Soheili, Zahra-Soheila
   Moghanibashi, Mohamad-Mehdi
TI Downregulation of tropomyosin-1 in squamous cell carcinoma of esophagus,
   the role of Ras signaling and methylation
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE tropomyosin; esophagus cancer; downregulation; Ras signaling pathway;
   methylation
ID CANCER-CELLS; ACTIN CYTOSKELETON; TUMOR-SUPPRESSOR; TGF-BETA; K-RAS;
   TRANSFORMED FIBROBLASTS; NONMUSCLE TROPOMYOSIN; PROMOTER METHYLATION;
   BARRETTS-ESOPHAGUS; BREAST-CANCER
AB Tropomyosins (TMs) are a family of cytoskeletal proteins that bind to and stabilize actin microfilaments. Non-muscle cells express multiple isoforms of TMs including three high molecular weight (HMW) isoforms: TM1, TM2, and TM3. While reports have indicated downregulation of TMs in transformed cells and several human cancers, nevertheless, little is known about the underlying mechanism of TMs suppression. In present study the expression of HMW TMs was investigated in squamous cell carcinoma of esophagus (SCCE), relative to primary cell cultures of normal esophagus by western blotting and real-time RT-PCR. Our results showed that TM1, TM2, and TM3 were significantly downregulated in cell line of SCCE. Moreover, mRNA level of TPM1 and TPM2 were markedly decreased by 93% and 96%, in tumor cell line relative to esophagus normal epithelial cells. Therefore, downregulation of TMs could play an important role in tumorigenesis of esophageal cancer. To asses the mechanism of TM downregulation in esophageal cancer, the role of Ras dependent signaling and promoter hypermethylation were investigated. We found that inhibition of two Ras effectory downstream pathways; MEK/ERK and PI3K/Akt leads to significant increased expression of TM1 protein and both TPM1 and TPM2 mRNAs. In addition, methyltransferase inhibition significantly upregulated TM1, suggesting the prominent contribution of promoter hypermethylation in TM1 downregulation in esophageal cancer. These data indicate that downregulation of HMW TMs occurs basically in SCCE and the activation of MEK/ERK and PI3K/Akt pathways as well as the epigenetic mechanism of promoter hypermethylation play important role in TM1 suppression in SCCE. (c) 2011 Wiley Periodicals, Inc.
C1 [Jazii, Ferdous Rastgar] Hosp Sick Children Sickkids, Res Inst, Dept Mol Struct & Funct, Toronto, ON M5G 1X8, Canada.
   [Zare, Maryam; Jazii, Ferdous Rastgar; Soheili, Zahra-Soheila; Moghanibashi, Mohamad-Mehdi] Natl Inst Genet Engn & Biotechnol, Dept Biochem, Tehran, Iran.
   [Zare, Maryam] Payam Noor Univ, Dept Biol, Tehran, Iran.
C3 University of Toronto; Hospital for Sick Children (SickKids)
RP Jazii, FR (通讯作者)，Hosp Sick Children Sickkids, Res Inst, Dept Mol Struct & Funct, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
RI Moghanibashi, Mehdi/AAQ-5464-2021; Zare, Maryam/FDC-7564-2022; Soheili,
   Zahra-Soheila/W-8316-2018
OI Moghanibashi, Mehdi/0000-0003-0023-9399; Soheili,
   Zahra-Soheila/0000-0003-1292-465X; Zare, Maryam/0000-0001-6511-4963
CR Akimoto T, 2004, ANTICANCER RES, V24, P811
   Asamoto M, 2002, JPN J CANCER RES, V93, P744, DOI 10.1111/j.1349-7006.2002.tb01315.x
   Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353
   Bashir M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-13
   Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993
   Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2
   Clément G, 2006, ONCOGENE, V25, P3084, DOI 10.1038/sj.onc.1209338
   de Molina AR, 2004, CANCER LETT, V206, P137, DOI 10.1016/j.canlet.2003.08.031
   Dragovich T, 2009, J ONCOL, V2009, DOI 10.1155/2009/804108
   Ekman S, 2007, ONCOLOGIST, V12, P1165, DOI 10.1634/theoncologist.12-10-1165
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Friday BB, 2005, BBA-REV CANCER, V1756, P127, DOI 10.1016/j.bbcan.2005.08.001
   Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618
   Gu DY, 2007, FEBS LETT, V581, P382, DOI 10.1016/j.febslet.2006.12.043
   Gunning P, 2008, PHYSIOL REV, V88, P1, DOI 10.1152/physrev.00001.2007
   Gunning PW, 2005, TRENDS CELL BIOL, V15, P333, DOI 10.1016/j.tcb.2005.04.007
   Guo MZ, 2006, CLIN CANCER RES, V12, P4515, DOI 10.1158/1078-0432.CCR-05-2858
   Hawk ET, 2008, AM J GASTROENTEROL, V103, P838, DOI 10.1111/j.1572-0241.2007.01768.x
   HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633
   Hillberg L, 2006, EUR J CELL BIOL, V85, P399, DOI 10.1016/j.ejcb.2005.12.005
   Ishibe S, 2006, MOL CELL BIOL, V26, P9232, DOI 10.1128/MCB.01312-06
   Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182
   Janssen RAJ, 2003, MOL CELL BIOL, V23, P1786, DOI 10.1128/MCB.23.5.1786-1797.2003
   Jazii FR, 2006, WORLD J GASTROENTERO, V12, P7104, DOI 10.3748/wjg.v12.i44.7104
   Karpinski P, 2008, J APPL GENET, V49, P1, DOI 10.1007/BF03195243
   Kim PN, 2001, CELL GROWTH DIFFER, V12, P543
   KOZMA SC, 1987, NUCLEIC ACIDS RES, V15, P5963
   Kuwano H, 2005, SURG TODAY, V35, P7, DOI 10.1007/s00595-004-2885-3
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8
   Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565
   Lord RV, 2000, J GASTROEN HEPATOL, V15, P730, DOI 10.1046/j.1440-1746.2000.02163.x
   Lyronis ID, 2008, PATHOL ONCOL RES, V14, P267, DOI 10.1007/s12253-008-9032-1
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583
   Mohammad Ganji S, DIS ESOPHAGUS, V597-602
   Nguyen DM, 2004, J THORAC CARDIOV SUR, V127, P365, DOI 10.1016/j.jtcvs.2003.09.033
   O'Neill GM, 2008, SEMIN CANCER BIOL, V18, P35, DOI 10.1016/j.semcancer.2007.08.004
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pawlak G, 2004, INT J CANCER, V110, P368, DOI 10.1002/ijc.20151
   Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302
   Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4
   Peehl DM, 2005, ENDOCR-RELAT CANCER, V12, P19, DOI 10.1677/erc.1.00795
   PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8
   Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264
   Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719
   Schevzov G, 2005, J HISTOCHEM CYTOCHEM, V53, P557, DOI 10.1369/jhc.4A6505.2005
   Schrump DS, 2005, J SURG ONCOL, V92, P257, DOI 10.1002/jso.20367
   Senmaru N, 1998, INT J CANCER, V78, P366, DOI 10.1002/(SICI)1097-0215(19981029)78:3<366::AID-IJC18>3.0.CO;2-4
   Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291
   Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002
   Sommerer F, 2004, ONCOGENE, V23, P554, DOI 10.1038/sj.onc.1207189
   Stehn JR, 2006, CURR CANCER DRUG TAR, V6, P245, DOI 10.2174/156800906776842948
   Tomizawa Y, 2009, GASTROENTEROL CLIN N, V38, P59, DOI 10.1016/j.gtc.2009.01.014
   Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688
   Wang FL, 1996, CANCER RES, V56, P3634
   Yager ML, 2003, BRIT J CANCER, V89, P860, DOI 10.1038/sj.bjc.6601201
   Zare M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-24
   Zhao J, 2007, MOL CELL PROTEOMICS, V6, P987, DOI 10.1074/mcp.M600175-MCP200
   Zheng Q, 2008, INT J CANCER, V122, P78, DOI 10.1002/ijc.23025
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
NR 62
TC 14
Z9 19
U1 1
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD OCT
PY 2012
VL 51
IS 10
BP 796
EP 806
DI 10.1002/mc.20847
PG 11
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 003VR
UT WOS:000308640000004
PM 22965424
DA 2025-01-12
ER

PT J
AU Ott, M
   Litzenburger, UM
   Sahm, F
   Rauschenbach, KJ
   Tudoran, R
   Hartmann, C
   Marquez, VE
   von Deimling, A
   Wick, W
   Platten, M
AF Ott, Martina
   Litzenburger, Ulrike M.
   Sahm, Felix
   Rauschenbach, Katharina J.
   Tudoran, Ruxandra
   Hartmann, Christian
   Marquez, Victor E.
   von Deimling, Andreas
   Wick, Wolfgang
   Platten, Michael
TI Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2
   (EZH2) Is Mediated by AXL Receptor Kinase
SO PLOS ONE
LA English
DT Article
ID POLYCOMB-REPRESSIVE COMPLEX-2; METHYLTRANSFERASE GENE EZH2;
   ACUTE-LEUKEMIA CELLS; GROUP PROTEIN EZH2; TYROSINE KINASE;
   BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; COORDINATED REGULATION;
   THERAPEUTIC TARGET; PROLONGS SURVIVAL
AB Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the Polycomb-repressive complex 2 (PRC2) that epigenetically silences gene transcription through histone H3 lysine trimethylation (H3K27me3). EZH2 has been implicated in stem cell maintenance and is overexpressed in hematological and solid malignancie's including malignant glioma. EZH2 is thought to promote tumor progression by silencing tumor suppressor genes. Hence pharmacological disruption of the PRC2 is an attractive therapeutic strategy for cancer treatment. Here we show that EZH2 is expressed in human glioma and correlates with malignancy. Silencing of EZH2 reduced glioma cell proliferation and invasiveness. While we did not observe induction of cell cycle-associated tumor suppressor genes by silencing or pharmacological inhibition of EZH2, microarray analyses demonstrated a strong transcriptional reduction of the AXL receptor kinase. Neither histone nor DNA methylation appeared to be involved in the positive regulation of AXL by EZH2. Silencing AXL mimicked the antiinvasive effects of EZH2 knockdown. Finally, AXL expression is found in human gliomas with high EZH2 expression. Collectively these data suggest that EZH2 drives glioma invasiveness via transcriptional control of AXL independent of histone or DNA methylation.
C1 [Ott, Martina; Litzenburger, Ulrike M.; Rauschenbach, Katharina J.; Tudoran, Ruxandra; Wick, Wolfgang; Platten, Michael] Univ Heidelberg Hosp, Dept Neurooncol, Heidelberg, Germany.
   [Sahm, Felix; Hartmann, Christian; von Deimling, Andreas] Univ Heidelberg Hosp, Inst Neuropathol, Heidelberg, Germany.
   [Ott, Martina; Litzenburger, Ulrike M.; Rauschenbach, Katharina J.; Tudoran, Ruxandra; Platten, Michael] German Canc Res Ctr, Clin Cooperat Unit, D-6900 Heidelberg, Germany.
   [Ott, Martina; Litzenburger, Ulrike M.; Rauschenbach, Katharina J.; Tudoran, Ruxandra; Platten, Michael] German Canc Res Ctr, Helmholtz Grp Expt Neuroimmunol, D-6900 Heidelberg, Germany.
   [Wick, Wolfgang] German Canc Res Ctr, Dept Neurooncol, D-6900 Heidelberg, Germany.
   [Sahm, Felix; Hartmann, Christian; von Deimling, Andreas] German Canc Res Ctr, Dept Neuropathol, D-6900 Heidelberg, Germany.
   [Hartmann, Christian] Hannover Med Sch, Inst Pathol, Dept Neuropathol, D-3000 Hannover, Germany.
   [Marquez, Victor E.] NCI, Biol Chem Lab, Frederick, MD 21701 USA.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ);
   Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); Hannover Medical
   School; National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI)
RP Platten, M (通讯作者)，Univ Heidelberg Hosp, Dept Neurooncol, Heidelberg, Germany.
EM michael.platten@med.uni-heidelberg.de
RI Marquez, Victor/KWD-9188-2024; Hartmann, Christian/D-1882-2010; Wick,
   Wolfgang/AAA-2545-2020; Platten, Michael/F-2902-2013; Sahm,
   Felix/GQY-8202-2022; von Deimling, Andreas/F-7774-2013
OI Platten, Michael/0000-0002-4746-887X; Sahm, Felix/0000-0001-5441-1962;
   Hartmann, Christian/0009-0004-3700-3536; von Deimling,
   Andreas/0000-0002-5863-540X
FU Helmholtz Association [VH-NG-306]; Hertie Foundation; Intramural
   Research Program of the National Institutes of Health, National Cancer
   Institute, Center for Cancer Research
FX This work was supported by grants from the Helmholtz Association
   (VH-NG-306) to MP and the Hertie Foundation to WW and by the Intramural
   Research Program of the National Institutes of Health, National Cancer
   Institute, Center for Cancer Research to VM. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009
   Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679
   Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186
   Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499
   Bommi PV, 2010, CELL CYCLE, V9, P2663, DOI 10.4161/cc.9.13.12147
   Breton CV, 2011, EPIGENETICS, V6
   Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Capper D, 2009, ACTA NEUROPATHOL
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   de Haan G, 2007, ANN NY ACAD SCI, V1106, P233, DOI 10.1196/annals.1392.008
   EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Fiskus W, 2006, MOL CANCER THER, V5, P3096, DOI 10.1158/1535-7163.MCT-06-0418
   Fiskus W, 2009, CANCER BIOL THER, V8, P939, DOI 10.4161/cbt.8.10.8213
   Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107
   GLAZER RI, 1986, BIOCHEM PHARMACOL, V35, P4523, DOI 10.1016/0006-2952(86)90774-4
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997
   Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862
   Jung JW, 2010, CELL MOL LIFE SCI, V67, P1165, DOI 10.1007/s00018-009-0242-9
   Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005
   Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066
   Lemke D, 2012, CLIN CANCER RES, V18, P105, DOI 10.1158/1078-0432.CCR-11-0880
   Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212
   Liu R, 2010, BLOOD, V116, P297, DOI 10.1182/blood-2009-12-257154
   Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016
   Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13
   Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046
   Mudduluru G, 2011, BIOL CELL, V103, P21, DOI 10.1042/BC20100094
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491
   Opitz CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019823
   Opitz CA, 2009, STEM CELLS, V27, P909, DOI 10.1002/stem.7
   Orzan F, 2011, NEUROPATH APPL NEURO, V37, P381, DOI 10.1111/j.1365-2990.2010.01132.x
   Ou WB, 2011, ONCOGENE, V30, P1643, DOI 10.1038/onc.2010.555
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Prezioso C, 2011, FEBS LETT, V585, P2067, DOI 10.1016/j.febslet.2011.04.062
   Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267
   Schmitt M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp581
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Smits M, 2010, ONCOTARGET, V1, P710, DOI 10.18632/oncotarget.205
   Song XZ, 2011, CANCER-AM CANCER SOC, V117, P734, DOI 10.1002/cncr.25483
   Staflin K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-206
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5
   Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tsang DPF, 2011, J GASTROEN HEPATOL, V26, P19, DOI 10.1111/j.1440-1746.2010.06447.x
   Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509
   Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683
   Wick W, 2011, NEURO-ONCOLOGY, V13, P566, DOI 10.1093/neuonc/nor039
   Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162
   Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268
   Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661
   Zheng SC, 2011, NEURO-ONCOLOGY, V13, P280, DOI 10.1093/neuonc/noq190
NR 66
TC 41
Z9 44
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2012
VL 7
IS 10
AR e47663
DI 10.1371/journal.pone.0047663
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 022WO
UT WOS:000309995100151
PM 23077658
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Bosviel, R
   Durif, J
   Déchelotte, P
   Bignon, YJ
   Bernard-Gallon, D
AF Bosviel, Remy
   Durif, Julie
   Dechelotte, Pierre
   Bignon, Yves-Jean
   Bernard-Gallon, Dominique
TI Epigenetic modulation of <i>BRCA1</i> and <i>BRCA2</i> gene expression
   by equol in breast cancer cell lines
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Equol; Breast cancer susceptibility genes 1 and 2; Breast cancer
ID TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; DNA METHYLATION; SOY
   PHYTOESTROGENS; CYCLE ARREST; GENISTEIN; ISOFLAVONES; BINDING;
   DEMETHYLATION; DAIDZEIN
AB S-Equol is a metabolite resulting from the conversion of daidzein, a soya phyto-oestrogen, by the gut microflora. The potential protective effects of equol in breast cancer are still under debate. Consequently, we investigated the effects of equol on DNA methylation of breast cancer susceptibility genes (BRCA1 and BRCA2) and oncosuppressors in breast cancer cell lines (MDA-MB-231 and MCF-7) and in a dystrophic breast cell line (MCF-10a) following exposure to S-equol (2 mu M) for 3 weeks. We demonstrated by quantitative analysis of methylated alleles a significant decrease in the methylation of the cytosine phosphate guanine (CpG) islands in the promoters of BRCA1 and BRCA2 after the S-equol treatment in MCF-7 and MDA-MB-231 cells and a trend in MCF-10a cells. We also showed that S-equol increases BRCA1 and BRCA2 protein expression in the nuclei and the cytoplasm in MCF-7, MDA-MB-231 and MCF-10a cell lines by immunohistochemistry. The increase in BRCA1 and BRCA2 proteins was also found after Western blotting in the studied cell lines. In summary, we demonstrated the demethylating effect of S-equol on the CpG islands inside the promoters of BRCA1 and BRCA2 genes, resulting in an increase in the level of expressed oncosuppressors in breast cancer cell lines.
C1 [Bosviel, Remy; Durif, Julie; Bignon, Yves-Jean; Bernard-Gallon, Dominique] Ctr Jean Perrin, Dept Oncogenet, CBRV, F-63001 Clermont Ferrand, France.
   [Bosviel, Remy; Durif, Julie; Dechelotte, Pierre; Bignon, Yves-Jean; Bernard-Gallon, Dominique] Univ Auvergne, EA 4233, F-63001 Clermont Ferrand, France.
   [Dechelotte, Pierre] CHU, Nouvel Hop Estaing, Serv Anat Pathol, F-63100 Clermont Ferrand, France.
C3 UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); CHU
   Clermont Ferrand
RP Bignon, YJ (通讯作者)，Ctr Jean Perrin, Dept Oncogenet, CBRV, 28 Pl Henri Dunant,BP 38, F-63001 Clermont Ferrand, France.
EM yves-jean.bignon@cjp.fr
RI Bernard-Gallon, Dominique/L-6079-2015
FU Auvergne Regional Council/CPER [32316 - 0930FDBG - 106NL]
FX We thank Nicolas Sonnier and Christelle Picard for helpful technical
   assistance. R. B. is the recipient of a grant from the Auvergne Regional
   Council/CPER 2008 + FEDER no. 32316 - 0930FDBG - 106NL. R. B., P. D.,
   Y.-J. B. and D. B.-G. contributed to the experimental design. R. B. and
   J. D. were responsible for performing the experiments. R. B., J. D. and
   P. D. contributed to the data analysis. R. B. and D. B.-G. contributed
   to manuscript preparation. The authors declare that they have no
   conflict of interest.
CR AXELSON M, 1982, BIOCHEM J, V201, P353, DOI 10.1042/bj2010353
   Bennetau-Pelissero C, 2003, FOOD CHEM, V82, P645, DOI 10.1016/S0308-8146(03)00121-3
   Berner C, 2011, ANN NUTR METAB, V57, P183, DOI 10.1159/000321514
   Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7
   Bosviel R, 2011, CLIN CHIM ACTA, V412, P1472, DOI 10.1016/j.cca.2011.04.027
   Cable PL, 2003, MOL CARCINOGEN, V38, P85, DOI 10.1002/mc.10148
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Choi EJ, 2008, MOL MED REP, V1, P239
   Cucer N, 2008, J GENET, V87, P155, DOI 10.1007/s12041-008-0023-5
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2005, INT J ONCOL, V26, P615
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Guerrero-Bosagna Carlos M., 2008, BMC Physiology, V8, P17, DOI 10.1186/1472-6793-8-17
   Guha N, 2009, BREAST CANCER RES TR, V118, P395, DOI 10.1007/s10549-009-0321-5
   Hong T, 2004, BIOCHEM BIOPH RES CO, V317, P259, DOI 10.1016/j.bbrc.2004.03.041
   Jawaid K, 2010, J STEROID BIOCHEM, V120, P164, DOI 10.1016/j.jsbmb.2010.04.007
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jhanwar-Uniyal M, 2003, FRONT BIOSCI-LANDMRK, V8, pS1107, DOI 10.2741/1131
   Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Korde LA, 2009, CANCER EPIDEM BIOMAR, V18, P1050, DOI 10.1158/1055-9965.EPI-08-0405
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Lambie H, 2003, J PATHOL, V200, P207, DOI 10.1002/path.1348
   Lerebours F, 2002, CRIT REV ONCOL HEMAT, V44, P121, DOI 10.1016/S1040-8428(01)00191-3
   LYNCOOK BD, 1995, P SOC EXP BIOL MED, V208, P116
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Marrian GF, 1932, BIOCHEM J, V26, P1227, DOI 10.1042/bj0261227
   Mathey J, 2006, J PHARMACEUT BIOMED, V41, P957, DOI 10.1016/j.jpba.2006.01.051
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Muthyala RS, 2004, BIOORGAN MED CHEM, V12, P1559, DOI 10.1016/j.bmc.2003.11.035
   Pfitscher A, 2008, J STEROID BIOCHEM, V112, P87, DOI 10.1016/j.jsbmb.2008.08.007
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Satih S, 2008, CURR NUTR FOOD SCI, V4, P259, DOI 10.2174/157340108786263658
   Setchell KDR, 2005, J AGR FOOD CHEM, V53, P1938, DOI 10.1021/jf0488099
   SETCHELL KDR, 1984, AM J CLIN NUTR, V40, P569, DOI 10.1093/ajcn/40.3.569
   Setchell KDR, 2006, J NUTR, V136, P2188, DOI 10.1093/jn/136.8.2188
   Setchell KDR, 2010, J NUTR, V140, p1355S, DOI 10.3945/jn.109.119776
   SOULE HD, 1990, CANCER RES, V50, P6075
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Takeuchi S, 2009, BIOL PHARM BULL, V32, P195, DOI 10.1248/bpb.32.195
   Tang WY, 2008, ENDOCRINOLOGY, V149, P5922, DOI 10.1210/en.2008-0682
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Vanhees K, 2011, FASEB J, V25, P797, DOI 10.1096/fj.10-172155
   Vardi A, 2010, IN VIVO, V24, P393
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Vidarsson H, 2002, FEBS LETT, V532, P247, DOI 10.1016/S0014-5793(02)03684-0
   Vissac-Sabatier C, 2003, NUTR CANCER, V45, P247, DOI 10.1207/S15327914NC4502_15
   Wang ZG, 2010, ANTICANCER RES, V30, P4537
   Watanabe Y, 2010, ADV CLIN CHEM, V52, P145, DOI 10.1016/S0065-2423(10)52006-7
   Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
NR 59
TC 35
Z9 36
U1 0
U2 10
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT 14
PY 2012
VL 108
IS 7
BP 1187
EP 1193
DI 10.1017/S000711451100657X
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 022HD
UT WOS:000309947600006
PM 22217331
OA Bronze
DA 2025-01-12
ER

PT J
AU Zheng, SS
   Rollet, M
   Yang, KF
   Pan, YX
AF Zheng, Shasha
   Rollet, Michelle
   Yang, Kefeng
   Pan, Yuan-Xiang
TI A gestational low-protein diet represses p21<SUP>WAF1/Cip1</SUP>
   expression in the mammary gland of offspring rats through promoter
   histone modifications
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Pregnancy; Epigenetics; Developmental programming; Thrifty phenotype
   hypothesis
ID BREAST-CANCER; C-MYC; TRANSCRIPTION FACTORS; POSTNATAL-GROWTH;
   GENE-EXPRESSION; RNA-POLYMERASE; RESTRICTION; P21; FETAL; UNDERNUTRITION
AB Maternal exposure to environmental agents throughout pregnancy may change certain metabolic processes during the offspring's mammary gland development and alter the epigenome. This may predispose the offspring to breast cancer later in life. The purpose of the present study was to examine the effect of maternal protein restriction on the regulation of cyclin-dependent kinase inhibitor 1 (p21) gene expression in the mammary gland of rat offspring. Timed-mated Sprague-Dawley rats were fed one of the two isoenergetic diets, control (C, 18% casein) or low protein (LP, 9% casein), during gestation. Compared with the C group, LP offspring showed a decrease of p21 in the mammary gland at both the mRNA and protein levels. Chromatin immunoprecipitation assay demonstrated that the down-regulation of p21 transcription in LP offspring was associated with reduced acetylation of histone H3 and dimethylation of H3K4 within the p21 promoter region, but was not associated with acetylation of histone H4 or histone methylation. DNA methylation analysis using bisulphite sequencing did not detect differences in methylation at the p21 promoter between the offspring of the C and LP groups. We conclude that maternal protein restriction inhibits p21 gene expression in the mammary gland of offspring through histone modifications at the promoter region of the p21 gene.
C1 [Zheng, Shasha; Rollet, Michelle; Yang, Kefeng; Pan, Yuan-Xiang] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana-Champaign
RP Pan, YX (通讯作者)，Univ Illinois, Dept Food Sci & Human Nutr, 461 Bevier Hall,MC 182,905 S Goodwin Ave, Urbana, IL 61801 USA.
EM yxpan@illinois.edu
RI 杨, 科峰/ISB-7962-2023; Pan, Yuan-Xiang/C-6576-2019
OI Pan, Yuan-Xiang/0000-0003-3219-4367
FU USDA Cooperative State Research, Education and Extension Service
   [ILLU-698-374]; National Institutes of Health [CA-139557]
FX This project was supported, in whole or in part, by the USDA Cooperative
   State Research, Education and Extension Service, Hatch project no.
   ILLU-698-374, and by National Institutes of Health Grants CA-139557 (to
   Y.-X. P.). The experiments were performed in the laboratory of Y.-X. P.
   at University of Illinois at Urbana-Champaign. Y.-X. P. and S. Z. are
   responsible for the conception and design of the experiments. S. Z., M.
   R. and K. Y. conducted the experiments and collected the data. S. Z.
   analysed the data and drafted the manuscript. Y.-X. P. and S. Z. have
   primary responsibility for the final content. All authors read and
   approved the final manuscript. The authors thank Hong Chen (University
   of Illinois) for sharing her expertise and experiences in epigenome
   analysis. The authors declare that there is no conflict of interest that
   could be perceived as prejudicing the impartiality of the research
   reported.
CR [Anonymous], 2009, NATL VITAL STAT REP
   Bai L, 2007, BIOCHEM BIOPH RES CO, V359, P817, DOI 10.1016/j.bbrc.2007.05.197
   Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104
   Bártová E, 2008, J HISTOCHEM CYTOCHEM, V56, P711, DOI 10.1369/jhc.2008.951251
   Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509
   Buffat C, 2007, J PATHOL, V213, P337, DOI 10.1002/path.2233
   Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897
   Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200
   Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950
   Conaway RC, 1997, PROG NUCLEIC ACID RE, V56, P327, DOI 10.1016/S0079-6603(08)61009-0
   Derbyshire Emma, 2007, Br J Nurs, V16, P144
   Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005
   Fernandez-Twinn DS, 2007, CARCINOGENESIS, V28, P545, DOI 10.1093/carcin/bgl166
   Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4
   Guzmán C, 2006, J PHYSIOL-LONDON, V572, P97, DOI 10.1113/jphysiol.2005.103903
   Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002
   Hwang-Verslues WW, 2008, MOL ENDOCRINOL, V22, P78, DOI 10.1210/me.2007-0298
   Iwasa T, 2010, J PHYSIOL-LONDON, V588, P821, DOI 10.1113/jphysiol.2009.183558
   Jousse C, 2011, FASEB J, V25, P3271, DOI 10.1096/fj.11-181792
   Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kwong WY, 2000, DEVELOPMENT, V127, P4195
   Lillycrop KA, 2005, J NUTR, V135, P1382, DOI 10.1093/jn/135.6.1382
   Martín-Caballero J, 2001, CANCER RES, V61, P6234
   McArdle HJ, 2006, PLACENTA, V27, pS56, DOI 10.1016/j.placenta.2006.01.014
   Mellemkjær L, 2003, CANCER CAUSE CONTROL, V14, P61, DOI 10.1023/A:1022570305704
   Mitani Y, 2005, J PATHOL, V205, P65, DOI 10.1002/path.1684
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Park K, 2009, EXP MOL MED, V41, P371, DOI 10.3858/emm.2009.41.6.042
   Pham TD, 2003, AM J PHYSIOL-REG I, V285, pR962, DOI 10.1152/ajpregu.00201.2003
   Plentz RR, 2007, HEPATOLOGY, V45, P968, DOI 10.1002/hep.21552
   Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994
   Qumachigui A, 2002, NUTR REV, V60, pS64, DOI 10.1301/00296640260130768
   ROEDER RG, 1969, NATURE, V224, P234, DOI 10.1038/224234a0
   SINHA YN, 1966, AM J PHYSIOL, V210, P601, DOI 10.1152/ajplegacy.1966.210.3.601
   Sluncheva B, 2010, Akush Ginekol (Sofiia), V49, P33
   Sohi G, 2011, MOL ENDOCRINOL, V25, P785, DOI 10.1210/me.2010-0395
   Somlo G, 2008, ANN ONCOL, V19, P1853, DOI 10.1093/annonc/mdn402
   Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x
   Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van Weissenbruch MM, 2005, ENDOCRIN DEV, V8, P15, DOI 10.1159/000084084
   WAN JS, 1995, P NATL ACAD SCI USA, V92, P5664, DOI 10.1073/pnas.92.12.5664
   Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439
   Willenbring H, 2008, CANCER CELL, V14, P59, DOI 10.1016/j.ccr.2008.05.004
   Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285
NR 46
TC 17
Z9 20
U1 0
U2 11
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD SEP 28
PY 2012
VL 108
IS 6
BP 998
EP 1007
DI 10.1017/S0007114511006222
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 003BO
UT WOS:000308583400007
PM 22152918
OA Bronze
DA 2025-01-12
ER

PT J
AU Mirzaei, MH
   Noruzinia, M
   Karbassian, H
   Shafeghati, Y
   Keyhanee, M
   Bidmeshki-Pour, A
AF Mirzaei, Mehri Hajikhan
   Noruzinia, Mehrdad
   Karbassian, Hamid
   Shafeghati, Yousef
   Keyhanee, Mousa
   Bidmeshki-Pour, Ali
TI Evaluation of Methylation Status in the 5′UTR Promoter Region of the
   <i>DBC2</i> Gene as a Biomarker in Sporadic Breast Cancer
SO CELL JOURNAL
LA English
DT Article
DE Breast Neoplasm; DNA Methylation; DBC2; Iran
ID HETEROZYGOSITY; CANDIDATE; RHOBTB2; DNA
AB Objective: Breast cancer is one of the most common malignancies in women worldwide. It is caused by a number of genetic and epigenetic factors. Aberrant hypermethylation of the promoter regions in specific genes is a key event in the formation and progression of breast cancers as well as the DBC2 gene, as a tumor suppressor gene. Different studies show that the DBC2 gene is inactivated through epigenetic mechanisms such as methylation in its promoter region. In this study, authors have tried to analyze methylation status in the promoter region of DBC2 gene in affected women and healthy controls.
   Materials and Methods: In this experimental study, we evaluated the methylation status of DBC2 gene with nested methylation-specific PCR (MSPCR) using specific methylated and unmethylated primer sets, in three separate PCR reactions. We used 50 tissue and blood samples of patients with breast cancer, 5 normal tissues and also 30 normal blood samples. Results were evaluated by the Mann-Whitney test, SPSS 16.0 statistical software.
   Results: Nested MSPCR results demonstrated that the frequency of the DBC2 promoter region methylation status in tumor and blood samples of the affected patients was significantly higher than that of the corresponding normal controls.
   Conclusion: DBC2 gene inactivation by methylation of CpG islands in the promoter region probably is a crucial step in the process of cell proliferation and susceptibility to different cancers, including breast cancer. Our study provides new evidence that aberrant methylation of the DBC2 gene is involved in the tumorigenesis of breast cancer. DNA methylation in this gene is proven to be a potential marker for tumor diagnosis and prognosis, as well as a novel therapeutic target.
C1 [Mirzaei, Mehri Hajikhan; Bidmeshki-Pour, Ali] Razi Univ, Fac Sci, Dept Biol, Kermanshah, Iran.
   [Mirzaei, Mehri Hajikhan; Noruzinia, Mehrdad; Shafeghati, Yousef; Keyhanee, Mousa] Sarem Womens Hosp, Dept Cell Res Ctr & Med Genet, Tehran, Iran.
   [Noruzinia, Mehrdad] Tarbiat Modares Univ, Fac Med Sci, Dept Med Genet, Tehran, Iran.
   [Karbassian, Hamid] Atiyeh Hosp, Dept Surg, Tehran, Iran.
   [Shafeghati, Yousef] Univ Social Welf Sci & Rehabil, GRC, Tehran, Iran.
C3 Razi University; Tarbiat Modares University
RP Bidmeshki-Pour, A (通讯作者)，Razi Univ, Fac Sci, Dept Biol, POB 6714967346, Kermanshah, Iran.
EM abidmeshki@razi.ac.ir
OI noruzinia, mehrdad/0000-0002-1325-3758
FU Surgical Ward at Atiyeh Hospital; Medical Genetics Department of Sarem
   Women's Hospital; Sarem Cell Research Center
FX The authors would wholeheartedly like to thank all the patients and
   their family for their participation in this study. This article is the
   result of an MSc student's final graduation research project. We are
   grateful to Dr Mohammad reza Nategh for statistical analysis, Dr. Parisa
   Azimi-Nejadan, Parisa Fateh-Manesh, and Sahar Mohammadi-Fateh for their
   assistance. We express our appreciation to the Surgical Ward at Atiyeh
   Hospital, the Medical Genetics Department of Sarem Women's Hospital, and
   Sarem Cell Research Center for their help in the sampling, execution,
   and financial support of this study. There is no conflict of interest in
   this study.
CR Balfe PJ, 2004, EJSO-EUR J SURG ONC, V30, P1043, DOI 10.1016/j.ejso.2004.06.019
   Bi Ye, 2008, Zhonghua Zhongliu Zazhi, V30, P749
   Bissonauth V, 2008, CANCER DETECT PREV, V32, P52, DOI 10.1016/j.cdp.2008.01.005
   Callahan R, 1998, BIOCHEM SOC SYMP, P211
   CALLAHAN R, 1993, J CELL BIOCHEM, P167
   Chang FK, 2006, J MOL BIOL, V364, P302, DOI 10.1016/j.jmb.2006.09.026
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   Couch F., 1998, GENETIC BASIS HUMAN, P537
   Ellisen LW, 1998, ANNU REV MED, V49, P425
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099
   Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jelen L, 2008, INT J AP MAT COM-POL, V18, P75, DOI 10.2478/v10006-008-0007-x
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433
   Lu TY, 2009, J CELL BIOCHEM, V108, P315, DOI 10.1002/jcb.22256
   Miller BJ, 2003, AM J HUM GENET, V73, P748, DOI 10.1086/378522
   MILLER SA, 1988, NUCLEIC ACIDS RES, V0016
   Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876
   Shi Y, 2008, UROL ONCOL-SEMIN ORI, V26, P465, DOI 10.1016/j.urolonc.2007.08.009
   Shiry S, 2011, CELL JOUANAL S1, V12, P88
   Siripurapu V, 2005, J MOL BIOL, V346, P83, DOI 10.1016/j.jmb.2004.11.043
   Wilkins A, 2004, GENE DEV, V18, P856, DOI 10.1101/gad.1177904
   Yoshihara T, 2007, BIOCHEM BIOPH RES CO, V358, P1076, DOI 10.1016/j.bbrc.2007.05.037
   Zemlyakova V. V., 2003, Molekulyarnaya Biologiya (Moscow), V37, P696
NR 26
TC 9
Z9 10
U1 0
U2 3
PU ROYAN INST
PI TEHRAN
PA PO BOX 19395-4644, TEHRAN, 00000, IRAN
SN 2228-5806
EI 2228-5814
J9 CELL J
JI Cell J.
PD SPR
PY 2012
VL 14
IS 1
BP 19
EP 24
PG 6
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 002HX
UT WOS:000308523800003
PM 23626933
DA 2025-01-12
ER

PT J
AU Wu, ZQ
   Li, XY
   Hu, CY
   Ford, M
   Kleer, CG
   Weiss, SJ
AF Wu, Zhao-Qiu
   Li, Xiao-Yan
   Hu, Casey Yuexian
   Ford, Michael
   Kleer, Celina G.
   Weiss, Stephen J.
TI Canonical Wnt signaling regulates Slug activity and links
   epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early
   Onset (BRCA1) repression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE invasion; phosphoserine; E-cadherin; vimentin; fibronectin
ID GENE-EXPRESSION; SNAG DOMAIN; E-CADHERIN; BETA-TRCP; PROTEIN; SNAIL1;
   PHOSPHORYLATION; METASTASIS; CELLS; PHENOTYPE
AB Slug (Snail2) plays critical roles in regulating the epithelial-mesenchymal transition (EMT) programs operative during development and disease. However, the means by which Slug activity is controlled remain unclear. Herein we identify an unrecognized canonical Wnt/GSK3 beta/beta-Trcp1 axis that controls Slug activity. In the absence of Wnt signaling, Slug is phosphorylated by GSK3 beta and subsequently undergoes beta-Trcp1-dependent ubiquitination and proteosomal degradation. Alternatively, in the presence of canonical Wnt ligands, GSK3 beta kinase activity is inhibited, nuclear Slug levels increase, and EMT programs are initiated. Consistent with recent studies describing correlative associations in basal-like breast cancers between Wnt signaling, increased Slug levels, and reduced expression of the tumor suppressor Breast Cancer 1, Early Onset (BRCA1), further studies demonstrate that Slug-as well as Snail-directly represses BRCA1 expression by recruiting the chromatin-demethylase, LSD1, and binding to a series of E-boxes located within the BRCA1 promoter. Consonant with these findings, nuclear Slug and Snail expression are increased in association with BRCA1 repression in a cohort of triple-negative breast cancer patients. Together, these findings establish unique functional links between canonical Wnt signaling, Slug expression, EMT, and BRCA1 regulation.
C1 [Wu, Zhao-Qiu; Li, Xiao-Yan; Hu, Casey Yuexian; Weiss, Stephen J.] Univ Michigan, Dept Internal Med, Inst Life Sci, Div Mol Med & Genet, Ann Arbor, MI 48109 USA.
   [Ford, Michael] MS Bioworks LLC, Ann Arbor, MI 48108 USA.
   [Kleer, Celina G.] Univ Michigan, Dept Pathol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Weiss, SJ (通讯作者)，Univ Michigan, Dept Internal Med, Inst Life Sci, Div Mol Med & Genet, Ann Arbor, MI 48109 USA.
EM sjweiss@umich.edu
RI Liu, Xiaoling/HGD-3566-2022
FU National Institutes of Health (NIH) Grant [CA116516, CA107469, CA125577,
   CA154224]; Breast Cancer Research Foundation Grant; Michigan Diabetes
   Research and Training Center Cell and Molecular Biology Core NIH Grant
   [P60 DK020572]; National Cancer Institute [R01CA125577, R01CA107469]
   Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health (NIH) Grant
   CA116516 (to S.J.W.), CA107469 (to C.G.K.), CA125577 (to C.G.K.),
   CA154224 (to C.G.K.), and the Breast Cancer Research Foundation Grant
   (to S.J.W.). Work on this study was also supported by Michigan Diabetes
   Research and Training Center Cell and Molecular Biology Core NIH Grant
   P60 DK020572.
CR Ayyanathan K, 2007, CANCER RES, V67, P9097, DOI 10.1158/0008-5472.CAN-07-2987
   Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330
   Coene ED, 2011, J CELL BIOL, V192, P497, DOI 10.1083/jcb.201004136
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Domínguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003
   Eldar-Finkelman H, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00032
   Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396
   Geradts J, 2011, HUM PATHOL, V42, P1125, DOI 10.1016/j.humpath.2010.11.004
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634
   Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744
   Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097
   Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Lu YH, 2011, MOL CELL BIOL, V31, P3339, DOI 10.1128/MCB.01121-10
   Luo DC, 2011, MOL CANCER RES, V9, P234, DOI 10.1158/1541-7786.MCR-10-0214
   Mittal MK, 2011, J BIOL CHEM, V286, P469, DOI 10.1074/jbc.M110.164384
   Nieto MA, 2012, SEMIN CANC BIOL
   Ota I, 2009, P NATL ACAD SCI USA, V106, P20318, DOI 10.1073/pnas.0910962106
   Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007
   MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254
   Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Viñas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995
   Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109
   Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101
   Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
   Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371
NR 42
TC 246
Z9 285
U1 0
U2 30
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 9
PY 2012
VL 109
IS 41
BP 16654
EP 16659
DI 10.1073/pnas.1205822109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 026LQ
UT WOS:000310280300057
PM 23011797
OA Green Published
DA 2025-01-12
ER

PT J
AU Koboldt, DC
   Fulton, RS
   McLellan, MD
   Schmidt, H
   Kalicki-Veizer, J
   McMichael, JF
   Fulton, LL
   Dooling, DJ
   Ding, L
   Mardis, ER
   Wilson, RK
   Ally, A
   Balasundaram, M
   Butterfield, YSN
   Carlsen, R
   Carter, C
   Chu, A
   Chuah, E
   Chun, HJE
   Coope, RJN
   Dhalla, N
   Guin, R
   Hirst, C
   Hirst, M
   Holt, RA
   Lee, D
   Li, HYI
   Mayo, M
   Moore, RA
   Mungall, AJ
   Pleasance, E
   Robertson, AG
   Schein, JE
   Shafiei, A
   Sipahimalani, P
   Slobodan, JR
   Stoll, D
   Tam, A
   Thiessen, N
   Varhol, RJ
   Wye, N
   Zeng, T
   Zhao, YJ
   Birol, I
   Jones, SJM
   Marra, MA
   Cherniack, AD
   Saksena, G
   Onofrio, RC
   Pho, NH
   Carter, SL
   Schumacher, SE
   Tabak, B
   Hernandez, B
   Gentry, J
   Nguyen, H
   Crenshaw, A
   Ardlie, K
   Beroukhim, R
   Winckler, W
   Getz, G
   Gabriel, SB
   Meyerson, M
   Chin, L
   Park, PJ
   Kucherlapati, R
   Hoadley, KA
   Auman, JT
   Fan, C
   Turman, YJ
   Shi, Y
   Li, L
   Topal, MD
   He, XP
   Chao, HH
   Prat, A
   Silva, GO
   Iglesia, MD
   Zhao, W
   Usary, J
   Berg, JS
   Adams, M
   Booker, J
   Wu, JY
   Gulabani, A
   Bodenheimer, T
   Hoyle, AP
   Simons, JV
   Soloway, MG
   Mose, LE
   Jefferys, SR
   Balu, S
   Parker, JS
   Hayes, DN
   Perou, CM
   Malik, S
   Mahurkar, S
   Shen, H
   Weisenberger, DJ
   Triche, T
   Lai, PH
   Bootwalla, MS
   Maglinte, DT
   Berman, BP
   Van den Berg, DJ
   Baylin, SB
   Laird, PW
   Creighton, CJ
   Donehower, LA
   Getz, G
   Noble, M
   Voet, D
   Saksena, G
   Gehlenborg, N
   DiCara, D
   Zhang, JH
   Zhang, HL
   Wu, CJ
   Liu, SY
   Lawrence, MS
   Zou, LH
   Sivachenko, A
   Lin, P
   Stojanov, P
   Jing, R
   Cho, J
   Sinha, R
   Park, RW
   Nazaire, MD
   Robinson, J
   Thorvaldsdottir, H
   Mesirov, J
   Park, PJ
   Chin, L
   Reynolds, S
   Kreisberg, RB
   Bernard, B
   Bressler, R
   Erkkila, T
   Lin, J
   Thorsson, V
   Zhang, W
   Shmulevich, I
   Ciriello, G
   Weinhold, N
   Schultz, N
   Gao, JJ
   Cerami, E
   Gross, B
   Jacobsen, A
   Sinha, R
   Aksoy, BA
   Antipin, Y
   Reva, B
   Shen, RL
   Taylor, BS
   Ladanyi, M
   Sander, C
   Anur, P
   Spellman, PT
   Lu, YL
   Liu, WB
   Verhaak, RRG
   Mills, GB
   Akbani, R
   Zhang, NX
   Broom, BM
   Casasent, TD
   Wakefield, C
   Unruh, AK
   Baggerly, K
   Coombes, K
   Weinstein, JN
   Haussler, D
   Benz, CC
   Stuart, JM
   Benz, SC
   Zhu, JC
   Szeto, CC
   Scott, GK
   Yau, C
   Paul, EO
   Carlin, D
   Wong, C
   Sokolov, A
   Thusberg, J
   Mooney, S
   Ng, S
   Goldstein, TC
   Ellrott, K
   Grifford, M
   Wilks, C
   Ma, S
   Craft, B
   Yan, CH
   Hu, Y
   Meerzaman, D
   Gastier-Foster, JM
   Bowen, J
   Ramirez, NC
   Black, AD
   Pyatt, RE
   White, P
   Zmuda, EJ
   Frick, J
   Lichtenberg, T
   Brookens, R
   George, MM
   Gerken, MA
   Harper, HA
   Leraas, KM
   Wise, LJ
   Tabler, TR
   McAllister, C
   Barr, T
   Hart-Kothari, M
   Tarvin, K
   Saller, C
   Sandusky, G
   Mitchell, C
   Iacocca, MV
   Brown, J
   Rabeno, B
   Czerwinski, C
   Petrelli, N
   Dolzhansky, O
   Abramov, M
   Voronina, O
   Potapova, O
   Marks, JR
   Suchorska, WM
   Murawa, D
   Kycler, W
   Ibbs, M
   Korski, K
   Spychala, A
   Murawa, P
   Brzezinski, JJ
   Perz, H
   Lazniak, R
   Teresiak, M
   Tatka, H
   Leporowska, E
   Bogusz-Czerniewicz, M
   Malicki, J
   Mackiewicz, A
   Wiznerowicz, M
   Le, XV
   Kohl, B
   Tien, NV
   Thorp, R
   Bang, NV
   Sussman, H
   Phu, BD
   Hajek, R
   Hung, NP
   Tran, VTP
   Thang, HQ
   Khan, KZ
   Penny, R
   Mallery, D
   Curley, E
   Shelton, C
   Yena, P
   Ingle, JN
   Couch, FJ
   Lingle, WL
   King, TA
   Gonzalez-Angulo, AM
   Mills, GB
   Dyer, MD
   Liu, SY
   Meng, XL
   Patangan, M
   Waldman, F
   Stöppler, H
   Rathmell, WK
   Thorne, L
   Huang, M
   Boice, L
   Hill, A
   Morrison, C
   Gaudioso, C
   Bshara, W
   Daily, K
   Egea, SC
   Pegram, MD
   Gomez-Fernandez, C
   Dhir, R
   Bhargava, R
   Brufsky, A
   Shriver, CD
   Hooke, JA
   Campbell, JL
   Mural, RJ
   Hu, H
   Somiari, S
   Larson, C
   Deyarmin, B
   Kvecher, L
   Kovatich, AJ
   Ellis, MJ
   King, TA
   Hu, H
   Couch, FJ
   Mural, RJ
   Stricker, T
   White, K
   Olopade, O
   Ingle, JN
   Luo, CQ
   Chen, YQ
   Marks, JR
   Waldman, F
   Wiznerowicz, M
   Bose, R
   Chang, LW
   Beck, AH
   Gonzalez-Angulo, AM
   Pihl, T
   Jensen, M
   Sfeir, R
   Kahn, A
   Chu, A
   Kothiyal, P
   Wang, ZN
   Snyder, E
   Pontius, J
   Ayala, B
   Backus, M
   Walton, J
   Baboud, J
   Berton, D
   Nicholls, M
   Srinivasan, D
   Raman, R
   Girshik, S
   Kigonya, P
   Alonso, S
   Sanbhadti, R
   Barletta, S
   Pot, D
   Sheth, M
   Demchok, JA
   Shaw, KRM
   Yang, LM
   Eley, G
   Ferguson, ML
   Tarnuzzer, RW
   Zhang, JS
   Dillon, LAL
   Buetow, K
   Fielding, P
   Ozenberger, BA
   Guyer, MS
   Sofia, HJ
   Palchik, JD
AF Koboldt, Daniel C.
   Fulton, Robert S.
   McLellan, Michael D.
   Schmidt, Heather
   Kalicki-Veizer, Joelle
   McMichael, Joshua F.
   Fulton, Lucinda L.
   Dooling, David J.
   Ding, Li
   Mardis, Elaine R.
   Wilson, Richard K.
   Ally, Adrian
   Balasundaram, Miruna
   Butterfield, Yaron S. N.
   Carlsen, Rebecca
   Carter, Candace
   Chu, Andy
   Chuah, Eric
   Chun, Hye-Jung E.
   Coope, Robin J. N.
   Dhalla, Noreen
   Guin, Ranabir
   Hirst, Carrie
   Hirst, Martin
   Holt, Robert A.
   Lee, Darlene
   Li, Haiyan I.
   Mayo, Michael
   Moore, Richard A.
   Mungall, Andrew J.
   Pleasance, Erin
   Robertson, A. Gordon
   Schein, Jacqueline E.
   Shafiei, Arash
   Sipahimalani, Payal
   Slobodan, Jared R.
   Stoll, Dominik
   Tam, Angela
   Thiessen, Nina
   Varhol, Richard J.
   Wye, Natasja
   Zeng, Thomas
   Zhao, Yongjun
   Birol, Inanc
   Jones, Steven J. M.
   Marra, Marco A.
   Cherniack, Andrew D.
   Saksena, Gordon
   Onofrio, Robert C.
   Pho, Nam H.
   Carter, Scott L.
   Schumacher, Steven E.
   Tabak, Barbara
   Hernandez, Bryan
   Gentry, Jeff
   Huy Nguyen
   Crenshaw, Andrew
   Ardlie, Kristin
   Beroukhim, Rameen
   Winckler, Wendy
   Getz, Gad
   Gabriel, Stacey B.
   Meyerson, Matthew
   Chin, Lynda
   Park, Peter J.
   Kucherlapati, Raju
   Hoadley, Katherine A.
   Auman, J. Todd
   Fan, Cheng
   Turman, Yidi J.
   Shi, Yan
   Li, Ling
   Topal, Michael D.
   He, Xiaping
   Chao, Hann-Hsiang
   Prat, Aleix
   Silva, Grace O.
   Iglesia, Michael D.
   Zhao, Wei
   Usary, Jerry
   Berg, Jonathan S.
   Adams, Michael
   Booker, Jessica
   Wu, Junyuan
   Gulabani, Anisha
   Bodenheimer, Tom
   Hoyle, Alan P.
   Simons, Janae V.
   Soloway, Matthew G.
   Mose, Lisle E.
   Jefferys, Stuart R.
   Balu, Saianand
   Parker, Joel S.
   Hayes, D. Neil
   Perou, Charles M.
   Malik, Simeen
   Mahurkar, Swapna
   Shen, Hui
   Weisenberger, Daniel J.
   Triche, Timothy, Jr.
   Lai, Phillip H.
   Bootwalla, Moiz S.
   Maglinte, Dennis T.
   Berman, Benjamin P.
   Van den Berg, David J.
   Baylin, Stephen B.
   Laird, Peter W.
   Creighton, Chad J.
   Donehower, Lawrence A.
   Getz, Gad
   Noble, Michael
   Voet, Doug
   Saksena, Gordon
   Gehlenborg, Nils
   DiCara, Daniel
   Zhang, Juinhua
   Zhang, Hailei
   Wu, Chang-Jiun
   Liu, Spring Yingchun
   Lawrence, Michael S.
   Zou, Lihua
   Sivachenko, Andrey
   Lin, Pei
   Stojanov, Petar
   Jing, Rui
   Cho, Juok
   Sinha, Raktim
   Park, Richard W.
   Nazaire, Marc-Danie
   Robinson, Jim
   Thorvaldsdottir, Helga
   Mesirov, Jill
   Park, Peter J.
   Chin, Lynda
   Reynolds, Sheila
   Kreisberg, Richard B.
   Bernard, Brady
   Bressler, Ryan
   Erkkila, Timo
   Lin, Jake
   Thorsson, Vesteinn
   Zhang, Wei
   Shmulevich, Ilya
   Ciriello, Giovanni
   Weinhold, Nils
   Schultz, Nikolaus
   Gao, Jianjiong
   Cerami, Ethan
   Gross, Benjamin
   Jacobsen, Anders
   Sinha, Rileen
   Aksoy, B. Arman
   Antipin, Yevgeniy
   Reva, Boris
   Shen, Ronglai
   Taylor, Barry S.
   Ladanyi, Marc
   Sander, Chris
   Anur, Pavana
   Spellman, Paul T.
   Lu, Yiling
   Liu, Wenbin
   Verhaak, Roel R. G.
   Mills, Gordon B.
   Akbani, Rehan
   Zhang, Nianxiang
   Broom, Bradley M.
   Casasent, Tod D.
   Wakefield, Chris
   Unruh, Anna K.
   Baggerly, Keith
   Coombes, Kevin
   Weinstein, John N.
   Haussler, David
   Benz, Christopher C.
   Stuart, Joshua M.
   Benz, Stephen C.
   Zhu, Jingchun
   Szeto, Christopher C.
   Scott, Gary K.
   Yau, Christina
   Paul, Evan O.
   Carlin, Daniel
   Wong, Christopher
   Sokolov, Artem
   Thusberg, Janita
   Mooney, Sean
   Sam Ng
   Goldstein, Theodore C.
   Ellrott, Kyle
   Grifford, Mia
   Wilks, Christopher
   Ma, Singer
   Craft, Brian
   Yan, Chunhua
   Hu, Ying
   Meerzaman, Daoud
   Gastier-Foster, Julie M.
   Bowen, Jay
   Ramirez, Nilsa C.
   Black, Aaron D.
   Pyatt, Robert E.
   White, Peter
   Zmuda, Erik J.
   Frick, Jessica
   Lichtenberg, Taram.
   Brookens, Robin
   George, Myra M.
   Gerken, Mark A.
   Harper, Hollie A.
   Leraas, Kristen M.
   Wise, Lisa J.
   Tabler, Teresa R.
   McAllister, Cynthia
   Barr, Thomas
   Hart-Kothari, Melissa
   Tarvin, Katie
   Saller, Charles
   Sandusky, George
   Mitchell, Colleen
   Iacocca, Mary V.
   Brown, Jennifer
   Rabeno, Brenda
   Czerwinski, Christine
   Petrelli, Nicholas
   Dolzhansky, Oleg
   Abramov, Mikhail
   Voronina, Olga
   Potapova, Olga
   Marks, Jeffrey R.
   Suchorska, Wiktoria M.
   Murawa, Dawid
   Kycler, Witold
   Ibbs, Matthew
   Korski, Konstanty
   Spychala, Arkadiusz
   Murawa, Pawel
   Brzezinski, Jacek J.
   Perz, Hanna
   Lazniak, Radoslaw
   Teresiak, Marek
   Tatka, Honorata
   Leporowska, Ewa
   Bogusz-Czerniewicz, Marta
   Malicki, Julian
   Mackiewicz, Andrzej
   Wiznerowicz, Maciej
   Xuan Van Le
   Kohl, Bernard
   Nguyen Viet Tien
   Thorp, Richard
   Nguyen Van Bang
   Sussman, Howard
   Bui Duc Phu
   Hajek, Richard
   Nguyen Phi Hung
   Tran Viet The Phuong
   Huynh Quyet Thang
   Khan, Khurram Zaki
   Penny, Robert
   Mallery, David
   Curley, Erin
   Shelton, Candace
   Yena, Peggy
   Ingle, James N.
   Couch, Fergus J.
   Lingle, Wilma L.
   King, Tari A.
   Gonzalez-Angulo, Ana Maria
   Mills, Gordon B.
   Dyer, Mary D.
   Liu, Shuying
   Meng, Xiaolong
   Patangan, Modesto
   Waldman, Frederic
   Stoeppler, Hubert
   Rathmell, W. Kimryn
   Thorne, Leigh
   Huang, Mei
   Boice, Lori
   Hill, Ashley
   Morrison, Carl
   Gaudioso, Carmelo
   Bshara, Wiam
   Daily, Kelly
   Egea, Sophie C.
   Pegram, Mark D.
   Gomez-Fernandez, Carmen
   Dhir, Rajiv
   Bhargava, Rohit
   Brufsky, Adam
   Shriver, Craig D.
   Hooke, Jeffrey A.
   Campbell, Jamie Leigh
   Mural, Richard J.
   Hu, Hai
   Somiari, Stella
   Larson, Caroline
   Deyarmin, Brenda
   Kvecher, Leonid
   Kovatich, Albert J.
   Ellis, Matthew J.
   King, Tari A.
   Hu, Hai
   Couch, Fergus J.
   Mural, Richard J.
   Stricker, Thomas
   White, Kevin
   Olopade, Olufunmilayo
   Ingle, James N.
   Luo, Chunqing
   Chen, Yaqin
   Marks, Jeffrey R.
   Waldman, Frederic
   Wiznerowicz, Maciej
   Bose, Ron
   Chang, Li-Wei
   Beck, Andrew H.
   Gonzalez-Angulo, Ana Maria
   Pihl, Todd
   Jensen, Mark
   Sfeir, Robert
   Kahn, Ari
   Chu, Anna
   Kothiyal, Prachi
   Wang, Zhining
   Snyder, Eric
   Pontius, Joan
   Ayala, Brenda
   Backus, Mark
   Walton, Jessica
   Baboud, Julien
   Berton, Dominique
   Nicholls, Matthew
   Srinivasan, Deepak
   Raman, Rohini
   Girshik, Stanley
   Kigonya, Peter
   Alonso, Shelley
   Sanbhadti, Rashmi
   Barletta, Sean
   Pot, David
   Sheth, Margi
   Demchok, John A.
   Shaw, Kenna R. Mills
   Yang, Liming
   Eley, Greg
   Ferguson, Martin L.
   Tarnuzzer, Roy W.
   Zhang, Jiashan
   Dillon, Laura A. L.
   Buetow, Kenneth
   Fielding, Peter
   Ozenberger, Bradley A.
   Guyer, Mark S.
   Sofia, Heidi J.
   Palchik, Jacqueline D.
CA Canc Genome Atlas Network
TI Comprehensive molecular portraits of human breast tumours
SO NATURE
LA English
DT Article
ID BASAL-LIKE; MUTATIONAL EVOLUTION; HIGH-FREQUENCY; PIK3CA GENE;
   LUMINAL-B; CANCER; SUPPRESSOR; SUBTYPES; PATHWAYS; TARGET
AB We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer.
C1 [Hoadley, Katherine A.; He, Xiaping; Chao, Hann-Hsiang; Prat, Aleix; Silva, Grace O.; Iglesia, Michael D.; Zhao, Wei; Berg, Jonathan S.; Adams, Michael; Weisenberger, Daniel J.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
   [Koboldt, Daniel C.; Fulton, Robert S.; McLellan, Michael D.; Schmidt, Heather; Kalicki-Veizer, Joelle; McMichael, Joshua F.; Fulton, Lucinda L.; Dooling, David J.; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Genome Inst, St Louis, MO 63108 USA.
   [Ding, Li; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Dept Genet, St Louis, MO 63110 USA.
   [Mardis, Elaine R.; Wilson, Richard K.; Ellis, Matthew J.; Bose, Ron] Washington Univ, Siteman Canc Ctr, St Louis, MO 63110 USA.
   [Ally, Adrian; Balasundaram, Miruna; Butterfield, Yaron S. N.; Carlsen, Rebecca; Carter, Candace; Chu, Andy; Chuah, Eric; Chun, Hye-Jung E.; Coope, Robin J. N.; Dhalla, Noreen; Guin, Ranabir; Hirst, Carrie; Hirst, Martin; Holt, Robert A.; Lee, Darlene; Li, Haiyan I.; Mayo, Michael; Moore, Richard A.; Mungall, Andrew J.; Pleasance, Erin; Robertson, A. Gordon; Schein, Jacqueline E.; Shafiei, Arash; Sipahimalani, Payal; Slobodan, Jared R.; Stoll, Dominik; Tam, Angela; Thiessen, Nina; Varhol, Richard J.; Wye, Natasja; Zeng, Thomas; Zhao, Yongjun; Birol, Inanc; Jones, Steven J. M.; Marra, Marco A.] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z, Canada.
   [Cherniack, Andrew D.; Saksena, Gordon; Onofrio, Robert C.; Pho, Nam H.; Carter, Scott L.; Schumacher, Steven E.; Tabak, Barbara; Hernandez, Bryan; Gentry, Jeff; Huy Nguyen; Crenshaw, Andrew; Ardlie, Kristin; Beroukhim, Rameen; Winckler, Wendy; Getz, Gad; Gabriel, Stacey B.; Meyerson, Matthew] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Schumacher, Steven E.; Tabak, Barbara; Beroukhim, Rameen; Nguyen Phi Hung] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
   [Beroukhim, Rameen] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Beroukhim, Rameen; Meyerson, Matthew; Chin, Lynda] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Beroukhim, Rameen; Meyerson, Matthew; Chin, Lynda] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
   [Meyerson, Matthew; Beck, Andrew H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
   [Chin, Lynda] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
   [Park, Peter J.; Gehlenborg, Nils; Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
   [Kucherlapati, Raju] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
   [Kucherlapati, Raju] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Hoadley, Katherine A.; Fan, Cheng; Turman, Yidi J.; Shi, Yan; Li, Ling; Topal, Michael D.; He, Xiaping; Chao, Hann-Hsiang; Prat, Aleix; Silva, Grace O.; Iglesia, Michael D.; Zhao, Wei; Usary, Jerry; Berg, Jonathan S.; Wu, Junyuan; Gulabani, Anisha; Bodenheimer, Tom; Hoyle, Alan P.; Simons, Janae V.; Soloway, Matthew G.; Mose, Lisle E.; Jefferys, Stuart R.; Balu, Saianand; Parker, Joel S.; Hayes, D. Neil; Perou, Charles M.; Malik, Simeen; Mahurkar, Swapna; Shen, Hui; Weisenberger, Daniel J.; Rathmell, W. Kimryn; Thorne, Leigh; Huang, Mei; Boice, Lori; Hill, Ashley] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Auman, J. Todd] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
   [Auman, J. Todd] Univ N Carolina, Inst Pharmacogenet & Individualized Therapy, Chapel Hill, NC 27599 USA.
   [Topal, Michael D.; Booker, Jessica; Weisenberger, Daniel J.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   [Shen, Hui] Univ N Carolina, Div Med Oncol, Dept Internal Med, Chapel Hill, NC 27599 USA.
   [Triche, Timothy, Jr.; Lai, Phillip H.; Bootwalla, Moiz S.; Maglinte, Dennis T.; Berman, Benjamin P.; Van den Berg, David J.; Laird, Peter W.] Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90033 USA.
   [Baylin, Stephen B.] Johns Hopkins Univ, Div Canc Biol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   [Creighton, Chad J.; Donehower, Lawrence A.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Creighton, Chad J.; Donehower, Lawrence A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
   [Donehower, Lawrence A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Donehower, Lawrence A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Getz, Gad; Noble, Michael; Voet, Doug; Saksena, Gordon; Gehlenborg, Nils; DiCara, Daniel; Zhang, Hailei; Liu, Spring Yingchun; Lawrence, Michael S.; Zou, Lihua; Sivachenko, Andrey; Lin, Pei; Stojanov, Petar; Jing, Rui; Cho, Juok; Sinha, Raktim; Park, Richard W.; Nazaire, Marc-Danie; Robinson, Jim; Thorvaldsdottir, Helga; Mesirov, Jill; Chin, Lynda] Eli & Edythe L Broad Inst Massachusetts Inst Tech, Cambridge, MA 02142 USA.
   [Zhang, Juinhua; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Inst Appl Canc Sci, Houston, TX 77054 USA.
   [Wu, Chang-Jiun] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77054 USA.
   [Park, Peter J.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Park, Peter J.] Childrens Hosp, Informat Program, Boston, MA 02115 USA.
   [Reynolds, Sheila; Kreisberg, Richard B.; Bernard, Brady; Bressler, Ryan; Lin, Jake; Thorsson, Vesteinn; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA 98109 USA.
   [Erkkila, Timo] Tampere Univ Technol, FIN-33101 Tampere, Finland.
   [Zhang, Wei] Univ Texas MD Anderson Canc Ctr, Canc Genom Core Lab, Houston, TX 77030 USA.
   [Ciriello, Giovanni; Weinhold, Nils; Schultz, Nikolaus; Gao, Jianjiong; Cerami, Ethan; Gross, Benjamin; Jacobsen, Anders; Sinha, Rileen; Aksoy, B. Arman; Antipin, Yevgeniy; Reva, Boris; Taylor, Barry S.; Sander, Chris] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA.
   [Shen, Ronglai] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
   [Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
   [Anur, Pavana; Spellman, Paul T.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
   [Lu, Yiling; Mills, Gordon B.; Gonzalez-Angulo, Ana Maria] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Lu, Yiling; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Kleberg Ctr Mol Markers, Houston, TX 77030 USA.
   [Liu, Wenbin; Verhaak, Roel R. G.; Akbani, Rehan; Zhang, Nianxiang; Broom, Bradley M.; Casasent, Tod D.; Wakefield, Chris; Unruh, Anna K.; Baggerly, Keith; Coombes, Kevin; Weinstein, John N.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
   [Haussler, David; Stuart, Joshua M.; Benz, Stephen C.; Zhu, Jingchun; Szeto, Christopher C.; Paul, Evan O.; Carlin, Daniel; Wong, Christopher; Sokolov, Artem; Sam Ng; Goldstein, Theodore C.; Ellrott, Kyle; Grifford, Mia; Wilks, Christopher; Ma, Singer; Craft, Brian] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.
   [Haussler, David; Stuart, Joshua M.; Benz, Stephen C.; Zhu, Jingchun; Szeto, Christopher C.; Paul, Evan O.; Carlin, Daniel; Wong, Christopher; Sokolov, Artem; Sam Ng; Goldstein, Theodore C.; Ellrott, Kyle; Grifford, Mia; Wilks, Christopher; Ma, Singer; Craft, Brian] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.
   [Haussler, David] Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA.
   [Benz, Christopher C.; Scott, Gary K.; Yau, Christina; Thusberg, Janita; Mooney, Sean] Buck Inst Res Aging, Novato, CA 94945 USA.
   [Yan, Chunhua; Hu, Ying; Meerzaman, Daoud; Buetow, Kenneth] NCI, Ctr Bioinformat & Informat Technol, Rockville, MD 20852 USA.
   [Gastier-Foster, Julie M.; Ramirez, Nilsa C.; Pyatt, Robert E.; White, Peter] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43205 USA.
   [Gastier-Foster, Julie M.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43205 USA.
   [Gastier-Foster, Julie M.; Bowen, Jay; Ramirez, Nilsa C.; Black, Aaron D.; Pyatt, Robert E.; White, Peter; Zmuda, Erik J.; Frick, Jessica; Lichtenberg, Taram.; Brookens, Robin; George, Myra M.; Gerken, Mark A.; Harper, Hollie A.; Leraas, Kristen M.; Wise, Lisa J.; Tabler, Teresa R.; McAllister, Cynthia; Barr, Thomas; Hart-Kothari, Melissa] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA.
   [Tarvin, Katie] ABS Inc, Indianapolis, IN 46204 USA.
   [Saller, Charles] ABS Inc, Wilmington, DE 19801 USA.
   [Sandusky, George; Mitchell, Colleen] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Iacocca, Mary V.; Brown, Jennifer; Rabeno, Brenda; Czerwinski, Christine; Petrelli, Nicholas] Christiana Care, Helen F Graham Canc Ctr, Newark, DE 19713 USA.
   [Dolzhansky, Oleg] Moscow Hlth Dept, Moscow City Clin Oncol Dispensary 1, Moscow 105005, Russia.
   [Dolzhansky, Oleg] Moscow Hlth Dept, Cent IHC Lab, Moscow 105005, Russia.
   [Abramov, Mikhail] Russian Canc Res Ctr, Moscow 115478, Russia.
   [Voronina, Olga; Potapova, Olga] Cureline Inc, San Francisco, CA 94080 USA.
   [Marks, Jeffrey R.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   [Suchorska, Wiktoria M.; Murawa, Dawid; Kycler, Witold; Ibbs, Matthew; Korski, Konstanty; Spychala, Arkadiusz; Murawa, Pawel; Brzezinski, Jacek J.; Perz, Hanna; Lazniak, Radoslaw; Teresiak, Marek; Tatka, Honorata; Leporowska, Ewa; Bogusz-Czerniewicz, Marta; Malicki, Julian; Mackiewicz, Andrzej; Wiznerowicz, Maciej] Greater Poland Canc Ctr, PL-61866 Poznan, Poland.
   [Bogusz-Czerniewicz, Marta; Malicki, Julian; Mackiewicz, Andrzej] Poznan Univ Med Sci, PL-61701 Poznan, Poland.
   [Xuan Van Le; Kohl, Bernard] ILSBio LLC, Chestertown, MD 21620 USA.
   [Nguyen Viet Tien] Minist Hlth, Hanoi, Vietnam.
   [Thorp, Richard; Khan, Khurram Zaki] ILSBio LLC, Karachi, Pakistan.
   [Nguyen Van Bang; Bui Duc Phu] Hue Cent Hosp, Hue City, Vietnam.
   [Sussman, Howard] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
   [Hajek, Richard] Univ Texas MD Anderson Canc Ctr, Ctr Minor Hlth Res, Houston, TX 77030 USA.
   [Nguyen Phi Hung] Natl Canc Inst, Hanoi, Vietnam.
   [Tran Viet The Phuong] Ho Chi Minh City Canc Ctr, Ho Chi Minh City, Vietnam.
   [Huynh Quyet Thang] Can Tho Canc Ctr, Can Tho, Vietnam.
   [Penny, Robert; Mallery, David; Curley, Erin; Shelton, Candace; Yena, Peggy] Int Genom Consortium, Phoenix, AZ 85004 USA.
   [Ingle, James N.; Couch, Fergus J.; Lingle, Wilma L.] Mayo Clin, Rochester, MN 55905 USA.
   [King, Tari A.] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10065 USA.
   [Mills, Gordon B.; Dyer, Mary D.; Liu, Shuying; Meng, Xiaolong; Patangan, Modesto] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Waldman, Frederic] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   Canc Diagnost, San Juan Capistrano, CA 92675 USA.
   Quest Diagnost, Nichols Inst, San Juan Capistrano, CA 92675 USA.
   [Stoeppler, Hubert] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA.
   [Thorne, Leigh; Huang, Mei; Boice, Lori] UNC Lineberger Canc Ctr, Dept Pathol, UNC Tissue Procurement Facil, Chapel Hill, NC 27599 USA.
   [Morrison, Carl; Gaudioso, Carmelo; Bshara, Wiam] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.
   [Daily, Kelly; Egea, Sophie C.; Pegram, Mark D.; Gomez-Fernandez, Carmen] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Pathol, Miami, FL 33136 USA.
   [Dhir, Rajiv] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
   [Bhargava, Rohit; Brufsky, Adam] Univ Pittsburgh Med Ctr, Magee Womens Hosp, Pittsburgh, PA 15213 USA.
   [Shriver, Craig D.; Hooke, Jeffrey A.; Campbell, Jamie Leigh] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20899 USA.
   [Mural, Richard J.; Hu, Hai; Somiari, Stella; Larson, Caroline; Deyarmin, Brenda; Kvecher, Leonid; Luo, Chunqing; Chen, Yaqin] Windber Res Inst, Windber, PA 15963 USA.
   [Kovatich, Albert J.] MDR Global LLC, Windber, PA 15963 USA.
   [Ellis, Matthew J.; Bose, Ron] Washington Univ, Breast Canc Program, St Louis, MO 63110 USA.
   [Ellis, Matthew J.; Bose, Ron] Washington Univ, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA.
   [Stricker, Thomas; White, Kevin] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA.
   [Olopade, Olufunmilayo] Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
   [Chang, Li-Wei] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Pihl, Todd; Jensen, Mark; Sfeir, Robert; Kahn, Ari; Chu, Anna; Kothiyal, Prachi; Wang, Zhining; Snyder, Eric; Pontius, Joan; Ayala, Brenda; Backus, Mark; Walton, Jessica; Baboud, Julien; Berton, Dominique; Nicholls, Matthew; Srinivasan, Deepak; Raman, Rohini; Girshik, Stanley; Kigonya, Peter; Alonso, Shelley; Sanbhadti, Rashmi; Barletta, Sean; Pot, David] SRA Int, Fairfax, VA 22033 USA.
   [Sheth, Margi; Demchok, John A.; Shaw, Kenna R. Mills; Yang, Liming; Tarnuzzer, Roy W.; Zhang, Jiashan; Dillon, Laura A. L.; Fielding, Peter] NCI, Canc Genome Atlas Program Off, Ctr Canc Genom, Bethesda, MD 20892 USA.
   [Eley, Greg] Scimentis LLC, TCGA, Statham, GA 30666 USA.
   [Ferguson, Martin L.] MLF Consulting, Arlington, MA 02474 USA.
   [Ozenberger, Bradley A.; Guyer, Mark S.; Sofia, Heidi J.; Palchik, Jacqueline D.] NHGRI, NIH, Bethesda, MD 20892 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Siteman Cancer Center; British Columbia Cancer
   Agency; Harvard University; Massachusetts Institute of Technology (MIT);
   Broad Institute; Harvard University; Dana-Farber Cancer Institute;
   Harvard University; Harvard Medical School; Harvard University;
   Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Harvard Medical School; Harvard
   University; Dana-Farber Cancer Institute; Harvard University; Harvard
   Medical School; Harvard University; Harvard Medical School; Harvard
   University; Brigham & Women's Hospital; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina;
   University of North Carolina Chapel Hill; University of North Carolina;
   University of North Carolina Chapel Hill; University of Southern
   California; Johns Hopkins University; Johns Hopkins Medicine; Baylor
   College of Medicine; Baylor College of Medicine; Baylor College of
   Medicine; Baylor College of Medicine; Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; University of Texas
   System; UTMD Anderson Cancer Center; University of Texas System; UTMD
   Anderson Cancer Center; Harvard University; Brigham & Women's Hospital;
   Harvard University; Boston Children's Hospital; Institute for Systems
   Biology (ISB); Tampere University; University of Texas System; UTMD
   Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial
   Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center;
   Oregon Health & Science University; University of Texas System; UTMD
   Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; UTMD Anderson Cancer Center;
   University of California System; University of California Santa Cruz;
   University of California System; University of California Santa Cruz;
   Howard Hughes Medical Institute; University of California System;
   University of California Santa Cruz; Buck Institute for Research on
   Aging; National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); University System of Ohio; Ohio State University;
   University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; Nationwide Childrens Hospital; Research
   Institute at Nationwide Children's Hospital; Indiana University System;
   Indiana University Bloomington; Christiana Care Health System; Helen F.
   Graham Cancer Center & Research Institute; Duke University;
   Wielkopolskie Centrum Onkologii; Poznan University of Medical Sciences;
   Stanford University; University of Texas System; UTMD Anderson Cancer
   Center; International Genomics Consortium; Mayo Clinic; Memorial Sloan
   Kettering Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of California System; University of California
   San Francisco; Nichols Institute; University of California System;
   University of California San Francisco; UCSF Medical Center; UCSF Helen
   Diller Family Comprehensive Cancer Center; Roswell Park Comprehensive
   Cancer Center; University of Miami; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Walter Reed National Military Medical Center; Windber
   Research Institute; Washington University (WUSTL); Washington University
   (WUSTL); University of Chicago; University of Chicago; Washington
   University (WUSTL); SRA International; International Genomics
   Consortium; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); Center for Cancer Genomics (CCG); International
   Genomics Consortium; National Institutes of Health (NIH) - USA; NIH
   National Human Genome Research Institute (NHGRI)
RP Perou, CM (通讯作者)，Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
EM cperou@med.unc.edu
RI Zhang, Hailei/AAB-2435-2020; Gastier-Foster, Julie/E-3105-2011; Munro,
   James/C-5489-2009; Malicki, Julian/Q-7606-2017; Akbani,
   Rehan/AAG-1490-2019; Mills, Gordon/HCI-9369-2022; Liu,
   Shu-Ying/GYQ-6383-2022; Wang, Jun/A-7261-2013; Mills,
   Gordon/L-5416-2014; Ibbs, Matthew/AAU-1511-2021; Hayes, D/AIA-2263-2022;
   li, zy/HZM-1892-2023; Mardis, Elaine/W-2202-2019; Stoll,
   Dieter/HJA-6202-2022; Hoadley, Katherine/JXY-5615-2024; Getz,
   Gad/ABW-5118-2022; Kucherlapati, Raju/ABC-8807-2021; Park,
   Peter/ADM-1744-2022; Wang, Jun/C-8434-2016; Noble, Michelle/C-4653-2011;
   Thang, Huynh/U-1826-2019; Marra, Marco/B-5987-2008; Jones,
   Steven/C-3621-2009; Kycler, Witold/H-3810-2014; Parker,
   Joel/AAG-1108-2019; Weisenberger, Daniel/AAA-8314-2020; Triche,
   Tim/JRX-1507-2023; Cherniack, Andrew/AAC-5310-2019; Schein,
   Jacquie/G-3674-2015; Van Den Berg, David/G-8598-2017; Mesirov,
   Jill/AGF-7626-2022; Gong, Caifeng/HOA-5533-2023; Wang,
   Jiayin/HJP-0287-2023; Moore, Richard/AGU-0985-2022; Wilson,
   Richard/AAF-4139-2019; Reva, Boris/AAB-8932-2022; Stojanov,
   Petar/GQI-4462-2022; wang, lili/HDL-7210-2022; Yang, Liming/D-8222-2019;
   Brown, Jennifer/ADL-7279-2022; Schumacher, Steven/E-9821-2013; Zhao,
   Yong/Z-3231-2019; hu, ying/IVV-6516-2023; Ladanyi, Marc/AAG-8585-2019;
   Lawrence, Michael/AAC-8202-2020; Verhaak, Roel/ABE-7058-2020; Bhargava,
   Rohit/B-6866-2008; Auman, James/AAY-7748-2020; Joshi,
   Swapna/JBJ-7680-2023; Chin, Lynda/D-2295-2010; Hirst,
   Martin/B-7684-2016; Brufsky, Adam/AAE-7470-2020; Suchorska,
   Wiktoria/CAG-0479-2022; Liu, Wenbin/GVU-0680-2022; sun,
   lingdong/AAJ-8058-2020; BERMAN, BENJAMIN/AAT-3720-2021; Pearson,
   John/AAT-4211-2020; White, Peter/E-4301-2011; Holt, Robert/C-3303-2009;
   LAIRD, PETER W/G-8683-2012; Jacobsen Skanderup, Anders/K-1081-2013;
   Mungall, Andrew/U-7067-2018; Reva, Boris/B-6436-2014; Berman,
   Benjamin/D-5942-2014; Birol, Inanc/G-5440-2011; Prat, Aleix/P-8561-2014;
   Perou, Charles/H-9934-2014; Gao, Jianjiong/B-5673-2016
OI Coombes, Kevin/0000-0002-7630-2123; , Rameen/0000-0001-6303-3609; White,
   Peter/0000-0002-5218-5903; Gehlenborg, Nils/0000-0003-0327-8297; Holt,
   Robert/0000-0002-7259-1247; Jensen, Mark/0000-0001-5215-101X; Schultz,
   Nikolaus/0000-0002-0131-4904; Stoll, Dominik/0000-0003-0701-4301; Shen,
   Hui/0000-0001-9767-4084; MOONEY, SEAN D/0000-0003-2654-0833; Meyerson,
   Matthew/0000-0002-9133-8108; Weinstein, John/0000-0001-9401-6908;
   Mahurkar-Joshi, Swapna/0000-0001-9591-4590; LAIRD, PETER
   W/0000-0001-9117-3641; Casasent, Anna/0000-0002-7857-179X; Jacobsen
   Skanderup, Anders/0000-0001-6847-4980; Kovatich,
   Albert/0000-0002-5169-4087; Triche, Tim/0000-0001-5665-946X; Benz,
   Stephen/0000-0002-4067-0602; Rathmell, Wendy Kimryn/0000-0002-4984-0225;
   Sinha, Rileen/0000-0001-5497-5055; Lin, Jake/0000-0001-9928-1663;
   Hoadley, Katherine/0000-0002-1216-477X; Pho, Nam/0000-0002-0456-2532;
   Malicki, Julian/0000-0002-5558-5558; Hayes, D. Neil/0000-0001-6203-7771;
   MCLELLAN, MICHAEL/0000-0002-2703-8784; Stuart,
   Joshua/0000-0002-2171-565X; Brufsky, Adam/0000-0001-8080-7960; Mungall,
   Andrew/0000-0002-0905-2742; Reva, Boris/0000-0002-8805-389X; Bowen,
   Jay/0000-0001-6861-9043; Tarnuzzer, Roy/0000-0002-3725-4173; Hu,
   Hai/0000-0001-5345-8371; Berman, Benjamin/0000-0002-2099-9005; Quyet
   Thang, Huynh/0000-0002-0788-6380; Birol, Inanc/0000-0003-0950-7839;
   Prat, Aleix/0000-0003-2377-540X; Ciriello, Giovanni/0000-0003-2021-8683;
   Suchorska, Wiktoria/0000-0003-4742-2465; Perou,
   Charles/0000-0001-9827-2247; Gao, Jianjiong/0000-0002-5739-1781; Park,
   Peter/0000-0001-9378-960X; Ibbs, Matthew/0000-0003-2510-3447; Jones,
   Steven/0000-0003-3394-2208; Berg, Jonathan/0000-0003-2360-2664; Pot,
   David/0000-0002-1480-9826
FU USA National Institutes of Health [U24CA143883, U24CA143858,
   U24CA143840, U24CA143799, U24CA143835, U24CA143845, U24CA143882,
   U24CA143867, U24CA143866, U24CA143848, U24CA144025, U54HG003079,
   P50CA116201, P50CA58223]; Susan G. Komen for the Cure; US Department of
   Defense through the Henry M. Jackson Foundation for the Advancement of
   Military Medicine; Breast Cancer Research Foundation
FX We thank M. Sheth and S. Lucas for administrative coordination of TCGA
   activities, and C. Gunter for critical reading of the manuscript. This
   work was supported by the following grants from the USA National
   Institutes of Health: U24CA143883, U24CA143858, U24CA143840,
   U24CA143799, U24CA143835, U24CA143845, U24CA143882, U24CA143867,
   U24CA143866, U24CA143848, U24CA144025, U54HG003079, P50CA116201 and
   P50CA58223. Additional support was provided by the Susan G. Komen for
   the Cure, the US Department of Defense through the Henry M. Jackson
   Foundation for the Advancement of Military Medicine, and the Breast
   Cancer Research Foundation. The views expressed in this paper are those
   of the authors and do not reflect the official policy of the Department
   of Defense, or US Government.
CR Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994
   Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311
   Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chandriani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006693
   Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039
   Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111
   Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007
   Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111
   Deisenroth C, 2010, MOL CELL BIOL, V30, P3981, DOI 10.1128/MCB.01284-09
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006
   González-Pérez A, 2011, AM J HUM GENET, V88, P440, DOI 10.1016/j.ajhg.2011.03.004
   Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y
   Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142
   Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Lara MF, 2008, MOL CARCINOGEN, V47, P209, DOI 10.1002/mc.20376
   Li QY, 1997, NAT GENET, V15, P21
   Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   Malcovati L, 2011, BLOOD, V118, P6239, DOI 10.1182/blood-2011-09-377275
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854
   Troester MA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-276
   Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107
   Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016
   Weigman VJ, 2012, BREAST CANCER RES TR, V133, P865, DOI 10.1007/s10549-011-1846-y
NR 56
TC 9254
Z9 10377
U1 48
U2 1687
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 4
PY 2012
VL 490
IS 7418
BP 61
EP 70
DI 10.1038/nature11412
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 015LG
UT WOS:000309446800032
PM 23000897
OA Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Katoh, H
   Yamashita, K
   Waraya, M
   Margalit, O
   Ooki, A
   Tamaki, H
   Sakagami, H
   Kokubo, K
   Sidransky, D
   Watanabe, M
AF Katoh, Hiroshi
   Yamashita, Keishi
   Waraya, Mina
   Margalit, Ofer
   Ooki, Akira
   Tamaki, Hideaki
   Sakagami, Hiroyuki
   Kokubo, Kenichi
   Sidransky, David
   Watanabe, Masahiko
TI Epigenetic Silencing of HOPX Promotes Cancer Progression in Colorectal
   Cancer
SO NEOPLASIA
LA English
DT Article
ID EPHA2 OVEREXPRESSION; BREAST-CANCER; HOMEOBOX GENE; GROWTH-FACTOR;
   CYR61; METHYLATION; ANGIOGENESIS; DNA; MICROENVIRONMENT; MIGRATION
AB Homeodomain-only protein X (HOPX)-beta promoter methylation was recently shown to be frequent in human cancers and was suggested as tumor suppressor gene in esophageal and gastric cancer. The aim of this study was to investigate the mechanistic roles of HOPX-beta promoter methylation and its clinical relevance in colorectal cancer (CRC). HOPX-beta promoter methylation was assessed in human CRC cell lines and 294 CRC tissues. HOPX mRNA and protein levels were measured in relation to HOPX-beta promoter methylation. The effects of forced HOPX expression on tumorigenesis were studied using in vitro and in vivo assays. The association between HOPX-beta promoter methylation and clinical relevance of CRC patients was determined. HOPX-beta promoter methylation is cancer-specific and frequently found in CRC cell lines and tissues, resulting in the down-regulation of HOPX mRNA and protein levels. In CRC cell lines, forced expression of HOPX suppressed proliferation, invasion, and anchorage-independent growth. DNA microarray analyses suggested critical downstream genes that are associated with cancer cell proliferation, invasion or angiogenesis. In a mouse xenograft model, HOPX inhibited tumorigenesis and angiogenesis. Finally, HOPX-beta promoter methylation was associated with worse prognosis of stage III CRC patients (hazard ratio = 1.40, P = .035) and also with poor differentiation (P = .014). In conclusion, HOPX-beta promoter methylation is a frequent and cancer-specific event in CRC progression. This epigenetic alteration may have clinical ramifications in the diagnosis and treatment of CRC patients.
C1 [Katoh, Hiroshi] Kitasato Univ, Sch Med, Dept Surg, Minami Ku, Sagamihara, Kanagawa 2520374, Japan.
   [Katoh, Hiroshi; Margalit, Ofer] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   [Margalit, Ofer] Chaim Sheba Med Ctr, Talpiot Med Leadership Program, IL-52621 Tel Hashomer, Israel.
   [Tamaki, Hideaki; Sakagami, Hiroyuki] Kitasato Univ, Sch Med, Dept Anat, Sagamihara, Kanagawa 2520374, Japan.
   [Kokubo, Kenichi] Kitasato Univ, Sch Allied Hlth Sci, Dept Med Engn & Technol, Sagamihara, Kanagawa 2520374, Japan.
   [Sidransky, David] Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Head & Neck Canc Res Div, Baltimore, MD 21205 USA.
C3 Kitasato University; University of Texas System; UTMD Anderson Cancer
   Center; Chaim Sheba Medical Center; Kitasato University; Kitasato
   University; Johns Hopkins University
RP Katoh, H (通讯作者)，Kitasato Univ, Sch Med, Dept Surg, Minami Ku, Kitasato 1-15-1, Sagamihara, Kanagawa 2520374, Japan.
EM gekaw@med.kitasato-u.ac.jp
RI Kokubo, Kenichi/E-6667-2011; Ooki, Akira/HKF-8173-2023
OI Ooki, Akira/0000-0001-7618-5775
FU Grants-in-Aid for Scientific Research [22300114, 23659101] Funding
   Source: KAKEN
CR Albrecht I, 2010, EUR J IMMUNOL, V40, P2993, DOI 10.1002/eji.201040936
   Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355
   Baeten CIM, 2009, DIS COLON RECTUM, V52, P2028, DOI 10.1007/DCR.0b013e3181beb4ff
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje
   Choi YD, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-88
   Harada Y, 2011, ANTICANCER RES, V31, P2889
   Hawkins N, 2002, GASTROENTEROLOGY, V122, P1376, DOI 10.1053/gast.2002.32997
   Herath NI, 2012, EUR J CANCER, V48, P753, DOI 10.1016/j.ejca.2011.07.003
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x
   Katoh H, 2010, AM J PATHOL, V176, P1469, DOI 10.2353/ajpath.2010.090607
   Kim MS, 2008, ONCOGENE, V27, P2045, DOI 10.1038/sj.onc.1210842
   Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Kim MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009003
   Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639
   Lin YG, 2007, CANCER, V109, P332, DOI 10.1002/cncr.22415
   MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901
   Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009
   Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082
   Ooki A, 2010, ONCOGENE, V29, P3263, DOI 10.1038/onc.2010.76
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214
   Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682
   Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Xie D, 2001, CANCER RES, V61, P8917
   Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200
   Xie JJ, 2010, AM J PATHOL, V176, P939, DOI 10.2353/ajpath.2010.090118
   Yamashita K, 2006, CANCER RES, V66, P3921, DOI 10.1158/0008-5472.CAN-05-1511
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Yamashita K, 2008, MOL CANCER RES, V6, P31, DOI 10.1158/1541-7786.MCR-07-0213
   Yamashita K, 2009, CANCER SCI, V100, P195, DOI 10.1111/j.1349-7006.2008.01022.x
NR 35
TC 55
Z9 62
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD JUL
PY 2012
VL 14
IS 7
BP 559
EP +
DI 10.1593/neo.12330
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 001VZ
UT WOS:000308489500001
PM 22904674
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Barekati, Z
   Radpour, R
   Lu, Q
   Bitzer, J
   Zheng, H
   Toniolo, P
   Lenner, P
   Zhong, XY
AF Barekati, Zeinab
   Radpour, Ramin
   Lu, Qing
   Bitzer, Johannes
   Zheng, Hong
   Toniolo, Paolo
   Lenner, Per
   Zhong, Xiao Yan
TI Methylation signature of lymph node metastases in breast cancer patients
SO BMC CANCER
LA English
DT Article
DE Methylation; Metastasis; Breast cancer; Biomarker
ID BONE MORPHOGENETIC PROTEIN-6; TUMOR-SUPPRESSOR GENES; PROMOTER
   METHYLATION; DNA METHYLATION; MASS ARRAY; EXPRESSION; CELLS; CARCINOMA;
   PATTERNS; PROFILE
AB Background: Invasion and metastasis are two important hallmarks of malignant tumors caused by complex genetic and epigenetic alterations. The present study investigated the contribution of aberrant methylation profiles of cancer related genes, APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14 (ARF), P16 (CDKN2A), P21 (CDKN1A), PTEN, and TIMP3, in the matched axillary lymph node metastasis in comparison to the primary tumor tissue and the adjacent normal tissue from the same breast cancer patients to identify the potential of candidate genes methylation as metastatic markers.
   Methods: The quantitative methylation analysis was performed using the SEQUENOM's EpiTYPER (TM) assay which relies on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
   Results: The quantitative DNA methylation analysis of the candidate genes showed higher methylation proportion in the primary tumor tissue than that of the matched normal tissue and the differences were significant for the APC, BIN1, BMP6, BRCA1, CST6, ESR-b, P16, PTEN and TIMP3 promoter regions (P<0.05). Among those candidate methylated genes, APC, BMP6, BRCA1 and P16 displayed higher methylation proportion in the matched lymph node metastasis than that found in the normal tissue (P<0.05). The pathway analysis revealed that BMP6, BRCA1 and P16 have a role in prevention of neoplasm metastasis.
   Conclusions: The results of the present study showed methylation heterogeneity between primary tumors and metastatic lesion. The contribution of aberrant methylation alterations of BMP6, BRCA1 and P16 genes in lymph node metastasis might provide a further clue to establish useful biomarkers for screening metastasis.
C1 [Barekati, Zeinab; Radpour, Ramin; Zhong, Xiao Yan] Univ Basel, Lab Gynecol Oncol, Womens Hosp, Dept Biomed, CH-4031 Basel, Switzerland.
   [Lu, Qing] Sichuan Univ, Dept Breast Surg, W China Hosp, W China Sch Med, Chengdu 610064, Peoples R China.
   [Bitzer, Johannes] Univ Basel, Dept Obstet & Gynecol, Womens Hosp, CH-4031 Basel, Switzerland.
   [Zheng, Hong] Sichuan Univ, Dept Oncol, State Key Lab Biotherapy, W China Hosp,W China Sch Med, Chengdu 610064, Peoples R China.
   [Zheng, Hong] Sichuan Univ, Ctr Canc, W China Hosp, W China Sch Med, Chengdu 610064, Peoples R China.
   [Zheng, Hong] Sichuan Univ, Lab Mol Diag Canc, W China Hosp, W China Sch Med, Chengdu 610064, Peoples R China.
   [Toniolo, Paolo] New York Univ, Dept Obstet & Gynecol, Sch Med, Inst Univ Med Sociale & Prevent,CHUV, CH-1005 Lausanne, Switzerland.
   [Lenner, Per] Umea Univ Hosp, Dept Oncol, S-90185 Umea, Sweden.
C3 University of Basel; Sichuan University; University of Basel; Sichuan
   University; Sichuan University; Sichuan University; University of
   Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Umea
   University
RP Zhong, XY (通讯作者)，Univ Basel, Lab Gynecol Oncol, Womens Hosp, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland.
EM zhongx@uhbs.ch
RI Radpour, PD Dr. Ramin/J-4949-2014
OI Radpour, PD Dr. Ramin/0000-0002-5632-7833
FU Swiss National Science Foundation [320030_124958/1]; Swiss National
   Science Foundation (SNF) [320030_124958] Funding Source: Swiss National
   Science Foundation (SNF)
FX We are indebted to the patients for their cooperation. We thank Ms.
   Vivian Kiefer for her help. This work was supported by Swiss National
   Science Foundation (320030_124958/1).
CR Akiyoshi T, 2004, VET PATHOL, V41, P154, DOI 10.1354/vp.41-2-154
   Andrews J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008665
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2
   Cavalli LR, 2003, CANCER GENET CYTOGEN, V146, P33, DOI 10.1016/S0165-4608(03)00123-7
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chen L, 2009, BREAST CANCER RES TR, V116, P471, DOI 10.1007/s10549-008-0147-6
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Feng Jing, 2009, Ai Zheng, V28, P436
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kim JH, 2009, ONCOL REP, V21, P1251, DOI 10.3892/or_00000348
   Lindahl T, 2000, ACTA ONCOL, V39, P319, DOI 10.1080/028418600750013087
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Messick CA, 2010, ANN SURG ONCOL, V17, P425, DOI 10.1245/s10434-009-0783-z
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Radpour R, 2010, MODERN PATHOL, V23, P763, DOI 10.1038/modpathol.2009.195
   Radpour R, 2009, J PROTEOME RES, V8, P5264, DOI 10.1021/pr900591w
   Reintgen Douglas, 2000, Breast J, V6, P299, DOI 10.1046/j.1524-4741.2000.20057.x
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Su PF, 2010, ORAL ONCOL, V46, P734, DOI 10.1016/j.oraloncology.2010.07.002
   Yang S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-211
   Zhang M, 2007, J STEROID BIOCHEM, V105, P91, DOI 10.1016/j.jsbmb.2007.01.002
   Zhao Ying-fang, 2010, Chinese Journal of Pathology, V39, P377, DOI 10.3760/cma.j.issn.0529-5807.2010.06.004
   Zidan J, 2005, BRIT J CANCER, V93, P552, DOI 10.1038/sj.bjc.6602738
NR 35
TC 53
Z9 60
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 13
PY 2012
VL 12
AR 244
DI 10.1186/1471-2407-12-244
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 001PN
UT WOS:000308472700001
PM 22695536
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Botla, SK
   Gholami, AM
   Malekpour, M
   Moskalev, EA
   Fallah, M
   Jandaghi, P
   Aghajani, A
   Bondar, IS
   Omranipour, R
   Malekpour, F
   Mohajeri, A
   Babadi, AJ
   Sahin, Ö
   Bubnov, VV
   Najmabadi, H
   Hoheisel, JD
   Riazalhosseini, Y
AF Botla, Sandeep Kumar
   Gholami, Amin Moghaddas
   Malekpour, Mahdi
   Moskalev, Evgeny A.
   Fallah, Mahdi
   Jandaghi, Pouria
   Aghajani, Ali
   Bondar, Irina S.
   Omranipour, Ramesh
   Malekpour, Fatemeh
   Mohajeri, Abbas
   Babadi, Azin Jahangiri
   Sahin, Oezguer
   Bubnov, Vladimir V.
   Najmabadi, Hossein
   Hoheisel, Joerg D.
   Riazalhosseini, Yasser
TI Diagnostic values of <i>GHSR</i> DNA methylation pattern in breast
   cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE DNA methylation; Breast cancer; Diagnosis; GHSR; Epigenetics
ID NEEDLE-ASPIRATION-CYTOLOGY; FIELD DEFECT; BIOPSY; CELLS;
   HYPERMETHYLATION; IDENTIFICATION; EPIGENETICS; EPITHELIUM; RISK; AGE
AB DNA methylation patterns have been recognised as cancer-specific markers with high potential for clinical applications. We aimed at identifying methylation variations that differentiate between breast cancers and other breast tissue entities to establish a signature for diagnosis. Candidate genomic loci were analysed in 117 fresh-frozen breast specimens, which included cancer, benign and normal breast tissues from patients as well as material from healthy individuals. A cancer-specific DNA methylation signature was identified by microarray analysis in a test set of samples (n = 52, p < 2.1 x 10(-4)) and its performance was assessed through bisulphite pyrosequencing in an independent validation set (n = 65, p < 1.9 x 10(-7)). The signature is associated with SFRP2 and GHSR genes, and exhibited significant hypermethylation in cancers. Normal-appearing breast tissues from cancer patients were also methylated at these loci but to a markedly lower extent. This occurrence of methylated DNA in normal breast tissue of cancer patients is indicative of an epigenetic field defect. Concerning diagnosis, receiver operating characteristic curves and the corresponding area under the curve (AUC) analysis demonstrated a very high sensitivity and specificity of 89.3 and 100 %, respectively, for the GHSR methylation pattern (AUC > 0.99). To date, this represents the DNA methylation marker of the highest sensitivity and specificity for breast cancer diagnosis. Functionally, ectopic expression of GHSR in a cell line model reduced breast cancer cell invasion without affecting cell viability upon stimulation of cells with ghrelin. Our data suggest a link between epigenetic down-regulation of GHSR and breast cancer cell invasion.
C1 [Gholami, Amin Moghaddas] Tech Univ Munich, Chair Prote & Bioanalyt, D-85354 Freising Weihenstephan, Germany.
   [Malekpour, Mahdi; Omranipour, Ramesh] Univ Tehran Med Sci, Inst Canc, Imam Khomeini Hosp, Tehran 1145765111, Iran.
   [Malekpour, Mahdi] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA.
   [Fallah, Mahdi] German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany.
   [Jandaghi, Pouria] Tehran Med Branch, IAU, Res Ctr Med Sci, Tehran, Iran.
   [Aghajani, Ali; Najmabadi, Hossein] Univ Social Welf & Rehabil Sci, Genet Res Ctr, Tehran 3834198571, Iran.
   [Bondar, Irina S.] Reg Oncol Clin, UA-265026 Odessa, Ukraine.
   [Malekpour, Fatemeh] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Tehran 1989934148, Iran.
   [Mohajeri, Abbas] Zahravi Pharmaceut Co, Dept Res & Dev, Tabriz 515755367, Iran.
   [Botla, Sandeep Kumar; Moskalev, Evgeny A.; Jandaghi, Pouria; Babadi, Azin Jahangiri; Hoheisel, Joerg D.; Riazalhosseini, Yasser] German Canc Res Ctr, Div Funct Genome Anal, D-69120 Heidelberg, Germany.
   [Sahin, Oezguer] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Germany.
   [Bubnov, Vladimir V.] Odessa State Med Univ, Dept Genom & Immunol, UA-265026 Odessa, Ukraine.
C3 Technical University of Munich; Tehran University of Medical Sciences;
   Vanderbilt University; Helmholtz Association; German Cancer Research
   Center (DKFZ); Shahid Beheshti University Medical Sciences; Helmholtz
   Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); Odessa National
   Medical University
RP Riazalhosseini, Y (通讯作者)，McGill Univ, Dept Human Genet, 740 Dr Penfield Ave, Montreal, PQ H3A 0G1, Canada.
EM y.riazalhosseini@dkfz.de
RI omranipour, ramesh/D-4871-2018; Moskalev, Evgeny/A-3050-2012; Bondar,
   Ivan/AAB-9874-2020; Najmabadi, Hossein/P-8182-2017; Malekpour,
   Mahdi/B-6174-2009; Fallah, Mahdi/A-8745-2008; Sahin, Ozgur/F-4403-2014
OI Fallah, Mahdi/0000-0002-6639-065X; Najmabadi,
   Hossein/0000-0002-6084-7778; Botla, Sandeep/0000-0001-9937-0455; Bondar,
   Ivan S./0000-0001-7376-5643; Sahin, Ozgur/0000-0002-8033-7089; Bubnov,
   Vladymyr/0000-0002-4940-5223
FU Bundesministerium fur Bildung und Forschung as part of the NGFN
   programme [01GS08117]
FX This study was supported by Bundesministerium fur Bildung und Forschung
   as part of the NGFN programme (Grant Number 01GS08117). The authors
   thank Verena Beier and Neeme Tonisson for discussions, and Achim Stephan
   for technical support.
CR André F, 2009, LANCET ONCOL, V10, P381, DOI 10.1016/S1470-2045(09)70024-5
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Bailey VJ, 2010, CLIN CHEM, V56, P1022, DOI 10.1373/clinchem.2009.140244
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Braakhuis BJM, 2003, CANCER RES, V63, P1727
   Brena RM, 2006, PLOS MED, V3, P2184, DOI 10.1371/journal.pmed.0030479
   Dua RS, 2006, J CLIN ONCOL, V24, P1209, DOI 10.1200/JCO.2005.04.1830
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hoheisel JD, 2006, NAT REV GENET, V7, P200, DOI 10.1038/nrg1809
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Komenaka IK, 2004, CANCER, V100, P2079, DOI 10.1002/cncr.20221
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Lieske B, 2006, BRIT J CANCER, V95, P62, DOI 10.1038/sj.bjc.6603211
   Meunier M, 2002, EUR J RADIOL, V42, P10, DOI 10.1016/S0720-048X(01)00480-6
   Moskalev EA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr213
   Ordway JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001314
   PEREZ RP, 1993, CANCER, V71, P1571, DOI 10.1002/cncr.2820710424
   Riazalhosseini Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-11-405
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Suijkerbuijk KPM, 2011, ANN ONCOL, V22, P24, DOI 10.1093/annonc/mdq305
   Suijkerbuijk KPM, 2010, FAM CANCER, V9, P321, DOI 10.1007/s10689-010-9344-7
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Vimpeli SM, 2008, ACTA RADIOL, V49, P863, DOI 10.1080/02841850802235751
   Wang LS, 2011, CLIN CANCER RES, V17, P598, DOI 10.1158/1078-0432.CCR-10-1260
   Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Zhang YY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000438
NR 38
TC 16
Z9 20
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2012
VL 135
IS 3
BP 705
EP 713
DI 10.1007/s10549-012-2197-z
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 003ZB
UT WOS:000308648800008
PM 22899222
DA 2025-01-12
ER

PT J
AU Yildirim, S
   Altun, S
   Gumushan, H
   Patel, A
   Djamgoz, MBA
AF Yildirim, Senay
   Altun, Seyhan
   Gumushan, Hatice
   Patel, Anup
   Djamgoz, Mustafa B. A.
TI Voltage-gated sodium channel activity promotes prostate cancer
   metastasis <i>in vivo</i>
SO CANCER LETTERS
LA English
DT Article
DE Prostate cancer; Metastasis; Dunning cell; Mat-LyLu; Voltage-gated
   sodium channel; Tetrodotoxin
ID CELL-LINES; BREAST-CANCER; EXPRESSION; RAT; VITRO; INVASIVENESS;
   INVASION; NAV1.5; GENES
AB Epigenetic upregulation of voltage-gated sodium channels (VGSCs) has been reported in a number of carcinoma cell lines and tissues. Furthermore, a large body of experimental evidence suggested that functional VGSC expression enhances various in vitro cell behaviours, such as directional motility, that would be involved in the metastatic cascade. However, it is not known if VGSC activity promotes metastasis in vivo. Here, using the Copenhagen rat model of prostate cancer and blocking VGSC activity in primary tumours with tetrodotoxin, we show (1) that the number of lung metastasis is reduced by >40% and (2) that lifespan is significantly improved. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Yildirim, Senay; Djamgoz, Mustafa B. A.] Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Cell & Mol Biol, London SW7 2AZ, England.
   [Yildirim, Senay; Altun, Seyhan; Gumushan, Hatice] Istanbul Univ, Fac Sci, Dept Biol, TR-34134 Istanbul, Turkey.
   [Gumushan, Hatice] Harran Univ, Fac Sci & Arts, Dept Biol, Sanliurfa, Turkey.
   [Patel, Anup] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Urol, London W2 1NY, England.
   [Djamgoz, Mustafa B. A.] Cyprus Int Univ, Biotechnol Res Ctr, TR-10 N Cyprus, Mersin, Turkey.
C3 Imperial College London; Istanbul University; Harran University;
   Imperial College London; Cyprus International University
RP Djamgoz, MBA (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, Div Cell & Mol Biol, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.
EM m.djamgoz@imperial.ac.uk
RI Altun, Seyhan/AAG-4184-2019; Djamgoz, Mustafa/KJL-8515-2024; Aktas,
   Hatice/ABF-3949-2020
OI Gumushan Aktas, Hatice/0000-0002-6650-184X
FU TUBITAK (The Scientific and Technological Research Council of Turkey)
   [104T031]; Pro Cancer Research Fund (PCRF, UK); Omer Anil Scholarship of
   Kanser Arastirma Vakfi (KAV, TRNC)
FX This study is a part of a PhD (SY) and was supported by TUBITAK (The
   Scientific and Technological Research Council of Turkey), project
   number: 104T031. Additional support was provided by the Pro Cancer
   Research Fund (PCRF, UK). The work of SY at Imperial College London was
   made possible by the Omer Anil Scholarship of Kanser Arastirma Vakfi
   (KAV, TRNC).
CR Boehnke SE, 2001, J NEUROSCI METH, V105, P133, DOI 10.1016/S0165-0270(00)00348-4
   Brackenbury WJ, 2007, BREAST CANCER RES TR, V101, P149, DOI 10.1007/s10549-006-9281-1
   Brackenbury WJ, 2006, J PHYSIOL-LONDON, V573, P343, DOI 10.1113/jphysiol.2006.106906
   Brisson L, 2011, ONCOGENE, V30, P2070, DOI 10.1038/onc.2010.574
   Clare JJ, 2000, DRUG DISCOV TODAY, V5, P506, DOI 10.1016/S1359-6446(00)01570-1
   Diss JKJ, 2005, PROSTATE CANCER P D, V8, P266, DOI 10.1038/sj.pcan.4500796
   Diss JKJ, 2001, PROSTATE, V48, P165, DOI 10.1002/pros.1095
   DUNNING W. F., 1963, NATL CANCER INST MONOGR, V12, P351
   Fiske JL, 2006, CANCER METAST REV, V25, P493, DOI 10.1007/s10555-006-9017-z
   Fraser SP, 2003, J CELL PHYSIOL, V195, P479, DOI 10.1002/jcp.10312
   Fraser SP, 2000, PROSTATE, V44, P61, DOI 10.1002/1097-0045(20000615)44:1<61::AID-PROS9>3.0.CO;2-3
   Fraser SP, 2005, CLIN CANCER RES, V11, P5381, DOI 10.1158/1078-0432.CCR-05-0327
   Galati S, 2009, J PHYSIOL-LONDON, V587, P4405, DOI 10.1113/jphysiol.2009.172759
   GARROW GC, 1993, SEMIN ONCOL, V20, P287
   Gillet L, 2009, J BIOL CHEM, V284, P8671, DOI 10.1074/jbc.M806891200
   Grimes JA, 1998, J CELL PHYSIOL, V175, P50, DOI 10.1002/(SICI)1097-4652(199804)175:1<50::AID-JCP6>3.0.CO;2-B
   GRIMES JA, 1995, FEBS LETT, V369, P290, DOI 10.1016/0014-5793(95)00772-2
   House CD, 2010, CANCER RES, V70, P6957, DOI 10.1158/0008-5472.CAN-10-1169
   Ilie CP, 2009, CURR OPIN UROL, V19, P20, DOI 10.1097/MOU.0b013e328316c33f
   ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306
   Laniado ME, 1997, AM J PATHOL, V150, P1213
   Mamelak AN, 2006, J CLIN ONCOL, V24, P3644, DOI 10.1200/JCO.2005.05.4569
   Nakajima T, 2009, BRIT J PHARMACOL, V156, P420, DOI 10.1111/j.1476-5381.2008.00059.x
   Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1
   Onkal R, 2009, EUR J PHARMACOL, V625, P206, DOI 10.1016/j.ejphar.2009.08.040
   Palmer CP, 2008, EUR BIOPHYS J BIOPHY, V37, P359, DOI 10.1007/s00249-007-0219-2
   Rodriguez-Navarro AJ, 2007, ANESTHESIOLOGY, V106, P339, DOI 10.1097/00000542-200702000-00023
   Stafford LJ, 2008, INT J BIOCHEM CELL B, V40, P874, DOI 10.1016/j.biocel.2007.12.016
NR 28
TC 87
Z9 91
U1 0
U2 32
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD OCT 1
PY 2012
VL 323
IS 1
BP 58
EP 61
DI 10.1016/j.canlet.2012.03.036
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 964UA
UT WOS:000305721000007
PM 22484465
DA 2025-01-12
ER

PT J
AU Ha, G
   Roth, A
   Lai, D
   Bashashati, A
   Ding, JR
   Goya, R
   Giuliany, R
   Rosner, J
   Oloumi, A
   Shumansky, K
   Chin, SF
   Turashvili, G
   Hirst, M
   Caldas, C
   Marra, MA
   Aparicio, S
   Shah, SP
AF Ha, Gavin
   Roth, Andrew
   Lai, Daniel
   Bashashati, Ali
   Ding, Jiarui
   Goya, Rodrigo
   Giuliany, Ryan
   Rosner, Jamie
   Oloumi, Arusha
   Shumansky, Karey
   Chin, Suet-Feung
   Turashvili, Gulisa
   Hirst, Martin
   Caldas, Carlos
   Marra, Marco A.
   Aparicio, Samuel
   Shah, Sohrab P.
TI Integrative analysis of genome-wide loss of heterozygosity and
   monoallelic expression at nucleotide resolution reveals disrupted
   pathways in triple-negative breast cancer
SO GENOME RESEARCH
LA English
DT Article
ID LOSS-OF-HETEROZYGOSITY; COPY-NUMBER VARIATION; HIDDEN-MARKOV MODEL;
   SOMATIC MUTATIONS; EVOLUTION; EXOME; GENES
AB Loss of heterozygosity (LOH) and copy number alteration (CNA) feature prominently in the somatic genomic landscape of tumors. As such, karyotypic aberrations in cancer genomes have been studied extensively to discover novel oncogenes and tumor-suppressor genes. Advances in sequencing technology have enabled the cost-effective detection of tumor genome and transcriptome mutation events at single-base-pair resolution; however, computational methods for predicting segmental regions of LOH in this context are not yet fully explored. Consequently, whole transcriptome, nucleotide-level resolution analysis of monoallelic expression patterns associated with LOH has not yet been undertaken in cancer. We developed a novel approach for inference of LOH from paired tumor/normal sequence data and applied it to a cohort of 23 triple-negative breast cancer (TNBC) genomes. Following extensive benchmarking experiments, we describe the nucleotide-resolution landscape of LOH in TNBC and assess the consequent effect of LOH on the transcriptomes of these tumors using RNA-seq-derived measurements of allele-specific expression. We show that the majority of monoallelic expression in the transcriptomes of triple-negative breast cancer can be explained by genomic regions of LOH and establish an upper bound for monoallelic expression that may be explained by other tumor-specific modifications such as epigenetics or mutations. Monoallelically expressed genes associated with LOH reveal that cell cycle, homologous recombination and actin-cytoskeletal functions are putatively disrupted by LOH in TNBC. Finally, we show how inference of LOH can be used to interpret allele frequencies of somatic mutations and postulate on temporal ordering of mutations in the evolutionary history of these tumors.
C1 [Ha, Gavin; Roth, Andrew; Bashashati, Ali; Ding, Jiarui; Giuliany, Ryan; Rosner, Jamie; Oloumi, Arusha; Shumansky, Karey; Turashvili, Gulisa; Aparicio, Samuel; Shah, Sohrab P.] British Columbia Canc Agcy, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada.
   [Ha, Gavin; Roth, Andrew; Lai, Daniel; Goya, Rodrigo; Giuliany, Ryan] Univ British Columbia, Bioinformat Training Program, Vancouver, BC V6T 1Z4, Canada.
   [Lai, Daniel; Ding, Jiarui; Shah, Sohrab P.] Univ British Columbia, Dept Comp Sci, Vancouver, BC V6T 1Z4, Canada.
   [Goya, Rodrigo; Hirst, Martin; Marra, Marco A.] British Columbia Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada.
   [Chin, Suet-Feung; Caldas, Carlos] Li Ka Shing Ctr, Cambridge Res Inst, Cambridge CB2 0RE, England.
   [Aparicio, Samuel; Shah, Sohrab P.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
C3 British Columbia Cancer Agency; University of British Columbia;
   University of British Columbia; British Columbia Cancer Agency; CRUK
   Cambridge Institute; University of Cambridge; University of British
   Columbia
RP Shah, SP (通讯作者)，British Columbia Canc Agcy, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada.
EM sshah@bccrc.ca
RI Ha, Gavin/N-1984-2019; Hirst, Martin/B-7684-2016; Marra,
   Marco/B-5987-2008; Caldas, Carlos/U-7250-2019; Turashvili,
   Gulisa/A-2431-2008
OI Caldas, Carlos/0000-0003-3547-1489; chin,
   suet-feung/0000-0001-5697-1082; Roth, Andrew/0000-0003-3422-8823; Lai,
   Daniel/0000-0001-9203-6323; Ha, Gavin/0000-0001-7578-7272; Rosner,
   Jamie/0000-0001-8901-7228; Turashvili, Gulisa/0000-0001-6125-5865;
   Aparicio, Samuel/0000-0002-0487-9599
FU Canadian Breast Cancer Foundation; Michael Smith Foundation for Health
   Research; Natural Sciences and Engineering Research Council of Canada
FX This study was funded by the Canadian Breast Cancer Foundation. S.P.S.
   is supported by the Michael Smith Foundation for Health Research. G.H.
   is supported by the Natural Sciences and Engineering Research Council of
   Canada.
CR Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bengtsson H, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-245
   Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275
   Beroukhim R, 2006, PLOS COMPUT BIOL, V2, P323, DOI 10.1371/journal.pcbi.0020041
   Boeva V, 2012, BIOINFORMATICS, V28, P423, DOI 10.1093/bioinformatics/btr670
   Bowtell DDL, 2010, NAT REV CANCER, V10, P803, DOI 10.1038/nrc2946
   Cingolani P., 2012, snpEff: Variant effect prediction
   Colella S, 2007, NUCLEIC ACIDS RES, V35, P2013, DOI 10.1093/nar/gkm076
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Date O, 2006, CANCER RES, V66, P6018, DOI 10.1158/0008-5472.CAN-05-2803
   Dewal N, 2012, GENOME RES, V22, P362, DOI 10.1101/gr.122564.111
   Ding JR, 2012, BIOINFORMATICS, V28, P167, DOI 10.1093/bioinformatics/btr629
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Dutt A, 2007, CURR OPIN ONCOL, V19, P43, DOI 10.1097/CCO.0b013e328011a8c1
   Goya R, 2010, BIOINFORMATICS, V26, P730, DOI 10.1093/bioinformatics/btq040
   Greenman CD, 2012, GENOME RES, V22, P346, DOI 10.1101/gr.118414.110
   Greenman CD, 2010, BIOSTATISTICS, V11, P164, DOI 10.1093/biostatistics/kxp045
   Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028
   Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453
   LaFramboise T, 2005, PLOS COMPUT BIOL, V1, P507, DOI 10.1371/journal.pcbi.0010065
   Laframboise T, 2007, BIOSTATISTICS, V8, P323, DOI 10.1093/biostatistics/kxl012
   LaFramboise T, 2009, NUCLEIC ACIDS RES, V37, P4181, DOI 10.1093/nar/gkp552
   Li A, 2011, NUCLEIC ACIDS RES, V39, P4928, DOI 10.1093/nar/gkr014
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069
   Mardis ER, 2009, HUM MOL GENET, V18, pR163, DOI 10.1093/hmg/ddp396
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Närvä E, 2010, NAT BIOTECHNOL, V28, P371, DOI 10.1038/nbt.1615
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629
   Roth A, 2012, BIOINFORMATICS, V28, P907, DOI 10.1093/bioinformatics/bts053
   Sathirapongsasuti JF, 2011, BIOINFORMATICS, V27, P2648, DOI 10.1093/bioinformatics/btr462
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Staaf J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-409
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Thacker J, 2003, DNA REPAIR, V2, P655, DOI 10.1016/S1568-7864(03)00062-4
   Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659
   Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107
   Wu GM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r53
   Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025
   Yau C, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-9-r92
   Zhao Q, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-11-r114
NR 47
TC 193
Z9 210
U1 0
U2 31
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD OCT
PY 2012
VL 22
IS 10
BP 1995
EP 2007
DI 10.1101/gr.137570.112
PG 13
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 013SJ
UT WOS:000309325900016
PM 22637570
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Ben Gacem, R
   Hachana, M
   Ziadi, S
   Ben Abdelkarim, S
   Hidar, S
   Trimeche, M
AF Ben Gacem, Riadh
   Hachana, Mohamed
   Ziadi, Sonia
   Ben Abdelkarim, Soumaya
   Hidar, Samir
   Trimeche, Mounir
TI Clinicopathologic significance of DNA methyltransferase 1, 3a, and 3b
   overexpression in Tunisian breast cancers
SO HUMAN PATHOLOGY
LA English
DT Article
DE Breast cancer; DNA methyltransferases; Immunohistochemistry; Tunisia
ID PROMOTER HYPERMETHYLATION; SPORADIC BREAST; CLINICAL-SIGNIFICANCE;
   GENE-EXPRESSION; METHYLATION; INACTIVATION; DNMT3B; BRCA1; TUMOR;
   ZEBULARINE
AB DNA methyltransferase 1, 3a, and 3b affect DNA methylation, and it is thought that they play an important role in the malignant transformation of various cancers. The current study was designed to analyze DNA methyltransferase expression by immunohistochemistry in a series of 94 Tunisian sporadic breast carcinomas. Results were correlated to clinicopathologic parameters and promoter methylation status of 8 tumor suppressor genes (BRCA1, BRCA2, RASSFA1, TIMP3, CDH1, P16, RAR beta 2, and DAPK). Overexpression of DNA methyltransferase I, 3a, and 3b was detected in 46.8%, 32%, and 44.7% of cases, respectively. A significant correlation was found between DNA methyltransferase I overexpression and Scarff-Bloom-Richardson histologic grade III (P = .01). DNA methyltransferase 3a overexpression was significantly associated with menopausal status (P = .01), Scarff-Bloom-Richardson histologic grade III (P = .0001), estrogen (P = .04) and progesterone (P = .007) receptor negativity, and HER2 overexpression (P = .004). However, DNA methyltransferase 3a overexpression was found less frequently in the lumina! A intrinsic breast cancer subtype (9.7%) than in luminal B (53%), HER2 (41%), and triple-negative (50%) subtypes (P = .001). DNA methyltransferase 3b overexpression shows significant correlation with promoter hypermethylation of BRCA1 (P = .03) and RASSFA1 (P = .04) and with the hypermethylator phenotype (more than 4 methylated genes, P = .01). These data suggest that overexpression of various DNA methyltransferases might represent a critical event responsible for the epigenetic inactivation of multiple tumor suppressor genes, leading to the development of aggressive forms of sporadic breast cancer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Ben Gacem, Riadh; Hachana, Mohamed; Ziadi, Sonia; Ben Abdelkarim, Soumaya; Trimeche, Mounir] Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia.
   [Hidar, Samir] Farhat Hached Hosp, Dept Gynecol & Obstet, Sousse 4000, Tunisia.
C3 Universite de Sousse; Hopital Farhat Hached; Universite de Sousse;
   Hopital Farhat Hached
RP Trimeche, M (通讯作者)，Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia.
EM m_trimech@yahoo.fr
RI Hidar, Samir/AAN-3925-2021
OI hidar, samir/0000-0002-1267-3451; HACHANA, Mohamed
   Ridha/0000-0003-0991-8857
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chen Chun-ling, 2005, Zhonghua Fu Chan Ke Za Zhi, V40, P770
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5
   Ding WJ, 2008, DIGEST DIS SCI, V53, P2083, DOI 10.1007/s10620-007-0145-2
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Gao BN, 2008, CANCER RES, V68, P22, DOI 10.1158/0008-5472.CAN-07-5183
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Gras E, 2001, CANCER-AM CANCER SOC, V92, P787, DOI 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Oh BK, 2007, INT J MOL MED, V20, P65
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pan YM, 2010, SCI RES ESSAYS, V5, P3939
   Rahman MM, 2010, HUM PATHOL, V41, P1069, DOI 10.1016/j.humpath.2010.01.011
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0
   Toyooka S, 2003, CLIN CANCER RES, V9, P3034
   Uhrhammer Nancy, 2008, Int J Med Sci, V5, P197
   Xiong YN, 2005, GYNECOL ONCOL, V96, P601, DOI 10.1016/j.ygyno.2004.11.047
   Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441
NR 35
TC 23
Z9 24
U1 0
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD OCT
PY 2012
VL 43
IS 10
BP 1731
EP 1738
DI 10.1016/j.humpath.2011.12.022
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 018VC
UT WOS:000309693600026
PM 22520950
OA Green Published
DA 2025-01-12
ER

PT J
AU Papoutsis, AJ
   Borg, JL
   Selmin, OI
   Romagnolo, DF
AF Papoutsis, Andreas J.
   Borg, Jamie L.
   Selmin, Ornella I.
   Romagnolo, Donato F.
TI BRCA-1 promoter hypermethylation and silencing induced by the aromatic
   hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7
   Cells
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
ID SPORADIC BREAST-CANCER; BINDING-PROTEIN MBD2; CPG ISLAND PROMOTER;
   MAMMARY-GLAND; MESSENGER-RNA; TRANSCRIPTIONAL REPRESSION; DNA
   METHYLTRANSFERASES; CHEMOPREVENTIVE AGENT; HEALTHY-VOLUNTEERS;
   ESTROGEN-RECEPTOR
AB Epigenetic mechanisms may contribute to reduced expression of the tumor suppressor gene BRCA-1 in sporadic breast cancers. Through environmental exposure and diet, humans are exposed to xenobiotics and food compounds that bind the aromatic hydrocarbon receptor (AhR). AhR-ligands include the dioxin-like and tumor promoter 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD). The activated AhR regulates transcription through binding to xenobiotic response elements (XREs=GCGTG) and interactions with transcription cofactors. Previously, we reported on the presence of several XREs in the proximal BRCA-1 promoter and that the expression of endogenous AhR was required for silencing of BRCA-1 expression by TCDD. Here, we document that in estrogen receptor-alpha-positive and BRCA-1 wild-type MCF-7 breast cancer cells, the treatment with TCDD attenuated 17 beta-estradiol-dependent stimulation of BRCA-1 protein and induced hypermethylation of a CpG island spanning the BRCA-1 transcriptional start site of exon-1a. Additionally, we found that TCDD enhanced the association of the AhR; DNA methyl transferase (DNMT)1. DNMT3a and DNMT3b; methyl binding protein (MBD)2; and trimethylated H3K9 (H3K9me3) with the BRCA-1 promoter. Conversely, the phytoalexin resveratrol, selected as a prototype dietary AhR antagonist, antagonized at physiologically relevant doses (1 mu mol/L) the TCDD-induced repression of BRCA-1 protein, BRCA-1 promoter methylation and the recruitment of the AhR, MBD2, H3K9me3 and DNMTs (1, 3a and 3b). Taken together, these observations provide mechanistic evidence for AhR agonists in the establishment of BRCA-1 promoter hypermethylation and the basis for the development of prevention strategies based on AhR antagonists. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Papoutsis, Andreas J.; Borg, Jamie L.; Selmin, Ornella I.; Romagnolo, Donato F.] Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.
   [Borg, Jamie L.; Selmin, Ornella I.; Romagnolo, Donato F.] Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA.
C3 University of Arizona; University of Arizona
RP Romagnolo, DF (通讯作者)，Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.
EM donato@u.arizona.edu
RI Selmin, Ornella/ABC-8971-2020
FU Arizona Biomedical Research Commission [0819]; Susan G. Komen for the
   Cure [BCTR0707643]; US ARMY Medical Research and Material Command [DAMD
   10-1-0215]; Arizona Cancer Center [P30CA23074]; Midwest Research
   Institute [64 CFR 72090, 64 CFR28205]
FX Grant support: This study was supported by grants from the Arizona
   Biomedical Research Commission (0819), Susan G. Komen for the Cure
   (BCTR0707643), US ARMY Medical Research and Material Command (DAMD
   10-1-0215) and the Arizona Cancer Center Support (Grant P30CA23074).
   TCDD was supplied by the National Cancer Institute, Division of Cancer
   Biology, Chemical and Physical Carcinogenesis Branch, and distributed by
   Midwest Research Institute under a contract to NCI (64 CFR 72090, 64
   CFR28205).
CR Amakura Y, 2008, PHYTOCHEMISTRY, V69, P3117, DOI 10.1016/j.phytochem.2007.07.022
   Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N
   Beedanagari SR, 2009, TOXICOL SCI, V110, P61, DOI 10.1093/toxsci/kfp079
   Berger J, 2005, BIOCHEM SOC T, V33, P1537, DOI 10.1042/BST0331537
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Brenner C, 2006, CURR TOP MICROBIOL, V301, P45
   Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Casper RF, 1999, MOL PHARMACOL, V56, P784
   Degner SC, 2007, NUTR CANCER, V59, P248, DOI 10.1080/01635580701485585
   Dialyna IA, 2001, INT J MOL MED, V8, P79
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Eisinger F, 1998, CANCER RES, V58, P1588
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fang MZ, 2003, CANCER RES, V63, P7563
   Filomeni G, 2007, GENES NUTR, V2, P295, DOI 10.1007/s12263-007-0059-9
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   GIERTHY JF, 1987, CANCER RES, V47, P6198
   GUDAS JM, 1995, CANCER RES, V55, P4561
   Hockings JK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1987
   Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619
   HOLCOMB M, 1994, CANCER LETT, V82, P43, DOI 10.1016/0304-3835(94)90144-9
   Hooper K, 1998, ENVIRON HEALTH PERSP, V106, P797, DOI 10.2307/3434123
   Hublitz P, 2009, INT J DEV BIOL, V53, P335, DOI 10.1387/ijdb.082717ph
   Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508
   Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256
   Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004
   Jeuken A, 2003, J AGR FOOD CHEM, V51, P5478, DOI 10.1021/jf030252u
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Korzeniewski N, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-153
   Levy-Lahad E, 2007, BRIT J CANCER, V96, P11, DOI 10.1038/sj.bjc.6603535
   Lu F, 2008, CANCER PREV RES, V1, P135, DOI 10.1158/1940-6207.CAPR-08-0037
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Miksits M, 2009, PLANTA MED, V75, P1227, DOI 10.1055/s-0029-1185533
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462
   Ray SS, 2004, J BIOL CHEM, V279, P27187, DOI 10.1074/jbc.M402771200
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Romagnolo D, 1998, MOL CARCINOGEN, V22, P102, DOI 10.1002/(SICI)1098-2744(199806)22:2<102::AID-MC5>3.0.CO;2-O
   Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145
   Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Weiss J, 2003, ACTA PAEDIATR, V92, P467, DOI 10.1111/j.1651-2227.2003.tb00580.x
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yang XH, 2008, J CELL BIOCHEM, V104, P402, DOI 10.1002/jcb.21630
NR 59
TC 54
Z9 62
U1 0
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0955-2863
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD OCT
PY 2012
VL 23
IS 10
BP 1324
EP 1332
DI 10.1016/j.jnutbio.2011.08.001
PG 9
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 013GV
UT WOS:000309294800017
PM 22197621
DA 2025-01-12
ER

PT J
AU Nagata, S
   Hamada, T
   Yamada, N
   Yokoyama, S
   Kitamoto, S
   Kanmura, Y
   Nomura, M
   Kamikawa, Y
   Yonezawa, S
   Sugihara, K
AF Nagata, Satoshi
   Hamada, Tomofumi
   Yamada, Norishige
   Yokoyama, Seiya
   Kitamoto, Sho
   Kanmura, Yuji
   Nomura, Masahiro
   Kamikawa, Yoshiaki
   Yonezawa, Suguru
   Sugihara, Kazumasa
TI Aberrant DNA methylation of tumor-related genes in oral rinse A
   Noninvasive Method for Detection of Oral Squamous Cell Carcinoma
SO CANCER
LA English
DT Article
DE epigenetics; DNA methylation; oral rinse; oral cancer; oral squamous
   cell carcinoma
ID PROMOTER HYPERMETHYLATION; FIELD CANCERIZATION; COLORECTAL-CANCER;
   MULTIPLE GENES; BREAST-CANCER; HEAD; NECK; INACTIVATION; RADIOTHERAPY;
   EXPRESSION
AB BACKGROUND: The early detection of oral squamous cell carcinoma (OSCC) is important, and a screening test with high sensitivity and specificity is urgently needed. Therefore, in this study, the authors investigated the methylation status of tumor-related genes with the objective of establishing a noninvasive method for the detection of OSCC. METHODS: Oral rinse samples were obtained from 34 patients with OSCC and from 24 healthy individuals (controls). The methylation status of 13 genes was determined by using methylation-specific polymerase chain reaction analysis and was quantified using a microchip electrophoresis system. Promoter methylation in each participant was screened by receiver operating characteristic analysis, and the utility of each gene's methylation status, alone and in combination with other genes, was evaluated as a tool for oral cancer detection. RESULTS: Eight of the 13 genes had significantly higher levels of DNA methylation in samples from patients with OSCC than in controls. The genes E-cadherin (ECAD), transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains 2 (TMEFF2), retinoic acid receptor beta (RAR beta), and O-6 methylguanine DNA methyltransferase (MGMT) had high sensitivity (>75%) and specificity for the detection of oral cancer. OSCC was detected with 100% sensitivity and 87.5% specificity using a combination of ECAD, TMEFF2, RAR beta, and MGMT and with 97.1% sensitivity and 91.7% specificity using a combination of ECAD, TMEFF2, and MGMT. CONCLUSIONS: The aberrant methylation of a combination of marker genes present in oral rinse samples was used to detect OSCC with >90% sensitivity and specificity. The detection of methylated marker genes from oral rinse samples has great potential for the noninvasive detection of OSCC. Cancer 2012. (c) 2012 American Cancer Society.
C1 [Hamada, Tomofumi; Kamikawa, Yoshiaki; Sugihara, Kazumasa] Kagoshima Univ Hosp, Dept Oral Surg, Kagoshima 8908544, Japan.
   [Nagata, Satoshi; Kanmura, Yuji; Nomura, Masahiro; Sugihara, Kazumasa] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Maxillofacial Diagnost & Surg Sci, Field Oral & Maxillofacial Rehabil, Kagoshima 890, Japan.
   [Yamada, Norishige] Cincinnati Childrens Hosp Med Ctr, Div Reprod Sci, Cincinnati, OH USA.
   [Yokoyama, Seiya; Kitamoto, Sho; Yonezawa, Suguru] Kagoshima Univ, Grad Sch Med & Dent Sci, Field Oncol, Dept Human Pathol, Kagoshima 890, Japan.
C3 Kagoshima University; Kagoshima University; Cincinnati Children's
   Hospital Medical Center; Kagoshima University
RP Hamada, T (通讯作者)，Kagoshima Univ Hosp, Dept Oral Surg, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.
EM thamada@dent.kagoshima-u.ac.jp
RI , 野村政宏/N-5826-2018; Yokoyama, Seiya/KLY-3572-2024; Kitamoto,
   Sho/AAE-4549-2021
OI Yokoyama, Seiya/0009-0007-9781-6397; Kitamoto, Sho/0000-0003-3597-6647
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan
   [19390521, 23390466, 19791533, 23390085]; Grants-in-Aid for Scientific
   Research [23390466, 19791533, 23390085, 21792020, 19390521] Funding
   Source: KAKEN
FX This work was supported in part by Grants-in-Aid 19390521 (K. Sugihara),
   23390466 (K. Sugihara), 19791533 (T. Hamada), and 23390085 (S. Yonezawa)
   from the Ministry of Education, Culture, Sports, Science, and
   Technology, Japan.
CR [Anonymous], BIOTECHNOL RES INT
   Arai E, 2009, CARCINOGENESIS, V30, P214, DOI 10.1093/carcin/bgn268
   Bretthauer M, 2011, J INTERN MED, V270, P87, DOI 10.1111/j.1365-2796.2011.02399.x
   Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722
   Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Elmore JG, 2009, RADIOLOGY, V253, P641, DOI 10.1148/radiol.2533082308
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4
   Ha PK, 2003, CRIT REV ORAL BIOL M, V14, P363, DOI 10.1177/154411130301400506
   Hirose Y, 2009, LUNG CANCER, V64, P155, DOI 10.1016/j.lungcan.2008.07.015
   Huang KH, 2009, CLIN CANCER RES, V15, P4174, DOI 10.1158/1078-0432.CCR-08-2929
   Huang ZH, 2007, WORLD J GASTROENTERO, V13, P950, DOI 10.3748/wjg.v13.i6.950
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kresty LA, 2002, CANCER RES, V62, P5295
   Kujan Omar, 2005, J Dent Educ, V69, P255
   Kulkarni V, 2004, ORAL ONCOL, V40, P145, DOI 10.1016/S1368-8375(03)00143-X
   Kusumoto T, 2011, J ORAL MAXILLOFAC SU
   Li M, 2009, NAT BIOTECHNOL, V27, P858, DOI 10.1038/nbt.1559
   Maruya SI, 2004, CLIN CANCER RES, V10, P3825, DOI 10.1158/1078-0432.CCR-03-0370
   Nagler RM, 2009, ORAL ONCOL, V45, P1006, DOI 10.1016/j.oraloncology.2009.07.005
   Nishino K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002085
   Ogi K, 2002, CLIN CANCER RES, V8, P3164
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Radhakrishnan R, 2011, J ORAL PATHOL MED
   Rethman MP, 2010, J AM DENT ASSOC, V141, P509, DOI 10.14219/jada.archive.2010.0223
   Righini CA, 2007, CLIN CANCER RES, V13, P1179, DOI 10.1158/1078-0432.CCR-06-2027
   Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014
   Supic G, 2011, ORAL ONCOL, V47, P702, DOI 10.1016/j.oraloncology.2011.05.014
   Suzuki M, 2005, BRIT J CANCER, V92, P942, DOI 10.1038/sj.bjc.6602376
   van Oijen MGCT, 2000, CANCER EPIDEM BIOMAR, V9, P249
   Vanderschaeghe D, 2010, ANAL CHEM, V82, P7408, DOI 10.1021/ac101560a
   Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002
   Yamamoto K, 2010, J EPIDEMIOL, V20, P287, DOI 10.2188/jea.JE20090116
   Yang EN, 2007, INT J CANCER, V121, P567, DOI 10.1002/ijc.22706
   Yang ZY, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-26
   Yeh KT, 2002, ANTICANCER RES, V22, P3971
NR 38
TC 71
Z9 76
U1 0
U2 22
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD SEP 1
PY 2012
VL 118
IS 17
BP 4298
EP 4308
DI 10.1002/cncr.27417
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 993GN
UT WOS:000307845200028
PM 22252571
OA Bronze
DA 2025-01-12
ER

PT J
AU Mitra, A
   Rostas, JW
   Dyess, DL
   Shevde, LA
   Samant, RS
AF Mitra, Aparna
   Rostas, Jack W.
   Dyess, Donna L.
   Shevde, Lalita A.
   Samant, Rajeev S.
TI Micro-RNA-632 downregulates DNAJB6 in breast cancer
SO LABORATORY INVESTIGATION
LA English
DT Article
DE DnaJB6; hsa-miR-632
ID EPITHELIAL-MESENCHYMAL TRANSITION; CO-CHAPERONE; HUMAN MICRORNA; GENE
   NETWORKS; CELL-CYCLE; MRJ; EXPRESSION; METASTASIS; TARGETS;
   IDENTIFICATION
AB DNAJB6 is a constitutively expressed member of the HSP40 family. It has been described as a negative regulator of breast tumor progression and a regulator of epithelial phenotype. Expression of DNAJB6 is reported to be compromised with tumor progression. However, factors responsible for its downregulation are still undefined. We used a knowledge-based screen for identifying miRNAs capable of targeting DNAJB6. In this work, we present our findings that hsa-miR-632 (miR-632) targets the coding region of DNAJB6. Invasive and metastatic breast cancer cells express high levels of miR-632 compared with mammary epithelial cells. Analysis of RNA from breast tumor specimens reveals inverse expression patterns of DNAJB6 transcript and miR-632. In response to exogenous miR-632 expression, DNAJB6 protein levels are downregulated and the resultant cell population shows significantly increased invasive ability. Silencing endogenous miR-632 abrogates invasive ability of breast cancer cells and promotes epithelial like characteristics noted by E-cadherin expression with concomitant decrease in mesenchymal markers such as Zeb2 and Slug. Thus, miR-632 is a potentially important epigenetic regulator of DNAJB6, which contributes to the downregulation of DNAJB6 and plays a supportive role in malignant progression. Laboratory Investigation (2012) 92, 1310-1317; doi:10.1038/labinvest.2012.87; published online 18 June 2012
C1 [Mitra, Aparna; Rostas, Jack W.; Dyess, Donna L.; Shevde, Lalita A.; Samant, Rajeev S.] Univ S Alabama, Dept Oncol Sci, Mitchell Canc Inst, Mobile, AL 36604 USA.
C3 University of South Alabama
RP Samant, RS (通讯作者)，Univ S Alabama, Dept Oncol Sci, Mitchell Canc Inst, 1660 Spring Hill Ave, Mobile, AL 36604 USA.
EM rsamant@usouthal.edu
OI Samant, Rajeev/0000-0001-5681-4976
FU USPHS [CA140472, CA138850]; American Medical Association; Mayer Mitchell
   Award for Excellence in Cancer Research
FX USPHS Grants CA140472 (RS Samant) and CA138850 (LA Shevde). J Rostas is
   a recipient of the American Medical Association Seed Grant 2011. RS
   Samant is the recipient of the Mayer Mitchell Award for Excellence in
   Cancer Research and acknowledges the support.
CR Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800
   Chuang JZ, 2002, J BIOL CHEM, V277, P19831, DOI 10.1074/jbc.M109613200
   Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1
   Dahiya N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002436
   Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949
   de Bock CE, 2010, INT J ONCOL, V36, P1155, DOI 10.3892/ijo_00000598
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dey S, 2009, MOL CELL BIOCHEM, V322, P137, DOI 10.1007/s11010-008-9950-y
   Du LQ, 2009, MOL CANCER RES, V7, P1234, DOI 10.1158/1541-7786.MCR-08-0507
   Dumont N, 2009, CANCER CELL, V16, P3, DOI 10.1016/j.ccr.2009.06.013
   Durrenberger PF, 2009, J NEUROSCI RES, V87, P238, DOI 10.1002/jnr.21819
   Erdogan B, 2011, EXP HEMATOL, V39, P915, DOI 10.1016/j.exphem.2011.06.002
   Fayazi Z, 2006, NEUROBIOL DIS, V24, P226, DOI 10.1016/j.nbd.2006.06.015
   Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488
   Greene SB, 2010, CURR DRUG TARGETS, V11, P1059
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harms MB, 2012, ANN NEUROL, V71, P407, DOI 10.1002/ana.22683
   Harris LG, 2012, ONCOGENE, V31, P3370, DOI 10.1038/onc.2011.496
   Heneghan HM, 2010, CURR OPIN PHARMACOL, V10, P543, DOI 10.1016/j.coph.2010.05.010
   Hunter PJ, 1999, DEVELOPMENT, V126, P1247
   Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Lehmann U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-109
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789
   Menezes ME, 2012, BIOCHEM J, V444, P573, DOI 10.1042/BJ20120205
   Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847
   Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x
   Mitra A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1874
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Morrow KA, 2011, J BIOL CHEM, V286, P40376, DOI 10.1074/jbc.M111.250035
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484
   Pfeffer U, 2009, CLIN EXP METASTAS, V26, P547, DOI 10.1007/s10585-009-9254-y
   Rachagani S, 2010, CANCER LETT, V292, P8, DOI 10.1016/j.canlet.2009.11.010
   Rameshwar P, 2009, CURR PHARM BIOTECHNO, V10, P148, DOI 10.2174/138920109787315024
   Sarparanta J, 2012, NAT GENET, V44, P450, DOI 10.1038/ng.1103
   Shi M, 2010, CANCER METAST REV, V29, P785, DOI 10.1007/s10555-010-9265-9
   Weber F, 2006, J CLIN ENDOCR METAB, V91, P3584, DOI 10.1210/jc.2006-0693
   Wright JA, 2010, J MAMMARY GLAND BIOL, V15, P213, DOI 10.1007/s10911-010-9183-z
   Yu ZR, 2010, AM J PATHOL, V176, P1058, DOI 10.2353/ajpath.2010.090664
   Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023
NR 52
TC 32
Z9 39
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD SEP
PY 2012
VL 92
IS 9
BP 1310
EP 1317
DI 10.1038/labinvest.2012.87
PG 8
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 998XV
UT WOS:000308274600006
PM 22710984
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Pang, D
   Zhao, YS
   Xue, WN
   Shan, M
   Chen, YB
   Zhang, YX
   Zhang, GQ
   Liu, F
   Li, DL
   Yang, YM
AF Pang, Da
   Zhao, Yashuang
   Xue, Weinan
   Shan, Ming
   Chen, Yanbo
   Zhang, Youxue
   Zhang, Guoqiang
   Liu, Feng
   Li, Dalin
   Yang, Yanmei
TI Methylation profiles of the <i>BRCA1</i> promoter in hereditary and
   sporadic breast cancer among Han Chinese
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Breast cancer; Epigenetic; Methylation; Hereditary; BRCA1
ID DNA METHYLATION; ABERRANT METHYLATION; MESSENGER-RNA; GENE; BINDING;
   EXPRESSION; TUMORS; HYPERMETHYLATION; TRANSCRIPTION; FAMILIES
AB The development of breast cancer is a multistep process associated with complex changes in host gene expression patterns including inactivation of tumor suppressor genes and activation of oncogenes. Critically, hereditary predisposition plays a significant role in cancer susceptibility. However, mutation of the BRCA1 gene is found only in the minority of hereditary breast cancer, which indicates that there might be alternative, novel mechanisms contributing to inactivation of the BRCA1 gene. Studies have shown that aberrant methylation of genomic DNA plays an important role in carcinogenesis. The aim of this study was to investigate whether DNA methylation may be an alternative mechanism for the inactivation of BRCA1 as an epigenetic modification of the genome and whether hereditary breast cancer has a different BRCA1 methylation phenotype pattern than sporadic breast cancer. The pattern of CpG island methylation within the promoter region of BRCA1 was assessed by bisulfite sequencing DNA from peripheral blood cells of 72 patients with hereditary predisposition but without BRCA1 mutations and 30 sporadic breast cancer controls. The overall methylation level in patients with hereditary predisposition was significantly lower than that in the sporadic control group. However, patients with hereditary predisposition showed a significantly higher methylation susceptibility for the sites -518 when compared to controls. These results suggest that there might be different BRCA1 promoter methylation levels and patterns in sporadic and hereditary breast cancer in peripheral blood DNA. These findings may facilitate the early diagnosis of hereditary breast cancer.
C1 [Pang, Da; Xue, Weinan; Shan, Ming; Chen, Yanbo; Zhang, Youxue; Zhang, Guoqiang; Liu, Feng; Li, Dalin] Harbin Med Univ, Affiliated Hosp 3, Dept Breast Surg, Harbin, Peoples R China.
   [Pang, Da; Yang, Yanmei] Harbin Med Univ, Inst Canc Prevent & Treatment, Harbin 150081, Peoples R China.
   [Zhao, Yashuang] Harbin Med Univ, Dept Epidemiol, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Pang, D (通讯作者)，Harbin Med Univ, Affiliated Hosp 3, Dept Breast Surg, HaPing Rd 158, Harbin, Peoples R China.
EM viracocha@126.com; zhaoyashuang@263.com; xueweinan1983@163.com;
   shanming8145@126.com; cyb.0451@yahoo.com.cn;
   zhang.youxue1980@yahoo.com.cn; 6-fu@163.com; liufeng1979216@163.com;
   lidalin2010@126.com; yangyanmei1998@163.com
RI Li, Dalin/JRZ-1723-2023; Shan, Ming/K-8967-2019; Zhang,
   Guo-Qiang/AAG-6817-2019; Xue, Weinan/AAV-9600-2020
CR Abreu PA, 2008, EXPERT OPIN THER TAR, V12, P1035, DOI [10.1517/14728222.12.8.1035, 10.1517/14728222.12.8.1035 ]
   Ali A.B., 2010, Med Oncol
   Andrieu N, 2006, JNCI-J NATL CANCER I, V98, P535, DOI 10.1093/jnci/djj132
   Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Chen YL, 2009, CANCER SCI, V100, P1663, DOI 10.1111/j.1349-7006.2009.01225.x
   Chen Y, 2006, GENET TEST, V10, P281, DOI 10.1089/gte.2006.10.281
   Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9
   Dupont C, 2009, SEMIN REPROD MED, V27, P351, DOI 10.1055/s-0029-1237423
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Gorski JJ, 2009, CLIN CANCER RES, V15, P1514, DOI 10.1158/1078-0432.CCR-08-0640
   Hitchins MP, 2007, NAT GENET, V39, P1289, DOI 10.1038/ng1107-1289
   Honrado E, 2007, MODERN PATHOL, V20, P1298, DOI 10.1038/modpathol.3800969
   James CR, 2007, ONCOLOGIST, V12, P142, DOI 10.1634/theoncologist.12-2-142
   Jemal A., 2011, J CLIN, V61, P69
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Macis D, 2007, BREAST CANCER RES TR, V106, P263, DOI 10.1007/s10549-006-9491-6
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Pasche Boris, 2008, V141, P1
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yazici H, 2009, CANCER EPIDEM BIOMAR, V18, P2723, DOI 10.1158/1055-9965.EPI-08-1237
   Zhao ZM, 2009, BIOCHEM BIOPH RES CO, V382, P643, DOI 10.1016/j.bbrc.2009.03.076
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 36
TC 11
Z9 12
U1 0
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
J9 MED ONCOL
JI Med. Oncol.
PD SEP
PY 2012
VL 29
IS 3
BP 1561
EP 1568
DI 10.1007/s12032-011-0100-0
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 994WE
UT WOS:000307964100024
PM 22076508
DA 2025-01-12
ER

PT J
AU Zhao, L
   Yu, ZJ
   Li, YN
   Wen, XY
   Ma, WF
   Wang, L
   Ren, J
   Liu, CG
   He, M
   Bai, XF
   Sun, ML
   Zheng, ZH
   Mi, XY
   Wang, EH
   Olopade, OI
   Jin, F
   Wei, MJ
AF Zhao, Lin
   Yu, Zhaojin
   Li, Yunan
   Wen, Xiaoyan
   Ma, Wenfeng
   Wang, Lin
   Ren, Jie
   Liu, Caigang
   He, Miao
   Bai, Xuefeng
   Sun, Mingli
   Zheng, Zhihong
   Mi, Xiaoyi
   Wang, Enhua
   Olopade, Olufunmilayo I.
   Jin, Feng
   Wei, Minjie
TI Clinical implications of ERβ methylation on sporadic breast cancers in
   Chinese women
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Breast cancer; ER beta; Methylation; Chinese women
ID ESTROGEN-RECEPTOR-BETA; EXPRESSION; GENES; ALPHA; INACTIVATION
AB Estrogens play a key role in the genesis and progression of breast cancer, activating two estrogen receptors, alpha and beta (ER alpha and ER beta). We have previously observed that ER alpha methylation occurs in high frequency and may be one of the mechanisms of ER alpha expression silence in a subset of Chinese sporadic breast cancers. However, the ER beta promoter methylation status and the relationship between clinicopathological characteristics and ER beta methylation in sporadic breast cancer are still unknown, especially in Chinese women. This study acted to determine the methylation status of the ER beta promoter and its correlation with clinicopathological features of sporadic breast cancers in Chinese women, and lay a foundation for the management of breast cancer. In total, 178 cases with sporadic breast cancers were enrolled in the study. ER beta methylation was determined using a methylation-specific polymerase chain reaction (MSP). In general, ER beta promoter methylation was found in 44.9% (80/178) of breast tumor samples, significantly higher than the benign breast hyperplasia (44.9% vs. 14.3%, X-2 = 4.986, P = 0.026). A total of 58% (40/69) of ER beta-negative tumors got methylation compared with 36.7% (40/109) of ER beta-positive cases being methylated (X-2 = 7.728, P = 0.005). The levels of ER beta protein expression diminished with the frequency of ER beta methylation (r = -0.249, P < 0.0001). In addition, we observed a strong correlation between ER alpha promoter and ER beta promoter methylation (odds ratio 2.054, 95% confidence interval 1.086-3.886, P = 0.026), and the triple-negative tumors showed a significantly higher methylation rate of ER beta. This study presents, for what we believe to be the first time, that ER beta methylation is also a frequent event in breast cancer and maybe also one of the mechanisms of ER beta expression silence in a subset of Chinese sporadic breast cancers. Epigenetic alteration of the ER beta gene may play an important role in the pathogenesis of breast cancer.
C1 [Zhao, Lin; Yu, Zhaojin; Li, Yunan; Wen, Xiaoyan; Wang, Lin; Ren, Jie; He, Miao; Bai, Xuefeng; Sun, Mingli; Wei, Minjie] China Med Univ, Dept Pharmacol, Shenyang 110001, Liaoning, Peoples R China.
   [Ma, Wenfeng] China Med Univ, Affiliated Hosp 1, Dept Gen Surg, Shenyang 110001, Liaoning, Peoples R China.
   [Liu, Caigang; Jin, Feng] China Med Univ, Affiliated Hosp 1, Dept Surg Oncol, Shenyang 110001, Liaoning, Peoples R China.
   [Zheng, Zhihong; Mi, Xiaoyi; Wang, Enhua; Wei, Minjie] China Med Univ, Inst Pathophysiol, Shenyang 110001, Liaoning, Peoples R China.
   [Mi, Xiaoyi; Wang, Enhua] China Med Univ, Dept Pathol, Shenyang 110001, Liaoning, Peoples R China.
   [Olopade, Olufunmilayo I.] Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA.
C3 China Medical University; China Medical University; China Medical
   University; China Medical University; China Medical University;
   University of Chicago
RP Wei, MJ (通讯作者)，China Med Univ, Dept Pharmacol, Shenyang 110001, Liaoning, Peoples R China.
EM jinfeng66cn@hotmail.com; mjwei@mail.cmu.edu.cn
RI Chen, Huanhuan/HTO-5007-2023; Liu, Caigang/C-7179-2018
OI Liu, Caigang/0000-0003-2083-235X
FU National Natural Science Foundation of China [30873097, 30973559];
   science and technology department of Liao ning province [2010225001]
FX We are very grateful to Dr. Desheng Huang from the Department of
   Mathematics, College of Basic Medical Sciences, China Medical University
   for statistical analysis. This work was supported by grants from
   National Natural Science Foundation of China (No 30873097 and No
   30973559), and this study was also supported by the science and
   technology department of Liao ning province (No 2010225001).
CR Al-Nakhle H, 2010, CANCER RES, V70, P4778, DOI 10.1158/0008-5472.CAN-09-4104
   Allred DC, 2010, MODERN PATHOL, V23, pS52, DOI 10.1038/modpathol.2010.55
   Allred DC, 1998, MODERN PATHOL, V11, P155
   Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800
   Chen GG, 2008, MED RES REV, V28, P954, DOI 10.1002/med.20131
   Fox EM, 2008, STEROIDS, V73, P1039, DOI 10.1016/j.steroids.2008.04.006
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jensen EV, 2010, PHYSIOL BEHAV, V99, P151, DOI 10.1016/j.physbeh.2009.08.013
   Kim SJ, 2004, INT J MOL MED, V14, P289
   Li LC, 2000, BIOCHEM BIOPH RES CO, V275, P682, DOI 10.1006/bbrc.2000.3363
   Marotti JD, 2010, MODERN PATHOL, V23, P197, DOI 10.1038/modpathol.2009.158
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X
   Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088
   Roger P, 2001, CANCER RES, V61, P2537
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Skliris GP, 2002, J PATHOL, V197, P155, DOI 10.1002/path.1077
   Speirs V, 2002, J CLIN PATHOL, V55, P371, DOI 10.1136/jcp.55.5.371
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Swedenborg E, 2009, CELL MOL LIFE SCI, V66, P3873, DOI 10.1007/s00018-009-0118-z
   Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673
   Xu XR, 2010, BREAST CANCER RES TR, V121, P685, DOI 10.1007/s10549-009-0628-2
   Yang L, 2005, CANCER EPIDEM BIOMAR, V14, P243
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 24
TC 6
Z9 9
U1 0
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD SEP
PY 2012
VL 29
IS 3
BP 1569
EP 1575
DI 10.1007/s12032-011-0107-6
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 994WE
UT WOS:000307964100025
PM 22105146
DA 2025-01-12
ER

PT J
AU Lara, H
   Wang, YH
   Beltran, AS
   Juárez-Moreno, K
   Yuan, XN
   Kato, S
   Leisewitz, AV
   Fredes, MC
   Licea, AF
   Connolly, DC
   Huang, L
   Blancafort, P
AF Lara, Haydee
   Wang, Yuhua
   Beltran, Adriana S.
   Juarez-Moreno, Karla
   Yuan, Xinni
   Kato, Sumie
   Leisewitz, Andrea V.
   Cuello Fredes, Mauricio
   Licea, Alexei F.
   Connolly, Denise C.
   Huang, Leaf
   Blancafort, Pilar
TI Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger
   Transcription Factors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER; MASPIN EXPRESSION; FUNCTIONAL-CHARACTERIZATION;
   NUCLEAR-LOCALIZATION; GENE-EXPRESSION; C/EBP-DELTA; CHROMATIN; MAMMARY;
   CELLS; MRP-1/CD9
AB Ovarian cancer is the leading cause of death among gynecological malignancies. It is detected at late stages when the disease is spread through the abdominal cavity in a condition known as peritoneal carcinomatosis. Thus, there is an urgent need to develop novel therapeutic interventions to target advanced stages of ovarian cancer. Mammary serine protease inhibitor (Maspin) represents an important metastasis suppressor initially identified in breast cancer. Herein we have generated a sequence-specific zinc finger artificial transcription factor (ATF) to up-regulate the Maspin promoter in aggressive ovarian cancer cell lines and to interrogate the therapeutic potential of Maspin in ovarian cancer. We found that although Maspin was expressed in some primary ovarian tumors, the promoter was epigenetically silenced in cell lines derived from ascites. Transduction of the ATF in MOVCAR 5009 cells derived from ascitic cultures of a TgMISIIR-TAg mouse model of ovarian cancer resulted in tumor cell growth inhibition, impaired cell invasion, and severe disruption of actin cytoskeleton. Systemic delivery of lipid-protamine-RNA nanoparticles encapsulating a chemically modified ATF mRNA resulted in inhibition of ovarian cancer cell growth in nude mice accompanied with Maspin re-expression in the treated tumors. Gene expression microarrays of ATF-transduced cells revealed an exceptional specificity for the Maspin promoter. These analyses identified novel targets co-regulated with Maspin in human short-term cultures derived from ascites, such as TSPAN12, that could mediate the anti-metastatic phenotype of the ATF. Our work outlined the first targeted, non-viral delivery of ATFs into tumors with potential clinical applications for metastatic ovarian cancers.
C1 [Blancafort, Pilar] Univ N Carolina, UNC Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA.
   [Wang, Yuhua; Huang, Leaf] Univ N Carolina, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Beltran, Adriana S.; Blancafort, Pilar] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Lara, Haydee; Licea, Alexei F.] Ctr Invest Cient & Educ Super Ensenada, Dept Biotecnol Marina, Ensenada 22860, Baja California, Mexico.
   [Lara, Haydee] Univ Autonoma Baja California, Programa Doctorado Ecol Mol & Biotecnol, Ensenada 22860, Baja California, Mexico.
   [Kato, Sumie; Cuello Fredes, Mauricio] Pontificia Univ Catolica Chile 686 3409, Fac Med, Lab Obstet & Ginecol, Ctr Invest Med, Santiago, Chile.
   [Leisewitz, Andrea V.] Pontificia Univ Catolica Chile 686 3409, Fac Med, Dept Hematol Oncol, Santiago, Chile.
   [Connolly, Denise C.] Fox Chase Canc Ctr, Dev Therapeut Program, Philadelphia, PA 19111 USA.
   [Juarez-Moreno, Karla] Univ Nacl Autonoma Mexico, Ctr Nanociencias & Nanotecnol, Ensenada 22860, Baja California, Mexico.
C3 University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina; University of North Carolina Chapel Hill; CICESE - Centro de
   Investigacion Cientifica y de Educacion Superior de Ensenada;
   Universidad Autonoma de Baja California; Fox Chase Cancer Center;
   Universidad Nacional Autonoma de Mexico
RP Blancafort, P (通讯作者)，Univ N Carolina, UNC Sch Med, Dept Pharmacol, 4009 Genet Med Bldg,Campus Box 7365, Chapel Hill, NC 27599 USA.
EM pilar_blancafort@med.unc.edu
RI Blancafort, Pilar/K-9029-2012; Juarez-Moreno, Karla/E-2730-2016; Cuello,
   Mauricio/M-9817-2015; Licea, Alexei/B-4106-2016
OI Juarez-Moreno, Karla/0000-0002-6171-8601; Connolly,
   Denise/0000-0003-0888-2004; Blancafort, Pilar/0000-0002-3881-7396;
   Cuello, Mauricio/0000-0003-2812-0015; Licea, Alexei/0000-0003-4022-7405
FU National Institutes of Health [1R01CA125273, 3R01CA125273-03S1,
   CA129835, CA136596, CA083638, CA006927]; Department of of Defense
   [W81XWH-10-1-0265]; Fondo Nacional de Ciencia y Tecnologia [1080163];
   National Council of Science and Technology of Mexico; Baja California
   Sur State Government; Centro de Investigacion Cientifica y de Educacion
   Superior de Ensenada
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants 1R01CA125273 and 3R01CA125273-03S1 (NCI; to P. B.),
   CA129835 (to L. H.), and CA136596, CA083638, and CA006927 (NCI; to D. C.
   C.). This work was also supported by Department of of Defense Grant
   W81XWH-10-1-0265 (to P. B.), Fondo Nacional de Ciencia y Tecnologia
   Grant 1080163 (to M. C. F.), the National Council of Science and
   Technology of Mexico, and The Baja California Sur State Government and
   Centro de Investigacion Cientifica y de Educacion Superior de Ensenada
   (to H. L.).
CR Aydar E, 2006, CANCER LETT, V242, P245, DOI 10.1016/j.canlet.2005.11.011
   Banerjee R, 2004, INT J CANCER, V112, P693, DOI 10.1002/ijc.20452
   Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628
   Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697
   Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135
   Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072
   Beltran A, 2006, ASSAY DRUG DEV TECHN, V4, P317, DOI 10.1089/adt.2006.4.317
   Beltran AS, 2008, MOL CANCER THER, V7, P1080, DOI 10.1158/1535-7163.MCT-07-0526
   Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019
   Beltran AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024595
   Beltran AS, 2011, EPIGENETICS-US, V6, P224, DOI 10.4161/epi.6.2.13700
   Beltran AS, 2010, METHODS MOL BIOL, V649, P163, DOI 10.1007/978-1-60761-753-2_10
   Berkenblit A, 2005, J REPROD MED, V50, P426
   Blancafort P, 2005, P NATL ACAD SCI USA, V102, P11716, DOI 10.1073/pnas.0501162102
   Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794
   Blancafort P, 2008, COMB CHEM HIGH T SCR, V11, P146, DOI 10.2174/138620708783744453
   Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453
   Connolly DC, 2009, CANCER TREAT RES, V149, P353, DOI 10.1007/978-0-387-98094-2_17
   Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200
   Durai S, 2005, NUCLEIC ACIDS RES, V33, P5978, DOI 10.1093/nar/gki912
   Endsley MP, 2011, METHOD ENZYMOL, V499, P149, DOI 10.1016/B978-0-12-386471-0.00008-0
   Fu J, 2010, ACTA BIOCH BIOPH SIN, V42, P568, DOI 10.1093/abbs/gmq062
   Furuya M, 2005, CANCER RES, V65, P2617, DOI 10.1158/0008-5472.CAN-04-3123
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gardner GJ, 2011, CANCER CONTROL, V18, P44, DOI 10.1177/107327481101800106
   Goulet B, 2011, LAB INVEST, V91, P1181, DOI 10.1038/labinvest.2011.66
   Havrilesky L, 2003, J CLIN ONCOL, V21, P3814, DOI 10.1200/JCO.2003.11.052
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   Herrera FJ, 2004, J VIROL, V78, P9689, DOI 10.1128/JVI.78.18.9689-9696.2004
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108
   Higashiyama M, 1997, INT J CANCER, V74, P205, DOI 10.1002/(SICI)1097-0215(19970422)74:2<205::AID-IJC12>3.0.CO;2-C
   Holzer RG, 2003, BREAST CANCER RES TR, V77, P65, DOI 10.1023/A:1021175931177
   Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70
   Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8
   Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063
   IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090
   Li YL, 2009, ANAL BIOCHEM, V394, P110, DOI 10.1016/j.ab.2009.07.022
   Liu J, 2010, ONCOLOGY-NY, V24, P721
   Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200
   Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525
   Lonardo F, 2006, LUNG CANCER, V51, P31, DOI 10.1016/j.lungcan.2005.07.011
   Lonardo F, 2010, CURR PHARM DESIGN, V16, P1877, DOI 10.2174/138161210791208974
   Lu YC, 2006, J BIOL CHEM, V281, P39081, DOI 10.1074/jbc.M606687200
   MacLachlan Timothy K, 2003, Methods Mol Biol, V223, P129
   Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884
   Min Y, 2011, ONCOGENE, V30, P4901, DOI 10.1038/onc.2011.187
   Miosge N, 2001, HISTOCHEM J, V33, P523, DOI 10.1023/A:1014995523521
   Mohsin SK, 2003, J PATHOL, V199, P432, DOI 10.1002/path.1319
   Mussolino C., 2012, CURR OPIN B IN PRESS
   Odero-Marah VA, 2003, CANCER BIOL THER, V2, P398, DOI 10.4161/cbt.2.4.471
   PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256
   Quinn BA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-24
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Richardson MM, 2011, CLIN EXP METASTAS, V28, P261, DOI 10.1007/s10585-010-9365-5
   Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787
   Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025
   Rosen DG, 2009, FRONT BIOSCI-LANDMRK, V14, P2089, DOI 10.2741/3364
   Seftor REB, 1998, CANCER RES, V58, P5681
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   Solomon LA, 2006, GYNECOL ONCOL, V101, P385, DOI 10.1016/j.ygyno.2005.11.049
   Sood AK, 2002, CLIN CANCER RES, V8, P2924
   Sopel M, 2010, FOLIA MORPHOL, V69, P204
   Suehara Y, 2008, CLIN CANCER RES, V14, P1707, DOI 10.1158/1078-0432.CCR-07-1478
   Svirshchevskaya EV, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-176
   Wang HX, 2011, BIOCHEM SOC T, V39, P547, DOI 10.1042/BST0390547
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855
   Wright MH, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-29
   WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344
   Yasuniwa Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015330
   Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200
   Zou ZQ, 2002, CLIN CANCER RES, V8, P1172
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 76
TC 37
Z9 41
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 24
PY 2012
VL 287
IS 35
BP 29873
EP 29886
DI 10.1074/jbc.M112.360768
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 999CO
UT WOS:000308286900061
PM 22782891
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Delgado-Cruzata, L
   Wu, HC
   Perrin, M
   Liao, YY
   Kappil, MA
   Ferris, JS
   Flom, JD
   Yazici, H
   Santella, RM
   Terry, MB
AF Delgado-Cruzata, Lissette
   Wu, Hui-Chen
   Perrin, Mary
   Liao, Yuyan
   Kappil, Maya A.
   Ferris, Jennifer S.
   Flom, Julie D.
   Yazici, Hulya
   Santella, Regina M.
   Terry, Mary Beth
TI Global DNA methylation levels in white blood cell DNA from sisters
   discordant for breast cancer from the New York site of the breast cancer
   family registry
SO EPIGENETICS
LA English
DT Article
DE breast cancer; epigenetics; global DNA methylation; LUMA; methyl
   acceptance assay; white blood cells
ID LEUKOCYTE DNA; COLORECTAL ADENOMA; REPAIR CAPACITY; BLADDER-CANCER;
   HYPOMETHYLATION; FOLATE; RISK; ASSOCIATION; BIOMARKER; LINE-1
AB Lower global DNA methylation is associated with genomic instability and it is one of the epigenetic mechanisms relevant to carcinogenesis. Emerging evidence for several cancers suggests that lower overall levels of global DNA methylation in blood are associated with different cancer types, although less is known about breast cancer. We examined global DNA methylation levels using a sibling design in 273 sisters affected with breast cancer and 335 unaffected sisters from the New York site of the Breast Cancer Family Registry. We measured global DNA methylation in total white blood cell (WBC) and granulocyte DNA by two different methods, the [H-3]-methyl acceptance assay and the luminometric methylation assay (LUMA). Global methylation levels were only modestly correlated between sisters discordant for breast cancer (Spearman correlation coefficients ranged from -0.08 to 0.24 depending on assay and DNA source). Using conditional logistic regression models, women in the quartile with the lowest DNA methylation levels (as measured by the [3H]methyl acceptance assay) had a 1.8-fold (95% CI = 1.0-3.3) higher relative association with breast cancer than women in the quartile with the highest DNA methylation levels. When we examined the association on a continuous scale, we also observed a positive association (odds ratio, OR = 1.3, 95% CI = 1.0-1.7, for a one unit change in the natural logarithm of the DPM/mu g of DNA). We observed no association between measures by the LUMA assay and breast cancer risk. If replicated in prospective studies, this study suggests that global DNA methylation levels measured in WBC may be a potential biomarker of breast cancer risk even within families at higher risk of cancer.
C1 [Delgado-Cruzata, Lissette; Wu, Hui-Chen; Liao, Yuyan; Ferris, Jennifer S.; Flom, Julie D.; Terry, Mary Beth] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
   [Delgado-Cruzata, Lissette; Wu, Hui-Chen; Kappil, Maya A.; Santella, Regina M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA.
   [Perrin, Mary] NYU, Sch Med, Dept Psychiat, New York, NY USA.
   [Perrin, Mary] NYU, Sch Med, Dept Environm Med, New York, NY USA.
   [Yazici, Hulya] Istanbul Univ, Inst Oncol, Dept Basic Oncol, Istanbul, Turkey.
   [Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
C3 Columbia University; Columbia University; New York University; New York
   University; Istanbul University; Columbia University
RP Terry, MB (通讯作者)，Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
EM mt146@columbia.edu
RI YAZICI, HULYA/AAU-9491-2021; Wu, Lisa/JPA-4139-2023
OI Delgado-Cruzata, Lissette/0000-0002-2884-0234; Terry, Mary
   Beth/0000-0002-4106-5033; Deyssenroth, Maya/0000-0003-2913-2392
FU Breast Cancer Research Foundation; National Institute of Health [U01
   CA69398, P30 CA13696, P30 ES009089, K07 CA131094]; National Cancer
   Institute, National Institutes of Health under RFA [CA-06-503]; Columbia
   University [U01 CA69398]
FX This work was supported by an award from the Breast Cancer Research
   Foundation and National Institute of Health grants U01 CA69398, P30
   CA13696, P30 ES009089 and K07 CA131094. This work was also supported by
   the National Cancer Institute, National Institutes of Health under RFA
   #CA-06-503 and through cooperative agreements with members of the Breast
   Cancer Family Registry (BCFR) and Principal Investigators, including
   Columbia University (U01 CA69398). The content of this manuscript does
   not necessarily reflect the views or policies of the National Cancer
   Institute or any of the collaborating centers in the BCFR, nor does
   mention of trade names, commercial products or organizations imply
   endorsement by the US Government or the BCFR.
CR Alves G, 1996, GENE, V176, P39, DOI 10.1016/0378-1119(96)00205-3
   Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc
   BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750
   Basten GP, 2006, BRIT J CANCER, V94, P1942, DOI 10.1038/sj.bjc.6603197
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Deneberg S, 2010, LEUKEMIA, V24, P932, DOI 10.1038/leu.2010.41
   Fenech M, 1998, CARCINOGENESIS, V19, P1163, DOI 10.1093/carcin/19.7.1163
   Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   John EM, 2004, BREAST CANCER RES, V6, pR375, DOI 10.1186/bcr801
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Kennedy DO, 2005, JNCI-J NATL CANCER I, V97, P127, DOI 10.1093/jnci/dji013
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   LAPEYRE JN, 1979, BIOCHEM BIOPH RES CO, V87, P698, DOI 10.1016/0006-291X(79)92015-1
   Lee JJ, 2008, INT J ONCOL, V33, P861, DOI 10.3892/ijo_00000074
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   LU LJW, 1983, CANCER LETT, V19, P231, DOI 10.1016/0304-3835(83)90159-3
   Machella N, 2008, CARCINOGENESIS, V29, P1367, DOI 10.1093/carcin/bgn140
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423
   Oakeley EJ, 1999, PHARMACOL THERAPEUT, V84, P389, DOI 10.1016/S0163-7258(99)00043-1
   Pilsner JR, 2007, AM J CLIN NUTR, V86, P1179, DOI 10.1093/ajcn/86.4.1179
   Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P1466, DOI 10.1289/ehp.0800497
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Romermann D, 2007, Verh Dtsch Ges Pathol, V91, P338
   Shelnutt KP, 2004, J NUTR BIOCHEM, V15, P554, DOI 10.1016/j.jnutbio.2004.04.003
   Shen J, 2006, CANCER EPIDEM BIOMAR, V15, P1614, DOI 10.1158/1055-9965.EPI-06-0218
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Wilhelm CS, 2010, CLIN CANCER RES, V16, P1682, DOI 10.1158/1078-0432.CCR-09-2983
   Wu HC, 2012, CARCINOGENE IN PRESS
   Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zhu ZZ, 2011, CANCER CAUSE CONTROL, V22, P437, DOI 10.1007/s10552-010-9715-2
   Zipprich Jennifer, 2010, J Carcinog, V9, P4, DOI 10.4103/1477-3163.62535
   Zipprich J, 2009, CANCER RES, V69, P2966, DOI 10.1158/0008-5472.CAN-08-3418
NR 43
TC 33
Z9 36
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD AUG
PY 2012
VL 7
IS 8
BP 868
EP 874
DI 10.4161/epi.20830
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 985BW
UT WOS:000307239400009
PM 22705975
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Mostovich, LA
   Prudnikova, TY
   Kondratov, AG
   Gubanova, NV
   Kharchenko, OA
   Kutsenko, OS
   Vavilov, PV
   Haraldson, K
   Kashuba, VI
   Ernberg, I
   Zabarovsky, ER
   Grigorieva, EV
AF Mostovich, Luydmila A.
   Prudnikova, Tatiana Y.
   Kondratov, Aleksandr G.
   Gubanova, Natalya V.
   Kharchenko, Olga A.
   Kutsenko, Olesya S.
   Vavilov, Pavel V.
   Haraldson, Klas
   Kashuba, Vladimir I.
   Ernberg, Ingemar
   Zabarovsky, Eugene R.
   Grigorieva, Elvira V.
TI The TCF4/β-catenin pathway and chromatin structure cooperate to regulate
   <i>D</i>-<i>glucuronyl</i> <i>C5</i>-<i>epimerase</i> expression in
   breast cancer
SO EPIGENETICS
LA English
DT Article
DE D-glucuronyl C5-epimerase; GLCE; heparan sulphate proteoglycan;
   biosynthesis; tumor-suppressor gene; hypermethylation; chromatin
   structure; WNT signaling; TCF4/beta-catenin target; breast cancer
ID TUMOR-SUPPRESSOR GENE; L-IDURONIC ACID; HEPATOCELLULAR-CARCINOMA;
   HISTONE MODIFICATIONS; DNA METHYLATION; SULFATE; GROWTH; CELLS;
   PROTEOGLYCANS; EPIGENETICS
AB D-glucuronyl C5-epimerase (GLCE) is a potential tumor-suppressor gene involved in heparan sulfate biosynthesis. GLCE expression is significantly decreased in breast tumors; however, the underlying molecular mechanisms remain unclear. This study examined the possible epigenetic mechanisms for GLCE inactivation in breast cancer. Very little methylation of the GLCE promoter region was detected in breast tumors in vivo and in breast cancer cells (MCF7 and T47D) in vitro and GLCE expression in breast cancer cells was not altered by 5-deoxyazacytidine (5-aza-dC) treatment, suggesting that promoter methylation is not involved in regulating GLCE expression. Chromatin activation by Trichostatin A (TSA) or 5-aza-dC/TSA treatment increased GLCE expression by two to 3-fold due to an increased interaction between the GLCE promoter and the TCF4/beta-catenin transactivation complex, or H3K9ac and H3K4Me3 histone modifications. However, ectopic expression of TCF4/beta-catenin was not sufficient to activate GLCE expression in MCF7 cells, suggesting that chromatin structure plays a key role in GLCE regulation. Although TSA treatment significantly repressed canonical WNT signaling in MCF7 cells, it did not influence endogenous TCF4/beta-catenin mRNA levels and activated TCF4/beta-catenin-driven transcription from the GLCE promoter, indicating GLCE as a novel target for TCF4/beta-catenin complex in breast cancer cells. A correlation was observed between GLCE, TCF4 and beta-catenin expression in breast cancer cells and primary tumors, suggesting an important role for TCF4/beta-catenin in regulating GLCE expression both in vitro and in vivo. Taken together, the results indicate that GLCE expression in breast cancer is regulated by a combination of chromatin structure and TCF4/beta-catenin complex activity.
C1 [Mostovich, Luydmila A.; Prudnikova, Tatiana Y.; Kutsenko, Olesya S.; Vavilov, Pavel V.; Grigorieva, Elvira V.] Inst Mol Biol & Biophys SB RAMS, Novosibirsk, Russia.
   [Kondratov, Aleksandr G.; Kashuba, Vladimir I.] Ukrainian Acad Sci, Inst Mol Biol & Genet, UA-252627 Kiev, Ukraine.
   [Gubanova, Natalya V.] Inst Cytol & Genet SD RAS, Novosibirsk, Russia.
   [Kharchenko, Olga A.; Haraldson, Klas; Ernberg, Ingemar; Zabarovsky, Eugene R.; Grigorieva, Elvira V.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-10401 Stockholm, Sweden.
   [Zabarovsky, Eugene R.] Linkoping Univ, Inst Clin & Expt Med, Linkoping, Sweden.
C3 Russian Academy of Medical Sciences; National Academy of Sciences
   Ukraine; Institute of Molecular Biology & Genetics of NASU; Russian
   Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS;
   Karolinska Institutet; Linkoping University
RP Grigorieva, EV (通讯作者)，Inst Mol Biol & Biophys SB RAMS, Novosibirsk, Russia.
EM elv_grig@yahoo.com
RI Zabarovsky, Eugene/A-6645-2010; Grigorieva, Elvira/A-4937-2010; Kashuba,
   Vladimir/AAO-7742-2020; Gubanova, Natalya/F-9188-2012; Kashuba,
   Vladimir/N-3732-2017
OI Gubanova, Natalya/0000-0003-2940-3287; Kashuba,
   Vladimir/0000-0001-9416-8282; Kondratov, Oleksandr/0000-0001-8305-2989
FU Russian Foundation for Basic Research [11-04-90400-Ukr_f_a]; Ukranian
   State Foundation of Fundamental Research [F40/146-2011, F46/457-2011];
   Swedish Institute [2011/00888]; UICC International Cancer Technology
   Transfer Fellowship [ICRETT-09-069]; FEBS Short-term Fellowship;
   Karolinska Institute; Swedish Cancer Society; Swedish Research Council
FX The authors thank Dr Bystrov A.A. and Grigoriev A.D. for the help with
   statistical analysis. The work was supported by the research grants from
   Russian Foundation for Basic Research (11-04-90400-Ukr_f_a); Ukranian
   State Foundation of Fundamental Research (F40/146-2011, F46/457-2011);
   Swedish Institute (2011/00888); UICC International Cancer Technology
   Transfer Fellowship (TYP, ICRETT-09-069); FEBS Short-term Fellowship
   (TYP); Karolinska Institute; ERZ was supported by the Swedish Cancer
   Society and Swedish Research Council.
CR [Anonymous], 2011, Cold Spring Harb Perspect Biol
   Bui C, 2010, FASEB J, V24, P436, DOI 10.1096/fj.09-136291
   Bülow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4
   Cadwalader EL, 2012, DEVELOPMENT, V139, P1296, DOI 10.1242/dev.078238
   Catlow KR, 2008, J BIOL CHEM, V283, P5235, DOI 10.1074/jbc.M706589200
   Chen Z, 2009, INT J CANCER, V124, P739, DOI 10.1002/ijc.23960
   Chua CC, 2004, CIRC RES, V94, P316, DOI 10.1161/01.RES.0000112965.70691.AC
   Eshchenko TY, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1016, DOI 10.1134/S0006297907090143
   Feyerabend TB, 2006, NAT CHEM BIOL, V2, P195, DOI 10.1038/nchembio777
   Foltz Greg, 2010, Genes Cancer, V1, P81, DOI 10.1177/1947601909356103
   Ghisell G, 2005, BIOCHEM J, V390, P493, DOI 10.1042/BJ20050152
   Ghiselli G, 2005, BMC DEV BIOL, V5, DOI 10.1186/1471-213X-5-19
   Grigorieva EV, 2011, BRIT J CANCER, V105, P74, DOI 10.1038/bjc.2011.170
   Grigorieva E, 2008, INT J CANCER, V122, P1172, DOI 10.1002/ijc.23203
   Heinz S, 2012, CURR TOP MICROBIOL, V356, P1, DOI 10.1007/82_2011_142
   Iozzo RV, 2009, MOL CELLS, V27, P503, DOI 10.1007/s10059-009-0069-0
   Jia J, 2009, J BIOL CHEM, V284, P15942, DOI 10.1074/jbc.M809577200
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1
   Kim SK, 2008, CARCINOGENESIS, V29, P1623, DOI 10.1093/carcin/bgn110
   Kim SH, 2011, J ENDOCRINOL, V209, P139, DOI 10.1530/JOE-10-0377
   Kizuka Y, 2011, J BIOL CHEM, V286, P31875, DOI 10.1074/jbc.M111.251173
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200
   Lopes CC, 2006, BIOCHIMIE, V88, P1493, DOI 10.1016/j.biochi.2006.04.009
   Lustberg MB, 2009, DRUG NEWS PERSPECT, V22, P369, DOI 10.1358/dnp.2009.22.7.1405072
   Malavaki CJ, 2011, BIOMED CHROMATOGR, V25, P11, DOI 10.1002/bmc.1536
   Mazzio EA, 2012, EPIGENETICS-US, V7, P119, DOI 10.4161/epi.7.2.18764
   Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146
   Mostovich LA, 2010, SIBER J ONCOL, V2, P24
   Ori A, 2008, FRONT BIOSCI-LANDMRK, V13, P4309, DOI 10.2741/3007
   Prudnikova TY, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-27
   Ravindranath A, 2011, BRIT J CANCER, V105, P542, DOI 10.1038/bjc.2011.269
   Reijmers RM, 2011, BLOOD, V117, P6162, DOI 10.1182/blood-2010-12-325522
   Reijmers RM, 2010, J IMMUNOL, V184, P3656, DOI 10.4049/jimmunol.0902200
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Ropero S, 2004, HUM MOL GENET, V13, P2753, DOI 10.1093/hmg/ddh298
   Sakane H, 2012, J CELL SCI, V125, P449, DOI 10.1242/jcs.091876
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Small EM, 2010, CIRC RES, V107, P1336, DOI 10.1161/CIRCRESAHA.110.227926
   Wöhrle S, 2007, MOL CELL BIOL, V27, P8164, DOI 10.1128/MCB.00555-07
   Xiang YY, 2001, ONCOGENE, V20, P7408, DOI 10.1038/sj.onc.1204925
   Zhang C, 2007, J PATHOL, V212, P134, DOI 10.1002/path.2173
   Zhang CJ, 2010, J HEPATOL, V53, P889, DOI 10.1016/j.jhep.2010.05.012
NR 44
TC 10
Z9 10
U1 0
U2 14
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
J9 EPIGENETICS-US
JI Epigenetics
PD AUG
PY 2012
VL 7
IS 8
BP 930
EP 939
DI 10.4161/epi.21199
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 985BW
UT WOS:000307239400015
PM 22805760
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Ineson, J
   Stayner, C
   Hazlett, J
   Slobbe, L
   Robson, E
   Legge, M
   Eccles, MR
AF Ineson, Jessica
   Stayner, Cherie
   Hazlett, Jody
   Slobbe, Lynn
   Robson, Ewan
   Legge, Michael
   Eccles, Michael R.
TI Somatic Reactivation of Expression of the Silent Maternal <i>Mest</i>
   Allele and Acquisition of Normal Reproductive Behaviour in a Colony of
   <i>Peg1</i>/<i>Mest</i> Mutant Mice
SO JOURNAL OF REPRODUCTION AND DEVELOPMENT
LA English
DT Article
DE Adult brain expression; Epigenetic; Imprinting; Maternal behaviour;
   Somatic expression; Peg1/Mest
ID INVASIVE BREAST-CANCER; IMPRINTED GENE; FREQUENT LOSS; MOUSE;
   METHYLATION; GROWTH; TRANS; PEROMYSCUS; DEFECTS; HYBRIDS
AB Genomic imprinting confers allele-specific expression in less than 1% of genes, in a parent-of-origin specific fashion. In humans and mice the Peg1/Mest gene (Mest) is maternally repressed, and paternally expressed. Mest is expressed in embryogenic mesoderm-derived tissues and in adult brain, and paternal mutations in Mest lead to growth retardation and defective maternal behaviour. Despite our current understanding of mechanisms associated with the establishment of imprinting of Mest and other imprinted genes, it is unclear to what extent Mest imprinting needs to be maintained in adult tissues. Aberrations of imprinting are known to occur in certain rare syndromes, and involve either inherited mutations, or constitutive epigenetic alterations occurring soon after fertilization. Imprinting abnormalities may also occur in the aging somatic tissues of adult individuals. Here we report an occurrence of post-embryonic somatic variability of Mest allelic expression in a colony of mice where heterozygotes at the imprinted Mest locus for a mutation inherited from the father spontaneously expressed the normally silenced allele from the mother. In addition, a newly acquired ability to overcome the deficit in maternal reproductive behaviour had occurred in the mutant mice, but this appeared not to be directly linked to the Mest mutation. Our results suggest that at least one allele of Mest expression is required in the somatic tissues of adult individuals and that under certain conditions (such as in the presence of a Mest insertional mutation or in an altered genetic background), somatically acquired alterations of allelic expression at the Mest locus may occur.
C1 [Stayner, Cherie; Hazlett, Jody; Slobbe, Lynn; Robson, Ewan; Legge, Michael; Eccles, Michael R.] Univ Otago, Dept Pathol, Dunedin, New Zealand.
   [Ineson, Jessica] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
   [Legge, Michael] Univ Otago, Dept Biochem, Dunedin, New Zealand.
C3 University of Otago; University of Queensland; University of Otago
RP Eccles, MR (通讯作者)，Univ Otago, Dept Pathol, Dunedin, New Zealand.
EM michael.eccles@otago.ac.nz
OI Hazlett, Jody/0000-0001-5686-712X
FU Royal Society of New Zealand; Otago Medical Research Foundation; Dunedin
   School of Medicine Dean's Bequest Grant
FX The authors are grateful to Prof A Surani for the generous gift of Hest
   mutant mice, Prof L Lefebvre for helpful advice and comments, and Kate
   Rea, Gillian MacKay, and Jolene Jordaan for assistance with maternal
   behaviour assays. This work was funded by a Marsden grant from the Royal
   Society of New Zealand, the Otago Medical Research Foundation, and a
   Dunedin School of Medicine Dean's Bequest Grant.
CR Bennett-Baker PE, 2003, GENETICS, V165, P2055
   Bestor TH, 2003, PHILOS T ROY SOC B, V358, P1411, DOI 10.1098/rstb.2003.1323
   Croteau S, 2001, GENESIS, V31, P11, DOI 10.1002/gene.1077
   Croteau S, 2005, MAMM GENOME, V16, P127, DOI 10.1007/s00335-004-2434-9
   Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060
   Dean W, 1998, DEVELOPMENT, V125, P2273
   Dolinoy DC, 2007, PEDIATR RES, V61, p30R, DOI 10.1203/pdr.0b013e31804575f7
   Duvillié B, 1998, GENOMICS, V47, P52, DOI 10.1006/geno.1997.5070
   Dziarmaga A, 2003, J AM SOC NEPHROL, V14, P2767, DOI 10.1097/01.ASN.0000094082.11026.EE
   Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Garfield AS, 2011, NATURE, V469, P534, DOI 10.1038/nature09651
   Imamura T, 2005, J BIOL CHEM, V280, P20171, DOI 10.1074/jbc.M501749200
   Jaenisch Rudolf, 2005, V265, P107
   KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52
   Kerjean A, 2003, EUR J HUM GENET, V11, P493, DOI 10.1038/sj.ejhg.5200990
   Keverne E B, 2001, Prog Brain Res, V133, P279
   Kohda M, 2001, MOL CARCINOGEN, V31, P184, DOI 10.1002/mc.1053
   Kosaki K, 2000, AM J HUM GENET, V66, P309, DOI 10.1086/302712
   Landers M, 2005, NUCLEIC ACIDS RES, V33, P3976, DOI 10.1093/nar/gki705
   Lee YJ, 2000, FEBS LETT, V472, P230, DOI 10.1016/S0014-5793(00)01461-7
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Lefebvre L, 1997, HUM MOL GENET, V6, P1907, DOI 10.1093/hmg/6.11.1907
   Li T, 2002, J BIOL CHEM, V277, P13518, DOI 10.1074/jbc.M200458200
   Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247
   Lucifero D, 2004, HUM REPROD UPDATE, V10, P3, DOI 10.1093/humupd/dmh002
   Mann MRW, 2004, DEVELOPMENT, V131, P3727, DOI 10.1242/dev.01241
   Martin GM, 2005, P NATL ACAD SCI USA, V102, P10413, DOI 10.1073/pnas.0504743102
   Nakanishi H, 2004, ONCOL REP, V12, P1273
   Parker-Katiraee L, 2007, PLOS GENET, V3, P665, DOI 10.1371/journal.pgen.0030065
   Pedersen IS, 2002, HUM MOL GENET, V11, P1449, DOI 10.1093/hmg/11.12.1449
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Rando OJ, 2007, CELL, V128, P655, DOI 10.1016/j.cell.2007.01.023
   Riclet R, 2009, MOL BIOL CELL, V20, P296, DOI 10.1091/mbc.E08-05-0510
   Royo H, 2008, BIOL CELL, V100, P149, DOI 10.1042/BC20070126
   Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200
   Shi W, 2004, GENESIS, V39, P65, DOI 10.1002/gene.20027
   SIMON JA, 1987, NUCLEIC ACIDS RES, V15, P2971, DOI 10.1093/nar/15.7.2971
   Takahashi M, 2005, AM J PHYSIOL-ENDOC M, V288, pE117, DOI 10.1152/ajpendo.00244.2004
   Vrana PB, 2000, NAT GENET, V25, P120, DOI 10.1038/75518
   Vrana PB, 1998, NAT GENET, V20, P362, DOI 10.1038/3833
   Woodfine K, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-1
   Zechner U, 2004, J EVOLUTION BIOL, V17, P453, DOI 10.1046/j.1420-9101.2003.00656.x
NR 44
TC 10
Z9 11
U1 0
U2 4
PU SOCIETY REPRODUCTION & DEVELOPMENT-SRD
PI TSUKUBA
PA C/O KAZUHIRO KIKUCHI, PHD DVM, NATL INST AGROBIOLOGICAL SCIENCES
   KANNONDAI 2-1-2, TSUKUBA, IBARAKI 305-8602, JAPAN
SN 0916-8818
J9 J REPROD DEVELOP
JI J. Reprod. Dev.
PD AUG
PY 2012
VL 58
IS 4
BP 490
EP 500
DI 10.1262/jrd.11-115A
PG 11
WC Agriculture, Dairy & Animal Science; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Reproductive Biology
GA 995ZY
UT WOS:000308055000016
PM 22522229
OA gold
DA 2025-01-12
ER

PT J
AU Zhang, YS
   Li, J
   Hu, XX
   Li, N
AF Zhang, Yunsheng
   Li, Jing
   Hu, Xiaoxiang
   Li, Ning
TI The Activation of Akt/protein Kinase B Signaling Affects the Expression
   of Histone H3 Lysine 27 Methylase and Demethylase Genes in Mouse Cell
   Lines
SO JOURNAL OF ANIMAL AND VETERINARY ADVANCES
LA English
DT Article
DE Epigenetics; H3K27 methylation; Akt; Ezh1; Ezh2; Jmjd3; Utx
ID AGGRESSIVE BREAST-CANCER; EMBRYONIC STEM-CELLS; METHYLTRANSFERASE
   ACTIVITY; EZH2; POLYCOMB; PATHWAY; CHROMATIN; ENHANCER; JMJD3; UTX
AB H3K27 methylation plays an important role in the regulation of gene expression and chromatin stability and its expression is dynamically regulated by both specific methylases and demethylases. During development, the regulation of these enzymes is fine-tuned to co-determine the appropriate level of H3K27 methylation thus ensuring correct gene expression. However, it is not completely clear how this regulation is realized. Here, we found that Akt (Akt1 and Akt2), H3K27 methylases (Ezh1 and Ezh2) and demethylases (Jmjd3 and Utx) displayed varying levels of RNA and protein expression in mouse cell lines. Ezh2 was upregulated (p<0.05) at the protein level in an IGF-1-treated C2C12 cell line. The overexpression of p-Akt through myr-Alct vector transfection greatly downregulated the mRNA levels of Ezh1, Jmjd3 and Utx (p<0.01) but not Ezh2 (p>0.05). Therefore, the data suggest that the expression of both H3K27 methylase and demethylase genes is involved in the activation of the IGF-1/PI3K/Akt pathway.
C1 [Zhang, Yunsheng; Hu, Xiaoxiang; Li, Ning] China Agr Univ, State Key Lab AgroBiotechnol, Beijing 100193, Peoples R China.
   [Zhang, Yunsheng; Li, Jing] Xinjiang Agr Reclamat Acad, Res Inst Anim Husb & Vet, Shihezi 832000, Peoples R China.
   [Li, Jing] Shihezi Univ, Inst Anim Sci, Xinjiang 832000, Peoples R China.
C3 China Agricultural University; Shihezi University
RP Li, N (通讯作者)，China Agr Univ, State Key Lab AgroBiotechnol, Beijing 100193, Peoples R China.
RI Zhang, Yunsheng/GRO-0555-2022
FU State Major Basic Research Development Program of China [2009CB941600];
   National Key Scientific Program of China [2011ZX08009-003-006]
FX This research was supported by the State Major Basic Research
   Development Program of China under Grant No. 2009CB941600 and the
   National Key Scientific Program of China under Grant No.
   2011ZX08009-003-006. Researchers thank Professor Yaofeng Zhao for the
   helpful suggestions and we also thank Wenjie Liu, Tongxin Liu and Yang
   Lv for their technical assistance.
CR Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bödör C, 2011, LEUKEMIA, V25, P726, DOI 10.1038/leu.2010.311
   Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ezhkova E, 2011, GENE DEV, V25, P485, DOI 10.1101/gad.2019811
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood-2009-04-217620
   Jung JW, 2010, CELL MOL LIFE SCI, V67, P1165, DOI 10.1007/s00018-009-0242-9
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219
   Laviola L, 2007, CURR PHARM DESIGN, V13, P663, DOI 10.2174/138161207780249146
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   López-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200
   Mitsuuchi Y, 1998, J CELL BIOCHEM, V70, P433, DOI 10.1002/(SICI)1097-4644(19980915)70:4<433::AID-JCB1>3.0.CO;2-K
   Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840
   Rugg-Gunn PJ, 2010, P NATL ACAD SCI USA, V107, P10783, DOI 10.1073/pnas.0914507107
   Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295
   Sato K, 2006, MOL IMMUNOL, V43, P1443, DOI 10.1016/j.molimm.2005.07.035
   Seenundun S, 2010, EMBO J, V29, P1401, DOI 10.1038/emboj.2010.37
   Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508
   Shaw T, 2009, EMBO REP, V10, P881, DOI 10.1038/embor.2009.102
   Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131
   Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Wong CF, 2008, J BIOL CHEM, V283, P9836, DOI 10.1074/jbc.M709614200
   Xu J, 2008, J NEUROSCI, V28, P4521, DOI 10.1523/JNEUROSCI.5382-07.2008
NR 48
TC 1
Z9 1
U1 0
U2 9
PU MEDWELL ONLINE
PI FAISALABAD
PA ANSINET BUILDING, 308-LASANI TOWN, SARGODHA RD, FAISALABAD, 38090,
   PAKISTAN
SN 1680-5593
J9 J ANIM VET ADV
JI J. Anim. Vet. Adv.
PY 2012
VL 11
IS 14
BP 2469
EP 2479
PG 11
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA 992VS
UT WOS:000307808900018
DA 2025-01-12
ER

PT J
AU Andrade, FO
   Nagamine, MK
   De Conti, A
   Chaible, LM
   Fontelles, CC
   Jordao, AA
   Vannucchi, H
   Dagli, MLZ
   Bassoli, BK
   Moreno, FS
   Ong, TP
AF Andrade, F. O.
   Nagamine, M. K.
   De Conti, A.
   Chaible, L. M.
   Fontelles, C. C.
   Jordao Junior, A. A.
   Vannucchi, H.
   Dagli, M. L. Z.
   Bassoli, B. K.
   Moreno, F. S.
   Ong, T. P.
TI Efficacy of the dietary histone deacetylase inhibitor butyrate alone or
   in combination with vitamin A against proliferation of MCF-7 human
   breast cancer cells
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Breast cancer; MCF-7 cells; Butyric acid; Vitamin A; Epigenetics
ID TRANS-RETINOIC ACID; RAT HEPATOCARCINOGENESIS; SODIUM-BUTYRATE; DNA
   METHYLATION; DOWN-REGULATION; GENE; TRIBUTYRIN; EXPRESSION; RAR-BETA-2;
   PROMOTER
AB The combined treatment with histone deacetylase inhibitors (HDACi) and retinoids has been suggested as a potential epigenetic strategy for the control of cancer. In the present study, we investigated the effects of treatment with butyrate, a dietary HDACi, combined with vitamin A on MCF-7 human breast cancer cells. Cell proliferation was evaluated by the crystal violet staining method. MCF-7 cells were plated at 5 x 10(4) cells/mL and treated with butyrate (1 mM) alone or combined with vitamin A (10 mu M) for 24 to 120 h. Cell proliferation inhibition was 34, 10 and 46% following treatment with butyrate, vitamin A and their combination, respectively, suggesting that vitamin A potentiated the inhibitory activities of butyrate. Furthermore, exposure to this short-chain fatty acid increased the level of histone H3K9 acetylation by 9.5-fold (Western blot), but not of H4K16, and increased the expression levels of p21(WAF1) by 2.7-fold (Western blot) and of RAR beta by 2.0-fold (quantitative real-time PCR). Our data show that RAR beta may represent a molecular target for butyrate in breast cancer cells. Due to its effectiveness as a dietary HDACi, butyrate should be considered for use in combinatorial strategies with more active retinoids, especially in breast cancers in which RAR beta is epigenetically altered.
C1 [Andrade, F. O.; De Conti, A.; Fontelles, C. C.; Bassoli, B. K.; Moreno, F. S.; Ong, T. P.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Alimentos & Nutr Expt, Lab Dieta Nutr & Canc, BR-05508900 Sao Paulo, Brazil.
   [Nagamine, M. K.; Chaible, L. M.; Dagli, M. L. Z.] Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Patol, Expt Oncol Lab, BR-05508900 Sao Paulo, Brazil.
   [Jordao Junior, A. A.; Vannucchi, H.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Div Nutr, Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de
   Sao Paulo
RP Ong, TP (通讯作者)，Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Alimentos & Nutr Expt, Lab Dieta Nutr & Canc, Av Prof Lineu Prestes 580,Bloco 14, BR-05508900 Sao Paulo, Brazil.
EM tong@usp.br
RI Ong, Thomas/N-1272-2019; Vannucchi, Helio/B-8060-2013; Jordao,
   Alceu/D-7545-2014; Nagamine, Marcia/C-9798-2014; de Conti,
   Aline/I-1666-2013; Dagli, Maria/C-5809-2012; Castilho Fontelles,
   Camile/J-3722-2016; Moreno, Fernando/I-1943-2013; Chaible,
   Lucas/F-2403-2013
OI Ong, Thomas/0000-0002-7709-1866; /0000-0003-1288-0802; Dagli,
   Maria/0000-0001-7031-6711; Castilho Fontelles,
   Camile/0000-0001-9018-5122; Moreno, Fernando/0000-0002-1908-5046;
   Chaible, Lucas/0000-0002-9645-2663
FU FAPESP [2008/58697-9, 2008/51742-9]
FX Research supported by FAPESP (#2008/58697-9 and #2008/51742-9).
CR Alyaqoub FS, 2007, CARCINOGENESIS, V28, P124, DOI 10.1093/carcin/bgl136
   [Anonymous], 2008, WORLD HLTH STAT
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Arapshian A, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-13
   Belobrajdic DP, 2000, NUTR CANCER, V36, P217, DOI 10.1207/S15327914NC3602_11
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Chopin V, 2004, ONCOGENE, V23, P21, DOI 10.1038/sj.onc.1207020
   Conley BA, 1998, CLIN CANCER RES, V4, P629
   de Conti A, 2012, J NUTR BIOCHEM, V23, P860, DOI 10.1016/j.jnutbio.2011.04.010
   Delage B, 2008, ANNU REV NUTR, V28, P347, DOI 10.1146/annurev.nutr.28.061807.155354
   Druesne-Pecollo N, 2007, BIOCHEM BIOPH RES CO, V354, P140, DOI 10.1016/j.bbrc.2006.12.158
   Esteller M, 2002, CANCER RES, V62, P5902
   Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004
   Goldenberg D, 2004, ARCH OTOLARYNGOL, V130, P39, DOI 10.1001/archotol.130.1.39
   Hamer HM, 2008, ALIMENT PHARM THER, V27, P104, DOI 10.1111/j.1365-2036.2007.03562.x
   Hayden LJ, 2002, BREAST CANCER RES TR, V72, P95, DOI 10.1023/A:1014815112078
   Jeong J, 2003, EXP MOL PATHOL, V75, P256, DOI 10.1016/S0014-4800(03)00095-9
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kuroiwa-Trzmielina J, 2009, INT J CANCER, V124, P2520, DOI 10.1002/ijc.24212
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X
   Mira-y-Lopez R, 2000, J CELL PHYSIOL, V185, P302, DOI 10.1002/1097-4652(200011)185:2<302::AID-JCP15>3.0.CO;2-#
   Mongan NP, 2005, MOL CANCER THER, V4, P477
   MURRAY M, 1994, BBA-MOL CELL RES, V1222, P227, DOI 10.1016/0167-4889(94)90173-2
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Rahim R, 2009, ANTI-CANCER DRUG, V20, P736, DOI 10.1097/CAD.0b013e32832f4e50
   Ross S. A., 2007, Experimental Oncology, V29, P250
   Santos MDL, 2007, ENDOCR-RELAT CANCER, V14, P1021, DOI 10.1677/ERC-07-0144
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Simeone AM, 2004, CELL MOL LIFE SCI, V61, P1475, DOI 10.1007/s00018-004-4002-6
   Sirchia SM, 2002, CANCER RES, V62, P2455
   Spurling CC, 2008, NUTR CANCER, V60, P692, DOI 10.1080/01635580802008278
   Sun JY, 2011, MED ONCOL, V28, P1311, DOI 10.1007/s12032-010-9685-y
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
NR 38
TC 11
Z9 11
U1 0
U2 18
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD SEP
PY 2012
VL 45
IS 9
BP 841
EP 850
DI 10.1590/S0100-879X2012007500103
PG 10
WC Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 991PT
UT WOS:000307714400008
PM 22714808
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Gao, RF
   Ding, YB
   Liu, XQ
   Chen, XM
   Wang, YX
   Long, CL
   Li, S
   Guo, LR
   He, JL
AF Gao, Rufei
   Ding, Yubin
   Liu, Xueqing
   Chen, Xuemei
   Wang, Yingxiong
   Long, Chunlan
   Li, Shuang
   Guo, Liangrui
   He, Junlin
TI Effect of folate deficiency on promoter methylation and gene expression
   of <i>Esr1</i>, <i>Cdh1</i> and <i>Pgr</i>, and its influence on
   endometrial receptivity and embryo implantation
SO HUMAN REPRODUCTION
LA English
DT Article
DE endometrial receptivity; methylation; folate deficiency; estrogen
   receptor 1; Cadherin1
ID RECEPTOR-ALPHA EXPRESSION; E-CADHERIN GENE; DIFFERENTIAL EXPRESSION;
   PROGESTERONE-RECEPTOR; DNA METHYLATION; BREAST-CANCER; ER-ALPHA; UTERINE
   ENDOMETRIUM; CPG METHYLATION; MENSTRUAL-CYCLE
AB Folate, one of the B vitamins, provides the one-carbon units required for methylation. Folate deficiency has been associated with many pathologies. However, much less is known about the effect of it on human reproduction, especially on implantation. The establishment of uterine receptivity is crucial for successful embryo implantation. Gene expression can be influenced by both heredity and epigenetics such as DNA methylation. However, it is not known whether the methylation and expression of genes related to uterine receptivity can be affected by folate levels. To explore whether folate deficiency affected the epigenetic regulation of genes related to uterine receptivity, and their influence on implantation, we investigated the methylation and expression of cadherin 1 (Cdh1), progesterone receptor (Pgr) and estrogen receptor 1 (Esr1) genes during implantation and the implantation efficiency using a folate-deficient pregnant mouse model.
   Serum folate levels of pregnant mice were measured using the electro-chemiluminescence immunoassay. The methylation status of Cdh1, Pgr and Esr1 promoter regions was determined by methylation-specific PCR and bisulfite sequencing. The expression of Cdh1, Pgr and Esr1 in the implantation-site endometrium was examined by real-time PCR, western blot and immunohistochemistry. The number and the morphology of pinopodes, important morphological markers of endometrial receptivity, were examined using scanning electron microscopy. The number of implantation sites demarcated by distinct blue bands was recorded.
   Serum folate levels of the folate-deficient group were lower (5.42 1.35 ng/ml, n 42) than those of the normal group (24.13 4 .26 ng/ml, n 37; P 0.003). Here we show that the methylation status and mRNA levels of Esr1 were decreased (P 0.021, P 0.045, respectively), while the Cdh1 and Pgr expression levels were slightly but not significantly elevated and the methylation status did not vary in the folate-deficient mice compared with the wild type. Neither the number nor morphology of pinopodes was affected by folate deficiency. Furthermore, folate deficiency did not affect the number of implantation sites in mice.
   This study demonstrates for the first time that, unlike the effects on Esr1, folate deficiency in mice does not influence the methylation and expression of Pgr and Cdh1, two genes shown to be essential for uterine receptivity and embryo implantation. Embryo implantation in mice appears to be unaffected by a deficiency in folate, suggesting that abnormalities in a pregnancy caused by folate deficiency start to develop after implantation.
C1 [Gao, Rufei; Ding, Yubin; Liu, Xueqing; Chen, Xuemei; Wang, Yingxiong; Long, Chunlan; Li, Shuang; Guo, Liangrui; He, Junlin] Chongqing Med Univ, Sch Publ Hlth, Reprod Biol Lab, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University
RP He, JL (通讯作者)，Chongqing Med Univ, Sch Publ Hlth, Reprod Biol Lab, Box 197,1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM hejunlin_11@yahoo.com.cn
RI Li, chunbao/KHD-9616-2024; Wang, Ying/HJI-2509-2023; Ding,
   Yubin/W-4146-2017
FU National Natural Science foundation of China [30973195]; Natural Science
   Foundation of Chongqing (CSTC) [2009BA5082, 2010BB5365, JJA10007];
   Chongqing Education Commission [KJ100304]
FX This work was supported by the National Natural Science foundation of
   China (No. 30973195), the Natural Science Foundation of Chongqing (CSTC,
   2009BA5082, 2010BB5365, JJA10007) and the Chongqing Education Commission
   (KJ100304).
CR Ahmed H, 2007, BIOCHEM BIOPH RES CO, V358, P241, DOI 10.1016/j.bbrc.2007.04.114
   Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779
   Becker KF, 1999, AM J PATHOL, V155, P1803, DOI 10.1016/S0002-9440(10)65497-1
   Burgoon JM, 2002, TERATOLOGY, V65, P219, DOI 10.1002/tera.10040
   Chegini N, 2002, J REPROD IMMUNOL, V56, P93, DOI 10.1016/S0165-0378(02)00043-8
   Conneely OM, 2002, RECENT PROG HORM RES, V57, P339, DOI 10.1210/rp.57.1.339
   Corn PG, 2001, CLIN CANCER RES, V7, P2765
   Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417
   Das SK, 1997, P NATL ACAD SCI USA, V94, P12786, DOI 10.1073/pnas.94.24.12786
   Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020
   Dobosy JR, 2008, PROSTATE, V68, P1187, DOI 10.1002/pros.20782
   Durfort T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029213
   Eads CA, 2000, CANCER RES, V60, P5021
   Fujimoto J, 1996, GYNECOL ENDOCRINOL, V10, P187, DOI 10.3109/09513599609027987
   Ghoshal K, 2006, J NUTR, V136, P1522, DOI 10.1093/jn/136.6.1522
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Horne AW, 2002, BJOG-INT J OBSTET GY, V109, P610, DOI 10.1016/S1470-0328(02)01417-9
   Jacob RA, 2000, AM J CLIN NUTR, V72, P903
   Jha RK, 2006, FEBS LETT, V580, P5653, DOI 10.1016/j.febslet.2006.09.014
   Kanai Y, 1997, INT J CANCER, V71, P355
   Kim SJ, 2004, INT J MOL MED, V14, P289
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Kurita T, 2000, BIOL REPROD, V62, P831, DOI 10.1095/biolreprod62.4.831
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9
   Li C, 2011, CATAL TODAY, V175, P1, DOI 10.1016/j.cattod.2011.08.002
   Ling ZQ, 2011, INT J MOL MED, V27, P625, DOI 10.3892/ijmm.2011.640
   Liu ZJ, 2003, LIFE SCI, V73, P1963, DOI 10.1016/S0024-3205(03)00544-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162
   LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266
   Mills JL, 1996, J NUTR, V126, pS756, DOI 10.1093/jn/126.suppl_3.756S
   Mori M, 2011, J CLIN INVEST, V121, P318, DOI 10.1172/JCI44723
   Paria BC, 1999, ENDOCRINOLOGY, V140, P2704, DOI 10.1210/en.140.6.2704
   PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159
   Park Bo-hyun, 2005, J Prev Med Public Health, V38, P437
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012
   Quenby S, 2007, REPROD BIOMED ONLINE, V14, P224, DOI 10.1016/S1472-6483(10)60791-2
   Quinn CE, 2007, FERTIL STERIL, V88, P1021, DOI 10.1016/j.fertnstert.2006.11.157
   Rahnama F, 2009, ENDOCRINOLOGY, V150, P1466, DOI 10.1210/en.2008-1142
   Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569
   Tan Y, 2005, BIOL REPROD, V72, P556, DOI 10.1095/biolreprod.104.032821
   TANAKA K, 1983, CELL, V35, P457, DOI 10.1016/0092-8674(83)90179-4
   VEDEL M, 1983, NUCLEIC ACIDS RES, V11, P4335, DOI 10.1093/nar/11.13.4335
   Wang AM, 2011, GYNECOL ENDOCRINOL, V27, P251, DOI 10.3109/09513590.2010.487584
   Wang HB, 2006, NAT REV GENET, V7, P185, DOI 10.1038/nrg1808
   Wasson GR, 2006, J NUTR, V136, P2748, DOI 10.1093/jn/136.11.2748
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Williams KT, 2007, J NUTR, V137, P311, DOI 10.1093/jn/137.2.311
   Woo IS, 2004, ONCOL REP, V11, P617
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhao SL, 2006, J CHROMATOGR A, V1107, P290, DOI 10.1016/j.chroma.2005.11.052
NR 53
TC 30
Z9 36
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD SEP
PY 2012
VL 27
IS 9
BP 2756
EP 2765
DI 10.1093/humrep/des187
PG 10
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 988PC
UT WOS:000307502000022
PM 22706342
OA Bronze
DA 2025-01-12
ER

PT J
AU Banno, K
   Kisu, I
   Yanokura, M
   Tsuji, K
   Masuda, K
   Ueki, A
   Kobayashi, Y
   Yamagami, W
   Nomura, H
   Tominaga, E
   Susumu, N
   Aoki, D
AF Banno, Kouji
   Kisu, Iori
   Yanokura, Megumi
   Tsuji, Kosuke
   Masuda, Kenta
   Ueki, Arisa
   Kobayashi, Yusuke
   Yamagami, Wataru
   Nomura, Hiroyuki
   Tominaga, Eiichiro
   Susumu, Nobuyuki
   Aoki, Daisuke
TI Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome
   (Review)
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE epimutation; Lynch syndrome; human MutL homologue 1; human MutS
   homologue 2; epithelial cell adhesion molecule
ID NONPOLYPOSIS COLORECTAL-CANCER; MLH1 GERMLINE EPIMUTATIONS; FAMILIAL
   BREAST-CANCER; HMLH1 PROMOTER REGION; TUMOR-SUPPRESSOR GENE;
   MICROSATELLITE INSTABILITY; ESTROGEN-RECEPTOR; SPORADIC BREAST;
   METHYLATION; BRCA1
AB Epimutation is defined as abnormal transcriptional repression of active genes and/or abnormal activation of usually repressed genes caused by errors in epigenetic gene repression. Epimutation arises in somatic cells and the germline, and constitutional epimutation may also occur. Epimutation is the first step of tumorigenesis and can be a direct cause of carcinogenesis. Cancers associated with epimutation include Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC), chronic lymphocytic leukemia, breast cancer and ovarian cancer. Epimutation has been shown for many tumor suppressor genes, including RB, VHL, hMLHI, APC and BRCA1, in sporadic cancers. Methylation has recently been shown in DNA from normal tissues and peripheral blood in cases of sporadic colorectal cancer and many studies show constitutive epimutation in cancers. Epimutation of DNA mismatch repair (MMR) genes (BRCA1,hMLH1 and hMSH2) involved in development familial cancers has also been found. These results have led to a focus on epimutation as a novel oncogenic mechanism.
C1 [Banno, Kouji] Keio Univ, Dept Obstet & Gynecol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan.
C3 Keio University
RP Banno, K (通讯作者)，Keio Univ, Dept Obstet & Gynecol, Sch Med, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.
EM kbanno@z7.keio.jp
RI Banno, Kouji/C-9638-2014; Nomura, Hiroyuki/G-2668-2014; Yanokura,
   Megumi/W-2667-2017; Yamagami, Wataru/D-7754-2014; Kobayashi,
   Yusuke/M-5174-2019; Aoki, Daisuke/E-6650-2014
OI Kobayashi, Yusuke/0000-0002-4503-2845; Ueki, Arisa/0000-0001-9205-5452
FU Japan Society for the Promotion of Science (JSPS) [22591866, 21791573];
   Ichiro Kanehara Foundation; Kobayashi Foundation for Cancer Research;
   Keio University; Grants-in-Aid for Scientific Research [21791573,
   22591866] Funding Source: KAKEN
FX The authors gratefully acknowledge the grant support from the Japan
   Society for the Promotion of Science (JSPS) through a Grant-in-Aid for
   Scientific Research (KAKENHI); a Grant-in-Aid for Scientific Research
   (C) (22591866), and a Grant-in-Aid for Young Scientists (B) (21791573);
   the Ichiro Kanehara Foundation; Kobayashi Foundation for Cancer
   Research; and the Keio University Medical Science Fund through a
   Research Grant for Life Sciences and Medicine.
CR Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516
   Cooper WN, 2005, EUR J HUM GENET, V13, P1025, DOI 10.1038/sj.ejhg.5201463
   DAS OP, 1994, GENETICS, V136, P1121
   de la Chapelle A, 2009, ONCOGENE, V28, P3345, DOI 10.1038/onc.2009.194
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Gazzoli I, 2002, CANCER RES, V62, P3925
   GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709
   Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Hirata K, 2006, AM J GASTROENTEROL, V101, P193, DOI 10.1111/j.1572-0241.2005.00308.x
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   Hitchins MP, 2007, NAT GENET, V39, P1289, DOI 10.1038/ng1107-1289
   Hitchins MP, 2007, NEW ENGL J MED, V356, P697, DOI 10.1056/NEJMoa064522
   HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230
   HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Kane MF, 1997, CANCER RES, V57, P808
   Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616
   Miyakura Y, 2003, GENE CHROMOSOME CANC, V36, P17, DOI 10.1002/gcc.10134
   Miyakura Y, 2004, CLIN GASTROENTEROL H, V2, P147, DOI 10.1016/S1542-3565(03)00314-8
   Morak M, 2008, EUR J HUM GENET, V16, P804, DOI 10.1038/ejhg.2008.25
   Naruse H, 2009, FAM CANCER, V8, P509, DOI 10.1007/s10689-009-9280-6
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Peltomäki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Reddy AN, 2003, CANCER RES, V63, P7694
   Rose MG, 2009, NAT REV CLIN ONCOL, V6, P502, DOI 10.1038/nrclinonc.2009.125
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   Schönherr N, 2007, J MED GENET, V44, P59, DOI 10.1136/jmg.2006.044370
   Schofield PN, 2001, TOXICOL LETT, V120, P151, DOI 10.1016/S0378-4274(01)00294-6
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157
   Valle L, 2007, CLIN GENET, V71, P232, DOI 10.1111/j.1399-0004.2007.00751.x
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5
NR 46
TC 39
Z9 43
U1 0
U2 20
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD SEP
PY 2012
VL 41
IS 3
BP 793
EP 797
DI 10.3892/ijo.2012.1528
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 983WS
UT WOS:000307150000001
PM 22735547
OA Green Submitted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Thakur, S
   Feng, XL
   Shi, ZQ
   Ganapathy, A
   Mishra, MK
   Atadja, P
   Morris, D
   Riabowol, K
AF Thakur, Satbir
   Feng, Xiaolan
   Shi, Zhong Qiao
   Ganapathy, Amudha
   Mishra, Manoj Kumar
   Atadja, Peter
   Morris, Don
   Riabowol, Karl
TI ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell
   Growth
SO PLOS ONE
LA English
DT Article
ID CANDIDATE TUMOR-SUPPRESSOR; DEACETYLASE INHIBITORS; MESSENGER-RNA;
   APOPTOSIS; P33(ING1); EXPRESSION; P53; CARCINOMA; GENE; CHEMOSENSITIVITY
AB Background: Inhibitor of Growth (ING) proteins are epigenetic "readers'' that recognize trimethylated lysine 4 of histone H3 (H3K4Me3) and target histone acetyl transferase (HAT) and histone deacetylase (HDAC) complexes to chromatin.
   Methods and Principal Findings: Here we asked whether dysregulating two epigenetic pathways with chemical inhibitors showed synergistic effects on breast cancer cell line killing. We also tested whether ING1 could synergize better with chemotherapeutics that target the same epigenetic mechanism such as the HDAC inhibitor LBH589 (Panobinostat) or a different epigenetic mechanism such as 5-azacytidine (5azaC), which inhibits DNA methyl transferases. Simultaneous treatment of breast cancer cell lines with LBH589 and 5azaC did not show significant synergy in killing cells. However, combination treatment of ING1 with either LBH589 or 5azaC did show synergy. The combination of ING1b with 5azaC, which targets two distinct epigenetic mechanisms, was more effective at lower doses and enhanced apoptosis as determined by Annexin V staining and cleavage of caspase 3 and poly-ADP-ribose polymerase (PARP). ING1b plus 5azaC also acted synergistically to increase gamma H2AX staining indicating significant levels of DNA damage were induced. Adenoviral delivery of ING1b with 5azaC also inhibited cancer cell growth in a murine xenograft model and led to tumor regression when viral concentration was optimized in vivo.
   Conclusions: These data show that targeting distinct epigenetic pathways can be more effective in blocking cancer cell line growth than targeting the same pathway with multiple agents, and that using viral delivery of epigenetic regulators can be more effective in synergizing with a chemical agent than using two chemotherapeutic agents. This study also indicates that the ING1 epigenetic regulator may have additional activities in the cell when expressed at high levels.
C1 [Thakur, Satbir; Feng, Xiaolan; Ganapathy, Amudha; Riabowol, Karl] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.
   [Thakur, Satbir; Feng, Xiaolan; Shi, Zhong Qiao; Ganapathy, Amudha; Morris, Don; Riabowol, Karl] So Alberta Canc Res Inst, Calgary, AB, Canada.
   [Shi, Zhong Qiao; Morris, Don] Univ Calgary, Tom Baker Canc Ctr, Dept Med & Oncol, Calgary, AB, Canada.
   [Mishra, Manoj Kumar] Univ Calgary, Dept Oncol & Clin Neurosci, Calgary, AB, Canada.
   [Atadja, Peter] Novartis Inst Biomed Res, Shanghai, Peoples R China.
C3 University of Calgary; Tom Baker Cancer Clinic; University of Calgary;
   University of Calgary; Novartis
RP Thakur, S (通讯作者)，Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.
EM karl@ucalgary.ca
RI Feng, Xiaolan/J-9997-2019; Ganapathy, Amudha/ABI-6930-2020; Mishra,
   Manoj/A-7105-2018
OI Feng, Xiaolan/0000-0002-7333-8198; Mishra, Manoj/0000-0001-9636-4930
FU Alberta Cancer Foundation; Alberta Innovates Health Solutions; Canadian
   Institutes of Health Research; Alberta Heritage Foundation for Medical
   Research
FX This study was supported by grants to DM from the Alberta Cancer
   Foundation and Alberta Innovates Health Solutions, and to KR from
   Alberta Innovates Health Solutions and the Canadian Institutes of Health
   Research. XF is recipient of an Alberta Heritage Foundation for Medical
   Research Studentship and KR is a Scientist of the Alberta Heritage
   Foundation for Medical Research. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019
   Atadja PW, 2011, PROG DRUG RES, V67, P175, DOI 10.1007/978-3-7643-8989-5_9
   CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7
   Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007
   Eastman A, 1999, SEMIN ONCOL, V26, P7
   Garkavtsev I, 2005, CANCER BIOL THER, V4, P48
   Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415
   Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675
   HACKETT AJ, 1977, JNCI-J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795
   Han XJ, 2008, NAT CELL BIOL, V10, P1333, DOI 10.1038/ncb1792
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Helbing CC, 1997, CANCER RES, V57, P1255
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Kim TY, 2006, EPIGENETICS-US, V1, P14
   Kiziltepe T, 2007, MOL CANCER THER, V6, P1718, DOI 10.1158/1535-7163.MCT-07-0010
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Kuendgen A, 2008, ANN HEMATOL, V87, P601, DOI 10.1007/s00277-008-0477-9
   Li ZY, 2010, CANCER BIOTHER RADIO, V25, P427, DOI 10.1089/cbr.2010.0778
   Liu Jian-ying, 2003, Zhonghua Bing Li Xue Za Zhi, V32, P48
   Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000
   Maher Stacey K, 2009, Curr Drug Targets, V10, P392
   Mandili G, 2012, FEBS J, V279, P2182, DOI 10.1111/j.1742-4658.2012.08602.x
   Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115
   Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798
   Nouman GS, 2003, J CLIN PATHOL, V56, P507, DOI 10.1136/jcp.56.7.507
   Oki Y, 2007, CRIT REV ONCOL HEMAT, V61, P140, DOI 10.1016/j.critrevonc.2006.07.010
   Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Sánchez-Abarca LI, 2010, BLOOD, V115, P107, DOI 10.1182/blood-2009-03-210393
   Scott M, 2001, J CELL SCI, V114, P3455
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176
   Shinoura N, 1999, CANCER RES, V59, P5521
   Smith KT, 2010, CHEM BIOL, V17, P65, DOI 10.1016/j.chembiol.2009.12.010
   Soriano AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576
   SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4
   Tallen G, 2003, ANTICANCER RES, V23, P1631
   Thalappilly S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021065
   Tokunaga E, 2000, CANCER LETT, V152, P15, DOI 10.1016/S0304-3835(99)00434-6
   Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905
   Toyama T, 2003, J STEROID BIOCHEM, V87, P57, DOI 10.1016/S0960-0760(03)00388-1
   Toyama Tatsuya, 2004, Breast Cancer, V11, P33, DOI 10.1007/BF02967999
   Vieyra D, 2002, CANCER RES, V62, P4445
   Wu J C, 1985, Prog Clin Biol Res, V198, P119
   Xie Y, 2011, CANCER GENE THER, V18, P176, DOI 10.1038/cgt.2010.67
   Xie YF, 2008, CANCER LETT, V271, P105, DOI 10.1016/j.canlet.2008.05.050
   Zhang X, 2004, FEBS LETT, V570, P7, DOI 10.1016/j.febslet.2004.06.010
   Zhao Y, 2011, CANC LETT
   Zhu Jin-Jun, 2004, Ai Zheng, V23, P640
   Zhu Y, 2011, CANCER GENE THER, V18, P627, DOI 10.1038/cgt.2011.31
   Zhu Z, 2005, WORLD J GASTROENTERO, V11, P1903
NR 53
TC 28
Z9 31
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 20
PY 2012
VL 7
IS 8
AR e43671
DI 10.1371/journal.pone.0043671
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 991WJ
UT WOS:000307733800093
PM 22916295
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Palmieri, C
   Monteverde, M
   Lattanzio, L
   Gojis, O
   Rudraraju, B
   Fortunato, M
   Syed, N
   Thompson, A
   Garrone, O
   Merlano, M
   Lo Nigro, C
   Crook, T
AF Palmieri, C.
   Monteverde, M.
   Lattanzio, L.
   Gojis, O.
   Rudraraju, B.
   Fortunato, M.
   Syed, N.
   Thompson, A.
   Garrone, O.
   Merlano, M.
   Lo Nigro, C.
   Crook, T.
TI Site-specific CpG methylation in the CCAAT/enhancer binding protein
   delta (CEBPδ) CpG island in breast cancer is associated with metastatic
   relapse
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; CEBPD; methylation; metastasis
ID C/EBP-DELTA; GENE-EXPRESSION; TUMOR-SUPPRESSOR; CELL-LINE;
   DIFFERENTIATION; TARGETS
AB BACKGROUND: The CCAAT/enhancer binding protein delta (CEBP delta) is a member of a highly conserved family of basic region leucine zipper transcription factors. It has properties consistent with a tumour suppressor; however, other data suggest that CEBP delta may be involved in the metastatic process.
   METHODS: We analysed the expression of CEBP delta and the methylation status of the CpG island in human breast cancer cell lines, in 107 archival cases of primary breast cancer and in two series of metastatic breast cancers using qPCR and pyrosequencing.
   RESULTS: Expression of CEBP delta is downregulated in primary breast cancer by site-specific methylation in the CEBP delta CpG island. Expression is also downregulated in 50% of cases during progression from primary carcinoma to metastatic lesions. The CEBP delta CpG island is methylated in 81% metastatic breast cancer lesions, while methylation in the CEBP delta CpG island in primary cancers is associated with increased risk of relapse and metastasis.
   CONCLUSION: CCAAT/enhancer binding protein delta CpG island methylation is associated with metastasis in breast cancer. Detection of methylated CEBP delta genomic DNA may have utility as an epigenetic biomarker of primary breast carcinomas at increased risk of relapse and metastasis. British Journal of Cancer (2012) 107, 732-738. doi:10.1038/bjc.2012.308 www.bjcancer.com Published online 10 July 2012 (C) 2012 Cancer Research UK
C1 [Palmieri, C.; Gojis, O.; Rudraraju, B.] Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Translat & Expt Med, Canc Res UK Labs, Div Canc, London W12 0NN, England.
   [Monteverde, M.; Lattanzio, L.; Lo Nigro, C.] S Croce Gen Hosp, Dept Oncol, Lab Canc Res & Translat Oncol, Cuneo, Italy.
   [Gojis, O.] Charles Univ Prague, Dept Obstet & Gynaecol, Fac Med 3, Prague 10000 10, Czech Republic.
   [Gojis, O.] Charles Univ Prague, Dept Pathol, Fac Med 3, Prague 10000 10, Czech Republic.
   [Fortunato, M.] S Croce Gen Hosp, Dept Pathol, Cuneo, Italy.
   [Syed, N.] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Dept Pathol, London W6 8RF, England.
   [Thompson, A.; Crook, T.] Univ Dundee, Ninewells Hosp & Med Sch, Dundee Canc Ctr, Dundee DD1 9SY, Scotland.
C3 Cancer Research UK; Imperial College London; Charles University Prague;
   Charles University Prague; Imperial College London; University of Dundee
RP Palmieri, C (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Imperial Ctr Translat & Expt Med, Canc Res UK Labs, Div Canc, Du Cane Rd, London W12 0NN, England.
EM c.palmieri@imperial.ac.uk
RI Garrone, Ornella/HHS-9402-2022
OI Lo Nigro, Cristiana/0000-0002-3615-2431; Garrone,
   Ornella/0000-0001-7359-5410; Monteverde, Martino/0000-0003-2623-414X
FU Cancer Research UK; Imperial College Healthcare Charity; Ministry of
   Education of the Czech Republic [MSM 0021620808]; European Society of
   Medical Oncology; European Society for Surgical Oncology; Department of
   Health [C37/A7283]; Imperial Cancer Research UK Centre [C42671/A12196];
   Brain Tumour Research Campaign
FX Carlo Palmieri is the recipient of a Cancer Research UK Clinician
   Scientist award and also acknowledges support from Imperial College
   Healthcare Charity. Ondrej Gojis is in part funded by a grant from the
   Ministry of Education of the Czech Republic (Project 'Oncology' MSM
   0021620808) and is also a recipient of the Translational Research
   Fellowship from the European Society of Medical Oncology and a
   fellowship from the European Society for Surgical Oncology. The Division
   of Cancer at Imperial College London, Imperial College Healthcare NHS
   Trust is an Experimental Cancer Medicine Centre that is supported by
   funds from Cancer Research UK and the Department of Health (C37/A7283),
   and also forms part of the Imperial Cancer Research UK Centre
   (C42671/A12196). We would like to thank Prof Gerry Thomas, Sarah
   Chilcott-Burns and the Imperial College Healthcare NHS Trust, Human
   Biomaterials Resource Centre (Tissue Bank). Nelofer Syed acknowledges
   support from the Brain Tumour Research Campaign. Tim Crook is a Scottish
   Senior Clinical Fellow in Medical Oncology. We thank De Federico
   Roncaroli for his contribution to the work.
CR Agrawal S, 2007, BLOOD, V109, P3895, DOI 10.1182/blood-2006-08-040147
   Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280
   Barresi V, 2010, J NEURO-ONCOL, V97, P233, DOI 10.1007/s11060-009-0024-0
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371
   Gery S, 2005, ONCOGENE, V24, P1589, DOI 10.1038/sj.onc.1208393
   Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Ikezoe T, 2005, CANCER RES, V65, P4762, DOI 10.1158/0008-5472.CAN-03-3619
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Ko CY, 2008, J BIOL CHEM, V283, P30919, DOI 10.1074/jbc.M804029200
   Kuramoto T, 2002, CANCER RES, V62, P3592
   Naderi A, 2007, ONCOGENE, V26, P1507, DOI 10.1038/sj.onc.1209920
   ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291
   Osada S, 1996, J BIOL CHEM, V271, P3891
   Palmieri C, 2012, BRIT J CANCER, V107, P375, DOI 10.1038/bjc.2012.231
   Pawar SA, 2010, P NATL ACAD SCI USA, V107, P9210, DOI 10.1073/pnas.0913813107
   Porter D, 2003, MOL CANCER RES, V1, P362
   Porter DA, 2001, CANCER RES, V61, P5697
   Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508
   Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907
   Shah R, 2009, BRIT J CANCER, V100, P1687, DOI 10.1038/sj.bjc.6605042
   Sivko GS, 2004, J CELL BIOCHEM, V93, P830, DOI 10.1002/jcb.20223
   Stein T, 2009, J MAMMARY GLAND BIOL, V14, P99, DOI 10.1007/s10911-009-9120-1
   Tang D, 2006, BREAST CANCER RES TR, V95, P161, DOI 10.1007/s10549-005-9061-3
   Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050
   Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002
   WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557
   Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 30
TC 12
Z9 13
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG 7
PY 2012
VL 107
IS 4
BP 732
EP 738
DI 10.1038/bjc.2012.308
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 992IY
UT WOS:000307770300022
PM 22782348
OA Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Yee, KS
   Grochola, L
   Hamilton, G
   Grawenda, A
   Bond, EE
   Taubert, H
   Wurl, P
   Bond, GL
   O'Neill, E
AF Yee, Karen S.
   Grochola, Lukasz
   Hamilton, Garth
   Grawenda, Anna
   Bond, Elisabeth E.
   Taubert, Helge
   Wurl, Peter
   Bond, Gareth L.
   O'Neill, Eric
TI A RASSF1A Polymorphism Restricts p53/p73 Activation and Associates with
   Poor Survival and Accelerated Age of Onset of Soft Tissue Sarcoma
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR RASSF1A; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST-CANCER;
   EPIGENETIC INACTIVATION; COLORECTAL-CANCER; KINASE MST2; LUNG; PROMOTER;
   PROTEIN; GENE
AB RASSF1A (Ras association domain containing family 1A), a tumor suppressor gene that is frequently inactivated in human cancers, is phosphorylated by ataxia telangiectasia mutated (ATM) on Ser131 upon DNA damage, leading to activation of a p73-dependent apoptotic response. A single-nucleotide polymorphism located in the region of the key ATM activation site of RASSF1A predicts the conversion of alanine (encoded by the major G allele) to serine (encoded by the minor T allele) at residue 133 of RASSF1A (p.Ala133Ser). Secondary protein structure prediction studies suggest that an alpha helix containing the ATM recognition site is disrupted in the serine isoform of RASSF1A (RASSF1A-p.133Ser). In this study, we observed a reduced ability of ATM to recruit and phosphorylate RASSF1A-p.133Ser upon DNA damage. RASSF1A-p.133Ser failed to activate the MST2/LATS pathway, which is required for YAP/p73-mediated apoptosis, and negatively affected the activation of p53, culminating in a defective cellular response to DNA damage. Consistent with a defective p53 response, we found that male soft tissue sarcoma patients carrying the minor T allele encoding RASSF1A-p.133Ser exhibited poorer tumor-specific survival and earlier age of onset compared with patients homozygous for the major G allele. Our findings propose a model that suggests a certain subset of the population have inherently weaker p73/p53 activation due to inefficient signaling through RASSF1A, which affects both cancer incidence and survival. Cancer Res; 72(9); 2206-17. (C) 2012 AACR.
C1 [Yee, Karen S.; Hamilton, Garth; O'Neill, Eric] Univ Oxford, Dept Oncol, Gray Inst Radiat Oncol & Biol, Oxford OX3 7DQ, England.
   [Grochola, Lukasz; Grawenda, Anna; Bond, Elisabeth E.; Bond, Gareth L.] Univ Oxford, Nuffield Dept Clin Med, Ludwig Inst Canc Res, Oxford OX3 7DQ, England.
   [Taubert, Helge] Univ Halle Wittenberg, Dept Oral & Maxillofacial Plast Surg, Halle, Germany.
   [Wurl, Peter] Malteser St Franziskus Hosp, Dept Surg, Flensburg, Germany.
C3 University of Oxford; Ludwig Institute for Cancer Research; University
   of Oxford; Martin Luther University Halle Wittenberg
RP O'Neill, E (通讯作者)，Univ Oxford, Dept Oncol, Gray Inst Radiat Oncol & Biol, Old Rd,Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.
EM eric.oneill@oncology.ox.ac.uk
OI Taubert, Helge/0000-0002-9077-1727
FU Cancer Research UK; Ludwig Institute for Cancer Research; Medical
   Research Council (UK)
FX This work was funded by Cancer Research UK, Ludwig Institute for Cancer
   Research, and the Medical Research Council (UK).
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006
   Aylon Y, 2010, GENE DEV, V24, P2420, DOI 10.1101/gad.1954410
   Bergqvist J, 2010, FAM CANCER, V9, P263, DOI 10.1007/s10689-010-9335-8
   BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008
   Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022
   Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445
   CHAUDHURI PK, 1980, CANCER RES, V40, P861
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Gao BN, 2008, CANCER RES, V68, P22, DOI 10.1158/0008-5472.CAN-07-5183
   Grochola LF, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001032
   Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055
   Hamilton G, 2009, CURR BIOL, V19, P2020, DOI 10.1016/j.cub.2009.10.040
   Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342
   Honda S, 2008, INT J CANCER, V123, P1117, DOI 10.1002/ijc.23613
   Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623
   Kanzaki H, 2006, CANCER LETT, V238, P128, DOI 10.1016/j.canlet.2005.07.006
   Kashuba VI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005231
   Kawai Y, 2010, ANN ONCOL, V21, P1612, DOI 10.1093/annonc/mdp577
   Lahat G, 2008, ANN SURG ONCOL, V15, P2739, DOI 10.1245/s10434-008-9970-6
   Lerman MI, 2000, CANCER RES, V60, P6116
   Maat W, 2007, INVEST OPHTH VIS SCI, V48, P486, DOI 10.1167/iovs.06-0781
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   Martins AT, 2011, BREAST CANCER RES TR, V129, P1, DOI 10.1007/s10549-010-1160-0
   Matallanas D, 2008, CELL CYCLE, V7, P879, DOI 10.4161/cc.7.7.5630
   Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008
   O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233
   Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951
   Richter AM, 2010, EUR J CANCER, V46, P2986, DOI 10.1016/j.ejca.2010.06.128
   Schagdarsurengin U, 2005, INT J ONCOL, V27, P185
   Seidel C, 2005, INT J CANCER, V114, P442, DOI 10.1002/ijc.20707
   Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858
   Söderlund S, 2010, GASTROENTEROLOGY, V138, P1697, DOI 10.1053/j.gastro.2010.02.007
   Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115
   Song SJ, 2009, CANCER RES, V69, P8540, DOI 10.1158/0008-5472.CAN-09-1554
   Song SJ, 2009, CANCER RES, V69, P2314, DOI 10.1158/0008-5472.CAN-08-3984
   Spitzner M, 2010, INT J RADIAT ONCOL, V78, P1184, DOI 10.1016/j.ijrobp.2010.06.023
   Stieglitz B, 2008, EMBO J, V27, P1995, DOI 10.1038/emboj.2008.125
   Suzuki K, 2006, CANCER EPIDEM BIOMAR, V15, P1733, DOI 10.1158/1055-9965.EPI-06-0005
   Tian W, 2006, IMMUNOGENETICS, V58, P113, DOI 10.1007/s00251-006-0093-6
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
   Verma SK, 2008, FEBS LETT, V582, P2270, DOI 10.1016/j.febslet.2008.05.028
   Wang J, 2011, CARCINOGENESIS, V32, P411, DOI 10.1093/carcin/bgq266
   Xiao GQ, 2009, J HUAZHONG U SCI-MED, V29, P646, DOI 10.1007/s11596-009-0522-5
   Yuan F, 2011, J BIOL CHEM, V286, P6940, DOI 10.1074/jbc.M110.182543
   Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319
NR 50
TC 38
Z9 42
U1 0
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2012
VL 72
IS 9
BP 2206
EP 2217
DI 10.1158/0008-5472.CAN-11-2906
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 986MI
UT WOS:000307345300008
PM 22389451
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Jayaraj, P
   Sen, S
   Sharma, A
   Chosdol, K
   Kashyap, S
   Rai, A
   Pushker, N
   Bajaj, MS
   Ghose, S
AF Jayaraj, P.
   Sen, S.
   Sharma, A.
   Chosdol, K.
   Kashyap, S.
   Rai, A.
   Pushker, N.
   Bajaj, M. S.
   Ghose, S.
TI Epigenetic inactivation of the E-cadherin gene in eyelid sebaceous gland
   carcinoma
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Article
ID BETA-CATENIN; PROMOTER HYPERMETHYLATION; GASTRIC-CANCER; CELL-CARCINOMA;
   PROGNOSTIC-SIGNIFICANCE; PROTEIN EXPRESSION; BREAST-CANCER;
   SKIN-LESIONS; METHYLATION; TUMORS
AB Background E-cadherin and beta-catenin are crucial components of the cell-cell adhesion complex. Their loss has often been associated with tumour metastasis and poor clinical outcome. Both loss of E-cadherin at the cell membrane and a stabilizing mutation in CTNNB1 (beta-catenin gene) have been associated with ovarian, colorectal, hepatocellular and nonmelanoma skin cancer, such as squamous and basal cell carcinomas. Absence of E-cadherin may be caused by promoter hypermethylation of the E-cadherin gene (CDH1).
   Objectives To determine the role of E-cadherin promoter hypermethylation and CTNNB1 gene mutation in the aggressive behaviour of sebaceous gland carcinoma of the eyelid.
   Methods Thirty-six cases of sebaceous gland carcinoma were subjected to E-cadherin methylation-specific polymerase chain reaction and mutational analysis for the CTNNB1 gene. E-cadherin and beta-catenin staining was evaluated by immunohistochemistry.
   Results were correlated with the clinicopathological features of sebaceous gland carcinoma. Results Methylation of the E-cadherin promoter region was detected in 72% of eyelid sebaceous gland carcinoma cases and loss of E-cadherin immunostaining in 83%. E-cadherin promoter hypermethylation showed a significant association with the loss of membranous E-cadherin (P = 0.038) and it was of borderline significance with reduced disease-free survival (P = 0.05). It was also found to be associated with advanced age (73%), tumour size >= 2 cm (77%), orbital invasion (83%), lymph node metastasis (60%), tumour recurrence (60%) and poor histological differentiation (90%). DNA sequencing revealed no stabilizing beta-catenin gene mutation in sebaceous gland carcinoma. Loss of membranous beta-catenin was observed in 61% cases, which associated significantly with both E-cadherin promoter methylation (P = 0.0262) and loss of E-cadherin membranous localization (P = 0.0015).
   Conclusion Epigenetic inactivation of the E-cadherin gene causes loss of membrane-bound E-cadherin and could contribute to the reduced disease-free survival in eyelid sebaceous gland carcinoma. Mutations in the beta-catenin gene do not seem to be involved in the pathogenesis of eyelid sebaceous gland carcinoma.
C1 [Jayaraj, P.; Sen, S.; Kashyap, S.] All India Inst Med Sci, Dept Ocular Pathol, New Delhi 110029, India.
   [Sharma, A.] All India Inst Med Sci, Dept Ocular Microbiol, New Delhi, India.
   [Chosdol, K.] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.
   [Rai, A.] Natl Ctr Dis Control, Div Biochem & Biotechnol, New Delhi, India.
   [Pushker, N.; Bajaj, M. S.; Ghose, S.] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dept Ophthalmoplasty Serv, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; All India
   Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of
   Medical Sciences (AIIMS) New Delhi; National Centre for Disease Control
   (NCDC); All India Institute of Medical Sciences (AIIMS) New Delhi; Dr.
   Rajendra Prasad Centre for Ophthalmic Sciences
RP Sen, S (通讯作者)，All India Inst Med Sci, Dept Ocular Pathol, New Delhi 110029, India.
EM ssenop@rediffmail.com
RI Pushker, Neelam/LXV-5537-2024
OI chosdol, kunzang/0000-0002-7065-3395
FU CSIR (Council of Scientific and Industrial Research)
FX P.J. is grateful to the CSIR (Council of Scientific and Industrial
   Research) for providing a Senior Research Fellowship.
CR Abdi U, 1996, J Indian Med Assoc, V94, P405
   Abdi U, 1996, J INDIAN MED ASSOC, V94, P418
   Abdi U, 1996, J INDIAN MED ASSOC, V94, P416
   Ainbinder DJ, 2009, ARCH PATHOL LAB MED, V133, P1256, DOI 10.1043/1543-2165-133.8.1256
   Alsaad KO, 2007, J CLIN PATHOL, V60, P129, DOI 10.1136/jcp.2006.040337
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Chan AOO, 2003, GUT, V52, P502, DOI 10.1136/gut.52.4.502
   Chang HW, 2002, CANCER, V94, P386, DOI 10.1002/cncr.10211
   Chao AN, 2001, OPHTHALMOLOGY, V108, P1877, DOI 10.1016/S0161-6420(01)00719-9
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Chiles MC, 2003, MODERN PATHOL, V16, P1014, DOI 10.1097/01.MP.0000089779.35435.9D
   Doglioni C, 2003, AM J PATHOL, V163, P2277, DOI 10.1016/S0002-9440(10)63585-7
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Graff JR, 1998, CANCER RES, V58, P2063
   Graziano F, 2004, ANN ONCOL, V15, P489, DOI 10.1093/annonc/mdh108
   Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7
   Ho VH, 2007, ARCH OTOLARYNGOL, V133, P820, DOI 10.1001/archotol.133.8.820
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661
   Jayaraj P, 2011, BRIT J OPHTHALMOL, V95, P284, DOI 10.1136/bjo.2009.177204
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Kanazawa T, 2002, INT J CANCER, V102, P225, DOI 10.1002/ijc.10690
   Karam R, 2008, ONCOGENE, V27, P4255, DOI 10.1038/onc.2008.62
   Kase S, 2000, CLIN CANCER RES, V6, P4789
   Kazakov DV, 2009, AM J DERMATOPATH, V31, P248, DOI 10.1097/DAD.0b013e318198922a
   Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372
   Muqit MMK, 2004, EYE, V18, P49, DOI 10.1038/sj.eye.6700523
   Murao K, 2006, BRIT J DERMATOL, V155, P999, DOI 10.1111/j.1365-2133.2006.07487.x
   Ni C, 1982, Int Ophthalmol Clin, V22, P23, DOI 10.1097/00004397-198202210-00006
   Papadavid E, 2002, J PATHOL, V196, P154, DOI 10.1002/path.1019
   PIZARRO A, 1994, BRIT J CANCER, V69, P157, DOI 10.1038/bjc.1994.26
   Polakis P, 2000, GENE DEV, V14, P1837
   Saito T, 2003, CANCER-AM CANCER SOC, V97, P1002, DOI 10.1002/cncr.11157
   Sathyanarayana UG, 2007, CANCER LETT, V245, P112, DOI 10.1016/j.canlet.2005.12.042
   SOMMERS CL, 1994, CANCER RES, V54, P3544
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367
   Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R
   Young CH, 2010, MOL VIS, V16, P1047
NR 42
TC 14
Z9 17
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-0963
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD SEP
PY 2012
VL 167
IS 3
BP 583
EP 590
DI 10.1111/j.1365-2133.2012.10968.x
PG 8
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 996YN
UT WOS:000308130900020
PM 22458737
DA 2025-01-12
ER

PT J
AU Gillio-Tos, A
   Fiano, V
   Zugna, D
   Vizzini, L
   Pearce, N
   Delsedime, L
   Merletti, F
   Richiardi, L
AF Gillio-Tos, Anna
   Fiano, Valentina
   Zugna, Daniela
   Vizzini, Loredana
   Pearce, Neil
   Delsedime, Luisa
   Merletti, Franco
   Richiardi, Lorenzo
TI DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason
   score, and prostate cancer mortality: investigating causal relationships
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE DNA methylation; DNA methyltransferase 3b; Prostate cancer; Gleason
   score; Mortality; Causal relationship
ID SINGLE NUCLEOTIDE POLYMORPHISM; CPG ISLAND HYPERMETHYLATION; CELL
   LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; PROMOTER POLYMORPHISM;
   COLORECTAL-CANCER; GENETIC-VARIANTS; EPIGENETIC GENES; BREAST-CANCER;
   RISK
AB Aberrant DNA methylation plays a role in prostate cancer progression. We studied the relationships among DNA methyltransferase (DNMT) genotype, DNA methylation, Gleason score, and mortality in two cohorts of prostate cancer patients, previously reported with associations between DNA methylation in GSTP1, APC, and RUNX3 and prostate cancer mortality. Herein, we considered possible causal relationships between the studied variables, assuming that (1) DNMT activity affects tumor tissue methylation, (2) methylation status affects tumor morphology, and thus the Gleason score, and (3) DNA methylation affects mortality via Gleason score.
   The cohorts comprised 438 patients diagnosed at one Italian pathology ward before 1997, with DNA obtained from paraffin-embedded tumor tissues. The polymorphism rs406193 in the DNMT3b gene was assessed by allele discrimination in real-time PCR. According to the assumed causal model, we analyzed the effects of rs406193 (T carriers vs others) on the Gleason score without adjusting for gene methylation, and the effects of rs406193 on gene methylation and prostate cancer mortality without adjusting for Gleason score.
   We found no evidence of association between T carriers and the number of methylated genes. However, T carriers had reduced risk of a Gleason score 8+ (odds ratio = 0.57, 95 % CI 0.39-0.85), and a hazard ratio of 0.81 (0.61-1.09) of dying from prostate cancer, which would have been erroneously estimated of 0.93 if adjusted for Gleason score.
   These findings provide clues on the role of a DNMT3b SNP in prostate cancer progression and illustrate the importance of considering possible causal relationships in the analyses.
C1 [Gillio-Tos, Anna; Fiano, Valentina; Zugna, Daniela; Vizzini, Loredana; Merletti, Franco; Richiardi, Lorenzo] Univ Turin, Canc Epidemiol Unit, CERMS, I-10126 Turin, Italy.
   [Gillio-Tos, Anna; Fiano, Valentina; Zugna, Daniela; Vizzini, Loredana; Merletti, Franco; Richiardi, Lorenzo] Univ Turin, CPO Piemonte, I-10126 Turin, Italy.
   [Pearce, Neil; Merletti, Franco; Richiardi, Lorenzo] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand.
   [Pearce, Neil] Univ London London Sch Hyg & Trop Med, Fac Epidemiol & Publ Hlth, London WC1E 7HT, England.
   [Delsedime, Luisa] Molinette Mauriziano Hosp, Dept Pathol, Turin, Italy.
C3 University of Turin; University of Turin; Centro di Riferimento per
   Epidemiologia e la Prevenzione Oncologica in Piemonte; Massey
   University; University of London; London School of Hygiene & Tropical
   Medicine; A.O.U. Citta della Salute e della Scienza di Torino; AOU San
   Giovanni Battista-Molinette
RP Gillio-Tos, A (通讯作者)，Univ Turin, Canc Epidemiol Unit, CERMS, Via Santena 7, I-10126 Turin, Italy.
EM gilliotos.demarco@cpo.it
RI Dei Tos, Angelo/AAN-3244-2020; Pearce, Nicholas/B-5295-2009; richiardi,
   lorenzo/J-3480-2018
OI FIANO, VALENTINA/0000-0001-7978-372X; richiardi,
   lorenzo/0000-0003-0316-9402; Gillio-Tos, Anna/0000-0001-6553-5362;
   Pearce, Neil/0000-0002-9938-7852
FU Italian Association for Research on Cancer (AIRC); Compagnia San
   Paolo/Firms; Piedmont Region; EU [247642]; Master in Epidemiology,
   University of Turin; Compagnia di San Paolo; Health Research Council of
   New Zealand
FX The study was supported by the Italian Association for Research on
   Cancer (AIRC), the Compagnia San Paolo/Firms and the Piedmont Region.
   The research leading to these results has also received funding from the
   EU 7th Framework Programme under grant agreement number 247642, GEoCoDE.
   The work of Loredana Vizzini was partially supported by the Master in
   Epidemiology, University of Turin and Compagnia di San Paolo. The Centre
   for Public Health Research is supported by a Programme Grant from the
   Health Research Council of New Zealand.
CR Aung PP, 2005, ONCOL REP, V14, P1151
   Bastian PJ, 2004, EUR UROL, V46, P698, DOI 10.1016/j.eururo.2004.07.022
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   de Vogel S, 2009, CANCER EPIDEM BIOMAR, V18, P3086, DOI 10.1158/1055-9965.EPI-09-0289
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Ezzikouri S, 2009, INFECT GENET EVOL, V9, P877, DOI 10.1016/j.meegid.2009.05.012
   Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Jones JS, 2006, CANCER EPIDEM BIOMAR, V15, P886, DOI 10.1158/1055-9965.EPI-05-0644
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kaufman Jay S, 2004, Epidemiol Perspect Innov, V1, P4, DOI 10.1186/1742-5573-1-4
   Kim HJ, 2006, CANCER, V107, P1042, DOI 10.1002/cncr.22087
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lee SJ, 2005, CARCINOGENESIS, V26, P403, DOI 10.1093/carcin/bgh307
   Liu ZS, 2008, CANCER LETT, V268, P158, DOI 10.1016/j.canlet.2008.03.034
   Martin NE, 2011, CANCER J, V17, P429, DOI 10.1097/PPO.0b013e31823b042c
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Montgomery KG, 2004, BREAST CANCER RES, V6, pR390, DOI 10.1186/bcr807
   Park JY, 2010, CANCER CONTROL, V17, P245, DOI 10.1177/107327481001700405
   Petersen ML, 2006, EPIDEMIOLOGY, V17, P276, DOI 10.1097/01.ede.0000208475.99429.2d
   Phé V, 2010, BJU INT, V105, P1364, DOI 10.1111/j.1464-410X.2009.09167.x
   Relton CL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000356
   Richiardi L, 2009, J CLIN ONCOL, V27, P3161, DOI 10.1200/JCO.2008.18.2485
   Shen HB, 2002, CANCER RES, V62, P4992
   Singal R, 2005, ONCOL REP, V14, P569
   Troyer DA, 2009, CANCER EPIDEM BIOMAR, V18, P2717, DOI 10.1158/1055-9965.EPI-09-0068
   Wang L, 2004, INT J ONCOL, V25, P993
   Wu Y, 2007, WORLD J GASTROENTERO, V13, P6082, DOI 10.3748/wjg.13.6082
   Xing J, 2008, BRIT J CANCER, V98, P1716, DOI 10.1038/sj.bjc.6604343
NR 31
TC 7
Z9 9
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD SEP
PY 2012
VL 23
IS 9
BP 1549
EP 1555
DI 10.1007/s10552-012-0032-9
PG 7
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 987FD
UT WOS:000307401400015
PM 22810147
DA 2025-01-12
ER

PT J
AU Poage, GM
   Butler, RA
   Houseman, EA
   McClean, MD
   Nelson, HH
   Christensen, BC
   Marsit, CJ
   Kelsey, KT
AF Poage, Graham M.
   Butler, Rondi A.
   Houseman, E. Andres
   McClean, Michael D.
   Nelson, Heather H.
   Christensen, Brock C.
   Marsit, Carmen J.
   Kelsey, Karl T.
TI Identification of an Epigenetic Profile Classifier That Is Associated
   with Survival in Head and Neck Cancer
SO CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL-CARCINOMA; CLASS-I ANTIGEN; DNA METHYLATION PATTERNS;
   PROMOTER HYPERMETHYLATION; POOR-PROGNOSIS; ALDEHYDE DEHYDROGENASE;
   PROCESSING MACHINERY; CANDIDATE GENES; DOWN-REGULATION; BREAST-CANCER
AB Panels of prognostic biomarkers selected using candidate approaches often do not validate in independent populations, so additional strategies are needed to identify reliable classifiers. In this study, we used an array-based approach to measure DNA methylation and applied a novel method for grouping CpG dinucleotides according to well-characterized genomic sequence features. A hypermethylation profile among 13 CpG loci, characterized by polycomb group target genes, mammalian interspersed repeats, and transcription factor-binding sites (PcG/MIR/TFBS), was associated with reduced survival (HR, 3.98; P = 0.001) in patients with head and neck squamous cell carcinoma. This association was driven by CpGs associated with the TAP1 and ALDH3A1 genes, findings that were validated in an independent patient group (HR, 2.86; P = 0.04). Together, the data not only elucidate new potential targets for therapeutic intervention in head and neck cancer but also may aid in the identification of poor prognosis patients who may require more aggressive treatment regimens. Cancer Res; 72(11); 2728-37. (c) 2012 AACR.
C1 [Butler, Rondi A.; Houseman, E. Andres; Kelsey, Karl T.] Brown Univ, Dept Epidemiol, Providence, RI 02903 USA.
   [Poage, Graham M.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
   [Poage, Graham M.] Brown Univ, Dept Mol Pharmacol & Physiol, Providence, RI 02912 USA.
   [Kelsey, Karl T.] Brown Univ, Dept Pathol & Lab Med, Div Biol & Med, Providence, RI 02912 USA.
   [Houseman, E. Andres] Oregon State Univ, Dept Publ Hlth, Corvallis, OR 97331 USA.
   [McClean, Michael D.] Boston Univ, Dept Environm Hlth, Boston, MA 02215 USA.
   [Nelson, Heather H.] Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA.
   [Nelson, Heather H.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA.
   [Christensen, Brock C.; Marsit, Carmen J.] Dartmouth Coll, Giesel Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.
   [Christensen, Brock C.; Marsit, Carmen J.] Dartmouth Coll, Giesel Sch Med, Dept Community & Family Med, Hanover, NH 03755 USA.
C3 Brown University; University of Texas System; UTMD Anderson Cancer
   Center; Brown University; Brown University; Oregon State University;
   Boston University; University of Minnesota System; University of
   Minnesota Twin Cities; University of Minnesota System; University of
   Minnesota Twin Cities; Dartmouth College; Dartmouth College
RP Kelsey, KT (通讯作者)，Brown Univ, Dept Epidemiol, 70 Ship St,Box G-E4, Providence, RI 02903 USA.
EM Karl_Kelsey@Brown.edu
RI McClean, Michael/J-2934-2015; Christensen, Brock/B-8460-2009; Kelsey,
   Karl/I-1252-2014; Houseman, Eugene Andres/LXW-8656-2024
OI Nelson, Heather/0000-0003-1901-9513; McClean,
   Michael/0000-0002-3902-8823; Marsit, Carmen/0000-0003-4566-150X;
   Houseman, Eugene Andres/0000-0003-0703-1830
FU Flight Attendant Medical Research Institute; NIH [CA078609, CA100679]
FX This study was funded by the Flight Attendant Medical Research Institute
   (C.J. Marsit) and the NIH (grants CA078609, CA100679 to K.T. Kelsey).
CR Adelstein David J, 2009, Head Neck, V31, P1393, DOI 10.1002/hed.21269
   Afsar NA, 2010, BASIC CLIN PHARMACOL, V107, P570, DOI 10.1111/j.1742-7843.2009.00531.x
   Avissar M, 2009, CARCINOGENESIS, V30, P2059, DOI 10.1093/carcin/bgp277
   Bandoh N, 2010, ONCOL REP, V23, P933, DOI 10.3892/or_00000717
   Banh A, 2011, CLIN CANCER RES, V17, P7265, DOI 10.1158/1078-0432.CCR-11-0179
   BAYLIN SB, 2009, STEM CELL RES COMMUN, DOI DOI 10.3824/STEMBOOK.1.50.1
   Bennett KL, 2009, CANCER RES, V69, P9301, DOI 10.1158/0008-5472.CAN-09-3073
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Calmon MF, 2009, NEOPLASIA, V11, P1329, DOI 10.1593/neo.91110
   Chang KP, 2010, PROTEOMICS, V10, P2644, DOI 10.1002/pmic.200900620
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   Crabb DW, 2004, P NUTR SOC, V63, P49, DOI 10.1079/PNS2003327
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   Estécio MRH, 2010, GENOME RES, V20, P1369, DOI 10.1101/gr.107318.110
   Estilo CL, 2003, CLIN CANCER RES, V9, P2300
   Furniss CS, 2007, INT J CANCER, V120, P2386, DOI 10.1002/ijc.22633
   Ghosh A, 2010, CANCER SCI, V101, P1511, DOI 10.1111/j.1349-7006.2010.01551.x
   Guibal FC, 2002, J BIOL CHEM, V277, P218, DOI 10.1074/jbc.M108476200
   Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4
   Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528
   Hoque MO, 2008, J UROLOGY, V179, P743, DOI 10.1016/j.juro.2007.09.019
   Huang KH, 2009, CLIN CANCER RES, V15, P4174, DOI 10.1158/1078-0432.CCR-08-2929
   Kong KL, 2010, CANCER RES, V70, P8832, DOI 10.1158/0008-5472.CAN-10-0779
   Langevin SM, 2011, EPIGENETICS-US, V6, P908, DOI 10.4161/epi.6.7.16431
   Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Leibowitz MS, 2011, CANCER IMMUNOL IMMUN, V60, P525, DOI 10.1007/s00262-010-0961-7
   Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946
   Long NK, 2008, ORAL ONCOL, V44, P1052, DOI 10.1016/j.oraloncology.2008.02.004
   López-Albaitero A, 2006, J IMMUNOL, V176, P3402, DOI 10.4049/jimmunol.176.6.3402
   Lou YM, 2005, CANCER RES, V65, P7926, DOI 10.1158/0008-5472.CAN-04-3977
   Marsit CJ, 2008, CANCER-AM CANCER SOC, V113, P1566, DOI 10.1002/cncr.23770
   Marsit CJ, 2006, INT J CANCER, V119, P1761, DOI 10.1002/ijc.22051
   Marsit CJ, 2009, CARCINOGENESIS, V30, P416, DOI 10.1093/carcin/bgp006
   Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256
   Meissner M, 2005, CLIN CANCER RES, V11, P2552, DOI 10.1158/1078-0432.CCR-04-2146
   Misawa K, 2008, CLIN CANCER RES, V14, P7604, DOI 10.1158/1078-0432.CCR-07-4673
   Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007
   Nie L, 2011, CELL RES, V21, P754, DOI 10.1038/cr.2010.165
   Ogino T, 2006, CANCER RES, V66, P9281, DOI 10.1158/0008-5472.CAN-06-0488
   Pappa A, 2005, J BIOL CHEM, V280, P27998, DOI 10.1074/jbc.M503698200
   Poage GM, 2011, CLIN CANCER RES, V17, P3579, DOI 10.1158/1078-0432.CCR-11-0044
   Puri SK, 2005, AM J OTOLARYNG, V26, P12, DOI 10.1016/j.amjoto.2004.06.007
   Rosas SLB, 2001, CANCER RES, V61, P939
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Taylor KH, 2007, CANCER RES, V67, P2617, DOI 10.1158/0008-5472.CAN-06-3993
   Vlatkovic N, 2011, CANCER-AM CANCER SOC, V117, P2939, DOI 10.1002/cncr.25864
   Wang J, 2004, CLIN CANCER RES, V10, P6119, DOI 10.1158/1078-0432.CCR-04-0652
   Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335
NR 53
TC 32
Z9 33
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2012
VL 72
IS 11
BP 2728
EP 2737
DI 10.1158/0008-5472.CAN-11-4121-T
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 986NJ
UT WOS:000307348000006
PM 22507853
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Lamar, JM
   Stern, P
   Liu, H
   Schindler, JW
   Jiang, ZG
   Hynes, RO
AF Lamar, John M.
   Stern, Patrick
   Liu, Hui
   Schindler, Jeffrey W.
   Jiang, Zhi-Gang
   Hynes, Richard O.
TI The Hippo pathway target, YAP, promotes metastasis through its
   TEAD-interaction domain
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID YES-ASSOCIATED PROTEIN; ORGAN SIZE CONTROL; TUMOR-SUPPRESSOR;
   TRANSCRIPTIONAL COACTIVATOR; CONTACT INHIBITION; SIGNALING-PATHWAY;
   CANDIDATE ONCOGENE; CELL-PROLIFERATION; ALPHA-CATENIN; GROWTH
AB The transcriptional coactivator Yes-associated protein (YAP) is a major regulator of organ size and proliferation in vertebrates. As such, YAP can act as an oncogene in several tissue types if its activity is increased aberrantly. Although no activating mutations in the yap1 gene have been identified in human cancer, yap1 is located on the 11q22 amplicon, which is amplified in several human tumors. In addition, mutations or epigenetic silencing of members of the Hippo pathway, which represses YAP function, have been identified in human cancers. Here we demonstrate that, in addition to increasing tumor growth, increased YAP activity is potently prometastatic in breast cancer and melanoma cells. Using a Luminex-based approach to multiplex in vivo assays, we determined that the domain of YAP that interacts with the TEAD/TEF family of transcription factors but not the WW domains or PDZ-binding motif, is essential for YAP-mediated tumor growth and metastasis. We further demonstrate that, through its TEAD-interaction domain, YAP enhances multiple processes known to be important for tumor progression and metastasis, including cellular proliferation, transformation, migration, and invasion. Finally, we found that the metastatic potential of breast cancer and melanoma cells is strongly correlated with increased TEAD transcriptional activity. Together, our results suggest that increased YAP/TEAD activity plays a causal role in cancer progression and metastasis.
C1 [Lamar, John M.; Stern, Patrick; Liu, Hui; Schindler, Jeffrey W.; Jiang, Zhi-Gang; Hynes, Richard O.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
   [Liu, Hui; Schindler, Jeffrey W.; Hynes, Richard O.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
   [Jiang, Zhi-Gang; Hynes, Richard O.] MIT, Dept Biol, Cambridge, MA 02139 USA.
C3 Howard Hughes Medical Institute; Massachusetts Institute of Technology
   (MIT); Massachusetts Institute of Technology (MIT); Massachusetts
   Institute of Technology (MIT)
RP Hynes, RO (通讯作者)，MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.
EM rohynes@mit.edu
RI Lamar, John/R-5053-2019
FU Howard Hughes Medical Institute; National Institutes of Health (NIH);
   Integrative Center Biology Program; Tumor Microenvironment Network;
   Ludwig Center for Molecular Oncology; National Research and Service
   Award from the NIH; National Cancer Center; Ludwig Center for Molecular
   Oncology at the Massachusetts Institute of Technology
FX We thank Denise Crowley, Kwabena Badu-Nkansah, Supriya Gupta, Robb
   Onofrio, Yves Boie, Melissa Parkin, and Charlie Whittaker for
   experimental advice and assistance; Kun-Liang Guan, Fred Miller, and
   Iain Farrance for reagents; and Myriam Labelle for critical reading of
   the manuscript. This work was supported by the Howard Hughes Medical
   Institute, the National Institutes of Health (NIH), the Integrative
   Center Biology Program, the Tumor Microenvironment Network, and the
   Ludwig Center for Molecular Oncology. J.M.L. was supported by a National
   Research and Service Award from the NIH and a postdoctoral fellowship
   from the National Cancer Center. J.W.S. and H.L were supported by
   fellowships from the Ludwig Center for Molecular Oncology at the
   Massachusetts Institute of Technology.
CR ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Bao YJ, 2011, J BIOCHEM, V149, P361, DOI 10.1093/jb/mvr021
   Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1
   Cai J, 2010, GENE DEV, V24, P2383, DOI 10.1101/gad.1978810
   Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Fellmann C, 2011, MOL CELL, V41, P733, DOI 10.1016/j.molcel.2011.02.008
   Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379
   Ge L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027529
   Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242
   Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200
   Hill VK, 2011, EPIGENETICS-US, V6, P326, DOI 10.4161/epi.6.3.14404
   Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467
   Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108
   Lam-Himlin DM, 2006, J GASTROINTEST CANC, V37, P103, DOI 10.1007/s12029-007-0010-8
   Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019
   Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107
   Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063
   Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022
   Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810
   Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434
   Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008
   Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879
   Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254
   Neto-Silva RM, 2010, DEV CELL, V19, P507, DOI 10.1016/j.devcel.2010.09.009
   Oka T, 2009, GENES CELLS, V14, P607, DOI 10.1111/j.1365-2443.2009.01292.x
   Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151
   Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011
   Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031
   Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823
   Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107
   Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012
   Stern P, 2008, P NATL ACAD SCI USA, V105, P13895, DOI 10.1073/pnas.0806907105
   Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008
   Tamm C, 2011, J CELL SCI, V124, P1136, DOI 10.1242/jcs.075796
   Tufail R, 2012, BREAST CANCER RES TR, V131, P743, DOI 10.1007/s10549-011-1435-0
   Vitolol MI, 2007, CANCER BIOL THER, V6, P856, DOI 10.4161/cbt.6.6.4241
   Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987
   Wang KN, 2009, BIOCHEM CELL BIOL, V87, P77, DOI 10.1139/O08-114
   Wang P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024288
   Wang XD, 2012, EUR J CANCER, V48, P1227, DOI 10.1016/j.ejca.2011.10.001
   Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x
   Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007
   Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495
   Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108
   Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030
   Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108
   Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993
   Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015
   Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8
   Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592
   Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408
   Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907
   Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111
   Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210
   Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810
   Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997
   Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026
   Ziosi M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001140
NR 64
TC 478
Z9 554
U1 1
U2 77
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 11
PY 2012
VL 109
IS 37
BP E2441
EP E2450
DI 10.1073/pnas.1212021109
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 012AP
UT WOS:000309208000008
PM 22891335
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kuscu, C
   Evensen, N
   Kim, D
   Hu, YJ
   Zucker, S
   Cao, J
AF Kuscu, Cem
   Evensen, Nikki
   Kim, Deborah
   Hu, You-Jun
   Zucker, Stanley
   Cao, Jian
TI Transcriptional and Epigenetic Regulation of <i>KIAA1199</i> Gene
   Expression in Human Breast Cancer
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ANALYSIS; NF-KAPPA-B; DNA METHYLATION; PROMOTER
   HYPOMETHYLATION; GC BOX; CARCINOGENESIS; IDENTIFICATION; DEMETHYLATION;
   REPRESSION; DISEASE
AB Emerging evidence has demonstrated that upregulated expression of KIAA1199 in human cancer bodes for poor survival. The regulatory mechanism controlling KIAA1199 expression in cancer remains to be characterized. In the present study, we have isolated and characterized the human KIAA1199 promoter in terms of regulation of KIAA1199 gene expression. A 3.3 kb fragment of human genomic DNA containing the 5'-flanking sequence of the KIAA1199 gene possesses both suppressive and activating elements. Employing a deletion mutagenesis approach, a 1.4 kb proximal region was defined as the basic KIAA1199 promoter containing a TATA-box close to the transcription start site. A combination of 5'-primer extension study with 5'RACE DNA sequencing analysis revealed one major transcription start site that is utilized in the human KIAA1199 gene. Bioinformatics analysis suggested that the 1.4 kb KIAA1199 promoter contains putative activating regulatory elements, including activator protein-1(AP-1), Twist-1, and NF-kappa B sites. Sequential deletion and site-direct mutagenesis analysis demonstrated that the AP-1 and distal NF-kappa B sites are required for KIAA1199 gene expression. Further analyses using an electrophoretic mobility-shift assay and chromatin immunoprecipitation confirmed the requirement of these cis- and trans-acting elements in controlling KIAA1199 gene expression. Finally, we found that upregulated KIAA1199 expression in human breast cancer specimens correlated with hypomethylation of the regulatory region. Involvement of DNA methylation in regulation of KIAA1199 expression was recapitulated in human breast cancer cell lines. Taken together, our study unraveled the regulatory mechanisms controlling KIAA1199 gene expression in human cancer.
C1 [Kuscu, Cem; Evensen, Nikki; Kim, Deborah; Cao, Jian] SUNY Stony Brook, Dept Med Canc Prevent, Stony Brook, NY 11794 USA.
   [Hu, You-Jun; Cao, Jian] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.
   [Zucker, Stanley] SUNY Stony Brook, Dept Med Hematol & Oncol, Stony Brook, NY 11794 USA.
   [Zucker, Stanley] Vet Affairs Med Ctr, Dept Res, Northport, NY USA.
C3 State University of New York (SUNY) System; Stony Brook University;
   State University of New York (SUNY) System; Stony Brook University;
   State University of New York (SUNY) System; Stony Brook University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Kuscu, C (通讯作者)，SUNY Stony Brook, Dept Med Canc Prevent, Stony Brook, NY 11794 USA.
EM jian.cao@sunysb.edu
RI Hu, Youjun/B-7509-2015
OI Kim, Deborah/0000-0002-9388-5391; KUSCU, CEM/0000-0001-7154-6762
FU National Institutes of Health/National Cancer Institute [R01CA113553,
   R01CA166936]; Carol Baldwin Breast Cancer Foundation; Department of
   Veterans Affairs
FX This study was supported in part by National Institutes of
   Health/National Cancer Institute grants (R01CA113553 and R01CA166936)
   and the Carol Baldwin Breast Cancer Foundation (to JC); and a Merit
   Review grant from the Department of Veterans Affairs (to SZ). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. No additional
   external funding received for this study.
CR Abe S, 2003, J HUM GENET, V48, P564, DOI 10.1007/s10038-003-0079-2
   Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603
   Birkenkamp-Demtroder K, 2011, BRIT J CANCER, V105, P552, DOI 10.1038/bjc.2011.268
   Broadbent S, 2010, J MICROBIOL METH, V81, P256, DOI 10.1016/j.mimet.2010.03.021
   Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789
   D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fatemi M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni180
   Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144
   Grützmann R, 2004, NEOPLASIA, V6, P611, DOI 10.1593/neo.04295
   Guo JH, 2006, FEBS LETT, V580, P581, DOI 10.1016/j.febslet.2005.12.076
   HANADA M, 1993, BLOOD, V82, P1820
   Harbeck N, 2008, J CLIN ONCOL, V26, P5036, DOI 10.1200/JCO.2007.14.1697
   Hasegawa H, 2009, EXP CELL RES, V315, P1384, DOI 10.1016/j.yexcr.2009.02.019
   He QY, 2006, BIOINFORMATICS, V22, P2189, DOI 10.1093/bioinformatics/btl123
   Honda T, 2004, BRIT J CANCER, V90, P838, DOI 10.1038/sj.bjc.6601600
   Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312
   Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358
   Jun HJ, 2009, CANCER RES, V69, P2180, DOI 10.1158/0008-5472.CAN-08-3351
   Kawaji H, 2006, NUCLEIC ACIDS RES, V34, pD632, DOI 10.1093/nar/gkj034
   Ko YG, 2010, PLACENTA, V31, P969, DOI 10.1016/j.placenta.2010.08.010
   Kornberg RD, 2007, P NATL ACAD SCI USA, V104, P12955, DOI 10.1073/pnas.0704138104
   Matsuzaki S, 2009, ANN SURG ONCOL, V16, P2042, DOI 10.1245/s10434-009-0469-6
   Michishita E, 2006, CANCER LETT, V239, P71, DOI 10.1016/j.canlet.2005.07.028
   Miyajima A, 2009, DRUG METAB PHARMACOK, V24, P269, DOI 10.2133/dmpk.24.269
   Muckenfuss H, 2007, NUCLEIC ACIDS RES, V35, P3784, DOI 10.1093/nar/gkm340
   Nakayama M, 2002, GENOME RES, V12, P1773, DOI 10.1101/gr.406902
   Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340
   Ponticos M, 2009, NUCLEIC ACIDS RES, V37, P5378, DOI 10.1093/nar/gkp544
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Rupon JW, 2006, P NATL ACAD SCI USA, V103, P6617, DOI 10.1073/pnas.0509322103
   Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267
   SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100
   Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091
   Smith IM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004961
   SUZUKI S, 1995, MOL ENDOCRINOL, V9, P1288, DOI 10.1210/me.9.10.1288
   Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270
   Vaiopoulos AG, 2010, INT J BIOCHEM CELL B, V42, P1061, DOI 10.1016/j.biocel.2010.03.018
   WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136
   Watt PM, 2000, GENE CHROMOSOME CANC, V29, P371, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1050>3.0.CO;2-Y
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Zhou H, 2001, ONCOGENE, V20, P6009, DOI 10.1038/sj.onc.1204830
NR 47
TC 53
Z9 58
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 6
PY 2012
VL 7
IS 9
AR e44661
DI 10.1371/journal.pone.0044661
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 001KC
UT WOS:000308458400102
PM 22970280
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Englert, NA
   Turesky, RJ
   Han, WG
   Bessette, EE
   Spivack, SD
   Caggana, M
   Spink, DC
   Spink, BC
AF Englert, Neal A.
   Turesky, Robert J.
   Han, Weiguo
   Bessette, Erin E.
   Spivack, Simon D.
   Caggana, Michele
   Spink, David C.
   Spink, Barbara C.
TI Genetic and epigenetic regulation of <i>AHR</i> gene expression in MCF-7
   breast cancer cells: Role of the proximal promoter GC-rich region
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Aryl hydrocarbon receptor; Long-term estrogen exposure; Epigenetic;
   (GGGGC)(n) repeat polymorphism; Guanine-quadruplex;
   2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
ID ARYL-HYDROCARBON RECEPTOR; EPITHELIAL-CELLS; G-QUADRUPLEXES;
   DNA-BINDING; TRANSCRIPTION FACTORS; METABOLIC-ACTIVATION; CYTOCHROME
   P4501A1; MASS-SPECTROMETRY; DIOXIN RECEPTOR; HISTONE H3
AB The aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, contributes to carcinogenesis through its role in the regulation of cytochrome P450 1 (CYP1)-catalyzed metabolism of carcinogens. Here, we investigated genetic and epigenetic mechanisms that affect AhR expression. Analyses of the human AHR proximal promoter in MCF-7 human breast cancer cells using luciferase assays and electrophoretic mobility shift assays revealed multiple specificity protein (Sp) 1 binding sequences that are transcriptional activators in vitro. The regulation of AhR expression was evaluated in long-term estrogen exposed (LTEE) MCF-7 cells, which showed increased AhR expression, enhanced CYP1 inducibility, and increased capacity to form DNA adducts when exposed to the dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. The increased AhR expression in LTEE cells was found not to result from increased mRNA stability, differential RNA processing, or decreased DNA methylation. Analysis of the AHR proximal promoter region using chromatin immunoprecipitation confirmed that enhanced expression of AhR in LTEE cells involves changes in histone modifications, notably decreased trimethylation of histone 3, lysine 27. Upon further examination of the GC-rich Sp1-binding region, we confirmed that it contains a polymorphic (GGGGC)(n), repeat. In a population of newborns from New York State, the allele frequency of (GGGGC)(n) was n = 4 > 5 >> 6, 2. Circular dichroism spectroscopy revealed the ability of sequences of this GC-rich region to form guanine-quadruplex structures in vitro. These studies revealed multiple levels at which AhR expression may be controlled, and offer additional insights into mechanisms regulating AhR expression that can ultimately impact carcinogenesis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Englert, Neal A.; Turesky, Robert J.; Bessette, Erin E.; Caggana, Michele; Spink, David C.; Spink, Barbara C.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.
   [Englert, Neal A.; Turesky, Robert J.; Spink, David C.] SUNY Albany, Dept Environm Hlth Sci, Sch Publ Hlth, Albany, NY 12201 USA.
   [Han, Weiguo; Spivack, Simon D.] Albert Einstein Coll Med, Div Pulm Med, Bronx, NY 10461 USA.
C3 Wadsworth Center; State University of New York (SUNY) System; State
   University of New York (SUNY) System; University at Albany, SUNY;
   Yeshiva University; Montefiore Medical Center; Albert Einstein College
   of Medicine
RP Spink, DC (通讯作者)，New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.
EM spink@wadsworth.org
FU National Institutes of Health [R01 CA081243, R01 CA122320, R01 CA106186,
   R21 CA104812]
FX This work was supported by National Institutes of Health grants R01
   CA081243 (to DCS), R01 CA122320 (to RJT), R01 CA106186 (to SDS) and R21
   CA104812 (to SDS). The authors gratefully acknowledge use of the
   Wadsworth Center's Tissue Culture Facility and the Biochemistry and
   Applied Genomic Technologies Core Facilities. We thank our Wadsworth
   Center colleagues for the following DNA samples: from PANC-1 and HEK293
   cells, Dr. Erasmus Schneider; from A549 cells, Dr. Xinxin Ding; and from
   NCI-H23 and NCI-H292 lung cancer cell lines, and four leukemia cell
   lines, Dr. Noel Espina. DNA from A2780 and HOSE-1 cells was a kind gift
   of Dr. Gareth Owen of the Pontifical Catholic University of Chile
   (Santiago, Chile). The AHR promoter-luciferase reporter plasmid
   pGL3-hAhRP was a kind gift from Drs. Sandra Wolff and Josef Abel of the
   Medical Institute of Environmental Hygiene at the
   Heinrich-Heine-University, Dusseldorf, Germany.
CR Badia E, 2000, CANCER RES, V60, P4130
   Bessette EE, 2009, ANAL CHEM, V81, P809, DOI 10.1021/ac802096p
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Clamp A, 2002, LANCET ONCOL, V3, P611, DOI 10.1016/S1470-2045(02)00875-6
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Crofts FG, 1998, CARCINOGENESIS, V19, P1969, DOI 10.1093/carcin/19.11.1969
   Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z
   Englert NA, 2011, J STEROID BIOCHEM, V123, P140, DOI 10.1016/j.jsbmb.2010.12.010
   Fitzgerald CT, 1998, DNA CELL BIOL, V17, P811, DOI 10.1089/dna.1998.17.811
   Frericks M, 2007, TOXICOL APPL PHARM, V220, P320, DOI 10.1016/j.taap.2007.01.014
   Frey UH, 2008, NAT PROTOC, V3, P1312, DOI 10.1038/nprot.2008.112
   Fukushima-Uesaka Hiromi, 2004, Drug Metab Pharmacokinet, V19, P320, DOI 10.2133/dmpk.19.320
   Garrison PM, 2000, ARCH BIOCHEM BIOPHYS, V374, P161, DOI 10.1006/abbi.1999.1620
   Garrison PM, 2000, J BIOCHEM MOL TOXIC, V14, P1, DOI 10.1002/(SICI)1099-0461(2000)14:1<1::AID-JBT1>3.0.CO;2-4
   Gregory RI, 2001, MOL CELL BIOL, V21, P5426, DOI 10.1128/MCB.21.16.5426-5436.2001
   Gu D, 2012, CARCINOGENESIS, V33, P124, DOI 10.1093/carcin/bgr252
   Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519
   Han WG, 2006, ANAL BIOCHEM, V355, P50, DOI 10.1016/j.ab.2006.05.010
   Harper PA, 2006, BIOCHEM PHARMACOL, V72, P267, DOI 10.1016/j.bcp.2006.01.007
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Hubbard TJP, 2007, NUCLEIC ACIDS RES, V35, pD610, DOI 10.1093/nar/gkl996
   Huppert JL, 2007, NUCLEIC ACIDS RES, V35, P406, DOI 10.1093/nar/gkl1057
   Kikin O, 2006, NUCLEIC ACIDS RES, V34, pW676, DOI 10.1093/nar/gkl253
   KLEMAN MI, 1992, CARCINOGENESIS, V13, P1619, DOI 10.1093/carcin/13.9.1619
   Lew A, 2000, P NATL ACAD SCI USA, V97, P12508, DOI 10.1073/pnas.97.23.12508
   Liu WH, 2002, BIOCHEM BIOPH RES CO, V294, P347, DOI 10.1016/S0006-291X(02)00478-3
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432
   Mulero-Navarro S, 2006, CARCINOGENESIS, V27, P1099, DOI 10.1093/carcin/bgi344
   Nauwelaers G, 2011, CHEM RES TOXICOL, V24, P913, DOI 10.1021/tx200091y
   Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X
   Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E
   Ochsner SA, 2009, CANCER RES, V69, P23, DOI 10.1158/0008-5472.CAN-08-3492
   Palumbo SL, 2008, NUCLEIC ACIDS RES, V36, P1755, DOI 10.1093/nar/gkm1069
   Paramasivan S, 2007, METHODS, V43, P324, DOI 10.1016/j.ymeth.2007.02.009
   Patel DJ, 2007, NUCLEIC ACIDS RES, V35, P7429, DOI 10.1093/nar/gkm711
   Racky J, 2004, ARCH BIOCHEM BIOPHYS, V421, P91, DOI 10.1016/j.abb.2003.10.005
   Russo J, 2003, J STEROID BIOCHEM, V87, P1, DOI 10.1016/S0960-0760(03)00390-X
   SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782
   Sinha R, 2000, JNCI-J NATL CANCER I, V92, P1352, DOI 10.1093/jnci/92.16.1352
   Spink BC, 2009, TOXICOL APPL PHARM, V240, P355, DOI 10.1016/j.taap.2009.07.013
   Spink BC, 1998, J CELL BIOCHEM, V70, P289, DOI 10.1002/(SICI)1097-4644(19980901)70:3<289::AID-JCB1>3.0.CO;2-J
   Spink BC, MOL CARCINO IN PRESS
   Spink DC, 1998, CARCINOGENESIS, V19, P291, DOI 10.1093/carcin/19.2.291
   Spink DC, 2003, CARCINOGENESIS, V24, P1941, DOI 10.1093/carcin/bgg162
   Sun D, 2008, MOL CANCER THER, V7, P880, DOI 10.1158/1535-7163.MCT-07-2119
   Svotelis A, 2009, METHODS MOL BIOL, V543, P243, DOI 10.1007/978-1-60327-015-1_16
   Thomas RD, 2006, CHEM-BIOL INTERACT, V160, P204, DOI 10.1016/j.cbi.2006.01.007
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103
   Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238
   Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716
   Xue WL, 2005, TOXICOL APPL PHARM, V206, P73, DOI 10.1016/j.taap.2004.11.006
   Zhang ZZ, 2009, BIOTECHNIQUES, V47, P775, DOI 10.2144/000113203
NR 57
TC 29
Z9 38
U1 1
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD SEP 1
PY 2012
VL 84
IS 5
BP 722
EP 735
DI 10.1016/j.bcp.2012.06.013
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 987RS
UT WOS:000307435700015
PM 22728919
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Toor, AA
   Payne, KK
   Chung, HM
   Sabo, RT
   Hazlett, AF
   Kmieciak, M
   Sanford, K
   Williams, DC
   Clark, WB
   Roberts, CH
   McCarty, JM
   Manjili, MH
AF Toor, Amir A.
   Payne, Kyle K.
   Chung, Harold M.
   Sabo, Roy T.
   Hazlett, Allison F.
   Kmieciak, Maciej
   Sanford, Kimberly
   Williams, David C.
   Clark, William B.
   Roberts, Catherine H.
   McCarty, John M.
   Manjili, Masoud H.
TI Epigenetic induction of adaptive immune response in multiple myeloma:
   sequential azacitidine and lenalidomide generate cancer testis
   antigen-specific cellular immunity
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE multiple myeloma; epigenetic induction; cancer testis antigens; adaptive
   immunity
ID VERSUS-HOST-DISEASE; IMMUNOTHERAPEUTIC IMPLICATIONS; T-CELLS;
   ANTIBODY-RESPONSES; BREAST-CANCER; EXPRESSION; METHYLATION;
   TRANSPLANTATION; THALIDOMIDE; MELANOMA
AB Patients with multiple myeloma (MM) undergoing high dose therapy and autologous stem cell transplantation (SCT) remain at risk for disease progression. Induction of the expression of highly immunogenic cancer testis antigens (CTA) in malignant plasma cells in MM patients may trigger a protective immune response following SCT. We initiated a phase II clinical trial of the DNA hypomethylating agent, azacitidine (Aza) administered sequentially with lenalidomide (Rev) in patients with MM. Three cycles of Aza and Rev were administered and autologous lymphocytes were collected following the 2nd and 3rd cycles of Aza-Rev and cryopreserved. Subsequent stem cell mobilization was followed by high-dose melphalan and SCT. Autologous lymphocyte infusion (ALI) was performed in the second month following transplantation. Fourteen patients have completed the investigational therapy; autologous lymphocytes were collected from all of the patients. Thirteen patients have successfully completed SCT and 11 have undergone ALI. Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT. Epigenetic induction of an adaptive immune response to cancer testis antigens is safe and feasible in MM patients undergoing SCT.
C1 [Toor, Amir A.; Chung, Harold M.; Hazlett, Allison F.; Clark, William B.; Roberts, Catherine H.; McCarty, John M.] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, Bone Marrow Transplant Program, Richmond, VA 23298 USA.
   [Payne, Kyle K.; Kmieciak, Maciej; Manjili, Masoud H.] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Microbiol & Immunol, Richmond, VA 23298 USA.
   [Sabo, Roy T.] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Biostat, Richmond, VA 23298 USA.
   [Sanford, Kimberly; Williams, David C.] Virginia Commonwealth Univ, Massey Canc Ctr, Dept Pathol, Richmond, VA 23298 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University; Virginia Commonwealth University
RP Toor, AA (通讯作者)，Virginia Commonwealth Univ, Massey Canc Ctr, Dept Internal Med, Bone Marrow Transplant Program, 1300 E Marshall St, Richmond, VA 23298 USA.
EM atoor@vcu.edu; mmanjili@vcu.edu
RI Payne, Kyle/AAL-6614-2020; Manjili, Masoud/J-5679-2016; Toor,
   Amir/GNM-9504-2022
OI Payne, Kyle/0000-0002-6531-9835; Toor, Amir Ahmed/0000-0001-5317-8433
FU Celgene Corporation; VCU Massey Cancer Center; Commonwealth Foundation
   for Cancer Research
FX The authors gratefully acknowledge the contribution of the nurses,
   transplant coordinators, pharmacists, nurse practitioners, and
   physician's assistants in the BMT programme at VCU, particularly Mr.
   Richard Edwards PA-C and Ms. Christina McLaughlin in the VCU stem cell
   laboratory and Ms. Jennie Anderson in therapeutic apheresis. We also
   acknowledge Dr. Kevin Hogan for his critical review of our manuscript
   and Ms. Cheryl Jacocks-Terrell for help in preparing the manuscript. We
   gratefully acknowledge research support and the funding of this clinical
   trial by Celgene Corporation. We also thank VCU Massey Cancer Center and
   the Commonwealth Foundation for Cancer Research for support.
CR Ascierto ML, 2012, BREAST CANCER RES TR, V131, P871, DOI 10.1007/s10549-011-1470-x
   Atanackovic D, 2007, BLOOD, V109, P1103, DOI 10.1182/blood-2006-04-014480
   Bao L, 2011, CANCER IMMUNOL IMMUN, V60, P1299, DOI 10.1007/s00262-011-1037-z
   Barbaro ADL, 2008, INT IMMUNOL, V20, P1457, DOI 10.1093/intimm/dxn103
   Barlogie B, 2006, NEW ENGL J MED, V354, P1021, DOI 10.1056/NEJMoa053583
   Bellucci R, 2005, BLOOD, V105, P3945, DOI 10.1182/blood-2004-11-4463
   Bellucci R, 2004, BLOOD, V103, P656, DOI 10.1182/blood-2003-07-2559
   Chim CS, 2007, J CLIN PATHOL, V60, P664, DOI 10.1136/jcp.2006.038331
   Condomines M, 2007, J IMMUNOL, V178, P3307, DOI 10.4049/jimmunol.178.5.3307
   Coral S, 2006, J CELL PHYSIOL, V207, P58, DOI 10.1002/jcp.20540
   Coral S, 2002, CLIN CANCER RES, V8, P2690
   Corral LG, 1999, J IMMUNOL, V163, P380
   Cruz CR, 2011, CLIN CANCER RES, V17, P7058, DOI 10.1158/1078-0432.CCR-11-1873
   Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210
   Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284
   Fonsatti E, 2007, CLIN CANCER RES, V13, P3333, DOI 10.1158/1078-0432.CCR-06-3091
   Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474
   Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020
   Hayashi T, 2005, BRIT J HAEMATOL, V128, P192, DOI 10.1111/j.1365-2141.2004.05286.x
   Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105
   Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251
   Jungbluth AA, 2005, BLOOD, V106, P167, DOI 10.1182/blood-2004-12-4931
   Kiziltepe T, 2007, MOL CANCER THER, V6, P1718, DOI 10.1158/1535-7163.MCT-07-0010
   Klebanoff CA, 2005, TRENDS IMMUNOL, V26, P111, DOI 10.1016/j.it.2004.12.003
   Kmieciak M, 2011, J IMMUNOL, V187, P708, DOI 10.4049/jimmunol.1100502
   Kmieciak M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-35
   LeBlanc R, 2004, BLOOD, V103, P1787, DOI 10.1182/blood-2003-02-0361
   LECOUTRE B, 1995, STAT MED, V14, P1057, DOI 10.1002/sim.4780140924
   Lim SY, 2001, CANCER DETECT PREV, V25, P470
   Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349
   McLarnon A, 2010, HAEMATOL-HEMATOL J, V95, P1572, DOI 10.3324/haematol.2009.019539
   Meklat F, 2007, BRIT J HAEMATOL, V136, P769, DOI 10.1111/j.1365-2141.2006.06484.x
   Miklos DB, 2005, BLOOD, V105, P2973, DOI 10.1182/blood-2004-09-3660
   Moreno-Bost A, 2011, CYTOTHERAPY, V13, P618, DOI 10.3109/14653249.2010.529893
   Natsume A, 2008, INT J CANCER, V122, P2542, DOI 10.1002/ijc.23407
   Nojima M, 2009, CLIN CANCER RES, V15, P4356, DOI 10.1158/1078-0432.CCR-08-3336
   Rapoport AP, 2009, CLIN CANCER RES, V15, P4499, DOI 10.1158/1078-0432.CCR-09-0418
   Rapoport AP, 2005, NAT MED, V11, P1230, DOI 10.1038/nm1310
   Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Sloand EM, 2000, BLOOD, V95, P2269, DOI 10.1182/blood.V95.7.2269.007k37_2269_2274
   Tatetsu H, 2007, CANCER RES, V67, P5328, DOI 10.1158/0008-5472.CAN-06-4265
   van Rhee F, 2005, BLOOD, V105, P3939, DOI 10.1182/blood-2004-09-3707
   Wang ZQ, 2003, BLOOD, V101, P955, DOI 10.1182/blood-2002-06-1930
NR 44
TC 37
Z9 47
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD SEP
PY 2012
VL 158
IS 6
BP 700
EP 711
DI 10.1111/j.1365-2141.2012.09225.x
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 995TU
UT WOS:000308036600005
PM 22816680
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Dasgupta, C
   Chen, M
   Zhang, HT
   Yang, SM
   Zhang, LB
AF Dasgupta, Chiranjib
   Chen, Man
   Zhang, Haitao
   Yang, Shumei
   Zhang, Lubo
TI Chronic Hypoxia During Gestation Causes Epigenetic Repression of the
   Estrogen Receptor-α Gene in Ovine Uterine Arteries via Heightened
   Promoter Methylation
SO HYPERTENSION
LA English
DT Article
DE hypoxia; estrogen receptor; methylation; epigenetic modulation; uterine
   artery
ID UPSTREAM STIMULATORY FACTOR; K+ CHANNEL ACTIVITY; HUMAN BREAST-CANCER;
   BLOOD-FLOW; HIGH-ALTITUDE; TRANSCRIPTION FACTOR; MYOGENIC TONE; ENHANCED
   EXPRESSION; NORMAL-PREGNANCY; DNA METHYLATION
AB Estrogen receptor-alpha (ER alpha) plays a key role in the adaptation of increased uterine blood flow in pregnancy. Chronic hypoxia is a common stress to maternal cardiovascular homeostasis and causes increased risk of preeclampsia. Studies in pregnant sheep demonstrated that hypoxia during gestation downregulated ER alpha gene expression in uterine arteries. The present study tested the hypothesis that hypoxia causes epigenetic repression of the ER alpha gene in uterine arteries via heightened promoter methylation. Ovine ER alpha promoter of 2035 bp spanning from -2000 to +35 of the transcription start site was cloned. No estrogen or hypoxia-inducible factor response elements were found at the promoter. Two transcription factor binding sites, USF-15 and Sp1(-520), containing CpG dinucleotides were identified, which had significant effects on the promoter activity. The USF element binds transcription factors USF1 and USF2, and the Sp1 element binds Sp1, as well as ER alpha through Sp1. Deletion of the Sp1 site abrogated 17 beta-estradiol-induced increase in the promoter activity. In normoxic control sheep, CpG methylation at the Sp1 but not the USF site was significantly decreased in uterine arteries of pregnant as compared with nonpregnant animals. In pregnant sheep exposed to long-term high-altitude hypoxia, CpG methylation at both Sp1 and USF sites in uterine arteries was significantly increased. Methylation inhibited transcription factor binding and the promoter activity. The results provide evidence of hypoxia causing heightened promoter methylation and resultant ER alpha gene repression in uterine arteries and suggest new insights of molecular mechanisms linking gestational hypoxia to aberrant uteroplacental circulation and increased risk of preeclampsia. (Hypertension. 2012; 60: 697-704.)
C1 [Dasgupta, Chiranjib; Chen, Man; Zhang, Haitao; Zhang, Lubo] Loma Linda Univ, Sch Med, Ctr Perinatal Biol, Div Pharmacol,Dept Basic Sci, Loma Linda, CA 92350 USA.
   [Yang, Shumei] Calif State Univ San Bernardino, Dept Chem & Biochem, San Bernardino, CA 92407 USA.
C3 Loma Linda University; California State University System; California
   State University San Bernardino
RP Zhang, LB (通讯作者)，Loma Linda Univ, Sch Med, Ctr Perinatal Biol, Div Pharmacol,Dept Basic Sci, Loma Linda, CA 92350 USA.
EM lzhang@llu.edu
RI zhang, Haitao/AAF-4771-2021
OI Zhang, Lubo/0000-0002-9386-8938
FU National Institutes of Health [HD031226, HL089012, HL110125]
FX This work was supported by National Institutes of Health grants
   HD031226, HL089012, and HL110125 (all to L.Z.).
CR Alexander BT, 2001, NEWS PHYSIOL SCI, V16, P282
   Bogdarina I, 2007, CIRC RES, V100, P520, DOI 10.1161/01.RES.0000258855.60637.58
   Byers MJ, 2005, J PHYSIOL-LONDON, V565, P85, DOI 10.1113/jphysiol.2005.085753
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119
   Chang K, 2010, HYPERTENSION, V56, P750, DOI 10.1161/HYPERTENSIONAHA.110.155812
   Fleming JGW, 2006, ENDOCRINOLOGY, V147, P899, DOI 10.1210/en.2005-1120
   Fujimoto M, 2005, ONCOGENE, V24, P5108, DOI 10.1038/sj.onc.1208697
   Gluckman PD, 2009, NAT REV ENDOCRINOL, V5, P401, DOI 10.1038/nrendo.2009.102
   Grandien K, 1996, MOL CELL ENDOCRINOL, V116, P207, DOI 10.1016/0303-7207(95)03716-0
   Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008
   Harris AN, 1998, MOL ENDOCRINOL, V12, P714, DOI 10.1210/me.12.5.714
   Hu XQ, 2012, HYPERTENSION, V60, P214, DOI 10.1161/HYPERTENSIONAHA.112.196097
   Hu XQ, 2011, HYPERTENSION, V58, P1132, DOI 10.1161/HYPERTENSIONAHA.111.179952
   Issa JPJ, 1996, CANCER RES, V56, P973
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Keyes LE, 2003, PEDIATR RES, V54, P20, DOI 10.1203/01.PDR.0000069846.64389.DC
   KILLAM AP, 1973, AM J OBSTET GYNECOL, V115, P1045, DOI 10.1016/0002-9378(73)90552-8
   Kos M, 2002, J BIOL CHEM, V277, P37131, DOI 10.1074/jbc.M206325200
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Lawrence J, 2011, CARDIOVASC RES, V89, P89, DOI 10.1093/cvr/cvq270
   Madigou T, 1996, MOL CELL ENDOCRINOL, V121, P153, DOI 10.1016/0303-7207(96)03860-9
   Magness RR, 2005, J PHYSIOL-LONDON, V565, P71, DOI 10.1113/jphysiol.2005.086439
   MAGNESS RR, 1989, AM J PHYSIOL, V256, pE536, DOI 10.1152/ajpendo.1989.256.4.E536
   Magness RR, 1998, AM J PHYSIOL-HEART C, V275, pH731, DOI 10.1152/ajpheart.1998.275.3.H731
   MAGNESS RR, 1993, AM J PHYSIOL, V265, pE690, DOI 10.1152/ajpendo.1993.265.5.E690
   Meyer K, 2009, J MOL CELL CARDIOL, V47, P504, DOI 10.1016/j.yjmcc.2009.06.004
   Palmer SK, 1999, AM J OBSTET GYNECOL, V180, P1161, DOI 10.1016/S0002-9378(99)70611-3
   Patterson AJ, 2010, CIRC RES, V107, P365, DOI 10.1161/CIRCRESAHA.110.221259
   Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004
   Porter W, 1996, MOL ENDOCRINOL, V10, P1371, DOI 10.1210/me.10.11.1371
   Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569
   Reik W, 2001, ELECTROPHORESIS, V22, P2838, DOI 10.1002/1522-2683(200108)22:14<2838::AID-ELPS2838>3.0.CO;2-M
   Rosenfeld CR, 1996, J CLIN INVEST, V98, P2158, DOI 10.1172/JCI119022
   Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5
   Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379
   SAWADOGO M, 1988, J BIOL CHEM, V263, P11985
   Schwarz JM, ENDOCRINOLOGY, V151, P4871
   Sholook MM, 2007, AM J PHYSIOL-HEART C, V293, pH2080, DOI 10.1152/ajpheart.00667.2007
   Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758
   Sogon T, 2007, J STEROID BIOCHEM, V105, P106, DOI 10.1016/j.jsbmb.2006.12.104
   Szreder T, 2007, MOL BIOL REP, V34, P207, DOI 10.1007/s11033-006-9030-x
   Takahashi K, 2001, BIOSCI BIOTECH BIOCH, V65, P56, DOI 10.1271/bbb.65.56
   Tanimoto K, 1999, NUCLEIC ACIDS RES, V27, P903, DOI 10.1093/nar/27.3.903
   Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405
   Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008
   Westberry JM, 2010, ENDOCRINOLOGY, V151, P731, DOI 10.1210/en.2009-0955
   White MM, 2003, HIGH ALT MED BIOL, V4, P157, DOI 10.1089/152702903322022776
   Wilson ME, 2008, FRONT NEUROENDOCRIN, V29, P375, DOI 10.1016/j.yfrne.2008.03.002
   Xiao DL, 2009, HYPERTENSION, V54, P352, DOI 10.1161/HYPERTENSIONAHA.109.130781
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   ZAMUDIO S, 1995, J APPL PHYSIOL, V79, P7, DOI 10.1152/jappl.1995.79.1.7
   ZAMUDIO S, 1995, J APPL PHYSIOL, V79, P15, DOI 10.1152/jappl.1995.79.1.15
   ZAMUDIO S, 1993, J APPL PHYSIOL, V75, P1566, DOI 10.1152/jappl.1993.75.4.1566
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 57
TC 57
Z9 65
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD SEP
PY 2012
VL 60
IS 3
BP 697
EP +
DI 10.1161/HYPERTENSIONAHA.112.198242
PG 17
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 994SM
UT WOS:000307951900028
PM 22777938
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Buoncervello, M
   Borghi, P
   Romagnoli, G
   Spadaro, F
   Belardelli, F
   Toschi, E
   Gabriele, L
AF Buoncervello, Maria
   Borghi, Paola
   Romagnoli, Giulia
   Spadaro, Francesca
   Belardelli, Filippo
   Toschi, Elena
   Gabriele, Lucia
TI Apicidin and Docetaxel Combination Treatment Drives CTCFL Expression and
   HMGB1 Release Acting as Potential Antitumor Immune Response Inducers in
   Metastatic Breast Cancer Cells
SO NEOPLASIA
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; GROUP BOX 1; LUNG-CANCER; ANTICANCER
   CHEMOTHERAPY; DENDRITIC CELLS; FACTOR BORIS; IN-VIVO; THERAPY; ANTIGEN;
   MODULATION
AB Currently approved combination regimens available for the treatment of metastatic tumors, such as breast cancer, have been shown to increase response rates, often at the cost of a substantial increase in toxicity. An ideal combination strategy may consist of agents with different mechanisms of action leading to complementary antitumor activities and safety profiles. In the present study, we investigated the effects of the epigenetic modulator apicidin in combination with the cytotoxic agent docetaxel in tumor breast cell lines characterized by different grades of invasiveness. We report that combined treatment of apicidin and docetaxel, at low toxicity doses, stimulates in metastatic breast cancer cells the expression of CTCF-like protein and other cancer antigens, thus potentially favoring an antitumor immune response. In addition, apicidin and docetaxel co-treatment specifically stimulates apoptosis, characterized by an increased Bax/Bcl-2 ratio and caspase-8 activation. Importantly, following combined exposure to these agents, metastatic cells were also found to induce signals of immunogenic apoptosis such as cell surface expression of calreticulin and release of considerable amounts of high-mobility group box 1 protein, thus potentially promoting the translation of induced cell death into antitumor immune response. Altogether, our results indicate that the combined use of apicidin and docetaxel, at a low toxicity profile, may represent a potential innovative strategy able to activate complementary antitumor pathways in metastatic breast cancer cells, associated with a potential control of metastatic growth and possible induction of antitumor immunity. Neoplasia (2012) 14, 855-867
C1 [Buoncervello, Maria; Borghi, Paola; Romagnoli, Giulia; Spadaro, Francesca; Belardelli, Filippo; Toschi, Elena; Gabriele, Lucia] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy.
C3 Istituto Superiore di Sanita (ISS)
RP Gabriele, L (通讯作者)，Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.
EM lucia.gabriele@iss.it
RI Toschi, Elena/M-7051-2017; Gabriele, Lucia/J-8335-2016; Buoncervello,
   Maria/I-8197-2018; Spadaro, Francesca/M-7512-2017
OI Gabriele, Lucia/0000-0002-1483-866X; Belardelli,
   Filippo/0000-0002-3082-3169; romagnoli, giulia/0000-0002-0621-2579;
   Buoncervello, Maria/0000-0002-0028-4328; Toschi,
   Elena/0000-0002-9720-5971; Spadaro, Francesca/0000-0002-6610-350X
FU Italian Association for Research against Cancer (AIRC); Ministry of
   Health [7OAF1/4, ISS/NIH OF14]
FX This work was supported by grants from the Italian Association for
   Research against Cancer (AIRC) and from the Ministry of Health
   [www.salute.gov.it; "Progetto Integrato Oncologia" (7OAF1/4) and
   "Progetto ISS/NIH OF14"] to L.G.
CR Akers SN, 2010, FUTURE ONCOL, V6, P717, DOI 10.2217/FON.10.36
   Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323
   Bachmeier BE, 2005, EXP CELL RES, V305, P83, DOI 10.1016/j.yexcr.2004.12.019
   Bao L, 2011, CANCER IMMUNOL IMMUN, V60, P1299, DOI 10.1007/s00262-011-1037-z
   Bayet-Robert M, 2010, BREAST CANCER RES TR, V120, P613, DOI 10.1007/s10549-009-0430-1
   Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x
   D'Arcy V, 2008, BRIT J CANCER, V98, P571, DOI 10.1038/sj.bjc.6604181
   Darcy V, 2006, CLIN CANCER RES, V12, P5978, DOI 10.1158/1078-0432.CCR-05-2731
   de Necochea-Campion R, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-213
   Dong XD, 2007, J IMMUNOTHER, V30, P596, DOI 10.1097/CJI.0b013e31804efc76
   Evankovich J, 2010, J BIOL CHEM, V285, P39888, DOI 10.1074/jbc.M110.128348
   Fonsatti E, 2007, CLIN CANCER RES, V13, P3333, DOI 10.1158/1078-0432.CCR-06-3091
   Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003
   Geldmacher A, 2011, HUM VACCINES, V7, P115, DOI 10.4161/hv.7.0.14573
   Ghochikyan A, 2007, J IMMUNOL, V178, P566, DOI 10.4049/jimmunol.178.1.566
   Ginés J, 2011, CLIN TRANSL ONCOL, V13, P485, DOI 10.1007/s12094-011-0686-x
   Grimm D, 2011, CURR PHARM DESIGN, V17, P272, DOI 10.2174/138161211795049723
   Haynes NM, 2008, CURR OPIN IMMUNOL, V20, P545, DOI 10.1016/j.coi.2008.05.008
   Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152
   Hines WC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009738
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Huang B, 2011, GENE THER, V18, P164, DOI 10.1038/gt.2010.121
   Hwang JJ, 2012, INVEST NEW DRUG, V30, P1434, DOI 10.1007/s10637-011-9718-1
   Hwang JJ, 2010, J UROLOGY, V184, P2557, DOI 10.1016/j.juro.2010.07.035
   Im JY, 2008, CHEM-BIOL INTERACT, V172, P235, DOI 10.1016/j.cbi.2008.01.007
   Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683
   John J, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-14
   Jones P, 2008, J MED CHEM, V51, P2350, DOI 10.1021/jm800079s
   Kang Y, 2007, ONCOGENE, V26, P4394, DOI 10.1038/sj.onc.1210218
   Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4
   Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37
   Lai JP, 2009, J HEPATOL, V50, P1112, DOI 10.1016/j.jhep.2008.12.031
   Levitzki A, 2010, MOL ASPECTS MED, V31, P287, DOI 10.1016/j.mam.2010.04.001
   Linares A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/856985
   Liu QJ, 2008, CELL MOL IMMUNOL, V5, P171, DOI 10.1038/cmi.2008.21
   Locher C, 2010, ANN NY ACAD SCI, V1209, P99, DOI 10.1111/j.1749-6632.2010.05763.x
   Martin-Kleiner I, 2012, EUR J CANCER, V48, P929, DOI 10.1016/j.ejca.2011.09.009
   Miller CP, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/514261
   Montero A, 2005, LANCET ONCOL, V6, P229, DOI 10.1016/S1470-2045(05)70094-2
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Noh JH, 2009, INT J MOL MED, V24, P205, DOI 10.3892/ijmm_00000224
   Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1
   Park H, 2008, INT J MOL MED, V21, P325
   Pfannenstiel LW, 2010, CELL IMMUNOL, V263, P79, DOI 10.1016/j.cellimm.2010.03.001
   Pisetsky DS, 2011, ANTIOXID REDOX SIGN, V15, P2209, DOI 10.1089/ars.2010.3865
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Schiavoni G, 2011, CANCER RES, V71, P768, DOI 10.1158/0008-5472.CAN-10-2788
   Shurin GV, 2009, J IMMUNOL, V183, P137, DOI 10.4049/jimmunol.0900734
   Smith IM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004961
   Tanaka H, 2009, CANCER RES, V69, P6987, DOI 10.1158/0008-5472.CAN-09-1106
   Tang DL, 2010, AUTOPHAGY, V6, P1181, DOI 10.4161/auto.6.8.13367
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   Luu T, 2011, ONCOLOGIST, V16, P760, DOI 10.1634/theoncologist.2010-0345
   Thomas S, 2009, CANCER LETT, V280, P184, DOI 10.1016/j.canlet.2008.12.026
   Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]
   Torabi-Rahvar M, 2011, DRUG DISCOV TODAY, V16, P733, DOI 10.1016/j.drudis.2011.04.010
   Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Wan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032542
   Woan KV, 2012, IMMUNOL CELL BIOL, V90, P55, DOI 10.1038/icb.2011.96
   Wong ST, 2009, PHARMACOTHERAPY, V29, P954, DOI 10.1592/phco.29.8.954
   Yang D, 2007, J LEUKOCYTE BIOL, V81, P59, DOI 10.1189/jlb.0306180
   Yoon SL, 2010, BMB REP, V43, P698, DOI [10.3858/BMBRep.2010.43.10.698, 10.5483/BMBRep.2010.43.10.698]
   Zhuang WZ, 2009, ACTA BIOCH BIOPH SIN, V41, P341, DOI 10.1093/abbs/gmp028
NR 64
TC 29
Z9 32
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD SEP
PY 2012
VL 14
IS 9
BP 855
EP U112
DI 10.1593/neo.121020
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 068DR
UT WOS:000313345200009
PM 23019417
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Khaw, AK
   Yong, JWY
   Kalthur, G
   Hande, MP
AF Khaw, Aik Kia
   Yong, Jacklyn Wei Yan
   Kalthur, Guruprasad
   Hande, M. Prakash
TI Genistein induces growth arrest and suppresses telomerase activity in
   brain tumor cells
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; BREAST-CANCER; EPIGENETIC
   MECHANISMS; ISOFLAVONE GENISTEIN; CYCLE ARREST; G2/M ARREST; IN-VITRO;
   INHIBITION; SOY
AB Genistein, a soy isoflavone, has been reported to exhibit multiple effects, such as inducing cell cycle arrest, triggering apoptosis, inhibiting the activation of NFKB and inactivating several signaling cascades in human cancer cells. In vivo studies demonstrating antiangiogenesis and antimetastatic effects of genistein have also been reported. Here, we demonstrate that genistein inhibits the growth of glioblastoma multiforme and medulloblastoma cells with different TP53 mutations and radio-responses by arresting the cells at G2/M phase of the cell cycle. The cell cycle arrest was found to be independent of DNA damage and such an arrest was sustainable for at least 10 days even after drug removal. Annexin V staining revealed absence of apoptotic or necrotic cell populations after genistein treatment. This supports the observation that genistein induces insignificant DNA damage and indicates that the cell cycle arrest triggered does not lead to cell death. Gene and protein expression studies reveal similar changes in the same pathways following treatment in the cell types tested. Genistein was also able to inhibit telomerase activity resulting in telomere shortening. Thus, we demonstrate, for the first time, that genistein induces growth arrest in association with telomerase inhibition in brain tumor cells via the suppression of TR- and TERT mRNA. By elucidating the mechanisms of anticancer effects after genistein treatment in brain tumor cells, there will be a premise for the incorporation of genistein dietary sources to complement radiotherapy in brain tumor patients. (c) 2012 Wiley Periodicals, Inc.
C1 [Khaw, Aik Kia; Yong, Jacklyn Wei Yan; Kalthur, Guruprasad; Hande, M. Prakash] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Genome Stabil Lab, Singapore 117597, Singapore.
   [Kalthur, Guruprasad] Manipal Univ, Kasturba Med Coll, Dept Obstet & Gynaecol, Manipal 576104, Karnataka, India.
   [Hande, M. Prakash] Natl Univ Singapore, Tembusu Coll, Singapore 138598, Singapore.
C3 National University of Singapore; Manipal Academy of Higher Education
   (MAHE); Kasturba Medical College, Manipal; National University of
   Singapore
RP Hande, MP (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, MD6,14-02P,14 Med Dr, Singapore 117599, Singapore.
EM phsmph@nus.edu.sg
RI Hande, M Prakash/B-1645-2008
OI Hande, M Prakash/0000-0002-4511-6256
FU Academic Research Fund, Ministry of Education, Singapore [T206B3108WBS:
   185-000-153-112]; Department of Biotechnology, Government of India,
   Cutting Edge Research Enhancement and Scientific Training (CREST)
FX Supported by: Academic Research Fund, Ministry of Education, Singapore,
   Grant number: T206B3108WBS: 185-000-153-112; Department of
   Biotechnology, Government of India, Cutting Edge Research Enhancement
   and Scientific Training (CREST).
CR Alhasan SA, 2001, CLIN CANCER RES, V7, P4174
   Bouker KB, 2000, ENVIRON HEALTH PERSP, V108, P701, DOI 10.2307/3434722
   Casagrande F, 2000, EXP CELL RES, V258, P101, DOI 10.1006/excr.2000.4914
   Chen WF, 2003, BBA-MOL BASIS DIS, V1638, P187, DOI 10.1016/S0925-4439(03)00082-6
   Chinni SR, 2003, INT J MOL MED, V12, P29
   Choi YH, 2000, JPN J CANCER RES, V91, P164, DOI 10.1111/j.1349-7006.2000.tb00928.x
   Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363
   Faqi AS, 2004, REPROD TOXICOL, V18, P605, DOI 10.1016/j.reprotox.2004.02.013
   Farina HG, 2006, ONCOL REP, V16, P885
   FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491
   GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0
   GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9
   Ishikawa KI, 2006, INT J RADIAT ONCOL, V65, P234, DOI 10.1016/j.ijrobp.2005.12.048
   Jagadeesh S, 2006, CANCER RES, V66, P2107, DOI 10.1158/0008-5472.CAN-05-2494
   Jefferson WN, 2007, MOL NUTR FOOD RES, V51, P832, DOI 10.1002/mnfr.200600258
   Jian L, 2009, MOL NUTR FOOD RES, V53, P217, DOI 10.1002/mnfr.200800167
   Jin CY, 2009, CHEM-BIOL INTERACT, V180, P143, DOI 10.1016/j.cbi.2009.03.020
   Keith WN, 2004, NAT CLIN PRACT ONCOL, V1, P88, DOI 10.1038/ncponc0044
   Kim EJ, 2005, J MED FOOD, V8, P431, DOI 10.1089/jmf.2005.8.431
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Lamartiniere CA, 2000, AM J CLIN NUTR, V71, p1705S, DOI 10.1093/ajcn/71.6.1705S
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Li Z, 2008, CELL BIOL TOXICOL, V24, P401, DOI 10.1007/s10565-008-9054-1
   Luo HT, 2008, NUTR CANCER, V60, P800, DOI 10.1080/01635580802100851
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141
   Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955
   Ouchi H, 2005, INT J UROL, V12, P73, DOI 10.1111/j.1442-2042.2004.00973.x
   Parkinson EK, 2007, BIODRUGS, V21, P375, DOI 10.2165/00063030-200721060-00005
   Puli S, 2006, J NEURO-ONCOL, V79, P135, DOI 10.1007/s11060-006-9126-0
   Raffoul JJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-107
   Rucinska A, 2009, CELL BIOL INT, V33, P247, DOI 10.1016/j.cellbi.2008.11.003
   Rucinska A, 2007, CELL BIOL INT, V31, P1371, DOI 10.1016/j.cellbi.2007.05.012
   Schmidt F, 2008, ONCOL REP, V19, P1061
   Sha Gui-hua, 2008, Chinese Medical Sciences Journal, V23, P49
   Shay JW, 2005, CANCER CELL, V7, P1, DOI 10.1016/j.ccr.2004.12.012
   Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9
   Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2
   SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074
   Thasni KAA, 2008, EUR J PHARMACOL, V588, P158, DOI 10.1016/j.ejphar.2008.04.041
   Vulliamy TJ, 2001, BLOOD CELL MOL DIS, V27, P353, DOI 10.1006/bcmd.2001.0389
   YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0
   Yu JY, 2008, J PHARMACOL SCI, V107, P90, DOI 10.1254/jphs.08001FP
NR 43
TC 49
Z9 56
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD OCT
PY 2012
VL 51
IS 10
BP 961
EP 974
DI 10.1002/gcc.21979
PG 14
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA 982NM
UT WOS:000307052000006
PM 22736505
DA 2025-01-12
ER

PT J
AU Puppin, C
   Passon, N
   Hershman, JM
   Filetti, S
   Bulotta, S
   Celano, M
   Russo, D
   Damante, G
AF Puppin, Cinzia
   Passon, Nadia
   Hershman, Jerome M.
   Filetti, Sebastiano
   Bulotta, Stefania
   Celano, Marilena
   Russo, Diego
   Damante, Giuseppe
TI Cooperative effects of SAHA and VPA on <i>NIS</i> gene expression and
   proliferation of thyroid cancer cells
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; SODIUM-IODIDE SYMPORTER; SODIUM/IODIDE
   SYMPORTER; NA+/I-SYMPORTER; UPSTREAM ENHANCER; BREAST-CANCER; VALPROIC
   ACID; ACETYLATION; H3; IDENTIFICATION
AB Histone deacetylase inhibitors (HDACi) have shown both anti-proliferative and redifferentiating effects in thyroid cancer cells. Also, they induce the expression of the sodium-iodide symporter gene (NIS (SLC5A5)), a crucial step for radioiodine treatment of thyroid malignancies. Here we investigated the effects of suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA) on BCPAP and FRO thyroid cancer cells, extending our analysis on the epigenetic mechanisms underlying the NIS gene expression stimulation. In both cell lines we found a cooperative effect of the two compounds on either cell viability and NIS gene expression, resulting in acquired/increased ability to uptake the radioiodine. Such effect was specific since it was not observed for expression of other genes or when SAHA was used in combination with trichostatin A. By using chromatin immunoprecipitation, we investigated epigenetic mechanisms underlying SAHA and VPA effects. Cooperation among the two HDACi occurred on H3 histone trimethylation at lysine 4 (H3K4me3) and not on histone acetylation. However, effects on H3K4me3 were detected only at the level of NIS Proximal Basal Promoter (NIS-PBP) in FRO cells and only at the level of NIS Upstream Enhancer (NIS-NUE) in BCPAP cells. Our data indicate that epigenetic changes are involved in the synergistic effects of VPA and SAHA on NIS gene expression and that the cellular context modifies effects of HDACi in terms of H3K4me3 target sequence. Investigation of cooperation among different HDACi may provide clues for better defining their mechanism of action in view of their use in thyroid cancer treatment. Journal of Molecular Endocrinology (2012) 48, 217-227
C1 [Puppin, Cinzia; Passon, Nadia; Damante, Giuseppe] Univ Udine, Dipartimento Sci Med & Biol, I-33100 Udine, Italy.
   [Hershman, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
   [Filetti, Sebastiano] Univ Roma La Sapienza, Dipartimento Med Interna & Specialita Med, Rome, Italy.
   [Bulotta, Stefania; Celano, Marilena; Russo, Diego] Univ Catanzaro, Dipartimento Sci Farmacobiol, Catanzaro, Italy.
   [Damante, Giuseppe] Univ S Maria della Misericordia, Azienda Osped, Udine, Italy.
C3 University of Udine; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Greater Los Angeles Healthcare System; Sapienza
   University Rome; Magna Graecia University of Catanzaro; Hospital Santa
   Maria della Misericordia
RP Damante, G (通讯作者)，Univ Udine, Dipartimento Sci Med & Biol, Piazzale Kolbe 1, I-33100 Udine, Italy.
EM giuseppe.damante@uniud.it
RI Damante, Giuseppe/AAC-5200-2022
OI Damante, Giuseppe/0000-0003-2312-4009
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 10296]; MIUR
   (PRIN) [20093WAPIK_003]
FX This work was supported by grants to G D from Associazione Italiana per
   la Ricerca sul Cancro (AIRC) (grant number IG 10296) and MIUR (PRIN
   grant number 20093WAPIK_003).
CR Arturi F, 2000, EUR J ENDOCRINOL, V143, P623, DOI 10.1530/eje.0.1430623
   Arturi F, 2005, J CLIN ENDOCR METAB, V90, P2321, DOI 10.1210/jc.2004-1562
   Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013
   Batty N, 2009, CANCER LETT, V280, P192, DOI 10.1016/j.canlet.2009.03.013
   Cantley MD, 2011, J CELL PHYSIOL, V226, P3233, DOI 10.1002/jcp.22684
   Chang J, 2012, BRIT J CANCER, V106, P116, DOI 10.1038/bjc.2011.532
   Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383
   DE la Vieja A, 2000, PHYSIOL REV, V80, P1083, DOI 10.1152/physrev.2000.80.3.1083
   Dohán O, 2001, J CLIN ENDOCR METAB, V86, P2697, DOI 10.1210/jc.86.6.2697
   Dohán O, 2003, MOL CELL ENDOCRINOL, V213, P59, DOI 10.1016/j.mce.2003.10.059
   Duenas-Gonzalez A, 2008, CANCER TREAT REV, V34, P206, DOI 10.1016/j.ctrv.2007.11.003
   Fenton MS, 2008, ENDOCRINOLOGY, V149, P2592, DOI 10.1210/en.2007-1390
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Furuya F, 2004, ENDOCRINOLOGY, V145, P2865, DOI 10.1210/en.2003-1258
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Hingorani M, 2010, CURR CANCER DRUG TAR, V10, P242, DOI 10.2174/156800910791054194
   Hou P, 2010, J CLIN ENDOCR METAB, V95, P820, DOI 10.1210/jc.2009-1888
   Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702
   Kitazono M, 2001, J CLIN ENDOCR METAB, V86, P3430, DOI 10.1210/jc.86.7.3430
   Kogai T, 2006, ENDOCR-RELAT CANCER, V13, P797, DOI 10.1677/erc.1.01143
   Krämer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Lazar V, 1999, J CLIN ENDOCR METAB, V84, P3228, DOI 10.1210/jc.84.9.3228
   Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X
   Lin XQ, 2004, THYROID, V14, P19, DOI 10.1089/105072504322783803
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Nakagawa M, 2007, ONCOL REP, V18, P769
   Nightingale KP, 2007, J BIOL CHEM, V282, P4408, DOI 10.1074/jbc.M606773200
   Ohno M, 1999, MOL CELL BIOL, V19, P2051
   Puppin C, 2005, ENDOCRINOLOGY, V146, P3967, DOI 10.1210/en.2005-0128
   Rando OJ, 2007, CURR OPIN GENET DEV, V17, P94, DOI 10.1016/j.gde.2007.02.006
   Riedel C, 2001, TRENDS BIOCHEM SCI, V26, P490, DOI 10.1016/S0968-0004(01)01904-1
   Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248
   Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x
   Russo D, 2011, J MOL ENDOCRINOL, V46, pR73, DOI 10.1530/JME-10-0150
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Samuni Y, 2009, FREE RADICAL BIO MED, V47, P419, DOI 10.1016/j.freeradbiomed.2009.05.011
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Schlumberger M, 2007, NAT CLIN PRACT ENDOC, V3, P260, DOI 10.1038/ncpendmet0449
   Schmitt TL, 2001, EXP CLIN ENDOCR DIAB, V109, P27, DOI 10.1055/s-2001-11016
   Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Sodre AKMB, 2008, J CLIN ENDOCR METAB, V93, P4141, DOI 10.1210/jc.2007-0353
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Taki K, 2002, MOL ENDOCRINOL, V16, P2266, DOI 10.1210/me.2002-0109
   Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5
   Tell G, 1998, BIOCHEM BIOPH RES CO, V252, P178, DOI 10.1006/bbrc.1998.9548
   Trapasso F, 1999, EUR J ENDOCRINOL, V140, P447, DOI 10.1530/eje.0.1400447
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
NR 51
TC 11
Z9 11
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0952-5041
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD JUN
PY 2012
VL 48
IS 3
BP 217
EP 227
DI 10.1530/JME-11-0063
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 985PI
UT WOS:000307279100006
OA Bronze
DA 2025-01-12
ER

PT J
AU Klubo-Gwiezdzinska, J
   Jensen, K
   Bauer, A
   Patel, A
   Costello, J
   Burman, KD
   Wartofsky, L
   Hardwick, MJ
   Vasko, VV
AF Klubo-Gwiezdzinska, Joanna
   Jensen, Kirk
   Bauer, Andrew
   Patel, Aneeta
   Costello, John, Jr.
   Burman, Kenneth D.
   Wartofsky, Leonard
   Hardwick, Matthew J.
   Vasko, Vasyl V.
TI The expression of translocator protein in human thyroid cancer and its
   role in the response of thyroid cancer cells to oxidative stress
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID PERIPHERAL BENZODIAZEPINE-RECEPTOR; HUMAN GLIOBLASTOMA CELLS; HUMAN
   BREAST-CANCER; 18 KDA; MITOCHONDRIAL-MEMBRANE; INDUCED APOPTOSIS; CYCLE
   ARREST; LIGANDS; PROLIFERATION; ASTROCYTOMAS
AB The translocator protein (TSPO), formerly known as a peripheral benzodiazepine receptor, exerts pro-apoptotic function via regulation of mitochondrial membrane potential. We examined TSPO expression in human thyroid tumors (25 follicular adenomas (FA), 15 follicular cancers (FC), and 70 papillary cancers (PC)). The role of TSPO in the regulation of cell growth, migration, and apoptosis was examined in thyroid cancer cell lines after TSPO knockdown with siRNA and after treatment with TSPO antagonist (PK11195). Compared with normal thyroid, the level of TSPO expression was increased in FA, FC, and PC in 24, 26.6, and 55.7% of cases respectively. Thyroid cancer cell lines demonstrated variable levels of TSPO expression, without specific association with thyroid oncogene mutations. Treatment with inhibitors of PI3K/AKT or MEK/ERK signaling was not associated with changes in TSPO expression. Treatment with histone deacetylase inhibitor (valproic acid) increased TSPO expression in TSPO-deficient cell lines ( FTC236 cells). TSPO gene silencing or treatment with PK11195 did not affect thyroid cancer cell growth and migration but prevented depolarization of mitochondrial membranes induced by oxidative stress. Induction of TSPO expression by valproic acid was associated with increased sensitivity of FTC236 to oxidative stress-inducible apoptosis. Overall, we showed that TSPO expression is frequently increased in PC. In vitro data suggested the role of epigenetic mechanism(s) in the regulation of TSPO in thyroid cells. Implication of TSPO in the thyroid cancer cell response to oxidative stress suggested its potential role in the regulation of thyroid cancer cell response to treatment with radioiodine and warrants further investigation. Journal of Endocrinology (2012) 214, 207-216
C1 [Jensen, Kirk; Bauer, Andrew; Patel, Aneeta; Costello, John, Jr.; Vasko, Vasyl V.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA.
   [Klubo-Gwiezdzinska, Joanna; Burman, Kenneth D.; Wartofsky, Leonard] Washington Hosp Ctr, Dept Med, Div Endocrinol, Washington, DC 20010 USA.
   [Klubo-Gwiezdzinska, Joanna] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Dept Endocrinol & Diabetol, PL-85094 Bydgoszcz, Poland.
   [Hardwick, Matthew J.] Washington Hosp Ctr, Medstar Res Inst, Lab Clin Investigat, Washington, DC 20010 USA.
C3 Uniformed Services University of the Health Sciences - USA; MedStar
   Washington Hospital Center; Nicolaus Copernicus University; Ludwik
   Rydygier Collegium Medicum; MedStar Washington Hospital Center
RP Vasko, VV (通讯作者)，Uniformed Serv Univ Hlth Sci, Dept Pediat, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM vvasko@usuhs.edu
RI Klubo-Gwiezdzinska, Joanna/I-8303-2017
OI Klubo-Gwiezdzinska, Joanna/0000-0001-8633-4420
FU American Thyroid Association Grant; Department of Pediatrics USUHS
   [C086IZ]
FX The study was supported by the American Thyroid Association Grant to J
   K-G and by Grant from Department of Pediatrics USUHS (C086IZ) to V V V.
CR Akech J, 2005, BIOCHEM BIOPH RES CO, V333, P35, DOI 10.1016/j.bbrc.2005.05.071
   Batarseh A, 2012, BBA-GENE REGUL MECH, V1819, P38, DOI 10.1016/j.bbagrm.2011.09.001
   Batarseh A, 2010, BIOCHEMISTRY-US, V49, P4766, DOI 10.1021/bi100020e
   Chelli B, 2004, BIOCHEM PHARMACOL, V68, P125, DOI 10.1016/j.bcp.2004.03.008
   Corsi L, 2008, CURR CLIN PHARMACOL, V3, P38, DOI 10.2174/157488408783329878
   Fafalios A, 2009, CLIN CANCER RES, V15, P6177, DOI 10.1158/1078-0432.CCR-09-0844
   Hardwick M, 1999, CANCER RES, V59, P831
   Kugler W, 2008, CELL ONCOL, V30, P435, DOI 10.3233/CLO-2008-0431
   Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273
   Maaser K, 2005, CLIN CANCER RES, V11, P1751, DOI 10.1158/1078-0432.CCR-04-1955
   Maaser K, 2001, BRIT J CANCER, V85, P1771, DOI 10.1054/bjoc.2001.2181
   Marsee DK, 2004, J BIOL CHEM, V279, P43990, DOI 10.1074/jbc.M407503200
   Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005
   Rone MB, 2009, BIOCHEMISTRY-US, V48, P6909, DOI 10.1021/bi900854z
   Satoh T, 1997, J NEUROSCI RES, V50, P413, DOI 10.1002/(SICI)1097-4547(19971101)50:3<413::AID-JNR7>3.0.CO;2-L
   Schlumberger M, 2009, THYROID, V19, P1393, DOI 10.1089/thy.2009.1603
   Shen WT, 2005, SURGERY, V138, P979, DOI 10.1016/j.surg.2005.09.019
   Shoukrun R, 2008, PHARMACOGENET GENOM, V18, P977, DOI 10.1097/FPC.0b013e3283117d52
   Sutter AP, 2004, BIOCHEM PHARMACOL, V67, P1701, DOI 10.1016/j.bcp.2004.01.009
   Takaya S, 2007, J NEURO-ONCOL, V85, P95, DOI 10.1007/s11060-007-9396-1
   Veenman L, 2008, J BIOENERG BIOMEMBR, V40, P199, DOI 10.1007/s10863-008-9142-1
   Vlodavsky E, 2007, J NEURO-ONCOL, V81, P1, DOI 10.1007/s11060-006-9199-9
   Zeno S, 2009, BIOCHEMISTRY-US, V48, P4652, DOI 10.1021/bi900064t
NR 23
TC 16
Z9 18
U1 0
U2 12
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022-0795
J9 J ENDOCRINOL
JI J. Endocrinol.
PD AUG
PY 2012
VL 214
IS 2
BP 207
EP 216
DI 10.1530/JOE-12-0081
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 976CR
UT WOS:000306558600011
PM 22645299
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU White, WM
   Brost, BC
   Sun, ZF
   Rose, C
   Craici, I
   Wagner, SJ
   Turner, S
   Garovic, VD
AF White, Wendy M.
   Brost, Brian C.
   Sun, Zhifu
   Rose, Carl
   Craici, Iasmina
   Wagner, Steven J.
   Turner, Stephen
   Garovic, Vesna D.
TI Normal early pregnancy A transient state of epigenetic change favoring
   hypomethylation
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; epigenetics; pregnancy; leukocyte; maternal; immune;
   postpartum
ID HAPTOGLOBIN-RELATED PROTEIN; DNA METHYLATION; PROMOTER HYPOMETHYLATION;
   WIDE ASSOCIATION; BREAST-CANCER; EXPRESSION; PLACENTA; GENES; WOMEN
AB The objective of this study was to analyze genome-wide differential methylation patterns in maternal leukocyte DNA in early pregnant and non-pregnant states. This is an age and body mass index matched case-control study comparing the methylation patterns of 27,578 cytosine-guanine (CpG) sites in 14,495 genes in maternal leukocyte DNA in early pregnancy (n = 14), in the same women postpartum (n = 14), and in nulligravid women (n = 14) on a BeadChip platform. Transient widespread hypomethylation was found in early pregnancy as compared with the non-pregnant states. Methylation of nine genes was significantly different in early pregnancy compared with both postpartum and nulligravid states (<10% False Discovery Rate). Early pregnancy may be characterized by widespread hypomethylation compared with non-pregnant states; there is no apparent permanent methylation imprint after a normal term gestation. Nine potential candidate genes were identified as differentially methylated in early pregnancy and may play a role in the maternal adaptation to pregnancy.
C1 [White, Wendy M.; Brost, Brian C.; Rose, Carl] Mayo Clin, Coll Med, Div Maternal Fetal Med, Dept OB GYN, Rochester, MN 55905 USA.
   [Sun, Zhifu] Mayo Clin, Coll Med, Dept Biomed Stat & Informat, Rochester, MN USA.
   [Craici, Iasmina; Wagner, Steven J.; Turner, Stephen; Garovic, Vesna D.] Mayo Clin, Coll Med, Div Nephrol & Hypertens, Dept Internal Med, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP White, WM (通讯作者)，Mayo Clin, Coll Med, Div Maternal Fetal Med, Dept OB GYN, Rochester, MN 55905 USA.
EM white.wendy@mayo.edu
RI Turner, Stephen/GXM-4654-2022
OI Brost, Brian/0000-0002-4903-4186; Garovic, Vesna/0000-0001-6891-0578;
   Sun, Zhifu/0000-0001-8461-7523
FU Mayo Clinic Foundation: Mary Kathryn and Michael B. Panitch Career
   Development Award; Eunice Kennedy Shriver National Institute of Child
   Health and Human Development [K08HD051714]
FX This work was funded by the Mayo Clinic Foundation: Mary Kathryn and
   Michael B. Panitch Career Development Award and K08HD051714 (Vesna D.
   Garovic) from the Eunice Kennedy Shriver National Institute of Child
   Health and Human Development. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the Eunice Kennedy Shriver National Institute of Child Health and Human
   Development or the National Institutes of Health.
CR [Anonymous], 2010, PROD INF MAN HUM IL
   Avila L, 2010, PLACENTA, V31, P1070, DOI 10.1016/j.placenta.2010.09.011
   Bell CG, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-33
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Bouchard L, 2010, DIABETES CARE, V33, P2436, DOI 10.2337/dc10-1024
   Bourque DK, 2010, PLACENTA, V31, P197, DOI 10.1016/j.placenta.2009.12.003
   Chiu RWK, 2007, AM J PATHOL, V170, P941, DOI 10.2353/ajpath.2007.060641
   Chow SSW, 2008, CYTOKINE, V44, P78, DOI 10.1016/j.cyto.2008.06.009
   Feinberg AP, 2010, VIRCHOWS ARCH, V456, P13, DOI 10.1007/s00428-009-0847-2
   Herrmann-Lavoie C, 2007, ENDOCRINOLOGY, V148, P5377, DOI 10.1210/en.2007-0368
   Hoffman LH, 1996, BIOL REPROD, V55, P176, DOI 10.1095/biolreprod55.1.176
   Ioannidis JPA, 2009, NAT REV GENET, V10, P318, DOI 10.1038/nrg2544
   Katari S, 2009, HUM MOL GENET, V18, P3769, DOI 10.1093/hmg/ddp319
   KUHAJDA FP, 1989, NEW ENGL J MED, V321, P636, DOI 10.1056/NEJM198909073211003
   KUHAJDA FP, 1989, P NATL ACAD SCI USA, V86, P1188, DOI 10.1073/pnas.86.4.1188
   Kulkarni A, 2011, DNA CELL BIOL, V30, P79, DOI 10.1089/dna.2010.1084
   LIBRACH CL, 1994, J BIOL CHEM, V269, P17125
   Liu YJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004037
   Bellido ML, 2010, BIOL REPROD, V82, P745, DOI 10.1095/biolreprod.109.082271
   Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x
   Müller HM, 2004, CLIN CHEM, V50, P1065, DOI 10.1373/clinchem.2003.030387
   Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000
   Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834
   Storey John D, 2003, Methods Mol Biol, V224, P149
   Sun ZF, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-84
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Tost J, 2010, MOL BIOTECHNOL, V44, P71, DOI 10.1007/s12033-009-9216-2
   van Nieuwenhoven ALV, 2003, HUM REPROD UPDATE, V9, P347, DOI 10.1093/humupd/dmg026
   Yuen RKC, 2010, EUR J HUM GENET, V18, P1006, DOI 10.1038/ejhg.2010.63
   Yuen RKC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007389
   Zhao AM, 2011, MOL HUM REPROD, V17, P199, DOI 10.1093/molehr/gaq092
NR 32
TC 15
Z9 15
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JUL
PY 2012
VL 7
IS 7
BP 729
EP 734
DI 10.4161/epi.20388
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 972QJ
UT WOS:000306291900009
PM 22647708
OA Green Accepted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Murphy, SK
   Huang, ZQ
   Hoyo, C
AF Murphy, Susan K.
   Huang, Zhiqing
   Hoyo, Cathrine
TI Differentially Methylated Regions of Imprinted Genes in Prenatal,
   Perinatal and Postnatal Human Tissues
SO PLOS ONE
LA English
DT Article
ID FOLIC-ACID USE; DNA METHYLATION; CHINESE FAMINE; MATERNAL-BEHAVIOR;
   BREAST-CANCER; DUTCH FAMINE; EARLY-LIFE; IGF2 GENE; EXPOSURE; EXPRESSION
AB Epigenetic plasticity in relation to in utero exposures may mechanistically explain observed differences in the likelihood of developing common complex diseases including hypertension, diabetes and cardiovascular disease through the cumulative effects of subtle alterations in gene expression. Imprinted genes are essential mediators of growth and development and are characterized by differentially methylated regulatory regions (DMRs) that carry parental allele-specific methylation profiles. This theoretical 50% level of methylation provides a baseline from which endogenously-or exogenously-induced deviations in methylation can be detected. We quantified DNA methylation at imprinted gene DMRs in a large panel of human conceptal tissues, in matched buccal cell specimens collected at birth and at one year of age, and in the major cell fractions of umbilical cord blood to assess the stability of methylation at these regions. DNA methylation was measured using validated pyrosequencing assays at seven DMRs regulating the IGF2/H19, DLK1/MEG3, MEST, NNAT and SGCE/PEG10 imprinted domains. DMR methylation did not significantly differ for the H19, MEST and SGCE/PEG10 DMRs across all conceptal tissues analyzed (ANOVA p > 0.10). Methylation differences at several DMRs were observed in tissues from brain (IGF2 and MEG3-IG DMRs), liver (IGF2 and MEG3 DMRs) and placenta (both DLK1/MEG3 DMRs and NNAT DMR). In most infants, methylation profiles in buccal cells at birth and at one year of age were comparable, as was methylation in the major cell fractions of umbilical cord blood. Several infants showed temporal deviations in methylation at multiple DMRs. Similarity of inter-individual and intra-individual methylation at some, but not all of the DMRs analyzed supports the possibility that methylation of these regions can serve as useful biosensors of exposure.
C1 [Murphy, Susan K.; Huang, Zhiqing; Hoyo, Cathrine] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA.
C3 Duke University
RP Murphy, SK (通讯作者)，Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA.
EM susan.murphy@duke.edu
RI Murphy, Susan/R-3903-2019
OI Murphy, Susan/0000-0001-8298-7272
FU United States National Institutes of Health [R21ES014947, R01ES016772,
   R01DK085173]; Duke Comprehensive Cancer Center
FX This research was supported by United States National Institutes of
   Health grants R21ES014947, R01ES016772, R01DK085173 and by funding from
   the Duke Comprehensive Cancer Center. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Chen DY, 2011, NATURE, V469, P491, DOI 10.1038/nature09667
   Chu K, 2005, DIABETES, V54, P1064, DOI 10.2337/diabetes.54.4.1064
   Coolen MW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025590
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700
   Elias SG, 2004, JNCI-J NATL CANCER I, V96, P539, DOI 10.1093/jnci/djh087
   Frost JM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001015
   Gertz J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002228
   Gong L, 2010, EPIGENETICS-US, V5, P619, DOI 10.4161/epi.5.7.12882
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Heijmans BT, 2009, EPIGENETICS-US, V4, P526, DOI 10.4161/epi.4.8.10265
   Hishida T, 2007, FEBS LETT, V581, P4272, DOI 10.1016/j.febslet.2007.07.074
   Hoyo C, 2012, CANCER CAUSE CONTROL, V23, P635, DOI 10.1007/s10552-012-9932-y
   Hoyo C, 2011, EPIGENETICS-US, V6, P928, DOI 10.4161/epi.6.7.16263
   Hoyo C, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-46
   Hoyo C, 2009, J EPIDEMIOL COMMUN H, V63, P683, DOI 10.1136/jech.2009.090803
   Huang C, 2010, J NUTR, V140, P1874, DOI 10.3945/jn.110.121293
   Hughes S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-91
   Hulshoff HE, 2000, AM J PSYCHIAT, V157, P1170, DOI 10.1176/appi.ajp.157.7.1170
   Isles AR, 2000, TRENDS COGN SCI, V4, P309, DOI 10.1016/S1364-6613(00)01504-7
   Lee K, 2003, J CLIN INVEST, V111, P453, DOI 10.1172/JCI15924
   Lee PS, 2010, INT J CANCER, V126, P1378, DOI 10.1002/ijc.24797
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330
   Li YP, 2010, DIABETES, V59, P2400, DOI 10.2337/db10-0385
   Liu TL, 2010, EPIDEMIOLOGY, V21, P736, DOI 10.1097/EDE.0b013e3181e9c118
   Lumey L H, 1993, Paediatr Perinat Epidemiol, V7, P354, DOI 10.1111/j.1365-3016.1993.tb00415.x
   Ma D, 2004, J CLIN INVEST, V114, P339, DOI 10.1172/jci200419876
   Mathers JC, 2008, P NUTR SOC, V67, P390, DOI 10.1017/S0029665108008744
   Mikeska T, 2007, J MOL DIAGN, V9, P368, DOI 10.2353/jmoldx.2007.060167
   Murphy SK, 2006, MOL CANCER RES, V4, P283, DOI 10.1158/1541-7786.MCR-05-0138
   Murphy SK, 2003, BIOESSAYS, V25, P577, DOI 10.1002/bies.10277
   Murphy SK, 2012, GENE, V494, P36, DOI 10.1016/j.gene.2011.11.062
   Nomura Y, 2010, J NERV MENT DIS, V198, P672, DOI 10.1097/NMD.0b013e3181ef3489
   Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564
   Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811
   Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9
   Reed K, 2010, ANAL BIOCHEM, V397, P96, DOI 10.1016/j.ab.2009.10.021
   Reik W, 2003, J PHYSIOL-LONDON, V547, P35, DOI 10.1113/jphysiol.2002.033274
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595
   Sciberras E, 2011, J ABNORM CHILD PSYCH, V39, P1025, DOI 10.1007/s10802-011-9504-8
   Soubry A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-2
   Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845
   Susser E, 2008, ANN NY ACAD SCI, V1136, P185, DOI 10.1196/annals.1425.024
   Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Uribe-Lewis S, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399410001717
   Wallace C, 2010, NAT GENET, V42, P68, DOI 10.1038/ng.493
   Wang YH, 2010, OBESITY, V18, P588, DOI 10.1038/oby.2009.296
   Wang YH, 2006, J NUTR, V136, P2953, DOI 10.1093/jn/136.12.2953
   Wang YH, 2009, CELL METAB, V9, P287, DOI 10.1016/j.cmet.2009.01.013
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Waterland RA, 2006, GENESIS, V44, P401, DOI 10.1002/dvg.20230
   Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252
   Wong HL, 2006, BIOTECHNIQUES, V41, P734, DOI 10.2144/000112305
   Woodfine K, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-1
   Xu MQ, 2009, SCHIZOPHRENIA BULL, V35, P568, DOI 10.1093/schbul/sbn168
   Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0
   Zhang YY, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r138
NR 63
TC 144
Z9 156
U1 0
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2012
VL 7
IS 7
AR e40924
DI 10.1371/journal.pone.0040924
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 974CF
UT WOS:000306406700069
PM 22808284
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Stone, A
   Valdés-Mora, F
   Gee, JMW
   Farrow, L
   McClelland, RA
   Fiegl, H
   Dutkowski, C
   McCloy, RA
   Sutherland, RL
   Musgrove, EA
   Nicholson, RI
AF Stone, Andrew
   Valdes-Mora, Fatima
   Gee, Julia M. W.
   Farrow, Lynne
   McClelland, Richard A.
   Fiegl, Heidi
   Dutkowski, Carol
   McCloy, Rachael A.
   Sutherland, Robert L.
   Musgrove, Elizabeth A.
   Nicholson, Robert I.
TI Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in
   Anti-Hormone Resistant Breast Cancer
SO PLOS ONE
LA English
DT Article
ID BETA SUPERFAMILY MEMBER; GENOME-WIDE ANALYSIS; GROWTH-FACTOR-BETA;
   ENDOCRINE RESISTANCE; APOPTOTIC RESPONSE; DNA METHYLATION; TARGET GENE;
   RECEPTOR; CELLS; EXPRESSION
AB In the present study, we have taken the novel approach of using an in vitro model representative of tamoxifen-withdrawal subsequent to clinical relapse to achieve a greater understanding of the mechanisms that serve to maintain the resistant-cell phenotype, independent of any agonistic impact of tamoxifen, to identify potential novel therapeutic approaches for this disease state. Following tamoxifen withdrawal, tamoxifen-resistant MCF-7 cells conserved both drug resistance and an increased basal rate of proliferation in an oestrogen deprived environment, despite reduced epidermal growth-factor receptor expression and reduced sensitivity to gefitinib challenge. Although tamoxifen-withdrawn cells retained ER expression, a sub-set of ER-responsive genes, including pS2 and progesterone receptor (PgR), were down-regulated by promoter DNA methylation, as confirmed by clonal bisulphite sequencing experiments. Following promoter demethylation with 5-Azacytidine (5-Aza), the co-addition of oestradiol (E2) restored gene expression in these cells. In addition, 5-Aza/E2 co-treatment induced a significant anti-proliferative effect in the tamoxifen-withdrawn cells, in-contrast to either agent used alone. Microarray analysis was undertaken to identify genes specifically up regulated by this co-treatment. Several anti-proliferative gene candidates were identified and their promoters were confirmed as more heavily methylated in the tamoxifen resistant vs sensitive cells. One such gene candidate, growth differentiation factor 15 (GDF15), was carried forward for functional analysis. The addition of 5-Aza/E2 was sufficient to de-methylate and activate GDF15 expression in the tamoxifen resistant cell-lines, whilst in parallel, treatment with recombinant GDF15 protein decreased cell survival. These data provide evidence to support a novel concept that long-term tamoxifen exposure induces epigenetic silencing of a cohort of oestrogen-responsive genes whose function is associated with negative proliferation control. Furthermore, reactivation of such genes using epigenetic drugs could provide a potential therapeutic avenue for the management of tamoxifen-resistant breast cancer.
C1 [Stone, Andrew; Gee, Julia M. W.; Farrow, Lynne; McClelland, Richard A.; Dutkowski, Carol; Nicholson, Robert I.] Cardiff Univ, Welsh Sch Pharm, Cardiff, S Glam, Wales.
   [Stone, Andrew; McCloy, Rachael A.; Sutherland, Robert L.; Musgrove, Elizabeth A.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW, Australia.
   [Stone, Andrew; McCloy, Rachael A.; Sutherland, Robert L.; Musgrove, Elizabeth A.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia.
   [Valdes-Mora, Fatima] Garvan Inst Med Res, Dept Epigenet, Sydney, NSW, Australia.
   [Fiegl, Heidi] Innsbruck Med Univ, Dept Obstet & Gynaecol, Innsbruck, Austria.
   [Sutherland, Robert L.; Musgrove, Elizabeth A.] Univ New S Wales, St Vincents Clin Sch, Fac Med, St Vincents Hosp, Sydney, NSW, Australia.
C3 Cardiff University; The Kinghorn Cancer Centre; Garvan Institute of
   Medical Research; Garvan Institute of Medical Research; Garvan Institute
   of Medical Research; Medical University of Innsbruck; University of New
   South Wales Sydney; NSW Health; St Vincents Hospital Sydney
RP Stone, A (通讯作者)，Cardiff Univ, Welsh Sch Pharm, Redwood Bldg, Cardiff, S Glam, Wales.
EM a.stone@garvan.org.au
RI Mora, Fatima/AAB-9728-2021; Gee, Julia/N-3995-2014; Fiegl,
   Heidi/K-4445-2017
OI Gee, Julia/0000-0001-6483-2015; McCloy, Rachael/0000-0001-7791-4044;
   Fiegl, Heidi/0000-0002-1236-6806; Valdes-Mora,
   Fatima/0000-0001-7490-0114
FU AstraZeneca; Breast Cancer Campaign; National Health and Medical
   Research Council Australia; Cancer Institute New South Wales; RT Hall
   Trust; Petre Foundation; Australian Cancer Research Foundation; Prostate
   Cancer Foundation of Australia; FWF Austrian Science Fund [V33-B13]
FX Julia M. W. Gee and Robert I. Nicholson were in receipt of funding from
   AstraZeneca. Julia M. W. Gee was also in receipt of funding from Breast
   Cancer Campaign. Robert L. Sutherland and Elizabeth A. Musgrove were in
   receipt of funding from the National Health and Medical Research Council
   Australia, Cancer Institute New South Wales, RT Hall Trust, Petre
   Foundation and the Australian Cancer Research Foundation. Fatima
   Valdes-Mora was in receipt of funding from the Prostate Cancer
   Foundation of Australia. Heidi Fiegl was funded by the FWF Austrian
   Science Fund (V33-B13). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610
   Aung CS, 2009, CARCINOGENESIS
   Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Badia E, 2000, CANCER RES, V60, P4130
   Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901
   Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514
   BRUNNER N, 1993, CANCER RES, V53, P3229
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   El-Aziz SHA, 2007, CANCER SCI, V98, P1330, DOI 10.1111/j.1349-7006.2007.00547.x
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gee JMW, 2006, ENDOCR-RELAT CANCER, V13, pS77, DOI 10.1677/erc.1.01274
   Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200
   Gupta M, 1998, J STEROID BIOCHEM, V67, P413, DOI 10.1016/S0960-0760(98)00135-6
   Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172
   Gutteridge E, 2010, INT J CANCER, V126, P1806, DOI 10.1002/ijc.24884
   Hostanska K, 2004, BREAST CANCER RES TR, V84, P151, DOI 10.1023/B:BREA.0000018413.98636.80
   Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380
   Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104
   JOHNSTON SRD, 1995, CANCER RES, V55, P3331
   Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1
   Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620
   Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   LEVENSON AS, 1994, J STEROID BIOCHEM, V51, P229, DOI 10.1016/0960-0760(94)90035-3
   Lewis JS, 2005, JNCI-J NATL CANCER I, V97, P1746, DOI 10.1093/jnci/dji400
   Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199
   Licznar A, 2003, FEBS LETT, V553, P445, DOI 10.1016/S0014-5793(03)01090-1
   Lim HW, 2010, J REPROD DEVELOP, V56, P86, DOI 10.1262/jrd.20247
   Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200
   McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776
   Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947
   Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521
   Mossman D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023127
   Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Naughton C, 2007, MOL ENDOCRINOL, V21, P2615, DOI 10.1210/me.2007-0110
   Nicholson RI, 2007, REV ENDOCR METAB DIS, V8, P241, DOI 10.1007/s11154-007-9033-5
   Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459
   Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369
   Patterson K, 2011, JOVE-J VIS EXP, DOI 10.3791/3170
   Peethambaram PP, 1999, BREAST CANCER RES TR, V54, P117, DOI 10.1023/A:1006185805079
   Reisner PD, 1997, CELL CALCIUM, V21, P53, DOI 10.1016/S0143-4160(97)90096-8
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Robertson JFR, 2001, BRIT J CANCER, V85, P11, DOI 10.1054/bjoc.2001.1982
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Sadikovic B, 2004, BREAST CANCER RES, V6, pR329, DOI 10.1186/bcr799
   Schiff R, 2003, CLIN CANCER RES, V9, p447S
   Song RXD, 2001, J NATL CANCER I, V93, P1714, DOI 10.1093/jnci/93.22.1714
   Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109
   Treeck O, 2004, ANTI-CANCER DRUG, V15, P787, DOI 10.1097/00001813-200409000-00008
   VANAGTHOVEN T, 1994, MOL ENDOCRINOL, V8, P1474, DOI 10.1210/me.8.11.1474
   Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200
   Wu MH, 2007, MOL CANCER RES, V5, P1285, DOI 10.1158/1541-7786.MCR-07-0126
   Zhang L, 2009, J GASTROENTEROL, V44, P305, DOI 10.1007/s00535-009-0027-9
NR 61
TC 51
Z9 58
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 10
PY 2012
VL 7
IS 7
AR e40466
DI 10.1371/journal.pone.0040466
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 973JD
UT WOS:000306355500044
PM 22808167
OA Green Published, Green Submitted, gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Catalano, MG
   Fortunati, N
   Pugliese, M
   Marano, F
   Ortoleva, L
   Poli, R
   Asioli, S
   Bandino, A
   Palestini, N
   Grange, C
   Bussolati, B
   Boccuzzi, G
AF Catalano, Maria Graziella
   Fortunati, Nicoletta
   Pugliese, Mariateresa
   Marano, Francesca
   Ortoleva, Loredana
   Poli, Roberta
   Asioli, Sofia
   Bandino, Andrea
   Palestini, Nicola
   Grange, Cristina
   Bussolati, Benedetta
   Boccuzzi, Giuseppe
TI Histone Deacetylase Inhibition Modulates E-Cadherin Expression and
   Suppresses Migration and Invasion of Anaplastic Thyroid Cancer Cells
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID VALPROIC ACID; ADHESION MOLECULE; CYCLIN D1; CLINICAL-SIGNIFICANCE;
   DOWN-REGULATION; BREAST-CANCER; BETA-CATENIN; TRANSCRIPTION; SNAIL;
   OVEREXPRESSION
AB Context: Anaplastic thyroid cancer cells are characterized by a mesenchymal phenotype, as revealed by spindle-shaped cells and absent or reduced levels of E-cadherin. Epigenetic silencing is considered one of the leading mechanisms of E-cadherin impairment, which causes the acquisition of the invasive and metastatic phenotype of anaplastic thyroid cancer.
   Objectives: In this study we investigated the effects of histone deacetylase inhibition on E-cadherin expression, cell motility, and invasion in anaplastic thyroid cancer cell cultures.
   Design: Three stabilized cell lines and primary cultures of anaplastic thyroid cancer were treated with various histone deacetylase inhibitors. After treatment, we evaluated histone acetylation by Western blotting and E-cadherin expression by RT-real time PCR. The proper localization of E-cadherin/beta-catenin complex was assessed by immunofluorescence and Western blot. Transcription activity of beta-catenin was measured by luciferase reporter gene and cyclin D1 expression. The effect on cell motility and invasion was studied both in vitro using scratch-wound and transwell invasion assays and in anaplastic thyroid carcinomas tumor xenografts in mice in vivo.
   Results: Histone deacetylase inhibition induced the E-cadherin expression and the proper membrane localization of the E-cadherin/beta-catenin complex, leading to reduced cancer cell migration and invasion.
   Conclusions: We here demonstrate an additional molecular mechanism for the anticancer effect of histone deacetylase inhibition. The antiinvasive effect in addition to the cytotoxic activity of histone deacetylase inhibitors opens up therapeutic perspectives for the anaplastic thyroid tumor that does not respond to conventional therapy. (J Clin Endocrinol Metab 97: E1150-E1159, 2012)
C1 [Catalano, Maria Graziella; Pugliese, Mariateresa; Marano, Francesca; Ortoleva, Loredana; Poli, Roberta; Boccuzzi, Giuseppe] Univ Turin, Dipartimento Fisiopatol Clin, I-10126 Turin, Italy.
   [Asioli, Sofia] Univ Turin, Dept Biomed Sci & Human Oncol, I-10126 Turin, Italy.
   [Grange, Cristina; Boccuzzi, Giuseppe] Univ Turin, Dept Internal Med, I-10126 Turin, Italy.
   [Palestini, Nicola] Univ Turin, Dept Surg, I-10126 Turin, Italy.
   [Bandino, Andrea] Univ Turin, Dept Expt Med & Oncol, Biochem Sect, I-10126 Turin, Italy.
   [Palestini, Nicola; Boccuzzi, Giuseppe] AUO San Giovanni Battista, Dept Oncol Endocrinol, I-10124 Turin, Italy.
C3 University of Turin; University of Turin; University of Turin;
   University of Turin; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista-Molinette
RP Boccuzzi, G (通讯作者)，Univ Turin, Dipartimento Fisiopatol Clin, Via Genova 3, I-10126 Turin, Italy.
EM giuseppe.boccuzzi@unito.it
RI Asioli, Sofia/K-1501-2016; Poli, Roberta/LIF-2522-2024; Bussolati,
   Benedetta/AAA-9058-2022; Fortunati, Nicoletta/K-3081-2016; CATALANO,
   Maria Graziella/J-4320-2016
OI Fortunati, Nicoletta/0000-0001-8069-9621; GRANGE,
   CRISTINA/0000-0002-6960-5476; Bussolati, Benedetta/0000-0002-3663-5134;
   Asioli, Sofia/0000-0002-5035-2448; CATALANO, Maria
   Graziella/0000-0002-1170-8245
FU Fondazione CRT, Turin, Italy; Regione Piemonte
FX This work was supported by Fondazione CRT, Turin, Italy, and by Regione
   Piemonte (to G.B.).
CR Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Beck J, 2005, J CLIN ONCOL, V23, p228S
   Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x
   Borbone E, 2010, ONCOGENE, V29, P105, DOI 10.1038/onc.2009.306
   Bordonaro M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027308
   Catalano MG, 2007, ENDOCR-RELAT CANCER, V14, P839, DOI 10.1677/ERC-07-0096
   Catalano MG, 2006, J ENDOCRINOL, V191, P465, DOI 10.1677/joe.1.06970
   Catalano MG, 2012, INT J CANCER, V130, P694, DOI 10.1002/ijc.26057
   Catalano MG, 2010, MOL ASPECTS MED, V31, P215, DOI 10.1016/j.mam.2010.02.006
   Catalano MG, 2005, J CLIN ENDOCR METAB, V90, P1383, DOI 10.1210/jc.2004-1355
   Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276
   Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7
   Dong XY, 2011, ENDOCR-RELAT CANCER, V18, P301, DOI 10.1530/ERC-10-0320
   Fortunati N, 2004, J CLIN ENDOCR METAB, V89, P1006, DOI 10.1210/jc.2003-031407
   Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   Hardy RG, 2007, AM J PATHOL, V171, P1037, DOI 10.2353/ajpath.2007.061211
   Hayashi A, 2010, INT J CANCER, V127, P1332, DOI 10.1002/ijc.25151
   Huang SH, 1999, THYROID, V9, P1095, DOI 10.1089/thy.1999.9.1095
   Jacobs K, 2011, EUR J CANCER PREV, V20, P207, DOI 10.1097/CEJ.0b013e3283429e8b
   Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jc.87.4.1814
   Kim NH, 2011, BIOCHEM BIOPH RES CO, V404, P915, DOI 10.1016/j.bbrc.2010.12.081
   LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4
   Mitselou A., 2007, Experimental Oncology, V29, P54
   Naito A, 2001, J SURG ONCOL, V76, P176, DOI 10.1002/jso.1031
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Pesutic-Pisac V, 2008, CROAT MED J, V49, P643, DOI 10.3325/cmj.2008.5.643
   Ringel MD, 2009, CURR OPIN ENDOCRINOL, V16, P361, DOI 10.1097/MED.0b013e32832ff2cb
   SCHEUMMAN GFW, 1995, J CLIN ENDOCR METAB, V80, P2168, DOI 10.1210/jc.80.7.2168
   Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102
   Soares P, 1997, INT J CANCER, V70, P32
   Srivastava RK, 2010, MOL CANCER THER, V9, P3254, DOI 10.1158/1535-7163.MCT-10-0582
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   vonWasielewski R, 1997, CANCER RES, V57, P2501
   Wanczyk M, 2011, FRONT BIOSCI-LANDMRK, V16, P340, DOI 10.2741/3691
   Wang S, 2000, MODERN PATHOL, V13, P882, DOI 10.1038/modpathol.3880157
   Wiseman SM, 2006, AM J SURG, V191, P581, DOI 10.1016/j.amjsurg.2006.02.005
NR 39
TC 37
Z9 45
U1 0
U2 9
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2012
VL 97
IS 7
BP E1150
EP E1159
DI 10.1210/jc.2011-2970
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 972OJ
UT WOS:000306286100008
PM 22563106
OA Bronze
DA 2025-01-12
ER

PT J
AU Robinson, G
   Parker, M
   Kranenburg, TA
   Lu, C
   Chen, X
   Ding, L
   Phoenix, TN
   Hedlund, E
   Wei, L
   Zhu, XY
   Chalhoub, N
   Baker, SJ
   Huether, R
   Kriwacki, R
   Curley, N
   Thiruvenkatam, R
   Wang, JM
   Wu, G
   Rusch, M
   Hong, X
   Becksfort, J
   Gupta, P
   Ma, J
   Easton, J
   Vadodaria, B
   Onar-Thomas, A
   Lin, T
   Li, SY
   Pounds, S
   Paugh, S
   Zhao, D
   Kawauchi, D
   Roussel, MF
   Finkelstein, D
   Ellison, DW
   Lau, CC
   Bouffet, E
   Hassall, T
   Gururangan, S
   Cohn, R
   Fulton, RS
   Fulton, LL
   Dooling, DJ
   Ochoa, K
   Gajjar, A
   Mardis, ER
   Wilson, RK
   Downing, JR
   Zhang, JH
   Gilbertson, RJ
AF Robinson, Giles
   Parker, Matthew
   Kranenburg, Tanya A.
   Lu, Charles
   Chen, Xiang
   Ding, Li
   Phoenix, Timothy N.
   Hedlund, Erin
   Wei, Lei
   Zhu, Xiaoyan
   Chalhoub, Nader
   Baker, Suzanne J.
   Huether, Robert
   Kriwacki, Richard
   Curley, Natasha
   Thiruvenkatam, Radhika
   Wang, Jianmin
   Wu, Gang
   Rusch, Michael
   Hong, Xin
   Becksfort, Jared
   Gupta, Pankaj
   Ma, Jing
   Easton, John
   Vadodaria, Bhavin
   Onar-Thomas, Arzu
   Lin, Tong
   Li, Shaoyi
   Pounds, Stanley
   Paugh, Steven
   Zhao, David
   Kawauchi, Daisuke
   Roussel, Martine F.
   Finkelstein, David
   Ellison, David W.
   Lau, Ching C.
   Bouffet, Eric
   Hassall, Tim
   Gururangan, Sridharan
   Cohn, Richard
   Fulton, Robert S.
   Fulton, Lucinda L.
   Dooling, David J.
   Ochoa, Kerri
   Gajjar, Amar
   Mardis, Elaine R.
   Wilson, Richard K.
   Downing, James R.
   Zhang, Jinghui
   Gilbertson, Richard J.
TI Novel mutations target distinct subgroups of medulloblastoma
SO NATURE
LA English
DT Article
ID BOX RNA HELICASE; E-CADHERIN GENE; BETA-CATENIN; SOMATIC MUTATIONS;
   BREAST-CANCER; STEM-CELLS; DROSOPHILA; EZH2; TRANSACTIVATION;
   METHYLATION
AB Medulloblastoma is a malignant childhood brain tumour comprising four discrete subgroups. Here, to identify mutations that drive medulloblastoma, we sequenced the entire genomes of 37 tumours and matched normal blood. One-hundred and thirty-six genes harbouring somatic mutations in this discovery set were sequenced in an additional 56 medulloblastomas. Recurrent mutations were detected in 41 genes not yet implicated in medulloblastoma; several target distinct components of the epigenetic machinery in different disease subgroups, such as regulators of H3K27 and H3K4 trimethylation in subgroups 3 and 4 (for example, KDM6A and ZMYM3), and CTNNB1-associated chromatin re-modellers in WNT-subgroup tumours (for example, SMARCA4 and CREBBP). Modelling of mutations in mouse lower rhombic lip progenitors that generate WNT-subgroup tumours identified genes that maintain this cell lineage (DDX3X), as well as mutated genes that initiate (CDH1) or cooperate (PIK3CA) in tumorigenesis. These data provide important new insights into the pathogenesis of medulloblastoma subgroups and highlight targets for therapeutic development.
C1 [Robinson, Giles; Parker, Matthew; Kranenburg, Tanya A.; Lu, Charles; Chen, Xiang; Ding, Li; Phoenix, Timothy N.; Hedlund, Erin; Wei, Lei; Zhu, Xiaoyan; Chalhoub, Nader; Baker, Suzanne J.; Huether, Robert; Kriwacki, Richard; Curley, Natasha; Thiruvenkatam, Radhika; Wang, Jianmin; Wu, Gang; Rusch, Michael; Hong, Xin; Becksfort, Jared; Gupta, Pankaj; Ma, Jing; Easton, John; Vadodaria, Bhavin; Onar-Thomas, Arzu; Lin, Tong; Li, Shaoyi; Pounds, Stanley; Paugh, Steven; Zhao, David; Kawauchi, Daisuke; Roussel, Martine F.; Finkelstein, David; Ellison, David W.; Lau, Ching C.; Bouffet, Eric; Hassall, Tim; Gururangan, Sridharan; Cohn, Richard; Fulton, Robert S.; Fulton, Lucinda L.; Dooling, David J.; Ochoa, Kerri; Gajjar, Amar; Mardis, Elaine R.; Wilson, Richard K.; Downing, James R.; Zhang, Jinghui; Gilbertson, Richard J.] Washington Univ, St Jude Childrens Res Hosp, Pediat Canc Genome Project, Memphis, TN 38105 USA.
   [Robinson, Giles; Kranenburg, Tanya A.; Phoenix, Timothy N.; Zhu, Xiaoyan; Chalhoub, Nader; Baker, Suzanne J.; Curley, Natasha; Thiruvenkatam, Radhika; Gilbertson, Richard J.] St Jude Childrens Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA.
   [Robinson, Giles; Gajjar, Amar; Gilbertson, Richard J.] St Jude Childrens Hosp, Dept Oncol, Memphis, TN 38105 USA.
   [Parker, Matthew; Chen, Xiang; Hedlund, Erin; Wei, Lei; Huether, Robert; Wu, Gang; Rusch, Michael; Easton, John; Vadodaria, Bhavin; Finkelstein, David; Zhang, Jinghui] St Jude Childrens Hosp, Dept Computat Biol & Bioinformat, Memphis, TN 38105 USA.
   [Lu, Charles; Ding, Li; Hong, Xin; Fulton, Robert S.; Fulton, Lucinda L.; Dooling, David J.; Ochoa, Kerri; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Genome Inst, St Louis, MO 63108 USA.
   [Ding, Li; Fulton, Robert S.; Fulton, Lucinda L.; Dooling, David J.; Ochoa, Kerri; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA.
   [Wei, Lei; Ma, Jing; Ellison, David W.; Downing, James R.] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA.
   [Huether, Robert; Kriwacki, Richard] St Jude Childrens Hosp, Dept Biol Struct, Memphis, TN 38105 USA.
   [Wang, Jianmin; Becksfort, Jared; Gupta, Pankaj; Zhao, David] St Jude Childrens Hosp, Dept Informat Sci, Memphis, TN 38105 USA.
   [Onar-Thomas, Arzu; Lin, Tong; Li, Shaoyi; Pounds, Stanley] St Jude Childrens Hosp, Dept Biostat, Memphis, TN 38105 USA.
   [Paugh, Steven] St Jude Childrens Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA.
   [Kawauchi, Daisuke; Roussel, Martine F.] St Jude Childrens Hosp, Dept Tumour Biol & Genet, Memphis, TN 38105 USA.
   [Lau, Ching C.] Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA.
   [Bouffet, Eric] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
   [Hassall, Tim] Royal Childrens Hosp, Parkville, Vic 3052, Australia.
   [Gururangan, Sridharan] Duke Univ, Med Ctr, Durham, NC 27710 USA.
   [Cohn, Richard] Univ New S Wales, Sch Womens & Childrens Hlth, Kensington, NSW 2052, Australia.
   [Mardis, Elaine R.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63108 USA.
   [Wilson, Richard K.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63108 USA.
C3 St Jude Children's Research Hospital; St Jude Children's Research
   Hospital; St Jude Children's Research Hospital; St Jude Children's
   Research Hospital; Washington University (WUSTL); Washington University
   (WUSTL); St Jude Children's Research Hospital; St Jude Children's
   Research Hospital; St Jude Children's Research Hospital; St Jude
   Children's Research Hospital; University of Tennessee System; University
   of Tennessee Health Science Center; St Jude Children's Research
   Hospital; St Jude Children's Research Hospital; Texas Children's Cancer
   Center; University of Toronto; Hospital for Sick Children (SickKids);
   Royal Children's Hospital Melbourne; Duke University; University of New
   South Wales Sydney; Washington University (WUSTL); Siteman Cancer
   Center; Washington University (WUSTL)
RP Gilbertson, RJ (通讯作者)，Washington Univ, St Jude Childrens Res Hosp, Pediat Canc Genome Project, Memphis, TN 38105 USA.
EM Jinghui.Zhang@stjude.org; Richard.Gilbertson@stjude.org
RI Wilson, Richard/AAF-4139-2019; Gilbertson, Richard/ABE-1346-2021;
   Ellison, David/N-4806-2018; Wu, Gang/M-8012-2014; Gajjar,
   Amar/N-8059-2018; Kriwacki, Richard/N-8154-2018; Mardis,
   Elaine/W-2202-2019; Lau, Ching/P-7989-2017; Lin, Tong/G-4105-2012;
   Rusch, Michael/AAG-1998-2019; Wang, Jianmin/AAA-2496-2020; Onar-Thomas,
   Arzu/M-9356-2018; Phoenix, Timothy/JNT-6193-2023; Downing,
   James/N-8102-2018; Kawauchi, Daisuke/ABE-9133-2021; Bouffet,
   Eric/AAB-8999-2020; Zhang, JInghui/IAP-9823-2023; Baker,
   Suzanne/N-8167-2018; Pounds, Stanley/N-2480-2018; Robinson,
   Giles/N-8095-2018; Huether, Robert/E-9638-2012; Paugh,
   Steven/A-7739-2008; Roussel, Martine F./F-1469-2016; Chen,
   Xiang/N-2524-2018; Kranenburg, Tanya/F-7138-2012
OI Pounds, Stanley/0000-0002-9167-2114; Easton, John/0000-0003-4503-6608;
   Wu, Gang/0000-0002-1678-5864; Hassall, Timothy/0000-0002-7883-3710;
   Robinson, Giles/0000-0001-7441-9486; Parker,
   Matthew/0000-0003-2999-3870; Gilbertson, Richard/0000-0001-7539-9472;
   Huether, Robert/0000-0001-7077-7470; Paugh, Steven/0000-0001-5697-9228;
   Roussel, Martine F./0000-0002-1740-8139; Cohn,
   Richard/0000-0002-2400-1353; Chen, Xiang/0000-0002-2499-8261;
   Kranenburg, Tanya/0000-0002-5329-4968
FU St Jude Children's Research Hospital, Washington University Pediatric
   Cancer Genome Project; National Institutes of Health [R01CA129541,
   P01CA96832, P30CA021765]; Collaborative Ependymoma Research Network
   (CERN); Musicians against Childhood Cancer (MACC); Noyes Brain Tumour
   Foundation; American Lebanese Syrian Associated Charities (ALSAC)
FX This research was supported as part of the St Jude Children's Research
   Hospital, Washington University Pediatric Cancer Genome Project. This
   work was supported by grants from the National Institutes of Health
   (R01CA129541, P01CA96832 and P30CA021765; R.J.G.), the Collaborative
   Ependymoma Research Network (CERN), Musicians against Childhood Cancer
   (MACC), The Noyes Brain Tumour Foundation, and by the American Lebanese
   Syrian Associated Charities (ALSAC). We are grateful to S. Temple for
   the gift of reagents and the staff of the Hartwell Center for
   Bioinformatics and Biotechnology and ARC at St Jude Children's Research
   Hospital for technical assistance.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Andäng M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488
   Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935
   BECKER KF, 1994, CANCER RES, V54, P3845
   Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Carrera I, 2008, P NATL ACAD SCI USA, V105, P6644, DOI 10.1073/pnas.0709749105
   Castellino RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010849
   *CENTR BRAIN TUM R, 2006, STAT REP PRIM BRAIN
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587
   Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4
   HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302
   Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839
   Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023
   Khan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005076
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088
   Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Lindqvist L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001583
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654
   Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703
   Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324
   Orsulic S, 1999, J CELL SCI, V112, P1237
   Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Pek JW, 2011, P NATL ACAD SCI USA, V108, P12007, DOI 10.1073/pnas.1106245108
   Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013
   RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Schnetz MP, 2009, GENOME RES, V19, P590, DOI 10.1101/gr.086983.108
   Schröder M, 2010, BIOCHEM PHARMACOL, V79, P297, DOI 10.1016/j.bcp.2009.08.032
   Schüller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005
   Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413
   Taylor MD, 2001, PEDIATR NEUROSURG, V35, P235, DOI 10.1159/000050428
   Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z
   Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wang JM, 2011, NAT METHODS, V8, P652, DOI [10.1038/NMETH.1628, 10.1038/nmeth.1628]
   Yang F, 2010, GENOME RES, V20, P614, DOI 10.1101/gr.103200.109
   Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003
   Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725
NR 50
TC 662
Z9 757
U1 1
U2 64
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD AUG 2
PY 2012
VL 488
IS 7409
BP 43
EP 48
DI 10.1038/nature11213
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 981ZE
UT WOS:000307010700029
PM 22722829
OA hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Lirk, P
   Berger, R
   Hollmann, MW
   Fiegl, H
AF Lirk, P.
   Berger, R.
   Hollmann, M. W.
   Fiegl, H.
TI Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid
   in breast cancer cell lines <i>in vitro</i>
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE cancer; demethylation; epigenetics; lidocaine; local anaesthetic
ID ANESTHETIC TECHNIQUE; DNA METHYLATION; RETROSPECTIVE ANALYSIS; NEURAXIAL
   ANESTHESIA; EPIDURAL-ANESTHESIA; LOCAL-ANESTHETICS; COLORECTAL-CANCER;
   FREE SURVIVAL; SURGERY; RECURRENCE
AB Anaesthetic management of cancer surgery may influence tumour recurrence. The modulation of gene expression by methylation of deoxyribonucleic acid (DNA) (epigenetics) is increasingly recognized as a major hallmark of cancer. Next to direct effects of local anaesthetics upon tumour cells, the ester-type local anaesthetic, procaine, has been shown to affect methylation status in several tumour cell lines, promoting the reactivation of tumour suppressor genes. We sought to determine whether the prototype amide-type local anaesthetic, lidocaine, influences the survival and epigenetic status of oestrogen receptor (ER)-positive and -negative breast cancer cell lines in vitro.
   Breast cancer cell lines BT-20 (ER-negative) and MCF-7 (ER-positive) were incubated with lidocaine and procaine as the reference substance. We performed cell count and determined apoptosis using TUNEL stain. Further, we assessed global methylation status, and methylation of three known tumour suppressor genes (RASSF1A, MYOD1, and GSTP1) using the MethyLight assay and real-time quantitative polymerase chain reaction, respectively.
   Baseline methylation was 100-fold higher in BT-20 cells. Here, we observed a dose-dependent decrease in DNA methylation in response to lidocaine (1, 0.01, and 0.01 mM) after 72 h (P0.001, 0.001, and 0.004, respectively). The corresponding changes were smaller in MCF-7 cells. Global methylation status was profoundly influenced, but the methylation and mRNA expression status of three tumour suppressor genes was unchanged.
   Our findings suggest that demethylating tumour-suppressive effects of anaesthetic interventions may only be detectable in specific types of cancer due to differential methylation profiles. In conclusion, at clinically relevant concentrations, lidocaine demethylates DNA of breast cancer cell lines in vitro.
C1 [Lirk, P.; Hollmann, M. W.] Univ Amsterdam, Acad Med Ctr, Dept Anaesthesiol, NL-1105 AZ Amsterdam, Netherlands.
   [Lirk, P.] Innsbruck Med Univ, Dept Anaesthesiol & Crit Care Med, A-6020 Innsbruck, Austria.
   [Berger, R.; Fiegl, H.] Innsbruck Med Univ, Dept Obstet & Gynaecol, A-6020 Innsbruck, Austria.
C3 University of Amsterdam; Academic Medical Center Amsterdam; Medical
   University of Innsbruck; Medical University of Innsbruck
RP Lirk, P (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Anaesthesiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM p.lirk@amc.uva.nl; heidelinde.fiegl@i-med.ac.at
RI Fiegl, Heidi/K-4445-2017
OI Fiegl, Heidi/0000-0002-1236-6806
FU Department of Anaesthesiology and Critical Care Medicine, Innsbruck
   Medical University, Austria; Department of Gynaecology and Obstetrics,
   Innsbruck Medical University, Austria
FX This work was supported by departmental funds of the Departments of
   Anaesthesiology and Critical Care Medicine, and Gynaecology and
   Obstetrics, Innsbruck Medical University, Austria.
CR Arai Y, 2002, J BIOL CHEM, V277, P18986, DOI 10.1074/jbc.M108084200
   Bièche I, 1999, CLIN CHEM, V45, P1148
   Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73
   Castellano S, 2008, J MED CHEM, V51, P2321, DOI 10.1021/jm7015705
   Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55
   de Oliveira GS, 2011, REGION ANESTH PAIN M, V36, P271, DOI 10.1097/AAP.0b013e318217aada
   Deegan CA, 2009, BRIT J ANAESTH, V103, P685, DOI 10.1093/bja/aep261
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   ESPOSITO M, 1990, JNCI-J NATL CANCER I, V82, P677, DOI 10.1093/jnci/82.8.677
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008
   Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d
   Gottschalk A, 2010, ANESTH ANALG, V110, P1636, DOI 10.1213/ANE.0b013e3181de0ab6
   Gupta A, 2011, BRIT J ANAESTH, V107, P164, DOI 10.1093/bja/aer100
   Herroeder S, 2007, ANN SURG, V246, P192, DOI 10.1097/SLA.0b013e31805dac11
   Hollmann MW, 2001, REGION ANESTH PAIN M, V26, P215, DOI 10.1053/rapm.2001.23209
   Ismail H, 2010, BRIT J ANAESTH, V105, P145, DOI 10.1093/bja/aeq156
   KENNEDY KA, 1986, INT J RADIAT ONCOL, V12, P1367, DOI 10.1016/0360-3016(86)90173-2
   Lai RC, 2012, ANESTH ANALG, V114, P290, DOI 10.1213/ANE.0b013e318239c2e3
   LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1
   Lin L, 2011, BRIT J ANAESTH, V106, P814, DOI 10.1093/bja/aer055
   Mammoto T, 2002, J CELL PHYSIOL, V192, P351, DOI 10.1002/jcp.10145
   Müller HM, 2003, BRIT J CANCER, V89, P1934, DOI 10.1038/sj.bjc.6601392
   Myles PS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1491
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Parson W, 2005, FASEB J, V19, P434, DOI 10.1096/fj.04-3062fje
   Perez-Castro R, 2009, ANESTH ANALG, V108, P997, DOI 10.1213/ane.0b013e31819385e1
   Schlagenhauff B, 2000, MELANOMA RES, V10, P165, DOI 10.1097/00008390-200010020-00009
   Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164
   Tada M, 2007, HEPATOL INT, V1, P355, DOI 10.1007/s12072-007-9014-5
   Tang P, 2009, DIAGN MOL PATHOL, V18, P125, DOI 10.1097/PDM.0b013e31818d107b
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Tsui BC, 2009, CAN J ANAESTH, V57, P107
   Villar-Garea A, 2003, CANCER RES, V63, P4984
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec
   Zwischenberger JB, 2004, ANN THORAC SURG, V77, P1916, DOI 10.1016/j.athoracsur.2003.10.111
NR 38
TC 106
Z9 112
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD AUG
PY 2012
VL 109
IS 2
BP 200
EP 207
DI 10.1093/bja/aes128
PG 8
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA 973MJ
UT WOS:000306363900011
PM 22542536
OA Bronze
DA 2025-01-12
ER

PT J
AU Park, SJ
   Jang, HR
   Kim, M
   Kim, JH
   Kwon, OH
   Park, JL
   Noh, SM
   Song, KS
   Kim, SY
   Kim, YH
   Kim, YS
AF Park, Sung-Joon
   Jang, Hay-Ran
   Kim, Mirang
   Kim, Jeong-Hwan
   Kwon, Oh-Hyung
   Park, Jong-Lyul
   Noh, Seung-Moo
   Song, Kyu-Sang
   Kim, Seon-Young
   Kim, Yeul-Hong
   Kim, Yong Sung
TI Epigenetic alteration of <i>CCDC67</i> and its tumor suppressor function
   in gastric cancer
SO CARCINOGENESIS
LA English
DT Article
ID CPG-ISLAND METHYLATION; PROMOTER HYPERMETHYLATION; CELL-MIGRATION;
   BREAST-CANCER; GENE; EXPRESSION; PROTEIN; DNA; GENOME; INACTIVATION
AB In this study, the promoter of the gene coiled-coil domain-containing 67 (CCDC67) was found to be frequently methylated in gastric cancer cell lines and in primary gastric tumors, as examined by restriction landmark genomic scanning. In addition, CCDC67 expression was down-regulated in 72.7% of gastric cancer cell lines tested. In most cases, gene down-regulation was associated with CpG hypermethylation in the CCDC67 promoter. Treatment with 5-aza-2'-deoxycytidine and/or trichostatin A restored CCDC67 expression in down-regulated cell lines. Pyrosequencing analysis of 150 paired primary gastric cancer samples revealed that promoter CpG methylation was increased in 74% of tested tumors compared with paired adjacent normal tissues, and this hypermethylation correlated significantly with down-regulation of CCDC67. CCDC67 protein was localized to the cell membrane by immunocytochemistry. Stable transfection of a CCDC67 gene in one gastric cancer cell line inhibited adhesion-dependent and -independent colony formation, and CCDC67 expression suppressed tumorigenesis in nude mice. We suggest that CCDC67 is a putative tumor suppressor gene that is silenced in gastric cancers by promoter CpG methylation and that it may play an important role in cell signaling and migration related to tumorigenesis.
C1 [Park, Sung-Joon; Jang, Hay-Ran; Kim, Mirang; Kim, Jeong-Hwan; Kwon, Oh-Hyung; Park, Jong-Lyul; Kim, Seon-Young; Kim, Yong Sung] Korea Res Inst Biosci & Biotechnol, Med Genom Res Ctr, Taejon 305806, South Korea.
   [Park, Sung-Joon; Kim, Yeul-Hong] Korea Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul 136705, South Korea.
   [Park, Jong-Lyul; Kim, Seon-Young; Kim, Yong Sung] Univ Sci & Technol, Dept Funct Genom, Taejon 305333, South Korea.
   [Song, Kyu-Sang] Chungnam Natl Univ, Dept Pathol, Coll Med, Taejon 301747, South Korea.
   [Noh, Seung-Moo] Chungnam Natl Univ, Dept Gen Surg, Coll Med, Taejon 301747, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea
   University; Korea University Medicine (KU Medicine); Chungnam National
   University; Chungnam National University
RP Kim, SY (通讯作者)，Korea Res Inst Biosci & Biotechnol, Med Genom Res Ctr, Taejon 305806, South Korea.
EM kimsy@kribb.re.kr; yongsung@kribb.re.kr
RI Kim, Han/AAA-5787-2021; Kim, Sunghoon/AAE-8314-2020; Kim,
   Tae-You/J-2750-2012; Park, Jun Won/KSM-8932-2024; KIM, SEON
   HAHN/JTU-1415-2023; Kim, Jin Young/AAB-6510-2020
OI Kim, Yeul Hong/0000-0002-2555-2333; Kim, Mirang/0000-0001-7415-0077
FU National Research Foundation of Korea (NRK); Korea Government (MEST)
   [2011003769]; National R&D Program for Cancer Control; Ministry for
   Health and Welfare, Republic of Korea [1020360]; A3 Foresight Program
   from the National Research Foundation of Korea; KRIBB Research
   Initiative Grant
FX National Research Foundation of Korea (NRK) grant funded by the Korea
   Government (MEST) (2011003769); National R&D Program for Cancer Control;
   Ministry for Health and Welfare, Republic of Korea (1020360); A3
   Foresight Program from the National Research Foundation of Korea; KRIBB
   Research Initiative Grant.
CR Barth JL, 2010, DEV DYNAM, V239, P2024, DOI 10.1002/dvdy.22341
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5
   Chen M, 2009, CARCINOGENESIS, V30, P841, DOI 10.1093/carcin/bgn288
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Feng Bin, 2007, Zhonghua Wai Ke Za Zhi, V45, P1629
   Gargiulo G, 2009, INT J BIOCHEM CELL B, V41, P127, DOI 10.1016/j.biocel.2008.07.021
   Grassi MA, 2011, HUM MOL GENET, V20, P2472, DOI 10.1093/hmg/ddr121
   HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523
   Hu X.T., 2011, CHIN J CANC, V30
   Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jung S, 2010, ONCOL REP, V23, P1675, DOI 10.3892/or_00000811
   Kang GH, 2003, LAB INVEST, V83, P635, DOI 10.1097/01.LAB.0000067481.08984.3F
   Kim Jeong-Hwan, 2006, Genomics & Informatics, V4, P1
   Kim M, 2008, CANCER RES, V68, P7147, DOI 10.1158/0008-5472.CAN-08-0667
   Kim M, 2008, CARCINOGENESIS, V29, P629, DOI 10.1093/carcin/bgm291
   Kim M, 2008, MOL CANCER RES, V6, P222, DOI 10.1158/1541-7786.MCR-07-0142
   Kim M, 2010, CARCINOGENESIS, V31, P1685, DOI 10.1093/carcin/bgq144
   Kim SK, 2006, BIOCHEM BIOPH RES CO, V349, P1032, DOI 10.1016/j.bbrc.2006.08.128
   Kobayashi S, 2010, BIOCHEM BIOPH RES CO, V392, P29, DOI 10.1016/j.bbrc.2009.12.142
   Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2
   Liu Z, 2011, INT J CANCER, V128, P2562, DOI 10.1002/ijc.25595
   Lo PK, 2010, CANCER RES, V70, P6047, DOI 10.1158/0008-5472.CAN-10-1576
   Modamio-Hoybjor S, 2007, AM J HUM GENET, V80, P1076, DOI 10.1086/518311
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   NAGAI H, 1994, CANCER RES, V54, P1545
   Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9
   Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703
   Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106
   Takada H, 2010, CANCER GENET CYTOGEN, V197, P16, DOI 10.1016/j.cancergencyto.2009.11.004
   Toyota M, 1999, CANCER RES, V59, P5438
   Tuskan RG, 2008, EPIGENETICS-US, V3, P43, DOI 10.4161/epi.3.1.5469
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Wanajo A, 2008, GASTROENTEROLOGY, V135, P580, DOI 10.1053/j.gastro.2008.05.041
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466
NR 39
TC 35
Z9 41
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD AUG
PY 2012
VL 33
IS 8
BP 1494
EP 1501
DI 10.1093/carcin/bgs178
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 992MO
UT WOS:000307781000008
PM 22610074
OA Bronze
DA 2025-01-12
ER

PT J
AU Lian, ZQ
   Wang, Q
   Li, WP
   Zhang, AQ
   Wu, L
AF Lian, Zhen-Qiang
   Wang, Qi
   Li, Wen-Ping
   Zhang, An-Qin
   Wu, Ling
TI Screening of significantly hypermethylated genes in breast cancer using
   microarray-based methylated-CpG island recovery assay and identification
   of their expression levels
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE breast cancer; CpG island methylation; Methyl-CpG binding protein;
   microarray; gene expression; combined bisulfite restriction analysis
ID TUMOR SUPPRESSOR GENE; GENOME-WIDE ANALYSIS; DNA-METHYLATION; PROMOTER
   METHYLATION; LUNG-CANCER; WT1; MULTICENTER; EPIGENETICS; DISEASE
AB To screen candidate methylation markers for early detection of breast cancer and to explore the relationship between methylation and gene expression, we performed methylated-CpG island recovery assay (MIRA) combined with CpG island array on 61982 CpG sites across 4162 genes in 10 cancerous and 10 non-cancerous breast tissues. Direct bisulfite sequencing and combined bisulfite restriction analysis (COBRA) were carried out in independent cancerous and non-cancerous samples. Gene expression was analyzed by microarrays and validated using RT-PCR. We detected 70 significantly hypermethylated genes in breast cancer tissues, including many novel hypermethylated genes such as ITGA4, NFIX, OTX2 and FGFI2. Direct bisulfite sequencing showed widespread methylation occurring in intragenic regions of the WTI, PAX6 and ITGA4 genes and in the promoter region of the OTX2 gene in breast cancer tissues. COBRA assay confirmed that the WTI, OTX2 and PAX6 genes were hypermethylated in breast cancer tissues. Clustering analysis of the gene expression of 70 significantly hypermethylated genes revealed that most hypermethylated genes in breast cancer were not expressed in breast tissues. RT-PCR assay confirmed that WTI and PITX2 were only weakly expressed in the breast cancer tissues and were not expressed in most non-cancerous breast tissues. OTX2 and PAX6 were not expressed in either breast cancer or non-cancerous tissues. In conclusion, these results will expand our knowledge of hypermethylated genes and methylation sites for early detection of breast cancer and deepen our understanding of the relationship between methylation and gene expression. The MIRA approach can screen candidate methylated genes for further clinical validation more effectively than gene expression microarray-based strategy.
C1 [Lian, Zhen-Qiang; Wang, Qi; Li, Wen-Ping; Zhang, An-Qin; Wu, Ling] Guangdong Women & Children Hosp, Guangzhou Med Coll, Breast Dis Ctr, Guangzhou 510010, Guangdong, Peoples R China.
C3 Guangzhou Medical University
RP Wang, Q (通讯作者)，Guangdong Women & Children Hosp, Guangzhou Med Coll, Breast Dis Ctr, Guangzhou 510010, Guangdong, Peoples R China.
EM wangqigz@hotmail.com
RI Qi, Wang/GZM-0551-2022
FU Guangdong Natural Science Foundation [S2011010003747]
FX This work was supported by the Guangdong Natural Science Foundation
   Grant No. S2011010003747. We thank Dr Liang Zhang and BioChain (Beijing)
   Science & Technology Inc. for their technical assistance.
CR Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Harbeck N, 2008, J CLIN ONCOL, V26, P5036, DOI 10.1200/JCO.2007.14.1697
   Ibanez de Caceres I, 2010, ONCOGENE, V29, P1681, DOI 10.1038/onc.2009.454
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Laux DE, 1999, BREAST CANCER RES TR, V56, P35, DOI 10.1023/A:1006222803788
   Leung TY, 2011, ULTRASOUND OBST GYN, V38, P314, DOI 10.1002/uog.8988
   Loeb DM, 2001, CANCER RES, V61, P921
   Maier S, 2007, EUR J CANCER, V43, P1679, DOI 10.1016/j.ejca.2007.04.025
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   Ngan CY, 2007, BRIT J CANCER, V96, P986, DOI 10.1038/sj.bjc.6603651
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rauch Tibor A., 2009, V507, P65, DOI 10.1007/978-1-59745-522-0_6
   Richards AA, 2008, PEDIATR RES, V64, P358, DOI 10.1203/PDR.0b013e31818095d0
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yang Ju-lun, 2007, Chinese Journal of Pathology, V36, P253
NR 24
TC 29
Z9 32
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD AUG
PY 2012
VL 41
IS 2
BP 629
EP 638
DI 10.3892/ijo.2012.1464
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 970TE
UT WOS:000306154400028
PM 22581028
OA Bronze
DA 2025-01-12
ER

PT J
AU Chai, SY
   Smith, R
   Zakar, T
   Mitchell, C
   Madsen, G
AF Chai, S. Y.
   Smith, R.
   Zakar, T.
   Mitchell, C.
   Madsen, G.
TI Term myometrium is characterized by increased activating epigenetic
   modifications at the progesterone receptor-A promoter
SO MOLECULAR HUMAN REPRODUCTION
LA English
DT Article
DE progesterone receptors; myometrium; labour; histone modifications;
   epigenetic
ID BREAST-CANCER; HISTONE-H3 LYSINE-4; ENDOMETRIAL CANCER; MIFEPRISTONE
   RU486; HUMAN PARTURITION; PREGNANT UTERUS; GENE-EXPRESSION; HUMAN LABOR;
   CELL LINES; B-ISOFORM
AB Term human myometrial expression of progesterone receptor (PR)-A is increased relative to PR-B, and as PR-A is a repressor of progesterone action mediated through PR-B, this increase may mediate the withdrawal of progesterone action and precipitate the onset of labour. PR-A and PR-B expression is regulated by two separate promoters of the PR gene. We hypothesized that epigenetic histone modifications at the two promoters contribute to the labour-associated regulation of PR-A and PR-B expression in term myometrium. PR total, PR-B and PR-A mRNA levels were determined using quantitative real-time PCR, and chromatin immunoprecipitation was used to determine the levels of activating and repressive histone modifications at the PR-A and PR-B promoters in human myometrial samples not in labour (n 4) and in labour (n 4). Chromatin extracts were immunoprecipitated with antibodies against activating (histone H3 and H4 acetylation and histone H3 lysine 4 trimethylation), and repressive (histone H3 lysine 9 trimethylation, histone H3 lysine 27 trimethylation and asymmetrical histone H3 arginine 2 dimethylation) histone modifications. PR-A mRNA levels increased during labour, while PR-B mRNA levels remained constant resulting in an increase of PR-A/PR-B mRNA ratio, as expected. Regardless of labour status, significantly higher levels of the activating histone modifications were found at the PR-A promoter compared with the PR-B promoter (P 0.001). H3K4me3 increased significantly at both promoters with labour onset (P 0.001). Low levels of the repressive histone modifications were also present at both promoters, with no labour-associated changes observed. Our data indicate that the PR-A promoter is epigenetically marked for activation in term myometrium more extensively than the PR-B promoter, and that labour is associated with an increase in H3K4me3 activating modification, consistent with the previously described increase in PR protein at this time.
C1 [Chai, S. Y.; Smith, R.; Zakar, T.; Mitchell, C.; Madsen, G.] Univ Newcastle, Mothers & Babies Res Ctr, Hunter Med Res Inst, Newcastle, NSW 2310, Australia.
C3 University of Newcastle; Hunter Medical Research Institute
RP Madsen, G (通讯作者)，Univ Newcastle, Mothers & Babies Res Ctr, Hunter Med Res Inst, Newcastle, NSW 2310, Australia.
EM gemma.madsen@newcastle.edu.au
RI Zakar, Tamas/G-7507-2013
OI Smith, Roger/0000-0003-4720-0280; Zakar, Tamas/0000-0002-1690-1159
FU National Health and Medical Research Council of Australia [631026]; John
   Hunter Hospital Charitable Trust; University of Newcastle, Australia
FX This study was supported by the National Health and Medical Research
   Council of Australia (Project Grant #631026), the John Hunter Hospital
   Charitable Trust and the University of Newcastle, Australia.
CR Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581
   An Woojin, 2007, Subcell Biochem, V41, P351
   AVRECH OM, 1991, FERTIL STERIL, V56, P385
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Binda O, 2010, EPIGENETICS-US, V5, P767, DOI 10.4161/epi.5.8.13278
   CHALBOS D, 1994, J BIOL CHEM, V269, P23007
   CHWALISZ K, 1995, ANN NY ACAD SCI, V761, P202, DOI 10.1111/j.1749-6632.1995.tb31380.x
   Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100
   CSAPO A, 1956, AM J ANAT, V98, P273, DOI 10.1002/aja.1000980206
   Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961
   FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129
   FRYDMAN R, 1988, HUM REPROD, V3, P803, DOI 10.1093/oxfordjournals.humrep.a136786
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291
   Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Kirmizis A, 2007, NATURE, V449, P928, DOI 10.1038/nature06160
   Kishimoto M, 2006, ENDOCR J, V53, P157, DOI 10.1507/endocrj.53.157
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Leonhardt SA, 2002, EXP BIOL MED, V227, P969, DOI 10.1177/153537020222701104
   Liu ZJ, 2003, LIFE SCI, V73, P1963, DOI 10.1016/S0024-3205(03)00544-7
   Madsen G, 2004, J CLIN ENDOCR METAB, V89, P1010, DOI 10.1210/jc.2003-031037
   Mc Cormack O, 2008, BREAST CANCER RES TR, V111, P45, DOI 10.1007/s10549-007-9757-7
   MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2
   Merlino AA, 2007, J CLIN ENDOCR METAB, V92, P1927, DOI 10.1210/jc.2007-0077
   Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924
   Mesiano S, 2011, REPROD SCI, V18, P6, DOI 10.1177/1933719110382922
   Neilson JP, 2000, COCHRANE DB SYST REV, V4
   Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029
   Pieber D, 2001, MOL HUM REPROD, V7, P875, DOI 10.1093/molehr/7.9.875
   Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4
   Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200
   Sasaki M, 2001, CANCER RES, V61, P97
   Sasaki M, 2003, MOL CELL ENDOCRINOL, V202, P201, DOI 10.1016/S0303-7207(03)00084-4
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Scarpin Katherine M, 2009, Nucl Recept Signal, V7, pe009, DOI 10.1621/nrs.07009
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sheehan PM, 2005, MOL HUM REPROD, V11, P495, DOI 10.1093/molehr/gah201
   Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010
   TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256
   VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356
   Wu Y, 2006, EPIGENETICS-US, V1, P106, DOI 10.4161/epi.1.2.2766
   Xiong YN, 2005, GYNECOL ONCOL, V99, P135, DOI 10.1016/j.ygyno.2005.05.035
   Xu XJ, 2004, GENE, V328, P143, DOI 10.1016/j.gene.2003.12.003
   Zakar T, 2007, AM J OBSTET GYNECOL, V196, P289, DOI 10.1016/j.ajog.2006.09.005
NR 48
TC 24
Z9 25
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 1460-2407
J9 MOL HUM REPROD
JI Mol. Hum. Reprod.
PD AUG
PY 2012
VL 18
IS 8
BP 401
EP 409
DI 10.1093/molehr/gas012
PG 9
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA 971BV
UT WOS:000306178100003
PM 22369759
OA Bronze
DA 2025-01-12
ER

PT J
AU Ansari, KI
   Kasiri, S
   Mishra, BP
   Mandal, SS
AF Ansari, K. I.
   Kasiri, S.
   Mishra, B. P.
   Mandal, S. S.
TI Mixed lineage leukaemia-4 regulates cell-cycle progression and cell
   viability and its depletion suppresses growth of xenografted tumour
   <i>in vivo</i>
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE mixed lineage leukaemia; MLL4; histone methylation; tumour suppression;
   tumour xenograft; MLL-antisense
ID ESTROGEN-RECEPTOR; GENE-EXPRESSION; BREAST-CANCER; METHYLTRANSFERASE
   ACTIVITY; MLL3; ROLES; IDENTIFICATION; COACTIVATOR; COMPLEXES; CHROMATIN
AB BACKGROUND: Mixed lineage leukaemia-4 (MLL4) is one of the MLL family of histone H3 lysine-4 (H3K4)-specific methyl transferases that have critical roles in gene expression and epigenetics in human. Though MLLs are well recognised as crucial players in histone methylation and gene regulation; little is known about the biochemical functions of MLL4 and its roles in cancer.
   METHODS: Herein, we have investigated the roles of MLL4 in cell viability, cell-cycle progression and explored its potential roles in tumour growth using antisense-mediated knockdown experiments, flow-cytometry analysis, chromatin immunoprecipitation, immunofluorescence staining and animal models.
   RESULTS: Our studies demonstrated that knockdown of MLL4 severely affects cell-cycle progression and induces apoptotic cell death in cultured tumour cells. Knockdown of MLL4 induced nuclear condensation, fragmentation, cytochrome-c release from mitochondria to cytosol and activated caspase-3/7 indicating apoptotic cell death. The MLL4 regulates expression of various critical cell-cycle regulatory genes such as cyclin D, cyclin E, p27, HOXA5 and HOXB7 via histone H3K4 trimethylation and recruitment of RNA polymerase II. Interestingly, application of MLL4 antisense suppressed tumour growth in vivo in colon cancer xenograft implanted in nude mouse. The MLL4 antisense specifically knocked down MLL4 in tumour tissue and also downregulated the expression of various growth and angiogenic factors resulting in tumour suppression.
   CONCLUSION: Our results demonstrated that MLL4 is a crucial player in cell viability, cell-cycle progression and is critical for tumour growth in vivo. British Journal of Cancer (2012) 107, 315-324. doi:10.1038/bjc.2012.263 www.bjcancer.com Published online 19 June 2012 (c) 2012 Cancer Research UK
C1 [Ansari, K. I.; Kasiri, S.; Mishra, B. P.; Mandal, S. S.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
C3 University of Texas System; University of Texas Arlington
RP Mandal, SS (通讯作者)，Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
EM smandal@uta.edu
RI Ansari, Khairul/C-9791-2011; Kasiri, Sahba/F-1064-2011
OI Ansari, Khairul I/0000-0002-9564-2107; Mandal,
   Subhrangsu/0000-0001-8495-9881
FU NIH [1R15 ES019129-01, 2R15 CA113747-02]
FX We thank Mandal laboratory members for discussion. We thank Dr Linda
   Perrotti and Samara Morris-Bobzean for their help with tissue
   sectioning. Mandal research is supported by grants from NIH (1R15
   ES019129-01, 2R15 CA113747-02).
CR Ajiro Kozo, 2002, Tanpakushitsu Kakusan Koso, V47, P753
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x
   Ansari KI, 2009, ORG BIOMOL CHEM, V7, P926, DOI 10.1039/b816858j
   Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337
   Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Favaro E, 2011, GENOME MED, V3, DOI 10.1186/gm271
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005
   Hoeksema KA, 2011, ONCOTARGETS THER, V4, P149, DOI 10.2147/OTT.S21553
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106
   Lee J, 2008, P NATL ACAD SCI USA, V105, P19229, DOI 10.1073/pnas.0810100105
   Lee S, 2008, MOL ENDOCRINOL, V22, P1312, DOI 10.1210/me.2008-0012
   Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533
   Marschalek R, 2010, FEBS J, V277, P1822, DOI 10.1111/j.1742-4658.2010.07608.x
   Mishra BP, 2009, FEBS J, V276, P1629, DOI 10.1111/j.1742-4658.2009.06895.x
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056
   Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892
   Paulussen ADC, 2011, HUM MUTAT, V32, pE2018, DOI 10.1002/humu.21416
   POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197
   Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006
   Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124
   Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200
   Tammali R, 2006, CANCER RES, V66, P9705, DOI 10.1158/0008-5472.CAN-06-2105
   Tan YC, 2001, CANCER DETECT PREV, V25, P454
   Wang H, 2002, INT J ONCOL, V21, P73
   Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377
NR 33
TC 27
Z9 35
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUL 10
PY 2012
VL 107
IS 2
BP 315
EP 324
DI 10.1038/bjc.2012.263
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 973AY
UT WOS:000306324600015
PM 22713656
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Palmieri, C
   Rudraraju, B
   Monteverde, M
   Lattanzio, L
   Gojis, O
   Brizio, R
   Garrone, O
   Merlano, M
   Syed, N
   Lo Nigro, C
   Crook, T
AF Palmieri, C.
   Rudraraju, B.
   Monteverde, M.
   Lattanzio, L.
   Gojis, O.
   Brizio, R.
   Garrone, O.
   Merlano, M.
   Syed, N.
   Lo Nigro, C.
   Crook, T.
TI Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3)
   predicts site-specific relapse in oestrogen receptor-positive primary
   breast carcinomas
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; metastasis; calcium channels; epigenetics
ID SRC-3/AIB1 COACTIVATOR; GASTRIC-CANCER; CELL CARCINOMA; GENE;
   IDENTIFICATION; APOPTOSIS; CLONING; TARGET; REGION; CA2+
AB BACKGROUND: Calcium is an important intracellular messenger that mediates many biological processes that are relevant to the malignant process. Calcium ion channels are key in controlling the intracellular calcium, and little is known about their role in human cancer.
   METHODS: We used qPCR and pyrosequencing to investigate expression and epigenetic regulation of the calcium channel regulatory subunit alpha 2 delta-3 (CACNA2D3) in breast cancer cell lines, primary cancers and metastatic lesions.
   RESULTS: Expression of CACNA2D3 mRNA is regulated in breast cancer cell lines by methylation in the CpG island located in the 50 regulatory region of the gene. Expression is upregulated by azacytidine (AZA) in cells with CpG island methylation but unaffected in cells lacking methylation. In primary breast carcinomas, methylation is more common in cancers, which subsequently relapse with loco-regional and, particularly, visceral metastatic disease in both oestrogen receptor-alpha (ER)-positive and -negative cases. Furthermore, CACNA2D3 CpG island is frequently methylated in breast cancer that has metastasised to the central nervous system.
   CONCLUSION: Methylation-dependent transcriptional silencing of CACNA2D3 may contribute to the metastatic phenotype of breast cancer. Analysis of methylation in the CACNA2D3 CpG island may have potential as a biomarker for risk of development of metastatic disease. British Journal of Cancer (2012) 107, 375-381. doi:10.1038/bjc.2012.231 www.bjcancer.com Published online 29 May 2012 (c) 2012 Cancer Research UK
C1 [Palmieri, C.; Rudraraju, B.; Gojis, O.] Univ London Imperial Coll Sci Technol & Med, Canc Res UK Labs, Imperial Ctr Translat & Expt Med, Div Canc, London W12 0NN, England.
   [Monteverde, M.; Lattanzio, L.; Lo Nigro, C.] S Croce Gen Hosp, Lab Canc Genet & Translat Oncol, Cuneo, Italy.
   [Gojis, O.] Charles Univ Prague, Fac Med 3, Dept Obstet & Gynaecol, Prague 10000 10, Czech Republic.
   [Gojis, O.] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague 10000 10, Czech Republic.
   [Brizio, R.] S Croce Gen Hosp, Dept Pathol, Cuneo, Italy.
   [Garrone, O.; Merlano, M.] S Croce Gen Hosp, Dept Oncol, Cuneo, Italy.
   [Syed, N.] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Neurooncol Lab, London W6 8RF, England.
   [Crook, T.] Ninewells Hosp, Dundee Canc Ctr, Dundee DD1 9SY, Scotland.
C3 Cancer Research UK; Imperial College London; Charles University Prague;
   Charles University Prague; Imperial College London; University of Dundee
RP Palmieri, C (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Canc Res UK Labs, Imperial Ctr Translat & Expt Med, Div Canc, Du Cane Rd, London W12 0NN, England.
EM c.palmieri@imperial.ac.uk
RI Garrone, Ornella/HHS-9402-2022
OI Lo Nigro, Cristiana/0000-0002-3615-2431; Garrone,
   Ornella/0000-0001-7359-5410; Monteverde, Martino/0000-0003-2623-414X
FU Cancer Research UK Clinician Scientist award; Imperial College
   Healthcare Charity; Ministry of Education of the Czech Republic (Project
   'Oncology') [MSM 0021620808]; Translational Research Fellowship from the
   European Society of Medical Oncology; European Society for Surgical
   Oncology; Cancer Research UK; Department of Health [C37/A7283]; Brain
   Tumour Research Campaign (BTRC)
FX Carlo Palmieri is the recipient of a Cancer Research UK Clinician
   Scientist award and also acknowledges support from Imperial College
   Healthcare Charity. Ondrej Gojis is in part funded by a grant from the
   Ministry of Education of the Czech Republic (Project 'Oncology' MSM
   0021620808) and is also a recipient of the Translational Research
   Fellowship from the European Society of Medical Oncology and a
   fellowship from the European Society for Surgical Oncology. The Division
   of Cancer at Imperial College London, Imperial College Healthcare NHS
   Trust is an Experimental Cancer Medicine Centre that is supported by
   funds from Cancer Research UK and the Department of Health (C37/A7283)
   and also forms part of the Imperial Cancer Research UK Centre
   (C42671/A12196). We thank Professor Gerry Thomas, Sarah Chilcott-Burns
   and the Imperial College Healthcare NHS Trust, Human Biomaterials
   Resource Centre (Tissue Bank). Nelofer Syed acknowledges support from
   the Brain Tumour Research Campaign (BTRC). We thank De Federico
   Roncaroli for his contribution to the work.
CR Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7
   Becchetti A, 2011, AM J PHYSIOL-CELL PH, V301, pC255, DOI 10.1152/ajpcell.00047.2011
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406
   Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134
   Davies A, 2007, TRENDS PHARMACOL SCI, V28, P220, DOI 10.1016/j.tips.2007.03.005
   De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84
   Gojis O, 2010, NAT REV CLIN ONCOL, V7, P83, DOI 10.1038/nrclinonc.2009.219
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanke S, 2001, GENE, V264, P69, DOI 10.1016/S0378-1119(00)00600-4
   Huang JB, 2004, CANCER RES, V64, P2482, DOI 10.1158/0008-5472.CAN-03-3501
   Kim SG, 2003, GASTROENTEROLOGY, V124, P1300, DOI 10.1016/S0016-5085(03)00278-6
   Labhart P, 2005, P NATL ACAD SCI USA, V102, P1339, DOI 10.1073/pnas.0409578102
   Li C, 2008, MOL CELL, V31, P835, DOI 10.1016/j.molcel.2008.07.019
   Li B, 2008, CANCER LETT, V261, P64, DOI 10.1016/j.canlet.2007.11.013
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Patton AM, 2003, CURR PHARM DESIGN, V9, P543, DOI 10.2174/1381612033391559
   Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226
   Qin N, 2002, MOL PHARMACOL, V62, P485, DOI 10.1124/mol.62.3.485
   Qin YR, 2008, INT J CANCER, V123, P826, DOI 10.1002/ijc.23577
   Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105
   Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005
   Tai ALS, 2006, CANCER RES, V66, P4133, DOI 10.1158/0008-5472.CAN-05-2775
   Thorell K, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-53
   Toyota M, 1999, CANCER RES, V59, P4535
   Wanajo A, 2008, GASTROENTEROLOGY, V135, P580, DOI 10.1053/j.gastro.2008.05.041
   Wei MH, 1996, CANCER RES, V56, P1487
   Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259
   Xiong W, 2009, CHINESE MED J-PEKING, V122, P2737, DOI 10.3760/cma.j.issn.0366-6999.2009.22.012
   Yuasa Y, 2009, INT J CANCER, V124, P2677, DOI 10.1002/ijc.24231
NR 30
TC 30
Z9 30
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUL 10
PY 2012
VL 107
IS 2
BP 375
EP 381
DI 10.1038/bjc.2012.231
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 973AY
UT WOS:000306324600023
PM 22644305
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Morita, S
   Takahashi, RU
   Yamashita, R
   Toyoda, A
   Horii, T
   Kimura, M
   Fujiyama, A
   Nakai, K
   Tajima, S
   Matoba, R
   Ochiya, T
   Hatada, I
AF Morita, Sumiyo
   Takahashi, Ryou-u
   Yamashita, Riu
   Toyoda, Atsushi
   Horii, Takuro
   Kimura, Mika
   Fujiyama, Asao
   Nakai, Kenta
   Tajima, Shoji
   Matoba, Ryo
   Ochiya, Takahiro
   Hatada, Izuho
TI Genome-Wide Analysis of DNA Methylation and Expression of MicroRNAs in
   Breast Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE DNA methylation; microRNA; cancer
ID RNA-POLYMERASE III; PROMOTER HYPERMETHYLATION; DOWN-REGULATION; SCANNING
   METHOD; GENE; CHROMATIN; TRANSCRIPTION; ASSOCIATION; ISLANDS; FAMILY
AB DNA methylation of promoters is linked to transcriptional silencing of protein-coding genes, and its alteration plays important roles in cancer formation. For example, hypermethylation of tumor suppressor genes has been seen in some cancers. Alteration of methylation in the promoters of microRNAs (miRNAs) has also been linked to transcriptional changes in cancers; however, no systematic studies of methylation and transcription of miRNAs have been reported. In the present study, to clarify the relation between DNA methylation and transcription of miRNAs, next-generation sequencing and microarrays were used to analyze the methylation and expression of miRNAs, protein-coding genes, other non-coding RNAs (ncRNAs), and pseudogenes in the human breast cancer cell lines MCF7 and the adriamycin (ADR) resistant cell line MCF7/ADR. DNA methylation in the proximal promoter of miRNAs is tightly linked to transcriptional silencing, as it is with protein-coding genes. In protein-coding genes, highly expressed genes have CpG-rich proximal promoters whereas weakly expressed genes do not. This is only rarely observed in other gene categories, including miRNAs. The present study highlights the epigenetic similarities and differences between miRNA and protein-coding genes.
C1 [Morita, Sumiyo; Horii, Takuro; Kimura, Mika; Hatada, Izuho] Gunma Univ, Inst Mol & Cellular Regulat, Lab Genome Sci, Biosignal Genome Resource Ctr, Gunma 3718512, Japan.
   [Takahashi, Ryou-u; Ochiya, Takahiro] Natl Canc Ctr, Div Mol & Cellular Med, Chuo Ku, Tokyo 1040045, Japan.
   [Yamashita, Riu] Tohoku Univ, Med Megabank Org, Dept Integrat Genom, Aoba Ku, Sendai, Miyagi 9808579, Japan.
   [Toyoda, Atsushi; Fujiyama, Asao] Natl Inst Genet, Ctr Genet Resource Informat, Shizuoka 4118540, Japan.
   [Nakai, Kenta] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan.
   [Tajima, Shoji] Osaka Univ, Inst Prot Res, Lab Epigenet, Suita, Osaka 5650871, Japan.
   [Matoba, Ryo] DNA Chip Res Inc, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan.
C3 Gunma University; National Cancer Center - Japan; Tohoku University;
   Research Organization of Information & Systems (ROIS); National
   Institute of Genetics (NIG) - Japan; University of Tokyo; Osaka
   University; DNA Chip Research Inc.
RP Hatada, I (通讯作者)，Gunma Univ, Inst Mol & Cellular Regulat, Lab Genome Sci, Biosignal Genome Resource Ctr, Gunma 3718512, Japan.
EM msumiyo@gunma-u.ac.jp; rytakaha@ncc.go.jp;
   ryamasi@megabank.tohoku.ac.jp; atoyoda@lab.nig.ac.jp;
   horii@gunma-u.ac.jp; mikimura@showa.gunma-u.ac.jp;
   afujiyam@lab.nig.ac.jp; knakai@ims.u-tokyo.ac.jp;
   tajima@protein.osaka-u.ac.jp; matoba@dna-chip.co.jp; tochiya@ncc.go.jp;
   hatada@gunma-u.ac.jp
RI Nakai, Kenta/B-7293-2009; Ochiya, Takahiro/AAH-7585-2019
OI xing zhi, shi zhi/0000-0003-3289-5681
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Ministry of Health, Labour and Welfare of Japan; National Institute of
   Biomedical Innovation; Takeda Science Foundation; Grants-in-Aid for
   Scientific Research [24116515, 22370053] Funding Source: KAKEN
FX This work was supported in part by grants from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan; the
   Ministry of Health, Labour and Welfare of Japan; the National Institute
   of Biomedical Innovation; and the Takeda Science Foundation.
CR Ai LB, 2008, CARCINOGENESIS, V29, P510, DOI 10.1093/carcin/bgm280
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   David GL, 2004, CANCER BIOL THER, V3, P540, DOI 10.4161/cbt.3.6.845
   FAIRCHILD CR, 1987, CANCER RES, V47, P5141
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   HATADA I, 1993, NUCLEIC ACIDS RES, V21, P5577, DOI 10.1093/nar/21.24.5577
   HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523
   Hatada I, 2010, OMICS PERSPECTIVE ON CANCER RESEARCH, P51, DOI 10.1007/978-90-481-2675-0_4
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Marshall L, 2008, NAT REV CANCER, V8, P911, DOI 10.1038/nrc2539
   Ohgane J, 1998, DEV GENET, V22, P132, DOI 10.1002/(SICI)1520-6408(1998)22:2<132::AID-DVG3>3.0.CO;2-7
   Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275
   Selvakumar T, 2012, J BIOL CHEM, V287, P7039, DOI 10.1074/jbc.M111.285601
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
NR 28
TC 32
Z9 36
U1 0
U2 19
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1661-6596
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2012
VL 13
IS 7
BP 8259
EP 8272
DI 10.3390/ijms13078259
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 971XI
UT WOS:000306239200024
PM 22942701
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Iwasaki, M
   Ono, H
   Kuchiba, A
   Kasuga, Y
   Yokoyama, S
   Onuma, H
   Nishimura, H
   Kusama, R
   Yoshida, T
   Tsugane, S
AF Iwasaki, Motoki
   Ono, Hiroe
   Kuchiba, Aya
   Kasuga, Yoshio
   Yokoyama, Shiro
   Onuma, Hiroshi
   Nishimura, Hideki
   Kusama, Ritsu
   Yoshida, Teruhiko
   Tsugane, Shoichiro
TI Association of postmenopausal endogenous sex hormones with global
   methylation level of leukocyte DNA among Japanese women
SO BMC CANCER
LA English
DT Article
DE Cross-sectional study; Endogenous sex hormones; Global methylation
   level; Luminometric methylation assay; Peripheral blood leukocyte DNA
ID BREAST-CANCER RISK; METHYLENETETRAHYDROFOLATE REDUCTASE; COMMON
   MUTATION; MOUSE UTERUS; HYPOMETHYLATION; FOLATE; BLOOD; EPIGENETICS;
   BRAZILIANS; BIOMARKER
AB Background: Although global hypomethylation of leukocyte DNA has been associated with an increased risk of several sites of cancer, including breast cancer, determinants of global methylation level among healthy individuals remain largely unexplored. Here, we examined whether postmenopausal endogenous sex hormones were associated with the global methylation level of leukocyte DNA.
   Methods: A cross-sectional study was conducted using the control group of a breast cancer case-control study in Nagano, Japan. Subjects were postmenopausal women aged 55 years or over who provided blood samples. We measured global methylation level of peripheral blood leukocyte DNA by luminometric methylation assay; estradiol, estrone, androstenedione, dehydroepiandrosterone sulfate, testosterone and free testosterone by radioimmunoassay; bioavailable estradiol by the ammonium sulfate precipitation method; and sex-hormone binding globulin by immunoradiometric assay. A linear trend of association between methylation and hormone levels was evaluated by regression coefficients in a multivariable liner regression model. A total of 185 women were included in the analyses.
   Results: Mean global methylation level (standard deviation) was 70.3% (3.1) and range was from 60.3% to 79.2%. Global methylation level decreased 0.27% per quartile category for estradiol and 0.39% per quartile category for estrone while it increased 0.41% per quartile category for bioavailable estradiol. However, we found no statistically significant association of any sex hormone level measured in the present study with global methylation level of leukocyte DNA.
   Conclusions: Our findings suggest that endogenous sex hormones are not major determinants of the global methylation level of leukocyte DNA.
C1 [Iwasaki, Motoki; Tsugane, Shoichiro] Natl Canc Ctr, Epidemiol & Prevent Div, Res Ctr Canc Prevent & Screening, Chuo Ku, Tokyo 1040045, Japan.
   [Ono, Hiroe; Kuchiba, Aya; Yoshida, Teruhiko] Natl Canc Ctr, Div Genet, Res Inst, Chuo Ku, Tokyo 1040045, Japan.
   [Ono, Hiroe] Tokyo Med & Dent Univ, Biomed Sci PhD Program, Bunkyo Ku, Tokyo 1138510, Japan.
   [Kuchiba, Aya] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
   [Kasuga, Yoshio] Matsushiro Gen Hosp, Dept Surg, Nagano 3811231, Japan.
   [Yokoyama, Shiro; Onuma, Hiroshi] Nagano Red Cross Hosp, Dept Breast & Thyroid Surg, Nagano 3808582, Japan.
   [Nishimura, Hideki] Nagano Municipal Hosp, Dept Surg, Nagano 3818551, Japan.
   [Kusama, Ritsu] Nagano Hokushin Gen Hosp, Dept Surg, Nagano 3838505, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan;
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Harvard University; Dana-Farber Cancer Institute; Nagano Red Cross
   Hospital
RP Iwasaki, M (通讯作者)，Natl Canc Ctr, Epidemiol & Prevent Div, Res Ctr Canc Prevent & Screening, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM moiwasak@ncc.go.jp
RI Tsugane, Shoichiro/A-2424-2015; Yoshida, Teruhiko/JGM-7448-2023
FU Ministry of Health, Labor and Welfare of Japan; National Institute of
   Biomedical Innovation (NIBIO); Ministry of Education, Culture, Sports,
   Science, and Technology of Japan [17015049, 221S0001, 22700934]; Japan
   Society for the Promotion of Science; Foundation for Promotion of Cancer
   Research in Japan; Grants-in-Aid for Scientific Research [22700934]
   Funding Source: KAKEN
FX This study was supported by Grants-in-Aid for the Third Term
   Comprehensive Ten-Year Strategy for Cancer Control and for the Research
   on Applying Health Technology from the Ministry of Health, Labor and
   Welfare of Japan; by the Program for Promotion of Fundamental Studies in
   Health Sciences of the National Institute of Biomedical Innovation
   (NIBIO), by Grants-in-Aid for Scientific Research on Priority Areas
   (17015049), and for Scientific Research on Innovative Areas (221S0001),
   and for Young Scientists (B) (22700934) from the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan and the Japan Society
   for the Promotion of Science, and by Foundation for Promotion of Cancer
   Research in Japan.
CR Adami HO, 2008, TEXTBOOD CANC EPIDEM
   [Anonymous], 2012, Nutritional epidemiology
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606
   EICHNER ER, 1973, J CLIN INVEST, V52, P584, DOI 10.1172/JCI107219
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Foley DL, 2009, AM J EPIDEMIOL, V169, P389, DOI 10.1093/aje/kwn380
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   HILLMAN RS, 1982, ANNU REV MED, V33, P345, DOI 10.1146/annurev.me.33.020182.002021
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Ishihara J, 2006, J EPIDEMIOL, V16, P107, DOI 10.2188/jea.16.107
   Iwasaki M, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-16
   Iwasaki M, 2009, CANCER SCI, V100, P927, DOI 10.1111/j.1349-7006.2009.01118.x
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Key TJ, 2001, LANCET ONCOL, V2, P133, DOI 10.1016/S1470-2045(00)00254-0
   Li SF, 1997, CANCER RES, V57, P4356
   Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147
   Ma E, 2009, NUTR CANCER, V61, P447, DOI 10.1080/01635580802610123
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   The Council for Science and Technology and Ministry of Education Culture Sports Science and Technology Japan, 2005, STAND TABL FOOD COMP
   Tsubono Y, 1996, J Epidemiol, V6, P45
   van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 30
TC 15
Z9 16
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 29
PY 2012
VL 12
AR 323
DI 10.1186/1471-2407-12-323
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 026YC
UT WOS:000310318000001
PM 22839213
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kagara, N
   Huynh, KT
   Kuo, C
   Okano, H
   Sim, MS
   Elashoff, D
   Chong, K
   Giuliano, AE
   Hoon, DSB
AF Kagara, Naofumi
   Huynh, Kelly T.
   Kuo, Christine
   Okano, Hideyuki
   Sim, Myung Shin
   Elashoff, David
   Chong, Kelly
   Giuliano, Armando E.
   Hoon, Dave S. B.
TI Epigenetic Regulation of Cancer Stem Cell Genes in Triple-Negative
   Breast Cancer
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID DNA METHYLATION PATTERNS; IMMUNOHISTOCHEMICAL ANALYSIS; EXPRESSION
   PATTERNS; COLORECTAL-CANCER; ESTROGEN-RECEPTOR; UP-REGULATION; BASAL;
   PHENOTYPE; DISEASE; MARKER
AB Expression of specific breast cancer stem cells (BCSCs) is seen in aggressive tumors, but their regulation is unclear. Epigenetic changes influence gene expression and are implicated in breast cancer progression. We hypothesized that promoter methylation regulates specific BCSC-related genes [CD44,CD133,CD24, MSH1 (alias, Musashi-1), and ALDH1] and that this epigenetic profile can identify aggressive subtypes, such as triple-negative breast cancer (TNBC). Methylation analysis was performed using MassARRAY EpiTYPER sequencing; CpG-rich sites were identified in the promoter regions of BCSC genes, except ALDH1. These sites were screened by treatment with 5-aza-2'-deoxycytidine in four TN and five non-TNBC cell lines. The specific regulatory CpG site demonstrating the most significant inverse correlation between CpG site methylation and mRNA expression was identified for CD44, CD133, and Musashi-1, but not for CD24. Methylation of CD44,CD133, and Musashi-1 was evaluated in 91 American Joint Committee on Cancer stage I to III primary breast cancer tumors, and these sites were significantly hypomethylated in TNBC versus non-TNBC. The MC staining of primary tumors with the highest and lowest methylation levels revealed the strongest staining in hypomethylated specimens, suggesting that hypomethylation leads to gene activation. We demonstrate that methylation is a significant mechanism regulating CD44, CD133, and Musashi-1, and that gene hypomethylation correlates with TNBC. Assessment of epigenetic changes in BCSC genes may provide a more accurate classification of TNBC and could be developed as potential therapeutic targets. (Am J Pathol 2012, 181:257-267; http://dx.doi.org/10.1016/j.ajpath.2012.03.019)
C1 [Kagara, Naofumi; Huynh, Kelly T.; Kuo, Christine; Chong, Kelly; Hoon, Dave S. B.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   [Sim, Myung Shin] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Biostat, Santa Monica, CA 90404 USA.
   [Giuliano, Armando E.] St Johns Hlth Ctr, John Wayne Canc Inst, Margie Robert Petersen Breast Ctr, Santa Monica, CA 90404 USA.
   [Okano, Hideyuki] Keio Univ Med, Dept Physiol, Tokyo, Japan.
   [Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
C3 John Wayne Cancer Institute; John Wayne Cancer Institute; John Wayne
   Cancer Institute; Keio University; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Hoon, DSB (通讯作者)，St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.
EM hoon@jwci.org
RI Okano, Hideyuki/I-7584-2019; Chong, Kelly/JXN-8770-2024; Hoon,
   Dave/C-7146-2018
OI Okano, Hideyuki/0000-0001-7482-5935; Hoon, Dave/0000-0003-1915-3683
FU Leslie and Susan Gonda (Goldschmied) Foundation (Los Angeles, CA); ABC
   Foundation (Beverly Hills, CA); Ruth and Martin H. Weil Fund (Los
   Angeles, CA); Susan G. Komen Breast Cancer Foundation [BCTR0707528]
FX Supported in part by the Leslie and Susan Gonda (Goldschmied) Foundation
   (Los Angeles, CA) (D.H.), ABC Foundation (Beverly Hills, CA) (D.H.),
   Ruth and Martin H. Weil Fund (Los Angeles, CA) (D.H.), and a grant from
   the Susan G. Komen Breast Cancer Foundation (BCTR0707528 to D.H.).
CR Abraham BK, 2005, CLIN CANCER RES, V11, P1154
   AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008
   Asaga S, 2011, CLIN CHEM, V57, P84, DOI 10.1373/clinchem.2010.151845
   Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518
   Bidard FC, 2007, ANN ONCOL, V18, P1285, DOI 10.1093/annonc/mdm360
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Bonazzi VF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026121
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   D'Anello L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-300
   de Maat MFG, 2008, J CLIN ONCOL, V26, P2327, DOI 10.1200/JCO.2007.14.0723
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gloss BS, 2012, CANCER LETT, V318, P76, DOI 10.1016/j.canlet.2011.12.003
   Hao L, 2010, ONCOGENE, V29, P201, DOI 10.1038/onc.2009.323
   Harris LN, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1622
   Hayashi K, 2009, CELL STEM CELL, V4, P493, DOI 10.1016/j.stem.2009.05.007
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435
   Kim MJ, 2006, HUM PATHOL, V37, P1217, DOI 10.1016/j.humpath.2006.04.015
   Klingbeil P, 2010, BREAST CANCER RES TR, V120, P95, DOI 10.1007/s10549-009-0380-7
   Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Morimoto K, 2009, CANCER SCI, V100, P1062, DOI 10.1111/j.1349-7006.2009.01151.x
   Nair SS, 2011, EPIGENETICS-US, V6, P34, DOI 10.4161/epi.6.1.13313
   NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056
   Nicholl MB, 2011, ANN SURG, V253, P116, DOI 10.1097/SLA.0b013e3181fca894
   Okano H, 2002, J CELL SCI, V115, P1355
   Oliveras-Ferraros C, 2010, BIOCHEM BIOPH RES CO, V397, P27, DOI 10.1016/j.bbrc.2010.05.041
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rappa G, 2008, STEM CELLS, V26, P3008, DOI 10.1634/stemcells.2008-0601
   Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Smith JF, 2007, EPIGENETICS-US, V2, P161, DOI 10.4161/epi.2.3.4805
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507
   Subik K, 2010, BREAST CANCER-BASIC, V4, P35
   Wang XY, 2008, MOL CELL BIOL, V28, P3589, DOI 10.1128/MCB.00040-08
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855
   Yoshimura T, 2011, EPIGENETICS-US, V6, P1001, DOI 10.4161/epi.6.8.16063
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
NR 54
TC 74
Z9 85
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUL
PY 2012
VL 181
IS 1
BP 257
EP 267
DI 10.1016/j.ajpath.2012.03.019
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 966PY
UT WOS:000305851100025
PM 22626806
OA Bronze
DA 2025-01-12
ER

PT J
AU Slee, RB
   Steiner, CM
   Herbert, BS
   Vance, GH
   Hickey, RJ
   Schwarz, T
   Christan, S
   Radovich, M
   Schneider, BP
   Schindelhauer, D
   Grimes, BR
AF Slee, R. B.
   Steiner, C. M.
   Herbert, B-S
   Vance, G. H.
   Hickey, R. J.
   Schwarz, T.
   Christan, S.
   Radovich, M.
   Schneider, B. P.
   Schindelhauer, D.
   Grimes, B. R.
TI Cancer-associated alteration of pericentromeric heterochromatin may
   contribute to chromosome instability
SO ONCOGENE
LA English
DT Article
DE pericentromeric heterochromatin; chromosome instability; JMJD2
   demethylase
ID ALPHA-SATELLITE DNA; CENP-B BOX; HISTONE DEMETHYLASES; HUMAN
   KINETOCHORE; CHROMATIN; CENTROMERE; DISTINCT; OVEREXPRESSION;
   INACTIVATION; ORGANIZATION
AB Many tumors exhibit elevated chromosome mis-segregation termed chromosome instability (CIN), which is likely to be a potent driver of tumor progression and drug resistance. Causes of CIN are poorly understood but probably include prior genome tetraploidization, centrosome amplification and mitotic checkpoint defects. This study identifies epigenetic alteration of the centromere as a potential contributor to the CIN phenotype. The centromere controls chromosome segregation and consists of higher-order repeat (HOR) alpha-satellite DNA packaged into two chromatin domains: the kinetochore, harboring the centromere-specific H3 variant centromere protein A (CENP-A), and the pericentromeric heterochromatin, considered important for cohesion. Perturbation of centromeric chromatin in model systems causes CIN. As cancer cells exhibit widespread chromatin changes, we hypothesized that pericentromeric chromatin structure could also be affected, contributing to CIN. Cytological and chromatin immunoprecipitation and PCR (ChIP-PCR)-based analyses of HT1080 cancer cells showed that only one of the two HORs on chromosomes 5 and 7 incorporate CENP-A, an organization conserved in all normal and cancer-derived cells examined. Contrastingly, the heterochromatin marker H3K9me3 (trimethylation of H3 lysine 9) mapped to all four HORs and ChIP-PCR showed an altered pattern of H3K9me3 in cancer cell lines and breast tumors, consistent with a reduction on the kinetochore-forming HORs. The JMJD2B demethylase is overexpressed in breast tumors with a CIN phenotype, and overexpression of exogenous JMJD2B in cultured breast epithelial cells caused loss of centromere-associated H3K9me3 and increased CIN. These findings suggest that impaired maintenance of pericentromeric heterochromatin may contribute to CIN in cancer and be a novel therapeutic target. Oncogene (2012) 31, 3244-3253; doi:10.1038/onc.2011.502; published online 28 November 2011
C1 [Slee, R. B.; Steiner, C. M.; Herbert, B-S; Vance, G. H.; Radovich, M.; Schneider, B. P.; Grimes, B. R.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Slee, R. B.; Herbert, B-S; Vance, G. H.; Hickey, R. J.; Schneider, B. P.; Grimes, B. R.] Indiana Univ Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA.
   [Hickey, R. J.; Schneider, B. P.] IUSM, Dept Med, Indianapolis, IN 46202 USA.
   [Schwarz, T.; Christan, S.; Schindelhauer, D.] Univ Munich, Dept Med Genet, Munich, Germany.
C3 Indiana University System; Indiana University Bloomington; University of
   Munich
RP Grimes, BR (通讯作者)，Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
EM brgrimes@iupui.edu
OI Schwarz, Tobias/0009-0009-3004-4067
FU INGEN (Indiana Genomics Initiative); IUSM Cytogenetics Division; US DOD
   BCRP [W81XWH-09-1-0424]; American Cancer Society [IRG-84-002-24]; IUSM
   Biomedical Research Grants; NCI [N01 CN-43300]; Deutsche
   Forschungsgemeinschaft; Friedrich Baur Institute; Lilly Endowment; NIH
   [NRSA 1 T32 CA 111198]
FX We thank Kinya Yoda for advice with ChIP assays; Simone Schuffenhauer
   and Jan Murken for BF cells; Hunt Willard, Mariano Rocci and Theo
   Hulsebos for centromere plasmid probes; Tim Yen for CENP-E antibodies;
   Mervin Yoder for HUVEC samples; Virginia Thurston for advice on the
   patient BF sample and Andrew Ross, Nikki Collins, Janak Bhavsar, Tony
   Brown, Waylan Bessler and Laura Mead for technical assistance. This
   research was supported in part by INGEN (Indiana Genomics Initiative),
   the IUSM Cytogenetics Division and grants from the US DOD BCRP
   (W81XWH-09-1-0424) and American Cancer Society (IRG-84-002-24) awarded
   to BRG, IUSM Biomedical Research Grants awarded to RBS and an NCI grant
   (N01 CN-43300) to BSH. DS was supported by Deutsche
   Forschungsgemeinschaft and the Friedrich Baur Institute. INGEN is
   supported in part by Lilly Endowment. MR was supported by an NIH
   pre-doctoral fellowship (NRSA 1 T32 CA 111198 Cancer Biology Training
   Program).
CR Alonso A, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-6
   Amato A, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-119
   ARCHIDIACONO N, 1995, GENOMICS, V25, P477, DOI 10.1016/0888-7543(95)80048-Q
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bergmann JH, 2011, EMBO J, V30, P328, DOI 10.1038/emboj.2010.329
   Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027
   Bourgo RJ, 2009, MOL BIOL CELL, V20, P3192, DOI 10.1091/mbc.E08-12-1224
   Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X
   Cardinale S, 2009, MOL BIOL CELL, V20, P4194, DOI 10.1091/mbc.E09-06-0489
   David G, 2006, ONCOGENE, V25, P7354, DOI 10.1038/sj.onc.1209734
   David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403
   Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Finelli P, 1996, GENOMICS, V38, P325, DOI 10.1006/geno.1996.0635
   Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206
   Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235
   Grimes BR, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r89
   Grimes BR, 2009, STEM CELLS DEV, V18, P717, DOI 10.1089/scd.2008.0255
   Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109
   HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697
   Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902
   Hochreiter AE, 2006, CLIN CANCER RES, V12, P3184, DOI 10.1158/1078-0432.CCR-05-2760
   HULSEBOS T, 1988, CYTOGENET CELL GENET, V47, P144, DOI 10.1159/000132533
   Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714
   Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508
   Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Lohse B, 2011, BIOORGAN MED CHEM, V19, P3625, DOI 10.1016/j.bmc.2011.01.046
   Malorni L, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.10621
   Mitelman F., 1994, CATALOG CHROMOSOME A
   Mravinac B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006602
   Nakano M, 2008, DEV CELL, V14, P507, DOI 10.1016/j.devcel.2008.02.001
   Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112
   PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805
   Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Radovich M, TRANSCRIPTIONA UNPUB
   Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rosandic M, 2006, CHROMOSOME RES, V14, P735, DOI 10.1007/s10577-006-1078-x
   Rose NR, 2010, J MED CHEM, V53, P1810, DOI 10.1021/jm901680b
   SCHINDELHAUER D, 1995, GENOMICS, V28, P605, DOI 10.1006/geno.1995.1202
   Schuffenhauer S, 1996, AM J MED GENET, V65, P56, DOI 10.1002/(SICI)1096-8628(19961002)65:1<56::AID-AJMG9>3.3.CO;2-X
   Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502
   Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845
   Sullivan BA, 1999, PRACT APPROACH SER, P81
   Sullivan LL, 2011, CHROMOSOME RES, V19, P457, DOI 10.1007/s10577-011-9208-5
   Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Tomonaga T, 2003, CANCER RES, V63, P3511
   Vafa O, 1997, CURR BIOL, V7, P897, DOI 10.1016/S0960-9822(06)00381-2
   Verdaasdonk JS, 2011, NAT REV MOL CELL BIO, V12, P320, DOI 10.1038/nrm3107
   Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4
   Warburton PE., 1996, HUMAN GENOME EVOLUTI, P121
   WAYE JS, 1987, MOL CELL BIOL, V7, P349, DOI 10.1128/MCB.7.1.349
   WEVRICK R, 1991, NUCLEIC ACIDS RES, V19, P2295, DOI 10.1093/nar/19.9.2295
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wong LH, 2007, GENOME RES, V17, P1146, DOI 10.1101/gr.6022807
   Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413
   Yoda K, 2004, METHOD ENZYMOL, V375, P253
NR 61
TC 82
Z9 95
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL
PY 2012
VL 31
IS 27
BP 3244
EP 3253
DI 10.1038/onc.2011.502
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 970FL
UT WOS:000306113400004
PM 22081068
DA 2025-01-12
ER

PT J
AU Gerhäuser, C
AF Gerhaeuser, Clarissa
TI Cancer cell metabolism, epigenetics and the potential influence of
   dietary components - A perspective
SO BIOMEDICAL RESEARCH-INDIA
LA English
DT Article
DE Cancer cell metabolism; Warburg effect; epigenomics; DNA methylation;
   histone modifications; metabonomics; dietary compounds; cancer
   prevention
ID TUMOR-SUPPRESSOR GENES; HUMAN PROSTATE-CANCER; HISTONE DEACETYLASE
   INHIBITOR; FACTOR-KAPPA-B; DNA METHYLATION; SODIUM-BUTYRATE;
   ENERGY-METABOLISM; BREAST-CANCER; COLON-CANCER; PHENETHYL ISOTHIOCYANATE
AB Cancer cells are characterized by alterations in cell metabolism including increased glucose consumption and aerobic glycolysis, commonly known as the "Warburg effect". Underlying mechanisms for this metabolic switch have been associated with genetic defects in pathways regulating metabolic processes. Recent research indicates that epigenetic alterations, e.g. in DNA methylation of promoter regions of glycolytic enzymes, might contribute to the deregulated expression of enzymes involved in cell metabolism. Alternatively, changes in cell metabolism could alter the availability of co-factors for epigenetic processes. This perspective will summarize current knowledge on interactions between cancer cell metabolism and epigenetic modulation of gene regulation, and how both processes can be affected by dietary components. Natural compounds with reported mechanisms targeting cancer cell metabolism include folate, flavonoids, green tea polyphenols, genistein from soy, silymarin from milk thistle, and the anthraquinone derivative shikonin. Reversible acetylation of histones and non-histone proteins has been shown to affect cell metabolism and other cellular processes, and can be targeted by inhibitors of histone deacetylases (HDACs) and histone acetyl transferases (HATs). Natural compounds with HDAC or HAT inhibitory activity include butyrate, sulforaphane from broccoli, diallyldisulfide (DADS) from garlic, cambinol and dihydrocoumarin, diindolylmethane, epigallocatechin gallate (EGCG), curcumin, anacardic acid and garcinol. Currently we can only speculate whether their influence on epigenetic mechanisms is of importance for normalization of the deregulated cancer cell metabolism. It can be anticipated that the emergence of sensitive metabonomics technologies and genome-wide detection of epigenetic alterations in DNA methylation, histone modifications, and miRNA expression, will improve our understanding of the relationship between epigenetics and cancer cell metabolism.
C1 [Gerhaeuser, Clarissa] German Canc Res Ctr, Div Epigen & Canc Risk Factors, D-6900 Heidelberg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ)
RP Gerhäuser, C (通讯作者)，Deutsch Krebsforschungszentrum DKFZ, Div Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
OI Gerhauser, Clarissa/0000-0002-5792-3901
CR Amoedo ND, 2011, RECENT PAT ANTI-CANC, V6, P15
   Amoêdo ND, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022264
   Arasaradnam RP, 2008, EPIGENETICS-US, V3, P193, DOI 10.4161/epi.3.4.6508
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200
   Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200
   Banerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Basak S, 2008, MOL CANCER THER, V7, P3195, DOI 10.1158/1535-7163.MCT-08-0617
   Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991
   Bertl E, 2006, MOL CANCER THER, V5, P575, DOI 10.1158/1535-7163.MCT-05-0324
   Bianchini F, 2001, ENVIRON HEALTH PERSP, V109, P893
   Bommareddy A, 2009, CANCER RES, V69, P3704, DOI 10.1158/0008-5472.CAN-08-4344
   Boros LG, 2001, PANCREAS, V22, P1, DOI 10.1097/00006676-200101000-00001
   Boros LG, 1998, MED HYPOTHESES, V50, P55, DOI 10.1016/S0306-9877(98)90178-5
   Brait M, 2011, TOXICOL MECH METHOD, V21, P275, DOI 10.3109/15376516.2011.562671
   Bruce KD, 2011, TOXICOL MECH METHOD, V21, P353, DOI 10.3109/15376516.2011.559370
   Buchakjian MR, 2010, NAT REV MOL CELL BIO, V11, P715, DOI 10.1038/nrm2972
   Caiafa P, 2009, FASEB J, V23, P672, DOI 10.1096/fj.08-123265
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7
   Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137
   Chen X, 2002, PHYTOTHER RES, V16, P199, DOI 10.1002/ptr.1100
   Chen Y, 2007, BASIC CLIN PHARMACOL, V101, P427, DOI 10.1111/j.1742-7843.2007.00142.x
   Cheung KL, 2010, AAPS J, V12, P87, DOI 10.1208/s12248-009-9162-8
   Chia N, 2011, EPIGENETICS-US, V6, P853, DOI 10.4161/epi.6.7.16461
   Choi SW, 2009, NUTRIENTS AND EPIGENETICS, P1, DOI 10.1201/9781420063561
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Choudhuri S, 2011, TOXICOL MECH METHOD, V21, P252, DOI 10.3109/15376516.2011.559695
   Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171
   Cioce M, 2011, MOL CELL, V44, P515, DOI 10.1016/j.molcel.2011.11.003
   Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018
   Comín-Anduix B, 2002, J BIOL CHEM, V277, P46408, DOI 10.1074/jbc.M206150200
   Cui W, 2009, WORLD J GASTROENTERO, V15, P1943, DOI 10.3748/wjg.15.1943
   Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9
   Dashwood RH, 2007, SEMIN CANCER BIOL, V17, P363, DOI 10.1016/j.semcancer.2007.04.001
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192
   Duthie SJ., 2010, J. Inherit Metab Dis
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fang MZ, 2003, CANCER RES, V63, P7563
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Fu SQ, 2010, CANCER-AM CANCER SOC, V116, P4670, DOI 10.1002/cncr.25414
   Füllgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121
   Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56
   GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883
   Gilbert ER, 2010, CURR MED CHEM, V17, P1756, DOI 10.2174/092986710791111161
   Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200
   Gottlieb E, 2011, NAT CELL BIOL, V13, P195, DOI 10.1038/ncb2177
   Hamer HM, 2008, ALIMENT PHARM THER, V27, P104, DOI 10.1111/j.1365-2036.2007.03562.x
   Hauser AT, 2008, PLANTA MED, V74, P1593, DOI 10.1055/s-2008-1081347
   Hecht SS, 2000, DRUG METAB REV, V32, P395, DOI 10.1081/DMR-100102342
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Helferich W. G., 2008, Inflammopharmacology, V16, P219, DOI 10.1007/s10787-008-8020-0
   Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617
   Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5
   Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   HERUTH DP, 1993, J BIOL CHEM, V268, P20466
   Hitchler MJ, 2007, FREE RADICAL BIO MED, V43, P1023, DOI 10.1016/j.freeradbiomed.2007.06.027
   Hitchler MJ, 2009, FREE RADICAL BIO MED, V47, P115, DOI 10.1016/j.freeradbiomed.2009.04.010
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Huang J., 2010, Current drug targets
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jian L, 2009, MOL NUTR FOOD RES, V53, P217, DOI 10.1002/mnfr.200800167
   Johnson IT, 2008, FOOD CHEM TOXICOL, V46, P1346, DOI 10.1016/j.fct.2007.09.101
   Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5
   Kang JH, 2005, BIOCHEM PHARMACOL, V69, P1205, DOI 10.1016/j.bcp.2005.01.014
   Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Kim YI, 2004, ENVIRON MOL MUTAGEN, V44, P10, DOI 10.1002/em.20025
   Kim YI, 2005, J NUTR, V135, P2703, DOI 10.1093/jn/135.11.2703
   Kim YS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/721213
   Kinney SRM, 2009, CANCER PREV RES, V2, P1065, DOI 10.1158/1940-6207.CAPR-09-0010
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kroll DJ, 2007, INTEGR CANCER THER, V6, P110, DOI 10.1177/1534735407301825
   Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144
   Lea MA, 2002, NUTR CANCER, V43, P90, DOI 10.1207/S15327914NC431_11
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Li LH, 2007, J ASIAN NAT PROD RES, V9, P245, DOI 10.1080/10286020600604260
   Li XL, 2011, INT J BIOL SCI, V7, P575, DOI 10.7150/ijbs.7.575
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YM, 2010, CANCER RES, V70, P646, DOI 10.1158/0008-5472.CAN-09-1924
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Lin JD, 2009, MOL ENDOCRINOL, V23, P2, DOI 10.1210/me.2008-0344
   Lin YY, 2009, CELL, V136, P1073, DOI 10.1016/j.cell.2009.01.033
   Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332
   Loguercio C, 2011, WORLD J GASTROENTERO, V17, P2288, DOI 10.3748/wjg.v17.i18.2288
   Love DC, 2010, SEMIN CELL DEV BIOL, V21, P646, DOI 10.1016/j.semcdb.2010.05.001
   Lu R, 2008, EPIGENETICS-US, V3, P330, DOI 10.4161/epi.3.6.7125
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025
   Maddocks ODK, 2011, J MOL MED, V89, P237, DOI 10.1007/s00109-011-0735-5
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009
   Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705
   Messina M, 2006, JNCI-J NATL CANCER I, V98, P1275, DOI 10.1093/jnci/djj356
   Molinié B, 2009, DRUG NEWS PERSPECT, V22, P247, DOI 10.1358/dnp.2009.22.5.1378633
   Mottet D, 2008, CLIN EXP METASTAS, V25, P183, DOI 10.1007/s10585-007-9131-5
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Navarro SL, 2011, FOOD FUNCT, V2, P579, DOI 10.1039/c1fo10114e
   Nian H, 2009, ENVIRON MOL MUTAGEN, V50, P213, DOI 10.1002/em.20454
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Olaharski AJ, 2005, PLOS GENET, V1, P689, DOI 10.1371/journal.pgen.0010077
   Padhye S, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-38
   Pappa G, 2006, MUTAT RES-FUND MOL M, V599, P76, DOI 10.1016/j.mrfmmm.2006.01.007
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Powolny AA, 2008, CANCER LETT, V269, P305, DOI 10.1016/j.canlet.2008.05.027
   Raina K, 2009, CANCER RES, V69, P3731, DOI 10.1158/0008-5472.CAN-09-0096
   Ramasamy K, 2008, CANCER LETT, V269, P352, DOI 10.1016/j.canlet.2008.03.053
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x
   RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0
   Roy Claude C, 2006, Nutr Clin Pract, V21, P351, DOI 10.1177/0115426506021004351
   Safe S, 2008, CANCER LETT, V269, P326, DOI 10.1016/j.canlet.2008.04.021
   Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500
   Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963
   SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9
   Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Smeenk L, 2010, INT J ONCOL, V37, P1061, DOI 10.3892/ijo_00000757
   Solanky KS, 2005, J NUTR BIOCHEM, V16, P236, DOI 10.1016/j.jnutbio.2004.12.005
   Solanky KS, 2003, ANAL BIOCHEM, V323, P197, DOI 10.1016/j.ab.2003.08.028
   Steiner C, 2008, BRIT J NUTR, V99, pES78, DOI 10.1017/S0007114508965788
   Stilling RM, 2011, NEUROBIOL LEARN MEM, V96, P19, DOI 10.1016/j.nlm.2011.04.002
   Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703
   Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272
   Sun YL, 2006, FEBS LETT, V580, P4353, DOI 10.1016/j.febslet.2006.06.092
   Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood-2007-10-117994
   Surh YJ, 2007, ADV EXP MED BIOL, V595, P149
   Suzuki T, 2006, CURR MED CHEM, V13, P935, DOI 10.2174/092986706776361067
   Tamayo C, 2007, INTEGR CANCER THER, V6, P146, DOI 10.1177/1534735407301942
   Taylor CK, 2009, NUTR REV, V67, P398, DOI 10.1111/j.1753-4887.2009.00213.x
   Teperino R, 2010, CELL METAB, V12, P321, DOI 10.1016/j.cmet.2010.09.004
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Verkerk R, 2009, MOL NUTR FOOD RES, V53, pS219, DOI 10.1002/mnfr.200800065
   Verma M, 2004, CRIT REV CL LAB SCI, V41, P585, DOI 10.1080/10408360490516922
   Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097
   West LE, 2011, EPIGENOMICS-UK, V3, P361, DOI 10.2217/EPI.11.21
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wolf A, 2011, NEUROBIOL DIS, V44, P84, DOI 10.1016/j.nbd.2011.06.007
   World Cancer Research Fund and American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P
   Xiao D, 2007, CANCER RES, V67, P2239, DOI 10.1158/0008-5472.CAN-06-3645
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yang CS, 2009, NAT REV CANCER, V9, P429, DOI 10.1038/nrc2641
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhang Y, 2007, ACTA PHARMACOL SIN, V28, P1343, DOI 10.1111/j.1745-7254.2007.00679.x
   Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689
NR 169
TC 11
Z9 11
U1 1
U2 40
PU ALLIED ACAD
PI LONDON
PA 40 BLOOMSBURY WAY, LOWER GROUND FLR, LONDON, WC1A 2SE, ENGLAND
SN 0970-938X
EI 0976-1683
J9 BIOMED RES-INDIA
JI Biomed. Res.-India
PD FEB
PY 2012
VL 23
SI SI
BP 69
EP 89
PG 21
WC Engineering, Biomedical; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Research & Experimental Medicine
GA 967DH
UT WOS:000305886100011
DA 2025-01-12
ER

PT J
AU Li, QY
   Zhu, FF
   Chen, PX
AF Li, Qiaoyan
   Zhu, Fufan
   Chen, Puxiang
TI miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A
   and Claudin-6 by targeting HoxB3 in breast cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE HoxB3; microRNA-7; microRNA-218; DNA methylation; Histone modification
ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; ESTROGEN-RECEPTOR;
   DOWN-REGULATION; MICRORNA-7; PATHWAY; EXPRESSION; REGIONS
AB Many microRNAs have been implicated as key regulators of cellular growth and differentiation and have been found to dysregulate proliferation in human tumors, including breast cancer. Cancer-linked microRNAs also alter the epigenetic landscape by way of DNA methylation and post-translational modifications of histones. Aberrations in Hox gene expression are important for oncogene or tumor suppressor during abnormal development and malignancy. Although recent studies suggest that HoxB3 is critical in breast cancer, the putative role(s) of microRNAs impinging on HoxB3 is not yet fully understood. In this study, we found that the expression levels of miR-7 and miR-218 were strongly and reversely associated with HoxB3 expression. Stable overexpression of miR-7 and miR-218 was accompanied by reactivation of tumor suppressor genes including RASSF1A and Claudin-6 by means of epigenetic switches in DNA methylation and histone modification, giving rise to inhibition of the cell cycle and clone formation of breast cancer cells. The current study provides a novel link between overexpression of collinear Hox genes and multiple microRNAs in human breast malignancy. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Li, Qiaoyan; Zhu, Fufan; Chen, Puxiang] Cent S Univ, Xiangya Hosp 2, Dept Gynecol & Obstet, Changsha 410011, Hunan, Peoples R China.
C3 Central South University
RP Li, QY (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Gynecol & Obstet, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM swallow0108@yahoo.cn; xiongjing792004@Yahoo.com.cn
FU Fundamental Research Funds for the Central Universities
FX We would like to thanks members of the lab for critical discussions of
   this manuscript. The Fundamental Research Funds for the Central
   Universities supported this work.
CR Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754
   Almeida MI, 2012, GASTROENTEROLOGY, V142, P886, DOI 10.1053/j.gastro.2011.12.047
   [Anonymous], HEPATOLOGY
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230
   Chopra VS, 2006, BIOESSAYS, V28, P445, DOI 10.1002/bies.20401
   Davidson MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012560
   Eklund E. A., 2011, Critical Reviews in Oncogenesis, V16, P65
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Kastl L, 2012, BREAST CANCER RES TR, V131, P445, DOI 10.1007/s10549-011-1424-3
   Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639
   Kong D, 2011, ONCOGENE
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919
   McInnes N, 2012, ONCOGENE, V31, P1045, DOI 10.1038/onc.2011.293
   Mueller DW, 2011, INT J CANCER, V129, P1064, DOI 10.1002/ijc.25768
   Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373
   Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103
   Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Tao YG, 2011, NUCLEIC ACIDS RES, V39, P9508, DOI 10.1093/nar/gkr611
   Tatarano S, 2011, INT J ONCOL, V39, P13, DOI 10.3892/ijo.2011.1012
   Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879
   Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200
   White NMA, 2011, J UROLOGY, V186, P1077, DOI 10.1016/j.juro.2011.04.110
   Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341
   Xi SC, 2009, STEM CELLS, V27, P2691, DOI 10.1002/stem.183
   Xiong SD, 2011, INT J BIOL SCI, V7, P805, DOI 10.7150/ijbs.7.805
   Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434
   Zhou XY, 2010, GYNECOL ONCOL, V117, P287, DOI 10.1016/j.ygyno.2010.01.020
NR 38
TC 74
Z9 83
U1 0
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 20
PY 2012
VL 424
IS 1
BP 28
EP 33
DI 10.1016/j.bbrc.2012.06.028
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 983RF
UT WOS:000307135700006
PM 22705304
DA 2025-01-12
ER

PT J
AU Kikuyama, M
   Takeshima, H
   Kinoshita, T
   Okochi-Takada, E
   Wakabayashi, M
   Akashi-Tanaka, S
   Ogawa, T
   Seto, Y
   Ushijima, T
AF Kikuyama, Mizuho
   Takeshima, Hideyuki
   Kinoshita, Takayuki
   Okochi-Takada, Eriko
   Wakabayashi, Mika
   Akashi-Tanaka, Sadako
   Ogawa, Toshihisa
   Seto, Yasuyuki
   Ushijima, Toshikazu
TI Development of a novel approach, the epigenome-based outlier approach,
   to identify tumor-suppressor genes silenced by aberrant DNA methylation
SO CANCER LETTERS
LA English
DT Article
DE Epigenetics; Aberrant DNA methylation; Tumor-suppressor gene
ID HELICOBACTER-PYLORI INFECTION; BRCA1 PROMOTER METHYLATION; ZINC-FINGER
   PROTEIN; SPORADIC BREAST; ALTERED METHYLATION; PROSTATE-CANCER;
   GASTRIC-CANCER; MASPIN GENE; HEDGEHOG; EXPRESSION
AB Identification of tumor-suppressor genes (TSGs) silenced by aberrant methylation of promoter CpG islands (CGIs) is important, but hampered by a large number of genes methylated as passengers of carcinogenesis. To overcome this issue, we here took advantage of the fact that the vast majority of genes methylated in cancers lack, in normal cells, RNA polymerase II (Pol II) and have trimethylation of histone H3 lysine 27 (H3K27me3) in their promoter CGIs. First, we demonstrated that three of six known TSGs in breast cancer and two of three in colon cancer had Pol II and lacked H3K27me3 in normal cells, being outliers to the general rule. BRCA1, HOXA5, MLH1, and RASSF1A had high Pol II, but were expressed only at low levels in normal cells, and were unlikely to be identified as outliers by their expression statuses in normal cells. Then, using epigenome statuses (Pol II binding and H3K27me3) in normal cells, we made a genome-wide search for outliers in breast cancers, and identified 14 outlier promoter CGIs. Among these, DZIP1, FBN2, HOXA5, and HOXC9 were confirmed to be methylated in primary breast cancer samples. Knockdown of DZIP1 in breast cancer cell lines led to increases of their growth, suggesting it to be a novel TSG. The outliers based on their epigenome statuses contained unique TSGs, including DZIP1, compared with those identified by the expression microarray data. These results showed that the epigenome-based outlier approach is capable of identifying a different set of TSGs, compared to the expression-based outlier approach. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Kikuyama, Mizuho; Takeshima, Hideyuki; Okochi-Takada, Eriko; Wakabayashi, Mika; Ushijima, Toshikazu] Natl Canc Ctr, Div Epigen, Chuo Ku, Tokyo 1040045, Japan.
   [Kikuyama, Mizuho; Ogawa, Toshihisa; Seto, Yasuyuki] Univ Tokyo, Dept Metab Care & Endocrine Surg, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Kinoshita, Takayuki; Akashi-Tanaka, Sadako] Natl Canc Ctr, Breast Surg Div, Chuo Ku, Tokyo 1040045, Japan.
C3 National Cancer Center - Japan; University of Tokyo; National Cancer
   Center - Japan
RP Ushijima, T (通讯作者)，Natl Canc Ctr, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM tushijim@ncc.go.jp
RI Akashi-Tanaka, Sadako/GMX-0687-2022; Kinoshita, Takayuki/AAA-5722-2020;
   Ushijima, Toshikazu/AAP-5742-2021
OI Takeshima, Hideyuki/0000-0002-8552-2427; Ushijima,
   Toshikazu/0000-0003-3405-7817
FU Foundation for Promotion of Cancer Research; Ministry of Health, Labour
   and Welfare, Japan; Japan Society for the Promotion of Science (JSPS);
   Grants-in-Aid for Scientific Research [23710227] Funding Source: KAKEN
FX M.K. is a recipient of Research Resident Fellowships from the Foundation
   for Promotion of Cancer Research. This work was supported by
   Grants-in-Aid for the Third-Term Comprehensive Cancer Control Strategy
   from the Ministry of Health, Labour and Welfare, Japan; for Young
   Scientists (B) from Japan Society for the Promotion of Science (JSPS);
   and a grant from the Foundation for Promotion of Cancer Research.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1
   [Anonymous], 2010, NATURE, V463, P587, DOI 10.1038/463587a
   Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972
   De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2002, CANCER RES, V62, P5902
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Farias EF, 2005, J NATL CANCER I, V97, P21, DOI 10.1093/jnci/dji004
   Gupta S., 2011, THER ADV MED ONCOL, V2, P237
   Hatsell S, 2007, J MAMMARY GLAND BIOL, V12, P163, DOI 10.1007/s10911-007-9048-2
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kaneda A, 2004, CANCER LETT, V212, P203, DOI 10.1016/j.canlet.2004.03.020
   Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962
   Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751
   Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455
   Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   Naito Y, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-392
   Nakajima T, 2009, INT J CANCER, V124, P905, DOI 10.1002/ijc.24018
   Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755
   Okochi-Takada E, 2006, INT J CANCER, V119, P1338, DOI 10.1002/ijc.22025
   Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07
   Pulukuri SMK, 2005, INT J ONCOL, V26, P863
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Sekimizu K, 2004, DEVELOPMENT, V131, P2521, DOI 10.1242/dev.01059
   Seo HS, 2011, NUTR RES, V31, P139, DOI 10.1016/j.nutres.2011.01.011
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Steiner MS, 2000, ONCOGENE, V19, P1297, DOI 10.1038/sj.onc.1203428
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takeshima H, 2011, GENOMICS, V98, P182, DOI 10.1016/j.ygeno.2011.06.003
   Takeshima H, 2010, EPIGENETICS-US, V5, P89, DOI 10.4161/epi.5.2.10774
   Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109
   Tanaka K, 2007, ONCOGENE, V26, P6456, DOI 10.1038/sj.onc.1210459
   Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009
   Toyota M, 2009, CANCER SCI, V100, P787, DOI 10.1111/j.1349-7006.2009.01095.x
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466
   Vokes SA, 2004, CURR BIOL, V14, pR668, DOI 10.1016/j.cub.2004.08.015
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Wang LH, 2006, MODERN PATHOL, V19, P675, DOI 10.1038/modpathol.3800573
   Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wolff C, 2004, GENE DEV, V18, P1565, DOI 10.1101/gad.296004
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Yamashita S, 2009, DNA RES, V16, P275, DOI 10.1093/dnares/dsp017
   Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26
NR 59
TC 31
Z9 32
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 28
PY 2012
VL 322
IS 2
BP 204
EP 212
DI 10.1016/j.canlet.2012.03.016
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 964TY
UT WOS:000305720800011
PM 22433712
DA 2025-01-12
ER

PT J
AU Wang, N
   Eckert, KA
   Zomorrodi, AR
   Xin, P
   Pan, WH
   Shearer, DA
   Weisz, J
   Maranus, CD
   Clawson, GA
AF Wang, Ning
   Eckert, Kristin A.
   Zomorrodi, Ali R.
   Xin, Ping
   Pan, Weihua
   Shearer, Debra A.
   Weisz, Judith
   Maranus, Costas D.
   Clawson, Gary A.
TI Down-Regulation of HtrA1 Activates the Epithelial-Mesenchymal Transition
   and ATM DNA Damage Response Pathways
SO PLOS ONE
LA English
DT Article
ID SERINE-PROTEASE HTRA1; OXIDATIVE STRESS; AKT PHOSPHORYLATION; ACCESSIBLE
   SITES; GENE-EXPRESSION; MESSENGER-RNA; HUMAN BREAST; TUMOR-CELLS;
   STEM-CELLS; CANCER
AB Expression of the serine protease HtrA1 is decreased or abrogated in a variety of human primary cancers, and higher levels of HtrA1 expression are directly related to better response to chemotherapeutics. However, the precise mechanisms leading to HtrA1 down regulation during malignant transformation are unclear. To investigate HtrA1 gene regulation in breast cancer, we characterized expression in primary breast tissues and seven human breast epithelial cell lines, including two non-tumorigenic cell lines. In human breast tissues, HtrA1 expression was prominent in normal ductal glands. In DCIS and in invasive cancers, HtrA1 expression was greatly reduced or lost entirely. HtrA1 staining was also reduced in all of the human breast cancer cell lines, compared with the normal tissue and non-tumorigenic cell line controls. Loss of HtrA1 gene expression was attributable primarily to epigenetic silencing mechanisms, with different mechanisms operative in the various cell lines. To mechanistically examine the functional consequences of HtrA1 loss, we stably reduced and/or overexpressed HtrA1 in the non-tumorigenic MCF10A cell line. Reduction of HtrA1 levels resulted in the epithelial-to-mesenchymal transition with acquisition of mesenchymal phenotypic characteristics, including increased growth rate, migration, and invasion, as well as expression of mesenchymal biomarkers. A concomitant decrease in expression of epithelial biomarkers and all microRNA 200 family members was also observed. Moreover, reduction of HtrA1 expression resulted in activation of the ATM and DNA damage response, whereas overexpression of HtrA1 prevented this activation. Collectively, these results suggest that HtrA1 may function as a tumor suppressor by controlling the epithelial-to-mesenchymal transition, and may function in chemotherapeutic responsiveness by mediating DNA damage response pathways.
C1 [Wang, Ning; Eckert, Kristin A.; Xin, Ping; Pan, Weihua; Clawson, Gary A.] Penn State Univ, Gittlen Canc Res Inst, Coll Med, Hershey, PA USA.
   [Wang, Ning; Eckert, Kristin A.; Xin, Ping; Pan, Weihua; Clawson, Gary A.] Penn State Univ, Dept Pathol, Coll Med, Hershey, PA USA.
   [Zomorrodi, Ali R.; Maranus, Costas D.] Penn State Univ, Dept Chem Engn, University Pk, PA 16802 USA.
   [Shearer, Debra A.; Weisz, Judith] Penn State Univ, Dept Obstet & Gynecol, Hershey, PA USA.
   [Clawson, Gary A.] Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Pennsylvania
   State University - University Park; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park
RP Wang, N (通讯作者)，Penn State Univ, Gittlen Canc Res Inst, Coll Med, Hershey, PA USA.
EM gac4@psu.edu
RI Maranas, Costas/A-4774-2011
OI Maranas, Costas/0000-0002-1508-1398
FU National Institutes of Health [CA40145]; Gittlen Cancer Research
   Foundation
FX Funds for this study were obtained from the National Institutes of
   Health (CA40145; www.nih.gov) and from the Gittlen Cancer Research
   Foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abdi Herve., 2007, ENCY MEASUREMENT STA, P1
   López JA, 2011, BIOCHEM BIOPH RES CO, V409, P513, DOI 10.1016/j.bbrc.2011.05.036
   Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   [Anonymous], CANC BIOL THERAPY
   [Anonymous], SCI SIGNALING
   [Anonymous], CANC RES
   Axelson H, 2005, SEMIN CELL DEV BIOL, V16, P554, DOI 10.1016/j.semcdb.2005.03.007
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Baldi A, 2008, PHARMACOGENOMICS, V9, P1069, DOI 10.2217/14622416.9.8.1069
   Benjamini Y, 2001, ANN STAT, V29, P1165
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078-0432.CCR-06-0952
   Bowden MA, 2006, GYNECOL ONCOL, V103, P253, DOI 10.1016/j.ygyno.2006.03.006
   Catalano V, 2011, HISTOPATHOLOGY, V58, P669, DOI 10.1111/j.1365-2559.2011.03818.x
   Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052
   Chan N, 2008, CANCER RES, V68, P605, DOI 10.1158/0008-5472.CAN-07-5472
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Chien J, 2009, J CELL BIOCHEM, V107, P253, DOI 10.1002/jcb.22121
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101
   Clawson GA, 2008, J CELL BIOCHEM, V105, P81, DOI 10.1002/jcb.21804
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Folgueira MAAK, 2005, CLIN CANCER RES, V11, P7434
   Fukutake T, 2011, J STROKE CEREBROVASC, V20, P85, DOI 10.1016/j.jstrokecerebrovasdis.2010.11.008
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912
   Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269
   Holian J, 2008, AM J PHYSIOL-RENAL, V295, pF1388, DOI 10.1152/ajprenal.00055.2008
   Hubbi ME, 2011, MOL CELL, V42, P700, DOI 10.1016/j.molcel.2011.03.029
   Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356
   Ivanovic V, 2006, CLIN CHIM ACTA, V371, P191, DOI 10.1016/j.cca.2006.02.027
   Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x
   Kalyanaraman B, 2002, MOL CELL BIOCHEM, V234, P119, DOI 10.1023/A:1015976430790
   Kaufman L., 2009, Finding groups in data: an introduction to cluster analysis
   Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728
   Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453
   Kotamraju S, 2004, METHOD ENZYMOL, V378, P362
   Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7
   López-Otín C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228
   Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305
   Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321
   Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346
   Mullany SA, 2011, CLIN CANCER RES, V17, P427, DOI 10.1158/1078-0432.CCR-09-3069
   Narkiewicz J, 2009, ONCOL REP, V21, P1529, DOI 10.3892/or_00000385
   Narklewicz J, 2008, CLIN BIOCHEM, V41, P561, DOI 10.1016/j.clinbiochem.2008.01.004
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884
   Pan WH, 2006, CURR MED CHEM, V13, P3083, DOI 10.2174/092986706778521788
   Pan WH, 2010, J CELL BIOCHEM, V109, P509, DOI 10.1002/jcb.22428
   Pan WH, 2004, MOL THER, V9, P596, DOI 10.1016/j.ymthe.2003.12.013
   Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Radisky DC, 2006, CURR OPIN GENET DEV, V16, P45, DOI 10.1016/j.gde.2005.12.011
   Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905
   ROGERS KR, 1989, INT J TISSUE REACT, V11, P309
   Saito H, 2000, ANTICANCER RES, V20, P4489
   Shariat SF, 2001, CANCER-AM CANCER SOC, V92, P2985, DOI 10.1002/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5
   Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Strnad P, 2008, HISTOCHEM CELL BIOL, V129, P735, DOI 10.1007/s00418-008-0431-x
   Tang JT, 2011, CARCINOGENESIS, V32, P1207, DOI 10.1093/carcin/bgr114
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Van den Eynden GG, 2007, CLIN EXP METASTAS, V24, P13, DOI 10.1007/s10585-006-9049-3
   Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Wang ZW, 2010, CURR STEM CELL RES T, V5, P74, DOI 10.2174/157488810790442813
   Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988
   Yang SX, 2010, J CLIN ONCOL, V28, P2974, DOI 10.1200/JCO.2009.26.1602
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Ye G, 2011, J CELL SCI, V124, P359, DOI 10.1242/jcs.072223
   Yoo YG, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002072
   Yoo YG, 2011, CANCER RES, V71, P1244, DOI 10.1158/0008-5472.CAN-10-2360
   Zhu F, 2010, HEPATOB PANCREAT DIS, V9, P508
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
   Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06
   Zurawa-Janicka D, 2008, ACTA BIOCHIM POL, V55, P9, DOI 10.18388/abp.2008_3123
   Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867
NR 89
TC 33
Z9 37
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2012
VL 7
IS 6
AR e39446
DI 10.1371/journal.pone.0039446
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 966AK
UT WOS:000305808700028
PM 22761798
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Min, KN
   Joung, KE
   Kim, DK
   Sheen, YY
AF Min, Kyung Nan
   Joung, Ki Eun
   Kim, Dae-Kee
   Sheen, Yhun Yhong
TI Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer
SO BIOMOLECULES & THERAPEUTICS
LA English
DT Article
DE IN-2001; MDA-MB-231; HDAC
ID HISTONE-DEACETYLASE INHIBITORS; CELL-CYCLE; GENE-EXPRESSION; HDAC
   INHIBITORS; TRICHOSTATIN-A; ACETYLATION; DIFFERENTIATION; P21(WAF1);
   GROWTH; ACTIVATION
AB In recent years, inhibition of HDACs has emerged as a potential strategy to reverse aberrant epigenetic changes associated with cancer, and several classes of HDAC inhibitors have been found to have potent and specific anticancer activities in preclinical studies. But their precise mechanism of action has not been elucidated. In this study, a novel synthetic inhibitor of HDAC, 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide [IN-2001] was examined for its antitumor activity and the underlying molecular mechanisms of any such activity on human breast cancer cell lines. IN-2001 effectively inhibited cellular HDAC activity (IC50 = 0.585 nM) inMDA-MB-231 human breast cancer cells. IN-2001 caused a significant dose-dependent inhibition of cell proliferation in estrogen receptor (ER) negative MDA-MB-231human breast cancer cells. Cell cycle analysis revealed that the growth inhibitory effects of IN-2001 might be attributed to cell cycle arrest at G(0)/G, and/or G(2)/Mphase and subsequent apoptosis in human breast cancer cells. These events are accompanied by modulating several cell cycle and apoptosis regulatory genes such as CDK inhibitors p21(WAF1) and p27(KIP1) cyclin D1, and other tumor suppressor genes such as cyclin D2. Collectively, IN-2001 inhibited cell proliferation and induced apoptosis in human breast cancer cells and these findings may provide new therapeutic approaches, combination of antiestrogen together with a HDAC inhibitor, in the hormonal therapy-resistant ER-negative breast cancers. In summary, our data suggest that this histone deacetylase inhibitor, IN-2001, is a novel promising therapeutic agent with potent antitumor effects against human breast cancers.
C1 [Min, Kyung Nan; Joung, Ki Eun; Kim, Dae-Kee; Sheen, Yhun Yhong] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.
C3 Ewha Womans University
RP Sheen, YY (通讯作者)，Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea.
EM yysheen@ewha.ac.kr
FU KOSEF [2006-KRF-531-E00112]
FX This work was supported by grant 2006-KRF-531-E00112 from KOSEF.
CR Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791
   Banwell CM, 2003, RECENT RESULTS CANC, V164, P83
   Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755
   Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317
   Butler L. M., 2000, P AM ASSOC CANC RES, V41, P289
   Butler LM, 2000, CANCER RES, V60, P5165
   Butler LM, 2001, CLIN CANCER RES, V7, P962
   Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043
   Davis T, 2000, CLIN CANCER RES, V6, P4334
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668
   Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652
   Fournel M, 2002, CANCER RES, V62, P4325
   Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X
   Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176
   Krämer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493
   REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Rosato RR, 2001, INT J ONCOL, V19, P181
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001
   Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372
NR 36
TC 5
Z9 5
U1 0
U2 1
PU KOREAN SOC APPLIED PHARMACOLOGY
PI SEOUL
PA RM 805, KOREAN FEDERATION SCIENCE & TECHNOLOGY B/D, 635-4 YEOKSAM-DONG,
   KANGNAM-GU, SEOUL, 135-703, SOUTH KOREA
SN 1976-9148
EI 2005-4483
J9 BIOMOL THER
JI Biomol. Ther.
PD MAY 31
PY 2012
VL 20
IS 3
BP 313
EP 319
DI 10.4062/biomolther.2012.20.3.313
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 966OO
UT WOS:000305847500010
PM 24130929
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Dela Cruz, F
   Matushansky, I
AF Dela Cruz, Filemon
   Matushansky, Igor
TI Solid Tumor Differentiation Therapy - Is It Possible?
SO ONCOTARGET
LA English
DT Article
DE Differentiation therapy; soft tissue sarcoma; retinoids; histone
   deacetylase inhibitor; PPAR-gamma agonist; trabectedin
ID ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ACTIVATED
   RECEPTOR-GAMMA; HISTONE DEACETYLASE INHIBITOR; RHABDOMYOSARCOMA
   CELL-LINES; MESENCHYMAL STEM-CELLS; BREAST-CANCER CELLS; PPAR-GAMMA;
   CHONDROSARCOMA CELLS; LIPOSARCOMA CELLS
AB Genetic and epigenetic events within a cell which promote a block in normal development or differentiation coupled with unregulated proliferation are hallmarks of neoplastic transformation. Differentiation therapy involves the use of agents with the ability to induce differentiation in cells that have lost this ability, i.e. cancer cells. The promise of differentiation-based therapy as a viable treatment modality is perhaps best characterized by the addition of retinoids in the treatment of acute promyelocytic leukemia (APML) revolutionizing the management of APML and dramatically improving survival. However, interest and application of differentiation-based therapy for the treatment of solid malignancies have lagged due to deficiencies in our understanding of differentiation pathways in solid malignancies. Over the past decade, a differentiation-based developmental model for solid tumors has emerged providing insights into the biology of various solid tumors as well as identification of targetable pathways capable of re-activating blocked terminal differentiation programs. Furthermore, a variety of agents including retinoids, histone deacetylase inhibitors (HDACI), PPAR. agonists, and others, currently in use for a variety of malignancies, have been shown to induce differentiation in solid tumors. Herein we discuss the relevancy of differentiation-based therapies in solid tumors, using soft tissue sarcomas (STS) as a biologic and clinical model, and review the preclinical data to support its role as a promising modality of therapy for the treatment of solid tumors.
C1 [Matushansky, Igor] Columbia Univ Coll Phys & Surg, Dept Med, Div Med Oncol, New York, NY USA.
   [Dela Cruz, Filemon] Columbia Univ Coll Phys & Surg, Dept Pediat, Div Pediat Oncol, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP Matushansky, I (通讯作者)，Columbia Univ Coll Phys & Surg, Dept Med, Div Med Oncol, New York, NY USA.
EM im17@columbia.edu
FU Hyundai Hope on Wheels; John M. Driscoll, Jr., M.D. Children's Fund
   Award; Jaime Deutsch Foundation; NCI; Damon Runyon Cancer Research Fund
FX F.D.C. is supported by grants from Hyundai Hope on Wheels, the John M.
   Driscoll, Jr., M.D. Children's Fund Award, and the Jaime Deutsch
   Foundation. I.M. receives funding from the NCI and the Damon Runyon
   Cancer Research Fund.
CR Allavena P, 2005, CANCER RES, V65, P2964, DOI 10.1158/0008-5472.CAN-04-4037
   Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9
   Barlow JW, 2006, PEDIATR BLOOD CANCER, V47, P773, DOI 10.1002/pbc.20650
   Brodowicz T, 1999, BRIT J CANCER, V80, P1350, DOI 10.1038/sj.bjc.6690528
   Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   CROUCH GD, 1991, CANCER RES, V51, P4882
   CUNNINGHAM I, 1989, BLOOD, V73, P1116
   D'Incalci M, 2010, MOL CANCER THER, V9, P2157, DOI 10.1158/1535-7163.MCT-10-0263
   De Botton S, 1998, BLOOD, V92, P2712, DOI 10.1182/blood.V92.8.2712.420k03_2712_2718
   Debrock G, 2003, BRIT J CANCER, V89, P1409, DOI 10.1038/sj.bjc.6601306
   Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951
   Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806
   Fenaux P, 2000, LEUKEMIA, V14, P1371, DOI 10.1038/sj.leu.2401859
   Forni C, 2009, MOL CANCER THER, V8, P449, DOI 10.1158/1535-7163.MCT-08-0848
   Garattini E, 2007, VITAM HORM, V75, P301, DOI 10.1016/S0083-6729(06)75012-9
   GARVIN AJ, 1986, AM J PATHOL, V125, P208
   Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335
   Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8
   Grosso F, 2007, LANCET ONCOL, V8, P595, DOI 10.1016/S1470-2045(07)70175-4
   Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   KANTARJIAN HM, 1986, AM J MED, V80, P789, DOI 10.1016/0002-9343(86)90617-0
   Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047
   Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Mandelli F, 1997, BLOOD, V90, P1014
   Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Martirosyan AR, 2004, BIOCHEM PHARMACOL, V68, P1729, DOI 10.1016/j.bcp.2004.05.003
   Matushansky I, 2008, AM J PATHOL, V172, P1069, DOI 10.2353/ajpath.2008.070284
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088
   Munster PN, 2001, CANCER RES, V61, P8492
   NG KW, 1985, CANCER RES, V45, P5106
   PIERCE GB, 1971, CANCER RES, V31, P127
   PIERCE GB, 1983, AM J PATHOL, V113, P115
   Pitha-Rowe I, 2003, LEUKEMIA, V17, P1723, DOI 10.1038/sj.leu.2403065
   Platta CS, 2007, J SURG RES
   Rephaeli A, 2005, INT J CANCER, V116, P226, DOI 10.1002/ijc.21030
   Riester M, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000777
   Rinehart KL, 2000, MED RES REV, V20, P1
   Sakimura R, 2007, CLIN CANCER RES, V13, P275, DOI 10.1158/1078-0432.CCR-06-1696
   Sanz MA, 1999, BLOOD, V94, P3015
   Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030
   Sertznig P, 2007, J CELL PHYSIOL, V212, P1, DOI 10.1002/jcp.20998
   Sherman EJ, 2009, J CLIN ONCOL, V27
   Siddiqi S, 2010, CURR STEM CELL RES T, V5, P63, DOI 10.2174/157488810790442859
   STONE RM, 1988, BLOOD, V71, P690
   Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501
   Tallman MS, 2002, BLOOD, V100, P4298, DOI 10.1182/blood-2002-02-0632
   Testi AM, 2005, BLOOD, V106, P447, DOI 10.1182/blood-2004-05-1971
   THEIN R, 1982, CANCER RES, V42, P4771
   Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4
   Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1
NR 58
TC 77
Z9 93
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY
PY 2012
VL 3
IS 5
BP 559
EP 567
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 966BM
UT WOS:000305811700007
PM 22643847
OA hybrid, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Giacinti, L
   Giacinti, C
   Gabellini, C
   Rizzuto, E
   Lopez, M
   Giordano, A
AF Giacinti, L.
   Giacinti, C.
   Gabellini, C.
   Rizzuto, E.
   Lopez, M.
   Giordano, A.
TI Scriptaid effects on breast cancer cell lines
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION;
   CPG ISLAND; ACTIVATION; ER; TRANSCRIPTION; METHYLATION; DERIVATIVES;
   MECHANISMS
AB In breast cancer tumor expression of estrogen receptors (ERs) is important as a marker of prognosis and mostly as a predictor of response to endocrine therapy. In fact, the loss of a-ER expression leads to unresponsiveness to anti-hormone treatment. In a significant fraction of breast cancers, this loss of expression is a result of epigenetic mechanisms, such as DNA methylation and histone deacetylation, within the a-ER promoter. Previous studies have shown that pharmacologic inhibition of these mechanisms using the DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (AZA), and the histone deacetylase (HDAC) inhibitor, Trichostatin A (TSA), results in expression of functional a-ER mRNA and protein. Moreover, the activity of a novel HDAC inhibitor, Scriptaid, has been shown to induce inhibition of tumor growth in breast cancer and to cause re-expression of functional a-ER in a-ER negative breast cancer cells. We sought to better characterize the effects of Scriptaid on cell growth, apoptosis, and a-ER expression in a-ER-positive (MCF-7), a-ER-negative (MDA-MB-231), and a-ER-negative/Her-2 over-expressing (SKBr-3) human breast cancer cell lines. In all of these cell lines Scriptaid treatment resulted in significant growth inhibition and apoptosis, and RT-PCR confirmed an increase of a-ER mRNA transcript in MDA-MB-231 after 48?h of Scriptaid treatment. Furthermore, following treatment with Scriptaid, the formerly unresponsive MDA-MB-231 and SKBr-3 breast cancer cells became responsive to tamoxifen. These results show that the HDAC inhibitor Scriptaid is able to sensitize tamoxifen hormone-resistant breast cancer cells, and that Scriptaid or related HDAC inhibitors are candidates for further study in breast cancer. J. Cell. Physiol. 227: 34263433, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Giacinti, L.; Lopez, M.] Regina Elena Inst Canc Res, Div Med Oncol B, Rome, Italy.
   [Giacinti, L.; Giacinti, C.; Giordano, A.] Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA.
   [Giacinti, C.; Rizzuto, E.] Univ Roma La Sapienza, Dept Histol & Med Embryol IIM, Rome, Italy.
   [Gabellini, C.] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy.
   [Giordano, A.] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy.
C3 IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Sapienza University Rome; IRCCS Istituti Fisioterapici
   Ospitalieri (IFO); IRCCS Regina Elena; University of Siena
RP Giacinti, L (通讯作者)，Spolverini Hosp, Div Med Oncol, 2 Cerquette St, I-00040 Monte Porzio Catone, Italy.
EM lauragiacinti@yahoo.it; giordano@temple.edu
RI ; Gabellini, Chiara/M-2539-2014; Giordano, Antonio/F-1927-2010; Rizzuto,
   Emanuele/K-9437-2016
OI GIACINTI, Cristina/0000-0002-5596-6967; Gabellini,
   Chiara/0000-0002-5544-1570; Giordano, Antonio/0000-0002-5959-016X;
   Rizzuto, Emanuele/0000-0003-2314-6128
FU Sbarro Health Research Organization; Human Health Foundation
   Spoleto-Terni; AIRC
FX Contract grant sponsor: Sbarro Health Research Organization
   (www.shro.org).Contract grant sponsor: Human Health Foundation
   Spoleto-Terni (www.hhfonlus.org).Contract grant sponsor: AIRC.
CR BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Bouchain G, 2003, CURR MED CHEM, V10, P2359, DOI 10.2174/0929867033456585
   Bouchain G, 2003, J MED CHEM, V46, P820, DOI 10.1021/jm020377a
   Caligiuri I, 2012, J CELL PHYSIOL, V227, P2988, DOI 10.1002/jcp.24031
   Cui XJ, 2005, J CLIN ONCOL, V23, P7721, DOI 10.1200/JCO.2005.09.004
   Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961
   Fiorentino FP, 2012, J CELL PHYSIOL, V227, P479, DOI 10.1002/jcp.22780
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Giordano Antonio, 2012, Front Biosci (Schol Ed), V4, P356
   Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200
   Han JW, 2000, CANCER RES, V60, P6068
   Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243
   Hu J, 2005, MOL CANCER RES, V3, P100, DOI 10.1158/1541-7786.MCR-04-0070
   Iwase Hirotaka, 2003, Breast Cancer, V10, P89, DOI 10.1007/BF02967632
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Marks P.A., 2004, NOVARTIS FDN S, V259, P281
   Marks PA, 2004, CELL CYCLE, V3, P534
   Marks Paul A, 2004, Novartis Found Symp, V259, P269
   McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884
   Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200
   Rosato RR, 2003, CANCER RES, V63, P3637
   Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940
   Singh RR, 2005, J CELL BIOCHEM, V96, P490, DOI 10.1002/jcb.20566
   Su GH, 2000, CANCER RES, V60, P3137
   Takai N, 2006, INT J MOL MED, V17, P323
   Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001
   Voorhees PM, 2003, CLIN CANCER RES, V9, P6316
   WEIGEL RJ, 1993, CANCER RES, V53, P3472
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
NR 37
TC 27
Z9 32
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2012
VL 227
IS 10
BP 3426
EP 3433
DI 10.1002/jcp.24043
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 961ZY
UT WOS:000305509900009
PM 22213035
DA 2025-01-12
ER

PT J
AU Menezes, ME
   Mitra, A
   Shevde, LA
   Samant, RS
AF Menezes, Mitchell E.
   Mitra, Aparna
   Shevde, Lalita A.
   Samant, Rajeev S.
TI DNAJB6 governs a novel regulatory loop determining Wnt/β-catenin
   signalling activity
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE dickkopf 1 homologue (DKK1); DnaJ (heat-shock protein 40 kDa) homologue;
   subfamily B; member 6 (DNAJB6); epithelial-mesenchymal transition (EMT);
   muscle segment homeobox 1 (MSX1); Wnt
ID MAMMARY-GLAND DEVELOPMENT; EPITHELIAL-MESENCHYMAL TRANSITIONS;
   TUMOR-SUPPRESSOR; WNT ANTAGONIST; BETA-CATENIN; BREAST-CANCER;
   EPIGENETIC INACTIVATION; MALIGNANT ACTIVITY; DOWNSTREAM TARGET; TOOTH
   DEVELOPMENT
AB DKK1 (dickkopf 1 homologue) is a secreted inhibitor of the Wnt signalling pathway and a critical modulator of tumour promotion and the tumour microenvironment. However, mechanisms regulating DKK1 expression are understudied. DNAJB6 {DnaJ [HSP40 (heat-shock protein 40 kDa)] homologue, subfamily B, member 6} is an HSP40 family member whose expression is compromized during progression of breast cancer and melanoma. Inhibition of the Wnt/beta-catenin signalling pathway by up-regulation of DKK1 is one of the key mechanisms by which DNAJB6 suppresses tumour metastasis and EMT (epithelial mesenchymal transition). Analysis of the DKKI promoter to define the cis-site responsible for its up-regulation by DNAJB6 revealed the presence of two binding sites for a transcriptional repressor, MSX1 (muscle segment homeobox 1). Our investigations showed that MSX1 binds the DKKI promoter and inhibits DKK1 transcription. Interestingly, silencing DNAJB6 resulted in up-regulation of MSX1 concomitant with increased stabilization of beta-catenin. ChIP (chromatin immunoprecipitation) studies revealed that beta-catenin binds the MSX1 promoter and stabilization of beta-catenin elevates MSX1 transcription, indicating that beta-catenin works as a transcription co-activator for MSX1. Functionally, exogenous expression of MSX1 in DNAJB6-expressing cells promotes the mesenchymal phenotype by suppression of DKK1. Thus we have identified a novel regulatory mechanism of DNAJB6-mediated DKK1 transcriptional up-regulation that can influence EMT. DKK1 is a feedback regulator of beta-catenin levels and thus our studies also define an additional negative control of this beta-catenin/DKK1 feedback loop by MSX1, which may potentially contribute to excessive stabilization of beta-catenin.
C1 [Menezes, Mitchell E.; Mitra, Aparna; Shevde, Lalita A.; Samant, Rajeev S.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA.
C3 University of South Alabama
RP Samant, RS (通讯作者)，Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, 1660 Spring Hill Ave, Mobile, AL 36604 USA.
EM rsamant@usouthal.edu
OI Samant, Rajeev/0000-0001-5681-4976
FU United States Public Health Service [CA140472, CA138850]
FX This work was supported by the United States Public Health Service
   [grant numbers CA140472 (to R.S.S.) and CA138850 (to L.A.S.)].
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413
   Bei M, 1998, DEVELOPMENT, V125, P4325
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460
   Chen CY, 2009, J PATHOL, V219, P347, DOI 10.1002/path.2604
   Chen HW, 2008, CANCER RES, V68, P7428, DOI 10.1158/0008-5472.CAN-07-6734
   Chetcuti A, 2011, PEDIATR BLOOD CANCER, V57, P950, DOI 10.1002/pbc.23003
   Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276
   Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579
   Friedmann Y, 1996, DEV BIOL, V177, P347, DOI 10.1006/dbio.1996.0168
   Gonzálex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805
   Hall CL, 2010, CANCER RES, V70, P9916, DOI 10.1158/0008-5472.CAN-10-0440
   Hirata H, 2011, INT J CANCER, V128, P1793, DOI 10.1002/ijc.25507
   Hu GZ, 2001, DEVELOPMENT, V128, P2373
   Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004
   Hunter PJ, 1999, DEVELOPMENT, V126, P1247
   Katoh M, 2007, INT J MOL MED, V19, P197
   Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323
   Kuphal S, 2006, ONCOGENE, V25, P5027, DOI 10.1038/sj.onc.1209508
   Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Liu SH, 2009, CLIN EXP METASTAS, V26, P739, DOI 10.1007/s10585-009-9273-8
   Menezes ME, 2012, INT J CANCER, V130, P1477, DOI 10.1002/ijc.26449
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549-007-9867-2
   Mitra A., 2012, ONCOGENE, DOI [10.1038/onc.2011.655, DOI 10.1038/ONC.2011.655]
   Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847
   Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x
   Mitra A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1874
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7
   Park K, 2005, CANCER RES, V65, P749
   Phippard DJ, 1996, DEVELOPMENT, V122, P2729
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Qiao L, 2008, CANCER LETT, V269, P67, DOI 10.1016/j.canlet.2008.04.032
   Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491
   Revet I, 2008, EXP CELL RES, V314, P707, DOI 10.1016/j.yexcr.2007.12.008
   Revet I, 2010, CANCER LETT, V289, P195, DOI 10.1016/j.canlet.2009.08.019
   Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5
   SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348
   SIMON HG, 1995, DEV DYNAM, V202, P1, DOI 10.1002/aja.1002020102
   Sliwinski T, 2010, CANCER EPIDEMIOL, V34, P652, DOI 10.1016/j.canep.2010.06.003
   Song LY, 2009, DEVELOPMENT, V136, P3161, DOI 10.1242/dev.037440
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229
   Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215
   Watson ED, 2007, DEVELOPMENT, V134, P1809, DOI 10.1242/dev.02843
   Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920
NR 54
TC 38
Z9 45
U1 0
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD JUN 15
PY 2012
VL 444
BP 573
EP 580
DI 10.1042/BJ20120205
PN 3
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 962KZ
UT WOS:000305545300021
PM 22455953
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Mitra, S
   Mazumder-Indra, D
   Mondal, RK
   Basu, PS
   Roy, A
   Roychoudhury, S
   Panda, CK
AF Mitra, Sraboni
   Mazumder-Indra, Dipanjana
   Mondal, Ranajit K.
   Basu, Partha S.
   Roy, Anup
   Roychoudhury, Susanta
   Panda, Chinmay K.
TI Inactivation of <i>SLIT2</i>-<i>ROBO1</i>/<i>2</i> Pathway in
   Premalignant Lesions of Uterine Cervix: Clinical and Prognostic
   Significances
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; FREQUENT EPIGENETIC INACTIVATION; SQUAMOUS-CELL
   CARCINOMA; SLIT-ROBO PATHWAY; BREAST-CANCER; POOR-PROGNOSIS; HUMAN
   HOMOLOG; BETA-CATENIN; LUNG-CANCER; METHYLATION
AB The SLIT2-ROBO1/2 pathways control diverse biological processes, including growth regulation. To understand the role of SLIT2 and ROBO1/2 in cervical carcinogenesis, firstly their RNA expression profiles were screened in 21 primary uterine cervical carcinoma (CACX) samples and two CACX cell lines. Highly reduced expressions of these genes were evident. Concomitant alterations [deletion/methylation] of the genes were then analyzed in 23 cervical intraepithelial neoplasia (CIN) and 110 CACX samples. In CIN, SLIT2 was deleted in 22% samples compared to 9% for ROBO1 and none for ROBO2, whereas comparable methylation was observed for both SLIT2 (30%) and ROBO1 (22%) followed by ROBO2 (9%). In CACX, alteration of the genes were in the following order: Deletion: ROBO1 (48%) > SLIT2 (35%) > ROBO2 (33%), Methylation: SLIT2 (34%) > ROBO1 (29%) > ROBO2 (26%). Overall alterations of SLIT2 and/or ROBO1 (44%) and SLIT2 and/or ROBO2 (39%) were high in CIN followed by significant increase in stage I/II tumors, suggesting deregulation of these interactions in premalignant lesions and early invasive tumors. Immunohistochemical analysis of SLIT2 and ROBO1/2 in CACX also showed reduced expression concordant with molecular alterations. Alteration of all these genes predicted poor patient outcome. Multiparous (>= 5) women with altered SLIT2 and ROBO1 along with advanced tumor stage (III/IV) and early sexual debut (<19 years) had worst prognosis. Our data suggests the importance of abrogation of SLIT2-ROBO1 and SLIT2-ROBO2 interactions in the initiation and progression of CACX and also for early diagnosis and prognosis of the disease.
C1 [Mitra, Sraboni; Mazumder-Indra, Dipanjana; Panda, Chinmay K.] Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, Kolkata, West Bengal, India.
   [Mondal, Ranajit K.; Basu, Partha S.] Chittaranjan Natl Canc Inst, Dept Gynaecol Oncol, Kolkata, West Bengal, India.
   [Roy, Anup] N Bengal Med Coll, Siliguri, West Bengal, India.
   [Roychoudhury, Susanta] Indian Inst Chem Biol, Mol & Human Genet Div, Kolkata, West Bengal, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Indian Institute of Chemical Biology (IICB)
RP Mitra, S (通讯作者)，Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ckpanda.cnci@gmail.com
RI Roychoudhury, Susanta/AAD-7946-2021
FU Council for Scientific and Industrial Research (CSIR), Government of
   India [27 (0111)/00/EMR-II]; Department of Science and Technology (DST),
   Government of India [SR/SO/HS-116/2007(G)]; CSIR funded Senior Research
   Fellowship [CSIR-SRF(Ext)] [09/030(0064)/2011EMR-I]; CSIR funded Junior
   Research Fellowship through the National Eligibility Test [CSIR-JRF/NET]
   Fellowship [9/30(44)/2005-EMR-I]; CSIR-Project [IAP-001]
FX Financial support for this work was provided by grants: [no. 27
   (0111)/00/EMR-II] from Council for Scientific and Industrial Research
   (CSIR), Government of India and [SR/SO/HS-116/2007(G)] from the
   Department of Science and Technology (DST), Government of India to Dr.
   Panda, CSIR funded Senior Research Fellowship [CSIR-SRF(Ext)] grant
   no:[09/030(0064)/2011EMR-I] to Ms Sraboni Mitra, CSIR funded Junior
   Research Fellowship selected through the National Eligibility Test
   [CSIR-JRF/NET] Fellowship grant no: [9/30(44)/2005-EMR-I] to Ms.
   Mazumder-Indra and CSIR-Project (IAP-001) to Dr. Roychoudhury. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Allen DG, 2000, BRIT J CANCER, V83, P1659, DOI 10.1054/bjoc.2000.1509
   Angeloni D, 2006, GENE CHROMOSOME CANC, V45, P676, DOI 10.1002/gcc.20332
   Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447
   Atkin NB, 1997, CANCER GENET CYTOGEN, V95, P33, DOI 10.1016/S0165-4608(97)83452-8
   Bièche I, 2004, CLIN CANCER RES, V10, P6789, DOI 10.1158/1078-0432.CCR-04-0306
   Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687
   Dallol A, 2003, CANCER RES, V63, P1054
   Dallol A, 2002, CANCER RES, V62, P5874
   Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421
   Dasgupta S, 2002, ORAL ONCOL, V38, P6, DOI 10.1016/S1368-8375(00)00131-7
   Dickinson RE, 2010, REPRODUCTION, V139, P697, DOI 10.1530/REP-10-0017
   Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137
   Ghosh S, 2009, HUM GENET, V125, P189, DOI 10.1007/s00439-008-0610-9
   Hampton GM, 1996, P NATL ACAD SCI USA, V93, P6704, DOI 10.1073/pnas.93.13.6704
   Harris CP, 2003, GENE CHROMOSOME CANC, V36, P233, DOI 10.1002/gcc.10158
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479
   Ichimura K, 2000, CANCER RES, V60, P417
   Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821
   Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635
   Li LC, 2004, BIOCHEM BIOPH RES CO, V321, P455, DOI 10.1016/j.bbrc.2004.06.164
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loginov V I, 2004, Mol Biol (Mosk), V38, P654
   Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137
   Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300
   Mitra S, 2010, MOL CARCINOGEN, V49, P935, DOI 10.1002/mc.20671
   Murthy N. S., 1999, Indian Journal of Cancer, V36, P154
   Narayan G, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-16
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Perrone F, 2006, CLIN CANCER RES, V12, P6643, DOI 10.1158/1078-0432.CCR-06-1759
   Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200
   Sambrook J., 1989, MOL CLONING LAB MANU, Vsecond
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sen U, 2002, INT J CANCER, V100, P86, DOI 10.1002/ijc.10446
   Singh RK, 2007, HUM GENET, V122, P71, DOI 10.1007/s00439-007-0375-6
   Singh RK, 2005, J CANCER RES CLIN, V131, P395, DOI 10.1007/s00432-004-0655-7
   SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331
   Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103
   Tseng RC, 2010, CANCER RES, V70, P543, DOI 10.1158/0008-5472.CAN-09-2084
   Yiin JJ, 2009, NEURO-ONCOLOGY, V11, P779, DOI 10.1215/15228517-2008-017
   Yuasa Y, 2005, CARCINOGENESIS, V26, P193, DOI 10.1093/carcin/bgh304
   Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835
   Zheng Dan, 2009, Zhonghua Gan Zang Bing Za Zhi, V17, P198
   zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690
NR 45
TC 26
Z9 27
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2012
VL 7
IS 6
AR e38342
DI 10.1371/journal.pone.0038342
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959UV
UT WOS:000305341900024
PM 22719878
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhao, KL
   Wang, WX
   Yu, XH
   Zhou, X
   Shi, Q
   Hu, YF
AF Zhao, Kailiang
   Wang, Weixing
   Yu, Xiaohui
   Zhou, Xing
   Shi, Qiao
   Hu, Yunfei
TI Triptolide-Induced Apoptosis of Androgen-Independent Prostatic Cancer
   (AIPC) via Modulation of Histone Methylation
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
DE triptolide; histone methylation; EZH2; human hormone independent
   prostatic cancer
ID AGGRESSIVE BREAST-CANCER; GROUP PROTEIN EZH2; ZESTE HOMOLOG-2;
   CELL-PROLIFERATION; EPITHELIAL-CELLS; DNA METHYLATION; E-CADHERIN;
   IN-VITRO; EXPRESSION; ENHANCER
AB Strategy, Management and Health Policy Enabling Technology, Genomics, Proteomics Preclinical Research Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics Clinical Development Phases I-III Regulatory, Quality, Manufacturing Postmarketing Phase IV Triptolide is the principal active ingredient in extracts from the Chinese herb, Tripterygium wilfordii Hook.F (TwHF) and has various biological functions including immunosuppression, anti-inflammatory, antiviral, and antitumor properties. Triptolide has antitumor activity in a variety of tumors, and numerous studies have attempted to elucidate the potential antitumor mechanism. Triptolide can modulate histone methylation, suggesting that epigenetic mechanisms may play an important role in its antitumor activity. The present study assessed the association between the antitumor effects of triptolide in androgen-independent prostatic cancer and the regulation of histone methylation. Triptolide inhibited the proliferation of the androgen-independent prostatic cancer cell line, Du145 and induced apoptosis in a time- and dose-dependent manner. Triptolide decreased histone H3K27me3 methylation via downregulation of histone methyltransferase enhancer of zeste 2, which may represent the antitumor mechanism of triptolide.
C1 [Yu, Xiaohui; Hu, Yunfei] Wuhan Univ, Dept Urol, Renmin Hosp, Wuhan 430060, Hubei Province, Peoples R China.
   [Zhao, Kailiang; Wang, Weixing; Zhou, Xing; Shi, Qiao] Wuhan Univ, Dept Gen Surg, Renmin Hosp, Wuhan 430060, Hubei Province, Peoples R China.
C3 Wuhan University; Wuhan University
RP Hu, YF (通讯作者)，Wuhan Univ, Dept Urol, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Hubei Province, Peoples R China.
EM hyf6606@163.com
RI wang, wy/JDD-3603-2023; Shi, Qiao/CAG-4624-2022
FU Self-research program for Doctoral Candidates of Wuhan University;
   National Natural Sciences Foundation of China [81070368]
FX The authors would like to thank the Department of Central Laboratory,
   Renmin Hospital, Wuhan University, Wuhan, China, for providing relevant
   experimental facilities and technical support. This work was supported
   by "Self-research program for Doctoral Candidates of Wuhan University in
   2012" and by the National Natural Sciences Foundation of China
   (No.81070368).
CR Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771
   Dobosy JR, 2007, J UROLOGY, V177, P822, DOI 10.1016/j.juro.2006.10.063
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x
   Kiviharju TM, 2002, CLIN CANCER RES, V8, P2666
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Pigneux A, 2008, EXP HEMATOL, V36, P1648, DOI 10.1016/j.exphem.2008.08.002
   Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Weikert S, 2005, INT J MOL MED, V16, P349
   Yang SM, 2003, MOL CANCER THER, V2, P65
   Zhang C, 2007, CHINESE J CANCER RES, V19, P27, DOI 10.1007/s11670-007-0027-3
   Zhang C, 2006, ACTA PHARMACOL SIN, V27, P1438, DOI 10.1111/j.1745-7254.2006.00415.x
NR 21
TC 1
Z9 1
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD JUN
PY 2012
VL 73
IS 4
BP 222
EP 228
DI 10.1002/ddr.21011
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 961HM
UT WOS:000305455100005
DA 2025-01-12
ER

PT J
AU Peng, ZG
   Shen, RL
   Li, YW
   Teng, KY
   Shapiro, CL
   Lin, HJL
AF Peng, Zhengang
   Shen, Rulong
   Li, Ying-Wei
   Teng, Kun-Yu
   Shapiro, Charles L.
   Lin, Huey-Jen L.
TI Epigenetic Repression of <i>RARRES1</i> Is Mediated by Methylation of a
   Proximal Promoter and a Loss of CTCF Binding
SO PLOS ONE
LA English
DT Article
ID TAZAROTENE-INDUCED GENE-1; HIGH ALDEHYDE DEHYDROGENASE; RETINOID
   RESPONSE GENE; ACID RECEPTOR-BETA; CANCER-CELL-LINES; TUMOR-SUPPRESSOR;
   DNA METHYLATION; CHROMATIN MODIFICATIONS; TRANSCRIPTION FACTOR;
   STEM-CELLS
AB Background: The cis-acting promoter element responsible for epigenetic silencing of retinoic acid receptor responder 1 (RARRES1) by methylation is unclear. Likewise, how aberrant methylation interplays effectors and thus affects breast neoplastic features remains largely unknown.
   Methodology/Principal Findings: We first compared methylation occurring at the sequences (-664 similar to+420) flanking the RARRES1 promoter in primary breast carcinomas to that in adjacent benign tissues. Surprisingly, tumor cores displayed significantly elevated methylation occurring solely at the upstream region (-664 similar to-86), while the downstream element (-85 similar to+420) proximal to the transcriptional start site (+1) remained largely unchanged. Yet, hypermethylation at the former did not result in appreciable silencing effect. In contrast, the proximal sequence displayed full promoter activity and methylation of which remarkably silenced RARRES1 transcription. This phenomenon was recapitulated in breast cancer cell lines, in which methylation at the proximal region strikingly coincided with downregulation. We also discovered that CTCF occupancy was enriched at the unmethylayed promoter bound with transcription-active histone markings. Furthermore, knocking-down CTCF expression hampered RARRES1 expression, suggesting CTCF positively regulated RARRES1 transcription presumably by binding to unmethylated promoter poised at transcription-ready state. Moreover, RARRES1 restoration not only impeded cell invasion but also promoted death induced by chemotherapeutic agents, denoting its tumor suppressive effect. Its role of attenuating invasion agreed with data generated from clinical specimens revealing that RARRES1 was generally downregulated in metastatic lymph nodes compared to the tumor cores.
   Conclusion/Significance: This report delineated silencing of RARRES1 by hypermethylation is occurring at a proximal promoter element and is associated with a loss of binding to CTCF, an activator for RARRES1 expression. We also revealed the tumor suppressive roles exerted by RARRES1 in part by promoting breast epithelial cell death and by impeding cell invasion that is an important property for metastatic spread.
C1 [Peng, Zhengang; Li, Ying-Wei; Teng, Kun-Yu; Lin, Huey-Jen L.] Ohio State Univ, Med Ctr, Sch Allied Med Profess, Div Med Technol, Columbus, OH 43210 USA.
   [Peng, Zhengang; Li, Ying-Wei; Teng, Kun-Yu; Lin, Huey-Jen L.] Ohio State Univ, Med Ctr, Ctr Comprehens Canc, Mol Biol & Canc Genet Program, Columbus, OH 43210 USA.
   [Shen, Rulong] Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA.
   [Shapiro, Charles L.] Ohio State Univ, Med Ctr, Dept Med Oncol, Columbus, OH 43210 USA.
   [Lin, Huey-Jen L.] Univ Delaware, Dept Med Technol, Newark, DE USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University; James Cancer Hospital & Solove Research
   Institute; University System of Ohio; Ohio State University; University
   System of Ohio; Ohio State University; University of Delaware
RP Peng, ZG (通讯作者)，Ohio State Univ, Med Ctr, Sch Allied Med Profess, Div Med Technol, Columbus, OH 43210 USA.
EM hueyjenlin@gmail.com
RI Shen, Rulong/E-4079-2011
FU Department of Defense [BC073892]; Susan G. Komen Breast Cancer
   Foundation [KG081123]
FX This work was supported by a Breast Cancer Idea Award from the
   Department of Defense (BC073892) and a grant from the Susan G. Komen
   Breast Cancer Foundation (KG081123) to HL. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Belancio VP, 2010, NUCLEIC ACIDS RES, V38, P3909, DOI 10.1093/nar/gkq132
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x
   De la Rosa-Velázquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024
   Dell G, 2001, Methods Mol Biol, V181, P251
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Farrar D, 2010, MOL CELL BIOL, V30, P1199, DOI 10.1128/MCB.00827-09
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Fujimoto R, 2011, PLANT J, V66, P831, DOI 10.1111/j.1365-313X.2011.04549.x
   Fuso A, 2010, CELL CYCLE, V9, P3965, DOI 10.4161/cc.9.19.13193
   Gomes NP, 2010, GENE DEV, V24, P1022, DOI 10.1101/gad.1881010
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jia L, 2008, CANCER CHEMOTH PHARM, V61, P63, DOI 10.1007/s00280-007-0446-3
   Jing C, 2002, JNCI-J NATL CANCER I, V94, P482
   Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kwok WK, 2009, CANCER GENET CYTOGEN, V194, P58, DOI 10.1016/j.cancergencyto.2009.06.005
   Kwong J, 2005, INT J CANCER, V113, P386, DOI 10.1002/ijc.20593
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   Moriguchi K, 2007, CANCER LETT, V249, P178, DOI 10.1016/j.canlet.2006.08.014
   Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ohnishi S, 2009, CELL PROLIFERAT, V42, P309, DOI 10.1111/j.1365-2184.2008.00592.x
   Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001
   Sakazume S, 2012, HUM GENET, V131, P121, DOI 10.1007/s00439-011-1051-4
   Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392
   Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29
   Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690
   Tamura G, 2009, PATHOL INT, V59, P895, DOI 10.1111/j.1440-1827.2009.02458.x
   Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306
   Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x
   van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Youssef EM, 2004, CANCER RES, V64, P2411, DOI 10.1158/0008-5472.CAN-03-0164
   Zampieri M, 2012, BIOCHEM J, V441, P645, DOI 10.1042/BJ20111417
   Zhang H, 2011, J CELL BIOL, V193, P475, DOI 10.1083/jcb.201101021
   Zhang JM, 2004, ONCOGENE, V23, P2241, DOI 10.1038/sj.onc.1207328
NR 47
TC 18
Z9 21
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2012
VL 7
IS 5
AR e36891
DI 10.1371/journal.pone.0036891
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959UQ
UT WOS:000305341200024
PM 22615834
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Du, J
   Zhou, NN
   Liu, HX
   Jiang, F
   Wang, YB
   Hu, CY
   Qi, H
   Zhong, CY
   Wang, XR
   Li, Z
AF Du, Juan
   Zhou, Nannan
   Liu, Hongxia
   Jiang, Fei
   Wang, Yubang
   Hu, Chunyan
   Qi, Hong
   Zhong, Caiyun
   Wang, Xinru
   Li, Zhong
TI Arsenic Induces Functional Re-Expression of Estrogen Receptor α by
   Demethylation of DNA in Estrogen Receptor-Negative Human Breast Cancer
SO PLOS ONE
LA English
DT Article
ID CELL-PROLIFERATION; GENE-EXPRESSION; TRIOXIDE; METHYLATION; INHIBITION;
   ACTIVATION; RESISTANCE; METHYLTRANSFERASE; MECHANISMS
AB Estrogen receptor a (ER alpha) is a marker predictive for response of breast cancers to endocrine therapy. About 30% of breast cancers, however, are hormone-independent because of lack of ER alpha expression. New strategies are needed for re-expression of ER alpha and sensitization of ER-negative breast cancer cells to selective ER modulators. The present report shows that arsenic trioxide induces reactivated ER alpha, providing a target for therapy with ER antagonists. Exposure of ER-negative breast cancer cells to arsenic trioxide leads to re-expression of ER alpha mRNA and functional ER alpha protein in in vitro and in vivo. Luciferase reporter gene assays and 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)- 2-(4-sulfophenyl)- 2H-tetrazolium (MTS) assays show that, upon exposure to arsenic trioxide, formerly unresponsive, ER-negative MDA-MB-231 breast cancer cells become responsive to ER antagonists, 4-hydroxytamoxifen and ICI 182,780. Furthermore, methylation-specific PCR and bisulfite-sequencing PCR assays show that arsenic trioxide induces partial demethylation of the ER alpha promoter. A methyl donor, S-adenosylmethionine (SAM), reduces the degree of arsenic trioxide-induced re-expression of ER alpha and demethylation. Moreover, Western blot and ChIP assays show that arsenic trioxide represses expression of DNMT1 and DNMT3a along with partial dissociation of DNMT1 from the ER alpha promoter. Thus, arsenic trioxide exhibits a previously undefined function which induces re-expression ER alpha in ER-negative breast cancer cells through demethylation of the ER alpha promoter. These findings could provide important information regarding the application of therapeutic agents targeting epigenetic changes in breast cancers and potential implication of arsenic trioxide as a new drug for the treatment of ER-negative human breast cancer.
C1 [Du, Juan; Zhou, Nannan; Jiang, Fei; Wang, Yubang; Qi, Hong; Zhong, Caiyun; Wang, Xinru; Li, Zhong] Nanjing Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Modern Toxicol, Nanjing, Peoples R China.
   [Wang, Xinru; Li, Zhong] Nanjing Med Univ, Inst Toxicol, State Key Lab Reprod Med, Nanjing, Peoples R China.
   [Liu, Hongxia; Hu, Chunyan; Zhong, Caiyun; Li, Zhong] Nanjing Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Nanjing, Peoples R China.
   [Wang, Yubang] Safety Assessment & Res Ctr Drugs, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Du, J (通讯作者)，Nanjing Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Modern Toxicol, Nanjing, Peoples R China.
EM uiuclz@126.com
FU National Natural Science Foundation of China [30972507, 30901186];
   National High Technology Research and Development Program of China (863
   Program) [2010AA023001]; Qing Lan Project; Priority Academic Program
   Development of Jiangsu Higher Education Institutions
FX This work was supported by grant from the National Natural Science
   Foundation of China (30972507, 30901186), the National High Technology
   Research and Development Program of China (863 Program) (2010AA023001),
   Qing Lan Project (to ZL) and a project funded by the Priority Academic
   Program Development of Jiangsu Higher Education Institutions. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BECHTHOLD A, 1994, EUR J BIOCHEM, V224, P431, DOI 10.1111/j.1432-1033.1994.00431.x
   Billam M, 2009, CANC BIOL THER, P8
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cai X, 2000, LEUKEMIA, V14, P262, DOI 10.1038/sj.leu.2401650
   Chen GQ, 1997, BLOOD, V89, P3345
   Chow SKY, 2004, J ENDOCRINOL, V182, P325, DOI 10.1677/joe.0.1820325
   COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8
   CROOKS PA, 1984, J PHARM PHARMACOL, V36, P85, DOI 10.1111/j.2042-7158.1984.tb02999.x
   Cui X, 2006, HUM PATHOL, V37, P298, DOI 10.1016/j.humpath.2005.10.013
   Davison K, 2002, SEMIN HEMATOL, V39, P3, DOI 10.1053/shem.2002.33610
   Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   González-Fraile MI, 2002, BRIT J HAEMATOL, V117, P890, DOI 10.1046/j.1365-2141.2002.03502.x
   Hu Y, 1998, MUTAT RES-DNA REPAIR, V408, P203, DOI 10.1016/S0921-8777(98)00035-4
   JOHNSTON SRD, 1992, ANN ONCOL, V3, P503, DOI 10.1093/oxfordjournals.annonc.a058251
   Kito M, 2003, CANCER SCI, V94, P1010, DOI 10.1111/j.1349-7006.2003.tb01393.x
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Li Jin-Qing, 2004, Ai Zheng, V23, P626
   Li Q, 2009, MOL PHARMACOL, V76, P1072, DOI 10.1124/mol.109.056291
   Liu HQ, 2010, J NUTR BIOCHEM, V21, P390, DOI 10.1016/j.jnutbio.2009.01.016
   Mass MJ, 1997, MUTAT RES-REV MUTAT, V386, P263, DOI 10.1016/S1383-5742(97)00008-2
   MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   PRICE JE, 1990, CANCER RES, V50, P717
   Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8
   ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Stoica A, 2000, ENDOCRINOLOGY, V141, P3595, DOI 10.1210/en.141.10.3595
   Takeyoshi M, 2002, TOXICOL LETT, V126, P91, DOI 10.1016/S0378-4274(01)00446-5
   Tong Hongyan, 2002, Zhonghua Xue Ye Xue Za Zhi, V23, P638
   Vahter M, 2002, TOXICOLOGY, V181, P211, DOI 10.1016/S0300-483X(02)00285-8
   WAALKES MP, 1988, CHEM-BIOL INTERACT, V66, P189, DOI 10.1016/0009-2797(88)90071-3
   Wang Ming-Ming, 2008, Ai Zheng, V27, P1150
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang L, 2009, CHIN J CANCER, V28, P209
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Zhang P, 2000, Zhonghua Xue Ye Xue Za Zhi, V21, P67
   Zhang WJ, 2011, ONCOL REP, V26, P621, DOI 10.3892/or.2011.1352
NR 43
TC 53
Z9 60
U1 0
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 27
PY 2012
VL 7
IS 4
AR e35957
DI 10.1371/journal.pone.0035957
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959TJ
UT WOS:000305336000091
PM 22558281
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Tyan, SW
   Hsu, CH
   Peng, KL
   Chen, CC
   Kuo, WH
   Lee, EYHP
   Shew, JY
   Chang, KJ
   Juan, LJ
   Lee, WH
AF Tyan, Shiaw-Wei
   Hsu, Chih-Hung
   Peng, Kai-Lin
   Chen, Chun-Chin
   Kuo, Wen-Hung
   Lee, Eva Y. -H. P.
   Shew, Jin-Yuh
   Chang, King-Jen
   Juan, Li-Jung
   Lee, Wen-Hwa
TI Breast Cancer Cells Induce Stromal Fibroblasts to Secrete ADAMTS1 for
   Cancer Invasion through an Epigenetic Change
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION PATTERNS; H3K27 DEMETHYLASES; TUMOR STROMA; IN-VIVO;
   CHROMATIN; TUMORIGENESIS; EXPRESSION
AB Microenvironment plays an important role in cancer development. We have reported that the cancer-associated stromal cells exhibit phenotypic and functional changes compared to stromal cells neighboring to normal tissues. However, the molecular mechanisms as well as the maintenance of these changes remain elusive. Here we showed that through co-culture with breast cancer cells for at least three to four passages, breast normal tissue-associated fibroblasts (NAFs) gained persistent activity for promoting cancer cell invasion, partly via up-regulating ADAM metallopeptidase with thrombospondin type 1 motif, 1 (ADAMTS1). Furthermore, we demonstrated that the DNA methylation pattern in the ADAMTS1 promoter has no alteration. Instead, the loss of EZH2 binding to the ADAMTS1 promoter and the resulting decrease of promoter-associated histone H3K27 methylation may account for the up-regulation of ADAMTS1. Importantly, the lack of EZH2 binding and the H3K27 methylation on the ADAMTS1 promoter were sustained in cancer cell-precocultured NAFs after removal of cancer cells. These results suggest that cancer cells are capable of inducing stromal fibroblasts to secrete ADAMTS1 persistently for their invasion and the effect is epigenetically inheritable.
C1 [Tyan, Shiaw-Wei; Hsu, Chih-Hung; Peng, Kai-Lin; Chen, Chun-Chin; Lee, Eva Y. -H. P.; Shew, Jin-Yuh; Juan, Li-Jung; Lee, Wen-Hwa] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Peng, Kai-Lin] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Kuo, Wen-Hung; Chang, King-Jen] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.
   [Chang, King-Jen] Cheng Ching Gen Hosp, Taichung, Taiwan.
   [Lee, Eva Y. -H. P.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA.
   [Lee, Eva Y. -H. P.; Lee, Wen-Hwa] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA.
C3 Academia Sinica - Taiwan; National Yang Ming Chiao Tung University;
   National Taiwan University; National Taiwan University Hospital;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Tyan, SW (通讯作者)，Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
EM kingjen@ntu.edu.tw; ljjuan@gate.sinica.edu.tw; whlee@uci.edu
RI Chang, Kuang-Jung/J-2193-2012; Juan, Li-Jung/H-6631-2015; Lee,
   Wen-Hwa/C-2519-2014; Hsu, Chih-Hung/AEM-8298-2022
OI KUO, WEN-HUNG/0000-0002-9881-4605; Chen, Chun-Chin/0000-0001-8247-8734;
   Hsu, Chih-Hung/0000-0001-8071-0122; Chang, King jen/0000-0001-9811-3422
FU Academia Sinica
FX This work was supported by grants from Academia Sinica to WHL and LJJ.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Canals F, 2006, PROTEOMICS, V6, pS28, DOI 10.1002/pmic.200500446
   Rodríguez-Manzaneque JC, 2009, INT J BIOCHEM CELL B, V41, P800, DOI 10.1016/j.biocel.2008.08.014
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Hsu CH, 2004, EMBO J, V23, P2269, DOI 10.1038/sj.emboj.7600239
   Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006
   Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011
   Kolset SO, 2008, CELL MOL LIFE SCI, V65, P1073, DOI 10.1007/s00018-007-7455-6
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lind GE, 2006, CELL ONCOL, V28, P259
   Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287
   Longpré JM, 2004, J BIOL CHEM, V279, P33237, DOI 10.1074/jbc.M313151200
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   Rocks N, 2008, CANCER RES, V68, P9541, DOI 10.1158/0008-5472.CAN-08-0548
   Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200
   Sorensen AL, 2010, MOL BIOL CELL, V21, P2066, DOI 10.1091/mbc.E10-01-0018
   Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322
   Tyan SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015313
   Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003
   Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934
   Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005
   Yao JY, 2010, J BIOL CHEM, V285, P18828, DOI 10.1074/jbc.M109.077974
   Zhu B, 2011, CELL RES, V21, P435, DOI 10.1038/cr.2011.26
NR 30
TC 59
Z9 66
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 13
PY 2012
VL 7
IS 4
AR e35128
DI 10.1371/journal.pone.0035128
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959UT
UT WOS:000305341600120
PM 22514714
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhang, YX
   Andrews, GK
   Wang, L
AF Zhang, Yuxia
   Andrews, Glen K.
   Wang, Li
TI Zinc-induced Dnmt1 expression involves antagonism between MTF-1 and
   nuclear receptor SHP
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID SMALL HETERODIMER PARTNER; TRANSCRIPTION FACTOR-I; NEGATIVE
   FEEDBACK-REGULATION; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; FINGER
   PROTEINS; BREAST-CANCER; GROWTH-FACTOR; HEPATITIS-B; LIVER
AB Dnmt1 is frequently overexpressed in cancers, which contributes significantly to cancer-associated epigenetic silencing of tumor suppressor genes. However, the mechanism of Dnmt1 overexpression remains elusive. Herein, we elucidate a pathway through which nuclear receptor SHP inhibits zinc-dependent induction of Dnmt1 by antagonizing metal-responsive transcription factor-1 (MTF-1). Zinc treatment induces Dnmt1 transcription by increasing the occupancy of MTF-1 on the Dnmt1 promoter while decreasing SHP expression. SHP in turn represses MTF-1 expression and abolishes zinc-mediated changes in the chromatin configuration of the Dnmt1 promoter. Dnmt1 expression is increased in SHP-knockout (sko) mice but decreased in SHP-transgenic (stg) mice. In human hepatocellular carcinoma (HCC), increased DNMT1 expression is negatively correlated with SHP levels. Our study provides a molecular explanation for increased Dnmt1 expression in HCC and highlights SHP as a potential therapeutic target.
C1 [Zhang, Yuxia; Wang, Li] Univ Utah, Sch Med, Huntsman Canc Inst, Dept Med & Oncol Sci, Salt Lake City, UT 84132 USA.
   [Andrews, Glen K.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA.
C3 Utah System of Higher Education; University of Utah; Huntsman Cancer
   Institute; University of Kansas; University of Kansas Medical Center
RP Wang, L (通讯作者)，Univ Utah, Sch Med, Huntsman Canc Inst, Dept Med & Oncol Sci, Salt Lake City, UT 84132 USA.
EM l.wang@hsc.utah.edu
RI Zhang, Yuxia/AEO-0635-2022
FU LTCDS under the NIH (Minneapolis, MN, USA) [N01-DK-7-0004/HHSN
   267200700004C]; Multidisciplinary Cancer Research Training Program
   (MCRTP) [T32CA092347]; National Institutes of Health [DK080440]
FX HCC specimens were obtained through the LTCDS under the NIH Contract #
   N01-DK-7-0004/HHSN 267200700004C (Minneapolis, MN, USA).T32CA092347
   Multidisciplinary Cancer Research Training Program (MCRTP) (to Y.Z.) and
   National Institutes of Health (DK080440) (L. W., partial). Y.Z. is
   supported by T32CA092347 Multidisciplinary Cancer Research Training
   Program (MCRTP). This work is in part supported by National Institutes
   of Health (DK080440) to L. W. Funding for open access charge:
   Institutional start up fund.
CR Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114
   [Anonymous], 2010, CANCER BIOL THER, DOI DOI 10.4161/CBT.9.6.10979
   Avila MA, 2006, ONCOGENE, V25, P3866, DOI 10.1038/sj.onc.1209550
   Boulias K, 2005, EMBO J, V24, P2624, DOI 10.1038/sj.emboj.7600728
   Chan AOO, 2006, CURR MOL MED, V6, P401, DOI 10.2174/156652406777435417
   Chung MJ, 2006, EXP BIOL MED, V231, P1555, DOI 10.1177/153537020623100916
   Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Estève PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106
   Fiorucci S, 2004, GASTROENTEROLOGY, V127, P1497, DOI 10.1053/j.gastro.2004.08.001
   Green CJ, 2001, CANCER RES, V61, P2696
   Haroon ZA, 2004, FASEB J, V18, P1176, DOI 10.1096/fj.03-1205com
   Hartman HB, 2009, J LIPID RES, V50, P193, DOI 10.1194/jlr.M800323-JLR200
   He N, 2008, GASTROENTEROLOGY, V134, P793, DOI 10.1053/j.gastro.2008.01.006
   Huang JS, 2007, HEPATOLOGY, V46, P147, DOI 10.1002/hep.21632
   Huang JS, 2010, AM J PHYSIOL-GASTR L, V299, pG1211, DOI 10.1152/ajpgi.00322.2010
   Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660
   Jinawath A, 2005, BIOCHEM J, V385, P557, DOI 10.1042/BJ20040684
   Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5
   Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406
   Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x
   Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547
   Lee CF, 2010, J CLIN INVEST, V120, P2920, DOI 10.1172/JCI42275
   Li Y, 2008, MOL CELL BIOL, V28, P4275, DOI 10.1128/MCB.00369-08
   Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161
   McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266
   Ostrakhovitch EA, 2007, J CELL BIOCHEM, V102, P1571, DOI 10.1002/jcb.21381
   Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060
   PAN X, CELL METAB, V12, P174
   Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017
   Park YJ, 2008, HEPATOLOGY, V47, P1578, DOI 10.1002/hep.22196
   Park YY, 2010, MOL CELLS, V30, P485, DOI 10.1007/s10059-010-0136-6
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Saydam N, 2003, J BIOL CHEM, V278, P31879, DOI 10.1074/jbc.M302138200
   Seeff LB, 2006, ONCOGENE, V25, P3771, DOI 10.1038/sj.onc.1209560
   Shukla V, 2010, CELL RES, V20, P1201, DOI 10.1038/cr.2010.128
   Song GS, 2008, NUCLEIC ACIDS RES, V36, P5727, DOI 10.1093/nar/gkn567
   Song GS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007829
   Song GS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006880
   Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862
   Tabbi-Anneni I., AM J PHYSL ENDOCRINO, V298, pE961
   Takamura M, 2010, INT J ONCOL, V36, P245, DOI 10.3892/ijo_00000495
   Tamura Y, 2005, ONCOGENE, V24, P399, DOI 10.1038/sj.onc.1208197
   Torrisani J, 2007, MOL CELL BIOL, V27, P395, DOI 10.1128/MCB.01236-06
   Vire E., 2006, NATURE, V439, P871
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Wang L, 2003, J BIOL CHEM, V278, P44475, DOI 10.1074/jbc.M305258200
   Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9
   Wang L, 2005, CELL METAB, V2, P227, DOI 10.1016/j.cmet.2005.08.010
   Wang Y, 2004, FASEB J, V18, P1071, DOI 10.1096/fj.03-1282com
   Weaver Benjamin P, 2010, PLoS One, V5, DOI 10.1371/journal.pone.0013158
   Williams KJ, 2001, BREAST CANCER RES, V3, P328, DOI 10.1186/bcr316
   Zhang Q, 2006, BLOOD, V108, P1058, DOI 10.1182/blood-2005-08-007377
   Zhang Y., J BIOL CHEM, V286, P29635
   Zhang Y., FEBS LETT, V585, P1269
   Zhang Y., MOL CELL BIOL, V30, P1341
   Zhang YX, 2008, HEPATOLOGY, V48, P289, DOI 10.1002/hep.22342
   Zhang YX, 2011, BBA-MOL BASIS DIS, V1812, P893, DOI 10.1016/j.bbadis.2010.10.006
   Zhou T., J BIOL CHEM, V285, P24871
NR 60
TC 20
Z9 22
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN
PY 2012
VL 40
IS 11
BP 4850
EP 4860
DI 10.1093/nar/gks159
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 955PF
UT WOS:000305032500021
PM 22362755
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Truax, AD
   Thakkar, M
   Greer, SF
AF Truax, Agnieszka D.
   Thakkar, Meghna
   Greer, Susanna F.
TI Dysregulated Recruitment of the Histone Methyltransferase EZH2 to the
   Class II Transactivator (CIITA) Promoter IV in Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID MAJOR HISTOCOMPATIBILITY COMPLEX; CREB BINDING-PROTEIN; T-CELLS; MHC2TA
   TRANSCRIPTION; ANTIGEN EXPRESSION; UVEAL MELANOMA; ATPASE SUG1;
   IFN-GAMMA; TUMOR; GENES
AB One mechanism frequently utilized by tumor cells to escape immune system recognition and elimination is suppression of cell surface expression of Major Histocompatibility Class II (MHC II) molecules. Expression of MHC II is regulated primarily at the level of transcription by the Class II Transactivator, CIITA, and decreased CIITA expression is observed in multiple tumor types. We investigate here contributions of epigenetic modifications to transcriptional silencing of CIITA in variants of the human breast cancer cell line MDA MB 435. Significant increases in histone H3 lysine 27 trimethylation upon IFN-gamma stimulation correlate with reductions in transcription factor recruitment to the interferon-gamma inducible CIITA promoter, CIITApIV, and with significantly increased CIITApIV occupancy by the histone methyltransferase enhancer of zeste homolog 2 (EZH2). Most compelling is evidence that decreased expression of EZH2 in MDA MB 435 variants results in significant increases in CIITA and HLA-DRA mRNA expression, even in the absence of interferon-gamma stimulation, as well as increased cell surface expression of MHC II. Together, these data add mechanistic insight to prior observations of increased EZH2 expression and decreased CIITA expression in multiple tumor types.
C1 [Truax, Agnieszka D.; Thakkar, Meghna; Greer, Susanna F.] Georgia State Univ, Dept Biol, Div Cellular & Mol Biol & Physiol, Atlanta, GA 30302 USA.
C3 University System of Georgia; Georgia State University
RP Truax, AD (通讯作者)，Georgia State Univ, Dept Biol, Div Cellular & Mol Biol & Physiol, Atlanta, GA 30302 USA.
EM sgreer@gsu.edu
FU American Cancer Society [RSG-09-067-01-L1B]
FX This work was funded by the American Cancer Society, RSG-09-067-01-L1B.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bannister AJ, 2004, METHOD ENZYMOL, V376, P269
   Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810
   Bhat KP, 2008, MOL IMMUNOL, V45, P2214, DOI 10.1016/j.molimm.2007.12.001
   Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5
   BROCKER EB, 1984, J INVEST DERMATOL, V82, P244, DOI 10.1111/1523-1747.ep12260181
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chan HM, 2001, J CELL SCI, V114, P2363
   CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Concha A, 1991, Semin Cancer Biol, V2, P47
   Croce M, 2003, ONCOGENE, V22, P7848, DOI 10.1038/sj.onc.1207054
   DADMARZ R, 1995, CANCER IMMUNOL IMMUN, V40, P1
   DEWAARDSIEBINGA I, 1995, HUM IMMUNOL, V44, P111, DOI 10.1016/0198-8859(95)00083-G
   Drozina G, 2005, CURR TOP MICROBIOL, V290, P147
   Fontes JD, 1997, NUCLEIC ACIDS RES, V25, P2522, DOI 10.1093/nar/25.12.2522
   Fontes JD, 1999, MOL CELL BIOL, V19, P941
   FUJIWARA H, 1984, J IMMUNOL, V133, P1671
   Garrido F, 1991, Semin Cancer Biol, V2, P3
   GORELIK E, 1993, CLIN EXP METASTAS, V11, P439, DOI 10.1007/BF00054935
   GREENBERG PD, 1981, J EXP MED, V154, P952, DOI 10.1084/jem.154.3.952
   HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291
   Holen I, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2769
   Holling TM, 2007, J IMMUNOL, V179, P5317, DOI 10.4049/jimmunol.179.8.5317
   Holling TM, 2006, BIOCHEM PHARMACOL, V72, P1570, DOI 10.1016/j.bcp.2006.06.034
   Humphreys J S, 2000, Aust J Rural Health, V8, P120
   KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koues OI, 2008, MOL CELL BIOL, V28, P5837, DOI 10.1128/MCB.00535-08
   Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Landmann S, 2001, J EXP MED, V194, P379, DOI 10.1084/jem.194.4.379
   Langlade-Demoyen P, 2003, EUR J IMMUNOL, V33, P720, DOI 10.1002/eji.200323287
   LAURITZSEN GF, 1994, P NATL ACAD SCI USA, V91, P5700, DOI 10.1073/pnas.91.12.5700
   Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202
   Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324
   MAIORANA A, 1995, CLIN EXP METASTAS, V13, P43, DOI 10.1007/BF00144017
   Mehta NT, 2011, EPIGENETICS, V6
   Morris AC, 2002, MOL CELL BIOL, V22, P4781, DOI 10.1128/MCB.22.13.4781-4791.2002
   Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143
   Muhlethaler-Mottet A, 2004, J BIOL CHEM, V279, P40529, DOI 10.1074/jbc.M406585200
   Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9
   MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851
   Ni ZY, 2005, P NATL ACAD SCI USA, V102, P14611, DOI 10.1073/pnas.0503070102
   Pai RK, 2002, J IMMUNOL, V169, P1326, DOI 10.4049/jimmunol.169.3.1326
   Piskurich JF, 2006, MOL IMMUNOL, V43, P519, DOI 10.1016/j.molimm.2005.05.005
   Piskurich JF, 1999, MOL CELL BIOL, V19, P431
   PRICE JE, 1990, CANCER-AM CANCER SOC, V66, P1313, DOI 10.1002/1097-0142(19900915)66:14+<1313::AID-CNCR2820661403>3.0.CO;2-4
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Reijm EA, BREAST CANC RES TREA
   RUIZCABELLO F, 1991, IMMUNOL LETT, V29, P181, DOI 10.1016/0165-2478(91)90168-A
   Rybtsova N, 2007, NUCLEIC ACIDS RES, V35, P3431, DOI 10.1093/nar/gkm214
   Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144
   Shi B, 2006, INT J BIOCHEM CELL B, V38, P544, DOI 10.1016/j.biocel.2005.07.012
   Sotiriadou R, 2001, BRIT J CANCER, V85, P1527, DOI 10.1054/bjoc.2001.2089
   Spilianakis C, 2003, EMBO J, V22, P5125, DOI 10.1093/emboj/cdg496
   Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7
   Truax AD, 2012, METHODS MOL BIOL, V809, P175, DOI 10.1007/978-1-61779-376-9_12
   Truax AD, 2010, J MOL BIOL, V395, P254, DOI 10.1016/j.jmb.2009.10.035
   van den Elsen PJ, 2001, J REPROD IMMUNOL, V52, P129, DOI 10.1016/S0165-0378(01)00115-2
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Walter W, 2000, BRIT J CANCER, V83, P1192, DOI 10.1054/bjoc.2000.1415
   Warabi M, 2000, PATHOL RES PRACT, V196, P807, DOI 10.1016/S0344-0338(00)80080-1
   Wong AW, 2002, J IMMUNOL, V169, P3112, DOI 10.4049/jimmunol.169.6.3112
   Wright KL, 2006, TRENDS IMMUNOL, V27, P405, DOI 10.1016/j.it.2006.07.007
   Xiao Y, 2011, INT J BIOCH CELL BIO
   Yan X, 2006, INT J BIOCHEM CELL B, V38, P2102, DOI 10.1016/j.biocel.2006.06.002
   ZHANG RD, 1991, INVAS METAST, V11, P204
   Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003
NR 72
TC 34
Z9 43
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 26
PY 2012
VL 7
IS 4
AR e36013
DI 10.1371/journal.pone.0036013
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959WQ
UT WOS:000305349100060
PM 22563434
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Tessema, M
   Yingling, CM
   Grimes, MJ
   Thomas, CL
   Liu, YS
   Leng, SG
   Joste, N
   Belinsky, SA
AF Tessema, Mathewos
   Yingling, Christin M.
   Grimes, Marcie J.
   Thomas, Cynthia L.
   Liu, Yushi
   Leng, Shuguang
   Joste, Nancy
   Belinsky, Steven A.
TI Differential Epigenetic Regulation of TOX Subfamily High Mobility Group
   Box Genes in Lung and Breast Cancers
SO PLOS ONE
LA English
DT Article
ID ABERRANT PROMOTER METHYLATION; CPG ISLAND; COLORECTAL-CANCER; HMGB
   PROTEINS; HUMAN TUMORS; DNA; IDENTIFICATION; EXPRESSION; CELLS;
   ADENOCARCINOMAS
AB Aberrant cytosine methylation affects regulation of hundreds of genes during cancer development. In this study, a novel aberrantly hypermethylated CpG island in cancer was discovered within the TOX2 promoter. TOX2 was unmethylated in normal cells but 28% lung (n = 190) and 23% breast (n = 80) tumors were methylated. Expression of two novel TOX2 transcripts identified was significantly reduced in primary lung tumors than distant normal lung (p<0.05). These transcripts were silenced in methylated lung and breast cancer cells and 5-Aza-2-deoxycytidine treatment re-expressed both. Extension of these assays to TOX, TOX3, and TOX4 genes that share similar genomic structure and protein homology with TOX2 revealed distinct methylation profiles by smoking status, histology, and cancer type. TOX was almost exclusively methylated in breast (43%) than lung (5%) cancer, whereas TOX3 was frequently methylated in lung (58%) than breast (30%) tumors. TOX4 was unmethylated in all samples and showed the highest expression in normal lung. Compared to TOX4, expression of TOX, TOX2 and TOX3 in normal lung was 25, 44, and 88% lower, respectively, supporting the premise that reduced promoter activity confers increased susceptibility to methylation during lung carcinogenesis. Genome-wide assays revealed that siRNA-mediated TOX2 knockdown modulated multiple pathways while TOX3 inactivation targeted neuronal development and function. Although these knockdowns did not result in further phenotypic changes of lung cancer cells in vitro, the impact on tissue remodeling, inflammatory response, and cell differentiation pathways suggest a potential role for TOX2 in modulating tumor microenvironment.
C1 [Tessema, Mathewos; Yingling, Christin M.; Grimes, Marcie J.; Thomas, Cynthia L.; Liu, Yushi; Leng, Shuguang; Belinsky, Steven A.] Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM USA.
   [Joste, Nancy] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA.
C3 Lovelace Respiratory Research Institute; University of New Mexico
RP Tessema, M (通讯作者)，Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM USA.
EM sbelinsk@LRRI.org
RI Liu, Yushi/A-1533-2014
OI Liu, Yushi/0000-0003-4185-4187
FU National Institutes of Health [R01ES008801, ES015262, P50 CA58184]
FX This work was supported by National Institutes of Health Grant numbers
   [R01ES008801], [ES015262], and [P50 CA58184] to SAB. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Belinsky SA, 2002, CANCER RES, V62, P2370
   Belinsky SA, 2011, CANCER RES, V71, P454, DOI 10.1158/0008-5472.CAN-10-3184
   Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105
   Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086
   Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563
   Chung W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002079
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Deloukas P, 2001, NATURE, V414, P865, DOI 10.1038/414865a
   Dittmer S, 2011, J CELL SCI, V124, P252, DOI 10.1242/jcs.068759
   du Puch CBM, 2011, ARCH BIOCHEM BIOPHYS, V507, P296, DOI 10.1016/j.abb.2010.12.021
   Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251
   Jia XP, 2011, J MOL CELL BIOL, V3, P230, DOI 10.1093/jmcb/mjr002
   Jia Y, 2010, EPIGENETICS-US, V5, P743, DOI 10.4161/epi.5.8.13104
   Kajitani T, 2004, ENDOCRINOLOGY, V145, P2307, DOI 10.1210/en.2003-1343
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marsit CJ, 2006, CANCER RES, V66, P10621, DOI 10.1158/0008-5472.CAN-06-1687
   O'Flaherty E, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-13
   Oyer JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004832
   Palmisano WA, 2003, CANCER RES, V63, P4620
   Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703
   Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913
   Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453
   Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102
   Soullier S, 1999, J MOL EVOL, V48, P517, DOI 10.1007/PL00006495
   Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008
   Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001
   Tessema M, 2010, ONCOGENE, V29, P5159, DOI 10.1038/onc.2010.255
   Tessema M, 2012, ONCOGENE        1212, DOI 101038/onc2011577
   Tessema M, 2008, CANCER RES, V68, P1707, DOI 10.1158/0008-5472.CAN-07-6325
   Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1
   Toyota M, 1999, CANCER RES, V59, P2307
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P4535
   Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741
   Treff NR, 2004, ONCOGENE, V23, P777, DOI 10.1038/sj.onc.1207167
   Ueki T, 2001, CANCER RES, V61, P8540
   Wilkinson B, 2002, NAT IMMUNOL, V3, P272, DOI 10.1038/ni767
   Yuan FH, 2004, J BIOL CHEM, V279, P20935, DOI 10.1074/jbc.M401931200
   Yuan SH, 2009, P NATL ACAD SCI USA, V106, P2909, DOI 10.1073/pnas.0805555106
   Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349
NR 43
TC 48
Z9 56
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 4
PY 2012
VL 7
IS 4
AR e34850
DI 10.1371/journal.pone.0034850
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 953GO
UT WOS:000304855200085
PM 22496870
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Fumagalli, C
   Pruneri, G
   Possanzini, P
   Manzotti, M
   Barile, M
   Feroce, I
   Colleoni, M
   Bonanni, B
   Maisonneuve, P
   Radice, P
   Viale, G
   Barberis, M
AF Fumagalli, Caterina
   Pruneri, Giancarlo
   Possanzini, Paola
   Manzotti, Michela
   Barile, Monica
   Feroce, Irene
   Colleoni, Marco
   Bonanni, Bernardo
   Maisonneuve, Patrick
   Radice, Paolo
   Viale, Giuseppe
   Barberis, Massimo
TI Methylation of <i>O</i><SUP>6</SUP>-methylguanine-DNA methyltransferase
   (MGMT) promoter gene in triple-negative breast cancer patients
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Triple negative breast cancer; MGMT; BRCA1
ID DNA-REPAIR; PROGNOSTIC-SIGNIFICANCE; PROGESTERONE-RECEPTORS; THERAPEUTIC
   STRATEGIES; MOLECULAR PORTRAITS; RANDOMIZED-TRIAL; PREDICTIVE-VALUE;
   TEMOZOLOMIDE; HYPERMETHYLATION; TUMORS
AB Triple-negative breast cancers are characterized by the triple-negative (ER/PgR/Her2 negative) phenotype, are frequently associated with BRCA gene mutation, and are not candidate to currently available endocrine and HER2-targeted treatments. MGMT is involved in direct DNA repair exerted by cleavage of mutagenic alkyl adducts within DNA, and its epigenetic silencing confers susceptibility to DNA-damaging alkylating agents in glioblastomas and melanomas. MGMT methylation status has not been extensively investigated in breast cancer patients. The goal of our study was to evaluate the MGMT methylation status in TNBC patients, for most of which BRCA1 and BRCA2 mutational status was known. We evaluated MGMT methylation status by methylation-specific PCR (MSP) in formalin-fixed and paraffin-embedded tumor specimens from 92 TNBC patients. By using the GelDoc system (Biorad) software, the cases were further classified as follows: 0 (absence of methylated signal), 1 (prevalence of unmethylated signal, U/M ratio > 1), 2 (prevalence of methylated signal, U/M ratio < 1), and 3 (absence of unmethylated signal). MSP products were obtained in 89 (96.7%) of the cases. Overall, 15 (16.9%) cases were classified as 0, 33 (37.1%) cases as 1, 39 (43.8%) cases as 2, and 2 (2.2%) cases as 3. The 48 cases classified as 0 and 1 were considered as MGMT unmethylated, and the 41 cases classified as 2 and 3 as MGMT methylated. The prevalence of MGMT methylation in patients with BRCA1 mutated, wild-type, and unknown was 30.2% (13/43), 63.6% (14/22), and 58.3% (14/24), respectively. MGMT methylation was unrelated to the main clinical pathological characteristics, with the exception of a weak association with advanced age. In conclusion, our data suggest that in TNBC with wild-type BRCA1, the direct DNA repair system may be frequently (63.6%) silenced by MGMT methylation. The evaluation of the MGMT status could offer a new adjunct in predicting tumor response to alkylating drugs in TNBC patients.
C1 [Pruneri, Giancarlo; Viale, Giuseppe] Univ Milan, Sch Med, Milan, Italy.
   [Fumagalli, Caterina; Pruneri, Giancarlo; Possanzini, Paola; Manzotti, Michela; Viale, Giuseppe; Barberis, Massimo] European Inst Oncol, Div Pathol, I-20141 Milan, Italy.
   [Barile, Monica; Feroce, Irene; Bonanni, Bernardo] European Inst Oncol, Div Canc Prevent & Genet, I-20141 Milan, Italy.
   [Colleoni, Marco] European Inst Oncol, Res Unit Med Senol, Dept Med, I-20141 Milan, Italy.
   [Maisonneuve, Patrick] European Inst Oncol, Dept Epidemiol & Biostat, I-20141 Milan, Italy.
   [Radice, Paolo] Fdn IRCCS Ist Nazl Tumori, Unit Mol Bases Genet Risk & Genet Testing, Dept Prevent & Predict Med, Milan, Italy.
   [Radice, Paolo] IFOM Fdn Ist FIRC Oncol Mol, Milan, Italy.
C3 University of Milan; IRCCS European Institute of Oncology (IEO); IRCCS
   European Institute of Oncology (IEO); IRCCS European Institute of
   Oncology (IEO); IRCCS European Institute of Oncology (IEO); Fondazione
   IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of
   Molecular Oncology
RP Pruneri, G (通讯作者)，Univ Milan, Sch Med, Milan, Italy.
EM giancarlo.pruneri@unimi.it
RI Feroce, irene/AAQ-7760-2020; Bonanni, Bernardo/AAM-7928-2020; Viale,
   Giuseppe/AAE-8921-2019; Fumagalli, Caterina/J-1048-2018; Barberis,
   Massimo/AAL-5446-2020; Colleoni, Marco/AAN-8647-2020; Radice,
   Paolo/O-3119-2013; Maisonneuve, Patrick/U-9789-2018; Pruneri,
   Giancarlo/AAC-7767-2022
OI Fumagalli, Caterina/0000-0001-5417-7985; feroce,
   irene/0000-0001-9312-2020; Radice, Paolo/0000-0001-6298-4111;
   Maisonneuve, Patrick/0000-0002-5309-4704; colleoni,
   marco/0000-0002-5743-3013; Pruneri, Giancarlo/0000-0002-7963-7172
CR Alli E, 2009, CANCER RES, V69, P3589, DOI 10.1158/0008-5472.CAN-08-4016
   Augustine CK, 2009, CLIN CANCER RES, V15, P502, DOI 10.1158/1078-0432.CCR-08-1916
   Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200
   Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633
   Busch C, 2010, EUR J CANCER, V46, P2127, DOI 10.1016/j.ejca.2010.04.023
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Neto JC, 2011, PATHOL RES PRACT, V207, P492, DOI 10.1016/j.prp.2011.06.003
   Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791
   Davis JD, 2011, WORLD J CLIN ONCOL, V2, P329, DOI 10.5306/wjco.v2.i9.329
   DeCensi A, 2011, ANN ONCOL, V22, P582, DOI 10.1093/annonc/mdq427
   Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393
   Dunn J, 2009, BRIT J CANCER, V101, P124, DOI 10.1038/sj.bjc.6605127
   Edge S.B., 2010, AJCC cancer staging manual, V649
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Glas M, 2009, J CLIN ONCOL, V27, P1257, DOI 10.1200/JCO.2008.19.2195
   Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560
   Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48
   Harden SV, 2003, CLIN CANCER RES, V9, P1370
   Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hou P, 2006, CANCER-AM CANCER SOC, V106, P1602, DOI 10.1002/cncr.21762
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Irvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034
   Isakoff SJ, 2010, CANCER J, V16, P53, DOI 10.1097/PPO.0b013e3181d24ff7
   James CR, 2007, ONCOLOGIST, V12, P142, DOI 10.1634/theoncologist.12-2-142
   Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005
   Keimling M, 2008, INT J CANCER, V123, P730, DOI 10.1002/ijc.23551
   Kim JI, 2009, HUM PATHOL, V40, P934, DOI 10.1016/j.humpath.2009.01.005
   Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476
   Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930
   Matsukura S, 2001, ANN SURG ONCOL, V8, P807, DOI 10.1007/s10434-001-0807-9
   Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6
   Munot K, 2006, HUM PATHOL, V37, P989, DOI 10.1016/j.humpath.2006.04.013
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rasmussen BB, 2008, LANCET ONCOL, V9, P23, DOI 10.1016/S1470-2045(07)70386-8
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Sirohi B, 2008, ANN ONCOL, V19, P1847, DOI 10.1093/annonc/mdn395
   Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205
   Staudacher L, 2011, ANN ONCOL, V22, P848, DOI 10.1093/annonc/mdq461
   Tan AR, 2008, CANCER J, V14, P343, DOI 10.1097/PPO.0b013e31818d839b
   Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012
   Viale G, 2007, J CLIN ONCOL, V25, P3846, DOI 10.1200/JCO.2007.11.9453
NR 48
TC 29
Z9 29
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2012
VL 134
IS 1
BP 131
EP 137
DI 10.1007/s10549-011-1945-9
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 974LS
UT WOS:000306437500013
PM 22228432
DA 2025-01-12
ER

PT J
AU Wan, ES
   Qiu, WL
   Baccarelli, A
   Carey, VJ
   Bacherman, H
   Rennard, SI
   Agusti, A
   Anderson, W
   Lomas, DA
   Demeo, DL
AF Wan, Emily S.
   Qiu, Weiliang
   Baccarelli, Andrea
   Carey, Vincent J.
   Bacherman, Helene
   Rennard, Stephen I.
   Agusti, Alvar
   Anderson, Wayne
   Lomas, David A.
   DeMeo, Dawn L.
TI Cigarette smoking behaviors and time since quitting are associated with
   differential DNA methylation across the human genome
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID LIGHT-CHAIN-KINASE; OBSTRUCTIVE PULMONARY-DISEASE; GENE-EXPRESSION
   SIGNATURE; SELF-REPORTED SMOKING; LINEAR MIXED MODELS; ACUTE LUNG
   INJURY; PROMOTER METHYLATION; BREAST-CANCER; WHOLE-BLOOD; RISK
AB The impact of cigarette smoking can persist for extended periods following smoking cessation and may involve epigenetic reprogramming. Changes in DNA methylation associated with smoking may help to identify molecular pathways that contribute to the latency between exposure and disease onset. Cross-sectional cohort data from subjects in the International COPD Genetics Network (n 1085) and the Boston Early-Onset COPD study (n 369) were analyzed as the discovery and replication cohorts, respectively. Genome-wide methylation data on 27 578 CpG sites in 14 475 genes were obtained on DNA from peripheral blood leukocytes using the Illumina HumanMethylation27K Beadchip in both cohorts. We identified 15 sites significantly associated with current smoking, 2 sites associated with cumulative smoke exposure, and, within the subset of former smokers, 3 sites associated with time since quitting cigarettes. Two loci, factor II receptor-like 3 (F2RL3) and G-protein-coupled receptor 15 (GPR15), were significantly associated in all three analyses and were validated by pyrosequencing. These findings (i) identify a novel locus (GPR15) associated with cigarette smoking and (ii) suggest the existence of dynamic, site-specific methylation changes in response to smoking which may contribute to the extended risks associated with cigarette smoking that persist after cessation.
C1 [Wan, Emily S.; Qiu, Weiliang; Carey, Vincent J.; Bacherman, Helene; DeMeo, Dawn L.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
   [Wan, Emily S.; Qiu, Weiliang; Carey, Vincent J.; Bacherman, Helene; DeMeo, Dawn L.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA.
   [Baccarelli, Andrea] Harvard Univ, Sch Publ Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA.
   [Rennard, Stephen I.] Univ Nebraska Med Ctr, Sect Pulm & Crit Care, Omaha, NE USA.
   [Agusti, Alvar] Fundacio Caubet Cimera, CIBERES, Palma De Mallorca, Spain.
   [Agusti, Alvar] Hosp Clin Barcelona, Thorax Inst, IDIBAPS, Barcelona, Spain.
   [Anderson, Wayne] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA.
   [Lomas, David A.] Univ Cambridge, Cambridge Inst Med Res, Cambridge, England.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School
   of Public Health; University of Nebraska System; University of Nebraska
   Medical Center; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   GlaxoSmithKline; University of Cambridge
RP Wan, ES (通讯作者)，181 Longwood Ave, Boston, MA 02115 USA.
EM reesw@channing.harvard.edu
RI Agusti Garcia-Navarro, Alvar/F-4474-2015
OI Agusti Garcia-Navarro, Alvar/0000-0003-3271-3788; Wan,
   Emily/0000-0002-4126-2467; Baccarelli, Andrea/0000-0002-3436-0640; Qiu,
   Weiliang/0000-0002-9155-6957
FU GlaxoSmithKline; AstraZeneca; Otsuka; Pfizer; Nabi; Merck; Almirall;
   Nycomed; National Institutes of Health [R01 HL089438, R01 HL075478, T32
   HL007427, K12 HL089990, P01 HL105339]; Doris Duke Foundation Clinician
   Scientist Development Award; National Institute of Environmental Health
   Sciences-Harvard School of Public Health New Investigator Fund
   [ES00002]; MRC [G0901786] Funding Source: UKRI
FX E.S.W., H. B. W. Q., V.J.C., A. B. and D. L. D. have no conflicts of
   interest to report. D. A. L. has received grant funding, consultancy
   fees and honoraria from GlaxoSmithKline. W. A. was an employee of
   GlaxoSmithKline at the time of the analyses. S. R. has consulted or
   participated in advisory boards for: ABIM, Adelphi Research,
   Almirall/Forest, APT, AstraZeneca, Boehringer Ingelheim/Pfizer, BoomCom,
   Capital Research, CommonHealth, Decision Resources, Easton Associates,
   Equinox, Forest (Cory Paeth), Fulcrum, Gerson Lehman, GSK Eclipse,
   Guidepoint, Informed, Insyght, MedImmune, Novartis, Oriel, Pearl, Pfizer
   (Varenicline), PharmaVentures, Prescott, Propagate Pulmonary Reviews,
   Roche, Schering Plough, Smith Research, Talecris, UBC. S. R. has given
   lectures for: American College of Osteopathic Physicians, Asan Medical
   Center, American Thoracic Society, COPD Foundation, Creative Education
   Concepts, Duke, Information TV, Nycomed, Otsuka, University of
   Washington, University of Alabama-Birmingham. S. R. has received
   industry-sponsored grants from: AstraZeneca, Otsuka, Pfizer, Nabi,
   Merck. A. A. a board member of GlaxoSmithKline, Almirall,
   Boheringer-Ingelheim, Astra-Zeneca, Esteve, Novartis, Nycomed and Roche.
   A. A. has grants (current or pending) from GlaxoSmithKline, Almirall and
   Nycomed. A. A. has received payment for lectures and educational
   presentations from GlaxoSmithKline, Almirall, Boheringer-Ingelheim,
   Astra-Zeneca, Esteve and Nycomed.This work was supported by the National
   Institutes of Health (R01 HL089438, R01 HL075478, T32 HL007427, K12
   HL089990, P01 HL105339); the Doris Duke Foundation Clinician Scientist
   Development Award (to D. L. D.); and the National Institute of
   Environmental Health Sciences-Harvard School of Public Health New
   Investigator Fund (ES00002 to A. B.). None of the funding sources played
   a role in the management, analysis or interpretation of the data, nor
   did they influence the preparation, review or decision to submit for
   publication.
CR Ally MS, 2009, CANCER EPIDEM BIOMAR, V18, P922, DOI 10.1158/1055-9965.EPI-08-0703
   Beane J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r201
   Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blaak H, 2005, J VIROL, V79, P1686, DOI 10.1128/JVI.79.3.1686-1700.2005
   Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681
   Bouloukaki I, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-35
   Braber S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-99
   Brait M, 2009, CANCER EPIDEM BIOMAR, V18, P2984, DOI 10.1158/1055-9965.EPI-08-1245
   Breitling LP, 2011, AM J HUM GENET, V88, P450, DOI 10.1016/j.ajhg.2011.03.003
   BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Büttner P, 2007, IMMUNOGENETICS, V59, P37, DOI 10.1007/s00251-006-0177-3
   Charlesworth JC, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-29
   Chen HT, 2010, J CELL PHYSIOL, V223, P737, DOI 10.1002/jcp.22083
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Christie JD, 2008, CRIT CARE MED, V36, P2794, DOI 10.1097/CCM.0b013e318186b843
   Cilliers T, 2005, VIROLOGY, V339, P136, DOI 10.1016/j.virol.2005.05.027
   Clayburgh DR, 2004, J BIOL CHEM, V279, P55506, DOI 10.1074/jbc.M408822200
   Conen D, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-11-201106070-00003
   Connell LE, 2006, J CELL SCI, V119, P2269, DOI 10.1242/jcs.02926
   Dudek SM, 2004, J BIOL CHEM, V279, P24692, DOI 10.1074/jbc.M313969200
   Dumeaux V, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000873
   Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405
   Flores C, 2007, GENET EPIDEMIOL, V31, P296, DOI 10.1002/gepi.20210
   Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC
   Guerrero-Preston R, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12378
   Heiber M, 1996, GENOMICS, V32, P462, DOI 10.1006/geno.1996.0143
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042
   KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232
   Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651
   Lee SO, 2009, MOL CELLS, V27, P175, DOI 10.1007/s10059-009-0022-2
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Leek JT, 2008, P NATL ACAD SCI USA, V105, P18718, DOI 10.1073/pnas.0808709105
   Léguillette R, 2009, AM J RESP CRIT CARE, V179, P194, DOI 10.1164/rccm.200609-1367OC
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu F, 2010, ONCOGENE, V29, P3650, DOI 10.1038/onc.2010.129
   Louhelainen N, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-13
   Luo JH, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1016
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   MURRAY RP, 1993, AM J PUBLIC HEALTH, V83, P1251, DOI 10.2105/AJPH.83.9.1251
   NEWCOMB PA, 1992, MED CLIN N AM, V76, P305, DOI 10.1016/S0025-7125(16)30355-8
   Patel BD, 2008, AM J RESP CRIT CARE, V178, P500, DOI 10.1164/rccm.200801-059OC
   PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086
   Qiu WL, 2012, AM J RESP CRIT CARE, V185, P373, DOI 10.1164/rccm.201108-1382OC
   Rea TD, 2002, ANN INTERN MED, V137, P494, DOI 10.7326/0003-4819-137-6-200209170-00009
   Rose JE, 2010, MOL MED, V16, P247, DOI 10.2119/molmed.2009.00159
   Rotunno M, 2011, CANCER PREV RES, V4, P1599, DOI 10.1158/1940-6207.CAPR-10-0170
   Russo JM, 2005, GASTROENTEROLOGY, V128, P987, DOI 10.1053/j.gastro.2005.01.004
   Satta R, 2008, P NATL ACAD SCI USA, V105, P16356, DOI 10.1073/pnas.0808699105
   SCHALL R, 1991, BIOMETRIKA, V78, P719
   Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106
   Showe MK, 2009, CANCER RES, V69, P9202, DOI 10.1158/0008-5472.CAN-09-1378
   Silverman EK, 1998, AM J RESP CRIT CARE, V157, P1770, DOI 10.1164/ajrccm.157.6.9706014
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Umemura S, 2008, CARCINOGENESIS, V29, P1845, DOI 10.1093/carcin/bgn169
   Venables W.N., 2002, Modern Applied Statistics with S, V4th ed.
   Vernooy JH, 2002, AM J RESP CRIT CARE, V166, P1218, DOI 10.1164/rccm.2202023
   Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014
   WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33
   Wang FJ, 2005, AM J PATHOL, V166, P409, DOI 10.1016/S0002-9440(10)62264-X
   Wang L, 2010, AM J HUM GENET, V87, P701, DOI 10.1016/j.ajhg.2010.10.006
   Willemse BWM, 2005, EUR RESPIR J, V26, P835, DOI 10.1183/09031936.05.00108904
   WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554
   Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642
   Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335
   Zhu G, 2007, AM J RESP CRIT CARE, V176, P167, DOI 10.1164/rccm.200611-1723OC
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 70
TC 238
Z9 257
U1 1
U2 29
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2012
VL 21
IS 13
BP 3073
EP 3082
DI 10.1093/hmg/dds135
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 961II
UT WOS:000305457700020
PM 22492999
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Bernatsky, S
   Easton, DF
   Dunning, A
   Michailidou, K
   Ramsey-Goldman, R
   Gordon, C
   Clarke, AE
   Foulkes, W
AF Bernatsky, S.
   Easton, D. F.
   Dunning, A.
   Michailidou, K.
   Ramsey-Goldman, R.
   Gordon, C.
   Clarke, A. E.
   Foulkes, W.
TI Decreased breast cancer risk in systemic lupus erythematosus: the search
   for a genetic basis continues
SO LUPUS
LA English
DT Article
DE Systemic lupus; breast cancer risk
ID GENOME-WIDE ASSOCIATION; COHORT; ITGAM
AB Purpose: Recent work has demonstrated an important decrease in breast cancers for women with systemic lupus erythematosus (SLE). The reason behind this phenomenon is unknown. Our purpose was to explore whether the single nucleotide polymorphisms (SNPs) predisposing to SLE might be protective against breast cancer (in women in the general population). Methods: We focused on loci relevant to 10 SNPs associated with SLE (with a p value of < 10(-9)). We determined whether we could establish a decreased frequency of these SNPs in breast cancer cases versus controls, within the general population. To do this we used a large breast cancer genome-wide association study (GWAS) dataset, involving 3,659 breast cancer cases and 4,897controls. These subjects were all primarily of European ancestry. Results: The population-based GWAS breast cancer data we examined suggested little evidence for important associations between breast cancer and SLE-related SNPs. Within the general population GWAS data, a cytosine(C) nucleotide substitution at rs9888739 (on chromosome 16p11.2) showed a very weak inverse association with breast cancer. The odds ratio (OR) for the rs9888739-C allele was 0.907551 (p value 0.049899) in the GWAS breast cancer sample, compared to controls. There was a slightly stronger, positive, association with breast cancer for rs6445975-G (Guanine) on chromosome 3p14.3, with a breast cancer OR of 1.0911 (p value 0.0097). Conclusions: Within this large breast cancer dataset, we did not demonstrate important associations with 10 lupus-associated SNPs. If decreased breast cancer risk in SLE is influenced by genetic profiles, this may be due to complex interactions and/or epigenetic factors. Lupus (2012) 21, 896-899.
C1 [Bernatsky, S.] McGill Univ, Res Inst, Div Clin Epidemiol, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.
   [Bernatsky, S.] McGill Univ, Div Rheumatol, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.
   [Easton, D. F.; Dunning, A.; Michailidou, K.] Univ Cambridge, Ctr Canc Genet Epidemiol, Strangeways Res Lab, Dept Oncol Publ Hlth & Primary Care, Cambridge, England.
   [Ramsey-Goldman, R.] Northwestern Univ, Div Rheumatol, Chicago, IL 60611 USA.
   [Gordon, C.] City Hosp, Sandwell & W Birmingham Hosp NHS Trust, Dept Rheumatol, Birmingham, W Midlands, England.
   [Clarke, A. E.] McGill Univ, Div Allergy & Clin Immunol, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.
   [Foulkes, W.] McGill Univ, Program Canc Genet, Dept Oncol, Montreal, PQ H3A 1A1, Canada.
   [Foulkes, W.] McGill Univ, Program Canc Genet, Dept Human Genet, Montreal, PQ H3A 1A1, Canada.
C3 McGill University; McGill University; University of Cambridge;
   Northwestern University; University of Birmingham; McGill University;
   McGill University; McGill University
RP Bernatsky, S (通讯作者)，McGill Univ, Res Inst, Div Clin Epidemiol, Ctr Hlth, 687 Pine Ave W,V Bldg,Room V2-09, Montreal, PQ H3A 1A1, Canada.
EM sasha.bernatsky@mail.mcgill.ca
RI Foulkes, William/AAR-9586-2021; Michailidou, Kyriaki/ABD-5122-2020
OI Dunning, Alison Margaret/0000-0001-6651-7166; Gordon,
   Caroline/0000-0002-1244-6443; Michailidou, Kyriaki/0000-0001-7065-1237;
   Foulkes, William/0000-0001-7427-4651
FU Cancer Research UK [A10119, A10123, A10118, A11021]
FX The following funding sources are acknowledged: Cancer Research UK
   (grant numbers A10119, A10123, A10118, A11021).
CR [Anonymous], 2011, GENES TO SYSTEMS BRE
   Bernatsky S, 2005, ARTHRITIS RHEUM-US, V52, P1481, DOI 10.1002/art.21029
   Bernatsky S, 2011, BRIT J CANCER, V104, P1478, DOI 10.1038/bjc.2011.115
   Bernatsky S, 2011, RHEUMATOL INT, V31, P549, DOI 10.1007/s00296-010-1591-2
   Björnådal L, 2002, SCAND J RHEUMATOL, V31, P66
   Graham RR, 2009, J INTERN MED, V265, P680, DOI 10.1111/j.1365-2796.2009.02096.x
   Harley JB, 1998, CURR OPIN IMMUNOL, V10, P690, DOI 10.1016/S0952-7915(98)80090-3
   Hindorff L.A., 2011, CATALOG PUBLISHED GE
   Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865
   Kang KY, 2010, CLIN RHEUMATOL, V29, P381, DOI 10.1007/s10067-009-1332-7
   Kozyrev SV, 2008, NAT GENET, V40, P211, DOI 10.1038/ng.79
   Li JM, 2011, BREAST CANCER RES TR, V126, P717, DOI 10.1007/s10549-010-1172-9
   Mellemkjaer L, 1997, ARTHRITIS RHEUM-US, V40, P761, DOI 10.1002/art.1780400424
   Nath SK, 2008, NAT GENET, V40, P152, DOI 10.1038/ng.71
   Parikh-Patel A, 2008, CANCER CAUSE CONTROL, V19, P887, DOI 10.1007/s10552-008-9151-8
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238
   Remmers EF, 2007, NEW ENGL J MED, V357, P977, DOI 10.1056/NEJMoa073003
   Sigurdsson S, 2005, AM J HUM GENET, V76, P528, DOI 10.1086/428480
   Turnbull C, 2010, NAT GENET, V42, P504, DOI 10.1038/ng.586
   Yuan H, 2010, MOD RHEUMATOL, V20, P257, DOI 10.1007/s10165-010-0275-9
NR 20
TC 17
Z9 23
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0961-2033
EI 1477-0962
J9 LUPUS
JI Lupus
PD JUL
PY 2012
VL 21
IS 8
BP 896
EP 899
DI 10.1177/0961203312443992
PG 4
WC Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rheumatology
GA 951EL
UT WOS:000304703500013
PM 22495874
DA 2025-01-12
ER

PT J
AU Li, X
   Cheung, KF
   Ma, X
   Tian, L
   Zhao, J
   Go, MYY
   Shen, B
   Cheng, ASL
   Ying, J
   Tao, Q
   Sung, JJY
   Kung, HF
   Yu, J
AF Li, X.
   Cheung, K. F.
   Ma, X.
   Tian, L.
   Zhao, J.
   Go, M. Y. Y.
   Shen, B.
   Cheng, A. S. L.
   Ying, J.
   Tao, Q.
   Sung, J. J. Y.
   Kung, H-F
   Yu, J.
TI Epigenetic inactivation of <i>paired box gene 5</i>, a novel tumor
   suppressor gene, through direct upregulation of p53 is associated with
   prognosis in gastric cancer patients
SO ONCOGENE
LA English
DT Article
DE paired box gene 5; gastric cancer; tumor suppressor gene; epigenetic
   alteration; prognosis
ID TRANSCRIPTION FACTOR BSAP; HEPATOCYTE GROWTH-FACTOR; CPG ISLAND
   METHYLATION; DOWN-REGULATION; BREAST-CANCER; MATRIX METALLOPROTEINASES;
   MET PROTOONCOGENE; CELL-DEVELOPMENT; B-LYMPHOPOIESIS; LUNG-CANCER
AB Using genome-wide methylation screening, we identified that paired box gene 5 (PAX5) is involved in human cancer development. However, the function of PAX5 in gastric cancer (GC) development is largely unclear. We analyzed its epigenetic inactivation, biological functions and clinical application in GC. PAX5 was silenced in seven out of eight GC cell lines. A significant downregulation was also detected in paired gastric tumors compared with adjacent non-cancerous tissues. The downregulation of PAX5 was closely linked to the promoter hypermethylation status and could be restored with demethylation treatment. Ectopic expression of PAX5 in silenced GC cell lines (AGS and BGC823) inhibited colony formation and cell viability, arrested cell cycle, induced apoptosis, suppressed cell migration and invasion and repressed tumorigenicity in nude mice. Consistent with the induction of apoptosis by PAX5 in vitro, terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) staining showed significantly enhanced apoptotic cells in PAX5-expressed tumors compared with the vector control tumors. On the other hand, knockdown of PAX5 by PAX5-short hairpin RNA increased the cell viability and proliferation. The anti-tumorigenic function of PAX5 was revealed to be mediated by upregulating downstream targets of tumor protein 53 (p53), p21, BCL2-associated X protein, metastasis suppressor 1 and tissue inhibitors of metalloproteinase 1, and downregulating BCL2, cyclin D1, mesenchymal-epithelial transition factor (MET) and matrix metalloproteinase 1. Immunoprecipitation assay demonstrated that PAX5 directly bound to the promoters of p53 and MET. Moreover, PAX5 hypermethylation was detected in 77% (144 of 187) of primary GCs compared with 10.5% (2/19) of normal gastric tissues (P<0.0001). GC patients with PAX5 methylation had a significant poor survival compared with the unmethylated cases as demonstrated by Cox regression model and log-rank test. In conclusion, PAX5 is a novel functional tumor suppressor in gastric carcinogenesis. Detection of methylated PAX5 can be utilized as an independent prognostic factor in GC. Oncogene (2012) 31, 3419-3430; doi:10.1038/onc.2011.511; published online 21 November 2011
C1 [Li, X.; Cheung, K. F.; Ma, X.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.
   [Li, X.; Cheung, K. F.; Ma, X.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
   [Ma, X.] Hebei Med Univ, Hosp 1, Dept Neurol, Shijiazhuang, Peoples R China.
   [Tian, L.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China.
   [Shen, B.] Guangzhou First Municipal Peoples Hosp, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China.
   [Ying, J.; Tao, Q.] Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
   [Kung, H-F] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Prince of Wales Hospital; Hebei Medical
   University; Chinese University of Hong Kong; South China University of
   Technology; Chinese University of Hong Kong; Chinese University of Hong
   Kong
RP Yu, J (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.
EM junyu@cuhk.edu.hk
RI Cheng, Alfred/C-3327-2014; Tian, Linwei/A-9736-2009; SUNG, Joseph J
   Y/R-3203-2018; Jun, Yu/D-8569-2015; Li, Xiaoxing/B-9114-2008; Tao,
   Qian/T-4743-2018
OI Cheng, Alfred/0000-0003-2345-6951; Tian, Linwei/0000-0002-4739-1534;
   SUNG, Joseph J Y/0000-0003-3125-5199; Tian, Linwei/0000-0003-2240-8886;
   Jun, Yu/0000-0001-5008-2153; Li, Xiaoxing/0000-0001-8791-7505; Tao,
   Qian/0000-0001-5383-4808
FU National Basic Research Program of China (973 Program) [2010CB529305];
   Hong Kong General Research Fund [473008]; RFCID [11100022, 10090942];
   CUHK Group Research Scheme [3110043]; Scheme C
FX This study was supported by research grants of National Basic Research
   Program of China (973 Program, 2010CB529305), Hong Kong General Research
   Fund (473008), RFCID (11100022, 10090942), CUHK Group Research Scheme
   (3110043) and Scheme C.
CR ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589
   BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849
   Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183
   BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706
   Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129
   Carotta S, 2006, CELL CYCLE, V5, P2452, DOI 10.4161/cc.5.21.3396
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649
   HALDAR S, 1994, CANCER RES, V54, P2095
   He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474
   HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961
   Holmes ML, 2006, GENE DEV, V20, P933, DOI 10.1101/gad.1396206
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65
   Kanteti R, 2009, LAB INVEST, V89, P301, DOI 10.1038/labinvest.2008.168
   KISHIMOTO Y, 1992, CANCER RES, V52, P4799
   Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200
   KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662
   Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190
   Lazzi S, 2009, HUM PATHOL, V40, P1252, DOI 10.1016/j.humpath.2009.01.007
   Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232
   Lee JH, 2004, ONCOGENE, V23, P4646, DOI 10.1038/sj.onc.1207588
   Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231
   Levine A J, 1989, Princess Takamatsu Symp, V20, P221
   Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124
   MALKIN D, 1994, CANCER RES, V54, P2077
   Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801
   Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P709, DOI 10.1136/jcp.2006.039917
   MIYASHITA T, 1995, CELL, V80, P293
   MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022
   Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019
   QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559
   Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003
   Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090
   Sauter W, 2008, CANCER EPIDEM BIOMAR, V17, P1127, DOI 10.1158/1055-9965.EPI-07-2840
   Souabni A, 2002, IMMUNITY, V17, P781, DOI 10.1016/S1074-7613(02)00472-7
   STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292
   STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Yu J, 2010, GASTROENTEROLOGY, V138, P694, DOI 10.1053/j.gastro.2009.09.058
   ZWOLLO P, 1994, J BIOL CHEM, V269, P15310
NR 49
TC 60
Z9 67
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUL
PY 2012
VL 31
IS 29
BP 3419
EP 3430
DI 10.1038/onc.2011.511
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 976FN
UT WOS:000306566400003
PM 22105368
DA 2025-01-12
ER

PT J
AU Branham, MT
   Marzese, DM
   Laurito, SR
   Gago, FE
   Orozco, JI
   Tello, OM
   Vargas-Roig, LM
   Roqué, M
AF Branham, M. T.
   Marzese, D. M.
   Laurito, S. R.
   Gago, F. E.
   Orozco, J. I.
   Tello, O. M.
   Vargas-Roig, L. M.
   Roque, M.
TI Methylation profile of triple-negative breast carcinomas
SO ONCOGENESIS
LA English
DT Article
DE CpG island; triple negative breast tumors; methylation profile
ID EXPRESSION; CANCER; SEQUENCES
AB Breast cancer is a group of clinically, histopathologically and molecularly heterogeneous diseases, with different outcomes and responses to treatment. Triple-negative (TN) breast cancers are defined as tumors that lack the expression of estrogen receptor, progesterone receptor and epidermal growth factor receptor 2. This subgroup accounts for 15% of all types of breast cancer and its prevalence is higher among young African, African-American and Latino women. The hypermethylation of CpG islands (CpGI) is a common epigenetic alteration for suppressing gene expression in breast cancer and has been shown to be a key factor in breast carcinogenesis. In this study we analyzed the hypermethylation of 110 CpGI within 69 cancer-related genes in TN tumors. For the methylation analysis, we used the methyl-specific multiplex-ligation probe amplification assay. We found that the number of methylated CpGI is similar between TN and non-TN tumors, but the methylated genes between the groups are different. The methylation profile of TN tumors is defined by the methylation of five genes (that is, CDKN2B, CD44, MGMT, RB and p73) plus the non-methylation of 11 genes (that is, GSTP1, PMS2, MSH2, MLH1, MSH3, MSH6, DLC1, CACNA1A, CACNA1G, TWIST1 and ID4). We conclude that TN tumors have a specific methylation profile. Our findings give new information for better understanding tumor etiology and encourage future studies on potential drug targets for triple-negative breast tumors, which now lack a specific treatment.
C1 [Branham, M. T.; Marzese, D. M.; Laurito, S. R.; Roque, M.] Natl Univ Cuyo, IHEM CCT CONICET, Lab Cellular & Mol Biol, Sch Med Sci, RA-5500 Mendoza, Argentina.
   [Gago, F. E.; Orozco, J. I.] Med Ctr Mendoza, Dept Gynecol & Obstet, Mendoza, Argentina.
   [Gago, F. E.; Orozco, J. I.] Med Ctr Mendoza, Inst Gineco Mamario, Mendoza, Argentina.
   [Tello, O. M.] Natl Univ Cuyo, Sch Odontol, RA-5500 Mendoza, Argentina.
   [Branham, M. T.; Marzese, D. M.; Laurito, S. R.; Gago, F. E.; Orozco, J. I.; Vargas-Roig, L. M.; Roque, M.] Natl Univ Cuyo, Sch Med Sci, RA-5500 Mendoza, Argentina.
   [Vargas-Roig, L. M.] IMBECU CCT CONICET, Lab Tumor Biol, Mendoza, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza;
   University Nacional Cuyo Mendoza
RP Branham, MT (通讯作者)，Natl Univ Cuyo, IHEM CCT CONICET, Lab Cellular & Mol Biol, Sch Med Sci, Parque Gen San Martin, RA-5500 Mendoza, Argentina.
EM mbranham@fcm.uncu.edu.ar
RI Marzese, Diego/AAA-3547-2022
OI Roque, Maria/0000-0002-9564-1032
FU National Institute of Cancer ('Instituto Nacional del Cancer'); National
   University of Cuyo Argentina
FX This study was supported in part by the National Institute of Cancer
   ('Instituto Nacional del Cancer') and the National University of Cuyo
   Argentina.
CR Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Carey LA, 2011, ONCOLOGIST, V16, P71, DOI 10.1634/theoncologist.2011-S1-71
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fumagalli C, 2012, BREAST CANC RES TREA
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Kashiwagi S, 2010, BRIT J CANCER, V103, P249, DOI 10.1038/sj.bjc.6605735
   Kim YS, 2012, INT J RAD ONCOL BIOL
   Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Martin SA, 2010, CLIN CANCER RES, V16, P5107, DOI 10.1158/1078-0432.CCR-10-0821
   Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   Reddy KB, 2011, CURR ONCOL, V18, pE173
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
NR 22
TC 46
Z9 52
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD JUL
PY 2012
VL 1
AR e17
DI 10.1038/oncsis.2012.17
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA V36NT
UT WOS:000209219200002
PM 23552734
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Bosviel, R
   Garcia, S
   Lavediaux, G
   Michard, E
   Dravers, M
   Kwiatkowski, F
   Bignon, YJ
   Bernard-Gallon, DJ
AF Bosviel, Remy
   Garcia, Stephane
   Lavediaux, Guillaume
   Michard, Emilie
   Dravers, Marine
   Kwiatkowski, Fabrice
   Bignon, Yves-Jean
   Bernard-Gallon, Dominique J.
TI <i>BRCA1</i> promoter methylation in peripheral blood DNA was identified
   in sporadic breast cancer and controls
SO CANCER EPIDEMIOLOGY
LA English
DT Article
DE Breast cancer; BRCA1; DNA methylation
ID MESSENGER-RNA; GENE; HYPERMETHYLATION; TUMOR; RISK; SERUM; ASSOCIATION
AB Objective Epigenetics, particularly DNA methylation, has recently been shown to be important in breast cancer initiation. We investigated the clinical and prognostic importance of whole blood breast cancer early onset gene 1 (BRCA1) DNA methylation in sporadic breast cancer. Methods Genomic DNA was extracted from the peripheral blood cells (PBCs) of 902 breast cancer patients at diagnosis, with no BRCA1 mutation, and 990 control women. DNA methylation was measured by quantitative analysis of methylated alleles (QAMA) to estimate the extent of methylation of 2 CpG sites in the promoter region of BRCA1 oncosuppressor. Results BRCA1 promoter methylation rate in PBCs was 47.1% with a 95% confidence interval [46.1; 48.1] in breast cancer patients, and 45.9% with a 95% confidence interval [45.0; 46.8] in controls. We found a trend toward BRCA1 promoter hypermethylation in PBCs of sporadic breast cancer patients compared with controls. Association between methylation and clinicopathological features was evaluated using statistical tests. BRCA1 promoter methylation in PBCs increased significantly in breast cancer patients compared with controls, for age over 70 years (p = 0.022), in post-menopausal status (p = 0.013), for a body mass index (BMI) <20 (p = 0.0095) or a waist-to-hip ratio (WHR) <= 76.8 (p = 0.0027). We also found an association of increased BRCA1 promoter methylation in PBCs with ACA/ACA genotype for the SNP Thr594Thr in ESR (estrogen receptor gene), known to be associated with breast cancer risk (p = 0.092), reflecting the reduced presence of this genotype in this breast cancer case-control study. Conclusion Analysis of site-specific DNA methylation in PBCs by QAMA provides quantitative DNA methylation values that may serve as important prognostic indicators. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Bosviel, Remy; Garcia, Stephane; Lavediaux, Guillaume; Michard, Emilie; Dravers, Marine; Kwiatkowski, Fabrice; Bignon, Yves-Jean; Bernard-Gallon, Dominique J.] CBRV, Dept Oncogenet, Ctr Jean Perrin, F-63001 Clermont Ferrand, France.
   [Bosviel, Remy; Garcia, Stephane; Lavediaux, Guillaume; Michard, Emilie; Dravers, Marine; Kwiatkowski, Fabrice; Bignon, Yves-Jean; Bernard-Gallon, Dominique J.] CRNH, F-63009 Clermont Ferrand, France.
   [Bosviel, Remy; Garcia, Stephane; Lavediaux, Guillaume; Michard, Emilie; Dravers, Marine; Kwiatkowski, Fabrice; Bignon, Yves-Jean; Bernard-Gallon, Dominique J.] Univ Auvergne, EA Nutr Cancerogenese & Therapie Antitumorale 423, F-63001 Clermont Ferrand, France.
C3 UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA)
RP Bignon, YJ (通讯作者)，Ctr Jean Perrin, Dept Oncogenet, 58 Rue Montalembert,BP 392, F-63011 Clermont Ferrand, France.
EM remy.bosviel@u-clermont1.fr; steph0.63@hotmail.fr;
   lavediaux.guillaume@wanadoo.fr; emilie.michard03@gmail.com;
   m.dravers@laposte.net; fabrice.kwiatkowski@cjp.fr;
   yves-jean.bignon@cjp.fr; dominique.bernard-gallon@cjp.fr
RI Bernard-Gallon, Dominique/L-6079-2015
FU "Ligue Nationale Francaise de Lutte Contre le Cancer" (Puy-de-Dome,
   Allier and Cantal); Auvergne Regional Council/CPER [32316 - 0930FDBG -
   106NL]
FX This study was supported by "Ligue Nationale Francaise de Lutte Contre
   le Cancer" (Puy-de-Dome, Allier and Cantal). Remy Bosviel is a recipient
   of a grant from the Auvergne Regional Council/CPER 2008 + FEDER No.
   32316 - 0930FDBG - 106NL.
CR Al-Moundhri MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015585
   Bernard-Gallon D, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-36
   Bosviel R, 2011, CLIN CHIM ACTA, V412, P1472, DOI 10.1016/j.cca.2011.04.027
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225
   Delort L, 2007, ANTICANCER RES, V27, P1087
   Delort L, 2010, NUTR CANCER, V62, P243, DOI 10.1080/01635580903305300
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   Jing F, 2007, ONKOLOGIE, V30, P14, DOI 10.1159/000096892
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Li YR, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000533
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Pal R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-303
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Sharma G, 2010, LIFE SCI, V87, P83, DOI 10.1016/j.lfs.2010.05.001
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122
NR 28
TC 44
Z9 47
U1 0
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1877-7821
EI 1877-783X
J9 CANCER EPIDEMIOL
JI Cancer Epidemiol.
PD JUN
PY 2012
VL 36
IS 3
BP E177
EP E182
DI 10.1016/j.canep.2012.02.001
PG 6
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA 954ZU
UT WOS:000304987700005
PM 22402307
DA 2025-01-12
ER

PT J
AU Chen, FM
   Chang, HW
   Yang, SF
   Huang, YF
   Nien, PY
   Yeh, YT
   Hou, MF
AF Chen, Fang-Ming
   Chang, Hsueh-Wei
   Yang, Sheau-Fang
   Huang, Ya-Fang
   Nien, Pei-Yung
   Yeh, Yao-Tsung
   Hou, Ming-Feng
TI The mitogen-activated protein kinase phosphatase-1 (<i>MKP-1</i>) gene
   is a potential methylation biomarker for malignancy of breast cancer
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
DE biological markers; breast neoplasms; DNA methylation; DUSP1 protein
   human; epigenesis genetic
ID PROMOTER METHYLATION; METABOLIC DISEASE; DNA METHYLATION; E-CADHERIN;
   EXPRESSION; HYPERMETHYLATION; CARCINOMA; MARKER; CELLS; PCR
AB The mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) belongs to the MAPK cascades which are central to cell proliferation and apoptosis. The carcinogenic role of MKP-1 has been reported in many types of cancer but it has rarely been investigated in breast cancer. The present study was designed to evaluate the MKP-1 mRNA expression and its possible regulation by methylation of MKP-1 promoter in the model of several breast cancer cell lines and tissues as well as controls. Our data demonstrate MKP-1 mRNA expression significantly decreased in five breast cancer cell lines compared to breast controls (P < 0.01). Using the methylation-specific PCR (MSP) analysis, the unmethylated reaction (U) is dominant in both normal cell lines and benign breast tumors (100% vs. 86.2%), whereas the methylated reaction (M) is dominant in both breast cancer cell lines and invasive breast tumors (100% vs. 57.2%). In terms of methylation ratio (M/M+U), methylation level in MKP-1 promoter is significantly higher in the invasive breast tumor tissues (n = 152) than in benign breast tumor tissues (n = 29) (P < 0.0001). Assessing the methylation ratio of the promoter of MKP-1 gene to diagnose the breast malignancy (invasive vs. benign), the area under the receiver-operating characteristic (ROC) curve was 0.809 (95% Cl: 0.711-0.906, P < 0.001). The best performance for this prediction has a sensitivity of 76.32% and a specificity of 82.76% at the cutoff value of 0.38. Taken together, we firstly demonstrated that the promoter methylation of MKP-1 gene is a potential breast cancer biomarker for breast malignancy.
C1 [Yeh, Yao-Tsung] Fooyin Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung 807, Taiwan.
   [Chen, Fang-Ming] Kaohsiung Med Univ, Dept Surg, Sch Med, Kaohsiung 807, Taiwan.
   [Chen, Fang-Ming; Hou, Ming-Feng] Kaohsiung Med Univ Hosp, Div Gen & Gastroenterol Surg, Dept Surg, Kaohsiung 807, Taiwan.
   [Chen, Fang-Ming; Chang, Hsueh-Wei; Huang, Ya-Fang; Nien, Pei-Yung; Hou, Ming-Feng] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung 807, Taiwan.
   [Chang, Hsueh-Wei] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Grad Inst Nat Prod, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan.
   [Yang, Sheau-Fang] Kaohsiung Municipal Tatung Hosp, Dept Pathol, Kaohsiung 807, Taiwan.
   [Yang, Sheau-Fang] Kaohsiung Med Univ, Dept Pathol, Fac Med, Coll Med, Kaohsiung 807, Taiwan.
   [Hou, Ming-Feng] Kaohsiung Med Univ, Inst Clin Med, Kaohsiung 807, Taiwan.
   [Hou, Ming-Feng] Kaohsiung Med Univ, Natl Sun Yat Sen Univ, Joint Res Ctr, Kaohsiung 807, Taiwan.
C3 Fooyin University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung
   Hospital; Kaohsiung Medical University; Kaohsiung Medical University;
   National Sun Yat Sen University; Kaohsiung Medical University
RP Yeh, YT (通讯作者)，Fooyin Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung 807, Taiwan.
EM glycosamine@yahoo.com.tw; mifeho@kmu.edu.tw
RI Chang, Hsueh-Wei/C-9654-2009; Hou, Ming-Feng/D-5506-2009; Chen,
   Fang-Ming/D-4721-2009
OI Yeh, Yao-Tsung/0000-0002-7780-7983; Huang, Ya-Fang/0000-0002-7790-8071;
   Yang, Sheau-Fang/0000-0002-1773-3716; Chang,
   Hsueh-Wei/0000-0003-0068-2366; Hou, Ming-Feng/0000-0001-6030-9702
FU NSC [NSC99-2314-B-037-016-MY3]; Department of Health, Executive Yuan,
   R.O.C. [DOH100-TD-C-111-002]; Kaohsiung Medical University Research
   Foundation [KMUER014]
FX This study was partly supported by NSC grants
   (NSC99-2314-B-037-016-MY3), grand from the Department of Health,
   Executive Yuan, R.O.C. (DOH100-TD-C-111-002), and grant from the
   Kaohsiung Medical University Research Foundation (KMUER014).
CR Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Boutros T, 2008, PHARMACOL REV, V60, P261, DOI 10.1124/pr.107.00106
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Cairns P, 2007, NAT REV CANCER, V7, P531, DOI 10.1038/nrc2170
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Chang HW, 2007, INT J BIOL MARKER, V22, P287, DOI 10.1177/172460080702200408
   Chang HW, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-12
   Chang HW, 2002, JNCI-J NATL CANCER I, V94, P1697
   Esteller M, 2001, CANCER RES, V61, P3225
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Flach RJR, 2010, EXPERT OPIN THER TAR, V14, P1323, DOI 10.1517/14728222.2010.528395
   Flach RJR, 2010, AGING-US, V2, P170, DOI 10.18632/aging.100135
   Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008
   Henneges C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-104
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lee JK, 2004, EXP MOL MED, V36, P165, DOI 10.1038/emm.2004.23
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loda M, 1996, AM J PATHOL, V149, P1553
   Marsh Sharon, 2007, V373, P15
   Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   Park HY, 2007, EXP MOL MED, V39, P195, DOI 10.1038/emm.2007.22
   Park WS, 2005, EXP MOL MED, V37, P276, DOI 10.1038/emm.2005.37
   Parrella P, 2010, BREAST CARE, V5, P66, DOI 10.1159/000309138
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rauhala HE, 2005, INT J CANCER, V117, P738, DOI 10.1002/ijc.21270
   Seniski GG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-80
   Shames DS, 2007, CANCER LETT, V251, P187, DOI 10.1016/j.canlet.2006.10.014
   Shieh YS, 2005, CANCER-AM CANCER SOC, V104, P1013, DOI 10.1002/cncr.21278
   Shih IM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.08.003
   Shimada K, 2007, AM J PATHOL, V171, P1003, DOI 10.2353/ajpath.2007.070010
   Suijkerbuijk KPM, 2011, ANN ONCOL, V22, P24, DOI 10.1093/annonc/mdq305
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   Whitmarsh A J, 1999, Sci STKE, V1999, pPE1, DOI 10.1126/stke.1999.1.pe1
   Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-32
   Yan PS, 2006, CLIN CANCER RES, V12, P6626, DOI 10.1158/1078-0432.CCR-06-0467
   Yen CY, 2009, BIOMARKERS, V14, P244, DOI 10.1080/13547500902829375
   Zhu WZ, 2010, INT J CANCER, V126, P474, DOI 10.1002/ijc.24728
   Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217
NR 42
TC 11
Z9 15
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD MAY 31
PY 2012
VL 44
IS 5
BP 356
EP 362
DI 10.3858/emm.2012.44.5.040
PG 7
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 953TR
UT WOS:000304896600006
PM 22333693
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Gong, Y
   Li, YL
   Abdolmaleky, HM
   Li, LL
   Zhou, JR
AF Gong, Yi
   Li, Yanli
   Abdolmaleky, Hamid M.
   Li, Linglin
   Zhou, Jin-Rong
TI Tanshinones Inhibit the Growth of Breast Cancer Cells through Epigenetic
   Modification of Aurora A Expression and Function
SO PLOS ONE
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; PROSTATE-CANCER; SALVIA-MILTIORRHIZA; KINASE
   INHIBITORS; CYCLE ARREST; RAT PLASMA; IIA; APOPTOSIS; CRYPTOTANSHINONE;
   CYTOTOXICITY
AB The objectives of this study were to evaluate the effects of tanshinones from a Chinese herb Salvia Miltiorrhiza on the growth of breast cancer cells, and to elucidate cellular and molecular mechanisms of action. Tanshinones showed the dose-dependent effect on the growth inhibition of breast cancer cells in vitro, with tanshinone I (T1) the most potent agent. T1 was also the only tanshinone to have potent activity in inhibiting the growth of the triple-negative breast cancer cell line MDA-MB231. T1 caused cell cycle arrests of both estrogen-dependent and estrogen-independent cell lines associated with alterations of cyclinD, CDK4 and cyclinB, and induced breast cancer cell apoptosis associated with upregulation of c-PARP and downregulation of survivin and Aurora A. Among these associated biomarkers, Aurora A showed the most consistent pattern with the anti-growth activity of tanshinones. Overexpression of Aurora A was also verified in breast tumors. The gene function assay showed that knockdown of Aurora A by siRNA dramatically reduced the growth-inhibition and apoptosis-induction activities of T1, suggesting Aurora A as an important functional target of T1 action. On the other hand, tanshinones had much less adverse effects on normal mammary epithelial cells. Epigenetic mechanism studies showed that overexpression of Aurora A gene in breast cancer cells was not regulated by gene promoter DNA methylation, but by histone acetylation. T1 treatment significantly reduced acetylation levels of histone H3 associated with Aurora A gene. Our results supported the potent activity of T1 in inhibiting the growth of breast cancer cells in vitro in part by downregulation of Aurora A gene function. Our previous studies also demonstrated that T1 had potent anti-angiogenesis activity and minimal side effects in vivo. Altogether, this study warrants further investigation to develop T1 as an effective and safe agent for the therapy and prevention of breast cancer.
C1 [Gong, Yi; Li, Yanli; Abdolmaleky, Hamid M.; Li, Linglin; Zhou, Jin-Rong] Harvard Univ, Sch Med, Dept Surg, Nutr Metab Lab,Beth Israel Deaconess Med, Boston, MA 02115 USA.
   [Li, Yanli; Zhou, Jin-Rong] E China Normal Univ, Inst Mol & Expt Therapeut, Shanghai 200062, Peoples R China.
C3 Harvard University; Harvard Medical School; Beth Israel Deaconess
   Medical Center; East China Normal University
RP Gong, Y (通讯作者)，Harvard Univ, Sch Med, Dept Surg, Nutr Metab Lab,Beth Israel Deaconess Med, Boston, MA 02115 USA.
EM jrzhou@bidmc.harvard.edu
RI li, yanli/AAT-2012-2021
OI Mostafavi Abdolmaleky, Hamid/0000-0002-8872-5174
FU National Cancer Institute [R21 CA133865]; Department of Defense
   [PC073988]
FX This work was supported in part by grants to JRZ from the National
   Cancer Institute (R21 CA133865) and the Department of Defense
   (PC073988). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abdolmaleky Hamid Mostafavi, 2008, V448, P187, DOI 10.1007/978-1-59745-205-2_9
   American Cancer Society, 2010, OV BREST CANC MAN WO
   Banerjee HN, 2009, BIOMARK MED, V3, P397, DOI 10.2217/BMM.09.26
   Bi HC, 2007, BIOMED CHROMATOGR, V21, P473, DOI 10.1002/bmc.778
   Buschhorn HM, 2005, PROSTATE, V64, P341, DOI 10.1002/pros.20247
   Compérat E, 2007, VIRCHOWS ARCH, V450, P419, DOI 10.1007/s00428-007-0383-x
   Compérat E, 2008, UROLOGY, V72, P873, DOI 10.1016/j.urology.2007.12.026
   Cui Y, 2008, LIFE SCI, V82, P247, DOI 10.1016/j.lfs.2007.11.013
   Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765
   Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Giet R, 1999, J CELL SCI, V112, P3591
   Görgün G, 2010, BLOOD, V115, P5202, DOI 10.1182/blood-2009-12-259523
   Gong Y, 2011, INT J CANCER, V129, P1042, DOI 10.1002/ijc.25678
   Hao HP, 2006, J PHARMACEUT BIOMED, V40, P382, DOI 10.1016/j.jpba.2005.07.029
   Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323
   Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502
   Lea MA, 2002, NUTR CANCER, V43, P90, DOI 10.1207/S15327914NC431_11
   Lee CY, 2008, MOL CANCER THER, V7, P3527, DOI 10.1158/1535-7163.MCT-07-2288
   Lee ECY, 2006, CANCER RES, V66, P4996, DOI 10.1158/0008-5472.CAN-05-2796
   Lee WYW, 2008, FOOD CHEM TOXICOL, V46, P328, DOI 10.1016/j.fct.2007.08.013
   Lentini L, 2008, ONCOL RES, V17, P115, DOI 10.3727/096504008785055521
   Li DH, 2003, CLIN CANCER RES, V9, P991
   Li J, 2005, J CHROMATOGR B, V826, P26, DOI 10.1016/j.jchromb.2005.07.048
   Li Y, 2012, MOL CARCINO IN PRESS
   Lima SC, 2010, CURR OPIN MOL THER, V12, P316
   Liu JJ, 2009, ONCOL REP, V21, P1075, DOI 10.3892/or_00000326
   Mai ZM, 2007, CARCINOGENESIS, V28, P1217, DOI 10.1093/carcin/bgm004
   Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526
   Matarasso N, 2007, NEOPLASIA, V9, P707, DOI 10.1593/neo.07322
   Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006
   Mosaddik MA, 2003, PHYTOMEDICINE, V10, P682, DOI 10.1078/0944-7113-00321
   Nizamutdinova IT, 2008, CARCINOGENESIS, V29, P1885, DOI 10.1093/carcin/bgn151
   Nizamutdinova IT, 2008, INT J ONCOL, V33, P485, DOI 10.3892/ijo_00000031
   Qu Y, 2008, CANCER GENE THER, V15, P517, DOI 10.1038/cgt.2008.22
   Qu Yi, 2008, Sichuan Da Xue Xue Bao Yi Xue Ban, V39, P1
   Singh AV, 2006, CANCER RES, V66, P1851, DOI 10.1158/0008-5472.CAN-05-1332
   Song M, 2005, J CHROMATOGR B, V827, P205, DOI 10.1016/j.jchromb.2005.09.014
   Staff S, 2010, ONCOL REP, V23, P307, DOI 10.3892/or_00000637
   Su CC, 2008, INT J MOL MED, V22, P357, DOI 10.3892/ijmm_00000030
   Vankayalapati H, 2003, MOL CANCER THER, V2, P283
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wang J, 2007, J NEURO-ONCOL, V82, P11, DOI 10.1007/s11060-006-9242-x
   Wang X, 1996, Zhonghua Zhong Liu Za Zhi, V18, P412
   Wang XJ, 2005, INT J CANCER, V116, P799, DOI 10.1002/ijc.20880
   Yuan S, 2002, HUA XI YI KE DA XUE, V33, P90
   Yuan SL, 2004, WORLD J GASTROENTERO, V10, P2024, DOI 10.3748/wjg.v10.i14.2024
   Yuan Shulan, 2002, Journal of West China University of Medical Sciences, V33, P84
   Zhang P, 1999, Zhongguo Zhong Xi Yi Jie He Za Zhi, V19, P103
NR 50
TC 61
Z9 65
U1 1
U2 33
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2012
VL 7
IS 4
AR e33656
DI 10.1371/journal.pone.0033656
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 952GU
UT WOS:000304780500023
PM 22485147
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Nopavichai, C
   Sanpawat, A
   Kantabandit, P
   Mutirangura, A
   Shuangshoti, S
AF Nopavichai, Chatchai
   Sanpawat, Anapat
   Kantabandit, Peerapan
   Mutirangura, Apiwat
   Shuangshoti, Shanop
TI Changes in LINE-1 methylation level in cancers during metastasis
SO ASIAN BIOMEDICINE
LA English
DT Article
DE LINE-1 methylation; metastasis; multi-step oncogenesis; primary tumor;
   tumor progression
ID SQUAMOUS-CELL CARCINOMA; EML4-ALK FUSION GENE; MICROSATELLITE
   INSTABILITY; COLORECTAL-CANCER; THYROID-CANCER; BREAST-CANCER;
   LUNG-CANCER; NECK-CANCER; HYPOMETHYLATION; DNA
AB Background: Significantly lower LINE-1 methylation levels have been observed in several cancers compared to their normal cell counterparts. It is of interest to note that this epigenetic phenomenon is rather common to cancers with multistage oncogenesis.
   Objective: We compared LINE-1 methylation levels of cancer cells between the primary and matched metastatic sites.
   Methods: COBRA method was used to determine LINE-1 methylation levels of tumor cells at the primary and matched metastatic sites in five malignancies (10 cases each of head and neck squamous carcinoma, papillary thyroid carcinoma, non-small cell lung cancer, invasive mammary ductal carcinoma, and colorectal adenocarcinoma). LINE-1 methylation levels between the primary and matched metastatic site were compared.
   Results: Significantly lower LINE-1 methylation levels were observed at metastatic sites (as compared to primary sites) in head and neck squamous cell carcinoma (p = 0.002) and non-small cell lung cancer (p = 0.012).
   Conclusion: In head, neck, and pulmonary cancers, significantly lower LINE-1 methylation levels were found at metastatic sites, as compared to the matched primary tumor. Further studies are warranted to determine whether this altered methylation is the result or the cause of cancer metastasis.
C1 [Nopavichai, Chatchai; Sanpawat, Anapat; Kantabandit, Peerapan; Shuangshoti, Shanop] Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand.
   [Mutirangura, Apiwat] Chulalongkorn Univ, Fac Med, Ctr Excellence Mol Genet Canc & Human Dis, Dept Anat, Bangkok 10330, Thailand.
   [Shuangshoti, Shanop] Chulalongkorn Univ, Fac Med, Chulalongkorn GenePRO Ctr, Bangkok 10330, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; Chulalongkorn
   University
RP Shuangshoti, S (通讯作者)，Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand.
EM Shanop@gmail.com
FU Chulalongkorn University; Four Seasons Hotel Bangkok; Thai Red Cross
   Society 4th Cancer Care Charity; Ratchadapisek Somphot Endowment Fund
FX This work was funded by the Ratchadapisek Somphot Endowment Fund,
   Chulalongkorn University, and Four Seasons Hotel Bangkok and the Thai
   Red Cross Society 4th Cancer Care Charity. The authors have no conflict
   of interest to declare.
CR ALMEIDA A, 1993, HUM GENET, V91, P538
   Benchekroun MT, 2010, CANCER PREV RES, V3, P800, DOI 10.1158/1940-6207.CAPR-09-0163
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   El-Naggar AK, 1999, HUM PATHOL, V30, P1013, DOI 10.1016/S0046-8177(99)90217-4
   Estécio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399
   Forestiere A, 2011, NEW ENGL J MED, V345, P1890
   Frattini M, 2004, ONCOGENE, V23, P7436, DOI 10.1038/sj.onc.1207980
   GRANDIS JR, 1993, J CELL BIOCHEM, P188
   Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jurgens B, 1996, CANCER RES, V56, P5698
   Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961
   Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19
   Kim MM, 2004, INT J CANCER, V112, P545, DOI 10.1002/ijc.20379
   Kimura ET, 2003, CANCER RES, V63, P1454
   Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441
   Lingen MW, 2011, ORAL DIS, V17, P7, DOI 10.1111/j.1601-0825.2011.01789.x
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Matsuzaki K, 2005, CLIN CANCER RES, V11, P8564, DOI 10.1158/1078-0432.CCR-05-0859
   Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Nikiforova MN, 2008, EXPERT REV MOL DIAGN, V8, P83, DOI 10.1586/14737159.8.1.83
   Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470
   Pobsook T, 2011, CLIN CHIM ACTA, V412, P314, DOI 10.1016/j.cca.2010.10.030
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092
   Schulz WA, 2006, J BIOMED BIOTECHNOL, V65, P8635
   Shuangshoti S, 2007, ASIAN PAC J CANCER P, V8, P307
   Smith IM, 2007, INT J CANCER, V121, P1724, DOI 10.1002/ijc.22889
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Subbalekha K, 2009, ORAL ONCOL, V45, P184, DOI 10.1016/j.oraloncology.2008.05.002
   Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190
   Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079
   Wong DWS, 2009, CANCER-AM CANCER SOC, V115, P1723, DOI 10.1002/cncr.24181
   Zhu ZW, 2006, J CLIN ENDOCR METAB, V91, P3603, DOI 10.1210/jc.2006-1006
NR 36
TC 1
Z9 1
U1 0
U2 2
PU CHULALONGKORN UNIV, FAC MED
PI BANGKOK
PA CHULALONGKORN UNIV, FAC MED, 1873, RAMA 4, BANGKOK, 10330, THAILAND
SN 1905-7415
J9 ASIAN BIOMED
JI Asian Biomed.
PD APR
PY 2012
VL 6
IS 2
BP 307
EP 312
DI 10.5372/1905-7415.0602.059
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 951OF
UT WOS:000304729200021
DA 2025-01-12
ER

PT J
AU Lo Nigro, C
   Monteverde, M
   Lee, S
   Lattanzio, L
   Vivenza, D
   Comino, A
   Syed, N
   McHugh, A
   Wang, H
   Proby, C
   Garrone, O
   Merlano, M
   Hatzimichael, E
   Briasoulis, E
   Gojis, O
   Palmieri, C
   Jordan, L
   Quinlan, P
   Thompson, A
   Crook, T
AF Lo Nigro, C.
   Monteverde, M.
   Lee, S.
   Lattanzio, L.
   Vivenza, D.
   Comino, A.
   Syed, N.
   McHugh, A.
   Wang, H.
   Proby, C.
   Garrone, O.
   Merlano, M.
   Hatzimichael, E.
   Briasoulis, E.
   Gojis, O.
   Palmieri, C.
   Jordan, L.
   Quinlan, P.
   Thompson, A.
   Crook, T.
TI NT5E CpG island methylation is a favourable breast cancer biomarker
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE NT5E; breast cancer; metastasis; epigenetics; triple-negative breast
   cancer
ID ECTO-5'-NUCLEOTIDASE CD73; GENE-EXPRESSION; PROGNOSTIC-FACTORS;
   ECTO-5-NUCLEOTIDASE; CELLS; RECURRENCE; METASTASES; MANAGEMENT;
   APOPTOSIS; MIGRATION
AB BACKGROUND: Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5'-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer.
   METHODS: We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and primary and breast carcinomas.
   RESULTS: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series, patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P = 0.003, OR = 0.34, 95% CI: 0.17-0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary tumours (P = 0.01, OR = 11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS) (P = 0.001, HR = 2.7) and overall survival (OS) (P 0.001, HR 3). The favourable prognostic value of NT5E methylation was confirmed in oestrogen receptor negative (P = 0.011, HR = 3.27, 95% CI: 1.31-8.12) and in triple negative cases (P = 0.004; HR = 6.2, 95% CI: 1.9-20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose tumours were positive for NT5E CpG island methylation: DFS (P = 0.0016, HR = 5.1, 95% CI: 1.8-14.37) and OS (P = 0.0005, HR = 7.4, 95% CI: 2.416-23.08).
   CONCLUSION: NT5E CpG island methylation is a promising breast cancer biomarker. British Journal of Cancer (2012) 107, 75-83. doi:10.1038/bjc.2012.212 www.bjcancer.com Published online 31 May 2012 (C) 2012 Cancer Research UK
C1 [Jordan, L.; Quinlan, P.; Thompson, A.; Crook, T.] Univ Dundee, Div Canc Res, Med Res Inst, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.
   [Lo Nigro, C.; Monteverde, M.; Lattanzio, L.; Vivenza, D.] S Croce Gen Hosp, Lab Canc Genet & Translat Oncol, Dept Oncol, Cuneo, Italy.
   [Lee, S.] London Res Inst, Immunobiol Lab, Lincolns Inn Fields Labs, London, England.
   [Comino, A.] S Croce Gen Hosp, Dept Pathol, Cuneo, Italy.
   [Syed, N.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Ctr Neurosci, Charing Cross Hosp, London, England.
   [McHugh, A.; Wang, H.; Proby, C.] Univ Dundee, Wellcome Trust Ctr Mol Med, Div Med Sci, Clin Res Ctr,Ninewells Hosp, Dundee DD1 9SY, Scotland.
   [Garrone, O.; Merlano, M.] S Croce Gen Hosp, Dept Oncol, Cuneo, Italy.
   [McHugh, A.; Wang, H.; Proby, C.] Univ Dundee, Dept Dermatol, Ninewells Hosp, Dundee DD1 9SY, Scotland.
   [Hatzimichael, E.; Briasoulis, E.] Univ Ioannina, Intersci Mol Oncol Lab, Canc Biobank Ctr, GR-45110 Ioannina, Greece.
   [Gojis, O.; Palmieri, C.] Univ London Imperial Coll Sci Technol & Med, Canc Res UK Labs, Div Canc, London, England.
C3 University of Dundee; Imperial College London; University of Dundee;
   University of Dundee; University of Ioannina; Imperial College London;
   Cancer Research UK
RP Crook, T (通讯作者)，Univ Dundee, Div Canc Res, Med Res Inst, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.
EM tr.crook@gmail.com
RI Garrone, Ornella/HHS-9402-2022; Hatzimichael, Eleftheria/AAT-4835-2020
OI Garrone, Ornella/0000-0001-7359-5410; Quinlan,
   Philip/0000-0002-3012-6646; Monteverde, Martino/0000-0003-2623-414X;
   Hatzimichael, Eleftheria/0000-0002-4408-5646; Lo Nigro,
   Cristiana/0000-0002-3615-2431
FU Brain Tumour Research Charity (BTRC); Cancer Research-UK; Breast Cancer
   Research (Scotland); Tayside Tissue Bank; Hellenic Society of
   Haematology Foundation; Ministry of Education of the Czech Republic [MSM
   0021620808]; European Society of Medical Oncology; European Society for
   Surgical Oncology; Department of Health [C37/A7283]
FX The work was supported by the Brain Tumour Research Charity (BTRC),
   Cancer Research-UK, Breast Cancer Research (Scotland) and the Tayside
   Tissue Bank. Eleftheria Hatzimichael received funding as a scholar from
   the Hellenic Society of Haematology Foundation. Carlo Palmieri is the
   recipient of a Cancer Research UK Clinician Scientist award. Ondrej
   Gojis is in part funded by a grant from the Ministry of Education of the
   Czech Republic (Project 'Oncology' MSM 0021620808) and is also a
   recipient of the Translational Research Fellowship from the European
   Society of Medical Oncology and a fellowship from the European Society
   for Surgical Oncology. The Division of Cancer at Imperial College
   London, Imperial College Healthcare NHS Trust is an Experimental Cancer
   Medicine Centre (ECMC) that is supported by funds from Cancer Research
   UK and the Department of Health (C37/A7283) and also forms part of the
   Imperial Cancer Research UK Centre (C42671/A12196). Tim Crook is a
   Scottish Senior Clinical Fellow. We thank F Roncaroli for his
   contribution.
CR Aitken SJ, 2010, ANN ONCOL, V21, P1254, DOI 10.1093/annonc/mdp427
   Andrade CMB, 2011, CELL TISSUE RES, V344, P279, DOI 10.1007/s00441-011-1140-7
   Andreopoulou E, 2008, J CLIN ONCOL, V26, P3660, DOI 10.1200/JCO.2008.16.1026
   BOYLE JM, 1988, HUM GENET, V81, P88, DOI 10.1007/BF00283737
   Chandra D, 2006, CELL, V125, P1333, DOI 10.1016/j.cell.2006.05.026
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Korde LA, 2011, J CLIN ONCOL, V29, P3600, DOI 10.1200/JCO.2011.35.7038
   KRUGER KH, 1991, BRIT J CANCER, V63, P114, DOI 10.1038/bjc.1991.23
   Lopez J, 2009, BRIT J CANCER, V100, P571, DOI 10.1038/sj.bjc.6604930
   Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7
   MCGUIRE WL, 1991, J NATL CANCER I, V83, P154, DOI 10.1093/jnci/83.3.154
   Mikhailov A, 2008, J IMMUNOL, V181, P464, DOI 10.4049/jimmunol.181.1.464
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Perez EA, 2011, ONCOLOGIST, V16, P20, DOI 10.1634/theoncologist.2011-S1-20
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Roukos DH, 2007, CANCER BIOL THER, V6, P308, DOI 10.4161/cbt.6.3.3994
   Shah R, 2009, BRIT J CANCER, V100, P1687, DOI 10.1038/sj.bjc.6605042
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Spychala J, 2004, CLIN CANCER RES, V10, P708, DOI 10.1158/1078-0432.CCR-0811-03
   Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246
   Thompson AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2771
   UJHAZY P, 1994, INT J CANCER, V59, P83, DOI 10.1002/ijc.2910590117
   Ujhazy P, 1996, INT J CANCER, V68, P493, DOI 10.1002/(SICI)1097-0215(19961115)68:4<493::AID-IJC15>3.3.CO;2-Y
   Visvanathan K, 2006, CLIN CANCER RES, V12, P6591, DOI 10.1158/1078-0432.CCR-06-2001
   Wang L, 2008, J CANCER RES CLIN, V134, P365, DOI 10.1007/s00432-007-0292-z
   Zhi XL, 2010, CANCER SCI, V101, P2561, DOI 10.1111/j.1349-7006.2010.01733.x
   Zhou P, 2007, CANCER BIOL THER, V6, P426, DOI 10.4161/cbt.6.3.3762
   Zhou XR, 2007, ONCOL REP, V17, P1341
   ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345
NR 30
TC 37
Z9 37
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUN 26
PY 2012
VL 107
IS 1
BP 75
EP 83
DI 10.1038/bjc.2012.212
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 967EE
UT WOS:000305888400012
PM 22653144
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Zhou, X
   Marian, C
   Makambi, KH
   Kosti, O
   Kallakury, BVS
   Loffredo, CA
   Zheng, YL
AF Zhou, Xin
   Marian, Catalin
   Makambi, Kepher H.
   Kosti, Ourania
   Kallakury, Bhaskar V. S.
   Loffredo, Christopher A.
   Zheng, Yun-Ling
TI MicroRNA-9 as Potential Biomarker for Breast Cancer Local Recurrence and
   Tumor Estrogen Receptor Status
SO PLOS ONE
LA English
DT Article
ID CONSERVING THERAPY; EXPRESSION PROFILES; EPIGENETIC REGULATION;
   RISK-FACTORS; CELL; CARCINOMAS; MASTECTOMY; SURVIVAL; SURGERY;
   RADIOTHERAPY
AB MicroRNAs (miRs) are small, non-protein coding transcripts involved in many cellular functions. Many miRs have emerged as important cancer biomarkers. In the present study, we investigated whether miR levels in breast tumors are predictive of breast cancer local recurrence (LR). Sixty-eight women who were diagnosed with breast cancer at the Lombardi Comprehensive Cancer Center were included in this study. Breast cancer patients with LR and those without LR were matched on year of surgery, age at diagnosis, and type of surgery. Candidate miRs were identified by screening the expression levels of 754 human miRs using miR arrays in 16 breast tumor samples from 8 cases with LR and 8 cases without LR. Eight candidate miRs that showed significant differences between tumors with and without LR were further verified in 52 tumor samples using real-time PCR. Higher expression of miR-9 was significantly associated with breast cancer LR in all cases as well as the subset of estrogen receptor (ER) positive cases (p = 0.02). The AUCs (Area Under Curve) of receiver operating characteristic (ROC) curves of miR-9 for all tumors and ER positive tumors are 0.68 (p = 0.02) and 0.69 (p = 0.02), respectively. In ER positive cases, Kaplan-Meier analysis showed that patients with lower miR-9 levels had significantly better 10-year LR-free survival (67.9% vs 30.8%, p = 0.02). Expression levels of miR-9 and another miR candidate, miR-375, were also strongly associated with ER status (p<0.001 for both). The potential of miR-9 as a biomarker for LR warrants further investigation with larger sample size.
C1 [Zhou, Xin; Marian, Catalin; Makambi, Kepher H.; Kosti, Ourania; Loffredo, Christopher A.; Zheng, Yun-Ling] Georgetown Univ, Canc Prevent & Control Program, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.
   [Kallakury, Bhaskar V. S.] Georgetown Univ, Dept Pathol, Lombardi Comprehens Canc Ctr, Washington, DC USA.
C3 Georgetown University; Georgetown University
RP Zhou, X (通讯作者)，Georgetown Univ, Canc Prevent & Control Program, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.
EM yz37@georgetown.edu
RI Marian, Catalin/KHU-8477-2024; Marian, Catalin/P-2885-2019
OI Marian, Viorica/0000-0002-8335-1433; Marian, Catalin/0000-0002-7749-1384
FU Susan G Komen for the Cure [BCTR0707157]; CMESR (Clinical and Molecular
   Epidemiology Shared Resource); HTSR (Histopathology and Tissue Shared
   Resource); GESR (Genomics & Epigenomics Shared Resource) of the Lombardi
   Comprehensive Cancer Center [National Institutes of Health] [P30
   CA51008]
FX This work was supported by a grant from Susan G Komen for the Cure
   [BCTR0707157 to YZ, ww5.komen.org/] and by the CMESR (Clinical and
   Molecular Epidemiology Shared Resource), HTSR (Histopathology and Tissue
   Shared Resource) and GESR (Genomics & Epigenomics Shared Resource) of
   the Lombardi Comprehensive Cancer Center [National Institutes of Health
   grant P30 CA51008, www.nih.gov]. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
   [Anonymous], INT J CANC
   Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bartels CL, 2009, CLIN CHEM, V55, P623, DOI 10.1373/clinchem.2008.112805
   Basu Aruna, 2011, Genes Cancer, V2, P108, DOI 10.1177/1947601911409212
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   BORGER J, 1994, J CLIN ONCOL, V12, P653, DOI 10.1200/JCO.1994.12.4.653
   Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Elkhuizen PHM, 1998, INT J RADIAT ONCOL, V40, P859, DOI 10.1016/S0360-3016(97)00917-6
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   Heneghan HM, 2010, J ONCOL, V2010, DOI 10.1155/2010/950201
   Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305
   Hofvind S, 2008, JNCI-J NATL CANCER I, V100, P1082, DOI 10.1093/jnci/djn224
   Iorio MV, 2008, EUR J CANCER, V44, P2753, DOI 10.1016/j.ejca.2008.09.037
   Jay C, 2007, DNA CELL BIOL, V26, P293, DOI 10.1089/dna.2006.0554
   Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209
   Kim N, 2011, HEPATOL RES, V41, P170, DOI 10.1111/j.1872-034X.2010.00752.x
   Komatsu S, 2011, BRIT J CANCER, V105, P104, DOI 10.1038/bjc.2011.198
   Kong KL, 2011, GUT
   Kreike B, 2006, CLIN CANCER RES, V12, P5705, DOI 10.1158/1078-0432.CCR-06-0805
   Lajer CB, 2011, BRIT J CANCER, V104, P830, DOI 10.1038/bjc.2011.29
   Li LM, 2010, CANCER RES, V70, P9798, DOI 10.1158/0008-5472.CAN-10-1001
   Li XL, 2011, DIGEST DIS SCI, V56, P2849, DOI 10.1007/s10620-011-1711-1
   Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82
   Magee B, 1996, RADIOTHER ONCOL, V39, P223, DOI 10.1016/0167-8140(96)01747-1
   Mazar J, 2011, FEBS LETT, V585, P2467, DOI 10.1016/j.febslet.2011.06.025
   Negrini M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1867
   Nuyten DSA, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1614
   Onnis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012960
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Park CC, 2000, J CLIN ONCOL, V18, P1668, DOI 10.1200/JCO.2000.18.8.1668
   Schraivogel D, 2011, EMBO J, V30, P4309, DOI 10.1038/emboj.2011.301
   Shibata M, 2011, J NEUROSCI, V31, P3407, DOI 10.1523/JNEUROSCI.5085-10.2011
   Shigehara K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023584
   Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Tan HX, 2010, MED ONCOL, V27, P654, DOI 10.1007/s12032-009-9264-2
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tsitsiou E, 2009, CURR OPIN PHARMACOL, V9, P514, DOI 10.1016/j.coph.2009.05.003
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van Dongen JA, 2000, JNCI-J NATL CANCER I, V92, P1143, DOI 10.1093/jnci/92.14.1143
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Voogd AC, 1999, EUR J CANCER, V35, P1828, DOI 10.1016/S0959-8049(99)00220-8
   Voogd AC, 2001, J CLIN ONCOL, V19, P1688, DOI 10.1200/JCO.2001.19.6.1688
   Wach S, 2012, INT J CANCER, V130, P611, DOI 10.1002/ijc.26064
   Zhang X, 2011, ANN ONCOL, V22, P2257, DOI 10.1093/annonc/mdq758
   Zhu L., 2011, Med Oncol
NR 54
TC 154
Z9 202
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2012
VL 7
IS 6
AR e39011
DI 10.1371/journal.pone.0039011
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 962XO
UT WOS:000305583300080
PM 22916227
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Ren, G
   Baritaki, S
   Marathe, H
   Feng, JW
   Park, S
   Beach, S
   Bazeley, PS
   Beshir, AB
   Fenteany, G
   Mehra, R
   Daignault, S
   Al-Mulla, F
   Keller, E
   Bonavida, B
   de la Serna, I
   Yeung, KC
AF Ren, Gang
   Baritaki, Stavroula
   Marathe, Himangi
   Feng, Jingwei
   Park, Sungdae
   Beach, Sandy
   Bazeley, Peter S.
   Beshir, Anwar B.
   Fenteany, Gabriel
   Mehra, Rohit
   Daignault, Stephanie
   Al-Mulla, Fahd
   Keller, Evan
   Bonavida, Ben
   de la Serna, Ivana
   Yeung, Kam C.
TI Polycomb Protein EZH2 Regulates Tumor Invasion via the Transcriptional
   Repression of the Metastasis Suppressor RKIP in Breast and Prostate
   Cancer
SO CANCER RESEARCH
LA English
DT Article
ID HISTONE METHYLTRANSFERASE EZH2; LONG NONCODING RNA; NF-KAPPA-B;
   E-CADHERIN; KINASE; INHIBITOR; EXPRESSION; CHROMATIN; SNAIL; METHYLATION
AB Epigenetic modifications such as histone methylation play an important role in human cancer metastasis. Enhancer of zeste homolog 2 (EZH2), which encodes the histone methyltransferase component of the polycomb repressive complex 2 (PRC2), is overexpressed widely in breast and prostate cancers and epigenetically silences tumor suppressor genes. Expression levels of the novel tumor and metastasis suppressor Raf-1 kinase inhibitor protein (RKIP) have been shown to correlate negatively with those of EZH2 in breast and prostate cell lines as well as in clinical cancer tissues. Here, we show that the RKIP/EZH2 ratio significantly decreases with the severity of disease and is negatively associated with relapse-free survival in breast cancer. Using a combination of loss-and gain-of-function approaches, we found that EZH2 negatively regulated RKIP transcription through repression-associated histone modifications. Direct recruitment of EZH2 and suppressor of zeste 12 (Suz12) to the proximal E-boxes of the RKIP promoter was accompanied by H3-K27-me3 and H3-K9-me3 modifications. The repressing activity of EZH2 on RKIP expression was dependent on histone deacetylase promoter recruitment and was negatively regulated upstream by miR-101. Together, our findings indicate that EZH2 accelerates cancer cell invasion, in part, via RKIP inhibition. These data also implicate EZH2 in the regulation of RKIP transcription, suggesting a potential mechanism by which EZH2 promotes tumor progression and metastasis. Cancer Res; 72(12); 3091-104. (C)2012 AACR.
C1 [Ren, Gang; Marathe, Himangi; Feng, Jingwei; Park, Sungdae; Beach, Sandy; Bazeley, Peter S.; de la Serna, Ivana; Yeung, Kam C.] Univ Toledo, Dept Biochem & Canc Biol, Coll Med, Toledo, OH 43614 USA.
   [Baritaki, Stavroula; Bonavida, Ben] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Beshir, Anwar B.; Fenteany, Gabriel] Univ Connecticut, Dept Chem, Storrs, CT USA.
   [Mehra, Rohit; Daignault, Stephanie; Keller, Evan] Univ Michigan, Dept Urol & Pathol, Ann Arbor, MI 48109 USA.
   [Al-Mulla, Fahd] Kuwait Univ, Hlth Sci Ctr, Dept Pathol, Fac Med, Safat, Kuwait.
C3 University System of Ohio; University of Toledo; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of
   Connecticut; University of Michigan System; University of Michigan;
   Kuwait University
RP Yeung, KC (通讯作者)，Univ Toledo, Dept Biochem & Canc Biol, Coll Med, 3000 Arlington Av, Toledo, OH 43614 USA.
EM kam.yeung@utoledo.edu
RI Daignault-Newton, Stephanie/GYD-6133-2022; Baritaki,
   Voula/AAA-9544-2021; Keller, Evan/M-1446-2016; Fenteany,
   Gabriel/F-4944-2018; Al-Mulla, Fahd/E-2068-2015
OI Fenteany, Gabriel/0000-0003-0335-4587; Fenteany,
   Gabriel/0000-0001-7407-2195; Ren, Gang/0000-0002-2555-7804; Al-Mulla,
   Fahd/0000-0001-5409-3829
FU NIH [RO1CA133479]
FX This work was supported by NIH grant (RO1CA133479) to K.C. Yeung.
CR Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214
   Baritaki S, 2009, CANCER RES, V69, P8376, DOI 10.1158/0008-5472.CAN-09-1069
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Beach S, 2008, ONCOGENE, V27, P2243, DOI 10.1038/sj.onc.1210860
   Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Beshir AB, 2010, CANCER LETT, V299, P137, DOI 10.1016/j.canlet.2010.08.012
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200
   Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878
   Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319
   Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hoffmann MJ, 2007, CANCER BIOL THER, V6, P1403, DOI 10.4161/cbt.6.9.4542
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Rubin MA, 2000, CLIN CANCER RES, V6, P1038
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107
   Tang HH, 2010, FEBS LETT, V584, P662, DOI 10.1016/j.febslet.2009.12.051
   Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935
   Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vandamme J, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002642
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009
   Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686
   Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312
NR 50
TC 173
Z9 208
U1 0
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2012
VL 72
IS 12
BP 3091
EP 3104
DI 10.1158/0008-5472.CAN-11-3546
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 986NO
UT WOS:000307348500019
PM 22505648
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Vaiopoulos, AG
   Kostakis, ID
   Athanasoula, KC
   Papavassiliou, AG
AF Vaiopoulos, Aristeidis G.
   Kostakis, Ioannis D.
   Athanasoula, Kalliopi Ch.
   Papavassiliou, Athanasios G.
TI Targeting transcription factor corepressors in tumor cells
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Corepressors; HDAC; Inhibitor; Cancer; Therapy
ID ANDROGEN RECEPTOR COREGULATORS; ELEVATED NCOR1 DISRUPTS; BREAST-CANCER
   CELLS; PROSTATE-CANCER; CO-REPRESSORS; NUCLEAR RECEPTORS;
   GENE-EXPRESSION; DEMETHYLASE 1; COMPLEX; GROWTH
AB By being the "integration" center of transcriptional control as they move and target transcription factors, corepressors fine-tune the epigenetic status of the nucleus. Many of them utilize enzymatic activities to modulate chromatin through histone modification or chromatin remodeling. The clinical and etiological relevance of the corepressors to neoplastic growth is increasingly being recognized. Aberrant expression or function (both loss and gain of) of corepressors has been associated with malignancy and contribute to the generation of transcriptional "inflexibility" manifested as distorted signaling along certain axes. Understanding and predicting the consequences of corepressor alterations in tumor cells has diagnostic and prognostic value, and also have the capacity to be targeted through selective epigenetic regimens. Here, we evaluate corepressors with the most promising therapeutic potential based on their physiological roles and involvement in malignant development, and also highlight areas that can be exploited for molecular targeting of a large proportion of clinical cancers and their complications.
C1 [Vaiopoulos, Aristeidis G.; Kostakis, Ioannis D.; Athanasoula, Kalliopi Ch.; Papavassiliou, Athanasios G.] Univ Athens, Sch Med, Dept Biol Chem, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens
RP Papavassiliou, AG (通讯作者)，Univ Athens, Sch Med, Dept Biol Chem, GR-11527 Athens, Greece.
EM papavas@med.uoa.gr
RI Vaiopoulos, Aristeidis/JJE-2503-2023
OI Papavassiliou, Athanasios/0000-0001-5803-4527; Vaiopoulos,
   Aristeidis/0000-0002-8838-5309
CR Abedin SA, 2006, ANTICANCER RES, V26, P2557
   Abedin SA, 2009, CARCINOGENESIS, V30, P449, DOI 10.1093/carcin/bgp005
   Asim M, 2011, J BIOL CHEM, V286, P37108, DOI 10.1074/jbc.M111.292771
   Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Battaglia S, 2010, CARCINOGENESIS, V31, P1650, DOI 10.1093/carcin/bgq086
   Battaglia S, 2010, INT J CANCER, V126, P2511, DOI 10.1002/ijc.25181
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Biancotto C, 2010, ADV GENET, V70, P341, DOI [10.1016/B978-0-12-380866-0.60013-7, 10.1016/S0065-2660(10)70013-4]
   Buchanan G, 2011, MOL CELL ENDOCRINOL, V342, P20, DOI 10.1016/j.mce.2011.05.023
   Campos B, 2011, CANCER SCI, V102, P387, DOI 10.1111/j.1349-7006.2010.01792.x
   Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050
   Cheng YH, 2011, J MOL ENDOCRINOL, V46, P139, DOI 10.1530/JME-10-0064
   Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349
   Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365
   Deng Y, 2010, ONCOGENE, V29, P6603, DOI 10.1038/onc.2010.406
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Eisold M, 2009, J MOL ENDOCRINOL, V42, P429, DOI 10.1677/JME-08-0084
   Ellison-Zelski SJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-263
   Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107
   Graham JS, 2009, EUR J CANCER, V45, P1129, DOI 10.1016/j.ejca.2009.01.003
   Grivas PD, 2011, TRENDS MOL MED, V17, P537, DOI 10.1016/j.molmed.2011.06.005
   Grzenda A, 2009, BBA-GENE REGUL MECH, V1789, P443, DOI 10.1016/j.bbagrm.2009.05.007
   Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562
   Gurevich I, 2007, TOXICOL APPL PHARM, V223, P288, DOI 10.1016/j.taap.2007.05.019
   Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32
   Hong W, 2010, BIOCHEM BIOPH RES CO, V396, P299, DOI 10.1016/j.bbrc.2010.04.085
   Hsia EY, 2010, ADV DRUG DELIVER REV, V62, P1227, DOI 10.1016/j.addr.2010.09.016
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   Hurst DR, 2011, FEBS LETT, V585, P3185, DOI 10.1016/j.febslet.2011.07.045
   Jennings BH, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-205
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kai L, 2010, INT J CANCER, V126, P1538, DOI 10.1002/ijc.24928
   Konduri SD, 2010, P NATL ACAD SCI USA, V107, P15081, DOI 10.1073/pnas.1009575107
   Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091
   Lakowski B, 2006, J MOL NEUROSCI, V29, P227, DOI 10.1385/JMN:29:3:227
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Liu YZ, 2007, CANCER CELL, V11, P483, DOI 10.1016/j.ccr.2007.04.010
   Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012
   Lonard DM, 2007, ENDOCR REV, V28, P575, DOI 10.1210/er.2007-0012
   Manavathi Bramanandam, 2007, Nucl Recept Signal, V5, pe010, DOI 10.1621/nrs.05010
   Mann Monica, 2011, Cancers (Basel), V3, P1691, DOI 10.3390/cancers3021691
   Papaioannou Maria, 2007, Nucl Recept Signal, V5, pe008, DOI 10.1621/nrs.05008
   Payankaulam S, 2010, CURR BIOL, V20, pR764, DOI 10.1016/j.cub.2010.06.037
   Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736
   Ramírez J, 2009, EPIGENETICS-US, V4, P532, DOI 10.4161/epi.4.8.10108
   Reeb CA, 2011, ENDOCRINOLOGY, V152, P2174, DOI 10.1210/en.2011-0149
   Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Silverstein RA, 2005, CURR GENET, V47, P1, DOI 10.1007/s00294-004-0541-5
   Smith KT, 2010, CHEM BIOL, V17, P65, DOI 10.1016/j.chembiol.2009.12.010
   Stewart MD, 2009, PROG MOL BIOL TRANSL, V87, P235, DOI 10.1016/S1877-1173(09)87007-5
   Straza MW, 2010, CELL CYCLE, V9, P3740, DOI 10.4161/cc.9.18.12936
   Thillainadesan G, 2008, MOL CELL BIOL, V28, P6066, DOI 10.1128/MCB.00246-08
   van de Wijngaart DJ, 2012, MOL CELL ENDOCRINOL, V352, P57, DOI 10.1016/j.mce.2011.08.007
   Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Watson PJ, 2012, MOL CELL ENDOCRINOL, V348, P440, DOI 10.1016/j.mce.2011.08.033
   Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433
   Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068
   Zhao LZ, 2010, CELL CYCLE, V9, P3645, DOI 10.4161/cc.9.18.13221
NR 63
TC 12
Z9 15
U1 0
U2 2
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JUN
PY 2012
VL 69
IS 11
BP 1745
EP 1753
DI 10.1007/s00018-012-0986-5
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 943KZ
UT WOS:000304121600001
PM 22527719
OA Green Published
DA 2025-01-12
ER

PT J
AU Lee, H
   Zhang, P
   Herrmann, A
   Yang, CM
   Xin, H
   Wang, ZH
   Hoon, DSB
   Forman, SJ
   Jove, R
   Riggs, AD
   Yu, H
AF Lee, Heehyoung
   Zhang, Peng
   Herrmann, Andreas
   Yang, Chunmei
   Xin, Hong
   Wang, Zhenghe
   Hoon, Dave S. B.
   Forman, Stephen J.
   Jove, Richard
   Riggs, Arthur D.
   Yu, Hua
TI Acetylated STAT3 is crucial for methylation of tumor-suppressor gene
   promoters and inhibition by resveratrol results in demethylation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID NF-KAPPA-B; RECEPTOR CPG ISLAND; HUMAN CANCER-CELLS; ESTROGEN-RECEPTOR;
   REVERSIBLE ACETYLATION; EPIGENETIC THERAPY; DNA METHYLATION; EXPRESSION;
   COLON; CHAIN
AB The mechanisms underlying hypermethylation of tumor-suppressor gene promoters in cancer is not well understood. Here, we report that lysine acetylation of the oncogenic transcription factor STAT3 is elevated in tumors. We also show that genetically altering STAT3 at Lys685 reduces tumor growth, which is accompanied by demethylation and reactivation of several tumor-suppressor genes. Moreover, mutating STAT3 at Lys685 disrupts DNA methyltransferase 1-STAT3 interactions in cultured tumor cells and in tumors. These observations are confirmed by treatment with an acetylation inhibitor, resveratrol. Furthermore, reduction of acetylated STAT3 in triple-negative breast cancer cells leads to demethylation and activation of the estrogen receptor-alpha gene, sensitizing the tumor cells to antiestrogens. Our results also demonstrate a correlation between STAT3 acetylation and methylation of estrogen receptor-alpha in melanoma, which predicts melanoma progression. Taken together, these results suggest a role of STAT3 acetylation in regulating CpG island methylation, which may partially explain aberrant gene silencing in cancer. These findings also provide a rationale for targeting acetylated STAT3 for chemoprevention and cancer therapy.
C1 [Riggs, Arthur D.] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Diabet & Metab Dis, Duarte, CA 91010 USA.
   [Lee, Heehyoung; Herrmann, Andreas; Yang, Chunmei; Xin, Hong; Yu, Hua] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA.
   [Forman, Stephen J.] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Hematopoiet Cell Transplantat, Duarte, CA 91010 USA.
   [Jove, Richard] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA.
   [Zhang, Peng; Wang, Zhenghe] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Zhang, Peng; Wang, Zhenghe] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
   [Hoon, Dave S. B.] John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA.
   [Yu, Hua] Shanghai Zhangjiang High Tech Pk, Ctr Translat Med, Pudong New Area, Shanghai 201203, Peoples R China.
C3 City of Hope; Beckman Research Institute of City of Hope; City of Hope;
   Beckman Research Institute of City of Hope; City of Hope; Beckman
   Research Institute of City of Hope; City of Hope; Beckman Research
   Institute of City of Hope; University System of Ohio; Case Western
   Reserve University; University System of Ohio; Case Western Reserve
   University; John Wayne Cancer Institute
RP Riggs, AD (通讯作者)，City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Diabet & Metab Dis, Duarte, CA 91010 USA.
EM ariggs@coh.org; hyu@coh.org
RI Hoon, Dave/C-7146-2018
OI Riggs, Arthur/0000-0002-8184-5288; YU, Hua/0000-0003-0931-1000; Hoon,
   Dave/0000-0003-1915-3683
FU Markel Foundation; Tim Nesviq Foundation at City of Hope Comprehensive
   Cancer Center; Keck Foundation; National Institutes of Health [R01
   CA115815, R01 CA115674, P30 CA033572]; National Cancer Institute
FX We thank the Functional Genomics Core, Bioinformatics Core, Light
   Microscopy Core, Pathology Core, Flow Cytometry Core, and Animal
   Facility Core at City of Hope Comprehensive Cancer Center for their
   excellent technical assistance. This work is funded by the Markel
   Foundation and Tim Nesviq Foundation at City of Hope Comprehensive
   Cancer Center; the Keck Foundation; and National Institutes of Health
   Grants R01 CA115815 and R01 CA115674, and P30 CA033572 to the City of
   Hope Comprehensive Cancer Center from the National Cancer Institute.
CR Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Chen ZX, 2011, J BIOL CHEM, V286, P18347, DOI 10.1074/jbc.R110.205286
   COCCONI G, 1992, NEW ENGL J MED, V327, P516, DOI 10.1056/NEJM199208203270803
   de Maat MFG, 2007, J CLIN ONCOL, V25, P4887, DOI 10.1200/JCO.2006.09.8921
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Issa JPJ, 1996, CANCER RES, V56, P3655
   JOHNSTON SRD, 1995, CANCER RES, V55, P3331
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lee H, 2011, CANCER RES, V71, P3772, DOI 10.1158/0008-5472.CAN-10-3304
   Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250
   Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mohn Fabio, 2009, V507, P55, DOI 10.1007/978-1-59745-522-0_5
   Mori T, 2006, CANCER RES, V66, P6692, DOI 10.1158/0008-5472.CAN-06-0801
   Nie YZ, 2009, NAT CELL BIOL, V11, P492, DOI 10.1038/ncb1857
   Niu GL, 2005, MOL CELL BIOL, V25, P7432, DOI 10.1128/MCB.25.17.7432-7440.2005
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Ren CH, 2002, MOL CELL BIOL, V22, P3345, DOI 10.1128/MCB.22.10.3345-3357.2002
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Shively JE, 2004, ONCOGENE, V23, P9303, DOI 10.1038/sj.onc.1208266
   Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200
   Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
   Ying J, 2009, BRIT J CANCER, V100, P663, DOI 10.1038/sj.bjc.6604888
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166
   Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
   Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102
   Zhang Q, 2007, NAT MED, V13, P1341, DOI 10.1038/nm1659
   Zhang Q, 2011, P NATL ACAD SCI USA, V108, P11977, DOI 10.1073/pnas.1100319108
   Zhang XD, 2008, NAT METHODS, V5, P163, DOI 10.1038/NMETH1170
NR 43
TC 178
Z9 202
U1 0
U2 23
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 15
PY 2012
VL 109
IS 20
BP 7765
EP 7769
DI 10.1073/pnas.1205132109
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 946QW
UT WOS:000304369800046
PM 22547799
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Ramezani, F
   Salami, S
   Omrani, MD
   Maleki, D
AF Ramezani, Fatemeh
   Salami, Siamak
   Omrani, Mir Davood
   Maleki, Davood
TI CpG Island Methylation Profile of Estrogen Receptor Alpha in Iranian
   Females with Triple Negative or Non-triple Negative Breast Cancer: New
   Marker of Poor Prognosis
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Estrogen receptor alpha; CpG islands methylation; triple negative
   phenotype; breast cancer
ID PROMOTER METHYLATION; GENE PROMOTER; ER-ALPHA; HYPERMETHYLATION;
   EXPRESSION; TAMOXIFEN; REGISTRY; IMPACT; BRCA1; DNA
AB One decade early onset of the breast cancer in Iranian females was reported but the basis of the observed difference has remained unclear and difference in gene silencing by epigenetic processes is suggested. Hence, this study was sought to map the methylation status of estrogen receptor (ER) gene CpG islands and its impact on clinicopathological factors of triple negative and non-triple negative ductal cell carcinoma of the breast in Iranian females. Surgically resected formalin-fixed paraffin-embedded breast tissues from sixty Iranian women with confirmed invasive ductal carcinoma were assessed by methylation-specific PCR using primer sets encompassing some of the 29 CpGs across the ER gene CpG island. The estrogen and progesterone receptors, Her-2(+) overexpression, and nuclear accumulation of P53 were examined using immunohistochemistry (IHC). Methylated ER3, ER4, and ER5 were found in 41.7, 11.3, and 43.3% of the samples, respectively. Significantly higher methylation of ER4 was found in the tumors with nuclear accumulation of P53, and significantly higher methylation of ER5 was found in patients with lymph node involvement and tumor with bigger size or higher grades. Furthermore, significantly higher rate of ER5 methylation was found in patients with Her-2(+) tumors and in postmenopausal patients with ER-, PgR-, or ER-/PgR- tumors. However, no significant difference in ERs methylation status was found between triple negative and non-triple negative tumors in pre- and postmenopausal patients. Findings revealed that aberrant hypermethylation of the ER-alpha gene frequently occurs in Iranian women with invasive ductal cell carcinoma of the breast. However, methylation of different CpG islands produced a diverse impact on the prognosis of breast cancer, and ER5 was found to be the most frequently methylated region in the Iranian women, and could serve as a marker of poor prognosis.
C1 [Salami, Siamak] Shahid Beheshti Univ Med Sci, Fac Med, Dept Clin Biochem, Tehran, Iran.
   [Omrani, Mir Davood] Shahid Beheshti Univ Med Sci, Fac Med, Dept Med Genet, Tehran, Iran.
   [Ramezani, Fatemeh] Urmia Univ Med Sci, Fac Med, Dept Clin Biochem & Nutr, Orumiyeh, Iran.
   [Maleki, Davood] Urmia Univ Med Sci, Fac Med, Dept Hematol & Oncol, Orumiyeh, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Urmia University of Medical Sciences; Urmia University
   of Medical Sciences
RP Salami, S (通讯作者)，Shahid Beheshti Univ Med Sci, Fac Med, Dept Clin Biochem, Tehran, Iran.
EM salami.si@gmail.com
RI Salami, Siamak/G-5327-2011
OI Salami, Siamak/0000-0003-0393-5058
FU office of Vice Chancellor for research and technology, Urmia University
   of Medical Sciences
FX Part of this work was supported by a grant from the office of Vice
   Chancellor for research and technology, Urmia University of Medical
   Sciences.
CR Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Buyru N, 2009, CANCER INVEST, V27, P307, DOI 10.1080/07357900802350814
   Conte P, 2009, EJC SUPPL, V7, P14, DOI 10.1016/S1359-6349(09)70005-9
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Hanstein B, 2004, EUR J ENDOCRINOL, V150, P243, DOI 10.1530/eje.0.1500243
   Harirchi I, 2000, PUBLIC HEALTH, V114, P143, DOI 10.1016/S0033-3506(00)00324-3
   Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Kolahdoozan S, 2010, ARCH IRAN MED, V13, P143
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Le Romancer M, 2010, STEROIDS, V75, P560, DOI 10.1016/j.steroids.2010.01.013
   Lee JS, 2008, CANCER BIOL THER, V7, P1400
   Liu CG, 2010, MED ONCOL, V27, P747, DOI 10.1007/s12032-009-9279-8
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mohagheghi MA, 2009, ARCH IRAN MED, V12, P15
   Mousavi SM, 2007, BREAST J, V13, P383, DOI 10.1111/j.1524-4741.2007.00446.x
   Mousavi SM, 2008, ASIAN PAC J CANCER P, V9, P275
   Mousavi Seyed Mohsen, 2006, Asian Pac J Cancer Prev, V7, P571
   Parl FF, 2003, PHARMACOGENOMICS J, V3, P251, DOI 10.1038/sj.tpj.6500201
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004
   Rasti M, 2009, IRAN J MED SCI, V34, P186
   Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016
   Sadjadi Alireza, 2005, Asian Pac J Cancer Prev, V6, P359
   Salami S, 2003, CLIN BIOCHEM, V36, P247, DOI 10.1016/S0009-9120(03)00007-9
   Salami S, 2011, ASIAN PAC J CANCER P, V12, P719
   Seal MD, 2010, CANCER J, V16, P12, DOI 10.1097/PPO.0b013e3181cf04be
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Vahdaninia Mariam, 2004, Asian Pac J Cancer Prev, V5, P223
   Viale Giuseppe, 2009, Eur J Cancer, V45 Suppl 1, P5, DOI 10.1016/S0959-8049(09)70011-5
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 37
TC 12
Z9 12
U1 0
U2 0
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2012
VL 13
IS 2
BP 451
EP 457
DI 10.7314/APJCP.2012.13.2.451
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 942WK
UT WOS:000304081800007
PM 22524805
OA Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Rubinek, T
   Shulman, M
   Israeli, S
   Bose, S
   Avraham, A
   Zundelevich, A
   Evron, E
   Gal-Yam, EN
   Kaufman, B
   Wolf, I
AF Rubinek, Tami
   Shulman, Michal
   Israeli, Shira
   Bose, Shikha
   Avraham, Ayelet
   Zundelevich, Adi
   Evron, Ella
   Gal-Yam, Einav Nili
   Kaufman, Bella
   Wolf, Ido
TI Epigenetic silencing of the tumor suppressor klotho in human breast
   cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Klotho; Breast cancer; Methylation; Histone acetylation
ID TRANSCRIPTS ENCODING MEMBRANE; PROMOTER METHYLATION; MOLECULAR-CLONING;
   CELL-LINE; GENE; GROWTH; EXPRESSION; PROTEIN; PROGRESSION; CARCINOMA
AB Klotho is a single pass transmembrane protein, associated with premature aging. We identified tumor suppressor activities for klotho, associated with reduced expression in breast cancer. We now aimed to analyze klotho expression in early stages of breast tumorigenesis and elucidate mechanisms leading to klotho silencing in breast tumors. We studied klotho expression, using immunohistochemistry, and found high klotho expression in all normal and mild hyperplasia samples, whereas reduced expression was associated with moderate and atypical ductal hyperplasia. Promoter methylation and histone deacetylation were studied as possible mechanisms for klotho silencing. Using bisulfite sequencing, and methylation-specific PCR, we identified KLOTHO promoter methylation in five breast cancer cell lines and in hyperplastic MCF-12A cells, but not in the non-tumorous mammary cell line HB2. Importantly, methylation status inversely correlated with klotho mRNA levels, and treatment of breast caner cells with 5-aza-2-deoxycytidine elevated klotho expression by up to 150-fold. KLOTHO promoter methylation was detected in 8/23 of breast cancer samples but not in normal breast samples. Chromatin immunoprecipitation revealed that in HB2 KLOTHO promoter was enriched with AcH3K9; however, in breast cancer cells, H3K9 was deacetylated, and treatment with the histone deacetylase inhibitor suberoylanilide bishydroxamide (SAHA) restored H3K9 acetylation. Taken together, these data indicate loss of klotho expression as an early event in breast cancer development, and suggest a role for DNA methylation and histone deacetylation in klotho silencing. Klotho expression and methylation may, therefore, serve as early markers for breast tumorigenesis.
C1 [Rubinek, Tami; Shulman, Michal; Israeli, Shira; Zundelevich, Adi; Gal-Yam, Einav Nili; Kaufman, Bella; Wolf, Ido] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel.
   [Bose, Shikha] Cedars Sinai Med Ctr, Dept Anat Pathol, Los Angeles, CA 90048 USA.
   [Avraham, Ayelet; Evron, Ella] Assaf Harofeh Med Ctr, Dept Oncol, IL-70300 Zerifin, Israel.
   [Evron, Ella; Wolf, Ido] Tel Aviv Univ, IL-69978 Tel Aviv, Israel.
C3 Chaim Sheba Medical Center; Cedars Sinai Medical Center; Shamir Medical
   Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University
RP Rubinek, T (通讯作者)，Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Ramat Gan, Israel.
EM tamar.rubinek@sheba.health.gov.il
OI Gal-Yam, Einav/0000-0003-1059-7923; Evron, Ella/0000-0002-1003-5042
FU Sheba Medical Center; Chief Scientist Office of the Ministry of Health,
   Israel [4055_3]; Israel Cancer Association; Israel Science Foundation;
   "Talpiut" Sheba Career Development Award; Sackler Faculty of Medicine,
   Tel Aviv University, Tel Aviv, Israel
FX This research was supported by The Riva and Joel Koschitzky Fund for
   Breast Cancer Research at the Sheba Medical Center; the Chief Scientist
   Office of the Ministry of Health, Israel (grant no. 4055_3 to IW); the
   Israel Cancer Association Research Grant; The Israel Science Foundation
   (to I. W.); the "Talpiut" Sheba Career Development Award; and the
   Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
CR Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105
   Chen B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-99
   Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104
   Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Geck P, 2000, P NATL ACAD SCI USA, V97, P10185, DOI 10.1073/pnas.97.18.10185
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Hoque MO, 2009, CANCER EPIDEM BIOMAR, V18, P2694, DOI 10.1158/1055-9965.EPI-08-0821
   Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090
   Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc
   Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lu L, 2008, CANCER INVEST, V26, P185, DOI 10.1080/07357900701638343
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
   Ohyama Y, 1998, BIOCHEM BIOPH RES CO, V251, P920, DOI 10.1006/bbrc.1998.9576
   Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003
   Schnitt SJ, 2003, AM J SURG PATHOL, V27, P836, DOI 10.1097/00000478-200306000-00017
   SCHOTT DR, 1994, CANCER RES, V54, P1393
   SCHUTTE M, 1995, CANCER RES, V55, P4570
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Wang XL, 2011, ONCOL REP, V25, P1465, DOI 10.3892/or.2011.1178
   Wolf I, 2005, LANCET ONCOL, V6, P103, DOI 10.1016/S1470-2045(05)01736-5
   Wolf I, 2010, ONCOGENE, V29, P26, DOI 10.1038/onc.2009.301
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   Wolf I, 2007, BREAST CANCER RES TR, V105, P139, DOI 10.1007/s10549-006-9440-4
   Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389
   Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368
   Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963
NR 36
TC 81
Z9 85
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2012
VL 133
IS 2
BP 649
EP 657
DI 10.1007/s10549-011-1824-4
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 949XJ
UT WOS:000304610600023
PM 22042362
DA 2025-01-12
ER

PT J
AU Simpson, NE
   Tryndyak, VP
   Beland, FA
   Pogribny, IP
AF Simpson, Natalie E.
   Tryndyak, Volodymyr P.
   Beland, Frederick A.
   Pogribny, Igor P.
TI An in vitro investigation of metabolically sensitive biomarkers in
   breast cancer progression
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Epigenetics; Glutamine metabolism; Histone acetylation;
   Biomarkers
ID MAMMARY EPITHELIAL-CELLS; E-CADHERIN EXPRESSION; NF-KAPPA-B; MESENCHYMAL
   TRANSITION; HISTONE MODIFICATIONS; GROWTH; TRIMETHYLATION; EPIGENETICS;
   PROTEIN; SIRT6
AB Epigenetic biomarkers are emerging as determinants of breast cancer prognosis. Breast cancer cells display unique alterations in major cellular metabolic pathways and it is becoming widely recognized that enzymes that regulate epigenetic alterations are metabolically sensitive. In this study, we used microarray data from the GEO database to compare gene expression for regulators of metabolism and epigenetic alterations among non-invasive epithelial (MCF-7, MDA-MB-361, and T-47D) and invasive mesenchymal (MDA-MB-231, Hs-578T, and BT-549) breast cancer cell lines. The expression of genes, including GLS1, GFPT2, LDHA, HDAC9, MYST2, and SUV420H2, was assessed using RT-PCR. There was differential expression between epithelial and mesenchymal cell lines. MYST2 and SUV420H2 regulate the levels of the epigenetic biomarkers histone H4 lysine 16 acetylation (H4K16ac) and histone H4 lysine 20 trimethylation (H4K20me3), respectively. Reduced amounts of H4K16ac and H4K20me3 correlated with lower levels of MYST2 and SUV420H2 in mesenchymal cells and, along with reduced amounts of histone H3 lysine 9 acetylation (H3K9ac), were found to distinguish epithelial from mesenchymal cells. In addition, both GLS1 and GFPT2 play roles in glutamine metabolism and were observed to be more highly expressed in mesenchymal cell lines, and when glutamine and glutamate levels reported in the NCI-60 metabolomics dataset were compared, the ratio of glutamate/glutamine was found to be higher in mesenchymal cells. Blocking the conversion of glutamine to glutamate using an allosteric inhibitor, Compound 968, against GLS1, increased H4K16ac in T-47D and MDA-MB-231 cells, linking glutamine metabolism to a particular histone modification in breast cancer. These findings support the concept that metabolically sensitive histone modifications and corresponding histone modifying enzymes can be used as diagnostic and prognostic biomarkers for breast cancer. It also further emphasizes the importance of glutamine metabolism in tumor progression and that inhibitors of cellular metabolic pathways may join histone deacetylase inhibitors as a form of epigenetic therapy.
C1 [Simpson, Natalie E.; Tryndyak, Volodymyr P.; Beland, Frederick A.; Pogribny, Igor P.] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA)
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
OI Tryndyak, Volodymyr/0000-0002-8319-2954; Beland,
   Frederick/0000-0002-2113-6260
CR Asiago VM, 2010, CANCER RES, V70, P8309, DOI 10.1158/0008-5472.CAN-10-1319
   Bhattacharya S, 2009, BIOCHEM SOC T, V37, P855, DOI 10.1042/BST0370855
   BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5
   Burgio G, 2010, BBA-GENE REGUL MECH, V1799, P671, DOI 10.1016/j.bbagrm.2010.05.007
   Choi YL, 2010, CANCER RES, V70, P2296, DOI 10.1158/0008-5472.CAN-09-3141
   Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gao Z, 2011, BIOCHEM BIOPH RES CO, V404, P428, DOI 10.1016/j.bbrc.2010.11.138
   Gilles C, 1999, J CELL SCI, V112, P4615
   Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612
   GOLDMAN RD, 1964, CANCER RES, V24, P389
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kapoor-Vazirani P, 2011, MOL CELL BIOL, V31, P1594, DOI 10.1128/MCB.00524-10
   Kashiwagi S, 2010, BRIT J CANCER, V103, P249, DOI 10.1038/sj.bjc.6605735
   Kim HJ, 2007, MOL CELL BIOL, V27, P3165, DOI 10.1128/MCB.01315-06
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Kurdistani SK, 2011, PROG DRUG RES, V67, P91, DOI 10.1007/978-3-7643-8989-5_5
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723
   McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008
   Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736
   Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395
   Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x
   Nanda R, 2007, REV RECENT CLIN TRIA, V2, P111, DOI 10.2174/157488707780599375
   Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200
   Richardson AD, 2008, BREAST CANCER RES TR, V110, P297, DOI 10.1007/s10549-007-9732-3
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schwer B, 2010, P NATL ACAD SCI USA, V107, P21790, DOI 10.1073/pnas.1016306107
   Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Sparano JA, 2008, J CLIN ONCOL, V26, P721, DOI 10.1200/JCO.2008.16.7528
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652
   Teperino R, 2010, CELL METAB, V12, P321, DOI 10.1016/j.cmet.2010.09.004
   Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058
   Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148
   Tryndyak VP, 2006, CANCER BIOL THER, V5, P65, DOI 10.4161/cbt.5.1.2288
   Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009
   Wang WZ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-140
   Warburg O., 1925, KLIN WOCHENSCHR, V4, P534
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
NR 50
TC 58
Z9 65
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2012
VL 133
IS 3
BP 959
EP 968
DI 10.1007/s10549-011-1871-x
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 967NM
UT WOS:000305914900015
PM 22101407
DA 2025-01-12
ER

PT J
AU Xu, XR
   Gammon, MD
   Hernandez-Vargas, H
   Herceg, Z
   Wetmur, JG
   Teitelbaum, SL
   Bradshaw, PT
   Neugut, AI
   Santella, RM
   Chen, J
AF Xu, Xinran
   Gammon, Marilie D.
   Hernandez-Vargas, Hector
   Herceg, Zdenko
   Wetmur, James G.
   Teitelbaum, Susan L.
   Bradshaw, Patrick T.
   Neugut, Alfred I.
   Santella, Regina M.
   Chen, Jia
TI DNA methylation in peripheral blood measured by LUMA is associated with
   breast cancer in a population-based study
SO FASEB JOURNAL
LA English
DT Article
DE epigenetics; biomarker; 1-carbon metabolism
ID ONE-CARBON METABOLISM; RISK-FACTORS; LONG-ISLAND; HYPOMETHYLATION;
   POLYMORPHISM; SUSCEPTIBILITY; LEUKOCYTES; BIOMARKER; LINE-1; MTHFR
AB Our purpose was to identify epigenetic markers of breast cancer risk, which can be reliably measured in peripheral blood and are amenable for large population screening. We used 2 independent assays, luminometric methylation assay (LUMA) and long interspersed elements-1 (LINE-1) to measure "global methylation content" in peripheral blood DNA from a well-characterized population-based case-control study. We examined associations between methylation levels and breast cancer risk among 1055 cases and 1101 controls and potential influences of 1-carbon metabolism on global methylation. Compared with women in the lowest quintile of LUMA methylation, those in the highest quintile had a 2.41-fold increased risk of breast cancer (95% confidence interval: 1.83-3.16; P, trend<0.0001). The association did not vary by other key tumor characteristics and lifestyle risk factors. Consistent with LUMA findings, genome-wide methylation profiling of a subset of samples revealed greater promoter hypermethylation in breast cancer case participants (P=0.04); higher LUMA was associated with higher promoter methylation in the controls (P=0.05). LUMA levels were also associated with functional sodium nitroprusside in key 1-carbon metabolizing genes, MTHFR C677T (P=0.001) and MTRR A66G (P=0.018). LINE-1 methylation was associated with neither breast cancer risk nor 1-carbon metabolism. Our results show that global promoter hypermethylation measured in peripheral blood was associated with breast cancer risk.-Xu, X., Gammon, M. D., Hernandez-Vargas, H., Herceg, Z., Wetmur, J. G., Teitelbaum, S. L., Bradshaw, P. T., Neugut, A. I., Santella, R. M., Chen, J. DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study. FASEB J. 26, 2657-2666 (2012). www.fasebj.org
C1 [Xu, Xinran; Teitelbaum, Susan L.; Chen, Jia] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA.
   [Wetmur, James G.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.
   [Wetmur, James G.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
   [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
   [Xu, Xinran] Tongji Univ, Shanghai E Hosp, Sch Med, Res Ctr Translat Med,Minist Educ, Shanghai 200120, Peoples R China.
   [Xu, Xinran] Tongji Univ, Shanghai E Hosp, Sch Med, Minist Educ,Key Lab Arrhythmias, Shanghai 200120, Peoples R China.
   [Gammon, Marilie D.; Bradshaw, Patrick T.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Epidemiol, New York, NY USA.
   [Neugut, Alfred I.] Columbia Univ, Dept Med, New York, NY USA.
   [Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA.
   [Hernandez-Vargas, Hector; Herceg, Zdenko] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon, France.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Tongji
   University; Tongji University; University of North Carolina; University
   of North Carolina Chapel Hill; Columbia University; Columbia University;
   Columbia University; World Health Organization; International Agency for
   Research on Cancer (IARC)
RP Chen, J (通讯作者)，Mt Sinai Sch Med, Dept Prevent Med, Box 1057,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM xu_xinran@hotmail.com; jia.chen@mssm.edu
RI Bradshaw, Patrick/AAJ-7529-2021; Herceg, Zdenko/JOZ-6188-2023
OI Hernandez-Vargas, Hector/0000-0001-6045-2103; Xu,
   Xinran/0000-0001-6435-8181
FU U.S. National Cancer Institute [R01CA109753, 3R01CA109753-04S1];
   Department of Defense [BC031746, W81XWH-06-1-0298]; National Cancer
   Institute; National Institute of Environmental Health and Sciences
   [UO1CA/ES66572, UO1CA66572, P30CA013696, P30ES009089, P30ES10126]
FX This work was supported by grants from the U.S. National Cancer
   Institute (R01CA109753 and 3R01CA109753-04S1) and in part by grants from
   Department of Defense (BC031746 and W81XWH-06-1-0298) and National
   Cancer Institute and National Institute of Environmental Health and
   Sciences (UO1CA/ES66572, UO1CA66572, P30CA013696, P30ES009089, and
   P30ES10126). The authors acknowledge the invaluable help of Dr. Thomas
   Kraus, who performed cell fractionation, and Alexander Rialdi, who
   performed the LUMA assay for the fractionated cells.
CR [Anonymous], 2012, Nutritional epidemiology
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Brody T., 1994, NUTR BIOCH
   Brooks JD, 2010, CANCER EPIDEMIOL, V34, P717, DOI 10.1016/j.canep.2010.05.006
   Castro R, 2004, J MED GENET, V41, P454, DOI 10.1136/jmg.2003.017244
   Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Estécio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   Figueiredo JC, 2009, CANCER EPIDEM BIOMAR, V18, P1041, DOI 10.1158/1055-9965.EPI-08-0926
   Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854
   Gammon MD, 2002, CANCER EPIDEM BIOMAR, V11, P677
   Gaudet MM, 2004, CANCER EPIDEM BIOMAR, V13, P1485
   Graziano F, 2006, INT J CANCER, V118, P628, DOI 10.1002/ijc.21397
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961
   Matthews RG, 2007, CLIN CHEM LAB MED, V45, P1700, DOI 10.1515/CCLM.2007.324
   McKay JA, 2011, MOL NUTR FOOD RES, V55, P1026, DOI 10.1002/mnfr.201100008
   Medvedeva YA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-48
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   RUSSO J, 1998, FRONT BIOSCI, V3, P944, DOI DOI 10.2741/A335
   Sohn KJ, 2009, INT J CANCER, V124, P1999, DOI 10.1002/ijc.24003
   Stern LL, 2000, CANCER EPIDEM BIOMAR, V9, P849
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Xu XR, 2008, CANCER EPIDEM BIOMAR, V17, P2109, DOI 10.1158/1055-9965.EPI-07-2900
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
   Xu XR, 2007, CARCINOGENESIS, V28, P1504, DOI 10.1093/carcin/bgm061
   Xu XR, 2007, AM J CLIN NUTR, V85, P1098, DOI 10.1093/ajcn/85.4.1098
   Xu XR, 2009, FASEB J, V23, P4022, DOI 10.1096/fj.09-136507
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zeisel SH, 2003, J NUTR, V133, P1302
NR 41
TC 71
Z9 77
U1 0
U2 14
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2012
VL 26
IS 6
BP 2657
EP 2666
DI 10.1096/fj.11-197251
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 955KI
UT WOS:000305017200041
PM 22371529
OA Green Published
DA 2025-01-12
ER

PT J
AU Sleeman, JP
   Christofori, G
   Fodde, R
   Collard, JG
   Berx, G
   Decraene, C
   Rüegg, C
AF Sleeman, Jonathan P.
   Christofori, Gerhard
   Fodde, Riccardo
   Collard, John G.
   Berx, Geert
   Decraene, Charles
   Rueegg, Curzio
TI Concepts of metastasis in flux: The stromal progression model
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Article
DE Metastasis; Seed and soil; Clonal selection; Parallel progression; EMT;
   Cancer stem cell; Metastatic niche; Microenvironment; Stromal
   progression
ID EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULATING TUMOR-CELLS; CANCER
   STEM-CELLS; BREAST-CANCER; TGF-BETA; CARCINOMA-CELLS; BONE-MARROW;
   LYMPH-NODE; E-CADHERIN; COLORECTAL-CANCER
AB The ability of tumor cells to leave a primary tumor, to disseminate through the body, and to ultimately seed new secondary tumors is universally agreed to be the basis for metastasis formation. An accurate description of the cellular and molecular mechanisms that underlie this multistep process would greatly facilitate the rational development of therapies that effectively allow metastatic disease to be controlled and treated. A number of disparate and sometimes conflicting hypotheses and models have been suggested to explain various aspects of the process, and no single concept explains the mechanism of metastasis in its entirety or encompasses all observations and experimental findings. The exciting progress made in metastasis research in recent years has refined existing ideas, as well as giving rise to new ones. In this review we survey some of the main theories that currently exist in the field, and show that significant convergence is emerging, allowing a synthesis of several models to give a more comprehensive overview of the process of metastasis. As a result we postulate a stromal progression model of metastasis. In this model, progressive modification of the tumor microenvironment is equally as important as genetic and epigenetic changes in tumor cells during primary tumor progression. Mutual regulatory interactions between stroma and tumor cells modify the stemness of the cells that drive tumor growth, in a manner that involves epithelial-mesenchymal and mesenchymal-epithelial-like transitions. Similar interactions need to be recapitulated at secondary sites for metastases to grow. Early disseminating tumor cells can progress at the secondary site in parallel to the primary tumor, both in terms of genetic changes, as well as progressive development of a metastatic stroma. Although this model brings together many ideas in the field, there remain nevertheless a number of major open questions, underscoring the need for further research to fully understand metastasis, and thereby identify new and effective ways of treating metastatic disease. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Sleeman, Jonathan P.] Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, D-68167 Mannheim, Germany.
   [Christofori, Gerhard] Univ Basel, Inst Biochem & Genet, Dept Biomed, CH-4058 Basel, Switzerland.
   [Fodde, Riccardo] Erasmus MC, Josephine Netkens Inst, Dept Pathol, Rotterdam, Netherlands.
   [Collard, John G.] Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands.
   [Berx, Geert] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol & Cellular Oncol, B-9052 Ghent, Belgium.
   [Berx, Geert] Univ Ghent, Dept Biomed Biol, B-9052 Ghent, Belgium.
   [Decraene, Charles] Inst Curie, Translat Res Dept, Ctr Rech, Paris, France.
   [Decraene, Charles] CNRS, UMR144, Paris, France.
   [Rueegg, Curzio] Univ Fribourg, Dept Med, Fac Sci, CH-1700 Fribourg, Switzerland.
C3 Ruprecht Karls University Heidelberg; University of Basel; Erasmus
   University Rotterdam; Erasmus MC; Netherlands Cancer Institute; Flanders
   Institute for Biotechnology (VIB); Ghent University; Ghent University;
   UNICANCER; Universite PSL; Institut Curie; Sorbonne Universite; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB); Universite PSL; UNICANCER; Institut Curie;
   University of Fribourg
RP Sleeman, JP (通讯作者)，Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, TRIDOMUS Gebaude Haus C,Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.
EM Sleeman@medma.uni-heidelberg.de
RI Fodde, Riccardo/IIS-2405-2023; Sleeman, Jonathan/H-2515-2013
OI Berx, Geert/0000-0001-5770-2458; Sleeman, Jonathan/0000-0003-1718-7687;
   Fodde, Riccardo/0000-0001-9839-4324
FU European Union [HEALTH-F2-2008-201662]
FX All authors gratefully acknowledge funding from the European Union under
   the auspices of the FP7 collaborative project TuMIC, Contract No.
   HEALTH-F2-2008-201662.
CR Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356
   Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027
   Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525
   Bednarz-Knoll N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2940
   Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a
   Bertran E, 2009, CELL SIGNAL, V21, P1595, DOI 10.1016/j.cellsig.2009.06.006
   Berx G, 2007, CLIN EXP METASTAS, V24, P587, DOI 10.1007/s10585-007-9114-6
   Bidard FC, 2010, ANN ONCOL, V21, P729, DOI 10.1093/annonc/mdp391
   Blanco MJ, 2007, DEVELOPMENT, V134, P4073, DOI 10.1242/dev.006858
   Borovski T, 2011, CANCER RES, V71, P634, DOI 10.1158/0008-5472.CAN-10-3220
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Browne G, 2010, CELL CYCLE, V9, P886, DOI 10.4161/cc.9.5.10839
   Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Cameron MD, 2000, CANCER RES, V60, P2541
   Castellana D, 2009, CANCER RES, V69, P785, DOI 10.1158/0008-5472.CAN-08-1946
   Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001
   Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025
   Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872
   Cichon MA, 2010, J MAMMARY GLAND BIOL, V15, P389, DOI 10.1007/s10911-010-9195-8
   Comen E, 2011, NAT REV CLIN ONCOL, V8, P369, DOI 10.1038/nrclinonc.2011.64
   Comen EA, 2011, J CLIN ONCOL, V29, P2610, DOI 10.1200/JCO.2011.36.1873
   Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048
   Cristofanilli M, 2005, J CLIN ONCOL, V23, P1420, DOI 10.1200/JCO.2005.08.140
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Cristofanilli M, 2010, JAMA-J AM MED ASSOC, V303, P1092, DOI 10.1001/jama.2010.292
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Davalos V, 2011, ONCOGENE
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Dohadwala M, 2010, OTOLARYNG HEAD NECK, V142, P753, DOI 10.1016/j.otohns.2010.01.034
   Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Ellenbroek SIJ, 2012, SEMIN CANCER BIOL, V22, P208, DOI 10.1016/j.semcancer.2012.02.012
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Ennis RD, 1997, CANCER, V79, P2402, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2402::AID-CNCR16>3.0.CO;2-V
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Ewing J., 1928, Neoplastic diseases: a treatise on tumors
   Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002
   Fehm T, 2010, BREAST CANCER RES TR, V124, P403, DOI 10.1007/s10549-010-1163-x
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927
   Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5
   Fischer ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121
   Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184
   Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973
   Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397
   Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040
   GOLDMAN EE, 1906, LANCET, V1, P23
   Gonzaga-Jauregui C, 2012, ANNU REV MED, V63, P35, DOI 10.1146/annurev-med-051010-162644
   Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794
   Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507
   Hofstetter CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030059
   Horak CE, 2008, APMIS, V116, P586, DOI 10.1111/j.1600-0463.2008.01213.x
   Huang CY, 2009, J CELL PHYSIOL, V221, P204, DOI 10.1002/jcp.21846
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   ISRAELI RS, 1994, CANCER RES, V54, P6306
   Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822
   Kallergi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2149
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407
   KERBEL RS, 1988, CANCER SURV, V7, P597
   Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627
   Knutsen T, 1998, GENE CHROMOSOME CANC, V23, P44, DOI 10.1002/(SICI)1098-2264(199809)23:1<44::AID-GCC7>3.0.CO;2-6
   Kuukasjarvi T, 1997, CANCER RES, V57, P1597
   Le NH, 2008, BRIT J CANCER, V98, P1886, DOI 10.1038/sj.bjc.6604401
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Leight JL, 2012, MOL BIOL CELL
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Lin Q, 2010, CANCER BIOL THER, V9, P949, DOI 10.4161/cbt.9.12.12347
   LING V, 1985, CANCER METAST REV, V4, P173, DOI 10.1007/BF00050694
   Liu MC, 2009, J CLIN ONCOL, V27, P5153, DOI 10.1200/JCO.2008.20.6664
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Lukanidin E, 2012, SEMIN CANCER BIOL, V22, P216, DOI 10.1016/j.semcancer.2012.02.006
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406
   Melchior SW, 1997, CLIN CANCER RES, V3, P249
   Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362
   López-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011
   Molloy TJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2898
   Morgan TM, 2009, CLIN CANCER RES, V15, P677, DOI 10.1158/1078-0432.CCR-08-1754
   Mori M, 1996, INT J CANCER, V68, P739
   Morra L, 2011, VIRCHOWS ARCH, V459, P465, DOI 10.1007/s00428-011-1151-5
   Munzone E, 2010, CLIN BREAST CANCER, V10, P392, DOI 10.3816/CBC.2010.n.052
   Naumov GN, 2003, BREAST CANCER RES TR, V82, P199, DOI 10.1023/B:BREA.0000004377.12288.3c
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619
   Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008-5472.CAN-09-3880
   Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Onoue T, 2006, INT J ONCOL, V29, P1133
   Orlichenko LS, 2008, CLIN EXP METASTAS, V25, P593, DOI 10.1007/s10585-008-9143-9
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0
   Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Pantel K, 2007, NAT CLIN PRACT ONCOL, V4, P62, DOI 10.1038/ncponc0737
   Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781
   Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621
   Psaila B.LydenD, 2011, J THROMB HAEMOST
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Rhodes LV, 2011, EXP CELL RES, V317, P2573, DOI 10.1016/j.yexcr.2011.08.016
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Riethdorf S, 2010, CLIN CANCER RES, V16, P2634, DOI 10.1158/1078-0432.CCR-09-2042
   Santos SCL, 2008, CYTOGENET GENOME RES, V122, P16, DOI 10.1159/000151311
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292
   Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108
   Schrader J, 2011, HEPATOLOGY, V53, P1192, DOI 10.1002/hep.24108
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Singh A, 2009, CELL CYCLE, V8, P2676, DOI 10.4161/cc.8.17.9336
   Sleeman JP, 2011, CELL, V145, DOI 10.1016/j.cell.2011.03.029
   Sleeman JP, 2011, INT J CANCER, V128, P2511, DOI 10.1002/ijc.26027
   Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916
   Sugarbaker EV., 1981, CANCER BIOL REV, V2, P235
   Taki M, 2008, ONCOL REP, V19, P993
   Talmadge JE, 2007, CANCER RES, V67, P11471, DOI 10.1158/0008-5472.CAN-07-2496
   Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13
   Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699
   Théry C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Torres L, 2007, BREAST CANCER RES TR, V102, P143, DOI 10.1007/s10549-006-9317-6
   Tran DD, 2011, MOL CANCER RES, V9, P1644, DOI 10.1158/1541-7786.MCR-11-0371
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang XY, 2008, BBA-MOL BASIS DIS, V1782, P51, DOI 10.1016/j.bbadis.2007.11.002
   Wang Z, 2008, BRIT J CANCER, V99, P1695, DOI 10.1038/sj.bjc.6604745
   Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100
   Weiss L, 2000, CANCER METAST REV, V19, P193, DOI 10.1023/A:1010646304844
   Weitz J, 1998, CLIN CANCER RES, V4, P343
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108
   Wong CC, 2012, J MOL MED BERL
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262
   Yilmaz M, 2011, EMBO J, V30, P4489, DOI 10.1038/emboj.2011.319
   Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021
   Zumsteg A, 2009, CURR OPIN ONCOL, V21, P60, DOI 10.1097/CCO.0b013e32831bed7e
NR 183
TC 71
Z9 78
U1 0
U2 22
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
EI 1096-3650
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD JUN
PY 2012
VL 22
IS 3
BP 174
EP 186
DI 10.1016/j.semcancer.2012.02.007
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 956TE
UT WOS:000305111200002
PM 22374376
OA Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Zeng, HM
   Irwin, ML
   Lu, LG
   Risch, H
   Mayne, S
   Mu, LN
   Deng, Q
   Scarampi, L
   Mitidieri, M
   Katsaros, D
   Yu, H
AF Zeng, Hongmei
   Irwin, Melinda L.
   Lu, Lingeng
   Risch, Harvey
   Mayne, Susan
   Mu, Lina
   Deng, Qian
   Scarampi, Luca
   Mitidieri, Marco
   Katsaros, Dionyssios
   Yu, Herbert
TI Physical activity and breast cancer survival: an epigenetic link through
   reduced methylation of a tumor suppressor gene L3MBTL1
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Physical activity; Survival; DNA methylation; L3MBTL1; Tumor suppressor
   gene
ID RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; FASTING INSULIN;
   CLINICAL-TRIAL; GROWTH-FACTORS; YALE EXERCISE; EXPRESSION;
   HYPERMETHYLATION; SURVIVORSHIP; PROGRESSION
AB The study was conducted to determine the effect of physical activity on DNA methylation and to predict the consequence of this effect concerning gene expression and breast cancer survival. Blood samples, collected from 12 breast cancer patients who participated in a randomized clinical trial of exercise, were examined for exercise-related changes in DNA methylation using a methylation microarray. Tumor samples of 348 breast cancer patients were analyzed with qRT-PCR and qMSP to determine gene expression and methylation identified in the microarray analysis. Cox regression models were developed to predict survival outcomes in association with gene expression and methylation. After 6 months of moderate-intensity aerobic exercise, changes in DNA methylation (P < 5 x 10(-5)) in peripheral blood leukocytes were detected in 43 genes from a panel of 14 495. Based on the list, we analyzed gene expression in association with overall survival in breast tumors and found three genes whose methylation was reduced after exercise were favorably in association with overall survival, i.e., higher expression associated with better survival. Of the three genes, L3MBTL1 was a putative tumor suppressor gene with known function to repress chromatin for transcription, which is activated mainly in germline stem cells. Further analyses of tumor features among patients indicated that high expression of L3MBTL1 was associated with low grade and hormone receptor-positive tumors, as well as low risk of disease recurrence and breast cancer death. In conclusion, the study suggests that increasing physical activity after a breast cancer diagnosis may affect epigenetic regulation of tumor suppressor genes, which have favorable impacts on survival outcomes of breast cancer patients.
C1 [Zeng, Hongmei; Irwin, Melinda L.; Lu, Lingeng; Risch, Harvey; Mayne, Susan; Deng, Qian; Yu, Herbert] Yale Univ, Sch Publ Hlth, Yale Canc Ctr, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Zeng, Hongmei] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Minist Educ, Dept Canc Epidemiol,Key Lab Carcinogenesis & Tran, Beijing 100871, Peoples R China.
   [Mu, Lina] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14214 USA.
   [Scarampi, Luca; Mitidieri, Marco; Katsaros, Dionyssios] Univ Turin, Dept Obstet & Gynecol, Gynecol Oncol & Breast Canc Unit, Turin, Italy.
C3 Yale University; Peking University; State University of New York (SUNY)
   System; University at Buffalo, SUNY; University of Turin
RP Yu, H (通讯作者)，Yale Univ, Sch Publ Hlth, Yale Canc Ctr, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.
EM herbert.yu@yale.edu
OI Zeng, Hongmei/0000-0003-3999-3081
CR Addou-Klouche L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-213
   Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009
   Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004
   Bench AJ, 2004, BRIT J HAEMATOL, V127, P509, DOI 10.1111/j.1365-2141.2004.05278.x
   Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200
   Bonasio R, 2010, SEMIN CELL DEV BIOL, V21, P221, DOI 10.1016/j.semcdb.2009.09.010
   Buehmeyer K, 2008, ANN ANAT, V190, P71, DOI 10.1016/j.aanat.2007.04.002
   Coyle YM, 2007, CANCER EPIDEM BIOMAR, V16, P192, DOI 10.1158/1055-9965.EPI-06-0700
   DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746
   Fairey AS, 2003, CANCER EPIDEM BIOMAR, V12, P721
   Goodwin PJ, 2002, BREAST CANCER RES TR, V74, P65, DOI 10.1023/A:1016075709022
   Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42
   Holick CN, 2008, CANCER EPIDEM BIOMAR, V17, P379, DOI 10.1158/1055-9965.EPI-07-0771
   Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479
   Irwin ML, 2008, J CLIN ONCOL, V26, P3958, DOI 10.1200/JCO.2007.15.9822
   Irwin ML, 2008, CANCER-AM CANCER SOC, V112, P2593, DOI 10.1002/cncr.23446
   Irwin ML, 2009, CANCER EPIDEM BIOMAR, V18, P306, DOI 10.1158/1055-9965.EPI-08-0531
   Janic A, 2010, SCIENCE, V330, P1824, DOI 10.1126/science.1195481
   Ligibel JA, 2008, J CLIN ONCOL, V26, P907, DOI 10.1200/JCO.2007.12.7357
   Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544
   LUSTER AD, 1987, P NATL ACAD SCI USA, V84, P2868, DOI 10.1073/pnas.84.9.2868
   McTiernan A, 2004, CANCER EPIDEM BIOMAR, V13, P1099
   McTiernan A, 2004, CANCER RES, V64, P2923, DOI 10.1158/0008-5472.CAN-03-3393
   Mu L, 2008, BRIT J CANCER, V99, P1357, DOI 10.1038/sj.bjc.6604689
   Nakajima K, 2010, INT J SPORTS MED, V31, P671, DOI 10.1055/s-0029-1246140
   Neilson HK, 2009, CANCER EPIDEM BIOMAR, V18, P11, DOI 10.1158/1055-9965.EPI-08-0756
   Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336
   O'Donovan N, 1999, CYTOGENET CELL GENET, V84, P39, DOI 10.1159/000015209
   Plaitakis A, 2001, J NEUROSCI RES, V66, P899, DOI 10.1002/jnr.10054
   Satoh K, 2004, J MAMMARY GLAND BIOL, V9, P195, DOI 10.1023/B:JOMG.0000037162.84758.b5
   Schmitz KH, 2005, CANCER EPIDEM BIOMAR, V14, P1672, DOI 10.1158/1055-9965.EPI-04-0736
   UEDA K, 1987, J BIOL CHEM, V262, P505
   WONG WT, 1994, ONCOGENE, V9, P1591
   Yuasa Y, 2009, INT J CANCER, V124, P2677, DOI 10.1002/ijc.24231
NR 34
TC 69
Z9 78
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY
PY 2012
VL 133
IS 1
BP 127
EP 135
DI 10.1007/s10549-011-1716-7
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 935HH
UT WOS:000303509200012
PM 21837478
DA 2025-01-12
ER

PT J
AU Brönneke, S
   Brückner, B
   Peters, N
   Bosch, TCG
   Stäb, F
   Wenck, H
   Hagemann, S
   Winnefeld, M
AF Broenneke, Simone
   Brueckner, Bodo
   Peters, Nils
   Bosch, Thomas C. G.
   Staeb, Franz
   Wenck, Horst
   Hagemann, Sabine
   Winnefeld, Marc
TI DNA methylation regulates lineage-specifying genes in primary lymphatic
   and blood endothelial cells
SO ANGIOGENESIS
LA English
DT Article
DE Primary human endothelial cells; Gene expression; DNA methylation;
   Transdifferentiation; Endothelial plasticity; Biomarker
ID ACID-BINDING-PROTEIN; GROWTH-FACTOR-C; MAMMALIAN DEVELOPMENT; MOLECULAR
   REGULATION; SKIN INFLAMMATION; BREAST-CANCER; HUMAN-DISEASE; MUTANT
   MICE; VEGF-C; EXPRESSION
AB During embryonic development, the lymphatic system emerges by transdifferentiation from the cardinal vein. Although lymphatic and blood vasculature share a close molecular and developmental relationship, they display distinct features and functions. However, even after terminal differentiation, transitions between blood endothelial cells (BEC) and lymphatic endothelial cells (LEC) have been reported. Since phenotypic plasticity and cellular differentiation processes frequently involve epigenetic mechanisms, we hypothesized that DNA methylation might play a role in regulating cell type-specific expression in endothelial cells. By analyzing global gene expression and methylation patterns of primary human dermal LEC and BEC, we identified a highly significant set of genes, which were differentially methylated and expressed. Pathway analyses of the differentially methylated and upregulated genes in LEC revealed involvement in developmental and transdifferentiation processes. We further identified a set of novel genes, which might be implicated in regulating BEC-LEC plasticity and could serve as therapeutic targets and/or biomarkers in vascular diseases associated with alterations in the endothelial phenotype.
C1 [Broenneke, Simone; Peters, Nils; Staeb, Franz; Wenck, Horst; Hagemann, Sabine; Winnefeld, Marc] Beiersdorf AG, Res & Dev, Hamburg, Germany.
   [Bosch, Thomas C. G.] Univ Kiel, Inst Zool, D-24098 Kiel, Germany.
C3 Beiersdorf AG; University of Kiel
RP Winnefeld, M (通讯作者)，Beiersdorf AG, Res & Dev, Hamburg, Germany.
EM Marc.Winnefeld@Beiersdorf.com
RI Bosch, Thomas/D-5218-2011
CR Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Adamson J, 2003, ONCOGENE, V22, P2739, DOI 10.1038/sj.onc.1206341
   Al-Rawi MAA, 2005, INT J ONCOL, V27, P721
   Al-Rawi MAA, 2005, BRIT J SURG, V92, P305, DOI 10.1002/bjs.4832
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Ayadi A, 2001, EMBO J, V20, P5139, DOI 10.1093/emboj/20.18.5139
   Baluk P, 2008, ANN NY ACAD SCI, V1131, P1, DOI 10.1196/annals.1413.001
   BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bibikova M, 2009, WILEY INTERDISCIP RE, V2, P210
   Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Bixel MG, 2008, GENE DEV, V22, P3232, DOI 10.1101/gad.1751908
   Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Chan Y, 2004, J BIOL CHEM, V279, P35087, DOI 10.1074/jbc.M405063200
   Cooley LS, 2010, J CELL SCI, V123, P3808, DOI 10.1242/jcs.064279
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Gröger M, 2007, J INVEST DERMATOL, V127, P2893, DOI 10.1038/sj.jid.5701031
   Grönniger E, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000971
   Gröger M, 2004, J IMMUNOL, V173, P7161, DOI 10.4049/jimmunol.173.12.7161
   Hellman A, 2007, SCIENCE, V315, P1141, DOI 10.1126/science.1136352
   Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5
   Hong YK, 2004, DEV DYNAM, V231, P462, DOI 10.1002/dvdy.20179
   Hong YK, 2004, NAT GENET, V36, P683, DOI 10.1038/ng1383
   Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016
   Jing C, 2001, CANCER RES, V61, P4357
   KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566
   Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515
   Kärpänen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com
   Kim JY, 2009, EPIGENETICS-US, V4, P313, DOI 10.4161/epi.4.5.9160
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797
   Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Lin CI, 2008, CELL MOL LIFE SCI, V65, P2740, DOI 10.1007/s00018-008-8314-9
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641
   Matsumura S, 2007, INT J CANCER, V120, P1689, DOI 10.1002/ijc.22433
   Münz M, 2005, CANCER LETT, V225, P151, DOI 10.1016/j.canlet.2004.11.048
   Nelson GM, 2007, NEOPLASIA, V9, P1038, DOI 10.1593/neo.07643
   Oliver G, 2002, ANN NY ACAD SCI, V979, P159, DOI 10.1111/j.1749-6632.2002.tb04876.x
   Olszewski W, 2002, ANN NY ACAD SCI, V979, P188
   Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470
   Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Ribatti D, 2009, ANGIOGENESIS, V12, P101, DOI 10.1007/s10456-008-9125-1
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rocha SF, 2009, ANGIOGENESIS, V12, P139, DOI 10.1007/s10456-009-9132-x
   Romanowska M, 2008, J INVEST DERMATOL, V128, P110, DOI 10.1038/sj.jid.5700943
   Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383
   Saharinen P, 2004, TRENDS IMMUNOL, V25, P387, DOI 10.1016/j.it.2004.05.003
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sozzani R, 2010, NATURE, V466, P128, DOI 10.1038/nature09143
   Srinivasan RS, 2007, GENE DEV, V21, P2422, DOI 10.1101/gad.1588407
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045
   Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8
   Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1
   Yuan L, 2002, DEVELOPMENT, V129, P4797
   Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929
NR 71
TC 18
Z9 19
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
J9 ANGIOGENESIS
JI Angiogenesis
PD JUN
PY 2012
VL 15
IS 2
BP 317
EP 329
DI 10.1007/s10456-012-9264-2
PG 13
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 934TU
UT WOS:000303470400012
PM 22434260
DA 2025-01-12
ER

PT J
AU Naldini, A
   Filippi, I
   Cini, E
   Rodriquez, M
   Carraro, F
   Taddei, M
AF Naldini, Antonella
   Filippi, Irene
   Cini, Elena
   Rodriquez, Manuela
   Carraro, Fabio
   Taddei, Maurizio
TI Downregulation of Hypoxia-related Responses by Novel Antitumor Histone
   Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Angiogenesis; Anticancer drugs; Breast cancer; Carbonic anhydrase; Cell
   proliferation; Epigenetic regulation; Gene expression; Glucose
   transporter; Hypoxia; Hypoxia-inducible factor (HIF)-1alpha; Histone
   deacetylase inhibitors; Metabolism; Transcription factors; Tumor
   microenvironment; Vascular endothelial growth factor
ID INDUCIBLE FACTOR-1-ALPHA; SOLID TUMORS; ANGIOGENESIS; HIF-1;
   HIF-1-ALPHA; OXYGENATION; METABOLISM; EXPRESSION; BNIP3L; GROWTH
AB The tumor microenvironment is characterized by a poor circulation which results in the selection of neoplastic cells that can grow or survive under hypoxic conditions. The relationship between hypoxia and histone deacetylase ( HDAC) inhibitors has been previously established. In this work we evaluated the effects of novel HDAC inhibitors (the natural peptide FR235222 and three tetrapeptide analogs) in the human breast cancer cell line MDAMB231, cultured under hypoxia (2% O-2 approximate to 14 mmHg) or normoxia (20% O-2 approximate to 140 mmHg).
   First, we found that the novel HDAC inhibitors reduced cell proliferation in MDAMB231 cells at an extent which was similar or even higher than that exerted by the classic HDAC inhibitors trichostatin-A and suberoylanilide hydroxamic acid. More interestingly, the antiproliferative effects of the novel HDAC inhibitors were, in general, significantly higher in hypoxic cells than in normoxic controls. Hypoxic MDAMB231 cells expressed high levels of the hypoxia-inducible factor (HIF)-1 alpha and HIF-1 alpha-related genes, such as vascular endothelial growth factor, Bcl-2/E1B 19 kDa interacting protein-3, glucose transporter-1, carbonic anhydrase IX, as determined by Western blot analysis and qRT-PCR. Finally, we found that HIF-1 alpha and HIF-1 alpha-related genes were significantly downregulated by FR235222 and analogs. In conclusion, the identification of novel effects exerted by the HDAC inhibitors, characterized by a strong efficacy in inhibiting the expression of HIF-1 alpha and its related genes, may have important implications in the pharmacological control of several tumors, including breast cancer, characterized by the presence of hypoxia, angiogenesis and metabolic derangements.
C1 [Naldini, Antonella; Filippi, Irene; Carraro, Fabio] Univ Siena, Dept Physiol, I-53100 Siena, Italy.
   [Cini, Elena; Taddei, Maurizio] Univ Siena, Dept Pharmaceut & Appl Chem, I-53100 Siena, Italy.
   [Rodriquez, Manuela] Univ Salerno, Dept Pharmaceut Sci, I-84084 Salerno, Italy.
C3 University of Siena; University of Siena; University of Salerno
RP Naldini, A (通讯作者)，Univ Siena, Dept Physiol, Via Aldo Moro, I-53100 Siena, Italy.
EM Naldini@Unisi.it
RI Carraro, Fabio/ABI-6098-2020; Carraro, Fabio/N-2613-2013; Rodriquez,
   Manuela/G-2459-2011; naldini, antonella/O-6522-2015
OI Cini, Elena/0000-0003-4420-8930; Carraro, Fabio/0000-0003-0771-042X;
   Filippi, Irene/0000-0001-7712-1474; Rodriquez,
   Manuela/0000-0002-4412-238X; naldini, antonella/0000-0002-9600-2486
FU Regione Toscana; Fondazione MPS; Ministero Istruzione Universita Ricerca
FX This work was supported by grants from Regione Toscana Grant ITT 2008
   and Fondazione MPS, Grandi Attrezzature 2008 to A. Naldini and Ministero
   Istruzione Universita Ricerca (PRIN 2007) to F. Carraro and A. Naldini.
CR Abramova MV, 2006, J BIOL CHEM, V281, P21040, DOI 10.1074/jbc.M511059200
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4
   Boraldi F, 2007, BBA-PROTEINS PROTEOM, V1774, P1402, DOI 10.1016/j.bbapap.2007.08.011
   Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010
   Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3
   Brown JM, 1998, CANCER RES, V58, P1408
   Chen SY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/197946
   Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470
   Denko NC, 2001, CANCER RES, V61, P795
   Ellis L, 2009, CANCER LETT, V280, P145, DOI 10.1016/j.canlet.2008.11.012
   Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258
   Gomez-Paloma L, 2007, CHEMMEDCHEM, V2, P1511, DOI 10.1002/cmdc.200700095
   Goonewardene TI, 2002, MICROSC RES TECHNIQ, V59, P41, DOI 10.1002/jemt.10175
   HOCKEL M, 1991, CANCER RES, V51, P6098
   Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1
   KALLINOWSKI F, 1989, CANCER RES, V49, P3759
   Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0
   Manetti F, 2008, J MED CHEM, V51, P1252, DOI 10.1021/jm701240c
   Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Naldini A, 1997, J CELL PHYSIOL, V173, P335, DOI 10.1002/(SICI)1097-4652(199712)173:3<335::AID-JCP5>3.0.CO;2-O
   Naldini A, 2010, J LEUKOCYTE BIOL, V87, P365, DOI 10.1189/jlb.0709460
   Naldini A, 2009, EUR J CANCER, V45, P454, DOI 10.1016/j.ejca.2008.10.012
   Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003
   Petrella A, 2008, EUR J CANCER, V44, P740, DOI 10.1016/j.ejca.2008.01.023
   Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006
   Pouysségur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Robey IF, 2008, NEOPLASIA, V10, P745, DOI 10.1593/neo.07724
   Rodriquez M, 2006, J ORG CHEM, V71, P103, DOI 10.1021/jo0518250
   Sasamura S, 2010, J ANTIBIOT, V63, P633, DOI 10.1038/ja.2010.51
   Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2007, DRUG DISCOV TODAY, V12, P853, DOI 10.1016/j.drudis.2007.08.006
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   VAUPEL P, 1991, CANCER RES, V51, P3316
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Yu JL, 2002, DIFFERENTIATION, V70, P599, DOI 10.1046/j.1432-0436.2002.700913.x
   Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586
NR 48
TC 14
Z9 15
U1 0
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PD MAY
PY 2012
VL 12
IS 4
BP 407
EP 413
DI 10.2174/187152012800228706
PG 7
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 936UA
UT WOS:000303614300011
PM 22043993
DA 2025-01-12
ER

PT J
AU Fan, H
   Chen, L
   Zhang, F
   Quan, Y
   Su, X
   Qiu, X
   Zhao, Z
   Kong, KL
   Dong, S
   Song, Y
   Chan, THM
   Guan, XY
AF Fan, H.
   Chen, L.
   Zhang, F.
   Quan, Y.
   Su, X.
   Qiu, X.
   Zhao, Z.
   Kong, K. L.
   Dong, S.
   Song, Y.
   Chan, T. H. M.
   Guan, X-Y
TI MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor
   suppressor in hepatocellular carcinoma
SO ONCOGENE
LA English
DT Article
DE DNMT3B; MTSS1; cell cycle; methylation; TSG; HCC
ID DE-NOVO METHYLATION; PERICENTROMERIC SATELLITE REGIONS; CANCER
   CELL-LINES; HUMAN HEPATOCARCINOGENESIS; BLADDER-CANCER; BREAST-CANCER;
   MESSENGER-RNA; CYCLIN-B; EXPRESSION; DNMT3B
AB DNA methyltransferase 3B (DNMT3B) mediates gene silencing via epigenetic mechanisms during hepatocellular carcinoma (HCC) progression. We aimed to identify novel targets of DNMT3B and their potential regulatory mechanisms in HCC. Metastasis suppressor 1 (MTSS1) was one of the DNMT3B targets and selected for further study. DNMT3B overexpression was detected in 81.25% of clinical HCC specimens and was negatively associated with MTSS1 in HCC cells and clinical samples. The underlying mechanism by which DNMT3B silences MTSS1 was studied using a combination of methylation-specific polymerase chain reaction (PCR) and bisulfite genome sequencing, chromatin immunoprecipitation-PCR and luciferase reporter assays. We found that the MTSS1 promoter region was sparsely methylated, and the methylation inhibitors failed to abolish DNMT3B-mediated MTSS1 silencing. DNMT3B protein bound directly to the 5'-flanking region (-865/-645) of the MTSS1 gene to inhibit its transcription. The functional role of MTSS1 was investigated using in vitro and in vivo tumorigenicity assays. As a result, MTSS1 exerted tumor suppressor effects and arrested cells in the G2/M phase, but not the G1/S phase of the cell cycle when it was depleted or overexpressed in HCC cells. Taken together, MTSS1, a novel target of DNMT3B, is repressed by DNMT3B via a DNA methylation-independent mechanism. MTSS1 was further characterized as a novel tumor suppressor gene in HCC. These findings highlight how DNMT3B regulates MTSS1, and such data may be useful for the development of new treatment options for HCC. Oncogene (2012) 31, 2298-2308; doi:10.1038/onc.2011.411; published online 12 September 2011
C1 [Fan, H.; Zhang, F.; Quan, Y.; Su, X.; Qiu, X.] Southeast Univ, Sch Med, Key Lab Dev Genes & Human Dis, Minist Educ,Dept Med Genet & Dev Biol, Nanjing 210009, Peoples R China.
   [Chen, L.; Chan, T. H. M.; Guan, X-Y] Univ Hong Kong, State Key Lab Liver Canc, Pokfulam, Hong Kong, Peoples R China.
   [Chen, L.; Zhao, Z.; Kong, K. L.; Dong, S.; Song, Y.; Chan, T. H. M.; Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China.
   [Chen, L.; Guan, X-Y] Sun Yat Sen Univ, State Key Lab Oncol So China, Dept Clin Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
C3 Southeast University - China; University of Hong Kong; University of
   Hong Kong; Sun Yat Sen University
RP Fan, H (通讯作者)，Southeast Univ, Sch Med, Key Lab Dev Genes & Human Dis, Minist Educ,Dept Genet & Dev Biol, Nanjing 210009, Peoples R China.
EM fanh@seu.edu.cn; xyguan@hkucc.hku.hk
RI Fan, Hong/KMA-7361-2024; CHEN, Ling/JDW-6781-2023; song,
   yang/HOF-4505-2023; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009
OI /0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017
FU National Natural Science Foundation of China [30971605]; HKU Li Ka Shing
   Faculty of Medicine
FX This work was supported by The National Natural Science Foundation of
   China, No. 30971605, and in part by the Dr Cheng Yu Tung Fellowships
   2007/08 under the HKU Li Ka Shing Faculty of Medicine. We are grateful
   to Professor Dianqing WU in UConn Health Center USA for providing siRNA
   expression vector. We are also grateful to Dr Stephanie Ma in Department
   of Pathology in University of Hong Kong for helping in MTSS1 antibody.
CR Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200
   Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685
   Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665
   Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5
   Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814
   Cross FR, 2005, MOL BIOL CELL, V16, P2129, DOI 10.1091/mbc.E04-10-0897
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200
   Huang Xiu-yan, 2010, Zhonghua Gan Zang Bing Za Zhi, V18, P915, DOI 10.3760/cma.j.issn.1007-3418.2010.12.008
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jun Xu, 2005, Acta Genetica Sinica, V32, P1115
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633
   Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231
   Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007
   Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428
   Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004
   McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002
   Oh BK, 2007, INT J MOL MED, V20, P65
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019
   Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4
   Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799
   Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507
   Shafiei F, 2008, ONCOGENE, V27, P2602, DOI 10.1038/sj.onc.1210917
   SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x
   Simao TDA, 2006, HUM EXP TOXICOL, V25, P515, DOI 10.1191/0960327106het649oa
   Takeshima H, 2006, J BIOCHEM, V139, P503, DOI 10.1093/jb/mvj044
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Utikal J, 2006, INT J CANCER, V119, P2287, DOI 10.1002/ijc.22106
   Wang J, 2007, CANCER RES, V67, P10647, DOI 10.1158/0008-5472.CAN-07-1337
   Weisenberger DJ, 2004, MOL CANCER RES, V2, P62
NR 48
TC 51
Z9 61
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAY
PY 2012
VL 31
IS 18
BP 2298
EP 2308
DI 10.1038/onc.2011.411
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 936SR
UT WOS:000303610800005
PM 21909138
OA Bronze
DA 2025-01-12
ER

PT J
AU Rasti, M
   Arabsolghar, R
   Khatooni, Z
   Mostafavi-Pour, Z
AF Rasti, Mozhgan
   Arabsolghar, Rita
   Khatooni, Zahed
   Mostafavi-Pour, Zoherh
TI p53 Binds to <i>Estrogen Receptor 1</i> Promoter in Human Breast Cancer
   Cells
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Breast cancer; Estrogen receptor 1; Methylated promoter; p53; Epigenetic
ID ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITION; CPG-ISLAND
   METHYLATION; IARC TP53 DATABASE; MUTANT P53; TRANSCRIPTIONAL REPRESSION;
   DNA METHYLATION; ER-ALPHA; GENE; EXPRESSION
AB p53 is a tumor suppressor protein that regulates estrogen receptor 1 (ESR1) expression. To investigate the mechanism of ESR1 gene regulation by p53, chromatin immunoprecipitation was applied to assess the binding of p53, DNMT1, HDAC1 and MeCP2 to both silenced ESR1 promoter in MDA-MB-468 cells and active ESR1 promoter in MCF-7 breast cancer cells. The results of chromatin immunoprecipitation experiments showed that p53 protein binds to both unmethylated CpG island of the ESR1 promoter in the ER-positive MCF-7 and the hypermethylated ESR1 promoter in the ER-negative MDA-MB-468 cells. However, repression complex including DNMT1, HDAC1 and MeCP2 is only associated with silenced ESR1 in ER-negative MDA-MB-468 human breast cancer cells. In addition, ectopically expressed wild type p53 failed to reactivate the ESR1 gene in these cells. These results suggest that specific p53 mutations may contribute to loss of estrogen receptor alpha expression in breast tumors and also support the hypothesis that mutant p53 is likely to impact DNA methylation.
C1 [Rasti, Mozhgan; Arabsolghar, Rita; Khatooni, Zahed; Mostafavi-Pour, Zoherh] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Recombinant Prot Lab, Shiraz, Iran.
C3 Shiraz University of Medical Science
RP Rasti, M (通讯作者)，Shiraz Univ Med Sci, Sch Med, Dept Biochem, Recombinant Prot Lab, Shiraz, Iran.
EM rasti31@yahoo.com
RI Arabsolghar, Rita/S-3994-2017; khatooni, zahed/AAD-5456-2021;
   mostafavi-pour, zohreh/T-5588-2018
OI mostafavi-pour, zohreh/0000-0002-3779-177X; Arabsolghar,
   Rita/0000-0001-9725-8005
FU Shiraz University of Medical Sciences, Iran [87-4153, 89-5176]
FX This work was supported by grants No: 87-4153 and 89-5176 from Shiraz
   University of Medical Sciences, Iran for Mr. Zahed Khatooni's thesis and
   Mrs Rita Arabsolghar's thesis, respectively.
CR Akaogi K, 2009, ONCOGENE, V28, P2894, DOI 10.1038/onc.2009.151
   Amaral JD, 2010, DISCOV MED, V9, P145
   Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497
   AVILA MA, 1994, CANCER RES, V54, P2424
   Berns EMJJ, 1996, GENE CHROMOSOME CANC, V16, P170, DOI 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W
   Bertheau P, 2008, PATHOBIOLOGY, V75, P132, DOI 10.1159/000123851
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dhar G, 2008, CANCER RES, V68, P4580, DOI 10.1158/0008-5472.CAN-08-0316
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Estève PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784
   Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4
   Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091
   Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005
   Horvath MM, 2007, PLOS GENET, V3, P1284, DOI 10.1371/journal.pgen.0030127
   Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005
   Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Li SY, 2006, ONCOL REP, V15, P221
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Millau JF, 2009, MUTAT RES-REV MUTAT, V681, P118, DOI 10.1016/j.mrrev.2008.06.002
   Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021
   Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490
   Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081
   Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
   Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121
   Sengupta S, 2005, ONCOGENE, V24, P1738, DOI 10.1038/sj.onc.1208380
   SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Shirley SH, 2009, CANCER RES, V69, P3405, DOI 10.1158/0008-5472.CAN-08-3628
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Vinyals A, 1999, GENE THER, V6, P22, DOI 10.1038/sj.gt.3300786
   Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
NR 41
TC 22
Z9 26
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD APR
PY 2012
VL 18
IS 2
BP 169
EP 175
DI 10.1007/s12253-011-9423-6
PG 7
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA 935RP
UT WOS:000303538200007
PM 21655924
DA 2025-01-12
ER

PT J
AU Jiang, Y
   Cui, L
   Chen, WD
   Shen, SH
   Ding, LD
AF Jiang, Yong
   Cui, Lin
   Chen, Wen-de
   Shen, Shi-hai
   Ding, Li-dong
TI The Prognostic Role of <i>RASSF1A</i> Promoter Methylation in Breast
   Cancer: A Meta-Analysis of Published Data
SO PLOS ONE
LA English
DT Article
ID ASSOCIATION DOMAIN FAMILY-1; DNA METHYLATION; POOR-PROGNOSIS;
   HYPERMETHYLATION; MARKER; SERUM; GENE
AB Purpose: Epigenetic alterations have been investigated as prognostic indicators in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. We present the results of a meta-analysis of the associations between RASSF1A promoter methylation status and both disease free survival (DFS) and overall survival (OS) in female breast cancer.
   Methods: Eligible studies were identified through searching the PubMed, Web of Science and Embase databases. Studies were pooled and summary hazard ratios (HR) with corresponding confidence intervals (CIs) were calculated. Funnel plots were also carried out to evaluate publication bias.
   Results: A total of 1795 patients from eight studies were included in the meta-analysis. There are eight studies which investigated DFS in 1795 cases. The relative hazard estimates ranged from 1.77-5.64 with a combined HR of 2.75 (95% CI 1.96-3.84). The HR of RASSF1A promoter methylation on DFS adjusted for other potential prognostic factors was 2.54 (95% CI 1.77-3.66). There has been five trials which analyzed the associations of RASSF1A promoter methylation status with OS in 1439 patients. The hazard estimates ranged from 1.21-6.90 with a combined random-effects estimates of 3.47 (95% CI 1.44-8.34). OS reported in multivariate analysis was evaluated in four series comprising 1346 cases and the summarized random-effects HR estimate was 3.35 (95% CI 1.14-9.85). Additionally, no publication bias was detected for both OS and DFS.
   Conclusion: The results of this meta-analysis suggest that RASSF1A promoter hypermethylation confers a higher risk of relapse and a worse survival in patients with breast cancer. Large prospective studies are now needed to establish the clinical utility of RASSF1A promoter methylation.
C1 [Jiang, Yong; Cui, Lin] Yangzhou Univ, Affiliated Hosp, Jiangyan Peoples Hosp, Dept Oncol, Jiangyan, Peoples R China.
   [Chen, Wen-de; Shen, Shi-hai; Ding, Li-dong] Yangzhou Univ, Affiliated Hosp, Jiangyan Peoples Hosp, Dept Sci Res, Jiangyan, Peoples R China.
C3 Yangzhou University; Yangzhou University
RP Jiang, Y (通讯作者)，Yangzhou Univ, Affiliated Hosp, Jiangyan Peoples Hosp, Dept Oncol, Jiangyan, Peoples R China.
EM cuilintz@126.com
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   [Anonymous], BREAST CANC RES TREA
   [Anonymous], BREAST CANC RES TREA
   Bax L, 2009, AM J EPIDEMIOL, V169, P249, DOI 10.1093/aje/kwn340
   Buhmeida A, 2011, ANTICANCER RES, V31, P2975
   Dallol A, 2007, CANCER RES, V67, P492, DOI 10.1158/0008-5472.CAN-06-3604
   DerSimonian R, 1996, STAT MED, V15, P1237, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438
   Hamilton MG, 2011, J NEURO-ONCOL, V102, P255, DOI 10.1007/s11060-010-0307-5
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jo H, 2006, ONCOL RES, V16, P205, DOI 10.3727/000000006783981125
   Karray-Chouayekh S, 2010, J CANCER RES CLIN, V136, P203, DOI 10.1007/s00432-009-0649-6
   Kawai Y, 2010, ANN ONCOL, V21, P1612, DOI 10.1093/annonc/mdp577
   Kim C, 2010, NAT REV CLIN ONCOL, V7, P340, DOI 10.1038/nrclinonc.2010.61
   Kioulafa M, 2009, CLIN BIOCHEM, V42, P970, DOI 10.1016/j.clinbiochem.2009.04.003
   Martins AT, 2011, BREAST CANCER RES TR, V129, P1, DOI 10.1007/s10549-010-1160-0
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
   Misawa A, 2009, BRIT J CANCER, V100, P399, DOI 10.1038/sj.bjc.6604887
   Müller HM, 2003, CANCER RES, V63, P7641
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   Rakha EA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2607
   Sharma G, 2009, CELL ONCOL, V31, P487, DOI 10.3233/CLO-2009-0507
   Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091
   Tanemura A, 2009, CLIN CANCER RES, V15, P1801, DOI 10.1158/1078-0432.CCR-08-1361
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Tommasi S, 2005, CANCER RES, V65, P92
   Wang J, 2011, CARCINOGENESIS, V32, P411, DOI 10.1093/carcin/bgq266
NR 30
TC 45
Z9 50
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2012
VL 7
IS 5
AR e36780
DI 10.1371/journal.pone.0036780
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959UQ
UT WOS:000305341200020
PM 22615811
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

EF